Pre-operative	10052279	0	13	B-Intervention
short-term	10052279	14	24	I-Intervention
pulmonary	10052279	25	34	I-Intervention
rehabilitation	10052279	35	49	I-Intervention
for	10052279	50	53	O
patients	10052279	54	62	O
of	10052279	63	65	O
chronic	10052279	66	73	B-Participant
obstructive	10052279	74	85	I-Participant
pulmonary	10052279	86	95	I-Participant
disease	10052279	96	103	I-Participant
undergoing	10052279	104	114	O
coronary	10052279	115	123	B-Participant
artery	10052279	124	130	I-Participant
bypass	10052279	131	137	I-Participant
graft	10052279	138	143	I-Participant
surgery	10052279	144	151	I-Participant
.	10052279	152	153	O

The	10052279	154	157	O
role	10052279	158	162	O
of	10052279	163	165	O
pre-operative	10052279	166	179	B-Intervention
short-term	10052279	180	190	I-Intervention
pulmonary	10052279	191	200	I-Intervention
rehabilitation	10052279	201	215	I-Intervention
in	10052279	216	218	O
patients	10052279	219	227	O
with	10052279	228	232	O
chronic	10052279	233	240	B-Participant
obstructive	10052279	241	252	I-Participant
pulmonary	10052279	253	262	I-Participant
disease	10052279	263	270	I-Participant
who	10052279	271	274	O
undergo	10052279	275	282	O
coronary	10052279	283	291	B-Participant
artery	10052279	292	298	I-Participant
bypass	10052279	299	305	I-Participant
graft	10052279	306	311	I-Participant
surgery	10052279	312	319	I-Participant
has	10052279	320	323	O
been	10052279	324	328	O
assessed	10052279	329	337	O
for	10052279	338	341	O
the	10052279	342	345	O
first	10052279	346	351	O
time	10052279	352	356	O
prospectively	10052279	357	370	O
.	10052279	371	372	O

Forty-five	10052279	373	383	O
patients	10052279	384	392	O
posted	10052279	393	399	O
for	10052279	400	403	O
coronary	10052279	404	412	B-Participant
artery	10052279	413	419	I-Participant
bypass	10052279	420	426	I-Participant
graft	10052279	427	432	I-Participant
surgery	10052279	433	440	I-Participant
were	10052279	441	445	O
randomised	10052279	446	456	O
to	10052279	457	459	O
receive	10052279	460	467	O
either	10052279	468	474	O
short-term	10052279	475	485	B-Intervention
pulmonary	10052279	486	495	I-Intervention
rehabilitation	10052279	496	510	I-Intervention
(	10052279	511	512	I-Intervention
group	10052279	513	518	I-Intervention
I	10052279	519	520	I-Intervention
)	10052279	521	522	I-Intervention
or	10052279	523	525	O
no	10052279	526	528	B-Intervention
such	10052279	529	533	I-Intervention
programme	10052279	534	543	I-Intervention
(	10052279	544	545	I-Intervention
group	10052279	546	551	I-Intervention
II	10052279	552	554	I-Intervention
)	10052279	555	556	I-Intervention
.	10052279	557	558	O

Patients	10052279	559	567	O
of	10052279	568	570	O
both	10052279	571	575	O
the	10052279	576	579	O
groups	10052279	580	586	O
were	10052279	587	591	O
evenly	10052279	592	598	O
matched	10052279	599	606	O
with	10052279	607	611	O
respect	10052279	612	619	O
to	10052279	620	622	O
age	10052279	623	626	O
,	10052279	627	628	O
sex	10052279	629	632	O
,	10052279	633	634	O
body	10052279	635	639	O
surface	10052279	640	647	O
area	10052279	648	652	O
,	10052279	653	654	O
duration	10052279	655	663	O
and	10052279	664	667	O
severity	10052279	668	676	O
of	10052279	677	679	O
chronic	10052279	680	687	O
obstructive	10052279	688	699	O
pulmonary	10052279	700	709	O
disease	10052279	710	717	O
and	10052279	718	721	O
coronary	10052279	722	730	O
artery	10052279	731	737	O
disease	10052279	738	745	O
.	10052279	746	747	O

Normal	10052279	748	754	O
individuals	10052279	755	766	O
who	10052279	767	770	O
evenly	10052279	771	777	O
matched	10052279	778	785	O
with	10052279	786	790	O
the	10052279	791	794	O
study	10052279	795	800	O
group	10052279	801	806	O
were	10052279	807	811	O
assessed	10052279	812	820	O
for	10052279	821	824	O
normal	10052279	825	831	O
respiratory	10052279	832	843	O
function	10052279	844	852	O
parameters	10052279	853	863	O
.	10052279	864	865	O

Pre-operative	10052279	866	879	B-Outcome
and	10052279	880	883	I-Outcome
post-operative	10052279	884	898	I-Outcome
peak	10052279	899	903	I-Outcome
expiratory	10052279	904	914	I-Outcome
flow	10052279	915	919	I-Outcome
rate	10052279	920	924	I-Outcome
,	10052279	925	926	O
inspiratory	10052279	927	938	B-Outcome
capacity	10052279	939	947	I-Outcome
,	10052279	948	949	O
post-operative	10052279	950	964	B-Outcome
ventilation	10052279	965	976	I-Outcome
time	10052279	977	981	I-Outcome
,	10052279	982	983	O
post-operative	10052279	984	998	B-Outcome
pulmonary	10052279	999	1008	I-Outcome
complication	10052279	1009	1021	I-Outcome
and	10052279	1022	1025	O
hospital	10052279	1026	1034	B-Outcome
stay	10052279	1035	1039	I-Outcome
were	10052279	1040	1044	O
determined	10052279	1045	1055	O
in	10052279	1056	1058	O
both	10052279	1059	1063	B-Intervention
the	10052279	1064	1067	I-Intervention
groups	10052279	1068	1074	I-Intervention
.	10052279	1075	1076	O

Peak	10052279	1077	1081	B-Outcome
expiratory	10052279	1082	1092	I-Outcome
flow	10052279	1093	1097	I-Outcome
rate	10052279	1098	1102	I-Outcome
(	10052279	1103	1104	O
220.0	10052279	1105	1110	B-Observation
+	10052279	1111	1112	I-Observation
/-	10052279	1112	1114	I-Observation
12.9	10052279	1115	1119	I-Observation
and	10052279	1120	1123	I-Observation
324.3	10052279	1124	1129	I-Observation
+	10052279	1130	1131	I-Observation
/-	10052279	1131	1133	I-Observation
84.3	10052279	1134	1138	I-Observation
in	10052279	1139	1141	O
group	10052279	1142	1147	B-Intervention
I	10052279	1148	1149	I-Intervention
,	10052279	1150	1151	O
218.0	10052279	1152	1157	B-Observation
+	10052279	1158	1159	I-Observation
/-	10052279	1159	1161	I-Observation
16.4	10052279	1162	1166	I-Observation
and	10052279	1167	1170	I-Observation
260.5	10052279	1171	1176	I-Observation
+	10052279	1177	1178	I-Observation
/-	10052279	1178	1180	I-Observation
35.2	10052279	1181	1185	I-Observation
in	10052279	1186	1188	O
group	10052279	1189	1194	B-Intervention
II	10052279	1195	1197	I-Intervention
)	10052279	1198	1199	O
and	10052279	1200	1203	O
inspiratory	10052279	1204	1215	B-Outcome
capacity	10052279	1216	1224	I-Outcome
(	10052279	1225	1226	O
844.0	10052279	1227	1232	B-Observation
+	10052279	1233	1234	I-Observation
/-	10052279	1234	1236	I-Observation
147.4	10052279	1237	1242	I-Observation
and	10052279	1243	1246	I-Observation
1100.0	10052279	1247	1253	I-Observation
+	10052279	1254	1255	I-Observation
/-	10052279	1255	1257	I-Observation
158.1	10052279	1258	1263	I-Observation
in	10052279	1264	1266	O
group	10052279	1267	1272	B-Intervention
I	10052279	1273	1274	I-Intervention
,	10052279	1275	1276	O
830.0	10052279	1277	1282	B-Observation
+	10052279	1283	1284	I-Observation
/-	10052279	1284	1286	I-Observation
117.4	10052279	1287	1292	I-Observation
and	10052279	1293	1296	I-Observation
1090	10052279	1297	1301	I-Observation
+	10052279	1302	1303	I-Observation
/-	10052279	1303	1305	I-Observation
137	10052279	1306	1309	I-Observation
in	10052279	1310	1312	O
group	10052279	1313	1318	B-Intervention
II	10052279	1319	1321	I-Intervention
)	10052279	1322	1323	O
were	10052279	1324	1328	O
significantly	10052279	1329	1342	B-Observation
lower	10052279	1343	1348	I-Observation
before	10052279	1349	1355	O
and	10052279	1356	1359	O
after	10052279	1360	1365	O
surgery	10052279	1366	1373	O
respectively	10052279	1374	1386	O
in	10052279	1387	1389	O
both	10052279	1390	1394	B-Intervention
groups	10052279	1395	1401	I-Intervention
compared	10052279	1402	1410	O
to	10052279	1411	1413	O
normal	10052279	1414	1420	O
values	10052279	1421	1427	O
.	10052279	1428	1429	O

Even	10052279	1430	1434	O
though	10052279	1435	1441	O
both	10052279	1442	1446	B-Intervention
groups	10052279	1447	1453	I-Intervention
showed	10052279	1454	1460	O
a	10052279	1461	1462	O
significant	10052279	1463	1474	B-Observation
rise	10052279	1475	1479	I-Observation
in	10052279	1480	1482	O
post-operative	10052279	1483	1497	B-Outcome
peak	10052279	1498	1502	I-Outcome
expiratory	10052279	1503	1513	I-Outcome
flow	10052279	1514	1518	I-Outcome
rate	10052279	1519	1523	I-Outcome
and	10052279	1524	1527	O
inspiratory	10052279	1528	1539	B-Outcome
capacity	10052279	1540	1548	I-Outcome
after	10052279	1549	1554	O
surgery	10052279	1555	1562	O
,	10052279	1563	1564	O
the	10052279	1565	1568	O
post-operative	10052279	1569	1583	B-Outcome
peak	10052279	1584	1588	I-Outcome
expiratory	10052279	1589	1599	I-Outcome
flow	10052279	1600	1604	I-Outcome
rate	10052279	1605	1609	I-Outcome
and	10052279	1610	1613	O
inspiratory	10052279	1614	1625	B-Outcome
capacity	10052279	1626	1634	I-Outcome
in	10052279	1635	1637	O
group	10052279	1638	1643	B-Intervention
I	10052279	1644	1645	I-Intervention
was	10052279	1646	1649	O
significantly	10052279	1650	1663	B-Observation
higher	10052279	1664	1670	I-Observation
than	10052279	1671	1675	O
in	10052279	1676	1678	O
group	10052279	1679	1684	B-Intervention
II	10052279	1685	1687	I-Intervention
.	10052279	1688	1689	O

In	10052279	1690	1692	O
group	10052279	1693	1698	B-Intervention
I	10052279	1699	1700	I-Intervention
,	10052279	1701	1702	O
the	10052279	1703	1706	O
post-operative	10052279	1707	1721	B-Outcome
ventilation	10052279	1722	1733	I-Outcome
time	10052279	1734	1738	I-Outcome
(	10052279	1739	1740	O
24.5	10052279	1741	1745	B-Observation
+	10052279	1746	1747	I-Observation
/-	10052279	1747	1749	I-Observation
6.00	10052279	1750	1754	I-Observation
hours	10052279	1755	1760	I-Observation
)	10052279	1761	1762	O
,	10052279	1763	1764	O
post-operative	10052279	1765	1779	B-Outcome
complications	10052279	1780	1793	I-Outcome
(	10052279	1794	1795	O
n	10052279	1796	1797	B-Count
=	10052279	1798	1799	I-Count
4	10052279	1800	1801	I-Count
)	10052279	1802	1803	O
and	10052279	1804	1807	O
hospital	10052279	1808	1816	B-Outcome
stay	10052279	1817	1821	I-Outcome
(	10052279	1822	1823	O
12.4	10052279	1824	1828	B-Observation
+	10052279	1829	1830	I-Observation
/-	10052279	1830	1832	I-Observation
3.6	10052279	1833	1836	I-Observation
days	10052279	1837	1841	I-Observation
)	10052279	1842	1843	O
were	10052279	1844	1848	O
significantly	10052279	1849	1862	B-Observation
lower	10052279	1863	1868	I-Observation
than	10052279	1869	1873	O
in	10052279	1874	1876	O
group	10052279	1877	1882	B-Intervention
II	10052279	1883	1885	I-Intervention
(	10052279	1886	1887	O
35.2	10052279	1888	1892	B-Observation
+	10052279	1893	1894	I-Observation
/-	10052279	1894	1896	I-Observation
22.3	10052279	1897	1901	I-Observation
hours	10052279	1902	1907	I-Observation
,	10052279	1908	1909	O
n	10052279	1910	1911	B-Count
=	10052279	1912	1913	I-Count
11	10052279	1914	1916	I-Count
,	10052279	1917	1918	O
18.8	10052279	1919	1923	B-Observation
+	10052279	1924	1925	I-Observation
/-	10052279	1925	1927	I-Observation
6.6	10052279	1928	1931	I-Observation
days	10052279	1932	1936	I-Observation
respectively	10052279	1937	1949	O
)	10052279	1950	1951	O
.	10052279	1952	1953	O

These	10052279	1954	1959	O
data	10052279	1960	1964	O
suggest	10052279	1965	1972	O
that	10052279	1973	1977	O
short-term	10052279	1978	1988	B-Intervention
pulmonary	10052279	1989	1998	I-Intervention
rehabilitation	10052279	1999	2013	I-Intervention
is	10052279	2014	2016	O
feasible	10052279	2017	2025	O
and	10052279	2026	2029	O
effective	10052279	2030	2039	O
in	10052279	2040	2042	O
improving	10052279	2043	2052	B-Observation
pulmonary	10052279	2053	2062	B-Outcome
functions	10052279	2063	2072	I-Outcome
before	10052279	2073	2079	O
and	10052279	2080	2083	O
after	10052279	2084	2089	O
surgery	10052279	2090	2097	B-Participant
and	10052279	2098	2101	O
in	10052279	2102	2104	O
reducing	10052279	2105	2113	B-Observation
surgical	10052279	2114	2122	B-Outcome
morbidity	10052279	2123	2132	I-Outcome
and	10052279	2133	2136	O
cost	10052279	2137	2141	B-Outcome
of	10052279	2142	2144	I-Outcome
medical	10052279	2145	2152	I-Outcome
care	10052279	2153	2157	I-Outcome
significantly	10052279	2158	2171	O
.	10052279	2172	2173	O

Anesthesia	10071998	0	10	B-Outcome
for	10071998	11	14	O
in	10071998	15	17	B-Participant
vitro	10071998	18	23	I-Participant
fertilization	10071998	24	37	I-Participant
:	10071998	38	39	O
the	10071998	40	43	O
addition	10071998	44	52	B-Intervention
of	10071998	53	55	I-Intervention
fentanyl	10071998	56	64	I-Intervention
to	10071998	65	67	I-Intervention
1.5	10071998	68	71	I-Intervention
%	10071998	72	73	I-Intervention
lidocaine	10071998	74	83	I-Intervention
.	10071998	84	85	O

UNLABELLED	10071998	86	96	O
Ultrasonically	10071998	97	111	O
guided	10071998	112	118	O
transvaginal	10071998	119	131	O
oocyte	10071998	132	138	O
retrieval	10071998	139	148	O
is	10071998	149	151	O
relatively	10071998	152	162	O
short	10071998	163	168	O
procedure	10071998	169	178	O
that	10071998	179	183	O
is	10071998	184	186	O
performed	10071998	187	196	O
on	10071998	197	199	O
an	10071998	200	202	O
out-patient	10071998	203	214	O
basis	10071998	215	220	O
.	10071998	221	222	O

The	10071998	223	226	O
optimal	10071998	227	234	O
anesthetic	10071998	235	245	O
technique	10071998	246	255	O
should	10071998	256	262	O
allow	10071998	263	268	O
good	10071998	269	273	O
surgical	10071998	274	282	O
anesthesia	10071998	283	293	O
with	10071998	294	298	O
minimal	10071998	299	306	O
side	10071998	307	311	O
effects	10071998	312	319	O
,	10071998	320	321	O
a	10071998	322	323	O
short	10071998	324	329	O
recovery	10071998	330	338	O
time	10071998	339	343	O
,	10071998	344	345	O
and	10071998	346	349	O
,	10071998	350	351	O
if	10071998	352	354	O
possible	10071998	355	363	O
,	10071998	364	365	O
a	10071998	366	367	O
high	10071998	368	372	O
rate	10071998	373	377	O
of	10071998	378	380	O
successful	10071998	381	391	O
pregnancy	10071998	392	401	O
.	10071998	402	403	O

Spinal	10071998	404	410	O
anesthesia	10071998	411	421	O
is	10071998	422	424	O
often	10071998	425	430	O
used	10071998	431	435	O
in	10071998	436	438	O
this	10071998	439	443	O
institution	10071998	444	455	O
,	10071998	456	457	O
as	10071998	458	460	O
well	10071998	461	465	O
as	10071998	466	468	O
many	10071998	469	473	O
others	10071998	474	480	O
,	10071998	481	482	O
for	10071998	483	486	O
this	10071998	487	491	O
procedure	10071998	492	501	O
.	10071998	502	503	O

The	10071998	504	507	O
addition	10071998	508	516	O
of	10071998	517	519	O
fentanyl	10071998	520	528	O
may	10071998	529	532	O
be	10071998	533	535	O
effective	10071998	536	545	O
for	10071998	546	549	O
both	10071998	550	554	O
intraoperative	10071998	555	569	O
and	10071998	570	573	O
postoperative	10071998	574	587	O
pain	10071998	588	592	O
relief	10071998	593	599	O
.	10071998	600	601	O

We	10071998	602	604	O
assessed	10071998	605	613	O
the	10071998	614	617	O
effect	10071998	618	624	O
of	10071998	625	627	O
adding	10071998	628	634	B-Intervention
fentanyl	10071998	635	643	I-Intervention
to	10071998	644	646	I-Intervention
1.5	10071998	647	650	I-Intervention
%	10071998	651	652	I-Intervention
lidocaine	10071998	653	662	I-Intervention
in	10071998	663	665	O
women	10071998	666	671	B-Participant
undergoing	10071998	672	682	O
ultrasonically	10071998	683	697	B-Participant
guided	10071998	698	704	I-Participant
oocyte	10071998	705	711	I-Participant
retrieval	10071998	712	721	I-Participant
.	10071998	722	723	O

Seventy-eight	10071998	724	737	O
women	10071998	738	743	B-Participant
were	10071998	744	748	O
randomized	10071998	749	759	O
to	10071998	760	762	O
receive	10071998	763	770	O
45	10071998	771	773	O
mg	10071998	774	776	O
of	10071998	777	779	O
hyperbaric	10071998	780	790	B-Intervention
1.5	10071998	791	794	I-Intervention
%	10071998	795	796	I-Intervention
lidocaine	10071998	797	806	I-Intervention
with	10071998	807	811	I-Intervention
or	10071998	812	814	I-Intervention
without	10071998	815	822	I-Intervention
10	10071998	823	825	I-Intervention
microg	10071998	826	832	I-Intervention
of	10071998	833	835	I-Intervention
fentanyl	10071998	836	844	I-Intervention
.	10071998	845	846	O

Visual	10071998	847	853	B-Outcome
analog	10071998	854	860	I-Outcome
scale	10071998	861	866	I-Outcome
(	10071998	867	868	I-Outcome
VAS	10071998	869	872	I-Outcome
)	10071998	873	874	I-Outcome
pain	10071998	875	879	I-Outcome
scores	10071998	880	886	I-Outcome
were	10071998	887	891	O
lower	10071998	892	897	B-Observation
in	10071998	898	900	O
the	10071998	901	904	O
operating	10071998	905	914	O
room	10071998	915	919	O
(	10071998	920	921	O
OR	10071998	922	924	O
)	10071998	925	926	O
(	10071998	927	928	O
P	10071998	929	930	O
<	10071998	931	932	O
0.05	10071998	933	937	O
)	10071998	938	939	O
and	10071998	940	943	O
postanesthesia	10071998	944	958	O
care	10071998	959	963	O
unit	10071998	964	968	O
(	10071998	969	970	O
PACU	10071998	971	975	O
)	10071998	976	977	O
(	10071998	978	979	O
P	10071998	980	981	O
<	10071998	982	983	O
0.0005	10071998	984	990	O
)	10071998	991	992	O
for	10071998	993	996	O
the	10071998	997	1000	O
group	10071998	1001	1006	O
that	10071998	1007	1011	O
received	10071998	1012	1020	O
fentanyl	10071998	1021	1029	B-Intervention
.	10071998	1030	1031	O

In	10071998	1032	1034	O
addition	10071998	1035	1043	O
,	10071998	1044	1045	O
the	10071998	1046	1049	O
amount	10071998	1050	1056	B-Outcome
of	10071998	1057	1059	I-Outcome
narcotic	10071998	1060	1068	I-Outcome
required	10071998	1069	1077	I-Outcome
in	10071998	1078	1080	I-Outcome
the	10071998	1081	1084	I-Outcome
PACU	10071998	1085	1089	I-Outcome
was	10071998	1090	1093	O
less	10071998	1094	1098	B-Observation
in	10071998	1099	1101	O
the	10071998	1102	1105	O
fentanyl	10071998	1106	1114	B-Intervention
group	10071998	1115	1120	O
(	10071998	1121	1122	O
P	10071998	1123	1124	O
<	10071998	1125	1126	O
0.005	10071998	1127	1132	O
)	10071998	1133	1134	O
.	10071998	1135	1136	O

There	10071998	1137	1142	O
was	10071998	1143	1146	O
no	10071998	1147	1149	O
difference	10071998	1150	1160	B-Observation
in	10071998	1161	1163	O
VAS	10071998	1164	1167	B-Outcome
scores	10071998	1168	1174	I-Outcome
the	10071998	1175	1178	O
evening	10071998	1179	1186	O
of	10071998	1187	1189	O
or	10071998	1190	1192	O
24	10071998	1193	1195	O
h	10071998	1196	1197	O
after	10071998	1198	1203	O
the	10071998	1204	1207	O
procedure	10071998	1208	1217	O
.	10071998	1218	1219	O

The	10071998	1220	1223	O
amount	10071998	1224	1230	B-Outcome
of	10071998	1231	1233	I-Outcome
analgesics	10071998	1234	1244	I-Outcome
and	10071998	1245	1248	I-Outcome
narcotics	10071998	1249	1258	I-Outcome
required	10071998	1259	1267	I-Outcome
after	10071998	1268	1273	I-Outcome
discharge	10071998	1274	1283	I-Outcome
was	10071998	1284	1287	O
the	10071998	1288	1291	O
same	10071998	1292	1296	B-Observation
for	10071998	1297	1300	O
both	10071998	1301	1305	B-Intervention
groups	10071998	1306	1312	I-Intervention
.	10071998	1313	1314	O

Timed	10071998	1315	1320	B-Outcome
variables	10071998	1321	1330	I-Outcome
,	10071998	1331	1332	O
such	10071998	1333	1337	O
as	10071998	1338	1340	O
time	10071998	1341	1345	B-Outcome
to	10071998	1346	1348	I-Outcome
urination	10071998	1349	1358	I-Outcome
,	10071998	1359	1360	I-Outcome
ambulation	10071998	1361	1371	I-Outcome
,	10071998	1372	1373	I-Outcome
and	10071998	1374	1377	I-Outcome
discharge	10071998	1378	1387	I-Outcome
,	10071998	1388	1389	O
were	10071998	1390	1394	O
the	10071998	1395	1398	O
same	10071998	1399	1403	B-Observation
for	10071998	1404	1407	O
both	10071998	1408	1412	B-Intervention
groups	10071998	1413	1419	I-Intervention
of	10071998	1420	1422	O
women	10071998	1423	1428	B-Participant
.	10071998	1429	1430	O

The	10071998	1431	1434	O
addition	10071998	1435	1443	B-Intervention
of	10071998	1444	1446	I-Intervention
fentanyl	10071998	1447	1455	I-Intervention
to	10071998	1456	1458	I-Intervention
lidocaine	10071998	1459	1468	I-Intervention
for	10071998	1469	1472	O
transvaginal	10071998	1473	1485	B-Participant
oocyte	10071998	1486	1492	I-Participant
retrieval	10071998	1493	1502	I-Participant
results	10071998	1503	1510	O
in	10071998	1511	1513	O
a	10071998	1514	1515	O
more	10071998	1516	1520	B-Observation
comfortable	10071998	1521	1532	I-Observation
patient	10071998	1533	1540	O
in	10071998	1541	1543	O
the	10071998	1544	1547	O
OR	10071998	1548	1550	O
and	10071998	1551	1554	O
PACU	10071998	1555	1559	O
.	10071998	1560	1561	O

IMPLICATIONS	10071998	1562	1574	O
This	10071998	1575	1579	O
study	10071998	1580	1585	O
demonstrates	10071998	1586	1598	O
that	10071998	1599	1603	O
when	10071998	1604	1608	O
fentanyl	10071998	1609	1617	B-Intervention
is	10071998	1618	1620	I-Intervention
added	10071998	1621	1626	I-Intervention
to	10071998	1627	1629	I-Intervention
a	10071998	1630	1631	I-Intervention
local	10071998	1632	1637	I-Intervention
anesthetic	10071998	1638	1648	I-Intervention
,	10071998	1649	1650	I-Intervention
lidocaine	10071998	1651	1660	I-Intervention
,	10071998	1661	1662	O
with	10071998	1663	1667	O
spinal	10071998	1668	1674	O
anesthesia	10071998	1675	1685	O
for	10071998	1686	1689	O
egg	10071998	1690	1693	B-Participant
retrieval	10071998	1694	1703	I-Participant
procedures	10071998	1704	1714	I-Participant
,	10071998	1715	1716	O
patients	10071998	1717	1725	O
are	10071998	1726	1729	O
more	10071998	1730	1734	B-Observation
comfortable	10071998	1735	1746	I-Observation
during	10071998	1747	1753	O
the	10071998	1754	1757	O
procedure	10071998	1758	1767	B-Participant
compared	10071998	1768	1776	O
with	10071998	1777	1781	O
those	10071998	1782	1787	O
who	10071998	1788	1791	O
receive	10071998	1792	1799	O
lidocaine	10071998	1800	1809	B-Intervention
alone	10071998	1810	1815	I-Intervention
.	10071998	1816	1817	O

In	10071998	1818	1820	O
addition	10071998	1821	1829	O
,	10071998	1830	1831	O
the	10071998	1832	1835	O
narcotic	10071998	1836	1844	B-Outcome
requirements	10071998	1845	1857	I-Outcome
of	10071998	1858	1860	O
patients	10071998	1861	1869	O
are	10071998	1870	1873	O
less	10071998	1874	1878	B-Observation
in	10071998	1879	1881	O
the	10071998	1882	1885	O
postanesthesia	10071998	1886	1900	O
care	10071998	1901	1905	O
unit	10071998	1906	1910	O
.	10071998	1911	1912	O

Switching	10077140	0	9	O
patients	10077140	10	18	O
with	10077140	19	23	O
asthma	10077140	24	30	B-Participant
from	10077140	31	35	O
chlorofluorocarbon	10077140	36	54	B-Intervention
(	10077140	55	56	I-Intervention
CFC	10077140	57	60	I-Intervention
)	10077140	61	62	I-Intervention
albuterol	10077140	63	72	I-Intervention
to	10077140	73	75	O
hydrofluoroalkane-134a	10077140	76	98	B-Intervention
(	10077140	99	100	I-Intervention
HFA	10077140	101	104	I-Intervention
)	10077140	105	106	I-Intervention
albuterol	10077140	107	116	I-Intervention
.	10077140	117	118	O

Chlorofluorocarbon	10077140	119	137	O
(	10077140	138	139	O
CFC	10077140	140	143	O
)	10077140	144	145	O
propellants	10077140	146	157	O
deplete	10077140	158	165	O
stratospheric	10077140	166	179	O
ozone	10077140	180	185	O
.	10077140	186	187	O

Production	10077140	188	198	O
and	10077140	199	202	O
use	10077140	203	206	O
of	10077140	207	209	O
CFCs	10077140	210	214	O
,	10077140	215	216	O
except	10077140	217	223	O
for	10077140	224	227	O
certain	10077140	228	235	O
critical	10077140	236	244	O
exemptions	10077140	245	255	O
,	10077140	256	257	O
has	10077140	258	261	O
been	10077140	262	266	O
prohibited	10077140	267	277	O
by	10077140	278	280	O
the	10077140	281	284	O
Montreal	10077140	285	293	O
Protocol	10077140	294	302	O
.	10077140	303	304	O

Use	10077140	305	308	O
of	10077140	309	311	O
CFCs	10077140	312	316	O
as	10077140	317	319	O
propellants	10077140	320	331	O
in	10077140	332	334	O
metered-dose	10077140	335	347	O
inhalers	10077140	348	356	O
(	10077140	357	358	O
MDIs	10077140	359	363	O
)	10077140	364	365	O
is	10077140	366	368	O
still	10077140	369	374	O
allowed	10077140	375	382	O
,	10077140	383	384	O
but	10077140	385	388	O
the	10077140	389	392	O
U.S.	10077140	393	397	O
Food	10077140	398	402	O
and	10077140	403	406	O
Drug	10077140	407	411	O
Administration	10077140	412	426	O
is	10077140	427	429	O
planning	10077140	430	438	O
the	10077140	439	442	O
transition	10077140	443	453	O
to	10077140	454	456	O
alternative	10077140	457	468	O
propellants	10077140	469	480	O
for	10077140	481	484	O
use	10077140	485	488	O
in	10077140	489	491	O
MDIs	10077140	492	496	O
.	10077140	497	498	O

Hydrofluoroalkane-134a	10077140	499	521	O
(	10077140	522	523	O
HFA	10077140	524	527	O
)	10077140	528	529	O
,	10077140	530	531	O
a	10077140	532	533	O
non-ozone-depleting	10077140	534	553	O
propellant	10077140	554	564	O
,	10077140	565	566	O
has	10077140	567	570	O
been	10077140	571	575	O
used	10077140	576	580	O
to	10077140	581	583	O
reformulate	10077140	584	595	O
albuterol	10077140	596	605	O
(	10077140	606	607	O
HFA	10077140	608	611	O
albuterol	10077140	612	621	O
)	10077140	622	623	O
.	10077140	624	625	O

This	10077140	626	630	O
study	10077140	631	636	O
evaluates	10077140	637	646	O
whether	10077140	647	654	O
comparable	10077140	655	665	B-Outcome
safety	10077140	666	672	I-Outcome
and	10077140	673	676	O
efficacy	10077140	677	685	B-Outcome
continues	10077140	686	695	B-Observation
for	10077140	696	699	O
12	10077140	700	702	O
weeks	10077140	703	708	O
after	10077140	709	714	O
patients	10077140	715	723	O
with	10077140	724	728	O
asthma	10077140	729	735	B-Participant
are	10077140	736	739	O
switched	10077140	740	748	B-Intervention
from	10077140	749	753	I-Intervention
CFC	10077140	754	757	I-Intervention
albuterol	10077140	758	767	I-Intervention
to	10077140	768	770	I-Intervention
HFA	10077140	771	774	I-Intervention
albuterol	10077140	775	784	I-Intervention
.	10077140	785	786	O

Patients	10077140	787	795	O
with	10077140	796	800	O
asthma	10077140	801	807	B-Participant
stabilized	10077140	808	818	O
on	10077140	819	821	O
CFC	10077140	822	825	B-Intervention
albuterol	10077140	826	835	I-Intervention
during	10077140	836	842	O
a	10077140	843	844	O
12-week	10077140	845	852	O
safety	10077140	853	859	O
and	10077140	860	863	O
efficacy	10077140	864	872	O
trial	10077140	873	878	O
were	10077140	879	883	O
randomized	10077140	884	894	O
to	10077140	895	897	O
either	10077140	898	904	O
continue	10077140	905	913	B-Intervention
receiving	10077140	914	923	I-Intervention
CFC	10077140	924	927	I-Intervention
albuterol	10077140	928	937	I-Intervention
or	10077140	938	940	O
to	10077140	941	943	O
be	10077140	944	946	O
switched	10077140	947	955	B-Intervention
to	10077140	956	958	I-Intervention
receive	10077140	959	966	I-Intervention
HFA	10077140	967	970	I-Intervention
albuterol	10077140	971	980	I-Intervention
in	10077140	981	983	O
a	10077140	984	985	O
yearlong	10077140	986	994	O
safety	10077140	995	1001	B-Outcome
and	10077140	1002	1005	O
efficacy	10077140	1006	1014	B-Outcome
trial	10077140	1015	1020	O
.	10077140	1021	1022	O

Safety	10077140	1023	1029	B-Outcome
and	10077140	1030	1033	O
efficacy	10077140	1034	1042	B-Outcome
were	10077140	1043	1047	O
compared	10077140	1048	1056	O
over	10077140	1057	1061	O
the	10077140	1062	1065	O
first	10077140	1066	1071	O
12	10077140	1072	1074	O
weeks	10077140	1075	1080	O
of	10077140	1081	1083	O
the	10077140	1084	1087	O
yearlong	10077140	1088	1096	O
trial	10077140	1097	1102	O
between	10077140	1103	1110	O
patients	10077140	1111	1119	O
who	10077140	1120	1123	O
had	10077140	1124	1127	O
remained	10077140	1128	1136	B-Intervention
on	10077140	1137	1139	I-Intervention
CFC	10077140	1140	1143	I-Intervention
albuterol	10077140	1144	1153	I-Intervention
and	10077140	1154	1157	O
those	10077140	1158	1163	O
who	10077140	1164	1167	O
had	10077140	1168	1171	O
been	10077140	1172	1176	O
switched	10077140	1177	1185	B-Intervention
to	10077140	1186	1188	I-Intervention
HFA	10077140	1189	1192	I-Intervention
albuterol	10077140	1193	1202	I-Intervention
.	10077140	1203	1204	O

Bronchodilator	10077140	1205	1219	B-Outcome
efficacy	10077140	1220	1228	I-Outcome
was	10077140	1229	1232	O
evaluated	10077140	1233	1242	O
by	10077140	1243	1245	O
serial	10077140	1246	1252	O
spirometry	10077140	1253	1263	O
for	10077140	1264	1267	O
6	10077140	1268	1269	O
hr	10077140	1270	1272	O
after	10077140	1273	1278	O
the	10077140	1279	1282	O
patients	10077140	1283	1291	O
self-administered	10077140	1292	1309	O
the	10077140	1310	1313	O
study	10077140	1314	1319	B-Intervention
drug	10077140	1320	1324	I-Intervention
in	10077140	1325	1327	O
the	10077140	1328	1331	O
clinic	10077140	1332	1338	O
.	10077140	1339	1340	O

Safety	10077140	1341	1347	B-Outcome
was	10077140	1348	1351	O
assessed	10077140	1352	1360	O
by	10077140	1361	1363	O
measuring	10077140	1364	1373	O
changes	10077140	1374	1381	B-Observation
in	10077140	1382	1384	O
pulse	10077140	1385	1390	B-Outcome
rate	10077140	1391	1395	I-Outcome
,	10077140	1396	1397	O
blood	10077140	1398	1403	B-Outcome
pressure	10077140	1404	1412	I-Outcome
,	10077140	1413	1414	O
and	10077140	1415	1418	O
electrocardiogram	10077140	1419	1436	B-Outcome
(	10077140	1437	1438	I-Outcome
ECG	10077140	1439	1442	I-Outcome
)	10077140	1443	1444	I-Outcome
intervals	10077140	1445	1454	I-Outcome
after	10077140	1455	1460	O
dosing	10077140	1461	1467	O
with	10077140	1468	1472	O
study	10077140	1473	1478	B-Intervention
drug	10077140	1479	1483	I-Intervention
,	10077140	1484	1485	O
monitoring	10077140	1486	1496	O
adverse	10077140	1497	1504	B-Outcome
events	10077140	1505	1511	I-Outcome
,	10077140	1512	1513	O
and	10077140	1514	1517	O
performing	10077140	1518	1528	O
prestudy	10077140	1529	1537	O
and	10077140	1538	1541	O
poststudy	10077140	1542	1551	O
laboratory	10077140	1552	1562	O
testing	10077140	1563	1570	O
and	10077140	1571	1574	O
physical	10077140	1575	1583	O
examinations	10077140	1584	1596	O
.	10077140	1597	1598	O

No	10077140	1599	1601	O
significant	10077140	1602	1613	B-Observation
differences	10077140	1614	1625	I-Observation
in	10077140	1626	1628	O
bronchodilator	10077140	1629	1643	B-Outcome
efficacy	10077140	1644	1652	I-Outcome
between	10077140	1653	1660	O
the	10077140	1661	1664	O
patients	10077140	1665	1673	O
continuing	10077140	1674	1684	B-Intervention
to	10077140	1685	1687	I-Intervention
receive	10077140	1688	1695	I-Intervention
CFC	10077140	1696	1699	I-Intervention
albuterol	10077140	1700	1709	I-Intervention
and	10077140	1710	1713	O
those	10077140	1714	1719	O
switched	10077140	1720	1728	B-Intervention
to	10077140	1729	1731	I-Intervention
HFA	10077140	1732	1735	I-Intervention
albuterol	10077140	1736	1745	I-Intervention
were	10077140	1746	1750	O
found	10077140	1751	1756	O
in	10077140	1757	1759	O
the	10077140	1760	1763	O
12	10077140	1764	1766	O
weeks	10077140	1767	1772	O
after	10077140	1773	1778	O
the	10077140	1779	1782	O
switch	10077140	1783	1789	O
.	10077140	1790	1791	O

No	10077140	1792	1794	O
differences	10077140	1795	1806	B-Observation
between	10077140	1807	1814	B-Intervention
the	10077140	1815	1818	I-Intervention
two	10077140	1819	1822	I-Intervention
products	10077140	1823	1831	I-Intervention
were	10077140	1832	1836	O
found	10077140	1837	1842	O
for	10077140	1843	1846	O
changes	10077140	1847	1854	B-Outcome
in	10077140	1855	1857	I-Outcome
pulse	10077140	1858	1863	I-Outcome
rate	10077140	1864	1868	I-Outcome
,	10077140	1869	1870	I-Outcome
blood	10077140	1871	1876	I-Outcome
pressure	10077140	1877	1885	I-Outcome
,	10077140	1886	1887	I-Outcome
and	10077140	1888	1891	I-Outcome
ECG	10077140	1892	1895	I-Outcome
intervals	10077140	1896	1905	I-Outcome
.	10077140	1906	1907	O

Adverse	10077140	1908	1915	B-Outcome
event	10077140	1916	1921	I-Outcome
profiles	10077140	1922	1930	I-Outcome
were	10077140	1931	1935	O
similar	10077140	1936	1943	B-Observation
for	10077140	1944	1947	O
the	10077140	1948	1951	O
two	10077140	1952	1955	B-Intervention
products	10077140	1956	1964	I-Intervention
,	10077140	1965	1966	O
except	10077140	1967	1973	O
the	10077140	1974	1977	O
patients	10077140	1978	1986	O
remaining	10077140	1987	1996	B-Intervention
on	10077140	1997	1999	I-Intervention
CFC	10077140	2000	2003	I-Intervention
albuterol	10077140	2004	2013	I-Intervention
reported	10077140	2014	2022	O
increased	10077140	2023	2032	B-Outcome
asthma	10077140	2033	2039	I-Outcome
symptoms	10077140	2040	2048	I-Outcome
and	10077140	2049	2052	I-Outcome
rhinitis	10077140	2053	2061	I-Outcome
significantly	10077140	2062	2075	B-Observation
more	10077140	2076	2080	I-Observation
often	10077140	2081	2086	I-Observation
than	10077140	2087	2091	O
the	10077140	2092	2095	O
patients	10077140	2096	2104	O
switched	10077140	2105	2113	B-Intervention
to	10077140	2114	2116	I-Intervention
HFA	10077140	2117	2120	I-Intervention
albuterol	10077140	2121	2130	I-Intervention
.	10077140	2131	2132	O

No	10077140	2133	2135	O
clinically	10077140	2136	2146	B-Observation
meaningful	10077140	2147	2157	I-Observation
changes	10077140	2158	2165	I-Observation
in	10077140	2166	2168	O
laboratory	10077140	2169	2179	B-Outcome
tests	10077140	2180	2185	I-Outcome
or	10077140	2186	2188	O
physical	10077140	2189	2197	B-Outcome
examinations	10077140	2198	2210	I-Outcome
were	10077140	2211	2215	O
found	10077140	2216	2221	O
in	10077140	2222	2224	O
either	10077140	2225	2231	B-Intervention
treatment	10077140	2232	2241	I-Intervention
group	10077140	2242	2247	I-Intervention
.	10077140	2248	2249	O

Patients	10077140	2250	2258	O
with	10077140	2259	2263	O
asthma	10077140	2264	2270	B-Participant
switched	10077140	2271	2279	B-Intervention
from	10077140	2280	2284	I-Intervention
CFC	10077140	2285	2288	I-Intervention
albuterol	10077140	2289	2298	I-Intervention
to	10077140	2299	2301	I-Intervention
HFA	10077140	2302	2305	I-Intervention
albuterol	10077140	2306	2315	I-Intervention
receive	10077140	2316	2323	O
comparable	10077140	2324	2334	B-Observation
bronchodilation	10077140	2335	2350	B-Outcome
with	10077140	2351	2355	O
a	10077140	2356	2357	O
similar	10077140	2358	2365	B-Observation
safety	10077140	2366	2372	B-Outcome
profile	10077140	2373	2380	O
as	10077140	2381	2383	O
those	10077140	2384	2389	O
continuing	10077140	2390	2400	B-Intervention
to	10077140	2401	2403	I-Intervention
receive	10077140	2404	2411	I-Intervention
CFC	10077140	2412	2415	I-Intervention
albuterol	10077140	2416	2425	I-Intervention
.	10077140	2426	2427	O

Behavioral	10078672	0	10	B-Outcome
and	10078672	11	14	I-Outcome
physiological	10078672	15	28	I-Outcome
effects	10078672	29	36	I-Outcome
of	10078672	37	39	O
remifentanil	10078672	40	52	B-Intervention
and	10078672	53	56	O
alfentanil	10078672	57	67	B-Intervention
in	10078672	68	70	O
healthy	10078672	71	78	B-Participant
volunteers	10078672	79	89	O
.	10078672	90	91	O

BACKGROUND	10078672	92	102	O
The	10078672	103	106	O
subjective	10078672	107	117	O
and	10078672	118	121	O
psychomotor	10078672	122	133	O
effects	10078672	134	141	O
of	10078672	142	144	O
remifentanil	10078672	145	157	O
have	10078672	158	162	O
not	10078672	163	166	O
been	10078672	167	171	O
evaluated	10078672	172	181	O
.	10078672	182	183	O

Accordingly	10078672	184	195	O
,	10078672	196	197	O
the	10078672	198	201	O
authors	10078672	202	209	O
used	10078672	210	214	O
mood	10078672	215	219	B-Outcome
inventories	10078672	220	231	I-Outcome
and	10078672	232	235	O
psychomotor	10078672	236	247	B-Outcome
tests	10078672	248	253	I-Outcome
to	10078672	254	256	O
characterize	10078672	257	269	O
the	10078672	270	273	O
effects	10078672	274	281	O
of	10078672	282	284	O
remifentanil	10078672	285	297	B-Intervention
in	10078672	298	300	O
healthy	10078672	301	308	B-Participant
,	10078672	309	310	O
non-drug-abusing	10078672	311	327	B-Participant
volunteers	10078672	328	338	O
.	10078672	339	340	O

Alfentanil	10078672	341	351	B-Intervention
was	10078672	352	355	O
used	10078672	356	360	O
as	10078672	361	363	O
a	10078672	364	365	O
comparator	10078672	366	376	O
drug	10078672	377	381	O
.	10078672	382	383	O

METHODS	10078672	384	391	O
Ten	10078672	392	395	O
healthy	10078672	396	403	B-Participant
volunteers	10078672	404	414	O
were	10078672	415	419	O
enrolled	10078672	420	428	O
in	10078672	429	431	O
a	10078672	432	433	O
randomized	10078672	434	444	O
,	10078672	445	446	O
double-blinded	10078672	447	461	O
,	10078672	462	463	O
placebo-controlled	10078672	464	482	O
,	10078672	483	484	O
crossover	10078672	485	494	O
trial	10078672	495	500	O
in	10078672	501	503	O
which	10078672	504	509	O
they	10078672	510	514	O
received	10078672	515	523	O
an	10078672	524	526	O
infusion	10078672	527	535	O
of	10078672	536	538	O
saline	10078672	539	545	B-Intervention
,	10078672	546	547	O
remifentanil	10078672	548	560	B-Intervention
,	10078672	561	562	O
or	10078672	563	565	O
alfentanil	10078672	566	576	B-Intervention
for	10078672	577	580	O
120	10078672	581	584	O
min	10078672	585	588	O
.	10078672	589	590	O

The	10078672	591	594	O
age-	10078672	595	599	O
and	10078672	600	603	O
weight-adjusted	10078672	604	619	O
infusions	10078672	620	629	O
(	10078672	630	631	O
determined	10078672	632	642	O
with	10078672	643	647	O
STANPUMP	10078672	648	656	O
,	10078672	657	658	O
a	10078672	659	660	O
computer	10078672	661	669	O
modeling	10078672	670	678	O
software	10078672	679	687	O
package	10078672	688	695	O
)	10078672	696	697	O
were	10078672	698	702	O
given	10078672	703	708	O
to	10078672	709	711	O
achieve	10078672	712	719	O
three	10078672	720	725	O
predicted	10078672	726	735	O
constant	10078672	736	744	O
plasma	10078672	745	751	O
levels	10078672	752	758	O
for	10078672	759	762	O
40	10078672	763	765	O
min	10078672	766	769	O
each	10078672	770	774	O
of	10078672	775	777	O
remifentanil	10078672	778	790	B-Intervention
(	10078672	791	792	O
0.75	10078672	793	797	O
,	10078672	798	799	O
1.5	10078672	800	803	O
,	10078672	804	805	O
and	10078672	806	809	O
3	10078672	810	811	O
ng/ml	10078672	812	817	O
)	10078672	818	819	O
and	10078672	820	823	O
alfentanil	10078672	824	834	B-Intervention
(	10078672	835	836	O
16	10078672	837	839	O
,	10078672	840	841	O
32	10078672	842	844	O
,	10078672	845	846	O
and	10078672	847	850	O
64	10078672	851	853	O
ng/ml	10078672	854	859	O
)	10078672	860	861	O
.	10078672	862	863	O

Mood	10078672	864	868	B-Outcome
forms	10078672	869	874	I-Outcome
and	10078672	875	878	O
psychomotor	10078672	879	890	B-Outcome
tests	10078672	891	896	I-Outcome
were	10078672	897	901	O
completed	10078672	902	911	O
,	10078672	912	913	O
and	10078672	914	917	O
miosis	10078672	918	924	B-Outcome
was	10078672	925	928	O
assessed	10078672	929	937	O
,	10078672	938	939	O
during	10078672	940	946	O
and	10078672	947	950	O
after	10078672	951	956	O
the	10078672	957	960	O
infusions	10078672	961	970	O
.	10078672	971	972	O

In	10078672	973	975	O
addition	10078672	976	984	O
,	10078672	985	986	O
analgesia	10078672	987	996	B-Outcome
was	10078672	997	1000	O
tested	10078672	1001	1007	O
at	10078672	1008	1010	O
each	10078672	1011	1015	O
dose	10078672	1016	1020	O
level	10078672	1021	1026	O
using	10078672	1027	1032	O
a	10078672	1033	1034	O
cold-pressor	10078672	1035	1047	O
test	10078672	1048	1052	O
.	10078672	1053	1054	O

RESULTS	10078672	1055	1062	O
Remifentanil	10078672	1063	1075	B-Intervention
had	10078672	1076	1079	O
prototypic	10078672	1080	1090	B-Outcome
micro-like	10078672	1091	1101	I-Outcome
opioid	10078672	1102	1108	I-Outcome
subjective	10078672	1109	1119	I-Outcome
effects	10078672	1120	1127	I-Outcome
,	10078672	1128	1129	O
impaired	10078672	1130	1138	B-Observation
psychomotor	10078672	1139	1150	B-Outcome
performance	10078672	1151	1162	I-Outcome
,	10078672	1163	1164	O
and	10078672	1165	1168	O
produced	10078672	1169	1177	B-Observation
analgesia	10078672	1178	1187	B-Outcome
.	10078672	1188	1189	O

Alfentanil	10078672	1190	1200	B-Intervention
at	10078672	1201	1203	O
the	10078672	1204	1207	O
dose	10078672	1208	1212	O
range	10078672	1213	1218	O
tested	10078672	1219	1225	O
had	10078672	1226	1229	O
more	10078672	1230	1234	B-Observation
mild	10078672	1235	1239	B-Outcome
effects	10078672	1240	1247	I-Outcome
on	10078672	1248	1250	O
these	10078672	1251	1256	O
measures	10078672	1257	1265	O
,	10078672	1266	1267	O
and	10078672	1268	1271	O
the	10078672	1272	1275	O
analgesia	10078672	1276	1285	B-Outcome
data	10078672	1286	1290	O
indicated	10078672	1291	1300	O
that	10078672	1301	1305	O
a	10078672	1306	1307	O
40:1	10078672	1308	1312	B-Observation
potency	10078672	1313	1320	I-Observation
ratio	10078672	1321	1326	I-Observation
,	10078672	1327	1328	O
rather	10078672	1329	1335	O
than	10078672	1336	1340	O
the	10078672	1341	1344	O
20:1	10078672	1345	1349	O
ratio	10078672	1350	1355	O
we	10078672	1356	1358	O
used	10078672	1359	1363	O
,	10078672	1364	1365	O
may	10078672	1366	1369	O
exist	10078672	1370	1375	O
between	10078672	1376	1383	O
remifentanil	10078672	1384	1396	B-Intervention
and	10078672	1397	1400	O
alfentanil	10078672	1401	1411	B-Intervention
.	10078672	1412	1413	O

A	10078672	1414	1415	O
psychomotor	10078672	1416	1427	B-Outcome
test	10078672	1428	1432	I-Outcome
administered	10078672	1433	1445	O
60	10078672	1446	1448	O
min	10078672	1449	1452	O
after	10078672	1453	1458	O
the	10078672	1459	1462	O
remifentanil	10078672	1463	1475	B-Intervention
infusion	10078672	1476	1484	I-Intervention
was	10078672	1485	1488	O
discontinued	10078672	1489	1501	O
showed	10078672	1502	1508	O
that	10078672	1509	1513	O
the	10078672	1514	1517	O
volunteers	10078672	1518	1528	O
were	10078672	1529	1533	O
still	10078672	1534	1539	O
impaired	10078672	1540	1548	B-Observation
,	10078672	1549	1550	O
although	10078672	1551	1559	O
they	10078672	1560	1564	O
reported	10078672	1565	1573	O
feeling	10078672	1574	1581	O
no	10078672	1582	1584	O
drug	10078672	1585	1589	B-Outcome
effects	10078672	1590	1597	I-Outcome
.	10078672	1598	1599	O

CONCLUSIONS	10078672	1600	1611	O
The	10078672	1612	1615	O
notion	10078672	1616	1622	O
that	10078672	1623	1627	O
the	10078672	1628	1631	O
pharmacodynamic	10078672	1632	1647	B-Outcome
effects	10078672	1648	1655	I-Outcome
of	10078672	1656	1658	O
remifentanil	10078672	1659	1671	B-Intervention
are	10078672	1672	1675	O
extremely	10078672	1676	1685	B-Observation
short-lived	10078672	1686	1697	I-Observation
after	10078672	1698	1703	O
the	10078672	1704	1707	O
drug	10078672	1708	1712	O
is	10078672	1713	1715	O
no	10078672	1716	1718	O
longer	10078672	1719	1725	O
administered	10078672	1726	1738	O
must	10078672	1739	1743	O
be	10078672	1744	1746	O
questioned	10078672	1747	1757	O
given	10078672	1758	1763	O
our	10078672	1764	1767	O
findings	10078672	1768	1776	O
that	10078672	1777	1781	O
psychomotor	10078672	1782	1793	B-Outcome
effects	10078672	1794	1801	I-Outcome
were	10078672	1802	1806	O
still	10078672	1807	1812	O
apparent	10078672	1813	1821	B-Observation
1	10078672	1822	1823	O
h	10078672	1824	1825	O
after	10078672	1826	1831	O
the	10078672	1832	1835	O
infusion	10078672	1836	1844	B-Intervention
was	10078672	1845	1848	O
discontinued	10078672	1849	1861	O
.	10078672	1862	1863	O

Comparison	10078673	0	10	O
of	10078673	11	13	O
three	10078673	14	19	O
solutions	10078673	20	29	B-Intervention
of	10078673	30	32	I-Intervention
ropivacaine/fentanyl	10078673	33	53	I-Intervention
for	10078673	54	57	O
postoperative	10078673	58	71	B-Outcome
patient-controlled	10078673	72	90	I-Outcome
epidural	10078673	91	99	I-Outcome
analgesia	10078673	100	109	I-Outcome
.	10078673	110	111	O

BACKGROUND	10078673	112	122	O
Ropivacaine	10078673	123	134	O
,	10078673	135	136	O
0.2	10078673	137	140	O
%	10078673	141	142	O
,	10078673	143	144	O
is	10078673	145	147	O
a	10078673	148	149	O
new	10078673	150	153	O
local	10078673	154	159	O
anesthetic	10078673	160	170	O
approved	10078673	171	179	O
for	10078673	180	183	O
epidural	10078673	184	192	O
analgesia	10078673	193	202	O
.	10078673	203	204	O

The	10078673	205	208	O
addition	10078673	209	217	O
of	10078673	218	220	O
4	10078673	221	222	O
microg/ml	10078673	223	232	O
fentanyl	10078673	233	241	O
improves	10078673	242	250	O
analgesia	10078673	251	260	O
from	10078673	261	265	O
epidural	10078673	266	274	O
ropivacaine	10078673	275	286	O
.	10078673	287	288	O

Use	10078673	289	292	O
of	10078673	293	295	O
a	10078673	296	297	O
lower	10078673	298	303	O
concentration	10078673	304	317	O
of	10078673	318	320	O
ropivacaine-fentanyl	10078673	321	341	O
may	10078673	342	345	O
further	10078673	346	353	O
improve	10078673	354	361	O
analgesia	10078673	362	371	O
or	10078673	372	374	O
decrease	10078673	375	383	O
side	10078673	384	388	O
effects	10078673	389	396	O
.	10078673	397	398	O

METHODS	10078673	399	406	O
Thirty	10078673	407	413	O
patients	10078673	414	422	O
undergoing	10078673	423	433	O
lower	10078673	434	439	B-Participant
abdominal	10078673	440	449	I-Participant
surgery	10078673	450	457	I-Participant
were	10078673	458	462	O
randomized	10078673	463	473	O
in	10078673	474	476	O
a	10078673	477	478	O
double-blinded	10078673	479	493	O
manner	10078673	494	500	O
to	10078673	501	503	O
receive	10078673	504	511	O
one	10078673	512	515	O
of	10078673	516	518	O
three	10078673	519	524	O
solutions	10078673	525	534	O
:	10078673	535	536	O
0.2	10078673	537	540	B-Intervention
%	10078673	541	542	I-Intervention
ropivacaine-4	10078673	543	556	I-Intervention
microg	10078673	557	563	I-Intervention
fentanyl	10078673	564	572	I-Intervention
0.1	10078673	573	576	B-Intervention
%	10078673	577	578	I-Intervention
ropivacaine-2	10078673	579	592	I-Intervention
microg	10078673	593	599	I-Intervention
fentanyl	10078673	600	608	I-Intervention
,	10078673	609	610	O
or	10078673	611	613	O
0.05	10078673	614	618	B-Intervention
%	10078673	619	620	I-Intervention
ropivacaine-1	10078673	621	634	I-Intervention
microg	10078673	635	641	I-Intervention
fentanyl	10078673	642	650	I-Intervention
for	10078673	651	654	O
patient-controlled	10078673	655	673	B-Outcome
epidural	10078673	674	682	I-Outcome
analgesia	10078673	683	692	I-Outcome
after	10078673	693	698	O
standardized	10078673	699	711	O
combined	10078673	712	720	O
epidural	10078673	721	729	O
and	10078673	730	733	O
general	10078673	734	741	O
anesthesia	10078673	742	752	O
.	10078673	753	754	O

Patient-controlled	10078673	755	773	B-Outcome
epidural	10078673	774	782	I-Outcome
analgesia	10078673	783	792	I-Outcome
settings	10078673	793	801	O
and	10078673	802	805	O
adjustments	10078673	806	817	O
for	10078673	818	821	O
the	10078673	822	825	O
three	10078673	826	831	O
solutions	10078673	832	841	O
were	10078673	842	846	O
standardized	10078673	847	859	O
to	10078673	860	862	O
deliver	10078673	863	870	O
equivalent	10078673	871	881	O
drug	10078673	882	886	O
doses	10078673	887	892	O
.	10078673	893	894	O

Pain	10078673	895	899	B-Outcome
scores	10078673	900	906	I-Outcome
(	10078673	907	908	O
rest	10078673	909	913	B-Outcome
,	10078673	914	915	O
cough	10078673	916	921	B-Outcome
,	10078673	922	923	O
and	10078673	924	927	O
ambulation	10078673	928	938	B-Outcome
)	10078673	939	940	O
,	10078673	941	942	O
side	10078673	943	947	B-Outcome
effects	10078673	948	955	I-Outcome
(	10078673	956	957	O
nausea	10078673	958	964	B-Outcome
,	10078673	965	966	O
pruritus	10078673	967	975	B-Outcome
,	10078673	976	977	O
sedation	10078673	978	986	B-Outcome
,	10078673	987	988	O
motor	10078673	989	994	B-Outcome
block	10078673	995	1000	I-Outcome
,	10078673	1001	1002	O
hypotension	10078673	1003	1014	B-Outcome
,	10078673	1015	1016	O
and	10078673	1017	1020	O
orthostasis	10078673	1021	1032	B-Outcome
)	10078673	1033	1034	O
,	10078673	1035	1036	O
and	10078673	1037	1040	O
patient-controlled	10078673	1041	1059	B-Outcome
epidural	10078673	1060	1068	I-Outcome
analgesia	10078673	1069	1078	I-Outcome
consumption	10078673	1079	1090	I-Outcome
were	10078673	1091	1095	O
measured	10078673	1096	1104	O
for	10078673	1105	1108	O
48	10078673	1109	1111	O
h.	10078673	1112	1114	O
RESULTS	10078673	1115	1122	O
All	10078673	1123	1126	B-Intervention
three	10078673	1127	1132	I-Intervention
solutions	10078673	1133	1142	I-Intervention
produced	10078673	1143	1151	O
equivalent	10078673	1152	1162	B-Observation
analgesia	10078673	1163	1172	B-Outcome
.	10078673	1173	1174	O

Motor	10078673	1175	1180	B-Outcome
block	10078673	1181	1186	I-Outcome
was	10078673	1187	1190	O
significantly	10078673	1191	1204	B-Observation
more	10078673	1205	1209	I-Observation
common	10078673	1210	1216	I-Observation
(	10078673	1217	1218	O
30	10078673	1219	1221	B-Count
vs.	10078673	1222	1225	O
0	10078673	1226	1227	B-Count
%	10078673	1228	1229	I-Count
)	10078673	1230	1231	O
and	10078673	1232	1235	O
more	10078673	1236	1240	B-Observation
intense	10078673	1241	1248	I-Observation
with	10078673	1249	1253	O
the	10078673	1254	1257	O
0.2	10078673	1258	1261	B-Intervention
%	10078673	1262	1263	I-Intervention
ropivacaine-4	10078673	1264	1277	I-Intervention
microg	10078673	1278	1284	I-Intervention
fentanyl	10078673	1285	1293	I-Intervention
solution	10078673	1294	1302	I-Intervention
.	10078673	1303	1304	O

Other	10078673	1305	1310	B-Outcome
side	10078673	1311	1315	I-Outcome
effects	10078673	1316	1323	I-Outcome
were	10078673	1324	1328	O
equivalent	10078673	1329	1339	B-Observation
between	10078673	1340	1347	B-Intervention
solutions	10078673	1348	1357	I-Intervention
and	10078673	1358	1361	O
mild	10078673	1362	1366	B-Observation
in	10078673	1367	1369	O
severity	10078673	1370	1378	B-Outcome
.	10078673	1379	1380	O

A	10078673	1381	1382	O
significantly	10078673	1383	1396	B-Observation
smaller	10078673	1397	1404	I-Observation
volume	10078673	1405	1411	B-Outcome
of	10078673	1412	1414	O
0.2	10078673	1415	1418	B-Intervention
%	10078673	1419	1420	I-Intervention
ropivacaine-4	10078673	1421	1434	I-Intervention
microg	10078673	1435	1441	I-Intervention
fentanyl	10078673	1442	1450	I-Intervention
solution	10078673	1451	1459	I-Intervention
was	10078673	1460	1463	O
used	10078673	1464	1468	O
,	10078673	1469	1470	O
whereas	10078673	1471	1478	O
the	10078673	1479	1482	O
0.1	10078673	1483	1486	B-Intervention
%	10078673	1487	1488	I-Intervention
ropivacaine-2	10078673	1489	1502	I-Intervention
microg	10078673	1503	1509	I-Intervention
fentanyl	10078673	1510	1518	I-Intervention
group	10078673	1519	1524	O
used	10078673	1525	1529	O
a	10078673	1530	1531	O
significantly	10078673	1532	1545	B-Observation
greater	10078673	1546	1553	I-Observation
amount	10078673	1554	1560	B-Outcome
of	10078673	1561	1563	I-Outcome
ropivacaine	10078673	1564	1575	I-Outcome
and	10078673	1576	1579	I-Outcome
fentanyl	10078673	1580	1588	I-Outcome
.	10078673	1589	1590	O

CONCLUSIONS	10078673	1591	1602	O
Lesser	10078673	1603	1609	B-Intervention
concentrations	10078673	1610	1624	I-Intervention
of	10078673	1625	1627	I-Intervention
ropivacaine	10078673	1628	1639	I-Intervention
and	10078673	1640	1643	I-Intervention
fentanyl	10078673	1644	1652	I-Intervention
provide	10078673	1653	1660	O
comparable	10078673	1661	1671	B-Observation
analgesia	10078673	1672	1681	B-Outcome
with	10078673	1682	1686	O
less	10078673	1687	1691	B-Observation
motor	10078673	1692	1697	B-Outcome
block	10078673	1698	1703	I-Outcome
despite	10078673	1704	1711	O
the	10078673	1712	1715	O
use	10078673	1716	1719	O
of	10078673	1720	1722	O
similar	10078673	1723	1730	B-Observation
amounts	10078673	1731	1738	B-Outcome
of	10078673	1739	1741	I-Outcome
ropivacaine	10078673	1742	1753	I-Outcome
and	10078673	1754	1757	I-Outcome
fentanyl	10078673	1758	1766	I-Outcome
.	10078673	1767	1768	O

This	10078673	1769	1773	O
finding	10078673	1774	1781	O
suggests	10078673	1782	1790	O
that	10078673	1791	1795	O
concentration	10078673	1796	1809	B-Intervention
of	10078673	1810	1812	I-Intervention
local	10078673	1813	1818	I-Intervention
anesthetic	10078673	1819	1829	I-Intervention
solution	10078673	1830	1838	I-Intervention
at	10078673	1839	1841	I-Intervention
low	10078673	1842	1845	I-Intervention
doses	10078673	1846	1851	I-Intervention
is	10078673	1852	1854	O
a	10078673	1855	1856	O
primary	10078673	1857	1864	B-Observation
determinant	10078673	1865	1876	I-Observation
of	10078673	1877	1879	O
motor	10078673	1880	1885	B-Outcome
block	10078673	1886	1891	I-Outcome
with	10078673	1892	1896	I-Outcome
patient-controlled	10078673	1897	1915	I-Outcome
epidural	10078673	1916	1924	I-Outcome
analgesia	10078673	1925	1934	I-Outcome
after	10078673	1935	1940	O
lower	10078673	1941	1946	B-Participant
abdominal	10078673	1947	1956	I-Participant
surgery	10078673	1957	1964	I-Participant
.	10078673	1965	1966	O

Masticatory	10080319	0	11	B-Outcome
performance	10080319	12	23	I-Outcome
and	10080319	24	27	O
chewing	10080319	28	35	B-Outcome
experience	10080319	36	46	I-Outcome
with	10080319	47	51	O
implant-retained	10080319	52	68	B-Intervention
mandibular	10080319	69	79	I-Intervention
overdentures	10080319	80	92	I-Intervention
.	10080319	93	94	O

The	10080319	95	98	O
relationship	10080319	99	111	O
between	10080319	112	119	O
masticatory	10080319	120	131	O
performance	10080319	132	143	O
and	10080319	144	147	O
chewing	10080319	148	155	O
experience	10080319	156	166	O
has	10080319	167	170	O
not	10080319	171	174	O
yet	10080319	175	178	O
been	10080319	179	183	O
explored	10080319	184	192	O
for	10080319	193	196	O
patients	10080319	197	205	O
with	10080319	206	210	O
implant-retained	10080319	211	227	O
overdentures	10080319	228	240	O
.	10080319	241	242	O

Although	10080319	243	251	O
many	10080319	252	256	O
relationships	10080319	257	270	O
have	10080319	271	275	O
been	10080319	276	280	O
found	10080319	281	286	O
between	10080319	287	294	O
parameters	10080319	295	305	O
of	10080319	306	308	O
objective	10080319	309	318	O
and	10080319	319	322	O
subjective	10080319	323	333	O
oral	10080319	334	338	O
function	10080319	339	347	O
,	10080319	348	349	O
the	10080319	350	353	O
structure	10080319	354	363	O
of	10080319	364	366	O
these	10080319	367	372	O
relationships	10080319	373	386	O
remain	10080319	387	393	O
unclear	10080319	394	401	O
.	10080319	402	403	O

Therefore	10080319	404	413	O
,	10080319	414	415	O
we	10080319	416	418	O
studied	10080319	419	426	O
in	10080319	427	429	O
a	10080319	430	431	O
randomized	10080319	432	442	O
clinical	10080319	443	451	O
trial	10080319	452	457	O
the	10080319	458	461	O
relationship	10080319	462	474	B-Observation
between	10080319	475	482	B-Outcome
the	10080319	483	486	I-Outcome
comminution	10080319	487	498	I-Outcome
of	10080319	499	501	I-Outcome
an	10080319	502	504	I-Outcome
artificial	10080319	505	515	I-Outcome
test	10080319	516	520	I-Outcome
food	10080319	521	525	I-Outcome
,	10080319	526	527	O
i.e	10080319	528	531	O
.	10080319	532	533	O

masticatory	10080319	534	545	B-Outcome
performance	10080319	546	557	I-Outcome
,	10080319	558	559	O
and	10080319	560	563	O
the	10080319	564	567	O
subjective	10080319	568	578	B-Outcome
chewing	10080319	579	586	I-Outcome
experience	10080319	587	597	I-Outcome
.	10080319	598	599	O

The	10080319	600	603	O
trial	10080319	604	609	O
involved	10080319	610	618	O
a	10080319	619	620	O
comparison	10080319	621	631	O
between	10080319	632	639	O
two	10080319	640	643	O
groups	10080319	644	650	O
receiving	10080319	651	660	O
implant	10080319	661	668	B-Intervention
treatment	10080319	669	678	I-Intervention
and	10080319	679	682	O
one	10080319	683	686	O
group	10080319	687	692	O
receiving	10080319	693	702	O
conventional	10080319	703	715	B-Intervention
complete	10080319	716	724	I-Intervention
dentures	10080319	725	733	I-Intervention
(	10080319	734	735	I-Intervention
CD	10080319	736	738	I-Intervention
)	10080319	739	740	I-Intervention
.	10080319	741	742	O

The	10080319	743	746	O
implant	10080319	747	754	O
treatment	10080319	755	764	O
involved	10080319	765	773	O
either	10080319	774	780	O
a	10080319	781	782	O
mainly	10080319	783	789	B-Intervention
implant-supported	10080319	790	807	I-Intervention
mandibular	10080319	808	818	I-Intervention
overdenture	10080319	819	830	I-Intervention
on	10080319	831	833	I-Intervention
a	10080319	834	835	I-Intervention
transmandibular	10080319	836	851	I-Intervention
implant	10080319	852	859	I-Intervention
(	10080319	860	861	I-Intervention
TMI	10080319	862	865	I-Intervention
)	10080319	866	867	I-Intervention
or	10080319	868	870	O
an	10080319	871	873	O
implant-tissue-supported	10080319	874	898	B-Intervention
mandibular	10080319	899	909	I-Intervention
overdenture	10080319	910	921	I-Intervention
on	10080319	922	924	I-Intervention
two	10080319	925	928	I-Intervention
IMZ	10080319	929	932	I-Intervention
implants	10080319	933	941	I-Intervention
(	10080319	942	943	I-Intervention
IMZ	10080319	944	947	I-Intervention
)	10080319	948	949	I-Intervention
.	10080319	950	951	O

Masticatory	10080319	952	963	B-Outcome
performance	10080319	964	975	I-Outcome
as	10080319	976	978	O
well	10080319	979	983	O
as	10080319	984	986	O
chewing	10080319	987	994	B-Outcome
experience	10080319	995	1005	I-Outcome
were	10080319	1006	1010	O
substantially	10080319	1011	1024	B-Observation
better	10080319	1025	1031	I-Observation
for	10080319	1032	1035	O
the	10080319	1036	1039	O
implant-retained	10080319	1040	1056	B-Intervention
overdentures	10080319	1057	1069	I-Intervention
compared	10080319	1070	1078	O
with	10080319	1079	1083	O
the	10080319	1084	1087	O
complete	10080319	1088	1096	B-Intervention
denture	10080319	1097	1104	I-Intervention
group	10080319	1105	1110	I-Intervention
.	10080319	1111	1112	O

No	10080319	1113	1115	O
significant	10080319	1116	1127	B-Observation
differences	10080319	1128	1139	I-Observation
emerged	10080319	1140	1147	O
between	10080319	1148	1155	O
the	10080319	1156	1159	O
TMI	10080319	1160	1163	B-Intervention
and	10080319	1164	1167	O
the	10080319	1168	1171	O
IMZ	10080319	1172	1175	B-Intervention
group	10080319	1176	1181	O
.	10080319	1182	1183	O

Piperacillin/tazobactam	10089089	0	23	B-Intervention
plus	10089089	24	28	I-Intervention
tobramycin	10089089	29	39	I-Intervention
versus	10089089	40	46	O
ceftazidime	10089089	47	58	B-Intervention
plus	10089089	59	63	I-Intervention
tobramycin	10089089	64	74	I-Intervention
as	10089089	75	77	O
empiric	10089089	78	85	O
therapy	10089089	86	93	O
for	10089089	94	97	O
fever	10089089	98	103	B-Participant
in	10089089	104	106	O
severely	10089089	107	115	B-Participant
neutropenic	10089089	116	127	I-Participant
patients	10089089	128	136	O
.	10089089	137	138	O

The	10089089	139	142	O
objective	10089089	143	152	O
of	10089089	153	155	O
this	10089089	156	160	O
trial	10089089	161	166	O
was	10089089	167	170	O
to	10089089	171	173	O
evaluate	10089089	174	182	O
the	10089089	183	186	O
potential	10089089	187	196	B-Observation
advantages	10089089	197	207	I-Observation
of	10089089	208	210	O
the	10089089	211	214	O
combination	10089089	215	226	B-Intervention
of	10089089	227	229	I-Intervention
piperacillin	10089089	230	242	I-Intervention
and	10089089	243	246	I-Intervention
tazobactam	10089089	247	257	I-Intervention
in	10089089	258	260	O
the	10089089	261	264	O
control	10089089	265	272	B-Outcome
of	10089089	273	275	O
fever	10089089	276	281	B-Participant
in	10089089	282	284	O
neutropenic	10089089	285	296	B-Participant
patients	10089089	297	305	O
.	10089089	306	307	O

In	10089089	308	310	O
this	10089089	311	315	O
single-center	10089089	316	329	O
study	10089089	330	335	O
,	10089089	336	337	O
patients	10089089	338	346	O
who	10089089	347	350	O
experienced	10089089	351	362	O
a	10089089	363	364	O
total	10089089	365	370	O
of	10089089	371	373	O
247	10089089	374	377	O
febrile	10089089	378	385	B-Participant
episodes	10089089	386	394	I-Participant
were	10089089	395	399	O
prospectively	10089089	400	413	O
randomized	10089089	414	424	O
to	10089089	425	427	O
receive	10089089	428	435	O
either	10089089	436	442	O
our	10089089	443	446	O
standard	10089089	447	455	B-Intervention
regimen	10089089	456	463	I-Intervention
,	10089089	464	465	I-Intervention
ceftazidime	10089089	466	477	I-Intervention
3	10089089	478	479	I-Intervention
g/day	10089089	480	485	I-Intervention
(	10089089	486	487	I-Intervention
1	10089089	488	489	I-Intervention
g	10089089	490	491	I-Intervention
t.i.d	10089089	492	497	I-Intervention
.	10089089	498	499	I-Intervention
)	10089089	500	501	I-Intervention
plus	10089089	502	506	I-Intervention
tobramycin	10089089	507	517	I-Intervention
3	10089089	518	519	I-Intervention
mg/kg	10089089	520	525	I-Intervention
per	10089089	526	529	I-Intervention
day	10089089	530	533	I-Intervention
(	10089089	534	535	I-Intervention
1.5	10089089	536	539	I-Intervention
mg/kg	10089089	540	545	I-Intervention
b.i.d	10089089	546	551	I-Intervention
.	10089089	552	553	I-Intervention
)	10089089	554	555	I-Intervention
,	10089089	556	557	O
or	10089089	558	560	O
piperacillin	10089089	561	573	B-Intervention
12	10089089	574	576	I-Intervention
g/day	10089089	577	582	I-Intervention
plus	10089089	583	587	I-Intervention
tazobactam	10089089	588	598	I-Intervention
1.5	10089089	599	602	I-Intervention
g/day	10089089	603	608	I-Intervention
(	10089089	609	610	I-Intervention
4	10089089	611	612	I-Intervention
g+0.5	10089089	613	618	I-Intervention
g	10089089	619	620	I-Intervention
t.i.d	10089089	621	626	I-Intervention
.	10089089	627	628	I-Intervention
)	10089089	629	630	I-Intervention
plus	10089089	631	635	I-Intervention
tobramycin	10089089	636	646	I-Intervention
3	10089089	647	648	I-Intervention
mg/kg	10089089	649	654	I-Intervention
per	10089089	655	658	I-Intervention
day	10089089	659	662	I-Intervention
(	10089089	663	664	I-Intervention
1.5	10089089	665	668	I-Intervention
mg/kg	10089089	669	674	I-Intervention
b.i.d	10089089	675	680	I-Intervention
.	10089089	680	681	I-Intervention
)	10089089	682	683	I-Intervention
.	10089089	684	685	O

Vancomycin	10089089	686	696	B-Intervention
was	10089089	697	700	O
added	10089089	701	706	O
in	10089089	707	709	O
all	10089089	710	713	O
cases	10089089	714	719	O
of	10089089	720	722	O
persistent	10089089	723	733	B-Participant
fever	10089089	734	739	I-Participant
in	10089089	740	742	O
the	10089089	743	746	O
ceftazidime	10089089	747	758	B-Intervention
arm	10089089	759	762	O
,	10089089	763	764	O
but	10089089	765	768	O
only	10089089	769	773	O
when	10089089	774	778	O
there	10089089	779	784	O
was	10089089	785	788	O
microbiologically	10089089	789	806	B-Participant
documented	10089089	807	817	I-Participant
resistance	10089089	818	828	I-Participant
in	10089089	829	831	O
the	10089089	832	835	O
piperacillin/tazobactam	10089089	836	859	B-Intervention
arm	10089089	860	863	O
.	10089089	864	865	O

All	10089089	866	869	O
247	10089089	870	873	O
episodes	10089089	874	882	O
were	10089089	883	887	O
evaluable	10089089	888	897	O
by	10089089	898	900	O
intent-to-treat	10089089	901	916	O
analysis	10089089	917	925	O
.	10089089	926	927	O

The	10089089	928	931	O
two	10089089	932	935	O
populations	10089089	936	947	O
were	10089089	948	952	O
well	10089089	953	957	O
matched	10089089	958	965	O
in	10089089	966	968	O
terms	10089089	969	974	O
of	10089089	975	977	O
age	10089089	978	981	O
,	10089089	982	983	O
gender	10089089	984	990	O
,	10089089	991	992	O
underlying	10089089	993	1003	O
disease	10089089	1004	1011	O
,	10089089	1012	1013	O
chemotherapy	10089089	1014	1026	O
received	10089089	1027	1035	O
,	10089089	1036	1037	O
oral	10089089	1038	1042	O
decontamination	10089089	1043	1058	O
,	10089089	1059	1060	O
clinical	10089089	1061	1069	O
and	10089089	1070	1073	O
bacterial	10089089	1074	1083	O
documentation	10089089	1084	1097	O
,	10089089	1098	1099	O
and	10089089	1100	1103	O
severity	10089089	1104	1112	O
and	10089089	1113	1116	O
duration	10089089	1117	1125	O
of	10089089	1126	1128	O
neutropenia	10089089	1129	1140	O
.	10089089	1141	1142	O

Initial	10089089	1143	1150	O
antibacterial	10089089	1151	1164	O
therapy	10089089	1165	1172	O
was	10089089	1173	1176	O
successful	10089089	1177	1187	B-Outcome
(	10089089	1188	1189	O
apyrexia	10089089	1190	1198	B-Outcome
at	10089089	1199	1201	O
72	10089089	1202	1204	O
h	10089089	1205	1206	O
,	10089089	1207	1208	O
without	10089089	1209	1216	O
antibiotic	10089089	1217	1227	O
change	10089089	1228	1234	O
)	10089089	1235	1236	O
more	10089089	1237	1241	B-Observation
frequently	10089089	1242	1252	I-Observation
(	10089089	1253	1254	O
P	10089089	1255	1256	O
=	10089089	1257	1258	O
0.008	10089089	1259	1264	O
)	10089089	1265	1266	O
with	10089089	1267	1271	O
the	10089089	1272	1275	O
regimen	10089089	1276	1283	B-Intervention
containing	10089089	1284	1294	I-Intervention
piperacillin/tazobactam	10089089	1295	1318	I-Intervention
(	10089089	1319	1320	O
54.4	10089089	1321	1325	B-Count
%	10089089	1326	1327	I-Count
)	10089089	1328	1329	O
than	10089089	1330	1334	O
with	10089089	1335	1339	O
the	10089089	1340	1343	B-Intervention
one	10089089	1344	1347	I-Intervention
including	10089089	1348	1357	I-Intervention
ceftazidime	10089089	1358	1369	I-Intervention
(	10089089	1370	1371	O
37.6	10089089	1372	1376	B-Count
%	10089089	1377	1378	I-Count
)	10089089	1379	1380	O
.	10089089	1381	1382	O

Fewer	10089089	1383	1388	B-Observation
(	10089089	1389	1390	O
P	10089089	1391	1392	O
=	10089089	1393	1394	O
0.02	10089089	1395	1399	O
)	10089089	1400	1401	O
major	10089089	1402	1407	B-Outcome
infectious	10089089	1408	1418	I-Outcome
events	10089089	1419	1425	I-Outcome
(	10089089	1426	1427	O
infectious	10089089	1428	1438	B-Outcome
death	10089089	1439	1444	I-Outcome
or	10089089	1445	1447	O
delay	10089089	1448	1453	B-Outcome
in	10089089	1454	1456	I-Outcome
treatment	10089089	1457	1466	I-Outcome
of	10089089	1467	1469	I-Outcome
underlying	10089089	1470	1480	I-Outcome
disease	10089089	1481	1488	I-Outcome
due	10089089	1489	1492	I-Outcome
to	10089089	1493	1495	I-Outcome
infection	10089089	1496	1505	I-Outcome
)	10089089	1506	1507	O
were	10089089	1508	1512	O
observed	10089089	1513	1521	O
during	10089089	1522	1528	O
piperacillin/tazobactam	10089089	1529	1552	B-Intervention
treatment	10089089	1553	1562	I-Intervention
(	10089089	1563	1564	O
2.6	10089089	1565	1568	B-Count
%	10089089	1569	1570	I-Count
)	10089089	1571	1572	O
than	10089089	1573	1577	O
with	10089089	1578	1582	O
the	10089089	1583	1586	O
ceftazidime	10089089	1587	1598	B-Intervention
regimen	10089089	1599	1606	I-Intervention
(	10089089	1607	1608	O
11.3	10089089	1609	1613	B-Count
%	10089089	1614	1615	I-Count
)	10089089	1616	1617	O
,	10089089	1618	1619	O
despite	10089089	1620	1627	O
a	10089089	1628	1629	O
lower	10089089	1630	1635	B-Observation
frequency	10089089	1636	1645	B-Outcome
of	10089089	1646	1648	I-Outcome
glycopeptide	10089089	1649	1661	I-Outcome
addition	10089089	1662	1670	I-Outcome
when	10089089	1671	1675	O
piperacillin/tazobactam	10089089	1676	1699	B-Intervention
was	10089089	1700	1703	O
used	10089089	1704	1708	O
(	10089089	1709	1710	O
54.4	10089089	1711	1715	B-Observation
%	10089089	1716	1717	I-Observation
versus	10089089	1718	1724	O
77.4	10089089	1725	1729	B-Observation
%	10089089	1730	1731	I-Observation
)	10089089	1732	1733	O
according	10089089	1734	1743	O
to	10089089	1744	1746	O
the	10089089	1747	1750	O
rules	10089089	1751	1756	O
adopted	10089089	1757	1764	O
.	10089089	1765	1766	O

This	10089089	1767	1771	O
trial	10089089	1772	1777	O
confirmed	10089089	1778	1787	O
the	10089089	1788	1791	O
efficacy	10089089	1792	1800	B-Outcome
of	10089089	1801	1803	O
the	10089089	1804	1807	O
piperacillin/tazobactam	10089089	1808	1831	B-Intervention
combination	10089089	1832	1843	I-Intervention
for	10089089	1844	1847	O
empirical	10089089	1848	1857	O
treatment	10089089	1858	1867	O
of	10089089	1868	1870	O
febrile	10089089	1871	1878	B-Participant
neutropenic	10089089	1879	1890	I-Participant
patients	10089089	1891	1899	O
.	10089089	1900	1901	O

This	10089089	1902	1906	O
antibiotic	10089089	1907	1917	B-Intervention
combination	10089089	1918	1929	I-Intervention
permitted	10089089	1930	1939	O
a	10089089	1940	1941	O
dramatic	10089089	1942	1950	B-Observation
decrease	10089089	1951	1959	I-Observation
in	10089089	1960	1962	O
empiric	10089089	1963	1970	B-Outcome
glycopeptide	10089089	1971	1983	I-Outcome
antibiotic	10089089	1984	1994	I-Outcome
administration	10089089	1995	2009	I-Outcome
in	10089089	2010	2012	O
such	10089089	2013	2017	O
patients	10089089	2018	2026	O
.	10089089	2027	2028	O

A	10093945	0	1	O
comparative	10093945	2	13	O
study	10093945	14	19	O
of	10093945	20	22	O
ofloxacin	10093945	23	32	B-Intervention
and	10093945	33	36	O
cefixime	10093945	37	45	B-Intervention
for	10093945	46	49	O
treatment	10093945	50	59	O
of	10093945	60	62	O
typhoid	10093945	63	70	B-Participant
fever	10093945	71	76	I-Participant
in	10093945	77	79	O
children	10093945	80	88	B-Participant
.	10093945	89	90	O

The	10093945	91	94	O
Dong	10093945	95	99	O
Nai	10093945	100	103	O
Pediatric	10093945	104	113	O
Center	10093945	114	120	O
Typhoid	10093945	121	128	O
Study	10093945	129	134	O
Group	10093945	135	140	O
.	10093945	141	142	O

BACKGROUND	10093945	143	153	O
Despite	10093945	154	161	O
concerns	10093945	162	170	O
about	10093945	171	176	O
safety	10093945	177	183	O
in	10093945	184	186	O
children	10093945	187	195	O
,	10093945	196	197	O
fluoroquinolone	10093945	198	213	O
antibiotics	10093945	214	225	O
have	10093945	226	230	O
become	10093945	231	237	O
the	10093945	238	241	O
treatment	10093945	242	251	O
of	10093945	252	254	O
choice	10093945	255	261	O
in	10093945	262	264	O
patients	10093945	265	273	O
with	10093945	274	278	O
multidrug-resistant	10093945	279	298	O
typhoid	10093945	299	306	O
fever	10093945	307	312	O
in	10093945	313	315	O
Vietnam	10093945	316	323	O
.	10093945	324	325	O

However	10093945	326	333	O
,	10093945	334	335	O
quinolone-resistant	10093945	336	355	O
strains	10093945	356	363	O
of	10093945	364	366	O
Salmonella	10093945	367	377	O
typhi	10093945	378	383	O
have	10093945	384	388	O
recently	10093945	389	397	O
been	10093945	398	402	O
reported	10093945	403	411	O
from	10093945	412	416	O
Vietnam	10093945	417	424	O
;	10093945	425	426	O
and	10093945	427	430	O
if	10093945	431	433	O
quinolone	10093945	434	443	O
resistance	10093945	444	454	O
becomes	10093945	455	462	O
established	10093945	463	474	O
,	10093945	475	476	O
alternative	10093945	477	488	O
oral	10093945	489	493	O
treatment	10093945	494	503	O
options	10093945	504	511	O
will	10093945	512	516	O
be	10093945	517	519	O
needed	10093945	520	526	O
.	10093945	527	528	O

OBJECTIVE	10093945	529	538	O
Cefixime	10093945	539	547	B-Intervention
,	10093945	548	549	O
an	10093945	550	552	O
orally	10093945	553	559	O
administered	10093945	560	572	O
third	10093945	573	578	O
generation	10093945	579	589	O
cephalosporin	10093945	590	603	O
,	10093945	604	605	O
was	10093945	606	609	O
compared	10093945	610	618	O
with	10093945	619	623	O
ofloxacin	10093945	624	633	B-Intervention
for	10093945	634	637	O
the	10093945	638	641	O
treatment	10093945	642	651	O
of	10093945	652	654	O
uncomplicated	10093945	655	668	B-Participant
typhoid	10093945	669	676	I-Participant
fever	10093945	677	682	I-Participant
in	10093945	683	685	O
children	10093945	686	694	B-Participant
.	10093945	695	696	O

METHODS	10093945	697	704	O
In	10093945	705	707	O
an	10093945	708	710	O
open	10093945	711	715	O
trial	10093945	716	721	O
children	10093945	722	730	B-Participant
with	10093945	731	735	O
suspected	10093945	736	745	B-Participant
typhoid	10093945	746	753	I-Participant
fever	10093945	754	759	I-Participant
were	10093945	760	764	O
randomized	10093945	765	775	O
to	10093945	776	778	O
receive	10093945	779	786	O
either	10093945	787	793	O
ofloxacin	10093945	794	803	B-Intervention
(	10093945	804	805	O
10	10093945	806	808	O
mg/kg/day	10093945	809	818	O
in	10093945	819	821	O
two	10093945	822	825	O
divided	10093945	826	833	O
doses	10093945	834	839	O
)	10093945	840	841	O
for	10093945	842	845	O
5	10093945	846	847	O
days	10093945	848	852	O
or	10093945	853	855	O
cefixime	10093945	856	864	B-Intervention
(	10093945	865	866	O
20	10093945	867	869	O
mg/kg/day	10093945	870	879	O
in	10093945	880	882	O
two	10093945	883	886	O
divided	10093945	887	894	O
doses	10093945	895	900	O
)	10093945	901	902	O
for	10093945	903	906	O
7	10093945	907	908	O
days	10093945	909	913	O
.	10093945	914	915	O

RESULTS	10093945	916	923	O
S.	10093945	924	926	B-Outcome
typhi	10093945	927	932	I-Outcome
was	10093945	933	936	O
isolated	10093945	937	945	O
from	10093945	946	950	O
82	10093945	951	953	B-Count
patients	10093945	954	962	I-Count
(	10093945	963	964	O
44	10093945	965	967	B-Count
in	10093945	968	970	O
the	10093945	971	974	O
cefixime	10093945	975	983	B-Intervention
group	10093945	984	989	O
,	10093945	990	991	O
38	10093945	992	994	B-Count
in	10093945	995	997	O
the	10093945	998	1001	O
ofloxacin	10093945	1002	1011	B-Intervention
group	10093945	1012	1017	O
)	10093945	1018	1019	O
and	10093945	1020	1023	O
70	10093945	1024	1026	B-Count
(	10093945	1027	1028	I-Count
85	10093945	1029	1031	I-Count
%	10093945	1032	1033	I-Count
)	10093945	1034	1035	I-Count
of	10093945	1036	1038	I-Count
the	10093945	1039	1042	I-Count
isolates	10093945	1043	1051	I-Count
were	10093945	1052	1056	O
multidrug-resistant	10093945	1057	1076	B-Outcome
.	10093945	1077	1078	O

Median	10093945	1079	1085	B-Outcome
(	10093945	1086	1087	I-Outcome
95	10093945	1088	1090	I-Outcome
%	10093945	1091	1092	I-Outcome
confidence	10093945	1093	1103	I-Outcome
interval	10093945	1104	1112	I-Outcome
,	10093945	1113	1114	I-Outcome
range	10093945	1115	1120	I-Outcome
)	10093945	1121	1122	I-Outcome
fever	10093945	1123	1128	I-Outcome
clearance	10093945	1129	1138	I-Outcome
times	10093945	1139	1144	I-Outcome
were	10093945	1145	1149	O
4.4	10093945	1150	1153	B-Observation
(	10093945	1154	1155	I-Observation
4	10093945	1156	1157	I-Observation
to	10093945	1158	1160	I-Observation
5.2	10093945	1161	1164	I-Observation
,	10093945	1165	1166	I-Observation
0.2	10093945	1167	1170	I-Observation
to	10093945	1171	1173	I-Observation
9.9	10093945	1174	1177	I-Observation
)	10093945	1178	1179	I-Observation
days	10093945	1180	1184	I-Observation
for	10093945	1185	1188	O
ofloxacin	10093945	1189	1198	B-Intervention
recipients	10093945	1199	1209	O
and	10093945	1210	1213	O
8.5	10093945	1214	1217	B-Observation
(	10093945	1218	1219	I-Observation
4.2	10093945	1220	1223	I-Observation
to	10093945	1224	1226	I-Observation
9	10093945	1227	1228	I-Observation
,	10093945	1229	1230	I-Observation
1.8	10093945	1231	1234	I-Observation
to	10093945	1235	1237	I-Observation
15.2	10093945	1238	1242	I-Observation
)	10093945	1243	1244	I-Observation
days	10093945	1245	1249	I-Observation
for	10093945	1250	1253	O
cefixime-treated	10093945	1254	1270	B-Intervention
patients	10093945	1271	1279	O
(	10093945	1280	1281	O
P	10093945	1282	1283	O
<	10093945	1284	1285	O
0.0001	10093945	1286	1292	O
)	10093945	1293	1294	O
.	10093945	1295	1296	O

There	10093945	1297	1302	O
were	10093945	1303	1307	O
11	10093945	1308	1310	B-Count
treatment	10093945	1311	1320	B-Outcome
failures	10093945	1321	1329	I-Outcome
(	10093945	1330	1331	O
10	10093945	1332	1334	B-Count
acute	10093945	1335	1340	B-Outcome
and	10093945	1341	1344	O
one	10093945	1345	1348	B-Count
relapse	10093945	1349	1356	B-Outcome
)	10093945	1357	1358	O
in	10093945	1359	1361	O
the	10093945	1362	1365	O
cefixime	10093945	1366	1374	B-Intervention
group	10093945	1375	1380	O
and	10093945	1381	1384	O
1	10093945	1385	1386	B-Count
acute	10093945	1387	1392	B-Outcome
treatment	10093945	1393	1402	I-Outcome
failure	10093945	1403	1410	I-Outcome
in	10093945	1411	1413	O
the	10093945	1414	1417	O
ofloxacin	10093945	1418	1427	B-Intervention
group	10093945	1428	1433	O
(	10093945	1434	1435	O
mean	10093945	1436	1440	O
difference	10093945	1441	1451	O
,	10093945	1452	1453	O
22	10093945	1454	1456	O
%	10093945	1457	1458	O
;	10093945	1459	1460	O
95	10093945	1461	1463	O
%	10093945	1464	1465	O
confidence	10093945	1466	1476	O
interval	10093945	1477	1485	O
,	10093945	1486	1487	O
9	10093945	1488	1489	O
to	10093945	1490	1492	O
36	10093945	1493	1495	O
%	10093945	1496	1497	O
)	10093945	1498	1499	O
.	10093945	1500	1501	O

CONCLUSION	10093945	1502	1512	O
Short	10093945	1513	1518	O
course	10093945	1519	1525	O
treatment	10093945	1526	1535	O
with	10093945	1536	1540	O
cefixime	10093945	1541	1549	B-Intervention
may	10093945	1550	1553	O
provide	10093945	1554	1561	O
a	10093945	1562	1563	O
useful	10093945	1564	1570	B-Observation
alternative	10093945	1571	1582	B-Outcome
treatment	10093945	1583	1592	I-Outcome
in	10093945	1593	1595	O
cases	10093945	1596	1601	O
of	10093945	1602	1604	O
uncomplicated	10093945	1605	1618	B-Participant
typhoid	10093945	1619	1626	I-Participant
fever	10093945	1627	1632	I-Participant
in	10093945	1633	1635	O
children	10093945	1636	1644	B-Participant
,	10093945	1645	1646	O
but	10093945	1647	1650	O
it	10093945	1651	1653	O
is	10093945	1654	1656	O
less	10093945	1657	1661	B-Observation
effective	10093945	1662	1671	I-Observation
than	10093945	1672	1676	O
short	10093945	1677	1682	O
course	10093945	1683	1689	O
treatment	10093945	1690	1699	O
with	10093945	1700	1704	O
ofloxacin	10093945	1705	1714	B-Intervention
.	10093945	1715	1716	O

Efficacy	10188144	0	8	B-Outcome
and	10188144	9	12	O
safety	10188144	13	19	B-Outcome
of	10188144	20	22	O
mizolastine	10188144	23	34	B-Intervention
10	10188144	35	37	O
mg	10188144	38	40	O
in	10188144	41	43	O
a	10188144	44	45	O
placebo-controlled	10188144	46	64	O
comparison	10188144	65	75	O
with	10188144	76	80	O
loratadine	10188144	81	91	B-Intervention
in	10188144	92	94	O
chronic	10188144	95	102	B-Participant
idiopathic	10188144	103	113	I-Participant
urticaria	10188144	114	123	I-Participant
:	10188144	124	125	O
results	10188144	126	133	O
of	10188144	134	136	O
the	10188144	137	140	O
MILOR	10188144	141	146	O
Study	10188144	147	152	O
.	10188144	153	154	O

BACKGROUND	10188144	155	165	O
Mizolastine	10188144	166	177	O
is	10188144	178	180	O
a	10188144	181	182	O
novel	10188144	183	188	O
histamine	10188144	189	198	O
H1-antagonist	10188144	199	212	O
registered	10188144	213	223	O
in	10188144	224	226	O
Europe	10188144	227	233	O
for	10188144	234	237	O
the	10188144	238	241	O
management	10188144	242	252	O
of	10188144	253	255	O
allergic	10188144	256	264	O
rhinitis	10188144	265	273	O
and	10188144	274	277	O
urticaria	10188144	278	287	O
.	10188144	288	289	O

OBJECTIVES	10188144	290	300	O
To	10188144	301	303	O
compare	10188144	304	311	O
the	10188144	312	315	O
clinical	10188144	316	324	B-Outcome
efficacy	10188144	325	333	I-Outcome
and	10188144	334	337	O
safety	10188144	338	344	B-Outcome
of	10188144	345	347	O
mizolastine	10188144	348	359	B-Intervention
with	10188144	360	364	O
loratadine	10188144	365	375	B-Intervention
and	10188144	376	379	O
placebo	10188144	380	387	B-Intervention
in	10188144	388	390	O
patients	10188144	391	399	O
with	10188144	400	404	O
chronic	10188144	405	412	B-Participant
idiopathic	10188144	413	423	I-Participant
urticaria	10188144	424	433	I-Participant
(	10188144	434	435	I-Participant
CIU	10188144	436	439	I-Participant
)	10188144	440	441	I-Participant
.	10188144	442	443	O

METHODS	10188144	444	451	O
A	10188144	452	453	O
multicentre	10188144	454	465	O
,	10188144	466	467	O
double-blind	10188144	468	480	O
,	10188144	481	482	O
parallel	10188144	483	491	O
group	10188144	492	497	O
study	10188144	498	503	O
was	10188144	504	507	O
designed	10188144	508	516	O
in	10188144	517	519	O
which	10188144	520	525	O
247	10188144	526	529	O
patients	10188144	530	538	O
with	10188144	539	543	O
CIU	10188144	544	547	B-Participant
were	10188144	548	552	O
randomised	10188144	553	563	O
after	10188144	564	569	O
a	10188144	570	571	O
1-week	10188144	572	578	O
placebo	10188144	579	586	O
run-in	10188144	587	593	O
period	10188144	594	600	O
to	10188144	601	603	O
10	10188144	604	606	O
mg	10188144	607	609	O
daily	10188144	610	615	O
mizolastine	10188144	616	627	B-Intervention
(	10188144	628	629	O
n	10188144	630	631	O
=	10188144	632	633	O
88	10188144	634	636	O
)	10188144	637	638	O
,	10188144	639	640	O
10	10188144	641	643	O
mg	10188144	644	646	O
daily	10188144	647	652	O
loratadine	10188144	653	663	B-Intervention
(	10188144	664	665	O
n	10188144	666	667	O
=	10188144	668	669	O
79	10188144	670	672	O
)	10188144	673	674	O
,	10188144	675	676	O
or	10188144	677	679	O
placebo	10188144	680	687	B-Intervention
(	10188144	688	689	O
n	10188144	690	691	O
=	10188144	692	693	O
80	10188144	694	696	O
)	10188144	697	698	O
for	10188144	699	702	O
a	10188144	703	704	O
4-week	10188144	705	711	O
treatment	10188144	712	721	O
period	10188144	722	728	O
.	10188144	729	730	O

RESULTS	10188144	731	738	O
Mizolastine	10188144	739	750	B-Intervention
and	10188144	751	754	O
loratadine	10188144	755	765	B-Intervention
both	10188144	766	770	O
relieved	10188144	771	779	B-Observation
symptoms	10188144	780	788	B-Outcome
of	10188144	789	791	O
CIU	10188144	792	795	B-Participant
.	10188144	796	797	O

After	10188144	798	803	O
2	10188144	804	805	O
weeks	10188144	806	811	O
'	10188144	812	813	O
treatment	10188144	814	823	O
,	10188144	824	825	O
the	10188144	826	829	O
severity	10188144	830	838	B-Outcome
of	10188144	839	841	I-Outcome
pruritus	10188144	842	850	I-Outcome
(	10188144	851	852	O
visual	10188144	853	859	B-Outcome
analogue	10188144	860	868	I-Outcome
score	10188144	869	874	I-Outcome
(	10188144	875	876	I-Outcome
VAS	10188144	877	880	I-Outcome
)	10188144	881	882	I-Outcome
assessed	10188144	883	891	O
by	10188144	892	894	O
patients	10188144	895	903	O
)	10188144	904	905	O
decreased	10188144	906	915	B-Observation
significantly	10188144	916	929	I-Observation
in	10188144	930	932	O
both	10188144	933	937	O
the	10188144	938	941	O
mizolastine	10188144	942	953	B-Intervention
and	10188144	954	957	O
loratadine	10188144	958	968	B-Intervention
groups	10188144	969	975	O
compared	10188144	976	984	O
with	10188144	985	989	O
placebo	10188144	990	997	B-Intervention
(	10188144	998	999	O
mizolastine	10188144	1000	1011	B-Intervention
:	10188144	1012	1013	O
-36.7	10188144	1014	1019	B-Observation
mm	10188144	1020	1022	I-Observation
,	10188144	1023	1024	O
P	10188144	1025	1026	O
=	10188144	1027	1028	O
0.0001	10188144	1029	1035	O
;	10188144	1036	1037	O
loratadine	10188144	1038	1048	B-Intervention
:	10188144	1049	1050	O
-29.8	10188144	1051	1056	B-Observation
,	10188144	1057	1058	O
P	10188144	1059	1060	O
=	10188144	1061	1062	O
0.0071	10188144	1063	1069	O
;	10188144	1070	1071	O
placebo	10188144	1072	1079	B-Intervention
:	10188144	1080	1081	O
-16.3	10188144	1082	1087	B-Observation
)	10188144	1088	1089	O
;	10188144	1090	1091	O
this	10188144	1092	1096	O
improvement	10188144	1097	1108	B-Outcome
with	10188144	1109	1113	O
both	10188144	1114	1118	O
active	10188144	1119	1125	B-Intervention
treatments	10188144	1126	1136	I-Intervention
was	10188144	1137	1140	O
maintained	10188144	1141	1151	B-Observation
throughout	10188144	1152	1162	O
the	10188144	1163	1166	O
treatment	10188144	1167	1176	O
period	10188144	1177	1183	O
,	10188144	1184	1185	O
the	10188144	1186	1189	O
difference	10188144	1190	1200	B-Observation
being	10188144	1201	1206	I-Observation
significant	10188144	1207	1218	I-Observation
only	10188144	1219	1223	O
for	10188144	1224	1227	O
the	10188144	1228	1231	O
mizolastine	10188144	1232	1243	B-Intervention
group	10188144	1244	1249	O
(	10188144	1250	1251	O
P	10188144	1252	1253	O
=	10188144	1254	1255	O
0.0090	10188144	1256	1262	O
)	10188144	1263	1264	O
.	10188144	1265	1266	O

Both	10188144	1267	1271	B-Intervention
active	10188144	1272	1278	I-Intervention
treatments	10188144	1279	1289	I-Intervention
were	10188144	1290	1294	O
also	10188144	1295	1299	O
associated	10188144	1300	1310	O
with	10188144	1311	1315	O
reduced	10188144	1316	1323	B-Observation
weekly	10188144	1324	1330	B-Outcome
episodes	10188144	1331	1339	I-Outcome
of	10188144	1340	1342	I-Outcome
urticaria	10188144	1343	1352	I-Outcome
compared	10188144	1353	1361	O
with	10188144	1362	1366	O
placebo	10188144	1367	1374	B-Intervention
,	10188144	1375	1376	O
which	10188144	1377	1382	O
was	10188144	1383	1386	O
significant	10188144	1387	1398	O
after	10188144	1399	1404	O
2	10188144	1405	1406	O
weeks	10188144	1407	1412	O
'	10188144	1413	1414	O
treatment	10188144	1415	1424	O
(	10188144	1425	1426	O
mizolastine	10188144	1427	1438	B-Intervention
:	10188144	1439	1440	O
7.9	10188144	1441	1444	B-Observation
episodes	10188144	1445	1453	I-Observation
,	10188144	1454	1455	O
P	10188144	1456	1457	O
=	10188144	1458	1459	O
0.0061	10188144	1460	1466	O
;	10188144	1467	1468	O
loratadine	10188144	1469	1479	B-Intervention
:	10188144	1480	1481	O
8.3	10188144	1482	1485	B-Observation
,	10188144	1486	1487	O
P	10188144	1488	1489	O
=	10188144	1490	1491	O
0.0221	10188144	1492	1498	O
;	10188144	1499	1500	O
placebo	10188144	1501	1508	B-Intervention
:	10188144	1509	1510	O
13.3	10188144	1511	1515	B-Observation
)	10188144	1516	1517	O
.	10188144	1518	1519	O

Angioedema	10188144	1520	1530	B-Outcome
was	10188144	1531	1534	O
improved	10188144	1535	1543	B-Observation
to	10188144	1544	1546	I-Observation
a	10188144	1547	1548	I-Observation
clinically	10188144	1549	1559	I-Observation
significant	10188144	1560	1571	I-Observation
extent	10188144	1572	1578	I-Observation
with	10188144	1579	1583	O
mizolastine	10188144	1584	1595	B-Intervention
,	10188144	1596	1597	O
and	10188144	1598	1601	O
loratadine	10188144	1602	1612	B-Intervention
compared	10188144	1613	1621	O
with	10188144	1622	1626	O
placebo	10188144	1627	1634	B-Intervention
in	10188144	1635	1637	O
those	10188144	1638	1643	O
patients	10188144	1644	1652	O
who	10188144	1653	1656	O
had	10188144	1657	1660	O
this	10188144	1661	1665	O
symptom	10188144	1666	1673	O
before	10188144	1674	1680	O
treatment	10188144	1681	1690	O
.	10188144	1691	1692	O

Overall	10188144	1693	1700	B-Outcome
tolerability	10188144	1701	1713	I-Outcome
of	10188144	1714	1716	O
both	10188144	1717	1721	B-Intervention
treatments	10188144	1722	1732	I-Intervention
was	10188144	1733	1736	O
similar	10188144	1737	1744	B-Observation
to	10188144	1745	1747	O
placebo	10188144	1748	1755	B-Intervention
,	10188144	1756	1757	O
and	10188144	1758	1761	O
there	10188144	1762	1767	O
were	10188144	1768	1772	O
no	10188144	1773	1775	O
clinically	10188144	1776	1786	B-Observation
relevant	10188144	1787	1795	I-Observation
effects	10188144	1796	1803	I-Observation
on	10188144	1804	1806	O
cardiac	10188144	1807	1814	B-Outcome
repolarisation	10188144	1815	1829	I-Outcome
with	10188144	1830	1834	O
either	10188144	1835	1841	O
mizolastine	10188144	1842	1853	B-Intervention
or	10188144	1854	1856	O
loratadine	10188144	1857	1867	B-Intervention
.	10188144	1868	1869	O

CONCLUSION	10188144	1870	1880	O
Mizolastine	10188144	1881	1892	B-Intervention
(	10188144	1893	1894	O
10	10188144	1895	1897	O
mg	10188144	1898	1900	O
daily	10188144	1901	1906	O
)	10188144	1907	1908	O
is	10188144	1909	1911	O
confirmed	10188144	1912	1921	O
as	10188144	1922	1924	O
an	10188144	1925	1927	O
effective	10188144	1928	1937	B-Observation
and	10188144	1938	1941	O
well	10188144	1942	1946	B-Observation
tolerated	10188144	1947	1956	I-Observation
agent	10188144	1957	1962	O
,	10188144	1963	1964	O
comparable	10188144	1965	1975	B-Observation
to	10188144	1976	1978	O
loratadine	10188144	1979	1989	B-Intervention
and	10188144	1990	1993	O
superior	10188144	1994	2002	B-Observation
to	10188144	2003	2005	O
placebo	10188144	2006	2013	B-Intervention
,	10188144	2014	2015	O
for	10188144	2016	2019	O
the	10188144	2020	2023	O
management	10188144	2024	2034	B-Outcome
of	10188144	2035	2037	I-Outcome
CIU	10188144	2038	2041	I-Outcome
.	10188144	2042	2043	O

Mizolastine	10188144	2044	2055	B-Intervention
acted	10188144	2056	2061	O
as	10188144	2062	2064	O
rapidly	10188144	2065	2072	B-Observation
as	10188144	2073	2075	O
loratadine	10188144	2076	2086	B-Intervention
in	10188144	2087	2089	O
improving	10188144	2090	2099	B-Observation
urticarial	10188144	2100	2110	B-Outcome
symptoms	10188144	2111	2119	I-Outcome
from	10188144	2120	2124	O
the	10188144	2125	2128	O
first	10188144	2129	2134	O
day	10188144	2135	2138	O
of	10188144	2139	2141	O
treatment	10188144	2142	2151	O
.	10188144	2152	2153	O

Rett	10190267	0	4	B-Participant
syndrome	10190267	5	13	I-Participant
:	10190267	14	15	O
randomized	10190267	16	26	O
controlled	10190267	27	37	O
trial	10190267	38	43	O
of	10190267	44	46	O
L-carnitine	10190267	47	58	B-Intervention
.	10190267	59	60	O

Rett	10190267	61	65	O
syndrome	10190267	66	74	O
is	10190267	75	77	O
a	10190267	78	79	O
severe	10190267	80	86	O
neurodevelopmental	10190267	87	105	O
disorder	10190267	106	114	O
of	10190267	115	117	O
unknown	10190267	118	125	O
etiology	10190267	126	134	O
,	10190267	135	136	O
occurring	10190267	137	146	O
almost	10190267	147	153	O
exclusively	10190267	154	165	O
in	10190267	166	168	O
female	10190267	169	175	O
patients	10190267	176	184	O
.	10190267	185	186	O

The	10190267	187	190	O
etiology	10190267	191	199	O
and	10190267	200	203	O
functional	10190267	204	214	O
significance	10190267	215	227	O
of	10190267	228	230	O
plasma	10190267	231	237	O
carnitine	10190267	238	247	O
deficiency	10190267	248	258	O
seen	10190267	259	263	O
in	10190267	264	266	O
some	10190267	267	271	O
patients	10190267	272	280	O
with	10190267	281	285	O
Rett	10190267	286	290	O
syndrome	10190267	291	299	O
is	10190267	300	302	O
unknown	10190267	303	310	O
.	10190267	311	312	O

To	10190267	313	315	O
investigate	10190267	316	327	O
whether	10190267	328	335	O
L-carnitine	10190267	336	347	B-Intervention
might	10190267	348	353	O
be	10190267	354	356	O
of	10190267	357	359	O
benefit	10190267	360	367	B-Observation
in	10190267	368	370	O
Rett	10190267	371	375	B-Participant
syndrome	10190267	376	384	I-Participant
,	10190267	385	386	O
a	10190267	387	388	O
randomized	10190267	389	399	O
,	10190267	400	401	O
placebo-controlled	10190267	402	420	O
,	10190267	421	422	O
double-blind	10190267	423	435	O
crossover	10190267	436	445	O
trial	10190267	446	451	O
of	10190267	452	454	O
L-carnitine	10190267	455	466	B-Intervention
has	10190267	467	470	O
been	10190267	471	475	O
completed	10190267	476	485	O
in	10190267	486	488	O
35	10190267	489	491	O
subjects	10190267	492	500	O
.	10190267	501	502	O

Eight-week	10190267	503	513	O
treatment	10190267	514	523	O
phases	10190267	524	530	O
were	10190267	531	535	O
completed	10190267	536	545	O
for	10190267	546	549	O
both	10190267	550	554	O
a	10190267	555	556	O
placebo	10190267	557	564	B-Intervention
and	10190267	565	568	O
L-carnitine	10190267	569	580	B-Intervention
.	10190267	581	582	O

Outcome	10190267	583	590	O
was	10190267	591	594	O
measured	10190267	595	603	O
by	10190267	604	606	O
parents/caregivers	10190267	607	625	O
and	10190267	626	629	O
at	10190267	630	632	O
medical	10190267	633	640	O
follow-up	10190267	641	650	O
using	10190267	651	656	O
three	10190267	657	662	O
established	10190267	663	674	O
tools	10190267	675	680	O
:	10190267	681	682	O
the	10190267	683	686	O
Rett	10190267	687	691	B-Outcome
Syndrome	10190267	692	700	I-Outcome
Motor	10190267	701	706	I-Outcome
Behavioral	10190267	707	717	I-Outcome
Assessment	10190267	718	728	I-Outcome
,	10190267	729	730	O
the	10190267	731	734	O
Hand	10190267	735	739	B-Outcome
Apraxia	10190267	740	747	I-Outcome
Scale	10190267	748	753	I-Outcome
,	10190267	754	755	O
and	10190267	756	759	O
the	10190267	760	763	O
Patient	10190267	764	771	B-Outcome
Well-Being	10190267	772	782	I-Outcome
Index	10190267	783	788	I-Outcome
.	10190267	789	790	O

Analysis	10190267	791	799	O
comparing	10190267	800	809	O
change	10190267	810	816	O
between	10190267	817	824	O
baseline	10190267	825	833	O
and	10190267	834	837	O
week	10190267	838	842	O
8	10190267	843	844	O
of	10190267	845	847	O
treatment	10190267	848	857	O
for	10190267	858	861	O
L-carnitine	10190267	862	873	B-Intervention
and	10190267	874	877	O
the	10190267	878	881	O
placebo	10190267	882	889	B-Intervention
showed	10190267	890	896	O
that	10190267	897	901	O
both	10190267	902	906	O
parents/caregivers	10190267	907	925	O
and	10190267	926	929	O
medical	10190267	930	937	O
follow-up	10190267	938	947	O
detected	10190267	948	956	O
improvements	10190267	957	969	B-Observation
in	10190267	970	972	O
the	10190267	973	976	O
subjects	10190267	977	985	O
'	10190267	986	987	O
well-being	10190267	988	998	B-Outcome
.	10190267	999	1000	O

In	10190267	1001	1003	O
addition	10190267	1004	1012	O
,	10190267	1013	1014	O
medical	10190267	1015	1022	O
review	10190267	1023	1029	O
showed	10190267	1030	1036	O
an	10190267	1037	1039	O
improvement	10190267	1040	1051	B-Observation
on	10190267	1052	1054	O
the	10190267	1055	1058	O
Hand	10190267	1059	1063	B-Outcome
Apraxia	10190267	1064	1071	I-Outcome
Scale	10190267	1072	1077	I-Outcome
for	10190267	1078	1081	O
a	10190267	1082	1083	O
higher	10190267	1084	1090	B-Participant
proportion	10190267	1091	1101	I-Participant
of	10190267	1102	1104	I-Participant
girls	10190267	1105	1110	I-Participant
on	10190267	1111	1113	O
L-carnitine	10190267	1114	1125	B-Intervention
.	10190267	1126	1127	O

Identification	10190267	1128	1142	O
of	10190267	1143	1145	O
predictors	10190267	1146	1156	O
of	10190267	1157	1159	O
clinical	10190267	1160	1168	O
improvement	10190267	1169	1180	O
has	10190267	1181	1184	O
been	10190267	1185	1189	O
limited	10190267	1190	1197	O
by	10190267	1198	1200	O
the	10190267	1201	1204	O
power	10190267	1205	1210	O
of	10190267	1211	1213	O
the	10190267	1214	1217	O
study	10190267	1218	1223	O
.	10190267	1224	1225	O

These	10190267	1226	1231	O
findings	10190267	1232	1240	O
suggest	10190267	1241	1248	O
that	10190267	1249	1253	O
L-carnitine	10190267	1254	1265	B-Intervention
is	10190267	1266	1268	O
of	10190267	1269	1271	O
benefit	10190267	1272	1279	B-Observation
in	10190267	1280	1282	O
some	10190267	1283	1287	O
patients	10190267	1288	1296	O
with	10190267	1297	1301	O
Rett	10190267	1302	1306	B-Participant
syndrome	10190267	1307	1315	I-Participant
.	10190267	1316	1317	O

While	10190267	1318	1323	O
L-carnitine	10190267	1324	1335	B-Intervention
did	10190267	1336	1339	O
not	10190267	1340	1343	O
lead	10190267	1344	1348	O
to	10190267	1349	1351	O
major	10190267	1352	1357	B-Observation
functional	10190267	1358	1368	I-Observation
changes	10190267	1369	1376	I-Observation
in	10190267	1377	1379	O
ability	10190267	1380	1387	B-Outcome
,	10190267	1388	1389	O
the	10190267	1390	1393	O
type	10190267	1394	1398	O
of	10190267	1399	1401	O
changes	10190267	1402	1409	O
reported	10190267	1410	1418	O
could	10190267	1419	1424	O
still	10190267	1425	1430	O
have	10190267	1431	1435	O
a	10190267	1436	1437	O
substantial	10190267	1438	1449	B-Observation
impact	10190267	1450	1456	I-Observation
on	10190267	1457	1459	O
the	10190267	1460	1463	O
girls	10190267	1464	1469	B-Participant
and	10190267	1470	1473	O
their	10190267	1474	1479	O
families	10190267	1480	1488	B-Participant
.	10190267	1489	1490	O

Information	10190267	1491	1502	O
is	10190267	1503	1505	O
still	10190267	1506	1511	O
needed	10190267	1512	1518	O
,	10190267	1519	1520	O
however	10190267	1521	1528	O
,	10190267	1529	1530	O
to	10190267	1531	1533	O
determine	10190267	1534	1543	O
if	10190267	1544	1546	O
only	10190267	1547	1551	O
subgroups	10190267	1552	1561	O
of	10190267	1562	1564	O
girls	10190267	1565	1570	O
with	10190267	1571	1575	O
the	10190267	1576	1579	O
disorder	10190267	1580	1588	O
are	10190267	1589	1592	O
responsive	10190267	1593	1603	O
to	10190267	1604	1606	O
L-carnitine	10190267	1607	1618	O
and	10190267	1619	1622	O
the	10190267	1623	1626	O
appropriate	10190267	1627	1638	O
duration	10190267	1639	1647	O
of	10190267	1648	1650	O
therapy	10190267	1651	1658	O
.	10190267	1659	1660	O

High-pressure	10194485	0	13	B-Intervention
,	10194485	14	15	I-Intervention
rapid-inflation	10194485	16	31	I-Intervention
pneumatic	10194485	32	41	I-Intervention
compression	10194485	42	53	I-Intervention
improves	10194485	54	62	B-Observation
venous	10194485	63	69	B-Outcome
hemodynamics	10194485	70	82	I-Outcome
in	10194485	83	85	O
healthy	10194485	86	93	B-Participant
volunteers	10194485	94	104	O
and	10194485	105	108	O
patients	10194485	109	117	O
who	10194485	118	121	O
are	10194485	122	125	O
post-thrombotic	10194485	126	141	B-Participant
.	10194485	142	143	O

PURPOSE	10194485	144	151	O
Deep	10194485	152	156	O
vein	10194485	157	161	O
thrombosis	10194485	162	172	O
(	10194485	173	174	O
DVT	10194485	175	178	O
)	10194485	179	180	O
is	10194485	181	183	O
a	10194485	184	185	O
preventable	10194485	186	197	O
cause	10194485	198	203	O
of	10194485	204	206	O
morbidity	10194485	207	216	O
and	10194485	217	220	O
mortality	10194485	221	230	O
in	10194485	231	233	O
patients	10194485	234	242	O
who	10194485	243	246	O
are	10194485	247	250	O
hospitalized	10194485	251	263	O
.	10194485	264	265	O

An	10194485	266	268	O
important	10194485	269	278	O
part	10194485	279	283	O
of	10194485	284	286	O
the	10194485	287	290	O
mechanism	10194485	291	300	O
of	10194485	301	303	O
DVT	10194485	304	307	O
prophylaxis	10194485	308	319	O
with	10194485	320	324	O
intermittent	10194485	325	337	O
pneumatic	10194485	338	347	O
compression	10194485	348	359	O
(	10194485	360	361	O
IPC	10194485	362	365	O
)	10194485	366	367	O
is	10194485	368	370	O
reduced	10194485	371	378	O
venous	10194485	379	385	O
stasis	10194485	386	392	O
with	10194485	393	397	O
increased	10194485	398	407	O
velocity	10194485	408	416	O
of	10194485	417	419	O
venous	10194485	420	426	O
return	10194485	427	433	O
.	10194485	434	435	O

The	10194485	436	439	O
conventional	10194485	440	452	O
methods	10194485	453	460	O
of	10194485	461	463	O
IPC	10194485	464	467	O
use	10194485	468	471	O
low	10194485	472	475	O
pressure	10194485	476	484	O
and	10194485	485	488	O
slow	10194485	489	493	O
inflation	10194485	494	503	O
of	10194485	504	506	O
the	10194485	507	510	O
air	10194485	511	514	O
bladder	10194485	515	522	O
on	10194485	523	525	O
the	10194485	526	529	O
leg	10194485	530	533	O
to	10194485	534	536	O
augment	10194485	537	544	O
venous	10194485	545	551	O
return	10194485	552	558	O
.	10194485	559	560	O

Recently	10194485	561	569	O
,	10194485	570	571	O
compression	10194485	572	583	O
devices	10194485	584	591	O
have	10194485	592	596	O
been	10194485	597	601	O
designed	10194485	602	610	O
that	10194485	611	615	O
produce	10194485	616	623	O
high	10194485	624	628	O
pressure	10194485	629	637	O
and	10194485	638	641	O
rapid	10194485	642	647	O
inflation	10194485	648	657	O
of	10194485	658	660	O
air	10194485	661	664	O
cuffs	10194485	665	670	O
on	10194485	671	673	O
the	10194485	674	677	O
plantar	10194485	678	685	O
plexus	10194485	686	692	O
of	10194485	693	695	O
the	10194485	696	699	O
foot	10194485	700	704	O
and	10194485	705	708	O
the	10194485	709	712	O
calf	10194485	713	717	O
.	10194485	718	719	O

The	10194485	720	723	O
purpose	10194485	724	731	O
of	10194485	732	734	O
this	10194485	735	739	O
study	10194485	740	745	O
is	10194485	746	748	O
to	10194485	749	751	O
evaluate	10194485	752	760	O
the	10194485	761	764	O
venous	10194485	765	771	B-Outcome
velocity	10194485	772	780	I-Outcome
response	10194485	781	789	I-Outcome
to	10194485	790	792	O
high-pressure	10194485	793	806	B-Intervention
,	10194485	807	808	I-Intervention
rapid-inflation	10194485	809	824	I-Intervention
compression	10194485	825	836	I-Intervention
devices	10194485	837	844	I-Intervention
versus	10194485	845	851	O
standard	10194485	852	860	B-Intervention
,	10194485	861	862	I-Intervention
low-pressure	10194485	863	875	I-Intervention
,	10194485	876	877	I-Intervention
slow-inflation	10194485	878	892	I-Intervention
compression	10194485	893	904	I-Intervention
devices	10194485	905	912	I-Intervention
in	10194485	913	915	O
healthy	10194485	916	923	B-Participant
volunteers	10194485	924	934	O
and	10194485	935	938	O
patients	10194485	939	947	O
with	10194485	948	952	O
severe	10194485	953	959	B-Participant
post-thrombotic	10194485	960	975	I-Participant
venous	10194485	976	982	I-Participant
disease	10194485	983	990	I-Participant
.	10194485	991	992	O

METHOD	10194485	993	999	O
Twenty-two	10194485	1000	1010	O
lower	10194485	1011	1016	O
extremities	10194485	1017	1028	O
from	10194485	1029	1033	O
healthy	10194485	1034	1041	B-Participant
volunteers	10194485	1042	1052	O
and	10194485	1053	1056	O
11	10194485	1057	1059	O
lower	10194485	1060	1065	O
extremities	10194485	1066	1077	O
from	10194485	1078	1082	O
patients	10194485	1083	1091	O
with	10194485	1092	1096	O
class	10194485	1097	1102	B-Participant
4	10194485	1103	1104	I-Participant
to	10194485	1105	1107	I-Participant
class	10194485	1108	1113	I-Participant
6	10194485	1114	1115	I-Participant
post-thrombotic	10194485	1116	1131	I-Participant
chronic	10194485	1132	1139	I-Participant
venous	10194485	1140	1146	I-Participant
insufficiency	10194485	1147	1160	I-Participant
were	10194485	1161	1165	O
studied	10194485	1166	1173	O
.	10194485	1174	1175	O

With	10194485	1176	1180	O
duplex	10194485	1181	1187	O
ultrasound	10194485	1188	1198	O
scanning	10194485	1199	1207	O
(	10194485	1208	1209	O
ATL-Ultramark	10194485	1210	1223	O
9	10194485	1224	1225	O
,	10194485	1226	1227	O
Advanced	10194485	1228	1236	O
Tech	10194485	1237	1241	O
Laboratory	10194485	1242	1252	O
,	10194485	1253	1254	O
Bothell	10194485	1255	1262	O
,	10194485	1263	1264	O
Wash	10194485	1265	1269	O
)	10194485	1270	1271	O
,	10194485	1272	1273	O
acute	10194485	1274	1279	B-Participant
DVT	10194485	1280	1283	I-Participant
was	10194485	1284	1287	O
excluded	10194485	1288	1296	O
before	10194485	1297	1303	O
subject	10194485	1304	1311	O
evaluation	10194485	1312	1322	O
.	10194485	1323	1324	O

Venous	10194485	1325	1331	B-Outcome
velocities	10194485	1332	1342	I-Outcome
were	10194485	1343	1347	O
monitored	10194485	1348	1357	O
after	10194485	1358	1363	O
the	10194485	1364	1367	O
application	10194485	1368	1379	O
of	10194485	1380	1382	O
each	10194485	1383	1387	O
of	10194485	1388	1390	O
five	10194485	1391	1395	O
IPC	10194485	1396	1399	B-Intervention
devices	10194485	1400	1407	I-Intervention
,	10194485	1408	1409	O
with	10194485	1410	1414	O
all	10194485	1415	1418	O
the	10194485	1419	1422	O
patients	10194485	1423	1431	O
in	10194485	1432	1434	O
the	10194485	1435	1438	O
supine	10194485	1439	1445	O
position	10194485	1446	1454	O
.	10194485	1455	1456	O

Three	10194485	1457	1462	O
high-pressure	10194485	1463	1476	B-Intervention
,	10194485	1477	1478	I-Intervention
rapid-compression	10194485	1479	1496	I-Intervention
devices	10194485	1497	1504	I-Intervention
and	10194485	1505	1508	O
two	10194485	1509	1512	O
standard	10194485	1513	1521	B-Intervention
,	10194485	1522	1523	I-Intervention
low-pressure	10194485	1524	1536	I-Intervention
,	10194485	1537	1538	I-Intervention
slow-inflation	10194485	1539	1553	I-Intervention
compression	10194485	1554	1565	I-Intervention
devices	10194485	1566	1573	I-Intervention
were	10194485	1574	1578	O
applied	10194485	1579	1586	O
in	10194485	1587	1589	O
a	10194485	1590	1591	O
random	10194485	1592	1598	O
sequence	10194485	1599	1607	O
.	10194485	1608	1609	O

Maximal	10194485	1610	1617	B-Outcome
venous	10194485	1618	1624	I-Outcome
velocities	10194485	1625	1635	I-Outcome
were	10194485	1636	1640	O
obtained	10194485	1641	1649	O
at	10194485	1650	1652	O
the	10194485	1653	1656	O
common	10194485	1657	1663	O
femoral	10194485	1664	1671	O
vein	10194485	1672	1676	O
and	10194485	1677	1680	O
the	10194485	1681	1684	O
popliteal	10194485	1685	1694	O
vein	10194485	1695	1699	O
for	10194485	1700	1703	O
all	10194485	1704	1707	O
the	10194485	1708	1711	O
devices	10194485	1712	1719	O
and	10194485	1720	1723	O
were	10194485	1724	1728	O
recorded	10194485	1729	1737	O
as	10194485	1738	1740	O
the	10194485	1741	1744	O
mean	10194485	1745	1749	B-Outcome
peak	10194485	1750	1754	I-Outcome
velocity	10194485	1755	1763	I-Outcome
of	10194485	1764	1766	I-Outcome
three	10194485	1767	1772	I-Outcome
compression	10194485	1773	1784	I-Outcome
cycles	10194485	1785	1791	I-Outcome
and	10194485	1792	1795	O
compared	10194485	1796	1804	O
with	10194485	1805	1809	O
baseline	10194485	1810	1818	O
velocities	10194485	1819	1829	O
.	10194485	1830	1831	O

RESULTS	10194485	1832	1839	O
The	10194485	1840	1843	O
baseline	10194485	1844	1852	B-Outcome
venous	10194485	1853	1859	I-Outcome
velocities	10194485	1860	1870	I-Outcome
were	10194485	1871	1875	O
higher	10194485	1876	1882	B-Observation
in	10194485	1883	1885	O
the	10194485	1886	1889	O
femoral	10194485	1890	1897	O
veins	10194485	1898	1903	O
than	10194485	1904	1908	O
in	10194485	1909	1911	O
the	10194485	1912	1915	O
popliteal	10194485	1916	1925	O
veins	10194485	1926	1931	O
in	10194485	1932	1934	O
both	10194485	1935	1939	O
the	10194485	1940	1943	O
volunteers	10194485	1944	1954	B-Participant
and	10194485	1955	1958	O
the	10194485	1959	1962	O
post-thrombotic	10194485	1963	1978	B-Participant
subjects	10194485	1979	1987	O
.	10194485	1988	1989	O

Standard	10194485	1990	1998	B-Intervention
and	10194485	1999	2002	I-Intervention
high-pressure	10194485	2003	2016	I-Intervention
,	10194485	2017	2018	I-Intervention
rapid-inflation	10194485	2019	2034	I-Intervention
compression	10194485	2035	2046	I-Intervention
significantly	10194485	2047	2060	B-Observation
increased	10194485	2061	2070	I-Observation
the	10194485	2071	2074	O
popliteal	10194485	2075	2084	B-Outcome
and	10194485	2085	2088	I-Outcome
femoral	10194485	2089	2096	I-Outcome
vein	10194485	2097	2101	I-Outcome
velocities	10194485	2102	2112	I-Outcome
in	10194485	2113	2115	O
healthy	10194485	2116	2123	B-Participant
and	10194485	2124	2127	O
post-thrombotic	10194485	2128	2143	B-Participant
subjects	10194485	2144	2152	O
.	10194485	2153	2154	O

High-pressure	10194485	2155	2168	B-Intervention
,	10194485	2169	2170	I-Intervention
rapid-inflation	10194485	2171	2186	I-Intervention
compression	10194485	2187	2198	I-Intervention
produced	10194485	2199	2207	O
significantly	10194485	2208	2221	B-Observation
higher	10194485	2222	2228	I-Observation
maximal	10194485	2229	2236	B-Outcome
venous	10194485	2237	2243	I-Outcome
velocities	10194485	2244	2254	I-Outcome
in	10194485	2255	2257	I-Outcome
the	10194485	2258	2261	I-Outcome
popliteal	10194485	2262	2271	I-Outcome
and	10194485	2272	2275	I-Outcome
femoral	10194485	2276	2283	I-Outcome
veins	10194485	2284	2289	I-Outcome
in	10194485	2290	2292	O
both	10194485	2293	2297	O
healthy	10194485	2298	2305	B-Participant
volunteers	10194485	2306	2316	O
and	10194485	2317	2320	O
patients	10194485	2321	2329	O
who	10194485	2330	2333	O
were	10194485	2334	2338	O
post-thrombotic	10194485	2339	2354	B-Participant
as	10194485	2355	2357	O
compared	10194485	2358	2366	O
with	10194485	2367	2371	O
standard	10194485	2372	2380	B-Intervention
compression	10194485	2381	2392	I-Intervention
.	10194485	2393	2394	O

Compared	10194485	2395	2403	O
with	10194485	2404	2408	O
the	10194485	2409	2412	O
healthy	10194485	2413	2420	B-Participant
volunteers	10194485	2421	2431	O
,	10194485	2432	2433	O
the	10194485	2434	2437	O
patients	10194485	2438	2446	O
who	10194485	2447	2450	O
were	10194485	2451	2455	O
post-thrombotic	10194485	2456	2471	B-Participant
had	10194485	2472	2475	O
a	10194485	2476	2477	O
significantly	10194485	2478	2491	B-Observation
attenuated	10194485	2492	2502	I-Observation
velocity	10194485	2503	2511	B-Outcome
response	10194485	2512	2520	I-Outcome
at	10194485	2521	2523	I-Outcome
both	10194485	2524	2528	I-Outcome
the	10194485	2529	2532	I-Outcome
popliteal	10194485	2533	2542	I-Outcome
and	10194485	2543	2546	I-Outcome
the	10194485	2547	2550	I-Outcome
femoral	10194485	2551	2558	I-Outcome
vein	10194485	2559	2563	I-Outcome
levels	10194485	2564	2570	I-Outcome
.	10194485	2571	2572	O

CONCLUSION	10194485	2573	2583	O
High-pressure	10194485	2584	2597	B-Intervention
,	10194485	2598	2599	I-Intervention
rapid-inflation	10194485	2600	2615	I-Intervention
pneumatic	10194485	2616	2625	I-Intervention
compression	10194485	2626	2637	I-Intervention
increases	10194485	2638	2647	B-Observation
popliteal	10194485	2648	2657	B-Outcome
and	10194485	2658	2661	I-Outcome
femoral	10194485	2662	2669	I-Outcome
vein	10194485	2670	2674	I-Outcome
velocity	10194485	2675	2683	I-Outcome
as	10194485	2684	2686	O
compared	10194485	2687	2695	O
with	10194485	2696	2700	O
standard	10194485	2701	2709	B-Intervention
,	10194485	2710	2711	I-Intervention
low-pressure	10194485	2712	2724	I-Intervention
,	10194485	2725	2726	I-Intervention
slow-inflation	10194485	2727	2741	I-Intervention
pneumatic	10194485	2742	2751	I-Intervention
compression	10194485	2752	2763	I-Intervention
.	10194485	2764	2765	O

Patients	10194485	2766	2774	O
with	10194485	2775	2779	O
post-thrombotic	10194485	2780	2795	B-Participant
venous	10194485	2796	2802	I-Participant
disease	10194485	2803	2810	I-Participant
have	10194485	2811	2815	O
a	10194485	2816	2817	O
compromised	10194485	2818	2829	B-Observation
hemodynamic	10194485	2830	2841	B-Outcome
response	10194485	2842	2850	I-Outcome
to	10194485	2851	2853	O
all	10194485	2854	2857	B-Intervention
IPC	10194485	2858	2861	I-Intervention
devices	10194485	2862	2869	I-Intervention
.	10194485	2870	2871	O

However	10194485	2872	2879	O
,	10194485	2880	2881	O
an	10194485	2882	2884	O
increased	10194485	2885	2894	B-Observation
velocity	10194485	2895	2903	B-Outcome
response	10194485	2904	2912	I-Outcome
to	10194485	2913	2915	O
the	10194485	2916	2919	O
high-pressure	10194485	2920	2933	B-Intervention
,	10194485	2934	2935	I-Intervention
rapid-inflation	10194485	2936	2951	I-Intervention
compression	10194485	2952	2963	I-Intervention
device	10194485	2964	2970	I-Intervention
is	10194485	2971	2973	O
preserved	10194485	2974	2983	O
.	10194485	2984	2985	O

High-pressure	10194485	2986	2999	B-Intervention
,	10194485	3000	3001	I-Intervention
rapid-inflation	10194485	3002	3017	I-Intervention
pneumatic	10194485	3018	3027	I-Intervention
compression	10194485	3028	3039	I-Intervention
may	10194485	3040	3043	O
offer	10194485	3044	3049	O
additional	10194485	3050	3060	B-Observation
protection	10194485	3061	3071	I-Observation
from	10194485	3072	3076	O
thrombotic	10194485	3077	3087	B-Outcome
complications	10194485	3088	3101	I-Outcome
on	10194485	3102	3104	O
the	10194485	3105	3108	O
basis	10194485	3109	3114	O
of	10194485	3115	3117	O
an	10194485	3118	3120	O
improved	10194485	3121	3129	B-Observation
hemodynamic	10194485	3130	3141	B-Outcome
response	10194485	3142	3150	I-Outcome
,	10194485	3151	3152	O
both	10194485	3153	3157	O
in	10194485	3158	3160	O
healthy	10194485	3161	3168	B-Participant
volunteers	10194485	3169	3179	O
and	10194485	3180	3183	O
in	10194485	3184	3186	O
patients	10194485	3187	3195	O
who	10194485	3196	3199	O
were	10194485	3200	3204	O
post-thrombotic	10194485	3205	3220	B-Participant
.	10194485	3221	3222	O

A	10195003	0	1	O
comparison	10195003	2	12	O
of	10195003	13	15	O
a	10195003	16	17	O
non-ionic	10195003	18	27	O
dimer	10195003	28	33	O
,	10195003	34	35	O
iodixanol	10195003	36	45	B-Intervention
with	10195003	46	50	O
a	10195003	51	52	O
non-ionic	10195003	53	62	O
monomer	10195003	63	70	O
,	10195003	71	72	O
iohexol	10195003	73	80	B-Intervention
in	10195003	81	83	O
low	10195003	84	87	B-Participant
dose	10195003	88	92	I-Participant
intravenous	10195003	93	104	I-Participant
urography	10195003	105	114	I-Participant
.	10195003	115	116	O

A	10195003	117	118	O
prospective	10195003	119	130	O
,	10195003	131	132	O
double-blind	10195003	133	145	O
study	10195003	146	151	O
of	10195003	152	154	O
392	10195003	155	158	O
patients	10195003	159	167	O
randomized	10195003	168	178	O
into	10195003	179	183	O
four	10195003	184	188	O
groups	10195003	189	195	O
was	10195003	196	199	O
performed	10195003	200	209	O
to	10195003	210	212	O
establish	10195003	213	222	O
whether	10195003	223	230	O
diagnostic	10195003	231	241	B-Outcome
intravenous	10195003	242	253	I-Outcome
urograms	10195003	254	262	I-Outcome
could	10195003	263	268	O
be	10195003	269	271	O
obtained	10195003	272	280	B-Observation
with	10195003	281	285	O
a	10195003	286	287	O
lower	10195003	288	293	B-Participant
dose	10195003	294	298	I-Participant
of	10195003	299	301	I-Participant
iodine	10195003	302	308	I-Participant
when	10195003	309	313	O
using	10195003	314	319	O
the	10195003	320	323	O
dimeric	10195003	324	331	B-Intervention
,	10195003	332	333	I-Intervention
non-ionic	10195003	334	343	I-Intervention
contrast	10195003	344	352	I-Intervention
medium	10195003	353	359	I-Intervention
iodixanol	10195003	360	369	I-Intervention
compared	10195003	370	378	O
with	10195003	379	383	O
the	10195003	384	387	O
monomeric	10195003	388	397	B-Intervention
,	10195003	398	399	I-Intervention
non-ionic	10195003	400	409	I-Intervention
iohexol	10195003	410	417	I-Intervention
.	10195003	418	419	O

Patients	10195003	420	428	O
received	10195003	429	437	O
iodixanol	10195003	438	447	B-Intervention
or	10195003	448	450	I-Intervention
iohexol	10195003	451	458	I-Intervention
containing	10195003	459	469	I-Intervention
either	10195003	470	476	I-Intervention
9	10195003	477	478	I-Intervention
or	10195003	479	481	I-Intervention
12	10195003	482	484	I-Intervention
g	10195003	485	486	I-Intervention
of	10195003	487	489	I-Intervention
iodine	10195003	490	496	I-Intervention
(	10195003	497	498	I-Intervention
gI	10195003	499	501	I-Intervention
)	10195003	502	503	I-Intervention
.	10195003	504	505	O

The	10195003	506	509	O
primary	10195003	510	517	O
parameter	10195003	518	527	O
was	10195003	528	531	O
the	10195003	532	535	O
diagnostic	10195003	536	546	B-Outcome
quality	10195003	547	554	I-Outcome
of	10195003	555	557	O
the	10195003	558	561	O
6	10195003	562	563	O
min	10195003	564	567	O
film	10195003	568	572	O
,	10195003	573	574	O
assessed	10195003	575	583	O
in	10195003	584	586	O
a	10195003	587	588	O
blinded	10195003	589	596	O
fashion	10195003	597	604	O
,	10195003	605	606	O
by	10195003	607	609	O
consensus	10195003	610	619	O
,	10195003	620	621	O
by	10195003	622	624	O
four	10195003	625	629	O
radiologists	10195003	630	642	O
.	10195003	643	644	O

Iodixanol	10195003	645	654	B-Intervention
at	10195003	655	657	I-Intervention
both	10195003	658	662	I-Intervention
doses	10195003	663	668	I-Intervention
was	10195003	669	672	O
diagnostic	10195003	673	683	B-Outcome
in	10195003	684	686	O
over	10195003	687	691	B-Count
90	10195003	692	694	I-Count
%	10195003	695	696	I-Count
of	10195003	697	699	I-Count
cases	10195003	700	705	I-Count
.	10195003	706	707	O

Iohexol	10195003	708	715	B-Intervention
was	10195003	716	719	O
only	10195003	720	724	O
diagnostic	10195003	725	735	B-Outcome
in	10195003	736	738	O
74	10195003	739	741	B-Count
%	10195003	742	743	I-Count
(	10195003	744	745	O
9	10195003	746	747	B-Intervention
gI	10195003	748	750	I-Intervention
)	10195003	751	752	O
and	10195003	753	756	O
81.8	10195003	757	761	B-Count
%	10195003	762	763	I-Count
(	10195003	764	765	O
12	10195003	766	768	B-Intervention
gI	10195003	769	771	I-Intervention
)	10195003	772	773	O
.	10195003	774	775	O

Pairwise	10195003	776	784	O
comparisons	10195003	785	796	O
revealed	10195003	797	805	O
that	10195003	806	810	O
iodixanol	10195003	811	820	B-Intervention
9	10195003	821	822	I-Intervention
gI	10195003	823	825	I-Intervention
was	10195003	826	829	O
significantly	10195003	830	843	B-Observation
better	10195003	844	850	I-Observation
than	10195003	851	855	O
both	10195003	856	860	O
iohexol	10195003	861	868	B-Intervention
9	10195003	869	870	I-Intervention
gI	10195003	871	873	I-Intervention
(	10195003	874	875	O
p	10195003	876	877	O
=	10195003	878	879	O
0.0005	10195003	880	886	O
)	10195003	887	888	O
and	10195003	889	892	O
12	10195003	893	895	B-Intervention
gI	10195003	896	898	I-Intervention
(	10195003	899	900	O
p	10195003	901	902	O
=	10195003	903	904	O
0.014	10195003	905	910	O
)	10195003	911	912	O
.	10195003	913	914	O

No	10195003	915	917	O
significant	10195003	918	929	B-Observation
difference	10195003	930	940	I-Observation
was	10195003	941	944	O
present	10195003	945	952	O
for	10195003	953	956	O
different	10195003	957	966	B-Intervention
doses	10195003	967	972	I-Intervention
within	10195003	973	979	I-Intervention
the	10195003	980	983	I-Intervention
same	10195003	984	988	I-Intervention
contrast	10195003	989	997	I-Intervention
medium	10195003	998	1004	I-Intervention
group	10195003	1005	1010	I-Intervention
.	10195003	1011	1012	O

Iodixanol	10195003	1013	1022	B-Intervention
resulted	10195003	1023	1031	O
in	10195003	1032	1034	O
poorer	10195003	1035	1041	B-Observation
bladder	10195003	1042	1049	B-Outcome
distension	10195003	1050	1060	I-Outcome
than	10195003	1061	1065	O
iohexol	10195003	1066	1073	B-Intervention
.	10195003	1074	1075	O

Iodixanol	10195003	1076	1085	B-Intervention
caused	10195003	1086	1092	O
significantly	10195003	1093	1106	B-Observation
less	10195003	1107	1111	I-Observation
discomfort	10195003	1112	1122	B-Outcome
than	10195003	1123	1127	O
iohexol	10195003	1128	1135	B-Intervention
.	10195003	1136	1137	O

Isoniazid	10197379	0	9	B-Intervention
prophylaxis	10197379	10	21	I-Intervention
for	10197379	22	25	O
tuberculosis	10197379	26	38	B-Outcome
in	10197379	39	41	O
HIV	10197379	42	45	B-Participant
infection	10197379	46	55	I-Participant
:	10197379	56	57	O
a	10197379	58	59	O
meta-analysis	10197379	60	73	O
of	10197379	74	76	O
randomized	10197379	77	87	O
controlled	10197379	88	98	O
trials	10197379	99	105	O
.	10197379	106	107	O

OBJECTIVES	10197379	108	118	O
To	10197379	119	121	O
evaluate	10197379	122	130	O
the	10197379	131	134	O
efficacy	10197379	135	143	O
of	10197379	144	146	O
isoniazid	10197379	147	156	B-Intervention
for	10197379	157	160	O
the	10197379	161	164	O
prevention	10197379	165	175	B-Observation
of	10197379	176	178	O
tuberculosis	10197379	179	191	B-Outcome
in	10197379	192	194	O
tuberculin	10197379	195	205	B-Participant
skin	10197379	206	210	I-Participant
test-positive	10197379	211	224	I-Participant
and	10197379	225	228	I-Participant
negative	10197379	229	237	I-Participant
individuals	10197379	238	249	O
with	10197379	250	254	O
HIV	10197379	255	258	B-Participant
infection	10197379	259	268	I-Participant
.	10197379	269	270	O

DESIGN	10197379	271	277	O
Meta-analysis	10197379	278	291	O
of	10197379	292	294	O
randomized	10197379	295	305	O
controlled	10197379	306	316	O
trials	10197379	317	323	O
.	10197379	324	325	O

SETTING	10197379	326	333	O
Seven	10197379	334	339	O
trials	10197379	340	346	O
from	10197379	347	351	O
Mexico	10197379	352	358	O
,	10197379	359	360	O
Haiti	10197379	361	366	O
,	10197379	367	368	O
the	10197379	369	372	O
United	10197379	373	379	O
States	10197379	380	386	O
,	10197379	387	388	O
Zambia	10197379	389	395	O
,	10197379	396	397	O
Uganda	10197379	398	404	O
and	10197379	405	408	O
Kenya	10197379	409	414	O
.	10197379	415	416	O

PATIENTS	10197379	417	425	O
Individuals	10197379	426	437	O
free	10197379	438	442	B-Participant
from	10197379	443	447	I-Participant
tuberculosis	10197379	448	460	I-Participant
,	10197379	461	462	O
2367	10197379	463	467	O
persons	10197379	468	475	O
in	10197379	476	478	O
the	10197379	479	482	O
intervention	10197379	483	495	O
and	10197379	496	499	O
2162	10197379	500	504	O
in	10197379	505	507	O
the	10197379	508	511	O
control	10197379	512	519	O
groups	10197379	520	526	O
.	10197379	527	528	O

INTERVENTION	10197379	529	541	O
Comparison	10197379	542	552	O
of	10197379	553	555	O
isoniazid	10197379	556	565	B-Intervention
with	10197379	566	570	O
placebo	10197379	571	578	B-Intervention
or	10197379	579	581	O
no	10197379	582	584	B-Intervention
prophylaxis	10197379	585	596	I-Intervention
.	10197379	597	598	O

METHODS	10197379	599	606	O
A	10197379	607	608	O
systematic	10197379	609	619	O
search	10197379	620	626	O
of	10197379	627	629	O
the	10197379	630	633	O
literature	10197379	634	644	O
was	10197379	645	648	O
carried	10197379	649	656	O
out	10197379	657	660	O
from	10197379	661	665	O
1985	10197379	666	670	O
to	10197379	671	673	O
October	10197379	674	681	O
1997	10197379	682	686	O
for	10197379	687	690	O
randomized	10197379	691	701	O
controlled	10197379	702	712	O
trials	10197379	713	719	O
of	10197379	720	722	O
isoniazid	10197379	723	732	B-Intervention
prophylaxis	10197379	733	744	I-Intervention
in	10197379	745	747	O
HIV-infected	10197379	748	760	B-Participant
persons	10197379	761	768	O
.	10197379	769	770	O

Two	10197379	771	774	O
reviewers	10197379	775	784	O
evaluated	10197379	785	794	O
the	10197379	795	798	O
relevance	10197379	799	808	O
of	10197379	809	811	O
each	10197379	812	816	O
candidate	10197379	817	826	O
study	10197379	827	832	O
and	10197379	833	836	O
the	10197379	837	840	O
validity	10197379	841	849	O
of	10197379	850	852	O
eligible	10197379	853	861	O
trials	10197379	862	868	O
.	10197379	869	870	O

Studies	10197379	871	878	O
were	10197379	879	883	O
pooled	10197379	884	890	O
using	10197379	891	896	O
a	10197379	897	898	O
random	10197379	899	905	O
effect	10197379	906	912	O
model	10197379	913	918	O
,	10197379	919	920	O
conducting	10197379	921	931	O
secondary	10197379	932	941	O
analyses	10197379	942	950	O
for	10197379	951	954	O
tuberculin	10197379	955	965	B-Participant
skin	10197379	966	970	I-Participant
test-positive	10197379	971	984	I-Participant
and	10197379	985	988	I-Participant
negative	10197379	989	997	I-Participant
persons	10197379	998	1005	O
.	10197379	1006	1007	O

RESULTS	10197379	1008	1015	O
Mean	10197379	1016	1020	O
follow-up	10197379	1021	1030	O
in	10197379	1031	1033	O
trials	10197379	1034	1040	O
varied	10197379	1041	1047	O
between	10197379	1048	1055	O
0.4	10197379	1056	1059	O
and	10197379	1060	1063	O
3.2	10197379	1064	1067	O
years	10197379	1068	1073	O
.	10197379	1074	1075	O

Pooling	10197379	1076	1083	O
all	10197379	1084	1087	O
seven	10197379	1088	1093	O
trials	10197379	1094	1100	O
,	10197379	1101	1102	O
a	10197379	1103	1104	O
risk	10197379	1105	1109	B-Outcome
ratio	10197379	1110	1115	I-Outcome
was	10197379	1116	1119	O
found	10197379	1120	1125	O
for	10197379	1126	1129	O
persons	10197379	1130	1137	O
treated	10197379	1138	1145	O
with	10197379	1146	1150	O
isoniazid	10197379	1151	1160	B-Intervention
for	10197379	1161	1164	O
developing	10197379	1165	1175	B-Outcome
tuberculosis	10197379	1176	1188	I-Outcome
of	10197379	1189	1191	O
0.58	10197379	1192	1196	B-Observation
[	10197379	1197	1198	O
95	10197379	1199	1201	O
%	10197379	1202	1203	O
confidence	10197379	1204	1214	O
interval	10197379	1215	1223	O
(	10197379	1224	1225	O
CI	10197379	1226	1228	O
)	10197379	1229	1230	O
,	10197379	1231	1232	O
0.43	10197379	1233	1237	O
-	10197379	1237	1238	O
0.80	10197379	1238	1242	O
]	10197379	1243	1244	O
and	10197379	1245	1248	O
0.94	10197379	1249	1253	B-Observation
(	10197379	1254	1255	O
95	10197379	1256	1258	O
%	10197379	1259	1260	O
CI	10197379	1261	1263	O
,	10197379	1264	1265	O
0.83	10197379	1266	1270	O
-	10197379	1270	1271	O
1.07	10197379	1271	1275	O
)	10197379	1276	1277	O
for	10197379	1278	1281	O
death	10197379	1282	1287	B-Outcome
.	10197379	1288	1289	O

In	10197379	1290	1292	O
groups	10197379	1293	1299	O
of	10197379	1300	1302	O
tuberculin	10197379	1303	1313	B-Participant
skin	10197379	1314	1318	I-Participant
test-positive	10197379	1319	1332	I-Participant
and	10197379	1333	1336	I-Participant
negative	10197379	1337	1345	I-Participant
persons	10197379	1346	1353	O
,	10197379	1354	1355	O
the	10197379	1356	1359	O
risk	10197379	1360	1364	B-Outcome
ratio	10197379	1365	1370	I-Outcome
of	10197379	1371	1373	I-Outcome
tuberculosis	10197379	1374	1386	I-Outcome
was	10197379	1387	1390	O
0.40	10197379	1391	1395	B-Observation
(	10197379	1396	1397	O
95	10197379	1398	1400	O
%	10197379	1401	1402	O
CI	10197379	1403	1405	O
,	10197379	1406	1407	O
0.24	10197379	1408	1412	O
-	10197379	1412	1413	O
0.65	10197379	1413	1417	O
)	10197379	1418	1419	O
and	10197379	1420	1423	O
0.84	10197379	1424	1428	B-Observation
(	10197379	1429	1430	O
95	10197379	1431	1433	O
%	10197379	1434	1435	O
CI	10197379	1436	1438	O
,	10197379	1439	1440	O
0.54	10197379	1441	1445	O
-	10197379	1445	1446	O
1.30	10197379	1446	1450	O
)	10197379	1451	1452	O
,	10197379	1453	1454	O
respectively	10197379	1455	1467	O
,	10197379	1468	1469	O
and	10197379	1470	1473	O
the	10197379	1474	1477	O
difference	10197379	1478	1488	B-Outcome
in	10197379	1489	1491	I-Outcome
the	10197379	1492	1495	I-Outcome
effectiveness	10197379	1496	1509	I-Outcome
of	10197379	1510	1512	O
isoniazid	10197379	1513	1522	B-Intervention
versus	10197379	1523	1529	O
placebo	10197379	1530	1537	B-Intervention
between	10197379	1538	1545	O
these	10197379	1546	1551	O
groups	10197379	1552	1558	O
was	10197379	1559	1562	O
statistically	10197379	1563	1576	B-Observation
significant	10197379	1577	1588	I-Observation
(	10197379	1589	1590	O
P	10197379	1591	1592	O
=	10197379	1593	1594	O
0.03	10197379	1595	1599	O
,	10197379	1600	1601	O
for	10197379	1602	1605	O
the	10197379	1606	1609	O
difference	10197379	1610	1620	B-Outcome
of	10197379	1621	1623	I-Outcome
summary	10197379	1624	1631	I-Outcome
estimates	10197379	1632	1641	I-Outcome
)	10197379	1642	1643	O
.	10197379	1644	1645	O

Consistency	10197379	1646	1657	O
of	10197379	1658	1660	O
results	10197379	1661	1668	O
was	10197379	1669	1672	O
found	10197379	1673	1678	O
across	10197379	1679	1685	O
trials	10197379	1686	1692	O
(	10197379	1693	1694	O
P	10197379	1695	1696	O
>	10197379	1697	1698	O
0.10	10197379	1699	1703	O
,	10197379	1704	1705	O
heterogeneity	10197379	1706	1719	O
value	10197379	1720	1725	O
)	10197379	1726	1727	O
for	10197379	1728	1731	O
all	10197379	1732	1735	O
comparisons	10197379	1736	1747	O
.	10197379	1748	1749	O

CONCLUSIONS	10197379	1750	1761	O
Prophylaxis	10197379	1762	1773	B-Intervention
with	10197379	1774	1778	I-Intervention
isoniazid	10197379	1779	1788	I-Intervention
reduces	10197379	1789	1796	B-Observation
the	10197379	1797	1800	O
risk	10197379	1801	1805	B-Outcome
of	10197379	1806	1808	I-Outcome
tuberculosis	10197379	1809	1821	I-Outcome
in	10197379	1822	1824	O
persons	10197379	1825	1832	O
with	10197379	1833	1837	O
HIV	10197379	1838	1841	B-Participant
infection	10197379	1842	1851	I-Participant
.	10197379	1852	1853	O

The	10197379	1854	1857	O
effect	10197379	1858	1864	B-Outcome
is	10197379	1865	1867	O
restricted	10197379	1868	1878	B-Observation
to	10197379	1879	1881	O
tuberculin	10197379	1882	1892	B-Participant
skin	10197379	1893	1897	I-Participant
test-positive	10197379	1898	1911	I-Participant
persons	10197379	1912	1919	O
.	10197379	1920	1921	O

Effects	10209728	0	7	O
of	10209728	8	10	O
oral	10209728	11	15	B-Intervention
brovincamine	10209728	16	28	I-Intervention
on	10209728	29	31	O
visual	10209728	32	38	B-Outcome
field	10209728	39	44	I-Outcome
damage	10209728	45	51	I-Outcome
in	10209728	52	54	O
patients	10209728	55	63	O
with	10209728	64	68	O
normal-tension	10209728	69	83	B-Participant
glaucoma	10209728	84	92	I-Participant
with	10209728	93	97	O
low-normal	10209728	98	108	B-Participant
intraocular	10209728	109	120	I-Participant
pressure	10209728	121	129	I-Participant
.	10209728	130	131	O

PURPOSE	10209728	132	139	O
To	10209728	140	142	O
prospectively	10209728	143	156	O
study	10209728	157	162	O
the	10209728	163	166	O
effect	10209728	167	173	O
of	10209728	174	176	O
oral	10209728	177	181	B-Intervention
brovincamine	10209728	182	194	I-Intervention
,	10209728	195	196	O
a	10209728	197	198	O
relatively	10209728	199	209	O
selective	10209728	210	219	O
cerebral	10209728	220	228	O
vasodilator	10209728	229	240	O
,	10209728	241	242	O
on	10209728	243	245	O
further	10209728	246	253	B-Outcome
deterioration	10209728	254	267	I-Outcome
of	10209728	268	270	I-Outcome
visual	10209728	271	277	I-Outcome
field	10209728	278	283	I-Outcome
in	10209728	284	286	O
patients	10209728	287	295	O
with	10209728	296	300	O
normal-tension	10209728	301	315	B-Participant
glaucoma	10209728	316	324	I-Participant
(	10209728	325	326	I-Participant
NTG	10209728	327	330	I-Participant
)	10209728	331	332	I-Participant
with	10209728	333	337	O
low-normal	10209728	338	348	B-Participant
intraocular	10209728	349	360	I-Participant
pressure	10209728	361	369	I-Participant
(	10209728	370	371	I-Participant
IOP	10209728	372	375	I-Participant
)	10209728	376	377	I-Participant
.	10209728	378	379	O

METHODS	10209728	380	387	O
Fifty-two	10209728	388	397	O
patients	10209728	398	406	O
with	10209728	407	411	O
NTG	10209728	412	415	B-Participant
(	10209728	416	417	O
average	10209728	418	425	O
age	10209728	426	429	O
57.7	10209728	430	434	O
years	10209728	435	440	O
)	10209728	441	442	O
with	10209728	443	447	O
an	10209728	448	450	O
IOP	10209728	451	454	B-Participant
that	10209728	455	459	O
was	10209728	460	463	O
consistently	10209728	464	476	O
less	10209728	477	481	O
than	10209728	482	486	O
15	10209728	487	489	O
mmHg	10209728	490	494	O
were	10209728	495	499	O
randomly	10209728	500	508	O
assigned	10209728	509	517	O
to	10209728	518	520	O
receive	10209728	521	528	O
oral	10209728	529	533	B-Intervention
brovincamine	10209728	534	546	I-Intervention
(	10209728	547	548	O
20	10209728	549	551	O
mg	10209728	552	554	O
three	10209728	555	560	O
times	10209728	561	566	O
daily	10209728	567	572	O
)	10209728	573	574	O
or	10209728	575	577	O
to	10209728	578	580	O
an	10209728	581	583	O
untreated	10209728	584	593	B-Intervention
control	10209728	594	601	I-Intervention
group	10209728	602	607	O
.	10209728	608	609	O

The	10209728	610	613	O
groups	10209728	614	620	O
were	10209728	621	625	O
prospectively	10209728	626	639	O
followed	10209728	640	648	O
for	10209728	649	652	O
2	10209728	653	654	O
years	10209728	655	660	O
with	10209728	661	665	O
visual	10209728	666	672	O
field	10209728	673	678	O
examinations	10209728	679	691	O
every	10209728	692	697	O
4	10209728	698	699	O
months	10209728	700	706	O
,	10209728	707	708	O
using	10209728	709	714	O
the	10209728	715	718	O
30	10209728	719	721	O
-	10209728	721	722	O
2	10209728	722	723	O
Humphrey	10209728	724	732	O
perimeter	10209728	733	742	O
program	10209728	743	750	O
.	10209728	751	752	O

Changes	10209728	753	760	B-Observation
in	10209728	761	763	O
mean	10209728	764	768	B-Outcome
deviation	10209728	769	778	I-Outcome
(	10209728	779	780	I-Outcome
MD	10209728	781	783	I-Outcome
)	10209728	784	785	I-Outcome
,	10209728	786	787	O
corrected	10209728	788	797	B-Outcome
pattern	10209728	798	805	I-Outcome
standard	10209728	806	814	I-Outcome
deviation	10209728	815	824	I-Outcome
(	10209728	825	826	I-Outcome
CPSD	10209728	827	831	I-Outcome
)	10209728	832	833	I-Outcome
,	10209728	834	835	O
and	10209728	836	839	O
total	10209728	840	845	B-Outcome
deviation	10209728	846	855	I-Outcome
(	10209728	856	857	I-Outcome
TD	10209728	858	860	I-Outcome
)	10209728	861	862	I-Outcome
at	10209728	863	865	O
74	10209728	866	868	O
test	10209728	869	873	O
points	10209728	874	880	O
were	10209728	881	885	O
analyzed	10209728	886	894	O
using	10209728	895	900	O
regression	10209728	901	911	O
analysis	10209728	912	920	O
with	10209728	921	925	O
linear	10209728	926	932	O
mixed	10209728	933	938	O
model	10209728	939	944	O
.	10209728	945	946	O

Data	10209728	947	951	O
from	10209728	952	956	O
one	10209728	957	960	O
eye	10209728	961	964	O
without	10209728	965	972	O
media	10209728	973	978	O
opacity	10209728	979	986	O
of	10209728	987	989	O
each	10209728	990	994	O
subject	10209728	995	1002	O
were	10209728	1003	1007	O
analyzed	10209728	1008	1016	O
.	10209728	1017	1018	O

RESULTS	10209728	1019	1026	O
There	10209728	1027	1032	O
were	10209728	1033	1037	O
no	10209728	1038	1040	O
differences	10209728	1041	1052	O
between	10209728	1053	1060	O
groups	10209728	1061	1067	O
in	10209728	1068	1070	O
age	10209728	1071	1074	O
;	10209728	1075	1076	O
sex	10209728	1077	1080	O
distribution	10209728	1081	1093	O
;	10209728	1094	1095	O
refraction	10209728	1096	1106	O
;	10209728	1107	1108	O
blood	10209728	1109	1114	O
pressure	10209728	1115	1123	O
;	10209728	1124	1125	O
baseline	10209728	1126	1134	O
IOP	10209728	1135	1138	O
;	10209728	1139	1140	O
MD	10209728	1141	1143	O
,	10209728	1144	1145	O
CPSD	10209728	1146	1150	O
,	10209728	1151	1152	O
or	10209728	1153	1155	O
TD	10209728	1156	1158	O
at	10209728	1159	1161	O
each	10209728	1162	1166	O
point	10209728	1167	1172	O
.	10209728	1173	1174	O

Changes	10209728	1175	1182	B-Outcome
in	10209728	1183	1185	I-Outcome
MD	10209728	1186	1188	I-Outcome
(	10209728	1189	1190	O
standard	10209728	1191	1199	O
error	10209728	1200	1205	O
[	10209728	1206	1207	O
SE	10209728	1208	1210	O
]	10209728	1211	1212	O
)	10209728	1213	1214	O
during	10209728	1215	1221	O
the	10209728	1222	1225	O
study	10209728	1226	1231	O
period	10209728	1232	1238	O
were	10209728	1239	1243	O
-0.778	10209728	1244	1250	B-Observation
(	10209728	1251	1252	I-Observation
0.178	10209728	1253	1258	I-Observation
)	10209728	1259	1260	I-Observation
and	10209728	1261	1264	O
-0.071	10209728	1265	1271	B-Observation
(	10209728	1272	1273	I-Observation
0.195	10209728	1274	1279	I-Observation
)	10209728	1280	1281	I-Observation
dB/year	10209728	1282	1289	I-Observation
in	10209728	1290	1292	O
the	10209728	1293	1296	O
control	10209728	1297	1304	B-Intervention
and	10209728	1305	1308	O
brovincamine	10209728	1309	1321	B-Intervention
groups	10209728	1322	1328	O
,	10209728	1329	1330	O
respectively	10209728	1331	1343	O
;	10209728	1344	1345	O
change	10209728	1346	1352	B-Outcome
in	10209728	1353	1355	O
the	10209728	1356	1359	O
control	10209728	1360	1367	B-Intervention
group	10209728	1368	1373	O
was	10209728	1374	1377	O
significantly	10209728	1378	1391	B-Observation
more	10209728	1392	1396	I-Observation
negative	10209728	1397	1405	I-Observation
than	10209728	1406	1410	O
in	10209728	1411	1413	O
the	10209728	1414	1417	O
brovincamine	10209728	1418	1430	B-Intervention
group	10209728	1431	1436	O
.	10209728	1437	1438	O

Change	10209728	1439	1445	B-Outcome
in	10209728	1446	1448	I-Outcome
CPSD	10209728	1449	1453	I-Outcome
(	10209728	1454	1455	I-Outcome
SE	10209728	1456	1458	I-Outcome
)	10209728	1459	1460	I-Outcome
was	10209728	1461	1464	O
0.032	10209728	1465	1470	B-Observation
(	10209728	1471	1472	I-Observation
0.015	10209728	1473	1478	I-Observation
)	10209728	1479	1480	I-Observation
and	10209728	1481	1484	O
0.004	10209728	1485	1490	B-Observation
(	10209728	1491	1492	I-Observation
0.016	10209728	1493	1498	I-Observation
)	10209728	1499	1500	I-Observation
dB/year	10209728	1501	1508	I-Observation
in	10209728	1509	1511	O
the	10209728	1512	1515	O
control	10209728	1516	1523	B-Intervention
and	10209728	1524	1527	O
brovincamine	10209728	1528	1540	B-Intervention
groups	10209728	1541	1547	O
,	10209728	1548	1549	O
respectively	10209728	1550	1562	O
.	10209728	1563	1564	O

Change	10209728	1565	1571	B-Outcome
in	10209728	1572	1574	O
the	10209728	1575	1578	O
control	10209728	1579	1586	B-Intervention
group	10209728	1587	1592	O
was	10209728	1593	1596	O
significantly	10209728	1597	1610	B-Observation
positive	10209728	1611	1619	I-Observation
,	10209728	1620	1621	O
but	10209728	1622	1625	O
the	10209728	1626	1629	O
intergroup	10209728	1630	1640	B-Outcome
difference	10209728	1641	1651	I-Outcome
was	10209728	1652	1655	O
not	10209728	1656	1659	O
significant	10209728	1660	1671	B-Observation
.	10209728	1672	1673	O

Change	10209728	1674	1680	B-Outcome
in	10209728	1681	1683	I-Outcome
TD	10209728	1684	1686	I-Outcome
was	10209728	1687	1690	O
significantly	10209728	1691	1704	B-Observation
negative	10209728	1705	1713	I-Observation
at	10209728	1714	1716	O
six	10209728	1717	1720	O
test	10209728	1721	1725	O
points	10209728	1726	1732	O
in	10209728	1733	1735	O
the	10209728	1736	1739	O
control	10209728	1740	1747	B-Intervention
group	10209728	1748	1753	O
,	10209728	1754	1755	O
whereas	10209728	1756	1763	O
no	10209728	1764	1766	O
points	10209728	1767	1773	O
showed	10209728	1774	1780	O
a	10209728	1781	1782	O
significant	10209728	1783	1794	B-Observation
trend	10209728	1795	1800	I-Observation
in	10209728	1801	1803	O
the	10209728	1804	1807	O
brovincamine	10209728	1808	1820	B-Intervention
group	10209728	1821	1826	O
;	10209728	1827	1828	O
the	10209728	1829	1832	O
intergroup	10209728	1833	1843	B-Outcome
difference	10209728	1844	1854	I-Outcome
was	10209728	1855	1858	O
significant	10209728	1859	1870	B-Observation
.	10209728	1871	1872	O

The	10209728	1873	1876	O
average	10209728	1877	1884	B-Outcome
IOP	10209728	1885	1888	I-Outcome
was	10209728	1889	1892	O
13.2	10209728	1893	1897	B-Observation
mmHg	10209728	1898	1902	I-Observation
and	10209728	1903	1906	O
13.1	10209728	1907	1911	B-Observation
mmHg	10209728	1912	1916	I-Observation
in	10209728	1917	1919	O
the	10209728	1920	1923	O
control	10209728	1924	1931	B-Intervention
and	10209728	1932	1935	O
brovincamine	10209728	1936	1948	B-Intervention
groups	10209728	1949	1955	O
,	10209728	1956	1957	O
respectively	10209728	1958	1970	O
,	10209728	1971	1972	O
and	10209728	1973	1976	O
there	10209728	1977	1982	O
was	10209728	1983	1986	O
no	10209728	1987	1989	O
significant	10209728	1990	2001	B-Observation
intergroup	10209728	2002	2012	I-Observation
difference	10209728	2013	2023	I-Observation
.	10209728	2024	2025	O

CONCLUSION	10209728	2026	2036	O
Oral	10209728	2037	2041	B-Intervention
brovincamine	10209728	2042	2054	I-Intervention
may	10209728	2055	2058	O
retard	10209728	2059	2065	B-Observation
further	10209728	2066	2073	B-Outcome
visual	10209728	2074	2080	I-Outcome
field	10209728	2081	2086	I-Outcome
deterioration	10209728	2087	2100	I-Outcome
in	10209728	2101	2103	O
patients	10209728	2104	2112	O
with	10209728	2113	2117	O
NTG	10209728	2118	2121	B-Participant
who	10209728	2122	2125	O
have	10209728	2126	2130	O
low-normal	10209728	2131	2141	B-Participant
IOP	10209728	2142	2145	I-Participant
.	10209728	2146	2147	O

Local	10211492	0	5	B-Intervention
injection	10211492	6	15	I-Intervention
of	10211492	16	18	I-Intervention
bupivacaine	10211492	19	30	I-Intervention
after	10211492	31	36	O
rubber	10211492	37	43	B-Participant
band	10211492	44	48	I-Participant
ligation	10211492	49	57	I-Participant
of	10211492	58	60	I-Participant
hemorrhoids	10211492	61	72	I-Participant
:	10211492	73	74	O
prospective	10211492	75	86	O
,	10211492	87	88	O
randomized	10211492	89	99	O
study	10211492	100	105	O
.	10211492	106	107	O

PURPOSE	10211492	108	115	O
The	10211492	116	119	O
aim	10211492	120	123	O
of	10211492	124	126	O
this	10211492	127	131	O
study	10211492	132	137	O
was	10211492	138	141	O
to	10211492	142	144	O
determine	10211492	145	154	O
if	10211492	155	157	O
local	10211492	158	163	B-Intervention
injection	10211492	164	173	I-Intervention
of	10211492	174	176	I-Intervention
bupivacaine	10211492	177	188	I-Intervention
after	10211492	189	194	O
hemorrhoidal	10211492	195	207	B-Participant
banding	10211492	208	215	I-Participant
causes	10211492	216	222	O
a	10211492	223	224	O
decrease	10211492	225	233	B-Observation
in	10211492	234	236	O
pain	10211492	237	241	B-Outcome
and	10211492	242	245	O
in	10211492	246	248	O
the	10211492	249	252	O
incidence	10211492	253	262	B-Outcome
of	10211492	263	265	I-Outcome
associated	10211492	266	276	I-Outcome
symptoms	10211492	277	285	I-Outcome
.	10211492	286	287	O

METHODS	10211492	288	295	O
After	10211492	296	301	O
hemorrhoidal	10211492	302	314	B-Participant
banding	10211492	315	322	I-Participant
,	10211492	323	324	O
patients	10211492	325	333	O
were	10211492	334	338	O
randomly	10211492	339	347	O
assigned	10211492	348	356	O
to	10211492	357	359	O
receive	10211492	360	367	O
a	10211492	368	369	O
local	10211492	370	375	B-Intervention
injection	10211492	376	385	I-Intervention
of	10211492	386	388	I-Intervention
bupivacaine	10211492	389	400	I-Intervention
with	10211492	401	405	O
1:200,000	10211492	406	415	O
epinephrine	10211492	416	427	O
,	10211492	428	429	O
an	10211492	430	432	O
injection	10211492	433	442	O
of	10211492	443	445	O
normal	10211492	446	452	B-Intervention
saline	10211492	453	459	I-Intervention
,	10211492	460	461	O
or	10211492	462	464	O
no	10211492	465	467	B-Intervention
injection	10211492	468	477	I-Intervention
,	10211492	478	479	O
just	10211492	480	484	O
superior	10211492	485	493	O
to	10211492	494	496	O
each	10211492	497	501	O
band	10211492	502	506	O
.	10211492	507	508	O

Pain	10211492	509	513	B-Outcome
was	10211492	514	517	O
graded	10211492	518	524	O
by	10211492	525	527	O
the	10211492	528	531	O
patient	10211492	532	539	O
and	10211492	540	543	O
by	10211492	544	546	O
the	10211492	547	550	O
study	10211492	551	556	O
nurse	10211492	557	562	O
within	10211492	563	569	O
30	10211492	570	572	O
minutes	10211492	573	580	O
,	10211492	581	582	O
and	10211492	583	586	O
any	10211492	587	590	O
associated	10211492	591	601	B-Outcome
symptoms	10211492	602	610	I-Outcome
were	10211492	611	615	O
recorded	10211492	616	624	O
.	10211492	625	626	O

At	10211492	627	629	O
intervals	10211492	630	639	O
6	10211492	640	641	O
,	10211492	642	643	O
24	10211492	644	646	O
,	10211492	647	648	O
and	10211492	649	652	O
48	10211492	653	655	O
hours	10211492	656	661	O
postbanding	10211492	662	673	O
,	10211492	674	675	O
the	10211492	676	679	O
patient	10211492	680	687	B-Outcome
recorded	10211492	688	696	I-Outcome
pain	10211492	697	701	I-Outcome
,	10211492	702	703	O
limitation	10211492	704	714	B-Outcome
of	10211492	715	717	I-Outcome
activities	10211492	718	728	I-Outcome
,	10211492	729	730	O
and	10211492	731	734	O
analgesic	10211492	735	744	B-Outcome
requirements	10211492	745	757	I-Outcome
.	10211492	758	759	O

Associated	10211492	760	770	B-Outcome
symptoms	10211492	771	779	I-Outcome
while	10211492	780	785	I-Outcome
at	10211492	786	788	I-Outcome
home	10211492	789	793	I-Outcome
were	10211492	794	798	O
recorded	10211492	799	807	O
.	10211492	808	809	O

RESULTS	10211492	810	817	O
Of	10211492	818	820	O
115	10211492	821	824	O
patients	10211492	825	833	O
studied	10211492	834	841	O
,	10211492	842	843	O
42	10211492	844	846	O
received	10211492	847	855	O
bupivacaine	10211492	856	867	B-Intervention
injection	10211492	868	877	I-Intervention
,	10211492	878	879	O
42	10211492	880	882	O
received	10211492	883	891	O
normal	10211492	892	898	B-Intervention
saline	10211492	899	905	I-Intervention
injection	10211492	906	915	I-Intervention
,	10211492	916	917	O
and	10211492	918	921	O
31	10211492	922	924	O
received	10211492	925	933	O
no	10211492	934	936	B-Intervention
injection	10211492	937	946	I-Intervention
.	10211492	947	948	O

In	10211492	949	951	O
patients	10211492	952	960	O
receiving	10211492	961	970	O
bupivacaine	10211492	971	982	B-Intervention
compared	10211492	983	991	O
with	10211492	992	996	O
no	10211492	997	999	B-Intervention
injection	10211492	1000	1009	I-Intervention
,	10211492	1010	1011	O
within	10211492	1012	1018	O
30	10211492	1019	1021	O
minutes	10211492	1022	1029	O
postbanding	10211492	1030	1041	O
there	10211492	1042	1047	O
was	10211492	1048	1051	O
a	10211492	1052	1053	O
significant	10211492	1054	1065	B-Observation
reduction	10211492	1066	1075	I-Observation
in	10211492	1076	1078	O
pain	10211492	1079	1083	B-Outcome
graded	10211492	1084	1090	I-Outcome
by	10211492	1091	1093	I-Outcome
the	10211492	1094	1097	I-Outcome
patient	10211492	1098	1105	I-Outcome
(	10211492	1106	1107	I-Outcome
P	10211492	1108	1109	I-Outcome
=	10211492	1110	1111	I-Outcome
0.000002	10211492	1112	1120	I-Outcome
)	10211492	1121	1122	I-Outcome
and	10211492	1123	1126	I-Outcome
by	10211492	1127	1129	I-Outcome
the	10211492	1130	1133	I-Outcome
nurse	10211492	1134	1139	I-Outcome
(	10211492	1140	1141	I-Outcome
P	10211492	1142	1143	I-Outcome
=	10211492	1144	1145	I-Outcome
0.000005	10211492	1146	1154	I-Outcome
)	10211492	1155	1156	I-Outcome
and	10211492	1157	1160	O
a	10211492	1161	1162	O
significant	10211492	1163	1174	B-Observation
reduction	10211492	1175	1184	I-Observation
in	10211492	1185	1187	O
incidence	10211492	1188	1197	B-Outcome
of	10211492	1198	1200	I-Outcome
nausea	10211492	1201	1207	I-Outcome
(	10211492	1208	1209	I-Outcome
P	10211492	1210	1211	I-Outcome
=	10211492	1212	1213	I-Outcome
0.01	10211492	1214	1218	I-Outcome
)	10211492	1219	1220	I-Outcome
and	10211492	1221	1224	I-Outcome
shaking	10211492	1225	1232	I-Outcome
(	10211492	1233	1234	I-Outcome
P	10211492	1235	1236	I-Outcome
=	10211492	1237	1238	I-Outcome
0.008	10211492	1239	1244	I-Outcome
)	10211492	1245	1246	I-Outcome
.	10211492	1247	1248	O

However	10211492	1249	1256	O
,	10211492	1257	1258	O
in	10211492	1259	1261	O
the	10211492	1262	1265	O
bupivacaine	10211492	1266	1277	B-Intervention
group	10211492	1278	1283	O
compared	10211492	1284	1292	O
with	10211492	1293	1297	O
the	10211492	1298	1301	O
other	10211492	1302	1307	B-Intervention
two	10211492	1308	1311	I-Intervention
groups	10211492	1312	1318	O
,	10211492	1319	1320	O
at	10211492	1321	1323	O
the	10211492	1324	1327	O
intervals	10211492	1328	1337	O
of	10211492	1338	1340	O
6	10211492	1341	1342	O
,	10211492	1343	1344	O
24	10211492	1345	1347	O
,	10211492	1348	1349	O
and	10211492	1350	1353	O
48	10211492	1354	1356	O
hours	10211492	1357	1362	O
postbanding	10211492	1363	1374	O
there	10211492	1375	1380	O
was	10211492	1381	1384	O
no	10211492	1385	1387	O
sustained	10211492	1388	1397	B-Observation
reduction	10211492	1398	1407	I-Observation
in	10211492	1408	1410	O
the	10211492	1411	1414	O
severity	10211492	1415	1423	B-Outcome
of	10211492	1424	1426	I-Outcome
pain	10211492	1427	1431	I-Outcome
and	10211492	1432	1435	O
no	10211492	1436	1438	O
reduction	10211492	1439	1448	B-Observation
in	10211492	1449	1451	O
analgesic	10211492	1452	1461	B-Outcome
requirements	10211492	1462	1474	I-Outcome
or	10211492	1475	1477	O
limitation	10211492	1478	1488	B-Outcome
of	10211492	1489	1491	I-Outcome
normal	10211492	1492	1498	I-Outcome
activities	10211492	1499	1509	I-Outcome
.	10211492	1510	1511	O

In	10211492	1512	1514	O
the	10211492	1515	1518	O
week	10211492	1519	1523	O
after	10211492	1524	1529	O
banding	10211492	1530	1537	O
,	10211492	1538	1539	O
there	10211492	1540	1545	O
was	10211492	1546	1549	O
no	10211492	1550	1552	O
difference	10211492	1553	1563	B-Observation
between	10211492	1564	1571	B-Intervention
groups	10211492	1572	1578	I-Intervention
in	10211492	1579	1581	O
symptoms	10211492	1582	1590	B-Outcome
of	10211492	1591	1593	I-Outcome
nausea	10211492	1594	1600	I-Outcome
,	10211492	1601	1602	I-Outcome
shaking	10211492	1603	1610	I-Outcome
,	10211492	1611	1612	I-Outcome
lightheadedness	10211492	1613	1628	I-Outcome
,	10211492	1629	1630	I-Outcome
urinary	10211492	1631	1638	I-Outcome
retention	10211492	1639	1648	I-Outcome
,	10211492	1649	1650	I-Outcome
or	10211492	1651	1653	I-Outcome
bleeding	10211492	1654	1662	I-Outcome
.	10211492	1663	1664	O

CONCLUSIONS	10211492	1665	1676	O
Bupivacaine	10211492	1677	1688	B-Intervention
injection	10211492	1689	1698	I-Intervention
may	10211492	1699	1702	O
be	10211492	1703	1705	O
useful	10211492	1706	1712	O
for	10211492	1713	1716	O
reducing	10211492	1717	1725	B-Observation
pain	10211492	1726	1730	B-Outcome
and	10211492	1731	1734	O
associated	10211492	1735	1745	B-Outcome
symptoms	10211492	1746	1754	I-Outcome
long	10211492	1755	1759	O
enough	10211492	1760	1766	O
to	10211492	1767	1769	O
tolerate	10211492	1770	1778	O
a	10211492	1779	1780	O
trip	10211492	1781	1785	O
home	10211492	1786	1790	O
from	10211492	1791	1795	O
the	10211492	1796	1799	O
outpatient	10211492	1800	1810	O
department	10211492	1811	1821	O
but	10211492	1822	1825	O
does	10211492	1826	1830	O
not	10211492	1831	1834	O
show	10211492	1835	1839	O
a	10211492	1840	1841	O
sustained	10211492	1842	1851	B-Observation
effect	10211492	1852	1858	B-Outcome
.	10211492	1859	1860	O

Microbiologic	10213233	0	13	B-Outcome
yields	10213233	14	20	I-Outcome
and	10213233	21	24	O
complication	10213233	25	37	B-Outcome
rates	10213233	38	43	I-Outcome
of	10213233	44	46	O
vitreous	10213233	47	55	B-Intervention
needle	10213233	56	62	I-Intervention
aspiration	10213233	63	73	I-Intervention
versus	10213233	74	80	O
mechanized	10213233	81	91	B-Intervention
vitreous	10213233	92	100	I-Intervention
biopsy	10213233	101	107	I-Intervention
in	10213233	108	110	O
the	10213233	111	114	O
Endophthalmitis	10213233	115	130	B-Participant
Vitrectomy	10213233	131	141	I-Participant
Study	10213233	142	147	O
.	10213233	148	149	O

PURPOSE	10213233	150	157	O
To	10213233	158	160	O
compare	10213233	161	168	O
the	10213233	169	172	O
microbiologic	10213233	173	186	B-Outcome
yields	10213233	187	193	I-Outcome
and	10213233	194	197	O
complication	10213233	198	210	B-Outcome
rates	10213233	211	216	I-Outcome
associated	10213233	217	227	O
with	10213233	228	232	O
vitreous	10213233	233	241	B-Intervention
needle	10213233	242	248	I-Intervention
tap	10213233	249	252	I-Intervention
and	10213233	253	256	O
vitreous	10213233	257	265	B-Intervention
biopsy	10213233	266	272	I-Intervention
in	10213233	273	275	O
the	10213233	276	279	O
Endophthalmitis	10213233	280	295	B-Participant
Vitrectomy	10213233	296	306	I-Participant
Study	10213233	307	312	I-Participant
(	10213233	313	314	I-Participant
EVS	10213233	315	318	I-Participant
)	10213233	319	320	I-Participant
.	10213233	321	322	O

METHODS	10213233	323	330	O
Of	10213233	331	333	O
420	10213233	334	337	O
EVS	10213233	338	341	B-Participant
patients	10213233	342	350	O
with	10213233	351	355	O
postoperative	10213233	356	369	B-Participant
endophthalmitis	10213233	370	385	I-Participant
,	10213233	386	387	O
201	10213233	388	391	O
received	10213233	392	400	O
immediate	10213233	401	410	O
vitreous	10213233	411	419	B-Intervention
tap	10213233	420	423	I-Intervention
or	10213233	424	426	O
biopsy	10213233	427	433	B-Intervention
(	10213233	434	435	O
without	10213233	436	443	O
pars	10213233	444	448	O
plana	10213233	449	454	O
vitrectomy	10213233	455	465	O
)	10213233	466	467	O
by	10213233	468	470	O
random	10213233	471	477	O
assignment	10213233	478	488	O
and	10213233	489	492	O
193	10213233	493	496	O
completed	10213233	497	506	O
9	10213233	507	508	O
-	10213233	508	509	O
12	10213233	509	511	O
months	10213233	512	518	O
of	10213233	519	521	O
follow-up	10213233	522	531	O
.	10213233	532	533	O

Vitreous	10213233	534	542	O
specimens	10213233	543	552	O
were	10213233	553	557	O
obtained	10213233	558	566	O
by	10213233	567	569	O
biopsy	10213233	570	576	B-Intervention
with	10213233	577	581	I-Intervention
a	10213233	582	583	I-Intervention
20-gauge	10213233	584	592	I-Intervention
vitrectomy	10213233	593	603	I-Intervention
cutting	10213233	604	611	I-Intervention
instrument	10213233	612	622	I-Intervention
or	10213233	623	625	O
by	10213233	626	628	O
needle	10213233	629	635	B-Intervention
tap	10213233	636	639	I-Intervention
with	10213233	640	644	I-Intervention
a	10213233	645	646	I-Intervention
22	10213233	647	649	I-Intervention
-	10213233	649	650	I-Intervention
27-gauge	10213233	650	658	I-Intervention
needle	10213233	659	665	I-Intervention
.	10213233	666	667	O

If	10213233	668	670	O
resistance	10213233	671	681	B-Participant
to	10213233	682	684	I-Participant
aspiration	10213233	685	695	I-Participant
by	10213233	696	698	I-Participant
needle	10213233	699	705	I-Participant
tap	10213233	706	709	I-Participant
was	10213233	710	713	O
noted	10213233	714	719	O
,	10213233	720	721	O
a	10213233	722	723	O
vitreous	10213233	724	732	B-Intervention
biopsy	10213233	733	739	I-Intervention
was	10213233	740	743	O
performed	10213233	744	753	O
.	10213233	754	755	O

RESULTS	10213233	756	763	O
Of	10213233	764	766	O
201	10213233	767	770	O
patients	10213233	771	779	O
undergoing	10213233	780	790	O
tap	10213233	791	794	B-Intervention
or	10213233	795	797	O
biopsy	10213233	798	804	B-Intervention
,	10213233	805	806	O
70	10213233	807	809	O
(	10213233	810	811	O
35	10213233	812	814	O
%	10213233	815	816	O
)	10213233	817	818	O
had	10213233	819	822	O
needle	10213233	823	829	B-Intervention
tap	10213233	830	833	I-Intervention
,	10213233	834	835	O
127	10213233	836	839	O
(	10213233	840	841	O
63	10213233	842	844	O
%	10213233	845	846	O
)	10213233	847	848	O
had	10213233	849	852	O
mechanized	10213233	853	863	B-Intervention
biopsy	10213233	864	870	I-Intervention
,	10213233	871	872	O
and	10213233	873	876	O
4	10213233	877	878	O
(	10213233	879	880	O
2	10213233	881	882	O
%	10213233	883	884	O
)	10213233	885	886	O
had	10213233	887	890	O
initial	10213233	891	898	B-Intervention
needle	10213233	899	905	I-Intervention
tap	10213233	906	909	I-Intervention
that	10213233	910	914	O
was	10213233	915	918	O
aborted	10213233	919	926	O
to	10213233	927	929	O
mechanized	10213233	930	940	O
biopsy	10213233	941	947	O
(	10213233	948	949	O
abort	10213233	950	955	O
eyes	10213233	956	960	O
)	10213233	961	962	O
.	10213233	963	964	O

Intraoperative	10213233	965	979	B-Outcome
hyphema	10213233	980	987	I-Outcome
occurred	10213233	988	996	O
in	10213233	997	999	O
2	10213233	1000	1001	B-Count
tap	10213233	1002	1005	B-Intervention
eyes	10213233	1006	1010	I-Intervention
(	10213233	1011	1012	O
3	10213233	1013	1014	B-Count
%	10213233	1015	1016	I-Count
)	10213233	1017	1018	O
,	10213233	1019	1020	O
3	10213233	1021	1022	B-Count
biopsy	10213233	1023	1029	B-Intervention
eyes	10213233	1030	1034	I-Intervention
(	10213233	1035	1036	O
2	10213233	1037	1038	B-Count
%	10213233	1039	1040	I-Count
)	10213233	1041	1042	O
,	10213233	1043	1044	O
and	10213233	1045	1048	O
0	10213233	1049	1050	B-Count
(	10213233	1051	1052	I-Count
0	10213233	1053	1054	I-Count
%	10213233	1055	1056	I-Count
)	10213233	1057	1058	I-Count
abort	10213233	1059	1064	B-Intervention
eyes	10213233	1065	1069	I-Intervention
.	10213233	1070	1071	O

Postoperative	10213233	1072	1085	B-Outcome
retinal	10213233	1086	1093	I-Outcome
detachment	10213233	1094	1104	I-Outcome
developed	10213233	1105	1114	O
in	10213233	1115	1117	O
8	10213233	1118	1119	B-Count
(	10213233	1120	1121	I-Count
11	10213233	1122	1124	I-Count
%	10213233	1125	1126	I-Count
)	10213233	1127	1128	I-Count
tap	10213233	1129	1132	B-Intervention
eyes	10213233	1133	1137	I-Intervention
,	10213233	1138	1139	O
10	10213233	1140	1142	B-Count
(	10213233	1143	1144	I-Count
8	10213233	1145	1146	I-Count
%	10213233	1147	1148	I-Count
)	10213233	1149	1150	I-Count
biopsy	10213233	1151	1157	B-Intervention
eyes	10213233	1158	1162	I-Intervention
,	10213233	1163	1164	O
and	10213233	1165	1168	O
0	10213233	1169	1170	B-Count
(	10213233	1171	1172	I-Count
0	10213233	1173	1174	I-Count
%	10213233	1175	1176	I-Count
)	10213233	1177	1178	I-Count
abort	10213233	1179	1184	B-Intervention
eyes	10213233	1185	1189	I-Intervention
(	10213233	1190	1191	O
not	10213233	1192	1195	O
significant	10213233	1196	1207	B-Observation
)	10213233	1208	1209	O
.	10213233	1210	1211	O

Respective	10213233	1212	1222	B-Outcome
rates	10213233	1223	1228	I-Outcome
of	10213233	1229	1231	I-Outcome
culture	10213233	1232	1239	I-Outcome
and	10213233	1240	1243	I-Outcome
gram	10213233	1244	1248	I-Outcome
stain	10213233	1249	1254	I-Outcome
positivity	10213233	1255	1265	I-Outcome
were	10213233	1266	1270	O
69	10213233	1271	1273	B-Count
%	10213233	1274	1275	I-Count
and	10213233	1276	1279	I-Count
42	10213233	1280	1282	I-Count
%	10213233	1283	1284	I-Count
in	10213233	1285	1287	O
tap	10213233	1288	1291	B-Intervention
eyes	10213233	1292	1296	I-Intervention
and	10213233	1297	1300	O
66	10213233	1301	1303	B-Count
%	10213233	1304	1305	I-Count
and	10213233	1306	1309	I-Count
41	10213233	1310	1312	I-Count
%	10213233	1313	1314	I-Count
in	10213233	1315	1317	O
biopsy	10213233	1318	1324	B-Intervention
eyes	10213233	1325	1329	I-Intervention
(	10213233	1330	1331	O
not	10213233	1332	1335	O
significant	10213233	1336	1347	B-Observation
)	10213233	1348	1349	O
.	10213233	1350	1351	O

The	10213233	1352	1355	O
rate	10213233	1356	1360	B-Outcome
of	10213233	1361	1363	I-Outcome
severe	10213233	1364	1370	I-Outcome
visual	10213233	1371	1377	I-Outcome
loss	10213233	1378	1382	I-Outcome
(	10213233	1383	1384	I-Outcome
final	10213233	1385	1390	I-Outcome
acuity	10213233	1391	1397	I-Outcome
<	10213233	1398	1399	I-Outcome
5/200	10213233	1400	1405	I-Outcome
)	10213233	1406	1407	I-Outcome
was	10213233	1408	1411	O
significantly	10213233	1412	1425	B-Observation
higher	10213233	1426	1432	I-Observation
in	10213233	1433	1435	O
tap	10213233	1436	1439	B-Intervention
eyes	10213233	1440	1444	I-Intervention
(	10213233	1445	1446	O
16	10213233	1447	1449	B-Count
eyes	10213233	1450	1454	I-Count
,	10213233	1455	1456	I-Count
24	10213233	1457	1459	I-Count
%	10213233	1460	1461	I-Count
)	10213233	1462	1463	O
compared	10213233	1464	1472	O
with	10213233	1473	1477	O
biopsy	10213233	1478	1484	B-Intervention
eyes	10213233	1485	1489	I-Intervention
(	10213233	1490	1491	O
13	10213233	1492	1494	B-Count
eyes	10213233	1495	1499	I-Count
,	10213233	1500	1501	I-Count
11	10213233	1502	1504	I-Count
%	10213233	1505	1506	I-Count
)	10213233	1507	1508	O
and	10213233	1509	1512	O
abort	10213233	1513	1518	B-Intervention
eyes	10213233	1519	1523	I-Intervention
(	10213233	1524	1525	O
0	10213233	1526	1527	B-Count
eyes	10213233	1528	1532	I-Count
,	10213233	1533	1534	I-Count
0	10213233	1535	1536	I-Count
%	10213233	1537	1538	I-Count
;	10213233	1539	1540	O
P	10213233	1541	1542	O
=	10213233	1543	1544	O
0.043	10213233	1545	1550	O
)	10213233	1551	1552	O
.	10213233	1553	1554	O

The	10213233	1555	1558	O
difference	10213233	1559	1569	O
was	10213233	1570	1573	O
largely	10213233	1574	1581	O
explained	10213233	1582	1591	O
by	10213233	1592	1594	O
the	10213233	1595	1598	O
greater	10213233	1599	1606	B-Observation
proportion	10213233	1607	1617	B-Outcome
of	10213233	1618	1620	I-Outcome
virulent	10213233	1621	1629	I-Outcome
organisms	10213233	1630	1639	I-Outcome
in	10213233	1640	1642	O
the	10213233	1643	1646	O
tap	10213233	1647	1650	B-Intervention
eyes	10213233	1651	1655	I-Intervention
compared	10213233	1656	1664	O
with	10213233	1665	1669	O
biopsy	10213233	1670	1676	B-Intervention
eyes	10213233	1677	1681	I-Intervention
.	10213233	1682	1683	O

When	10213233	1684	1688	O
visual	10213233	1689	1695	B-Outcome
acuity	10213233	1696	1702	I-Outcome
outcome	10213233	1703	1710	I-Outcome
was	10213233	1711	1714	O
defined	10213233	1715	1722	O
by	10213233	1723	1725	O
other	10213233	1726	1731	O
thresholds	10213233	1732	1742	O
(	10213233	1743	1744	O
20/40	10213233	1745	1750	O
and	10213233	1751	1754	O
20/100	10213233	1755	1761	O
)	10213233	1762	1763	O
,	10213233	1764	1765	O
the	10213233	1766	1769	O
difference	10213233	1770	1780	B-Observation
was	10213233	1781	1784	I-Observation
not	10213233	1785	1788	I-Observation
significant	10213233	1789	1800	I-Observation
.	10213233	1801	1802	O

CONCLUSIONS	10213233	1803	1814	O
This	10213233	1815	1819	O
study	10213233	1820	1825	O
showed	10213233	1826	1832	O
no	10213233	1833	1835	O
significant	10213233	1836	1847	B-Observation
differences	10213233	1848	1859	I-Observation
between	10213233	1860	1867	O
mechanized	10213233	1868	1878	B-Intervention
vitreous	10213233	1879	1887	I-Intervention
biopsy	10213233	1888	1894	I-Intervention
and	10213233	1895	1898	O
needle	10213233	1899	1905	B-Intervention
tap	10213233	1906	1909	I-Intervention
with	10213233	1910	1914	O
respect	10213233	1915	1922	O
to	10213233	1923	1925	O
microbiologic	10213233	1926	1939	B-Outcome
yield	10213233	1940	1945	I-Outcome
,	10213233	1946	1947	O
operative	10213233	1948	1957	B-Outcome
complications	10213233	1958	1971	I-Outcome
,	10213233	1972	1973	O
short-term	10213233	1974	1984	B-Outcome
(	10213233	1985	1986	I-Outcome
9	10213233	1987	1988	I-Outcome
-	10213233	1988	1989	I-Outcome
12	10213233	1989	1991	I-Outcome
months	10213233	1992	1998	I-Outcome
)	10213233	1999	2000	I-Outcome
retinal	10213233	2001	2008	I-Outcome
detachment	10213233	2009	2019	I-Outcome
risk	10213233	2020	2024	I-Outcome
,	10213233	2025	2026	O
or	10213233	2027	2029	O
visual	10213233	2030	2036	B-Outcome
outcome	10213233	2037	2044	I-Outcome
.	10213233	2045	2046	O

Choice	10213233	2047	2053	O
of	10213233	2054	2056	O
vitreous	10213233	2057	2065	O
sampling	10213233	2066	2074	O
procedure	10213233	2075	2084	O
must	10213233	2085	2089	O
depend	10213233	2090	2096	O
on	10213233	2097	2099	O
the	10213233	2100	2103	O
clinical	10213233	2104	2112	O
judgment	10213233	2113	2121	O
of	10213233	2122	2124	O
the	10213233	2125	2128	O
surgeon	10213233	2129	2136	O
.	10213233	2137	2138	O

Blood	10225743	0	5	B-Intervention
purification	10225743	6	18	I-Intervention
for	10225743	19	22	O
critical	10225743	23	31	B-Participant
care	10225743	32	36	I-Participant
medicine	10225743	37	45	I-Participant
:	10225743	46	47	O
endotoxin	10225743	48	57	B-Outcome
adsorption	10225743	58	68	I-Outcome
.	10225743	69	70	O

Many	10225743	71	75	O
kinds	10225743	76	81	O
of	10225743	82	84	O
blood	10225743	85	90	O
purifying	10225743	91	100	O
technologies	10225743	101	113	O
have	10225743	114	118	O
been	10225743	119	123	O
applied	10225743	124	131	O
to	10225743	132	134	O
the	10225743	135	138	O
treatment	10225743	139	148	O
of	10225743	149	151	O
critically	10225743	152	162	O
ill	10225743	163	166	O
patients	10225743	167	175	O
since	10225743	176	181	O
1979	10225743	182	186	O
when	10225743	187	191	O
plasma	10225743	192	198	O
exchange	10225743	199	207	O
with	10225743	208	212	O
hollow-fiber	10225743	213	225	O
membranes	10225743	226	235	O
was	10225743	236	239	O
developed	10225743	240	249	O
.	10225743	250	251	O

These	10225743	252	257	O
technologies	10225743	258	270	O
have	10225743	271	275	O
been	10225743	276	280	O
applied	10225743	281	288	O
not	10225743	289	292	O
only	10225743	293	297	O
to	10225743	298	300	O
the	10225743	301	304	O
removal	10225743	305	312	O
of	10225743	313	315	O
toxic	10225743	316	321	O
substances	10225743	322	332	O
,	10225743	333	334	O
but	10225743	335	338	O
also	10225743	339	343	O
to	10225743	344	346	O
the	10225743	347	350	O
treatment	10225743	351	360	O
of	10225743	361	363	O
objective	10225743	364	373	O
diseases	10225743	374	382	O
and	10225743	383	386	O
the	10225743	387	390	O
removal	10225743	391	398	O
of	10225743	399	401	O
the	10225743	402	405	O
factors	10225743	406	413	O
relating	10225743	414	422	O
to	10225743	423	425	O
the	10225743	426	429	O
associated	10225743	430	440	O
inflammation	10225743	441	453	O
.	10225743	454	455	O

This	10225743	456	460	O
article	10225743	461	468	O
summarizes	10225743	469	479	O
these	10225743	480	485	O
methods	10225743	486	493	O
and	10225743	494	497	O
their	10225743	498	503	O
efficacies	10225743	504	514	B-Outcome
for	10225743	515	518	O
critically	10225743	519	529	B-Participant
ill	10225743	530	533	I-Participant
patients	10225743	534	542	I-Participant
,	10225743	543	544	O
especially	10225743	545	555	O
those	10225743	556	561	O
with	10225743	562	566	O
severe	10225743	567	573	B-Participant
sepsis	10225743	574	580	I-Participant
.	10225743	581	582	O

Attempts	10225743	583	591	O
have	10225743	592	596	O
been	10225743	597	601	O
made	10225743	602	606	O
to	10225743	607	609	O
remove	10225743	610	616	B-Observation
endotoxin	10225743	617	626	B-Outcome
,	10225743	627	628	O
the	10225743	629	632	O
main	10225743	633	637	O
cause	10225743	638	643	O
of	10225743	644	646	O
sepsis	10225743	647	653	B-Participant
,	10225743	654	655	O
from	10225743	656	660	O
the	10225743	661	664	O
circulation	10225743	665	676	B-Intervention
using	10225743	677	682	O
polymyxin	10225743	683	692	B-Intervention
B	10225743	693	694	I-Intervention
immobilized	10225743	695	706	I-Intervention
fiber	10225743	707	712	I-Intervention
,	10225743	713	714	O
charcoal	10225743	715	723	B-Intervention
hemoperfusion	10225743	724	737	I-Intervention
,	10225743	738	739	O
and	10225743	740	743	O
plasma	10225743	744	750	B-Intervention
or	10225743	751	753	I-Intervention
whole	10225743	754	759	I-Intervention
blood	10225743	760	765	I-Intervention
exchange	10225743	766	774	I-Intervention
.	10225743	775	776	O

Attempts	10225743	777	785	O
have	10225743	786	790	O
also	10225743	791	795	O
been	10225743	796	800	O
made	10225743	801	805	O
to	10225743	806	808	O
remove	10225743	809	815	B-Observation
proinflammatory	10225743	816	831	B-Outcome
cytokines	10225743	832	841	I-Outcome
,	10225743	842	843	O
eicosanoides	10225743	844	856	B-Outcome
,	10225743	857	858	O
and	10225743	859	862	O
coagulative	10225743	863	874	B-Outcome
factors	10225743	875	882	I-Outcome
from	10225743	883	887	O
the	10225743	888	891	O
circulation	10225743	892	903	B-Intervention
in	10225743	904	906	I-Intervention
the	10225743	907	910	I-Intervention
human	10225743	911	916	I-Intervention
body	10225743	917	921	I-Intervention
.	10225743	922	923	O

Continuous	10225743	924	934	B-Intervention
hemofiltration	10225743	935	949	I-Intervention
or	10225743	950	952	I-Intervention
hemodiafiltration	10225743	953	970	I-Intervention
is	10225743	971	973	O
the	10225743	974	977	O
representative	10225743	978	992	O
technology	10225743	993	1003	O
.	10225743	1004	1005	O

The	10225743	1006	1009	O
efficacy	10225743	1010	1018	O
of	10225743	1019	1021	O
these	10225743	1022	1027	O
methods	10225743	1028	1035	O
has	10225743	1036	1039	O
been	10225743	1040	1044	O
established	10225743	1045	1056	O
,	10225743	1057	1058	O
but	10225743	1059	1062	O
several	10225743	1063	1070	O
issues	10225743	1071	1077	O
remain	10225743	1078	1084	O
unresolved	10225743	1085	1095	O
.	10225743	1096	1097	O

All	10225743	1098	1101	O
methods	10225743	1102	1109	O
of	10225743	1110	1112	O
the	10225743	1113	1116	O
treatment	10225743	1117	1126	O
of	10225743	1127	1129	O
severe	10225743	1130	1136	B-Participant
sepsis	10225743	1137	1143	I-Participant
are	10225743	1144	1147	O
discussed	10225743	1148	1157	O
with	10225743	1158	1162	O
reference	10225743	1163	1172	O
to	10225743	1173	1175	O
treatment	10225743	1176	1185	B-Outcome
indications	10225743	1186	1197	I-Outcome
,	10225743	1198	1199	O
efficacy	10225743	1200	1208	B-Outcome
,	10225743	1209	1210	O
and	10225743	1211	1214	O
outcome	10225743	1215	1222	B-Outcome
parameters	10225743	1223	1233	I-Outcome
.	10225743	1234	1235	O

In	10225743	1236	1238	O
particular	10225743	1239	1249	O
,	10225743	1250	1251	O
the	10225743	1252	1255	O
clinical	10225743	1256	1264	O
results	10225743	1265	1272	O
of	10225743	1273	1275	O
endotoxin	10225743	1276	1285	B-Outcome
removal	10225743	1286	1293	I-Outcome
with	10225743	1294	1298	O
polymyxin	10225743	1299	1308	B-Intervention
B	10225743	1309	1310	I-Intervention
immobilized	10225743	1311	1322	I-Intervention
fiber	10225743	1323	1328	I-Intervention
are	10225743	1329	1332	O
summarized	10225743	1333	1343	O
in	10225743	1344	1346	O
this	10225743	1347	1351	O
article	10225743	1352	1359	O
.	10225743	1360	1361	O

Naltrexone	10230191	0	10	B-Intervention
and	10230191	11	14	O
communication	10230191	15	28	B-Outcome
skills	10230191	29	35	I-Outcome
in	10230191	36	38	O
young	10230191	39	44	B-Participant
children	10230191	45	53	I-Participant
with	10230191	54	58	O
autism	10230191	59	65	B-Participant
.	10230191	66	67	O

OBJECTIVE	10230191	68	77	O
To	10230191	78	80	O
evaluate	10230191	81	89	O
the	10230191	90	93	O
effect	10230191	94	100	O
of	10230191	101	103	O
naltrexone	10230191	104	114	B-Intervention
on	10230191	115	117	O
communication	10230191	118	131	B-Outcome
skills	10230191	132	138	I-Outcome
of	10230191	139	141	O
young	10230191	142	147	B-Participant
children	10230191	148	156	I-Participant
with	10230191	157	161	O
autism	10230191	162	168	B-Participant
.	10230191	169	170	O

METHOD	10230191	171	177	O
Twenty-four	10230191	178	189	O
children	10230191	190	198	B-Participant
with	10230191	199	203	O
autism	10230191	204	210	B-Participant
,	10230191	211	212	O
3.0	10230191	213	216	B-Participant
to	10230191	217	219	I-Participant
8.3	10230191	220	223	I-Participant
years	10230191	224	229	I-Participant
old	10230191	230	233	I-Participant
(	10230191	234	235	O
mean	10230191	236	240	O
5.1	10230191	241	244	O
)	10230191	245	246	O
who	10230191	247	250	O
were	10230191	251	255	O
living	10230191	256	262	B-Participant
at	10230191	263	265	I-Participant
home	10230191	266	270	I-Participant
and	10230191	271	274	O
attending	10230191	275	284	B-Participant
appropriate	10230191	285	296	I-Participant
school	10230191	297	303	I-Participant
programs	10230191	304	312	I-Participant
,	10230191	313	314	O
participated	10230191	315	327	O
in	10230191	328	330	O
a	10230191	331	332	O
randomized	10230191	333	343	O
,	10230191	344	345	O
double-blind	10230191	346	358	O
,	10230191	359	360	O
placebo-controlled	10230191	361	379	O
,	10230191	380	381	O
crossover	10230191	382	391	O
trial	10230191	392	397	O
.	10230191	398	399	O

Naltrexone	10230191	400	410	B-Intervention
,	10230191	411	412	O
1.0	10230191	413	416	O
mg/kg	10230191	417	422	O
,	10230191	423	424	O
or	10230191	425	427	O
placebo	10230191	428	435	B-Intervention
was	10230191	436	439	O
administered	10230191	440	452	O
daily	10230191	453	458	O
for	10230191	459	462	O
2	10230191	463	464	O
weeks	10230191	465	470	O
.	10230191	471	472	O

Communication	10230191	473	486	B-Outcome
was	10230191	487	490	O
evaluated	10230191	491	500	O
from	10230191	501	505	O
videotaped	10230191	506	516	O
samples	10230191	517	524	O
of	10230191	525	527	O
seminaturalistic	10230191	528	544	B-Outcome
parent-child	10230191	545	557	I-Outcome
interaction	10230191	558	569	I-Outcome
.	10230191	570	571	O

Child	10230191	572	577	B-Outcome
and	10230191	578	581	I-Outcome
parent	10230191	582	588	I-Outcome
language	10230191	589	597	I-Outcome
were	10230191	598	602	O
assessed	10230191	603	611	O
using	10230191	612	617	O
similar	10230191	618	625	O
measures	10230191	626	634	O
.	10230191	635	636	O

RESULTS	10230191	637	644	O
In	10230191	645	647	O
this	10230191	648	652	O
heterogeneous	10230191	653	666	O
sample	10230191	667	673	O
,	10230191	674	675	O
the	10230191	676	679	O
median	10230191	680	686	B-Outcome
number	10230191	687	693	I-Outcome
of	10230191	694	696	I-Outcome
words	10230191	697	702	I-Outcome
the	10230191	703	706	I-Outcome
child	10230191	707	712	I-Outcome
produced	10230191	713	721	I-Outcome
on	10230191	722	724	O
placebo	10230191	725	732	B-Intervention
was	10230191	733	736	O
9.5	10230191	737	740	B-Observation
(	10230191	741	742	I-Observation
range	10230191	743	748	I-Observation
0	10230191	749	750	I-Observation
-	10230191	750	751	I-Observation
124	10230191	751	754	I-Observation
)	10230191	755	756	I-Observation
.	10230191	757	758	O

The	10230191	759	762	O
median	10230191	763	769	B-Outcome
proportion	10230191	770	780	I-Outcome
of	10230191	781	783	I-Outcome
utterances	10230191	784	794	I-Outcome
with	10230191	795	799	I-Outcome
echolalia	10230191	800	809	I-Outcome
was	10230191	810	813	O
0.16	10230191	814	818	B-Observation
.	10230191	819	820	O

No	10230191	821	823	O
differences	10230191	824	835	B-Observation
were	10230191	836	840	O
found	10230191	841	846	O
between	10230191	847	854	O
the	10230191	855	858	O
naltrexone	10230191	859	869	B-Intervention
and	10230191	870	873	O
placebo	10230191	874	881	B-Intervention
conditions	10230191	882	892	O
in	10230191	893	895	O
any	10230191	896	899	O
of	10230191	900	902	O
the	10230191	903	906	O
measures	10230191	907	915	B-Outcome
of	10230191	916	918	I-Outcome
children	10230191	919	927	I-Outcome
or	10230191	928	930	I-Outcome
parents	10230191	931	938	I-Outcome
'	10230191	939	940	I-Outcome
communication	10230191	941	954	I-Outcome
.	10230191	955	956	O

Significant	10230191	957	968	B-Observation
correlations	10230191	969	981	I-Observation
were	10230191	982	986	O
found	10230191	987	992	O
between	10230191	993	1000	O
the	10230191	1001	1004	O
child	10230191	1005	1010	B-Outcome
's	10230191	1011	1013	I-Outcome
number	10230191	1014	1020	I-Outcome
of	10230191	1021	1023	I-Outcome
words	10230191	1024	1029	I-Outcome
and	10230191	1030	1033	I-Outcome
developmental	10230191	1034	1047	I-Outcome
quotient	10230191	1048	1056	I-Outcome
(	10230191	1057	1058	O
Spearman	10230191	1059	1067	O
rho	10230191	1068	1071	O
=	10230191	1072	1073	O
0.58	10230191	1074	1078	O
,	10230191	1079	1080	O
p	10230191	1081	1082	O
=	10230191	1083	1084	O
.003	10230191	1085	1089	O
)	10230191	1090	1091	O
and	10230191	1092	1095	O
between	10230191	1096	1103	O
the	10230191	1104	1107	O
child	10230191	1108	1113	B-Outcome
's	10230191	1114	1116	I-Outcome
and	10230191	1117	1120	I-Outcome
parent	10230191	1121	1127	I-Outcome
's	10230191	1128	1130	I-Outcome
number	10230191	1131	1137	I-Outcome
of	10230191	1138	1140	I-Outcome
words	10230191	1141	1146	I-Outcome
(	10230191	1147	1148	O
rho	10230191	1149	1152	O
=	10230191	1153	1154	O
0.55	10230191	1155	1159	O
,	10230191	1160	1161	O
p	10230191	1162	1163	O
=	10230191	1164	1165	O
.005	10230191	1166	1170	O
)	10230191	1171	1172	O
.	10230191	1173	1174	O

CONCLUSIONS	10230191	1175	1186	O
Previous	10230191	1187	1195	O
studies	10230191	1196	1203	O
showed	10230191	1204	1210	O
that	10230191	1211	1215	O
naltrexone	10230191	1216	1226	B-Intervention
was	10230191	1227	1230	O
associated	10230191	1231	1241	O
with	10230191	1242	1246	O
modest	10230191	1247	1253	B-Observation
reduction	10230191	1254	1263	I-Observation
in	10230191	1264	1266	O
hyperactivity	10230191	1267	1280	B-Outcome
and	10230191	1281	1284	O
restlessness	10230191	1285	1297	B-Outcome
in	10230191	1298	1300	O
this	10230191	1301	1305	O
group	10230191	1306	1311	O
of	10230191	1312	1314	O
children	10230191	1315	1323	B-Participant
with	10230191	1324	1328	O
autism	10230191	1329	1335	B-Participant
.	10230191	1336	1337	O

In	10230191	1338	1340	O
this	10230191	1341	1345	O
short-term	10230191	1346	1356	O
study	10230191	1357	1362	O
,	10230191	1363	1364	O
the	10230191	1365	1368	O
medication	10230191	1369	1379	B-Intervention
did	10230191	1380	1383	O
not	10230191	1384	1387	O
lead	10230191	1388	1392	O
to	10230191	1393	1395	O
improvement	10230191	1396	1407	B-Observation
in	10230191	1408	1410	O
communication	10230191	1411	1424	B-Outcome
,	10230191	1425	1426	O
a	10230191	1427	1428	O
core	10230191	1429	1433	O
deficit	10230191	1434	1441	O
of	10230191	1442	1444	O
autism	10230191	1445	1451	B-Participant
.	10230191	1452	1453	O

Long	10235220	0	4	B-Outcome
term	10235220	5	9	I-Outcome
response	10235220	10	18	I-Outcome
to	10235220	19	21	O
therapy	10235220	22	29	O
of	10235220	30	32	O
chronic	10235220	33	40	B-Participant
anti-HBe-positive	10235220	41	58	I-Participant
hepatitis	10235220	59	68	I-Participant
B	10235220	69	70	I-Participant
is	10235220	71	73	O
poor	10235220	74	78	B-Observation
independent	10235220	79	90	I-Observation
of	10235220	91	93	O
type	10235220	94	98	B-Intervention
and	10235220	99	102	I-Intervention
schedule	10235220	103	111	I-Intervention
of	10235220	112	114	I-Intervention
interferon	10235220	115	125	I-Intervention
.	10235220	126	127	O

OBJECTIVE	10235220	128	137	O
The	10235220	138	141	O
response	10235220	142	150	B-Outcome
rate	10235220	151	155	I-Outcome
to	10235220	156	158	O
alpha	10235220	159	164	B-Intervention
interferon	10235220	165	175	I-Intervention
(	10235220	176	177	I-Intervention
IFN	10235220	178	181	I-Intervention
)	10235220	182	183	I-Intervention
of	10235220	184	186	O
chronic	10235220	187	194	B-Participant
anti-HBe-positive	10235220	195	212	I-Participant
hepatitis	10235220	213	222	I-Participant
B	10235220	223	224	I-Participant
is	10235220	225	227	O
variable	10235220	228	236	B-Observation
.	10235220	237	238	O

We	10235220	239	241	O
studied	10235220	242	249	O
whether	10235220	250	257	O
type	10235220	258	262	B-Intervention
,	10235220	263	264	I-Intervention
dose	10235220	265	269	I-Intervention
,	10235220	270	271	I-Intervention
and	10235220	272	275	I-Intervention
schedule	10235220	276	284	I-Intervention
of	10235220	285	287	I-Intervention
IFN	10235220	288	291	I-Intervention
,	10235220	292	293	O
and	10235220	294	297	O
type	10235220	298	302	B-Intervention
and	10235220	303	306	I-Intervention
frequency	10235220	307	316	I-Intervention
of	10235220	317	319	I-Intervention
posttreatment	10235220	320	333	I-Intervention
monitoring	10235220	334	344	I-Intervention
,	10235220	345	346	O
influence	10235220	347	356	O
the	10235220	357	360	O
response	10235220	361	369	B-Outcome
rate	10235220	370	374	I-Outcome
.	10235220	375	376	O

METHODS	10235220	377	384	O
Seventy-two	10235220	385	396	O
consecutive	10235220	397	408	B-Participant
anti-HBe-positive	10235220	409	426	I-Participant
chronic	10235220	427	434	I-Participant
hepatitis	10235220	435	444	I-Participant
B	10235220	445	446	I-Participant
patients	10235220	447	455	O
(	10235220	456	457	O
59	10235220	458	460	O
male	10235220	461	465	O
and	10235220	466	469	O
13	10235220	470	472	O
female	10235220	473	479	O
,	10235220	480	481	O
median	10235220	482	488	O
age	10235220	489	492	O
41	10235220	493	495	O
yr	10235220	496	498	O
)	10235220	499	500	O
stratified	10235220	501	511	O
by	10235220	512	514	O
sex	10235220	515	518	O
and	10235220	519	522	O
histology	10235220	523	532	O
were	10235220	533	537	O
randomly	10235220	538	546	O
allocated	10235220	547	556	O
to	10235220	557	559	O
three	10235220	560	565	O
treatment	10235220	566	575	O
arms	10235220	576	580	O
.	10235220	581	582	O

Twenty-seven	10235220	583	595	O
patients	10235220	596	604	O
(	10235220	605	606	O
A	10235220	607	608	O
)	10235220	609	610	O
received	10235220	611	619	O
10	10235220	620	622	O
million	10235220	623	630	O
units	10235220	631	636	O
alpha-N1	10235220	637	645	B-Intervention
IFN	10235220	646	649	I-Intervention
i.m	10235220	650	653	O
.	10235220	654	655	O

t.w	10235220	656	659	O
.	10235220	660	661	O

for	10235220	662	665	O
24	10235220	666	668	O
wk	10235220	669	671	O
(	10235220	672	673	O
total	10235220	674	679	O
dose	10235220	680	684	O
:	10235220	685	686	O
720	10235220	687	690	O
million	10235220	691	698	O
units	10235220	699	704	O
)	10235220	705	706	O
;	10235220	707	708	O
21	10235220	709	711	O
(	10235220	712	713	O
B	10235220	714	715	O
)	10235220	716	717	O
received	10235220	718	726	O
9	10235220	727	728	O
million	10235220	729	736	O
units	10235220	737	742	O
alpha-2a	10235220	743	751	B-Intervention
IFN	10235220	752	755	I-Intervention
i.m	10235220	756	759	O
.	10235220	760	761	O

t.w	10235220	762	765	O
.	10235220	766	767	O

for	10235220	768	771	O
4	10235220	772	773	O
wk	10235220	774	776	O
,	10235220	777	778	O
followed	10235220	779	787	O
by	10235220	788	790	O
18	10235220	791	793	O
million	10235220	794	801	O
units	10235220	802	807	O
for	10235220	808	811	O
12	10235220	812	814	O
wk	10235220	815	817	O
and	10235220	818	821	O
9	10235220	822	823	O
million	10235220	824	831	O
units	10235220	832	837	O
for	10235220	838	841	O
8	10235220	842	843	O
wk	10235220	844	846	O
(	10235220	847	848	O
972	10235220	849	852	O
million	10235220	853	860	O
units	10235220	861	866	O
)	10235220	867	868	O
;	10235220	869	870	O
24	10235220	871	873	O
(	10235220	874	875	O
C	10235220	876	877	O
)	10235220	878	879	O
received	10235220	880	888	O
2	10235220	889	890	B-Intervention
alpha-2a	10235220	891	899	I-Intervention
IFN	10235220	900	903	I-Intervention
courses	10235220	904	911	I-Intervention
(	10235220	912	913	O
9	10235220	914	915	O
million	10235220	916	923	O
units	10235220	924	929	O
i.m	10235220	930	933	O
.	10235220	934	935	O

t.w	10235220	936	939	O
.	10235220	940	941	O
for	10235220	942	945	O
16	10235220	946	948	O
and	10235220	949	952	O
12	10235220	953	955	O
wk	10235220	956	958	O
separated	10235220	959	968	O
by	10235220	969	971	O
a	10235220	972	973	O
6-month	10235220	974	981	O
interval	10235220	982	990	O
[	10235220	991	992	O
756	10235220	993	996	O
million	10235220	997	1004	O
units	10235220	1005	1010	O
]	10235220	1011	1012	O
)	10235220	1013	1014	O
.	10235220	1015	1016	O

Primary	10235220	1017	1024	B-Outcome
response	10235220	1025	1033	I-Outcome
was	10235220	1034	1037	O
defined	10235220	1038	1045	O
by	10235220	1046	1048	O
normal	10235220	1049	1055	B-Outcome
ALT	10235220	1056	1059	I-Outcome
and	10235220	1060	1063	O
serum	10235220	1064	1069	B-Outcome
HBV-DNA	10235220	1070	1077	I-Outcome
levels	10235220	1078	1084	I-Outcome
below	10235220	1085	1090	I-Outcome
10	10235220	1091	1093	I-Outcome
pg/ml	10235220	1094	1099	I-Outcome
at	10235220	1100	1102	O
the	10235220	1103	1106	O
end	10235220	1107	1110	O
of	10235220	1111	1113	O
therapy	10235220	1114	1121	O
and	10235220	1122	1125	O
sustained	10235220	1126	1135	B-Outcome
response	10235220	1136	1144	I-Outcome
by	10235220	1145	1147	O
normal	10235220	1148	1154	B-Outcome
ALT	10235220	1155	1158	I-Outcome
(	10235220	1159	1160	O
tested	10235220	1161	1167	O
monthly	10235220	1168	1175	O
)	10235220	1176	1177	O
,	10235220	1178	1179	O
undetectable	10235220	1180	1192	B-Outcome
HBV-DNA	10235220	1193	1200	I-Outcome
and	10235220	1201	1204	O
IgM	10235220	1205	1208	B-Outcome
anti-HBc	10235220	1209	1217	I-Outcome
(	10235220	1218	1219	O
<	10235220	1220	1221	O
7	10235220	1222	1223	O
I.U	10235220	1224	1227	O
.	10235220	1228	1229	O

Paul	10235220	1230	1234	O
Ehrlich	10235220	1235	1242	O
Institute	10235220	1243	1252	O
)	10235220	1253	1254	O
(	10235220	1255	1256	O
tested	10235220	1257	1263	O
every	10235220	1264	1269	O
3	10235220	1270	1271	O
months	10235220	1272	1278	O
)	10235220	1279	1280	O
during	10235220	1281	1287	O
the	10235220	1288	1291	O
posttreatment	10235220	1292	1305	O
follow-up	10235220	1306	1315	O
.	10235220	1316	1317	O

RESULTS	10235220	1318	1325	O
At	10235220	1326	1328	O
the	10235220	1329	1332	O
end	10235220	1333	1336	O
of	10235220	1337	1339	O
treatment	10235220	1340	1349	O
,	10235220	1350	1351	O
12	10235220	1352	1354	B-Count
,	10235220	1355	1356	O
8	10235220	1357	1358	B-Count
,	10235220	1359	1360	O
and	10235220	1361	1364	O
13	10235220	1365	1367	B-Count
patients	10235220	1368	1376	I-Count
from	10235220	1377	1381	O
groups	10235220	1382	1388	B-Intervention
A	10235220	1389	1390	I-Intervention
,	10235220	1391	1392	O
B	10235220	1393	1394	B-Intervention
,	10235220	1395	1396	O
and	10235220	1397	1400	O
C	10235220	1401	1402	B-Intervention
,	10235220	1403	1404	O
respectively	10235220	1405	1417	O
,	10235220	1418	1419	O
were	10235220	1420	1424	O
responders	10235220	1425	1435	B-Outcome
.	10235220	1436	1437	O

At	10235220	1438	1440	O
the	10235220	1441	1444	O
18-month	10235220	1445	1453	O
follow-up	10235220	1454	1463	O
,	10235220	1464	1465	O
two	10235220	1466	1469	B-Count
patients	10235220	1470	1478	I-Count
in	10235220	1479	1481	O
group	10235220	1482	1487	B-Intervention
A	10235220	1488	1489	I-Intervention
and	10235220	1490	1493	O
only	10235220	1494	1498	O
one	10235220	1499	1502	B-Count
in	10235220	1503	1505	O
groups	10235220	1506	1512	B-Intervention
B	10235220	1513	1514	I-Intervention
and	10235220	1515	1518	O
C	10235220	1519	1520	B-Intervention
maintained	10235220	1521	1531	B-Outcome
the	10235220	1532	1535	I-Outcome
response	10235220	1536	1544	I-Outcome
.	10235220	1545	1546	O

Overall	10235220	1547	1554	O
,	10235220	1555	1556	O
after	10235220	1557	1562	O
34	10235220	1563	1565	O
months	10235220	1566	1572	O
(	10235220	1573	1574	O
median	10235220	1575	1581	O
posttreatment	10235220	1582	1595	O
follow-up	10235220	1596	1605	O
)	10235220	1606	1607	O
,	10235220	1608	1609	O
three	10235220	1610	1615	B-Count
patients	10235220	1616	1624	I-Count
were	10235220	1625	1629	O
long	10235220	1630	1634	B-Outcome
term	10235220	1635	1639	I-Outcome
responders	10235220	1640	1650	I-Outcome
,	10235220	1651	1652	O
whereas	10235220	1653	1660	O
three	10235220	1661	1666	B-Count
showed	10235220	1667	1673	O
a	10235220	1674	1675	O
sustained	10235220	1676	1685	B-Outcome
remission	10235220	1686	1695	I-Outcome
after	10235220	1696	1701	O
relapse	10235220	1702	1709	O
.	10235220	1710	1711	O

CONCLUSIONS	10235220	1712	1723	O
The	10235220	1724	1727	O
rate	10235220	1728	1732	B-Outcome
of	10235220	1733	1735	I-Outcome
long	10235220	1736	1740	I-Outcome
term	10235220	1741	1745	I-Outcome
response	10235220	1746	1754	I-Outcome
to	10235220	1755	1757	O
interferon	10235220	1758	1768	B-Intervention
of	10235220	1769	1771	O
anti-HBe-positive	10235220	1772	1789	B-Participant
chronic	10235220	1790	1797	I-Participant
hepatitis	10235220	1798	1807	I-Participant
B	10235220	1808	1809	I-Participant
is	10235220	1810	1812	O
poor	10235220	1813	1817	B-Observation
,	10235220	1818	1819	O
independent	10235220	1820	1831	B-Observation
of	10235220	1832	1834	O
IFN	10235220	1835	1838	B-Intervention
type	10235220	1839	1843	I-Intervention
,	10235220	1844	1845	I-Intervention
dose	10235220	1846	1850	I-Intervention
,	10235220	1851	1852	I-Intervention
or	10235220	1853	1855	I-Intervention
schedule	10235220	1856	1864	I-Intervention
;	10235220	1865	1866	O
the	10235220	1867	1870	O
more	10235220	1871	1875	B-Intervention
stringent	10235220	1876	1885	I-Intervention
the	10235220	1886	1889	I-Intervention
monitoring	10235220	1890	1900	I-Intervention
,	10235220	1901	1902	O
the	10235220	1903	1906	O
higher	10235220	1907	1913	B-Observation
the	10235220	1914	1917	O
relapse	10235220	1918	1925	B-Outcome
rate	10235220	1926	1930	I-Outcome
.	10235220	1931	1932	O

Comparative	10337433	0	11	O
evaluation	10337433	12	22	O
of	10337433	23	25	O
olopatadine	10337433	26	37	B-Intervention
ophthalmic	10337433	38	48	I-Intervention
solution	10337433	49	57	I-Intervention
(	10337433	58	59	O
0.1	10337433	60	63	O
%	10337433	64	65	O
)	10337433	66	67	O
versus	10337433	68	74	O
ketorolac	10337433	75	84	B-Intervention
ophthalmic	10337433	85	95	I-Intervention
solution	10337433	96	104	I-Intervention
(	10337433	105	106	O
0.5	10337433	107	110	O
%	10337433	111	112	O
)	10337433	113	114	O
using	10337433	115	120	O
the	10337433	121	124	O
provocative	10337433	125	136	O
antigen	10337433	137	144	O
challenge	10337433	145	154	O
model	10337433	155	160	O
.	10337433	161	162	O

OBJECTIVE	10337433	163	172	O
This	10337433	173	177	O
study	10337433	178	183	O
was	10337433	184	187	O
conducted	10337433	188	197	O
to	10337433	198	200	O
compare	10337433	201	208	O
the	10337433	209	212	O
efficacy	10337433	213	221	B-Outcome
and	10337433	222	225	O
safety	10337433	226	232	B-Outcome
of	10337433	233	235	O
olopatadine	10337433	236	247	B-Intervention
ophthalmic	10337433	248	258	I-Intervention
solution	10337433	259	267	I-Intervention
(	10337433	268	269	O
0.1	10337433	270	273	O
%	10337433	274	275	O
)	10337433	276	277	O
with	10337433	278	282	O
ketorolac	10337433	283	292	B-Intervention
ophthalmic	10337433	293	303	I-Intervention
solution	10337433	304	312	I-Intervention
(	10337433	313	314	O
0.5	10337433	315	318	O
%	10337433	319	320	O
)	10337433	321	322	O
in	10337433	323	325	O
a	10337433	326	327	O
clinical	10337433	328	336	O
model	10337433	337	342	O
of	10337433	343	345	O
acute	10337433	346	351	B-Participant
allergic	10337433	352	360	I-Participant
conjunctivitis	10337433	361	375	I-Participant
.	10337433	376	377	O

Olopatadine	10337433	378	389	O
is	10337433	390	392	O
a	10337433	393	394	O
dual	10337433	395	399	O
acting	10337433	400	406	O
H1	10337433	407	409	O
histamine	10337433	410	419	O
receptor	10337433	420	428	O
antagonist	10337433	429	439	O
and	10337433	440	443	O
a	10337433	444	445	O
mast	10337433	446	450	O
cell	10337433	451	455	O
stabilizer	10337433	456	466	O
,	10337433	467	468	O
shown	10337433	469	474	O
to	10337433	475	477	O
be	10337433	478	480	O
effective	10337433	481	490	O
in	10337433	491	493	O
treating	10337433	494	502	O
allergic	10337433	503	511	O
conjunctivitis	10337433	512	526	O
.	10337433	527	528	O

Ketorolac	10337433	529	538	O
is	10337433	539	541	O
a	10337433	542	543	O
non-steroidal	10337433	544	557	O
anti-inflammatory	10337433	558	575	O
drug	10337433	576	580	O
approved	10337433	581	589	O
in	10337433	590	592	O
the	10337433	593	596	O
United	10337433	597	603	O
States	10337433	604	610	O
for	10337433	611	614	O
the	10337433	615	618	O
relief	10337433	619	625	O
of	10337433	626	628	O
ocular	10337433	629	635	O
itching	10337433	636	643	O
associated	10337433	644	654	O
with	10337433	655	659	O
seasonal	10337433	660	668	O
allergic	10337433	669	677	O
conjunctivitis	10337433	678	692	O
.	10337433	693	694	O

METHODS	10337433	695	702	O
The	10337433	703	706	O
provocative	10337433	707	718	O
antigen	10337433	719	726	O
challenge	10337433	727	736	O
model	10337433	737	742	O
was	10337433	743	746	O
used	10337433	747	751	O
in	10337433	752	754	O
this	10337433	755	759	O
randomized	10337433	760	770	O
,	10337433	771	772	O
double-blind	10337433	773	785	O
,	10337433	786	787	O
single-center	10337433	788	801	O
,	10337433	802	803	O
crossover	10337433	804	813	O
study	10337433	814	819	O
.	10337433	820	821	O

The	10337433	822	825	O
allergen	10337433	826	834	O
and	10337433	835	838	O
concentration	10337433	839	852	O
that	10337433	853	857	O
consistently	10337433	858	870	O
elicited	10337433	871	879	O
a	10337433	880	881	O
positive	10337433	882	890	B-Participant
allergic	10337433	891	899	I-Participant
reaction	10337433	900	908	I-Participant
was	10337433	909	912	O
used	10337433	913	917	O
for	10337433	918	921	O
challenge	10337433	922	931	O
.	10337433	932	933	O

After	10337433	934	939	O
at	10337433	940	942	O
least	10337433	943	948	O
14	10337433	949	951	O
days	10337433	952	956	O
,	10337433	957	958	O
subjects	10337433	959	967	O
were	10337433	968	972	O
randomized	10337433	973	983	O
to	10337433	984	986	O
receive	10337433	987	994	O
either	10337433	995	1001	O
olopatadine	10337433	1002	1013	B-Intervention
in	10337433	1014	1016	O
one	10337433	1017	1020	O
eye	10337433	1021	1024	O
and	10337433	1025	1028	O
placebo	10337433	1029	1036	B-Intervention
in	10337433	1037	1039	O
the	10337433	1040	1043	O
contralateral	10337433	1044	1057	O
eye	10337433	1058	1061	O
,	10337433	1062	1063	O
or	10337433	1064	1066	O
ketorolac	10337433	1067	1076	B-Intervention
in	10337433	1077	1079	O
one	10337433	1080	1083	O
eye	10337433	1084	1087	O
and	10337433	1088	1091	O
placebo	10337433	1092	1099	B-Intervention
in	10337433	1100	1102	O
the	10337433	1103	1106	O
contralateral	10337433	1107	1120	O
eye	10337433	1121	1124	O
.	10337433	1125	1126	O

Twenty-seven	10337433	1127	1139	O
minutes	10337433	1140	1147	O
after	10337433	1148	1153	O
drug	10337433	1154	1158	O
instillation	10337433	1159	1171	O
subjects	10337433	1172	1180	O
were	10337433	1181	1185	O
challenged	10337433	1186	1196	O
with	10337433	1197	1201	O
allergen	10337433	1202	1210	O
.	10337433	1211	1212	O

At	10337433	1213	1215	O
3	10337433	1216	1217	O
,	10337433	1218	1219	O
10	10337433	1220	1222	O
,	10337433	1223	1224	O
and	10337433	1225	1228	O
20	10337433	1229	1231	O
minutes	10337433	1232	1239	O
following	10337433	1240	1249	O
allergen	10337433	1250	1258	O
challenge	10337433	1259	1268	O
,	10337433	1269	1270	O
subjects	10337433	1271	1279	O
graded	10337433	1280	1286	O
ocular	10337433	1287	1293	B-Outcome
itching	10337433	1294	1301	I-Outcome
and	10337433	1302	1305	O
were	10337433	1306	1310	O
assessed	10337433	1311	1319	O
for	10337433	1320	1323	O
hyperemia	10337433	1324	1333	B-Outcome
in	10337433	1334	1336	O
conjunctival	10337433	1337	1349	O
,	10337433	1350	1351	O
ciliary	10337433	1352	1359	O
,	10337433	1360	1361	O
and	10337433	1362	1365	O
episcleral	10337433	1366	1376	O
vessel	10337433	1377	1383	O
beds	10337433	1384	1388	O
.	10337433	1389	1390	O

Approximately	10337433	1391	1404	O
14	10337433	1405	1407	O
days	10337433	1408	1412	O
later	10337433	1413	1418	O
,	10337433	1419	1420	O
subjects	10337433	1421	1429	O
received	10337433	1430	1438	O
the	10337433	1439	1442	O
alternate	10337433	1443	1452	B-Intervention
treatment	10337433	1453	1462	I-Intervention
in	10337433	1463	1465	O
one	10337433	1466	1469	O
eye	10337433	1470	1473	O
and	10337433	1474	1477	O
placebo	10337433	1478	1485	B-Intervention
in	10337433	1486	1488	O
the	10337433	1489	1492	O
contralateral	10337433	1493	1506	O
eye	10337433	1507	1510	O
.	10337433	1511	1512	O

They	10337433	1513	1517	O
were	10337433	1518	1522	O
again	10337433	1523	1528	O
challenged	10337433	1529	1539	O
with	10337433	1540	1544	O
allergen	10337433	1545	1553	O
and	10337433	1554	1557	O
their	10337433	1558	1563	O
responses	10337433	1564	1573	B-Outcome
were	10337433	1574	1578	O
rated	10337433	1579	1584	O
in	10337433	1585	1587	O
the	10337433	1588	1591	O
same	10337433	1592	1596	O
manner	10337433	1597	1603	O
.	10337433	1604	1605	O

RESULTS	10337433	1606	1613	O
Olopatadine	10337433	1614	1625	B-Intervention
significantly	10337433	1626	1639	B-Observation
(	10337433	1640	1641	I-Observation
p	10337433	1642	1643	I-Observation
<	10337433	1644	1645	I-Observation
0.0001	10337433	1646	1652	I-Observation
)	10337433	1653	1654	I-Observation
reduced	10337433	1655	1662	I-Observation
both	10337433	1663	1667	O
ocular	10337433	1668	1674	B-Outcome
itching	10337433	1675	1682	I-Outcome
and	10337433	1683	1686	O
hyperemia	10337433	1687	1696	B-Outcome
in	10337433	1697	1699	O
all	10337433	1700	1703	O
three	10337433	1704	1709	O
vessel	10337433	1710	1716	O
beds	10337433	1717	1721	O
compared	10337433	1722	1730	O
to	10337433	1731	1733	O
placebo	10337433	1734	1741	B-Intervention
at	10337433	1742	1744	O
all	10337433	1745	1748	O
time	10337433	1749	1753	O
points	10337433	1754	1760	O
tested	10337433	1761	1767	O
following	10337433	1768	1777	O
allergen	10337433	1778	1786	O
challenge	10337433	1787	1796	O
.	10337433	1797	1798	O

Ketorolac	10337433	1799	1808	B-Intervention
did	10337433	1809	1812	O
not	10337433	1813	1816	O
significantly	10337433	1817	1830	B-Observation
reduce	10337433	1831	1837	I-Observation
itching	10337433	1838	1845	B-Outcome
and	10337433	1846	1849	O
showed	10337433	1850	1856	O
a	10337433	1857	1858	O
trend	10337433	1859	1864	B-Observation
of	10337433	1865	1867	I-Observation
increased	10337433	1868	1877	I-Observation
hyperemia	10337433	1878	1887	B-Outcome
compared	10337433	1888	1896	O
to	10337433	1897	1899	O
placebo	10337433	1900	1907	B-Intervention
.	10337433	1908	1909	O

Olopatadine	10337433	1910	1921	B-Intervention
was	10337433	1922	1925	O
significantly	10337433	1926	1939	B-Observation
(	10337433	1940	1941	I-Observation
p	10337433	1942	1943	I-Observation
<	10337433	1944	1945	I-Observation
0.001	10337433	1946	1951	I-Observation
)	10337433	1952	1953	I-Observation
more	10337433	1954	1958	I-Observation
effective	10337433	1959	1968	I-Observation
than	10337433	1969	1973	O
ketorolac	10337433	1974	1983	B-Intervention
in	10337433	1984	1986	O
reducing	10337433	1987	1995	B-Observation
hyperemia	10337433	1996	2005	B-Outcome
and	10337433	2006	2009	O
ocular	10337433	2010	2016	B-Outcome
itching	10337433	2017	2024	I-Outcome
at	10337433	2025	2027	O
all	10337433	2028	2031	O
time	10337433	2032	2036	O
points	10337433	2037	2043	O
and	10337433	2044	2047	O
was	10337433	2048	2051	O
also	10337433	2052	2056	O
significantly	10337433	2057	2070	B-Observation
(	10337433	2071	2072	I-Observation
p	10337433	2073	2074	I-Observation
<	10337433	2075	2076	I-Observation
0.05	10337433	2077	2081	I-Observation
)	10337433	2082	2083	I-Observation
more	10337433	2084	2088	I-Observation
comfortable	10337433	2089	2100	I-Observation
than	10337433	2101	2105	O
ketorolac	10337433	2106	2115	B-Intervention
as	10337433	2116	2118	O
reported	10337433	2119	2127	O
by	10337433	2128	2130	O
subjects	10337433	2131	2139	O
immediately	10337433	2140	2151	O
following	10337433	2152	2161	O
drug	10337433	2162	2166	O
instillation	10337433	2167	2179	O
.	10337433	2180	2181	O

CONCLUSION	10337433	2182	2192	O
The	10337433	2193	2196	O
study	10337433	2197	2202	O
demonstrated	10337433	2203	2215	O
that	10337433	2216	2220	O
olopatadine	10337433	2221	2232	B-Intervention
is	10337433	2233	2235	O
effective	10337433	2236	2245	B-Observation
and	10337433	2246	2249	O
safe	10337433	2250	2254	B-Observation
in	10337433	2255	2257	O
preventing	10337433	2258	2268	O
and	10337433	2269	2272	O
treating	10337433	2273	2281	O
ocular	10337433	2282	2288	B-Outcome
itching	10337433	2289	2296	I-Outcome
and	10337433	2297	2300	O
hyperemia	10337433	2301	2310	B-Outcome
associated	10337433	2311	2321	O
with	10337433	2322	2326	O
acute	10337433	2327	2332	B-Participant
allergic	10337433	2333	2341	I-Participant
conjunctivitis	10337433	2342	2356	I-Participant
and	10337433	2357	2360	O
is	10337433	2361	2363	O
more	10337433	2364	2368	B-Observation
effective	10337433	2369	2378	I-Observation
and	10337433	2379	2382	O
more	10337433	2383	2387	B-Observation
comfortable	10337433	2388	2399	I-Observation
than	10337433	2400	2404	O
ketorolac	10337433	2405	2414	B-Intervention
.	10337433	2415	2416	O

Problem-solving	10337847	0	15	B-Intervention
counseling	10337847	16	26	I-Intervention
for	10337847	27	30	O
caregivers	10337847	31	41	B-Participant
of	10337847	42	44	I-Participant
the	10337847	45	48	I-Participant
cognitively	10337847	49	60	I-Participant
impaired	10337847	61	69	I-Participant
:	10337847	70	71	O
effective	10337847	72	81	O
for	10337847	82	85	O
whom	10337847	86	90	O
?	10337847	91	92	O

BACKGROUND	10337847	93	103	O
Individualized	10337847	104	118	O
problem-solving	10337847	119	134	O
counseling	10337847	135	145	O
for	10337847	146	149	O
caregivers	10337847	150	160	O
of	10337847	161	163	O
cognitively	10337847	164	175	O
impaired	10337847	176	184	O
relatives	10337847	185	194	O
is	10337847	195	197	O
thought	10337847	198	205	O
to	10337847	206	208	O
help	10337847	209	213	O
caregivers	10337847	214	224	O
cope	10337847	225	229	O
with	10337847	230	234	O
the	10337847	235	238	O
stress	10337847	239	245	O
and	10337847	246	249	O
burden	10337847	250	256	O
of	10337847	257	259	O
caregiving	10337847	260	270	O
.	10337847	271	272	O

Few	10337847	273	276	O
studies	10337847	277	284	O
have	10337847	285	289	O
shown	10337847	290	295	O
the	10337847	296	299	O
effectiveness	10337847	300	313	O
of	10337847	314	316	O
counseling	10337847	317	327	O
for	10337847	328	331	O
these	10337847	332	337	O
caregivers	10337847	338	348	O
.	10337847	349	350	O

OBJECTIVES	10337847	351	361	O
To	10337847	362	364	O
determine	10337847	365	374	O
the	10337847	375	378	O
effectiveness	10337847	379	392	B-Outcome
of	10337847	393	395	O
individualized	10337847	396	410	B-Intervention
problem-solving	10337847	411	426	I-Intervention
counseling	10337847	427	437	I-Intervention
by	10337847	438	440	I-Intervention
nurses	10337847	441	447	I-Intervention
for	10337847	448	451	O
caregivers	10337847	452	462	B-Participant
and	10337847	463	466	O
the	10337847	467	470	O
expenditures	10337847	471	483	B-Outcome
of	10337847	484	486	I-Outcome
health	10337847	487	493	I-Outcome
care	10337847	494	498	I-Outcome
utilization	10337847	499	510	I-Outcome
.	10337847	511	512	O

METHOD	10337847	513	519	O
Caregivers	10337847	520	530	B-Participant
(	10337847	531	532	I-Participant
n	10337847	533	534	I-Participant
=	10337847	535	536	I-Participant
77	10337847	537	539	I-Participant
)	10337847	540	541	I-Participant
of	10337847	542	544	I-Participant
the	10337847	545	548	I-Participant
cognitively	10337847	549	560	I-Participant
impaired	10337847	561	569	I-Participant
living	10337847	570	576	I-Participant
at	10337847	577	579	I-Participant
home	10337847	580	584	I-Participant
were	10337847	585	589	O
randomized	10337847	590	600	O
to	10337847	601	603	O
receive	10337847	604	611	O
nurse	10337847	612	617	B-Intervention
counseling	10337847	618	628	I-Intervention
or	10337847	629	631	O
not	10337847	632	635	B-Intervention
.	10337847	636	637	O

Psychosocial	10337847	638	650	B-Outcome
adjustment	10337847	651	661	I-Outcome
to	10337847	662	664	I-Outcome
their	10337847	665	670	I-Outcome
relative	10337847	671	679	I-Outcome
's	10337847	680	682	I-Outcome
illness	10337847	683	690	I-Outcome
,	10337847	691	692	I-Outcome
psychological	10337847	693	706	I-Outcome
distress	10337847	707	715	I-Outcome
,	10337847	716	717	I-Outcome
burden	10337847	718	724	I-Outcome
,	10337847	725	726	I-Outcome
coping	10337847	727	733	I-Outcome
skills	10337847	734	740	I-Outcome
,	10337847	741	742	I-Outcome
and	10337847	743	746	I-Outcome
expenditures	10337847	747	759	I-Outcome
were	10337847	760	764	O
measured	10337847	765	773	O
after	10337847	774	779	O
6	10337847	780	781	O
months	10337847	782	788	O
and	10337847	789	792	O
1	10337847	793	794	O
year	10337847	795	799	O
.	10337847	800	801	O

RESULTS	10337847	802	809	O
Although	10337847	810	818	O
on	10337847	819	821	O
average	10337847	822	829	O
,	10337847	830	831	O
all	10337847	832	835	O
caregivers	10337847	836	846	B-Participant
receiving	10337847	847	856	O
nurse	10337847	857	862	B-Intervention
counseling	10337847	863	873	I-Intervention
indicated	10337847	874	883	O
no	10337847	884	886	O
improvement	10337847	887	898	B-Observation
in	10337847	899	901	O
psychosocial	10337847	902	914	B-Outcome
adjustment	10337847	915	925	I-Outcome
to	10337847	926	928	I-Outcome
their	10337847	929	934	I-Outcome
relative	10337847	935	943	I-Outcome
's	10337847	944	946	I-Outcome
illness	10337847	947	954	I-Outcome
,	10337847	955	956	I-Outcome
psychological	10337847	957	970	I-Outcome
distress	10337847	971	979	I-Outcome
,	10337847	980	981	I-Outcome
or	10337847	982	984	I-Outcome
caregiver	10337847	985	994	I-Outcome
burden	10337847	995	1001	I-Outcome
,	10337847	1002	1003	O
they	10337847	1004	1008	O
found	10337847	1009	1014	O
counseling	10337847	1015	1025	B-Intervention
very	10337847	1026	1030	B-Observation
helpful	10337847	1031	1038	I-Observation
and	10337847	1039	1042	O
it	10337847	1043	1045	O
was	10337847	1046	1049	O
effective	10337847	1050	1059	B-Observation
for	10337847	1060	1063	O
a	10337847	1064	1065	O
subgroup	10337847	1066	1074	B-Participant
of	10337847	1075	1077	I-Participant
caregivers	10337847	1078	1088	I-Participant
.	10337847	1089	1090	O

Those	10337847	1091	1096	B-Participant
with	10337847	1097	1101	I-Participant
poor	10337847	1102	1106	I-Participant
logical	10337847	1107	1114	I-Participant
analysis	10337847	1115	1123	I-Participant
coping	10337847	1124	1130	I-Participant
skills	10337847	1131	1137	I-Participant
at	10337847	1138	1140	I-Participant
baseline	10337847	1141	1149	I-Participant
had	10337847	1150	1153	O
decreased	10337847	1154	1163	B-Observation
psychological	10337847	1164	1177	B-Outcome
distress	10337847	1178	1186	I-Outcome
(	10337847	1187	1188	O
F	10337847	1189	1190	O
(	10337847	1191	1192	O
1,53	10337847	1193	1197	O
)	10337847	1198	1199	O
=	10337847	1200	1201	O
9.7	10337847	1202	1205	O
,	10337847	1206	1207	O
p	10337847	1208	1209	O
=	10337847	1210	1211	O
.003	10337847	1212	1216	O
)	10337847	1217	1218	O
and	10337847	1219	1222	O
improved	10337847	1223	1231	B-Observation
psychosocial	10337847	1232	1244	B-Outcome
adjustment	10337847	1245	1255	I-Outcome
(	10337847	1256	1257	O
F	10337847	1258	1259	O
(	10337847	1260	1261	O
1,53	10337847	1262	1266	O
)	10337847	1267	1268	O
=	10337847	1269	1270	O
4.7	10337847	1271	1274	O
,	10337847	1275	1276	O
p	10337847	1277	1278	O
=	10337847	1279	1280	O
.035	10337847	1281	1285	O
)	10337847	1286	1287	O
after	10337847	1288	1293	O
1	10337847	1294	1295	O
year	10337847	1296	1300	O
.	10337847	1301	1302	O

Caregivers	10337847	1303	1313	B-Participant
in	10337847	1314	1316	O
control	10337847	1317	1324	B-Intervention
and	10337847	1325	1328	O
counseling	10337847	1329	1339	B-Intervention
groups	10337847	1340	1346	O
whose	10337847	1347	1352	B-Participant
relatives	10337847	1353	1362	I-Participant
entered	10337847	1363	1370	I-Participant
a	10337847	1371	1372	I-Participant
nursing	10337847	1373	1380	I-Participant
home	10337847	1381	1385	I-Participant
improved	10337847	1386	1394	B-Observation
their	10337847	1395	1400	O
psychosocial	10337847	1401	1413	B-Outcome
adjustment	10337847	1414	1424	I-Outcome
23	10337847	1425	1427	B-Observation
%	10337847	1428	1429	I-Observation
on	10337847	1430	1432	O
average	10337847	1433	1440	O
whereas	10337847	1441	1448	O
those	10337847	1449	1454	B-Participant
continuing	10337847	1455	1465	I-Participant
to	10337847	1466	1468	I-Participant
live	10337847	1469	1473	I-Participant
in	10337847	1474	1476	I-Participant
the	10337847	1477	1480	I-Participant
community	10337847	1481	1490	I-Participant
decreased	10337847	1491	1500	B-Observation
by	10337847	1501	1503	I-Observation
8	10337847	1504	1505	I-Observation
%	10337847	1506	1507	I-Observation
.	10337847	1508	1509	O

Almost	10337847	1510	1516	O
half	10337847	1517	1521	O
as	10337847	1522	1524	O
many	10337847	1525	1529	O
relatives	10337847	1530	1539	B-Participant
entered	10337847	1540	1547	I-Participant
nursing	10337847	1548	1555	I-Participant
homes	10337847	1556	1561	I-Participant
in	10337847	1562	1564	O
the	10337847	1565	1568	O
counseling	10337847	1569	1579	B-Intervention
group	10337847	1580	1585	O
(	10337847	1586	1587	O
n	10337847	1588	1589	B-Count
=	10337847	1590	1591	I-Count
9	10337847	1592	1593	I-Count
vs.	10337847	1594	1597	O
n	10337847	1598	1599	B-Count
=	10337847	1600	1601	I-Count
5	10337847	1602	1603	I-Count
)	10337847	1604	1605	O
but	10337847	1606	1609	O
these	10337847	1610	1615	O
compared	10337847	1616	1624	O
to	10337847	1625	1627	O
control	10337847	1628	1635	B-Intervention
group	10337847	1636	1641	O
relatives	10337847	1642	1651	O
had	10337847	1652	1655	O
greater	10337847	1656	1663	B-Observation
annualized	10337847	1664	1674	B-Outcome
per	10337847	1675	1678	I-Outcome
person	10337847	1679	1685	I-Outcome
expenditures	10337847	1686	1698	I-Outcome
for	10337847	1699	1702	I-Outcome
health	10337847	1703	1709	I-Outcome
and	10337847	1710	1713	I-Outcome
social	10337847	1714	1720	I-Outcome
services	10337847	1721	1729	I-Outcome
(	10337847	1730	1731	O
Cdn	10337847	1732	1735	B-Observation
$	10337847	1736	1737	I-Observation
23,437	10337847	1738	1744	I-Observation
vs.	10337847	1745	1748	O
Cdn	10337847	1749	1752	B-Observation
$	10337847	1753	1754	I-Observation
15,151	10337847	1755	1761	I-Observation
)	10337847	1762	1763	O
.	10337847	1764	1765	O

CONCLUSIONS	10337847	1766	1777	O
Caregivers	10337847	1778	1788	B-Participant
found	10337847	1789	1794	O
nurse	10337847	1795	1800	B-Intervention
counseling	10337847	1801	1811	I-Intervention
most	10337847	1812	1816	B-Observation
helpful	10337847	1817	1824	I-Observation
.	10337847	1825	1826	O

Those	10337847	1827	1832	O
indicating	10337847	1833	1843	O
infrequent	10337847	1844	1854	B-Intervention
use	10337847	1855	1858	I-Intervention
of	10337847	1859	1861	I-Intervention
logical	10337847	1862	1869	I-Intervention
analysis	10337847	1870	1878	I-Intervention
coping	10337847	1879	1885	I-Intervention
skills	10337847	1886	1892	I-Intervention
showed	10337847	1893	1899	O
benefits	10337847	1900	1908	B-Observation
.	10337847	1909	1910	O

Amphotericin	10348763	0	12	B-Intervention
B	10348763	13	14	I-Intervention
in	10348763	15	17	O
children	10348763	18	26	B-Participant
with	10348763	27	31	O
malignant	10348763	32	41	B-Participant
disease	10348763	42	49	I-Participant
:	10348763	50	51	O
a	10348763	52	53	O
comparison	10348763	54	64	O
of	10348763	65	67	O
the	10348763	68	71	O
toxicities	10348763	72	82	B-Outcome
and	10348763	83	86	O
pharmacokinetics	10348763	87	103	B-Outcome
of	10348763	104	106	O
amphotericin	10348763	107	119	B-Intervention
B	10348763	120	121	I-Intervention
administered	10348763	122	134	I-Intervention
in	10348763	135	137	I-Intervention
dextrose	10348763	138	146	I-Intervention
versus	10348763	147	153	O
lipid	10348763	154	159	B-Intervention
emulsion	10348763	160	168	I-Intervention
.	10348763	169	170	O

In	10348763	171	173	O
a	10348763	174	175	O
prospective	10348763	176	187	O
,	10348763	188	189	O
randomized	10348763	190	200	O
clinical	10348763	201	209	O
trial	10348763	210	215	O
,	10348763	216	217	O
the	10348763	218	221	O
toxicity	10348763	222	230	B-Outcome
of	10348763	231	233	O
1	10348763	234	235	O
mg	10348763	236	238	O
of	10348763	239	241	O
amphotericin	10348763	242	254	B-Intervention
B	10348763	255	256	I-Intervention
(	10348763	257	258	I-Intervention
AmB	10348763	259	262	I-Intervention
)	10348763	263	264	I-Intervention
per	10348763	265	268	I-Intervention
kg	10348763	269	271	I-Intervention
of	10348763	272	274	I-Intervention
body	10348763	275	279	I-Intervention
weight	10348763	280	286	I-Intervention
per	10348763	287	290	I-Intervention
day	10348763	291	294	I-Intervention
infused	10348763	295	302	I-Intervention
in	10348763	303	305	I-Intervention
5	10348763	306	307	I-Intervention
%	10348763	308	309	I-Intervention
dextrose	10348763	310	318	I-Intervention
was	10348763	319	322	O
compared	10348763	323	331	O
with	10348763	332	336	O
that	10348763	337	341	O
of	10348763	342	344	O
AmB	10348763	345	348	B-Intervention
infused	10348763	349	356	I-Intervention
in	10348763	357	359	I-Intervention
lipid	10348763	360	365	I-Intervention
emulsion	10348763	366	374	I-Intervention
in	10348763	375	377	O
children	10348763	378	386	B-Participant
with	10348763	387	391	O
malignant	10348763	392	401	B-Participant
disease	10348763	402	409	I-Participant
.	10348763	410	411	O

In	10348763	412	414	O
an	10348763	415	417	O
analysis	10348763	418	426	O
of	10348763	427	429	O
82	10348763	430	432	O
children	10348763	433	441	O
who	10348763	442	445	O
received	10348763	446	454	O
a	10348763	455	456	O
full	10348763	457	461	O
course	10348763	462	468	O
of	10348763	469	471	O
6	10348763	472	473	O
days	10348763	474	478	O
or	10348763	479	481	O
more	10348763	482	486	O
of	10348763	487	489	O
AmB	10348763	490	493	B-Intervention
(	10348763	494	495	O
117	10348763	496	499	O
courses	10348763	500	507	O
)	10348763	508	509	O
,	10348763	510	511	O
it	10348763	512	514	O
was	10348763	515	518	O
shown	10348763	519	524	O
that	10348763	525	529	O
there	10348763	530	535	O
were	10348763	536	540	O
significant	10348763	541	552	B-Observation
increases	10348763	553	562	I-Observation
in	10348763	563	565	O
plasma	10348763	566	572	B-Outcome
urea	10348763	573	577	I-Outcome
and	10348763	578	581	O
creatinine	10348763	582	592	B-Outcome
concentrations	10348763	593	607	I-Outcome
and	10348763	608	611	O
in	10348763	612	614	O
potassium	10348763	615	624	B-Outcome
requirement	10348763	625	636	I-Outcome
after	10348763	637	642	O
6	10348763	643	644	O
days	10348763	645	649	O
of	10348763	650	652	O
therapy	10348763	653	660	O
with	10348763	661	665	O
both	10348763	666	670	O
AmB	10348763	671	674	B-Intervention
infused	10348763	675	682	I-Intervention
in	10348763	683	685	I-Intervention
dextrose	10348763	686	694	I-Intervention
and	10348763	695	698	O
AmB	10348763	699	702	B-Intervention
infused	10348763	703	710	I-Intervention
in	10348763	711	713	I-Intervention
lipid	10348763	714	719	I-Intervention
emulsion	10348763	720	728	I-Intervention
,	10348763	729	730	O
with	10348763	731	735	O
there	10348763	736	741	O
being	10348763	742	747	O
no	10348763	748	750	O
difference	10348763	751	761	B-Observation
between	10348763	762	769	O
the	10348763	770	773	O
two	10348763	774	777	B-Intervention
methods	10348763	778	785	I-Intervention
of	10348763	786	788	I-Intervention
AmB	10348763	789	792	I-Intervention
administration	10348763	793	807	I-Intervention
.	10348763	808	809	O

An	10348763	810	812	O
intent-to-treat	10348763	813	828	O
comparison	10348763	829	839	O
of	10348763	840	842	O
the	10348763	843	846	O
numbers	10348763	847	854	B-Outcome
of	10348763	855	857	I-Outcome
courses	10348763	858	865	I-Outcome
affected	10348763	866	874	I-Outcome
by	10348763	875	877	I-Outcome
acute	10348763	878	883	I-Outcome
toxicity	10348763	884	892	I-Outcome
(	10348763	893	894	I-Outcome
fever	10348763	895	900	I-Outcome
,	10348763	901	902	I-Outcome
rigors	10348763	903	909	I-Outcome
)	10348763	910	911	I-Outcome
and	10348763	912	915	I-Outcome
chronic	10348763	916	923	I-Outcome
toxicity	10348763	924	932	I-Outcome
(	10348763	933	934	I-Outcome
nephrotoxicity	10348763	935	949	I-Outcome
)	10348763	950	951	I-Outcome
also	10348763	952	956	O
indicated	10348763	957	966	O
that	10348763	967	971	O
there	10348763	972	977	O
was	10348763	978	981	O
no	10348763	982	984	O
significant	10348763	985	996	B-Observation
difference	10348763	997	1007	I-Observation
between	10348763	1008	1015	O
AmB	10348763	1016	1019	B-Intervention
infused	10348763	1020	1027	I-Intervention
in	10348763	1028	1030	I-Intervention
dextrose	10348763	1031	1039	I-Intervention
(	10348763	1040	1041	O
78	10348763	1042	1044	O
courses	10348763	1045	1052	O
)	10348763	1053	1054	O
and	10348763	1055	1058	O
AmB	10348763	1059	1062	B-Intervention
infused	10348763	1063	1070	I-Intervention
in	10348763	1071	1073	I-Intervention
lipid	10348763	1074	1079	I-Intervention
emulsion	10348763	1080	1088	I-Intervention
(	10348763	1089	1090	O
84	10348763	1091	1093	O
courses	10348763	1094	1101	O
)	10348763	1102	1103	O
.	10348763	1104	1105	O

The	10348763	1106	1109	O
pharmacokinetics	10348763	1110	1126	B-Outcome
of	10348763	1127	1129	O
AmB	10348763	1130	1133	B-Intervention
were	10348763	1134	1138	O
investigated	10348763	1139	1151	O
in	10348763	1152	1154	O
20	10348763	1155	1157	O
children	10348763	1158	1166	O
who	10348763	1167	1170	O
received	10348763	1171	1179	O
AmB	10348763	1180	1183	B-Intervention
in	10348763	1184	1186	I-Intervention
dextrose	10348763	1187	1195	I-Intervention
and	10348763	1196	1199	O
15	10348763	1200	1202	O
children	10348763	1203	1211	O
who	10348763	1212	1215	O
received	10348763	1216	1224	O
AmB	10348763	1225	1228	B-Intervention
in	10348763	1229	1231	I-Intervention
lipid	10348763	1232	1237	I-Intervention
emulsion	10348763	1238	1246	I-Intervention
.	10348763	1247	1248	O

Blood	10348763	1249	1254	O
samples	10348763	1255	1262	O
were	10348763	1263	1267	O
collected	10348763	1268	1277	O
up	10348763	1278	1280	O
to	10348763	1281	1283	O
24	10348763	1284	1286	O
h	10348763	1287	1288	O
after	10348763	1289	1294	O
administration	10348763	1295	1309	O
of	10348763	1310	1312	O
the	10348763	1313	1316	O
first	10348763	1317	1322	O
dose	10348763	1323	1327	O
,	10348763	1328	1329	O
and	10348763	1330	1333	O
the	10348763	1334	1337	O
concentration	10348763	1338	1351	B-Outcome
of	10348763	1352	1354	I-Outcome
AmB	10348763	1355	1358	I-Outcome
in	10348763	1359	1361	I-Outcome
plasma	10348763	1362	1368	I-Outcome
was	10348763	1369	1372	O
analyzed	10348763	1373	1381	O
by	10348763	1382	1384	O
a	10348763	1385	1386	O
high-performance	10348763	1387	1403	O
liquid	10348763	1404	1410	O
chromatography	10348763	1411	1425	O
assay	10348763	1426	1431	O
.	10348763	1432	1433	O

The	10348763	1434	1437	O
clearance	10348763	1438	1447	B-Outcome
(	10348763	1448	1449	I-Outcome
CL	10348763	1450	1452	I-Outcome
)	10348763	1453	1454	I-Outcome
of	10348763	1455	1457	O
AmB	10348763	1458	1461	B-Intervention
in	10348763	1462	1464	I-Intervention
dextrose	10348763	1465	1473	I-Intervention
(	10348763	1474	1475	O
0.039	10348763	1476	1481	B-Observation
+	10348763	1482	1483	I-Observation
/-	10348763	1483	1485	I-Observation
0.016	10348763	1486	1491	I-Observation
liter	10348763	1492	1497	I-Observation
.	10348763	1498	1499	I-Observation

h-1	10348763	1500	1503	B-Observation
.	10348763	1504	1505	I-Observation

kg-1	10348763	1506	1510	B-Observation
)	10348763	1511	1512	O
was	10348763	1513	1516	O
significantly	10348763	1517	1530	B-Observation
lower	10348763	1531	1536	I-Observation
(	10348763	1537	1538	O
P	10348763	1539	1540	O
<	10348763	1541	1542	O
0.005	10348763	1543	1548	O
)	10348763	1549	1550	O
than	10348763	1551	1555	O
the	10348763	1556	1559	O
CL	10348763	1560	1562	B-Outcome
of	10348763	1563	1565	O
AmB	10348763	1566	1569	B-Intervention
in	10348763	1570	1572	I-Intervention
lipid	10348763	1573	1578	I-Intervention
emulsion	10348763	1579	1587	I-Intervention
(	10348763	1588	1589	O
0.062	10348763	1590	1595	B-Observation
+	10348763	1596	1597	I-Observation
/-	10348763	1597	1599	I-Observation
0	10348763	1600	1601	I-Observation
.	10348763	1602	1603	I-Observation

024	10348763	1604	1607	B-Observation
liter	10348763	1608	1613	I-Observation
.	10348763	1614	1615	I-Observation

h-1	10348763	1616	1619	B-Observation
.	10348763	1620	1621	I-Observation

kg-1	10348763	1622	1626	B-Observation
)	10348763	1627	1628	O
.	10348763	1629	1630	O

The	10348763	1631	1634	O
steady-state	10348763	1635	1647	B-Outcome
volume	10348763	1648	1654	I-Outcome
of	10348763	1655	1657	I-Outcome
distribution	10348763	1658	1670	I-Outcome
for	10348763	1671	1674	O
AmB	10348763	1675	1678	B-Intervention
in	10348763	1679	1681	I-Intervention
dextrose	10348763	1682	1690	I-Intervention
(	10348763	1691	1692	O
0.83	10348763	1693	1697	B-Observation
+	10348763	1698	1699	I-Observation
/-	10348763	1699	1701	I-Observation
0.33	10348763	1702	1706	I-Observation
liter	10348763	1707	1712	I-Observation
.	10348763	1713	1714	I-Observation

kg-1	10348763	1715	1719	B-Observation
)	10348763	1720	1721	O
was	10348763	1722	1725	O
also	10348763	1726	1730	O
significantly	10348763	1731	1744	B-Observation
lower	10348763	1745	1750	I-Observation
(	10348763	1751	1752	O
P	10348763	1753	1754	O
<	10348763	1755	1756	O
0.005	10348763	1757	1762	O
)	10348763	1763	1764	O
than	10348763	1765	1769	O
that	10348763	1770	1774	O
for	10348763	1775	1778	O
AmB	10348763	1779	1782	B-Intervention
in	10348763	1783	1785	I-Intervention
lipid	10348763	1786	1791	I-Intervention
emulsion	10348763	1792	1800	I-Intervention
(	10348763	1801	1802	O
1.47	10348763	1803	1807	B-Observation
+	10348763	1808	1809	I-Observation
/-	10348763	1809	1811	I-Observation
0.77	10348763	1812	1816	I-Observation
liter	10348763	1817	1822	I-Observation
.	10348763	1823	1824	I-Observation

kg-1	10348763	1825	1829	B-Observation
)	10348763	1830	1831	O
.	10348763	1832	1833	O

Although	10348763	1834	1842	O
AmB	10348763	1843	1846	B-Intervention
in	10348763	1847	1849	I-Intervention
lipid	10348763	1850	1855	I-Intervention
emulsion	10348763	1856	1864	I-Intervention
is	10348763	1865	1867	O
apparently	10348763	1868	1878	O
cleared	10348763	1879	1886	B-Outcome
faster	10348763	1887	1893	B-Observation
and	10348763	1894	1897	O
distributes	10348763	1898	1909	B-Outcome
more	10348763	1910	1914	B-Observation
widely	10348763	1915	1921	I-Observation
than	10348763	1922	1926	O
AmB	10348763	1927	1930	B-Intervention
in	10348763	1931	1933	I-Intervention
dextrose	10348763	1934	1942	I-Intervention
,	10348763	1943	1944	O
this	10348763	1945	1949	O
study	10348763	1950	1955	O
did	10348763	1956	1959	O
not	10348763	1960	1963	O
reveal	10348763	1964	1970	O
any	10348763	1971	1974	O
significant	10348763	1975	1986	B-Observation
advantage	10348763	1987	1996	I-Observation
with	10348763	1997	2001	O
respect	10348763	2002	2009	O
to	10348763	2010	2012	O
safety	10348763	2013	2019	B-Outcome
and	10348763	2020	2023	O
tolerance	10348763	2024	2033	B-Outcome
in	10348763	2034	2036	O
the	10348763	2037	2040	O
administration	10348763	2041	2055	O
of	10348763	2056	2058	O
AmB	10348763	2059	2062	B-Intervention
in	10348763	2063	2065	I-Intervention
lipid	10348763	2066	2071	I-Intervention
emulsion	10348763	2072	2080	I-Intervention
compared	10348763	2081	2089	O
to	10348763	2090	2092	O
its	10348763	2093	2096	B-Intervention
administration	10348763	2097	2111	I-Intervention
in	10348763	2112	2114	I-Intervention
dextrose	10348763	2115	2123	I-Intervention
in	10348763	2124	2126	O
children	10348763	2127	2135	B-Participant
with	10348763	2136	2140	O
malignant	10348763	2141	2150	B-Participant
disease	10348763	2151	2158	I-Participant
.	10348763	2159	2160	O

Effect	10352330	0	6	O
of	10352330	7	9	O
granulocyte/colony-stimulating	10352330	10	40	B-Intervention
factor	10352330	41	47	I-Intervention
on	10352330	48	50	O
the	10352330	51	54	O
onset	10352330	55	60	B-Outcome
of	10352330	61	63	I-Outcome
the	10352330	64	67	I-Outcome
adult	10352330	68	73	I-Outcome
respiratory	10352330	74	85	I-Outcome
distress	10352330	86	94	I-Outcome
syndrome	10352330	95	103	I-Outcome
.	10352330	104	105	O

To	10352330	106	108	O
evaluate	10352330	109	117	O
the	10352330	118	121	O
effect	10352330	122	128	O
of	10352330	129	131	O
granulocyte/colony-stimulating	10352330	132	162	B-Intervention
factor	10352330	163	169	I-Intervention
(	10352330	170	171	I-Intervention
G-CSF	10352330	172	177	I-Intervention
)	10352330	178	179	I-Intervention
on	10352330	180	182	O
the	10352330	183	186	O
onset	10352330	187	192	B-Outcome
of	10352330	193	195	I-Outcome
the	10352330	196	199	I-Outcome
adult	10352330	200	205	I-Outcome
respiratory	10352330	206	217	I-Outcome
distress	10352330	218	226	I-Outcome
syndrome	10352330	227	235	I-Outcome
(	10352330	236	237	I-Outcome
ARDS	10352330	238	242	I-Outcome
)	10352330	243	244	I-Outcome
,	10352330	245	246	O
we	10352330	247	249	O
investigated	10352330	250	262	O
whether	10352330	263	270	O
the	10352330	271	274	O
incidence	10352330	275	284	B-Outcome
of	10352330	285	287	I-Outcome
ARDS	10352330	288	292	I-Outcome
due	10352330	293	296	I-Outcome
to	10352330	297	299	I-Outcome
pulmonary	10352330	300	309	I-Outcome
infection	10352330	310	319	I-Outcome
differed	10352330	320	328	B-Observation
between	10352330	329	336	O
the	10352330	337	340	O
G-CSF	10352330	341	346	O
group	10352330	347	352	O
which	10352330	353	358	O
received	10352330	359	367	O
chemotherapy	10352330	368	380	B-Intervention
with	10352330	381	385	I-Intervention
G-CSF	10352330	386	391	I-Intervention
and	10352330	392	395	O
historical	10352330	396	406	B-Intervention
controls	10352330	407	415	I-Intervention
without	10352330	416	423	I-Intervention
G-CSF	10352330	424	429	I-Intervention
.	10352330	430	431	O

We	10352330	432	434	O
evaluated	10352330	435	444	O
132	10352330	445	448	O
patients	10352330	449	457	O
with	10352330	458	462	O
hematological	10352330	463	476	B-Participant
malignancy	10352330	477	487	I-Participant
in	10352330	488	490	I-Participant
complete	10352330	491	499	I-Participant
remission	10352330	500	509	I-Participant
without	10352330	510	517	O
any	10352330	518	521	O
main	10352330	522	526	B-Participant
organ	10352330	527	532	I-Participant
dysfunction	10352330	533	544	I-Participant
who	10352330	545	548	O
had	10352330	549	552	O
been	10352330	553	557	O
treated	10352330	558	565	O
between	10352330	566	573	O
April	10352330	574	579	O
1983	10352330	580	584	O
and	10352330	585	588	O
December	10352330	589	597	O
1997	10352330	598	602	O
.	10352330	603	604	O

We	10352330	605	607	O
compared	10352330	608	616	O
the	10352330	617	620	O
incidence	10352330	621	630	B-Outcome
of	10352330	631	633	I-Outcome
ARDS	10352330	634	638	I-Outcome
due	10352330	639	642	I-Outcome
to	10352330	643	645	I-Outcome
pulmonary	10352330	646	655	I-Outcome
infection	10352330	656	665	I-Outcome
between	10352330	666	673	O
those	10352330	674	679	O
who	10352330	680	683	O
received	10352330	684	692	O
G-CSF	10352330	693	698	B-Intervention
and	10352330	699	702	O
those	10352330	703	708	O
who	10352330	709	712	O
did	10352330	713	716	O
not	10352330	717	720	B-Intervention
.	10352330	721	722	O

There	10352330	723	728	O
was	10352330	729	732	O
no	10352330	733	735	O
remarkable	10352330	736	746	O
difference	10352330	747	757	O
in	10352330	758	760	O
the	10352330	761	764	O
number	10352330	765	771	O
of	10352330	772	774	O
patients	10352330	775	783	O
,	10352330	784	785	O
gender	10352330	786	792	O
,	10352330	793	794	O
age	10352330	795	798	O
,	10352330	799	800	O
or	10352330	801	803	O
distribution	10352330	804	816	O
of	10352330	817	819	O
primary	10352330	820	827	O
diseases	10352330	828	836	O
between	10352330	837	844	O
the	10352330	845	848	O
two	10352330	849	852	O
groups	10352330	853	859	O
.	10352330	860	861	O

The	10352330	862	865	O
intensity	10352330	866	875	O
of	10352330	876	878	O
chemotherapy	10352330	879	891	O
was	10352330	892	895	O
not	10352330	896	899	O
considered	10352330	900	910	O
to	10352330	911	913	O
significantly	10352330	914	927	O
differ	10352330	928	934	O
between	10352330	935	942	O
the	10352330	943	946	O
two	10352330	947	950	O
groups	10352330	951	957	O
,	10352330	958	959	O
though	10352330	960	966	O
the	10352330	967	970	O
chemotherapy	10352330	971	983	O
regimens	10352330	984	992	O
administered	10352330	993	1005	O
differed	10352330	1006	1014	O
slightly	10352330	1015	1023	O
.	10352330	1024	1025	O

In	10352330	1026	1028	O
the	10352330	1029	1032	O
G-CSF	10352330	1033	1038	B-Intervention
group	10352330	1039	1044	O
,	10352330	1045	1046	O
the	10352330	1047	1050	O
duration	10352330	1051	1059	B-Outcome
of	10352330	1060	1062	I-Outcome
neutropenia	10352330	1063	1074	I-Outcome
was	10352330	1075	1078	O
significantly	10352330	1079	1092	B-Observation
shorter	10352330	1093	1100	I-Observation
and	10352330	1101	1104	O
the	10352330	1105	1108	O
frequency	10352330	1109	1118	B-Outcome
of	10352330	1119	1121	I-Outcome
documented	10352330	1122	1132	I-Outcome
infection	10352330	1133	1142	I-Outcome
was	10352330	1143	1146	O
significantly	10352330	1147	1160	B-Observation
decreased	10352330	1161	1170	I-Observation
.	10352330	1171	1172	O

We	10352330	1173	1175	O
could	10352330	1176	1181	O
not	10352330	1182	1185	O
find	10352330	1186	1190	O
any	10352330	1191	1194	O
relationship	10352330	1195	1207	B-Observation
between	10352330	1208	1215	B-Outcome
ARDS	10352330	1216	1220	I-Outcome
due	10352330	1221	1224	I-Outcome
to	10352330	1225	1227	I-Outcome
pulmonary	10352330	1228	1237	I-Outcome
infection	10352330	1238	1247	I-Outcome
and	10352330	1248	1251	I-Outcome
any	10352330	1252	1255	I-Outcome
anticancer	10352330	1256	1266	I-Outcome
agent	10352330	1267	1272	I-Outcome
or	10352330	1273	1275	I-Outcome
antibiotics	10352330	1276	1287	I-Outcome
.	10352330	1288	1289	O

There	10352330	1290	1295	O
was	10352330	1296	1299	O
no	10352330	1300	1302	O
relationship	10352330	1303	1315	B-Observation
between	10352330	1316	1323	O
the	10352330	1324	1327	O
kind	10352330	1328	1332	B-Intervention
of	10352330	1333	1335	I-Intervention
G-CSF	10352330	1336	1341	I-Intervention
and	10352330	1342	1345	O
the	10352330	1346	1349	O
incidence	10352330	1350	1359	B-Outcome
of	10352330	1360	1362	I-Outcome
ARDS	10352330	1363	1367	I-Outcome
due	10352330	1368	1371	I-Outcome
to	10352330	1372	1374	I-Outcome
pulmonary	10352330	1375	1384	I-Outcome
infection	10352330	1385	1394	I-Outcome
(	10352330	1395	1396	O
per	10352330	1397	1400	O
chemotherapy	10352330	1401	1413	O
session	10352330	1414	1421	O
;	10352330	1422	1423	O
p	10352330	1424	1425	O
>	10352330	1426	1427	O
0.10	10352330	1428	1432	O
,	10352330	1433	1434	O
per	10352330	1435	1438	O
case	10352330	1439	1443	O
;	10352330	1444	1445	O
p	10352330	1446	1447	O
>	10352330	1448	1449	O
0.30	10352330	1450	1454	O
,	10352330	1455	1456	O
chi2	10352330	1457	1461	O
test	10352330	1462	1466	O
)	10352330	1467	1468	O
.	10352330	1469	1470	O

The	10352330	1471	1474	O
incidence	10352330	1475	1484	B-Outcome
of	10352330	1485	1487	I-Outcome
ARDS	10352330	1488	1492	I-Outcome
due	10352330	1493	1496	I-Outcome
to	10352330	1497	1499	I-Outcome
pulmonary	10352330	1500	1509	I-Outcome
infection	10352330	1510	1519	I-Outcome
per	10352330	1520	1523	I-Outcome
chemotherapy	10352330	1524	1536	I-Outcome
session	10352330	1537	1544	I-Outcome
was	10352330	1545	1548	O
4.21	10352330	1549	1553	B-Observation
%	10352330	1554	1555	I-Observation
,	10352330	1556	1557	O
and	10352330	1558	1561	O
showed	10352330	1562	1568	O
a	10352330	1569	1570	O
higher	10352330	1571	1577	B-Observation
tendency	10352330	1578	1586	I-Observation
in	10352330	1587	1589	O
the	10352330	1590	1593	O
G-CSF	10352330	1594	1599	B-Intervention
group	10352330	1600	1605	O
(	10352330	1606	1607	O
p	10352330	1608	1609	O
<	10352330	1610	1611	O
0.100	10352330	1612	1617	O
,	10352330	1618	1619	O
chi2	10352330	1620	1624	O
test	10352330	1625	1629	O
)	10352330	1630	1631	O
.	10352330	1632	1633	O

The	10352330	1634	1637	O
incidence	10352330	1638	1647	B-Outcome
of	10352330	1648	1650	I-Outcome
ARDS	10352330	1651	1655	I-Outcome
due	10352330	1656	1659	I-Outcome
to	10352330	1660	1662	I-Outcome
pulmonary	10352330	1663	1672	I-Outcome
infection	10352330	1673	1682	I-Outcome
per	10352330	1683	1686	I-Outcome
case	10352330	1687	1691	I-Outcome
was	10352330	1692	1695	O
25.4	10352330	1696	1700	B-Observation
%	10352330	1701	1702	I-Observation
and	10352330	1703	1706	O
was	10352330	1707	1710	O
significantly	10352330	1711	1724	B-Observation
higher	10352330	1725	1731	I-Observation
in	10352330	1732	1734	O
the	10352330	1735	1738	O
G-CSF	10352330	1739	1744	B-Intervention
group	10352330	1745	1750	O
(	10352330	1751	1752	O
p	10352330	1753	1754	O
<	10352330	1755	1756	O
0.025	10352330	1757	1762	O
,	10352330	1763	1764	O
chi2	10352330	1765	1769	O
test	10352330	1770	1774	O
)	10352330	1775	1776	O
.	10352330	1777	1778	O

The	10352330	1779	1782	O
incidence	10352330	1783	1792	B-Outcome
of	10352330	1793	1795	I-Outcome
ARDS	10352330	1796	1800	I-Outcome
due	10352330	1801	1804	I-Outcome
to	10352330	1805	1807	I-Outcome
pulmonary	10352330	1808	1817	I-Outcome
infection	10352330	1818	1827	I-Outcome
was	10352330	1828	1831	O
higher	10352330	1832	1838	B-Observation
in	10352330	1839	1841	O
the	10352330	1842	1845	O
G-CSF	10352330	1846	1851	B-Intervention
group	10352330	1852	1857	O
than	10352330	1858	1862	O
in	10352330	1863	1865	O
the	10352330	1866	1869	O
controls	10352330	1870	1878	B-Intervention
,	10352330	1879	1880	O
suggesting	10352330	1881	1891	O
that	10352330	1892	1896	O
G-CSF	10352330	1897	1902	B-Intervention
promotes	10352330	1903	1911	B-Observation
the	10352330	1912	1915	O
development	10352330	1916	1927	B-Outcome
of	10352330	1928	1930	I-Outcome
ARDS	10352330	1931	1935	I-Outcome
due	10352330	1936	1939	I-Outcome
to	10352330	1940	1942	I-Outcome
pulmonary	10352330	1943	1952	I-Outcome
infection	10352330	1953	1962	I-Outcome
.	10352330	1963	1964	O

Low-dose	10352397	0	8	B-Intervention
growth	10352397	9	15	I-Intervention
hormone	10352397	16	23	I-Intervention
treatment	10352397	24	33	I-Intervention
with	10352397	34	38	O
diet	10352397	39	43	B-Participant
restriction	10352397	44	55	I-Participant
accelerates	10352397	56	67	B-Observation
body	10352397	68	72	B-Outcome
fat	10352397	73	76	I-Outcome
loss	10352397	77	81	I-Outcome
,	10352397	82	83	O
exerts	10352397	84	90	B-Observation
anabolic	10352397	91	99	B-Outcome
effect	10352397	100	106	I-Outcome
and	10352397	107	110	O
improves	10352397	111	119	B-Observation
growth	10352397	120	126	B-Outcome
hormone	10352397	127	134	I-Outcome
secretory	10352397	135	144	I-Outcome
dysfunction	10352397	145	156	I-Outcome
in	10352397	157	159	O
obese	10352397	160	165	B-Participant
adults	10352397	166	172	I-Participant
.	10352397	173	174	O

Growth	10352397	175	181	O
hormone	10352397	182	189	O
(	10352397	190	191	O
GH	10352397	192	194	O
)	10352397	195	196	O
can	10352397	197	200	O
induce	10352397	201	207	O
an	10352397	208	210	O
accelerated	10352397	211	222	O
lipolysis	10352397	223	232	O
.	10352397	233	234	O

Impaired	10352397	235	243	O
secretion	10352397	244	253	O
of	10352397	254	256	O
GH	10352397	257	259	O
in	10352397	260	262	O
obesity	10352397	263	270	O
results	10352397	271	278	O
in	10352397	279	281	O
the	10352397	282	285	O
consequent	10352397	286	296	O
loss	10352397	297	301	O
of	10352397	302	304	O
the	10352397	305	308	O
lipolytic	10352397	309	318	O
effect	10352397	319	325	O
of	10352397	326	328	O
GH	10352397	329	331	O
.	10352397	332	333	O

Dietary	10352397	334	341	O
restriction	10352397	342	353	O
as	10352397	354	356	O
a	10352397	357	358	O
basic	10352397	359	364	O
treatment	10352397	365	374	O
for	10352397	375	378	O
obesity	10352397	379	386	O
is	10352397	387	389	O
complicated	10352397	390	401	O
by	10352397	402	404	O
poor	10352397	405	409	O
compliance	10352397	410	420	O
,	10352397	421	422	O
protein	10352397	423	430	O
catabolism	10352397	431	441	O
,	10352397	442	443	O
and	10352397	444	447	O
slow	10352397	448	452	O
rates	10352397	453	458	O
or	10352397	459	461	O
weight	10352397	462	468	O
loss	10352397	469	473	O
.	10352397	474	475	O

GH	10352397	476	478	O
has	10352397	479	482	O
an	10352397	483	485	O
anabolic	10352397	486	494	O
effect	10352397	495	501	O
by	10352397	502	504	O
increasing	10352397	505	515	O
insulin-like	10352397	516	528	O
growth	10352397	529	535	O
factor	10352397	536	542	O
(	10352397	543	544	O
IGF	10352397	545	548	O
)	10352397	549	550	O
-I	10352397	551	553	O
.	10352397	554	555	O

We	10352397	556	558	O
investigated	10352397	559	571	O
the	10352397	572	575	O
effects	10352397	576	583	O
of	10352397	584	586	O
GH	10352397	587	589	B-Intervention
treatment	10352397	590	599	I-Intervention
and	10352397	600	603	O
dietary	10352397	604	611	B-Participant
restriction	10352397	612	623	I-Participant
on	10352397	624	626	O
lipolytic	10352397	627	636	B-Outcome
and	10352397	637	640	I-Outcome
anabolic	10352397	641	649	I-Outcome
actions	10352397	650	657	I-Outcome
,	10352397	658	659	O
as	10352397	660	662	O
well	10352397	663	667	O
as	10352397	668	670	O
the	10352397	671	674	O
consequent	10352397	675	685	B-Observation
changes	10352397	686	693	I-Observation
in	10352397	694	696	O
insulin	10352397	697	704	B-Outcome
and	10352397	705	708	I-Outcome
GH	10352397	709	711	I-Outcome
secretion	10352397	712	721	I-Outcome
in	10352397	722	724	O
obesity	10352397	725	732	B-Participant
.	10352397	733	734	O

24	10352397	735	737	O
obese	10352397	738	743	B-Participant
subjects	10352397	744	752	O
(	10352397	753	754	O
22	10352397	755	757	O
women	10352397	758	763	O
and	10352397	764	767	O
2	10352397	768	769	O
men	10352397	770	773	O
;	10352397	774	775	O
22	10352397	776	778	O
-	10352397	778	779	O
46	10352397	779	781	O
years	10352397	782	787	O
old	10352397	788	791	O
)	10352397	792	793	O
were	10352397	794	798	O
fed	10352397	799	802	O
a	10352397	803	804	O
diet	10352397	805	809	B-Participant
of	10352397	810	812	O
25	10352397	813	815	O
kcal/kg	10352397	816	823	O
ideal	10352397	824	829	O
body	10352397	830	834	O
weight	10352397	835	841	O
(	10352397	842	843	O
IBW	10352397	844	847	O
)	10352397	848	849	O
with	10352397	850	854	O
1.2	10352397	855	858	O
g	10352397	859	860	O
protein/kg	10352397	861	871	O
IBW	10352397	872	875	O
daily	10352397	876	881	O
and	10352397	882	885	O
were	10352397	886	890	O
treated	10352397	891	898	O
with	10352397	899	903	O
recombinant	10352397	904	915	B-Intervention
human	10352397	916	921	I-Intervention
GH	10352397	922	924	I-Intervention
(	10352397	925	926	O
n	10352397	927	928	O
=	10352397	929	930	O
12	10352397	931	933	O
,	10352397	934	935	O
0.18	10352397	936	940	B-Observation
U/kg	10352397	941	945	I-Observation
IBW/week	10352397	946	954	O
)	10352397	955	956	O
or	10352397	957	959	O
placebo	10352397	960	967	B-Intervention
(	10352397	968	969	O
n	10352397	970	971	O
=	10352397	972	973	O
12	10352397	974	976	O
,	10352397	977	978	O
vehicle	10352397	979	986	O
injection	10352397	987	996	O
)	10352397	997	998	O
in	10352397	999	1001	O
a	10352397	1002	1003	O
12-week	10352397	1004	1011	O
randomized	10352397	1012	1022	O
,	10352397	1023	1024	O
double-blind	10352397	1025	1037	O
and	10352397	1038	1041	O
placebo-controlled	10352397	1042	1060	O
trial	10352397	1061	1066	O
.	10352397	1067	1068	O

GH	10352397	1069	1071	B-Intervention
treatment	10352397	1072	1081	I-Intervention
caused	10352397	1082	1088	O
a	10352397	1089	1090	O
1.6-fold	10352397	1091	1099	B-Observation
increase	10352397	1100	1108	I-Observation
in	10352397	1109	1111	O
the	10352397	1112	1115	O
fraction	10352397	1116	1124	B-Outcome
of	10352397	1125	1127	I-Outcome
body	10352397	1128	1132	I-Outcome
weight	10352397	1133	1139	I-Outcome
lost	10352397	1140	1144	I-Outcome
as	10352397	1145	1147	I-Outcome
fat	10352397	1148	1151	I-Outcome
and	10352397	1152	1155	O
a	10352397	1156	1157	O
greater	10352397	1158	1165	B-Observation
loss	10352397	1166	1170	B-Outcome
of	10352397	1171	1173	I-Outcome
visceral	10352397	1174	1182	I-Outcome
fat	10352397	1183	1186	I-Outcome
area	10352397	1187	1191	I-Outcome
than	10352397	1192	1196	O
placebo	10352397	1197	1204	B-Intervention
treatment	10352397	1205	1214	O
(	10352397	1215	1216	O
35.3	10352397	1217	1221	B-Observation
vs.	10352397	1222	1225	O
28.5	10352397	1226	1230	B-Observation
%	10352397	1231	1232	I-Observation
,	10352397	1233	1234	O
p	10352397	1235	1236	O
<	10352397	1237	1238	O
0.05	10352397	1239	1243	O
)	10352397	1244	1245	O
.	10352397	1246	1247	O

In	10352397	1248	1250	O
the	10352397	1251	1254	O
placebo	10352397	1255	1262	B-Intervention
group	10352397	1263	1268	O
,	10352397	1269	1270	O
there	10352397	1271	1276	O
was	10352397	1277	1280	O
a	10352397	1281	1282	O
loss	10352397	1283	1287	B-Observation
in	10352397	1288	1290	O
lean	10352397	1291	1295	B-Outcome
body	10352397	1296	1300	I-Outcome
mass	10352397	1301	1305	I-Outcome
(	10352397	1306	1307	O
-2.62	10352397	1308	1313	B-Observation
+	10352397	1314	1315	I-Observation
/-	10352397	1315	1317	I-Observation
1.51	10352397	1318	1322	I-Observation
kg	10352397	1323	1325	I-Observation
)	10352397	1326	1327	O
and	10352397	1328	1331	O
a	10352397	1332	1333	O
negative	10352397	1334	1342	B-Observation
nitrogen	10352397	1343	1351	B-Outcome
balance	10352397	1352	1359	I-Outcome
(	10352397	1360	1361	O
-4.52	10352397	1362	1367	B-Observation
+	10352397	1368	1369	I-Observation
/-	10352397	1369	1371	I-Observation
3.51	10352397	1372	1376	I-Observation
g/day	10352397	1377	1382	I-Observation
)	10352397	1383	1384	O
.	10352397	1385	1386	O

By	10352397	1387	1389	O
contrast	10352397	1390	1398	O
,	10352397	1399	1400	O
the	10352397	1401	1404	O
GH	10352397	1405	1407	B-Intervention
group	10352397	1408	1413	O
increased	10352397	1414	1423	B-Observation
in	10352397	1424	1426	O
lean	10352397	1427	1431	B-Outcome
body	10352397	1432	1436	I-Outcome
mass	10352397	1437	1441	I-Outcome
(	10352397	1442	1443	O
1.13	10352397	1444	1448	B-Observation
+	10352397	1449	1450	I-Observation
/-	10352397	1450	1452	I-Observation
1.04	10352397	1453	1457	I-Observation
kg	10352397	1458	1460	I-Observation
)	10352397	1461	1462	O
and	10352397	1463	1466	O
had	10352397	1467	1470	O
a	10352397	1471	1472	O
positive	10352397	1473	1481	B-Observation
nitrogen	10352397	1482	1490	B-Outcome
balance	10352397	1491	1498	I-Outcome
(	10352397	1499	1500	O
1.81	10352397	1501	1505	B-Observation
+	10352397	1506	1507	I-Observation
/-	10352397	1507	1509	I-Observation
2.06	10352397	1510	1514	I-Observation
g/day	10352397	1515	1520	I-Observation
)	10352397	1521	1522	O
.	10352397	1523	1524	O

GH	10352397	1525	1527	B-Intervention
injections	10352397	1528	1538	I-Intervention
caused	10352397	1539	1545	O
a	10352397	1546	1547	O
1.6-fold	10352397	1548	1556	B-Observation
increase	10352397	1557	1565	I-Observation
in	10352397	1566	1568	O
IGF-I	10352397	1569	1574	B-Outcome
,	10352397	1575	1576	O
despite	10352397	1577	1584	O
caloric	10352397	1585	1592	O
restriction	10352397	1593	1604	O
.	10352397	1605	1606	O

GH	10352397	1607	1609	B-Outcome
response	10352397	1610	1618	I-Outcome
to	10352397	1619	1621	I-Outcome
L-dopa	10352397	1622	1628	I-Outcome
stimulation	10352397	1629	1640	I-Outcome
was	10352397	1641	1644	O
blunted	10352397	1645	1652	B-Observation
in	10352397	1653	1655	O
all	10352397	1656	1659	B-Count
subjects	10352397	1660	1668	I-Count
and	10352397	1669	1672	O
it	10352397	1673	1675	O
was	10352397	1676	1679	O
increased	10352397	1680	1689	B-Observation
after	10352397	1690	1695	O
treatment	10352397	1696	1705	O
in	10352397	1706	1708	O
both	10352397	1709	1713	B-Intervention
groups	10352397	1714	1720	I-Intervention
.	10352397	1721	1722	O

GH	10352397	1723	1725	B-Intervention
treatment	10352397	1726	1735	O
did	10352397	1736	1739	O
not	10352397	1740	1743	O
induce	10352397	1744	1750	O
a	10352397	1751	1752	O
further	10352397	1753	1760	B-Observation
increase	10352397	1761	1769	I-Observation
in	10352397	1770	1772	O
insulin	10352397	1773	1780	B-Outcome
levels	10352397	1781	1787	I-Outcome
during	10352397	1788	1794	O
an	10352397	1795	1797	O
oral	10352397	1798	1802	O
glucose	10352397	1803	1810	O
tolerance	10352397	1811	1820	O
test	10352397	1821	1825	O
(	10352397	1826	1827	O
OGTT	10352397	1828	1832	O
)	10352397	1833	1834	O
but	10352397	1835	1838	O
significantly	10352397	1839	1852	B-Observation
decreased	10352397	1853	1862	I-Observation
free	10352397	1863	1867	B-Outcome
fatty	10352397	1868	1873	I-Outcome
acid	10352397	1874	1878	I-Outcome
(	10352397	1879	1880	I-Outcome
FFA	10352397	1881	1884	I-Outcome
)	10352397	1885	1886	I-Outcome
levels	10352397	1887	1893	I-Outcome
during	10352397	1894	1900	O
OGTT	10352397	1901	1905	O
.	10352397	1906	1907	O

The	10352397	1908	1911	O
decrease	10352397	1912	1920	B-Observation
in	10352397	1921	1923	O
FFA	10352397	1924	1927	B-Outcome
area	10352397	1928	1932	I-Outcome
under	10352397	1933	1938	I-Outcome
the	10352397	1939	1942	I-Outcome
curve	10352397	1943	1948	I-Outcome
during	10352397	1949	1955	O
OGTT	10352397	1956	1960	O
was	10352397	1961	1964	O
positively	10352397	1965	1975	B-Observation
correlated	10352397	1976	1986	I-Observation
with	10352397	1987	1991	O
visceral	10352397	1992	2000	B-Outcome
fat	10352397	2001	2004	I-Outcome
loss	10352397	2005	2009	I-Outcome
.	10352397	2010	2011	O

This	10352397	2012	2016	O
study	10352397	2017	2022	O
demonstrates	10352397	2023	2035	O
that	10352397	2036	2040	O
in	10352397	2041	2043	O
obese	10352397	2044	2049	B-Participant
subjects	10352397	2050	2058	O
given	10352397	2059	2064	O
a	10352397	2065	2066	O
hypocaloric	10352397	2067	2078	B-Participant
diet	10352397	2079	2083	I-Participant
,	10352397	2084	2085	O
GH	10352397	2086	2088	B-Intervention
accelerates	10352397	2089	2100	B-Observation
body	10352397	2101	2105	B-Outcome
fat	10352397	2106	2109	I-Outcome
loss	10352397	2110	2114	I-Outcome
,	10352397	2115	2116	O
exerts	10352397	2117	2123	B-Observation
anabolic	10352397	2124	2132	B-Outcome
effects	10352397	2133	2140	I-Outcome
and	10352397	2141	2144	O
improves	10352397	2145	2153	B-Observation
GH	10352397	2154	2156	B-Outcome
secretion	10352397	2157	2166	I-Outcome
.	10352397	2167	2168	O

These	10352397	2169	2174	O
findings	10352397	2175	2183	O
suggest	10352397	2184	2191	O
a	10352397	2192	2193	O
possible	10352397	2194	2202	B-Observation
therapeutic	10352397	2203	2214	I-Observation
role	10352397	2215	2219	I-Observation
of	10352397	2220	2222	O
low-dose	10352397	2223	2231	B-Intervention
GH	10352397	2232	2234	I-Intervention
with	10352397	2235	2239	O
caloric	10352397	2240	2247	B-Participant
restriction	10352397	2248	2259	I-Participant
for	10352397	2260	2263	O
obesity	10352397	2264	2271	B-Participant
.	10352397	2272	2273	O

A	10355394	0	1	O
prospective	10355394	2	13	O
randomized	10355394	14	24	O
trial	10355394	25	30	O
of	10355394	31	33	O
Duraflo	10355394	34	41	B-Intervention
II	10355394	42	44	I-Intervention
heparin-coated	10355394	45	59	I-Intervention
circuits	10355394	60	68	I-Intervention
in	10355394	69	71	O
cardiac	10355394	72	79	B-Participant
reoperations	10355394	80	92	I-Participant
.	10355394	93	94	O

BACKGROUND	10355394	95	105	O
Heparin-coated	10355394	106	120	O
circuits	10355394	121	129	O
in	10355394	130	132	O
cardiopulmonary	10355394	133	148	O
bypass	10355394	149	155	O
have	10355394	156	160	O
been	10355394	161	165	O
shown	10355394	166	171	O
to	10355394	172	174	O
decrease	10355394	175	183	O
the	10355394	184	187	O
systemic	10355394	188	196	O
inflammatory	10355394	197	209	O
responses	10355394	210	219	O
associated	10355394	220	230	O
with	10355394	231	235	O
cardiopulmonary	10355394	236	251	O
bypass	10355394	252	258	O
.	10355394	259	260	O

Previous	10355394	261	269	O
clinical	10355394	270	278	O
studies	10355394	279	286	O
on	10355394	287	289	O
low-risk	10355394	290	298	O
patients	10355394	299	307	O
who	10355394	308	311	O
had	10355394	312	315	O
coronary	10355394	316	324	O
artery	10355394	325	331	O
bypass	10355394	332	338	O
grafting	10355394	339	347	O
(	10355394	348	349	O
CABG	10355394	350	354	O
)	10355394	355	356	O
and	10355394	357	360	O
received	10355394	361	369	O
full-dose	10355394	370	379	O
systemic	10355394	380	388	O
heparin	10355394	389	396	O
did	10355394	397	400	O
not	10355394	401	404	O
have	10355394	405	409	O
clearly	10355394	410	417	O
improved	10355394	418	426	O
clinical	10355394	427	435	O
outcomes	10355394	436	444	O
.	10355394	445	446	O

We	10355394	447	449	O
hypothesized	10355394	450	462	O
that	10355394	463	467	O
the	10355394	468	471	O
beneficial	10355394	472	482	B-Outcome
effects	10355394	483	490	I-Outcome
of	10355394	491	493	O
heparin-coated	10355394	494	508	B-Intervention
circuits	10355394	509	517	I-Intervention
might	10355394	518	523	O
be	10355394	524	526	O
seen	10355394	527	531	O
in	10355394	532	534	O
patients	10355394	535	543	O
who	10355394	544	547	O
had	10355394	548	551	O
cardiac	10355394	552	559	B-Participant
reoperations	10355394	560	572	I-Participant
.	10355394	573	574	O

METHODS	10355394	575	582	O
Three	10355394	583	588	O
hundred	10355394	589	596	O
fifty	10355394	597	602	O
patients	10355394	603	611	O
who	10355394	612	615	O
had	10355394	616	619	O
reoperation	10355394	620	631	B-Participant
with	10355394	632	636	O
CABG	10355394	637	641	B-Participant
only	10355394	642	646	O
(	10355394	647	648	O
58	10355394	649	651	O
%	10355394	652	653	O
)	10355394	654	655	O
,	10355394	656	657	O
or	10355394	658	660	O
with	10355394	661	665	O
valve	10355394	666	671	B-Participant
operations	10355394	672	682	I-Participant
(	10355394	683	684	O
42	10355394	685	687	O
%	10355394	688	689	O
)	10355394	690	691	O
were	10355394	692	696	O
randomly	10355394	697	705	O
assigned	10355394	706	714	O
to	10355394	715	717	O
receive	10355394	718	725	O
either	10355394	726	732	O
a	10355394	733	734	O
heparin-coated	10355394	735	749	B-Intervention
(	10355394	750	751	O
Duraflo	10355394	752	759	O
II	10355394	760	762	O
;	10355394	763	764	O
study	10355394	765	770	O
group	10355394	771	776	O
)	10355394	777	778	O
or	10355394	779	781	O
uncoated	10355394	782	790	B-Intervention
(	10355394	791	792	O
control	10355394	793	800	O
group	10355394	801	806	O
)	10355394	807	808	O
circuit	10355394	809	816	O
.	10355394	817	818	O

Clinical	10355394	819	827	B-Outcome
outcomes	10355394	828	836	I-Outcome
were	10355394	837	841	O
compared	10355394	842	850	O
and	10355394	851	854	O
the	10355394	855	858	O
variables	10355394	859	868	O
were	10355394	869	873	O
analyzed	10355394	874	882	O
using	10355394	883	888	O
the	10355394	889	892	O
following	10355394	893	902	O
three	10355394	903	908	O
groups	10355394	909	915	O
:	10355394	916	917	O
entire	10355394	918	924	B-Participant
populations	10355394	925	936	I-Participant
of	10355394	937	939	O
study	10355394	940	945	O
group	10355394	946	951	O
and	10355394	952	955	O
control	10355394	956	963	O
group	10355394	964	969	O
,	10355394	970	971	O
subgroup	10355394	972	980	O
of	10355394	981	983	O
patients	10355394	984	992	O
who	10355394	993	996	O
had	10355394	997	1000	O
CABG	10355394	1001	1005	B-Participant
reoperation	10355394	1006	1017	I-Participant
only	10355394	1018	1022	I-Participant
,	10355394	1023	1024	O
and	10355394	1025	1028	O
a	10355394	1029	1030	O
subgroup	10355394	1031	1039	O
who	10355394	1040	1043	O
had	10355394	1044	1047	O
valve	10355394	1048	1053	B-Participant
reoperation	10355394	1054	1065	I-Participant
or	10355394	1066	1068	O
combined	10355394	1069	1077	B-Participant
valve	10355394	1078	1083	I-Participant
and	10355394	1084	1087	I-Participant
CABG	10355394	1088	1092	I-Participant
reoperation	10355394	1093	1104	I-Participant
.	10355394	1105	1106	O

RESULTS	10355394	1107	1114	O
Preoperative	10355394	1115	1127	O
variables	10355394	1128	1137	O
were	10355394	1138	1142	O
the	10355394	1143	1146	O
same	10355394	1147	1151	O
in	10355394	1152	1154	O
both	10355394	1155	1159	O
groups	10355394	1160	1166	O
.	10355394	1167	1168	O

No	10355394	1169	1171	O
difference	10355394	1172	1182	B-Observation
in	10355394	1183	1185	O
clinical	10355394	1186	1194	B-Outcome
outcomes	10355394	1195	1203	I-Outcome
could	10355394	1204	1209	O
be	10355394	1210	1212	O
demonstrated	10355394	1213	1225	O
except	10355394	1226	1232	O
that	10355394	1233	1237	O
the	10355394	1238	1241	O
percentage	10355394	1242	1252	B-Outcome
of	10355394	1253	1255	I-Outcome
patients	10355394	1256	1264	I-Outcome
with	10355394	1265	1269	I-Outcome
major	10355394	1270	1275	I-Outcome
bleeding	10355394	1276	1284	I-Outcome
episodes	10355394	1285	1293	I-Outcome
was	10355394	1294	1297	O
significantly	10355394	1298	1311	B-Observation
lower	10355394	1312	1317	I-Observation
in	10355394	1318	1320	O
the	10355394	1321	1324	O
study	10355394	1325	1330	B-Intervention
group	10355394	1331	1336	O
(	10355394	1337	1338	O
1.2	10355394	1339	1342	B-Count
%	10355394	1343	1344	I-Count
versus	10355394	1345	1351	O
5.4	10355394	1352	1355	B-Count
%	10355394	1356	1357	I-Count
,	10355394	1358	1359	O
p	10355394	1360	1361	O
=	10355394	1362	1363	O
0.035	10355394	1364	1369	O
)	10355394	1370	1371	O
.	10355394	1372	1373	O

In	10355394	1374	1376	O
the	10355394	1377	1380	O
subgroup	10355394	1381	1389	O
analysis	10355394	1390	1398	O
of	10355394	1399	1401	O
patients	10355394	1402	1410	O
who	10355394	1411	1414	O
had	10355394	1415	1418	O
valve	10355394	1419	1424	B-Participant
reoperations	10355394	1425	1437	I-Participant
,	10355394	1438	1439	O
lower	10355394	1440	1445	B-Observation
blood	10355394	1446	1451	B-Outcome
transfusion	10355394	1452	1463	I-Outcome
requirements	10355394	1464	1476	I-Outcome
in	10355394	1477	1479	I-Outcome
the	10355394	1480	1483	I-Outcome
intensive	10355394	1484	1493	I-Outcome
care	10355394	1494	1498	I-Outcome
unit	10355394	1499	1503	I-Outcome
(	10355394	1504	1505	O
p	10355394	1506	1507	O
=	10355394	1508	1509	O
0.013	10355394	1510	1515	O
)	10355394	1516	1517	O
were	10355394	1518	1522	O
found	10355394	1523	1528	O
in	10355394	1529	1531	O
the	10355394	1532	1535	O
study	10355394	1536	1541	B-Intervention
group	10355394	1542	1547	O
.	10355394	1548	1549	O

When	10355394	1550	1554	O
the	10355394	1555	1558	O
subgroup	10355394	1559	1567	O
of	10355394	1568	1570	O
patients	10355394	1571	1579	O
who	10355394	1580	1583	O
had	10355394	1584	1587	O
CABG	10355394	1588	1592	B-Participant
reoperations	10355394	1593	1605	I-Participant
was	10355394	1606	1609	O
analyzed	10355394	1610	1618	O
separately	10355394	1619	1629	O
,	10355394	1630	1631	O
there	10355394	1632	1637	O
was	10355394	1638	1641	O
a	10355394	1642	1643	O
trend	10355394	1644	1649	B-Observation
toward	10355394	1650	1656	I-Observation
less	10355394	1657	1661	I-Observation
reoperation	10355394	1662	1673	B-Outcome
for	10355394	1674	1677	I-Outcome
bleeding	10355394	1678	1686	I-Outcome
in	10355394	1687	1689	O
the	10355394	1690	1693	O
study	10355394	1694	1699	B-Intervention
group	10355394	1700	1705	O
(	10355394	1706	1707	O
0	10355394	1708	1709	B-Observation
%	10355394	1710	1711	I-Observation
versus	10355394	1712	1718	O
4.0	10355394	1719	1722	B-Observation
%	10355394	1723	1724	I-Observation
,	10355394	1725	1726	O
p	10355394	1727	1728	O
=	10355394	1729	1730	O
0.058	10355394	1731	1736	O
)	10355394	1737	1738	O
.	10355394	1739	1740	O

CONCLUSIONS	10355394	1741	1752	O
We	10355394	1753	1755	O
conclude	10355394	1756	1764	O
that	10355394	1765	1769	O
the	10355394	1770	1773	O
use	10355394	1774	1777	O
of	10355394	1778	1780	O
heparin-coated	10355394	1781	1795	B-Intervention
circuits	10355394	1796	1804	I-Intervention
was	10355394	1805	1808	O
safe	10355394	1809	1813	B-Observation
and	10355394	1814	1817	O
imparted	10355394	1818	1826	B-Observation
protection	10355394	1827	1837	I-Observation
from	10355394	1838	1842	O
reoperations	10355394	1843	1855	B-Outcome
for	10355394	1856	1859	I-Outcome
bleeding	10355394	1860	1868	I-Outcome
and	10355394	1869	1872	O
major	10355394	1873	1878	B-Outcome
bleeding	10355394	1879	1887	I-Outcome
episodes	10355394	1888	1896	I-Outcome
.	10355394	1897	1898	O

Material-independent	10355394	1899	1919	O
blood	10355394	1920	1925	O
activation	10355394	1926	1936	O
(	10355394	1937	1938	O
eg	10355394	1939	1941	O
,	10355394	1942	1943	O
blood-air	10355394	1944	1953	O
interface	10355394	1954	1963	O
and	10355394	1964	1967	O
cardiotomy	10355394	1968	1978	O
suction	10355394	1979	1986	O
)	10355394	1987	1988	O
blunted	10355394	1989	1996	O
the	10355394	1997	2000	O
total	10355394	2001	2006	O
effect	10355394	2007	2013	O
of	10355394	2014	2016	O
the	10355394	2017	2020	O
heparin-coated	10355394	2021	2035	O
surface	10355394	2036	2043	O
.	10355394	2044	2045	O

Event-related	10356632	0	13	B-Outcome
potential	10356632	14	23	I-Outcome
indices	10356632	24	31	I-Outcome
of	10356632	32	34	I-Outcome
auditory	10356632	35	43	I-Outcome
selective	10356632	44	53	I-Outcome
attention	10356632	54	63	I-Outcome
in	10356632	64	66	O
dependent	10356632	67	76	B-Intervention
amphetamine	10356632	77	88	I-Intervention
users	10356632	89	94	I-Intervention
.	10356632	95	96	O

BACKGROUND	10356632	97	107	O
The	10356632	108	111	O
aim	10356632	112	115	O
of	10356632	116	118	O
the	10356632	119	122	O
present	10356632	123	130	O
study	10356632	131	136	O
was	10356632	137	140	O
to	10356632	141	143	O
further	10356632	144	151	O
investigate	10356632	152	163	O
a	10356632	164	165	O
previously	10356632	166	176	O
reported	10356632	177	185	O
attention-related	10356632	186	203	B-Outcome
impairment	10356632	204	214	I-Outcome
in	10356632	215	217	O
dependent	10356632	218	227	B-Intervention
amphetamine	10356632	228	239	I-Intervention
users	10356632	240	245	I-Intervention
using	10356632	246	251	O
event-related	10356632	252	265	O
potential	10356632	266	275	O
(	10356632	276	277	O
ERP	10356632	278	281	O
)	10356632	282	283	O
indices	10356632	284	291	O
of	10356632	292	294	O
selective	10356632	295	304	O
attention	10356632	305	314	O
.	10356632	315	316	O

METHODS	10356632	317	324	O
ERPs	10356632	325	329	B-Outcome
were	10356632	330	334	O
recorded	10356632	335	343	O
during	10356632	344	350	O
an	10356632	351	353	O
auditory	10356632	354	362	O
selective	10356632	363	372	O
attention	10356632	373	382	O
task	10356632	383	387	O
(	10356632	388	389	O
SAT	10356632	390	393	O
)	10356632	394	395	O
that	10356632	396	400	O
involved	10356632	401	409	O
detecting	10356632	410	419	O
infrequent	10356632	420	430	O
long-duration	10356632	431	444	O
target	10356632	445	451	O
tones	10356632	452	457	O
presented	10356632	458	467	O
among	10356632	468	473	O
short-duration	10356632	474	488	O
tones	10356632	489	494	O
that	10356632	495	499	O
varied	10356632	500	506	O
in	10356632	507	509	O
location	10356632	510	518	O
(	10356632	519	520	O
left	10356632	521	525	O
vs.	10356632	526	529	O
right	10356632	530	535	O
ear	10356632	536	539	O
)	10356632	540	541	O
and	10356632	542	545	O
pitch	10356632	546	551	O
(	10356632	552	553	O
low	10356632	554	557	O
vs.	10356632	558	561	O
high	10356632	562	566	O
)	10356632	567	568	O
.	10356632	569	570	O

Amphetamine	10356632	571	582	B-Participant
users	10356632	583	588	I-Participant
(	10356632	589	590	O
n	10356632	591	592	O
=	10356632	593	594	O
19	10356632	595	597	O
)	10356632	598	599	O
were	10356632	600	604	O
divided	10356632	605	612	O
into	10356632	613	617	O
two	10356632	618	621	O
groups	10356632	622	628	O
,	10356632	629	630	O
high	10356632	631	635	B-Intervention
dependence	10356632	636	646	I-Intervention
(	10356632	647	648	O
n	10356632	649	650	O
=	10356632	651	652	O
10	10356632	653	655	O
)	10356632	656	657	O
and	10356632	658	661	O
low	10356632	662	665	B-Intervention
dependence	10356632	666	676	I-Intervention
(	10356632	677	678	O
n	10356632	679	680	O
=	10356632	681	682	O
10	10356632	683	685	O
)	10356632	686	687	O
,	10356632	688	689	O
based	10356632	690	695	O
on	10356632	696	698	O
amphetamine	10356632	699	710	O
Severity	10356632	711	719	O
of	10356632	720	722	O
Dependence	10356632	723	733	O
Scale	10356632	734	739	O
scores	10356632	740	746	O
,	10356632	747	748	O
and	10356632	749	752	O
compared	10356632	753	761	O
to	10356632	762	764	O
an	10356632	765	767	O
age-matched	10356632	768	779	B-Intervention
control	10356632	780	787	I-Intervention
group	10356632	788	793	O
(	10356632	794	795	O
n	10356632	796	797	O
=	10356632	798	799	O
9	10356632	800	801	O
)	10356632	802	803	O
.	10356632	804	805	O

RESULTS	10356632	806	813	O
The	10356632	814	817	O
high-dependence	10356632	818	833	B-Intervention
group	10356632	834	839	O
showed	10356632	840	846	O
slowed	10356632	847	853	B-Observation
reaction	10356632	854	862	B-Outcome
time	10356632	863	867	I-Outcome
and	10356632	868	871	O
reduced	10356632	872	879	B-Observation
early	10356632	880	885	B-Outcome
processing	10356632	886	896	I-Outcome
negativity	10356632	897	907	I-Outcome
and	10356632	908	911	O
peak	10356632	912	916	B-Outcome
N1	10356632	917	919	I-Outcome
amplitude	10356632	920	929	I-Outcome
to	10356632	930	932	I-Outcome
location-relevant	10356632	933	950	I-Outcome
nontarget	10356632	951	960	I-Outcome
stimuli	10356632	961	968	I-Outcome
.	10356632	969	970	O

Poor	10356632	971	975	B-Observation
performance	10356632	976	987	I-Observation
on	10356632	988	990	O
the	10356632	991	994	O
SAT	10356632	995	998	B-Outcome
was	10356632	999	1002	O
highly	10356632	1003	1009	B-Observation
correlated	10356632	1010	1020	I-Observation
with	10356632	1021	1025	O
deficits	10356632	1026	1034	B-Outcome
in	10356632	1035	1037	O
early	10356632	1038	1043	O
processing	10356632	1044	1054	O
,	10356632	1055	1056	O
which	10356632	1057	1062	O
were	10356632	1063	1067	O
also	10356632	1068	1072	O
related	10356632	1073	1080	O
to	10356632	1081	1083	O
poor	10356632	1084	1088	B-Observation
performance	10356632	1089	1100	I-Observation
on	10356632	1101	1103	O
the	10356632	1104	1107	O
Wechsler	10356632	1108	1116	B-Outcome
Memory	10356632	1117	1123	I-Outcome
Scale	10356632	1124	1129	I-Outcome
Attention/Concentration	10356632	1130	1153	I-Outcome
index	10356632	1154	1159	I-Outcome
.	10356632	1160	1161	O

CONCLUSIONS	10356632	1162	1173	O
It	10356632	1174	1176	O
is	10356632	1177	1179	O
suggested	10356632	1180	1189	O
that	10356632	1190	1194	O
severely	10356632	1195	1203	B-Intervention
dependent	10356632	1204	1213	I-Intervention
users	10356632	1214	1219	I-Intervention
suffer	10356632	1220	1226	B-Observation
an	10356632	1227	1229	O
inability	10356632	1230	1239	B-Outcome
to	10356632	1240	1242	I-Outcome
selectively	10356632	1243	1254	I-Outcome
enhance	10356632	1255	1262	I-Outcome
the	10356632	1263	1266	I-Outcome
sensory	10356632	1267	1274	I-Outcome
processing	10356632	1275	1285	I-Outcome
of	10356632	1286	1288	I-Outcome
relevant	10356632	1289	1297	I-Outcome
auditory	10356632	1298	1306	I-Outcome
information	10356632	1307	1318	I-Outcome
.	10356632	1319	1320	O

This	10356632	1321	1325	O
may	10356632	1326	1329	O
produce	10356632	1330	1337	O
poor	10356632	1338	1342	B-Observation
automatic	10356632	1343	1352	B-Outcome
preferential	10356632	1353	1365	I-Outcome
processing	10356632	1366	1376	I-Outcome
of	10356632	1377	1379	I-Outcome
relevant	10356632	1380	1388	I-Outcome
information	10356632	1389	1400	I-Outcome
and	10356632	1401	1404	O
increase	10356632	1405	1413	B-Observation
load	10356632	1414	1418	B-Outcome
on	10356632	1419	1421	I-Outcome
limited	10356632	1422	1429	I-Outcome
attentional	10356632	1430	1441	I-Outcome
resources	10356632	1442	1451	I-Outcome
.	10356632	1452	1453	O

A	10360656	0	1	O
randomized	10360656	2	12	O
phase	10360656	13	18	O
II	10360656	19	21	O
trial	10360656	22	27	O
of	10360656	28	30	O
5-fluorouracil	10360656	31	45	B-Intervention
,	10360656	46	47	I-Intervention
with	10360656	48	52	I-Intervention
or	10360656	53	55	I-Intervention
without	10360656	56	63	I-Intervention
human	10360656	64	69	I-Intervention
interferon-beta	10360656	70	85	I-Intervention
,	10360656	86	87	O
for	10360656	88	91	O
advanced	10360656	92	100	B-Participant
colorectal	10360656	101	111	I-Participant
cancer	10360656	112	118	I-Participant
.	10360656	119	120	O

This	10360656	121	125	O
study	10360656	126	131	O
compared	10360656	132	140	O
the	10360656	141	144	O
efficacy	10360656	145	153	B-Outcome
and	10360656	154	157	O
safety	10360656	158	164	B-Outcome
of	10360656	165	167	O
5-fluorouracil	10360656	168	182	B-Intervention
(	10360656	183	184	I-Intervention
5-FU	10360656	185	189	I-Intervention
)	10360656	190	191	I-Intervention
monotherapy	10360656	192	203	I-Intervention
to	10360656	204	206	O
that	10360656	207	211	O
of	10360656	212	214	O
5-FU	10360656	215	219	B-Intervention
combined	10360656	220	228	I-Intervention
with	10360656	229	233	I-Intervention
natural	10360656	234	241	I-Intervention
human	10360656	242	247	I-Intervention
interferon-beta	10360656	248	263	I-Intervention
(	10360656	264	265	I-Intervention
IFN-beta	10360656	266	274	I-Intervention
)	10360656	275	276	I-Intervention
in	10360656	277	279	O
patients	10360656	280	288	O
with	10360656	289	293	O
unresectable	10360656	294	306	B-Participant
,	10360656	307	308	I-Participant
advanced	10360656	309	317	I-Participant
colorectal	10360656	318	328	I-Participant
carcinoma	10360656	329	338	I-Participant
.	10360656	339	340	O

Forty-nine	10360656	341	351	O
chemotherapy-naive	10360656	352	370	B-Participant
patients	10360656	371	379	O
were	10360656	380	384	O
randomized	10360656	385	395	O
to	10360656	396	398	O
5-FU	10360656	399	403	B-Intervention
alone	10360656	404	409	I-Intervention
or	10360656	410	412	O
to	10360656	413	415	O
the	10360656	416	419	O
combination	10360656	420	431	B-Intervention
.	10360656	432	433	O

All	10360656	434	437	O
patients	10360656	438	446	O
received	10360656	447	455	O
750	10360656	456	459	O
mg	10360656	460	462	O
m	10360656	463	464	O
(	10360656	465	466	O
-2	10360656	467	469	O
)	10360656	470	471	O
day	10360656	472	475	O
(	10360656	476	477	O
-1	10360656	478	480	O
)	10360656	481	482	O
5-FU	10360656	483	487	B-Intervention
for	10360656	488	491	O
5	10360656	492	493	O
days	10360656	494	498	O
by	10360656	499	501	O
continuous	10360656	502	512	O
intravenous	10360656	513	524	O
(	10360656	525	526	O
i.v	10360656	527	530	O
.	10360656	531	532	O
)	10360656	533	534	O
infusion	10360656	535	543	O
,	10360656	544	545	O
followed	10360656	546	554	O
after	10360656	555	560	O
day	10360656	561	564	O
15	10360656	565	567	O
by	10360656	568	570	O
a	10360656	571	572	O
weekly	10360656	573	579	O
i.v	10360656	580	583	O
.	10360656	584	585	O

bolus	10360656	586	591	O
of	10360656	592	594	O
750	10360656	595	598	O
mg	10360656	599	601	O
m	10360656	602	603	O
(	10360656	604	605	O
-2	10360656	606	608	O
)	10360656	609	610	O
.	10360656	611	612	O

IFN-beta	10360656	613	621	B-Intervention
was	10360656	622	625	O
injected	10360656	626	634	O
intramuscularly	10360656	635	650	O
three	10360656	651	656	O
times	10360656	657	662	O
weekly	10360656	663	669	O
at	10360656	670	672	O
9	10360656	673	674	O
M	10360656	675	676	O
IU	10360656	677	679	O
.	10360656	680	681	O

Treatment	10360656	682	691	O
continued	10360656	692	701	O
for	10360656	702	705	O
52	10360656	706	708	O
weeks	10360656	709	714	O
,	10360656	715	716	O
or	10360656	717	719	O
until	10360656	720	725	O
disease	10360656	726	733	B-Outcome
progression	10360656	734	745	I-Outcome
or	10360656	746	748	O
intolerable	10360656	749	760	B-Outcome
toxicity	10360656	761	769	I-Outcome
.	10360656	770	771	O

Clinical	10360656	772	780	O
endpoints	10360656	781	790	O
were	10360656	791	795	O
tumor	10360656	796	801	B-Outcome
response	10360656	802	810	I-Outcome
,	10360656	811	812	O
time	10360656	813	817	B-Outcome
to	10360656	818	820	I-Outcome
progression	10360656	821	832	I-Outcome
,	10360656	833	834	O
survival	10360656	835	843	B-Outcome
and	10360656	844	847	O
toxicity	10360656	848	856	B-Outcome
.	10360656	857	858	O

The	10360656	859	862	O
addition	10360656	863	871	B-Intervention
of	10360656	872	874	I-Intervention
IFN-3	10360656	875	880	I-Intervention
to	10360656	881	883	I-Intervention
5-FU	10360656	884	888	I-Intervention
significantly	10360656	889	902	B-Observation
improved	10360656	903	911	I-Observation
response	10360656	912	920	B-Outcome
rate	10360656	921	925	I-Outcome
(	10360656	926	927	O
33.3	10360656	928	932	B-Observation
%	10360656	933	934	I-Observation
vs	10360656	935	937	O
4.5	10360656	938	941	B-Observation
%	10360656	942	943	I-Observation
for	10360656	944	947	O
evaluable	10360656	948	957	O
patients	10360656	958	966	O
;	10360656	967	968	O
P	10360656	969	970	O
=	10360656	971	972	O
0.021	10360656	973	978	O
)	10360656	979	980	O
,	10360656	981	982	O
time	10360656	983	987	B-Outcome
to	10360656	988	990	I-Outcome
progression	10360656	991	1002	I-Outcome
(	10360656	1003	1004	O
median	10360656	1005	1011	O
7.2	10360656	1012	1015	B-Observation
vs	10360656	1016	1018	O
4.2	10360656	1019	1022	B-Observation
months	10360656	1023	1029	I-Observation
;	10360656	1030	1031	O
P	10360656	1032	1033	O
=	10360656	1034	1035	O
0.0435	10360656	1036	1042	O
)	10360656	1043	1044	O
,	10360656	1045	1046	O
and	10360656	1047	1050	O
survival	10360656	1051	1059	B-Outcome
time	10360656	1060	1064	I-Outcome
(	10360656	1065	1066	O
median	10360656	1067	1073	O
15.9	10360656	1074	1078	B-Observation
vs	10360656	1079	1081	O
7.2	10360656	1082	1085	B-Observation
months	10360656	1086	1092	I-Observation
;	10360656	1093	1094	O
P	10360656	1095	1096	O
=	10360656	1097	1098	O
0.038	10360656	1099	1104	O
)	10360656	1105	1106	O
without	10360656	1107	1114	O
significantly	10360656	1115	1128	B-Observation
increasing	10360656	1129	1139	I-Observation
toxicity	10360656	1140	1148	B-Outcome
compared	10360656	1149	1157	O
to	10360656	1158	1160	O
5-FU	10360656	1161	1165	B-Intervention
alone	10360656	1166	1171	I-Intervention
.	10360656	1172	1173	O

Cumulative	10360656	1174	1184	B-Outcome
5-FU	10360656	1185	1189	I-Outcome
dose	10360656	1190	1194	I-Outcome
was	10360656	1195	1198	O
higher	10360656	1199	1205	B-Observation
with	10360656	1206	1210	O
combined	10360656	1211	1219	B-Intervention
therapy	10360656	1220	1227	I-Intervention
(	10360656	1228	1229	O
P	10360656	1230	1231	O
<	10360656	1232	1233	O
0.001	10360656	1234	1239	O
)	10360656	1240	1241	O
:	10360656	1242	1243	O
more	10360656	1244	1248	B-Count
patients	10360656	1249	1257	I-Count
receiving	10360656	1258	1267	O
monotherapy	10360656	1268	1279	B-Intervention
discontinued	10360656	1280	1292	B-Outcome
treatment	10360656	1293	1302	I-Outcome
because	10360656	1303	1310	I-Outcome
of	10360656	1311	1313	I-Outcome
disease	10360656	1314	1321	I-Outcome
progression	10360656	1322	1333	I-Outcome
.	10360656	1334	1335	O

Fever	10360656	1336	1341	B-Outcome
was	10360656	1342	1345	O
more	10360656	1346	1350	B-Count
frequent	10360656	1351	1359	I-Count
with	10360656	1360	1364	O
combined	10360656	1365	1373	B-Intervention
therapy	10360656	1374	1381	I-Intervention
(	10360656	1382	1383	O
P	10360656	1384	1385	O
=	10360656	1386	1387	O
0.008	10360656	1388	1393	O
)	10360656	1394	1395	O
;	10360656	1396	1397	O
there	10360656	1398	1403	O
were	10360656	1404	1408	O
no	10360656	1409	1411	O
other	10360656	1412	1417	B-Observation
differences	10360656	1418	1429	I-Observation
in	10360656	1430	1432	O
toxicity	10360656	1433	1441	B-Outcome
.	10360656	1442	1443	O

The	10360656	1444	1447	O
only	10360656	1448	1452	O
grade	10360656	1453	1458	O
IV	10360656	1459	1461	O
toxicity	10360656	1462	1470	O
observed	10360656	1471	1479	O
was	10360656	1480	1483	O
neutropenia	10360656	1484	1495	B-Outcome
(	10360656	1496	1497	O
two	10360656	1498	1501	B-Count
patients	10360656	1502	1510	I-Count
per	10360656	1511	1514	O
group	10360656	1515	1520	B-Intervention
)	10360656	1521	1522	O
.	10360656	1523	1524	O

A	10360656	1525	1526	O
randomized	10360656	1527	1537	O
phase	10360656	1538	1543	O
III	10360656	1544	1547	O
trial	10360656	1548	1553	O
has	10360656	1554	1557	O
been	10360656	1558	1562	O
initiated	10360656	1563	1572	O
to	10360656	1573	1575	O
confirm	10360656	1576	1583	B-Observation
the	10360656	1584	1587	O
synergy	10360656	1588	1595	B-Outcome
between	10360656	1596	1603	O
5-FU	10360656	1604	1608	B-Intervention
and	10360656	1609	1612	O
IFN-beta	10360656	1613	1621	B-Intervention
.	10360656	1622	1623	O

Effects	10361382	0	7	O
of	10361382	8	10	O
pyridostigmine	10361382	11	25	B-Intervention
and	10361382	26	29	O
naloxone	10361382	30	38	B-Intervention
on	10361382	39	41	O
the	10361382	42	45	O
abnormal	10361382	46	54	B-Outcome
TSH	10361382	55	58	I-Outcome
response	10361382	59	67	I-Outcome
to	10361382	68	70	I-Outcome
TRH	10361382	71	74	I-Outcome
during	10361382	75	81	I-Outcome
starvation	10361382	82	92	I-Outcome
in	10361382	93	95	O
humans	10361382	96	102	O
.	10361382	103	104	O

BACKGROUND	10361382	105	115	O
Starvation	10361382	116	126	O
is	10361382	127	129	O
associated	10361382	130	140	O
with	10361382	141	145	O
a	10361382	146	147	O
blunted	10361382	148	155	O
TSH	10361382	156	159	O
response	10361382	160	168	O
to	10361382	169	171	O
thyrotropin-releasing	10361382	172	193	O
hormone	10361382	194	201	O
(	10361382	202	203	O
TRH	10361382	204	207	O
)	10361382	208	209	O
(	10361382	210	211	O
peak	10361382	212	216	O
minus	10361382	217	222	O
baseline	10361382	223	231	O
<	10361382	232	233	O
5	10361382	234	235	O
mIU/L	10361382	236	241	O
)	10361382	242	243	O
,	10361382	244	245	O
despite	10361382	246	253	O
basal	10361382	254	259	O
TSH	10361382	260	263	O
and	10361382	264	267	O
thyroid	10361382	268	275	O
hormone	10361382	276	283	O
levels	10361382	284	290	O
within	10361382	291	297	O
the	10361382	298	301	O
normal	10361382	302	308	O
range	10361382	309	314	O
.	10361382	315	316	O

In	10361382	317	319	O
light	10361382	320	325	O
of	10361382	326	328	O
the	10361382	329	332	O
inhibitory	10361382	333	343	B-Observation
effect	10361382	344	350	I-Observation
of	10361382	351	353	O
somatostatin	10361382	354	366	B-Outcome
on	10361382	367	369	I-Outcome
TSH	10361382	370	373	I-Outcome
secretion	10361382	374	383	I-Outcome
,	10361382	384	385	O
we	10361382	386	388	O
examined	10361382	389	397	O
whether	10361382	398	405	O
this	10361382	406	410	O
condition	10361382	411	420	O
is	10361382	421	423	O
caused	10361382	424	430	O
by	10361382	431	433	O
an	10361382	434	436	O
increased	10361382	437	446	B-Intervention
hypothalamic	10361382	447	459	I-Intervention
somatostatinergic	10361382	460	477	I-Intervention
tone	10361382	478	482	I-Intervention
in	10361382	483	485	O
starving	10361382	486	494	B-Participant
subjects	10361382	495	503	O
.	10361382	504	505	O

The	10361382	506	509	O
possible	10361382	510	518	O
involvement	10361382	519	530	O
of	10361382	531	533	O
endogenous	10361382	534	544	B-Intervention
opioids	10361382	545	552	I-Intervention
in	10361382	553	555	O
the	10361382	556	559	O
mechanism	10361382	560	569	O
underlying	10361382	570	580	O
the	10361382	581	584	O
abnormal	10361382	585	593	B-Observation
TSH	10361382	594	597	B-Outcome
response	10361382	598	606	I-Outcome
to	10361382	607	609	I-Outcome
TRH	10361382	610	613	I-Outcome
was	10361382	614	617	O
also	10361382	618	622	O
evaluated	10361382	623	632	O
.	10361382	633	634	O

METHODS	10361382	635	642	O
The	10361382	643	646	O
TSH	10361382	647	650	B-Outcome
response	10361382	651	659	I-Outcome
to	10361382	660	662	I-Outcome
TRH	10361382	663	666	I-Outcome
(	10361382	667	668	O
25	10361382	669	671	O
micrograms	10361382	672	682	O
in	10361382	683	685	O
an	10361382	686	688	O
intravenous	10361382	689	700	O
bolus	10361382	701	706	O
)	10361382	707	708	O
,	10361382	709	710	O
serum	10361382	711	716	B-Outcome
total	10361382	717	722	I-Outcome
and	10361382	723	726	I-Outcome
free	10361382	727	731	I-Outcome
T4	10361382	732	734	I-Outcome
and	10361382	735	738	I-Outcome
T3	10361382	739	741	I-Outcome
levels	10361382	742	748	I-Outcome
,	10361382	749	750	O
and	10361382	751	754	O
24-hour	10361382	755	762	B-Outcome
urinary-free	10361382	763	775	I-Outcome
cortisol	10361382	776	784	I-Outcome
levels	10361382	785	791	I-Outcome
were	10361382	792	796	O
measured	10361382	797	805	O
in	10361382	806	808	O
28	10361382	809	811	O
normal	10361382	812	818	B-Participant
men	10361382	819	822	B-Participant
(	10361382	823	824	O
age	10361382	825	828	B-Participant
27	10361382	829	831	I-Participant
-	10361382	831	832	I-Participant
35	10361382	832	834	I-Participant
years	10361382	835	840	I-Participant
)	10361382	841	842	O
within	10361382	843	849	B-Participant
10	10361382	850	852	I-Participant
%	10361382	853	854	I-Participant
of	10361382	855	857	I-Participant
their	10361382	858	863	I-Participant
ideal	10361382	864	869	I-Participant
body	10361382	870	874	I-Participant
weight	10361382	875	881	I-Participant
.	10361382	882	883	O

They	10361382	884	888	O
were	10361382	889	893	O
randomly	10361382	894	902	O
divided	10361382	903	910	O
into	10361382	911	915	O
4	10361382	916	917	O
groups	10361382	918	924	O
of	10361382	925	927	O
7	10361382	928	929	O
.	10361382	930	931	O

In	10361382	932	934	O
21	10361382	935	937	O
subjects	10361382	938	946	O
(	10361382	947	948	O
groups	10361382	949	955	O
1	10361382	956	957	O
,	10361382	958	959	O
2	10361382	960	961	O
,	10361382	962	963	O
and	10361382	964	967	O
3	10361382	968	969	O
)	10361382	970	971	O
,	10361382	972	973	O
TRH	10361382	974	977	B-Outcome
tests	10361382	978	983	I-Outcome
were	10361382	984	988	O
performed	10361382	989	998	O
after	10361382	999	1004	O
an	10361382	1005	1007	O
overnight	10361382	1008	1017	O
(	10361382	1018	1019	O
8	10361382	1020	1021	O
hours	10361382	1022	1027	O
)	10361382	1028	1029	O
fast	10361382	1030	1034	O
,	10361382	1035	1036	O
placebo	10361382	1037	1044	B-Intervention
administrations	10361382	1045	1060	O
(	10361382	1061	1062	O
control	10361382	1063	1070	O
test	10361382	1071	1075	O
)	10361382	1076	1077	O
,	10361382	1078	1079	O
and	10361382	1080	1083	O
after	10361382	1084	1089	O
prolonged	10361382	1090	1099	O
(	10361382	1100	1101	O
56	10361382	1102	1104	O
hours	10361382	1105	1110	O
)	10361382	1111	1112	O
starvation	10361382	1113	1123	O
.	10361382	1124	1125	O

TRH	10361382	1126	1129	B-Outcome
tests	10361382	1130	1135	I-Outcome
after	10361382	1136	1141	I-Outcome
prolonged	10361382	1142	1151	I-Outcome
starvation	10361382	1152	1162	I-Outcome
were	10361382	1163	1167	O
performed	10361382	1168	1177	O
either	10361382	1178	1184	O
after	10361382	1185	1190	O
placebos	10361382	1191	1199	B-Intervention
(	10361382	1200	1201	O
in	10361382	1202	1204	O
all	10361382	1205	1208	O
subjects	10361382	1209	1217	O
)	10361382	1218	1219	O
or	10361382	1220	1222	O
the	10361382	1223	1226	O
administration	10361382	1227	1241	O
of	10361382	1242	1244	O
pyridostigmine	10361382	1245	1259	B-Intervention
(	10361382	1260	1261	O
180	10361382	1262	1265	O
mg	10361382	1266	1268	O
orally	10361382	1269	1275	O
)	10361382	1276	1277	O
(	10361382	1278	1279	O
in	10361382	1280	1282	O
7	10361382	1283	1284	O
subjects	10361382	1285	1293	O
,	10361382	1294	1295	O
group	10361382	1296	1301	O
1	10361382	1302	1303	O
)	10361382	1304	1305	O
;	10361382	1306	1307	O
naloxone	10361382	1308	1316	B-Intervention
(	10361382	1317	1318	O
0.8	10361382	1319	1322	O
mg	10361382	1323	1325	O
in	10361382	1326	1328	O
an	10361382	1329	1331	O
i.v	10361382	1332	1335	O
.	10361382	1336	1337	O

bolus	10361382	1338	1343	O
injection	10361382	1344	1353	O
)	10361382	1354	1355	O
(	10361382	1356	1357	O
in	10361382	1358	1360	O
7	10361382	1361	1362	O
subjects	10361382	1363	1371	O
,	10361382	1372	1373	O
group	10361382	1374	1379	O
2	10361382	1380	1381	O
)	10361382	1382	1383	O
;	10361382	1384	1385	O
or	10361382	1386	1388	O
the	10361382	1389	1392	O
combination	10361382	1393	1404	B-Intervention
of	10361382	1405	1407	I-Intervention
pyridostigmine	10361382	1408	1422	I-Intervention
and	10361382	1423	1426	I-Intervention
naloxone	10361382	1427	1435	I-Intervention
(	10361382	1436	1437	O
in	10361382	1438	1440	O
7	10361382	1441	1442	O
subjects	10361382	1443	1451	O
,	10361382	1452	1453	O
group	10361382	1454	1459	O
3	10361382	1460	1461	O
)	10361382	1462	1463	O
.	10361382	1464	1465	O

The	10361382	1466	1469	O
remaining	10361382	1470	1479	O
7	10361382	1480	1481	O
subjects	10361382	1482	1490	O
(	10361382	1491	1492	O
group	10361382	1493	1498	O
4	10361382	1499	1500	O
)	10361382	1501	1502	O
were	10361382	1503	1507	O
tested	10361382	1508	1514	O
at	10361382	1515	1517	O
weekly	10361382	1518	1524	O
intervals	10361382	1525	1534	O
with	10361382	1535	1539	O
TRH	10361382	1540	1543	B-Intervention
plus	10361382	1544	1548	I-Intervention
placebo	10361382	1549	1556	I-Intervention
,	10361382	1557	1558	O
TRH	10361382	1559	1562	B-Intervention
plus	10361382	1563	1567	I-Intervention
naloxone	10361382	1568	1576	I-Intervention
,	10361382	1577	1578	O
TRH	10361382	1579	1582	B-Intervention
plus	10361382	1583	1587	I-Intervention
pyridostigmine	10361382	1588	1602	I-Intervention
,	10361382	1603	1604	O
and	10361382	1605	1608	O
TRH	10361382	1609	1612	B-Intervention
plus	10361382	1613	1617	I-Intervention
naloxone	10361382	1618	1626	I-Intervention
plus	10361382	1627	1631	I-Intervention
pyridostigmine	10361382	1632	1646	I-Intervention
after	10361382	1647	1652	O
a	10361382	1653	1654	O
fasting	10361382	1655	1662	O
period	10361382	1663	1669	O
of	10361382	1670	1672	O
8	10361382	1673	1674	O
hours	10361382	1675	1680	O
.	10361382	1681	1682	O

RESULTS	10361382	1683	1690	O
In	10361382	1691	1693	O
all	10361382	1694	1697	B-Count
subjects	10361382	1698	1706	I-Count
of	10361382	1707	1709	O
groups	10361382	1710	1716	O
1	10361382	1717	1718	B-Intervention
,	10361382	1719	1720	O
2	10361382	1721	1722	B-Intervention
,	10361382	1723	1724	O
and	10361382	1725	1728	O
3	10361382	1729	1730	B-Intervention
,	10361382	1731	1732	O
TRH-induced	10361382	1733	1744	B-Outcome
TSH	10361382	1745	1748	I-Outcome
rise	10361382	1749	1753	I-Outcome
was	10361382	1754	1757	O
significantly	10361382	1758	1771	B-Observation
lower	10361382	1772	1777	I-Observation
after	10361382	1778	1783	O
prolonged	10361382	1784	1793	O
starvation	10361382	1794	1804	O
than	10361382	1805	1809	O
after	10361382	1810	1815	O
overnight	10361382	1816	1825	O
fast	10361382	1826	1830	O
.	10361382	1831	1832	O

Neither	10361382	1833	1840	O
pyridostigmine	10361382	1841	1855	B-Intervention
nor	10361382	1856	1859	O
naloxone	10361382	1860	1868	B-Intervention
,	10361382	1869	1870	O
given	10361382	1871	1876	O
alone	10361382	1877	1882	O
,	10361382	1883	1884	O
changed	10361382	1885	1892	B-Observation
the	10361382	1893	1896	O
basal	10361382	1897	1902	B-Outcome
levels	10361382	1903	1909	I-Outcome
of	10361382	1910	1912	I-Outcome
TSH	10361382	1913	1916	I-Outcome
and	10361382	1917	1920	O
the	10361382	1921	1924	O
TSH	10361382	1925	1928	B-Outcome
response	10361382	1929	1937	I-Outcome
to	10361382	1938	1940	I-Outcome
TRH	10361382	1941	1944	I-Outcome
after	10361382	1945	1950	I-Outcome
prolonged	10361382	1951	1960	I-Outcome
starvation	10361382	1961	1971	I-Outcome
.	10361382	1972	1973	O

In	10361382	1974	1976	O
contrast	10361382	1977	1985	O
,	10361382	1986	1987	O
the	10361382	1988	1991	O
concomitant	10361382	1992	2003	B-Intervention
administration	10361382	2004	2018	I-Intervention
of	10361382	2019	2021	I-Intervention
naloxone	10361382	2022	2030	I-Intervention
and	10361382	2031	2034	I-Intervention
pyridostigmine	10361382	2035	2049	I-Intervention
significantly	10361382	2050	2063	B-Observation
enhanced	10361382	2064	2072	I-Observation
the	10361382	2073	2076	O
TRH-induced	10361382	2077	2088	B-Outcome
TSH	10361382	2089	2092	I-Outcome
rise	10361382	2093	2097	I-Outcome
.	10361382	2098	2099	O

After	10361382	2100	2105	O
overnight	10361382	2106	2115	O
fasting	10361382	2116	2123	O
,	10361382	2124	2125	O
naloxone	10361382	2126	2134	B-Intervention
administration	10361382	2135	2149	I-Intervention
in	10361382	2150	2152	I-Intervention
group	10361382	2153	2158	I-Intervention
4	10361382	2159	2160	I-Intervention
subjects	10361382	2161	2169	O
did	10361382	2170	2173	O
not	10361382	2174	2177	O
change	10361382	2178	2184	B-Observation
the	10361382	2185	2188	O
TSH	10361382	2189	2192	B-Outcome
response	10361382	2193	2201	I-Outcome
to	10361382	2202	2204	I-Outcome
TRH	10361382	2205	2208	I-Outcome
,	10361382	2209	2210	O
whereas	10361382	2211	2218	O
pyridostigmine	10361382	2219	2233	B-Intervention
significantly	10361382	2234	2247	B-Observation
enhanced	10361382	2248	2256	I-Observation
the	10361382	2257	2260	O
TSH	10361382	2261	2264	B-Outcome
response	10361382	2265	2273	I-Outcome
to	10361382	2274	2276	I-Outcome
TRH	10361382	2277	2280	I-Outcome
.	10361382	2281	2282	O

When	10361382	2283	2287	O
naloxone	10361382	2288	2296	B-Intervention
was	10361382	2297	2300	I-Intervention
given	10361382	2301	2306	I-Intervention
together	10361382	2307	2315	I-Intervention
with	10361382	2316	2320	I-Intervention
pyridostigmine	10361382	2321	2335	I-Intervention
and	10361382	2336	2339	I-Intervention
TRH	10361382	2340	2343	I-Intervention
the	10361382	2344	2347	O
TSH	10361382	2348	2351	B-Outcome
response	10361382	2352	2360	I-Outcome
was	10361382	2361	2364	O
similar	10361382	2365	2372	B-Observation
to	10361382	2373	2375	O
that	10361382	2376	2380	O
observed	10361382	2381	2389	O
in	10361382	2390	2392	O
the	10361382	2393	2396	O
TRH	10361382	2397	2400	B-Intervention
plus	10361382	2401	2405	I-Intervention
pyridostigmine	10361382	2406	2420	I-Intervention
test	10361382	2421	2425	O
.	10361382	2426	2427	O

CONCLUSIONS	10361382	2428	2439	O
These	10361382	2440	2445	O
data	10361382	2446	2450	O
indicate	10361382	2451	2459	O
that	10361382	2460	2464	O
naloxone-sensitive	10361382	2465	2483	B-Intervention
endogenous	10361382	2484	2494	I-Intervention
opioids	10361382	2495	2502	I-Intervention
exert	10361382	2503	2508	O
an	10361382	2509	2511	O
inhibitory	10361382	2512	2522	B-Observation
effect	10361382	2523	2529	I-Observation
on	10361382	2530	2532	O
the	10361382	2533	2536	O
cholinergic	10361382	2537	2548	B-Outcome
stimulatory	10361382	2549	2560	I-Outcome
control	10361382	2561	2568	I-Outcome
of	10361382	2569	2571	I-Outcome
TSH	10361382	2572	2575	I-Outcome
secretion	10361382	2576	2585	I-Outcome
during	10361382	2586	2592	O
prolonged	10361382	2593	2602	O
starvation	10361382	2603	2613	O
.	10361382	2614	2615	O

This	10361382	2616	2620	O
suggests	10361382	2621	2629	O
that	10361382	2630	2634	O
an	10361382	2635	2637	O
enhanced	10361382	2638	2646	B-Intervention
hypothalamic	10361382	2647	2659	I-Intervention
somatostatinergic	10361382	2660	2677	I-Intervention
activity	10361382	2678	2686	I-Intervention
is	10361382	2687	2689	O
involved	10361382	2690	2698	O
in	10361382	2699	2701	O
the	10361382	2702	2705	O
mechanism	10361382	2706	2715	O
underlying	10361382	2716	2726	O
the	10361382	2727	2730	O
reduced	10361382	2731	2738	B-Observation
TSH	10361382	2739	2742	B-Outcome
response	10361382	2743	2751	I-Outcome
to	10361382	2752	2754	I-Outcome
TRH	10361382	2755	2758	I-Outcome
.	10361382	2759	2760	O

Effects	10361648	0	7	O
of	10361648	8	10	O
a	10361648	11	12	O
videotape	10361648	13	22	B-Intervention
information	10361648	23	34	I-Intervention
intervention	10361648	35	47	I-Intervention
at	10361648	48	50	I-Intervention
discharge	10361648	51	60	I-Intervention
on	10361648	61	63	O
diet	10361648	64	68	B-Outcome
and	10361648	69	72	I-Outcome
exercise	10361648	73	81	I-Outcome
compliance	10361648	82	92	I-Outcome
after	10361648	93	98	O
coronary	10361648	99	107	B-Participant
bypass	10361648	108	114	I-Participant
surgery	10361648	115	122	I-Participant
.	10361648	123	124	O

BACKGROUND	10361648	125	135	O
This	10361648	136	140	O
study	10361648	141	146	O
evaluated	10361648	147	156	O
the	10361648	157	160	O
relative	10361648	161	169	O
effects	10361648	170	177	O
on	10361648	178	180	O
compliance	10361648	181	191	B-Outcome
with	10361648	192	196	I-Outcome
recommended	10361648	197	208	I-Outcome
lifestyle	10361648	209	218	I-Outcome
changes	10361648	219	226	I-Outcome
of	10361648	227	229	O
two	10361648	230	233	O
experimental	10361648	234	246	B-Intervention
videotapes	10361648	247	257	I-Intervention
that	10361648	258	262	O
involved	10361648	263	271	O
different	10361648	272	281	O
approaches	10361648	282	292	O
for	10361648	293	296	O
preparing	10361648	297	306	O
coronary	10361648	307	315	B-Participant
artery	10361648	316	322	I-Participant
bypass	10361648	323	329	I-Participant
graft	10361648	330	335	I-Participant
(	10361648	336	337	I-Participant
CABG	10361648	338	342	I-Participant
)	10361648	343	344	I-Participant
patients	10361648	345	353	O
for	10361648	354	357	O
the	10361648	358	361	O
posthospital	10361648	362	374	O
recovery	10361648	375	383	O
period	10361648	384	390	O
.	10361648	391	392	O

The	10361648	393	396	O
tapes	10361648	397	402	O
differed	10361648	403	411	O
in	10361648	412	414	O
the	10361648	415	418	O
extent	10361648	419	425	O
to	10361648	426	428	O
which	10361648	429	434	O
they	10361648	435	439	O
portrayed	10361648	440	449	O
the	10361648	450	453	O
recovery	10361648	454	462	O
period	10361648	463	469	O
as	10361648	470	472	O
a	10361648	473	474	O
steady	10361648	475	481	O
,	10361648	482	483	O
forward	10361648	484	491	O
progression	10361648	492	503	O
versus	10361648	504	510	O
a	10361648	511	512	O
series	10361648	513	519	O
of	10361648	520	522	O
ups	10361648	523	526	O
and	10361648	527	530	O
downs	10361648	531	536	O
.	10361648	537	538	O

METHODS	10361648	539	546	O
Two	10361648	547	550	O
hundred	10361648	551	558	O
sixteen	10361648	559	566	O
male	10361648	567	571	B-Participant
and	10361648	572	575	O
female	10361648	576	582	B-Participant
CABG	10361648	583	587	B-Participant
patients	10361648	588	596	O
were	10361648	597	601	O
assigned	10361648	602	610	O
randomly	10361648	611	619	O
either	10361648	620	626	O
to	10361648	627	629	O
view	10361648	630	634	O
one	10361648	635	638	O
of	10361648	639	641	O
the	10361648	642	645	O
two	10361648	646	649	O
videotapes	10361648	650	660	B-Intervention
before	10361648	661	667	I-Intervention
discharge	10361648	668	677	I-Intervention
from	10361648	678	682	O
the	10361648	683	686	O
hospital	10361648	687	695	O
or	10361648	696	698	O
to	10361648	699	701	O
receive	10361648	702	709	O
only	10361648	710	714	O
the	10361648	715	718	O
standard	10361648	719	727	B-Intervention
discharge	10361648	728	737	I-Intervention
preparation	10361648	738	749	I-Intervention
provided	10361648	750	758	O
by	10361648	759	761	O
the	10361648	762	765	O
hospital	10361648	766	774	O
.	10361648	775	776	O

All	10361648	777	780	O
patients	10361648	781	789	O
completed	10361648	790	799	O
measures	10361648	800	808	O
of	10361648	809	811	O
anxiety	10361648	812	819	B-Outcome
and	10361648	820	823	O
self-efficacy	10361648	824	837	B-Outcome
at	10361648	838	840	O
discharge	10361648	841	850	O
,	10361648	851	852	O
1	10361648	853	854	O
month	10361648	855	860	O
and	10361648	861	864	O
3	10361648	865	866	O
months	10361648	867	873	O
after	10361648	874	879	O
discharge	10361648	880	889	O
from	10361648	890	894	O
the	10361648	895	898	O
hospital	10361648	899	907	O
.	10361648	908	909	O

Patients	10361648	910	918	O
also	10361648	919	923	O
completed	10361648	924	933	O
measures	10361648	934	942	O
of	10361648	943	945	O
dietary	10361648	946	953	B-Outcome
fat	10361648	954	957	I-Outcome
consumption	10361648	958	969	I-Outcome
and	10361648	970	973	O
activity	10361648	974	982	B-Outcome
level	10361648	983	988	I-Outcome
1	10361648	989	990	O
and	10361648	991	994	O
3	10361648	995	996	O
months	10361648	997	1003	O
after	10361648	1004	1009	O
discharge	10361648	1010	1019	O
.	10361648	1020	1021	O

RESULTS	10361648	1022	1029	O
Relative	10361648	1030	1038	O
to	10361648	1039	1041	O
controls	10361648	1042	1050	B-Intervention
,	10361648	1051	1052	O
patients	10361648	1053	1061	O
who	10361648	1062	1065	O
viewed	10361648	1066	1072	O
either	10361648	1073	1079	O
of	10361648	1080	1082	O
the	10361648	1083	1086	O
videotapes	10361648	1087	1097	B-Intervention
before	10361648	1098	1104	I-Intervention
hospital	10361648	1105	1113	I-Intervention
release	10361648	1114	1121	I-Intervention
reported	10361648	1122	1130	O
higher	10361648	1131	1137	B-Observation
self-efficacy	10361648	1138	1151	B-Outcome
for	10361648	1152	1155	I-Outcome
adhering	10361648	1156	1164	I-Outcome
to	10361648	1165	1167	I-Outcome
the	10361648	1168	1171	I-Outcome
recommended	10361648	1172	1183	I-Outcome
low-fat	10361648	1184	1191	I-Outcome
diet	10361648	1192	1196	I-Outcome
both	10361648	1197	1201	O
at	10361648	1202	1204	O
discharge	10361648	1205	1214	O
and	10361648	1215	1218	O
1	10361648	1219	1220	O
month	10361648	1221	1226	O
after	10361648	1227	1232	O
surgery	10361648	1233	1240	O
.	10361648	1241	1242	O

Viewing	10361648	1243	1250	O
either	10361648	1251	1257	O
of	10361648	1258	1260	O
the	10361648	1261	1264	O
videotapes	10361648	1265	1275	B-Intervention
also	10361648	1276	1280	O
resulted	10361648	1281	1289	O
in	10361648	1290	1292	O
significantly	10361648	1293	1306	B-Observation
less	10361648	1307	1311	I-Observation
dietary	10361648	1312	1319	B-Outcome
fat	10361648	1320	1323	I-Outcome
intake	10361648	1324	1330	I-Outcome
1	10361648	1331	1332	O
month	10361648	1333	1338	O
after	10361648	1339	1344	O
hospital	10361648	1345	1353	O
release	10361648	1354	1361	O
compared	10361648	1362	1370	O
with	10361648	1371	1375	O
controls	10361648	1376	1384	B-Intervention
.	10361648	1385	1386	O

Patients	10361648	1387	1395	O
who	10361648	1396	1399	O
viewed	10361648	1400	1406	O
the	10361648	1407	1410	O
tape	10361648	1411	1415	B-Intervention
that	10361648	1416	1420	I-Intervention
portrayed	10361648	1421	1430	I-Intervention
the	10361648	1431	1434	I-Intervention
recovery	10361648	1435	1443	I-Intervention
period	10361648	1444	1450	I-Intervention
as	10361648	1451	1453	I-Intervention
consisting	10361648	1454	1464	I-Intervention
of	10361648	1465	1467	I-Intervention
ups	10361648	1468	1471	I-Intervention
and	10361648	1472	1475	I-Intervention
downs	10361648	1476	1481	I-Intervention
also	10361648	1482	1486	O
reported	10361648	1487	1495	O
significantly	10361648	1496	1509	B-Observation
more	10361648	1510	1514	I-Observation
frequent	10361648	1515	1523	I-Observation
moderate	10361648	1524	1532	B-Outcome
exercise	10361648	1533	1541	I-Outcome
at	10361648	1542	1544	O
1	10361648	1545	1546	O
month	10361648	1547	1552	O
and	10361648	1553	1556	O
more	10361648	1557	1561	B-Observation
frequent	10361648	1562	1570	I-Observation
strenuous	10361648	1571	1580	B-Outcome
exercise	10361648	1581	1589	I-Outcome
3	10361648	1590	1591	O
months	10361648	1592	1598	O
after	10361648	1599	1604	O
discharge	10361648	1605	1614	O
.	10361648	1615	1616	O

CONCLUSIONS	10361648	1617	1628	O
The	10361648	1629	1632	O
experimental	10361648	1633	1645	B-Intervention
videotapes	10361648	1646	1656	I-Intervention
proved	10361648	1657	1663	O
to	10361648	1664	1666	O
be	10361648	1667	1669	O
an	10361648	1670	1672	O
effective	10361648	1673	1682	O
method	10361648	1683	1689	O
for	10361648	1690	1693	O
increasing	10361648	1694	1704	B-Observation
dietary	10361648	1705	1712	B-Outcome
and	10361648	1713	1716	I-Outcome
exercise	10361648	1717	1725	I-Outcome
compliance	10361648	1726	1736	I-Outcome
during	10361648	1737	1743	O
the	10361648	1744	1747	O
first	10361648	1748	1753	O
3	10361648	1754	1755	O
months	10361648	1756	1762	O
after	10361648	1763	1768	O
CABG	10361648	1769	1773	B-Participant
.	10361648	1774	1775	O

Primary	10374155	0	7	B-Participant
capsulectomy	10374155	8	20	I-Participant
,	10374155	21	22	O
anterior	10374155	23	31	B-Participant
vitrectomy	10374155	32	42	I-Participant
,	10374155	43	44	O
lensectomy	10374155	45	55	B-Participant
,	10374155	56	57	O
and	10374155	58	61	O
posterior	10374155	62	71	B-Participant
chamber	10374155	72	79	I-Participant
lens	10374155	80	84	I-Participant
implantation	10374155	85	97	I-Participant
in	10374155	98	100	O
children	10374155	101	109	B-Participant
:	10374155	110	111	O
limbal	10374155	112	118	B-Intervention
versus	10374155	119	125	O
pars	10374155	126	130	B-Intervention
plana	10374155	131	136	I-Intervention
.	10374155	137	138	O

PURPOSE	10374155	139	146	O
To	10374155	147	149	O
compare	10374155	150	157	O
the	10374155	158	161	O
results	10374155	162	169	O
of	10374155	170	172	O
a	10374155	173	174	O
limbal	10374155	175	181	B-Intervention
versus	10374155	182	188	O
a	10374155	189	190	O
pars	10374155	191	195	B-Intervention
plana	10374155	196	201	I-Intervention
approach	10374155	202	210	O
for	10374155	211	214	O
primary	10374155	215	222	B-Participant
posterior	10374155	223	232	I-Participant
capsulectomy	10374155	233	245	I-Participant
and	10374155	246	249	O
anterior	10374155	250	258	B-Participant
vitrectomy	10374155	259	269	I-Participant
in	10374155	270	272	O
the	10374155	273	276	O
management	10374155	277	287	B-Observation
of	10374155	288	290	O
childhood	10374155	291	300	B-Outcome
cataract	10374155	301	309	I-Outcome
.	10374155	310	311	O

SETTING	10374155	312	319	O
Department	10374155	320	330	O
of	10374155	331	333	O
Ophthalmology	10374155	334	347	O
,	10374155	348	349	O
Labbafinejad	10374155	350	362	O
Medical	10374155	363	370	O
Center	10374155	371	377	O
,	10374155	378	379	O
Tehran	10374155	380	386	O
,	10374155	387	388	O
Iran	10374155	389	393	O
.	10374155	394	395	O

METHODS	10374155	396	403	O
A	10374155	404	405	O
randomized	10374155	406	416	O
,	10374155	417	418	O
controlled	10374155	419	429	O
,	10374155	430	431	O
double-masked	10374155	432	445	O
clinical	10374155	446	454	O
trial	10374155	455	460	O
of	10374155	461	463	O
45	10374155	464	466	O
eyes	10374155	467	471	O
was	10374155	472	475	O
conducted	10374155	476	485	O
.	10374155	486	487	O

After	10374155	488	493	O
being	10374155	494	499	O
matched	10374155	500	507	O
,	10374155	508	509	O
38	10374155	510	512	O
eyes	10374155	513	517	O
were	10374155	518	522	O
included	10374155	523	531	O
in	10374155	532	534	O
the	10374155	535	538	O
study	10374155	539	544	O
and	10374155	545	548	O
were	10374155	549	553	O
divided	10374155	554	561	O
into	10374155	562	566	O
2	10374155	567	568	O
equal	10374155	569	574	O
groups	10374155	575	581	O
for	10374155	582	585	O
data	10374155	586	590	O
analysis	10374155	591	599	O
.	10374155	600	601	O

All	10374155	602	605	O
eyes	10374155	606	610	O
had	10374155	611	614	O
lensectomy	10374155	615	625	B-Participant
and	10374155	626	629	O
posterior	10374155	630	639	B-Participant
chamber	10374155	640	647	I-Participant
intraocular	10374155	648	659	I-Participant
lens	10374155	660	664	I-Participant
(	10374155	665	666	I-Participant
PC	10374155	667	669	I-Participant
IOL	10374155	670	673	I-Participant
)	10374155	674	675	I-Participant
implantation	10374155	676	688	I-Participant
.	10374155	689	690	O

Primary	10374155	691	698	B-Participant
posterior	10374155	699	708	I-Participant
capsulectomy	10374155	709	721	I-Participant
and	10374155	722	725	O
anterior	10374155	726	734	B-Participant
vitrectomy	10374155	735	745	I-Participant
were	10374155	746	750	O
performed	10374155	751	760	O
through	10374155	761	768	O
the	10374155	769	772	O
limbus	10374155	773	779	B-Intervention
in	10374155	780	782	O
half	10374155	783	787	O
of	10374155	788	790	O
the	10374155	791	794	O
eyes	10374155	795	799	O
and	10374155	800	803	O
the	10374155	804	807	O
pars	10374155	808	812	B-Intervention
plana	10374155	813	818	I-Intervention
in	10374155	819	821	O
the	10374155	822	825	O
other	10374155	826	831	O
half	10374155	832	836	O
.	10374155	837	838	O

Main	10374155	839	843	B-Outcome
outcome	10374155	844	851	I-Outcome
measures	10374155	852	860	I-Outcome
included	10374155	861	869	O
visual	10374155	870	876	B-Outcome
acuity	10374155	877	883	I-Outcome
,	10374155	884	885	O
estimated	10374155	886	895	B-Outcome
red	10374155	896	899	I-Outcome
reflex	10374155	900	906	I-Outcome
,	10374155	907	908	O
postsurgical	10374155	909	921	B-Outcome
inflammatory	10374155	922	934	I-Outcome
reaction	10374155	935	943	I-Outcome
,	10374155	944	945	O
corneal	10374155	946	953	B-Outcome
clarity	10374155	954	961	I-Outcome
,	10374155	962	963	O
posterior	10374155	964	973	B-Outcome
synechias	10374155	974	983	I-Outcome
,	10374155	984	985	O
iris	10374155	986	990	B-Outcome
capture	10374155	991	998	I-Outcome
,	10374155	999	1000	O
IOL	10374155	1001	1004	B-Outcome
position	10374155	1005	1013	I-Outcome
,	10374155	1014	1015	O
capsulectomy	10374155	1016	1028	B-Outcome
size	10374155	1029	1033	I-Outcome
,	10374155	1034	1035	O
glaucoma	10374155	1036	1044	B-Outcome
,	10374155	1045	1046	O
cystoid	10374155	1047	1054	B-Outcome
macular	10374155	1055	1062	I-Outcome
edema	10374155	1063	1068	I-Outcome
,	10374155	1069	1070	O
retinal	10374155	1071	1078	B-Outcome
tear	10374155	1079	1083	I-Outcome
,	10374155	1084	1085	O
and	10374155	1086	1089	O
postoperative	10374155	1090	1103	B-Outcome
refraction	10374155	1104	1114	I-Outcome
.	10374155	1115	1116	O

RESULTS	10374155	1117	1124	O
No	10374155	1125	1127	O
statistically	10374155	1128	1141	B-Observation
significant	10374155	1142	1153	I-Observation
differences	10374155	1154	1165	I-Observation
were	10374155	1166	1170	O
found	10374155	1171	1176	O
between	10374155	1177	1184	B-Intervention
the	10374155	1185	1188	I-Intervention
2	10374155	1189	1190	I-Intervention
approaches	10374155	1191	1201	I-Intervention
in	10374155	1202	1204	O
the	10374155	1205	1208	O
outcome	10374155	1209	1216	B-Outcome
measures	10374155	1217	1225	I-Outcome
.	10374155	1226	1227	O

CONCLUSION	10374155	1228	1238	O
The	10374155	1239	1242	O
anatomic	10374155	1243	1251	B-Outcome
and	10374155	1252	1255	I-Outcome
visual	10374155	1256	1262	I-Outcome
results	10374155	1263	1270	I-Outcome
were	10374155	1271	1275	O
encouraging	10374155	1276	1287	B-Observation
when	10374155	1288	1292	O
posterior	10374155	1293	1302	B-Participant
capsulectomy	10374155	1303	1315	I-Participant
and	10374155	1316	1319	O
anterior	10374155	1320	1328	B-Participant
vitrectomy	10374155	1329	1339	I-Participant
,	10374155	1340	1341	O
using	10374155	1342	1347	O
a	10374155	1348	1349	O
limbal	10374155	1350	1356	B-Intervention
or	10374155	1357	1359	O
pars	10374155	1360	1364	B-Intervention
plana	10374155	1365	1370	I-Intervention
approach	10374155	1371	1379	O
,	10374155	1380	1381	O
were	10374155	1382	1386	O
combined	10374155	1387	1395	O
with	10374155	1396	1400	O
lensectomy	10374155	1401	1411	B-Participant
and	10374155	1412	1415	O
PC	10374155	1416	1418	B-Participant
IOL	10374155	1419	1422	I-Participant
implantation	10374155	1423	1435	I-Participant
in	10374155	1436	1438	O
children	10374155	1439	1447	B-Participant
.	10374155	1448	1449	O

The	10374155	1450	1453	O
application	10374155	1454	1465	O
of	10374155	1466	1468	O
these	10374155	1469	1474	O
techniques	10374155	1475	1485	O
depends	10374155	1486	1493	O
on	10374155	1494	1496	O
surgeon	10374155	1497	1504	O
experience	10374155	1505	1515	O
and	10374155	1516	1519	O
skill	10374155	1520	1525	O
.	10374155	1526	1527	O

Calcitriol	10385063	0	10	B-Intervention
for	10385063	11	14	O
bone	10385063	15	19	B-Participant
disease	10385063	20	27	I-Participant
in	10385063	28	30	O
patients	10385063	31	39	O
with	10385063	40	44	O
cirrhosis	10385063	45	54	B-Participant
of	10385063	55	57	I-Participant
the	10385063	58	61	I-Participant
liver	10385063	62	67	I-Participant
.	10385063	68	69	O

BACKGROUND	10385063	70	80	O
Osteoporosis	10385063	81	93	O
is	10385063	94	96	O
associated	10385063	97	107	O
with	10385063	108	112	O
cirrhosis	10385063	113	122	O
of	10385063	123	125	O
the	10385063	126	129	O
liver	10385063	130	135	O
,	10385063	136	137	O
but	10385063	138	141	O
the	10385063	142	145	O
effects	10385063	146	153	O
of	10385063	154	156	O
therapy	10385063	157	164	O
for	10385063	165	168	O
osteoporosis	10385063	169	181	O
associated	10385063	182	192	O
with	10385063	193	197	O
cirrhosis	10385063	198	207	O
are	10385063	208	211	O
still	10385063	212	217	O
controversial	10385063	218	231	O
.	10385063	232	233	O

METHODS	10385063	234	241	O
We	10385063	242	244	O
evaluated	10385063	245	254	O
the	10385063	255	258	O
effects	10385063	259	266	O
of	10385063	267	269	O
calcitriol	10385063	270	280	B-Intervention
(	10385063	281	282	O
1alpha,25-dihydroxyvitamin	10385063	283	309	O
D3	10385063	310	312	O
)	10385063	313	314	O
on	10385063	315	317	O
bone	10385063	318	322	B-Outcome
mineral	10385063	323	330	I-Outcome
density	10385063	331	338	I-Outcome
(	10385063	339	340	I-Outcome
BMD	10385063	341	344	I-Outcome
)	10385063	345	346	I-Outcome
in	10385063	347	349	O
76	10385063	350	352	O
patients	10385063	353	361	O
(	10385063	362	363	O
26	10385063	364	366	O
men	10385063	367	370	O
and	10385063	371	374	O
50	10385063	375	377	O
women	10385063	378	383	O
)	10385063	384	385	O
with	10385063	386	390	O
cirrhosis	10385063	391	400	B-Participant
who	10385063	401	404	O
were	10385063	405	409	O
assigned	10385063	410	418	O
randomly	10385063	419	427	O
to	10385063	428	430	O
receive	10385063	431	438	O
calcitriol	10385063	439	449	B-Intervention
(	10385063	450	451	O
0.5	10385063	452	455	O
mg	10385063	456	458	O
twice	10385063	459	464	O
per	10385063	465	468	O
day	10385063	469	472	O
)	10385063	473	474	O
or	10385063	475	477	O
not	10385063	478	481	B-Intervention
.	10385063	482	483	O

The	10385063	484	487	O
BMD	10385063	488	491	B-Outcome
of	10385063	492	494	I-Outcome
the	10385063	495	498	I-Outcome
lumbar	10385063	499	505	I-Outcome
vertebrae	10385063	506	515	I-Outcome
was	10385063	516	519	O
measured	10385063	520	528	O
by	10385063	529	531	O
dual-energy	10385063	532	543	O
X-ray	10385063	544	549	O
absorptiometry	10385063	550	564	O
at	10385063	565	567	O
least	10385063	568	573	O
twice	10385063	574	579	O
,	10385063	580	581	O
12	10385063	582	584	O
-	10385063	584	585	O
57	10385063	585	587	O
months	10385063	588	594	O
apart	10385063	595	600	O
.	10385063	601	602	O

RESULTS	10385063	603	610	O
For	10385063	611	614	O
men	10385063	615	618	B-Participant
,	10385063	619	620	O
the	10385063	621	624	O
mean	10385063	625	629	B-Outcome
annual	10385063	630	636	I-Outcome
change	10385063	637	643	I-Outcome
in	10385063	644	646	I-Outcome
BMD	10385063	647	650	I-Outcome
was	10385063	651	654	O
1.1	10385063	655	658	B-Observation
%	10385063	659	660	I-Observation
in	10385063	661	663	O
the	10385063	664	667	O
treated	10385063	668	675	B-Intervention
group	10385063	676	681	O
and	10385063	682	685	O
-0.4	10385063	686	690	B-Observation
%	10385063	691	692	I-Observation
in	10385063	693	695	O
the	10385063	696	699	O
control	10385063	700	707	B-Intervention
group	10385063	708	713	O
.	10385063	714	715	O

The	10385063	716	719	O
median	10385063	720	726	B-Outcome
(	10385063	727	728	I-Outcome
25th	10385063	729	733	I-Outcome
and	10385063	734	737	I-Outcome
75th	10385063	738	742	I-Outcome
percentiles	10385063	743	754	I-Outcome
)	10385063	755	756	I-Outcome
annual	10385063	757	763	I-Outcome
change	10385063	764	770	I-Outcome
in	10385063	771	773	I-Outcome
BMD	10385063	774	777	I-Outcome
was	10385063	778	781	O
0.6	10385063	782	785	B-Observation
(	10385063	786	787	O
-0.1	10385063	788	792	O
,	10385063	793	794	O
2.1	10385063	795	798	O
%	10385063	799	800	O
)	10385063	801	802	O
in	10385063	803	805	O
the	10385063	806	809	O
treated	10385063	810	817	B-Intervention
group	10385063	818	823	O
and	10385063	824	827	O
-1.4	10385063	828	832	B-Observation
(	10385063	833	834	O
-1.9	10385063	835	839	O
,	10385063	840	841	O
1.6	10385063	842	845	O
%	10385063	846	847	O
)	10385063	848	849	O
in	10385063	850	852	O
the	10385063	853	856	O
control	10385063	857	864	B-Intervention
group	10385063	865	870	O
.	10385063	871	872	O

The	10385063	873	876	O
difference	10385063	877	887	B-Outcome
in	10385063	888	890	I-Outcome
the	10385063	891	894	I-Outcome
median	10385063	895	901	I-Outcome
annual	10385063	902	908	I-Outcome
change	10385063	909	915	I-Outcome
between	10385063	916	923	O
the	10385063	924	927	O
two	10385063	928	931	B-Intervention
groups	10385063	932	938	I-Intervention
was	10385063	939	942	O
significant	10385063	943	954	B-Observation
(	10385063	955	956	O
P	10385063	957	958	O
=	10385063	959	960	O
0.013	10385063	961	966	O
)	10385063	967	968	O
.	10385063	969	970	O

For	10385063	971	974	O
women	10385063	975	980	B-Participant
,	10385063	981	982	O
the	10385063	983	986	O
mean	10385063	987	991	B-Outcome
annual	10385063	992	998	I-Outcome
change	10385063	999	1005	I-Outcome
in	10385063	1006	1008	I-Outcome
BMD	10385063	1009	1012	I-Outcome
was	10385063	1013	1016	O
-0.5	10385063	1017	1021	B-Observation
%	10385063	1022	1023	I-Observation
in	10385063	1024	1026	O
the	10385063	1027	1030	O
treated	10385063	1031	1038	B-Intervention
group	10385063	1039	1044	O
and	10385063	1045	1048	O
-2.3	10385063	1049	1053	B-Observation
%	10385063	1054	1055	I-Observation
in	10385063	1056	1058	O
the	10385063	1059	1062	O
control	10385063	1063	1070	B-Intervention
group	10385063	1071	1076	O
.	10385063	1077	1078	O

The	10385063	1079	1082	O
median	10385063	1083	1089	B-Outcome
(	10385063	1090	1091	I-Outcome
25th	10385063	1092	1096	I-Outcome
and	10385063	1097	1100	I-Outcome
75th	10385063	1101	1105	I-Outcome
percentiles	10385063	1106	1117	I-Outcome
)	10385063	1118	1119	I-Outcome
annual	10385063	1120	1126	I-Outcome
change	10385063	1127	1133	I-Outcome
in	10385063	1134	1136	I-Outcome
BMD	10385063	1137	1140	I-Outcome
was	10385063	1141	1144	O
-0.5	10385063	1145	1149	B-Observation
(	10385063	1150	1151	O
-1.8	10385063	1152	1156	O
,	10385063	1157	1158	O
1.3	10385063	1159	1162	O
%	10385063	1163	1164	O
)	10385063	1165	1166	O
in	10385063	1167	1169	O
the	10385063	1170	1173	O
treated	10385063	1174	1181	B-Intervention
group	10385063	1182	1187	O
and	10385063	1188	1191	O
-1.5	10385063	1192	1196	B-Observation
(	10385063	1197	1198	O
-3.8	10385063	1199	1203	O
,	10385063	1204	1205	O
-0.7	10385063	1206	1210	O
%	10385063	1211	1212	O
)	10385063	1213	1214	O
in	10385063	1215	1217	O
the	10385063	1218	1221	O
control	10385063	1222	1229	B-Intervention
group	10385063	1230	1235	O
.	10385063	1236	1237	O

This	10385063	1238	1242	O
difference	10385063	1243	1253	B-Outcome
was	10385063	1254	1257	O
significant	10385063	1258	1269	B-Observation
(	10385063	1270	1271	O
P	10385063	1272	1273	O
=	10385063	1274	1275	O
0.011	10385063	1276	1281	O
)	10385063	1282	1283	O
.	10385063	1284	1285	O

CONCLUSIONS	10385063	1286	1297	O
Our	10385063	1298	1301	O
results	10385063	1302	1309	O
suggest	10385063	1310	1317	O
that	10385063	1318	1322	O
calcitriol	10385063	1323	1333	B-Intervention
can	10385063	1334	1337	O
prevent	10385063	1338	1345	B-Observation
bone	10385063	1346	1350	B-Outcome
loss	10385063	1351	1355	I-Outcome
and	10385063	1356	1359	O
,	10385063	1360	1361	O
therefore	10385063	1362	1371	O
,	10385063	1372	1373	O
may	10385063	1374	1377	O
be	10385063	1378	1380	O
useful	10385063	1381	1387	B-Observation
for	10385063	1388	1391	O
the	10385063	1392	1395	O
treatment	10385063	1396	1405	B-Outcome
of	10385063	1406	1408	O
bone	10385063	1409	1413	B-Participant
disease	10385063	1414	1421	I-Participant
in	10385063	1422	1424	O
patients	10385063	1425	1433	O
with	10385063	1434	1438	O
cirrhosis	10385063	1439	1448	B-Participant
of	10385063	1449	1451	I-Participant
the	10385063	1452	1455	I-Participant
liver	10385063	1456	1461	I-Participant
.	10385063	1462	1463	O

Comparison	10390407	0	10	O
of	10390407	11	13	O
the	10390407	14	17	O
relative	10390407	18	26	B-Outcome
efficacy	10390407	27	35	I-Outcome
of	10390407	36	38	O
formoterol	10390407	39	49	B-Intervention
and	10390407	50	53	O
salmeterol	10390407	54	64	B-Intervention
in	10390407	65	67	O
asthmatic	10390407	68	77	B-Participant
patients	10390407	78	86	O
.	10390407	87	88	O

Studies	10390407	89	96	O
performed	10390407	97	106	O
on	10390407	107	109	O
airway	10390407	110	116	O
smooth	10390407	117	123	O
muscle	10390407	124	130	O
in	10390407	131	133	O
vitro	10390407	134	139	O
have	10390407	140	144	O
indicated	10390407	145	154	O
that	10390407	155	159	O
salmeterol	10390407	160	170	O
is	10390407	171	173	O
a	10390407	174	175	O
partial	10390407	176	183	O
agonist	10390407	184	191	O
on	10390407	192	194	O
the	10390407	195	198	O
beta2-receptor	10390407	199	213	O
in	10390407	214	216	O
comparison	10390407	217	227	O
to	10390407	228	230	O
formoterol	10390407	231	241	O
.	10390407	242	243	O

In	10390407	244	246	O
the	10390407	247	250	O
present	10390407	251	258	O
study	10390407	259	264	O
we	10390407	265	267	O
evaluated	10390407	268	277	O
whether	10390407	278	285	O
these	10390407	286	291	O
pharmacological	10390407	292	307	B-Outcome
differences	10390407	308	319	I-Outcome
between	10390407	320	327	O
salmeterol	10390407	328	338	B-Intervention
and	10390407	339	342	O
formoterol	10390407	343	353	B-Intervention
also	10390407	354	358	O
are	10390407	359	362	O
applicable	10390407	363	373	O
to	10390407	374	376	O
asthmatic	10390407	377	386	B-Participant
patients	10390407	387	395	O
.	10390407	396	397	O

The	10390407	398	401	O
protective	10390407	402	412	B-Observation
effects	10390407	413	420	I-Observation
by	10390407	421	423	O
increasing	10390407	424	434	O
cumulative	10390407	435	445	O
doses	10390407	446	451	O
of	10390407	452	454	O
formoterol	10390407	455	465	B-Intervention
(	10390407	466	467	O
12	10390407	468	470	O
,	10390407	471	472	O
60	10390407	473	475	O
,	10390407	476	477	O
120	10390407	478	481	O
micrograms	10390407	482	492	O
)	10390407	493	494	O
and	10390407	495	498	O
salmeterol	10390407	499	509	B-Intervention
(	10390407	510	511	O
50	10390407	512	514	O
,	10390407	515	516	O
250	10390407	517	520	O
,	10390407	521	522	O
500	10390407	523	526	O
micrograms	10390407	527	537	O
)	10390407	538	539	O
on	10390407	540	542	O
methacholine-induced	10390407	543	563	B-Outcome
bronchoconstriction	10390407	564	583	I-Outcome
were	10390407	584	588	O
evaluated	10390407	589	598	O
in	10390407	599	601	O
a	10390407	602	603	O
double-blind	10390407	604	616	O
,	10390407	617	618	O
crossover	10390407	619	628	O
,	10390407	629	630	O
placebo-controlled	10390407	631	649	O
design	10390407	650	656	O
.	10390407	657	658	O

Patients	10390407	659	667	O
were	10390407	668	672	O
regularly	10390407	673	682	O
treated	10390407	683	690	O
with	10390407	691	695	O
salbutamol	10390407	696	706	B-Intervention
200	10390407	707	710	O
micrograms	10390407	711	721	O
twice	10390407	722	727	O
daily	10390407	728	733	O
during	10390407	734	740	O
the	10390407	741	744	O
study	10390407	745	750	O
period	10390407	751	757	O
,	10390407	758	759	O
to	10390407	760	762	O
avoid	10390407	763	768	O
variability	10390407	769	780	O
in	10390407	781	783	O
beta2-adrenoceptor	10390407	784	802	O
tolerance	10390407	803	812	O
.	10390407	813	814	O

S-potassium	10390407	815	826	B-Outcome
,	10390407	827	828	O
heart	10390407	829	834	B-Outcome
rate	10390407	835	839	I-Outcome
corrected	10390407	840	849	I-Outcome
Q-T	10390407	850	853	I-Outcome
interval	10390407	854	862	I-Outcome
(	10390407	863	864	I-Outcome
Q-Tc	10390407	865	869	I-Outcome
)	10390407	870	871	I-Outcome
,	10390407	872	873	O
and	10390407	874	877	O
tremor	10390407	878	884	B-Outcome
score	10390407	885	890	I-Outcome
were	10390407	891	895	O
followed	10390407	896	904	O
as	10390407	905	907	O
measures	10390407	908	916	O
of	10390407	917	919	O
systemic	10390407	920	928	O
effects	10390407	929	936	O
.	10390407	937	938	O

Formoterol	10390407	939	949	B-Intervention
dose-dependently	10390407	950	966	B-Observation
protected	10390407	967	976	I-Observation
against	10390407	977	984	O
methacholine	10390407	985	997	B-Outcome
responsiveness	10390407	998	1012	I-Outcome
(	10390407	1013	1014	O
4.6	10390407	1015	1018	B-Observation
doubling	10390407	1019	1027	I-Observation
doses	10390407	1028	1033	I-Observation
after	10390407	1034	1039	I-Observation
120	10390407	1040	1043	I-Observation
micrograms	10390407	1044	1054	I-Observation
)	10390407	1055	1056	O
.	10390407	1057	1058	O

Salmeterol	10390407	1059	1069	B-Intervention
,	10390407	1070	1071	O
however	10390407	1072	1079	O
,	10390407	1080	1081	O
showed	10390407	1082	1088	O
a	10390407	1089	1090	O
flatter	10390407	1091	1098	B-Observation
dose-response	10390407	1099	1112	B-Outcome
curve	10390407	1113	1118	I-Outcome
,	10390407	1119	1120	O
and	10390407	1121	1124	O
a	10390407	1125	1126	O
significantly	10390407	1127	1140	B-Observation
weaker	10390407	1141	1147	I-Observation
maximal	10390407	1148	1155	B-Outcome
protective	10390407	1156	1166	I-Outcome
effect	10390407	1167	1173	I-Outcome
(	10390407	1174	1175	O
2.8	10390407	1176	1179	B-Observation
doubling	10390407	1180	1188	I-Observation
doses	10390407	1189	1194	I-Observation
after	10390407	1195	1200	I-Observation
250	10390407	1201	1204	I-Observation
micrograms	10390407	1205	1215	I-Observation
)	10390407	1216	1217	O
.	10390407	1218	1219	O

Formoterol	10390407	1220	1230	B-Intervention
caused	10390407	1231	1237	O
a	10390407	1238	1239	O
significantly	10390407	1240	1253	B-Observation
higher	10390407	1254	1260	I-Observation
tremor	10390407	1261	1267	B-Outcome
score	10390407	1268	1273	I-Outcome
and	10390407	1274	1277	O
a	10390407	1278	1279	O
larger	10390407	1280	1286	B-Observation
drop	10390407	1287	1291	B-Outcome
in	10390407	1292	1294	I-Outcome
S-potassium	10390407	1295	1306	I-Outcome
than	10390407	1307	1311	O
salmeterol	10390407	1312	1322	B-Intervention
at	10390407	1323	1325	O
the	10390407	1326	1329	O
highest	10390407	1330	1337	O
doses	10390407	1338	1343	O
.	10390407	1344	1345	O

These	10390407	1346	1351	O
data	10390407	1352	1356	O
show	10390407	1357	1361	O
that	10390407	1362	1366	O
salmeterol	10390407	1367	1377	B-Intervention
is	10390407	1378	1380	O
a	10390407	1381	1382	O
partial	10390407	1383	1390	B-Observation
agonist	10390407	1391	1398	I-Observation
on	10390407	1399	1401	O
the	10390407	1402	1405	O
beta2-receptor	10390407	1406	1420	B-Outcome
in	10390407	1421	1423	O
relation	10390407	1424	1432	O
to	10390407	1433	1435	O
formoterol	10390407	1436	1446	B-Intervention
in	10390407	1447	1449	O
human	10390407	1450	1455	O
airways	10390407	1456	1463	O
in	10390407	1464	1466	O
vivo	10390407	1467	1471	O
.	10390407	1472	1473	O

Further	10390407	1474	1481	O
studies	10390407	1482	1489	O
are	10390407	1490	1493	O
required	10390407	1494	1502	O
to	10390407	1503	1505	O
document	10390407	1506	1514	O
the	10390407	1515	1518	O
clinical	10390407	1519	1527	O
consequences	10390407	1528	1540	O
of	10390407	1541	1543	O
this	10390407	1544	1548	O
finding	10390407	1549	1556	O
,	10390407	1557	1558	O
for	10390407	1559	1562	O
example	10390407	1563	1570	O
in	10390407	1571	1573	O
severe	10390407	1574	1580	O
asthmatic	10390407	1581	1590	O
patients	10390407	1591	1599	O
.	10390407	1600	1601	O

Adjuvant	10402369	0	8	B-Intervention
L-arginine	10402369	9	19	I-Intervention
treatment	10402369	20	29	O
for	10402369	30	33	O
in-vitro	10402369	34	42	B-Participant
fertilization	10402369	43	56	I-Participant
in	10402369	57	59	O
poor	10402369	60	64	B-Participant
responder	10402369	65	74	I-Participant
patients	10402369	75	83	O
.	10402369	84	85	O

The	10402369	86	89	O
objective	10402369	90	99	O
of	10402369	100	102	O
the	10402369	103	106	O
present	10402369	107	114	O
study	10402369	115	120	O
was	10402369	121	124	O
prospectively	10402369	125	138	O
and	10402369	139	142	O
randomly	10402369	143	151	O
to	10402369	152	154	O
evaluate	10402369	155	163	O
the	10402369	164	167	O
role	10402369	168	172	O
of	10402369	173	175	O
L-arginine	10402369	176	186	B-Intervention
in	10402369	187	189	O
improving	10402369	190	199	B-Observation
uterine	10402369	200	207	B-Outcome
and	10402369	208	211	I-Outcome
follicular	10402369	212	222	I-Outcome
Doppler	10402369	223	230	I-Outcome
flow	10402369	231	235	I-Outcome
and	10402369	236	239	O
in	10402369	240	242	O
improving	10402369	243	252	B-Observation
ovarian	10402369	253	260	B-Outcome
response	10402369	261	269	I-Outcome
to	10402369	270	272	I-Outcome
gonadotrophin	10402369	273	286	I-Outcome
in	10402369	287	289	O
poor	10402369	290	294	B-Participant
responder	10402369	295	304	I-Participant
women	10402369	305	310	B-Participant
.	10402369	311	312	O

A	10402369	313	314	O
total	10402369	315	320	O
of	10402369	321	323	O
34	10402369	324	326	O
patients	10402369	327	335	O
undergoing	10402369	336	346	O
assisted	10402369	347	355	B-Participant
reproduction	10402369	356	368	I-Participant
was	10402369	369	372	O
divided	10402369	373	380	O
in	10402369	381	383	O
two	10402369	384	387	O
groups	10402369	388	394	O
according	10402369	395	404	O
to	10402369	405	407	O
different	10402369	408	417	O
ovarian	10402369	418	425	O
stimulation	10402369	426	437	O
protocols	10402369	438	447	O
:	10402369	448	449	O
(	10402369	450	451	O
i	10402369	452	453	O
)	10402369	454	455	O
flare-up	10402369	456	464	B-Intervention
gonadotrophin-releasing	10402369	465	488	I-Intervention
hormone	10402369	489	496	I-Intervention
analogue	10402369	497	505	I-Intervention
(	10402369	506	507	I-Intervention
GnRHa	10402369	508	513	I-Intervention
)	10402369	514	515	I-Intervention
plus	10402369	516	520	I-Intervention
elevated	10402369	521	529	I-Intervention
pure	10402369	530	534	I-Intervention
follicle	10402369	535	543	I-Intervention
stimulating	10402369	544	555	I-Intervention
hormone	10402369	556	563	I-Intervention
(	10402369	564	565	I-Intervention
pFSH	10402369	566	570	I-Intervention
)	10402369	571	572	I-Intervention
(	10402369	573	574	O
n	10402369	575	576	O
=	10402369	577	578	O
17	10402369	579	581	O
)	10402369	582	583	O
;	10402369	584	585	O
and	10402369	586	589	O
(	10402369	590	591	O
ii	10402369	592	594	O
)	10402369	595	596	O
flare-up	10402369	597	605	B-Intervention
GnRHa	10402369	606	611	I-Intervention
plus	10402369	612	616	I-Intervention
elevated	10402369	617	625	I-Intervention
pFSH	10402369	626	630	I-Intervention
plus	10402369	631	635	I-Intervention
oral	10402369	636	640	I-Intervention
L-arginine	10402369	641	651	I-Intervention
(	10402369	652	653	O
n	10402369	654	655	O
=	10402369	656	657	O
17	10402369	658	660	O
)	10402369	661	662	O
.	10402369	663	664	O

During	10402369	665	671	O
the	10402369	672	675	O
ovarian	10402369	676	683	O
stimulation	10402369	684	695	O
regimen	10402369	696	703	O
,	10402369	704	705	O
the	10402369	706	709	O
patients	10402369	710	718	O
were	10402369	719	723	O
submitted	10402369	724	733	O
to	10402369	734	736	O
hormonal	10402369	737	745	B-Outcome
(	10402369	746	747	I-Outcome
oestradiol	10402369	748	758	I-Outcome
and	10402369	759	762	I-Outcome
growth	10402369	763	769	I-Outcome
hormone	10402369	770	777	I-Outcome
)	10402369	778	779	I-Outcome
,	10402369	780	781	I-Outcome
ultrasonographic	10402369	782	798	I-Outcome
(	10402369	799	800	I-Outcome
follicular	10402369	801	811	I-Outcome
number	10402369	812	818	I-Outcome
and	10402369	819	822	I-Outcome
diameter	10402369	823	831	I-Outcome
,	10402369	832	833	I-Outcome
endometrial	10402369	834	845	I-Outcome
thickness	10402369	846	855	I-Outcome
)	10402369	856	857	I-Outcome
and	10402369	858	861	I-Outcome
Doppler	10402369	862	869	I-Outcome
(	10402369	870	871	I-Outcome
uterine	10402369	872	879	I-Outcome
and	10402369	880	883	I-Outcome
perifollicular	10402369	884	898	I-Outcome
arteries	10402369	899	907	I-Outcome
)	10402369	908	909	I-Outcome
evaluations	10402369	910	921	I-Outcome
.	10402369	922	923	O

Furthermore	10402369	924	935	O
,	10402369	936	937	O
the	10402369	938	941	B-Outcome
plasma	10402369	942	948	I-Outcome
and	10402369	949	952	I-Outcome
follicular	10402369	953	963	I-Outcome
fluid	10402369	964	969	I-Outcome
concentrations	10402369	970	984	I-Outcome
of	10402369	985	987	I-Outcome
arginine	10402369	988	996	I-Outcome
,	10402369	997	998	I-Outcome
citrulline	10402369	999	1009	I-Outcome
,	10402369	1010	1011	I-Outcome
nitrite/nitrate	10402369	1012	1027	I-Outcome
(	10402369	1028	1029	I-Outcome
NO2-/NO3-	10402369	1030	1039	I-Outcome
)	10402369	1040	1041	I-Outcome
,	10402369	1042	1043	I-Outcome
and	10402369	1044	1047	I-Outcome
insulin-like	10402369	1048	1060	I-Outcome
growth	10402369	1061	1067	I-Outcome
factor-1	10402369	1068	1076	I-Outcome
(	10402369	1077	1078	I-Outcome
IGF-1	10402369	1079	1084	I-Outcome
)	10402369	1085	1086	I-Outcome
were	10402369	1087	1091	O
assayed	10402369	1092	1099	O
.	10402369	1100	1101	O

All	10402369	1102	1105	O
34	10402369	1106	1108	O
patients	10402369	1109	1117	O
completed	10402369	1118	1127	O
the	10402369	1128	1131	O
study	10402369	1132	1137	O
.	10402369	1138	1139	O

In	10402369	1140	1142	O
the	10402369	1143	1146	O
L-arginine	10402369	1147	1157	B-Intervention
treated	10402369	1158	1165	I-Intervention
group	10402369	1166	1171	O
a	10402369	1172	1173	O
lower	10402369	1174	1179	B-Observation
cancellation	10402369	1180	1192	B-Outcome
rate	10402369	1193	1197	I-Outcome
,	10402369	1198	1199	O
an	10402369	1200	1202	O
increased	10402369	1203	1212	B-Observation
number	10402369	1213	1219	B-Outcome
of	10402369	1220	1222	I-Outcome
oocytes	10402369	1223	1230	I-Outcome
collected	10402369	1231	1240	I-Outcome
,	10402369	1241	1242	O
and	10402369	1243	1246	O
embryos	10402369	1247	1254	B-Outcome
transferred	10402369	1255	1266	I-Outcome
were	10402369	1267	1271	O
observed	10402369	1272	1280	O
.	10402369	1281	1282	O

In	10402369	1283	1285	O
the	10402369	1286	1289	O
same	10402369	1290	1294	B-Intervention
group	10402369	1295	1300	I-Intervention
,	10402369	1301	1302	O
increased	10402369	1303	1312	B-Observation
plasma	10402369	1313	1319	B-Outcome
and	10402369	1320	1323	I-Outcome
follicular	10402369	1324	1334	I-Outcome
fluid	10402369	1335	1340	I-Outcome
concentrations	10402369	1341	1355	I-Outcome
of	10402369	1356	1358	I-Outcome
arginine	10402369	1359	1367	I-Outcome
,	10402369	1368	1369	O
citrulline	10402369	1370	1380	B-Outcome
,	10402369	1381	1382	O
NO2-/NO3-	10402369	1383	1392	B-Outcome
,	10402369	1393	1394	O
and	10402369	1395	1398	O
IGF-1	10402369	1399	1404	B-Outcome
was	10402369	1405	1408	O
observed	10402369	1409	1417	O
.	10402369	1418	1419	O

Significant	10402369	1420	1431	B-Observation
Doppler	10402369	1432	1439	B-Outcome
flow	10402369	1440	1444	I-Outcome
improvement	10402369	1445	1456	B-Observation
was	10402369	1457	1460	O
obtained	10402369	1461	1469	O
in	10402369	1470	1472	O
the	10402369	1473	1476	O
L-arginine	10402369	1477	1487	B-Intervention
supplemented	10402369	1488	1500	I-Intervention
group	10402369	1501	1506	O
.	10402369	1507	1508	O

Three	10402369	1509	1514	B-Count
pregnancies	10402369	1515	1526	B-Outcome
were	10402369	1527	1531	O
registered	10402369	1532	1542	O
in	10402369	1543	1545	O
these	10402369	1546	1551	O
patients	10402369	1552	1560	O
.	10402369	1561	1562	O

No	10402369	1563	1565	B-Count
pregnancies	10402369	1566	1577	B-Outcome
were	10402369	1578	1582	O
observed	10402369	1583	1591	O
in	10402369	1592	1594	O
the	10402369	1595	1598	O
other	10402369	1599	1604	B-Intervention
group	10402369	1605	1610	I-Intervention
.	10402369	1611	1612	O

It	10402369	1613	1615	O
was	10402369	1616	1619	O
concluded	10402369	1620	1629	O
that	10402369	1630	1634	O
oral	10402369	1635	1639	B-Intervention
L-arginine	10402369	1640	1650	I-Intervention
supplementation	10402369	1651	1666	I-Intervention
in	10402369	1667	1669	O
poor	10402369	1670	1674	B-Participant
responder	10402369	1675	1684	I-Participant
patients	10402369	1685	1693	O
may	10402369	1694	1697	O
improve	10402369	1698	1705	B-Observation
ovarian	10402369	1706	1713	B-Outcome
response	10402369	1714	1722	I-Outcome
,	10402369	1723	1724	O
endometrial	10402369	1725	1736	B-Outcome
receptivity	10402369	1737	1748	I-Outcome
and	10402369	1749	1752	O
pregnancy	10402369	1753	1762	B-Outcome
rate	10402369	1763	1767	I-Outcome
.	10402369	1768	1769	O

[	10408075	0	1	O
Validity	10408075	2	10	B-Observation
of	10408075	11	13	O
cardiotocography	10408075	14	30	B-Intervention
in	10408075	31	33	O
the	10408075	34	37	O
detection	10408075	38	47	B-Outcome
of	10408075	48	50	I-Outcome
umbilical	10408075	51	60	I-Outcome
cord	10408075	61	65	I-Outcome
complications	10408075	66	79	I-Outcome
]	10408075	80	81	O
.	10408075	82	83	O

OBJECTIVE	10408075	84	93	O
The	10408075	94	97	O
purpose	10408075	98	105	O
of	10408075	106	108	O
this	10408075	109	113	O
study	10408075	114	119	O
was	10408075	120	123	O
to	10408075	124	126	O
investigate	10408075	127	138	O
the	10408075	139	142	O
validity	10408075	143	151	B-Observation
of	10408075	152	154	O
cardiotocography	10408075	155	171	B-Intervention
for	10408075	172	175	O
the	10408075	176	179	O
detection	10408075	180	189	B-Outcome
of	10408075	190	192	I-Outcome
cord	10408075	193	197	I-Outcome
complications	10408075	198	211	I-Outcome
.	10408075	212	213	O

MATERIAL	10408075	214	222	O
AND	10408075	223	226	O
METHODS	10408075	227	234	O
A	10408075	235	236	O
low-risk	10408075	237	245	B-Participant
population	10408075	246	256	O
of	10408075	257	259	O
4196	10408075	260	264	O
cases	10408075	265	270	O
was	10408075	271	274	O
selected	10408075	275	283	O
in	10408075	284	286	O
which	10408075	287	292	O
cord	10408075	293	297	B-Participant
complications	10408075	298	311	I-Participant
have	10408075	312	316	O
been	10408075	317	321	O
recognized	10408075	322	332	O
in	10408075	333	335	O
34.3	10408075	336	340	O
%	10408075	341	342	O
.	10408075	343	344	O

Cases	10408075	345	350	O
with	10408075	351	355	O
cord	10408075	356	360	O
complications	10408075	361	374	O
and	10408075	375	378	O
controls	10408075	379	387	O
were	10408075	388	392	O
paired	10408075	393	399	O
by	10408075	400	402	O
parity	10408075	403	409	O
,	10408075	410	411	O
gestational	10408075	412	423	O
age	10408075	424	427	O
,	10408075	428	429	O
maternal	10408075	430	438	O
age	10408075	439	442	O
and	10408075	443	446	O
mode	10408075	447	451	O
of	10408075	452	454	O
delivery	10408075	455	463	O
.	10408075	464	465	O

25	10408075	466	468	O
pairs	10408075	469	474	O
were	10408075	475	479	O
randomly	10408075	480	488	O
selected	10408075	489	497	O
.	10408075	498	499	O

50	10408075	500	502	O
tracings	10408075	503	511	O
were	10408075	512	516	O
presented	10408075	517	526	O
twice	10408075	527	532	O
to	10408075	533	535	O
4	10408075	536	537	O
obstetricians	10408075	538	551	O
in	10408075	552	554	O
a	10408075	555	556	O
double-blind	10408075	557	569	O
manner	10408075	570	576	O
.	10408075	577	578	O

As	10408075	579	581	O
parameters	10408075	582	592	O
for	10408075	593	596	O
the	10408075	597	600	O
determination	10408075	601	614	O
of	10408075	615	617	O
the	10408075	618	621	O
validity	10408075	622	630	B-Observation
of	10408075	631	633	O
fetal	10408075	634	639	O
monitoring	10408075	640	650	O
the	10408075	651	654	O
reliability	10408075	655	666	B-Outcome
,	10408075	667	668	O
positive	10408075	669	677	B-Outcome
(	10408075	678	679	I-Outcome
ppv	10408075	680	683	I-Outcome
)	10408075	684	685	I-Outcome
and	10408075	686	689	O
negative	10408075	690	698	B-Outcome
predictive	10408075	699	709	I-Outcome
value	10408075	710	715	I-Outcome
(	10408075	716	717	I-Outcome
npv	10408075	718	721	I-Outcome
)	10408075	722	723	I-Outcome
,	10408075	724	725	O
sensitivity	10408075	726	737	B-Outcome
and	10408075	738	741	O
specificity	10408075	742	753	B-Outcome
were	10408075	754	758	O
used	10408075	759	763	O
.	10408075	764	765	O

Inter-	10408075	766	772	B-Outcome
and	10408075	773	776	I-Outcome
intra-observer	10408075	777	791	I-Outcome
variability	10408075	792	803	I-Outcome
were	10408075	804	808	O
also	10408075	809	813	O
examined	10408075	814	822	O
.	10408075	823	824	O

RESULTS	10408075	825	832	O
Reliability	10408075	833	844	B-Outcome
52	10408075	845	847	B-Observation
%	10408075	848	849	I-Observation
,	10408075	850	851	O
ppv	10408075	852	855	B-Outcome
52	10408075	856	858	B-Observation
%	10408075	859	860	I-Observation
,	10408075	861	862	O
npv	10408075	863	866	B-Outcome
52	10408075	867	869	B-Observation
%	10408075	870	871	I-Observation
,	10408075	872	873	O
sensitivity	10408075	874	885	B-Outcome
46	10408075	886	888	B-Observation
%	10408075	889	890	I-Observation
,	10408075	891	892	O
specificity	10408075	893	904	B-Outcome
58	10408075	905	907	B-Observation
%	10408075	908	909	I-Observation
.	10408075	910	911	O

Interobserver	10408075	912	925	B-Outcome
variability	10408075	926	937	I-Outcome
:	10408075	938	939	O
All	10408075	940	943	O
4	10408075	944	945	O
obstetricians	10408075	946	959	O
agreed	10408075	960	966	O
in	10408075	967	969	O
47	10408075	970	972	B-Observation
of	10408075	973	975	I-Observation
100	10408075	976	979	I-Observation
evaluations	10408075	980	991	I-Observation
.	10408075	992	993	O

The	10408075	994	997	O
level	10408075	998	1003	B-Outcome
of	10408075	1004	1006	I-Outcome
agreement	10408075	1007	1016	I-Outcome
was	10408075	1017	1020	O
higher	10408075	1021	1027	B-Observation
in	10408075	1028	1030	O
the	10408075	1031	1034	O
controls	10408075	1035	1043	B-Participant
(	10408075	1044	1045	O
63	10408075	1046	1048	B-Observation
%	10408075	1049	1050	I-Observation
)	10408075	1051	1052	O
than	10408075	1053	1057	O
in	10408075	1058	1060	O
the	10408075	1061	1064	O
cord	10408075	1065	1069	B-Participant
complication	10408075	1070	1082	I-Participant
group	10408075	1083	1088	O
(	10408075	1089	1090	O
56	10408075	1091	1093	B-Observation
%	10408075	1094	1095	I-Observation
)	10408075	1096	1097	O
.	10408075	1098	1099	O

The	10408075	1100	1103	O
intraobserver	10408075	1104	1117	B-Outcome
variability	10408075	1118	1129	I-Outcome
was	10408075	1130	1133	O
25	10408075	1134	1136	B-Observation
%	10408075	1137	1138	I-Observation
.	10408075	1139	1140	O

CONCLUSIONS	10408075	1141	1152	O
Cardiotocography	10408075	1153	1169	B-Intervention
is	10408075	1170	1172	O
not	10408075	1173	1176	O
useful	10408075	1177	1183	B-Observation
for	10408075	1184	1187	O
the	10408075	1188	1191	O
detection	10408075	1192	1201	B-Outcome
of	10408075	1202	1204	I-Outcome
cord	10408075	1205	1209	I-Outcome
complications	10408075	1210	1223	I-Outcome
.	10408075	1224	1225	O

The	10408075	1226	1229	O
range	10408075	1230	1235	O
of	10408075	1236	1238	O
possibilities	10408075	1239	1252	O
has	10408075	1253	1256	O
not	10408075	1257	1260	O
been	10408075	1261	1265	O
exploited	10408075	1266	1275	O
yet	10408075	1276	1279	O
,	10408075	1280	1281	O
even	10408075	1282	1286	O
for	10408075	1287	1290	O
the	10408075	1291	1294	O
evaluation	10408075	1295	1305	O
of	10408075	1306	1308	O
the	10408075	1309	1312	O
fetal	10408075	1313	1318	O
state	10408075	1319	1324	O
.	10408075	1325	1326	O

[	10410152	0	1	O
Efficacy	10410152	2	10	O
of	10410152	11	13	O
combination	10410152	14	25	B-Intervention
with	10410152	26	30	I-Intervention
granisetron	10410152	31	42	I-Intervention
and	10410152	43	46	I-Intervention
methylprednisolone	10410152	47	65	I-Intervention
for	10410152	66	69	O
nausea	10410152	70	76	B-Outcome
,	10410152	77	78	O
vomiting	10410152	79	87	B-Outcome
and	10410152	88	91	O
appetite	10410152	92	100	B-Outcome
loss	10410152	101	105	I-Outcome
in	10410152	106	108	O
remission	10410152	109	118	B-Participant
induction	10410152	119	128	I-Participant
chemotherapy	10410152	129	141	I-Participant
of	10410152	142	144	I-Participant
acute	10410152	145	150	I-Participant
myeloid	10410152	151	158	I-Participant
leukemia	10410152	159	167	I-Participant
--	10410152	168	170	O
a	10410152	171	172	O
randomized	10410152	173	183	O
comparative	10410152	184	195	O
trial	10410152	196	201	O
between	10410152	202	209	O
granisetron	10410152	210	221	B-Intervention
alone	10410152	222	227	I-Intervention
and	10410152	228	231	O
granisetron	10410152	232	243	B-Intervention
plus	10410152	244	248	I-Intervention
methylprednisolone	10410152	249	267	I-Intervention
]	10410152	268	269	O
.	10410152	270	271	O

The	10410152	272	275	O
prevention	10410152	276	286	B-Observation
of	10410152	287	289	O
nausea	10410152	290	296	B-Outcome
,	10410152	297	298	O
vomiting	10410152	299	307	B-Outcome
and	10410152	308	311	O
appetite	10410152	312	320	B-Outcome
loss	10410152	321	325	I-Outcome
induced	10410152	326	333	O
by	10410152	334	336	O
remission	10410152	337	346	B-Participant
induction	10410152	347	356	I-Participant
chemotherapy	10410152	357	369	I-Participant
for	10410152	370	373	I-Participant
acute	10410152	374	379	I-Participant
myeloid	10410152	380	387	I-Participant
leukemia	10410152	388	396	I-Participant
was	10410152	397	400	O
compared	10410152	401	409	O
by	10410152	410	412	O
randomization	10410152	413	426	O
between	10410152	427	434	O
granisetron	10410152	435	446	B-Intervention
alone	10410152	447	452	I-Intervention
and	10410152	453	456	O
combination	10410152	457	468	B-Intervention
with	10410152	469	473	I-Intervention
granisetron	10410152	474	485	I-Intervention
plus	10410152	486	490	I-Intervention
methylprednisolone	10410152	491	509	I-Intervention
.	10410152	510	511	O

Granisetron	10410152	512	523	B-Intervention
was	10410152	524	527	O
administered	10410152	528	540	O
at	10410152	541	543	O
40	10410152	544	546	O
micrograms/kg	10410152	547	560	O
during	10410152	561	567	O
chemotherapy	10410152	568	580	B-Participant
,	10410152	581	582	O
and	10410152	583	586	O
methylprednisolone	10410152	587	605	B-Intervention
was	10410152	606	609	O
administered	10410152	610	622	O
concomitantly	10410152	623	636	O
at	10410152	637	639	O
125	10410152	640	643	O
mg/body	10410152	644	651	O
for	10410152	652	655	O
3	10410152	656	657	O
days	10410152	658	662	O
or	10410152	663	665	O
more	10410152	666	670	O
in	10410152	671	673	O
the	10410152	674	677	O
combination	10410152	678	689	O
group	10410152	690	695	O
.	10410152	696	697	O

The	10410152	698	701	O
single	10410152	702	708	B-Intervention
and	10410152	709	712	O
combination	10410152	713	724	B-Intervention
groups	10410152	725	731	O
comprised	10410152	732	741	O
14	10410152	742	744	O
and	10410152	745	748	O
13	10410152	749	751	O
patients	10410152	752	760	O
,	10410152	761	762	O
respectively	10410152	763	775	O
,	10410152	776	777	O
and	10410152	778	781	O
there	10410152	782	787	O
was	10410152	788	791	O
no	10410152	792	794	O
significant	10410152	795	806	O
difference	10410152	807	817	O
between	10410152	818	825	O
the	10410152	826	829	O
background	10410152	830	840	O
of	10410152	841	843	O
both	10410152	844	848	O
groups	10410152	849	855	O
.	10410152	856	857	O

To	10410152	858	860	O
evaluate	10410152	861	869	O
the	10410152	870	873	O
effect	10410152	874	880	O
they	10410152	881	885	O
were	10410152	886	890	O
scored	10410152	891	897	O
according	10410152	898	907	O
to	10410152	908	910	O
4	10410152	911	912	O
grades	10410152	913	919	O
,	10410152	920	921	O
and	10410152	922	925	O
evaluated	10410152	926	935	O
every	10410152	936	941	O
24	10410152	942	944	O
hours	10410152	945	950	O
from	10410152	951	955	O
the	10410152	956	959	O
start	10410152	960	965	O
of	10410152	966	968	O
chemotherapy	10410152	969	981	O
to	10410152	982	984	O
5	10410152	985	986	O
days	10410152	987	991	O
after	10410152	992	997	O
its	10410152	998	1001	O
completion	10410152	1002	1012	O
.	10410152	1013	1014	O

The	10410152	1015	1018	O
complete	10410152	1019	1027	B-Outcome
inhibition	10410152	1028	1038	I-Outcome
rate	10410152	1039	1043	I-Outcome
of	10410152	1044	1046	I-Outcome
vomiting	10410152	1047	1055	I-Outcome
was	10410152	1056	1059	O
as	10410152	1060	1062	O
high	10410152	1063	1067	O
as	10410152	1068	1070	O
71.4	10410152	1071	1075	B-Observation
%	10410152	1076	1077	I-Observation
and	10410152	1078	1081	O
92.3	10410152	1082	1086	B-Observation
%	10410152	1087	1088	I-Observation
in	10410152	1089	1091	O
the	10410152	1092	1095	O
single	10410152	1096	1102	B-Intervention
and	10410152	1103	1106	O
combination	10410152	1107	1118	B-Intervention
groups	10410152	1119	1125	O
,	10410152	1126	1127	O
respectively	10410152	1128	1140	O
,	10410152	1141	1142	O
showing	10410152	1143	1150	O
no	10410152	1151	1153	O
significant	10410152	1154	1165	B-Observation
difference	10410152	1166	1176	I-Observation
.	10410152	1177	1178	O

The	10410152	1179	1182	O
grade	10410152	1183	1188	B-Outcome
of	10410152	1189	1191	I-Outcome
vomiting	10410152	1192	1200	I-Outcome
was	10410152	1201	1204	O
mild	10410152	1205	1209	B-Observation
in	10410152	1210	1212	O
both	10410152	1213	1217	B-Intervention
groups	10410152	1218	1224	I-Intervention
.	10410152	1225	1226	O

Nausea	10410152	1227	1233	B-Outcome
was	10410152	1234	1237	O
noted	10410152	1238	1243	O
in	10410152	1244	1246	O
71.4	10410152	1247	1251	B-Count
%	10410152	1252	1253	I-Count
and	10410152	1254	1257	O
46.2	10410152	1258	1262	B-Count
%	10410152	1263	1264	I-Count
,	10410152	1265	1266	O
respectively	10410152	1267	1279	O
,	10410152	1280	1281	O
and	10410152	1282	1285	O
the	10410152	1286	1289	O
inhibitory	10410152	1290	1300	B-Outcome
effect	10410152	1301	1307	I-Outcome
tended	10410152	1308	1314	O
to	10410152	1315	1317	O
be	10410152	1318	1320	O
higher	10410152	1321	1327	B-Observation
in	10410152	1328	1330	O
the	10410152	1331	1334	O
combination	10410152	1335	1346	B-Intervention
group	10410152	1347	1352	O
.	10410152	1353	1354	O

Appetite	10410152	1355	1363	B-Outcome
loss	10410152	1364	1368	I-Outcome
developed	10410152	1369	1378	O
in	10410152	1379	1381	O
92.9	10410152	1382	1386	B-Count
%	10410152	1387	1388	I-Count
and	10410152	1389	1392	O
41.7	10410152	1393	1397	B-Count
%	10410152	1398	1399	I-Count
,	10410152	1400	1401	O
respectively	10410152	1402	1414	O
,	10410152	1415	1416	O
and	10410152	1417	1420	O
the	10410152	1421	1424	O
prevention	10410152	1425	1435	B-Outcome
effect	10410152	1436	1442	I-Outcome
was	10410152	1443	1446	O
clearly	10410152	1447	1454	O
higher	10410152	1455	1461	B-Observation
in	10410152	1462	1464	O
the	10410152	1465	1468	O
combination	10410152	1469	1480	B-Intervention
group	10410152	1481	1486	O
.	10410152	1487	1488	O

The	10410152	1489	1492	O
prevention	10410152	1493	1503	B-Observation
effects	10410152	1504	1511	I-Observation
on	10410152	1512	1514	O
nausea	10410152	1515	1521	B-Outcome
7	10410152	1522	1523	O
,	10410152	1524	1525	O
8	10410152	1526	1527	O
and	10410152	1528	1531	O
10	10410152	1532	1534	O
days	10410152	1535	1539	O
after	10410152	1540	1545	O
the	10410152	1546	1549	O
start	10410152	1550	1555	O
of	10410152	1556	1558	O
chemotherapy	10410152	1559	1571	O
,	10410152	1572	1573	O
on	10410152	1574	1576	O
appetite	10410152	1577	1585	B-Outcome
loss	10410152	1586	1590	I-Outcome
2	10410152	1591	1592	O
-	10410152	1592	1593	O
10	10410152	1593	1595	O
days	10410152	1596	1600	O
after	10410152	1601	1606	O
it	10410152	1607	1609	O
,	10410152	1610	1611	O
and	10410152	1612	1615	O
2	10410152	1616	1617	O
-	10410152	1617	1618	O
5	10410152	1618	1619	O
days	10410152	1620	1624	O
after	10410152	1625	1630	O
its	10410152	1631	1634	O
completion	10410152	1635	1645	O
,	10410152	1646	1647	O
were	10410152	1648	1652	O
higher	10410152	1653	1659	B-Observation
in	10410152	1660	1662	O
the	10410152	1663	1666	O
combination	10410152	1667	1678	B-Intervention
group	10410152	1679	1684	O
.	10410152	1685	1686	O

Granisetron	10410152	1687	1698	B-Intervention
revealed	10410152	1699	1707	O
an	10410152	1708	1710	O
excellent	10410152	1711	1720	B-Observation
inhibitory	10410152	1721	1731	I-Observation
effect	10410152	1732	1738	I-Observation
on	10410152	1739	1741	O
vomiting	10410152	1742	1750	B-Outcome
induced	10410152	1751	1758	O
by	10410152	1759	1761	O
remission	10410152	1762	1771	B-Participant
induction	10410152	1772	1781	I-Participant
chemotherapy	10410152	1782	1794	I-Participant
for	10410152	1795	1798	I-Participant
acute	10410152	1799	1804	I-Participant
myeloid	10410152	1805	1812	I-Participant
leukemia	10410152	1813	1821	I-Participant
,	10410152	1822	1823	O
but	10410152	1824	1827	O
combination	10410152	1828	1839	B-Intervention
with	10410152	1840	1844	I-Intervention
granisetron	10410152	1845	1856	I-Intervention
and	10410152	1857	1860	I-Intervention
methylprednisolone	10410152	1861	1879	I-Intervention
was	10410152	1880	1883	O
considered	10410152	1884	1894	O
useful	10410152	1895	1901	B-Observation
for	10410152	1902	1905	O
nausea	10410152	1906	1912	B-Outcome
in	10410152	1913	1915	O
the	10410152	1916	1919	O
latter	10410152	1920	1926	O
half	10410152	1927	1931	O
of	10410152	1932	1934	O
the	10410152	1935	1938	O
treatment	10410152	1939	1948	O
period	10410152	1949	1955	O
and	10410152	1956	1959	O
for	10410152	1960	1963	O
appetite	10410152	1964	1972	B-Outcome
loss	10410152	1973	1977	I-Outcome
during	10410152	1978	1984	O
the	10410152	1985	1988	O
whole	10410152	1989	1994	O
period	10410152	1995	2001	O
.	10410152	2002	2003	O

Moderate-intensity	10414756	0	18	B-Intervention
exercise	10414756	19	27	I-Intervention
training	10414756	28	36	I-Intervention
with	10414756	37	41	I-Intervention
elements	10414756	42	50	I-Intervention
of	10414756	51	53	I-Intervention
step	10414756	54	58	I-Intervention
aerobics	10414756	59	67	I-Intervention
in	10414756	68	70	O
patients	10414756	71	79	O
with	10414756	80	84	O
severe	10414756	85	91	B-Participant
chronic	10414756	92	99	I-Participant
heart	10414756	100	105	I-Participant
failure	10414756	106	113	I-Participant
.	10414756	114	115	O

OBJECTIVE	10414756	116	125	O
To	10414756	126	128	O
evaluate	10414756	129	137	O
whether	10414756	138	145	O
a	10414756	146	147	O
specific	10414756	148	156	O
program	10414756	157	164	O
of	10414756	165	167	O
moderate-intensity	10414756	168	186	B-Intervention
step	10414756	187	191	I-Intervention
aerobics	10414756	192	200	I-Intervention
training	10414756	201	209	I-Intervention
may	10414756	210	213	O
be	10414756	214	216	O
sufficient	10414756	217	227	O
to	10414756	228	230	O
improve	10414756	231	238	B-Observation
the	10414756	239	242	O
exercise	10414756	243	251	B-Outcome
tolerance	10414756	252	261	I-Outcome
of	10414756	262	264	O
patients	10414756	265	273	O
with	10414756	274	278	O
severe	10414756	279	285	B-Participant
chronic	10414756	286	293	I-Participant
heart	10414756	294	299	I-Participant
failure	10414756	300	307	I-Participant
.	10414756	308	309	O

PATIENTS	10414756	310	318	O
Twenty-six	10414756	319	329	O
patients	10414756	330	338	O
(	10414756	339	340	O
22	10414756	341	343	O
men	10414756	344	347	O
,	10414756	348	349	O
4	10414756	350	351	O
women	10414756	352	357	O
;	10414756	358	359	O
mean	10414756	360	364	O
+	10414756	365	366	O
/-	10414756	366	368	O
SD	10414756	369	371	O
age	10414756	372	375	O
,	10414756	376	377	O
54	10414756	378	380	O
+	10414756	381	382	O
/-	10414756	382	384	O
9yrs	10414756	385	389	O
)	10414756	390	391	O
with	10414756	392	396	O
a	10414756	397	398	O
history	10414756	399	406	O
of	10414756	407	409	O
severe	10414756	410	416	B-Participant
chronic	10414756	417	424	I-Participant
heart	10414756	425	430	I-Participant
failure	10414756	431	438	I-Participant
(	10414756	439	440	O
left	10414756	441	445	O
ventricular	10414756	446	457	O
ejection	10414756	458	466	O
fraction	10414756	467	475	O
of	10414756	476	478	O
18	10414756	479	481	O
%	10414756	482	483	O
+	10414756	484	485	O
/-	10414756	485	487	O
8	10414756	488	489	O
%	10414756	490	491	O
)	10414756	492	493	O
.	10414756	494	495	O

STUDY	10414756	496	501	O
DESIGN	10414756	502	508	O
Prospective	10414756	509	520	O
,	10414756	521	522	O
randomized	10414756	523	533	O
,	10414756	534	535	O
controlled	10414756	536	546	O
trial	10414756	547	552	O
.	10414756	553	554	O

Patients	10414756	555	563	O
were	10414756	564	568	O
randomized	10414756	569	579	O
into	10414756	580	584	O
exercise	10414756	585	593	B-Intervention
and	10414756	594	597	O
control	10414756	598	605	B-Intervention
groups	10414756	606	612	O
.	10414756	613	614	O

All	10414756	615	618	O
patients	10414756	619	627	O
underwent	10414756	628	637	O
a	10414756	638	639	O
clinical	10414756	640	648	O
examination	10414756	649	660	O
and	10414756	661	664	O
a	10414756	665	666	O
ramp	10414756	667	671	O
pattern	10414756	672	679	O
cycle	10414756	680	685	O
exercise	10414756	686	694	O
test	10414756	695	699	O
before	10414756	700	706	O
and	10414756	707	710	O
after	10414756	711	716	O
the	10414756	717	720	O
observation	10414756	721	732	O
period	10414756	733	739	O
.	10414756	740	741	O

The	10414756	742	745	O
exercise	10414756	746	754	B-Intervention
group	10414756	755	760	O
underwent	10414756	761	770	O
a	10414756	771	772	O
moderate-intensity	10414756	773	791	B-Intervention
(	10414756	792	793	I-Intervention
50	10414756	794	796	I-Intervention
%	10414756	797	798	I-Intervention
of	10414756	799	801	I-Intervention
peak	10414756	802	806	I-Intervention
oxygen	10414756	807	813	I-Intervention
uptake	10414756	814	820	I-Intervention
)	10414756	821	822	I-Intervention
12-week	10414756	823	830	I-Intervention
training	10414756	831	839	I-Intervention
program	10414756	840	847	I-Intervention
,	10414756	848	849	O
progressing	10414756	850	861	O
to	10414756	862	864	O
100	10414756	865	868	B-Intervention
minutes	10414756	869	876	I-Intervention
per	10414756	877	880	I-Intervention
week	10414756	881	885	I-Intervention
of	10414756	886	888	I-Intervention
step	10414756	889	893	I-Intervention
aerobics	10414756	894	902	I-Intervention
and	10414756	903	906	I-Intervention
50	10414756	907	909	I-Intervention
minutes	10414756	910	917	I-Intervention
per	10414756	918	921	I-Intervention
week	10414756	922	926	I-Intervention
of	10414756	927	929	I-Intervention
cycling	10414756	930	937	I-Intervention
.	10414756	938	939	O

The	10414756	940	943	O
control	10414756	944	951	B-Intervention
group	10414756	952	957	O
did	10414756	958	961	O
not	10414756	962	965	O
perform	10414756	966	973	O
a	10414756	974	975	O
training	10414756	976	984	B-Intervention
program	10414756	985	992	I-Intervention
.	10414756	993	994	O

MAIN	10414756	995	999	O
OUTCOME	10414756	1000	1007	O
MEASURES	10414756	1008	1016	O
Peak	10414756	1017	1021	B-Outcome
oxygen	10414756	1022	1028	I-Outcome
uptake	10414756	1029	1035	I-Outcome
,	10414756	1036	1037	O
peak	10414756	1038	1042	B-Outcome
workload	10414756	1043	1051	I-Outcome
,	10414756	1052	1053	O
percent	10414756	1054	1061	B-Outcome
of	10414756	1062	1064	I-Outcome
predicted	10414756	1065	1074	I-Outcome
power	10414756	1075	1080	I-Outcome
ability	10414756	1081	1088	I-Outcome
.	10414756	1089	1090	O

RESULTS	10414756	1091	1098	O
Significant	10414756	1099	1110	B-Observation
increases	10414756	1111	1120	I-Observation
in	10414756	1121	1123	O
peak	10414756	1124	1128	B-Outcome
oxygen	10414756	1129	1135	I-Outcome
uptake	10414756	1136	1142	I-Outcome
(	10414756	1143	1144	O
15	10414756	1145	1147	B-Observation
+	10414756	1148	1149	I-Observation
/-	10414756	1149	1151	I-Observation
3.4	10414756	1152	1155	I-Observation
to	10414756	1156	1158	I-Observation
18.5	10414756	1159	1163	I-Observation
+	10414756	1164	1165	I-Observation
/-	10414756	1165	1167	I-Observation
2.9mL/kg/min	10414756	1168	1180	I-Observation
;	10414756	1181	1182	O
p	10414756	1183	1184	O
=	10414756	1185	1186	O
.001	10414756	1187	1191	O
)	10414756	1192	1193	O
,	10414756	1194	1195	O
peak	10414756	1196	1200	B-Outcome
workload	10414756	1201	1209	I-Outcome
(	10414756	1210	1211	O
77	10414756	1212	1214	B-Observation
+	10414756	1215	1216	I-Observation
/-	10414756	1216	1218	I-Observation
26	10414756	1219	1221	I-Observation
to	10414756	1222	1224	I-Observation
99	10414756	1225	1227	I-Observation
+	10414756	1228	1229	I-Observation
/-	10414756	1229	1231	I-Observation
31	10414756	1232	1234	I-Observation
watts	10414756	1235	1240	I-Observation
;	10414756	1241	1242	O
p	10414756	1243	1244	O
=	10414756	1245	1246	O
.000	10414756	1247	1251	O
)	10414756	1252	1253	O
,	10414756	1254	1255	O
and	10414756	1256	1259	O
percent	10414756	1260	1267	B-Outcome
of	10414756	1268	1270	I-Outcome
predicted	10414756	1271	1280	I-Outcome
power	10414756	1281	1286	I-Outcome
ability	10414756	1287	1294	I-Outcome
(	10414756	1295	1296	O
43	10414756	1297	1299	B-Observation
%	10414756	1300	1301	I-Observation
+	10414756	1302	1303	I-Observation
/-	10414756	1303	1305	I-Observation
10	10414756	1306	1308	I-Observation
%	10414756	1309	1310	I-Observation
to	10414756	1311	1313	I-Observation
56	10414756	1314	1316	I-Observation
%	10414756	1317	1318	I-Observation
+	10414756	1319	1320	I-Observation
/-	10414756	1320	1322	I-Observation
13	10414756	1323	1325	I-Observation
%	10414756	1326	1327	I-Observation
;	10414756	1328	1329	O
p	10414756	1330	1331	O
=	10414756	1332	1333	O
.000	10414756	1334	1338	O
)	10414756	1339	1340	O
were	10414756	1341	1345	O
observed	10414756	1346	1354	O
in	10414756	1355	1357	O
the	10414756	1358	1361	O
exercise	10414756	1362	1370	B-Intervention
group	10414756	1371	1376	O
.	10414756	1377	1378	O

No	10414756	1379	1381	O
significant	10414756	1382	1393	B-Observation
changes	10414756	1394	1401	I-Observation
in	10414756	1402	1404	O
baseline	10414756	1405	1413	B-Outcome
parameters	10414756	1414	1424	I-Outcome
occurred	10414756	1425	1433	O
in	10414756	1434	1436	O
the	10414756	1437	1440	O
control	10414756	1441	1448	B-Intervention
group	10414756	1449	1454	O
.	10414756	1455	1456	O

There	10414756	1457	1462	O
were	10414756	1463	1467	O
no	10414756	1468	1470	O
critical	10414756	1471	1479	B-Observation
changes	10414756	1480	1487	I-Observation
in	10414756	1488	1490	O
heart	10414756	1491	1496	B-Outcome
rate	10414756	1497	1501	I-Outcome
or	10414756	1502	1504	O
blood	10414756	1505	1510	B-Outcome
pressure	10414756	1511	1519	I-Outcome
in	10414756	1520	1522	O
either	10414756	1523	1529	B-Intervention
group	10414756	1530	1535	I-Intervention
.	10414756	1536	1537	O

CONCLUSION	10414756	1538	1548	O
Moderate-intensity	10414756	1549	1567	B-Intervention
step	10414756	1568	1572	I-Intervention
aerobics	10414756	1573	1581	I-Intervention
training	10414756	1582	1590	I-Intervention
significantly	10414756	1591	1604	B-Observation
increases	10414756	1605	1614	I-Observation
peak	10414756	1615	1619	B-Outcome
oxygen	10414756	1620	1626	I-Outcome
uptake	10414756	1627	1633	I-Outcome
and	10414756	1634	1637	O
peak	10414756	1638	1642	B-Outcome
workloads	10414756	1643	1652	I-Outcome
in	10414756	1653	1655	O
patients	10414756	1656	1664	O
with	10414756	1665	1669	O
severe	10414756	1670	1676	B-Participant
chronic	10414756	1677	1684	I-Participant
heart	10414756	1685	1690	I-Participant
failure	10414756	1691	1698	I-Participant
.	10414756	1699	1700	O

Effects	10424316	0	7	O
of	10424316	8	10	O
captopril	10424316	11	20	B-Intervention
and	10424316	21	24	O
enalapril	10424316	25	34	B-Intervention
on	10424316	35	37	O
electroencephalogram	10424316	38	58	B-Outcome
and	10424316	59	62	O
cognitive	10424316	63	72	B-Outcome
performance	10424316	73	84	I-Outcome
in	10424316	85	87	O
healthy	10424316	88	95	B-Participant
volunteers	10424316	96	106	O
.	10424316	107	108	O

OBJECTIVE	10424316	109	118	O
Captopril	10424316	119	128	B-Intervention
and	10424316	129	132	O
enalapril	10424316	133	142	B-Intervention
have	10424316	143	147	O
been	10424316	148	152	O
reported	10424316	153	161	O
to	10424316	162	164	O
influence	10424316	165	174	O
cognitive	10424316	175	184	B-Outcome
functions	10424316	185	194	I-Outcome
and	10424316	195	198	O
quality	10424316	199	206	B-Outcome
of	10424316	207	209	I-Outcome
life	10424316	210	214	I-Outcome
in	10424316	215	217	O
hypertensive	10424316	218	230	B-Participant
patients	10424316	231	239	O
.	10424316	240	241	O

METHODS	10424316	242	249	O
The	10424316	250	253	O
effects	10424316	254	261	O
of	10424316	262	264	O
captopril	10424316	265	274	B-Intervention
(	10424316	275	276	O
12.5	10424316	277	281	O
mg	10424316	282	284	O
and	10424316	285	288	O
25	10424316	289	291	O
mg	10424316	292	294	O
)	10424316	295	296	O
and	10424316	297	300	O
enalapril	10424316	301	310	B-Intervention
(	10424316	311	312	O
5	10424316	313	314	O
mg	10424316	315	317	O
and	10424316	318	321	O
10	10424316	322	324	O
mg	10424316	325	327	O
)	10424316	328	329	O
administered	10424316	330	342	O
during	10424316	343	349	O
7-day	10424316	350	355	O
periods	10424316	356	363	O
on	10424316	364	366	O
electroencephalogram	10424316	367	387	B-Outcome
(	10424316	388	389	I-Outcome
EEG	10424316	390	393	I-Outcome
)	10424316	394	395	I-Outcome
,	10424316	396	397	O
cognitive	10424316	398	407	B-Outcome
functions	10424316	408	417	I-Outcome
,	10424316	418	419	O
and	10424316	420	423	O
subjective	10424316	424	434	B-Outcome
assessments	10424316	435	446	I-Outcome
were	10424316	447	451	O
investigated	10424316	452	464	O
in	10424316	465	467	O
healthy	10424316	468	475	B-Participant
males	10424316	476	481	I-Participant
.	10424316	482	483	O

RESULTS	10424316	484	491	O
Neither	10424316	492	499	O
captopril	10424316	500	509	B-Intervention
nor	10424316	510	513	O
enalapril	10424316	514	523	B-Intervention
influenced	10424316	524	534	O
EEG	10424316	535	538	B-Outcome
and	10424316	539	542	O
cognitive	10424316	543	552	B-Outcome
functions	10424316	553	562	I-Outcome
compared	10424316	563	571	O
with	10424316	572	576	O
placebo	10424316	577	584	B-Intervention
.	10424316	585	586	O

Captopril	10424316	587	596	B-Intervention
12.5	10424316	597	601	I-Intervention
mg	10424316	602	604	I-Intervention
decreased	10424316	605	614	B-Observation
subjective	10424316	615	625	B-Outcome
activity	10424316	626	634	I-Outcome
compared	10424316	635	643	O
with	10424316	644	648	O
placebo	10424316	649	656	B-Intervention
.	10424316	657	658	O

Enalapril	10424316	659	668	B-Intervention
did	10424316	669	672	O
not	10424316	673	676	O
alter	10424316	677	682	B-Observation
subjective	10424316	683	693	B-Outcome
ratings	10424316	694	701	I-Outcome
.	10424316	702	703	O

Both	10424316	704	708	O
systolic	10424316	709	717	B-Outcome
and	10424316	718	721	I-Outcome
diastolic	10424316	722	731	I-Outcome
blood	10424316	732	737	I-Outcome
pressure	10424316	738	746	I-Outcome
were	10424316	747	751	O
significantly	10424316	752	765	B-Observation
lower	10424316	766	771	I-Observation
after	10424316	772	777	O
administration	10424316	778	792	O
of	10424316	793	795	O
captopril	10424316	796	805	B-Intervention
25	10424316	806	808	I-Intervention
mg	10424316	809	811	I-Intervention
,	10424316	812	813	O
whereas	10424316	814	821	O
blood	10424316	822	827	B-Outcome
pressure	10424316	828	836	I-Outcome
was	10424316	837	840	O
unaffected	10424316	841	851	B-Observation
by	10424316	852	854	O
enalapril	10424316	855	864	B-Intervention
compared	10424316	865	873	O
with	10424316	874	878	O
placebo	10424316	879	886	B-Intervention
.	10424316	887	888	O

CONCLUSION	10424316	889	899	O
Our	10424316	900	903	O
results	10424316	904	911	O
suggest	10424316	912	919	O
that	10424316	920	924	O
central	10424316	925	932	B-Outcome
effects	10424316	933	940	I-Outcome
of	10424316	941	943	O
captopril	10424316	944	953	B-Intervention
and	10424316	954	957	O
enalapril	10424316	958	967	B-Intervention
were	10424316	968	972	O
minor	10424316	973	978	B-Observation
and	10424316	979	982	O
not	10424316	983	986	O
constant	10424316	987	995	B-Observation
in	10424316	996	998	O
young	10424316	999	1004	B-Participant
healthy	10424316	1005	1012	I-Participant
men	10424316	1013	1016	I-Participant
.	10424316	1017	1018	O

Why	10429005	0	3	O
the	10429005	4	7	O
prone	10429005	8	13	B-Intervention
position	10429005	14	22	I-Intervention
is	10429005	23	25	O
a	10429005	26	27	O
risk	10429005	28	32	B-Observation
factor	10429005	33	39	I-Observation
for	10429005	40	43	O
sudden	10429005	44	50	B-Outcome
infant	10429005	51	57	I-Outcome
death	10429005	58	63	I-Outcome
syndrome	10429005	64	72	I-Outcome
.	10429005	73	74	O

INTRODUCTION	10429005	75	87	O
The	10429005	88	91	O
laryngeal	10429005	92	101	O
chemoreflex	10429005	102	113	O
may	10429005	114	117	O
explain	10429005	118	125	O
why	10429005	126	129	O
prone	10429005	130	135	O
sleeping	10429005	136	144	O
increases	10429005	145	154	O
the	10429005	155	158	O
risk	10429005	159	163	O
of	10429005	164	166	O
sudden	10429005	167	173	O
infant	10429005	174	180	O
death	10429005	181	186	O
syndrome	10429005	187	195	O
(	10429005	196	197	O
SIDS	10429005	198	202	O
)	10429005	203	204	O
.	10429005	205	206	O

Swallowing	10429005	207	217	O
and	10429005	218	221	O
arousal	10429005	222	229	O
are	10429005	230	233	O
crucial	10429005	234	241	O
to	10429005	242	244	O
prevent	10429005	245	252	O
laryngeal	10429005	253	262	O
chemoreflex	10429005	263	274	O
stimulation	10429005	275	286	O
.	10429005	287	288	O

Our	10429005	289	292	O
aim	10429005	293	296	O
was	10429005	297	300	O
to	10429005	301	303	O
examine	10429005	304	311	O
these	10429005	312	317	O
reflexes	10429005	318	326	B-Outcome
and	10429005	327	330	O
breathing	10429005	331	340	B-Outcome
responses	10429005	341	350	I-Outcome
in	10429005	351	353	O
healthy	10429005	354	361	B-Participant
neonates	10429005	362	370	I-Participant
after	10429005	371	376	O
pharyngeal	10429005	377	387	B-Intervention
infusion	10429005	388	396	I-Intervention
of	10429005	397	399	I-Intervention
water	10429005	400	405	I-Intervention
in	10429005	406	408	I-Intervention
the	10429005	409	412	I-Intervention
supine	10429005	413	419	I-Intervention
versus	10429005	420	426	O
the	10429005	427	430	O
prone	10429005	431	436	B-Intervention
position	10429005	437	445	I-Intervention
,	10429005	446	447	O
controlling	10429005	448	459	O
for	10429005	460	463	O
sleep	10429005	464	469	O
state	10429005	470	475	O
.	10429005	476	477	O

METHODS	10429005	478	485	O
A	10429005	486	487	O
total	10429005	488	493	O
of	10429005	494	496	O
10	10429005	497	499	B-Participant
term	10429005	500	504	I-Participant
infants	10429005	505	512	I-Participant
were	10429005	513	517	O
recruited	10429005	518	527	O
after	10429005	528	533	O
parental	10429005	534	542	O
consent	10429005	543	550	O
and	10429005	551	554	O
ethics	10429005	555	561	O
approval	10429005	562	570	O
.	10429005	571	572	O

Polygraphic	10429005	573	584	B-Outcome
recordings	10429005	585	595	I-Outcome
included	10429005	596	604	O
sleep	10429005	605	610	B-Outcome
state	10429005	611	616	I-Outcome
(	10429005	617	618	O
active	10429005	619	625	B-Outcome
and	10429005	626	629	I-Outcome
quiet	10429005	630	635	I-Outcome
sleep	10429005	636	641	I-Outcome
by	10429005	642	644	O
electroencephalogram	10429005	645	665	O
,	10429005	666	667	O
eye	10429005	668	671	B-Outcome
movements	10429005	672	681	I-Outcome
,	10429005	682	683	O
breathing	10429005	684	693	B-Outcome
,	10429005	694	695	O
and	10429005	696	699	O
behavior	10429005	700	708	B-Outcome
)	10429005	709	710	O
,	10429005	711	712	O
cardiorespiratory	10429005	713	730	B-Outcome
measurements	10429005	731	743	I-Outcome
(	10429005	744	745	O
nasal	10429005	746	751	B-Outcome
airflow	10429005	752	759	I-Outcome
,	10429005	760	761	O
chest	10429005	762	767	B-Outcome
wall	10429005	768	772	I-Outcome
movements	10429005	773	782	I-Outcome
,	10429005	783	784	O
heart	10429005	785	790	B-Outcome
rate	10429005	791	795	I-Outcome
,	10429005	796	797	O
and	10429005	798	801	O
oxygen	10429005	802	808	B-Outcome
saturation	10429005	809	819	I-Outcome
)	10429005	820	821	O
,	10429005	822	823	O
swallowing	10429005	824	834	B-Outcome
,	10429005	835	836	O
and	10429005	837	840	O
esophageal	10429005	841	851	B-Outcome
activity	10429005	852	860	I-Outcome
(	10429005	861	862	O
solid	10429005	863	868	B-Outcome
state	10429005	869	874	I-Outcome
pressure	10429005	875	883	I-Outcome
catheter	10429005	884	892	I-Outcome
)	10429005	893	894	O
.	10429005	895	896	O

Initial	10429005	897	904	B-Intervention
sleeping	10429005	905	913	I-Intervention
position	10429005	914	922	I-Intervention
was	10429005	923	926	O
assigned	10429005	927	935	O
randomly	10429005	936	944	O
.	10429005	945	946	O

Measurements	10429005	947	959	O
were	10429005	960	964	O
made	10429005	965	969	O
for	10429005	970	973	O
1	10429005	974	975	O
minute	10429005	976	982	O
before	10429005	983	989	O
and	10429005	990	993	O
after	10429005	994	999	O
0.4	10429005	1000	1003	O
mL	10429005	1004	1006	O
of	10429005	1007	1009	O
water	10429005	1010	1015	O
was	10429005	1016	1019	O
instilled	10429005	1020	1029	O
into	10429005	1030	1034	O
the	10429005	1035	1038	O
oropharynx	10429005	1039	1049	O
.	10429005	1050	1051	O

To	10429005	1052	1054	O
detect	10429005	1055	1061	O
a	10429005	1062	1063	O
30	10429005	1064	1066	O
%	10429005	1067	1068	O
decrease	10429005	1069	1077	O
in	10429005	1078	1080	O
swallowing	10429005	1081	1091	O
,	10429005	1092	1093	O
power	10429005	1094	1099	O
analysis	10429005	1100	1108	O
indicated	10429005	1109	1118	O
that	10429005	1119	1123	O
>	10429005	1124	1125	O
/=10	10429005	1126	1130	O
babies	10429005	1131	1137	O
were	10429005	1138	1142	O
required	10429005	1143	1151	O
.	10429005	1152	1153	O

Analysis	10429005	1154	1162	O
,	10429005	1163	1164	O
blinded	10429005	1165	1172	O
to	10429005	1173	1175	O
position	10429005	1176	1184	O
,	10429005	1185	1186	O
was	10429005	1187	1190	O
made	10429005	1191	1195	O
using	10429005	1196	1201	O
nonparametric	10429005	1202	1215	O
statistics	10429005	1216	1226	O
.	10429005	1227	1228	O

RESULTS	10429005	1229	1236	O
Of	10429005	1237	1239	O
the	10429005	1240	1243	O
164	10429005	1244	1247	O
infusions	10429005	1248	1257	O
,	10429005	1258	1259	O
the	10429005	1260	1263	O
most	10429005	1264	1268	O
commonly	10429005	1269	1277	O
evoked	10429005	1278	1284	O
airway	10429005	1285	1291	B-Outcome
protective	10429005	1292	1302	I-Outcome
responses	10429005	1303	1312	I-Outcome
to	10429005	1313	1315	I-Outcome
pharyngeal	10429005	1316	1326	I-Outcome
infusion	10429005	1327	1335	I-Outcome
were	10429005	1336	1340	O
swallowing	10429005	1341	1351	B-Outcome
(	10429005	1352	1353	O
95	10429005	1354	1356	B-Observation
%	10429005	1357	1358	I-Observation
)	10429005	1359	1360	O
and	10429005	1361	1364	O
arousal	10429005	1365	1372	B-Outcome
(	10429005	1373	1374	O
54	10429005	1375	1377	B-Observation
%	10429005	1378	1379	I-Observation
)	10429005	1380	1381	O
.	10429005	1382	1383	O

After	10429005	1384	1389	O
infusion	10429005	1390	1398	O
in	10429005	1399	1401	O
active	10429005	1402	1408	O
sleep	10429005	1409	1414	O
,	10429005	1415	1416	O
there	10429005	1417	1422	O
was	10429005	1423	1426	O
a	10429005	1427	1428	O
significant	10429005	1429	1440	B-Observation
reduction	10429005	1441	1450	I-Observation
in	10429005	1451	1453	O
swallowing	10429005	1454	1464	B-Outcome
and	10429005	1465	1468	O
breathing	10429005	1469	1478	B-Outcome
when	10429005	1479	1483	O
the	10429005	1484	1487	O
prone	10429005	1488	1493	B-Intervention
position	10429005	1494	1502	I-Intervention
was	10429005	1503	1506	O
compared	10429005	1507	1515	O
with	10429005	1516	1520	O
the	10429005	1521	1524	O
supine	10429005	1525	1531	B-Intervention
position	10429005	1532	1540	I-Intervention
(	10429005	1541	1542	O
prone	10429005	1543	1548	B-Intervention
:	10429005	1549	1550	O
21.3	10429005	1551	1555	B-Observation
[	10429005	1556	1557	I-Observation
1.0	10429005	1558	1561	I-Observation
]	10429005	1562	1563	I-Observation
swallows/min	10429005	1564	1576	I-Observation
and	10429005	1577	1580	O
-9.6	10429005	1581	1585	B-Observation
[	10429005	1586	1587	I-Observation
2.1	10429005	1588	1591	I-Observation
]	10429005	1592	1593	I-Observation
breaths/min	10429005	1594	1605	I-Observation
;	10429005	1606	1607	O
and	10429005	1608	1611	O
supine	10429005	1612	1618	B-Intervention
:	10429005	1619	1620	O
32	10429005	1621	1623	B-Observation
(	10429005	1624	1625	I-Observation
2.2	10429005	1626	1629	I-Observation
)	10429005	1630	1631	I-Observation
and	10429005	1632	1635	O
-2	10429005	1636	1638	B-Observation
.	10429005	1639	1640	I-Observation

9	10429005	1641	1642	B-Observation
(	10429005	1643	1644	I-Observation
1.5	10429005	1645	1648	I-Observation
)	10429005	1649	1650	I-Observation
,	10429005	1651	1652	O
respectively	10429005	1653	1665	O
)	10429005	1666	1667	O
.	10429005	1668	1669	O

However	10429005	1670	1677	O
,	10429005	1678	1679	O
there	10429005	1680	1685	O
was	10429005	1686	1689	O
no	10429005	1690	1692	O
difference	10429005	1693	1703	B-Observation
in	10429005	1704	1706	O
the	10429005	1707	1710	O
occurrence	10429005	1711	1721	B-Outcome
of	10429005	1722	1724	I-Outcome
arousal	10429005	1725	1732	I-Outcome
after	10429005	1733	1738	O
water	10429005	1739	1744	O
infusion	10429005	1745	1753	O
.	10429005	1754	1755	O

CONCLUSION	10429005	1756	1766	O
These	10429005	1767	1772	O
data	10429005	1773	1777	O
suggest	10429005	1778	1785	O
that	10429005	1786	1790	O
airway	10429005	1791	1797	B-Outcome
protection	10429005	1798	1808	I-Outcome
is	10429005	1809	1811	O
compromised	10429005	1812	1823	B-Observation
in	10429005	1824	1826	O
the	10429005	1827	1830	O
prone	10429005	1831	1836	B-Intervention
sleeping	10429005	1837	1845	I-Intervention
position	10429005	1846	1854	I-Intervention
during	10429005	1855	1861	O
active	10429005	1862	1868	B-Participant
sleep	10429005	1869	1874	I-Participant
,	10429005	1875	1876	O
even	10429005	1877	1881	O
in	10429005	1882	1884	O
healthy	10429005	1885	1892	B-Participant
infants	10429005	1893	1900	I-Participant
exposed	10429005	1901	1908	O
to	10429005	1909	1911	O
minute	10429005	1912	1918	O
pharyngeal	10429005	1919	1929	O
fluid	10429005	1930	1935	O
volumes	10429005	1936	1943	O
of	10429005	1944	1946	O
0.4	10429005	1947	1950	O
mL	10429005	1951	1953	O
.	10429005	1954	1955	O

This	10429005	1956	1960	O
is	10429005	1961	1963	O
because	10429005	1964	1971	O
swallowing	10429005	1972	1982	B-Outcome
rate	10429005	1983	1987	I-Outcome
is	10429005	1988	1990	O
reduced	10429005	1991	1998	B-Observation
significantly	10429005	1999	2012	I-Observation
,	10429005	2013	2014	O
and	10429005	2015	2018	O
there	10429005	2019	2024	O
is	10429005	2025	2027	O
no	10429005	2028	2030	O
compensatory	10429005	2031	2043	B-Observation
increase	10429005	2044	2052	I-Observation
in	10429005	2053	2055	O
arousal	10429005	2056	2063	B-Outcome
.	10429005	2064	2065	O

The	10429005	2066	2069	O
reduction	10429005	2070	2079	B-Observation
in	10429005	2080	2082	O
airway	10429005	2083	2089	B-Outcome
protective	10429005	2090	2100	I-Outcome
reflexes	10429005	2101	2109	I-Outcome
when	10429005	2110	2114	O
in	10429005	2115	2117	O
the	10429005	2118	2121	O
prone	10429005	2122	2127	B-Intervention
position	10429005	2128	2136	I-Intervention
and	10429005	2137	2140	O
in	10429005	2141	2143	O
active	10429005	2144	2150	O
sleep	10429005	2151	2156	O
may	10429005	2157	2160	O
be	10429005	2161	2163	O
the	10429005	2164	2167	O
mechanism	10429005	2168	2177	O
for	10429005	2178	2181	O
the	10429005	2182	2185	O
increased	10429005	2186	2195	B-Observation
risk	10429005	2196	2200	B-Outcome
of	10429005	2201	2203	I-Outcome
SIDS	10429005	2204	2208	I-Outcome
in	10429005	2209	2211	O
the	10429005	2212	2215	O
prone	10429005	2216	2221	B-Intervention
position	10429005	2222	2230	I-Intervention
.	10429005	2231	2232	O

Preoperative	10439763	0	12	B-Intervention
small-dose	10439763	13	23	I-Intervention
ketamine	10439763	24	32	I-Intervention
has	10439763	33	36	O
no	10439763	37	39	O
preemptive	10439763	40	50	B-Outcome
analgesic	10439763	51	60	I-Outcome
effect	10439763	61	67	I-Outcome
in	10439763	68	70	O
patients	10439763	71	79	O
undergoing	10439763	80	90	O
total	10439763	91	96	B-Participant
mastectomy	10439763	97	107	I-Participant
.	10439763	108	109	O

UNLABELLED	10439763	110	120	O
We	10439763	121	123	O
evaluated	10439763	124	133	O
the	10439763	134	137	O
preemptive	10439763	138	148	B-Outcome
analgesic	10439763	149	158	I-Outcome
effect	10439763	159	165	I-Outcome
of	10439763	166	168	O
a	10439763	169	170	O
small	10439763	171	176	B-Intervention
dose	10439763	177	181	I-Intervention
of	10439763	182	184	I-Intervention
ketamine	10439763	185	193	I-Intervention
given	10439763	194	199	I-Intervention
before	10439763	200	206	I-Intervention
or	10439763	207	209	I-Intervention
immediately	10439763	210	221	I-Intervention
after	10439763	222	227	I-Intervention
surgery	10439763	228	235	I-Intervention
in	10439763	236	238	O
a	10439763	239	240	O
randomized	10439763	241	251	O
,	10439763	252	253	O
double-blinded	10439763	254	268	O
study	10439763	269	274	O
performed	10439763	275	284	O
in	10439763	285	287	O
128	10439763	288	291	O
women	10439763	292	297	B-Participant
undergoing	10439763	298	308	O
total	10439763	309	314	B-Participant
mastectomy	10439763	315	325	I-Participant
.	10439763	326	327	O

Group	10439763	328	333	O
1	10439763	334	335	O
patients	10439763	336	344	O
received	10439763	345	353	O
ketamine	10439763	354	362	B-Intervention
0.15	10439763	363	367	I-Intervention
mg/kg	10439763	368	373	I-Intervention
as	10439763	374	376	I-Intervention
a	10439763	377	378	I-Intervention
5-mL	10439763	379	383	I-Intervention
i.v	10439763	384	387	I-Intervention
.	10439763	388	389	I-Intervention

injection	10439763	390	399	B-Intervention
5	10439763	400	401	I-Intervention
min	10439763	402	405	I-Intervention
before	10439763	406	412	I-Intervention
surgery	10439763	413	420	I-Intervention
and	10439763	421	424	I-Intervention
isotonic	10439763	425	433	I-Intervention
saline	10439763	434	440	I-Intervention
5	10439763	441	442	I-Intervention
mL	10439763	443	445	I-Intervention
i.v	10439763	446	449	I-Intervention
.	10439763	450	451	I-Intervention

at	10439763	452	454	B-Intervention
the	10439763	455	458	I-Intervention
time	10439763	459	463	I-Intervention
of	10439763	464	466	I-Intervention
skin	10439763	467	471	I-Intervention
closure	10439763	472	479	I-Intervention
.	10439763	480	481	O

Group	10439763	482	487	O
2	10439763	488	489	O
received	10439763	490	498	O
5	10439763	499	500	B-Intervention
mL	10439763	501	503	I-Intervention
i.v	10439763	504	507	I-Intervention
.	10439763	508	509	I-Intervention

of	10439763	510	512	B-Intervention
isotonic	10439763	513	521	I-Intervention
saline	10439763	522	528	I-Intervention
,	10439763	529	530	I-Intervention
then	10439763	531	535	I-Intervention
0.15	10439763	536	540	I-Intervention
mg/kg	10439763	541	546	I-Intervention
i.v	10439763	547	550	I-Intervention
.	10439763	551	552	I-Intervention

ketamine	10439763	553	561	B-Intervention
.	10439763	562	563	O

A	10439763	564	565	O
standard	10439763	566	574	O
general	10439763	575	582	O
anesthesia	10439763	583	593	O
procedure	10439763	594	603	O
including	10439763	604	613	O
sufentanil	10439763	614	624	O
was	10439763	625	628	O
used	10439763	629	633	O
.	10439763	634	635	O

In	10439763	636	638	O
the	10439763	639	642	O
recovery	10439763	643	651	O
room	10439763	652	656	O
,	10439763	657	658	O
patient-controlled	10439763	659	677	O
analgesia	10439763	678	687	O
i.v	10439763	688	691	O
.	10439763	692	693	O

morphine	10439763	694	702	O
was	10439763	703	706	O
used	10439763	707	711	O
for	10439763	712	715	O
postoperative	10439763	716	729	O
analgesia	10439763	730	739	O
.	10439763	740	741	O

Postoperative	10439763	742	755	B-Outcome
pain	10439763	756	760	I-Outcome
was	10439763	761	764	O
assessed	10439763	765	773	O
by	10439763	774	776	O
measuring	10439763	777	786	O
morphine	10439763	787	795	B-Outcome
consumption	10439763	796	807	I-Outcome
and	10439763	808	811	O
visual	10439763	812	818	B-Outcome
analog	10439763	819	825	I-Outcome
scale	10439763	826	831	I-Outcome
pain	10439763	832	836	I-Outcome
scores	10439763	837	843	I-Outcome
.	10439763	844	845	O

No	10439763	846	848	O
significant	10439763	849	860	B-Observation
intergroup	10439763	861	871	I-Observation
differences	10439763	872	883	I-Observation
were	10439763	884	888	O
seen	10439763	889	893	O
in	10439763	894	896	O
the	10439763	897	900	O
pain	10439763	901	905	B-Outcome
scores	10439763	906	912	I-Outcome
.	10439763	913	914	O

Patient-controlled	10439763	915	933	B-Outcome
analgesia	10439763	934	943	I-Outcome
morphine	10439763	944	952	I-Outcome
consumption	10439763	953	964	I-Outcome
was	10439763	965	968	O
lower	10439763	969	974	B-Observation
during	10439763	975	981	O
the	10439763	982	985	O
first	10439763	986	991	O
2	10439763	992	993	O
h	10439763	994	995	O
after	10439763	996	1001	O
surgery	10439763	1002	1009	O
in	10439763	1010	1012	O
patients	10439763	1013	1021	O
given	10439763	1022	1027	O
ketamine	10439763	1028	1036	B-Intervention
at	10439763	1037	1039	I-Intervention
the	10439763	1040	1043	I-Intervention
time	10439763	1044	1048	I-Intervention
of	10439763	1049	1051	I-Intervention
skin	10439763	1052	1056	I-Intervention
closure	10439763	1057	1064	I-Intervention
.	10439763	1065	1066	O

No	10439763	1067	1069	B-Count
patient	10439763	1070	1077	I-Count
complained	10439763	1078	1088	O
of	10439763	1089	1091	O
hallucinations	10439763	1092	1106	B-Outcome
or	10439763	1107	1109	O
nightmares	10439763	1110	1120	B-Outcome
.	10439763	1121	1122	O

The	10439763	1123	1126	O
incidence	10439763	1127	1136	B-Outcome
of	10439763	1137	1139	I-Outcome
adverse	10439763	1140	1147	I-Outcome
effects	10439763	1148	1155	I-Outcome
was	10439763	1156	1159	O
not	10439763	1160	1163	O
different	10439763	1164	1173	B-Observation
between	10439763	1174	1181	B-Intervention
the	10439763	1182	1185	I-Intervention
two	10439763	1186	1189	I-Intervention
groups	10439763	1190	1196	I-Intervention
.	10439763	1197	1198	O

In	10439763	1199	1201	O
conclusion	10439763	1202	1212	O
,	10439763	1213	1214	O
administering	10439763	1215	1228	O
ketamine	10439763	1229	1237	B-Intervention
at	10439763	1238	1240	I-Intervention
the	10439763	1241	1244	I-Intervention
end	10439763	1245	1248	I-Intervention
of	10439763	1249	1251	I-Intervention
surgery	10439763	1252	1259	I-Intervention
is	10439763	1260	1262	O
more	10439763	1263	1267	B-Observation
effective	10439763	1268	1277	I-Observation
in	10439763	1278	1280	I-Observation
reducing	10439763	1281	1289	I-Observation
morphine	10439763	1290	1298	B-Outcome
consumption	10439763	1299	1310	I-Outcome
than	10439763	1311	1315	O
it	10439763	1316	1318	O
is	10439763	1319	1321	O
when	10439763	1322	1326	O
given	10439763	1327	1332	B-Intervention
before	10439763	1333	1339	I-Intervention
surgery	10439763	1340	1347	I-Intervention
.	10439763	1348	1349	O

IMPLICATIONS	10439763	1350	1362	O
We	10439763	1363	1365	O
administered	10439763	1366	1378	O
the	10439763	1379	1382	O
same	10439763	1383	1387	B-Intervention
small	10439763	1388	1393	I-Intervention
dose	10439763	1394	1398	I-Intervention
of	10439763	1399	1401	I-Intervention
ketamine	10439763	1402	1410	I-Intervention
before	10439763	1411	1417	O
or	10439763	1418	1420	O
after	10439763	1421	1426	O
surgery	10439763	1427	1434	O
.	10439763	1435	1436	O

The	10439763	1437	1440	O
preoperative	10439763	1441	1453	B-Intervention
administration	10439763	1454	1468	I-Intervention
of	10439763	1469	1471	I-Intervention
0.15	10439763	1472	1476	I-Intervention
mg/kg	10439763	1477	1482	I-Intervention
ketamine	10439763	1483	1491	I-Intervention
in	10439763	1492	1494	O
patients	10439763	1495	1503	O
undergoing	10439763	1504	1514	O
total	10439763	1515	1520	B-Participant
mastectomy	10439763	1521	1531	I-Participant
did	10439763	1532	1535	O
not	10439763	1536	1539	O
elicit	10439763	1540	1546	B-Observation
a	10439763	1547	1548	O
preemptive	10439763	1549	1559	B-Outcome
analgesic	10439763	1560	1569	I-Outcome
effect	10439763	1570	1576	I-Outcome
.	10439763	1577	1578	O

Ketamine	10439763	1579	1587	B-Intervention
given	10439763	1588	1593	I-Intervention
at	10439763	1594	1596	I-Intervention
closure	10439763	1597	1604	I-Intervention
reduced	10439763	1605	1612	B-Observation
the	10439763	1613	1616	O
patient-controlled	10439763	1617	1635	B-Outcome
analgesia	10439763	1636	1645	I-Outcome
morphine	10439763	1646	1654	I-Outcome
requirement	10439763	1655	1666	I-Outcome
in	10439763	1667	1669	O
the	10439763	1670	1673	O
first	10439763	1674	1679	O
2	10439763	1680	1681	O
h	10439763	1682	1683	O
after	10439763	1684	1689	O
surgery	10439763	1690	1697	O
.	10439763	1698	1699	O

Phenobarbital	10441604	0	13	B-Intervention
compared	10441604	14	22	O
with	10441604	23	27	O
phenytoin	10441604	28	37	B-Intervention
for	10441604	38	41	O
the	10441604	42	45	O
treatment	10441604	46	55	O
of	10441604	56	58	O
neonatal	10441604	59	67	B-Participant
seizures	10441604	68	76	I-Participant
.	10441604	77	78	O

BACKGROUND	10441604	79	89	O
Seizures	10441604	90	98	O
occur	10441604	99	104	O
in	10441604	105	107	O
1	10441604	108	109	O
to	10441604	110	112	O
2	10441604	113	114	O
percent	10441604	115	122	O
of	10441604	123	125	O
neonates	10441604	126	134	O
admitted	10441604	135	143	O
to	10441604	144	146	O
an	10441604	147	149	O
intensive	10441604	150	159	O
care	10441604	160	164	O
unit	10441604	165	169	O
.	10441604	170	171	O

The	10441604	172	175	O
treatment	10441604	176	185	O
is	10441604	186	188	O
usually	10441604	189	196	O
with	10441604	197	201	O
either	10441604	202	208	O
phenobarbital	10441604	209	222	O
or	10441604	223	225	O
phenytoin	10441604	226	235	O
,	10441604	236	237	O
but	10441604	238	241	O
the	10441604	242	245	O
efficacy	10441604	246	254	O
of	10441604	255	257	O
the	10441604	258	261	O
two	10441604	262	265	O
drugs	10441604	266	271	O
has	10441604	272	275	O
not	10441604	276	279	O
been	10441604	280	284	O
compared	10441604	285	293	O
directly	10441604	294	302	O
.	10441604	303	304	O

METHODS	10441604	305	312	O
From	10441604	313	317	O
1990	10441604	318	322	O
to	10441604	323	325	O
1995	10441604	326	330	O
,	10441604	331	332	O
we	10441604	333	335	O
studied	10441604	336	343	O
59	10441604	344	346	O
neonates	10441604	347	355	B-Participant
with	10441604	356	360	O
seizures	10441604	361	369	B-Participant
that	10441604	370	374	O
were	10441604	375	379	O
confirmed	10441604	380	389	O
by	10441604	390	392	O
electroencephalography	10441604	393	415	O
.	10441604	416	417	O

The	10441604	418	421	O
neonates	10441604	422	430	B-Participant
were	10441604	431	435	O
randomly	10441604	436	444	O
assigned	10441604	445	453	O
to	10441604	454	456	O
receive	10441604	457	464	O
either	10441604	465	471	O
phenobarbital	10441604	472	485	B-Intervention
or	10441604	486	488	O
phenytoin	10441604	489	498	B-Intervention
intravenously	10441604	499	512	O
,	10441604	513	514	O
at	10441604	515	517	O
doses	10441604	518	523	O
sufficient	10441604	524	534	O
to	10441604	535	537	O
achieve	10441604	538	545	O
free	10441604	546	550	O
plasma	10441604	551	557	O
concentrations	10441604	558	572	O
of	10441604	573	575	O
25	10441604	576	578	O
microg	10441604	579	585	O
per	10441604	586	589	O
milliliter	10441604	590	600	O
for	10441604	601	604	O
phenobarbital	10441604	605	618	B-Intervention
and	10441604	619	622	O
3	10441604	623	624	O
microg	10441604	625	631	O
per	10441604	632	635	O
milliliter	10441604	636	646	O
for	10441604	647	650	O
phenytoin	10441604	651	660	B-Intervention
.	10441604	661	662	O

Neonates	10441604	663	671	B-Participant
whose	10441604	672	677	O
seizures	10441604	678	686	B-Participant
were	10441604	687	691	O
not	10441604	692	695	O
controlled	10441604	696	706	O
by	10441604	707	709	O
the	10441604	710	713	O
assigned	10441604	714	722	O
drug	10441604	723	727	O
were	10441604	728	732	O
then	10441604	733	737	O
treated	10441604	738	745	O
with	10441604	746	750	O
both	10441604	751	755	O
drugs	10441604	756	761	O
.	10441604	762	763	O

Seizure	10441604	764	771	B-Outcome
control	10441604	772	779	I-Outcome
was	10441604	780	783	O
assessed	10441604	784	792	O
by	10441604	793	795	O
electroencephalographic	10441604	796	819	O
criteria	10441604	820	828	O
.	10441604	829	830	O

RESULTS	10441604	831	838	O
Seizures	10441604	839	847	B-Outcome
were	10441604	848	852	I-Outcome
controlled	10441604	853	863	I-Outcome
in	10441604	864	866	O
13	10441604	867	869	B-Count
of	10441604	870	872	I-Count
the	10441604	873	876	I-Count
30	10441604	877	879	I-Count
neonates	10441604	880	888	I-Count
assigned	10441604	889	897	O
to	10441604	898	900	O
receive	10441604	901	908	O
phenobarbital	10441604	909	922	B-Intervention
(	10441604	923	924	O
43	10441604	925	927	B-Count
percent	10441604	928	935	I-Count
)	10441604	936	937	O
and	10441604	938	941	O
13	10441604	942	944	B-Count
of	10441604	945	947	I-Count
the	10441604	948	951	I-Count
29	10441604	952	954	I-Count
neonates	10441604	955	963	I-Count
assigned	10441604	964	972	O
to	10441604	973	975	O
receive	10441604	976	983	O
phenytoin	10441604	984	993	B-Intervention
(	10441604	994	995	O
45	10441604	996	998	B-Count
percent	10441604	999	1006	I-Count
;	10441604	1007	1008	O
P=1.00	10441604	1009	1015	O
)	10441604	1016	1017	O
.	10441604	1018	1019	O

When	10441604	1020	1024	O
combined	10441604	1025	1033	O
treatment	10441604	1034	1043	O
is	10441604	1044	1046	O
considered	10441604	1047	1057	O
,	10441604	1058	1059	O
seizure	10441604	1060	1067	B-Outcome
control	10441604	1068	1075	I-Outcome
was	10441604	1076	1079	O
achieved	10441604	1080	1088	O
in	10441604	1089	1091	O
17	10441604	1092	1094	B-Count
(	10441604	1095	1096	I-Count
57	10441604	1097	1099	I-Count
percent	10441604	1100	1107	I-Count
)	10441604	1108	1109	I-Count
of	10441604	1110	1112	I-Count
the	10441604	1113	1116	I-Count
neonates	10441604	1117	1125	I-Count
assigned	10441604	1126	1134	O
to	10441604	1135	1137	O
receive	10441604	1138	1145	O
phenobarbital	10441604	1146	1159	B-Intervention
first	10441604	1160	1165	O
and	10441604	1166	1169	O
18	10441604	1170	1172	B-Count
(	10441604	1173	1174	I-Count
62	10441604	1175	1177	I-Count
percent	10441604	1178	1185	I-Count
)	10441604	1186	1187	I-Count
of	10441604	1188	1190	I-Count
those	10441604	1191	1196	I-Count
assigned	10441604	1197	1205	O
to	10441604	1206	1208	O
receive	10441604	1209	1216	O
phenytoin	10441604	1217	1226	B-Intervention
first	10441604	1227	1232	O
(	10441604	1233	1234	O
P=0.67	10441604	1235	1241	O
)	10441604	1242	1243	O
.	10441604	1244	1245	O

The	10441604	1246	1249	O
severity	10441604	1250	1258	B-Participant
of	10441604	1259	1261	I-Participant
the	10441604	1262	1265	I-Participant
seizures	10441604	1266	1274	I-Participant
was	10441604	1275	1278	O
a	10441604	1279	1280	O
stronger	10441604	1281	1289	B-Observation
predictor	10441604	1290	1299	I-Observation
of	10441604	1300	1302	O
the	10441604	1303	1306	O
success	10441604	1307	1314	B-Outcome
of	10441604	1315	1317	I-Outcome
treatment	10441604	1318	1327	I-Outcome
than	10441604	1328	1332	O
was	10441604	1333	1336	O
the	10441604	1337	1340	O
assigned	10441604	1341	1349	B-Intervention
agent	10441604	1350	1355	I-Intervention
.	10441604	1356	1357	O

Neonates	10441604	1358	1366	B-Participant
with	10441604	1367	1371	O
mild	10441604	1372	1376	B-Participant
seizures	10441604	1377	1385	I-Participant
or	10441604	1386	1388	O
with	10441604	1389	1393	O
seizures	10441604	1394	1402	B-Participant
that	10441604	1403	1407	I-Participant
were	10441604	1408	1412	I-Participant
decreasing	10441604	1413	1423	I-Participant
in	10441604	1424	1426	I-Participant
severity	10441604	1427	1435	I-Participant
before	10441604	1436	1442	O
treatment	10441604	1443	1452	O
were	10441604	1453	1457	O
more	10441604	1458	1462	B-Observation
likely	10441604	1463	1469	I-Observation
to	10441604	1470	1472	O
have	10441604	1473	1477	O
their	10441604	1478	1483	O
seizures	10441604	1484	1492	B-Outcome
end	10441604	1493	1496	I-Outcome
,	10441604	1497	1498	O
regardless	10441604	1499	1509	O
of	10441604	1510	1512	O
the	10441604	1513	1516	O
treatment	10441604	1517	1526	B-Intervention
assignment	10441604	1527	1537	I-Intervention
.	10441604	1538	1539	O

CONCLUSIONS	10441604	1540	1551	O
Phenobarbital	10441604	1552	1565	B-Intervention
and	10441604	1566	1569	O
phenytoin	10441604	1570	1579	B-Intervention
are	10441604	1580	1583	O
equally	10441604	1584	1591	B-Observation
but	10441604	1592	1595	I-Observation
incompletely	10441604	1596	1608	I-Observation
effective	10441604	1609	1618	I-Observation
as	10441604	1619	1621	O
anticonvulsants	10441604	1622	1637	B-Outcome
in	10441604	1638	1640	O
neonates	10441604	1641	1649	B-Participant
.	10441604	1650	1651	O

With	10441604	1652	1656	O
either	10441604	1657	1663	B-Intervention
drug	10441604	1664	1668	I-Intervention
given	10441604	1669	1674	O
alone	10441604	1675	1680	O
,	10441604	1681	1682	O
the	10441604	1683	1686	O
seizures	10441604	1687	1695	B-Outcome
were	10441604	1696	1700	I-Outcome
controlled	10441604	1701	1711	I-Outcome
in	10441604	1712	1714	O
fewer	10441604	1715	1720	B-Count
than	10441604	1721	1725	I-Count
half	10441604	1726	1730	I-Count
of	10441604	1731	1733	I-Count
the	10441604	1734	1737	I-Count
neonates	10441604	1738	1746	I-Count
.	10441604	1747	1748	O

Effects	10442506	0	7	O
of	10442506	8	10	O
amlodipine	10442506	11	21	B-Intervention
and	10442506	22	25	O
enalapril	10442506	26	35	B-Intervention
on	10442506	36	38	O
platelet	10442506	39	47	B-Outcome
function	10442506	48	56	I-Outcome
in	10442506	57	59	O
patients	10442506	60	68	O
with	10442506	69	73	O
mild	10442506	74	78	B-Participant
to	10442506	79	81	I-Participant
moderate	10442506	82	90	I-Participant
hypertension	10442506	91	103	I-Participant
.	10442506	104	105	O

OBJECTIVE	10442506	106	115	O
The	10442506	116	119	O
aim	10442506	120	123	O
of	10442506	124	126	O
this	10442506	127	131	O
study	10442506	132	137	O
was	10442506	138	141	O
to	10442506	142	144	O
compare	10442506	145	152	O
the	10442506	153	156	O
effect	10442506	157	163	O
of	10442506	164	166	O
amlodipine	10442506	167	177	B-Intervention
and	10442506	178	181	O
enalapril	10442506	182	191	B-Intervention
on	10442506	192	194	O
platelet	10442506	195	203	B-Outcome
aggregation	10442506	204	215	I-Outcome
,	10442506	216	217	O
and	10442506	218	221	O
platelet	10442506	222	230	B-Outcome
production	10442506	231	241	I-Outcome
of	10442506	242	244	I-Outcome
malondialdehyde	10442506	245	260	I-Outcome
in	10442506	261	263	O
patients	10442506	264	272	O
with	10442506	273	277	O
mild	10442506	278	282	B-Participant
to	10442506	283	285	I-Participant
moderate	10442506	286	294	I-Participant
arterial	10442506	295	303	I-Participant
hypertension	10442506	304	316	I-Participant
.	10442506	317	318	O

PATIENTS	10442506	319	327	O
AND	10442506	328	331	O
METHODS	10442506	332	339	O
A	10442506	340	341	O
parallel	10442506	342	350	O
,	10442506	351	352	O
double-blind	10442506	353	365	O
,	10442506	366	367	O
placebo-controlled	10442506	368	386	O
study	10442506	387	392	O
was	10442506	393	396	O
carried	10442506	397	404	O
out	10442506	405	408	O
in	10442506	409	411	O
24	10442506	412	414	O
patients	10442506	415	423	O
(	10442506	424	425	O
2	10442506	426	427	O
groups	10442506	428	434	O
of	10442506	435	437	O
12	10442506	438	440	O
patients	10442506	441	449	O
each	10442506	450	454	O
)	10442506	455	456	O
.	10442506	457	458	O

Initially	10442506	459	468	O
all	10442506	469	472	O
patients	10442506	473	481	O
received	10442506	482	490	O
placebo	10442506	491	498	B-Intervention
for	10442506	499	502	O
four	10442506	503	507	O
weeks	10442506	508	513	O
;	10442506	514	515	O
then	10442506	516	520	O
amlodipine	10442506	521	531	B-Intervention
,	10442506	532	533	O
5	10442506	534	535	O
mg	10442506	536	538	O
daily	10442506	539	544	O
or	10442506	545	547	O
enalapril	10442506	548	557	B-Intervention
20	10442506	558	560	O
mg	10442506	561	563	O
daily	10442506	564	569	O
taken	10442506	570	575	O
once	10442506	576	580	O
a	10442506	581	582	O
day	10442506	583	586	O
at	10442506	587	589	O
7	10442506	590	591	O
am	10442506	592	594	O
.	10442506	595	596	O

Dosage	10442506	597	603	O
was	10442506	604	607	O
doubled	10442506	608	615	O
after	10442506	616	621	O
4	10442506	622	623	O
weeks	10442506	624	629	O
when	10442506	630	634	O
diastolic	10442506	635	644	O
blood	10442506	645	650	O
pressure	10442506	651	659	O
was	10442506	660	663	O
>	10442506	664	665	O
90	10442506	666	668	O
mmHg	10442506	669	673	O
in	10442506	674	676	O
sitting	10442506	677	684	O
position	10442506	685	693	O
,	10442506	694	695	O
the	10442506	696	699	O
treatment	10442506	700	709	O
was	10442506	710	713	O
continued	10442506	714	723	O
for	10442506	724	727	O
12	10442506	728	730	O
weeks	10442506	731	736	O
.	10442506	737	738	O

At	10442506	739	741	O
the	10442506	742	745	O
end	10442506	746	749	O
of	10442506	750	752	O
placebo	10442506	753	760	B-Intervention
and	10442506	761	764	O
active	10442506	765	771	B-Intervention
phases	10442506	772	778	I-Intervention
a	10442506	779	780	O
platelet	10442506	781	789	B-Outcome
aggregation	10442506	790	801	I-Outcome
test	10442506	802	806	I-Outcome
,	10442506	807	808	O
using	10442506	809	814	O
adenosine	10442506	815	824	O
diphosphate	10442506	825	836	O
,	10442506	837	838	O
collagen	10442506	839	847	O
and	10442506	848	851	O
adrenaline	10442506	852	862	O
,	10442506	863	864	O
and	10442506	865	868	O
a	10442506	869	870	O
platelet	10442506	871	879	B-Outcome
malondialdehyde	10442506	880	895	I-Outcome
production	10442506	896	906	I-Outcome
test	10442506	907	911	I-Outcome
,	10442506	912	913	O
either	10442506	914	920	O
in	10442506	921	923	O
basal	10442506	924	929	O
conditions	10442506	930	940	O
(	10442506	941	942	O
MDA-basal	10442506	943	952	O
)	10442506	953	954	O
and	10442506	955	958	O
after	10442506	959	964	O
the	10442506	965	968	O
stimulation	10442506	969	980	O
of	10442506	981	983	O
arachidonic	10442506	984	995	O
acid	10442506	996	1000	O
pathway	10442506	1001	1008	O
by	10442506	1009	1011	O
adding	10442506	1012	1018	O
ethylmaleimide	10442506	1019	1033	O
(	10442506	1034	1035	O
MDA-activated	10442506	1036	1049	O
)	10442506	1050	1051	O
were	10442506	1052	1056	O
carried	10442506	1057	1064	O
out	10442506	1065	1068	O
.	10442506	1069	1070	O

RESULTS	10442506	1071	1078	O
Blood	10442506	1079	1084	B-Outcome
pressure	10442506	1085	1093	I-Outcome
was	10442506	1094	1097	O
reduced	10442506	1098	1105	B-Observation
by	10442506	1106	1108	O
both	10442506	1109	1113	B-Intervention
agents	10442506	1114	1120	I-Intervention
,	10442506	1121	1122	O
enalapril	10442506	1123	1132	B-Intervention
and	10442506	1133	1136	O
amlodipine	10442506	1137	1147	B-Intervention
.	10442506	1148	1149	O

Enalapril	10442506	1150	1159	B-Intervention
controlled	10442506	1160	1170	B-Outcome
58.3	10442506	1171	1175	B-Count
%	10442506	1176	1177	I-Count
of	10442506	1178	1180	I-Count
hypertensive	10442506	1181	1193	I-Count
patients	10442506	1194	1202	I-Count
with	10442506	1203	1207	O
an	10442506	1208	1210	O
average	10442506	1211	1218	B-Outcome
dosage	10442506	1219	1225	I-Outcome
of	10442506	1226	1228	O
31.7	10442506	1229	1233	B-Observation
mg/daily	10442506	1234	1242	I-Observation
.	10442506	1243	1244	O

Amlodipine	10442506	1245	1255	B-Intervention
controlled	10442506	1256	1266	B-Outcome
75	10442506	1267	1269	B-Count
%	10442506	1270	1271	I-Count
of	10442506	1272	1274	I-Count
patients	10442506	1275	1283	I-Count
with	10442506	1284	1288	O
a	10442506	1289	1290	O
dosage	10442506	1291	1297	B-Outcome
of	10442506	1298	1300	O
7.1	10442506	1301	1304	B-Observation
mg/daily	10442506	1305	1313	I-Observation
.	10442506	1314	1315	O

Platelet	10442506	1316	1324	B-Outcome
aggregation	10442506	1325	1336	I-Outcome
was	10442506	1337	1340	O
reduced	10442506	1341	1348	B-Observation
by	10442506	1349	1351	O
amlodipine	10442506	1352	1362	B-Intervention
in	10442506	1363	1365	O
15.9	10442506	1366	1370	B-Count
%	10442506	1371	1372	I-Count
for	10442506	1373	1376	O
ADP	10442506	1377	1380	B-Outcome
(	10442506	1381	1382	O
10	10442506	1383	1385	O
microM	10442506	1386	1392	O
)	10442506	1393	1394	O
;	10442506	1395	1396	O
17.4	10442506	1397	1401	B-Count
%	10442506	1402	1403	I-Count
for	10442506	1404	1407	O
collagen	10442506	1408	1416	B-Outcome
(	10442506	1417	1418	O
2	10442506	1419	1420	B-Observation
microg/ml	10442506	1421	1430	I-Observation
)	10442506	1431	1432	O
and	10442506	1433	1436	O
19.9	10442506	1437	1441	B-Count
%	10442506	1442	1443	I-Count
for	10442506	1444	1447	O
adrenaline	10442506	1448	1458	B-Outcome
(	10442506	1459	1460	O
2	10442506	1461	1462	B-Observation
microM	10442506	1463	1469	I-Observation
)	10442506	1470	1471	O
(	10442506	1472	1473	O
p	10442506	1474	1475	O
<	10442506	1476	1477	O
0.025	10442506	1478	1483	O
)	10442506	1484	1485	O
.	10442506	1486	1487	O

Meanwhile	10442506	1488	1497	O
enalapril	10442506	1498	1507	B-Intervention
slightly	10442506	1508	1516	B-Observation
increased	10442506	1517	1526	I-Observation
platelet	10442506	1527	1535	B-Outcome
aggregation	10442506	1536	1547	I-Outcome
by	10442506	1548	1550	O
6.7	10442506	1551	1554	B-Observation
%	10442506	1555	1556	I-Observation
,	10442506	1557	1558	O
1.3	10442506	1559	1562	B-Observation
%	10442506	1563	1564	I-Observation
and	10442506	1565	1568	O
5.6	10442506	1569	1572	B-Observation
%	10442506	1573	1574	I-Observation
for	10442506	1575	1578	O
the	10442506	1579	1582	O
three	10442506	1583	1588	B-Outcome
agents	10442506	1589	1595	I-Outcome
,	10442506	1596	1597	O
respectively	10442506	1598	1610	O
(	10442506	1611	1612	O
p	10442506	1613	1614	O
>	10442506	1615	1616	O
0.05	10442506	1617	1621	O
,	10442506	1622	1623	O
ns	10442506	1624	1626	O
)	10442506	1627	1628	O
.	10442506	1629	1630	O

Malondialdehyde	10442506	1631	1646	B-Outcome
was	10442506	1647	1650	O
reduced	10442506	1651	1658	B-Observation
by	10442506	1659	1661	O
amlodipine	10442506	1662	1672	B-Intervention
in	10442506	1673	1675	O
45.33	10442506	1676	1681	B-Observation
%	10442506	1682	1683	I-Observation
(	10442506	1684	1685	O
p	10442506	1686	1687	O
<	10442506	1688	1689	O
0.05	10442506	1690	1694	O
)	10442506	1695	1696	O
for	10442506	1697	1700	O
MDA-basal	10442506	1701	1710	B-Outcome
;	10442506	1711	1712	O
3.76	10442506	1713	1717	B-Count
%	10442506	1718	1719	I-Count
(	10442506	1720	1721	O
p	10442506	1722	1723	O
>	10442506	1724	1725	O
0.05	10442506	1726	1730	O
)	10442506	1731	1732	O
for	10442506	1733	1736	O
MDA-activated	10442506	1737	1750	B-Outcome
;	10442506	1751	1752	O
and	10442506	1753	1756	O
the	10442506	1757	1760	O
ratio	10442506	1761	1766	B-Outcome
MDA-basal	10442506	1767	1776	I-Outcome
:	10442506	1777	1778	I-Outcome
MDA-activated	10442506	1779	1792	I-Outcome
in	10442506	1793	1795	O
36.79	10442506	1796	1801	B-Count
%	10442506	1802	1803	I-Count
(	10442506	1804	1805	O
p	10442506	1806	1807	O
<	10442506	1808	1809	O
0.005	10442506	1810	1815	O
)	10442506	1816	1817	O
.	10442506	1818	1819	O

Meanwhile	10442506	1820	1829	O
enalapril	10442506	1830	1839	B-Intervention
increased	10442506	1840	1849	B-Observation
MDA-basal	10442506	1850	1859	B-Outcome
in	10442506	1860	1862	O
2.89	10442506	1863	1867	B-Count
%	10442506	1868	1869	I-Count
;	10442506	1870	1871	O
MDA-activated	10442506	1872	1885	B-Outcome
in	10442506	1886	1888	O
3.58	10442506	1889	1893	B-Count
%	10442506	1894	1895	I-Count
and	10442506	1896	1899	O
reduced	10442506	1900	1907	B-Observation
the	10442506	1908	1911	O
ratio	10442506	1912	1917	B-Outcome
MDA-basal	10442506	1918	1927	I-Outcome
:	10442506	1928	1929	I-Outcome
MDA-activated	10442506	1930	1943	I-Outcome
,	10442506	1944	1945	O
in	10442506	1946	1948	O
10.34	10442506	1949	1954	B-Count
%	10442506	1955	1956	I-Count
(	10442506	1957	1958	O
p	10442506	1959	1960	O
>	10442506	1961	1962	O
0.05	10442506	1963	1967	O
)	10442506	1968	1969	O
.	10442506	1970	1971	O

CONCLUSION	10442506	1972	1982	O
Both	10442506	1983	1987	B-Intervention
agents	10442506	1988	1994	I-Intervention
,	10442506	1995	1996	O
enalapril	10442506	1997	2006	B-Intervention
and	10442506	2007	2010	O
amlodipine	10442506	2011	2021	B-Intervention
,	10442506	2022	2023	O
reduced	10442506	2024	2031	B-Observation
blood	10442506	2032	2037	B-Outcome
pressure	10442506	2038	2046	I-Outcome
,	10442506	2047	2048	O
but	10442506	2049	2052	O
only	10442506	2053	2057	O
amlodipine	10442506	2058	2068	B-Intervention
reduced	10442506	2069	2076	B-Observation
platelet	10442506	2077	2085	B-Outcome
aggregation	10442506	2086	2097	I-Outcome
and	10442506	2098	2101	O
platelet	10442506	2102	2110	B-Outcome
production	10442506	2111	2121	I-Outcome
of	10442506	2122	2124	I-Outcome
malondialdehyde	10442506	2125	2140	I-Outcome
,	10442506	2141	2142	O
indicating	10442506	2143	2153	O
its	10442506	2154	2157	O
action	10442506	2158	2164	O
on	10442506	2165	2167	O
the	10442506	2168	2171	O
arachidonic	10442506	2172	2183	O
acid	10442506	2184	2188	O
metabolic	10442506	2189	2198	O
pathway	10442506	2199	2206	O
.	10442506	2207	2208	O

Continued	10443725	0	9	B-Observation
improvement	10443725	10	21	I-Observation
in	10443725	22	24	O
pressure-flow	10443725	25	38	B-Outcome
parameters	10443725	39	49	I-Outcome
in	10443725	50	52	O
men	10443725	53	56	B-Participant
receiving	10443725	57	66	O
finasteride	10443725	67	78	B-Intervention
for	10443725	79	82	O
2	10443725	83	84	O
years	10443725	85	90	O
.	10443725	91	92	O

Finasteride	10443725	93	104	O
Urodynamics	10443725	105	116	O
Study	10443725	117	122	O
Group	10443725	123	128	O
.	10443725	129	130	O

OBJECTIVES	10443725	131	141	O
To	10443725	142	144	O
assess	10443725	145	151	O
the	10443725	152	155	O
long-term	10443725	156	165	B-Observation
effects	10443725	166	173	I-Observation
of	10443725	174	176	O
finasteride	10443725	177	188	B-Intervention
on	10443725	189	191	O
pressure-flow	10443725	192	205	B-Outcome
parameters	10443725	206	216	I-Outcome
in	10443725	217	219	O
men	10443725	220	223	B-Participant
with	10443725	224	228	O
urodynamically	10443725	229	243	B-Participant
documented	10443725	244	254	I-Participant
bladder	10443725	255	262	I-Participant
outflow	10443725	263	270	I-Participant
obstruction	10443725	271	282	I-Participant
(	10443725	283	284	I-Participant
BOO	10443725	285	288	I-Participant
)	10443725	289	290	I-Participant
.	10443725	291	292	O

METHODS	10443725	293	300	O
One	10443725	301	304	O
hundred	10443725	305	312	O
twenty-one	10443725	313	323	O
men	10443725	324	327	B-Participant
with	10443725	328	332	O
benign	10443725	333	339	B-Participant
prostatic	10443725	340	349	I-Participant
enlargement	10443725	350	361	I-Participant
(	10443725	362	363	I-Participant
BPE	10443725	364	367	I-Participant
)	10443725	368	369	I-Participant
and	10443725	370	373	O
lower	10443725	374	379	B-Participant
urinary	10443725	380	387	I-Participant
tract	10443725	388	393	I-Participant
symptoms	10443725	394	402	I-Participant
(	10443725	403	404	I-Participant
LUTS	10443725	405	409	I-Participant
)	10443725	410	411	I-Participant
underwent	10443725	412	421	O
a	10443725	422	423	O
pressure-flow	10443725	424	437	B-Participant
study	10443725	438	443	I-Participant
(	10443725	444	445	I-Participant
PFS	10443725	446	449	I-Participant
)	10443725	450	451	I-Participant
at	10443725	452	454	O
1	10443725	455	456	O
of	10443725	457	459	O
11	10443725	460	462	O
clinical	10443725	463	471	O
centers	10443725	472	479	O
.	10443725	480	481	O

The	10443725	482	485	O
PFS	10443725	486	489	O
technique	10443725	490	499	O
was	10443725	500	503	O
standardized	10443725	504	516	O
,	10443725	517	518	O
and	10443725	519	522	O
all	10443725	523	526	O
tracings	10443725	527	535	O
were	10443725	536	540	O
read	10443725	541	545	O
by	10443725	546	548	O
a	10443725	549	550	O
single	10443725	551	557	O
reader	10443725	558	564	O
unaware	10443725	565	572	O
of	10443725	573	575	O
the	10443725	576	579	O
treatment	10443725	580	589	O
group	10443725	590	595	O
.	10443725	596	597	O

Patients	10443725	598	606	O
who	10443725	607	610	O
were	10443725	611	615	O
obstructed	10443725	616	626	B-Participant
according	10443725	627	636	O
to	10443725	637	639	O
a	10443725	640	641	O
modified	10443725	642	650	B-Participant
Abrams-Griffiths	10443725	651	667	I-Participant
nomogram	10443725	668	676	I-Participant
were	10443725	677	681	O
randomized	10443725	682	692	O
to	10443725	693	695	O
5	10443725	696	697	O
mg	10443725	698	700	O
finasteride	10443725	701	712	B-Intervention
(	10443725	713	714	O
n	10443725	715	716	O
=	10443725	717	718	O
81	10443725	719	721	O
)	10443725	722	723	O
or	10443725	724	726	O
placebo	10443725	727	734	B-Intervention
(	10443725	735	736	O
n	10443725	737	738	O
=	10443725	739	740	O
40	10443725	741	743	O
)	10443725	744	745	O
for	10443725	746	749	O
12	10443725	750	752	O
months	10443725	753	759	O
;	10443725	760	761	O
all	10443725	762	765	O
patients	10443725	766	774	O
continuing	10443725	775	785	O
into	10443725	786	790	O
an	10443725	791	793	O
open	10443725	794	798	O
extension	10443725	799	808	O
received	10443725	809	817	O
finasteride	10443725	818	829	B-Intervention
during	10443725	830	836	O
the	10443725	837	840	O
second	10443725	841	847	O
12	10443725	848	850	O
months	10443725	851	857	O
of	10443725	858	860	O
therapy	10443725	861	868	O
.	10443725	869	870	O

Results	10443725	871	878	O
of	10443725	879	881	O
the	10443725	882	885	O
initial	10443725	886	893	O
12-month	10443725	894	902	O
study	10443725	903	908	O
demonstrated	10443725	909	921	O
the	10443725	922	925	O
benefit	10443725	926	933	B-Observation
of	10443725	934	936	O
finasteride	10443725	937	948	B-Intervention
treatment	10443725	949	958	O
on	10443725	959	961	O
PFS	10443725	962	965	B-Outcome
parameters	10443725	966	976	I-Outcome
.	10443725	977	978	O

To	10443725	979	981	O
examine	10443725	982	989	O
the	10443725	990	993	O
continuing	10443725	994	1004	B-Observation
effects	10443725	1005	1012	I-Observation
over	10443725	1013	1017	O
time	10443725	1018	1022	O
,	10443725	1023	1024	O
an	10443725	1025	1027	O
analysis	10443725	1028	1036	O
of	10443725	1037	1039	O
the	10443725	1040	1043	O
data	10443725	1044	1048	O
from	10443725	1049	1053	O
54	10443725	1054	1056	O
patients	10443725	1057	1065	O
who	10443725	1066	1069	O
completed	10443725	1070	1079	O
24	10443725	1080	1082	O
months	10443725	1083	1089	O
of	10443725	1090	1092	O
treatment	10443725	1093	1102	O
with	10443725	1103	1107	O
finasteride	10443725	1108	1119	B-Intervention
is	10443725	1120	1122	O
provided	10443725	1123	1131	O
.	10443725	1132	1133	O

RESULTS	10443725	1134	1141	O
Detrusor	10443725	1142	1150	B-Outcome
pressure	10443725	1151	1159	I-Outcome
at	10443725	1160	1162	I-Outcome
maximum	10443725	1163	1170	I-Outcome
flow	10443725	1171	1175	I-Outcome
(	10443725	1176	1177	I-Outcome
PdetQmax	10443725	1178	1186	I-Outcome
)	10443725	1187	1188	I-Outcome
continued	10443725	1189	1198	B-Observation
to	10443725	1199	1201	I-Observation
decrease	10443725	1202	1210	I-Observation
during	10443725	1211	1217	O
the	10443725	1218	1221	O
second	10443725	1222	1228	O
12	10443725	1229	1231	O
months	10443725	1232	1238	O
of	10443725	1239	1241	O
therapy	10443725	1242	1249	B-Intervention
(	10443725	1250	1251	O
decreases	10443725	1252	1261	B-Observation
of	10443725	1262	1264	I-Observation
5.3	10443725	1265	1268	I-Observation
and	10443725	1269	1272	I-Observation
11.7	10443725	1273	1277	I-Observation
cm	10443725	1278	1280	I-Observation
H2O	10443725	1281	1284	I-Observation
at	10443725	1285	1287	O
months	10443725	1288	1294	O
12	10443725	1295	1297	O
and	10443725	1298	1301	O
24	10443725	1302	1304	O
,	10443725	1305	1306	O
respectively	10443725	1307	1319	O
)	10443725	1320	1321	O
.	10443725	1322	1323	O

The	10443725	1324	1327	O
percentage	10443725	1328	1338	B-Outcome
of	10443725	1339	1341	I-Outcome
patients	10443725	1342	1350	I-Outcome
obstructed	10443725	1351	1361	I-Outcome
by	10443725	1362	1364	I-Outcome
Abrams-Griffiths	10443725	1365	1381	I-Outcome
classification	10443725	1382	1396	I-Outcome
decreased	10443725	1397	1406	B-Observation
from	10443725	1407	1411	I-Observation
76.2	10443725	1412	1416	I-Observation
%	10443725	1417	1418	I-Observation
at	10443725	1419	1421	I-Observation
baseline	10443725	1422	1430	I-Observation
to	10443725	1431	1433	I-Observation
66.7	10443725	1434	1438	I-Observation
%	10443725	1439	1440	I-Observation
at	10443725	1441	1443	I-Observation
month	10443725	1444	1449	I-Observation
12	10443725	1450	1452	I-Observation
and	10443725	1453	1456	I-Observation
59.6	10443725	1457	1461	I-Observation
%	10443725	1462	1463	I-Observation
at	10443725	1464	1466	I-Observation
month	10443725	1467	1472	I-Observation
24	10443725	1473	1475	I-Observation
.	10443725	1476	1477	O

An	10443725	1478	1480	O
intention-to-treat	10443725	1481	1499	O
analysis	10443725	1500	1508	O
yielded	10443725	1509	1516	O
similar	10443725	1517	1524	O
results	10443725	1525	1532	O
.	10443725	1533	1534	O

CONCLUSIONS	10443725	1535	1546	O
Finasteride	10443725	1547	1558	B-Intervention
improves	10443725	1559	1567	B-Observation
urodynamic	10443725	1568	1578	B-Outcome
measures	10443725	1579	1587	I-Outcome
of	10443725	1588	1590	I-Outcome
obstruction	10443725	1591	1602	I-Outcome
in	10443725	1603	1605	O
men	10443725	1606	1609	B-Participant
with	10443725	1610	1614	O
BPE	10443725	1615	1618	B-Participant
and	10443725	1619	1622	O
LUTS	10443725	1623	1627	B-Participant
,	10443725	1628	1629	O
with	10443725	1630	1634	O
continued	10443725	1635	1644	B-Observation
improvement	10443725	1645	1656	I-Observation
during	10443725	1657	1663	O
the	10443725	1664	1667	O
second	10443725	1668	1674	O
12	10443725	1675	1677	O
months	10443725	1678	1684	O
of	10443725	1685	1687	O
therapy	10443725	1688	1695	O
.	10443725	1696	1697	O

Effect	10470636	0	6	O
of	10470636	7	9	O
spinal	10470636	10	16	B-Intervention
versus	10470636	17	23	O
general	10470636	24	31	B-Intervention
anesthesia	10470636	32	42	I-Intervention
on	10470636	43	45	O
bladder	10470636	46	53	B-Outcome
compliance	10470636	54	64	I-Outcome
and	10470636	65	68	O
intraabdominal	10470636	69	83	B-Outcome
pressure	10470636	84	92	I-Outcome
during	10470636	93	99	O
transurethral	10470636	100	113	B-Participant
procedures	10470636	114	124	I-Participant
.	10470636	125	126	O

STUDY	10470636	127	132	O
OBJECTIVE	10470636	133	142	O
To	10470636	143	145	O
evaluate	10470636	146	154	O
the	10470636	155	158	O
influence	10470636	159	168	O
of	10470636	169	171	O
spinal	10470636	172	178	B-Intervention
versus	10470636	179	185	O
general	10470636	186	193	B-Intervention
anesthesia	10470636	194	204	I-Intervention
on	10470636	205	207	O
bladder	10470636	208	215	B-Outcome
compliance	10470636	216	226	I-Outcome
and	10470636	227	230	O
intraabdominal	10470636	231	245	B-Outcome
pressure	10470636	246	254	I-Outcome
in	10470636	255	257	O
elderly	10470636	258	265	B-Participant
males	10470636	266	271	I-Participant
undergoing	10470636	272	282	O
elective	10470636	283	291	B-Participant
transurethral	10470636	292	305	I-Participant
resection	10470636	306	315	I-Participant
of	10470636	316	318	I-Participant
the	10470636	319	322	I-Participant
prostate	10470636	323	331	I-Participant
.	10470636	332	333	O

DESIGN	10470636	334	340	O
Prospective	10470636	341	352	O
,	10470636	353	354	O
randomized	10470636	355	365	O
,	10470636	366	367	O
open-label	10470636	368	378	O
study	10470636	379	384	O
.	10470636	385	386	O

SETTING	10470636	387	394	O
Teaching	10470636	395	403	O
hospital	10470636	404	412	O
.	10470636	413	414	O

PATIENTS	10470636	415	423	O
21	10470636	424	426	O
ASA	10470636	427	430	O
physical	10470636	431	439	O
status	10470636	440	446	O
I	10470636	447	448	O
,	10470636	449	450	O
II	10470636	451	453	O
,	10470636	454	455	O
and	10470636	456	459	O
III	10470636	460	463	O
patients	10470636	464	472	O
at	10470636	473	475	O
least	10470636	476	481	O
18	10470636	482	484	O
years	10470636	485	490	O
of	10470636	491	493	O
age	10470636	494	497	O
,	10470636	498	499	O
undergoing	10470636	500	510	O
transurethral	10470636	511	524	B-Participant
surgery	10470636	525	532	I-Participant
.	10470636	533	534	O

INTERVENTIONS	10470636	535	548	O
According	10470636	549	558	O
to	10470636	559	561	O
a	10470636	562	563	O
computer-generated	10470636	564	582	O
randomization	10470636	583	596	O
schedule	10470636	597	605	O
,	10470636	606	607	O
patients	10470636	608	616	O
were	10470636	617	621	O
allocated	10470636	622	631	O
to	10470636	632	634	O
one	10470636	635	638	O
of	10470636	639	641	O
two	10470636	642	645	O
groups	10470636	646	652	O
.	10470636	653	654	O

In	10470636	655	657	O
Group	10470636	658	663	O
Spinal	10470636	664	670	O
(	10470636	671	672	O
S	10470636	673	674	O
)	10470636	675	676	O
,	10470636	677	678	O
10	10470636	679	681	O
mg	10470636	682	684	O
of	10470636	685	687	O
hyperbaric	10470636	688	698	B-Intervention
tetracaine	10470636	699	709	I-Intervention
was	10470636	710	713	O
administered	10470636	714	726	O
intrathecally	10470636	727	740	O
.	10470636	741	742	O

In	10470636	743	745	O
Group	10470636	746	751	O
General	10470636	752	759	O
Anesthesia	10470636	760	770	O
(	10470636	771	772	O
GA	10470636	773	775	O
)	10470636	776	777	O
,	10470636	778	779	O
patients	10470636	780	788	O
received	10470636	789	797	O
,	10470636	798	799	O
fentanyl	10470636	800	808	B-Intervention
intravenous	10470636	809	820	I-Intervention
(	10470636	821	822	O
i.v	10470636	823	826	O
.	10470636	827	828	O
1	10470636	829	830	O
to	10470636	831	833	O
2	10470636	834	835	O
micrograms/kg	10470636	836	849	O
and	10470636	850	853	O
propofol	10470636	854	862	O
i.v	10470636	863	866	O
.	10470636	867	868	O
1.0	10470636	869	872	O
to	10470636	873	875	O
2.0	10470636	876	879	O
mg/kg	10470636	880	885	O
for	10470636	886	889	O
induction	10470636	890	899	O
of	10470636	900	902	O
anesthesia	10470636	903	913	O
.	10470636	914	915	O

Thereafter	10470636	916	926	O
,	10470636	927	928	O
a	10470636	929	930	O
laryngeal	10470636	931	940	O
mask	10470636	941	945	O
airway	10470636	946	952	O
was	10470636	953	956	O
inserted	10470636	957	965	O
and	10470636	966	969	O
,	10470636	970	971	O
with	10470636	972	976	O
spontaneous	10470636	977	988	O
ventilation	10470636	989	1000	O
,	10470636	1001	1002	O
anesthesia	10470636	1003	1013	O
was	10470636	1014	1017	O
maintained	10470636	1018	1028	O
by	10470636	1029	1031	O
administering	10470636	1032	1045	O
isoflurane	10470636	1046	1056	B-Intervention
(	10470636	1057	1058	O
end-tidal	10470636	1059	1068	O
0.7	10470636	1069	1072	O
%	10470636	1073	1074	O
to	10470636	1075	1077	O
1.2	10470636	1078	1081	O
%	10470636	1082	1083	O
)	10470636	1084	1085	O
and	10470636	1086	1089	O
70	10470636	1090	1092	B-Intervention
%	10470636	1093	1094	I-Intervention
nitrous	10470636	1095	1102	I-Intervention
oxide	10470636	1103	1108	I-Intervention
(	10470636	1109	1110	I-Intervention
N2O	10470636	1111	1114	I-Intervention
)	10470636	1115	1116	I-Intervention
in	10470636	1117	1119	I-Intervention
oxygen	10470636	1120	1126	I-Intervention
.	10470636	1127	1128	O

Intraabdominal	10470636	1129	1143	B-Outcome
pressure	10470636	1144	1152	I-Outcome
and	10470636	1153	1156	O
bladder	10470636	1157	1164	B-Outcome
compliance	10470636	1165	1175	I-Outcome
were	10470636	1176	1180	O
recorded	10470636	1181	1189	O
prior	10470636	1190	1195	O
to	10470636	1196	1198	O
the	10470636	1199	1202	O
induction	10470636	1203	1212	O
of	10470636	1213	1215	O
anesthesia	10470636	1216	1226	O
and	10470636	1227	1230	O
immediately	10470636	1231	1242	O
before	10470636	1243	1249	O
the	10470636	1250	1253	O
onset	10470636	1254	1259	O
of	10470636	1260	1262	O
the	10470636	1263	1266	O
surgical	10470636	1267	1275	O
procedure	10470636	1276	1285	O
.	10470636	1286	1287	O

MEASUREMENTS	10470636	1288	1300	O
AND	10470636	1301	1304	O
MAIN	10470636	1305	1309	O
RESULTS	10470636	1310	1317	O
The	10470636	1318	1321	O
two	10470636	1322	1325	O
groups	10470636	1326	1332	O
were	10470636	1333	1337	O
demographically	10470636	1338	1353	O
comparable	10470636	1354	1364	O
.	10470636	1365	1366	O

In	10470636	1367	1369	O
Group	10470636	1370	1375	B-Intervention
S	10470636	1376	1377	I-Intervention
,	10470636	1378	1379	O
mean	10470636	1380	1384	B-Outcome
bladder	10470636	1385	1392	I-Outcome
compliance	10470636	1393	1403	I-Outcome
was	10470636	1404	1407	O
significantly	10470636	1408	1421	B-Observation
(	10470636	1422	1423	I-Observation
p	10470636	1424	1425	I-Observation
=	10470636	1426	1427	I-Observation
0.003	10470636	1428	1433	I-Observation
)	10470636	1434	1435	I-Observation
higher	10470636	1436	1442	I-Observation
and	10470636	1443	1446	O
mean	10470636	1447	1451	B-Outcome
intraabdominal	10470636	1452	1466	I-Outcome
pressure	10470636	1467	1475	I-Outcome
significantly	10470636	1476	1489	B-Observation
lower	10470636	1490	1495	I-Observation
(	10470636	1496	1497	O
p	10470636	1498	1499	O
=	10470636	1500	1501	O
0.007	10470636	1502	1507	O
)	10470636	1508	1509	O
when	10470636	1510	1514	O
compared	10470636	1515	1523	O
to	10470636	1524	1526	O
baseline	10470636	1527	1535	O
preanesthetic	10470636	1536	1549	O
values	10470636	1550	1556	O
.	10470636	1557	1558	O

In	10470636	1559	1561	O
Group	10470636	1562	1567	B-Intervention
GA	10470636	1568	1570	I-Intervention
,	10470636	1571	1572	O
mean	10470636	1573	1577	B-Outcome
intraabdominal	10470636	1578	1592	I-Outcome
pressure	10470636	1593	1601	I-Outcome
significantly	10470636	1602	1615	B-Observation
(	10470636	1616	1617	I-Observation
p	10470636	1618	1619	I-Observation
=	10470636	1620	1621	I-Observation
0.006	10470636	1622	1627	I-Observation
)	10470636	1628	1629	I-Observation
decreased	10470636	1630	1639	I-Observation
when	10470636	1640	1644	O
compared	10470636	1645	1653	O
to	10470636	1654	1656	O
baseline	10470636	1657	1665	O
preanesthetic	10470636	1666	1679	O
recordings	10470636	1680	1690	O
.	10470636	1691	1692	O

Following	10470636	1693	1702	O
the	10470636	1703	1706	O
induction	10470636	1707	1716	O
of	10470636	1717	1719	O
general	10470636	1720	1727	B-Intervention
anesthesia	10470636	1728	1738	I-Intervention
,	10470636	1739	1740	O
a	10470636	1741	1742	O
small	10470636	1743	1748	B-Observation
change	10470636	1749	1755	I-Observation
in	10470636	1756	1758	O
bladder	10470636	1759	1766	B-Outcome
compliance	10470636	1767	1777	I-Outcome
was	10470636	1778	1781	O
noted	10470636	1782	1787	O
.	10470636	1788	1789	O

However	10470636	1790	1797	O
,	10470636	1798	1799	O
statistical	10470636	1800	1811	B-Observation
significance	10470636	1812	1824	I-Observation
was	10470636	1825	1828	O
not	10470636	1829	1832	O
reached	10470636	1833	1840	O
.	10470636	1841	1842	O

Data	10470636	1843	1847	O
were	10470636	1848	1852	O
analyzed	10470636	1853	1861	O
and	10470636	1862	1865	O
compared	10470636	1866	1874	O
using	10470636	1875	1880	O
Student	10470636	1881	1888	O
's	10470636	1889	1891	O
t-test	10470636	1892	1898	O
(	10470636	1899	1900	O
p	10470636	1901	1902	O
<	10470636	1903	1904	O
0.05	10470636	1905	1909	O
was	10470636	1910	1913	O
considered	10470636	1914	1924	O
statistically	10470636	1925	1938	O
significant	10470636	1939	1950	O
)	10470636	1951	1952	O
.	10470636	1953	1954	O

CONCLUSION	10470636	1955	1965	O
Both	10470636	1966	1970	O
spinal	10470636	1971	1977	B-Intervention
and	10470636	1978	1981	I-Intervention
general	10470636	1982	1989	I-Intervention
anesthesia	10470636	1990	2000	I-Intervention
induced	10470636	2001	2008	O
a	10470636	2009	2010	O
significant	10470636	2011	2022	B-Observation
decrease	10470636	2023	2031	I-Observation
in	10470636	2032	2034	O
intraabdominal	10470636	2035	2049	B-Outcome
pressure	10470636	2050	2058	I-Outcome
.	10470636	2059	2060	O

While	10470636	2061	2066	O
both	10470636	2067	2071	B-Intervention
techniques	10470636	2072	2082	I-Intervention
were	10470636	2083	2087	O
associated	10470636	2088	2098	O
with	10470636	2099	2103	O
an	10470636	2104	2106	O
increase	10470636	2107	2115	B-Observation
in	10470636	2116	2118	O
bladder	10470636	2119	2126	B-Outcome
compliance	10470636	2127	2137	I-Outcome
,	10470636	2138	2139	O
statistical	10470636	2140	2151	B-Observation
significance	10470636	2152	2164	I-Observation
was	10470636	2165	2168	O
demonstrated	10470636	2169	2181	O
only	10470636	2182	2186	O
in	10470636	2187	2189	O
the	10470636	2190	2193	O
spinal	10470636	2194	2200	B-Intervention
anesthesia	10470636	2201	2211	I-Intervention
treatment	10470636	2212	2221	I-Intervention
group	10470636	2222	2227	O
.	10470636	2228	2229	O

Trial	10476617	0	5	O
of	10476617	6	8	O
prophylactic	10476617	9	21	O
administration	10476617	22	36	O
of	10476617	37	39	O
TXA2	10476617	40	44	B-Intervention
synthetase	10476617	45	55	I-Intervention
inhibitor	10476617	56	65	I-Intervention
,	10476617	66	67	O
ozagrel	10476617	68	75	B-Intervention
hydrochloride	10476617	76	89	I-Intervention
,	10476617	90	91	O
for	10476617	92	95	O
preeclampsia	10476617	96	108	B-Outcome
.	10476617	109	110	O

OBJECTIVE	10476617	111	120	O
In	10476617	121	123	O
an	10476617	124	126	O
attempt	10476617	127	134	O
to	10476617	135	137	O
investigate	10476617	138	149	O
the	10476617	150	153	O
prophylactic	10476617	154	166	B-Outcome
effect	10476617	167	173	I-Outcome
of	10476617	174	176	O
a	10476617	177	178	O
thromboxane	10476617	179	190	B-Intervention
A2	10476617	191	193	I-Intervention
(	10476617	194	195	I-Intervention
TXA2	10476617	196	200	I-Intervention
)	10476617	201	202	I-Intervention
synthetase	10476617	203	213	I-Intervention
inhibitor	10476617	214	223	I-Intervention
on	10476617	224	226	O
pregnant	10476617	227	235	B-Participant
women	10476617	236	241	I-Participant
with	10476617	242	246	O
a	10476617	247	248	O
high	10476617	249	253	B-Participant
risk	10476617	254	258	I-Participant
of	10476617	259	261	I-Participant
preeclampsia	10476617	262	274	I-Participant
,	10476617	275	276	O
the	10476617	277	280	O
following	10476617	281	290	O
clinical	10476617	291	299	O
study	10476617	300	305	O
was	10476617	306	309	O
undertaken	10476617	310	320	O
.	10476617	321	322	O

METHODS	10476617	323	330	O
Forty	10476617	331	336	O
pregnant	10476617	337	345	B-Participant
women	10476617	346	351	I-Participant
were	10476617	352	356	O
randomly	10476617	357	365	O
allocated	10476617	366	375	O
to	10476617	376	378	O
control	10476617	379	386	B-Intervention
or	10476617	387	389	O
treatment	10476617	390	399	B-Intervention
groups	10476617	400	406	O
.	10476617	407	408	O

Ozagrel	10476617	409	416	B-Intervention
Hydrochloride	10476617	417	430	I-Intervention
(	10476617	431	432	O
400	10476617	433	436	O
mg/day	10476617	437	443	O
,	10476617	444	445	O
orally	10476617	446	452	O
)	10476617	453	454	O
and	10476617	455	458	O
placebo	10476617	459	466	B-Intervention
were	10476617	467	471	O
started	10476617	472	479	O
at	10476617	480	482	O
20	10476617	483	485	O
weeks	10476617	486	491	O
of	10476617	492	494	O
gestation	10476617	495	504	O
and	10476617	505	508	O
continued	10476617	509	518	O
until	10476617	519	524	O
delivery	10476617	525	533	O
.	10476617	534	535	O

RESULTS	10476617	536	543	O
Seventeen	10476617	544	553	B-Count
of	10476617	554	556	I-Count
20	10476617	557	559	I-Count
(	10476617	560	561	I-Count
85	10476617	562	564	I-Count
%	10476617	565	566	I-Count
)	10476617	567	568	I-Count
women	10476617	569	574	I-Count
in	10476617	575	577	O
the	10476617	578	581	O
control	10476617	582	589	B-Intervention
group	10476617	590	595	I-Intervention
developed	10476617	596	605	O
preeclampsia	10476617	606	618	B-Outcome
,	10476617	619	620	O
whereas	10476617	621	628	O
9	10476617	629	630	B-Count
of	10476617	631	633	I-Count
20	10476617	634	636	I-Count
(	10476617	637	638	I-Count
45	10476617	639	641	I-Count
%	10476617	642	643	I-Count
)	10476617	644	645	I-Count
in	10476617	646	648	O
the	10476617	649	652	O
treatment	10476617	653	662	B-Intervention
group	10476617	663	668	I-Intervention
developed	10476617	669	678	O
preeclampsia	10476617	679	691	B-Outcome
.	10476617	692	693	O

Ozagrel	10476617	694	701	B-Intervention
Hydrochloride	10476617	702	715	I-Intervention
significantly	10476617	716	729	B-Observation
(	10476617	730	731	I-Observation
p	10476617	732	733	I-Observation
<	10476617	734	735	I-Observation
0.01	10476617	736	740	I-Observation
)	10476617	741	742	I-Observation
reduced	10476617	743	750	I-Observation
the	10476617	751	754	O
occurrence	10476617	755	765	B-Outcome
of	10476617	766	768	I-Outcome
preeclampsia	10476617	769	781	I-Outcome
,	10476617	782	783	O
and	10476617	784	787	O
the	10476617	788	791	O
incidence	10476617	792	801	B-Outcome
of	10476617	802	804	I-Outcome
both	10476617	805	809	I-Outcome
hypertension	10476617	810	822	I-Outcome
(	10476617	823	824	I-Outcome
p	10476617	825	826	I-Outcome
<	10476617	827	828	I-Outcome
0.05	10476617	829	833	I-Outcome
)	10476617	834	835	I-Outcome
and	10476617	836	839	I-Outcome
proteinuria	10476617	840	851	I-Outcome
(	10476617	852	853	I-Outcome
p	10476617	854	855	I-Outcome
<	10476617	856	857	I-Outcome
0.01	10476617	858	862	I-Outcome
)	10476617	863	864	I-Outcome
was	10476617	865	868	O
significantly	10476617	869	882	B-Observation
less	10476617	883	887	I-Observation
in	10476617	888	890	O
the	10476617	891	894	O
treatment	10476617	895	904	B-Intervention
group	10476617	905	910	O
compared	10476617	911	919	O
with	10476617	920	924	O
the	10476617	925	928	O
control	10476617	929	936	B-Intervention
group	10476617	937	942	O
.	10476617	943	944	O

One	10476617	945	948	O
month	10476617	949	954	O
after	10476617	955	960	O
administration	10476617	961	975	O
,	10476617	976	977	O
the	10476617	978	981	O
mean	10476617	982	986	B-Outcome
plasma	10476617	987	993	I-Outcome
concentration	10476617	994	1007	I-Outcome
of	10476617	1008	1010	I-Outcome
TXB2	10476617	1011	1015	I-Outcome
,	10476617	1016	1017	O
a	10476617	1018	1019	O
metabolite	10476617	1020	1030	O
of	10476617	1031	1033	O
TXA2	10476617	1034	1038	O
,	10476617	1039	1040	O
was	10476617	1041	1044	O
significantly	10476617	1045	1058	B-Observation
decreased	10476617	1059	1068	I-Observation
(	10476617	1069	1070	I-Observation
p	10476617	1071	1072	I-Observation
<	10476617	1073	1074	I-Observation
0.01	10476617	1075	1079	I-Observation
)	10476617	1080	1081	I-Observation
to	10476617	1082	1084	I-Observation
62.4	10476617	1085	1089	I-Observation
+	10476617	1090	1091	I-Observation
/-	10476617	1091	1093	I-Observation
13.6	10476617	1094	1098	I-Observation
%	10476617	1099	1100	I-Observation
,	10476617	1101	1102	O
whereas	10476617	1103	1110	O
that	10476617	1111	1115	B-Outcome
of	10476617	1116	1118	I-Outcome
6-keto	10476617	1119	1125	I-Outcome
prostaglandin	10476617	1126	1139	I-Outcome
F1	10476617	1140	1142	I-Outcome
alpha	10476617	1143	1148	I-Outcome
,	10476617	1149	1150	O
a	10476617	1151	1152	O
metabolite	10476617	1153	1163	O
of	10476617	1164	1166	O
PGI2	10476617	1167	1171	O
,	10476617	1172	1173	O
was	10476617	1174	1177	O
significantly	10476617	1178	1191	B-Observation
increased	10476617	1192	1201	I-Observation
(	10476617	1202	1203	I-Observation
p	10476617	1204	1205	I-Observation
<	10476617	1206	1207	I-Observation
0.01	10476617	1208	1212	I-Observation
)	10476617	1213	1214	I-Observation
to	10476617	1215	1217	I-Observation
206.7	10476617	1218	1223	I-Observation
+	10476617	1224	1225	I-Observation
/-	10476617	1225	1227	I-Observation
52.8	10476617	1228	1232	I-Observation
%	10476617	1233	1234	I-Observation
.	10476617	1235	1236	O

There	10476617	1237	1242	O
were	10476617	1243	1247	O
no	10476617	1248	1250	O
maternal	10476617	1251	1259	B-Outcome
or	10476617	1260	1262	I-Outcome
fetal	10476617	1263	1268	I-Outcome
side	10476617	1269	1273	I-Outcome
effects	10476617	1274	1281	I-Outcome
observed	10476617	1282	1290	O
.	10476617	1291	1292	O

CONCLUSIONS	10476617	1293	1304	O
It	10476617	1305	1307	O
seems	10476617	1308	1313	O
likely	10476617	1314	1320	O
that	10476617	1321	1325	O
Ozagrel	10476617	1326	1333	B-Intervention
Hydrochloride	10476617	1334	1347	I-Intervention
could	10476617	1348	1353	O
be	10476617	1354	1356	O
used	10476617	1357	1361	O
for	10476617	1362	1365	O
the	10476617	1366	1369	O
prevention	10476617	1370	1380	B-Observation
of	10476617	1381	1383	O
preeclampsia	10476617	1384	1396	B-Outcome
in	10476617	1397	1399	O
high-risk	10476617	1400	1409	B-Participant
pregnant	10476617	1410	1418	I-Participant
women	10476617	1419	1424	I-Participant
.	10476617	1425	1426	O

Assessment	10489959	0	10	O
of	10489959	11	13	O
the	10489959	14	17	O
pain	10489959	18	22	B-Outcome
of	10489959	23	25	O
blood-sugar	10489959	26	37	B-Participant
testing	10489959	38	45	I-Participant
:	10489959	46	47	O
a	10489959	48	49	O
randomised	10489959	50	60	O
controlled	10489959	61	71	O
trial	10489959	72	77	O
.	10489959	78	79	O

Lancet	10489959	80	86	B-Intervention
puncture	10489959	87	95	I-Intervention
to	10489959	96	98	I-Intervention
the	10489959	99	102	I-Intervention
side	10489959	103	107	I-Intervention
of	10489959	108	110	I-Intervention
the	10489959	111	114	I-Intervention
thumb	10489959	115	120	I-Intervention
resulted	10489959	121	129	O
in	10489959	130	132	O
less	10489959	133	137	B-Observation
pain	10489959	138	142	B-Outcome
than	10489959	143	147	O
lancet	10489959	148	154	B-Intervention
puncture	10489959	155	163	I-Intervention
to	10489959	164	166	I-Intervention
the	10489959	167	170	I-Intervention
finger	10489959	171	177	I-Intervention
or	10489959	178	180	O
venepuncture	10489959	181	193	B-Intervention
at	10489959	194	196	I-Intervention
the	10489959	197	200	I-Intervention
elbow	10489959	201	206	I-Intervention
.	10489959	207	208	O

Success	10489959	209	216	B-Outcome
rates	10489959	217	222	I-Outcome
were	10489959	223	227	O
the	10489959	228	231	O
same	10489959	232	236	B-Observation
.	10489959	237	238	O

Chemotherapy	10492627	0	12	B-Intervention
for	10492627	13	16	O
operable	10492627	17	25	B-Participant
gastric	10492627	26	33	I-Participant
cancer	10492627	34	40	I-Participant
:	10492627	41	42	O
results	10492627	43	50	O
of	10492627	51	53	O
the	10492627	54	57	O
Dutch	10492627	58	63	O
randomised	10492627	64	74	O
FAMTX	10492627	75	80	O
trial	10492627	81	86	O
.	10492627	87	88	O

The	10492627	89	92	O
Dutch	10492627	93	98	O
Gastric	10492627	99	106	O
Cancer	10492627	107	113	O
Group	10492627	114	119	O
(	10492627	120	121	O
DGCG	10492627	122	126	O
)	10492627	127	128	O
.	10492627	129	130	O

The	10492627	131	134	O
aim	10492627	135	138	O
of	10492627	139	141	O
this	10492627	142	146	O
trial	10492627	147	152	O
was	10492627	153	156	O
to	10492627	157	159	O
investigate	10492627	160	171	O
whether	10492627	172	179	O
pre-operative	10492627	180	193	B-Intervention
chemotherapy	10492627	194	206	I-Intervention
leads	10492627	207	212	O
to	10492627	213	215	O
a	10492627	216	217	O
15	10492627	218	220	B-Observation
%	10492627	221	222	I-Observation
higher	10492627	223	229	I-Observation
curative	10492627	230	238	B-Outcome
resectability	10492627	239	252	I-Outcome
rate	10492627	253	257	I-Outcome
in	10492627	258	260	O
patients	10492627	261	269	O
with	10492627	270	274	O
operable	10492627	275	283	B-Participant
gastric	10492627	284	291	I-Participant
cancer	10492627	292	298	I-Participant
.	10492627	299	300	O

In	10492627	301	303	O
this	10492627	304	308	O
randomised	10492627	309	319	O
trial	10492627	320	325	O
,	10492627	326	327	O
patients	10492627	328	336	O
were	10492627	337	341	O
allocated	10492627	342	351	O
to	10492627	352	354	O
receive	10492627	355	362	O
either	10492627	363	369	O
four	10492627	370	374	B-Intervention
courses	10492627	375	382	I-Intervention
of	10492627	383	385	I-Intervention
chemotherapy	10492627	386	398	I-Intervention
using	10492627	399	404	I-Intervention
5-fluorouracil	10492627	405	419	I-Intervention
,	10492627	420	421	I-Intervention
doxorubicin	10492627	422	433	I-Intervention
and	10492627	434	437	I-Intervention
methotrexate	10492627	438	450	I-Intervention
(	10492627	451	452	I-Intervention
FAMTX	10492627	453	458	I-Intervention
)	10492627	459	460	I-Intervention
prior	10492627	461	466	I-Intervention
to	10492627	467	469	I-Intervention
surgery	10492627	470	477	I-Intervention
or	10492627	478	480	O
to	10492627	481	483	O
undergo	10492627	484	491	O
surgery	10492627	492	499	B-Intervention
only	10492627	500	504	I-Intervention
.	10492627	505	506	O

Patients	10492627	507	515	O
younger	10492627	516	523	O
than	10492627	524	528	O
75	10492627	529	531	O
years	10492627	532	537	O
of	10492627	538	540	O
age	10492627	541	544	O
with	10492627	545	549	O
a	10492627	550	551	O
good	10492627	552	556	B-Participant
physical	10492627	557	565	I-Participant
and	10492627	566	569	I-Participant
mental	10492627	570	576	I-Participant
condition	10492627	577	586	I-Participant
and	10492627	587	590	O
a	10492627	591	592	O
histologically	10492627	593	607	B-Participant
proven	10492627	608	614	I-Participant
adenocarcinoma	10492627	615	629	I-Participant
of	10492627	630	632	I-Participant
the	10492627	633	636	I-Participant
stomach	10492627	637	644	I-Participant
without	10492627	645	652	O
clinical	10492627	653	661	B-Participant
or	10492627	662	664	I-Participant
radiographic	10492627	665	677	I-Participant
(	10492627	678	679	I-Participant
computed	10492627	680	688	I-Participant
tomography	10492627	689	699	I-Participant
scan	10492627	700	704	I-Participant
)	10492627	705	706	I-Participant
evidence	10492627	707	715	I-Participant
of	10492627	716	718	I-Participant
distant	10492627	719	726	I-Participant
metastases	10492627	727	737	I-Participant
were	10492627	738	742	O
eligible	10492627	743	751	O
for	10492627	752	755	O
this	10492627	756	760	O
trial	10492627	761	766	O
.	10492627	767	768	O

Early	10492627	769	774	B-Participant
gastric	10492627	775	782	I-Participant
cancer	10492627	783	789	I-Participant
or	10492627	790	792	O
cardia	10492627	793	799	B-Participant
carcinoma	10492627	800	809	I-Participant
were	10492627	810	814	O
excluded	10492627	815	823	O
.	10492627	824	825	O

The	10492627	826	829	O
response	10492627	830	838	B-Outcome
to	10492627	839	841	I-Outcome
chemotherapy	10492627	842	854	I-Outcome
was	10492627	855	858	O
evaluated	10492627	859	868	O
after	10492627	869	874	O
two	10492627	875	878	O
and	10492627	879	882	O
four	10492627	883	887	O
courses	10492627	888	895	O
.	10492627	896	897	O

In	10492627	898	900	O
case	10492627	901	905	O
of	10492627	906	908	O
progressive	10492627	909	920	B-Outcome
disease	10492627	921	928	I-Outcome
(	10492627	929	930	I-Outcome
PD	10492627	931	933	I-Outcome
)	10492627	934	935	I-Outcome
after	10492627	936	941	O
two	10492627	942	945	O
courses	10492627	946	953	O
,	10492627	954	955	O
patients	10492627	956	964	O
were	10492627	965	969	O
operated	10492627	970	978	O
upon	10492627	979	983	O
as	10492627	984	986	O
soon	10492627	987	991	O
as	10492627	992	994	O
possible	10492627	995	1003	O
.	10492627	1004	1005	O

Otherwise	10492627	1006	1015	O
complete	10492627	1016	1024	B-Outcome
response	10492627	1025	1033	I-Outcome
(	10492627	1034	1035	I-Outcome
CR	10492627	1036	1038	I-Outcome
)	10492627	1039	1040	I-Outcome
partial	10492627	1041	1048	B-Outcome
response	10492627	1049	1057	I-Outcome
(	10492627	1058	1059	I-Outcome
PR	10492627	1060	1062	I-Outcome
)	10492627	1063	1064	I-Outcome
or	10492627	1065	1067	O
stable	10492627	1068	1074	B-Outcome
disease	10492627	1075	1082	I-Outcome
(	10492627	1083	1084	I-Outcome
SD	10492627	1085	1087	I-Outcome
)	10492627	1088	1089	I-Outcome
,	10492627	1090	1091	O
two	10492627	1092	1095	O
more	10492627	1096	1100	O
courses	10492627	1101	1108	O
were	10492627	1109	1113	O
scheduled	10492627	1114	1123	O
.	10492627	1124	1125	O

The	10492627	1126	1129	O
standard	10492627	1130	1138	O
surgical	10492627	1139	1147	O
procedure	10492627	1148	1157	O
was	10492627	1158	1161	O
a	10492627	1162	1163	O
limited	10492627	1164	1171	O
lymphadenectomy	10492627	1172	1187	O
(	10492627	1188	1189	O
D1	10492627	1190	1192	O
)	10492627	1193	1194	O
with	10492627	1195	1199	O
staging	10492627	1200	1207	O
biopsy	10492627	1208	1214	O
of	10492627	1215	1217	O
the	10492627	1218	1221	O
para-aortic	10492627	1222	1233	O
lymph	10492627	1234	1239	O
nodes	10492627	1240	1245	O
.	10492627	1246	1247	O

Between	10492627	1248	1255	O
September	10492627	1256	1265	O
1993	10492627	1266	1270	O
and	10492627	1271	1274	O
February	10492627	1275	1283	O
1996	10492627	1284	1288	O
,	10492627	1289	1290	O
56	10492627	1291	1293	O
eligible	10492627	1294	1302	O
and	10492627	1303	1306	O
evaluable	10492627	1307	1316	O
patients	10492627	1317	1325	O
were	10492627	1326	1330	O
entered	10492627	1331	1338	O
:	10492627	1339	1340	O
27	10492627	1341	1343	O
were	10492627	1344	1348	O
randomised	10492627	1349	1359	O
to	10492627	1360	1362	O
receive	10492627	1363	1370	O
FAMTX	10492627	1371	1376	B-Intervention
before	10492627	1377	1383	I-Intervention
surgery	10492627	1384	1391	I-Intervention
and	10492627	1392	1395	O
29	10492627	1396	1398	O
to	10492627	1399	1401	O
undergo	10492627	1402	1409	O
surgery	10492627	1410	1417	B-Intervention
only	10492627	1418	1422	I-Intervention
.	10492627	1423	1424	O

In	10492627	1425	1427	O
the	10492627	1428	1431	O
FAMTX	10492627	1432	1437	B-Intervention
+	10492627	1438	1439	I-Intervention
surgery	10492627	1440	1447	I-Intervention
treatment	10492627	1448	1457	I-Intervention
group	10492627	1458	1463	O
,	10492627	1464	1465	O
15/27	10492627	1466	1471	B-Count
(	10492627	1472	1473	I-Count
56	10492627	1474	1476	I-Count
%	10492627	1477	1478	I-Count
)	10492627	1479	1480	I-Count
had	10492627	1481	1484	O
curative	10492627	1485	1493	B-Outcome
resections	10492627	1494	1504	I-Outcome
versus	10492627	1505	1511	O
18/29	10492627	1512	1517	B-Count
(	10492627	1518	1519	I-Count
62	10492627	1520	1522	I-Count
%	10492627	1523	1524	I-Count
)	10492627	1525	1526	I-Count
in	10492627	1527	1529	O
the	10492627	1530	1533	O
surgery	10492627	1534	1541	B-Intervention
only	10492627	1542	1546	I-Intervention
arm	10492627	1547	1550	O
.	10492627	1551	1552	O

There	10492627	1553	1558	O
was	10492627	1559	1562	O
no	10492627	1563	1565	O
difference	10492627	1566	1576	B-Observation
in	10492627	1577	1579	O
the	10492627	1580	1583	O
frequency	10492627	1584	1593	B-Outcome
of	10492627	1594	1596	I-Outcome
TNM	10492627	1597	1600	I-Outcome
stages	10492627	1601	1607	I-Outcome
I	10492627	1608	1609	I-Outcome
+	10492627	1610	1611	I-Outcome
II	10492627	1612	1614	I-Outcome
in	10492627	1615	1617	O
both	10492627	1618	1622	B-Intervention
treatment	10492627	1623	1632	I-Intervention
arms	10492627	1633	1637	O
:	10492627	1638	1639	O
15/27	10492627	1640	1645	B-Count
versus	10492627	1646	1652	O
15/29	10492627	1653	1658	B-Count
.	10492627	1659	1660	O

Due	10492627	1661	1664	O
to	10492627	1665	1667	O
PD	10492627	1668	1670	B-Outcome
and/or	10492627	1671	1677	O
toxicity	10492627	1678	1686	B-Outcome
,	10492627	1687	1688	O
12	10492627	1689	1691	B-Count
patients	10492627	1692	1700	I-Count
(	10492627	1701	1702	I-Count
44	10492627	1703	1705	I-Count
%	10492627	1706	1707	I-Count
)	10492627	1708	1709	I-Count
could	10492627	1710	1715	O
not	10492627	1716	1719	O
complete	10492627	1720	1728	O
the	10492627	1729	1732	O
planned	10492627	1733	1740	O
four	10492627	1741	1745	O
courses	10492627	1746	1753	O
of	10492627	1754	1756	O
FAMTX	10492627	1757	1762	B-Intervention
.	10492627	1763	1764	O

Response	10492627	1765	1773	O
evaluation	10492627	1774	1784	O
after	10492627	1785	1790	O
chemotherapy	10492627	1791	1803	B-Intervention
was	10492627	1804	1807	O
possible	10492627	1808	1816	O
in	10492627	1817	1819	O
25	10492627	1820	1822	O
patients	10492627	1823	1831	O
:	10492627	1832	1833	O
2	10492627	1834	1835	B-Count
CR	10492627	1836	1838	B-Outcome
,	10492627	1839	1840	O
6	10492627	1841	1842	B-Count
PR	10492627	1843	1845	B-Outcome
,	10492627	1846	1847	O
8	10492627	1848	1849	B-Count
SD	10492627	1850	1852	B-Outcome
and	10492627	1853	1856	O
9	10492627	1857	1858	B-Count
PD	10492627	1859	1861	B-Outcome
.	10492627	1862	1863	O

The	10492627	1864	1867	O
difference	10492627	1868	1878	B-Outcome
in	10492627	1879	1881	I-Outcome
curative	10492627	1882	1890	I-Outcome
resectability	10492627	1891	1904	I-Outcome
rate	10492627	1905	1909	I-Outcome
was	10492627	1910	1913	O
6.5	10492627	1914	1917	B-Observation
%	10492627	1918	1919	I-Observation
(	10492627	1920	1921	O
95	10492627	1922	1924	O
%	10492627	1925	1926	O
confidence	10492627	1927	1937	O
interval	10492627	1938	1946	O
-32	10492627	1947	1950	O
to	10492627	1951	1953	O
+	10492627	1954	1955	O
19	10492627	1955	1957	O
%	10492627	1958	1959	O
)	10492627	1960	1961	O
in	10492627	1962	1964	O
favour	10492627	1965	1971	O
of	10492627	1972	1974	O
surgery	10492627	1975	1982	B-Intervention
only	10492627	1983	1987	I-Intervention
.	10492627	1988	1989	O

Downstaging	10492627	1990	2001	B-Outcome
for	10492627	2002	2005	I-Outcome
stages	10492627	2006	2012	I-Outcome
I	10492627	2013	2014	I-Outcome
+	10492627	2015	2016	I-Outcome
II	10492627	2017	2019	I-Outcome
did	10492627	2020	2023	O
not	10492627	2024	2027	O
occur	10492627	2028	2033	O
.	10492627	2034	2035	O

PD	10492627	2036	2038	B-Outcome
was	10492627	2039	2042	O
more	10492627	2043	2047	B-Observation
often	10492627	2048	2053	I-Observation
the	10492627	2054	2057	O
reason	10492627	2058	2064	O
for	10492627	2065	2068	O
not	10492627	2069	2072	O
completing	10492627	2073	2083	O
the	10492627	2084	2087	O
planned	10492627	2088	2095	O
four	10492627	2096	2100	O
courses	10492627	2101	2108	O
than	10492627	2109	2113	O
toxicity	10492627	2114	2122	B-Outcome
.	10492627	2123	2124	O

More	10492627	2125	2129	O
active	10492627	2130	2136	O
regimens	10492627	2137	2145	O
than	10492627	2146	2150	O
FAMTX	10492627	2151	2156	O
are	10492627	2157	2160	O
required	10492627	2161	2169	O
for	10492627	2170	2173	O
future	10492627	2174	2180	O
randomised	10492627	2181	2191	O
trials	10492627	2192	2198	O
.	10492627	2199	2200	O

Gabexate	10499652	0	8	B-Intervention
mesilate	10499652	9	17	I-Intervention
and	10499652	18	21	O
antithrombin	10499652	22	34	B-Intervention
III	10499652	35	38	I-Intervention
for	10499652	39	42	O
intraoperative	10499652	43	57	B-Outcome
anticoagulation	10499652	58	73	I-Outcome
in	10499652	74	76	O
heparin	10499652	77	84	B-Participant
pretreated	10499652	85	95	I-Participant
patients	10499652	96	104	O
.	10499652	105	106	O

Thirty	10499652	107	113	O
patients	10499652	114	122	O
scheduled	10499652	123	132	O
for	10499652	133	136	O
elective	10499652	137	145	B-Participant
myocardial	10499652	146	156	I-Participant
revascularization	10499652	157	174	I-Participant
and	10499652	175	178	O
having	10499652	179	185	O
undergone	10499652	186	195	O
preoperative	10499652	196	208	B-Participant
heparin	10499652	209	216	I-Participant
treatment	10499652	217	226	I-Participant
have	10499652	227	231	O
been	10499652	232	236	O
admitted	10499652	237	245	O
to	10499652	246	248	O
this	10499652	249	253	O
prospective	10499652	254	265	O
,	10499652	266	267	O
randomized	10499652	268	278	O
study	10499652	279	284	O
.	10499652	285	286	O

The	10499652	287	290	O
aim	10499652	291	294	O
of	10499652	295	297	O
the	10499652	298	301	O
study	10499652	302	307	O
was	10499652	308	311	O
to	10499652	312	314	O
test	10499652	315	319	O
two	10499652	320	323	O
different	10499652	324	333	O
strategies	10499652	334	344	O
for	10499652	345	348	O
preserving	10499652	349	359	B-Observation
circulating	10499652	360	371	B-Outcome
antithrombin	10499652	372	384	I-Outcome
III	10499652	385	388	I-Outcome
(	10499652	389	390	I-Outcome
AT-III	10499652	391	397	I-Outcome
)	10499652	398	399	I-Outcome
during	10499652	400	406	O
cardiopulmonary	10499652	407	422	B-Participant
bypass	10499652	423	429	I-Participant
.	10499652	430	431	O

Patients	10499652	432	440	O
in	10499652	441	443	O
the	10499652	444	447	O
control	10499652	448	455	O
group	10499652	456	461	O
(	10499652	462	463	O
group	10499652	464	469	O
C	10499652	470	471	O
,	10499652	472	473	O
n	10499652	474	475	O
=	10499652	476	477	O
10	10499652	478	480	O
)	10499652	481	482	O
were	10499652	483	487	O
treated	10499652	488	495	O
with	10499652	496	500	O
a	10499652	501	502	O
standard	10499652	503	511	B-Intervention
heparinization	10499652	512	526	I-Intervention
(	10499652	527	528	O
300	10499652	529	532	O
IU/kg	10499652	533	538	O
)	10499652	539	540	O
.	10499652	541	542	O

Patients	10499652	543	551	O
in	10499652	552	554	O
group	10499652	555	560	O
A	10499652	561	562	O
(	10499652	563	564	O
n	10499652	565	566	O
=	10499652	567	568	O
10	10499652	569	571	O
)	10499652	572	573	O
received	10499652	574	582	O
the	10499652	583	586	O
same	10499652	587	591	B-Intervention
management	10499652	592	602	I-Intervention
plus	10499652	603	607	I-Intervention
two	10499652	608	611	I-Intervention
doses	10499652	612	617	I-Intervention
of	10499652	618	620	I-Intervention
purified	10499652	621	629	I-Intervention
antithrombin	10499652	630	642	I-Intervention
III	10499652	643	646	I-Intervention
(	10499652	647	648	O
1000	10499652	649	653	O
IU	10499652	654	656	O
each	10499652	657	661	O
)	10499652	662	663	O
.	10499652	664	665	O

Patients	10499652	666	674	O
in	10499652	675	677	O
group	10499652	678	683	O
GA	10499652	684	686	O
received	10499652	687	695	O
200	10499652	696	699	B-Intervention
IU/kg	10499652	700	705	I-Intervention
heparin	10499652	706	713	I-Intervention
and	10499652	714	717	I-Intervention
a	10499652	718	719	I-Intervention
continuous	10499652	720	730	I-Intervention
infusion	10499652	731	739	I-Intervention
of	10499652	740	742	I-Intervention
heparin	10499652	743	750	I-Intervention
(	10499652	751	752	I-Intervention
100	10499652	753	756	I-Intervention
IU/kg/h	10499652	757	764	I-Intervention
)	10499652	765	766	I-Intervention
and	10499652	767	770	I-Intervention
gabexate	10499652	771	779	I-Intervention
mesilate	10499652	780	788	I-Intervention
(	10499652	789	790	I-Intervention
2	10499652	791	792	I-Intervention
mg/kg/h	10499652	793	800	I-Intervention
)	10499652	801	802	I-Intervention
plus	10499652	803	807	I-Intervention
the	10499652	808	811	I-Intervention
same	10499652	812	816	I-Intervention
dose	10499652	817	821	I-Intervention
of	10499652	822	824	I-Intervention
antithrombin	10499652	825	837	I-Intervention
III	10499652	838	841	I-Intervention
as	10499652	842	844	O
group	10499652	845	850	O
A	10499652	851	852	O
.	10499652	853	854	O

Both	10499652	855	859	O
group	10499652	860	865	B-Intervention
A	10499652	866	867	I-Intervention
and	10499652	868	871	O
group	10499652	872	877	B-Intervention
GA	10499652	878	880	I-Intervention
demonstrated	10499652	881	893	O
a	10499652	894	895	O
preservation	10499652	896	908	B-Observation
of	10499652	909	911	O
circulating	10499652	912	923	B-Outcome
AT-III	10499652	924	930	I-Outcome
when	10499652	931	935	O
compared	10499652	936	944	O
to	10499652	945	947	O
group	10499652	948	953	B-Intervention
C	10499652	954	955	I-Intervention
;	10499652	956	957	O
this	10499652	958	962	O
effect	10499652	963	969	B-Outcome
was	10499652	970	973	O
more	10499652	974	978	B-Observation
pronounced	10499652	979	989	I-Observation
in	10499652	990	992	O
group	10499652	993	998	B-Intervention
GA	10499652	999	1001	I-Intervention
.	10499652	1002	1003	O

The	10499652	1004	1007	O
total	10499652	1008	1013	B-Outcome
heparin	10499652	1014	1021	I-Outcome
dosage	10499652	1022	1028	I-Outcome
was	10499652	1029	1032	O
less	10499652	1033	1037	B-Observation
in	10499652	1038	1040	O
group	10499652	1041	1046	B-Intervention
GA	10499652	1047	1049	I-Intervention
than	10499652	1050	1054	O
in	10499652	1055	1057	O
groups	10499652	1058	1064	B-Intervention
A	10499652	1065	1066	I-Intervention
and	10499652	1067	1070	O
C.	10499652	1071	1073	B-Intervention
Purified	10499652	1074	1082	I-Intervention
AT-III	10499652	1083	1089	I-Intervention
administration	10499652	1090	1104	O
is	10499652	1105	1107	O
recommended	10499652	1108	1119	B-Observation
in	10499652	1120	1122	O
heparin	10499652	1123	1130	B-Participant
pretreated	10499652	1131	1141	I-Participant
patients	10499652	1142	1150	O
;	10499652	1151	1152	O
the	10499652	1153	1156	O
addition	10499652	1157	1165	B-Intervention
of	10499652	1166	1168	I-Intervention
gabexate	10499652	1169	1177	I-Intervention
mesilate	10499652	1178	1186	I-Intervention
to	10499652	1187	1189	I-Intervention
this	10499652	1190	1194	I-Intervention
protocol	10499652	1195	1203	I-Intervention
decreases	10499652	1204	1213	B-Observation
the	10499652	1214	1217	O
heparin	10499652	1218	1225	B-Outcome
requirement	10499652	1226	1237	I-Outcome
and	10499652	1238	1241	O
increases	10499652	1242	1251	B-Observation
the	10499652	1252	1255	O
AT-III	10499652	1256	1262	B-Outcome
preservation	10499652	1263	1275	I-Outcome
.	10499652	1276	1277	O

Tactile	10509459	0	7	B-Outcome
feedback	10509459	8	16	I-Outcome
is	10509459	17	19	O
present	10509459	20	27	O
during	10509459	28	34	O
minimally	10509459	35	44	B-Intervention
invasive	10509459	45	53	I-Intervention
surgery	10509459	54	61	I-Intervention
.	10509459	62	63	O

BACKGROUND	10509459	64	74	O
The	10509459	75	78	O
applications	10509459	79	91	O
of	10509459	92	94	O
minimally	10509459	95	104	O
invasive	10509459	105	113	O
surgery	10509459	114	121	O
(	10509459	122	123	O
MIS	10509459	124	127	O
)	10509459	128	129	O
and	10509459	130	133	O
laparoscopy	10509459	134	145	O
are	10509459	146	149	O
rapidly	10509459	150	157	O
expanding	10509459	158	167	O
.	10509459	168	169	O

Despite	10509459	170	177	O
this	10509459	178	182	O
expansion	10509459	183	192	O
,	10509459	193	194	O
our	10509459	195	198	O
understanding	10509459	199	212	O
of	10509459	213	215	O
the	10509459	216	219	O
importance	10509459	220	230	O
of	10509459	231	233	O
haptic	10509459	234	240	O
feedback	10509459	241	249	O
during	10509459	250	256	O
laparoscopic	10509459	257	269	O
surgery	10509459	270	277	O
is	10509459	278	280	O
incomplete	10509459	281	291	O
.	10509459	292	293	O

Although	10509459	294	302	O
many	10509459	303	307	O
surgeons	10509459	308	316	O
believe	10509459	317	324	O
that	10509459	325	329	O
the	10509459	330	333	O
use	10509459	334	337	O
of	10509459	338	340	O
minimally	10509459	341	350	O
invasive	10509459	351	359	O
techniques	10509459	360	370	O
eliminates	10509459	371	381	O
force	10509459	382	387	O
feedback	10509459	388	396	O
and	10509459	397	400	O
tactile	10509459	401	408	O
sensation	10509459	409	418	O
(	10509459	419	420	O
haptics	10509459	421	428	O
)	10509459	429	430	O
,	10509459	431	432	O
the	10509459	433	436	O
importance	10509459	437	447	O
of	10509459	448	450	O
haptics	10509459	451	458	O
in	10509459	459	461	O
MIS	10509459	462	465	O
has	10509459	466	469	O
not	10509459	470	473	O
been	10509459	474	478	O
fully	10509459	479	484	O
evaluated	10509459	485	494	O
.	10509459	495	496	O

There	10509459	497	502	O
is	10509459	503	505	O
considerable	10509459	506	518	O
interest	10509459	519	527	O
in	10509459	528	530	O
the	10509459	531	534	O
development	10509459	535	546	O
of	10509459	547	549	O
simulators	10509459	550	560	O
for	10509459	561	564	O
MIS	10509459	565	568	O
even	10509459	569	573	O
though	10509459	574	580	O
the	10509459	581	584	O
importance	10509459	585	595	O
of	10509459	596	598	O
force	10509459	599	604	O
feedback	10509459	605	613	O
remains	10509459	614	621	O
poorly	10509459	622	628	O
understood	10509459	629	639	O
.	10509459	640	641	O

This	10509459	642	646	O
study	10509459	647	652	O
was	10509459	653	656	O
designed	10509459	657	665	O
to	10509459	666	668	O
determine	10509459	669	678	O
the	10509459	679	682	O
ability	10509459	683	690	O
of	10509459	691	693	O
experienced	10509459	694	705	B-Participant
surgeons	10509459	706	714	I-Participant
to	10509459	715	717	O
interpret	10509459	718	727	O
haptic	10509459	728	734	B-Outcome
feedback	10509459	735	743	I-Outcome
with	10509459	744	748	I-Outcome
respect	10509459	749	756	I-Outcome
to	10509459	757	759	I-Outcome
texture	10509459	760	767	I-Outcome
,	10509459	768	769	I-Outcome
shape	10509459	770	775	I-Outcome
,	10509459	776	777	I-Outcome
and	10509459	778	781	I-Outcome
consistency	10509459	782	793	I-Outcome
of	10509459	794	796	I-Outcome
an	10509459	797	799	I-Outcome
object	10509459	800	806	I-Outcome
.	10509459	807	808	O

STUDY	10509459	809	814	O
DESIGN	10509459	815	821	O
A	10509459	822	823	O
randomized	10509459	824	834	O
,	10509459	835	836	O
single-blinded	10509459	837	851	O
study	10509459	852	857	O
was	10509459	858	861	O
designed	10509459	862	870	O
.	10509459	871	872	O

Twenty	10509459	873	879	O
surgeons	10509459	880	888	B-Participant
were	10509459	889	893	O
presented	10509459	894	903	O
objects	10509459	904	911	O
in	10509459	912	914	O
a	10509459	915	916	O
random	10509459	917	923	O
order	10509459	924	929	O
,	10509459	930	931	O
with	10509459	932	936	O
participants	10509459	937	949	O
blinded	10509459	950	957	O
as	10509459	958	960	O
to	10509459	961	963	O
their	10509459	964	969	O
identity	10509459	970	978	O
.	10509459	979	980	O

Inspection	10509459	981	991	O
by	10509459	992	994	O
direct	10509459	995	1001	B-Intervention
palpation	10509459	1002	1011	I-Intervention
,	10509459	1012	1013	O
conventional	10509459	1014	1026	B-Intervention
instruments	10509459	1027	1038	I-Intervention
,	10509459	1039	1040	O
and	10509459	1041	1044	O
laparoscopic	10509459	1045	1057	B-Intervention
instruments	10509459	1058	1069	I-Intervention
was	10509459	1070	1073	O
performed	10509459	1074	1083	O
on	10509459	1084	1086	O
all	10509459	1087	1090	O
objects	10509459	1091	1098	O
.	10509459	1099	1100	O

Statistic	10509459	1101	1110	O
analysis	10509459	1111	1119	O
of	10509459	1120	1122	O
the	10509459	1123	1126	O
data	10509459	1127	1131	O
was	10509459	1132	1135	O
performed	10509459	1136	1145	O
using	10509459	1146	1151	O
chi-square	10509459	1152	1162	O
analysis	10509459	1163	1171	O
and	10509459	1172	1175	O
,	10509459	1176	1177	O
when	10509459	1178	1182	O
appropriate	10509459	1183	1194	O
,	10509459	1195	1196	O
a	10509459	1197	1198	O
Fischer	10509459	1199	1206	O
exact	10509459	1207	1212	O
probability	10509459	1213	1224	O
test	10509459	1225	1229	O
.	10509459	1230	1231	O

RESULTS	10509459	1232	1239	O
Direct	10509459	1240	1246	B-Intervention
palpation	10509459	1247	1256	I-Intervention
was	10509459	1257	1260	O
associated	10509459	1261	1271	O
with	10509459	1272	1276	O
the	10509459	1277	1280	O
highest	10509459	1281	1288	B-Observation
accuracy	10509459	1289	1297	B-Outcome
for	10509459	1298	1301	I-Outcome
shape	10509459	1302	1307	I-Outcome
identification	10509459	1308	1322	I-Outcome
and	10509459	1323	1326	O
was	10509459	1327	1330	O
superior	10509459	1331	1339	B-Observation
to	10509459	1340	1342	O
both	10509459	1343	1347	O
conventional	10509459	1348	1360	B-Intervention
instruments	10509459	1361	1372	I-Intervention
(	10509459	1373	1374	O
p	10509459	1375	1376	O
<	10509459	1377	1378	O
0.001	10509459	1379	1384	O
)	10509459	1385	1386	O
and	10509459	1387	1390	O
laparoscopic	10509459	1391	1403	B-Intervention
instruments	10509459	1404	1415	I-Intervention
(	10509459	1416	1417	O
p	10509459	1418	1419	O
<	10509459	1420	1421	O
0.001	10509459	1422	1427	O
)	10509459	1428	1429	O
.	10509459	1430	1431	O

Fine	10509459	1432	1436	B-Outcome
texture	10509459	1437	1444	I-Outcome
analysis	10509459	1445	1453	I-Outcome
with	10509459	1454	1458	O
either	10509459	1459	1465	O
a	10509459	1466	1467	O
conventional	10509459	1468	1480	B-Intervention
instrument	10509459	1481	1491	I-Intervention
or	10509459	1492	1494	O
a	10509459	1495	1496	O
laparoscopic	10509459	1497	1509	B-Intervention
instrument	10509459	1510	1520	I-Intervention
was	10509459	1521	1524	O
superior	10509459	1525	1533	B-Observation
to	10509459	1534	1536	O
direct	10509459	1537	1543	B-Intervention
palpation	10509459	1544	1553	I-Intervention
(	10509459	1554	1555	O
p	10509459	1556	1557	O
<	10509459	1558	1559	O
0.05	10509459	1560	1564	O
)	10509459	1565	1566	O
.	10509459	1567	1568	O

Finally	10509459	1569	1576	O
,	10509459	1577	1578	O
the	10509459	1579	1582	O
three	10509459	1583	1588	B-Intervention
methods	10509459	1589	1596	I-Intervention
of	10509459	1597	1599	O
analysis	10509459	1600	1608	O
were	10509459	1609	1613	O
comparable	10509459	1614	1624	B-Observation
for	10509459	1625	1628	O
consistency	10509459	1629	1640	B-Outcome
analysis	10509459	1641	1649	I-Outcome
.	10509459	1650	1651	O

CONCLUSIONS	10509459	1652	1663	O
These	10509459	1664	1669	O
data	10509459	1670	1674	O
indicate	10509459	1675	1683	O
that	10509459	1684	1688	O
laparoscopic	10509459	1689	1701	B-Intervention
instruments	10509459	1702	1713	I-Intervention
do	10509459	1714	1716	O
,	10509459	1717	1718	O
in	10509459	1719	1721	O
fact	10509459	1722	1726	O
,	10509459	1727	1728	O
provide	10509459	1729	1736	O
surgeons	10509459	1737	1745	B-Participant
with	10509459	1746	1750	O
haptic	10509459	1751	1757	B-Outcome
feedback	10509459	1758	1766	I-Outcome
.	10509459	1767	1768	O

Interpretation	10509459	1769	1783	B-Outcome
of	10509459	1784	1786	I-Outcome
the	10509459	1787	1790	I-Outcome
texture	10509459	1791	1798	I-Outcome
,	10509459	1799	1800	I-Outcome
shape	10509459	1801	1806	I-Outcome
,	10509459	1807	1808	O
and	10509459	1809	1812	O
consistency	10509459	1813	1824	B-Outcome
of	10509459	1825	1827	I-Outcome
objects	10509459	1828	1835	I-Outcome
can	10509459	1836	1839	O
be	10509459	1840	1842	O
performed	10509459	1843	1852	O
.	10509459	1853	1854	O

In	10509459	1855	1857	O
some	10509459	1858	1862	O
situations	10509459	1863	1873	O
,	10509459	1874	1875	O
laparoscopic	10509459	1876	1888	B-Intervention
instruments	10509459	1889	1900	I-Intervention
appear	10509459	1901	1907	O
to	10509459	1908	1910	O
amplify	10509459	1911	1918	B-Observation
the	10509459	1919	1922	O
haptic	10509459	1923	1929	B-Outcome
information	10509459	1930	1941	I-Outcome
available	10509459	1942	1951	O
.	10509459	1952	1953	O

Our	10509459	1954	1957	O
ongoing	10509459	1958	1965	O
work	10509459	1966	1970	O
is	10509459	1971	1973	O
directed	10509459	1974	1982	O
at	10509459	1983	1985	O
further	10509459	1986	1993	O
defining	10509459	1994	2002	O
force	10509459	2003	2008	O
interactions	10509459	2009	2021	O
.	10509459	2022	2023	O

Ciprofloxacin	10517189	0	13	B-Intervention
and	10517189	14	17	I-Intervention
rifampicin	10517189	18	28	I-Intervention
versus	10517189	29	35	O
doxycycline	10517189	36	47	B-Intervention
and	10517189	48	51	I-Intervention
rifampicin	10517189	52	62	I-Intervention
in	10517189	63	65	O
the	10517189	66	69	O
treatment	10517189	70	79	O
of	10517189	80	82	O
brucellosis	10517189	83	94	B-Participant
.	10517189	95	96	O

The	10517189	97	100	O
present	10517189	101	108	O
study	10517189	109	114	O
was	10517189	115	118	O
undertaken	10517189	119	129	O
to	10517189	130	132	O
evaluate	10517189	133	141	O
the	10517189	142	145	O
efficacy	10517189	146	154	B-Outcome
,	10517189	155	156	O
safety	10517189	157	163	B-Outcome
,	10517189	164	165	O
and	10517189	166	169	O
patient	10517189	170	177	B-Outcome
tolerability	10517189	178	190	I-Outcome
of	10517189	191	193	O
two	10517189	194	197	B-Intervention
antibiotic	10517189	198	208	I-Intervention
regimens	10517189	209	217	I-Intervention
for	10517189	218	221	O
the	10517189	222	225	O
treatment	10517189	226	235	O
of	10517189	236	238	O
brucellosis	10517189	239	250	B-Participant
:	10517189	251	252	O
rifampicin	10517189	253	263	B-Intervention
600	10517189	264	267	I-Intervention
mg/day	10517189	268	274	I-Intervention
and	10517189	275	278	I-Intervention
doxycycline	10517189	279	290	I-Intervention
200	10517189	291	294	I-Intervention
mg/day	10517189	295	301	I-Intervention
for	10517189	302	305	I-Intervention
45	10517189	306	308	I-Intervention
days	10517189	309	313	I-Intervention
(	10517189	314	315	O
group	10517189	316	321	O
1	10517189	322	323	O
)	10517189	324	325	O
,	10517189	326	327	O
versus	10517189	328	334	O
rifampicin	10517189	335	345	B-Intervention
600	10517189	346	349	I-Intervention
mg/day	10517189	350	356	I-Intervention
and	10517189	357	360	I-Intervention
ciprofloxacin	10517189	361	374	I-Intervention
1	10517189	375	376	I-Intervention
g/day	10517189	377	382	I-Intervention
for	10517189	383	386	I-Intervention
30	10517189	387	389	I-Intervention
days	10517189	390	394	I-Intervention
(	10517189	395	396	O
group	10517189	397	402	O
2	10517189	403	404	O
)	10517189	405	406	O
.	10517189	407	408	O

Forty	10517189	409	414	O
patients	10517189	415	423	O
were	10517189	424	428	O
diagnosed	10517189	429	438	O
with	10517189	439	443	O
brucellosis	10517189	444	455	B-Participant
based	10517189	456	461	O
on	10517189	462	464	O
clinical	10517189	465	473	O
and	10517189	474	477	O
microbiological	10517189	478	493	O
findings	10517189	494	502	O
.	10517189	503	504	O

The	10517189	505	508	O
two	10517189	509	512	O
groups	10517189	513	519	O
were	10517189	520	524	O
comparable	10517189	525	535	O
regarding	10517189	536	545	O
age	10517189	546	549	O
and	10517189	550	553	O
sex	10517189	554	557	O
distribution	10517189	558	570	O
.	10517189	571	572	O

The	10517189	573	576	O
average	10517189	577	584	B-Outcome
number	10517189	585	591	I-Outcome
of	10517189	592	594	I-Outcome
days	10517189	595	599	I-Outcome
without	10517189	600	607	I-Outcome
fever	10517189	608	613	I-Outcome
and	10517189	614	617	I-Outcome
symptoms	10517189	618	626	I-Outcome
was	10517189	627	630	O
lower	10517189	631	636	B-Observation
in	10517189	637	639	O
group	10517189	640	645	B-Intervention
2	10517189	646	647	I-Intervention
patients	10517189	648	656	O
than	10517189	657	661	O
in	10517189	662	664	O
group	10517189	665	670	B-Intervention
1	10517189	671	672	I-Intervention
patients	10517189	673	681	O
(	10517189	682	683	O
mean+/-SD	10517189	684	693	O
:	10517189	694	695	O
3.85+/-1.98	10517189	696	707	B-Observation
for	10517189	708	711	O
group	10517189	712	717	B-Intervention
1	10517189	718	719	I-Intervention
vs.	10517189	720	723	O
2.78+/-1.03	10517189	724	735	B-Observation
for	10517189	736	739	O
group	10517189	740	745	B-Intervention
2	10517189	746	747	I-Intervention
,	10517189	748	749	O
P=0.044	10517189	750	757	O
)	10517189	758	759	O
.	10517189	760	761	O

During	10517189	762	768	O
the	10517189	769	772	O
1-year	10517189	773	779	O
follow-up	10517189	780	789	O
period	10517189	790	796	O
,	10517189	797	798	O
three	10517189	799	804	B-Count
(	10517189	805	806	I-Count
15	10517189	807	809	I-Count
%	10517189	810	811	I-Count
)	10517189	812	813	I-Count
patients	10517189	814	822	I-Count
in	10517189	823	825	O
group	10517189	826	831	B-Intervention
2	10517189	832	833	I-Intervention
and	10517189	834	837	O
two	10517189	838	841	B-Count
(	10517189	842	843	I-Count
10	10517189	844	846	I-Count
%	10517189	847	848	I-Count
)	10517189	849	850	I-Count
patients	10517189	851	859	I-Count
in	10517189	860	862	O
group	10517189	863	868	B-Intervention
1	10517189	869	870	I-Intervention
had	10517189	871	874	O
clinical	10517189	875	883	B-Outcome
relapses	10517189	884	892	I-Outcome
;	10517189	893	894	O
these	10517189	895	900	O
rates	10517189	901	906	B-Outcome
were	10517189	907	911	O
not	10517189	912	915	O
significantly	10517189	916	929	B-Observation
different	10517189	930	939	I-Observation
.	10517189	940	941	O

Ciprofloxacin	10517189	942	955	B-Intervention
and	10517189	956	959	I-Intervention
rifampicin	10517189	960	970	I-Intervention
treatment	10517189	971	980	O
for	10517189	981	984	O
brucellosis	10517189	985	996	B-Participant
is	10517189	997	999	O
as	10517189	1000	1002	O
effective	10517189	1003	1012	B-Observation
as	10517189	1013	1015	O
the	10517189	1016	1019	O
standard	10517189	1020	1028	O
regimen	10517189	1029	1036	O
of	10517189	1037	1039	O
doxycycline	10517189	1040	1051	B-Intervention
and	10517189	1052	1055	I-Intervention
rifampicin	10517189	1056	1066	I-Intervention
and	10517189	1067	1070	O
offers	10517189	1071	1077	O
the	10517189	1078	1081	O
advantage	10517189	1082	1091	O
of	10517189	1092	1094	O
a	10517189	1095	1096	O
shorter	10517189	1097	1104	B-Observation
duration	10517189	1105	1113	B-Outcome
of	10517189	1114	1116	I-Outcome
treatment	10517189	1117	1126	I-Outcome
.	10517189	1127	1128	O

Use	10517426	0	3	O
of	10517426	4	6	O
the	10517426	7	10	O
oral	10517426	11	15	B-Intervention
neuraminidase	10517426	16	29	I-Intervention
inhibitor	10517426	30	39	I-Intervention
oseltamivir	10517426	40	51	I-Intervention
in	10517426	52	54	O
experimental	10517426	55	67	B-Participant
human	10517426	68	73	I-Participant
influenza	10517426	74	83	I-Participant
:	10517426	84	85	O
randomized	10517426	86	96	O
controlled	10517426	97	107	O
trials	10517426	108	114	O
for	10517426	115	118	O
prevention	10517426	119	129	O
and	10517426	130	133	O
treatment	10517426	134	143	O
.	10517426	144	145	O

CONTEXT	10517426	146	153	O
Influenza	10517426	154	163	O
virus	10517426	164	169	O
neuraminidase	10517426	170	183	O
is	10517426	184	186	O
thought	10517426	187	194	O
to	10517426	195	197	O
be	10517426	198	200	O
essential	10517426	201	210	O
for	10517426	211	214	O
virus	10517426	215	220	O
replication	10517426	221	232	O
in	10517426	233	235	O
humans	10517426	236	242	O
;	10517426	243	244	O
however	10517426	245	252	O
,	10517426	253	254	O
to	10517426	255	257	O
date	10517426	258	262	O
,	10517426	263	264	O
available	10517426	265	274	O
neuraminidase	10517426	275	288	O
inhibitors	10517426	289	299	O
are	10517426	300	303	O
limited	10517426	304	311	O
to	10517426	312	314	O
zanamivir	10517426	315	324	O
,	10517426	325	326	O
which	10517426	327	332	O
is	10517426	333	335	O
topically	10517426	336	345	O
administered	10517426	346	358	O
.	10517426	359	360	O

OBJECTIVE	10517426	361	370	O
To	10517426	371	373	O
determine	10517426	374	383	O
the	10517426	384	387	O
safety	10517426	388	394	B-Outcome
,	10517426	395	396	O
tolerability	10517426	397	409	B-Outcome
,	10517426	410	411	O
and	10517426	412	415	O
antiviral	10517426	416	425	B-Outcome
activity	10517426	426	434	I-Outcome
of	10517426	435	437	O
oral	10517426	438	442	B-Intervention
neuraminidase	10517426	443	456	I-Intervention
inhibitor	10517426	457	466	I-Intervention
oseltamivir	10517426	467	478	I-Intervention
(	10517426	479	480	O
GS4104/Ro64	10517426	481	492	O
-	10517426	492	493	O
0796	10517426	493	497	O
)	10517426	498	499	O
for	10517426	500	503	O
prevention	10517426	504	514	O
and	10517426	515	518	O
the	10517426	519	522	O
early	10517426	523	528	O
treatment	10517426	529	538	O
of	10517426	539	541	O
influenza	10517426	542	551	B-Participant
in	10517426	552	554	O
experimentally	10517426	555	569	O
infected	10517426	570	578	O
humans	10517426	579	585	O
.	10517426	586	587	O

DESIGN	10517426	588	594	O
Two	10517426	595	598	O
randomized	10517426	599	609	O
,	10517426	610	611	O
double-blind	10517426	612	624	O
,	10517426	625	626	O
placebo-controlled	10517426	627	645	O
trials	10517426	646	652	O
conducted	10517426	653	662	O
between	10517426	663	670	O
June	10517426	671	675	O
and	10517426	676	679	O
July	10517426	680	684	O
1997	10517426	685	689	O
.	10517426	690	691	O

SETTING	10517426	692	699	O
Individual	10517426	700	710	O
hotel	10517426	711	716	O
rooms	10517426	717	722	O
;	10517426	723	724	O
2	10517426	725	726	O
large	10517426	727	732	O
US	10517426	733	735	O
university	10517426	736	746	O
medical	10517426	747	754	O
schools	10517426	755	762	O
.	10517426	763	764	O

PARTICIPANTS	10517426	765	777	O
A	10517426	778	779	O
total	10517426	780	785	O
of	10517426	786	788	O
117	10517426	789	792	O
healthy	10517426	793	800	B-Participant
adult	10517426	801	806	I-Participant
volunteers	10517426	807	817	O
(	10517426	818	819	O
aged	10517426	820	824	O
18	10517426	825	827	O
-	10517426	827	828	O
40	10517426	828	830	O
years	10517426	831	836	O
;	10517426	837	838	O
median	10517426	839	845	O
age	10517426	846	849	O
,	10517426	850	851	O
21	10517426	852	854	O
years	10517426	855	860	O
)	10517426	861	862	O
who	10517426	863	866	O
were	10517426	867	871	O
susceptible	10517426	872	883	O
(	10517426	884	885	O
hemagglutination-inhibition	10517426	886	913	O
antibody	10517426	914	922	O
titer	10517426	923	928	O
<	10517426	929	930	O
or	10517426	931	933	O
=	10517426	934	935	O
1:8	10517426	935	938	O
)	10517426	939	940	O
.	10517426	941	942	O

INTERVENTIONS	10517426	943	956	O
All	10517426	957	960	O
subjects	10517426	961	969	O
were	10517426	970	974	O
inoculated	10517426	975	985	O
intranasally	10517426	986	998	O
with	10517426	999	1003	O
influenza	10517426	1004	1013	O
A/Texas/36/91	10517426	1014	1027	O
(	10517426	1028	1029	O
H1N1	10517426	1030	1034	O
)	10517426	1035	1036	O
virus	10517426	1037	1042	O
.	10517426	1043	1044	O

For	10517426	1045	1048	O
the	10517426	1049	1052	O
prophylaxis	10517426	1053	1064	O
study	10517426	1065	1070	O
,	10517426	1071	1072	O
oral	10517426	1073	1077	B-Intervention
oseltamivir	10517426	1078	1089	I-Intervention
(	10517426	1090	1091	O
100	10517426	1092	1095	O
mg	10517426	1096	1098	O
once	10517426	1099	1103	O
daily	10517426	1104	1109	O
[	10517426	1110	1111	O
n	10517426	1112	1113	O
=	10517426	1114	1115	O
12	10517426	1116	1118	O
]	10517426	1119	1120	O
,	10517426	1121	1122	O
100	10517426	1123	1126	O
mg	10517426	1127	1129	O
twice	10517426	1130	1135	O
daily	10517426	1136	1141	O
[	10517426	1142	1143	O
n	10517426	1144	1145	O
=	10517426	1146	1147	O
12	10517426	1148	1150	O
]	10517426	1151	1152	O
,	10517426	1153	1154	O
or	10517426	1155	1157	O
matching	10517426	1158	1166	O
placebo	10517426	1167	1174	B-Intervention
[	10517426	1175	1176	O
n	10517426	1177	1178	O
=	10517426	1179	1180	O
13	10517426	1181	1183	O
]	10517426	1184	1185	O
,	10517426	1186	1187	O
starting	10517426	1188	1196	O
26	10517426	1197	1199	O
hours	10517426	1200	1205	O
before	10517426	1206	1212	O
virus	10517426	1213	1218	O
inoculation	10517426	1219	1230	O
)	10517426	1231	1232	O
was	10517426	1233	1236	O
administered	10517426	1237	1249	O
.	10517426	1250	1251	O

For	10517426	1252	1255	O
the	10517426	1256	1259	O
treatment	10517426	1260	1269	O
study	10517426	1270	1275	O
,	10517426	1276	1277	O
the	10517426	1278	1281	O
same	10517426	1282	1286	B-Intervention
drug	10517426	1287	1291	I-Intervention
was	10517426	1292	1295	O
given	10517426	1296	1301	O
(	10517426	1302	1303	O
20	10517426	1304	1306	O
mg	10517426	1307	1309	O
,	10517426	1310	1311	O
100	10517426	1312	1315	O
mg	10517426	1316	1318	O
,	10517426	1319	1320	O
or	10517426	1321	1323	O
200	10517426	1324	1327	O
mg	10517426	1328	1330	O
twice	10517426	1331	1336	O
daily	10517426	1337	1342	O
,	10517426	1343	1344	O
200	10517426	1345	1348	O
mg	10517426	1349	1351	O
once	10517426	1352	1356	O
daily	10517426	1357	1362	O
,	10517426	1363	1364	O
or	10517426	1365	1367	O
matching	10517426	1368	1376	B-Intervention
placebo	10517426	1377	1384	I-Intervention
[	10517426	1385	1386	O
n	10517426	1387	1388	O
=	10517426	1389	1390	O
16	10517426	1391	1393	O
]	10517426	1394	1395	O
,	10517426	1396	1397	O
in	10517426	1398	1400	O
each	10517426	1401	1405	O
group	10517426	1406	1411	O
starting	10517426	1412	1420	O
28	10517426	1421	1423	O
hours	10517426	1424	1429	O
after	10517426	1430	1435	O
inoculation	10517426	1436	1447	O
)	10517426	1448	1449	O
.	10517426	1450	1451	O

All	10517426	1452	1455	O
regimens	10517426	1456	1464	O
were	10517426	1465	1469	O
continued	10517426	1470	1479	O
for	10517426	1480	1483	O
5	10517426	1484	1485	O
days	10517426	1486	1490	O
.	10517426	1491	1492	O

MAIN	10517426	1493	1497	O
OUTCOME	10517426	1498	1505	O
MEASURES	10517426	1506	1514	O
Comparing	10517426	1515	1524	O
placebo	10517426	1525	1532	B-Intervention
groups	10517426	1533	1539	O
with	10517426	1540	1544	O
pooled	10517426	1545	1551	O
treatment	10517426	1552	1561	B-Intervention
groups	10517426	1562	1568	O
,	10517426	1569	1570	O
for	10517426	1571	1574	O
prophylaxis	10517426	1575	1586	B-Outcome
,	10517426	1587	1588	O
outcomes	10517426	1589	1597	O
included	10517426	1598	1606	O
frequency	10517426	1607	1616	B-Outcome
of	10517426	1617	1619	I-Outcome
infection	10517426	1620	1629	I-Outcome
and	10517426	1630	1633	O
viral	10517426	1634	1639	B-Outcome
shedding	10517426	1640	1648	I-Outcome
;	10517426	1649	1650	O
for	10517426	1651	1654	O
treatment	10517426	1655	1664	B-Outcome
,	10517426	1665	1666	O
viral	10517426	1667	1672	B-Outcome
shedding	10517426	1673	1681	I-Outcome
in	10517426	1682	1684	I-Outcome
titers	10517426	1685	1691	I-Outcome
.	10517426	1692	1693	O

RESULTS	10517426	1694	1701	O
In	10517426	1702	1704	O
the	10517426	1705	1708	O
prophylaxis	10517426	1709	1720	O
study	10517426	1721	1726	O
,	10517426	1727	1728	O
8	10517426	1729	1730	B-Count
(	10517426	1731	1732	I-Count
67	10517426	1733	1735	I-Count
%	10517426	1736	1737	I-Count
)	10517426	1738	1739	I-Count
of	10517426	1740	1742	I-Count
12	10517426	1743	1745	I-Count
placebo	10517426	1746	1753	B-Intervention
and	10517426	1754	1757	O
8	10517426	1758	1759	B-Count
(	10517426	1760	1761	I-Count
38	10517426	1762	1764	I-Count
%	10517426	1765	1766	I-Count
)	10517426	1767	1768	I-Count
of	10517426	1769	1771	I-Count
21	10517426	1772	1774	I-Count
oseltamivir	10517426	1775	1786	B-Intervention
recipients	10517426	1787	1797	O
became	10517426	1798	1804	O
infected	10517426	1805	1813	B-Outcome
(	10517426	1814	1815	O
P	10517426	1816	1817	O
=	10517426	1818	1819	O
.16	10517426	1820	1823	O
;	10517426	1824	1825	O
efficacy	10517426	1826	1834	O
,	10517426	1835	1836	O
61	10517426	1837	1839	O
%	10517426	1840	1841	O
)	10517426	1842	1843	O
;	10517426	1844	1845	O
6	10517426	1846	1847	B-Count
(	10517426	1848	1849	I-Count
50	10517426	1850	1852	I-Count
%	10517426	1853	1854	I-Count
)	10517426	1855	1856	I-Count
placebo	10517426	1857	1864	B-Intervention
compared	10517426	1865	1873	O
with	10517426	1874	1878	O
0	10517426	1879	1880	B-Count
oseltamivir	10517426	1881	1892	B-Intervention
recipients	10517426	1893	1903	O
shed	10517426	1904	1908	B-Outcome
virus	10517426	1909	1914	I-Outcome
(	10517426	1915	1916	O
P	10517426	1917	1918	O
<	10517426	1919	1920	O
.001	10517426	1921	1925	O
;	10517426	1926	1927	O
efficacy	10517426	1928	1936	O
,	10517426	1937	1938	O
100	10517426	1939	1942	O
%	10517426	1943	1944	O
)	10517426	1945	1946	O
,	10517426	1947	1948	O
and	10517426	1949	1952	O
33	10517426	1953	1955	B-Count
%	10517426	1956	1957	I-Count
of	10517426	1958	1960	O
placebo	10517426	1961	1968	B-Intervention
but	10517426	1969	1972	O
no	10517426	1973	1975	B-Count
oseltamivir	10517426	1976	1987	B-Intervention
recipient	10517426	1988	1997	O
had	10517426	1998	2001	O
infection-related	10517426	2002	2019	B-Outcome
respiratory	10517426	2020	2031	I-Outcome
illness	10517426	2032	2039	I-Outcome
(	10517426	2040	2041	O
P	10517426	2042	2043	O
<	10517426	2044	2045	O
.01	10517426	2046	2049	O
)	10517426	2050	2051	O
.	10517426	2052	2053	O

Among	10517426	2054	2059	O
infected	10517426	2060	2068	O
subjects	10517426	2069	2077	O
in	10517426	2078	2080	O
the	10517426	2081	2084	O
treatment	10517426	2085	2094	O
study	10517426	2095	2100	O
(	10517426	2101	2102	O
n	10517426	2103	2104	O
=	10517426	2105	2106	O
69	10517426	2107	2109	O
)	10517426	2110	2111	O
,	10517426	2112	2113	O
the	10517426	2114	2117	O
viral	10517426	2118	2123	B-Outcome
titer	10517426	2124	2129	I-Outcome
area	10517426	2130	2134	I-Outcome
under	10517426	2135	2140	I-Outcome
the	10517426	2141	2144	I-Outcome
curve	10517426	2145	2150	I-Outcome
of	10517426	2151	2153	O
the	10517426	2154	2157	O
combined	10517426	2158	2166	B-Intervention
oseltamivir	10517426	2167	2178	I-Intervention
groups	10517426	2179	2185	O
(	10517426	2186	2187	O
n	10517426	2188	2189	O
=	10517426	2190	2191	O
56	10517426	2192	2194	O
)	10517426	2195	2196	O
was	10517426	2197	2200	O
lower	10517426	2201	2206	B-Observation
(	10517426	2207	2208	O
median	10517426	2209	2215	O
[	10517426	2216	2217	O
interquartile	10517426	2218	2231	O
range	10517426	2232	2237	O
[	10517426	2238	2239	O
IQR	10517426	2240	2243	O
]	10517426	2244	2245	O
]	10517426	2246	2247	O
,	10517426	2248	2249	O
80	10517426	2250	2252	O
[	10517426	2253	2254	O
23	10517426	2255	2257	O
-	10517426	2257	2258	O
151	10517426	2258	2261	O
]	10517426	2262	2263	O
vs	10517426	2264	2266	O
273	10517426	2267	2270	O
[	10517426	2271	2272	O
79	10517426	2273	2275	O
-	10517426	2275	2276	O
306	10517426	2276	2279	O
]	10517426	2280	2281	O
log10	10517426	2282	2287	O
tissue	10517426	2288	2294	O
culture-infective	10517426	2295	2312	O
doses50	10517426	2313	2320	O
per	10517426	2321	2324	O
milliliter	10517426	2325	2335	O
x	10517426	2336	2337	O
hour	10517426	2338	2342	O
;	10517426	2343	2344	O
P	10517426	2345	2346	O
=	10517426	2347	2348	O
.02	10517426	2349	2352	O
)	10517426	2353	2354	O
than	10517426	2355	2359	O
the	10517426	2360	2363	O
placebo	10517426	2364	2371	B-Intervention
group	10517426	2372	2377	O
(	10517426	2378	2379	O
n	10517426	2380	2381	O
=	10517426	2382	2383	O
13	10517426	2384	2386	O
)	10517426	2387	2388	O
,	10517426	2389	2390	O
and	10517426	2391	2394	O
the	10517426	2395	2398	O
median	10517426	2399	2405	B-Outcome
(	10517426	2406	2407	I-Outcome
IQR	10517426	2408	2411	I-Outcome
)	10517426	2412	2413	I-Outcome
duration	10517426	2414	2422	I-Outcome
of	10517426	2423	2425	I-Outcome
viral	10517426	2426	2431	I-Outcome
shedding	10517426	2432	2440	I-Outcome
with	10517426	2441	2445	I-Outcome
therapy	10517426	2446	2453	I-Outcome
was	10517426	2454	2457	O
reduced	10517426	2458	2465	B-Observation
from	10517426	2466	2470	I-Observation
107	10517426	2471	2474	I-Observation
(	10517426	2475	2476	I-Observation
83	10517426	2477	2479	I-Observation
-	10517426	2479	2480	I-Observation
131	10517426	2480	2483	I-Observation
)	10517426	2484	2485	I-Observation
to	10517426	2486	2488	I-Observation
58	10517426	2489	2491	I-Observation
(	10517426	2492	2493	I-Observation
35	10517426	2494	2496	I-Observation
-	10517426	2496	2497	I-Observation
59	10517426	2497	2499	I-Observation
)	10517426	2500	2501	I-Observation
hours	10517426	2502	2507	I-Observation
(	10517426	2508	2509	O
P	10517426	2510	2511	O
=	10517426	2512	2513	O
.003	10517426	2514	2518	O
)	10517426	2519	2520	O
.	10517426	2521	2522	O

Oseltamivir	10517426	2523	2534	B-Intervention
treatment	10517426	2535	2544	O
also	10517426	2545	2549	O
reduced	10517426	2550	2557	B-Observation
symptom	10517426	2558	2565	B-Outcome
scores	10517426	2566	2572	I-Outcome
(	10517426	2573	2574	O
median	10517426	2575	2581	O
[	10517426	2582	2583	O
IQR	10517426	2584	2587	O
]	10517426	2588	2589	O
score-hours	10517426	2590	2601	O
,	10517426	2602	2603	O
225	10517426	2604	2607	O
[	10517426	2608	2609	O
97	10517426	2610	2612	O
-	10517426	2612	2613	O
349	10517426	2613	2616	O
]	10517426	2617	2618	O
vs	10517426	2619	2621	O
400	10517426	2622	2625	O
[	10517426	2626	2627	O
189	10517426	2628	2631	O
-	10517426	2631	2632	O
645	10517426	2632	2635	O
]	10517426	2636	2637	O
;	10517426	2638	2639	O
P	10517426	2640	2641	O
=	10517426	2642	2643	O
.05	10517426	2644	2647	O
)	10517426	2648	2649	O
,	10517426	2650	2651	O
and	10517426	2652	2655	O
nasal	10517426	2656	2661	B-Outcome
proinflammatory	10517426	2662	2677	I-Outcome
cytokine	10517426	2678	2686	I-Outcome
levels	10517426	2687	2693	I-Outcome
.	10517426	2694	2695	O

Transient	10517426	2696	2705	B-Outcome
mild	10517426	2706	2710	I-Outcome
to	10517426	2711	2713	I-Outcome
moderate	10517426	2714	2722	I-Outcome
nausea	10517426	2723	2729	I-Outcome
after	10517426	2730	2735	O
dosing	10517426	2736	2742	O
was	10517426	2743	2746	O
observed	10517426	2747	2755	O
in	10517426	2756	2758	O
15	10517426	2759	2761	B-Count
(	10517426	2762	2763	I-Count
17	10517426	2764	2766	I-Count
%	10517426	2767	2768	I-Count
)	10517426	2769	2770	I-Count
of	10517426	2771	2773	I-Count
88	10517426	2774	2776	I-Count
oseltamivir	10517426	2777	2788	B-Intervention
and	10517426	2789	2792	O
2	10517426	2793	2794	B-Count
(	10517426	2795	2796	I-Count
7	10517426	2797	2798	I-Count
%	10517426	2799	2800	I-Count
)	10517426	2801	2802	I-Count
of	10517426	2803	2805	I-Count
29	10517426	2806	2808	I-Count
placebo	10517426	2809	2816	B-Intervention
recipients	10517426	2817	2827	O
(	10517426	2828	2829	O
95	10517426	2830	2832	O
%	10517426	2833	2834	O
confidence	10517426	2835	2845	O
interval	10517426	2846	2854	O
for	10517426	2855	2858	O
difference	10517426	2859	2869	O
,	10517426	2870	2871	O
-11	10517426	2872	2875	O
%	10517426	2876	2877	O
to	10517426	2878	2880	O
68	10517426	2881	2883	O
%	10517426	2884	2885	O
)	10517426	2886	2887	O
,	10517426	2888	2889	O
which	10517426	2890	2895	O
was	10517426	2896	2899	O
largely	10517426	2900	2907	O
prevented	10517426	2908	2917	O
by	10517426	2918	2920	O
ingestion	10517426	2921	2930	O
with	10517426	2931	2935	O
food	10517426	2936	2940	O
.	10517426	2941	2942	O

CONCLUSIONS	10517426	2943	2954	O
In	10517426	2955	2957	O
these	10517426	2958	2963	O
trials	10517426	2964	2970	O
,	10517426	2971	2972	O
prophylaxis	10517426	2973	2984	O
and	10517426	2985	2988	O
early	10517426	2989	2994	O
treatment	10517426	2995	3004	O
with	10517426	3005	3009	O
oral	10517426	3010	3014	B-Intervention
oseltamivir	10517426	3015	3026	I-Intervention
were	10517426	3027	3031	O
both	10517426	3032	3036	O
associated	10517426	3037	3047	O
with	10517426	3048	3052	O
significant	10517426	3053	3064	B-Observation
antiviral	10517426	3065	3074	B-Outcome
and	10517426	3075	3078	I-Outcome
clinical	10517426	3079	3087	I-Outcome
effects	10517426	3088	3095	I-Outcome
in	10517426	3096	3098	O
experimental	10517426	3099	3111	B-Participant
human	10517426	3112	3117	I-Participant
influenza	10517426	3118	3127	I-Participant
.	10517426	3128	3129	O

An	10525558	0	2	O
empirical	10525558	3	12	O
comparison	10525558	13	23	O
of	10525558	24	26	O
the	10525558	27	30	O
St	10525558	31	33	B-Intervention
George	10525558	34	40	I-Intervention
's	10525558	41	43	I-Intervention
Respiratory	10525558	44	55	I-Intervention
Questionnaire	10525558	56	69	I-Intervention
(	10525558	70	71	I-Intervention
SGRQ	10525558	72	76	I-Intervention
)	10525558	77	78	I-Intervention
and	10525558	79	82	O
the	10525558	83	86	O
Chronic	10525558	87	94	B-Intervention
Respiratory	10525558	95	106	I-Intervention
Disease	10525558	107	114	I-Intervention
Questionnaire	10525558	115	128	I-Intervention
(	10525558	129	130	I-Intervention
CRQ	10525558	131	134	I-Intervention
)	10525558	135	136	I-Intervention
in	10525558	137	139	O
a	10525558	140	141	O
clinical	10525558	142	150	O
trial	10525558	151	156	O
setting	10525558	157	164	O
.	10525558	165	166	O

BACKGROUND	10525558	167	177	O
The	10525558	178	181	O
Chronic	10525558	182	189	O
Respiratory	10525558	190	201	O
Questionnaire	10525558	202	215	O
(	10525558	216	217	O
CRQ	10525558	218	221	O
)	10525558	222	223	O
and	10525558	224	227	O
the	10525558	228	231	O
St	10525558	232	234	O
George	10525558	235	241	O
's	10525558	242	244	O
Respiratory	10525558	245	256	O
Questionnaire	10525558	257	270	O
(	10525558	271	272	O
SGRQ	10525558	273	277	O
)	10525558	278	279	O
are	10525558	280	283	O
the	10525558	284	287	O
two	10525558	288	291	O
most	10525558	292	296	O
widely	10525558	297	303	O
used	10525558	304	308	O
quality	10525558	309	316	O
of	10525558	317	319	O
life	10525558	320	324	O
questionnaires	10525558	325	339	O
in	10525558	340	342	O
chronic	10525558	343	350	O
obstructive	10525558	351	362	O
pulmonary	10525558	363	372	O
disease	10525558	373	380	O
(	10525558	381	382	O
COPD	10525558	383	387	O
)	10525558	388	389	O
.	10525558	390	391	O

A	10525558	392	393	O
study	10525558	394	399	O
was	10525558	400	403	O
undertaken	10525558	404	414	O
to	10525558	415	417	O
compare	10525558	418	425	O
directly	10525558	426	434	O
the	10525558	435	438	O
self-administered	10525558	439	456	O
version	10525558	457	464	O
of	10525558	465	467	O
the	10525558	468	471	O
CRQ	10525558	472	475	B-Intervention
and	10525558	476	479	O
the	10525558	480	483	O
SGRQ	10525558	484	488	B-Intervention
with	10525558	489	493	O
respect	10525558	494	501	O
to	10525558	502	504	O
feasibility	10525558	505	516	B-Outcome
,	10525558	517	518	O
internal	10525558	519	527	B-Outcome
consistency	10525558	528	539	I-Outcome
,	10525558	540	541	O
validity	10525558	542	550	B-Outcome
,	10525558	551	552	O
and	10525558	553	556	O
sensitivity	10525558	557	568	B-Outcome
to	10525558	569	571	I-Outcome
changes	10525558	572	579	I-Outcome
resulting	10525558	580	589	O
from	10525558	590	594	O
bronchodilator	10525558	595	609	B-Participant
therapy	10525558	610	617	I-Participant
.	10525558	618	619	O

METHODS	10525558	620	627	O
One	10525558	628	631	O
hundred	10525558	632	639	O
and	10525558	640	643	O
forty	10525558	644	649	O
four	10525558	650	654	O
patients	10525558	655	663	O
with	10525558	664	668	O
moderate	10525558	669	677	B-Participant
or	10525558	678	680	I-Participant
severe	10525558	681	687	I-Participant
COPD	10525558	688	692	I-Participant
were	10525558	693	697	O
randomly	10525558	698	706	O
assigned	10525558	707	715	O
to	10525558	716	718	O
receive	10525558	719	726	O
three	10525558	727	732	O
months	10525558	733	739	O
of	10525558	740	742	O
treatment	10525558	743	752	O
with	10525558	753	757	O
either	10525558	758	764	O
salmeterol	10525558	765	775	B-Participant
,	10525558	776	777	O
salmeterol	10525558	778	788	B-Participant
+	10525558	789	790	I-Participant
ipratropium	10525558	791	802	I-Participant
bromide	10525558	803	810	I-Participant
,	10525558	811	812	O
or	10525558	813	815	O
placebo	10525558	816	823	B-Participant
.	10525558	824	825	O

Quality	10525558	826	833	B-Outcome
of	10525558	834	836	I-Outcome
life	10525558	837	841	I-Outcome
was	10525558	842	845	O
measured	10525558	846	854	O
at	10525558	855	857	O
baseline	10525558	858	866	O
and	10525558	867	870	O
after	10525558	871	876	O
12	10525558	877	879	O
weeks	10525558	880	885	O
of	10525558	886	888	O
treatment	10525558	889	898	O
.	10525558	899	900	O

RESULTS	10525558	901	908	O
The	10525558	909	912	O
proportions	10525558	913	924	B-Outcome
of	10525558	925	927	I-Outcome
missing	10525558	928	935	I-Outcome
values	10525558	936	942	I-Outcome
per	10525558	943	946	I-Outcome
patient	10525558	947	954	I-Outcome
were	10525558	955	959	O
low	10525558	960	963	B-Observation
for	10525558	964	967	O
both	10525558	968	972	B-Intervention
questionnaires	10525558	973	987	I-Intervention
(	10525558	988	989	O
0.54	10525558	990	994	B-Observation
%	10525558	995	996	I-Observation
for	10525558	997	1000	O
the	10525558	1001	1004	O
CRQ	10525558	1005	1008	B-Intervention
and	10525558	1009	1012	O
2	10525558	1013	1014	B-Observation
%	10525558	1015	1016	I-Observation
for	10525558	1017	1020	O
the	10525558	1021	1024	O
SGRQ	10525558	1025	1029	B-Intervention
)	10525558	1030	1031	O
.	10525558	1032	1033	O

The	10525558	1034	1037	O
internal	10525558	1038	1046	B-Outcome
consistency	10525558	1047	1058	I-Outcome
was	10525558	1059	1062	O
good	10525558	1063	1067	B-Observation
for	10525558	1068	1071	O
both	10525558	1072	1076	B-Intervention
questionnaires	10525558	1077	1091	I-Intervention
(	10525558	1092	1093	O
Cronbach	10525558	1094	1102	B-Outcome
's	10525558	1103	1105	I-Outcome
alpha	10525558	1106	1111	I-Outcome
coefficients	10525558	1112	1124	I-Outcome
>	10525558	1125	1126	B-Observation
/=	10525558	1127	1129	I-Observation
0.84	10525558	1130	1134	I-Observation
for	10525558	1135	1138	O
the	10525558	1139	1142	O
CRQ	10525558	1143	1146	B-Intervention
and	10525558	1147	1150	O
>	10525558	1151	1152	B-Observation
/=	10525558	1153	1155	I-Observation
0.76	10525558	1156	1160	I-Observation
for	10525558	1161	1164	O
the	10525558	1165	1168	O
SGRQ	10525558	1169	1173	B-Intervention
)	10525558	1174	1175	O
.	10525558	1176	1177	O

Factor	10525558	1178	1184	O
analysis	10525558	1185	1193	O
confirmed	10525558	1194	1203	O
the	10525558	1204	1207	O
original	10525558	1208	1216	B-Outcome
domain	10525558	1217	1223	I-Outcome
structure	10525558	1224	1233	I-Outcome
of	10525558	1234	1236	O
the	10525558	1237	1240	O
CRQ	10525558	1241	1244	B-Intervention
but	10525558	1245	1248	O
not	10525558	1249	1252	O
of	10525558	1253	1255	O
the	10525558	1256	1259	O
SGRQ	10525558	1260	1264	B-Intervention
.	10525558	1265	1266	O

Correlations	10525558	1267	1279	B-Outcome
with	10525558	1280	1284	I-Outcome
forced	10525558	1285	1291	I-Outcome
expiratory	10525558	1292	1302	I-Outcome
volume	10525558	1303	1309	I-Outcome
in	10525558	1310	1312	I-Outcome
one	10525558	1313	1316	I-Outcome
second	10525558	1317	1323	I-Outcome
(	10525558	1324	1325	I-Outcome
FEV	10525558	1326	1329	I-Outcome
(	10525558	1330	1331	I-Outcome
1	10525558	1332	1333	I-Outcome
)	10525558	1334	1335	I-Outcome
)	10525558	1336	1337	I-Outcome
%	10525558	1338	1339	I-Outcome
predicted	10525558	1340	1349	I-Outcome
and	10525558	1350	1353	O
peak	10525558	1354	1358	B-Outcome
expiratory	10525558	1359	1369	I-Outcome
flow	10525558	1370	1374	I-Outcome
rate	10525558	1375	1379	I-Outcome
(	10525558	1380	1381	I-Outcome
PEFR	10525558	1382	1386	I-Outcome
)	10525558	1387	1388	I-Outcome
were	10525558	1389	1393	O
low	10525558	1394	1397	B-Observation
for	10525558	1398	1401	O
both	10525558	1402	1406	B-Intervention
questionnaires	10525558	1407	1421	I-Intervention
but	10525558	1422	1425	O
better	10525558	1426	1432	B-Observation
for	10525558	1433	1436	O
the	10525558	1437	1440	O
SGRQ	10525558	1441	1445	B-Intervention
than	10525558	1446	1450	O
for	10525558	1451	1454	O
the	10525558	1455	1458	O
CRQ	10525558	1459	1462	B-Intervention
.	10525558	1463	1464	O

The	10525558	1465	1468	O
ability	10525558	1469	1476	B-Outcome
to	10525558	1477	1479	I-Outcome
discriminate	10525558	1480	1492	I-Outcome
between	10525558	1493	1500	I-Outcome
subjects	10525558	1501	1509	I-Outcome
with	10525558	1510	1514	I-Outcome
different	10525558	1515	1524	I-Outcome
levels	10525558	1525	1531	I-Outcome
of	10525558	1532	1534	I-Outcome
FEV	10525558	1535	1538	I-Outcome
(	10525558	1539	1540	I-Outcome
1	10525558	1541	1542	I-Outcome
)	10525558	1543	1544	I-Outcome
was	10525558	1545	1548	O
somewhat	10525558	1549	1557	B-Observation
better	10525558	1558	1564	I-Observation
for	10525558	1565	1568	O
the	10525558	1569	1572	O
SGRQ	10525558	1573	1577	B-Intervention
.	10525558	1578	1579	O

The	10525558	1580	1583	O
correlations	10525558	1584	1596	B-Outcome
with	10525558	1597	1601	I-Outcome
symptom	10525558	1602	1609	I-Outcome
scores	10525558	1610	1616	I-Outcome
were	10525558	1617	1621	O
comparable	10525558	1622	1632	B-Observation
for	10525558	1633	1636	O
both	10525558	1637	1641	B-Intervention
questionnaires	10525558	1642	1656	I-Intervention
.	10525558	1657	1658	O

Cross	10525558	1659	1664	O
sectionally	10525558	1665	1676	O
,	10525558	1677	1678	O
the	10525558	1679	1682	O
scores	10525558	1683	1689	B-Outcome
of	10525558	1690	1692	O
the	10525558	1693	1696	O
two	10525558	1697	1700	B-Intervention
questionnaires	10525558	1701	1715	I-Intervention
were	10525558	1716	1720	O
moderately	10525558	1721	1731	B-Observation
to	10525558	1732	1734	I-Observation
highly	10525558	1735	1741	I-Observation
correlated	10525558	1742	1752	I-Observation
(	10525558	1753	1754	O
coefficients	10525558	1755	1767	B-Outcome
ranged	10525558	1768	1774	O
from	10525558	1775	1779	B-Observation
0.35	10525558	1780	1784	I-Observation
to	10525558	1785	1787	I-Observation
0.72	10525558	1788	1792	I-Observation
)	10525558	1793	1794	O
.	10525558	1795	1796	O

Longitudinally	10525558	1797	1811	O
,	10525558	1812	1813	O
these	10525558	1814	1819	O
correlations	10525558	1820	1832	B-Outcome
were	10525558	1833	1837	O
lower	10525558	1838	1843	B-Observation
(	10525558	1844	1845	O
coefficients	10525558	1846	1858	B-Outcome
ranged	10525558	1859	1865	O
from	10525558	1866	1870	B-Observation
0.17	10525558	1871	1875	I-Observation
to	10525558	1876	1878	I-Observation
0.54	10525558	1879	1883	I-Observation
)	10525558	1884	1885	O
but	10525558	1886	1889	O
were	10525558	1890	1894	O
still	10525558	1895	1900	O
significant	10525558	1901	1912	B-Observation
.	10525558	1913	1914	O

The	10525558	1915	1918	O
CRQ	10525558	1919	1922	B-Outcome
total	10525558	1923	1928	I-Outcome
and	10525558	1929	1932	I-Outcome
emotions	10525558	1933	1941	I-Outcome
score	10525558	1942	1947	I-Outcome
and	10525558	1948	1951	O
the	10525558	1952	1955	O
SGRQ	10525558	1956	1960	B-Outcome
symptoms	10525558	1961	1969	I-Outcome
score	10525558	1970	1975	I-Outcome
were	10525558	1976	1980	O
the	10525558	1981	1984	O
most	10525558	1985	1989	B-Observation
responsive	10525558	1990	2000	I-Observation
to	10525558	2001	2003	I-Observation
change	10525558	2004	2010	I-Observation
.	10525558	2011	2012	O

The	10525558	2013	2016	O
SGRQ	10525558	2017	2021	B-Outcome
symptoms	10525558	2022	2030	I-Outcome
domain	10525558	2031	2037	I-Outcome
was	10525558	2038	2041	O
the	10525558	2042	2045	O
only	10525558	2046	2050	O
domain	10525558	2051	2057	O
where	10525558	2058	2063	O
the	10525558	2064	2067	O
improvement	10525558	2068	2079	O
in	10525558	2080	2082	O
patients	10525558	2083	2091	O
receiving	10525558	2092	2101	O
combination	10525558	2102	2113	B-Participant
treatment	10525558	2114	2123	I-Participant
crossed	10525558	2124	2131	O
the	10525558	2132	2135	O
threshold	10525558	2136	2145	O
for	10525558	2146	2149	O
clinical	10525558	2150	2158	O
relevance	10525558	2159	2168	O
.	10525558	2169	2170	O

CONCLUSIONS	10525558	2171	2182	O
Since	10525558	2183	2188	O
this	10525558	2189	2193	O
analysis	10525558	2194	2202	O
of	10525558	2203	2205	O
reliability	10525558	2206	2217	B-Outcome
,	10525558	2218	2219	O
validity	10525558	2220	2228	B-Outcome
,	10525558	2229	2230	O
and	10525558	2231	2234	O
responsiveness	10525558	2235	2249	B-Outcome
to	10525558	2250	2252	I-Outcome
change	10525558	2253	2259	I-Outcome
did	10525558	2260	2263	O
not	10525558	2264	2267	O
clearly	10525558	2268	2275	O
favour	10525558	2276	2282	B-Observation
one	10525558	2283	2286	B-Intervention
instrument	10525558	2287	2297	I-Intervention
above	10525558	2298	2303	O
the	10525558	2304	2307	O
other	10525558	2308	2313	O
,	10525558	2314	2315	O
the	10525558	2316	2319	O
choice	10525558	2320	2326	O
between	10525558	2327	2334	O
the	10525558	2335	2338	O
CRQ	10525558	2339	2342	B-Intervention
and	10525558	2343	2346	O
the	10525558	2347	2350	O
SGRQ	10525558	2351	2355	B-Intervention
can	10525558	2356	2359	O
be	10525558	2360	2362	O
based	10525558	2363	2368	O
on	10525558	2369	2371	O
other	10525558	2372	2377	O
considerations	10525558	2378	2392	O
such	10525558	2393	2397	O
as	10525558	2398	2400	O
the	10525558	2401	2404	O
required	10525558	2405	2413	O
sample	10525558	2414	2420	O
size	10525558	2421	2425	O
or	10525558	2426	2428	O
the	10525558	2429	2432	O
availability	10525558	2433	2445	O
of	10525558	2446	2448	O
reference	10525558	2449	2458	O
values	10525558	2459	2465	O
.	10525558	2466	2467	O

A	10554799	0	1	O
randomized	10554799	2	12	O
controlled	10554799	13	23	O
trial	10554799	24	29	O
of	10554799	30	32	O
itraconazole	10554799	33	45	B-Intervention
versus	10554799	46	52	O
fluconazole	10554799	53	64	B-Intervention
for	10554799	65	68	O
the	10554799	69	72	O
prevention	10554799	73	83	B-Observation
of	10554799	84	86	O
fungal	10554799	87	93	B-Outcome
infections	10554799	94	104	I-Outcome
in	10554799	105	107	O
patients	10554799	108	116	O
with	10554799	117	121	O
haematological	10554799	122	136	B-Participant
malignancies	10554799	137	149	I-Participant
.	10554799	150	151	O

U.K.	10554799	152	156	O
Multicentre	10554799	157	168	O
Antifungal	10554799	169	179	O
Prophylaxis	10554799	180	191	O
Study	10554799	192	197	O
Group	10554799	198	203	O
.	10554799	204	205	O

Fluconazole	10554799	206	217	O
is	10554799	218	220	O
widely	10554799	221	227	O
used	10554799	228	232	O
as	10554799	233	235	O
antifungal	10554799	236	246	O
prophylaxis	10554799	247	258	O
but	10554799	259	262	O
it	10554799	263	265	O
is	10554799	266	268	O
ineffective	10554799	269	280	O
against	10554799	281	288	O
Aspergillus	10554799	289	300	O
.	10554799	301	302	O

Itraconazole	10554799	303	315	O
has	10554799	316	319	O
a	10554799	320	321	O
broader	10554799	322	329	O
spectrum	10554799	330	338	O
of	10554799	339	341	O
activity	10554799	342	350	O
but	10554799	351	354	O
the	10554799	355	358	O
capsules	10554799	359	367	O
give	10554799	368	372	O
erratic	10554799	373	380	O
bioavailability	10554799	381	396	O
in	10554799	397	399	O
neutropenic	10554799	400	411	O
patients	10554799	412	420	O
.	10554799	421	422	O

We	10554799	423	425	O
compared	10554799	426	434	O
itraconazole	10554799	435	447	B-Intervention
oral	10554799	448	452	I-Intervention
solution	10554799	453	461	I-Intervention
(	10554799	462	463	O
which	10554799	464	469	O
has	10554799	470	473	O
an	10554799	474	476	O
improved	10554799	477	485	O
pharmacokinetic	10554799	486	501	O
profile	10554799	502	509	O
)	10554799	510	511	O
with	10554799	512	516	O
fluconazole	10554799	517	528	B-Intervention
for	10554799	529	532	O
antifungal	10554799	533	543	B-Outcome
prophylaxis	10554799	544	555	I-Outcome
.	10554799	556	557	O

Adults	10554799	558	564	O
with	10554799	565	569	O
haematological	10554799	570	584	B-Participant
malignancies	10554799	585	597	I-Participant
receiving	10554799	598	607	O
chemotherapy	10554799	608	620	B-Participant
or	10554799	621	623	O
bone	10554799	624	628	B-Participant
marrow	10554799	629	635	I-Participant
transplants	10554799	636	647	I-Participant
were	10554799	648	652	O
randomly	10554799	653	661	O
allocated	10554799	662	671	O
5	10554799	672	673	O
mg/kg/d	10554799	674	681	O
itraconazole	10554799	682	694	B-Intervention
(	10554799	695	696	I-Intervention
itra	10554799	697	701	I-Intervention
)	10554799	702	703	I-Intervention
solution	10554799	704	712	I-Intervention
(	10554799	713	714	O
288	10554799	715	718	O
episodes	10554799	719	727	O
)	10554799	728	729	O
or	10554799	730	732	O
100	10554799	733	736	O
mg	10554799	737	739	O
fluconazole	10554799	740	751	B-Intervention
suspension	10554799	752	762	I-Intervention
(	10554799	763	764	I-Intervention
flu	10554799	765	768	I-Intervention
)	10554799	769	770	I-Intervention
(	10554799	771	772	O
293	10554799	773	776	O
episodes	10554799	777	785	O
)	10554799	786	787	O
from	10554799	788	792	O
before	10554799	793	799	O
the	10554799	800	803	O
onset	10554799	804	809	O
of	10554799	810	812	O
neutropenia	10554799	813	824	O
until	10554799	825	830	O
neutrophil	10554799	831	841	B-Outcome
recovery	10554799	842	850	I-Outcome
or	10554799	851	853	O
suspected	10554799	854	863	B-Outcome
fungal	10554799	864	870	I-Outcome
infection	10554799	871	880	I-Outcome
.	10554799	881	882	O

Outcomes	10554799	883	891	O
were	10554799	892	896	O
assessed	10554799	897	905	O
by	10554799	906	908	O
independent	10554799	909	920	O
reviewers	10554799	921	930	O
unaware	10554799	931	938	O
of	10554799	939	941	O
the	10554799	942	945	O
prophylaxis	10554799	946	957	O
allocation	10554799	958	968	O
.	10554799	969	970	O

More	10554799	971	975	B-Observation
proven	10554799	976	982	B-Outcome
systemic	10554799	983	991	I-Outcome
fungal	10554799	992	998	I-Outcome
infections	10554799	999	1009	I-Outcome
occurred	10554799	1010	1018	O
in	10554799	1019	1021	O
flu	10554799	1022	1025	B-Intervention
(	10554799	1026	1027	O
Aspergillus	10554799	1028	1039	B-Outcome
four	10554799	1040	1044	B-Count
,	10554799	1045	1046	O
Candida	10554799	1047	1054	B-Outcome
tropicalis	10554799	1055	1065	I-Outcome
one	10554799	1066	1069	B-Count
,	10554799	1070	1071	O
C.	10554799	1072	1074	B-Outcome
krusei	10554799	1075	1081	I-Outcome
one	10554799	1082	1085	B-Count
)	10554799	1086	1087	O
than	10554799	1088	1092	O
itra	10554799	1093	1097	B-Intervention
(	10554799	1098	1099	O
C.	10554799	1100	1102	B-Outcome
albicans	10554799	1103	1111	I-Outcome
one	10554799	1112	1115	B-Count
)	10554799	1116	1117	O
and	10554799	1118	1121	O
more	10554799	1122	1126	B-Observation
of	10554799	1127	1129	O
these	10554799	1130	1135	O
were	10554799	1136	1140	O
fatal	10554799	1141	1146	B-Outcome
(	10554799	1147	1148	O
four	10554799	1149	1153	B-Count
versus	10554799	1154	1160	O
nil	10554799	1161	1164	B-Count
)	10554799	1165	1166	O
.	10554799	1167	1168	O

This	10554799	1169	1173	O
difference	10554799	1174	1184	B-Observation
reached	10554799	1185	1192	I-Observation
statistical	10554799	1193	1204	I-Observation
significance	10554799	1205	1217	I-Observation
when	10554799	1218	1222	O
first	10554799	1223	1228	O
study	10554799	1229	1234	B-Intervention
episodes	10554799	1235	1243	I-Intervention
were	10554799	1244	1248	O
considered	10554799	1249	1259	O
separately	10554799	1260	1270	O
(	10554799	1271	1272	O
six	10554799	1273	1276	B-Count
flu	10554799	1277	1280	B-Intervention
versus	10554799	1281	1287	O
nil	10554799	1288	1291	B-Count
itra	10554799	1292	1296	B-Intervention
,	10554799	1297	1298	O
P	10554799	1299	1300	O
=	10554799	1301	1302	O
0.03	10554799	1303	1307	O
)	10554799	1308	1309	O
.	10554799	1310	1311	O

Significantly	10554799	1312	1325	B-Count
more	10554799	1326	1330	I-Count
deaths	10554799	1331	1337	B-Outcome
of	10554799	1338	1340	I-Outcome
presumed	10554799	1341	1349	I-Outcome
fungal	10554799	1350	1356	I-Outcome
origin	10554799	1357	1363	I-Outcome
occurred	10554799	1364	1372	O
in	10554799	1373	1375	O
flu	10554799	1376	1379	B-Intervention
than	10554799	1380	1384	O
itra	10554799	1385	1389	B-Intervention
(	10554799	1390	1391	O
seven	10554799	1392	1397	B-Count
versus	10554799	1398	1404	O
nil	10554799	1405	1408	B-Count
,	10554799	1409	1410	O
P	10554799	1411	1412	O
=	10554799	1413	1414	O
0.024	10554799	1415	1420	O
)	10554799	1421	1422	O
.	10554799	1423	1424	O

There	10554799	1425	1430	O
were	10554799	1431	1435	O
significantly	10554799	1436	1449	B-Observation
more	10554799	1450	1454	I-Observation
cases	10554799	1455	1460	B-Outcome
of	10554799	1461	1463	I-Outcome
proven	10554799	1464	1470	I-Outcome
aspergillosis	10554799	1471	1484	I-Outcome
in	10554799	1485	1487	O
flu	10554799	1488	1491	B-Intervention
than	10554799	1492	1496	O
itra	10554799	1497	1501	B-Intervention
(	10554799	1502	1503	O
six	10554799	1504	1507	B-Count
versus	10554799	1508	1514	O
nil	10554799	1515	1518	B-Count
,	10554799	1519	1520	O
P	10554799	1521	1522	O
=	10554799	1523	1524	O
0.038	10554799	1525	1530	O
,	10554799	1531	1532	O
5/6	10554799	1533	1536	O
cases	10554799	1537	1542	O
were	10554799	1543	1547	O
fatal	10554799	1548	1553	O
)	10554799	1554	1555	O
if	10554799	1556	1558	O
those	10554799	1559	1564	O
occurring	10554799	1565	1574	O
outside	10554799	1575	1582	O
the	10554799	1583	1586	O
study	10554799	1587	1592	O
period	10554799	1593	1599	O
are	10554799	1600	1603	O
included	10554799	1604	1612	O
.	10554799	1613	1614	O

Significantly	10554799	1615	1628	B-Observation
more	10554799	1629	1633	I-Observation
patients	10554799	1634	1642	I-Observation
receiving	10554799	1643	1652	O
flu	10554799	1653	1656	B-Intervention
required	10554799	1657	1665	O
amphotericin	10554799	1666	1678	B-Outcome
B	10554799	1679	1680	I-Outcome
(	10554799	1681	1682	O
58	10554799	1683	1685	B-Count
v	10554799	1686	1687	O
39	10554799	1688	1690	B-Count
,	10554799	1691	1692	O
P	10554799	1693	1694	O
=	10554799	1695	1696	O
0.043	10554799	1697	1702	O
)	10554799	1703	1704	O
but	10554799	1705	1708	O
this	10554799	1709	1713	O
may	10554799	1714	1717	O
have	10554799	1718	1722	O
been	10554799	1723	1727	O
affected	10554799	1728	1736	O
by	10554799	1737	1739	O
the	10554799	1740	1743	O
fact	10554799	1744	1748	O
that	10554799	1749	1753	O
the	10554799	1754	1757	O
study	10554799	1758	1763	O
was	10554799	1764	1767	O
not	10554799	1768	1771	O
blinded	10554799	1772	1779	O
.	10554799	1780	1781	O

There	10554799	1782	1787	O
were	10554799	1788	1792	O
11	10554799	1793	1795	B-Count
proven	10554799	1796	1802	B-Outcome
mucosal	10554799	1803	1810	I-Outcome
candidal	10554799	1811	1819	I-Outcome
infections	10554799	1820	1830	I-Outcome
in	10554799	1831	1833	O
flu	10554799	1834	1837	B-Intervention
and	10554799	1838	1841	O
four	10554799	1842	1846	B-Count
in	10554799	1847	1849	O
itra	10554799	1850	1854	B-Intervention
.	10554799	1855	1856	O

Itraconazole	10554799	1857	1869	B-Intervention
solution	10554799	1870	1878	I-Intervention
and	10554799	1879	1882	O
fluconazole	10554799	1883	1894	B-Intervention
provide	10554799	1895	1902	O
effective	10554799	1903	1912	B-Observation
prophylaxis	10554799	1913	1924	B-Outcome
against	10554799	1925	1932	I-Outcome
Candida	10554799	1933	1940	I-Outcome
but	10554799	1941	1944	O
itraconazole	10554799	1945	1957	B-Intervention
affords	10554799	1958	1965	O
greater	10554799	1966	1973	B-Observation
protection	10554799	1974	1984	I-Observation
against	10554799	1985	1992	O
fatal	10554799	1993	1998	B-Outcome
aspergillosis	10554799	1999	2012	I-Outcome
.	10554799	2013	2014	O

The	10555930	0	3	O
effect	10555930	4	10	O
of	10555930	11	13	O
Cys	10555930	14	17	B-Intervention
LT1	10555930	18	21	I-Intervention
receptor	10555930	22	30	I-Intervention
blockade	10555930	31	39	I-Intervention
on	10555930	40	42	O
airway	10555930	43	49	B-Outcome
responses	10555930	50	59	I-Outcome
to	10555930	60	62	I-Outcome
allergen	10555930	63	71	I-Outcome
.	10555930	72	73	O

STUDY	10555930	74	79	O
OBJECTIVE	10555930	80	89	O
To	10555930	90	92	O
evaluate	10555930	93	101	O
the	10555930	102	105	O
effect	10555930	106	112	O
of	10555930	113	115	O
a	10555930	116	117	O
potent	10555930	118	124	O
experimental	10555930	125	137	O
leukotriene	10555930	138	149	O
receptor	10555930	150	158	O
antagonist	10555930	159	169	O
,	10555930	170	171	O
MK-571	10555930	172	178	B-Intervention
,	10555930	179	180	O
on	10555930	181	183	O
airway	10555930	184	190	B-Outcome
responses	10555930	191	200	I-Outcome
to	10555930	201	203	I-Outcome
inhaled	10555930	204	211	I-Outcome
allergen	10555930	212	220	I-Outcome
.	10555930	221	222	O

DESIGN	10555930	223	229	O
Randomized	10555930	230	240	O
,	10555930	241	242	O
double-blind	10555930	243	255	O
,	10555930	256	257	O
placebo-controlled	10555930	258	276	O
,	10555930	277	278	O
crossover	10555930	279	288	O
trial	10555930	289	294	O
.	10555930	295	296	O

SETTING	10555930	297	304	O
Clinical	10555930	305	313	O
research	10555930	314	322	O
center	10555930	323	329	O
.	10555930	330	331	O

SUBJECTS	10555930	332	340	O
Eight	10555930	341	346	O
male	10555930	347	351	B-Participant
volunteers	10555930	352	362	O
with	10555930	363	367	O
allergic	10555930	368	376	B-Participant
asthma	10555930	377	383	I-Participant
.	10555930	384	385	O

INTERVENTIONS	10555930	386	399	O
An	10555930	400	402	O
intravenous	10555930	403	414	O
loading	10555930	415	422	O
dose	10555930	423	427	O
was	10555930	428	431	O
followed	10555930	432	440	O
by	10555930	441	443	O
an	10555930	444	446	O
8-hour	10555930	447	453	O
infusion	10555930	454	462	O
of	10555930	463	465	O
MK-571	10555930	466	472	B-Intervention
or	10555930	473	475	O
placebo	10555930	476	483	B-Intervention
,	10555930	484	485	O
with	10555930	486	490	O
a	10555930	491	492	O
7-	10555930	493	495	O
to	10555930	496	498	O
14-day	10555930	499	505	O
washout	10555930	506	513	O
between	10555930	514	521	O
treatments	10555930	522	532	O
.	10555930	533	534	O

Allergen	10555930	535	543	O
challenge	10555930	544	553	O
was	10555930	554	557	O
performed	10555930	558	567	O
after	10555930	568	573	O
the	10555930	574	577	O
loading	10555930	578	585	O
dose	10555930	586	590	O
and	10555930	591	594	O
a	10555930	595	596	O
histamine	10555930	597	606	O
challenge	10555930	607	616	O
was	10555930	617	620	O
performed	10555930	621	630	O
before	10555930	631	637	O
and	10555930	638	641	O
24	10555930	642	644	O
hours	10555930	645	650	O
after	10555930	651	656	O
allergen	10555930	657	665	O
.	10555930	666	667	O

MEASUREMENTS	10555930	668	680	O
AND	10555930	681	684	O
MAIN	10555930	685	689	O
RESULTS	10555930	690	697	O
Forced	10555930	698	704	B-Outcome
expiratory	10555930	705	715	I-Outcome
volume	10555930	716	722	I-Outcome
in	10555930	723	725	I-Outcome
1	10555930	726	727	I-Outcome
second	10555930	728	734	I-Outcome
was	10555930	735	738	O
measured	10555930	739	747	O
serially	10555930	748	756	O
.	10555930	757	758	O

MK-571	10555930	759	765	B-Intervention
provided	10555930	766	774	O
about	10555930	775	780	O
50	10555930	781	783	B-Observation
%	10555930	784	785	I-Observation
protection	10555930	786	796	B-Outcome
during	10555930	797	803	I-Outcome
maximum	10555930	804	811	I-Outcome
early	10555930	812	817	I-Outcome
and	10555930	818	821	I-Outcome
late	10555930	822	826	I-Outcome
responses	10555930	827	836	I-Outcome
compared	10555930	837	845	O
with	10555930	846	850	O
placebo	10555930	851	858	B-Intervention
(	10555930	859	860	O
p=0.005	10555930	861	868	O
)	10555930	869	870	O
,	10555930	871	872	O
but	10555930	873	876	O
airway	10555930	877	883	B-Outcome
obstruction	10555930	884	895	I-Outcome
persisted	10555930	896	905	B-Observation
8	10555930	906	907	O
-	10555930	907	908	O
24	10555930	908	910	O
hours	10555930	911	916	O
after	10555930	917	922	O
allergen	10555930	923	931	O
on	10555930	932	934	O
both	10555930	935	939	B-Intervention
treatment	10555930	940	949	I-Intervention
days	10555930	950	954	O
.	10555930	955	956	O

Airway	10555930	957	963	B-Outcome
responsiveness	10555930	964	978	I-Outcome
to	10555930	979	981	I-Outcome
histamine	10555930	982	991	I-Outcome
was	10555930	992	995	O
not	10555930	996	999	O
significantly	10555930	1000	1013	B-Observation
attenuated	10555930	1014	1024	I-Observation
at	10555930	1025	1027	O
24	10555930	1028	1030	O
hours	10555930	1031	1036	O
.	10555930	1037	1038	O

CONCLUSION	10555930	1039	1049	O
Blocking	10555930	1050	1058	B-Intervention
Cys	10555930	1059	1062	I-Intervention
LT1	10555930	1063	1066	I-Intervention
receptors	10555930	1067	1076	I-Intervention
for	10555930	1077	1080	O
8	10555930	1081	1082	O
hours	10555930	1083	1088	O
attenuated	10555930	1089	1099	B-Observation
the	10555930	1100	1103	O
early	10555930	1104	1109	B-Outcome
and	10555930	1110	1113	I-Outcome
late	10555930	1114	1118	I-Outcome
responses	10555930	1119	1128	I-Outcome
but	10555930	1129	1132	O
did	10555930	1133	1136	O
not	10555930	1137	1140	O
interrupt	10555930	1141	1150	B-Observation
the	10555930	1151	1154	O
cascade	10555930	1155	1162	B-Outcome
of	10555930	1163	1165	I-Outcome
events	10555930	1166	1172	I-Outcome
leading	10555930	1173	1180	O
to	10555930	1181	1183	O
subsequent	10555930	1184	1194	B-Outcome
allergen-induced	10555930	1195	1211	I-Outcome
airway	10555930	1212	1218	I-Outcome
obstruction	10555930	1219	1230	I-Outcome
and	10555930	1231	1234	O
hyperreactivity	10555930	1235	1250	B-Outcome
.	10555930	1251	1252	O

Intra-luminal	10563544	0	13	B-Intervention
nicotine	10563544	14	22	I-Intervention
reduces	10563544	23	30	B-Observation
smooth	10563544	31	37	B-Outcome
muscle	10563544	38	44	I-Outcome
tone	10563544	45	49	I-Outcome
and	10563544	50	53	O
contractile	10563544	54	65	B-Outcome
activity	10563544	66	74	I-Outcome
in	10563544	75	77	I-Outcome
the	10563544	78	81	I-Outcome
distal	10563544	82	88	I-Outcome
large	10563544	89	94	I-Outcome
bowel	10563544	95	100	I-Outcome
.	10563544	101	102	O

BACKGROUND	10563544	103	113	O
Nicotine	10563544	114	122	O
may	10563544	123	126	O
be	10563544	127	129	O
of	10563544	130	132	O
therapeutic	10563544	133	144	O
value	10563544	145	150	O
in	10563544	151	153	O
ulcerative	10563544	154	164	O
colitis	10563544	165	172	O
(	10563544	173	174	O
UC	10563544	175	177	O
)	10563544	178	179	O
,	10563544	180	181	O
although	10563544	182	190	O
its	10563544	191	194	O
mechanism	10563544	195	204	O
of	10563544	205	207	O
action	10563544	208	214	O
has	10563544	215	218	O
not	10563544	219	222	O
been	10563544	223	227	O
established	10563544	228	239	O
.	10563544	240	241	O

OBJECTIVE	10563544	242	251	O
To	10563544	252	254	O
examine	10563544	255	262	O
the	10563544	263	266	O
effect	10563544	267	273	O
of	10563544	274	276	O
a	10563544	277	278	O
solution	10563544	279	287	B-Intervention
of	10563544	288	290	I-Intervention
nicotine	10563544	291	299	I-Intervention
on	10563544	300	302	O
sustained	10563544	303	312	B-Outcome
resting	10563544	313	320	I-Outcome
pressure	10563544	321	329	I-Outcome
(	10563544	330	331	I-Outcome
tone	10563544	332	336	I-Outcome
)	10563544	337	338	I-Outcome
and	10563544	339	342	O
contractile	10563544	343	354	B-Outcome
activity	10563544	355	363	I-Outcome
in	10563544	364	366	I-Outcome
the	10563544	367	370	I-Outcome
human	10563544	371	376	I-Outcome
colon	10563544	377	382	I-Outcome
.	10563544	383	384	O

METHODS	10563544	385	392	O
Ten	10563544	393	396	O
healthy	10563544	397	404	B-Participant
volunteers	10563544	405	415	O
,	10563544	416	417	O
and	10563544	418	421	O
seven	10563544	422	427	O
with	10563544	428	432	O
UC	10563544	433	435	B-Participant
in	10563544	436	438	I-Participant
symptomatic	10563544	439	450	I-Participant
remission	10563544	451	460	I-Participant
took	10563544	461	465	O
part	10563544	466	470	O
;	10563544	471	472	O
all	10563544	473	476	O
were	10563544	477	481	O
non-smokers	10563544	482	493	B-Participant
.	10563544	494	495	O

All	10563544	496	499	O
17	10563544	500	502	O
subjects	10563544	503	511	O
were	10563544	512	516	O
given	10563544	517	522	O
nicotine	10563544	523	531	B-Intervention
or	10563544	532	534	O
placebo	10563544	535	542	B-Intervention
solution	10563544	543	551	O
on	10563544	552	554	O
two	10563544	555	558	O
separate	10563544	559	567	O
occasions	10563544	568	577	O
in	10563544	578	580	O
a	10563544	581	582	O
randomized	10563544	583	593	O
sequence	10563544	594	602	O
.	10563544	603	604	O

A	10563544	605	606	O
water-perfused	10563544	607	621	O
manometry	10563544	622	631	O
catheter	10563544	632	640	O
,	10563544	641	642	O
with	10563544	643	647	O
openings	10563544	648	656	O
at	10563544	657	659	O
5	10563544	660	661	O
,	10563544	662	663	O
10	10563544	664	666	O
and	10563544	667	670	O
15	10563544	671	673	O
cm	10563544	674	676	O
from	10563544	677	681	O
the	10563544	682	685	O
tip	10563544	686	689	O
,	10563544	690	691	O
was	10563544	692	695	O
placed	10563544	696	702	O
by	10563544	703	705	O
rigid	10563544	706	711	O
sigmoidoscopy	10563544	712	725	O
in	10563544	726	728	O
the	10563544	729	732	O
recto-sigmoid	10563544	733	746	O
region	10563544	747	753	O
.	10563544	754	755	O

Baseline	10563544	756	764	O
tone	10563544	765	769	B-Outcome
and	10563544	770	773	O
activity	10563544	774	782	B-Outcome
were	10563544	783	787	O
measured	10563544	788	796	O
for	10563544	797	800	O
15	10563544	801	803	O
min	10563544	804	807	O
prior	10563544	808	813	O
to	10563544	814	816	O
instillation	10563544	817	829	O
of	10563544	830	832	O
20	10563544	833	835	O
ml	10563544	836	838	O
of	10563544	839	841	O
saline	10563544	842	848	B-Intervention
alone	10563544	849	854	I-Intervention
or	10563544	855	857	O
with	10563544	858	862	B-Intervention
nicotine	10563544	863	871	I-Intervention
,	10563544	872	873	O
1.2	10563544	874	877	O
mg	10563544	878	880	O
,	10563544	881	882	O
at	10563544	883	885	O
pH	10563544	886	888	O
4.5	10563544	889	892	O
.	10563544	893	894	O

Observations	10563544	895	907	O
were	10563544	908	912	O
made	10563544	913	917	O
over	10563544	918	922	O
the	10563544	923	926	O
subsequent	10563544	927	937	O
15	10563544	938	940	O
-	10563544	940	941	O
20	10563544	941	943	O
min	10563544	944	947	O
.	10563544	948	949	O

RESULTS	10563544	950	957	O
Baseline	10563544	958	966	B-Outcome
spontaneous	10563544	967	978	I-Outcome
activity	10563544	979	987	I-Outcome
in	10563544	988	990	O
all	10563544	991	994	B-Count
subjects	10563544	995	1003	I-Count
showed	10563544	1004	1010	O
both	10563544	1011	1015	O
high-	10563544	1016	1021	B-Observation
and	10563544	1022	1025	I-Observation
low-frequency	10563544	1026	1039	I-Observation
components	10563544	1040	1050	I-Observation
;	10563544	1051	1052	O
in	10563544	1053	1055	O
three	10563544	1056	1061	B-Count
patients	10563544	1062	1070	I-Count
with	10563544	1071	1075	O
UC	10563544	1076	1078	B-Participant
,	10563544	1079	1080	O
the	10563544	1081	1084	O
low-frequency	10563544	1085	1098	B-Outcome
activity	10563544	1099	1107	I-Outcome
was	10563544	1108	1111	O
of	10563544	1112	1114	O
high	10563544	1115	1119	B-Observation
amplitude	10563544	1120	1129	I-Observation
.	10563544	1130	1131	O

The	10563544	1132	1135	O
nicotine	10563544	1136	1144	B-Intervention
reduced	10563544	1145	1152	B-Observation
both	10563544	1153	1157	O
tone	10563544	1158	1162	B-Outcome
and	10563544	1163	1166	O
activity	10563544	1167	1175	B-Outcome
in	10563544	1176	1178	O
all	10563544	1179	1182	B-Count
subjects	10563544	1183	1191	I-Count
,	10563544	1192	1193	O
with	10563544	1194	1198	O
reduction	10563544	1199	1208	B-Observation
or	10563544	1209	1211	O
abolition	10563544	1212	1221	B-Observation
of	10563544	1222	1224	O
the	10563544	1225	1228	O
large	10563544	1229	1234	B-Outcome
contractions	10563544	1235	1247	I-Outcome
in	10563544	1248	1250	I-Outcome
UC	10563544	1251	1253	I-Outcome
.	10563544	1254	1255	O

Tone	10563544	1256	1260	B-Outcome
in	10563544	1261	1263	O
all	10563544	1264	1267	O
17	10563544	1268	1270	B-Count
subjects	10563544	1271	1279	I-Count
was	10563544	1280	1283	O
reduced	10563544	1284	1291	B-Observation
significantly	10563544	1292	1305	I-Observation
at	10563544	1306	1308	O
3	10563544	1309	1310	O
min	10563544	1311	1314	O
after	10563544	1315	1320	O
nicotine	10563544	1321	1329	B-Intervention
(	10563544	1330	1331	O
P	10563544	1332	1333	O
=	10563544	1334	1335	O
0.000015	10563544	1336	1344	O
,	10563544	1345	1346	O
sign	10563544	1347	1351	O
test	10563544	1352	1356	O
)	10563544	1357	1358	O
;	10563544	1359	1360	O
the	10563544	1361	1364	O
rate	10563544	1365	1369	B-Outcome
of	10563544	1370	1372	I-Outcome
recovery	10563544	1373	1381	I-Outcome
varied	10563544	1382	1388	B-Observation
in	10563544	1389	1391	O
individuals	10563544	1392	1403	O
.	10563544	1404	1405	O

Results	10563544	1406	1413	B-Outcome
from	10563544	1414	1418	O
normals	10563544	1419	1426	B-Participant
and	10563544	1427	1430	O
UC	10563544	1431	1433	B-Participant
did	10563544	1434	1437	O
not	10563544	1438	1441	O
differ	10563544	1442	1448	B-Observation
significantly	10563544	1449	1462	I-Observation
from	10563544	1463	1467	O
each	10563544	1468	1472	O
other	10563544	1473	1478	O
.	10563544	1479	1480	O

No	10563544	1481	1483	O
significant	10563544	1484	1495	B-Observation
change	10563544	1496	1502	I-Observation
in	10563544	1503	1505	O
tone	10563544	1506	1510	B-Outcome
or	10563544	1511	1513	O
activity	10563544	1514	1522	B-Outcome
was	10563544	1523	1526	O
observed	10563544	1527	1535	O
with	10563544	1536	1540	O
the	10563544	1541	1544	O
saline	10563544	1545	1551	B-Intervention
solution	10563544	1552	1560	I-Intervention
.	10563544	1561	1562	O

CONCLUSION	10563544	1563	1573	O
Intra-luminal	10563544	1574	1587	B-Intervention
nicotine	10563544	1588	1596	I-Intervention
significantly	10563544	1597	1610	B-Observation
reduces	10563544	1611	1618	I-Observation
both	10563544	1619	1623	O
smooth	10563544	1624	1630	B-Outcome
muscle	10563544	1631	1637	I-Outcome
tone	10563544	1638	1642	I-Outcome
and	10563544	1643	1646	O
contractile	10563544	1647	1658	B-Outcome
activity	10563544	1659	1667	I-Outcome
in	10563544	1668	1670	I-Outcome
the	10563544	1671	1674	I-Outcome
recto-sigmoid	10563544	1675	1688	I-Outcome
colon	10563544	1689	1694	I-Outcome
in	10563544	1695	1697	O
both	10563544	1698	1702	O
normal	10563544	1703	1709	B-Participant
subjects	10563544	1710	1718	O
and	10563544	1719	1722	O
patients	10563544	1723	1731	O
with	10563544	1732	1736	O
UC	10563544	1737	1739	B-Participant
.	10563544	1740	1741	O

A	10566623	0	1	O
comparison	10566623	2	12	O
of	10566623	13	15	O
recombinant	10566623	16	27	B-Intervention
human	10566623	28	33	I-Intervention
thyrotropin	10566623	34	45	I-Intervention
and	10566623	46	49	O
thyroid	10566623	50	57	B-Intervention
hormone	10566623	58	65	I-Intervention
withdrawal	10566623	66	76	I-Intervention
for	10566623	77	80	O
the	10566623	81	84	O
detection	10566623	85	94	B-Outcome
of	10566623	95	97	I-Outcome
thyroid	10566623	98	105	I-Outcome
remnant	10566623	106	113	I-Outcome
or	10566623	114	116	I-Outcome
cancer	10566623	117	123	I-Outcome
.	10566623	124	125	O

Recombinant	10566623	126	137	O
human	10566623	138	143	O
TSH	10566623	144	147	O
has	10566623	148	151	O
been	10566623	152	156	O
developed	10566623	157	166	O
to	10566623	167	169	O
facilitate	10566623	170	180	O
monitoring	10566623	181	191	O
for	10566623	192	195	O
thyroid	10566623	196	203	O
carcinoma	10566623	204	213	O
recurrence	10566623	214	224	O
or	10566623	225	227	O
persistence	10566623	228	239	O
without	10566623	240	247	O
the	10566623	248	251	O
attendant	10566623	252	261	O
morbidity	10566623	262	271	O
of	10566623	272	274	O
hypothyroidism	10566623	275	289	O
seen	10566623	290	294	O
after	10566623	295	300	O
thyroid	10566623	301	308	O
hormone	10566623	309	316	O
withdrawal	10566623	317	327	O
.	10566623	328	329	O

The	10566623	330	333	O
objectives	10566623	334	344	O
of	10566623	345	347	O
this	10566623	348	352	O
study	10566623	353	358	O
were	10566623	359	363	O
to	10566623	364	366	O
compare	10566623	367	374	O
the	10566623	375	378	O
effect	10566623	379	385	O
of	10566623	386	388	O
administered	10566623	389	401	O
recombinant	10566623	402	413	B-Intervention
human	10566623	414	419	I-Intervention
TSH	10566623	420	423	I-Intervention
with	10566623	424	428	O
thyroid	10566623	429	436	B-Intervention
hormone	10566623	437	444	I-Intervention
withdrawal	10566623	445	455	I-Intervention
on	10566623	456	458	O
the	10566623	459	462	O
results	10566623	463	470	O
of	10566623	471	473	O
radioiodine	10566623	474	485	B-Outcome
whole	10566623	486	491	I-Outcome
body	10566623	492	496	I-Outcome
scanning	10566623	497	505	I-Outcome
(	10566623	506	507	I-Outcome
WBS	10566623	508	511	I-Outcome
)	10566623	512	513	I-Outcome
and	10566623	514	517	O
serum	10566623	518	523	B-Outcome
thyroglobulin	10566623	524	537	I-Outcome
(	10566623	538	539	I-Outcome
Tg	10566623	540	542	I-Outcome
)	10566623	543	544	I-Outcome
levels	10566623	545	551	I-Outcome
.	10566623	552	553	O

Two	10566623	554	557	O
hundred	10566623	558	565	O
and	10566623	566	569	O
twenty-nine	10566623	570	581	O
adult	10566623	582	587	B-Participant
patients	10566623	588	596	O
with	10566623	597	601	O
differentiated	10566623	602	616	B-Participant
thyroid	10566623	617	624	I-Participant
cancer	10566623	625	631	I-Participant
requiring	10566623	632	641	I-Participant
radioiodine	10566623	642	653	I-Participant
WBS	10566623	654	657	I-Participant
were	10566623	658	662	O
studied	10566623	663	670	O
.	10566623	671	672	O

Radioiodine	10566623	673	684	B-Outcome
WBS	10566623	685	688	I-Outcome
and	10566623	689	692	O
serum	10566623	693	698	B-Outcome
Tg	10566623	699	701	I-Outcome
measurements	10566623	702	714	O
were	10566623	715	719	O
performed	10566623	720	729	O
after	10566623	730	735	O
administration	10566623	736	750	O
of	10566623	751	753	O
recombinant	10566623	754	765	B-Intervention
human	10566623	766	771	I-Intervention
TSH	10566623	772	775	I-Intervention
and	10566623	776	779	O
again	10566623	780	785	O
after	10566623	786	791	O
thyroid	10566623	792	799	B-Intervention
hormone	10566623	800	807	I-Intervention
withdrawal	10566623	808	818	I-Intervention
in	10566623	819	821	O
each	10566623	822	826	O
patient	10566623	827	834	O
.	10566623	835	836	O

Radioiodine	10566623	837	848	B-Outcome
whole	10566623	849	854	I-Outcome
body	10566623	855	859	I-Outcome
scans	10566623	860	865	I-Outcome
were	10566623	866	870	O
concordant	10566623	871	881	B-Observation
between	10566623	882	889	B-Intervention
the	10566623	890	893	I-Intervention
recombinant	10566623	894	905	I-Intervention
TSH-stimulated	10566623	906	920	I-Intervention
and	10566623	921	924	I-Intervention
thyroid	10566623	925	932	I-Intervention
hormone	10566623	933	940	I-Intervention
withdrawal	10566623	941	951	I-Intervention
phases	10566623	952	958	O
in	10566623	959	961	O
195	10566623	962	965	B-Count
of	10566623	966	968	I-Count
220	10566623	969	972	I-Count
(	10566623	973	974	I-Count
89	10566623	975	977	I-Count
%	10566623	978	979	I-Count
)	10566623	980	981	I-Count
patients	10566623	982	990	O
.	10566623	991	992	O

Of	10566623	993	995	O
the	10566623	996	999	O
discordant	10566623	1000	1010	O
scans	10566623	1011	1016	O
,	10566623	1017	1018	O
8	10566623	1019	1020	B-Count
(	10566623	1021	1022	I-Count
4	10566623	1023	1024	I-Count
%	10566623	1025	1026	I-Count
)	10566623	1027	1028	I-Count
had	10566623	1029	1032	O
superior	10566623	1033	1041	B-Observation
scans	10566623	1042	1047	B-Outcome
after	10566623	1048	1053	O
recombinant	10566623	1054	1065	B-Intervention
human	10566623	1066	1071	I-Intervention
TSH	10566623	1072	1075	I-Intervention
administration	10566623	1076	1090	O
,	10566623	1091	1092	O
and	10566623	1093	1096	O
17	10566623	1097	1099	B-Count
(	10566623	1100	1101	I-Count
8	10566623	1102	1103	I-Count
%	10566623	1104	1105	I-Count
)	10566623	1106	1107	I-Count
had	10566623	1108	1111	O
superior	10566623	1112	1120	B-Observation
scans	10566623	1121	1126	B-Outcome
after	10566623	1127	1132	O
thyroid	10566623	1133	1140	B-Intervention
hormone	10566623	1141	1148	I-Intervention
withdrawal	10566623	1149	1159	I-Intervention
(	10566623	1160	1161	O
P	10566623	1162	1163	O
=	10566623	1164	1165	O
0.108	10566623	1166	1171	O
)	10566623	1172	1173	O
.	10566623	1174	1175	O

Based	10566623	1176	1181	O
on	10566623	1182	1184	O
a	10566623	1185	1186	O
serum	10566623	1187	1192	O
Tg	10566623	1193	1195	O
level	10566623	1196	1201	O
of	10566623	1202	1204	O
2	10566623	1205	1206	O
ng/mL	10566623	1207	1212	O
or	10566623	1213	1215	O
more	10566623	1216	1220	O
,	10566623	1221	1222	O
thyroid	10566623	1223	1230	B-Outcome
tissue	10566623	1231	1237	I-Outcome
or	10566623	1238	1240	I-Outcome
cancer	10566623	1241	1247	I-Outcome
was	10566623	1248	1251	I-Outcome
detected	10566623	1252	1260	I-Outcome
during	10566623	1261	1267	O
thyroid	10566623	1268	1275	B-Intervention
hormone	10566623	1276	1283	I-Intervention
therapy	10566623	1284	1291	I-Intervention
in	10566623	1292	1294	O
22	10566623	1295	1297	B-Count
%	10566623	1298	1299	I-Count
,	10566623	1300	1301	O
after	10566623	1302	1307	O
recombinant	10566623	1308	1319	B-Intervention
human	10566623	1320	1325	I-Intervention
TSH	10566623	1326	1329	I-Intervention
stimulation	10566623	1330	1341	I-Intervention
in	10566623	1342	1344	O
52	10566623	1345	1347	B-Count
%	10566623	1348	1349	I-Count
,	10566623	1350	1351	O
and	10566623	1352	1355	O
after	10566623	1356	1361	O
thyroid	10566623	1362	1369	B-Intervention
hormone	10566623	1370	1377	I-Intervention
withdrawal	10566623	1378	1388	I-Intervention
in	10566623	1389	1391	O
56	10566623	1392	1394	B-Count
%	10566623	1395	1396	I-Count
of	10566623	1397	1399	I-Count
patients	10566623	1400	1408	I-Count
with	10566623	1409	1413	O
disease	10566623	1414	1421	B-Participant
or	10566623	1422	1424	I-Participant
tissue	10566623	1425	1431	I-Participant
limited	10566623	1432	1439	I-Participant
to	10566623	1440	1442	I-Participant
the	10566623	1443	1446	I-Participant
thyroid	10566623	1447	1454	I-Participant
bed	10566623	1455	1458	I-Participant
and	10566623	1459	1462	O
in	10566623	1463	1465	O
80	10566623	1466	1468	B-Count
%	10566623	1469	1470	I-Count
,	10566623	1471	1472	O
100	10566623	1473	1476	B-Count
%	10566623	1477	1478	I-Count
,	10566623	1479	1480	O
and	10566623	1481	1484	O
100	10566623	1485	1488	B-Count
%	10566623	1489	1490	I-Count
of	10566623	1491	1493	I-Count
patients	10566623	1494	1502	I-Count
,	10566623	1503	1504	O
respectively	10566623	1505	1517	O
,	10566623	1518	1519	O
with	10566623	1520	1524	O
metastatic	10566623	1525	1535	B-Participant
disease	10566623	1536	1543	I-Participant
.	10566623	1544	1545	O

A	10566623	1546	1547	O
combination	10566623	1548	1559	O
of	10566623	1560	1562	O
radioiodine	10566623	1563	1574	O
WBS	10566623	1575	1578	O
and	10566623	1579	1582	O
serum	10566623	1583	1588	O
Tg	10566623	1589	1591	O
after	10566623	1592	1597	O
recombinant	10566623	1598	1609	B-Intervention
human	10566623	1610	1615	I-Intervention
TSH	10566623	1616	1619	I-Intervention
stimulation	10566623	1620	1631	I-Intervention
detected	10566623	1632	1640	B-Outcome
thyroid	10566623	1641	1648	I-Outcome
tissue	10566623	1649	1655	I-Outcome
or	10566623	1656	1658	I-Outcome
cancer	10566623	1659	1665	I-Outcome
in	10566623	1666	1668	O
93	10566623	1669	1671	B-Count
%	10566623	1672	1673	I-Count
of	10566623	1674	1676	I-Count
patients	10566623	1677	1685	I-Count
with	10566623	1686	1690	O
disease	10566623	1691	1698	B-Participant
or	10566623	1699	1701	I-Participant
tissue	10566623	1702	1708	I-Participant
limited	10566623	1709	1716	I-Participant
to	10566623	1717	1719	I-Participant
the	10566623	1720	1723	I-Participant
thyroid	10566623	1724	1731	I-Participant
bed	10566623	1732	1735	I-Participant
and	10566623	1736	1739	O
100	10566623	1740	1743	B-Count
%	10566623	1744	1745	I-Count
of	10566623	1746	1748	I-Count
patients	10566623	1749	1757	I-Count
with	10566623	1758	1762	O
metastatic	10566623	1763	1773	B-Participant
disease	10566623	1774	1781	I-Participant
.	10566623	1782	1783	O

In	10566623	1784	1786	O
conclusion	10566623	1787	1797	O
,	10566623	1798	1799	O
recombinant	10566623	1800	1811	B-Intervention
human	10566623	1812	1817	I-Intervention
TSH	10566623	1818	1821	I-Intervention
administration	10566623	1822	1836	O
is	10566623	1837	1839	O
a	10566623	1840	1841	O
safe	10566623	1842	1846	B-Observation
and	10566623	1847	1850	O
effective	10566623	1851	1860	B-Observation
means	10566623	1861	1866	O
of	10566623	1867	1869	O
stimulating	10566623	1870	1881	O
radioiodine	10566623	1882	1893	B-Outcome
uptake	10566623	1894	1900	I-Outcome
and	10566623	1901	1904	O
serum	10566623	1905	1910	B-Outcome
Tg	10566623	1911	1913	I-Outcome
levels	10566623	1914	1920	I-Outcome
in	10566623	1921	1923	O
patients	10566623	1924	1932	O
undergoing	10566623	1933	1943	O
evaluation	10566623	1944	1954	B-Participant
for	10566623	1955	1958	I-Participant
thyroid	10566623	1959	1966	I-Participant
cancer	10566623	1967	1973	I-Participant
persistence	10566623	1974	1985	I-Participant
and	10566623	1986	1989	I-Participant
recurrence	10566623	1990	2000	I-Participant
.	10566623	2001	2002	O

Effect	10568568	0	6	O
of	10568568	7	9	O
nitric-oxide-generating	10568568	10	33	B-Intervention
system	10568568	34	40	I-Intervention
on	10568568	41	43	O
microcirculatory	10568568	44	60	B-Outcome
blood	10568568	61	66	I-Outcome
flow	10568568	67	71	I-Outcome
in	10568568	72	74	O
skin	10568568	75	79	O
of	10568568	80	82	O
patients	10568568	83	91	O
with	10568568	92	96	O
severe	10568568	97	103	B-Participant
Raynaud	10568568	104	111	I-Participant
's	10568568	112	114	I-Participant
syndrome	10568568	115	123	I-Participant
:	10568568	124	125	O
a	10568568	126	127	O
randomised	10568568	128	138	O
trial	10568568	139	144	O
.	10568568	145	146	O

BACKGROUND	10568568	147	157	O
Patients	10568568	158	166	O
with	10568568	167	171	O
Raynaud	10568568	172	179	O
's	10568568	180	182	O
syndrome	10568568	183	191	O
have	10568568	192	196	O
abnormal	10568568	197	205	O
digital	10568568	206	213	O
vasoconstriction	10568568	214	230	O
,	10568568	231	232	O
which	10568568	233	238	O
may	10568568	239	242	O
be	10568568	243	245	O
secondary	10568568	246	255	O
to	10568568	256	258	O
impaired	10568568	259	267	O
synthesis	10568568	268	277	O
of	10568568	278	280	O
,	10568568	281	282	O
or	10568568	283	285	O
impaired	10568568	286	294	O
sensitivity	10568568	295	306	O
to	10568568	307	309	O
,	10568568	310	311	O
nitric	10568568	312	318	O
oxide	10568568	319	324	O
.	10568568	325	326	O

We	10568568	327	329	O
studied	10568568	330	337	O
the	10568568	338	341	O
effect	10568568	342	348	O
on	10568568	349	351	O
microcirculation	10568568	352	368	B-Outcome
of	10568568	369	371	O
a	10568568	372	373	O
nitric-oxide-generating	10568568	374	397	B-Intervention
system	10568568	398	404	I-Intervention
applied	10568568	405	412	O
topically	10568568	413	422	O
to	10568568	423	425	O
the	10568568	426	429	O
finger	10568568	430	436	O
and	10568568	437	440	O
forearm	10568568	441	448	O
of	10568568	449	451	O
healthy	10568568	452	459	B-Participant
volunteers	10568568	460	470	O
and	10568568	471	474	O
patients	10568568	475	483	O
with	10568568	484	488	O
primary	10568568	489	496	B-Participant
Raynaud	10568568	497	504	I-Participant
's	10568568	505	507	I-Participant
syndrome	10568568	508	516	I-Participant
.	10568568	517	518	O

METHODS	10568568	519	526	O
We	10568568	527	529	O
did	10568568	530	533	O
a	10568568	534	535	O
single-blind	10568568	536	548	O
,	10568568	549	550	O
randomised	10568568	551	561	O
,	10568568	562	563	O
placebo	10568568	564	571	O
controlled	10568568	572	582	O
,	10568568	583	584	O
cross-over	10568568	585	595	O
study	10568568	596	601	O
of	10568568	602	604	O
the	10568568	605	608	O
microcirculatory	10568568	609	625	B-Outcome
response	10568568	626	634	I-Outcome
to	10568568	635	637	O
topical	10568568	638	645	O
application	10568568	646	657	O
of	10568568	658	660	O
a	10568568	661	662	O
nitric-oxidegenerating	10568568	663	685	B-Intervention
gel	10568568	686	689	I-Intervention
in	10568568	690	692	O
20	10568568	693	695	O
patients	10568568	696	704	O
with	10568568	705	709	O
severe	10568568	710	716	B-Participant
Raynaud	10568568	717	724	I-Participant
's	10568568	725	727	I-Participant
syndrome	10568568	728	736	I-Participant
,	10568568	737	738	O
and	10568568	739	742	O
ten	10568568	743	746	O
healthy	10568568	747	754	B-Participant
volunteers	10568568	755	765	O
.	10568568	766	767	O

We	10568568	768	770	O
prepared	10568568	771	779	O
the	10568568	780	783	O
nitric-oxide-generating	10568568	784	807	B-Intervention
system	10568568	808	814	I-Intervention
by	10568568	815	817	O
mixing	10568568	818	824	O
a	10568568	825	826	O
solution	10568568	827	835	O
of	10568568	836	838	O
KY	10568568	839	841	O
jelly	10568568	842	847	O
and	10568568	848	851	O
sodium	10568568	852	858	O
nitrite	10568568	859	866	O
(	10568568	867	868	O
5	10568568	869	870	O
%	10568568	871	872	O
weight/volume	10568568	873	886	O
)	10568568	887	888	O
,	10568568	889	890	O
with	10568568	891	895	O
a	10568568	896	897	O
solution	10568568	898	906	O
of	10568568	907	909	O
KY	10568568	910	912	O
jelly	10568568	913	918	O
and	10568568	919	922	O
ascorbic	10568568	923	931	O
acid	10568568	932	936	O
(	10568568	937	938	O
5	10568568	939	940	O
%	10568568	941	942	O
weight/volume	10568568	943	956	O
)	10568568	957	958	O
.	10568568	959	960	O

About	10568568	961	966	O
0.5	10568568	967	970	O
mL	10568568	971	973	O
of	10568568	974	976	O
each	10568568	977	981	O
solution	10568568	982	990	O
was	10568568	991	994	O
separately	10568568	995	1005	O
applied	10568568	1006	1013	O
to	10568568	1014	1016	O
the	10568568	1017	1020	O
skin	10568568	1021	1025	O
of	10568568	1026	1028	O
the	10568568	1029	1032	O
forearm	10568568	1033	1040	O
(	10568568	1041	1042	O
3	10568568	1043	1044	O
cm2	10568568	1045	1048	O
)	10568568	1049	1050	O
,	10568568	1051	1052	O
and	10568568	1053	1056	O
then	10568568	1057	1061	O
mixed	10568568	1062	1067	O
with	10568568	1068	1072	O
a	10568568	1073	1074	O
sterile	10568568	1075	1082	O
cotton	10568568	1083	1089	O
bud	10568568	1090	1093	O
.	10568568	1094	1095	O

A	10568568	1096	1097	O
similar	10568568	1098	1105	O
procedure	10568568	1106	1115	O
was	10568568	1116	1119	O
done	10568568	1120	1124	O
simultaneously	10568568	1125	1139	O
on	10568568	1140	1142	O
the	10568568	1143	1146	O
other	10568568	1147	1152	O
arm	10568568	1153	1156	O
with	10568568	1157	1161	O
KY	10568568	1162	1164	B-Intervention
jelly	10568568	1165	1170	I-Intervention
only	10568568	1171	1175	I-Intervention
(	10568568	1176	1177	I-Intervention
placebo	10568568	1178	1185	I-Intervention
)	10568568	1186	1187	I-Intervention
.	10568568	1188	1189	O

The	10568568	1190	1193	O
procedure	10568568	1194	1203	O
was	10568568	1204	1207	O
then	10568568	1208	1212	O
repeated	10568568	1213	1221	O
on	10568568	1222	1224	O
the	10568568	1225	1228	O
finger	10568568	1229	1235	O
pulps	10568568	1236	1241	O
.	10568568	1242	1243	O

Changes	10568568	1244	1251	B-Observation
in	10568568	1252	1254	O
skin	10568568	1255	1259	B-Outcome
microcirculatory	10568568	1260	1276	I-Outcome
volume	10568568	1277	1283	I-Outcome
and	10568568	1284	1287	I-Outcome
flux	10568568	1288	1292	I-Outcome
were	10568568	1293	1297	O
measured	10568568	1298	1306	O
bilaterally	10568568	1307	1318	O
by	10568568	1319	1321	O
infrared	10568568	1322	1330	O
photoplethysmography	10568568	1331	1351	O
and	10568568	1352	1355	O
laser	10568568	1356	1361	O
doppler	10568568	1362	1369	O
fluxmetry	10568568	1370	1379	O
,	10568568	1380	1381	O
respectively	10568568	1382	1394	O
.	10568568	1395	1396	O

FINDINGS	10568568	1397	1405	O
In	10568568	1406	1408	O
the	10568568	1409	1412	O
forearm	10568568	1413	1420	O
,	10568568	1421	1422	O
blood	10568568	1423	1428	B-Outcome
flow	10568568	1429	1433	I-Outcome
increased	10568568	1434	1443	B-Observation
significantly	10568568	1444	1457	I-Observation
after	10568568	1458	1463	O
application	10568568	1464	1475	O
of	10568568	1476	1478	O
the	10568568	1479	1482	O
active	10568568	1483	1489	B-Intervention
gel	10568568	1490	1493	I-Intervention
both	10568568	1494	1498	O
in	10568568	1499	1501	O
patients	10568568	1502	1510	O
with	10568568	1511	1515	O
Raynaud	10568568	1516	1523	B-Participant
's	10568568	1524	1526	I-Participant
syndrome	10568568	1527	1535	I-Participant
(	10568568	1536	1537	O
microcirculatory	10568568	1538	1554	B-Outcome
volume	10568568	1555	1561	I-Outcome
from	10568568	1562	1566	B-Observation
mean	10568568	1567	1571	I-Observation
area	10568568	1572	1576	I-Observation
under	10568568	1577	1582	I-Observation
the	10568568	1583	1586	I-Observation
curve	10568568	1587	1592	I-Observation
98	10568568	1593	1595	I-Observation
[	10568568	1596	1597	I-Observation
SE	10568568	1598	1600	I-Observation
14	10568568	1601	1603	I-Observation
]	10568568	1604	1605	I-Observation
to	10568568	1606	1608	I-Observation
1024	10568568	1609	1613	I-Observation
[	10568568	1614	1615	I-Observation
130	10568568	1616	1619	I-Observation
]	10568568	1620	1621	I-Observation
;	10568568	1622	1623	O
microcirculatory	10568568	1624	1640	B-Outcome
flux	10568568	1641	1645	I-Outcome
from	10568568	1646	1650	B-Observation
5060	10568568	1651	1655	I-Observation
[	10568568	1656	1657	I-Observation
462	10568568	1658	1661	I-Observation
]	10568568	1662	1663	I-Observation
to	10568568	1664	1666	I-Observation
74,800	10568568	1667	1673	I-Observation
[	10568568	1674	1675	I-Observation
3940	10568568	1676	1680	I-Observation
]	10568568	1681	1682	I-Observation
)	10568568	1683	1684	O
and	10568568	1685	1688	O
in	10568568	1689	1691	O
healthy	10568568	1692	1699	B-Participant
controls	10568568	1700	1708	O
(	10568568	1709	1710	O
volume	10568568	1711	1717	B-Outcome
from	10568568	1718	1722	B-Observation
85	10568568	1723	1725	I-Observation
[	10568568	1726	1727	I-Observation
19	10568568	1728	1730	I-Observation
]	10568568	1731	1732	I-Observation
to	10568568	1733	1735	I-Observation
1020	10568568	1736	1740	I-Observation
[	10568568	1741	1742	I-Observation
60	10568568	1743	1745	I-Observation
]	10568568	1746	1747	I-Observation
;	10568568	1748	1749	O
flux	10568568	1750	1754	B-Outcome
from	10568568	1755	1759	B-Observation
4420	10568568	1760	1764	I-Observation
[	10568568	1765	1766	I-Observation
435	10568568	1767	1770	I-Observation
]	10568568	1771	1772	I-Observation
to	10568568	1773	1775	I-Observation
84,500	10568568	1776	1782	I-Observation
[	10568568	1783	1784	I-Observation
7000	10568568	1785	1789	I-Observation
]	10568568	1790	1791	I-Observation
)	10568568	1792	1793	O
.	10568568	1794	1795	O

In	10568568	1796	1798	O
the	10568568	1799	1802	O
fingers	10568568	1803	1810	O
,	10568568	1811	1812	O
although	10568568	1813	1821	O
baseline	10568568	1822	1830	O
blood	10568568	1831	1836	O
flow	10568568	1837	1841	O
was	10568568	1842	1845	O
lower	10568568	1846	1851	O
in	10568568	1852	1854	O
patients	10568568	1855	1863	O
than	10568568	1864	1868	O
in	10568568	1869	1871	O
controls	10568568	1872	1880	O
,	10568568	1881	1882	O
both	10568568	1883	1887	O
groups	10568568	1888	1894	O
showed	10568568	1895	1901	O
increases	10568568	1902	1911	B-Observation
with	10568568	1912	1916	O
application	10568568	1917	1928	O
of	10568568	1929	1931	O
active	10568568	1932	1938	B-Intervention
gel	10568568	1939	1942	I-Intervention
(	10568568	1943	1944	O
volume	10568568	1945	1951	B-Outcome
from	10568568	1952	1956	B-Observation
1100	10568568	1957	1961	I-Observation
[	10568568	1962	1963	I-Observation
194	10568568	1964	1967	I-Observation
]	10568568	1968	1969	I-Observation
to	10568568	1970	1972	I-Observation
3280	10568568	1973	1977	I-Observation
[	10568568	1978	1979	I-Observation
672	10568568	1980	1983	I-Observation
]	10568568	1984	1985	I-Observation
and	10568568	1986	1989	O
2380	10568568	1990	1994	B-Observation
[	10568568	1995	1996	I-Observation
441	10568568	1997	2000	I-Observation
]	10568568	2001	2002	I-Observation
to	10568568	2003	2005	I-Observation
6160	10568568	2006	2010	I-Observation
[	10568568	2011	2012	I-Observation
1160	10568568	2013	2017	I-Observation
]	10568568	2018	2019	I-Observation
,	10568568	2020	2021	O
respectively	10568568	2022	2034	O
;	10568568	2035	2036	O
flux	10568568	2037	2041	B-Outcome
from	10568568	2042	2046	B-Observation
33,400	10568568	2047	2053	I-Observation
[	10568568	2054	2055	I-Observation
4200	10568568	2056	2060	I-Observation
]	10568568	2061	2062	I-Observation
to	10568568	2063	2065	I-Observation
108,000	10568568	2066	2073	I-Observation
[	10568568	2074	2075	I-Observation
13,600	10568568	2076	2082	I-Observation
]	10568568	2083	2084	I-Observation
and	10568568	2085	2088	O
52,000	10568568	2089	2095	B-Observation
[	10568568	2096	2097	I-Observation
8950	10568568	2098	2102	I-Observation
]	10568568	2103	2104	I-Observation
to	10568568	2105	2107	I-Observation
185,000	10568568	2108	2115	I-Observation
[	10568568	2116	2117	I-Observation
19,500	10568568	2118	2124	I-Observation
]	10568568	2125	2126	I-Observation
)	10568568	2127	2128	O
.	10568568	2129	2130	O

Increases	10568568	2131	2140	B-Observation
in	10568568	2141	2143	O
blood	10568568	2144	2149	B-Outcome
flow	10568568	2150	2154	I-Outcome
with	10568568	2155	2159	O
placebo	10568568	2160	2167	B-Intervention
gel	10568568	2168	2171	I-Intervention
were	10568568	2172	2176	O
not	10568568	2177	2180	O
significant	10568568	2181	2192	B-Observation
.	10568568	2193	2194	O

No	10568568	2195	2197	B-Count
adverse	10568568	2198	2205	B-Outcome
effects	10568568	2206	2213	I-Outcome
were	10568568	2214	2218	O
reported	10568568	2219	2227	O
.	10568568	2228	2229	O

INTERPRETATION	10568568	2230	2244	O
In	10568568	2245	2247	O
primary	10568568	2248	2255	B-Participant
Raynaud	10568568	2256	2263	I-Participant
's	10568568	2264	2266	I-Participant
syndrome	10568568	2267	2275	I-Participant
,	10568568	2276	2277	O
topical	10568568	2278	2285	O
application	10568568	2286	2297	O
of	10568568	2298	2300	O
a	10568568	2301	2302	O
nitric-oxide-generating	10568568	2303	2326	B-Intervention
system	10568568	2327	2333	I-Intervention
can	10568568	2334	2337	O
stimulate	10568568	2338	2347	O
an	10568568	2348	2350	O
increase	10568568	2351	2359	B-Observation
in	10568568	2360	2362	O
both	10568568	2363	2367	O
microcirculatory	10568568	2368	2384	B-Outcome
volume	10568568	2385	2391	I-Outcome
and	10568568	2392	2395	I-Outcome
flux	10568568	2396	2400	I-Outcome
.	10568568	2401	2402	O

Lack	10588965	0	4	B-Observation
of	10588965	5	7	O
benefit	10588965	8	15	B-Outcome
of	10588965	16	18	O
a	10588965	19	20	O
single	10588965	21	27	O
dose	10588965	28	32	O
of	10588965	33	35	O
synthetic	10588965	36	45	B-Intervention
human	10588965	46	51	I-Intervention
secretin	10588965	52	60	I-Intervention
in	10588965	61	63	O
the	10588965	64	67	O
treatment	10588965	68	77	O
of	10588965	78	80	O
autism	10588965	81	87	B-Participant
and	10588965	88	91	O
pervasive	10588965	92	101	B-Participant
developmental	10588965	102	115	I-Participant
disorder	10588965	116	124	I-Participant
.	10588965	125	126	O

BACKGROUND	10588965	127	137	O
Secretin	10588965	138	146	O
is	10588965	147	149	O
a	10588965	150	151	O
peptide	10588965	152	159	O
hormone	10588965	160	167	O
that	10588965	168	172	O
stimulates	10588965	173	183	O
pancreatic	10588965	184	194	O
secretion	10588965	195	204	O
.	10588965	205	206	O

After	10588965	207	212	O
recent	10588965	213	219	O
publicity	10588965	220	229	O
about	10588965	230	235	O
a	10588965	236	237	O
child	10588965	238	243	O
with	10588965	244	248	O
autism	10588965	249	255	O
whose	10588965	256	261	O
condition	10588965	262	271	O
markedly	10588965	272	280	O
improved	10588965	281	289	O
after	10588965	290	295	O
a	10588965	296	297	O
single	10588965	298	304	O
dose	10588965	305	309	O
of	10588965	310	312	O
secretin	10588965	313	321	O
,	10588965	322	323	O
thousands	10588965	324	333	O
of	10588965	334	336	O
children	10588965	337	345	O
with	10588965	346	350	O
autistic	10588965	351	359	O
disorders	10588965	360	369	O
may	10588965	370	373	O
have	10588965	374	378	O
received	10588965	379	387	O
secretin	10588965	388	396	O
injections	10588965	397	407	O
.	10588965	408	409	O

METHODS	10588965	410	417	O
We	10588965	418	420	O
conducted	10588965	421	430	O
a	10588965	431	432	O
double-blind	10588965	433	445	O
,	10588965	446	447	O
placebo-controlled	10588965	448	466	O
trial	10588965	467	472	O
of	10588965	473	475	O
a	10588965	476	477	O
single	10588965	478	484	O
intravenous	10588965	485	496	O
dose	10588965	497	501	O
of	10588965	502	504	O
synthetic	10588965	505	514	B-Intervention
human	10588965	515	520	I-Intervention
secretin	10588965	521	529	I-Intervention
in	10588965	530	532	O
60	10588965	533	535	O
children	10588965	536	544	B-Participant
(	10588965	545	546	O
age	10588965	547	550	O
,	10588965	551	552	O
3	10588965	553	554	O
to	10588965	555	557	O
14	10588965	558	560	O
years	10588965	561	566	O
)	10588965	567	568	O
with	10588965	569	573	O
autism	10588965	574	580	B-Participant
or	10588965	581	583	O
pervasive	10588965	584	593	B-Participant
developmental	10588965	594	607	I-Participant
disorder	10588965	608	616	I-Participant
.	10588965	617	618	O

The	10588965	619	622	O
children	10588965	623	631	O
were	10588965	632	636	O
randomly	10588965	637	645	O
assigned	10588965	646	654	O
to	10588965	655	657	O
treatment	10588965	658	667	O
with	10588965	668	672	O
an	10588965	673	675	O
intravenous	10588965	676	687	O
infusion	10588965	688	696	O
of	10588965	697	699	O
synthetic	10588965	700	709	B-Intervention
human	10588965	710	715	I-Intervention
secretin	10588965	716	724	I-Intervention
(	10588965	725	726	O
0.4	10588965	727	730	O
microg	10588965	731	737	O
per	10588965	738	741	O
kilogram	10588965	742	750	O
of	10588965	751	753	O
body	10588965	754	758	O
weight	10588965	759	765	O
)	10588965	766	767	O
or	10588965	768	770	O
saline	10588965	771	777	B-Intervention
placebo	10588965	778	785	I-Intervention
.	10588965	786	787	O

We	10588965	788	790	O
used	10588965	791	795	O
standardized	10588965	796	808	B-Outcome
behavioral	10588965	809	819	I-Outcome
measures	10588965	820	828	I-Outcome
of	10588965	829	831	I-Outcome
the	10588965	832	835	I-Outcome
primary	10588965	836	843	I-Outcome
and	10588965	844	847	I-Outcome
secondary	10588965	848	857	I-Outcome
features	10588965	858	866	I-Outcome
of	10588965	867	869	I-Outcome
autism	10588965	870	876	I-Outcome
,	10588965	877	878	O
including	10588965	879	888	O
the	10588965	889	892	O
Autism	10588965	893	899	B-Outcome
Behavior	10588965	900	908	I-Outcome
Checklist	10588965	909	918	I-Outcome
,	10588965	919	920	O
to	10588965	921	923	O
assess	10588965	924	930	O
the	10588965	931	934	O
degree	10588965	935	941	B-Outcome
of	10588965	942	944	I-Outcome
impairment	10588965	945	955	I-Outcome
at	10588965	956	958	O
base	10588965	959	963	O
line	10588965	964	968	O
and	10588965	969	972	O
over	10588965	973	977	O
the	10588965	978	981	O
course	10588965	982	988	O
of	10588965	989	991	O
a	10588965	992	993	O
four-week	10588965	994	1003	O
period	10588965	1004	1010	O
after	10588965	1011	1016	O
treatment	10588965	1017	1026	O
.	10588965	1027	1028	O

RESULTS	10588965	1029	1036	O
Of	10588965	1037	1039	O
the	10588965	1040	1043	O
60	10588965	1044	1046	O
children	10588965	1047	1055	O
,	10588965	1056	1057	O
4	10588965	1058	1059	O
could	10588965	1060	1065	O
not	10588965	1066	1069	O
be	10588965	1070	1072	O
evaluated	10588965	1073	1082	O
-	10588965	1083	1084	O
2	10588965	1085	1086	O
received	10588965	1087	1095	O
secretin	10588965	1096	1104	O
outside	10588965	1105	1112	O
the	10588965	1113	1116	O
study	10588965	1117	1122	O
,	10588965	1123	1124	O
and	10588965	1125	1128	O
2	10588965	1129	1130	O
did	10588965	1131	1134	O
not	10588965	1135	1138	O
return	10588965	1139	1145	O
for	10588965	1146	1149	O
follow-up	10588965	1150	1159	O
.	10588965	1160	1161	O

Thus	10588965	1162	1166	O
,	10588965	1167	1168	O
56	10588965	1169	1171	O
children	10588965	1172	1180	O
(	10588965	1181	1182	O
28	10588965	1183	1185	O
in	10588965	1186	1188	O
each	10588965	1189	1193	O
group	10588965	1194	1199	O
)	10588965	1200	1201	O
completed	10588965	1202	1211	O
the	10588965	1212	1215	O
study	10588965	1216	1221	O
.	10588965	1222	1223	O

As	10588965	1224	1226	O
compared	10588965	1227	1235	O
with	10588965	1236	1240	O
placebo	10588965	1241	1248	B-Intervention
,	10588965	1249	1250	O
secretin	10588965	1251	1259	B-Intervention
treatment	10588965	1260	1269	O
was	10588965	1270	1273	O
not	10588965	1274	1277	O
associated	10588965	1278	1288	O
with	10588965	1289	1293	O
significant	10588965	1294	1305	B-Observation
improvements	10588965	1306	1318	I-Observation
in	10588965	1319	1321	O
any	10588965	1322	1325	B-Outcome
of	10588965	1326	1328	I-Outcome
the	10588965	1329	1332	I-Outcome
outcome	10588965	1333	1340	I-Outcome
measures	10588965	1341	1349	I-Outcome
.	10588965	1350	1351	O

Among	10588965	1352	1357	O
the	10588965	1358	1361	O
children	10588965	1362	1370	O
in	10588965	1371	1373	O
the	10588965	1374	1377	O
secretin	10588965	1378	1386	B-Intervention
group	10588965	1387	1392	I-Intervention
,	10588965	1393	1394	O
the	10588965	1395	1398	O
mean	10588965	1399	1403	B-Outcome
total	10588965	1404	1409	I-Outcome
score	10588965	1410	1415	I-Outcome
on	10588965	1416	1418	I-Outcome
the	10588965	1419	1422	I-Outcome
Autism	10588965	1423	1429	I-Outcome
Behavior	10588965	1430	1438	I-Outcome
Checklist	10588965	1439	1448	I-Outcome
at	10588965	1449	1451	I-Outcome
base	10588965	1452	1456	I-Outcome
line	10588965	1457	1461	I-Outcome
was	10588965	1462	1465	O
59.0	10588965	1466	1470	B-Observation
(	10588965	1471	1472	O
range	10588965	1473	1478	O
of	10588965	1479	1481	O
possible	10588965	1482	1490	O
values	10588965	1491	1497	O
,	10588965	1498	1499	O
0	10588965	1500	1501	O
to	10588965	1502	1504	O
158	10588965	1505	1508	O
,	10588965	1509	1510	O
with	10588965	1511	1515	O
a	10588965	1516	1517	O
larger	10588965	1518	1524	O
value	10588965	1525	1530	O
corresponding	10588965	1531	1544	O
to	10588965	1545	1547	O
greater	10588965	1548	1555	O
impairment	10588965	1556	1566	O
)	10588965	1567	1568	O
,	10588965	1569	1570	O
and	10588965	1571	1574	O
among	10588965	1575	1580	O
those	10588965	1581	1586	O
in	10588965	1587	1589	O
the	10588965	1590	1593	O
placebo	10588965	1594	1601	B-Intervention
group	10588965	1602	1607	O
it	10588965	1608	1610	O
was	10588965	1611	1614	O
63.2	10588965	1615	1619	B-Observation
.	10588965	1620	1621	O

The	10588965	1622	1625	O
mean	10588965	1626	1630	B-Outcome
decreases	10588965	1631	1640	I-Outcome
in	10588965	1641	1643	I-Outcome
scores	10588965	1644	1650	I-Outcome
over	10588965	1651	1655	O
the	10588965	1656	1659	O
four-week	10588965	1660	1669	O
period	10588965	1670	1676	O
were	10588965	1677	1681	O
8.9	10588965	1682	1685	B-Observation
in	10588965	1686	1688	O
the	10588965	1689	1692	O
secretin	10588965	1693	1701	B-Intervention
group	10588965	1702	1707	I-Intervention
and	10588965	1708	1711	O
17.8	10588965	1712	1716	B-Observation
in	10588965	1717	1719	O
the	10588965	1720	1723	O
placebo	10588965	1724	1731	B-Intervention
group	10588965	1732	1737	I-Intervention
(	10588965	1738	1739	O
mean	10588965	1740	1744	O
difference	10588965	1745	1755	O
,	10588965	1756	1757	O
-8.9	10588965	1758	1762	O
;	10588965	1763	1764	O
95	10588965	1765	1767	O
percent	10588965	1768	1775	O
confidence	10588965	1776	1786	O
interval	10588965	1787	1795	O
,	10588965	1796	1797	O
-19.4	10588965	1798	1803	O
to	10588965	1804	1806	O
1.6	10588965	1807	1810	O
;	10588965	1811	1812	O
P=0.11	10588965	1813	1819	O
)	10588965	1820	1821	O
.	10588965	1822	1823	O

None	10588965	1824	1828	B-Count
of	10588965	1829	1831	I-Count
the	10588965	1832	1835	I-Count
children	10588965	1836	1844	I-Count
had	10588965	1845	1848	O
treatment-limiting	10588965	1849	1867	B-Outcome
adverse	10588965	1868	1875	I-Outcome
effects	10588965	1876	1883	I-Outcome
.	10588965	1884	1885	O

After	10588965	1886	1891	O
they	10588965	1892	1896	O
were	10588965	1897	1901	O
told	10588965	1902	1906	O
the	10588965	1907	1910	O
results	10588965	1911	1918	O
,	10588965	1919	1920	O
69	10588965	1921	1923	O
percent	10588965	1924	1931	O
of	10588965	1932	1934	O
the	10588965	1935	1938	O
parents	10588965	1939	1946	O
of	10588965	1947	1949	O
the	10588965	1950	1953	O
children	10588965	1954	1962	O
in	10588965	1963	1965	O
this	10588965	1966	1970	O
study	10588965	1971	1976	O
said	10588965	1977	1981	O
they	10588965	1982	1986	O
remained	10588965	1987	1995	O
interested	10588965	1996	2006	O
in	10588965	2007	2009	O
secretin	10588965	2010	2018	O
as	10588965	2019	2021	O
a	10588965	2022	2023	O
treatment	10588965	2024	2033	O
for	10588965	2034	2037	O
their	10588965	2038	2043	O
children	10588965	2044	2052	O
.	10588965	2053	2054	O

CONCLUSIONS	10588965	2055	2066	O
A	10588965	2067	2068	O
single	10588965	2069	2075	O
dose	10588965	2076	2080	O
of	10588965	2081	2083	O
synthetic	10588965	2084	2093	B-Intervention
human	10588965	2094	2099	I-Intervention
secretin	10588965	2100	2108	I-Intervention
is	10588965	2109	2111	O
not	10588965	2112	2115	O
an	10588965	2116	2118	O
effective	10588965	2119	2128	B-Observation
treatment	10588965	2129	2138	O
for	10588965	2139	2142	O
autism	10588965	2143	2149	B-Participant
or	10588965	2150	2152	O
pervasive	10588965	2153	2162	B-Participant
developmental	10588965	2163	2176	I-Participant
disorder	10588965	2177	2185	I-Participant
.	10588965	2186	2187	O

A	10592853	0	1	O
comparative	10592853	2	13	O
study	10592853	14	19	O
of	10592853	20	22	O
the	10592853	23	26	O
safety	10592853	27	33	B-Outcome
and	10592853	34	37	O
efficacy	10592853	38	46	B-Outcome
of	10592853	47	49	O
FemCap	10592853	50	56	B-Intervention
,	10592853	57	58	O
a	10592853	59	60	O
new	10592853	61	64	O
vaginal	10592853	65	72	O
barrier	10592853	73	80	O
contraceptive	10592853	81	94	O
,	10592853	95	96	O
and	10592853	97	100	O
the	10592853	101	104	O
Ortho	10592853	105	110	B-Intervention
All-Flex	10592853	111	119	I-Intervention
diaphragm	10592853	120	129	I-Intervention
.	10592853	130	131	O

The	10592853	132	135	O
FemCap	10592853	136	142	O
Investigators	10592853	143	156	O
'	10592853	157	158	O
Group	10592853	159	164	O
.	10592853	165	166	O

The	10592853	167	170	O
FemCap	10592853	171	177	O
is	10592853	178	180	O
a	10592853	181	182	O
new	10592853	183	186	O
silicone	10592853	187	195	O
rubber	10592853	196	202	O
barrier	10592853	203	210	O
contraceptive	10592853	211	224	O
shaped	10592853	225	231	O
like	10592853	232	236	O
a	10592853	237	238	O
sailor	10592853	239	245	O
's	10592853	246	248	O
hat	10592853	249	252	O
,	10592853	253	254	O
with	10592853	255	259	O
a	10592853	260	261	O
dome	10592853	262	266	O
that	10592853	267	271	O
covers	10592853	272	278	O
the	10592853	279	282	O
cervix	10592853	283	289	O
,	10592853	290	291	O
a	10592853	292	293	O
rim	10592853	294	297	O
that	10592853	298	302	O
fits	10592853	303	307	O
into	10592853	308	312	O
the	10592853	313	316	O
fornices	10592853	317	325	O
,	10592853	326	327	O
and	10592853	328	331	O
a	10592853	332	333	O
brim	10592853	334	338	O
that	10592853	339	343	O
conforms	10592853	344	352	O
to	10592853	353	355	O
the	10592853	356	359	O
vaginal	10592853	360	367	O
walls	10592853	368	373	O
around	10592853	374	380	O
the	10592853	381	384	O
cervix	10592853	385	391	O
.	10592853	392	393	O

It	10592853	394	396	O
was	10592853	397	400	O
designed	10592853	401	409	O
to	10592853	410	412	O
result	10592853	413	419	O
in	10592853	420	422	O
fewer	10592853	423	428	O
dislodgments	10592853	429	441	O
and	10592853	442	445	O
less	10592853	446	450	O
pressure	10592853	451	459	O
on	10592853	460	462	O
the	10592853	463	466	O
urethra	10592853	467	474	O
than	10592853	475	479	O
the	10592853	480	483	O
cervical	10592853	484	492	O
cap	10592853	493	496	O
and	10592853	497	500	O
diaphragm	10592853	501	510	O
,	10592853	511	512	O
respectively	10592853	513	525	O
,	10592853	526	527	O
and	10592853	528	531	O
to	10592853	532	534	O
require	10592853	535	542	O
less	10592853	543	547	O
clinician	10592853	548	557	O
time	10592853	558	562	O
for	10592853	563	566	O
fitting	10592853	567	574	O
.	10592853	575	576	O

This	10592853	577	581	O
was	10592853	582	585	O
a	10592853	586	587	O
phase	10592853	588	593	O
II/III	10592853	594	600	O
,	10592853	601	602	O
multicenter	10592853	603	614	O
,	10592853	615	616	O
randomized	10592853	617	627	O
,	10592853	628	629	O
open-label	10592853	630	640	O
,	10592853	641	642	O
parallel	10592853	643	651	O
group	10592853	652	657	O
study	10592853	658	663	O
of	10592853	664	666	O
841	10592853	667	670	O
women	10592853	671	676	B-Participant
at	10592853	677	679	B-Participant
risk	10592853	680	684	I-Participant
for	10592853	685	688	I-Participant
pregnancy	10592853	689	698	I-Participant
.	10592853	699	700	O

A	10592853	701	702	O
subset	10592853	703	709	O
of	10592853	710	712	O
42	10592853	713	715	O
women	10592853	716	721	B-Participant
at	10592853	722	724	O
one	10592853	725	728	O
site	10592853	729	733	O
underwent	10592853	734	743	O
colposcopy	10592853	744	754	B-Participant
.	10592853	755	756	O

Women	10592853	757	762	O
were	10592853	763	767	O
randomized	10592853	768	778	O
to	10592853	779	781	O
use	10592853	782	785	O
the	10592853	786	789	O
FemCap	10592853	790	796	B-Intervention
or	10592853	797	799	O
Ortho	10592853	800	805	B-Intervention
All-Flex	10592853	806	814	I-Intervention
contraceptive	10592853	815	828	I-Intervention
diaphragm	10592853	829	838	I-Intervention
,	10592853	839	840	O
both	10592853	841	845	O
with	10592853	846	850	O
2	10592853	851	852	O
%	10592853	853	854	O
nonoxynol-9	10592853	855	866	O
spermicide	10592853	867	877	O
,	10592853	878	879	O
for	10592853	880	883	O
28	10592853	884	886	O
weeks	10592853	887	892	O
.	10592853	893	894	O

The	10592853	895	898	O
objectives	10592853	899	909	O
were	10592853	910	914	O
to	10592853	915	917	O
compare	10592853	918	925	O
the	10592853	926	929	O
two	10592853	930	933	O
devices	10592853	934	941	O
with	10592853	942	946	O
regard	10592853	947	953	O
to	10592853	954	956	O
their	10592853	957	962	O
safety	10592853	963	969	B-Outcome
and	10592853	970	973	O
acceptability	10592853	974	987	B-Outcome
and	10592853	988	991	O
to	10592853	992	994	O
determine	10592853	995	1004	O
whether	10592853	1005	1012	O
the	10592853	1013	1016	O
probability	10592853	1017	1028	B-Outcome
of	10592853	1029	1031	I-Outcome
pregnancy	10592853	1032	1041	I-Outcome
among	10592853	1042	1047	O
FemCap	10592853	1048	1054	B-Intervention
users	10592853	1055	1060	O
was	10592853	1061	1064	O
no	10592853	1065	1067	O
worse	10592853	1068	1073	B-Observation
than	10592853	1074	1078	O
that	10592853	1079	1083	O
of	10592853	1084	1086	O
the	10592853	1087	1090	O
diaphragm	10592853	1091	1100	B-Intervention
(	10592853	1101	1102	O
meaning	10592853	1103	1110	O
not	10592853	1111	1114	O
more	10592853	1115	1119	O
than	10592853	1120	1124	O
6	10592853	1125	1126	O
percentage	10592853	1127	1137	O
points	10592853	1138	1144	O
higher	10592853	1145	1151	O
)	10592853	1152	1153	O
.	10592853	1154	1155	O

The	10592853	1156	1159	O
6-month	10592853	1160	1167	B-Outcome
Kaplan-Meier	10592853	1168	1180	I-Outcome
cumulative	10592853	1181	1191	I-Outcome
unadjusted	10592853	1192	1202	I-Outcome
typical	10592853	1203	1210	I-Outcome
use	10592853	1211	1214	I-Outcome
pregnancy	10592853	1215	1224	I-Outcome
probabilities	10592853	1225	1238	I-Outcome
were	10592853	1239	1243	O
13.5	10592853	1244	1248	B-Observation
%	10592853	1249	1250	I-Observation
among	10592853	1251	1256	O
FemCap	10592853	1257	1263	B-Intervention
users	10592853	1264	1269	O
and	10592853	1270	1273	O
7.9	10592853	1274	1277	B-Observation
%	10592853	1278	1279	I-Observation
among	10592853	1280	1285	O
diaphragm	10592853	1286	1295	B-Intervention
users	10592853	1296	1301	O
.	10592853	1302	1303	O

The	10592853	1304	1307	O
adjusted	10592853	1308	1316	B-Outcome
risk	10592853	1317	1321	I-Outcome
of	10592853	1322	1324	I-Outcome
pregnancy	10592853	1325	1334	I-Outcome
among	10592853	1335	1340	O
FemCap	10592853	1341	1347	B-Intervention
users	10592853	1348	1353	O
was	10592853	1354	1357	O
1.96	10592853	1358	1362	B-Observation
times	10592853	1363	1368	I-Observation
that	10592853	1369	1373	O
among	10592853	1374	1379	O
diaphragm	10592853	1380	1389	B-Intervention
users	10592853	1390	1395	O
,	10592853	1396	1397	O
with	10592853	1398	1402	O
an	10592853	1403	1405	O
upper	10592853	1406	1411	O
95	10592853	1412	1414	O
%	10592853	1415	1416	O
confidence	10592853	1417	1427	O
limit	10592853	1428	1433	O
of	10592853	1434	1436	O
3.01	10592853	1437	1441	O
.	10592853	1442	1443	O

Clinical	10592853	1444	1452	B-Observation
equivalence	10592853	1453	1464	I-Observation
(	10592853	1465	1466	I-Observation
noninferiority	10592853	1467	1481	I-Observation
)	10592853	1482	1483	I-Observation
of	10592853	1484	1486	O
the	10592853	1487	1490	O
FemCap	10592853	1491	1497	B-Intervention
compared	10592853	1498	1506	O
with	10592853	1507	1511	O
the	10592853	1512	1515	O
diaphragm	10592853	1516	1525	B-Intervention
,	10592853	1526	1527	O
as	10592853	1528	1530	O
defined	10592853	1531	1538	O
in	10592853	1539	1541	O
this	10592853	1542	1546	O
study	10592853	1547	1552	O
,	10592853	1553	1554	O
would	10592853	1555	1560	O
mean	10592853	1561	1565	O
that	10592853	1566	1570	O
the	10592853	1571	1574	O
true	10592853	1575	1579	B-Outcome
risk	10592853	1580	1584	I-Outcome
of	10592853	1585	1587	I-Outcome
pregnancy	10592853	1588	1597	I-Outcome
among	10592853	1598	1603	O
FemCap	10592853	1604	1610	B-Intervention
users	10592853	1611	1616	O
was	10592853	1617	1620	O
no	10592853	1621	1623	O
more	10592853	1624	1628	B-Observation
than	10592853	1629	1633	I-Observation
1.73	10592853	1634	1638	I-Observation
times	10592853	1639	1644	I-Observation
the	10592853	1645	1648	O
pregnancy	10592853	1649	1658	B-Outcome
risk	10592853	1659	1663	I-Outcome
of	10592853	1664	1666	O
diaphragm	10592853	1667	1676	B-Intervention
users	10592853	1677	1682	O
.	10592853	1683	1684	O

Because	10592853	1685	1692	O
the	10592853	1693	1696	O
observed	10592853	1697	1705	O
upper	10592853	1706	1711	O
95	10592853	1712	1714	O
%	10592853	1715	1716	O
confidence	10592853	1717	1727	O
limit	10592853	1728	1733	O
(	10592853	1734	1735	O
and	10592853	1736	1739	O
even	10592853	1740	1744	O
the	10592853	1745	1748	O
point	10592853	1749	1754	O
estimate	10592853	1755	1763	O
)	10592853	1764	1765	O
exceeded	10592853	1766	1774	O
1.73	10592853	1775	1779	O
,	10592853	1780	1781	O
the	10592853	1782	1785	O
probability	10592853	1786	1797	B-Outcome
of	10592853	1798	1800	I-Outcome
pregnancy	10592853	1801	1810	I-Outcome
among	10592853	1811	1816	O
FemCap	10592853	1817	1823	B-Intervention
users	10592853	1824	1829	O
,	10592853	1830	1831	O
compared	10592853	1832	1840	O
with	10592853	1841	1845	O
that	10592853	1846	1850	O
among	10592853	1851	1856	O
diaphragm	10592853	1857	1866	B-Intervention
users	10592853	1867	1872	O
,	10592853	1873	1874	O
did	10592853	1875	1878	O
not	10592853	1879	1882	O
meet	10592853	1883	1887	O
the	10592853	1888	1891	O
definition	10592853	1892	1902	O
of	10592853	1903	1905	O
clinical	10592853	1906	1914	B-Observation
equivalence	10592853	1915	1926	I-Observation
used	10592853	1927	1931	O
in	10592853	1932	1934	O
this	10592853	1935	1939	O
study	10592853	1940	1945	O
.	10592853	1946	1947	O

The	10592853	1948	1951	O
FemCap	10592853	1952	1958	B-Intervention
was	10592853	1959	1962	O
believed	10592853	1963	1971	O
to	10592853	1972	1974	O
be	10592853	1975	1977	O
safe	10592853	1978	1982	B-Observation
and	10592853	1983	1986	O
was	10592853	1987	1990	O
associated	10592853	1991	2001	O
with	10592853	2002	2006	O
significantly	10592853	2007	2020	B-Count
fewer	10592853	2021	2026	I-Count
urinary	10592853	2027	2034	B-Outcome
tract	10592853	2035	2040	I-Outcome
infections	10592853	2041	2051	I-Outcome
.	10592853	2052	2053	O

More	10592853	2054	2058	B-Count
women	10592853	2059	2064	I-Count
reported	10592853	2065	2073	O
problems	10592853	2074	2082	O
with	10592853	2083	2087	O
the	10592853	2088	2091	O
FemCap	10592853	2092	2098	B-Intervention
with	10592853	2099	2103	O
regard	10592853	2104	2110	O
to	10592853	2111	2113	O
insertion	10592853	2114	2123	B-Outcome
,	10592853	2124	2125	O
dislodgement	10592853	2126	2138	B-Outcome
,	10592853	2139	2140	O
and	10592853	2141	2144	O
especially	10592853	2145	2155	O
removal	10592853	2156	2163	B-Outcome
,	10592853	2164	2165	O
although	10592853	2166	2174	O
their	10592853	2175	2180	O
general	10592853	2181	2188	B-Outcome
assessments	10592853	2189	2200	I-Outcome
were	10592853	2201	2205	O
positive	10592853	2206	2214	B-Observation
.	10592853	2215	2216	O

The	10592853	2217	2220	O
two	10592853	2221	2224	B-Intervention
devices	10592853	2225	2232	I-Intervention
were	10592853	2233	2237	O
comparable	10592853	2238	2248	B-Observation
with	10592853	2249	2253	O
regard	10592853	2254	2260	O
to	10592853	2261	2263	O
safety	10592853	2264	2270	B-Outcome
and	10592853	2271	2274	O
acceptability	10592853	2275	2288	B-Outcome
,	10592853	2289	2290	O
but	10592853	2291	2294	O
a	10592853	2295	2296	O
6-point	10592853	2297	2304	B-Observation
difference	10592853	2305	2315	I-Observation
in	10592853	2316	2318	O
the	10592853	2319	2322	O
true	10592853	2323	2327	B-Outcome
6-month	10592853	2328	2335	I-Outcome
pregnancy	10592853	2336	2345	I-Outcome
probabilities	10592853	2346	2359	I-Outcome
of	10592853	2360	2362	O
the	10592853	2363	2366	O
two	10592853	2367	2370	B-Intervention
devices	10592853	2371	2378	I-Intervention
could	10592853	2379	2384	O
not	10592853	2385	2388	O
be	10592853	2389	2391	O
ruled	10592853	2392	2397	O
out	10592853	2398	2401	O
.	10592853	2402	2403	O

Further	10592853	2404	2411	O
studies	10592853	2412	2419	O
are	10592853	2420	2423	O
needed	10592853	2424	2430	O
to	10592853	2431	2433	O
determine	10592853	2434	2443	O
whether	10592853	2444	2451	O
design	10592853	2452	2458	O
modifications	10592853	2459	2472	O
can	10592853	2473	2476	O
simplify	10592853	2477	2485	O
insertion	10592853	2486	2495	O
and	10592853	2496	2499	O
removal	10592853	2500	2507	O
.	10592853	2508	2509	O

Cholesterol-lowering	10593347	0	20	B-Outcome
effect	10593347	21	27	I-Outcome
of	10593347	28	30	O
stanol	10593347	31	37	B-Intervention
ester	10593347	38	43	I-Intervention
in	10593347	44	46	O
a	10593347	47	48	O
US	10593347	49	51	O
population	10593347	52	62	O
of	10593347	63	65	O
mildly	10593347	66	72	B-Participant
hypercholesterolemic	10593347	73	93	I-Participant
men	10593347	94	97	B-Participant
and	10593347	98	101	O
women	10593347	102	107	B-Participant
:	10593347	108	109	O
a	10593347	110	111	O
randomized	10593347	112	122	O
controlled	10593347	123	133	O
trial	10593347	134	139	O
.	10593347	140	141	O

OBJECTIVE	10593347	142	151	O
To	10593347	152	154	O
determine	10593347	155	164	O
the	10593347	165	168	O
efficacy	10593347	169	177	O
of	10593347	178	180	O
stanol	10593347	181	187	B-Intervention
esters	10593347	188	194	I-Intervention
in	10593347	195	197	O
lowering	10593347	198	206	B-Observation
cholesterol	10593347	207	218	B-Outcome
in	10593347	219	221	O
a	10593347	222	223	O
US	10593347	224	226	O
population	10593347	227	237	O
.	10593347	238	239	O

SUBJECTS	10593347	240	248	O
AND	10593347	249	252	O
METHODS	10593347	253	260	O
After	10593347	261	266	O
a	10593347	267	268	O
run-in	10593347	269	275	O
phase	10593347	276	281	O
,	10593347	282	283	O
318	10593347	284	287	O
subjects	10593347	288	296	O
were	10593347	297	301	O
randomized	10593347	302	312	O
to	10593347	313	315	O
receive	10593347	316	323	O
one	10593347	324	327	O
of	10593347	328	330	O
the	10593347	331	334	O
following	10593347	335	344	O
margarine-like	10593347	345	359	O
spreads	10593347	360	367	O
containing	10593347	368	378	O
stanol	10593347	379	385	O
ester	10593347	386	391	O
or	10593347	392	394	O
placebo	10593347	395	402	O
for	10593347	403	406	O
8	10593347	407	408	O
weeks	10593347	409	414	O
:	10593347	415	416	O
EU	10593347	417	419	O
3	10593347	420	421	O
G	10593347	422	423	O
:	10593347	424	425	O
1	10593347	426	427	B-Intervention
g	10593347	428	429	I-Intervention
of	10593347	430	432	I-Intervention
stanol	10593347	433	439	I-Intervention
(	10593347	440	441	O
ester	10593347	442	447	O
form	10593347	448	452	O
)	10593347	453	454	O
per	10593347	455	458	O
8-g	10593347	459	462	O
serving	10593347	463	470	O
of	10593347	471	473	O
a	10593347	474	475	O
European	10593347	476	484	O
formula	10593347	485	492	O
3	10593347	493	494	O
times	10593347	495	500	O
a	10593347	501	502	O
day	10593347	503	506	O
;	10593347	507	508	O
US	10593347	509	511	O
3	10593347	512	513	O
G	10593347	514	515	O
:	10593347	516	517	O
1	10593347	518	519	B-Intervention
g	10593347	520	521	I-Intervention
of	10593347	522	524	I-Intervention
stanol	10593347	525	531	I-Intervention
(	10593347	532	533	O
ester	10593347	534	539	O
form	10593347	540	544	O
)	10593347	545	546	O
per	10593347	547	550	O
8-g	10593347	551	554	O
serving	10593347	555	562	O
of	10593347	563	565	O
a	10593347	566	567	O
US	10593347	568	570	O
reformulation	10593347	571	584	O
3	10593347	585	586	O
times	10593347	587	592	O
a	10593347	593	594	O
day	10593347	595	598	O
;	10593347	599	600	O
US	10593347	601	603	B-Intervention
2	10593347	604	605	I-Intervention
G	10593347	606	607	I-Intervention
:	10593347	608	609	O
0.67	10593347	610	614	O
g	10593347	615	616	O
of	10593347	617	619	O
stanol	10593347	620	626	O
(	10593347	627	628	O
ester	10593347	629	634	O
form	10593347	635	639	O
)	10593347	640	641	O
per	10593347	642	645	O
8-g	10593347	646	649	O
serving	10593347	650	657	O
of	10593347	658	660	O
a	10593347	661	662	O
US	10593347	663	665	O
reformulation	10593347	666	679	O
3	10593347	680	681	O
times	10593347	682	687	O
a	10593347	688	689	O
day	10593347	690	693	O
;	10593347	694	695	O
or	10593347	696	698	O
placebo	10593347	699	706	B-Intervention
spread	10593347	707	713	O
.	10593347	714	715	O

RESULTS	10593347	716	723	O
Mean	10593347	724	728	O
+	10593347	729	730	O
/-	10593347	730	732	O
SD	10593347	733	735	O
baseline	10593347	736	744	B-Outcome
total	10593347	745	750	I-Outcome
cholesterol	10593347	751	762	I-Outcome
(	10593347	763	764	I-Outcome
TC	10593347	765	767	I-Outcome
)	10593347	768	769	I-Outcome
and	10593347	770	773	O
low-density	10593347	774	785	B-Outcome
lipoprotein	10593347	786	797	I-Outcome
cholesterol	10593347	798	809	I-Outcome
(	10593347	810	811	I-Outcome
LDL-C	10593347	812	817	I-Outcome
)	10593347	818	819	I-Outcome
levels	10593347	820	826	I-Outcome
were	10593347	827	831	O
233+/-20	10593347	832	840	B-Observation
and	10593347	841	844	O
153	10593347	845	848	B-Observation
+	10593347	848	849	I-Observation
21	10593347	849	851	I-Observation
mg+/-dL	10593347	852	859	I-Observation
,	10593347	860	861	O
respectively	10593347	862	874	O
.	10593347	875	876	O

In	10593347	877	879	O
the	10593347	880	883	O
US	10593347	884	886	O
3	10593347	887	888	O
G	10593347	889	890	O
group	10593347	891	896	O
,	10593347	897	898	O
3	10593347	899	900	B-Intervention
g	10593347	901	902	I-Intervention
daily	10593347	903	908	I-Intervention
of	10593347	909	911	I-Intervention
stanol	10593347	912	918	I-Intervention
esters	10593347	919	925	I-Intervention
lowered	10593347	926	933	B-Observation
TC	10593347	934	936	B-Outcome
and	10593347	937	940	O
LDL-C	10593347	941	946	B-Outcome
levels	10593347	947	953	I-Outcome
by	10593347	954	956	O
6.4	10593347	957	960	B-Observation
%	10593347	961	962	I-Observation
and	10593347	963	966	O
10.1	10593347	967	971	B-Observation
%	10593347	972	973	I-Observation
,	10593347	974	975	O
respectively	10593347	976	988	O
.	10593347	989	990	O

There	10593347	991	996	O
was	10593347	997	1000	O
a	10593347	1001	1002	O
dose-dependent	10593347	1003	1017	B-Outcome
response	10593347	1018	1026	I-Outcome
compared	10593347	1027	1035	O
with	10593347	1036	1040	O
2	10593347	1041	1042	B-Intervention
g	10593347	1043	1044	I-Intervention
daily	10593347	1045	1050	I-Intervention
(	10593347	1051	1052	O
US	10593347	1053	1055	O
2	10593347	1056	1057	O
G	10593347	1058	1059	O
)	10593347	1060	1061	O
.	10593347	1062	1063	O

Triglyceride	10593347	1064	1076	B-Outcome
and	10593347	1077	1080	I-Outcome
high-density	10593347	1081	1093	I-Outcome
lipoprotein	10593347	1094	1105	I-Outcome
cholesterol	10593347	1106	1117	I-Outcome
levels	10593347	1118	1124	I-Outcome
were	10593347	1125	1129	O
unchanged	10593347	1130	1139	B-Observation
.	10593347	1140	1141	O

The	10593347	1142	1145	O
incidence	10593347	1146	1155	B-Outcome
of	10593347	1156	1158	I-Outcome
adverse	10593347	1159	1166	I-Outcome
effects	10593347	1167	1174	I-Outcome
was	10593347	1175	1178	O
not	10593347	1179	1182	O
different	10593347	1183	1192	B-Observation
from	10593347	1193	1197	O
placebo	10593347	1198	1205	B-Intervention
.	10593347	1206	1207	O

Serum	10593347	1208	1213	B-Outcome
vitamin	10593347	1214	1221	I-Outcome
A	10593347	1222	1223	I-Outcome
and	10593347	1224	1227	I-Outcome
25-hydroxyvitamin	10593347	1228	1245	I-Outcome
D	10593347	1246	1247	I-Outcome
levels	10593347	1248	1254	I-Outcome
were	10593347	1255	1259	O
not	10593347	1260	1263	O
affected	10593347	1264	1272	B-Observation
.	10593347	1273	1274	O

CONCLUSIONS	10593347	1275	1286	O
Stanol	10593347	1287	1293	B-Intervention
esters	10593347	1294	1300	I-Intervention
lowered	10593347	1301	1308	B-Observation
TC	10593347	1309	1311	B-Outcome
and	10593347	1312	1315	I-Outcome
LDL-C	10593347	1316	1321	I-Outcome
levels	10593347	1322	1328	I-Outcome
in	10593347	1329	1331	O
a	10593347	1332	1333	O
mildly	10593347	1334	1340	B-Participant
hypercholesterolemic	10593347	1341	1361	I-Participant
US	10593347	1362	1364	I-Participant
population	10593347	1365	1375	I-Participant
without	10593347	1376	1383	O
evidence	10593347	1384	1392	O
of	10593347	1393	1395	O
adverse	10593347	1396	1403	B-Outcome
effects	10593347	1404	1411	I-Outcome
.	10593347	1412	1413	O

It	10593347	1414	1416	O
may	10593347	1417	1420	O
be	10593347	1421	1423	O
a	10593347	1424	1425	O
useful	10593347	1426	1432	O
dietary	10593347	1433	1440	B-Intervention
adjunct	10593347	1441	1448	I-Intervention
to	10593347	1449	1451	O
lower	10593347	1452	1457	B-Observation
cholesterol	10593347	1458	1469	B-Outcome
.	10593347	1470	1471	O

Ursodeoxycholic	10594393	0	15	B-Intervention
acid	10594393	16	20	I-Intervention
has	10594393	21	24	O
no	10594393	25	27	O
influence	10594393	28	37	B-Observation
on	10594393	38	40	O
function	10594393	41	49	B-Outcome
after	10594393	50	55	O
restorative	10594393	56	67	B-Participant
proctocolectomy	10594393	68	83	I-Participant
in	10594393	84	86	O
ulcerative	10594393	87	97	B-Participant
colitis	10594393	98	105	I-Participant
.	10594393	106	107	O

BACKGROUND	10594393	108	118	O
Poor	10594393	119	123	O
pouch	10594393	124	129	O
function	10594393	130	138	O
is	10594393	139	141	O
associated	10594393	142	152	O
with	10594393	153	157	O
impaired	10594393	158	166	O
bile	10594393	167	171	O
acid	10594393	172	176	O
absorption	10594393	177	187	O
and	10594393	188	191	O
increased	10594393	192	201	O
faecal	10594393	202	208	O
loss	10594393	209	213	O
of	10594393	214	216	O
bile	10594393	217	221	O
acids	10594393	222	227	O
.	10594393	228	229	O

Bile	10594393	230	234	O
acid	10594393	235	239	O
replacement	10594393	240	251	O
therapy	10594393	252	259	O
might	10594393	260	265	O
therefore	10594393	266	275	O
be	10594393	276	278	O
of	10594393	279	281	O
clinical	10594393	282	290	O
benefit	10594393	291	298	O
,	10594393	299	300	O
provided	10594393	301	309	O
that	10594393	310	314	O
diarrhoea	10594393	315	324	O
is	10594393	325	327	O
not	10594393	328	331	O
aggravated	10594393	332	342	O
by	10594393	343	345	O
therapy	10594393	346	353	O
.	10594393	354	355	O

AIM	10594393	356	359	O
To	10594393	360	362	O
investigate	10594393	363	374	O
the	10594393	375	378	O
role	10594393	379	383	O
of	10594393	384	386	O
exogenous	10594393	387	396	B-Intervention
bile	10594393	397	401	I-Intervention
acid	10594393	402	406	I-Intervention
therapy	10594393	407	414	I-Intervention
in	10594393	415	417	O
patients	10594393	418	426	O
with	10594393	427	431	O
poor	10594393	432	436	B-Participant
pouch	10594393	437	442	I-Participant
function	10594393	443	451	I-Participant
after	10594393	452	457	O
restorative	10594393	458	469	B-Participant
proctocolectomy	10594393	470	485	I-Participant
for	10594393	486	489	O
ulcerative	10594393	490	500	B-Participant
colitis	10594393	501	508	I-Participant
.	10594393	509	510	O

PATIENTS	10594393	511	519	O
AND	10594393	520	523	O
METHODS	10594393	524	531	O
Twenty	10594393	532	538	O
ulcerative	10594393	539	549	B-Participant
colitis	10594393	550	557	I-Participant
patients	10594393	558	566	O
with	10594393	567	571	O
poor	10594393	572	576	B-Participant
pouch	10594393	577	582	I-Participant
function	10594393	583	591	I-Participant
(	10594393	592	593	O
score	10594393	594	599	O
>	10594393	600	601	O
4	10594393	602	603	O
on	10594393	604	606	O
a	10594393	607	608	O
12-point	10594393	609	617	O
score	10594393	618	623	O
)	10594393	624	625	O
were	10594393	626	630	O
recruited	10594393	631	640	O
for	10594393	641	644	O
inclusion	10594393	645	654	O
to	10594393	655	657	O
a	10594393	658	659	O
prospective	10594393	660	671	O
,	10594393	672	673	O
randomized	10594393	674	684	O
,	10594393	685	686	O
double-blind	10594393	687	699	O
crossover	10594393	700	709	O
,	10594393	710	711	O
placebo-controlled	10594393	712	730	O
trial	10594393	731	736	O
of	10594393	737	739	O
ursodeoxycholic	10594393	740	755	B-Intervention
acid	10594393	756	760	I-Intervention
(	10594393	761	762	O
10	10594393	763	765	O
mg/kg	10594393	766	771	O
per	10594393	772	775	O
day	10594393	776	779	O
in	10594393	780	782	O
two	10594393	783	786	O
divided	10594393	787	794	O
doses	10594393	795	800	O
for	10594393	801	804	O
1	10594393	805	806	O
month	10594393	807	812	O
)	10594393	813	814	O
.	10594393	815	816	O

RESULTS	10594393	817	824	O
A	10594393	825	826	O
total	10594393	827	832	O
of	10594393	833	835	O
16	10594393	836	838	O
patients	10594393	839	847	O
completed	10594393	848	857	O
the	10594393	858	861	O
study	10594393	862	867	O
.	10594393	868	869	O

There	10594393	870	875	O
was	10594393	876	879	O
no	10594393	880	882	O
significant	10594393	883	894	B-Observation
difference	10594393	895	905	I-Observation
in	10594393	906	908	O
the	10594393	909	912	O
functional	10594393	913	923	B-Outcome
score	10594393	924	929	I-Outcome
or	10594393	930	932	O
bowel	10594393	933	938	B-Outcome
frequency	10594393	939	948	I-Outcome
following	10594393	949	958	O
treatment	10594393	959	968	O
irrespective	10594393	969	981	O
of	10594393	982	984	O
whether	10594393	985	992	O
the	10594393	993	996	O
active	10594393	997	1003	B-Intervention
treatment	10594393	1004	1013	I-Intervention
was	10594393	1014	1017	I-Intervention
given	10594393	1018	1023	I-Intervention
before	10594393	1024	1030	I-Intervention
or	10594393	1031	1033	I-Intervention
after	10594393	1034	1039	I-Intervention
placebo	10594393	1040	1047	I-Intervention
.	10594393	1048	1049	O

CONCLUSIONS	10594393	1050	1061	O
We	10594393	1062	1064	O
conclude	10594393	1065	1073	O
that	10594393	1074	1078	O
ursodeoxycholic	10594393	1079	1094	B-Intervention
acid	10594393	1095	1099	I-Intervention
given	10594393	1100	1105	O
over	10594393	1106	1110	O
4	10594393	1111	1112	O
weeks	10594393	1113	1118	O
had	10594393	1119	1122	O
no	10594393	1123	1125	O
influence	10594393	1126	1135	B-Observation
on	10594393	1136	1138	O
functional	10594393	1139	1149	B-Outcome
score	10594393	1150	1155	I-Outcome
or	10594393	1156	1158	O
bowel	10594393	1159	1164	B-Outcome
frequency	10594393	1165	1174	I-Outcome
after	10594393	1175	1180	O
restorative	10594393	1181	1192	B-Participant
proctocolectomy	10594393	1193	1208	I-Participant
for	10594393	1209	1212	O
U.C	10594393	1213	1216	B-Participant
.	10594393	1217	1218	O

Standard-dose	10594396	0	13	B-Intervention
lansoprazole	10594396	14	26	I-Intervention
is	10594396	27	29	O
more	10594396	30	34	B-Observation
effective	10594396	35	44	I-Observation
than	10594396	45	49	O
high-dose	10594396	50	59	B-Intervention
ranitidine	10594396	60	70	I-Intervention
in	10594396	71	73	O
achieving	10594396	74	83	O
endoscopic	10594396	84	94	B-Outcome
healing	10594396	95	102	I-Outcome
and	10594396	103	106	O
symptom	10594396	107	114	B-Outcome
relief	10594396	115	121	I-Outcome
in	10594396	122	124	O
patients	10594396	125	133	O
with	10594396	134	138	O
moderately	10594396	139	149	B-Participant
severe	10594396	150	156	I-Participant
reflux	10594396	157	163	I-Participant
oesophagitis	10594396	164	176	I-Participant
.	10594396	177	178	O

The	10594396	179	182	O
Dutch	10594396	183	188	O
Lansoprazole	10594396	189	201	O
Study	10594396	202	207	O
Group	10594396	208	213	O
.	10594396	214	215	O

BACKGROUND	10594396	216	226	O
In	10594396	227	229	O
the	10594396	230	233	O
treatment	10594396	234	243	O
of	10594396	244	246	O
reflux	10594396	247	253	O
oesophagitis	10594396	254	266	O
,	10594396	267	268	O
H2-receptor	10594396	269	280	O
antagonists	10594396	281	292	O
are	10594396	293	296	O
still	10594396	297	302	O
widely	10594396	303	309	O
used	10594396	310	314	O
in	10594396	315	317	O
spite	10594396	318	323	O
of	10594396	324	326	O
the	10594396	327	330	O
apparent	10594396	331	339	O
higher	10594396	340	346	O
efficacy	10594396	347	355	O
of	10594396	356	358	O
proton	10594396	359	365	O
pump	10594396	366	370	O
inhibitors	10594396	371	381	O
.	10594396	382	383	O

In	10594396	384	386	O
an	10594396	387	389	O
attempt	10594396	390	397	O
to	10594396	398	400	O
compensate	10594396	401	411	O
for	10594396	412	415	O
the	10594396	416	419	O
lower	10594396	420	425	O
efficacy	10594396	426	434	O
,	10594396	435	436	O
H2-receptor	10594396	437	448	O
antagonists	10594396	449	460	O
are	10594396	461	464	O
now	10594396	465	468	O
increasingly	10594396	469	481	O
being	10594396	482	487	O
used	10594396	488	492	O
at	10594396	493	495	O
a	10594396	496	497	O
higher	10594396	498	504	O
dose	10594396	505	509	O
.	10594396	510	511	O

OBJECTIVE	10594396	512	521	O
To	10594396	522	524	O
assess	10594396	525	531	O
whether	10594396	532	539	O
or	10594396	540	542	O
not	10594396	543	546	O
standard-dose	10594396	547	560	B-Intervention
lansoprazole	10594396	561	573	I-Intervention
(	10594396	574	575	O
30	10594396	576	578	O
mg	10594396	579	581	O
o.d	10594396	582	585	O
.	10594396	586	587	O
)	10594396	588	589	O
is	10594396	590	592	O
more	10594396	593	597	B-Observation
effective	10594396	598	607	I-Observation
than	10594396	608	612	O
high-dose	10594396	613	622	B-Intervention
ranitidine	10594396	623	633	I-Intervention
(	10594396	634	635	O
300	10594396	636	639	O
mg	10594396	640	642	O
b.d	10594396	643	646	O
.	10594396	647	648	O
)	10594396	649	650	O
in	10594396	651	653	O
moderately	10594396	654	664	B-Participant
severe	10594396	665	671	I-Participant
reflux	10594396	672	678	I-Participant
oesophagitis	10594396	679	691	I-Participant
(	10594396	692	693	I-Participant
grades	10594396	694	700	I-Participant
II-III	10594396	701	707	I-Participant
)	10594396	708	709	I-Participant
.	10594396	710	711	O

METHODS	10594396	712	719	O
Lansoprazole	10594396	720	732	B-Intervention
or	10594396	733	735	O
ranitidine	10594396	736	746	B-Intervention
was	10594396	747	750	O
given	10594396	751	756	O
to	10594396	757	759	O
133	10594396	760	763	O
patients	10594396	764	772	O
for	10594396	773	776	O
4	10594396	777	778	O
-	10594396	778	779	O
8	10594396	779	780	O
weeks	10594396	781	786	O
in	10594396	787	789	O
a	10594396	790	791	O
double-blind	10594396	792	804	O
,	10594396	805	806	O
randomized	10594396	807	817	O
,	10594396	818	819	O
parallel	10594396	820	828	O
group	10594396	829	834	O
,	10594396	835	836	O
multicentre	10594396	837	848	O
trial	10594396	849	854	O
.	10594396	855	856	O

RESULTS	10594396	857	864	O
The	10594396	865	868	O
percentage	10594396	869	879	B-Outcome
of	10594396	880	882	I-Outcome
patients	10594396	883	891	I-Outcome
with	10594396	892	896	I-Outcome
endoscopically-verified	10594396	897	920	I-Outcome
healing	10594396	921	928	I-Outcome
was	10594396	929	932	O
significantly	10594396	933	946	B-Observation
higher	10594396	947	953	I-Observation
on	10594396	954	956	O
lansoprazole	10594396	957	969	B-Intervention
than	10594396	970	974	O
on	10594396	975	977	O
ranitidine	10594396	978	988	B-Intervention
both	10594396	989	993	O
after	10594396	994	999	O
4	10594396	1000	1001	O
weeks	10594396	1002	1007	O
(	10594396	1008	1009	O
79	10594396	1010	1012	B-Observation
%	10594396	1013	1014	I-Observation
vs.	10594396	1015	1018	O
42	10594396	1019	1021	B-Observation
%	10594396	1022	1023	I-Observation
)	10594396	1024	1025	O
and	10594396	1026	1029	O
8	10594396	1030	1031	O
weeks	10594396	1032	1037	O
(	10594396	1038	1039	O
91	10594396	1040	1042	B-Observation
%	10594396	1043	1044	I-Observation
vs.	10594396	1045	1048	O
66	10594396	1049	1051	B-Observation
%	10594396	1052	1053	I-Observation
)	10594396	1054	1055	O
,	10594396	1056	1057	O
though	10594396	1058	1064	O
smoking	10594396	1065	1072	B-Participant
had	10594396	1073	1076	O
a	10594396	1077	1078	O
negative	10594396	1079	1087	B-Observation
impact	10594396	1088	1094	I-Observation
on	10594396	1095	1097	O
oesophagitis	10594396	1098	1110	B-Outcome
healing	10594396	1111	1118	I-Outcome
with	10594396	1119	1123	O
lansoprazole	10594396	1124	1136	B-Intervention
.	10594396	1137	1138	O

Heartburn	10594396	1139	1148	B-Outcome
,	10594396	1149	1150	O
retrosternal	10594396	1151	1163	B-Outcome
pain	10594396	1164	1168	I-Outcome
and	10594396	1169	1172	O
belching	10594396	1173	1181	B-Outcome
improved	10594396	1182	1190	B-Observation
significantly	10594396	1191	1204	I-Observation
better	10594396	1205	1211	I-Observation
with	10594396	1212	1216	O
lansoprazole	10594396	1217	1229	B-Intervention
than	10594396	1230	1234	O
with	10594396	1235	1239	O
ranitidine	10594396	1240	1250	B-Intervention
,	10594396	1251	1252	O
as	10594396	1253	1255	O
did	10594396	1256	1259	O
the	10594396	1260	1263	O
patient-rated	10594396	1264	1277	B-Outcome
overall	10594396	1278	1285	I-Outcome
symptom	10594396	1286	1293	I-Outcome
severity	10594396	1294	1302	I-Outcome
.	10594396	1303	1304	O

Relief	10594396	1305	1311	B-Outcome
of	10594396	1312	1314	I-Outcome
heartburn	10594396	1315	1324	I-Outcome
appeared	10594396	1325	1333	O
somewhat	10594396	1334	1342	B-Observation
faster	10594396	1343	1349	I-Observation
with	10594396	1350	1354	O
ranitidine	10594396	1355	1365	B-Intervention
,	10594396	1366	1367	O
but	10594396	1368	1371	O
was	10594396	1372	1375	O
more	10594396	1376	1380	B-Observation
pronounced	10594396	1381	1391	I-Observation
with	10594396	1392	1396	O
lansoprazole	10594396	1397	1409	B-Intervention
.	10594396	1410	1411	O

The	10594396	1412	1415	O
number	10594396	1416	1422	B-Outcome
of	10594396	1423	1425	I-Outcome
patients	10594396	1426	1434	I-Outcome
with	10594396	1435	1439	I-Outcome
adverse	10594396	1440	1447	I-Outcome
events	10594396	1448	1454	I-Outcome
was	10594396	1455	1458	O
similar	10594396	1459	1466	B-Observation
in	10594396	1467	1469	O
both	10594396	1470	1474	B-Intervention
treatment	10594396	1475	1484	I-Intervention
groups	10594396	1485	1491	I-Intervention
.	10594396	1492	1493	O

CONCLUSION	10594396	1494	1504	O
Standard-dose	10594396	1505	1518	B-Intervention
lansoprazole	10594396	1519	1531	I-Intervention
is	10594396	1532	1534	O
better	10594396	1535	1541	B-Observation
than	10594396	1542	1546	O
high-dose	10594396	1547	1556	B-Intervention
ranitidine	10594396	1557	1567	I-Intervention
in	10594396	1568	1570	O
moderately	10594396	1571	1581	B-Participant
severe	10594396	1582	1588	I-Participant
reflux	10594396	1589	1595	I-Participant
oesophagitis	10594396	1596	1608	I-Participant
.	10594396	1609	1610	O

Enalapril	10599355	0	9	B-Intervention
(	10599355	10	11	O
10	10599355	12	14	O
mg/day	10599355	15	21	O
)	10599355	22	23	O
in	10599355	24	26	O
systemic	10599355	27	35	B-Participant
sclerosis	10599355	36	45	I-Participant
.	10599355	46	47	O

One	10599355	48	51	O
year	10599355	52	56	O
,	10599355	57	58	O
double	10599355	59	65	O
blind	10599355	66	71	O
,	10599355	72	73	O
randomised	10599355	74	84	O
study	10599355	85	90	O
(	10599355	91	92	O
ESS-1	10599355	93	98	O
)	10599355	99	100	O
:	10599355	101	102	O
echocardiographic	10599355	103	120	O
substudy	10599355	121	129	O
--	10599355	130	132	O
three	10599355	133	138	O
months	10599355	139	145	O
follow-up	10599355	146	155	O
.	10599355	156	157	O

The	10599355	158	161	O
ESS-1	10599355	162	167	O
study	10599355	168	173	O
was	10599355	174	177	O
designed	10599355	178	186	O
to	10599355	187	189	O
evaluate	10599355	190	198	O
the	10599355	199	202	O
long-term	10599355	203	212	O
effects	10599355	213	220	O
of	10599355	221	223	O
the	10599355	224	227	O
angiotensin	10599355	228	239	B-Intervention
converting	10599355	240	250	I-Intervention
enzyme	10599355	251	257	I-Intervention
inhibitor	10599355	258	267	I-Intervention
(	10599355	268	269	I-Intervention
ACEI	10599355	270	274	I-Intervention
)	10599355	275	276	I-Intervention
enalapril	10599355	277	286	I-Intervention
(	10599355	287	288	O
10	10599355	289	291	O
mg	10599355	292	294	O
per	10599355	295	298	O
day	10599355	299	302	O
)	10599355	303	304	O
on	10599355	305	307	O
the	10599355	308	311	O
cardio-pulmonary	10599355	312	328	B-Outcome
system	10599355	329	335	I-Outcome
in	10599355	336	338	O
patients	10599355	339	347	O
with	10599355	348	352	O
scleroderma	10599355	353	364	B-Participant
(	10599355	365	366	I-Participant
SSc	10599355	367	370	I-Participant
)	10599355	371	372	I-Participant
.	10599355	373	374	O

We	10599355	375	377	O
estimated	10599355	378	387	O
changes	10599355	388	395	B-Observation
in	10599355	396	398	O
heart	10599355	399	404	B-Outcome
diameters	10599355	405	414	I-Outcome
,	10599355	415	416	O
systolic	10599355	417	425	B-Outcome
and	10599355	426	429	I-Outcome
diastolic	10599355	430	439	I-Outcome
left	10599355	440	444	I-Outcome
ventricle	10599355	445	454	I-Outcome
function	10599355	455	463	I-Outcome
and	10599355	464	467	O
mean	10599355	468	472	B-Outcome
values	10599355	473	479	I-Outcome
of	10599355	480	482	I-Outcome
pulmonary	10599355	483	492	I-Outcome
artery	10599355	493	499	I-Outcome
pressure	10599355	500	508	I-Outcome
after	10599355	509	514	O
3	10599355	515	516	O
months	10599355	517	523	O
treatment	10599355	524	533	O
.	10599355	534	535	O

The	10599355	536	539	O
study	10599355	540	545	O
group	10599355	546	551	O
comprise	10599355	552	560	O
41	10599355	561	563	O
patients	10599355	564	572	O
with	10599355	573	577	O
SSc	10599355	578	581	B-Participant
.	10599355	582	583	O

18	10599355	584	586	O
patients	10599355	587	595	O
received	10599355	596	604	O
placebo	10599355	605	612	B-Intervention
and	10599355	613	616	O
23	10599355	617	619	O
ones	10599355	620	624	O
were	10599355	625	629	O
given	10599355	630	635	O
enalapril	10599355	636	645	B-Intervention
.	10599355	646	647	O

After	10599355	648	653	O
3	10599355	654	655	O
months	10599355	656	662	O
of	10599355	663	665	O
treatment	10599355	666	675	O
we	10599355	676	678	O
did	10599355	679	682	O
not	10599355	683	686	O
observe	10599355	687	694	O
statistically	10599355	695	708	B-Observation
significant	10599355	709	720	I-Observation
differences	10599355	721	732	I-Observation
in	10599355	733	735	O
heart	10599355	736	741	B-Outcome
diameters	10599355	742	751	I-Outcome
and	10599355	752	755	O
left	10599355	756	760	B-Outcome
ventricle	10599355	761	770	I-Outcome
systolic	10599355	771	779	I-Outcome
function	10599355	780	788	I-Outcome
parameters	10599355	789	799	I-Outcome
between	10599355	800	807	O
treated	10599355	808	815	B-Intervention
group	10599355	816	821	O
and	10599355	822	825	O
placebo	10599355	826	833	B-Intervention
.	10599355	834	835	O

Enalapril	10599355	836	845	B-Intervention
therapy	10599355	846	853	I-Intervention
did	10599355	854	857	O
not	10599355	858	861	O
affect	10599355	862	868	B-Observation
left	10599355	869	873	B-Outcome
ventricle	10599355	874	883	I-Outcome
diastolic	10599355	884	893	I-Outcome
function	10599355	894	902	I-Outcome
,	10599355	903	904	O
nevertheless	10599355	905	917	O
differences	10599355	918	929	B-Outcome
in	10599355	930	932	I-Outcome
MVA	10599355	933	936	I-Outcome
were	10599355	937	941	O
almost	10599355	942	948	O
of	10599355	949	951	O
statistical	10599355	952	963	B-Observation
significance	10599355	964	976	I-Observation
.	10599355	977	978	O

Echocardiographic	10599355	979	996	B-Outcome
signs	10599355	997	1002	I-Outcome
of	10599355	1003	1005	I-Outcome
pulmonary	10599355	1006	1015	I-Outcome
hypertension	10599355	1016	1028	I-Outcome
were	10599355	1029	1033	O
found	10599355	1034	1039	O
in	10599355	1040	1042	O
4	10599355	1043	1044	B-Count
patients	10599355	1045	1053	I-Count
.	10599355	1054	1055	O

Ciprofloxacin	10602739	0	13	B-Intervention
,	10602739	14	15	O
lomefloxacin	10602739	16	28	B-Intervention
,	10602739	29	30	O
or	10602739	31	33	O
levofloxacin	10602739	34	46	B-Intervention
as	10602739	47	49	O
treatment	10602739	50	59	O
for	10602739	60	63	O
chronic	10602739	64	71	B-Participant
osteomyelitis	10602739	72	85	I-Participant
.	10602739	86	87	O

The	10602739	88	91	O
efficacy	10602739	92	100	B-Outcome
and	10602739	101	104	O
safety	10602739	105	111	B-Outcome
of	10602739	112	114	O
three	10602739	115	120	O
oral	10602739	121	125	B-Intervention
fluoroquinolones	10602739	126	142	I-Intervention
(	10602739	143	144	O
lomefloxacin	10602739	145	157	B-Intervention
,	10602739	158	159	O
levofloxacin	10602739	160	172	B-Intervention
,	10602739	173	174	O
and	10602739	175	178	O
ciprofloxacin	10602739	179	192	B-Intervention
)	10602739	193	194	O
for	10602739	195	198	O
the	10602739	199	202	O
treatment	10602739	203	212	O
of	10602739	213	215	O
chronic	10602739	216	223	B-Participant
osteomyelitis	10602739	224	237	I-Participant
were	10602739	238	242	O
analyzed	10602739	243	251	O
.	10602739	252	253	O

Twenty-seven	10602739	254	266	O
patients	10602739	267	275	O
had	10602739	276	279	O
documented	10602739	280	290	O
infections	10602739	291	301	B-Participant
with	10602739	302	306	I-Participant
quinolone-sensitive	10602739	307	326	I-Participant
organisms	10602739	327	336	I-Participant
and	10602739	337	340	O
received	10602739	341	349	O
either	10602739	350	356	O
lomefloxacin	10602739	357	369	B-Intervention
,	10602739	370	371	O
levofloxacin	10602739	372	384	B-Intervention
,	10602739	385	386	O
or	10602739	387	389	O
ciprofloxacin	10602739	390	403	B-Intervention
.	10602739	404	405	O

Levofloxacin	10602739	406	418	B-Intervention
was	10602739	419	422	O
effective	10602739	423	432	B-Observation
therapy	10602739	433	440	O
for	10602739	441	444	O
9	10602739	445	446	B-Count
of	10602739	447	449	I-Count
15	10602739	450	452	I-Count
(	10602739	453	454	I-Count
60	10602739	455	457	I-Count
%	10602739	458	459	I-Count
)	10602739	460	461	I-Count
patients	10602739	462	470	I-Count
.	10602739	471	472	O

Lomefloxacin	10602739	473	485	B-Intervention
was	10602739	486	489	O
effective	10602739	490	499	B-Observation
therapy	10602739	500	507	O
for	10602739	508	511	O
five	10602739	512	516	B-Count
of	10602739	517	519	I-Count
seven	10602739	520	525	I-Count
(	10602739	526	527	I-Count
71	10602739	528	530	I-Count
%	10602739	531	532	I-Count
)	10602739	533	534	I-Count
patients	10602739	535	543	I-Count
,	10602739	544	545	O
and	10602739	546	549	O
ciprofloxacin	10602739	550	563	B-Intervention
was	10602739	564	567	O
effective	10602739	568	577	B-Observation
therapy	10602739	578	585	O
for	10602739	586	589	O
two	10602739	590	593	B-Count
of	10602739	594	596	I-Count
five	10602739	597	601	I-Count
patients	10602739	602	610	I-Count
(	10602739	611	612	I-Count
40	10602739	613	615	I-Count
%	10602739	616	617	I-Count
)	10602739	618	619	I-Count
.	10602739	620	621	O

Average	10602739	622	629	O
follow-up	10602739	630	639	O
was	10602739	640	643	O
11.8	10602739	644	648	O
months	10602739	649	655	O
for	10602739	656	659	O
patients	10602739	660	668	O
who	10602739	669	672	O
completed	10602739	673	682	O
the	10602739	683	686	O
course	10602739	687	693	O
of	10602739	694	696	O
therapy	10602739	697	704	O
,	10602739	705	706	O
and	10602739	707	710	O
the	10602739	711	714	O
average	10602739	715	722	B-Outcome
duration	10602739	723	731	I-Outcome
of	10602739	732	734	I-Outcome
therapy	10602739	735	742	I-Outcome
was	10602739	743	746	O
60.6	10602739	747	751	B-Observation
days	10602739	752	756	I-Observation
.	10602739	757	758	O

Gram-positive	10602739	759	772	B-Outcome
bacteria	10602739	773	781	I-Outcome
were	10602739	782	786	O
isolated	10602739	787	795	O
from	10602739	796	800	O
18	10602739	801	803	B-Count
patients	10602739	804	812	I-Count
,	10602739	813	814	O
and	10602739	815	818	O
11	10602739	819	821	B-Count
patients	10602739	822	830	I-Count
were	10602739	831	835	O
cured	10602739	836	841	B-Outcome
.	10602739	842	843	O

Oral	10602739	844	848	B-Intervention
fluoroquinolones	10602739	849	865	I-Intervention
can	10602739	866	869	O
be	10602739	870	872	O
safe	10602739	873	877	B-Observation
,	10602739	878	879	O
effective	10602739	880	889	B-Observation
therapy	10602739	890	897	O
if	10602739	898	900	O
they	10602739	901	905	O
are	10602739	906	909	O
given	10602739	910	915	O
for	10602739	916	919	O
a	10602739	920	921	O
prolonged	10602739	922	931	O
course	10602739	932	938	O
as	10602739	939	941	O
treatment	10602739	942	951	O
for	10602739	952	955	O
infections	10602739	956	966	B-Participant
caused	10602739	967	973	I-Participant
by	10602739	974	976	I-Participant
susceptible	10602739	977	988	I-Participant
gram-positive	10602739	989	1002	I-Participant
as	10602739	1003	1005	I-Participant
well	10602739	1006	1010	I-Participant
as	10602739	1011	1013	I-Participant
gram-negative	10602739	1014	1027	I-Participant
organisms	10602739	1028	1037	I-Participant
and	10602739	1038	1041	O
in	10602739	1042	1044	O
combination	10602739	1045	1056	O
with	10602739	1057	1061	O
adequate	10602739	1062	1070	B-Participant
surgical	10602739	1071	1079	I-Participant
debridement	10602739	1080	1091	I-Participant
.	10602739	1092	1093	O

Focal	10632537	0	5	B-Outcome
therapeutic	10632537	6	17	I-Outcome
efficacy	10632537	18	26	I-Outcome
of	10632537	27	29	O
transcatheter	10632537	30	43	B-Intervention
arterial	10632537	44	52	I-Intervention
infusion	10632537	53	61	I-Intervention
of	10632537	62	64	I-Intervention
styrene	10632537	65	72	I-Intervention
maleic	10632537	73	79	I-Intervention
acid	10632537	80	84	I-Intervention
neocarzinostatin	10632537	85	101	I-Intervention
for	10632537	102	105	O
hepatocellular	10632537	106	120	B-Participant
carcinoma	10632537	121	130	I-Participant
.	10632537	131	132	O

We	10632537	133	135	O
evaluated	10632537	136	145	O
the	10632537	146	149	O
focal	10632537	150	155	B-Outcome
therapeutic	10632537	156	167	I-Outcome
effect	10632537	168	174	I-Outcome
of	10632537	175	177	O
oily	10632537	178	182	B-Intervention
carcinostatic	10632537	183	196	I-Intervention
agents	10632537	197	203	I-Intervention
administered	10632537	204	216	I-Intervention
by	10632537	217	219	I-Intervention
transcatheter	10632537	220	233	I-Intervention
arterial	10632537	234	242	I-Intervention
infusion	10632537	243	251	I-Intervention
(	10632537	252	253	I-Intervention
TAI	10632537	254	257	I-Intervention
)	10632537	258	259	I-Intervention
as	10632537	260	262	O
the	10632537	263	266	O
initial	10632537	267	274	O
therapy	10632537	275	282	O
in	10632537	283	285	O
patients	10632537	286	294	O
with	10632537	295	299	O
hepatocellular	10632537	300	314	B-Participant
carcinoma	10632537	315	324	I-Participant
in	10632537	325	327	O
a	10632537	328	329	O
randomized	10632537	330	340	O
controlled	10632537	341	351	O
clinical	10632537	352	360	O
trial	10632537	361	366	O
.	10632537	367	368	O

Group	10632537	369	374	O
A	10632537	375	376	O
(	10632537	377	378	O
19	10632537	379	381	O
patients	10632537	382	390	O
)	10632537	391	392	O
received	10632537	393	401	O
4	10632537	402	403	B-Intervention
mg	10632537	404	406	I-Intervention
of	10632537	407	409	I-Intervention
styrene	10632537	410	417	I-Intervention
maleic	10632537	418	424	I-Intervention
acid	10632537	425	429	I-Intervention
neocarzinostatin	10632537	430	446	I-Intervention
in	10632537	447	449	I-Intervention
4	10632537	450	451	I-Intervention
ml	10632537	452	454	I-Intervention
of	10632537	455	457	I-Intervention
Lipiodol	10632537	458	466	I-Intervention
,	10632537	467	468	O
and	10632537	469	472	O
group	10632537	473	478	O
B	10632537	479	480	O
(	10632537	481	482	O
18	10632537	483	485	O
patients	10632537	486	494	O
)	10632537	495	496	O
received	10632537	497	505	O
100	10632537	506	509	B-Intervention
mg	10632537	510	512	I-Intervention
of	10632537	513	515	I-Intervention
epirubicin	10632537	516	526	I-Intervention
in	10632537	527	529	I-Intervention
4	10632537	530	531	I-Intervention
ml	10632537	532	534	I-Intervention
of	10632537	535	537	I-Intervention
Lipiodol	10632537	538	546	I-Intervention
via	10632537	547	550	O
the	10632537	551	554	O
tumor	10632537	555	560	O
feeding	10632537	561	568	O
arteries	10632537	569	577	O
as	10632537	578	580	O
peripherally	10632537	581	593	O
as	10632537	594	596	O
possible	10632537	597	605	O
.	10632537	606	607	O

The	10632537	608	611	O
grade	10632537	612	617	B-Outcome
of	10632537	618	620	I-Outcome
Lipiodol	10632537	621	629	I-Outcome
accumulation	10632537	630	642	I-Outcome
and	10632537	643	646	O
the	10632537	647	650	O
tumor	10632537	651	656	B-Outcome
regression	10632537	657	667	I-Outcome
rate	10632537	668	672	I-Outcome
were	10632537	673	677	O
determined	10632537	678	688	O
2	10632537	689	690	O
weeks	10632537	691	696	O
after	10632537	697	702	O
TAI	10632537	703	706	B-Intervention
by	10632537	707	709	O
computerized	10632537	710	722	O
tomography	10632537	723	733	O
.	10632537	734	735	O

Adverse	10632537	736	743	B-Outcome
effects	10632537	744	751	I-Outcome
within	10632537	752	758	O
2	10632537	759	760	O
weeks	10632537	761	766	O
after	10632537	767	772	O
TAI	10632537	773	776	B-Intervention
were	10632537	777	781	O
evaluated	10632537	782	791	O
by	10632537	792	794	O
subjective	10632537	795	805	B-Outcome
signs	10632537	806	811	I-Outcome
and	10632537	812	815	I-Outcome
symptoms	10632537	816	824	I-Outcome
such	10632537	825	829	O
as	10632537	830	832	O
fever	10632537	833	838	B-Outcome
(	10632537	839	840	O
maximum	10632537	841	848	O
body	10632537	849	853	O
temperature	10632537	854	865	O
)	10632537	866	867	O
and	10632537	868	871	O
the	10632537	872	875	O
frequency	10632537	876	885	B-Outcome
of	10632537	886	888	I-Outcome
shaking	10632537	889	896	I-Outcome
chills	10632537	897	903	I-Outcome
and	10632537	904	907	O
abdominal	10632537	908	917	B-Outcome
pain	10632537	918	922	I-Outcome
,	10632537	923	924	O
and	10632537	925	928	O
by	10632537	929	931	O
biochemical	10632537	932	943	B-Outcome
parameters	10632537	944	954	I-Outcome
such	10632537	955	959	O
as	10632537	960	962	O
albumin	10632537	963	970	B-Outcome
,	10632537	971	972	O
prothrombin	10632537	973	984	B-Outcome
time	10632537	985	989	I-Outcome
,	10632537	990	991	O
and	10632537	992	995	O
aspartate	10632537	996	1005	B-Outcome
and	10632537	1006	1009	I-Outcome
alanine	10632537	1010	1017	I-Outcome
aminotransferases	10632537	1018	1035	I-Outcome
.	10632537	1036	1037	O

Lipiodol	10632537	1038	1046	B-Outcome
accumulation	10632537	1047	1059	I-Outcome
in	10632537	1060	1062	I-Outcome
the	10632537	1063	1066	I-Outcome
tumor	10632537	1067	1072	I-Outcome
was	10632537	1073	1076	O
significantly	10632537	1077	1090	B-Observation
greater	10632537	1091	1098	I-Observation
in	10632537	1099	1101	O
group	10632537	1102	1107	B-Intervention
A	10632537	1108	1109	I-Intervention
(	10632537	1110	1111	O
12/19	10632537	1112	1117	B-Count
;	10632537	1118	1119	I-Count
63.2	10632537	1120	1124	I-Count
%	10632537	1125	1126	I-Count
showing	10632537	1127	1134	O
grade	10632537	1135	1140	B-Outcome
IV	10632537	1141	1143	I-Outcome
Lipiodol	10632537	1144	1152	I-Outcome
accumulation	10632537	1153	1165	I-Outcome
)	10632537	1166	1167	O
than	10632537	1168	1172	O
in	10632537	1173	1175	O
group	10632537	1176	1181	B-Intervention
B	10632537	1182	1183	I-Intervention
(	10632537	1184	1185	O
3/18	10632537	1186	1190	B-Observation
;	10632537	1191	1192	I-Observation
16.7	10632537	1193	1197	I-Observation
%	10632537	1198	1199	I-Observation
showing	10632537	1200	1207	O
grade	10632537	1208	1213	B-Outcome
IV	10632537	1214	1216	I-Outcome
)	10632537	1217	1218	O
(	10632537	1219	1220	O
P	10632537	1221	1222	O
<	10632537	1223	1224	O
0.05	10632537	1225	1229	O
)	10632537	1230	1231	O
.	10632537	1232	1233	O

The	10632537	1234	1237	O
tumor	10632537	1238	1243	B-Outcome
regression	10632537	1244	1254	I-Outcome
rate	10632537	1255	1259	I-Outcome
was	10632537	1260	1263	O
also	10632537	1264	1268	O
significantly	10632537	1269	1282	B-Observation
greater	10632537	1283	1290	I-Observation
in	10632537	1291	1293	O
group	10632537	1294	1299	B-Intervention
A	10632537	1300	1301	I-Intervention
(	10632537	1302	1303	O
8/17	10632537	1304	1308	B-Count
;	10632537	1309	1310	I-Count
47.1	10632537	1311	1315	I-Count
%	10632537	1316	1317	I-Count
showing	10632537	1318	1325	O
more	10632537	1326	1330	B-Outcome
than	10632537	1331	1335	I-Outcome
25	10632537	1336	1338	I-Outcome
%	10632537	1339	1340	I-Outcome
tumor	10632537	1341	1346	I-Outcome
regression	10632537	1347	1357	I-Outcome
)	10632537	1358	1359	O
than	10632537	1360	1364	O
in	10632537	1365	1367	O
group	10632537	1368	1373	B-Intervention
B	10632537	1374	1375	I-Intervention
(	10632537	1376	1377	O
1/13	10632537	1378	1382	B-Count
;	10632537	1383	1384	I-Count
7.7	10632537	1385	1388	I-Count
%	10632537	1389	1390	I-Count
showing	10632537	1391	1398	O
more	10632537	1399	1403	B-Outcome
than	10632537	1404	1408	I-Outcome
25	10632537	1409	1411	I-Outcome
%	10632537	1412	1413	I-Outcome
tumor	10632537	1414	1419	I-Outcome
regression	10632537	1420	1430	I-Outcome
)	10632537	1431	1432	O
(	10632537	1433	1434	O
P	10632537	1435	1436	O
<	10632537	1437	1438	O
0.05	10632537	1439	1443	O
)	10632537	1444	1445	O
.	10632537	1446	1447	O

Although	10632537	1448	1456	O
clinically	10632537	1457	1467	O
significant	10632537	1468	1479	O
elevations	10632537	1480	1490	B-Outcome
of	10632537	1491	1493	I-Outcome
aminotransferases	10632537	1494	1511	I-Outcome
and	10632537	1512	1515	O
reductions	10632537	1516	1526	B-Outcome
of	10632537	1527	1529	I-Outcome
cholinesterase	10632537	1530	1544	I-Outcome
,	10632537	1545	1546	I-Outcome
and	10632537	1547	1550	I-Outcome
shaking	10632537	1551	1558	I-Outcome
chills	10632537	1559	1565	I-Outcome
were	10632537	1566	1570	O
observed	10632537	1571	1579	O
more	10632537	1580	1584	B-Count
often	10632537	1585	1590	I-Count
in	10632537	1591	1593	O
group	10632537	1594	1599	B-Intervention
A	10632537	1600	1601	I-Intervention
than	10632537	1602	1606	O
in	10632537	1607	1609	O
group	10632537	1610	1615	B-Intervention
B	10632537	1616	1617	I-Intervention
(	10632537	1618	1619	O
P	10632537	1620	1621	O
<	10632537	1622	1623	O
0.0001	10632537	1624	1630	O
)	10632537	1631	1632	O
,	10632537	1633	1634	O
these	10632537	1635	1640	O
factors	10632537	1641	1648	O
had	10632537	1649	1652	O
little	10632537	1653	1659	O
influence	10632537	1660	1669	O
on	10632537	1670	1672	O
the	10632537	1673	1676	O
clinical	10632537	1677	1685	O
outcome	10632537	1686	1693	O
.	10632537	1694	1695	O

Our	10632537	1696	1699	O
results	10632537	1700	1707	O
suggest	10632537	1708	1715	O
that	10632537	1716	1720	O
styrene	10632537	1721	1728	B-Intervention
maleic	10632537	1729	1735	I-Intervention
acid	10632537	1736	1740	I-Intervention
neocarzinostatin	10632537	1741	1757	I-Intervention
in	10632537	1758	1760	I-Intervention
Lipiodol	10632537	1761	1769	I-Intervention
exerts	10632537	1770	1776	O
a	10632537	1777	1778	O
more	10632537	1779	1783	B-Observation
favorable	10632537	1784	1793	I-Observation
focal	10632537	1794	1799	B-Outcome
therapeutic	10632537	1800	1811	I-Outcome
effect	10632537	1812	1818	I-Outcome
than	10632537	1819	1823	O
does	10632537	1824	1828	O
epirubicin	10632537	1829	1839	B-Intervention
in	10632537	1840	1842	I-Intervention
Lipiodol	10632537	1843	1851	I-Intervention
in	10632537	1852	1854	O
the	10632537	1855	1858	O
initial	10632537	1859	1866	O
treatment	10632537	1867	1876	O
of	10632537	1877	1879	O
hepatocellular	10632537	1880	1894	B-Participant
carcinoma	10632537	1895	1904	I-Participant
.	10632537	1905	1906	O

Randomised	10634835	0	10	O
controlled	10634835	11	21	O
trial	10634835	22	27	O
of	10634835	28	30	O
patient	10634835	31	38	B-Intervention
triggered	10634835	39	48	I-Intervention
and	10634835	49	52	I-Intervention
conventional	10634835	53	65	I-Intervention
fast	10634835	66	70	I-Intervention
rate	10634835	71	75	I-Intervention
ventilation	10634835	76	87	I-Intervention
in	10634835	88	90	O
neonatal	10634835	91	99	B-Participant
respiratory	10634835	100	111	I-Participant
distress	10634835	112	120	I-Participant
syndrome	10634835	121	129	I-Participant
.	10634835	130	131	O

AIM	10634835	132	135	O
To	10634835	136	138	O
compare	10634835	139	146	O
patient	10634835	147	154	B-Intervention
triggered	10634835	155	164	I-Intervention
,	10634835	165	166	O
with	10634835	167	171	O
conventional	10634835	172	184	B-Intervention
fast	10634835	185	189	I-Intervention
rate	10634835	190	194	I-Intervention
,	10634835	195	196	I-Intervention
ventilation	10634835	197	208	I-Intervention
in	10634835	209	211	O
a	10634835	212	213	O
randomised	10634835	214	224	O
controlled	10634835	225	235	O
trial	10634835	236	241	O
using	10634835	242	247	O
the	10634835	248	251	O
incidence	10634835	252	261	B-Outcome
of	10634835	262	264	I-Outcome
chronic	10634835	265	272	I-Outcome
lung	10634835	273	277	I-Outcome
disease	10634835	278	285	I-Outcome
as	10634835	286	288	O
the	10634835	289	292	O
primary	10634835	293	300	O
outcome	10634835	301	308	O
measure	10634835	309	316	O
.	10634835	317	318	O

METHODS	10634835	319	326	O
Three	10634835	327	332	O
hundred	10634835	333	340	O
and	10634835	341	344	O
eighty	10634835	345	351	O
six	10634835	352	355	O
preterm	10634835	356	363	B-Participant
infants	10634835	364	371	I-Participant
with	10634835	372	376	O
birthweights	10634835	377	389	B-Participant
from	10634835	390	394	O
1000	10634835	395	399	O
to	10634835	400	402	O
2000	10634835	403	407	O
g	10634835	408	409	O
,	10634835	410	411	O
and	10634835	412	415	O
requiring	10634835	416	425	O
ventilation	10634835	426	437	B-Participant
for	10634835	438	441	O
respiratory	10634835	442	453	B-Participant
distress	10634835	454	462	I-Participant
syndrome	10634835	463	471	I-Participant
within	10634835	472	478	O
24	10634835	479	481	O
hours	10634835	482	487	O
of	10634835	488	490	O
birth	10634835	491	496	O
,	10634835	497	498	O
were	10634835	499	503	O
randomised	10634835	504	514	O
to	10634835	515	517	O
receive	10634835	518	525	O
either	10634835	526	532	O
conventional	10634835	533	545	B-Intervention
or	10634835	546	548	O
trigger	10634835	549	556	B-Intervention
ventilation	10634835	557	568	I-Intervention
with	10634835	569	573	O
the	10634835	574	577	O
SLE	10634835	578	581	O
2000	10634835	582	586	O
ventilator	10634835	587	597	O
.	10634835	598	599	O

RESULTS	10634835	600	607	O
There	10634835	608	613	O
were	10634835	614	618	O
no	10634835	619	621	O
significant	10634835	622	633	B-Observation
differences	10634835	634	645	I-Observation
in	10634835	646	648	O
the	10634835	649	652	O
incidence	10634835	653	662	B-Outcome
of	10634835	663	665	I-Outcome
chronic	10634835	666	673	I-Outcome
lung	10634835	674	678	I-Outcome
disease	10634835	679	686	I-Outcome
(	10634835	687	688	O
28	10634835	689	691	O
day	10634835	692	695	O
and	10634835	696	699	O
36	10634835	700	702	O
week	10634835	703	707	O
definitions	10634835	708	719	O
)	10634835	720	721	O
,	10634835	722	723	O
death	10634835	724	729	B-Outcome
,	10634835	730	731	O
pneumothorax	10634835	732	744	B-Outcome
,	10634835	745	746	O
intraventricular	10634835	747	763	B-Outcome
haemorrhage	10634835	764	775	I-Outcome
,	10634835	776	777	O
number	10634835	778	784	B-Outcome
of	10634835	785	787	I-Outcome
ventilator	10634835	788	798	I-Outcome
days	10634835	799	803	I-Outcome
,	10634835	804	805	O
or	10634835	806	808	O
length	10634835	809	815	B-Outcome
of	10634835	816	818	I-Outcome
oxygen	10634835	819	825	I-Outcome
dependency	10634835	826	836	I-Outcome
between	10634835	837	844	B-Intervention
groups	10634835	845	851	I-Intervention
.	10634835	852	853	O

CONCLUSIONS	10634835	854	865	O
Patient	10634835	866	873	B-Intervention
triggered	10634835	874	883	I-Intervention
ventilation	10634835	884	895	I-Intervention
in	10634835	896	898	O
preterm	10634835	899	906	B-Participant
infants	10634835	907	914	I-Participant
with	10634835	915	919	O
respiratory	10634835	920	931	B-Participant
distress	10634835	932	940	I-Participant
syndrome	10634835	941	949	I-Participant
is	10634835	950	952	O
feasible	10634835	953	961	B-Observation
.	10634835	962	963	O

No	10634835	964	966	O
significant	10634835	967	978	B-Observation
differences	10634835	979	990	I-Observation
,	10634835	991	992	O
when	10634835	993	997	O
compared	10634835	998	1006	O
with	10634835	1007	1011	O
conventional	10634835	1012	1024	B-Intervention
fast	10634835	1025	1029	I-Intervention
rate	10634835	1030	1034	I-Intervention
ventilation	10634835	1035	1046	I-Intervention
in	10634835	1047	1049	O
important	10634835	1050	1059	B-Outcome
medium	10634835	1060	1066	I-Outcome
and	10634835	1067	1070	I-Outcome
longer	10634835	1071	1077	I-Outcome
term	10634835	1078	1082	I-Outcome
outcome	10634835	1083	1090	I-Outcome
measures	10634835	1091	1099	I-Outcome
,	10634835	1100	1101	O
were	10634835	1102	1106	O
evident	10634835	1107	1114	O
.	10634835	1115	1116	O

Treatment	10636373	0	9	O
of	10636373	10	12	O
hypertension	10636373	13	25	B-Participant
with	10636373	26	30	O
ascorbic	10636373	31	39	B-Intervention
acid	10636373	40	44	I-Intervention
.	10636373	45	46	O

In	10636373	47	49	O
a	10636373	50	51	O
randomised	10636373	52	62	O
,	10636373	63	64	O
double-blind	10636373	65	77	O
,	10636373	78	79	O
placebo-controlled	10636373	80	98	O
study	10636373	99	104	O
we	10636373	105	107	O
showed	10636373	108	114	O
that	10636373	115	119	O
treatment	10636373	120	129	O
of	10636373	130	132	O
hypertensive	10636373	133	145	B-Participant
patients	10636373	146	154	O
with	10636373	155	159	O
ascorbic	10636373	160	168	B-Intervention
acid	10636373	169	173	I-Intervention
lowers	10636373	174	180	B-Observation
blood	10636373	181	186	B-Outcome
pressure	10636373	187	195	I-Outcome
.	10636373	196	197	O

Comparison	10637238	0	10	O
of	10637238	11	13	O
chemotherapy	10637238	14	26	B-Intervention
with	10637238	27	31	O
chemohormonal	10637238	32	45	B-Intervention
therapy	10637238	46	53	I-Intervention
as	10637238	54	56	O
first-line	10637238	57	67	O
therapy	10637238	68	75	O
for	10637238	76	79	O
metastatic	10637238	80	90	B-Participant
,	10637238	91	92	I-Participant
hormone-sensitive	10637238	93	110	I-Participant
breast	10637238	111	117	I-Participant
cancer	10637238	118	124	I-Participant
:	10637238	125	126	O
An	10637238	127	129	O
Eastern	10637238	130	137	O
Cooperative	10637238	138	149	O
Oncology	10637238	150	158	O
Group	10637238	159	164	O
study	10637238	165	170	O
.	10637238	171	172	O

PURPOSE	10637238	173	180	O
Although	10637238	181	189	O
hormonal	10637238	190	198	O
therapy	10637238	199	206	O
represents	10637238	207	217	O
standard	10637238	218	226	O
therapy	10637238	227	234	O
for	10637238	235	238	O
metastatic	10637238	239	249	O
hormone-sensitive	10637238	250	267	O
disease	10637238	268	275	O
,	10637238	276	277	O
many	10637238	278	282	O
patients	10637238	283	291	O
receive	10637238	292	299	O
initial	10637238	300	307	O
chemotherapy	10637238	308	320	O
because	10637238	321	328	O
of	10637238	329	331	O
the	10637238	332	335	O
location	10637238	336	344	O
,	10637238	345	346	O
bulk	10637238	347	351	O
,	10637238	352	353	O
or	10637238	354	356	O
aggressiveness	10637238	357	371	O
of	10637238	372	374	O
their	10637238	375	380	O
disease	10637238	381	388	O
.	10637238	389	390	O

It	10637238	391	393	O
is	10637238	394	396	O
uncertain	10637238	397	406	O
whether	10637238	407	414	O
simultaneous	10637238	415	427	B-Intervention
hormonal	10637238	428	436	I-Intervention
therapy	10637238	437	444	I-Intervention
provides	10637238	445	453	O
additional	10637238	454	464	B-Observation
benefit	10637238	465	472	B-Outcome
compared	10637238	473	481	O
with	10637238	482	486	O
chemotherapy	10637238	487	499	B-Intervention
alone	10637238	500	505	I-Intervention
.	10637238	506	507	O

Eastern	10637238	508	515	O
Cooperative	10637238	516	527	O
Oncology	10637238	528	536	O
Group	10637238	537	542	O
trial	10637238	543	548	O
E3186	10637238	549	554	O
was	10637238	555	558	O
initiated	10637238	559	568	O
to	10637238	569	571	O
explore	10637238	572	579	O
this	10637238	580	584	O
question	10637238	585	593	O
.	10637238	594	595	O

PATIENTS	10637238	596	604	O
AND	10637238	605	608	O
METHODS	10637238	609	616	O
Between	10637238	617	624	O
January	10637238	625	632	O
1988	10637238	633	637	O
and	10637238	638	641	O
December	10637238	642	650	O
1992	10637238	651	655	O
,	10637238	656	657	O
231	10637238	658	661	O
patients	10637238	662	670	O
with	10637238	671	675	O
estrogen	10637238	676	684	B-Participant
receptor	10637238	685	693	I-Participant
(	10637238	694	695	I-Participant
ER	10637238	696	698	I-Participant
)	10637238	699	700	I-Participant
-positive	10637238	701	710	I-Participant
or	10637238	711	713	I-Participant
ER-unknown	10637238	714	724	I-Participant
metastatic	10637238	725	735	I-Participant
breast	10637238	736	742	I-Participant
cancer	10637238	743	749	I-Participant
were	10637238	750	754	O
randomized	10637238	755	765	O
to	10637238	766	768	O
receive	10637238	769	776	O
either	10637238	777	783	O
chemotherapy	10637238	784	796	B-Intervention
(	10637238	797	798	O
cyclophosphamide	10637238	799	815	O
,	10637238	816	817	O
doxorubicin	10637238	818	829	O
,	10637238	830	831	O
and	10637238	832	835	O
fluorouracil	10637238	836	848	O
?	10637238	849	850	O

CAF	10637238	850	853	O
)	10637238	854	855	O
or	10637238	856	858	O
chemohormonal	10637238	859	872	B-Intervention
therapy	10637238	873	880	I-Intervention
(	10637238	881	882	O
CAF	10637238	883	886	O
plus	10637238	887	891	O
tamoxifen	10637238	892	901	O
and	10637238	902	905	O
Halotestin	10637238	906	916	O
?	10637238	917	918	O
fluoxymesterone	10637238	918	933	O
;	10637238	934	935	O
Pharmacia-Upjohn	10637238	936	952	O
,	10637238	953	954	O
Kalamazoo	10637238	955	964	O
,	10637238	965	966	O
MI	10637238	967	969	O
?	10637238	970	971	O
CAFTH	10637238	971	976	O
)	10637238	977	978	O
as	10637238	979	981	O
front-line	10637238	982	992	O
therapy	10637238	993	1000	O
for	10637238	1001	1004	O
metastatic	10637238	1005	1015	B-Participant
breast	10637238	1016	1022	I-Participant
cancer	10637238	1023	1029	I-Participant
.	10637238	1030	1031	O

Patients	10637238	1032	1040	O
who	10637238	1041	1044	O
experienced	10637238	1045	1056	O
a	10637238	1057	1058	O
complete	10637238	1059	1067	O
response	10637238	1068	1076	O
to	10637238	1077	1079	O
induction	10637238	1080	1089	O
therapy	10637238	1090	1097	O
either	10637238	1098	1104	O
received	10637238	1105	1113	O
or	10637238	1114	1116	O
did	10637238	1117	1120	O
not	10637238	1121	1124	O
receive	10637238	1125	1132	O
maintenance	10637238	1133	1144	O
cyclophosphamide	10637238	1145	1161	O
,	10637238	1162	1163	O
methotrexate	10637238	1164	1176	O
,	10637238	1177	1178	O
fluorouracil	10637238	1179	1191	O
,	10637238	1192	1193	O
prednisone	10637238	1194	1204	O
,	10637238	1205	1206	O
and	10637238	1207	1210	O
TH	10637238	1211	1213	O
as	10637238	1214	1216	O
a	10637238	1217	1218	O
secondary	10637238	1219	1228	O
randomization	10637238	1229	1242	O
.	10637238	1243	1244	O

RESULTS	10637238	1245	1252	O
The	10637238	1253	1256	O
response	10637238	1257	1265	B-Outcome
rates	10637238	1266	1271	I-Outcome
(	10637238	1272	1273	O
complete	10637238	1274	1282	B-Outcome
response	10637238	1283	1291	I-Outcome
and	10637238	1292	1295	I-Outcome
partial	10637238	1296	1303	I-Outcome
response	10637238	1304	1312	I-Outcome
)	10637238	1313	1314	O
of	10637238	1315	1317	O
patients	10637238	1318	1326	O
who	10637238	1327	1330	O
received	10637238	1331	1339	O
CAF	10637238	1340	1343	B-Intervention
and	10637238	1344	1347	O
CAFTH	10637238	1348	1353	B-Intervention
were	10637238	1354	1358	O
similar	10637238	1359	1366	B-Observation
(	10637238	1367	1368	O
69.2	10637238	1369	1373	B-Observation
%	10637238	1374	1375	I-Observation
v	10637238	1376	1377	O
68.9	10637238	1378	1382	B-Observation
%	10637238	1383	1384	I-Observation
,	10637238	1385	1386	O
respectively	10637238	1387	1399	O
;	10637238	1400	1401	O
P	10637238	1402	1403	O
=	10637238	1404	1405	O
.99	10637238	1405	1408	O
)	10637238	1409	1410	O
.	10637238	1411	1412	O

Time	10637238	1413	1417	B-Outcome
to	10637238	1418	1420	I-Outcome
treatment	10637238	1421	1430	I-Outcome
failure	10637238	1431	1438	I-Outcome
(	10637238	1439	1440	I-Outcome
TTF	10637238	1441	1444	I-Outcome
)	10637238	1445	1446	I-Outcome
was	10637238	1447	1450	O
slightly	10637238	1451	1459	B-Observation
longer	10637238	1460	1466	I-Observation
for	10637238	1467	1470	O
patients	10637238	1471	1479	O
who	10637238	1480	1483	O
received	10637238	1484	1492	O
chemohormonal	10637238	1493	1506	B-Intervention
therapy	10637238	1507	1514	I-Intervention
compared	10637238	1515	1523	O
with	10637238	1524	1528	O
chemotherapy	10637238	1529	1541	B-Intervention
alone	10637238	1542	1547	I-Intervention
patients	10637238	1548	1556	O
(	10637238	1557	1558	O
13.4	10637238	1559	1563	B-Observation
months	10637238	1564	1570	I-Observation
v	10637238	1571	1572	O
10.3	10637238	1573	1577	B-Observation
months	10637238	1578	1584	I-Observation
,	10637238	1585	1586	O
respectively	10637238	1587	1599	O
;	10637238	1600	1601	O
P	10637238	1602	1603	O
=	10637238	1604	1605	O
.087	10637238	1605	1609	O
)	10637238	1610	1611	O
,	10637238	1612	1613	O
and	10637238	1614	1617	O
TTF	10637238	1618	1621	B-Outcome
was	10637238	1622	1625	O
significantly	10637238	1626	1639	B-Observation
longer	10637238	1640	1646	I-Observation
in	10637238	1647	1649	O
ER-positive	10637238	1650	1661	B-Participant
compared	10637238	1662	1670	O
with	10637238	1671	1675	O
ER-negative	10637238	1676	1687	B-Participant
patients	10637238	1688	1696	I-Participant
(	10637238	1697	1698	O
17.4	10637238	1699	1703	B-Observation
months	10637238	1704	1710	I-Observation
v	10637238	1711	1712	O
10.3	10637238	1713	1717	B-Observation
months	10637238	1718	1724	I-Observation
,	10637238	1725	1726	O
respectively	10637238	1727	1739	O
;	10637238	1740	1741	O
P	10637238	1742	1743	O
=	10637238	1744	1745	O
.048	10637238	1745	1749	O
)	10637238	1750	1751	O
.	10637238	1752	1753	O

However	10637238	1754	1761	O
,	10637238	1762	1763	O
ER	10637238	1764	1766	B-Participant
status	10637238	1767	1773	I-Participant
had	10637238	1774	1777	O
no	10637238	1778	1780	O
effect	10637238	1781	1787	O
on	10637238	1788	1790	O
overall	10637238	1791	1798	B-Outcome
survival	10637238	1799	1807	I-Outcome
(	10637238	1808	1809	O
30.0	10637238	1810	1814	B-Observation
months	10637238	1815	1821	I-Observation
for	10637238	1822	1825	O
CAF	10637238	1826	1829	B-Intervention
v	10637238	1830	1831	O
29.3	10637238	1832	1836	B-Observation
months	10637238	1837	1843	I-Observation
for	10637238	1844	1847	O
CAFTH	10637238	1848	1853	B-Intervention
)	10637238	1854	1855	O
.	10637238	1856	1857	O

CONCLUSION	10637238	1858	1868	O
In	10637238	1869	1871	O
patients	10637238	1872	1880	O
with	10637238	1881	1885	O
potentially	10637238	1886	1897	O
hormone-sensitive	10637238	1898	1915	B-Participant
metastatic	10637238	1916	1926	I-Participant
breast	10637238	1927	1933	I-Participant
cancer	10637238	1934	1940	I-Participant
,	10637238	1941	1942	O
chemohormonal	10637238	1943	1956	B-Intervention
therapy	10637238	1957	1964	I-Intervention
prolongs	10637238	1965	1973	B-Observation
TTF	10637238	1974	1977	B-Outcome
for	10637238	1978	1981	O
ER-positive	10637238	1982	1993	B-Participant
patients	10637238	1994	2002	O
without	10637238	2003	2010	O
improving	10637238	2011	2020	B-Observation
overall	10637238	2021	2028	B-Outcome
survival	10637238	2029	2037	I-Outcome
.	10637238	2038	2039	O

The	10643677	0	3	O
effect	10643677	4	10	O
of	10643677	11	13	O
body	10643677	14	18	B-Intervention
weight	10643677	19	25	I-Intervention
changes	10643677	26	33	I-Intervention
and	10643677	34	37	O
endurance	10643677	38	47	B-Intervention
training	10643677	48	56	I-Intervention
on	10643677	57	59	O
24h	10643677	60	63	B-Outcome
substrate	10643677	64	73	I-Outcome
oxidation	10643677	74	83	I-Outcome
.	10643677	84	85	O

OBJECTIVE	10643677	86	95	O
To	10643677	96	98	O
investigate	10643677	99	110	O
the	10643677	111	114	O
effect	10643677	115	121	O
of	10643677	122	124	O
exercise	10643677	125	133	B-Intervention
training	10643677	134	142	I-Intervention
and	10643677	143	146	O
dietary	10643677	147	154	B-Intervention
macronutrient	10643677	155	168	I-Intervention
composition	10643677	169	180	I-Intervention
on	10643677	181	183	O
24	10643677	184	186	B-Outcome
h	10643677	187	188	I-Outcome
substrate	10643677	189	198	I-Outcome
oxidation	10643677	199	208	I-Outcome
in	10643677	209	211	O
male	10643677	212	216	B-Participant
,	10643677	217	218	O
obese	10643677	219	224	B-Participant
subjects	10643677	225	233	O
.	10643677	234	235	O

DESIGN	10643677	236	242	O
A	10643677	243	244	O
16	10643677	245	247	O
month	10643677	248	253	O
exercise	10643677	254	262	B-Intervention
intervention	10643677	263	275	I-Intervention
study	10643677	276	281	O
was	10643677	282	285	O
executed	10643677	286	294	O
,	10643677	295	296	O
including	10643677	297	306	O
a	10643677	307	308	O
weight	10643677	309	315	B-Intervention
loss	10643677	316	320	I-Intervention
period	10643677	321	327	I-Intervention
with	10643677	328	332	I-Intervention
a	10643677	333	334	I-Intervention
very	10643677	335	339	I-Intervention
low	10643677	340	343	I-Intervention
energy	10643677	344	350	I-Intervention
diet	10643677	351	355	I-Intervention
(	10643677	356	357	I-Intervention
VLED	10643677	358	362	I-Intervention
)	10643677	363	364	I-Intervention
for	10643677	365	368	O
2	10643677	369	370	O
months	10643677	371	377	O
at	10643677	378	380	O
the	10643677	381	384	O
start	10643677	385	390	O
of	10643677	391	393	O
the	10643677	394	397	O
study	10643677	398	403	O
.	10643677	404	405	O

SUBJECTS	10643677	406	414	O
Twelve	10643677	415	421	O
male	10643677	422	426	B-Participant
,	10643677	427	428	O
obese	10643677	429	434	B-Participant
subjects	10643677	435	443	O
(	10643677	444	445	O
age	10643677	446	449	O
36.3+/-5.1	10643677	450	460	O
y	10643677	461	462	O
;	10643677	463	464	O
body	10643677	465	469	O
weight	10643677	470	476	O
94.6+/-13.9	10643677	477	488	O
kg	10643677	489	491	O
;	10643677	492	493	O
body	10643677	494	498	O
mass	10643677	499	503	O
index	10643677	504	509	O
,	10643677	510	511	O
BMI	10643677	512	515	O
30.8+/-3.0	10643677	516	526	O
kg/m2	10643677	527	532	O
)	10643677	533	534	O
and	10643677	535	538	O
in	10643677	539	541	O
an	10643677	542	544	O
additional	10643677	545	555	O
study	10643677	556	561	O
15	10643677	562	564	O
lean	10643677	565	569	B-Participant
,	10643677	570	571	O
well-trained	10643677	572	584	B-Participant
subjects	10643677	585	593	O
(	10643677	594	595	O
age	10643677	596	599	O
36.2+/-7.2	10643677	600	610	O
y	10643677	611	612	O
;	10643677	613	614	O
body	10643677	615	619	O
weight	10643677	620	626	O
72.2+/-5.9	10643677	627	637	O
kg	10643677	638	640	O
;	10643677	641	642	O
BMI	10643677	643	646	O
22.3+/-1.7	10643677	647	657	O
kg/m2	10643677	658	663	O
)	10643677	664	665	O
participated	10643677	666	678	O
.	10643677	679	680	O

MEASUREMENTS	10643677	681	693	O
Substrate	10643677	694	703	B-Outcome
oxidation	10643677	704	713	I-Outcome
was	10643677	714	717	O
measured	10643677	718	726	O
during	10643677	727	733	O
a	10643677	734	735	O
standardized	10643677	736	748	O
36	10643677	749	751	O
h	10643677	752	753	O
stay	10643677	754	758	O
in	10643677	759	761	O
the	10643677	762	765	O
respiration	10643677	766	777	O
chamber	10643677	778	785	O
at	10643677	786	788	O
the	10643677	789	792	O
start	10643677	793	798	O
of	10643677	799	801	O
the	10643677	802	805	O
study	10643677	806	811	O
(	10643677	812	813	O
0	10643677	814	815	O
months	10643677	816	822	O
)	10643677	823	824	O
,	10643677	825	826	O
and	10643677	827	830	O
at	10643677	831	833	O
4	10643677	834	835	O
,	10643677	836	837	O
10	10643677	838	840	O
and	10643677	841	844	O
16	10643677	845	847	O
months	10643677	848	854	O
.	10643677	855	856	O

In	10643677	857	859	O
the	10643677	860	863	O
respiration	10643677	864	875	O
chamber	10643677	876	883	O
subjects	10643677	884	892	O
were	10643677	893	897	O
randomly	10643677	898	906	O
assigned	10643677	907	915	O
to	10643677	916	918	O
a	10643677	919	920	O
high-fat	10643677	921	929	B-Intervention
(	10643677	930	931	I-Intervention
Hi	10643677	932	934	I-Intervention
.	10643677	934	935	I-Intervention
F	10643677	935	936	I-Intervention
)	10643677	937	938	I-Intervention
diet	10643677	939	943	I-Intervention
(	10643677	944	945	O
60	10643677	946	948	O
%	10643677	949	950	O
of	10643677	951	953	O
energy	10643677	954	960	O
(	10643677	961	962	O
En	10643677	963	965	O
%	10643677	966	967	O
)	10643677	968	969	O
fat	10643677	970	973	O
)	10643677	974	975	O
or	10643677	976	978	O
a	10643677	979	980	O
reduced-fat	10643677	981	992	B-Intervention
(	10643677	993	994	I-Intervention
Red	10643677	995	998	I-Intervention
.	10643677	998	999	I-Intervention
F	10643677	999	1000	I-Intervention
)	10643677	1001	1002	I-Intervention
diet	10643677	1003	1007	I-Intervention
(	10643677	1008	1009	O
30	10643677	1010	1012	O
En	10643677	1013	1015	O
%	10643677	1016	1017	O
fat	10643677	1018	1021	O
)	10643677	1022	1023	O
.	10643677	1024	1025	O

The	10643677	1026	1029	O
well-trained	10643677	1030	1042	B-Participant
group	10643677	1043	1048	O
was	10643677	1049	1052	O
measured	10643677	1053	1061	O
once	10643677	1062	1066	O
in	10643677	1067	1069	O
the	10643677	1070	1073	O
respiration	10643677	1074	1085	O
chamber	10643677	1086	1093	O
for	10643677	1094	1097	O
36	10643677	1098	1100	O
h	10643677	1101	1102	O
according	10643677	1103	1112	O
to	10643677	1113	1115	O
the	10643677	1116	1119	O
same	10643677	1120	1124	O
protocol	10643677	1125	1133	O
.	10643677	1134	1135	O

RESULTS	10643677	1136	1143	O
At	10643677	1144	1146	O
any	10643677	1147	1150	O
time	10643677	1151	1155	O
point	10643677	1156	1161	O
,	10643677	1162	1163	O
independent	10643677	1164	1175	B-Intervention
of	10643677	1176	1178	I-Intervention
the	10643677	1179	1182	I-Intervention
diet	10643677	1183	1187	I-Intervention
consumed	10643677	1188	1196	O
,	10643677	1197	1198	O
the	10643677	1199	1202	O
24	10643677	1203	1205	B-Outcome
h	10643677	1206	1207	I-Outcome
carbohydrate	10643677	1208	1220	I-Outcome
(	10643677	1221	1222	I-Outcome
CHO	10643677	1223	1226	I-Outcome
)	10643677	1227	1228	I-Outcome
balances	10643677	1229	1237	I-Outcome
in	10643677	1238	1240	O
the	10643677	1241	1244	O
chamber	10643677	1245	1252	O
were	10643677	1253	1257	O
mostly	10643677	1258	1264	B-Observation
negative	10643677	1265	1273	I-Observation
(	10643677	1274	1275	O
means	10643677	1276	1281	B-Outcome
ranging	10643677	1282	1289	B-Observation
from	10643677	1290	1294	I-Observation
+	10643677	1295	1296	I-Observation
31	10643677	1296	1298	I-Observation
to	10643677	1299	1301	I-Observation
-98	10643677	1302	1305	I-Observation
g/d	10643677	1306	1309	I-Observation
)	10643677	1310	1311	O
and	10643677	1312	1315	O
the	10643677	1316	1319	O
fat	10643677	1320	1323	B-Outcome
balances	10643677	1324	1332	I-Outcome
mostly	10643677	1333	1339	B-Observation
positive	10643677	1340	1348	I-Observation
(	10643677	1349	1350	O
means	10643677	1351	1356	B-Outcome
ranging	10643677	1357	1364	B-Observation
from	10643677	1365	1369	I-Observation
-26	10643677	1370	1373	I-Observation
to	10643677	1374	1376	I-Observation
+	10643677	1377	1378	I-Observation
38	10643677	1378	1380	I-Observation
g/d	10643677	1381	1384	I-Observation
)	10643677	1385	1386	O
for	10643677	1387	1390	O
the	10643677	1391	1394	O
obese	10643677	1395	1400	B-Participant
a	10643677	1401	1402	O
well	10643677	1403	1407	O
as	10643677	1408	1410	O
for	10643677	1411	1414	O
the	10643677	1415	1418	O
lean	10643677	1419	1423	B-Participant
,	10643677	1424	1425	O
well-trained	10643677	1426	1438	B-Participant
group	10643677	1439	1444	O
.	10643677	1445	1446	O

For	10643677	1447	1450	O
both	10643677	1451	1455	B-Intervention
diets	10643677	1456	1461	I-Intervention
an	10643677	1462	1464	O
increased	10643677	1465	1474	B-Observation
shortage	10643677	1475	1483	B-Outcome
of	10643677	1484	1486	I-Outcome
70	10643677	1487	1489	I-Outcome
g	10643677	1490	1491	I-Outcome
of	10643677	1492	1494	I-Outcome
CHO	10643677	1495	1498	I-Outcome
was	10643677	1499	1502	O
found	10643677	1503	1508	O
at	10643677	1509	1511	O
16	10643677	1512	1514	O
months	10643677	1515	1521	O
compared	10643677	1522	1530	O
with	10643677	1531	1535	O
4	10643677	1536	1537	O
months	10643677	1538	1544	O
,	10643677	1545	1546	O
and	10643677	1547	1550	O
an	10643677	1551	1553	O
increase	10643677	1554	1562	B-Observation
in	10643677	1563	1565	O
fat	10643677	1566	1569	B-Outcome
balance	10643677	1570	1577	I-Outcome
of	10643677	1578	1580	I-Outcome
33	10643677	1581	1583	I-Outcome
g	10643677	1584	1585	I-Outcome
during	10643677	1586	1592	O
the	10643677	1593	1596	O
same	10643677	1597	1601	O
time	10643677	1602	1606	O
period	10643677	1607	1613	O
in	10643677	1614	1616	O
the	10643677	1617	1620	O
obese	10643677	1621	1626	B-Participant
subjects	10643677	1627	1635	O
,	10643677	1636	1637	O
indicating	10643677	1638	1648	O
that	10643677	1649	1653	O
CHO	10643677	1654	1657	B-Outcome
oxidation	10643677	1658	1667	I-Outcome
had	10643677	1668	1671	O
increased	10643677	1672	1681	B-Observation
with	10643677	1682	1686	O
12	10643677	1687	1689	O
months	10643677	1690	1696	O
endurance	10643677	1697	1706	B-Intervention
training	10643677	1707	1715	I-Intervention
.	10643677	1716	1717	O

In	10643677	1718	1720	O
the	10643677	1721	1724	O
well-trained	10643677	1725	1737	B-Participant
group	10643677	1738	1743	O
the	10643677	1744	1747	O
24h	10643677	1748	1751	B-Outcome
CHO	10643677	1752	1755	I-Outcome
balance	10643677	1756	1763	I-Outcome
was	10643677	1764	1767	O
even	10643677	1768	1772	O
more	10643677	1773	1777	B-Observation
negative	10643677	1778	1786	I-Observation
for	10643677	1787	1790	O
both	10643677	1791	1795	B-Intervention
types	10643677	1796	1801	I-Intervention
of	10643677	1802	1804	I-Intervention
diet	10643677	1805	1809	I-Intervention
(	10643677	1810	1811	O
-103	10643677	1812	1816	B-Observation
to	10643677	1817	1819	O
-185	10643677	1820	1824	B-Observation
g/d	10643677	1825	1828	I-Observation
for	10643677	1829	1832	O
the	10643677	1833	1836	O
Red	10643677	1837	1840	B-Intervention
.	10643677	1840	1841	I-Intervention

F	10643677	1841	1842	B-Intervention
and	10643677	1843	1846	O
Hi	10643677	1847	1849	B-Intervention
.	10643677	1849	1850	I-Intervention

F	10643677	1850	1851	B-Intervention
diet	10643677	1852	1856	I-Intervention
,	10643677	1857	1858	O
respectively	10643677	1859	1871	O
)	10643677	1872	1873	O
under	10643677	1874	1879	O
similar	10643677	1880	1887	O
conditions	10643677	1888	1898	O
compared	10643677	1899	1907	O
with	10643677	1908	1912	O
the	10643677	1913	1916	O
trained	10643677	1917	1924	B-Participant
obese	10643677	1925	1930	I-Participant
group	10643677	1931	1936	O
.	10643677	1937	1938	O

CONCLUSION	10643677	1939	1949	O
The	10643677	1950	1953	O
changes	10643677	1954	1961	B-Observation
in	10643677	1962	1964	O
24	10643677	1965	1967	B-Outcome
h	10643677	1968	1969	I-Outcome
substrate	10643677	1970	1979	I-Outcome
utilization	10643677	1980	1991	I-Outcome
in	10643677	1992	1994	O
the	10643677	1995	1998	O
obese	10643677	1999	2004	B-Participant
,	10643677	2005	2006	O
as	10643677	2007	2009	O
well	10643677	2010	2014	O
as	10643677	2015	2017	O
in	10643677	2018	2020	O
the	10643677	2021	2024	O
well-trained	10643677	2025	2037	B-Participant
group	10643677	2038	2043	O
,	10643677	2044	2045	O
suggest	10643677	2046	2053	O
that	10643677	2054	2058	O
endurance	10643677	2059	2068	B-Intervention
training	10643677	2069	2077	I-Intervention
increased	10643677	2078	2087	B-Observation
the	10643677	2088	2091	O
reliance	10643677	2092	2100	B-Outcome
on	10643677	2101	2103	I-Outcome
carbohydrate	10643677	2104	2116	I-Outcome
oxidation	10643677	2117	2126	I-Outcome
and	10643677	2127	2130	O
therefore	10643677	2131	2140	O
did	10643677	2141	2144	O
not	10643677	2145	2148	O
increase	10643677	2149	2157	B-Observation
24	10643677	2158	2160	B-Outcome
fat	10643677	2161	2164	I-Outcome
oxidation	10643677	2165	2174	I-Outcome
.	10643677	2175	2176	O

Effectiveness	10651597	0	13	O
of	10651597	14	16	O
manual	10651597	17	23	B-Intervention
physical	10651597	24	32	I-Intervention
therapy	10651597	33	40	I-Intervention
and	10651597	41	44	O
exercise	10651597	45	53	B-Intervention
in	10651597	54	56	O
osteoarthritis	10651597	57	71	B-Participant
of	10651597	72	74	I-Participant
the	10651597	75	78	I-Participant
knee	10651597	79	83	I-Participant
.	10651597	84	85	O

A	10651597	86	87	O
randomized	10651597	88	98	O
,	10651597	99	100	O
controlled	10651597	101	111	O
trial	10651597	112	117	O
.	10651597	118	119	O

BACKGROUND	10651597	120	130	O
Few	10651597	131	134	O
investigations	10651597	135	149	O
include	10651597	150	157	O
both	10651597	158	162	O
subjective	10651597	163	173	O
and	10651597	174	177	O
objective	10651597	178	187	O
measurements	10651597	188	200	O
of	10651597	201	203	O
the	10651597	204	207	O
effectiveness	10651597	208	221	O
of	10651597	222	224	O
treatments	10651597	225	235	O
for	10651597	236	239	O
osteoarthritis	10651597	240	254	O
of	10651597	255	257	O
the	10651597	258	261	O
knee	10651597	262	266	O
.	10651597	267	268	O

Beneficial	10651597	269	279	O
interventions	10651597	280	293	O
may	10651597	294	297	O
decrease	10651597	298	306	O
the	10651597	307	310	O
disability	10651597	311	321	O
associated	10651597	322	332	O
with	10651597	333	337	O
osteoarthritis	10651597	338	352	O
and	10651597	353	356	O
the	10651597	357	360	O
need	10651597	361	365	O
for	10651597	366	369	O
more	10651597	370	374	O
invasive	10651597	375	383	O
treatments	10651597	384	394	O
.	10651597	395	396	O

OBJECTIVE	10651597	397	406	O
To	10651597	407	409	O
evaluate	10651597	410	418	O
the	10651597	419	422	O
effectiveness	10651597	423	436	O
of	10651597	437	439	O
physical	10651597	440	448	B-Intervention
therapy	10651597	449	456	I-Intervention
for	10651597	457	460	O
osteoarthritis	10651597	461	475	B-Participant
of	10651597	476	478	I-Participant
the	10651597	479	482	I-Participant
knee	10651597	483	487	I-Participant
,	10651597	488	489	O
applied	10651597	490	497	O
by	10651597	498	500	O
experienced	10651597	501	512	O
physical	10651597	513	521	O
therapists	10651597	522	532	O
with	10651597	533	537	O
formal	10651597	538	544	O
training	10651597	545	553	O
in	10651597	554	556	O
manual	10651597	557	563	O
therapy	10651597	564	571	O
.	10651597	572	573	O

DESIGN	10651597	574	580	O
Randomized	10651597	581	591	O
,	10651597	592	593	O
controlled	10651597	594	604	O
clinical	10651597	605	613	O
trial	10651597	614	619	O
.	10651597	620	621	O

SETTING	10651597	622	629	O
Outpatient	10651597	630	640	O
physical	10651597	641	649	O
therapy	10651597	650	657	O
department	10651597	658	668	O
of	10651597	669	671	O
a	10651597	672	673	O
large	10651597	674	679	O
military	10651597	680	688	O
medical	10651597	689	696	O
center	10651597	697	703	O
.	10651597	704	705	O

PATIENTS	10651597	706	714	O
83	10651597	715	717	O
patients	10651597	718	726	O
with	10651597	727	731	O
osteoarthritis	10651597	732	746	B-Participant
of	10651597	747	749	I-Participant
the	10651597	750	753	I-Participant
knee	10651597	754	758	I-Participant
who	10651597	759	762	O
were	10651597	763	767	O
randomly	10651597	768	776	O
assigned	10651597	777	785	O
to	10651597	786	788	O
receive	10651597	789	796	O
treatment	10651597	797	806	B-Intervention
(	10651597	807	808	O
n	10651597	809	810	O
=	10651597	811	812	O
42	10651597	813	815	O
;	10651597	816	817	O
15	10651597	818	820	O
men	10651597	821	824	O
and	10651597	825	828	O
27	10651597	829	831	O
women	10651597	832	837	O
[	10651597	838	839	O
mean	10651597	840	844	O
age	10651597	845	848	O
,	10651597	849	850	O
60	10651597	851	853	O
+	10651597	854	855	O
/-	10651597	855	857	O
11	10651597	858	860	O
years	10651597	861	866	O
]	10651597	867	868	O
)	10651597	869	870	O
or	10651597	871	873	O
placebo	10651597	874	881	B-Intervention
(	10651597	882	883	O
n	10651597	884	885	O
=	10651597	886	887	O
41	10651597	888	890	O
;	10651597	891	892	O
19	10651597	893	895	O
men	10651597	896	899	O
and	10651597	900	903	O
22	10651597	904	906	O
women	10651597	907	912	O
[	10651597	913	914	O
mean	10651597	915	919	O
age	10651597	920	923	O
,	10651597	924	925	O
62	10651597	926	928	O
+	10651597	929	930	O
/-	10651597	930	932	O
10	10651597	933	935	O
years	10651597	936	941	O
]	10651597	942	943	O
)	10651597	944	945	O
.	10651597	946	947	O

INTERVENTION	10651597	948	960	O
The	10651597	961	964	O
treatment	10651597	965	974	O
group	10651597	975	980	O
received	10651597	981	989	O
manual	10651597	990	996	B-Intervention
therapy	10651597	997	1004	I-Intervention
,	10651597	1005	1006	O
applied	10651597	1007	1014	O
to	10651597	1015	1017	O
the	10651597	1018	1021	O
knee	10651597	1022	1026	O
as	10651597	1027	1029	O
well	10651597	1030	1034	O
as	10651597	1035	1037	O
to	10651597	1038	1040	O
the	10651597	1041	1044	O
lumbar	10651597	1045	1051	O
spine	10651597	1052	1057	O
,	10651597	1058	1059	O
hip	10651597	1060	1063	O
,	10651597	1064	1065	O
and	10651597	1066	1069	O
ankle	10651597	1070	1075	O
as	10651597	1076	1078	O
required	10651597	1079	1087	O
,	10651597	1088	1089	O
and	10651597	1090	1093	O
performed	10651597	1094	1103	O
a	10651597	1104	1105	O
standardized	10651597	1106	1118	B-Intervention
knee	10651597	1119	1123	I-Intervention
exercise	10651597	1124	1132	I-Intervention
program	10651597	1133	1140	O
in	10651597	1141	1143	O
the	10651597	1144	1147	O
clinic	10651597	1148	1154	O
and	10651597	1155	1158	O
at	10651597	1159	1161	O
home	10651597	1162	1166	O
.	10651597	1167	1168	O

The	10651597	1169	1172	O
placebo	10651597	1173	1180	O
group	10651597	1181	1186	O
had	10651597	1187	1190	O
subtherapeutic	10651597	1191	1205	B-Intervention
ultrasound	10651597	1206	1216	I-Intervention
to	10651597	1217	1219	O
the	10651597	1220	1223	O
knee	10651597	1224	1228	O
at	10651597	1229	1231	O
an	10651597	1232	1234	O
intensity	10651597	1235	1244	O
of	10651597	1245	1247	O
0.1	10651597	1248	1251	O
W/cm2	10651597	1252	1257	O
with	10651597	1258	1262	O
a	10651597	1263	1264	O
10	10651597	1265	1267	O
%	10651597	1268	1269	O
pulsed	10651597	1270	1276	O
mode	10651597	1277	1281	O
.	10651597	1282	1283	O

Both	10651597	1284	1288	O
groups	10651597	1289	1295	O
were	10651597	1296	1300	O
treated	10651597	1301	1308	O
at	10651597	1309	1311	O
the	10651597	1312	1315	O
clinic	10651597	1316	1322	O
twice	10651597	1323	1328	O
weekly	10651597	1329	1335	O
for	10651597	1336	1339	O
4	10651597	1340	1341	O
weeks	10651597	1342	1347	O
.	10651597	1348	1349	O

MEASUREMENTS	10651597	1350	1362	O
Distance	10651597	1363	1371	B-Outcome
walked	10651597	1372	1378	I-Outcome
in	10651597	1379	1381	I-Outcome
6	10651597	1382	1383	I-Outcome
minutes	10651597	1384	1391	I-Outcome
and	10651597	1392	1395	O
sum	10651597	1396	1399	B-Outcome
of	10651597	1400	1402	I-Outcome
the	10651597	1403	1406	I-Outcome
function	10651597	1407	1415	I-Outcome
,	10651597	1416	1417	I-Outcome
pain	10651597	1418	1422	I-Outcome
,	10651597	1423	1424	I-Outcome
and	10651597	1425	1428	I-Outcome
stiffness	10651597	1429	1438	I-Outcome
subscores	10651597	1439	1448	I-Outcome
of	10651597	1449	1451	I-Outcome
the	10651597	1452	1455	I-Outcome
Western	10651597	1456	1463	I-Outcome
Ontario	10651597	1464	1471	I-Outcome
and	10651597	1472	1475	I-Outcome
McMaster	10651597	1476	1484	I-Outcome
Universities	10651597	1485	1497	I-Outcome
Osteoarthritis	10651597	1498	1512	I-Outcome
Index	10651597	1513	1518	I-Outcome
(	10651597	1519	1520	I-Outcome
WOMAC	10651597	1521	1526	I-Outcome
)	10651597	1527	1528	I-Outcome
.	10651597	1529	1530	O

A	10651597	1531	1532	O
tester	10651597	1533	1539	O
who	10651597	1540	1543	O
was	10651597	1544	1547	O
blinded	10651597	1548	1555	O
to	10651597	1556	1558	O
group	10651597	1559	1564	O
assignment	10651597	1565	1575	O
made	10651597	1576	1580	O
group	10651597	1581	1586	O
comparisons	10651597	1587	1598	O
at	10651597	1599	1601	O
the	10651597	1602	1605	O
initial	10651597	1606	1613	O
visit	10651597	1614	1619	O
(	10651597	1620	1621	O
before	10651597	1622	1628	O
initiation	10651597	1629	1639	O
of	10651597	1640	1642	O
treatment	10651597	1643	1652	O
)	10651597	1653	1654	O
,	10651597	1655	1656	O
4	10651597	1657	1658	O
weeks	10651597	1659	1664	O
,	10651597	1665	1666	O
8	10651597	1667	1668	O
weeks	10651597	1669	1674	O
,	10651597	1675	1676	O
and	10651597	1677	1680	O
1	10651597	1681	1682	O
year	10651597	1683	1687	O
.	10651597	1688	1689	O

RESULTS	10651597	1690	1697	O
Clinically	10651597	1698	1708	B-Observation
and	10651597	1709	1712	I-Observation
statistically	10651597	1713	1726	I-Observation
significant	10651597	1727	1738	I-Observation
improvements	10651597	1739	1751	I-Observation
in	10651597	1752	1754	O
6-minute	10651597	1755	1763	B-Outcome
walk	10651597	1764	1768	I-Outcome
distance	10651597	1769	1777	I-Outcome
and	10651597	1778	1781	O
WOMAC	10651597	1782	1787	B-Outcome
score	10651597	1788	1793	I-Outcome
at	10651597	1794	1796	O
4	10651597	1797	1798	O
weeks	10651597	1799	1804	O
and	10651597	1805	1808	O
8	10651597	1809	1810	O
weeks	10651597	1811	1816	O
were	10651597	1817	1821	O
seen	10651597	1822	1826	O
in	10651597	1827	1829	O
the	10651597	1830	1833	O
treatment	10651597	1834	1843	B-Intervention
group	10651597	1844	1849	O
but	10651597	1850	1853	O
not	10651597	1854	1857	O
the	10651597	1858	1861	O
placebo	10651597	1862	1869	B-Intervention
group	10651597	1870	1875	O
.	10651597	1876	1877	O

By	10651597	1878	1880	O
8	10651597	1881	1882	O
weeks	10651597	1883	1888	O
,	10651597	1889	1890	O
average	10651597	1891	1898	B-Outcome
6-minute	10651597	1899	1907	I-Outcome
walk	10651597	1908	1912	I-Outcome
distances	10651597	1913	1922	I-Outcome
had	10651597	1923	1926	O
improved	10651597	1927	1935	B-Observation
by	10651597	1936	1938	I-Observation
13.1	10651597	1939	1943	I-Observation
%	10651597	1944	1945	I-Observation
and	10651597	1946	1949	O
WOMAC	10651597	1950	1955	B-Outcome
scores	10651597	1956	1962	I-Outcome
had	10651597	1963	1966	O
improved	10651597	1967	1975	B-Observation
by	10651597	1976	1978	I-Observation
55.8	10651597	1979	1983	I-Observation
%	10651597	1984	1985	I-Observation
over	10651597	1986	1990	O
baseline	10651597	1991	1999	O
values	10651597	2000	2006	O
in	10651597	2007	2009	O
the	10651597	2010	2013	O
treatment	10651597	2014	2023	B-Intervention
group	10651597	2024	2029	O
(	10651597	2030	2031	O
P	10651597	2032	2033	O
<	10651597	2034	2035	O
0.05	10651597	2036	2040	O
)	10651597	2041	2042	O
.	10651597	2043	2044	O

After	10651597	2045	2050	O
controlling	10651597	2051	2062	O
for	10651597	2063	2066	O
potential	10651597	2067	2076	O
confounding	10651597	2077	2088	O
variables	10651597	2089	2098	O
,	10651597	2099	2100	O
the	10651597	2101	2104	O
average	10651597	2105	2112	B-Outcome
distance	10651597	2113	2121	I-Outcome
walked	10651597	2122	2128	I-Outcome
in	10651597	2129	2131	I-Outcome
6	10651597	2132	2133	I-Outcome
minutes	10651597	2134	2141	I-Outcome
at	10651597	2142	2144	O
8	10651597	2145	2146	O
weeks	10651597	2147	2152	O
among	10651597	2153	2158	O
patients	10651597	2159	2167	O
in	10651597	2168	2170	O
the	10651597	2171	2174	O
treatment	10651597	2175	2184	B-Intervention
group	10651597	2185	2190	O
was	10651597	2191	2194	O
170	10651597	2195	2198	B-Observation
m	10651597	2199	2200	I-Observation
(	10651597	2201	2202	I-Observation
95	10651597	2203	2205	I-Observation
%	10651597	2206	2207	I-Observation
CI	10651597	2208	2210	I-Observation
,	10651597	2211	2212	I-Observation
71	10651597	2213	2215	I-Observation
to	10651597	2216	2218	I-Observation
270	10651597	2219	2222	I-Observation
m	10651597	2223	2224	I-Observation
)	10651597	2225	2226	I-Observation
more	10651597	2227	2231	I-Observation
than	10651597	2232	2236	O
that	10651597	2237	2241	O
in	10651597	2242	2244	O
the	10651597	2245	2248	O
placebo	10651597	2249	2256	B-Intervention
group	10651597	2257	2262	O
and	10651597	2263	2266	O
the	10651597	2267	2270	O
average	10651597	2271	2278	B-Outcome
WOMAC	10651597	2279	2284	I-Outcome
scores	10651597	2285	2291	I-Outcome
were	10651597	2292	2296	O
599	10651597	2297	2300	B-Observation
mm	10651597	2301	2303	I-Observation
higher	10651597	2304	2310	I-Observation
(	10651597	2311	2312	O
95	10651597	2313	2315	O
%	10651597	2316	2317	O
CI	10651597	2318	2320	O
,	10651597	2321	2322	O
197	10651597	2323	2326	O
to	10651597	2327	2329	O
1002	10651597	2330	2334	O
mm	10651597	2335	2337	O
)	10651597	2338	2339	O
.	10651597	2340	2341	O

At	10651597	2342	2344	O
1	10651597	2345	2346	O
year	10651597	2347	2351	O
,	10651597	2352	2353	O
patients	10651597	2354	2362	O
in	10651597	2363	2365	O
the	10651597	2366	2369	O
treatment	10651597	2370	2379	B-Intervention
group	10651597	2380	2385	O
had	10651597	2386	2389	O
clinically	10651597	2390	2400	B-Observation
and	10651597	2401	2404	I-Observation
statistically	10651597	2405	2418	I-Observation
significant	10651597	2419	2430	I-Observation
gains	10651597	2431	2436	I-Observation
over	10651597	2437	2441	O
baseline	10651597	2442	2450	B-Outcome
WOMAC	10651597	2451	2456	I-Outcome
scores	10651597	2457	2463	I-Outcome
and	10651597	2464	2467	O
walking	10651597	2468	2475	B-Outcome
distance	10651597	2476	2484	I-Outcome
;	10651597	2485	2486	O
20	10651597	2487	2489	B-Count
%	10651597	2490	2491	I-Count
of	10651597	2492	2494	I-Count
patients	10651597	2495	2503	I-Count
in	10651597	2504	2506	O
the	10651597	2507	2510	O
placebo	10651597	2511	2518	B-Intervention
group	10651597	2519	2524	O
and	10651597	2525	2528	O
5	10651597	2529	2530	B-Count
%	10651597	2531	2532	I-Count
of	10651597	2533	2535	I-Count
patients	10651597	2536	2544	I-Count
in	10651597	2545	2547	O
the	10651597	2548	2551	O
treatment	10651597	2552	2561	B-Intervention
group	10651597	2562	2567	O
had	10651597	2568	2571	O
undergone	10651597	2572	2581	O
knee	10651597	2582	2586	B-Outcome
arthroplasty	10651597	2587	2599	I-Outcome
.	10651597	2600	2601	O

CONCLUSIONS	10651597	2602	2613	O
A	10651597	2614	2615	O
combination	10651597	2616	2627	B-Intervention
of	10651597	2628	2630	I-Intervention
manual	10651597	2631	2637	I-Intervention
physical	10651597	2638	2646	I-Intervention
therapy	10651597	2647	2654	I-Intervention
and	10651597	2655	2658	I-Intervention
supervised	10651597	2659	2669	I-Intervention
exercise	10651597	2670	2678	I-Intervention
yields	10651597	2679	2685	O
functional	10651597	2686	2696	B-Outcome
benefits	10651597	2697	2705	I-Outcome
for	10651597	2706	2709	O
patients	10651597	2710	2718	O
with	10651597	2719	2723	O
osteoarthritis	10651597	2724	2738	B-Participant
of	10651597	2739	2741	I-Participant
the	10651597	2742	2745	I-Participant
knee	10651597	2746	2750	I-Participant
and	10651597	2751	2754	O
may	10651597	2755	2758	O
delay	10651597	2759	2764	B-Observation
or	10651597	2765	2767	O
prevent	10651597	2768	2775	B-Observation
the	10651597	2776	2779	O
need	10651597	2780	2784	B-Outcome
for	10651597	2785	2788	I-Outcome
surgical	10651597	2789	2797	I-Outcome
intervention	10651597	2798	2810	I-Outcome
.	10651597	2811	2812	O

Regression	10660161	0	10	B-Outcome
of	10660161	11	13	O
left	10660161	14	18	B-Participant
ventricular	10660161	19	30	I-Participant
hypertrophy	10660161	31	42	I-Participant
after	10660161	43	48	O
stentless	10660161	49	58	B-Intervention
versus	10660161	59	65	I-Intervention
conventional	10660161	66	78	I-Intervention
aortic	10660161	79	85	I-Intervention
valve	10660161	86	91	I-Intervention
replacement	10660161	92	103	I-Intervention
.	10660161	104	105	O

The	10660161	106	109	O
goal	10660161	110	114	O
of	10660161	115	117	O
this	10660161	118	122	O
study	10660161	123	128	O
was	10660161	129	132	O
to	10660161	133	135	O
analyze	10660161	136	143	O
regression	10660161	144	154	B-Outcome
of	10660161	155	157	O
left	10660161	158	162	B-Participant
ventricular	10660161	163	174	I-Participant
hypertrophy	10660161	175	186	I-Participant
after	10660161	187	192	O
randomization	10660161	193	206	O
to	10660161	207	209	O
conventional	10660161	210	222	B-Intervention
biological	10660161	223	233	I-Intervention
versus	10660161	234	240	O
stentless	10660161	241	250	B-Intervention
aortic	10660161	251	257	I-Intervention
valve	10660161	258	263	I-Intervention
replacement	10660161	264	275	I-Intervention
.	10660161	276	277	O

Stentless	10660161	278	287	B-Intervention
(	10660161	288	289	O
Freestyle	10660161	290	299	O
,	10660161	300	301	O
Toronto	10660161	302	309	O
,	10660161	310	311	O
n	10660161	312	313	O
=	10660161	314	315	O
106	10660161	316	319	O
)	10660161	320	321	O
or	10660161	322	324	O
conventional	10660161	325	337	B-Intervention
biological	10660161	338	348	I-Intervention
aortic	10660161	349	355	I-Intervention
valves	10660161	356	362	I-Intervention
(	10660161	363	364	O
Carpentier-Edwards	10660161	365	383	O
,	10660161	384	385	O
n	10660161	386	387	O
=	10660161	388	389	O
74	10660161	390	392	O
)	10660161	393	394	O
were	10660161	395	399	O
evaluated	10660161	400	409	O
prospectively	10660161	410	423	O
.	10660161	424	425	O

Preoperatively	10660161	426	440	O
there	10660161	441	446	O
were	10660161	447	451	O
no	10660161	452	454	O
differences	10660161	455	466	B-Observation
with	10660161	467	471	O
regard	10660161	472	478	O
to	10660161	479	481	O
aortic	10660161	482	488	B-Outcome
valve	10660161	489	494	I-Outcome
pathology	10660161	495	504	I-Outcome
,	10660161	505	506	O
left	10660161	507	511	B-Outcome
ventricular	10660161	512	523	I-Outcome
function	10660161	524	532	I-Outcome
,	10660161	533	534	O
and	10660161	535	538	O
pressure	10660161	539	547	B-Outcome
gradients	10660161	548	557	I-Outcome
between	10660161	558	565	B-Intervention
the	10660161	566	569	I-Intervention
two	10660161	570	573	I-Intervention
patient	10660161	574	581	I-Intervention
groups	10660161	582	588	I-Intervention
.	10660161	589	590	O

The	10660161	591	594	O
patient	10660161	595	602	B-Outcome
annulus	10660161	603	610	I-Outcome
index	10660161	611	616	I-Outcome
(	10660161	617	618	O
13.55	10660161	619	624	B-Observation
vs.	10660161	625	628	O
13.46	10660161	629	634	B-Observation
mm	10660161	635	637	I-Observation
;	10660161	638	639	O
NS	10660161	640	642	O
)	10660161	643	644	O
measured	10660161	645	653	O
intraoperatively	10660161	654	670	O
was	10660161	671	674	O
used	10660161	675	679	O
as	10660161	680	682	O
baseline	10660161	683	691	O
for	10660161	692	695	O
further	10660161	696	703	O
comparison	10660161	704	714	O
.	10660161	715	716	O

Postoperatively	10660161	717	732	O
,	10660161	733	734	O
left	10660161	735	739	B-Outcome
ventricular	10660161	740	751	I-Outcome
mass	10660161	752	756	I-Outcome
index	10660161	757	762	I-Outcome
was	10660161	763	766	O
213+/-77	10660161	767	775	B-Observation
g/m2	10660161	776	780	I-Observation
(	10660161	781	782	O
stentless	10660161	783	792	B-Intervention
)	10660161	793	794	O
compared	10660161	795	803	O
with	10660161	804	808	O
202+/-72	10660161	809	817	B-Observation
(	10660161	818	819	O
conventional	10660161	820	832	B-Intervention
group	10660161	833	838	O
)	10660161	839	840	O
g/m2	10660161	841	845	O
(	10660161	846	847	O
NS	10660161	848	850	O
)	10660161	851	852	O
,	10660161	853	854	O
whereas	10660161	855	862	O
after	10660161	863	868	O
6	10660161	869	870	O
months	10660161	871	877	O
it	10660161	878	880	O
was	10660161	881	884	O
141+/-41	10660161	885	893	B-Observation
g/m2	10660161	894	898	I-Observation
in	10660161	899	901	O
the	10660161	902	905	O
stentless	10660161	906	915	B-Intervention
and	10660161	916	919	O
170+/-43	10660161	920	928	B-Observation
g/m2	10660161	929	933	I-Observation
in	10660161	934	936	O
the	10660161	937	940	O
conventional	10660161	941	953	B-Intervention
group	10660161	954	959	O
(	10660161	960	961	O
P	10660161	962	963	O
<	10660161	964	965	O
.05	10660161	966	969	O
)	10660161	970	971	O
.	10660161	972	973	O

Regression	10660161	974	984	B-Outcome
of	10660161	985	987	O
left	10660161	988	992	B-Participant
ventricular	10660161	993	1004	I-Participant
hypertrophy	10660161	1005	1016	I-Participant
occurs	10660161	1017	1023	O
in	10660161	1024	1026	O
all	10660161	1027	1030	B-Count
patients	10660161	1031	1039	I-Count
after	10660161	1040	1045	O
aortic	10660161	1046	1052	B-Intervention
valve	10660161	1053	1058	I-Intervention
replacement	10660161	1059	1070	I-Intervention
.	10660161	1071	1072	O

Nevertheless	10660161	1073	1085	O
,	10660161	1086	1087	O
the	10660161	1088	1091	O
use	10660161	1092	1095	O
of	10660161	1096	1098	O
stentless	10660161	1099	1108	B-Intervention
bioprostheses	10660161	1109	1122	I-Intervention
leads	10660161	1123	1128	O
to	10660161	1129	1131	O
a	10660161	1132	1133	O
significant	10660161	1134	1145	B-Observation
enhancement	10660161	1146	1157	I-Observation
,	10660161	1158	1159	O
which	10660161	1160	1165	O
may	10660161	1166	1169	O
result	10660161	1170	1176	O
in	10660161	1177	1179	O
a	10660161	1180	1181	O
reduction	10660161	1182	1191	B-Observation
of	10660161	1192	1194	O
the	10660161	1195	1198	O
cardiac	10660161	1199	1206	B-Outcome
risk	10660161	1207	1211	I-Outcome
profile	10660161	1212	1219	I-Outcome
for	10660161	1220	1223	O
the	10660161	1224	1227	O
patient	10660161	1228	1235	O
.	10660161	1236	1237	O

Changes	10661479	0	7	B-Observation
in	10661479	8	10	O
cardiac	10661479	11	18	B-Outcome
muscle	10661479	19	25	I-Outcome
mass	10661479	26	30	I-Outcome
and	10661479	31	34	I-Outcome
function	10661479	35	43	I-Outcome
in	10661479	44	46	O
hemodialysis	10661479	47	59	B-Participant
patients	10661479	60	68	O
during	10661479	69	75	O
growth	10661479	76	82	B-Intervention
hormone	10661479	83	90	I-Intervention
treatment	10661479	91	100	I-Intervention
.	10661479	101	102	O

BACKGROUND	10661479	103	113	O
Adult	10661479	114	119	O
patients	10661479	120	128	O
with	10661479	129	133	O
chronic	10661479	134	141	O
renal	10661479	142	147	O
failure	10661479	148	155	O
(	10661479	156	157	O
CRF	10661479	158	161	O
)	10661479	162	163	O
often	10661479	164	169	O
show	10661479	170	174	O
symptoms	10661479	175	183	O
as	10661479	184	186	O
fatigue	10661479	187	194	O
,	10661479	195	196	O
wasting	10661479	197	204	O
,	10661479	205	206	O
and	10661479	207	210	O
reduced	10661479	211	218	O
working	10661479	219	226	O
capacity	10661479	227	235	O
with	10661479	236	240	O
concomitant	10661479	241	252	O
findings	10661479	253	261	O
of	10661479	262	264	O
reduced	10661479	265	272	O
cardiac	10661479	273	280	O
performance	10661479	281	292	O
and	10661479	293	296	O
muscle	10661479	297	303	O
mass	10661479	304	308	O
.	10661479	309	310	O

This	10661479	311	315	O
state	10661479	316	321	O
may	10661479	322	325	O
in	10661479	326	328	O
part	10661479	329	333	O
be	10661479	334	336	O
caused	10661479	337	343	O
by	10661479	344	346	O
an	10661479	347	349	O
imbalance	10661479	350	359	O
in	10661479	360	362	O
the	10661479	363	366	O
somatostatin/somatomedine	10661479	367	392	O
axis	10661479	393	397	O
resulting	10661479	398	407	O
in	10661479	408	410	O
increased	10661479	411	420	O
catabolism	10661479	421	431	O
.	10661479	432	433	O

During	10661479	434	440	O
an	10661479	441	443	O
attempt	10661479	444	451	O
to	10661479	452	454	O
correct	10661479	455	462	O
this	10661479	463	467	O
catabolic	10661479	468	477	O
state	10661479	478	483	O
by	10661479	484	486	O
administration	10661479	487	501	O
of	10661479	502	504	O
exogenous	10661479	505	514	B-Intervention
growth	10661479	515	521	I-Intervention
hormone	10661479	522	529	I-Intervention
,	10661479	530	531	O
cardiac	10661479	532	539	B-Outcome
muscle	10661479	540	546	I-Outcome
mass	10661479	547	551	I-Outcome
and	10661479	552	555	I-Outcome
performance	10661479	556	567	I-Outcome
were	10661479	568	572	O
studied	10661479	573	580	O
.	10661479	581	582	O

METHODS	10661479	583	590	O
In	10661479	591	593	O
a	10661479	594	595	O
double-blind	10661479	596	608	O
,	10661479	609	610	O
placebo-controlled	10661479	611	629	O
6-month	10661479	630	637	O
study	10661479	638	643	O
comprising	10661479	644	654	O
20	10661479	655	657	O
adult	10661479	658	663	B-Participant
enfeebled	10661479	664	673	O
hemodialysis	10661479	674	686	B-Participant
patients	10661479	687	695	O
,	10661479	696	697	O
9	10661479	698	699	O
patients	10661479	700	708	O
were	10661479	709	713	O
treated	10661479	714	721	O
with	10661479	722	726	O
a	10661479	727	728	O
single	10661479	729	735	O
daily	10661479	736	741	O
subcutaneous	10661479	742	754	O
injection	10661479	755	764	O
of	10661479	765	767	O
recombinant	10661479	768	779	B-Intervention
human	10661479	780	785	I-Intervention
growth	10661479	786	792	I-Intervention
hormone	10661479	793	800	I-Intervention
(	10661479	801	802	I-Intervention
rhGH	10661479	803	807	I-Intervention
)	10661479	808	809	I-Intervention
4	10661479	810	811	O
IU/m2	10661479	812	817	O
and	10661479	818	821	O
11	10661479	822	824	O
with	10661479	825	829	O
placebo	10661479	830	837	B-Intervention
injections	10661479	838	848	O
.	10661479	849	850	O

Left	10661479	851	855	B-Outcome
ventricular	10661479	856	867	I-Outcome
muscle	10661479	868	874	I-Outcome
mass	10661479	875	879	I-Outcome
(	10661479	880	881	I-Outcome
LVM	10661479	882	885	I-Outcome
)	10661479	886	887	I-Outcome
and	10661479	888	891	O
ejection	10661479	892	900	B-Outcome
fraction	10661479	901	909	I-Outcome
(	10661479	910	911	I-Outcome
EF	10661479	912	914	I-Outcome
)	10661479	915	916	I-Outcome
were	10661479	917	921	O
evaluated	10661479	922	931	O
by	10661479	932	934	O
echocardiography	10661479	935	951	O
and	10661479	952	955	O
the	10661479	956	959	O
maximal	10661479	960	967	B-Outcome
working	10661479	968	975	I-Outcome
capacity	10661479	976	984	I-Outcome
(	10661479	985	986	I-Outcome
MWC	10661479	987	990	I-Outcome
)	10661479	991	992	I-Outcome
was	10661479	993	996	O
measured	10661479	997	1005	O
by	10661479	1006	1008	O
a	10661479	1009	1010	O
bicycle	10661479	1011	1018	O
exercise	10661479	1019	1027	O
test	10661479	1028	1032	O
performed	10661479	1033	1042	O
before	10661479	1043	1049	O
and	10661479	1050	1053	O
after	10661479	1054	1059	O
the	10661479	1060	1063	O
treatment	10661479	1064	1073	O
period	10661479	1074	1080	O
.	10661479	1081	1082	O

Supplementary	10661479	1083	1096	B-Outcome
electrocardiography	10661479	1097	1116	I-Outcome
(	10661479	1117	1118	I-Outcome
ECG	10661479	1119	1122	I-Outcome
)	10661479	1123	1124	I-Outcome
was	10661479	1125	1128	O
performed	10661479	1129	1138	O
before	10661479	1139	1145	O
and	10661479	1146	1149	O
after	10661479	1150	1155	O
6-month	10661479	1156	1163	O
treatment	10661479	1164	1173	O
.	10661479	1174	1175	O

RESULTS	10661479	1176	1183	O
Median	10661479	1184	1190	B-Outcome
LVM	10661479	1191	1194	I-Outcome
increased	10661479	1195	1204	B-Observation
significantly	10661479	1205	1218	I-Observation
from	10661479	1219	1223	I-Observation
172	10661479	1224	1227	I-Observation
to	10661479	1228	1230	I-Observation
220	10661479	1231	1234	I-Observation
g	10661479	1235	1236	I-Observation
(	10661479	1237	1238	O
p	10661479	1239	1240	O
=	10661479	1241	1242	O
0.03	10661479	1243	1247	O
)	10661479	1248	1249	O
in	10661479	1250	1252	O
the	10661479	1253	1256	O
rhGH-treated	10661479	1257	1269	B-Intervention
group	10661479	1270	1275	O
,	10661479	1276	1277	O
while	10661479	1278	1283	O
an	10661479	1284	1286	O
insignificant	10661479	1287	1300	B-Observation
decrease	10661479	1301	1309	I-Observation
was	10661479	1310	1313	O
observed	10661479	1314	1322	O
in	10661479	1323	1325	O
the	10661479	1326	1329	O
placebo	10661479	1330	1337	B-Intervention
group	10661479	1338	1343	O
from	10661479	1344	1348	B-Observation
281	10661479	1349	1352	I-Observation
to	10661479	1353	1355	I-Observation
200	10661479	1356	1359	I-Observation
g	10661479	1360	1361	I-Observation
(	10661479	1362	1363	O
p	10661479	1364	1365	O
=	10661479	1366	1367	O
0.3	10661479	1368	1371	O
)	10661479	1372	1373	O
.	10661479	1374	1375	O

The	10661479	1376	1379	O
EF	10661479	1380	1382	B-Outcome
showed	10661479	1383	1389	O
no	10661479	1390	1392	O
significant	10661479	1393	1404	B-Observation
changes	10661479	1405	1412	I-Observation
in	10661479	1413	1415	O
the	10661479	1416	1419	O
two	10661479	1420	1423	B-Intervention
groups	10661479	1424	1430	I-Intervention
.	10661479	1431	1432	O

MWC	10661479	1433	1436	B-Outcome
showed	10661479	1437	1443	O
a	10661479	1444	1445	O
slight	10661479	1446	1452	B-Observation
,	10661479	1453	1454	I-Observation
insignificant	10661479	1455	1468	I-Observation
decrease	10661479	1469	1477	I-Observation
in	10661479	1478	1480	O
both	10661479	1481	1485	B-Intervention
groups	10661479	1486	1492	I-Intervention
.	10661479	1493	1494	O

From	10661479	1495	1499	O
ECG	10661479	1500	1503	O
no	10661479	1504	1506	O
significant	10661479	1507	1518	B-Observation
ST	10661479	1519	1521	B-Outcome
deviations	10661479	1522	1532	I-Outcome
were	10661479	1533	1537	O
found	10661479	1538	1543	O
and	10661479	1544	1547	O
no	10661479	1548	1550	O
significant	10661479	1551	1562	B-Observation
changes	10661479	1563	1570	I-Observation
regarding	10661479	1571	1580	O
B-Hb	10661479	1581	1585	B-Outcome
,	10661479	1586	1587	O
blood	10661479	1588	1593	B-Outcome
pressure	10661479	1594	1602	I-Outcome
or	10661479	1603	1605	O
pulse	10661479	1606	1611	B-Outcome
were	10661479	1612	1616	O
observed	10661479	1617	1625	O
in	10661479	1626	1628	O
the	10661479	1629	1632	O
two	10661479	1633	1636	B-Intervention
groups	10661479	1637	1643	I-Intervention
.	10661479	1644	1645	O

Irregular	10661479	1646	1655	B-Outcome
heart	10661479	1656	1661	I-Outcome
rhythm	10661479	1662	1668	I-Outcome
aggravated	10661479	1669	1679	B-Observation
in	10661479	1680	1682	O
one	10661479	1683	1686	B-Count
patient	10661479	1687	1694	I-Count
during	10661479	1695	1701	O
the	10661479	1702	1705	O
first	10661479	1706	1711	O
month	10661479	1712	1717	O
of	10661479	1718	1720	O
treatment	10661479	1721	1730	O
with	10661479	1731	1735	O
rhGH	10661479	1736	1740	B-Intervention
,	10661479	1741	1742	O
but	10661479	1743	1746	O
was	10661479	1747	1750	O
overcome	10661479	1751	1759	O
by	10661479	1760	1762	O
a	10661479	1763	1764	O
-blocking	10661479	1765	1774	O
agent	10661479	1775	1780	O
.	10661479	1781	1782	O

CONCLUSION	10661479	1783	1793	O
The	10661479	1794	1797	O
treatment	10661479	1798	1807	O
with	10661479	1808	1812	O
rhGH	10661479	1813	1817	B-Intervention
of	10661479	1818	1820	O
adult	10661479	1821	1826	B-Participant
chronic	10661479	1827	1834	I-Participant
hemodialysis	10661479	1835	1847	I-Participant
patients	10661479	1848	1856	O
for	10661479	1857	1860	O
6	10661479	1861	1862	O
months	10661479	1863	1869	O
increased	10661479	1870	1879	B-Observation
the	10661479	1880	1883	O
left	10661479	1884	1888	B-Outcome
ventricular	10661479	1889	1900	I-Outcome
mass	10661479	1901	1905	I-Outcome
significantly	10661479	1906	1919	O
,	10661479	1920	1921	O
but	10661479	1922	1925	O
without	10661479	1926	1933	O
any	10661479	1934	1937	O
effect	10661479	1938	1944	O
on	10661479	1945	1947	O
ejection	10661479	1948	1956	B-Outcome
fraction	10661479	1957	1965	I-Outcome
or	10661479	1966	1968	O
maximal	10661479	1969	1976	B-Outcome
working	10661479	1977	1984	I-Outcome
capacity	10661479	1985	1993	I-Outcome
.	10661479	1994	1995	O

No	10661479	1996	1998	O
electrocardiographic	10661479	1999	2019	B-Outcome
signs	10661479	2020	2025	I-Outcome
of	10661479	2026	2028	I-Outcome
ischemia	10661479	2029	2037	I-Outcome
were	10661479	2038	2042	O
associated	10661479	2043	2053	O
with	10661479	2054	2058	O
the	10661479	2059	2062	O
increasing	10661479	2063	2073	B-Observation
muscle	10661479	2074	2080	B-Outcome
mass	10661479	2081	2085	I-Outcome
and	10661479	2086	2089	O
only	10661479	2090	2094	O
one	10661479	2095	2098	B-Count
patient	10661479	2099	2106	I-Count
developed	10661479	2107	2116	O
symptoms	10661479	2117	2125	B-Outcome
that	10661479	2126	2130	I-Outcome
might	10661479	2131	2136	I-Outcome
relate	10661479	2137	2143	I-Outcome
to	10661479	2144	2146	I-Outcome
ischemia	10661479	2147	2155	I-Outcome
.	10661479	2156	2157	O

No	10661479	2158	2160	O
changes	10661479	2161	2168	B-Observation
in	10661479	2169	2171	O
B-Hb	10661479	2172	2176	B-Outcome
,	10661479	2177	2178	O
blood	10661479	2179	2184	B-Outcome
pressure	10661479	2185	2193	I-Outcome
or	10661479	2194	2196	O
pulse	10661479	2197	2202	B-Outcome
were	10661479	2203	2207	O
observed	10661479	2208	2216	O
during	10661479	2217	2223	O
the	10661479	2224	2227	O
treatment	10661479	2228	2237	B-Intervention
period	10661479	2238	2244	O
.	10661479	2245	2246	O

Randomized	10663363	0	10	O
trial	10663363	11	16	O
of	10663363	17	19	O
the	10663363	20	23	O
effects	10663363	24	31	O
of	10663363	32	34	O
risedronate	10663363	35	46	B-Intervention
on	10663363	47	49	O
vertebral	10663363	50	59	B-Outcome
fractures	10663363	60	69	I-Outcome
in	10663363	70	72	O
women	10663363	73	78	B-Participant
with	10663363	79	83	O
established	10663363	84	95	B-Participant
postmenopausal	10663363	96	110	I-Participant
osteoporosis	10663363	111	123	I-Participant
.	10663363	124	125	O

Vertebral	10663363	126	135	O
Efficacy	10663363	136	144	O
with	10663363	145	149	O
Risedronate	10663363	150	161	O
Therapy	10663363	162	169	O
(	10663363	170	171	O
VERT	10663363	172	176	O
)	10663363	177	178	O
Study	10663363	179	184	O
Group	10663363	185	190	O
.	10663363	191	192	O

The	10663363	193	196	O
purpose	10663363	197	204	O
of	10663363	205	207	O
this	10663363	208	212	O
randomized	10663363	213	223	O
,	10663363	224	225	O
double-masked	10663363	226	239	O
,	10663363	240	241	O
placebo-controlled	10663363	242	260	O
study	10663363	261	266	O
was	10663363	267	270	O
to	10663363	271	273	O
determine	10663363	274	283	O
the	10663363	284	287	O
efficacy	10663363	288	296	B-Outcome
and	10663363	297	300	O
safety	10663363	301	307	B-Outcome
of	10663363	308	310	O
risedronate	10663363	311	322	B-Intervention
in	10663363	323	325	O
the	10663363	326	329	O
prevention	10663363	330	340	B-Outcome
of	10663363	341	343	I-Outcome
vertebral	10663363	344	353	I-Outcome
fractures	10663363	354	363	I-Outcome
in	10663363	364	366	O
postmenopausal	10663363	367	381	B-Participant
women	10663363	382	387	I-Participant
with	10663363	388	392	O
established	10663363	393	404	B-Participant
osteoporosis	10663363	405	417	I-Participant
.	10663363	418	419	O

The	10663363	420	423	O
study	10663363	424	429	O
was	10663363	430	433	O
conducted	10663363	434	443	O
at	10663363	444	446	O
80	10663363	447	449	O
study	10663363	450	455	O
centers	10663363	456	463	O
in	10663363	464	466	O
Europe	10663363	467	473	O
and	10663363	474	477	O
Australia	10663363	478	487	O
.	10663363	488	489	O

Postmenopausal	10663363	490	504	B-Participant
women	10663363	505	510	I-Participant
(	10663363	511	512	O
n	10663363	513	514	O
=	10663363	515	516	O
1226	10663363	517	521	O
)	10663363	522	523	O
with	10663363	524	528	O
two	10663363	529	532	B-Participant
or	10663363	533	535	I-Participant
more	10663363	536	540	I-Participant
prevalent	10663363	541	550	I-Participant
vertebral	10663363	551	560	I-Participant
fractures	10663363	561	570	I-Participant
received	10663363	571	579	O
risedronate	10663363	580	591	B-Intervention
2.5	10663363	592	595	O
or	10663363	596	598	O
5	10663363	599	600	O
mg/day	10663363	601	607	O
or	10663363	608	610	O
placebo	10663363	611	618	B-Intervention
;	10663363	619	620	O
all	10663363	621	624	O
subjects	10663363	625	633	O
also	10663363	634	638	O
received	10663363	639	647	O
elemental	10663363	648	657	B-Intervention
calcium	10663363	658	665	I-Intervention
1000	10663363	666	670	O
mg/day	10663363	671	677	O
,	10663363	678	679	O
and	10663363	680	683	O
up	10663363	684	686	O
to	10663363	687	689	O
500	10663363	690	693	O
IU/day	10663363	694	700	O
vitamin	10663363	701	708	B-Intervention
D	10663363	709	710	I-Intervention
if	10663363	711	713	O
baseline	10663363	714	722	O
levels	10663363	723	729	O
were	10663363	730	734	O
low	10663363	735	738	O
.	10663363	739	740	O

The	10663363	741	744	O
study	10663363	745	750	O
duration	10663363	751	759	O
was	10663363	760	763	O
3	10663363	764	765	O
years	10663363	766	771	O
;	10663363	772	773	O
however	10663363	774	781	O
,	10663363	782	783	O
the	10663363	784	787	O
2.5	10663363	788	791	B-Intervention
mg	10663363	792	794	I-Intervention
group	10663363	795	800	O
was	10663363	801	804	O
discontinued	10663363	805	817	O
by	10663363	818	820	O
protocol	10663363	821	829	O
amendment	10663363	830	839	O
after	10663363	840	845	O
2	10663363	846	847	O
years	10663363	848	853	O
.	10663363	854	855	O

Lateral	10663363	856	863	O
spinal	10663363	864	870	O
radiographs	10663363	871	882	O
were	10663363	883	887	O
taken	10663363	888	893	O
annually	10663363	894	902	O
for	10663363	903	906	O
assessment	10663363	907	917	O
of	10663363	918	920	O
vertebral	10663363	921	930	B-Outcome
fractures	10663363	931	940	I-Outcome
,	10663363	941	942	O
and	10663363	943	946	O
bone	10663363	947	951	B-Outcome
mineral	10663363	952	959	I-Outcome
density	10663363	960	967	I-Outcome
was	10663363	968	971	O
measured	10663363	972	980	O
by	10663363	981	983	O
dual-energy	10663363	984	995	O
X-ray	10663363	996	1001	O
absorptiometry	10663363	1002	1016	O
at	10663363	1017	1019	O
6-month	10663363	1020	1027	O
intervals	10663363	1028	1037	O
.	10663363	1038	1039	O

Risedronate	10663363	1040	1051	B-Intervention
5	10663363	1052	1053	I-Intervention
mg	10663363	1054	1056	I-Intervention
reduced	10663363	1057	1064	B-Observation
the	10663363	1065	1068	O
risk	10663363	1069	1073	B-Outcome
of	10663363	1074	1076	I-Outcome
new	10663363	1077	1080	I-Outcome
vertebral	10663363	1081	1090	I-Outcome
fractures	10663363	1091	1100	I-Outcome
by	10663363	1101	1103	O
49	10663363	1104	1106	B-Observation
%	10663363	1107	1108	I-Observation
over	10663363	1109	1113	O
3	10663363	1114	1115	O
years	10663363	1116	1121	O
compared	10663363	1122	1130	O
with	10663363	1131	1135	O
control	10663363	1136	1143	B-Intervention
(	10663363	1144	1145	O
p	10663363	1146	1147	O
<	10663363	1148	1149	O
0.001	10663363	1150	1155	O
)	10663363	1156	1157	O
.	10663363	1158	1159	O

A	10663363	1160	1161	O
significant	10663363	1162	1173	B-Observation
reduction	10663363	1174	1183	I-Observation
of	10663363	1184	1186	I-Observation
61	10663363	1187	1189	I-Observation
%	10663363	1190	1191	I-Observation
was	10663363	1192	1195	O
seen	10663363	1196	1200	O
within	10663363	1201	1207	O
the	10663363	1208	1211	O
first	10663363	1212	1217	O
year	10663363	1218	1222	O
(	10663363	1223	1224	O
p	10663363	1225	1226	O
=	10663363	1227	1228	O
0.001	10663363	1229	1234	O
)	10663363	1235	1236	O
.	10663363	1237	1238	O

The	10663363	1239	1242	O
fracture	10663363	1243	1251	B-Outcome
reduction	10663363	1252	1261	I-Outcome
with	10663363	1262	1266	O
risedronate	10663363	1267	1278	B-Intervention
2.5	10663363	1279	1282	I-Intervention
mg	10663363	1283	1285	O
was	10663363	1286	1289	O
similar	10663363	1290	1297	B-Observation
to	10663363	1298	1300	O
that	10663363	1301	1305	O
in	10663363	1306	1308	O
the	10663363	1309	1312	O
5	10663363	1313	1314	B-Intervention
mg	10663363	1315	1317	I-Intervention
group	10663363	1318	1323	I-Intervention
over	10663363	1324	1328	O
2	10663363	1329	1330	O
years	10663363	1331	1336	O
.	10663363	1337	1338	O

The	10663363	1339	1342	O
risk	10663363	1343	1347	B-Outcome
of	10663363	1348	1350	I-Outcome
nonvertebral	10663363	1351	1363	I-Outcome
fractures	10663363	1364	1373	I-Outcome
was	10663363	1374	1377	O
reduced	10663363	1378	1385	B-Observation
by	10663363	1386	1388	I-Observation
33	10663363	1389	1391	I-Observation
%	10663363	1392	1393	I-Observation
compared	10663363	1394	1402	O
with	10663363	1403	1407	O
control	10663363	1408	1415	B-Intervention
over	10663363	1416	1420	O
3	10663363	1421	1422	O
years	10663363	1423	1428	O
(	10663363	1429	1430	O
p	10663363	1431	1432	O
=	10663363	1433	1434	O
0.06	10663363	1435	1439	O
)	10663363	1440	1441	O
.	10663363	1442	1443	O

Risedronate	10663363	1444	1455	B-Intervention
significantly	10663363	1456	1469	B-Observation
increased	10663363	1470	1479	I-Observation
bone	10663363	1480	1484	B-Outcome
mineral	10663363	1485	1492	I-Outcome
density	10663363	1493	1500	I-Outcome
at	10663363	1501	1503	I-Outcome
the	10663363	1504	1507	I-Outcome
spine	10663363	1508	1513	I-Outcome
and	10663363	1514	1517	I-Outcome
hip	10663363	1518	1521	I-Outcome
within	10663363	1522	1528	O
6	10663363	1529	1530	O
months	10663363	1531	1537	O
.	10663363	1538	1539	O

The	10663363	1540	1543	O
adverse-event	10663363	1544	1557	B-Outcome
profile	10663363	1558	1565	I-Outcome
of	10663363	1566	1568	O
risedronate	10663363	1569	1580	B-Intervention
,	10663363	1581	1582	O
including	10663363	1583	1592	O
gastrointestinal	10663363	1593	1609	B-Outcome
adverse	10663363	1610	1617	I-Outcome
events	10663363	1618	1624	I-Outcome
,	10663363	1625	1626	O
was	10663363	1627	1630	O
similar	10663363	1631	1638	B-Observation
to	10663363	1639	1641	O
that	10663363	1642	1646	O
of	10663363	1647	1649	O
control	10663363	1650	1657	B-Intervention
.	10663363	1658	1659	O

Risedronate	10663363	1660	1671	B-Intervention
5	10663363	1672	1673	I-Intervention
mg	10663363	1674	1676	I-Intervention
provides	10663363	1677	1685	O
effective	10663363	1686	1695	B-Observation
and	10663363	1696	1699	O
well-tolerated	10663363	1700	1714	B-Observation
therapy	10663363	1715	1722	O
for	10663363	1723	1726	O
severe	10663363	1727	1733	B-Participant
postmenopausal	10663363	1734	1748	I-Participant
osteoporosis	10663363	1749	1761	I-Participant
,	10663363	1762	1763	O
reducing	10663363	1764	1772	B-Observation
the	10663363	1773	1776	O
incidence	10663363	1777	1786	B-Outcome
of	10663363	1787	1789	I-Outcome
vertebral	10663363	1790	1799	I-Outcome
fractures	10663363	1800	1809	I-Outcome
and	10663363	1810	1813	O
improving	10663363	1814	1823	B-Observation
bone	10663363	1824	1828	B-Outcome
density	10663363	1829	1836	I-Outcome
in	10663363	1837	1839	O
women	10663363	1840	1845	B-Participant
with	10663363	1846	1850	O
established	10663363	1851	1862	B-Participant
disease	10663363	1863	1870	I-Participant
.	10663363	1871	1872	O

Bronchodilatory	10665129	0	15	B-Outcome
responses	10665129	16	25	I-Outcome
to	10665129	26	28	O
formoterol	10665129	29	39	B-Intervention
,	10665129	40	41	O
ipratropium	10665129	42	53	B-Intervention
,	10665129	54	55	O
and	10665129	56	59	O
their	10665129	60	65	O
combination	10665129	66	77	B-Intervention
in	10665129	78	80	O
patients	10665129	81	89	O
with	10665129	90	94	O
stable	10665129	95	101	B-Participant
COPD	10665129	102	106	I-Participant
.	10665129	107	108	O

We	10665129	109	111	O
studied	10665129	112	119	O
27	10665129	120	122	O
patients	10665129	123	131	O
with	10665129	132	136	O
stable	10665129	137	143	B-Participant
chronic	10665129	144	151	I-Participant
obstuctive	10665129	152	162	I-Participant
pulmonary	10665129	163	172	I-Participant
disease	10665129	173	180	I-Participant
(	10665129	181	182	I-Participant
COPD	10665129	183	187	I-Participant
)	10665129	188	189	I-Participant
in	10665129	190	192	O
a	10665129	193	194	O
randomised	10665129	195	205	O
,	10665129	206	207	O
single-blind	10665129	208	220	O
,	10665129	221	222	O
within-patient	10665129	223	237	O
,	10665129	238	239	O
placebo-controlled	10665129	240	258	O
clinical	10665129	259	267	O
study	10665129	268	273	O
.	10665129	274	275	O

Each	10665129	276	280	O
patient	10665129	281	288	O
was	10665129	289	292	O
assigned	10665129	293	301	O
on	10665129	302	304	O
six	10665129	305	308	O
separate	10665129	309	317	O
days	10665129	318	322	O
to	10665129	323	325	O
receive	10665129	326	333	O
one	10665129	334	337	O
of	10665129	338	340	O
the	10665129	341	344	O
following	10665129	345	354	O
drug	10665129	355	359	O
regimens	10665129	360	368	O
in	10665129	369	371	O
random	10665129	372	378	O
order	10665129	379	384	O
:	10665129	385	386	O
A	10665129	387	388	O
.	10665129	389	390	O

40	10665129	391	393	B-Intervention
micrograms	10665129	394	404	I-Intervention
ipratropium	10665129	405	416	I-Intervention
bromide	10665129	417	424	I-Intervention
(	10665129	425	426	I-Intervention
Atrovent	10665129	427	435	I-Intervention
MDI	10665129	436	439	I-Intervention
,	10665129	440	441	I-Intervention
20	10665129	442	444	I-Intervention
micrograms/puff	10665129	445	460	I-Intervention
)	10665129	461	462	I-Intervention
plus	10665129	463	467	I-Intervention
2	10665129	468	469	I-Intervention
puffs	10665129	470	475	I-Intervention
placebo	10665129	476	483	I-Intervention
;	10665129	484	485	O
B	10665129	486	487	O
.	10665129	488	489	O

12	10665129	490	492	B-Intervention
micrograms	10665129	493	503	I-Intervention
formoterol	10665129	504	514	I-Intervention
fumarate	10665129	515	523	I-Intervention
(	10665129	524	525	I-Intervention
Foradil	10665129	526	533	I-Intervention
MDI	10665129	534	537	I-Intervention
,	10665129	538	539	I-Intervention
12	10665129	540	542	I-Intervention
micrograms/puff	10665129	543	558	I-Intervention
)	10665129	559	560	I-Intervention
plus	10665129	561	565	I-Intervention
3	10665129	566	567	I-Intervention
puffs	10665129	568	573	I-Intervention
placebo	10665129	574	581	I-Intervention
;	10665129	582	583	O
C.	10665129	584	586	O
80	10665129	587	589	B-Intervention
micrograms	10665129	590	600	I-Intervention
ipratropium	10665129	601	612	I-Intervention
;	10665129	613	614	O
D.	10665129	615	617	O
24	10665129	618	620	B-Intervention
micrograms	10665129	621	631	I-Intervention
formoterol	10665129	632	642	I-Intervention
plus	10665129	643	647	I-Intervention
2	10665129	648	649	I-Intervention
puffs	10665129	650	655	I-Intervention
placebo	10665129	656	663	I-Intervention
;	10665129	664	665	O
E.	10665129	666	668	O
12	10665129	669	671	B-Intervention
micrograms	10665129	672	682	I-Intervention
formoterol	10665129	683	693	I-Intervention
plus	10665129	694	698	I-Intervention
40	10665129	699	701	I-Intervention
micrograms	10665129	702	712	I-Intervention
ipratropium	10665129	713	724	I-Intervention
plus	10665129	725	729	I-Intervention
1	10665129	730	731	I-Intervention
puff	10665129	732	736	I-Intervention
placebo	10665129	737	744	I-Intervention
;	10665129	745	746	O
F.	10665129	747	749	O
4	10665129	750	751	B-Intervention
puffs	10665129	752	757	I-Intervention
placebo	10665129	758	765	I-Intervention
.	10665129	766	767	O

On	10665129	768	770	O
each	10665129	771	775	O
study	10665129	776	781	O
day	10665129	782	785	O
,	10665129	786	787	O
spirometric	10665129	788	799	B-Outcome
indices	10665129	800	807	I-Outcome
and	10665129	808	811	O
vital	10665129	812	817	B-Outcome
signs	10665129	818	823	I-Outcome
were	10665129	824	828	O
measured	10665129	829	837	O
at	10665129	838	840	O
5	10665129	841	842	O
,	10665129	843	844	O
10	10665129	845	847	O
,	10665129	848	849	O
15	10665129	850	852	O
and	10665129	853	856	O
60	10665129	857	859	O
minutes	10665129	860	867	O
,	10665129	868	869	O
and	10665129	870	873	O
hourly	10665129	874	880	O
thereafter	10665129	881	891	O
up	10665129	892	894	O
to	10665129	895	897	O
and	10665129	898	901	O
including	10665129	902	911	O
12	10665129	912	914	O
hours	10665129	915	920	O
after	10665129	921	926	O
study	10665129	927	932	O
drug	10665129	933	937	O
administration	10665129	938	952	O
.	10665129	953	954	O

Mean	10665129	955	959	B-Outcome
peak	10665129	960	964	I-Outcome
FEV1	10665129	965	969	I-Outcome
change	10665129	970	976	I-Outcome
(	10665129	977	978	O
primary	10665129	979	986	O
endpoint	10665129	987	995	O
)	10665129	996	997	O
was	10665129	998	1001	O
maximum	10665129	1002	1009	B-Observation
with	10665129	1010	1014	O
the	10665129	1015	1018	O
administration	10665129	1019	1033	O
of	10665129	1034	1036	O
the	10665129	1037	1040	O
combination	10665129	1041	1052	B-Intervention
of	10665129	1053	1055	I-Intervention
ipratropium	10665129	1056	1067	I-Intervention
and	10665129	1068	1071	I-Intervention
formoterol	10665129	1072	1082	I-Intervention
(	10665129	1083	1084	O
335.2	10665129	1085	1090	B-Observation
ml	10665129	1091	1093	I-Observation
,	10665129	1094	1095	O
SE	10665129	1096	1098	O
24.6	10665129	1099	1103	O
)	10665129	1104	1105	O
,	10665129	1106	1107	O
and	10665129	1108	1111	O
it	10665129	1112	1114	O
differed	10665129	1115	1123	B-Observation
significantly	10665129	1124	1137	I-Observation
from	10665129	1138	1142	O
the	10665129	1143	1146	O
observed	10665129	1147	1155	B-Outcome
peak	10665129	1156	1160	I-Outcome
changes	10665129	1161	1168	I-Outcome
following	10665129	1169	1178	O
single	10665129	1179	1185	O
administration	10665129	1186	1200	O
of	10665129	1201	1203	O
the	10665129	1204	1207	O
two	10665129	1208	1211	B-Intervention
tested	10665129	1212	1218	I-Intervention
doses	10665129	1219	1224	I-Intervention
of	10665129	1225	1227	I-Intervention
ipratropium	10665129	1228	1239	I-Intervention
(	10665129	1240	1241	O
p	10665129	1242	1243	O
<	10665129	1244	1245	O
0.05	10665129	1246	1250	O
and	10665129	1251	1254	O
p	10665129	1255	1256	O
<	10665129	1257	1258	O
0.05	10665129	1259	1263	O
respectively	10665129	1264	1276	O
)	10665129	1277	1278	O
.	10665129	1279	1280	O

Safety	10665129	1281	1287	B-Outcome
and	10665129	1288	1291	O
tolerability	10665129	1292	1304	B-Outcome
were	10665129	1305	1309	O
satisfactory	10665129	1310	1322	B-Observation
throughout	10665129	1323	1333	O
the	10665129	1334	1337	O
study	10665129	1338	1343	O
.	10665129	1344	1345	O

Granulocyte-macrophage	10671339	0	22	B-Intervention
colony-stimulating	10671339	23	41	I-Intervention
factor	10671339	42	48	I-Intervention
as	10671339	49	51	O
immunomodulating	10671339	52	68	O
factor	10671339	69	75	O
together	10671339	76	84	O
with	10671339	85	89	O
influenza	10671339	90	99	B-Participant
vaccination	10671339	100	111	I-Participant
in	10671339	112	114	O
stem	10671339	115	119	B-Participant
cell	10671339	120	124	I-Participant
transplant	10671339	125	135	I-Participant
patients	10671339	136	144	O
.	10671339	145	146	O

The	10671339	147	150	O
effect	10671339	151	157	O
of	10671339	158	160	O
granulocyte-macrophage	10671339	161	183	B-Intervention
colony-stimulating	10671339	184	202	I-Intervention
factor	10671339	203	209	I-Intervention
(	10671339	210	211	I-Intervention
GM-CSF	10671339	212	218	I-Intervention
)	10671339	219	220	I-Intervention
on	10671339	221	223	O
the	10671339	224	227	O
serological	10671339	228	239	B-Outcome
response	10671339	240	248	I-Outcome
at	10671339	249	251	I-Outcome
influenza	10671339	252	261	I-Outcome
vaccination	10671339	262	273	I-Outcome
was	10671339	274	277	O
studied	10671339	278	285	O
in	10671339	286	288	O
117	10671339	289	292	O
patients	10671339	293	301	O
who	10671339	302	305	O
had	10671339	306	309	O
undergone	10671339	310	319	O
stem	10671339	320	324	B-Participant
cell	10671339	325	329	I-Participant
transplantation	10671339	330	345	I-Participant
(	10671339	346	347	I-Participant
SCT	10671339	348	351	I-Participant
)	10671339	352	353	I-Participant
.	10671339	354	355	O

The	10671339	356	359	O
vaccine	10671339	360	367	B-Outcome
response	10671339	368	376	I-Outcome
was	10671339	377	380	O
evaluated	10671339	381	390	O
as	10671339	391	393	O
significant	10671339	394	405	B-Observation
increases	10671339	406	415	I-Observation
in	10671339	416	418	O
levels	10671339	419	425	B-Outcome
of	10671339	426	428	I-Outcome
influenza	10671339	429	438	I-Outcome
hemagglutination-inhibition	10671339	439	466	I-Outcome
(	10671339	467	468	I-Outcome
HAI	10671339	469	472	I-Outcome
)	10671339	473	474	I-Outcome
antibodies	10671339	475	485	I-Outcome
and	10671339	486	489	I-Outcome
of	10671339	490	492	I-Outcome
IgG	10671339	493	496	I-Outcome
antibodies	10671339	497	507	I-Outcome
measured	10671339	508	516	O
by	10671339	517	519	O
enzyme-linked	10671339	520	533	O
immunosorbent	10671339	534	547	O
assay	10671339	548	553	O
(	10671339	554	555	O
ELISA	10671339	556	561	O
)	10671339	562	563	O
.	10671339	564	565	O

There	10671339	566	571	O
was	10671339	572	575	O
no	10671339	576	578	O
difference	10671339	579	589	B-Observation
in	10671339	590	592	O
antibody	10671339	593	601	B-Outcome
response	10671339	602	610	I-Outcome
to	10671339	611	613	I-Outcome
either	10671339	614	620	I-Outcome
influenza	10671339	621	630	I-Outcome
A	10671339	631	632	I-Outcome
or	10671339	633	635	I-Outcome
B	10671339	636	637	I-Outcome
in	10671339	638	640	O
64	10671339	641	643	O
patients	10671339	644	652	O
who	10671339	653	656	O
received	10671339	657	665	O
GM-CSF	10671339	666	672	B-Intervention
at	10671339	673	675	O
vaccination	10671339	676	687	O
,	10671339	688	689	O
compared	10671339	690	698	O
with	10671339	699	703	O
the	10671339	704	707	O
53	10671339	708	710	O
who	10671339	711	714	O
did	10671339	715	718	O
not	10671339	719	722	B-Intervention
.	10671339	723	724	O

In	10671339	725	727	O
the	10671339	728	731	O
subgroup	10671339	732	740	O
of	10671339	741	743	O
allogeneic	10671339	744	754	B-Participant
SCT	10671339	755	758	I-Participant
patients	10671339	759	767	O
,	10671339	768	769	O
HAI	10671339	770	773	B-Outcome
showed	10671339	774	780	O
that	10671339	781	785	O
the	10671339	786	789	O
response	10671339	790	798	B-Outcome
rate	10671339	799	803	I-Outcome
to	10671339	804	806	I-Outcome
the	10671339	807	810	I-Outcome
influenza	10671339	811	820	I-Outcome
B	10671339	821	822	I-Outcome
vaccine	10671339	823	830	I-Outcome
was	10671339	831	834	O
significantly	10671339	835	848	B-Observation
higher	10671339	849	855	I-Observation
in	10671339	856	858	O
the	10671339	859	862	O
treatment	10671339	863	872	B-Intervention
group	10671339	873	878	O
(	10671339	879	880	O
P	10671339	881	882	O
<	10671339	883	884	O
.05	10671339	885	888	O
)	10671339	889	890	O
.	10671339	891	892	O

ELISA	10671339	893	898	O
showed	10671339	899	905	O
that	10671339	906	910	O
autologous	10671339	911	921	B-Participant
SCT	10671339	922	925	I-Participant
patients	10671339	926	934	I-Participant
with	10671339	935	939	I-Participant
breast	10671339	940	946	I-Participant
cancer	10671339	947	953	I-Participant
who	10671339	954	957	O
received	10671339	958	966	O
GM-CSF	10671339	967	973	B-Intervention
had	10671339	974	977	O
a	10671339	978	979	O
better	10671339	980	986	B-Observation
response	10671339	987	995	B-Outcome
to	10671339	996	998	I-Outcome
influenza	10671339	999	1008	I-Outcome
A	10671339	1009	1010	I-Outcome
(	10671339	1011	1012	I-Outcome
P	10671339	1013	1014	I-Outcome
<	10671339	1015	1016	I-Outcome
.05	10671339	1017	1020	I-Outcome
)	10671339	1021	1022	I-Outcome
and	10671339	1023	1026	I-Outcome
B	10671339	1027	1028	I-Outcome
(	10671339	1029	1030	I-Outcome
P	10671339	1031	1032	I-Outcome
<	10671339	1033	1034	I-Outcome
.01	10671339	1035	1038	I-Outcome
)	10671339	1039	1040	I-Outcome
.	10671339	1041	1042	O

At	10671339	1043	1045	O
early	10671339	1046	1051	O
vaccination	10671339	1052	1063	O
,	10671339	1064	1065	O
4	10671339	1066	1067	O
-	10671339	1067	1068	O
12	10671339	1068	1070	O
months	10671339	1071	1077	O
after	10671339	1078	1083	O
stem	10671339	1084	1088	B-Participant
cell	10671339	1089	1093	I-Participant
transplantation	10671339	1094	1109	I-Participant
,	10671339	1110	1111	O
these	10671339	1112	1117	O
responses	10671339	1118	1127	B-Outcome
were	10671339	1128	1132	O
more	10671339	1133	1137	B-Observation
pronounced	10671339	1138	1148	I-Observation
.	10671339	1149	1150	O

GM-CSF	10671339	1151	1157	B-Intervention
appears	10671339	1158	1165	O
to	10671339	1166	1168	O
improve	10671339	1169	1176	B-Observation
the	10671339	1177	1180	O
response	10671339	1181	1189	B-Outcome
to	10671339	1190	1192	I-Outcome
influenza	10671339	1193	1202	I-Outcome
vaccination	10671339	1203	1214	I-Outcome
in	10671339	1215	1217	O
some	10671339	1218	1222	O
groups	10671339	1223	1229	O
of	10671339	1230	1232	O
SCT	10671339	1233	1236	B-Participant
patients	10671339	1237	1245	O
,	10671339	1246	1247	O
but	10671339	1248	1251	O
only	10671339	1252	1256	O
to	10671339	1257	1259	O
a	10671339	1260	1261	O
limited	10671339	1262	1269	B-Observation
extent	10671339	1270	1276	I-Observation
.	10671339	1277	1278	O

Assessment	10674680	0	10	O
of	10674680	11	13	O
therapeutic	10674680	14	25	B-Outcome
response	10674680	26	34	I-Outcome
of	10674680	35	37	O
Plasmodium	10674680	38	48	B-Participant
falciparum	10674680	49	59	I-Participant
to	10674680	60	62	O
chloroquine	10674680	63	74	B-Intervention
and	10674680	75	78	O
sulfadoxine-pyrimethamine	10674680	79	104	B-Intervention
in	10674680	105	107	O
an	10674680	108	110	O
area	10674680	111	115	B-Participant
of	10674680	116	118	I-Participant
low	10674680	119	122	I-Participant
malaria	10674680	123	130	I-Participant
transmission	10674680	131	143	I-Participant
in	10674680	144	146	O
Colombia	10674680	147	155	O
.	10674680	156	157	O

Although	10674680	158	166	O
chloroquine	10674680	167	178	O
(	10674680	179	180	O
CQ	10674680	181	183	O
)	10674680	184	185	O
resistance	10674680	186	196	O
was	10674680	197	200	O
first	10674680	201	206	O
reported	10674680	207	215	O
in	10674680	216	218	O
Colombia	10674680	219	227	O
in	10674680	228	230	O
1961	10674680	231	235	O
and	10674680	236	239	O
sulfadoxine-pyrimethamine	10674680	240	265	O
(	10674680	266	267	O
SP	10674680	268	270	O
)	10674680	271	272	O
resistance	10674680	273	283	O
in	10674680	284	286	O
1981	10674680	287	291	O
,	10674680	292	293	O
the	10674680	294	297	O
frequency	10674680	298	307	O
of	10674680	308	310	O
treatment	10674680	311	320	O
failures	10674680	321	329	O
to	10674680	330	332	O
these	10674680	333	338	O
drugs	10674680	339	344	O
in	10674680	345	347	O
Colombia	10674680	348	356	O
is	10674680	357	359	O
unclear	10674680	360	367	O
.	10674680	368	369	O

A	10674680	370	371	O
modified	10674680	372	380	B-Outcome
World	10674680	381	386	I-Outcome
Health	10674680	387	393	I-Outcome
Organization	10674680	394	406	I-Outcome
14-day	10674680	407	413	I-Outcome
in	10674680	414	416	I-Outcome
vivo	10674680	417	421	I-Outcome
drug	10674680	422	426	I-Outcome
efficacy	10674680	427	435	I-Outcome
test	10674680	436	440	I-Outcome
for	10674680	441	444	O
uncomplicated	10674680	445	458	B-Participant
Plasmodium	10674680	459	469	I-Participant
falciparum	10674680	470	480	I-Participant
malaria	10674680	481	488	I-Participant
in	10674680	489	491	O
areas	10674680	492	497	O
with	10674680	498	502	O
intense	10674680	503	510	B-Participant
malaria	10674680	511	518	I-Participant
transmission	10674680	519	531	I-Participant
was	10674680	532	535	O
adapted	10674680	536	543	O
to	10674680	544	546	O
reflect	10674680	547	554	O
the	10674680	555	558	O
clinical	10674680	559	567	B-Outcome
and	10674680	568	571	I-Outcome
epidemiologic	10674680	572	585	I-Outcome
features	10674680	586	594	I-Outcome
of	10674680	595	597	O
a	10674680	598	599	O
low-intensity	10674680	600	613	B-Participant
malaria	10674680	614	621	I-Participant
transmission	10674680	622	634	I-Participant
area	10674680	635	639	I-Participant
in	10674680	640	642	O
the	10674680	643	646	O
Pacific	10674680	647	654	O
Coast	10674680	655	660	O
Region	10674680	661	667	O
of	10674680	668	670	O
Colombia	10674680	671	679	O
.	10674680	680	681	O

Patients	10674680	682	690	O
>	10674680	691	692	B-Participant
or	10674680	693	695	I-Participant
=	10674680	696	697	I-Participant
1	10674680	697	698	I-Participant
year	10674680	699	703	I-Participant
of	10674680	704	706	I-Participant
age	10674680	707	710	I-Participant
with	10674680	711	715	O
a	10674680	716	717	O
parasite	10674680	718	726	B-Participant
density	10674680	727	734	I-Participant
>	10674680	735	736	I-Participant
or	10674680	737	739	I-Participant
=	10674680	740	741	I-Participant
1,000	10674680	741	746	I-Participant
asexual	10674680	747	754	I-Participant
parasites	10674680	755	764	I-Participant
per	10674680	765	768	I-Participant
microliter	10674680	769	779	I-Participant
were	10674680	780	784	O
enrolled	10674680	785	793	O
in	10674680	794	796	O
this	10674680	797	801	O
study	10674680	802	807	O
.	10674680	808	809	O

Forty-four	10674680	810	820	B-Count
percent	10674680	821	828	I-Count
(	10674680	829	830	I-Count
24	10674680	831	833	I-Count
of	10674680	834	836	I-Count
54	10674680	837	839	I-Count
)	10674680	840	841	I-Count
of	10674680	842	844	O
the	10674680	845	848	O
CQ-treated	10674680	849	859	B-Intervention
patients	10674680	860	868	O
were	10674680	869	873	O
therapeutic	10674680	874	885	B-Outcome
failures	10674680	886	894	I-Outcome
,	10674680	895	896	O
including	10674680	897	906	O
7	10674680	907	908	B-Count
early	10674680	909	914	B-Outcome
treatment	10674680	915	924	I-Outcome
failures	10674680	925	933	I-Outcome
(	10674680	934	935	I-Outcome
ETFs	10674680	936	940	I-Outcome
)	10674680	941	942	I-Outcome
and	10674680	943	946	O
17	10674680	947	949	B-Count
late	10674680	950	954	B-Outcome
treatment	10674680	955	964	I-Outcome
failures	10674680	965	973	I-Outcome
(	10674680	974	975	I-Outcome
LTFs	10674680	976	980	I-Outcome
)	10674680	981	982	I-Outcome
.	10674680	983	984	O

Four	10674680	985	989	B-Count
(	10674680	990	991	I-Count
6	10674680	992	993	I-Count
%	10674680	994	995	I-Count
)	10674680	996	997	I-Count
of	10674680	998	1000	I-Count
67	10674680	1001	1003	I-Count
SP-treated	10674680	1004	1014	B-Intervention
patients	10674680	1015	1023	O
were	10674680	1024	1028	O
therapeutic	10674680	1029	1040	B-Outcome
failures	10674680	1041	1049	I-Outcome
(	10674680	1050	1051	O
2	10674680	1052	1053	B-Count
ETFs	10674680	1054	1058	B-Outcome
and	10674680	1059	1062	O
2	10674680	1063	1064	B-Count
LTFs	10674680	1065	1069	B-Outcome
)	10674680	1070	1071	O
.	10674680	1072	1073	O

Therapeutic	10674680	1074	1085	B-Outcome
failure	10674680	1086	1093	I-Outcome
in	10674680	1094	1096	O
the	10674680	1097	1100	O
CQ-treated	10674680	1101	1111	B-Intervention
group	10674680	1112	1117	O
was	10674680	1118	1121	O
associated	10674680	1122	1132	B-Observation
with	10674680	1133	1137	O
an	10674680	1138	1140	O
age	10674680	1141	1144	B-Participant
<	10674680	1145	1146	I-Participant
15	10674680	1147	1149	I-Participant
years	10674680	1150	1155	I-Participant
old	10674680	1156	1159	I-Participant
(	10674680	1160	1161	O
P	10674680	1162	1163	O
<	10674680	1164	1165	O
0.01	10674680	1166	1170	O
)	10674680	1171	1172	O
,	10674680	1173	1174	O
but	10674680	1175	1178	O
was	10674680	1179	1182	O
not	10674680	1183	1186	O
associated	10674680	1187	1197	B-Observation
with	10674680	1198	1202	O
initial	10674680	1203	1210	B-Participant
parasite	10674680	1211	1219	I-Participant
density	10674680	1220	1227	I-Participant
,	10674680	1228	1229	O
the	10674680	1230	1233	O
presence	10674680	1234	1242	B-Participant
of	10674680	1243	1245	I-Participant
CQ	10674680	1246	1248	I-Participant
or	10674680	1249	1251	I-Participant
sulfa-containing	10674680	1252	1268	I-Participant
drugs	10674680	1269	1274	I-Participant
in	10674680	1275	1277	I-Participant
urine	10674680	1278	1283	I-Participant
,	10674680	1284	1285	O
or	10674680	1286	1288	O
a	10674680	1289	1290	O
history	10674680	1291	1298	B-Participant
of	10674680	1299	1301	I-Participant
malaria	10674680	1302	1309	I-Participant
.	10674680	1310	1311	O

The	10674680	1312	1315	O
high	10674680	1316	1320	B-Observation
level	10674680	1321	1326	B-Outcome
of	10674680	1327	1329	I-Outcome
therapeutic	10674680	1330	1341	I-Outcome
failures	10674680	1342	1350	I-Outcome
to	10674680	1351	1353	O
CQ	10674680	1354	1356	B-Intervention
detected	10674680	1357	1365	O
in	10674680	1366	1368	O
this	10674680	1369	1373	O
study	10674680	1374	1379	O
underscores	10674680	1380	1391	O
the	10674680	1392	1395	O
need	10674680	1396	1400	O
and	10674680	1401	1404	O
importance	10674680	1405	1415	O
of	10674680	1416	1418	O
drug	10674680	1419	1423	O
efficacy	10674680	1424	1432	O
evaluation	10674680	1433	1443	O
in	10674680	1444	1446	O
the	10674680	1447	1450	O
development	10674680	1451	1462	O
of	10674680	1463	1465	O
a	10674680	1466	1467	O
rational	10674680	1468	1476	O
national	10674680	1477	1485	O
antimalarial	10674680	1486	1498	O
drug	10674680	1499	1503	O
policy	10674680	1504	1510	O
.	10674680	1511	1512	O

The	10674680	1513	1516	O
relatively	10674680	1517	1527	B-Observation
low	10674680	1528	1531	I-Observation
level	10674680	1532	1537	B-Outcome
of	10674680	1538	1540	I-Outcome
therapeutic	10674680	1541	1552	I-Outcome
failures	10674680	1553	1561	I-Outcome
to	10674680	1562	1564	O
SP	10674680	1565	1567	B-Intervention
compared	10674680	1568	1576	O
with	10674680	1577	1581	O
other	10674680	1582	1587	O
South	10674680	1588	1593	O
American	10674680	1594	1602	O
countries	10674680	1603	1612	O
raises	10674680	1613	1619	O
further	10674680	1620	1627	O
questions	10674680	1628	1637	O
regarding	10674680	1638	1647	O
factors	10674680	1648	1655	O
that	10674680	1656	1660	O
might	10674680	1661	1666	O
have	10674680	1667	1671	O
prevented	10674680	1672	1681	O
the	10674680	1682	1685	O
rapid	10674680	1686	1691	O
development	10674680	1692	1703	O
of	10674680	1704	1706	O
in	10674680	1707	1709	O
vivo	10674680	1710	1714	O
resistance	10674680	1715	1725	O
to	10674680	1726	1728	O
this	10674680	1729	1733	O
drug	10674680	1734	1738	O
combination	10674680	1739	1750	O
.	10674680	1751	1752	O

Efficacy	10674681	0	8	O
of	10674681	9	11	O
primaquine	10674681	12	22	B-Intervention
regimens	10674681	23	31	I-Intervention
for	10674681	32	35	O
primaquine-resistant	10674681	36	56	B-Participant
Plasmodium	10674681	57	67	I-Participant
vivax	10674681	68	73	I-Participant
malaria	10674681	74	81	I-Participant
in	10674681	82	84	O
Thailand	10674681	85	93	O
.	10674681	94	95	O

To	10674681	96	98	O
define	10674681	99	105	O
the	10674681	106	109	O
current	10674681	110	117	O
efficacy	10674681	118	126	B-Outcome
of	10674681	127	129	O
Fansidar	10674681	130	138	B-Intervention
(	10674681	139	140	O
F.	10674681	141	143	O
Hoffmann-La	10674681	144	155	O
Roche	10674681	156	161	O
Ltd.	10674681	162	166	O
,	10674681	167	168	O
Basel	10674681	169	174	O
Switzerland	10674681	175	186	O
)	10674681	187	188	O
(	10674681	189	190	O
pyrimethamine	10674681	191	204	B-Intervention
and	10674681	205	208	I-Intervention
sulfadoxine	10674681	209	220	I-Intervention
)	10674681	221	222	O
,	10674681	223	224	O
primaquine	10674681	225	235	B-Intervention
in	10674681	236	238	I-Intervention
a	10674681	239	240	I-Intervention
high	10674681	241	245	I-Intervention
dose	10674681	246	250	I-Intervention
,	10674681	251	252	O
and	10674681	253	256	O
artesunate	10674681	257	267	B-Intervention
for	10674681	268	271	O
treating	10674681	272	280	O
acute	10674681	281	286	B-Participant
Plasmodium	10674681	287	297	I-Participant
vivax	10674681	298	303	I-Participant
malaria	10674681	304	311	I-Participant
,	10674681	312	313	O
we	10674681	314	316	O
conducted	10674681	317	326	O
a	10674681	327	328	O
comparative	10674681	329	340	O
clinical	10674681	341	349	O
trial	10674681	350	355	O
of	10674681	356	358	O
these	10674681	359	364	O
3	10674681	365	366	O
drugs	10674681	367	372	O
in	10674681	373	375	O
an	10674681	376	378	O
open-label	10674681	379	389	O
study	10674681	390	395	O
.	10674681	396	397	O

Patients	10674681	398	406	O
(	10674681	407	408	O
15	10674681	409	411	O
-	10674681	411	412	O
65	10674681	412	414	O
years	10674681	415	420	O
old	10674681	421	424	O
)	10674681	425	426	O
were	10674681	427	431	O
assigned	10674681	432	440	O
to	10674681	441	443	O
1	10674681	444	445	O
of	10674681	446	448	O
4	10674681	449	450	O
treatments	10674681	451	461	O
regimens	10674681	462	470	O
in	10674681	471	473	O
a	10674681	474	475	O
serial	10674681	476	482	O
order	10674681	483	488	O
.	10674681	489	490	O

Ninety	10674681	491	497	O
percent	10674681	498	505	O
of	10674681	506	508	O
the	10674681	509	512	O
patients	10674681	513	521	O
were	10674681	522	526	O
infected	10674681	527	535	O
at	10674681	536	538	O
Thailand-Myanmar	10674681	539	555	B-Participant
border	10674681	556	562	I-Participant
.	10674681	563	564	O

Patients	10674681	565	573	O
in	10674681	574	576	O
group	10674681	577	582	O
I	10674681	583	584	O
(	10674681	585	586	O
n	10674681	587	588	O
=	10674681	589	590	O
23	10674681	591	593	O
)	10674681	594	595	O
received	10674681	596	604	O
Fansidar	10674681	605	613	B-Intervention
(	10674681	614	615	O
3	10674681	616	617	O
tablets	10674681	618	625	O
,	10674681	626	627	O
75	10674681	628	630	O
mg	10674681	631	633	O
of	10674681	634	636	O
pyrimethamine	10674681	637	650	O
and	10674681	651	654	O
1,500	10674681	655	660	O
mg	10674681	661	663	O
of	10674681	664	666	O
sulfadoxine	10674681	667	678	O
,	10674681	679	680	O
a	10674681	681	682	O
single	10674681	683	689	O
dose	10674681	690	694	O
on	10674681	695	697	O
the	10674681	698	701	O
first	10674681	702	707	O
day	10674681	708	711	O
)	10674681	712	713	O
,	10674681	714	715	O
group	10674681	716	721	O
II	10674681	722	724	O
(	10674681	725	726	O
n	10674681	727	728	O
=	10674681	729	730	O
23	10674681	731	733	O
)	10674681	734	735	O
received	10674681	736	744	O
Fansidar	10674681	745	753	B-Intervention
(	10674681	754	755	O
3	10674681	756	757	O
tablets	10674681	758	765	O
,	10674681	766	767	O
75	10674681	768	770	O
mg	10674681	771	773	O
of	10674681	774	776	O
pyrimethamine	10674681	777	790	O
and	10674681	791	794	O
1,500	10674681	795	800	O
mg	10674681	801	803	O
of	10674681	804	806	O
sulfadoxine	10674681	807	818	O
,	10674681	819	820	O
a	10674681	821	822	O
single	10674681	823	829	O
dose	10674681	830	834	O
on	10674681	835	837	O
the	10674681	838	841	O
first	10674681	842	847	O
day	10674681	848	851	O
)	10674681	852	853	O
and	10674681	854	857	O
then	10674681	858	862	O
received	10674681	863	871	O
primaquine	10674681	872	882	B-Intervention
(	10674681	883	884	O
30	10674681	885	887	O
mg	10674681	888	890	O
a	10674681	891	892	O
day	10674681	893	896	O
for	10674681	897	900	O
14	10674681	901	903	O
days	10674681	904	908	O
)	10674681	909	910	O
,	10674681	911	912	O
group	10674681	913	918	O
III	10674681	919	922	O
(	10674681	923	924	O
n	10674681	925	926	O
=	10674681	927	928	O
23	10674681	929	931	O
)	10674681	932	933	O
received	10674681	934	942	O
primaquine	10674681	943	953	B-Intervention
(	10674681	954	955	O
30	10674681	956	958	O
mg	10674681	959	961	O
a	10674681	962	963	O
day	10674681	964	967	O
for	10674681	968	971	O
14	10674681	972	974	O
days	10674681	975	979	O
)	10674681	980	981	O
,	10674681	982	983	O
and	10674681	984	987	O
group	10674681	988	993	O
IV	10674681	994	996	O
(	10674681	997	998	O
n	10674681	999	1000	O
=	10674681	1001	1002	O
23	10674681	1003	1005	O
)	10674681	1006	1007	O
received	10674681	1008	1016	O
artesunate	10674681	1017	1027	B-Intervention
(	10674681	1028	1029	O
200	10674681	1030	1033	O
mg	10674681	1034	1036	O
once	10674681	1037	1041	O
a	10674681	1042	1043	O
day	10674681	1044	1047	O
for	10674681	1048	1051	O
3	10674681	1052	1053	O
days	10674681	1054	1058	O
)	10674681	1059	1060	O
and	10674681	1061	1064	O
then	10674681	1065	1069	O
primaquine	10674681	1070	1080	B-Intervention
(	10674681	1081	1082	O
30	10674681	1083	1085	O
mg	10674681	1086	1088	O
a	10674681	1089	1090	O
day	10674681	1091	1094	O
for	10674681	1095	1098	O
14	10674681	1099	1101	O
days	10674681	1102	1106	O
)	10674681	1107	1108	O
.	10674681	1109	1110	O

Cure	10674681	1111	1115	B-Outcome
rates	10674681	1116	1121	I-Outcome
on	10674681	1122	1124	O
day	10674681	1125	1128	O
28	10674681	1129	1131	O
of	10674681	1132	1134	O
follow-up	10674681	1135	1144	O
were	10674681	1145	1149	O
40	10674681	1150	1152	B-Observation
%	10674681	1153	1154	I-Observation
,	10674681	1155	1156	O
100	10674681	1157	1160	B-Observation
%	10674681	1161	1162	I-Observation
,	10674681	1163	1164	O
100	10674681	1165	1168	B-Observation
%	10674681	1169	1170	I-Observation
,	10674681	1171	1172	O
and	10674681	1173	1176	O
100	10674681	1177	1180	B-Observation
%	10674681	1181	1182	I-Observation
in	10674681	1183	1185	O
groups	10674681	1186	1192	B-Intervention
I	10674681	1193	1194	I-Intervention
,	10674681	1195	1196	O
II	10674681	1197	1199	B-Intervention
,	10674681	1200	1201	O
II	10674681	1202	1204	B-Intervention
,	10674681	1205	1206	O
and	10674681	1207	1210	O
IV	10674681	1211	1213	B-Intervention
,	10674681	1214	1215	O
respectively	10674681	1216	1228	O
.	10674681	1229	1230	O

There	10674681	1231	1236	O
were	10674681	1237	1241	O
4	10674681	1242	1243	B-Count
and	10674681	1244	1247	I-Count
5	10674681	1248	1249	I-Count
patients	10674681	1250	1258	I-Count
in	10674681	1259	1261	O
group	10674681	1262	1267	B-Intervention
I	10674681	1268	1269	I-Intervention
showing	10674681	1270	1277	O
post-treatment	10674681	1278	1292	B-Outcome
reappearance	10674681	1293	1305	I-Outcome
of	10674681	1306	1308	I-Outcome
parasitemia	10674681	1309	1320	I-Outcome
at	10674681	1321	1323	O
<	10674681	1324	1325	O
or	10674681	1326	1328	O
=	10674681	1329	1330	O
16	10674681	1331	1333	O
days	10674681	1334	1338	O
and	10674681	1339	1342	O
between	10674681	1343	1350	O
17	10674681	1351	1353	O
and	10674681	1354	1357	O
28	10674681	1358	1360	O
days	10674681	1361	1365	O
,	10674681	1366	1367	O
respectively	10674681	1368	1380	O
.	10674681	1381	1382	O

Patients	10674681	1383	1391	O
in	10674681	1392	1394	O
the	10674681	1395	1398	O
other	10674681	1399	1404	B-Intervention
3	10674681	1405	1406	I-Intervention
groups	10674681	1407	1413	I-Intervention
showed	10674681	1414	1420	O
negative	10674681	1421	1429	B-Observation
parasitemias	10674681	1430	1442	B-Outcome
within	10674681	1443	1449	O
7	10674681	1450	1451	O
days	10674681	1452	1456	O
after	10674681	1457	1462	O
treatment	10674681	1463	1472	O
.	10674681	1473	1474	O

Artesunate	10674681	1475	1485	B-Intervention
plus	10674681	1486	1490	I-Intervention
primaquine	10674681	1491	1501	I-Intervention
(	10674681	1502	1503	O
group	10674681	1504	1509	O
IV	10674681	1510	1512	O
)	10674681	1513	1514	O
cleared	10674681	1515	1522	B-Outcome
parasitemia	10674681	1523	1534	I-Outcome
faster	10674681	1535	1541	B-Observation
than	10674681	1542	1546	O
the	10674681	1547	1550	O
other	10674681	1551	1556	B-Intervention
3	10674681	1557	1558	I-Intervention
regimens	10674681	1559	1567	I-Intervention
.	10674681	1568	1569	O

There	10674681	1570	1575	O
is	10674681	1576	1578	O
a	10674681	1579	1580	O
high	10674681	1581	1585	B-Observation
proportion	10674681	1586	1596	I-Observation
of	10674681	1597	1599	O
ineffectiveness	10674681	1600	1615	B-Outcome
of	10674681	1616	1618	O
Fansidar	10674681	1619	1627	B-Intervention
for	10674681	1628	1631	O
treatment	10674681	1632	1641	O
of	10674681	1642	1644	O
P.	10674681	1645	1647	B-Participant
vivax	10674681	1648	1653	I-Participant
malaria	10674681	1654	1661	I-Participant
and	10674681	1662	1665	O
it	10674681	1666	1668	O
should	10674681	1669	1675	O
be	10674681	1676	1678	O
no	10674681	1679	1681	O
longer	10674681	1682	1688	O
used	10674681	1689	1693	O
for	10674681	1694	1697	O
treatment	10674681	1698	1707	O
of	10674681	1708	1710	O
P.	10674681	1711	1713	B-Participant
vivax	10674681	1714	1719	I-Participant
malaria	10674681	1720	1727	I-Participant
acquired	10674681	1728	1736	O
at	10674681	1737	1739	O
the	10674681	1740	1743	O
Thailand-Myanmar	10674681	1744	1760	O
border	10674681	1761	1767	O
.	10674681	1768	1769	O

A	10674681	1770	1771	O
high	10674681	1772	1776	B-Intervention
dose	10674681	1777	1781	I-Intervention
of	10674681	1782	1784	I-Intervention
primaquine	10674681	1785	1795	I-Intervention
is	10674681	1796	1798	O
safe	10674681	1799	1803	B-Observation
and	10674681	1804	1807	O
effective	10674681	1808	1817	B-Observation
in	10674681	1818	1820	O
the	10674681	1821	1824	O
treatment	10674681	1825	1834	O
of	10674681	1835	1837	O
P.	10674681	1838	1840	B-Participant
vivax	10674681	1841	1846	I-Participant
malaria	10674681	1847	1854	I-Participant
during	10674681	1855	1861	O
the	10674681	1862	1865	O
28-day	10674681	1866	1872	O
follow-up	10674681	1873	1882	O
period	10674681	1883	1889	O
.	10674681	1890	1891	O

Safety	10678548	0	6	B-Outcome
of	10678548	7	9	O
the	10678548	10	13	O
combination	10678548	14	25	B-Intervention
of	10678548	26	28	I-Intervention
valsartan	10678548	29	38	I-Intervention
and	10678548	39	42	I-Intervention
benazepril	10678548	43	53	I-Intervention
in	10678548	54	56	O
patients	10678548	57	65	O
with	10678548	66	70	O
chronic	10678548	71	78	B-Participant
renal	10678548	79	84	I-Participant
disease	10678548	85	92	I-Participant
.	10678548	93	94	O

European	10678548	95	103	O
Group	10678548	104	109	O
for	10678548	110	113	O
the	10678548	114	117	O
Investigation	10678548	118	131	O
of	10678548	132	134	O
Valsartan	10678548	135	144	B-Intervention
in	10678548	145	147	O
Chronic	10678548	148	155	B-Participant
Renal	10678548	156	161	I-Participant
Disease	10678548	162	169	I-Participant
.	10678548	170	171	O

OBJECTIVE	10678548	172	181	O
Several	10678548	182	189	O
experimental	10678548	190	202	O
and	10678548	203	206	O
clinical	10678548	207	215	O
studies	10678548	216	223	O
indicate	10678548	224	232	O
that	10678548	233	237	O
the	10678548	238	241	O
renin	10678548	242	247	O
system	10678548	248	254	O
may	10678548	255	258	O
play	10678548	259	263	O
a	10678548	264	265	O
pivotal	10678548	266	273	O
role	10678548	274	278	O
in	10678548	279	281	O
progressing	10678548	282	293	O
renal	10678548	294	299	O
disease	10678548	300	307	O
.	10678548	308	309	O

The	10678548	310	313	O
combination	10678548	314	325	O
of	10678548	326	328	O
an	10678548	329	331	O
angiotensin-converting	10678548	332	354	O
enzyme	10678548	355	361	O
inhibitor	10678548	362	371	O
and	10678548	372	375	O
an	10678548	376	378	O
angiotensin	10678548	379	390	O
receptor	10678548	391	399	O
blocker	10678548	400	407	O
could	10678548	408	413	O
provide	10678548	414	421	O
a	10678548	422	423	O
higher	10678548	424	430	O
degree	10678548	431	437	O
of	10678548	438	440	O
blockade	10678548	441	449	O
of	10678548	450	452	O
the	10678548	453	456	O
renin-angiotensin	10678548	457	474	O
system	10678548	475	481	O
than	10678548	482	486	O
either	10678548	487	493	O
agent	10678548	494	499	O
alone	10678548	500	505	O
.	10678548	506	507	O

Such	10678548	508	512	O
enhanced	10678548	513	521	O
suppression	10678548	522	533	O
might	10678548	534	539	O
be	10678548	540	542	O
of	10678548	543	545	O
benefit	10678548	546	553	O
for	10678548	554	557	O
patients	10678548	558	566	O
exhibiting	10678548	567	577	O
a	10678548	578	579	O
progressive	10678548	580	591	O
decline	10678548	592	599	O
in	10678548	600	602	O
renal	10678548	603	608	O
function	10678548	609	617	O
because	10678548	618	625	O
of	10678548	626	628	O
chronic	10678548	629	636	O
renal	10678548	637	642	O
disease	10678548	643	650	O
.	10678548	651	652	O

METHODS	10678548	653	660	O
A	10678548	661	662	O
pilot	10678548	663	668	O
multinational	10678548	669	682	O
,	10678548	683	684	O
multicentre	10678548	685	696	O
,	10678548	697	698	O
randomized	10678548	699	709	O
,	10678548	710	711	O
active-controlled	10678548	712	729	O
,	10678548	730	731	O
parallel	10678548	732	740	O
group	10678548	741	746	O
open-label	10678548	747	757	O
study	10678548	758	763	O
has	10678548	764	767	O
been	10678548	768	772	O
conducted	10678548	773	782	O
in	10678548	783	785	O
a	10678548	786	787	O
group	10678548	788	793	O
of	10678548	794	796	O
patients	10678548	797	805	O
with	10678548	806	810	O
progressive	10678548	811	822	B-Participant
chronic	10678548	823	830	I-Participant
renal	10678548	831	836	I-Participant
failure	10678548	837	844	I-Participant
(	10678548	845	846	O
creatinine	10678548	847	857	O
clearance	10678548	858	867	O
20	10678548	868	870	O
-	10678548	870	871	O
45	10678548	871	873	O
ml/min	10678548	874	880	O
)	10678548	881	882	O
either	10678548	883	889	O
with	10678548	890	894	O
or	10678548	895	897	O
without	10678548	898	905	O
proteinuria	10678548	906	917	B-Participant
and	10678548	918	921	O
hypertension	10678548	922	934	B-Participant
.	10678548	935	936	O

The	10678548	937	940	O
primary	10678548	941	948	O
aim	10678548	949	952	O
of	10678548	953	955	O
the	10678548	956	959	O
study	10678548	960	965	O
was	10678548	966	969	O
to	10678548	970	972	O
investigate	10678548	973	984	O
the	10678548	985	988	O
safety	10678548	989	995	B-Outcome
and	10678548	996	999	O
tolerability	10678548	1000	1012	B-Outcome
of	10678548	1013	1015	O
the	10678548	1016	1019	O
combination	10678548	1020	1031	B-Intervention
of	10678548	1032	1034	I-Intervention
valsartan	10678548	1035	1044	I-Intervention
and	10678548	1045	1048	I-Intervention
benazepril	10678548	1049	1059	I-Intervention
.	10678548	1060	1061	O

Patients	10678548	1062	1070	O
were	10678548	1071	1075	O
randomly	10678548	1076	1084	O
assigned	10678548	1085	1093	O
to	10678548	1094	1096	O
one	10678548	1097	1100	O
of	10678548	1101	1103	O
three	10678548	1104	1109	O
groups	10678548	1110	1116	O
:	10678548	1117	1118	O
group	10678548	1119	1124	O
1	10678548	1125	1126	O
received	10678548	1127	1135	O
valsartan	10678548	1136	1145	B-Intervention
160	10678548	1146	1149	I-Intervention
mg	10678548	1150	1152	I-Intervention
once	10678548	1153	1157	I-Intervention
daily	10678548	1158	1163	I-Intervention
(	10678548	1164	1165	O
n	10678548	1166	1167	B-Count
=	10678548	1168	1169	I-Count
22	10678548	1170	1172	I-Count
)	10678548	1173	1174	O
;	10678548	1175	1176	O
group	10678548	1177	1182	O
2	10678548	1183	1184	O
received	10678548	1185	1193	O
valsartan	10678548	1194	1203	B-Intervention
80	10678548	1204	1206	I-Intervention
mg	10678548	1207	1209	I-Intervention
once	10678548	1210	1214	I-Intervention
daily	10678548	1215	1220	I-Intervention
plus	10678548	1221	1225	I-Intervention
benazepril	10678548	1226	1236	I-Intervention
5	10678548	1237	1238	I-Intervention
or	10678548	1239	1241	I-Intervention
10	10678548	1242	1244	I-Intervention
mg	10678548	1245	1247	I-Intervention
once	10678548	1248	1252	I-Intervention
daily	10678548	1253	1258	I-Intervention
(	10678548	1259	1260	O
n	10678548	1261	1262	B-Count
=	10678548	1263	1264	I-Count
42	10678548	1265	1267	I-Count
)	10678548	1268	1269	O
;	10678548	1270	1271	O
group	10678548	1272	1277	O
3	10678548	1278	1279	O
received	10678548	1280	1288	O
valsartan	10678548	1289	1298	B-Intervention
160	10678548	1299	1302	I-Intervention
mg	10678548	1303	1305	I-Intervention
once	10678548	1306	1310	I-Intervention
daily	10678548	1311	1316	I-Intervention
plus	10678548	1317	1321	I-Intervention
benazepril	10678548	1322	1332	I-Intervention
5	10678548	1333	1334	I-Intervention
or	10678548	1335	1337	I-Intervention
10	10678548	1338	1340	I-Intervention
mg	10678548	1341	1343	I-Intervention
once	10678548	1344	1348	I-Intervention
daily	10678548	1349	1354	I-Intervention
(	10678548	1355	1356	O
n	10678548	1357	1358	B-Count
=	10678548	1359	1360	I-Count
44	10678548	1361	1363	I-Count
)	10678548	1364	1365	O
.	10678548	1366	1367	O

The	10678548	1368	1371	O
study	10678548	1372	1377	O
lasted	10678548	1378	1384	O
for	10678548	1385	1388	O
5	10678548	1389	1390	O
weeks	10678548	1391	1396	O
,	10678548	1397	1398	O
and	10678548	1399	1402	O
in	10678548	1403	1405	O
groups	10678548	1406	1412	O
2	10678548	1413	1414	O
and	10678548	1415	1418	O
3	10678548	1419	1420	O
benazepril	10678548	1421	1431	O
was	10678548	1432	1435	O
added	10678548	1436	1441	O
on	10678548	1442	1444	O
top	10678548	1445	1448	O
of	10678548	1449	1451	O
valsartan	10678548	1452	1461	O
after	10678548	1462	1467	O
the	10678548	1468	1471	O
first	10678548	1472	1477	O
week	10678548	1478	1482	O
of	10678548	1483	1485	O
therapy	10678548	1486	1493	O
with	10678548	1494	1498	O
the	10678548	1499	1502	O
angiotensin	10678548	1503	1514	O
receptor	10678548	1515	1523	O
blocker	10678548	1524	1531	O
.	10678548	1532	1533	O

RESULTS	10678548	1534	1541	O
Serum	10678548	1542	1547	B-Outcome
creatinine	10678548	1548	1558	I-Outcome
increased	10678548	1559	1568	B-Observation
in	10678548	1569	1571	O
all	10678548	1572	1575	B-Intervention
three	10678548	1576	1581	I-Intervention
groups	10678548	1582	1588	I-Intervention
(	10678548	1589	1590	O
mean	10678548	1591	1595	B-Outcome
change	10678548	1596	1602	I-Outcome
within	10678548	1603	1609	O
a	10678548	1610	1611	O
group	10678548	1612	1617	O
:	10678548	1618	1619	O
11	10678548	1620	1622	B-Observation
micromol/l	10678548	1623	1633	I-Observation
in	10678548	1634	1636	O
group	10678548	1637	1642	B-Intervention
1	10678548	1643	1644	I-Intervention
,	10678548	1645	1646	O
P=	10678548	1647	1649	O
0.045	10678548	1650	1655	O
;	10678548	1656	1657	O
9	10678548	1658	1659	B-Observation
micromol/l	10678548	1660	1670	I-Observation
in	10678548	1671	1673	O
group	10678548	1674	1679	B-Intervention
2	10678548	1680	1681	I-Intervention
,	10678548	1682	1683	O
P=	10678548	1684	1686	O
0.030	10678548	1687	1692	O
;	10678548	1693	1694	O
15	10678548	1695	1697	B-Observation
micromol/l	10678548	1698	1708	I-Observation
in	10678548	1709	1711	O
group	10678548	1712	1717	B-Intervention
3	10678548	1718	1719	I-Intervention
,	10678548	1720	1721	O
P=	10678548	1722	1724	O
0.0006	10678548	1725	1731	O
)	10678548	1732	1733	O
.	10678548	1734	1735	O

Serum	10678548	1736	1741	B-Outcome
potassium	10678548	1742	1751	I-Outcome
also	10678548	1752	1756	O
increased	10678548	1757	1766	B-Observation
in	10678548	1767	1769	O
all	10678548	1770	1773	B-Intervention
three	10678548	1774	1779	I-Intervention
groups	10678548	1780	1786	I-Intervention
of	10678548	1787	1789	O
patients	10678548	1790	1798	O
(	10678548	1799	1800	O
mean	10678548	1801	1805	B-Outcome
change	10678548	1806	1812	I-Outcome
within	10678548	1813	1819	O
a	10678548	1820	1821	O
group	10678548	1822	1827	O
:	10678548	1828	1829	O
0.28	10678548	1830	1834	B-Observation
mmol/l	10678548	1835	1841	I-Observation
in	10678548	1842	1844	O
group	10678548	1845	1850	B-Intervention
1	10678548	1851	1852	I-Intervention
,	10678548	1853	1854	O
P=	10678548	1855	1857	O
0.28	10678548	1858	1862	O
;	10678548	1863	1864	O
0.48	10678548	1865	1869	B-Observation
mmol/l	10678548	1870	1876	I-Observation
in	10678548	1877	1879	O
group	10678548	1880	1885	B-Intervention
2	10678548	1886	1887	I-Intervention
,	10678548	1888	1889	O
P=	10678548	1890	1892	O
0.0008	10678548	1893	1899	O
;	10678548	1900	1901	O
0.36	10678548	1902	1906	B-Observation
mmol/l	10678548	1907	1913	I-Observation
in	10678548	1914	1916	O
group	10678548	1917	1922	B-Intervention
3	10678548	1923	1924	I-Intervention
,	10678548	1925	1926	O
P=	10678548	1927	1929	O
0.02	10678548	1930	1934	O
)	10678548	1935	1936	O
.	10678548	1937	1938	O

After	10678548	1939	1944	O
5	10678548	1945	1946	O
weeks	10678548	1947	1952	O
of	10678548	1953	1955	O
treatment	10678548	1956	1965	O
,	10678548	1966	1967	O
the	10678548	1968	1971	O
largest	10678548	1972	1979	B-Observation
decrease	10678548	1980	1988	I-Observation
in	10678548	1989	1991	O
blood	10678548	1992	1997	B-Outcome
pressure	10678548	1998	2006	I-Outcome
was	10678548	2007	2010	O
observed	10678548	2011	2019	O
in	10678548	2020	2022	O
group	10678548	2023	2028	B-Intervention
3	10678548	2029	2030	I-Intervention
(	10678548	2031	2032	O
the	10678548	2033	2036	O
mean	10678548	2037	2041	B-Outcome
change	10678548	2042	2048	I-Outcome
from	10678548	2049	2053	I-Outcome
baseline	10678548	2054	2062	I-Outcome
in	10678548	2063	2065	I-Outcome
seated	10678548	2066	2072	I-Outcome
diastolic	10678548	2073	2082	I-Outcome
blood	10678548	2083	2088	I-Outcome
pressure	10678548	2089	2097	I-Outcome
(	10678548	2098	2099	I-Outcome
SDBP	10678548	2100	2104	I-Outcome
)	10678548	2105	2106	I-Outcome
and	10678548	2107	2110	I-Outcome
seated	10678548	2111	2117	I-Outcome
systolic	10678548	2118	2126	I-Outcome
blood	10678548	2127	2132	I-Outcome
pressure	10678548	2133	2141	I-Outcome
(	10678548	2142	2143	I-Outcome
SSBP	10678548	2144	2148	I-Outcome
)	10678548	2149	2150	I-Outcome
,	10678548	2151	2152	O
respectively	10678548	2153	2165	O
,	10678548	2166	2167	O
were	10678548	2168	2172	O
:	10678548	2173	2174	O
-2.0	10678548	2175	2179	B-Observation
and	10678548	2180	2183	I-Observation
-11.5	10678548	2184	2189	I-Observation
mmHg	10678548	2190	2194	I-Observation
in	10678548	2195	2197	O
group	10678548	2198	2203	B-Intervention
1	10678548	2204	2205	I-Intervention
;	10678548	2206	2207	O
-7.6	10678548	2208	2212	B-Observation
and	10678548	2213	2216	I-Observation
-15.4	10678548	2217	2222	I-Observation
mmHg	10678548	2223	2227	I-Observation
in	10678548	2228	2230	O
group	10678548	2231	2236	B-Intervention
2	10678548	2237	2238	I-Intervention
;	10678548	2239	2240	O
-12.6	10678548	2241	2246	B-Observation
and	10678548	2247	2250	I-Observation
-21.6	10678548	2251	2256	I-Observation
mmHg	10678548	2257	2261	I-Observation
in	10678548	2262	2264	O
group	10678548	2265	2270	B-Intervention
3	10678548	2271	2272	I-Intervention
)	10678548	2273	2274	O
.	10678548	2275	2276	O

In	10678548	2277	2279	O
addition	10678548	2280	2288	O
,	10678548	2289	2290	O
both	10678548	2291	2295	B-Intervention
combination	10678548	2296	2307	I-Intervention
treatments	10678548	2308	2318	I-Intervention
resulted	10678548	2319	2327	O
in	10678548	2328	2330	O
the	10678548	2331	2334	O
reduction	10678548	2335	2344	B-Observation
of	10678548	2345	2347	O
proteinuria	10678548	2348	2359	B-Outcome
.	10678548	2360	2361	O

The	10678548	2362	2365	O
total	10678548	2366	2371	B-Outcome
number	10678548	2372	2378	I-Outcome
of	10678548	2379	2381	I-Outcome
patients	10678548	2382	2390	I-Outcome
with	10678548	2391	2395	I-Outcome
adverse	10678548	2396	2403	I-Outcome
experiences	10678548	2404	2415	I-Outcome
were	10678548	2416	2420	O
10	10678548	2421	2423	B-Observation
(	10678548	2424	2425	I-Observation
45.5	10678548	2426	2430	I-Observation
%	10678548	2431	2432	I-Observation
)	10678548	2433	2434	I-Observation
,	10678548	2435	2436	O
14	10678548	2437	2439	B-Observation
(	10678548	2440	2441	I-Observation
33.3	10678548	2442	2446	I-Observation
%	10678548	2447	2448	I-Observation
)	10678548	2449	2450	I-Observation
and	10678548	2451	2454	O
11	10678548	2455	2457	B-Observation
(	10678548	2458	2459	I-Observation
25	10678548	2460	2462	I-Observation
%	10678548	2463	2464	I-Observation
)	10678548	2465	2466	I-Observation
in	10678548	2467	2469	O
groups	10678548	2470	2476	B-Intervention
1,2	10678548	2477	2480	I-Intervention
and	10678548	2481	2484	O
3	10678548	2485	2486	B-Intervention
,	10678548	2487	2488	O
respectively	10678548	2489	2501	O
.	10678548	2502	2503	O

In	10678548	2504	2506	O
six	10678548	2507	2510	B-Count
patients	10678548	2511	2519	I-Count
(	10678548	2520	2521	I-Count
5.6	10678548	2522	2525	I-Count
%	10678548	2526	2527	I-Count
)	10678548	2528	2529	I-Count
therapy	10678548	2530	2537	O
was	10678548	2538	2541	O
discontinued	10678548	2542	2554	B-Outcome
as	10678548	2555	2557	I-Outcome
a	10678548	2558	2559	I-Outcome
result	10678548	2560	2566	I-Outcome
of	10678548	2567	2569	I-Outcome
adverse	10678548	2570	2577	I-Outcome
experiences	10678548	2578	2589	I-Outcome
.	10678548	2590	2591	O

Only	10678548	2592	2596	O
one	10678548	2597	2600	B-Count
patient	10678548	2601	2608	I-Count
in	10678548	2609	2611	O
each	10678548	2612	2616	B-Intervention
of	10678548	2617	2619	I-Intervention
the	10678548	2620	2623	I-Intervention
combined	10678548	2624	2632	I-Intervention
therapy	10678548	2633	2640	I-Intervention
groups	10678548	2641	2647	O
withdrew	10678548	2648	2656	B-Outcome
from	10678548	2657	2661	I-Outcome
the	10678548	2662	2665	I-Outcome
study	10678548	2666	2671	I-Outcome
because	10678548	2672	2679	I-Outcome
of	10678548	2680	2682	I-Outcome
hyperkalaemia	10678548	2683	2696	I-Outcome
and	10678548	2697	2700	O
no	10678548	2701	2703	B-Count
patients	10678548	2704	2712	I-Count
were	10678548	2713	2717	O
forced	10678548	2718	2724	O
to	10678548	2725	2727	O
withdraw	10678548	2728	2736	B-Outcome
because	10678548	2737	2744	I-Outcome
of	10678548	2745	2747	I-Outcome
an	10678548	2748	2750	I-Outcome
increase	10678548	2751	2759	I-Outcome
in	10678548	2760	2762	I-Outcome
serum	10678548	2763	2768	I-Outcome
creatinine	10678548	2769	2779	I-Outcome
,	10678548	2780	2781	I-Outcome
acute	10678548	2782	2787	I-Outcome
renal	10678548	2788	2793	I-Outcome
failure	10678548	2794	2801	I-Outcome
or	10678548	2802	2804	I-Outcome
hospitalization	10678548	2805	2820	I-Outcome
.	10678548	2821	2822	O

CONCLUSIONS	10678548	2823	2834	O
These	10678548	2835	2840	O
results	10678548	2841	2848	O
indicate	10678548	2849	2857	O
that	10678548	2858	2862	O
short-term	10678548	2863	2873	B-Intervention
combination	10678548	2874	2885	I-Intervention
of	10678548	2886	2888	I-Intervention
an	10678548	2889	2891	I-Intervention
angiotensin-converting	10678548	2892	2914	I-Intervention
enzyme	10678548	2915	2921	I-Intervention
inhibitor	10678548	2922	2931	I-Intervention
and	10678548	2932	2935	I-Intervention
an	10678548	2936	2938	I-Intervention
angiotensin	10678548	2939	2950	I-Intervention
receptor	10678548	2951	2959	I-Intervention
blocker	10678548	2960	2967	I-Intervention
is	10678548	2968	2970	O
safe	10678548	2971	2975	B-Observation
and	10678548	2976	2979	O
well	10678548	2980	2984	B-Observation
tolerated	10678548	2985	2994	I-Observation
in	10678548	2995	2997	O
patients	10678548	2998	3006	O
with	10678548	3007	3011	O
moderate	10678548	3012	3020	B-Participant
chronic	10678548	3021	3028	I-Participant
renal	10678548	3029	3034	I-Participant
failure	10678548	3035	3042	I-Participant
.	10678548	3043	3044	O

[	10682031	0	1	O
Administration	10682031	2	16	O
of	10682031	17	19	O
tobramycin	10682031	20	30	B-Intervention
aerosols	10682031	31	39	I-Intervention
in	10682031	40	42	O
patients	10682031	43	51	O
with	10682031	52	56	O
nosocomial	10682031	57	67	B-Participant
pneumonia	10682031	68	77	I-Participant
:	10682031	78	79	O
a	10682031	80	81	O
preliminary	10682031	82	93	O
study	10682031	94	99	O
]	10682031	100	101	O
.	10682031	102	103	O

OBJECTIVE	10682031	104	113	O
The	10682031	114	117	O
aim	10682031	118	121	O
of	10682031	122	124	O
this	10682031	125	129	O
study	10682031	130	135	O
was	10682031	136	139	O
to	10682031	140	142	O
assess	10682031	143	149	O
renal	10682031	150	155	B-Outcome
and	10682031	156	159	I-Outcome
respiratory	10682031	160	171	I-Outcome
tolerance	10682031	172	181	I-Outcome
of	10682031	182	184	O
aerosolized	10682031	185	196	B-Intervention
tobramycin	10682031	197	207	I-Intervention
in	10682031	208	210	O
intubated	10682031	211	220	B-Participant
and	10682031	221	224	O
mechanically	10682031	225	237	B-Participant
ventilated	10682031	238	248	I-Participant
patients	10682031	249	257	O
with	10682031	258	262	O
nosocomial	10682031	263	273	B-Participant
pneumonia	10682031	274	283	I-Participant
.	10682031	284	285	O

PATIENTS	10682031	286	294	O
AND	10682031	295	298	O
METHODS	10682031	299	306	O
This	10682031	307	311	O
was	10682031	312	315	O
a	10682031	316	317	O
multicenter	10682031	318	329	O
,	10682031	330	331	O
randomized	10682031	332	342	O
,	10682031	343	344	O
double-blind	10682031	345	357	O
,	10682031	358	359	O
placebo	10682031	360	367	O
controlled	10682031	368	378	O
study	10682031	379	384	O
.	10682031	385	386	O

Thirty-eight	10682031	387	399	O
mechanically	10682031	400	412	B-Participant
ventilated	10682031	413	423	I-Participant
patients	10682031	424	432	O
with	10682031	433	437	O
documented	10682031	438	448	B-Participant
nosocomial	10682031	449	459	I-Participant
pneumonia	10682031	460	469	I-Participant
were	10682031	470	474	O
included	10682031	475	483	O
.	10682031	484	485	O

Patients	10682031	486	494	O
treated	10682031	495	502	O
with	10682031	503	507	O
intravenous	10682031	508	519	B-Participant
betalactam	10682031	520	530	I-Participant
and	10682031	531	534	O
tobramycin	10682031	535	545	B-Participant
were	10682031	546	550	O
randomly	10682031	551	559	O
allocated	10682031	560	569	O
to	10682031	570	572	O
receive	10682031	573	580	O
aerosolized	10682031	581	592	B-Intervention
tobramycin	10682031	593	603	I-Intervention
(	10682031	604	605	O
6	10682031	606	607	O
mg/kg/day	10682031	608	617	O
,	10682031	618	619	O
n	10682031	620	621	O
=	10682031	622	623	O
21	10682031	624	626	O
)	10682031	627	628	O
or	10682031	629	631	O
placebo	10682031	632	639	B-Intervention
(	10682031	640	641	O
n	10682031	642	643	O
=	10682031	644	645	O
17	10682031	646	648	O
)	10682031	649	650	O
.	10682031	651	652	O

The	10682031	653	656	O
aerosol	10682031	657	664	B-Intervention
was	10682031	665	668	O
administered	10682031	669	681	O
via	10682031	682	685	O
a	10682031	686	687	O
pneumatic	10682031	688	697	O
nebulizer	10682031	698	707	O
once	10682031	708	712	O
a	10682031	713	714	O
day	10682031	715	718	O
for	10682031	719	722	O
5	10682031	723	724	O
days	10682031	725	729	O
.	10682031	730	731	O

RESULTS	10682031	732	739	O
Respiratory	10682031	740	751	B-Outcome
tolerance	10682031	752	761	I-Outcome
was	10682031	762	765	O
good	10682031	766	770	B-Observation
in	10682031	771	773	O
all	10682031	774	777	B-Count
but	10682031	778	781	I-Count
two	10682031	782	785	I-Count
patients	10682031	786	794	I-Count
.	10682031	795	796	O

No	10682031	797	799	B-Count
acute	10682031	800	805	B-Outcome
renal	10682031	806	811	I-Outcome
failure	10682031	812	819	I-Outcome
occurred	10682031	820	828	O
.	10682031	829	830	O

By	10682031	831	833	O
day	10682031	834	837	O
10	10682031	838	840	O
,	10682031	841	842	O
7	10682031	843	844	B-Count
patients	10682031	845	853	I-Count
in	10682031	854	856	O
the	10682031	857	860	O
tobramycin	10682031	861	871	B-Intervention
group	10682031	872	877	O
(	10682031	878	879	O
35	10682031	880	882	B-Count
%	10682031	883	884	I-Count
)	10682031	885	886	O
had	10682031	887	890	O
been	10682031	891	895	O
extubated	10682031	896	905	B-Outcome
versus	10682031	906	912	O
3	10682031	913	914	B-Count
in	10682031	915	917	O
the	10682031	918	921	O
placebo	10682031	922	929	B-Intervention
group	10682031	930	935	O
(	10682031	936	937	O
18.5	10682031	938	942	B-Count
%	10682031	943	944	I-Count
,	10682031	945	946	O
p	10682031	947	948	O
=	10682031	949	950	O
0.18	10682031	951	955	O
)	10682031	956	957	O
.	10682031	958	959	O

By	10682031	960	962	O
day	10682031	963	966	O
28	10682031	967	969	O
,	10682031	970	971	O
6	10682031	972	973	B-Count
patients	10682031	974	982	I-Count
had	10682031	983	986	O
died	10682031	987	991	B-Outcome
(	10682031	992	993	O
2	10682031	994	995	B-Count
in	10682031	996	998	O
the	10682031	999	1002	O
tobramycin	10682031	1003	1013	B-Intervention
group	10682031	1014	1019	O
and	10682031	1020	1023	O
4	10682031	1024	1025	B-Count
in	10682031	1026	1028	O
the	10682031	1029	1032	O
placebo	10682031	1033	1040	B-Intervention
group	10682031	1041	1046	O
,	10682031	1047	1048	O
p	10682031	1049	1050	O
=	10682031	1051	1052	O
0.23	10682031	1053	1057	O
)	10682031	1058	1059	O
.	10682031	1060	1061	O

CONCLUSION	10682031	1062	1072	O
Aerosolized	10682031	1073	1084	B-Intervention
tobramycin	10682031	1085	1095	I-Intervention
was	10682031	1096	1099	O
well	10682031	1100	1104	B-Observation
tolerated	10682031	1105	1114	I-Observation
in	10682031	1115	1117	O
ventilated	10682031	1118	1128	B-Participant
patients	10682031	1129	1137	O
with	10682031	1138	1142	O
documented	10682031	1143	1153	B-Participant
nosocomial	10682031	1154	1164	I-Participant
pneumonia	10682031	1165	1174	I-Participant
.	10682031	1175	1176	O

Efficacy	10685722	0	8	B-Outcome
and	10685722	9	12	O
safety	10685722	13	19	B-Outcome
of	10685722	20	22	O
a	10685722	23	24	O
fixed	10685722	25	30	B-Intervention
low-dose	10685722	31	39	I-Intervention
perindopril/indapamide	10685722	40	62	I-Intervention
combination	10685722	63	74	I-Intervention
in	10685722	75	77	O
essential	10685722	78	87	B-Participant
hypertension	10685722	88	100	I-Participant
.	10685722	101	102	O

A	10685722	103	104	O
randomised	10685722	105	115	O
controlled	10685722	116	126	O
study	10685722	127	132	O
.	10685722	133	134	O

This	10685722	135	139	O
multicenter	10685722	140	151	O
,	10685722	152	153	O
double-blind	10685722	154	166	O
,	10685722	167	168	O
parallel-group	10685722	169	183	O
study	10685722	184	189	O
was	10685722	190	193	O
designed	10685722	194	202	O
to	10685722	203	205	O
assess	10685722	206	212	O
the	10685722	213	216	O
efficacy	10685722	217	225	B-Outcome
and	10685722	226	229	O
the	10685722	230	233	O
safety	10685722	234	240	B-Outcome
of	10685722	241	243	O
fixed	10685722	244	249	B-Intervention
low	10685722	250	253	I-Intervention
dose	10685722	254	258	I-Intervention
combination	10685722	259	270	I-Intervention
perindopril	10685722	271	282	I-Intervention
2	10685722	283	284	I-Intervention
mg/indapamide	10685722	285	298	I-Intervention
0.625	10685722	299	304	I-Intervention
mg	10685722	305	307	I-Intervention
(	10685722	308	309	I-Intervention
Per/Ind	10685722	310	317	I-Intervention
)	10685722	318	319	I-Intervention
versus	10685722	320	326	O
atenolol	10685722	327	335	B-Intervention
50	10685722	336	338	I-Intervention
mg	10685722	339	341	I-Intervention
(	10685722	342	343	I-Intervention
Ate	10685722	344	347	I-Intervention
)	10685722	348	349	I-Intervention
.	10685722	350	351	O

After	10685722	352	357	O
a	10685722	358	359	O
4-week	10685722	360	366	O
placebo	10685722	367	374	O
run-in	10685722	375	381	O
,	10685722	382	383	O
446	10685722	384	387	O
hypertensive	10685722	388	400	B-Participant
patients	10685722	401	409	O
(	10685722	410	411	O
mean	10685722	412	416	O
age	10685722	417	420	O
:	10685722	421	422	O
55.8	10685722	423	427	O
+	10685722	428	429	O
/-	10685722	429	431	O
11.0	10685722	432	436	O
years	10685722	437	442	O
)	10685722	443	444	O
were	10685722	445	449	O
randomised	10685722	450	460	O
to	10685722	461	463	O
receive	10685722	464	471	O
Per/Ind	10685722	472	479	B-Intervention
or	10685722	480	482	O
Ate	10685722	483	486	B-Intervention
for	10685722	487	490	O
12	10685722	491	493	O
weeks	10685722	494	499	O
.	10685722	500	501	O

The	10685722	502	505	O
primary	10685722	506	513	O
outcome	10685722	514	521	O
measures	10685722	522	530	O
were	10685722	531	535	O
the	10685722	536	539	O
changes	10685722	540	547	B-Observation
in	10685722	548	550	O
trough	10685722	551	557	B-Outcome
supine	10685722	558	564	I-Outcome
systolic	10685722	565	573	I-Outcome
and	10685722	574	577	I-Outcome
diastolic	10685722	578	587	I-Outcome
blood	10685722	588	593	I-Outcome
pressure	10685722	594	602	I-Outcome
(	10685722	603	604	I-Outcome
sSBP	10685722	605	609	I-Outcome
,	10685722	610	611	I-Outcome
sDBP	10685722	612	616	I-Outcome
)	10685722	617	618	I-Outcome
between	10685722	619	626	O
baseline	10685722	627	635	O
and	10685722	636	639	O
the	10685722	640	643	O
last	10685722	644	648	O
observation	10685722	649	660	O
.	10685722	661	662	O

Equivalence	10685722	663	674	B-Outcome
was	10685722	675	678	O
assessed	10685722	679	687	O
in	10685722	688	690	O
an	10685722	691	693	O
intention-to-treat	10685722	694	712	O
analysis	10685722	713	721	O
using	10685722	722	727	O
a	10685722	728	729	O
two	10685722	730	733	O
one-sided	10685722	734	743	O
tests	10685722	744	749	O
procedure	10685722	750	759	O
.	10685722	760	761	O

Per/Ind	10685722	762	769	B-Intervention
and	10685722	770	773	O
Ate	10685722	774	777	B-Intervention
decreased	10685722	778	787	B-Observation
sSBP	10685722	788	792	B-Outcome
by	10685722	793	795	O
-20.5	10685722	796	801	B-Observation
mmHg	10685722	802	806	I-Observation
and	10685722	807	810	O
-20.1	10685722	811	816	B-Observation
mmHg	10685722	817	821	I-Observation
,	10685722	822	823	O
respectively	10685722	824	836	O
;	10685722	837	838	O
the	10685722	839	842	O
90	10685722	843	845	O
%	10685722	846	847	O
confidence	10685722	848	858	O
interval	10685722	859	867	O
[	10685722	868	869	O
-2.3	10685722	870	874	O
;	10685722	875	876	O
1.5	10685722	877	880	O
]	10685722	881	882	O
of	10685722	883	885	O
the	10685722	886	889	O
intertreatment	10685722	890	904	B-Outcome
difference	10685722	905	915	I-Outcome
(	10685722	916	917	O
-0.4	10685722	918	922	B-Observation
mmHg	10685722	923	927	I-Observation
)	10685722	928	929	O
fell	10685722	930	934	O
within	10685722	935	941	O
the	10685722	942	945	O
predefined	10685722	946	956	B-Observation
equivalence	10685722	957	968	I-Observation
interval	10685722	969	977	I-Observation
[	10685722	978	979	O
-8	10685722	980	982	O
;	10685722	983	984	O
+	10685722	985	986	O
8	10685722	986	987	O
mmHg	10685722	988	992	O
]	10685722	993	994	O
.	10685722	995	996	O

Similarly	10685722	997	1006	O
,	10685722	1007	1008	O
the	10685722	1009	1012	O
sDBP	10685722	1013	1017	B-Outcome
decreased	10685722	1018	1027	B-Observation
by	10685722	1028	1030	I-Observation
-15.1	10685722	1031	1036	I-Observation
mmHg	10685722	1037	1041	I-Observation
(	10685722	1042	1043	O
Per/Ind	10685722	1044	1051	B-Intervention
)	10685722	1052	1053	O
and	10685722	1054	1057	O
-16.2	10685722	1058	1063	B-Observation
mmHg	10685722	1064	1068	I-Observation
(	10685722	1069	1070	O
Ate	10685722	1071	1074	B-Intervention
)	10685722	1075	1076	O
with	10685722	1077	1081	O
an	10685722	1082	1084	O
intertreatment	10685722	1085	1099	B-Outcome
difference	10685722	1100	1110	I-Outcome
of	10685722	1111	1113	O
1.1	10685722	1114	1117	B-Observation
mmHg	10685722	1118	1122	I-Observation
whose	10685722	1123	1128	O
90	10685722	1129	1131	O
%	10685722	1132	1133	O
confidence	10685722	1134	1144	O
interval	10685722	1145	1153	O
[	10685722	1154	1155	O
-0.1	10685722	1156	1160	O
;	10685722	1161	1162	O
2.2	10685722	1163	1166	O
mmHg	10685722	1167	1171	O
]	10685722	1172	1173	O
fell	10685722	1174	1178	O
within	10685722	1179	1185	O
the	10685722	1186	1189	O
predefined	10685722	1190	1200	B-Observation
equivalence	10685722	1201	1212	I-Observation
interval	10685722	1213	1221	I-Observation
[	10685722	1222	1223	O
-4	10685722	1224	1226	O
;	10685722	1227	1228	O
+	10685722	1229	1230	O
4	10685722	1230	1231	O
mmHg	10685722	1232	1236	O
]	10685722	1237	1238	O
;	10685722	1239	1240	O
thus	10685722	1241	1245	O
antihypertensive	10685722	1246	1262	B-Outcome
efficacy	10685722	1263	1271	I-Outcome
of	10685722	1272	1274	O
Per/Ind	10685722	1275	1282	B-Intervention
and	10685722	1283	1286	O
Ate	10685722	1287	1290	B-Intervention
were	10685722	1291	1295	O
equivalent	10685722	1296	1306	B-Observation
(	10685722	1307	1308	O
P	10685722	1309	1310	O
<	10685722	1311	1312	O
0.001	10685722	1313	1318	O
)	10685722	1319	1320	O
.	10685722	1321	1322	O

In	10685722	1323	1325	O
patients	10685722	1326	1334	B-Participant
older	10685722	1335	1340	I-Participant
than	10685722	1341	1345	I-Participant
65	10685722	1346	1348	I-Participant
,	10685722	1349	1350	O
Per/Ind	10685722	1351	1358	B-Intervention
induces	10685722	1359	1366	O
a	10685722	1367	1368	O
statistically	10685722	1369	1382	B-Observation
greater	10685722	1383	1390	I-Observation
decrease	10685722	1391	1399	I-Observation
in	10685722	1400	1402	O
sSBP	10685722	1403	1407	B-Outcome
than	10685722	1408	1412	O
Ate	10685722	1413	1416	B-Intervention
(	10685722	1417	1418	O
P	10685722	1419	1420	O
<	10685722	1421	1422	O
0.05	10685722	1423	1427	O
)	10685722	1428	1429	O
.	10685722	1430	1431	O

Per/Ind	10685722	1432	1439	B-Intervention
was	10685722	1440	1443	O
well	10685722	1444	1448	B-Observation
tolerated	10685722	1449	1458	I-Observation
.	10685722	1459	1460	O

Further	10685722	1461	1468	O
controlled	10685722	1469	1479	O
studies	10685722	1480	1487	O
are	10685722	1488	1491	O
needed	10685722	1492	1498	O
to	10685722	1499	1501	O
confirm	10685722	1502	1509	O
these	10685722	1510	1515	O
results	10685722	1516	1523	O
on	10685722	1524	1526	O
a	10685722	1527	1528	O
long-term	10685722	1529	1538	O
period	10685722	1539	1545	O
.	10685722	1546	1547	O

Treatment	10685817	0	9	O
of	10685817	10	12	O
whiplash	10685817	13	21	B-Participant
associated	10685817	22	32	I-Participant
neck	10685817	33	37	I-Participant
pain	10685817	38	42	I-Participant
[	10685817	43	44	O
corrected	10685817	45	54	O
]	10685817	55	56	O
with	10685817	57	61	O
botulinum	10685817	62	71	B-Intervention
toxin-A	10685817	72	79	I-Intervention
:	10685817	80	81	O
a	10685817	82	83	O
pilot	10685817	84	89	O
study	10685817	90	95	O
.	10685817	96	97	O

OBJECTIVE	10685817	98	107	O
Up	10685817	108	110	O
to	10685817	111	113	O
87	10685817	114	116	O
%	10685817	117	118	O
of	10685817	119	121	O
patients	10685817	122	130	O
with	10685817	131	135	O
whiplash	10685817	136	144	O
associated	10685817	145	155	O
disorder	10685817	156	164	O
(	10685817	165	166	O
WAD	10685817	167	170	O
)	10685817	171	172	O
have	10685817	173	177	O
some	10685817	178	182	O
degree	10685817	183	189	O
of	10685817	190	192	O
muscle	10685817	193	199	O
spasm	10685817	200	205	O
that	10685817	206	210	O
is	10685817	211	213	O
contributory	10685817	214	226	O
to	10685817	227	229	O
both	10685817	230	234	O
pain	10685817	235	239	O
and	10685817	240	243	O
dysfunction	10685817	244	255	O
.	10685817	256	257	O

Botulinum	10685817	258	267	O
toxin	10685817	268	273	O
A	10685817	274	275	O
(	10685817	276	277	O
BTX-A	10685817	278	283	O
)	10685817	284	285	O
produces	10685817	286	294	O
prolonged	10685817	295	304	O
muscle	10685817	305	311	O
relaxation	10685817	312	322	O
that	10685817	323	327	O
is	10685817	328	330	O
dose-dependent	10685817	331	345	O
and	10685817	346	349	O
can	10685817	350	353	O
be	10685817	354	356	O
easily	10685817	357	363	O
targeted	10685817	364	372	O
to	10685817	373	375	O
affected	10685817	376	384	O
muscles	10685817	385	392	O
.	10685817	393	394	O

BTX-A	10685817	395	400	O
therapy	10685817	401	408	O
may	10685817	409	412	O
be	10685817	413	415	O
an	10685817	416	418	O
effective	10685817	419	428	O
form	10685817	429	433	O
of	10685817	434	436	O
therapy	10685817	437	444	O
offering	10685817	445	453	O
an	10685817	454	456	O
alternative	10685817	457	468	O
or	10685817	469	471	O
adjunct	10685817	472	479	O
to	10685817	480	482	O
conventional	10685817	483	495	O
modalities	10685817	496	506	O
.	10685817	507	508	O

We	10685817	509	511	O
investigated	10685817	512	524	O
BTX-A	10685817	525	530	B-Intervention
as	10685817	531	533	O
therapy	10685817	534	541	O
in	10685817	542	544	O
patients	10685817	545	553	O
with	10685817	554	558	O
WAD	10685817	559	562	B-Participant
.	10685817	563	564	O

METHODS	10685817	565	572	O
This	10685817	573	577	O
randomized	10685817	578	588	O
,	10685817	589	590	O
double	10685817	591	597	O
blind	10685817	598	603	O
,	10685817	604	605	O
placebo	10685817	606	613	O
controlled	10685817	614	624	O
study	10685817	625	630	O
compares	10685817	631	639	O
outcome	10685817	640	647	O
measures	10685817	648	656	O
in	10685817	657	659	O
26	10685817	660	662	O
patients	10685817	663	671	O
with	10685817	672	676	O
chronic	10685817	677	684	B-Participant
neck	10685817	685	689	I-Participant
pain	10685817	690	694	I-Participant
(	10685817	695	696	I-Participant
WAD-II	10685817	697	703	I-Participant
chronic	10685817	704	711	I-Participant
)	10685817	712	713	I-Participant
subsequent	10685817	714	724	O
to	10685817	725	727	O
a	10685817	728	729	O
motor	10685817	730	735	B-Participant
vehicle	10685817	736	743	I-Participant
accident	10685817	744	752	I-Participant
.	10685817	753	754	O

One-half	10685817	755	763	O
of	10685817	764	766	O
the	10685817	767	770	O
patients	10685817	771	779	O
received	10685817	780	788	O
100	10685817	789	792	O
units	10685817	793	798	O
BTX-A	10685817	799	804	B-Intervention
,	10685817	805	806	O
diluted	10685817	807	814	O
in	10685817	815	817	O
1	10685817	818	819	O
ml	10685817	820	822	O
saline	10685817	823	829	O
,	10685817	830	831	O
while	10685817	832	837	O
the	10685817	838	841	O
other	10685817	842	847	O
half	10685817	848	852	O
received	10685817	853	861	O
just	10685817	862	866	O
saline	10685817	867	873	B-Intervention
(	10685817	874	875	O
1	10685817	876	877	O
ml	10685817	878	880	O
)	10685817	881	882	O
.	10685817	883	884	O

Five	10685817	885	889	O
trigger	10685817	890	897	O
points	10685817	898	904	O
received	10685817	905	913	O
0.2	10685817	914	917	O
ml	10685817	918	920	O
each	10685817	921	925	O
of	10685817	926	928	O
injectant	10685817	929	938	O
via	10685817	939	942	O
a	10685817	943	944	O
30	10685817	945	947	O
gauge	10685817	948	953	O
needle	10685817	954	960	O
.	10685817	961	962	O

Outcome	10685817	963	970	O
measures	10685817	971	979	O
included	10685817	980	988	O
total	10685817	989	994	B-Outcome
subjective	10685817	995	1005	I-Outcome
neck	10685817	1006	1010	I-Outcome
,	10685817	1011	1012	I-Outcome
shoulder	10685817	1013	1021	I-Outcome
,	10685817	1022	1023	I-Outcome
and	10685817	1024	1027	I-Outcome
head	10685817	1028	1032	I-Outcome
pain	10685817	1033	1037	I-Outcome
based	10685817	1038	1043	O
on	10685817	1044	1046	O
visual	10685817	1047	1053	B-Outcome
analog	10685817	1054	1060	I-Outcome
scales	10685817	1061	1067	I-Outcome
;	10685817	1068	1069	O
objective	10685817	1070	1079	B-Outcome
total	10685817	1080	1085	I-Outcome
range	10685817	1086	1091	I-Outcome
of	10685817	1092	1094	I-Outcome
neck	10685817	1095	1099	I-Outcome
motion	10685817	1100	1106	I-Outcome
(	10685817	1107	1108	I-Outcome
ROM	10685817	1109	1112	I-Outcome
)	10685817	1113	1114	I-Outcome
,	10685817	1115	1116	O
and	10685817	1117	1120	O
the	10685817	1121	1124	O
Vernon-Mior	10685817	1125	1136	B-Outcome
subjective	10685817	1137	1147	I-Outcome
function	10685817	1148	1156	I-Outcome
index	10685817	1157	1162	I-Outcome
.	10685817	1163	1164	O

Followup	10685817	1165	1173	O
assessments	10685817	1174	1185	O
were	10685817	1186	1190	O
carried	10685817	1191	1198	O
out	10685817	1199	1202	O
at	10685817	1203	1205	O
2	10685817	1206	1207	O
and	10685817	1208	1211	O
4	10685817	1212	1213	O
weeks	10685817	1214	1219	O
post-treatment	10685817	1220	1234	O
.	10685817	1235	1236	O

RESULTS	10685817	1237	1244	O
Fourteen	10685817	1245	1253	B-Count
subjects	10685817	1254	1262	I-Count
receiving	10685817	1263	1272	O
BTX-A	10685817	1273	1278	B-Intervention
and	10685817	1279	1282	O
12	10685817	1283	1285	B-Count
receiving	10685817	1286	1295	O
saline	10685817	1296	1302	B-Intervention
completed	10685817	1303	1312	B-Outcome
the	10685817	1313	1316	I-Outcome
study	10685817	1317	1322	I-Outcome
.	10685817	1323	1324	O

The	10685817	1325	1328	O
treatment	10685817	1329	1338	B-Intervention
group	10685817	1339	1344	O
showed	10685817	1345	1351	O
a	10685817	1352	1353	O
trend	10685817	1354	1359	B-Observation
toward	10685817	1360	1366	I-Observation
improvement	10685817	1367	1378	I-Observation
in	10685817	1379	1381	O
ROM	10685817	1382	1385	B-Outcome
and	10685817	1386	1389	O
reduction	10685817	1390	1399	B-Observation
in	10685817	1400	1402	O
pain	10685817	1403	1407	B-Outcome
at	10685817	1408	1410	O
2	10685817	1411	1412	O
weeks	10685817	1413	1418	O
post-injection	10685817	1419	1433	O
.	10685817	1434	1435	O

At	10685817	1436	1438	O
4	10685817	1439	1440	O
weeks	10685817	1441	1446	O
post-injection	10685817	1447	1461	O
the	10685817	1462	1465	O
treatment	10685817	1466	1475	B-Intervention
group	10685817	1476	1481	O
was	10685817	1482	1485	O
significantly	10685817	1486	1499	B-Observation
improved	10685817	1500	1508	I-Observation
from	10685817	1509	1513	O
preinjection	10685817	1514	1526	B-Outcome
levels	10685817	1527	1533	I-Outcome
(	10685817	1534	1535	O
p	10685817	1536	1537	O
<	10685817	1538	1539	O
0.01	10685817	1540	1544	O
)	10685817	1545	1546	O
.	10685817	1547	1548	O

The	10685817	1549	1552	O
placebo	10685817	1553	1560	B-Intervention
group	10685817	1561	1566	O
showed	10685817	1567	1573	O
no	10685817	1574	1576	O
statistically	10685817	1577	1590	B-Observation
significant	10685817	1591	1602	I-Observation
changes	10685817	1603	1610	I-Observation
at	10685817	1611	1613	O
any	10685817	1614	1617	O
post-treatment	10685817	1618	1632	O
time	10685817	1633	1637	O
.	10685817	1638	1639	O

The	10685817	1640	1643	O
Vernon-Mior	10685817	1644	1655	B-Outcome
scale	10685817	1656	1661	I-Outcome
revealed	10685817	1662	1670	O
a	10685817	1671	1672	O
trend	10685817	1673	1678	B-Observation
to	10685817	1679	1681	I-Observation
improvement	10685817	1682	1693	I-Observation
for	10685817	1694	1697	O
both	10685817	1698	1702	B-Intervention
groups	10685817	1703	1709	I-Intervention
.	10685817	1710	1711	O

CONCLUSION	10685817	1712	1722	O
BTX-A	10685817	1723	1728	B-Intervention
treatment	10685817	1729	1738	O
of	10685817	1739	1741	O
subjects	10685817	1742	1750	O
with	10685817	1751	1755	O
chronic	10685817	1756	1763	B-Participant
WAD	10685817	1764	1767	I-Participant
II	10685817	1768	1770	I-Participant
neck	10685817	1771	1775	I-Participant
pain	10685817	1776	1780	I-Participant
resulted	10685817	1781	1789	O
in	10685817	1790	1792	O
a	10685817	1793	1794	O
significant	10685817	1795	1806	B-Observation
(	10685817	1807	1808	I-Observation
p	10685817	1809	1810	I-Observation
<	10685817	1811	1812	I-Observation
0.01	10685817	1813	1817	I-Observation
)	10685817	1818	1819	I-Observation
improvement	10685817	1820	1831	I-Observation
in	10685817	1832	1834	O
ROM	10685817	1835	1838	B-Outcome
and	10685817	1839	1842	O
subjective	10685817	1843	1853	B-Outcome
pain	10685817	1854	1858	I-Outcome
compared	10685817	1859	1867	O
to	10685817	1868	1870	O
a	10685817	1871	1872	O
placebo	10685817	1873	1880	B-Intervention
group	10685817	1881	1886	O
,	10685817	1887	1888	O
but	10685817	1889	1892	O
only	10685817	1893	1897	O
a	10685817	1898	1899	O
trend	10685817	1900	1905	B-Observation
to	10685817	1906	1908	I-Observation
improvement	10685817	1909	1920	I-Observation
in	10685817	1921	1923	O
subjective	10685817	1924	1934	B-Outcome
functioning	10685817	1935	1946	I-Outcome
.	10685817	1947	1948	O

Sun	10693733	0	3	B-Outcome
protection	10693733	4	14	I-Outcome
counseling	10693733	15	25	I-Outcome
for	10693733	26	29	I-Outcome
children	10693733	30	38	I-Outcome
:	10693733	39	40	O
primary	10693733	41	48	B-Outcome
care	10693733	49	53	I-Outcome
practice	10693733	54	62	I-Outcome
patterns	10693733	63	71	I-Outcome
and	10693733	72	75	O
effect	10693733	76	82	O
of	10693733	83	85	O
an	10693733	86	88	O
intervention	10693733	89	101	B-Intervention
on	10693733	102	104	O
clinicians	10693733	105	115	B-Participant
.	10693733	116	117	O

OBJECTIVES	10693733	118	128	O
To	10693733	129	131	O
describe	10693733	132	140	O
current	10693733	141	148	B-Outcome
primary	10693733	149	156	I-Outcome
care	10693733	157	161	I-Outcome
sun	10693733	162	165	I-Outcome
protection	10693733	166	176	I-Outcome
advice	10693733	177	183	I-Outcome
for	10693733	184	187	I-Outcome
children	10693733	188	196	I-Outcome
and	10693733	197	200	O
assess	10693733	201	207	O
the	10693733	208	211	O
effect	10693733	212	218	O
on	10693733	219	221	O
clinicians	10693733	222	232	B-Participant
of	10693733	233	235	O
an	10693733	236	238	O
intervention	10693733	239	251	B-Intervention
to	10693733	252	254	O
enhance	10693733	255	262	B-Observation
their	10693733	263	268	O
sun	10693733	269	272	B-Outcome
protection	10693733	273	283	I-Outcome
advocacy	10693733	284	292	I-Outcome
.	10693733	293	294	O

SETTING	10693733	295	302	O
Primary	10693733	303	310	O
care	10693733	311	315	O
practices	10693733	316	325	O
caring	10693733	326	332	O
for	10693733	333	336	O
children	10693733	337	345	O
in	10693733	346	348	O
New	10693733	349	352	O
Hampshire	10693733	353	362	O
with	10693733	363	367	O
special	10693733	368	375	O
attention	10693733	376	385	O
to	10693733	386	388	O
clinicians	10693733	389	399	O
serving	10693733	400	407	O
10	10693733	408	410	O
towns	10693733	411	416	O
that	10693733	417	421	O
were	10693733	422	426	O
involved	10693733	427	435	O
in	10693733	436	438	O
a	10693733	439	440	O
randomized	10693733	441	451	O
controlled	10693733	452	462	O
trial	10693733	463	468	O
of	10693733	469	471	O
the	10693733	472	475	O
multicomponent	10693733	476	490	B-Intervention
SunSafe	10693733	491	498	I-Intervention
intervention	10693733	499	511	I-Intervention
involving	10693733	512	521	O
schools	10693733	522	529	B-Participant
,	10693733	530	531	O
recreation	10693733	532	542	B-Participant
areas	10693733	543	548	I-Participant
,	10693733	549	550	O
and	10693733	551	554	O
primary	10693733	555	562	B-Participant
care	10693733	563	567	I-Participant
practices	10693733	568	577	I-Participant
.	10693733	578	579	O

DESIGN/INTERVENTION	10693733	580	599	O
A	10693733	600	601	O
statewide	10693733	602	611	O
survey	10693733	612	618	O
of	10693733	619	621	O
all	10693733	622	625	O
primary	10693733	626	633	B-Participant
care	10693733	634	638	I-Participant
clinicians	10693733	639	649	I-Participant
serving	10693733	650	657	I-Participant
children	10693733	658	666	I-Participant
addressed	10693733	667	676	O
their	10693733	677	682	O
self-reported	10693733	683	696	B-Outcome
sun	10693733	697	700	I-Outcome
protection	10693733	701	711	I-Outcome
advocacy	10693733	712	720	I-Outcome
practices	10693733	721	730	I-Outcome
.	10693733	731	732	O

Clinicians	10693733	733	743	B-Participant
in	10693733	744	746	O
10	10693733	747	749	O
systematically	10693733	750	764	O
selected	10693733	765	773	O
rural	10693733	774	779	O
towns	10693733	780	785	O
were	10693733	786	790	O
involved	10693733	791	799	O
in	10693733	800	802	O
the	10693733	803	806	O
subsequent	10693733	807	817	O
intervention	10693733	818	830	B-Intervention
study	10693733	831	836	O
.	10693733	837	838	O

The	10693733	839	842	O
primary	10693733	843	850	B-Intervention
care	10693733	851	855	I-Intervention
intervention	10693733	856	868	I-Intervention
provided	10693733	869	877	O
assistance	10693733	878	888	B-Intervention
to	10693733	889	891	I-Intervention
practices	10693733	892	901	I-Intervention
in	10693733	902	904	O
establishing	10693733	905	917	O
an	10693733	918	920	O
office	10693733	921	927	B-Intervention
system	10693733	928	934	I-Intervention
that	10693733	935	939	O
promoted	10693733	940	948	B-Observation
sun	10693733	949	952	B-Outcome
protection	10693733	953	963	I-Outcome
advice	10693733	964	970	I-Outcome
to	10693733	971	973	I-Outcome
children	10693733	974	982	I-Outcome
and	10693733	983	986	I-Outcome
their	10693733	987	992	I-Outcome
parents	10693733	993	1000	I-Outcome
during	10693733	1001	1007	O
office	10693733	1008	1014	O
visits	10693733	1015	1021	O
.	10693733	1022	1023	O

MAIN	10693733	1024	1028	O
OUTCOME	10693733	1029	1036	O
MEASURES	10693733	1037	1045	O
Sun	10693733	1046	1049	B-Outcome
protection	10693733	1050	1060	I-Outcome
promotion	10693733	1061	1070	I-Outcome
activities	10693733	1071	1081	I-Outcome
of	10693733	1082	1084	O
primary	10693733	1085	1092	B-Participant
care	10693733	1093	1097	I-Participant
clinicians	10693733	1098	1108	I-Participant
as	10693733	1109	1111	O
determined	10693733	1112	1122	O
by	10693733	1123	1125	O
their	10693733	1126	1131	O
self	10693733	1132	1136	B-Outcome
report	10693733	1137	1143	I-Outcome
,	10693733	1144	1145	O
research	10693733	1146	1154	B-Outcome
assistant	10693733	1155	1164	I-Outcome
observation	10693733	1165	1176	I-Outcome
,	10693733	1177	1178	O
and	10693733	1179	1182	O
parent	10693733	1183	1189	B-Outcome
interviews	10693733	1190	1200	I-Outcome
.	10693733	1201	1202	O

RESULTS	10693733	1203	1210	O
Of	10693733	1211	1213	O
261	10693733	1214	1217	B-Count
eligible	10693733	1218	1226	O
clinicians	10693733	1227	1237	B-Participant
responding	10693733	1238	1248	O
to	10693733	1249	1251	O
the	10693733	1252	1255	O
statewide	10693733	1256	1265	O
survey	10693733	1266	1272	O
,	10693733	1273	1274	O
about	10693733	1275	1280	O
half	10693733	1281	1285	B-Count
provide	10693733	1286	1293	O
sun	10693733	1294	1297	B-Outcome
protection	10693733	1298	1308	I-Outcome
counseling	10693733	1309	1319	I-Outcome
most	10693733	1320	1324	B-Observation
of	10693733	1325	1327	I-Observation
the	10693733	1328	1331	I-Observation
time	10693733	1332	1336	I-Observation
or	10693733	1337	1339	I-Observation
almost	10693733	1340	1346	I-Observation
always	10693733	1347	1353	I-Observation
during	10693733	1354	1360	O
summer	10693733	1361	1367	O
well	10693733	1368	1372	O
care	10693733	1373	1377	O
visits	10693733	1378	1384	O
.	10693733	1385	1386	O

Pediatricians	10693733	1387	1400	B-Participant
do	10693733	1401	1403	O
so	10693733	1404	1406	O
more	10693733	1407	1411	B-Observation
often	10693733	1412	1417	I-Observation
than	10693733	1418	1422	O
family	10693733	1423	1429	B-Participant
physicians	10693733	1430	1440	I-Participant
.	10693733	1441	1442	O

Clinicians	10693733	1443	1453	B-Participant
involved	10693733	1454	1462	O
in	10693733	1463	1465	O
the	10693733	1466	1469	O
intervention	10693733	1470	1482	B-Intervention
increased	10693733	1483	1492	B-Observation
their	10693733	1493	1498	O
use	10693733	1499	1502	B-Outcome
of	10693733	1503	1505	I-Outcome
handouts	10693733	1506	1514	I-Outcome
,	10693733	1515	1516	O
waiting	10693733	1517	1524	B-Outcome
room	10693733	1525	1529	I-Outcome
educational	10693733	1530	1541	I-Outcome
materials	10693733	1542	1551	I-Outcome
,	10693733	1552	1553	O
and	10693733	1554	1557	O
sunscreen	10693733	1558	1567	B-Outcome
samples	10693733	1568	1575	I-Outcome
.	10693733	1576	1577	O

Compared	10693733	1578	1586	O
with	10693733	1587	1591	O
control	10693733	1592	1599	B-Intervention
town	10693733	1600	1604	I-Intervention
parents	10693733	1605	1612	I-Intervention
,	10693733	1613	1614	O
parents	10693733	1615	1622	B-Intervention
in	10693733	1623	1625	I-Intervention
intervention	10693733	1626	1638	I-Intervention
towns	10693733	1639	1644	I-Intervention
reported	10693733	1645	1653	O
an	10693733	1654	1656	O
increase	10693733	1657	1665	B-Observation
in	10693733	1666	1668	O
clinician	10693733	1669	1678	B-Outcome
sun	10693733	1679	1682	I-Outcome
protection	10693733	1683	1693	I-Outcome
advice	10693733	1694	1700	I-Outcome
.	10693733	1701	1702	O

CONCLUSIONS	10693733	1703	1714	O
The	10693733	1715	1718	O
SunSafe	10693733	1719	1726	B-Intervention
primary	10693733	1727	1734	I-Intervention
care	10693733	1735	1739	I-Intervention
intervention	10693733	1740	1752	I-Intervention
increased	10693733	1753	1762	B-Observation
sun	10693733	1763	1766	B-Outcome
protection	10693733	1767	1777	I-Outcome
counseling	10693733	1778	1788	I-Outcome
activities	10693733	1789	1799	I-Outcome
of	10693733	1800	1802	O
participating	10693733	1803	1816	B-Participant
clinicians	10693733	1817	1827	I-Participant
.	10693733	1828	1829	O

A	10693733	1830	1831	O
single-focus	10693733	1832	1844	O
preventive	10693733	1845	1855	O
service	10693733	1856	1863	O
office	10693733	1864	1870	O
system	10693733	1871	1877	O
is	10693733	1878	1880	O
feasible	10693733	1881	1889	O
to	10693733	1890	1892	O
include	10693733	1893	1900	O
in	10693733	1901	1903	O
community	10693733	1904	1913	O
interventions	10693733	1914	1927	O
to	10693733	1928	1930	O
promote	10693733	1931	1938	O
sun	10693733	1939	1942	O
protection	10693733	1943	1953	O
.	10693733	1954	1955	O

Efficacy	10703628	0	8	O
of	10703628	9	11	O
a	10703628	12	13	O
barrier	10703628	14	21	B-Intervention
cream	10703628	22	27	I-Intervention
and	10703628	28	31	O
its	10703628	32	35	O
vehicle	10703628	36	43	B-Intervention
as	10703628	44	46	O
protective	10703628	47	57	B-Observation
measures	10703628	58	66	I-Observation
against	10703628	67	74	O
occupational	10703628	75	87	B-Outcome
irritant	10703628	88	96	I-Outcome
contact	10703628	97	104	I-Outcome
dermatitis	10703628	105	115	I-Outcome
.	10703628	116	117	O

The	10703628	118	121	O
actual	10703628	122	128	O
advantage	10703628	129	138	O
of	10703628	139	141	O
barrier	10703628	142	149	O
creams	10703628	150	156	O
over	10703628	157	161	O
bland	10703628	162	167	O
emollients	10703628	168	178	O
for	10703628	179	182	O
skin	10703628	183	187	O
protection	10703628	188	198	O
is	10703628	199	201	O
still	10703628	202	207	O
hotly	10703628	208	213	O
debated	10703628	214	221	O
.	10703628	222	223	O

In	10703628	224	226	O
a	10703628	227	228	O
randomized	10703628	229	239	O
,	10703628	240	241	O
double-blinded	10703628	242	256	O
study	10703628	257	262	O
,	10703628	263	264	O
a	10703628	265	266	O
newly-introduced	10703628	267	283	O
barrier	10703628	284	291	B-Intervention
cream	10703628	292	297	I-Intervention
and	10703628	298	301	O
its	10703628	302	305	O
moisturizing	10703628	306	318	B-Intervention
vehicle	10703628	319	326	I-Intervention
were	10703628	327	331	O
compared	10703628	332	340	O
regarding	10703628	341	350	O
their	10703628	351	356	O
skin	10703628	357	361	B-Outcome
compatibility	10703628	362	375	I-Outcome
,	10703628	376	377	O
efficacy	10703628	378	386	B-Outcome
and	10703628	387	390	O
resulting	10703628	391	400	B-Outcome
acceptance	10703628	401	411	I-Outcome
.	10703628	412	413	O

Thus	10703628	414	418	O
,	10703628	419	420	O
2	10703628	421	422	O
panels	10703628	423	429	O
of	10703628	430	432	O
25	10703628	433	435	O
hospital	10703628	436	444	O
nurses	10703628	445	451	O
with	10703628	452	456	O
mild	10703628	457	461	B-Participant
signs	10703628	462	467	I-Participant
of	10703628	468	470	I-Participant
skin	10703628	471	475	I-Participant
irritation	10703628	476	486	I-Participant
were	10703628	487	491	O
asked	10703628	492	497	O
to	10703628	498	500	O
use	10703628	501	504	O
1	10703628	505	506	O
of	10703628	507	509	O
the	10703628	510	513	O
test	10703628	514	518	B-Intervention
products	10703628	519	527	I-Intervention
provided	10703628	528	536	O
(	10703628	537	538	O
verum	10703628	539	544	B-Intervention
or	10703628	545	547	O
vehicle	10703628	548	555	B-Intervention
)	10703628	556	557	O
over	10703628	558	562	O
a	10703628	563	564	O
period	10703628	565	571	O
of	10703628	572	574	O
4	10703628	575	576	O
weeks	10703628	577	582	O
.	10703628	583	584	O

Effects	10703628	585	592	O
of	10703628	593	595	O
both	10703628	596	600	B-Intervention
types	10703628	601	606	I-Intervention
of	10703628	607	609	I-Intervention
preparations	10703628	610	622	I-Intervention
were	10703628	623	627	O
studied	10703628	628	635	O
weekly	10703628	636	642	O
by	10703628	643	645	O
clinical	10703628	646	654	B-Outcome
examination	10703628	655	666	I-Outcome
and	10703628	667	670	O
the	10703628	671	674	O
instrumental	10703628	675	687	O
assessment	10703628	688	698	O
of	10703628	699	701	O
bioengineering	10703628	702	716	B-Outcome
parameters	10703628	717	727	I-Outcome
.	10703628	728	729	O

Results	10703628	730	737	O
showed	10703628	738	744	O
no	10703628	745	747	O
significant	10703628	748	759	B-Observation
differences	10703628	760	771	I-Observation
between	10703628	772	779	O
barrier	10703628	780	787	B-Intervention
cream	10703628	788	793	I-Intervention
and	10703628	794	797	O
vehicle	10703628	798	805	B-Intervention
.	10703628	806	807	O

In	10703628	808	810	O
both	10703628	811	815	B-Intervention
groups	10703628	816	822	I-Intervention
,	10703628	823	824	O
clinical	10703628	825	833	B-Outcome
skin	10703628	834	838	I-Outcome
status	10703628	839	845	I-Outcome
improved	10703628	846	854	B-Observation
and	10703628	855	858	O
stratum	10703628	859	866	B-Outcome
corneum	10703628	867	874	I-Outcome
hydration	10703628	875	884	I-Outcome
increased	10703628	885	894	B-Observation
significantly	10703628	895	908	I-Observation
during	10703628	909	915	O
the	10703628	916	919	O
study	10703628	920	925	O
period	10703628	926	932	O
.	10703628	933	934	O

Both	10703628	935	939	B-Intervention
preparations	10703628	940	952	I-Intervention
were	10703628	953	957	O
tolerated	10703628	958	967	B-Observation
and	10703628	968	971	O
accepted	10703628	972	980	B-Observation
well	10703628	981	985	I-Observation
,	10703628	986	987	O
thus	10703628	988	992	O
showing	10703628	993	1000	O
both	10703628	1001	1005	O
skin	10703628	1006	1010	B-Outcome
protection	10703628	1011	1021	I-Outcome
and	10703628	1022	1025	O
skin	10703628	1026	1030	B-Outcome
care	10703628	1031	1035	I-Outcome
.	10703628	1036	1037	O

These	10703628	1038	1043	O
results	10703628	1044	1051	O
contribute	10703628	1052	1062	O
to	10703628	1063	1065	O
the	10703628	1066	1069	O
debate	10703628	1070	1076	O
as	10703628	1077	1079	O
to	10703628	1080	1082	O
whether	10703628	1083	1090	O
a	10703628	1091	1092	O
strict	10703628	1093	1099	O
distinction	10703628	1100	1111	O
between	10703628	1112	1119	O
skin	10703628	1120	1124	O
care	10703628	1125	1129	O
and	10703628	1130	1133	O
skin	10703628	1134	1138	O
protection	10703628	1139	1149	O
products	10703628	1150	1158	O
is	10703628	1159	1161	O
justified	10703628	1162	1171	O
.	10703628	1172	1173	O

The	10703628	1174	1177	O
vehicle	10703628	1178	1185	B-Intervention
alone	10703628	1186	1191	I-Intervention
is	10703628	1192	1194	O
capable	10703628	1195	1202	B-Observation
of	10703628	1203	1205	I-Observation
positively	10703628	1206	1216	I-Observation
influencing	10703628	1217	1228	I-Observation
skin	10703628	1229	1233	B-Outcome
status	10703628	1234	1240	I-Outcome
.	10703628	1241	1242	O

Emphasis	10703628	1243	1251	O
must	10703628	1252	1256	O
be	10703628	1257	1259	O
laid	10703628	1260	1264	O
on	10703628	1265	1267	O
regular	10703628	1268	1275	O
,	10703628	1276	1277	O
frequent	10703628	1278	1286	O
,	10703628	1287	1288	O
and	10703628	1289	1292	O
correct	10703628	1293	1300	O
application	10703628	1301	1312	O
of	10703628	1313	1315	O
a	10703628	1316	1317	O
product	10703628	1318	1325	O
for	10703628	1326	1329	O
it	10703628	1330	1332	O
to	10703628	1333	1335	O
be	10703628	1336	1338	O
effective	10703628	1339	1348	O
.	10703628	1349	1350	O

Blood	10719133	0	5	B-Intervention
pressure	10719133	6	14	I-Intervention
biofeedback	10719133	15	26	I-Intervention
treatment	10719133	27	36	I-Intervention
of	10719133	37	39	O
white-coat	10719133	40	50	B-Participant
hypertension	10719133	51	63	I-Participant
.	10719133	64	65	O

OBJECTIVE	10719133	66	75	O
The	10719133	76	79	O
objective	10719133	80	89	O
of	10719133	90	92	O
the	10719133	93	96	O
study	10719133	97	102	O
was	10719133	103	106	O
to	10719133	107	109	O
compare	10719133	110	117	O
blood	10719133	118	123	B-Intervention
pressure	10719133	124	132	I-Intervention
(	10719133	133	134	I-Intervention
BP	10719133	135	137	I-Intervention
)	10719133	138	139	I-Intervention
biofeedback	10719133	140	151	I-Intervention
treatment	10719133	152	161	I-Intervention
(	10719133	162	163	I-Intervention
BF	10719133	164	166	I-Intervention
)	10719133	167	168	I-Intervention
effects	10719133	169	176	O
between	10719133	177	184	O
white-coat	10719133	185	195	B-Participant
hypertension	10719133	196	208	I-Participant
and	10719133	209	212	O
essential	10719133	213	222	B-Participant
hypertension	10719133	223	235	I-Participant
.	10719133	236	237	O

METHODS	10719133	238	245	O
Fifteen	10719133	246	253	O
white-coat	10719133	254	264	B-Participant
hypertensive	10719133	265	277	I-Participant
out-patients	10719133	278	290	I-Participant
and	10719133	291	294	O
23	10719133	295	297	O
essential	10719133	298	307	B-Participant
hypertensive	10719133	308	320	I-Participant
out-patients	10719133	321	333	I-Participant
were	10719133	334	338	O
randomly	10719133	339	347	O
assigned	10719133	348	356	O
to	10719133	357	359	O
groups	10719133	360	366	B-Intervention
A	10719133	367	368	I-Intervention
or	10719133	369	371	O
B	10719133	372	373	B-Intervention
.	10719133	374	375	O

Subjects	10719133	376	384	O
in	10719133	385	387	O
group	10719133	388	393	B-Intervention
A	10719133	394	395	I-Intervention
underwent	10719133	396	405	O
BF	10719133	406	408	B-Intervention
once	10719133	409	413	I-Intervention
a	10719133	414	415	I-Intervention
week	10719133	416	420	I-Intervention
for	10719133	421	424	I-Intervention
a	10719133	425	426	I-Intervention
total	10719133	427	432	I-Intervention
of	10719133	433	435	I-Intervention
four	10719133	436	440	I-Intervention
sessions	10719133	441	449	I-Intervention
.	10719133	450	451	O

Those	10719133	452	457	O
in	10719133	458	460	O
group	10719133	461	466	B-Intervention
B	10719133	467	468	I-Intervention
visited	10719133	469	476	O
the	10719133	477	480	O
clinic	10719133	481	487	O
only	10719133	488	492	O
to	10719133	493	495	O
measure	10719133	496	503	O
BP	10719133	504	506	B-Outcome
and	10719133	507	510	O
later	10719133	511	516	O
underwent	10719133	517	526	O
the	10719133	527	530	O
same	10719133	531	535	B-Intervention
BF	10719133	536	538	I-Intervention
.	10719133	539	540	O

RESULTS	10719133	541	548	O
In	10719133	549	551	O
group	10719133	552	557	B-Intervention
A	10719133	558	559	I-Intervention
,	10719133	560	561	O
BPs	10719133	562	565	B-Outcome
of	10719133	566	568	O
white-coat	10719133	569	579	B-Participant
hypertensives	10719133	580	593	I-Participant
and	10719133	594	597	O
essential	10719133	598	607	B-Participant
hypertensives	10719133	608	621	I-Participant
were	10719133	622	626	O
significantly	10719133	627	640	B-Observation
reduced	10719133	641	648	I-Observation
by	10719133	649	651	O
22/11	10719133	652	657	B-Observation
and	10719133	658	661	O
14/8	10719133	662	666	B-Observation
mmHg	10719133	667	671	I-Observation
,	10719133	672	673	O
respectively	10719133	674	686	O
.	10719133	687	688	O

In	10719133	689	691	O
group	10719133	692	697	B-Intervention
B	10719133	698	699	I-Intervention
,	10719133	700	701	O
they	10719133	702	706	O
were	10719133	707	711	O
unchanged	10719133	712	721	B-Observation
during	10719133	722	728	O
the	10719133	729	732	O
same	10719133	733	737	O
period	10719133	738	744	O
but	10719133	745	748	O
later	10719133	749	754	B-Observation
suppressed	10719133	755	765	I-Observation
by	10719133	766	768	O
BF	10719133	769	771	B-Intervention
.	10719133	772	773	O

Under	10719133	774	779	O
BF	10719133	780	782	B-Intervention
,	10719133	783	784	O
pulse	10719133	785	790	B-Outcome
and	10719133	791	794	I-Outcome
respiratory	10719133	795	806	I-Outcome
rates	10719133	807	812	I-Outcome
were	10719133	813	817	O
significantly	10719133	818	831	B-Observation
higher	10719133	832	838	I-Observation
,	10719133	839	840	O
and	10719133	841	844	O
elevation	10719133	845	854	B-Outcome
of	10719133	855	857	I-Outcome
diastolic	10719133	858	867	I-Outcome
BP	10719133	868	870	I-Outcome
due	10719133	871	874	I-Outcome
to	10719133	875	877	I-Outcome
mental	10719133	878	884	I-Outcome
stress	10719133	885	891	I-Outcome
testing	10719133	892	899	I-Outcome
was	10719133	900	903	O
better	10719133	904	910	B-Observation
suppressed	10719133	911	921	I-Observation
in	10719133	922	924	O
white-coat	10719133	925	935	B-Participant
hypertensives	10719133	936	949	I-Participant
than	10719133	950	954	O
in	10719133	955	957	O
essential	10719133	958	967	B-Participant
hypertensives	10719133	968	981	I-Participant
.	10719133	982	983	O

CONCLUSION	10719133	984	994	O
This	10719133	995	999	O
treatment	10719133	1000	1009	B-Intervention
was	10719133	1010	1013	O
effective	10719133	1014	1023	B-Observation
in	10719133	1024	1026	O
both	10719133	1027	1031	B-Participant
types	10719133	1032	1037	I-Participant
of	10719133	1038	1040	I-Participant
hypertension	10719133	1041	1053	I-Participant
,	10719133	1054	1055	O
and	10719133	1056	1059	O
pressor	10719133	1060	1067	O
response	10719133	1068	1076	O
to	10719133	1077	1079	O
stress	10719133	1080	1086	O
seems	10719133	1087	1092	O
to	10719133	1093	1095	O
be	10719133	1096	1098	O
important	10719133	1099	1108	O
in	10719133	1109	1111	O
the	10719133	1112	1115	O
differentiated	10719133	1116	1130	O
BF	10719133	1131	1133	B-Intervention
effect	10719133	1134	1140	I-Intervention
.	10719133	1141	1142	O

Growth	10720081	0	6	B-Outcome
hormone	10720081	7	14	I-Outcome
(	10720081	15	16	I-Outcome
GH	10720081	17	19	I-Outcome
)	10720081	20	21	I-Outcome
responses	10720081	22	31	I-Outcome
to	10720081	32	34	O
GH-releasing	10720081	35	47	B-Intervention
hormone	10720081	48	55	I-Intervention
alone	10720081	56	61	I-Intervention
or	10720081	62	64	O
combined	10720081	65	73	B-Intervention
with	10720081	74	78	I-Intervention
arginine	10720081	79	87	I-Intervention
in	10720081	88	90	O
patients	10720081	91	99	O
with	10720081	100	104	O
adrenal	10720081	105	112	B-Participant
incidentaloma	10720081	113	126	I-Participant
:	10720081	127	128	O
evidence	10720081	129	137	O
for	10720081	138	141	O
enhanced	10720081	142	150	O
somatostatinergic	10720081	151	168	O
tone	10720081	169	173	O
.	10720081	174	175	O

Spontaneous	10720081	176	187	O
and	10720081	188	191	O
stimulated	10720081	192	202	O
GH	10720081	203	205	O
secretion	10720081	206	215	O
is	10720081	216	218	O
blunted	10720081	219	226	O
in	10720081	227	229	O
hypercortisolemic	10720081	230	247	O
states	10720081	248	254	O
due	10720081	255	258	O
to	10720081	259	261	O
increased	10720081	262	271	O
hypothalamic	10720081	272	284	O
somatostatinergic	10720081	285	302	O
tone	10720081	303	307	O
.	10720081	308	309	O

However	10720081	310	317	O
,	10720081	318	319	O
no	10720081	320	322	O
data	10720081	323	327	O
are	10720081	328	331	O
available	10720081	332	341	O
on	10720081	342	344	O
the	10720081	345	348	O
characteristics	10720081	349	364	O
of	10720081	365	367	O
GH	10720081	368	370	O
secretion	10720081	371	380	O
in	10720081	381	383	O
patients	10720081	384	392	O
with	10720081	393	397	O
incidentally	10720081	398	410	O
discovered	10720081	411	421	O
adrenal	10720081	422	429	O
adenomas	10720081	430	438	O
.	10720081	439	440	O

They	10720081	441	445	O
represent	10720081	446	455	O
an	10720081	456	458	O
interesting	10720081	459	470	O
model	10720081	471	476	O
for	10720081	477	480	O
studying	10720081	481	489	O
GH	10720081	490	492	O
secretion	10720081	493	502	O
,	10720081	503	504	O
as	10720081	505	507	O
a	10720081	508	509	O
slight	10720081	510	516	O
degree	10720081	517	523	O
of	10720081	524	526	O
cortisol	10720081	527	535	O
excess	10720081	536	542	O
may	10720081	543	546	O
frequently	10720081	547	557	O
be	10720081	558	560	O
observed	10720081	561	569	O
in	10720081	570	572	O
such	10720081	573	577	O
patients	10720081	578	586	O
who	10720081	587	590	O
do	10720081	591	593	O
not	10720081	594	597	O
present	10720081	598	605	O
with	10720081	606	610	O
any	10720081	611	614	O
clear	10720081	615	620	O
Cushingoid	10720081	621	631	O
sign	10720081	632	636	O
.	10720081	637	638	O

In	10720081	639	641	O
the	10720081	642	645	O
present	10720081	646	653	O
study	10720081	654	659	O
,	10720081	660	661	O
10	10720081	662	664	B-Count
patients	10720081	665	673	I-Count
(	10720081	674	675	O
3	10720081	676	677	O
men	10720081	678	681	O
and	10720081	682	685	O
7	10720081	686	687	O
women	10720081	688	693	O
,	10720081	694	695	O
aged	10720081	696	700	O
48	10720081	701	703	O
-	10720081	703	704	O
63	10720081	704	706	O
yr	10720081	707	709	O
)	10720081	710	711	O
with	10720081	712	716	O
an	10720081	717	719	O
adrenal	10720081	720	727	B-Participant
mass	10720081	728	732	I-Participant
discovered	10720081	733	743	I-Participant
serendipitously	10720081	744	759	I-Participant
underwent	10720081	760	769	O
,	10720081	770	771	O
on	10720081	772	774	O
separate	10720081	775	783	O
occasions	10720081	784	793	O
,	10720081	794	795	O
a	10720081	796	797	O
GHRH	10720081	798	802	B-Intervention
injection	10720081	803	812	I-Intervention
alone	10720081	813	818	I-Intervention
or	10720081	819	821	O
combined	10720081	822	830	B-Intervention
with	10720081	831	835	I-Intervention
an	10720081	836	838	I-Intervention
infusion	10720081	839	847	I-Intervention
of	10720081	848	850	I-Intervention
the	10720081	851	854	I-Intervention
functional	10720081	855	865	I-Intervention
somatostatin	10720081	866	878	I-Intervention
antagonist	10720081	879	889	I-Intervention
,	10720081	890	891	I-Intervention
arginine	10720081	892	900	I-Intervention
.	10720081	901	902	O

Thirteen	10720081	903	911	B-Count
age-matched	10720081	912	923	B-Participant
healthy	10720081	924	931	I-Participant
volunteers	10720081	932	942	O
served	10720081	943	949	O
as	10720081	950	952	O
controls	10720081	953	961	B-Intervention
.	10720081	962	963	O

Briefly	10720081	964	971	O
,	10720081	972	973	O
arginine	10720081	974	982	B-Intervention
(	10720081	983	984	O
30	10720081	985	987	O
g	10720081	988	989	O
)	10720081	990	991	O
was	10720081	992	995	O
infused	10720081	996	1003	O
from	10720081	1004	1008	O
-30	10720081	1009	1012	O
to	10720081	1013	1015	O
0	10720081	1016	1017	O
min	10720081	1018	1021	O
,	10720081	1022	1023	O
and	10720081	1024	1027	O
GHRH	10720081	1028	1032	B-Intervention
(	10720081	1033	1034	O
100	10720081	1035	1038	O
microg	10720081	1039	1045	O
)	10720081	1046	1047	O
was	10720081	1048	1051	O
injected	10720081	1052	1060	O
as	10720081	1061	1063	O
a	10720081	1064	1065	O
bolus	10720081	1066	1071	O
at	10720081	1072	1074	O
0	10720081	1075	1076	O
min	10720081	1077	1080	O
,	10720081	1081	1082	O
with	10720081	1083	1087	O
measurement	10720081	1088	1099	O
of	10720081	1100	1102	O
serum	10720081	1103	1108	B-Outcome
GH	10720081	1109	1111	I-Outcome
[	10720081	1112	1113	O
immunoradiometric	10720081	1114	1131	O
assay	10720081	1132	1137	O
(	10720081	1138	1139	O
IRMA	10720081	1140	1144	O
)	10720081	1145	1146	O
]	10720081	1147	1148	O
every	10720081	1149	1154	O
15	10720081	1155	1157	O
min	10720081	1158	1161	O
for	10720081	1162	1165	O
150	10720081	1166	1169	O
min	10720081	1170	1173	O
.	10720081	1174	1175	O

Plasma	10720081	1176	1182	B-Outcome
IGF-I	10720081	1183	1188	I-Outcome
(	10720081	1189	1190	O
RIA	10720081	1191	1194	O
after	10720081	1195	1200	O
acid-ethanol	10720081	1201	1213	O
extraction	10720081	1214	1224	O
)	10720081	1225	1226	O
was	10720081	1227	1230	O
measured	10720081	1231	1239	O
in	10720081	1240	1242	O
a	10720081	1243	1244	O
morning	10720081	1245	1252	O
sample	10720081	1253	1259	O
.	10720081	1260	1261	O

The	10720081	1262	1265	O
diagnosis	10720081	1266	1275	O
of	10720081	1276	1278	O
cortical	10720081	1279	1287	B-Participant
adenoma	10720081	1288	1295	I-Participant
was	10720081	1296	1299	O
based	10720081	1300	1305	O
on	10720081	1306	1308	O
computed	10720081	1309	1317	O
tomography	10720081	1318	1328	O
features	10720081	1329	1337	O
and	10720081	1338	1341	O
pattern	10720081	1342	1349	O
of	10720081	1350	1352	O
uptake	10720081	1353	1359	O
on	10720081	1360	1362	O
adrenal	10720081	1363	1370	O
scintigraphy	10720081	1371	1383	O
.	10720081	1384	1385	O

Patients	10720081	1386	1394	O
with	10720081	1395	1399	O
obesity	10720081	1400	1407	B-Participant
and/or	10720081	1408	1414	O
diabetes	10720081	1415	1423	B-Participant
were	10720081	1424	1428	O
excluded	10720081	1429	1437	O
.	10720081	1438	1439	O

The	10720081	1440	1443	O
study	10720081	1444	1449	O
design	10720081	1450	1456	O
included	10720081	1457	1465	O
also	10720081	1466	1470	O
an	10720081	1471	1473	O
endocrine	10720081	1474	1483	O
work-up	10720081	1484	1491	O
aimed	10720081	1492	1497	O
to	10720081	1498	1500	O
study	10720081	1501	1506	O
the	10720081	1507	1510	O
hypothalamic-pituitary-adrenal	10720081	1511	1541	B-Outcome
axis	10720081	1542	1546	I-Outcome
[	10720081	1547	1548	O
urinary	10720081	1549	1556	B-Outcome
free	10720081	1557	1561	I-Outcome
cortisol	10720081	1562	1570	I-Outcome
(	10720081	1571	1572	I-Outcome
UFC	10720081	1573	1576	I-Outcome
)	10720081	1577	1578	I-Outcome
excretion	10720081	1579	1588	I-Outcome
,	10720081	1589	1590	O
serum	10720081	1591	1596	B-Outcome
cortisol	10720081	1597	1605	I-Outcome
at	10720081	1606	1608	I-Outcome
0800	10720081	1609	1613	I-Outcome
h	10720081	1614	1615	I-Outcome
,	10720081	1616	1617	O
plasma	10720081	1618	1624	B-Outcome
ACTH	10720081	1625	1629	I-Outcome
at	10720081	1630	1632	I-Outcome
0800	10720081	1633	1637	I-Outcome
h	10720081	1638	1639	I-Outcome
,	10720081	1640	1641	O
morning	10720081	1642	1649	B-Outcome
cortisol	10720081	1650	1658	I-Outcome
after	10720081	1659	1664	I-Outcome
overnight	10720081	1665	1674	I-Outcome
1	10720081	1675	1676	I-Outcome
mg	10720081	1677	1679	I-Outcome
dexamethasone	10720081	1680	1693	I-Outcome
]	10720081	1694	1695	O
.	10720081	1696	1697	O

Five	10720081	1698	1702	B-Count
of	10720081	1703	1705	I-Count
10	10720081	1706	1708	I-Count
patients	10720081	1709	1717	I-Count
showed	10720081	1718	1724	O
abnormalities	10720081	1725	1738	B-Observation
of	10720081	1739	1741	O
the	10720081	1742	1745	O
hypothalamic-pituitary-adrenal	10720081	1746	1776	B-Outcome
axis	10720081	1777	1781	I-Outcome
,	10720081	1782	1783	O
including	10720081	1784	1793	O
borderline	10720081	1794	1804	B-Observation
or	10720081	1805	1807	I-Observation
increased	10720081	1808	1817	I-Observation
UFC	10720081	1818	1821	B-Outcome
excretion	10720081	1822	1831	I-Outcome
in	10720081	1832	1834	O
4	10720081	1835	1836	B-Count
of	10720081	1837	1839	I-Count
them	10720081	1840	1844	I-Count
accompanied	10720081	1845	1856	O
by	10720081	1857	1859	O
blunted	10720081	1860	1867	B-Observation
ACTH	10720081	1868	1872	B-Outcome
in	10720081	1873	1875	O
2	10720081	1876	1877	B-Count
cases	10720081	1878	1883	I-Count
and	10720081	1884	1887	O
failure	10720081	1888	1895	B-Outcome
of	10720081	1896	1898	I-Outcome
cortisol	10720081	1899	1907	I-Outcome
to	10720081	1908	1910	I-Outcome
suppress	10720081	1911	1919	I-Outcome
after	10720081	1920	1925	I-Outcome
dexamethasone	10720081	1926	1939	I-Outcome
in	10720081	1940	1942	O
1	10720081	1943	1944	B-Count
;	10720081	1945	1946	O
the	10720081	1947	1950	O
fifth	10720081	1951	1956	B-Count
patient	10720081	1957	1964	I-Count
displayed	10720081	1965	1974	O
low	10720081	1975	1978	B-Observation
ACTH	10720081	1979	1983	B-Outcome
and	10720081	1984	1987	O
resistance	10720081	1988	1998	B-Outcome
to	10720081	1999	2001	I-Outcome
dexamethasone	10720081	2002	2015	I-Outcome
suppression	10720081	2016	2027	I-Outcome
.	10720081	2028	2029	O

However	10720081	2030	2037	O
,	10720081	2038	2039	O
all	10720081	2040	2043	B-Count
patients	10720081	2044	2052	I-Count
had	10720081	2053	2056	O
a	10720081	2057	2058	O
unilateral	10720081	2059	2069	B-Outcome
uptake	10720081	2070	2076	I-Outcome
of	10720081	2077	2079	I-Outcome
the	10720081	2080	2083	I-Outcome
tracer	10720081	2084	2090	I-Outcome
on	10720081	2091	2093	I-Outcome
the	10720081	2094	2097	I-Outcome
side	10720081	2098	2102	I-Outcome
of	10720081	2103	2105	I-Outcome
the	10720081	2106	2109	I-Outcome
mass	10720081	2110	2114	I-Outcome
with	10720081	2115	2119	I-Outcome
suppression	10720081	2120	2131	I-Outcome
of	10720081	2132	2134	I-Outcome
the	10720081	2135	2138	I-Outcome
contralateral	10720081	2139	2152	I-Outcome
normal	10720081	2153	2159	I-Outcome
adrenal	10720081	2160	2167	I-Outcome
gland	10720081	2168	2173	I-Outcome
.	10720081	2174	2175	O

As	10720081	2176	2178	O
a	10720081	2179	2180	O
group	10720081	2181	2186	B-Intervention
,	10720081	2187	2188	O
the	10720081	2189	2192	O
patients	10720081	2193	2201	O
displayed	10720081	2202	2211	O
greater	10720081	2212	2219	B-Observation
UFC	10720081	2220	2223	B-Outcome
excretion	10720081	2224	2233	I-Outcome
and	10720081	2234	2237	O
lower	10720081	2238	2243	B-Observation
ACTH	10720081	2244	2248	B-Outcome
concentrations	10720081	2249	2263	I-Outcome
than	10720081	2264	2268	O
the	10720081	2269	2272	O
controls	10720081	2273	2281	B-Intervention
.	10720081	2282	2283	O

GH	10720081	2284	2286	B-Outcome
release	10720081	2287	2294	I-Outcome
after	10720081	2295	2300	O
GHRH	10720081	2301	2305	B-Intervention
treatment	10720081	2306	2315	O
was	10720081	2316	2319	O
blunted	10720081	2320	2327	B-Observation
in	10720081	2328	2330	O
patients	10720081	2331	2339	O
bearing	10720081	2340	2347	O
adrenal	10720081	2348	2355	B-Participant
incidentaloma	10720081	2356	2369	I-Participant
compared	10720081	2370	2378	O
with	10720081	2379	2383	O
controls	10720081	2384	2392	B-Intervention
(	10720081	2393	2394	O
GH	10720081	2395	2397	B-Outcome
peak	10720081	2398	2402	I-Outcome
,	10720081	2403	2404	O
5.7	10720081	2405	2408	B-Observation
+	10720081	2409	2410	I-Observation
/-	10720081	2410	2412	I-Observation
5.2	10720081	2413	2416	I-Observation
vs.	10720081	2417	2420	O
18.0	10720081	2421	2425	B-Observation
+	10720081	2426	2427	I-Observation
/-	10720081	2427	2429	I-Observation
7.0	10720081	2430	2433	I-Observation
microg/L	10720081	2434	2442	I-Observation
;	10720081	2443	2444	O
P	10720081	2445	2446	O
<	10720081	2447	2448	O
0.0001	10720081	2449	2455	O
)	10720081	2456	2457	O
,	10720081	2458	2459	O
whereas	10720081	2460	2467	O
GHRH	10720081	2468	2472	B-Intervention
plus	10720081	2473	2477	I-Intervention
arginine	10720081	2478	2486	I-Intervention
was	10720081	2487	2490	O
able	10720081	2491	2495	O
to	10720081	2496	2498	O
elicit	10720081	2499	2505	O
a	10720081	2506	2507	O
comparable	10720081	2508	2518	B-Observation
response	10720081	2519	2527	B-Outcome
in	10720081	2528	2530	O
the	10720081	2531	2534	O
2	10720081	2535	2536	B-Intervention
groups	10720081	2537	2543	I-Intervention
(	10720081	2544	2545	O
GH	10720081	2546	2548	B-Outcome
peak	10720081	2549	2553	I-Outcome
,	10720081	2554	2555	O
33.5	10720081	2556	2560	B-Observation
+	10720081	2561	2562	I-Observation
/-	10720081	2562	2564	I-Observation
20.3	10720081	2565	2569	I-Observation
vs.	10720081	2570	2573	O
33.7	10720081	2574	2578	B-Observation
+	10720081	2579	2580	I-Observation
/-	10720081	2580	2582	I-Observation
17.5	10720081	2583	2587	I-Observation
microg/L	10720081	2588	2596	I-Observation
;	10720081	2597	2598	O
P	10720081	2599	2600	O
=	10720081	2601	2602	O
NS	10720081	2603	2605	O
)	10720081	2606	2607	O
.	10720081	2608	2609	O

The	10720081	2610	2613	O
ratio	10720081	2614	2619	B-Outcome
between	10720081	2620	2627	I-Outcome
GH	10720081	2628	2630	I-Outcome
peaks	10720081	2631	2636	I-Outcome
after	10720081	2637	2642	O
GHRH	10720081	2643	2647	B-Intervention
plus	10720081	2648	2652	I-Intervention
arginine	10720081	2653	2661	I-Intervention
and	10720081	2662	2665	O
after	10720081	2666	2671	O
GHRH	10720081	2672	2676	B-Intervention
plus	10720081	2677	2681	I-Intervention
saline	10720081	2682	2688	I-Intervention
was	10720081	2689	2692	O
significantly	10720081	2693	2706	B-Observation
greater	10720081	2707	2714	I-Observation
in	10720081	2715	2717	O
patients	10720081	2718	2726	O
than	10720081	2727	2731	O
in	10720081	2732	2734	O
controls	10720081	2735	2743	B-Intervention
(	10720081	2744	2745	O
751	10720081	2746	2749	B-Observation
+	10720081	2750	2751	I-Observation
/-	10720081	2751	2753	I-Observation
531	10720081	2754	2757	I-Observation
%	10720081	2758	2759	I-Observation
vs.	10720081	2760	2763	O
81	10720081	2764	2766	B-Observation
+	10720081	2767	2768	I-Observation
/-	10720081	2768	2770	I-Observation
45	10720081	2771	2773	I-Observation
%	10720081	2774	2775	I-Observation
;	10720081	2776	2777	O
P	10720081	2778	2779	O
=	10720081	2780	2781	O
0.0001	10720081	2782	2788	O
)	10720081	2789	2790	O
.	10720081	2791	2792	O

Similar	10720081	2793	2800	B-Observation
data	10720081	2801	2805	I-Observation
were	10720081	2806	2810	O
obtained	10720081	2811	2819	O
when	10720081	2820	2824	O
comparing	10720081	2825	2834	O
GH	10720081	2835	2837	B-Outcome
area	10720081	2838	2842	I-Outcome
under	10720081	2843	2848	I-Outcome
the	10720081	2849	2852	I-Outcome
curve	10720081	2853	2858	I-Outcome
after	10720081	2859	2864	O
GHRH	10720081	2865	2869	B-Intervention
plus	10720081	2870	2874	I-Intervention
saline	10720081	2875	2881	I-Intervention
or	10720081	2882	2884	O
GHRH	10720081	2885	2889	B-Intervention
plus	10720081	2890	2894	I-Intervention
arginine	10720081	2895	2903	I-Intervention
between	10720081	2904	2911	O
the	10720081	2912	2915	O
2	10720081	2916	2917	O
groups	10720081	2918	2924	O
.	10720081	2925	2926	O

In	10720081	2927	2929	O
summary	10720081	2930	2937	O
,	10720081	2938	2939	O
the	10720081	2940	2943	O
present	10720081	2944	2951	O
data	10720081	2952	2956	O
suggest	10720081	2957	2964	O
that	10720081	2965	2969	O
in	10720081	2970	2972	O
patients	10720081	2973	2981	O
with	10720081	2982	2986	O
incidental	10720081	2987	2997	B-Participant
adrenal	10720081	2998	3005	I-Participant
adenomas	10720081	3006	3014	I-Participant
the	10720081	3015	3018	O
GH	10720081	3019	3021	B-Outcome
response	10720081	3022	3030	I-Outcome
to	10720081	3031	3033	I-Outcome
GHRH	10720081	3034	3038	I-Outcome
is	10720081	3039	3041	O
blunted	10720081	3042	3049	B-Observation
due	10720081	3050	3053	O
to	10720081	3054	3056	O
increased	10720081	3057	3066	O
somatostatinergic	10720081	3067	3084	O
tone	10720081	3085	3089	O
,	10720081	3090	3091	O
as	10720081	3092	3094	O
it	10720081	3095	3097	O
can	10720081	3098	3101	O
be	10720081	3102	3104	O
restored	10720081	3105	3113	B-Observation
to	10720081	3114	3116	I-Observation
normal	10720081	3117	3123	I-Observation
by	10720081	3124	3126	O
pretreatment	10720081	3127	3139	B-Intervention
with	10720081	3140	3144	I-Intervention
the	10720081	3145	3148	I-Intervention
functional	10720081	3149	3159	I-Intervention
somatostatin	10720081	3160	3172	I-Intervention
antagonist	10720081	3173	3183	I-Intervention
arginine	10720081	3184	3192	I-Intervention
.	10720081	3193	3194	O

The	10720081	3195	3198	O
blunted	10720081	3199	3206	O
GH	10720081	3207	3209	O
release	10720081	3210	3217	O
to	10720081	3218	3220	O
GHRH	10720081	3221	3225	O
may	10720081	3226	3229	O
be	10720081	3230	3232	O
an	10720081	3233	3235	O
early	10720081	3236	3241	O
and	10720081	3242	3245	O
long	10720081	3246	3250	O
lasting	10720081	3251	3258	O
sign	10720081	3259	3263	O
of	10720081	3264	3266	O
autonomous	10720081	3267	3277	O
cortisol	10720081	3278	3286	O
secretion	10720081	3287	3296	O
by	10720081	3297	3299	O
the	10720081	3300	3303	O
adrenal	10720081	3304	3311	O
adenoma	10720081	3312	3319	O
.	10720081	3320	3321	O

A	10735838	0	1	O
comparison	10735838	2	12	O
of	10735838	13	15	O
local	10735838	16	21	B-Intervention
anaesthetics	10735838	22	34	I-Intervention
for	10735838	35	38	O
venepuncture	10735838	39	51	B-Participant
.	10735838	52	53	O

AIM	10735838	54	57	O
To	10735838	58	60	O
compare	10735838	61	68	O
the	10735838	69	72	O
effectiveness	10735838	73	86	O
of	10735838	87	89	O
EMLA	10735838	90	94	B-Intervention
cream	10735838	95	100	I-Intervention
and	10735838	101	104	O
Ametop	10735838	105	111	B-Intervention
gel	10735838	112	115	I-Intervention
in	10735838	116	118	O
providing	10735838	119	128	O
analgesia	10735838	129	138	B-Outcome
for	10735838	139	142	O
venous	10735838	143	149	B-Participant
cannulation	10735838	150	161	I-Participant
.	10735838	162	163	O

METHODS	10735838	164	171	O
Single	10735838	172	178	O
blind	10735838	179	184	O
study	10735838	185	190	O
in	10735838	191	193	O
120	10735838	194	197	O
children	10735838	198	206	B-Participant
.	10735838	207	208	O

RESULTS	10735838	209	216	O
Both	10735838	217	221	B-Intervention
anaesthetic	10735838	222	233	I-Intervention
agents	10735838	234	240	I-Intervention
produced	10735838	241	249	O
adequate	10735838	250	258	B-Observation
analgesia	10735838	259	268	B-Outcome
.	10735838	269	270	O

However	10735838	271	278	O
,	10735838	279	280	O
Ametop	10735838	281	287	B-Intervention
gel	10735838	288	291	I-Intervention
was	10735838	292	295	O
more	10735838	296	300	B-Observation
effective	10735838	301	310	I-Observation
,	10735838	311	312	O
with	10735838	313	317	O
a	10735838	318	319	O
statistically	10735838	320	333	B-Observation
significant	10735838	334	345	I-Observation
difference	10735838	346	356	I-Observation
in	10735838	357	359	O
the	10735838	360	363	O
pain	10735838	364	368	B-Outcome
scores	10735838	369	375	I-Outcome
of	10735838	376	378	O
the	10735838	379	382	O
two	10735838	383	386	B-Intervention
groups	10735838	387	393	I-Intervention
(	10735838	394	395	O
p	10735838	396	397	O
<	10735838	398	399	O
0.05	10735838	400	404	O
)	10735838	405	406	O
.	10735838	407	408	O

Use	10735900	0	3	O
of	10735900	4	6	O
recombinant	10735900	7	18	B-Intervention
human	10735900	19	24	I-Intervention
granulocyte	10735900	25	36	I-Intervention
colony-stimulating	10735900	37	55	I-Intervention
factor	10735900	56	62	I-Intervention
to	10735900	63	65	O
increase	10735900	66	74	B-Observation
chemotherapy	10735900	75	87	B-Outcome
dose-intensity	10735900	88	102	I-Outcome
:	10735900	103	104	O
a	10735900	105	106	O
randomized	10735900	107	117	O
trial	10735900	118	123	O
in	10735900	124	126	O
very	10735900	127	131	B-Participant
high-risk	10735900	132	141	I-Participant
childhood	10735900	142	151	I-Participant
acute	10735900	152	157	I-Participant
lymphoblastic	10735900	158	171	I-Participant
leukemia	10735900	172	180	I-Participant
.	10735900	181	182	O

PURPOSE	10735900	183	190	O
To	10735900	191	193	O
determine	10735900	194	203	O
whether	10735900	204	211	O
the	10735900	212	215	O
use	10735900	216	219	O
of	10735900	220	222	O
a	10735900	223	224	O
recombinant	10735900	225	236	B-Intervention
human	10735900	237	242	I-Intervention
granulocyte	10735900	243	254	I-Intervention
colony-stimulating	10735900	255	273	I-Intervention
factor	10735900	274	280	I-Intervention
(	10735900	281	282	I-Intervention
[	10735900	283	284	I-Intervention
G-CSF	10735900	285	290	I-Intervention
]	10735900	291	292	I-Intervention
lenogastrim	10735900	293	304	I-Intervention
)	10735900	305	306	I-Intervention
can	10735900	307	310	O
increase	10735900	311	319	B-Observation
the	10735900	320	323	O
chemotherapy	10735900	324	336	B-Outcome
dose-intensity	10735900	337	351	I-Outcome
(	10735900	352	353	I-Outcome
CDI	10735900	354	357	I-Outcome
)	10735900	358	359	I-Outcome
delivered	10735900	360	369	O
during	10735900	370	376	O
consolidation	10735900	377	390	O
chemotherapy	10735900	391	403	O
of	10735900	404	406	O
childhood	10735900	407	416	B-Participant
acute	10735900	417	422	I-Participant
lymphoblastic	10735900	423	436	I-Participant
leukemia	10735900	437	445	I-Participant
(	10735900	446	447	I-Participant
ALL	10735900	448	451	I-Participant
)	10735900	452	453	I-Participant
.	10735900	454	455	O

PATIENTS	10735900	456	464	O
AND	10735900	465	468	O
METHODS	10735900	469	476	O
Sixty-seven	10735900	477	488	O
children	10735900	489	497	B-Participant
with	10735900	498	502	O
very	10735900	503	507	B-Participant
high-risk	10735900	508	517	I-Participant
ALL	10735900	518	521	I-Participant
were	10735900	522	526	O
randomized	10735900	527	537	O
(	10735900	538	539	O
slow	10735900	540	544	B-Participant
early	10735900	545	550	I-Participant
response	10735900	551	559	I-Participant
to	10735900	560	562	I-Participant
therapy	10735900	563	570	I-Participant
,	10735900	571	572	O
55	10735900	573	575	O
patients	10735900	576	584	O
;	10735900	585	586	O
translocation	10735900	587	600	B-Participant
t	10735900	601	602	I-Participant
(	10735900	603	604	I-Participant
9	10735900	605	606	I-Participant
;	10735900	607	608	I-Participant
22	10735900	609	611	I-Participant
)	10735900	612	613	I-Participant
or	10735900	614	616	I-Participant
t	10735900	617	618	I-Participant
(	10735900	619	620	I-Participant
4	10735900	621	622	I-Participant
;	10735900	623	624	I-Participant
11	10735900	625	627	I-Participant
)	10735900	628	629	I-Participant
,	10735900	630	631	O
12	10735900	632	634	O
patients	10735900	635	643	O
)	10735900	644	645	O
.	10735900	646	647	O

Consolidation	10735900	648	661	O
consisted	10735900	662	671	O
of	10735900	672	674	O
six	10735900	675	678	O
courses	10735900	679	686	O
of	10735900	687	689	O
chemotherapy	10735900	690	702	O
;	10735900	703	704	O
the	10735900	705	708	O
first	10735900	709	714	O
,	10735900	715	716	O
third	10735900	717	722	O
,	10735900	723	724	O
and	10735900	725	728	O
fifth	10735900	729	734	O
courses	10735900	735	742	O
were	10735900	743	747	O
a	10735900	748	749	O
combination	10735900	750	761	O
of	10735900	762	764	O
high-dose	10735900	765	774	O
cytarabine	10735900	775	785	O
,	10735900	786	787	O
etoposide	10735900	788	797	O
,	10735900	798	799	O
and	10735900	800	803	O
dexamethasone	10735900	804	817	O
(	10735900	818	819	O
R3	10735900	820	822	O
)	10735900	823	824	O
,	10735900	825	826	O
whereas	10735900	827	834	O
the	10735900	835	838	O
second	10735900	839	845	O
,	10735900	846	847	O
fourth	10735900	848	854	O
,	10735900	855	856	O
and	10735900	857	860	O
sixth	10735900	861	866	O
courses	10735900	867	874	O
included	10735900	875	883	O
vincristine	10735900	884	895	O
,	10735900	896	897	O
prednisone	10735900	898	908	O
,	10735900	909	910	O
cyclophosphamide	10735900	911	927	O
,	10735900	928	929	O
doxorubicin	10735900	930	941	O
,	10735900	942	943	O
and	10735900	944	947	O
methotrexate	10735900	948	960	O
(	10735900	961	962	O
COPADM	10735900	963	969	O
)	10735900	970	971	O
.	10735900	972	973	O

G-CSF	10735900	974	979	B-Intervention
was	10735900	980	983	O
given	10735900	984	989	O
after	10735900	990	995	O
each	10735900	996	1000	O
course	10735900	1001	1007	O
,	10735900	1008	1009	O
and	10735900	1010	1013	O
the	10735900	1014	1017	O
next	10735900	1018	1022	O
scheduled	10735900	1023	1032	O
course	10735900	1033	1039	O
was	10735900	1040	1043	O
started	10735900	1044	1051	O
as	10735900	1052	1054	O
soon	10735900	1055	1059	O
as	10735900	1060	1062	O
neutrophil	10735900	1063	1073	O
count	10735900	1074	1079	O
was	10735900	1080	1083	O
>	10735900	1084	1085	O
1	10735900	1086	1087	O
x	10735900	1088	1089	O
10	10735900	1090	1092	O
(	10735900	1093	1094	O
9	10735900	1095	1096	O
)	10735900	1097	1098	O
/L	10735900	1099	1101	O
and	10735900	1102	1105	O
platelet	10735900	1106	1114	O
count	10735900	1115	1120	O
was	10735900	1121	1124	O
>	10735900	1125	1126	O
100	10735900	1127	1130	O
x	10735900	1131	1132	O
10	10735900	1133	1135	O
(	10735900	1136	1137	O
9	10735900	1138	1139	O
)	10735900	1140	1141	O
/L	10735900	1142	1144	O
.	10735900	1145	1146	O

CDI	10735900	1147	1150	B-Outcome
was	10735900	1151	1154	O
calculated	10735900	1155	1165	O
using	10735900	1166	1171	O
the	10735900	1172	1175	O
interval	10735900	1176	1184	O
from	10735900	1185	1189	O
day	10735900	1190	1193	O
1	10735900	1194	1195	O
of	10735900	1196	1198	O
the	10735900	1199	1202	O
first	10735900	1203	1208	O
course	10735900	1209	1215	O
to	10735900	1216	1218	O
hematologic	10735900	1219	1230	O
recovery	10735900	1231	1239	O
after	10735900	1240	1245	O
the	10735900	1246	1249	O
fifth	10735900	1250	1255	O
course	10735900	1256	1262	O
(	10735900	1263	1264	O
100	10735900	1265	1268	O
%	10735900	1269	1270	O
CDI	10735900	1271	1274	O
=	10735900	1275	1276	O
105-day	10735900	1277	1284	O
interval	10735900	1285	1293	O
)	10735900	1294	1295	O
.	10735900	1296	1297	O

RESULTS	10735900	1298	1305	O
CDI	10735900	1306	1309	B-Outcome
was	10735900	1310	1313	O
significantly	10735900	1314	1327	B-Observation
increased	10735900	1328	1337	I-Observation
in	10735900	1338	1340	O
the	10735900	1341	1344	O
G-CSF	10735900	1345	1350	B-Intervention
group	10735900	1351	1356	O
compared	10735900	1357	1365	O
with	10735900	1366	1370	O
the	10735900	1371	1374	O
non-G-CSF	10735900	1375	1384	B-Intervention
group	10735900	1385	1390	O
(	10735900	1391	1392	O
mean	10735900	1393	1397	O
+	10735900	1398	1399	O
/-	10735900	1399	1401	O
95	10735900	1402	1404	O
%	10735900	1405	1406	O
confidence	10735900	1407	1417	O
interval	10735900	1418	1426	O
,	10735900	1427	1428	O
105	10735900	1429	1432	B-Observation
+	10735900	1433	1434	I-Observation
/-	10735900	1434	1436	I-Observation
5	10735900	1437	1438	I-Observation
%	10735900	1439	1440	I-Observation
v	10735900	1441	1442	O
91	10735900	1443	1445	B-Observation
+	10735900	1446	1447	I-Observation
/-	10735900	1447	1449	I-Observation
4	10735900	1450	1451	I-Observation
%	10735900	1452	1453	I-Observation
;	10735900	1454	1455	O
P	10735900	1456	1457	O
<	10735900	1458	1459	O
.001	10735900	1460	1464	O
)	10735900	1465	1466	O
.	10735900	1467	1468	O

This	10735900	1469	1473	O
higher	10735900	1474	1480	B-Observation
intensity	10735900	1481	1490	B-Outcome
was	10735900	1491	1494	O
a	10735900	1495	1496	O
result	10735900	1497	1503	O
of	10735900	1504	1506	O
shorter	10735900	1507	1514	B-Observation
post-R3	10735900	1515	1522	B-Outcome
intervals	10735900	1523	1532	I-Outcome
in	10735900	1533	1535	O
the	10735900	1536	1539	O
G-CSF	10735900	1540	1545	B-Intervention
group	10735900	1546	1551	O
,	10735900	1552	1553	O
whereas	10735900	1554	1561	O
the	10735900	1562	1565	O
post-COPADM	10735900	1566	1577	B-Outcome
intervals	10735900	1578	1587	I-Outcome
were	10735900	1588	1592	O
not	10735900	1593	1596	O
statistically	10735900	1597	1610	B-Observation
reduced	10735900	1611	1618	I-Observation
.	10735900	1619	1620	O

After	10735900	1621	1626	O
the	10735900	1627	1630	O
R3	10735900	1631	1633	O
courses	10735900	1634	1641	O
,	10735900	1642	1643	O
the	10735900	1644	1647	O
number	10735900	1648	1654	B-Outcome
of	10735900	1655	1657	I-Outcome
days	10735900	1658	1662	I-Outcome
with	10735900	1663	1667	I-Outcome
fever	10735900	1668	1673	I-Outcome
and	10735900	1674	1677	I-Outcome
intravenous	10735900	1678	1689	I-Outcome
antibiotics	10735900	1690	1701	I-Outcome
and	10735900	1702	1705	O
duration	10735900	1706	1714	B-Outcome
of	10735900	1715	1717	I-Outcome
hospitalization	10735900	1718	1733	I-Outcome
were	10735900	1734	1738	O
significantly	10735900	1739	1752	B-Observation
decreased	10735900	1753	1762	I-Observation
by	10735900	1763	1765	O
G-CSF	10735900	1766	1771	B-Intervention
,	10735900	1772	1773	O
whereas	10735900	1774	1781	O
reductions	10735900	1782	1792	B-Observation
observed	10735900	1793	1801	O
after	10735900	1802	1807	B-Outcome
COPADM	10735900	1808	1814	I-Outcome
were	10735900	1815	1819	O
not	10735900	1820	1823	O
statistically	10735900	1824	1837	B-Observation
significant	10735900	1838	1849	I-Observation
.	10735900	1850	1851	O

Duration	10735900	1852	1860	B-Outcome
of	10735900	1861	1863	I-Outcome
granulocytopenia	10735900	1864	1880	I-Outcome
was	10735900	1881	1884	O
reduced	10735900	1885	1892	B-Observation
in	10735900	1893	1895	O
the	10735900	1896	1899	O
G-CSF	10735900	1900	1905	B-Intervention
group	10735900	1906	1911	O
,	10735900	1912	1913	O
but	10735900	1914	1917	O
thrombocytopenia	10735900	1918	1934	B-Outcome
was	10735900	1935	1938	O
prolonged	10735900	1939	1948	B-Observation
,	10735900	1949	1950	O
and	10735900	1951	1954	O
the	10735900	1955	1958	O
number	10735900	1959	1965	B-Outcome
of	10735900	1966	1968	I-Outcome
platelet	10735900	1969	1977	I-Outcome
transfusions	10735900	1978	1990	I-Outcome
was	10735900	1991	1994	O
increased	10735900	1995	2004	B-Observation
.	10735900	2005	2006	O

Finally	10735900	2007	2014	O
,	10735900	2015	2016	O
the	10735900	2017	2020	O
3-year	10735900	2021	2027	B-Outcome
probability	10735900	2028	2039	I-Outcome
of	10735900	2040	2042	I-Outcome
event-free	10735900	2043	2053	I-Outcome
survival	10735900	2054	2062	I-Outcome
was	10735900	2063	2066	O
not	10735900	2067	2070	O
different	10735900	2071	2080	B-Observation
between	10735900	2081	2088	B-Intervention
the	10735900	2089	2092	I-Intervention
two	10735900	2093	2096	I-Intervention
groups	10735900	2097	2103	I-Intervention
.	10735900	2104	2105	O

CONCLUSION	10735900	2106	2116	O
G-CSF	10735900	2117	2122	B-Intervention
can	10735900	2123	2126	O
increase	10735900	2127	2135	B-Observation
CDI	10735900	2136	2139	B-Outcome
in	10735900	2140	2142	O
high-risk	10735900	2143	2152	B-Participant
childhood	10735900	2153	2162	I-Participant
ALL	10735900	2163	2166	I-Participant
.	10735900	2167	2168	O

Its	10735900	2169	2172	O
effects	10735900	2173	2180	O
depend	10735900	2181	2187	O
on	10735900	2188	2190	O
the	10735900	2191	2194	O
chemotherapy	10735900	2195	2207	O
regimen	10735900	2208	2215	O
given	10735900	2216	2221	O
before	10735900	2222	2228	O
G-CSF	10735900	2229	2234	O
administration	10735900	2235	2249	O
.	10735900	2250	2251	O

In	10735900	2252	2254	O
our	10735900	2255	2258	O
study	10735900	2259	2264	O
,	10735900	2265	2266	O
a	10735900	2267	2268	O
higher	10735900	2269	2275	B-Observation
CDI	10735900	2276	2279	B-Outcome
did	10735900	2280	2283	O
not	10735900	2284	2287	O
improve	10735900	2288	2295	B-Observation
disease	10735900	2296	2303	B-Outcome
control	10735900	2304	2311	I-Outcome
.	10735900	2312	2313	O

Comparison	10741095	0	10	O
of	10741095	11	13	O
different	10741095	14	23	O
long-term	10741095	24	33	B-Intervention
asthma	10741095	34	40	I-Intervention
treatments	10741095	41	51	I-Intervention
in	10741095	52	54	O
subjects	10741095	55	63	O
with	10741095	64	68	O
mild-to-moderate	10741095	69	85	B-Participant
asthma	10741095	86	92	I-Participant
.	10741095	93	94	O

In	10741095	95	97	O
order	10741095	98	103	O
to	10741095	104	106	O
compare	10741095	107	114	O
the	10741095	115	118	O
efficacy	10741095	119	127	O
of	10741095	128	130	O
different	10741095	131	140	O
asthma	10741095	141	147	B-Intervention
treatment	10741095	148	157	I-Intervention
in	10741095	158	160	O
subjects	10741095	161	169	O
with	10741095	170	174	O
mild-to-moderate	10741095	175	191	B-Participant
asthma	10741095	192	198	I-Participant
,	10741095	199	200	O
three	10741095	201	206	O
groups	10741095	207	213	O
of	10741095	214	216	O
11	10741095	217	219	O
patients	10741095	220	228	O
were	10741095	229	233	O
treated	10741095	234	241	O
with	10741095	242	246	O
nedocromil	10741095	247	257	B-Intervention
sodium	10741095	258	264	I-Intervention
(	10741095	265	266	I-Intervention
NS	10741095	267	269	I-Intervention
)	10741095	270	271	I-Intervention
,	10741095	272	273	O
beclomethasone	10741095	274	288	B-Intervention
dipropionate	10741095	289	301	I-Intervention
(	10741095	302	303	I-Intervention
BDP	10741095	304	307	I-Intervention
)	10741095	308	309	I-Intervention
and	10741095	310	313	O
beclomethasone	10741095	314	328	B-Intervention
dipropionate	10741095	329	341	I-Intervention
plus	10741095	342	346	I-Intervention
salmeterol	10741095	347	357	I-Intervention
(	10741095	358	359	I-Intervention
BDP	10741095	360	363	I-Intervention
+	10741095	364	365	I-Intervention
S	10741095	366	367	I-Intervention
)	10741095	368	369	I-Intervention
in	10741095	370	372	O
an	10741095	373	375	O
open	10741095	376	380	O
,	10741095	381	382	O
randomized	10741095	383	393	O
study	10741095	394	399	O
.	10741095	400	401	O

Symptom	10741095	402	409	B-Outcome
score	10741095	410	415	I-Outcome
,	10741095	416	417	O
peak	10741095	418	422	B-Outcome
expiratory	10741095	423	433	I-Outcome
flow	10741095	434	438	I-Outcome
(	10741095	439	440	I-Outcome
PEF	10741095	441	444	I-Outcome
)	10741095	445	446	I-Outcome
maximal	10741095	447	454	I-Outcome
amplitude	10741095	455	464	I-Outcome
,	10741095	465	466	O
forced	10741095	467	473	B-Outcome
expiratory	10741095	474	484	I-Outcome
volume	10741095	485	491	I-Outcome
in	10741095	492	494	I-Outcome
one	10741095	495	498	I-Outcome
second	10741095	499	505	I-Outcome
(	10741095	506	507	I-Outcome
FEV1	10741095	508	512	I-Outcome
)	10741095	513	514	I-Outcome
,	10741095	515	516	O
and	10741095	517	520	O
methacholine	10741095	521	533	B-Outcome
reactivity	10741095	534	544	I-Outcome
were	10741095	545	549	O
measured	10741095	550	558	O
at	10741095	559	561	O
the	10741095	562	565	O
baseline	10741095	566	574	O
and	10741095	575	578	O
at	10741095	579	581	O
intervals	10741095	582	591	O
of	10741095	592	594	O
3	10741095	595	596	O
months	10741095	597	603	O
up	10741095	604	606	O
to	10741095	607	609	O
12	10741095	610	612	O
months	10741095	613	619	O
.	10741095	620	621	O

After	10741095	622	627	O
3	10741095	628	629	O
months	10741095	630	636	O
,	10741095	637	638	O
symptoms	10741095	639	647	B-Outcome
reduced	10741095	648	655	B-Observation
significantly	10741095	656	669	I-Observation
in	10741095	670	672	O
all	10741095	673	676	B-Intervention
treatment	10741095	677	686	I-Intervention
groups	10741095	687	693	O
,	10741095	694	695	O
while	10741095	696	701	O
PEF	10741095	702	705	B-Outcome
variability	10741095	706	717	I-Outcome
improved	10741095	718	726	B-Observation
in	10741095	727	729	O
BDP	10741095	730	733	B-Intervention
and	10741095	734	737	O
BDP	10741095	738	741	B-Intervention
+	10741095	742	743	I-Intervention
S	10741095	744	745	I-Intervention
groups	10741095	746	752	O
;	10741095	753	754	O
FEV1	10741095	755	759	B-Outcome
and	10741095	760	763	O
bronchial	10741095	764	773	B-Outcome
responsiveness	10741095	774	788	I-Outcome
to	10741095	789	791	I-Outcome
methacholine	10741095	792	804	I-Outcome
were	10741095	805	809	O
significantly	10741095	810	823	B-Observation
improved	10741095	824	832	I-Observation
in	10741095	833	835	O
comparison	10741095	836	846	O
with	10741095	847	851	O
baseline	10741095	852	860	O
value	10741095	861	866	O
in	10741095	867	869	O
the	10741095	870	873	O
BDP	10741095	874	877	B-Intervention
+	10741095	878	879	I-Intervention
S	10741095	880	881	I-Intervention
group	10741095	882	887	O
only	10741095	888	892	O
.	10741095	893	894	O

No	10741095	895	897	O
significant	10741095	898	909	B-Observation
difference	10741095	910	920	I-Observation
was	10741095	921	924	O
observed	10741095	925	933	O
after	10741095	934	939	O
6	10741095	940	941	O
and	10741095	942	945	O
12	10741095	946	948	O
months	10741095	949	955	O
of	10741095	956	958	O
treatment	10741095	959	968	O
in	10741095	969	971	O
PEF	10741095	972	975	B-Outcome
variability	10741095	976	987	I-Outcome
,	10741095	988	989	O
FEV1	10741095	990	994	B-Outcome
or	10741095	995	997	O
bronchial	10741095	998	1007	B-Outcome
hyperreactivity	10741095	1008	1023	I-Outcome
in	10741095	1024	1026	O
the	10741095	1027	1030	O
NS	10741095	1031	1033	B-Intervention
group	10741095	1034	1039	O
compared	10741095	1040	1048	O
with	10741095	1049	1053	O
baseline	10741095	1054	1062	O
values	10741095	1063	1069	O
,	10741095	1070	1071	O
while	10741095	1072	1077	O
a	10741095	1078	1079	O
significant	10741095	1080	1091	B-Observation
difference	10741095	1092	1102	I-Observation
was	10741095	1103	1106	O
observed	10741095	1107	1115	O
in	10741095	1116	1118	O
symptom	10741095	1119	1126	B-Outcome
score	10741095	1127	1132	I-Outcome
.	10741095	1133	1134	O

BDP	10741095	1135	1138	B-Intervention
group	10741095	1139	1144	O
showed	10741095	1145	1151	O
a	10741095	1152	1153	O
significant	10741095	1154	1165	B-Observation
improvement	10741095	1166	1177	I-Observation
in	10741095	1178	1180	O
FEV1	10741095	1181	1185	B-Outcome
and	10741095	1186	1189	O
bronchial	10741095	1190	1199	B-Outcome
reactivity	10741095	1200	1210	I-Outcome
to	10741095	1211	1213	I-Outcome
methacholine	10741095	1214	1226	I-Outcome
after	10741095	1227	1232	O
6	10741095	1233	1234	O
and	10741095	1235	1238	O
12	10741095	1239	1241	O
months	10741095	1242	1248	O
of	10741095	1249	1251	O
treatment	10741095	1252	1261	O
.	10741095	1262	1263	O

In	10741095	1264	1266	O
the	10741095	1267	1270	O
BDP	10741095	1271	1274	B-Intervention
+	10741095	1275	1276	I-Intervention
S	10741095	1277	1278	I-Intervention
group	10741095	1279	1284	O
,	10741095	1285	1286	O
the	10741095	1287	1290	O
improvement	10741095	1291	1302	B-Observation
in	10741095	1303	1305	O
symptoms	10741095	1306	1314	B-Outcome
and	10741095	1315	1318	O
pulmonary	10741095	1319	1328	B-Outcome
function	10741095	1329	1337	I-Outcome
persisted	10741095	1338	1347	O
until	10741095	1348	1353	O
the	10741095	1354	1357	O
end	10741095	1358	1361	O
of	10741095	1362	1364	O
the	10741095	1365	1368	O
study	10741095	1369	1374	O
.	10741095	1375	1376	O

In	10741095	1377	1379	O
conclusion	10741095	1380	1390	O
,	10741095	1391	1392	O
the	10741095	1393	1396	O
combination	10741095	1397	1408	B-Intervention
of	10741095	1409	1411	I-Intervention
beclomethasone	10741095	1412	1426	I-Intervention
dipropionate	10741095	1427	1439	I-Intervention
and	10741095	1440	1443	I-Intervention
salmeterol	10741095	1444	1454	I-Intervention
improved	10741095	1455	1463	B-Observation
pulmonary	10741095	1464	1473	B-Outcome
function	10741095	1474	1482	I-Outcome
and	10741095	1483	1486	O
bronchial	10741095	1487	1496	B-Outcome
reactivity	10741095	1497	1507	I-Outcome
earlier	10741095	1508	1515	B-Observation
than	10741095	1516	1520	O
beclomethasone	10741095	1521	1535	B-Intervention
dipropionate	10741095	1536	1548	I-Intervention
alone	10741095	1549	1554	I-Intervention
,	10741095	1555	1556	O
while	10741095	1557	1562	O
nedocromil	10741095	1563	1573	B-Intervention
sodium	10741095	1574	1580	I-Intervention
improved	10741095	1581	1589	B-Observation
symptoms	10741095	1590	1598	B-Outcome
but	10741095	1599	1602	O
not	10741095	1603	1606	O
pulmonary	10741095	1607	1616	B-Outcome
function	10741095	1617	1625	I-Outcome
.	10741095	1626	1627	O

Assuming	10741095	1628	1636	O
that	10741095	1637	1641	O
bronchial	10741095	1642	1651	O
reactivity	10741095	1652	1662	O
could	10741095	1663	1668	O
be	10741095	1669	1671	O
an	10741095	1672	1674	O
indirect	10741095	1675	1683	O
measurement	10741095	1684	1695	O
of	10741095	1696	1698	O
airway	10741095	1699	1705	O
inflammation	10741095	1706	1718	O
,	10741095	1719	1720	O
overtreatment	10741095	1721	1734	O
of	10741095	1735	1737	O
asthma	10741095	1738	1744	O
in	10741095	1745	1747	O
relationship	10741095	1748	1760	O
with	10741095	1761	1765	O
the	10741095	1766	1769	O
classification	10741095	1770	1784	O
of	10741095	1785	1787	O
asthma	10741095	1788	1794	O
severity	10741095	1795	1803	O
of	10741095	1804	1806	O
the	10741095	1807	1810	O
International	10741095	1811	1824	O
Guidelines	10741095	1825	1835	O
could	10741095	1836	1841	O
improve	10741095	1842	1849	O
both	10741095	1850	1854	O
airway	10741095	1855	1861	O
inflammation	10741095	1862	1874	O
and	10741095	1875	1878	O
the	10741095	1879	1882	O
prognosis	10741095	1883	1892	O
of	10741095	1893	1895	O
airway	10741095	1896	1902	O
obstruction	10741095	1903	1914	O
.	10741095	1915	1916	O

The	10754477	0	3	O
GH	10754477	4	6	B-Outcome
response	10754477	7	15	I-Outcome
to	10754477	16	18	O
low-dose	10754477	19	27	B-Intervention
bolus	10754477	28	33	I-Intervention
growth	10754477	34	40	I-Intervention
hormone-releasing	10754477	41	58	I-Intervention
hormone	10754477	59	66	I-Intervention
(	10754477	67	68	I-Intervention
GHRH	10754477	69	73	I-Intervention
(	10754477	74	75	I-Intervention
1	10754477	76	77	I-Intervention
-	10754477	77	78	I-Intervention
29	10754477	78	80	I-Intervention
)	10754477	81	82	I-Intervention
NH2	10754477	83	86	I-Intervention
)	10754477	87	88	I-Intervention
is	10754477	89	91	O
attenuated	10754477	92	102	B-Observation
in	10754477	103	105	O
patients	10754477	106	114	O
with	10754477	115	119	O
longstanding	10754477	120	132	B-Participant
post-irradiation	10754477	133	149	I-Participant
GH	10754477	150	152	I-Participant
insufficiency	10754477	153	166	I-Participant
.	10754477	167	168	O

OBJECTIVE	10754477	169	178	O
Previous	10754477	179	187	O
studies	10754477	188	195	O
have	10754477	196	200	O
suggested	10754477	201	210	O
that	10754477	211	215	O
post-irradiation	10754477	216	232	O
GH	10754477	233	235	O
insufficiency	10754477	236	249	O
results	10754477	250	257	O
from	10754477	258	262	O
a	10754477	263	264	O
loss	10754477	265	269	O
of	10754477	270	272	O
GHRH	10754477	273	277	O
secretion	10754477	278	287	O
,	10754477	288	289	O
since	10754477	290	295	O
many	10754477	296	300	O
patients	10754477	301	309	O
were	10754477	310	314	O
able	10754477	315	319	O
to	10754477	320	322	O
release	10754477	323	330	O
GH	10754477	331	333	O
following	10754477	334	343	O
exogenous	10754477	344	353	O
GHRH	10754477	354	358	O
stimulation	10754477	359	370	O
.	10754477	371	372	O

However	10754477	373	380	O
,	10754477	381	382	O
supramaximal	10754477	383	395	O
doses	10754477	396	401	O
of	10754477	402	404	O
GHRH	10754477	405	409	O
were	10754477	410	414	O
used	10754477	415	419	O
and	10754477	420	423	O
the	10754477	424	427	O
response	10754477	428	436	O
may	10754477	437	440	O
decline	10754477	441	448	O
with	10754477	449	453	O
time	10754477	454	458	O
after	10754477	459	464	O
radiotherapy	10754477	465	477	O
.	10754477	478	479	O

We	10754477	480	482	O
re-evaluated	10754477	483	495	O
the	10754477	496	499	O
GHRH	10754477	500	504	B-Outcome
dose-response	10754477	505	518	I-Outcome
curve	10754477	519	524	I-Outcome
in	10754477	525	527	O
patients	10754477	528	536	O
post	10754477	537	541	B-Intervention
cranial	10754477	542	549	I-Intervention
irradiation	10754477	550	561	I-Intervention
and	10754477	562	565	O
in	10754477	566	568	O
controls	10754477	569	577	B-Intervention
.	10754477	578	579	O

DESIGN	10754477	580	586	O
Randomized	10754477	587	597	O
controlled	10754477	598	608	O
study	10754477	609	614	O
.	10754477	615	616	O

METHODS	10754477	617	624	O
Five	10754477	625	629	O
adult	10754477	630	635	B-Participant
male	10754477	636	640	I-Participant
long-term	10754477	641	650	I-Participant
survivors	10754477	651	660	I-Participant
of	10754477	661	663	I-Participant
childhood	10754477	664	673	I-Participant
brain	10754477	674	679	I-Participant
tumours	10754477	680	687	I-Participant
(	10754477	688	689	O
median	10754477	690	696	O
age	10754477	697	700	O
21.8	10754477	701	705	O
years	10754477	706	711	O
(	10754477	712	713	O
18.4	10754477	714	718	O
-	10754477	718	719	O
26.7	10754477	719	723	O
)	10754477	724	725	O
;	10754477	726	727	O
13.7	10754477	728	732	O
years	10754477	733	738	O
(	10754477	739	740	O
11.4	10754477	741	745	O
-	10754477	745	746	O
15.7	10754477	746	750	O
)	10754477	751	752	O
post-radiotherapy	10754477	753	770	O
,	10754477	771	772	O
>	10754477	773	774	O
30Gy	10754477	775	779	O
)	10754477	780	781	O
and	10754477	782	785	O
five	10754477	786	790	O
matched	10754477	791	798	O
controls	10754477	799	807	O
were	10754477	808	812	O
studied	10754477	813	820	O
.	10754477	821	822	O

An	10754477	823	825	O
intravenous	10754477	826	837	B-Intervention
bolus	10754477	838	843	I-Intervention
of	10754477	844	846	I-Intervention
GHRH	10754477	847	851	I-Intervention
(	10754477	852	853	I-Intervention
1	10754477	854	855	I-Intervention
-	10754477	855	856	I-Intervention
29	10754477	856	858	I-Intervention
)	10754477	859	860	I-Intervention
NH	10754477	861	863	I-Intervention
(	10754477	864	865	I-Intervention
2	10754477	866	867	I-Intervention
)	10754477	868	869	I-Intervention
was	10754477	870	873	O
administered	10754477	874	886	O
in	10754477	887	889	O
doses	10754477	890	895	O
at	10754477	896	898	O
the	10754477	899	902	O
lower	10754477	903	908	B-Intervention
(	10754477	909	910	I-Intervention
0.05	10754477	911	915	I-Intervention
microg/kg	10754477	916	925	I-Intervention
)	10754477	926	927	I-Intervention
and	10754477	928	931	O
upper	10754477	932	937	B-Intervention
(	10754477	938	939	I-Intervention
0.15	10754477	940	944	I-Intervention
microg/kg	10754477	945	954	I-Intervention
)	10754477	955	956	I-Intervention
range	10754477	957	962	O
of	10754477	963	965	O
the	10754477	966	969	O
dose-response	10754477	970	983	O
curves	10754477	984	990	O
for	10754477	991	994	O
young	10754477	995	1000	B-Participant
males	10754477	1001	1006	I-Participant
,	10754477	1007	1008	O
as	10754477	1009	1011	O
well	10754477	1012	1016	O
as	10754477	1017	1019	O
the	10754477	1020	1023	O
standard	10754477	1024	1032	B-Intervention
supramaximal	10754477	1033	1045	I-Intervention
dose	10754477	1046	1050	I-Intervention
(	10754477	1051	1052	I-Intervention
1	10754477	1053	1054	I-Intervention
.	10754477	1055	1056	I-Intervention
0	10754477	1057	1058	I-Intervention
microg/kg	10754477	1059	1068	I-Intervention
)	10754477	1069	1070	I-Intervention
.	10754477	1071	1072	O

GH	10754477	1073	1075	B-Outcome
was	10754477	1076	1079	O
measured	10754477	1080	1088	O
before	10754477	1089	1095	O
stimulation	10754477	1096	1107	O
,	10754477	1108	1109	O
every	10754477	1110	1115	O
2min	10754477	1116	1120	O
for	10754477	1121	1124	O
the	10754477	1125	1128	O
first	10754477	1129	1134	O
hour	10754477	1135	1139	O
and	10754477	1140	1143	O
every	10754477	1144	1149	O
5min	10754477	1150	1154	O
for	10754477	1155	1158	O
the	10754477	1159	1162	O
second	10754477	1163	1169	O
hour	10754477	1170	1174	O
.	10754477	1175	1176	O

All	10754477	1177	1180	O
studies	10754477	1181	1188	O
were	10754477	1189	1193	O
conducted	10754477	1194	1203	O
in	10754477	1204	1206	O
a	10754477	1207	1208	O
random	10754477	1209	1215	O
fashion	10754477	1216	1223	O
.	10754477	1224	1225	O

RESULTS	10754477	1226	1233	O
Significantly	10754477	1234	1247	B-Observation
lower	10754477	1248	1253	I-Observation
peak	10754477	1254	1258	B-Outcome
and	10754477	1259	1262	I-Outcome
area	10754477	1263	1267	I-Outcome
under	10754477	1268	1273	I-Outcome
the	10754477	1274	1277	I-Outcome
curve	10754477	1278	1283	I-Outcome
(	10754477	1284	1285	I-Outcome
AUC	10754477	1286	1289	I-Outcome
)	10754477	1290	1291	I-Outcome
GH	10754477	1292	1294	I-Outcome
concentrations	10754477	1295	1309	I-Outcome
occurred	10754477	1310	1318	O
in	10754477	1319	1321	O
the	10754477	1322	1325	O
irradiated	10754477	1326	1336	B-Intervention
group	10754477	1337	1342	I-Intervention
using	10754477	1343	1348	I-Intervention
0.15	10754477	1349	1353	I-Intervention
microg/kg	10754477	1354	1363	I-Intervention
(	10754477	1364	1365	O
median	10754477	1366	1372	B-Outcome
peak	10754477	1373	1377	I-Outcome
Irradiated	10754477	1378	1388	B-Intervention
,	10754477	1389	1390	O
4	10754477	1391	1392	B-Observation
.	10754477	1393	1394	I-Observation

5mU/l	10754477	1395	1400	B-Observation
vs	10754477	1401	1403	O
median	10754477	1404	1410	B-Outcome
Controls	10754477	1411	1419	B-Intervention
,	10754477	1420	1421	O
37.4mU/l	10754477	1422	1430	B-Observation
;	10754477	1431	1432	O
P	10754477	1433	1434	O
<	10754477	1435	1436	O
0.01	10754477	1437	1441	O
)	10754477	1442	1443	O
and	10754477	1444	1447	O
1.0	10754477	1448	1451	B-Intervention
microg/kg	10754477	1452	1461	I-Intervention
(	10754477	1462	1463	O
median	10754477	1464	1470	B-Outcome
peak	10754477	1471	1475	I-Outcome
Irradiated	10754477	1476	1486	B-Intervention
,	10754477	1487	1488	O
4.8mU/l	10754477	1489	1496	B-Observation
vs	10754477	1497	1499	O
median	10754477	1500	1506	B-Outcome
Controls	10754477	1507	1515	B-Intervention
,	10754477	1516	1517	O
15.2mU/l	10754477	1518	1526	B-Observation
;	10754477	1527	1528	O
P	10754477	1529	1530	O
<	10754477	1531	1532	O
0	10754477	1533	1534	O
.	10754477	1535	1536	O
05	10754477	1537	1539	O
)	10754477	1540	1541	O
GHRH	10754477	1542	1546	B-Intervention
(	10754477	1547	1548	I-Intervention
1	10754477	1549	1550	I-Intervention
-	10754477	1550	1551	I-Intervention
29	10754477	1551	1553	I-Intervention
)	10754477	1554	1555	I-Intervention
NH	10754477	1556	1558	I-Intervention
(	10754477	1559	1560	I-Intervention
2	10754477	1561	1562	I-Intervention
)	10754477	1563	1564	I-Intervention
.	10754477	1565	1566	O

In	10754477	1567	1569	O
irradiated	10754477	1570	1580	B-Intervention
subjects	10754477	1581	1589	O
there	10754477	1590	1595	O
was	10754477	1596	1599	O
an	10754477	1600	1602	O
incremental	10754477	1603	1614	B-Observation
rise	10754477	1615	1619	I-Observation
in	10754477	1620	1622	O
GH	10754477	1623	1625	B-Outcome
output	10754477	1626	1632	I-Outcome
with	10754477	1633	1637	I-Outcome
increasing	10754477	1638	1648	I-Outcome
doses	10754477	1649	1654	I-Outcome
of	10754477	1655	1657	I-Outcome
GHRH	10754477	1658	1662	I-Outcome
(	10754477	1663	1664	I-Outcome
1	10754477	1665	1666	I-Outcome
-	10754477	1666	1667	I-Outcome
29	10754477	1667	1669	I-Outcome
)	10754477	1670	1671	I-Outcome
NH	10754477	1672	1674	I-Outcome
(	10754477	1675	1676	I-Outcome
2	10754477	1677	1678	I-Outcome
)	10754477	1679	1680	I-Outcome
(	10754477	1681	1682	O
median	10754477	1683	1689	B-Outcome
AUC	10754477	1690	1693	I-Outcome
:	10754477	1694	1695	O
122mU/l.min	10754477	1696	1707	B-Observation
vs	10754477	1708	1710	O
179mU/l.min	10754477	1711	1722	B-Observation
vs	10754477	1723	1725	O
268mU/l.min	10754477	1726	1737	B-Observation
;	10754477	1738	1739	O
P=0.007	10754477	1740	1747	O
)	10754477	1748	1749	O
reflecting	10754477	1750	1760	O
altered	10754477	1761	1768	B-Observation
pituitary	10754477	1769	1778	B-Outcome
sensitivity	10754477	1779	1790	I-Outcome
and	10754477	1791	1794	O
reduced	10754477	1795	1802	B-Observation
responsiveness	10754477	1803	1817	B-Outcome
.	10754477	1818	1819	O

CONCLUSION	10754477	1820	1830	O
The	10754477	1831	1834	O
GH	10754477	1835	1837	B-Outcome
response	10754477	1838	1846	I-Outcome
to	10754477	1847	1849	O
bolus	10754477	1850	1855	B-Intervention
GHRH	10754477	1856	1860	I-Intervention
(	10754477	1861	1862	I-Intervention
1	10754477	1863	1864	I-Intervention
-	10754477	1864	1865	I-Intervention
29	10754477	1865	1867	I-Intervention
)	10754477	1868	1869	I-Intervention
NH	10754477	1870	1872	I-Intervention
(	10754477	1873	1874	I-Intervention
2	10754477	1875	1876	I-Intervention
)	10754477	1877	1878	I-Intervention
is	10754477	1879	1881	O
attenuated	10754477	1882	1892	B-Observation
in	10754477	1893	1895	O
adult	10754477	1896	1901	B-Participant
long-term	10754477	1902	1911	I-Participant
survivors	10754477	1912	1921	I-Participant
of	10754477	1922	1924	I-Participant
childhood	10754477	1925	1934	I-Participant
brain	10754477	1935	1940	I-Participant
tumours	10754477	1941	1948	I-Participant
.	10754477	1949	1950	O

This	10754477	1951	1955	O
may	10754477	1956	1959	O
reflect	10754477	1960	1967	O
direct	10754477	1968	1974	O
pituitary	10754477	1975	1984	O
damage	10754477	1985	1991	O
and/or	10754477	1992	1998	O
the	10754477	1999	2002	O
loss	10754477	2003	2007	O
of	10754477	2008	2010	O
the	10754477	2011	2014	O
tropic	10754477	2015	2021	O
effects	10754477	2022	2029	O
of	10754477	2030	2032	O
chronic	10754477	2033	2040	O
GHRH	10754477	2041	2045	O
deficiency	10754477	2046	2056	O
.	10754477	2057	2058	O

Auditory	10755175	0	8	B-Intervention
integration	10755175	9	20	I-Intervention
training	10755175	21	29	I-Intervention
for	10755175	30	33	O
children	10755175	34	42	B-Participant
with	10755175	43	47	O
autism	10755175	48	54	B-Participant
:	10755175	55	56	O
no	10755175	57	59	O
behavioral	10755175	60	70	B-Outcome
benefits	10755175	71	79	I-Outcome
detected	10755175	80	88	O
.	10755175	89	90	O

Auditory	10755175	91	99	B-Intervention
integration	10755175	100	111	I-Intervention
training	10755175	112	120	I-Intervention
and	10755175	121	124	O
a	10755175	125	126	O
control	10755175	127	134	B-Intervention
treatment	10755175	135	144	O
were	10755175	145	149	O
provided	10755175	150	158	O
for	10755175	159	162	O
16	10755175	163	165	O
children	10755175	166	174	B-Participant
with	10755175	175	179	O
autism	10755175	180	186	B-Participant
in	10755175	187	189	O
a	10755175	190	191	O
crossover	10755175	192	201	O
experimental	10755175	202	214	O
design	10755175	215	221	O
.	10755175	222	223	O

Measures	10755175	224	232	O
,	10755175	233	234	O
blind	10755175	235	240	O
to	10755175	241	243	O
treatment	10755175	244	253	O
order	10755175	254	259	O
,	10755175	260	261	O
included	10755175	262	270	O
parent	10755175	271	277	B-Outcome
and	10755175	278	281	I-Outcome
teacher	10755175	282	289	I-Outcome
ratings	10755175	290	297	I-Outcome
of	10755175	298	300	I-Outcome
behavior	10755175	301	309	I-Outcome
,	10755175	310	311	O
direct	10755175	312	318	B-Outcome
observational	10755175	319	332	I-Outcome
recordings	10755175	333	343	I-Outcome
,	10755175	344	345	O
IQ	10755175	346	348	B-Outcome
,	10755175	349	350	O
language	10755175	351	359	B-Outcome
,	10755175	360	361	O
and	10755175	362	365	O
social/adaptive	10755175	366	381	B-Outcome
tests	10755175	382	387	I-Outcome
.	10755175	388	389	O

Significant	10755175	390	401	B-Observation
differences	10755175	402	413	I-Observation
tended	10755175	414	420	O
to	10755175	421	423	O
show	10755175	424	428	O
that	10755175	429	433	O
the	10755175	434	437	O
control	10755175	438	445	B-Intervention
condition	10755175	446	455	O
was	10755175	456	459	O
superior	10755175	460	468	B-Observation
on	10755175	469	471	O
parent-rated	10755175	472	484	B-Outcome
measures	10755175	485	493	I-Outcome
of	10755175	494	496	I-Outcome
hyperactivity	10755175	497	510	I-Outcome
and	10755175	511	514	O
on	10755175	515	517	O
direct	10755175	518	524	B-Outcome
observational	10755175	525	538	I-Outcome
measures	10755175	539	547	I-Outcome
of	10755175	548	550	I-Outcome
ear-occlusion	10755175	551	564	I-Outcome
.	10755175	565	566	O

No	10755175	567	569	O
differences	10755175	570	581	B-Observation
were	10755175	582	586	O
detected	10755175	587	595	O
on	10755175	596	598	O
teacher-rated	10755175	599	612	B-Outcome
measures	10755175	613	621	I-Outcome
.	10755175	622	623	O

Children	10755175	624	632	O
's	10755175	633	635	O
IQs	10755175	636	639	B-Outcome
and	10755175	640	643	O
language	10755175	644	652	B-Outcome
comprehension	10755175	653	666	I-Outcome
did	10755175	667	670	O
not	10755175	671	674	O
increase	10755175	675	683	B-Observation
,	10755175	684	685	O
but	10755175	686	689	O
adaptive/social	10755175	690	705	B-Outcome
behavior	10755175	706	714	I-Outcome
scores	10755175	715	721	I-Outcome
and	10755175	722	725	O
expressive	10755175	726	736	B-Outcome
language	10755175	737	745	I-Outcome
quotients	10755175	746	755	I-Outcome
decreased	10755175	756	765	B-Observation
.	10755175	766	767	O

The	10755175	768	771	O
majority	10755175	772	780	O
of	10755175	781	783	O
parents	10755175	784	791	O
(	10755175	792	793	O
56	10755175	794	796	O
%	10755175	797	798	O
)	10755175	799	800	O
were	10755175	801	805	O
unable	10755175	806	812	O
to	10755175	813	815	O
report	10755175	816	822	O
in	10755175	823	825	O
retrospect	10755175	826	836	O
when	10755175	837	841	O
their	10755175	842	847	O
child	10755175	848	853	O
had	10755175	854	857	O
received	10755175	858	866	O
auditory	10755175	867	875	O
integration	10755175	876	887	O
training	10755175	888	896	O
.	10755175	897	898	O

No	10755175	899	901	B-Count
individual	10755175	902	912	I-Count
child	10755175	913	918	I-Count
was	10755175	919	922	O
identified	10755175	923	933	O
as	10755175	934	936	O
benefiting	10755175	937	947	B-Observation
clinically	10755175	948	958	I-Observation
or	10755175	959	961	I-Observation
educationally	10755175	962	975	I-Observation
from	10755175	976	980	O
the	10755175	981	984	O
treatment	10755175	985	994	B-Intervention
.	10755175	995	996	O

Antisaccade	10757250	0	11	B-Outcome
and	10757250	12	15	O
smooth	10757250	16	22	B-Outcome
pursuit	10757250	23	30	I-Outcome
eye	10757250	31	34	I-Outcome
movements	10757250	35	44	I-Outcome
in	10757250	45	47	O
healthy	10757250	48	55	B-Participant
subjects	10757250	56	64	O
receiving	10757250	65	74	O
sertraline	10757250	75	85	B-Intervention
and	10757250	86	89	O
lorazepam	10757250	90	99	B-Intervention
.	10757250	100	101	O

Patients	10757250	102	110	O
suffering	10757250	111	120	O
from	10757250	121	125	O
some	10757250	126	130	O
psychiatric	10757250	131	142	O
and	10757250	143	146	O
neurological	10757250	147	159	O
disorders	10757250	160	169	O
demonstrate	10757250	170	181	O
abnormally	10757250	182	192	O
high	10757250	193	197	O
levels	10757250	198	204	O
of	10757250	205	207	O
saccadic	10757250	208	216	O
distractibility	10757250	217	232	O
when	10757250	233	237	O
carrying	10757250	238	246	O
out	10757250	247	250	O
the	10757250	251	254	O
antisaccade	10757250	255	266	O
task	10757250	267	271	O
.	10757250	272	273	O

This	10757250	274	278	O
has	10757250	279	282	O
been	10757250	283	287	O
particularly	10757250	288	300	O
thoroughly	10757250	301	311	O
demonstrated	10757250	312	324	O
in	10757250	325	327	O
patients	10757250	328	336	O
with	10757250	337	341	O
schizophrenia	10757250	342	355	O
.	10757250	356	357	O

A	10757250	358	359	O
large	10757250	360	365	O
body	10757250	366	370	O
of	10757250	371	373	O
evidence	10757250	374	382	O
has	10757250	383	386	O
been	10757250	387	391	O
accumulated	10757250	392	403	O
from	10757250	404	408	O
studies	10757250	409	416	O
of	10757250	417	419	O
patients	10757250	420	428	O
which	10757250	429	434	O
suggests	10757250	435	443	O
that	10757250	444	448	O
such	10757250	449	453	O
eye	10757250	454	457	O
movement	10757250	458	466	O
abnormalities	10757250	467	480	O
may	10757250	481	484	O
arise	10757250	485	490	O
from	10757250	491	495	O
frontal	10757250	496	503	O
lobe	10757250	504	508	O
dysfunction	10757250	509	520	O
.	10757250	521	522	O

The	10757250	523	526	O
psychopharmacology	10757250	527	545	O
of	10757250	546	548	O
saccadic	10757250	549	557	O
distractibility	10757250	558	573	O
is	10757250	574	576	O
less	10757250	577	581	O
well	10757250	582	586	O
understood	10757250	587	597	O
,	10757250	598	599	O
but	10757250	600	603	O
is	10757250	604	606	O
relevant	10757250	607	615	O
both	10757250	616	620	O
to	10757250	621	623	O
interpreting	10757250	624	636	O
patient	10757250	637	644	O
studies	10757250	645	652	O
and	10757250	653	656	O
to	10757250	657	659	O
establishing	10757250	660	672	O
the	10757250	673	676	O
neurological	10757250	677	689	O
basis	10757250	690	695	O
of	10757250	696	698	O
their	10757250	699	704	O
findings	10757250	705	713	O
.	10757250	714	715	O

Twenty	10757250	716	722	O
healthy	10757250	723	730	O
subjects	10757250	731	739	O
received	10757250	740	748	O
lorazepam	10757250	749	758	B-Intervention
0.5	10757250	759	762	O
mg	10757250	763	765	O
,	10757250	766	767	O
1	10757250	768	769	O
mg	10757250	770	772	O
and	10757250	773	776	O
2	10757250	777	778	O
mg	10757250	779	781	O
,	10757250	782	783	O
sertraline	10757250	784	794	B-Intervention
50	10757250	795	797	O
mg	10757250	798	800	O
and	10757250	801	804	O
placebo	10757250	805	812	B-Intervention
in	10757250	813	815	O
a	10757250	816	817	O
balanced	10757250	818	826	O
,	10757250	827	828	O
repeated	10757250	829	837	O
measures	10757250	838	846	O
study	10757250	847	852	O
design	10757250	853	859	O
.	10757250	860	861	O

Antisaccade	10757250	862	873	B-Outcome
,	10757250	874	875	O
no-saccade	10757250	876	886	B-Outcome
,	10757250	887	888	O
visually	10757250	889	897	B-Outcome
guided	10757250	898	904	I-Outcome
saccade	10757250	905	912	I-Outcome
and	10757250	913	916	O
smooth	10757250	917	923	B-Outcome
pursuit	10757250	924	931	I-Outcome
tasks	10757250	932	937	I-Outcome
were	10757250	938	942	O
carried	10757250	943	950	O
out	10757250	951	954	O
and	10757250	955	958	O
the	10757250	959	962	O
effects	10757250	963	970	B-Outcome
of	10757250	971	973	I-Outcome
practice	10757250	974	982	I-Outcome
and	10757250	983	986	I-Outcome
drugs	10757250	987	992	I-Outcome
measured	10757250	993	1001	O
.	10757250	1002	1003	O

Lorazepam	10757250	1004	1013	B-Intervention
increased	10757250	1014	1023	B-Observation
direction	10757250	1024	1033	B-Outcome
errors	10757250	1034	1040	I-Outcome
in	10757250	1041	1043	I-Outcome
the	10757250	1044	1047	I-Outcome
antisaccade	10757250	1048	1059	I-Outcome
and	10757250	1060	1063	I-Outcome
no-saccade	10757250	1064	1074	I-Outcome
tasks	10757250	1075	1080	I-Outcome
in	10757250	1081	1083	O
a	10757250	1084	1085	O
dose-dependent	10757250	1086	1100	O
manner	10757250	1101	1107	O
.	10757250	1108	1109	O

Sertraline	10757250	1110	1120	B-Intervention
had	10757250	1121	1124	O
no	10757250	1125	1127	O
effect	10757250	1128	1134	B-Observation
on	10757250	1135	1137	O
these	10757250	1138	1143	B-Outcome
measures	10757250	1144	1152	I-Outcome
.	10757250	1153	1154	O

Correlation	10757250	1155	1166	O
showed	10757250	1167	1173	O
a	10757250	1174	1175	O
statistically	10757250	1176	1189	B-Observation
significant	10757250	1190	1201	I-Observation
,	10757250	1202	1203	I-Observation
but	10757250	1204	1207	I-Observation
rather	10757250	1208	1214	I-Observation
weak	10757250	1215	1219	I-Observation
,	10757250	1220	1221	I-Observation
association	10757250	1222	1233	I-Observation
between	10757250	1234	1241	O
direction	10757250	1242	1251	B-Outcome
errors	10757250	1252	1258	I-Outcome
and	10757250	1259	1262	O
smooth	10757250	1263	1269	B-Outcome
pursuit	10757250	1270	1277	I-Outcome
measures	10757250	1278	1286	I-Outcome
.	10757250	1287	1288	O

Practice	10757250	1289	1297	O
was	10757250	1298	1301	O
shown	10757250	1302	1307	O
to	10757250	1308	1310	O
have	10757250	1311	1315	O
a	10757250	1316	1317	O
powerful	10757250	1318	1326	B-Observation
effect	10757250	1327	1333	I-Observation
on	10757250	1334	1336	O
antisaccade	10757250	1337	1348	B-Outcome
direction	10757250	1349	1358	I-Outcome
errors	10757250	1359	1365	I-Outcome
.	10757250	1366	1367	O

This	10757250	1368	1372	O
study	10757250	1373	1378	O
supports	10757250	1379	1387	O
our	10757250	1388	1391	O
previous	10757250	1392	1400	O
work	10757250	1401	1405	O
by	10757250	1406	1408	O
confirming	10757250	1409	1419	O
that	10757250	1420	1424	O
lorazepam	10757250	1425	1434	B-Intervention
reliably	10757250	1435	1443	B-Observation
worsens	10757250	1444	1451	I-Observation
saccadic	10757250	1452	1460	B-Outcome
distractibility	10757250	1461	1476	I-Outcome
,	10757250	1477	1478	O
in	10757250	1479	1481	O
contrast	10757250	1482	1490	O
to	10757250	1491	1493	O
other	10757250	1494	1499	O
psychotropic	10757250	1500	1512	O
drugs	10757250	1513	1518	O
such	10757250	1519	1523	O
as	10757250	1524	1526	O
sertraline	10757250	1527	1537	B-Intervention
and	10757250	1538	1541	O
chlorpromazine	10757250	1542	1556	B-Intervention
.	10757250	1557	1558	O

Our	10757250	1559	1562	O
results	10757250	1563	1570	O
also	10757250	1571	1575	O
suggest	10757250	1576	1583	O
that	10757250	1584	1588	O
other	10757250	1589	1594	O
studies	10757250	1595	1602	O
in	10757250	1603	1605	O
this	10757250	1606	1610	O
field	10757250	1611	1616	O
,	10757250	1617	1618	O
particularly	10757250	1619	1631	O
those	10757250	1632	1637	O
using	10757250	1638	1643	O
parallel	10757250	1644	1652	O
groups	10757250	1653	1659	O
design	10757250	1660	1666	O
,	10757250	1667	1668	O
should	10757250	1669	1675	O
take	10757250	1676	1680	O
account	10757250	1681	1688	O
of	10757250	1689	1691	O
practice	10757250	1692	1700	O
effects	10757250	1701	1708	O
.	10757250	1709	1710	O

Ropivacaine-clonidine	10757579	0	21	B-Intervention
combination	10757579	22	33	I-Intervention
for	10757579	34	37	O
caudal	10757579	38	44	B-Participant
blockade	10757579	45	53	I-Participant
in	10757579	54	56	O
children	10757579	57	65	B-Participant
.	10757579	66	67	O

BACKGROUND	10757579	68	78	O
Adding	10757579	79	85	O
clonidine	10757579	86	95	O
to	10757579	96	98	O
weak	10757579	99	103	O
ropivacaine	10757579	104	115	O
solutions	10757579	116	125	O
(	10757579	126	127	O
<	10757579	128	129	O
0.2	10757579	130	133	O
%	10757579	134	135	O
)	10757579	136	137	O
could	10757579	138	143	O
potentially	10757579	144	155	O
enhance	10757579	156	163	O
analgesia	10757579	164	173	O
as	10757579	174	176	O
well	10757579	177	181	O
as	10757579	182	184	O
further	10757579	185	192	O
reduce	10757579	193	199	O
the	10757579	200	203	O
risk	10757579	204	208	O
for	10757579	209	212	O
unwanted	10757579	213	221	O
motor	10757579	222	227	O
blockade	10757579	228	236	O
.	10757579	237	238	O

The	10757579	239	242	O
aim	10757579	243	246	O
of	10757579	247	249	O
the	10757579	250	253	O
present	10757579	254	261	O
study	10757579	262	267	O
was	10757579	268	271	O
to	10757579	272	274	O
compare	10757579	275	282	O
the	10757579	283	286	O
postoperative	10757579	287	300	B-Outcome
pain-relieving	10757579	301	315	I-Outcome
quality	10757579	316	323	I-Outcome
of	10757579	324	326	O
a	10757579	327	328	O
ropivacaine	10757579	329	340	B-Intervention
0.1	10757579	341	344	I-Intervention
%	10757579	345	346	I-Intervention
-clonidine	10757579	347	357	I-Intervention
mixture	10757579	358	365	I-Intervention
to	10757579	366	368	O
that	10757579	369	373	O
of	10757579	374	376	O
plain	10757579	377	382	B-Intervention
ropivacaine	10757579	383	394	I-Intervention
0.2	10757579	395	398	I-Intervention
%	10757579	399	400	I-Intervention
following	10757579	401	410	O
caudal	10757579	411	417	O
administration	10757579	418	432	O
in	10757579	433	435	O
children	10757579	436	444	B-Participant
.	10757579	445	446	O

METHODS	10757579	447	454	O
In	10757579	455	457	O
a	10757579	458	459	O
prospective	10757579	460	471	O
,	10757579	472	473	O
observer-blinded	10757579	474	490	O
fashion	10757579	491	498	O
,	10757579	499	500	O
40	10757579	501	503	B-Count
ASA	10757579	504	507	B-Participant
1	10757579	508	509	I-Participant
paediatric	10757579	510	520	I-Participant
patients	10757579	521	529	O
undergoing	10757579	530	540	O
subumbilical	10757579	541	553	B-Participant
surgery	10757579	554	561	I-Participant
were	10757579	562	566	O
randomly	10757579	567	575	O
allocated	10757579	576	585	O
to	10757579	586	588	O
receive	10757579	589	596	O
a	10757579	597	598	O
caudal	10757579	599	605	O
injection	10757579	606	615	O
of	10757579	616	618	O
either	10757579	619	625	O
plain	10757579	626	631	B-Intervention
ropivacaine	10757579	632	643	I-Intervention
0.2	10757579	644	647	I-Intervention
%	10757579	648	649	I-Intervention
(	10757579	650	651	O
1	10757579	652	653	O
ml/kg	10757579	654	659	O
)	10757579	660	661	O
(	10757579	662	663	O
R0.2	10757579	664	668	O
)	10757579	669	670	O
or	10757579	671	673	O
a	10757579	674	675	O
mixture	10757579	676	683	B-Intervention
of	10757579	684	686	I-Intervention
ropivacaine	10757579	687	698	I-Intervention
0.1	10757579	699	702	I-Intervention
%	10757579	703	704	I-Intervention
with	10757579	705	709	I-Intervention
clonidine	10757579	710	719	I-Intervention
2	10757579	720	721	I-Intervention
microg/kg	10757579	722	731	I-Intervention
(	10757579	732	733	O
1	10757579	734	735	O
ml/kg	10757579	736	741	O
)	10757579	742	743	O
(	10757579	744	745	O
R0.1C	10757579	746	751	O
)	10757579	752	753	O
.	10757579	754	755	O

Objective	10757579	756	765	B-Outcome
pain	10757579	766	770	I-Outcome
scale	10757579	771	776	I-Outcome
score	10757579	777	782	I-Outcome
and	10757579	783	786	O
need	10757579	787	791	B-Outcome
for	10757579	792	795	I-Outcome
supplemental	10757579	796	808	I-Outcome
analgesia	10757579	809	818	I-Outcome
were	10757579	819	823	O
used	10757579	824	828	O
to	10757579	829	831	O
evaluate	10757579	832	840	O
analgesia	10757579	841	850	O
during	10757579	851	857	O
the	10757579	858	861	O
first	10757579	862	867	O
24	10757579	868	870	O
h	10757579	871	872	O
postoperatively	10757579	873	888	O
.	10757579	889	890	O

Residual	10757579	891	899	B-Outcome
postoperative	10757579	900	913	I-Outcome
sedation	10757579	914	922	I-Outcome
was	10757579	923	926	O
also	10757579	927	931	O
assessed	10757579	932	940	O
.	10757579	941	942	O

RESULTS	10757579	943	950	O
A	10757579	951	952	O
significantly	10757579	953	966	B-Observation
higher	10757579	967	973	I-Observation
number	10757579	974	980	I-Observation
of	10757579	981	983	I-Observation
patients	10757579	984	992	I-Observation
in	10757579	993	995	O
the	10757579	996	999	O
R0.1C	10757579	1000	1005	B-Intervention
group	10757579	1006	1011	O
(	10757579	1012	1013	O
18/20	10757579	1014	1019	B-Count
)	10757579	1020	1021	O
could	10757579	1022	1027	O
be	10757579	1028	1030	O
managed	10757579	1031	1038	B-Outcome
without	10757579	1039	1046	I-Outcome
supplemental	10757579	1047	1059	I-Outcome
analgesia	10757579	1060	1069	I-Outcome
during	10757579	1070	1076	O
the	10757579	1077	1080	O
first	10757579	1081	1086	O
24	10757579	1087	1089	O
h	10757579	1090	1091	O
postoperatively	10757579	1092	1107	O
compared	10757579	1108	1116	O
to	10757579	1117	1119	O
the	10757579	1120	1123	O
R0.2	10757579	1124	1128	B-Intervention
group	10757579	1129	1134	O
(	10757579	1135	1136	O
11/20	10757579	1137	1142	B-Count
)	10757579	1143	1144	O
(	10757579	1145	1146	O
P=0.034	10757579	1147	1154	O
)	10757579	1155	1156	O
.	10757579	1157	1158	O

Both	10757579	1159	1163	O
the	10757579	1164	1167	O
degree	10757579	1168	1174	B-Outcome
and	10757579	1175	1178	I-Outcome
the	10757579	1179	1182	I-Outcome
duration	10757579	1183	1191	I-Outcome
of	10757579	1192	1194	I-Outcome
postoperative	10757579	1195	1208	I-Outcome
sedation	10757579	1209	1217	I-Outcome
was	10757579	1218	1221	O
similar	10757579	1222	1229	B-Observation
in	10757579	1230	1232	O
both	10757579	1233	1237	B-Intervention
groups	10757579	1238	1244	I-Intervention
.	10757579	1245	1246	O

No	10757579	1247	1249	O
signs	10757579	1250	1255	B-Outcome
of	10757579	1256	1258	I-Outcome
postoperative	10757579	1259	1272	I-Outcome
motor	10757579	1273	1278	I-Outcome
blockade	10757579	1279	1287	I-Outcome
were	10757579	1288	1292	O
observed	10757579	1293	1301	O
.	10757579	1302	1303	O

CONCLUSIONS	10757579	1304	1315	O
The	10757579	1316	1319	O
combination	10757579	1320	1331	B-Intervention
of	10757579	1332	1334	I-Intervention
clonidine	10757579	1335	1344	I-Intervention
(	10757579	1345	1346	I-Intervention
2	10757579	1347	1348	I-Intervention
microg/kg	10757579	1349	1358	I-Intervention
)	10757579	1359	1360	I-Intervention
and	10757579	1361	1364	I-Intervention
ropivacaine	10757579	1365	1376	I-Intervention
0.1	10757579	1377	1380	I-Intervention
%	10757579	1381	1382	I-Intervention
is	10757579	1383	1385	O
associated	10757579	1386	1396	O
with	10757579	1397	1401	O
an	10757579	1402	1404	O
improved	10757579	1405	1413	B-Observation
quality	10757579	1414	1421	I-Observation
of	10757579	1422	1424	O
postoperative	10757579	1425	1438	B-Outcome
analgesia	10757579	1439	1448	I-Outcome
compared	10757579	1449	1457	O
to	10757579	1458	1460	O
plain	10757579	1461	1466	B-Intervention
0.2	10757579	1467	1470	I-Intervention
%	10757579	1471	1472	I-Intervention
ropivacaine	10757579	1473	1484	I-Intervention
.	10757579	1485	1486	O

The	10757579	1487	1490	O
improved	10757579	1491	1499	B-Observation
analgesic	10757579	1500	1509	B-Outcome
quality	10757579	1510	1517	I-Outcome
of	10757579	1518	1520	O
the	10757579	1521	1524	O
clonidine-ropivacaine	10757579	1525	1546	B-Intervention
mixture	10757579	1547	1554	I-Intervention
is	10757579	1555	1557	O
achieved	10757579	1558	1566	O
without	10757579	1567	1574	O
causing	10757579	1575	1582	B-Observation
any	10757579	1583	1586	O
significant	10757579	1587	1598	B-Outcome
degree	10757579	1599	1605	I-Outcome
of	10757579	1606	1608	I-Outcome
postoperative	10757579	1609	1622	I-Outcome
sedation	10757579	1623	1631	I-Outcome
.	10757579	1632	1633	O

Pharmacokinetic	10759619	0	15	B-Outcome
interaction	10759619	16	27	I-Outcome
between	10759619	28	35	O
proton	10759619	36	42	B-Intervention
pump	10759619	43	47	I-Intervention
inhibitors	10759619	48	58	I-Intervention
and	10759619	59	62	O
roxithromycin	10759619	63	76	B-Intervention
in	10759619	77	79	O
volunteers	10759619	80	90	O
.	10759619	91	92	O

BACKGROUND	10759619	93	103	O
Triple	10759619	104	110	O
therapy	10759619	111	118	O
including	10759619	119	128	O
two	10759619	129	132	O
antibiotics	10759619	133	144	O
and	10759619	145	148	O
a	10759619	149	150	O
proton	10759619	151	157	O
pump	10759619	158	162	O
inhibitor	10759619	163	172	O
is	10759619	173	175	O
a	10759619	176	177	O
rational	10759619	178	186	O
approach	10759619	187	195	O
to	10759619	196	198	O
the	10759619	199	202	O
treatment	10759619	203	212	O
of	10759619	213	215	O
Helicobacter	10759619	216	228	O
pylori	10759619	229	235	O
induced	10759619	236	243	O
peptic	10759619	244	250	O
ulcer	10759619	251	256	O
disease	10759619	257	264	O
.	10759619	265	266	O

The	10759619	267	270	O
interaction	10759619	271	282	O
of	10759619	283	285	O
antimicrobial	10759619	286	299	O
therapy	10759619	300	307	O
and	10759619	308	311	O
acid	10759619	312	316	O
suppression	10759619	317	328	O
is	10759619	329	331	O
not	10759619	332	335	O
yet	10759619	336	339	O
well	10759619	340	344	O
elucidated	10759619	345	355	O
.	10759619	356	357	O

AIMS	10759619	358	362	O
To	10759619	363	365	O
investigate	10759619	366	377	O
the	10759619	378	381	O
effects	10759619	382	389	O
of	10759619	390	392	O
proton	10759619	393	399	B-Intervention
pump	10759619	400	404	I-Intervention
inhibitors	10759619	405	415	I-Intervention
on	10759619	416	418	O
roxithromycin	10759619	419	432	B-Outcome
levels	10759619	433	439	I-Outcome
in	10759619	440	442	I-Outcome
plasma	10759619	443	449	I-Outcome
and	10759619	450	453	I-Outcome
gastric	10759619	454	461	I-Outcome
tissue	10759619	462	468	I-Outcome
under	10759619	469	474	O
steady-state	10759619	475	487	B-Participant
conditions	10759619	488	498	I-Participant
in	10759619	499	501	O
volunteers	10759619	502	512	O
.	10759619	513	514	O

METHODS	10759619	515	522	O
In	10759619	523	525	O
two	10759619	526	529	O
crossover	10759619	530	539	O
studies	10759619	540	547	O
omeprazole	10759619	548	558	B-Intervention
20	10759619	559	561	O
mg	10759619	562	564	O
b.d	10759619	565	568	O
.	10759619	568	569	O
,	10759619	570	571	O
lansoprazole	10759619	572	584	B-Intervention
30	10759619	585	587	O
mg	10759619	588	590	O
b.d	10759619	591	594	O
.	10759619	594	595	O
,	10759619	596	597	O
roxithromycin	10759619	598	611	B-Intervention
300	10759619	612	615	O
mg	10759619	616	618	O
b.d	10759619	619	622	O
.	10759619	622	623	O
,	10759619	624	625	O
and	10759619	626	629	O
the	10759619	630	633	O
combination	10759619	634	645	B-Intervention
of	10759619	646	648	I-Intervention
roxithromycin	10759619	649	662	I-Intervention
with	10759619	663	667	I-Intervention
either	10759619	668	674	I-Intervention
omeprazole	10759619	675	685	I-Intervention
or	10759619	686	688	I-Intervention
lansoprazole	10759619	689	701	I-Intervention
were	10759619	702	706	O
administered	10759619	707	719	O
to	10759619	720	722	O
12	10759619	723	725	O
healthy	10759619	726	733	B-Participant
volunteers	10759619	734	744	O
over	10759619	745	749	O
6	10759619	750	751	O
days	10759619	752	756	O
.	10759619	757	758	O

Blood	10759619	759	764	B-Outcome
plasma	10759619	765	771	I-Outcome
levels	10759619	772	778	I-Outcome
of	10759619	779	781	I-Outcome
the	10759619	782	785	I-Outcome
drugs	10759619	786	791	I-Outcome
were	10759619	792	796	O
measured	10759619	797	805	O
.	10759619	806	807	O

In	10759619	808	810	O
addition	10759619	811	819	O
,	10759619	820	821	O
roxithromycin	10759619	822	835	B-Outcome
concentrations	10759619	836	850	I-Outcome
were	10759619	851	855	O
also	10759619	856	860	O
determined	10759619	861	871	O
in	10759619	872	874	O
gastric	10759619	875	882	O
juice	10759619	883	888	O
and	10759619	889	892	O
gastric	10759619	893	900	O
tissue	10759619	901	907	O
obtained	10759619	908	916	O
during	10759619	917	923	O
endoscopy	10759619	924	933	O
.	10759619	934	935	O

RESULTS	10759619	936	943	O
The	10759619	944	947	O
proton	10759619	948	954	B-Intervention
pump	10759619	955	959	I-Intervention
inhibitors	10759619	960	970	I-Intervention
and	10759619	971	974	O
roxithromycin	10759619	975	988	B-Intervention
did	10759619	989	992	O
not	10759619	993	996	O
alter	10759619	997	1002	B-Observation
the	10759619	1003	1006	O
blood	10759619	1007	1012	B-Outcome
plasma	10759619	1013	1019	I-Outcome
pharmacokinetics	10759619	1020	1036	I-Outcome
of	10759619	1037	1039	O
each	10759619	1040	1044	O
other	10759619	1045	1050	O
.	10759619	1051	1052	O

When	10759619	1053	1057	O
compared	10759619	1058	1066	O
to	10759619	1067	1069	O
roxithromycin	10759619	1070	1083	B-Intervention
administered	10759619	1084	1096	I-Intervention
alone	10759619	1097	1102	I-Intervention
,	10759619	1103	1104	O
its	10759619	1105	1108	O
combination	10759619	1109	1120	B-Intervention
with	10759619	1121	1125	I-Intervention
a	10759619	1126	1127	I-Intervention
proton	10759619	1128	1134	I-Intervention
pump	10759619	1135	1139	I-Intervention
inhibitor	10759619	1140	1149	I-Intervention
significantly	10759619	1150	1163	B-Observation
increased	10759619	1164	1173	I-Observation
the	10759619	1174	1177	O
roxithromycin	10759619	1178	1191	B-Outcome
concentrations	10759619	1192	1206	I-Outcome
in	10759619	1207	1209	I-Outcome
gastric	10759619	1210	1217	I-Outcome
juice	10759619	1218	1223	I-Outcome
(	10759619	1224	1225	O
3.0	10759619	1226	1229	B-Observation
-	10759619	1229	1230	I-Observation
5.0	10759619	1230	1233	I-Observation
microg/mL	10759619	1234	1243	I-Observation
vs.	10759619	1244	1247	O
0.3	10759619	1248	1251	B-Observation
-	10759619	1251	1252	I-Observation
0.4	10759619	1252	1255	I-Observation
microg/mL	10759619	1256	1265	I-Observation
)	10759619	1266	1267	O
and	10759619	1268	1271	O
gastric	10759619	1272	1279	B-Outcome
tissue	10759619	1280	1286	I-Outcome
(	10759619	1287	1288	O
antrum	10759619	1289	1295	O
:	10759619	1296	1297	O
3.8	10759619	1298	1301	B-Observation
-	10759619	1301	1302	I-Observation
4.0	10759619	1302	1305	I-Observation
vs.	10759619	1306	1309	O
2.8	10759619	1310	1313	B-Observation
microg/g	10759619	1314	1322	I-Observation
,	10759619	1323	1324	O
fundus	10759619	1325	1331	O
:	10759619	1332	1333	O
5.9	10759619	1334	1337	B-Observation
-	10759619	1337	1338	I-Observation
7.4	10759619	1338	1341	I-Observation
vs.	10759619	1342	1345	O
4.2	10759619	1346	1349	B-Observation
-	10759619	1349	1350	I-Observation
4.4	10759619	1350	1353	I-Observation
microg/g	10759619	1354	1362	I-Observation
)	10759619	1363	1364	O
.	10759619	1365	1366	O

CONCLUSIONS	10759619	1367	1378	O
Proton	10759619	1379	1385	B-Intervention
pump	10759619	1386	1390	I-Intervention
inhibitors	10759619	1391	1401	I-Intervention
and	10759619	1402	1405	O
roxithromycin	10759619	1406	1419	B-Intervention
do	10759619	1420	1422	O
not	10759619	1423	1426	O
alter	10759619	1427	1432	B-Observation
the	10759619	1433	1436	O
systemic	10759619	1437	1445	B-Outcome
bioavailability	10759619	1446	1461	I-Outcome
of	10759619	1462	1464	O
each	10759619	1465	1469	O
other	10759619	1470	1475	O
.	10759619	1476	1477	O

However	10759619	1478	1485	O
,	10759619	1486	1487	O
proton	10759619	1488	1494	B-Intervention
pump	10759619	1495	1499	I-Intervention
inhibitors	10759619	1500	1510	I-Intervention
increase	10759619	1511	1519	B-Observation
the	10759619	1520	1523	O
local	10759619	1524	1529	B-Outcome
concentration	10759619	1530	1543	I-Outcome
of	10759619	1544	1546	I-Outcome
roxithromycin	10759619	1547	1560	I-Outcome
in	10759619	1561	1563	I-Outcome
the	10759619	1564	1567	I-Outcome
stomach	10759619	1568	1575	I-Outcome
which	10759619	1576	1581	O
may	10759619	1582	1585	O
contribute	10759619	1586	1596	O
to	10759619	1597	1599	O
the	10759619	1600	1603	O
clinically	10759619	1604	1614	O
proven	10759619	1615	1621	O
synergic	10759619	1622	1630	O
beneficial	10759619	1631	1641	O
action	10759619	1642	1648	O
in	10759619	1649	1651	O
eradication	10759619	1652	1663	O
therapy	10759619	1664	1671	O
of	10759619	1672	1674	O
H.	10759619	1675	1677	O
pylori	10759619	1678	1684	O
.	10759619	1685	1686	O

Photodynamic	10768434	0	12	O
therapy	10768434	13	20	O
with	10768434	21	25	O
5-aminolaevulinic	10768434	26	43	B-Intervention
acid	10768434	44	48	I-Intervention
or	10768434	49	51	O
placebo	10768434	52	59	B-Intervention
for	10768434	60	63	O
recalcitrant	10768434	64	76	B-Participant
foot	10768434	77	81	I-Participant
and	10768434	82	85	I-Participant
hand	10768434	86	90	I-Participant
warts	10768434	91	96	I-Participant
:	10768434	97	98	O
randomised	10768434	99	109	O
double-blind	10768434	110	122	O
trial	10768434	123	128	O
.	10768434	129	130	O

BACKGROUND	10768434	131	141	O
Photodynamic	10768434	142	154	O
therapy	10768434	155	162	O
(	10768434	163	164	O
PDT	10768434	165	168	O
)	10768434	169	170	O
with	10768434	171	175	O
topical	10768434	176	183	O
5-aminolaevulinic	10768434	184	201	O
acid	10768434	202	206	O
(	10768434	207	208	O
ALA	10768434	209	212	O
)	10768434	213	214	O
followed	10768434	215	223	O
by	10768434	224	226	O
irradiation	10768434	227	238	O
with	10768434	239	243	O
incoherent	10768434	244	254	O
light	10768434	255	260	O
(	10768434	261	262	O
ALA-PDT	10768434	263	270	O
)	10768434	271	272	O
for	10768434	273	276	O
recalcitrant	10768434	277	289	O
warts	10768434	290	295	O
have	10768434	296	300	O
had	10768434	301	304	O
beneficial	10768434	305	315	O
results	10768434	316	323	O
.	10768434	324	325	O

Therefore	10768434	326	335	O
,	10768434	336	337	O
we	10768434	338	340	O
undertook	10768434	341	350	O
a	10768434	351	352	O
randomised	10768434	353	363	O
,	10768434	364	365	O
parallel	10768434	366	374	O
,	10768434	375	376	O
double-blind	10768434	377	389	O
clinical	10768434	390	398	O
trial	10768434	399	404	O
of	10768434	405	407	O
ALA-PDT	10768434	408	415	B-Intervention
versus	10768434	416	422	O
placeboPDT	10768434	423	433	B-Intervention
for	10768434	434	437	O
recalcitrant	10768434	438	450	B-Participant
foot	10768434	451	455	I-Participant
and	10768434	456	459	I-Participant
hand	10768434	460	464	I-Participant
warts	10768434	465	470	I-Participant
.	10768434	471	472	O

METHODS	10768434	473	480	O
Recalcitrant	10768434	481	493	B-Participant
foot	10768434	494	498	I-Participant
and	10768434	499	502	I-Participant
hand	10768434	503	507	I-Participant
warts	10768434	508	513	I-Participant
were	10768434	514	518	O
randomly	10768434	519	527	O
assigned	10768434	528	536	O
to	10768434	537	539	O
six	10768434	540	543	O
repetitive	10768434	544	554	O
ALA-PDT	10768434	555	562	B-Intervention
or	10768434	563	565	O
placebo-PDT	10768434	566	577	B-Intervention
interventions	10768434	578	591	O
combined	10768434	592	600	O
with	10768434	601	605	O
standard	10768434	606	614	O
treatment	10768434	615	624	O
encompassing	10768434	625	637	O
paring	10768434	638	644	O
followed	10768434	645	653	O
by	10768434	654	656	O
a	10768434	657	658	O
keratolytic	10768434	659	670	O
(	10768434	671	672	O
Verucid	10768434	673	680	O
)	10768434	681	682	O
.	10768434	683	684	O

Standardised	10768434	685	697	B-Outcome
photographs	10768434	698	709	I-Outcome
of	10768434	710	712	O
each	10768434	713	717	O
wart	10768434	718	722	O
were	10768434	723	727	O
taken	10768434	728	733	O
before	10768434	734	740	O
,	10768434	741	742	O
during	10768434	743	749	O
(	10768434	750	751	O
week	10768434	752	756	O
7	10768434	757	758	O
)	10768434	759	760	O
and	10768434	761	764	O
after	10768434	765	770	O
treatment	10768434	771	780	O
(	10768434	781	782	O
weeks	10768434	783	788	O
14	10768434	789	791	O
and	10768434	792	795	O
18	10768434	796	798	O
)	10768434	799	800	O
.	10768434	801	802	O

The	10768434	803	806	O
area	10768434	807	811	B-Outcome
of	10768434	812	814	I-Outcome
each	10768434	815	819	I-Outcome
wart	10768434	820	824	I-Outcome
compared	10768434	825	833	I-Outcome
with	10768434	834	838	I-Outcome
entry	10768434	839	844	I-Outcome
area	10768434	845	849	I-Outcome
was	10768434	850	853	O
the	10768434	854	857	O
primary	10768434	858	865	O
outcome	10768434	866	873	O
variable	10768434	874	882	O
,	10768434	883	884	O
measured	10768434	885	893	O
from	10768434	894	898	O
photographs	10768434	899	910	O
by	10768434	911	913	O
an	10768434	914	916	O
evaluator	10768434	917	926	O
unaware	10768434	927	934	O
of	10768434	935	937	O
treatment	10768434	938	947	O
allocation	10768434	948	958	O
for	10768434	959	962	O
intervention	10768434	963	975	O
.	10768434	976	977	O

Pain	10768434	978	982	B-Outcome
intensity	10768434	983	992	I-Outcome
immediately	10768434	993	1004	O
and	10768434	1005	1008	O
24	10768434	1009	1011	O
h	10768434	1012	1013	O
after	10768434	1014	1019	O
each	10768434	1020	1024	O
intervention	10768434	1025	1037	O
was	10768434	1038	1041	O
assessed	10768434	1042	1050	O
by	10768434	1051	1053	O
a	10768434	1054	1055	O
five-point	10768434	1056	1066	O
scale	10768434	1067	1072	O
.	10768434	1073	1074	O

FINDINGS	10768434	1075	1083	O
A	10768434	1084	1085	O
total	10768434	1086	1091	O
of	10768434	1092	1094	O
232	10768434	1095	1098	B-Count
foot	10768434	1099	1103	B-Participant
and	10768434	1104	1107	I-Participant
hand	10768434	1108	1112	I-Participant
warts	10768434	1113	1118	I-Participant
in	10768434	1119	1121	O
45	10768434	1122	1124	O
patients	10768434	1125	1133	O
were	10768434	1134	1138	O
entered	10768434	1139	1146	O
into	10768434	1147	1151	O
the	10768434	1152	1155	O
trial	10768434	1156	1161	O
:	10768434	1162	1163	O
117	10768434	1164	1167	B-Count
warts	10768434	1168	1173	I-Count
were	10768434	1174	1178	O
allocated	10768434	1179	1188	O
to	10768434	1189	1191	O
ALA-PDT	10768434	1192	1199	B-Intervention
and	10768434	1200	1203	O
115	10768434	1204	1207	B-Count
warts	10768434	1208	1213	I-Count
to	10768434	1214	1216	O
placebo-PDT	10768434	1217	1228	B-Intervention
.	10768434	1229	1230	O

In	10768434	1231	1233	O
week	10768434	1234	1238	O
14	10768434	1239	1241	O
,	10768434	1242	1243	O
the	10768434	1244	1247	O
median	10768434	1248	1254	B-Outcome
relative	10768434	1255	1263	I-Outcome
reduction	10768434	1264	1273	I-Outcome
in	10768434	1274	1276	I-Outcome
wart	10768434	1277	1281	I-Outcome
area	10768434	1282	1286	I-Outcome
was	10768434	1287	1290	O
98	10768434	1291	1293	B-Observation
%	10768434	1294	1295	I-Observation
in	10768434	1296	1298	O
the	10768434	1299	1302	O
ALA-PDT	10768434	1303	1310	B-Intervention
group	10768434	1311	1316	O
(	10768434	1317	1318	O
interquartile	10768434	1319	1332	O
range	10768434	1333	1338	O
100	10768434	1339	1342	O
%	10768434	1343	1344	O
,	10768434	1345	1346	O
55	10768434	1347	1349	O
%	10768434	1350	1351	O
)	10768434	1352	1353	O
versus	10768434	1354	1360	O
52	10768434	1361	1363	B-Observation
%	10768434	1364	1365	I-Observation
(	10768434	1366	1367	O
100	10768434	1368	1371	O
%	10768434	1372	1373	O
,	10768434	1374	1375	O
0	10768434	1376	1377	O
)	10768434	1378	1379	O
in	10768434	1380	1382	O
the	10768434	1383	1386	O
placebo	10768434	1387	1394	B-Intervention
group	10768434	1395	1400	O
(	10768434	1401	1402	O
p=0.0006	10768434	1403	1411	O
)	10768434	1412	1413	O
.	10768434	1414	1415	O

In	10768434	1416	1418	O
week	10768434	1419	1423	O
18	10768434	1424	1426	O
,	10768434	1427	1428	O
the	10768434	1429	1432	O
median	10768434	1433	1439	B-Outcome
relative	10768434	1440	1448	I-Outcome
reduction	10768434	1449	1458	I-Outcome
in	10768434	1459	1461	I-Outcome
wart	10768434	1462	1466	I-Outcome
area	10768434	1467	1471	I-Outcome
was	10768434	1472	1475	O
100	10768434	1476	1479	B-Observation
%	10768434	1480	1481	I-Observation
in	10768434	1482	1484	O
the	10768434	1485	1488	O
ALA-PDT	10768434	1489	1496	B-Intervention
group	10768434	1497	1502	O
(	10768434	1503	1504	O
100	10768434	1505	1508	O
%	10768434	1509	1510	O
,	10768434	1511	1512	O
57	10768434	1513	1515	O
%	10768434	1516	1517	O
)	10768434	1518	1519	O
versus	10768434	1520	1526	O
71	10768434	1527	1529	B-Observation
%	10768434	1530	1531	I-Observation
(	10768434	1532	1533	O
100	10768434	1534	1537	O
%	10768434	1538	1539	O
,	10768434	1540	1541	O
0	10768434	1542	1543	O
)	10768434	1544	1545	O
in	10768434	1546	1548	O
the	10768434	1549	1552	O
placebo-PDT	10768434	1553	1564	B-Intervention
arm	10768434	1565	1568	O
(	10768434	1569	1570	O
p=0.008	10768434	1571	1578	O
)	10768434	1579	1580	O
.	10768434	1581	1582	O

Both	10768434	1583	1587	O
the	10768434	1588	1591	O
number	10768434	1592	1598	B-Outcome
of	10768434	1599	1601	I-Outcome
vanishing	10768434	1602	1611	I-Outcome
warts	10768434	1612	1617	I-Outcome
and	10768434	1618	1621	O
the	10768434	1622	1625	O
difference	10768434	1626	1636	B-Outcome
in	10768434	1637	1639	I-Outcome
relative	10768434	1640	1648	I-Outcome
wart	10768434	1649	1653	I-Outcome
area	10768434	1654	1658	I-Outcome
of	10768434	1659	1661	I-Outcome
persisting	10768434	1662	1672	I-Outcome
warts	10768434	1673	1678	I-Outcome
at	10768434	1679	1681	O
week	10768434	1682	1686	O
14	10768434	1687	1689	O
and	10768434	1690	1693	O
18	10768434	1694	1696	O
were	10768434	1697	1701	O
significant	10768434	1702	1713	B-Observation
(	10768434	1714	1715	O
p	10768434	1716	1717	O
<	10768434	1718	1719	O
0.05	10768434	1720	1724	O
)	10768434	1725	1726	O
in	10768434	1727	1729	O
favour	10768434	1730	1736	O
of	10768434	1737	1739	O
ALA-PDT	10768434	1740	1747	B-Intervention
.	10768434	1748	1749	O

Significantly	10768434	1750	1763	B-Observation
more	10768434	1764	1768	I-Observation
ALA-PDT	10768434	1769	1776	B-Intervention
warts	10768434	1777	1782	B-Participant
were	10768434	1783	1787	O
graded	10768434	1788	1794	O
at	10768434	1795	1797	O
a	10768434	1798	1799	O
higher	10768434	1800	1806	B-Outcome
pain	10768434	1807	1811	I-Outcome
intensity	10768434	1812	1821	I-Outcome
after	10768434	1822	1827	O
treatment	10768434	1828	1837	O
than	10768434	1838	1842	O
placebo-PDT	10768434	1843	1854	B-Intervention
warts	10768434	1855	1860	B-Participant
.	10768434	1861	1862	O

INTERPRETATION	10768434	1863	1877	O
ALA-PDT	10768434	1878	1885	B-Intervention
is	10768434	1886	1888	O
superior	10768434	1889	1897	B-Observation
to	10768434	1898	1900	O
placebo-PDT	10768434	1901	1912	B-Intervention
when	10768434	1913	1917	O
both	10768434	1918	1922	O
wart	10768434	1923	1927	B-Outcome
area	10768434	1928	1932	I-Outcome
and	10768434	1933	1936	O
number	10768434	1937	1943	B-Outcome
of	10768434	1944	1946	I-Outcome
vanishing	10768434	1947	1956	I-Outcome
warts	10768434	1957	1962	I-Outcome
are	10768434	1963	1966	O
considered	10768434	1967	1977	O
.	10768434	1978	1979	O

Lack	10770979	0	4	B-Observation
of	10770979	5	7	I-Observation
effect	10770979	8	14	I-Observation
of	10770979	15	17	O
a	10770979	18	19	O
low-fat	10770979	20	27	B-Intervention
,	10770979	28	29	I-Intervention
high-fiber	10770979	30	40	I-Intervention
diet	10770979	41	45	I-Intervention
on	10770979	46	48	O
the	10770979	49	52	O
recurrence	10770979	53	63	B-Outcome
of	10770979	64	66	I-Outcome
colorectal	10770979	67	77	I-Outcome
adenomas	10770979	78	86	I-Outcome
.	10770979	87	88	O

Polyp	10770979	89	94	O
Prevention	10770979	95	105	O
Trial	10770979	106	111	O
Study	10770979	112	117	O
Group	10770979	118	123	O
.	10770979	124	125	O

BACKGROUND	10770979	126	136	O
We	10770979	137	139	O
tested	10770979	140	146	O
the	10770979	147	150	O
hypothesis	10770979	151	161	O
that	10770979	162	166	O
dietary	10770979	167	174	B-Intervention
intervention	10770979	175	187	I-Intervention
can	10770979	188	191	O
inhibit	10770979	192	199	B-Observation
the	10770979	200	203	O
development	10770979	204	215	B-Outcome
of	10770979	216	218	I-Outcome
recurrent	10770979	219	228	I-Outcome
colorectal	10770979	229	239	I-Outcome
adenomas	10770979	240	248	I-Outcome
,	10770979	249	250	O
which	10770979	251	256	O
are	10770979	257	260	O
precursors	10770979	261	271	O
of	10770979	272	274	O
most	10770979	275	279	O
large-bowel	10770979	280	291	O
cancers	10770979	292	299	O
.	10770979	300	301	O

METHODS	10770979	302	309	O
We	10770979	310	312	O
randomly	10770979	313	321	O
assigned	10770979	322	330	O
2079	10770979	331	335	O
men	10770979	336	339	O
and	10770979	340	343	O
women	10770979	344	349	O
who	10770979	350	353	O
were	10770979	354	358	O
35	10770979	359	361	O
years	10770979	362	367	O
of	10770979	368	370	O
age	10770979	371	374	O
or	10770979	375	377	O
older	10770979	378	383	O
and	10770979	384	387	O
who	10770979	388	391	O
had	10770979	392	395	O
had	10770979	396	399	O
one	10770979	400	403	B-Participant
or	10770979	404	406	I-Participant
more	10770979	407	411	I-Participant
histologically	10770979	412	426	I-Participant
confirmed	10770979	427	436	I-Participant
colorectal	10770979	437	447	I-Participant
adenomas	10770979	448	456	I-Participant
removed	10770979	457	464	I-Participant
within	10770979	465	471	I-Participant
six	10770979	472	475	I-Participant
months	10770979	476	482	I-Participant
before	10770979	483	489	O
randomization	10770979	490	503	O
to	10770979	504	506	O
one	10770979	507	510	O
of	10770979	511	513	O
two	10770979	514	517	O
groups	10770979	518	524	O
:	10770979	525	526	O
an	10770979	527	529	O
intervention	10770979	530	542	O
group	10770979	543	548	O
given	10770979	549	554	O
intensive	10770979	555	564	B-Intervention
counseling	10770979	565	575	I-Intervention
and	10770979	576	579	O
assigned	10770979	580	588	O
to	10770979	589	591	O
follow	10770979	592	598	O
a	10770979	599	600	O
diet	10770979	601	605	B-Intervention
that	10770979	606	610	I-Intervention
was	10770979	611	614	I-Intervention
low	10770979	615	618	I-Intervention
in	10770979	619	621	I-Intervention
fat	10770979	622	625	I-Intervention
(	10770979	626	627	I-Intervention
20	10770979	628	630	I-Intervention
percent	10770979	631	638	I-Intervention
of	10770979	639	641	I-Intervention
total	10770979	642	647	I-Intervention
calories	10770979	648	656	I-Intervention
)	10770979	657	658	I-Intervention
and	10770979	659	662	I-Intervention
high	10770979	663	667	I-Intervention
in	10770979	668	670	I-Intervention
fiber	10770979	671	676	I-Intervention
(	10770979	677	678	I-Intervention
18	10770979	679	681	I-Intervention
g	10770979	682	683	I-Intervention
of	10770979	684	686	I-Intervention
dietary	10770979	687	694	I-Intervention
fiber	10770979	695	700	I-Intervention
per	10770979	701	704	I-Intervention
1000	10770979	705	709	I-Intervention
kcal	10770979	710	714	I-Intervention
)	10770979	715	716	I-Intervention
and	10770979	717	720	O
fruits	10770979	721	727	B-Intervention
and	10770979	728	731	I-Intervention
vegetables	10770979	732	742	I-Intervention
(	10770979	743	744	I-Intervention
3.5	10770979	745	748	I-Intervention
servings	10770979	749	757	I-Intervention
per	10770979	758	761	I-Intervention
1000	10770979	762	766	I-Intervention
kcal	10770979	767	771	I-Intervention
)	10770979	772	773	I-Intervention
,	10770979	774	775	O
and	10770979	776	779	O
a	10770979	780	781	O
control	10770979	782	789	O
group	10770979	790	795	O
given	10770979	796	801	O
a	10770979	802	803	O
standard	10770979	804	812	B-Intervention
brochure	10770979	813	821	I-Intervention
on	10770979	822	824	I-Intervention
healthy	10770979	825	832	I-Intervention
eating	10770979	833	839	I-Intervention
and	10770979	840	843	O
assigned	10770979	844	852	O
to	10770979	853	855	O
follow	10770979	856	862	O
their	10770979	863	868	O
usual	10770979	869	874	B-Intervention
diet	10770979	875	879	I-Intervention
.	10770979	880	881	O

Subjects	10770979	882	890	O
entered	10770979	891	898	O
the	10770979	899	902	O
study	10770979	903	908	O
after	10770979	909	914	O
undergoing	10770979	915	925	O
complete	10770979	926	934	B-Participant
colonoscopy	10770979	935	946	I-Participant
and	10770979	947	950	O
removal	10770979	951	958	B-Participant
of	10770979	959	961	I-Participant
adenomatous	10770979	962	973	I-Participant
polyps	10770979	974	980	I-Participant
;	10770979	981	982	O
they	10770979	983	987	O
remained	10770979	988	996	O
in	10770979	997	999	O
the	10770979	1000	1003	O
study	10770979	1004	1009	O
for	10770979	1010	1013	O
approximately	10770979	1014	1027	O
four	10770979	1028	1032	O
years	10770979	1033	1038	O
,	10770979	1039	1040	O
undergoing	10770979	1041	1051	O
colonoscopy	10770979	1052	1063	O
one	10770979	1064	1067	O
and	10770979	1068	1071	O
four	10770979	1072	1076	O
years	10770979	1077	1082	O
after	10770979	1083	1088	O
randomization	10770979	1089	1102	O
.	10770979	1103	1104	O

RESULTS	10770979	1105	1112	O
A	10770979	1113	1114	B-Count
total	10770979	1115	1120	I-Count
of	10770979	1121	1123	I-Count
1905	10770979	1124	1128	I-Count
of	10770979	1129	1131	I-Count
the	10770979	1132	1135	I-Count
randomized	10770979	1136	1146	I-Count
subjects	10770979	1147	1155	I-Count
(	10770979	1156	1157	I-Count
91.6	10770979	1158	1162	I-Count
percent	10770979	1163	1170	I-Count
)	10770979	1171	1172	I-Count
completed	10770979	1173	1182	B-Outcome
the	10770979	1183	1186	I-Outcome
study	10770979	1187	1192	I-Outcome
.	10770979	1193	1194	O

Of	10770979	1195	1197	O
the	10770979	1198	1201	O
958	10770979	1202	1205	B-Count
subjects	10770979	1206	1214	I-Count
in	10770979	1215	1217	O
the	10770979	1218	1221	O
intervention	10770979	1222	1234	B-Intervention
group	10770979	1235	1240	O
and	10770979	1241	1244	O
the	10770979	1245	1248	O
947	10770979	1249	1252	B-Count
in	10770979	1253	1255	O
the	10770979	1256	1259	O
control	10770979	1260	1267	B-Intervention
group	10770979	1268	1273	O
who	10770979	1274	1277	O
completed	10770979	1278	1287	B-Outcome
the	10770979	1288	1291	I-Outcome
study	10770979	1292	1297	I-Outcome
,	10770979	1298	1299	O
39.7	10770979	1300	1304	B-Count
percent	10770979	1305	1312	I-Count
and	10770979	1313	1316	O
39.5	10770979	1317	1321	B-Count
percent	10770979	1322	1329	I-Count
,	10770979	1330	1331	O
respectively	10770979	1332	1344	O
,	10770979	1345	1346	O
had	10770979	1347	1350	O
at	10770979	1351	1353	B-Outcome
least	10770979	1354	1359	I-Outcome
one	10770979	1360	1363	I-Outcome
recurrent	10770979	1364	1373	I-Outcome
adenoma	10770979	1374	1381	I-Outcome
;	10770979	1382	1383	O
the	10770979	1384	1387	O
unadjusted	10770979	1388	1398	B-Outcome
risk	10770979	1399	1403	I-Outcome
ratio	10770979	1404	1409	I-Outcome
was	10770979	1410	1413	O
1.00	10770979	1414	1418	B-Observation
(	10770979	1419	1420	O
95	10770979	1421	1423	O
percent	10770979	1424	1431	O
confidence	10770979	1432	1442	O
interval	10770979	1443	1451	O
,	10770979	1452	1453	O
0.90	10770979	1454	1458	O
to	10770979	1459	1461	O
1.12	10770979	1462	1466	O
)	10770979	1467	1468	O
.	10770979	1469	1470	O

Among	10770979	1471	1476	O
subjects	10770979	1477	1485	O
with	10770979	1486	1490	O
recurrent	10770979	1491	1500	O
adenomas	10770979	1501	1509	O
,	10770979	1510	1511	O
the	10770979	1512	1515	O
mean	10770979	1516	1520	B-Outcome
(	10770979	1521	1522	I-Outcome
+	10770979	1523	1524	I-Outcome
/-SE	10770979	1524	1528	I-Outcome
)	10770979	1529	1530	I-Outcome
number	10770979	1531	1537	I-Outcome
of	10770979	1538	1540	I-Outcome
such	10770979	1541	1545	I-Outcome
lesions	10770979	1546	1553	I-Outcome
was	10770979	1554	1557	O
1.85+/-0.08	10770979	1558	1569	B-Observation
in	10770979	1570	1572	O
the	10770979	1573	1576	O
intervention	10770979	1577	1589	B-Intervention
group	10770979	1590	1595	O
and	10770979	1596	1599	O
1.84+/-0.07	10770979	1600	1611	B-Observation
in	10770979	1612	1614	O
the	10770979	1615	1618	O
control	10770979	1619	1626	B-Intervention
group	10770979	1627	1632	O
.	10770979	1633	1634	O

The	10770979	1635	1638	O
rate	10770979	1639	1643	B-Outcome
of	10770979	1644	1646	I-Outcome
recurrence	10770979	1647	1657	I-Outcome
of	10770979	1658	1660	I-Outcome
large	10770979	1661	1666	I-Outcome
adenomas	10770979	1667	1675	I-Outcome
(	10770979	1676	1677	O
with	10770979	1678	1682	O
a	10770979	1683	1684	O
maximal	10770979	1685	1692	O
diameter	10770979	1693	1701	O
of	10770979	1702	1704	O
at	10770979	1705	1707	O
least	10770979	1708	1713	O
1	10770979	1714	1715	O
cm	10770979	1716	1718	O
)	10770979	1719	1720	O
and	10770979	1721	1724	O
advanced	10770979	1725	1733	B-Outcome
adenomas	10770979	1734	1742	I-Outcome
(	10770979	1743	1744	O
defined	10770979	1745	1752	O
as	10770979	1753	1755	O
lesions	10770979	1756	1763	O
that	10770979	1764	1768	O
had	10770979	1769	1772	O
a	10770979	1773	1774	O
maximal	10770979	1775	1782	O
diameter	10770979	1783	1791	O
of	10770979	1792	1794	O
at	10770979	1795	1797	O
least	10770979	1798	1803	O
1	10770979	1804	1805	O
cm	10770979	1806	1808	O
or	10770979	1809	1811	O
at	10770979	1812	1814	O
least	10770979	1815	1820	O
25	10770979	1821	1823	O
percent	10770979	1824	1831	O
villous	10770979	1832	1839	O
elements	10770979	1840	1848	O
or	10770979	1849	1851	O
evidence	10770979	1852	1860	O
of	10770979	1861	1863	O
high-grade	10770979	1864	1874	O
dysplasia	10770979	1875	1884	O
,	10770979	1885	1886	O
including	10770979	1887	1896	O
carcinoma	10770979	1897	1906	O
)	10770979	1907	1908	O
did	10770979	1909	1912	O
not	10770979	1913	1916	O
differ	10770979	1917	1923	B-Observation
significantly	10770979	1924	1937	I-Observation
between	10770979	1938	1945	B-Intervention
the	10770979	1946	1949	I-Intervention
two	10770979	1950	1953	I-Intervention
groups	10770979	1954	1960	I-Intervention
.	10770979	1961	1962	O

CONCLUSIONS	10770979	1963	1974	O
Adopting	10770979	1975	1983	O
a	10770979	1984	1985	O
diet	10770979	1986	1990	B-Intervention
that	10770979	1991	1995	I-Intervention
is	10770979	1996	1998	I-Intervention
low	10770979	1999	2002	I-Intervention
in	10770979	2003	2005	I-Intervention
fat	10770979	2006	2009	I-Intervention
and	10770979	2010	2013	I-Intervention
high	10770979	2014	2018	I-Intervention
in	10770979	2019	2021	I-Intervention
fiber	10770979	2022	2027	I-Intervention
,	10770979	2028	2029	I-Intervention
fruits	10770979	2030	2036	I-Intervention
,	10770979	2037	2038	I-Intervention
and	10770979	2039	2042	I-Intervention
vegetables	10770979	2043	2053	I-Intervention
does	10770979	2054	2058	O
not	10770979	2059	2062	O
influence	10770979	2063	2072	B-Observation
the	10770979	2073	2076	O
risk	10770979	2077	2081	B-Outcome
of	10770979	2082	2084	I-Outcome
recurrence	10770979	2085	2095	I-Outcome
of	10770979	2096	2098	I-Outcome
colorectal	10770979	2099	2109	I-Outcome
adenomas	10770979	2110	2118	I-Outcome
.	10770979	2119	2120	O

Human	10778276	0	5	B-Outcome
motor	10778276	6	11	I-Outcome
responses	10778276	12	21	I-Outcome
to	10778276	22	24	O
simultaneous	10778276	25	37	B-Intervention
aversive	10778276	38	46	I-Intervention
stimulation	10778276	47	58	I-Intervention
and	10778276	59	62	O
failure	10778276	63	70	B-Intervention
on	10778276	71	73	O
a	10778276	74	75	O
valued	10778276	76	82	O
task	10778276	83	87	O
.	10778276	88	89	O

The	10778276	90	93	O
effects	10778276	94	101	O
of	10778276	102	104	O
presentation	10778276	105	117	O
of	10778276	118	120	O
an	10778276	121	123	O
aversive	10778276	124	132	B-Intervention
stimulus	10778276	133	141	I-Intervention
and	10778276	142	145	I-Intervention
simultaneous	10778276	146	158	I-Intervention
failure	10778276	159	166	I-Intervention
on	10778276	167	169	O
a	10778276	170	171	O
bogus	10778276	172	177	O
intelligence	10778276	178	190	O
test	10778276	191	195	O
upon	10778276	196	200	O
a	10778276	201	202	O
subject	10778276	203	210	O
's	10778276	211	213	O
aggressive	10778276	214	224	B-Outcome
reactions	10778276	225	234	I-Outcome
were	10778276	235	239	O
studied	10778276	240	247	O
.	10778276	248	249	O

The	10778276	250	253	O
subject	10778276	254	261	O
's	10778276	262	264	O
fist	10778276	265	269	B-Outcome
clenching	10778276	270	279	I-Outcome
was	10778276	280	283	O
used	10778276	284	288	O
as	10778276	289	291	O
an	10778276	292	294	O
indicator	10778276	295	304	O
of	10778276	305	307	O
aggression	10778276	308	318	B-Outcome
.	10778276	319	320	O

Four	10778276	321	325	O
conditions	10778276	326	336	O
,	10778276	337	338	O
generated	10778276	339	348	O
by	10778276	349	351	O
the	10778276	352	355	O
combinations	10778276	356	368	B-Intervention
of	10778276	369	371	I-Intervention
two	10778276	372	375	I-Intervention
kinds	10778276	376	381	I-Intervention
of	10778276	382	384	I-Intervention
stimulus	10778276	385	393	I-Intervention
delivered	10778276	394	403	O
to	10778276	404	406	O
the	10778276	407	410	O
subjects	10778276	411	419	O
(	10778276	420	421	O
aversive	10778276	422	430	O
or	10778276	431	433	O
nonaversive	10778276	434	445	O
)	10778276	446	447	O
and	10778276	448	451	O
two	10778276	452	455	O
outcomes	10778276	456	464	B-Intervention
of	10778276	465	467	I-Intervention
the	10778276	468	471	I-Intervention
task	10778276	472	476	I-Intervention
(	10778276	477	478	I-Intervention
failure	10778276	479	486	I-Intervention
or	10778276	487	489	I-Intervention
success	10778276	490	497	I-Intervention
)	10778276	498	499	I-Intervention
,	10778276	500	501	O
were	10778276	502	506	O
investigated	10778276	507	519	O
.	10778276	520	521	O

20	10778276	522	524	O
female	10778276	525	531	O
and	10778276	532	535	O
20	10778276	536	538	O
male	10778276	539	543	O
students	10778276	544	552	O
(	10778276	553	554	O
ages	10778276	555	559	O
:	10778276	560	561	O
17	10778276	562	564	O
-	10778276	564	565	O
34	10778276	565	567	O
years	10778276	568	573	O
)	10778276	574	575	O
were	10778276	576	580	O
instructed	10778276	581	591	O
,	10778276	592	593	O
upon	10778276	594	598	O
the	10778276	599	602	O
reception	10778276	603	612	O
of	10778276	613	615	O
an	10778276	616	618	O
aversive	10778276	619	627	B-Intervention
or	10778276	628	630	I-Intervention
nonaversive	10778276	631	642	I-Intervention
acoustic	10778276	643	651	I-Intervention
signal	10778276	652	658	I-Intervention
,	10778276	659	660	O
to	10778276	661	663	O
press	10778276	664	669	O
with	10778276	670	674	O
the	10778276	675	678	O
right	10778276	679	684	O
hand	10778276	685	689	O
a	10778276	690	691	O
device	10778276	692	698	O
that	10778276	699	703	O
displayed	10778276	704	713	O
a	10778276	714	715	O
slide	10778276	716	721	O
.	10778276	722	723	O

Each	10778276	724	728	O
slide	10778276	729	734	O
presented	10778276	735	744	O
an	10778276	745	747	O
item	10778276	748	752	O
from	10778276	753	757	O
an	10778276	758	760	O
intelligence	10778276	761	773	O
test	10778276	774	778	O
,	10778276	779	780	O
to	10778276	781	783	O
which	10778276	784	789	O
the	10778276	790	793	O
subjects	10778276	794	802	O
were	10778276	803	807	O
either	10778276	808	814	O
allowed	10778276	815	822	O
to	10778276	823	825	O
answer	10778276	826	832	O
successfully	10778276	833	845	B-Intervention
(	10778276	846	847	I-Intervention
success	10778276	848	855	I-Intervention
)	10778276	856	857	I-Intervention
or	10778276	858	860	O
not	10778276	861	864	B-Intervention
(	10778276	865	866	I-Intervention
failure	10778276	867	874	I-Intervention
)	10778276	875	876	I-Intervention
.	10778276	877	878	O

Failure	10778276	879	886	B-Intervention
increased	10778276	887	896	B-Observation
the	10778276	897	900	O
subject	10778276	901	908	O
's	10778276	909	911	O
autonomic	10778276	912	921	B-Outcome
arousal	10778276	922	929	I-Outcome
,	10778276	930	931	O
as	10778276	932	934	O
measured	10778276	935	943	O
by	10778276	944	946	O
photoplethysmographic	10778276	947	968	O
sensors	10778276	969	976	O
,	10778276	977	978	O
in	10778276	979	981	O
all	10778276	982	985	O
stimulation	10778276	986	997	O
conditions	10778276	998	1008	O
,	10778276	1009	1010	O
but	10778276	1011	1014	O
only	10778276	1015	1019	O
the	10778276	1020	1023	O
condition	10778276	1024	1033	O
with	10778276	1034	1038	O
aversive	10778276	1039	1047	B-Intervention
stimulation	10778276	1048	1059	I-Intervention
increased	10778276	1060	1069	B-Observation
the	10778276	1070	1073	O
speed	10778276	1074	1079	B-Outcome
of	10778276	1080	1082	I-Outcome
clenching	10778276	1083	1092	I-Outcome
.	10778276	1093	1094	O

This	10778276	1095	1099	O
was	10778276	1100	1103	O
interpreted	10778276	1104	1115	O
as	10778276	1116	1118	O
indicating	10778276	1119	1129	O
subject	10778276	1130	1137	O
's	10778276	1138	1140	O
tendencies	10778276	1141	1151	B-Observation
to	10778276	1152	1154	O
aggression	10778276	1155	1165	B-Outcome
.	10778276	1166	1167	O

These	10778276	1168	1173	O
results	10778276	1174	1181	O
are	10778276	1182	1185	O
discussed	10778276	1186	1195	O
in	10778276	1196	1198	O
relation	10778276	1199	1207	O
to	10778276	1208	1210	O
the	10778276	1211	1214	O
effects	10778276	1215	1222	O
of	10778276	1223	1225	O
frustration	10778276	1226	1237	O
.	10778276	1238	1239	O

Increased	10808042	0	9	B-Observation
growth	10808042	10	16	B-Outcome
hormone	10808042	17	24	I-Outcome
response	10808042	25	33	I-Outcome
to	10808042	34	36	I-Outcome
sumatriptan	10808042	37	48	I-Outcome
challenge	10808042	49	58	I-Outcome
in	10808042	59	61	O
adult	10808042	62	67	B-Intervention
autistic	10808042	68	76	I-Intervention
disorders	10808042	77	86	I-Intervention
.	10808042	87	88	O

Serotonergic	10808042	89	101	O
(	10808042	102	103	O
5-HT	10808042	104	108	O
)	10808042	109	110	O
abnormalities	10808042	111	124	O
have	10808042	125	129	O
been	10808042	130	134	O
documented	10808042	135	145	O
in	10808042	146	148	O
autism	10808042	149	155	O
.	10808042	156	157	O

To	10808042	158	160	O
assess	10808042	161	167	O
sensitivity	10808042	168	179	B-Outcome
of	10808042	180	182	I-Outcome
the	10808042	183	186	I-Outcome
5-HT1d	10808042	187	193	I-Outcome
receptor	10808042	194	202	I-Outcome
,	10808042	203	204	O
growth	10808042	205	211	B-Outcome
hormone	10808042	212	219	I-Outcome
response	10808042	220	228	I-Outcome
to	10808042	229	231	I-Outcome
the	10808042	232	235	I-Outcome
5-HT1d	10808042	236	242	I-Outcome
receptor	10808042	243	251	I-Outcome
agonist	10808042	252	259	I-Outcome
sumatriptan	10808042	260	271	I-Outcome
was	10808042	272	275	O
studied	10808042	276	283	O
in	10808042	284	286	O
adult	10808042	287	292	B-Intervention
autistic	10808042	293	301	I-Intervention
patients	10808042	302	310	I-Intervention
and	10808042	311	314	O
matched	10808042	315	322	B-Intervention
normal	10808042	323	329	I-Intervention
controls	10808042	330	338	I-Intervention
.	10808042	339	340	O

In	10808042	341	343	O
this	10808042	344	348	O
study	10808042	349	354	O
,	10808042	355	356	O
11	10808042	357	359	O
adult	10808042	360	365	B-Participant
patients	10808042	366	374	O
with	10808042	375	379	O
autism	10808042	380	386	B-Intervention
or	10808042	387	389	O
Asperger	10808042	390	398	B-Intervention
's	10808042	399	401	I-Intervention
disorder	10808042	402	410	I-Intervention
were	10808042	411	415	O
compared	10808042	416	424	O
with	10808042	425	429	O
nine	10808042	430	434	O
matched	10808042	435	442	B-Intervention
controls	10808042	443	451	I-Intervention
.	10808042	452	453	O

All	10808042	454	457	O
subjects	10808042	458	466	O
were	10808042	467	471	O
randomized	10808042	472	482	O
to	10808042	483	485	O
single	10808042	486	492	O
dose	10808042	493	497	O
sumatriptan	10808042	498	509	B-Intervention
(	10808042	510	511	O
6	10808042	512	513	O
mg	10808042	514	516	O
SQ	10808042	517	519	O
)	10808042	520	521	O
and	10808042	522	525	O
placebo	10808042	526	533	B-Intervention
challenges	10808042	534	544	O
,	10808042	545	546	O
separated	10808042	547	556	O
by	10808042	557	559	O
a	10808042	560	561	O
1-week	10808042	562	568	O
interval	10808042	569	577	O
,	10808042	578	579	O
and	10808042	580	583	O
growth	10808042	584	590	B-Outcome
hormone	10808042	591	598	I-Outcome
was	10808042	599	602	O
measured	10808042	603	611	O
before	10808042	612	618	O
and	10808042	619	622	O
during	10808042	623	629	O
the	10808042	630	633	O
challenges	10808042	634	644	O
.	10808042	645	646	O

The	10808042	647	650	O
results	10808042	651	658	O
showed	10808042	659	665	O
a	10808042	666	667	O
highly	10808042	668	674	B-Observation
significant	10808042	675	686	I-Observation
diagnosisxdrugxtime	10808042	687	706	B-Outcome
interaction	10808042	707	718	I-Outcome
on	10808042	719	721	O
repeated	10808042	722	730	O
measure	10808042	731	738	O
analysis	10808042	739	747	O
covaried	10808042	748	756	O
for	10808042	757	760	O
baseline	10808042	761	769	O
.	10808042	770	771	O

This	10808042	772	776	O
suggests	10808042	777	785	O
that	10808042	786	790	O
autistic	10808042	791	799	B-Intervention
patients	10808042	800	808	O
had	10808042	809	812	O
significantly	10808042	813	826	B-Observation
greater	10808042	827	834	I-Observation
growth	10808042	835	841	B-Outcome
hormone	10808042	842	849	I-Outcome
response	10808042	850	858	I-Outcome
to	10808042	859	861	I-Outcome
sumatriptan	10808042	862	873	I-Outcome
than	10808042	874	878	O
normal	10808042	879	885	B-Intervention
controls	10808042	886	894	I-Intervention
,	10808042	895	896	O
independent	10808042	897	908	O
of	10808042	909	911	O
placebo	10808042	912	919	O
effects	10808042	920	927	O
.	10808042	928	929	O

Therefore	10808042	930	939	O
,	10808042	940	941	O
abnormalities	10808042	942	955	B-Observation
in	10808042	956	958	O
5-HT	10808042	959	963	B-Outcome
regulation	10808042	964	974	I-Outcome
in	10808042	975	977	O
autism	10808042	978	984	B-Intervention
may	10808042	985	988	O
be	10808042	989	991	O
related	10808042	992	999	O
to	10808042	1000	1002	O
increased	10808042	1003	1012	B-Observation
sensitivity	10808042	1013	1024	B-Outcome
of	10808042	1025	1027	I-Outcome
the	10808042	1028	1031	I-Outcome
5-HT1d	10808042	1032	1038	I-Outcome
inhibitory	10808042	1039	1049	I-Outcome
receptor	10808042	1050	1058	I-Outcome
in	10808042	1059	1061	O
autism	10808042	1062	1068	B-Intervention
.	10808042	1069	1070	O

Outcome	10811665	0	7	B-Outcome
of	10811665	8	10	O
CNS	10811665	11	14	B-Intervention
disease	10811665	15	22	I-Intervention
at	10811665	23	25	I-Intervention
diagnosis	10811665	26	35	I-Intervention
in	10811665	36	38	O
disseminated	10811665	39	51	B-Participant
small	10811665	52	57	I-Participant
noncleaved-cell	10811665	58	73	I-Participant
lymphoma	10811665	74	82	I-Participant
and	10811665	83	86	O
B-cell	10811665	87	93	B-Participant
leukemia	10811665	94	102	I-Participant
:	10811665	103	104	O
a	10811665	105	106	O
Children	10811665	107	115	O
's	10811665	116	118	O
Cancer	10811665	119	125	O
Group	10811665	126	131	O
study	10811665	132	137	O
.	10811665	138	139	O

PURPOSE	10811665	140	147	O
To	10811665	148	150	O
examine	10811665	151	158	O
the	10811665	159	162	O
impact	10811665	163	169	O
of	10811665	170	172	O
initial	10811665	173	180	B-Intervention
CNS	10811665	181	184	I-Intervention
involvement	10811665	185	196	I-Intervention
on	10811665	197	199	O
outcome	10811665	200	207	B-Outcome
and	10811665	208	211	O
patterns	10811665	212	220	B-Outcome
of	10811665	221	223	I-Outcome
failure	10811665	224	231	I-Outcome
in	10811665	232	234	O
patients	10811665	235	243	O
with	10811665	244	248	O
disseminated	10811665	249	261	B-Participant
small	10811665	262	267	I-Participant
noncleaved-cell	10811665	268	283	I-Participant
lymphoma	10811665	284	292	I-Participant
and	10811665	293	296	O
B-cell	10811665	297	303	B-Participant
leukemia	10811665	304	312	I-Participant
who	10811665	313	316	O
were	10811665	317	321	O
treated	10811665	322	329	O
in	10811665	330	332	O
four	10811665	333	337	O
successive	10811665	338	348	O
Children	10811665	349	357	O
's	10811665	358	360	O
Cancer	10811665	361	367	O
Group	10811665	368	373	O
trials	10811665	374	380	O
.	10811665	381	382	O

PATIENTS	10811665	383	391	O
AND	10811665	392	395	O
METHODS	10811665	396	403	O
Of	10811665	404	406	O
462	10811665	407	410	O
patients	10811665	411	419	O
with	10811665	420	424	O
disseminated	10811665	425	437	B-Participant
disease	10811665	438	445	I-Participant
,	10811665	446	447	O
49	10811665	448	450	O
(	10811665	451	452	O
10.6	10811665	453	457	O
%	10811665	458	459	O
)	10811665	460	461	O
had	10811665	462	465	O
CNS	10811665	466	469	B-Intervention
disease	10811665	470	477	I-Intervention
at	10811665	478	480	I-Intervention
diagnosis	10811665	481	490	I-Intervention
(	10811665	491	492	I-Intervention
CNS+	10811665	493	497	I-Intervention
)	10811665	498	499	I-Intervention
.	10811665	500	501	O

CNS	10811665	502	505	B-Intervention
disease	10811665	506	513	I-Intervention
included	10811665	514	522	O
meningeal	10811665	523	532	B-Intervention
disease	10811665	533	540	I-Intervention
or	10811665	541	543	O
CNS	10811665	544	547	B-Intervention
parenchymal	10811665	548	559	I-Intervention
masses	10811665	560	566	I-Intervention
with	10811665	567	571	I-Intervention
or	10811665	572	574	I-Intervention
without	10811665	575	582	I-Intervention
cranial	10811665	583	590	I-Intervention
neuropathies	10811665	591	603	I-Intervention
(	10811665	604	605	O
CSF+/Mass	10811665	606	615	B-Intervention
;	10811665	616	617	I-Intervention
CNPs	10811665	618	622	I-Intervention
)	10811665	623	624	O
in	10811665	625	627	O
36	10811665	628	630	O
patients	10811665	631	639	O
and	10811665	640	643	O
isolated	10811665	644	652	B-Intervention
CNPs	10811665	653	657	I-Intervention
in	10811665	658	660	O
13	10811665	661	663	O
.	10811665	664	665	O

Of	10811665	666	668	O
the	10811665	669	672	O
CNS+	10811665	673	677	B-Intervention
patients	10811665	678	686	O
,	10811665	687	688	O
28	10811665	689	691	O
had	10811665	692	695	O
M2	10811665	696	698	B-Participant
(	10811665	699	700	I-Participant
5	10811665	701	702	I-Participant
%	10811665	703	704	I-Participant
to	10811665	705	707	I-Participant
25	10811665	708	710	I-Participant
%	10811665	711	712	I-Participant
blasts	10811665	713	719	I-Participant
)	10811665	720	721	I-Participant
or	10811665	722	724	I-Participant
M3	10811665	725	727	I-Participant
(	10811665	728	729	I-Participant
>	10811665	730	731	I-Participant
25	10811665	732	734	I-Participant
%	10811665	735	736	I-Participant
blasts	10811665	737	743	I-Participant
)	10811665	744	745	I-Participant
bone	10811665	746	750	I-Participant
marrow	10811665	751	757	I-Participant
involvement	10811665	758	769	I-Participant
.	10811665	770	771	O

All	10811665	772	775	O
patients	10811665	776	784	O
received	10811665	785	793	O
protocol-based	10811665	794	808	B-Participant
systemic	10811665	809	817	I-Participant
and	10811665	818	821	I-Participant
intrathecal	10811665	822	833	I-Participant
chemotherapy	10811665	834	846	I-Participant
.	10811665	847	848	O

Thirty-six	10811665	849	859	O
patients	10811665	860	868	O
also	10811665	869	873	O
received	10811665	874	882	O
CNS	10811665	883	886	B-Participant
irradiation	10811665	887	898	I-Participant
.	10811665	899	900	O

RESULTS	10811665	901	908	O
Relapses	10811665	909	917	B-Outcome
occurred	10811665	918	926	O
in	10811665	927	929	O
21	10811665	930	932	B-Count
(	10811665	933	934	I-Count
43	10811665	935	937	I-Count
%	10811665	938	939	I-Count
)	10811665	940	941	I-Count
of	10811665	942	944	I-Count
49	10811665	945	947	I-Count
patients	10811665	948	956	I-Count
,	10811665	957	958	O
predominantly	10811665	959	972	O
in	10811665	973	975	O
the	10811665	976	979	O
CNS	10811665	980	983	B-Outcome
(	10811665	984	985	O
71	10811665	986	988	B-Count
%	10811665	989	990	I-Count
)	10811665	991	992	O
and	10811665	993	996	O
bone	10811665	997	1001	B-Outcome
marrow	10811665	1002	1008	I-Outcome
(	10811665	1009	1010	O
52	10811665	1011	1013	B-Count
%	10811665	1014	1015	I-Count
)	10811665	1016	1017	O
.	10811665	1018	1019	O

The	10811665	1020	1023	O
3-year	10811665	1024	1030	B-Outcome
event-free	10811665	1031	1041	I-Outcome
survival	10811665	1042	1050	I-Outcome
+	10811665	1051	1052	I-Outcome
/-	10811665	1052	1054	I-Outcome
SE	10811665	1055	1057	I-Outcome
for	10811665	1058	1061	O
all	10811665	1062	1065	O
patients	10811665	1066	1074	O
with	10811665	1075	1079	O
CNS+	10811665	1080	1084	B-Intervention
disease	10811665	1085	1092	I-Intervention
was	10811665	1093	1096	O
45	10811665	1097	1099	B-Observation
%	10811665	1100	1101	I-Observation
+	10811665	1102	1103	I-Observation
/-	10811665	1103	1105	I-Observation
7	10811665	1106	1107	I-Observation
%	10811665	1108	1109	I-Observation
.	10811665	1110	1111	O

Patients	10811665	1112	1120	O
with	10811665	1121	1125	O
CSF+/Mass	10811665	1126	1135	B-Intervention
had	10811665	1136	1139	O
a	10811665	1140	1141	O
nominally	10811665	1142	1151	B-Observation
higher	10811665	1152	1158	I-Observation
treatment	10811665	1159	1168	B-Outcome
failure	10811665	1169	1176	I-Outcome
rate	10811665	1177	1181	I-Outcome
compared	10811665	1182	1190	O
with	10811665	1191	1195	O
patients	10811665	1196	1204	O
with	10811665	1205	1209	O
CNS-	10811665	1210	1214	B-Intervention
after	10811665	1215	1220	O
adjusting	10811665	1221	1230	O
for	10811665	1231	1234	O
marrow	10811665	1235	1241	O
status	10811665	1242	1248	O
and	10811665	1249	1252	O
lactate	10811665	1253	1260	O
dehydrogenase	10811665	1261	1274	O
(	10811665	1275	1276	O
LDH	10811665	1277	1280	O
)	10811665	1281	1282	O
diagnosis	10811665	1283	1292	O
,	10811665	1293	1294	O
with	10811665	1295	1299	O
a	10811665	1300	1301	O
relative	10811665	1302	1310	B-Outcome
failure	10811665	1311	1318	I-Outcome
rate	10811665	1319	1323	I-Outcome
(	10811665	1324	1325	I-Outcome
RFR	10811665	1326	1329	I-Outcome
)	10811665	1330	1331	I-Outcome
of	10811665	1332	1334	O
1.52	10811665	1335	1339	B-Observation
(	10811665	1340	1341	O
95	10811665	1342	1344	O
%	10811665	1345	1346	O
confidence	10811665	1347	1357	O
interval	10811665	1358	1366	O
[	10811665	1367	1368	O
CI	10811665	1369	1371	O
]	10811665	1372	1373	O
,	10811665	1374	1375	O
0.88	10811665	1376	1380	O
to	10811665	1381	1383	O
2.6	10811665	1384	1387	O
;	10811665	1388	1389	O
P	10811665	1390	1391	O
=	10811665	1392	1393	O
.15	10811665	1393	1396	O
)	10811665	1397	1398	O
.	10811665	1399	1400	O

In	10811665	1401	1403	O
comparison	10811665	1404	1414	O
,	10811665	1415	1416	O
the	10811665	1417	1420	O
RFRs	10811665	1421	1425	B-Outcome
for	10811665	1426	1429	O
patients	10811665	1430	1438	O
with	10811665	1439	1443	O
M2	10811665	1444	1446	B-Participant
or	10811665	1447	1449	O
M3	10811665	1450	1452	B-Participant
marrow	10811665	1453	1459	I-Participant
and	10811665	1460	1463	O
for	10811665	1464	1467	O
those	10811665	1468	1473	O
with	10811665	1474	1478	O
LDH	10811665	1479	1482	B-Participant
levels	10811665	1483	1489	I-Participant
greater	10811665	1490	1497	I-Participant
than	10811665	1498	1502	I-Participant
500	10811665	1503	1506	I-Participant
IU/L	10811665	1507	1511	I-Participant
after	10811665	1512	1517	O
adjusting	10811665	1518	1527	O
for	10811665	1528	1531	O
CNS	10811665	1532	1535	O
disease	10811665	1536	1543	O
were	10811665	1544	1548	O
1.4	10811665	1549	1552	B-Observation
(	10811665	1553	1554	O
95	10811665	1555	1557	O
%	10811665	1558	1559	O
CI	10811665	1560	1562	O
,	10811665	1563	1564	O
0.96	10811665	1565	1569	O
to	10811665	1570	1572	O
2.0	10811665	1573	1576	O
;	10811665	1577	1578	O
P	10811665	1579	1580	O
=	10811665	1581	1582	O
.029	10811665	1582	1586	O
)	10811665	1587	1588	O
and	10811665	1589	1592	O
2.2	10811665	1593	1596	B-Observation
(	10811665	1597	1598	O
95	10811665	1599	1601	O
%	10811665	1602	1603	O
CI	10811665	1604	1606	O
,	10811665	1607	1608	O
1.5	10811665	1609	1612	O
to	10811665	1613	1615	O
3.0	10811665	1616	1619	O
;	10811665	1620	1621	O
P	10811665	1622	1623	O
<	10811665	1624	1625	O
.001	10811665	1626	1630	O
)	10811665	1631	1632	O
,	10811665	1633	1634	O
respectively	10811665	1635	1647	O
.	10811665	1648	1649	O

The	10811665	1650	1653	O
RFR	10811665	1654	1657	B-Outcome
for	10811665	1658	1661	O
patients	10811665	1662	1670	O
with	10811665	1671	1675	O
isolated	10811665	1676	1684	B-Intervention
CNPs	10811665	1685	1689	I-Intervention
was	10811665	1690	1693	O
0.87	10811665	1694	1698	B-Observation
(	10811665	1699	1700	O
95	10811665	1701	1703	O
%	10811665	1704	1705	O
CI	10811665	1706	1708	O
,	10811665	1709	1710	O
0.36	10811665	1711	1715	O
to	10811665	1716	1718	O
2.1	10811665	1719	1722	O
;	10811665	1723	1724	O
P	10811665	1725	1726	O
=	10811665	1727	1728	O
.76	10811665	1728	1731	O
)	10811665	1732	1733	O
.	10811665	1734	1735	O

CONCLUSION	10811665	1736	1746	O
We	10811665	1747	1749	O
conclude	10811665	1750	1758	O
that	10811665	1759	1763	O
,	10811665	1764	1765	O
with	10811665	1766	1770	O
the	10811665	1771	1774	O
treatments	10811665	1775	1785	O
used	10811665	1786	1790	O
during	10811665	1791	1797	O
the	10811665	1798	1801	O
period	10811665	1802	1808	O
covered	10811665	1809	1816	O
by	10811665	1817	1819	O
these	10811665	1820	1825	O
studies	10811665	1826	1833	O
,	10811665	1834	1835	O
the	10811665	1836	1839	O
presence	10811665	1840	1848	B-Intervention
of	10811665	1849	1851	I-Intervention
CSF+/Mass	10811665	1852	1861	I-Intervention
CNS	10811665	1862	1865	I-Intervention
disease	10811665	1866	1873	I-Intervention
at	10811665	1874	1876	I-Intervention
diagnosis	10811665	1877	1886	I-Intervention
was	10811665	1887	1890	O
associated	10811665	1891	1901	O
with	10811665	1902	1906	O
a	10811665	1907	1908	O
nominally	10811665	1909	1918	B-Observation
worse	10811665	1919	1924	I-Observation
outcome	10811665	1925	1932	B-Outcome
independent	10811665	1933	1944	O
of	10811665	1945	1947	O
initial	10811665	1948	1955	O
bone	10811665	1956	1960	O
marrow	10811665	1961	1967	O
status	10811665	1968	1974	O
and	10811665	1975	1978	O
LDH	10811665	1979	1982	O
level	10811665	1983	1988	O
,	10811665	1989	1990	O
but	10811665	1991	1994	O
the	10811665	1995	1998	O
effect	10811665	1999	2005	O
was	10811665	2006	2009	O
not	10811665	2010	2013	O
statistically	10811665	2014	2027	B-Observation
significant	10811665	2028	2039	I-Observation
.	10811665	2040	2041	O

Does	10817768	0	4	O
waiting	10817768	5	12	B-Intervention
matter	10817768	13	19	O
?	10817768	20	21	O

A	10817768	22	23	O
randomized	10817768	24	34	O
controlled	10817768	35	45	O
trial	10817768	46	51	O
of	10817768	52	54	O
new	10817768	55	58	O
non-urgent	10817768	59	69	B-Participant
rheumatology	10817768	70	82	I-Participant
out-patient	10817768	83	94	I-Participant
referrals	10817768	95	104	I-Participant
.	10817768	105	106	O

OBJECTIVE	10817768	107	116	O
To	10817768	117	119	O
examine	10817768	120	127	O
the	10817768	128	131	O
effect	10817768	132	138	O
of	10817768	139	141	O
waiting	10817768	142	149	B-Intervention
times	10817768	150	155	I-Intervention
on	10817768	156	158	O
the	10817768	159	162	O
health	10817768	163	169	B-Outcome
status	10817768	170	176	I-Outcome
of	10817768	177	179	I-Outcome
patients	10817768	180	188	I-Outcome
referred	10817768	189	197	I-Outcome
for	10817768	198	201	I-Outcome
a	10817768	202	203	I-Outcome
non-urgent	10817768	204	214	I-Outcome
rheumatology	10817768	215	227	I-Outcome
opinion	10817768	228	235	I-Outcome
.	10817768	236	237	O

METHODS	10817768	238	245	O
The	10817768	246	249	O
study	10817768	250	255	O
was	10817768	256	259	O
a	10817768	260	261	O
randomized	10817768	262	272	O
controlled	10817768	273	283	O
clinical	10817768	284	292	O
study	10817768	293	298	O
evaluating	10817768	299	309	O
a	10817768	310	311	O
'	10817768	312	313	B-Intervention
fast	10817768	313	317	I-Intervention
track	10817768	318	323	I-Intervention
'	10817768	324	325	I-Intervention
appointment	10817768	326	337	I-Intervention
with	10817768	338	342	O
a	10817768	343	344	O
6-week	10817768	345	351	O
target	10817768	352	358	O
waiting	10817768	359	366	O
time	10817768	367	371	O
against	10817768	372	379	O
an	10817768	380	382	O
'	10817768	383	384	B-Intervention
ordinary	10817768	384	392	I-Intervention
'	10817768	393	394	I-Intervention
appointment	10817768	395	406	I-Intervention
in	10817768	407	409	O
the	10817768	410	413	O
main	10817768	414	418	O
city	10817768	419	423	O
out-patient	10817768	424	435	O
clinic	10817768	436	442	O
of	10817768	443	445	O
the	10817768	446	449	O
rheumatology	10817768	450	462	B-Participant
service	10817768	463	470	I-Participant
for	10817768	471	474	O
the	10817768	475	478	O
Lothian	10817768	479	486	O
and	10817768	487	490	O
Borders	10817768	491	498	O
region	10817768	499	505	O
(	10817768	506	507	O
population	10817768	508	518	O
approximately	10817768	519	532	O
1	10817768	533	534	O
million	10817768	535	542	O
)	10817768	543	544	O
.	10817768	545	546	O

Health	10817768	547	553	B-Outcome
status	10817768	554	560	I-Outcome
was	10817768	561	564	O
measured	10817768	565	573	O
using	10817768	574	579	O
the	10817768	580	583	O
SF12	10817768	584	588	O
physical	10817768	589	597	O
and	10817768	598	601	O
mental	10817768	602	608	O
summary	10817768	609	616	O
component	10817768	617	626	O
T-scores	10817768	627	635	O
and	10817768	636	639	O
pain	10817768	640	644	B-Outcome
was	10817768	645	648	O
measured	10817768	649	657	O
with	10817768	658	662	O
a	10817768	663	664	O
100	10817768	665	668	O
mm	10817768	669	671	O
visual	10817768	672	678	O
analogue	10817768	679	687	O
pain	10817768	688	692	O
scale	10817768	693	698	O
.	10817768	699	700	O

Secondary	10817768	701	710	O
outcomes	10817768	711	719	O
were	10817768	720	724	O
health	10817768	725	731	B-Outcome
utility	10817768	732	739	I-Outcome
and	10817768	740	743	O
perceived	10817768	744	753	B-Outcome
health	10817768	754	760	I-Outcome
both	10817768	761	765	O
measured	10817768	766	774	O
with	10817768	775	779	O
the	10817768	780	783	O
EuroQol	10817768	784	791	B-Outcome
instrument	10817768	792	802	I-Outcome
,	10817768	803	804	O
mental	10817768	805	811	B-Outcome
health	10817768	812	818	I-Outcome
measured	10817768	819	827	O
with	10817768	828	832	O
the	10817768	833	836	O
Hospital	10817768	837	845	O
Anxiety	10817768	846	853	O
and	10817768	854	857	O
Depression	10817768	858	868	O
scale	10817768	869	874	O
,	10817768	875	876	O
disability	10817768	877	887	O
with	10817768	888	892	O
the	10817768	893	896	O
modified	10817768	897	905	O
Health	10817768	906	912	O
Assessment	10817768	913	923	O
Questionnaire	10817768	924	937	O
and	10817768	938	941	O
economic	10817768	942	950	B-Outcome
costs	10817768	951	956	I-Outcome
measured	10817768	957	965	O
from	10817768	966	970	O
a	10817768	971	972	O
societal	10817768	973	981	O
perspective	10817768	982	993	O
.	10817768	994	995	O

RESULTS	10817768	996	1003	O
Mean	10817768	1004	1008	B-Outcome
waiting	10817768	1009	1016	I-Outcome
times	10817768	1017	1022	I-Outcome
were	10817768	1023	1027	O
43	10817768	1028	1030	B-Observation
days	10817768	1031	1035	I-Observation
(	10817768	1036	1037	O
sigma	10817768	1038	1043	O
=	10817768	1044	1045	O
+	10817768	1046	1047	O
/-16	10817768	1047	1051	O
)	10817768	1052	1053	O
and	10817768	1054	1057	O
105	10817768	1058	1061	B-Observation
days	10817768	1062	1066	I-Observation
(	10817768	1067	1068	O
sigma	10817768	1069	1074	O
=	10817768	1075	1076	O
+	10817768	1077	1078	O
/-51	10817768	1078	1082	O
)	10817768	1083	1084	O
for	10817768	1085	1088	O
'	10817768	1089	1090	B-Intervention
fast	10817768	1090	1094	I-Intervention
track	10817768	1095	1100	I-Intervention
'	10817768	1101	1102	I-Intervention
and	10817768	1103	1106	O
'	10817768	1107	1108	B-Intervention
ordinary	10817768	1108	1116	I-Intervention
'	10817768	1117	1118	I-Intervention
appointments	10817768	1119	1131	I-Intervention
,	10817768	1132	1133	O
respectively	10817768	1134	1146	O
.	10817768	1147	1148	O

Both	10817768	1149	1153	B-Intervention
groups	10817768	1154	1160	I-Intervention
showed	10817768	1161	1167	O
significant	10817768	1168	1179	B-Observation
improvements	10817768	1180	1192	I-Observation
in	10817768	1193	1195	O
mean	10817768	1196	1200	B-Outcome
[	10817768	1201	1202	I-Outcome
95	10817768	1203	1205	I-Outcome
%	10817768	1206	1207	I-Outcome
confidence	10817768	1208	1218	I-Outcome
interval	10817768	1219	1227	I-Outcome
(	10817768	1228	1229	I-Outcome
CI	10817768	1230	1232	I-Outcome
)	10817768	1233	1234	I-Outcome
]	10817768	1235	1236	I-Outcome
scores	10817768	1237	1243	I-Outcome
for	10817768	1244	1247	I-Outcome
pain	10817768	1248	1252	I-Outcome
:	10817768	1253	1254	O
11	10817768	1255	1257	B-Observation
(	10817768	1258	1259	O
7	10817768	1260	1261	O
,	10817768	1262	1263	O
16	10817768	1264	1266	O
)	10817768	1267	1268	O
(	10817768	1269	1270	O
P	10817768	1271	1272	O
<	10817768	1273	1274	O
0.001	10817768	1275	1280	O
)	10817768	1281	1282	O
;	10817768	1283	1284	O
physical	10817768	1285	1293	B-Outcome
health	10817768	1294	1300	I-Outcome
status	10817768	1301	1307	I-Outcome
:	10817768	1308	1309	O
4	10817768	1310	1311	B-Observation
(	10817768	1312	1313	O
2	10817768	1314	1315	O
,	10817768	1316	1317	O
5	10817768	1318	1319	O
)	10817768	1320	1321	O
(	10817768	1322	1323	O
P	10817768	1324	1325	O
<	10817768	1326	1327	O
0.001	10817768	1328	1333	O
)	10817768	1334	1335	O
;	10817768	1336	1337	O
mental	10817768	1338	1344	B-Outcome
health	10817768	1345	1351	I-Outcome
status	10817768	1352	1358	I-Outcome
:	10817768	1359	1360	O
2	10817768	1361	1362	B-Observation
(	10817768	1363	1364	O
0.1	10817768	1365	1368	O
,	10817768	1369	1370	O
4	10817768	1371	1372	O
)	10817768	1373	1374	O
(	10817768	1375	1376	O
P	10817768	1377	1378	O
<	10817768	1379	1380	O
0.02	10817768	1381	1385	O
)	10817768	1386	1387	O
;	10817768	1388	1389	O
and	10817768	1390	1393	O
health	10817768	1394	1400	B-Outcome
utility	10817768	1401	1408	I-Outcome
:	10817768	1409	1410	O
0.11	10817768	1411	1415	B-Observation
(	10817768	1416	1417	O
0.07	10817768	1418	1422	O
,	10817768	1423	1424	O
0.16	10817768	1425	1429	O
)	10817768	1430	1431	O
(	10817768	1432	1433	O
P	10817768	1434	1435	O
<	10817768	1436	1437	O
0.001	10817768	1438	1443	O
)	10817768	1444	1445	O
by	10817768	1446	1448	O
the	10817768	1449	1452	O
end	10817768	1453	1456	O
of	10817768	1457	1459	O
the	10817768	1460	1463	O
15-month	10817768	1464	1472	O
period	10817768	1473	1479	O
of	10817768	1480	1482	O
the	10817768	1483	1486	O
study	10817768	1487	1492	O
,	10817768	1493	1494	O
but	10817768	1495	1498	O
there	10817768	1499	1504	O
was	10817768	1505	1508	O
no	10817768	1509	1511	O
significant	10817768	1512	1523	B-Observation
difference	10817768	1524	1534	I-Observation
between	10817768	1535	1542	B-Intervention
either	10817768	1543	1549	I-Intervention
arm	10817768	1550	1553	I-Intervention
of	10817768	1554	1556	O
the	10817768	1557	1560	O
study	10817768	1561	1566	O
.	10817768	1567	1568	O

CONCLUSIONS	10817768	1569	1580	O
Rationing	10817768	1581	1590	B-Intervention
by	10817768	1591	1593	I-Intervention
delay	10817768	1594	1599	I-Intervention
was	10817768	1600	1603	O
not	10817768	1604	1607	O
detrimental	10817768	1608	1619	B-Observation
to	10817768	1620	1622	O
either	10817768	1623	1629	O
mental	10817768	1630	1636	B-Outcome
or	10817768	1637	1639	I-Outcome
physical	10817768	1640	1648	I-Outcome
health	10817768	1649	1655	I-Outcome
and	10817768	1656	1659	O
patients	10817768	1660	1668	O
in	10817768	1669	1671	O
both	10817768	1672	1676	B-Intervention
arms	10817768	1677	1681	I-Intervention
of	10817768	1682	1684	O
the	10817768	1685	1688	O
study	10817768	1689	1694	O
showed	10817768	1695	1701	O
significant	10817768	1702	1713	B-Observation
and	10817768	1714	1717	I-Observation
similar	10817768	1718	1725	I-Observation
improvement	10817768	1726	1737	I-Observation
in	10817768	1738	1740	O
health	10817768	1741	1747	B-Outcome
by	10817768	1748	1750	O
15	10817768	1751	1753	O
months	10817768	1754	1760	O
.	10817768	1761	1762	O

Expenditure	10817768	1763	1774	O
of	10817768	1775	1777	O
resources	10817768	1778	1787	O
on	10817768	1788	1790	O
waiting	10817768	1791	1798	O
times	10817768	1799	1804	O
without	10817768	1805	1812	O
regard	10817768	1813	1819	O
to	10817768	1820	1822	O
clinical	10817768	1823	1831	O
outcomes	10817768	1832	1840	O
is	10817768	1841	1843	O
likely	10817768	1844	1850	O
to	10817768	1851	1853	O
be	10817768	1854	1856	O
wasteful	10817768	1857	1865	O
and	10817768	1866	1869	O
additional	10817768	1870	1880	O
resources	10817768	1881	1890	O
should	10817768	1891	1897	O
be	10817768	1898	1900	O
directed	10817768	1901	1909	O
at	10817768	1910	1912	O
achieving	10817768	1913	1922	O
the	10817768	1923	1926	O
greatest	10817768	1927	1935	O
clinical	10817768	1936	1944	O
benefit	10817768	1945	1952	O
.	10817768	1953	1954	O

More	10817768	1955	1959	O
research	10817768	1960	1968	O
into	10817768	1969	1973	O
effective	10817768	1974	1983	O
methods	10817768	1984	1991	O
of	10817768	1992	1994	O
controlling	10817768	1995	2006	O
demand	10817768	2007	2013	O
and	10817768	2014	2017	O
better	10817768	2018	2024	O
identification	10817768	2025	2039	O
of	10817768	2040	2042	O
those	10817768	2043	2048	O
who	10817768	2049	2052	O
would	10817768	2053	2058	O
benefit	10817768	2059	2066	O
from	10817768	2067	2071	O
access	10817768	2072	2078	O
to	10817768	2079	2081	O
specialist	10817768	2082	2092	O
care	10817768	2093	2097	O
is	10817768	2098	2100	O
needed	10817768	2101	2107	O
.	10817768	2108	2109	O

Identifying	10826576	0	11	O
the	10826576	12	15	O
indications	10826576	16	27	B-Outcome
for	10826576	28	31	O
laparoscopically	10826576	32	48	B-Intervention
assisted	10826576	49	57	I-Intervention
vaginal	10826576	58	65	I-Intervention
hysterectomy	10826576	66	78	I-Intervention
:	10826576	79	80	O
a	10826576	81	82	O
prospective	10826576	83	94	O
,	10826576	95	96	O
randomised	10826576	97	107	O
comparison	10826576	108	118	O
with	10826576	119	123	O
abdominal	10826576	124	133	B-Intervention
hysterectomy	10826576	134	146	I-Intervention
in	10826576	147	149	O
patients	10826576	150	158	O
with	10826576	159	163	O
symptomatic	10826576	164	175	B-Participant
uterine	10826576	176	183	I-Participant
fibroids	10826576	184	192	I-Participant
.	10826576	193	194	O

OBJECTIVE	10826576	195	204	O
To	10826576	205	207	O
compare	10826576	208	215	O
laparoscopically	10826576	216	232	B-Intervention
assisted	10826576	233	241	I-Intervention
vaginal	10826576	242	249	I-Intervention
hysterectomy	10826576	250	262	I-Intervention
(	10826576	263	264	I-Intervention
LAVH	10826576	265	269	I-Intervention
)	10826576	270	271	I-Intervention
and	10826576	272	275	O
total	10826576	276	281	B-Intervention
abdominal	10826576	282	291	I-Intervention
hysterectomy	10826576	292	304	I-Intervention
(	10826576	305	306	I-Intervention
TAH	10826576	307	310	I-Intervention
)	10826576	311	312	I-Intervention
in	10826576	313	315	O
patients	10826576	316	324	O
with	10826576	325	329	O
uterine	10826576	330	337	B-Participant
fibroids	10826576	338	346	I-Participant
.	10826576	347	348	O

DESIGN	10826576	349	355	O
A	10826576	356	357	O
prospective	10826576	358	369	O
randomised	10826576	370	380	O
study	10826576	381	386	O
.	10826576	387	388	O

SETTING	10826576	389	396	O
The	10826576	397	400	O
San	10826576	401	404	O
Paolo	10826576	405	410	O
Hospital	10826576	411	419	O
,	10826576	420	421	O
Milan	10826576	422	427	O
.	10826576	428	429	O

POPULATION	10826576	430	440	O
Sixty-two	10826576	441	450	O
patients	10826576	451	459	O
,	10826576	460	461	O
who	10826576	462	465	O
were	10826576	466	470	O
not	10826576	471	474	O
suitable	10826576	475	483	O
for	10826576	484	487	O
a	10826576	488	489	O
vaginal	10826576	490	497	B-Participant
hysterectomy	10826576	498	510	I-Participant
,	10826576	511	512	O
requiring	10826576	513	522	O
treatment	10826576	523	532	O
for	10826576	533	536	O
uterine	10826576	537	544	B-Participant
fibroids	10826576	545	553	I-Participant
.	10826576	554	555	O

METHODS	10826576	556	563	O
Randomisation	10826576	564	577	O
between	10826576	578	585	O
LAVH	10826576	586	590	B-Intervention
and	10826576	591	594	O
TAH	10826576	595	598	B-Intervention
.	10826576	599	600	O

Comparison	10826576	601	611	O
of	10826576	612	614	O
outcomes	10826576	615	623	O
on	10826576	624	626	O
the	10826576	627	630	O
whole	10826576	631	636	O
series	10826576	637	643	O
,	10826576	644	645	O
patients	10826576	646	654	O
with	10826576	655	659	O
uteri	10826576	660	665	B-Participant
<	10826576	666	667	I-Participant
or	10826576	668	670	I-Participant
=	10826576	671	672	I-Participant
500	10826576	673	676	I-Participant
g	10826576	677	678	I-Participant
(	10826576	679	680	O
Group	10826576	681	686	O
1	10826576	687	688	O
)	10826576	689	690	O
and	10826576	691	694	O
patients	10826576	695	703	O
with	10826576	704	708	O
uteri	10826576	709	714	B-Participant
>	10826576	715	716	I-Participant
500	10826576	717	720	I-Participant
g	10826576	721	722	I-Participant
(	10826576	723	724	O
Group	10826576	725	730	O
2	10826576	731	732	O
)	10826576	733	734	O
.	10826576	735	736	O

MAIN	10826576	737	741	O
OUTCOME	10826576	742	749	O
MEASURES	10826576	750	758	O
To	10826576	759	761	O
establish	10826576	762	771	O
operating	10826576	772	781	B-Outcome
time	10826576	782	786	I-Outcome
,	10826576	787	788	O
blood	10826576	789	794	B-Outcome
loss	10826576	795	799	I-Outcome
,	10826576	800	801	O
complications	10826576	802	815	B-Outcome
,	10826576	816	817	O
febrile	10826576	818	825	B-Outcome
morbidity	10826576	826	835	I-Outcome
,	10826576	836	837	O
analgesics	10826576	838	848	B-Outcome
administration	10826576	849	863	I-Outcome
and	10826576	864	867	O
hospital	10826576	868	876	B-Outcome
stay	10826576	877	881	I-Outcome
for	10826576	882	885	O
both	10826576	886	890	O
treatment	10826576	891	900	O
approaches	10826576	901	911	O
.	10826576	912	913	O

RESULTS	10826576	914	921	O
Median	10826576	922	928	B-Outcome
uterine	10826576	929	936	I-Outcome
weight	10826576	937	943	I-Outcome
was	10826576	944	947	O
400	10826576	948	951	B-Observation
g	10826576	952	953	I-Observation
in	10826576	954	956	O
both	10826576	957	961	O
LAVH	10826576	962	966	B-Intervention
and	10826576	967	970	O
TAH	10826576	971	974	B-Intervention
group	10826576	975	980	O
.	10826576	981	982	O

Median	10826576	983	989	B-Outcome
operating	10826576	990	999	I-Outcome
time	10826576	1000	1004	I-Outcome
was	10826576	1005	1008	O
longer	10826576	1009	1015	B-Observation
for	10826576	1016	1019	O
LAVH	10826576	1020	1024	B-Intervention
(	10826576	1025	1026	O
135	10826576	1027	1030	B-Observation
min	10826576	1031	1034	I-Observation
compared	10826576	1035	1043	O
with	10826576	1044	1048	O
120	10826576	1049	1052	B-Observation
min	10826576	1053	1056	I-Observation
for	10826576	1057	1060	O
TAH	10826576	1061	1064	B-Intervention
;	10826576	1065	1066	O
P	10826576	1067	1068	O
=	10826576	1069	1070	O
0.001	10826576	1071	1076	O
)	10826576	1077	1078	O
,	10826576	1079	1080	O
but	10826576	1081	1084	O
patients	10826576	1085	1093	O
undergoing	10826576	1094	1104	O
LAVH	10826576	1105	1109	B-Intervention
had	10826576	1110	1113	O
less	10826576	1114	1118	B-Count
analgesics	10826576	1119	1129	B-Outcome
administration	10826576	1130	1144	I-Outcome
(	10826576	1145	1146	O
23	10826576	1147	1149	B-Count
%	10826576	1150	1151	I-Count
compared	10826576	1152	1160	O
with	10826576	1161	1165	O
77	10826576	1166	1168	B-Count
%	10826576	1169	1170	I-Count
,	10826576	1171	1172	O
P	10826576	1173	1174	O
<	10826576	1175	1176	O
0.001	10826576	1177	1182	O
)	10826576	1183	1184	O
and	10826576	1185	1188	O
a	10826576	1189	1190	O
shorter	10826576	1191	1198	B-Observation
median	10826576	1199	1205	B-Outcome
hospital	10826576	1206	1214	I-Outcome
stay	10826576	1215	1219	I-Outcome
(	10826576	1220	1221	O
3.8	10826576	1222	1225	B-Observation
compared	10826576	1226	1234	O
with	10826576	1235	1239	O
5.8	10826576	1240	1243	B-Observation
days	10826576	1244	1248	I-Observation
;	10826576	1249	1250	O
P	10826576	1251	1252	O
<	10826576	1253	1254	O
0.001	10826576	1255	1260	O
)	10826576	1261	1262	O
.	10826576	1263	1264	O

LAVH	10826576	1265	1269	B-Intervention
,	10826576	1270	1271	O
when	10826576	1272	1276	O
compared	10826576	1277	1285	O
with	10826576	1286	1290	O
TAH	10826576	1291	1294	B-Intervention
in	10826576	1295	1297	O
the	10826576	1298	1301	O
two	10826576	1302	1305	O
weight	10826576	1306	1312	O
subgroups	10826576	1313	1322	O
,	10826576	1323	1324	O
required	10826576	1325	1333	O
a	10826576	1334	1335	O
significantly	10826576	1336	1349	B-Observation
longer	10826576	1350	1356	I-Observation
operating	10826576	1357	1366	B-Outcome
time	10826576	1367	1371	I-Outcome
only	10826576	1372	1376	O
in	10826576	1377	1379	O
Group	10826576	1380	1385	B-Participant
2	10826576	1386	1387	I-Participant
,	10826576	1388	1389	O
significantly	10826576	1390	1403	B-Observation
reduced	10826576	1404	1411	I-Observation
analgesics	10826576	1412	1422	B-Outcome
administration	10826576	1423	1437	I-Outcome
only	10826576	1438	1442	O
in	10826576	1443	1445	O
Group	10826576	1446	1451	B-Participant
1	10826576	1452	1453	I-Participant
,	10826576	1454	1455	O
and	10826576	1456	1459	O
significantly	10826576	1460	1473	B-Observation
reduced	10826576	1474	1481	I-Observation
hospital	10826576	1482	1490	B-Outcome
stay	10826576	1491	1495	I-Outcome
in	10826576	1496	1498	O
both	10826576	1499	1503	B-Participant
groups	10826576	1504	1510	I-Participant
.	10826576	1511	1512	O

Conversions	10826576	1513	1524	B-Outcome
of	10826576	1525	1527	I-Outcome
LAVH	10826576	1528	1532	I-Outcome
to	10826576	1533	1535	I-Outcome
laparotomy	10826576	1536	1546	I-Outcome
were	10826576	1547	1551	O
significantly	10826576	1552	1565	B-Observation
more	10826576	1566	1570	I-Observation
frequent	10826576	1571	1579	I-Observation
in	10826576	1580	1582	O
Group	10826576	1583	1588	B-Participant
2	10826576	1589	1590	I-Participant
(	10826576	1591	1592	O
3/11	10826576	1593	1597	O
)	10826576	1598	1599	O
than	10826576	1600	1604	O
in	10826576	1605	1607	O
Group	10826576	1608	1613	B-Participant
1	10826576	1614	1615	I-Participant
(	10826576	1616	1617	O
0/20	10826576	1618	1622	O
)	10826576	1623	1624	O
(	10826576	1625	1626	O
P	10826576	1627	1628	O
=	10826576	1629	1630	O
0.04	10826576	1631	1635	O
)	10826576	1636	1637	O
.	10826576	1638	1639	O

CONCLUSIONS	10826576	1640	1651	O
Compared	10826576	1652	1660	O
with	10826576	1661	1665	O
TAH	10826576	1666	1669	B-Intervention
,	10826576	1670	1671	O
LAVH	10826576	1672	1676	B-Intervention
has	10826576	1677	1680	O
advantages	10826576	1681	1691	B-Observation
in	10826576	1692	1694	O
removing	10826576	1695	1703	B-Outcome
uteri	10826576	1704	1709	I-Outcome
weighing	10826576	1710	1718	I-Outcome
<	10826576	1719	1720	I-Outcome
or	10826576	1721	1723	I-Outcome
=	10826576	1724	1725	I-Outcome
500	10826576	1726	1729	I-Outcome
g	10826576	1730	1731	I-Outcome
,	10826576	1732	1733	O
with	10826576	1734	1738	O
comparable	10826576	1739	1749	B-Observation
operating	10826576	1750	1759	B-Outcome
time	10826576	1760	1764	I-Outcome
,	10826576	1765	1766	O
less	10826576	1767	1771	B-Observation
post-operative	10826576	1772	1786	B-Outcome
pain	10826576	1787	1791	I-Outcome
and	10826576	1792	1795	O
shorter	10826576	1796	1803	B-Observation
recovery	10826576	1804	1812	B-Outcome
.	10826576	1813	1814	O

Among	10826576	1815	1820	O
uteri	10826576	1821	1826	B-Participant
weighing	10826576	1827	1835	I-Participant
>	10826576	1836	1837	I-Participant
500	10826576	1838	1841	I-Participant
g	10826576	1842	1843	I-Participant
LAVH	10826576	1844	1848	B-Intervention
showed	10826576	1849	1855	O
a	10826576	1856	1857	O
shorter	10826576	1858	1865	B-Observation
recovery	10826576	1866	1874	B-Outcome
,	10826576	1875	1876	O
but	10826576	1877	1880	O
longer	10826576	1881	1887	B-Observation
operating	10826576	1888	1897	B-Outcome
time	10826576	1898	1902	I-Outcome
than	10826576	1903	1907	O
TAH	10826576	1908	1911	B-Intervention
and	10826576	1912	1915	O
a	10826576	1916	1917	O
27	10826576	1918	1920	B-Observation
%	10826576	1921	1922	I-Observation
rate	10826576	1923	1927	B-Outcome
of	10826576	1928	1930	I-Outcome
conversion	10826576	1931	1941	I-Outcome
to	10826576	1942	1944	I-Outcome
laparotomy	10826576	1945	1955	I-Outcome
.	10826576	1956	1957	O

Secretin	10832772	0	8	B-Intervention
and	10832772	9	12	O
autism	10832772	13	19	B-Participant
:	10832772	20	21	O
a	10832772	22	23	O
two-part	10832772	24	32	O
clinical	10832772	33	41	O
investigation	10832772	42	55	O
.	10832772	56	57	O

Recent	10832772	58	64	O
anecdotal	10832772	65	74	O
reports	10832772	75	82	O
have	10832772	83	87	O
touted	10832772	88	94	O
the	10832772	95	98	O
gastrointestinal	10832772	99	115	O
(	10832772	116	117	O
GI	10832772	118	120	O
)	10832772	121	122	O
hormone	10832772	123	130	O
secretin	10832772	131	139	O
as	10832772	140	142	O
a	10832772	143	144	O
treatment	10832772	145	154	O
modality	10832772	155	163	O
for	10832772	164	167	O
autism	10832772	168	174	O
,	10832772	175	176	O
though	10832772	177	183	O
there	10832772	184	189	O
is	10832772	190	192	O
little	10832772	193	199	O
clinical	10832772	200	208	O
evidence	10832772	209	217	O
or	10832772	218	220	O
literature	10832772	221	231	O
to	10832772	232	234	O
support	10832772	235	242	O
its	10832772	243	246	O
viability	10832772	247	256	O
.	10832772	257	258	O

We	10832772	259	261	O
undertook	10832772	262	271	O
a	10832772	272	273	O
two-part	10832772	274	282	O
clinical	10832772	283	291	O
trial	10832772	292	297	O
to	10832772	298	300	O
investigate	10832772	301	312	O
these	10832772	313	318	O
claims	10832772	319	325	O
.	10832772	326	327	O

Fifty-six	10832772	328	337	O
patients	10832772	338	346	O
(	10832772	347	348	O
49	10832772	349	351	O
boys	10832772	352	356	O
,	10832772	357	358	O
7	10832772	359	360	O
girls	10832772	361	366	O
,	10832772	367	368	O
mean	10832772	369	373	O
age	10832772	374	377	O
=	10832772	378	379	O
6.4	10832772	380	383	O
years	10832772	384	389	O
,	10832772	390	391	O
SD	10832772	392	394	O
=	10832772	395	396	O
2.7	10832772	397	400	O
)	10832772	401	402	O
enrolled	10832772	403	411	O
in	10832772	412	414	O
an	10832772	415	417	O
open-label	10832772	418	428	O
trial	10832772	429	434	O
of	10832772	435	437	O
secretin	10832772	438	446	O
,	10832772	447	448	O
during	10832772	449	455	O
which	10832772	456	461	O
they	10832772	462	466	O
received	10832772	467	475	O
one	10832772	476	479	O
injection	10832772	480	489	O
of	10832772	490	492	O
the	10832772	493	496	O
hormone	10832772	497	504	B-Intervention
(	10832772	505	506	O
2	10832772	507	508	O
IU/kg	10832772	509	514	O
)	10832772	515	516	O
.	10832772	517	518	O

All	10832772	519	522	O
subjects	10832772	523	531	O
were	10832772	532	536	O
evaluated	10832772	537	546	O
by	10832772	547	549	O
their	10832772	550	555	O
parents	10832772	556	563	O
at	10832772	564	566	O
baseline	10832772	567	575	O
and	10832772	576	579	O
follow-up	10832772	580	589	O
visits	10832772	590	596	O
(	10832772	597	598	O
3	10832772	599	600	O
-	10832772	600	601	O
6	10832772	601	602	O
weeks	10832772	603	608	O
later	10832772	609	614	O
,	10832772	615	616	O
M	10832772	617	618	O
=	10832772	619	620	O
3.7	10832772	621	624	O
,	10832772	625	626	O
SD	10832772	627	629	O
=	10832772	630	631	O
1.4	10832772	632	635	O
weeks	10832772	636	641	O
)	10832772	642	643	O
with	10832772	644	648	O
Childhood	10832772	649	658	B-Outcome
Autism	10832772	659	665	I-Outcome
Rating	10832772	666	672	I-Outcome
Scales	10832772	673	679	I-Outcome
(	10832772	680	681	I-Outcome
CARS	10832772	682	686	I-Outcome
)	10832772	687	688	I-Outcome
.	10832772	689	690	O

Thirty-four	10832772	691	702	O
patients	10832772	703	711	O
were	10832772	712	716	O
labeled	10832772	717	724	O
with	10832772	725	729	O
Pervasive	10832772	730	739	B-Participant
Developmental	10832772	740	753	I-Participant
Disorder	10832772	754	762	I-Participant
Not	10832772	763	766	I-Participant
Otherwise	10832772	767	776	I-Participant
Specified	10832772	777	786	I-Participant
,	10832772	787	788	O
and	10832772	789	792	O
22	10832772	793	795	O
met	10832772	796	799	O
diagnostic	10832772	800	810	O
criteria	10832772	811	819	O
for	10832772	820	823	O
Autistic	10832772	824	832	B-Participant
Disorder	10832772	833	841	I-Participant
.	10832772	842	843	O

Forty-five	10832772	844	854	O
patients	10832772	855	863	O
were	10832772	864	868	O
concurrently	10832772	869	881	O
on	10832772	882	884	O
other	10832772	885	890	O
drug	10832772	891	895	O
treatments	10832772	896	906	O
.	10832772	907	908	O

At	10832772	909	911	O
follow-up	10832772	912	921	O
,	10832772	922	923	O
some	10832772	924	928	O
reported	10832772	929	937	O
minimal	10832772	938	945	B-Observation
but	10832772	946	949	I-Observation
potentially	10832772	950	961	I-Observation
significant	10832772	962	973	I-Observation
improvements	10832772	974	986	B-Outcome
including	10832772	987	996	O
changes	10832772	997	1004	B-Observation
in	10832772	1005	1007	O
GI	10832772	1008	1010	B-Outcome
symptoms	10832772	1011	1019	I-Outcome
,	10832772	1020	1021	O
expressive	10832772	1022	1032	B-Outcome
and/or	10832772	1033	1039	I-Outcome
receptive	10832772	1040	1049	I-Outcome
language	10832772	1050	1058	I-Outcome
function	10832772	1059	1067	I-Outcome
,	10832772	1068	1069	O
and	10832772	1070	1073	O
improved	10832772	1074	1082	B-Observation
awareness	10832772	1083	1092	B-Outcome
and	10832772	1093	1096	O
social	10832772	1097	1103	B-Outcome
interactions	10832772	1104	1116	I-Outcome
.	10832772	1117	1118	O

No	10832772	1119	1121	B-Count
adverse	10832772	1122	1129	B-Outcome
effects	10832772	1130	1137	I-Outcome
were	10832772	1138	1142	O
reported	10832772	1143	1151	O
or	10832772	1152	1154	O
observed	10832772	1155	1163	O
.	10832772	1164	1165	O

Subsequently	10832772	1166	1178	O
,	10832772	1179	1180	O
17	10832772	1181	1183	O
of	10832772	1184	1186	O
the	10832772	1187	1190	O
most	10832772	1191	1195	O
responsive	10832772	1196	1206	O
patients	10832772	1207	1215	O
from	10832772	1216	1220	O
Study	10832772	1221	1226	O
1	10832772	1227	1228	O
began	10832772	1229	1234	O
a	10832772	1235	1236	O
double-blind	10832772	1237	1249	O
trial	10832772	1250	1255	O
that	10832772	1256	1260	O
also	10832772	1261	1265	O
included	10832772	1266	1274	O
8	10832772	1275	1276	O
newly	10832772	1277	1282	O
enrolled	10832772	1283	1291	O
patients	10832772	1292	1300	O
.	10832772	1301	1302	O

Patients	10832772	1303	1311	O
in	10832772	1312	1314	O
this	10832772	1315	1319	O
second	10832772	1320	1326	O
study	10832772	1327	1332	O
were	10832772	1333	1337	O
alternatively	10832772	1338	1351	O
entered	10832772	1352	1359	O
into	10832772	1360	1364	O
one	10832772	1365	1368	O
of	10832772	1369	1371	O
two	10832772	1372	1375	O
groups	10832772	1376	1382	O
and	10832772	1383	1386	O
received	10832772	1387	1395	O
injections	10832772	1396	1406	O
of	10832772	1407	1409	O
secretin	10832772	1410	1418	B-Intervention
or	10832772	1419	1421	O
placebo	10832772	1422	1429	B-Intervention
with	10832772	1430	1434	O
crossover	10832772	1435	1444	O
at	10832772	1445	1447	O
4	10832772	1448	1449	O
weeks	10832772	1450	1455	O
.	10832772	1456	1457	O

Patients	10832772	1458	1466	O
from	10832772	1467	1471	O
Study	10832772	1472	1477	O
1	10832772	1478	1479	O
entered	10832772	1480	1487	O
into	10832772	1488	1492	O
Study	10832772	1493	1498	O
2	10832772	1499	1500	O
at	10832772	1501	1503	O
an	10832772	1504	1506	O
average	10832772	1507	1514	O
of	10832772	1515	1517	O
6.5	10832772	1518	1521	O
(	10832772	1522	1523	O
SD	10832772	1524	1526	O
=	10832772	1527	1528	O
0.8	10832772	1529	1532	O
)	10832772	1533	1534	O
weeks	10832772	1535	1540	O
after	10832772	1541	1546	O
beginning	10832772	1547	1556	O
Study	10832772	1557	1562	O
1	10832772	1563	1564	O
.	10832772	1565	1566	O

Results	10832772	1567	1574	O
of	10832772	1575	1577	O
both	10832772	1578	1582	O
inquiries	10832772	1583	1592	O
indicate	10832772	1593	1601	O
that	10832772	1602	1606	O
although	10832772	1607	1615	O
treatment	10832772	1616	1625	O
with	10832772	1626	1630	O
secretin	10832772	1631	1639	B-Intervention
was	10832772	1640	1643	O
reported	10832772	1644	1652	O
to	10832772	1653	1655	O
cause	10832772	1656	1661	O
transient	10832772	1662	1671	B-Observation
changes	10832772	1672	1679	I-Observation
in	10832772	1680	1682	O
speech	10832772	1683	1689	B-Outcome
and	10832772	1690	1693	O
behavior	10832772	1694	1702	B-Outcome
in	10832772	1703	1705	O
some	10832772	1706	1710	O
children	10832772	1711	1719	B-Participant
,	10832772	1720	1721	O
overall	10832772	1722	1729	O
it	10832772	1730	1732	O
produced	10832772	1733	1741	O
few	10832772	1742	1745	B-Observation
clinically	10832772	1746	1756	I-Observation
meaningful	10832772	1757	1767	I-Observation
changes	10832772	1768	1775	I-Observation
when	10832772	1776	1780	O
compared	10832772	1781	1789	O
to	10832772	1790	1792	O
children	10832772	1793	1801	B-Participant
given	10832772	1802	1807	O
placebo	10832772	1808	1815	B-Intervention
injections	10832772	1816	1826	O
.	10832772	1827	1828	O

Comparison	10837440	0	10	O
of	10837440	11	13	O
a	10837440	14	15	O
5	10837440	16	17	B-Intervention
day	10837440	18	21	I-Intervention
regimen	10837440	22	29	I-Intervention
of	10837440	30	32	I-Intervention
cefdinir	10837440	33	41	I-Intervention
with	10837440	42	46	O
a	10837440	47	48	O
10	10837440	49	51	B-Intervention
day	10837440	52	55	I-Intervention
regimen	10837440	56	63	I-Intervention
of	10837440	64	66	I-Intervention
cefprozil	10837440	67	76	I-Intervention
for	10837440	77	80	O
treatment	10837440	81	90	O
of	10837440	91	93	O
acute	10837440	94	99	B-Participant
exacerbations	10837440	100	113	I-Participant
of	10837440	114	116	I-Participant
chronic	10837440	117	124	I-Participant
bronchitis	10837440	125	135	I-Participant
.	10837440	136	137	O

Patients	10837440	138	146	O
with	10837440	147	151	O
acute	10837440	152	157	B-Participant
exacerbations	10837440	158	171	I-Participant
of	10837440	172	174	I-Participant
chronic	10837440	175	182	I-Participant
bronchitis	10837440	183	193	I-Participant
were	10837440	194	198	O
treated	10837440	199	206	O
with	10837440	207	211	O
cefdinir	10837440	212	220	B-Intervention
300	10837440	221	224	O
mg	10837440	225	227	O
bd	10837440	228	230	O
for	10837440	231	234	O
5	10837440	235	236	O
days	10837440	237	241	O
or	10837440	242	244	O
cefprozil	10837440	245	254	B-Intervention
500	10837440	255	258	O
mg	10837440	259	261	O
bd	10837440	262	264	O
for	10837440	265	268	O
10	10837440	269	271	O
days	10837440	272	276	O
in	10837440	277	279	O
a	10837440	280	281	O
prospective	10837440	282	293	O
,	10837440	294	295	O
randomized	10837440	296	306	O
,	10837440	307	308	O
double-blind	10837440	309	321	O
,	10837440	322	323	O
multicentre	10837440	324	335	O
study	10837440	336	341	O
.	10837440	342	343	O

Of	10837440	344	346	O
the	10837440	347	350	O
548	10837440	351	354	O
patients	10837440	355	363	O
enrolled	10837440	364	372	O
,	10837440	373	374	O
281	10837440	375	378	O
(	10837440	379	380	O
51	10837440	381	383	O
%	10837440	384	385	O
)	10837440	386	387	O
were	10837440	388	392	O
evaluable	10837440	393	402	O
.	10837440	403	404	O

The	10837440	405	408	O
clinical	10837440	409	417	B-Outcome
cure	10837440	418	422	I-Outcome
rates	10837440	423	428	I-Outcome
at	10837440	429	431	I-Outcome
the	10837440	432	435	I-Outcome
test-of-cure	10837440	436	448	I-Outcome
visit	10837440	449	454	I-Outcome
were	10837440	455	459	O
80	10837440	460	462	B-Count
%	10837440	463	464	I-Count
(	10837440	465	466	I-Count
114/142	10837440	467	474	I-Count
)	10837440	475	476	I-Count
and	10837440	477	480	O
72	10837440	481	483	B-Count
%	10837440	484	485	I-Count
(	10837440	486	487	I-Count
100/139	10837440	488	495	I-Count
)	10837440	496	497	I-Count
for	10837440	498	501	O
the	10837440	502	505	O
evaluable	10837440	506	515	O
patients	10837440	516	524	O
treated	10837440	525	532	O
with	10837440	533	537	O
cefdinir	10837440	538	546	B-Intervention
and	10837440	547	550	O
cefprozil	10837440	551	560	B-Intervention
,	10837440	561	562	O
respectively	10837440	563	575	O
.	10837440	576	577	O

Respiratory	10837440	578	589	B-Outcome
tract	10837440	590	595	I-Outcome
pathogens	10837440	596	605	I-Outcome
were	10837440	606	610	O
isolated	10837440	611	619	O
from	10837440	620	624	O
409	10837440	625	628	B-Count
(	10837440	629	630	I-Count
75	10837440	631	633	I-Count
%	10837440	634	635	I-Count
)	10837440	636	637	I-Count
of	10837440	638	640	I-Count
548	10837440	641	644	I-Count
admission	10837440	645	654	I-Count
sputum	10837440	655	661	I-Count
specimens	10837440	662	671	I-Count
,	10837440	672	673	O
with	10837440	674	678	O
the	10837440	679	682	O
predominant	10837440	683	694	B-Observation
pathogens	10837440	695	704	I-Observation
being	10837440	705	710	O
Haemophilus	10837440	711	722	B-Outcome
parainfluenzae	10837440	723	737	I-Outcome
,	10837440	738	739	O
Haemophilus	10837440	740	751	B-Outcome
influenzae	10837440	752	762	I-Outcome
,	10837440	763	764	O
Staphylococcus	10837440	765	779	B-Outcome
aureus	10837440	780	786	I-Outcome
and	10837440	787	790	O
Moraxella	10837440	791	800	B-Outcome
catarrhalis	10837440	801	812	I-Outcome
.	10837440	813	814	O

The	10837440	815	818	O
microbiological	10837440	819	834	B-Outcome
eradication	10837440	835	846	I-Outcome
rates	10837440	847	852	I-Outcome
at	10837440	853	855	I-Outcome
the	10837440	856	859	I-Outcome
test-of-cure	10837440	860	872	I-Outcome
visit	10837440	873	878	I-Outcome
were	10837440	879	883	O
81	10837440	884	886	B-Observation
%	10837440	887	888	I-Observation
(	10837440	889	890	I-Observation
157	10837440	891	894	I-Observation
of	10837440	895	897	I-Observation
193	10837440	898	901	I-Observation
pathogens	10837440	902	911	I-Observation
)	10837440	912	913	I-Observation
and	10837440	914	917	O
84	10837440	918	920	B-Observation
%	10837440	921	922	I-Observation
(	10837440	923	924	I-Observation
166	10837440	925	928	I-Observation
of	10837440	929	931	I-Observation
198	10837440	932	935	I-Observation
pathogens	10837440	936	945	I-Observation
)	10837440	946	947	I-Observation
for	10837440	948	951	O
the	10837440	952	955	O
evaluable	10837440	956	965	O
patients	10837440	966	974	O
treated	10837440	975	982	O
with	10837440	983	987	O
cefdinir	10837440	988	996	B-Intervention
and	10837440	997	1000	O
cefprozil	10837440	1001	1010	B-Intervention
,	10837440	1011	1012	O
respectively	10837440	1013	1025	O
.	10837440	1026	1027	O

Adverse	10837440	1028	1035	B-Outcome
event	10837440	1036	1041	I-Outcome
rates	10837440	1042	1047	I-Outcome
while	10837440	1048	1053	I-Outcome
on	10837440	1054	1056	I-Outcome
treatment	10837440	1057	1066	I-Outcome
were	10837440	1067	1071	O
equivalent	10837440	1072	1082	B-Observation
between	10837440	1083	1090	B-Intervention
the	10837440	1091	1094	I-Intervention
two	10837440	1095	1098	I-Intervention
treatment	10837440	1099	1108	I-Intervention
groups	10837440	1109	1115	O
.	10837440	1116	1117	O

The	10837440	1118	1121	O
incidence	10837440	1122	1131	B-Outcome
of	10837440	1132	1134	I-Outcome
diarrhoea	10837440	1135	1144	I-Outcome
during	10837440	1145	1151	I-Outcome
therapy	10837440	1152	1159	I-Outcome
was	10837440	1160	1163	O
higher	10837440	1164	1170	B-Observation
for	10837440	1171	1174	O
patients	10837440	1175	1183	O
treated	10837440	1184	1191	O
with	10837440	1192	1196	O
cefdinir	10837440	1197	1205	B-Intervention
(	10837440	1206	1207	O
17	10837440	1208	1210	B-Observation
%	10837440	1211	1212	I-Observation
)	10837440	1213	1214	O
than	10837440	1215	1219	O
for	10837440	1220	1223	O
patients	10837440	1224	1232	O
treated	10837440	1233	1240	O
with	10837440	1241	1245	O
cefprozil	10837440	1246	1255	B-Intervention
(	10837440	1256	1257	O
6	10837440	1258	1259	B-Observation
%	10837440	1260	1261	I-Observation
)	10837440	1262	1263	O
(	10837440	1264	1265	O
P	10837440	1266	1267	O
<	10837440	1268	1269	O
0.01	10837440	1270	1274	O
)	10837440	1275	1276	O
,	10837440	1277	1278	O
but	10837440	1279	1282	O
most	10837440	1283	1287	O
cases	10837440	1288	1293	O
were	10837440	1294	1298	O
mild	10837440	1299	1303	O
and	10837440	1304	1307	O
did	10837440	1308	1311	O
not	10837440	1312	1315	O
lead	10837440	1316	1320	O
to	10837440	1321	1323	O
discontinuation	10837440	1324	1339	O
of	10837440	1340	1342	O
treatment	10837440	1343	1352	O
.	10837440	1353	1354	O

These	10837440	1355	1360	O
results	10837440	1361	1368	O
indicate	10837440	1369	1377	O
that	10837440	1378	1382	O
a	10837440	1383	1384	O
5	10837440	1385	1386	B-Intervention
day	10837440	1387	1390	I-Intervention
regimen	10837440	1391	1398	I-Intervention
of	10837440	1399	1401	I-Intervention
cefdinir	10837440	1402	1410	I-Intervention
is	10837440	1411	1413	O
as	10837440	1414	1416	B-Observation
effective	10837440	1417	1426	I-Observation
and	10837440	1427	1430	I-Observation
safe	10837440	1431	1435	I-Observation
in	10837440	1436	1438	O
the	10837440	1439	1442	O
treatment	10837440	1443	1452	O
of	10837440	1453	1455	O
patients	10837440	1456	1464	O
with	10837440	1465	1469	O
acute	10837440	1470	1475	B-Participant
exacerbations	10837440	1476	1489	I-Participant
of	10837440	1490	1492	I-Participant
chronic	10837440	1493	1500	I-Participant
bronchitis	10837440	1501	1511	I-Participant
as	10837440	1512	1514	O
a	10837440	1515	1516	O
10	10837440	1517	1519	B-Intervention
day	10837440	1520	1523	I-Intervention
regimen	10837440	1524	1531	I-Intervention
of	10837440	1532	1534	I-Intervention
cefprozil	10837440	1535	1544	I-Intervention
.	10837440	1545	1546	O

The	10848655	0	3	O
effectiveness	10848655	4	17	O
of	10848655	18	20	O
omeprazole	10848655	21	31	B-Intervention
,	10848655	32	33	O
clarithromycin	10848655	34	48	B-Intervention
and	10848655	49	52	O
tinidazole	10848655	53	63	B-Intervention
in	10848655	64	66	O
eradicating	10848655	67	78	B-Outcome
Helicobacter	10848655	79	91	B-Participant
pylori	10848655	92	98	I-Participant
in	10848655	99	101	O
a	10848655	102	103	O
community	10848655	104	113	O
screen	10848655	114	120	O
and	10848655	121	124	O
treat	10848655	125	130	O
programme	10848655	131	140	O
.	10848655	141	142	O

Leeds	10848655	143	148	O
Help	10848655	149	153	O
Study	10848655	154	159	O
Group	10848655	160	165	O
.	10848655	166	167	O

INTRODUCTION	10848655	168	180	O
Helicobacter	10848655	181	193	O
pylori	10848655	194	200	O
screening	10848655	201	210	O
and	10848655	211	214	O
treatment	10848655	215	224	O
has	10848655	225	228	O
been	10848655	229	233	O
proposed	10848655	234	242	O
as	10848655	243	245	O
a	10848655	246	247	O
cost-effective	10848655	248	262	O
method	10848655	263	269	O
of	10848655	270	272	O
preventing	10848655	273	283	O
gastric	10848655	284	291	O
cancer	10848655	292	298	O
.	10848655	299	300	O

AIM	10848655	301	304	O
To	10848655	305	307	O
assess	10848655	308	314	O
,	10848655	315	316	O
in	10848655	317	319	O
a	10848655	320	321	O
randomized	10848655	322	332	O
controlled	10848655	333	343	O
trial	10848655	344	349	O
,	10848655	350	351	O
the	10848655	352	355	O
efficacy	10848655	356	364	O
of	10848655	365	367	O
therapy	10848655	368	375	B-Intervention
in	10848655	376	378	O
eradicating	10848655	379	390	B-Outcome
H.	10848655	391	393	B-Participant
pylori	10848655	394	400	I-Participant
as	10848655	401	403	O
part	10848655	404	408	O
of	10848655	409	411	O
a	10848655	412	413	O
screening	10848655	414	423	O
programme	10848655	424	433	O
,	10848655	434	435	O
and	10848655	436	439	O
to	10848655	440	442	O
report	10848655	443	449	O
the	10848655	450	453	O
adverse	10848655	454	461	B-Outcome
events	10848655	462	468	I-Outcome
associated	10848655	469	479	O
with	10848655	480	484	O
this	10848655	485	489	O
strategy	10848655	490	498	O
.	10848655	499	500	O

METHODS	10848655	501	508	O
Subjects	10848655	509	517	O
between	10848655	518	525	O
the	10848655	526	529	O
ages	10848655	530	534	O
of	10848655	535	537	O
40	10848655	538	540	O
-	10848655	540	541	O
49	10848655	541	543	O
years	10848655	544	549	O
were	10848655	550	554	O
randomly	10848655	555	563	O
selected	10848655	564	572	O
from	10848655	573	577	O
the	10848655	578	581	O
lists	10848655	582	587	O
of	10848655	588	590	O
36	10848655	591	593	O
primary	10848655	594	601	O
care	10848655	602	606	O
centres	10848655	607	614	O
.	10848655	615	616	O

Participants	10848655	617	629	O
attended	10848655	630	638	O
their	10848655	639	644	O
local	10848655	645	650	O
practice	10848655	651	659	O
and	10848655	660	663	O
H.	10848655	664	666	O
pylori	10848655	667	673	O
status	10848655	674	680	O
was	10848655	681	684	O
determined	10848655	685	695	O
by	10848655	696	698	O
13C-urea	10848655	699	707	O
breath	10848655	708	714	O
test	10848655	715	719	O
.	10848655	720	721	O

Infected	10848655	722	730	O
subjects	10848655	731	739	O
were	10848655	740	744	O
randomized	10848655	745	755	O
to	10848655	756	758	O
receive	10848655	759	766	O
omeprazole	10848655	767	777	B-Intervention
20	10848655	778	780	O
mg	10848655	781	783	O
b.d	10848655	784	787	O
.	10848655	787	788	O
,	10848655	789	790	O
clarithromycin	10848655	791	805	B-Intervention
250	10848655	806	809	O
mg	10848655	810	812	O
b.d	10848655	813	816	O
.	10848655	817	818	O
and	10848655	819	822	O
tinidazole	10848655	823	833	B-Intervention
500	10848655	834	837	O
mg	10848655	838	840	O
b.d	10848655	841	844	O
.	10848655	845	846	O

for	10848655	847	850	O
7	10848655	851	852	O
days	10848655	853	857	O
(	10848655	858	859	O
OCT	10848655	860	863	O
)	10848655	864	865	O
or	10848655	866	868	O
identical	10848655	869	878	B-Intervention
placebos	10848655	879	887	I-Intervention
.	10848655	888	889	O

Eradication	10848655	890	901	B-Outcome
was	10848655	902	905	O
determined	10848655	906	916	O
by	10848655	917	919	O
a	10848655	920	921	O
13C-urea	10848655	922	930	O
breath	10848655	931	937	O
test	10848655	938	942	O
6	10848655	943	944	O
months	10848655	945	951	O
and	10848655	952	955	O
2	10848655	956	957	O
years	10848655	958	963	O
after	10848655	964	969	O
the	10848655	970	973	O
first	10848655	974	979	O
visit	10848655	980	985	O
.	10848655	986	987	O

Successful	10848655	988	998	B-Outcome
eradication	10848655	999	1010	I-Outcome
was	10848655	1011	1014	O
defined	10848655	1015	1022	O
as	10848655	1023	1025	O
two	10848655	1026	1029	O
negative	10848655	1030	1038	O
13C-urea	10848655	1039	1047	O
breath	10848655	1048	1054	O
tests	10848655	1055	1060	O
or	10848655	1061	1063	O
one	10848655	1064	1067	O
negative	10848655	1068	1076	O
and	10848655	1077	1080	O
one	10848655	1081	1084	O
missing	10848655	1085	1092	O
test	10848655	1093	1097	O
.	10848655	1098	1099	O

Adverse	10848655	1100	1107	B-Outcome
events	10848655	1108	1114	I-Outcome
and	10848655	1115	1118	O
compliance	10848655	1119	1129	B-Outcome
were	10848655	1130	1134	O
assessed	10848655	1135	1143	O
at	10848655	1144	1146	O
the	10848655	1147	1150	O
6-month	10848655	1151	1158	O
visit	10848655	1159	1164	O
.	10848655	1165	1166	O

RESULTS	10848655	1167	1174	O
A	10848655	1175	1176	O
total	10848655	1177	1182	O
of	10848655	1183	1185	O
32	10848655	1186	1188	O
929	10848655	1189	1192	O
subjects	10848655	1193	1201	O
were	10848655	1202	1206	O
invited	10848655	1207	1214	O
to	10848655	1215	1217	O
attend	10848655	1218	1224	O
,	10848655	1225	1226	O
8407	10848655	1227	1231	O
were	10848655	1232	1236	O
evaluable	10848655	1237	1246	O
,	10848655	1247	1248	O
and	10848655	1249	1252	O
2329	10848655	1253	1257	O
(	10848655	1258	1259	O
28	10848655	1260	1262	O
%	10848655	1263	1264	O
)	10848655	1265	1266	O
of	10848655	1267	1269	O
these	10848655	1270	1275	O
were	10848655	1276	1280	O
H.	10848655	1281	1283	O
pylori-positive	10848655	1284	1299	O
.	10848655	1300	1301	O

A	10848655	1302	1303	O
total	10848655	1304	1309	O
of	10848655	1310	1312	O
1161	10848655	1313	1317	O
subjects	10848655	1318	1326	O
were	10848655	1327	1331	O
randomized	10848655	1332	1342	O
to	10848655	1343	1345	O
OCT	10848655	1346	1349	B-Intervention
and	10848655	1350	1353	O
1163	10848655	1354	1358	O
to	10848655	1359	1361	O
placebo	10848655	1362	1369	B-Intervention
;	10848655	1370	1371	O
over	10848655	1372	1376	O
80	10848655	1377	1379	O
%	10848655	1380	1381	O
returned	10848655	1382	1390	O
for	10848655	1391	1394	O
a	10848655	1395	1396	O
repeat	10848655	1397	1403	O
13C-urea	10848655	1404	1412	O
breath	10848655	1413	1419	O
test	10848655	1420	1424	O
on	10848655	1425	1427	O
at	10848655	1428	1430	O
least	10848655	1431	1436	O
one	10848655	1437	1440	O
occasion	10848655	1441	1449	O
.	10848655	1450	1451	O

The	10848655	1452	1455	O
eradication	10848655	1456	1467	B-Outcome
rates	10848655	1468	1473	I-Outcome
in	10848655	1474	1476	O
those	10848655	1477	1482	O
allocated	10848655	1483	1492	O
to	10848655	1493	1495	O
OCT	10848655	1496	1499	B-Intervention
were	10848655	1500	1504	O
as	10848655	1505	1507	O
follows	10848655	1508	1515	O
:	10848655	1516	1517	O
intention-to-treat	10848655	1518	1536	B-Participant
,	10848655	1537	1538	O
710	10848655	1539	1542	B-Count
out	10848655	1543	1546	I-Count
of	10848655	1547	1549	I-Count
1161	10848655	1550	1554	I-Count
(	10848655	1555	1556	O
61	10848655	1557	1559	O
%	10848655	1560	1561	O
;	10848655	1562	1563	O
95	10848655	1564	1566	O
%	10848655	1567	1568	O
confidence	10848655	1569	1579	O
interval	10848655	1580	1588	O
:	10848655	1589	1590	O
58	10848655	1591	1593	O
-	10848655	1593	1594	O
64	10848655	1594	1596	O
%	10848655	1597	1598	O
)	10848655	1599	1600	O
;	10848655	1601	1602	O
evaluable	10848655	1603	1612	B-Participant
710	10848655	1613	1616	B-Count
out	10848655	1617	1620	I-Count
of	10848655	1621	1623	I-Count
967	10848655	1624	1627	I-Count
(	10848655	1628	1629	O
73	10848655	1630	1632	O
%	10848655	1633	1634	O
;	10848655	1635	1636	O
95	10848655	1637	1639	O
%	10848655	1640	1641	O
CI	10848655	1642	1644	O
:	10848655	1645	1646	O
71	10848655	1647	1649	O
-	10848655	1649	1650	O
76	10848655	1650	1652	O
%	10848655	1653	1654	O
)	10848655	1655	1656	O
;	10848655	1657	1658	O
took	10848655	1659	1663	B-Participant
all	10848655	1664	1667	I-Participant
medication	10848655	1668	1678	I-Participant
645	10848655	1679	1682	B-Count
out	10848655	1683	1686	I-Count
of	10848655	1687	1689	I-Count
769	10848655	1690	1693	I-Count
(	10848655	1694	1695	O
84	10848655	1696	1698	O
%	10848655	1699	1700	O
;	10848655	1701	1702	O
95	10848655	1703	1705	O
%	10848655	1706	1707	O
CI	10848655	1708	1710	O
:	10848655	1711	1712	O
81	10848655	1713	1715	O
-	10848655	1715	1716	O
87	10848655	1716	1718	O
%	10848655	1719	1720	O
)	10848655	1721	1722	O
.	10848655	1723	1724	O

Adverse	10848655	1725	1732	B-Outcome
events	10848655	1733	1739	I-Outcome
occurred	10848655	1740	1748	O
in	10848655	1749	1751	O
45	10848655	1752	1754	B-Count
%	10848655	1755	1756	I-Count
of	10848655	1757	1759	O
the	10848655	1760	1763	O
treatment	10848655	1764	1773	B-Intervention
group	10848655	1774	1779	O
and	10848655	1780	1783	O
in	10848655	1784	1786	O
18	10848655	1787	1789	B-Count
%	10848655	1790	1791	I-Count
of	10848655	1792	1794	O
the	10848655	1795	1798	O
placebo	10848655	1799	1806	B-Intervention
group	10848655	1807	1812	O
(	10848655	1813	1814	O
relative	10848655	1815	1823	O
risk	10848655	1824	1828	O
2.5	10848655	1829	1832	O
;	10848655	1833	1834	O
95	10848655	1835	1837	O
%	10848655	1838	1839	O
CI	10848655	1840	1842	O
:	10848655	1843	1844	O
2.1	10848655	1845	1848	O
-	10848655	1848	1849	O
2.9	10848655	1849	1852	O
)	10848655	1853	1854	O
.	10848655	1855	1856	O

Compliance	10848655	1857	1867	O
,	10848655	1868	1869	O
male	10848655	1870	1874	O
gender	10848655	1875	1881	O
,	10848655	1882	1883	O
no	10848655	1884	1886	O
antibiotic	10848655	1887	1897	O
prescription	10848655	1898	1910	O
in	10848655	1911	1913	O
the	10848655	1914	1917	O
subsequent	10848655	1918	1928	O
2	10848655	1929	1930	O
years	10848655	1931	1936	O
and	10848655	1937	1940	O
experiencing	10848655	1941	1953	O
a	10848655	1954	1955	O
bitter	10848655	1956	1962	O
taste	10848655	1963	1968	O
with	10848655	1969	1973	O
the	10848655	1974	1977	O
medication	10848655	1978	1988	O
were	10848655	1989	1993	O
independently	10848655	1994	2007	O
associated	10848655	2008	2018	O
with	10848655	2019	2023	O
treatment	10848655	2024	2033	B-Outcome
success	10848655	2034	2041	I-Outcome
.	10848655	2042	2043	O

CONCLUSIONS	10848655	2044	2055	O
The	10848655	2056	2059	O
OCT	10848655	2060	2063	B-Intervention
regimen	10848655	2064	2071	I-Intervention
has	10848655	2072	2075	O
an	10848655	2076	2078	O
eradication	10848655	2079	2090	B-Outcome
rate	10848655	2091	2095	I-Outcome
of	10848655	2096	2098	O
61	10848655	2099	2101	B-Observation
%	10848655	2102	2103	I-Observation
in	10848655	2104	2106	O
intention-to-treat	10848655	2107	2125	O
analysis	10848655	2126	2134	O
and	10848655	2135	2138	O
is	10848655	2139	2141	O
therefore	10848655	2142	2151	O
less	10848655	2152	2156	B-Observation
successful	10848655	2157	2167	I-Observation
in	10848655	2168	2170	O
treating	10848655	2171	2179	O
H.	10848655	2180	2182	B-Participant
pylori	10848655	2183	2189	I-Participant
as	10848655	2190	2192	O
part	10848655	2193	2197	O
of	10848655	2198	2200	O
a	10848655	2201	2202	O
screening	10848655	2203	2212	O
programme	10848655	2213	2222	O
compared	10848655	2223	2231	O
with	10848655	2232	2236	O
hospital	10848655	2237	2245	O
studies	10848655	2246	2253	O
in	10848655	2254	2256	O
dyspeptic	10848655	2257	2266	O
patients	10848655	2267	2275	O
.	10848655	2276	2277	O

Reduction	10850381	0	9	B-Observation
of	10850381	10	12	O
oral	10850381	13	17	B-Outcome
mucositis	10850381	18	27	I-Outcome
by	10850381	28	30	O
filgrastim	10850381	31	41	B-Intervention
(	10850381	42	43	I-Intervention
r-metHuG-CSF	10850381	44	56	I-Intervention
)	10850381	57	58	I-Intervention
in	10850381	59	61	O
patients	10850381	62	70	O
receiving	10850381	71	80	O
chemotherapy	10850381	81	93	B-Participant
.	10850381	94	95	O

Mucositis	10850381	96	105	O
,	10850381	106	107	O
the	10850381	108	111	O
inflammation	10850381	112	124	O
and	10850381	125	128	O
necrosis	10850381	129	137	O
of	10850381	138	140	O
mucosal	10850381	141	148	O
membranes	10850381	149	158	O
,	10850381	159	160	O
is	10850381	161	163	O
a	10850381	164	165	O
serious	10850381	166	173	O
and	10850381	174	177	O
debilitating	10850381	178	190	O
consequence	10850381	191	202	O
of	10850381	203	205	O
many	10850381	206	210	O
cancer	10850381	211	217	O
therapies	10850381	218	227	O
.	10850381	228	229	O

We	10850381	230	232	O
were	10850381	233	237	O
interested	10850381	238	248	O
in	10850381	249	251	O
the	10850381	252	255	O
potential	10850381	256	265	O
role	10850381	266	270	O
of	10850381	271	273	O
filgrastim	10850381	274	284	B-Intervention
(	10850381	285	286	I-Intervention
recombinant	10850381	287	298	I-Intervention
methionyl	10850381	299	308	I-Intervention
human	10850381	309	314	I-Intervention
granulocyte	10850381	315	326	I-Intervention
colony-stimulating	10850381	327	345	I-Intervention
factor	10850381	346	352	I-Intervention
,	10850381	353	354	I-Intervention
r-metHuG-CSF	10850381	355	367	I-Intervention
)	10850381	368	369	I-Intervention
in	10850381	370	372	O
the	10850381	373	376	O
reduction	10850381	377	386	B-Observation
of	10850381	387	389	O
mucositis	10850381	390	399	B-Outcome
.	10850381	400	401	O

Patients	10850381	402	410	O
with	10850381	411	415	O
newly	10850381	416	421	B-Participant
diagnosed	10850381	422	431	I-Participant
small-cell	10850381	432	442	I-Participant
lung	10850381	443	447	I-Participant
cancer	10850381	448	454	I-Participant
(	10850381	455	456	I-Participant
SCLC	10850381	457	461	I-Participant
)	10850381	462	463	I-Participant
were	10850381	464	468	O
treated	10850381	469	476	O
with	10850381	477	481	O
CAE	10850381	482	485	B-Intervention
chemotherapy	10850381	486	498	I-Intervention
(	10850381	499	500	I-Intervention
cyclophosphamide	10850381	501	517	I-Intervention
,	10850381	518	519	I-Intervention
doxorubicin	10850381	520	531	I-Intervention
,	10850381	532	533	I-Intervention
and	10850381	534	537	I-Intervention
etoposide	10850381	538	547	I-Intervention
)	10850381	548	549	I-Intervention
and	10850381	550	553	O
placebo	10850381	554	561	B-Intervention
or	10850381	562	564	O
filgrastim	10850381	565	575	B-Intervention
.	10850381	576	577	O

If	10850381	578	580	O
patients	10850381	581	589	O
had	10850381	590	593	O
an	10850381	594	596	O
episode	10850381	597	604	O
of	10850381	605	607	O
febrile	10850381	608	615	B-Outcome
neutropenia	10850381	616	627	I-Outcome
,	10850381	628	629	O
they	10850381	630	634	O
received	10850381	635	643	O
unblinded	10850381	644	653	B-Intervention
filgrastim	10850381	654	664	I-Intervention
in	10850381	665	667	O
subsequent	10850381	668	678	O
CAE	10850381	679	682	O
cycles	10850381	683	689	O
.	10850381	690	691	O

Oral	10850381	692	696	B-Outcome
mucositis	10850381	697	706	I-Outcome
was	10850381	707	710	O
considered	10850381	711	721	O
to	10850381	722	724	O
have	10850381	725	729	O
occurred	10850381	730	738	O
if	10850381	739	741	O
a	10850381	742	743	O
patient	10850381	744	751	O
reported	10850381	752	760	O
any	10850381	761	764	O
clinical	10850381	765	773	O
sign	10850381	774	778	O
or	10850381	779	781	O
symptom	10850381	782	789	O
of	10850381	790	792	O
oral	10850381	793	797	B-Outcome
mucositis	10850381	798	807	I-Outcome
with	10850381	808	812	I-Outcome
or	10850381	813	815	I-Outcome
without	10850381	816	823	I-Outcome
oral	10850381	824	828	I-Outcome
candidiasis	10850381	829	840	I-Outcome
.	10850381	841	842	O

Oral	10850381	843	847	B-Outcome
mucositis	10850381	848	857	I-Outcome
was	10850381	858	861	O
analyzed	10850381	862	870	O
using	10850381	871	876	O
the	10850381	877	880	O
unadjusted	10850381	881	891	O
chi-square	10850381	892	902	O
test	10850381	903	907	O
,	10850381	908	909	O
and	10850381	910	913	O
time	10850381	914	918	B-Outcome
to	10850381	919	921	I-Outcome
first	10850381	922	927	I-Outcome
episode	10850381	928	935	I-Outcome
of	10850381	936	938	I-Outcome
mucositis	10850381	939	948	I-Outcome
was	10850381	949	952	O
analyzed	10850381	953	961	O
using	10850381	962	967	O
the	10850381	968	971	O
stratified	10850381	972	982	O
log-rank	10850381	983	991	O
test	10850381	992	996	O
as	10850381	997	999	O
well	10850381	1000	1004	O
as	10850381	1005	1007	O
the	10850381	1008	1011	O
Cox	10850381	1012	1015	O
proportional	10850381	1016	1028	O
hazards	10850381	1029	1036	O
regression	10850381	1037	1047	O
model	10850381	1048	1053	O
.	10850381	1054	1055	O

During	10850381	1056	1062	O
cycle	10850381	1063	1068	O
1	10850381	1069	1070	O
,	10850381	1071	1072	O
placebo-treated	10850381	1073	1088	B-Intervention
patients	10850381	1089	1097	I-Intervention
had	10850381	1098	1101	O
more	10850381	1102	1106	B-Count
episodes	10850381	1107	1115	B-Outcome
of	10850381	1116	1118	I-Outcome
mucositis	10850381	1119	1128	I-Outcome
(	10850381	1129	1130	O
47	10850381	1131	1133	B-Count
%	10850381	1134	1135	I-Count
)	10850381	1136	1137	O
compared	10850381	1138	1146	O
with	10850381	1147	1151	O
those	10850381	1152	1157	O
patients	10850381	1158	1166	O
randomized	10850381	1167	1177	O
to	10850381	1178	1180	O
filgrastim	10850381	1181	1191	B-Intervention
(	10850381	1192	1193	O
28	10850381	1194	1196	B-Count
%	10850381	1197	1198	I-Count
)	10850381	1199	1200	O
.	10850381	1201	1202	O

Across	10850381	1203	1209	O
all	10850381	1210	1213	O
cycles	10850381	1214	1220	O
of	10850381	1221	1223	O
treatment	10850381	1224	1233	O
,	10850381	1234	1235	O
70	10850381	1236	1238	B-Count
%	10850381	1239	1240	I-Count
of	10850381	1241	1243	O
placebo-treated	10850381	1244	1259	B-Intervention
patients	10850381	1260	1268	O
experienced	10850381	1269	1280	O
mucositis	10850381	1281	1290	B-Outcome
,	10850381	1291	1292	O
compared	10850381	1293	1301	O
with	10850381	1302	1306	O
53	10850381	1307	1309	B-Count
%	10850381	1310	1311	I-Count
of	10850381	1312	1314	I-Count
patients	10850381	1315	1323	I-Count
randomized	10850381	1324	1334	O
to	10850381	1335	1337	O
filgrastim	10850381	1338	1348	B-Intervention
.	10850381	1349	1350	O

A	10850381	1351	1352	O
significant	10850381	1353	1364	B-Observation
reduction	10850381	1365	1374	I-Observation
in	10850381	1375	1377	O
the	10850381	1378	1381	O
incidence	10850381	1382	1391	B-Outcome
of	10850381	1392	1394	I-Outcome
chemotherapy-related	10850381	1395	1415	I-Outcome
oral	10850381	1416	1420	I-Outcome
mucositis	10850381	1421	1430	I-Outcome
occurred	10850381	1431	1439	O
across	10850381	1440	1446	O
multiple	10850381	1447	1455	O
cycles	10850381	1456	1462	O
of	10850381	1463	1465	O
treatment	10850381	1466	1475	O
in	10850381	1476	1478	O
patients	10850381	1479	1487	O
treated	10850381	1488	1495	O
with	10850381	1496	1500	O
filgrastim	10850381	1501	1511	B-Intervention
.	10850381	1512	1513	O

A	10860330	0	1	O
laser-powered	10860330	2	15	B-Intervention
hydrokinetic	10860330	16	28	I-Intervention
system	10860330	29	35	I-Intervention
for	10860330	36	39	O
caries	10860330	40	46	B-Participant
removal	10860330	47	54	I-Participant
and	10860330	55	58	O
cavity	10860330	59	65	B-Participant
preparation	10860330	66	77	I-Participant
.	10860330	78	79	O

BACKGROUND	10860330	80	90	O
Laser	10860330	91	96	O
systems	10860330	97	104	O
have	10860330	105	109	O
been	10860330	110	114	O
developed	10860330	115	124	O
for	10860330	125	128	O
the	10860330	129	132	O
cutting	10860330	133	140	O
of	10860330	141	143	O
dental	10860330	144	150	O
hard	10860330	151	155	O
tissues	10860330	156	163	O
.	10860330	164	165	O

The	10860330	166	169	O
erbium	10860330	170	176	O
,	10860330	177	178	O
chromium	10860330	179	187	O
:	10860330	188	189	O
yttrium-scandium-gallium-garnet	10860330	190	221	O
,	10860330	222	223	O
or	10860330	224	226	O
Er	10860330	227	229	O
,	10860330	230	231	O
Cr	10860330	232	234	O
:	10860330	235	236	O
YSGG	10860330	237	241	O
,	10860330	242	243	O
laser	10860330	244	249	O
system	10860330	250	256	O
used	10860330	257	261	O
in	10860330	262	264	O
conjunction	10860330	265	276	O
with	10860330	277	281	O
an	10860330	282	284	O
air-water	10860330	285	294	O
spray	10860330	295	300	O
has	10860330	301	304	O
been	10860330	305	309	O
shown	10860330	310	315	O
to	10860330	316	318	O
be	10860330	319	321	O
efficacious	10860330	322	333	O
in	10860330	334	336	O
vitro	10860330	337	342	O
for	10860330	343	346	O
cavity	10860330	347	353	O
preparation	10860330	354	365	O
.	10860330	366	367	O

METHODS	10860330	368	375	O
The	10860330	376	379	O
authors	10860330	380	387	O
randomly	10860330	388	396	O
selected	10860330	397	405	O
subjects	10860330	406	414	O
for	10860330	415	418	O
cavity	10860330	419	425	B-Participant
preparation	10860330	426	437	I-Participant
with	10860330	438	442	O
conventional	10860330	443	455	B-Intervention
air	10860330	456	459	I-Intervention
turbine/bur	10860330	460	471	I-Intervention
dental	10860330	472	478	I-Intervention
surgery	10860330	479	486	I-Intervention
or	10860330	487	489	O
an	10860330	490	492	O
Er	10860330	493	495	B-Intervention
,	10860330	496	497	I-Intervention
Cr	10860330	498	500	I-Intervention
:	10860330	501	502	I-Intervention
YSGG	10860330	503	507	I-Intervention
laser-powered	10860330	508	521	I-Intervention
system	10860330	522	528	I-Intervention
using	10860330	529	534	O
a	10860330	535	536	O
split-mouth	10860330	537	548	O
design	10860330	549	555	O
.	10860330	556	557	O

They	10860330	558	562	O
prepared	10860330	563	571	O
Class	10860330	572	577	B-Participant
I	10860330	578	579	I-Participant
,	10860330	580	581	I-Participant
III	10860330	582	585	I-Participant
and	10860330	586	589	I-Participant
V	10860330	590	591	I-Participant
cavities	10860330	592	600	I-Participant
,	10860330	601	602	O
placed	10860330	603	609	B-Participant
resin	10860330	610	615	I-Participant
restorations	10860330	616	628	I-Participant
and	10860330	629	632	O
evaluated	10860330	633	642	O
subjects	10860330	643	651	O
on	10860330	652	654	O
the	10860330	655	658	O
day	10860330	659	662	O
of	10860330	663	665	O
the	10860330	666	669	O
procedure	10860330	670	679	O
and	10860330	680	683	O
30	10860330	684	686	O
days	10860330	687	691	O
and	10860330	692	695	O
six	10860330	696	699	O
months	10860330	700	706	O
postoperatively	10860330	707	722	O
for	10860330	723	726	O
pulp	10860330	727	731	B-Outcome
vitality	10860330	732	740	I-Outcome
,	10860330	741	742	O
recurrent	10860330	743	752	B-Outcome
caries	10860330	753	759	I-Outcome
,	10860330	760	761	O
pain	10860330	762	766	B-Outcome
and	10860330	767	770	I-Outcome
discomfort	10860330	771	781	I-Outcome
,	10860330	782	783	O
and	10860330	784	787	O
restoration	10860330	788	799	B-Outcome
retention	10860330	800	809	I-Outcome
.	10860330	810	811	O

Sixty-seven	10860330	812	823	O
subjects	10860330	824	832	O
completed	10860330	833	842	O
the	10860330	843	846	O
study	10860330	847	852	O
.	10860330	853	854	O

RESULTS	10860330	855	862	O
There	10860330	863	868	O
were	10860330	869	873	O
no	10860330	874	876	O
statistical	10860330	877	888	B-Observation
differences	10860330	889	900	I-Observation
between	10860330	901	908	B-Intervention
the	10860330	909	912	I-Intervention
two	10860330	913	916	I-Intervention
treatment	10860330	917	926	I-Intervention
groups	10860330	927	933	I-Intervention
for	10860330	934	937	O
the	10860330	938	941	O
parameters	10860330	942	952	B-Outcome
measured	10860330	953	961	I-Outcome
with	10860330	962	966	I-Outcome
one	10860330	967	970	I-Outcome
exception	10860330	971	980	I-Outcome
;	10860330	981	982	O
there	10860330	983	988	O
was	10860330	989	992	O
a	10860330	993	994	O
statistically	10860330	995	1008	B-Observation
significant	10860330	1009	1020	I-Observation
decrease	10860330	1021	1029	I-Observation
in	10860330	1030	1032	O
discomfort	10860330	1033	1043	B-Outcome
levels	10860330	1044	1050	I-Outcome
for	10860330	1051	1054	O
the	10860330	1055	1058	O
laser	10860330	1059	1064	B-Intervention
system	10860330	1065	1071	I-Intervention
at	10860330	1072	1074	O
the	10860330	1075	1078	O
time	10860330	1079	1083	O
of	10860330	1084	1086	O
cavity	10860330	1087	1093	B-Participant
preparation	10860330	1094	1105	I-Participant
for	10860330	1106	1109	O
subjects	10860330	1110	1118	O
who	10860330	1119	1122	O
declined	10860330	1123	1131	O
to	10860330	1132	1134	O
receive	10860330	1135	1142	O
local	10860330	1143	1148	O
anesthetic	10860330	1149	1159	O
.	10860330	1160	1161	O

CONCLUSIONS	10860330	1162	1173	O
The	10860330	1174	1177	O
Er	10860330	1178	1180	B-Intervention
,	10860330	1181	1182	I-Intervention
Cr	10860330	1183	1185	I-Intervention
:	10860330	1186	1187	I-Intervention
YSGG	10860330	1188	1192	I-Intervention
laser	10860330	1193	1198	I-Intervention
system	10860330	1199	1205	I-Intervention
is	10860330	1206	1208	O
effective	10860330	1209	1218	B-Observation
for	10860330	1219	1222	O
preparation	10860330	1223	1234	B-Participant
of	10860330	1235	1237	I-Participant
Class	10860330	1238	1243	I-Participant
I	10860330	1244	1245	I-Participant
,	10860330	1246	1247	I-Participant
III	10860330	1248	1251	I-Participant
and	10860330	1252	1255	I-Participant
V	10860330	1256	1257	I-Participant
cavities	10860330	1258	1266	I-Participant
and	10860330	1267	1270	O
resin	10860330	1271	1276	B-Outcome
restorations	10860330	1277	1289	I-Outcome
are	10860330	1290	1293	O
retained	10860330	1294	1302	B-Observation
by	10860330	1303	1305	O
lased	10860330	1306	1311	B-Intervention
tooth	10860330	1312	1317	I-Intervention
surfaces	10860330	1318	1326	I-Intervention
.	10860330	1327	1328	O

CLINICAL	10860330	1329	1337	O
IMPLICATIONS	10860330	1338	1350	O
Hard-tissue	10860330	1351	1362	B-Intervention
cutting	10860330	1363	1370	I-Intervention
lasers	10860330	1371	1377	I-Intervention
are	10860330	1378	1381	O
being	10860330	1382	1387	O
introduced	10860330	1388	1398	O
for	10860330	1399	1402	O
use	10860330	1403	1406	O
in	10860330	1407	1409	O
operative	10860330	1410	1419	O
dentistry	10860330	1420	1429	O
.	10860330	1430	1431	O

In	10860330	1432	1434	O
this	10860330	1435	1439	O
study	10860330	1440	1445	O
,	10860330	1446	1447	O
an	10860330	1448	1450	O
Er	10860330	1451	1453	B-Intervention
,	10860330	1454	1455	I-Intervention
Cr	10860330	1456	1458	I-Intervention
:	10860330	1459	1460	I-Intervention
YSGG	10860330	1461	1465	I-Intervention
laser	10860330	1466	1471	I-Intervention
has	10860330	1472	1475	O
been	10860330	1476	1480	O
shown	10860330	1481	1486	O
to	10860330	1487	1489	O
be	10860330	1490	1492	O
effective	10860330	1493	1502	B-Observation
for	10860330	1503	1506	O
cavity	10860330	1507	1513	B-Participant
preparation	10860330	1514	1525	I-Participant
and	10860330	1526	1529	I-Participant
restoration	10860330	1530	1541	I-Participant
replacement	10860330	1542	1553	I-Participant
.	10860330	1554	1555	O

Plasma	10871578	0	6	B-Outcome
antioxidant	10871578	7	18	I-Outcome
status	10871578	19	25	I-Outcome
after	10871578	26	31	O
high-dose	10871578	32	41	B-Intervention
chemotherapy	10871578	42	54	I-Intervention
:	10871578	55	56	O
a	10871578	57	58	O
randomized	10871578	59	69	O
trial	10871578	70	75	O
of	10871578	76	78	O
parenteral	10871578	79	89	B-Intervention
nutrition	10871578	90	99	I-Intervention
in	10871578	100	102	O
bone	10871578	103	107	B-Participant
marrow	10871578	108	114	I-Participant
transplantation	10871578	115	130	I-Participant
patients	10871578	131	139	O
.	10871578	140	141	O

BACKGROUND	10871578	142	152	O
Chemotherapy	10871578	153	165	O
and	10871578	166	169	O
radiation	10871578	170	179	O
therapy	10871578	180	187	O
result	10871578	188	194	O
in	10871578	195	197	O
increased	10871578	198	207	O
free	10871578	208	212	O
radical	10871578	213	220	O
formation	10871578	221	230	O
and	10871578	231	234	O
depletion	10871578	235	244	O
of	10871578	245	247	O
tissue	10871578	248	254	O
antioxidants	10871578	255	267	O
.	10871578	268	269	O

It	10871578	270	272	O
is	10871578	273	275	O
not	10871578	276	279	O
known	10871578	280	285	O
whether	10871578	286	293	O
parenteral	10871578	294	304	O
nutrition	10871578	305	314	O
(	10871578	315	316	O
PN	10871578	317	319	O
)	10871578	320	321	O
administered	10871578	322	334	O
during	10871578	335	341	O
bone	10871578	342	346	O
marrow	10871578	347	353	O
transplantation	10871578	354	369	O
(	10871578	370	371	O
BMT	10871578	372	375	O
)	10871578	376	377	O
supports	10871578	378	386	O
systemic	10871578	387	395	O
antioxidant	10871578	396	407	O
status	10871578	408	414	O
.	10871578	415	416	O

OBJECTIVE	10871578	417	426	O
The	10871578	427	430	O
aims	10871578	431	435	O
of	10871578	436	438	O
the	10871578	439	442	O
study	10871578	443	448	O
were	10871578	449	453	O
to	10871578	454	456	O
determine	10871578	457	466	O
1	10871578	467	468	O
)	10871578	469	470	O
whether	10871578	471	478	O
high-dose	10871578	479	488	B-Intervention
chemotherapy	10871578	489	501	I-Intervention
decreases	10871578	502	511	B-Observation
concentrations	10871578	512	526	B-Outcome
of	10871578	527	529	I-Outcome
major	10871578	530	535	I-Outcome
circulating	10871578	536	547	I-Outcome
antioxidants	10871578	548	560	I-Outcome
in	10871578	561	563	O
patients	10871578	564	572	O
undergoing	10871578	573	583	O
BMT	10871578	584	587	B-Participant
and	10871578	588	591	O
2	10871578	592	593	O
)	10871578	594	595	O
whether	10871578	596	603	O
administration	10871578	604	618	O
of	10871578	619	621	O
standard	10871578	622	630	B-Intervention
PN	10871578	631	633	I-Intervention
maintains	10871578	634	643	B-Observation
systemic	10871578	644	652	B-Outcome
antioxidant	10871578	653	664	I-Outcome
concentrations	10871578	665	679	I-Outcome
compared	10871578	680	688	O
with	10871578	689	693	O
PN	10871578	694	696	B-Intervention
containing	10871578	697	707	I-Intervention
micronutrients	10871578	708	722	I-Intervention
and	10871578	723	726	I-Intervention
minimal	10871578	727	734	I-Intervention
lipids	10871578	735	741	I-Intervention
alone	10871578	742	747	I-Intervention
.	10871578	748	749	O

DESIGN	10871578	750	756	O
Twenty-four	10871578	757	768	O
BMT	10871578	769	772	B-Participant
patients	10871578	773	781	O
were	10871578	782	786	O
randomly	10871578	787	795	O
assigned	10871578	796	804	O
to	10871578	805	807	O
receive	10871578	808	815	O
either	10871578	816	822	O
standard	10871578	823	831	B-Intervention
PN	10871578	832	834	I-Intervention
containing	10871578	835	845	I-Intervention
conventional	10871578	846	858	I-Intervention
amounts	10871578	859	866	I-Intervention
of	10871578	867	869	I-Intervention
dextrose	10871578	870	878	I-Intervention
,	10871578	879	880	I-Intervention
amino	10871578	881	886	I-Intervention
acids	10871578	887	892	I-Intervention
,	10871578	893	894	I-Intervention
micronutrients	10871578	895	909	I-Intervention
,	10871578	910	911	I-Intervention
and	10871578	912	915	I-Intervention
lipid	10871578	916	921	I-Intervention
(	10871578	922	923	I-Intervention
120	10871578	924	927	I-Intervention
kJ/d	10871578	928	932	I-Intervention
)	10871578	933	934	I-Intervention
or	10871578	935	937	O
a	10871578	938	939	O
solution	10871578	940	948	B-Intervention
containing	10871578	949	959	I-Intervention
only	10871578	960	964	I-Intervention
micronutrients	10871578	965	979	I-Intervention
(	10871578	980	981	I-Intervention
identical	10871578	982	991	I-Intervention
to	10871578	992	994	I-Intervention
those	10871578	995	1000	I-Intervention
in	10871578	1001	1003	I-Intervention
standard	10871578	1004	1012	I-Intervention
PN	10871578	1013	1015	I-Intervention
)	10871578	1016	1017	I-Intervention
and	10871578	1018	1021	I-Intervention
a	10871578	1022	1023	I-Intervention
small	10871578	1024	1029	I-Intervention
amount	10871578	1030	1036	I-Intervention
of	10871578	1037	1039	I-Intervention
lipid	10871578	1040	1045	I-Intervention
(	10871578	1046	1047	I-Intervention
12	10871578	1048	1050	I-Intervention
kJ/d	10871578	1051	1055	I-Intervention
)	10871578	1056	1057	I-Intervention
.	10871578	1058	1059	O

Plasma	10871578	1060	1066	B-Outcome
antioxidant	10871578	1067	1078	I-Outcome
status	10871578	1079	1085	I-Outcome
was	10871578	1086	1089	O
measured	10871578	1090	1098	O
before	10871578	1099	1105	O
conditioning	10871578	1106	1118	B-Intervention
therapy	10871578	1119	1126	I-Intervention
and	10871578	1127	1130	O
serially	10871578	1131	1139	O
at	10871578	1140	1142	O
days	10871578	1143	1147	O
1	10871578	1148	1149	O
,	10871578	1150	1151	O
3	10871578	1152	1153	O
,	10871578	1154	1155	O
7	10871578	1156	1157	O
,	10871578	1158	1159	O
10	10871578	1160	1162	O
,	10871578	1163	1164	O
and	10871578	1165	1168	O
14	10871578	1169	1171	O
after	10871578	1172	1177	O
BMT	10871578	1178	1181	B-Participant
.	10871578	1182	1183	O

RESULTS	10871578	1184	1191	O
Plasma	10871578	1192	1198	B-Outcome
glutathione	10871578	1199	1210	I-Outcome
(	10871578	1211	1212	I-Outcome
GSH	10871578	1213	1216	I-Outcome
)	10871578	1217	1218	I-Outcome
and	10871578	1219	1222	O
alpha-	10871578	1223	1229	B-Outcome
and	10871578	1230	1233	I-Outcome
gamma-tocopherol	10871578	1234	1250	I-Outcome
concentrations	10871578	1251	1265	I-Outcome
decreased	10871578	1266	1275	B-Observation
and	10871578	1276	1279	O
the	10871578	1280	1283	O
GSH	10871578	1284	1287	B-Outcome
redox	10871578	1288	1293	I-Outcome
state	10871578	1294	1299	I-Outcome
became	10871578	1300	1306	O
more	10871578	1307	1311	B-Observation
oxidized	10871578	1312	1320	I-Observation
after	10871578	1321	1326	O
conditioning	10871578	1327	1339	O
chemotherapy	10871578	1340	1352	B-Intervention
.	10871578	1353	1354	O

Plasma	10871578	1355	1361	B-Outcome
cysteine	10871578	1362	1370	I-Outcome
concentrations	10871578	1371	1385	I-Outcome
were	10871578	1386	1390	O
unchanged	10871578	1391	1400	B-Observation
,	10871578	1401	1402	O
whereas	10871578	1403	1410	O
cystine	10871578	1411	1418	B-Outcome
concentrations	10871578	1419	1433	I-Outcome
increased	10871578	1434	1443	B-Observation
.	10871578	1444	1445	O

Plasma	10871578	1446	1452	B-Outcome
vitamin	10871578	1453	1460	I-Outcome
C	10871578	1461	1462	I-Outcome
and	10871578	1463	1466	I-Outcome
zinc	10871578	1467	1471	I-Outcome
concentrations	10871578	1472	1486	I-Outcome
and	10871578	1487	1490	O
GSH	10871578	1491	1494	B-Outcome
peroxidase	10871578	1495	1505	I-Outcome
activity	10871578	1506	1514	I-Outcome
increased	10871578	1515	1524	B-Observation
over	10871578	1525	1529	O
time	10871578	1530	1534	O
.	10871578	1535	1536	O

Plasma	10871578	1537	1543	B-Outcome
alpha-tocopherol	10871578	1544	1560	I-Outcome
concentrations	10871578	1561	1575	I-Outcome
were	10871578	1576	1580	O
lower	10871578	1581	1586	B-Observation
in	10871578	1587	1589	O
patients	10871578	1590	1598	O
given	10871578	1599	1604	O
standard	10871578	1605	1613	B-Intervention
PN	10871578	1614	1616	I-Intervention
.	10871578	1617	1618	O

There	10871578	1619	1624	O
were	10871578	1625	1629	O
no	10871578	1630	1632	O
differences	10871578	1633	1644	B-Observation
in	10871578	1645	1647	O
other	10871578	1648	1653	B-Outcome
plasma	10871578	1654	1660	I-Outcome
antioxidants	10871578	1661	1673	I-Outcome
between	10871578	1674	1681	B-Intervention
groups	10871578	1682	1688	I-Intervention
.	10871578	1689	1690	O

CONCLUSIONS	10871578	1691	1702	O
A	10871578	1703	1704	O
significant	10871578	1705	1716	B-Observation
decline	10871578	1717	1724	I-Observation
in	10871578	1725	1727	O
GSH-glutathione	10871578	1728	1743	B-Outcome
disulfide	10871578	1744	1753	I-Outcome
,	10871578	1754	1755	O
cysteine-cystine	10871578	1756	1772	B-Outcome
,	10871578	1773	1774	O
and	10871578	1775	1778	O
vitamin	10871578	1779	1786	B-Outcome
E	10871578	1787	1788	I-Outcome
status	10871578	1789	1795	I-Outcome
occurs	10871578	1796	1802	O
after	10871578	1803	1808	O
chemotherapy	10871578	1809	1821	B-Intervention
and	10871578	1822	1825	O
BMT	10871578	1826	1829	B-Participant
.	10871578	1830	1831	O

Standard	10871578	1832	1840	B-Intervention
PN	10871578	1841	1843	I-Intervention
does	10871578	1844	1848	O
not	10871578	1849	1852	O
improve	10871578	1853	1860	B-Observation
antioxidant	10871578	1861	1872	B-Outcome
status	10871578	1873	1879	I-Outcome
compared	10871578	1880	1888	O
with	10871578	1889	1893	O
administration	10871578	1894	1908	O
of	10871578	1909	1911	O
micronutrients	10871578	1912	1926	B-Intervention
alone	10871578	1927	1932	I-Intervention
.	10871578	1933	1934	O

Further	10871578	1935	1942	O
evaluation	10871578	1943	1953	O
of	10871578	1954	1956	O
PN	10871578	1957	1959	O
formulations	10871578	1960	1972	O
to	10871578	1973	1975	O
support	10871578	1976	1983	O
patients	10871578	1984	1992	O
undergoing	10871578	1993	2003	O
high-dose	10871578	2004	2013	O
chemotherapy	10871578	2014	2026	O
and	10871578	2027	2030	O
BMT	10871578	2031	2034	O
are	10871578	2035	2038	O
needed	10871578	2039	2045	O
.	10871578	2046	2047	O

Atrophy	10889149	0	7	B-Outcome
and	10889149	8	11	O
intestinal	10889149	12	22	B-Outcome
metaplasia	10889149	23	33	I-Outcome
one	10889149	34	37	O
year	10889149	38	42	O
after	10889149	43	48	O
cure	10889149	49	53	B-Intervention
of	10889149	54	56	O
H.	10889149	57	59	B-Participant
pylori	10889149	60	66	I-Participant
infection	10889149	67	76	I-Participant
:	10889149	77	78	O
a	10889149	79	80	O
prospective	10889149	81	92	O
,	10889149	93	94	O
randomized	10889149	95	105	O
study	10889149	106	111	O
.	10889149	112	113	O

BACKGROUND	10889149	114	124	O
&	10889149	125	126	O
AIMS	10889149	127	131	O
Helicobacter	10889149	132	144	O
pylori-infected	10889149	145	160	O
gastric	10889149	161	168	O
mucosa	10889149	169	175	O
evolves	10889149	176	183	O
through	10889149	184	191	O
stages	10889149	192	198	O
of	10889149	199	201	O
chronic	10889149	202	209	O
gastritis	10889149	210	219	O
,	10889149	220	221	O
intestinal	10889149	222	232	O
metaplasia	10889149	233	243	O
(	10889149	244	245	O
IM	10889149	246	248	O
)	10889149	249	250	O
,	10889149	251	252	O
glandular	10889149	253	262	O
atrophy	10889149	263	270	O
(	10889149	271	272	O
GA	10889149	273	275	O
)	10889149	276	277	O
,	10889149	278	279	O
and	10889149	280	283	O
dysplasia	10889149	284	293	O
before	10889149	294	300	O
carcinoma	10889149	301	310	O
develops	10889149	311	319	O
.	10889149	320	321	O

We	10889149	322	324	O
studied	10889149	325	332	O
if	10889149	333	335	O
H.	10889149	336	338	B-Intervention
pylori	10889149	339	345	I-Intervention
eradication	10889149	346	357	I-Intervention
would	10889149	358	363	O
alter	10889149	364	369	B-Observation
the	10889149	370	373	O
course	10889149	374	380	B-Outcome
of	10889149	381	383	I-Outcome
premalignant	10889149	384	396	I-Outcome
histologic	10889149	397	407	I-Outcome
changes	10889149	408	415	I-Outcome
in	10889149	416	418	O
the	10889149	419	422	O
stomach	10889149	423	430	O
.	10889149	431	432	O

METHODS	10889149	433	440	O
Volunteers	10889149	441	451	O
from	10889149	452	456	O
the	10889149	457	460	O
Yantai	10889149	461	467	O
County	10889149	468	474	O
in	10889149	475	477	O
China	10889149	478	483	O
underwent	10889149	484	493	O
upper	10889149	494	499	B-Participant
endoscopy	10889149	500	509	I-Participant
with	10889149	510	514	O
biopsy	10889149	515	521	O
specimens	10889149	522	531	O
obtained	10889149	532	540	O
from	10889149	541	545	O
the	10889149	546	549	O
antrum	10889149	550	556	O
and	10889149	557	560	O
corpus	10889149	561	567	O
.	10889149	568	569	O

H.	10889149	570	572	B-Participant
pylori-infected	10889149	573	588	I-Participant
subjects	10889149	589	597	O
were	10889149	598	602	O
randomized	10889149	603	613	O
to	10889149	614	616	O
receive	10889149	617	624	O
either	10889149	625	631	O
a	10889149	632	633	O
1-week	10889149	634	640	O
course	10889149	641	647	O
of	10889149	648	650	O
omeprazole	10889149	651	661	B-Intervention
,	10889149	662	663	I-Intervention
amoxicillin	10889149	664	675	I-Intervention
,	10889149	676	677	I-Intervention
and	10889149	678	681	I-Intervention
clarithromycin	10889149	682	696	I-Intervention
(	10889149	697	698	I-Intervention
OAC	10889149	699	702	I-Intervention
)	10889149	703	704	I-Intervention
or	10889149	705	707	O
placebo	10889149	708	715	B-Intervention
.	10889149	716	717	O

At	10889149	718	720	O
1	10889149	721	722	O
year	10889149	723	727	O
,	10889149	728	729	O
endoscopies	10889149	730	741	O
with	10889149	742	746	O
biopsies	10889149	747	755	O
were	10889149	756	760	O
repeated	10889149	761	769	O
.	10889149	770	771	O

RESULTS	10889149	772	779	O
A	10889149	780	781	O
total	10889149	782	787	O
of	10889149	788	790	O
587	10889149	791	794	O
H.	10889149	795	797	B-Participant
pylori-infected	10889149	798	813	I-Participant
subjects	10889149	814	822	O
were	10889149	823	827	O
randomized	10889149	828	838	O
to	10889149	839	841	O
OAC	10889149	842	845	B-Intervention
(	10889149	846	847	O
n	10889149	848	849	O
=	10889149	850	851	O
295	10889149	852	855	O
)	10889149	856	857	O
and	10889149	858	861	O
placebo	10889149	862	869	B-Intervention
(	10889149	870	871	O
n	10889149	872	873	O
=	10889149	874	875	O
292	10889149	876	879	O
)	10889149	880	881	O
.	10889149	882	883	O

At	10889149	884	886	O
1	10889149	887	888	O
year	10889149	889	893	O
,	10889149	894	895	O
H.	10889149	896	898	B-Outcome
pylori	10889149	899	905	I-Outcome
was	10889149	906	909	I-Outcome
eradicated	10889149	910	920	I-Outcome
in	10889149	921	923	I-Outcome
226	10889149	924	927	B-Count
subjects	10889149	928	936	I-Count
assigned	10889149	937	945	O
to	10889149	946	948	O
OAC	10889149	949	952	B-Intervention
.	10889149	953	954	O

In	10889149	955	957	O
the	10889149	958	961	O
placebo	10889149	962	969	B-Intervention
group	10889149	970	975	O
,	10889149	976	977	O
245	10889149	978	981	B-Count
patients	10889149	982	990	I-Count
remained	10889149	991	999	O
H.	10889149	1000	1002	B-Outcome
pylori	10889149	1003	1009	I-Outcome
infected	10889149	1010	1018	I-Outcome
.	10889149	1019	1020	O

Analysis	10889149	1021	1029	O
of	10889149	1030	1032	O
paired	10889149	1033	1039	O
samples	10889149	1040	1047	O
obtained	10889149	1048	1056	O
from	10889149	1057	1061	O
the	10889149	1062	1065	O
same	10889149	1066	1070	O
patients	10889149	1071	1079	O
showed	10889149	1080	1086	O
that	10889149	1087	1091	O
acute	10889149	1092	1097	B-Outcome
and	10889149	1098	1101	I-Outcome
chronic	10889149	1102	1109	I-Outcome
gastritis	10889149	1110	1119	I-Outcome
decreased	10889149	1120	1129	B-Observation
in	10889149	1130	1132	O
both	10889149	1133	1137	O
the	10889149	1138	1141	O
antrum	10889149	1142	1148	O
and	10889149	1149	1152	O
corpus	10889149	1153	1159	O
after	10889149	1160	1165	O
H.	10889149	1166	1168	B-Intervention
pylori	10889149	1169	1175	I-Intervention
eradication	10889149	1176	1187	I-Intervention
(	10889149	1188	1189	O
P	10889149	1190	1191	O
<	10889149	1192	1193	O
0.001	10889149	1194	1199	O
)	10889149	1200	1201	O
and	10889149	1202	1205	O
activity	10889149	1206	1214	B-Outcome
of	10889149	1215	1217	I-Outcome
IM	10889149	1218	1220	I-Outcome
decreased	10889149	1221	1230	B-Observation
in	10889149	1231	1233	O
antrum	10889149	1234	1240	O
(	10889149	1241	1242	O
P	10889149	1243	1244	O
=	10889149	1245	1246	O
0.014	10889149	1247	1252	O
)	10889149	1253	1254	O
.	10889149	1255	1256	O

In	10889149	1257	1259	O
the	10889149	1260	1263	O
H.	10889149	1264	1266	B-Intervention
pylori-infected	10889149	1267	1282	I-Intervention
group	10889149	1283	1288	O
,	10889149	1289	1290	O
antral	10889149	1291	1297	O
biopsy	10889149	1298	1304	B-Participant
specimens	10889149	1305	1314	I-Participant
had	10889149	1315	1318	O
more	10889149	1319	1323	B-Count
pronounced	10889149	1324	1334	B-Outcome
acute	10889149	1335	1340	I-Outcome
gastritis	10889149	1341	1350	I-Outcome
(	10889149	1351	1352	O
P	10889149	1353	1354	O
=	10889149	1355	1356	O
0.01	10889149	1357	1361	O
)	10889149	1362	1363	O
,	10889149	1364	1365	O
whereas	10889149	1366	1373	O
corpus	10889149	1374	1380	B-Participant
specimens	10889149	1381	1390	I-Participant
showed	10889149	1391	1397	O
increased	10889149	1398	1407	B-Observation
acute	10889149	1408	1413	B-Outcome
and	10889149	1414	1417	I-Outcome
chronic	10889149	1418	1425	I-Outcome
gastritis	10889149	1426	1435	I-Outcome
(	10889149	1436	1437	O
P	10889149	1438	1439	O
<	10889149	1440	1441	O
0.001	10889149	1442	1447	O
)	10889149	1448	1449	O
and	10889149	1450	1453	O
a	10889149	1454	1455	O
marginal	10889149	1456	1464	B-Observation
increase	10889149	1465	1473	I-Observation
in	10889149	1474	1476	O
GA	10889149	1477	1479	B-Outcome
(	10889149	1480	1481	O
P	10889149	1482	1483	O
=	10889149	1484	1485	O
0.052	10889149	1486	1491	O
)	10889149	1492	1493	O
.	10889149	1494	1495	O

When	10889149	1496	1500	O
histologic	10889149	1501	1511	O
changes	10889149	1512	1519	O
were	10889149	1520	1524	O
compared	10889149	1525	1533	O
between	10889149	1534	1541	O
the	10889149	1542	1545	O
2	10889149	1546	1547	O
groups	10889149	1548	1554	O
,	10889149	1555	1556	O
decrease	10889149	1557	1565	B-Outcome
in	10889149	1566	1568	I-Outcome
acute	10889149	1569	1574	I-Outcome
and	10889149	1575	1578	I-Outcome
chronic	10889149	1579	1586	I-Outcome
gastritis	10889149	1587	1596	I-Outcome
was	10889149	1597	1600	O
more	10889149	1601	1605	B-Observation
frequent	10889149	1606	1614	I-Observation
after	10889149	1615	1620	O
H.	10889149	1621	1623	B-Intervention
pylori	10889149	1624	1630	I-Intervention
eradication	10889149	1631	1642	I-Intervention
(	10889149	1643	1644	O
P	10889149	1645	1646	O
<	10889149	1647	1648	O
0.001	10889149	1649	1654	O
)	10889149	1655	1656	O
but	10889149	1657	1660	O
changes	10889149	1661	1668	B-Outcome
in	10889149	1669	1671	I-Outcome
IM	10889149	1672	1674	I-Outcome
were	10889149	1675	1679	O
similar	10889149	1680	1687	B-Observation
.	10889149	1688	1689	O

In	10889149	1690	1692	O
the	10889149	1693	1696	O
H.	10889149	1697	1699	B-Intervention
pylori-infected	10889149	1700	1715	I-Intervention
group	10889149	1716	1721	O
,	10889149	1722	1723	O
increase	10889149	1724	1732	B-Observation
in	10889149	1733	1735	O
GA	10889149	1736	1738	B-Outcome
was	10889149	1739	1742	O
seen	10889149	1743	1747	O
in	10889149	1748	1750	O
the	10889149	1751	1754	O
corpus	10889149	1755	1761	B-Participant
(	10889149	1762	1763	O
P	10889149	1764	1765	O
=	10889149	1766	1767	O
0.01	10889149	1768	1772	O
)	10889149	1773	1774	O
.	10889149	1775	1776	O

CONCLUSIONS	10889149	1777	1788	O
At	10889149	1789	1791	O
1	10889149	1792	1793	O
year	10889149	1794	1798	O
,	10889149	1799	1800	O
H.	10889149	1801	1803	B-Intervention
pylori	10889149	1804	1810	I-Intervention
eradication	10889149	1811	1822	I-Intervention
is	10889149	1823	1825	O
beneficial	10889149	1826	1836	B-Observation
in	10889149	1837	1839	I-Observation
preventing	10889149	1840	1850	I-Observation
progression	10889149	1851	1862	B-Outcome
of	10889149	1863	1865	I-Outcome
pathologic	10889149	1866	1876	I-Outcome
changes	10889149	1877	1884	I-Outcome
of	10889149	1885	1887	I-Outcome
the	10889149	1888	1891	I-Outcome
gastric	10889149	1892	1899	I-Outcome
mucosa	10889149	1900	1906	I-Outcome
.	10889149	1907	1908	O

Transesophageal	10901647	0	15	B-Participant
echocardiography	10901647	16	32	I-Participant
in	10901647	33	35	O
quantification	10901647	36	50	B-Outcome
of	10901647	51	53	I-Outcome
emboli	10901647	54	60	I-Outcome
during	10901647	61	67	O
femoral	10901647	68	75	B-Participant
nailing	10901647	76	83	I-Participant
:	10901647	84	85	O
reamed	10901647	86	92	B-Intervention
versus	10901647	93	99	O
unreamed	10901647	100	108	B-Intervention
techniques	10901647	109	119	O
.	10901647	120	121	O

We	10901647	122	124	O
quantified	10901647	125	135	O
the	10901647	136	139	O
embolic	10901647	140	147	B-Outcome
load	10901647	148	152	I-Outcome
to	10901647	153	155	I-Outcome
the	10901647	156	159	I-Outcome
lungs	10901647	160	165	I-Outcome
created	10901647	166	173	O
with	10901647	174	178	O
two	10901647	179	182	O
different	10901647	183	192	O
techniques	10901647	193	203	B-Intervention
of	10901647	204	206	I-Intervention
femoral	10901647	207	214	I-Intervention
nailing	10901647	215	222	I-Intervention
.	10901647	223	224	O

Eleven	10901647	225	231	O
patients	10901647	232	240	O
with	10901647	241	245	O
12	10901647	246	248	O
traumatic	10901647	249	258	B-Participant
femur	10901647	259	264	I-Participant
fractures	10901647	265	274	I-Participant
were	10901647	275	279	O
randomized	10901647	280	290	O
to	10901647	291	293	O
reamed	10901647	294	300	B-Intervention
(	10901647	301	302	O
7	10901647	303	304	O
fractures	10901647	305	314	O
)	10901647	315	316	O
and	10901647	317	320	O
unreamed	10901647	321	329	B-Intervention
(	10901647	330	331	O
5	10901647	332	333	O
fractures	10901647	334	343	O
)	10901647	344	345	O
groups	10901647	346	352	O
.	10901647	353	354	O

Intramedullary	10901647	355	369	O
nailing	10901647	370	377	O
was	10901647	378	381	O
with	10901647	382	386	O
the	10901647	387	390	O
AO/ASIF	10901647	391	398	O
*	10901647	398	399	O
universal	10901647	400	409	O
reamed	10901647	410	416	O
or	10901647	417	419	O
unreamed	10901647	420	428	O
nail	10901647	429	433	O
.	10901647	434	435	O

Transesophageal	10901647	436	451	O
echocardiography	10901647	452	468	O
(	10901647	469	470	O
TEE	10901647	471	474	O
)	10901647	475	476	O
was	10901647	477	480	O
used	10901647	481	485	O
to	10901647	486	488	O
evaluate	10901647	489	497	O
the	10901647	498	501	O
quantity	10901647	502	510	B-Outcome
and	10901647	511	514	I-Outcome
quality	10901647	515	522	I-Outcome
of	10901647	523	525	I-Outcome
emboli	10901647	526	532	I-Outcome
generated	10901647	533	542	O
by	10901647	543	545	O
nailing	10901647	546	553	B-Intervention
.	10901647	554	555	O

Data	10901647	556	560	O
were	10901647	561	565	O
analyzed	10901647	566	574	O
using	10901647	575	580	O
software	10901647	581	589	O
that	10901647	590	594	O
digitized	10901647	595	604	O
the	10901647	605	608	O
TEE	10901647	609	612	O
images	10901647	613	619	O
and	10901647	620	623	O
quantified	10901647	624	634	O
the	10901647	635	638	O
area	10901647	639	643	O
of	10901647	644	646	O
embolic	10901647	647	654	O
particles	10901647	655	664	O
in	10901647	665	667	O
each	10901647	668	672	O
frame	10901647	673	678	O
.	10901647	679	680	O

The	10901647	681	684	O
duration	10901647	685	693	B-Outcome
of	10901647	694	696	I-Outcome
each	10901647	697	701	I-Outcome
level	10901647	702	707	I-Outcome
of	10901647	708	710	I-Outcome
embolic	10901647	711	718	I-Outcome
phenomena	10901647	719	728	I-Outcome
(	10901647	729	730	O
zero	10901647	731	735	O
,	10901647	736	737	O
moderate	10901647	738	746	O
,	10901647	747	748	O
severe	10901647	749	755	O
)	10901647	756	757	O
was	10901647	758	761	O
used	10901647	762	766	O
to	10901647	767	769	O
determine	10901647	770	779	O
total	10901647	780	785	B-Outcome
embolic	10901647	786	793	I-Outcome
load	10901647	794	798	I-Outcome
with	10901647	799	803	O
various	10901647	804	811	O
steps	10901647	812	817	O
(	10901647	818	819	O
fracture	10901647	820	828	O
manipulation	10901647	829	841	O
,	10901647	842	843	O
proximal	10901647	844	852	O
portal	10901647	853	859	O
opening	10901647	860	867	O
,	10901647	868	869	O
reaming	10901647	870	877	O
,	10901647	878	879	O
and	10901647	880	883	O
nail	10901647	884	888	O
passage	10901647	889	896	O
)	10901647	897	898	O
.	10901647	899	900	O

Manual	10901647	901	907	B-Outcome
grading	10901647	908	915	I-Outcome
of	10901647	916	918	I-Outcome
emboli	10901647	919	925	I-Outcome
correlated	10901647	926	936	B-Observation
highly	10901647	937	943	I-Observation
with	10901647	944	948	O
software	10901647	949	957	B-Outcome
quantification	10901647	958	972	I-Outcome
.	10901647	973	974	O

Our	10901647	975	978	O
data	10901647	979	983	O
confirm	10901647	984	991	O
the	10901647	992	995	O
presence	10901647	996	1004	B-Observation
and	10901647	1005	1008	I-Observation
similarity	10901647	1009	1019	I-Observation
of	10901647	1020	1022	O
emboli	10901647	1023	1029	B-Outcome
generation	10901647	1030	1040	I-Outcome
with	10901647	1041	1045	O
both	10901647	1046	1050	B-Intervention
methods	10901647	1051	1058	I-Intervention
of	10901647	1059	1061	I-Intervention
intramedullary	10901647	1062	1076	I-Intervention
nailing	10901647	1077	1084	I-Intervention
.	10901647	1085	1086	O

Unreamed	10901647	1087	1095	B-Intervention
nails	10901647	1096	1101	I-Intervention
do	10901647	1102	1104	O
not	10901647	1105	1108	O
protect	10901647	1109	1116	B-Observation
the	10901647	1117	1120	O
patient	10901647	1121	1128	O
from	10901647	1129	1133	O
pulmonary	10901647	1134	1143	B-Outcome
embolization	10901647	1144	1156	I-Outcome
of	10901647	1157	1159	I-Outcome
marrow	10901647	1160	1166	I-Outcome
contents	10901647	1167	1175	I-Outcome
.	10901647	1176	1177	O

[	10902449	0	1	O
Comparative	10902449	2	13	O
study	10902449	14	19	O
between	10902449	20	27	O
5	10902449	28	29	B-Intervention
%	10902449	30	31	I-Intervention
prilocaine	10902449	32	42	I-Intervention
and	10902449	43	46	O
2	10902449	47	48	B-Intervention
%	10902449	49	50	I-Intervention
mepivacaine	10902449	51	62	I-Intervention
by	10902449	63	65	O
the	10902449	66	69	O
subarachnoid	10902449	70	82	O
route	10902449	83	88	O
in	10902449	89	91	O
transurethral	10902449	92	105	B-Participant
resections	10902449	106	116	I-Participant
]	10902449	117	118	O
.	10902449	119	120	O

OBJECTIVE	10902449	121	130	O
To	10902449	131	133	O
compare	10902449	134	141	O
the	10902449	142	145	O
duration	10902449	146	154	B-Outcome
of	10902449	155	157	I-Outcome
spinal	10902449	158	164	I-Outcome
block	10902449	165	170	I-Outcome
with	10902449	171	175	O
5	10902449	176	177	B-Intervention
%	10902449	178	179	I-Intervention
prilocaine	10902449	180	190	I-Intervention
and	10902449	191	194	O
2	10902449	195	196	B-Intervention
%	10902449	197	198	I-Intervention
mepivacaine	10902449	199	210	I-Intervention
in	10902449	211	213	O
short	10902449	214	219	B-Participant
procedures	10902449	220	230	I-Participant
for	10902449	231	234	O
transurethral	10902449	235	248	B-Participant
resection	10902449	249	258	I-Participant
and	10902449	259	262	O
to	10902449	263	265	O
assess	10902449	266	272	O
possible	10902449	273	281	B-Outcome
complications	10902449	282	295	I-Outcome
in	10902449	296	298	O
the	10902449	299	302	O
immediate	10902449	303	312	O
postoperative	10902449	313	326	O
period	10902449	327	333	O
.	10902449	334	335	O

MATERIAL	10902449	336	344	O
AND	10902449	345	348	O
METHODS	10902449	349	356	O
Fifty-seven	10902449	357	368	O
patients	10902449	369	377	O
scheduled	10902449	378	387	O
for	10902449	388	391	O
transurethral	10902449	392	405	B-Participant
resection	10902449	406	415	I-Participant
of	10902449	416	418	I-Participant
the	10902449	419	422	I-Participant
prostate	10902449	423	431	I-Participant
or	10902449	432	434	I-Participant
a	10902449	435	436	I-Participant
vesical	10902449	437	444	I-Participant
tumor	10902449	445	450	I-Participant
.	10902449	451	452	O

Patients	10902449	453	461	O
were	10902449	462	466	O
ASA	10902449	467	470	B-Participant
I-III	10902449	471	476	I-Participant
,	10902449	477	478	O
over	10902449	479	483	O
55	10902449	484	486	O
years	10902449	487	492	O
of	10902449	493	495	O
age	10902449	496	499	O
and	10902449	500	503	O
randomly	10902449	504	512	O
assigned	10902449	513	521	O
to	10902449	522	524	O
two	10902449	525	528	O
groups	10902449	529	535	O
to	10902449	536	538	O
receive	10902449	539	546	O
5	10902449	547	548	B-Intervention
%	10902449	549	550	I-Intervention
prilocaine	10902449	551	561	I-Intervention
(	10902449	562	563	O
1	10902449	564	565	O
mg/kg	10902449	566	571	O
,	10902449	572	573	O
n	10902449	574	575	O
=	10902449	576	577	O
27	10902449	578	580	O
)	10902449	581	582	O
or	10902449	583	585	O
2	10902449	586	587	B-Intervention
%	10902449	588	589	I-Intervention
mepivacaine	10902449	590	601	I-Intervention
(	10902449	602	603	O
0.8	10902449	604	607	O
mg/kg	10902449	608	613	O
,	10902449	614	615	O
n	10902449	616	617	O
=	10902449	618	619	O
30	10902449	620	622	O
)	10902449	623	624	O
.	10902449	625	626	O

We	10902449	627	629	O
collected	10902449	630	639	O
data	10902449	640	644	O
on	10902449	645	647	O
anesthetic	10902449	648	658	O
technique	10902449	659	668	O
,	10902449	669	670	O
levels	10902449	671	677	B-Outcome
of	10902449	678	680	I-Outcome
extension	10902449	681	690	I-Outcome
of	10902449	691	693	I-Outcome
motor	10902449	694	699	I-Outcome
and	10902449	700	703	I-Outcome
sensory	10902449	704	711	I-Outcome
blockades	10902449	712	721	I-Outcome
,	10902449	722	723	O
duration	10902449	724	732	B-Outcome
of	10902449	733	735	I-Outcome
blockades	10902449	736	745	I-Outcome
and	10902449	746	749	O
complications	10902449	750	763	B-Outcome
within	10902449	764	770	O
the	10902449	771	774	O
first	10902449	775	780	O
24	10902449	781	783	O
hours	10902449	784	789	O
after	10902449	790	795	O
surgery	10902449	796	803	B-Participant
.	10902449	804	805	O

RESULTS	10902449	806	813	O
Demographic	10902449	814	825	O
data	10902449	826	830	O
,	10902449	831	832	O
ASA	10902449	833	836	O
classification	10902449	837	851	O
and	10902449	852	855	O
duration	10902449	856	864	O
of	10902449	865	867	O
surgery	10902449	868	875	O
were	10902449	876	880	O
similar	10902449	881	888	O
in	10902449	889	891	O
both	10902449	892	896	O
groups	10902449	897	903	O
.	10902449	904	905	O

We	10902449	906	908	O
found	10902449	909	914	O
statistically	10902449	915	928	B-Observation
significant	10902449	929	940	I-Observation
differences	10902449	941	952	I-Observation
(	10902449	953	954	O
p	10902449	955	956	O
<	10902449	957	958	O
0.05	10902449	959	963	O
)	10902449	964	965	O
in	10902449	966	968	O
duration	10902449	969	977	B-Outcome
of	10902449	978	980	I-Outcome
sensory	10902449	981	988	I-Outcome
blockade	10902449	989	997	I-Outcome
(	10902449	998	999	O
120.92	10902449	1000	1006	B-Observation
+	10902449	1007	1008	I-Observation
/-	10902449	1008	1010	I-Observation
36.21	10902449	1011	1016	I-Observation
min	10902449	1017	1020	I-Observation
with	10902449	1021	1025	O
prilocaine	10902449	1026	1036	B-Intervention
and	10902449	1037	1040	O
145.83	10902449	1041	1047	B-Observation
+	10902449	1048	1049	I-Observation
/-	10902449	1049	1051	I-Observation
35.81	10902449	1052	1057	I-Observation
min	10902449	1058	1061	I-Observation
with	10902449	1062	1066	O
mepivacaine	10902449	1067	1078	B-Intervention
)	10902449	1079	1080	O
and	10902449	1081	1084	O
in	10902449	1085	1087	O
motor	10902449	1088	1093	B-Outcome
blockade	10902449	1094	1102	I-Outcome
(	10902449	1103	1104	O
106.29	10902449	1105	1111	B-Observation
+	10902449	1112	1113	I-Observation
/-	10902449	1113	1115	I-Observation
38.16	10902449	1116	1121	I-Observation
min	10902449	1122	1125	I-Observation
with	10902449	1126	1130	O
prilocaine	10902449	1131	1141	B-Intervention
and	10902449	1142	1145	O
133.16	10902449	1146	1152	B-Observation
+	10902449	1153	1154	I-Observation
/-	10902449	1154	1156	I-Observation
42.21	10902449	1157	1162	I-Observation
min	10902449	1163	1166	I-Observation
with	10902449	1167	1171	O
mepivacaine	10902449	1172	1183	B-Intervention
)	10902449	1184	1185	O
.	10902449	1186	1187	O

Five	10902449	1188	1192	B-Count
cases	10902449	1193	1198	I-Count
of	10902449	1199	1201	O
hypotension	10902449	1202	1213	B-Outcome
and	10902449	1214	1217	O
4	10902449	1218	1219	B-Count
of	10902449	1220	1222	O
bradycardia	10902449	1223	1234	B-Outcome
occurred	10902449	1235	1243	O
in	10902449	1244	1246	O
each	10902449	1247	1251	B-Intervention
group	10902449	1252	1257	I-Intervention
and	10902449	1258	1261	O
one	10902449	1262	1265	B-Count
patient	10902449	1266	1273	I-Count
in	10902449	1274	1276	O
the	10902449	1277	1280	O
mepivacaine	10902449	1281	1292	B-Intervention
group	10902449	1293	1298	O
suffered	10902449	1299	1307	O
slight	10902449	1308	1314	B-Outcome
postoperative	10902449	1315	1328	I-Outcome
cephalea	10902449	1329	1337	I-Outcome
.	10902449	1338	1339	O

CONCLUSIONS	10902449	1340	1351	O
Both	10902449	1352	1356	B-Intervention
local	10902449	1357	1362	I-Intervention
anesthetics	10902449	1363	1374	I-Intervention
offer	10902449	1375	1380	O
good	10902449	1381	1385	B-Observation
surgical	10902449	1386	1394	B-Outcome
conditions	10902449	1395	1405	I-Outcome
with	10902449	1406	1410	I-Outcome
hemodynamic	10902449	1411	1422	I-Outcome
stability	10902449	1423	1432	I-Outcome
and	10902449	1433	1436	O
few	10902449	1437	1440	B-Count
complications	10902449	1441	1454	B-Outcome
.	10902449	1455	1456	O

The	10902449	1457	1460	O
duration	10902449	1461	1469	B-Outcome
of	10902449	1470	1472	I-Outcome
sensory	10902449	1473	1480	I-Outcome
and	10902449	1481	1484	I-Outcome
motor	10902449	1485	1490	I-Outcome
blockade	10902449	1491	1499	I-Outcome
is	10902449	1500	1502	O
shorter	10902449	1503	1510	B-Observation
with	10902449	1511	1515	O
prilocaine	10902449	1516	1526	B-Intervention
than	10902449	1527	1531	O
with	10902449	1532	1536	O
mepivacaine	10902449	1537	1548	B-Intervention
,	10902449	1549	1550	O
making	10902449	1551	1557	O
prilocaine	10902449	1558	1568	B-Intervention
more	10902449	1569	1573	B-Observation
appropriate	10902449	1574	1585	I-Observation
for	10902449	1586	1589	O
short	10902449	1590	1595	O
interventions	10902449	1596	1609	O
.	10902449	1610	1611	O

5-fluorouracil	10939601	0	14	B-Intervention
plus	10939601	15	19	I-Intervention
folinic	10939601	20	27	I-Intervention
acid	10939601	28	32	I-Intervention
with	10939601	33	37	I-Intervention
or	10939601	38	40	I-Intervention
without	10939601	41	48	I-Intervention
ifosfamide	10939601	49	59	I-Intervention
in	10939601	60	62	O
advanced	10939601	63	71	B-Participant
colorectal	10939601	72	82	I-Participant
cancer	10939601	83	89	I-Participant
:	10939601	90	91	O
a	10939601	92	93	O
phase	10939601	94	99	O
II	10939601	100	102	O
randomized	10939601	103	113	O
trial	10939601	114	119	O
.	10939601	120	121	O

AIM	10939601	122	125	O
This	10939601	126	130	O
phase	10939601	131	136	O
II	10939601	137	139	O
trial	10939601	140	145	O
evaluated	10939601	146	155	O
the	10939601	156	159	O
biomodulation	10939601	160	173	B-Outcome
of	10939601	174	176	O
5-fluorouracil	10939601	177	191	B-Intervention
(	10939601	192	193	I-Intervention
5-FU	10939601	194	198	I-Intervention
)	10939601	199	200	I-Intervention
plus	10939601	201	205	I-Intervention
folinic	10939601	206	213	I-Intervention
acid	10939601	214	218	I-Intervention
(	10939601	219	220	I-Intervention
FA	10939601	221	223	I-Intervention
)	10939601	224	225	I-Intervention
with	10939601	226	230	I-Intervention
or	10939601	231	233	I-Intervention
without	10939601	234	241	I-Intervention
ifosfamide	10939601	242	252	I-Intervention
(	10939601	253	254	I-Intervention
IFO	10939601	255	258	I-Intervention
)	10939601	259	260	I-Intervention
in	10939601	261	263	O
chemotherapy-naive	10939601	264	282	B-Participant
patients	10939601	283	291	O
with	10939601	292	296	O
colorectal	10939601	297	307	B-Participant
cancer	10939601	308	314	I-Participant
.	10939601	315	316	O

PATIENTS	10939601	317	325	O
AND	10939601	326	329	O
METHODS	10939601	330	337	O
Forty-eight	10939601	338	349	O
patients	10939601	350	358	O
were	10939601	359	363	O
randomized	10939601	364	374	O
to	10939601	375	377	O
receive	10939601	378	385	O
:	10939601	386	387	O
FA	10939601	388	390	B-Intervention
(	10939601	391	392	I-Intervention
25	10939601	393	395	I-Intervention
mg/m2	10939601	396	401	I-Intervention
iv	10939601	402	404	I-Intervention
bolus	10939601	405	410	I-Intervention
days	10939601	411	415	I-Intervention
1	10939601	416	417	I-Intervention
to	10939601	418	420	I-Intervention
3	10939601	421	422	I-Intervention
)	10939601	423	424	I-Intervention
,	10939601	425	426	I-Intervention
followed	10939601	427	435	I-Intervention
by	10939601	436	438	I-Intervention
5-FU	10939601	439	443	I-Intervention
(	10939601	444	445	I-Intervention
750	10939601	446	449	I-Intervention
mg/m2	10939601	450	455	I-Intervention
iv	10939601	456	458	I-Intervention
bolus	10939601	459	464	I-Intervention
days	10939601	465	469	I-Intervention
1	10939601	470	471	I-Intervention
to	10939601	472	474	I-Intervention
3	10939601	475	476	I-Intervention
)	10939601	477	478	I-Intervention
,	10939601	479	480	O
arm	10939601	481	484	O
A	10939601	485	486	O
;	10939601	487	488	O
or	10939601	489	491	O
FA	10939601	492	494	B-Intervention
(	10939601	495	496	I-Intervention
25	10939601	497	499	I-Intervention
mg/m2	10939601	500	505	I-Intervention
iv	10939601	506	508	I-Intervention
bolus	10939601	509	514	I-Intervention
days	10939601	515	519	I-Intervention
1	10939601	520	521	I-Intervention
to	10939601	522	524	I-Intervention
3	10939601	525	526	I-Intervention
)	10939601	527	528	I-Intervention
,	10939601	529	530	I-Intervention
followed	10939601	531	539	I-Intervention
by	10939601	540	542	I-Intervention
5-FU	10939601	543	547	I-Intervention
(	10939601	548	549	I-Intervention
750	10939601	550	553	I-Intervention
mg/m2	10939601	554	559	I-Intervention
iv	10939601	560	562	I-Intervention
bolus	10939601	563	568	I-Intervention
days	10939601	569	573	I-Intervention
1	10939601	574	575	I-Intervention
to	10939601	576	578	I-Intervention
3	10939601	579	580	I-Intervention
)	10939601	581	582	I-Intervention
plus	10939601	583	587	I-Intervention
IFO	10939601	588	591	I-Intervention
(	10939601	592	593	I-Intervention
2,000	10939601	594	599	I-Intervention
mg/m2	10939601	600	605	I-Intervention
in	10939601	606	608	I-Intervention
1000	10939601	609	613	I-Intervention
mL	10939601	614	616	I-Intervention
5	10939601	617	618	I-Intervention
%	10939601	619	620	I-Intervention
dextrose	10939601	621	629	I-Intervention
in	10939601	630	632	I-Intervention
a	10939601	633	634	I-Intervention
2-hr	10939601	635	639	I-Intervention
infusion	10939601	640	648	I-Intervention
,	10939601	649	650	I-Intervention
days	10939601	651	655	I-Intervention
1	10939601	656	657	I-Intervention
to	10939601	658	660	I-Intervention
3	10939601	661	662	I-Intervention
)	10939601	663	664	I-Intervention
,	10939601	665	666	O
arm	10939601	667	670	O
B.	10939601	671	673	O
Mesna	10939601	674	679	O
was	10939601	680	683	O
added	10939601	684	689	O
during	10939601	690	696	O
and	10939601	697	700	O
after	10939601	701	706	O
IFO	10939601	707	710	O
to	10939601	711	713	O
prevent	10939601	714	721	O
hemorrhagic	10939601	722	733	O
cystitis	10939601	734	742	O
.	10939601	743	744	O

Treatment	10939601	745	754	O
was	10939601	755	758	O
repeated	10939601	759	767	O
every	10939601	768	773	O
21	10939601	774	776	O
days	10939601	777	781	O
in	10939601	782	784	O
both	10939601	785	789	O
arms	10939601	790	794	O
.	10939601	795	796	O

RESULTS	10939601	797	804	O
Forty-five	10939601	805	815	O
patients	10939601	816	824	O
were	10939601	825	829	O
assessable	10939601	830	840	O
for	10939601	841	844	O
response	10939601	845	853	O
:	10939601	854	855	O
in	10939601	856	858	O
arm	10939601	859	862	B-Intervention
A	10939601	863	864	I-Intervention
,	10939601	865	866	O
5	10939601	867	868	B-Count
patients	10939601	869	877	I-Count
achieved	10939601	878	886	O
a	10939601	887	888	O
partial	10939601	889	896	B-Outcome
response	10939601	897	905	I-Outcome
(	10939601	906	907	O
overall	10939601	908	915	B-Outcome
response	10939601	916	924	I-Outcome
,	10939601	925	926	O
25	10939601	927	929	B-Count
%	10939601	930	931	I-Count
)	10939601	932	933	O
,	10939601	934	935	O
and	10939601	936	939	O
in	10939601	940	942	O
arm	10939601	943	946	B-Intervention
B	10939601	947	948	I-Intervention
,	10939601	949	950	O
2	10939601	951	952	B-Count
patients	10939601	953	961	I-Count
achieved	10939601	962	970	O
a	10939601	971	972	O
complete	10939601	973	981	B-Outcome
and	10939601	982	985	O
1	10939601	986	987	B-Count
a	10939601	988	989	O
partial	10939601	990	997	B-Outcome
response	10939601	998	1006	I-Outcome
(	10939601	1007	1008	O
overall	10939601	1009	1016	B-Outcome
response	10939601	1017	1025	I-Outcome
,	10939601	1026	1027	O
12	10939601	1028	1030	B-Count
%	10939601	1031	1032	I-Count
)	10939601	1033	1034	O
.	10939601	1035	1036	O

Time	10939601	1037	1041	B-Outcome
to	10939601	1042	1044	I-Outcome
failure	10939601	1045	1052	I-Outcome
was	10939601	1053	1056	O
3.5	10939601	1057	1060	B-Observation
months	10939601	1061	1067	I-Observation
(	10939601	1068	1069	O
range	10939601	1070	1075	O
,	10939601	1076	1077	O
1	10939601	1078	1079	O
-	10939601	1079	1080	O
38	10939601	1080	1082	O
)	10939601	1083	1084	O
in	10939601	1085	1087	O
patients	10939601	1088	1096	O
treated	10939601	1097	1104	O
with	10939601	1105	1109	O
5-FU	10939601	1110	1114	B-Intervention
plus	10939601	1115	1119	I-Intervention
FA	10939601	1120	1122	I-Intervention
,	10939601	1123	1124	O
and	10939601	1125	1128	O
3	10939601	1129	1130	B-Observation
months	10939601	1131	1137	I-Observation
(	10939601	1138	1139	O
range	10939601	1140	1145	O
,	10939601	1146	1147	O
1	10939601	1148	1149	O
-	10939601	1149	1150	O
21	10939601	1150	1152	O
)	10939601	1153	1154	O
in	10939601	1155	1157	O
patients	10939601	1158	1166	O
treated	10939601	1167	1174	O
with	10939601	1175	1179	O
the	10939601	1180	1183	O
IFO	10939601	1184	1187	B-Intervention
combination	10939601	1188	1199	I-Intervention
.	10939601	1200	1201	O

The	10939601	1202	1205	O
median	10939601	1206	1212	B-Outcome
survival	10939601	1213	1221	I-Outcome
time	10939601	1222	1226	I-Outcome
was	10939601	1227	1230	O
13.5	10939601	1231	1235	B-Observation
months	10939601	1236	1242	I-Observation
(	10939601	1243	1244	O
range	10939601	1245	1250	O
,	10939601	1251	1252	O
1	10939601	1253	1254	O
-	10939601	1254	1255	O
49	10939601	1255	1257	O
months	10939601	1258	1264	O
)	10939601	1265	1266	O
in	10939601	1267	1269	O
arm	10939601	1270	1273	B-Intervention
A	10939601	1274	1275	I-Intervention
and	10939601	1276	1279	O
16	10939601	1280	1282	B-Observation
months	10939601	1283	1289	I-Observation
(	10939601	1290	1291	O
range	10939601	1292	1297	O
,	10939601	1298	1299	O
1	10939601	1300	1301	O
-	10939601	1301	1302	O
43	10939601	1302	1304	O
months	10939601	1305	1311	O
)	10939601	1312	1313	O
in	10939601	1314	1316	O
arm	10939601	1317	1320	B-Intervention
B	10939601	1321	1322	I-Intervention
.	10939601	1323	1324	O

Diarrhea	10939601	1325	1333	B-Outcome
,	10939601	1334	1335	O
stomatitis	10939601	1336	1346	B-Outcome
and	10939601	1347	1350	O
vomiting	10939601	1351	1359	B-Outcome
were	10939601	1360	1364	O
the	10939601	1365	1368	O
most	10939601	1369	1373	B-Observation
common	10939601	1374	1380	I-Observation
nonhematologic	10939601	1381	1395	B-Outcome
toxicities	10939601	1396	1406	I-Outcome
in	10939601	1407	1409	O
both	10939601	1410	1414	B-Intervention
arms	10939601	1415	1419	I-Intervention
.	10939601	1420	1421	O

The	10939601	1422	1425	O
most	10939601	1426	1430	B-Observation
notable	10939601	1431	1438	I-Observation
hematologic	10939601	1439	1450	B-Outcome
toxicity	10939601	1451	1459	I-Outcome
was	10939601	1460	1463	O
leukopenia	10939601	1464	1474	B-Outcome
;	10939601	1475	1476	O
15	10939601	1477	1479	B-Count
%	10939601	1480	1481	I-Count
and	10939601	1482	1485	O
20	10939601	1486	1488	B-Count
%	10939601	1489	1490	I-Count
of	10939601	1491	1493	I-Count
patients	10939601	1494	1502	I-Count
experienced	10939601	1503	1514	O
grade	10939601	1515	1520	B-Outcome
4	10939601	1521	1522	I-Outcome
in	10939601	1523	1525	O
arm	10939601	1526	1529	B-Intervention
A	10939601	1530	1531	I-Intervention
and	10939601	1532	1535	O
arm	10939601	1536	1539	B-Intervention
B	10939601	1540	1541	I-Intervention
,	10939601	1542	1543	O
respectively	10939601	1544	1556	O
.	10939601	1557	1558	O

CONCLUSIONS	10939601	1559	1570	O
IFO	10939601	1571	1574	B-Intervention
does	10939601	1575	1579	O
not	10939601	1580	1583	O
increase	10939601	1584	1592	B-Observation
the	10939601	1593	1596	O
activity	10939601	1597	1605	B-Outcome
of	10939601	1606	1608	I-Outcome
the	10939601	1609	1612	I-Outcome
5-FU	10939601	1613	1617	I-Outcome
plus	10939601	1618	1622	I-Outcome
FA	10939601	1623	1625	I-Outcome
combination	10939601	1626	1637	I-Outcome
in	10939601	1638	1640	O
advanced	10939601	1641	1649	B-Participant
colorectal	10939601	1650	1660	I-Participant
cancer	10939601	1661	1667	I-Participant
.	10939601	1668	1669	O

Combination	10945514	0	11	B-Intervention
hydrocodone	10945514	12	23	I-Intervention
and	10945514	24	27	I-Intervention
ibuprofen	10945514	28	37	I-Intervention
versus	10945514	38	44	O
combination	10945514	45	56	B-Intervention
codeine	10945514	57	64	I-Intervention
and	10945514	65	68	I-Intervention
acetaminophen	10945514	69	82	I-Intervention
for	10945514	83	86	O
the	10945514	87	90	O
treatment	10945514	91	100	O
of	10945514	101	103	O
chronic	10945514	104	111	B-Participant
pain	10945514	112	116	I-Participant
.	10945514	117	118	O

OBJECTIVE	10945514	119	128	O
The	10945514	129	132	O
objective	10945514	133	142	O
of	10945514	143	145	O
this	10945514	146	150	O
study	10945514	151	156	O
was	10945514	157	160	O
to	10945514	161	163	O
compare	10945514	164	171	O
the	10945514	172	175	O
effectiveness	10945514	176	189	O
of	10945514	190	192	O
combination	10945514	193	204	B-Intervention
hydrocodone	10945514	205	216	I-Intervention
7.5	10945514	217	220	I-Intervention
mg	10945514	221	223	I-Intervention
and	10945514	224	227	I-Intervention
ibuprofen	10945514	228	237	I-Intervention
200	10945514	238	241	I-Intervention
mg	10945514	242	244	I-Intervention
with	10945514	245	249	O
that	10945514	250	254	O
of	10945514	255	257	O
combination	10945514	258	269	B-Intervention
codeine	10945514	270	277	I-Intervention
30	10945514	278	280	I-Intervention
mg	10945514	281	283	I-Intervention
and	10945514	284	287	I-Intervention
acetaminophen	10945514	288	301	I-Intervention
300	10945514	302	305	I-Intervention
mg	10945514	306	308	I-Intervention
for	10945514	309	312	O
the	10945514	313	316	O
treatment	10945514	317	326	O
of	10945514	327	329	O
chronic	10945514	330	337	B-Participant
pain	10945514	338	342	I-Participant
.	10945514	343	344	O

BACKGROUND	10945514	345	355	O
Hydrocodone	10945514	356	367	O
7.5	10945514	368	371	O
mg	10945514	372	374	O
with	10945514	375	379	O
ibuprofen	10945514	380	389	O
200	10945514	390	393	O
mg	10945514	394	396	O
is	10945514	397	399	O
the	10945514	400	403	O
only	10945514	404	408	O
approved	10945514	409	417	O
fixed-dose	10945514	418	428	O
combination	10945514	429	440	O
analgesic	10945514	441	450	O
containing	10945514	451	461	O
an	10945514	462	464	O
opioid	10945514	465	471	O
and	10945514	472	475	O
ibuprofen	10945514	476	485	O
.	10945514	486	487	O

METHODS	10945514	488	495	O
In	10945514	496	498	O
this	10945514	499	503	O
randomized	10945514	504	514	O
,	10945514	515	516	O
parallel-group	10945514	517	531	O
,	10945514	532	533	O
double-blind	10945514	534	546	O
,	10945514	547	548	O
repeated-dose	10945514	549	562	O
,	10945514	563	564	O
active-comparator	10945514	565	582	O
,	10945514	583	584	O
4-week	10945514	585	591	O
,	10945514	592	593	O
multicenter	10945514	594	605	O
study	10945514	606	611	O
,	10945514	612	613	O
469	10945514	614	617	O
patients	10945514	618	626	O
were	10945514	627	631	O
randomly	10945514	632	640	O
assigned	10945514	641	649	O
to	10945514	650	652	O
receive	10945514	653	660	O
a	10945514	661	662	O
1-tablet	10945514	663	671	B-Intervention
(	10945514	672	673	O
n	10945514	674	675	O
=	10945514	676	677	O
156	10945514	678	681	O
)	10945514	682	683	O
or	10945514	684	686	O
2-tablet	10945514	687	695	B-Intervention
(	10945514	696	697	I-Intervention
n	10945514	698	699	I-Intervention
=	10945514	700	701	I-Intervention
153	10945514	702	705	I-Intervention
)	10945514	706	707	I-Intervention
dose	10945514	708	712	I-Intervention
of	10945514	713	715	I-Intervention
combination	10945514	716	727	I-Intervention
hydrocodone	10945514	728	739	I-Intervention
7.5	10945514	740	743	I-Intervention
mg	10945514	744	746	I-Intervention
and	10945514	747	750	I-Intervention
ibuprofen	10945514	751	760	I-Intervention
200	10945514	761	764	I-Intervention
mg	10945514	765	767	I-Intervention
(	10945514	768	769	O
HI1	10945514	770	773	O
and	10945514	774	777	O
HI2	10945514	778	781	O
,	10945514	782	783	O
respectively	10945514	784	796	O
)	10945514	797	798	O
or	10945514	799	801	O
a	10945514	802	803	O
2-tablet	10945514	804	812	B-Intervention
dose	10945514	813	817	I-Intervention
of	10945514	818	820	I-Intervention
combination	10945514	821	832	I-Intervention
codeine	10945514	833	840	I-Intervention
30	10945514	841	843	I-Intervention
mg	10945514	844	846	I-Intervention
and	10945514	847	850	I-Intervention
acetaminophen	10945514	851	864	I-Intervention
300	10945514	865	868	I-Intervention
mg	10945514	869	871	I-Intervention
(	10945514	872	873	O
CA	10945514	874	876	O
,	10945514	877	878	O
n	10945514	879	880	O
=	10945514	881	882	O
160	10945514	883	886	O
)	10945514	887	888	O
,	10945514	889	890	O
the	10945514	891	894	O
active	10945514	895	901	O
comparator	10945514	902	912	O
,	10945514	913	914	O
every	10945514	915	920	O
6	10945514	921	922	O
to	10945514	923	925	O
8	10945514	926	927	O
hours	10945514	928	933	O
as	10945514	934	936	O
needed	10945514	937	943	O
for	10945514	944	947	O
pain	10945514	948	952	B-Participant
.	10945514	953	954	O

Efficacy	10945514	955	963	O
was	10945514	964	967	O
measured	10945514	968	976	O
through	10945514	977	984	O
pain	10945514	985	989	B-Outcome
relief	10945514	990	996	I-Outcome
scores	10945514	997	1003	I-Outcome
,	10945514	1004	1005	O
number	10945514	1006	1012	B-Outcome
of	10945514	1013	1015	I-Outcome
daily	10945514	1016	1021	I-Outcome
doses	10945514	1022	1027	I-Outcome
of	10945514	1028	1030	I-Outcome
study	10945514	1031	1036	I-Outcome
medication	10945514	1037	1047	I-Outcome
,	10945514	1048	1049	O
number	10945514	1050	1056	B-Outcome
of	10945514	1057	1059	I-Outcome
daily	10945514	1060	1065	I-Outcome
doses	10945514	1066	1071	I-Outcome
of	10945514	1072	1074	I-Outcome
supplemental	10945514	1075	1087	I-Outcome
analgesics	10945514	1088	1098	I-Outcome
,	10945514	1099	1100	O
number	10945514	1101	1107	B-Outcome
of	10945514	1108	1110	I-Outcome
patients	10945514	1111	1119	I-Outcome
who	10945514	1120	1123	I-Outcome
discontinued	10945514	1124	1136	I-Outcome
therapy	10945514	1137	1144	I-Outcome
due	10945514	1145	1148	I-Outcome
to	10945514	1149	1151	I-Outcome
an	10945514	1152	1154	I-Outcome
unsatisfactory	10945514	1155	1169	I-Outcome
analgesic	10945514	1170	1179	I-Outcome
response	10945514	1180	1188	I-Outcome
,	10945514	1189	1190	O
and	10945514	1191	1194	O
global	10945514	1195	1201	B-Outcome
assessment	10945514	1202	1212	I-Outcome
scores	10945514	1213	1219	I-Outcome
.	10945514	1220	1221	O

RESULTS	10945514	1222	1229	O
Of	10945514	1230	1232	O
the	10945514	1233	1236	O
469	10945514	1237	1240	O
patients	10945514	1241	1249	O
,	10945514	1250	1251	O
255	10945514	1252	1255	O
(	10945514	1256	1257	O
54.4	10945514	1258	1262	O
%	10945514	1263	1264	O
)	10945514	1265	1266	O
were	10945514	1267	1271	O
female	10945514	1272	1278	O
and	10945514	1279	1282	O
214	10945514	1283	1286	O
(	10945514	1287	1288	O
45.6	10945514	1289	1293	O
%	10945514	1294	1295	O
)	10945514	1296	1297	O
were	10945514	1298	1302	O
male	10945514	1303	1307	O
.	10945514	1308	1309	O

The	10945514	1310	1313	O
mean	10945514	1314	1318	O
age	10945514	1319	1322	O
was	10945514	1323	1326	O
51.1	10945514	1327	1331	O
years	10945514	1332	1337	O
.	10945514	1338	1339	O

Types	10945514	1340	1345	O
of	10945514	1346	1348	O
chronic	10945514	1349	1356	B-Participant
pain	10945514	1357	1361	I-Participant
included	10945514	1362	1370	O
back	10945514	1371	1375	B-Participant
(	10945514	1376	1377	O
214	10945514	1378	1381	B-Count
;	10945514	1382	1383	I-Count
45.6	10945514	1384	1388	I-Count
%	10945514	1389	1390	I-Count
)	10945514	1391	1392	O
,	10945514	1393	1394	O
arthritic	10945514	1395	1404	B-Participant
(	10945514	1405	1406	O
145	10945514	1407	1410	B-Count
;	10945514	1411	1412	I-Count
30.9	10945514	1413	1417	I-Count
%	10945514	1418	1419	I-Count
)	10945514	1420	1421	O
,	10945514	1422	1423	O
other	10945514	1424	1429	B-Participant
musculoskeletal	10945514	1430	1445	I-Participant
(	10945514	1446	1447	O
65	10945514	1448	1450	B-Count
;	10945514	1451	1452	I-Count
13.9	10945514	1453	1457	I-Count
%	10945514	1458	1459	I-Count
)	10945514	1460	1461	O
,	10945514	1462	1463	O
cancer	10945514	1464	1470	B-Participant
(	10945514	1471	1472	O
6	10945514	1473	1474	B-Count
;	10945514	1475	1476	I-Count
1.3	10945514	1477	1480	I-Count
%	10945514	1481	1482	I-Count
)	10945514	1483	1484	O
,	10945514	1485	1486	O
diabetic	10945514	1487	1495	B-Participant
neuropathic	10945514	1496	1507	I-Participant
(	10945514	1508	1509	O
3	10945514	1510	1511	B-Count
;	10945514	1512	1513	I-Count
0.6	10945514	1514	1517	I-Count
%	10945514	1518	1519	I-Count
)	10945514	1520	1521	O
,	10945514	1522	1523	O
postherpetic	10945514	1524	1536	B-Participant
neuralgic	10945514	1537	1546	I-Participant
(	10945514	1547	1548	O
5	10945514	1549	1550	B-Count
;	10945514	1551	1552	I-Count
1.1	10945514	1553	1556	I-Count
%	10945514	1557	1558	I-Count
)	10945514	1559	1560	O
,	10945514	1561	1562	O
other	10945514	1563	1568	B-Participant
neurologic	10945514	1569	1579	I-Participant
(	10945514	1580	1581	O
21	10945514	1582	1584	B-Count
;	10945514	1585	1586	I-Count
4.5	10945514	1587	1590	I-Count
%	10945514	1591	1592	I-Count
)	10945514	1593	1594	O
,	10945514	1595	1596	O
and	10945514	1597	1600	O
other	10945514	1601	1606	B-Participant
unclassified	10945514	1607	1619	I-Participant
chronic	10945514	1620	1627	I-Participant
pain	10945514	1628	1632	I-Participant
(	10945514	1633	1634	O
10	10945514	1635	1637	B-Count
;	10945514	1638	1639	I-Count
2.1	10945514	1640	1643	I-Count
%	10945514	1644	1645	I-Count
)	10945514	1646	1647	O
.	10945514	1648	1649	O

During	10945514	1650	1656	O
the	10945514	1657	1660	O
48	10945514	1661	1663	O
hours	10945514	1664	1669	O
prior	10945514	1670	1675	O
to	10945514	1676	1678	O
the	10945514	1679	1682	O
study	10945514	1683	1688	O
,	10945514	1689	1690	O
351	10945514	1691	1694	B-Count
(	10945514	1695	1696	I-Count
74.8	10945514	1697	1701	I-Count
%	10945514	1702	1703	I-Count
)	10945514	1704	1705	I-Count
patients	10945514	1706	1714	O
had	10945514	1715	1718	O
been	10945514	1719	1723	O
treated	10945514	1724	1731	O
with	10945514	1732	1736	O
opioid	10945514	1737	1743	B-Intervention
or	10945514	1744	1746	I-Intervention
opioid-nonopioid	10945514	1747	1763	I-Intervention
combination	10945514	1764	1775	I-Intervention
analgesics	10945514	1776	1786	I-Intervention
.	10945514	1787	1788	O

The	10945514	1789	1792	O
overall	10945514	1793	1800	B-Outcome
mean	10945514	1801	1805	I-Outcome
daily	10945514	1806	1811	I-Outcome
pain	10945514	1812	1816	I-Outcome
relief	10945514	1817	1823	I-Outcome
score	10945514	1824	1829	I-Outcome
was	10945514	1830	1833	O
significantly	10945514	1834	1847	B-Observation
greater	10945514	1848	1855	I-Observation
in	10945514	1856	1858	O
the	10945514	1859	1862	O
HI2	10945514	1863	1866	B-Intervention
group	10945514	1867	1872	O
(	10945514	1873	1874	O
2.25+/-0.89	10945514	1875	1886	B-Observation
)	10945514	1887	1888	O
than	10945514	1889	1893	O
in	10945514	1894	1896	O
the	10945514	1897	1900	O
HI1	10945514	1901	1904	B-Intervention
group	10945514	1905	1910	O
(	10945514	1911	1912	O
1.98+/-0.87	10945514	1913	1924	B-Observation
)	10945514	1925	1926	O
(	10945514	1927	1928	O
P	10945514	1929	1930	O
=	10945514	1931	1932	O
0.003	10945514	1933	1938	O
)	10945514	1939	1940	O
or	10945514	1941	1943	O
the	10945514	1944	1947	O
CA	10945514	1948	1950	B-Intervention
group	10945514	1951	1956	O
(	10945514	1957	1958	O
1.85+/-0.96	10945514	1959	1970	B-Observation
)	10945514	1971	1972	O
(	10945514	1973	1974	O
P	10945514	1975	1976	O
<	10945514	1977	1978	O
0.001	10945514	1979	1984	O
)	10945514	1985	1986	O
.	10945514	1987	1988	O

The	10945514	1989	1992	O
overall	10945514	1993	2000	B-Outcome
mean	10945514	2001	2005	I-Outcome
number	10945514	2006	2012	I-Outcome
of	10945514	2013	2015	I-Outcome
daily	10945514	2016	2021	I-Outcome
doses	10945514	2022	2027	I-Outcome
of	10945514	2028	2030	I-Outcome
study	10945514	2031	2036	I-Outcome
medication	10945514	2037	2047	I-Outcome
was	10945514	2048	2051	O
significantly	10945514	2052	2065	B-Observation
less	10945514	2066	2070	I-Observation
in	10945514	2071	2073	O
the	10945514	2074	2077	O
HI2	10945514	2078	2081	B-Intervention
group	10945514	2082	2087	O
(	10945514	2088	2089	O
2.94+/-0.99	10945514	2090	2101	B-Observation
)	10945514	2102	2103	O
than	10945514	2104	2108	O
in	10945514	2109	2111	O
the	10945514	2112	2115	O
HI1	10945514	2116	2119	B-Intervention
group	10945514	2120	2125	O
(	10945514	2126	2127	O
3.23+/-0.76	10945514	2128	2139	B-Observation
)	10945514	2140	2141	O
(	10945514	2142	2143	O
P	10945514	2144	2145	O
=	10945514	2146	2147	O
0.036	10945514	2148	2153	O
)	10945514	2154	2155	O
or	10945514	2156	2158	O
the	10945514	2159	2162	O
CA	10945514	2163	2165	B-Intervention
group	10945514	2166	2171	O
(	10945514	2172	2173	O
3.26+/-0.75	10945514	2174	2185	B-Observation
)	10945514	2186	2187	O
(	10945514	2188	2189	O
P	10945514	2190	2191	O
=	10945514	2192	2193	O
0.014	10945514	2194	2199	O
)	10945514	2200	2201	O
.	10945514	2202	2203	O

The	10945514	2204	2207	O
overall	10945514	2208	2215	B-Outcome
mean	10945514	2216	2220	I-Outcome
number	10945514	2221	2227	I-Outcome
of	10945514	2228	2230	I-Outcome
daily	10945514	2231	2236	I-Outcome
doses	10945514	2237	2242	I-Outcome
of	10945514	2243	2245	I-Outcome
supplemental	10945514	2246	2258	I-Outcome
analgesics	10945514	2259	2269	I-Outcome
was	10945514	2270	2273	O
significantly	10945514	2274	2287	B-Observation
less	10945514	2288	2292	I-Observation
in	10945514	2293	2295	O
the	10945514	2296	2299	O
HI2	10945514	2300	2303	B-Intervention
group	10945514	2304	2309	O
(	10945514	2310	2311	O
0.24+/-0.49	10945514	2312	2323	B-Observation
)	10945514	2324	2325	O
than	10945514	2326	2330	O
in	10945514	2331	2333	O
the	10945514	2334	2337	O
HI1	10945514	2338	2341	B-Intervention
group	10945514	2342	2347	O
(	10945514	2348	2349	O
0.34+/-0.58	10945514	2350	2361	B-Observation
)	10945514	2362	2363	O
(	10945514	2364	2365	O
P	10945514	2366	2367	O
=	10945514	2368	2369	O
0.021	10945514	2370	2375	O
)	10945514	2376	2377	O
or	10945514	2378	2380	O
CA	10945514	2381	2383	B-Intervention
group	10945514	2384	2389	O
(	10945514	2390	2391	O
0.49+/-0.85	10945514	2392	2403	B-Observation
)	10945514	2404	2405	O
(	10945514	2406	2407	O
P	10945514	2408	2409	O
=	10945514	2410	2411	O
0.010	10945514	2412	2417	O
)	10945514	2418	2419	O
.	10945514	2420	2421	O

The	10945514	2422	2425	O
number	10945514	2426	2432	B-Outcome
of	10945514	2433	2435	I-Outcome
patients	10945514	2436	2444	I-Outcome
who	10945514	2445	2448	I-Outcome
discontinued	10945514	2449	2461	I-Outcome
treatment	10945514	2462	2471	I-Outcome
due	10945514	2472	2475	I-Outcome
to	10945514	2476	2478	I-Outcome
an	10945514	2479	2481	I-Outcome
unsatisfactory	10945514	2482	2496	I-Outcome
analgesic	10945514	2497	2506	I-Outcome
response	10945514	2507	2515	I-Outcome
was	10945514	2516	2519	O
significantly	10945514	2520	2533	B-Observation
less	10945514	2534	2538	I-Observation
in	10945514	2539	2541	O
the	10945514	2542	2545	O
HI2	10945514	2546	2549	B-Intervention
group	10945514	2550	2555	O
(	10945514	2556	2557	O
2	10945514	2558	2559	B-Count
;	10945514	2560	2561	I-Count
1.3	10945514	2562	2565	I-Count
%	10945514	2566	2567	I-Count
)	10945514	2568	2569	O
than	10945514	2570	2574	O
in	10945514	2575	2577	O
the	10945514	2578	2581	O
CA	10945514	2582	2584	B-Intervention
group	10945514	2585	2590	O
(	10945514	2591	2592	O
12	10945514	2593	2595	B-Count
;	10945514	2596	2597	I-Count
7.5	10945514	2598	2601	I-Count
%	10945514	2602	2603	I-Count
)	10945514	2604	2605	O
(	10945514	2606	2607	O
P	10945514	2608	2609	O
=	10945514	2610	2611	O
0.008	10945514	2612	2617	O
)	10945514	2618	2619	O
.	10945514	2620	2621	O

HI2	10945514	2622	2625	B-Intervention
was	10945514	2626	2629	O
more	10945514	2630	2634	B-Observation
effective	10945514	2635	2644	I-Observation
than	10945514	2645	2649	O
HI1	10945514	2650	2653	B-Intervention
and	10945514	2654	2657	O
CA	10945514	2658	2660	B-Intervention
as	10945514	2661	2663	O
measured	10945514	2664	2672	O
by	10945514	2673	2675	O
pain	10945514	2676	2680	B-Outcome
relief	10945514	2681	2687	I-Outcome
scores	10945514	2688	2694	I-Outcome
for	10945514	2695	2698	I-Outcome
week	10945514	2699	2703	I-Outcome
1	10945514	2704	2705	I-Outcome
(	10945514	2706	2707	O
P	10945514	2708	2709	O
<	10945514	2710	2711	O
0.001	10945514	2712	2717	O
vs	10945514	2718	2720	O
HI1	10945514	2721	2724	B-Intervention
and	10945514	2725	2728	O
CA	10945514	2729	2731	B-Intervention
)	10945514	2732	2733	O
,	10945514	2734	2735	O
week	10945514	2736	2740	O
2	10945514	2741	2742	O
(	10945514	2743	2744	O
P	10945514	2745	2746	O
<	10945514	2747	2748	O
0.001	10945514	2749	2754	O
vs	10945514	2755	2757	O
HI1	10945514	2758	2761	B-Intervention
and	10945514	2762	2765	O
CA	10945514	2766	2768	B-Intervention
)	10945514	2769	2770	O
,	10945514	2771	2772	O
and	10945514	2773	2776	O
week	10945514	2777	2781	O
3	10945514	2782	2783	O
(	10945514	2784	2785	O
P	10945514	2786	2787	O
=	10945514	2788	2789	O
0.008	10945514	2790	2795	O
vs	10945514	2796	2798	O
HI1	10945514	2799	2802	B-Intervention
and	10945514	2803	2806	O
P	10945514	2807	2808	O
<	10945514	2809	2810	O
0.001	10945514	2811	2816	O
vs	10945514	2817	2819	O
CA	10945514	2820	2822	B-Intervention
)	10945514	2823	2824	O
;	10945514	2825	2826	O
daily	10945514	2827	2832	B-Outcome
doses	10945514	2833	2838	I-Outcome
of	10945514	2839	2841	I-Outcome
study	10945514	2842	2847	I-Outcome
medication	10945514	2848	2858	I-Outcome
for	10945514	2859	2862	I-Outcome
week	10945514	2863	2867	I-Outcome
1	10945514	2868	2869	I-Outcome
(	10945514	2870	2871	O
P	10945514	2872	2873	O
=	10945514	2874	2875	O
0.019	10945514	2876	2881	O
vs	10945514	2882	2884	O
HI1	10945514	2885	2888	B-Intervention
and	10945514	2889	2892	O
P	10945514	2893	2894	O
=	10945514	2895	2896	O
0.011	10945514	2897	2902	O
vs	10945514	2903	2905	O
CA	10945514	2906	2908	B-Intervention
)	10945514	2909	2910	O
;	10945514	2911	2912	O
daily	10945514	2913	2918	B-Outcome
doses	10945514	2919	2924	I-Outcome
of	10945514	2925	2927	I-Outcome
supplemental	10945514	2928	2940	I-Outcome
analgesics	10945514	2941	2951	I-Outcome
for	10945514	2952	2955	I-Outcome
week	10945514	2956	2960	I-Outcome
1	10945514	2961	2962	I-Outcome
(	10945514	2963	2964	O
P	10945514	2965	2966	O
=	10945514	2967	2968	O
0.010	10945514	2969	2974	O
vs	10945514	2975	2977	O
HI1	10945514	2978	2981	B-Intervention
and	10945514	2982	2985	O
CA	10945514	2986	2988	B-Intervention
)	10945514	2989	2990	O
;	10945514	2991	2992	O
and	10945514	2993	2996	O
global	10945514	2997	3003	B-Outcome
assessment	10945514	3004	3014	I-Outcome
scores	10945514	3015	3021	I-Outcome
for	10945514	3022	3025	I-Outcome
week	10945514	3026	3030	I-Outcome
1	10945514	3031	3032	I-Outcome
(	10945514	3033	3034	O
P	10945514	3035	3036	O
=	10945514	3037	3038	O
0.018	10945514	3039	3044	O
vs	10945514	3045	3047	O
HI1	10945514	3048	3051	B-Intervention
and	10945514	3052	3055	O
P	10945514	3056	3057	O
<	10945514	3058	3059	O
0.001	10945514	3060	3065	O
vs	10945514	3066	3068	O
CA	10945514	3069	3071	B-Intervention
)	10945514	3072	3073	O
,	10945514	3074	3075	O
week	10945514	3076	3080	O
2	10945514	3081	3082	O
(	10945514	3083	3084	O
P	10945514	3085	3086	O
=	10945514	3087	3088	O
0.005	10945514	3089	3094	O
vs	10945514	3095	3097	O
HI1	10945514	3098	3101	B-Intervention
and	10945514	3102	3105	O
P	10945514	3106	3107	O
<	10945514	3108	3109	O
0.001	10945514	3110	3115	O
vs	10945514	3116	3118	O
CA	10945514	3119	3121	B-Intervention
)	10945514	3122	3123	O
,	10945514	3124	3125	O
and	10945514	3126	3129	O
week	10945514	3130	3134	O
4	10945514	3135	3136	O
(	10945514	3137	3138	O
P	10945514	3139	3140	O
=	10945514	3141	3142	O
0.013	10945514	3143	3148	O
vs	10945514	3149	3151	O
HI1	10945514	3152	3155	B-Intervention
and	10945514	3156	3159	O
P	10945514	3160	3161	O
=	10945514	3162	3163	O
0.023	10945514	3164	3169	O
vs	10945514	3170	3172	O
CA	10945514	3173	3175	B-Intervention
)	10945514	3176	3177	O
.	10945514	3178	3179	O

There	10945514	3180	3185	O
were	10945514	3186	3190	O
no	10945514	3191	3193	O
significant	10945514	3194	3205	B-Observation
differences	10945514	3206	3217	I-Observation
between	10945514	3218	3225	O
HI1	10945514	3226	3229	B-Intervention
and	10945514	3230	3233	O
CA	10945514	3234	3236	B-Intervention
in	10945514	3237	3239	O
any	10945514	3240	3243	O
efficacy	10945514	3244	3252	B-Outcome
variable	10945514	3253	3261	I-Outcome
.	10945514	3262	3263	O

There	10945514	3264	3269	O
were	10945514	3270	3274	O
no	10945514	3275	3277	O
significant	10945514	3278	3289	B-Observation
differences	10945514	3290	3301	I-Observation
in	10945514	3302	3304	O
the	10945514	3305	3308	O
number	10945514	3309	3315	B-Outcome
of	10945514	3316	3318	I-Outcome
patients	10945514	3319	3327	I-Outcome
experiencing	10945514	3328	3340	I-Outcome
adverse	10945514	3341	3348	I-Outcome
events	10945514	3349	3355	I-Outcome
in	10945514	3356	3358	O
the	10945514	3359	3362	O
HI2	10945514	3363	3366	B-Intervention
(	10945514	3367	3368	O
127	10945514	3369	3372	B-Count
;	10945514	3373	3374	I-Count
83	10945514	3375	3377	I-Count
%	10945514	3378	3379	I-Count
)	10945514	3380	3381	O
,	10945514	3382	3383	O
HI1	10945514	3384	3387	B-Intervention
(	10945514	3388	3389	O
124	10945514	3390	3393	B-Count
;	10945514	3394	3395	I-Count
79.5	10945514	3396	3400	I-Count
%	10945514	3401	3402	I-Count
)	10945514	3403	3404	O
,	10945514	3405	3406	O
and	10945514	3407	3410	O
CA	10945514	3411	3413	B-Intervention
(	10945514	3414	3415	O
129	10945514	3416	3419	B-Count
;	10945514	3420	3421	I-Count
80.6	10945514	3422	3426	I-Count
%	10945514	3427	3428	I-Count
)	10945514	3429	3430	O
groups	10945514	3431	3437	O
.	10945514	3438	3439	O

However	10945514	3440	3447	O
,	10945514	3448	3449	O
the	10945514	3450	3453	O
mean	10945514	3454	3458	B-Outcome
number	10945514	3459	3465	I-Outcome
of	10945514	3466	3468	I-Outcome
patients	10945514	3469	3477	I-Outcome
who	10945514	3478	3481	I-Outcome
discontinued	10945514	3482	3494	I-Outcome
treatment	10945514	3495	3504	I-Outcome
due	10945514	3505	3508	I-Outcome
to	10945514	3509	3511	I-Outcome
adverse	10945514	3512	3519	I-Outcome
events	10945514	3520	3526	I-Outcome
was	10945514	3527	3530	O
significantly	10945514	3531	3544	B-Observation
greater	10945514	3545	3552	I-Observation
in	10945514	3553	3555	O
the	10945514	3556	3559	O
HI2	10945514	3560	3563	B-Intervention
group	10945514	3564	3569	O
(	10945514	3570	3571	O
40	10945514	3572	3574	B-Count
;	10945514	3575	3576	I-Count
26.1	10945514	3577	3581	I-Count
%	10945514	3582	3583	I-Count
)	10945514	3584	3585	O
than	10945514	3586	3590	O
in	10945514	3591	3593	O
the	10945514	3594	3597	O
HI1	10945514	3598	3601	B-Intervention
group	10945514	3602	3607	O
(	10945514	3608	3609	O
23	10945514	3610	3612	B-Count
;	10945514	3613	3614	I-Count
14.7	10945514	3615	3619	I-Count
%	10945514	3620	3621	I-Count
)	10945514	3622	3623	O
(	10945514	3624	3625	O
P	10945514	3626	3627	O
=	10945514	3628	3629	O
0.013	10945514	3630	3635	O
)	10945514	3636	3637	O
.	10945514	3638	3639	O

CONCLUSIONS	10945514	3640	3651	O
The	10945514	3652	3655	O
results	10945514	3656	3663	O
of	10945514	3664	3666	O
this	10945514	3667	3671	O
study	10945514	3672	3677	O
suggest	10945514	3678	3685	O
that	10945514	3686	3690	O
2-tablet	10945514	3691	3699	B-Intervention
doses	10945514	3700	3705	I-Intervention
of	10945514	3706	3708	I-Intervention
combination	10945514	3709	3720	I-Intervention
hydrocodone	10945514	3721	3732	I-Intervention
7.5	10945514	3733	3736	I-Intervention
mg	10945514	3737	3739	I-Intervention
and	10945514	3740	3743	I-Intervention
ibuprofen	10945514	3744	3753	I-Intervention
200	10945514	3754	3757	I-Intervention
mg	10945514	3758	3760	I-Intervention
may	10945514	3761	3764	O
be	10945514	3765	3767	O
more	10945514	3768	3772	B-Observation
effective	10945514	3773	3782	I-Observation
than	10945514	3783	3787	O
either	10945514	3788	3794	O
1-tablet	10945514	3795	3803	B-Intervention
doses	10945514	3804	3809	I-Intervention
of	10945514	3810	3812	I-Intervention
this	10945514	3813	3817	I-Intervention
combination	10945514	3818	3829	I-Intervention
or	10945514	3830	3832	O
2-tablet	10945514	3833	3841	B-Intervention
doses	10945514	3842	3847	I-Intervention
of	10945514	3848	3850	I-Intervention
combination	10945514	3851	3862	I-Intervention
codeine	10945514	3863	3870	I-Intervention
30	10945514	3871	3873	I-Intervention
mg	10945514	3874	3876	I-Intervention
and	10945514	3877	3880	I-Intervention
acetaminophen	10945514	3881	3894	I-Intervention
300	10945514	3895	3898	I-Intervention
mg	10945514	3899	3901	I-Intervention
.	10945514	3902	3903	O

Moreover	10945514	3904	3912	O
,	10945514	3913	3914	O
1-tablet	10945514	3915	3923	B-Intervention
doses	10945514	3924	3929	I-Intervention
of	10945514	3930	3932	I-Intervention
combination	10945514	3933	3944	I-Intervention
hydrocodone	10945514	3945	3956	I-Intervention
7.5	10945514	3957	3960	I-Intervention
mg	10945514	3961	3963	I-Intervention
and	10945514	3964	3967	I-Intervention
ibuprofen	10945514	3968	3977	I-Intervention
200	10945514	3978	3981	I-Intervention
mg	10945514	3982	3984	I-Intervention
may	10945514	3985	3988	O
be	10945514	3989	3991	O
as	10945514	3992	3994	B-Observation
effective	10945514	3995	4004	I-Observation
as	10945514	4005	4007	O
2-tablet	10945514	4008	4016	B-Intervention
doses	10945514	4017	4022	I-Intervention
of	10945514	4023	4025	I-Intervention
combination	10945514	4026	4037	I-Intervention
codeine	10945514	4038	4045	I-Intervention
30	10945514	4046	4048	I-Intervention
mg	10945514	4049	4051	I-Intervention
and	10945514	4052	4055	I-Intervention
acetaminophen	10945514	4056	4069	I-Intervention
300	10945514	4070	4073	I-Intervention
mg	10945514	4074	4076	I-Intervention
.	10945514	4077	4078	O

The	10947757	0	3	O
effect	10947757	4	10	O
of	10947757	11	13	O
halothane	10947757	14	23	B-Intervention
and	10947757	24	27	O
isoflurane	10947757	28	38	B-Intervention
on	10947757	39	41	O
plasma	10947757	42	48	B-Outcome
cytokine	10947757	49	57	I-Outcome
levels	10947757	58	64	I-Outcome
.	10947757	65	66	O

The	10947757	67	70	O
aim	10947757	71	74	O
of	10947757	75	77	O
this	10947757	78	82	O
study	10947757	83	88	O
was	10947757	89	92	O
to	10947757	93	95	O
investigate	10947757	96	107	O
the	10947757	108	111	O
effect	10947757	112	118	O
of	10947757	119	121	O
halothane	10947757	122	131	B-Intervention
vs.	10947757	132	135	O
isoflurane	10947757	136	146	B-Intervention
on	10947757	147	149	O
cytokine	10947757	150	158	B-Outcome
production	10947757	159	169	I-Outcome
during	10947757	170	176	O
minor	10947757	177	182	B-Participant
elective	10947757	183	191	I-Participant
surgery	10947757	192	199	I-Participant
.	10947757	200	201	O

Forty	10947757	202	207	O
adult	10947757	208	213	B-Participant
patients	10947757	214	222	O
,	10947757	223	224	O
ASA	10947757	225	228	B-Participant
I-II	10947757	229	233	I-Participant
were	10947757	234	238	O
randomly	10947757	239	247	O
allocated	10947757	248	257	O
to	10947757	258	260	O
receive	10947757	261	268	O
halothane	10947757	269	278	B-Intervention
or	10947757	279	281	O
isoflurane	10947757	282	292	B-Intervention
.	10947757	293	294	O

Venous	10947757	295	301	O
samples	10947757	302	309	O
for	10947757	310	313	O
interleukin	10947757	314	325	B-Outcome
(	10947757	326	327	I-Outcome
IL	10947757	328	330	I-Outcome
)	10947757	331	332	I-Outcome
-1beta	10947757	333	339	I-Outcome
,	10947757	340	341	O
IL-2	10947757	342	346	B-Outcome
,	10947757	347	348	O
IL-6	10947757	349	353	B-Outcome
,	10947757	354	355	O
tumour	10947757	356	362	B-Outcome
necrosis	10947757	363	371	I-Outcome
factor-alpha	10947757	372	384	I-Outcome
(	10947757	385	386	I-Outcome
TNF-alpha	10947757	387	396	I-Outcome
)	10947757	397	398	I-Outcome
and	10947757	399	402	O
interferon-gamma	10947757	403	419	B-Outcome
(	10947757	420	421	I-Outcome
IFN-gamma	10947757	422	431	I-Outcome
)	10947757	432	433	I-Outcome
were	10947757	434	438	O
taken	10947757	439	444	O
before	10947757	445	451	O
anaesthesia	10947757	452	463	O
,	10947757	464	465	O
before	10947757	466	472	O
incision	10947757	473	481	O
,	10947757	482	483	O
at	10947757	484	486	O
the	10947757	487	490	O
end	10947757	491	494	O
of	10947757	495	497	O
anaesthesia	10947757	498	509	O
and	10947757	510	513	O
24	10947757	514	516	O
h	10947757	517	518	O
postoperatively	10947757	519	534	O
.	10947757	535	536	O

In	10947757	537	539	O
both	10947757	540	544	B-Intervention
groups	10947757	545	551	I-Intervention
,	10947757	552	553	O
IL-6	10947757	554	558	B-Outcome
and	10947757	559	562	O
TNF-alpha	10947757	563	572	B-Outcome
levels	10947757	573	579	I-Outcome
remained	10947757	580	588	B-Observation
low	10947757	589	592	I-Observation
throughout	10947757	593	603	O
the	10947757	604	607	O
study	10947757	608	613	O
period	10947757	614	620	O
.	10947757	621	622	O

Before	10947757	623	629	O
incision	10947757	630	638	O
,	10947757	639	640	O
in	10947757	641	643	O
both	10947757	644	648	B-Intervention
groups	10947757	649	655	I-Intervention
IL-1beta	10947757	656	664	B-Outcome
and	10947757	665	668	O
IFN-gamma	10947757	669	678	B-Outcome
showed	10947757	679	685	O
a	10947757	686	687	O
decrease	10947757	688	696	B-Observation
(	10947757	697	698	O
p	10947757	699	700	O
<	10947757	701	702	O
0.01	10947757	703	707	O
for	10947757	708	711	O
IL-1beta	10947757	712	720	B-Outcome
in	10947757	721	723	O
isoflurane	10947757	724	734	B-Intervention
group	10947757	735	740	I-Intervention
and	10947757	741	744	O
p	10947757	745	746	O
<	10947757	747	748	O
0.05	10947757	749	753	O
for	10947757	754	757	O
the	10947757	758	761	O
others	10947757	762	768	O
)	10947757	769	770	O
compared	10947757	771	779	O
with	10947757	780	784	O
pre-induction	10947757	785	798	O
.	10947757	799	800	O

By	10947757	801	803	O
the	10947757	804	807	O
end	10947757	808	811	O
of	10947757	812	814	O
anaesthesia	10947757	815	826	O
and	10947757	827	830	O
surgery	10947757	831	838	O
,	10947757	839	840	O
IL-1beta	10947757	841	849	B-Outcome
had	10947757	850	853	O
increased	10947757	854	863	B-Observation
significantly	10947757	864	877	I-Observation
(	10947757	878	879	O
p	10947757	880	881	O
<	10947757	882	883	O
0.05	10947757	884	888	O
)	10947757	889	890	O
and	10947757	891	894	O
IFN-gamma	10947757	895	904	B-Outcome
had	10947757	905	908	O
decreased	10947757	909	918	B-Observation
significantly	10947757	919	932	I-Observation
(	10947757	933	934	O
p	10947757	935	936	O
<	10947757	937	938	O
0.05	10947757	939	943	O
)	10947757	944	945	O
in	10947757	946	948	O
both	10947757	949	953	B-Intervention
groups	10947757	954	960	I-Intervention
compared	10947757	961	969	O
with	10947757	970	974	O
pre-incisional	10947757	975	989	O
levels	10947757	990	996	O
.	10947757	997	998	O

By	10947757	999	1001	O
24	10947757	1002	1004	O
h	10947757	1005	1006	O
postoperatively	10947757	1007	1022	O
in	10947757	1023	1025	O
both	10947757	1026	1030	B-Intervention
groups	10947757	1031	1037	I-Intervention
,	10947757	1038	1039	O
IL-1beta	10947757	1040	1048	B-Outcome
had	10947757	1049	1052	O
decreased	10947757	1053	1062	B-Observation
significantly	10947757	1063	1076	I-Observation
(	10947757	1077	1078	O
p	10947757	1079	1080	O
<	10947757	1081	1082	O
0.05	10947757	1083	1087	O
)	10947757	1088	1089	O
,	10947757	1090	1091	O
whereas	10947757	1092	1099	O
IFN-gamma	10947757	1100	1109	B-Outcome
had	10947757	1110	1113	O
increased	10947757	1114	1123	B-Observation
significantly	10947757	1124	1137	I-Observation
(	10947757	1138	1139	O
p	10947757	1140	1141	O
<	10947757	1142	1143	O
0.05	10947757	1144	1148	O
)	10947757	1149	1150	O
compared	10947757	1151	1159	O
with	10947757	1160	1164	O
the	10947757	1165	1168	O
end	10947757	1169	1172	O
of	10947757	1173	1175	O
anaesthesia	10947757	1176	1187	O
and	10947757	1188	1191	O
surgery	10947757	1192	1199	O
level	10947757	1200	1205	O
.	10947757	1206	1207	O

Pre-incisionally	10947757	1208	1224	O
,	10947757	1225	1226	O
IL-2	10947757	1227	1231	B-Outcome
increased	10947757	1232	1241	B-Observation
in	10947757	1242	1244	O
the	10947757	1245	1248	O
halothane	10947757	1249	1258	B-Intervention
group	10947757	1259	1264	O
(	10947757	1265	1266	O
p	10947757	1267	1268	O
<	10947757	1269	1270	O
0.01	10947757	1271	1275	O
)	10947757	1276	1277	O
,	10947757	1278	1279	O
whereas	10947757	1280	1287	O
it	10947757	1288	1290	O
decreased	10947757	1291	1300	B-Observation
significantly	10947757	1301	1314	I-Observation
in	10947757	1315	1317	O
the	10947757	1318	1321	O
isoflurane	10947757	1322	1332	B-Intervention
group	10947757	1333	1338	O
(	10947757	1339	1340	O
p	10947757	1341	1342	O
<	10947757	1343	1344	O
0.001	10947757	1345	1350	O
)	10947757	1351	1352	O
compared	10947757	1353	1361	O
with	10947757	1362	1366	O
the	10947757	1367	1370	O
pre-induction	10947757	1371	1384	O
level	10947757	1385	1390	O
.	10947757	1391	1392	O

By	10947757	1393	1395	O
the	10947757	1396	1399	O
end	10947757	1400	1403	O
of	10947757	1404	1406	O
anaesthesia	10947757	1407	1418	O
and	10947757	1419	1422	O
surgery	10947757	1423	1430	O
and	10947757	1431	1434	O
by	10947757	1435	1437	O
24	10947757	1438	1440	O
h	10947757	1441	1442	O
postoperatively	10947757	1443	1458	O
,	10947757	1459	1460	O
IL-2	10947757	1461	1465	B-Outcome
had	10947757	1466	1469	O
decreased	10947757	1470	1479	B-Observation
significantly	10947757	1480	1493	I-Observation
in	10947757	1494	1496	O
the	10947757	1497	1500	O
halothane	10947757	1501	1510	B-Intervention
group	10947757	1511	1516	O
(	10947757	1517	1518	O
p	10947757	1519	1520	O
<	10947757	1521	1522	O
0.001	10947757	1523	1528	O
)	10947757	1529	1530	O
,	10947757	1531	1532	O
whereas	10947757	1533	1540	O
it	10947757	1541	1543	O
increased	10947757	1544	1553	B-Observation
significantly	10947757	1554	1567	I-Observation
in	10947757	1568	1570	O
the	10947757	1571	1574	O
isoflurane	10947757	1575	1585	B-Intervention
group	10947757	1586	1591	O
(	10947757	1592	1593	O
p	10947757	1594	1595	O
<	10947757	1596	1597	O
0.001	10947757	1598	1603	O
)	10947757	1604	1605	O
compared	10947757	1606	1614	O
with	10947757	1615	1619	O
pre-incision	10947757	1620	1632	O
and	10947757	1633	1636	O
end	10947757	1637	1640	O
of	10947757	1641	1643	O
anaesthesia	10947757	1644	1655	O
and	10947757	1656	1659	O
surgery	10947757	1660	1667	O
levels	10947757	1668	1674	O
,	10947757	1675	1676	O
respectively	10947757	1677	1689	O
.	10947757	1690	1691	O

A	10957888	0	1	O
comparative	10957888	2	13	O
efficacy	10957888	14	22	B-Outcome
and	10957888	23	26	O
safety	10957888	27	33	B-Outcome
study	10957888	34	39	O
of	10957888	40	42	O
clarithromycin	10957888	43	57	B-Intervention
,	10957888	58	59	O
roxithromycin	10957888	60	73	B-Intervention
and	10957888	74	77	O
erythromycin	10957888	78	90	B-Intervention
stearate	10957888	91	99	I-Intervention
in	10957888	100	102	O
mild	10957888	103	107	B-Participant
pneumonia	10957888	108	117	I-Participant
.	10957888	118	119	O

The	10957888	120	123	O
efficacy	10957888	124	132	B-Outcome
and	10957888	133	136	O
safety	10957888	137	143	B-Outcome
of	10957888	144	146	O
clarithromycin	10957888	147	161	B-Intervention
,	10957888	162	163	O
roxithromycin	10957888	164	177	B-Intervention
and	10957888	178	181	O
erythromycin	10957888	182	194	B-Intervention
stearate	10957888	195	203	I-Intervention
in	10957888	204	206	O
mild	10957888	207	211	B-Participant
pneumonia	10957888	212	221	I-Participant
were	10957888	222	226	O
compared	10957888	227	235	O
in	10957888	236	238	O
an	10957888	239	241	O
open	10957888	242	246	O
randomized	10957888	247	257	O
trial	10957888	258	263	O
.	10957888	264	265	O

Eighty-six	10957888	266	276	O
male	10957888	277	281	B-Participant
patients	10957888	282	290	O
,	10957888	291	292	O
doing	10957888	293	298	O
their	10957888	299	304	O
obligatory	10957888	305	315	B-Participant
military	10957888	316	324	I-Participant
service	10957888	325	332	I-Participant
,	10957888	333	334	O
ranging	10957888	335	342	O
between	10957888	343	350	O
19	10957888	351	353	O
and	10957888	354	357	O
24	10957888	358	360	O
years	10957888	361	366	O
of	10957888	367	369	O
age	10957888	370	373	O
(	10957888	374	375	O
mean	10957888	376	380	O
20	10957888	381	383	O
)	10957888	384	385	O
,	10957888	386	387	O
were	10957888	388	392	O
randomly	10957888	393	401	O
treated	10957888	402	409	O
:	10957888	410	411	O
29	10957888	412	414	O
with	10957888	415	419	O
clarithromycin	10957888	420	434	B-Intervention
500	10957888	435	438	O
mg	10957888	439	441	O
12-hourly	10957888	442	451	O
,	10957888	452	453	O
30	10957888	454	456	O
with	10957888	457	461	O
roxithromycin	10957888	462	475	B-Intervention
150	10957888	476	479	O
mg	10957888	480	482	O
12-hourly	10957888	483	492	O
,	10957888	493	494	O
and	10957888	495	498	O
27	10957888	499	501	O
with	10957888	502	506	O
erythromycin	10957888	507	519	B-Intervention
stearate	10957888	520	528	I-Intervention
500	10957888	529	532	O
mg	10957888	533	535	O
6-hourly	10957888	536	544	O
,	10957888	545	546	O
each	10957888	547	551	O
course	10957888	552	558	O
being	10957888	559	564	O
administered	10957888	565	577	O
for	10957888	578	581	O
10	10957888	582	584	O
days	10957888	585	589	O
.	10957888	590	591	O

Seventy-eight	10957888	592	605	O
patients	10957888	606	614	O
were	10957888	615	619	O
able	10957888	620	624	O
to	10957888	625	627	O
be	10957888	628	630	O
evaluated	10957888	631	640	O
for	10957888	641	644	O
efficacy	10957888	645	653	B-Outcome
,	10957888	654	655	O
28	10957888	656	658	O
receiving	10957888	659	668	O
clarithromycin	10957888	669	683	B-Intervention
,	10957888	684	685	O
28	10957888	686	688	O
roxithromycin	10957888	689	702	B-Intervention
,	10957888	703	704	O
and	10957888	705	708	O
22	10957888	709	711	O
erythromycin	10957888	712	724	B-Intervention
stearate	10957888	725	733	I-Intervention
.	10957888	734	735	O

There	10957888	736	741	O
were	10957888	742	746	O
no	10957888	747	749	O
significant	10957888	750	761	B-Observation
differences	10957888	762	773	I-Observation
among	10957888	774	779	B-Intervention
the	10957888	780	783	I-Intervention
groups	10957888	784	790	I-Intervention
in	10957888	791	793	O
terms	10957888	794	799	O
of	10957888	800	802	O
clinical	10957888	803	811	B-Outcome
success	10957888	812	819	I-Outcome
rates	10957888	820	825	I-Outcome
(	10957888	826	827	O
clinical	10957888	828	836	B-Outcome
cure	10957888	837	841	I-Outcome
or	10957888	842	844	I-Outcome
improvement	10957888	845	856	I-Outcome
:	10957888	857	858	O
89	10957888	859	861	B-Observation
%	10957888	862	863	I-Observation
for	10957888	864	867	O
clarithromycin	10957888	868	882	B-Intervention
,	10957888	883	884	O
82	10957888	885	887	B-Observation
%	10957888	888	889	I-Observation
for	10957888	890	893	O
roxithromycin	10957888	894	907	B-Intervention
,	10957888	908	909	O
and	10957888	910	913	O
73	10957888	914	916	B-Observation
%	10957888	917	918	I-Observation
for	10957888	919	922	O
erythromycin	10957888	923	935	B-Intervention
stearate	10957888	936	944	I-Intervention
,	10957888	945	946	O
p	10957888	947	948	O
=	10957888	949	950	O
0.32	10957888	951	955	O
)	10957888	956	957	O
.	10957888	958	959	O

However	10957888	960	967	O
,	10957888	968	969	O
we	10957888	970	972	O
found	10957888	973	978	O
that	10957888	979	983	O
there	10957888	984	989	O
were	10957888	990	994	O
significant	10957888	995	1006	B-Observation
differences	10957888	1007	1018	I-Observation
among	10957888	1019	1024	B-Intervention
the	10957888	1025	1028	I-Intervention
groups	10957888	1029	1035	I-Intervention
in	10957888	1036	1038	O
terms	10957888	1039	1044	O
of	10957888	1045	1047	O
clinical	10957888	1048	1056	B-Outcome
cure	10957888	1057	1061	I-Outcome
rates	10957888	1062	1067	I-Outcome
(	10957888	1068	1069	O
75	10957888	1070	1072	B-Observation
%	10957888	1073	1074	I-Observation
for	10957888	1075	1078	O
clarithromycin	10957888	1079	1093	B-Intervention
,	10957888	1094	1095	O
64	10957888	1096	1098	B-Observation
%	10957888	1099	1100	I-Observation
for	10957888	1101	1104	O
roxithromycin	10957888	1105	1118	B-Intervention
,	10957888	1119	1120	O
and	10957888	1121	1124	O
41	10957888	1125	1127	B-Observation
%	10957888	1128	1129	I-Observation
for	10957888	1130	1133	O
erythromycin	10957888	1134	1146	B-Intervention
stearate	10957888	1147	1155	I-Intervention
,	10957888	1156	1157	O
p	10957888	1158	1159	O
=	10957888	1160	1161	O
0.04	10957888	1162	1166	O
)	10957888	1167	1168	O
.	10957888	1169	1170	O

Adverse	10957888	1171	1178	B-Outcome
events	10957888	1179	1185	I-Outcome
,	10957888	1186	1187	O
mostly	10957888	1188	1194	O
gastrointestinal	10957888	1195	1211	B-Outcome
,	10957888	1212	1213	O
caused	10957888	1214	1220	O
discontinuation	10957888	1221	1236	B-Outcome
of	10957888	1237	1239	I-Outcome
treatment	10957888	1240	1249	I-Outcome
in	10957888	1250	1252	O
3.4	10957888	1253	1256	B-Observation
%	10957888	1257	1258	I-Observation
of	10957888	1259	1261	I-Observation
the	10957888	1262	1265	I-Observation
patients	10957888	1266	1274	I-Observation
in	10957888	1275	1277	O
the	10957888	1278	1281	O
clarithromycin	10957888	1282	1296	B-Intervention
group	10957888	1297	1302	O
,	10957888	1303	1304	O
in	10957888	1305	1307	O
6.6	10957888	1308	1311	B-Count
%	10957888	1312	1313	I-Count
of	10957888	1314	1316	I-Count
the	10957888	1317	1320	I-Count
patients	10957888	1321	1329	I-Count
in	10957888	1330	1332	O
the	10957888	1333	1336	O
roxithromycin	10957888	1337	1350	B-Intervention
group	10957888	1351	1356	O
,	10957888	1357	1358	O
and	10957888	1359	1362	O
in	10957888	1363	1365	O
18.5	10957888	1366	1370	B-Count
%	10957888	1371	1372	I-Count
of	10957888	1373	1375	I-Count
the	10957888	1376	1379	I-Count
patients	10957888	1380	1388	I-Count
in	10957888	1389	1391	O
the	10957888	1392	1395	O
erythromycin	10957888	1396	1408	B-Intervention
stearate	10957888	1409	1417	I-Intervention
group	10957888	1418	1423	O
.	10957888	1424	1425	O

The	10957888	1426	1429	O
results	10957888	1430	1437	O
indicate	10957888	1438	1446	O
that	10957888	1447	1451	O
there	10957888	1452	1457	O
were	10957888	1458	1462	O
no	10957888	1463	1465	O
statistically	10957888	1466	1479	B-Observation
significant	10957888	1480	1491	I-Observation
differences	10957888	1492	1503	I-Observation
among	10957888	1504	1509	O
the	10957888	1510	1513	O
three	10957888	1514	1519	B-Intervention
treatment	10957888	1520	1529	I-Intervention
groups	10957888	1530	1536	I-Intervention
in	10957888	1537	1539	O
terms	10957888	1540	1545	O
of	10957888	1546	1548	O
clinical	10957888	1549	1557	B-Outcome
success	10957888	1558	1565	I-Outcome
rates	10957888	1566	1571	I-Outcome
,	10957888	1572	1573	O
but	10957888	1574	1577	O
that	10957888	1578	1582	O
clarithromycin	10957888	1583	1597	B-Intervention
and	10957888	1598	1601	O
roxithromycin	10957888	1602	1615	B-Intervention
were	10957888	1616	1620	O
better	10957888	1621	1627	B-Observation
tolerated	10957888	1628	1637	I-Observation
.	10957888	1638	1639	O

The	10960380	0	3	O
anesthetic	10960380	4	14	B-Outcome
and	10960380	15	18	O
recovery	10960380	19	27	B-Outcome
profile	10960380	28	35	I-Outcome
of	10960380	36	38	O
two	10960380	39	42	B-Intervention
doses	10960380	43	48	I-Intervention
(	10960380	49	50	I-Intervention
60	10960380	51	53	I-Intervention
and	10960380	54	57	I-Intervention
80	10960380	58	60	I-Intervention
mg	10960380	61	63	I-Intervention
)	10960380	64	65	I-Intervention
of	10960380	66	68	I-Intervention
plain	10960380	69	74	I-Intervention
mepivacaine	10960380	75	86	I-Intervention
for	10960380	87	90	O
ambulatory	10960380	91	101	B-Participant
spinal	10960380	102	108	I-Participant
anesthesia	10960380	109	119	I-Participant
.	10960380	120	121	O

UNLABELLED	10960380	122	132	O
Reports	10960380	133	140	O
of	10960380	141	143	O
transient	10960380	144	153	O
neurological	10960380	154	166	O
symptoms	10960380	167	175	O
with	10960380	176	180	O
the	10960380	181	184	O
use	10960380	185	188	O
of	10960380	189	191	O
subarachnoid	10960380	192	204	O
lidocaine	10960380	205	214	O
has	10960380	215	218	O
generated	10960380	219	228	O
interest	10960380	229	237	O
in	10960380	238	240	O
alternate	10960380	241	250	O
local	10960380	251	256	O
anesthetics	10960380	257	268	O
of	10960380	269	271	O
intermediate	10960380	272	284	O
duration	10960380	285	293	O
,	10960380	294	295	O
such	10960380	296	300	O
as	10960380	301	303	O
mepivacaine	10960380	304	315	O
.	10960380	316	317	O

This	10960380	318	322	O
prospective	10960380	323	334	O
randomized	10960380	335	345	O
,	10960380	346	347	O
double-blinded	10960380	348	362	O
,	10960380	363	364	O
dose-response	10960380	365	378	O
study	10960380	379	384	O
examined	10960380	385	393	O
the	10960380	394	397	O
anesthetic	10960380	398	408	B-Outcome
and	10960380	409	412	O
recovery	10960380	413	421	B-Outcome
profiles	10960380	422	430	I-Outcome
of	10960380	431	433	O
60-	10960380	434	437	B-Intervention
and	10960380	438	441	I-Intervention
80-mg	10960380	442	447	I-Intervention
doses	10960380	448	453	I-Intervention
of	10960380	454	456	I-Intervention
preservative-free	10960380	457	474	I-Intervention
plain	10960380	475	480	I-Intervention
mepivacaine	10960380	481	492	I-Intervention
for	10960380	493	496	O
ambulatory	10960380	497	507	B-Participant
spinal	10960380	508	514	I-Participant
anesthesia	10960380	515	525	I-Participant
.	10960380	526	527	O

Sixty	10960380	528	533	O
patients	10960380	534	542	O
undergoing	10960380	543	553	O
ambulatory	10960380	554	564	B-Participant
anterior	10960380	565	573	I-Participant
cruciate	10960380	574	582	I-Participant
ligament	10960380	583	591	I-Participant
repair	10960380	592	598	I-Participant
of	10960380	599	601	I-Participant
the	10960380	602	605	I-Participant
knee	10960380	606	610	I-Participant
under	10960380	611	616	O
spinal	10960380	617	623	B-Participant
anesthesia	10960380	624	634	I-Participant
were	10960380	635	639	O
randomized	10960380	640	650	O
into	10960380	651	655	O
two	10960380	656	659	O
groups	10960380	660	666	O
;	10960380	667	668	O
Group	10960380	669	674	O
1	10960380	675	676	O
(	10960380	677	678	O
29	10960380	679	681	O
patients	10960380	682	690	O
)	10960380	691	692	O
received	10960380	693	701	O
4	10960380	702	703	B-Intervention
mL	10960380	704	706	I-Intervention
of	10960380	707	709	I-Intervention
1.5	10960380	710	713	I-Intervention
%	10960380	714	715	I-Intervention
(	10960380	716	717	I-Intervention
60-mg	10960380	718	723	I-Intervention
dose	10960380	724	728	I-Intervention
)	10960380	729	730	I-Intervention
and	10960380	731	734	O
Group	10960380	735	740	O
2	10960380	741	742	O
(	10960380	743	744	O
31	10960380	745	747	O
patients	10960380	748	756	O
)	10960380	757	758	O
received	10960380	759	767	O
4	10960380	768	769	B-Intervention
mL	10960380	770	772	I-Intervention
of	10960380	773	775	I-Intervention
2	10960380	776	777	I-Intervention
%	10960380	778	779	I-Intervention
(	10960380	780	781	I-Intervention
80-mg	10960380	782	787	I-Intervention
dose	10960380	788	792	I-Intervention
)	10960380	793	794	I-Intervention
of	10960380	795	797	I-Intervention
plain	10960380	798	803	I-Intervention
mepivacaine	10960380	804	815	I-Intervention
.	10960380	816	817	O

All	10960380	818	821	O
patients	10960380	822	830	O
received	10960380	831	839	O
a	10960380	840	841	O
combined	10960380	842	850	O
spinal-epidural	10960380	851	866	O
anesthetic	10960380	867	877	O
technique	10960380	878	887	O
.	10960380	888	889	O

The	10960380	890	893	O
epidural	10960380	894	902	O
catheter	10960380	903	911	O
was	10960380	912	915	O
used	10960380	916	920	O
only	10960380	921	925	O
in	10960380	926	928	O
the	10960380	929	932	O
event	10960380	933	938	O
the	10960380	939	942	O
surgery	10960380	943	950	O
outlasted	10960380	951	960	O
the	10960380	961	964	O
duration	10960380	965	973	O
of	10960380	974	976	O
surgical	10960380	977	985	O
anesthesia	10960380	986	996	O
with	10960380	997	1001	O
subarachnoid	10960380	1002	1014	O
mepivacaine	10960380	1015	1026	O
.	10960380	1027	1028	O

Epidural	10960380	1029	1037	O
supplementation	10960380	1038	1053	O
was	10960380	1054	1057	O
administered	10960380	1058	1070	O
in	10960380	1071	1073	O
three	10960380	1074	1079	O
patients	10960380	1080	1088	O
(	10960380	1089	1090	O
12	10960380	1091	1093	O
%	10960380	1094	1095	O
)	10960380	1096	1097	O
in	10960380	1098	1100	O
Group	10960380	1101	1106	O
1	10960380	1107	1108	O
and	10960380	1109	1112	O
one	10960380	1113	1116	O
patient	10960380	1117	1124	O
(	10960380	1125	1126	O
3	10960380	1127	1128	O
%	10960380	1129	1130	O
)	10960380	1131	1132	O
in	10960380	1133	1135	O
Group	10960380	1136	1141	O
2	10960380	1142	1143	O
when	10960380	1144	1148	O
the	10960380	1149	1152	O
sensory	10960380	1153	1160	O
block	10960380	1161	1166	O
regressed	10960380	1167	1176	O
to	10960380	1177	1179	O
L-1	10960380	1180	1183	O
with	10960380	1184	1188	O
surgery	10960380	1189	1196	O
expected	10960380	1197	1205	O
to	10960380	1206	1208	O
last	10960380	1209	1213	O
longer	10960380	1214	1220	O
than	10960380	1221	1225	O
15	10960380	1226	1228	O
min	10960380	1229	1232	O
.	10960380	1233	1234	O

The	10960380	1235	1238	O
cephalad	10960380	1239	1247	B-Outcome
dermatome	10960380	1248	1257	I-Outcome
level	10960380	1258	1263	I-Outcome
of	10960380	1264	1266	I-Outcome
the	10960380	1267	1270	I-Outcome
block	10960380	1271	1276	I-Outcome
and	10960380	1277	1280	O
degree	10960380	1281	1287	B-Outcome
of	10960380	1288	1290	I-Outcome
motor	10960380	1291	1296	I-Outcome
block	10960380	1297	1302	I-Outcome
was	10960380	1303	1306	O
comparable	10960380	1307	1317	B-Observation
in	10960380	1318	1320	O
the	10960380	1321	1324	O
two	10960380	1325	1328	B-Intervention
groups	10960380	1329	1335	I-Intervention
.	10960380	1336	1337	O

Times	10960380	1338	1343	B-Outcome
to	10960380	1344	1346	I-Outcome
two-segment	10960380	1347	1358	I-Outcome
and	10960380	1359	1362	I-Outcome
T-10	10960380	1363	1367	I-Outcome
regression	10960380	1368	1378	I-Outcome
were	10960380	1379	1383	O
comparable	10960380	1384	1394	B-Observation
in	10960380	1395	1397	O
the	10960380	1398	1401	O
two	10960380	1402	1405	B-Intervention
groups	10960380	1406	1412	I-Intervention
(	10960380	1413	1414	O
112	10960380	1415	1418	B-Observation
+	10960380	1419	1420	I-Observation
/-	10960380	1420	1422	I-Observation
26	10960380	1423	1425	I-Observation
min	10960380	1426	1429	I-Observation
in	10960380	1430	1432	O
Group	10960380	1433	1438	B-Intervention
1	10960380	1439	1440	I-Intervention
versus	10960380	1441	1447	O
122	10960380	1448	1451	B-Observation
+	10960380	1452	1453	I-Observation
/-	10960380	1453	1455	I-Observation
28	10960380	1456	1458	I-Observation
min	10960380	1459	1462	I-Observation
in	10960380	1463	1465	O
Group	10960380	1466	1471	B-Intervention
2	10960380	1472	1473	I-Intervention
)	10960380	1474	1475	O
.	10960380	1476	1477	O

Time	10960380	1478	1482	B-Outcome
to	10960380	1483	1485	I-Outcome
L-1	10960380	1486	1489	I-Outcome
regression	10960380	1490	1500	I-Outcome
was	10960380	1501	1504	O
significantly	10960380	1505	1518	B-Observation
longer	10960380	1519	1525	I-Observation
in	10960380	1526	1528	O
Group	10960380	1529	1534	B-Intervention
2	10960380	1535	1536	I-Intervention
(	10960380	1537	1538	O
146	10960380	1539	1542	B-Observation
+	10960380	1543	1544	I-Observation
/-	10960380	1544	1546	I-Observation
28	10960380	1547	1549	I-Observation
min	10960380	1550	1553	I-Observation
in	10960380	1554	1556	O
Group	10960380	1557	1562	B-Intervention
1	10960380	1563	1564	I-Intervention
versus	10960380	1565	1571	O
159	10960380	1572	1575	B-Observation
+	10960380	1576	1577	I-Observation
/-	10960380	1577	1579	I-Observation
19	10960380	1580	1582	I-Observation
min	10960380	1583	1586	I-Observation
in	10960380	1587	1589	O
Group	10960380	1590	1595	B-Intervention
2	10960380	1596	1597	I-Intervention
)	10960380	1598	1599	O
.	10960380	1600	1601	O

All	10960380	1602	1605	B-Outcome
of	10960380	1606	1608	I-Outcome
the	10960380	1609	1612	I-Outcome
ambulatory	10960380	1613	1623	I-Outcome
milestones	10960380	1624	1634	I-Outcome
were	10960380	1635	1639	O
significantly	10960380	1640	1653	B-Observation
faster	10960380	1654	1660	I-Observation
in	10960380	1661	1663	O
Group	10960380	1664	1669	B-Intervention
1	10960380	1670	1671	I-Intervention
.	10960380	1672	1673	O

Side	10960380	1674	1678	B-Outcome
effects	10960380	1679	1686	I-Outcome
,	10960380	1687	1688	O
such	10960380	1689	1693	O
as	10960380	1694	1696	O
hypotension	10960380	1697	1708	B-Outcome
and	10960380	1709	1712	O
emesis	10960380	1713	1719	B-Outcome
were	10960380	1720	1724	O
negligible	10960380	1725	1735	B-Observation
,	10960380	1736	1737	O
severe	10960380	1738	1744	B-Outcome
bradycardia	10960380	1745	1756	I-Outcome
and	10960380	1757	1760	O
urinary	10960380	1761	1768	B-Outcome
retention	10960380	1769	1778	I-Outcome
did	10960380	1779	1782	O
not	10960380	1783	1786	O
occur	10960380	1787	1792	O
,	10960380	1793	1794	O
and	10960380	1795	1798	O
none	10960380	1799	1803	B-Count
of	10960380	1804	1806	I-Count
the	10960380	1807	1810	I-Count
patients	10960380	1811	1819	I-Count
in	10960380	1820	1822	O
the	10960380	1823	1826	O
two	10960380	1827	1830	B-Intervention
groups	10960380	1831	1837	I-Intervention
reported	10960380	1838	1846	O
transient	10960380	1847	1856	B-Outcome
neurological	10960380	1857	1869	I-Outcome
symptoms	10960380	1870	1878	I-Outcome
over	10960380	1879	1883	O
24	10960380	1884	1886	O
h.	10960380	1887	1889	O
In	10960380	1890	1892	O
conclusion	10960380	1893	1903	O
,	10960380	1904	1905	O
plain	10960380	1906	1911	B-Intervention
mepivacaine	10960380	1912	1923	I-Intervention
in	10960380	1924	1926	I-Intervention
a	10960380	1927	1928	I-Intervention
60-	10960380	1929	1932	I-Intervention
or	10960380	1933	1935	I-Intervention
80-mg	10960380	1936	1941	I-Intervention
dose	10960380	1942	1946	I-Intervention
is	10960380	1947	1949	O
a	10960380	1950	1951	O
suitable	10960380	1952	1960	B-Observation
local	10960380	1961	1966	O
anesthetic	10960380	1967	1977	O
choice	10960380	1978	1984	O
for	10960380	1985	1988	O
ambulatory	10960380	1989	1999	B-Participant
spinal	10960380	2000	2006	I-Participant
anesthesia	10960380	2007	2017	I-Participant
with	10960380	2018	2022	O
respect	10960380	2023	2030	O
to	10960380	2031	2033	O
anesthetic	10960380	2034	2044	B-Outcome
,	10960380	2045	2046	O
as	10960380	2047	2049	O
well	10960380	2050	2054	O
as	10960380	2055	2057	O
recovery	10960380	2058	2066	B-Outcome
profiles	10960380	2067	2075	I-Outcome
.	10960380	2076	2077	O

IMPLICATIONS	10960380	2078	2090	O
We	10960380	2091	2093	O
evaluated	10960380	2094	2103	O
the	10960380	2104	2107	O
anesthetic	10960380	2108	2118	B-Outcome
and	10960380	2119	2122	I-Outcome
recovery	10960380	2123	2131	I-Outcome
profiles	10960380	2132	2140	I-Outcome
of	10960380	2141	2143	O
60-	10960380	2144	2147	B-Intervention
and	10960380	2148	2151	I-Intervention
80-mg	10960380	2152	2157	I-Intervention
doses	10960380	2158	2163	I-Intervention
of	10960380	2164	2166	I-Intervention
plain	10960380	2167	2172	I-Intervention
mepivacaine	10960380	2173	2184	I-Intervention
for	10960380	2185	2188	O
ambulatory	10960380	2189	2199	B-Participant
spinal	10960380	2200	2206	I-Participant
anesthesia	10960380	2207	2217	I-Participant
.	10960380	2218	2219	O

Both	10960380	2220	2224	B-Intervention
doses	10960380	2225	2230	I-Intervention
produced	10960380	2231	2239	O
comparable	10960380	2240	2250	B-Observation
sensory	10960380	2251	2258	B-Outcome
and	10960380	2259	2262	I-Outcome
motor	10960380	2263	2268	I-Outcome
block	10960380	2269	2274	I-Outcome
.	10960380	2275	2276	O

Sensory	10960380	2277	2284	B-Outcome
and	10960380	2285	2288	I-Outcome
motor	10960380	2289	2294	I-Outcome
regression	10960380	2295	2305	I-Outcome
and	10960380	2306	2309	O
ambulatory	10960380	2310	2320	B-Outcome
milestones	10960380	2321	2331	I-Outcome
were	10960380	2332	2336	O
20	10960380	2337	2339	B-Observation
-	10960380	2339	2340	I-Observation
30	10960380	2340	2342	I-Observation
min	10960380	2343	2346	I-Observation
longer	10960380	2347	2353	I-Observation
with	10960380	2354	2358	O
the	10960380	2359	2362	O
80-mg	10960380	2363	2368	B-Intervention
dose	10960380	2369	2373	I-Intervention
.	10960380	2374	2375	O

Side	10960380	2376	2380	B-Outcome
effects	10960380	2381	2388	I-Outcome
were	10960380	2389	2393	O
negligible	10960380	2394	2404	B-Observation
and	10960380	2405	2408	O
transient	10960380	2409	2418	B-Outcome
neurological	10960380	2419	2431	I-Outcome
symptoms	10960380	2432	2440	I-Outcome
were	10960380	2441	2445	O
not	10960380	2446	2449	O
reported	10960380	2450	2458	O
during	10960380	2459	2465	O
a	10960380	2466	2467	O
24-h	10960380	2468	2472	O
follow-up	10960380	2473	2482	O
.	10960380	2483	2484	O

Epirubicin-based	10963640	0	16	B-Intervention
chemotherapy	10963640	17	29	I-Intervention
in	10963640	30	32	O
metastatic	10963640	33	43	B-Participant
breast	10963640	44	50	I-Participant
cancer	10963640	51	57	I-Participant
patients	10963640	58	66	O
:	10963640	67	68	O
role	10963640	69	73	O
of	10963640	74	76	O
dose-intensity	10963640	77	91	B-Intervention
and	10963640	92	95	I-Intervention
duration	10963640	96	104	I-Intervention
of	10963640	105	107	O
treatment	10963640	108	117	O
.	10963640	118	119	O

PURPOSE	10963640	120	127	O
To	10963640	128	130	O
determine	10963640	131	140	O
whether	10963640	141	148	O
the	10963640	149	152	O
duration	10963640	153	161	B-Intervention
and	10963640	162	165	I-Intervention
the	10963640	166	169	I-Intervention
dose	10963640	170	174	I-Intervention
of	10963640	175	177	I-Intervention
epirubicin	10963640	178	188	I-Intervention
modify	10963640	189	195	B-Observation
the	10963640	196	199	O
long-term	10963640	200	209	B-Outcome
outcome	10963640	210	217	I-Outcome
of	10963640	218	220	O
patients	10963640	221	229	O
with	10963640	230	234	O
metastatic	10963640	235	245	B-Participant
breast	10963640	246	252	I-Participant
cancer	10963640	253	259	I-Participant
(	10963640	260	261	I-Participant
MBC	10963640	262	265	I-Participant
)	10963640	266	267	I-Participant
.	10963640	268	269	O

PATIENTS	10963640	270	278	O
AND	10963640	279	282	O
METHODS	10963640	283	290	O
Four	10963640	291	295	O
hundred	10963640	296	303	O
seventeen	10963640	304	313	O
anthracycline-naive	10963640	314	333	B-Participant
MBC	10963640	334	337	I-Participant
patients	10963640	338	346	O
were	10963640	347	351	O
randomized	10963640	352	362	O
to	10963640	363	365	O
receive	10963640	366	373	O
one	10963640	374	377	O
of	10963640	378	380	O
the	10963640	381	384	O
following	10963640	385	394	O
regimens	10963640	395	403	O
:	10963640	404	405	O
arm	10963640	406	409	B-Intervention
A	10963640	410	411	I-Intervention
:	10963640	412	413	O
11	10963640	414	416	B-Intervention
cycles	10963640	417	423	I-Intervention
of	10963640	424	426	I-Intervention
fluorouracil	10963640	427	439	I-Intervention
500	10963640	440	443	I-Intervention
mg/m	10963640	444	448	I-Intervention
(	10963640	449	450	I-Intervention
2	10963640	451	452	I-Intervention
)	10963640	453	454	I-Intervention
,	10963640	455	456	I-Intervention
epirubicin	10963640	457	467	I-Intervention
75	10963640	468	470	I-Intervention
mg/m	10963640	471	475	I-Intervention
(	10963640	476	477	I-Intervention
2	10963640	478	479	I-Intervention
)	10963640	480	481	I-Intervention
,	10963640	482	483	I-Intervention
and	10963640	484	487	I-Intervention
cyclophosphamide	10963640	488	504	I-Intervention
500	10963640	505	508	I-Intervention
mg/m	10963640	509	513	I-Intervention
(	10963640	514	515	I-Intervention
2	10963640	516	517	I-Intervention
)	10963640	518	519	I-Intervention
(	10963640	520	521	I-Intervention
FEC	10963640	522	525	I-Intervention
75	10963640	526	528	I-Intervention
)	10963640	529	530	I-Intervention
every	10963640	531	536	I-Intervention
21	10963640	537	539	I-Intervention
days	10963640	540	544	I-Intervention
;	10963640	545	546	O
arm	10963640	547	550	B-Intervention
B	10963640	551	552	I-Intervention
:	10963640	553	554	O
four	10963640	555	559	B-Intervention
cycles	10963640	560	566	I-Intervention
of	10963640	567	569	I-Intervention
FEC	10963640	570	573	I-Intervention
100	10963640	574	577	I-Intervention
(	10963640	578	579	I-Intervention
same	10963640	580	584	I-Intervention
regimen	10963640	585	592	I-Intervention
but	10963640	593	596	I-Intervention
with	10963640	597	601	I-Intervention
epirubicin	10963640	602	612	I-Intervention
100	10963640	613	616	I-Intervention
mg/m	10963640	617	621	I-Intervention
(	10963640	622	623	I-Intervention
2	10963640	624	625	I-Intervention
)	10963640	626	627	I-Intervention
)	10963640	628	629	I-Intervention
then	10963640	630	634	I-Intervention
eight	10963640	635	640	I-Intervention
cycles	10963640	641	647	I-Intervention
of	10963640	648	650	I-Intervention
FEC	10963640	651	654	I-Intervention
50	10963640	655	657	I-Intervention
(	10963640	658	659	I-Intervention
epirubicin	10963640	660	670	I-Intervention
50	10963640	671	673	I-Intervention
mg/m	10963640	674	678	I-Intervention
(	10963640	679	680	I-Intervention
2	10963640	681	682	I-Intervention
)	10963640	683	684	I-Intervention
)	10963640	685	686	I-Intervention
;	10963640	687	688	O
and	10963640	689	692	O
arm	10963640	693	696	B-Intervention
C	10963640	697	698	I-Intervention
:	10963640	699	700	O
four	10963640	701	705	B-Intervention
cycles	10963640	706	712	I-Intervention
of	10963640	713	715	I-Intervention
FEC	10963640	716	719	I-Intervention
100	10963640	720	723	I-Intervention
then	10963640	724	728	I-Intervention
restart	10963640	729	736	I-Intervention
the	10963640	737	740	I-Intervention
same	10963640	741	745	I-Intervention
regimen	10963640	746	753	I-Intervention
at	10963640	754	756	I-Intervention
disease	10963640	757	764	I-Intervention
progression	10963640	765	776	I-Intervention
in	10963640	777	779	I-Intervention
case	10963640	780	784	I-Intervention
of	10963640	785	787	I-Intervention
prior	10963640	788	793	I-Intervention
response	10963640	794	802	I-Intervention
or	10963640	803	805	I-Intervention
stabilization	10963640	806	819	I-Intervention
.	10963640	820	821	O

RESULTS	10963640	822	829	O
Hematologic	10963640	830	841	B-Outcome
toxicity	10963640	842	850	I-Outcome
was	10963640	851	854	O
similar	10963640	855	862	B-Observation
.	10963640	863	864	O

Nausea/vomiting	10963640	865	880	B-Outcome
and	10963640	881	884	O
stomatitis	10963640	885	895	B-Outcome
were	10963640	896	900	O
significantly	10963640	901	914	B-Observation
less	10963640	915	919	I-Observation
frequent	10963640	920	928	I-Observation
in	10963640	929	931	O
arm	10963640	932	935	B-Intervention
A	10963640	936	937	I-Intervention
as	10963640	938	940	O
was	10963640	941	944	O
left	10963640	945	949	B-Outcome
ventricular	10963640	950	961	I-Outcome
ejection	10963640	962	970	I-Outcome
fraction	10963640	971	979	I-Outcome
decrease	10963640	980	988	B-Observation
in	10963640	989	991	O
arm	10963640	992	995	B-Intervention
C	10963640	996	997	I-Intervention
(	10963640	998	999	O
A	10963640	1000	1001	B-Intervention
=	10963640	1002	1003	O
six	10963640	1004	1007	B-Count
patients	10963640	1008	1016	I-Count
,	10963640	1017	1018	O
B	10963640	1019	1020	B-Intervention
=	10963640	1021	1022	O
five	10963640	1023	1027	B-Count
patients	10963640	1028	1036	I-Count
,	10963640	1037	1038	O
and	10963640	1039	1042	O
C	10963640	1043	1044	B-Intervention
=	10963640	1045	1046	O
one	10963640	1047	1050	B-Count
patient	10963640	1051	1058	I-Count
)	10963640	1059	1060	O
.	10963640	1061	1062	O

Six	10963640	1063	1066	B-Count
patients	10963640	1067	1075	I-Count
died	10963640	1076	1080	B-Outcome
of	10963640	1081	1083	I-Outcome
infections	10963640	1084	1094	I-Outcome
(	10963640	1095	1096	O
A	10963640	1097	1098	B-Intervention
=	10963640	1099	1100	O
four	10963640	1101	1105	B-Count
patients	10963640	1106	1114	I-Count
and	10963640	1115	1118	O
C	10963640	1119	1120	B-Intervention
=	10963640	1121	1122	O
two	10963640	1123	1126	B-Count
patients	10963640	1127	1135	I-Count
)	10963640	1136	1137	O
.	10963640	1138	1139	O

After	10963640	1140	1145	O
four	10963640	1146	1150	O
cycles	10963640	1151	1157	O
,	10963640	1158	1159	O
the	10963640	1160	1163	O
objective	10963640	1164	1173	B-Outcome
response	10963640	1174	1182	I-Outcome
rate	10963640	1183	1187	I-Outcome
(	10963640	1188	1189	I-Outcome
ORR	10963640	1190	1193	I-Outcome
)	10963640	1194	1195	I-Outcome
was	10963640	1196	1199	O
better	10963640	1200	1206	B-Observation
with	10963640	1207	1211	O
FEC	10963640	1212	1215	B-Intervention
100	10963640	1216	1219	I-Intervention
than	10963640	1220	1224	O
with	10963640	1225	1229	O
FEC	10963640	1230	1233	B-Intervention
75	10963640	1234	1236	I-Intervention
(	10963640	1237	1238	O
49.2	10963640	1239	1243	B-Observation
%	10963640	1244	1245	I-Observation
v	10963640	1246	1247	O
40	10963640	1248	1250	B-Observation
%	10963640	1251	1252	I-Observation
,	10963640	1253	1254	O
respectively	10963640	1255	1267	O
;	10963640	1268	1269	O
P	10963640	1270	1271	O
:	10963640	1272	1273	O
=	10963640	1274	1275	O
.07	10963640	1275	1278	O
)	10963640	1279	1280	O
.	10963640	1281	1282	O

The	10963640	1283	1286	O
ORR	10963640	1287	1290	B-Outcome
was	10963640	1291	1294	O
better	10963640	1295	1301	B-Observation
with	10963640	1302	1306	O
the	10963640	1307	1310	O
longer	10963640	1311	1317	B-Intervention
regimens	10963640	1318	1326	I-Intervention
(	10963640	1327	1328	O
arm	10963640	1329	1332	B-Intervention
A	10963640	1333	1334	I-Intervention
,	10963640	1335	1336	O
56.9	10963640	1337	1341	B-Observation
%	10963640	1342	1343	I-Observation
;	10963640	1344	1345	O
B	10963640	1346	1347	B-Intervention
,	10963640	1348	1349	O
64	10963640	1350	1352	B-Observation
%	10963640	1353	1354	I-Observation
;	10963640	1355	1356	O
and	10963640	1357	1360	O
C	10963640	1361	1362	B-Intervention
,	10963640	1363	1364	O
47.6	10963640	1365	1369	B-Observation
%	10963640	1370	1371	I-Observation
;	10963640	1372	1373	O
P	10963640	1374	1375	O
:	10963640	1376	1377	O
=	10963640	1378	1379	O
.06	10963640	1379	1382	O
)	10963640	1383	1384	O
and	10963640	1385	1388	O
was	10963640	1389	1392	O
41	10963640	1393	1395	B-Observation
%	10963640	1396	1397	I-Observation
after	10963640	1398	1403	O
second-line	10963640	1404	1415	B-Intervention
FEC	10963640	1416	1419	I-Intervention
100	10963640	1420	1423	I-Intervention
.	10963640	1424	1425	O

After	10963640	1426	1431	O
a	10963640	1432	1433	O
median	10963640	1434	1440	O
follow-up	10963640	1441	1450	O
of	10963640	1451	1453	O
41	10963640	1454	1456	O
months	10963640	1457	1463	O
,	10963640	1464	1465	O
the	10963640	1466	1469	O
response	10963640	1470	1478	B-Outcome
duration	10963640	1479	1487	I-Outcome
and	10963640	1488	1491	O
time	10963640	1492	1496	B-Outcome
to	10963640	1497	1499	I-Outcome
progression	10963640	1500	1511	I-Outcome
(	10963640	1512	1513	I-Outcome
TTP	10963640	1514	1517	I-Outcome
)	10963640	1518	1519	I-Outcome
were	10963640	1520	1524	O
significantly	10963640	1525	1538	B-Observation
better	10963640	1539	1545	I-Observation
with	10963640	1546	1550	O
arm	10963640	1551	1554	B-Intervention
B	10963640	1555	1556	I-Intervention
,	10963640	1557	1558	O
the	10963640	1559	1562	O
longer	10963640	1563	1569	O
regimen	10963640	1570	1577	O
(	10963640	1578	1579	O
P	10963640	1580	1581	O
:	10963640	1582	1583	O
=	10963640	1584	1585	O
.012	10963640	1585	1589	O
and	10963640	1590	1593	O
P	10963640	1594	1595	O
:	10963640	1596	1597	O
<	10963640	1598	1599	O
10	10963640	1600	1602	O
(	10963640	1603	1604	O
-3	10963640	1605	1607	O
)	10963640	1608	1609	O
,	10963640	1610	1611	O
respectively	10963640	1612	1624	O
)	10963640	1625	1626	O
.	10963640	1627	1628	O

The	10963640	1629	1632	O
median	10963640	1633	1639	B-Outcome
survival	10963640	1640	1648	I-Outcome
times	10963640	1649	1654	I-Outcome
for	10963640	1655	1658	O
arms	10963640	1659	1663	B-Intervention
A	10963640	1664	1665	I-Intervention
,	10963640	1666	1667	O
B	10963640	1668	1669	B-Intervention
,	10963640	1670	1671	O
and	10963640	1672	1675	O
C	10963640	1676	1677	B-Intervention
were	10963640	1678	1682	O
similar	10963640	1683	1690	B-Observation
(	10963640	1691	1692	O
17.9	10963640	1693	1697	B-Observation
,	10963640	1698	1699	O
18.9	10963640	1700	1704	B-Observation
,	10963640	1705	1706	O
and	10963640	1707	1710	O
16	10963640	1711	1713	B-Observation
.	10963640	1714	1715	I-Observation
3	10963640	1716	1717	I-Observation
months	10963640	1718	1724	I-Observation
,	10963640	1725	1726	O
respectively	10963640	1727	1739	O
;	10963640	1740	1741	O
P	10963640	1742	1743	O
:	10963640	1744	1745	O
=	10963640	1746	1747	O
.49	10963640	1747	1750	O
)	10963640	1751	1752	O
.	10963640	1753	1754	O

CONCLUSION	10963640	1755	1765	O
In	10963640	1766	1768	O
MBC	10963640	1769	1772	B-Participant
,	10963640	1773	1774	O
longer	10963640	1775	1781	B-Intervention
epirubicin-based	10963640	1782	1798	I-Intervention
regimens	10963640	1799	1807	I-Intervention
are	10963640	1808	1811	O
better	10963640	1812	1818	B-Observation
in	10963640	1819	1821	O
terms	10963640	1822	1827	O
of	10963640	1828	1830	O
response	10963640	1831	1839	B-Outcome
duration	10963640	1840	1848	I-Outcome
and	10963640	1849	1852	O
TTP	10963640	1853	1856	B-Outcome
.	10963640	1857	1858	O

FEC	10963640	1859	1862	B-Intervention
100	10963640	1863	1866	I-Intervention
regimens	10963640	1867	1875	I-Intervention
improve	10963640	1876	1883	B-Observation
the	10963640	1884	1887	O
ORR	10963640	1888	1891	B-Outcome
.	10963640	1892	1893	O

However	10963640	1894	1901	O
,	10963640	1902	1903	O
four	10963640	1904	1908	B-Intervention
initial	10963640	1909	1916	I-Intervention
cycles	10963640	1917	1923	I-Intervention
of	10963640	1924	1926	I-Intervention
FEC	10963640	1927	1930	I-Intervention
100	10963640	1931	1934	I-Intervention
and	10963640	1935	1938	I-Intervention
identical	10963640	1939	1948	I-Intervention
retreatment	10963640	1949	1960	I-Intervention
at	10963640	1961	1963	I-Intervention
disease	10963640	1964	1971	I-Intervention
progression	10963640	1972	1983	I-Intervention
yielded	10963640	1984	1991	O
equivalent	10963640	1992	2002	B-Observation
overall	10963640	2003	2010	B-Outcome
survival	10963640	2011	2019	I-Outcome
to	10963640	2020	2022	O
longer	10963640	2023	2029	B-Intervention
regimens	10963640	2030	2038	I-Intervention
.	10963640	2039	2040	O

The	10968308	0	3	O
effect	10968308	4	10	O
of	10968308	11	13	O
case	10968308	14	18	B-Intervention
management	10968308	19	29	I-Intervention
on	10968308	30	32	O
the	10968308	33	36	O
costs	10968308	37	42	B-Outcome
of	10968308	43	45	I-Outcome
health	10968308	46	52	I-Outcome
care	10968308	53	57	I-Outcome
for	10968308	58	61	O
enrollees	10968308	62	71	O
in	10968308	72	74	O
Medicare	10968308	75	83	B-Participant
Plus	10968308	84	88	I-Participant
Choice	10968308	89	95	I-Participant
plans	10968308	96	101	I-Participant
:	10968308	102	103	O
a	10968308	104	105	O
randomized	10968308	106	116	O
trial	10968308	117	122	O
.	10968308	123	124	O

OBJECTIVE	10968308	125	134	O
To	10968308	135	137	O
measure	10968308	138	145	O
the	10968308	146	149	O
effects	10968308	150	157	O
of	10968308	158	160	O
case	10968308	161	165	B-Intervention
management	10968308	166	176	I-Intervention
on	10968308	177	179	O
an	10968308	180	182	O
older	10968308	183	188	B-Participant
population	10968308	189	199	I-Participant
's	10968308	200	202	O
costs	10968308	203	208	B-Outcome
of	10968308	209	211	I-Outcome
health	10968308	212	218	I-Outcome
care	10968308	219	223	I-Outcome
.	10968308	224	225	O

DESIGN	10968308	226	232	O
A	10968308	233	234	O
1-year	10968308	235	241	O
randomized	10968308	242	252	O
controlled	10968308	253	263	O
trial	10968308	264	269	O
.	10968308	270	271	O

SETTING	10968308	272	279	O
Multiple	10968308	280	288	O
sites	10968308	289	294	O
of	10968308	295	297	O
care	10968308	298	302	O
in	10968308	303	305	O
San	10968308	306	309	O
Francisco	10968308	310	319	O
,	10968308	320	321	O
California	10968308	322	332	O
.	10968308	333	334	O

PARTICIPANTS	10968308	335	347	O
Patients	10968308	348	356	O
aged	10968308	357	361	O
65	10968308	362	364	O
or	10968308	365	367	O
older	10968308	368	373	O
of	10968308	374	376	O
primary	10968308	377	384	O
care	10968308	385	389	O
physicians	10968308	390	400	O
in	10968308	401	403	O
a	10968308	404	405	O
large	10968308	406	411	O
provider	10968308	412	420	O
organization	10968308	421	433	O
bearing	10968308	434	441	O
financial	10968308	442	451	B-Participant
risk	10968308	452	456	I-Participant
for	10968308	457	460	I-Participant
their	10968308	461	466	I-Participant
care	10968308	467	471	I-Participant
(	10968308	472	473	O
n	10968308	474	475	O
=	10968308	476	477	O
6409	10968308	478	482	O
)	10968308	483	484	O
.	10968308	485	486	O

INTERVENTION	10968308	487	499	O
Screening	10968308	500	509	B-Intervention
for	10968308	510	513	I-Intervention
high	10968308	514	518	I-Intervention
risk	10968308	519	523	I-Intervention
and	10968308	524	527	O
provision	10968308	528	537	B-Intervention
of	10968308	538	540	I-Intervention
social	10968308	541	547	I-Intervention
work-based	10968308	548	558	I-Intervention
case	10968308	559	563	I-Intervention
management	10968308	564	574	I-Intervention
.	10968308	575	576	O

OUTCOME	10968308	577	584	O
MEASURES	10968308	585	593	O
Volume	10968308	594	600	B-Outcome
and	10968308	601	604	I-Outcome
cost	10968308	605	609	I-Outcome
of	10968308	610	612	I-Outcome
hospital	10968308	613	621	I-Outcome
,	10968308	622	623	O
physician	10968308	624	633	B-Outcome
,	10968308	634	635	O
case	10968308	636	640	B-Outcome
management	10968308	641	651	I-Outcome
,	10968308	652	653	O
and	10968308	654	657	O
other	10968308	658	663	O
health-related	10968308	664	678	B-Outcome
services	10968308	679	687	I-Outcome
.	10968308	688	689	O

RESULTS	10968308	690	697	O
The	10968308	698	701	O
experimental	10968308	702	714	B-Intervention
group	10968308	715	720	O
used	10968308	721	725	O
more	10968308	726	730	B-Observation
case	10968308	731	735	B-Outcome
management	10968308	736	746	I-Outcome
services	10968308	747	755	I-Outcome
than	10968308	756	760	O
the	10968308	761	764	O
control	10968308	765	772	B-Intervention
group	10968308	773	778	O
(	10968308	779	780	O
0.09	10968308	781	785	B-Observation
vs.	10968308	786	789	O
0.02	10968308	790	794	B-Observation
months	10968308	795	801	I-Observation
per	10968308	802	805	I-Observation
person	10968308	806	812	I-Observation
,	10968308	813	814	O
P	10968308	815	816	O
<	10968308	817	818	O
.001	10968308	819	823	O
)	10968308	824	825	O
.	10968308	826	827	O

The	10968308	828	831	O
experimental	10968308	832	844	B-Intervention
group	10968308	845	850	O
's	10968308	851	853	O
average	10968308	854	861	B-Outcome
total	10968308	862	867	I-Outcome
payments	10968308	868	876	I-Outcome
for	10968308	877	880	I-Outcome
health	10968308	881	887	I-Outcome
care	10968308	888	892	I-Outcome
were	10968308	893	897	O
slightly	10968308	898	906	B-Observation
lower	10968308	907	912	I-Observation
(	10968308	913	914	O
$	10968308	915	916	B-Observation
3148	10968308	917	921	I-Observation
vs	10968308	922	924	O
$	10968308	925	926	B-Observation
3277	10968308	927	931	I-Observation
,	10968308	932	933	O
P	10968308	934	935	O
=	10968308	936	937	O
.40	10968308	938	941	O
)	10968308	942	943	O
.	10968308	944	945	O

CONCLUSIONS	10968308	946	957	O
This	10968308	958	962	O
study	10968308	963	968	O
provides	10968308	969	977	O
no	10968308	978	980	O
statistically	10968308	981	994	O
significant	10968308	995	1006	O
evidence	10968308	1007	1015	O
that	10968308	1016	1020	O
social	10968308	1021	1027	B-Intervention
work-oriented	10968308	1028	1041	I-Intervention
case	10968308	1042	1046	I-Intervention
management	10968308	1047	1057	I-Intervention
reduces	10968308	1058	1065	B-Observation
the	10968308	1066	1069	O
use	10968308	1070	1073	B-Outcome
or	10968308	1074	1076	I-Outcome
the	10968308	1077	1080	I-Outcome
cost	10968308	1081	1085	I-Outcome
of	10968308	1086	1088	I-Outcome
health	10968308	1089	1095	I-Outcome
care	10968308	1096	1100	I-Outcome
for	10968308	1101	1104	O
high-risk	10968308	1105	1114	B-Participant
older	10968308	1115	1120	I-Participant
people	10968308	1121	1127	O
.	10968308	1128	1129	O

Other	10968308	1130	1135	O
potentially	10968308	1136	1147	O
favorable	10968308	1148	1157	O
effects	10968308	1158	1165	O
of	10968308	1166	1168	O
this	10968308	1169	1173	O
type	10968308	1174	1178	O
of	10968308	1179	1181	O
case	10968308	1182	1186	O
management	10968308	1187	1197	O
need	10968308	1198	1202	O
to	10968308	1203	1205	O
be	10968308	1206	1208	O
evaluated	10968308	1209	1218	O
,	10968308	1219	1220	O
as	10968308	1221	1223	O
do	10968308	1224	1226	O
the	10968308	1227	1230	O
effects	10968308	1231	1238	O
of	10968308	1239	1241	O
other	10968308	1242	1247	O
types	10968308	1248	1253	O
of	10968308	1254	1256	O
case	10968308	1257	1261	O
management	10968308	1262	1272	O
.	10968308	1273	1274	O

Influence	10971307	0	9	O
of	10971307	10	12	O
asimadoline	10971307	13	24	B-Intervention
,	10971307	25	26	O
a	10971307	27	28	O
new	10971307	29	32	O
kappa-opioid	10971307	33	45	O
receptor	10971307	46	54	O
agonist	10971307	55	62	O
,	10971307	63	64	O
on	10971307	65	67	O
tubular	10971307	68	75	B-Outcome
water	10971307	76	81	I-Outcome
absorption	10971307	82	92	I-Outcome
and	10971307	93	96	O
vasopressin	10971307	97	108	B-Outcome
secretion	10971307	109	118	I-Outcome
in	10971307	119	121	O
man	10971307	122	125	B-Participant
.	10971307	126	127	O

AIMS	10971307	128	132	O
The	10971307	133	136	O
purpose	10971307	137	144	O
of	10971307	145	147	O
the	10971307	148	151	O
study	10971307	152	157	O
was	10971307	158	161	O
to	10971307	162	164	O
investigate	10971307	165	176	O
the	10971307	177	180	O
effects	10971307	181	188	O
of	10971307	189	191	O
asimadoline	10971307	192	203	B-Intervention
,	10971307	204	205	O
a	10971307	206	207	O
new	10971307	208	211	O
kappa-opioid	10971307	212	224	O
agonist	10971307	225	232	O
,	10971307	233	234	O
on	10971307	235	237	O
renal	10971307	238	243	B-Outcome
function	10971307	244	252	I-Outcome
and	10971307	253	256	O
on	10971307	257	259	O
hormones	10971307	260	268	B-Outcome
related	10971307	269	276	I-Outcome
to	10971307	277	279	I-Outcome
body	10971307	280	284	I-Outcome
fluid	10971307	285	290	I-Outcome
balance	10971307	291	298	I-Outcome
as	10971307	299	301	O
well	10971307	302	306	O
as	10971307	307	309	O
its	10971307	310	313	O
tolerability	10971307	314	326	B-Outcome
in	10971307	327	329	O
healthy	10971307	330	337	B-Participant
subjects	10971307	338	346	O
.	10971307	347	348	O

METHODS	10971307	349	356	O
In	10971307	357	359	O
a	10971307	360	361	O
placebo-controlled	10971307	362	380	O
,	10971307	381	382	O
randomised	10971307	383	393	O
,	10971307	394	395	O
double-blind	10971307	396	408	O
crossover	10971307	409	418	O
design	10971307	419	425	O
we	10971307	426	428	O
studied	10971307	429	436	O
the	10971307	437	440	O
effects	10971307	441	448	O
of	10971307	449	451	O
single	10971307	452	458	O
oral	10971307	459	463	O
doses	10971307	464	469	O
of	10971307	470	472	O
1	10971307	473	474	B-Intervention
,	10971307	475	476	I-Intervention
5	10971307	477	478	I-Intervention
,	10971307	479	480	I-Intervention
and	10971307	481	484	I-Intervention
10	10971307	485	487	I-Intervention
mg	10971307	488	490	I-Intervention
of	10971307	491	493	I-Intervention
asimadoline	10971307	494	505	I-Intervention
,	10971307	506	507	O
in	10971307	508	510	O
24	10971307	511	513	O
healthy	10971307	514	521	B-Participant
volunteers	10971307	522	532	O
.	10971307	533	534	O

Two	10971307	535	538	O
hour	10971307	539	543	O
control	10971307	544	551	O
urine	10971307	552	557	O
collections	10971307	558	569	O
were	10971307	570	574	O
followed	10971307	575	583	O
by	10971307	584	586	O
2	10971307	587	588	O
h	10971307	589	590	O
postdose	10971307	591	599	O
urine	10971307	600	605	O
collections	10971307	606	617	O
and	10971307	618	621	O
subsequently	10971307	622	634	O
2.5	10971307	635	638	O
%	10971307	639	640	O
saline	10971307	641	647	O
was	10971307	648	651	O
given	10971307	652	657	O
i.v	10971307	658	661	O
.	10971307	662	663	O
at	10971307	664	666	O
a	10971307	667	668	O
rate	10971307	669	673	O
of	10971307	674	676	O
0.3	10971307	677	680	O
ml	10971307	681	683	O
min	10971307	684	687	O
(	10971307	688	689	O
-1	10971307	690	692	O
)	10971307	693	694	O
kg	10971307	695	697	O
(	10971307	698	699	O
-1	10971307	700	702	O
)	10971307	703	704	O
during	10971307	705	711	O
another	10971307	712	719	O
2	10971307	720	721	O
h	10971307	722	723	O
urine	10971307	724	729	O
collection	10971307	730	740	O
.	10971307	741	742	O

Blood	10971307	743	748	O
was	10971307	749	752	O
obtained	10971307	753	761	O
hourly	10971307	762	768	O
.	10971307	769	770	O

Arginine-vasopressin	10971307	771	791	B-Outcome
(	10971307	792	793	I-Outcome
AVP	10971307	794	797	I-Outcome
)	10971307	798	799	I-Outcome
,	10971307	800	801	O
atrial	10971307	802	808	B-Outcome
natriuretic	10971307	809	820	I-Outcome
peptide	10971307	821	828	I-Outcome
(	10971307	829	830	I-Outcome
alpha-hANP	10971307	831	841	I-Outcome
)	10971307	842	843	I-Outcome
,	10971307	844	845	O
endothelin	10971307	846	856	B-Outcome
(	10971307	857	858	I-Outcome
ET-1	10971307	859	863	I-Outcome
)	10971307	864	865	I-Outcome
and	10971307	866	869	O
cAMP	10971307	870	874	B-Outcome
were	10971307	875	879	O
determined	10971307	880	890	O
by	10971307	891	893	O
r.i.a	10971307	894	899	O
.	10971307	900	901	O

or	10971307	902	904	O

ELISA	10971307	905	910	O
.	10971307	911	912	O

RESULTS	10971307	913	920	O
GC-MS	10971307	921	926	O
measurements	10971307	927	939	O
revealed	10971307	940	948	O
Cmax	10971307	949	953	B-Outcome
values	10971307	954	960	I-Outcome
of	10971307	961	963	I-Outcome
asimadoline	10971307	964	975	I-Outcome
in	10971307	976	978	I-Outcome
plasma	10971307	979	985	I-Outcome
ranging	10971307	986	993	O
from	10971307	994	998	O
18	10971307	999	1001	B-Observation
ng	10971307	1002	1004	I-Observation
ml	10971307	1005	1007	I-Observation
(	10971307	1008	1009	I-Observation
-1	10971307	1010	1012	I-Observation
)	10971307	1013	1014	I-Observation
at	10971307	1015	1017	O
the	10971307	1018	1021	O
1	10971307	1022	1023	B-Intervention
mg	10971307	1024	1026	I-Intervention
dose	10971307	1027	1031	I-Intervention
,	10971307	1032	1033	O
91	10971307	1034	1036	B-Observation
ng	10971307	1037	1039	I-Observation
ml	10971307	1040	1042	I-Observation
(	10971307	1043	1044	I-Observation
-1	10971307	1045	1047	I-Observation
)	10971307	1048	1049	I-Observation
at	10971307	1050	1052	O
the	10971307	1053	1056	O
5	10971307	1057	1058	B-Intervention
mg	10971307	1059	1061	I-Intervention
dose	10971307	1062	1066	I-Intervention
,	10971307	1067	1068	O
to	10971307	1069	1071	O
214	10971307	1072	1075	B-Observation
ng	10971307	1076	1078	I-Observation
ml	10971307	1079	1081	I-Observation
(	10971307	1082	1083	O
-1	10971307	1084	1086	O
)	10971307	1087	1088	O
at	10971307	1089	1091	O
the	10971307	1092	1095	O
10	10971307	1096	1098	B-Intervention
mg	10971307	1099	1101	I-Intervention
dose	10971307	1102	1106	I-Intervention
after	10971307	1107	1112	O
an	10971307	1113	1115	O
average	10971307	1116	1123	O
of	10971307	1124	1126	O
1.1	10971307	1127	1130	O
-	10971307	1130	1131	O
1.4	10971307	1131	1134	O
h.	10971307	1135	1137	O
Without	10971307	1138	1145	O
effects	10971307	1146	1153	O
on	10971307	1154	1156	O
blood	10971307	1157	1162	B-Outcome
pressure	10971307	1163	1171	I-Outcome
,	10971307	1172	1173	O
heart	10971307	1174	1179	B-Outcome
rate	10971307	1180	1184	I-Outcome
,	10971307	1185	1186	O
GFR	10971307	1187	1190	B-Outcome
or	10971307	1191	1193	O
urine	10971307	1194	1199	B-Outcome
electrolyte	10971307	1200	1211	I-Outcome
excretion	10971307	1212	1221	I-Outcome
,	10971307	1222	1223	O
urine	10971307	1224	1229	B-Outcome
volume	10971307	1230	1236	I-Outcome
increased	10971307	1237	1246	B-Observation
after	10971307	1247	1252	O
1	10971307	1253	1254	O
-	10971307	1254	1255	O
2	10971307	1255	1256	O
h	10971307	1257	1258	O
after	10971307	1259	1264	O
administration	10971307	1265	1279	O
of	10971307	1280	1282	O
5	10971307	1283	1284	B-Intervention
and	10971307	1285	1288	O
10	10971307	1289	1291	B-Intervention
mg	10971307	1292	1294	I-Intervention
asimadoline	10971307	1295	1306	I-Intervention
from	10971307	1307	1311	B-Observation
3.3+/-1.3	10971307	1312	1321	I-Observation
to	10971307	1322	1324	I-Observation
5.6+/-1.4	10971307	1325	1334	I-Observation
(	10971307	1335	1336	O
P	10971307	1337	1338	O
<	10971307	1339	1340	O
0.05	10971307	1341	1345	O
)	10971307	1346	1347	O
and	10971307	1348	1351	O
from	10971307	1352	1356	B-Observation
3.2	10971307	1357	1360	I-Observation
+	10971307	1361	1362	I-Observation
/-1.6	10971307	1362	1367	I-Observation
to	10971307	1368	1370	I-Observation
5.5+/-2.2	10971307	1371	1380	I-Observation
ml	10971307	1381	1383	I-Observation
min	10971307	1384	1387	I-Observation
(	10971307	1388	1389	I-Observation
-1	10971307	1390	1392	I-Observation
)	10971307	1393	1394	I-Observation
(	10971307	1395	1396	O
P	10971307	1397	1398	O
<	10971307	1399	1400	O
0.01	10971307	1401	1405	O
)	10971307	1406	1407	O
,	10971307	1408	1409	O
respectively	10971307	1410	1422	O
.	10971307	1423	1424	O

CH2O	10971307	1425	1429	B-Outcome
rose	10971307	1430	1434	B-Observation
from	10971307	1435	1439	I-Observation
0.2+/-1.5	10971307	1440	1449	I-Observation
to	10971307	1450	1452	I-Observation
2.0+/-1.6	10971307	1453	1462	I-Observation
(	10971307	1463	1464	O
P	10971307	1465	1466	O
<	10971307	1467	1468	O
0.05	10971307	1469	1473	O
)	10971307	1474	1475	O
and	10971307	1476	1479	O
from	10971307	1480	1484	B-Observation
0.6+/-1.6	10971307	1485	1494	I-Observation
to	10971307	1495	1497	I-Observation
3.0+/-1.6	10971307	1498	1507	I-Observation
ml	10971307	1508	1510	I-Observation
min	10971307	1511	1514	I-Observation
(	10971307	1515	1516	I-Observation
-1	10971307	1517	1519	I-Observation
)	10971307	1520	1521	I-Observation
(	10971307	1522	1523	O
P	10971307	1524	1525	O
<	10971307	1526	1527	O
0.01	10971307	1528	1532	O
)	10971307	1533	1534	O
.	10971307	1535	1536	O

Urinary	10971307	1537	1544	B-Outcome
excretion	10971307	1545	1554	I-Outcome
of	10971307	1555	1557	I-Outcome
AVP	10971307	1558	1561	I-Outcome
was	10971307	1562	1565	O
suppressed	10971307	1566	1576	B-Observation
only	10971307	1577	1581	O
with	10971307	1582	1586	O
the	10971307	1587	1590	O
10	10971307	1591	1593	B-Intervention
mg	10971307	1594	1596	I-Intervention
dose	10971307	1597	1601	I-Intervention
from	10971307	1602	1606	B-Observation
46+/-23	10971307	1607	1614	I-Observation
to	10971307	1615	1617	I-Observation
25+/-15	10971307	1618	1625	I-Observation
fmol	10971307	1626	1630	I-Observation
min	10971307	1631	1634	I-Observation
(	10971307	1635	1636	I-Observation
-1	10971307	1637	1639	I-Observation
)	10971307	1640	1641	I-Observation
(	10971307	1642	1643	O
P	10971307	1644	1645	O
<	10971307	1646	1647	O
0.05	10971307	1648	1652	O
)	10971307	1653	1654	O
without	10971307	1655	1662	O
and	10971307	1663	1666	O
from	10971307	1667	1671	B-Observation
410+/-206	10971307	1672	1681	I-Observation
to	10971307	1682	1684	I-Observation
181+/-125	10971307	1685	1694	I-Observation
fmol	10971307	1695	1699	I-Observation
min	10971307	1700	1703	I-Observation
(	10971307	1704	1705	I-Observation
-1	10971307	1706	1708	I-Observation
)	10971307	1709	1710	I-Observation
(	10971307	1711	1712	O
P	10971307	1713	1714	O
<	10971307	1715	1716	O
0.05	10971307	1717	1721	O
)	10971307	1722	1723	O
with	10971307	1724	1728	O
stimulation	10971307	1729	1740	O
by	10971307	1741	1743	O
2.5	10971307	1744	1747	O
%	10971307	1748	1749	O
saline	10971307	1750	1756	O
.	10971307	1757	1758	O

Plasma	10971307	1759	1765	B-Outcome
AVP	10971307	1766	1769	I-Outcome
was	10971307	1770	1773	O
suppressed	10971307	1774	1784	B-Observation
only	10971307	1785	1789	O
by	10971307	1790	1792	O
the	10971307	1793	1796	O
10	10971307	1797	1799	B-Intervention
mg	10971307	1800	1802	I-Intervention
dose	10971307	1803	1807	I-Intervention
of	10971307	1808	1810	I-Intervention
asimadoline	10971307	1811	1822	I-Intervention
in	10971307	1823	1825	O
six	10971307	1826	1829	B-Count
of	10971307	1830	1832	I-Count
eight	10971307	1833	1838	I-Count
subjects	10971307	1839	1847	I-Count
during	10971307	1848	1854	O
the	10971307	1855	1858	O
2.5	10971307	1859	1862	O
%	10971307	1863	1864	O
saline	10971307	1865	1871	O
infusion	10971307	1872	1880	O
.	10971307	1881	1882	O

Changes	10971307	1883	1890	B-Observation
in	10971307	1891	1893	O
the	10971307	1894	1897	O
alpha-hANP	10971307	1898	1908	B-Outcome
or	10971307	1909	1911	I-Outcome
ET-1	10971307	1912	1916	I-Outcome
systems	10971307	1917	1924	I-Outcome
were	10971307	1925	1929	O
not	10971307	1930	1933	O
affected	10971307	1934	1942	O
by	10971307	1943	1945	O
asimadoline	10971307	1946	1957	B-Intervention
.	10971307	1958	1959	O

CONCLUSIONS	10971307	1960	1971	O
Asimadoline	10971307	1972	1983	B-Intervention
is	10971307	1984	1986	O
diuretic	10971307	1987	1995	B-Outcome
in	10971307	1996	1998	O
man	10971307	1999	2002	B-Participant
after	10971307	2003	2008	O
single	10971307	2009	2015	B-Intervention
doses	10971307	2016	2021	I-Intervention
of	10971307	2022	2024	I-Intervention
5	10971307	2025	2026	I-Intervention
or	10971307	2027	2029	I-Intervention
10	10971307	2030	2032	I-Intervention
mg	10971307	2033	2035	I-Intervention
probably	10971307	2036	2044	O
through	10971307	2045	2052	O
a	10971307	2053	2054	O
direct	10971307	2055	2061	B-Observation
effect	10971307	2062	2068	I-Observation
at	10971307	2069	2071	O
the	10971307	2072	2075	O
renal	10971307	2076	2081	B-Outcome
tubular	10971307	2082	2089	I-Outcome
level	10971307	2090	2095	I-Outcome
.	10971307	2096	2097	O

Suppression	10971307	2098	2109	B-Outcome
of	10971307	2110	2112	I-Outcome
AVP	10971307	2113	2116	I-Outcome
secretion	10971307	2117	2126	I-Outcome
was	10971307	2127	2130	O
observed	10971307	2131	2139	O
only	10971307	2140	2144	O
at	10971307	2145	2147	O
the	10971307	2148	2151	O
highest	10971307	2152	2159	B-Intervention
dose	10971307	2160	2164	I-Intervention
level	10971307	2165	2170	I-Intervention
of	10971307	2171	2173	I-Intervention
10	10971307	2174	2176	I-Intervention
mg	10971307	2177	2179	I-Intervention
of	10971307	2180	2182	I-Intervention
asimadoline	10971307	2183	2194	I-Intervention
.	10971307	2195	2196	O

Uvulopalatopharyngoplasty	10971538	0	25	B-Intervention
versus	10971538	26	32	O
laser	10971538	33	38	B-Intervention
assisted	10971538	39	47	I-Intervention
uvulopalatoplasty	10971538	48	65	I-Intervention
for	10971538	66	69	O
the	10971538	70	73	O
treatment	10971538	74	83	O
of	10971538	84	86	O
snoring	10971538	87	94	B-Participant
:	10971538	95	96	O
an	10971538	97	99	O
objective	10971538	100	109	O
randomised	10971538	110	120	O
clinical	10971538	121	129	O
trial	10971538	130	135	O
.	10971538	136	137	O

This	10971538	138	142	O
study	10971538	143	148	O
was	10971538	149	152	O
designed	10971538	153	161	O
to	10971538	162	164	O
evaluate	10971538	165	173	O
objectively	10971538	174	185	O
the	10971538	186	189	O
clinical	10971538	190	198	O
effectiveness	10971538	199	212	O
of	10971538	213	215	O
surgery	10971538	216	223	B-Intervention
for	10971538	224	227	O
snoring	10971538	228	235	B-Participant
and	10971538	236	239	O
to	10971538	240	242	O
compare	10971538	243	250	O
the	10971538	251	254	O
results	10971538	255	262	O
of	10971538	263	265	O
conventional	10971538	266	278	B-Intervention
uvulopalatopharyngoplasty	10971538	279	304	I-Intervention
(	10971538	305	306	I-Intervention
UPPP	10971538	307	311	I-Intervention
)	10971538	312	313	I-Intervention
and	10971538	314	317	O
laser	10971538	318	323	B-Intervention
assisted	10971538	324	332	I-Intervention
uvulopalatoplasty	10971538	333	350	I-Intervention
(	10971538	351	352	I-Intervention
LAUP	10971538	353	357	I-Intervention
)	10971538	358	359	I-Intervention
in	10971538	360	362	O
the	10971538	363	366	O
treatment	10971538	367	376	O
of	10971538	377	379	O
snoring	10971538	380	387	B-Participant
.	10971538	388	389	O

Patients	10971538	390	398	O
who	10971538	399	402	O
had	10971538	403	406	O
been	10971538	407	411	O
referred	10971538	412	420	O
for	10971538	421	424	O
investigation	10971538	425	438	O
and	10971538	439	442	O
treatment	10971538	443	452	O
of	10971538	453	455	O
their	10971538	456	461	O
snoring	10971538	462	469	B-Participant
were	10971538	470	474	O
randomly	10971538	475	483	O
allocated	10971538	484	493	O
to	10971538	494	496	O
receive	10971538	497	504	O
either	10971538	505	511	O
UPPP	10971538	512	516	B-Intervention
or	10971538	517	519	O
LAUP	10971538	520	524	B-Intervention
.	10971538	525	526	O

Forty-seven	10971538	527	538	O
patients	10971538	539	547	O
with	10971538	548	552	O
confirmed	10971538	553	562	O
palatal	10971538	563	570	B-Participant
flutter	10971538	571	578	I-Participant
had	10971538	579	582	O
surgery	10971538	583	590	B-Intervention
and	10971538	591	594	O
all	10971538	595	598	O
of	10971538	599	601	O
them	10971538	602	606	O
had	10971538	607	610	O
a	10971538	611	612	O
preoperative	10971538	613	625	B-Outcome
and	10971538	626	629	I-Outcome
postoperative	10971538	630	643	I-Outcome
objective	10971538	644	653	I-Outcome
assessment	10971538	654	664	I-Outcome
of	10971538	665	667	I-Outcome
their	10971538	668	673	I-Outcome
snoring	10971538	674	681	I-Outcome
loudness	10971538	682	690	I-Outcome
and	10971538	691	694	I-Outcome
duration	10971538	695	703	I-Outcome
in	10971538	704	706	O
the	10971538	707	710	O
home	10971538	711	715	O
.	10971538	716	717	O

The	10971538	718	721	O
recording	10971538	722	731	O
device	10971538	732	738	O
(	10971538	739	740	O
Snore	10971538	741	746	O
Box	10971538	747	750	O
)	10971538	751	752	O
is	10971538	753	755	O
simple	10971538	756	762	O
for	10971538	763	766	O
the	10971538	767	770	O
patient	10971538	771	778	O
to	10971538	779	781	O
operate	10971538	782	789	O
,	10971538	790	791	O
portable	10971538	792	800	O
with	10971538	801	805	O
a	10971538	806	807	O
built	10971538	808	813	O
in	10971538	814	816	O
microphone	10971538	817	827	O
,	10971538	828	829	O
and	10971538	830	833	O
able	10971538	834	838	O
to	10971538	839	841	O
produce	10971538	842	849	O
objective	10971538	850	859	O
results	10971538	860	867	O
,	10971538	868	869	O
which	10971538	870	875	O
can	10971538	876	879	O
be	10971538	880	882	O
automatically	10971538	883	896	O
analysed	10971538	897	905	O
.	10971538	906	907	O

Of	10971538	908	910	O
the	10971538	911	914	O
38	10971538	915	917	O
patients	10971538	918	926	O
,	10971538	927	928	O
who	10971538	929	932	O
had	10971538	933	936	O
technically	10971538	937	948	O
valid	10971538	949	954	O
recordings	10971538	955	965	O
,	10971538	966	967	O
22	10971538	968	970	O
underwent	10971538	971	980	O
LAUP	10971538	981	985	B-Intervention
and	10971538	986	989	O
16	10971538	990	992	O
UPPP	10971538	993	997	B-Intervention
.	10971538	998	999	O

Overall	10971538	1000	1007	O
the	10971538	1008	1011	O
mean	10971538	1012	1016	B-Outcome
postoperative	10971538	1017	1030	I-Outcome
Snore	10971538	1031	1036	I-Outcome
Index	10971538	1037	1042	I-Outcome
(	10971538	1043	1044	I-Outcome
SI	10971538	1045	1047	I-Outcome
)	10971538	1048	1049	I-Outcome
was	10971538	1050	1053	O
less	10971538	1054	1058	B-Observation
than	10971538	1059	1063	O
the	10971538	1064	1067	O
preoperative	10971538	1068	1080	B-Outcome
SI	10971538	1081	1083	I-Outcome
(	10971538	1084	1085	O
P	10971538	1086	1087	O
<	10971538	1088	1089	O
0.0001	10971538	1090	1096	O
)	10971538	1097	1098	O
,	10971538	1099	1100	O
the	10971538	1101	1104	O
average	10971538	1105	1112	B-Outcome
difference	10971538	1113	1123	I-Outcome
being	10971538	1124	1129	O
78.2	10971538	1130	1134	B-Observation
snores/h	10971538	1135	1143	I-Observation
.	10971538	1144	1145	O

There	10971538	1146	1151	O
was	10971538	1152	1155	O
no	10971538	1156	1158	O
significant	10971538	1159	1170	B-Observation
difference	10971538	1171	1181	I-Observation
between	10971538	1182	1189	O
the	10971538	1190	1193	O
LAUP	10971538	1194	1198	B-Intervention
and	10971538	1199	1202	O
UPPP	10971538	1203	1207	B-Intervention
regarding	10971538	1208	1217	O
the	10971538	1218	1221	O
fall	10971538	1222	1226	B-Outcome
in	10971538	1227	1229	I-Outcome
the	10971538	1230	1233	I-Outcome
SI	10971538	1234	1236	I-Outcome
.	10971538	1237	1238	O

This	10971538	1239	1243	O
study	10971538	1244	1249	O
is	10971538	1250	1252	O
the	10971538	1253	1256	O
first	10971538	1257	1262	O
objective	10971538	1263	1272	O
comparative	10971538	1273	1284	O
study	10971538	1285	1290	O
to	10971538	1291	1293	O
demonstrate	10971538	1294	1305	O
the	10971538	1306	1309	O
effectiveness	10971538	1310	1323	O
of	10971538	1324	1326	O
snoring	10971538	1327	1334	O
surgery	10971538	1335	1342	O
.	10971538	1343	1344	O

Randomized	10973645	0	10	O
trial	10973645	11	16	O
of	10973645	17	19	O
a	10973645	20	21	O
stage-of-change	10973645	22	37	B-Intervention
oriented	10973645	38	46	I-Intervention
smoking	10973645	47	54	I-Intervention
cessation	10973645	55	64	I-Intervention
intervention	10973645	65	77	I-Intervention
in	10973645	78	80	O
infertile	10973645	81	90	B-Participant
and	10973645	91	94	O
pregnant	10973645	95	103	B-Participant
women	10973645	104	109	I-Participant
.	10973645	110	111	O

OBJECTIVE	10973645	112	121	O
To	10973645	122	124	O
assess	10973645	125	131	O
a	10973645	132	133	O
stage-of-change	10973645	134	149	B-Intervention
oriented	10973645	150	158	I-Intervention
smoking	10973645	159	166	I-Intervention
cessation	10973645	167	176	I-Intervention
intervention	10973645	177	189	I-Intervention
for	10973645	190	193	O
infertile	10973645	194	203	B-Participant
and	10973645	204	207	O
pregnant	10973645	208	216	B-Participant
women	10973645	217	222	I-Participant
,	10973645	223	224	O
compared	10973645	225	233	O
with	10973645	234	238	O
standard	10973645	239	247	B-Intervention
of	10973645	248	250	I-Intervention
care	10973645	251	255	I-Intervention
.	10973645	256	257	O

DESIGN	10973645	258	264	O
Randomized	10973645	265	275	O
controlled	10973645	276	286	O
trial	10973645	287	292	O
.	10973645	293	294	O

SETTING	10973645	295	302	O
Three	10973645	303	308	O
university	10973645	309	319	O
teaching	10973645	320	328	O
hospitals	10973645	329	338	O
in	10973645	339	341	O
Hamilton	10973645	342	350	O
,	10973645	351	352	O
Ontario	10973645	353	360	O
,	10973645	361	362	O
Canada	10973645	363	369	O
.	10973645	370	371	O

PATIENT	10973645	372	379	O
(	10973645	380	381	O
S	10973645	382	383	O
)	10973645	384	385	O
Infertile	10973645	386	395	B-Participant
women	10973645	396	401	I-Participant
at	10973645	402	404	O
their	10973645	405	410	O
first	10973645	411	416	B-Participant
visit	10973645	417	422	I-Participant
to	10973645	423	425	I-Participant
a	10973645	426	427	I-Participant
tertiary	10973645	428	436	I-Participant
referral	10973645	437	445	I-Participant
infertility	10973645	446	457	I-Participant
clinic	10973645	458	464	I-Participant
(	10973645	465	466	O
n	10973645	467	468	O
=	10973645	469	470	O
94	10973645	471	473	O
)	10973645	474	475	O
and	10973645	476	479	O
new	10973645	480	483	B-Participant
patients	10973645	484	492	I-Participant
seeking	10973645	493	500	I-Participant
pre-natal	10973645	501	510	I-Participant
care	10973645	511	515	I-Participant
(	10973645	516	517	O
n	10973645	518	519	O
=	10973645	520	521	O
110	10973645	522	525	O
)	10973645	526	527	O
who	10973645	528	531	O
had	10973645	532	535	O
smoked	10973645	536	542	B-Participant
>	10973645	543	544	I-Participant
/=	10973645	545	547	I-Participant
3	10973645	548	549	I-Participant
cigarettes	10973645	550	560	I-Participant
in	10973645	561	563	O
the	10973645	564	567	O
past	10973645	568	572	O
six	10973645	573	576	O
months	10973645	577	583	O
.	10973645	584	585	O

INTERVENTION	10973645	586	598	O
(	10973645	599	600	O
S	10973645	601	602	O
)	10973645	603	604	O
A	10973645	605	606	O
three	10973645	607	612	B-Intervention
to	10973645	613	615	I-Intervention
five	10973645	616	620	I-Intervention
minute	10973645	621	627	I-Intervention
scripted	10973645	628	636	I-Intervention
intervention	10973645	637	649	I-Intervention
and	10973645	650	653	I-Intervention
booklet	10973645	654	661	I-Intervention
specific	10973645	662	670	I-Intervention
to	10973645	671	673	I-Intervention
the	10973645	674	677	I-Intervention
woman	10973645	678	683	I-Intervention
's	10973645	684	686	I-Intervention
stage-of-change	10973645	687	702	I-Intervention
in	10973645	703	705	I-Intervention
the	10973645	706	709	I-Intervention
smoking	10973645	710	717	I-Intervention
continuum	10973645	718	727	I-Intervention
,	10973645	728	729	O
versus	10973645	730	736	O
standard	10973645	737	745	B-Intervention
of	10973645	746	748	I-Intervention
care	10973645	749	753	I-Intervention
.	10973645	754	755	O

Exhaled	10973645	756	763	O
carbon-monoxide	10973645	764	779	O
(	10973645	780	781	O
CO	10973645	782	784	O
)	10973645	785	786	O
monitoring	10973645	787	797	O
was	10973645	798	801	O
used	10973645	802	806	O
to	10973645	807	809	O
validate	10973645	810	818	O
exposure	10973645	819	827	O
in	10973645	828	830	O
both	10973645	831	835	O
groups	10973645	836	842	O
.	10973645	843	844	O

MAIN	10973645	845	849	O
OUTCOME	10973645	850	857	O
MEASURE	10973645	858	865	O
(	10973645	866	867	O
S	10973645	868	869	O
)	10973645	870	871	O
Delta	10973645	872	877	B-Outcome
stage-of-change	10973645	878	893	I-Outcome
and	10973645	894	897	O
rate	10973645	898	902	B-Outcome
of	10973645	903	905	I-Outcome
maintained	10973645	906	916	I-Outcome
cessation	10973645	917	926	I-Outcome
at	10973645	927	929	O
12	10973645	930	932	O
months	10973645	933	939	O
post	10973645	940	944	O
follow-up	10973645	945	954	O
.	10973645	955	956	O

RESULT	10973645	957	963	O
(	10973645	964	965	O
S	10973645	966	967	O
)	10973645	968	969	O
Intervention	10973645	970	982	B-Intervention
and	10973645	983	986	O
control	10973645	987	994	B-Intervention
were	10973645	995	999	O
similarly	10973645	1000	1009	B-Observation
effective	10973645	1010	1019	I-Observation
for	10973645	1020	1023	O
infertile	10973645	1024	1033	B-Participant
women	10973645	1034	1039	I-Participant
:	10973645	1040	1041	O
the	10973645	1042	1045	O
rate	10973645	1046	1050	B-Outcome
of	10973645	1051	1053	I-Outcome
maintained	10973645	1054	1064	I-Outcome
cessation	10973645	1065	1074	I-Outcome
rose	10973645	1075	1079	B-Observation
significantly	10973645	1080	1093	I-Observation
from	10973645	1094	1098	I-Observation
4	10973645	1099	1100	I-Observation
%	10973645	1101	1102	I-Observation
to	10973645	1103	1105	I-Observation
24	10973645	1106	1108	I-Observation
%	10973645	1109	1110	I-Observation
over	10973645	1111	1115	O
twelve	10973645	1116	1122	O
months	10973645	1123	1129	O
,	10973645	1130	1131	O
with	10973645	1132	1136	O
a	10973645	1137	1138	O
mean	10973645	1139	1143	B-Outcome
delta	10973645	1144	1149	I-Outcome
stage-of-change	10973645	1150	1165	I-Outcome
0.28	10973645	1166	1170	B-Observation
.	10973645	1171	1172	O

In	10973645	1173	1175	O
prenatal	10973645	1176	1184	B-Participant
women	10973645	1185	1190	I-Participant
,	10973645	1191	1192	O
neither	10973645	1193	1200	O
approach	10973645	1201	1209	B-Intervention
was	10973645	1210	1213	O
effective	10973645	1214	1223	B-Observation
.	10973645	1224	1225	O

Maintained	10973645	1226	1236	B-Outcome
cessation	10973645	1237	1246	I-Outcome
did	10973645	1247	1250	O
not	10973645	1251	1254	O
significantly	10973645	1255	1268	B-Observation
change	10973645	1269	1275	I-Observation
from	10973645	1276	1280	O
0	10973645	1281	1282	O
to	10973645	1283	1285	O
12	10973645	1286	1288	O
months	10973645	1289	1295	O
(	10973645	1296	1297	O
19	10973645	1298	1300	B-Observation
%	10973645	1301	1302	I-Observation
to	10973645	1303	1305	I-Observation
18	10973645	1306	1308	I-Observation
%	10973645	1309	1310	I-Observation
)	10973645	1311	1312	O
.	10973645	1313	1314	O

Mean	10973645	1315	1319	B-Outcome
delta	10973645	1320	1325	I-Outcome
stage-of-change	10973645	1326	1341	I-Outcome
declined	10973645	1342	1350	B-Observation
by	10973645	1351	1353	I-Observation
-0.62	10973645	1354	1359	I-Observation
.	10973645	1360	1361	O

CONCLUSION	10973645	1362	1372	O
(	10973645	1373	1374	O
S	10973645	1375	1376	O
)	10973645	1377	1378	O
For	10973645	1379	1382	O
infertile	10973645	1383	1392	B-Participant
women	10973645	1393	1398	I-Participant
,	10973645	1399	1400	O
basic	10973645	1401	1406	O
information	10973645	1407	1418	O
describing	10973645	1419	1429	O
the	10973645	1430	1433	O
impact	10973645	1434	1440	O
of	10973645	1441	1443	O
smoking	10973645	1444	1451	O
on	10973645	1452	1454	O
fertility	10973645	1455	1464	O
,	10973645	1465	1466	O
along	10973645	1467	1472	O
with	10973645	1473	1477	O
exhaled	10973645	1478	1485	O
CO	10973645	1486	1488	O
monitoring	10973645	1489	1499	O
and	10973645	1500	1503	O
a	10973645	1504	1505	O
more	10973645	1506	1510	B-Intervention
intensive	10973645	1511	1520	I-Intervention
intervention	10973645	1521	1533	I-Intervention
were	10973645	1534	1538	O
both	10973645	1539	1543	O
highly	10973645	1544	1550	B-Observation
effective	10973645	1551	1560	I-Observation
.	10973645	1561	1562	O

In	10973645	1563	1565	O
pregnant	10973645	1566	1574	B-Participant
women	10973645	1575	1580	I-Participant
neither	10973645	1581	1588	O
approach	10973645	1589	1597	B-Intervention
was	10973645	1598	1601	O
beneficial	10973645	1602	1612	B-Observation
,	10973645	1613	1614	O
with	10973645	1615	1619	O
some	10973645	1620	1624	O
evidence	10973645	1625	1633	O
of	10973645	1634	1636	O
post-partum	10973645	1637	1648	B-Outcome
relapse	10973645	1649	1656	I-Outcome
.	10973645	1657	1658	O

Effect	10986219	0	6	O
of	10986219	7	9	O
L-ornithine-L-aspartate	10986219	10	33	B-Intervention
on	10986219	34	36	O
patients	10986219	37	45	O
with	10986219	46	50	B-Participant
and	10986219	51	54	I-Participant
without	10986219	55	62	I-Participant
TIPS	10986219	63	67	I-Participant
undergoing	10986219	68	78	O
glutamine	10986219	79	88	B-Participant
challenge	10986219	89	98	I-Participant
:	10986219	99	100	O
a	10986219	101	102	O
double	10986219	103	109	O
blind	10986219	110	115	O
,	10986219	116	117	O
placebo	10986219	118	125	O
controlled	10986219	126	136	O
trial	10986219	137	142	O
.	10986219	143	144	O

BACKGROUND	10986219	145	155	O
AND	10986219	156	159	O
AIM	10986219	160	163	O
An	10986219	164	166	O
oral	10986219	167	171	O
glutamine	10986219	172	181	O
load	10986219	182	186	O
in	10986219	187	189	O
cirrhotic	10986219	190	199	O
patients	10986219	200	208	O
awaiting	10986219	209	217	O
liver	10986219	218	223	O
transplantation	10986219	224	239	O
was	10986219	240	243	O
shown	10986219	244	249	O
to	10986219	250	252	O
cause	10986219	253	258	O
a	10986219	259	260	O
rise	10986219	261	265	O
in	10986219	266	268	O
blood	10986219	269	274	O
ammonia	10986219	275	282	O
and	10986219	283	286	O
psychometric	10986219	287	299	O
abnormalities	10986219	300	313	O
which	10986219	314	319	O
were	10986219	320	324	O
reversed	10986219	325	333	O
by	10986219	334	336	O
hepatic	10986219	337	344	O
transplantation	10986219	345	360	O
.	10986219	361	362	O

L-Ornithine-L-aspartate	10986219	363	386	O
(	10986219	387	388	O
LOLA	10986219	389	393	O
)	10986219	394	395	O
has	10986219	396	399	O
been	10986219	400	404	O
shown	10986219	405	410	O
to	10986219	411	413	O
reduce	10986219	414	420	O
ammonia	10986219	421	428	O
and	10986219	429	432	O
improve	10986219	433	440	O
psychometric	10986219	441	453	O
function	10986219	454	462	O
in	10986219	463	465	O
patients	10986219	466	474	O
with	10986219	475	479	O
hepatic	10986219	480	487	O
encephalopathy	10986219	488	502	O
.	10986219	503	504	O

The	10986219	505	508	O
aim	10986219	509	512	O
of	10986219	513	515	O
the	10986219	516	519	O
present	10986219	520	527	O
study	10986219	528	533	O
was	10986219	534	537	O
to	10986219	538	540	O
assess	10986219	541	547	O
the	10986219	548	551	O
effect	10986219	552	558	O
of	10986219	559	561	O
LOLA	10986219	562	566	B-Intervention
in	10986219	567	569	O
healthy	10986219	570	577	B-Participant
patients	10986219	578	586	O
with	10986219	587	591	O
cirrhosis	10986219	592	601	B-Participant
and	10986219	602	605	O
no	10986219	606	608	O
evidence	10986219	609	617	O
of	10986219	618	620	O
clinical	10986219	621	629	B-Participant
encephalopathy	10986219	630	644	I-Participant
after	10986219	645	650	O
challenging	10986219	651	662	O
the	10986219	663	666	O
central	10986219	667	674	O
nervous	10986219	675	682	O
system	10986219	683	689	O
by	10986219	690	692	O
administration	10986219	693	707	O
of	10986219	708	710	O
oral	10986219	711	715	B-Participant
glutamine	10986219	716	725	I-Participant
.	10986219	726	727	O

PATIENTS	10986219	728	736	O
AND	10986219	737	740	O
METHODS	10986219	741	748	O
Eight	10986219	749	754	O
cirrhotics	10986219	755	765	B-Participant
(	10986219	766	767	O
Child	10986219	768	773	B-Participant
's	10986219	774	776	I-Participant
B	10986219	777	778	I-Participant
or	10986219	779	781	I-Participant
C	10986219	782	783	I-Participant
)	10986219	784	785	O
without	10986219	786	793	O
transjugular	10986219	794	806	B-Participant
intrahepatic	10986219	807	819	I-Participant
portosystemic	10986219	820	833	I-Participant
shunts	10986219	834	840	I-Participant
(	10986219	841	842	I-Participant
TIPS	10986219	843	847	I-Participant
)	10986219	848	849	I-Participant
and	10986219	850	853	O
seven	10986219	854	859	O
with	10986219	860	864	O
TIPS	10986219	865	869	B-Participant
underwent	10986219	870	879	O
two	10986219	880	883	O
oral	10986219	884	888	B-Participant
glutamine	10986219	889	898	I-Participant
(	10986219	899	900	I-Participant
20	10986219	901	903	I-Participant
g	10986219	904	905	I-Participant
)	10986219	906	907	I-Participant
challenges	10986219	908	918	I-Participant
,	10986219	919	920	O
receiving	10986219	921	930	O
LOLA	10986219	931	935	B-Intervention
(	10986219	936	937	O
5	10986219	938	939	O
g	10986219	940	941	O
intravenously	10986219	942	955	O
)	10986219	956	957	O
on	10986219	958	960	O
one	10986219	961	964	O
occasion	10986219	965	973	O
and	10986219	974	977	O
placebo	10986219	978	985	B-Intervention
on	10986219	986	988	O
the	10986219	989	992	O
other	10986219	993	998	O
in	10986219	999	1001	O
random	10986219	1002	1008	O
order	10986219	1009	1014	O
.	10986219	1015	1016	O

Psychometric	10986219	1017	1029	B-Outcome
tests	10986219	1030	1035	I-Outcome
,	10986219	1036	1037	O
including	10986219	1038	1047	O
choice	10986219	1048	1054	B-Outcome
reaction	10986219	1055	1063	I-Outcome
time	10986219	1064	1068	I-Outcome
(	10986219	1069	1070	I-Outcome
CRT	10986219	1071	1074	I-Outcome
)	10986219	1075	1076	I-Outcome
and	10986219	1077	1080	O
number	10986219	1081	1087	B-Outcome
connection	10986219	1088	1098	I-Outcome
test	10986219	1099	1103	I-Outcome
,	10986219	1104	1105	O
were	10986219	1106	1110	O
performed	10986219	1111	1120	O
before	10986219	1121	1127	O
and	10986219	1128	1131	O
after	10986219	1132	1137	O
glutamine	10986219	1138	1147	B-Participant
,	10986219	1148	1149	O
together	10986219	1150	1158	O
with	10986219	1159	1163	O
electroencephalography	10986219	1164	1186	B-Outcome
and	10986219	1187	1190	O
blood	10986219	1191	1196	B-Outcome
ammonia	10986219	1197	1204	I-Outcome
.	10986219	1205	1206	O

RESULTS	10986219	1207	1214	O
Mean	10986219	1215	1219	B-Outcome
basal	10986219	1220	1225	I-Outcome
ammonia	10986219	1226	1233	I-Outcome
was	10986219	1234	1237	O
27	10986219	1238	1240	B-Observation
(	10986219	1241	1242	I-Observation
SEM	10986219	1243	1246	I-Observation
5	10986219	1247	1248	I-Observation
)	10986219	1249	1250	I-Observation
micromol/l	10986219	1251	1261	I-Observation
in	10986219	1262	1264	O
non-TIPS	10986219	1265	1273	B-Participant
and	10986219	1274	1277	O
76	10986219	1278	1280	B-Observation
(	10986219	1281	1282	I-Observation
10	10986219	1283	1285	I-Observation
)	10986219	1286	1287	I-Observation
micromol/l	10986219	1288	1298	I-Observation
in	10986219	1299	1301	O
TIPS	10986219	1302	1306	B-Participant
patients	10986219	1307	1315	O
(	10986219	1316	1317	O
p	10986219	1318	1319	O
<	10986219	1320	1321	O
0.05	10986219	1322	1326	O
)	10986219	1327	1328	O
.	10986219	1329	1330	O

Basal	10986219	1331	1336	B-Outcome
CRT	10986219	1337	1340	I-Outcome
2	10986219	1341	1342	I-Outcome
was	10986219	1343	1346	O
0.643	10986219	1347	1352	B-Observation
(	10986219	1353	1354	I-Observation
0.033	10986219	1355	1360	I-Observation
)	10986219	1361	1362	I-Observation
s	10986219	1363	1364	I-Observation
in	10986219	1365	1367	O
non-TIPS	10986219	1368	1376	B-Participant
and	10986219	1377	1380	O
0.825	10986219	1381	1386	B-Observation
(	10986219	1387	1388	I-Observation
0.076	10986219	1389	1394	I-Observation
)	10986219	1395	1396	I-Observation
s	10986219	1397	1398	I-Observation
in	10986219	1399	1401	O
TIPS	10986219	1402	1406	B-Participant
patients	10986219	1407	1415	O
(	10986219	1416	1417	O
p	10986219	1418	1419	O
<	10986219	1420	1421	O
0.02	10986219	1422	1426	O
)	10986219	1427	1428	O
.	10986219	1429	1430	O

In	10986219	1431	1433	O
non-TIPS	10986219	1434	1442	B-Participant
patients	10986219	1443	1451	I-Participant
,	10986219	1452	1453	O
ammonia	10986219	1454	1461	B-Outcome
increased	10986219	1462	1471	B-Observation
to	10986219	1472	1474	I-Observation
36	10986219	1475	1477	I-Observation
(	10986219	1478	1479	I-Observation
10	10986219	1480	1482	I-Observation
)	10986219	1483	1484	I-Observation
micromol/l	10986219	1485	1495	I-Observation
when	10986219	1496	1500	O
LOLA	10986219	1501	1505	B-Intervention
was	10986219	1506	1509	O
administered	10986219	1510	1522	O
and	10986219	1523	1526	O
to	10986219	1527	1529	O
62	10986219	1530	1532	B-Observation
(	10986219	1533	1534	I-Observation
13	10986219	1535	1537	I-Observation
)	10986219	1538	1539	I-Observation
micromol/l	10986219	1540	1550	I-Observation
with	10986219	1551	1555	O
placebo	10986219	1556	1563	B-Intervention
(	10986219	1564	1565	O
p	10986219	1566	1567	O
<	10986219	1568	1569	O
0.02	10986219	1570	1574	O
)	10986219	1575	1576	O
.	10986219	1577	1578	O

There	10986219	1579	1584	O
was	10986219	1585	1588	O
no	10986219	1589	1591	O
alteration	10986219	1592	1602	B-Observation
in	10986219	1603	1605	O
psychometric	10986219	1606	1618	B-Outcome
function	10986219	1619	1627	I-Outcome
in	10986219	1628	1630	O
non-TIPS	10986219	1631	1639	B-Participant
patients	10986219	1640	1648	O
after	10986219	1649	1654	O
glutamine	10986219	1655	1664	B-Participant
when	10986219	1665	1669	O
LOLA	10986219	1670	1674	B-Intervention
was	10986219	1675	1678	O
given	10986219	1679	1684	O
but	10986219	1685	1688	O
when	10986219	1689	1693	O
placebo	10986219	1694	1701	B-Intervention
was	10986219	1702	1705	O
given	10986219	1706	1711	O
,	10986219	1712	1713	O
glutamine	10986219	1714	1723	B-Participant
caused	10986219	1724	1730	O
prolongation	10986219	1731	1743	B-Observation
of	10986219	1744	1746	O
CRT	10986219	1747	1750	B-Outcome
(	10986219	1751	1752	O
p=0.02	10986219	1753	1759	O
)	10986219	1760	1761	O
.	10986219	1762	1763	O

Glutamine	10986219	1764	1773	B-Participant
did	10986219	1774	1777	O
not	10986219	1778	1781	O
affect	10986219	1782	1788	O
psychometric	10986219	1789	1801	B-Outcome
function	10986219	1802	1810	I-Outcome
in	10986219	1811	1813	O
TIPS	10986219	1814	1818	B-Participant
patients	10986219	1819	1827	O
with	10986219	1828	1832	B-Intervention
or	10986219	1833	1835	I-Intervention
without	10986219	1836	1843	I-Intervention
LOLA	10986219	1844	1848	I-Intervention
.	10986219	1849	1850	O

CONCLUSION	10986219	1851	1861	O
This	10986219	1862	1866	O
study	10986219	1867	1872	O
showed	10986219	1873	1879	O
that	10986219	1880	1884	O
LOLA	10986219	1885	1889	B-Intervention
ameliorated	10986219	1890	1901	B-Observation
the	10986219	1902	1905	O
deleterious	10986219	1906	1917	B-Outcome
psychometric	10986219	1918	1930	I-Outcome
effects	10986219	1931	1938	I-Outcome
of	10986219	1939	1941	O
glutamine	10986219	1942	1951	B-Participant
in	10986219	1952	1954	O
Child	10986219	1955	1960	B-Participant
's	10986219	1961	1963	I-Participant
grade	10986219	1964	1969	I-Participant
B	10986219	1970	1971	I-Participant
and	10986219	1972	1975	I-Participant
C	10986219	1976	1977	I-Participant
patients	10986219	1978	1986	O
with	10986219	1987	1991	O
cirrhosis	10986219	1992	2001	B-Participant
without	10986219	2002	2009	O
TIPS	10986219	2010	2014	B-Participant
and	10986219	2015	2018	O
supports	10986219	2019	2027	B-Observation
its	10986219	2028	2031	O
use	10986219	2032	2035	O
in	10986219	2036	2038	O
clinical	10986219	2039	2047	O
practice	10986219	2048	2056	O
in	10986219	2057	2059	O
hepatic	10986219	2060	2067	B-Participant
encephalopathy	10986219	2068	2082	I-Participant
.	10986219	2083	2084	O

Superior	10986363	0	8	B-Observation
modulation	10986363	9	19	B-Outcome
of	10986363	20	22	I-Outcome
activation	10986363	23	33	I-Outcome
levels	10986363	34	40	I-Outcome
of	10986363	41	43	I-Outcome
stimulus	10986363	44	52	I-Outcome
representations	10986363	53	68	I-Outcome
does	10986363	69	73	O
not	10986363	74	77	O
underlie	10986363	78	86	O
superior	10986363	87	95	B-Observation
discrimination	10986363	96	110	B-Outcome
in	10986363	111	113	O
autism	10986363	114	120	B-Intervention
.	10986363	121	122	O

The	10986363	123	126	O
performance	10986363	127	138	B-Outcome
of	10986363	139	141	O
children	10986363	142	150	B-Intervention
with	10986363	151	155	I-Intervention
and	10986363	156	159	I-Intervention
without	10986363	160	167	I-Intervention
autism	10986363	168	174	I-Intervention
was	10986363	175	178	O
compared	10986363	179	187	O
in	10986363	188	190	O
object-based	10986363	191	203	O
positive	10986363	204	212	O
and	10986363	213	216	O
negative	10986363	217	225	O
priming	10986363	226	233	O
tasks	10986363	234	239	O
within	10986363	240	246	O
a	10986363	247	248	O
visual	10986363	249	255	O
search	10986363	256	262	O
procedure	10986363	263	272	O
.	10986363	273	274	O

Object-based	10986363	275	287	B-Outcome
positive	10986363	288	296	I-Outcome
and	10986363	297	300	I-Outcome
negative	10986363	301	309	I-Outcome
priming	10986363	310	317	I-Outcome
effects	10986363	318	325	I-Outcome
were	10986363	326	330	O
found	10986363	331	336	O
in	10986363	337	339	O
both	10986363	340	344	B-Intervention
groups	10986363	345	351	I-Intervention
of	10986363	352	354	I-Intervention
children	10986363	355	363	I-Intervention
.	10986363	364	365	O

This	10986363	366	370	O
result	10986363	371	377	O
provides	10986363	378	386	O
the	10986363	387	390	O
first	10986363	391	396	O
evidence	10986363	397	405	O
for	10986363	406	409	O
the	10986363	410	413	O
activation	10986363	414	424	O
of	10986363	425	427	O
object-based	10986363	428	440	O
representations	10986363	441	456	O
during	10986363	457	463	O
visual	10986363	464	470	O
search	10986363	471	477	O
task	10986363	478	482	O
performance	10986363	483	494	O
and	10986363	495	498	O
further	10986363	499	506	O
supports	10986363	507	515	O
the	10986363	516	519	O
notion	10986363	520	526	O
that	10986363	527	531	O
both	10986363	532	536	O
excitatory	10986363	537	547	O
and	10986363	548	551	O
inhibitory	10986363	552	562	O
guidance	10986363	563	571	O
mechanisms	10986363	572	582	O
are	10986363	583	586	O
involved	10986363	587	595	O
in	10986363	596	598	O
target	10986363	599	605	O
location	10986363	606	614	O
in	10986363	615	617	O
visual	10986363	618	624	O
search	10986363	625	631	O
.	10986363	632	633	O

The	10986363	634	637	O
children	10986363	638	646	B-Intervention
with	10986363	647	651	I-Intervention
autism	10986363	652	658	I-Intervention
were	10986363	659	663	O
overall	10986363	664	671	B-Observation
better	10986363	672	678	I-Observation
than	10986363	679	683	O
the	10986363	684	687	O
typically	10986363	688	697	B-Intervention
developing	10986363	698	708	I-Intervention
children	10986363	709	717	I-Intervention
at	10986363	718	720	O
visual	10986363	721	727	B-Outcome
search	10986363	728	734	I-Outcome
,	10986363	735	736	O
thus	10986363	737	741	O
replicating	10986363	742	753	O
demonstrations	10986363	754	768	O
of	10986363	769	771	O
superior	10986363	772	780	B-Observation
discrimination	10986363	781	795	B-Outcome
in	10986363	796	798	O
autism	10986363	799	805	B-Intervention
.	10986363	806	807	O

Furthermore	10986363	808	819	O
,	10986363	820	821	O
there	10986363	822	827	O
was	10986363	828	831	O
no	10986363	832	834	O
difference	10986363	835	845	B-Observation
between	10986363	846	853	O
the	10986363	854	857	O
magnitude	10986363	858	867	B-Outcome
of	10986363	868	870	I-Outcome
the	10986363	871	874	I-Outcome
positive	10986363	875	883	I-Outcome
nor	10986363	884	887	I-Outcome
the	10986363	888	891	I-Outcome
negative	10986363	892	900	I-Outcome
priming	10986363	901	908	I-Outcome
effects	10986363	909	916	I-Outcome
of	10986363	917	919	O
the	10986363	920	923	B-Intervention
groups	10986363	924	930	I-Intervention
.	10986363	931	932	O

This	10986363	933	937	O
finding	10986363	938	945	O
suggests	10986363	946	954	O
that	10986363	955	959	O
excitatory	10986363	960	970	B-Outcome
and	10986363	971	974	I-Outcome
inhibitory	10986363	975	985	I-Outcome
control	10986363	986	993	I-Outcome
operate	10986363	994	1001	O
comparably	10986363	1002	1012	B-Observation
in	10986363	1013	1015	O
autism	10986363	1016	1022	B-Intervention
and	10986363	1023	1026	O
normal	10986363	1027	1033	B-Intervention
development	10986363	1034	1045	I-Intervention
.	10986363	1046	1047	O

These	10986363	1048	1053	O
results	10986363	1054	1061	O
are	10986363	1062	1065	O
discussed	10986363	1066	1075	O
in	10986363	1076	1078	O
the	10986363	1079	1082	O
light	10986363	1083	1088	O
of	10986363	1089	1091	O
the	10986363	1092	1095	O
superior	10986363	1096	1104	O
ability	10986363	1105	1112	O
of	10986363	1113	1115	O
individuals	10986363	1116	1127	O
with	10986363	1128	1132	O
autism	10986363	1133	1139	O
to	10986363	1140	1142	O
discriminate	10986363	1143	1155	O
between	10986363	1156	1163	O
items	10986363	1164	1169	O
.	10986363	1170	1171	O

More	10986363	1172	1176	O
specifically	10986363	1177	1189	O
,	10986363	1190	1191	O
it	10986363	1192	1194	O
is	10986363	1195	1197	O
argued	10986363	1198	1204	O
that	10986363	1205	1209	O
superior	10986363	1210	1218	O
discrimination	10986363	1219	1233	O
in	10986363	1234	1236	O
autism	10986363	1237	1243	O
does	10986363	1244	1248	O
not	10986363	1249	1252	O
result	10986363	1253	1259	O
from	10986363	1260	1264	O
enhanced	10986363	1265	1273	O
top-down	10986363	1274	1282	O
excitatory	10986363	1283	1293	O
and	10986363	1294	1297	O
inhibitory	10986363	1298	1308	O
control	10986363	1309	1316	O
.	10986363	1317	1318	O

Onset/offset	10992833	0	12	B-Outcome
characteristics	10992833	13	28	I-Outcome
and	10992833	29	32	O
intubating	10992833	33	43	B-Outcome
conditions	10992833	44	54	I-Outcome
of	10992833	55	57	O
rapacuronium	10992833	58	70	B-Intervention
:	10992833	71	72	O
a	10992833	73	74	O
comparison	10992833	75	85	O
with	10992833	86	90	O
rocuronium	10992833	91	101	B-Intervention
.	10992833	102	103	O

We	10992833	104	106	O
compared	10992833	107	115	O
onset	10992833	116	121	B-Outcome
and	10992833	122	125	I-Outcome
offset	10992833	126	132	I-Outcome
of	10992833	133	135	I-Outcome
action	10992833	136	142	I-Outcome
and	10992833	143	146	O
tracheal	10992833	147	155	B-Outcome
intubating	10992833	156	166	I-Outcome
conditions	10992833	167	177	I-Outcome
after	10992833	178	183	O
rapacuronium	10992833	184	196	B-Intervention
and	10992833	197	200	O
rocuronium	10992833	201	211	B-Intervention
in	10992833	212	214	O
60	10992833	215	217	O
patients	10992833	218	226	O
in	10992833	227	229	O
a	10992833	230	231	O
randomized	10992833	232	242	O
,	10992833	243	244	O
assessor-blinded	10992833	245	261	O
study	10992833	262	267	O
.	10992833	268	269	O

Following	10992833	270	279	O
induction	10992833	280	289	O
of	10992833	290	292	O
anaesthesia	10992833	293	304	B-Participant
with	10992833	305	309	O
propofol	10992833	310	318	B-Participant
2.5	10992833	319	322	O
mg	10992833	323	325	O
kg-1	10992833	326	330	O
,	10992833	331	332	O
either	10992833	333	339	O
rapacuronium	10992833	340	352	B-Intervention
1.5	10992833	353	356	O
mg	10992833	357	359	O
kg-1	10992833	360	364	O
(	10992833	365	366	O
n	10992833	367	368	O
=	10992833	369	370	O
30	10992833	371	373	O
)	10992833	374	375	O
or	10992833	376	378	O
rocuronium	10992833	379	389	B-Intervention
0.6	10992833	390	393	O
mg	10992833	394	396	O
kg-1	10992833	397	401	O
(	10992833	402	403	O
n	10992833	404	405	O
=	10992833	406	407	O
30	10992833	408	410	O
)	10992833	411	412	O
was	10992833	413	416	O
administered	10992833	417	429	O
to	10992833	430	432	O
facilitate	10992833	433	443	O
tracheal	10992833	444	452	B-Outcome
intubation	10992833	453	463	I-Outcome
.	10992833	464	465	O

Anaesthesia	10992833	466	477	B-Participant
was	10992833	478	481	O
maintained	10992833	482	492	O
with	10992833	493	497	O
either	10992833	498	504	O
a	10992833	505	506	O
propofol	10992833	507	515	B-Participant
infusion	10992833	516	524	I-Participant
(	10992833	525	526	O
100	10992833	527	530	O
micrograms	10992833	531	541	O
kg-1	10992833	542	546	O
min-1	10992833	547	552	O
)	10992833	553	554	O
or	10992833	555	557	O
sevoflurane	10992833	558	569	B-Participant
(	10992833	570	571	I-Participant
1	10992833	572	573	I-Participant
%	10992833	574	575	I-Participant
end-tidal	10992833	576	585	I-Participant
)	10992833	586	587	I-Participant
with	10992833	588	592	I-Participant
66	10992833	593	595	I-Participant
%	10992833	596	597	I-Participant
nitrous	10992833	598	605	I-Participant
oxide	10992833	606	611	I-Participant
(	10992833	612	613	I-Participant
N2O	10992833	614	617	I-Participant
)	10992833	618	619	I-Participant
,	10992833	620	621	O
n	10992833	622	623	O
=	10992833	624	625	O
15	10992833	626	628	O
in	10992833	629	631	O
each	10992833	632	636	O
subgroup	10992833	637	645	O
.	10992833	646	647	O

Neuromuscular	10992833	648	661	B-Outcome
monitoring	10992833	662	672	I-Outcome
was	10992833	673	676	O
performed	10992833	677	686	O
using	10992833	687	692	O
an	10992833	693	695	O
electromyographic	10992833	696	713	O
(	10992833	714	715	O
EMG	10992833	716	719	O
)	10992833	720	721	O
device	10992833	722	728	O
(	10992833	729	730	O
Datex	10992833	731	736	O
Relaxograph	10992833	737	748	O
)	10992833	749	750	O
.	10992833	751	752	O

The	10992833	753	756	O
lag	10992833	757	760	B-Outcome
times	10992833	761	766	I-Outcome
(	10992833	767	768	O
mean	10992833	769	773	B-Outcome
42	10992833	774	776	B-Observation
(	10992833	777	778	I-Observation
SD	10992833	779	781	I-Observation
11	10992833	782	784	I-Observation
)	10992833	785	786	I-Observation
s	10992833	787	788	I-Observation
and	10992833	789	792	O
44	10992833	793	795	B-Observation
(	10992833	796	797	I-Observation
16	10992833	798	800	I-Observation
)	10992833	801	802	I-Observation
s	10992833	803	804	I-Observation
)	10992833	805	806	O
,	10992833	807	808	O
maximum	10992833	809	816	B-Outcome
block	10992833	817	822	I-Outcome
(	10992833	823	824	O
99	10992833	825	827	B-Observation
(	10992833	828	829	I-Observation
2	10992833	830	831	I-Observation
)	10992833	832	833	I-Observation
%	10992833	834	835	I-Observation
and	10992833	836	839	O
98	10992833	840	842	B-Observation
(	10992833	843	844	I-Observation
3	10992833	845	846	I-Observation
)	10992833	847	848	I-Observation
%	10992833	849	850	I-Observation
)	10992833	851	852	O
and	10992833	853	856	O
intubating	10992833	857	867	B-Outcome
conditions	10992833	868	878	I-Outcome
at	10992833	879	881	I-Outcome
60	10992833	882	884	I-Outcome
s	10992833	885	886	I-Outcome
(	10992833	887	888	O
good-to-excellent	10992833	889	906	B-Outcome
in	10992833	907	909	O
86	10992833	910	912	B-Count
%	10992833	913	914	I-Count
and	10992833	915	918	O
84	10992833	919	921	B-Count
%	10992833	922	923	I-Count
of	10992833	924	926	I-Count
patients	10992833	927	935	I-Count
)	10992833	936	937	O
were	10992833	938	942	O
similar	10992833	943	950	B-Observation
for	10992833	951	954	O
rapacuronium	10992833	955	967	B-Intervention
and	10992833	968	971	O
rocuronium	10992833	972	982	B-Intervention
,	10992833	983	984	O
respectively	10992833	985	997	O
.	10992833	998	999	O

The	10992833	1000	1003	O
onset	10992833	1004	1009	B-Outcome
time	10992833	1010	1014	I-Outcome
of	10992833	1015	1017	O
rapacuronium	10992833	1018	1030	B-Intervention
was	10992833	1031	1034	O
shorter	10992833	1035	1042	B-Observation
than	10992833	1043	1047	O
rocuronium	10992833	1048	1058	B-Intervention
(	10992833	1059	1060	O
87	10992833	1061	1063	B-Observation
(	10992833	1064	1065	I-Observation
20	10992833	1066	1068	I-Observation
)	10992833	1069	1070	I-Observation
vs	10992833	1071	1073	O
141	10992833	1074	1077	B-Observation
(	10992833	1078	1079	I-Observation
65	10992833	1080	1082	I-Observation
)	10992833	1083	1084	I-Observation
s	10992833	1085	1086	I-Observation
,	10992833	1087	1088	O
P	10992833	1089	1090	O
<	10992833	1091	1092	O
0.001	10992833	1093	1098	O
)	10992833	1099	1100	O
,	10992833	1101	1102	O
and	10992833	1103	1106	O
the	10992833	1107	1110	O
degree	10992833	1111	1117	B-Outcome
of	10992833	1118	1120	I-Outcome
block	10992833	1121	1126	I-Outcome
at	10992833	1127	1129	I-Outcome
60	10992833	1130	1132	I-Outcome
s	10992833	1133	1134	I-Outcome
was	10992833	1135	1138	O
greater	10992833	1139	1146	B-Observation
(	10992833	1147	1148	O
69	10992833	1149	1151	B-Observation
(	10992833	1152	1153	I-Observation
26	10992833	1154	1156	I-Observation
)	10992833	1157	1158	I-Observation
vs	10992833	1159	1161	O
50	10992833	1162	1164	B-Observation
(	10992833	1165	1166	I-Observation
27	10992833	1167	1169	I-Observation
)	10992833	1170	1171	I-Observation
%	10992833	1172	1173	I-Observation
,	10992833	1174	1175	O
P	10992833	1176	1177	O
<	10992833	1178	1179	O
0.05	10992833	1180	1184	O
)	10992833	1185	1186	O
.	10992833	1187	1188	O

Twenty-five	10992833	1189	1200	B-Outcome
per	10992833	1201	1204	I-Outcome
cent	10992833	1205	1209	I-Outcome
recovery	10992833	1210	1218	I-Outcome
was	10992833	1219	1222	O
shorter	10992833	1223	1230	B-Observation
with	10992833	1231	1235	O
rapacuronium	10992833	1236	1248	B-Intervention
than	10992833	1249	1253	O
rocuronium	10992833	1254	1264	B-Intervention
during	10992833	1265	1271	O
propofol	10992833	1272	1280	B-Participant
(	10992833	1281	1282	O
15.0	10992833	1283	1287	B-Observation
(	10992833	1288	1289	I-Observation
3.2	10992833	1290	1293	I-Observation
)	10992833	1294	1295	I-Observation
vs	10992833	1296	1298	O
39.1	10992833	1299	1303	B-Observation
(	10992833	1304	1305	I-Observation
14.2	10992833	1306	1310	I-Observation
)	10992833	1311	1312	I-Observation
min	10992833	1313	1316	I-Observation
,	10992833	1317	1318	O
P	10992833	1319	1320	O
<	10992833	1321	1322	O
0.001	10992833	1323	1328	O
)	10992833	1329	1330	O
and	10992833	1331	1334	O
sevoflurane	10992833	1335	1346	B-Participant
(	10992833	1347	1348	O
15.1	10992833	1349	1353	B-Observation
(	10992833	1354	1355	I-Observation
4.2	10992833	1356	1359	I-Observation
)	10992833	1360	1361	I-Observation
vs	10992833	1362	1364	O
47.8	10992833	1365	1369	B-Observation
(	10992833	1370	1371	I-Observation
19.0	10992833	1372	1376	I-Observation
)	10992833	1377	1378	I-Observation
min	10992833	1379	1382	I-Observation
,	10992833	1383	1384	O
P	10992833	1385	1386	O
<	10992833	1387	1388	O
0.001	10992833	1389	1394	O
)	10992833	1395	1396	O
anaesthesia	10992833	1397	1408	B-Participant
.	10992833	1409	1410	O

We	10992833	1411	1413	O
conclude	10992833	1414	1422	O
that	10992833	1423	1427	O
rapacuronium	10992833	1428	1440	B-Intervention
1.5	10992833	1441	1444	O
mg	10992833	1445	1447	O
kg-1	10992833	1448	1452	O
had	10992833	1453	1456	O
a	10992833	1457	1458	O
more	10992833	1459	1463	B-Observation
rapid	10992833	1464	1469	I-Observation
onset	10992833	1470	1475	B-Outcome
,	10992833	1476	1477	O
similar	10992833	1478	1485	B-Observation
intubating	10992833	1486	1496	B-Outcome
conditions	10992833	1497	1507	I-Outcome
,	10992833	1508	1509	O
and	10992833	1510	1513	O
shorter	10992833	1514	1521	B-Observation
recovery	10992833	1522	1530	B-Outcome
times	10992833	1531	1536	I-Outcome
than	10992833	1537	1541	O
rocuronium	10992833	1542	1552	B-Intervention
0.6	10992833	1553	1556	O
mg	10992833	1557	1559	O
kg-1	10992833	1560	1564	O
.	10992833	1565	1566	O

Comparison	10992834	0	10	O
of	10992834	11	13	O
succinylcholine	10992834	14	29	B-Intervention
with	10992834	30	34	O
two	10992834	35	38	B-Intervention
doses	10992834	39	44	I-Intervention
of	10992834	45	47	I-Intervention
rocuronium	10992834	48	58	I-Intervention
using	10992834	59	64	O
a	10992834	65	66	O
new	10992834	67	70	O
method	10992834	71	77	O
of	10992834	78	80	O
monitoring	10992834	81	91	O
neuromuscular	10992834	92	105	B-Outcome
block	10992834	106	111	I-Outcome
at	10992834	112	114	I-Outcome
the	10992834	115	118	I-Outcome
laryngeal	10992834	119	128	I-Outcome
muscles	10992834	129	136	I-Outcome
by	10992834	137	139	O
surface	10992834	140	147	O
laryngeal	10992834	148	157	O
electromyography	10992834	158	174	O
.	10992834	175	176	O

We	10992834	177	179	O
compared	10992834	180	188	O
the	10992834	189	192	O
onset	10992834	193	198	B-Outcome
of	10992834	199	201	I-Outcome
neuromuscular	10992834	202	215	I-Outcome
block	10992834	216	221	I-Outcome
with	10992834	222	226	O
succinylcholine	10992834	227	242	B-Intervention
(	10992834	243	244	O
1	10992834	245	246	O
mg	10992834	247	249	O
kg-1	10992834	250	254	O
)	10992834	255	256	O
and	10992834	257	260	O
two	10992834	261	264	B-Intervention
doses	10992834	265	270	I-Intervention
of	10992834	271	273	I-Intervention
rocuronium	10992834	274	284	I-Intervention
(	10992834	285	286	O
0.6	10992834	287	290	O
and	10992834	291	294	O
0.9	10992834	295	298	O
mg	10992834	299	301	O
kg-1	10992834	302	306	O
)	10992834	307	308	O
at	10992834	309	311	O
the	10992834	312	315	O
adductor	10992834	316	324	O
pollicis	10992834	325	333	O
muscle	10992834	334	340	O
using	10992834	341	346	O
electromyography	10992834	347	363	O
(	10992834	364	365	O
EMG	10992834	366	369	O
)	10992834	370	371	O
and	10992834	372	375	O
acceleromyography	10992834	376	393	O
(	10992834	394	395	O
AMG	10992834	396	399	O
)	10992834	400	401	O
,	10992834	402	403	O
and	10992834	404	407	O
at	10992834	408	410	O
the	10992834	411	414	O
adductor	10992834	415	423	O
laryngeal	10992834	424	433	O
muscles	10992834	434	441	O
with	10992834	442	446	O
a	10992834	447	448	O
new	10992834	449	452	O
electromyographic	10992834	453	470	O
method	10992834	471	477	O
using	10992834	478	483	O
a	10992834	484	485	O
disposable	10992834	486	496	O
surface	10992834	497	504	O
electrode	10992834	505	514	O
attached	10992834	515	523	O
to	10992834	524	526	O
the	10992834	527	530	O
cuff	10992834	531	535	O
of	10992834	536	538	O
a	10992834	539	540	O
tracheal	10992834	541	549	O
tube	10992834	550	554	O
.	10992834	555	556	O

At	10992834	557	559	O
the	10992834	560	563	O
larynx	10992834	564	570	O
,	10992834	571	572	O
the	10992834	573	576	O
mean	10992834	577	581	B-Outcome
(	10992834	582	583	I-Outcome
+	10992834	584	585	I-Outcome
/-	10992834	585	587	I-Outcome
SD	10992834	588	590	I-Outcome
)	10992834	591	592	I-Outcome
time	10992834	593	597	I-Outcome
to	10992834	598	600	I-Outcome
90	10992834	601	603	I-Outcome
%	10992834	604	605	I-Outcome
block	10992834	606	611	I-Outcome
and	10992834	612	615	O
the	10992834	616	619	O
onset	10992834	620	625	B-Outcome
time	10992834	626	630	I-Outcome
of	10992834	631	633	O
succinylcholine	10992834	634	649	B-Intervention
(	10992834	650	651	O
38	10992834	652	654	B-Observation
+	10992834	655	656	I-Observation
/-	10992834	656	658	I-Observation
15	10992834	659	661	I-Observation
and	10992834	662	665	O
47	10992834	666	668	B-Observation
+	10992834	669	670	I-Observation
/-	10992834	670	672	I-Observation
19	10992834	673	675	I-Observation
s	10992834	676	677	I-Observation
,	10992834	678	679	O
respectively	10992834	680	692	O
)	10992834	693	694	O
were	10992834	695	699	O
significantly	10992834	700	713	B-Observation
shorter	10992834	714	721	I-Observation
(	10992834	722	723	O
P	10992834	724	725	O
<	10992834	726	727	O
0.01	10992834	728	732	O
)	10992834	733	734	O
than	10992834	735	739	O
for	10992834	740	743	O
rocuronium	10992834	744	754	B-Intervention
0.6	10992834	755	758	I-Intervention
mg	10992834	759	761	I-Intervention
kg-1	10992834	762	766	I-Intervention
(	10992834	767	768	O
92	10992834	769	771	B-Observation
+	10992834	772	773	I-Observation
/-	10992834	773	775	I-Observation
42	10992834	776	778	I-Observation
and	10992834	779	782	O
106	10992834	783	786	B-Observation
+	10992834	787	788	I-Observation
/-	10992834	788	790	I-Observation
38	10992834	791	793	I-Observation
s	10992834	794	795	I-Observation
)	10992834	796	797	O
and	10992834	798	801	O
rocuronium	10992834	802	812	B-Intervention
0.9	10992834	813	816	I-Intervention
mg	10992834	817	819	I-Intervention
kg-1	10992834	820	824	I-Intervention
(	10992834	825	826	O
52	10992834	827	829	B-Observation
+	10992834	830	831	I-Observation
/-	10992834	831	833	I-Observation
31	10992834	834	836	I-Observation
and	10992834	837	840	O
64	10992834	841	843	B-Observation
+	10992834	844	845	I-Observation
/-	10992834	845	847	I-Observation
30	10992834	848	850	I-Observation
s	10992834	851	852	I-Observation
)	10992834	853	854	O
.	10992834	855	856	O

We	10992834	857	859	O
found	10992834	860	865	O
that	10992834	866	870	O
,	10992834	871	872	O
with	10992834	873	877	O
comparable	10992834	878	888	B-Observation
degrees	10992834	889	896	B-Outcome
of	10992834	897	899	I-Outcome
neuromuscular	10992834	900	913	I-Outcome
block	10992834	914	919	I-Outcome
,	10992834	920	921	O
the	10992834	922	925	O
onset	10992834	926	931	B-Outcome
time	10992834	932	936	I-Outcome
of	10992834	937	939	O
succinylcholine	10992834	940	955	B-Intervention
at	10992834	956	958	O
the	10992834	959	962	O
adductor	10992834	963	971	O
pollicis	10992834	972	980	O
was	10992834	981	984	O
significantly	10992834	985	998	B-Observation
shorter	10992834	999	1006	I-Observation
(	10992834	1007	1008	O
P	10992834	1009	1010	O
<	10992834	1011	1012	O
0.01	10992834	1013	1017	O
)	10992834	1018	1019	O
than	10992834	1020	1024	O
for	10992834	1025	1028	O
rocuronium	10992834	1029	1039	B-Intervention
0.6	10992834	1040	1043	I-Intervention
mg	10992834	1044	1046	I-Intervention
kg-1	10992834	1047	1051	I-Intervention
and	10992834	1052	1055	O
0.9	10992834	1056	1059	B-Intervention
mg	10992834	1060	1062	I-Intervention
kg-1	10992834	1063	1067	I-Intervention
(	10992834	1068	1069	O
EMG	10992834	1070	1073	B-Outcome
,	10992834	1074	1075	O
80	10992834	1076	1078	B-Observation
+	10992834	1079	1080	I-Observation
/-	10992834	1080	1082	I-Observation
39	10992834	1083	1085	I-Observation
vs	10992834	1086	1088	O
145	10992834	1089	1092	B-Observation
+	10992834	1093	1094	I-Observation
/-	10992834	1094	1096	I-Observation
48	10992834	1097	1099	I-Observation
s	10992834	1100	1101	I-Observation
and	10992834	1102	1105	O
99	10992834	1106	1108	B-Observation
+	10992834	1109	1110	I-Observation
/-	10992834	1110	1112	I-Observation
31	10992834	1113	1115	I-Observation
s	10992834	1116	1117	I-Observation
;	10992834	1118	1119	O
AMG	10992834	1120	1123	B-Outcome
,	10992834	1124	1125	O
90	10992834	1126	1128	B-Observation
+	10992834	1129	1130	I-Observation
/-	10992834	1130	1132	I-Observation
39	10992834	1133	1135	I-Observation
vs	10992834	1136	1138	O
124	10992834	1139	1142	B-Observation
+	10992834	1143	1144	I-Observation
/-	10992834	1144	1146	I-Observation
53	10992834	1147	1149	I-Observation
s	10992834	1150	1151	I-Observation
and	10992834	1152	1155	O
106	10992834	1156	1159	B-Observation
+	10992834	1160	1161	I-Observation
/-	10992834	1161	1163	I-Observation
38	10992834	1164	1166	I-Observation
s	10992834	1167	1168	I-Observation
)	10992834	1169	1170	O
.	10992834	1171	1172	O

Clinical	10992834	1173	1181	B-Outcome
duration	10992834	1182	1190	I-Outcome
at	10992834	1191	1193	I-Outcome
the	10992834	1194	1197	I-Outcome
adductor	10992834	1198	1206	I-Outcome
pollicis	10992834	1207	1215	I-Outcome
(	10992834	1216	1217	I-Outcome
AMG	10992834	1218	1221	I-Outcome
)	10992834	1222	1223	I-Outcome
was	10992834	1224	1227	O
significantly	10992834	1228	1241	B-Observation
longer	10992834	1242	1248	I-Observation
(	10992834	1249	1250	O
P	10992834	1251	1252	O
<	10992834	1253	1254	O
0.01	10992834	1255	1259	O
)	10992834	1260	1261	O
for	10992834	1262	1265	O
both	10992834	1266	1270	B-Intervention
rocuronium	10992834	1271	1281	I-Intervention
groups	10992834	1282	1288	I-Intervention
than	10992834	1289	1293	O
for	10992834	1294	1297	O
succinylcholine	10992834	1298	1313	B-Intervention
(	10992834	1314	1315	O
T4	10992834	1316	1318	B-Outcome
:	10992834	1319	1320	I-Outcome
T1	10992834	1321	1323	I-Outcome
=	10992834	1324	1325	O
0.7	10992834	1326	1329	B-Observation
,	10992834	1330	1331	O
54	10992834	1332	1334	B-Observation
+	10992834	1335	1336	I-Observation
/-	10992834	1336	1338	I-Observation
18	10992834	1339	1341	I-Observation
and	10992834	1342	1345	O
77	10992834	1346	1348	B-Observation
+	10992834	1349	1350	I-Observation
/-	10992834	1350	1352	I-Observation
21	10992834	1353	1355	I-Observation
vs	10992834	1356	1358	O
8	10992834	1359	1360	B-Observation
+	10992834	1361	1362	I-Observation
/-	10992834	1362	1364	I-Observation
6	10992834	1365	1366	I-Observation
min	10992834	1367	1370	I-Observation
)	10992834	1371	1372	O
.	10992834	1373	1374	O

The	10992834	1375	1378	O
surface	10992834	1379	1386	O
laryngeal	10992834	1387	1396	O
electrode	10992834	1397	1406	O
proved	10992834	1407	1413	O
non-invasive	10992834	1414	1426	O
,	10992834	1427	1428	O
easy	10992834	1429	1433	O
to	10992834	1434	1436	O
use	10992834	1437	1440	O
and	10992834	1441	1444	O
reliable	10992834	1445	1453	O
in	10992834	1454	1456	O
measuring	10992834	1457	1466	O
onset	10992834	1467	1472	O
of	10992834	1473	1475	O
the	10992834	1476	1479	O
neuromuscular	10992834	1480	1493	O
block	10992834	1494	1499	O
at	10992834	1500	1502	O
the	10992834	1503	1506	O
larynx	10992834	1507	1513	O
.	10992834	1514	1515	O

Sublingual	10993031	0	10	B-Intervention
administration	10993031	11	25	I-Intervention
of	10993031	26	28	I-Intervention
micronized	10993031	29	39	I-Intervention
estradiol	10993031	40	49	I-Intervention
and	10993031	50	53	I-Intervention
progesterone	10993031	54	66	I-Intervention
,	10993031	67	68	I-Intervention
with	10993031	69	73	I-Intervention
and	10993031	74	77	I-Intervention
without	10993031	78	85	I-Intervention
micronized	10993031	86	96	I-Intervention
testosterone	10993031	97	109	I-Intervention
:	10993031	110	111	O
effect	10993031	112	118	O
on	10993031	119	121	O
biochemical	10993031	122	133	B-Outcome
markers	10993031	134	141	I-Outcome
of	10993031	142	144	I-Outcome
bone	10993031	145	149	I-Outcome
metabolism	10993031	150	160	I-Outcome
and	10993031	161	164	O
bone	10993031	165	169	B-Outcome
mineral	10993031	170	177	I-Outcome
density	10993031	178	185	I-Outcome
.	10993031	186	187	O

OBJECTIVES	10993031	188	198	O
The	10993031	199	202	O
purpose	10993031	203	210	O
of	10993031	211	213	O
this	10993031	214	218	O
investigation	10993031	219	232	O
was	10993031	233	236	O
to	10993031	237	239	O
evaluate	10993031	240	248	O
the	10993031	249	252	O
relative	10993031	253	261	O
efficacy	10993031	262	270	O
of	10993031	271	273	O
the	10993031	274	277	O
sublingual	10993031	278	288	B-Intervention
administration	10993031	289	303	I-Intervention
of	10993031	304	306	I-Intervention
micronized	10993031	307	317	I-Intervention
estradiol	10993031	318	327	I-Intervention
(	10993031	328	329	I-Intervention
E2	10993031	330	332	I-Intervention
)	10993031	333	334	I-Intervention
,	10993031	335	336	I-Intervention
progesterone	10993031	337	349	I-Intervention
(	10993031	350	351	I-Intervention
P4	10993031	352	354	I-Intervention
)	10993031	355	356	I-Intervention
,	10993031	357	358	I-Intervention
and	10993031	359	362	I-Intervention
testosterone	10993031	363	375	I-Intervention
(	10993031	376	377	I-Intervention
T	10993031	378	379	I-Intervention
)	10993031	380	381	I-Intervention
on	10993031	382	384	O
bone	10993031	385	389	B-Outcome
mineral	10993031	390	397	I-Outcome
density	10993031	398	405	I-Outcome
and	10993031	406	409	O
biochemical	10993031	410	421	B-Outcome
markers	10993031	422	429	I-Outcome
of	10993031	430	432	I-Outcome
bone	10993031	433	437	I-Outcome
metabolism	10993031	438	448	I-Outcome
.	10993031	449	450	O

DESIGN	10993031	451	457	O
In	10993031	458	460	O
this	10993031	461	465	O
double-blind	10993031	466	478	O
,	10993031	479	480	O
prospective	10993031	481	492	O
study	10993031	493	498	O
,	10993031	499	500	O
postmenopausal	10993031	501	515	B-Participant
women	10993031	516	521	I-Participant
were	10993031	522	526	O
randomly	10993031	527	535	O
assigned	10993031	536	544	O
to	10993031	545	547	O
one	10993031	548	551	O
of	10993031	552	554	O
four	10993031	555	559	O
treatment	10993031	560	569	O
groups	10993031	570	576	O
:	10993031	577	578	O
hysterectomized	10993031	579	594	B-Participant
women	10993031	595	600	I-Participant
were	10993031	601	605	O
assigned	10993031	606	614	O
to	10993031	615	617	O
either	10993031	618	624	O
1	10993031	625	626	O
)	10993031	627	628	O
micronized	10993031	629	639	B-Intervention
E2	10993031	640	642	I-Intervention
(	10993031	643	644	I-Intervention
0.5	10993031	645	648	I-Intervention
mg	10993031	649	651	I-Intervention
)	10993031	652	653	I-Intervention
or	10993031	654	656	O
2	10993031	657	658	O
)	10993031	659	660	O
micronized	10993031	661	671	B-Intervention
E2	10993031	672	674	I-Intervention
(	10993031	675	676	I-Intervention
0.5	10993031	677	680	I-Intervention
mg	10993031	681	683	I-Intervention
)	10993031	684	685	I-Intervention
+	10993031	686	687	I-Intervention
micronized	10993031	688	698	I-Intervention
T	10993031	699	700	I-Intervention
(	10993031	701	702	I-Intervention
1.25	10993031	703	707	I-Intervention
mg	10993031	708	710	I-Intervention
)	10993031	711	712	I-Intervention
.	10993031	713	714	O

Women	10993031	715	720	B-Participant
with	10993031	721	725	O
intact	10993031	726	732	B-Participant
uteri	10993031	733	738	I-Participant
were	10993031	739	743	O
assigned	10993031	744	752	O
to	10993031	753	755	O
either	10993031	756	762	O
3	10993031	763	764	O
)	10993031	765	766	O
micronized	10993031	767	777	B-Intervention
E2	10993031	778	780	I-Intervention
(	10993031	781	782	I-Intervention
0.5	10993031	783	786	I-Intervention
mg	10993031	787	789	I-Intervention
)	10993031	790	791	I-Intervention
+	10993031	792	793	I-Intervention
micronized	10993031	794	804	I-Intervention
P4	10993031	805	807	I-Intervention
(	10993031	808	809	I-Intervention
100	10993031	810	813	I-Intervention
mg	10993031	814	816	I-Intervention
)	10993031	817	818	I-Intervention
or	10993031	819	821	O
4	10993031	822	823	O
)	10993031	824	825	O
micronized	10993031	826	836	B-Intervention
E2	10993031	837	839	I-Intervention
(	10993031	840	841	I-Intervention
0.5	10993031	842	845	I-Intervention
mg	10993031	846	848	I-Intervention
)	10993031	849	850	I-Intervention
+	10993031	851	852	I-Intervention
micronized	10993031	853	863	I-Intervention
P4	10993031	864	866	I-Intervention
(	10993031	867	868	I-Intervention
100	10993031	869	872	I-Intervention
mcg	10993031	873	876	I-Intervention
)	10993031	877	878	I-Intervention
+	10993031	879	880	I-Intervention
micronized	10993031	881	891	I-Intervention
T	10993031	892	893	I-Intervention
(	10993031	894	895	I-Intervention
1.25	10993031	896	900	I-Intervention
mg	10993031	901	903	I-Intervention
)	10993031	904	905	I-Intervention
.	10993031	906	907	O

For	10993031	908	911	O
the	10993031	912	915	O
purpose	10993031	916	923	O
of	10993031	924	926	O
this	10993031	927	931	O
study	10993031	932	937	O
,	10993031	938	939	O
the	10993031	940	943	O
four	10993031	944	948	O
treatment	10993031	949	958	O
groups	10993031	959	965	O
were	10993031	966	970	O
combined	10993031	971	979	O
into	10993031	980	984	O
two	10993031	985	988	O
groups	10993031	989	995	O
for	10993031	996	999	O
all	10993031	1000	1003	O
comparisons	10993031	1004	1015	O
.	10993031	1016	1017	O

The	10993031	1018	1021	O
E2	10993031	1022	1024	O
and	10993031	1025	1028	O
E2+P4	10993031	1029	1034	O
groups	10993031	1035	1041	O
were	10993031	1042	1046	O
combined	10993031	1047	1055	O
into	10993031	1056	1060	O
the	10993031	1061	1064	O
HRT	10993031	1065	1068	B-Intervention
alone	10993031	1069	1074	I-Intervention
group	10993031	1075	1080	O
(	10993031	1081	1082	O
n=30	10993031	1083	1087	O
)	10993031	1088	1089	O
,	10993031	1090	1091	O
and	10993031	1092	1095	O
the	10993031	1096	1099	O
E2+T	10993031	1100	1104	O
and	10993031	1105	1108	O
E2+P4+T	10993031	1109	1116	O
groups	10993031	1117	1123	O
were	10993031	1124	1128	O
combined	10993031	1129	1137	O
into	10993031	1138	1142	O
the	10993031	1143	1146	O
HRT	10993031	1147	1150	B-Intervention
+	10993031	1151	1152	I-Intervention
T	10993031	1153	1154	I-Intervention
group	10993031	1155	1160	O
(	10993031	1161	1162	O
n=27	10993031	1163	1167	O
)	10993031	1168	1169	O
.	10993031	1170	1171	O

Hormones	10993031	1172	1180	O
were	10993031	1181	1185	O
administered	10993031	1186	1198	O
sublingually	10993031	1199	1211	O
as	10993031	1212	1214	O
a	10993031	1215	1216	O
single	10993031	1217	1223	O
tablet	10993031	1224	1230	O
twice	10993031	1231	1236	O
a	10993031	1237	1238	O
day	10993031	1239	1242	O
for	10993031	1243	1246	O
12	10993031	1247	1249	O
months	10993031	1250	1256	O
.	10993031	1257	1258	O

Bone	10993031	1259	1263	B-Outcome
mineral	10993031	1264	1271	I-Outcome
density	10993031	1272	1279	I-Outcome
was	10993031	1280	1283	O
measured	10993031	1284	1292	O
in	10993031	1293	1295	O
the	10993031	1296	1299	O
anterior-posterior	10993031	1300	1318	O
lumbar	10993031	1319	1325	O
spine	10993031	1326	1331	O
and	10993031	1332	1335	O
total	10993031	1336	1341	O
left	10993031	1342	1346	O
hip	10993031	1347	1350	O
via	10993031	1351	1354	O
dual	10993031	1355	1359	O
energy	10993031	1360	1366	O
x-ray	10993031	1367	1372	O
absorptiometry	10993031	1373	1387	O
.	10993031	1388	1389	O

Bone	10993031	1390	1394	B-Outcome
metabolism	10993031	1395	1405	I-Outcome
was	10993031	1406	1409	O
assessed	10993031	1410	1418	O
via	10993031	1419	1422	O
serum	10993031	1423	1428	O
bone-specific	10993031	1429	1442	O
alkaline	10993031	1443	1451	O
phosphatase	10993031	1452	1463	O
and	10993031	1464	1467	O
urinary	10993031	1468	1475	B-Outcome
deoxypyridinoline	10993031	1476	1493	I-Outcome
and	10993031	1494	1497	O
cross-linked	10993031	1498	1510	B-Outcome
N-telopeptide	10993031	1511	1524	I-Outcome
of	10993031	1525	1527	I-Outcome
type	10993031	1528	1532	I-Outcome
I	10993031	1533	1534	I-Outcome
collagen	10993031	1535	1543	I-Outcome
,	10993031	1544	1545	O
both	10993031	1546	1550	O
normalized	10993031	1551	1561	O
to	10993031	1562	1564	O
creatinine	10993031	1565	1575	O
.	10993031	1576	1577	O

Data	10993031	1578	1582	O
were	10993031	1583	1587	O
analyzed	10993031	1588	1596	O
via	10993031	1597	1600	O
a	10993031	1601	1602	O
repeated	10993031	1603	1611	O
measures	10993031	1612	1620	O
analysis	10993031	1621	1629	O
of	10993031	1630	1632	O
variance	10993031	1633	1641	O
and	10993031	1642	1645	O
a	10993031	1646	1647	O
Student	10993031	1648	1655	O
's	10993031	1656	1658	O
t	10993031	1659	1660	O
test	10993031	1661	1665	O
(	10993031	1666	1667	O
alpha=0.05	10993031	1668	1678	O
)	10993031	1679	1680	O
.	10993031	1681	1682	O

RESULTS	10993031	1683	1690	O
The	10993031	1691	1694	O
subjects	10993031	1695	1703	O
were	10993031	1704	1708	O
of	10993031	1709	1711	O
similar	10993031	1712	1719	O
age	10993031	1720	1723	O
(	10993031	1724	1725	O
54.0	10993031	1726	1730	O
+	10993031	1731	1732	O
/-	10993031	1732	1734	O
0.8	10993031	1735	1738	O
years	10993031	1739	1744	O
)	10993031	1745	1746	O
,	10993031	1747	1748	O
height	10993031	1749	1755	O
(	10993031	1756	1757	O
64.0	10993031	1758	1762	O
+	10993031	1763	1764	O
/-	10993031	1764	1766	O
0.3	10993031	1767	1770	O
in	10993031	1771	1773	O
)	10993031	1774	1775	O
,	10993031	1776	1777	O
weight	10993031	1778	1784	O
(	10993031	1785	1786	O
157.6	10993031	1787	1792	O
+	10993031	1793	1794	O
/-	10993031	1794	1796	O
4.2	10993031	1797	1800	O
lb	10993031	1801	1803	O
)	10993031	1804	1805	O
,	10993031	1806	1807	O
and	10993031	1808	1811	O
had	10993031	1812	1815	O
similar	10993031	1816	1823	O
baseline	10993031	1824	1832	O
follicle-stimulating	10993031	1833	1853	O
hormone	10993031	1854	1861	O
(	10993031	1862	1863	O
66.4	10993031	1864	1868	O
+	10993031	1869	1870	O
/-	10993031	1870	1872	O
3.2	10993031	1873	1876	O
mIU/L	10993031	1877	1882	O
)	10993031	1883	1884	O
,	10993031	1885	1886	O
E2	10993031	1887	1889	O
(	10993031	1890	1891	O
26.4	10993031	1892	1896	O
+	10993031	1897	1898	O
/-	10993031	1898	1900	O
1.5	10993031	1901	1904	O
pg/ml	10993031	1905	1910	O
)	10993031	1911	1912	O
,	10993031	1913	1914	O
P4	10993031	1915	1917	O
(	10993031	1918	1919	O
0.3	10993031	1920	1923	O
+	10993031	1924	1925	O
/-	10993031	1925	1927	O
0.1	10993031	1928	1931	O
ng/ml	10993031	1932	1937	O
)	10993031	1938	1939	O
,	10993031	1940	1941	O
total	10993031	1942	1947	O
T	10993031	1948	1949	O
(	10993031	1950	1951	O
19.0	10993031	1952	1956	O
+	10993031	1957	1958	O
/-	10993031	1958	1960	O
1.5	10993031	1961	1964	O
ng/dL	10993031	1965	1970	O
)	10993031	1971	1972	O
,	10993031	1973	1974	O
and	10993031	1975	1978	O
bioavailable	10993031	1979	1991	O
T	10993031	1992	1993	O
(	10993031	1994	1995	O
3.7	10993031	1996	1999	O
+	10993031	2000	2001	O
/-	10993031	2001	2003	O
0.3	10993031	2004	2007	O
ng/dL	10993031	2008	2013	O
)	10993031	2014	2015	O
levels	10993031	2016	2022	O
.	10993031	2023	2024	O

During	10993031	2025	2031	O
therapy	10993031	2032	2039	O
,	10993031	2040	2041	O
serum	10993031	2042	2047	B-Outcome
levels	10993031	2048	2054	I-Outcome
increased	10993031	2055	2064	B-Observation
(	10993031	2065	2066	O
p	10993031	2067	2068	O
<	10993031	2069	2070	O
0.05	10993031	2071	2075	O
)	10993031	2076	2077	O
for	10993031	2078	2081	O
each	10993031	2082	2086	B-Outcome
hormone	10993031	2087	2094	I-Outcome
.	10993031	2095	2096	O

Bone	10993031	2097	2101	B-Outcome
mineral	10993031	2102	2109	I-Outcome
density	10993031	2110	2117	I-Outcome
and	10993031	2118	2121	O
bone	10993031	2122	2126	B-Outcome
markers	10993031	2127	2134	I-Outcome
at	10993031	2135	2137	O
baseline	10993031	2138	2146	O
were	10993031	2147	2151	O
similar	10993031	2152	2159	B-Observation
for	10993031	2160	2163	O
each	10993031	2164	2168	B-Intervention
treatment	10993031	2169	2178	I-Intervention
group	10993031	2179	2184	O
.	10993031	2185	2186	O

Bone-specific	10993031	2187	2200	B-Outcome
alkaline	10993031	2201	2209	I-Outcome
phosphatase	10993031	2210	2221	I-Outcome
decreased	10993031	2222	2231	B-Observation
(	10993031	2232	2233	I-Observation
p	10993031	2234	2235	I-Observation
<	10993031	2236	2237	I-Observation
0.05	10993031	2238	2242	I-Observation
)	10993031	2243	2244	I-Observation
by	10993031	2245	2247	I-Observation
-14.3	10993031	2248	2253	I-Observation
+	10993031	2254	2255	I-Observation
/-	10993031	2255	2257	I-Observation
4.1	10993031	2258	2261	I-Observation
%	10993031	2262	2263	I-Observation
in	10993031	2264	2266	O
the	10993031	2267	2270	O
HRT	10993031	2271	2274	B-Intervention
alone	10993031	2275	2280	I-Intervention
group	10993031	2281	2286	O
and	10993031	2287	2290	O
by	10993031	2291	2293	B-Observation
-8.2	10993031	2294	2298	I-Observation
+	10993031	2299	2300	I-Observation
/-	10993031	2300	2302	I-Observation
4.6	10993031	2303	2306	I-Observation
%	10993031	2307	2308	I-Observation
in	10993031	2309	2311	O
the	10993031	2312	2315	O
HRT	10993031	2316	2319	B-Intervention
+	10993031	2320	2321	I-Intervention
T	10993031	2322	2323	I-Intervention
group	10993031	2324	2329	O
.	10993031	2330	2331	O

Deoxypyridinoline	10993031	2332	2349	B-Outcome
levels	10993031	2350	2356	I-Outcome
decreased	10993031	2357	2366	B-Observation
significantly	10993031	2367	2380	I-Observation
in	10993031	2381	2383	O
the	10993031	2384	2387	O
HRT	10993031	2388	2391	B-Intervention
alone	10993031	2392	2397	I-Intervention
and	10993031	2398	2401	O
HRT	10993031	2402	2405	B-Intervention
+	10993031	2406	2407	I-Intervention
T	10993031	2408	2409	I-Intervention
groups	10993031	2410	2416	O
,	10993031	2417	2418	O
-	10993031	2419	2420	B-Observation
14.4	10993031	2421	2425	I-Observation
+	10993031	2426	2427	I-Observation
/-	10993031	2427	2429	I-Observation
6.8	10993031	2430	2433	I-Observation
%	10993031	2434	2435	I-Observation
and	10993031	2436	2439	O
-26.9	10993031	2440	2445	B-Observation
+	10993031	2446	2447	I-Observation
/-	10993031	2447	2449	I-Observation
7.6	10993031	2450	2453	I-Observation
%	10993031	2454	2455	I-Observation
,	10993031	2456	2457	O
respectively	10993031	2458	2470	O
.	10993031	2471	2472	O

Significant	10993031	2473	2484	B-Observation
reductions	10993031	2485	2495	I-Observation
(	10993031	2496	2497	O
p	10993031	2498	2499	O
<	10993031	2500	2501	O
0.05	10993031	2502	2506	O
)	10993031	2507	2508	O
in	10993031	2509	2511	O
cross-linked	10993031	2512	2524	B-Outcome
N-telopeptide	10993031	2525	2538	I-Outcome
of	10993031	2539	2541	I-Outcome
type	10993031	2542	2546	I-Outcome
I	10993031	2547	2548	I-Outcome
collagen	10993031	2549	2557	I-Outcome
were	10993031	2558	2562	O
also	10993031	2563	2567	O
observed	10993031	2568	2576	O
in	10993031	2577	2579	O
both	10993031	2580	2584	B-Intervention
groups	10993031	2585	2591	I-Intervention
,	10993031	2592	2593	O
-24.4	10993031	2594	2599	B-Observation
+	10993031	2600	2601	I-Observation
/-	10993031	2601	2603	I-Observation
6.5	10993031	2604	2607	I-Observation
%	10993031	2608	2609	I-Observation
and	10993031	2610	2613	O
-39.5	10993031	2614	2619	B-Observation
+	10993031	2620	2621	I-Observation
/-	10993031	2621	2623	I-Observation
8.6	10993031	2624	2627	I-Observation
%	10993031	2628	2629	I-Observation
,	10993031	2630	2631	O
respectively	10993031	2632	2644	O
.	10993031	2645	2646	O

Bone	10993031	2647	2651	B-Outcome
mineral	10993031	2652	2659	I-Outcome
density	10993031	2660	2667	I-Outcome
in	10993031	2668	2670	I-Outcome
the	10993031	2671	2674	I-Outcome
lumbar	10993031	2675	2681	I-Outcome
spine	10993031	2682	2687	I-Outcome
increased	10993031	2688	2697	B-Observation
(	10993031	2698	2699	I-Observation
p	10993031	2700	2701	I-Observation
<	10993031	2702	2703	I-Observation
0.05	10993031	2704	2708	I-Observation
)	10993031	2709	2710	I-Observation
by	10993031	2711	2713	I-Observation
+	10993031	2714	2715	I-Observation
2.2	10993031	2715	2718	I-Observation
+	10993031	2719	2720	I-Observation
/-	10993031	2720	2722	I-Observation
0.5	10993031	2723	2726	I-Observation
%	10993031	2727	2728	I-Observation
the	10993031	2729	2732	O
HRT	10993031	2733	2736	B-Intervention
alone	10993031	2737	2742	I-Intervention
group	10993031	2743	2748	O
and	10993031	2749	2752	O
by	10993031	2753	2755	B-Observation
+	10993031	2756	2757	I-Observation
1.8	10993031	2758	2761	I-Observation
+	10993031	2762	2763	I-Observation
/-	10993031	2763	2765	I-Observation
0.6	10993031	2766	2769	I-Observation
%	10993031	2770	2771	I-Observation
in	10993031	2772	2774	O
the	10993031	2775	2778	O
HRT	10993031	2779	2782	B-Intervention
+	10993031	2783	2784	I-Intervention
T	10993031	2785	2786	I-Intervention
group	10993031	2787	2792	O
.	10993031	2793	2794	O

Total	10993031	2795	2800	B-Outcome
hip	10993031	2801	2804	I-Outcome
bone	10993031	2805	2809	I-Outcome
mineral	10993031	2810	2817	I-Outcome
density	10993031	2818	2825	I-Outcome
was	10993031	2826	2829	O
maintained	10993031	2830	2840	B-Observation
in	10993031	2841	2843	O
the	10993031	2844	2847	O
HRT	10993031	2848	2851	B-Intervention
alone	10993031	2852	2857	I-Intervention
group	10993031	2858	2863	O
(	10993031	2864	2865	O
+	10993031	2866	2867	B-Observation
0.4	10993031	2867	2870	I-Observation
+	10993031	2871	2872	I-Observation
/-	10993031	2872	2874	I-Observation
0.4	10993031	2875	2878	I-Observation
%	10993031	2879	2880	I-Observation
)	10993031	2881	2882	O
and	10993031	2883	2886	O
increased	10993031	2887	2896	B-Observation
(	10993031	2897	2898	O
p	10993031	2899	2900	O
<	10993031	2901	2902	O
0.05	10993031	2903	2907	O
)	10993031	2908	2909	O
in	10993031	2910	2912	O
the	10993031	2913	2916	O
HRT	10993031	2917	2920	B-Intervention
+	10993031	2921	2922	I-Intervention
T	10993031	2923	2924	I-Intervention
group	10993031	2925	2930	O
(	10993031	2931	2932	O
+	10993031	2933	2934	B-Observation
1.8	10993031	2935	2938	I-Observation
+	10993031	2939	2940	I-Observation
/-	10993031	2940	2942	I-Observation
0.5	10993031	2943	2946	I-Observation
%	10993031	2947	2948	I-Observation
)	10993031	2949	2950	O
.	10993031	2951	2952	O

CONCLUSIONS	10993031	2953	2964	O
Sublingual	10993031	2965	2975	B-Intervention
micronized	10993031	2976	2986	I-Intervention
HRT	10993031	2987	2990	I-Intervention
favorably	10993031	2991	3000	O
decreases	10993031	3001	3010	B-Observation
serum	10993031	3011	3016	B-Outcome
and	10993031	3017	3020	I-Outcome
urine	10993031	3021	3026	I-Outcome
markers	10993031	3027	3034	I-Outcome
of	10993031	3035	3037	I-Outcome
bone	10993031	3038	3042	I-Outcome
metabolism	10993031	3043	3053	I-Outcome
,	10993031	3054	3055	O
prevents	10993031	3056	3064	B-Observation
bone	10993031	3065	3069	B-Outcome
loss	10993031	3070	3074	I-Outcome
,	10993031	3075	3076	O
and	10993031	3077	3080	O
results	10993031	3081	3088	O
in	10993031	3089	3091	O
a	10993031	3092	3093	O
slight	10993031	3094	3100	B-Observation
increase	10993031	3101	3109	I-Observation
in	10993031	3110	3112	O
spine	10993031	3113	3118	B-Outcome
and	10993031	3119	3122	I-Outcome
hip	10993031	3123	3126	I-Outcome
bone	10993031	3127	3131	I-Outcome
mineral	10993031	3132	3139	I-Outcome
density	10993031	3140	3147	I-Outcome
.	10993031	3148	3149	O

Although	10993031	3150	3158	O
the	10993031	3159	3162	O
addition	10993031	3163	3171	B-Intervention
of	10993031	3172	3174	I-Intervention
testosterone	10993031	3175	3187	I-Intervention
to	10993031	3188	3190	I-Intervention
HRT	10993031	3191	3194	I-Intervention
for	10993031	3195	3198	O
1	10993031	3199	3200	O
year	10993031	3201	3205	O
did	10993031	3206	3209	O
not	10993031	3210	3213	O
result	10993031	3214	3220	O
in	10993031	3221	3223	O
added	10993031	3224	3229	B-Observation
benefit	10993031	3230	3237	I-Observation
to	10993031	3238	3240	O
the	10993031	3241	3244	O
spine	10993031	3245	3250	B-Outcome
bone	10993031	3251	3255	I-Outcome
mineral	10993031	3256	3263	I-Outcome
density	10993031	3264	3271	I-Outcome
,	10993031	3272	3273	O
it	10993031	3274	3276	O
did	10993031	3277	3280	O
result	10993031	3281	3287	O
in	10993031	3288	3290	O
a	10993031	3291	3292	O
significant	10993031	3293	3304	B-Observation
increase	10993031	3305	3313	I-Observation
in	10993031	3314	3316	O
hip	10993031	3317	3320	B-Outcome
bone	10993031	3321	3325	I-Outcome
mineral	10993031	3326	3333	I-Outcome
density	10993031	3334	3341	I-Outcome
.	10993031	3342	3343	O

Longer	10993031	3344	3350	O
duration	10993031	3351	3359	O
of	10993031	3360	3362	O
therapy	10993031	3363	3370	O
may	10993031	3371	3374	O
have	10993031	3375	3379	O
further	10993031	3380	3387	O
improved	10993031	3388	3396	O
these	10993031	3397	3402	O
outcomes	10993031	3403	3411	O
.	10993031	3412	3413	O

Paclitaxel	10997806	0	10	B-Intervention
(	10997806	11	12	I-Intervention
175	10997806	13	16	I-Intervention
mg/m2	10997806	17	22	I-Intervention
)	10997806	23	24	I-Intervention
plus	10997806	25	29	I-Intervention
carboplatin	10997806	30	41	I-Intervention
(	10997806	42	43	I-Intervention
6	10997806	44	45	I-Intervention
AUC	10997806	46	49	I-Intervention
)	10997806	50	51	I-Intervention
versus	10997806	52	58	O
paclitaxel	10997806	59	69	B-Intervention
(	10997806	70	71	I-Intervention
225	10997806	72	75	I-Intervention
mg/m2	10997806	76	81	I-Intervention
)	10997806	82	83	I-Intervention
plus	10997806	84	88	I-Intervention
carboplatin	10997806	89	100	I-Intervention
(	10997806	101	102	I-Intervention
6	10997806	103	104	I-Intervention
AUC	10997806	105	108	I-Intervention
)	10997806	109	110	I-Intervention
in	10997806	111	113	O
advanced	10997806	114	122	B-Participant
non-small-cell	10997806	123	137	I-Participant
lung	10997806	138	142	I-Participant
cancer	10997806	143	149	I-Participant
(	10997806	150	151	I-Participant
NSCLC	10997806	152	157	I-Participant
)	10997806	158	159	I-Participant
:	10997806	160	161	O
a	10997806	162	163	O
multicenter	10997806	164	175	O
randomized	10997806	176	186	O
trial	10997806	187	192	O
.	10997806	193	194	O

Hellenic	10997806	195	203	O
Cooperative	10997806	204	215	O
Oncology	10997806	216	224	O
Group	10997806	225	230	O
(	10997806	231	232	O
HeCOG	10997806	233	238	O
)	10997806	239	240	O
.	10997806	241	242	O

PURPOSE	10997806	243	250	O
The	10997806	251	254	O
combination	10997806	255	266	O
of	10997806	267	269	O
paclitaxel	10997806	270	280	O
and	10997806	281	284	O
carboplatin	10997806	285	296	O
has	10997806	297	300	O
become	10997806	301	307	O
a	10997806	308	309	O
widely	10997806	310	316	O
used	10997806	317	321	O
regimen	10997806	322	329	O
in	10997806	330	332	O
NSCLC	10997806	333	338	O
due	10997806	339	342	O
to	10997806	343	345	O
phase	10997806	346	351	O
II	10997806	352	354	O
reports	10997806	355	362	O
of	10997806	363	365	O
moderate	10997806	366	374	O
toxicity	10997806	375	383	O
,	10997806	384	385	O
reasonable	10997806	386	396	O
activity	10997806	397	405	O
and	10997806	406	409	O
easy	10997806	410	414	O
outpatient	10997806	415	425	O
administration	10997806	426	440	O
.	10997806	441	442	O

Purpose	10997806	443	450	O
of	10997806	451	453	O
our	10997806	454	457	O
present	10997806	458	465	O
prospective	10997806	466	477	O
study	10997806	478	483	O
was	10997806	484	487	O
to	10997806	488	490	O
evaluate	10997806	491	499	O
the	10997806	500	503	O
dose	10997806	504	508	B-Outcome
response	10997806	509	517	I-Outcome
relationship	10997806	518	530	I-Outcome
of	10997806	531	533	O
paclitaxel	10997806	534	544	B-Intervention
.	10997806	545	546	O

PATIENTS	10997806	547	555	O
AND	10997806	556	559	O
METHODS	10997806	560	567	O
Since	10997806	568	573	O
July	10997806	574	578	O
1996	10997806	579	583	O
,	10997806	584	585	O
198	10997806	586	589	O
patients	10997806	590	598	O
with	10997806	599	603	O
non-operable	10997806	604	616	B-Participant
NSCLC	10997806	617	622	I-Participant
and	10997806	623	626	O
measurable	10997806	627	637	B-Participant
disease	10997806	638	645	I-Participant
without	10997806	646	653	O
previous	10997806	654	662	O
chemotherapy	10997806	663	675	B-Participant
entered	10997806	676	683	O
the	10997806	684	687	O
trial	10997806	688	693	O
.	10997806	694	695	O

Ninety	10997806	696	702	O
nine	10997806	703	707	O
patients	10997806	708	716	O
(	10997806	717	718	O
group	10997806	719	724	O
A	10997806	725	726	O
)	10997806	727	728	O
were	10997806	729	733	O
randomized	10997806	734	744	O
to	10997806	745	747	O
receive	10997806	748	755	O
paclitaxel	10997806	756	766	B-Intervention
175	10997806	767	770	I-Intervention
mg/m2	10997806	771	776	I-Intervention
in	10997806	777	779	I-Intervention
three-hour	10997806	780	790	I-Intervention
infusion	10997806	791	799	I-Intervention
plus	10997806	800	804	I-Intervention
carboplatin	10997806	805	816	I-Intervention
dosed	10997806	817	822	I-Intervention
to	10997806	823	825	I-Intervention
an	10997806	826	828	I-Intervention
area	10997806	829	833	I-Intervention
under	10997806	834	839	I-Intervention
the	10997806	840	843	I-Intervention
concentration-time	10997806	844	862	I-Intervention
curve	10997806	863	868	I-Intervention
of	10997806	869	871	I-Intervention
6	10997806	872	873	I-Intervention
every	10997806	874	879	O
3	10997806	880	881	O
weeks	10997806	882	887	O
and	10997806	888	891	O
99	10997806	892	894	O
(	10997806	895	896	O
group	10997806	897	902	O
B	10997806	903	904	O
)	10997806	905	906	O
to	10997806	907	909	O
receive	10997806	910	917	O
the	10997806	918	921	O
same	10997806	922	926	B-Intervention
regimen	10997806	927	934	I-Intervention
with	10997806	935	939	I-Intervention
paclitaxel	10997806	940	950	I-Intervention
increased	10997806	951	960	I-Intervention
to	10997806	961	963	I-Intervention
225	10997806	964	967	I-Intervention
mg/m2	10997806	968	973	I-Intervention
.	10997806	974	975	O

Eligibility	10997806	976	987	O
criteria	10997806	988	996	O
included	10997806	997	1005	O
WHO	10997806	1006	1009	B-Participant
performance	10997806	1010	1021	I-Participant
status	10997806	1022	1028	I-Participant
0	10997806	1029	1030	I-Participant
-	10997806	1030	1031	I-Participant
2	10997806	1031	1032	I-Participant
,	10997806	1033	1034	O
documented	10997806	1035	1045	B-Participant
inoperable	10997806	1046	1056	I-Participant
stage	10997806	1057	1062	I-Participant
IIIA	10997806	1063	1067	I-Participant
and	10997806	1068	1071	I-Participant
IIIB	10997806	1072	1076	I-Participant
,	10997806	1077	1078	I-Participant
IV	10997806	1079	1081	I-Participant
,	10997806	1082	1083	O
no	10997806	1084	1086	O
brain	10997806	1087	1092	B-Participant
metastasis	10997806	1093	1103	I-Participant
,	10997806	1104	1105	O
no	10997806	1106	1108	O
prior	10997806	1109	1114	B-Participant
chemotherapy	10997806	1115	1127	I-Participant
and	10997806	1128	1131	O
adequate	10997806	1132	1140	B-Participant
renal	10997806	1141	1146	I-Participant
and	10997806	1147	1150	I-Participant
hepatic	10997806	1151	1158	I-Participant
function	10997806	1159	1167	I-Participant
.	10997806	1168	1169	O

Patients	10997806	1170	1178	O
in	10997806	1179	1181	O
both	10997806	1182	1186	O
groups	10997806	1187	1193	O
were	10997806	1194	1198	O
well-matched	10997806	1199	1211	O
with	10997806	1212	1216	O
baseline	10997806	1217	1225	O
disease	10997806	1226	1233	O
characteristics	10997806	1234	1249	O
.	10997806	1250	1251	O

RESULTS	10997806	1252	1259	O
In	10997806	1260	1262	O
group	10997806	1263	1268	B-Intervention
A	10997806	1269	1270	I-Intervention
with	10997806	1271	1275	O
90	10997806	1276	1278	O
evaluable	10997806	1279	1288	O
patients	10997806	1289	1297	O
,	10997806	1298	1299	O
the	10997806	1300	1303	O
response	10997806	1304	1312	B-Outcome
rate	10997806	1313	1317	I-Outcome
was	10997806	1318	1321	O
25.6	10997806	1322	1326	B-Observation
%	10997806	1327	1328	I-Observation
(	10997806	1329	1330	O
6	10997806	1331	1332	B-Count
CR	10997806	1333	1335	B-Outcome
,	10997806	1336	1337	O
17	10997806	1338	1340	B-Count
PR	10997806	1341	1343	B-Outcome
)	10997806	1344	1345	O
whereas	10997806	1346	1353	O
in	10997806	1354	1356	O
group	10997806	1357	1362	B-Intervention
B	10997806	1363	1364	I-Intervention
with	10997806	1365	1369	O
88	10997806	1370	1372	O
evaluable	10997806	1373	1382	O
patients	10997806	1383	1391	O
,	10997806	1392	1393	O
the	10997806	1394	1397	O
response	10997806	1398	1406	B-Outcome
rate	10997806	1407	1411	I-Outcome
was	10997806	1412	1415	O
31.8	10997806	1416	1420	B-Observation
%	10997806	1421	1422	I-Observation
(	10997806	1423	1424	O
3	10997806	1425	1426	B-Count
CR	10997806	1427	1429	B-Outcome
,	10997806	1430	1431	O
25	10997806	1432	1434	B-Count
PR	10997806	1435	1437	B-Outcome
)	10997806	1438	1439	O
,	10997806	1440	1441	O
P	10997806	1442	1443	O
=	10997806	1444	1445	O
0.733	10997806	1446	1451	O
.	10997806	1452	1453	O

Median	10997806	1454	1460	B-Outcome
time	10997806	1461	1465	I-Outcome
to	10997806	1466	1468	I-Outcome
progression	10997806	1469	1480	I-Outcome
favored	10997806	1481	1488	B-Observation
the	10997806	1489	1492	O
high-dose	10997806	1493	1502	B-Intervention
paclitaxel	10997806	1503	1513	I-Intervention
(	10997806	1514	1515	O
4.3	10997806	1516	1519	B-Observation
vs.	10997806	1520	1523	O
6.4	10997806	1524	1527	B-Observation
months	10997806	1528	1534	I-Observation
,	10997806	1535	1536	O
P	10997806	1537	1538	O
=	10997806	1539	1540	O
0.044	10997806	1541	1546	O
)	10997806	1547	1548	O
.	10997806	1549	1550	O

The	10997806	1551	1554	O
median	10997806	1555	1561	B-Outcome
survival	10997806	1562	1570	I-Outcome
was	10997806	1571	1574	O
9.5	10997806	1575	1578	B-Observation
months	10997806	1579	1585	I-Observation
for	10997806	1586	1589	O
group	10997806	1590	1595	B-Intervention
A	10997806	1596	1597	I-Intervention
versus	10997806	1598	1604	O
11.4	10997806	1605	1609	B-Observation
months	10997806	1610	1616	I-Observation
for	10997806	1617	1620	O
group	10997806	1621	1626	B-Intervention
B	10997806	1627	1628	I-Intervention
(	10997806	1629	1630	O
P	10997806	1631	1632	O
=	10997806	1633	1634	O
0.16	10997806	1635	1639	O
)	10997806	1640	1641	O
.	10997806	1642	1643	O

The	10997806	1644	1647	O
one-year	10997806	1648	1656	B-Outcome
survival	10997806	1657	1665	I-Outcome
was	10997806	1666	1669	O
37	10997806	1670	1672	B-Observation
%	10997806	1673	1674	I-Observation
for	10997806	1675	1678	O
group	10997806	1679	1684	B-Intervention
A	10997806	1685	1686	I-Intervention
and	10997806	1687	1690	O
44	10997806	1691	1693	B-Observation
%	10997806	1694	1695	I-Observation
for	10997806	1696	1699	O
group	10997806	1700	1705	B-Intervention
B	10997806	1706	1707	I-Intervention
(	10997806	1708	1709	O
P	10997806	1710	1711	O
=	10997806	1712	1713	O
0.35	10997806	1714	1718	O
)	10997806	1719	1720	O
.	10997806	1721	1722	O

The	10997806	1723	1726	O
best	10997806	1727	1731	B-Outcome
prognostic	10997806	1732	1742	I-Outcome
factor	10997806	1743	1749	I-Outcome
for	10997806	1750	1753	I-Outcome
one-year	10997806	1754	1762	I-Outcome
survival	10997806	1763	1771	I-Outcome
was	10997806	1772	1775	O
the	10997806	1776	1779	O
response	10997806	1780	1788	B-Outcome
rate	10997806	1789	1793	I-Outcome
(	10997806	1794	1795	O
P	10997806	1796	1797	O
<	10997806	1798	1799	O
0.0001	10997806	1800	1806	O
)	10997806	1807	1808	O
.	10997806	1809	1810	O

With	10997806	1811	1815	O
a	10997806	1816	1817	O
relative	10997806	1818	1826	O
dose	10997806	1827	1831	O
intensity	10997806	1832	1841	O
of	10997806	1842	1844	O
paclitaxel	10997806	1845	1855	O
0.94	10997806	1856	1860	O
in	10997806	1861	1863	O
both	10997806	1864	1868	O
groups	10997806	1869	1875	O
,	10997806	1876	1877	O
neurotoxicity	10997806	1878	1891	B-Outcome
(	10997806	1892	1893	O
P	10997806	1894	1895	O
=	10997806	1896	1897	O
0.025	10997806	1898	1903	O
)	10997806	1904	1905	O
and	10997806	1906	1909	O
leucopenia	10997806	1910	1920	B-Outcome
(	10997806	1921	1922	O
P	10997806	1923	1924	O
=	10997806	1925	1926	O
0.038	10997806	1927	1932	O
)	10997806	1933	1934	O
were	10997806	1935	1939	O
more	10997806	1940	1944	B-Observation
pronounced	10997806	1945	1955	I-Observation
in	10997806	1956	1958	O
group	10997806	1959	1964	B-Intervention
B	10997806	1965	1966	I-Intervention
patients	10997806	1967	1975	O
.	10997806	1976	1977	O

No	10997806	1978	1980	B-Count
toxic	10997806	1981	1986	B-Outcome
death	10997806	1987	1992	I-Outcome
was	10997806	1993	1996	O
observed	10997806	1997	2005	O
.	10997806	2006	2007	O

CONCLUSIONS	10997806	2008	2019	O
Higher	10997806	2020	2026	B-Intervention
dose	10997806	2027	2031	I-Intervention
paclitaxel	10997806	2032	2042	I-Intervention
prolongs	10997806	2043	2051	B-Observation
the	10997806	2052	2055	O
median	10997806	2056	2062	B-Outcome
time	10997806	2063	2067	I-Outcome
to	10997806	2068	2070	I-Outcome
progression	10997806	2071	2082	I-Outcome
but	10997806	2083	2086	O
causes	10997806	2087	2093	O
more	10997806	2094	2098	B-Count
neurotoxicity	10997806	2099	2112	B-Outcome
and	10997806	2113	2116	O
leucopenia	10997806	2117	2127	B-Outcome
.	10997806	2128	2129	O

The	10997806	2130	2133	O
better	10997806	2134	2140	B-Observation
response	10997806	2141	2149	B-Outcome
rate	10997806	2150	2154	I-Outcome
,	10997806	2155	2156	O
the	10997806	2157	2160	O
longer	10997806	2161	2167	B-Observation
overall	10997806	2168	2175	B-Outcome
and	10997806	2176	2179	O
better	10997806	2180	2186	B-Observation
one-year	10997806	2187	2195	B-Outcome
survival	10997806	2196	2204	I-Outcome
seen	10997806	2205	2209	O
with	10997806	2210	2214	O
the	10997806	2215	2218	O
higher	10997806	2219	2225	B-Intervention
dose	10997806	2226	2230	I-Intervention
of	10997806	2231	2233	I-Intervention
paclitaxel	10997806	2234	2244	I-Intervention
are	10997806	2245	2248	O
not	10997806	2249	2252	O
statistically	10997806	2253	2266	O
significant	10997806	2267	2278	O
.	10997806	2279	2280	O

Phase	11013280	0	5	O
III	11013280	6	9	O
comparative	11013280	10	21	O
study	11013280	22	27	O
of	11013280	28	30	O
high-dose	11013280	31	40	B-Intervention
cisplatin	11013280	41	50	I-Intervention
versus	11013280	51	57	O
a	11013280	58	59	O
combination	11013280	60	71	B-Intervention
of	11013280	72	74	I-Intervention
paclitaxel	11013280	75	85	I-Intervention
and	11013280	86	89	I-Intervention
cisplatin	11013280	90	99	I-Intervention
in	11013280	100	102	O
patients	11013280	103	111	O
with	11013280	112	116	O
advanced	11013280	117	125	B-Participant
non-small-cell	11013280	126	140	I-Participant
lung	11013280	141	145	I-Participant
cancer	11013280	146	152	I-Participant
.	11013280	153	154	O

PURPOSE	11013280	155	162	O
New	11013280	163	166	O
effective	11013280	167	176	O
chemotherapy	11013280	177	189	O
is	11013280	190	192	O
needed	11013280	193	199	O
to	11013280	200	202	O
improve	11013280	203	210	O
the	11013280	211	214	O
outcome	11013280	215	222	O
of	11013280	223	225	O
patients	11013280	226	234	O
with	11013280	235	239	O
advanced	11013280	240	248	O
non-small-cell	11013280	249	263	O
lung	11013280	264	268	O
cancer	11013280	269	275	O
(	11013280	276	277	O
NSCLC	11013280	278	283	O
)	11013280	284	285	O
.	11013280	286	287	O

Paclitaxel	11013280	288	298	O
administered	11013280	299	311	O
as	11013280	312	314	O
a	11013280	315	316	O
single	11013280	317	323	O
agent	11013280	324	329	O
or	11013280	330	332	O
in	11013280	333	335	O
combination	11013280	336	347	O
with	11013280	348	352	O
cisplatin	11013280	353	362	O
has	11013280	363	366	O
been	11013280	367	371	O
shown	11013280	372	377	O
to	11013280	378	380	O
be	11013280	381	383	O
a	11013280	384	385	O
potentially	11013280	386	397	O
new	11013280	398	401	O
useful	11013280	402	408	O
agent	11013280	409	414	O
for	11013280	415	418	O
the	11013280	419	422	O
treatment	11013280	423	432	O
of	11013280	433	435	O
NSCLC	11013280	436	441	O
.	11013280	442	443	O

PATIENTS	11013280	444	452	O
AND	11013280	453	456	O
METHODS	11013280	457	464	O
Between	11013280	465	472	O
January	11013280	473	480	O
1995	11013280	481	485	O
and	11013280	486	489	O
April	11013280	490	495	O
1996	11013280	496	500	O
,	11013280	501	502	O
414	11013280	503	506	O
patients	11013280	507	515	O
with	11013280	516	520	O
stage	11013280	521	526	B-Participant
IIIB	11013280	527	531	I-Participant
or	11013280	532	534	I-Participant
IV	11013280	535	537	I-Participant
NSCLC	11013280	538	543	I-Participant
were	11013280	544	548	O
randomized	11013280	549	559	O
to	11013280	560	562	O
received	11013280	563	571	O
either	11013280	572	578	O
a	11013280	579	580	O
control	11013280	581	588	O
arm	11013280	589	592	O
of	11013280	593	595	O
high-dose	11013280	596	605	B-Intervention
cisplatin	11013280	606	615	I-Intervention
(	11013280	616	617	I-Intervention
100	11013280	618	621	I-Intervention
mg/m	11013280	622	626	I-Intervention
(	11013280	627	628	I-Intervention
2	11013280	629	630	I-Intervention
)	11013280	631	632	I-Intervention
)	11013280	633	634	I-Intervention
or	11013280	635	637	O
a	11013280	638	639	O
combination	11013280	640	651	B-Intervention
of	11013280	652	654	I-Intervention
paclitaxel	11013280	655	665	I-Intervention
(	11013280	666	667	I-Intervention
175	11013280	668	671	I-Intervention
mg/m	11013280	672	676	I-Intervention
(	11013280	677	678	I-Intervention
2	11013280	679	680	I-Intervention
)	11013280	681	682	I-Intervention
,	11013280	683	684	I-Intervention
3-hour	11013280	685	691	I-Intervention
infusion	11013280	692	700	I-Intervention
)	11013280	701	702	I-Intervention
and	11013280	703	706	I-Intervention
cisplatin	11013280	707	716	I-Intervention
(	11013280	717	718	I-Intervention
80	11013280	719	721	I-Intervention
mg/m	11013280	722	726	I-Intervention
(	11013280	727	728	I-Intervention
2	11013280	729	730	I-Intervention
)	11013280	731	732	I-Intervention
)	11013280	733	734	I-Intervention
every	11013280	735	740	O
21	11013280	741	743	O
days	11013280	744	748	O
.	11013280	749	750	O

RESULTS	11013280	751	758	O
Compared	11013280	759	767	O
with	11013280	768	772	O
the	11013280	773	776	O
cisplatin-only	11013280	777	791	B-Intervention
arm	11013280	792	795	O
,	11013280	796	797	O
there	11013280	798	803	O
was	11013280	804	807	O
a	11013280	808	809	O
9	11013280	810	811	B-Observation
%	11013280	812	813	I-Observation
improvement	11013280	814	825	I-Observation
(	11013280	826	827	O
95	11013280	828	830	O
%	11013280	831	832	O
confidence	11013280	833	843	O
interval	11013280	844	852	O
,	11013280	853	854	O
0	11013280	855	856	O
%	11013280	857	858	O
to	11013280	859	861	O
19	11013280	862	864	O
%	11013280	865	866	O
)	11013280	867	868	O
in	11013280	869	871	O
overall	11013280	872	879	B-Outcome
response	11013280	880	888	I-Outcome
rate	11013280	889	893	I-Outcome
for	11013280	894	897	O
the	11013280	898	901	O
paclitaxel/cisplatin	11013280	902	922	B-Intervention
arm	11013280	923	926	O
(	11013280	927	928	O
17	11013280	929	931	B-Observation
%	11013280	932	933	I-Observation
v	11013280	934	935	O
26	11013280	936	938	B-Observation
%	11013280	939	940	I-Observation
,	11013280	941	942	O
respectively	11013280	943	955	O
;	11013280	956	957	O
P=.028	11013280	958	964	O
)	11013280	965	966	O
.	11013280	967	968	O

Median	11013280	969	975	B-Outcome
time	11013280	976	980	I-Outcome
to	11013280	981	983	I-Outcome
progression	11013280	984	995	I-Outcome
was	11013280	996	999	O
2.7	11013280	1000	1003	B-Observation
and	11013280	1004	1007	O
4.1	11013280	1008	1011	B-Observation
months	11013280	1012	1018	I-Observation
in	11013280	1019	1021	O
the	11013280	1022	1025	O
control	11013280	1026	1033	B-Intervention
and	11013280	1034	1037	O
paclitaxel/cisplatin	11013280	1038	1058	B-Intervention
arm	11013280	1059	1062	O
,	11013280	1063	1064	O
respectively	11013280	1065	1077	O
(	11013280	1078	1079	O
P=.026	11013280	1080	1086	B-Observation
)	11013280	1087	1088	O
.	11013280	1089	1090	O

The	11013280	1091	1094	O
study	11013280	1095	1100	O
,	11013280	1101	1102	O
however	11013280	1103	1110	O
,	11013280	1111	1112	O
failed	11013280	1113	1119	O
to	11013280	1120	1122	O
show	11013280	1123	1127	O
a	11013280	1128	1129	O
significant	11013280	1130	1141	B-Observation
improvement	11013280	1142	1153	I-Observation
in	11013280	1154	1156	O
median	11013280	1157	1163	B-Outcome
survival	11013280	1164	1172	I-Outcome
for	11013280	1173	1176	O
the	11013280	1177	1180	O
paclitaxel/cisplatin	11013280	1181	1201	B-Intervention
arm	11013280	1202	1205	I-Intervention
(	11013280	1206	1207	O
8.6	11013280	1208	1211	B-Observation
months	11013280	1212	1218	I-Observation
in	11013280	1219	1221	O
the	11013280	1222	1225	O
control	11013280	1226	1233	B-Intervention
arm	11013280	1234	1237	O
v	11013280	1238	1239	O
8.1	11013280	1240	1243	B-Observation
months	11013280	1244	1250	I-Observation
in	11013280	1251	1253	O
the	11013280	1254	1257	O
paclitaxel/cisplatin	11013280	1258	1278	B-Intervention
arm	11013280	1279	1282	O
,	11013280	1283	1284	O
P=.862	11013280	1285	1291	O
)	11013280	1292	1293	O
.	11013280	1294	1295	O

There	11013280	1296	1301	O
was	11013280	1302	1305	O
more	11013280	1306	1310	B-Count
hematotoxicity	11013280	1311	1325	B-Outcome
,	11013280	1326	1327	O
peripheral	11013280	1328	1338	B-Outcome
neuropathy	11013280	1339	1349	I-Outcome
,	11013280	1350	1351	O
and	11013280	1352	1355	O
arthralgia/myalgia	11013280	1356	1374	B-Outcome
on	11013280	1375	1377	O
the	11013280	1378	1381	O
paclitaxel/cisplatin	11013280	1382	1402	B-Intervention
arm	11013280	1403	1406	O
,	11013280	1407	1408	O
whereas	11013280	1409	1416	O
the	11013280	1417	1420	O
high-dose	11013280	1421	1430	B-Intervention
cisplatin	11013280	1431	1440	I-Intervention
arm	11013280	1441	1444	O
produced	11013280	1445	1453	O
more	11013280	1454	1458	B-Count
ototoxicity	11013280	1459	1470	B-Outcome
,	11013280	1471	1472	O
nausea	11013280	1473	1479	B-Outcome
,	11013280	1480	1481	O
vomiting	11013280	1482	1490	B-Outcome
,	11013280	1491	1492	O
and	11013280	1493	1496	O
nephrotoxicity	11013280	1497	1511	B-Outcome
.	11013280	1512	1513	O

Quality	11013280	1514	1521	B-Outcome
of	11013280	1522	1524	I-Outcome
life	11013280	1525	1529	I-Outcome
(	11013280	1530	1531	I-Outcome
QOL	11013280	1532	1535	I-Outcome
)	11013280	1536	1537	I-Outcome
was	11013280	1538	1541	O
similar	11013280	1542	1549	B-Observation
overall	11013280	1550	1557	I-Observation
between	11013280	1558	1565	B-Intervention
the	11013280	1566	1569	I-Intervention
two	11013280	1570	1573	I-Intervention
arms	11013280	1574	1578	I-Intervention
.	11013280	1579	1580	O

CONCLUSION	11013280	1581	1591	O
This	11013280	1592	1596	O
large	11013280	1597	1602	O
randomized	11013280	1603	1613	O
phase	11013280	1614	1619	O
III	11013280	1620	1623	O
trial	11013280	1624	1629	O
failed	11013280	1630	1636	O
to	11013280	1637	1639	O
show	11013280	1640	1644	O
a	11013280	1645	1646	O
significant	11013280	1647	1658	B-Observation
improvement	11013280	1659	1670	I-Observation
in	11013280	1671	1673	O
survival	11013280	1674	1682	B-Outcome
for	11013280	1683	1686	O
the	11013280	1687	1690	O
paclitaxel/cisplatin	11013280	1691	1711	B-Intervention
combination	11013280	1712	1723	I-Intervention
compared	11013280	1724	1732	O
with	11013280	1733	1737	O
high-dose	11013280	1738	1747	B-Intervention
cisplatin	11013280	1748	1757	I-Intervention
in	11013280	1758	1760	O
patients	11013280	1761	1769	O
with	11013280	1770	1774	O
advanced	11013280	1775	1783	B-Participant
NSCLC	11013280	1784	1789	I-Participant
.	11013280	1790	1791	O

However	11013280	1792	1799	O
,	11013280	1800	1801	O
the	11013280	1802	1805	O
paclitaxel/cisplatin	11013280	1806	1826	B-Intervention
combination	11013280	1827	1838	I-Intervention
did	11013280	1839	1842	O
produce	11013280	1843	1850	O
a	11013280	1851	1852	O
better	11013280	1853	1859	B-Observation
clinical	11013280	1860	1868	B-Outcome
response	11013280	1869	1877	I-Outcome
,	11013280	1878	1879	O
resulting	11013280	1880	1889	O
in	11013280	1890	1892	O
an	11013280	1893	1895	O
increased	11013280	1896	1905	B-Observation
time	11013280	1906	1910	B-Outcome
to	11013280	1911	1913	I-Outcome
progression	11013280	1914	1925	I-Outcome
while	11013280	1926	1931	O
providing	11013280	1932	1941	O
a	11013280	1942	1943	O
similar	11013280	1944	1951	B-Observation
QOL	11013280	1952	1955	B-Outcome
.	11013280	1956	1957	O

Treatment	11013281	0	9	O
of	11013281	10	12	O
brain	11013281	13	18	B-Participant
metastases	11013281	19	29	I-Participant
of	11013281	30	32	O
small-cell	11013281	33	43	B-Participant
lung	11013281	44	48	I-Participant
cancer	11013281	49	55	I-Participant
:	11013281	56	57	O
comparing	11013281	58	67	O
teniposide	11013281	68	78	B-Intervention
and	11013281	79	82	O
teniposide	11013281	83	93	B-Intervention
with	11013281	94	98	I-Intervention
whole-brain	11013281	99	110	I-Intervention
radiotherapy	11013281	111	123	I-Intervention
--	11013281	124	126	O
a	11013281	127	128	O
phase	11013281	129	134	O
III	11013281	135	138	O
study	11013281	139	144	O
of	11013281	145	147	O
the	11013281	148	151	O
European	11013281	152	160	O
Organization	11013281	161	173	O
for	11013281	174	177	O
the	11013281	178	181	O
Research	11013281	182	190	O
and	11013281	191	194	O
Treatment	11013281	195	204	O
of	11013281	205	207	O
Cancer	11013281	208	214	O
Lung	11013281	215	219	O
Cancer	11013281	220	226	O
Cooperative	11013281	227	238	O
Group	11013281	239	244	O
.	11013281	245	246	O

PURPOSE	11013281	247	254	O
Approximately	11013281	255	268	O
60	11013281	269	271	O
%	11013281	272	273	O
of	11013281	274	276	O
patients	11013281	277	285	O
with	11013281	286	290	O
small-cell	11013281	291	301	O
lung	11013281	302	306	O
cancer	11013281	307	313	O
(	11013281	314	315	O
SCLC	11013281	316	320	O
)	11013281	321	322	O
develop	11013281	323	330	O
brain	11013281	331	336	O
metastases	11013281	337	347	O
.	11013281	348	349	O

Whole-brain	11013281	350	361	O
radiotherapy	11013281	362	374	O
(	11013281	375	376	O
WBRT	11013281	377	381	O
)	11013281	382	383	O
gives	11013281	384	389	O
symptomatic	11013281	390	401	O
improvement	11013281	402	413	O
in	11013281	414	416	O
more	11013281	417	421	O
than	11013281	422	426	O
50	11013281	427	429	O
%	11013281	430	431	O
of	11013281	432	434	O
these	11013281	435	440	O
patients	11013281	441	449	O
.	11013281	450	451	O

Because	11013281	452	459	O
brain	11013281	460	465	O
metastases	11013281	466	476	O
are	11013281	477	480	O
a	11013281	481	482	O
sign	11013281	483	487	O
of	11013281	488	490	O
systemic	11013281	491	499	O
progression	11013281	500	511	O
,	11013281	512	513	O
and	11013281	514	517	O
chemotherapy	11013281	518	530	O
was	11013281	531	534	O
found	11013281	535	540	O
to	11013281	541	543	O
be	11013281	544	546	O
effective	11013281	547	556	O
as	11013281	557	559	O
well	11013281	560	564	O
,	11013281	565	566	O
it	11013281	567	569	O
becomes	11013281	570	577	O
questionable	11013281	578	590	O
whether	11013281	591	598	O
WBRT	11013281	599	603	O
is	11013281	604	606	O
the	11013281	607	610	O
only	11013281	611	615	O
appropriate	11013281	616	627	O
therapy	11013281	628	635	O
in	11013281	636	638	O
this	11013281	639	643	O
situation	11013281	644	653	O
.	11013281	654	655	O

PATIENTS	11013281	656	664	O
AND	11013281	665	668	O
METHODS	11013281	669	676	O
In	11013281	677	679	O
a	11013281	680	681	O
phase	11013281	682	687	O
III	11013281	688	691	O
study	11013281	692	697	O
,	11013281	698	699	O
SCLC	11013281	700	704	B-Participant
patients	11013281	705	713	O
with	11013281	714	718	O
brain	11013281	719	724	B-Participant
metastases	11013281	725	735	I-Participant
were	11013281	736	740	O
randomized	11013281	741	751	O
to	11013281	752	754	O
receive	11013281	755	762	O
teniposide	11013281	763	773	B-Intervention
with	11013281	774	778	I-Intervention
or	11013281	779	781	I-Intervention
without	11013281	782	789	I-Intervention
WBRT	11013281	790	794	I-Intervention
.	11013281	795	796	O

Teniposide	11013281	797	807	B-Intervention
120	11013281	808	811	O
mg/m	11013281	812	816	O
(	11013281	817	818	O
2	11013281	819	820	O
)	11013281	821	822	O
was	11013281	823	826	O
given	11013281	827	832	O
intravenously	11013281	833	846	O
three	11013281	847	852	O
times	11013281	853	858	O
a	11013281	859	860	O
week	11013281	861	865	O
,	11013281	866	867	O
every	11013281	868	873	O
3	11013281	874	875	O
weeks	11013281	876	881	O
.	11013281	882	883	O

WBRT	11013281	884	888	B-Intervention
(	11013281	889	890	O
10	11013281	891	893	O
fractions	11013281	894	903	O
of	11013281	904	906	O
3	11013281	907	908	O
Gy	11013281	909	911	O
)	11013281	912	913	O
had	11013281	914	917	O
to	11013281	918	920	O
start	11013281	921	926	O
within	11013281	927	933	O
3	11013281	934	935	O
weeks	11013281	936	941	O
from	11013281	942	946	O
the	11013281	947	950	O
start	11013281	951	956	O
of	11013281	957	959	O
chemotherapy	11013281	960	972	O
.	11013281	973	974	O

Response	11013281	975	983	B-Outcome
was	11013281	984	987	O
measured	11013281	988	996	O
clinically	11013281	997	1007	O
and	11013281	1008	1011	O
by	11013281	1012	1014	O
computed	11013281	1015	1023	O
tomography	11013281	1024	1034	O
of	11013281	1035	1037	O
the	11013281	1038	1041	O
brain	11013281	1042	1047	O
.	11013281	1048	1049	O

RESULTS	11013281	1050	1057	O
One	11013281	1058	1061	O
hundred	11013281	1062	1069	O
twenty	11013281	1070	1076	O
eligible	11013281	1077	1085	O
patients	11013281	1086	1094	O
were	11013281	1095	1099	O
randomized	11013281	1100	1110	O
.	11013281	1111	1112	O

A	11013281	1113	1114	O
57	11013281	1115	1117	B-Observation
%	11013281	1118	1119	I-Observation
response	11013281	1120	1128	B-Outcome
rate	11013281	1129	1133	I-Outcome
was	11013281	1134	1137	O
seen	11013281	1138	1142	O
in	11013281	1143	1145	O
the	11013281	1146	1149	O
combined-modality	11013281	1150	1167	B-Intervention
arm	11013281	1168	1171	O
(	11013281	1172	1173	O
95	11013281	1174	1176	O
%	11013281	1177	1178	O
confidence	11013281	1179	1189	O
interval	11013281	1190	1198	O
[	11013281	1199	1200	O
CI	11013281	1201	1203	O
]	11013281	1204	1205	O
,	11013281	1206	1207	O
43	11013281	1208	1210	O
%	11013281	1211	1212	O
to	11013281	1213	1215	O
69	11013281	1216	1218	O
%	11013281	1219	1220	O
)	11013281	1221	1222	O
,	11013281	1223	1224	O
and	11013281	1225	1228	O
a	11013281	1229	1230	O
22	11013281	1231	1233	B-Observation
%	11013281	1234	1235	I-Observation
response	11013281	1236	1244	B-Outcome
rate	11013281	1245	1249	I-Outcome
was	11013281	1250	1253	O
seen	11013281	1254	1258	O
in	11013281	1259	1261	O
the	11013281	1262	1265	O
teniposide-alone	11013281	1266	1282	B-Intervention
arm	11013281	1283	1286	O
(	11013281	1287	1288	O
95	11013281	1289	1291	O
%	11013281	1292	1293	O
CI	11013281	1294	1296	O
,	11013281	1297	1298	O
12	11013281	1299	1301	O
%	11013281	1302	1303	O
to	11013281	1304	1306	O
34	11013281	1307	1309	O
%	11013281	1310	1311	O
)	11013281	1312	1313	O
(	11013281	1314	1315	O
P	11013281	1316	1317	O
<	11013281	1318	1319	O
.001	11013281	1320	1324	O
)	11013281	1325	1326	O
.	11013281	1327	1328	O

Time	11013281	1329	1333	B-Outcome
to	11013281	1334	1336	I-Outcome
progression	11013281	1337	1348	I-Outcome
in	11013281	1349	1351	I-Outcome
the	11013281	1352	1355	I-Outcome
brain	11013281	1356	1361	I-Outcome
was	11013281	1362	1365	O
longer	11013281	1366	1372	B-Observation
in	11013281	1373	1375	O
the	11013281	1376	1379	O
combined-modality	11013281	1380	1397	B-Intervention
group	11013281	1398	1403	I-Intervention
(	11013281	1404	1405	O
P=.005	11013281	1406	1412	O
)	11013281	1413	1414	O
.	11013281	1415	1416	O

Clinical	11013281	1417	1425	B-Outcome
response	11013281	1426	1434	I-Outcome
and	11013281	1435	1438	O
response	11013281	1439	1447	B-Outcome
outside	11013281	1448	1455	I-Outcome
the	11013281	1456	1459	I-Outcome
brain	11013281	1460	1465	I-Outcome
were	11013281	1466	1470	O
not	11013281	1471	1474	O
different	11013281	1475	1484	B-Observation
.	11013281	1485	1486	O

The	11013281	1487	1490	O
median	11013281	1491	1497	B-Outcome
survival	11013281	1498	1506	I-Outcome
time	11013281	1507	1511	I-Outcome
was	11013281	1512	1515	O
3.5	11013281	1516	1519	B-Observation
months	11013281	1520	1526	I-Observation
in	11013281	1527	1529	O
the	11013281	1530	1533	O
combined-modality	11013281	1534	1551	B-Intervention
arm	11013281	1552	1555	O
and	11013281	1556	1559	O
3.2	11013281	1560	1563	B-Observation
months	11013281	1564	1570	I-Observation
in	11013281	1571	1573	O
the	11013281	1574	1577	O
teniposide-alone	11013281	1578	1594	B-Intervention
arm	11013281	1595	1598	O
.	11013281	1599	1600	O

Overall	11013281	1601	1608	B-Outcome
survival	11013281	1609	1617	I-Outcome
in	11013281	1618	1620	O
both	11013281	1621	1625	B-Intervention
groups	11013281	1626	1632	I-Intervention
was	11013281	1633	1636	O
not	11013281	1637	1640	O
different	11013281	1641	1650	B-Observation
(	11013281	1651	1652	O
P=.087	11013281	1653	1659	O
)	11013281	1660	1661	O
.	11013281	1662	1663	O

CONCLUSION	11013281	1664	1674	O
Adding	11013281	1675	1681	B-Intervention
WBRT	11013281	1682	1686	I-Intervention
to	11013281	1687	1689	I-Intervention
teniposide	11013281	1690	1700	I-Intervention
results	11013281	1701	1708	O
in	11013281	1709	1711	O
a	11013281	1712	1713	O
much	11013281	1714	1718	B-Observation
higher	11013281	1719	1725	I-Observation
response	11013281	1726	1734	B-Outcome
rate	11013281	1735	1739	I-Outcome
of	11013281	1740	1742	I-Outcome
brain	11013281	1743	1748	I-Outcome
metastases	11013281	1749	1759	I-Outcome
and	11013281	1760	1763	O
in	11013281	1764	1766	O
a	11013281	1767	1768	O
longer	11013281	1769	1775	B-Observation
time	11013281	1776	1780	B-Outcome
to	11013281	1781	1783	I-Outcome
progression	11013281	1784	1795	I-Outcome
of	11013281	1796	1798	I-Outcome
brain	11013281	1799	1804	I-Outcome
metastases	11013281	1805	1815	I-Outcome
than	11013281	1816	1820	O
teniposide	11013281	1821	1831	B-Intervention
alone	11013281	1832	1837	I-Intervention
.	11013281	1838	1839	O

Survival	11013281	1840	1848	B-Outcome
was	11013281	1849	1852	O
poor	11013281	1853	1857	B-Observation
in	11013281	1858	1860	O
both	11013281	1861	1865	B-Intervention
groups	11013281	1866	1872	I-Intervention
and	11013281	1873	1876	O
not	11013281	1877	1880	O
significantly	11013281	1881	1894	B-Observation
different	11013281	1895	1904	I-Observation
.	11013281	1905	1906	O

[	11013775	0	1	O
Effectiveness	11013775	2	15	O
of	11013775	16	18	O
morphine	11013775	19	27	B-Intervention
by	11013775	28	30	O
periarticular	11013775	31	44	O
injections	11013775	45	55	O
after	11013775	56	61	O
shoulder	11013775	62	70	B-Participant
arthroscopy	11013775	71	82	I-Participant
]	11013775	83	84	O
.	11013775	85	86	O

Peripheral	11013775	87	97	O
opioid	11013775	98	104	O
receptors	11013775	105	114	O
have	11013775	115	119	O
been	11013775	120	124	O
found	11013775	125	130	O
in	11013775	131	133	O
inflamed	11013775	134	142	O
synovia	11013775	143	150	O
and	11013775	151	154	O
the	11013775	155	158	O
analgesic	11013775	159	168	O
effect	11013775	169	175	O
of	11013775	176	178	O
intra-articularly	11013775	179	196	O
administered	11013775	197	209	O
morphine	11013775	210	218	O
after	11013775	219	224	O
arthroscopic	11013775	225	237	O
knee	11013775	238	242	O
surgery	11013775	243	250	O
has	11013775	251	254	O
been	11013775	255	259	O
proven	11013775	260	266	O
.	11013775	267	268	O

There	11013775	269	274	O
is	11013775	275	277	O
controversy	11013775	278	289	O
about	11013775	290	295	O
efficacy	11013775	296	304	O
of	11013775	305	307	O
intraarticular	11013775	308	322	O
morphine	11013775	323	331	O
after	11013775	332	337	O
shoulder	11013775	338	346	O
arthroscopy	11013775	347	358	O
.	11013775	359	360	O

Thirty-two	11013775	361	371	O
patients	11013775	372	380	O
with	11013775	381	385	O
impingement	11013775	386	397	B-Participant
syndrome	11013775	398	406	I-Participant
underwent	11013775	407	416	O
subacromial	11013775	417	428	B-Participant
decompression	11013775	429	442	I-Participant
in	11013775	443	445	O
the	11013775	446	449	O
course	11013775	450	456	O
of	11013775	457	459	O
arthroscopic	11013775	460	472	B-Participant
shoulder	11013775	473	481	I-Participant
surgery	11013775	482	489	I-Participant
.	11013775	490	491	O

At	11013775	492	494	O
the	11013775	495	498	O
end	11013775	499	502	O
of	11013775	503	505	O
the	11013775	506	509	O
operation	11013775	510	519	O
morphine	11013775	520	528	B-Intervention
(	11013775	529	530	O
5	11013775	531	532	B-Observation
mg	11013775	533	535	I-Observation
)	11013775	536	537	O
or	11013775	538	540	O
saline	11013775	541	547	B-Intervention
was	11013775	548	551	O
injected	11013775	552	560	O
periarticularly	11013775	561	576	O
.	11013775	577	578	O

Pain	11013775	579	583	B-Outcome
intensity	11013775	584	593	I-Outcome
(	11013775	594	595	O
rest	11013775	596	600	O
and	11013775	601	604	O
passive	11013775	605	612	O
mobilisation	11013775	613	625	O
)	11013775	626	627	O
was	11013775	628	631	O
recorded	11013775	632	640	O
after	11013775	641	646	O
recovery	11013775	647	655	O
and	11013775	656	659	O
after	11013775	660	665	O
1,2,4	11013775	666	671	O
,	11013775	672	673	O
and	11013775	674	677	O
24	11013775	678	680	O
hours	11013775	681	686	O
(	11013775	687	688	O
Numeric	11013775	689	696	O
Rating	11013775	697	703	O
Scale	11013775	704	709	O
)	11013775	710	711	O
;	11013775	712	713	O
the	11013775	714	717	O
use	11013775	718	721	B-Outcome
of	11013775	722	724	I-Outcome
rescue	11013775	725	731	I-Outcome
medication	11013775	732	742	I-Outcome
(	11013775	743	744	O
piritramide	11013775	745	756	B-Outcome
by	11013775	757	759	I-Outcome
patient	11013775	760	767	I-Outcome
controlled	11013775	768	778	I-Outcome
analgesia	11013775	779	788	I-Outcome
)	11013775	789	790	O
was	11013775	791	794	O
noted	11013775	795	800	O
.	11013775	801	802	O

No	11013775	803	805	O
relevant	11013775	806	814	B-Outcome
pain	11013775	815	819	I-Outcome
reduction	11013775	820	829	I-Outcome
was	11013775	830	833	O
apparent	11013775	834	842	B-Observation
in	11013775	843	845	O
the	11013775	846	849	O
morphine	11013775	850	858	B-Intervention
group	11013775	859	864	I-Intervention
.	11013775	865	866	O

Piritramide	11013775	867	878	B-Outcome
consumption	11013775	879	890	I-Outcome
was	11013775	891	894	O
identical	11013775	895	904	B-Observation
in	11013775	905	907	O
both	11013775	908	912	B-Intervention
groups	11013775	913	919	I-Intervention
(	11013775	920	921	O
19.7	11013775	922	926	B-Observation
+	11013775	927	928	I-Observation
/-	11013775	928	930	I-Observation
16	11013775	931	933	I-Observation
mg	11013775	934	936	I-Observation
vs.	11013775	937	940	O
19.8	11013775	941	945	B-Observation
+	11013775	946	947	I-Observation
/-	11013775	947	949	I-Observation
19	11013775	950	952	I-Observation
mg	11013775	953	955	I-Observation
)	11013775	956	957	O
.	11013775	958	959	O

We	11013775	960	962	O
conclude	11013775	963	971	O
that	11013775	972	976	O
periarticularly	11013775	977	992	B-Intervention
administered	11013775	993	1005	I-Intervention
morphine	11013775	1006	1014	I-Intervention
in	11013775	1015	1017	O
arthroscopic	11013775	1018	1030	B-Participant
subacromial	11013775	1031	1042	I-Participant
decompression	11013775	1043	1056	I-Participant
in	11013775	1057	1059	O
the	11013775	1060	1063	O
dosage	11013775	1064	1070	O
applied	11013775	1071	1078	O
in	11013775	1079	1081	O
this	11013775	1082	1086	O
study	11013775	1087	1092	O
does	11013775	1093	1097	O
exert	11013775	1098	1103	O
no	11013775	1104	1106	O
relevant	11013775	1107	1115	B-Outcome
analgesic	11013775	1116	1125	I-Outcome
effect	11013775	1126	1132	I-Outcome
.	11013775	1133	1134	O

This	11013775	1135	1139	O
is	11013775	1140	1142	O
possibly	11013775	1143	1151	O
due	11013775	1152	1155	O
to	11013775	1156	1158	O
the	11013775	1159	1162	O
fact	11013775	1163	1167	O
that	11013775	1168	1172	O
either	11013775	1173	1179	O
subacromial	11013775	1180	1191	O
tissue	11013775	1192	1198	O
,	11013775	1199	1200	O
despite	11013775	1201	1208	O
of	11013775	1209	1211	O
chronic	11013775	1212	1219	O
inflammation	11013775	1220	1232	O
,	11013775	1233	1234	O
does	11013775	1235	1239	O
not	11013775	1240	1243	O
show	11013775	1244	1248	O
the	11013775	1249	1252	O
same	11013775	1253	1257	O
reagibility	11013775	1258	1269	O
as	11013775	1270	1272	O
synovia	11013775	1273	1280	O
or	11013775	1281	1283	O
it	11013775	1284	1286	O
is	11013775	1287	1289	O
a	11013775	1290	1291	O
problem	11013775	1292	1299	O
of	11013775	1300	1302	O
the	11013775	1303	1306	O
nearly	11013775	1307	1313	O
complete	11013775	1314	1322	O
resection	11013775	1323	1332	O
of	11013775	1333	1335	O
the	11013775	1336	1339	O
subacromial	11013775	1340	1351	O
bursa	11013775	1352	1357	O
.	11013775	1358	1359	O

Cost-effectiveness	11015817	0	18	B-Outcome
of	11015817	19	21	O
clozapine	11015817	22	31	B-Intervention
compared	11015817	32	40	O
with	11015817	41	45	O
conventional	11015817	46	58	B-Intervention
antipsychotic	11015817	59	72	I-Intervention
medication	11015817	73	83	I-Intervention
for	11015817	84	87	O
patients	11015817	88	96	O
in	11015817	97	99	O
state	11015817	100	105	B-Participant
hospitals	11015817	106	115	I-Participant
.	11015817	116	117	O

BACKGROUND	11015817	118	128	O
An	11015817	129	131	O
open-label	11015817	132	142	O
,	11015817	143	144	O
randomized	11015817	145	155	O
controlled	11015817	156	166	O
trial	11015817	167	172	O
compared	11015817	173	181	O
clozapine	11015817	182	191	B-Intervention
with	11015817	192	196	O
physicians'-choice	11015817	197	215	B-Intervention
medications	11015817	216	227	I-Intervention
among	11015817	228	233	O
long-term	11015817	234	243	B-Participant
state	11015817	244	249	I-Participant
hospital	11015817	250	258	I-Participant
inpatients	11015817	259	269	I-Participant
in	11015817	270	272	O
Connecticut	11015817	273	284	O
.	11015817	285	286	O

The	11015817	287	290	O
goal	11015817	291	295	O
was	11015817	296	299	O
to	11015817	300	302	O
examine	11015817	303	310	O
clozapine	11015817	311	320	B-Intervention
's	11015817	321	323	O
cost-effectiveness	11015817	324	342	B-Outcome
in	11015817	343	345	O
routine	11015817	346	353	O
practice	11015817	354	362	O
for	11015817	363	366	O
people	11015817	367	373	O
experiencing	11015817	374	386	O
lengthy	11015817	387	394	B-Participant
hospitalizations	11015817	395	411	I-Participant
.	11015817	412	413	O

METHODS	11015817	414	421	O
Long-stay	11015817	422	431	B-Participant
patients	11015817	432	440	I-Participant
with	11015817	441	445	I-Participant
schizophrenia	11015817	446	459	I-Participant
in	11015817	460	462	O
a	11015817	463	464	O
state	11015817	465	470	B-Participant
hospital	11015817	471	479	I-Participant
were	11015817	480	484	O
randomly	11015817	485	493	O
assigned	11015817	494	502	O
to	11015817	503	505	O
begin	11015817	506	511	O
open-label	11015817	512	522	O
clozapine	11015817	523	532	B-Intervention
(	11015817	533	534	O
n	11015817	535	536	O
=	11015817	537	538	O
138	11015817	539	542	O
)	11015817	543	544	O
or	11015817	545	547	O
to	11015817	548	550	O
continue	11015817	551	559	O
receiving	11015817	560	569	O
conventional	11015817	570	582	B-Intervention
antipsychotic	11015817	583	596	I-Intervention
medications	11015817	597	608	I-Intervention
(	11015817	609	610	O
n	11015817	611	612	O
=	11015817	613	614	O
89	11015817	615	617	O
)	11015817	618	619	O
.	11015817	620	621	O

We	11015817	622	624	O
interviewed	11015817	625	636	O
study	11015817	637	642	O
participants	11015817	643	655	O
every	11015817	656	661	O
4	11015817	662	663	O
months	11015817	664	670	O
for	11015817	671	674	O
2	11015817	675	676	O
years	11015817	677	682	O
to	11015817	683	685	O
assess	11015817	686	692	O
psychiatric	11015817	693	704	B-Outcome
symptoms	11015817	705	713	I-Outcome
and	11015817	714	717	O
functional	11015817	718	728	B-Outcome
status	11015817	729	735	I-Outcome
,	11015817	736	737	O
and	11015817	738	741	O
we	11015817	742	744	O
collected	11015817	745	754	O
continuous	11015817	755	765	O
measures	11015817	766	774	O
of	11015817	775	777	O
prescribed	11015817	778	788	B-Outcome
medications	11015817	789	800	I-Outcome
,	11015817	801	802	O
service	11015817	803	810	B-Outcome
utilization	11015817	811	822	I-Outcome
,	11015817	823	824	O
and	11015817	825	828	O
other	11015817	829	834	O
costs	11015817	835	840	B-Outcome
.	11015817	841	842	O

We	11015817	843	845	O
used	11015817	846	850	O
both	11015817	851	855	O
parametric	11015817	856	866	O
and	11015817	867	870	O
nonparametric	11015817	871	884	O
techniques	11015817	885	895	O
to	11015817	896	898	O
examine	11015817	899	906	O
changes	11015817	907	914	B-Observation
in	11015817	915	917	O
cost	11015817	918	922	B-Outcome
and	11015817	923	926	O
parametric	11015817	927	937	O
analyses	11015817	938	946	O
to	11015817	947	949	O
examine	11015817	950	957	O
changes	11015817	958	965	B-Observation
in	11015817	966	968	O
effectiveness	11015817	969	982	B-Outcome
.	11015817	983	984	O

We	11015817	985	987	O
used	11015817	988	992	O
bootstrap	11015817	993	1002	O
techniques	11015817	1003	1013	O
to	11015817	1014	1016	O
estimate	11015817	1017	1025	O
incremental	11015817	1026	1037	B-Outcome
cost-effectiveness	11015817	1038	1056	I-Outcome
ratios	11015817	1057	1063	I-Outcome
and	11015817	1064	1067	O
create	11015817	1068	1074	O
cost-effectiveness	11015817	1075	1093	B-Outcome
acceptability	11015817	1094	1107	I-Outcome
curves	11015817	1108	1114	I-Outcome
.	11015817	1115	1116	O

RESULTS	11015817	1117	1124	O
Both	11015817	1125	1129	B-Intervention
groups	11015817	1130	1136	I-Intervention
incurred	11015817	1137	1145	O
similar	11015817	1146	1153	B-Observation
costs	11015817	1154	1159	B-Outcome
during	11015817	1160	1166	O
the	11015817	1167	1170	O
2-year	11015817	1171	1177	O
study	11015817	1178	1183	O
period	11015817	1184	1190	O
,	11015817	1191	1192	O
with	11015817	1193	1197	O
a	11015817	1198	1199	O
trend	11015817	1200	1205	O
for	11015817	1206	1209	O
clozapine	11015817	1210	1219	B-Intervention
to	11015817	1220	1222	O
be	11015817	1223	1225	O
less	11015817	1226	1230	B-Observation
costly	11015817	1231	1237	I-Observation
than	11015817	1238	1242	O
usual	11015817	1243	1248	B-Intervention
care	11015817	1249	1253	I-Intervention
in	11015817	1254	1256	O
the	11015817	1257	1260	O
second	11015817	1261	1267	O
study	11015817	1268	1273	O
year	11015817	1274	1278	O
.	11015817	1279	1280	O

Clozapine	11015817	1281	1290	B-Intervention
was	11015817	1291	1294	O
more	11015817	1295	1299	B-Observation
effective	11015817	1300	1309	I-Observation
than	11015817	1310	1314	O
usual	11015817	1315	1320	B-Intervention
care	11015817	1321	1325	I-Intervention
on	11015817	1326	1328	O
many	11015817	1329	1333	B-Outcome
but	11015817	1334	1337	I-Outcome
not	11015817	1338	1341	I-Outcome
all	11015817	1342	1345	I-Outcome
measures	11015817	1346	1354	I-Outcome
.	11015817	1355	1356	O

With	11015817	1357	1361	O
the	11015817	1362	1365	O
use	11015817	1366	1369	O
of	11015817	1370	1372	O
effectiveness	11015817	1373	1386	B-Outcome
measures	11015817	1387	1395	I-Outcome
that	11015817	1396	1400	O
favored	11015817	1401	1408	B-Observation
clozapine	11015817	1409	1418	B-Intervention
(	11015817	1419	1420	O
extrapyramidal	11015817	1421	1435	B-Outcome
side	11015817	1436	1440	I-Outcome
effects	11015817	1441	1448	I-Outcome
,	11015817	1449	1450	O
disruptiveness	11015817	1451	1465	B-Outcome
)	11015817	1466	1467	O
,	11015817	1468	1469	O
bootstrap	11015817	1470	1479	O
techniques	11015817	1480	1490	O
indicated	11015817	1491	1500	O
that	11015817	1501	1505	O
,	11015817	1506	1507	O
even	11015817	1508	1512	O
when	11015817	1513	1517	O
a	11015817	1518	1519	O
payer	11015817	1520	1525	O
is	11015817	1526	1528	O
unwilling	11015817	1529	1538	O
to	11015817	1539	1541	O
incur	11015817	1542	1547	O
any	11015817	1548	1551	O
additional	11015817	1552	1562	O
cost	11015817	1563	1567	O
for	11015817	1568	1571	O
gains	11015817	1572	1577	O
in	11015817	1578	1580	O
effectiveness	11015817	1581	1594	O
,	11015817	1595	1596	O
the	11015817	1597	1600	O
probability	11015817	1601	1612	O
that	11015817	1613	1617	O
clozapine	11015817	1618	1627	B-Intervention
is	11015817	1628	1630	O
more	11015817	1631	1635	B-Observation
cost-effective	11015817	1636	1650	B-Outcome
than	11015817	1651	1655	O
usual	11015817	1656	1661	B-Intervention
care	11015817	1662	1666	I-Intervention
is	11015817	1667	1669	O
at	11015817	1670	1672	O
least	11015817	1673	1678	O
0.80	11015817	1679	1683	O
.	11015817	1684	1685	O

These	11015817	1686	1691	O
findings	11015817	1692	1700	O
were	11015817	1701	1705	O
not	11015817	1706	1709	O
as	11015817	1710	1712	O
evident	11015817	1713	1720	O
when	11015817	1721	1725	O
outcomes	11015817	1726	1734	O
where	11015817	1735	1740	O
clozapine	11015817	1741	1750	B-Intervention
was	11015817	1751	1754	O
not	11015817	1755	1758	O
clearly	11015817	1759	1766	B-Observation
superior	11015817	1767	1775	I-Observation
(	11015817	1776	1777	O
psychotic	11015817	1778	1787	B-Outcome
symptoms	11015817	1788	1796	I-Outcome
,	11015817	1797	1798	O
weight	11015817	1799	1805	B-Outcome
gain	11015817	1806	1810	I-Outcome
)	11015817	1811	1812	O
were	11015817	1813	1817	O
examined	11015817	1818	1826	O
.	11015817	1827	1828	O

CONCLUSION	11015817	1829	1839	O
Clozapine	11015817	1840	1849	B-Intervention
demonstrated	11015817	1850	1862	O
cost-effectiveness	11015817	1863	1881	B-Outcome
on	11015817	1882	1884	O
some	11015817	1885	1889	O
but	11015817	1890	1893	O
not	11015817	1894	1897	O
all	11015817	1898	1901	O
measures	11015817	1902	1910	O
of	11015817	1911	1913	O
effectiveness	11015817	1914	1927	O
when	11015817	1928	1932	O
the	11015817	1933	1936	O
alternative	11015817	1937	1948	O
was	11015817	1949	1952	O
a	11015817	1953	1954	O
range	11015817	1955	1960	O
of	11015817	1961	1963	O
conventional	11015817	1964	1976	B-Intervention
antipsychotic	11015817	1977	1990	I-Intervention
medications	11015817	1991	2002	I-Intervention
.	11015817	2003	2004	O

Beta	11021553	0	4	B-Intervention
radiation	11021553	5	14	I-Intervention
as	11021553	15	17	O
an	11021553	18	20	O
adjunct	11021553	21	28	O
to	11021553	29	31	O
low-risk	11021553	32	40	B-Participant
trabeculectomy	11021553	41	55	I-Participant
.	11021553	56	57	O

PURPOSE	11021553	58	65	O
To	11021553	66	68	O
assess	11021553	69	75	O
a	11021553	76	77	O
single	11021553	78	84	B-Intervention
dose	11021553	85	89	I-Intervention
of	11021553	90	92	I-Intervention
intraoperative	11021553	93	107	I-Intervention
beta	11021553	108	112	I-Intervention
radiation	11021553	113	122	I-Intervention
used	11021553	123	127	O
to	11021553	128	130	O
enhance	11021553	131	138	O
the	11021553	139	142	O
success	11021553	143	150	B-Outcome
rate	11021553	151	155	I-Outcome
of	11021553	156	158	O
trabeculectomy	11021553	159	173	B-Participant
in	11021553	174	176	O
a	11021553	177	178	O
population	11021553	179	189	O
of	11021553	190	192	O
low-risk	11021553	193	201	B-Participant
glaucoma	11021553	202	210	I-Participant
patients	11021553	211	219	O
in	11021553	220	222	O
whom	11021553	223	227	O
antimetabolites	11021553	228	243	B-Participant
might	11021553	244	249	O
not	11021553	250	253	O
be	11021553	254	256	O
indicated	11021553	257	266	O
.	11021553	267	268	O

METHODS	11021553	269	276	O
A	11021553	277	278	O
prospective	11021553	279	290	O
randomized	11021553	291	301	O
trial	11021553	302	307	O
of	11021553	308	310	O
65	11021553	311	313	O
eyes	11021553	314	318	O
was	11021553	319	322	O
designed	11021553	323	331	O
,	11021553	332	333	O
with	11021553	334	338	O
31	11021553	339	341	O
eyes	11021553	342	346	O
receiving	11021553	347	356	O
750	11021553	357	360	O
rads	11021553	361	365	O
of	11021553	366	368	O
intraoperative	11021553	369	383	B-Intervention
beta	11021553	384	388	I-Intervention
radiation	11021553	389	398	I-Intervention
(	11021553	399	400	O
group	11021553	401	406	O
1	11021553	407	408	O
)	11021553	409	410	O
,	11021553	411	412	O
and	11021553	413	416	O
34	11021553	417	419	O
eyes	11021553	420	424	O
receiving	11021553	425	434	O
no	11021553	435	437	B-Intervention
supplementation	11021553	438	453	I-Intervention
(	11021553	454	455	O
group	11021553	456	461	O
2	11021553	462	463	O
)	11021553	464	465	O
.	11021553	466	467	O

RESULTS	11021553	468	475	O
Mean	11021553	476	480	O
follow-up	11021553	481	490	O
time	11021553	491	495	O
was	11021553	496	499	O
24	11021553	500	502	O
months	11021553	503	509	O
.	11021553	510	511	O

Mean	11021553	512	516	B-Outcome
postoperative	11021553	517	530	I-Outcome
intraocular	11021553	531	542	I-Outcome
pressure	11021553	543	551	I-Outcome
was	11021553	552	555	O
12.2	11021553	556	560	B-Observation
mmHg	11021553	561	565	I-Observation
in	11021553	566	568	O
group	11021553	569	574	B-Intervention
1	11021553	575	576	I-Intervention
,	11021553	577	578	O
and	11021553	579	582	O
13.7	11021553	583	587	B-Observation
mmHg	11021553	588	592	I-Observation
in	11021553	593	595	O
group	11021553	596	601	B-Intervention
2	11021553	602	603	I-Intervention
(	11021553	604	605	O
P	11021553	606	607	O
=	11021553	608	609	O
0.16	11021553	610	614	O
)	11021553	615	616	O
.	11021553	617	618	O

Mean	11021553	619	623	B-Outcome
decrease	11021553	624	632	I-Outcome
in	11021553	633	635	I-Outcome
intraocular	11021553	636	647	I-Outcome
pressure	11021553	648	656	I-Outcome
was	11021553	657	660	O
10.3	11021553	661	665	B-Observation
mmHg	11021553	666	670	I-Observation
in	11021553	671	673	O
group	11021553	674	679	B-Intervention
1	11021553	680	681	I-Intervention
,	11021553	682	683	O
and	11021553	684	687	O
9.3	11021553	688	691	B-Observation
mmHg	11021553	692	696	I-Observation
in	11021553	697	699	O
group	11021553	700	705	B-Intervention
2	11021553	706	707	I-Intervention
(	11021553	708	709	O
P	11021553	710	711	O
=	11021553	712	713	O
0.49	11021553	714	718	O
)	11021553	719	720	O
.	11021553	721	722	O

The	11021553	723	726	O
two	11021553	727	730	B-Intervention
groups	11021553	731	737	I-Intervention
were	11021553	738	742	O
not	11021553	743	746	O
significantly	11021553	747	760	B-Observation
different	11021553	761	770	I-Observation
in	11021553	771	773	O
terms	11021553	774	779	O
of	11021553	780	782	O
surgical	11021553	783	791	B-Outcome
complications	11021553	792	805	I-Outcome
.	11021553	806	807	O

CONCLUSION	11021553	808	818	O
For	11021553	819	822	O
this	11021553	823	827	O
population	11021553	828	838	O
of	11021553	839	841	O
low-risk	11021553	842	850	B-Participant
patients	11021553	851	859	I-Participant
,	11021553	860	861	O
there	11021553	862	867	O
was	11021553	868	871	O
no	11021553	872	874	O
significant	11021553	875	886	B-Observation
difference	11021553	887	897	I-Observation
in	11021553	898	900	O
outcome	11021553	901	908	B-Outcome
after	11021553	909	914	O
applications	11021553	915	927	O
of	11021553	928	930	O
a	11021553	931	932	O
single	11021553	933	939	O
intraoperative	11021553	940	954	O
dose	11021553	955	959	O
of	11021553	960	962	O
beta	11021553	963	967	B-Intervention
radiation	11021553	968	977	I-Intervention
.	11021553	978	979	O

Outcomes	11022066	0	8	O
of	11022066	9	11	O
early	11022066	12	17	B-Intervention
endovascular	11022066	18	30	I-Intervention
versus	11022066	31	37	I-Intervention
surgical	11022066	38	46	I-Intervention
treatment	11022066	47	56	I-Intervention
of	11022066	57	59	O
ruptured	11022066	60	68	B-Participant
cerebral	11022066	69	77	I-Participant
aneurysms	11022066	78	87	I-Participant
.	11022066	88	89	O

A	11022066	90	91	O
prospective	11022066	92	103	O
randomized	11022066	104	114	O
study	11022066	115	120	O
.	11022066	121	122	O

BACKGROUND	11022066	123	133	O
AND	11022066	134	137	O
PURPOSE	11022066	138	145	O
This	11022066	146	150	O
prospective	11022066	151	162	O
study	11022066	163	168	O
was	11022066	169	172	O
conducted	11022066	173	182	O
to	11022066	183	185	O
compare	11022066	186	193	O
the	11022066	194	197	O
outcomes	11022066	198	206	O
of	11022066	207	209	O
surgical	11022066	210	218	B-Intervention
clipping	11022066	219	227	I-Intervention
and	11022066	228	231	O
endovascular	11022066	232	244	B-Intervention
treatment	11022066	245	254	I-Intervention
in	11022066	255	257	O
acute	11022066	258	263	B-Participant
(	11022066	264	265	I-Participant
<	11022066	266	267	I-Participant
72	11022066	268	270	I-Participant
hours	11022066	271	276	I-Participant
)	11022066	277	278	I-Participant
aneurysmal	11022066	279	289	I-Participant
subarachnoid	11022066	290	302	I-Participant
hemorrhage	11022066	303	313	I-Participant
(	11022066	314	315	I-Participant
SAH	11022066	316	319	I-Participant
)	11022066	320	321	I-Participant
.	11022066	322	323	O

METHODS	11022066	324	331	O
One	11022066	332	335	O
hundred	11022066	336	343	O
nine	11022066	344	348	O
consecutive	11022066	349	360	O
patients	11022066	361	369	O
were	11022066	370	374	O
randomly	11022066	375	383	O
assigned	11022066	384	392	O
to	11022066	393	395	O
either	11022066	396	402	O
surgical	11022066	403	411	B-Intervention
(	11022066	412	413	O
n=57	11022066	414	418	O
)	11022066	419	420	O
or	11022066	421	423	O
endovascular	11022066	424	436	B-Intervention
(	11022066	437	438	O
n=52	11022066	439	443	O
)	11022066	444	445	O
treatment	11022066	446	455	O
.	11022066	456	457	O

Clinical	11022066	458	466	B-Outcome
and	11022066	467	470	I-Outcome
neuropsychological	11022066	471	489	I-Outcome
outcome	11022066	490	497	I-Outcome
was	11022066	498	501	O
assessed	11022066	502	510	O
at	11022066	511	513	O
3	11022066	514	515	O
and	11022066	516	519	O
12	11022066	520	522	O
months	11022066	523	529	O
after	11022066	530	535	O
treatment	11022066	536	545	O
;	11022066	546	547	O
MRI	11022066	548	551	B-Outcome
of	11022066	552	554	I-Outcome
the	11022066	555	558	I-Outcome
brain	11022066	559	564	I-Outcome
was	11022066	565	568	O
performed	11022066	569	578	O
at	11022066	579	581	O
12	11022066	582	584	O
months	11022066	585	591	O
.	11022066	592	593	O

Follow-up	11022066	594	603	O
angiography	11022066	604	615	O
was	11022066	616	619	O
scheduled	11022066	620	629	O
after	11022066	630	635	O
clipping	11022066	636	644	B-Intervention
and	11022066	645	648	O
3	11022066	649	650	O
and	11022066	651	654	O
12	11022066	655	657	O
months	11022066	658	664	O
after	11022066	665	670	O
endovascular	11022066	671	683	B-Intervention
treatment	11022066	684	693	I-Intervention
.	11022066	694	695	O

RESULTS	11022066	696	703	O
One	11022066	704	707	O
year	11022066	708	712	O
postoperatively	11022066	713	728	O
,	11022066	729	730	O
43/41	11022066	731	736	B-Count
(	11022066	737	738	O
surgical/endovascular	11022066	739	760	B-Intervention
)	11022066	761	762	O
patients	11022066	763	771	O
had	11022066	772	775	O
good	11022066	776	780	B-Outcome
or	11022066	781	783	I-Outcome
moderate	11022066	784	792	I-Outcome
recovery	11022066	793	801	I-Outcome
,	11022066	802	803	O
5/4	11022066	804	807	B-Count
had	11022066	808	811	O
severe	11022066	812	818	B-Outcome
disability	11022066	819	829	I-Outcome
or	11022066	830	832	I-Outcome
were	11022066	833	837	I-Outcome
in	11022066	838	840	I-Outcome
a	11022066	841	842	I-Outcome
vegetative	11022066	843	853	I-Outcome
state	11022066	854	859	I-Outcome
,	11022066	860	861	O
and	11022066	862	865	O
9/7	11022066	866	869	B-Count
had	11022066	870	873	O
died	11022066	874	878	B-Outcome
(	11022066	879	880	I-Outcome
NS	11022066	881	883	I-Outcome
)	11022066	884	885	I-Outcome
according	11022066	886	895	O
to	11022066	896	898	O
intention	11022066	899	908	O
to	11022066	909	911	O
treat	11022066	912	917	O
.	11022066	918	919	O

Patients	11022066	920	928	O
with	11022066	929	933	O
good	11022066	934	938	B-Outcome
clinical	11022066	939	947	I-Outcome
recovery	11022066	948	956	I-Outcome
did	11022066	957	960	O
not	11022066	961	964	O
differ	11022066	965	971	B-Observation
in	11022066	972	974	O
their	11022066	975	980	O
neuropsychological	11022066	981	999	B-Outcome
test	11022066	1000	1004	I-Outcome
scores	11022066	1005	1011	I-Outcome
.	11022066	1012	1013	O

Symptomatic	11022066	1014	1025	B-Outcome
vasospasm	11022066	1026	1035	I-Outcome
(	11022066	1036	1037	O
OR	11022066	1038	1040	O
2.47	11022066	1041	1045	O
;	11022066	1046	1047	O
95	11022066	1048	1050	O
%	11022066	1051	1052	O
CI	11022066	1053	1055	O
1.45	11022066	1056	1060	O
to	11022066	1061	1063	O
4.19	11022066	1064	1068	O
;	11022066	1069	1070	O
P	11022066	1071	1072	O
<	11022066	1073	1074	O
0.001	11022066	1075	1080	O
)	11022066	1081	1082	O
,	11022066	1083	1084	O
poorer	11022066	1085	1091	B-Observation
Hunt	11022066	1092	1096	B-Outcome
and	11022066	1097	1100	I-Outcome
Hess	11022066	1101	1105	I-Outcome
grade	11022066	1106	1111	I-Outcome
(	11022066	1112	1113	O
OR	11022066	1114	1116	O
2.50	11022066	1117	1121	O
;	11022066	1122	1123	O
95	11022066	1124	1126	O
%	11022066	1127	1128	O
CI	11022066	1129	1131	O
1.31	11022066	1132	1136	O
to	11022066	1137	1139	O
4.75	11022066	1140	1144	O
;	11022066	1145	1146	O
P=0.005	11022066	1147	1154	O
)	11022066	1155	1156	O
,	11022066	1157	1158	O
need	11022066	1159	1163	B-Outcome
for	11022066	1164	1167	I-Outcome
permanent	11022066	1168	1177	I-Outcome
shunt	11022066	1178	1183	I-Outcome
(	11022066	1184	1185	O
OR	11022066	1186	1188	O
8.90	11022066	1189	1193	O
;	11022066	1194	1195	O
95	11022066	1196	1198	O
%	11022066	1199	1200	O
CI	11022066	1201	1203	O
1.80	11022066	1204	1208	O
to	11022066	1209	1211	O
44.15	11022066	1212	1217	O
;	11022066	1218	1219	O
P=0.008	11022066	1220	1227	O
)	11022066	1228	1229	O
,	11022066	1230	1231	O
and	11022066	1232	1235	O
larger	11022066	1236	1242	B-Observation
size	11022066	1243	1247	B-Outcome
of	11022066	1248	1250	I-Outcome
the	11022066	1251	1254	I-Outcome
aneurysm	11022066	1255	1263	I-Outcome
(	11022066	1264	1265	O
OR	11022066	1266	1268	O
1	11022066	1269	1270	O
.	11022066	1271	1272	O
22	11022066	1273	1275	O
;	11022066	1276	1277	O
95	11022066	1278	1280	O
%	11022066	1281	1282	O
CI	11022066	1283	1285	O
1.02	11022066	1286	1290	O
to	11022066	1291	1293	O
1.45	11022066	1294	1298	O
;	11022066	1299	1300	O
P=0.032	11022066	1301	1308	O
)	11022066	1309	1310	O
independently	11022066	1311	1324	O
predicted	11022066	1325	1334	O
worsened	11022066	1335	1343	B-Observation
clinical	11022066	1344	1352	B-Outcome
outcome	11022066	1353	1360	I-Outcome
regardless	11022066	1361	1371	O
of	11022066	1372	1374	O
the	11022066	1375	1378	O
treatment	11022066	1379	1388	B-Intervention
modality	11022066	1389	1397	I-Intervention
.	11022066	1398	1399	O

In	11022066	1400	1402	O
MRI	11022066	1403	1406	O
,	11022066	1407	1408	O
superficial	11022066	1409	1420	B-Outcome
brain	11022066	1421	1426	I-Outcome
retraction	11022066	1427	1437	I-Outcome
deficits	11022066	1438	1446	I-Outcome
(	11022066	1447	1448	O
P	11022066	1449	1450	O
<	11022066	1451	1452	O
0.001	11022066	1453	1458	O
)	11022066	1459	1460	O
and	11022066	1461	1464	O
ischemic	11022066	1465	1473	B-Outcome
lesions	11022066	1474	1481	I-Outcome
in	11022066	1482	1484	I-Outcome
the	11022066	1485	1488	I-Outcome
territory	11022066	1489	1498	I-Outcome
of	11022066	1499	1501	I-Outcome
the	11022066	1502	1505	I-Outcome
ruptured	11022066	1506	1514	I-Outcome
aneurysm	11022066	1515	1523	I-Outcome
(	11022066	1524	1525	O
P=0.025	11022066	1526	1533	O
)	11022066	1534	1535	O
were	11022066	1536	1540	O
more	11022066	1541	1545	B-Observation
frequent	11022066	1546	1554	I-Observation
in	11022066	1555	1557	O
the	11022066	1558	1561	O
surgical	11022066	1562	1570	B-Intervention
group	11022066	1571	1576	O
.	11022066	1577	1578	O

Kaplan-Meier	11022066	1579	1591	O
analysis	11022066	1592	1600	O
(	11022066	1601	1602	O
mean+/-SD	11022066	1603	1612	O
follow-up	11022066	1613	1622	O
39+/-18	11022066	1623	1630	O
months	11022066	1631	1637	O
)	11022066	1638	1639	O
revealed	11022066	1640	1648	O
equal	11022066	1649	1654	B-Observation
survival	11022066	1655	1663	B-Outcome
in	11022066	1664	1666	O
both	11022066	1667	1671	B-Intervention
treatment	11022066	1672	1681	I-Intervention
groups	11022066	1682	1688	O
.	11022066	1689	1690	O

No	11022066	1691	1693	B-Count
late	11022066	1694	1698	B-Outcome
rebleedings	11022066	1699	1710	I-Outcome
have	11022066	1711	1715	O
occurred	11022066	1716	1724	O
.	11022066	1725	1726	O

CONCLUSIONS	11022066	1727	1738	O
One-year	11022066	1739	1747	B-Outcome
clinical	11022066	1748	1756	I-Outcome
and	11022066	1757	1760	I-Outcome
neuropsychological	11022066	1761	1779	I-Outcome
outcomes	11022066	1780	1788	I-Outcome
seem	11022066	1789	1793	O
comparable	11022066	1794	1804	B-Observation
after	11022066	1805	1810	O
early	11022066	1811	1816	B-Intervention
surgical	11022066	1817	1825	I-Intervention
and	11022066	1826	1829	I-Intervention
endovascular	11022066	1830	1842	I-Intervention
treatment	11022066	1843	1852	I-Intervention
of	11022066	1853	1855	O
ruptured	11022066	1856	1864	B-Participant
intracranial	11022066	1865	1877	I-Participant
aneurysms	11022066	1878	1887	I-Participant
.	11022066	1888	1889	O

The	11022066	1890	1893	O
long-term	11022066	1894	1903	O
efficacy	11022066	1904	1912	O
of	11022066	1913	1915	O
endovascular	11022066	1916	1928	O
treatment	11022066	1929	1938	O
in	11022066	1939	1941	O
preventing	11022066	1942	1952	O
rebleeding	11022066	1953	1963	O
remains	11022066	1964	1971	O
open	11022066	1972	1976	O
.	11022066	1977	1978	O

Tromethamine	11029345	0	12	B-Intervention
buffer	11029345	13	19	I-Intervention
modifies	11029345	20	28	B-Observation
the	11029345	29	32	O
depressant	11029345	33	43	B-Outcome
effect	11029345	44	50	I-Outcome
of	11029345	51	53	I-Outcome
permissive	11029345	54	64	I-Outcome
hypercapnia	11029345	65	76	I-Outcome
on	11029345	77	79	I-Outcome
myocardial	11029345	80	90	I-Outcome
contractility	11029345	91	104	I-Outcome
in	11029345	105	107	O
patients	11029345	108	116	O
with	11029345	117	121	O
acute	11029345	122	127	B-Participant
respiratory	11029345	128	139	I-Participant
distress	11029345	140	148	I-Participant
syndrome	11029345	149	157	I-Participant
.	11029345	158	159	O

In	11029345	160	162	O
patients	11029345	163	171	O
with	11029345	172	176	O
acute	11029345	177	182	O
respiratory	11029345	183	194	O
distress	11029345	195	203	O
syndrome	11029345	204	212	O
(	11029345	213	214	O
ARDS	11029345	215	219	O
)	11029345	220	221	O
,	11029345	222	223	O
permissive	11029345	224	234	O
hypercapnia	11029345	235	246	O
is	11029345	247	249	O
a	11029345	250	251	O
strategy	11029345	252	260	O
to	11029345	261	263	O
decrease	11029345	264	272	O
airway	11029345	273	279	O
pressures	11029345	280	289	O
to	11029345	290	292	O
prevent	11029345	293	300	O
ventilator-induced	11029345	301	319	O
lung	11029345	320	324	O
damage	11029345	325	331	O
by	11029345	332	334	O
lowering	11029345	335	343	O
tidal	11029345	344	349	O
volumes	11029345	350	357	O
and	11029345	358	361	O
tolerating	11029345	362	372	O
higher	11029345	373	379	O
arterial	11029345	380	388	O
carbon	11029345	389	395	O
dioxide	11029345	396	403	O
tension	11029345	404	411	O
.	11029345	412	413	O

However	11029345	414	421	O
,	11029345	422	423	O
in	11029345	424	426	O
experimental	11029345	427	439	O
studies	11029345	440	447	O
hypercapnia	11029345	448	459	O
impairs	11029345	460	467	O
myocardial	11029345	468	478	O
contractility	11029345	479	492	O
and	11029345	493	496	O
hemodynamic	11029345	497	508	O
function	11029345	509	517	O
.	11029345	518	519	O

We	11029345	520	522	O
investigated	11029345	523	535	O
the	11029345	536	539	O
effect	11029345	540	546	O
of	11029345	547	549	O
short-term	11029345	550	560	B-Intervention
permissive	11029345	561	571	I-Intervention
hypercapnia	11029345	572	583	I-Intervention
on	11029345	584	586	O
myocardial	11029345	587	597	B-Outcome
contractility	11029345	598	611	I-Outcome
and	11029345	612	615	O
hemodynamics	11029345	616	628	B-Outcome
in	11029345	629	631	O
patients	11029345	632	640	O
with	11029345	641	645	O
ARDS	11029345	646	650	B-Participant
.	11029345	651	652	O

We	11029345	653	655	O
hypothesized	11029345	656	668	O
that	11029345	669	673	O
the	11029345	674	677	O
administration	11029345	678	692	O
of	11029345	693	695	O
tromethamine	11029345	696	708	B-Intervention
(	11029345	709	710	I-Intervention
THAM	11029345	711	715	I-Intervention
)	11029345	716	717	I-Intervention
,	11029345	718	719	O
a	11029345	720	721	O
buffer	11029345	722	728	O
which	11029345	729	734	O
does	11029345	735	739	O
not	11029345	740	743	O
increase	11029345	744	752	O
carbon	11029345	753	759	O
dioxide	11029345	760	767	O
production	11029345	768	778	O
,	11029345	779	780	O
would	11029345	781	786	O
modify	11029345	787	793	B-Observation
these	11029345	794	799	B-Outcome
changes	11029345	800	807	I-Outcome
.	11029345	808	809	O

In	11029345	810	812	O
12	11029345	813	815	O
patients	11029345	816	824	O
with	11029345	825	829	O
ARDS	11029345	830	834	B-Participant
,	11029345	835	836	O
permissive	11029345	837	847	B-Intervention
hypercapnia	11029345	848	859	I-Intervention
was	11029345	860	863	O
implemented	11029345	864	875	O
for	11029345	876	879	O
2	11029345	880	881	O
h	11029345	882	883	O
with	11029345	884	888	O
a	11029345	889	890	O
target	11029345	891	897	O
Pa	11029345	898	900	O
(	11029345	901	902	O
CO	11029345	903	905	O
(	11029345	906	907	O
2	11029345	908	909	O
)	11029345	910	911	O
)	11029345	912	913	O
of	11029345	914	916	O
80	11029345	917	919	O
mm	11029345	920	922	O
Hg	11029345	923	925	O
.	11029345	926	927	O

Patients	11029345	928	936	O
were	11029345	937	941	O
randomized	11029345	942	952	O
to	11029345	953	955	O
have	11029345	956	960	O
respiratory	11029345	961	972	B-Intervention
acidosis	11029345	973	981	I-Intervention
corrected	11029345	982	991	I-Intervention
by	11029345	992	994	I-Intervention
THAM	11029345	995	999	I-Intervention
(	11029345	1000	1001	O
pH-corrected	11029345	1002	1014	O
group	11029345	1015	1020	O
)	11029345	1021	1022	O
,	11029345	1023	1024	O
or	11029345	1025	1027	O
not	11029345	1028	1031	B-Intervention
corrected	11029345	1032	1041	I-Intervention
(	11029345	1042	1043	O
pH-uncorrected	11029345	1044	1058	O
group	11029345	1059	1064	O
)	11029345	1065	1066	O
.	11029345	1067	1068	O

Hemodynamic	11029345	1069	1080	B-Outcome
responses	11029345	1081	1090	I-Outcome
were	11029345	1091	1095	O
measured	11029345	1096	1104	O
,	11029345	1105	1106	O
and	11029345	1107	1110	O
transesophageal	11029345	1111	1126	O
echocardiography	11029345	1127	1143	O
(	11029345	1144	1145	O
TEE	11029345	1146	1149	O
)	11029345	1150	1151	O
was	11029345	1152	1155	O
used	11029345	1156	1160	O
to	11029345	1161	1163	O
determine	11029345	1164	1173	O
myocardial	11029345	1174	1184	B-Outcome
contractility	11029345	1185	1198	I-Outcome
.	11029345	1199	1200	O

Permissive	11029345	1201	1211	B-Intervention
hypercapnia	11029345	1212	1223	I-Intervention
resulted	11029345	1224	1232	O
in	11029345	1233	1235	O
significant	11029345	1236	1247	B-Observation
decreases	11029345	1248	1257	I-Observation
in	11029345	1258	1260	O
systemic	11029345	1261	1269	B-Outcome
vascular	11029345	1270	1278	I-Outcome
resistance	11029345	1279	1289	I-Outcome
(	11029345	1290	1291	I-Outcome
SVR	11029345	1292	1295	I-Outcome
)	11029345	1296	1297	I-Outcome
and	11029345	1298	1301	O
increases	11029345	1302	1311	B-Observation
in	11029345	1312	1314	O
cardiac	11029345	1315	1322	B-Outcome
output	11029345	1323	1329	I-Outcome
(	11029345	1330	1331	I-Outcome
Q	11029345	1332	1333	I-Outcome
)	11029345	1334	1335	I-Outcome
.	11029345	1336	1337	O

Myocardial	11029345	1338	1348	B-Outcome
contractility	11029345	1349	1362	I-Outcome
decreased	11029345	1363	1372	B-Observation
in	11029345	1373	1375	O
both	11029345	1376	1380	B-Intervention
groups	11029345	1381	1387	I-Intervention
but	11029345	1388	1391	O
significantly	11029345	1392	1405	B-Observation
less	11029345	1406	1410	I-Observation
in	11029345	1411	1413	O
the	11029345	1414	1417	O
pH-corrected	11029345	1418	1430	B-Intervention
group	11029345	1431	1436	I-Intervention
(	11029345	1437	1438	O
approximately	11029345	1439	1452	B-Observation
10	11029345	1453	1455	I-Observation
%	11029345	1456	1457	I-Observation
)	11029345	1458	1459	O
than	11029345	1460	1464	O
in	11029345	1465	1467	O
the	11029345	1468	1471	O
pH-uncorrected	11029345	1472	1486	B-Intervention
group	11029345	1487	1492	O
(	11029345	1493	1494	O
approximately	11029345	1495	1508	B-Observation
18	11029345	1509	1511	I-Observation
%	11029345	1512	1513	I-Observation
,	11029345	1514	1515	O
p	11029345	1516	1517	O
<	11029345	1518	1519	O
0.05	11029345	1520	1524	O
)	11029345	1525	1526	O
.	11029345	1527	1528	O

Mean	11029345	1529	1533	B-Outcome
arterial	11029345	1534	1542	I-Outcome
pressure	11029345	1543	1551	I-Outcome
decreased	11029345	1552	1561	B-Observation
and	11029345	1562	1565	O
mean	11029345	1566	1570	B-Outcome
pulmonary	11029345	1571	1580	I-Outcome
arterial	11029345	1581	1589	I-Outcome
pressure	11029345	1590	1598	I-Outcome
increased	11029345	1599	1608	B-Observation
significantly	11029345	1609	1622	I-Observation
only	11029345	1623	1627	O
in	11029345	1628	1630	O
the	11029345	1631	1634	O
pH-uncorrected	11029345	1635	1649	B-Intervention
group	11029345	1650	1655	O
.	11029345	1656	1657	O

All	11029345	1658	1661	O
values	11029345	1662	1668	O
returned	11029345	1669	1677	O
to	11029345	1678	1680	O
baseline	11029345	1681	1689	O
conditions	11029345	1690	1700	O
1	11029345	1701	1702	O
h	11029345	1703	1704	O
after	11029345	1705	1710	O
permissive	11029345	1711	1721	B-Intervention
hypercapnia	11029345	1722	1733	I-Intervention
was	11029345	1734	1737	O
terminated	11029345	1738	1748	O
.	11029345	1749	1750	O

Our	11029345	1751	1754	O
study	11029345	1755	1760	O
demonstrates	11029345	1761	1773	O
a	11029345	1774	1775	O
reversible	11029345	1776	1786	B-Outcome
depression	11029345	1787	1797	I-Outcome
of	11029345	1798	1800	I-Outcome
myocardial	11029345	1801	1811	I-Outcome
contractility	11029345	1812	1825	I-Outcome
and	11029345	1826	1829	O
hemodynamic	11029345	1830	1841	B-Outcome
alterations	11029345	1842	1853	I-Outcome
during	11029345	1854	1860	O
rapid	11029345	1861	1866	B-Intervention
permissive	11029345	1867	1877	I-Intervention
hypercapnia	11029345	1878	1889	I-Intervention
which	11029345	1890	1895	O
were	11029345	1896	1900	O
attenuated	11029345	1901	1911	B-Observation
by	11029345	1912	1914	O
buffering	11029345	1915	1924	O
with	11029345	1925	1929	O
THAM	11029345	1930	1934	B-Intervention
.	11029345	1935	1936	O

This	11029345	1937	1941	O
may	11029345	1942	1945	O
have	11029345	1946	1950	O
applicability	11029345	1951	1964	O
to	11029345	1965	1967	O
the	11029345	1968	1971	O
clinical	11029345	1972	1980	O
strategy	11029345	1981	1989	O
of	11029345	1990	1992	O
permissive	11029345	1993	2003	O
hypercapnia	11029345	2004	2015	O
and	11029345	2016	2019	O
allow	11029345	2020	2025	O
the	11029345	2026	2029	O
benefit	11029345	2030	2037	O
of	11029345	2038	2040	O
decreased	11029345	2041	2050	O
airway	11029345	2051	2057	O
pressures	11029345	2058	2067	O
to	11029345	2068	2070	O
be	11029345	2071	2073	O
realized	11029345	2074	2082	O
while	11029345	2083	2088	O
minimizing	11029345	2089	2099	O
the	11029345	2100	2103	O
adverse	11029345	2104	2111	O
hemodynamic	11029345	2112	2123	O
effects	11029345	2124	2131	O
of	11029345	2132	2134	O
hypercapnic	11029345	2135	2146	O
acidosis	11029345	2147	2155	O
.	11029345	2156	2157	O

Epidural	11029568	0	8	B-Intervention
fentanyl-bupivacaine	11029568	9	29	I-Intervention
compared	11029568	30	38	O
with	11029568	39	43	O
clonidine-bupivacaine	11029568	44	65	B-Intervention
for	11029568	66	69	O
analgesia	11029568	70	79	B-Outcome
in	11029568	80	82	O
labour	11029568	83	89	B-Participant
.	11029568	90	91	O

Alpha-adrenergic	11029568	92	108	O
agonists	11029568	109	117	O
produce	11029568	118	125	O
pain	11029568	126	130	O
relief	11029568	131	137	O
through	11029568	138	145	O
an	11029568	146	148	O
opioid	11029568	149	155	O
independent	11029568	156	167	O
mechanism	11029568	168	177	O
and	11029568	178	181	O
may	11029568	182	185	O
be	11029568	186	188	O
alternatives	11029568	189	201	O
to	11029568	202	204	O
opioids	11029568	205	212	O
for	11029568	213	216	O
combination	11029568	217	228	O
with	11029568	229	233	O
local	11029568	234	239	O
anaesthetics	11029568	240	252	O
for	11029568	253	256	O
analgesia	11029568	257	266	O
during	11029568	267	273	O
labour	11029568	274	280	O
.	11029568	281	282	O

We	11029568	283	285	O
studied	11029568	286	293	O
41	11029568	294	296	O
pregnant	11029568	297	305	B-Participant
women	11029568	306	311	I-Participant
.	11029568	312	313	O

Epidural	11029568	314	322	B-Intervention
block	11029568	323	328	I-Intervention
was	11029568	329	332	I-Intervention
performed	11029568	333	342	I-Intervention
with	11029568	343	347	I-Intervention
75	11029568	348	350	I-Intervention
microg	11029568	351	357	I-Intervention
clonidine	11029568	358	367	I-Intervention
(	11029568	368	369	O
n	11029568	370	371	O
=	11029568	372	373	O
20	11029568	374	376	O
)	11029568	377	378	O
or	11029568	379	381	O
50	11029568	382	384	B-Intervention
microg	11029568	385	391	I-Intervention
fentanyl	11029568	392	400	I-Intervention
(	11029568	401	402	I-Intervention
n	11029568	403	404	I-Intervention
=	11029568	405	406	I-Intervention
21	11029568	407	409	I-Intervention
)	11029568	410	411	I-Intervention
combined	11029568	412	420	I-Intervention
with	11029568	421	425	I-Intervention
0.125	11029568	426	431	I-Intervention
%	11029568	432	433	I-Intervention
bupivacaine	11029568	434	445	I-Intervention
(	11029568	446	447	O
10	11029568	448	450	O
mL	11029568	451	453	O
)	11029568	454	455	O
.	11029568	456	457	O

Maternal	11029568	458	466	B-Outcome
vital	11029568	467	472	I-Outcome
parameters	11029568	473	483	I-Outcome
were	11029568	484	488	O
measured	11029568	489	497	O
.	11029568	498	499	O

Analgesia	11029568	500	509	B-Outcome
was	11029568	510	513	O
evaluated	11029568	514	523	O
using	11029568	524	529	O
a	11029568	530	531	O
visual	11029568	532	538	B-Outcome
analogue	11029568	539	547	I-Outcome
scale	11029568	548	553	I-Outcome
(	11029568	554	555	I-Outcome
VAS	11029568	556	559	I-Outcome
)	11029568	560	561	I-Outcome
;	11029568	562	563	O
sedation	11029568	564	572	B-Outcome
was	11029568	573	576	O
scored	11029568	577	583	O
using	11029568	584	589	O
a	11029568	590	591	O
five-point	11029568	592	602	O
scale	11029568	603	608	O
.	11029568	609	610	O

There	11029568	611	616	O
were	11029568	617	621	O
no	11029568	622	624	O
differences	11029568	625	636	B-Observation
in	11029568	637	639	O
maternal	11029568	640	648	B-Outcome
vital	11029568	649	654	I-Outcome
parameters	11029568	655	665	I-Outcome
,	11029568	666	667	O
fetal	11029568	668	673	B-Outcome
heart	11029568	674	679	I-Outcome
rate	11029568	680	684	I-Outcome
(	11029568	685	686	I-Outcome
FHR	11029568	687	690	I-Outcome
)	11029568	691	692	I-Outcome
or	11029568	693	695	O
Apgar	11029568	696	701	B-Outcome
scores	11029568	702	708	I-Outcome
between	11029568	709	716	B-Intervention
the	11029568	717	720	I-Intervention
groups	11029568	721	727	I-Intervention
.	11029568	728	729	O

Analgesia	11029568	730	739	B-Outcome
lasted	11029568	740	746	O
longer	11029568	747	753	B-Observation
in	11029568	754	756	O
the	11029568	757	760	O
bupivacaine-clonidine	11029568	761	782	B-Intervention
group	11029568	783	788	O
(	11029568	789	790	O
139.4	11029568	791	796	B-Observation
+	11029568	797	798	I-Observation
/-	11029568	798	800	I-Observation
31	11029568	801	803	I-Observation
min	11029568	804	807	I-Observation
)	11029568	808	809	O
compared	11029568	810	818	O
with	11029568	819	823	O
the	11029568	824	827	O
bupivacaine-fentanyl	11029568	828	848	B-Intervention
group	11029568	849	854	O
(	11029568	855	856	O
127.9	11029568	857	862	B-Observation
+	11029568	863	864	I-Observation
/-	11029568	864	866	I-Observation
48	11029568	867	869	I-Observation
min	11029568	870	873	I-Observation
)	11029568	874	875	O
(	11029568	876	877	O
P	11029568	878	879	O
=	11029568	880	881	O
0.42	11029568	882	886	O
)	11029568	887	888	O
.	11029568	889	890	O

Additional	11029568	891	901	B-Outcome
analgesic	11029568	902	911	I-Outcome
requirement	11029568	912	923	I-Outcome
was	11029568	924	927	O
more	11029568	928	932	B-Observation
often	11029568	933	938	I-Observation
in	11029568	939	941	O
the	11029568	942	945	O
fentanyl-bupivacaine	11029568	946	966	B-Intervention
group	11029568	967	972	O
and	11029568	973	976	O
total	11029568	977	982	B-Outcome
bupivacaine	11029568	983	994	I-Outcome
requirement	11029568	995	1006	I-Outcome
was	11029568	1007	1010	O
less	11029568	1011	1015	B-Observation
in	11029568	1016	1018	O
the	11029568	1019	1022	O
clonidine-bupivacaine	11029568	1023	1044	B-Intervention
group	11029568	1045	1050	O
(	11029568	1051	1052	O
22.5	11029568	1053	1057	B-Observation
+	11029568	1058	1059	I-Observation
/-	11029568	1059	1061	I-Observation
12.5	11029568	1062	1066	I-Observation
mg	11029568	1067	1069	I-Observation
vs.	11029568	1070	1073	O
30.9	11029568	1074	1078	B-Observation
+	11029568	1079	1080	I-Observation
/-	11029568	1080	1082	I-Observation
12.8	11029568	1083	1087	I-Observation
mg	11029568	1088	1090	I-Observation
)	11029568	1091	1092	O
(	11029568	1093	1094	O
P	11029568	1095	1096	O
=	11029568	1097	1098	O
0.04	11029568	1099	1103	O
)	11029568	1104	1105	O
.	11029568	1106	1107	O

This	11029568	1108	1112	O
small	11029568	1113	1118	O
study	11029568	1119	1124	O
confirms	11029568	1125	1133	O
that	11029568	1134	1138	O
this	11029568	1139	1143	O
combination	11029568	1144	1155	B-Intervention
of	11029568	1156	1158	I-Intervention
bupivacaine	11029568	1159	1170	I-Intervention
and	11029568	1171	1174	I-Intervention
clonidine	11029568	1175	1184	I-Intervention
provides	11029568	1185	1193	O
satisfactory	11029568	1194	1206	B-Observation
analgesia	11029568	1207	1216	B-Outcome
for	11029568	1217	1220	O
first-stage	11029568	1221	1232	B-Participant
labour	11029568	1233	1239	I-Participant
,	11029568	1240	1241	O
and	11029568	1242	1245	O
of	11029568	1246	1248	O
longer	11029568	1249	1255	B-Observation
duration	11029568	1256	1264	B-Outcome
than	11029568	1265	1269	O
bupivacaine-fentanyl	11029568	1270	1290	B-Intervention
.	11029568	1291	1292	O

Randomized	11034038	0	10	O
,	11034038	11	12	O
placebo-controlled	11034038	13	31	O
trial	11034038	32	37	O
of	11034038	38	40	O
oral	11034038	41	45	B-Intervention
phytonadione	11034038	46	58	I-Intervention
for	11034038	59	62	O
excessive	11034038	63	72	B-Outcome
anticoagulation	11034038	73	88	I-Outcome
.	11034038	89	90	O

STUDY	11034038	91	96	O
OBJECTIVE	11034038	97	106	O
To	11034038	107	109	O
compare	11034038	110	117	O
the	11034038	118	121	O
efficacy	11034038	122	130	O
of	11034038	131	133	O
managing	11034038	134	142	O
excessive	11034038	143	152	B-Outcome
anticoagulation	11034038	153	168	I-Outcome
in	11034038	169	171	O
the	11034038	172	175	O
absence	11034038	176	183	B-Participant
of	11034038	184	186	I-Participant
bleeding	11034038	187	195	I-Participant
by	11034038	196	198	O
either	11034038	199	205	O
omitting	11034038	206	214	B-Intervention
warfarin	11034038	215	223	I-Intervention
therapy	11034038	224	231	I-Intervention
alone	11034038	232	237	I-Intervention
or	11034038	238	240	O
administering	11034038	241	254	O
oral	11034038	255	259	B-Intervention
phytonadione	11034038	260	272	I-Intervention
in	11034038	273	275	I-Intervention
addition	11034038	276	284	I-Intervention
to	11034038	285	287	I-Intervention
omitting	11034038	288	296	I-Intervention
warfarin	11034038	297	305	I-Intervention
therapy	11034038	306	313	O
.	11034038	314	315	O

DESIGN	11034038	316	322	O
Randomized	11034038	323	333	O
,	11034038	334	335	O
double-blind	11034038	336	348	O
,	11034038	349	350	O
placebo-controlled	11034038	351	369	O
study	11034038	370	375	O
.	11034038	376	377	O

SETTING	11034038	378	385	O
Clinical	11034038	386	394	O
pharmacy	11034038	395	403	O
anticoagulation	11034038	404	419	O
service	11034038	420	427	O
in	11034038	428	430	O
a	11034038	431	432	O
group	11034038	433	438	O
model	11034038	439	444	O
health	11034038	445	451	O
maintenance	11034038	452	463	O
organization	11034038	464	476	O
.	11034038	477	478	O

SUBJECTS	11034038	479	487	O
Thirty	11034038	488	494	O
nonbleeding	11034038	495	506	B-Participant
patients	11034038	507	515	O
with	11034038	516	520	O
international	11034038	521	534	B-Participant
normalized	11034038	535	545	I-Participant
ratios	11034038	546	552	I-Participant
(	11034038	553	554	I-Participant
INRs	11034038	555	559	I-Participant
)	11034038	560	561	I-Participant
ranging	11034038	562	569	I-Participant
from	11034038	570	574	I-Participant
6.0	11034038	575	578	I-Participant
-	11034038	578	579	I-Participant
10.0	11034038	579	583	I-Participant
.	11034038	584	585	O

INTERVENTIONS	11034038	586	599	O
Patients	11034038	600	608	O
were	11034038	609	613	O
randomized	11034038	614	624	O
to	11034038	625	627	O
receive	11034038	628	635	O
either	11034038	636	642	O
a	11034038	643	644	O
single	11034038	645	651	O
oral	11034038	652	656	O
dose	11034038	657	661	O
of	11034038	662	664	O
phytonadione	11034038	665	677	B-Intervention
2.5	11034038	678	681	O
mg	11034038	682	684	O
or	11034038	685	687	O
placebo	11034038	688	695	B-Intervention
.	11034038	696	697	O

Both	11034038	698	702	O
groups	11034038	703	709	O
omitted	11034038	710	717	B-Intervention
warfarin	11034038	718	726	I-Intervention
doses	11034038	727	732	O
until	11034038	733	738	O
the	11034038	739	742	O
INR	11034038	743	746	O
became	11034038	747	753	O
less	11034038	754	758	O
than	11034038	759	763	O
or	11034038	764	766	O
equal	11034038	767	772	O
to	11034038	773	775	O
4.0	11034038	776	779	O
.	11034038	780	781	O

MEASUREMENTS	11034038	782	794	O
AND	11034038	795	798	O
RESULTS	11034038	799	806	O
The	11034038	807	810	O
mean	11034038	811	815	B-Outcome
calculated	11034038	816	826	I-Outcome
time	11034038	827	831	I-Outcome
to	11034038	832	834	I-Outcome
reach	11034038	835	840	I-Outcome
an	11034038	841	843	I-Outcome
INR	11034038	844	847	I-Outcome
of	11034038	848	850	I-Outcome
4.0	11034038	851	854	I-Outcome
was	11034038	855	858	O
significantly	11034038	859	872	B-Observation
greater	11034038	873	880	I-Observation
in	11034038	881	883	O
the	11034038	884	887	O
placebo	11034038	888	895	B-Intervention
than	11034038	896	900	O
the	11034038	901	904	O
phytonadione	11034038	905	917	B-Intervention
group	11034038	918	923	O
(	11034038	924	925	O
2.6	11034038	926	929	B-Observation
vs	11034038	930	932	O
1.4	11034038	933	936	B-Observation
days	11034038	937	941	I-Observation
,	11034038	942	943	O
p=0.006	11034038	944	951	O
)	11034038	952	953	O
.	11034038	954	955	O

Overcorrection	11034038	956	970	B-Outcome
of	11034038	971	973	I-Outcome
anticoagulation	11034038	974	989	I-Outcome
was	11034038	990	993	O
significantly	11034038	994	1007	B-Observation
more	11034038	1008	1012	I-Observation
common	11034038	1013	1019	I-Observation
in	11034038	1020	1022	O
patients	11034038	1023	1031	O
receiving	11034038	1032	1041	O
phytonadione	11034038	1042	1054	B-Intervention
.	11034038	1055	1056	O

Overt	11034038	1057	1062	B-Outcome
warfarin	11034038	1063	1071	I-Outcome
resistance	11034038	1072	1082	I-Outcome
was	11034038	1083	1086	O
not	11034038	1087	1090	O
observed	11034038	1091	1099	O
in	11034038	1100	1102	O
either	11034038	1103	1109	B-Intervention
group	11034038	1110	1115	I-Intervention
after	11034038	1116	1121	O
reinitiating	11034038	1122	1134	O
warfarin	11034038	1135	1143	O
therapy	11034038	1144	1151	O
.	11034038	1152	1153	O

No	11034038	1154	1156	B-Count
major	11034038	1157	1162	B-Outcome
bleeding	11034038	1163	1171	I-Outcome
or	11034038	1172	1174	O
thromboembolic	11034038	1175	1189	B-Outcome
complications	11034038	1190	1203	I-Outcome
occurred	11034038	1204	1212	O
,	11034038	1213	1214	O
and	11034038	1215	1218	O
minor	11034038	1219	1224	B-Outcome
bleeding	11034038	1225	1233	I-Outcome
episodes	11034038	1234	1242	I-Outcome
were	11034038	1243	1247	O
similar	11034038	1248	1255	B-Observation
in	11034038	1256	1258	O
both	11034038	1259	1263	B-Intervention
groups	11034038	1264	1270	I-Intervention
.	11034038	1271	1272	O

CONCLUSION	11034038	1273	1283	O
The	11034038	1284	1287	O
addition	11034038	1288	1296	B-Intervention
of	11034038	1297	1299	I-Intervention
oral	11034038	1300	1304	I-Intervention
phytonadione	11034038	1305	1317	I-Intervention
2.5	11034038	1318	1321	O
mg	11034038	1322	1324	O
reduced	11034038	1325	1332	B-Observation
the	11034038	1333	1336	O
time	11034038	1337	1341	B-Outcome
to	11034038	1342	1344	I-Outcome
achieve	11034038	1345	1352	I-Outcome
an	11034038	1353	1355	I-Outcome
INR	11034038	1356	1359	I-Outcome
of	11034038	1360	1362	I-Outcome
4.0	11034038	1363	1366	I-Outcome
by	11034038	1367	1369	O
approximately	11034038	1370	1383	O
1	11034038	1384	1385	B-Observation
day	11034038	1386	1389	I-Observation
compared	11034038	1390	1398	O
with	11034038	1399	1403	O
omitting	11034038	1404	1412	B-Intervention
warfarin	11034038	1413	1421	I-Intervention
therapy	11034038	1422	1429	I-Intervention
alone	11034038	1430	1435	I-Intervention
.	11034038	1436	1437	O

Adverse	11034038	1438	1445	B-Outcome
events	11034038	1446	1452	I-Outcome
did	11034038	1453	1456	O
not	11034038	1457	1460	O
differ	11034038	1461	1467	B-Observation
between	11034038	1468	1475	B-Intervention
the	11034038	1476	1479	I-Intervention
two	11034038	1480	1483	I-Intervention
groups	11034038	1484	1490	I-Intervention
.	11034038	1491	1492	O

Both	11034038	1493	1497	B-Intervention
strategies	11034038	1498	1508	I-Intervention
were	11034038	1509	1513	O
effective	11034038	1514	1523	B-Observation
in	11034038	1524	1526	O
managing	11034038	1527	1535	O
asymptomatic	11034038	1536	1548	B-Participant
patients	11034038	1549	1557	O
with	11034038	1558	1562	O
INRs	11034038	1563	1567	B-Participant
of	11034038	1568	1570	I-Participant
6.0	11034038	1571	1574	I-Participant
-	11034038	1574	1575	I-Participant
10.0	11034038	1575	1579	I-Participant
.	11034038	1580	1581	O

Oral	11034038	1582	1586	B-Intervention
phytonadione	11034038	1587	1599	I-Intervention
may	11034038	1600	1603	O
be	11034038	1604	1606	O
most	11034038	1607	1611	B-Observation
appropriate	11034038	1612	1623	I-Observation
for	11034038	1624	1627	O
patients	11034038	1628	1636	O
at	11034038	1637	1639	O
high	11034038	1640	1644	B-Participant
risk	11034038	1645	1649	I-Participant
for	11034038	1650	1653	I-Participant
bleeding	11034038	1654	1662	I-Participant
in	11034038	1663	1665	O
whom	11034038	1666	1670	O
the	11034038	1671	1674	O
benefit	11034038	1675	1682	O
of	11034038	1683	1685	O
prompt	11034038	1686	1692	O
INR	11034038	1693	1696	O
reduction	11034038	1697	1706	O
would	11034038	1707	1712	O
outweigh	11034038	1713	1721	O
the	11034038	1722	1725	O
thromboembolic	11034038	1726	1740	O
risk	11034038	1741	1745	O
associated	11034038	1746	1756	O
with	11034038	1757	1761	O
INR	11034038	1762	1765	O
overcorrection	11034038	1766	1780	O
.	11034038	1781	1782	O

Depressive	11056245	0	10	B-Outcome
mood	11056245	11	15	I-Outcome
symptoms	11056245	16	24	I-Outcome
associated	11056245	25	35	O
with	11056245	36	40	O
ovarian	11056245	41	48	B-Participant
suppression	11056245	49	60	I-Participant
.	11056245	61	62	O

OBJECTIVE	11056245	63	72	O
To	11056245	73	75	O
determine	11056245	76	85	O
if	11056245	86	88	O
sertraline	11056245	89	99	B-Intervention
is	11056245	100	102	O
helpful	11056245	103	110	O
in	11056245	111	113	O
the	11056245	114	117	O
management	11056245	118	128	O
of	11056245	129	131	O
depressive	11056245	132	142	B-Outcome
symptoms	11056245	143	151	I-Outcome
associated	11056245	152	162	O
with	11056245	163	167	O
ovarian	11056245	168	175	B-Participant
suppression	11056245	176	187	I-Participant
during	11056245	188	194	O
GnRH	11056245	195	199	B-Participant
agonist	11056245	200	207	I-Participant
therapy	11056245	208	215	I-Participant
as	11056245	216	218	O
compared	11056245	219	227	O
with	11056245	228	232	O
a	11056245	233	234	O
placebo-controlled	11056245	235	253	B-Intervention
group	11056245	254	259	O
.	11056245	260	261	O

DESIGN	11056245	262	268	O
Double-blind	11056245	269	281	O
placebo-controlled	11056245	282	300	O
prospective	11056245	301	312	O
study	11056245	313	318	O
design	11056245	319	325	O
.	11056245	326	327	O

SETTING	11056245	328	335	O
An	11056245	336	338	O
obstetrics/gynecological	11056245	339	363	O
office	11056245	364	370	O
specializing	11056245	371	383	O
in	11056245	384	386	O
infertility	11056245	387	398	O
in	11056245	399	401	O
an	11056245	402	404	O
academic	11056245	405	413	O
environment	11056245	414	425	O
.	11056245	426	427	O

PATIENT	11056245	428	435	O
(	11056245	436	437	O
S	11056245	438	439	O
)	11056245	440	441	O
Premenstrual	11056245	442	454	B-Participant
women	11056245	455	460	I-Participant
with	11056245	461	465	O
laparoscopically	11056245	466	482	O
diagnosed	11056245	483	492	O
endometriosis	11056245	493	506	B-Participant
who	11056245	507	510	O
required	11056245	511	519	O
GnRH	11056245	520	524	B-Participant
agonist	11056245	525	532	I-Participant
therapy	11056245	533	540	I-Participant
for	11056245	541	544	O
treatment	11056245	545	554	O
and	11056245	555	558	O
did	11056245	559	562	O
not	11056245	563	566	O
have	11056245	567	571	O
significant	11056245	572	583	O
depressive	11056245	584	594	B-Participant
or	11056245	595	597	I-Participant
premenstrual	11056245	598	610	I-Participant
mood	11056245	611	615	I-Participant
symptoms	11056245	616	624	I-Participant
at	11056245	625	627	O
baseline	11056245	628	636	O
.	11056245	637	638	O

INTERVENTION	11056245	639	651	O
(	11056245	652	653	O
S	11056245	654	655	O
)	11056245	656	657	O
Participants	11056245	658	670	O
were	11056245	671	675	O
randomly	11056245	676	684	O
assigned	11056245	685	693	O
to	11056245	694	696	O
either	11056245	697	703	O
the	11056245	704	707	O
sertraline	11056245	708	718	B-Intervention
treatment	11056245	719	728	O
group	11056245	729	734	O
or	11056245	735	737	O
to	11056245	738	740	O
the	11056245	741	744	O
placebo	11056245	745	752	B-Intervention
group	11056245	753	758	O
for	11056245	759	762	O
the	11056245	763	766	O
3-month	11056245	767	774	O
duration	11056245	775	783	O
of	11056245	784	786	O
the	11056245	787	790	O
GnRH	11056245	791	795	B-Participant
agonist	11056245	796	803	I-Participant
therapy	11056245	804	811	I-Participant
.	11056245	812	813	O

MAIN	11056245	814	818	O
OUTCOME	11056245	819	826	O
MEASURE	11056245	827	834	O
(	11056245	835	836	O
S	11056245	837	838	O
)	11056245	839	840	O
The	11056245	841	844	O
21-item	11056245	845	852	B-Outcome
Hamilton	11056245	853	861	I-Outcome
Rating	11056245	862	868	I-Outcome
Scale	11056245	869	874	I-Outcome
for	11056245	875	878	I-Outcome
Depression	11056245	879	889	I-Outcome
(	11056245	890	891	I-Outcome
HRSD	11056245	892	896	I-Outcome
)	11056245	897	898	I-Outcome
,	11056245	899	900	O
which	11056245	901	906	O
is	11056245	907	909	O
an	11056245	910	912	O
instrument	11056245	913	923	O
designed	11056245	924	932	O
to	11056245	933	935	O
assess	11056245	936	942	O
depressive	11056245	943	953	O
symptomatology	11056245	954	968	O
.	11056245	969	970	O

RESULT	11056245	971	977	O
(	11056245	978	979	O
S	11056245	980	981	O
)	11056245	982	983	O
A	11056245	984	985	O
Hotellings	11056245	986	996	O
T	11056245	997	998	O
(	11056245	999	1000	O
2	11056245	1001	1002	O
)	11056245	1003	1004	O
test	11056245	1005	1009	O
for	11056245	1010	1013	O
repeated	11056245	1014	1022	O
measure	11056245	1023	1030	O
analysis	11056245	1031	1039	O
indicated	11056245	1040	1049	O
a	11056245	1050	1051	O
statistically	11056245	1052	1065	B-Observation
significant	11056245	1066	1077	I-Observation
(	11056245	1078	1079	I-Observation
P	11056245	1080	1081	I-Observation
<	11056245	1082	1083	I-Observation
.05	11056245	1084	1087	I-Observation
)	11056245	1088	1089	I-Observation
between-group	11056245	1090	1103	I-Observation
difference	11056245	1104	1114	I-Observation
across	11056245	1115	1121	I-Observation
time	11056245	1122	1126	I-Observation
for	11056245	1127	1130	O
the	11056245	1131	1134	O
HRSD	11056245	1135	1139	B-Outcome
(	11056245	1140	1141	O
T	11056245	1142	1143	O
(	11056245	1144	1145	O
2	11056245	1146	1147	O
)	11056245	1148	1149	O
=	11056245	1150	1151	O
13.3	11056245	1152	1156	O
;	11056245	1157	1158	O
F	11056245	1159	1160	O
[	11056245	1161	1162	O
3	11056245	1163	1164	O
,	11056245	1165	1166	O
28	11056245	1167	1169	O
]	11056245	1170	1171	O
=	11056245	1172	1173	O
4.1	11056245	1174	1177	O
;	11056245	1178	1179	O
P=.02	11056245	1180	1185	O
)	11056245	1186	1187	O
with	11056245	1188	1192	O
the	11056245	1193	1196	O
sertraline	11056245	1197	1207	B-Intervention
treatment	11056245	1208	1217	O
group	11056245	1218	1223	O
manifesting	11056245	1224	1235	O
significantly	11056245	1236	1249	B-Observation
fewer	11056245	1250	1255	I-Observation
depressive	11056245	1256	1266	B-Outcome
symptoms	11056245	1267	1275	I-Outcome
than	11056245	1276	1280	O
the	11056245	1281	1284	O
control	11056245	1285	1292	B-Intervention
group	11056245	1293	1298	O
.	11056245	1299	1300	O

CONCLUSION	11056245	1301	1311	O
(	11056245	1312	1313	O
S	11056245	1314	1315	O
)	11056245	1316	1317	O
The	11056245	1318	1321	O
results	11056245	1322	1329	O
indicate	11056245	1330	1338	O
that	11056245	1339	1343	O
sertraline	11056245	1344	1354	B-Intervention
is	11056245	1355	1357	O
an	11056245	1358	1360	O
effective	11056245	1361	1370	B-Observation
option	11056245	1371	1377	O
in	11056245	1378	1380	O
the	11056245	1381	1384	O
management	11056245	1385	1395	O
of	11056245	1396	1398	O
depressive	11056245	1399	1409	B-Outcome
mood	11056245	1410	1414	I-Outcome
symptoms	11056245	1415	1423	I-Outcome
associated	11056245	1424	1434	O
with	11056245	1435	1439	O
ovarian	11056245	1440	1447	B-Participant
suppression	11056245	1448	1459	I-Participant
during	11056245	1460	1466	O
GnRH	11056245	1467	1471	B-Participant
agonist	11056245	1472	1479	I-Participant
therapy	11056245	1480	1487	I-Participant
.	11056245	1488	1489	O

Comparison	11064610	0	10	O
of	11064610	11	13	O
alfentanil	11064610	14	24	B-Intervention
,	11064610	25	26	O
fentanyl	11064610	27	35	B-Intervention
and	11064610	36	39	O
sufentanil	11064610	40	50	B-Intervention
for	11064610	51	54	O
total	11064610	55	60	B-Participant
intravenous	11064610	61	72	I-Participant
anaesthesia	11064610	73	84	I-Participant
with	11064610	85	89	O
propofol	11064610	90	98	B-Intervention
in	11064610	99	101	O
patients	11064610	102	110	O
undergoing	11064610	111	121	O
coronary	11064610	122	130	B-Participant
artery	11064610	131	137	I-Participant
bypass	11064610	138	144	I-Participant
surgery	11064610	145	152	I-Participant
.	11064610	153	154	O

We	11064610	155	157	O
have	11064610	158	162	O
studied	11064610	163	170	O
the	11064610	171	174	O
pharmacokinetics	11064610	175	191	B-Outcome
and	11064610	192	195	O
pharmacodynamics	11064610	196	212	B-Outcome
of	11064610	213	215	O
alfentanil	11064610	216	226	B-Intervention
,	11064610	227	228	O
fentanyl	11064610	229	237	B-Intervention
and	11064610	238	241	O
sufentanil	11064610	242	252	B-Intervention
together	11064610	253	261	O
with	11064610	262	266	O
propofol	11064610	267	275	B-Intervention
in	11064610	276	278	O
patients	11064610	279	287	O
undergoing	11064610	288	298	O
coronary	11064610	299	307	B-Participant
artery	11064610	308	314	I-Participant
bypass	11064610	315	321	I-Participant
graft	11064610	322	327	I-Participant
surgery	11064610	328	335	I-Participant
(	11064610	336	337	I-Participant
CABG	11064610	338	342	I-Participant
)	11064610	343	344	I-Participant
.	11064610	345	346	O

Sixty	11064610	347	352	O
patients	11064610	353	361	O
(	11064610	362	363	O
age	11064610	364	367	O
40	11064610	368	370	O
-	11064610	370	371	O
73	11064610	371	373	O
yr	11064610	374	376	O
,	11064610	377	378	O
56	11064610	379	381	O
male	11064610	382	386	O
)	11064610	387	388	O
were	11064610	389	393	O
assigned	11064610	394	402	O
randomly	11064610	403	411	O
to	11064610	412	414	O
receive	11064610	415	422	O
alfentanil	11064610	423	433	B-Intervention
,	11064610	434	435	O
fentanyl	11064610	436	444	B-Intervention
or	11064610	445	447	O
sufentanil	11064610	448	458	B-Intervention
and	11064610	459	462	O
propofol	11064610	463	471	B-Intervention
.	11064610	472	473	O

Plasma	11064610	474	480	B-Outcome
concentrations	11064610	481	495	I-Outcome
of	11064610	496	498	O
these	11064610	499	504	O
drugs	11064610	505	510	O
and	11064610	511	514	O
times	11064610	515	520	B-Outcome
for	11064610	521	524	I-Outcome
the	11064610	525	528	I-Outcome
plasma	11064610	529	535	I-Outcome
concentration	11064610	536	549	I-Outcome
to	11064610	550	552	I-Outcome
decrease	11064610	553	561	I-Outcome
by	11064610	562	564	I-Outcome
50	11064610	565	567	I-Outcome
%	11064610	568	569	I-Outcome
(	11064610	570	571	I-Outcome
t50	11064610	572	575	I-Outcome
)	11064610	576	577	I-Outcome
and	11064610	578	581	I-Outcome
80	11064610	582	584	I-Outcome
%	11064610	585	586	I-Outcome
(	11064610	587	588	I-Outcome
t80	11064610	589	592	I-Outcome
)	11064610	593	594	I-Outcome
after	11064610	595	600	I-Outcome
cessation	11064610	601	610	I-Outcome
of	11064610	611	613	I-Outcome
the	11064610	614	617	I-Outcome
infusion	11064610	618	626	I-Outcome
were	11064610	627	631	O
determined	11064610	632	642	O
.	11064610	643	644	O

Times	11064610	645	650	B-Outcome
were	11064610	651	655	I-Outcome
recorded	11064610	656	664	I-Outcome
to	11064610	665	667	I-Outcome
awakening	11064610	668	677	I-Outcome
and	11064610	678	681	I-Outcome
tracheal	11064610	682	690	I-Outcome
extubation	11064610	691	701	I-Outcome
.	11064610	702	703	O

Total	11064610	704	709	B-Outcome
dose	11064610	710	714	I-Outcome
and	11064610	715	718	I-Outcome
plasma	11064610	719	725	I-Outcome
concentrations	11064610	726	740	I-Outcome
of	11064610	741	743	I-Outcome
propofol	11064610	744	752	I-Outcome
were	11064610	753	757	O
similar	11064610	758	765	B-Observation
in	11064610	766	768	O
all	11064610	769	772	B-Intervention
groups	11064610	773	779	I-Intervention
.	11064610	780	781	O

Mean	11064610	782	786	B-Outcome
total	11064610	787	792	I-Outcome
doses	11064610	793	798	I-Outcome
of	11064610	799	801	O
alfentanil	11064610	802	812	B-Intervention
,	11064610	813	814	O
fentanyl	11064610	815	823	B-Intervention
and	11064610	824	827	O
sufentanil	11064610	828	838	B-Intervention
were	11064610	839	843	O
443	11064610	844	847	B-Observation
,	11064610	848	849	O
45	11064610	850	852	B-Observation
and	11064610	853	856	O
4.4	11064610	857	860	B-Observation
micrograms	11064610	861	871	I-Observation
kg-1	11064610	872	876	I-Observation
,	11064610	877	878	O
respectively	11064610	879	891	O
.	11064610	892	893	O

Time	11064610	894	898	B-Outcome
to	11064610	899	901	I-Outcome
awakening	11064610	902	911	I-Outcome
did	11064610	912	915	O
not	11064610	916	919	O
differ	11064610	920	926	B-Observation
significantly	11064610	927	940	I-Observation
.	11064610	941	942	O

In	11064610	943	945	O
patients	11064610	946	954	O
receiving	11064610	955	964	O
fentanyl	11064610	965	973	B-Intervention
,	11064610	974	975	O
the	11064610	976	979	O
trachea	11064610	980	987	B-Outcome
was	11064610	988	991	I-Outcome
extubated	11064610	992	1001	I-Outcome
on	11064610	1002	1004	I-Outcome
average	11064610	1005	1012	I-Outcome
2	11064610	1013	1014	B-Observation
h	11064610	1015	1016	I-Observation
later	11064610	1017	1022	I-Observation
than	11064610	1023	1027	O
in	11064610	1028	1030	O
those	11064610	1031	1036	O
receiving	11064610	1037	1046	O
sufentanil	11064610	1047	1057	B-Intervention
and	11064610	1058	1061	O
3	11064610	1062	1063	B-Observation
h	11064610	1064	1065	I-Observation
later	11064610	1066	1071	I-Observation
than	11064610	1072	1076	O
in	11064610	1077	1079	O
those	11064610	1080	1085	O
receiving	11064610	1086	1095	O
alfentanil	11064610	1096	1106	B-Intervention
(	11064610	1107	1108	O
P	11064610	1109	1110	O
<	11064610	1111	1112	O
0.05	11064610	1113	1117	O
)	11064610	1118	1119	O
.	11064610	1120	1121	O

The	11064610	1122	1125	O
t80	11064610	1126	1129	B-Outcome
of	11064610	1130	1132	O
fentanyl	11064610	1133	1141	B-Intervention
was	11064610	1142	1145	O
longer	11064610	1146	1152	B-Observation
(	11064610	1153	1154	O
P	11064610	1155	1156	O
<	11064610	1157	1158	O
0.05	11064610	1159	1163	O
)	11064610	1164	1165	O
than	11064610	1166	1170	O
that	11064610	1171	1175	O
of	11064610	1176	1178	O
alfentanil	11064610	1179	1189	B-Intervention
or	11064610	1190	1192	O
sufentanil	11064610	1193	1203	B-Intervention
,	11064610	1204	1205	O
and	11064610	1206	1209	O
there	11064610	1210	1215	O
was	11064610	1216	1219	O
a	11064610	1220	1221	O
linear	11064610	1222	1228	B-Observation
correlation	11064610	1229	1240	I-Observation
between	11064610	1241	1248	O
the	11064610	1249	1252	O
t80	11064610	1253	1256	B-Outcome
of	11064610	1257	1259	O
the	11064610	1260	1263	O
opioid	11064610	1264	1270	B-Intervention
and	11064610	1271	1274	O
the	11064610	1275	1278	O
time	11064610	1279	1283	B-Outcome
to	11064610	1284	1286	I-Outcome
tracheal	11064610	1287	1295	I-Outcome
extubation	11064610	1296	1306	I-Outcome
(	11064610	1307	1308	O
r	11064610	1309	1310	O
=	11064610	1311	1312	O
0.51	11064610	1313	1317	O
;	11064610	1318	1319	O
P	11064610	1320	1321	O
<	11064610	1322	1323	O
0.01	11064610	1324	1328	O
)	11064610	1329	1330	O
.	11064610	1331	1332	O

However	11064610	1333	1340	O
,	11064610	1341	1342	O
the	11064610	1343	1346	O
t50	11064610	1347	1350	B-Outcome
values	11064610	1351	1357	I-Outcome
for	11064610	1358	1361	O
these	11064610	1362	1367	O
opioids	11064610	1368	1375	B-Intervention
were	11064610	1376	1380	O
similar	11064610	1381	1388	B-Observation
and	11064610	1389	1392	O
did	11064610	1393	1396	O
not	11064610	1397	1400	O
correlate	11064610	1401	1410	B-Observation
with	11064610	1411	1415	O
recovery	11064610	1416	1424	B-Outcome
time	11064610	1425	1429	I-Outcome
.	11064610	1430	1431	O

In	11064610	1432	1434	O
conclusion	11064610	1435	1445	O
,	11064610	1446	1447	O
patients	11064610	1448	1456	O
undergoing	11064610	1457	1467	O
CABG	11064610	1468	1472	B-Participant
and	11064610	1473	1476	O
who	11064610	1477	1480	O
were	11064610	1481	1485	O
anaesthetized	11064610	1486	1499	B-Participant
with	11064610	1500	1504	O
fentanyl	11064610	1505	1513	B-Intervention
and	11064610	1514	1517	I-Intervention
propofol	11064610	1518	1526	I-Intervention
needed	11064610	1527	1533	O
mechanical	11064610	1534	1544	B-Outcome
ventilatory	11064610	1545	1556	I-Outcome
support	11064610	1557	1564	I-Outcome
for	11064610	1565	1568	O
a	11064610	1569	1570	O
significantly	11064610	1571	1584	B-Observation
longer	11064610	1585	1591	I-Observation
time	11064610	1592	1596	I-Observation
than	11064610	1597	1601	O
those	11064610	1602	1607	O
receiving	11064610	1608	1617	O
alfentanil	11064610	1618	1628	B-Intervention
or	11064610	1629	1631	I-Intervention
sufentanil	11064610	1632	1642	I-Intervention
and	11064610	1643	1646	I-Intervention
propofol	11064610	1647	1655	I-Intervention
.	11064610	1656	1657	O

On	11064610	1658	1660	O
the	11064610	1661	1664	O
basis	11064610	1665	1670	O
of	11064610	1671	1673	O
the	11064610	1674	1677	O
interindividual	11064610	1678	1693	O
variation	11064610	1694	1703	O
observed	11064610	1704	1712	O
,	11064610	1713	1714	O
the	11064610	1715	1718	O
time	11064610	1719	1723	B-Outcome
to	11064610	1724	1726	I-Outcome
tracheal	11064610	1727	1735	I-Outcome
extubation	11064610	1736	1746	I-Outcome
was	11064610	1747	1750	O
most	11064610	1751	1755	B-Observation
predictable	11064610	1756	1767	I-Observation
in	11064610	1768	1770	O
patients	11064610	1771	1779	O
receiving	11064610	1780	1789	O
alfentanil	11064610	1790	1800	B-Intervention
and	11064610	1801	1804	O
most	11064610	1805	1809	B-Observation
variable	11064610	1810	1818	I-Observation
in	11064610	1819	1821	O
patients	11064610	1822	1830	O
receiving	11064610	1831	1840	O
fentanyl	11064610	1841	1849	B-Intervention
,	11064610	1850	1851	O
a	11064610	1852	1853	O
finding	11064610	1854	1861	O
which	11064610	1862	1867	O
may	11064610	1868	1871	O
be	11064610	1872	1874	O
important	11064610	1875	1884	O
if	11064610	1885	1887	O
the	11064610	1888	1891	O
patients	11064610	1892	1900	O
are	11064610	1901	1904	O
transferred	11064610	1905	1916	O
to	11064610	1917	1919	O
a	11064610	1920	1921	O
step-down	11064610	1922	1931	O
unit	11064610	1932	1936	O
on	11064610	1937	1939	O
the	11064610	1940	1943	O
evening	11064610	1944	1951	O
of	11064610	1952	1954	O
the	11064610	1955	1958	O
operation	11064610	1959	1968	O
.	11064610	1969	1970	O

Probiotics	11069570	0	10	B-Intervention
in	11069570	11	13	O
the	11069570	14	17	O
management	11069570	18	28	O
of	11069570	29	31	O
atopic	11069570	32	38	B-Participant
eczema	11069570	39	45	I-Participant
.	11069570	46	47	O

BACKGROUND	11069570	48	58	O
Over	11069570	59	63	O
the	11069570	64	67	O
last	11069570	68	72	O
two	11069570	73	76	O
decades	11069570	77	84	O
the	11069570	85	88	O
incidence	11069570	89	98	O
of	11069570	99	101	O
allergic	11069570	102	110	O
diseases	11069570	111	119	O
has	11069570	120	123	O
increased	11069570	124	133	O
in	11069570	134	136	O
industrialized	11069570	137	151	O
countries	11069570	152	161	O
,	11069570	162	163	O
and	11069570	164	167	O
consequently	11069570	168	180	O
new	11069570	181	184	O
approaches	11069570	185	195	O
have	11069570	196	200	O
to	11069570	201	203	O
be	11069570	204	206	O
explored	11069570	207	215	O
.	11069570	216	217	O

OBJECTIVE	11069570	218	227	O
The	11069570	228	231	O
potential	11069570	232	241	O
of	11069570	242	244	O
probiotics	11069570	245	255	B-Intervention
to	11069570	256	258	O
control	11069570	259	266	O
allergic	11069570	267	275	B-Participant
inflammation	11069570	276	288	I-Participant
at	11069570	289	291	I-Participant
an	11069570	292	294	I-Participant
early	11069570	295	300	I-Participant
age	11069570	301	304	O
was	11069570	305	308	O
assessed	11069570	309	317	O
in	11069570	318	320	O
a	11069570	321	322	O
randomized	11069570	323	333	O
double-blind	11069570	334	346	O
placebo-controlled	11069570	347	365	O
study	11069570	366	371	O
.	11069570	372	373	O

METHODS	11069570	374	381	O
A	11069570	382	383	O
total	11069570	384	389	O
of	11069570	390	392	O
27	11069570	393	395	O
infants	11069570	396	403	B-Participant
,	11069570	404	405	O
mean	11069570	406	410	O
age	11069570	411	414	O
4.6	11069570	415	418	O
months	11069570	419	425	O
,	11069570	426	427	O
who	11069570	428	431	O
manifested	11069570	432	442	O
atopic	11069570	443	449	B-Participant
eczema	11069570	450	456	I-Participant
during	11069570	457	463	O
exclusive	11069570	464	473	B-Participant
breast-feeding	11069570	474	488	I-Participant
and	11069570	489	492	O
who	11069570	493	496	O
have	11069570	497	501	O
had	11069570	502	505	O
no	11069570	506	508	O
exposure	11069570	509	517	B-Participant
to	11069570	518	520	I-Participant
any	11069570	521	524	I-Participant
infant	11069570	525	531	I-Participant
or	11069570	532	534	I-Participant
substitute	11069570	535	545	I-Participant
formula	11069570	546	553	I-Participant
were	11069570	554	558	O
weaned	11069570	559	565	O
to	11069570	566	568	O
probiotic-supplemented	11069570	569	591	O
,	11069570	592	593	O
Bifidobacterium	11069570	594	609	B-Intervention
lactis	11069570	610	616	I-Intervention
Bb-12	11069570	617	622	I-Intervention
or	11069570	623	625	O
Lactobacillus	11069570	626	639	B-Intervention
strain	11069570	640	646	I-Intervention
GG	11069570	647	649	I-Intervention
(	11069570	650	651	I-Intervention
ATCC	11069570	652	656	I-Intervention
53103	11069570	657	662	I-Intervention
)	11069570	663	664	I-Intervention
,	11069570	665	666	O
extensively	11069570	667	678	O
hydrolysed	11069570	679	689	O
whey	11069570	690	694	O
formulas	11069570	695	703	O
or	11069570	704	706	O
to	11069570	707	709	O
the	11069570	710	713	O
same	11069570	714	718	B-Intervention
formula	11069570	719	726	I-Intervention
without	11069570	727	734	I-Intervention
probiotics	11069570	735	745	I-Intervention
.	11069570	746	747	O

The	11069570	748	751	O
extent	11069570	752	758	B-Outcome
and	11069570	759	762	I-Outcome
severity	11069570	763	771	I-Outcome
of	11069570	772	774	I-Outcome
atopic	11069570	775	781	I-Outcome
eczema	11069570	782	788	I-Outcome
,	11069570	789	790	O
the	11069570	791	794	O
growth	11069570	795	801	B-Outcome
and	11069570	802	805	I-Outcome
nutrition	11069570	806	815	I-Outcome
of	11069570	816	818	I-Outcome
infants	11069570	819	826	I-Outcome
,	11069570	827	828	O
and	11069570	829	832	O
concentrations	11069570	833	847	B-Outcome
of	11069570	848	850	I-Outcome
circulating	11069570	851	862	I-Outcome
cytokines/chemokines	11069570	863	883	I-Outcome
and	11069570	884	887	I-Outcome
soluble	11069570	888	895	I-Outcome
cell	11069570	896	900	I-Outcome
surface	11069570	901	908	I-Outcome
adhesion	11069570	909	917	I-Outcome
molecules	11069570	918	927	I-Outcome
in	11069570	928	930	I-Outcome
serum	11069570	931	936	I-Outcome
and	11069570	937	940	O
methyl-histamine	11069570	941	957	B-Outcome
and	11069570	958	961	I-Outcome
eosinophilic	11069570	962	974	I-Outcome
protein	11069570	975	982	I-Outcome
X	11069570	983	984	I-Outcome
in	11069570	985	987	I-Outcome
urine	11069570	988	993	I-Outcome
were	11069570	994	998	O
determined	11069570	999	1009	O
.	11069570	1010	1011	O

RESULTS	11069570	1012	1019	O
The	11069570	1020	1023	O
SCORAD	11069570	1024	1030	B-Outcome
score	11069570	1031	1036	I-Outcome
reflecting	11069570	1037	1047	O
the	11069570	1048	1051	O
extent	11069570	1052	1058	B-Outcome
and	11069570	1059	1062	I-Outcome
severity	11069570	1063	1071	I-Outcome
of	11069570	1072	1074	I-Outcome
atopic	11069570	1075	1081	I-Outcome
eczema	11069570	1082	1088	I-Outcome
was	11069570	1089	1092	O
16	11069570	1093	1095	B-Observation
(	11069570	1096	1097	I-Observation
7	11069570	1098	1099	I-Observation
-	11069570	1099	1100	I-Observation
25	11069570	1100	1102	I-Observation
)	11069570	1103	1104	I-Observation
during	11069570	1105	1111	O
breast-feeding	11069570	1112	1126	O
,	11069570	1127	1128	O
median	11069570	1129	1135	O
(	11069570	1136	1137	O
interquartile	11069570	1138	1151	O
range	11069570	1152	1157	O
)	11069570	1158	1159	O
.	11069570	1160	1161	O

After	11069570	1162	1167	O
2	11069570	1168	1169	O
months	11069570	1170	1176	O
,	11069570	1177	1178	O
a	11069570	1179	1180	O
significant	11069570	1181	1192	B-Observation
improvement	11069570	1193	1204	I-Observation
in	11069570	1205	1207	O
skin	11069570	1208	1212	B-Outcome
condition	11069570	1213	1222	I-Outcome
occurred	11069570	1223	1231	O
in	11069570	1232	1234	O
patients	11069570	1235	1243	O
given	11069570	1244	1249	O
probiotic-supplemented	11069570	1250	1272	B-Intervention
formulas	11069570	1273	1281	I-Intervention
,	11069570	1282	1283	O
as	11069570	1284	1286	O
compared	11069570	1287	1295	O
to	11069570	1296	1298	O
the	11069570	1299	1302	O
unsupplemented	11069570	1303	1317	B-Intervention
group	11069570	1318	1323	O
;	11069570	1324	1325	O
chi	11069570	1326	1329	O
(	11069570	1330	1331	O
2	11069570	1332	1333	O
)	11069570	1334	1335	O
=	11069570	1336	1337	O
12.27	11069570	1338	1343	O
,	11069570	1344	1345	O
P	11069570	1346	1347	O
=	11069570	1348	1349	O
0.002	11069570	1350	1355	O
.	11069570	1356	1357	O

SCORAD	11069570	1358	1364	B-Outcome
decreased	11069570	1365	1374	B-Observation
in	11069570	1375	1377	O
the	11069570	1378	1381	O
Bifidobacterium	11069570	1382	1397	B-Intervention
lactis	11069570	1398	1404	I-Intervention
Bb-12	11069570	1405	1410	I-Intervention
group	11069570	1411	1416	O
to	11069570	1417	1419	O
0	11069570	1420	1421	B-Observation
(	11069570	1422	1423	I-Observation
0	11069570	1424	1425	I-Observation
-	11069570	1425	1426	I-Observation
3.8	11069570	1426	1429	I-Observation
)	11069570	1430	1431	I-Observation
,	11069570	1432	1433	O
and	11069570	1434	1437	O
in	11069570	1438	1440	O
the	11069570	1441	1444	O
Lactobacillus	11069570	1445	1458	B-Intervention
GG	11069570	1459	1461	I-Intervention
group	11069570	1462	1467	O
to	11069570	1468	1470	O
1	11069570	1471	1472	B-Observation
(	11069570	1473	1474	I-Observation
0.1	11069570	1475	1478	I-Observation
-	11069570	1478	1479	I-Observation
8.7	11069570	1479	1482	I-Observation
)	11069570	1483	1484	I-Observation
,	11069570	1485	1486	O
vs	11069570	1487	1489	O
unsupplemented	11069570	1490	1504	B-Intervention
13.4	11069570	1505	1509	B-Observation
(	11069570	1510	1511	I-Observation
4.5	11069570	1512	1515	I-Observation
-	11069570	1515	1516	I-Observation
18.2	11069570	1516	1520	I-Observation
)	11069570	1521	1522	I-Observation
,	11069570	1523	1524	O
median	11069570	1525	1531	O
(	11069570	1532	1533	O
interquartile	11069570	1534	1547	O
range	11069570	1548	1553	O
)	11069570	1554	1555	O
,	11069570	1556	1557	O
in	11069570	1558	1560	O
parallel	11069570	1561	1569	O
with	11069570	1570	1574	O
a	11069570	1575	1576	O
reduction	11069570	1577	1586	B-Observation
in	11069570	1587	1589	O
the	11069570	1590	1593	O
concentration	11069570	1594	1607	B-Outcome
of	11069570	1608	1610	I-Outcome
soluble	11069570	1611	1618	I-Outcome
CD4	11069570	1619	1622	I-Outcome
in	11069570	1623	1625	I-Outcome
serum	11069570	1626	1631	I-Outcome
and	11069570	1632	1635	I-Outcome
eosinophilic	11069570	1636	1648	I-Outcome
protein	11069570	1649	1656	I-Outcome
X	11069570	1657	1658	I-Outcome
in	11069570	1659	1661	I-Outcome
urine	11069570	1662	1667	I-Outcome
.	11069570	1668	1669	O

CONCLUSION	11069570	1670	1680	O
The	11069570	1681	1684	O
results	11069570	1685	1692	O
provide	11069570	1693	1700	O
the	11069570	1701	1704	O
first	11069570	1705	1710	O
clinical	11069570	1711	1719	O
demonstration	11069570	1720	1733	O
of	11069570	1734	1736	O
specific	11069570	1737	1745	B-Intervention
probiotic	11069570	1746	1755	I-Intervention
strains	11069570	1756	1763	I-Intervention
modifying	11069570	1764	1773	B-Observation
the	11069570	1774	1777	O
changes	11069570	1778	1785	B-Outcome
related	11069570	1786	1793	I-Outcome
to	11069570	1794	1796	I-Outcome
allergic	11069570	1797	1805	I-Outcome
inflammation	11069570	1806	1818	I-Outcome
.	11069570	1819	1820	O

The	11069570	1821	1824	O
data	11069570	1825	1829	O
further	11069570	1830	1837	O
indicate	11069570	1838	1846	O
that	11069570	1847	1851	O
probiotics	11069570	1852	1862	B-Intervention
may	11069570	1863	1866	O
counteract	11069570	1867	1877	B-Observation
inflammatory	11069570	1878	1890	B-Outcome
responses	11069570	1891	1900	I-Outcome
beyond	11069570	1901	1907	I-Outcome
the	11069570	1908	1911	I-Outcome
intestinal	11069570	1912	1922	I-Outcome
milieu	11069570	1923	1929	I-Outcome
.	11069570	1930	1931	O

The	11069570	1932	1935	O
combined	11069570	1936	1944	O
effects	11069570	1945	1952	O
of	11069570	1953	1955	O
these	11069570	1956	1961	O
probiotic	11069570	1962	1971	O
strains	11069570	1972	1979	O
will	11069570	1980	1984	O
guide	11069570	1985	1990	O
infants	11069570	1991	1998	O
through	11069570	1999	2006	O
the	11069570	2007	2010	O
weaning	11069570	2011	2018	O
period	11069570	2019	2025	O
,	11069570	2026	2027	O
when	11069570	2028	2032	O
sensitization	11069570	2033	2046	O
to	11069570	2047	2049	O
newly	11069570	2050	2055	O
encountered	11069570	2056	2067	O
antigens	11069570	2068	2076	O
is	11069570	2077	2079	O
initiated	11069570	2080	2089	O
.	11069570	2090	2091	O

The	11069570	2092	2095	O
probiotic	11069570	2096	2105	O
approach	11069570	2106	2114	O
may	11069570	2115	2118	O
thus	11069570	2119	2123	O
offer	11069570	2124	2129	O
a	11069570	2130	2131	O
new	11069570	2132	2135	O
direction	11069570	2136	2145	O
in	11069570	2146	2148	O
the	11069570	2149	2152	O
search	11069570	2153	2159	O
for	11069570	2160	2163	O
future	11069570	2164	2170	O
foods	11069570	2171	2176	O
for	11069570	2177	2180	O
allergy	11069570	2181	2188	O
treatment	11069570	2189	2198	O
and	11069570	2199	2202	O
prevention	11069570	2203	2213	O
strategies	11069570	2214	2224	O
.	11069570	2225	2226	O

Calcium	11073017	0	7	B-Intervention
and	11073017	8	11	O
fibre	11073017	12	17	B-Intervention
supplementation	11073017	18	33	I-Intervention
in	11073017	34	36	O
prevention	11073017	37	47	O
of	11073017	48	50	O
colorectal	11073017	51	61	B-Outcome
adenoma	11073017	62	69	I-Outcome
recurrence	11073017	70	80	I-Outcome
:	11073017	81	82	O
a	11073017	83	84	O
randomised	11073017	85	95	O
intervention	11073017	96	108	O
trial	11073017	109	114	O
.	11073017	115	116	O

European	11073017	117	125	O
Cancer	11073017	126	132	O
Prevention	11073017	133	143	O
Organisation	11073017	144	156	O
Study	11073017	157	162	O
Group	11073017	163	168	O
.	11073017	169	170	O

BACKGROUND	11073017	171	181	O
Some	11073017	182	186	O
epidemiological	11073017	187	202	O
studies	11073017	203	210	O
have	11073017	211	215	O
suggested	11073017	216	225	O
that	11073017	226	230	O
high	11073017	231	235	O
dietary	11073017	236	243	O
intake	11073017	244	250	O
of	11073017	251	253	O
calcium	11073017	254	261	O
and	11073017	262	265	O
fibre	11073017	266	271	O
reduces	11073017	272	279	O
colorectal	11073017	280	290	O
carcinogenesis	11073017	291	305	O
.	11073017	306	307	O

Available	11073017	308	317	O
data	11073017	318	322	O
are	11073017	323	326	O
not	11073017	327	330	O
sufficient	11073017	331	341	O
to	11073017	342	344	O
serve	11073017	345	350	O
as	11073017	351	353	O
a	11073017	354	355	O
basis	11073017	356	361	O
for	11073017	362	365	O
firm	11073017	366	370	O
dietary	11073017	371	378	O
advice	11073017	379	385	O
.	11073017	386	387	O

We	11073017	388	390	O
undertook	11073017	391	400	O
a	11073017	401	402	O
multicentre	11073017	403	414	O
randomised	11073017	415	425	O
trial	11073017	426	431	O
to	11073017	432	434	O
test	11073017	435	439	O
the	11073017	440	443	O
effect	11073017	444	450	O
of	11073017	451	453	O
diet	11073017	454	458	B-Intervention
supplementation	11073017	459	474	I-Intervention
with	11073017	475	479	I-Intervention
calcium	11073017	480	487	I-Intervention
and	11073017	488	491	I-Intervention
fibre	11073017	492	497	I-Intervention
on	11073017	498	500	O
adenoma	11073017	501	508	B-Outcome
recurrence	11073017	509	519	I-Outcome
.	11073017	520	521	O

METHODS	11073017	522	529	O
We	11073017	530	532	O
randomly	11073017	533	541	O
assigned	11073017	542	550	O
665	11073017	551	554	O
patients	11073017	555	563	O
with	11073017	564	568	O
a	11073017	569	570	O
history	11073017	571	578	O
of	11073017	579	581	O
colorectal	11073017	582	592	B-Participant
adenomas	11073017	593	601	I-Participant
to	11073017	602	604	O
three	11073017	605	610	O
treatment	11073017	611	620	O
groups	11073017	621	627	O
,	11073017	628	629	O
in	11073017	630	632	O
a	11073017	633	634	O
parallel	11073017	635	643	O
design	11073017	644	650	O
:	11073017	651	652	O
calcium	11073017	653	660	B-Intervention
gluconolactate	11073017	661	675	I-Intervention
and	11073017	676	679	I-Intervention
carbonate	11073017	680	689	I-Intervention
(	11073017	690	691	O
2	11073017	692	693	O
g	11073017	694	695	O
elemental	11073017	696	705	O
calcium	11073017	706	713	O
daily	11073017	714	719	O
)	11073017	720	721	O
,	11073017	722	723	O
fibre	11073017	724	729	B-Intervention
(	11073017	730	731	O
3.5	11073017	732	735	O
g	11073017	736	737	O
ispaghula	11073017	738	747	O
husk	11073017	748	752	O
)	11073017	753	754	O
,	11073017	755	756	O
or	11073017	757	759	O
placebo	11073017	760	767	B-Intervention
.	11073017	768	769	O

Participants	11073017	770	782	O
had	11073017	783	786	O
colonoscopy	11073017	787	798	O
after	11073017	799	804	O
3	11073017	805	806	O
years	11073017	807	812	O
of	11073017	813	815	O
follow-up	11073017	816	825	O
.	11073017	826	827	O

The	11073017	828	831	O
primary	11073017	832	839	O
endpoint	11073017	840	848	O
was	11073017	849	852	O
adenoma	11073017	853	860	B-Outcome
recurrence	11073017	861	871	I-Outcome
.	11073017	872	873	O

Analyses	11073017	874	882	O
were	11073017	883	887	O
by	11073017	888	890	O
intention	11073017	891	900	O
to	11073017	901	903	O
treat	11073017	904	909	O
.	11073017	910	911	O

FINDINGS	11073017	912	920	O
23	11073017	921	923	O
patients	11073017	924	932	O
died	11073017	933	937	O
,	11073017	938	939	O
15	11073017	940	942	O
were	11073017	943	947	O
lost	11073017	948	952	O
to	11073017	953	955	O
follow-up	11073017	956	965	O
,	11073017	966	967	O
45	11073017	968	970	O
refused	11073017	971	978	O
repeat	11073017	979	985	O
colonoscopy	11073017	986	997	O
,	11073017	998	999	O
and	11073017	1000	1003	O
five	11073017	1004	1008	O
developed	11073017	1009	1018	O
severe	11073017	1019	1025	O
contraindications	11073017	1026	1043	O
to	11073017	1044	1046	O
colonoscopy	11073017	1047	1058	O
.	11073017	1059	1060	O

Among	11073017	1061	1066	O
the	11073017	1067	1070	O
552	11073017	1071	1074	O
participants	11073017	1075	1087	O
who	11073017	1088	1091	O
completed	11073017	1092	1101	O
the	11073017	1102	1105	O
follow-up	11073017	1106	1115	O
examination	11073017	1116	1127	O
,	11073017	1128	1129	O
94	11073017	1130	1132	O
stopped	11073017	1133	1140	O
treatment	11073017	1141	1150	O
early	11073017	1151	1156	O
.	11073017	1157	1158	O

At	11073017	1159	1161	B-Outcome
least	11073017	1162	1167	I-Outcome
one	11073017	1168	1171	I-Outcome
adenoma	11073017	1172	1179	I-Outcome
developed	11073017	1180	1189	O
in	11073017	1190	1192	O
28	11073017	1193	1195	B-Count
(	11073017	1196	1197	I-Count
15.9	11073017	1198	1202	I-Count
%	11073017	1203	1204	I-Count
)	11073017	1205	1206	I-Count
of	11073017	1207	1209	I-Count
176	11073017	1210	1213	I-Count
patients	11073017	1214	1222	I-Count
in	11073017	1223	1225	O
the	11073017	1226	1229	O
calcium	11073017	1230	1237	B-Intervention
group	11073017	1238	1243	O
,	11073017	1244	1245	O
58	11073017	1246	1248	B-Count
(	11073017	1249	1250	I-Count
29.3	11073017	1251	1255	I-Count
%	11073017	1256	1257	I-Count
)	11073017	1258	1259	I-Count
of	11073017	1260	1262	I-Count
198	11073017	1263	1266	I-Count
in	11073017	1267	1269	O
the	11073017	1270	1273	O
fibre	11073017	1274	1279	B-Intervention
group	11073017	1280	1285	O
,	11073017	1286	1287	O
and	11073017	1288	1291	O
36	11073017	1292	1294	B-Count
(	11073017	1295	1296	I-Count
20.2	11073017	1297	1301	I-Count
%	11073017	1302	1303	I-Count
)	11073017	1304	1305	I-Count
of	11073017	1306	1308	I-Count
178	11073017	1309	1312	I-Count
in	11073017	1313	1315	O
the	11073017	1316	1319	O
placebo	11073017	1320	1327	B-Intervention
group	11073017	1328	1333	O
.	11073017	1334	1335	O

The	11073017	1336	1339	O
adjusted	11073017	1340	1348	B-Outcome
odds	11073017	1349	1353	I-Outcome
ratio	11073017	1354	1359	I-Outcome
for	11073017	1360	1363	I-Outcome
recurrence	11073017	1364	1374	I-Outcome
was	11073017	1375	1378	O
0.66	11073017	1379	1383	B-Observation
(	11073017	1384	1385	O
95	11073017	1386	1388	O
%	11073017	1389	1390	O
CI	11073017	1391	1393	O
0.38	11073017	1394	1398	O
-	11073017	1398	1399	O
1.17	11073017	1399	1403	O
;	11073017	1404	1405	O
p=0.16	11073017	1406	1412	O
)	11073017	1413	1414	O
for	11073017	1415	1418	O
calcium	11073017	1419	1426	B-Intervention
treatment	11073017	1427	1436	O
and	11073017	1437	1440	O
1.67	11073017	1441	1445	B-Observation
(	11073017	1446	1447	O
1.01	11073017	1448	1452	O
-	11073017	1452	1453	O
2.76	11073017	1453	1457	O
,	11073017	1458	1459	O
p=0.042	11073017	1460	1467	O
)	11073017	1468	1469	O
for	11073017	1470	1473	O
the	11073017	1474	1477	O
fibre	11073017	1478	1483	B-Intervention
treatment	11073017	1484	1493	O
.	11073017	1494	1495	O

The	11073017	1496	1499	O
odds	11073017	1500	1504	B-Outcome
ratio	11073017	1505	1510	I-Outcome
associated	11073017	1511	1521	O
with	11073017	1522	1526	O
the	11073017	1527	1530	O
fibre	11073017	1531	1536	B-Intervention
treatment	11073017	1537	1546	O
was	11073017	1547	1550	O
significantly	11073017	1551	1564	B-Observation
higher	11073017	1565	1571	I-Observation
in	11073017	1572	1574	O
participants	11073017	1575	1587	O
with	11073017	1588	1592	O
baseline	11073017	1593	1601	B-Participant
dietary	11073017	1602	1609	I-Participant
calcium	11073017	1610	1617	I-Participant
intake	11073017	1618	1624	I-Participant
above	11073017	1625	1630	I-Participant
the	11073017	1631	1634	I-Participant
median	11073017	1635	1641	I-Participant
than	11073017	1642	1646	O
in	11073017	1647	1649	O
those	11073017	1650	1655	O
with	11073017	1656	1660	O
intake	11073017	1661	1667	B-Participant
below	11073017	1668	1673	I-Participant
the	11073017	1674	1677	I-Participant
median	11073017	1678	1684	I-Participant
(	11073017	1685	1686	O
interaction	11073017	1687	1698	O
test	11073017	1699	1703	O
,	11073017	1704	1705	O
p=0.028	11073017	1706	1713	O
)	11073017	1714	1715	O
INTERPRETATION	11073017	1716	1730	O
Supplementation	11073017	1731	1746	B-Intervention
with	11073017	1747	1751	I-Intervention
fibre	11073017	1752	1757	I-Intervention
as	11073017	1758	1760	I-Intervention
ispaghula	11073017	1761	1770	I-Intervention
husk	11073017	1771	1775	I-Intervention
may	11073017	1776	1779	O
have	11073017	1780	1784	O
adverse	11073017	1785	1792	B-Observation
effects	11073017	1793	1800	I-Observation
on	11073017	1801	1803	O
colorectal	11073017	1804	1814	B-Outcome
adenoma	11073017	1815	1822	I-Outcome
recurrence	11073017	1823	1833	I-Outcome
,	11073017	1834	1835	O
especially	11073017	1836	1846	O
in	11073017	1847	1849	O
patients	11073017	1850	1858	O
with	11073017	1859	1863	O
high	11073017	1864	1868	B-Participant
dietary	11073017	1869	1876	I-Participant
calcium	11073017	1877	1884	I-Participant
intake	11073017	1885	1891	I-Participant
.	11073017	1892	1893	O

Calcium	11073017	1894	1901	B-Intervention
supplementation	11073017	1902	1917	I-Intervention
was	11073017	1918	1921	O
associated	11073017	1922	1932	O
with	11073017	1933	1937	O
a	11073017	1938	1939	O
modest	11073017	1940	1946	B-Observation
but	11073017	1947	1950	I-Observation
not	11073017	1951	1954	I-Observation
significant	11073017	1955	1966	I-Observation
reduction	11073017	1967	1976	I-Observation
in	11073017	1977	1979	O
the	11073017	1980	1983	O
risk	11073017	1984	1988	B-Outcome
of	11073017	1989	1991	I-Outcome
adenoma	11073017	1992	1999	I-Outcome
recurrence	11073017	2000	2010	I-Outcome
.	11073017	2011	2012	O

Effects	11074150	0	7	O
of	11074150	8	10	O
nicotine	11074150	11	19	B-Intervention
on	11074150	20	22	O
regional	11074150	23	31	B-Outcome
cerebral	11074150	32	40	I-Outcome
glucose	11074150	41	48	I-Outcome
metabolism	11074150	49	59	I-Outcome
in	11074150	60	62	O
awake	11074150	63	68	B-Participant
resting	11074150	69	76	I-Participant
tobacco	11074150	77	84	I-Participant
smokers	11074150	85	92	I-Participant
.	11074150	93	94	O

Eleven	11074150	95	101	O
healthy	11074150	102	109	B-Participant
tobacco	11074150	110	117	B-Participant
smoking	11074150	118	125	I-Participant
adult	11074150	126	131	B-Participant
male	11074150	132	136	B-Participant
volunteers	11074150	137	147	O
of	11074150	148	150	O
mixed	11074150	151	156	B-Participant
race	11074150	157	161	I-Participant
were	11074150	162	166	O
tobacco	11074150	167	174	O
abstinent	11074150	175	184	O
overnight	11074150	185	194	O
for	11074150	195	198	O
this	11074150	199	203	O
study	11074150	204	209	O
.	11074150	210	211	O

In	11074150	212	214	O
each	11074150	215	219	O
subject	11074150	220	227	O
,	11074150	228	229	O
positron	11074150	230	238	B-Outcome
emission	11074150	239	247	I-Outcome
tomographic	11074150	248	259	I-Outcome
images	11074150	260	266	I-Outcome
of	11074150	267	269	I-Outcome
regional	11074150	270	278	I-Outcome
cerebral	11074150	279	287	I-Outcome
metabolism	11074150	288	298	I-Outcome
of	11074150	299	301	I-Outcome
glucose	11074150	302	309	I-Outcome
with	11074150	310	314	I-Outcome
[	11074150	315	316	I-Outcome
18F	11074150	317	320	I-Outcome
]	11074150	321	322	I-Outcome
fluorodeoxyglucose	11074150	323	341	I-Outcome
were	11074150	342	346	O
obtained	11074150	347	355	O
in	11074150	356	358	O
two	11074150	359	362	O
conditions	11074150	363	373	O
in	11074150	374	376	O
the	11074150	377	380	O
morning	11074150	381	388	O
on	11074150	389	391	O
different	11074150	392	401	O
days	11074150	402	406	O
:	11074150	407	408	O
about	11074150	409	414	O
3min	11074150	415	419	O
after	11074150	420	425	O
approximately	11074150	426	439	O
1	11074150	440	441	O
-	11074150	441	442	O
2	11074150	442	443	O
mg	11074150	443	445	O
of	11074150	446	448	O
nasal	11074150	449	454	B-Intervention
nicotine	11074150	455	463	I-Intervention
spray	11074150	464	469	I-Intervention
and	11074150	470	473	O
after	11074150	474	479	O
an	11074150	480	482	O
equivalent	11074150	483	493	O
volume	11074150	494	500	O
of	11074150	501	503	O
an	11074150	504	506	O
active	11074150	507	513	B-Intervention
placebo	11074150	514	521	I-Intervention
spray	11074150	522	527	I-Intervention
of	11074150	528	530	I-Intervention
oleoresin	11074150	531	540	I-Intervention
of	11074150	541	543	I-Intervention
pepper	11074150	544	550	I-Intervention
in	11074150	551	553	O
a	11074150	554	555	O
random	11074150	556	562	O
counterbalanced	11074150	563	578	O
design	11074150	579	585	O
.	11074150	586	587	O

A	11074150	588	589	O
Siemens/CTI	11074150	590	601	O
931/08	11074150	602	608	O
-	11074150	608	609	O
12	11074150	609	611	O
scanner	11074150	612	619	O
with	11074150	620	624	O
the	11074150	625	628	O
capability	11074150	629	639	O
of	11074150	640	642	O
15	11074150	643	645	O
horizontal	11074150	646	656	O
brain	11074150	657	662	O
slices	11074150	663	669	O
was	11074150	670	673	O
used	11074150	674	678	O
.	11074150	679	680	O

The	11074150	681	684	O
images	11074150	685	691	O
were	11074150	692	696	O
further	11074150	697	704	O
converted	11074150	705	714	O
into	11074150	715	719	O
a	11074150	720	721	O
standard	11074150	722	730	O
uniform	11074150	731	738	O
brain	11074150	739	744	O
format	11074150	745	751	O
in	11074150	752	754	O
which	11074150	755	760	O
the	11074150	761	764	O
mean	11074150	765	769	O
data	11074150	770	774	O
of	11074150	775	777	O
all	11074150	778	781	O
11	11074150	782	784	O
subjects	11074150	785	793	O
were	11074150	794	798	O
obtained	11074150	799	807	O
.	11074150	808	809	O

Images	11074150	810	816	O
were	11074150	817	821	O
analysed	11074150	822	830	O
in	11074150	831	833	O
stereotactic	11074150	834	846	O
coordinates	11074150	847	858	O
using	11074150	859	864	O
pixel-wise	11074150	865	875	O
t	11074150	876	877	O
statistics	11074150	878	888	O
and	11074150	889	892	O
a	11074150	893	894	O
smoothed	11074150	895	903	O
Gaussian	11074150	904	912	O
model	11074150	913	918	O
.	11074150	919	920	O

Peak	11074150	921	925	B-Outcome
plasma	11074150	926	932	I-Outcome
nicotine	11074150	933	941	I-Outcome
levels	11074150	942	948	I-Outcome
varied	11074150	949	955	B-Observation
three-fold	11074150	956	966	I-Observation
and	11074150	967	970	O
the	11074150	971	974	O
areas	11074150	975	980	B-Outcome
under	11074150	981	986	I-Outcome
the	11074150	987	990	I-Outcome
curve	11074150	991	996	I-Outcome
(	11074150	997	998	I-Outcome
0	11074150	999	1000	I-Outcome
-	11074150	1000	1001	I-Outcome
30min	11074150	1001	1006	I-Outcome
)	11074150	1007	1008	I-Outcome
varied	11074150	1009	1015	B-Observation
seven-fold	11074150	1016	1026	I-Observation
among	11074150	1027	1032	O
the	11074150	1033	1036	O
individual	11074150	1037	1047	O
subjects	11074150	1048	1056	O
.	11074150	1057	1058	O

Nicotine	11074150	1059	1067	B-Intervention
caused	11074150	1068	1074	O
a	11074150	1075	1076	O
small	11074150	1077	1082	B-Observation
overall	11074150	1083	1090	I-Observation
reduction	11074150	1091	1100	I-Observation
in	11074150	1101	1103	O
global	11074150	1104	1110	B-Outcome
cerebral	11074150	1111	1119	I-Outcome
metabolism	11074150	1120	1130	I-Outcome
of	11074150	1131	1133	I-Outcome
glucose	11074150	1134	1141	I-Outcome
but	11074150	1142	1145	O
,	11074150	1146	1147	O
when	11074150	1148	1152	O
the	11074150	1153	1156	O
data	11074150	1157	1161	O
were	11074150	1162	1166	O
normalized	11074150	1167	1177	O
,	11074150	1178	1179	O
several	11074150	1180	1187	O
brain	11074150	1188	1193	O
regions	11074150	1194	1201	O
showed	11074150	1202	1208	O
relative	11074150	1209	1217	B-Observation
increases	11074150	1218	1227	I-Observation
in	11074150	1228	1230	O
activity	11074150	1231	1239	B-Outcome
.	11074150	1240	1241	O

Cerebral	11074150	1242	1250	O
structures	11074150	1251	1261	O
specifically	11074150	1262	1274	O
activated	11074150	1275	1284	B-Observation
by	11074150	1285	1287	O
nicotine	11074150	1288	1296	B-Intervention
(	11074150	1297	1298	O
nicotine	11074150	1299	1307	O
minus	11074150	1308	1313	O
pepper	11074150	1314	1320	O
,	11074150	1321	1322	O
Z	11074150	1323	1324	O
score	11074150	1325	1330	O
>	11074150	1331	1332	O
4.0	11074150	1333	1336	O
)	11074150	1337	1338	O
included	11074150	1339	1347	O
:	11074150	1348	1349	O
left	11074150	1350	1354	B-Outcome
inferior	11074150	1355	1363	I-Outcome
frontal	11074150	1364	1371	I-Outcome
gyrus	11074150	1372	1377	I-Outcome
,	11074150	1378	1379	O
left	11074150	1380	1384	B-Outcome
posterior	11074150	1385	1394	I-Outcome
cingulate	11074150	1395	1404	I-Outcome
gyrus	11074150	1405	1410	I-Outcome
and	11074150	1411	1414	O
right	11074150	1415	1420	B-Outcome
thalamus	11074150	1421	1429	I-Outcome
.	11074150	1430	1431	O

The	11074150	1432	1435	O
visual	11074150	1436	1442	O
cortex	11074150	1443	1449	O
,	11074150	1450	1451	O
including	11074150	1452	1461	O
the	11074150	1462	1465	O
right	11074150	1466	1471	O
and	11074150	1472	1475	O
left	11074150	1476	1480	O
cuneus	11074150	1481	1487	O
and	11074150	1488	1491	O
left	11074150	1492	1496	O
lateral	11074150	1497	1504	O
occipito-temporal	11074150	1505	1522	O
gyrus	11074150	1523	1528	O
fusiformis	11074150	1529	1539	O
,	11074150	1540	1541	O
also	11074150	1542	1546	O
showed	11074150	1547	1553	O
an	11074150	1554	1556	O
increase	11074150	1557	1565	B-Observation
in	11074150	1566	1568	O
regional	11074150	1569	1577	B-Outcome
cerebral	11074150	1578	1586	I-Outcome
metabolism	11074150	1587	1597	I-Outcome
of	11074150	1598	1600	I-Outcome
glucose	11074150	1601	1608	I-Outcome
with	11074150	1609	1613	O
Z	11074150	1614	1615	O
scores	11074150	1616	1622	O
>	11074150	1623	1624	O
3	11074150	1625	1626	O
.	11074150	1627	1628	O

6	11074150	1629	1630	O
.	11074150	1631	1632	O

Structures	11074150	1633	1643	O
with	11074150	1644	1648	O
a	11074150	1649	1650	O
decrease	11074150	1651	1659	B-Observation
in	11074150	1660	1662	O
regional	11074150	1663	1671	B-Outcome
cerebral	11074150	1672	1680	I-Outcome
metabolism	11074150	1681	1691	I-Outcome
of	11074150	1692	1694	I-Outcome
glucose	11074150	1695	1702	I-Outcome
(	11074150	1703	1704	O
pepper	11074150	1705	1711	O
minus	11074150	1712	1717	O
nicotine	11074150	1718	1726	O
)	11074150	1727	1728	O
were	11074150	1729	1733	O
the	11074150	1734	1737	O
left	11074150	1738	1742	O
insula	11074150	1743	1749	O
and	11074150	1750	1753	O
right	11074150	1754	1759	O
inferior	11074150	1760	1768	O
occipital	11074150	1769	1778	O
gyrus	11074150	1779	1784	O
,	11074150	1785	1786	O
with	11074150	1787	1791	O
Z	11074150	1792	1793	O
scores	11074150	1794	1800	O
>	11074150	1801	1802	O
3.5	11074150	1803	1806	O
.	11074150	1807	1808	O

Especially	11074150	1809	1819	O
important	11074150	1820	1829	O
is	11074150	1830	1832	O
the	11074150	1833	1836	O
fact	11074150	1837	1841	O
that	11074150	1842	1846	O
the	11074150	1847	1850	O
thalamus	11074150	1851	1859	B-Outcome
is	11074150	1860	1862	O
activated	11074150	1863	1872	B-Observation
by	11074150	1873	1875	O
nicotine	11074150	1876	1884	B-Intervention
.	11074150	1885	1886	O

This	11074150	1887	1891	O
is	11074150	1892	1894	O
consistent	11074150	1895	1905	O
with	11074150	1906	1910	O
the	11074150	1911	1914	O
high	11074150	1915	1919	O
density	11074150	1920	1927	O
of	11074150	1928	1930	O
nicotinic	11074150	1931	1940	O
cholinoceptors	11074150	1941	1955	O
in	11074150	1956	1958	O
that	11074150	1959	1963	O
brain	11074150	1964	1969	O
region	11074150	1970	1976	O
.	11074150	1977	1978	O

However	11074150	1979	1986	O
,	11074150	1987	1988	O
not	11074150	1989	1992	O
all	11074150	1993	1996	O
brain	11074150	1997	2002	O
regions	11074150	2003	2010	O
affected	11074150	2011	2019	O
by	11074150	2020	2022	O
nicotine	11074150	2023	2031	O
are	11074150	2032	2035	O
known	11074150	2036	2041	O
to	11074150	2042	2044	O
have	11074150	2045	2049	O
many	11074150	2050	2054	O
nicotinic	11074150	2055	2064	O
cholinoceptors	11074150	2065	2079	O
.	11074150	2080	2081	O

The	11074150	2082	2085	O
results	11074150	2086	2093	O
are	11074150	2094	2097	O
discussed	11074150	2098	2107	O
in	11074150	2108	2110	O
relation	11074150	2111	2119	O
to	11074150	2120	2122	O
the	11074150	2123	2126	O
cognitive	11074150	2127	2136	O
effects	11074150	2137	2144	O
of	11074150	2145	2147	O
nicotine	11074150	2148	2156	O
.	11074150	2157	2158	O

Effect	11077389	0	6	O
of	11077389	7	9	O
systemic	11077389	10	18	B-Intervention
penicillin	11077389	19	29	I-Intervention
on	11077389	30	32	O
pain	11077389	33	37	B-Outcome
in	11077389	38	40	O
untreated	11077389	41	50	B-Participant
irreversible	11077389	51	63	I-Participant
pulpitis	11077389	64	72	I-Participant
.	11077389	73	74	O

OBJECTIVE	11077389	75	84	O
The	11077389	85	88	O
purpose	11077389	89	96	O
of	11077389	97	99	O
this	11077389	100	104	O
prospective	11077389	105	116	O
,	11077389	117	118	O
randomized	11077389	119	129	O
,	11077389	130	131	O
double-blind	11077389	132	144	O
study	11077389	145	150	O
was	11077389	151	154	O
to	11077389	155	157	O
determine	11077389	158	167	O
the	11077389	168	171	O
effect	11077389	172	178	O
of	11077389	179	181	O
penicillin	11077389	182	192	B-Intervention
on	11077389	193	195	O
pain	11077389	196	200	B-Outcome
in	11077389	201	203	O
untreated	11077389	204	213	B-Participant
teeth	11077389	214	219	I-Participant
diagnosed	11077389	220	229	O
with	11077389	230	234	O
irreversible	11077389	235	247	B-Participant
pulpitis	11077389	248	256	I-Participant
.	11077389	257	258	O

STUDY	11077389	259	264	O
DESIGN	11077389	265	271	O
Forty	11077389	272	277	O
emergency	11077389	278	287	B-Participant
patients	11077389	288	296	I-Participant
participated	11077389	297	309	O
,	11077389	310	311	O
and	11077389	312	315	O
each	11077389	316	320	O
had	11077389	321	324	O
a	11077389	325	326	O
clinical	11077389	327	335	O
diagnosis	11077389	336	345	O
of	11077389	346	348	O
an	11077389	349	351	O
irreversible	11077389	352	364	B-Participant
pulpitis	11077389	365	373	I-Participant
.	11077389	374	375	O

Patients	11077389	376	384	O
randomly	11077389	385	393	O
received	11077389	394	402	O
a	11077389	403	404	O
7-day	11077389	405	410	O
oral	11077389	411	415	O
dose	11077389	416	420	O
(	11077389	421	422	O
28	11077389	423	425	O
capsules	11077389	426	434	O
,	11077389	435	436	O
500	11077389	437	440	O
mg	11077389	441	443	O
each	11077389	444	448	O
,	11077389	449	450	O
to	11077389	451	453	O
be	11077389	454	456	O
taken	11077389	457	462	O
every	11077389	463	468	O
6	11077389	469	470	O
hours	11077389	471	476	O
)	11077389	477	478	O
of	11077389	479	481	O
either	11077389	482	488	O
penicillin	11077389	489	499	B-Intervention
or	11077389	500	502	O
a	11077389	503	504	O
placebo	11077389	505	512	B-Intervention
control	11077389	513	520	I-Intervention
in	11077389	521	523	O
a	11077389	524	525	O
double-blind	11077389	526	538	O
manner	11077389	539	545	O
.	11077389	546	547	O

No	11077389	548	550	O
endodontic	11077389	551	561	O
treatment	11077389	562	571	O
was	11077389	572	575	O
performed	11077389	576	585	O
.	11077389	586	587	O

Each	11077389	588	592	O
patient	11077389	593	600	O
also	11077389	601	605	O
received	11077389	606	614	O
ibuprofen	11077389	615	624	B-Intervention
;	11077389	625	626	I-Intervention
acetaminophen	11077389	627	640	I-Intervention
with	11077389	641	645	I-Intervention
codeine	11077389	646	653	I-Intervention
(	11077389	654	655	I-Intervention
30	11077389	656	658	I-Intervention
mg	11077389	659	661	I-Intervention
)	11077389	662	663	I-Intervention
;	11077389	664	665	O
and	11077389	666	669	O
a	11077389	670	671	O
7-day	11077389	672	677	O
diary	11077389	678	683	O
to	11077389	684	686	O
record	11077389	687	693	O
pain	11077389	694	698	B-Outcome
,	11077389	699	700	O
percussion	11077389	701	711	B-Outcome
pain	11077389	712	716	I-Outcome
,	11077389	717	718	O
and	11077389	719	722	O
number	11077389	723	729	B-Outcome
and	11077389	730	733	I-Outcome
type	11077389	734	738	I-Outcome
of	11077389	739	741	I-Outcome
pain	11077389	742	746	I-Outcome
medication	11077389	747	757	I-Outcome
taken	11077389	758	763	I-Outcome
.	11077389	764	765	O

RESULTS	11077389	766	773	O
The	11077389	774	777	O
administration	11077389	778	792	O
of	11077389	793	795	O
penicillin	11077389	796	806	B-Intervention
did	11077389	807	810	O
not	11077389	811	814	O
significantly	11077389	815	828	B-Observation
(	11077389	829	830	I-Observation
P	11077389	831	832	I-Observation
>	11077389	833	834	I-Observation
.05	11077389	835	838	I-Observation
)	11077389	839	840	I-Observation
reduce	11077389	841	847	I-Observation
pain	11077389	848	852	B-Outcome
,	11077389	853	854	O
percussion	11077389	855	865	B-Outcome
pain	11077389	866	870	I-Outcome
,	11077389	871	872	O
or	11077389	873	875	O
the	11077389	876	879	O
number	11077389	880	886	B-Outcome
of	11077389	887	889	I-Outcome
analgesic	11077389	890	899	I-Outcome
medications	11077389	900	911	I-Outcome
taken	11077389	912	917	I-Outcome
by	11077389	918	920	O
patients	11077389	921	929	O
with	11077389	930	934	O
untreated	11077389	935	944	B-Participant
irreversible	11077389	945	957	I-Participant
pulpitis	11077389	958	966	I-Participant
.	11077389	967	968	O

The	11077389	969	972	O
majority	11077389	973	981	B-Count
of	11077389	982	984	I-Count
patients	11077389	985	993	I-Count
with	11077389	994	998	O
untreated	11077389	999	1008	B-Participant
irreversible	11077389	1009	1021	I-Participant
pulpitis	11077389	1022	1030	I-Participant
had	11077389	1031	1034	O
significant	11077389	1035	1046	B-Outcome
pain	11077389	1047	1051	I-Outcome
and	11077389	1052	1055	O
required	11077389	1056	1064	B-Outcome
analgesics	11077389	1065	1075	I-Outcome
to	11077389	1076	1078	O
manage	11077389	1079	1085	O
this	11077389	1086	1090	O
pain	11077389	1091	1095	O
.	11077389	1096	1097	O

CONCLUSION	11077389	1098	1108	O
Penicillin	11077389	1109	1119	B-Intervention
should	11077389	1120	1126	O
not	11077389	1127	1130	O
be	11077389	1131	1133	O
prescribed	11077389	1134	1144	B-Observation
for	11077389	1145	1148	O
untreated	11077389	1149	1158	B-Participant
irreversible	11077389	1159	1171	I-Participant
pulpitis	11077389	1172	1180	I-Participant
because	11077389	1181	1188	O
penicillin	11077389	1189	1199	B-Intervention
is	11077389	1200	1202	O
ineffective	11077389	1203	1214	B-Observation
for	11077389	1215	1218	O
pain	11077389	1219	1223	B-Outcome
relief	11077389	1224	1230	I-Outcome
.	11077389	1231	1232	O

Somatostatin	11100343	0	12	B-Intervention
and	11100343	13	16	O
ranitidine	11100343	17	27	B-Intervention
in	11100343	28	30	O
the	11100343	31	34	O
treatment	11100343	35	44	O
of	11100343	45	47	O
non-variceal	11100343	48	60	B-Participant
upper	11100343	61	66	I-Participant
gastrointestinal	11100343	67	83	I-Participant
bleeding	11100343	84	92	I-Participant
:	11100343	93	94	O
a	11100343	95	96	O
prospective	11100343	97	108	O
,	11100343	109	110	O
randomized	11100343	111	121	O
,	11100343	122	123	O
double-blind	11100343	124	136	O
,	11100343	137	138	O
controlled	11100343	139	149	O
study	11100343	150	155	O
.	11100343	156	157	O

BACKGROUND/AIMS	11100343	158	173	O
The	11100343	174	177	O
aim	11100343	178	181	O
of	11100343	182	184	O
this	11100343	185	189	O
study	11100343	190	195	O
was	11100343	196	199	O
to	11100343	200	202	O
compare	11100343	203	210	O
the	11100343	211	214	O
efficacy	11100343	215	223	O
of	11100343	224	226	O
somatostatin	11100343	227	239	B-Intervention
vs.	11100343	240	243	O
ranitidine	11100343	244	254	B-Intervention
in	11100343	255	257	O
controlling	11100343	258	269	O
acute	11100343	270	275	B-Participant
non-variceal	11100343	276	288	I-Participant
gastrointestinal	11100343	289	305	I-Participant
bleeding	11100343	306	314	I-Participant
.	11100343	315	316	O

METHODOLOGY	11100343	317	328	O
A	11100343	329	330	O
total	11100343	331	336	O
of	11100343	337	339	O
48	11100343	340	342	O
patients	11100343	343	351	O
with	11100343	352	356	O
acute	11100343	357	362	B-Participant
upper	11100343	363	368	I-Participant
gastrointestinal	11100343	369	385	I-Participant
bleeding	11100343	386	394	I-Participant
due	11100343	395	398	O
to	11100343	399	401	O
duodenal	11100343	402	410	B-Participant
or	11100343	411	413	I-Participant
gastric	11100343	414	421	I-Participant
ulcer	11100343	422	427	I-Participant
were	11100343	428	432	O
divided	11100343	433	440	O
into	11100343	441	445	O
2	11100343	446	447	O
groups	11100343	448	454	O
.	11100343	455	456	O

Group	11100343	457	462	O
I	11100343	463	464	O
consisted	11100343	465	474	O
of	11100343	475	477	O
15	11100343	478	480	O
patients	11100343	481	489	O
with	11100343	490	494	O
Forrest	11100343	495	502	B-Participant
IB	11100343	503	505	I-Participant
and	11100343	506	509	O
Group	11100343	510	515	O
II	11100343	516	518	O
consisted	11100343	519	528	O
of	11100343	529	531	O
30	11100343	532	534	O
patients	11100343	535	543	O
with	11100343	544	548	O
Forrest	11100343	549	556	B-Participant
II	11100343	557	559	I-Participant
.	11100343	560	561	O

Two	11100343	562	565	O
regimens	11100343	566	574	O
were	11100343	575	579	O
randomly	11100343	580	588	O
allocated	11100343	589	598	O
to	11100343	599	601	O
all	11100343	602	605	O
patients	11100343	606	614	O
within	11100343	615	621	O
half	11100343	622	626	O
an	11100343	627	629	O
hour	11100343	630	634	O
after	11100343	635	640	O
the	11100343	641	644	O
endoscopic	11100343	645	655	B-Participant
procedure	11100343	656	665	I-Participant
:	11100343	666	667	O
1	11100343	668	669	O
)	11100343	670	671	O
somatostatin-UCB	11100343	672	688	B-Intervention
250	11100343	689	692	O
mcg	11100343	693	696	O
i.v	11100343	697	700	O
.	11100343	701	702	O

bolus	11100343	703	708	O
followed	11100343	709	717	O
by	11100343	718	720	O
continuous	11100343	721	731	O
i.v	11100343	732	735	O
.	11100343	736	737	O

infusion	11100343	738	746	O
at	11100343	747	749	O
a	11100343	750	751	O
rate	11100343	752	756	O
of	11100343	757	759	O
6	11100343	760	761	O
mg/d	11100343	762	766	O
for	11100343	767	770	O
72	11100343	771	773	O
h	11100343	774	775	O
,	11100343	776	777	O
or	11100343	778	780	O
2	11100343	781	782	O
)	11100343	783	784	O
ranitidine	11100343	785	795	B-Intervention
300	11100343	796	799	O
mg/d	11100343	800	804	O
by	11100343	805	807	O
continuous	11100343	808	818	O
i.v	11100343	819	822	O
.	11100343	823	824	O

infusion	11100343	825	833	O
for	11100343	834	837	O
72	11100343	838	840	O
h.	11100343	841	843	O
RESULTS	11100343	844	851	O
In	11100343	852	854	O
Group	11100343	855	860	B-Participant
I	11100343	861	862	I-Participant
,	11100343	863	864	O
although	11100343	865	873	O
mean	11100343	874	878	B-Outcome
blood	11100343	879	884	I-Outcome
transfusion	11100343	885	896	I-Outcome
requirements	11100343	897	909	I-Outcome
(	11100343	910	911	O
no	11100343	912	914	O
.	11100343	915	916	O
of	11100343	917	919	O
units	11100343	920	925	O
)	11100343	926	927	O
were	11100343	928	932	O
lower	11100343	933	938	B-Observation
in	11100343	939	941	O
patients	11100343	942	950	O
treated	11100343	951	958	O
with	11100343	959	963	O
somatostatin	11100343	964	976	B-Intervention
than	11100343	977	981	O
in	11100343	982	984	O
those	11100343	985	990	O
treated	11100343	991	998	O
with	11100343	999	1003	O
ranitidine	11100343	1004	1014	B-Intervention
,	11100343	1015	1016	O
this	11100343	1017	1021	O
was	11100343	1022	1025	O
not	11100343	1026	1029	O
statistically	11100343	1030	1043	B-Observation
significant	11100343	1044	1055	I-Observation
(	11100343	1056	1057	O
mean	11100343	1058	1062	O
+	11100343	1063	1064	O
/-	11100343	1064	1066	O
SD	11100343	1067	1069	O
:	11100343	1070	1071	O
2.56	11100343	1072	1076	B-Observation
+	11100343	1077	1078	I-Observation
/-	11100343	1078	1080	I-Observation
3.05	11100343	1081	1085	I-Observation
vs.	11100343	1086	1089	O
5.17	11100343	1090	1094	B-Observation
+	11100343	1095	1096	I-Observation
/-	11100343	1096	1098	I-Observation
4.96	11100343	1099	1103	I-Observation
,	11100343	1104	1105	O
respectively	11100343	1106	1118	O
;	11100343	1119	1120	O
P	11100343	1121	1122	O
>	11100343	1123	1124	O
0.05	11100343	1125	1129	O
)	11100343	1130	1131	O
;	11100343	1132	1133	O
the	11100343	1134	1137	O
time	11100343	1138	1142	B-Outcome
of	11100343	1143	1145	I-Outcome
bleeding	11100343	1146	1154	I-Outcome
stop	11100343	1155	1159	I-Outcome
was	11100343	1160	1163	O
shorter	11100343	1164	1171	B-Observation
in	11100343	1172	1174	O
the	11100343	1175	1178	O
somatostatin	11100343	1179	1191	B-Intervention
group	11100343	1192	1197	O
than	11100343	1198	1202	O
in	11100343	1203	1205	O
the	11100343	1206	1209	O
ranitidine	11100343	1210	1220	B-Intervention
group	11100343	1221	1226	O
(	11100343	1227	1228	O
mean	11100343	1229	1233	O
+	11100343	1234	1235	O
/-	11100343	1235	1237	O
SD	11100343	1238	1240	O
:	11100343	1241	1242	O
3.24	11100343	1243	1247	B-Observation
+	11100343	1248	1249	I-Observation
/-	11100343	1249	1251	I-Observation
2.45	11100343	1252	1256	I-Observation
vs.	11100343	1257	1260	O
11.25	11100343	1261	1266	B-Observation
+	11100343	1267	1268	I-Observation
/-	11100343	1268	1270	I-Observation
11.63	11100343	1271	1276	I-Observation
,	11100343	1277	1278	O
respectively	11100343	1279	1291	O
;	11100343	1292	1293	O
P	11100343	1294	1295	O
=	11100343	1296	1297	O
0.0383	11100343	1298	1304	O
)	11100343	1305	1306	O
.	11100343	1307	1308	O

The	11100343	1309	1312	O
rebleeding	11100343	1313	1323	B-Outcome
and	11100343	1324	1327	O
the	11100343	1328	1331	O
mortality	11100343	1332	1341	B-Outcome
rates	11100343	1342	1347	I-Outcome
did	11100343	1348	1351	O
not	11100343	1352	1355	O
differ	11100343	1356	1362	B-Observation
between	11100343	1363	1370	O
the	11100343	1371	1374	O
treatment	11100343	1375	1384	B-Intervention
groups	11100343	1385	1391	I-Intervention
in	11100343	1392	1394	O
both	11100343	1395	1399	O
Group	11100343	1400	1405	B-Participant
I	11100343	1406	1407	I-Participant
and	11100343	1408	1411	O
Group	11100343	1412	1417	B-Participant
II	11100343	1418	1420	I-Participant
.	11100343	1421	1422	O

CONCLUSIONS	11100343	1423	1434	O
Somatostatin	11100343	1435	1447	B-Intervention
is	11100343	1448	1450	O
more	11100343	1451	1455	B-Observation
effective	11100343	1456	1465	I-Observation
than	11100343	1466	1470	O
ranitidine	11100343	1471	1481	B-Intervention
in	11100343	1482	1484	O
controlling	11100343	1485	1496	O
acute	11100343	1497	1502	B-Participant
non-variceal	11100343	1503	1515	I-Participant
gastrointestinal	11100343	1516	1532	I-Participant
bleeding	11100343	1533	1541	I-Participant
in	11100343	1542	1544	O
patients	11100343	1545	1553	O
with	11100343	1554	1558	O
Forrest	11100343	1559	1566	B-Participant
IB	11100343	1567	1569	I-Participant
bleeding	11100343	1570	1578	I-Participant
activity	11100343	1579	1587	I-Participant
.	11100343	1588	1589	O

Somatostatin	11100343	1590	1602	B-Intervention
has	11100343	1603	1606	O
no	11100343	1607	1609	O
additional	11100343	1610	1620	B-Observation
benefit	11100343	1621	1628	I-Observation
in	11100343	1629	1631	O
those	11100343	1632	1637	O
with	11100343	1638	1642	O
Forrest	11100343	1643	1650	B-Participant
II	11100343	1651	1653	I-Participant
bleeding	11100343	1654	1662	I-Participant
activity	11100343	1663	1671	I-Participant
.	11100343	1672	1673	O

Effect	11132252	0	6	O
of	11132252	7	9	O
secretin	11132252	10	18	B-Intervention
on	11132252	19	21	O
children	11132252	22	30	B-Participant
with	11132252	31	35	O
autism	11132252	36	42	B-Participant
:	11132252	43	44	O
a	11132252	45	46	O
randomized	11132252	47	57	O
controlled	11132252	58	68	O
trial	11132252	69	74	O
.	11132252	75	76	O

To	11132252	77	79	O
determine	11132252	80	89	O
the	11132252	90	93	O
effect	11132252	94	100	O
of	11132252	101	103	O
intravenous	11132252	104	115	B-Intervention
porcine	11132252	116	123	I-Intervention
secretin	11132252	124	132	I-Intervention
on	11132252	133	135	O
autistic	11132252	136	144	B-Outcome
behaviours	11132252	145	155	I-Outcome
in	11132252	156	158	O
children	11132252	159	167	B-Participant
aged	11132252	168	172	O
2	11132252	173	174	O
to	11132252	175	177	O
7	11132252	178	179	O
years	11132252	180	185	O
,	11132252	186	187	O
the	11132252	188	191	O
effects	11132252	192	199	O
of	11132252	200	202	O
secretin	11132252	203	211	B-Intervention
on	11132252	212	214	O
(	11132252	215	216	O
1	11132252	217	218	O
)	11132252	219	220	O
performance	11132252	221	232	B-Outcome
on	11132252	233	235	I-Outcome
a	11132252	236	237	I-Outcome
standardized	11132252	238	250	I-Outcome
language	11132252	251	259	I-Outcome
measure	11132252	260	267	I-Outcome
,	11132252	268	269	O
and	11132252	270	273	O
(	11132252	274	275	O
2	11132252	276	277	O
)	11132252	278	279	O
autistic	11132252	280	288	B-Outcome
behaviours	11132252	289	299	I-Outcome
,	11132252	300	301	O
as	11132252	302	304	O
rated	11132252	305	310	O
by	11132252	311	313	O
parents	11132252	314	321	O
and	11132252	322	325	O
child	11132252	326	331	O
development	11132252	332	343	O
professionals	11132252	344	357	O
was	11132252	358	361	O
examined	11132252	362	370	O
.	11132252	371	372	O

Employing	11132252	373	382	O
a	11132252	383	384	O
randomized	11132252	385	395	O
,	11132252	396	397	O
double-blind	11132252	398	410	O
,	11132252	411	412	O
placebo-controlled	11132252	413	431	O
design	11132252	432	438	O
,	11132252	439	440	O
95	11132252	441	443	O
participants	11132252	444	456	O
were	11132252	457	461	O
assigned	11132252	462	470	O
to	11132252	471	473	O
one	11132252	474	477	O
of	11132252	478	480	O
two	11132252	481	484	O
groups	11132252	485	491	O
and	11132252	492	495	O
administered	11132252	496	508	O
a	11132252	509	510	O
single	11132252	511	517	O
dose	11132252	518	522	O
of	11132252	523	525	O
either	11132252	526	532	O
secretin	11132252	533	541	B-Intervention
or	11132252	542	544	O
placebo	11132252	545	552	B-Intervention
.	11132252	553	554	O

A	11132252	555	556	O
follow-up	11132252	557	566	O
assessment	11132252	567	577	O
was	11132252	578	581	O
conducted	11132252	582	591	O
3	11132252	592	593	O
weeks	11132252	594	599	O
after	11132252	600	605	O
the	11132252	606	609	O
injection	11132252	610	619	B-Intervention
.	11132252	620	621	O

No	11132252	622	624	O
significant	11132252	625	636	B-Observation
differences	11132252	637	648	I-Observation
in	11132252	649	651	O
language	11132252	652	660	B-Outcome
or	11132252	661	663	I-Outcome
autistic	11132252	664	672	I-Outcome
behaviour	11132252	673	682	I-Outcome
measures	11132252	683	691	I-Outcome
were	11132252	692	696	O
observed	11132252	697	705	O
at	11132252	706	708	O
the	11132252	709	712	O
3-week	11132252	713	719	O
follow-up	11132252	720	729	O
between	11132252	730	737	B-Intervention
the	11132252	738	741	I-Intervention
groups	11132252	742	748	I-Intervention
.	11132252	749	750	O

Also	11132252	751	755	O
,	11132252	756	757	O
there	11132252	758	763	O
was	11132252	764	767	O
no	11132252	768	770	O
significant	11132252	771	782	B-Observation
difference	11132252	783	793	I-Observation
in	11132252	794	796	O
the	11132252	797	800	O
proportion	11132252	801	811	B-Outcome
of	11132252	812	814	I-Outcome
individuals	11132252	815	826	I-Outcome
who	11132252	827	830	I-Outcome
improved	11132252	831	839	I-Outcome
by	11132252	840	842	I-Outcome
>	11132252	843	844	I-Outcome
or	11132252	845	847	I-Outcome
=	11132252	848	849	I-Outcome
6	11132252	850	851	I-Outcome
points	11132252	852	858	I-Outcome
on	11132252	859	861	I-Outcome
the	11132252	862	865	I-Outcome
language	11132252	866	874	I-Outcome
measure	11132252	875	882	I-Outcome
at	11132252	883	885	O
follow-up	11132252	886	895	O
.	11132252	896	897	O

This	11132252	898	902	O
study	11132252	903	908	O
showed	11132252	909	915	O
no	11132252	916	918	O
significant	11132252	919	930	B-Observation
effects	11132252	931	938	I-Observation
of	11132252	939	941	O
secretin	11132252	942	950	B-Intervention
on	11132252	951	953	O
children	11132252	954	962	B-Participant
with	11132252	963	967	O
autism	11132252	968	974	B-Participant
.	11132252	975	976	O

Our	11132252	977	980	O
results	11132252	981	988	O
are	11132252	989	992	O
consistent	11132252	993	1003	O
with	11132252	1004	1008	O
a	11132252	1009	1010	O
systematic	11132252	1011	1021	O
review	11132252	1022	1028	O
of	11132252	1029	1031	O
randomized	11132252	1032	1042	O
controlled	11132252	1043	1053	O
trials	11132252	1054	1060	O
evaluating	11132252	1061	1071	O
the	11132252	1072	1075	O
effect	11132252	1076	1082	O
of	11132252	1083	1085	O
secretin	11132252	1086	1094	B-Intervention
in	11132252	1095	1097	O
children	11132252	1098	1106	B-Participant
with	11132252	1107	1111	O
autism	11132252	1112	1118	B-Participant
.	11132252	1119	1120	O

Cardiovascular	11136837	0	14	B-Outcome
effects	11136837	15	22	I-Outcome
of	11136837	23	25	O
tamoxifen	11136837	26	35	B-Intervention
in	11136837	36	38	O
women	11136837	39	44	B-Participant
with	11136837	45	49	I-Participant
and	11136837	50	53	I-Participant
without	11136837	54	61	I-Participant
heart	11136837	62	67	I-Participant
disease	11136837	68	75	I-Participant
:	11136837	76	77	O
breast	11136837	78	84	B-Participant
cancer	11136837	85	91	I-Participant
prevention	11136837	92	102	O
trial	11136837	103	108	O
.	11136837	109	110	O

National	11136837	111	119	O
Surgical	11136837	120	128	O
Adjuvant	11136837	129	137	O
Breast	11136837	138	144	O
and	11136837	145	148	O
Bowel	11136837	149	154	O
Project	11136837	155	162	O
Breast	11136837	163	169	O
Cancer	11136837	170	176	O
Prevention	11136837	177	187	O
Trial	11136837	188	193	O
Investigators	11136837	194	207	O
.	11136837	208	209	O

BACKGROUND	11136837	210	220	O
The	11136837	221	224	O
overall	11136837	225	232	O
effect	11136837	233	239	O
of	11136837	240	242	O
prophylactic	11136837	243	255	O
tamoxifen	11136837	256	265	O
in	11136837	266	268	O
women	11136837	269	274	O
depends	11136837	275	282	O
on	11136837	283	285	O
the	11136837	286	289	O
balance	11136837	290	297	O
between	11136837	298	305	O
the	11136837	306	309	O
effects	11136837	310	317	O
of	11136837	318	320	O
the	11136837	321	324	O
drug	11136837	325	329	O
,	11136837	330	331	O
which	11136837	332	337	O
include	11136837	338	345	O
preventing	11136837	346	356	O
breast	11136837	357	363	O
cancer	11136837	364	370	O
and	11136837	371	374	O
altering	11136837	375	383	O
cardiovascular	11136837	384	398	O
risk	11136837	399	403	O
.	11136837	404	405	O

In	11136837	406	408	O
a	11136837	409	410	O
recent	11136837	411	417	O
clinical	11136837	418	426	O
trial	11136837	427	432	O
,	11136837	433	434	O
postmenopausal	11136837	435	449	O
estrogen-progestin	11136837	450	468	O
therapy	11136837	469	476	O
was	11136837	477	480	O
shown	11136837	481	486	O
to	11136837	487	489	O
increase	11136837	490	498	O
the	11136837	499	502	O
risk	11136837	503	507	O
of	11136837	508	510	O
early	11136837	511	516	O
cardiovascular	11136837	517	531	O
events	11136837	532	538	O
among	11136837	539	544	O
women	11136837	545	550	O
with	11136837	551	555	O
a	11136837	556	557	O
history	11136837	558	565	O
of	11136837	566	568	O
coronary	11136837	569	577	O
heart	11136837	578	583	O
disease	11136837	584	591	O
(	11136837	592	593	O
CHD	11136837	594	597	O
)	11136837	598	599	O
.	11136837	600	601	O

The	11136837	602	605	O
cardiovascular	11136837	606	620	O
effects	11136837	621	628	O
of	11136837	629	631	O
tamoxifen	11136837	632	641	O
in	11136837	642	644	O
women	11136837	645	650	O
with	11136837	651	655	O
and	11136837	656	659	O
without	11136837	660	667	O
CHD	11136837	668	671	O
are	11136837	672	675	O
not	11136837	676	679	O
known	11136837	680	685	O
.	11136837	686	687	O

The	11136837	688	691	O
National	11136837	692	700	O
Surgical	11136837	701	709	O
Adjuvant	11136837	710	718	O
Breast	11136837	719	725	O
and	11136837	726	729	O
Bowel	11136837	730	735	O
Project	11136837	736	743	O
Breast	11136837	744	750	O
Cancer	11136837	751	757	O
Prevention	11136837	758	768	O
Trial	11136837	769	774	O
(	11136837	775	776	O
BCPT	11136837	777	781	O
)	11136837	782	783	O
is	11136837	784	786	O
the	11136837	787	790	O
only	11136837	791	795	O
clinical	11136837	796	804	O
trial	11136837	805	810	O
that	11136837	811	815	O
provides	11136837	816	824	O
data	11136837	825	829	O
to	11136837	830	832	O
assess	11136837	833	839	O
the	11136837	840	843	O
cardiovascular	11136837	844	858	B-Outcome
effects	11136837	859	866	I-Outcome
of	11136837	867	869	O
tamoxifen	11136837	870	879	B-Intervention
in	11136837	880	882	O
women	11136837	883	888	B-Participant
with	11136837	889	893	I-Participant
and	11136837	894	897	I-Participant
without	11136837	898	905	I-Participant
CHD	11136837	906	909	I-Participant
.	11136837	910	911	O

METHODS	11136837	912	919	O
A	11136837	920	921	O
total	11136837	922	927	O
of	11136837	928	930	O
13	11136837	931	933	O
388	11136837	934	937	O
women	11136837	938	943	B-Participant
at	11136837	944	946	O
increased	11136837	947	956	B-Participant
risk	11136837	957	961	I-Participant
for	11136837	962	965	I-Participant
breast	11136837	966	972	I-Participant
cancer	11136837	973	979	I-Participant
were	11136837	980	984	O
randomly	11136837	985	993	O
assigned	11136837	994	1002	O
in	11136837	1003	1005	O
the	11136837	1006	1009	O
BCPT	11136837	1010	1014	O
to	11136837	1015	1017	O
receive	11136837	1018	1025	O
either	11136837	1026	1032	O
tamoxifen	11136837	1033	1042	B-Intervention
(	11136837	1043	1044	O
20	11136837	1045	1047	O
mg/day	11136837	1048	1054	O
)	11136837	1055	1056	O
or	11136837	1057	1059	O
placebo	11136837	1060	1067	B-Intervention
.	11136837	1068	1069	O

Cardiovascular	11136837	1070	1084	O
follow-up	11136837	1085	1094	O
was	11136837	1095	1098	O
available	11136837	1099	1108	O
for	11136837	1109	1112	O
13	11136837	1113	1115	O
194	11136837	1116	1119	O
women	11136837	1120	1125	B-Participant
,	11136837	1126	1127	O
1048	11136837	1128	1132	O
of	11136837	1133	1135	O
whom	11136837	1136	1140	O
had	11136837	1141	1144	O
prior	11136837	1145	1150	B-Participant
clinical	11136837	1151	1159	I-Participant
CHD	11136837	1160	1163	I-Participant
.	11136837	1164	1165	O

Fatal	11136837	1166	1171	B-Outcome
and	11136837	1172	1175	I-Outcome
nonfatal	11136837	1176	1184	I-Outcome
myocardial	11136837	1185	1195	I-Outcome
infarction	11136837	1196	1206	I-Outcome
,	11136837	1207	1208	O
unstable	11136837	1209	1217	B-Outcome
angina	11136837	1218	1224	I-Outcome
,	11136837	1225	1226	O
and	11136837	1227	1230	O
severe	11136837	1231	1237	B-Outcome
angina	11136837	1238	1244	I-Outcome
were	11136837	1245	1249	O
tabulated	11136837	1250	1259	O
(	11136837	1260	1261	O
mean	11136837	1262	1266	O
follow-up	11136837	1267	1276	O
:	11136837	1277	1278	O
49	11136837	1279	1281	O
months	11136837	1282	1288	O
)	11136837	1289	1290	O
.	11136837	1291	1292	O

All	11136837	1293	1296	O
statistical	11136837	1297	1308	O
tests	11136837	1309	1314	O
were	11136837	1315	1319	O
two-sided	11136837	1320	1329	O
.	11136837	1330	1331	O

RESULTS	11136837	1332	1339	O
Cardiovascular	11136837	1340	1354	B-Outcome
event	11136837	1355	1360	I-Outcome
rates	11136837	1361	1366	I-Outcome
were	11136837	1367	1371	O
not	11136837	1372	1375	O
statistically	11136837	1376	1389	B-Observation
significantly	11136837	1390	1403	I-Observation
different	11136837	1404	1413	I-Observation
between	11136837	1414	1421	O
women	11136837	1422	1427	B-Participant
assigned	11136837	1428	1436	O
to	11136837	1437	1439	O
receive	11136837	1440	1447	O
tamoxifen	11136837	1448	1457	B-Intervention
and	11136837	1458	1461	O
those	11136837	1462	1467	O
assigned	11136837	1468	1476	O
to	11136837	1477	1479	O
receive	11136837	1480	1487	O
placebo	11136837	1488	1495	B-Intervention
,	11136837	1496	1497	O
independent	11136837	1498	1509	O
of	11136837	1510	1512	O
pre-existing	11136837	1513	1525	B-Participant
CHD	11136837	1526	1529	I-Participant
.	11136837	1530	1531	O

Among	11136837	1532	1537	O
women	11136837	1538	1543	B-Participant
without	11136837	1544	1551	I-Participant
CHD	11136837	1552	1555	I-Participant
(	11136837	1556	1557	O
6074	11136837	1558	1562	O
on	11136837	1563	1565	O
tamoxifen	11136837	1566	1575	B-Intervention
versus	11136837	1576	1582	O
6072	11136837	1583	1587	O
on	11136837	1588	1590	O
placebo	11136837	1591	1598	B-Intervention
)	11136837	1599	1600	O
,	11136837	1601	1602	O
risk	11136837	1603	1607	B-Outcome
ratios	11136837	1608	1614	I-Outcome
(	11136837	1615	1616	O
95	11136837	1617	1619	O
%	11136837	1620	1621	O
confidence	11136837	1622	1632	O
intervals	11136837	1633	1642	O
[	11136837	1643	1644	O
CIs	11136837	1645	1648	O
]	11136837	1649	1650	O
)	11136837	1651	1652	O
for	11136837	1653	1656	O
tamoxifen	11136837	1657	1666	B-Intervention
users	11136837	1667	1672	O
were	11136837	1673	1677	O
1.75	11136837	1678	1682	B-Observation
(	11136837	1683	1684	I-Observation
0.44	11136837	1685	1689	I-Observation
to	11136837	1690	1692	I-Observation
8.13	11136837	1693	1697	I-Observation
)	11136837	1698	1699	I-Observation
for	11136837	1700	1703	O
fatal	11136837	1704	1709	B-Outcome
myocardial	11136837	1710	1720	I-Outcome
infarction	11136837	1721	1731	I-Outcome
,	11136837	1732	1733	O
1.11	11136837	1734	1738	B-Observation
(	11136837	1739	1740	I-Observation
0.55	11136837	1741	1745	I-Observation
to	11136837	1746	1748	I-Observation
2.28	11136837	1749	1753	I-Observation
)	11136837	1754	1755	I-Observation
for	11136837	1756	1759	O
nonfatal	11136837	1760	1768	B-Outcome
myocardial	11136837	1769	1779	I-Outcome
infarction	11136837	1780	1790	I-Outcome
,	11136837	1791	1792	O
0.69	11136837	1793	1797	B-Observation
(	11136837	1798	1799	I-Observation
0.29	11136837	1800	1804	I-Observation
to	11136837	1805	1807	I-Observation
1.57	11136837	1808	1812	I-Observation
)	11136837	1813	1814	I-Observation
for	11136837	1815	1818	O
unstable	11136837	1819	1827	B-Outcome
angina	11136837	1828	1834	I-Outcome
,	11136837	1835	1836	O
and	11136837	1837	1840	O
0.83	11136837	1841	1845	B-Observation
(	11136837	1846	1847	I-Observation
0.32	11136837	1848	1852	I-Observation
to	11136837	1853	1855	I-Observation
2.10	11136837	1856	1860	I-Observation
)	11136837	1861	1862	I-Observation
for	11136837	1863	1866	O
severe	11136837	1867	1873	B-Outcome
angina	11136837	1874	1880	I-Outcome
.	11136837	1881	1882	O

In	11136837	1883	1885	O
women	11136837	1886	1891	B-Participant
with	11136837	1892	1896	I-Participant
CHD	11136837	1897	1900	I-Participant
(	11136837	1901	1902	O
516	11136837	1903	1906	O
on	11136837	1907	1909	O
tamoxifen	11136837	1910	1919	B-Intervention
versus	11136837	1920	1926	O
532	11136837	1927	1930	O
on	11136837	1931	1933	O
placebo	11136837	1934	1941	B-Intervention
)	11136837	1942	1943	O
,	11136837	1944	1945	O
risk	11136837	1946	1950	B-Outcome
ratios	11136837	1951	1957	I-Outcome
(	11136837	1958	1959	O
95	11136837	1960	1962	O
%	11136837	1963	1964	O
CIs	11136837	1965	1968	O
)	11136837	1969	1970	O
for	11136837	1971	1974	O
tamoxifen	11136837	1975	1984	B-Intervention
users	11136837	1985	1990	O
were	11136837	1991	1995	O
0.00	11136837	1996	2000	B-Observation
(	11136837	2001	2002	I-Observation
0	11136837	2003	2004	I-Observation
to	11136837	2005	2007	I-Observation
1.58	11136837	2008	2012	I-Observation
)	11136837	2013	2014	I-Observation
for	11136837	2015	2018	O
fatal	11136837	2019	2024	B-Outcome
myocardial	11136837	2025	2035	I-Outcome
infarction	11136837	2036	2046	I-Outcome
,	11136837	2047	2048	O
1.25	11136837	2049	2053	B-Observation
(	11136837	2054	2055	I-Observation
0.32	11136837	2056	2060	I-Observation
to	11136837	2061	2063	I-Observation
5.18	11136837	2064	2068	I-Observation
)	11136837	2069	2070	I-Observation
for	11136837	2071	2074	O
nonfatal	11136837	2075	2083	B-Outcome
myocardial	11136837	2084	2094	I-Outcome
infarction	11136837	2095	2105	I-Outcome
,	11136837	2106	2107	O
2.26	11136837	2108	2112	B-Observation
(	11136837	2113	2114	I-Observation
0.87	11136837	2115	2119	I-Observation
to	11136837	2120	2122	I-Observation
6.55	11136837	2123	2127	I-Observation
)	11136837	2128	2129	I-Observation
for	11136837	2130	2133	O
unstable	11136837	2134	2142	B-Outcome
angina	11136837	2143	2149	I-Outcome
,	11136837	2150	2151	O
and	11136837	2152	2155	O
1.39	11136837	2156	2160	B-Observation
(	11136837	2161	2162	I-Observation
0.23	11136837	2163	2167	I-Observation
to	11136837	2168	2170	I-Observation
9.47	11136837	2171	2175	I-Observation
)	11136837	2176	2177	I-Observation
for	11136837	2178	2181	O
severe	11136837	2182	2188	B-Outcome
angina	11136837	2189	2195	I-Outcome
.	11136837	2196	2197	O

There	11136837	2198	2203	O
was	11136837	2204	2207	O
no	11136837	2208	2210	O
evidence	11136837	2211	2219	O
that	11136837	2220	2224	O
the	11136837	2225	2228	O
lack	11136837	2229	2233	B-Observation
of	11136837	2234	2236	I-Observation
association	11136837	2237	2248	I-Observation
between	11136837	2249	2256	O
tamoxifen	11136837	2257	2266	B-Intervention
and	11136837	2267	2270	O
cardiovascular	11136837	2271	2285	B-Outcome
events	11136837	2286	2292	I-Outcome
was	11136837	2293	2296	O
related	11136837	2297	2304	O
to	11136837	2305	2307	O
an	11136837	2308	2310	O
early	11136837	2311	2316	O
increase	11136837	2317	2325	O
in	11136837	2326	2328	O
risk	11136837	2329	2333	O
that	11136837	2334	2338	O
may	11136837	2339	2342	O
have	11136837	2343	2347	O
been	11136837	2348	2352	O
offset	11136837	2353	2359	O
by	11136837	2360	2362	O
a	11136837	2363	2364	O
late	11136837	2365	2369	O
decrease	11136837	2370	2378	O
in	11136837	2379	2381	O
risk	11136837	2382	2386	O
.	11136837	2387	2388	O

CONCLUSION	11136837	2389	2399	O
When	11136837	2400	2404	O
used	11136837	2405	2409	O
for	11136837	2410	2413	O
breast	11136837	2414	2420	O
cancer	11136837	2421	2427	O
prevention	11136837	2428	2438	O
in	11136837	2439	2441	O
women	11136837	2442	2447	B-Participant
with	11136837	2448	2452	I-Participant
or	11136837	2453	2455	I-Participant
without	11136837	2456	2463	I-Participant
heart	11136837	2464	2469	I-Participant
disease	11136837	2470	2477	I-Participant
,	11136837	2478	2479	O
tamoxifen	11136837	2480	2489	B-Intervention
is	11136837	2490	2492	O
not	11136837	2493	2496	O
associated	11136837	2497	2507	B-Observation
with	11136837	2508	2512	O
beneficial	11136837	2513	2523	B-Outcome
or	11136837	2524	2526	I-Outcome
adverse	11136837	2527	2534	I-Outcome
cardiovascular	11136837	2535	2549	I-Outcome
effects	11136837	2550	2557	I-Outcome
.	11136837	2558	2559	O

Do	11140546	0	2	O
heavier	11140546	3	10	B-Participant
women	11140546	11	16	I-Participant
benefit	11140546	17	24	B-Observation
from	11140546	25	29	O
a	11140546	30	31	O
higher	11140546	32	38	B-Intervention
dose	11140546	39	43	I-Intervention
of	11140546	44	46	I-Intervention
leuprolide	11140546	47	57	I-Intervention
acetate	11140546	58	65	I-Intervention
for	11140546	66	69	O
suppression	11140546	70	81	B-Outcome
of	11140546	82	84	I-Outcome
serum	11140546	85	90	I-Outcome
estradiol	11140546	91	100	I-Outcome
?	11140546	101	102	O

OBJECTIVE	11140546	103	112	O
To	11140546	113	115	O
determine	11140546	116	125	O
if	11140546	126	128	O
heavier	11140546	129	136	B-Participant
women	11140546	137	142	I-Participant
benefit	11140546	143	150	B-Observation
from	11140546	151	155	O
a	11140546	156	157	O
higher	11140546	158	164	B-Intervention
dose	11140546	165	169	I-Intervention
of	11140546	170	172	I-Intervention
the	11140546	173	176	I-Intervention
gonadotropin-releasing	11140546	177	199	I-Intervention
hormone	11140546	200	207	I-Intervention
analogue	11140546	208	216	I-Intervention
leuprolide	11140546	217	227	I-Intervention
acetate	11140546	228	235	I-Intervention
(	11140546	236	237	I-Intervention
LA	11140546	238	240	I-Intervention
)	11140546	241	242	I-Intervention
depot	11140546	243	248	I-Intervention
in	11140546	249	251	O
terms	11140546	252	257	O
of	11140546	258	260	O
suppression	11140546	261	272	B-Outcome
of	11140546	273	275	I-Outcome
serum	11140546	276	281	I-Outcome
estradiol	11140546	282	291	I-Outcome
.	11140546	292	293	O

METHODS	11140546	294	301	O
This	11140546	302	306	O
was	11140546	307	310	O
a	11140546	311	312	O
retrospective	11140546	313	326	O
analysis	11140546	327	335	O
of	11140546	336	338	O
the	11140546	339	342	O
effect	11140546	343	349	O
of	11140546	350	352	O
LA	11140546	353	355	B-Intervention
depot	11140546	356	361	I-Intervention
3.75	11140546	362	366	I-Intervention
mg	11140546	367	369	I-Intervention
and	11140546	370	373	O
7.5	11140546	374	377	B-Intervention
mg	11140546	378	380	I-Intervention
on	11140546	381	383	O
serum	11140546	384	389	B-Outcome
estradiol	11140546	390	399	I-Outcome
from	11140546	400	404	O
a	11140546	405	406	O
multicenter	11140546	407	418	O
,	11140546	419	420	O
double-blind	11140546	421	433	O
,	11140546	434	435	O
parallel-group	11140546	436	450	O
,	11140546	451	452	O
12-week	11140546	453	460	O
study	11140546	461	466	O
of	11140546	467	469	O
women	11140546	470	475	B-Participant
with	11140546	476	480	O
anemia	11140546	481	487	B-Participant
due	11140546	488	491	O
to	11140546	492	494	O
bleeding	11140546	495	503	B-Participant
from	11140546	504	508	O
uterine	11140546	509	516	B-Participant
leiomyomata	11140546	517	528	I-Participant
.	11140546	529	530	O

Serum	11140546	531	536	B-Outcome
estradiol	11140546	537	546	I-Outcome
levels	11140546	547	553	I-Outcome
were	11140546	554	558	O
obtained	11140546	559	567	O
at	11140546	568	570	O
baseline	11140546	571	579	O
and	11140546	580	583	O
at	11140546	584	586	O
week	11140546	587	591	O
12	11140546	592	594	O
.	11140546	595	596	O

Patients	11140546	597	605	O
were	11140546	606	610	O
divided	11140546	611	618	O
into	11140546	619	623	O
weight	11140546	624	630	O
quartiles	11140546	631	640	O
according	11140546	641	650	O
to	11140546	651	653	O
their	11140546	654	659	O
baseline	11140546	660	668	O
weight	11140546	669	675	O
in	11140546	676	678	O
kilograms	11140546	679	688	O
:	11140546	689	690	O
46-	11140546	691	694	O
<	11140546	695	696	O
64	11140546	697	699	O
,	11140546	700	701	O
64-	11140546	702	705	O
<	11140546	706	707	O
72	11140546	708	710	O
,	11140546	711	712	O
72-	11140546	713	716	O
<	11140546	717	718	O
89	11140546	719	721	O
,	11140546	722	723	O
89	11140546	724	726	O
-	11140546	726	727	O
159	11140546	727	730	O
(	11140546	731	732	O
pounds-102-	11140546	733	744	O
<	11140546	745	746	O
140	11140546	747	750	O
,	11140546	751	752	O
140-	11140546	753	757	O
<	11140546	758	759	O
159	11140546	760	763	O
,	11140546	764	765	O
159-	11140546	766	770	O
<	11140546	771	772	O
196	11140546	773	776	O
,	11140546	777	778	O
196	11140546	779	782	O
-	11140546	782	783	O
350	11140546	783	786	O
)	11140546	787	788	O
.	11140546	789	790	O

RESULTS	11140546	791	798	O
At	11140546	799	801	O
baseline	11140546	802	810	O
there	11140546	811	816	O
was	11140546	817	820	O
no	11140546	821	823	O
statistically	11140546	824	837	B-Observation
significant	11140546	838	849	I-Observation
difference	11140546	850	860	I-Observation
in	11140546	861	863	O
estradiol	11140546	864	873	B-Outcome
level	11140546	874	879	I-Outcome
between	11140546	880	887	B-Intervention
groups	11140546	888	894	I-Intervention
as	11140546	895	897	O
a	11140546	898	899	O
whole	11140546	900	905	O
or	11140546	906	908	O
within	11140546	909	915	O
weight	11140546	916	922	O
quartiles	11140546	923	932	O
.	11140546	933	934	O

Within	11140546	935	941	B-Intervention
each	11140546	942	946	I-Intervention
group	11140546	947	952	I-Intervention
there	11140546	953	958	O
was	11140546	959	962	O
no	11140546	963	965	O
relationship	11140546	966	978	B-Observation
between	11140546	979	986	O
weight	11140546	987	993	B-Outcome
and	11140546	994	997	I-Outcome
baseline	11140546	998	1006	I-Outcome
estradiol	11140546	1007	1016	I-Outcome
.	11140546	1017	1018	O

At	11140546	1019	1021	O
week	11140546	1022	1026	O
12	11140546	1027	1029	O
,	11140546	1030	1031	O
whereas	11140546	1032	1039	O
estradiol	11140546	1040	1049	B-Outcome
levels	11140546	1050	1056	I-Outcome
were	11140546	1057	1061	O
significantly	11140546	1062	1075	B-Observation
greater	11140546	1076	1083	I-Observation
in	11140546	1084	1086	O
the	11140546	1087	1090	O
heavier	11140546	1091	1098	B-Participant
patients	11140546	1099	1107	O
in	11140546	1108	1110	O
each	11140546	1111	1115	B-Intervention
of	11140546	1116	1118	I-Intervention
the	11140546	1119	1122	I-Intervention
groups	11140546	1123	1129	I-Intervention
(	11140546	1130	1131	O
LA	11140546	1132	1134	B-Intervention
3.75	11140546	1135	1139	I-Intervention
mg	11140546	1140	1142	I-Intervention
,	11140546	1143	1144	O
p	11140546	1145	1146	O
=	11140546	1147	1148	O
0.044	11140546	1149	1154	O
;	11140546	1155	1156	O
LA	11140546	1157	1159	B-Intervention
7.5	11140546	1160	1163	I-Intervention
mg	11140546	1164	1166	I-Intervention
,	11140546	1167	1168	O
p	11140546	1169	1170	O
=	11140546	1171	1172	O
0.002	11140546	1173	1178	O
)	11140546	1179	1180	O
,	11140546	1181	1182	O
there	11140546	1183	1188	O
was	11140546	1189	1192	O
no	11140546	1193	1195	O
significant	11140546	1196	1207	B-Observation
difference	11140546	1208	1218	I-Observation
in	11140546	1219	1221	O
estradiol	11140546	1222	1231	B-Outcome
between	11140546	1232	1239	B-Intervention
groups	11140546	1240	1246	I-Intervention
as	11140546	1247	1249	O
a	11140546	1250	1251	O
whole	11140546	1252	1257	O
or	11140546	1258	1260	O
within	11140546	1261	1267	O
any	11140546	1268	1271	O
of	11140546	1272	1274	O
the	11140546	1275	1278	O
weight	11140546	1279	1285	O
quartiles	11140546	1286	1295	O
.	11140546	1296	1297	O

Moreover	11140546	1298	1306	O
,	11140546	1307	1308	O
at	11140546	1309	1311	O
week	11140546	1312	1316	O
12	11140546	1317	1319	O
there	11140546	1320	1325	O
was	11140546	1326	1329	O
no	11140546	1330	1332	O
significant	11140546	1333	1344	B-Observation
difference	11140546	1345	1355	I-Observation
between	11140546	1356	1363	B-Intervention
groups	11140546	1364	1370	I-Intervention
in	11140546	1371	1373	O
the	11140546	1374	1377	O
percentage	11140546	1378	1388	O
of	11140546	1389	1391	O
patients	11140546	1392	1400	O
with	11140546	1401	1405	O
estradiol	11140546	1406	1415	B-Outcome
suppressed	11140546	1416	1426	I-Outcome
to	11140546	1427	1429	I-Outcome
the	11140546	1430	1433	I-Outcome
menopausal	11140546	1434	1444	I-Outcome
range	11140546	1445	1450	I-Outcome
.	11140546	1451	1452	O

CONCLUSION	11140546	1453	1463	O
Heavier	11140546	1464	1471	B-Participant
women	11140546	1472	1477	I-Participant
do	11140546	1478	1480	O
not	11140546	1481	1484	O
benefit	11140546	1485	1492	B-Observation
from	11140546	1493	1497	O
a	11140546	1498	1499	O
higher	11140546	1500	1506	B-Intervention
dose	11140546	1507	1511	I-Intervention
of	11140546	1512	1514	I-Intervention
LA	11140546	1515	1517	I-Intervention
depot	11140546	1518	1523	I-Intervention
(	11140546	1524	1525	O
7.5	11140546	1526	1529	B-Intervention
vs.	11140546	1530	1533	O
3.75	11140546	1534	1538	B-Intervention
mg	11140546	1539	1541	I-Intervention
)	11140546	1542	1543	O
for	11140546	1544	1547	O
suppression	11140546	1548	1559	B-Outcome
of	11140546	1560	1562	I-Outcome
serum	11140546	1563	1568	I-Outcome
levels	11140546	1569	1575	I-Outcome
of	11140546	1576	1578	I-Outcome
estradiol	11140546	1579	1588	I-Outcome
.	11140546	1589	1590	O

Unopposed	11154142	0	9	B-Intervention
estrogen	11154142	10	18	I-Intervention
increases	11154142	19	28	B-Observation
total	11154142	29	34	B-Outcome
plasma	11154142	35	41	I-Outcome
factor	11154142	42	48	I-Outcome
VII	11154142	49	52	I-Outcome
,	11154142	53	54	O
but	11154142	55	58	O
not	11154142	59	62	O
active	11154142	63	69	B-Outcome
factor	11154142	70	76	I-Outcome
VII	11154142	77	80	I-Outcome
--	11154142	81	83	O
a	11154142	84	85	O
short-term	11154142	86	96	O
placebo-controlled	11154142	97	115	O
study	11154142	116	121	O
in	11154142	122	124	O
healthy	11154142	125	132	B-Participant
postmenopausal	11154142	133	147	B-Participant
women	11154142	148	153	I-Participant
.	11154142	154	155	O

Estrogen	11154142	156	164	O
therapy	11154142	165	172	O
may	11154142	173	176	O
increase	11154142	177	185	O
the	11154142	186	189	O
risk	11154142	190	194	O
of	11154142	195	197	O
arterial	11154142	198	206	O
thromboembolism	11154142	207	222	O
,	11154142	223	224	O
at	11154142	225	227	O
least	11154142	228	233	O
in	11154142	234	236	O
the	11154142	237	240	O
short	11154142	241	246	O
term	11154142	247	251	O
.	11154142	252	253	O

In	11154142	254	256	O
a	11154142	257	258	O
randomized	11154142	259	269	O
,	11154142	270	271	O
double-blind	11154142	272	284	O
and	11154142	285	288	O
placebo-controlled	11154142	289	307	O
study	11154142	308	313	O
in	11154142	314	316	O
25	11154142	317	319	O
healthy	11154142	320	327	B-Participant
postmenopausal	11154142	328	342	B-Participant
women	11154142	343	348	I-Participant
(	11154142	349	350	O
52.5	11154142	351	355	O
+	11154142	356	357	O
/-	11154142	357	359	O
2.8	11154142	360	363	O
years	11154142	364	369	O
)	11154142	370	371	O
,	11154142	372	373	O
we	11154142	374	376	O
therefore	11154142	377	386	O
examined	11154142	387	395	O
the	11154142	396	399	O
short-term	11154142	400	410	O
effect	11154142	411	417	O
of	11154142	418	420	O
unopposed	11154142	421	430	B-Intervention
estrogen	11154142	431	439	I-Intervention
on	11154142	440	442	O
the	11154142	443	446	O
fasting	11154142	447	454	B-Outcome
and	11154142	455	458	I-Outcome
fat-load-stimulated	11154142	459	478	I-Outcome
plasma	11154142	479	485	I-Outcome
levels	11154142	486	492	I-Outcome
of	11154142	493	495	I-Outcome
total	11154142	496	501	I-Outcome
factor	11154142	502	508	I-Outcome
VII	11154142	509	512	I-Outcome
versus	11154142	513	519	I-Outcome
active	11154142	520	526	I-Outcome
factor	11154142	527	533	I-Outcome
VII	11154142	534	537	I-Outcome
.	11154142	538	539	O

Plasma	11154142	540	546	B-Outcome
total	11154142	547	552	I-Outcome
factor	11154142	553	559	I-Outcome
VII	11154142	560	563	I-Outcome
was	11154142	564	567	O
measured	11154142	568	576	O
by	11154142	577	579	O
use	11154142	580	583	O
of	11154142	584	586	O
a	11154142	587	588	O
chromogenic	11154142	589	600	O
assay	11154142	601	606	O
;	11154142	607	608	O
plasma	11154142	609	615	B-Outcome
active	11154142	616	622	I-Outcome
FVII	11154142	623	627	I-Outcome
by	11154142	628	630	O
a	11154142	631	632	O
recently	11154142	633	641	O
developed	11154142	642	651	O
method	11154142	652	658	O
using	11154142	659	664	O
truncated	11154142	665	674	O
tissue	11154142	675	681	O
factor	11154142	682	688	O
.	11154142	689	690	O

As	11154142	691	693	O
compared	11154142	694	702	O
to	11154142	703	705	O
placebo	11154142	706	713	B-Intervention
,	11154142	714	715	O
8	11154142	716	717	O
weeks	11154142	718	723	O
of	11154142	724	726	O
oral	11154142	727	731	O
17beta-estradiol	11154142	732	748	B-Intervention
(	11154142	749	750	O
2	11154142	751	752	O
mg	11154142	753	755	O
daily	11154142	756	761	O
)	11154142	762	763	O
increased	11154142	764	773	B-Observation
the	11154142	774	777	O
mean	11154142	778	782	B-Outcome
fasting	11154142	783	790	I-Outcome
and	11154142	791	794	I-Outcome
postprandial	11154142	795	807	I-Outcome
plasma	11154142	808	814	I-Outcome
levels	11154142	815	821	I-Outcome
of	11154142	822	824	I-Outcome
total	11154142	825	830	I-Outcome
factor	11154142	831	837	I-Outcome
VII	11154142	838	841	I-Outcome
by	11154142	842	844	O
17	11154142	845	847	B-Observation
and	11154142	848	851	I-Observation
21	11154142	852	854	I-Observation
%	11154142	855	856	I-Observation
points	11154142	857	863	I-Observation
,	11154142	864	865	O
respectively	11154142	866	878	O
(	11154142	879	880	O
both	11154142	881	885	O
P	11154142	886	887	O
<	11154142	888	889	O
0.01	11154142	890	894	O
)	11154142	895	896	O
,	11154142	897	898	O
but	11154142	899	902	O
did	11154142	903	906	O
not	11154142	907	910	O
affect	11154142	911	917	B-Observation
the	11154142	918	921	O
fasting	11154142	922	929	B-Outcome
and/or	11154142	930	936	I-Outcome
postprandial	11154142	937	949	I-Outcome
plasma	11154142	950	956	I-Outcome
levels	11154142	957	963	I-Outcome
of	11154142	964	966	I-Outcome
active	11154142	967	973	I-Outcome
factor	11154142	974	980	I-Outcome
VII	11154142	981	984	I-Outcome
(	11154142	985	986	O
mean	11154142	987	991	B-Outcome
change	11154142	992	998	I-Outcome
both	11154142	999	1003	O
0.05	11154142	1004	1008	B-Observation
ng/mL	11154142	1009	1014	I-Observation
;	11154142	1015	1016	O
P	11154142	1017	1018	O
>	11154142	1019	1020	O
0.35	11154142	1021	1025	O
)	11154142	1026	1027	O
.	11154142	1028	1029	O

Furthermore	11154142	1030	1041	O
,	11154142	1042	1043	O
the	11154142	1044	1047	O
change	11154142	1048	1054	B-Observation
in	11154142	1055	1057	O
the	11154142	1058	1061	O
fasting	11154142	1062	1069	B-Outcome
level	11154142	1070	1075	I-Outcome
of	11154142	1076	1078	I-Outcome
total	11154142	1079	1084	I-Outcome
factor	11154142	1085	1091	I-Outcome
VII	11154142	1092	1095	I-Outcome
after	11154142	1096	1101	O
therapy	11154142	1102	1109	O
was	11154142	1110	1113	O
not	11154142	1114	1117	O
associated	11154142	1118	1128	B-Observation
with	11154142	1129	1133	O
the	11154142	1134	1137	O
change	11154142	1138	1144	B-Observation
in	11154142	1145	1147	O
the	11154142	1148	1151	O
fasting	11154142	1152	1159	B-Outcome
level	11154142	1160	1165	I-Outcome
of	11154142	1166	1168	I-Outcome
active	11154142	1169	1175	I-Outcome
factor	11154142	1176	1182	I-Outcome
VII	11154142	1183	1186	I-Outcome
(	11154142	1187	1188	O
r	11154142	1189	1190	O
=	11154142	1191	1192	O
0.27	11154142	1193	1197	O
;	11154142	1198	1199	O
P	11154142	1200	1201	O
=	11154142	1202	1203	O
0.21	11154142	1204	1208	O
)	11154142	1209	1210	O
.	11154142	1211	1212	O

These	11154142	1213	1218	O
findings	11154142	1219	1227	O
argue	11154142	1228	1233	O
against	11154142	1234	1241	O
the	11154142	1242	1245	O
idea	11154142	1246	1250	O
that	11154142	1251	1255	O
elevated	11154142	1256	1264	B-Observation
levels	11154142	1265	1271	B-Outcome
of	11154142	1272	1274	I-Outcome
total	11154142	1275	1280	I-Outcome
factor	11154142	1281	1287	I-Outcome
VII	11154142	1288	1291	I-Outcome
underlie	11154142	1292	1300	O
an	11154142	1301	1303	O
increased	11154142	1304	1313	B-Observation
risk	11154142	1314	1318	B-Outcome
of	11154142	1319	1321	I-Outcome
arterial	11154142	1322	1330	I-Outcome
thromboembolism	11154142	1331	1346	I-Outcome
in	11154142	1347	1349	O
postmenopausal	11154142	1350	1364	B-Participant
women	11154142	1365	1370	I-Participant
using	11154142	1371	1376	O
unopposed	11154142	1377	1386	B-Intervention
estrogen	11154142	1387	1395	I-Intervention
replacement	11154142	1396	1407	I-Intervention
.	11154142	1408	1409	O

Sertraline	11156811	0	10	B-Intervention
treatment	11156811	11	20	O
of	11156811	21	23	O
generalized	11156811	24	35	B-Participant
social	11156811	36	42	I-Participant
phobia	11156811	43	49	I-Participant
:	11156811	50	51	O
a	11156811	52	53	O
20-week	11156811	54	61	O
,	11156811	62	63	O
double-blind	11156811	64	76	O
,	11156811	77	78	O
placebo-controlled	11156811	79	97	O
study	11156811	98	103	O
.	11156811	104	105	O

OBJECTIVE	11156811	106	115	O
The	11156811	116	119	O
authors	11156811	120	127	O
evaluated	11156811	128	137	O
the	11156811	138	141	O
efficacy	11156811	142	150	B-Outcome
,	11156811	151	152	O
safety	11156811	153	159	B-Outcome
,	11156811	160	161	O
and	11156811	162	165	O
tolerability	11156811	166	178	B-Outcome
of	11156811	179	181	O
sertraline	11156811	182	192	B-Intervention
,	11156811	193	194	O
a	11156811	195	196	O
selective	11156811	197	206	O
serotonin	11156811	207	216	O
reuptake	11156811	217	225	O
inhibitor	11156811	226	235	O
,	11156811	236	237	O
in	11156811	238	240	O
the	11156811	241	244	O
treatment	11156811	245	254	O
of	11156811	255	257	O
generalized	11156811	258	269	B-Participant
social	11156811	270	276	I-Participant
phobia	11156811	277	283	I-Participant
.	11156811	284	285	O

METHOD	11156811	286	292	O
Adult	11156811	293	298	B-Participant
outpatients	11156811	299	310	I-Participant
with	11156811	311	315	O
generalized	11156811	316	327	B-Participant
social	11156811	328	334	I-Participant
phobia	11156811	335	341	I-Participant
(	11156811	342	343	O
N=204	11156811	344	349	O
)	11156811	350	351	O
from	11156811	352	356	O
10	11156811	357	359	O
Canadian	11156811	360	368	O
centers	11156811	369	376	O
were	11156811	377	381	O
randomly	11156811	382	390	O
assigned	11156811	391	399	O
to	11156811	400	402	O
receive	11156811	403	410	O
sertraline	11156811	411	421	B-Intervention
or	11156811	422	424	O
placebo	11156811	425	432	B-Intervention
in	11156811	433	435	O
a	11156811	436	437	O
2:1	11156811	438	441	O
ratio	11156811	442	447	O
for	11156811	448	451	O
a	11156811	452	453	O
20-week	11156811	454	461	O
double-blind	11156811	462	474	O
study	11156811	475	480	O
following	11156811	481	490	O
a	11156811	491	492	O
1-week	11156811	493	499	O
,	11156811	500	501	O
single-blind	11156811	502	514	O
,	11156811	515	516	O
placebo	11156811	517	524	O
run-in	11156811	525	531	O
.	11156811	532	533	O

The	11156811	534	537	O
initial	11156811	538	545	O
dose	11156811	546	550	O
of	11156811	551	553	O
sertraline	11156811	554	564	B-Intervention
was	11156811	565	568	O
50	11156811	569	571	O
mg/day	11156811	572	578	O
with	11156811	579	583	O
increases	11156811	584	593	O
of	11156811	594	596	O
50	11156811	597	599	O
mg/day	11156811	600	606	O
every	11156811	607	612	O
3	11156811	613	614	O
weeks	11156811	615	620	O
permitted	11156811	621	630	O
after	11156811	631	636	O
the	11156811	637	640	O
fourth	11156811	641	647	O
week	11156811	648	652	O
of	11156811	653	655	O
treatment	11156811	656	665	O
(	11156811	666	667	O
dosing	11156811	668	674	O
was	11156811	675	678	O
flexible	11156811	679	687	O
up	11156811	688	690	O
to	11156811	691	693	O
a	11156811	694	695	O
maximum	11156811	696	703	O
of	11156811	704	706	O
200	11156811	707	710	O
mg/day	11156811	711	717	O
)	11156811	718	719	O
.	11156811	720	721	O

Primary	11156811	722	729	O
efficacy	11156811	730	738	O
assessments	11156811	739	750	O
were	11156811	751	755	O
the	11156811	756	759	O
percentage	11156811	760	770	B-Outcome
of	11156811	771	773	I-Outcome
patients	11156811	774	782	I-Outcome
rated	11156811	783	788	I-Outcome
much	11156811	789	793	I-Outcome
or	11156811	794	796	I-Outcome
very	11156811	797	801	I-Outcome
much	11156811	802	806	I-Outcome
improved	11156811	807	815	I-Outcome
on	11156811	816	818	I-Outcome
the	11156811	819	822	I-Outcome
Clinical	11156811	823	831	I-Outcome
Global	11156811	832	838	I-Outcome
Impression	11156811	839	849	I-Outcome
(	11156811	850	851	I-Outcome
CGI	11156811	852	855	I-Outcome
)	11156811	856	857	I-Outcome
improvement	11156811	858	869	I-Outcome
item	11156811	870	874	I-Outcome
and	11156811	875	878	O
the	11156811	879	882	O
mean	11156811	883	887	B-Outcome
changes	11156811	888	895	I-Outcome
from	11156811	896	900	I-Outcome
baseline	11156811	901	909	I-Outcome
to	11156811	910	912	I-Outcome
study	11156811	913	918	I-Outcome
endpoint	11156811	919	927	I-Outcome
in	11156811	928	930	I-Outcome
total	11156811	931	936	I-Outcome
score	11156811	937	942	I-Outcome
on	11156811	943	945	I-Outcome
the	11156811	946	949	I-Outcome
social	11156811	950	956	I-Outcome
phobia	11156811	957	963	I-Outcome
subscale	11156811	964	972	I-Outcome
of	11156811	973	975	I-Outcome
the	11156811	976	979	I-Outcome
Marks	11156811	980	985	I-Outcome
Fear	11156811	986	990	I-Outcome
Questionnaire	11156811	991	1004	I-Outcome
and	11156811	1005	1008	O
total	11156811	1009	1014	B-Outcome
score	11156811	1015	1020	I-Outcome
on	11156811	1021	1023	I-Outcome
the	11156811	1024	1027	I-Outcome
Brief	11156811	1028	1033	I-Outcome
Social	11156811	1034	1040	I-Outcome
Phobia	11156811	1041	1047	I-Outcome
Scale	11156811	1048	1053	I-Outcome
.	11156811	1054	1055	O

RESULTS	11156811	1056	1063	O
In	11156811	1064	1066	O
intent-to-treat	11156811	1067	1082	O
endpoint	11156811	1083	1091	O
analyses	11156811	1092	1100	O
of	11156811	1101	1103	O
203	11156811	1104	1107	O
of	11156811	1108	1110	O
the	11156811	1111	1114	O
patients	11156811	1115	1123	O
,	11156811	1124	1125	O
significantly	11156811	1126	1139	B-Count
more	11156811	1140	1144	I-Count
of	11156811	1145	1147	O
the	11156811	1148	1151	O
134	11156811	1152	1155	O
patients	11156811	1156	1164	O
given	11156811	1165	1170	O
sertraline	11156811	1171	1181	B-Intervention
(	11156811	1182	1183	O
N=71	11156811	1184	1188	O
[	11156811	1189	1190	O
53	11156811	1191	1193	O
%	11156811	1194	1195	O
]	11156811	1196	1197	O
)	11156811	1198	1199	O
than	11156811	1200	1204	O
of	11156811	1205	1207	O
the	11156811	1208	1211	O
69	11156811	1212	1214	O
patients	11156811	1215	1223	O
receiving	11156811	1224	1233	O
placebo	11156811	1234	1241	B-Intervention
(	11156811	1242	1243	O
N=20	11156811	1244	1248	O
[	11156811	1249	1250	O
29	11156811	1251	1253	O
%	11156811	1254	1255	O
]	11156811	1256	1257	O
)	11156811	1258	1259	O
were	11156811	1260	1264	O
considered	11156811	1265	1275	O
responders	11156811	1276	1286	B-Outcome
according	11156811	1287	1296	I-Outcome
to	11156811	1297	1299	I-Outcome
their	11156811	1300	1305	I-Outcome
CGI	11156811	1306	1309	I-Outcome
improvement	11156811	1310	1321	I-Outcome
scores	11156811	1322	1328	I-Outcome
at	11156811	1329	1331	O
the	11156811	1332	1335	O
end	11156811	1336	1339	O
of	11156811	1340	1342	O
treatment	11156811	1343	1352	O
.	11156811	1353	1354	O

The	11156811	1355	1358	O
mean	11156811	1359	1363	B-Outcome
reductions	11156811	1364	1374	I-Outcome
in	11156811	1375	1377	I-Outcome
the	11156811	1378	1381	I-Outcome
social	11156811	1382	1388	I-Outcome
phobia	11156811	1389	1395	I-Outcome
subscale	11156811	1396	1404	I-Outcome
of	11156811	1405	1407	I-Outcome
the	11156811	1408	1411	I-Outcome
Marks	11156811	1412	1417	I-Outcome
Fear	11156811	1418	1422	I-Outcome
Questionnaire	11156811	1423	1436	I-Outcome
and	11156811	1437	1440	O
in	11156811	1441	1443	B-Outcome
the	11156811	1444	1447	I-Outcome
total	11156811	1448	1453	I-Outcome
score	11156811	1454	1459	I-Outcome
on	11156811	1460	1462	I-Outcome
the	11156811	1463	1466	I-Outcome
Brief	11156811	1467	1472	I-Outcome
Social	11156811	1473	1479	I-Outcome
Phobia	11156811	1480	1486	I-Outcome
Scale	11156811	1487	1492	I-Outcome
were	11156811	1493	1497	O
32.6	11156811	1498	1502	B-Observation
%	11156811	1503	1504	I-Observation
and	11156811	1505	1508	O
34.3	11156811	1509	1513	B-Observation
%	11156811	1514	1515	I-Observation
in	11156811	1516	1518	O
the	11156811	1519	1522	O
sertraline	11156811	1523	1533	B-Intervention
group	11156811	1534	1539	O
and	11156811	1540	1543	O
10.8	11156811	1544	1548	B-Observation
%	11156811	1549	1550	I-Observation
and	11156811	1551	1554	O
18.6	11156811	1555	1559	B-Observation
%	11156811	1560	1561	I-Observation
in	11156811	1562	1564	O
the	11156811	1565	1568	O
placebo	11156811	1569	1576	B-Intervention
group	11156811	1577	1582	O
,	11156811	1583	1584	O
respectively	11156811	1585	1597	O
.	11156811	1598	1599	O

Analysis	11156811	1600	1608	O
of	11156811	1609	1611	O
covariance	11156811	1612	1622	O
showed	11156811	1623	1629	O
superiority	11156811	1630	1641	B-Observation
of	11156811	1642	1644	O
sertraline	11156811	1645	1655	B-Intervention
over	11156811	1656	1660	O
placebo	11156811	1661	1668	B-Intervention
on	11156811	1669	1671	O
all	11156811	1672	1675	B-Outcome
primary	11156811	1676	1683	I-Outcome
and	11156811	1684	1687	I-Outcome
secondary	11156811	1688	1697	I-Outcome
efficacy	11156811	1698	1706	I-Outcome
measures	11156811	1707	1715	I-Outcome
.	11156811	1716	1717	O

Sertraline	11156811	1718	1728	B-Intervention
was	11156811	1729	1732	O
well	11156811	1733	1737	B-Observation
tolerated	11156811	1738	1747	B-Outcome
:	11156811	1748	1749	O
103	11156811	1750	1753	B-Count
(	11156811	1754	1755	I-Count
76	11156811	1756	1758	I-Count
%	11156811	1759	1760	I-Count
)	11156811	1761	1762	I-Count
of	11156811	1763	1765	O
the	11156811	1766	1769	O
135	11156811	1770	1773	O
sertraline-treated	11156811	1774	1792	B-Intervention
patients	11156811	1793	1801	O
and	11156811	1802	1805	O
54	11156811	1806	1808	B-Count
(	11156811	1809	1810	I-Count
78	11156811	1811	1813	I-Count
%	11156811	1814	1815	I-Count
)	11156811	1816	1817	I-Count
of	11156811	1818	1820	O
the	11156811	1821	1824	O
69	11156811	1825	1827	O
placebo-treated	11156811	1828	1843	B-Intervention
patients	11156811	1844	1852	O
completed	11156811	1853	1862	B-Outcome
the	11156811	1863	1866	I-Outcome
study	11156811	1867	1872	I-Outcome
.	11156811	1873	1874	O

CONCLUSIONS	11156811	1875	1886	O
Sertraline	11156811	1887	1897	B-Intervention
is	11156811	1898	1900	O
an	11156811	1901	1903	O
effective	11156811	1904	1913	B-Observation
treatment	11156811	1914	1923	O
for	11156811	1924	1927	O
patients	11156811	1928	1936	O
with	11156811	1937	1941	O
generalized	11156811	1942	1953	B-Participant
social	11156811	1954	1960	I-Participant
phobia	11156811	1961	1967	I-Participant
.	11156811	1968	1969	O

The	11159256	0	3	O
response	11159256	4	12	O
of	11159256	13	15	O
neuropathic	11159256	16	27	B-Outcome
pain	11159256	28	32	I-Outcome
and	11159256	33	36	O
pain	11159256	37	41	B-Outcome
in	11159256	42	44	I-Outcome
complex	11159256	45	52	I-Outcome
regional	11159256	53	61	I-Outcome
pain	11159256	62	66	I-Outcome
syndrome	11159256	67	75	I-Outcome
I	11159256	76	77	I-Outcome
to	11159256	78	80	O
carbamazepine	11159256	81	94	B-Intervention
and	11159256	95	98	O
sustained-release	11159256	99	116	B-Intervention
morphine	11159256	117	125	I-Intervention
in	11159256	126	128	O
patients	11159256	129	137	O
pretreated	11159256	138	148	O
with	11159256	149	153	O
spinal	11159256	154	160	B-Participant
cord	11159256	161	165	I-Participant
stimulation	11159256	166	177	I-Participant
:	11159256	178	179	O
a	11159256	180	181	O
double-blinded	11159256	182	196	O
randomized	11159256	197	207	O
study	11159256	208	213	O
.	11159256	214	215	O

Forty-three	11159256	216	227	O
patients	11159256	228	236	O
with	11159256	237	241	O
peripheral	11159256	242	252	B-Participant
neuropathic	11159256	253	264	I-Participant
pain	11159256	265	269	I-Participant
,	11159256	270	271	O
exclusively	11159256	272	283	O
pain	11159256	284	288	O
reduced	11159256	289	296	O
by	11159256	297	299	O
spinal	11159256	300	306	B-Participant
cord	11159256	307	311	I-Participant
stimulation	11159256	312	323	I-Participant
(	11159256	324	325	I-Participant
SCS	11159256	326	329	I-Participant
)	11159256	330	331	I-Participant
,	11159256	332	333	O
were	11159256	334	338	O
switched	11159256	339	347	O
into	11159256	348	352	O
a	11159256	353	354	O
painful	11159256	355	362	O
state	11159256	363	368	O
after	11159256	369	374	O
SCS	11159256	375	378	O
inactivation	11159256	379	391	O
.	11159256	392	393	O

This	11159256	394	398	O
mode	11159256	399	403	O
was	11159256	404	407	O
used	11159256	408	412	O
to	11159256	413	415	O
assess	11159256	416	422	O
the	11159256	423	426	O
pain-relieving	11159256	427	441	B-Outcome
effect	11159256	442	448	I-Outcome
of	11159256	449	451	O
carbamazepine	11159256	452	465	B-Intervention
(	11159256	466	467	I-Intervention
CMZ	11159256	468	471	I-Intervention
)	11159256	472	473	I-Intervention
and	11159256	474	477	O
opioids	11159256	478	485	B-Intervention
in	11159256	486	488	O
a	11159256	489	490	O
double-blinded	11159256	491	505	O
,	11159256	506	507	O
placebo-controlled	11159256	508	526	O
trial	11159256	527	532	O
.	11159256	533	534	O

In	11159256	535	537	O
Phase	11159256	538	543	O
1	11159256	544	545	O
,	11159256	546	547	O
the	11159256	548	551	O
patients	11159256	552	560	O
were	11159256	561	565	O
randomly	11159256	566	574	O
allocated	11159256	575	584	O
to	11159256	585	587	O
receive	11159256	588	595	O
either	11159256	596	602	O
CMZ	11159256	603	606	B-Intervention
(	11159256	607	608	O
600	11159256	609	612	O
mg/d	11159256	613	617	O
)	11159256	618	619	O
or	11159256	620	622	O
placebo	11159256	623	630	B-Intervention
during	11159256	631	637	O
an	11159256	638	640	O
SCS-free	11159256	641	649	O
period	11159256	650	656	O
of	11159256	657	659	O
8	11159256	660	661	O
days	11159256	662	666	O
.	11159256	667	668	O

In	11159256	669	671	O
Phase	11159256	672	677	O
2	11159256	678	679	O
,	11159256	680	681	O
after	11159256	682	687	O
a	11159256	688	689	O
CMZ	11159256	690	693	O
elimination	11159256	694	705	O
interval	11159256	706	714	O
of	11159256	715	717	O
7	11159256	718	719	O
days	11159256	720	724	O
,	11159256	725	726	O
38	11159256	727	729	O
patients	11159256	730	738	O
received	11159256	739	747	O
either	11159256	748	754	O
sustained-release	11159256	755	772	B-Intervention
morphine	11159256	773	781	I-Intervention
(	11159256	782	783	O
90	11159256	784	786	O
mg/d	11159256	787	791	O
)	11159256	792	793	O
or	11159256	794	796	O
placebo	11159256	797	804	B-Intervention
for	11159256	805	808	O
8	11159256	809	810	O
days	11159256	811	815	O
.	11159256	816	817	O

In	11159256	818	820	O
cases	11159256	821	826	O
of	11159256	827	829	O
intolerable	11159256	830	841	B-Outcome
pain	11159256	842	846	I-Outcome
,	11159256	847	848	O
the	11159256	849	852	O
patients	11159256	853	861	O
were	11159256	862	866	O
authorized	11159256	867	877	O
to	11159256	878	880	O
reactivate	11159256	881	891	O
their	11159256	892	897	O
SCS	11159256	898	901	O
.	11159256	902	903	O

The	11159256	904	907	O
pain	11159256	908	912	B-Outcome
intensity	11159256	913	922	I-Outcome
was	11159256	923	926	O
rated	11159256	927	932	O
on	11159256	933	935	O
a	11159256	936	937	O
numeric	11159256	938	945	O
analog	11159256	946	952	O
scale	11159256	953	958	O
.	11159256	959	960	O

In	11159256	961	963	O
38	11159256	964	966	O
patients	11159256	967	975	O
who	11159256	976	979	O
completed	11159256	980	989	O
Phase	11159256	990	995	O
1	11159256	996	997	O
,	11159256	998	999	O
significant	11159256	1000	1011	B-Observation
delay	11159256	1012	1017	I-Observation
in	11159256	1018	1020	O
pain	11159256	1021	1025	B-Outcome
increase	11159256	1026	1034	I-Outcome
was	11159256	1035	1038	O
observed	11159256	1039	1047	O
in	11159256	1048	1050	O
the	11159256	1051	1054	O
CMZ	11159256	1055	1058	B-Intervention
group	11159256	1059	1064	O
as	11159256	1065	1067	O
compared	11159256	1068	1076	O
with	11159256	1077	1081	O
placebo	11159256	1082	1089	B-Intervention
(	11159256	1090	1091	O
P	11159256	1092	1093	O
=	11159256	1094	1095	O
0.038	11159256	1096	1101	O
)	11159256	1102	1103	O
.	11159256	1104	1105	O

In	11159256	1106	1108	O
Phase	11159256	1109	1114	O
2	11159256	1115	1116	O
,	11159256	1117	1118	O
the	11159256	1119	1122	O
trend	11159256	1123	1128	B-Outcome
observed	11159256	1129	1137	O
with	11159256	1138	1142	O
morphine	11159256	1143	1151	B-Intervention
was	11159256	1152	1155	O
insignificant	11159256	1156	1169	O
(	11159256	1170	1171	O
P	11159256	1172	1173	O
=	11159256	1174	1175	O
0.41	11159256	1176	1180	O
)	11159256	1181	1182	O
.	11159256	1183	1184	O

Two	11159256	1185	1188	B-Count
CMZ	11159256	1189	1192	B-Intervention
patients	11159256	1193	1201	O
and	11159256	1202	1205	O
one	11159256	1206	1209	B-Count
morphine	11159256	1210	1218	B-Intervention
patient	11159256	1219	1226	O
showed	11159256	1227	1233	O
complete	11159256	1234	1242	B-Outcome
pain	11159256	1243	1247	I-Outcome
relief	11159256	1248	1254	I-Outcome
and	11159256	1255	1258	O
preferred	11159256	1259	1268	O
to	11159256	1269	1271	O
continue	11159256	1272	1280	O
the	11159256	1281	1284	O
medication	11159256	1285	1295	O
.	11159256	1296	1297	O

Thirty-five	11159256	1298	1309	B-Count
patients	11159256	1310	1318	I-Count
returned	11159256	1319	1327	B-Outcome
to	11159256	1328	1330	I-Outcome
SCS	11159256	1331	1334	I-Outcome
.	11159256	1335	1336	O

We	11159256	1337	1339	O
conclude	11159256	1340	1348	O
that	11159256	1349	1353	O
CMZ	11159256	1354	1357	B-Intervention
is	11159256	1358	1360	O
effective	11159256	1361	1370	B-Observation
in	11159256	1371	1373	O
peripheral	11159256	1374	1384	B-Outcome
neuropathic	11159256	1385	1396	I-Outcome
pain	11159256	1397	1401	I-Outcome
.	11159256	1402	1403	O

Morphine	11159256	1404	1412	B-Intervention
obviously	11159256	1413	1422	O
requires	11159256	1423	1431	O
larger	11159256	1432	1438	B-Observation
individually	11159256	1439	1451	B-Outcome
titrated	11159256	1452	1460	I-Outcome
dosages	11159256	1461	1468	I-Outcome
than	11159256	1469	1473	O
those	11159256	1474	1479	O
used	11159256	1480	1484	O
in	11159256	1485	1487	O
this	11159256	1488	1492	O
study	11159256	1493	1498	O
for	11159256	1499	1502	O
results	11159256	1503	1510	O
to	11159256	1511	1513	O
be	11159256	1514	1516	O
adequately	11159256	1517	1527	O
interpreted	11159256	1528	1539	O
.	11159256	1540	1541	O

Counselor	11162323	0	9	B-Intervention
and	11162323	10	13	I-Intervention
stimulus	11162323	14	22	I-Intervention
control	11162323	23	30	I-Intervention
enhancements	11162323	31	43	I-Intervention
of	11162323	44	46	I-Intervention
a	11162323	47	48	I-Intervention
stage-matched	11162323	49	62	I-Intervention
expert	11162323	63	69	I-Intervention
system	11162323	70	76	I-Intervention
intervention	11162323	77	89	I-Intervention
for	11162323	90	93	O
smokers	11162323	94	101	B-Participant
in	11162323	102	104	O
a	11162323	105	106	O
managed	11162323	107	114	O
care	11162323	115	119	O
setting	11162323	120	127	O
.	11162323	128	129	O

BACKGROUND	11162323	130	140	O
Previous	11162323	141	149	O
research	11162323	150	158	O
has	11162323	159	162	O
demonstrated	11162323	163	175	O
the	11162323	176	179	O
efficacy	11162323	180	188	O
of	11162323	189	191	O
an	11162323	192	194	O
interactive	11162323	195	206	O
expert	11162323	207	213	O
system	11162323	214	220	O
intervention	11162323	221	233	O
for	11162323	234	237	O
smoking	11162323	238	245	O
cessation	11162323	246	255	O
for	11162323	256	259	O
a	11162323	260	261	O
general	11162323	262	269	O
population	11162323	270	280	O
.	11162323	281	282	O

The	11162323	283	286	O
intervention	11162323	287	299	O
provides	11162323	300	308	O
individualized	11162323	309	323	O
feedback	11162323	324	332	O
that	11162323	333	337	O
guides	11162323	338	344	O
participants	11162323	345	357	O
through	11162323	358	365	O
the	11162323	366	369	O
stages	11162323	370	376	O
of	11162323	377	379	O
change	11162323	380	386	O
for	11162323	387	390	O
cessation	11162323	391	400	O
.	11162323	401	402	O

Enhancing	11162323	403	412	O
the	11162323	413	416	O
expert	11162323	417	423	B-Intervention
system	11162323	424	430	I-Intervention
by	11162323	431	433	I-Intervention
adding	11162323	434	440	I-Intervention
proactive	11162323	441	450	I-Intervention
telephone	11162323	451	460	I-Intervention
counseling	11162323	461	471	I-Intervention
or	11162323	472	474	I-Intervention
a	11162323	475	476	I-Intervention
stimulus	11162323	477	485	I-Intervention
control	11162323	486	493	I-Intervention
computer	11162323	494	502	I-Intervention
designed	11162323	503	511	O
to	11162323	512	514	O
produce	11162323	515	522	O
nicotine	11162323	523	531	O
fading	11162323	532	538	O
could	11162323	539	544	O
produce	11162323	545	552	B-Observation
preventive	11162323	553	563	B-Outcome
programs	11162323	564	572	I-Outcome
with	11162323	573	577	O
greater	11162323	578	585	B-Observation
population	11162323	586	596	B-Outcome
impacts	11162323	597	604	I-Outcome
.	11162323	605	606	O

METHODS	11162323	607	614	O
Four	11162323	615	619	O
interventions	11162323	620	633	O
were	11162323	634	638	O
compared	11162323	639	647	O
:	11162323	648	649	O
(	11162323	650	651	O
a	11162323	652	653	O
)	11162323	654	655	O
the	11162323	656	659	O
interactive	11162323	660	671	B-Intervention
expert	11162323	672	678	I-Intervention
system	11162323	679	685	I-Intervention
intervention	11162323	686	698	I-Intervention
;	11162323	699	700	O
(	11162323	701	702	O
b	11162323	703	704	O
)	11162323	705	706	O
the	11162323	707	710	O
expert	11162323	711	717	B-Intervention
system	11162323	718	724	I-Intervention
intervention	11162323	725	737	I-Intervention
plus	11162323	738	742	I-Intervention
counselor	11162323	743	752	I-Intervention
calls	11162323	753	758	I-Intervention
;	11162323	759	760	O
(	11162323	761	762	O
c	11162323	763	764	O
)	11162323	765	766	O
the	11162323	767	770	O
expert	11162323	771	777	B-Intervention
system	11162323	778	784	I-Intervention
intervention	11162323	785	797	I-Intervention
plus	11162323	798	802	I-Intervention
the	11162323	803	806	I-Intervention
stimulus	11162323	807	815	I-Intervention
control	11162323	816	823	I-Intervention
computer	11162323	824	832	I-Intervention
;	11162323	833	834	O
and	11162323	835	838	O
(	11162323	839	840	O
d	11162323	841	842	O
)	11162323	843	844	O
an	11162323	845	847	B-Intervention
assessment	11162323	848	858	I-Intervention
only	11162323	859	863	I-Intervention
condition	11162323	864	873	I-Intervention
.	11162323	874	875	O

A	11162323	876	877	O
4	11162323	878	879	O
(	11162323	880	881	O
intervention	11162323	882	894	O
)	11162323	895	896	O
x	11162323	897	898	O
4	11162323	899	900	O
(	11162323	901	902	O
occasions	11162323	903	912	O
)	11162323	913	914	O
(	11162323	915	916	O
0,6,12	11162323	917	923	O
,	11162323	924	925	O
and	11162323	926	929	O
18	11162323	930	932	O
months	11162323	933	939	O
)	11162323	940	941	O
design	11162323	942	948	O
was	11162323	949	952	O
used	11162323	953	957	O
.	11162323	958	959	O

Smokers	11162323	960	967	B-Participant
were	11162323	968	972	O
contacted	11162323	973	982	O
at	11162323	983	985	O
home	11162323	986	990	O
via	11162323	991	994	O
telephone	11162323	995	1004	O
or	11162323	1005	1007	O
mail	11162323	1008	1012	O
.	11162323	1013	1014	O

The	11162323	1015	1018	O
initial	11162323	1019	1026	O
subject	11162323	1027	1034	O
pool	11162323	1035	1039	O
was	11162323	1040	1043	O
the	11162323	1044	1047	O
24,178	11162323	1048	1054	O
members	11162323	1055	1062	O
of	11162323	1063	1065	O
a	11162323	1066	1067	O
managed	11162323	1068	1075	O
care	11162323	1076	1080	O
company	11162323	1081	1088	O
.	11162323	1089	1090	O

Screening	11162323	1091	1100	O
was	11162323	1101	1104	O
completed	11162323	1105	1114	O
for	11162323	1115	1118	O
19,236	11162323	1119	1125	O
members	11162323	1126	1133	O
(	11162323	1134	1135	O
79.6	11162323	1136	1140	O
%	11162323	1141	1142	O
)	11162323	1143	1144	O
,	11162323	1145	1146	O
of	11162323	1147	1149	O
whom	11162323	1150	1154	O
4,653	11162323	1155	1160	O
were	11162323	1161	1165	O
smokers	11162323	1166	1173	B-Participant
;	11162323	1174	1175	O
85.3	11162323	1176	1180	O
%	11162323	1181	1182	O
of	11162323	1183	1185	O
the	11162323	1186	1189	O
smokers	11162323	1190	1197	B-Participant
were	11162323	1198	1202	O
enrolled	11162323	1203	1211	O
.	11162323	1212	1213	O

RESULTS	11162323	1214	1221	O
Thirty-eight	11162323	1222	1234	O
percent	11162323	1235	1242	O
were	11162323	1243	1247	O
in	11162323	1248	1250	O
the	11162323	1251	1254	O
precontemplation	11162323	1255	1271	B-Participant
stage	11162323	1272	1277	I-Participant
,	11162323	1278	1279	O
45	11162323	1280	1282	O
%	11162323	1283	1284	O
in	11162323	1285	1287	O
the	11162323	1288	1291	O
contemplation	11162323	1292	1305	B-Participant
stage	11162323	1306	1311	I-Participant
,	11162323	1312	1313	O
and	11162323	1314	1317	O
only	11162323	1318	1322	O
17	11162323	1323	1325	O
%	11162323	1326	1327	O
in	11162323	1328	1330	O
the	11162323	1331	1334	O
preparation	11162323	1335	1346	B-Participant
stage	11162323	1347	1352	I-Participant
.	11162323	1353	1354	O

At	11162323	1355	1357	O
18	11162323	1358	1360	O
months	11162323	1361	1367	O
,	11162323	1368	1369	O
the	11162323	1370	1373	O
expert	11162323	1374	1380	B-Intervention
system	11162323	1381	1387	I-Intervention
resulted	11162323	1388	1396	O
in	11162323	1397	1399	O
23.2	11162323	1400	1404	B-Observation
%	11162323	1405	1406	I-Observation
point	11162323	1407	1412	B-Outcome
prevalence	11162323	1413	1423	I-Outcome
abstinence	11162323	1424	1434	I-Outcome
,	11162323	1435	1436	O
which	11162323	1437	1442	O
was	11162323	1443	1446	O
33	11162323	1447	1449	B-Observation
%	11162323	1450	1451	I-Observation
greater	11162323	1452	1459	I-Observation
than	11162323	1460	1464	O
that	11162323	1465	1469	O
of	11162323	1470	1472	O
assessment	11162323	1473	1483	B-Intervention
only	11162323	1484	1488	I-Intervention
.	11162323	1489	1490	O

The	11162323	1491	1494	O
counselor	11162323	1495	1504	B-Intervention
enhancement	11162323	1505	1516	I-Intervention
produced	11162323	1517	1525	O
increased	11162323	1526	1535	B-Observation
cessation	11162323	1536	1545	B-Outcome
at	11162323	1546	1548	O
12	11162323	1549	1551	O
months	11162323	1552	1558	O
but	11162323	1559	1562	O
not	11162323	1563	1566	O
at	11162323	1567	1569	O
18	11162323	1570	1572	O
months	11162323	1573	1579	O
.	11162323	1580	1581	O

The	11162323	1582	1585	O
stimulus	11162323	1586	1594	B-Intervention
control	11162323	1595	1602	I-Intervention
computer	11162323	1603	1611	I-Intervention
produced	11162323	1612	1620	O
no	11162323	1621	1623	O
improvement	11162323	1624	1635	B-Outcome
,	11162323	1636	1637	O
resulting	11162323	1638	1647	O
in	11162323	1648	1650	O
20	11162323	1651	1653	B-Observation
%	11162323	1654	1655	I-Observation
worse	11162323	1656	1661	I-Observation
cessation	11162323	1662	1671	B-Outcome
rates	11162323	1672	1677	I-Outcome
than	11162323	1678	1682	O
the	11162323	1683	1686	O
assessment	11162323	1687	1697	B-Intervention
only	11162323	1698	1702	I-Intervention
condition	11162323	1703	1712	I-Intervention
.	11162323	1713	1714	O

CONCLUSIONS	11162323	1715	1726	O
The	11162323	1727	1730	O
enhanced	11162323	1731	1739	B-Intervention
conditions	11162323	1740	1750	I-Intervention
failed	11162323	1751	1757	O
to	11162323	1758	1760	O
outperform	11162323	1761	1771	B-Observation
the	11162323	1772	1775	O
expert	11162323	1776	1782	B-Intervention
system	11162323	1783	1789	I-Intervention
alone	11162323	1790	1795	I-Intervention
.	11162323	1796	1797	O

The	11162323	1798	1801	O
study	11162323	1802	1807	O
also	11162323	1808	1812	O
demonstrated	11162323	1813	1825	O
the	11162323	1826	1829	O
ability	11162323	1830	1837	O
of	11162323	1838	1840	O
the	11162323	1841	1844	O
interactive	11162323	1845	1856	B-Intervention
expert	11162323	1857	1863	I-Intervention
system	11162323	1864	1870	I-Intervention
to	11162323	1871	1873	O
produce	11162323	1874	1881	O
significantly	11162323	1882	1895	B-Observation
greater	11162323	1896	1903	I-Observation
cessation	11162323	1904	1913	B-Outcome
in	11162323	1914	1916	O
a	11162323	1917	1918	O
population	11162323	1919	1929	O
of	11162323	1930	1932	O
smokers	11162323	1933	1940	B-Participant
than	11162323	1941	1945	O
assessment	11162323	1946	1956	B-Intervention
alone	11162323	1957	1962	I-Intervention
.	11162323	1963	1964	O

Spatial	11196013	0	7	B-Intervention
orientation	11196013	8	19	I-Intervention
adjustments	11196013	20	31	I-Intervention
in	11196013	32	34	O
children	11196013	35	43	B-Participant
with	11196013	44	48	O
autism	11196013	49	55	B-Participant
in	11196013	56	58	O
Hong	11196013	59	63	O
Kong	11196013	64	68	O
.	11196013	69	70	O

Abnormal	11196013	71	79	O
spatial	11196013	80	87	O
orientation	11196013	88	99	O
and	11196013	100	103	O
body	11196013	104	108	O
postures	11196013	109	117	O
in	11196013	118	120	O
children	11196013	121	129	O
with	11196013	130	134	O
autism	11196013	135	141	O
often	11196013	142	147	O
interfere	11196013	148	157	O
with	11196013	158	162	O
visual	11196013	163	169	O
abilities	11196013	170	179	O
to	11196013	180	182	O
attend	11196013	183	189	O
tasks	11196013	190	195	O
and	11196013	196	199	O
social	11196013	200	206	O
interactions	11196013	207	219	O
.	11196013	220	221	O

Twenty-four	11196013	222	233	O
children	11196013	234	242	B-Participant
diagnosed	11196013	243	252	O
with	11196013	253	257	O
autism	11196013	258	264	B-Participant
from	11196013	265	269	O
Kowloon	11196013	270	277	O
,	11196013	278	279	O
Hong	11196013	280	284	O
Kong	11196013	285	289	O
were	11196013	290	294	O
assessed	11196013	295	303	O
for	11196013	304	307	O
spatial	11196013	308	315	B-Outcome
orientation	11196013	316	327	I-Outcome
and	11196013	328	331	O
spatial	11196013	332	339	B-Outcome
management	11196013	340	350	I-Outcome
abilities	11196013	351	360	I-Outcome
.	11196013	361	362	O

Positive	11196013	363	371	B-Observation
changes	11196013	372	379	I-Observation
in	11196013	380	382	O
spatial	11196013	383	390	B-Outcome
orientation	11196013	391	402	I-Outcome
were	11196013	403	407	O
evident	11196013	408	415	O
when	11196013	416	420	O
the	11196013	421	424	O
children	11196013	425	433	O
wore	11196013	434	438	O
ambient	11196013	439	446	B-Intervention
prism	11196013	447	452	I-Intervention
lenses	11196013	453	459	I-Intervention
and	11196013	460	463	O
included	11196013	464	472	O
changes	11196013	473	480	O
in	11196013	481	483	O
posture	11196013	484	491	O
from	11196013	492	496	O
slanted	11196013	497	504	O
to	11196013	505	507	O
erect	11196013	508	513	O
.	11196013	514	515	O

Adjustments	11196013	516	527	B-Intervention
in	11196013	528	530	I-Intervention
spatial	11196013	531	538	I-Intervention
management	11196013	539	549	I-Intervention
were	11196013	550	554	O
evident	11196013	555	562	O
in	11196013	563	565	O
improved	11196013	566	574	B-Observation
ball	11196013	575	579	B-Outcome
catching	11196013	580	588	I-Outcome
ability	11196013	589	596	I-Outcome
,	11196013	597	598	O
a	11196013	599	600	O
task	11196013	601	605	O
requiring	11196013	606	615	O
visual	11196013	616	622	O
tracking	11196013	623	631	O
and	11196013	632	635	O
eye-hand	11196013	636	644	O
coordination	11196013	645	657	O
.	11196013	658	659	O

The	11196013	660	663	O
findings	11196013	664	672	O
suggest	11196013	673	680	O
that	11196013	681	685	O
alterations	11196013	686	697	B-Intervention
to	11196013	698	700	I-Intervention
the	11196013	701	704	I-Intervention
sensory	11196013	705	712	I-Intervention
systems	11196013	713	720	I-Intervention
may	11196013	721	724	O
lead	11196013	725	729	O
to	11196013	730	732	O
behavioral	11196013	733	743	B-Outcome
change	11196013	744	750	I-Outcome
in	11196013	751	753	O
some	11196013	754	758	O
children	11196013	759	767	B-Participant
.	11196013	768	769	O

Comparison	11196396	0	10	O
of	11196396	11	13	O
the	11196396	14	17	O
efficacy	11196396	18	26	O
of	11196396	27	29	O
fluoxetine	11196396	30	40	B-Intervention
alone	11196396	41	46	I-Intervention
vs.	11196396	47	50	O
fluoxetine	11196396	51	61	B-Intervention
plus	11196396	62	66	I-Intervention
local	11196396	67	72	I-Intervention
lidocaine	11196396	73	82	I-Intervention
ointment	11196396	83	91	I-Intervention
in	11196396	92	94	O
the	11196396	95	98	O
treatment	11196396	99	108	O
of	11196396	109	111	O
premature	11196396	112	121	B-Participant
ejaculation	11196396	122	133	I-Participant
.	11196396	134	135	O

OBJECTIVE	11196396	136	145	O
The	11196396	146	149	O
present	11196396	150	157	O
study	11196396	158	163	O
compares	11196396	164	172	O
the	11196396	173	176	O
efficacy	11196396	177	185	B-Outcome
and	11196396	186	189	O
side	11196396	190	194	B-Outcome
effects	11196396	195	202	I-Outcome
of	11196396	203	205	O
fluoxetine	11196396	206	216	B-Intervention
alone	11196396	217	222	I-Intervention
vs.	11196396	223	226	O
fluoxetine	11196396	227	237	B-Intervention
plus	11196396	238	242	I-Intervention
local	11196396	243	248	I-Intervention
lidocaine	11196396	249	258	I-Intervention
ointment	11196396	259	267	I-Intervention
in	11196396	268	270	O
the	11196396	271	274	O
treatment	11196396	275	284	O
of	11196396	285	287	O
premature	11196396	288	297	B-Participant
ejaculation	11196396	298	309	I-Participant
.	11196396	310	311	O

METHODS	11196396	312	319	O
Forty-three	11196396	320	331	O
patients	11196396	332	340	O
suffering	11196396	341	350	O
from	11196396	351	355	O
premature	11196396	356	365	B-Participant
ejaculation	11196396	366	377	I-Participant
were	11196396	378	382	O
studied	11196396	383	390	O
.	11196396	391	392	O

The	11196396	393	396	O
exclusion	11196396	397	406	O
criteria	11196396	407	415	O
were	11196396	416	420	O
erectile	11196396	421	429	B-Participant
dysfunction	11196396	430	441	I-Participant
,	11196396	442	443	O
loss	11196396	444	448	B-Participant
of	11196396	449	451	I-Participant
libido	11196396	452	458	I-Participant
,	11196396	459	460	O
alcohol	11196396	461	468	B-Participant
and	11196396	469	472	I-Participant
substance	11196396	473	482	I-Participant
abuse	11196396	483	488	I-Participant
,	11196396	489	490	O
mental	11196396	491	497	B-Participant
retardation	11196396	498	509	I-Participant
,	11196396	510	511	O
diabetes	11196396	512	520	B-Participant
mellitus	11196396	521	529	I-Participant
,	11196396	530	531	O
thyroid	11196396	532	539	B-Participant
disease	11196396	540	547	I-Participant
,	11196396	548	549	O
hypotension	11196396	550	561	B-Participant
,	11196396	562	563	O
previous	11196396	564	572	B-Participant
use	11196396	573	576	I-Participant
of	11196396	577	579	I-Participant
these	11196396	580	585	I-Participant
drugs	11196396	586	591	I-Participant
and	11196396	592	595	O
urogenital	11196396	596	606	B-Participant
infections	11196396	607	617	I-Participant
.	11196396	618	619	O

The	11196396	620	623	O
patients	11196396	624	632	O
'	11196396	633	634	O
ages	11196396	635	639	O
ranged	11196396	640	646	O
from	11196396	647	651	O
19	11196396	652	654	O
to	11196396	655	657	O
48	11196396	658	660	O
years	11196396	661	666	O
(	11196396	667	668	O
mean	11196396	669	673	O
age	11196396	674	677	O
28	11196396	678	680	O
+	11196396	681	682	O
/-	11196396	682	684	O
1.6	11196396	685	688	O
)	11196396	689	690	O
.	11196396	691	692	O

They	11196396	693	697	O
had	11196396	698	701	O
regular	11196396	702	709	B-Participant
sexual	11196396	710	716	I-Participant
lives	11196396	717	722	I-Participant
.	11196396	723	724	O

They	11196396	725	729	O
had	11196396	730	733	O
normal	11196396	734	740	B-Participant
psychiatric	11196396	741	752	I-Participant
consultation	11196396	753	765	I-Participant
and	11196396	766	769	O
the	11196396	770	773	O
Glombock	11196396	774	782	B-Participant
Rast	11196396	783	787	I-Participant
Sexual	11196396	788	794	I-Participant
Satisfactory	11196396	795	807	I-Participant
Test	11196396	808	812	I-Participant
(	11196396	813	814	I-Participant
GRISS	11196396	815	820	I-Participant
)	11196396	821	822	I-Participant
psychiatric	11196396	823	834	I-Participant
test	11196396	835	839	I-Participant
were	11196396	840	844	O
in	11196396	845	847	O
accordance	11196396	848	858	O
with	11196396	859	863	O
premature	11196396	864	873	B-Participant
ejaculation	11196396	874	885	I-Participant
.	11196396	886	887	O

RESULTS	11196396	888	895	O
The	11196396	896	899	O
patients	11196396	900	908	O
were	11196396	909	913	O
assigned	11196396	914	922	O
to	11196396	923	925	O
two	11196396	926	929	O
groups	11196396	930	936	O
.	11196396	937	938	O

Twenty-six	11196396	939	949	O
patients	11196396	950	958	O
,	11196396	959	960	O
aged	11196396	961	965	O
21	11196396	966	968	O
to	11196396	969	971	O
36	11196396	972	974	O
years	11196396	975	980	O
(	11196396	981	982	O
mean	11196396	983	987	O
age	11196396	988	991	O
27	11196396	992	994	O
)	11196396	995	996	O
,	11196396	997	998	O
received	11196396	999	1007	O
only	11196396	1008	1012	O
fluoxetine	11196396	1013	1023	B-Intervention
20	11196396	1024	1026	I-Intervention
mg/day	11196396	1027	1033	I-Intervention
(	11196396	1034	1035	I-Intervention
1	11196396	1036	1037	I-Intervention
capsule	11196396	1038	1045	I-Intervention
)	11196396	1046	1047	I-Intervention
for	11196396	1048	1051	I-Intervention
a	11196396	1052	1053	I-Intervention
week	11196396	1054	1058	I-Intervention
which	11196396	1059	1064	I-Intervention
was	11196396	1065	1068	I-Intervention
later	11196396	1069	1074	I-Intervention
increased	11196396	1075	1084	I-Intervention
to	11196396	1085	1087	I-Intervention
40	11196396	1088	1090	I-Intervention
mg/day	11196396	1091	1097	I-Intervention
(	11196396	1098	1099	I-Intervention
2	11196396	1100	1101	I-Intervention
capsules	11196396	1102	1110	I-Intervention
)	11196396	1111	1112	I-Intervention
.	11196396	1113	1114	O

Seventeen	11196396	1115	1124	O
patients	11196396	1125	1133	O
,	11196396	1134	1135	O
aged	11196396	1136	1140	O
19	11196396	1141	1143	O
to	11196396	1144	1146	O
48	11196396	1147	1149	O
years	11196396	1150	1155	O
(	11196396	1156	1157	O
mean	11196396	1158	1162	O
age	11196396	1163	1166	O
31	11196396	1167	1169	O
)	11196396	1170	1171	O
,	11196396	1172	1173	O
were	11196396	1174	1178	O
given	11196396	1179	1184	O
fluoxetine	11196396	1185	1195	B-Intervention
20	11196396	1196	1198	I-Intervention
mg/day	11196396	1199	1205	I-Intervention
plus	11196396	1206	1210	I-Intervention
local	11196396	1211	1216	I-Intervention
application	11196396	1217	1228	I-Intervention
of	11196396	1229	1231	I-Intervention
lidocaine	11196396	1232	1241	I-Intervention
ointment	11196396	1242	1250	I-Intervention
.	11196396	1251	1252	O

The	11196396	1253	1256	O
patients	11196396	1257	1265	O
and	11196396	1266	1269	O
partners	11196396	1270	1278	O
were	11196396	1279	1283	O
re-evaluated	11196396	1284	1296	O
8	11196396	1297	1298	O
weeks	11196396	1299	1304	O
after	11196396	1305	1310	O
the	11196396	1311	1314	O
treatment	11196396	1315	1324	O
.	11196396	1325	1326	O

The	11196396	1327	1330	O
results	11196396	1331	1338	O
were	11196396	1339	1343	O
classified	11196396	1344	1354	O
as	11196396	1355	1357	O
unsuccessful	11196396	1358	1370	B-Outcome
,	11196396	1371	1372	O
improvement	11196396	1373	1384	B-Outcome
and	11196396	1385	1388	O
cure	11196396	1389	1393	B-Outcome
.	11196396	1394	1395	O

The	11196396	1396	1399	O
chi-square	11196396	1400	1410	O
test	11196396	1411	1415	O
was	11196396	1416	1419	O
used	11196396	1420	1424	O
for	11196396	1425	1428	O
statistical	11196396	1429	1440	O
analysis	11196396	1441	1449	O
.	11196396	1450	1451	O

In	11196396	1452	1454	O
the	11196396	1455	1458	O
fluoxetine	11196396	1459	1469	B-Intervention
group	11196396	1470	1475	O
,	11196396	1476	1477	O
8	11196396	1478	1479	B-Count
(	11196396	1480	1481	I-Count
30.8	11196396	1482	1486	I-Count
%	11196396	1487	1488	I-Count
)	11196396	1489	1490	I-Count
patients	11196396	1491	1499	I-Count
cured	11196396	1500	1505	B-Outcome
,	11196396	1506	1507	O
11	11196396	1508	1510	B-Count
(	11196396	1511	1512	I-Count
42.2	11196396	1513	1517	I-Count
%	11196396	1518	1519	I-Count
)	11196396	1520	1521	I-Count
showed	11196396	1522	1528	O
improvement	11196396	1529	1540	B-Outcome
and	11196396	1541	1544	O
there	11196396	1545	1550	O
were	11196396	1551	1555	O
7	11196396	1556	1557	B-Count
failures	11196396	1558	1566	B-Outcome
(	11196396	1567	1568	O
26.9	11196396	1569	1573	B-Count
%	11196396	1574	1575	I-Count
)	11196396	1576	1577	O
.	11196396	1578	1579	O

In	11196396	1580	1582	O
the	11196396	1583	1586	O
combination	11196396	1587	1598	B-Intervention
treatment	11196396	1599	1608	I-Intervention
group	11196396	1609	1614	O
,	11196396	1615	1616	O
9	11196396	1617	1618	B-Count
(	11196396	1619	1620	I-Count
52.9	11196396	1621	1625	I-Count
%	11196396	1626	1627	I-Count
)	11196396	1628	1629	I-Count
patients	11196396	1630	1638	I-Count
cured	11196396	1639	1644	B-Outcome
,	11196396	1645	1646	O
improvement	11196396	1647	1658	B-Outcome
was	11196396	1659	1662	O
observed	11196396	1663	1671	O
in	11196396	1672	1674	O
5	11196396	1675	1676	B-Count
(	11196396	1677	1678	I-Count
29.4	11196396	1679	1683	I-Count
%	11196396	1684	1685	I-Count
)	11196396	1686	1687	I-Count
and	11196396	1688	1691	O
failure	11196396	1692	1699	B-Outcome
in	11196396	1700	1702	O
3	11196396	1703	1704	B-Count
(	11196396	1705	1706	I-Count
17.6	11196396	1707	1711	I-Count
%	11196396	1712	1713	I-Count
)	11196396	1714	1715	I-Count
.	11196396	1716	1717	O

Side	11196396	1718	1722	B-Outcome
effects	11196396	1723	1730	I-Outcome
in	11196396	1731	1733	O
group	11196396	1734	1739	B-Intervention
I	11196396	1740	1741	I-Intervention
were	11196396	1742	1746	O
observed	11196396	1747	1755	O
in	11196396	1756	1758	O
6	11196396	1759	1760	B-Count
patients	11196396	1761	1769	I-Count
(	11196396	1770	1771	I-Count
23	11196396	1772	1774	I-Count
%	11196396	1775	1776	I-Count
)	11196396	1777	1778	I-Count
and	11196396	1779	1782	O
in	11196396	1783	1785	O
5	11196396	1786	1787	B-Count
(	11196396	1788	1789	I-Count
29.4	11196396	1790	1794	I-Count
%	11196396	1795	1796	I-Count
)	11196396	1797	1798	I-Count
in	11196396	1799	1801	O
group	11196396	1802	1807	B-Intervention
II	11196396	1808	1810	I-Intervention
.	11196396	1811	1812	O

There	11196396	1813	1818	O
were	11196396	1819	1823	O
no	11196396	1824	1826	O
statistical	11196396	1827	1838	B-Observation
differences	11196396	1839	1850	I-Observation
between	11196396	1851	1858	B-Intervention
the	11196396	1859	1862	I-Intervention
two	11196396	1863	1866	I-Intervention
groups	11196396	1867	1873	I-Intervention
according	11196396	1874	1883	O
to	11196396	1884	1886	O
the	11196396	1887	1890	O
side	11196396	1891	1895	B-Outcome
effects	11196396	1896	1903	I-Outcome
(	11196396	1904	1905	O
p	11196396	1906	1907	O
>	11196396	1908	1909	O
0.01	11196396	1910	1914	O
)	11196396	1915	1916	O
.	11196396	1917	1918	O

No	11196396	1919	1921	B-Count
patients	11196396	1922	1930	I-Count
were	11196396	1931	1935	O
excluded	11196396	1936	1944	B-Outcome
from	11196396	1945	1949	I-Outcome
the	11196396	1950	1953	I-Outcome
study	11196396	1954	1959	I-Outcome
due	11196396	1960	1963	I-Outcome
to	11196396	1964	1966	I-Outcome
side	11196396	1967	1971	I-Outcome
effects	11196396	1972	1979	I-Outcome
.	11196396	1980	1981	O

CONCLUSION	11196396	1982	1992	O
The	11196396	1993	1996	O
combination	11196396	1997	2008	B-Intervention
of	11196396	2009	2011	I-Intervention
fluoxetine	11196396	2012	2022	I-Intervention
plus	11196396	2023	2027	I-Intervention
local	11196396	2028	2033	I-Intervention
application	11196396	2034	2045	I-Intervention
of	11196396	2046	2048	I-Intervention
lidocaine	11196396	2049	2058	I-Intervention
ointment	11196396	2059	2067	I-Intervention
was	11196396	2068	2071	O
found	11196396	2072	2077	O
to	11196396	2078	2080	O
be	11196396	2081	2083	O
more	11196396	2084	2088	B-Observation
effective	11196396	2089	2098	I-Observation
than	11196396	2099	2103	O
fluoxetine	11196396	2104	2114	B-Intervention
alone	11196396	2115	2120	I-Intervention
in	11196396	2121	2123	O
the	11196396	2124	2127	O
treatment	11196396	2128	2137	O
of	11196396	2138	2140	O
premature	11196396	2141	2150	B-Participant
ejaculation	11196396	2151	2162	I-Participant
.	11196396	2163	2164	O

However	11196396	2165	2172	O
,	11196396	2173	2174	O
the	11196396	2175	2178	O
results	11196396	2179	2186	O
should	11196396	2187	2193	O
be	11196396	2194	2196	O
confirmed	11196396	2197	2206	O
in	11196396	2207	2209	O
further	11196396	2210	2217	O
studies	11196396	2218	2225	O
with	11196396	2226	2230	O
a	11196396	2231	2232	O
placebo	11196396	2233	2240	O
group	11196396	2241	2246	O
to	11196396	2247	2249	O
rule	11196396	2250	2254	O
out	11196396	2255	2258	O
the	11196396	2259	2262	O
placebo	11196396	2263	2270	O
effect	11196396	2271	2277	O
.	11196396	2278	2279	O

Is	11199239	0	2	O
hands-on	11199239	3	11	B-Intervention
experience	11199239	12	22	I-Intervention
more	11199239	23	27	B-Observation
effective	11199239	28	37	I-Observation
than	11199239	38	42	O
didactic	11199239	43	51	B-Intervention
workshops	11199239	52	61	I-Intervention
in	11199239	62	64	O
postgraduate	11199239	65	77	B-Outcome
cancer	11199239	78	84	I-Outcome
pain	11199239	85	89	I-Outcome
education	11199239	90	99	I-Outcome
?	11199239	100	101	O

BACKGROUND	11199239	102	112	O
This	11199239	113	117	O
study	11199239	118	123	O
examined	11199239	124	132	O
the	11199239	133	136	O
nurse	11199239	137	142	B-Outcome
outcomes	11199239	143	151	I-Outcome
of	11199239	152	154	O
a	11199239	155	156	O
cancer	11199239	157	163	B-Intervention
pain	11199239	164	168	I-Intervention
education	11199239	169	178	I-Intervention
program	11199239	179	186	I-Intervention
for	11199239	187	190	O
nurses	11199239	191	197	B-Participant
of	11199239	198	200	O
patients	11199239	201	209	O
from	11199239	210	214	O
11	11199239	215	217	O
different	11199239	218	227	O
ethnic	11199239	228	234	O
groups	11199239	235	241	O
.	11199239	242	243	O

METHODS	11199239	244	251	O
Four	11199239	252	256	O
hundred	11199239	257	264	O
ninety	11199239	265	271	O
six	11199239	272	275	O
home	11199239	276	280	B-Participant
,	11199239	281	282	I-Participant
hospital	11199239	283	291	I-Participant
,	11199239	292	293	I-Participant
and	11199239	294	297	I-Participant
hospice	11199239	298	305	I-Participant
nurses	11199239	306	312	I-Participant
participated	11199239	313	325	O
in	11199239	326	328	O
a	11199239	329	330	O
one-day	11199239	331	338	B-Intervention
workshop	11199239	339	347	I-Intervention
or	11199239	348	350	I-Intervention
two	11199239	351	354	I-Intervention
half-day	11199239	355	363	I-Intervention
workshops	11199239	364	373	I-Intervention
on	11199239	374	376	I-Intervention
cancer	11199239	377	383	I-Intervention
pain	11199239	384	388	I-Intervention
assessment	11199239	389	399	I-Intervention
and	11199239	400	403	I-Intervention
management	11199239	404	414	I-Intervention
.	11199239	415	416	O

Of	11199239	417	419	O
these	11199239	420	425	O
,	11199239	426	427	O
116	11199239	428	431	O
were	11199239	432	436	O
randomized	11199239	437	447	O
to	11199239	448	450	O
participate	11199239	451	462	O
in	11199239	463	465	O
a	11199239	466	467	O
bedside-precepted	11199239	468	485	B-Intervention
visit	11199239	486	491	I-Intervention
with	11199239	492	496	I-Intervention
an	11199239	497	499	I-Intervention
oncology	11199239	500	508	I-Intervention
nurse	11199239	509	514	I-Intervention
specialist	11199239	515	525	I-Intervention
with	11199239	526	530	I-Intervention
pain	11199239	531	535	I-Intervention
specialization	11199239	536	550	I-Intervention
and	11199239	551	554	O
a	11199239	555	556	O
focus	11199239	557	562	B-Intervention
group	11199239	563	568	I-Intervention
to	11199239	569	571	I-Intervention
discuss	11199239	572	579	I-Intervention
attitudinal	11199239	580	591	I-Intervention
issues	11199239	592	598	I-Intervention
.	11199239	599	600	O

Eighty-six	11199239	601	611	O
nurses	11199239	612	618	O
served	11199239	619	625	O
as	11199239	626	628	O
controls	11199239	629	637	B-Intervention
.	11199239	638	639	O

Pre-	11199239	640	644	O
,	11199239	645	646	O
post-	11199239	647	652	O
and	11199239	653	656	O
one-year	11199239	657	665	O
follow-up	11199239	666	675	O
tests	11199239	676	681	O
were	11199239	682	686	O
administered	11199239	687	699	O
.	11199239	700	701	O

RESULTS	11199239	702	709	O
Attitudes	11199239	710	719	B-Outcome
,	11199239	720	721	O
knowledge	11199239	722	731	B-Outcome
,	11199239	732	733	O
and	11199239	734	737	O
application	11199239	738	749	B-Outcome
skills	11199239	750	756	I-Outcome
significantly	11199239	757	770	B-Observation
improved	11199239	771	779	I-Observation
for	11199239	780	783	O
workshop-only	11199239	784	797	B-Intervention
and	11199239	798	801	O
enriched-model	11199239	802	816	B-Intervention
nurses	11199239	817	823	O
relative	11199239	824	832	O
to	11199239	833	835	O
controls	11199239	836	844	B-Intervention
.	11199239	845	846	O

CONCLUSION	11199239	847	857	O
For	11199239	858	861	O
postgraduate	11199239	862	874	B-Participant
nurses	11199239	875	881	I-Participant
,	11199239	882	883	O
daylong	11199239	884	891	B-Intervention
cancer	11199239	892	898	I-Intervention
pain	11199239	899	903	I-Intervention
education	11199239	904	913	I-Intervention
workshops	11199239	914	923	I-Intervention
were	11199239	924	928	O
,	11199239	929	930	O
in	11199239	931	933	O
the	11199239	934	937	O
group	11199239	938	943	O
studied	11199239	944	951	O
,	11199239	952	953	O
as	11199239	954	956	O
effective	11199239	957	966	O
as	11199239	967	969	O
hands-on	11199239	970	978	B-Intervention
experience	11199239	979	989	I-Intervention
in	11199239	990	992	O
improving	11199239	993	1002	B-Observation
cancer	11199239	1003	1009	B-Outcome
pain	11199239	1010	1014	I-Outcome
knowledge	11199239	1015	1024	I-Outcome
and	11199239	1025	1028	O
changing	11199239	1029	1037	B-Outcome
attitudes	11199239	1038	1047	I-Outcome
.	11199239	1048	1049	O

Both	11199239	1050	1054	O
the	11199239	1055	1058	O
workshop-only	11199239	1059	1072	B-Intervention
and	11199239	1073	1076	O
the	11199239	1077	1080	O
enriched-model	11199239	1081	1095	B-Intervention
nurses	11199239	1096	1102	O
relative	11199239	1103	1111	O
to	11199239	1112	1114	O
controls	11199239	1115	1123	B-Intervention
had	11199239	1124	1127	O
significantly	11199239	1128	1141	B-Observation
improved	11199239	1142	1150	I-Observation
knowledge	11199239	1151	1160	B-Outcome
and	11199239	1161	1164	O
changed	11199239	1165	1172	B-Observation
attitudes	11199239	1173	1182	B-Outcome
towards	11199239	1183	1190	I-Outcome
optimal	11199239	1191	1198	I-Outcome
pain	11199239	1199	1203	I-Outcome
management	11199239	1204	1214	I-Outcome
.	11199239	1215	1216	O

Cognitive	11205419	0	9	B-Outcome
performance	11205419	10	21	I-Outcome
and	11205419	22	25	O
serotonergic	11205419	26	38	B-Outcome
function	11205419	39	47	I-Outcome
in	11205419	48	50	O
users	11205419	51	56	O
of	11205419	57	59	O
ecstasy	11205419	60	67	B-Intervention
.	11205419	68	69	O

RATIONALE	11205419	70	79	O
(	11205419	80	81	O
+	11205419	82	83	O
/-	11205419	83	85	O
)	11205419	86	87	O
3,4-Methylenedioxymethamphetamine	11205419	88	121	O
(	11205419	122	123	O
MDMA	11205419	124	128	O
or	11205419	129	131	O
ecstasy	11205419	132	139	O
)	11205419	140	141	O
has	11205419	142	145	O
been	11205419	146	150	O
shown	11205419	151	156	O
to	11205419	157	159	O
cause	11205419	160	165	O
long	11205419	166	170	O
term	11205419	171	175	O
damage	11205419	176	182	O
to	11205419	183	185	O
serotonergic	11205419	186	198	O
cerebral	11205419	199	207	O
neurons	11205419	208	215	O
in	11205419	216	218	O
animals	11205419	219	226	O
.	11205419	227	228	O

The	11205419	229	232	O
neurotoxic	11205419	233	243	O
effects	11205419	244	251	O
in	11205419	252	254	O
humans	11205419	255	261	O
are	11205419	262	265	O
less	11205419	266	270	O
clear	11205419	271	276	O
and	11205419	277	280	O
little	11205419	281	287	O
is	11205419	288	290	O
known	11205419	291	296	O
about	11205419	297	302	O
the	11205419	303	306	O
functional	11205419	307	317	O
consequences	11205419	318	330	O
,	11205419	331	332	O
although	11205419	333	341	O
some	11205419	342	346	O
studies	11205419	347	354	O
suggest	11205419	355	362	O
memory	11205419	363	369	O
impairment	11205419	370	380	O
.	11205419	381	382	O

Given	11205419	383	388	O
the	11205419	389	392	O
widespread	11205419	393	403	O
use	11205419	404	407	O
of	11205419	408	410	O
MDMA	11205419	411	415	O
,	11205419	416	417	O
our	11205419	418	421	O
lack	11205419	422	426	O
of	11205419	427	429	O
knowledge	11205419	430	439	O
raises	11205419	440	446	O
concerns	11205419	447	455	O
.	11205419	456	457	O

OBJECTIVE	11205419	458	467	O
We	11205419	468	470	O
investigated	11205419	471	483	O
,	11205419	484	485	O
in	11205419	486	488	O
humans	11205419	489	495	O
,	11205419	496	497	O
the	11205419	498	501	O
relation	11205419	502	510	B-Observation
between	11205419	511	518	O
past	11205419	519	523	B-Intervention
use	11205419	524	527	I-Intervention
of	11205419	528	530	I-Intervention
ecstasy	11205419	531	538	I-Intervention
and	11205419	539	542	O
cognitive	11205419	543	552	B-Outcome
performance	11205419	553	564	I-Outcome
as	11205419	565	567	O
well	11205419	568	572	O
as	11205419	573	575	O
serotonergic	11205419	576	588	B-Outcome
function	11205419	589	597	I-Outcome
.	11205419	598	599	O

METHODS	11205419	600	607	O
Two	11205419	608	611	O
groups	11205419	612	618	O
of	11205419	619	621	O
21	11205419	622	624	O
males	11205419	625	630	B-Participant
with	11205419	631	635	O
moderate	11205419	636	644	B-Intervention
and	11205419	645	648	I-Intervention
heavy	11205419	649	654	I-Intervention
recreational	11205419	655	667	I-Intervention
use	11205419	668	671	I-Intervention
of	11205419	672	674	I-Intervention
MDMA	11205419	675	679	I-Intervention
,	11205419	680	681	O
respectively	11205419	682	694	O
,	11205419	695	696	O
and	11205419	697	700	O
a	11205419	701	702	O
control	11205419	703	710	O
group	11205419	711	716	O
of	11205419	717	719	O
20	11205419	720	722	O
males	11205419	723	728	B-Participant
without	11205419	729	736	O
use	11205419	737	740	B-Intervention
of	11205419	741	743	I-Intervention
MDMA	11205419	744	748	I-Intervention
were	11205419	749	753	O
compared	11205419	754	762	O
.	11205419	763	764	O

All	11205419	765	768	O
were	11205419	769	773	O
from	11205419	774	778	O
the	11205419	779	782	O
same	11205419	783	787	O
subculture	11205419	788	798	O
.	11205419	799	800	O

Reaction	11205419	801	809	B-Outcome
time	11205419	810	814	I-Outcome
,	11205419	815	816	O
direct	11205419	817	823	B-Outcome
recall	11205419	824	830	I-Outcome
,	11205419	831	832	O
and	11205419	833	836	O
recognition	11205419	837	848	B-Outcome
were	11205419	849	853	O
assessed	11205419	854	862	O
.	11205419	863	864	O

Serotonergic	11205419	865	877	B-Outcome
function	11205419	878	886	I-Outcome
was	11205419	887	890	O
measured	11205419	891	899	O
by	11205419	900	902	O
the	11205419	903	906	O
neuro-endocrine	11205419	907	922	B-Outcome
response	11205419	923	931	I-Outcome
to	11205419	932	934	O
a	11205419	935	936	O
placebo-controlled	11205419	937	955	O
,	11205419	956	957	O
crossover	11205419	958	967	O
challenge	11205419	968	977	O
with	11205419	978	982	O
dexfenfluramine	11205419	983	998	O
.	11205419	999	1000	O

RESULTS	11205419	1001	1008	O
Ecstasy	11205419	1009	1016	B-Intervention
users	11205419	1017	1022	I-Intervention
showed	11205419	1023	1029	O
a	11205419	1030	1031	O
broad	11205419	1032	1037	B-Observation
pattern	11205419	1038	1045	I-Observation
of	11205419	1046	1048	I-Observation
statistically	11205419	1049	1062	I-Observation
significant	11205419	1063	1074	I-Observation
,	11205419	1075	1076	I-Observation
but	11205419	1077	1080	I-Observation
clinically	11205419	1081	1091	I-Observation
small	11205419	1092	1097	I-Observation
,	11205419	1098	1099	O
impairment	11205419	1100	1110	B-Outcome
of	11205419	1111	1113	I-Outcome
memory	11205419	1114	1120	I-Outcome
and	11205419	1121	1124	O
prolonged	11205419	1125	1134	B-Observation
reaction	11205419	1135	1143	B-Outcome
times	11205419	1144	1149	I-Outcome
.	11205419	1150	1151	O

Heavy	11205419	1152	1157	B-Intervention
users	11205419	1158	1163	I-Intervention
were	11205419	1164	1168	O
affected	11205419	1169	1177	B-Observation
stronger	11205419	1178	1186	I-Observation
than	11205419	1187	1191	O
moderate	11205419	1192	1200	B-Intervention
users	11205419	1201	1206	I-Intervention
.	11205419	1207	1208	O

Release	11205419	1209	1216	B-Outcome
of	11205419	1217	1219	I-Outcome
cortisol	11205419	1220	1228	I-Outcome
but	11205419	1229	1232	I-Outcome
not	11205419	1233	1236	I-Outcome
of	11205419	1237	1239	I-Outcome
prolactin	11205419	1240	1249	I-Outcome
after	11205419	1250	1255	I-Outcome
dexfenfluramine	11205419	1256	1271	I-Outcome
administration	11205419	1272	1286	I-Outcome
was	11205419	1287	1290	O
significantly	11205419	1291	1304	B-Observation
reduced	11205419	1305	1312	I-Observation
in	11205419	1313	1315	O
both	11205419	1316	1320	B-Intervention
groups	11205419	1321	1327	I-Intervention
of	11205419	1328	1330	I-Intervention
ecstasy	11205419	1331	1338	I-Intervention
users	11205419	1339	1344	I-Intervention
compared	11205419	1345	1353	O
with	11205419	1354	1358	O
the	11205419	1359	1362	O
controls	11205419	1363	1371	B-Intervention
.	11205419	1372	1373	O

Analyses	11205419	1374	1382	O
of	11205419	1383	1385	O
covariance	11205419	1386	1396	O
showed	11205419	1397	1403	O
that	11205419	1404	1408	O
likely	11205419	1409	1415	O
confounding	11205419	1416	1427	O
variables	11205419	1428	1437	O
including	11205419	1438	1447	O
recent	11205419	1448	1454	O
exposure	11205419	1455	1463	O
to	11205419	1464	1466	O
ecstasy	11205419	1467	1474	O
,	11205419	1475	1476	O
psychosocial	11205419	1477	1489	O
profiles	11205419	1490	1498	O
and	11205419	1499	1502	O
use	11205419	1503	1506	O
of	11205419	1507	1509	O
other	11205419	1510	1515	O
drugs	11205419	1516	1521	O
did	11205419	1522	1525	O
not	11205419	1526	1529	O
explain	11205419	1530	1537	O
the	11205419	1538	1541	O
differences	11205419	1542	1553	O
found	11205419	1554	1559	O
between	11205419	1560	1567	O
the	11205419	1568	1571	O
groups	11205419	1572	1578	O
.	11205419	1579	1580	O

CONCLUSIONS	11205419	1581	1592	O
These	11205419	1593	1598	O
results	11205419	1599	1606	O
provide	11205419	1607	1614	O
further	11205419	1615	1622	O
evidence	11205419	1623	1631	O
that	11205419	1632	1636	O
use	11205419	1637	1640	O
of	11205419	1641	1643	O
ecstasy	11205419	1644	1651	B-Intervention
may	11205419	1652	1655	O
be	11205419	1656	1658	O
associated	11205419	1659	1669	B-Observation
with	11205419	1670	1674	O
impairment	11205419	1675	1685	B-Outcome
of	11205419	1686	1688	I-Outcome
memory	11205419	1689	1695	I-Outcome
and	11205419	1696	1699	I-Outcome
of	11205419	1700	1702	I-Outcome
serotonergic	11205419	1703	1715	I-Outcome
function	11205419	1716	1724	I-Outcome
.	11205419	1725	1726	O

These	11205419	1727	1732	O
findings	11205419	1733	1741	O
are	11205419	1742	1745	O
compatible	11205419	1746	1756	O
with	11205419	1757	1761	O
neurotoxicity	11205419	1762	1775	O
of	11205419	1776	1778	O
ecstasy	11205419	1779	1786	O
as	11205419	1787	1789	O
shown	11205419	1790	1795	O
in	11205419	1796	1798	O
animals	11205419	1799	1806	O
.	11205419	1807	1808	O

The	11207836	0	3	O
effect	11207836	4	10	O
of	11207836	11	13	O
aging	11207836	14	19	B-Intervention
on	11207836	20	22	O
circulating	11207836	23	34	B-Outcome
levels	11207836	35	41	I-Outcome
of	11207836	42	44	I-Outcome
proinflammatory	11207836	45	60	I-Outcome
cytokines	11207836	61	70	I-Outcome
during	11207836	71	77	O
septic	11207836	78	84	B-Participant
shock	11207836	85	90	I-Participant
.	11207836	91	92	O

Norasept	11207836	93	101	O
II	11207836	102	104	O
Study	11207836	105	110	O
Investigators	11207836	111	124	O
.	11207836	125	126	O

BACKGROUND	11207836	127	137	O
As	11207836	138	140	O
the	11207836	141	144	O
proportion	11207836	145	155	O
of	11207836	156	158	O
the	11207836	159	162	O
population	11207836	163	173	O
that	11207836	174	178	O
is	11207836	179	181	O
older	11207836	182	187	O
continues	11207836	188	197	O
to	11207836	198	200	O
rise	11207836	201	205	O
,	11207836	206	207	O
infection	11207836	208	217	O
in	11207836	218	220	O
older	11207836	221	226	O
people	11207836	227	233	O
has	11207836	234	237	O
become	11207836	238	244	O
an	11207836	245	247	O
important	11207836	248	257	O
healthcare	11207836	258	268	O
problem	11207836	269	276	O
.	11207836	277	278	O

Although	11207836	279	287	O
aging	11207836	288	293	O
is	11207836	294	296	O
associated	11207836	297	307	O
with	11207836	308	312	O
multiple	11207836	313	321	O
abnormalities	11207836	322	335	O
in	11207836	336	338	O
immune	11207836	339	345	O
function	11207836	346	354	O
,	11207836	355	356	O
the	11207836	357	360	O
effect	11207836	361	367	O
of	11207836	368	370	O
aging	11207836	371	376	O
on	11207836	377	379	O
the	11207836	380	383	O
production	11207836	384	394	O
of	11207836	395	397	O
proinflammatory	11207836	398	413	O
cytokines	11207836	414	423	O
has	11207836	424	427	O
not	11207836	428	431	O
been	11207836	432	436	O
well	11207836	437	441	O
studied	11207836	442	449	O
under	11207836	450	455	O
conditions	11207836	456	466	O
of	11207836	467	469	O
clinical	11207836	470	478	O
stress	11207836	479	485	O
.	11207836	486	487	O

OBJECTIVES	11207836	488	498	O
The	11207836	499	502	O
aim	11207836	503	506	O
of	11207836	507	509	O
this	11207836	510	514	O
study	11207836	515	520	O
was	11207836	521	524	O
to	11207836	525	527	O
examine	11207836	528	535	O
the	11207836	536	539	O
effect	11207836	540	546	O
of	11207836	547	549	O
aging	11207836	550	555	B-Intervention
on	11207836	556	558	O
circulating	11207836	559	570	B-Outcome
levels	11207836	571	577	I-Outcome
of	11207836	578	580	I-Outcome
the	11207836	581	584	I-Outcome
proinflammatory	11207836	585	600	I-Outcome
cytokines	11207836	601	610	I-Outcome
in	11207836	611	613	O
a	11207836	614	615	O
large	11207836	616	621	O
cohort	11207836	622	628	O
of	11207836	629	631	O
septic	11207836	632	638	B-Participant
shock	11207836	639	644	I-Participant
patients	11207836	645	653	O
.	11207836	654	655	O

We	11207836	656	658	O
hypothesized	11207836	659	671	O
that	11207836	672	676	O
aging	11207836	677	682	B-Intervention
would	11207836	683	688	O
be	11207836	689	691	O
associated	11207836	692	702	O
with	11207836	703	707	O
a	11207836	708	709	O
diminished	11207836	710	720	B-Observation
proinflammatory	11207836	721	736	B-Outcome
cytokine	11207836	737	745	I-Outcome
response	11207836	746	754	I-Outcome
to	11207836	755	757	I-Outcome
sepsis	11207836	758	764	I-Outcome
.	11207836	765	766	O

DESIGN	11207836	767	773	O
Patients	11207836	774	782	O
with	11207836	783	787	O
septic	11207836	788	794	B-Participant
shock	11207836	795	800	I-Participant
who	11207836	801	804	O
were	11207836	805	809	O
enrolled	11207836	810	818	O
in	11207836	819	821	O
the	11207836	822	825	O
placebo	11207836	826	833	O
limb	11207836	834	838	O
of	11207836	839	841	O
the	11207836	842	845	O
North	11207836	846	851	O
American	11207836	852	860	O
Sepsis	11207836	861	867	O
Trial	11207836	868	873	O
(	11207836	874	875	O
NORASEPT	11207836	876	884	O
II	11207836	885	887	O
)	11207836	888	889	O
study	11207836	890	895	O
were	11207836	896	900	O
analyzed	11207836	901	909	O
.	11207836	910	911	O

SETTING	11207836	912	919	O
The	11207836	920	923	O
intensive	11207836	924	933	O
care	11207836	934	938	O
units	11207836	939	944	O
of	11207836	945	947	O
105	11207836	948	951	O
hospitals	11207836	952	961	O
in	11207836	962	964	O
the	11207836	965	968	O
United	11207836	969	975	O
States	11207836	976	982	O
and	11207836	983	986	O
Canada	11207836	987	993	O
.	11207836	994	995	O

PARTICIPANTS	11207836	996	1008	O
Nine	11207836	1009	1013	O
hundred	11207836	1014	1021	O
and	11207836	1022	1025	O
thirty	11207836	1026	1032	O
patients	11207836	1033	1041	O
presenting	11207836	1042	1052	O
to	11207836	1053	1055	O
hospital	11207836	1056	1064	O
within	11207836	1065	1071	O
12	11207836	1072	1074	O
hours	11207836	1075	1080	O
of	11207836	1081	1083	O
the	11207836	1084	1087	O
onset	11207836	1088	1093	O
of	11207836	1094	1096	O
septic	11207836	1097	1103	B-Participant
shock	11207836	1104	1109	I-Participant
.	11207836	1110	1111	O

MEASUREMENTS	11207836	1112	1124	O
Interleukin-6	11207836	1125	1138	B-Outcome
(	11207836	1139	1140	I-Outcome
IL-6	11207836	1141	1145	I-Outcome
)	11207836	1146	1147	I-Outcome
,	11207836	1148	1149	O
tumor	11207836	1150	1155	B-Outcome
necrosis	11207836	1156	1164	I-Outcome
factor-alpha	11207836	1165	1177	I-Outcome
(	11207836	1178	1179	I-Outcome
TNF-alpha	11207836	1180	1189	I-Outcome
)	11207836	1190	1191	I-Outcome
,	11207836	1192	1193	O
soluble	11207836	1194	1201	B-Outcome
tumor	11207836	1202	1207	I-Outcome
necrosis	11207836	1208	1216	I-Outcome
factor-receptor-55	11207836	1217	1235	I-Outcome
(	11207836	1236	1237	I-Outcome
sTNF-R55	11207836	1238	1246	I-Outcome
)	11207836	1247	1248	I-Outcome
,	11207836	1249	1250	O
and	11207836	1251	1254	O
soluble	11207836	1255	1262	B-Outcome
tumor	11207836	1263	1268	I-Outcome
necrosis	11207836	1269	1277	I-Outcome
factor-receptor-75	11207836	1278	1296	I-Outcome
(	11207836	1297	1298	I-Outcome
sTNF-R75	11207836	1299	1307	I-Outcome
)	11207836	1308	1309	I-Outcome
concentrations	11207836	1310	1324	I-Outcome
were	11207836	1325	1329	O
measured	11207836	1330	1338	O
at	11207836	1339	1341	O
enrollment	11207836	1342	1352	O
.	11207836	1353	1354	O

The	11207836	1355	1358	O
study	11207836	1359	1364	O
population	11207836	1365	1375	O
was	11207836	1376	1379	O
broken	11207836	1380	1386	O
down	11207836	1387	1391	O
into	11207836	1392	1396	O
five	11207836	1397	1401	B-Intervention
age	11207836	1402	1405	I-Intervention
groups	11207836	1406	1412	I-Intervention
as	11207836	1413	1415	O
follows	11207836	1416	1423	O
:	11207836	1424	1425	O
less	11207836	1426	1430	B-Intervention
than	11207836	1431	1435	I-Intervention
50	11207836	1436	1438	I-Intervention
years	11207836	1439	1444	I-Intervention
(	11207836	1445	1446	O
group	11207836	1447	1452	O
one	11207836	1453	1456	O
)	11207836	1457	1458	O
,	11207836	1459	1460	O
50	11207836	1461	1463	B-Intervention
to	11207836	1464	1466	I-Intervention
64	11207836	1467	1469	I-Intervention
years	11207836	1470	1475	I-Intervention
(	11207836	1476	1477	O
group	11207836	1478	1483	O
two	11207836	1484	1487	O
)	11207836	1488	1489	O
,	11207836	1490	1491	O
65	11207836	1492	1494	B-Intervention
to	11207836	1495	1497	I-Intervention
74	11207836	1498	1500	I-Intervention
years	11207836	1501	1506	I-Intervention
(	11207836	1507	1508	O
group	11207836	1509	1514	O
three	11207836	1515	1520	O
)	11207836	1521	1522	O
,	11207836	1523	1524	O
75	11207836	1525	1527	B-Intervention
to	11207836	1528	1530	I-Intervention
84	11207836	1531	1533	I-Intervention
years	11207836	1534	1539	I-Intervention
(	11207836	1540	1541	O
group	11207836	1542	1547	O
four	11207836	1548	1552	O
)	11207836	1553	1554	O
,	11207836	1555	1556	O
and	11207836	1557	1560	O
85	11207836	1561	1563	B-Intervention
or	11207836	1564	1566	I-Intervention
older	11207836	1567	1572	I-Intervention
(	11207836	1573	1574	O
group	11207836	1575	1580	O
five	11207836	1581	1585	O
)	11207836	1586	1587	O
.	11207836	1588	1589	O

Clinical	11207836	1590	1598	O
,	11207836	1599	1600	O
demographic	11207836	1601	1612	O
,	11207836	1613	1614	O
and	11207836	1615	1618	O
cytokine	11207836	1619	1627	O
data	11207836	1628	1632	O
were	11207836	1633	1637	O
extracted	11207836	1638	1647	O
to	11207836	1648	1650	O
describe	11207836	1651	1659	O
each	11207836	1660	1664	O
age	11207836	1665	1668	O
group	11207836	1669	1674	O
.	11207836	1675	1676	O

RESULTS	11207836	1677	1684	O
Data	11207836	1685	1689	O
were	11207836	1690	1694	O
available	11207836	1695	1704	O
for	11207836	1705	1708	O
930	11207836	1709	1712	O
patients	11207836	1713	1721	O
.	11207836	1722	1723	O

The	11207836	1724	1727	O
patients	11207836	1728	1736	O
'	11207836	1737	1738	O
mean	11207836	1739	1743	O
age	11207836	1744	1747	O
(	11207836	1748	1749	O
+	11207836	1750	1751	O
/-	11207836	1751	1753	O
SD	11207836	1754	1756	O
)	11207836	1757	1758	O
was	11207836	1759	1762	O
59	11207836	1763	1765	O
+	11207836	1766	1767	O
/-	11207836	1767	1769	O
17	11207836	1770	1772	O
years	11207836	1773	1778	O
(	11207836	1779	1780	O
range	11207836	1781	1786	O
,	11207836	1787	1788	O
18	11207836	1789	1791	O
to	11207836	1792	1794	O
102	11207836	1795	1798	O
)	11207836	1799	1800	O
.	11207836	1801	1802	O

There	11207836	1803	1808	O
were	11207836	1809	1813	O
280	11207836	1814	1817	O
patients	11207836	1818	1826	O
in	11207836	1827	1829	O
group	11207836	1830	1835	B-Intervention
one	11207836	1836	1839	I-Intervention
,	11207836	1840	1841	O
242	11207836	1842	1845	O
in	11207836	1846	1848	O
group	11207836	1849	1854	B-Intervention
two	11207836	1855	1858	I-Intervention
,	11207836	1859	1860	O
210	11207836	1861	1864	O
in	11207836	1865	1867	O
group	11207836	1868	1873	B-Intervention
three	11207836	1874	1879	I-Intervention
,	11207836	1880	1881	O
150	11207836	1882	1885	O
in	11207836	1886	1888	O
group	11207836	1889	1894	B-Intervention
four	11207836	1895	1899	I-Intervention
,	11207836	1900	1901	O
and	11207836	1902	1905	O
48	11207836	1906	1908	O
in	11207836	1909	1911	O
group	11207836	1912	1917	B-Intervention
five	11207836	1918	1922	I-Intervention
.	11207836	1923	1924	O

The	11207836	1925	1928	O
primary	11207836	1929	1936	B-Outcome
diagnoses	11207836	1937	1946	I-Outcome
;	11207836	1947	1948	O
clinical	11207836	1949	1957	B-Outcome
characteristics	11207836	1958	1973	I-Outcome
;	11207836	1974	1975	O
and	11207836	1976	1979	O
IL-6	11207836	1980	1984	B-Outcome
,	11207836	1985	1986	I-Outcome
sTNF-R55	11207836	1987	1995	I-Outcome
,	11207836	1996	1997	I-Outcome
and	11207836	1998	2001	I-Outcome
sTNF-R75	11207836	2002	2010	I-Outcome
levels	11207836	2011	2017	I-Outcome
were	11207836	2018	2022	O
similar	11207836	2023	2030	B-Observation
among	11207836	2031	2036	O
the	11207836	2037	2040	O
five	11207836	2041	2045	B-Intervention
age	11207836	2046	2049	I-Intervention
groups	11207836	2050	2056	I-Intervention
.	11207836	2057	2058	O

The	11207836	2059	2062	O
TNF-alpha	11207836	2063	2072	B-Outcome
levels	11207836	2073	2079	I-Outcome
were	11207836	2080	2084	O
significantly	11207836	2085	2098	B-Observation
higher	11207836	2099	2105	I-Observation
,	11207836	2106	2107	O
however	11207836	2108	2115	O
,	11207836	2116	2117	O
in	11207836	2118	2120	O
the	11207836	2121	2124	O
oldest	11207836	2125	2131	B-Intervention
group	11207836	2132	2137	I-Intervention
of	11207836	2138	2140	I-Intervention
patients	11207836	2141	2149	I-Intervention
(	11207836	2150	2151	I-Intervention
group	11207836	2152	2157	I-Intervention
five	11207836	2158	2162	I-Intervention
)	11207836	2163	2164	I-Intervention
.	11207836	2165	2166	O

The	11207836	2167	2170	O
28-day	11207836	2171	2177	B-Outcome
survival	11207836	2178	2186	I-Outcome
was	11207836	2187	2190	O
49	11207836	2191	2193	B-Observation
%	11207836	2194	2195	I-Observation
in	11207836	2196	2198	O
patients	11207836	2199	2207	O
over	11207836	2208	2212	B-Intervention
the	11207836	2213	2216	I-Intervention
age	11207836	2217	2220	I-Intervention
of	11207836	2221	2223	I-Intervention
75	11207836	2224	2226	I-Intervention
and	11207836	2227	2230	O
58	11207836	2231	2233	B-Observation
%	11207836	2234	2235	I-Observation
in	11207836	2236	2238	O
those	11207836	2239	2244	O
under	11207836	2245	2250	B-Intervention
75	11207836	2251	2253	I-Intervention
years	11207836	2254	2259	I-Intervention
(	11207836	2260	2261	O
P	11207836	2262	2263	O
=	11207836	2264	2265	O
.03	11207836	2266	2269	O
)	11207836	2270	2271	O
.	11207836	2272	2273	O

There	11207836	2274	2279	O
was	11207836	2280	2283	O
no	11207836	2284	2286	O
gender	11207836	2287	2293	B-Observation
difference	11207836	2294	2304	I-Observation
in	11207836	2305	2307	O
survival	11207836	2308	2316	B-Outcome
or	11207836	2317	2319	O
cytokine	11207836	2320	2328	B-Outcome
levels	11207836	2329	2335	I-Outcome
.	11207836	2336	2337	O

CONCLUSIONS	11207836	2338	2349	O
Contrary	11207836	2350	2358	O
to	11207836	2359	2361	O
our	11207836	2362	2365	O
expectations	11207836	2366	2378	O
,	11207836	2379	2380	O
we	11207836	2381	2383	O
found	11207836	2384	2389	O
that	11207836	2390	2394	O
aging	11207836	2395	2400	B-Intervention
was	11207836	2401	2404	O
not	11207836	2405	2408	O
associated	11207836	2409	2419	O
with	11207836	2420	2424	O
a	11207836	2425	2426	O
decline	11207836	2427	2434	B-Observation
in	11207836	2435	2437	O
the	11207836	2438	2441	O
circulating	11207836	2442	2453	B-Outcome
levels	11207836	2454	2460	I-Outcome
of	11207836	2461	2463	I-Outcome
proinflammatory	11207836	2464	2479	I-Outcome
cytokines	11207836	2480	2489	I-Outcome
.	11207836	2490	2491	O

Effect	11208371	0	6	O
of	11208371	7	9	O
surgical	11208371	10	18	B-Intervention
technique	11208371	19	28	I-Intervention
in	11208371	29	31	O
subtotal	11208371	32	40	B-Participant
and	11208371	41	44	I-Participant
bilateral	11208371	45	54	I-Participant
thyroidectomy	11208371	55	68	I-Participant
on	11208371	69	71	O
risk	11208371	72	76	B-Outcome
of	11208371	77	79	I-Outcome
postoperative	11208371	80	93	I-Outcome
parathyroid	11208371	94	105	I-Outcome
insufficiency	11208371	106	119	I-Outcome
development	11208371	120	131	I-Outcome
--	11208371	132	134	O
our	11208371	135	138	O
experience	11208371	139	149	O
.	11208371	150	151	O

One	11208371	152	155	O
of	11208371	156	158	O
the	11208371	159	162	O
postoperative	11208371	163	176	O
complications	11208371	177	190	O
after	11208371	191	196	O
strumectomy	11208371	197	208	O
is	11208371	209	211	O
hypoparathyroidism	11208371	212	230	O
.	11208371	231	232	O

Therefore	11208371	233	242	O
,	11208371	243	244	O
the	11208371	245	248	O
purpose	11208371	249	256	O
of	11208371	257	259	O
our	11208371	260	263	O
study	11208371	264	269	O
was	11208371	270	273	O
to	11208371	274	276	O
evaluate	11208371	277	285	O
the	11208371	286	289	O
effect	11208371	290	296	O
of	11208371	297	299	O
the	11208371	300	303	O
surgical	11208371	304	312	B-Intervention
technique	11208371	313	322	I-Intervention
on	11208371	323	325	O
the	11208371	326	329	O
development	11208371	330	341	B-Outcome
of	11208371	342	344	I-Outcome
parathyroid	11208371	345	356	I-Outcome
gland	11208371	357	362	I-Outcome
insufficiency	11208371	363	376	I-Outcome
in	11208371	377	379	O
our	11208371	380	383	O
group	11208371	384	389	O
of	11208371	390	392	O
patients	11208371	393	401	O
.	11208371	402	403	O

Subtotal	11208371	404	412	B-Participant
,	11208371	413	414	I-Participant
bilateral	11208371	415	424	I-Participant
strumectomies	11208371	425	438	I-Participant
were	11208371	439	443	O
performed	11208371	444	453	O
according	11208371	454	463	O
to	11208371	464	466	O
Rothmund	11208371	467	475	O
's	11208371	476	478	O
suggestions	11208371	479	490	O
.	11208371	491	492	O

Randomized	11208371	493	503	O
controlled	11208371	504	514	O
trial	11208371	515	520	O
was	11208371	521	524	O
performed	11208371	525	534	O
in	11208371	535	537	O
two	11208371	538	541	O
groups	11208371	542	548	O
.	11208371	549	550	O

In	11208371	551	553	O
the	11208371	554	557	O
first	11208371	558	563	O
group	11208371	564	569	O
of	11208371	570	572	O
19	11208371	573	575	O
patients	11208371	576	584	O
,	11208371	585	586	O
main	11208371	587	591	B-Intervention
trunk	11208371	592	597	I-Intervention
of	11208371	598	600	I-Intervention
the	11208371	601	604	I-Intervention
inferior	11208371	605	613	I-Intervention
thyroid	11208371	614	621	I-Intervention
artery	11208371	622	628	I-Intervention
was	11208371	629	632	I-Intervention
ligated	11208371	633	640	I-Intervention
and	11208371	641	644	O
in	11208371	645	647	O
the	11208371	648	651	O
second	11208371	652	658	O
one	11208371	659	662	O
consisting	11208371	663	673	O
of	11208371	674	676	O
18	11208371	677	679	O
patients	11208371	680	688	O
,	11208371	689	690	O
only	11208371	691	695	O
the	11208371	696	699	O
branches	11208371	700	708	B-Intervention
of	11208371	709	711	I-Intervention
this	11208371	712	716	I-Intervention
artery	11208371	717	723	I-Intervention
were	11208371	724	728	I-Intervention
ligated	11208371	729	736	I-Intervention
.	11208371	737	738	O

Total	11208371	739	744	B-Outcome
calcium	11208371	745	752	I-Outcome
and	11208371	753	756	I-Outcome
PTH	11208371	757	760	I-Outcome
levels	11208371	761	767	I-Outcome
were	11208371	768	772	O
evaluated	11208371	773	782	O
pre-	11208371	783	787	O
and	11208371	788	791	O
postoperatively	11208371	792	807	O
.	11208371	808	809	O

Based	11208371	810	815	O
on	11208371	816	818	O
the	11208371	819	822	O
biochemical	11208371	823	834	O
and	11208371	835	838	O
clinical	11208371	839	847	O
data	11208371	848	852	O
,	11208371	853	854	O
no	11208371	855	857	O
statistically	11208371	858	871	B-Observation
significant	11208371	872	883	I-Observation
differences	11208371	884	895	I-Observation
in	11208371	896	898	O
the	11208371	899	902	O
development	11208371	903	914	B-Outcome
of	11208371	915	917	I-Outcome
postoperative	11208371	918	931	I-Outcome
hypoparathyroidism	11208371	932	950	I-Outcome
in	11208371	951	953	O
relation	11208371	954	962	O
to	11208371	963	965	O
performed	11208371	966	975	O
surgical	11208371	976	984	B-Intervention
techniques	11208371	985	995	I-Intervention
were	11208371	996	1000	O
observed	11208371	1001	1009	O
.	11208371	1010	1011	O

Beneficial	11213870	0	10	B-Observation
effects	11213870	11	18	I-Observation
of	11213870	19	21	O
a	11213870	22	23	O
soy-based	11213870	24	33	B-Intervention
dietary	11213870	34	41	I-Intervention
supplement	11213870	42	52	I-Intervention
on	11213870	53	55	O
lipid	11213870	56	61	B-Outcome
levels	11213870	62	68	I-Outcome
and	11213870	69	72	O
cardiovascular	11213870	73	87	B-Outcome
risk	11213870	88	92	I-Outcome
markers	11213870	93	100	I-Outcome
in	11213870	101	103	O
type	11213870	104	108	B-Participant
2	11213870	109	110	I-Participant
diabetic	11213870	111	119	I-Participant
subjects	11213870	120	128	O
.	11213870	129	130	O

OBJECTIVE	11213870	131	140	O
Consumption	11213870	141	152	O
of	11213870	153	155	O
soy	11213870	156	159	O
protein	11213870	160	167	O
has	11213870	168	171	O
recently	11213870	172	180	O
been	11213870	181	185	O
shown	11213870	186	191	O
to	11213870	192	194	O
improve	11213870	195	202	O
the	11213870	203	206	O
blood	11213870	207	212	O
lipid	11213870	213	218	O
levels	11213870	219	225	O
in	11213870	226	228	O
nondiabetic	11213870	229	240	O
subjects	11213870	241	249	O
.	11213870	250	251	O

The	11213870	252	255	O
purpose	11213870	256	263	O
of	11213870	264	266	O
this	11213870	267	271	O
study	11213870	272	277	O
was	11213870	278	281	O
to	11213870	282	284	O
evaluate	11213870	285	293	O
if	11213870	294	296	O
a	11213870	297	298	O
dietary	11213870	299	306	B-Intervention
supplement	11213870	307	317	I-Intervention
of	11213870	318	320	I-Intervention
soy	11213870	321	324	I-Intervention
protein	11213870	325	332	I-Intervention
,	11213870	333	334	I-Intervention
isoflavones	11213870	335	346	I-Intervention
,	11213870	347	348	I-Intervention
and	11213870	349	352	I-Intervention
cotyledon	11213870	353	362	I-Intervention
fiber	11213870	363	368	I-Intervention
(	11213870	369	370	I-Intervention
Abalon	11213870	371	377	I-Intervention
)	11213870	378	379	I-Intervention
affects	11213870	380	387	O
cardiovascular	11213870	388	402	B-Outcome
risk	11213870	403	407	I-Outcome
markers	11213870	408	415	I-Outcome
,	11213870	416	417	O
blood	11213870	418	423	B-Outcome
glucose	11213870	424	431	I-Outcome
,	11213870	432	433	O
and	11213870	434	437	O
insulin	11213870	438	445	B-Outcome
levels	11213870	446	452	I-Outcome
in	11213870	453	455	O
type	11213870	456	460	B-Participant
2	11213870	461	462	I-Participant
diabetic	11213870	463	471	I-Participant
subjects	11213870	472	480	O
.	11213870	481	482	O

RESEARCH	11213870	483	491	O
DESIGN	11213870	492	498	O
AND	11213870	499	502	O
METHODS	11213870	503	510	O
Twenty	11213870	511	517	O
type	11213870	518	522	B-Participant
2	11213870	523	524	I-Participant
diabetic	11213870	525	533	I-Participant
subjects	11213870	534	542	O
participated	11213870	543	555	O
in	11213870	556	558	O
a	11213870	559	560	O
crossover	11213870	561	570	O
trial	11213870	571	576	O
.	11213870	577	578	O

They	11213870	579	583	O
were	11213870	584	588	O
randomized	11213870	589	599	O
to	11213870	600	602	O
double-blind	11213870	603	615	O
supplementation	11213870	616	631	O
for	11213870	632	635	O
6	11213870	636	637	O
weeks	11213870	638	643	O
with	11213870	644	648	O
Abalon	11213870	649	655	B-Intervention
(	11213870	656	657	O
soy	11213870	658	661	O
protein	11213870	662	669	O
[	11213870	670	671	O
50	11213870	672	674	O
g/day	11213870	675	680	O
]	11213870	681	682	O
with	11213870	683	687	O
high	11213870	688	692	O
levels	11213870	693	699	O
of	11213870	700	702	O
isoflavones	11213870	703	714	O
[	11213870	715	716	O
minimum	11213870	717	724	O
165	11213870	725	728	O
mg/day	11213870	729	735	O
]	11213870	736	737	O
and	11213870	738	741	O
cotyledon	11213870	742	751	O
fiber	11213870	752	757	O
[	11213870	758	759	O
20	11213870	760	762	O
g/day	11213870	763	768	O
]	11213870	769	770	O
)	11213870	771	772	O
or	11213870	773	775	O
placebo	11213870	776	783	B-Intervention
(	11213870	784	785	O
casein	11213870	786	792	O
[	11213870	793	794	O
50	11213870	795	797	O
g/day	11213870	798	803	O
]	11213870	804	805	O
and	11213870	806	809	O
cellulose	11213870	810	819	O
[	11213870	820	821	O
20	11213870	822	824	O
g/day	11213870	825	830	O
]	11213870	831	832	O
)	11213870	833	834	O
,	11213870	835	836	O
separated	11213870	837	846	O
by	11213870	847	849	O
a	11213870	850	851	O
3-week	11213870	852	858	O
wash-out	11213870	859	867	O
period	11213870	868	874	O
.	11213870	875	876	O

RESULTS	11213870	877	884	O
The	11213870	885	888	O
results	11213870	889	896	O
are	11213870	897	900	O
expressed	11213870	901	910	O
as	11213870	911	913	O
means	11213870	914	919	O
+	11213870	920	921	O
/-	11213870	921	923	O
SD	11213870	924	926	O
.	11213870	927	928	O

The	11213870	929	932	O
percentage	11213870	933	943	B-Outcome
mean	11213870	944	948	I-Outcome
treatment	11213870	949	958	I-Outcome
difference	11213870	959	969	I-Outcome
between	11213870	970	977	I-Outcome
Abalon	11213870	978	984	I-Outcome
and	11213870	985	988	I-Outcome
placebo	11213870	989	996	I-Outcome
demonstrated	11213870	997	1009	O
significantly	11213870	1010	1023	B-Observation
lower	11213870	1024	1029	I-Observation
mean	11213870	1030	1034	O
values	11213870	1035	1041	O
after	11213870	1042	1047	O
Abalon	11213870	1048	1054	B-Intervention
for	11213870	1055	1058	O
LDL	11213870	1059	1062	B-Outcome
cholesterol	11213870	1063	1074	I-Outcome
(	11213870	1075	1076	O
10	11213870	1077	1079	B-Observation
+	11213870	1080	1081	I-Observation
/-	11213870	1081	1083	I-Observation
15	11213870	1084	1086	I-Observation
%	11213870	1087	1088	I-Observation
,	11213870	1089	1090	O
P	11213870	1091	1092	O
<	11213870	1093	1094	O
0.05	11213870	1095	1099	O
)	11213870	1100	1101	O
,	11213870	1102	1103	O
LDL/UHDL	11213870	1104	1112	B-Outcome
ratio	11213870	1113	1118	I-Outcome
(	11213870	1119	1120	O
12	11213870	1121	1123	B-Observation
+	11213870	1124	1125	I-Observation
/-	11213870	1125	1127	I-Observation
18	11213870	1128	1130	I-Observation
%	11213870	1131	1132	I-Observation
,	11213870	1133	1134	O
P	11213870	1135	1136	O
<	11213870	1137	1138	O
0.05	11213870	1139	1143	O
)	11213870	1144	1145	O
,	11213870	1146	1147	O
apolipoprotein	11213870	1148	1162	B-Outcome
(	11213870	1163	1164	I-Outcome
apo	11213870	1165	1168	I-Outcome
)	11213870	1169	1170	I-Outcome
B100	11213870	1171	1175	I-Outcome
(	11213870	1176	1177	O
30	11213870	1178	1180	B-Observation
+	11213870	1181	1182	I-Observation
/-	11213870	1182	1184	I-Observation
38	11213870	1185	1187	I-Observation
%	11213870	1188	1189	I-Observation
,	11213870	1190	1191	O
P	11213870	1192	1193	O
<	11213870	1194	1195	O
0.01	11213870	1196	1200	O
)	11213870	1201	1202	O
,	11213870	1203	1204	O
triglycerides	11213870	1205	1218	B-Outcome
(	11213870	1219	1220	O
22	11213870	1221	1223	B-Observation
+	11213870	1224	1225	I-Observation
/-	11213870	1225	1227	I-Observation
10	11213870	1228	1230	I-Observation
%	11213870	1231	1232	I-Observation
,	11213870	1233	1234	O
P	11213870	1235	1236	O
<	11213870	1237	1238	O
0.05	11213870	1239	1243	O
)	11213870	1244	1245	O
,	11213870	1246	1247	O
and	11213870	1248	1251	O
homocysteine	11213870	1252	1264	B-Outcome
(	11213870	1265	1266	O
14	11213870	1267	1269	B-Observation
+	11213870	1270	1271	I-Observation
/-	11213870	1271	1273	I-Observation
21	11213870	1274	1276	I-Observation
%	11213870	1277	1278	I-Observation
,	11213870	1279	1280	O
P	11213870	1281	1282	O
<	11213870	1283	1284	O
0.01	11213870	1285	1289	O
)	11213870	1290	1291	O
,	11213870	1292	1293	O
whereas	11213870	1294	1301	O
the	11213870	1302	1305	O
total	11213870	1306	1311	B-Outcome
cholesterol	11213870	1312	1323	I-Outcome
value	11213870	1324	1329	I-Outcome
tended	11213870	1330	1336	O
to	11213870	1337	1339	O
be	11213870	1340	1342	O
less	11213870	1343	1347	B-Observation
significant	11213870	1348	1359	I-Observation
but	11213870	1360	1363	I-Observation
still	11213870	1364	1369	I-Observation
lower	11213870	1370	1375	I-Observation
(	11213870	1376	1377	O
8	11213870	1378	1379	B-Observation
+	11213870	1380	1381	I-Observation
/-	11213870	1381	1383	I-Observation
15	11213870	1384	1386	I-Observation
%	11213870	1387	1388	I-Observation
,	11213870	1389	1390	O
P	11213870	1391	1392	O
<	11213870	1393	1394	O
0.08	11213870	1395	1399	O
)	11213870	1400	1401	O
.	11213870	1402	1403	O

No	11213870	1404	1406	O
change	11213870	1407	1413	B-Observation
occurred	11213870	1414	1422	O
in	11213870	1423	1425	O
HDL	11213870	1426	1429	B-Outcome
cholesterol	11213870	1430	1441	I-Outcome
,	11213870	1442	1443	O
apo	11213870	1444	1447	B-Outcome
B100/apo	11213870	1448	1456	I-Outcome
A1	11213870	1457	1459	I-Outcome
ratio	11213870	1460	1465	I-Outcome
,	11213870	1466	1467	O
plasminogen	11213870	1468	1479	B-Outcome
activator	11213870	1480	1489	I-Outcome
inhibitor	11213870	1490	1499	I-Outcome
1	11213870	1500	1501	I-Outcome
,	11213870	1502	1503	O
factor	11213870	1504	1510	B-Outcome
VIIc	11213870	1511	1515	I-Outcome
,	11213870	1516	1517	O
von	11213870	1518	1521	B-Outcome
Willebrand	11213870	1522	1532	I-Outcome
factor	11213870	1533	1539	I-Outcome
,	11213870	1540	1541	O
fibrinogen	11213870	1542	1552	B-Outcome
,	11213870	1553	1554	O
lipoprotein	11213870	1555	1566	B-Outcome
(	11213870	1567	1568	I-Outcome
a	11213870	1569	1570	I-Outcome
)	11213870	1571	1572	I-Outcome
,	11213870	1573	1574	O
glucose	11213870	1575	1582	B-Outcome
,	11213870	1583	1584	O
HbA1c	11213870	1585	1590	B-Outcome
,	11213870	1591	1592	O
or	11213870	1593	1595	O
24-h	11213870	1596	1600	B-Outcome
blood	11213870	1601	1606	I-Outcome
pressure	11213870	1607	1615	I-Outcome
.	11213870	1616	1617	O

CONCLUSIONS	11213870	1618	1629	O
These	11213870	1630	1635	O
results	11213870	1636	1643	O
indicate	11213870	1644	1652	O
beneficial	11213870	1653	1663	B-Observation
effects	11213870	1664	1671	I-Observation
of	11213870	1672	1674	O
dietary	11213870	1675	1682	B-Intervention
supplementation	11213870	1683	1698	I-Intervention
with	11213870	1699	1703	I-Intervention
Abalon	11213870	1704	1710	I-Intervention
on	11213870	1711	1713	O
cardiovascular	11213870	1714	1728	B-Outcome
risk	11213870	1729	1733	I-Outcome
markers	11213870	1734	1741	I-Outcome
in	11213870	1742	1744	O
type	11213870	1745	1749	B-Participant
2	11213870	1750	1751	I-Participant
diabetic	11213870	1752	1760	I-Participant
subjects	11213870	1761	1769	O
.	11213870	1770	1771	O

This	11213870	1772	1776	O
improvement	11213870	1777	1788	B-Observation
is	11213870	1789	1791	O
seen	11213870	1792	1796	O
even	11213870	1797	1801	O
in	11213870	1802	1804	O
individuals	11213870	1805	1816	B-Participant
with	11213870	1817	1821	I-Participant
near-normal	11213870	1822	1833	I-Participant
lipid	11213870	1834	1839	I-Participant
values	11213870	1840	1846	I-Participant
.	11213870	1847	1848	O

Effect	11214014	0	6	O
of	11214014	7	9	O
allopurinol	11214014	10	21	B-Intervention
on	11214014	22	24	O
myocardial	11214014	25	35	B-Outcome
oxygen	11214014	36	42	I-Outcome
free	11214014	43	47	I-Outcome
radical	11214014	48	55	I-Outcome
production	11214014	56	66	I-Outcome
in	11214014	67	69	O
coronary	11214014	70	78	B-Participant
bypass	11214014	79	85	I-Participant
surgery	11214014	86	93	I-Participant
.	11214014	94	95	O

OBJECTIVES	11214014	96	106	O
Allopurinol	11214014	107	118	O
protects	11214014	119	127	O
the	11214014	128	131	O
heart	11214014	132	137	O
from	11214014	138	142	O
reperfusion	11214014	143	154	O
injury	11214014	155	161	O
.	11214014	162	163	O

The	11214014	164	167	O
aim	11214014	168	171	O
of	11214014	172	174	O
this	11214014	175	179	O
study	11214014	180	185	O
was	11214014	186	189	O
to	11214014	190	192	O
investigate	11214014	193	204	O
myocardial	11214014	205	215	B-Outcome
free	11214014	216	220	I-Outcome
radical	11214014	221	228	I-Outcome
production	11214014	229	239	I-Outcome
during	11214014	240	246	O
reperfusion	11214014	247	258	B-Participant
with	11214014	259	263	B-Intervention
and	11214014	264	267	I-Intervention
without	11214014	268	275	I-Intervention
allopurinol	11214014	276	287	I-Intervention
treatment	11214014	288	297	O
in	11214014	298	300	O
coronary	11214014	301	309	B-Participant
artery	11214014	310	316	I-Participant
bypass	11214014	317	323	I-Participant
grafting	11214014	324	332	I-Participant
patients	11214014	333	341	O
randomized	11214014	342	352	O
into	11214014	353	357	O
allopurinol	11214014	358	369	B-Intervention
(	11214014	370	371	O
n	11214014	372	373	O
=	11214014	374	375	O
14	11214014	376	378	O
)	11214014	379	380	O
or	11214014	381	383	O
placebo	11214014	384	391	B-Intervention
(	11214014	392	393	O
n	11214014	394	395	O
=	11214014	396	397	O
13	11214014	398	400	O
)	11214014	401	402	O
groups	11214014	403	409	O
.	11214014	410	411	O

DESIGN	11214014	412	418	O
Allopurinol	11214014	419	430	B-Intervention
(	11214014	431	432	O
1	11214014	433	434	O
g	11214014	435	436	O
)	11214014	437	438	O
was	11214014	439	442	O
given	11214014	443	448	O
blind	11214014	449	454	O
prior	11214014	455	460	O
to	11214014	461	463	O
cardiopulmonary	11214014	464	479	O
bypass	11214014	480	486	O
and	11214014	487	490	O
prior	11214014	491	496	O
to	11214014	497	499	O
opening	11214014	500	507	O
the	11214014	508	511	O
aorta	11214014	512	517	O
.	11214014	518	519	O

Oxygen	11214014	520	526	B-Outcome
free	11214014	527	531	I-Outcome
radicals	11214014	532	540	I-Outcome
were	11214014	541	545	O
measured	11214014	546	554	O
before	11214014	555	561	O
anesthesia	11214014	562	572	O
in	11214014	573	575	O
arterial	11214014	576	584	O
blood	11214014	585	590	O
,	11214014	591	592	O
before	11214014	593	599	O
cross-clamping	11214014	600	614	O
and	11214014	615	618	O
1	11214014	619	620	O
and	11214014	621	624	O
10	11214014	625	627	O
min	11214014	628	631	O
after	11214014	632	637	O
reperfusion	11214014	638	649	O
in	11214014	650	652	O
arterial	11214014	653	661	O
and	11214014	662	665	O
coronary	11214014	666	674	O
sinus	11214014	675	680	O
blood	11214014	681	686	O
.	11214014	687	688	O

Levels	11214014	689	695	B-Outcome
were	11214014	696	700	O
measured	11214014	701	709	O
as	11214014	710	712	O
relative	11214014	713	721	O
concentrations	11214014	722	736	O
by	11214014	737	739	O
the	11214014	740	743	O
electron	11214014	744	752	O
spin	11214014	753	757	O
resonance	11214014	758	767	O
method	11214014	768	774	O
.	11214014	775	776	O

RESULTS	11214014	777	784	O
One	11214014	785	788	O
minute	11214014	789	795	O
after	11214014	796	801	O
reperfusion	11214014	802	813	O
the	11214014	814	817	O
level	11214014	818	823	B-Outcome
of	11214014	824	826	I-Outcome
spin-trapped	11214014	827	839	I-Outcome
radicals	11214014	840	848	I-Outcome
in	11214014	849	851	O
arterial	11214014	852	860	O
blood	11214014	861	866	O
was	11214014	867	870	O
elevated	11214014	871	879	B-Observation
significantly	11214014	880	893	I-Observation
(	11214014	894	895	O
p	11214014	896	897	O
=	11214014	898	899	O
0.016	11214014	900	905	O
)	11214014	906	907	O
in	11214014	908	910	O
the	11214014	911	914	O
allopurinol	11214014	915	926	B-Intervention
group	11214014	927	932	O
,	11214014	933	934	O
from	11214014	935	939	B-Observation
7.7	11214014	940	943	I-Observation
(	11214014	944	945	I-Observation
SE	11214014	946	948	I-Observation
:	11214014	949	950	I-Observation
0.8	11214014	951	954	I-Observation
)	11214014	955	956	I-Observation
to	11214014	957	959	I-Observation
8.6	11214014	960	963	I-Observation
(	11214014	964	965	I-Observation
1.4	11214014	966	969	I-Observation
)	11214014	970	971	I-Observation
and	11214014	972	975	O
non-significantly	11214014	976	993	B-Observation
(	11214014	994	995	O
p	11214014	996	997	O
=	11214014	998	999	O
0.074	11214014	1000	1005	O
)	11214014	1006	1007	O
in	11214014	1008	1010	O
the	11214014	1011	1014	O
placebo	11214014	1015	1022	B-Intervention
group	11214014	1023	1028	O
,	11214014	1029	1030	O
from	11214014	1031	1035	B-Observation
7.3	11214014	1036	1039	I-Observation
(	11214014	1040	1041	I-Observation
0.7	11214014	1042	1045	I-Observation
)	11214014	1046	1047	I-Observation
to	11214014	1048	1050	I-Observation
8.3	11214014	1051	1054	I-Observation
(	11214014	1055	1056	I-Observation
0.8	11214014	1057	1060	I-Observation
)	11214014	1061	1062	I-Observation
.	11214014	1063	1064	O

Ten	11214014	1065	1068	O
minutes	11214014	1069	1076	O
after	11214014	1077	1082	O
reperfusion	11214014	1083	1094	O
the	11214014	1095	1098	O
arterial	11214014	1099	1107	B-Outcome
values	11214014	1108	1114	I-Outcome
were	11214014	1115	1119	O
8.6	11214014	1120	1123	B-Observation
(	11214014	1124	1125	I-Observation
1.5	11214014	1126	1129	I-Observation
)	11214014	1130	1131	I-Observation
in	11214014	1132	1134	O
the	11214014	1135	1138	O
allopurinol	11214014	1139	1150	B-Intervention
and	11214014	1151	1154	O
7.6	11214014	1155	1158	B-Observation
(	11214014	1159	1160	I-Observation
0.7	11214014	1161	1164	I-Observation
)	11214014	1165	1166	I-Observation
in	11214014	1167	1169	O
the	11214014	1170	1173	O
placebo	11214014	1174	1181	B-Intervention
group	11214014	1182	1187	O
,	11214014	1188	1189	O
the	11214014	1190	1193	O
sinus	11214014	1194	1199	B-Outcome
values	11214014	1200	1206	I-Outcome
being	11214014	1207	1212	O
7.6	11214014	1213	1216	B-Observation
(	11214014	1217	1218	I-Observation
1.3	11214014	1219	1222	I-Observation
)	11214014	1223	1224	I-Observation
and	11214014	1225	1228	O
8.3	11214014	1229	1232	B-Observation
(	11214014	1233	1234	I-Observation
0.8	11214014	1235	1238	I-Observation
)	11214014	1239	1240	I-Observation
,	11214014	1241	1242	O
respectively	11214014	1243	1255	O
.	11214014	1256	1257	O

Myocardial	11214014	1258	1268	B-Outcome
free	11214014	1269	1273	I-Outcome
radical	11214014	1274	1281	I-Outcome
production	11214014	1282	1292	I-Outcome
was	11214014	1293	1296	O
-0.94	11214014	1297	1302	B-Observation
(	11214014	1303	1304	I-Observation
1.21	11214014	1305	1309	I-Observation
)	11214014	1310	1311	I-Observation
in	11214014	1312	1314	O
the	11214014	1315	1318	O
allopurinol	11214014	1319	1330	B-Intervention
and	11214014	1331	1334	O
+	11214014	1335	1336	B-Observation
0.79	11214014	1336	1340	I-Observation
(	11214014	1341	1342	I-Observation
0.96	11214014	1343	1347	I-Observation
)	11214014	1348	1349	I-Observation
in	11214014	1350	1352	O
the	11214014	1353	1356	O
placebo	11214014	1357	1364	B-Intervention
group	11214014	1365	1370	O
after	11214014	1371	1376	O
10	11214014	1377	1379	O
min	11214014	1380	1383	O
reperfusion	11214014	1384	1395	O
,	11214014	1396	1397	O
the	11214014	1398	1401	O
difference	11214014	1402	1412	B-Observation
being	11214014	1413	1418	I-Observation
significant	11214014	1419	1430	I-Observation
(	11214014	1431	1432	O
p	11214014	1433	1434	O
=	11214014	1435	1436	O
0.043	11214014	1437	1442	O
)	11214014	1443	1444	O
.	11214014	1445	1446	O

CONCLUSIONS	11214014	1447	1458	O
All	11214014	1459	1462	O
patients	11214014	1463	1471	O
in	11214014	1472	1474	O
both	11214014	1475	1479	B-Intervention
groups	11214014	1480	1486	I-Intervention
had	11214014	1487	1490	O
an	11214014	1491	1493	O
increasing	11214014	1494	1504	B-Observation
tendency	11214014	1505	1513	I-Observation
to	11214014	1514	1516	O
free	11214014	1517	1521	B-Outcome
radical	11214014	1522	1529	I-Outcome
production	11214014	1530	1540	I-Outcome
during	11214014	1541	1547	O
early	11214014	1548	1553	B-Participant
reperfusion	11214014	1554	1565	I-Participant
.	11214014	1566	1567	O

Patients	11214014	1568	1576	O
treated	11214014	1577	1584	O
with	11214014	1585	1589	O
allopurinol	11214014	1590	1601	B-Intervention
showed	11214014	1602	1608	O
less	11214014	1609	1613	B-Observation
myocardial	11214014	1614	1624	B-Outcome
production	11214014	1625	1635	I-Outcome
of	11214014	1636	1638	I-Outcome
free	11214014	1639	1643	I-Outcome
radicals	11214014	1644	1652	I-Outcome
,	11214014	1653	1654	O
indicating	11214014	1655	1665	O
that	11214014	1666	1670	O
its	11214014	1671	1674	O
protective	11214014	1675	1685	O
effect	11214014	1686	1692	O
may	11214014	1693	1696	O
be	11214014	1697	1699	O
due	11214014	1700	1703	O
to	11214014	1704	1706	O
its	11214014	1707	1710	O
antioxidative	11214014	1711	1724	O
properties	11214014	1725	1735	O
.	11214014	1736	1737	O

TITLE	30380356	0	5	O
:	30380356	5	6	O
Beverage	30380356	7	15	B-Intervention
Containing	30380356	16	26	I-Intervention
Dispersible	30380356	27	38	I-Intervention
Yeast	30380356	39	44	I-Intervention
-Glucan	30380356	45	53	I-Intervention
Decreases	30380356	54	63	B-Observation
Cold/Flu	30380356	64	72	B-Outcome
Symptomatic	30380356	73	84	I-Outcome
Days	30380356	85	89	I-Outcome
After	30380356	90	95	O
Intense	30380356	96	103	B-Participant
Exercise	30380356	104	112	I-Participant
:	30380356	112	113	O
A	30380356	114	115	O
Randomized	30380356	116	126	O
Controlled	30380356	127	137	O
Trial	30380356	138	143	O
.	30380356	143	144	O

In	30380356	145	147	O
this	30380356	148	152	O
double-blind	30380356	153	165	O
,	30380356	165	166	O
randomized	30380356	167	177	O
,	30380356	177	178	O
placebo-controlled	30380356	179	197	O
parallel	30380356	198	206	O
study	30380356	207	212	O
,	30380356	212	213	O
we	30380356	214	216	O
examined	30380356	217	225	O
the	30380356	226	229	O
effect	30380356	230	236	O
of	30380356	237	239	O
dairy-based	30380356	240	251	O
beverages	30380356	252	261	O
(	30380356	262	263	O
250	30380356	263	266	O
mL/day	30380356	267	273	O
)	30380356	273	274	O
containing	30380356	275	285	O
250	30380356	286	289	O
mg	30380356	290	292	O
of	30380356	293	295	O
dispersible	30380356	296	307	O
baker	30380356	308	313	O
's	30380356	313	315	O
yeast	30380356	316	321	O
-glucan	30380356	322	330	O
(	30380356	331	332	O
Wellmune	30380356	332	340	O
)	30380356	340	341	O
compared	30380356	342	350	O
to	30380356	351	353	O
a	30380356	354	355	O
macronutrient-	30380356	356	370	B-Intervention
and	30380356	371	374	I-Intervention
calorie-matched	30380356	375	390	I-Intervention
control	30380356	391	398	I-Intervention
on	30380356	399	401	O
upper	30380356	402	407	B-Participant
respiratory	30380356	408	419	I-Participant
tract	30380356	420	425	I-Participant
infection	30380356	426	435	I-Participant
(	30380356	436	437	I-Participant
URTI	30380356	437	441	I-Participant
)	30380356	441	442	I-Participant
in	30380356	443	445	O
marathon	30380356	446	454	B-Participant
runners	30380356	455	462	I-Participant
.	30380356	462	463	O

Healthy	30380356	464	471	B-Participant
adults	30380356	472	478	I-Participant
running	30380356	479	486	O
in	30380356	487	489	O
the	30380356	490	493	O
2017	30380356	494	498	O
Austin	30380356	499	505	O
Marathon	30380356	506	514	B-Participant
consumed	30380356	515	523	O
either	30380356	524	530	O
-glucan	30380356	531	539	B-Intervention
(	30380356	540	541	O
N	30380356	541	542	O
=	30380356	543	544	O
132	30380356	545	548	O
)	30380356	548	549	O
or	30380356	550	552	O
control	30380356	553	560	B-Intervention
(	30380356	561	562	O
N	30380356	562	563	O
=	30380356	564	565	O
225	30380356	566	569	O
)	30380356	569	570	O
for	30380356	571	574	O
the	30380356	575	578	O
45	30380356	579	581	O
days	30380356	582	586	O
prior	30380356	587	592	O
to	30380356	593	595	O
,	30380356	595	596	O
day	30380356	597	600	O
of	30380356	601	603	O
,	30380356	603	604	O
and	30380356	605	608	O
45	30380356	609	611	O
days	30380356	612	616	O
after	30380356	617	622	O
the	30380356	623	626	O
marathon	30380356	627	635	O
(	30380356	636	637	O
91	30380356	637	639	O
days	30380356	640	644	O
total	30380356	645	650	O
)	30380356	650	651	O
.	30380356	651	652	O

Participants	30380356	653	665	O
completed	30380356	666	675	O
a	30380356	676	677	O
daily	30380356	678	683	O
online	30380356	684	690	O
survey	30380356	691	697	O
assessing	30380356	698	707	O
compliance	30380356	708	718	B-Outcome
,	30380356	718	719	O
training	30380356	720	728	B-Outcome
status	30380356	729	735	I-Outcome
,	30380356	735	736	O
and	30380356	737	740	O
URTI	30380356	741	745	B-Outcome
symptoms	30380356	746	754	I-Outcome
.	30380356	754	755	O

URTI	30380356	756	760	B-Outcome
occurrence	30380356	761	771	I-Outcome
and	30380356	772	775	O
severity	30380356	776	784	B-Outcome
were	30380356	785	789	O
evaluated	30380356	790	799	O
using	30380356	800	805	O
the	30380356	806	809	O
Jackson	30380356	810	817	O
Index	30380356	818	823	O
and	30380356	824	827	O
confirmed	30380356	828	837	O
by	30380356	838	840	O
the	30380356	841	844	O
study	30380356	845	850	O
physician	30380356	851	860	O
.	30380356	860	861	O

No	30380356	862	864	O
significant	30380356	865	876	B-Observation
differences	30380356	877	888	I-Observation
in	30380356	889	891	O
average	30380356	892	899	B-Outcome
duration	30380356	900	908	I-Outcome
and	30380356	909	912	I-Outcome
number	30380356	913	919	I-Outcome
of	30380356	920	922	I-Outcome
URTI	30380356	923	927	I-Outcome
episodes	30380356	928	936	I-Outcome
were	30380356	937	941	O
found	30380356	942	947	O
between	30380356	948	955	O
-glucan	30380356	956	964	B-Intervention
and	30380356	965	968	O
control	30380356	969	976	B-Intervention
.	30380356	976	977	O

However	30380356	978	985	O
,	30380356	985	986	O
those	30380356	987	992	O
who	30380356	993	996	O
completed	30380356	997	1006	O
the	30380356	1007	1010	O
study	30380356	1011	1016	O
per	30380356	1017	1020	O
protocol	30380356	1021	1029	O
on	30380356	1030	1032	O
the	30380356	1033	1036	O
-glucan	30380356	1037	1045	B-Intervention
beverage	30380356	1046	1054	I-Intervention
reported	30380356	1055	1063	O
significantly	30380356	1064	1077	B-Observation
fewer	30380356	1078	1083	I-Observation
URTI	30380356	1084	1088	B-Outcome
symptomatic	30380356	1089	1100	I-Outcome
days	30380356	1101	1105	I-Outcome
(	30380356	1106	1107	O
3.43	30380356	1107	1111	B-Observation
	30380356	1112	1113	I-Observation
6.44	30380356	1114	1118	I-Observation
days	30380356	1119	1123	I-Observation
,	30380356	1123	1124	I-Observation
max	30380356	1125	1128	I-Observation
27	30380356	1129	1131	I-Observation
days	30380356	1132	1136	I-Observation
)	30380356	1136	1137	O
compared	30380356	1138	1146	O
to	30380356	1147	1149	O
those	30380356	1150	1155	O
on	30380356	1156	1158	O
control	30380356	1159	1166	B-Intervention
beverage	30380356	1167	1175	I-Intervention
(	30380356	1176	1177	O
3.84	30380356	1177	1181	B-Observation
	30380356	1182	1183	I-Observation
6.84	30380356	1184	1188	I-Observation
days	30380356	1189	1193	I-Observation
,	30380356	1193	1194	I-Observation
max	30380356	1195	1198	I-Observation
49	30380356	1199	1201	I-Observation
days	30380356	1202	1206	I-Observation
)	30380356	1206	1207	O
.	30380356	1207	1208	O

Total	30380356	1209	1214	B-Outcome
URTI	30380356	1215	1219	I-Outcome
severity	30380356	1220	1228	I-Outcome
was	30380356	1229	1232	O
significantly	30380356	1233	1246	B-Observation
lower	30380356	1247	1252	I-Observation
for	30380356	1253	1256	O
-glucan	30380356	1257	1265	B-Intervention
(	30380356	1266	1267	O
4.52	30380356	1267	1271	B-Observation
	30380356	1272	1273	I-Observation
1.61	30380356	1274	1278	I-Observation
)	30380356	1278	1279	O
compared	30380356	1280	1288	O
to	30380356	1289	1291	O
control	30380356	1292	1299	B-Intervention
(	30380356	1300	1301	O
5.60	30380356	1301	1305	B-Observation
	30380356	1306	1307	I-Observation
2.23	30380356	1308	1312	I-Observation
)	30380356	1312	1313	O
.	30380356	1313	1314	O

Specifically	30380356	1315	1327	O
,	30380356	1327	1328	O
lower	30380356	1329	1334	B-Observation
(	30380356	1335	1336	I-Observation
p	30380356	1336	1337	I-Observation
<	30380356	1338	1339	I-Observation
.05	30380356	1340	1343	I-Observation
)	30380356	1343	1344	I-Observation
severity	30380356	1345	1353	I-Observation
ratings	30380356	1354	1361	I-Observation
for	30380356	1362	1365	O
nasal	30380356	1366	1371	B-Outcome
discharge	30380356	1372	1381	I-Outcome
and	30380356	1382	1385	O
sore	30380356	1386	1390	B-Outcome
throat	30380356	1391	1397	I-Outcome
were	30380356	1398	1402	O
reported	30380356	1403	1411	O
for	30380356	1412	1415	O
-glucan	30380356	1416	1424	B-Intervention
compared	30380356	1425	1433	O
to	30380356	1434	1436	O
control	30380356	1437	1444	B-Intervention
.	30380356	1444	1445	O

Average	30380356	1446	1453	B-Outcome
missed	30380356	1454	1460	I-Outcome
postmarathon	30380356	1461	1473	I-Outcome
workout	30380356	1474	1481	I-Outcome
days	30380356	1482	1486	I-Outcome
due	30380356	1487	1490	I-Outcome
to	30380356	1491	1493	I-Outcome
URTI	30380356	1494	1498	I-Outcome
were	30380356	1499	1503	O
significantly	30380356	1504	1517	B-Observation
less	30380356	1518	1522	I-Observation
for	30380356	1523	1526	O
-glucan	30380356	1527	1535	B-Intervention
(	30380356	1536	1537	O
0.09	30380356	1537	1541	B-Observation
	30380356	1542	1543	I-Observation
0.38	30380356	1544	1548	I-Observation
days	30380356	1549	1553	I-Observation
,	30380356	1553	1554	I-Observation
max	30380356	1555	1558	I-Observation
2	30380356	1559	1560	I-Observation
days	30380356	1561	1565	I-Observation
)	30380356	1565	1566	O
compared	30380356	1567	1575	O
to	30380356	1576	1578	O
control	30380356	1579	1586	B-Intervention
(	30380356	1587	1588	O
0.36	30380356	1588	1592	B-Observation
	30380356	1593	1594	I-Observation
1.40	30380356	1595	1599	I-Observation
days	30380356	1600	1604	I-Observation
,	30380356	1604	1605	I-Observation
max	30380356	1606	1609	I-Observation
10	30380356	1610	1612	I-Observation
days	30380356	1613	1617	I-Observation
)	30380356	1617	1618	O
.	30380356	1618	1619	O

Overall	30380356	1620	1627	O
,	30380356	1627	1628	O
consumption	30380356	1629	1640	O
of	30380356	1641	1643	O
dairy-based	30380356	1644	1655	B-Intervention
beverages	30380356	1656	1665	I-Intervention
containing	30380356	1666	1676	I-Intervention
dispersible	30380356	1677	1688	I-Intervention
yeast	30380356	1689	1694	I-Intervention
-glucan	30380356	1695	1703	I-Intervention
decreased	30380356	1704	1713	B-Observation
URTI	30380356	1714	1718	B-Outcome
symptomatic	30380356	1719	1730	I-Outcome
days	30380356	1731	1735	I-Outcome
,	30380356	1735	1736	O
severity	30380356	1737	1745	B-Outcome
of	30380356	1746	1748	I-Outcome
specific	30380356	1749	1757	I-Outcome
URTI	30380356	1758	1762	I-Outcome
symptoms	30380356	1763	1771	I-Outcome
,	30380356	1771	1772	O
and	30380356	1773	1776	O
missed	30380356	1777	1783	B-Outcome
postmarathon	30380356	1784	1796	I-Outcome
workout	30380356	1797	1804	I-Outcome
days	30380356	1805	1809	I-Outcome
due	30380356	1810	1813	O
to	30380356	1814	1816	O
URTI	30380356	1817	1821	B-Participant
,	30380356	1821	1822	O
without	30380356	1823	1830	O
affecting	30380356	1831	1840	B-Observation
duration	30380356	1841	1849	B-Outcome
and	30380356	1850	1853	I-Outcome
number	30380356	1854	1860	I-Outcome
of	30380356	1861	1863	I-Outcome
URTI	30380356	1864	1868	I-Outcome
episodes	30380356	1869	1877	I-Outcome
.	30380356	1877	1878	O

TITLE	30380357	0	5	O
:	30380357	5	6	O
Ameliorating	30380357	7	19	B-Observation
Effects	30380357	20	27	I-Observation
of	30380357	28	30	O
Four-Week	30380357	31	40	B-Intervention
Fiber-Multivitamin	30380357	41	59	I-Intervention
Combination	30380357	60	71	I-Intervention
Treatment	30380357	72	81	I-Intervention
on	30380357	82	84	O
Low-Density	30380357	85	96	B-Outcome
Lipoprotein	30380357	97	108	I-Outcome
Cholesterol	30380357	109	120	I-Outcome
,	30380357	120	121	O
Total	30380357	122	127	B-Outcome
Cholesterol	30380357	128	139	I-Outcome
,	30380357	139	140	O
and	30380357	141	144	O
Apolipoprotein	30380357	145	159	B-Outcome
B	30380357	160	161	I-Outcome
Profiles	30380357	162	170	I-Outcome
in	30380357	171	173	O
Hypercholesterolemic	30380357	174	194	B-Participant
Participants	30380357	195	207	O
.	30380357	207	208	O

Hyperlipidemia	30380357	209	223	O
is	30380357	224	226	O
one	30380357	227	230	O
of	30380357	231	233	O
the	30380357	234	237	O
leading	30380357	238	245	O
causes	30380357	246	252	O
of	30380357	253	255	O
death	30380357	256	261	O
and	30380357	262	265	O
requires	30380357	266	274	O
lipid-lowering	30380357	275	289	O
treatment	30380357	290	299	O
to	30380357	300	302	O
reduce	30380357	303	309	O
morbidity	30380357	310	319	O
and	30380357	320	323	O
mortality	30380357	324	333	O
.	30380357	333	334	O

Effective	30380357	335	344	O
and	30380357	345	348	O
safe	30380357	349	353	O
alternative	30380357	354	365	O
and	30380357	366	369	O
adjunctive	30380357	370	380	O
therapies	30380357	381	390	O
could	30380357	391	396	O
be	30380357	397	399	O
beneficial	30380357	400	410	O
for	30380357	411	414	O
patients	30380357	415	423	O
with	30380357	424	428	O
hyperlipidemia	30380357	429	443	O
.	30380357	443	444	O

To	30380357	445	447	O
assess	30380357	448	454	O
the	30380357	455	458	O
effect	30380357	459	465	O
of	30380357	466	468	O
a	30380357	469	470	O
fiber-multivitamin	30380357	471	489	B-Intervention
combination	30380357	490	501	I-Intervention
product	30380357	502	509	I-Intervention
on	30380357	510	512	O
the	30380357	513	516	O
lipid	30380357	517	522	B-Outcome
parameters	30380357	523	533	I-Outcome
low-density	30380357	534	545	I-Outcome
lipoprotein	30380357	546	557	I-Outcome
cholesterol	30380357	558	569	I-Outcome
(	30380357	570	571	I-Outcome
LDL-c	30380357	571	576	I-Outcome
)	30380357	576	577	I-Outcome
,	30380357	577	578	O
high-density	30380357	579	591	B-Outcome
lipoprotein	30380357	592	603	I-Outcome
cholesterol	30380357	604	615	I-Outcome
(	30380357	616	617	I-Outcome
HDL-c	30380357	617	622	I-Outcome
)	30380357	622	623	I-Outcome
,	30380357	623	624	O
total	30380357	625	630	B-Outcome
cholesterol	30380357	631	642	I-Outcome
(	30380357	643	644	I-Outcome
TC	30380357	644	646	I-Outcome
)	30380357	646	647	I-Outcome
,	30380357	647	648	O
triglyceride	30380357	649	661	B-Outcome
(	30380357	662	663	I-Outcome
TG	30380357	663	665	I-Outcome
)	30380357	665	666	I-Outcome
,	30380357	666	667	O
and	30380357	668	671	O
apolipoprotein	30380357	672	686	B-Outcome
B	30380357	687	688	I-Outcome
(	30380357	689	690	I-Outcome
Apo	30380357	690	693	I-Outcome
B	30380357	694	695	I-Outcome
)	30380357	695	696	I-Outcome
in	30380357	697	699	O
patients	30380357	700	708	O
with	30380357	709	713	O
hypercholesterolemia	30380357	714	734	B-Participant
,	30380357	734	735	O
we	30380357	736	738	O
conducted	30380357	739	748	O
a	30380357	749	750	O
double-blind	30380357	751	763	O
,	30380357	763	764	O
randomized	30380357	765	775	O
,	30380357	775	776	O
parallel-group	30380357	777	791	O
study	30380357	792	797	O
.	30380357	797	798	O

Forty-one	30380357	799	808	O
out	30380357	809	812	O
of	30380357	813	815	O
50	30380357	816	818	O
randomized	30380357	819	829	O
hypercholesterolemic	30380357	830	850	B-Participant
participants	30380357	851	863	O
recruited	30380357	864	873	O
between	30380357	874	881	O
August	30380357	882	888	O
2016	30380357	889	893	O
and	30380357	894	897	O
March	30380357	898	903	O
2018	30380357	904	908	O
completed	30380357	909	918	O
the	30380357	919	922	O
trial	30380357	923	928	O
.	30380357	928	929	O

The	30380357	930	933	O
participants	30380357	934	946	O
were	30380357	947	951	O
assigned	30380357	952	960	O
to	30380357	961	963	O
receive	30380357	964	971	O
either	30380357	972	978	O
test	30380357	979	983	B-Intervention
product	30380357	984	991	I-Intervention
(	30380357	992	993	O
treatment	30380357	993	1002	O
group	30380357	1003	1008	O
,	30380357	1008	1009	O
n	30380357	1010	1011	O
=	30380357	1012	1013	O
20	30380357	1014	1016	O
)	30380357	1016	1017	O
or	30380357	1018	1020	O
placebo	30380357	1021	1028	B-Intervention
(	30380357	1029	1030	O
placebo	30380357	1030	1037	O
group	30380357	1038	1043	O
,	30380357	1043	1044	O
n	30380357	1045	1046	O
=	30380357	1047	1048	O
21	30380357	1049	1051	O
)	30380357	1051	1052	O
for	30380357	1053	1056	O
4	30380357	1057	1058	O
weeks	30380357	1059	1064	O
following	30380357	1065	1074	O
a	30380357	1075	1076	O
6-week	30380357	1077	1083	O
dietary	30380357	1084	1091	O
intervention	30380357	1092	1104	O
(	30380357	1105	1106	O
based	30380357	1106	1111	O
on	30380357	1112	1114	O
education	30380357	1115	1124	O
from	30380357	1125	1129	O
a	30380357	1130	1131	O
dietitian	30380357	1132	1141	O
)	30380357	1141	1142	O
run-in	30380357	1143	1149	O
period	30380357	1150	1156	O
.	30380357	1156	1157	O

The	30380357	1158	1161	O
primary	30380357	1162	1169	O
outcome	30380357	1170	1177	O
was	30380357	1178	1181	O
LDL-c	30380357	1182	1187	B-Outcome
levels	30380357	1188	1194	I-Outcome
and	30380357	1195	1198	O
the	30380357	1199	1202	O
secondary	30380357	1203	1212	O
outcomes	30380357	1213	1221	O
were	30380357	1222	1226	O
HDL-c	30380357	1227	1232	B-Outcome
,	30380357	1232	1233	O
TC	30380357	1234	1236	B-Outcome
,	30380357	1236	1237	O
TG	30380357	1238	1240	B-Outcome
,	30380357	1240	1241	O
and	30380357	1242	1245	O
Apo	30380357	1246	1249	B-Outcome
B	30380357	1250	1251	I-Outcome
levels	30380357	1252	1258	I-Outcome
.	30380357	1258	1259	O

All	30380357	1260	1263	O
of	30380357	1264	1266	O
the	30380357	1267	1270	O
outcomes	30380357	1271	1279	O
were	30380357	1280	1284	O
measured	30380357	1285	1293	O
at	30380357	1294	1296	O
baseline	30380357	1297	1305	O
and	30380357	1306	1309	O
week	30380357	1310	1314	O
4	30380357	1315	1316	O
after	30380357	1317	1322	O
the	30380357	1323	1326	O
completion	30380357	1327	1337	O
of	30380357	1338	1340	O
run-in	30380357	1341	1347	O
period	30380357	1348	1354	O
.	30380357	1354	1355	O

Participants	30380357	1356	1368	O
in	30380357	1369	1371	O
both	30380357	1372	1376	B-Intervention
groups	30380357	1377	1383	I-Intervention
had	30380357	1384	1387	O
similar	30380357	1388	1395	B-Observation
LDL-c	30380357	1396	1401	B-Outcome
levels	30380357	1402	1408	I-Outcome
(	30380357	1409	1410	O
142	30380357	1410	1413	B-Observation
	30380357	1414	1415	I-Observation
15.7	30380357	1416	1420	I-Observation
vs.	30380357	1421	1424	O
143	30380357	1425	1428	B-Observation
	30380357	1429	1430	I-Observation
19.3	30380357	1431	1435	I-Observation
mg/dL	30380357	1436	1441	I-Observation
)	30380357	1441	1442	O
.	30380357	1442	1443	O

After	30380357	1444	1449	O
4	30380357	1450	1451	O
weeks	30380357	1452	1457	O
of	30380357	1458	1460	O
exposure	30380357	1461	1469	O
to	30380357	1470	1472	O
test	30380357	1473	1477	O
product	30380357	1478	1485	O
,	30380357	1485	1486	O
participants	30380357	1487	1499	O
in	30380357	1500	1502	O
the	30380357	1503	1506	O
treatment	30380357	1507	1516	B-Intervention
group	30380357	1517	1522	O
demonstrated	30380357	1523	1535	O
a	30380357	1536	1537	O
17.25	30380357	1538	1543	B-Observation
	30380357	1544	1545	I-Observation
22.26	30380357	1546	1551	I-Observation
reduction	30380357	1552	1561	I-Observation
in	30380357	1562	1564	O
LDL-c	30380357	1565	1570	B-Outcome
(	30380357	1571	1572	O
p	30380357	1572	1573	O
<	30380357	1574	1575	O
.05	30380357	1576	1579	O
vs.	30380357	1580	1583	O
placebo	30380357	1584	1591	B-Intervention
)	30380357	1591	1592	O
.	30380357	1592	1593	O

This	30380357	1594	1598	O
improvement	30380357	1599	1610	B-Observation
in	30380357	1611	1613	O
LDL-c	30380357	1614	1619	B-Outcome
was	30380357	1620	1623	O
accompanied	30380357	1624	1635	O
by	30380357	1636	1638	O
amelioration	30380357	1639	1651	B-Observation
in	30380357	1652	1654	O
TC	30380357	1655	1657	B-Outcome
and	30380357	1658	1661	O
Apo	30380357	1662	1665	B-Outcome
B	30380357	1666	1667	I-Outcome
levels	30380357	1668	1674	I-Outcome
,	30380357	1674	1675	O
without	30380357	1676	1683	O
any	30380357	1684	1687	O
detrimental	30380357	1688	1699	B-Observation
effects	30380357	1700	1707	I-Observation
on	30380357	1708	1710	O
HDL	30380357	1711	1714	B-Outcome
and	30380357	1715	1718	O
TG	30380357	1719	1721	B-Outcome
concentration	30380357	1722	1735	I-Outcome
.	30380357	1735	1736	O

Results	30380357	1737	1744	O
of	30380357	1745	1747	O
the	30380357	1748	1751	O
present	30380357	1752	1759	O
study	30380357	1760	1765	O
suggest	30380357	1766	1773	O
that	30380357	1774	1778	O
fiber-vitamin	30380357	1779	1792	O
combination	30380357	1793	1804	O
has	30380357	1805	1808	O
potential	30380357	1809	1818	O
to	30380357	1819	1821	O
be	30380357	1822	1824	O
used	30380357	1825	1829	O
as	30380357	1830	1832	O
an	30380357	1833	1835	O
adjunct	30380357	1836	1843	O
therapy	30380357	1844	1851	O
for	30380357	1852	1855	O
the	30380357	1856	1859	O
management	30380357	1860	1870	O
of	30380357	1871	1873	O
hypercholesterolemia	30380357	1874	1894	O
.	30380357	1894	1895	O

TITLE	30386978	0	5	O
:	30386978	5	6	O
Communicating	30386978	7	20	B-Intervention
Actively	30386978	21	29	I-Intervention
Responding	30386978	30	40	I-Intervention
Empathically	30386978	41	53	I-Intervention
(	30386978	54	55	I-Intervention
CARE	30386978	55	59	I-Intervention
):	30386978	59	61	I-Intervention
Comparison	30386978	62	72	O
of	30386978	73	75	O
Communication	30386978	76	89	B-Intervention
Training	30386978	90	98	I-Intervention
Workshops	30386978	99	108	I-Intervention
for	30386978	109	112	O
Health	30386978	113	119	B-Participant
Professionals	30386978	120	133	I-Participant
Working	30386978	134	141	B-Participant
in	30386978	142	144	I-Participant
Cancer	30386978	145	151	I-Participant
Care	30386978	152	156	I-Participant
.	30386978	156	157	O

Accessing	30386978	158	167	O
full-day	30386978	168	176	O
communication	30386978	177	190	O
skills	30386978	191	197	O
training	30386978	198	206	O
can	30386978	207	210	O
be	30386978	211	213	O
challenging	30386978	214	225	O
for	30386978	226	229	O
health	30386978	230	236	O
professionals	30386978	237	250	O
working	30386978	251	258	O
in	30386978	259	261	O
cancer	30386978	262	268	O
care	30386978	269	273	O
.	30386978	273	274	O

This	30386978	275	279	O
study	30386978	280	285	O
aimed	30386978	286	291	O
to	30386978	292	294	O
examine	30386978	295	302	O
the	30386978	303	306	O
effectiveness	30386978	307	320	B-Outcome
of	30386978	321	323	O
Communicating	30386978	324	337	B-Intervention
Actively	30386978	338	346	I-Intervention
,	30386978	346	347	I-Intervention
Responding	30386978	348	358	I-Intervention
Empathically	30386978	359	371	I-Intervention
(	30386978	372	373	I-Intervention
CARE	30386978	373	377	I-Intervention
Express	30386978	378	385	I-Intervention
)	30386978	385	386	I-Intervention
,	30386978	386	387	O
a	30386978	388	389	O
modified	30386978	390	398	O
2-h	30386978	399	402	O
communication	30386978	403	416	O
skills	30386978	417	423	O
training	30386978	424	432	O
course	30386978	433	439	O
,	30386978	439	440	O
across	30386978	441	447	O
measures	30386978	448	456	O
of	30386978	457	459	O
health	30386978	460	466	B-Participant
professional	30386978	467	479	I-Participant
confidence	30386978	480	490	B-Outcome
,	30386978	490	491	O
skills	30386978	492	498	B-Outcome
and	30386978	499	502	O
attitudes	30386978	503	512	B-Outcome
.	30386978	512	513	O

Cancer	30386978	514	520	B-Participant
care	30386978	521	525	I-Participant
health	30386978	526	532	I-Participant
professionals	30386978	533	546	I-Participant
(	30386978	547	548	O
n	30386978	548	549	O
=	30386978	550	551	O
147	30386978	552	555	O
)	30386978	555	556	O
were	30386978	557	561	O
recruited	30386978	562	571	O
from	30386978	572	576	O
allied	30386978	577	583	O
health	30386978	584	590	O
,	30386978	590	591	O
nursing	30386978	592	599	O
and	30386978	600	603	O
medical	30386978	604	611	O
disciplines	30386978	612	623	O
,	30386978	623	624	O
using	30386978	625	630	O
a	30386978	631	632	O
partial	30386978	633	640	O
randomisation	30386978	641	654	O
to	30386978	655	657	O
allocate	30386978	658	666	O
to	30386978	667	669	O
three	30386978	670	675	O
arms	30386978	676	680	O
:	30386978	680	681	O
control	30386978	682	689	B-Intervention
,	30386978	689	690	O
two-hour	30386978	691	699	B-Intervention
training	30386978	700	708	I-Intervention
(	30386978	709	710	I-Intervention
CARE	30386978	710	714	I-Intervention
Express	30386978	715	722	I-Intervention
)	30386978	722	723	I-Intervention
and	30386978	724	727	O
1-day	30386978	728	733	B-Intervention
training	30386978	734	742	I-Intervention
(	30386978	743	744	I-Intervention
CARE	30386978	744	748	I-Intervention
)	30386978	748	749	I-Intervention
.	30386978	749	750	O

Perceived	30386978	751	760	O
confidence	30386978	761	771	B-Outcome
and	30386978	772	775	O
skills	30386978	776	782	B-Outcome
were	30386978	783	787	O
measured	30386978	788	796	O
by	30386978	797	799	O
self-report	30386978	800	811	O
using	30386978	812	817	O
a	30386978	818	819	O
purpose-built	30386978	820	833	O
scale	30386978	834	839	O
,	30386978	839	840	O
and	30386978	841	844	O
written	30386978	845	852	O
responses	30386978	853	862	O
to	30386978	863	865	O
a	30386978	866	867	O
challenging	30386978	868	879	O
clinical	30386978	880	888	O
encounter	30386978	889	898	O
were	30386978	899	903	O
obtained	30386978	904	912	O
at	30386978	913	915	O
baseline	30386978	916	924	O
,	30386978	924	925	O
post-training	30386978	926	939	O
and	30386978	940	943	O
three-months	30386978	944	956	O
post-training	30386978	957	970	O
.	30386978	970	971	O

Attitudes	30386978	972	981	B-Outcome
toward	30386978	982	988	I-Outcome
psychosocial	30386978	989	1001	I-Outcome
issues	30386978	1002	1008	I-Outcome
were	30386978	1009	1013	O
evaluated	30386978	1014	1023	O
with	30386978	1024	1028	O
the	30386978	1029	1032	O
Physician	30386978	1033	1042	O
Belief	30386978	1043	1049	O
Scale	30386978	1050	1055	O
at	30386978	1056	1058	O
baseline	30386978	1059	1067	O
and	30386978	1068	1071	O
3	30386978	1072	1073	O
months	30386978	1074	1080	O
post-training	30386978	1081	1094	O
.	30386978	1094	1095	O

No	30386978	1096	1098	O
changes	30386978	1099	1106	B-Observation
were	30386978	1107	1111	O
observed	30386978	1112	1120	O
in	30386978	1121	1123	O
the	30386978	1124	1127	O
control	30386978	1128	1135	B-Intervention
group	30386978	1136	1141	O
(	30386978	1142	1143	O
n	30386978	1143	1144	O
=	30386978	1145	1146	O
50	30386978	1147	1149	O
)	30386978	1149	1150	O
from	30386978	1151	1155	O
baseline	30386978	1156	1164	O
to	30386978	1165	1167	O
3	30386978	1168	1169	O
months	30386978	1170	1176	O
follow-up	30386978	1177	1186	O
.	30386978	1186	1187	O

Participants	30386978	1188	1200	O
in	30386978	1201	1203	O
the	30386978	1204	1207	O
CARE	30386978	1208	1212	B-Intervention
Express	30386978	1213	1220	I-Intervention
(	30386978	1221	1222	O
n	30386978	1222	1223	O
=	30386978	1224	1225	O
48	30386978	1226	1228	O
)	30386978	1228	1229	O
and	30386978	1230	1233	O
CARE	30386978	1234	1238	B-Intervention
(	30386978	1239	1240	O
n	30386978	1240	1241	O
=	30386978	1242	1243	O
49	30386978	1244	1246	O
)	30386978	1246	1247	O
groups	30386978	1248	1254	O
had	30386978	1255	1258	O
significant	30386978	1259	1270	B-Observation
improvement	30386978	1271	1282	I-Observation
in	30386978	1283	1285	O
confidence	30386978	1286	1296	B-Outcome
in	30386978	1297	1299	I-Outcome
identifying/responding	30386978	1300	1322	I-Outcome
to	30386978	1323	1325	I-Outcome
emotions	30386978	1326	1334	I-Outcome
between	30386978	1335	1342	O
baseline	30386978	1343	1351	O
and	30386978	1352	1355	O
3	30386978	1356	1357	O
months	30386978	1358	1364	O
post-training	30386978	1365	1378	O
(	30386978	1379	1380	O
p	30386978	1380	1381	O
<	30386978	1382	1383	O
0.001	30386978	1384	1389	O
)	30386978	1389	1390	O
,	30386978	1390	1391	O
as	30386978	1392	1394	O
well	30386978	1395	1399	O
as	30386978	1400	1402	O
their	30386978	1403	1408	O
attitude	30386978	1409	1417	B-Outcome
toward	30386978	1418	1424	I-Outcome
psychosocial	30386978	1425	1437	I-Outcome
care	30386978	1438	1442	I-Outcome
(	30386978	1443	1444	O
p	30386978	1444	1445	O
<	30386978	1446	1447	O
0.001	30386978	1448	1453	O
)	30386978	1453	1454	O
.	30386978	1454	1455	O

A	30386978	1456	1457	O
significant	30386978	1458	1469	B-Observation
increase	30386978	1470	1478	I-Observation
in	30386978	1479	1481	O
"	30386978	1482	1483	B-Outcome
acknowledging	30386978	1483	1496	I-Outcome
"	30386978	1496	1497	I-Outcome
responses	30386978	1498	1507	I-Outcome
from	30386978	1508	1512	O
baseline	30386978	1513	1521	O
to	30386978	1522	1524	O
3	30386978	1525	1526	O
months	30386978	1527	1533	O
was	30386978	1534	1537	O
also	30386978	1538	1542	O
observed	30386978	1543	1551	O
for	30386978	1552	1555	O
CARE	30386978	1556	1560	B-Intervention
Express	30386978	1561	1568	I-Intervention
and	30386978	1569	1572	O
CARE	30386978	1573	1577	B-Intervention
(	30386978	1578	1579	O
p	30386978	1579	1580	O
<	30386978	1581	1582	O
0.001	30386978	1583	1588	O
)	30386978	1588	1589	O
,	30386978	1589	1590	O
with	30386978	1591	1595	O
no	30386978	1596	1598	B-Observation
difference	30386978	1599	1609	I-Observation
between	30386978	1610	1617	B-Intervention
groups	30386978	1618	1624	I-Intervention
.	30386978	1624	1625	O

CARE	30386978	1626	1630	B-Intervention
Express	30386978	1631	1638	I-Intervention
and	30386978	1639	1642	O
CARE	30386978	1643	1647	B-Intervention
resulted	30386978	1648	1656	O
in	30386978	1657	1659	O
changes	30386978	1660	1667	B-Observation
in	30386978	1668	1670	O
confidence	30386978	1671	1681	B-Outcome
in	30386978	1682	1684	I-Outcome
emotional	30386978	1685	1694	I-Outcome
identification/response	30386978	1695	1718	I-Outcome
,	30386978	1718	1719	O
psychosocial	30386978	1720	1732	B-Outcome
focus	30386978	1733	1738	I-Outcome
and	30386978	1739	1742	O
communication	30386978	1743	1756	B-Outcome
skills	30386978	1757	1763	I-Outcome
maintained	30386978	1764	1774	B-Observation
at	30386978	1775	1777	O
3	30386978	1778	1779	O
months	30386978	1780	1786	O
post-training	30386978	1787	1800	O
.	30386978	1800	1801	O

Whilst	30386978	1802	1808	O
the	30386978	1809	1812	O
1-day	30386978	1813	1818	B-Intervention
workshop	30386978	1819	1827	I-Intervention
has	30386978	1828	1831	O
been	30386978	1832	1836	O
regarded	30386978	1837	1845	O
as	30386978	1846	1848	O
gold	30386978	1849	1853	O
standard	30386978	1854	1862	O
,	30386978	1862	1863	O
this	30386978	1864	1868	O
study	30386978	1869	1874	O
has	30386978	1875	1878	O
revealed	30386978	1879	1887	O
positive	30386978	1888	1896	B-Observation
outcomes	30386978	1897	1905	B-Outcome
with	30386978	1906	1910	O
a	30386978	1911	1912	O
modified	30386978	1913	1921	B-Intervention
2-h	30386978	1922	1925	I-Intervention
version	30386978	1926	1933	I-Intervention
,	30386978	1933	1934	O
thus	30386978	1935	1939	O
offering	30386978	1940	1948	O
a	30386978	1949	1950	O
potential	30386978	1951	1960	O
alternate	30386978	1961	1970	O
training	30386978	1971	1979	O
model	30386978	1980	1985	O
.	30386978	1985	1986	O

TITLE	30403772	0	5	O
:	30403772	5	6	O
Metabolic	30403772	7	16	O
Effects	30403772	17	24	O
of	30403772	25	27	O
Breaking	30403772	28	36	O
Prolonged	30403772	37	46	B-Participant
Sitting	30403772	47	54	I-Participant
With	30403772	55	59	O
Standing	30403772	60	68	B-Intervention
or	30403772	69	71	O
Light	30403772	72	77	B-Intervention
Walking	30403772	78	85	I-Intervention
in	30403772	86	88	O
Older	30403772	89	94	B-Participant
South	30403772	95	100	I-Participant
Asians	30403772	101	107	I-Participant
and	30403772	108	111	I-Participant
White	30403772	112	117	I-Participant
Europeans	30403772	118	127	I-Participant
:	30403772	127	128	O
A	30403772	129	130	O
Randomized	30403772	131	141	O
Acute	30403772	142	147	O
Study	30403772	148	153	O
.	30403772	153	154	O

BACKGROUND	30403772	155	165	O
:	30403772	165	166	O
Prolonged	30403772	167	176	O
sitting	30403772	177	184	O
is	30403772	185	187	O
common	30403772	188	194	O
in	30403772	195	197	O
older	30403772	198	203	O
adults	30403772	204	210	O
and	30403772	211	214	O
is	30403772	215	217	O
associated	30403772	218	228	O
with	30403772	229	233	O
insulin	30403772	234	241	O
resistance	30403772	242	252	O
and	30403772	253	256	O
poor	30403772	257	261	O
cardiometabolic	30403772	262	277	O
health	30403772	278	284	O
.	30403772	284	285	O

We	30403772	286	288	O
investigate	30403772	289	300	O
whether	30403772	301	308	O
breaking	30403772	309	317	O
prolonged	30403772	318	327	B-Participant
sitting	30403772	328	335	I-Participant
with	30403772	336	340	O
regular	30403772	341	348	B-Intervention
short	30403772	349	354	I-Intervention
bouts	30403772	355	360	I-Intervention
of	30403772	361	363	I-Intervention
standing	30403772	364	372	I-Intervention
or	30403772	373	375	O
light	30403772	376	381	B-Intervention
walking	30403772	382	389	I-Intervention
improves	30403772	390	398	B-Observation
postprandial	30403772	399	411	B-Outcome
metabolism	30403772	412	422	I-Outcome
in	30403772	423	425	O
older	30403772	426	431	B-Participant
white	30403772	432	437	I-Participant
European	30403772	438	446	I-Participant
and	30403772	447	450	I-Participant
South	30403772	451	456	I-Participant
Asian	30403772	457	462	I-Participant
adults	30403772	463	469	I-Participant
and	30403772	470	473	O
whether	30403772	474	481	O
effects	30403772	482	489	O
are	30403772	490	493	O
modified	30403772	494	502	O
by	30403772	503	505	O
ethnic	30403772	506	512	O
group	30403772	513	518	O
.	30403772	518	519	O

METHODS	30403772	519	526	O
:	30403772	526	527	O
Thirty	30403772	528	534	O
South	30403772	535	540	O
Asian	30403772	541	546	O
(	30403772	547	548	O
15	30403772	548	550	O
women	30403772	551	556	O
)	30403772	556	557	O
and	30403772	558	561	O
30	30403772	562	564	O
white	30403772	565	570	O
European	30403772	571	579	O
(	30403772	580	581	O
14	30403772	581	583	O
women	30403772	584	589	O
)	30403772	589	590	O
older	30403772	591	596	O
adults	30403772	597	603	O
(	30403772	604	605	O
aged	30403772	605	609	O
65	30403772	610	612	O
-	30403772	612	613	O
79	30403772	613	615	O
years	30403772	616	621	O
)	30403772	621	622	O
undertook	30403772	623	632	O
three	30403772	633	638	O
experimental	30403772	639	651	O
conditions	30403772	652	662	O
in	30403772	663	665	O
random	30403772	666	672	O
order	30403772	673	678	O
.	30403772	678	679	O

(	30403772	680	681	O
a	30403772	681	682	O
)	30403772	682	683	O
Prolonged	30403772	684	693	B-Intervention
sitting	30403772	694	701	I-Intervention
:	30403772	701	702	O
continuous	30403772	703	713	O
sitting	30403772	714	721	O
during	30403772	722	728	O
an	30403772	729	731	O
observation	30403772	732	743	O
period	30403772	744	750	O
if	30403772	751	753	O
7.5	30403772	754	757	O
hours	30403772	758	763	O
consuming	30403772	764	773	O
two	30403772	774	777	O
standardized	30403772	778	790	O
mixed	30403772	791	796	O
meals	30403772	797	802	O
.	30403772	802	803	O
(	30403772	804	805	O
b	30403772	805	806	O
)	30403772	806	807	O
Standing	30403772	808	816	B-Intervention
breaks	30403772	817	823	I-Intervention
:	30403772	823	824	O
sitting	30403772	825	832	O
interrupted	30403772	833	844	O
with	30403772	845	849	O
5	30403772	850	851	O
minutes	30403772	852	859	O
of	30403772	860	862	O
standing	30403772	863	871	O
every	30403772	872	877	O
30	30403772	878	880	O
minutes	30403772	881	888	O
(	30403772	889	890	O
accumulating	30403772	890	902	O
60	30403772	903	905	O
minutes	30403772	906	913	O
of	30403772	914	916	O
standing	30403772	917	925	O
over	30403772	926	930	O
the	30403772	931	934	O
observation	30403772	935	946	O
period	30403772	947	953	O
)	30403772	953	954	O
.	30403772	954	955	O

(	30403772	956	957	O
c	30403772	957	958	O
)	30403772	958	959	O
Walking	30403772	960	967	B-Intervention
breaks	30403772	968	974	I-Intervention
:	30403772	974	975	O
sitting	30403772	976	983	O
interrupted	30403772	984	995	O
with	30403772	996	1000	O
5	30403772	1001	1002	O
minutes	30403772	1003	1010	O
of	30403772	1011	1013	O
self-paced	30403772	1014	1024	O
light	30403772	1025	1030	O
walking	30403772	1031	1038	O
every	30403772	1039	1044	O
30	30403772	1045	1047	O
minutes	30403772	1048	1055	O
(	30403772	1056	1057	O
accumulating	30403772	1057	1069	O
60	30403772	1070	1072	O
minutes	30403772	1073	1080	O
of	30403772	1081	1083	O
walking	30403772	1084	1091	O
)	30403772	1091	1092	O
.	30403772	1092	1093	O

Blood	30403772	1094	1099	B-Outcome
samples	30403772	1100	1107	I-Outcome
(	30403772	1108	1109	I-Outcome
glucose	30403772	1109	1116	I-Outcome
,	30403772	1116	1117	I-Outcome
insulin	30403772	1118	1125	I-Outcome
,	30403772	1125	1126	I-Outcome
triglycerides	30403772	1127	1140	I-Outcome
)	30403772	1140	1141	I-Outcome
and	30403772	1142	1145	O
blood	30403772	1146	1151	B-Outcome
pressure	30403772	1152	1160	I-Outcome
were	30403772	1161	1165	O
sampled	30403772	1166	1173	O
regularly	30403772	1174	1183	O
throughout	30403772	1184	1194	O
each	30403772	1195	1199	O
condition	30403772	1200	1209	O
.	30403772	1209	1210	O

RESULTS	30403772	1210	1217	O
:	30403772	1217	1218	O
Compared	30403772	1219	1227	O
with	30403772	1228	1232	O
prolonged	30403772	1233	1242	B-Intervention
sitting	30403772	1243	1250	I-Intervention
,	30403772	1250	1251	O
walking	30403772	1252	1259	B-Intervention
breaks	30403772	1260	1266	I-Intervention
lowered	30403772	1267	1274	B-Observation
postprandial	30403772	1275	1287	B-Outcome
insulin	30403772	1288	1295	I-Outcome
by	30403772	1296	1298	B-Observation
16.3	30403772	1299	1303	I-Observation
mU/L	30403772	1304	1308	I-Observation
,	30403772	1308	1309	O
(	30403772	1310	1311	O
95	30403772	1311	1313	O
%	30403772	1313	1314	O
CI	30403772	1315	1317	O
:	30403772	1317	1318	O
19.7	30403772	1319	1323	O
,	30403772	1323	1324	O
22.0	30403772	1325	1329	O
)	30403772	1329	1330	O
with	30403772	1331	1335	O
greater	30403772	1336	1343	B-Observation
reductions	30403772	1344	1354	I-Observation
(	30403772	1355	1356	O
p	30403772	1356	1357	O
=	30403772	1358	1359	O
.029	30403772	1360	1364	O
)	30403772	1364	1365	O
seen	30403772	1366	1370	O
in	30403772	1371	1373	O
South	30403772	1374	1379	B-Participant
Asians	30403772	1380	1386	I-Participant
(	30403772	1387	1388	O
22.4	30403772	1388	1392	O
mU/L	30403772	1393	1397	O
;	30403772	1397	1398	O
12.4	30403772	1399	1403	O
,	30403772	1403	1404	O
32.4	30403772	1405	1409	O
)	30403772	1409	1410	O
than	30403772	1411	1415	O
white	30403772	1416	1421	B-Participant
Europeans	30403772	1422	1431	I-Participant
(	30403772	1432	1433	O
10.3	30403772	1433	1437	O
mU/L	30403772	1438	1442	O
;	30403772	1442	1443	O
5.9	30403772	1444	1447	O
,	30403772	1447	1448	O
14.7	30403772	1449	1453	O
)	30403772	1453	1454	O
.	30403772	1454	1455	O

Glucose	30403772	1456	1463	B-Outcome
(	30403772	1464	1465	O
0.3	30403772	1465	1468	B-Observation
mmol/L	30403772	1469	1475	I-Observation
;	30403772	1475	1476	O
0.1	30403772	1477	1480	O
,	30403772	1480	1481	O
0.5	30403772	1482	1485	O
)	30403772	1485	1486	O
and	30403772	1487	1490	O
blood	30403772	1491	1496	B-Outcome
pressure	30403772	1497	1505	I-Outcome
(	30403772	1506	1507	O
4	30403772	1507	1508	B-Observation
mm	30403772	1509	1511	I-Observation
Hg	30403772	1512	1514	I-Observation
;	30403772	1514	1515	O
2	30403772	1516	1517	O
,	30403772	1517	1518	O
6	30403772	1519	1520	O
)	30403772	1520	1521	O
,	30403772	1521	1522	O
but	30403772	1523	1526	O
not	30403772	1527	1530	O
triglycerides	30403772	1531	1544	B-Outcome
,	30403772	1544	1545	O
were	30403772	1546	1550	O
lower	30403772	1551	1556	B-Observation
with	30403772	1557	1561	O
walking	30403772	1562	1569	B-Intervention
breaks	30403772	1570	1576	I-Intervention
,	30403772	1576	1577	O
with	30403772	1578	1582	O
no	30403772	1583	1585	O
ethnic	30403772	1586	1592	B-Participant
differences	30403772	1593	1604	I-Participant
.	30403772	1604	1605	O

Standing	30403772	1606	1614	B-Intervention
breaks	30403772	1615	1621	I-Intervention
did	30403772	1622	1625	O
not	30403772	1626	1629	O
improve	30403772	1630	1637	B-Observation
any	30403772	1638	1641	B-Outcome
outcome	30403772	1642	1649	I-Outcome
.	30403772	1649	1650	O

CONCLUSIONS	30403772	1650	1661	O
:	30403772	1661	1662	O
Breaking	30403772	1663	1671	O
prolonged	30403772	1672	1681	O
sitting	30403772	1682	1689	O
with	30403772	1690	1694	O
short	30403772	1695	1700	O
bouts	30403772	1701	1706	O
of	30403772	1707	1709	O
light	30403772	1710	1715	B-Intervention
walking	30403772	1716	1723	I-Intervention
,	30403772	1723	1724	O
but	30403772	1725	1728	O
not	30403772	1729	1732	O
standing	30403772	1733	1741	B-Intervention
,	30403772	1741	1742	O
resulted	30403772	1743	1751	O
in	30403772	1752	1754	O
clinically	30403772	1755	1765	B-Observation
meaningful	30403772	1766	1776	I-Observation
improvements	30403772	1777	1789	I-Observation
in	30403772	1790	1792	O
markers	30403772	1793	1800	B-Outcome
of	30403772	1801	1803	I-Outcome
metabolic	30403772	1804	1813	I-Outcome
health	30403772	1814	1820	I-Outcome
in	30403772	1821	1823	O
older	30403772	1824	1829	B-Participant
adults	30403772	1830	1836	I-Participant
,	30403772	1836	1837	O
with	30403772	1838	1842	O
South	30403772	1843	1848	B-Participant
Asians	30403772	1849	1855	I-Participant
gaining	30403772	1856	1863	O
a	30403772	1864	1865	O
greater	30403772	1866	1873	B-Observation
reduction	30403772	1874	1883	I-Observation
in	30403772	1884	1886	O
postprandial	30403772	1887	1899	B-Outcome
insulin	30403772	1900	1907	I-Outcome
.	30403772	1907	1908	O

TRIAL	30403772	1908	1913	O
REGISTRATION	30403772	1914	1926	O
:	30403772	1926	1927	O
NCT02453204	30403772	1928	1939	O
.	30403772	1939	1940	O

TITLE	30412233	0	5	O
:	30412233	5	6	O
A	30412233	7	8	O
Community	30412233	9	18	B-Intervention
Choir	30412233	19	24	I-Intervention
Intervention	30412233	25	37	I-Intervention
to	30412233	38	40	O
Promote	30412233	41	48	B-Observation
Well-Being	30412233	49	59	B-Outcome
Among	30412233	60	65	O
Diverse	30412233	66	73	B-Participant
Older	30412233	74	79	I-Participant
Adults	30412233	80	86	I-Participant
:	30412233	86	87	O
Results	30412233	88	95	O
From	30412233	96	100	O
the	30412233	101	104	O
Community	30412233	105	114	O
of	30412233	115	117	O
Voices	30412233	118	124	O
Trial	30412233	125	130	O
.	30412233	130	131	O

OBJECTIVES	30412233	132	142	O
:	30412233	142	143	O
To	30412233	144	146	O
test	30412233	147	151	O
effects	30412233	152	159	O
of	30412233	160	162	O
the	30412233	163	166	O
Community	30412233	167	176	B-Intervention
of	30412233	177	179	I-Intervention
Voices	30412233	180	186	I-Intervention
choir	30412233	187	192	I-Intervention
intervention	30412233	193	205	I-Intervention
on	30412233	206	208	O
the	30412233	209	212	O
health	30412233	213	219	B-Outcome
,	30412233	219	220	O
well-being	30412233	221	231	B-Outcome
,	30412233	231	232	O
and	30412233	233	236	O
health	30412233	237	243	B-Outcome
care	30412233	244	248	I-Outcome
costs	30412233	249	254	I-Outcome
of	30412233	255	257	O
racial/ethnically	30412233	258	275	B-Intervention
diverse	30412233	276	283	I-Intervention
older	30412233	284	289	I-Intervention
adults	30412233	290	296	I-Intervention
.	30412233	296	297	O

METHOD	30412233	297	303	O
:	30412233	303	304	O
Twelve	30412233	305	311	O
Administration-on-Aging-supported	30412233	312	345	O
senior	30412233	346	352	O
centers	30412233	353	360	O
were	30412233	361	365	O
cluster	30412233	366	373	O
randomized	30412233	374	384	O
into	30412233	385	389	O
two	30412233	390	393	O
groups	30412233	394	400	O
:	30412233	400	401	O
the	30412233	402	405	O
intervention	30412233	406	418	B-Intervention
group	30412233	419	424	I-Intervention
started	30412233	425	432	I-Intervention
the	30412233	433	436	I-Intervention
choir	30412233	437	442	I-Intervention
immediately	30412233	443	454	I-Intervention
and	30412233	455	458	O
a	30412233	459	460	O
wait-list	30412233	461	470	B-Intervention
control	30412233	471	478	I-Intervention
group	30412233	479	484	I-Intervention
began	30412233	485	490	I-Intervention
the	30412233	491	494	I-Intervention
choir	30412233	495	500	I-Intervention
6	30412233	501	502	I-Intervention
months	30412233	503	509	I-Intervention
later	30412233	510	515	I-Intervention
.	30412233	515	516	O

The	30412233	517	520	O
choir	30412233	521	526	B-Intervention
program	30412233	527	534	I-Intervention
was	30412233	535	538	O
designed	30412233	539	547	O
for	30412233	548	551	O
community-dwelling	30412233	552	570	B-Participant
adults	30412233	571	577	I-Participant
aged	30412233	578	582	B-Participant
60	30412233	583	585	I-Participant
years	30412233	586	591	I-Participant
and	30412233	592	595	I-Participant
older	30412233	596	601	I-Participant
.	30412233	601	602	O

The	30412233	603	606	O
multimodal	30412233	607	617	B-Intervention
intervention	30412233	618	630	I-Intervention
comprises	30412233	631	640	O
activities	30412233	641	651	O
that	30412233	652	656	O
engage	30412233	657	663	O
participants	30412233	664	676	O
cognitively	30412233	677	688	O
,	30412233	688	689	O
physically	30412233	690	700	O
,	30412233	700	701	O
and	30412233	702	705	O
socially	30412233	706	714	O
.	30412233	714	715	O

Outcome	30412233	716	723	O
measures	30412233	724	732	O
assessed	30412233	733	741	O
these	30412233	742	747	O
three	30412233	748	753	O
domains	30412233	754	761	O
as	30412233	762	764	O
well	30412233	765	769	O
as	30412233	770	772	O
health	30412233	773	779	B-Outcome
care	30412233	780	784	I-Outcome
utilization	30412233	785	796	I-Outcome
and	30412233	797	800	O
costs	30412233	801	806	B-Outcome
.	30412233	806	807	O

The	30412233	808	811	O
intention-to-treat	30412233	812	830	B-Outcome
comparison	30412233	831	841	I-Outcome
was	30412233	842	845	O
at	30412233	846	848	O
6	30412233	849	850	O
months	30412233	851	857	O
.	30412233	857	858	O

RESULTS	30412233	858	865	O
:	30412233	865	866	O
The	30412233	867	870	O
sample	30412233	871	877	O
(	30412233	878	879	O
N	30412233	879	880	O
=	30412233	881	882	O
390	30412233	883	886	O
)	30412233	886	887	O
had	30412233	888	891	O
a	30412233	892	893	O
mean	30412233	894	898	O
age	30412233	899	902	O
of	30412233	903	905	O
71.3	30412233	906	910	O
years	30412233	911	916	O
(	30412233	917	918	O
SD	30412233	918	920	O
=	30412233	921	922	O
7.2	30412233	923	926	O
)	30412233	926	927	O
;	30412233	927	928	O
65	30412233	929	931	O
%	30412233	931	932	O
were	30412233	933	937	O
nonwhite	30412233	938	946	O
.	30412233	946	947	O

Six-month	30412233	948	957	B-Outcome
retention	30412233	958	967	I-Outcome
was	30412233	968	971	O
92	30412233	972	974	B-Observation
%	30412233	974	975	I-Observation
.	30412233	975	976	O

Compared	30412233	977	985	O
to	30412233	986	988	O
controls	30412233	989	997	B-Intervention
,	30412233	997	998	O
intervention	30412233	999	1011	B-Intervention
group	30412233	1012	1017	O
members	30412233	1018	1025	O
experienced	30412233	1026	1037	O
significantly	30412233	1038	1051	B-Observation
greater	30412233	1052	1059	I-Observation
improvements	30412233	1060	1072	I-Observation
in	30412233	1073	1075	O
loneliness	30412233	1076	1086	B-Outcome
(	30412233	1087	1088	O
p	30412233	1088	1089	O
=	30412233	1090	1091	O
.02	30412233	1092	1095	O
;	30412233	1095	1096	O
standardized	30412233	1097	1109	O
effect	30412233	1110	1116	O
size	30412233	1117	1121	O
[	30412233	1122	1123	O
ES	30412233	1123	1125	O
=	30412233	1126	1127	O
0.34	30412233	1128	1132	O
]	30412233	1132	1133	O
and	30412233	1134	1137	O
interest	30412233	1138	1146	B-Outcome
in	30412233	1147	1149	I-Outcome
life	30412233	1150	1154	I-Outcome
(	30412233	1155	1156	O
p	30412233	1156	1157	O
=	30412233	1158	1159	O
.008	30412233	1160	1164	O
,	30412233	1164	1165	O
ES	30412233	1166	1168	O
=	30412233	1169	1170	O
0.39	30412233	1171	1175	O
)	30412233	1175	1176	O
.	30412233	1176	1177	O

No	30412233	1178	1180	O
significant	30412233	1181	1192	B-Observation
group	30412233	1193	1198	I-Observation
differences	30412233	1199	1210	I-Observation
were	30412233	1211	1215	O
observed	30412233	1216	1224	O
for	30412233	1225	1228	O
cognitive	30412233	1229	1238	B-Outcome
or	30412233	1239	1241	I-Outcome
physical	30412233	1242	1250	I-Outcome
outcomes	30412233	1251	1259	I-Outcome
or	30412233	1260	1262	O
for	30412233	1263	1266	O
health	30412233	1267	1273	B-Outcome
care	30412233	1274	1278	I-Outcome
costs	30412233	1279	1284	I-Outcome
.	30412233	1284	1285	O

DISCUSSION	30412233	1285	1295	O
:	30412233	1295	1296	O
Findings	30412233	1297	1305	O
support	30412233	1306	1313	O
adoption	30412233	1314	1322	O
of	30412233	1323	1325	O
community	30412233	1326	1335	B-Intervention
choirs	30412233	1336	1342	I-Intervention
for	30412233	1343	1346	O
reducing	30412233	1347	1355	B-Observation
loneliness	30412233	1356	1366	B-Outcome
and	30412233	1367	1370	O
increasing	30412233	1371	1381	B-Observation
interest	30412233	1382	1390	B-Outcome
in	30412233	1391	1393	I-Outcome
life	30412233	1394	1398	I-Outcome
among	30412233	1399	1404	O
diverse	30412233	1405	1412	B-Participant
older	30412233	1413	1418	I-Participant
adults	30412233	1419	1425	I-Participant
.	30412233	1425	1426	O

Further	30412233	1427	1434	O
efforts	30412233	1435	1442	O
need	30412233	1443	1447	O
to	30412233	1448	1450	O
examine	30412233	1451	1458	O
the	30412233	1459	1462	O
mechanisms	30412233	1463	1473	O
by	30412233	1474	1476	O
which	30412233	1477	1482	O
engagement	30412233	1483	1493	O
in	30412233	1494	1496	O
choirs	30412233	1497	1503	O
improves	30412233	1504	1512	O
aspects	30412233	1513	1520	O
of	30412233	1521	1523	O
well-being	30412233	1524	1534	O
and	30412233	1535	1538	O
reduces	30412233	1539	1546	O
health	30412233	1547	1553	O
disparities	30412233	1554	1565	O
among	30412233	1566	1571	O
older	30412233	1572	1577	O
adults	30412233	1578	1584	O
,	30412233	1584	1585	O
including	30412233	1586	1595	O
potential	30412233	1596	1605	O
longer-term	30412233	1606	1617	O
effects	30412233	1618	1625	O
.	30412233	1625	1626	O

CLINICALTRIALS.GOV	30412233	1626	1644	O
REGISTRATION	30412233	1645	1657	O
:	30412233	1657	1658	O
NCT01869179	30412233	1659	1670	O
registered	30412233	1671	1681	O
January	30412233	1682	1689	O
9	30412233	1690	1691	O
,	30412233	1691	1692	O
2013	30412233	1693	1697	O
.	30412233	1697	1698	O

TITLE	30431535	0	5	O
:	30431535	5	6	O
In-Season	30431535	7	16	B-Intervention
Integrative	30431535	17	28	I-Intervention
Neuromuscular	30431535	29	42	I-Intervention
Strength	30431535	43	51	I-Intervention
Training	30431535	52	60	I-Intervention
Improves	30431535	61	69	B-Observation
Performance	30431535	70	81	B-Outcome
of	30431535	82	84	O
Early-Adolescent	30431535	85	101	B-Participant
Soccer	30431535	102	108	I-Participant
Athletes	30431535	109	117	I-Participant
.	30431535	117	118	O

Panagoulis	30431535	119	129	O
,	30431535	129	130	O
C	30431535	131	132	O
,	30431535	132	133	O
Chatzinikolaou	30431535	134	148	O
,	30431535	148	149	O
A	30431535	150	151	O
,	30431535	151	152	O
Avloniti	30431535	153	161	O
,	30431535	161	162	O
A	30431535	163	164	O
,	30431535	164	165	O
Leontsini	30431535	166	175	O
,	30431535	175	176	O
D	30431535	177	178	O
,	30431535	178	179	O
Deli	30431535	180	184	O
,	30431535	184	185	O
CK	30431535	186	188	O
,	30431535	188	189	O
Draganidis	30431535	190	200	O
,	30431535	200	201	O
D	30431535	202	203	O
,	30431535	203	204	O
Stampoulis	30431535	205	215	O
,	30431535	215	216	O
T	30431535	217	218	O
,	30431535	218	219	O
Oikonomou	30431535	220	229	O
,	30431535	229	230	O
T	30431535	231	232	O
,	30431535	232	233	O
Papanikolaou	30431535	234	246	O
,	30431535	246	247	O
K	30431535	248	249	O
,	30431535	249	250	O
Rafailakis	30431535	251	261	O
,	30431535	261	262	O
L	30431535	263	264	O
,	30431535	264	265	O
Kambas	30431535	266	272	O
,	30431535	272	273	O
A	30431535	274	275	O
,	30431535	275	276	O
Jamurtas	30431535	277	285	O
,	30431535	285	286	O
AZ	30431535	287	289	O
,	30431535	289	290	O
and	30431535	291	294	O
Fatouros	30431535	295	303	O
,	30431535	303	304	O
IG	30431535	305	307	O
.	30431535	307	308	O

In-season	30431535	309	318	B-Intervention
integrative	30431535	319	330	I-Intervention
neuromuscular	30431535	331	344	I-Intervention
strength	30431535	345	353	I-Intervention
training	30431535	354	362	I-Intervention
improves	30431535	363	371	B-Observation
performance	30431535	372	383	B-Outcome
of	30431535	384	386	O
early-adolescent	30431535	387	403	B-Participant
soccer	30431535	404	410	I-Participant
athletes	30431535	411	419	I-Participant
.	30431535	419	420	O

J	30431535	421	422	O
Strength	30431535	423	431	O
Cond	30431535	432	436	O
Res	30431535	437	440	O
34(2	30431535	441	445	O
):	30431535	445	447	O
516	30431535	448	451	O
-	30431535	451	452	O
526	30431535	452	455	O
,	30431535	455	456	O
2020-Although	30431535	457	470	O
forms	30431535	471	476	O
of	30431535	477	479	O
integrative	30431535	480	491	O
neuromuscular	30431535	492	505	O
training	30431535	506	514	O
(	30431535	515	516	O
INT	30431535	516	519	O
)	30431535	519	520	O
are	30431535	521	524	O
used	30431535	525	529	O
extensively	30431535	530	541	O
for	30431535	542	545	O
injury	30431535	546	552	O
prevention	30431535	553	563	O
and	30431535	564	567	O
treatment	30431535	568	577	O
,	30431535	577	578	O
no	30431535	579	581	O
information	30431535	582	593	O
exists	30431535	594	600	O
about	30431535	601	606	O
its	30431535	607	610	O
effects	30431535	611	618	O
on	30431535	619	621	O
performance	30431535	622	633	O
of	30431535	634	636	O
adolescent	30431535	637	647	O
athletes	30431535	648	656	O
.	30431535	656	657	O

We	30431535	658	660	O
investigated	30431535	661	673	O
the	30431535	674	677	O
effects	30431535	678	685	O
of	30431535	686	688	O
an	30431535	689	691	O
in-season	30431535	692	701	B-Intervention
INT	30431535	702	705	I-Intervention
intervention	30431535	706	718	I-Intervention
on	30431535	719	721	O
performance	30431535	722	733	B-Outcome
of	30431535	734	736	O
early-adolescent	30431535	737	753	B-Participant
players	30431535	754	761	I-Participant
using	30431535	762	767	O
a	30431535	768	769	O
2-group	30431535	770	777	O
,	30431535	777	778	O
repeated-measures	30431535	779	796	O
design	30431535	797	803	O
.	30431535	803	804	O

Twenty-eight	30431535	805	817	O
early	30431535	818	823	B-Participant
adolescents	30431535	824	835	I-Participant
were	30431535	836	840	O
randomly	30431535	841	849	O
assigned	30431535	850	858	O
to	30431535	859	861	O
a	30431535	862	863	O
control	30431535	864	871	B-Intervention
group	30431535	872	877	O
(	30431535	878	879	O
CG	30431535	879	881	O
,	30431535	881	882	O
participated	30431535	883	895	B-Intervention
only	30431535	896	900	I-Intervention
in	30431535	901	903	I-Intervention
soccer	30431535	904	910	I-Intervention
training	30431535	911	919	I-Intervention
,	30431535	919	920	O
N	30431535	921	922	O
=	30431535	923	924	O
14	30431535	925	927	O
,	30431535	927	928	O
11.4	30431535	929	933	O
	30431535	934	935	O
0.57	30431535	936	940	O
years	30431535	941	946	O
,	30431535	946	947	O
Tanner	30431535	948	954	O
stage	30431535	955	960	O
2.8	30431535	961	964	O
	30431535	965	966	O
0.6	30431535	967	970	O
)	30431535	970	971	O
or	30431535	972	974	O
an	30431535	975	977	O
experimental	30431535	978	990	B-Intervention
group	30431535	991	996	O
(	30431535	997	998	O
INT	30431535	998	1001	B-Intervention
was	30431535	1002	1005	I-Intervention
added	30431535	1006	1011	I-Intervention
to	30431535	1012	1014	I-Intervention
conventional	30431535	1015	1027	I-Intervention
soccer	30431535	1028	1034	I-Intervention
training	30431535	1035	1043	I-Intervention
,	30431535	1043	1044	O
N	30431535	1045	1046	O
=	30431535	1047	1048	O
14	30431535	1049	1051	O
,	30431535	1051	1052	O
11.2	30431535	1053	1057	O
	30431535	1058	1059	O
0.5	30431535	1060	1063	O
years	30431535	1064	1069	O
,	30431535	1069	1070	O
Tanner	30431535	1071	1077	O
stage	30431535	1078	1083	O
2.6	30431535	1084	1087	O
	30431535	1088	1089	O
0.5	30431535	1090	1093	O
)	30431535	1093	1094	O
.	30431535	1094	1095	O

Integrative	30431535	1096	1107	B-Intervention
neuromuscular	30431535	1108	1121	I-Intervention
training	30431535	1122	1130	I-Intervention
(	30431535	1131	1132	O
8	30431535	1132	1133	O
weeks	30431535	1134	1139	O
,	30431535	1139	1140	O
3	30431535	1141	1142	O
sessionswk	30431535	1143	1154	O
)	30431535	1154	1155	O
aimed	30431535	1156	1161	O
to	30431535	1162	1164	O
develop	30431535	1165	1172	B-Observation
core	30431535	1173	1177	B-Outcome
strength	30431535	1178	1186	I-Outcome
,	30431535	1186	1187	O
hamstrings	30431535	1188	1198	B-Outcome
eccentric	30431535	1199	1208	I-Outcome
strength	30431535	1209	1217	I-Outcome
,	30431535	1217	1218	O
hip/knee	30431535	1219	1227	B-Outcome
musculature	30431535	1228	1239	I-Outcome
,	30431535	1239	1240	O
and	30431535	1241	1244	O
dynamic	30431535	1245	1252	B-Outcome
stability	30431535	1253	1262	I-Outcome
using	30431535	1263	1268	O
body	30431535	1269	1273	O
mass	30431535	1274	1278	O
exercises	30431535	1279	1288	O
,	30431535	1288	1289	O
medicine	30431535	1290	1298	O
balls	30431535	1299	1304	O
,	30431535	1304	1305	O
rocker	30431535	1306	1312	O
boards	30431535	1313	1319	O
,	30431535	1319	1320	O
Bosu	30431535	1321	1325	O
,	30431535	1325	1326	O
stability	30431535	1327	1336	O
balls	30431535	1337	1342	O
,	30431535	1342	1343	O
etc	30431535	1344	1347	O
.	30431535	1347	1348	O

Ball	30431535	1349	1353	B-Outcome
shooting	30431535	1354	1362	I-Outcome
speed	30431535	1363	1368	I-Outcome
,	30431535	1368	1369	O
speed	30431535	1370	1375	B-Outcome
(	30431535	1376	1377	O
10	30431535	1377	1379	O
,	30431535	1379	1380	O
20-m	30431535	1381	1385	O
)	30431535	1385	1386	O
,	30431535	1386	1387	O
change	30431535	1388	1394	B-Outcome
of	30431535	1395	1397	I-Outcome
direction	30431535	1398	1407	I-Outcome
(	30431535	1408	1409	I-Outcome
COD	30431535	1409	1412	I-Outcome
)	30431535	1412	1413	I-Outcome
,	30431535	1413	1414	O
jumping	30431535	1415	1422	B-Outcome
performance	30431535	1423	1434	I-Outcome
,	30431535	1434	1435	O
and	30431535	1436	1439	O
strength	30431535	1440	1448	B-Outcome
were	30431535	1449	1453	O
measured	30431535	1454	1462	O
before	30431535	1463	1469	O
and	30431535	1470	1473	O
after	30431535	1474	1479	O
training	30431535	1480	1488	O
.	30431535	1488	1489	O

A	30431535	1490	1491	O
2-way	30431535	1492	1497	O
repeated-measures	30431535	1498	1515	O
ANOVA	30431535	1516	1521	O
was	30431535	1522	1525	O
used	30431535	1526	1530	O
to	30431535	1531	1533	O
analyze	30431535	1534	1541	O
data	30431535	1542	1546	O
.	30431535	1546	1547	O

Integrative	30431535	1548	1559	B-Intervention
neuromuscular	30431535	1560	1573	I-Intervention
training	30431535	1574	1582	I-Intervention
improved	30431535	1583	1591	B-Observation
10-	30431535	1592	1595	B-Outcome
and	30431535	1596	1599	I-Outcome
20-m	30431535	1600	1604	I-Outcome
speed	30431535	1605	1610	I-Outcome
(	30431535	1611	1612	O
2.52	30431535	1612	1616	B-Observation
-	30431535	1616	1617	I-Observation
2.13	30431535	1617	1621	I-Observation
and	30431535	1622	1625	I-Observation
3.61	30431535	1626	1630	I-Observation
-	30431535	1630	1631	I-Observation
3.39	30431535	1631	1635	I-Observation
seconds	30431535	1636	1643	I-Observation
,	30431535	1643	1644	O
respectively	30431535	1645	1657	O
,	30431535	1657	1658	O
p	30431535	1659	1660	O
<	30431535	1661	1662	O
0.05	30431535	1663	1667	O
)	30431535	1667	1668	O
,	30431535	1668	1669	O
strength	30431535	1670	1678	B-Outcome
(	30431535	1679	1680	O
40.1	30431535	1680	1684	B-Observation
-	30431535	1684	1685	I-Observation
44.4	30431535	1685	1689	I-Observation
kg	30431535	1690	1692	I-Observation
,	30431535	1692	1693	O
p	30431535	1694	1695	O
<	30431535	1696	1697	O
0.05	30431535	1698	1702	O
)	30431535	1702	1703	O
,	30431535	1703	1704	O
jumping	30431535	1705	1712	B-Outcome
ability	30431535	1713	1720	I-Outcome
(	30431535	1721	1722	O
squat	30431535	1722	1727	B-Outcome
jump	30431535	1728	1732	I-Outcome
:	30431535	1732	1733	O
16.3	30431535	1734	1738	B-Observation
-	30431535	1738	1739	I-Observation
17.9	30431535	1739	1743	I-Observation
cm	30431535	1744	1746	I-Observation
;	30431535	1746	1747	O
countermovement	30431535	1748	1763	B-Outcome
jump	30431535	1764	1768	I-Outcome
:	30431535	1768	1769	O
19.1	30431535	1770	1774	B-Observation
-	30431535	1774	1775	I-Observation
20.3	30431535	1775	1779	I-Observation
cm	30431535	1780	1782	I-Observation
,	30431535	1782	1783	O
p	30431535	1784	1785	O
<	30431535	1786	1787	O
0.05	30431535	1788	1792	O
)	30431535	1792	1793	O
,	30431535	1793	1794	O
COD	30431535	1795	1798	B-Outcome
(	30431535	1799	1800	O
18.0	30431535	1800	1804	B-Observation
-	30431535	1804	1805	I-Observation
17.3	30431535	1805	1809	I-Observation
seconds	30431535	1810	1817	I-Observation
,	30431535	1817	1818	O
p	30431535	1819	1820	O
<	30431535	1821	1822	O
0.05	30431535	1823	1827	O
)	30431535	1827	1828	O
,	30431535	1828	1829	O
and	30431535	1830	1833	O
shooting	30431535	1834	1842	B-Outcome
speed	30431535	1843	1848	I-Outcome
(	30431535	1849	1850	O
73.8	30431535	1850	1854	B-Observation
-	30431535	1854	1855	I-Observation
79.0	30431535	1855	1859	I-Observation
kmh	30431535	1860	1864	I-Observation
,	30431535	1864	1865	O
p	30431535	1866	1867	O
<	30431535	1868	1869	O
0.05	30431535	1870	1874	O
)	30431535	1874	1875	O
.	30431535	1875	1876	O

In	30431535	1877	1879	O
the	30431535	1880	1883	O
CG	30431535	1884	1886	B-Intervention
,	30431535	1886	1887	O
soccer	30431535	1888	1894	O
training	30431535	1895	1903	O
caused	30431535	1904	1910	O
an	30431535	1911	1913	O
improvement	30431535	1914	1925	B-Observation
of	30431535	1926	1928	I-Observation
smaller	30431535	1929	1936	I-Observation
magnitude	30431535	1937	1946	I-Observation
in	30431535	1947	1949	O
10	30431535	1950	1952	B-Outcome
m	30431535	1953	1954	I-Outcome
and	30431535	1955	1958	O
shooting	30431535	1959	1967	B-Outcome
speed	30431535	1968	1973	I-Outcome
(	30431535	1974	1975	O
p	30431535	1975	1976	O
<	30431535	1977	1978	O
0.05	30431535	1979	1983	O
)	30431535	1983	1984	O
,	30431535	1984	1985	O
whereas	30431535	1986	1993	O
COD	30431535	1994	1997	B-Outcome
and	30431535	1998	2001	O
jumping	30431535	2002	2009	B-Outcome
performance	30431535	2010	2021	I-Outcome
remained	30431535	2022	2030	O
unaffected	30431535	2031	2041	B-Observation
while	30431535	2042	2047	O
20-m	30431535	2048	2052	B-Outcome
speed	30431535	2053	2058	I-Outcome
,	30431535	2058	2059	O
COD	30431535	2060	2063	B-Outcome
,	30431535	2063	2064	O
and	30431535	2065	2068	O
strength	30431535	2069	2077	B-Outcome
deteriorated	30431535	2078	2090	B-Observation
.	30431535	2090	2091	O

These	30431535	2092	2097	O
results	30431535	2098	2105	O
indicate	30431535	2106	2114	O
that	30431535	2115	2119	O
an	30431535	2120	2122	O
8-week	30431535	2123	2129	B-Intervention
INT	30431535	2130	2133	I-Intervention
program	30431535	2134	2141	I-Intervention
may	30431535	2142	2145	O
induce	30431535	2146	2152	O
positive	30431535	2153	2161	B-Observation
adaptations	30431535	2162	2173	I-Observation
in	30431535	2174	2176	O
performance	30431535	2177	2188	B-Outcome
of	30431535	2189	2191	O
early-adolescent	30431535	2192	2208	B-Participant
soccer	30431535	2209	2215	I-Participant
players	30431535	2216	2223	I-Participant
during	30431535	2224	2230	O
in-season	30431535	2231	2240	O
training	30431535	2241	2249	O
,	30431535	2249	2250	O
suggesting	30431535	2251	2261	O
that	30431535	2262	2266	O
INT	30431535	2267	2270	B-Intervention
may	30431535	2271	2274	O
be	30431535	2275	2277	O
an	30431535	2278	2280	O
effective	30431535	2281	2290	B-Observation
training	30431535	2291	2299	O
intervention	30431535	2300	2312	O
for	30431535	2313	2316	O
this	30431535	2317	2321	O
age	30431535	2322	2325	B-Participant
group	30431535	2326	2331	I-Participant
.	30431535	2331	2332	O

TITLE	30452705	0	5	O
:	30452705	5	6	O
Web-Based	30452705	7	16	B-Intervention
Contingency	30452705	17	28	I-Intervention
Management	30452705	29	39	I-Intervention
for	30452705	40	43	O
Adolescent	30452705	44	54	B-Participant
Tobacco	30452705	55	62	I-Participant
Smokers	30452705	63	70	I-Participant
:	30452705	70	71	O
A	30452705	72	73	O
Clinical	30452705	74	82	O
Trial	30452705	83	88	O
.	30452705	88	89	O

INTRODUCTION	30452705	90	102	O
:	30452705	102	103	O
Adolescence	30452705	104	115	O
is	30452705	116	118	O
a	30452705	119	120	O
critical	30452705	121	129	O
time	30452705	130	134	O
when	30452705	135	139	O
the	30452705	140	143	O
majority	30452705	144	152	O
of	30452705	153	155	O
tobacco	30452705	156	163	O
users	30452705	164	169	O
initiate	30452705	170	178	O
smoking	30452705	179	186	O
.	30452705	186	187	O

Contingency	30452705	188	199	O
management	30452705	200	210	O
for	30452705	211	214	O
adolescent	30452705	215	225	O
smoking	30452705	226	233	O
cessation	30452705	234	243	O
has	30452705	244	247	O
shown	30452705	248	253	O
promise	30452705	254	261	O
in	30452705	262	264	O
previous	30452705	265	273	O
studies	30452705	274	281	O
,	30452705	281	282	O
but	30452705	283	286	O
efficacy	30452705	287	295	O
following	30452705	296	305	O
removal	30452705	306	313	O
of	30452705	314	316	O
contingencies	30452705	317	330	O
is	30452705	331	333	O
not	30452705	334	337	O
well	30452705	338	342	O
understood	30452705	343	353	O
.	30452705	353	354	O

This	30452705	355	359	O
study	30452705	360	365	O
examined	30452705	366	374	O
a	30452705	375	376	O
remote	30452705	377	383	B-Intervention
form	30452705	384	388	I-Intervention
of	30452705	389	391	I-Intervention
contingency	30452705	392	403	I-Intervention
management	30452705	404	414	I-Intervention
among	30452705	415	420	O
non-treatment-seeking	30452705	421	442	B-Participant
adolescent	30452705	443	453	I-Participant
smokers	30452705	454	461	I-Participant
.	30452705	461	462	O

METHODS	30452705	462	469	O
:	30452705	469	470	O
Participants	30452705	471	483	O
(	30452705	484	485	O
N	30452705	485	486	O
=	30452705	487	488	O
127	30452705	489	492	O
)	30452705	492	493	O
submitted	30452705	494	503	O
breath	30452705	504	510	B-Outcome
carbon	30452705	511	517	I-Outcome
monoxide	30452705	518	526	I-Outcome
(	30452705	527	528	I-Outcome
CO	30452705	528	530	I-Outcome
)	30452705	530	531	I-Outcome
three	30452705	532	537	O
times	30452705	538	543	O
daily	30452705	544	549	O
throughout	30452705	550	560	O
a	30452705	561	562	O
42-day	30452705	563	569	O
program	30452705	570	577	O
.	30452705	577	578	O

For	30452705	579	582	O
this	30452705	583	587	O
randomized	30452705	588	598	O
trial	30452705	599	604	O
,	30452705	604	605	O
participants	30452705	606	618	O
in	30452705	619	621	O
the	30452705	622	625	O
active	30452705	626	632	B-Intervention
condition	30452705	633	642	I-Intervention
(	30452705	643	644	O
n	30452705	644	645	O
=	30452705	646	647	O
63	30452705	648	650	O
)	30452705	650	651	O
were	30452705	652	656	O
reinforced	30452705	657	667	O
for	30452705	668	671	O
providing	30452705	672	681	O
CO	30452705	682	684	B-Outcome
measurements	30452705	685	697	I-Outcome
on	30452705	698	700	O
schedule	30452705	701	709	O
and	30452705	710	713	O
below	30452705	714	719	O
a	30452705	720	721	O
set	30452705	722	725	O
criterion	30452705	726	735	O
,	30452705	735	736	O
whereas	30452705	737	744	O
those	30452705	745	750	O
in	30452705	751	753	O
the	30452705	754	757	O
control	30452705	758	765	B-Intervention
condition	30452705	766	775	I-Intervention
(	30452705	776	777	O
n	30452705	777	778	O
=	30452705	779	780	O
64	30452705	781	783	O
)	30452705	783	784	O
were	30452705	785	789	O
reinforced	30452705	790	800	O
for	30452705	801	804	O
providing	30452705	805	814	O
CO	30452705	815	817	B-Outcome
measurements	30452705	818	830	I-Outcome
on	30452705	831	833	O
schedule	30452705	834	842	O
.	30452705	842	843	O

Self-reported	30452705	844	857	B-Outcome
smoking	30452705	858	865	I-Outcome
and	30452705	866	869	O
urinary	30452705	870	877	B-Outcome
cotinine	30452705	878	886	I-Outcome
levels	30452705	887	893	I-Outcome
were	30452705	894	898	O
collected	30452705	899	908	O
at	30452705	909	911	O
several	30452705	912	919	O
timepoints	30452705	920	930	O
.	30452705	930	931	O

RESULTS	30452705	931	938	O
:	30452705	938	939	O
Active	30452705	940	946	B-Intervention
condition	30452705	947	956	I-Intervention
showed	30452705	957	963	O
greater	30452705	964	971	B-Observation
within-group	30452705	972	984	I-Observation
reductions	30452705	985	995	I-Observation
in	30452705	996	998	O
CO	30452705	999	1001	B-Outcome
levels	30452705	1002	1008	I-Outcome
relative	30452705	1009	1017	I-Outcome
to	30452705	1018	1020	O
control	30452705	1021	1028	B-Intervention
condition	30452705	1029	1038	I-Intervention
,	30452705	1038	1039	O
but	30452705	1040	1043	O
not	30452705	1044	1047	O
at	30452705	1048	1050	O
3-	30452705	1051	1053	O
or	30452705	1054	1056	O
6-month	30452705	1057	1064	O
follow-up	30452705	1065	1074	O
.	30452705	1074	1075	O

Active	30452705	1076	1082	B-Intervention
condition	30452705	1083	1092	I-Intervention
reported	30452705	1093	1101	O
significantly	30452705	1102	1115	B-Observation
less	30452705	1116	1120	I-Observation
smoking	30452705	1121	1128	B-Outcome
during	30452705	1129	1135	O
treatment	30452705	1136	1145	O
compared	30452705	1146	1154	O
to	30452705	1155	1157	O
control	30452705	1158	1165	B-Intervention
condition	30452705	1166	1175	I-Intervention
,	30452705	1175	1176	O
but	30452705	1177	1180	O
not	30452705	1181	1184	O
at	30452705	1185	1187	O
follow-up	30452705	1188	1197	O
.	30452705	1197	1198	O

There	30452705	1199	1204	O
were	30452705	1205	1209	O
no	30452705	1210	1212	O
significant	30452705	1213	1224	B-Observation
differences	30452705	1225	1236	I-Observation
for	30452705	1237	1240	O
urinary	30452705	1241	1248	B-Outcome
cotinine	30452705	1249	1257	I-Outcome
.	30452705	1257	1258	O

Overall	30452705	1259	1266	B-Outcome
treatment	30452705	1267	1276	I-Outcome
adherence	30452705	1277	1286	I-Outcome
was	30452705	1287	1290	O
low	30452705	1291	1294	B-Observation
,	30452705	1294	1295	O
with	30452705	1296	1300	O
only	30452705	1301	1305	O
37	30452705	1306	1308	B-Observation
%	30452705	1308	1309	I-Observation
and	30452705	1310	1313	O
51	30452705	1314	1316	B-Observation
%	30452705	1316	1317	I-Observation
of	30452705	1318	1320	I-Observation
possible	30452705	1321	1329	I-Observation
CO	30452705	1330	1332	I-Observation
samples	30452705	1333	1340	I-Observation
being	30452705	1341	1346	O
submitted	30452705	1347	1356	O
among	30452705	1357	1362	O
active	30452705	1363	1369	B-Intervention
and	30452705	1370	1373	O
control	30452705	1374	1381	B-Intervention
,	30452705	1381	1382	O
respectively	30452705	1383	1395	O
.	30452705	1395	1396	O

Poor	30452705	1397	1401	B-Observation
treatment	30452705	1402	1411	B-Outcome
adherence	30452705	1412	1421	I-Outcome
may	30452705	1422	1425	O
explain	30452705	1426	1433	O
the	30452705	1434	1437	O
disparity	30452705	1438	1447	B-Observation
between	30452705	1448	1455	B-Outcome
CO	30452705	1456	1458	I-Outcome
and	30452705	1459	1462	I-Outcome
cotinine	30452705	1463	1471	I-Outcome
results	30452705	1472	1479	I-Outcome
,	30452705	1479	1480	O
and	30452705	1481	1484	O
poor	30452705	1485	1489	B-Observation
follow-up	30452705	1490	1499	B-Outcome
treatment	30452705	1500	1509	I-Outcome
efficacy	30452705	1510	1518	I-Outcome
.	30452705	1518	1519	O

CONCLUSIONS	30452705	1519	1530	O
:	30452705	1530	1531	O
This	30452705	1532	1536	O
study	30452705	1537	1542	O
replicates	30452705	1543	1553	O
feasibility	30452705	1554	1565	B-Observation
of	30452705	1566	1568	O
a	30452705	1569	1570	O
remote	30452705	1571	1577	B-Intervention
form	30452705	1578	1582	I-Intervention
of	30452705	1583	1585	I-Intervention
contingency	30452705	1586	1597	I-Intervention
management	30452705	1598	1608	I-Intervention
for	30452705	1609	1612	O
adolescent	30452705	1613	1623	B-Participant
smoking	30452705	1624	1631	I-Participant
.	30452705	1631	1632	O

CO	30452705	1633	1635	O
results	30452705	1636	1643	O
suggest	30452705	1644	1651	O
active	30452705	1652	1658	B-Intervention
condition	30452705	1659	1668	I-Intervention
reduced	30452705	1669	1676	B-Observation
smoking	30452705	1677	1684	B-Outcome
within	30452705	1685	1691	I-Outcome
group	30452705	1692	1697	I-Outcome
,	30452705	1697	1698	O
but	30452705	1699	1702	O
treatment	30452705	1703	1712	B-Outcome
adherence	30452705	1713	1722	I-Outcome
and	30452705	1723	1726	O
posttreatment	30452705	1727	1740	B-Outcome
efficacy	30452705	1741	1749	I-Outcome
was	30452705	1750	1753	O
poor	30452705	1754	1758	B-Observation
.	30452705	1758	1759	O

Future	30452705	1760	1766	O
research	30452705	1767	1775	O
should	30452705	1776	1782	O
focus	30452705	1783	1788	O
on	30452705	1789	1791	O
increasing	30452705	1792	1802	O
adherence	30452705	1803	1812	O
for	30452705	1813	1816	O
this	30452705	1817	1821	O
type	30452705	1822	1826	O
of	30452705	1827	1829	O
program	30452705	1830	1837	O
among	30452705	1838	1843	O
adolescent	30452705	1844	1854	O
smokers	30452705	1855	1862	O
.	30452705	1862	1863	O

IMPLICATIONS	30452705	1863	1875	O
:	30452705	1875	1876	O
This	30452705	1877	1881	O
study	30452705	1882	1887	O
demonstrates	30452705	1888	1900	O
feasibility	30452705	1901	1912	O
of	30452705	1913	1915	O
a	30452705	1916	1917	O
remote	30452705	1918	1924	O
form	30452705	1925	1929	O
of	30452705	1930	1932	O
contingency	30452705	1933	1944	O
management	30452705	1945	1955	O
therapy	30452705	1956	1963	O
for	30452705	1964	1967	O
smoking	30452705	1968	1975	O
cessation	30452705	1976	1985	O
among	30452705	1986	1991	O
adolescents	30452705	1992	2003	O
,	30452705	2003	2004	O
while	30452705	2005	2010	O
providing	30452705	2011	2020	O
posttreatment	30452705	2021	2034	O
efficacy	30452705	2035	2043	O
data	30452705	2044	2048	O
.	30452705	2048	2049	O

Within-group	30452705	2050	2062	B-Outcome
efficacy	30452705	2063	2071	I-Outcome
of	30452705	2072	2074	O
this	30452705	2075	2079	O
form	30452705	2080	2084	B-Intervention
of	30452705	2085	2087	I-Intervention
treatment	30452705	2088	2097	I-Intervention
is	30452705	2098	2100	O
suggested	30452705	2101	2110	B-Observation
,	30452705	2110	2111	O
but	30452705	2112	2115	O
treatment	30452705	2116	2125	B-Outcome
adherence	30452705	2126	2135	I-Outcome
and	30452705	2136	2139	O
follow-up	30452705	2140	2149	B-Outcome
efficacy	30452705	2150	2158	I-Outcome
were	30452705	2159	2163	O
poor	30452705	2164	2168	B-Observation
.	30452705	2168	2169	O

This	30452705	2170	2174	O
study	30452705	2175	2180	O
underscores	30452705	2181	2192	O
the	30452705	2193	2196	O
need	30452705	2197	2201	O
for	30452705	2202	2205	O
further	30452705	2206	2213	O
development	30452705	2214	2225	O
of	30452705	2226	2228	O
contingency	30452705	2229	2240	O
management	30452705	2241	2251	O
therapy	30452705	2252	2259	O
for	30452705	2260	2263	O
adolescent	30452705	2264	2274	O
smoking	30452705	2275	2282	O
cessation	30452705	2283	2292	O
,	30452705	2292	2293	O
which	30452705	2294	2299	O
emphasizes	30452705	2300	2310	O
better	30452705	2311	2317	O
treatment	30452705	2318	2327	O
adherence	30452705	2328	2337	O
and	30452705	2338	2341	O
posttreatment	30452705	2342	2355	O
efficacy	30452705	2356	2364	O
.	30452705	2364	2365	O

TITLE	30452732	0	5	O
:	30452732	5	6	O
Efficacy	30452732	7	15	B-Outcome
and	30452732	16	19	O
Safety	30452732	20	26	B-Outcome
of	30452732	27	29	O
a	30452732	30	31	O
Nicotine	30452732	32	40	B-Intervention
Mouth	30452732	41	46	I-Intervention
Spray	30452732	47	52	I-Intervention
for	30452732	53	56	O
Smoking	30452732	57	64	B-Outcome
Cessation	30452732	65	74	I-Outcome
:	30452732	74	75	O
A	30452732	76	77	O
Randomized	30452732	78	88	O
,	30452732	88	89	O
Multicenter	30452732	90	101	O
,	30452732	101	102	O
Controlled	30452732	103	113	O
Study	30452732	114	119	O
in	30452732	120	122	O
a	30452732	123	124	O
Naturalistic	30452732	125	137	O
Setting	30452732	138	145	O
.	30452732	145	146	O

BACKGROUND	30452732	147	157	O
:	30452732	157	158	O
Nicotine	30452732	159	167	O
replacement	30452732	168	179	O
therapy	30452732	180	187	O
(	30452732	188	189	O
NRT	30452732	189	192	O
)	30452732	192	193	O
has	30452732	194	197	O
been	30452732	198	202	O
demonstrated	30452732	203	215	O
to	30452732	216	218	O
be	30452732	219	221	O
an	30452732	222	224	O
effective	30452732	225	234	O
pharmacological	30452732	235	250	O
treatment	30452732	251	260	O
for	30452732	261	264	O
smoking	30452732	265	272	O
cessation	30452732	273	282	O
,	30452732	282	283	O
and	30452732	284	287	O
most	30452732	288	292	O
types	30452732	293	298	O
of	30452732	299	301	O
NRT	30452732	302	305	O
have	30452732	306	310	O
been	30452732	311	315	O
approved	30452732	316	324	O
as	30452732	325	327	O
over-the-counter	30452732	328	344	O
(	30452732	345	346	O
OTC	30452732	346	349	O
)	30452732	349	350	O
medications	30452732	351	362	O
.	30452732	362	363	O

In	30452732	364	366	O
an	30452732	367	369	O
effort	30452732	370	376	O
to	30452732	377	379	O
create	30452732	380	386	O
a	30452732	387	388	O
fast-acting	30452732	389	400	O
,	30452732	400	401	O
flexible	30452732	402	410	O
,	30452732	410	411	O
and	30452732	412	415	O
discreet	30452732	416	424	O
NRT	30452732	425	428	O
,	30452732	428	429	O
a	30452732	430	431	O
nicotine	30452732	432	440	O
mouth	30452732	441	446	O
spray	30452732	447	452	O
(	30452732	453	454	O
NMS	30452732	454	457	O
)	30452732	457	458	O
has	30452732	459	462	O
been	30452732	463	467	O
developed	30452732	468	477	O
.	30452732	477	478	O

This	30452732	479	483	O
study	30452732	484	489	O
was	30452732	490	493	O
designed	30452732	494	502	O
to	30452732	503	505	O
assess	30452732	506	512	O
the	30452732	513	516	O
efficacy	30452732	517	525	B-Outcome
and	30452732	526	529	O
safety	30452732	530	536	B-Outcome
of	30452732	537	539	O
NMS	30452732	540	543	B-Intervention
in	30452732	544	546	O
a	30452732	547	548	O
naturalistic	30452732	549	561	B-Participant
setting	30452732	562	569	I-Participant
in	30452732	570	572	O
the	30452732	573	576	O
United	30452732	577	583	O
States	30452732	584	590	O
.	30452732	590	591	O

METHODS	30452732	591	598	O
:	30452732	598	599	O
This	30452732	600	604	O
was	30452732	605	608	O
a	30452732	609	610	O
multicenter	30452732	611	622	O
,	30452732	622	623	O
randomized	30452732	624	634	O
,	30452732	634	635	O
double-blind	30452732	636	648	O
,	30452732	648	649	O
placebo-controlled	30452732	650	668	O
,	30452732	668	669	O
parallel-group	30452732	670	684	O
,	30452732	684	685	O
26-week	30452732	686	693	O
study	30452732	694	699	O
in	30452732	700	702	O
1198	30452732	703	707	O
smokers	30452732	708	715	B-Participant
motivated	30452732	716	725	I-Participant
to	30452732	726	728	I-Participant
quit	30452732	729	733	I-Participant
.	30452732	733	734	O

The	30452732	735	738	O
study	30452732	739	744	O
was	30452732	745	748	O
designed	30452732	749	757	O
to	30452732	758	760	O
resemble	30452732	761	769	O
an	30452732	770	772	O
OTC	30452732	773	776	O
environment	30452732	777	788	O
,	30452732	788	789	O
and	30452732	790	793	O
thus	30452732	794	798	O
included	30452732	799	807	O
limited	30452732	808	815	O
intervention	30452732	816	828	O
,	30452732	828	829	O
limited	30452732	830	837	O
motivational	30452732	838	850	O
screening	30452732	851	860	O
,	30452732	860	861	O
and	30452732	862	865	O
no	30452732	866	868	O
behavioral	30452732	869	879	O
support	30452732	880	887	O
.	30452732	887	888	O

The	30452732	889	892	O
primary	30452732	893	900	O
efficacy	30452732	901	909	O
endpoint	30452732	910	918	O
was	30452732	919	922	O
carbon	30452732	923	929	B-Outcome
monoxide-verified	30452732	930	947	I-Outcome
,	30452732	947	948	O
self-reported	30452732	949	962	B-Outcome
continuous	30452732	963	973	I-Outcome
abstinence	30452732	974	984	I-Outcome
from	30452732	985	989	I-Outcome
smoking	30452732	990	997	I-Outcome
from	30452732	998	1002	I-Outcome
week	30452732	1003	1007	I-Outcome
2	30452732	1008	1009	I-Outcome
until	30452732	1010	1015	I-Outcome
week	30452732	1016	1020	I-Outcome
6	30452732	1021	1022	I-Outcome
.	30452732	1022	1023	O

The	30452732	1024	1027	O
safety	30452732	1028	1034	B-Outcome
of	30452732	1035	1037	O
NMS	30452732	1038	1041	B-Intervention
was	30452732	1042	1045	O
assessed	30452732	1046	1054	O
by	30452732	1055	1057	O
measuring	30452732	1058	1067	O
vital	30452732	1068	1073	B-Outcome
signs	30452732	1074	1079	I-Outcome
,	30452732	1079	1080	O
visual	30452732	1081	1087	B-Outcome
mouth	30452732	1088	1093	I-Outcome
inspection	30452732	1094	1104	I-Outcome
,	30452732	1104	1105	O
and	30452732	1106	1109	O
collection	30452732	1110	1120	B-Outcome
of	30452732	1121	1123	I-Outcome
subject-reported	30452732	1124	1140	I-Outcome
adverse	30452732	1141	1148	I-Outcome
events	30452732	1149	1155	I-Outcome
(AEs).RESULTS	30452732	1156	1169	I-Outcome
:	30452732	1169	1170	O
The	30452732	1171	1174	O
percentage	30452732	1175	1185	B-Outcome
of	30452732	1186	1188	I-Outcome
subjects	30452732	1189	1197	I-Outcome
with	30452732	1198	1202	I-Outcome
carbon	30452732	1203	1209	I-Outcome
monoxide-verified	30452732	1210	1227	I-Outcome
continuous	30452732	1228	1238	I-Outcome
abstinence	30452732	1239	1249	I-Outcome
from	30452732	1250	1254	I-Outcome
week	30452732	1255	1259	I-Outcome
2	30452732	1260	1261	I-Outcome
to	30452732	1262	1264	I-Outcome
week	30452732	1265	1269	I-Outcome
6	30452732	1270	1271	I-Outcome
was	30452732	1272	1275	O
statistically	30452732	1276	1289	B-Observation
significantly	30452732	1290	1303	I-Observation
greater	30452732	1304	1311	I-Observation
in	30452732	1312	1314	O
the	30452732	1315	1318	O
NMS	30452732	1319	1322	B-Intervention
group	30452732	1323	1328	O
compared	30452732	1329	1337	O
with	30452732	1338	1342	O
the	30452732	1343	1346	O
placebo	30452732	1347	1354	B-Intervention
group	30452732	1355	1360	O
(	30452732	1361	1362	O
5.0	30452732	1362	1365	B-Observation
%	30452732	1365	1366	I-Observation
vs.	30452732	1367	1370	O
2.5	30452732	1371	1374	B-Observation
%	30452732	1374	1375	I-Observation
,	30452732	1375	1376	O
p	30452732	1377	1378	O
=	30452732	1379	1380	O
.021	30452732	1381	1385	O
)	30452732	1385	1386	O
.	30452732	1386	1387	O

Statistically	30452732	1388	1401	B-Outcome
significant	30452732	1402	1413	I-Outcome
treatment	30452732	1414	1423	I-Outcome
effects	30452732	1424	1431	I-Outcome
for	30452732	1432	1435	O
the	30452732	1436	1439	O
NMS	30452732	1440	1443	B-Intervention
were	30452732	1444	1448	O
maintained	30452732	1449	1459	B-Observation
throughout	30452732	1460	1470	O
the	30452732	1471	1474	O
26-week	30452732	1475	1482	O
period	30452732	1483	1489	O
.	30452732	1489	1490	O

The	30452732	1491	1494	O
study	30452732	1495	1500	B-Intervention
medications	30452732	1501	1512	I-Intervention
were	30452732	1513	1517	O
generally	30452732	1518	1527	B-Observation
well	30452732	1528	1532	I-Observation
tolerated	30452732	1533	1542	B-Outcome
.	30452732	1542	1543	O

The	30452732	1544	1547	O
severity	30452732	1548	1556	B-Outcome
of	30452732	1557	1559	I-Outcome
AEs	30452732	1560	1563	I-Outcome
was	30452732	1564	1567	O
similar	30452732	1568	1575	B-Observation
for	30452732	1576	1579	O
both	30452732	1580	1584	B-Intervention
treatment	30452732	1585	1594	I-Intervention
groups	30452732	1595	1601	I-Intervention
,	30452732	1601	1602	O
and	30452732	1603	1606	O
most	30452732	1607	1611	B-Outcome
AEs	30452732	1612	1615	I-Outcome
were	30452732	1616	1620	O
of	30452732	1621	1623	O
mild	30452732	1624	1628	B-Observation
or	30452732	1629	1631	I-Observation
moderate	30452732	1632	1640	I-Observation
severity	30452732	1641	1649	I-Observation
.	30452732	1649	1650	O

CONCLUSIONS	30452732	1650	1661	O
:	30452732	1661	1662	O
These	30452732	1663	1668	O
study	30452732	1669	1674	O
results	30452732	1675	1682	O
demonstrate	30452732	1683	1694	O
that	30452732	1695	1699	O
the	30452732	1700	1703	O
NMS	30452732	1704	1707	B-Intervention
is	30452732	1708	1710	O
an	30452732	1711	1713	O
effective	30452732	1714	1723	B-Observation
and	30452732	1724	1727	O
safe	30452732	1728	1732	B-Observation
smoking	30452732	1733	1740	B-Outcome
cessation	30452732	1741	1750	I-Outcome
option	30452732	1751	1757	O
for	30452732	1758	1761	O
smokers	30452732	1762	1769	B-Participant
motivated	30452732	1770	1779	I-Participant
to	30452732	1780	1782	I-Participant
quit	30452732	1783	1787	I-Participant
,	30452732	1787	1788	O
even	30452732	1789	1793	O
in	30452732	1794	1796	O
a	30452732	1797	1798	O
naturalistic	30452732	1799	1811	B-Participant
setting	30452732	1812	1819	I-Participant
and	30452732	1820	1823	O
without	30452732	1824	1831	B-Participant
behavioral	30452732	1832	1842	I-Participant
support	30452732	1843	1850	I-Participant
.	30452732	1850	1851	O

IMPLICATIONS	30452732	1851	1863	O
:	30452732	1863	1864	O
This	30452732	1865	1869	O
study	30452732	1870	1875	O
demonstrated	30452732	1876	1888	O
the	30452732	1889	1892	O
safety	30452732	1893	1899	B-Outcome
,	30452732	1899	1900	O
efficacy	30452732	1901	1909	B-Outcome
,	30452732	1909	1910	O
and	30452732	1911	1914	O
acceptability	30452732	1915	1928	B-Outcome
of	30452732	1929	1931	O
an	30452732	1932	1934	O
NMS	30452732	1935	1938	B-Intervention
in	30452732	1939	1941	O
an	30452732	1942	1944	O
OTC	30452732	1945	1948	B-Participant
environment	30452732	1949	1960	I-Participant
with	30452732	1961	1965	I-Participant
no	30452732	1966	1968	I-Participant
behavioral	30452732	1969	1979	I-Participant
counseling	30452732	1980	1990	I-Participant
or	30452732	1991	1993	I-Participant
support	30452732	1994	2001	I-Participant
.	30452732	2001	2002	O

It	30452732	2003	2005	O
provides	30452732	2006	2014	O
an	30452732	2015	2017	O
additional	30452732	2018	2028	O
option	30452732	2029	2035	O
for	30452732	2036	2039	O
smokers	30452732	2040	2047	O
motivated	30452732	2048	2057	O
to	30452732	2058	2060	O
quit	30452732	2061	2065	O
.	30452732	2065	2066	O

TRIAL	30452732	2066	2071	O
REGISTRATION	30452732	2072	2084	O
:	30452732	2084	2085	O
ClinicalTrials.gov	30452732	2086	2104	O
(	30452732	2105	2106	O
number	30452732	2106	2112	O
NCT02355665	30452732	2113	2124	O
)	30452732	2124	2125	O
.	30452732	2125	2126	O

TITLE	30458655	0	5	O
:	30458655	5	6	O
Citrulline	30458655	7	17	B-Intervention
Malate	30458655	18	24	I-Intervention
Fails	30458655	25	30	O
to	30458655	31	33	O
Improve	30458655	34	41	B-Observation
German	30458655	42	48	B-Outcome
Volume	30458655	49	55	I-Outcome
Training	30458655	56	64	I-Outcome
Performance	30458655	65	76	I-Outcome
in	30458655	77	79	O
Healthy	30458655	80	87	B-Participant
Young	30458655	88	93	I-Participant
Men	30458655	94	97	I-Participant
and	30458655	98	101	I-Participant
Women	30458655	102	107	I-Participant
.	30458655	107	108	O

Citrulline	30458655	109	119	B-Intervention
malate	30458655	120	126	I-Intervention
(	30458655	127	128	I-Intervention
CM	30458655	128	130	I-Intervention
)	30458655	130	131	I-Intervention
is	30458655	132	134	O
purported	30458655	135	144	O
to	30458655	145	147	O
buffer	30458655	148	154	B-Observation
lactic	30458655	155	161	B-Outcome
acid	30458655	162	166	I-Outcome
,	30458655	166	167	O
enhance	30458655	168	175	B-Observation
oxygen	30458655	176	182	B-Outcome
delivery	30458655	183	191	I-Outcome
,	30458655	191	192	O
and	30458655	193	196	O
attenuate	30458655	197	206	B-Observation
muscle	30458655	207	213	B-Outcome
soreness	30458655	214	222	I-Outcome
.	30458655	222	223	O

Anaerobic	30458655	224	233	O
exercise	30458655	234	242	O
trials	30458655	243	249	O
with	30458655	250	254	O
CM	30458655	255	257	O
have	30458655	258	262	O
produced	30458655	263	271	O
conflicting	30458655	272	283	O
results	30458655	284	291	O
.	30458655	291	292	O

The	30458655	293	296	O
aim	30458655	297	300	O
of	30458655	301	303	O
the	30458655	304	307	O
current	30458655	308	315	O
investigation	30458655	316	329	O
was	30458655	330	333	O
to	30458655	334	336	O
test	30458655	337	341	O
the	30458655	342	345	O
efficacy	30458655	346	354	B-Outcome
of	30458655	355	357	O
CM	30458655	358	360	B-Intervention
on	30458655	361	363	O
resistance	30458655	364	374	B-Participant
training	30458655	375	383	I-Participant
(	30458655	384	385	I-Participant
RT	30458655	385	387	I-Participant
)	30458655	387	388	I-Participant
with	30458655	389	393	O
the	30458655	394	397	O
hypothesis	30458655	398	408	O
that	30458655	409	413	O
CM	30458655	414	416	B-Intervention
would	30458655	417	422	O
improve	30458655	423	430	B-Observation
performance	30458655	431	442	B-Outcome
.	30458655	442	443	O

A	30458655	444	445	O
double-blind	30458655	446	458	O
,	30458655	458	459	O
counter-balanced	30458655	460	476	O
,	30458655	476	477	O
randomized	30458655	478	488	O
control	30458655	489	496	O
trial	30458655	497	502	O
was	30458655	503	506	O
utilized	30458655	507	515	O
to	30458655	516	518	O
assess	30458655	519	525	O
the	30458655	526	529	O
effects	30458655	530	537	O
of	30458655	538	540	O
CM	30458655	541	543	B-Intervention
on	30458655	544	546	O
RT	30458655	547	549	B-Outcome
.	30458655	549	550	O

Nineteen	30458655	551	559	O
participants	30458655	560	572	O
(	30458655	573	574	O
8	30458655	574	575	O
female	30458655	576	582	O
)	30458655	582	583	O
(	30458655	584	585	O
25.7	30458655	585	589	O
	30458655	590	591	O
7.7	30458655	592	595	O
years	30458655	596	601	O
)	30458655	601	602	O
,	30458655	602	603	O
regularly	30458655	604	613	B-Participant
engaged	30458655	614	621	I-Participant
in	30458655	622	624	I-Participant
RT	30458655	625	627	I-Participant
,	30458655	627	628	O
consumed	30458655	629	637	O
either	30458655	638	644	O
8	30458655	645	646	O
g	30458655	647	648	O
of	30458655	649	651	O
CM	30458655	652	654	B-Intervention
(	30458655	655	656	O
1.1:1	30458655	656	661	O
ratio	30458655	662	667	O
)	30458655	667	668	O
or	30458655	669	671	O
a	30458655	672	673	O
placebo	30458655	674	681	B-Intervention
(	30458655	682	683	O
6	30458655	683	684	O
g	30458655	685	686	O
citric	30458655	687	693	O
acid	30458655	694	698	O
)	30458655	698	699	O
.	30458655	699	700	O

Participants	30458655	701	713	O
attempted	30458655	714	723	O
to	30458655	724	726	O
perform	30458655	727	734	O
a	30458655	735	736	O
German	30458655	737	743	B-Participant
Volume	30458655	744	750	I-Participant
Training	30458655	751	759	I-Participant
(	30458655	760	761	I-Participant
GVT	30458655	761	764	I-Participant
)	30458655	764	765	I-Participant
protocol	30458655	766	774	I-Participant
comprising	30458655	775	785	O
10	30458655	786	788	O
sets	30458655	789	793	O
of	30458655	794	796	O
10	30458655	797	799	O
repetitions	30458655	800	811	O
of	30458655	812	814	O
barbell	30458655	815	822	O
curls	30458655	823	828	O
at	30458655	829	831	O
80	30458655	832	834	O
%	30458655	834	835	O
of	30458655	836	838	O
their	30458655	839	844	O
one	30458655	845	848	O
repetition	30458655	849	859	O
maximum	30458655	860	867	O
.	30458655	867	868	O

Repeated	30458655	869	877	O
ANOVA	30458655	878	883	O
suggested	30458655	884	893	O
no	30458655	894	896	O
effect	30458655	897	903	O
of	30458655	904	906	O
CM	30458655	907	909	O
on	30458655	910	912	O
RT	30458655	913	915	O
performance	30458655	916	927	O
(	30458655	928	929	O
treatment	30458655	929	938	O
	30458655	939	940	O
time	30458655	941	945	O
	30458655	946	947	O
order	30458655	948	953	O
p	30458655	954	955	O
=	30458655	956	957	O
.217	30458655	958	962	O
)	30458655	962	963	O
.	30458655	963	964	O

There	30458655	965	970	O
was	30458655	971	974	O
no	30458655	975	977	O
difference	30458655	978	988	B-Observation
(	30458655	989	990	O
p	30458655	990	991	O
=	30458655	992	993	O
.320	30458655	994	998	O
)	30458655	998	999	O
in	30458655	1000	1002	O
the	30458655	1003	1006	O
total	30458655	1007	1012	B-Outcome
number	30458655	1013	1019	I-Outcome
of	30458655	1020	1022	I-Outcome
reps	30458655	1023	1027	I-Outcome
over	30458655	1028	1032	I-Outcome
the	30458655	1033	1036	I-Outcome
10	30458655	1037	1039	I-Outcome
sets	30458655	1040	1044	I-Outcome
(	30458655	1045	1046	O
CM	30458655	1046	1048	B-Intervention
median	30458655	1049	1055	B-Observation
=	30458655	1056	1057	I-Observation
57	30458655	1058	1060	I-Observation
,	30458655	1060	1061	I-Observation
IQR	30458655	1062	1065	I-Observation
45	30458655	1066	1068	I-Observation
-	30458655	1068	1069	I-Observation
73	30458655	1069	1071	I-Observation
;	30458655	1071	1072	O
placebo	30458655	1073	1080	B-Intervention
median	30458655	1081	1087	B-Observation
=	30458655	1088	1089	I-Observation
61	30458655	1090	1092	I-Observation
,	30458655	1092	1093	I-Observation
IQR	30458655	1094	1097	I-Observation
51	30458655	1098	1100	I-Observation
-	30458655	1100	1101	I-Observation
69	30458655	1101	1103	I-Observation
)	30458655	1103	1104	O
.	30458655	1104	1105	O

Blood	30458655	1106	1111	B-Outcome
lactate	30458655	1112	1119	I-Outcome
and	30458655	1120	1123	O
creatine	30458655	1124	1132	B-Outcome
kinase	30458655	1133	1139	I-Outcome
did	30458655	1140	1143	O
not	30458655	1144	1147	O
differ	30458655	1148	1154	B-Observation
between	30458655	1155	1162	O
CM	30458655	1163	1165	B-Intervention
and	30458655	1166	1169	O
placebo	30458655	1170	1177	B-Intervention
(	30458655	1178	1179	O
p	30458655	1179	1180	O
>	30458655	1181	1182	O
.05	30458655	1183	1186	O
)	30458655	1186	1187	O
.	30458655	1187	1188	O

Finally	30458655	1189	1196	O
,	30458655	1196	1197	O
total	30458655	1198	1203	B-Outcome
muscle	30458655	1204	1210	I-Outcome
soreness	30458655	1211	1219	I-Outcome
was	30458655	1220	1223	O
reduced	30458655	1224	1231	B-Observation
significantly	30458655	1232	1245	I-Observation
in	30458655	1246	1248	O
CM	30458655	1249	1251	B-Intervention
compared	30458655	1252	1260	O
to	30458655	1261	1263	O
placebo	30458655	1264	1271	B-Intervention
(	30458655	1272	1273	O
treatment	30458655	1273	1282	O
	30458655	1283	1284	O
time	30458655	1285	1289	O
	30458655	1290	1291	O
order	30458655	1292	1297	O
p	30458655	1298	1299	O
=	30458655	1300	1301	O
.004	30458655	1302	1306	O
)	30458655	1306	1307	O
.	30458655	1307	1308	O

These	30458655	1309	1314	O
results	30458655	1315	1322	O
require	30458655	1323	1330	O
corroboration	30458655	1331	1344	O
;	30458655	1344	1345	O
an	30458655	1346	1348	O
ergogenic	30458655	1349	1358	O
benefit	30458655	1359	1366	O
is	30458655	1367	1369	O
yet	30458655	1370	1373	O
to	30458655	1374	1376	O
be	30458655	1377	1379	O
established	30458655	1380	1391	O
,	30458655	1391	1392	O
and	30458655	1393	1396	O
weight	30458655	1397	1403	O
trainers	30458655	1404	1412	O
should	30458655	1413	1419	O
exercise	30458655	1420	1428	O
caution	30458655	1429	1436	O
when	30458655	1437	1441	O
assessing	30458655	1442	1451	O
the	30458655	1452	1455	O
efficacy	30458655	1456	1464	O
of	30458655	1465	1467	O
CM	30458655	1468	1470	O
.	30458655	1470	1471	O

Future	30458655	1472	1478	O
research	30458655	1479	1487	O
should	30458655	1488	1494	O
focus	30458655	1495	1500	O
on	30458655	1501	1503	O
the	30458655	1504	1507	O
potential	30458655	1508	1517	O
effects	30458655	1518	1525	O
of	30458655	1526	1528	O
loading	30458655	1529	1536	O
doses	30458655	1537	1542	O
of	30458655	1543	1545	O
CM	30458655	1546	1548	O
.	30458655	1548	1549	O

TITLE	30461315	0	5	O
:	30461315	5	6	O
Effects	30461315	7	14	O
of	30461315	15	17	O
Cognitive	30461315	18	27	B-Intervention
Behavioral	30461315	28	38	I-Intervention
Therapy	30461315	39	46	I-Intervention
for	30461315	47	50	O
Insomnia	30461315	51	59	B-Participant
on	30461315	60	62	O
Sleep	30461315	63	68	B-Outcome
,	30461315	68	69	O
Symptoms	30461315	70	78	B-Outcome
,	30461315	78	79	O
Stress	30461315	80	86	B-Outcome
,	30461315	86	87	O
and	30461315	88	91	O
Autonomic	30461315	92	101	B-Outcome
Function	30461315	102	110	I-Outcome
Among	30461315	111	116	O
Patients	30461315	117	125	O
With	30461315	126	130	O
Heart	30461315	131	136	B-Participant
Failure	30461315	137	144	I-Participant
.	30461315	144	145	O

Background	30461315	146	156	O
:	30461315	156	157	O
Insomnia	30461315	158	166	O
is	30461315	167	169	O
common	30461315	170	176	O
among	30461315	177	182	O
patients	30461315	183	191	O
with	30461315	192	196	O
stable	30461315	197	203	O
heart	30461315	204	209	O
failure	30461315	210	217	O
(	30461315	218	219	O
HF	30461315	219	221	O
)	30461315	221	222	O
and	30461315	223	226	O
associated	30461315	227	237	O
with	30461315	238	242	O
inflammation	30461315	243	255	O
and	30461315	256	259	O
altered	30461315	260	267	O
autonomic	30461315	268	277	O
function	30461315	278	286	O
.	30461315	286	287	O

Purpose	30461315	288	295	O
:	30461315	295	296	O
The	30461315	297	300	O
purposes	30461315	301	309	O
of	30461315	310	312	O
this	30461315	313	317	O
study	30461315	318	323	O
were	30461315	324	328	O
to	30461315	329	331	O
examine	30461315	332	339	O
the	30461315	340	343	O
effects	30461315	344	351	O
of	30461315	352	354	O
cognitive	30461315	355	364	B-Intervention
behavioral	30461315	365	375	I-Intervention
therapy	30461315	376	383	I-Intervention
for	30461315	384	387	O
insomnia	30461315	388	396	B-Participant
(	30461315	397	398	I-Participant
CBT-I	30461315	398	403	I-Participant
)	30461315	403	404	I-Participant
on	30461315	405	407	O
the	30461315	408	411	O
Hypothalamic	30461315	412	424	B-Outcome
Pituitary	30461315	425	434	I-Outcome
(	30461315	435	436	I-Outcome
HPA	30461315	436	439	I-Outcome
)	30461315	439	440	I-Outcome
Axis	30461315	441	445	I-Outcome
,	30461315	445	446	O
autonomic	30461315	447	456	B-Outcome
function	30461315	457	465	I-Outcome
,	30461315	465	466	O
inflammation	30461315	467	479	B-Outcome
,	30461315	479	480	O
and	30461315	481	484	O
circadian	30461315	485	494	B-Outcome
rhythmicity	30461315	495	506	I-Outcome
and	30461315	507	510	O
the	30461315	511	514	O
associations	30461315	515	527	B-Outcome
between	30461315	528	535	I-Outcome
these	30461315	536	541	I-Outcome
biomarkers	30461315	542	552	I-Outcome
and	30461315	553	556	I-Outcome
insomnia	30461315	557	565	I-Outcome
,	30461315	565	566	O
sleep	30461315	567	572	B-Outcome
characteristics	30461315	573	588	I-Outcome
,	30461315	588	589	O
symptoms	30461315	590	598	B-Outcome
,	30461315	598	599	O
functional	30461315	600	610	B-Outcome
performance	30461315	611	622	I-Outcome
,	30461315	622	623	O
and	30461315	624	627	O
sleep-related	30461315	628	641	B-Outcome
cognitions	30461315	642	652	I-Outcome
.	30461315	652	653	O

Methods	30461315	654	661	O
:	30461315	661	662	O
We	30461315	663	665	O
conducted	30461315	666	675	O
a	30461315	676	677	O
subanalysis	30461315	678	689	O
of	30461315	690	692	O
a	30461315	693	694	O
pilot	30461315	695	700	O
randomized	30461315	701	711	O
controlled	30461315	712	722	O
trial	30461315	723	728	O
(	30461315	729	730	O
RCT	30461315	730	733	O
,	30461315	733	734	O
NCT02827799	30461315	735	746	O
)	30461315	746	747	O
whose	30461315	748	753	O
primary	30461315	754	761	O
aim	30461315	762	765	O
was	30461315	766	769	O
to	30461315	770	772	O
test	30461315	773	777	O
the	30461315	778	781	O
effects	30461315	782	789	O
of	30461315	790	792	O
CBT-I	30461315	793	798	B-Intervention
on	30461315	799	801	O
insomnia	30461315	802	810	B-Participant
.	30461315	810	811	O

We	30461315	812	814	O
randomized	30461315	815	825	O
51	30461315	826	828	O
patients	30461315	829	837	O
with	30461315	838	842	O
stable	30461315	843	849	B-Participant
Class	30461315	850	855	I-Participant
II-IV	30461315	856	861	I-Participant
HF	30461315	862	864	I-Participant
to	30461315	865	867	O
CBT-I	30461315	868	873	B-Intervention
(	30461315	874	875	O
n	30461315	875	876	O
=	30461315	877	878	O
30	30461315	879	881	O
)	30461315	881	882	O
or	30461315	883	885	O
attention	30461315	886	895	B-Intervention
control	30461315	896	903	I-Intervention
(	30461315	904	905	O
n	30461315	905	906	O
=	30461315	907	908	O
21	30461315	909	911	O
)	30461315	911	912	O
.	30461315	912	913	O

Participants	30461315	914	926	O
completed	30461315	927	936	O
wrist	30461315	937	942	O
actigraphy	30461315	943	953	O
and	30461315	954	957	O
self-reported	30461315	958	971	B-Outcome
insomnia	30461315	972	980	I-Outcome
severity	30461315	981	989	I-Outcome
,	30461315	989	990	I-Outcome
sleep	30461315	991	996	B-Outcome
characteristics	30461315	997	1012	I-Outcome
,	30461315	1012	1013	O
sleep-related	30461315	1014	1027	B-Outcome
cognitions	30461315	1028	1038	I-Outcome
,	30461315	1038	1039	O
daytime	30461315	1040	1047	B-Outcome
symptoms	30461315	1048	1056	I-Outcome
,	30461315	1056	1057	O
and	30461315	1058	1061	O
functional	30461315	1062	1072	B-Outcome
performance	30461315	1073	1084	I-Outcome
.	30461315	1084	1085	O

We	30461315	1086	1088	O
measured	30461315	1089	1097	O
day	30461315	1098	1101	O
and	30461315	1102	1105	O
nighttime	30461315	1106	1115	O
urinary	30461315	1116	1123	B-Outcome
free	30461315	1124	1128	I-Outcome
cortisol	30461315	1129	1137	I-Outcome
,	30461315	1137	1138	O
melatonin	30461315	1139	1148	B-Outcome
sulfate	30461315	1149	1156	I-Outcome
,	30461315	1156	1157	O
epinephrine	30461315	1158	1169	B-Outcome
,	30461315	1169	1170	O
and	30461315	1171	1174	O
norepinephrine	30461315	1175	1189	B-Outcome
at	30461315	1190	1192	O
baseline	30461315	1193	1201	O
,	30461315	1201	1202	O
and	30461315	1203	1206	O
two	30461315	1207	1210	O
weeks	30461315	1211	1216	O
after	30461315	1217	1222	O
CBT-I	30461315	1223	1228	B-Intervention
and	30461315	1229	1232	O
computed	30461315	1233	1241	O
general	30461315	1242	1249	O
linear	30461315	1250	1256	O
models	30461315	1257	1263	O
and	30461315	1264	1267	O
partial	30461315	1268	1275	O
correlations	30461315	1276	1288	O
.	30461315	1288	1289	O

Results	30461315	1290	1297	O
:	30461315	1297	1298	O
CBT-I	30461315	1299	1304	B-Intervention
had	30461315	1305	1308	O
no	30461315	1309	1311	O
effects	30461315	1312	1319	B-Observation
on	30461315	1320	1322	O
the	30461315	1323	1326	O
biomarkers	30461315	1327	1337	B-Outcome
,	30461315	1337	1338	O
but	30461315	1339	1342	O
there	30461315	1343	1348	O
were	30461315	1349	1353	O
statistically	30461315	1354	1367	B-Observation
significant	30461315	1368	1379	I-Observation
negative	30461315	1380	1388	I-Observation
cross-sectional	30461315	1389	1404	I-Observation
correlations	30461315	1405	1417	I-Observation
between	30461315	1418	1425	B-Outcome
the	30461315	1426	1429	I-Outcome
ratio	30461315	1430	1435	I-Outcome
of	30461315	1436	1438	I-Outcome
day	30461315	1439	1442	I-Outcome
and	30461315	1443	1446	I-Outcome
night	30461315	1447	1452	I-Outcome
urinary	30461315	1453	1460	I-Outcome
free	30461315	1461	1465	I-Outcome
cortisol	30461315	1466	1474	I-Outcome
and	30461315	1475	1478	I-Outcome
sleep	30461315	1479	1484	I-Outcome
disturbance	30461315	1485	1496	I-Outcome
,	30461315	1496	1497	I-Outcome
anxiety	30461315	1498	1505	I-Outcome
,	30461315	1505	1506	I-Outcome
fatigue	30461315	1507	1514	I-Outcome
,	30461315	1514	1515	I-Outcome
depression	30461315	1516	1526	I-Outcome
,	30461315	1526	1527	I-Outcome
and	30461315	1528	1531	I-Outcome
negative	30461315	1532	1540	I-Outcome
sleep	30461315	1541	1546	I-Outcome
cognitions	30461315	1547	1557	I-Outcome
.	30461315	1557	1558	O

Increases	30461315	1559	1568	B-Observation
in	30461315	1569	1571	O
the	30461315	1572	1575	O
ratio	30461315	1576	1581	B-Outcome
between	30461315	1582	1589	I-Outcome
day	30461315	1590	1593	I-Outcome
and	30461315	1594	1597	I-Outcome
night	30461315	1598	1603	I-Outcome
cortisol	30461315	1604	1612	I-Outcome
were	30461315	1613	1617	O
associated	30461315	1618	1628	O
with	30461315	1629	1633	O
statistically	30461315	1634	1647	B-Observation
significant	30461315	1648	1659	I-Observation
improvements	30461315	1660	1672	I-Observation
in	30461315	1673	1675	O
fatigue	30461315	1676	1683	B-Outcome
,	30461315	1683	1684	O
depression	30461315	1685	1695	B-Outcome
,	30461315	1695	1696	O
sleep	30461315	1697	1702	B-Outcome
duration	30461315	1703	1711	I-Outcome
,	30461315	1711	1712	O
and	30461315	1713	1716	O
sleep-related	30461315	1717	1730	B-Outcome
cognitions	30461315	1731	1741	I-Outcome
.	30461315	1741	1742	O

Conclusions	30461315	1743	1754	O
:	30461315	1754	1755	O
Biomarkers	30461315	1756	1766	B-Outcome
of	30461315	1767	1769	I-Outcome
stress	30461315	1770	1776	I-Outcome
and	30461315	1777	1780	I-Outcome
autonomic	30461315	1781	1790	I-Outcome
function	30461315	1791	1799	I-Outcome
are	30461315	1800	1803	O
associated	30461315	1804	1814	O
with	30461315	1815	1819	O
sleep	30461315	1820	1825	B-Outcome
,	30461315	1825	1826	O
sleep-related	30461315	1827	1840	B-Outcome
symptoms	30461315	1841	1849	I-Outcome
,	30461315	1849	1850	O
and	30461315	1851	1854	O
cognitions	30461315	1855	1865	B-Outcome
among	30461315	1866	1871	O
people	30461315	1872	1878	O
with	30461315	1879	1883	O
chronic	30461315	1884	1891	B-Participant
HF	30461315	1892	1894	I-Participant
.	30461315	1894	1895	O

Future	30461315	1896	1902	O
studies	30461315	1903	1910	O
are	30461315	1911	1914	O
needed	30461315	1915	1921	O
to	30461315	1922	1924	O
identify	30461315	1925	1933	O
potential	30461315	1934	1943	O
causal	30461315	1944	1950	O
relationships	30461315	1951	1964	O
and	30461315	1965	1968	O
the	30461315	1969	1972	O
impact	30461315	1973	1979	O
of	30461315	1980	1982	O
sleep	30461315	1983	1988	O
interventions	30461315	1989	2002	O
.	30461315	2002	2003	O

TITLE	30496547	0	5	O
:	30496547	5	6	O
Psychophysiological	30496547	7	26	B-Outcome
Effects	30496547	27	34	I-Outcome
of	30496547	35	37	O
Dance	30496547	38	43	B-Intervention
Movement	30496547	44	52	I-Intervention
Therapy	30496547	53	60	I-Intervention
and	30496547	61	64	O
Physical	30496547	65	73	B-Intervention
Exercise	30496547	74	82	I-Intervention
on	30496547	83	85	O
Older	30496547	86	91	B-Participant
Adults	30496547	92	98	I-Participant
With	30496547	99	103	O
Mild	30496547	104	108	B-Participant
Dementia	30496547	109	117	I-Participant
:	30496547	117	118	O
A	30496547	119	120	O
Randomized	30496547	121	131	O
Controlled	30496547	132	142	O
Trial	30496547	143	148	O
.	30496547	148	149	O

OBJECTIVES	30496547	150	160	O
:	30496547	160	161	O
Dementia	30496547	162	170	O
interferes	30496547	171	181	O
with	30496547	182	186	O
older	30496547	187	192	O
adults	30496547	193	199	O
'	30496547	199	200	O
functioning	30496547	201	212	O
in	30496547	213	215	O
cognitive	30496547	216	225	O
,	30496547	225	226	O
daily	30496547	227	232	O
,	30496547	232	233	O
psychosocial	30496547	234	246	O
,	30496547	246	247	O
and	30496547	248	251	O
neuroendocrine	30496547	252	266	O
domains	30496547	267	274	O
.	30496547	274	275	O

The	30496547	276	279	O
present	30496547	280	287	O
study	30496547	288	293	O
examined	30496547	294	302	O
the	30496547	303	306	O
psychophysiological	30496547	307	326	B-Outcome
effects	30496547	327	334	I-Outcome
of	30496547	335	337	O
dance	30496547	338	343	B-Intervention
movement	30496547	344	352	I-Intervention
therapy	30496547	353	360	I-Intervention
(	30496547	361	362	I-Intervention
DMT	30496547	362	365	I-Intervention
)	30496547	365	366	I-Intervention
and	30496547	367	370	O
physical	30496547	371	379	B-Intervention
exercise	30496547	380	388	I-Intervention
for	30496547	389	392	O
older	30496547	393	398	B-Participant
adults	30496547	399	405	I-Participant
with	30496547	406	410	O
dementia	30496547	411	419	B-Participant
.	30496547	419	420	O

METHODS	30496547	420	427	O
:	30496547	427	428	O
This	30496547	429	433	O
randomized	30496547	434	444	O
controlled	30496547	445	455	O
trial	30496547	456	461	O
recruited	30496547	462	471	O
204	30496547	472	475	O
older	30496547	476	481	B-Participant
adults	30496547	482	488	I-Participant
diagnosed	30496547	489	498	O
with	30496547	499	503	O
mild	30496547	504	508	B-Participant
dementia	30496547	509	517	I-Participant
into	30496547	518	522	O
the	30496547	523	526	O
DMT	30496547	527	530	B-Intervention
,	30496547	530	531	O
exercise	30496547	532	540	B-Intervention
,	30496547	540	541	O
or	30496547	542	544	O
waitlist	30496547	545	553	B-Intervention
control	30496547	554	561	I-Intervention
group	30496547	562	567	O
.	30496547	567	568	O

Both	30496547	569	573	O
DMT	30496547	574	577	B-Intervention
and	30496547	578	581	O
exercise	30496547	582	590	B-Intervention
interventions	30496547	591	604	O
had	30496547	605	608	O
similar	30496547	609	616	O
intensity	30496547	617	626	O
and	30496547	627	630	O
comprised	30496547	631	640	O
24	30496547	641	643	O
hr	30496547	644	646	O
of	30496547	647	649	O
intervention	30496547	650	662	O
that	30496547	663	667	O
spanned	30496547	668	675	O
over	30496547	676	680	O
12	30496547	681	683	O
weeks	30496547	684	689	O
.	30496547	689	690	O

All	30496547	691	694	O
participants	30496547	695	707	O
completed	30496547	708	717	O
self-report	30496547	718	729	O
questionnaires	30496547	730	744	O
on	30496547	745	747	O
psychosocial	30496547	748	760	B-Outcome
well-being	30496547	761	771	I-Outcome
,	30496547	771	772	O
daily	30496547	773	778	B-Outcome
functioning	30496547	779	790	I-Outcome
,	30496547	790	791	I-Outcome
neurocognitive	30496547	792	806	B-Outcome
assessments	30496547	807	818	I-Outcome
,	30496547	818	819	O
and	30496547	820	823	O
salivary	30496547	824	832	B-Outcome
cortisol	30496547	833	841	I-Outcome
measures	30496547	842	850	I-Outcome
at	30496547	851	853	O
baseline	30496547	854	862	O
and	30496547	863	866	O
3	30496547	867	868	O
follow-up	30496547	869	878	O
measurements	30496547	879	891	O
more	30496547	892	896	O
than	30496547	897	901	O
1	30496547	902	903	O
year	30496547	904	908	O
.	30496547	908	909	O

RESULTS	30496547	909	916	O
:	30496547	916	917	O
The	30496547	918	921	O
DMT	30496547	922	925	B-Intervention
group	30496547	926	931	O
showed	30496547	932	938	O
significant	30496547	939	950	B-Observation
decreases	30496547	951	960	I-Observation
in	30496547	961	963	O
depression	30496547	964	974	B-Outcome
,	30496547	974	975	O
loneliness	30496547	976	986	B-Outcome
,	30496547	986	987	O
and	30496547	988	991	O
negative	30496547	992	1000	B-Outcome
mood	30496547	1001	1005	I-Outcome
(	30496547	1006	1007	O
d	30496547	1007	1008	O
=	30496547	1009	1010	O
0.33	30496547	1011	1015	O
-	30496547	1015	1016	O
0.42	30496547	1016	1020	O
,	30496547	1020	1021	O
p	30496547	1022	1023	O
<	30496547	1024	1025	O
.05	30496547	1026	1029	O
)	30496547	1029	1030	O
and	30496547	1031	1034	O
improved	30496547	1035	1043	B-Observation
daily	30496547	1044	1049	B-Outcome
functioning	30496547	1050	1061	I-Outcome
(	30496547	1062	1063	O
d	30496547	1063	1064	O
=	30496547	1065	1066	O
0.40	30496547	1067	1071	O
,	30496547	1071	1072	O
p	30496547	1073	1074	O
<	30496547	1075	1076	O
.01	30496547	1077	1080	O
)	30496547	1080	1081	O
and	30496547	1082	1085	O
diurnal	30496547	1086	1093	B-Outcome
cortisol	30496547	1094	1102	I-Outcome
slope	30496547	1103	1108	I-Outcome
(	30496547	1109	1110	O
d	30496547	1110	1111	O
=	30496547	1112	1113	O
0.30	30496547	1114	1118	O
,	30496547	1118	1119	O
p	30496547	1120	1121	O
<	30496547	1122	1123	O
.01	30496547	1124	1127	O
)	30496547	1127	1128	O
.	30496547	1128	1129	O

The	30496547	1130	1133	O
effects	30496547	1134	1141	O
on	30496547	1142	1144	O
daily	30496547	1145	1150	B-Outcome
functioning	30496547	1151	1162	I-Outcome
and	30496547	1163	1166	O
cortisol	30496547	1167	1175	B-Outcome
slope	30496547	1176	1181	I-Outcome
remained	30496547	1182	1190	B-Observation
at	30496547	1191	1193	O
1-year	30496547	1194	1200	O
follow-up	30496547	1201	1210	O
.	30496547	1210	1211	O

The	30496547	1212	1215	O
exercise	30496547	1216	1224	B-Intervention
group	30496547	1225	1230	O
of	30496547	1231	1233	O
matched	30496547	1234	1241	O
intensity	30496547	1242	1251	O
showed	30496547	1252	1258	O
no	30496547	1259	1261	O
significant	30496547	1262	1273	B-Observation
effects	30496547	1274	1281	I-Observation
on	30496547	1282	1284	O
the	30496547	1285	1288	O
outcomes	30496547	1289	1297	B-Outcome
.	30496547	1297	1298	O

DISCUSSION	30496547	1298	1308	O
:	30496547	1308	1309	O
The	30496547	1310	1313	O
study	30496547	1314	1319	O
findings	30496547	1320	1328	O
support	30496547	1329	1336	O
the	30496547	1337	1340	O
potential	30496547	1341	1350	O
utility	30496547	1351	1358	O
of	30496547	1359	1361	O
DMT	30496547	1362	1365	B-Intervention
as	30496547	1366	1368	O
a	30496547	1369	1370	O
multifaceted	30496547	1371	1383	O
intervention	30496547	1384	1396	O
for	30496547	1397	1400	O
improving	30496547	1401	1410	B-Observation
various	30496547	1411	1418	B-Outcome
aspects	30496547	1419	1426	I-Outcome
of	30496547	1427	1429	I-Outcome
functioning	30496547	1430	1441	I-Outcome
in	30496547	1442	1444	O
older	30496547	1445	1450	B-Participant
adults	30496547	1451	1457	I-Participant
with	30496547	1458	1462	O
declining	30496547	1463	1472	B-Participant
cognitive	30496547	1473	1482	I-Participant
abilities	30496547	1483	1492	I-Participant
.	30496547	1492	1493	O

The	30496547	1494	1497	O
lack	30496547	1498	1502	O
of	30496547	1503	1505	O
beneficial	30496547	1506	1516	B-Outcome
effects	30496547	1517	1524	I-Outcome
for	30496547	1525	1528	O
our	30496547	1529	1532	O
exercise	30496547	1533	1541	B-Intervention
intervention	30496547	1542	1554	O
and	30496547	1555	1558	O
long-term	30496547	1559	1568	B-Outcome
DMT	30496547	1569	1572	I-Outcome
effects	30496547	1573	1580	I-Outcome
highlights	30496547	1581	1591	O
the	30496547	1592	1595	O
need	30496547	1596	1600	O
to	30496547	1601	1603	O
maintain	30496547	1604	1612	O
persistent	30496547	1613	1623	O
levels	30496547	1624	1630	O
of	30496547	1631	1633	O
exercise	30496547	1634	1642	O
with	30496547	1643	1647	O
adequate	30496547	1648	1656	O
intensity	30496547	1657	1666	O
and	30496547	1667	1670	O
duration	30496547	1671	1679	O
.	30496547	1679	1680	O

A	32187464	0	1	O
Trial	32187464	2	7	O
of	32187464	8	10	O
Lopinavir-Ritonavir	32187464	11	30	B-Intervention
in	32187464	31	33	O
Adults	32187464	34	40	O
Hospitalized	32187464	41	53	O
with	32187464	54	58	O
Severe	32187464	59	65	B-Participant
Covid-19	32187464	66	74	I-Participant
.	32187464	75	76	O

No	32187464	77	79	O
therapeutics	32187464	80	92	O
have	32187464	93	97	O
yet	32187464	98	101	O
been	32187464	102	106	O
proven	32187464	107	113	O
effective	32187464	114	123	O
for	32187464	124	127	O
the	32187464	128	131	O
treatment	32187464	132	141	O
of	32187464	142	144	O
severe	32187464	145	151	O
illness	32187464	152	159	O
caused	32187464	160	166	O
by	32187464	167	169	O
SARS-CoV-2	32187464	170	180	O
.	32187464	181	182	O

We	32187464	183	185	O
conducted	32187464	186	195	O
a	32187464	196	197	O
randomized	32187464	198	208	O
,	32187464	209	210	O
controlled	32187464	211	221	O
,	32187464	222	223	O
open-label	32187464	224	234	O
trial	32187464	235	240	O
involving	32187464	241	250	O
hospitalized	32187464	251	263	B-Participant
adult	32187464	264	269	I-Participant
patients	32187464	270	278	I-Participant
with	32187464	279	283	O
confirmed	32187464	284	293	O
SARS-CoV-2	32187464	294	304	B-Participant
infection	32187464	305	314	I-Participant
,	32187464	315	316	O
which	32187464	317	322	O
causes	32187464	323	329	O
the	32187464	330	333	O
respiratory	32187464	334	345	B-Participant
illness	32187464	346	353	I-Participant
Covid-19	32187464	354	362	I-Participant
,	32187464	363	364	O
and	32187464	365	368	O
an	32187464	369	371	O
oxygen	32187464	372	378	B-Participant
saturation	32187464	379	389	I-Participant
(	32187464	390	391	I-Participant
Sao2	32187464	392	396	I-Participant
)	32187464	397	398	I-Participant
of	32187464	399	401	I-Participant
94	32187464	402	404	I-Participant
%	32187464	405	406	I-Participant
or	32187464	407	409	I-Participant
less	32187464	410	414	I-Participant
while	32187464	415	420	O
they	32187464	421	425	O
were	32187464	426	430	O
breathing	32187464	431	440	O
ambient	32187464	441	448	O
air	32187464	449	452	O
or	32187464	453	455	O
a	32187464	456	457	O
ratio	32187464	458	463	B-Participant
of	32187464	464	466	I-Participant
the	32187464	467	470	I-Participant
partial	32187464	471	478	I-Participant
pressure	32187464	479	487	I-Participant
of	32187464	488	490	I-Participant
oxygen	32187464	491	497	I-Participant
(	32187464	498	499	I-Participant
Pao2	32187464	500	504	I-Participant
)	32187464	505	506	I-Participant
to	32187464	507	509	I-Participant
the	32187464	510	513	I-Participant
fraction	32187464	514	522	I-Participant
of	32187464	523	525	I-Participant
inspired	32187464	526	534	I-Participant
oxygen	32187464	535	541	I-Participant
(	32187464	542	543	I-Participant
Fio2	32187464	544	548	I-Participant
)	32187464	549	550	I-Participant
of	32187464	551	553	I-Participant
less	32187464	554	558	I-Participant
than	32187464	559	563	I-Participant
300	32187464	564	567	I-Participant
mm	32187464	568	570	I-Participant
Hg	32187464	571	573	I-Participant
.	32187464	574	575	O

Patients	32187464	576	584	O
were	32187464	585	589	O
randomly	32187464	590	598	O
assigned	32187464	599	607	O
in	32187464	608	610	O
a	32187464	611	612	O
1:1	32187464	613	616	O
ratio	32187464	617	622	O
to	32187464	623	625	O
receive	32187464	626	633	O
either	32187464	634	640	O
lopinavir-ritonavir	32187464	641	660	B-Intervention
(	32187464	661	662	O
400	32187464	663	666	O
mg	32187464	667	669	O
and	32187464	670	673	O
100	32187464	674	677	O
mg	32187464	678	680	O
,	32187464	681	682	O
respectively	32187464	683	695	O
)	32187464	696	697	O
twice	32187464	698	703	O
a	32187464	704	705	O
day	32187464	706	709	O
for	32187464	710	713	O
14	32187464	714	716	O
days	32187464	717	721	O
,	32187464	722	723	O
in	32187464	724	726	B-Intervention
addition	32187464	727	735	I-Intervention
to	32187464	736	738	I-Intervention
standard	32187464	739	747	I-Intervention
care	32187464	748	752	I-Intervention
,	32187464	753	754	O
or	32187464	755	757	O
standard	32187464	758	766	B-Intervention
care	32187464	767	771	I-Intervention
alone	32187464	772	777	I-Intervention
.	32187464	778	779	O

The	32187464	780	783	O
primary	32187464	784	791	O
end	32187464	792	795	O
point	32187464	796	801	O
was	32187464	802	805	O
the	32187464	806	809	O
time	32187464	810	814	B-Outcome
to	32187464	815	817	I-Outcome
clinical	32187464	818	826	I-Outcome
improvement	32187464	827	838	I-Outcome
,	32187464	839	840	O
defined	32187464	841	848	O
as	32187464	849	851	O
the	32187464	852	855	O
time	32187464	856	860	B-Outcome
from	32187464	861	865	I-Outcome
randomization	32187464	866	879	I-Outcome
to	32187464	880	882	I-Outcome
either	32187464	883	889	I-Outcome
an	32187464	890	892	I-Outcome
improvement	32187464	893	904	I-Outcome
of	32187464	905	907	I-Outcome
two	32187464	908	911	I-Outcome
points	32187464	912	918	I-Outcome
on	32187464	919	921	I-Outcome
a	32187464	922	923	I-Outcome
seven-category	32187464	924	938	I-Outcome
ordinal	32187464	939	946	I-Outcome
scale	32187464	947	952	I-Outcome
or	32187464	953	955	I-Outcome
discharge	32187464	956	965	I-Outcome
from	32187464	966	970	I-Outcome
the	32187464	971	974	I-Outcome
hospital	32187464	975	983	I-Outcome
,	32187464	984	985	O
whichever	32187464	986	995	O
came	32187464	996	1000	O
first	32187464	1001	1006	O
.	32187464	1007	1008	O

A	32187464	1009	1010	O
total	32187464	1011	1016	O
of	32187464	1017	1019	O
199	32187464	1020	1023	O
patients	32187464	1024	1032	O
with	32187464	1033	1037	O
laboratory-confirmed	32187464	1038	1058	B-Participant
SARS-CoV-2	32187464	1059	1069	I-Participant
infection	32187464	1070	1079	I-Participant
underwent	32187464	1080	1089	O
randomization	32187464	1090	1103	O
;	32187464	1104	1105	O
99	32187464	1106	1108	O
were	32187464	1109	1113	O
assigned	32187464	1114	1122	O
to	32187464	1123	1125	O
the	32187464	1126	1129	O
lopinavir-ritonavir	32187464	1130	1149	B-Intervention
group	32187464	1150	1155	O
,	32187464	1156	1157	O
and	32187464	1158	1161	O
100	32187464	1162	1165	O
to	32187464	1166	1168	O
the	32187464	1169	1172	O
standard-care	32187464	1173	1186	B-Intervention
group	32187464	1187	1192	O
.	32187464	1193	1194	O

Treatment	32187464	1195	1204	O
with	32187464	1205	1209	O
lopinavir-ritonavir	32187464	1210	1229	B-Intervention
was	32187464	1230	1233	O
not	32187464	1234	1237	O
associated	32187464	1238	1248	O
with	32187464	1249	1253	O
a	32187464	1254	1255	O
difference	32187464	1256	1266	B-Observation
from	32187464	1267	1271	O
standard	32187464	1272	1280	B-Intervention
care	32187464	1281	1285	I-Intervention
in	32187464	1286	1288	O
the	32187464	1289	1292	O
time	32187464	1293	1297	B-Outcome
to	32187464	1298	1300	I-Outcome
clinical	32187464	1301	1309	I-Outcome
improvement	32187464	1310	1321	I-Outcome
(	32187464	1322	1323	O
hazard	32187464	1324	1330	O
ratio	32187464	1331	1336	O
for	32187464	1337	1340	O
clinical	32187464	1341	1349	O
improvement	32187464	1350	1361	O
,	32187464	1362	1363	O
1.31	32187464	1364	1368	O
;	32187464	1369	1370	O
95	32187464	1371	1373	O
%	32187464	1374	1375	O
confidence	32187464	1376	1386	O
interval	32187464	1387	1395	O
[	32187464	1396	1397	O
CI	32187464	1398	1400	O
]	32187464	1401	1402	O
,	32187464	1403	1404	O
0.95	32187464	1405	1409	O
to	32187464	1410	1412	O
1.80	32187464	1413	1417	O
)	32187464	1418	1419	O
.	32187464	1420	1421	O

Mortality	32187464	1422	1431	B-Outcome
at	32187464	1432	1434	I-Outcome
28	32187464	1435	1437	I-Outcome
days	32187464	1438	1442	I-Outcome
was	32187464	1443	1446	O
similar	32187464	1447	1454	B-Observation
in	32187464	1455	1457	O
the	32187464	1458	1461	O
lopinavir-ritonavir	32187464	1462	1481	B-Intervention
group	32187464	1482	1487	O
and	32187464	1488	1491	O
the	32187464	1492	1495	O
standard-care	32187464	1496	1509	B-Intervention
group	32187464	1510	1515	O
(	32187464	1516	1517	O
19.2	32187464	1518	1522	B-Observation
%	32187464	1523	1524	I-Observation
vs.	32187464	1525	1528	O
25.0	32187464	1529	1533	B-Observation
%	32187464	1534	1535	I-Observation
;	32187464	1536	1537	O
difference	32187464	1538	1548	O
,	32187464	1549	1550	O
-5.8	32187464	1551	1555	O
percentage	32187464	1556	1566	O
points	32187464	1567	1573	O
;	32187464	1574	1575	O
95	32187464	1576	1578	O
%	32187464	1579	1580	O
CI	32187464	1581	1583	O
,	32187464	1584	1585	O
-17.3	32187464	1586	1591	O
to	32187464	1592	1594	O
5.7	32187464	1595	1598	O
)	32187464	1599	1600	O
.	32187464	1601	1602	O

The	32187464	1603	1606	O
percentages	32187464	1607	1618	B-Outcome
of	32187464	1619	1621	I-Outcome
patients	32187464	1622	1630	I-Outcome
with	32187464	1631	1635	I-Outcome
detectable	32187464	1636	1646	I-Outcome
viral	32187464	1647	1652	I-Outcome
RNA	32187464	1653	1656	I-Outcome
at	32187464	1657	1659	I-Outcome
various	32187464	1660	1667	I-Outcome
time	32187464	1668	1672	I-Outcome
points	32187464	1673	1679	I-Outcome
were	32187464	1680	1684	O
similar	32187464	1685	1692	B-Observation
.	32187464	1693	1694	O

In	32187464	1695	1697	O
a	32187464	1698	1699	O
modified	32187464	1700	1708	O
intention-to-treat	32187464	1709	1727	O
analysis	32187464	1728	1736	O
,	32187464	1737	1738	O
lopinavir-ritonavir	32187464	1739	1758	B-Intervention
led	32187464	1759	1762	O
to	32187464	1763	1765	O
a	32187464	1766	1767	O
median	32187464	1768	1774	B-Outcome
time	32187464	1775	1779	I-Outcome
to	32187464	1780	1782	I-Outcome
clinical	32187464	1783	1791	I-Outcome
improvement	32187464	1792	1803	I-Outcome
that	32187464	1804	1808	O
was	32187464	1809	1812	O
shorter	32187464	1813	1820	B-Observation
by	32187464	1821	1823	I-Observation
1	32187464	1824	1825	I-Observation
day	32187464	1826	1829	I-Observation
than	32187464	1830	1834	O
that	32187464	1835	1839	O
observed	32187464	1840	1848	O
with	32187464	1849	1853	O
standard	32187464	1854	1862	B-Intervention
care	32187464	1863	1867	I-Intervention
(	32187464	1868	1869	O
hazard	32187464	1870	1876	O
ratio	32187464	1877	1882	O
,	32187464	1883	1884	O
1.39	32187464	1885	1889	O
;	32187464	1890	1891	O
95	32187464	1892	1894	O
%	32187464	1895	1896	O
CI	32187464	1897	1899	O
,	32187464	1900	1901	O
1.00	32187464	1902	1906	O
to	32187464	1907	1909	O
1.91	32187464	1910	1914	O
)	32187464	1915	1916	O
.	32187464	1917	1918	O

Gastrointestinal	32187464	1919	1935	B-Outcome
adverse	32187464	1936	1943	I-Outcome
events	32187464	1944	1950	I-Outcome
were	32187464	1951	1955	O
more	32187464	1956	1960	B-Observation
common	32187464	1961	1967	I-Observation
in	32187464	1968	1970	O
the	32187464	1971	1974	O
lopinavir-ritonavir	32187464	1975	1994	B-Intervention
group	32187464	1995	2000	O
,	32187464	2001	2002	O
but	32187464	2003	2006	O
serious	32187464	2007	2014	B-Outcome
adverse	32187464	2015	2022	I-Outcome
events	32187464	2023	2029	I-Outcome
were	32187464	2030	2034	O
more	32187464	2035	2039	B-Observation
common	32187464	2040	2046	I-Observation
in	32187464	2047	2049	O
the	32187464	2050	2053	O
standard-care	32187464	2054	2067	B-Intervention
group	32187464	2068	2073	O
.	32187464	2074	2075	O

Lopinavir-ritonavir	32187464	2076	2095	B-Intervention
treatment	32187464	2096	2105	I-Intervention
was	32187464	2106	2109	O
stopped	32187464	2110	2117	O
early	32187464	2118	2123	O
in	32187464	2124	2126	O
13	32187464	2127	2129	B-Count
patients	32187464	2130	2138	I-Count
(	32187464	2139	2140	I-Count
13.8	32187464	2141	2145	I-Count
%	32187464	2146	2147	I-Count
)	32187464	2148	2149	I-Count
because	32187464	2150	2157	O
of	32187464	2158	2160	O
adverse	32187464	2161	2168	B-Outcome
events	32187464	2169	2175	I-Outcome
.	32187464	2176	2177	O

In	32187464	2178	2180	O
hospitalized	32187464	2181	2193	B-Participant
adult	32187464	2194	2199	I-Participant
patients	32187464	2200	2208	I-Participant
with	32187464	2209	2213	O
severe	32187464	2214	2220	B-Participant
Covid-19	32187464	2221	2229	I-Participant
,	32187464	2230	2231	O
no	32187464	2232	2234	O
benefit	32187464	2235	2242	B-Observation
was	32187464	2243	2246	O
observed	32187464	2247	2255	O
with	32187464	2256	2260	O
lopinavir-ritonavir	32187464	2261	2280	B-Intervention
treatment	32187464	2281	2290	I-Intervention
beyond	32187464	2291	2297	O
standard	32187464	2298	2306	B-Intervention
care	32187464	2307	2311	I-Intervention
.	32187464	2312	2313	O

Future	32187464	2314	2320	O
trials	32187464	2321	2327	O
in	32187464	2328	2330	O
patients	32187464	2331	2339	O
with	32187464	2340	2344	O
severe	32187464	2345	2351	O
illness	32187464	2352	2359	O
may	32187464	2360	2363	O
help	32187464	2364	2368	O
to	32187464	2369	2371	O
confirm	32187464	2372	2379	O
or	32187464	2380	2382	O
exclude	32187464	2383	2390	O
the	32187464	2391	2394	O
possibility	32187464	2395	2406	O
of	32187464	2407	2409	O
a	32187464	2410	2411	O
treatment	32187464	2412	2421	O
benefit	32187464	2422	2429	O
.	32187464	2430	2431	O
(	32187464	2432	2433	O
Funded	32187464	2434	2440	O
by	32187464	2441	2443	O
Major	32187464	2444	2449	O
Projects	32187464	2450	2458	O
of	32187464	2459	2461	O
National	32187464	2462	2470	O
Science	32187464	2471	2478	O
and	32187464	2479	2482	O
Technology	32187464	2483	2493	O
on	32187464	2494	2496	O
New	32187464	2497	2500	O
Drug	32187464	2501	2505	O
Creation	32187464	2506	2514	O
and	32187464	2515	2518	O
Development	32187464	2519	2530	O
and	32187464	2531	2534	O
others	32187464	2535	2541	O
;	32187464	2542	2543	O
Chinese	32187464	2544	2551	O
Clinical	32187464	2552	2560	O
Trial	32187464	2561	2566	O
Register	32187464	2567	2575	O
number	32187464	2576	2582	O
,	32187464	2583	2584	O
ChiCTR2000029308	32187464	2585	2601	O
.	32187464	2602	2603	O
)	32187464	2604	2605	O
.	32187464	2606	2607	O


Therefore	32236562	0	9	O
,	32236562	10	11	O
we	32236562	12	14	O
included	32236562	15	23	O
Lopinavir/Ritonavir	32236562	24	43	B-Intervention
treatment	32236562	44	53	I-Intervention
as	32236562	54	56	O
a	32236562	57	58	O
control	32236562	59	66	O
group	32236562	67	72	O
.	32236562	73	74	O

In	32236562	75	77	O
our	32236562	78	81	O
study	32236562	82	87	O
,	32236562	88	89	O
efficacy	32236562	90	98	O
was	32236562	99	102	O
evaluated	32236562	103	112	O
by	32236562	113	115	O
(	32236562	116	117	O
i	32236562	118	119	O
)	32236562	120	121	O
real-time	32236562	122	131	B-Outcome
polymerase	32236562	132	142	I-Outcome
chain	32236562	143	148	I-Outcome
reaction	32236562	149	157	I-Outcome
(	32236562	158	159	O
RT-PCR	32236562	160	166	O
)	32236562	167	168	O
for	32236562	169	172	O
measuring	32236562	173	182	O
COVID-19	32236562	183	191	B-Outcome
viral	32236562	192	197	I-Outcome
RNAs	32236562	198	202	I-Outcome
,	32236562	203	204	O
(	32236562	205	206	O
ii	32236562	207	209	O
)	32236562	210	211	O
lung	32236562	212	216	B-Outcome
computerized	32236562	217	229	I-Outcome
tomography	32236562	230	240	I-Outcome
(	32236562	241	242	I-Outcome
CT	32236562	243	245	I-Outcome
)	32236562	246	247	I-Outcome
for	32236562	248	251	O
assessing	32236562	252	261	O
the	32236562	262	265	O
improvement	32236562	266	277	B-Outcome
of	32236562	278	280	I-Outcome
NCP	32236562	281	284	I-Outcome
,	32236562	285	286	O
and	32236562	287	290	O
(	32236562	291	292	O
iii	32236562	293	296	O
)	32236562	297	298	O
length	32236562	299	305	B-Outcome
of	32236562	306	308	I-Outcome
hospitalization	32236562	309	324	I-Outcome
for	32236562	325	328	I-Outcome
assessing	32236562	329	338	I-Outcome
patient	32236562	339	346	I-Outcome
recovery	32236562	347	355	I-Outcome
.	32236562	356	357	O

Safety	32236562	358	364	B-Outcome
was	32236562	365	368	O
evaluated	32236562	369	378	O
by	32236562	379	381	O
adverse	32236562	382	389	B-Outcome
event	32236562	390	395	I-Outcome
monitoring	32236562	396	406	O
.	32236562	407	408	O

Here	32236562	409	413	O
,	32236562	414	415	O
we	32236562	416	418	O
report	32236562	419	425	O
our	32236562	426	429	O
initial	32236562	430	437	O
results	32236562	438	445	O
on	32236562	446	448	O
Chloroquine	32236562	449	460	B-Intervention
therapy	32236562	461	468	O
of	32236562	469	471	O
COVID-19	32236562	472	480	B-Participant
patients	32236562	481	489	O
.	32236562	490	491	O

Firstly	32236562	492	499	O
,	32236562	500	501	O
among	32236562	502	507	O
the	32236562	508	511	O
82	32236562	512	514	O
patients	32236562	515	523	O
screened	32236562	524	532	O
,	32236562	533	534	O
22	32236562	535	537	O
met	32236562	538	541	O
the	32236562	542	545	O
enrollment	32236562	546	556	O
criteria	32236562	557	565	O
(	32236562	566	567	O
Figure	32236562	568	574	O
1A	32236562	575	577	O
;	32236562	578	579	O
Supplementary	32236562	580	593	O
material	32236562	594	602	O
)	32236562	603	604	O
.	32236562	605	606	O

All	32236562	607	610	O
the	32236562	611	614	O
22	32236562	615	617	O
patients	32236562	618	626	O
were	32236562	627	631	O
tested	32236562	632	638	O
positive	32236562	639	647	B-Participant
for	32236562	648	651	I-Participant
SARS-CoV-2	32236562	652	662	I-Participant
by	32236562	663	665	O
RT-PCR	32236562	666	672	O
assay	32236562	673	678	O
before	32236562	679	685	O
enrollment	32236562	686	696	O
.	32236562	697	698	O

Their	32236562	699	704	O
main	32236562	705	709	O
symptoms	32236562	710	718	O
were	32236562	719	723	O
dry	32236562	724	727	B-Participant
cough	32236562	728	733	I-Participant
,	32236562	734	735	O
fatigue	32236562	736	743	B-Participant
,	32236562	744	745	O
and	32236562	746	749	O
fever	32236562	750	755	B-Participant
,	32236562	756	757	O
and	32236562	758	761	O
severe	32236562	762	768	O
cases	32236562	769	774	O
were	32236562	775	779	O
characterized	32236562	780	793	O
by	32236562	794	796	O
dyspnea	32236562	797	804	B-Participant
,	32236562	805	806	O
hypoxemia	32236562	807	816	B-Participant
,	32236562	817	818	O
or	32236562	819	821	O
acute	32236562	822	827	B-Participant
respiratory	32236562	828	839	I-Participant
dysfunction	32236562	840	851	I-Participant
.	32236562	852	853	O

Patients	32236562	854	862	O
were	32236562	863	867	O
then	32236562	868	872	O
randomized	32236562	873	883	O
into	32236562	884	888	O
two	32236562	889	892	O
groups	32236562	893	899	O
:	32236562	900	901	O
10	32236562	902	904	O
patients	32236562	905	913	O
,	32236562	914	915	O
including	32236562	916	925	O
3	32236562	926	927	O
severe	32236562	928	934	O
and	32236562	935	938	O
7	32236562	939	940	O
moderate	32236562	941	949	O
cases	32236562	950	955	O
,	32236562	956	957	O
were	32236562	958	962	O
treated	32236562	963	970	O
with	32236562	971	975	O
Chloroquine	32236562	976	987	B-Intervention
500	32236562	988	991	O
mg	32236562	992	994	O
orally	32236562	995	1001	O
twice	32236562	1002	1007	O
daily	32236562	1008	1013	O
for	32236562	1014	1017	O
10	32236562	1018	1020	O
days	32236562	1021	1025	O
;	32236562	1026	1027	O
12	32236562	1028	1030	O
patients	32236562	1031	1039	O
,	32236562	1040	1041	O
including	32236562	1042	1051	O
5	32236562	1052	1053	O
severe	32236562	1054	1060	O
and	32236562	1061	1064	O
7	32236562	1065	1066	O
moderate	32236562	1067	1075	O
cases	32236562	1076	1081	O
,	32236562	1082	1083	O
were	32236562	1084	1088	O
treated	32236562	1089	1096	O
with	32236562	1097	1101	O
Lopinavir/Ritonavir	32236562	1102	1121	B-Intervention
400/100	32236562	1122	1129	O
mg	32236562	1130	1132	O
orally	32236562	1133	1139	O
twice	32236562	1140	1145	O
daily	32236562	1146	1151	O
for	32236562	1152	1155	O
10	32236562	1156	1158	O
days	32236562	1159	1163	O
.	32236562	1164	1165	O

Primary	32236562	1166	1173	O
baseline	32236562	1174	1182	O
demographic	32236562	1183	1194	O
and	32236562	1195	1198	O
clinical	32236562	1199	1207	O
features	32236562	1208	1216	O
of	32236562	1217	1219	O
the	32236562	1220	1223	O
patients	32236562	1224	1232	O
are	32236562	1233	1236	O
listed	32236562	1237	1243	O
in	32236562	1244	1246	O
Table	32236562	1247	1252	O
1	32236562	1253	1254	O
,	32236562	1255	1256	O
with	32236562	1257	1261	O
fairly	32236562	1262	1268	O
even	32236562	1269	1273	O
matched	32236562	1274	1281	O
characteristics	32236562	1282	1297	O
between	32236562	1298	1305	O
two	32236562	1306	1309	O
groups	32236562	1310	1316	O
.	32236562	1317	1318	O

We	32236562	1319	1321	O
initially	32236562	1322	1331	O
relied	32236562	1332	1338	O
on	32236562	1339	1341	O
RT-PCR	32236562	1342	1348	O
to	32236562	1349	1351	O
measure	32236562	1352	1359	O
virological	32236562	1360	1371	O
outcomes	32236562	1372	1380	O
and	32236562	1381	1384	O
showed	32236562	1385	1391	O
that	32236562	1392	1396	O
one	32236562	1397	1400	B-Count
patient	32236562	1401	1408	I-Count
in	32236562	1409	1411	O
the	32236562	1412	1415	O
Chloroquine	32236562	1416	1427	B-Intervention
group	32236562	1428	1433	O
became	32236562	1434	1440	O
SARS-CoV-2	32236562	1441	1451	B-Outcome
negative	32236562	1452	1460	I-Outcome
after	32236562	1461	1466	O
treatment	32236562	1467	1476	O
for	32236562	1477	1480	O
only	32236562	1481	1485	O
2	32236562	1486	1487	O
days	32236562	1488	1492	O
(	32236562	1493	1494	O
Figure	32236562	1495	1501	O
1B	32236562	1502	1504	O
,	32236562	1505	1506	O
left	32236562	1507	1511	O
panel	32236562	1512	1517	O
)	32236562	1518	1519	O
.	32236562	1520	1521	O

There	32236562	1522	1527	O
were	32236562	1528	1532	O
then	32236562	1533	1537	O
steady	32236562	1538	1544	B-Observation
increases	32236562	1545	1554	I-Observation
in	32236562	1555	1557	O
the	32236562	1558	1561	O
number	32236562	1562	1568	B-Outcome
of	32236562	1569	1571	I-Outcome
patients	32236562	1572	1580	I-Outcome
turning	32236562	1581	1588	I-Outcome
negative	32236562	1589	1597	I-Outcome
,	32236562	1598	1599	O
cumulating	32236562	1600	1610	O
at	32236562	1611	1613	O
Day	32236562	1614	1617	O
13	32236562	1618	1620	O
when	32236562	1621	1625	O
all	32236562	1626	1629	B-Count
of	32236562	1630	1632	O
the	32236562	1633	1636	O
Chloroquine-treated	32236562	1637	1656	B-Intervention
patients	32236562	1657	1665	O
became	32236562	1666	1672	O
negative	32236562	1673	1681	B-Outcome
(	32236562	1682	1683	O
Figure	32236562	1684	1690	O
1B	32236562	1691	1693	O
,	32236562	1694	1695	O
left	32236562	1696	1700	O
panel	32236562	1701	1706	O
;	32236562	1707	1708	O
Supplementary	32236562	1709	1722	O
Table	32236562	1723	1728	O
S2	32236562	1729	1731	O
)	32236562	1732	1733	O
.	32236562	1734	1735	O

In	32236562	1736	1738	O
comparison	32236562	1739	1749	O
,	32236562	1750	1751	O
patients	32236562	1752	1760	O
in	32236562	1761	1763	O
the	32236562	1764	1767	O
Lopinavir/Ritonavir	32236562	1768	1787	B-Intervention
group	32236562	1788	1793	O
only	32236562	1794	1798	O
became	32236562	1799	1805	O
SARS-CoV-2	32236562	1806	1816	B-Outcome
negative	32236562	1817	1825	I-Outcome
after	32236562	1826	1831	O
3	32236562	1832	1833	O
days	32236562	1834	1838	O
of	32236562	1839	1841	O
dosing	32236562	1842	1848	O
,	32236562	1849	1850	O
and	32236562	1851	1854	O
11	32236562	1855	1857	B-Count
out	32236562	1858	1861	I-Count
of	32236562	1862	1864	I-Count
12	32236562	1865	1867	I-Count
turned	32236562	1868	1874	O
negative	32236562	1875	1883	B-Outcome
at	32236562	1884	1886	O
Day	32236562	1887	1890	O
14	32236562	1891	1893	O
.	32236562	1894	1895	O

Comparing	32236562	1896	1905	O
to	32236562	1906	1908	O
the	32236562	1909	1912	O
Lopinavir/Ritonavir	32236562	1913	1932	B-Intervention
group	32236562	1933	1938	O
,	32236562	1939	1940	O
the	32236562	1941	1944	O
percentages	32236562	1945	1956	B-Outcome
of	32236562	1957	1959	I-Outcome
patients	32236562	1960	1968	I-Outcome
who	32236562	1969	1972	I-Outcome
became	32236562	1973	1979	I-Outcome
SARS-CoV-2	32236562	1980	1990	I-Outcome
negative	32236562	1991	1999	I-Outcome
in	32236562	2000	2002	O
the	32236562	2003	2006	O
Chloroquine	32236562	2007	2018	B-Intervention
group	32236562	2019	2024	O
were	32236562	2025	2029	O
slightly	32236562	2030	2038	B-Observation
higher	32236562	2039	2045	I-Observation
at	32236562	2046	2048	O
Day	32236562	2049	2052	O
7	32236562	2053	2054	O
,	32236562	2055	2056	O
Day	32236562	2057	2060	O
10	32236562	2061	2063	O
,	32236562	2064	2065	O
and	32236562	2066	2069	O
Day	32236562	2070	2073	O
14	32236562	2074	2076	O
(	32236562	2077	2078	O
Supplementary	32236562	2079	2092	O
Table	32236562	2093	2098	O
S2	32236562	2099	2101	O
)	32236562	2102	2103	O
.	32236562	2104	2105	O

These	32236562	2106	2111	O
results	32236562	2112	2119	O
suggest	32236562	2120	2127	O
that	32236562	2128	2132	O
Chloroquine	32236562	2133	2144	B-Intervention
has	32236562	2145	2148	O
slight	32236562	2149	2155	B-Observation
advantage	32236562	2156	2165	I-Observation
over	32236562	2166	2170	O
Lopinavir/Ritonavir	32236562	2171	2190	B-Intervention
based	32236562	2191	2196	O
on	32236562	2197	2199	O
RNA	32236562	2200	2203	B-Outcome
tests	32236562	2204	2209	I-Outcome
.	32236562	2210	2211	O

Besides	32236562	2212	2219	O
,	32236562	2220	2221	O
lung	32236562	2222	2226	B-Outcome
CT	32236562	2227	2229	I-Outcome
is	32236562	2230	2232	O
another	32236562	2233	2240	O
effective	32236562	2241	2250	O
indicator	32236562	2251	2260	O
to	32236562	2261	2263	O
clinically	32236562	2264	2274	O
evaluate	32236562	2275	2283	O
the	32236562	2284	2287	O
improvement	32236562	2288	2299	B-Outcome
of	32236562	2300	2302	I-Outcome
NCP	32236562	2303	2306	I-Outcome
.	32236562	2307	2308	O

The	32236562	2309	2312	O
first	32236562	2313	2318	B-Count
patient	32236562	2319	2326	I-Count
achieving	32236562	2327	2336	O
lung	32236562	2337	2341	B-Outcome
clearance	32236562	2342	2351	I-Outcome
based	32236562	2352	2357	O
on	32236562	2358	2360	O
CT	32236562	2361	2363	O
imaging	32236562	2364	2371	O
was	32236562	2372	2375	O
from	32236562	2376	2380	O
the	32236562	2381	2384	O
Lopinavir/Ritonavir	32236562	2385	2404	B-Intervention
group	32236562	2405	2410	O
at	32236562	2411	2413	O
Day	32236562	2414	2417	O
6	32236562	2418	2419	O
and	32236562	2420	2423	O
this	32236562	2424	2428	O
patient	32236562	2429	2436	O
became	32236562	2437	2443	O
SARS-CoV-2	32236562	2444	2454	B-Outcome
negative	32236562	2455	2463	I-Outcome
at	32236562	2464	2466	O
Day	32236562	2467	2470	O
3	32236562	2471	2472	O
.	32236562	2473	2474	O

In	32236562	2475	2477	O
the	32236562	2478	2481	O
Chloroquine	32236562	2482	2493	B-Intervention
group	32236562	2494	2499	O
,	32236562	2500	2501	O
the	32236562	2502	2505	O
first	32236562	2506	2511	B-Count
patient	32236562	2512	2519	I-Count
achieving	32236562	2520	2529	O
lung	32236562	2530	2534	B-Outcome
clearance	32236562	2535	2544	I-Outcome
was	32236562	2545	2548	O
recognized	32236562	2549	2559	O
at	32236562	2560	2562	O
Day	32236562	2563	2566	O
8	32236562	2567	2568	O
,	32236562	2569	2570	O
who	32236562	2571	2574	O
became	32236562	2575	2581	O
SARS-CoV-2	32236562	2582	2592	B-Outcome
negative	32236562	2593	2601	I-Outcome
at	32236562	2602	2604	O
Day	32236562	2605	2608	O
7	32236562	2609	2610	O
(	32236562	2611	2612	O
Figure	32236562	2613	2619	O
1B	32236562	2620	2622	O
,	32236562	2623	2624	O
middle	32236562	2625	2631	O
panel	32236562	2632	2637	O
)	32236562	2638	2639	O
.	32236562	2640	2641	O

These	32236562	2642	2647	O
data	32236562	2648	2652	O
suggest	32236562	2653	2660	O
that	32236562	2661	2665	O
viral	32236562	2666	2671	B-Outcome
clearance	32236562	2672	2681	I-Outcome
does	32236562	2682	2686	O
not	32236562	2687	2690	O
translate	32236562	2691	2700	O
immediately	32236562	2701	2712	O
into	32236562	2713	2717	O
pathological	32236562	2718	2730	B-Outcome
improvement	32236562	2731	2742	I-Outcome
in	32236562	2743	2745	I-Outcome
lungs	32236562	2746	2751	I-Outcome
.	32236562	2752	2753	O

By	32236562	2754	2756	O
Day	32236562	2757	2760	O
9	32236562	2761	2762	O
,	32236562	2763	2764	O
6	32236562	2765	2766	B-Count
patients	32236562	2767	2775	I-Count
(	32236562	2776	2777	I-Count
60	32236562	2778	2780	I-Count
%	32236562	2781	2782	I-Count
)	32236562	2783	2784	I-Count
in	32236562	2785	2787	O
the	32236562	2788	2791	O
Chloroquine	32236562	2792	2803	B-Intervention
group	32236562	2804	2809	O
reached	32236562	2810	2817	O
lung	32236562	2818	2822	B-Outcome
clearance	32236562	2823	2832	I-Outcome
,	32236562	2833	2834	O
compared	32236562	2835	2843	O
to	32236562	2844	2846	O
3	32236562	2847	2848	B-Count
(	32236562	2849	2850	I-Count
25	32236562	2851	2853	I-Count
%	32236562	2854	2855	I-Count
)	32236562	2856	2857	I-Count
from	32236562	2858	2862	O
the	32236562	2863	2866	O
Lopinavir/Ritonavir	32236562	2867	2886	B-Intervention
group	32236562	2887	2892	O
(	32236562	2893	2894	O
Figure	32236562	2895	2901	O
1B	32236562	2902	2904	O
,	32236562	2905	2906	O
middle	32236562	2907	2913	O
panel	32236562	2914	2919	O
)	32236562	2920	2921	O
.	32236562	2922	2923	O

By	32236562	2924	2926	O
Day	32236562	2927	2930	O
14	32236562	2931	2933	O
,	32236562	2934	2935	O
the	32236562	2936	2939	O
incidence	32236562	2940	2949	B-Outcome
rate	32236562	2950	2954	I-Outcome
of	32236562	2955	2957	I-Outcome
lung	32236562	2958	2962	I-Outcome
improvement	32236562	2963	2974	I-Outcome
based	32236562	2975	2980	I-Outcome
on	32236562	2981	2983	I-Outcome
CT	32236562	2984	2986	I-Outcome
imaging	32236562	2987	2994	I-Outcome
from	32236562	2995	2999	O
the	32236562	3000	3003	O
Chloroquine	32236562	3004	3015	B-Intervention
group	32236562	3016	3021	O
was	32236562	3022	3025	O
more	32236562	3026	3030	B-Observation
than	32236562	3031	3035	I-Observation
doubled	32236562	3036	3043	I-Observation
to	32236562	3044	3046	O
that	32236562	3047	3051	O
of	32236562	3052	3054	O
the	32236562	3055	3058	O
Lopinavir/Ritonavir	32236562	3059	3078	B-Intervention
group	32236562	3079	3084	O
(	32236562	3085	3086	O
rate	32236562	3087	3091	O
ratio	32236562	3092	3097	O
2.21	32236562	3098	3102	O
,	32236562	3103	3104	O
95	32236562	3105	3107	O
%	32236562	3108	3109	O
CI	32236562	3110	3112	O
0.816.62	32236562	3113	3122	O
)	32236562	3123	3124	O
.	32236562	3125	3126	O

These	32236562	3127	3132	O
results	32236562	3133	3140	O
suggest	32236562	3141	3148	O
that	32236562	3149	3153	O
patients	32236562	3154	3162	O
treated	32236562	3163	3170	O
with	32236562	3171	3175	O
Chloroquine	32236562	3176	3187	B-Intervention
appear	32236562	3188	3194	O
to	32236562	3195	3197	O
recover	32236562	3198	3205	B-Outcome
better	32236562	3206	3212	B-Observation
and	32236562	3213	3216	O
regain	32236562	3217	3223	B-Outcome
their	32236562	3224	3229	I-Outcome
pulmonary	32236562	3230	3239	I-Outcome
function	32236562	3240	3248	I-Outcome
quicker	32236562	3249	3256	B-Observation
than	32236562	3257	3261	O
those	32236562	3262	3267	O
treated	32236562	3268	3275	O
with	32236562	3276	3280	O
Lopinavir/Ritonavir	32236562	3281	3300	B-Intervention
.	32236562	3301	3302	O

In	32236562	3303	3305	O
addition	32236562	3306	3314	O
,	32236562	3315	3316	O
consistent	32236562	3317	3327	O
with	32236562	3328	3332	O
the	32236562	3333	3336	O
CT	32236562	3337	3339	O
imaging	32236562	3340	3347	O
data	32236562	3348	3352	O
(	32236562	3353	3354	O
Figure	32236562	3355	3361	O
1B	32236562	3362	3364	O
,	32236562	3365	3366	O
middle	32236562	3367	3373	O
panel	32236562	3374	3379	O
)	32236562	3380	3381	O
,	32236562	3382	3383	O
patients	32236562	3384	3392	O
treated	32236562	3393	3400	O
with	32236562	3401	3405	O
Chloroquine	32236562	3406	3417	B-Intervention
were	32236562	3418	3422	O
discharged	32236562	3423	3433	B-Outcome
from	32236562	3434	3438	I-Outcome
hospital	32236562	3439	3447	I-Outcome
in	32236562	3448	3450	O
a	32236562	3451	3452	O
much	32236562	3453	3457	B-Observation
quicker	32236562	3458	3465	I-Observation
pace	32236562	3466	3470	I-Observation
(	32236562	3471	3472	O
Figure	32236562	3473	3479	O
1B	32236562	3480	3482	O
,	32236562	3483	3484	O
right	32236562	3485	3490	O
panel	32236562	3491	3496	O
)	32236562	3497	3498	O
.	32236562	3499	3500	O

The	32236562	3501	3504	O
first	32236562	3505	3510	B-Count
patient	32236562	3511	3518	I-Count
discharged	32236562	3519	3529	B-Outcome
from	32236562	3530	3534	I-Outcome
hospital	32236562	3535	3543	I-Outcome
was	32236562	3544	3547	O
from	32236562	3548	3552	O
the	32236562	3553	3556	O
Lopinavir/Ritonavir	32236562	3557	3576	B-Intervention
group	32236562	3577	3582	O
at	32236562	3583	3585	O
Day	32236562	3586	3589	O
8	32236562	3590	3591	O
,	32236562	3592	3593	O
and	32236562	3594	3597	O
the	32236562	3598	3601	O
first	32236562	3602	3607	B-Count
discharged	32236562	3608	3618	B-Outcome
from	32236562	3619	3623	O
the	32236562	3624	3627	O
Chloroquine	32236562	3628	3639	B-Intervention
group	32236562	3640	3645	O
was	32236562	3646	3649	O
at	32236562	3650	3652	O
Day	32236562	3653	3656	O
9	32236562	3657	3658	O
.	32236562	3659	3660	O

Encouragingly	32236562	3661	3674	O
,	32236562	3675	3676	O
by	32236562	3677	3679	O
Day	32236562	3680	3683	O
14	32236562	3684	3686	O
,	32236562	3687	3688	O
all	32236562	3689	3692	B-Count
10	32236562	3693	3695	I-Count
patients	32236562	3696	3704	I-Count
(	32236562	3705	3706	I-Count
100	32236562	3707	3710	I-Count
%	32236562	3711	3712	I-Count
)	32236562	3713	3714	I-Count
from	32236562	3715	3719	O
the	32236562	3720	3723	O
Chloroquine	32236562	3724	3735	B-Intervention
group	32236562	3736	3741	O
were	32236562	3742	3746	O
discharged	32236562	3747	3757	B-Outcome
compared	32236562	3758	3766	O
to	32236562	3767	3769	O
6	32236562	3770	3771	B-Count
patients	32236562	3772	3780	I-Count
(	32236562	3781	3782	I-Count
50	32236562	3783	3785	I-Count
%	32236562	3786	3787	I-Count
)	32236562	3788	3789	I-Count
from	32236562	3790	3794	O
the	32236562	3795	3798	O
Lopinavir/Ritonavir	32236562	3799	3818	B-Intervention
group	32236562	3819	3824	O
(	32236562	3825	3826	O
Figure	32236562	3827	3833	O
1B	32236562	3834	3836	O
,	32236562	3837	3838	O
right	32236562	3839	3844	O
panel	32236562	3845	3850	O
;	32236562	3851	3852	O
Supplementary	32236562	3853	3866	O
Table	32236562	3867	3872	O
S2	32236562	3873	3875	O
)	32236562	3876	3877	O
.	32236562	3878	3879	O

Furthermore	32236562	3880	3891	O
,	32236562	3892	3893	O
Chloroquine	32236562	3894	3905	B-Intervention
also	32236562	3906	3910	O
appeared	32236562	3911	3919	O
to	32236562	3920	3922	O
promote	32236562	3923	3930	O
quicker	32236562	3931	3938	B-Observation
recovery	32236562	3939	3947	B-Outcome
compared	32236562	3948	3956	O
to	32236562	3957	3959	O
Lopinavir/Ritonavir	32236562	3960	3979	B-Intervention
recommended	32236562	3980	3991	O
by	32236562	3992	3994	O
health	32236562	3995	4001	O
authorities	32236562	4002	4013	O
in	32236562	4014	4016	O
China	32236562	4017	4022	O
.	32236562	4023	4024	O

During	32236562	4025	4031	O
Chloroquine	32236562	4032	4043	B-Intervention
treatment	32236562	4044	4053	O
period	32236562	4054	4060	O
,	32236562	4061	4062	O
we	32236562	4063	4065	O
observed	32236562	4066	4074	O
5	32236562	4075	4076	B-Count
patients	32236562	4077	4085	I-Count
who	32236562	4086	4089	O
experienced	32236562	4090	4101	O
a	32236562	4102	4103	O
total	32236562	4104	4109	O
of	32236562	4110	4112	O
9	32236562	4113	4114	B-Outcome
adverse	32236562	4115	4122	I-Outcome
events	32236562	4123	4129	I-Outcome
,	32236562	4130	4131	O
including	32236562	4132	4141	O
vomiting	32236562	4142	4150	B-Outcome
,	32236562	4151	4152	O
abdominal	32236562	4153	4162	B-Outcome
pain	32236562	4163	4167	I-Outcome
,	32236562	4168	4169	O
nausea	32236562	4170	4176	B-Outcome
,	32236562	4177	4178	O
diarrhea	32236562	4179	4187	B-Outcome
,	32236562	4188	4189	O
rash	32236562	4190	4194	B-Outcome
or	32236562	4195	4197	I-Outcome
itchy	32236562	4198	4203	I-Outcome
,	32236562	4204	4205	O
cough	32236562	4206	4211	B-Outcome
,	32236562	4212	4213	O
and	32236562	4214	4217	O
shortness	32236562	4218	4227	B-Outcome
of	32236562	4228	4230	I-Outcome
breath	32236562	4231	4237	I-Outcome
(	32236562	4238	4239	O
Supplementary	32236562	4240	4253	O
Table	32236562	4254	4259	O
S3	32236562	4260	4262	O
)	32236562	4263	4264	O
.	32236562	4265	4266	O

The	32236562	4267	4270	O
most	32236562	4271	4275	B-Observation
common	32236562	4276	4282	I-Observation
adverse	32236562	4283	4290	O
event	32236562	4291	4296	O
was	32236562	4297	4300	O
vomiting	32236562	4301	4309	B-Outcome
observed	32236562	4310	4318	O
in	32236562	4319	4321	O
4	32236562	4322	4323	B-Count
patients	32236562	4324	4332	I-Count
.	32236562	4333	4334	O

All	32236562	4335	4338	B-Outcome
observed	32236562	4339	4347	I-Outcome
adverse	32236562	4348	4355	I-Outcome
events	32236562	4356	4362	O
were	32236562	4363	4367	O
known	32236562	4368	4373	O
to	32236562	4374	4376	O
be	32236562	4377	4379	O
related	32236562	4380	4387	B-Observation
to	32236562	4388	4390	O
Chloroquine	32236562	4391	4402	B-Intervention
.	32236562	4403	4404	O

There	32236562	4405	4410	O
were	32236562	4411	4415	O
no	32236562	4416	4418	B-Count
serious	32236562	4419	4426	B-Outcome
adverse	32236562	4427	4434	I-Outcome
events	32236562	4435	4441	I-Outcome
or	32236562	4442	4444	O
patient	32236562	4445	4452	B-Outcome
withdrew	32236562	4453	4461	I-Outcome
from	32236562	4462	4466	O
Chloroquine	32236562	4467	4478	B-Intervention
during	32236562	4479	4485	O
the	32236562	4486	4489	O
treatment	32236562	4490	4499	O
period	32236562	4500	4506	O
.	32236562	4507	4508	O

Among	32236562	4509	4514	O
the	32236562	4515	4518	O
5	32236562	4519	4520	B-Count
patients	32236562	4521	4529	I-Count
with	32236562	4530	4534	O
adverse	32236562	4535	4542	B-Outcome
events	32236562	4543	4549	I-Outcome
,	32236562	4550	4551	O
3	32236562	4552	4553	B-Count
of	32236562	4554	4556	I-Count
them	32236562	4557	4561	I-Count
had	32236562	4562	4565	O
valid	32236562	4566	4571	B-Outcome
measurements	32236562	4572	4584	I-Outcome
of	32236562	4585	4587	I-Outcome
serum	32236562	4588	4593	I-Outcome
concentration	32236562	4594	4607	I-Outcome
of	32236562	4608	4610	O
Chloroquine	32236562	4611	4622	B-Intervention
at	32236562	4623	4625	O
14	32236562	4626	4628	O
days	32236562	4629	4633	O
after	32236562	4634	4639	O
treatment	32236562	4640	4649	O
completion	32236562	4650	4660	O
.	32236562	4661	4662	O

The	32236562	4663	4666	O
serum	32236562	4667	4672	B-Outcome
concentration	32236562	4673	4686	I-Outcome
of	32236562	4687	4689	O
Chloroquine	32236562	4690	4701	B-Intervention
decreased	32236562	4702	4711	B-Observation
to	32236562	4712	4714	I-Observation
the	32236562	4715	4718	I-Observation
range	32236562	4719	4724	I-Observation
of	32236562	4725	4727	I-Observation
0.260.61	32236562	4728	4737	I-Observation
mol/L	32236562	4738	4744	I-Observation
,	32236562	4745	4746	O
which	32236562	4747	4752	O
was	32236562	4753	4756	O
safe	32236562	4757	4761	B-Observation
to	32236562	4762	4764	O
patients	32236562	4765	4773	O
.	32236562	4774	4775	O

Overall	32236562	4776	4783	O
,	32236562	4784	4785	O
Chloroquine	32236562	4786	4797	B-Intervention
appears	32236562	4798	4805	O
well	32236562	4806	4810	B-Observation
tolerated	32236562	4811	4820	I-Observation
among	32236562	4821	4826	O
the	32236562	4827	4830	O
patients	32236562	4831	4839	O
we	32236562	4840	4842	O
treated	32236562	4843	4850	O
.	32236562	4851	4852	O

Adverse	32236562	4853	4860	O
reactions	32236562	4861	4870	O
can	32236562	4871	4874	O
be	32236562	4875	4877	O
avoided	32236562	4878	4885	O
by	32236562	4886	4888	O
strengthening	32236562	4889	4902	O
patient	32236562	4903	4910	O
monitoring	32236562	4911	4921	O
and	32236562	4922	4925	O
strictly	32236562	4926	4934	O
following	32236562	4935	4944	O
the	32236562	4945	4948	O
standard	32236562	4949	4957	O
oral	32236562	4958	4962	O
dosage	32236562	4963	4969	O
of	32236562	4970	4972	O
the	32236562	4973	4976	O
drug	32236562	4977	4981	O
.	32236562	4982	4983	O

To	32236562	4984	4986	O
further	32236562	4987	4994	O
investigate	32236562	4995	5006	O
the	32236562	5007	5010	O
change	32236562	5011	5017	B-Observation
of	32236562	5018	5020	O
immunity	32236562	5021	5029	B-Outcome
through	32236562	5030	5037	O
the	32236562	5038	5041	O
therapy	32236562	5042	5049	O
,	32236562	5050	5051	O
we	32236562	5052	5054	O
measured	32236562	5055	5063	O
T-cell	32236562	5064	5070	B-Outcome
counts	32236562	5071	5077	I-Outcome
of	32236562	5078	5080	O
the	32236562	5081	5084	O
10	32236562	5085	5087	B-Count
patients	32236562	5088	5096	I-Count
in	32236562	5097	5099	O
the	32236562	5100	5103	O
Chloroquine	32236562	5104	5115	B-Intervention
group	32236562	5116	5121	O
every	32236562	5122	5127	O
2	32236562	5128	5129	O
days	32236562	5130	5134	O
.	32236562	5135	5136	O

The	32236562	5137	5140	O
trajectories	32236562	5141	5153	O
of	32236562	5154	5156	O
CD3	32236562	5157	5160	O
+	32236562	5160	5161	O
,	32236562	5162	5163	O
CD4	32236562	5164	5167	O
+	32236562	5167	5168	O
,	32236562	5169	5170	O
and	32236562	5171	5174	O
CD8	32236562	5175	5178	O
+	32236562	5178	5179	O
counts	32236562	5180	5186	O
showed	32236562	5187	5193	O
that	32236562	5194	5198	O
there	32236562	5199	5204	O
was	32236562	5205	5208	O
no	32236562	5209	5211	O
significant	32236562	5212	5223	B-Observation
decrease	32236562	5224	5232	I-Observation
of	32236562	5233	5235	O
T-cell	32236562	5236	5242	B-Outcome
counts	32236562	5243	5249	I-Outcome
during	32236562	5250	5256	O
the	32236562	5257	5260	O
10-day	32236562	5261	5267	O
treatment	32236562	5268	5277	O
period	32236562	5278	5284	O
(	32236562	5285	5286	O
Figure	32236562	5287	5293	O
1C	32236562	5294	5296	O
)	32236562	5297	5298	O
,	32236562	5299	5300	O
indicating	32236562	5301	5311	O
that	32236562	5312	5316	O
the	32236562	5317	5320	O
short-term	32236562	5321	5331	B-Intervention
use	32236562	5332	5335	I-Intervention
of	32236562	5336	5338	I-Intervention
Chloroquine	32236562	5339	5350	I-Intervention
had	32236562	5351	5354	O
no	32236562	5355	5357	O
significant	32236562	5358	5369	B-Observation
effect	32236562	5370	5376	I-Observation
on	32236562	5377	5379	O
immune	32236562	5380	5386	B-Outcome
function	32236562	5387	5395	I-Outcome
of	32236562	5396	5398	O
patients	32236562	5399	5407	O
.	32236562	5408	5409	O

In	32236562	5410	5412	O
sum	32236562	5413	5416	O
,	32236562	5417	5418	O
our	32236562	5419	5422	O
preliminary	32236562	5423	5434	O
results	32236562	5435	5442	O
suggest	32236562	5443	5450	O
that	32236562	5451	5455	O
Chloroquine	32236562	5456	5467	B-Intervention
could	32236562	5468	5473	O
be	32236562	5474	5476	O
an	32236562	5477	5479	O
effective	32236562	5480	5489	B-Observation
and	32236562	5490	5493	O
inexpensive	32236562	5494	5505	B-Observation
option	32236562	5506	5512	O
among	32236562	5513	5518	O
many	32236562	5519	5523	O
proposed	32236562	5524	5532	O
therapies	32236562	5533	5542	O
,	32236562	5543	5544	O
e.g	32236562	5545	5548	O
.	32236562	5549	5550	O

Lopinavir/Ritonavir	32236562	5551	5570	B-Intervention
.	32236562	5571	5572	O


Effect	32330277	0	6	O
of	32330277	7	9	O
High	32330277	10	14	B-Intervention
vs	32330277	15	17	I-Intervention
Low	32330277	18	21	I-Intervention
Doses	32330277	22	27	I-Intervention
of	32330277	28	30	I-Intervention
Chloroquine	32330277	31	42	I-Intervention
Diphosphate	32330277	43	54	I-Intervention
as	32330277	55	57	O
Adjunctive	32330277	58	68	O
Therapy	32330277	69	76	O
for	32330277	77	80	O
Patients	32330277	81	89	O
Hospitalized	32330277	90	102	B-Participant
With	32330277	103	107	O
Severe	32330277	108	114	B-Participant
Acute	32330277	115	120	I-Participant
Respiratory	32330277	121	132	I-Participant
Syndrome	32330277	133	141	I-Participant
Coronavirus	32330277	142	153	I-Participant
2	32330277	154	155	I-Participant
(	32330277	156	157	I-Participant
SARS-CoV-2	32330277	158	168	I-Participant
)	32330277	169	170	I-Participant
Infection	32330277	171	180	I-Participant
:	32330277	181	182	O
A	32330277	183	184	O
Randomized	32330277	185	195	O
Clinical	32330277	196	204	O
Trial	32330277	205	210	O
.	32330277	211	212	O

There	32330277	213	218	O
is	32330277	219	221	O
no	32330277	222	224	O
specific	32330277	225	233	O
antiviral	32330277	234	243	O
therapy	32330277	244	251	O
recommended	32330277	252	263	O
for	32330277	264	267	O
coronavirus	32330277	268	279	O
disease	32330277	280	287	O
2019	32330277	288	292	O
(	32330277	293	294	O
COVID-19	32330277	295	303	O
)	32330277	304	305	O
.	32330277	306	307	O

In	32330277	308	310	O
vitro	32330277	311	316	O
studies	32330277	317	324	O
indicate	32330277	325	333	O
that	32330277	334	338	O
the	32330277	339	342	O
antiviral	32330277	343	352	O
effect	32330277	353	359	O
of	32330277	360	362	O
chloroquine	32330277	363	374	O
diphosphate	32330277	375	386	O
(	32330277	387	388	O
CQ	32330277	389	391	O
)	32330277	392	393	O
requires	32330277	394	402	O
a	32330277	403	404	O
high	32330277	405	409	O
concentration	32330277	410	423	O
of	32330277	424	426	O
the	32330277	427	430	O
drug	32330277	431	435	O
.	32330277	436	437	O

To	32330277	438	440	O
evaluate	32330277	441	449	O
the	32330277	450	453	O
safety	32330277	454	460	B-Outcome
and	32330277	461	464	O
efficacy	32330277	465	473	B-Outcome
of	32330277	474	476	O
2	32330277	477	478	B-Intervention
CQ	32330277	479	481	I-Intervention
dosages	32330277	482	489	I-Intervention
in	32330277	490	492	O
patients	32330277	493	501	O
with	32330277	502	506	O
severe	32330277	507	513	B-Participant
COVID-19	32330277	514	522	I-Participant
.	32330277	523	524	O

This	32330277	525	529	O
parallel	32330277	530	538	O
,	32330277	539	540	O
double-masked	32330277	541	554	O
,	32330277	555	556	O
randomized	32330277	557	567	O
,	32330277	568	569	O
phase	32330277	570	575	O
IIb	32330277	576	579	O
clinical	32330277	580	588	O
trial	32330277	589	594	O
with	32330277	595	599	O
81	32330277	600	602	O
adult	32330277	603	608	O
patients	32330277	609	617	O
who	32330277	618	621	O
were	32330277	622	626	O
hospitalized	32330277	627	639	B-Participant
with	32330277	640	644	O
severe	32330277	645	651	B-Participant
acute	32330277	652	657	I-Participant
respiratory	32330277	658	669	I-Participant
syndrome	32330277	670	678	I-Participant
coronavirus	32330277	679	690	I-Participant
2	32330277	691	692	I-Participant
(	32330277	693	694	I-Participant
SARS-CoV-2	32330277	695	705	I-Participant
)	32330277	706	707	I-Participant
infection	32330277	708	717	I-Participant
was	32330277	718	721	O
conducted	32330277	722	731	O
from	32330277	732	736	O
March	32330277	737	742	O
23	32330277	743	745	O
to	32330277	746	748	O
April	32330277	749	754	O
5	32330277	755	756	O
,	32330277	757	758	O
2020	32330277	759	763	O
,	32330277	764	765	O
at	32330277	766	768	O
a	32330277	769	770	O
tertiary	32330277	771	779	O
care	32330277	780	784	O
facility	32330277	785	793	O
in	32330277	794	796	O
Manaus	32330277	797	803	O
,	32330277	804	805	O
Brazilian	32330277	806	815	O
Amazon	32330277	816	822	O
.	32330277	823	824	O

Patients	32330277	825	833	O
were	32330277	834	838	O
allocated	32330277	839	848	O
to	32330277	849	851	O
receive	32330277	852	859	O
high-dosage	32330277	860	871	B-Intervention
CQ	32330277	872	874	I-Intervention
(	32330277	875	876	O
ie	32330277	877	879	O
,	32330277	880	881	O
600	32330277	882	885	O
mg	32330277	886	888	O
CQ	32330277	889	891	O
twice	32330277	892	897	O
daily	32330277	898	903	O
for	32330277	904	907	O
10	32330277	908	910	O
days	32330277	911	915	O
)	32330277	916	917	O
or	32330277	918	920	O
low-dosage	32330277	921	931	B-Intervention
CQ	32330277	932	934	I-Intervention
(	32330277	935	936	O
ie	32330277	937	939	O
,	32330277	940	941	O
450	32330277	942	945	O
mg	32330277	946	948	O
twice	32330277	949	954	O
daily	32330277	955	960	O
on	32330277	961	963	O
day	32330277	964	967	O
1	32330277	968	969	O
and	32330277	970	973	O
once	32330277	974	978	O
daily	32330277	979	984	O
for	32330277	985	988	O
4	32330277	989	990	O
days	32330277	991	995	O
)	32330277	996	997	O
.	32330277	998	999	O

Primary	32330277	1000	1007	O
outcome	32330277	1008	1015	O
was	32330277	1016	1019	O
reduction	32330277	1020	1029	B-Outcome
in	32330277	1030	1032	I-Outcome
lethality	32330277	1033	1042	I-Outcome
by	32330277	1043	1045	I-Outcome
at	32330277	1046	1048	I-Outcome
least	32330277	1049	1054	I-Outcome
50	32330277	1055	1057	I-Outcome
%	32330277	1058	1059	I-Outcome
in	32330277	1060	1062	O
the	32330277	1063	1066	O
high-dosage	32330277	1067	1078	B-Intervention
group	32330277	1079	1084	O
compared	32330277	1085	1093	O
with	32330277	1094	1098	O
the	32330277	1099	1102	O
low-dosage	32330277	1103	1113	B-Intervention
group	32330277	1114	1119	O
.	32330277	1120	1121	O

Data	32330277	1122	1126	O
presented	32330277	1127	1136	O
here	32330277	1137	1141	O
refer	32330277	1142	1147	O
primarily	32330277	1148	1157	O
to	32330277	1158	1160	O
safety	32330277	1161	1167	B-Outcome
and	32330277	1168	1171	O
lethality	32330277	1172	1181	B-Outcome
outcomes	32330277	1182	1190	O
during	32330277	1191	1197	O
treatment	32330277	1198	1207	O
on	32330277	1208	1210	O
day	32330277	1211	1214	O
13	32330277	1215	1217	O
.	32330277	1218	1219	O

Secondary	32330277	1220	1229	O
end	32330277	1230	1233	O
points	32330277	1234	1240	O
included	32330277	1241	1249	O
participant	32330277	1250	1261	O
clinical	32330277	1262	1270	B-Outcome
status	32330277	1271	1277	I-Outcome
,	32330277	1278	1279	O
laboratory	32330277	1280	1290	B-Outcome
examinations	32330277	1291	1303	I-Outcome
,	32330277	1304	1305	O
and	32330277	1306	1309	O
electrocardiogram	32330277	1310	1327	B-Outcome
results	32330277	1328	1335	I-Outcome
.	32330277	1336	1337	O

Outcomes	32330277	1338	1346	O
will	32330277	1347	1351	O
be	32330277	1352	1354	O
presented	32330277	1355	1364	O
to	32330277	1365	1367	O
day	32330277	1368	1371	O
28	32330277	1372	1374	O
.	32330277	1375	1376	O

Viral	32330277	1377	1382	B-Outcome
respiratory	32330277	1383	1394	I-Outcome
secretion	32330277	1395	1404	I-Outcome
RNA	32330277	1405	1408	I-Outcome
detection	32330277	1409	1418	I-Outcome
was	32330277	1419	1422	O
performed	32330277	1423	1432	O
on	32330277	1433	1435	O
days	32330277	1436	1440	O
0	32330277	1441	1442	O
and	32330277	1443	1446	O
4	32330277	1447	1448	O
.	32330277	1449	1450	O

Out	32330277	1451	1454	O
of	32330277	1455	1457	O
a	32330277	1458	1459	O
predefined	32330277	1460	1470	O
sample	32330277	1471	1477	O
size	32330277	1478	1482	O
of	32330277	1483	1485	O
440	32330277	1486	1489	O
patients	32330277	1490	1498	O
,	32330277	1499	1500	O
81	32330277	1501	1503	O
were	32330277	1504	1508	O
enrolled	32330277	1509	1517	O
(	32330277	1518	1519	O
41	32330277	1520	1522	O
[	32330277	1523	1524	O
50.6	32330277	1525	1529	O
%	32330277	1530	1531	O
]	32330277	1532	1533	O
to	32330277	1534	1536	O
high-dosage	32330277	1537	1548	B-Intervention
group	32330277	1549	1554	O
and	32330277	1555	1558	O
40	32330277	1559	1561	O
[	32330277	1562	1563	O
49.4	32330277	1564	1568	O
%	32330277	1569	1570	O
]	32330277	1571	1572	O
to	32330277	1573	1575	O
low-dosage	32330277	1576	1586	B-Intervention
group	32330277	1587	1592	O
)	32330277	1593	1594	O
.	32330277	1595	1596	O

Enrolled	32330277	1597	1605	O
patients	32330277	1606	1614	O
had	32330277	1615	1618	O
a	32330277	1619	1620	O
mean	32330277	1621	1625	O
(	32330277	1626	1627	O
SD	32330277	1628	1630	O
)	32330277	1631	1632	O
age	32330277	1633	1636	O
of	32330277	1637	1639	O
51.1	32330277	1640	1644	O
(	32330277	1645	1646	O
13.9	32330277	1647	1651	O
)	32330277	1652	1653	O
years	32330277	1654	1659	O
,	32330277	1660	1661	O
and	32330277	1662	1665	O
most	32330277	1666	1670	O
(	32330277	1671	1672	O
60	32330277	1673	1675	O
[	32330277	1676	1677	O
75.3	32330277	1678	1682	O
%	32330277	1683	1684	O
]	32330277	1685	1686	O
)	32330277	1687	1688	O
were	32330277	1689	1693	O
men	32330277	1694	1697	O
.	32330277	1698	1699	O

Older	32330277	1700	1705	B-Participant
age	32330277	1706	1709	I-Participant
(	32330277	1710	1711	O
mean	32330277	1712	1716	O
[	32330277	1717	1718	O
SD	32330277	1719	1721	O
]	32330277	1722	1723	O
age	32330277	1724	1727	O
,	32330277	1728	1729	O
54.7	32330277	1730	1734	O
[	32330277	1735	1736	O
13.7	32330277	1737	1741	O
]	32330277	1742	1743	O
years	32330277	1744	1749	O
vs	32330277	1750	1752	O
47.4	32330277	1753	1757	O
[	32330277	1758	1759	O
13.3	32330277	1760	1764	O
]	32330277	1765	1766	O
years	32330277	1767	1772	O
)	32330277	1773	1774	O
and	32330277	1775	1778	O
more	32330277	1779	1783	B-Participant
heart	32330277	1784	1789	I-Participant
disease	32330277	1790	1797	I-Participant
(	32330277	1798	1799	O
5	32330277	1800	1801	O
of	32330277	1802	1804	O
28	32330277	1805	1807	O
[	32330277	1808	1809	O
17.9	32330277	1810	1814	O
%	32330277	1815	1816	O
]	32330277	1817	1818	O
vs	32330277	1819	1821	O
0	32330277	1822	1823	O
)	32330277	1824	1825	O
were	32330277	1826	1830	O
seen	32330277	1831	1835	O
in	32330277	1836	1838	O
the	32330277	1839	1842	O
high-dose	32330277	1843	1852	B-Intervention
group	32330277	1853	1858	O
.	32330277	1859	1860	O

Viral	32330277	1861	1866	B-Outcome
RNA	32330277	1867	1870	I-Outcome
was	32330277	1871	1874	O
detected	32330277	1875	1883	O
in	32330277	1884	1886	O
31	32330277	1887	1889	B-Count
of	32330277	1890	1892	I-Count
40	32330277	1893	1895	I-Count
(	32330277	1896	1897	I-Count
77.5	32330277	1898	1902	I-Count
%	32330277	1903	1904	I-Count
)	32330277	1905	1906	I-Count
and	32330277	1907	1910	O
31	32330277	1911	1913	B-Count
of	32330277	1914	1916	I-Count
41	32330277	1917	1919	I-Count
(	32330277	1920	1921	I-Count
75.6	32330277	1922	1926	I-Count
%	32330277	1927	1928	I-Count
)	32330277	1929	1930	I-Count
patients	32330277	1931	1939	I-Count
in	32330277	1940	1942	O
the	32330277	1943	1946	O
low-dosage	32330277	1947	1957	B-Intervention
and	32330277	1958	1961	O
high-dosage	32330277	1962	1973	B-Intervention
groups	32330277	1974	1980	O
,	32330277	1981	1982	O
respectively	32330277	1983	1995	O
.	32330277	1996	1997	O

Lethality	32330277	1998	2007	B-Outcome
until	32330277	2008	2013	I-Outcome
day	32330277	2014	2017	I-Outcome
13	32330277	2018	2020	I-Outcome
was	32330277	2021	2024	O
39.0	32330277	2025	2029	B-Observation
%	32330277	2030	2031	I-Observation
in	32330277	2032	2034	O
the	32330277	2035	2038	O
high-dosage	32330277	2039	2050	B-Intervention
group	32330277	2051	2056	O
(	32330277	2057	2058	O
16	32330277	2059	2061	B-Count
of	32330277	2062	2064	I-Count
41	32330277	2065	2067	I-Count
)	32330277	2068	2069	O
and	32330277	2070	2073	O
15.0	32330277	2074	2078	B-Observation
%	32330277	2079	2080	I-Observation
in	32330277	2081	2083	O
the	32330277	2084	2087	O
low-dosage	32330277	2088	2098	B-Intervention
group	32330277	2099	2104	O
(	32330277	2105	2106	O
6	32330277	2107	2108	B-Count
of	32330277	2109	2111	I-Count
40	32330277	2112	2114	I-Count
)	32330277	2115	2116	O
.	32330277	2117	2118	O

The	32330277	2119	2122	O
high-dosage	32330277	2123	2134	B-Intervention
group	32330277	2135	2140	O
presented	32330277	2141	2150	O
more	32330277	2151	2155	B-Observation
instance	32330277	2156	2164	B-Outcome
of	32330277	2165	2167	I-Outcome
QTc	32330277	2168	2171	I-Outcome
interval	32330277	2172	2180	I-Outcome
greater	32330277	2181	2188	I-Outcome
than	32330277	2189	2193	I-Outcome
500	32330277	2194	2197	I-Outcome
milliseconds	32330277	2198	2210	I-Outcome
(	32330277	2211	2212	O
7	32330277	2213	2214	B-Count
of	32330277	2215	2217	I-Count
37	32330277	2218	2220	I-Count
[	32330277	2221	2222	I-Count
18.9	32330277	2223	2227	I-Count
%	32330277	2228	2229	I-Count
]	32330277	2230	2231	I-Count
)	32330277	2232	2233	O
compared	32330277	2234	2242	O
with	32330277	2243	2247	O
the	32330277	2248	2251	O
low-dosage	32330277	2252	2262	B-Intervention
group	32330277	2263	2268	O
(	32330277	2269	2270	O
4	32330277	2271	2272	B-Count
of	32330277	2273	2275	I-Count
36	32330277	2276	2278	I-Count
[	32330277	2279	2280	I-Count
11.1	32330277	2281	2285	I-Count
%	32330277	2286	2287	I-Count
]	32330277	2288	2289	I-Count
)	32330277	2290	2291	O
.	32330277	2292	2293	O

Respiratory	32330277	2294	2305	B-Outcome
secretion	32330277	2306	2315	I-Outcome
at	32330277	2316	2318	I-Outcome
day	32330277	2319	2322	I-Outcome
4	32330277	2323	2324	I-Outcome
was	32330277	2325	2328	O
negative	32330277	2329	2337	B-Observation
in	32330277	2338	2340	O
only	32330277	2341	2345	O
6	32330277	2346	2347	B-Count
of	32330277	2348	2350	I-Count
27	32330277	2351	2353	I-Count
patients	32330277	2354	2362	I-Count
(	32330277	2363	2364	I-Count
22.2	32330277	2365	2369	I-Count
%	32330277	2370	2371	I-Count
)	32330277	2372	2373	I-Count
.	32330277	2374	2375	O

The	32330277	2376	2379	O
preliminary	32330277	2380	2391	O
findings	32330277	2392	2400	O
of	32330277	2401	2403	O
this	32330277	2404	2408	O
study	32330277	2409	2414	O
suggest	32330277	2415	2422	O
that	32330277	2423	2427	O
the	32330277	2428	2431	O
higher	32330277	2432	2438	B-Intervention
CQ	32330277	2439	2441	I-Intervention
dosage	32330277	2442	2448	I-Intervention
should	32330277	2449	2455	O
not	32330277	2456	2459	O
be	32330277	2460	2462	O
recommended	32330277	2463	2474	B-Observation
for	32330277	2475	2478	O
critically	32330277	2479	2489	B-Participant
ill	32330277	2490	2493	I-Participant
patients	32330277	2494	2502	O
with	32330277	2503	2507	O
COVID-19	32330277	2508	2516	B-Participant
because	32330277	2517	2524	O
of	32330277	2525	2527	O
its	32330277	2528	2531	O
potential	32330277	2532	2541	O
safety	32330277	2542	2548	O
hazards	32330277	2549	2556	O
,	32330277	2557	2558	O
especially	32330277	2559	2569	O
when	32330277	2570	2574	O
taken	32330277	2575	2580	O
concurrently	32330277	2581	2593	O
with	32330277	2594	2598	O
azithromycin	32330277	2599	2611	B-Participant
and	32330277	2612	2615	O
oseltamivir	32330277	2616	2627	B-Participant
.	32330277	2628	2629	O

These	32330277	2630	2635	O
findings	32330277	2636	2644	O
can	32330277	2645	2648	O
not	32330277	2649	2652	O
be	32330277	2653	2655	O
extrapolated	32330277	2656	2668	O
to	32330277	2669	2671	O
patients	32330277	2672	2680	O
with	32330277	2681	2685	O
nonsevere	32330277	2686	2695	O
COVID-19	32330277	2696	2704	O
.	32330277	2705	2706	O

ClinicalTrials.gov	32330277	2707	2725	O
Identifier	32330277	2726	2736	O
:	32330277	2737	2738	O
NCT04323527	32330277	2739	2750	O
.	32330277	2751	2752	O


The	32335900	0	3	O
impact	32335900	4	10	O
of	32335900	11	13	O
respiratory	32335900	14	25	B-Intervention
protective	32335900	26	36	I-Intervention
equipment	32335900	37	46	I-Intervention
on	32335900	47	49	O
difficult	32335900	50	59	B-Outcome
airway	32335900	60	66	I-Outcome
management	32335900	67	77	I-Outcome
:	32335900	78	79	O
a	32335900	80	81	O
randomised	32335900	82	92	O
,	32335900	93	94	O
crossover	32335900	95	104	O
,	32335900	105	106	O
simulation	32335900	107	117	O
study	32335900	118	123	O
.	32335900	124	125	O

The	32335900	126	129	O
current	32335900	130	137	O
international	32335900	138	151	O
COVID-19	32335900	152	160	O
health	32335900	161	167	O
crisis	32335900	168	174	O
underlines	32335900	175	185	O
the	32335900	186	189	O
importance	32335900	190	200	O
of	32335900	201	203	O
adequate	32335900	204	212	O
and	32335900	213	216	O
suitable	32335900	217	225	O
personal	32335900	226	234	O
protective	32335900	235	245	O
equipment	32335900	246	255	O
for	32335900	256	259	O
clinical	32335900	260	268	O
staff	32335900	269	274	O
during	32335900	275	281	O
acute	32335900	282	287	O
airway	32335900	288	294	O
management	32335900	295	305	O
.	32335900	306	307	O

This	32335900	308	312	O
study	32335900	313	318	O
compares	32335900	319	327	O
the	32335900	328	331	O
impacts	32335900	332	339	O
of	32335900	340	342	O
standard	32335900	343	351	B-Intervention
air	32335900	352	355	I-Intervention
-	32335900	356	357	I-Intervention
purifying	32335900	358	367	I-Intervention
respirators	32335900	368	379	I-Intervention
and	32335900	380	383	O
powered	32335900	384	391	B-Intervention
air	32335900	392	395	I-Intervention
-	32335900	396	397	I-Intervention
purifying	32335900	398	407	I-Intervention
respirators	32335900	408	419	I-Intervention
during	32335900	420	426	O
simulated	32335900	427	436	O
difficult	32335900	437	446	B-Participant
airway	32335900	447	453	I-Participant
scenarios	32335900	454	463	O
.	32335900	464	465	O

Twenty	32335900	466	472	O
-	32335900	473	474	O
five	32335900	475	479	O
anaesthetists	32335900	480	493	B-Participant
carried	32335900	494	501	O
out	32335900	502	505	O
four	32335900	506	510	O
different	32335900	511	520	O
standardised	32335900	521	533	O
difficult	32335900	534	543	O
intubation	32335900	544	554	O
drills	32335900	555	561	O
,	32335900	562	563	O
either	32335900	564	570	O
unprotected	32335900	571	582	B-Intervention
(	32335900	583	584	O
control	32335900	585	592	O
)	32335900	593	594	O
,	32335900	595	596	O
or	32335900	597	599	O
wearing	32335900	600	607	O
a	32335900	608	609	O
standard	32335900	610	618	B-Intervention
or	32335900	619	621	O
a	32335900	622	623	O
powered	32335900	624	631	B-Intervention
respirator	32335900	632	642	I-Intervention
.	32335900	643	644	O

Treatment	32335900	645	654	B-Outcome
times	32335900	655	660	I-Outcome
and	32335900	661	664	O
wearer	32335900	665	671	B-Outcome
comfort	32335900	672	679	I-Outcome
were	32335900	680	684	O
determined	32335900	685	695	O
and	32335900	696	699	O
compared	32335900	700	708	O
.	32335900	709	710	O

In	32335900	711	713	O
the	32335900	714	717	O
wearer	32335900	718	724	O
comfort	32335900	725	732	O
evaluation	32335900	733	743	O
form	32335900	744	748	O
,	32335900	749	750	O
operators	32335900	751	760	O
rated	32335900	761	766	O
mobility	32335900	767	775	B-Outcome
,	32335900	776	777	O
noise	32335900	778	783	B-Outcome
,	32335900	784	785	O
heat	32335900	786	790	B-Outcome
,	32335900	791	792	O
vision	32335900	793	799	B-Outcome
and	32335900	800	803	O
speech	32335900	804	810	B-Outcome
intelligibility	32335900	811	826	I-Outcome
.	32335900	827	828	O

All	32335900	829	832	O
anaesthetists	32335900	833	846	B-Participant
accomplished	32335900	847	859	O
the	32335900	860	863	O
treatment	32335900	864	873	O
objectives	32335900	874	884	O
of	32335900	885	887	O
all	32335900	888	891	O
study	32335900	892	897	O
arms	32335900	898	902	O
without	32335900	903	910	O
adverse	32335900	911	918	B-Outcome
events	32335900	919	925	I-Outcome
.	32335900	926	927	O

Total	32335900	928	933	B-Outcome
mean	32335900	934	938	I-Outcome
(	32335900	939	940	I-Outcome
SD	32335900	941	943	I-Outcome
)	32335900	944	945	I-Outcome
intubation	32335900	946	956	I-Outcome
times	32335900	957	962	I-Outcome
for	32335900	963	966	O
the	32335900	967	970	O
four	32335900	971	975	O
interventions	32335900	976	989	O
did	32335900	990	993	O
not	32335900	994	997	O
show	32335900	998	1002	O
significant	32335900	1003	1014	B-Observation
differences	32335900	1015	1026	I-Observation
between	32335900	1027	1034	O
the	32335900	1035	1038	O
powered	32335900	1039	1046	B-Intervention
and	32335900	1047	1050	O
the	32335900	1051	1054	O
standard	32335900	1055	1063	B-Intervention
respirator	32335900	1064	1074	I-Intervention
groups	32335900	1075	1081	O
,	32335900	1082	1083	O
being	32335900	1084	1089	O
16.4	32335900	1090	1094	B-Observation
(	32335900	1095	1096	I-Observation
8.6	32335900	1097	1100	I-Observation
)	32335900	1101	1102	I-Observation
vs.	32335900	1103	1106	O
19.2	32335900	1107	1111	B-Observation
(	32335900	1112	1113	I-Observation
5.2	32335900	1114	1117	I-Observation
)	32335900	1118	1119	I-Observation
seconds	32335900	1120	1127	I-Observation
with	32335900	1128	1132	O
the	32335900	1133	1136	O
Airtraq	32335900	1137	1144	O
	32335900	1145	1146	O
;	32335900	1147	1148	O
11.4	32335900	1149	1153	B-Observation
(	32335900	1154	1155	I-Observation
3.4	32335900	1156	1159	I-Observation
)	32335900	1160	1161	I-Observation
vs.	32335900	1162	1165	O
10.0	32335900	1166	1170	B-Observation
(	32335900	1171	1172	I-Observation
2.1	32335900	1173	1176	I-Observation
)	32335900	1177	1178	I-Observation
seconds	32335900	1179	1186	I-Observation
with	32335900	1187	1191	O
the	32335900	1192	1195	O
videolaryngoscope	32335900	1196	1213	B-Participant
;	32335900	1214	1215	O
39.2	32335900	1216	1220	B-Observation
(	32335900	1221	1222	I-Observation
4.5	32335900	1223	1226	I-Observation
)	32335900	1227	1228	I-Observation
vs.	32335900	1229	1232	O
40.1	32335900	1233	1237	B-Observation
(	32335900	1238	1239	I-Observation
4.8	32335900	1240	1243	I-Observation
)	32335900	1244	1245	I-Observation
seconds	32335900	1246	1253	I-Observation
with	32335900	1254	1258	O
the	32335900	1259	1262	O
fibreoptic	32335900	1263	1273	B-Participant
bronchoscope	32335900	1274	1286	I-Participant
scope	32335900	1287	1292	I-Participant
;	32335900	1293	1294	O
and	32335900	1295	1298	O
15.4	32335900	1299	1303	B-Observation
(	32335900	1304	1305	I-Observation
5.7	32335900	1306	1309	I-Observation
)	32335900	1310	1311	I-Observation
vs.	32335900	1312	1315	O
15.1	32335900	1316	1320	B-Observation
(	32335900	1321	1322	I-Observation
5.0	32335900	1323	1326	I-Observation
)	32335900	1327	1328	I-Observation
seconds	32335900	1329	1336	I-Observation
for	32335900	1337	1340	O
standard	32335900	1341	1349	B-Participant
tracheal	32335900	1350	1358	I-Participant
intubation	32335900	1359	1369	I-Participant
by	32335900	1370	1372	I-Participant
direct	32335900	1373	1379	I-Participant
laryngoscopy	32335900	1380	1392	I-Participant
,	32335900	1393	1394	O
respectively	32335900	1395	1407	O
.	32335900	1408	1409	O

Videolaryngoscopy	32335900	1410	1427	B-Intervention
allowed	32335900	1428	1435	O
the	32335900	1436	1439	O
shortest	32335900	1440	1448	B-Observation
intubation	32335900	1449	1459	B-Outcome
times	32335900	1460	1465	I-Outcome
regardless	32335900	1466	1476	O
of	32335900	1477	1479	O
the	32335900	1480	1483	O
respiratory	32335900	1484	1495	O
protective	32335900	1496	1506	O
device	32335900	1507	1513	O
used	32335900	1514	1518	O
.	32335900	1519	1520	O

Anaesthetists	32335900	1521	1534	B-Participant
rated	32335900	1535	1540	O
heat	32335900	1541	1545	B-Outcome
and	32335900	1546	1549	O
vision	32335900	1550	1556	B-Outcome
significantly	32335900	1557	1570	B-Observation
higher	32335900	1571	1577	I-Observation
in	32335900	1578	1580	O
the	32335900	1581	1584	O
powered	32335900	1585	1592	B-Intervention
respirator	32335900	1593	1603	I-Intervention
group	32335900	1604	1609	O
;	32335900	1610	1611	O
however	32335900	1612	1619	O
,	32335900	1620	1621	O
noise	32335900	1622	1627	B-Outcome
levels	32335900	1628	1634	I-Outcome
were	32335900	1635	1639	O
perceived	32335900	1640	1649	O
to	32335900	1650	1652	O
be	32335900	1653	1655	O
significantly	32335900	1656	1669	B-Observation
lower	32335900	1670	1675	I-Observation
than	32335900	1676	1680	O
in	32335900	1681	1683	O
the	32335900	1684	1687	O
standard	32335900	1688	1696	B-Intervention
respirator	32335900	1697	1707	I-Intervention
group	32335900	1708	1713	O
.	32335900	1714	1715	O

We	32335900	1716	1718	O
conclude	32335900	1719	1727	O
that	32335900	1728	1732	O
standard	32335900	1733	1741	B-Intervention
and	32335900	1742	1745	O
powered	32335900	1746	1753	B-Intervention
respirators	32335900	1754	1765	I-Intervention
do	32335900	1766	1768	O
not	32335900	1769	1772	O
significantly	32335900	1773	1786	B-Observation
prolong	32335900	1787	1794	I-Observation
simulated	32335900	1795	1804	B-Outcome
advanced	32335900	1805	1813	I-Outcome
intubation	32335900	1814	1824	I-Outcome
procedures	32335900	1825	1835	I-Outcome
.	32335900	1836	1837	O


Effect	32339248	0	6	O
of	32339248	7	9	O
High	32339248	10	14	B-Intervention
vs	32339248	15	17	I-Intervention
Low	32339248	18	21	I-Intervention
Doses	32339248	22	27	I-Intervention
of	32339248	28	30	I-Intervention
Chloroquine	32339248	31	42	I-Intervention
Diphosphate	32339248	43	54	I-Intervention
as	32339248	55	57	O
Adjunctive	32339248	58	68	O
Therapy	32339248	69	76	O
for	32339248	77	80	O
Patients	32339248	81	89	O
Hospitalized	32339248	90	102	B-Participant
With	32339248	103	107	O
Severe	32339248	108	114	B-Participant
Acute	32339248	115	120	I-Participant
Respiratory	32339248	121	132	I-Participant
Syndrome	32339248	133	141	I-Participant
Coronavirus	32339248	142	153	I-Participant
2	32339248	154	155	I-Participant
(	32339248	156	157	I-Participant
SARS	32339248	158	162	I-Participant
-	32339248	163	164	I-Participant
CoV-2	32339248	165	170	I-Participant
)	32339248	171	172	I-Participant
Infection	32339248	173	182	I-Participant
:	32339248	183	184	O
A	32339248	185	186	O
Randomized	32339248	187	197	O
Clinical	32339248	198	206	O
Trial	32339248	207	212	O
.	32339248	213	214	O

There	32339248	215	220	O
is	32339248	221	223	O
no	32339248	224	226	O
specific	32339248	227	235	O
antiviral	32339248	236	245	O
therapy	32339248	246	253	O
recommended	32339248	254	265	O
for	32339248	266	269	O
coronavirus	32339248	270	281	O
disease	32339248	282	289	O
2019	32339248	290	294	O
(	32339248	295	296	O
COVID-19	32339248	297	305	O
)	32339248	306	307	O
.	32339248	308	309	O

In	32339248	310	312	O
vitro	32339248	313	318	O
studies	32339248	319	326	O
indicate	32339248	327	335	O
that	32339248	336	340	O
the	32339248	341	344	O
antiviral	32339248	345	354	O
effect	32339248	355	361	O
of	32339248	362	364	O
chloroquine	32339248	365	376	O
diphosphate	32339248	377	388	O
(	32339248	389	390	O
CQ	32339248	391	393	O
)	32339248	394	395	O
requires	32339248	396	404	O
a	32339248	405	406	O
high	32339248	407	411	O
concentration	32339248	412	425	O
of	32339248	426	428	O
the	32339248	429	432	O
drug	32339248	433	437	O
.	32339248	438	439	O

To	32339248	440	442	O
evaluate	32339248	443	451	O
the	32339248	452	455	O
safety	32339248	456	462	B-Outcome
and	32339248	463	466	O
efficacy	32339248	467	475	B-Outcome
of	32339248	476	478	O
2	32339248	479	480	B-Intervention
CQ	32339248	481	483	I-Intervention
dosages	32339248	484	491	I-Intervention
in	32339248	492	494	O
patients	32339248	495	503	O
with	32339248	504	508	O
severe	32339248	509	515	B-Participant
COVID-19	32339248	516	524	I-Participant
.	32339248	525	526	O

This	32339248	527	531	O
parallel	32339248	532	540	O
,	32339248	541	542	O
double	32339248	543	549	O
-	32339248	550	551	O
masked	32339248	552	558	O
,	32339248	559	560	O
randomized	32339248	561	571	O
,	32339248	572	573	O
phase	32339248	574	579	O
IIb	32339248	580	583	O
clinical	32339248	584	592	O
trial	32339248	593	598	O
with	32339248	599	603	O
81	32339248	604	606	O
adult	32339248	607	612	O
patients	32339248	613	621	O
who	32339248	622	625	O
were	32339248	626	630	O
hospitalized	32339248	631	643	B-Participant
with	32339248	644	648	O
severe	32339248	649	655	B-Participant
acute	32339248	656	661	I-Participant
respiratory	32339248	662	673	I-Participant
syndrome	32339248	674	682	I-Participant
coronavirus	32339248	683	694	I-Participant
2	32339248	695	696	I-Participant
(	32339248	697	698	I-Participant
SARS	32339248	699	703	I-Participant
-	32339248	704	705	I-Participant
CoV-2	32339248	706	711	I-Participant
)	32339248	712	713	I-Participant
infection	32339248	714	723	I-Participant
was	32339248	724	727	O
conducted	32339248	728	737	O
from	32339248	738	742	O
March	32339248	743	748	O
23	32339248	749	751	O
to	32339248	752	754	O
April	32339248	755	760	O
5	32339248	761	762	O
,	32339248	763	764	O
2020	32339248	765	769	O
,	32339248	770	771	O
at	32339248	772	774	O
a	32339248	775	776	O
tertiary	32339248	777	785	O
care	32339248	786	790	O
facility	32339248	791	799	O
in	32339248	800	802	O
Manaus	32339248	803	809	O
,	32339248	810	811	O
Brazilian	32339248	812	821	O
Amazon	32339248	822	828	O
.	32339248	829	830	O

Patients	32339248	831	839	O
were	32339248	840	844	O
allocated	32339248	845	854	O
to	32339248	855	857	O
receive	32339248	858	865	O
high	32339248	866	870	B-Intervention
-	32339248	871	872	I-Intervention
dosage	32339248	873	879	I-Intervention
CQ	32339248	880	882	I-Intervention
(	32339248	883	884	O
ie	32339248	885	887	O
,	32339248	888	889	O
600	32339248	890	893	O
mg	32339248	894	896	O
CQ	32339248	897	899	O
twice	32339248	900	905	O
daily	32339248	906	911	O
for	32339248	912	915	O
10	32339248	916	918	O
days	32339248	919	923	O
)	32339248	924	925	O
or	32339248	926	928	O
low	32339248	929	932	B-Intervention
-	32339248	933	934	I-Intervention
dosage	32339248	935	941	I-Intervention
CQ	32339248	942	944	I-Intervention
(	32339248	945	946	O
ie	32339248	947	949	O
,	32339248	950	951	O
450	32339248	952	955	O
mg	32339248	956	958	O
twice	32339248	959	964	O
daily	32339248	965	970	O
on	32339248	971	973	O
day	32339248	974	977	O
1	32339248	978	979	O
and	32339248	980	983	O
once	32339248	984	988	O
daily	32339248	989	994	O
for	32339248	995	998	O
4	32339248	999	1000	O
days	32339248	1001	1005	O
)	32339248	1006	1007	O
.	32339248	1008	1009	O

Primary	32339248	1010	1017	O
outcome	32339248	1018	1025	O
was	32339248	1026	1029	O
reduction	32339248	1030	1039	B-Outcome
in	32339248	1040	1042	I-Outcome
lethality	32339248	1043	1052	I-Outcome
by	32339248	1053	1055	I-Outcome
at	32339248	1056	1058	I-Outcome
least	32339248	1059	1064	I-Outcome
50	32339248	1065	1067	I-Outcome
%	32339248	1068	1069	I-Outcome
in	32339248	1070	1072	O
the	32339248	1073	1076	O
high	32339248	1077	1081	B-Intervention
-	32339248	1082	1083	I-Intervention
dosage	32339248	1084	1090	I-Intervention
group	32339248	1091	1096	O
compared	32339248	1097	1105	O
with	32339248	1106	1110	O
the	32339248	1111	1114	O
low	32339248	1115	1118	B-Intervention
-	32339248	1119	1120	I-Intervention
dosage	32339248	1121	1127	I-Intervention
group	32339248	1128	1133	O
.	32339248	1134	1135	O

Data	32339248	1136	1140	O
presented	32339248	1141	1150	O
here	32339248	1151	1155	O
refer	32339248	1156	1161	O
primarily	32339248	1162	1171	O
to	32339248	1172	1174	O
safety	32339248	1175	1181	B-Outcome
and	32339248	1182	1185	O
lethality	32339248	1186	1195	B-Outcome
outcomes	32339248	1196	1204	O
during	32339248	1205	1211	O
treatment	32339248	1212	1221	O
on	32339248	1222	1224	O
day	32339248	1225	1228	O
13	32339248	1229	1231	O
.	32339248	1232	1233	O

Secondary	32339248	1234	1243	O
end	32339248	1244	1247	O
points	32339248	1248	1254	O
included	32339248	1255	1263	O
participant	32339248	1264	1275	O
clinical	32339248	1276	1284	B-Outcome
status	32339248	1285	1291	I-Outcome
,	32339248	1292	1293	O
laboratory	32339248	1294	1304	B-Outcome
examinations	32339248	1305	1317	I-Outcome
,	32339248	1318	1319	O
and	32339248	1320	1323	O
electrocardiogram	32339248	1324	1341	B-Outcome
results	32339248	1342	1349	I-Outcome
.	32339248	1350	1351	O

Outcomes	32339248	1352	1360	O
will	32339248	1361	1365	O
be	32339248	1366	1368	O
presented	32339248	1369	1378	O
to	32339248	1379	1381	O
day	32339248	1382	1385	O
28	32339248	1386	1388	O
.	32339248	1389	1390	O

Viral	32339248	1391	1396	O
respiratory	32339248	1397	1408	O
secretion	32339248	1409	1418	O
RNA	32339248	1419	1422	O
detection	32339248	1423	1432	O
was	32339248	1433	1436	O
performed	32339248	1437	1446	O
on	32339248	1447	1449	O
days	32339248	1450	1454	O
0	32339248	1455	1456	O
and	32339248	1457	1460	O
4	32339248	1461	1462	O
.	32339248	1463	1464	O

Out	32339248	1465	1468	O
of	32339248	1469	1471	O
a	32339248	1472	1473	O
predefined	32339248	1474	1484	O
sample	32339248	1485	1491	O
size	32339248	1492	1496	O
of	32339248	1497	1499	O
440	32339248	1500	1503	O
patients	32339248	1504	1512	O
,	32339248	1513	1514	O
81	32339248	1515	1517	O
were	32339248	1518	1522	O
enrolled	32339248	1523	1531	O
(	32339248	1532	1533	O
41	32339248	1534	1536	O
[	32339248	1537	1538	O
50.6	32339248	1539	1543	O
%	32339248	1544	1545	O
]	32339248	1546	1547	O
to	32339248	1548	1550	O
high	32339248	1551	1555	B-Intervention
-	32339248	1556	1557	I-Intervention
dosage	32339248	1558	1564	I-Intervention
group	32339248	1565	1570	O
and	32339248	1571	1574	O
40	32339248	1575	1577	O
[	32339248	1578	1579	O
49.4	32339248	1580	1584	O
%	32339248	1585	1586	O
]	32339248	1587	1588	O
to	32339248	1589	1591	O
low	32339248	1592	1595	B-Intervention
-	32339248	1596	1597	I-Intervention
dosage	32339248	1598	1604	I-Intervention
group	32339248	1605	1610	O
)	32339248	1611	1612	O
.	32339248	1613	1614	O

Enrolled	32339248	1615	1623	O
patients	32339248	1624	1632	O
had	32339248	1633	1636	O
a	32339248	1637	1638	O
mean	32339248	1639	1643	O
(	32339248	1644	1645	O
SD	32339248	1646	1648	O
)	32339248	1649	1650	O
age	32339248	1651	1654	O
of	32339248	1655	1657	O
51.1	32339248	1658	1662	O
(	32339248	1663	1664	O
13.9	32339248	1665	1669	O
)	32339248	1670	1671	O
years	32339248	1672	1677	O
,	32339248	1678	1679	O
and	32339248	1680	1683	O
most	32339248	1684	1688	O
(	32339248	1689	1690	O
60	32339248	1691	1693	O
[	32339248	1694	1695	O
75.3	32339248	1696	1700	O
%	32339248	1701	1702	O
]	32339248	1703	1704	O
)	32339248	1705	1706	O
were	32339248	1707	1711	O
men	32339248	1712	1715	O
.	32339248	1716	1717	O

Older	32339248	1718	1723	O
age	32339248	1724	1727	O
(	32339248	1728	1729	O
mean	32339248	1730	1734	O
[	32339248	1735	1736	O
SD	32339248	1737	1739	O
]	32339248	1740	1741	O
age	32339248	1742	1745	O
,	32339248	1746	1747	O
54.7	32339248	1748	1752	O
[	32339248	1753	1754	O
13.7	32339248	1755	1759	O
]	32339248	1760	1761	O
years	32339248	1762	1767	O
vs	32339248	1768	1770	O
47.4	32339248	1771	1775	O
[	32339248	1776	1777	O
13.3	32339248	1778	1782	O
]	32339248	1783	1784	O
years	32339248	1785	1790	O
)	32339248	1791	1792	O
and	32339248	1793	1796	O
more	32339248	1797	1801	O
heart	32339248	1802	1807	O
disease	32339248	1808	1815	O
(	32339248	1816	1817	O
5	32339248	1818	1819	O
of	32339248	1820	1822	O
28	32339248	1823	1825	O
[	32339248	1826	1827	O
17.9	32339248	1828	1832	O
%	32339248	1833	1834	O
]	32339248	1835	1836	O
vs	32339248	1837	1839	O
0	32339248	1840	1841	O
)	32339248	1842	1843	O
were	32339248	1844	1848	O
seen	32339248	1849	1853	O
in	32339248	1854	1856	O
the	32339248	1857	1860	O
high	32339248	1861	1865	O
-	32339248	1866	1867	O
dose	32339248	1868	1872	O
group	32339248	1873	1878	O
.	32339248	1879	1880	O

Viral	32339248	1881	1886	B-Outcome
RNA	32339248	1887	1890	I-Outcome
was	32339248	1891	1894	O
detected	32339248	1895	1903	O
in	32339248	1904	1906	O
31	32339248	1907	1909	B-Count
of	32339248	1910	1912	I-Count
40	32339248	1913	1915	I-Count
(	32339248	1916	1917	I-Count
77.5	32339248	1918	1922	I-Count
%	32339248	1923	1924	I-Count
)	32339248	1925	1926	I-Count
and	32339248	1927	1930	O
31	32339248	1931	1933	B-Count
of	32339248	1934	1936	I-Count
41	32339248	1937	1939	I-Count
(	32339248	1940	1941	I-Count
75.6	32339248	1942	1946	I-Count
%	32339248	1947	1948	I-Count
)	32339248	1949	1950	I-Count
patients	32339248	1951	1959	O
in	32339248	1960	1962	O
the	32339248	1963	1966	O
low	32339248	1967	1970	B-Intervention
-	32339248	1971	1972	I-Intervention
dosage	32339248	1973	1979	I-Intervention
and	32339248	1980	1983	O
high	32339248	1984	1988	B-Intervention
-	32339248	1989	1990	I-Intervention
dosage	32339248	1991	1997	I-Intervention
groups	32339248	1998	2004	O
,	32339248	2005	2006	O
respectively	32339248	2007	2019	O
.	32339248	2020	2021	O

Lethality	32339248	2022	2031	B-Outcome
until	32339248	2032	2037	O
day	32339248	2038	2041	O
13	32339248	2042	2044	O
was	32339248	2045	2048	O
39.0	32339248	2049	2053	B-Observation
%	32339248	2054	2055	I-Observation
in	32339248	2056	2058	O
the	32339248	2059	2062	O
high	32339248	2063	2067	B-Intervention
-	32339248	2068	2069	I-Intervention
dosage	32339248	2070	2076	I-Intervention
group	32339248	2077	2082	O
(	32339248	2083	2084	O
16	32339248	2085	2087	B-Count
of	32339248	2088	2090	I-Count
41	32339248	2091	2093	I-Count
)	32339248	2094	2095	O
and	32339248	2096	2099	O
15.0	32339248	2100	2104	B-Observation
%	32339248	2105	2106	I-Observation
in	32339248	2107	2109	O
the	32339248	2110	2113	O
low	32339248	2114	2117	B-Intervention
-	32339248	2118	2119	I-Intervention
dosage	32339248	2120	2126	I-Intervention
group	32339248	2127	2132	O
(	32339248	2133	2134	O
6	32339248	2135	2136	B-Count
of	32339248	2137	2139	I-Count
40	32339248	2140	2142	I-Count
)	32339248	2143	2144	O
.	32339248	2145	2146	O

The	32339248	2147	2150	O
high	32339248	2151	2155	B-Intervention
-	32339248	2156	2157	I-Intervention
dosage	32339248	2158	2164	I-Intervention
group	32339248	2165	2170	O
presented	32339248	2171	2180	O
more	32339248	2181	2185	B-Count
instance	32339248	2186	2194	I-Count
of	32339248	2195	2197	O
QTc	32339248	2198	2201	B-Outcome
interval	32339248	2202	2210	I-Outcome
greater	32339248	2211	2218	I-Outcome
than	32339248	2219	2223	I-Outcome
500	32339248	2224	2227	I-Outcome
milliseconds	32339248	2228	2240	I-Outcome
(	32339248	2241	2242	O
7	32339248	2243	2244	B-Count
of	32339248	2245	2247	I-Count
37	32339248	2248	2250	I-Count
[	32339248	2251	2252	I-Count
18.9	32339248	2253	2257	I-Count
%	32339248	2258	2259	I-Count
]	32339248	2260	2261	I-Count
)	32339248	2262	2263	O
compared	32339248	2264	2272	O
with	32339248	2273	2277	O
the	32339248	2278	2281	O
low	32339248	2282	2285	B-Intervention
-	32339248	2286	2287	I-Intervention
dosage	32339248	2288	2294	I-Intervention
group	32339248	2295	2300	O
(	32339248	2301	2302	O
4	32339248	2303	2304	B-Count
of	32339248	2305	2307	I-Count
36	32339248	2308	2310	I-Count
[	32339248	2311	2312	I-Count
11.1	32339248	2313	2317	I-Count
%	32339248	2318	2319	I-Count
]	32339248	2320	2321	I-Count
)	32339248	2322	2323	O
.	32339248	2324	2325	O

Respiratory	32339248	2326	2337	B-Outcome
secretion	32339248	2338	2347	I-Outcome
at	32339248	2348	2350	I-Outcome
day	32339248	2351	2354	I-Outcome
4	32339248	2355	2356	I-Outcome
was	32339248	2357	2360	O
negative	32339248	2361	2369	B-Observation
in	32339248	2370	2372	O
only	32339248	2373	2377	O
6	32339248	2378	2379	B-Count
of	32339248	2380	2382	I-Count
27	32339248	2383	2385	I-Count
patients	32339248	2386	2394	I-Count
(	32339248	2395	2396	I-Count
22.2	32339248	2397	2401	I-Count
%	32339248	2402	2403	I-Count
)	32339248	2404	2405	I-Count
.	32339248	2406	2407	O

The	32339248	2408	2411	O
preliminary	32339248	2412	2423	O
findings	32339248	2424	2432	O
of	32339248	2433	2435	O
this	32339248	2436	2440	O
study	32339248	2441	2446	O
suggest	32339248	2447	2454	O
that	32339248	2455	2459	O
the	32339248	2460	2463	O
higher	32339248	2464	2470	B-Intervention
CQ	32339248	2471	2473	I-Intervention
dosage	32339248	2474	2480	I-Intervention
should	32339248	2481	2487	O
not	32339248	2488	2491	O
be	32339248	2492	2494	O
recommended	32339248	2495	2506	B-Observation
for	32339248	2507	2510	O
critically	32339248	2511	2521	B-Participant
ill	32339248	2522	2525	I-Participant
patients	32339248	2526	2534	O
with	32339248	2535	2539	O
COVID-19	32339248	2540	2548	B-Participant
because	32339248	2549	2556	O
of	32339248	2557	2559	O
its	32339248	2560	2563	O
potential	32339248	2564	2573	B-Outcome
safety	32339248	2574	2580	I-Outcome
hazards	32339248	2581	2588	I-Outcome
,	32339248	2589	2590	O
especially	32339248	2591	2601	O
when	32339248	2602	2606	O
taken	32339248	2607	2612	O
concurrently	32339248	2613	2625	O
with	32339248	2626	2630	O
azithromycin	32339248	2631	2643	O
and	32339248	2644	2647	O
oseltamivir	32339248	2648	2659	O
.	32339248	2660	2661	O

These	32339248	2662	2667	O
findings	32339248	2668	2676	O
can	32339248	2677	2680	O
not	32339248	2681	2684	O
be	32339248	2685	2687	O
extrapolated	32339248	2688	2700	O
to	32339248	2701	2703	O
patients	32339248	2704	2712	O
with	32339248	2713	2717	O
nonsevere	32339248	2718	2727	O
COVID-19	32339248	2728	2736	O
.	32339248	2737	2738	O

ClinicalTrials.gov	32339248	2739	2757	O
Identifier	32339248	2758	2768	O
:	32339248	2769	2770	O
NCT04323527	32339248	2771	2782	O
.	32339248	2783	2784	O

Respiratory	32379637	0	11	B-Intervention
rehabilitation	32379637	12	26	I-Intervention
in	32379637	27	29	O
elderly	32379637	30	37	B-Participant
patients	32379637	38	46	I-Participant
with	32379637	47	51	O
COVID-19	32379637	52	60	B-Participant
:	32379637	61	62	O
A	32379637	63	64	O
randomized	32379637	65	75	O
controlled	32379637	76	86	O
study	32379637	87	92	O
.	32379637	93	94	O

BACKGROUND	32379637	95	105	O
:	32379637	106	107	O
Different	32379637	108	117	O
degrees	32379637	118	125	O
of	32379637	126	128	O
disorders	32379637	129	138	O
are	32379637	139	142	O
reported	32379637	143	151	O
in	32379637	152	154	O
respiratory	32379637	155	166	O
function	32379637	167	175	O
,	32379637	176	177	O
physical	32379637	178	186	O
function	32379637	187	195	O
and	32379637	196	199	O
psychological	32379637	200	213	O
function	32379637	214	222	O
in	32379637	223	225	O
patients	32379637	226	234	O
with	32379637	235	239	O
corona	32379637	240	246	O
virus	32379637	247	252	O
disease	32379637	253	260	O
2019	32379637	261	265	O
(	32379637	266	267	O
COVID-19	32379637	268	276	O
)	32379637	277	278	O
,	32379637	279	280	O
especially	32379637	281	291	O
in	32379637	292	294	O
elderly	32379637	295	302	O
patients	32379637	303	311	O
.	32379637	312	313	O

With	32379637	314	318	O
the	32379637	319	322	O
experience	32379637	323	333	O
of	32379637	334	336	O
improved	32379637	337	345	O
and	32379637	346	349	O
discharged	32379637	350	360	O
COVID-19	32379637	361	369	O
patients	32379637	370	378	O
,	32379637	379	380	O
timely	32379637	381	387	O
respiratory	32379637	388	399	O
rehabilitation	32379637	400	414	O
intervention	32379637	415	427	O
may	32379637	428	431	O
improve	32379637	432	439	O
prognosis	32379637	440	449	O
,	32379637	450	451	O
maximize	32379637	452	460	O
functional	32379637	461	471	O
preservation	32379637	472	484	O
and	32379637	485	488	O
improve	32379637	489	496	O
quality	32379637	497	504	O
of	32379637	505	507	O
life	32379637	508	512	O
(	32379637	513	514	O
QoL	32379637	515	518	O
)	32379637	519	520	O
,	32379637	521	522	O
but	32379637	523	526	O
there	32379637	527	532	O
lacks	32379637	533	538	O
of	32379637	539	541	O
studies	32379637	542	549	O
worldwide	32379637	550	559	O
exploring	32379637	560	569	O
the	32379637	570	573	O
outcome	32379637	574	581	O
of	32379637	582	584	O
this	32379637	585	589	O
intervention	32379637	590	602	O
.	32379637	603	604	O

OBJECTIVE	32379637	605	614	O
:	32379637	615	616	O
To	32379637	617	619	O
investigate	32379637	620	631	O
the	32379637	632	635	O
effects	32379637	636	643	O
of	32379637	644	646	O
6-week	32379637	647	653	B-Intervention
respiratory	32379637	654	665	I-Intervention
rehabilitation	32379637	666	680	I-Intervention
training	32379637	681	689	I-Intervention
on	32379637	690	692	O
respiratory	32379637	693	704	B-Outcome
function	32379637	705	713	I-Outcome
,	32379637	714	715	O
QoL	32379637	716	719	B-Outcome
,	32379637	720	721	O
mobility	32379637	722	730	B-Outcome
and	32379637	731	734	O
psychological	32379637	735	748	B-Outcome
function	32379637	749	757	I-Outcome
in	32379637	758	760	O
elderly	32379637	761	768	B-Participant
patients	32379637	769	777	I-Participant
with	32379637	778	782	O
COVID-19	32379637	783	791	B-Participant
.	32379637	792	793	O

METHODS	32379637	794	801	O
:	32379637	802	803	O
This	32379637	804	808	O
paper	32379637	809	814	O
reported	32379637	815	823	O
the	32379637	824	827	O
findings	32379637	828	836	O
of	32379637	837	839	O
an	32379637	840	842	O
observational	32379637	843	856	O
,	32379637	857	858	O
prospective	32379637	859	870	O
,	32379637	871	872	O
quasi-experimental	32379637	873	891	O
study	32379637	892	897	O
,	32379637	898	899	O
which	32379637	900	905	O
totally	32379637	906	913	O
recruited	32379637	914	923	O
72	32379637	924	926	O
participants	32379637	927	939	O
,	32379637	940	941	O
of	32379637	942	944	O
which	32379637	945	950	O
36	32379637	951	953	O
patients	32379637	954	962	O
underwent	32379637	963	972	O
respiratory	32379637	973	984	B-Intervention
rehabilitation	32379637	985	999	I-Intervention
and	32379637	1000	1003	O
the	32379637	1004	1007	O
rest	32379637	1008	1012	O
without	32379637	1013	1020	O
any	32379637	1021	1024	O
rehabilitation	32379637	1025	1039	B-Intervention
intervention	32379637	1040	1052	I-Intervention
.	32379637	1053	1054	O

The	32379637	1055	1058	O
following	32379637	1059	1068	O
outcomes	32379637	1069	1077	O
were	32379637	1078	1082	O
measured	32379637	1083	1091	O
:	32379637	1092	1093	O
pulmonary	32379637	1094	1103	B-Outcome
function	32379637	1104	1112	I-Outcome
tests	32379637	1113	1118	I-Outcome
including	32379637	1119	1128	O
plethysmography	32379637	1129	1144	B-Outcome
and	32379637	1145	1148	O
diffusing	32379637	1149	1158	B-Outcome
lung	32379637	1159	1163	I-Outcome
capacity	32379637	1164	1172	I-Outcome
for	32379637	1173	1176	I-Outcome
carbon	32379637	1177	1183	I-Outcome
monoxide	32379637	1184	1192	I-Outcome
(	32379637	1193	1194	I-Outcome
DLCO	32379637	1195	1199	I-Outcome
)	32379637	1200	1201	I-Outcome
,	32379637	1202	1203	O
functional	32379637	1204	1214	B-Outcome
tests	32379637	1215	1220	I-Outcome
(	32379637	1221	1222	I-Outcome
6-min	32379637	1223	1228	I-Outcome
walk	32379637	1229	1233	I-Outcome
distance	32379637	1234	1242	I-Outcome
test	32379637	1243	1247	I-Outcome
)	32379637	1248	1249	I-Outcome
,	32379637	1250	1251	O
Quality	32379637	1252	1259	B-Outcome
of	32379637	1260	1262	I-Outcome
life	32379637	1263	1267	I-Outcome
(	32379637	1268	1269	I-Outcome
QoL	32379637	1270	1273	I-Outcome
)	32379637	1274	1275	I-Outcome
assessments	32379637	1276	1287	I-Outcome
(	32379637	1288	1289	O
SF-36	32379637	1290	1295	B-Outcome
scores	32379637	1296	1302	I-Outcome
)	32379637	1303	1304	O
,	32379637	1305	1306	O
activities	32379637	1307	1317	B-Outcome
of	32379637	1318	1320	I-Outcome
daily	32379637	1321	1326	I-Outcome
living	32379637	1327	1333	I-Outcome
(	32379637	1334	1335	O
Functional	32379637	1336	1346	B-Outcome
Independence	32379637	1347	1359	I-Outcome
Measure	32379637	1360	1367	I-Outcome
,	32379637	1368	1369	O
FIM	32379637	1370	1373	B-Outcome
scores	32379637	1374	1380	I-Outcome
)	32379637	1381	1382	O
,	32379637	1383	1384	O
and	32379637	1385	1388	O
mental	32379637	1389	1395	B-Outcome
status	32379637	1396	1402	I-Outcome
tests	32379637	1403	1408	I-Outcome
(	32379637	1409	1410	O
SAS	32379637	1411	1414	B-Outcome
anxiety	32379637	1415	1422	I-Outcome
and	32379637	1423	1426	I-Outcome
SDS	32379637	1427	1430	I-Outcome
depression	32379637	1431	1441	I-Outcome
scores	32379637	1442	1448	I-Outcome
)	32379637	1449	1450	O
.	32379637	1451	1452	O

RESULTS	32379637	1453	1460	O
:	32379637	1461	1462	O
After	32379637	1463	1468	O
6	32379637	1469	1470	O
weeks	32379637	1471	1476	O
of	32379637	1477	1479	O
respiratory	32379637	1480	1491	B-Intervention
rehabilitation	32379637	1492	1506	I-Intervention
in	32379637	1507	1509	O
the	32379637	1510	1513	O
intervention	32379637	1514	1526	O
group	32379637	1527	1532	O
,	32379637	1533	1534	O
there	32379637	1535	1540	O
disclosed	32379637	1541	1550	B-Observation
significant	32379637	1551	1562	I-Observation
differences	32379637	1563	1574	I-Observation
in	32379637	1575	1577	O
FEV1	32379637	1578	1582	B-Outcome
(	32379637	1583	1584	I-Outcome
L	32379637	1585	1586	I-Outcome
)	32379637	1587	1588	I-Outcome
,	32379637	1589	1590	O
FVC	32379637	1591	1594	B-Outcome
(	32379637	1595	1596	I-Outcome
L	32379637	1597	1598	I-Outcome
)	32379637	1599	1600	I-Outcome
,	32379637	1601	1602	O
FEV1/FVC	32379637	1603	1611	B-Outcome
%	32379637	1612	1613	I-Outcome
,	32379637	1614	1615	O
DLCO	32379637	1616	1620	B-Outcome
%	32379637	1621	1622	I-Outcome
and	32379637	1623	1626	O
6-min	32379637	1627	1632	B-Outcome
walk	32379637	1633	1637	I-Outcome
test	32379637	1638	1642	I-Outcome
.	32379637	1643	1644	O

The	32379637	1645	1648	O
SF-36	32379637	1649	1654	B-Outcome
scores	32379637	1655	1661	I-Outcome
,	32379637	1662	1663	O
in	32379637	1664	1666	O
8	32379637	1667	1668	O
dimensions	32379637	1669	1679	O
,	32379637	1680	1681	O
were	32379637	1682	1686	O
statistically	32379637	1687	1700	B-Observation
significant	32379637	1701	1712	I-Observation
within	32379637	1713	1719	B-Intervention
the	32379637	1720	1723	I-Intervention
intervention	32379637	1724	1736	I-Intervention
group	32379637	1737	1742	O
and	32379637	1743	1746	O
between	32379637	1747	1754	B-Intervention
the	32379637	1755	1758	I-Intervention
two	32379637	1759	1762	I-Intervention
groups	32379637	1763	1769	I-Intervention
.	32379637	1770	1771	O

SAS	32379637	1772	1775	B-Outcome
and	32379637	1776	1779	O
SDS	32379637	1780	1783	B-Outcome
scores	32379637	1784	1790	I-Outcome
in	32379637	1791	1793	O
the	32379637	1794	1797	O
intervention	32379637	1798	1810	B-Intervention
group	32379637	1811	1816	O
decreased	32379637	1817	1826	B-Observation
after	32379637	1827	1832	O
the	32379637	1833	1836	O
intervention	32379637	1837	1849	O
,	32379637	1850	1851	O
but	32379637	1852	1855	O
only	32379637	1856	1860	O
anxiety	32379637	1861	1868	B-Outcome
had	32379637	1869	1872	O
significant	32379637	1873	1884	B-Observation
statistical	32379637	1885	1896	I-Observation
significance	32379637	1897	1909	I-Observation
within	32379637	1910	1916	B-Intervention
and	32379637	1917	1920	I-Intervention
between	32379637	1921	1928	I-Intervention
the	32379637	1929	1932	I-Intervention
two	32379637	1933	1936	I-Intervention
groups	32379637	1937	1943	I-Intervention
.	32379637	1944	1945	O

CONCLUSIONS	32379637	1946	1957	O
:	32379637	1958	1959	O
Six-week	32379637	1960	1968	B-Intervention
respiratory	32379637	1969	1980	I-Intervention
rehabilitation	32379637	1981	1995	I-Intervention
can	32379637	1996	1999	O
improve	32379637	2000	2007	B-Observation
respiratory	32379637	2008	2019	B-Outcome
function	32379637	2020	2028	I-Outcome
,	32379637	2029	2030	O
QoL	32379637	2031	2034	B-Outcome
and	32379637	2035	2038	O
anxiety	32379637	2039	2046	B-Outcome
of	32379637	2047	2049	O
elderly	32379637	2050	2057	B-Participant
patients	32379637	2058	2066	I-Participant
with	32379637	2067	2071	O
COVID-19	32379637	2072	2080	B-Participant
,	32379637	2081	2082	O
but	32379637	2083	2086	O
it	32379637	2087	2089	O
has	32379637	2090	2093	O
little	32379637	2094	2100	B-Observation
significant	32379637	2101	2112	I-Observation
improvement	32379637	2113	2124	I-Observation
on	32379637	2125	2127	O
depression	32379637	2128	2138	B-Outcome
in	32379637	2139	2141	O
the	32379637	2142	2145	O
elderly	32379637	2146	2153	B-Participant
.	32379637	2154	2155	O

Published	32379637	2156	2165	O
by	32379637	2166	2168	O
Elsevier	32379637	2169	2177	O
Ltd	32379637	2178	2181	O
.	32379637	2182	2183	O


Effects	32379667	0	7	O
of	32379667	8	10	O
progressive	32379667	11	22	B-Intervention
muscle	32379667	23	29	I-Intervention
relaxation	32379667	30	40	I-Intervention
on	32379667	41	43	O
anxiety	32379667	44	51	B-Outcome
and	32379667	52	55	O
sleep	32379667	56	61	B-Outcome
quality	32379667	62	69	I-Outcome
in	32379667	70	72	O
patients	32379667	73	81	O
with	32379667	82	86	O
COVID-19	32379667	87	95	B-Participant
.	32379667	96	97	O

BACKGROUND	32379667	98	108	O
:	32379667	109	110	O
Patients	32379667	111	119	O
with	32379667	120	124	O
Coronavirus	32379667	125	136	O
Disease	32379667	137	144	O
2019	32379667	145	149	O
(	32379667	150	151	O
COVID-19	32379667	152	160	O
)	32379667	161	162	O
will	32379667	163	167	O
experience	32379667	168	178	O
high	32379667	179	183	O
levels	32379667	184	190	O
of	32379667	191	193	O
anxiety	32379667	194	201	O
and	32379667	202	205	O
low	32379667	206	209	O
sleep	32379667	210	215	O
quality	32379667	216	223	O
due	32379667	224	227	O
to	32379667	228	230	O
isolation	32379667	231	240	O
treatment	32379667	241	250	O
.	32379667	251	252	O

Some	32379667	253	257	O
sleep-improving	32379667	258	273	O
drugs	32379667	274	279	O
may	32379667	280	283	O
inhibit	32379667	284	291	O
the	32379667	292	295	O
respiratory	32379667	296	307	O
system	32379667	308	314	O
and	32379667	315	318	O
worsen	32379667	319	325	O
the	32379667	326	329	O
condition	32379667	330	339	O
.	32379667	340	341	O

Prolonged	32379667	342	351	O
bedside	32379667	352	359	O
instruction	32379667	360	371	O
may	32379667	372	375	O
increase	32379667	376	384	O
the	32379667	385	388	O
risk	32379667	389	393	O
of	32379667	394	396	O
medical	32379667	397	404	O
infections	32379667	405	415	O
.	32379667	416	417	O

OBJECTIVE	32379667	418	427	O
:	32379667	428	429	O
To	32379667	430	432	O
investigate	32379667	433	444	O
the	32379667	445	448	O
effect	32379667	449	455	O
of	32379667	456	458	O
progressive	32379667	459	470	B-Intervention
muscle	32379667	471	477	I-Intervention
relaxation	32379667	478	488	I-Intervention
on	32379667	489	491	O
anxiety	32379667	492	499	B-Outcome
and	32379667	500	503	O
sleep	32379667	504	509	B-Outcome
quality	32379667	510	517	I-Outcome
of	32379667	518	520	O
COVID-19	32379667	521	529	B-Participant
.	32379667	530	531	O

METHODS	32379667	532	539	O
:	32379667	540	541	O
In	32379667	542	544	O
this	32379667	545	549	O
randomized	32379667	550	560	O
controlled	32379667	561	571	O
clinical	32379667	572	580	O
trial	32379667	581	586	O
,	32379667	587	588	O
a	32379667	589	590	O
total	32379667	591	596	O
of	32379667	597	599	O
51	32379667	600	602	O
patients	32379667	603	611	O
who	32379667	612	615	O
entered	32379667	616	623	O
the	32379667	624	627	O
isolation	32379667	628	637	O
ward	32379667	638	642	O
were	32379667	643	647	O
included	32379667	648	656	O
in	32379667	657	659	O
the	32379667	660	663	O
study	32379667	664	669	O
and	32379667	670	673	O
randomly	32379667	674	682	O
divided	32379667	683	690	O
into	32379667	691	695	O
experimental	32379667	696	708	O
and	32379667	709	712	O
control	32379667	713	720	O
groups	32379667	721	727	O
.	32379667	728	729	O

The	32379667	730	733	O
experimental	32379667	734	746	O
group	32379667	747	752	O
used	32379667	753	757	O
progressive	32379667	758	769	B-Intervention
muscle	32379667	770	776	I-Intervention
relaxation	32379667	777	787	I-Intervention
(	32379667	788	789	I-Intervention
PMR	32379667	790	793	I-Intervention
)	32379667	794	795	I-Intervention
technology	32379667	796	806	I-Intervention
for	32379667	807	810	O
30	32379667	811	813	O
min	32379667	814	817	O
per	32379667	818	821	O
day	32379667	822	825	O
for	32379667	826	829	O
5	32379667	830	831	O
consecutive	32379667	832	843	O
days	32379667	844	848	O
.	32379667	849	850	O

During	32379667	851	857	O
this	32379667	858	862	O
period	32379667	863	869	O
,	32379667	870	871	O
the	32379667	872	875	O
control	32379667	876	883	O
group	32379667	884	889	O
received	32379667	890	898	O
only	32379667	899	903	O
routine	32379667	904	911	B-Intervention
care	32379667	912	916	I-Intervention
and	32379667	917	920	I-Intervention
treatment	32379667	921	930	I-Intervention
.	32379667	931	932	O

Before	32379667	933	939	O
and	32379667	940	943	O
after	32379667	944	949	O
the	32379667	950	953	O
intervention	32379667	954	966	O
,	32379667	967	968	O
the	32379667	969	972	O
Spielberger	32379667	973	984	B-Outcome
State-Trait	32379667	985	996	I-Outcome
Anxiety	32379667	997	1004	I-Outcome
Scale	32379667	1005	1010	I-Outcome
(	32379667	1011	1012	I-Outcome
STAI	32379667	1013	1017	I-Outcome
)	32379667	1018	1019	I-Outcome
and	32379667	1020	1023	O
Sleep	32379667	1024	1029	B-Outcome
State	32379667	1030	1035	I-Outcome
Self-Rating	32379667	1036	1047	I-Outcome
Scale	32379667	1048	1053	I-Outcome
(	32379667	1054	1055	I-Outcome
SRSS	32379667	1056	1060	I-Outcome
)	32379667	1061	1062	I-Outcome
were	32379667	1063	1067	O
used	32379667	1068	1072	O
to	32379667	1073	1075	O
measure	32379667	1076	1083	O
and	32379667	1084	1087	O
record	32379667	1088	1094	O
patient	32379667	1095	1102	O
anxiety	32379667	1103	1110	B-Outcome
and	32379667	1111	1114	O
sleep	32379667	1115	1120	B-Outcome
quality	32379667	1121	1128	I-Outcome
.	32379667	1129	1130	O

Finally	32379667	1131	1138	O
,	32379667	1139	1140	O
data	32379667	1141	1145	O
analysis	32379667	1146	1154	O
was	32379667	1155	1158	O
performed	32379667	1159	1168	O
using	32379667	1169	1174	O
SPSS	32379667	1175	1179	O
25.0	32379667	1180	1184	O
software	32379667	1185	1193	O
.	32379667	1194	1195	O

RESULTS	32379667	1196	1203	O
:	32379667	1204	1205	O
The	32379667	1206	1209	O
average	32379667	1210	1217	B-Outcome
anxiety	32379667	1218	1225	I-Outcome
score	32379667	1226	1231	I-Outcome
(	32379667	1232	1233	I-Outcome
STAI	32379667	1234	1238	I-Outcome
)	32379667	1239	1240	I-Outcome
before	32379667	1241	1247	O
intervention	32379667	1248	1260	B-Intervention
was	32379667	1261	1264	O
not	32379667	1265	1268	O
statistically	32379667	1269	1282	B-Observation
significant	32379667	1283	1294	I-Observation
(	32379667	1295	1296	O
P	32379667	1297	1298	O
=	32379667	1299	1300	O
0.730	32379667	1301	1306	O
)	32379667	1307	1308	O
,	32379667	1309	1310	O
and	32379667	1311	1314	O
the	32379667	1315	1318	O
average	32379667	1319	1326	B-Outcome
anxiety	32379667	1327	1334	I-Outcome
score	32379667	1335	1340	I-Outcome
after	32379667	1341	1346	B-Intervention
intervention	32379667	1347	1359	I-Intervention
was	32379667	1360	1363	O
statistically	32379667	1364	1377	B-Observation
significant	32379667	1378	1389	I-Observation
(	32379667	1390	1391	O
P	32379667	1392	1393	O
<	32379667	1394	1395	O
0.001	32379667	1396	1401	O
)	32379667	1402	1403	O
.	32379667	1404	1405	O

The	32379667	1406	1409	O
average	32379667	1410	1417	B-Outcome
sleep	32379667	1418	1423	I-Outcome
quality	32379667	1424	1431	I-Outcome
score	32379667	1432	1437	I-Outcome
(	32379667	1438	1439	I-Outcome
SRSS	32379667	1440	1444	I-Outcome
)	32379667	1445	1446	I-Outcome
of	32379667	1447	1449	O
the	32379667	1450	1453	O
two	32379667	1454	1457	O
groups	32379667	1458	1464	O
before	32379667	1465	1471	O
intervention	32379667	1472	1484	B-Intervention
was	32379667	1485	1488	O
not	32379667	1489	1492	O
statistically	32379667	1493	1506	B-Observation
significant	32379667	1507	1518	I-Observation
(	32379667	1519	1520	O
P	32379667	1521	1522	O
=	32379667	1523	1524	O
0.838	32379667	1525	1530	O
)	32379667	1531	1532	O
,	32379667	1533	1534	O
and	32379667	1535	1538	O
it	32379667	1539	1541	O
was	32379667	1542	1545	O
statistically	32379667	1546	1559	B-Observation
significant	32379667	1560	1571	I-Observation
after	32379667	1572	1577	O
intervention	32379667	1578	1590	B-Intervention
(	32379667	1591	1592	O
P	32379667	1593	1594	O
<	32379667	1595	1596	O
0.001	32379667	1597	1602	O
)	32379667	1603	1604	O
.	32379667	1605	1606	O

CONCLUSIONS	32379667	1607	1618	O
:	32379667	1619	1620	O
Progressive	32379667	1621	1632	B-Intervention
muscle	32379667	1633	1639	I-Intervention
relaxation	32379667	1640	1650	I-Intervention
as	32379667	1651	1653	O
an	32379667	1654	1656	O
auxiliary	32379667	1657	1666	O
method	32379667	1667	1673	O
can	32379667	1674	1677	O
reduce	32379667	1678	1684	B-Observation
anxiety	32379667	1685	1692	B-Outcome
and	32379667	1693	1696	O
improve	32379667	1697	1704	B-Observation
sleep	32379667	1705	1710	B-Outcome
quality	32379667	1711	1718	I-Outcome
in	32379667	1719	1721	O
patients	32379667	1722	1730	O
with	32379667	1731	1735	O
COVID-19	32379667	1736	1744	B-Participant
.	32379667	1745	1746	O


Observational	32379955	0	13	O
Study	32379955	14	19	O
of	32379955	20	22	O
Hydroxychloroquine	32379955	23	41	B-Intervention
in	32379955	42	44	O
Hospitalized	32379955	45	57	B-Participant
Patients	32379955	58	66	I-Participant
with	32379955	67	71	O
Covid-19	32379955	72	80	B-Participant
.	32379955	80	81	O

BACKGROUND	32379955	82	92	O
:	32379955	93	94	O
Hydroxychloroquine	32379955	95	113	O
has	32379955	114	117	O
been	32379955	118	122	O
widely	32379955	123	129	O
administered	32379955	130	142	O
to	32379955	143	145	O
patients	32379955	146	154	O
with	32379955	155	159	O
Covid-19	32379955	160	168	O
without	32379955	169	176	O
robust	32379955	177	183	O
evidence	32379955	184	192	O
supporting	32379955	193	203	O
its	32379955	204	207	O
use	32379955	208	211	O
.	32379955	212	213	O

METHODS	32379955	214	221	O
:	32379955	222	223	O
We	32379955	224	226	O
examined	32379955	227	235	O
the	32379955	236	239	O
association	32379955	240	251	B-Observation
between	32379955	252	259	O
hydroxychloroquine	32379955	260	278	B-Intervention
use	32379955	279	282	I-Intervention
and	32379955	283	286	O
intubation	32379955	287	297	B-Outcome
or	32379955	298	300	O
death	32379955	301	306	B-Outcome
at	32379955	307	309	O
a	32379955	310	311	O
large	32379955	312	317	O
medical	32379955	318	325	O
center	32379955	326	332	O
in	32379955	333	335	O
New	32379955	336	339	O
York	32379955	340	344	O
City	32379955	345	349	O
.	32379955	350	351	O

Data	32379955	352	356	O
were	32379955	357	361	O
obtained	32379955	362	370	O
regarding	32379955	371	380	O
consecutive	32379955	381	392	O
patients	32379955	393	401	O
hospitalized	32379955	402	414	B-Participant
with	32379955	415	419	O
Covid-19	32379955	420	428	B-Participant
,	32379955	429	430	O
excluding	32379955	431	440	O
those	32379955	441	446	O
who	32379955	447	450	O
were	32379955	451	455	O
intubated	32379955	456	465	B-Participant
,	32379955	466	467	O
died	32379955	468	472	B-Participant
,	32379955	473	474	O
or	32379955	475	477	O
discharged	32379955	478	488	B-Participant
within	32379955	489	495	O
24	32379955	496	498	O
hours	32379955	499	504	O
after	32379955	505	510	O
presentation	32379955	511	523	O
to	32379955	524	526	O
the	32379955	527	530	O
emergency	32379955	531	540	O
department	32379955	541	551	O
(	32379955	552	553	O
study	32379955	554	559	O
baseline	32379955	560	568	O
)	32379955	569	570	O
.	32379955	571	572	O

The	32379955	573	576	O
primary	32379955	577	584	O
end	32379955	585	588	O
point	32379955	589	594	O
was	32379955	595	598	O
a	32379955	599	600	O
composite	32379955	601	610	B-Outcome
of	32379955	611	613	I-Outcome
intubation	32379955	614	624	I-Outcome
or	32379955	625	627	I-Outcome
death	32379955	628	633	I-Outcome
in	32379955	634	636	O
a	32379955	637	638	O
time-to-event	32379955	639	652	O
analysis	32379955	653	661	O
.	32379955	662	663	O

We	32379955	664	666	O
compared	32379955	667	675	O
outcomes	32379955	676	684	B-Outcome
in	32379955	685	687	O
patients	32379955	688	696	O
who	32379955	697	700	O
received	32379955	701	709	O
hydroxychloroquine	32379955	710	728	B-Intervention
with	32379955	729	733	O
those	32379955	734	739	O
in	32379955	740	742	O
patients	32379955	743	751	O
who	32379955	752	755	O
did	32379955	756	759	O
not	32379955	760	763	B-Intervention
,	32379955	764	765	O
using	32379955	766	771	O
a	32379955	772	773	O
multivariable	32379955	774	787	O
Cox	32379955	788	791	O
model	32379955	792	797	O
with	32379955	798	802	O
inverse	32379955	803	810	O
probability	32379955	811	822	O
weighting	32379955	823	832	O
according	32379955	833	842	O
to	32379955	843	845	O
the	32379955	846	849	O
propensity	32379955	850	860	O
score	32379955	861	866	O
.	32379955	867	868	O

RESULTS	32379955	869	876	O
:	32379955	877	878	O
Of	32379955	879	881	O
1446	32379955	882	886	O
consecutive	32379955	887	898	O
patients	32379955	899	907	O
,	32379955	908	909	O
70	32379955	910	912	O
patients	32379955	913	921	O
were	32379955	922	926	O
intubated	32379955	927	936	B-Participant
,	32379955	937	938	O
died	32379955	939	943	B-Participant
,	32379955	944	945	O
or	32379955	946	948	O
discharged	32379955	949	959	B-Participant
within	32379955	960	966	O
24	32379955	967	969	O
hours	32379955	970	975	O
after	32379955	976	981	O
presentation	32379955	982	994	O
and	32379955	995	998	O
were	32379955	999	1003	O
excluded	32379955	1004	1012	O
from	32379955	1013	1017	O
the	32379955	1018	1021	O
analysis	32379955	1022	1030	O
.	32379955	1031	1032	O

Of	32379955	1033	1035	O
the	32379955	1036	1039	O
remaining	32379955	1040	1049	O
1376	32379955	1050	1054	O
patients	32379955	1055	1063	O
,	32379955	1064	1065	O
during	32379955	1066	1072	O
a	32379955	1073	1074	O
median	32379955	1075	1081	O
follow-up	32379955	1082	1091	O
of	32379955	1092	1094	O
22.5	32379955	1095	1099	O
days	32379955	1100	1104	O
,	32379955	1105	1106	O
811	32379955	1107	1110	O
(	32379955	1111	1112	O
58.9	32379955	1113	1117	O
%	32379955	1118	1119	O
)	32379955	1120	1121	O
received	32379955	1122	1130	O
hydroxychloroquine	32379955	1131	1149	B-Intervention
(	32379955	1150	1151	O
600	32379955	1152	1155	O
mg	32379955	1156	1158	O
twice	32379955	1159	1164	O
on	32379955	1165	1167	O
day	32379955	1168	1171	O
1	32379955	1172	1173	O
,	32379955	1174	1175	O
then	32379955	1176	1180	O
400	32379955	1181	1184	O
mg	32379955	1185	1187	O
daily	32379955	1188	1193	O
for	32379955	1194	1197	O
a	32379955	1198	1199	O
median	32379955	1200	1206	O
of	32379955	1207	1209	O
5	32379955	1210	1211	O
days	32379955	1212	1216	O
)	32379955	1217	1218	O
;	32379955	1219	1220	O
45.8	32379955	1221	1225	O
%	32379955	1226	1227	O
of	32379955	1228	1230	O
the	32379955	1231	1234	O
patients	32379955	1235	1243	O
were	32379955	1244	1248	O
treated	32379955	1249	1256	O
within	32379955	1257	1263	O
24	32379955	1264	1266	O
hours	32379955	1267	1272	O
after	32379955	1273	1278	O
presentation	32379955	1279	1291	O
to	32379955	1292	1294	O
the	32379955	1295	1298	O
emergency	32379955	1299	1308	O
department	32379955	1309	1319	O
,	32379955	1320	1321	O
and	32379955	1322	1325	O
85.9	32379955	1326	1330	O
%	32379955	1331	1332	O
within	32379955	1333	1339	O
48	32379955	1340	1342	O
hours	32379955	1343	1348	O
.	32379955	1349	1350	O

Hydroxychloroquine-treated	32379955	1351	1377	B-Intervention
patients	32379955	1378	1386	O
were	32379955	1387	1391	O
more	32379955	1392	1396	B-Observation
severely	32379955	1397	1405	B-Outcome
ill	32379955	1406	1409	I-Outcome
at	32379955	1410	1412	O
baseline	32379955	1413	1421	O
than	32379955	1422	1426	O
those	32379955	1427	1432	O
who	32379955	1433	1436	O
did	32379955	1437	1440	O
not	32379955	1441	1444	O
receive	32379955	1445	1452	O
hydroxychloroquine	32379955	1453	1471	B-Intervention
(	32379955	1472	1473	O
median	32379955	1474	1480	B-Outcome
ratio	32379955	1481	1486	I-Outcome
of	32379955	1487	1489	I-Outcome
partial	32379955	1490	1497	I-Outcome
pressure	32379955	1498	1506	I-Outcome
of	32379955	1507	1509	I-Outcome
arterial	32379955	1510	1518	I-Outcome
oxygen	32379955	1519	1525	I-Outcome
to	32379955	1526	1528	I-Outcome
the	32379955	1529	1532	I-Outcome
fraction	32379955	1533	1541	I-Outcome
of	32379955	1542	1544	I-Outcome
inspired	32379955	1545	1553	I-Outcome
oxygen	32379955	1554	1560	I-Outcome
,	32379955	1561	1562	O
223	32379955	1563	1566	B-Observation
vs.	32379955	1567	1570	O
360	32379955	1571	1574	B-Observation
)	32379955	1575	1576	O
.	32379955	1577	1578	O

Overall	32379955	1579	1586	O
,	32379955	1587	1588	O
346	32379955	1589	1592	B-Count
patients	32379955	1593	1601	I-Count
(	32379955	1602	1603	I-Count
25.1	32379955	1604	1608	I-Count
%	32379955	1609	1610	I-Count
)	32379955	1611	1612	I-Count
had	32379955	1613	1616	O
a	32379955	1617	1618	O
primary	32379955	1619	1626	B-Outcome
end-point	32379955	1627	1636	I-Outcome
event	32379955	1637	1642	I-Outcome
(	32379955	1643	1644	O
180	32379955	1645	1648	B-Count
patients	32379955	1649	1657	I-Count
were	32379955	1658	1662	O
intubated	32379955	1663	1672	B-Outcome
,	32379955	1673	1674	O
of	32379955	1675	1677	O
whom	32379955	1678	1682	O
66	32379955	1683	1685	B-Count
subsequently	32379955	1686	1698	B-Outcome
died	32379955	1699	1703	I-Outcome
,	32379955	1704	1705	O
and	32379955	1706	1709	O
166	32379955	1710	1713	B-Count
died	32379955	1714	1718	B-Outcome
without	32379955	1719	1726	I-Outcome
intubation	32379955	1727	1737	I-Outcome
)	32379955	1738	1739	O
.	32379955	1740	1741	O

In	32379955	1742	1744	O
the	32379955	1745	1748	O
main	32379955	1749	1753	O
analysis	32379955	1754	1762	O
,	32379955	1763	1764	O
there	32379955	1765	1770	O
was	32379955	1771	1774	O
no	32379955	1775	1777	O
significant	32379955	1778	1789	B-Observation
association	32379955	1790	1801	I-Observation
between	32379955	1802	1809	O
hydroxychloroquine	32379955	1810	1828	B-Intervention
use	32379955	1829	1832	I-Intervention
and	32379955	1833	1836	O
intubation	32379955	1837	1847	B-Outcome
or	32379955	1848	1850	O
death	32379955	1851	1856	B-Outcome
(	32379955	1857	1858	O
hazard	32379955	1859	1865	O
ratio	32379955	1866	1871	O
,	32379955	1872	1873	O
1.04	32379955	1874	1878	O
,	32379955	1879	1880	O
95	32379955	1881	1883	O
%	32379955	1884	1885	O
confidence	32379955	1886	1896	O
interval	32379955	1897	1905	O
,	32379955	1906	1907	O
0.82	32379955	1908	1912	O
to	32379955	1913	1915	O
1.32	32379955	1916	1920	O
)	32379955	1921	1922	O
.	32379955	1923	1924	O

Results	32379955	1925	1932	O
were	32379955	1933	1937	O
similar	32379955	1938	1945	O
in	32379955	1946	1948	O
multiple	32379955	1949	1957	O
sensitivity	32379955	1958	1969	O
analyses	32379955	1970	1978	O
.	32379955	1979	1980	O

CONCLUSIONS	32379955	1981	1992	O
:	32379955	1993	1994	O
In	32379955	1995	1997	O
this	32379955	1998	2002	O
observational	32379955	2003	2016	O
study	32379955	2017	2022	O
involving	32379955	2023	2032	O
patients	32379955	2033	2041	O
with	32379955	2042	2046	O
Covid-19	32379955	2047	2055	B-Participant
who	32379955	2056	2059	O
had	32379955	2060	2063	O
been	32379955	2064	2068	O
admitted	32379955	2069	2077	B-Participant
to	32379955	2078	2080	I-Participant
the	32379955	2081	2084	I-Participant
hospital	32379955	2085	2093	I-Participant
,	32379955	2094	2095	O
hydroxychloroquine	32379955	2096	2114	B-Intervention
administration	32379955	2115	2129	I-Intervention
was	32379955	2130	2133	O
not	32379955	2134	2137	O
associated	32379955	2138	2148	O
with	32379955	2149	2153	O
either	32379955	2154	2160	O
a	32379955	2161	2162	O
greatly	32379955	2163	2170	B-Observation
lowered	32379955	2171	2178	I-Observation
or	32379955	2179	2181	I-Observation
an	32379955	2182	2184	I-Observation
increased	32379955	2185	2194	I-Observation
risk	32379955	2195	2199	B-Outcome
of	32379955	2200	2202	I-Outcome
the	32379955	2203	2206	I-Outcome
composite	32379955	2207	2216	I-Outcome
end	32379955	2217	2220	I-Outcome
point	32379955	2221	2226	I-Outcome
of	32379955	2227	2229	I-Outcome
intubation	32379955	2230	2240	I-Outcome
or	32379955	2241	2243	I-Outcome
death	32379955	2244	2249	I-Outcome
.	32379955	2250	2251	O

Randomized	32379955	2252	2262	O
,	32379955	2263	2264	O
controlled	32379955	2265	2275	O
trials	32379955	2276	2282	O
of	32379955	2283	2285	O
hydroxychloroquine	32379955	2286	2304	O
in	32379955	2305	2307	O
patients	32379955	2308	2316	O
with	32379955	2317	2321	O
Covid-19	32379955	2322	2330	O
are	32379955	2331	2334	O
needed	32379955	2335	2341	O
.	32379955	2342	2343	O
(	32379955	2344	2345	O
Funded	32379955	2346	2352	O
by	32379955	2353	2355	O
the	32379955	2356	2359	O
National	32379955	2360	2368	O
Institutes	32379955	2369	2379	O
of	32379955	2380	2382	O
Health	32379955	2383	2389	O
.	32379955	2390	2391	O
)	32379955	2392	2393	O
.	32379955	2394	2395	O


Post	32383125	0	4	B-Outcome
-	32383125	5	6	I-Outcome
exposure	32383125	7	15	I-Outcome
prophylaxis	32383125	16	27	I-Outcome
or	32383125	28	30	O
pre	32383125	31	34	B-Outcome
-	32383125	35	36	I-Outcome
emptive	32383125	37	44	I-Outcome
therapy	32383125	45	52	I-Outcome
for	32383125	53	56	O
severe	32383125	57	63	B-Participant
acute	32383125	64	69	I-Participant
respiratory	32383125	70	81	I-Participant
syndrome	32383125	82	90	I-Participant
coronavirus	32383125	91	102	I-Participant
2	32383125	103	104	I-Participant
(	32383125	105	106	I-Participant
SARS	32383125	107	111	I-Participant
-	32383125	112	113	I-Participant
CoV-2	32383125	114	119	I-Participant
)	32383125	120	121	I-Participant
:	32383125	122	123	O
study	32383125	124	129	O
protocol	32383125	130	138	O
for	32383125	139	142	O
a	32383125	143	144	O
pragmatic	32383125	145	154	O
randomized	32383125	155	165	O
-	32383125	166	167	O
controlled	32383125	168	178	O
trial	32383125	179	184	O
.	32383125	185	186	O

The	32383125	187	190	O
severe	32383125	191	197	O
acute	32383125	198	203	O
respiratory	32383125	204	215	O
syndrome	32383125	216	224	O
coronavirus	32383125	225	236	O
2	32383125	237	238	O
(	32383125	239	240	O
SARS	32383125	241	245	O
-	32383125	246	247	O
CoV-2	32383125	248	253	O
)	32383125	254	255	O
emerged	32383125	256	263	O
in	32383125	264	266	O
December	32383125	267	275	O
2019	32383125	276	280	O
causing	32383125	281	288	O
the	32383125	289	292	O
coronavirus	32383125	293	304	O
disease	32383125	305	312	O
(	32383125	313	314	O
COVID-19	32383125	315	323	O
)	32383125	324	325	O
pandemic	32383125	326	334	O
.	32383125	335	336	O

Currently	32383125	337	346	O
,	32383125	347	348	O
there	32383125	349	354	O
is	32383125	355	357	O
a	32383125	358	359	O
lack	32383125	360	364	O
of	32383125	365	367	O
evidence	32383125	368	376	O
-	32383125	377	378	O
based	32383125	379	384	O
therapies	32383125	385	394	O
to	32383125	395	397	O
prevent	32383125	398	405	O
COVID-19	32383125	406	414	O
following	32383125	415	424	O
exposure	32383125	425	433	O
to	32383125	434	436	O
the	32383125	437	440	O
virus	32383125	441	446	O
,	32383125	447	448	O
or	32383125	449	451	O
to	32383125	452	454	O
prevent	32383125	455	462	O
worsening	32383125	463	472	O
of	32383125	473	475	O
symptoms	32383125	476	484	O
following	32383125	485	494	O
confirmed	32383125	495	504	O
infection	32383125	505	514	O
.	32383125	515	516	O

We	32383125	517	519	O
describe	32383125	520	528	O
the	32383125	529	532	O
design	32383125	533	539	O
of	32383125	540	542	O
a	32383125	543	544	O
clinical	32383125	545	553	O
trial	32383125	554	559	O
of	32383125	560	562	O
hydroxychloroquine	32383125	563	581	B-Intervention
for	32383125	582	585	O
post	32383125	586	590	B-Outcome
-	32383125	591	592	I-Outcome
exposure	32383125	593	601	I-Outcome
prophylaxis	32383125	602	613	I-Outcome
(	32383125	614	615	I-Outcome
PEP	32383125	616	619	I-Outcome
)	32383125	620	621	I-Outcome
and	32383125	622	625	O
pre	32383125	626	629	B-Outcome
-	32383125	630	631	I-Outcome
emptive	32383125	632	639	I-Outcome
therapy	32383125	640	647	I-Outcome
(	32383125	648	649	I-Outcome
PET	32383125	650	653	I-Outcome
)	32383125	654	655	I-Outcome
for	32383125	656	659	O
COVID-19	32383125	660	668	B-Participant
.	32383125	669	670	O

We	32383125	671	673	O
will	32383125	674	678	O
conduct	32383125	679	686	O
two	32383125	687	690	O
nested	32383125	691	697	O
multicentre	32383125	698	709	O
international	32383125	710	723	O
double	32383125	724	730	O
-	32383125	731	732	O
blind	32383125	733	738	O
randomized	32383125	739	749	O
placebo	32383125	750	757	O
-	32383125	758	759	O
controlled	32383125	760	770	O
clinical	32383125	771	779	O
trials	32383125	780	786	O
of	32383125	787	789	O
hydroxychloroquine	32383125	790	808	B-Intervention
for	32383125	809	812	O
:	32383125	813	814	O
1	32383125	815	816	O
)	32383125	817	818	O
PEP	32383125	819	822	B-Outcome
of	32383125	823	825	O
asymptomatic	32383125	826	838	B-Participant
household	32383125	839	848	I-Participant
contacts	32383125	849	857	I-Participant
or	32383125	858	860	O
healthcare	32383125	861	871	B-Participant
workers	32383125	872	879	I-Participant
exposed	32383125	880	887	I-Participant
to	32383125	888	890	I-Participant
COVID-19	32383125	891	899	I-Participant
within	32383125	900	906	I-Participant
the	32383125	907	910	I-Participant
past	32383125	911	915	I-Participant
four	32383125	916	920	I-Participant
days	32383125	921	925	I-Participant
,	32383125	926	927	O
and	32383125	928	931	O
2	32383125	932	933	O
)	32383125	934	935	O
PET	32383125	936	939	B-Outcome
for	32383125	940	943	O
symptomatic	32383125	944	955	B-Participant
outpatients	32383125	956	967	I-Participant
with	32383125	968	972	I-Participant
COVID-19	32383125	973	981	I-Participant
showing	32383125	982	989	I-Participant
symptoms	32383125	990	998	I-Participant
for	32383125	999	1002	I-Participant
less	32383125	1003	1007	I-Participant
than	32383125	1008	1012	I-Participant
four	32383125	1013	1017	I-Participant
days	32383125	1018	1022	I-Participant
.	32383125	1023	1024	O

We	32383125	1025	1027	O
will	32383125	1028	1032	O
recruit	32383125	1033	1040	O
1,500	32383125	1041	1046	O
patients	32383125	1047	1055	O
each	32383125	1056	1060	O
for	32383125	1061	1064	O
the	32383125	1065	1068	O
PEP	32383125	1069	1072	O
and	32383125	1073	1076	O
PET	32383125	1077	1080	O
trials	32383125	1081	1087	O
.	32383125	1088	1089	O

Participants	32383125	1090	1102	O
will	32383125	1103	1107	O
be	32383125	1108	1110	O
randomized	32383125	1111	1121	O
1:1	32383125	1122	1125	O
to	32383125	1126	1128	O
receive	32383125	1129	1136	O
five	32383125	1137	1141	O
days	32383125	1142	1146	O
of	32383125	1147	1149	O
hydroxychloroquine	32383125	1150	1168	B-Intervention
or	32383125	1169	1171	O
placebo	32383125	1172	1179	B-Intervention
.	32383125	1180	1181	O

The	32383125	1182	1185	O
primary	32383125	1186	1193	O
PEP	32383125	1194	1197	O
trial	32383125	1198	1203	O
outcome	32383125	1204	1211	O
will	32383125	1212	1216	O
be	32383125	1217	1219	O
the	32383125	1220	1223	O
incidence	32383125	1224	1233	B-Outcome
of	32383125	1234	1236	I-Outcome
symptomatic	32383125	1237	1248	I-Outcome
COVID-19	32383125	1249	1257	I-Outcome
.	32383125	1258	1259	O

The	32383125	1260	1263	O
primary	32383125	1264	1271	O
PET	32383125	1272	1275	O
trial	32383125	1276	1281	O
outcome	32383125	1282	1289	O
will	32383125	1290	1294	O
be	32383125	1295	1297	O
an	32383125	1298	1300	O
ordinal	32383125	1301	1308	B-Outcome
scale	32383125	1309	1314	I-Outcome
of	32383125	1315	1317	I-Outcome
disease	32383125	1318	1325	I-Outcome
severity	32383125	1326	1334	I-Outcome
(	32383125	1335	1336	O
not	32383125	1337	1340	B-Outcome
hospitalized	32383125	1341	1353	I-Outcome
,	32383125	1354	1355	O
hospitalized	32383125	1356	1368	B-Outcome
without	32383125	1369	1376	I-Outcome
intensive	32383125	1377	1386	I-Outcome
care	32383125	1387	1391	I-Outcome
,	32383125	1392	1393	O
hospitalization	32383125	1394	1409	B-Outcome
with	32383125	1410	1414	I-Outcome
intensive	32383125	1415	1424	I-Outcome
care	32383125	1425	1429	I-Outcome
,	32383125	1430	1431	O
or	32383125	1432	1434	O
death	32383125	1435	1440	B-Outcome
)	32383125	1441	1442	O
.	32383125	1443	1444	O

Participant	32383125	1445	1456	O
screening	32383125	1457	1466	O
,	32383125	1467	1468	O
informed	32383125	1469	1477	O
consent	32383125	1478	1485	O
,	32383125	1486	1487	O
and	32383125	1488	1491	O
follow	32383125	1492	1498	O
-	32383125	1499	1500	O
up	32383125	1501	1503	O
will	32383125	1504	1508	O
be	32383125	1509	1511	O
exclusively	32383125	1512	1523	O
internet	32383125	1524	1532	O
-	32383125	1533	1534	O
based	32383125	1535	1540	O
with	32383125	1541	1545	O
appropriate	32383125	1546	1557	O
regulatory	32383125	1558	1568	O
and	32383125	1569	1572	O
research	32383125	1573	1581	O
ethics	32383125	1582	1588	O
board	32383125	1589	1594	O
approvals	32383125	1595	1604	O
in	32383125	1605	1607	O
Canada	32383125	1608	1614	O
and	32383125	1615	1618	O
the	32383125	1619	1622	O
United	32383125	1623	1629	O
States	32383125	1630	1636	O
.	32383125	1637	1638	O

These	32383125	1639	1644	O
complementary	32383125	1645	1658	O
randomized	32383125	1659	1669	O
-	32383125	1670	1671	O
controlled	32383125	1672	1682	O
trials	32383125	1683	1689	O
are	32383125	1690	1693	O
innovatively	32383125	1694	1706	O
designed	32383125	1707	1715	O
and	32383125	1716	1719	O
adequately	32383125	1720	1730	O
powered	32383125	1731	1738	O
to	32383125	1739	1741	O
rapidly	32383125	1742	1749	O
answer	32383125	1750	1756	O
urgent	32383125	1757	1763	O
questions	32383125	1764	1773	O
regarding	32383125	1774	1783	O
the	32383125	1784	1787	O
effectiveness	32383125	1788	1801	O
of	32383125	1802	1804	O
hydroxychloroquine	32383125	1805	1823	B-Intervention
to	32383125	1824	1826	O
reduce	32383125	1827	1833	B-Observation
virus	32383125	1834	1839	B-Outcome
transmission	32383125	1840	1852	I-Outcome
and	32383125	1853	1856	O
disease	32383125	1857	1864	B-Outcome
severity	32383125	1865	1873	I-Outcome
of	32383125	1874	1876	O
COVID-19	32383125	1877	1885	B-Participant
during	32383125	1886	1892	O
a	32383125	1893	1894	O
pandemic	32383125	1895	1903	O
.	32383125	1904	1905	O

In	32383125	1906	1908	O
-	32383125	1909	1910	O
person	32383125	1911	1917	O
participant	32383125	1918	1929	O
follow	32383125	1930	1936	O
-	32383125	1937	1938	O
up	32383125	1939	1941	O
will	32383125	1942	1946	O
not	32383125	1947	1950	O
be	32383125	1951	1953	O
conducted	32383125	1954	1963	O
to	32383125	1964	1966	O
facilitate	32383125	1967	1977	O
social	32383125	1978	1984	O
distancing	32383125	1985	1995	O
strategies	32383125	1996	2006	O
and	32383125	2007	2010	O
reduce	32383125	2011	2017	O
risks	32383125	2018	2023	O
of	32383125	2024	2026	O
exposure	32383125	2027	2035	O
to	32383125	2036	2038	O
study	32383125	2039	2044	O
personnel	32383125	2045	2054	O
.	32383125	2055	2056	O

Innovative	32383125	2057	2067	O
trial	32383125	2068	2073	O
approaches	32383125	2074	2084	O
are	32383125	2085	2088	O
needed	32383125	2089	2095	O
to	32383125	2096	2098	O
urgently	32383125	2099	2107	O
assess	32383125	2108	2114	O
therapeutic	32383125	2115	2126	O
options	32383125	2127	2134	O
to	32383125	2135	2137	O
mitigate	32383125	2138	2146	O
the	32383125	2147	2150	O
global	32383125	2151	2157	O
impact	32383125	2158	2164	O
of	32383125	2165	2167	O
this	32383125	2168	2172	O
pandemic	32383125	2173	2181	O
.	32383125	2182	2183	O

clinicaltrials.gov	32383125	2184	2202	O
(	32383125	2203	2204	O
NCT04308668	32383125	2205	2216	O
)	32383125	2217	2218	O
;	32383125	2219	2220	O
registered	32383125	2221	2231	O
16	32383125	2232	2234	O
March	32383125	2235	2240	O
,	32383125	2241	2242	O
2020	32383125	2243	2247	O
.	32383125	2248	2249	O


[	32391667	0	1	O
A	32391667	2	3	O
pilot	32391667	4	9	O
study	32391667	10	15	O
of	32391667	16	18	O
hydroxychloroquine	32391667	19	37	B-Intervention
in	32391667	38	40	O
treatment	32391667	41	50	O
of	32391667	51	53	O
patients	32391667	54	62	O
with	32391667	63	67	O
moderate	32391667	68	76	B-Participant
COVID-19	32391667	77	85	I-Participant
]	32391667	86	87	O
.	32391667	88	89	O

OBJECTIVE	32391667	90	99	O
:	32391667	100	101	O
To	32391667	102	104	O
evaluate	32391667	105	113	O
the	32391667	114	117	O
efficacy	32391667	118	126	B-Outcome
and	32391667	127	130	O
safety	32391667	131	137	B-Outcome
of	32391667	138	140	O
hydroxychloroquine	32391667	141	159	B-Intervention
(	32391667	160	161	I-Intervention
HCQ	32391667	162	165	I-Intervention
)	32391667	166	167	I-Intervention
in	32391667	168	170	O
the	32391667	171	174	O
treatment	32391667	175	184	O
of	32391667	185	187	O
patients	32391667	188	196	O
with	32391667	197	201	O
moderate	32391667	202	210	B-Participant
coronavirus	32391667	211	222	I-Participant
disease	32391667	223	230	I-Participant
2019	32391667	231	235	I-Participant
(	32391667	236	237	I-Participant
COVID-19	32391667	238	246	I-Participant
)	32391667	247	248	I-Participant
.	32391667	249	250	O

METHODS	32391667	251	258	O
:	32391667	259	260	O
We	32391667	261	263	O
prospectively	32391667	264	277	O
enrolled	32391667	278	286	O
30	32391667	287	289	O
treatment-nave	32391667	290	305	B-Participant
patients	32391667	306	314	O
with	32391667	315	319	O
confirmed	32391667	320	329	B-Participant
COVID-19	32391667	330	338	I-Participant
after	32391667	339	344	O
informed	32391667	345	353	O
consent	32391667	354	361	O
at	32391667	362	364	O
Shanghai	32391667	365	373	O
Public	32391667	374	380	O
Health	32391667	381	387	O
Clinical	32391667	388	396	O
Center	32391667	397	403	O
.	32391667	404	405	O

The	32391667	406	409	O
patients	32391667	410	418	O
were	32391667	419	423	O
randomized	32391667	424	434	O
11	32391667	435	438	O
to	32391667	439	441	O
HCQ	32391667	442	445	B-Intervention
group	32391667	446	451	O
and	32391667	452	455	O
the	32391667	456	459	O
control	32391667	460	467	B-Intervention
group	32391667	468	473	O
.	32391667	474	475	O

Patients	32391667	476	484	O
in	32391667	485	487	O
HCQ	32391667	488	491	B-Intervention
group	32391667	492	497	O
were	32391667	498	502	O
given	32391667	503	508	O
HCQ	32391667	509	512	B-Intervention
400	32391667	513	516	O
mg	32391667	517	519	O
per	32391667	520	523	O
day	32391667	524	527	O
for	32391667	528	531	O
5	32391667	532	533	O
days	32391667	534	538	O
plus	32391667	539	543	O
conventional	32391667	544	556	B-Intervention
treatments	32391667	557	567	I-Intervention
,	32391667	568	569	O
while	32391667	570	575	O
those	32391667	576	581	O
in	32391667	582	584	O
the	32391667	585	588	O
control	32391667	589	596	B-Intervention
group	32391667	597	602	O
were	32391667	603	607	O
given	32391667	608	613	O
conventional	32391667	614	626	B-Intervention
treatment	32391667	627	636	I-Intervention
only	32391667	637	641	O
.	32391667	642	643	O

The	32391667	644	647	O
primary	32391667	648	655	O
endpoint	32391667	656	664	O
was	32391667	665	668	O
negative	32391667	669	677	B-Outcome
conversion	32391667	678	688	I-Outcome
rate	32391667	689	693	I-Outcome
of	32391667	694	696	I-Outcome
SARS-CoV-2	32391667	697	707	I-Outcome
nucleic	32391667	708	715	I-Outcome
acid	32391667	716	720	I-Outcome
in	32391667	721	723	O
respiratory	32391667	724	735	O
pharyngeal	32391667	736	746	O
swab	32391667	747	751	O
on	32391667	752	754	O
days	32391667	755	759	O
7	32391667	760	761	O
after	32391667	762	767	O
randomization	32391667	768	781	O
.	32391667	782	783	O

This	32391667	784	788	O
study	32391667	789	794	O
has	32391667	795	798	O
been	32391667	799	803	O
approved	32391667	804	812	O
by	32391667	813	815	O
the	32391667	816	819	O
Ethics	32391667	820	826	O
Committee	32391667	827	836	O
of	32391667	837	839	O
Shanghai	32391667	840	848	O
Public	32391667	849	855	O
Health	32391667	856	862	O
Clinical	32391667	863	871	O
Center	32391667	872	878	O
and	32391667	879	882	O
registered	32391667	883	893	O
online	32391667	894	900	O
(	32391667	901	902	O
NCT04261517	32391667	903	914	O
)	32391667	915	916	O
.	32391667	917	918	O

RESULTS	32391667	919	926	O
:	32391667	927	928	O
One	32391667	929	932	B-Count
patient	32391667	933	940	I-Count
in	32391667	941	943	O
HCQ	32391667	944	947	B-Intervention
group	32391667	948	953	O
developed	32391667	954	963	O
to	32391667	964	966	O
severe	32391667	967	973	B-Outcome
during	32391667	974	980	O
the	32391667	981	984	O
treatment	32391667	985	994	O
.	32391667	995	996	O

On	32391667	997	999	O
day	32391667	1000	1003	O
7	32391667	1004	1005	O
,	32391667	1006	1007	O
nucleic	32391667	1008	1015	B-Outcome
acid	32391667	1016	1020	I-Outcome
of	32391667	1021	1023	I-Outcome
throat	32391667	1024	1030	I-Outcome
swabs	32391667	1031	1036	I-Outcome
was	32391667	1037	1040	O
negative	32391667	1041	1049	B-Observation
in	32391667	1050	1052	O
13	32391667	1053	1055	B-Count
(	32391667	1056	1057	I-Count
86.7	32391667	1058	1062	I-Count
%	32391667	1063	1064	I-Count
)	32391667	1065	1066	I-Count
cases	32391667	1067	1072	I-Count
in	32391667	1073	1075	O
the	32391667	1076	1079	O
HCQ	32391667	1080	1083	B-Intervention
group	32391667	1084	1089	O
and	32391667	1090	1093	O
14	32391667	1094	1096	B-Count
(	32391667	1097	1098	I-Count
93.3	32391667	1099	1103	I-Count
%	32391667	1104	1105	I-Count
)	32391667	1106	1107	I-Count
cases	32391667	1108	1113	I-Count
in	32391667	1114	1116	O
the	32391667	1117	1120	O
control	32391667	1121	1128	B-Intervention
group	32391667	1129	1134	O
(	32391667	1135	1136	O
P	32391667	1137	1138	O
>	32391667	1139	1140	O
0.05	32391667	1141	1145	O
)	32391667	1146	1147	O
.	32391667	1148	1149	O

The	32391667	1150	1153	O
median	32391667	1154	1160	B-Outcome
duration	32391667	1161	1169	I-Outcome
from	32391667	1170	1174	I-Outcome
hospitalization	32391667	1175	1190	I-Outcome
to	32391667	1191	1193	I-Outcome
virus	32391667	1194	1199	I-Outcome
nucleic	32391667	1200	1207	I-Outcome
acid	32391667	1208	1212	I-Outcome
negative	32391667	1213	1221	I-Outcome
conservation	32391667	1222	1234	I-Outcome
was	32391667	1235	1238	O
4	32391667	1239	1240	B-Observation
(	32391667	1241	1242	I-Observation
1,9	32391667	1243	1246	I-Observation
)	32391667	1247	1248	I-Observation
days	32391667	1249	1253	I-Observation
in	32391667	1254	1256	O
HCQ	32391667	1257	1260	B-Intervention
group	32391667	1261	1266	O
,	32391667	1267	1268	O
which	32391667	1269	1274	O
is	32391667	1275	1277	O
comparable	32391667	1278	1288	B-Observation
to	32391667	1289	1291	O
that	32391667	1292	1296	O
in	32391667	1297	1299	O
the	32391667	1300	1303	O
control	32391667	1304	1311	B-Intervention
group	32391667	1312	1317	O
[	32391667	1318	1319	O
2	32391667	1320	1321	B-Observation
(	32391667	1322	1323	I-Observation
1,4	32391667	1324	1327	I-Observation
)	32391667	1328	1329	I-Observation
days	32391667	1330	1334	I-Observation
,	32391667	1335	1336	O
Z=1.27	32391667	1337	1343	O
,	32391667	1344	1345	O
P	32391667	1346	1347	O
>	32391667	1348	1349	O
0.05	32391667	1350	1354	O
]	32391667	1355	1356	O
.	32391667	1357	1358	O

The	32391667	1359	1362	O
median	32391667	1363	1369	B-Outcome
time	32391667	1370	1374	I-Outcome
for	32391667	1375	1378	I-Outcome
body	32391667	1379	1383	I-Outcome
temperature	32391667	1384	1395	I-Outcome
normalization	32391667	1396	1409	I-Outcome
in	32391667	1410	1412	O
HCQ	32391667	1413	1416	B-Intervention
group	32391667	1417	1422	O
was	32391667	1423	1426	O
1	32391667	1427	1428	B-Observation
(	32391667	1429	1430	I-Observation
0,2	32391667	1431	1434	I-Observation
)	32391667	1435	1436	I-Observation
day	32391667	1437	1440	I-Observation
after	32391667	1441	1446	O
hospitalization	32391667	1447	1462	O
,	32391667	1463	1464	O
which	32391667	1465	1470	O
was	32391667	1471	1474	O
also	32391667	1475	1479	O
comparable	32391667	1480	1490	B-Observation
to	32391667	1491	1493	O
that	32391667	1494	1498	O
in	32391667	1499	1501	O
the	32391667	1502	1505	O
control	32391667	1506	1513	B-Intervention
group	32391667	1514	1519	O
[	32391667	1520	1521	O
1	32391667	1522	1523	B-Observation
(	32391667	1524	1525	I-Observation
0,3	32391667	1526	1529	I-Observation
)	32391667	1530	1531	I-Observation
day	32391667	1532	1535	I-Observation
]	32391667	1536	1537	O
.	32391667	1538	1539	O

Radiological	32391667	1540	1552	B-Outcome
progression	32391667	1553	1564	I-Outcome
was	32391667	1565	1568	O
shown	32391667	1569	1574	O
on	32391667	1575	1577	O
CT	32391667	1578	1580	O
images	32391667	1581	1587	O
in	32391667	1588	1590	O
5	32391667	1591	1592	B-Count
cases	32391667	1593	1598	I-Count
(	32391667	1599	1600	I-Count
33.3	32391667	1601	1605	I-Count
%	32391667	1606	1607	I-Count
)	32391667	1608	1609	I-Count
of	32391667	1610	1612	O
the	32391667	1613	1616	O
HCQ	32391667	1617	1620	B-Intervention
group	32391667	1621	1626	O
and	32391667	1627	1630	O
7	32391667	1631	1632	B-Count
cases	32391667	1633	1638	I-Count
(	32391667	1639	1640	I-Count
46.7	32391667	1641	1645	I-Count
%	32391667	1646	1647	I-Count
)	32391667	1648	1649	I-Count
of	32391667	1650	1652	O
the	32391667	1653	1656	O
control	32391667	1657	1664	B-Intervention
group	32391667	1665	1670	O
,	32391667	1671	1672	O
and	32391667	1673	1676	O
all	32391667	1677	1680	B-Count
patients	32391667	1681	1689	I-Count
showed	32391667	1690	1696	O
improvement	32391667	1697	1708	B-Observation
in	32391667	1709	1711	O
follow-up	32391667	1712	1721	B-Outcome
examinations	32391667	1722	1734	I-Outcome
.	32391667	1735	1736	O

Four	32391667	1737	1741	B-Count
cases	32391667	1742	1747	I-Count
(	32391667	1748	1749	I-Count
26.7	32391667	1750	1754	I-Count
%	32391667	1755	1756	I-Count
)	32391667	1757	1758	I-Count
of	32391667	1759	1761	O
the	32391667	1762	1765	O
HCQ	32391667	1766	1769	B-Intervention
group	32391667	1770	1775	O
and	32391667	1776	1779	O
3	32391667	1780	1781	B-Count
cases	32391667	1782	1787	I-Count
(	32391667	1788	1789	I-Count
20	32391667	1790	1792	I-Count
%	32391667	1793	1794	I-Count
)	32391667	1795	1796	I-Count
of	32391667	1797	1799	O
the	32391667	1800	1803	O
control	32391667	1804	1811	B-Intervention
group	32391667	1812	1817	O
had	32391667	1818	1821	O
transient	32391667	1822	1831	B-Outcome
diarrhea	32391667	1832	1840	I-Outcome
and	32391667	1841	1844	O
abnormal	32391667	1845	1853	B-Outcome
liver	32391667	1854	1859	I-Outcome
function	32391667	1860	1868	I-Outcome
(	32391667	1869	1870	O
P	32391667	1871	1872	O
>	32391667	1873	1874	O
0.05	32391667	1875	1879	O
)	32391667	1880	1881	O
.	32391667	1882	1883	O

CONCLUSIONS	32391667	1884	1895	O
:	32391667	1896	1897	O
The	32391667	1898	1901	O
prognosis	32391667	1902	1911	B-Outcome
of	32391667	1912	1914	O
COVID-19	32391667	1915	1923	B-Participant
moderate	32391667	1924	1932	I-Participant
patients	32391667	1933	1941	O
is	32391667	1942	1944	O
good	32391667	1945	1949	B-Observation
.	32391667	1950	1951	O

Larger	32391667	1952	1958	O
sample	32391667	1959	1965	O
size	32391667	1966	1970	O
study	32391667	1971	1976	O
are	32391667	1977	1980	O
needed	32391667	1981	1987	O
to	32391667	1988	1990	O
investigate	32391667	1991	2002	O
the	32391667	2003	2006	O
effects	32391667	2007	2014	O
of	32391667	2015	2017	O
HCQ	32391667	2018	2021	O
in	32391667	2022	2024	O
the	32391667	2025	2028	O
treatment	32391667	2029	2038	O
of	32391667	2039	2041	O
COVID-19	32391667	2042	2050	O
.	32391667	2051	2052	O

Subsequent	32391667	2053	2063	O
research	32391667	2064	2072	O
should	32391667	2073	2079	O
determine	32391667	2080	2089	O
better	32391667	2090	2096	O
endpoint	32391667	2097	2105	O
and	32391667	2106	2109	O
fully	32391667	2110	2115	O
consider	32391667	2116	2124	O
the	32391667	2125	2128	O
feasibility	32391667	2129	2140	O
of	32391667	2141	2143	O
experiments	32391667	2144	2155	O
such	32391667	2156	2160	O
as	32391667	2161	2163	O
sample	32391667	2164	2170	O
size	32391667	2171	2175	O
.	32391667	2176	2177	O


[	32394650	0	1	O
Significance	32394650	2	14	B-Outcome
and	32394650	15	18	O
operation	32394650	19	28	B-Outcome
mode	32394650	29	33	I-Outcome
of	32394650	34	36	O
moxibustion	32394650	37	48	B-Intervention
intervention	32394650	49	61	O
for	32394650	62	65	O
the	32394650	66	69	O
group	32394650	70	75	O
under	32394650	76	81	B-Participant
quarantine	32394650	82	92	I-Participant
after	32394650	93	98	O
close	32394650	99	104	B-Participant
contact	32394650	105	112	I-Participant
with	32394650	113	117	I-Participant
COVID-19	32394650	118	126	I-Participant
]	32394650	127	128	O
.	32394650	129	130	O

On	32394650	131	133	O
the	32394650	134	137	O
base	32394650	138	142	O
of	32394650	143	145	O
the	32394650	146	149	O
idea	32394650	150	154	O
of	32394650	155	157	O
traditional	32394650	158	169	O
Chinese	32394650	170	177	O
medicine	32394650	178	186	O
as	32394650	187	189	O
"	32394650	190	191	O
disease	32394650	192	199	O
prevention	32394650	200	210	O
"	32394650	211	212	O
,	32394650	213	214	O
the	32394650	215	218	O
mode	32394650	219	223	O
and	32394650	224	227	O
the	32394650	228	231	O
protocol	32394650	232	240	O
of	32394650	241	243	O
the	32394650	244	247	O
moxibustion	32394650	248	259	O
intervention	32394650	260	272	O
for	32394650	273	276	O
the	32394650	277	280	O
group	32394650	281	286	O
under	32394650	287	292	O
quarantine	32394650	293	303	O
after	32394650	304	309	O
close	32394650	310	315	O
contact	32394650	316	323	O
with	32394650	324	328	O
coronavirus	32394650	329	340	O
disease	32394650	341	348	O
2019	32394650	349	353	O
(	32394650	354	355	O
COVID-19	32394650	356	364	O
)	32394650	365	366	O
were	32394650	367	371	O
explored	32394650	372	380	O
.	32394650	381	382	O

The	32394650	383	386	O
group	32394650	387	392	O
under	32394650	393	398	B-Participant
quarantine	32394650	399	409	I-Participant
after	32394650	410	415	O
close	32394650	416	421	B-Participant
contact	32394650	422	429	I-Participant
with	32394650	430	434	I-Participant
COVID-19	32394650	435	443	I-Participant
was	32394650	444	447	O
taken	32394650	448	453	O
as	32394650	454	456	O
the	32394650	457	460	O
subjects	32394650	461	469	O
.	32394650	470	471	O

By	32394650	472	474	O
the	32394650	475	478	O
non	32394650	479	482	O
-	32394650	483	484	O
contact	32394650	485	492	O
physician	32394650	493	502	O
-	32394650	503	504	O
patient	32394650	505	512	O
communication	32394650	513	526	O
network	32394650	527	534	O
platform	32394650	535	543	O
co	32394650	544	546	O
-	32394650	547	548	O
developed	32394650	549	558	O
by	32394650	559	561	O
China	32394650	562	567	O
Association	32394650	568	579	O
of	32394650	580	582	O
Acupuncture	32394650	583	594	O
-	32394650	595	596	O
Moxibustion	32394650	597	608	O
,	32394650	609	610	O
Hunan	32394650	611	616	O
Provincial	32394650	617	627	O
Association	32394650	628	639	O
of	32394650	640	642	O
Acupuncture	32394650	643	654	O
-	32394650	655	656	O
Moxibustion	32394650	657	668	O
,	32394650	669	670	O
Data	32394650	671	675	O
Center	32394650	676	682	O
of	32394650	683	685	O
China	32394650	686	691	O
Academy	32394650	692	699	O
of	32394650	700	702	O
Chinese	32394650	703	710	O
Medical	32394650	711	718	O
Sciences	32394650	719	727	O
and	32394650	728	731	O
Yuge	32394650	732	736	O
Medicine	32394650	737	745	O
Company	32394650	746	753	O
,	32394650	754	755	O
an	32394650	756	758	O
exploratory	32394650	759	770	O
randomized	32394650	771	781	O
controlled	32394650	782	792	O
trial	32394650	793	798	O
was	32394650	799	802	O
designed	32394650	803	811	O
.	32394650	812	813	O

A	32394650	814	815	O
total	32394650	816	821	O
of	32394650	822	824	O
100	32394650	825	828	O
cases	32394650	829	834	O
were	32394650	835	839	O
included	32394650	840	848	O
and	32394650	849	852	O
randomized	32394650	853	863	O
into	32394650	864	868	O
a	32394650	869	870	O
moxibustion	32394650	871	882	B-Intervention
group	32394650	883	888	O
and	32394650	889	892	O
a	32394650	893	894	O
conventional	32394650	895	907	B-Intervention
intervention	32394650	908	920	I-Intervention
group	32394650	921	926	O
,	32394650	927	928	O
50	32394650	929	931	O
cases	32394650	932	937	O
in	32394650	938	940	O
each	32394650	941	945	O
one	32394650	946	949	O
.	32394650	950	951	O

In	32394650	952	954	O
the	32394650	955	958	O
moxibustion	32394650	959	970	B-Intervention
group	32394650	971	976	O
,	32394650	977	978	O
moxibustion	32394650	979	990	B-Intervention
intervention	32394650	991	1003	O
was	32394650	1004	1007	O
used	32394650	1008	1012	O
.	32394650	1013	1014	O

In	32394650	1015	1017	O
the	32394650	1018	1021	O
conventional	32394650	1022	1034	B-Intervention
intervention	32394650	1035	1047	I-Intervention
group	32394650	1048	1053	O
,	32394650	1054	1055	O
the	32394650	1056	1059	O
conventional	32394650	1060	1072	B-Intervention
observation	32394650	1073	1084	I-Intervention
was	32394650	1085	1088	O
adopted	32394650	1089	1096	O
without	32394650	1097	1104	O
moxibusiton	32394650	1105	1116	O
intervention	32394650	1117	1129	O
applied	32394650	1130	1137	O
.	32394650	1138	1139	O

The	32394650	1140	1143	O
outcomes	32394650	1144	1152	O
included	32394650	1153	1161	O
the	32394650	1162	1165	O
symptoms	32394650	1166	1174	B-Outcome
changes	32394650	1175	1182	I-Outcome
,	32394650	1183	1184	O
e.g.	32394650	1185	1189	O
anxiety	32394650	1190	1197	B-Outcome
,	32394650	1198	1199	O
emotional	32394650	1200	1209	B-Outcome
disturbance	32394650	1210	1221	I-Outcome
,	32394650	1222	1223	O
fatigue	32394650	1224	1231	B-Outcome
,	32394650	1232	1233	O
headache	32394650	1234	1242	B-Outcome
and	32394650	1243	1246	O
diarrhea	32394650	1247	1255	B-Outcome
,	32394650	1256	1257	O
as	32394650	1258	1260	O
well	32394650	1261	1265	O
as	32394650	1266	1268	O
whether	32394650	1269	1276	O
quarantine	32394650	1277	1287	B-Outcome
release	32394650	1288	1295	I-Outcome
and	32394650	1296	1299	O
the	32394650	1300	1303	O
case	32394650	1304	1308	B-Outcome
confirmed	32394650	1309	1318	I-Outcome
or	32394650	1319	1321	O
not	32394650	1322	1325	O
,	32394650	1326	1327	O
etc	32394650	1328	1331	O
.	32394650	1332	1333	O

The	32394650	1334	1337	O
results	32394650	1338	1345	O
were	32394650	1346	1350	O
evaluated	32394650	1351	1360	O
before	32394650	1361	1367	O
intervention	32394650	1368	1380	O
,	32394650	1381	1382	O
in	32394650	1383	1385	O
14	32394650	1386	1388	O
days	32394650	1389	1393	O
of	32394650	1394	1396	O
intervention	32394650	1397	1409	O
and	32394650	1410	1413	O
2	32394650	1414	1415	O
weeks	32394650	1416	1421	O
after	32394650	1422	1427	O
intervention	32394650	1428	1440	O
separately	32394650	1441	1451	O
.	32394650	1452	1453	O

In	32394650	1454	1456	O
this	32394650	1457	1461	O
research	32394650	1462	1470	O
,	32394650	1471	1472	O
on	32394650	1473	1475	O
the	32394650	1476	1479	O
base	32394650	1480	1484	O
of	32394650	1485	1487	O
internet	32394650	1488	1496	O
plus	32394650	1497	1501	O
technology	32394650	1502	1512	O
and	32394650	1513	1516	O
with	32394650	1517	1521	O
the	32394650	1522	1525	O
internet	32394650	1526	1534	O
communication	32394650	1535	1548	O
platform	32394650	1549	1557	O
adopted	32394650	1558	1565	O
,	32394650	1566	1567	O
through	32394650	1568	1575	O
mobile	32394650	1576	1582	O
phone	32394650	1583	1588	O
WeChat	32394650	1589	1595	O
App	32394650	1596	1599	O
,	32394650	1600	1601	O
it	32394650	1602	1604	O
was	32394650	1605	1608	O
to	32394650	1609	1611	O
implement	32394650	1612	1621	O
the	32394650	1622	1625	O
subject	32394650	1626	1633	O
screen	32394650	1634	1640	O
,	32394650	1641	1642	O
the	32394650	1643	1646	O
random	32394650	1647	1653	O
allocation	32394650	1654	1664	O
and	32394650	1665	1668	O
the	32394650	1669	1672	O
instruction	32394650	1673	1684	O
of	32394650	1685	1687	O
moxibustion	32394650	1688	1699	O
intervention	32394650	1700	1712	O
as	32394650	1713	1715	O
well	32394650	1716	1720	O
as	32394650	1721	1723	O
the	32394650	1724	1727	O
quality	32394650	1728	1735	O
control	32394650	1736	1743	O
of	32394650	1744	1746	O
patient	32394650	1747	1754	O
's	32394650	1755	1757	O
diary	32394650	1758	1763	O
and	32394650	1764	1767	O
data	32394650	1768	1772	O
collection	32394650	1773	1783	O
.	32394650	1784	1785	O

It	32394650	1786	1788	O
is	32394650	1789	1791	O
anticipated	32394650	1792	1803	O
that	32394650	1804	1808	O
the	32394650	1809	1812	O
significance	32394650	1813	1825	B-Outcome
and	32394650	1826	1829	O
the	32394650	1830	1833	O
implementation	32394650	1834	1848	B-Outcome
mode	32394650	1849	1853	I-Outcome
of	32394650	1854	1856	O
moxibustion	32394650	1857	1868	B-Intervention
intervention	32394650	1869	1881	O
can	32394650	1882	1885	O
be	32394650	1886	1888	O
assessed	32394650	1889	1897	O
preliminarily	32394650	1898	1911	O
for	32394650	1912	1915	O
the	32394650	1916	1919	O
group	32394650	1920	1925	O
under	32394650	1926	1931	B-Participant
quarantine	32394650	1932	1942	I-Participant
after	32394650	1943	1948	O
close	32394650	1949	1954	B-Participant
contact	32394650	1955	1962	I-Participant
with	32394650	1963	1967	I-Participant
COVID-19	32394650	1968	1976	I-Participant
.	32394650	1977	1978	O


Triple	32401715	0	6	B-Intervention
combination	32401715	7	18	I-Intervention
of	32401715	19	21	I-Intervention
interferon	32401715	22	32	I-Intervention
beta-1b	32401715	33	40	I-Intervention
,	32401715	40	41	I-Intervention
lopinavir-ritonavir	32401715	42	61	I-Intervention
,	32401715	61	62	I-Intervention
and	32401715	63	66	I-Intervention
ribavirin	32401715	67	76	I-Intervention
in	32401715	77	79	O
the	32401715	80	83	O
treatment	32401715	84	93	O
of	32401715	94	96	O
patients	32401715	97	105	O
admitted	32401715	106	114	B-Participant
to	32401715	115	117	I-Participant
hospital	32401715	118	126	I-Participant
with	32401715	127	131	O
COVID-19	32401715	132	140	B-Participant
:	32401715	140	141	O
an	32401715	142	144	O
open-label	32401715	145	155	O
,	32401715	155	156	O
randomised	32401715	157	167	O
,	32401715	167	168	O
phase	32401715	169	174	O
2	32401715	175	176	O
trial	32401715	177	182	O
.	32401715	182	183	O

Effective	32401715	184	193	O
antiviral	32401715	194	203	O
therapy	32401715	204	211	O
is	32401715	212	214	O
important	32401715	215	224	O
for	32401715	225	228	O
tackling	32401715	229	237	O
the	32401715	238	241	O
coronavirus	32401715	242	253	O
disease	32401715	254	261	O
2019	32401715	262	266	O
(	32401715	267	268	O
COVID-19	32401715	268	276	O
)	32401715	276	277	O
pandemic	32401715	278	286	O
.	32401715	286	287	O

We	32401715	288	290	O
assessed	32401715	291	299	O
the	32401715	300	303	O
efficacy	32401715	304	312	B-Outcome
and	32401715	313	316	O
safety	32401715	317	323	B-Outcome
of	32401715	324	326	O
combined	32401715	327	335	B-Intervention
interferon	32401715	336	346	I-Intervention
beta-1b	32401715	347	354	I-Intervention
,	32401715	354	355	I-Intervention
lopinavir-ritonavir	32401715	356	375	I-Intervention
,	32401715	375	376	I-Intervention
and	32401715	377	380	I-Intervention
ribavirin	32401715	381	390	I-Intervention
for	32401715	391	394	O
treating	32401715	395	403	O
patients	32401715	404	412	O
with	32401715	413	417	O
COVID-19	32401715	418	426	B-Participant
.	32401715	426	427	O

This	32401715	428	432	O
was	32401715	433	436	O
a	32401715	437	438	O
multicentre	32401715	439	450	O
,	32401715	450	451	O
prospective	32401715	452	463	O
,	32401715	463	464	O
open-label	32401715	465	475	O
,	32401715	475	476	O
randomised	32401715	477	487	O
,	32401715	487	488	O
phase	32401715	489	494	O
2	32401715	495	496	O
trial	32401715	497	502	O
in	32401715	503	505	O
adults	32401715	506	512	O
with	32401715	513	517	O
COVID-19	32401715	518	526	O
who	32401715	527	530	O
were	32401715	531	535	O
admitted	32401715	536	544	O
to	32401715	545	547	O
six	32401715	548	551	O
hospitals	32401715	552	561	O
in	32401715	562	564	O
Hong	32401715	565	569	O
Kong	32401715	570	574	O
.	32401715	574	575	O

Patients	32401715	576	584	O
were	32401715	585	589	O
randomly	32401715	590	598	O
assigned	32401715	599	607	O
(	32401715	608	609	O
2:1	32401715	609	612	O
)	32401715	612	613	O
to	32401715	614	616	O
a	32401715	617	618	O
14-day	32401715	619	625	O
combination	32401715	626	637	B-Intervention
of	32401715	638	640	I-Intervention
lopinavir	32401715	641	650	I-Intervention
400	32401715	651	654	I-Intervention
mg	32401715	655	657	I-Intervention
and	32401715	658	661	I-Intervention
ritonavir	32401715	662	671	I-Intervention
100	32401715	672	675	I-Intervention
mg	32401715	676	678	I-Intervention
every	32401715	679	684	I-Intervention
12	32401715	685	687	I-Intervention
h	32401715	688	689	I-Intervention
,	32401715	689	690	I-Intervention
ribavirin	32401715	691	700	I-Intervention
400	32401715	701	704	I-Intervention
mg	32401715	705	707	I-Intervention
every	32401715	708	713	I-Intervention
12	32401715	714	716	I-Intervention
h	32401715	717	718	I-Intervention
,	32401715	718	719	I-Intervention
and	32401715	720	723	I-Intervention
three	32401715	724	729	I-Intervention
doses	32401715	730	735	I-Intervention
of	32401715	736	738	I-Intervention
8	32401715	739	740	I-Intervention
million	32401715	741	748	I-Intervention
international	32401715	749	762	I-Intervention
units	32401715	763	768	I-Intervention
of	32401715	769	771	I-Intervention
interferon	32401715	772	782	I-Intervention
beta-1b	32401715	783	790	I-Intervention
on	32401715	791	793	I-Intervention
alternate	32401715	794	803	I-Intervention
days	32401715	804	808	I-Intervention
(	32401715	809	810	O
combination	32401715	810	821	O
group	32401715	822	827	O
)	32401715	827	828	O
or	32401715	829	831	O
to	32401715	832	834	O
14	32401715	835	837	O
days	32401715	838	842	O
of	32401715	843	845	O
lopinavir	32401715	846	855	B-Intervention
400	32401715	856	859	I-Intervention
mg	32401715	860	862	I-Intervention
and	32401715	863	866	I-Intervention
ritonavir	32401715	867	876	I-Intervention
100	32401715	877	880	I-Intervention
mg	32401715	881	883	I-Intervention
every	32401715	884	889	I-Intervention
12	32401715	890	892	I-Intervention
h	32401715	893	894	I-Intervention
(	32401715	895	896	O
control	32401715	896	903	O
group	32401715	904	909	O
)	32401715	909	910	O
.	32401715	910	911	O

The	32401715	912	915	O
primary	32401715	916	923	O
endpoint	32401715	924	932	O
was	32401715	933	936	O
the	32401715	937	940	O
time	32401715	941	945	B-Outcome
to	32401715	946	948	I-Outcome
providing	32401715	949	958	I-Outcome
a	32401715	959	960	I-Outcome
nasopharyngeal	32401715	961	975	I-Outcome
swab	32401715	976	980	I-Outcome
negative	32401715	981	989	I-Outcome
for	32401715	990	993	O
severe	32401715	994	1000	B-Participant
acute	32401715	1001	1006	I-Participant
respiratory	32401715	1007	1018	I-Participant
syndrome	32401715	1019	1027	I-Participant
coronavirus	32401715	1028	1039	I-Participant
2	32401715	1040	1041	I-Participant
RT-PCR	32401715	1042	1048	I-Participant
,	32401715	1048	1049	O
and	32401715	1050	1053	O
was	32401715	1054	1057	O
done	32401715	1058	1062	O
in	32401715	1063	1065	O
the	32401715	1066	1069	O
intention-to-treat	32401715	1070	1088	O
population	32401715	1089	1099	O
.	32401715	1099	1100	O

The	32401715	1101	1104	O
study	32401715	1105	1110	O
is	32401715	1111	1113	O
registered	32401715	1114	1124	O
with	32401715	1125	1129	O
ClinicalTrials.gov	32401715	1130	1148	O
,	32401715	1148	1149	O
NCT04276688	32401715	1150	1161	O
.	32401715	1161	1162	O

Between	32401715	1163	1170	O
Feb	32401715	1171	1174	O
10	32401715	1175	1177	O
and	32401715	1178	1181	O
March	32401715	1182	1187	O
20	32401715	1188	1190	O
,	32401715	1190	1191	O
2020	32401715	1192	1196	O
,	32401715	1196	1197	O
127	32401715	1198	1201	O
patients	32401715	1202	1210	O
were	32401715	1211	1215	O
recruited	32401715	1216	1225	O
;	32401715	1225	1226	O
86	32401715	1227	1229	O
were	32401715	1230	1234	O
randomly	32401715	1235	1243	O
assigned	32401715	1244	1252	O
to	32401715	1253	1255	O
the	32401715	1256	1259	O
combination	32401715	1260	1271	B-Intervention
group	32401715	1272	1277	O
and	32401715	1278	1281	O
41	32401715	1282	1284	O
were	32401715	1285	1289	O
assigned	32401715	1290	1298	O
to	32401715	1299	1301	O
the	32401715	1302	1305	O
control	32401715	1306	1313	B-Intervention
group	32401715	1314	1319	O
.	32401715	1319	1320	O

The	32401715	1321	1324	O
median	32401715	1325	1331	B-Outcome
number	32401715	1332	1338	I-Outcome
of	32401715	1339	1341	I-Outcome
days	32401715	1342	1346	I-Outcome
from	32401715	1347	1351	I-Outcome
symptom	32401715	1352	1359	I-Outcome
onset	32401715	1360	1365	I-Outcome
to	32401715	1366	1368	I-Outcome
start	32401715	1369	1374	I-Outcome
of	32401715	1375	1377	I-Outcome
study	32401715	1378	1383	I-Outcome
treatment	32401715	1384	1393	I-Outcome
was	32401715	1394	1397	O
5	32401715	1398	1399	B-Observation
days	32401715	1400	1404	I-Observation
(	32401715	1405	1406	O
IQR	32401715	1406	1409	O
3	32401715	1410	1411	O
-	32401715	1411	1412	O
7	32401715	1412	1413	O
)	32401715	1413	1414	O
.	32401715	1414	1415	O

The	32401715	1416	1419	O
combination	32401715	1420	1431	B-Intervention
group	32401715	1432	1437	O
had	32401715	1438	1441	O
a	32401715	1442	1443	O
significantly	32401715	1444	1457	B-Observation
shorter	32401715	1458	1465	I-Observation
median	32401715	1466	1472	B-Outcome
time	32401715	1473	1477	I-Outcome
from	32401715	1478	1482	I-Outcome
start	32401715	1483	1488	I-Outcome
of	32401715	1489	1491	I-Outcome
study	32401715	1492	1497	I-Outcome
treatment	32401715	1498	1507	I-Outcome
to	32401715	1508	1510	I-Outcome
negative	32401715	1511	1519	I-Outcome
nasopharyngeal	32401715	1520	1534	I-Outcome
swab	32401715	1535	1539	I-Outcome
(	32401715	1540	1541	O
7	32401715	1541	1542	O
days	32401715	1543	1547	O
[	32401715	1548	1549	O
IQR	32401715	1549	1552	O
5	32401715	1553	1554	O
-	32401715	1554	1555	O
11	32401715	1555	1557	O
]	32401715	1557	1558	O
)	32401715	1558	1559	O
than	32401715	1560	1564	O
the	32401715	1565	1568	O
control	32401715	1569	1576	B-Intervention
group	32401715	1577	1582	O
(	32401715	1583	1584	O
12	32401715	1584	1586	O
days	32401715	1587	1591	O
[	32401715	1592	1593	O
8	32401715	1593	1594	O
-	32401715	1594	1595	O
15	32401715	1595	1597	O
]	32401715	1597	1598	O
;	32401715	1598	1599	O
hazard	32401715	1600	1606	O
ratio	32401715	1607	1612	O
437	32401715	1613	1617	O
[	32401715	1618	1619	O
95	32401715	1619	1621	O
%	32401715	1621	1622	O
CI	32401715	1623	1625	O
186	32401715	1626	1630	O
-	32401715	1630	1631	O
1024	32401715	1631	1636	O
]	32401715	1636	1637	O
,	32401715	1637	1638	O
p=00010	32401715	1639	1647	O
)	32401715	1647	1648	O
.	32401715	1648	1649	O

Adverse	32401715	1650	1657	B-Outcome
events	32401715	1658	1664	I-Outcome
included	32401715	1665	1673	O
self-limited	32401715	1674	1686	B-Outcome
nausea	32401715	1687	1693	I-Outcome
and	32401715	1694	1697	O
diarrhoea	32401715	1698	1707	B-Outcome
with	32401715	1708	1712	O
no	32401715	1713	1715	B-Observation
difference	32401715	1716	1726	I-Observation
between	32401715	1727	1734	B-Intervention
the	32401715	1735	1738	I-Intervention
two	32401715	1739	1742	I-Intervention
groups	32401715	1743	1749	I-Intervention
.	32401715	1749	1750	O

One	32401715	1751	1754	B-Count
patient	32401715	1755	1762	I-Count
in	32401715	1763	1765	O
the	32401715	1766	1769	O
control	32401715	1770	1777	B-Intervention
group	32401715	1778	1783	O
discontinued	32401715	1784	1796	O
lopinavir-ritonavir	32401715	1797	1816	O
because	32401715	1817	1824	O
of	32401715	1825	1827	O
biochemical	32401715	1828	1839	B-Outcome
hepatitis	32401715	1840	1849	I-Outcome
.	32401715	1849	1850	O

No	32401715	1851	1853	B-Count
patients	32401715	1854	1862	I-Count
died	32401715	1863	1867	B-Outcome
during	32401715	1868	1874	O
the	32401715	1875	1878	O
study	32401715	1879	1884	O
.	32401715	1884	1885	O

Early	32401715	1886	1891	B-Intervention
triple	32401715	1892	1898	I-Intervention
antiviral	32401715	1899	1908	I-Intervention
therapy	32401715	1909	1916	I-Intervention
was	32401715	1917	1920	O
safe	32401715	1921	1925	B-Observation
and	32401715	1926	1929	O
superior	32401715	1930	1938	B-Observation
to	32401715	1939	1941	O
lopinavir-ritonavir	32401715	1942	1961	B-Intervention
alone	32401715	1962	1967	I-Intervention
in	32401715	1968	1970	O
alleviating	32401715	1971	1982	B-Observation
symptoms	32401715	1983	1991	B-Outcome
and	32401715	1992	1995	O
shortening	32401715	1996	2006	B-Observation
the	32401715	2007	2010	O
duration	32401715	2011	2019	B-Outcome
of	32401715	2020	2022	I-Outcome
viral	32401715	2023	2028	I-Outcome
shedding	32401715	2029	2037	I-Outcome
and	32401715	2038	2041	O
hospital	32401715	2042	2050	B-Outcome
stay	32401715	2051	2055	I-Outcome
in	32401715	2056	2058	O
patients	32401715	2059	2067	O
with	32401715	2068	2072	O
mild	32401715	2073	2077	B-Participant
to	32401715	2078	2080	I-Participant
moderate	32401715	2081	2089	I-Participant
COVID-19	32401715	2090	2098	I-Participant
.	32401715	2098	2099	O

Future	32401715	2100	2106	O
clinical	32401715	2107	2115	O
study	32401715	2116	2121	O
of	32401715	2122	2124	O
a	32401715	2125	2126	O
double	32401715	2127	2133	O
antiviral	32401715	2134	2143	O
therapy	32401715	2144	2151	O
with	32401715	2152	2156	O
interferon	32401715	2157	2167	O
beta-1b	32401715	2168	2175	O
as	32401715	2176	2178	O
a	32401715	2179	2180	O
backbone	32401715	2181	2189	O
is	32401715	2190	2192	O
warranted	32401715	2193	2202	O
.	32401715	2202	2203	O

The	32401715	2204	2207	O
Shaw-Foundation	32401715	2208	2223	O
,	32401715	2223	2224	O
Richard	32401715	2225	2232	O
and	32401715	2233	2236	O
Carol	32401715	2237	2242	O
Yu	32401715	2243	2245	O
,	32401715	2245	2246	O
May	32401715	2247	2250	O
Tam	32401715	2251	2254	O
Mak	32401715	2255	2258	O
Mei	32401715	2259	2262	O
Yin	32401715	2263	2266	O
,	32401715	2266	2267	O
and	32401715	2268	2271	O
Sanming	32401715	2272	2279	O
Project	32401715	2280	2287	O
of	32401715	2288	2290	O
Medicine	32401715	2291	2299	O
.	32401715	2299	2300	O


Hydroxychloroquine	32409561	0	18	B-Intervention
in	32409561	19	21	O
patients	32409561	22	30	O
with	32409561	31	35	O
mainly	32409561	36	42	O
mild	32409561	43	47	B-Participant
to	32409561	48	50	I-Participant
moderate	32409561	51	59	I-Participant
coronavirus	32409561	60	71	I-Participant
disease	32409561	72	79	I-Participant
2019	32409561	80	84	I-Participant
:	32409561	85	86	O
open	32409561	87	91	O
label	32409561	92	97	O
,	32409561	98	99	O
randomised	32409561	100	110	O
controlled	32409561	111	121	O
trial	32409561	122	127	O
.	32409561	128	129	O

To	32409561	130	132	O
assess	32409561	133	139	O
the	32409561	140	143	O
efficacy	32409561	144	152	B-Outcome
and	32409561	153	156	O
safety	32409561	157	163	B-Outcome
of	32409561	164	166	O
hydroxychloroquine	32409561	167	185	B-Intervention
plus	32409561	186	190	I-Intervention
standard	32409561	191	199	I-Intervention
of	32409561	200	202	I-Intervention
care	32409561	203	207	I-Intervention
compared	32409561	208	216	O
with	32409561	217	221	O
standard	32409561	222	230	B-Intervention
of	32409561	231	233	I-Intervention
care	32409561	234	238	I-Intervention
alone	32409561	239	244	I-Intervention
in	32409561	245	247	O
adults	32409561	248	254	B-Participant
with	32409561	255	259	O
coronavirus	32409561	260	271	B-Participant
disease	32409561	272	279	I-Participant
2019	32409561	280	284	I-Participant
(	32409561	285	286	I-Participant
covid-19	32409561	287	295	I-Participant
)	32409561	296	297	I-Participant
.	32409561	298	299	O

Multicentre	32409561	300	311	O
,	32409561	312	313	O
open	32409561	314	318	O
label	32409561	319	324	O
,	32409561	325	326	O
randomised	32409561	327	337	O
controlled	32409561	338	348	O
trial	32409561	349	354	O
.	32409561	355	356	O

16	32409561	357	359	O
government	32409561	360	370	O
designated	32409561	371	381	O
covid-19	32409561	382	390	O
treatment	32409561	391	400	O
centres	32409561	401	408	O
in	32409561	409	411	O
China	32409561	412	417	O
,	32409561	418	419	O
11	32409561	420	422	O
to	32409561	423	425	O
29	32409561	426	428	O
February	32409561	429	437	O
2020	32409561	438	442	O
.	32409561	443	444	O

150	32409561	445	448	O
patients	32409561	449	457	O
admitted	32409561	458	466	B-Participant
to	32409561	467	469	I-Participant
hospital	32409561	470	478	I-Participant
with	32409561	479	483	O
laboratory	32409561	484	494	B-Participant
confirmed	32409561	495	504	I-Participant
covid-19	32409561	505	513	I-Participant
were	32409561	514	518	O
included	32409561	519	527	O
in	32409561	528	530	O
the	32409561	531	534	O
intention	32409561	535	544	O
to	32409561	545	547	O
treat	32409561	548	553	O
analysis	32409561	554	562	O
(	32409561	563	564	O
75	32409561	565	567	O
patients	32409561	568	576	O
assigned	32409561	577	585	O
to	32409561	586	588	O
hydroxychloroquine	32409561	589	607	O
plus	32409561	608	612	O
standard	32409561	613	621	O
of	32409561	622	624	O
care	32409561	625	629	O
,	32409561	630	631	O
75	32409561	632	634	O
to	32409561	635	637	O
standard	32409561	638	646	O
of	32409561	647	649	O
care	32409561	650	654	O
alone	32409561	655	660	O
)	32409561	661	662	O
.	32409561	663	664	O

Hydroxychloroquine	32409561	665	683	B-Intervention
administrated	32409561	684	697	O
at	32409561	698	700	O
a	32409561	701	702	O
loading	32409561	703	710	O
dose	32409561	711	715	O
of	32409561	716	718	O
1200	32409561	719	723	O
mg	32409561	724	726	O
daily	32409561	727	732	O
for	32409561	733	736	O
three	32409561	737	742	O
days	32409561	743	747	O
followed	32409561	748	756	O
by	32409561	757	759	O
a	32409561	760	761	O
maintenance	32409561	762	773	O
dose	32409561	774	778	O
of	32409561	779	781	O
800	32409561	782	785	O
mg	32409561	786	788	O
daily	32409561	789	794	O
(	32409561	795	796	O
total	32409561	797	802	O
treatment	32409561	803	812	O
duration	32409561	813	821	O
:	32409561	822	823	O
two	32409561	824	827	O
or	32409561	828	830	O
three	32409561	831	836	O
weeks	32409561	837	842	O
for	32409561	843	846	O
patients	32409561	847	855	O
with	32409561	856	860	O
mild	32409561	861	865	B-Participant
to	32409561	866	868	I-Participant
moderate	32409561	869	877	I-Participant
or	32409561	878	880	I-Participant
severe	32409561	881	887	I-Participant
disease	32409561	888	895	I-Participant
,	32409561	896	897	O
respectively	32409561	898	910	O
)	32409561	911	912	O
.	32409561	913	914	O

Negative	32409561	915	923	B-Outcome
conversion	32409561	924	934	I-Outcome
of	32409561	935	937	I-Outcome
severe	32409561	938	944	I-Outcome
acute	32409561	945	950	I-Outcome
respiratory	32409561	951	962	I-Outcome
syndrome	32409561	963	971	I-Outcome
coronavirus	32409561	972	983	I-Outcome
2	32409561	984	985	I-Outcome
by	32409561	986	988	O
28	32409561	989	991	O
days	32409561	992	996	O
,	32409561	997	998	O
analysed	32409561	999	1007	O
according	32409561	1008	1017	O
to	32409561	1018	1020	O
the	32409561	1021	1024	O
intention	32409561	1025	1034	O
to	32409561	1035	1037	O
treat	32409561	1038	1043	O
principle	32409561	1044	1053	O
.	32409561	1054	1055	O

Adverse	32409561	1056	1063	B-Outcome
events	32409561	1064	1070	I-Outcome
were	32409561	1071	1075	O
analysed	32409561	1076	1084	O
in	32409561	1085	1087	O
the	32409561	1088	1091	O
safety	32409561	1092	1098	O
population	32409561	1099	1109	O
in	32409561	1110	1112	O
which	32409561	1113	1118	O
hydroxychloroquine	32409561	1119	1137	B-Intervention
recipients	32409561	1138	1148	I-Intervention
were	32409561	1149	1153	O
participants	32409561	1154	1166	O
who	32409561	1167	1170	O
received	32409561	1171	1179	O
at	32409561	1180	1182	O
least	32409561	1183	1188	O
one	32409561	1189	1192	O
dose	32409561	1193	1197	O
of	32409561	1198	1200	O
hydroxychloroquine	32409561	1201	1219	B-Intervention
and	32409561	1220	1223	O
hydroxychloroquine	32409561	1224	1242	B-Intervention
non-recipients	32409561	1243	1257	I-Intervention
were	32409561	1258	1262	O
those	32409561	1263	1268	O
managed	32409561	1269	1276	O
with	32409561	1277	1281	O
standard	32409561	1282	1290	B-Intervention
of	32409561	1291	1293	I-Intervention
care	32409561	1294	1298	I-Intervention
alone	32409561	1299	1304	I-Intervention
.	32409561	1305	1306	O

Of	32409561	1307	1309	O
150	32409561	1310	1313	O
patients	32409561	1314	1322	O
,	32409561	1323	1324	O
148	32409561	1325	1328	B-Count
had	32409561	1329	1332	O
mild	32409561	1333	1337	B-Participant
to	32409561	1338	1340	I-Participant
moderate	32409561	1341	1349	I-Participant
disease	32409561	1350	1357	I-Participant
and	32409561	1358	1361	O
two	32409561	1362	1365	B-Count
had	32409561	1366	1369	O
severe	32409561	1370	1376	B-Participant
disease	32409561	1377	1384	I-Participant
.	32409561	1385	1386	O

The	32409561	1387	1390	O
mean	32409561	1391	1395	B-Outcome
duration	32409561	1396	1404	I-Outcome
from	32409561	1405	1409	I-Outcome
symptom	32409561	1410	1417	I-Outcome
onset	32409561	1418	1423	I-Outcome
to	32409561	1424	1426	I-Outcome
randomisation	32409561	1427	1440	I-Outcome
was	32409561	1441	1444	O
16.6	32409561	1445	1449	B-Observation
(	32409561	1450	1451	I-Observation
SD	32409561	1452	1454	I-Observation
10.5	32409561	1455	1459	I-Observation
;	32409561	1460	1461	I-Observation
range	32409561	1462	1467	I-Observation
3	32409561	1468	1469	I-Observation
-	32409561	1469	1470	I-Observation
41	32409561	1470	1472	I-Observation
)	32409561	1473	1474	I-Observation
days	32409561	1475	1479	I-Observation
.	32409561	1480	1481	O

A	32409561	1482	1483	B-Count
total	32409561	1484	1489	I-Count
of	32409561	1490	1492	I-Count
109	32409561	1493	1496	I-Count
(	32409561	1497	1498	I-Count
73	32409561	1499	1501	I-Count
%	32409561	1502	1503	I-Count
)	32409561	1504	1505	I-Count
patients	32409561	1506	1514	I-Count
(	32409561	1515	1516	O
56	32409561	1517	1519	B-Count
standard	32409561	1520	1528	B-Intervention
of	32409561	1529	1531	I-Intervention
care	32409561	1532	1536	I-Intervention
;	32409561	1537	1538	O
53	32409561	1539	1541	B-Count
standard	32409561	1542	1550	B-Intervention
of	32409561	1551	1553	I-Intervention
care	32409561	1554	1558	I-Intervention
plus	32409561	1559	1563	I-Intervention
hydroxychloroquine	32409561	1564	1582	I-Intervention
)	32409561	1583	1584	O
had	32409561	1585	1588	O
negative	32409561	1589	1597	B-Outcome
conversion	32409561	1598	1608	I-Outcome
well	32409561	1609	1613	O
before	32409561	1614	1620	O
28	32409561	1621	1623	O
days	32409561	1624	1628	O
,	32409561	1629	1630	O
and	32409561	1631	1634	O
the	32409561	1635	1638	O
remaining	32409561	1639	1648	O
41	32409561	1649	1651	B-Count
(	32409561	1652	1653	I-Count
27	32409561	1654	1656	I-Count
%	32409561	1657	1658	I-Count
)	32409561	1659	1660	I-Count
patients	32409561	1661	1669	I-Count
(	32409561	1670	1671	O
19	32409561	1672	1674	B-Count
standard	32409561	1675	1683	B-Intervention
of	32409561	1684	1686	I-Intervention
care	32409561	1687	1691	I-Intervention
;	32409561	1692	1693	O
22	32409561	1694	1696	B-Count
standard	32409561	1697	1705	B-Intervention
of	32409561	1706	1708	I-Intervention
care	32409561	1709	1713	I-Intervention
plus	32409561	1714	1718	I-Intervention
hydroxychloroquine	32409561	1719	1737	I-Intervention
)	32409561	1738	1739	O
were	32409561	1740	1744	O
censored	32409561	1745	1753	O
as	32409561	1754	1756	O
they	32409561	1757	1761	O
did	32409561	1762	1765	O
not	32409561	1766	1769	O
reach	32409561	1770	1775	O
negative	32409561	1776	1784	B-Outcome
conversion	32409561	1785	1795	I-Outcome
of	32409561	1796	1798	I-Outcome
virus	32409561	1799	1804	I-Outcome
.	32409561	1805	1806	O

The	32409561	1807	1810	O
probability	32409561	1811	1822	B-Outcome
of	32409561	1823	1825	I-Outcome
negative	32409561	1826	1834	I-Outcome
conversion	32409561	1835	1845	I-Outcome
by	32409561	1846	1848	I-Outcome
28	32409561	1849	1851	I-Outcome
days	32409561	1852	1856	I-Outcome
in	32409561	1857	1859	O
the	32409561	1860	1863	O
standard	32409561	1864	1872	B-Intervention
of	32409561	1873	1875	I-Intervention
care	32409561	1876	1880	I-Intervention
plus	32409561	1881	1885	I-Intervention
hydroxychloroquine	32409561	1886	1904	I-Intervention
group	32409561	1905	1910	O
was	32409561	1911	1914	O
85.4	32409561	1915	1919	B-Observation
%	32409561	1920	1921	I-Observation
(	32409561	1922	1923	O
95	32409561	1924	1926	O
%	32409561	1927	1928	O
confidence	32409561	1929	1939	O
interval	32409561	1940	1948	O
73.8	32409561	1949	1953	O
%	32409561	1954	1955	O
to	32409561	1956	1958	O
93.8	32409561	1959	1963	O
%	32409561	1964	1965	O
)	32409561	1966	1967	O
,	32409561	1968	1969	O
similar	32409561	1970	1977	B-Observation
to	32409561	1978	1980	O
that	32409561	1981	1985	O
in	32409561	1986	1988	O
the	32409561	1989	1992	O
standard	32409561	1993	2001	B-Intervention
of	32409561	2002	2004	I-Intervention
care	32409561	2005	2009	I-Intervention
group	32409561	2010	2015	O
(	32409561	2016	2017	O
81.3	32409561	2018	2022	B-Observation
%	32409561	2023	2024	I-Observation
,	32409561	2025	2026	O
71.2	32409561	2027	2031	O
%	32409561	2032	2033	O
to	32409561	2034	2036	O
89.6	32409561	2037	2041	O
%	32409561	2042	2043	O
)	32409561	2044	2045	O
.	32409561	2046	2047	O

The	32409561	2048	2051	O
difference	32409561	2052	2062	B-Outcome
between	32409561	2063	2070	B-Intervention
groups	32409561	2071	2077	I-Intervention
was	32409561	2078	2081	O
4.1	32409561	2082	2085	B-Observation
%	32409561	2086	2087	I-Observation
(	32409561	2088	2089	O
95	32409561	2090	2092	O
%	32409561	2093	2094	O
confidence	32409561	2095	2105	O
interval	32409561	2106	2114	O
-10.3	32409561	2115	2120	O
%	32409561	2121	2122	O
to	32409561	2123	2125	O
18.5	32409561	2126	2130	O
%	32409561	2131	2132	O
)	32409561	2133	2134	O
.	32409561	2135	2136	O

In	32409561	2137	2139	O
the	32409561	2140	2143	O
safety	32409561	2144	2150	O
population	32409561	2151	2161	O
,	32409561	2162	2163	O
adverse	32409561	2164	2171	B-Outcome
events	32409561	2172	2178	I-Outcome
were	32409561	2179	2183	O
recorded	32409561	2184	2192	O
in	32409561	2193	2195	O
7/80	32409561	2196	2200	B-Count
(	32409561	2201	2202	I-Count
9	32409561	2203	2204	I-Count
%	32409561	2205	2206	I-Count
)	32409561	2207	2208	I-Count
hydroxychloroquine	32409561	2209	2227	B-Intervention
non-recipients	32409561	2228	2242	I-Intervention
and	32409561	2243	2246	O
in	32409561	2247	2249	O
21/70	32409561	2250	2255	B-Count
(	32409561	2256	2257	I-Count
30	32409561	2258	2260	I-Count
%	32409561	2261	2262	I-Count
)	32409561	2263	2264	I-Count
hydroxychloroquine	32409561	2265	2283	B-Intervention
recipients	32409561	2284	2294	I-Intervention
.	32409561	2295	2296	O

The	32409561	2297	2300	O
most	32409561	2301	2305	O
common	32409561	2306	2312	O
adverse	32409561	2313	2320	O
event	32409561	2321	2326	O
in	32409561	2327	2329	O
the	32409561	2330	2333	O
hydroxychloroquine	32409561	2334	2352	B-Intervention
recipients	32409561	2353	2363	I-Intervention
was	32409561	2364	2367	O
diarrhoea	32409561	2368	2377	B-Outcome
,	32409561	2378	2379	O
reported	32409561	2380	2388	O
in	32409561	2389	2391	O
7/70	32409561	2392	2396	B-Count
(	32409561	2397	2398	I-Count
10	32409561	2399	2401	I-Count
%	32409561	2402	2403	I-Count
)	32409561	2404	2405	I-Count
patients	32409561	2406	2414	I-Count
.	32409561	2415	2416	O

Two	32409561	2417	2420	B-Count
hydroxychloroquine	32409561	2421	2439	B-Intervention
recipients	32409561	2440	2450	I-Intervention
reported	32409561	2451	2459	O
serious	32409561	2460	2467	B-Outcome
adverse	32409561	2468	2475	I-Outcome
events	32409561	2476	2482	I-Outcome
.	32409561	2483	2484	O

Administration	32409561	2485	2499	O
of	32409561	2500	2502	O
hydroxychloroquine	32409561	2503	2521	B-Intervention
did	32409561	2522	2525	O
not	32409561	2526	2529	O
result	32409561	2530	2536	O
in	32409561	2537	2539	O
a	32409561	2540	2541	O
significantly	32409561	2542	2555	B-Observation
higher	32409561	2556	2562	I-Observation
probability	32409561	2563	2574	B-Outcome
of	32409561	2575	2577	I-Outcome
negative	32409561	2578	2586	I-Outcome
conversion	32409561	2587	2597	I-Outcome
than	32409561	2598	2602	O
standard	32409561	2603	2611	B-Intervention
of	32409561	2612	2614	I-Intervention
care	32409561	2615	2619	I-Intervention
alone	32409561	2620	2625	I-Intervention
in	32409561	2626	2628	O
patients	32409561	2629	2637	O
admitted	32409561	2638	2646	B-Participant
to	32409561	2647	2649	I-Participant
hospital	32409561	2650	2658	I-Participant
with	32409561	2659	2663	O
mainly	32409561	2664	2670	O
persistent	32409561	2671	2681	B-Participant
mild	32409561	2682	2686	I-Participant
to	32409561	2687	2689	I-Participant
moderate	32409561	2690	2698	I-Participant
covid-19	32409561	2699	2707	I-Participant
.	32409561	2708	2709	O

Adverse	32409561	2710	2717	B-Outcome
events	32409561	2718	2724	I-Outcome
were	32409561	2725	2729	O
higher	32409561	2730	2736	B-Observation
in	32409561	2737	2739	O
hydroxychloroquine	32409561	2740	2758	B-Intervention
recipients	32409561	2759	2769	I-Intervention
than	32409561	2770	2774	O
in	32409561	2775	2777	O
non-recipients	32409561	2778	2792	B-Intervention
.	32409561	2793	2794	O

ChiCTR2000029868	32409561	2795	2811	O
.	32409561	2812	2813	O


Resuscitation	32419128	0	13	B-Outcome
of	32419128	14	16	O
the	32419128	17	20	O
patient	32419128	21	28	O
with	32419128	29	33	O
suspected	32419128	34	43	B-Participant
/	32419128	44	45	I-Participant
confirmed	32419128	46	55	I-Participant
COVID-19	32419128	56	64	I-Participant
when	32419128	65	69	O
wearing	32419128	70	77	O
personal	32419128	78	86	B-Participant
protective	32419128	87	97	I-Participant
equipment	32419128	98	107	I-Participant
:	32419128	108	109	O
A	32419128	110	111	O
randomized	32419128	112	122	O
multicenter	32419128	123	134	O
crossover	32419128	135	144	O
simulation	32419128	145	155	O
trial	32419128	156	161	O
.	32419128	162	163	O

The	32419128	164	167	O
aim	32419128	168	171	O
of	32419128	172	174	O
the	32419128	175	178	O
study	32419128	179	184	O
was	32419128	185	188	O
to	32419128	189	191	O
evaluate	32419128	192	200	O
various	32419128	201	208	O
methods	32419128	209	216	B-Intervention
of	32419128	217	219	I-Intervention
chest	32419128	220	225	I-Intervention
compressions	32419128	226	238	I-Intervention
in	32419128	239	241	O
patients	32419128	242	250	O
with	32419128	251	255	O
suspected	32419128	256	265	B-Participant
/	32419128	266	267	I-Participant
confirmed	32419128	268	277	I-Participant
SARS	32419128	278	282	I-Participant
-	32419128	283	284	I-Participant
CoV-2	32419128	285	290	I-Participant
infection	32419128	291	300	I-Participant
conducted	32419128	301	310	O
by	32419128	311	313	O
medical	32419128	314	321	B-Participant
students	32419128	322	330	I-Participant
wearing	32419128	331	338	O
full	32419128	339	343	B-Participant
personal	32419128	344	352	I-Participant
protective	32419128	353	363	I-Participant
equipment	32419128	364	373	I-Participant
(	32419128	374	375	I-Participant
PPE	32419128	376	379	I-Participant
)	32419128	380	381	I-Participant
for	32419128	382	385	O
aerosol	32419128	386	393	B-Participant
generating	32419128	394	404	I-Participant
procedures	32419128	405	415	I-Participant
(	32419128	416	417	I-Participant
AGP	32419128	418	421	I-Participant
)	32419128	422	423	I-Participant
.	32419128	424	425	O

This	32419128	426	430	O
was	32419128	431	434	O
prospective	32419128	435	446	O
,	32419128	447	448	O
randomized	32419128	449	459	O
,	32419128	460	461	O
multicenter	32419128	462	473	O
,	32419128	474	475	O
single	32419128	476	482	O
-	32419128	483	484	O
blinded	32419128	485	492	O
,	32419128	493	494	O
crossover	32419128	495	504	O
simulation	32419128	505	515	O
trial	32419128	516	521	O
.	32419128	522	523	O

Thirty	32419128	524	530	O
-	32419128	531	532	O
five	32419128	533	537	O
medical	32419128	538	545	O
students	32419128	546	554	O
after	32419128	555	560	O
an	32419128	561	563	O
advanced	32419128	564	572	O
cardiovascular	32419128	573	587	O
life	32419128	588	592	O
support	32419128	593	600	O
course	32419128	601	607	O
,	32419128	608	609	O
which	32419128	610	615	O
included	32419128	616	624	O
performing	32419128	625	635	O
2-min	32419128	636	641	O
continuous	32419128	642	652	O
chest	32419128	653	658	O
compression	32419128	659	670	O
scenarios	32419128	671	680	O
using	32419128	681	686	O
three	32419128	687	692	O
methods	32419128	693	700	O
:	32419128	701	702	O
(	32419128	703	704	O
A	32419128	705	706	O
)	32419128	707	708	O
manual	32419128	709	715	B-Intervention
chest	32419128	716	721	I-Intervention
compression	32419128	722	733	I-Intervention
(	32419128	734	735	I-Intervention
CC	32419128	736	738	I-Intervention
)	32419128	739	740	I-Intervention
,	32419128	741	742	O
(	32419128	743	744	O
B	32419128	745	746	O
)	32419128	747	748	O
compression	32419128	749	760	B-Intervention
with	32419128	761	765	I-Intervention
CPRMeter	32419128	766	774	I-Intervention
,	32419128	775	776	O
(	32419128	777	778	O
C	32419128	779	780	O
)	32419128	781	782	O
compression	32419128	783	794	B-Intervention
with	32419128	795	799	I-Intervention
LifeLine	32419128	800	808	I-Intervention
ARM	32419128	809	812	I-Intervention
device	32419128	813	819	I-Intervention
.	32419128	820	821	O

During	32419128	822	828	O
resuscitation	32419128	829	842	O
they	32419128	843	847	O
are	32419128	848	851	O
wearing	32419128	852	859	O
full	32419128	860	864	O
personal	32419128	865	873	O
protective	32419128	874	884	O
equipment	32419128	885	894	O
for	32419128	895	898	O
aerosol	32419128	899	906	O
generating	32419128	907	917	O
procedures	32419128	918	928	O
.	32419128	929	930	O

The	32419128	931	934	O
median	32419128	935	941	B-Outcome
chest	32419128	942	947	I-Outcome
compression	32419128	948	959	I-Outcome
depth	32419128	960	965	I-Outcome
using	32419128	966	971	O
manual	32419128	972	978	B-Intervention
CC	32419128	979	981	I-Intervention
,	32419128	982	983	O
CPRMeter	32419128	984	992	B-Intervention
and	32419128	993	996	O
LifeLine	32419128	997	1005	B-Intervention
ARM	32419128	1006	1009	I-Intervention
varied	32419128	1010	1016	B-Observation
and	32419128	1017	1020	O
amounted	32419128	1021	1029	O
to	32419128	1030	1032	O
40	32419128	1033	1035	B-Observation
(	32419128	1036	1037	I-Observation
38	32419128	1038	1040	I-Observation
-	32419128	1041	1042	I-Observation
45	32419128	1043	1045	I-Observation
)	32419128	1046	1047	I-Observation
vs.	32419128	1048	1051	O
45	32419128	1052	1054	B-Observation
(	32419128	1055	1056	I-Observation
40	32419128	1057	1059	I-Observation
-	32419128	1060	1061	I-Observation
50	32419128	1062	1064	I-Observation
)	32419128	1065	1066	I-Observation
vs.	32419128	1067	1070	O
51	32419128	1071	1073	B-Observation
(	32419128	1074	1075	I-Observation
50	32419128	1076	1078	I-Observation
-	32419128	1079	1080	I-Observation
52	32419128	1081	1083	I-Observation
)	32419128	1084	1085	I-Observation
mm	32419128	1086	1088	I-Observation
,	32419128	1089	1090	O
respectively	32419128	1091	1103	O
(	32419128	1104	1105	O
p	32419128	1106	1107	O
=	32419128	1108	1109	O
0.002	32419128	1110	1115	O
)	32419128	1116	1117	O
.	32419128	1118	1119	O

The	32419128	1120	1123	O
median	32419128	1124	1130	B-Outcome
chest	32419128	1131	1136	I-Outcome
compression	32419128	1137	1148	I-Outcome
rate	32419128	1149	1153	I-Outcome
was	32419128	1154	1157	O
109	32419128	1158	1161	B-Observation
(	32419128	1162	1163	I-Observation
IQR	32419128	1164	1167	I-Observation
;	32419128	1168	1169	I-Observation
102	32419128	1170	1173	I-Observation
-	32419128	1174	1175	I-Observation
131	32419128	1176	1179	I-Observation
)	32419128	1180	1181	I-Observation
compressions	32419128	1182	1194	I-Observation
per	32419128	1195	1198	I-Observation
minute	32419128	1199	1205	I-Observation
(	32419128	1206	1207	I-Observation
CPM	32419128	1208	1211	I-Observation
)	32419128	1212	1213	I-Observation
for	32419128	1214	1217	O
manual	32419128	1218	1224	B-Intervention
CC	32419128	1225	1227	I-Intervention
,	32419128	1228	1229	O
107	32419128	1230	1233	B-Observation
(	32419128	1234	1235	I-Observation
105	32419128	1236	1239	I-Observation
-	32419128	1240	1241	I-Observation
127	32419128	1242	1245	I-Observation
)	32419128	1246	1247	I-Observation
CPM	32419128	1248	1251	I-Observation
for	32419128	1252	1255	O
CPRMeter	32419128	1256	1264	B-Intervention
,	32419128	1265	1266	O
and	32419128	1267	1270	O
102	32419128	1271	1274	B-Observation
(	32419128	1275	1276	I-Observation
101	32419128	1277	1280	I-Observation
-	32419128	1281	1282	I-Observation
102	32419128	1283	1286	I-Observation
)	32419128	1287	1288	I-Observation
CPM	32419128	1289	1292	I-Observation
for	32419128	1293	1296	O
LifeLine	32419128	1297	1305	B-Intervention
ARM	32419128	1306	1309	I-Intervention
(	32419128	1310	1311	O
p	32419128	1312	1313	O
=	32419128	1314	1315	O
0.027	32419128	1316	1321	O
)	32419128	1322	1323	O
.	32419128	1324	1325	O

The	32419128	1326	1329	O
percentage	32419128	1330	1340	B-Outcome
of	32419128	1341	1343	I-Outcome
correct	32419128	1344	1351	I-Outcome
chest	32419128	1352	1357	I-Outcome
recoil	32419128	1358	1364	I-Outcome
was	32419128	1365	1368	O
the	32419128	1369	1372	O
highest	32419128	1373	1380	B-Observation
for	32419128	1381	1384	O
LifeLine	32419128	1385	1393	B-Intervention
ARM	32419128	1394	1397	I-Intervention
-	32419128	1398	1399	O
100	32419128	1400	1403	B-Observation
%	32419128	1404	1405	I-Observation
(	32419128	1406	1407	I-Observation
95	32419128	1408	1410	I-Observation
-	32419128	1411	1412	I-Observation
100	32419128	1413	1416	I-Observation
)	32419128	1417	1418	I-Observation
,	32419128	1419	1420	O
80	32419128	1421	1423	B-Observation
%	32419128	1424	1425	I-Observation
(	32419128	1426	1427	I-Observation
60	32419128	1428	1430	I-Observation
-	32419128	1431	1432	I-Observation
90	32419128	1433	1435	I-Observation
)	32419128	1436	1437	I-Observation
in	32419128	1438	1440	O
CPRMeter	32419128	1441	1449	B-Intervention
group	32419128	1450	1455	O
,	32419128	1456	1457	O
and	32419128	1458	1461	O
the	32419128	1462	1465	O
lowest	32419128	1466	1472	B-Observation
for	32419128	1473	1476	O
manual	32419128	1477	1483	B-Intervention
CC	32419128	1484	1486	I-Intervention
-	32419128	1487	1488	O
29	32419128	1489	1491	B-Observation
%	32419128	1492	1493	I-Observation
(	32419128	1494	1495	I-Observation
26	32419128	1496	1498	I-Observation
-	32419128	1499	1500	I-Observation
48	32419128	1501	1503	I-Observation
)	32419128	1504	1505	I-Observation
.	32419128	1506	1507	O

According	32419128	1508	1517	O
to	32419128	1518	1520	O
the	32419128	1521	1524	O
results	32419128	1525	1532	O
of	32419128	1533	1535	O
this	32419128	1536	1540	O
simulation	32419128	1541	1551	O
trial	32419128	1552	1557	O
,	32419128	1558	1559	O
automated	32419128	1560	1569	B-Intervention
chest	32419128	1570	1575	I-Intervention
compression	32419128	1576	1587	I-Intervention
devices	32419128	1588	1595	I-Intervention
(	32419128	1596	1597	I-Intervention
ACCD	32419128	1598	1602	I-Intervention
)	32419128	1603	1604	I-Intervention
should	32419128	1605	1611	O
be	32419128	1612	1614	O
used	32419128	1615	1619	O
for	32419128	1620	1623	O
chest	32419128	1624	1629	B-Outcome
compression	32419128	1630	1641	I-Outcome
of	32419128	1642	1644	O
patients	32419128	1645	1653	O
with	32419128	1654	1658	O
suspected	32419128	1659	1668	B-Participant
/	32419128	1669	1670	I-Participant
confirmed	32419128	1671	1680	I-Participant
COVID-19	32419128	1681	1689	I-Participant
.	32419128	1690	1691	O

In	32419128	1692	1694	O
the	32419128	1695	1698	O
absence	32419128	1699	1706	O
of	32419128	1707	1709	O
ACCD	32419128	1710	1714	O
,	32419128	1715	1716	O
it	32419128	1717	1719	O
seems	32419128	1720	1725	O
reasonable	32419128	1726	1736	O
to	32419128	1737	1739	O
change	32419128	1740	1746	O
the	32419128	1747	1750	O
cardiopulmonary	32419128	1751	1766	O
resuscitation	32419128	1767	1780	O
algorithm	32419128	1781	1790	O
(	32419128	1791	1792	O
in	32419128	1793	1795	O
the	32419128	1796	1799	O
context	32419128	1800	1807	O
of	32419128	1808	1810	O
patients	32419128	1811	1819	O
with	32419128	1820	1824	O
suspected	32419128	1825	1834	O
/	32419128	1835	1836	O
confirmed	32419128	1837	1846	O
COVID-19	32419128	1847	1855	O
)	32419128	1856	1857	O
by	32419128	1858	1860	O
reducing	32419128	1861	1869	O
the	32419128	1870	1873	O
duration	32419128	1874	1882	O
of	32419128	1883	1885	O
the	32419128	1886	1889	O
cardiopulmonary	32419128	1890	1905	O
resuscitation	32419128	1906	1919	O
cycle	32419128	1920	1925	O
from	32419128	1926	1930	O
the	32419128	1931	1934	O
current	32419128	1935	1942	O
2-min	32419128	1943	1948	O
to	32419128	1949	1951	O
1-min	32419128	1952	1957	O
cycles	32419128	1958	1964	O
due	32419128	1965	1968	O
to	32419128	1969	1971	O
a	32419128	1972	1973	O
statistically	32419128	1974	1987	O
significant	32419128	1988	1999	O
reduction	32419128	2000	2009	O
in	32419128	2010	2012	O
the	32419128	2013	2016	O
quality	32419128	2017	2024	O
of	32419128	2025	2027	O
chest	32419128	2028	2033	O
compressions	32419128	2034	2046	O
among	32419128	2047	2052	O
rescuers	32419128	2053	2061	O
wearing	32419128	2062	2069	O
PPE	32419128	2070	2073	O
AGP	32419128	2074	2077	O
.	32419128	2078	2079	O


Remdesivir	32423584	0	10	B-Intervention
in	32423584	11	13	O
adults	32423584	14	20	B-Participant
with	32423584	21	25	O
severe	32423584	26	32	B-Participant
COVID-19	32423584	33	41	I-Participant
:	32423584	42	43	O
a	32423584	44	45	O
randomised	32423584	46	56	O
,	32423584	57	58	O
double-blind	32423584	59	71	O
,	32423584	72	73	O
placebo-controlled	32423584	74	92	O
,	32423584	93	94	O
multicentre	32423584	95	106	O
trial	32423584	107	112	O
.	32423584	113	114	O

No	32423584	115	117	O
specific	32423584	118	126	O
antiviral	32423584	127	136	O
drug	32423584	137	141	O
has	32423584	142	145	O
been	32423584	146	150	O
proven	32423584	151	157	O
effective	32423584	158	167	O
for	32423584	168	171	O
treatment	32423584	172	181	O
of	32423584	182	184	O
patients	32423584	185	193	O
with	32423584	194	198	O
severe	32423584	199	205	O
coronavirus	32423584	206	217	O
disease	32423584	218	225	O
2019	32423584	226	230	O
(	32423584	231	232	O
COVID-19	32423584	233	241	O
)	32423584	242	243	O
.	32423584	244	245	O

Remdesivir	32423584	246	256	O
(	32423584	257	258	O
GS-5734	32423584	259	266	O
)	32423584	267	268	O
,	32423584	269	270	O
a	32423584	271	272	O
nucleoside	32423584	273	283	O
analogue	32423584	284	292	O
prodrug	32423584	293	300	O
,	32423584	301	302	O
has	32423584	303	306	O
inhibitory	32423584	307	317	O
effects	32423584	318	325	O
on	32423584	326	328	O
pathogenic	32423584	329	339	O
animal	32423584	340	346	O
and	32423584	347	350	O
human	32423584	351	356	O
coronaviruses	32423584	357	370	O
,	32423584	371	372	O
including	32423584	373	382	O
severe	32423584	383	389	O
acute	32423584	390	395	O
respiratory	32423584	396	407	O
syndrome	32423584	408	416	O
coronavirus	32423584	417	428	O
2	32423584	429	430	O
(	32423584	431	432	O
SARS-CoV-2	32423584	433	443	O
)	32423584	444	445	O
in	32423584	446	448	O
vitro	32423584	449	454	O
,	32423584	455	456	O
and	32423584	457	460	O
inhibits	32423584	461	469	O
Middle	32423584	470	476	O
East	32423584	477	481	O
respiratory	32423584	482	493	O
syndrome	32423584	494	502	O
coronavirus	32423584	503	514	O
,	32423584	515	516	O
SARS-CoV-1	32423584	517	527	O
,	32423584	528	529	O
and	32423584	530	533	O
SARS-CoV-2	32423584	534	544	O
replication	32423584	545	556	O
in	32423584	557	559	O
animal	32423584	560	566	O
models	32423584	567	573	O
.	32423584	574	575	O

We	32423584	576	578	O
did	32423584	579	582	O
a	32423584	583	584	O
randomised	32423584	585	595	O
,	32423584	596	597	O
double-blind	32423584	598	610	O
,	32423584	611	612	O
placebo-controlled	32423584	613	631	O
,	32423584	632	633	O
multicentre	32423584	634	645	O
trial	32423584	646	651	O
at	32423584	652	654	O
ten	32423584	655	658	O
hospitals	32423584	659	668	O
in	32423584	669	671	O
Hubei	32423584	672	677	O
,	32423584	678	679	O
China	32423584	680	685	O
.	32423584	686	687	O

Eligible	32423584	688	696	O
patients	32423584	697	705	O
were	32423584	706	710	O
adults	32423584	711	717	B-Participant
(	32423584	718	719	O
aged	32423584	720	724	B-Participant
18	32423584	725	728	I-Participant
years	32423584	729	734	I-Participant
)	32423584	735	736	O
admitted	32423584	737	745	B-Participant
to	32423584	746	748	I-Participant
hospital	32423584	749	757	I-Participant
with	32423584	758	762	O
laboratory-confirmed	32423584	763	783	B-Participant
SARS-CoV-2	32423584	784	794	I-Participant
infection	32423584	795	804	I-Participant
,	32423584	805	806	O
with	32423584	807	811	O
an	32423584	812	814	O
interval	32423584	815	823	B-Participant
from	32423584	824	828	I-Participant
symptom	32423584	829	836	I-Participant
onset	32423584	837	842	I-Participant
to	32423584	843	845	I-Participant
enrolment	32423584	846	855	I-Participant
of	32423584	856	858	I-Participant
12	32423584	859	861	I-Participant
days	32423584	862	866	I-Participant
or	32423584	867	869	I-Participant
less	32423584	870	874	I-Participant
,	32423584	875	876	O
oxygen	32423584	877	883	B-Participant
saturation	32423584	884	894	I-Participant
of	32423584	895	897	I-Participant
94	32423584	898	900	I-Participant
%	32423584	901	902	I-Participant
or	32423584	903	905	I-Participant
less	32423584	906	910	I-Participant
on	32423584	911	913	I-Participant
room	32423584	914	918	I-Participant
air	32423584	919	922	I-Participant
or	32423584	923	925	O
a	32423584	926	927	O
ratio	32423584	928	933	B-Participant
of	32423584	934	936	I-Participant
arterial	32423584	937	945	I-Participant
oxygen	32423584	946	952	I-Participant
partial	32423584	953	960	I-Participant
pressure	32423584	961	969	I-Participant
to	32423584	970	972	I-Participant
fractional	32423584	973	983	I-Participant
inspired	32423584	984	992	I-Participant
oxygen	32423584	993	999	I-Participant
of	32423584	1000	1002	I-Participant
300	32423584	1003	1006	I-Participant
mm	32423584	1007	1009	I-Participant
Hg	32423584	1010	1012	I-Participant
or	32423584	1013	1015	I-Participant
less	32423584	1016	1020	I-Participant
,	32423584	1021	1022	O
and	32423584	1023	1026	O
radiologically	32423584	1027	1041	B-Participant
confirmed	32423584	1042	1051	I-Participant
pneumonia	32423584	1052	1061	I-Participant
.	32423584	1062	1063	O

Patients	32423584	1064	1072	O
were	32423584	1073	1077	O
randomly	32423584	1078	1086	O
assigned	32423584	1087	1095	O
in	32423584	1096	1098	O
a	32423584	1099	1100	O
2:1	32423584	1101	1104	O
ratio	32423584	1105	1110	O
to	32423584	1111	1113	O
intravenous	32423584	1114	1125	O
remdesivir	32423584	1126	1136	B-Intervention
(	32423584	1137	1138	O
200	32423584	1139	1142	O
mg	32423584	1143	1145	O
on	32423584	1146	1148	O
day	32423584	1149	1152	O
1	32423584	1153	1154	O
followed	32423584	1155	1163	O
by	32423584	1164	1166	O
100	32423584	1167	1170	O
mg	32423584	1171	1173	O
on	32423584	1174	1176	O
days	32423584	1177	1181	O
2	32423584	1182	1183	O
-	32423584	1183	1184	O
10	32423584	1184	1186	O
in	32423584	1187	1189	O
single	32423584	1190	1196	O
daily	32423584	1197	1202	O
infusions	32423584	1203	1212	O
)	32423584	1213	1214	O
or	32423584	1215	1217	O
the	32423584	1218	1221	O
same	32423584	1222	1226	O
volume	32423584	1227	1233	O
of	32423584	1234	1236	O
placebo	32423584	1237	1244	B-Intervention
infusions	32423584	1245	1254	O
for	32423584	1255	1258	O
10	32423584	1259	1261	O
days	32423584	1262	1266	O
.	32423584	1267	1268	O

Patients	32423584	1269	1277	O
were	32423584	1278	1282	O
permitted	32423584	1283	1292	O
concomitant	32423584	1293	1304	O
use	32423584	1305	1308	O
of	32423584	1309	1311	O
lopinavir-ritonavir	32423584	1312	1331	O
,	32423584	1332	1333	O
interferons	32423584	1334	1345	O
,	32423584	1346	1347	O
and	32423584	1348	1351	O
corticosteroids	32423584	1352	1367	O
.	32423584	1368	1369	O

The	32423584	1370	1373	O
primary	32423584	1374	1381	O
endpoint	32423584	1382	1390	O
was	32423584	1391	1394	O
time	32423584	1395	1399	B-Outcome
to	32423584	1400	1402	I-Outcome
clinical	32423584	1403	1411	I-Outcome
improvement	32423584	1412	1423	I-Outcome
up	32423584	1424	1426	I-Outcome
to	32423584	1427	1429	I-Outcome
day	32423584	1430	1433	I-Outcome
28	32423584	1434	1436	I-Outcome
,	32423584	1437	1438	O
defined	32423584	1439	1446	O
as	32423584	1447	1449	O
the	32423584	1450	1453	O
time	32423584	1454	1458	O
(	32423584	1459	1460	O
in	32423584	1461	1463	O
days	32423584	1464	1468	O
)	32423584	1469	1470	O
from	32423584	1471	1475	O
randomisation	32423584	1476	1489	O
to	32423584	1490	1492	O
the	32423584	1493	1496	O
point	32423584	1497	1502	O
of	32423584	1503	1505	O
a	32423584	1506	1507	O
decline	32423584	1508	1515	O
of	32423584	1516	1518	O
two	32423584	1519	1522	O
levels	32423584	1523	1529	O
on	32423584	1530	1532	O
a	32423584	1533	1534	O
six-point	32423584	1535	1544	O
ordinal	32423584	1545	1552	O
scale	32423584	1553	1558	O
of	32423584	1559	1561	O
clinical	32423584	1562	1570	O
status	32423584	1571	1577	O
(	32423584	1578	1579	O
from	32423584	1580	1584	O
1=discharged	32423584	1585	1597	O
to	32423584	1598	1600	O
6=death	32423584	1601	1608	O
)	32423584	1609	1610	O
or	32423584	1611	1613	O
discharged	32423584	1614	1624	B-Outcome
alive	32423584	1625	1630	I-Outcome
from	32423584	1631	1635	I-Outcome
hospital	32423584	1636	1644	I-Outcome
,	32423584	1645	1646	O
whichever	32423584	1647	1656	O
came	32423584	1657	1661	O
first	32423584	1662	1667	O
.	32423584	1668	1669	O

Primary	32423584	1670	1677	O
analysis	32423584	1678	1686	O
was	32423584	1687	1690	O
done	32423584	1691	1695	O
in	32423584	1696	1698	O
the	32423584	1699	1702	O
intention-to-treat	32423584	1703	1721	O
(	32423584	1722	1723	O
ITT	32423584	1724	1727	O
)	32423584	1728	1729	O
population	32423584	1730	1740	O
and	32423584	1741	1744	O
safety	32423584	1745	1751	O
analysis	32423584	1752	1760	O
was	32423584	1761	1764	O
done	32423584	1765	1769	O
in	32423584	1770	1772	O
all	32423584	1773	1776	O
patients	32423584	1777	1785	O
who	32423584	1786	1789	O
started	32423584	1790	1797	O
their	32423584	1798	1803	O
assigned	32423584	1804	1812	O
treatment	32423584	1813	1822	O
.	32423584	1823	1824	O

This	32423584	1825	1829	O
trial	32423584	1830	1835	O
is	32423584	1836	1838	O
registered	32423584	1839	1849	O
with	32423584	1850	1854	O
ClinicalTrials.gov	32423584	1855	1873	O
,	32423584	1874	1875	O
NCT04257656	32423584	1876	1887	O
.	32423584	1888	1889	O

Between	32423584	1890	1897	O
Feb	32423584	1898	1901	O
6	32423584	1902	1903	O
,	32423584	1904	1905	O
2020	32423584	1906	1910	O
,	32423584	1911	1912	O
and	32423584	1913	1916	O
March	32423584	1917	1922	O
12	32423584	1923	1925	O
,	32423584	1926	1927	O
2020	32423584	1928	1932	O
,	32423584	1933	1934	O
237	32423584	1935	1938	O
patients	32423584	1939	1947	O
were	32423584	1948	1952	O
enrolled	32423584	1953	1961	O
and	32423584	1962	1965	O
randomly	32423584	1966	1974	O
assigned	32423584	1975	1983	O
to	32423584	1984	1986	O
a	32423584	1987	1988	O
treatment	32423584	1989	1998	O
group	32423584	1999	2004	O
(	32423584	2005	2006	O
158	32423584	2007	2010	O
to	32423584	2011	2013	O
remdesivir	32423584	2014	2024	B-Intervention
and	32423584	2025	2028	O
79	32423584	2029	2031	O
to	32423584	2032	2034	O
placebo	32423584	2035	2042	B-Intervention
)	32423584	2043	2044	O
;	32423584	2045	2046	O
one	32423584	2047	2050	B-Count
patient	32423584	2051	2058	I-Count
in	32423584	2059	2061	O
the	32423584	2062	2065	O
placebo	32423584	2066	2073	B-Intervention
group	32423584	2074	2079	O
who	32423584	2080	2083	O
withdrew	32423584	2084	2092	B-Outcome
after	32423584	2093	2098	O
randomisation	32423584	2099	2112	O
was	32423584	2113	2116	O
not	32423584	2117	2120	O
included	32423584	2121	2129	O
in	32423584	2130	2132	O
the	32423584	2133	2136	O
ITT	32423584	2137	2140	O
population	32423584	2141	2151	O
.	32423584	2152	2153	O

Remdesivir	32423584	2154	2164	B-Intervention
use	32423584	2165	2168	O
was	32423584	2169	2172	O
not	32423584	2173	2176	O
associated	32423584	2177	2187	O
with	32423584	2188	2192	O
a	32423584	2193	2194	O
difference	32423584	2195	2205	B-Observation
in	32423584	2206	2208	O
time	32423584	2209	2213	B-Outcome
to	32423584	2214	2216	I-Outcome
clinical	32423584	2217	2225	I-Outcome
improvement	32423584	2226	2237	I-Outcome
(	32423584	2238	2239	O
hazard	32423584	2240	2246	O
ratio	32423584	2247	2252	O
123	32423584	2253	2257	O
[	32423584	2258	2259	O
95	32423584	2260	2262	O
%	32423584	2263	2264	O
CI	32423584	2265	2267	O
087	32423584	2268	2272	O
-	32423584	2272	2273	O
175	32423584	2273	2277	O
]	32423584	2278	2279	O
)	32423584	2280	2281	O
.	32423584	2282	2283	O

Although	32423584	2284	2292	O
not	32423584	2293	2296	O
statistically	32423584	2297	2310	O
significant	32423584	2311	2322	O
,	32423584	2323	2324	O
patients	32423584	2325	2333	O
receiving	32423584	2334	2343	O
remdesivir	32423584	2344	2354	B-Intervention
had	32423584	2355	2358	O
a	32423584	2359	2360	O
numerically	32423584	2361	2372	B-Observation
faster	32423584	2373	2379	I-Observation
time	32423584	2380	2384	B-Outcome
to	32423584	2385	2387	I-Outcome
clinical	32423584	2388	2396	I-Outcome
improvement	32423584	2397	2408	I-Outcome
than	32423584	2409	2413	O
those	32423584	2414	2419	O
receiving	32423584	2420	2429	O
placebo	32423584	2430	2437	B-Intervention
among	32423584	2438	2443	O
patients	32423584	2444	2452	O
with	32423584	2453	2457	O
symptom	32423584	2458	2465	B-Participant
duration	32423584	2466	2474	I-Participant
of	32423584	2475	2477	I-Participant
10	32423584	2478	2480	I-Participant
days	32423584	2481	2485	I-Participant
or	32423584	2486	2488	I-Participant
less	32423584	2489	2493	I-Participant
(	32423584	2494	2495	O
hazard	32423584	2496	2502	O
ratio	32423584	2503	2508	O
152	32423584	2509	2513	O
[	32423584	2514	2515	O
095	32423584	2516	2520	O
-	32423584	2520	2521	O
243	32423584	2521	2525	O
]	32423584	2526	2527	O
)	32423584	2528	2529	O
.	32423584	2530	2531	O

Adverse	32423584	2532	2539	B-Outcome
events	32423584	2540	2546	I-Outcome
were	32423584	2547	2551	O
reported	32423584	2552	2560	O
in	32423584	2561	2563	O
102	32423584	2564	2567	B-Count
(	32423584	2568	2569	I-Count
66	32423584	2570	2572	I-Count
%	32423584	2573	2574	I-Count
)	32423584	2575	2576	I-Count
of	32423584	2577	2579	I-Count
155	32423584	2580	2583	I-Count
remdesivir	32423584	2584	2594	B-Intervention
recipients	32423584	2595	2605	I-Intervention
versus	32423584	2606	2612	O
50	32423584	2613	2615	B-Count
(	32423584	2616	2617	I-Count
64	32423584	2618	2620	I-Count
%	32423584	2621	2622	I-Count
)	32423584	2623	2624	I-Count
of	32423584	2625	2627	I-Count
78	32423584	2628	2630	I-Count
placebo	32423584	2631	2638	B-Intervention
recipients	32423584	2639	2649	I-Intervention
.	32423584	2650	2651	O

Remdesivir	32423584	2652	2662	B-Intervention
was	32423584	2663	2666	O
stopped	32423584	2667	2674	O
early	32423584	2675	2680	O
because	32423584	2681	2688	O
of	32423584	2689	2691	O
adverse	32423584	2692	2699	B-Outcome
events	32423584	2700	2706	I-Outcome
in	32423584	2707	2709	O
18	32423584	2710	2712	B-Count
(	32423584	2713	2714	I-Count
12	32423584	2715	2717	I-Count
%	32423584	2718	2719	I-Count
)	32423584	2720	2721	I-Count
patients	32423584	2722	2730	I-Count
versus	32423584	2731	2737	O
four	32423584	2738	2742	B-Count
(	32423584	2743	2744	I-Count
5	32423584	2745	2746	I-Count
%	32423584	2747	2748	I-Count
)	32423584	2749	2750	I-Count
patients	32423584	2751	2759	I-Count
who	32423584	2760	2763	O
stopped	32423584	2764	2771	O
placebo	32423584	2772	2779	B-Intervention
early	32423584	2780	2785	O
.	32423584	2786	2787	O

In	32423584	2788	2790	O
this	32423584	2791	2795	O
study	32423584	2796	2801	O
of	32423584	2802	2804	O
adult	32423584	2805	2810	B-Participant
patients	32423584	2811	2819	O
admitted	32423584	2820	2828	B-Participant
to	32423584	2829	2831	I-Participant
hospital	32423584	2832	2840	I-Participant
for	32423584	2841	2844	O
severe	32423584	2845	2851	B-Participant
COVID-19	32423584	2852	2860	I-Participant
,	32423584	2861	2862	O
remdesivir	32423584	2863	2873	B-Intervention
was	32423584	2874	2877	O
not	32423584	2878	2881	O
associated	32423584	2882	2892	O
with	32423584	2893	2897	O
statistically	32423584	2898	2911	B-Observation
significant	32423584	2912	2923	I-Observation
clinical	32423584	2924	2932	B-Outcome
benefits	32423584	2933	2941	I-Outcome
.	32423584	2942	2943	O

However	32423584	2944	2951	O
,	32423584	2952	2953	O
the	32423584	2954	2957	O
numerical	32423584	2958	2967	B-Observation
reduction	32423584	2968	2977	I-Observation
in	32423584	2978	2980	O
time	32423584	2981	2985	B-Outcome
to	32423584	2986	2988	I-Outcome
clinical	32423584	2989	2997	I-Outcome
improvement	32423584	2998	3009	I-Outcome
in	32423584	3010	3012	O
those	32423584	3013	3018	O
treated	32423584	3019	3026	O
earlier	32423584	3027	3034	O
requires	32423584	3035	3043	O
confirmation	32423584	3044	3056	O
in	32423584	3057	3059	O
larger	32423584	3060	3066	O
studies	32423584	3067	3074	O
.	32423584	3075	3076	O

Chinese	32423584	3077	3084	O
Academy	32423584	3085	3092	O
of	32423584	3093	3095	O
Medical	32423584	3096	3103	O
Sciences	32423584	3104	3112	O
Emergency	32423584	3113	3122	O
Project	32423584	3123	3130	O
of	32423584	3131	3133	O
COVID-19	32423584	3134	3142	O
,	32423584	3143	3144	O
National	32423584	3145	3153	O
Key	32423584	3154	3157	O
Research	32423584	3158	3166	O
and	32423584	3167	3170	O
Development	32423584	3171	3182	O
Program	32423584	3183	3190	O
of	32423584	3191	3193	O
China	32423584	3194	3199	O
,	32423584	3200	3201	O
the	32423584	3202	3205	O
Beijing	32423584	3206	3213	O
Science	32423584	3214	3221	O
and	32423584	3222	3225	O
Technology	32423584	3226	3236	O
Project	32423584	3237	3244	O
.	32423584	3245	3246	O


Efficacy	32425006	0	8	B-Observation
of	32425006	9	11	O
internet	32425006	12	20	B-Intervention
-	32425006	21	22	I-Intervention
based	32425006	23	28	I-Intervention
integrated	32425006	29	39	I-Intervention
intervention	32425006	40	52	I-Intervention
on	32425006	53	55	O
depression	32425006	56	66	B-Outcome
and	32425006	67	70	O
anxiety	32425006	71	78	B-Outcome
symptoms	32425006	79	87	O
in	32425006	88	90	O
patients	32425006	91	99	O
with	32425006	100	104	O
COVID-19	32425006	105	113	B-Participant
.	32425006	114	115	O

Public	32425006	116	122	O
health	32425006	123	129	O
crises	32425006	130	136	O
,	32425006	137	138	O
such	32425006	139	143	O
as	32425006	144	146	O
the	32425006	147	150	O
outbreak	32425006	151	159	O
of	32425006	160	162	O
severe	32425006	163	169	O
acute	32425006	170	175	O
respiratory	32425006	176	187	O
syndrome	32425006	188	196	O
coronavirus	32425006	197	208	O
2	32425006	209	210	O
(	32425006	211	212	O
SARS	32425006	213	217	O
-	32425006	218	219	O
CoV-2	32425006	220	225	O
)	32425006	226	227	O
since	32425006	228	233	O
Dec.	32425006	234	238	O
2019	32425006	239	243	O
,	32425006	244	245	O
are	32425006	246	249	O
widely	32425006	250	256	O
acknowledged	32425006	257	269	O
as	32425006	270	272	O
severe	32425006	273	279	O
traumatic	32425006	280	289	O
events	32425006	290	296	O
that	32425006	297	301	O
impose	32425006	302	308	O
threats	32425006	309	316	O
not	32425006	317	320	O
only	32425006	321	325	O
because	32425006	326	333	O
of	32425006	334	336	O
physical	32425006	337	345	O
concerns	32425006	346	354	O
but	32425006	355	358	O
also	32425006	359	363	O
because	32425006	364	371	O
of	32425006	372	374	O
the	32425006	375	378	O
psychological	32425006	379	392	O
distress	32425006	393	401	O
of	32425006	402	404	O
infected	32425006	405	413	O
patients	32425006	414	422	O
.	32425006	423	424	O

We	32425006	425	427	O
designed	32425006	428	436	O
an	32425006	437	439	O
internet	32425006	440	448	B-Intervention
-	32425006	449	450	I-Intervention
based	32425006	451	456	I-Intervention
integrated	32425006	457	467	I-Intervention
intervention	32425006	468	480	I-Intervention
and	32425006	481	484	O
evaluated	32425006	485	494	O
its	32425006	495	498	O
efficacy	32425006	499	507	B-Observation
on	32425006	508	510	O
depression	32425006	511	521	B-Outcome
and	32425006	522	525	O
anxiety	32425006	526	533	B-Outcome
symptoms	32425006	534	542	O
in	32425006	543	545	O
patients	32425006	546	554	O
infected	32425006	555	563	O
by	32425006	564	566	O
SARS	32425006	567	571	B-Participant
-	32425006	572	573	I-Participant
CoV-2	32425006	574	579	I-Participant
.	32425006	580	581	O


Repurposing	32425222	0	11	O
chlorpromazine	32425222	12	26	B-Intervention
to	32425222	27	29	O
treat	32425222	30	35	O
COVID-19	32425222	36	44	B-Participant
:	32425222	45	46	O
The	32425222	47	50	O
reCoVery	32425222	51	59	O
study	32425222	60	65	O
.	32425222	66	67	O

OBJECTIVE	32425222	68	77	O
:	32425222	78	79	O
The	32425222	80	83	O
ongoing	32425222	84	91	O
COVID-19	32425222	92	100	O
pandemic	32425222	101	109	O
has	32425222	110	113	O
caused	32425222	114	120	O
approximately	32425222	121	134	O
2,350,000	32425222	135	144	O
infections	32425222	145	155	O
worldwide	32425222	156	165	O
and	32425222	166	169	O
killed	32425222	170	176	O
more	32425222	177	181	O
than	32425222	182	186	O
160,000	32425222	187	194	O
individuals	32425222	195	206	O
.	32425222	207	208	O

In	32425222	209	211	O
Sainte	32425222	212	218	O
-	32425222	219	220	O
Anne	32425222	221	225	O
Hospital	32425222	226	234	O
(	32425222	235	236	O
GHU	32425222	237	240	O
PARIS	32425222	241	246	O
Psychiatrie	32425222	247	258	O
&	32425222	259	260	O
Neuroscience	32425222	261	273	O
,	32425222	274	275	O
Paris	32425222	276	281	O
,	32425222	282	283	O
France	32425222	284	290	O
)	32425222	291	292	O
we	32425222	293	295	O
have	32425222	296	300	O
observed	32425222	301	309	O
a	32425222	310	311	O
lower	32425222	312	317	O
incidence	32425222	318	327	O
of	32425222	328	330	O
symptomatic	32425222	331	342	O
forms	32425222	343	348	O
of	32425222	349	351	O
COVID-19	32425222	352	360	O
among	32425222	361	366	O
patients	32425222	367	375	O
than	32425222	376	380	O
among	32425222	381	386	O
our	32425222	387	390	O
clinical	32425222	391	399	O
staff	32425222	400	405	O
.	32425222	406	407	O

This	32425222	408	412	O
observation	32425222	413	424	O
led	32425222	425	428	O
us	32425222	429	431	O
to	32425222	432	434	O
hypothesize	32425222	435	446	O
that	32425222	447	451	O
psychotropic	32425222	452	464	O
drugs	32425222	465	470	O
could	32425222	471	476	O
have	32425222	477	481	O
a	32425222	482	483	O
prophylactic	32425222	484	496	O
action	32425222	497	503	O
against	32425222	504	511	O
SARS	32425222	512	516	O
-	32425222	517	518	O
CoV-2	32425222	519	524	O
and	32425222	525	528	O
protect	32425222	529	536	O
patients	32425222	537	545	O
from	32425222	546	550	O
the	32425222	551	554	O
symptomatic	32425222	555	566	O
and	32425222	567	570	O
virulent	32425222	571	579	O
forms	32425222	580	585	O
of	32425222	586	588	O
this	32425222	589	593	O
infection	32425222	594	603	O
,	32425222	604	605	O
since	32425222	606	611	O
several	32425222	612	619	O
of	32425222	620	622	O
these	32425222	623	628	O
psychotropic	32425222	629	641	O
drugs	32425222	642	647	O
have	32425222	648	652	O
documented	32425222	653	663	O
antiviral	32425222	664	673	O
properties	32425222	674	684	O
.	32425222	685	686	O

Chlorpromazine	32425222	687	701	O
(	32425222	702	703	O
CPZ	32425222	704	707	O
)	32425222	708	709	O
,	32425222	710	711	O
a	32425222	712	713	O
phenothiazine	32425222	714	727	O
derivative	32425222	728	738	O
,	32425222	739	740	O
is	32425222	741	743	O
also	32425222	744	748	O
known	32425222	749	754	O
for	32425222	755	758	O
its	32425222	759	762	O
antiviral	32425222	763	772	O
activity	32425222	773	781	O
via	32425222	782	785	O
the	32425222	786	789	O
inhibition	32425222	790	800	O
of	32425222	801	803	O
clathrin	32425222	804	812	O
-	32425222	813	814	O
mediated	32425222	815	823	O
endocytosis	32425222	824	835	O
.	32425222	836	837	O

Recentin	32425222	838	846	O
vitro	32425222	847	852	O
studies	32425222	853	860	O
have	32425222	861	865	O
reported	32425222	866	874	O
that	32425222	875	879	O
CPZ	32425222	880	883	O
exhibits	32425222	884	892	O
anti	32425222	893	897	O
-	32425222	898	899	O
MERS	32425222	900	904	O
-	32425222	905	906	O
CoV	32425222	907	910	O
and	32425222	911	914	O
anti	32425222	915	919	O
-	32425222	920	921	O
SARS	32425222	922	926	O
-	32425222	927	928	O
CoV-1	32425222	929	934	O
activity	32425222	935	943	O
.	32425222	944	945	O

METHODS	32425222	946	953	O
:	32425222	954	955	O
In	32425222	956	958	O
this	32425222	959	963	O
context	32425222	964	971	O
,	32425222	972	973	O
the	32425222	974	977	O
ReCoVery	32425222	978	986	O
study	32425222	987	992	O
aims	32425222	993	997	O
to	32425222	998	1000	O
repurpose	32425222	1001	1010	O
CPZ	32425222	1011	1014	B-Intervention
,	32425222	1015	1016	O
a	32425222	1017	1018	O
molecule	32425222	1019	1027	O
with	32425222	1028	1032	O
an	32425222	1033	1035	O
excellent	32425222	1036	1045	O
tolerance	32425222	1046	1055	O
profile	32425222	1056	1063	O
and	32425222	1064	1067	O
a	32425222	1068	1069	O
very	32425222	1070	1074	O
high	32425222	1075	1079	O
biodistribution	32425222	1080	1095	O
in	32425222	1096	1098	O
the	32425222	1099	1102	O
saliva	32425222	1103	1109	O
,	32425222	1110	1111	O
lungs	32425222	1112	1117	O
and	32425222	1118	1121	O
brain	32425222	1122	1127	O
.	32425222	1128	1129	O

We	32425222	1130	1132	O
hypothesize	32425222	1133	1144	O
that	32425222	1145	1149	O
CPZ	32425222	1150	1153	B-Intervention
could	32425222	1154	1159	O
reduce	32425222	1160	1166	B-Observation
the	32425222	1167	1170	O
unfavorable	32425222	1171	1182	B-Outcome
course	32425222	1183	1189	I-Outcome
of	32425222	1190	1192	O
COVID-19	32425222	1193	1201	B-Participant
infection	32425222	1202	1211	I-Participant
among	32425222	1212	1217	O
patients	32425222	1218	1226	O
requiring	32425222	1227	1236	B-Participant
respiratory	32425222	1237	1248	I-Participant
support	32425222	1249	1256	I-Participant
without	32425222	1257	1264	O
the	32425222	1265	1268	O
need	32425222	1269	1273	B-Participant
for	32425222	1274	1277	I-Participant
ICU	32425222	1278	1281	I-Participant
care	32425222	1282	1286	I-Participant
,	32425222	1287	1288	O
and	32425222	1289	1292	O
that	32425222	1293	1297	O
it	32425222	1298	1300	O
could	32425222	1301	1306	O
also	32425222	1307	1311	O
reduce	32425222	1312	1318	B-Observation
the	32425222	1319	1322	O
contagiousness	32425222	1323	1337	B-Outcome
of	32425222	1338	1340	O
SARS	32425222	1341	1345	B-Participant
-	32425222	1346	1347	I-Participant
CoV-2	32425222	1348	1353	I-Participant
.	32425222	1354	1355	O

For	32425222	1356	1359	O
this	32425222	1360	1364	O
purpose	32425222	1365	1372	O
,	32425222	1373	1374	O
we	32425222	1375	1377	O
plan	32425222	1378	1382	O
a	32425222	1383	1384	O
pilot	32425222	1385	1390	O
,	32425222	1391	1392	O
multicenter	32425222	1393	1404	O
,	32425222	1405	1406	O
randomized	32425222	1407	1417	O
,	32425222	1418	1419	O
single	32425222	1420	1426	O
blind	32425222	1427	1432	O
,	32425222	1433	1434	O
controlled	32425222	1435	1445	O
,	32425222	1446	1447	O
phase	32425222	1448	1453	O
III	32425222	1454	1457	O
therapeutic	32425222	1458	1469	O
trial	32425222	1470	1475	O
(	32425222	1476	1477	O
standard	32425222	1478	1486	B-Intervention
treatment	32425222	1487	1496	I-Intervention
vs.	32425222	1497	1500	O
CPZ+standard	32425222	1501	1513	B-Intervention
treatment	32425222	1514	1523	I-Intervention
)	32425222	1524	1525	O
.	32425222	1526	1527	O

CONCLUSIONS	32425222	1528	1539	O
:	32425222	1540	1541	O
This	32425222	1542	1546	O
repurposing	32425222	1547	1558	O
of	32425222	1559	1561	O
CPZ	32425222	1562	1565	B-Intervention
for	32425222	1566	1569	O
its	32425222	1570	1573	O
anti	32425222	1574	1578	O
-	32425222	1579	1580	O
SARS	32425222	1581	1585	O
-	32425222	1586	1587	O
CoV-2	32425222	1588	1593	O
activity	32425222	1594	1602	O
could	32425222	1603	1608	O
offer	32425222	1609	1614	O
an	32425222	1615	1617	O
alternative	32425222	1618	1629	O
,	32425222	1630	1631	O
rapid	32425222	1632	1637	O
strategy	32425222	1638	1646	O
to	32425222	1647	1649	O
alleviate	32425222	1650	1659	B-Observation
infection	32425222	1660	1669	B-Outcome
severity	32425222	1670	1678	I-Outcome
.	32425222	1679	1680	O

This	32425222	1681	1685	O
repurposing	32425222	1686	1697	O
strategy	32425222	1698	1706	O
also	32425222	1707	1711	O
avoids	32425222	1712	1718	O
numerous	32425222	1719	1727	O
developmental	32425222	1728	1741	O
and	32425222	1742	1745	O
experimental	32425222	1746	1758	O
steps	32425222	1759	1764	O
,	32425222	1765	1766	O
and	32425222	1767	1770	O
could	32425222	1771	1776	O
save	32425222	1777	1781	O
precious	32425222	1782	1790	O
time	32425222	1791	1795	O
to	32425222	1796	1798	O
rapidly	32425222	1799	1806	O
establish	32425222	1807	1816	O
an	32425222	1817	1819	O
anti	32425222	1820	1824	O
-	32425222	1825	1826	O
COVID-19	32425222	1827	1835	O
therapy	32425222	1836	1843	O
with	32425222	1844	1848	O
well	32425222	1849	1853	O
-	32425222	1854	1855	O
known	32425222	1856	1861	O
,	32425222	1862	1863	O
limited	32425222	1864	1871	O
and	32425222	1872	1875	O
easily	32425222	1876	1882	O
managed	32425222	1883	1890	O
side	32425222	1891	1895	O
effects	32425222	1896	1903	O
.	32425222	1904	1905	O


Remdesivir	32445440	0	10	B-Intervention
for	32445440	11	14	O
the	32445440	15	18	O
Treatment	32445440	19	28	O
of	32445440	29	31	O
Covid-19	32445440	32	40	B-Participant
-	32445440	41	42	O
Final	32445440	43	48	O
Report	32445440	49	55	O
.	32445440	56	57	O

Although	32445440	58	66	O
several	32445440	67	74	O
therapeutic	32445440	75	86	O
agents	32445440	87	93	O
have	32445440	94	98	O
been	32445440	99	103	O
evaluated	32445440	104	113	O
for	32445440	114	117	O
the	32445440	118	121	O
treatment	32445440	122	131	O
of	32445440	132	134	O
coronavirus	32445440	135	146	O
disease	32445440	147	154	O
2019	32445440	155	159	O
(	32445440	160	161	O
Covid-19	32445440	162	170	O
)	32445440	171	172	O
,	32445440	173	174	O
no	32445440	175	177	O
antiviral	32445440	178	187	O
agents	32445440	188	194	O
have	32445440	195	199	O
yet	32445440	200	203	O
been	32445440	204	208	O
shown	32445440	209	214	O
to	32445440	215	217	O
be	32445440	218	220	O
efficacious	32445440	221	232	O
.	32445440	233	234	O

We	32445440	235	237	O
conducted	32445440	238	247	O
a	32445440	248	249	O
double	32445440	250	256	O
-	32445440	257	258	O
blind	32445440	259	264	O
,	32445440	265	266	O
randomized	32445440	267	277	O
,	32445440	278	279	O
placebo	32445440	280	287	O
-	32445440	288	289	O
controlled	32445440	290	300	O
trial	32445440	301	306	O
of	32445440	307	309	O
intravenous	32445440	310	321	B-Intervention
remdesivir	32445440	322	332	I-Intervention
in	32445440	333	335	O
adults	32445440	336	342	B-Participant
who	32445440	343	346	O
were	32445440	347	351	O
hospitalized	32445440	352	364	B-Participant
with	32445440	365	369	O
Covid-19	32445440	370	378	B-Participant
and	32445440	379	382	O
had	32445440	383	386	O
evidence	32445440	387	395	O
of	32445440	396	398	O
lower	32445440	399	404	B-Participant
respiratory	32445440	405	416	I-Participant
tract	32445440	417	422	I-Participant
infection	32445440	423	432	I-Participant
.	32445440	433	434	O

Patients	32445440	435	443	O
were	32445440	444	448	O
randomly	32445440	449	457	O
assigned	32445440	458	466	O
to	32445440	467	469	O
receive	32445440	470	477	O
either	32445440	478	484	O
remdesivir	32445440	485	495	B-Intervention
(	32445440	496	497	O
200	32445440	498	501	O
mg	32445440	502	504	O
loading	32445440	505	512	O
dose	32445440	513	517	O
on	32445440	518	520	O
day	32445440	521	524	O
1	32445440	525	526	O
,	32445440	527	528	O
followed	32445440	529	537	O
by	32445440	538	540	O
100	32445440	541	544	O
mg	32445440	545	547	O
daily	32445440	548	553	O
for	32445440	554	557	O
up	32445440	558	560	O
to	32445440	561	563	O
9	32445440	564	565	O
additional	32445440	566	576	O
days	32445440	577	581	O
)	32445440	582	583	O
or	32445440	584	586	O
placebo	32445440	587	594	B-Intervention
for	32445440	595	598	O
up	32445440	599	601	O
to	32445440	602	604	O
10	32445440	605	607	O
days	32445440	608	612	O
.	32445440	613	614	O

The	32445440	615	618	O
primary	32445440	619	626	O
outcome	32445440	627	634	O
was	32445440	635	638	O
the	32445440	639	642	O
time	32445440	643	647	B-Outcome
to	32445440	648	650	I-Outcome
recovery	32445440	651	659	I-Outcome
,	32445440	660	661	O
defined	32445440	662	669	O
by	32445440	670	672	O
either	32445440	673	679	O
discharge	32445440	680	689	O
from	32445440	690	694	O
the	32445440	695	698	O
hospital	32445440	699	707	O
or	32445440	708	710	O
hospitalization	32445440	711	726	O
for	32445440	727	730	O
infection	32445440	731	740	O
-	32445440	741	742	O
control	32445440	743	750	O
purposes	32445440	751	759	O
only	32445440	760	764	O
.	32445440	765	766	O

A	32445440	767	768	O
total	32445440	769	774	O
of	32445440	775	777	O
1062	32445440	778	782	O
patients	32445440	783	791	O
underwent	32445440	792	801	O
randomization	32445440	802	815	O
(	32445440	816	817	O
with	32445440	818	822	O
541	32445440	823	826	O
assigned	32445440	827	835	O
to	32445440	836	838	O
remdesivir	32445440	839	849	B-Intervention
and	32445440	850	853	O
521	32445440	854	857	O
to	32445440	858	860	O
placebo	32445440	861	868	B-Intervention
)	32445440	869	870	O
.	32445440	871	872	O

Those	32445440	873	878	O
who	32445440	879	882	O
received	32445440	883	891	O
remdesivir	32445440	892	902	B-Intervention
had	32445440	903	906	O
a	32445440	907	908	O
median	32445440	909	915	B-Outcome
recovery	32445440	916	924	I-Outcome
time	32445440	925	929	I-Outcome
of	32445440	930	932	O
10	32445440	933	935	B-Observation
days	32445440	936	940	I-Observation
(	32445440	941	942	O
95	32445440	943	945	O
%	32445440	946	947	O
confidence	32445440	948	958	O
interval	32445440	959	967	O
[	32445440	968	969	O
CI	32445440	970	972	O
]	32445440	973	974	O
,	32445440	975	976	O
9	32445440	977	978	O
to	32445440	979	981	O
11	32445440	982	984	O
)	32445440	985	986	O
,	32445440	987	988	O
as	32445440	989	991	O
compared	32445440	992	1000	O
with	32445440	1001	1005	O
15	32445440	1006	1008	B-Observation
days	32445440	1009	1013	I-Observation
(	32445440	1014	1015	O
95	32445440	1016	1018	O
%	32445440	1019	1020	O
CI	32445440	1021	1023	O
,	32445440	1024	1025	O
13	32445440	1026	1028	O
to	32445440	1029	1031	O
18	32445440	1032	1034	O
)	32445440	1035	1036	O
among	32445440	1037	1042	O
those	32445440	1043	1048	O
who	32445440	1049	1052	O
received	32445440	1053	1061	O
placebo	32445440	1062	1069	B-Intervention
(	32445440	1070	1071	O
rate	32445440	1072	1076	O
ratio	32445440	1077	1082	O
for	32445440	1083	1086	O
recovery	32445440	1087	1095	O
,	32445440	1096	1097	O
1.29	32445440	1098	1102	O
;	32445440	1103	1104	O
95	32445440	1105	1107	O
%	32445440	1108	1109	O
CI	32445440	1110	1112	O
,	32445440	1113	1114	O
1.12	32445440	1115	1119	O
to	32445440	1120	1122	O
1.49	32445440	1123	1127	O
;	32445440	1128	1129	O
P<0.001	32445440	1130	1137	O
,	32445440	1138	1139	O
by	32445440	1140	1142	O
a	32445440	1143	1144	O
log	32445440	1145	1148	O
-	32445440	1149	1150	O
rank	32445440	1151	1155	O
test	32445440	1156	1160	O
)	32445440	1161	1162	O
.	32445440	1163	1164	O

In	32445440	1165	1167	O
an	32445440	1168	1170	O
analysis	32445440	1171	1179	O
that	32445440	1180	1184	O
used	32445440	1185	1189	O
a	32445440	1190	1191	O
proportional	32445440	1192	1204	O
-	32445440	1205	1206	O
odds	32445440	1207	1211	O
model	32445440	1212	1217	O
with	32445440	1218	1222	O
an	32445440	1223	1225	O
eight	32445440	1226	1231	O
-	32445440	1232	1233	O
category	32445440	1234	1242	O
ordinal	32445440	1243	1250	O
scale	32445440	1251	1256	O
,	32445440	1257	1258	O
the	32445440	1259	1262	O
patients	32445440	1263	1271	O
who	32445440	1272	1275	O
received	32445440	1276	1284	O
remdesivir	32445440	1285	1295	B-Intervention
were	32445440	1296	1300	O
found	32445440	1301	1306	O
to	32445440	1307	1309	O
be	32445440	1310	1312	O
more	32445440	1313	1317	B-Observation
likely	32445440	1318	1324	I-Observation
than	32445440	1325	1329	O
those	32445440	1330	1335	O
who	32445440	1336	1339	O
received	32445440	1340	1348	O
placebo	32445440	1349	1356	B-Intervention
to	32445440	1357	1359	O
have	32445440	1360	1364	O
clinical	32445440	1365	1373	B-Outcome
improvement	32445440	1374	1385	I-Outcome
at	32445440	1386	1388	I-Outcome
day	32445440	1389	1392	I-Outcome
15	32445440	1393	1395	I-Outcome
(	32445440	1396	1397	O
odds	32445440	1398	1402	O
ratio	32445440	1403	1408	O
,	32445440	1409	1410	O
1.5	32445440	1411	1414	O
;	32445440	1415	1416	O
95	32445440	1417	1419	O
%	32445440	1420	1421	O
CI	32445440	1422	1424	O
,	32445440	1425	1426	O
1.2	32445440	1427	1430	O
to	32445440	1431	1433	O
1.9	32445440	1434	1437	O
,	32445440	1438	1439	O
after	32445440	1440	1445	O
adjustment	32445440	1446	1456	O
for	32445440	1457	1460	O
actual	32445440	1461	1467	O
disease	32445440	1468	1475	O
severity	32445440	1476	1484	O
)	32445440	1485	1486	O
.	32445440	1487	1488	O

The	32445440	1489	1492	O
Kaplan	32445440	1493	1499	O
-	32445440	1500	1501	O
Meier	32445440	1502	1507	O
estimates	32445440	1508	1517	O
of	32445440	1518	1520	O
mortality	32445440	1521	1530	B-Outcome
were	32445440	1531	1535	O
6.7	32445440	1536	1539	B-Observation
%	32445440	1540	1541	I-Observation
with	32445440	1542	1546	O
remdesivir	32445440	1547	1557	B-Intervention
and	32445440	1558	1561	O
11.9	32445440	1562	1566	B-Observation
%	32445440	1567	1568	I-Observation
with	32445440	1569	1573	O
placebo	32445440	1574	1581	B-Intervention
by	32445440	1582	1584	O
day	32445440	1585	1588	O
15	32445440	1589	1591	O
and	32445440	1592	1595	O
11.4	32445440	1596	1600	B-Observation
%	32445440	1601	1602	I-Observation
with	32445440	1603	1607	O
remdesivir	32445440	1608	1618	B-Intervention
and	32445440	1619	1622	O
15.2	32445440	1623	1627	B-Observation
%	32445440	1628	1629	I-Observation
with	32445440	1630	1634	O
placebo	32445440	1635	1642	B-Intervention
by	32445440	1643	1645	O
day	32445440	1646	1649	O
29	32445440	1650	1652	O
(	32445440	1653	1654	O
hazard	32445440	1655	1661	O
ratio	32445440	1662	1667	O
,	32445440	1668	1669	O
0.73	32445440	1670	1674	O
;	32445440	1675	1676	O
95	32445440	1677	1679	O
%	32445440	1680	1681	O
CI	32445440	1682	1684	O
,	32445440	1685	1686	O
0.52	32445440	1687	1691	O
to	32445440	1692	1694	O
1.03	32445440	1695	1699	O
)	32445440	1700	1701	O
.	32445440	1702	1703	O

Serious	32445440	1704	1711	B-Outcome
adverse	32445440	1712	1719	I-Outcome
events	32445440	1720	1726	I-Outcome
were	32445440	1727	1731	O
reported	32445440	1732	1740	O
in	32445440	1741	1743	O
131	32445440	1744	1747	B-Count
of	32445440	1748	1750	I-Count
the	32445440	1751	1754	I-Count
532	32445440	1755	1758	I-Count
patients	32445440	1759	1767	I-Count
who	32445440	1768	1771	O
received	32445440	1772	1780	O
remdesivir	32445440	1781	1791	B-Intervention
(	32445440	1792	1793	O
24.6	32445440	1794	1798	B-Count
%	32445440	1799	1800	I-Count
)	32445440	1801	1802	O
and	32445440	1803	1806	O
in	32445440	1807	1809	O
163	32445440	1810	1813	B-Count
of	32445440	1814	1816	I-Count
the	32445440	1817	1820	I-Count
516	32445440	1821	1824	I-Count
patients	32445440	1825	1833	I-Count
who	32445440	1834	1837	O
received	32445440	1838	1846	O
placebo	32445440	1847	1854	B-Intervention
(	32445440	1855	1856	O
31.6	32445440	1857	1861	B-Count
%	32445440	1862	1863	I-Count
)	32445440	1864	1865	O
.	32445440	1866	1867	O

Our	32445440	1868	1871	O
data	32445440	1872	1876	O
show	32445440	1877	1881	O
that	32445440	1882	1886	O
remdesivir	32445440	1887	1897	B-Intervention
was	32445440	1898	1901	O
superior	32445440	1902	1910	B-Observation
to	32445440	1911	1913	O
placebo	32445440	1914	1921	B-Intervention
in	32445440	1922	1924	O
shortening	32445440	1925	1935	B-Observation
the	32445440	1936	1939	O
time	32445440	1940	1944	B-Outcome
to	32445440	1945	1947	I-Outcome
recovery	32445440	1948	1956	I-Outcome
in	32445440	1957	1959	O
adults	32445440	1960	1966	B-Participant
who	32445440	1967	1970	O
were	32445440	1971	1975	O
hospitalized	32445440	1976	1988	B-Participant
with	32445440	1989	1993	O
Covid-19	32445440	1994	2002	B-Participant
and	32445440	2003	2006	O
had	32445440	2007	2010	O
evidence	32445440	2011	2019	O
of	32445440	2020	2022	O
lower	32445440	2023	2028	B-Participant
respiratory	32445440	2029	2040	I-Participant
tract	32445440	2041	2046	I-Participant
infection	32445440	2047	2056	I-Participant
.	32445440	2057	2058	O

(	32445440	2059	2060	O
Funded	32445440	2061	2067	O
by	32445440	2068	2070	O
the	32445440	2071	2074	O
National	32445440	2075	2083	O
Institute	32445440	2084	2093	O
of	32445440	2094	2096	O
Allergy	32445440	2097	2104	O
and	32445440	2105	2108	O
Infectious	32445440	2109	2119	O
Diseases	32445440	2120	2128	O
and	32445440	2129	2132	O
others	32445440	2133	2139	O
;	32445440	2140	2141	O
ACTT-1	32445440	2142	2148	O
ClinicalTrials.gov	32445440	2149	2167	O
number	32445440	2168	2174	O
,	32445440	2175	2176	O
NCT04280705	32445440	2177	2188	O
.	32445440	2189	2190	O
)	32445440	2191	2192	O
.	32445440	2193	2194	O


Application	32448136	0	11	O
of	32448136	12	14	O
CareDose	32448136	15	23	B-Intervention
4D	32448136	24	26	I-Intervention
combined	32448136	27	35	I-Intervention
with	32448136	36	40	I-Intervention
Karl	32448136	41	45	I-Intervention
3D	32448136	46	48	I-Intervention
technology	32448136	49	59	I-Intervention
in	32448136	60	62	I-Intervention
the	32448136	63	66	I-Intervention
low	32448136	67	70	I-Intervention
dose	32448136	71	75	I-Intervention
computed	32448136	76	84	I-Intervention
tomography	32448136	85	95	I-Intervention
for	32448136	96	99	O
the	32448136	100	103	O
follow-up	32448136	104	113	B-Participant
of	32448136	114	116	I-Participant
COVID-19	32448136	117	125	I-Participant
.	32448136	125	126	O

Coronavirus	32448136	127	138	O
disease	32448136	139	146	O
2019	32448136	147	151	O
(	32448136	152	153	O
COVID-19	32448136	153	161	O
)	32448136	161	162	O
is	32448136	163	165	O
a	32448136	166	167	O
highly	32448136	168	174	O
infectious	32448136	175	185	O
disease	32448136	186	193	O
caused	32448136	194	200	O
by	32448136	201	203	O
the	32448136	204	207	O
new	32448136	208	211	O
coronavirus	32448136	212	223	O
.	32448136	223	224	O

Previous	32448136	225	233	O
studies	32448136	234	241	O
have	32448136	242	246	O
shown	32448136	247	252	O
that	32448136	253	257	O
the	32448136	258	261	O
chest	32448136	262	267	O
CT	32448136	268	270	O
examination	32448136	271	282	O
plays	32448136	283	288	O
an	32448136	289	291	O
important	32448136	292	301	O
role	32448136	302	306	O
in	32448136	307	309	O
the	32448136	310	313	O
diagnosis	32448136	314	323	O
and	32448136	324	327	O
monitoring	32448136	328	338	O
of	32448136	339	341	O
COVID-19	32448136	342	350	O
.	32448136	350	351	O

However	32448136	352	359	O
,	32448136	359	360	O
some	32448136	361	365	O
patients	32448136	366	374	O
with	32448136	375	379	O
COVID-19	32448136	380	388	O
had	32448136	389	392	O
low	32448136	393	396	O
white	32448136	397	402	O
blood	32448136	403	408	O
cell	32448136	409	413	O
counts	32448136	414	420	O
and	32448136	421	424	O
reduced	32448136	425	432	O
lymphocyte	32448136	433	443	O
ratios	32448136	444	450	O
.	32448136	450	451	O

Multiple	32448136	452	460	O
CT	32448136	461	463	O
examinations	32448136	464	476	O
may	32448136	477	480	O
cause	32448136	481	486	O
radiation	32448136	487	496	O
damages	32448136	497	504	O
as	32448136	505	507	O
well	32448136	508	512	O
as	32448136	513	515	O
increase	32448136	516	524	O
the	32448136	525	528	O
apoptosis	32448136	529	538	O
of	32448136	539	541	O
peripheral	32448136	542	552	O
blood	32448136	553	558	O
lymphocytes	32448136	559	570	O
.	32448136	570	571	O

A	32448136	572	573	O
new	32448136	574	577	O
low-dose	32448136	578	586	O
CT	32448136	587	589	O
method	32448136	590	596	O
should	32448136	597	603	O
be	32448136	604	606	O
developed	32448136	607	616	O
because	32448136	617	624	O
the	32448136	625	628	O
regular	32448136	629	636	O
CT	32448136	637	639	O
may	32448136	640	643	O
aggravate	32448136	644	653	O
the	32448136	654	657	O
disease	32448136	658	665	O
.	32448136	665	666	O

Sixty	32448136	667	672	O
cases	32448136	673	678	O
were	32448136	679	683	O
randomly	32448136	684	692	O
divided	32448136	693	700	O
into	32448136	701	705	O
the	32448136	706	709	O
study	32448136	710	715	B-Intervention
group	32448136	716	721	I-Intervention
(	32448136	722	723	O
n	32448136	723	724	O
=	32448136	725	726	O
30	32448136	727	729	O
)	32448136	729	730	O
and	32448136	731	734	O
control	32448136	735	742	B-Intervention
group	32448136	743	748	I-Intervention
(	32448136	749	750	O
n	32448136	750	751	O
=	32448136	752	753	O
30	32448136	754	756	O
)	32448136	756	757	O
.	32448136	757	758	O

The	32448136	759	762	O
lung	32448136	763	767	O
window	32448136	768	774	O
was	32448136	775	778	O
reconstructed	32448136	779	792	O
by	32448136	793	795	O
Karl	32448136	796	800	B-Intervention
3D	32448136	801	803	I-Intervention
iterative	32448136	804	813	I-Intervention
technique	32448136	814	823	I-Intervention
in	32448136	824	826	O
the	32448136	827	830	O
study	32448136	831	836	O
group	32448136	837	842	O
.	32448136	842	843	O

The	32448136	844	847	O
image	32448136	848	853	B-Outcome
quality	32448136	854	861	I-Outcome
was	32448136	862	865	O
subjectively	32448136	866	878	O
evaluated	32448136	879	888	O
by	32448136	889	891	O
two	32448136	892	895	O
senior	32448136	896	902	O
chest	32448136	903	908	O
group	32448136	909	914	O
diagnostic	32448136	915	925	O
physicians	32448136	926	936	O
using	32448136	937	942	O
a	32448136	943	944	O
5-point	32448136	945	952	O
double-blind	32448136	953	965	O
method	32448136	966	972	O
.	32448136	972	973	O

The	32448136	974	977	O
value	32448136	978	983	B-Outcome
of	32448136	984	986	I-Outcome
CT	32448136	987	989	I-Outcome
measurement	32448136	990	1001	I-Outcome
and	32448136	1002	1005	O
its	32448136	1006	1009	O
standard	32448136	1010	1018	B-Outcome
deviation	32448136	1019	1028	I-Outcome
(	32448136	1029	1030	I-Outcome
SD	32448136	1030	1032	I-Outcome
)	32448136	1032	1033	I-Outcome
was	32448136	1034	1037	O
used	32448136	1038	1042	O
as	32448136	1043	1045	O
an	32448136	1046	1048	O
objective	32448136	1049	1058	O
evaluation	32448136	1059	1069	O
criteria	32448136	1070	1078	O
.	32448136	1078	1079	O

The	32448136	1080	1083	O
volume	32448136	1084	1090	B-Outcome
of	32448136	1091	1093	I-Outcome
CT	32448136	1094	1096	I-Outcome
dose	32448136	1097	1101	I-Outcome
index	32448136	1102	1107	I-Outcome
(	32448136	1108	1109	I-Outcome
CTDIvol	32448136	1109	1116	I-Outcome
)	32448136	1116	1117	I-Outcome
,	32448136	1117	1118	O
dose	32448136	1119	1123	B-Outcome
length	32448136	1124	1130	I-Outcome
product	32448136	1131	1138	I-Outcome
(	32448136	1139	1140	I-Outcome
DLP	32448136	1140	1143	I-Outcome
)	32448136	1143	1144	I-Outcome
and	32448136	1145	1148	O
effective	32448136	1149	1158	B-Outcome
dose	32448136	1159	1163	I-Outcome
(	32448136	1164	1165	I-Outcome
ED	32448136	1165	1167	I-Outcome
)	32448136	1167	1168	I-Outcome
from	32448136	1169	1173	O
the	32448136	1174	1177	O
two	32448136	1178	1181	O
groups	32448136	1182	1188	O
were	32448136	1189	1193	O
compared	32448136	1194	1202	O
and	32448136	1203	1206	O
analyzed	32448136	1207	1215	O
statistically	32448136	1216	1229	O
.	32448136	1229	1230	O

There	32448136	1231	1236	O
was	32448136	1237	1240	O
no	32448136	1241	1243	O
significant	32448136	1244	1255	B-Observation
difference	32448136	1256	1266	I-Observation
in	32448136	1267	1269	O
the	32448136	1270	1273	O
occurrence	32448136	1274	1284	B-Outcome
rates	32448136	1285	1290	I-Outcome
of	32448136	1291	1293	I-Outcome
ground	32448136	1294	1300	I-Outcome
glass	32448136	1301	1306	I-Outcome
opacities	32448136	1307	1316	I-Outcome
,	32448136	1316	1317	O
consolidation	32448136	1318	1331	B-Outcome
,	32448136	1331	1332	O
crazy-paving	32448136	1333	1345	B-Outcome
pattern	32448136	1346	1353	I-Outcome
,	32448136	1353	1354	O
fiber	32448136	1355	1360	B-Outcome
cable	32448136	1361	1366	I-Outcome
shadow	32448136	1367	1373	I-Outcome
and	32448136	1374	1377	O
axial	32448136	1378	1383	B-Outcome
interstitial	32448136	1384	1396	I-Outcome
thickening	32448136	1397	1407	I-Outcome
between	32448136	1408	1415	O
the	32448136	1416	1419	O
study	32448136	1420	1425	B-Intervention
group	32448136	1426	1431	I-Intervention
and	32448136	1432	1435	O
control	32448136	1436	1443	B-Intervention
group	32448136	1444	1449	I-Intervention
(	32448136	1450	1451	O
p	32448136	1451	1452	O
>	32448136	1453	1454	O
0.05	32448136	1455	1459	O
)	32448136	1459	1460	O
.	32448136	1460	1461	O

In	32448136	1462	1464	O
addition	32448136	1465	1473	O
,	32448136	1473	1474	O
no	32448136	1475	1477	O
significant	32448136	1478	1489	B-Observation
difference	32448136	1490	1500	I-Observation
was	32448136	1501	1504	O
found	32448136	1505	1510	O
for	32448136	1511	1514	O
the	32448136	1515	1518	O
subjective	32448136	1519	1529	B-Outcome
score	32448136	1530	1535	I-Outcome
of	32448136	1536	1538	I-Outcome
overall	32448136	1539	1546	I-Outcome
image	32448136	1547	1552	I-Outcome
quality	32448136	1553	1560	I-Outcome
and	32448136	1561	1564	O
image	32448136	1565	1570	B-Outcome
noise	32448136	1571	1576	I-Outcome
level	32448136	1577	1582	I-Outcome
(	32448136	1583	1584	I-Outcome
SD	32448136	1584	1586	I-Outcome
)	32448136	1586	1587	I-Outcome
between	32448136	1588	1595	B-Intervention
the	32448136	1596	1599	I-Intervention
two	32448136	1600	1603	I-Intervention
groups	32448136	1604	1610	I-Intervention
(	32448136	1611	1612	O
p	32448136	1612	1613	O
>	32448136	1614	1615	O
0.05	32448136	1616	1620	O
)	32448136	1620	1621	O
.	32448136	1621	1622	O

However	32448136	1623	1630	O
,	32448136	1630	1631	O
significant	32448136	1632	1643	B-Observation
differences	32448136	1644	1655	I-Observation
was	32448136	1656	1659	O
found	32448136	1660	1665	O
in	32448136	1666	1668	O
CTDIvol	32448136	1669	1676	B-Outcome
,	32448136	1676	1677	O
DLP	32448136	1678	1681	B-Outcome
,	32448136	1681	1682	O
and	32448136	1683	1686	O
ED	32448136	1687	1689	B-Outcome
between	32448136	1690	1697	O
the	32448136	1698	1701	O
study	32448136	1702	1707	B-Intervention
group	32448136	1708	1713	I-Intervention
and	32448136	1714	1717	O
the	32448136	1718	1721	O
control	32448136	1722	1729	B-Intervention
group	32448136	1730	1735	I-Intervention
(	32448136	1736	1737	O
p	32448136	1737	1738	O
<	32448136	1739	1740	O
0.05	32448136	1741	1745	O
)	32448136	1745	1746	O
.	32448136	1746	1747	O

The	32448136	1748	1751	O
effective	32448136	1752	1761	B-Outcome
dose	32448136	1762	1766	I-Outcome
of	32448136	1767	1769	O
the	32448136	1770	1773	O
study	32448136	1774	1779	B-Intervention
group	32448136	1780	1785	I-Intervention
was	32448136	1786	1789	O
reduced	32448136	1790	1797	B-Observation
by	32448136	1798	1800	I-Observation
76	32448136	1801	1803	I-Observation
%	32448136	1803	1804	I-Observation
compared	32448136	1805	1813	O
to	32448136	1814	1816	O
the	32448136	1817	1820	O
control	32448136	1821	1828	B-Intervention
group	32448136	1829	1834	I-Intervention
.	32448136	1834	1835	O

CareDose	32448136	1836	1844	B-Intervention
4D	32448136	1845	1847	I-Intervention
low-dose	32448136	1848	1856	I-Intervention
scanning	32448136	1857	1865	I-Intervention
combined	32448136	1866	1874	I-Intervention
with	32448136	1875	1879	I-Intervention
Karl	32448136	1880	1884	I-Intervention
3D	32448136	1885	1887	I-Intervention
iterative	32448136	1888	1897	I-Intervention
reconstruction	32448136	1898	1912	I-Intervention
technology	32448136	1913	1923	I-Intervention
can	32448136	1924	1927	O
not	32448136	1928	1931	O
only	32448136	1932	1936	O
greatly	32448136	1937	1944	B-Observation
reduce	32448136	1945	1951	I-Observation
the	32448136	1952	1955	O
radiation	32448136	1956	1965	B-Outcome
dose	32448136	1966	1970	I-Outcome
,	32448136	1970	1971	O
but	32448136	1972	1975	O
also	32448136	1976	1980	O
provide	32448136	1981	1988	O
images	32448136	1989	1995	O
that	32448136	1996	2000	O
meet	32448136	2001	2005	B-Observation
the	32448136	2006	2009	O
diagnostic	32448136	2010	2020	B-Outcome
criteria	32448136	2021	2029	I-Outcome
of	32448136	2030	2032	O
COVID-19	32448136	2033	2041	B-Participant
,	32448136	2041	2042	O
which	32448136	2043	2048	O
can	32448136	2049	2052	O
be	32448136	2053	2055	O
used	32448136	2056	2060	O
as	32448136	2061	2063	O
a	32448136	2064	2065	O
routine	32448136	2066	2073	O
method	32448136	2074	2080	O
for	32448136	2081	2084	O
the	32448136	2085	2088	O
follow-up	32448136	2089	2098	B-Participant
of	32448136	2099	2101	I-Participant
COVID-19	32448136	2102	2110	I-Participant
patients	32448136	2111	2119	I-Participant
.	32448136	2119	2120	O


Remdesivir	32459919	0	10	B-Intervention
for	32459919	11	14	I-Intervention
5	32459919	15	16	I-Intervention
or	32459919	17	19	O
10	32459919	20	22	B-Intervention
Days	32459919	23	27	I-Intervention
in	32459919	28	30	O
Patients	32459919	31	39	O
with	32459919	40	44	O
Severe	32459919	45	51	B-Participant
Covid-19	32459919	52	60	I-Participant
.	32459919	61	62	O

Remdesivir	32459919	63	73	O
is	32459919	74	76	O
an	32459919	77	79	O
RNA	32459919	80	83	O
polymerase	32459919	84	94	O
inhibitor	32459919	95	104	O
with	32459919	105	109	O
potent	32459919	110	116	O
antiviral	32459919	117	126	O
activity	32459919	127	135	O
in	32459919	136	138	O
vitro	32459919	139	144	O
and	32459919	145	148	O
efficacy	32459919	149	157	O
in	32459919	158	160	O
animal	32459919	161	167	O
models	32459919	168	174	O
of	32459919	175	177	O
coronavirus	32459919	178	189	O
disease	32459919	190	197	O
2019	32459919	198	202	O
(	32459919	203	204	O
Covid-19	32459919	205	213	O
)	32459919	214	215	O
.	32459919	216	217	O

We	32459919	218	220	O
conducted	32459919	221	230	O
a	32459919	231	232	O
randomized	32459919	233	243	O
,	32459919	244	245	O
open	32459919	246	250	O
-	32459919	251	252	O
label	32459919	253	258	O
,	32459919	259	260	O
phase	32459919	261	266	O
3	32459919	267	268	O
trial	32459919	269	274	O
involving	32459919	275	284	O
hospitalized	32459919	285	297	O
patients	32459919	298	306	O
with	32459919	307	311	O
confirmed	32459919	312	321	O
SARS	32459919	322	326	B-Participant
-	32459919	327	328	I-Participant
CoV-2	32459919	329	334	I-Participant
infection	32459919	335	344	I-Participant
,	32459919	345	346	O
oxygen	32459919	347	353	B-Participant
saturation	32459919	354	364	I-Participant
of	32459919	365	367	I-Participant
94	32459919	368	370	I-Participant
%	32459919	371	372	I-Participant
or	32459919	373	375	I-Participant
less	32459919	376	380	I-Participant
while	32459919	381	386	O
they	32459919	387	391	O
were	32459919	392	396	O
breathing	32459919	397	406	B-Participant
ambient	32459919	407	414	I-Participant
air	32459919	415	418	I-Participant
,	32459919	419	420	O
and	32459919	421	424	O
radiologic	32459919	425	435	B-Participant
evidence	32459919	436	444	I-Participant
of	32459919	445	447	I-Participant
pneumonia	32459919	448	457	I-Participant
.	32459919	458	459	O

Patients	32459919	460	468	O
were	32459919	469	473	O
randomly	32459919	474	482	O
assigned	32459919	483	491	O
in	32459919	492	494	O
a	32459919	495	496	O
1:1	32459919	497	500	O
ratio	32459919	501	506	O
to	32459919	507	509	O
receive	32459919	510	517	O
intravenous	32459919	518	529	B-Intervention
remdesivir	32459919	530	540	I-Intervention
for	32459919	541	544	I-Intervention
either	32459919	545	551	I-Intervention
5	32459919	552	553	I-Intervention
days	32459919	554	558	I-Intervention
or	32459919	559	561	O
10	32459919	562	564	B-Intervention
days	32459919	565	569	I-Intervention
.	32459919	570	571	O

All	32459919	572	575	O
patients	32459919	576	584	O
received	32459919	585	593	O
200	32459919	594	597	O
mg	32459919	598	600	O
of	32459919	601	603	O
remdesivir	32459919	604	614	B-Intervention
on	32459919	615	617	O
day	32459919	618	621	O
1	32459919	622	623	O
and	32459919	624	627	O
100	32459919	628	631	O
mg	32459919	632	634	O
once	32459919	635	639	O
daily	32459919	640	645	O
on	32459919	646	648	O
subsequent	32459919	649	659	O
days	32459919	660	664	O
.	32459919	665	666	O

The	32459919	667	670	O
primary	32459919	671	678	O
end	32459919	679	682	O
point	32459919	683	688	O
was	32459919	689	692	O
clinical	32459919	693	701	B-Outcome
status	32459919	702	708	I-Outcome
on	32459919	709	711	I-Outcome
day	32459919	712	715	I-Outcome
14	32459919	716	718	I-Outcome
,	32459919	719	720	O
assessed	32459919	721	729	O
on	32459919	730	732	O
a	32459919	733	734	O
7-point	32459919	735	742	O
ordinal	32459919	743	750	O
scale	32459919	751	756	O
.	32459919	757	758	O

In	32459919	759	761	O
total	32459919	762	767	O
,	32459919	768	769	O
397	32459919	770	773	O
patients	32459919	774	782	O
underwent	32459919	783	792	O
randomization	32459919	793	806	O
and	32459919	807	810	O
began	32459919	811	816	O
treatment	32459919	817	826	O
(	32459919	827	828	O
200	32459919	829	832	O
patients	32459919	833	841	O
for	32459919	842	845	O
5	32459919	846	847	B-Intervention
days	32459919	848	852	I-Intervention
and	32459919	853	856	O
197	32459919	857	860	O
for	32459919	861	864	O
10	32459919	865	867	B-Intervention
days	32459919	868	872	I-Intervention
)	32459919	873	874	O
.	32459919	875	876	O

The	32459919	877	880	O
median	32459919	881	887	O
duration	32459919	888	896	O
of	32459919	897	899	O
treatment	32459919	900	909	O
was	32459919	910	913	O
5	32459919	914	915	O
days	32459919	916	920	O
(	32459919	921	922	O
interquartile	32459919	923	936	O
range	32459919	937	942	O
,	32459919	943	944	O
5	32459919	945	946	O
to	32459919	947	949	O
5	32459919	950	951	O
)	32459919	952	953	O
in	32459919	954	956	O
the	32459919	957	960	O
5-day	32459919	961	966	B-Intervention
group	32459919	967	972	O
and	32459919	973	976	O
9	32459919	977	978	O
days	32459919	979	983	O
(	32459919	984	985	O
interquartile	32459919	986	999	O
range	32459919	1000	1005	O
,	32459919	1006	1007	O
5	32459919	1008	1009	O
to	32459919	1010	1012	O
10	32459919	1013	1015	O
)	32459919	1016	1017	O
in	32459919	1018	1020	O
the	32459919	1021	1024	O
10-day	32459919	1025	1031	B-Intervention
group	32459919	1032	1037	O
.	32459919	1038	1039	O

At	32459919	1040	1042	O
baseline	32459919	1043	1051	O
,	32459919	1052	1053	O
patients	32459919	1054	1062	O
randomly	32459919	1063	1071	O
assigned	32459919	1072	1080	O
to	32459919	1081	1083	O
the	32459919	1084	1087	O
10-day	32459919	1088	1094	B-Intervention
group	32459919	1095	1100	O
had	32459919	1101	1104	O
significantly	32459919	1105	1118	B-Observation
worse	32459919	1119	1124	I-Observation
clinical	32459919	1125	1133	B-Outcome
status	32459919	1134	1140	I-Outcome
than	32459919	1141	1145	O
those	32459919	1146	1151	O
assigned	32459919	1152	1160	O
to	32459919	1161	1163	O
the	32459919	1164	1167	O
5-day	32459919	1168	1173	B-Intervention
group	32459919	1174	1179	O
(	32459919	1180	1181	O
P	32459919	1182	1183	O
=	32459919	1186	1187	O
0.02	32459919	1190	1194	O
)	32459919	1195	1196	O
.	32459919	1197	1198	O

By	32459919	1199	1201	O
day	32459919	1202	1205	O
14	32459919	1206	1208	O
,	32459919	1209	1210	O
a	32459919	1211	1212	O
clinical	32459919	1213	1221	B-Outcome
improvement	32459919	1222	1233	I-Outcome
of	32459919	1234	1236	I-Outcome
2	32459919	1237	1238	I-Outcome
points	32459919	1239	1245	I-Outcome
or	32459919	1246	1248	I-Outcome
more	32459919	1249	1253	I-Outcome
on	32459919	1254	1256	I-Outcome
the	32459919	1257	1260	I-Outcome
ordinal	32459919	1261	1268	I-Outcome
scale	32459919	1269	1274	I-Outcome
occurred	32459919	1275	1283	O
in	32459919	1284	1286	O
64	32459919	1287	1289	B-Count
%	32459919	1290	1291	I-Count
of	32459919	1292	1294	I-Count
patients	32459919	1295	1303	I-Count
in	32459919	1304	1306	O
the	32459919	1307	1310	O
5-day	32459919	1311	1316	B-Intervention
group	32459919	1317	1322	O
and	32459919	1323	1326	O
in	32459919	1327	1329	O
54	32459919	1330	1332	B-Count
%	32459919	1333	1334	I-Count
in	32459919	1335	1337	O
the	32459919	1338	1341	O
10-day	32459919	1342	1348	B-Intervention
group	32459919	1349	1354	O
.	32459919	1355	1356	O

After	32459919	1357	1362	O
adjustment	32459919	1363	1373	O
for	32459919	1374	1377	O
baseline	32459919	1378	1386	O
clinical	32459919	1387	1395	O
status	32459919	1396	1402	O
,	32459919	1403	1404	O
patients	32459919	1405	1413	O
in	32459919	1414	1416	O
the	32459919	1417	1420	O
10-day	32459919	1421	1427	B-Intervention
group	32459919	1428	1433	O
had	32459919	1434	1437	O
a	32459919	1438	1439	O
distribution	32459919	1440	1452	B-Outcome
in	32459919	1453	1455	I-Outcome
clinical	32459919	1456	1464	I-Outcome
status	32459919	1465	1471	I-Outcome
at	32459919	1472	1474	O
day	32459919	1475	1478	O
14	32459919	1479	1481	O
that	32459919	1482	1486	O
was	32459919	1487	1490	O
similar	32459919	1491	1498	B-Observation
to	32459919	1499	1501	O
that	32459919	1502	1506	O
among	32459919	1507	1512	O
patients	32459919	1513	1521	O
in	32459919	1522	1524	O
the	32459919	1525	1528	O
5-day	32459919	1529	1534	B-Intervention
group	32459919	1535	1540	O
(	32459919	1541	1542	O
P	32459919	1543	1544	O
=	32459919	1547	1548	O
0.14	32459919	1551	1555	O
)	32459919	1556	1557	O
.	32459919	1558	1559	O

The	32459919	1560	1563	O
most	32459919	1564	1568	B-Observation
common	32459919	1569	1575	I-Observation
adverse	32459919	1576	1583	I-Observation
events	32459919	1584	1590	I-Observation
were	32459919	1591	1595	O
nausea	32459919	1596	1602	B-Outcome
(	32459919	1603	1604	O
9	32459919	1605	1606	B-Count
%	32459919	1607	1608	I-Count
of	32459919	1609	1611	I-Count
patients	32459919	1612	1620	I-Count
)	32459919	1621	1622	O
,	32459919	1623	1624	O
worsening	32459919	1625	1634	B-Outcome
respiratory	32459919	1635	1646	I-Outcome
failure	32459919	1647	1654	I-Outcome
(	32459919	1655	1656	O
8	32459919	1657	1658	B-Count
%	32459919	1659	1660	I-Count
)	32459919	1661	1662	O
,	32459919	1663	1664	O
elevated	32459919	1665	1673	B-Outcome
alanine	32459919	1674	1681	I-Outcome
aminotransferase	32459919	1682	1698	I-Outcome
level	32459919	1699	1704	I-Outcome
(	32459919	1705	1706	O
7	32459919	1707	1708	B-Count
%	32459919	1709	1710	I-Count
)	32459919	1711	1712	O
,	32459919	1713	1714	O
and	32459919	1715	1718	O
constipation	32459919	1719	1731	B-Outcome
(	32459919	1732	1733	O
7	32459919	1734	1735	B-Count
%	32459919	1736	1737	I-Count
)	32459919	1738	1739	O
.	32459919	1740	1741	O

In	32459919	1742	1744	O
patients	32459919	1745	1753	O
with	32459919	1754	1758	O
severe	32459919	1759	1765	B-Participant
Covid-19	32459919	1766	1774	I-Participant
not	32459919	1775	1778	O
requiring	32459919	1779	1788	O
mechanical	32459919	1789	1799	B-Participant
ventilation	32459919	1800	1811	I-Participant
,	32459919	1812	1813	O
our	32459919	1814	1817	O
trial	32459919	1818	1823	O
did	32459919	1824	1827	O
not	32459919	1828	1831	O
show	32459919	1832	1836	O
a	32459919	1837	1838	O
significant	32459919	1839	1850	B-Observation
difference	32459919	1851	1861	I-Observation
between	32459919	1862	1869	O
a	32459919	1870	1871	O
5-day	32459919	1872	1877	B-Intervention
course	32459919	1878	1884	I-Intervention
and	32459919	1885	1888	O
a	32459919	1889	1890	O
10-day	32459919	1891	1897	B-Intervention
course	32459919	1898	1904	I-Intervention
of	32459919	1905	1907	I-Intervention
remdesivir	32459919	1908	1918	I-Intervention
.	32459919	1919	1920	O

With	32459919	1921	1925	O
no	32459919	1926	1928	O
placebo	32459919	1929	1936	O
control	32459919	1937	1944	O
,	32459919	1945	1946	O
however	32459919	1947	1954	O
,	32459919	1955	1956	O
the	32459919	1957	1960	O
magnitude	32459919	1961	1970	O
of	32459919	1971	1973	O
benefit	32459919	1974	1981	O
can	32459919	1982	1985	O
not	32459919	1986	1989	O
be	32459919	1990	1992	O
determined	32459919	1993	2003	O
.	32459919	2004	2005	O
(	32459919	2006	2007	O
Funded	32459919	2008	2014	O
by	32459919	2015	2017	O
Gilead	32459919	2018	2024	O
Sciences	32459919	2025	2033	O
;	32459919	2034	2035	O
GS	32459919	2036	2038	O
-	32459919	2039	2040	O
US-540	32459919	2041	2047	O
-	32459919	2048	2049	O
5773	32459919	2050	2054	O
ClinicalTrials.gov	32459919	2055	2073	O
number	32459919	2074	2080	O
,	32459919	2081	2082	O
NCT04292899	32459919	2083	2094	O
.	32459919	2095	2096	O
)	32459919	2097	2098	O
.	32459919	2099	2100	O


Colchicine	32461554	0	10	B-Intervention
's	32461554	11	13	O
effects	32461554	14	21	O
on	32461554	22	24	O
metabolic	32461554	25	34	B-Outcome
and	32461554	35	38	I-Outcome
inflammatory	32461554	39	51	I-Outcome
molecules	32461554	52	61	I-Outcome
in	32461554	62	64	O
adults	32461554	65	71	B-Participant
with	32461554	72	76	O
obesity	32461554	77	84	B-Participant
and	32461554	85	88	O
metabolic	32461554	89	98	B-Participant
syndrome	32461554	99	107	I-Participant
:	32461554	108	109	O
results	32461554	110	117	O
from	32461554	118	122	O
a	32461554	123	124	O
pilot	32461554	125	130	O
randomized	32461554	131	141	O
controlled	32461554	142	152	O
trial	32461554	153	158	O
.	32461554	159	160	O

Recent	32461554	161	167	O
clinical	32461554	168	176	O
trials	32461554	177	183	O
have	32461554	184	188	O
demonstrated	32461554	189	201	O
that	32461554	202	206	O
colchicine	32461554	207	217	O
may	32461554	218	221	O
have	32461554	222	226	O
metabolic	32461554	227	236	O
and	32461554	237	240	O
cardiovascular	32461554	241	255	O
and	32461554	256	259	O
benefits	32461554	260	268	O
in	32461554	269	271	O
at	32461554	272	274	O
-	32461554	275	276	O
risk	32461554	277	281	O
patients	32461554	282	290	O
;	32461554	291	292	O
however	32461554	293	300	O
,	32461554	301	302	O
the	32461554	303	306	O
mechanisms	32461554	307	317	O
through	32461554	318	325	O
which	32461554	326	331	O
colchicine	32461554	332	342	O
may	32461554	343	346	O
improve	32461554	347	354	O
outcomes	32461554	355	363	O
are	32461554	364	367	O
still	32461554	368	373	O
unclear	32461554	374	381	O
.	32461554	382	383	O

We	32461554	384	386	O
sought	32461554	387	393	O
to	32461554	394	396	O
examine	32461554	397	404	O
colchicine	32461554	405	415	O
's	32461554	416	418	O
effects	32461554	419	426	O
on	32461554	427	429	O
circulating	32461554	430	441	O
inflammatory	32461554	442	454	O
and	32461554	455	458	O
metabolic	32461554	459	468	O
molecules	32461554	469	478	O
in	32461554	479	481	O
adults	32461554	482	488	O
with	32461554	489	493	O
obesity	32461554	494	501	O
and	32461554	502	505	O
metabolic	32461554	506	515	O
syndrome	32461554	516	524	O
(	32461554	525	526	O
MetS	32461554	527	531	O
)	32461554	532	533	O
.	32461554	534	535	O

Blood	32461554	536	541	O
samples	32461554	542	549	O
were	32461554	550	554	O
collected	32461554	555	564	O
pre-	32461554	565	569	O
and	32461554	570	573	O
post	32461554	574	578	O
-	32461554	579	580	O
intervention	32461554	581	593	O
during	32461554	594	600	O
a	32461554	601	602	O
double	32461554	603	609	O
-	32461554	610	611	O
blind	32461554	612	617	O
randomized	32461554	618	628	O
controlled	32461554	629	639	O
trial	32461554	640	645	O
in	32461554	646	648	O
which	32461554	649	654	O
40	32461554	655	657	O
adults	32461554	658	664	B-Participant
with	32461554	665	669	O
obesity	32461554	670	677	B-Participant
and	32461554	678	681	O
MetS	32461554	682	686	B-Participant
were	32461554	687	691	O
randomized	32461554	692	702	O
to	32461554	703	705	O
colchicine	32461554	706	716	B-Intervention
0.6	32461554	717	720	O
mg	32461554	723	725	O
or	32461554	726	728	O
placebo	32461554	729	736	B-Intervention
twice	32461554	737	742	O
-	32461554	743	744	O
daily	32461554	745	750	O
for	32461554	751	754	O
3	32461554	755	756	O
months	32461554	757	763	O
.	32461554	764	765	O

Serum	32461554	766	771	O
samples	32461554	772	779	O
were	32461554	780	784	O
analyzed	32461554	785	793	O
for	32461554	794	797	O
1305	32461554	798	802	O
circulating	32461554	803	814	B-Outcome
factors	32461554	815	822	I-Outcome
using	32461554	823	828	O
the	32461554	829	832	O
SomaScan	32461554	833	841	O
Platform	32461554	842	850	O
.	32461554	851	852	O

The	32461554	853	856	O
Benjamini	32461554	857	866	O
-	32461554	867	868	O
Hochberg	32461554	869	877	O
procedure	32461554	878	887	O
was	32461554	888	891	O
used	32461554	892	896	O
to	32461554	897	899	O
adjust	32461554	900	906	O
the	32461554	907	910	O
false	32461554	911	916	O
discovery	32461554	917	926	O
rate	32461554	927	931	O
(	32461554	932	933	O
FDR	32461554	934	937	O
)	32461554	938	939	O
for	32461554	940	943	O
multiple	32461554	944	952	O
testing	32461554	953	960	O
.	32461554	961	962	O

At	32461554	963	965	O
baseline	32461554	966	974	O
,	32461554	975	976	O
age	32461554	977	980	O
(	32461554	981	982	O
48.0	32461554	983	987	O
	32461554	990	991	O
13.8	32461554	994	998	O
vs.	32461554	999	1002	O
44.7	32461554	1003	1007	O
	32461554	1010	1011	O
10.3	32461554	1014	1018	O
years	32461554	1019	1024	O
)	32461554	1025	1026	O
and	32461554	1027	1030	O
BMI	32461554	1031	1034	O
(	32461554	1035	1036	O
39.8	32461554	1037	1041	O
	32461554	1044	1045	O
6.4	32461554	1048	1051	O
vs.	32461554	1052	1055	O
41.8	32461554	1056	1060	O
	32461554	1063	1064	O
8.2	32461554	1067	1070	O
kg	32461554	1073	1075	O
/	32461554	1076	1077	O
m2	32461554	1078	1080	O
)	32461554	1081	1082	O
were	32461554	1083	1087	O
not	32461554	1088	1091	O
different	32461554	1092	1101	O
between	32461554	1102	1109	O
groups	32461554	1110	1116	O
.	32461554	1117	1118	O

After	32461554	1119	1124	O
controlling	32461554	1125	1136	O
for	32461554	1137	1140	O
the	32461554	1141	1144	O
FDR	32461554	1145	1148	O
,	32461554	1149	1150	O
34	32461554	1151	1153	B-Count
molecules	32461554	1154	1163	I-Count
were	32461554	1164	1168	O
significantly	32461554	1169	1182	B-Observation
changed	32461554	1183	1190	I-Observation
by	32461554	1191	1193	O
colchicine	32461554	1194	1204	B-Intervention
.	32461554	1205	1206	O

Colchicine	32461554	1207	1217	B-Intervention
decreased	32461554	1218	1227	B-Observation
concentrations	32461554	1228	1242	B-Outcome
of	32461554	1243	1245	I-Outcome
multiple	32461554	1246	1254	I-Outcome
inflammatory	32461554	1255	1267	I-Outcome
molecules	32461554	1268	1277	I-Outcome
,	32461554	1278	1279	O
including	32461554	1280	1289	O
C	32461554	1290	1291	B-Outcome
-	32461554	1292	1293	I-Outcome
reactive	32461554	1294	1302	I-Outcome
protein	32461554	1303	1310	I-Outcome
,	32461554	1311	1312	O
interleukin	32461554	1313	1324	B-Outcome
6	32461554	1325	1326	I-Outcome
,	32461554	1327	1328	O
and	32461554	1329	1332	O
resistin	32461554	1333	1341	B-Outcome
,	32461554	1342	1343	O
in	32461554	1344	1346	O
addition	32461554	1347	1355	O
to	32461554	1356	1358	O
vascular	32461554	1359	1367	B-Outcome
-	32461554	1368	1369	I-Outcome
related	32461554	1370	1377	I-Outcome
proteins	32461554	1378	1386	I-Outcome
(	32461554	1387	1388	O
e.g.	32461554	1389	1393	O
,	32461554	1394	1395	O
oxidized	32461554	1396	1404	B-Outcome
low	32461554	1405	1408	I-Outcome
-	32461554	1409	1410	I-Outcome
density	32461554	1411	1418	I-Outcome
lipoprotein	32461554	1419	1430	I-Outcome
receptor	32461554	1431	1439	I-Outcome
,	32461554	1440	1441	O
phosphodiesterase	32461554	1442	1459	B-Outcome
5A	32461554	1460	1462	I-Outcome
)	32461554	1463	1464	O
.	32461554	1465	1466	O

Conversely	32461554	1467	1477	O
,	32461554	1478	1479	O
relative	32461554	1480	1488	O
to	32461554	1489	1491	O
placebo	32461554	1492	1499	B-Intervention
,	32461554	1500	1501	O
colchicine	32461554	1502	1512	B-Intervention
significantly	32461554	1513	1526	B-Observation
increased	32461554	1527	1536	I-Observation
concentrations	32461554	1537	1551	B-Outcome
of	32461554	1552	1554	O
eight	32461554	1555	1560	B-Count
molecules	32461554	1561	1570	I-Count
including	32461554	1571	1580	O
secreted	32461554	1581	1589	B-Outcome
factors	32461554	1590	1597	I-Outcome
associated	32461554	1598	1608	I-Outcome
with	32461554	1609	1613	I-Outcome
metabolism	32461554	1614	1624	I-Outcome
and	32461554	1625	1628	I-Outcome
anti	32461554	1629	1633	I-Outcome
-	32461554	1634	1635	I-Outcome
thrombosis	32461554	1636	1646	I-Outcome
.	32461554	1647	1648	O

In	32461554	1649	1651	O
adults	32461554	1652	1658	B-Participant
with	32461554	1659	1663	O
obesity	32461554	1664	1671	B-Participant
,	32461554	1672	1673	O
colchicine	32461554	1674	1684	B-Intervention
significantly	32461554	1685	1698	B-Observation
affected	32461554	1699	1707	I-Observation
concentrations	32461554	1708	1722	B-Outcome
of	32461554	1723	1725	I-Outcome
proteins	32461554	1726	1734	I-Outcome
involved	32461554	1735	1743	I-Outcome
in	32461554	1744	1746	I-Outcome
the	32461554	1747	1750	I-Outcome
innate	32461554	1751	1757	I-Outcome
immune	32461554	1758	1764	I-Outcome
system	32461554	1765	1771	I-Outcome
,	32461554	1772	1773	O
endothelial	32461554	1774	1785	B-Outcome
function	32461554	1786	1794	I-Outcome
and	32461554	1795	1798	O
atherosclerosis	32461554	1799	1814	B-Outcome
,	32461554	1815	1816	O
uncovering	32461554	1817	1827	O
new	32461554	1828	1831	O
mechanisms	32461554	1832	1842	O
behind	32461554	1843	1849	O
its	32461554	1850	1853	O
cardiometabolic	32461554	1854	1869	O
effects	32461554	1870	1877	O
.	32461554	1878	1879	O

Further	32461554	1880	1887	O
research	32461554	1888	1896	O
is	32461554	1897	1899	O
warranted	32461554	1900	1909	O
to	32461554	1910	1912	O
investigate	32461554	1913	1924	O
whether	32461554	1925	1932	O
colchicine	32461554	1933	1943	O
's	32461554	1944	1946	O
IL-6	32461554	1947	1951	O
suppressive	32461554	1952	1963	O
effects	32461554	1964	1971	O
may	32461554	1972	1975	O
be	32461554	1976	1978	O
beneficial	32461554	1979	1989	O
in	32461554	1990	1992	O
COVID-19	32461554	1993	2001	O
.	32461554	2002	2003	O


Ruxolitinib	32470486	0	11	B-Intervention
in	32470486	12	14	O
treatment	32470486	15	24	O
of	32470486	25	27	O
severe	32470486	28	34	B-Participant
coronavirus	32470486	35	46	I-Participant
disease	32470486	47	54	I-Participant
2019	32470486	55	59	I-Participant
(	32470486	60	61	I-Participant
COVID-19	32470486	62	70	I-Participant
)	32470486	71	72	I-Participant
:	32470486	73	74	O
A	32470486	75	76	O
multicenter	32470486	79	90	O
,	32470486	91	92	O
single	32470486	93	99	O
-	32470486	100	101	O
blind	32470486	102	107	O
,	32470486	108	109	O
randomized	32470486	110	120	O
controlled	32470486	121	131	O
trial	32470486	132	137	O
.	32470486	138	139	O

BACKGROUND	32470486	140	150	O
:	32470486	151	152	O
Accumulating	32470486	153	165	O
evidence	32470486	166	174	O
proposed	32470486	175	183	O
Janus	32470486	184	189	O
-	32470486	190	191	O
associated	32470486	192	202	O
kinase	32470486	203	209	O
(	32470486	210	211	O
JAK	32470486	212	215	O
)	32470486	216	217	O
inhibitors	32470486	218	228	O
as	32470486	229	231	O
therapeutic	32470486	232	243	O
targets	32470486	244	251	O
warranting	32470486	252	262	O
rapid	32470486	263	268	O
investigation	32470486	269	282	O
.	32470486	283	284	O

OBJECTIVE	32470486	285	294	O
:	32470486	295	296	O
This	32470486	297	301	O
study	32470486	302	307	O
evaluated	32470486	308	317	O
the	32470486	318	321	O
efficacy	32470486	322	330	B-Outcome
and	32470486	331	334	O
safety	32470486	335	341	B-Outcome
of	32470486	342	344	O
ruxolitinib	32470486	345	356	B-Intervention
,	32470486	357	358	O
a	32470486	359	360	O
JAK1/2	32470486	361	367	O
inhibitor	32470486	368	377	O
,	32470486	378	379	O
for	32470486	380	383	O
coronavirus	32470486	384	395	B-Participant
disease	32470486	396	403	I-Participant
2019	32470486	404	408	I-Participant
.	32470486	409	410	O

METHODS	32470486	411	418	O
:	32470486	419	420	O
We	32470486	421	423	O
conducted	32470486	424	433	O
a	32470486	434	435	O
prospective	32470486	436	447	O
,	32470486	448	449	O
multicenter	32470486	450	461	O
,	32470486	462	463	O
single	32470486	464	470	O
-	32470486	471	472	O
blind	32470486	473	478	O
,	32470486	479	480	O
randomized	32470486	481	491	O
controlled	32470486	492	502	O
phase	32470486	503	508	O
II	32470486	509	511	O
trial	32470486	512	517	O
involving	32470486	518	527	O
patients	32470486	528	536	O
with	32470486	537	541	O
severe	32470486	542	548	B-Participant
coronavirus	32470486	549	560	I-Participant
disease	32470486	561	568	I-Participant
2019	32470486	569	573	I-Participant
.	32470486	574	575	O

RESULTS	32470486	576	583	O
:	32470486	584	585	O
Forty	32470486	586	591	O
-	32470486	592	593	O
three	32470486	594	599	O
patients	32470486	600	608	O
were	32470486	609	613	O
randomly	32470486	614	622	O
assigned	32470486	623	631	O
(	32470486	632	633	O
1:1	32470486	634	637	O
)	32470486	638	639	O
to	32470486	640	642	O
receive	32470486	643	650	O
ruxolitinib	32470486	651	662	B-Intervention
plus	32470486	663	667	I-Intervention
standard	32470486	668	676	I-Intervention
-	32470486	677	678	I-Intervention
of	32470486	679	681	I-Intervention
-	32470486	682	683	I-Intervention
care	32470486	684	688	I-Intervention
treatment	32470486	689	698	I-Intervention
(	32470486	699	700	O
22	32470486	701	703	O
patients	32470486	704	712	O
)	32470486	713	714	O
or	32470486	715	717	O
placebo	32470486	718	725	B-Intervention
based	32470486	726	731	I-Intervention
on	32470486	732	734	I-Intervention
standard	32470486	735	743	I-Intervention
-	32470486	744	745	I-Intervention
of	32470486	746	748	I-Intervention
-	32470486	749	750	I-Intervention
care	32470486	751	755	I-Intervention
treatment	32470486	756	765	I-Intervention
(	32470486	766	767	O
21	32470486	768	770	O
patients	32470486	771	779	O
)	32470486	780	781	O
.	32470486	782	783	O

After	32470486	784	789	O
exclusion	32470486	790	799	O
of	32470486	800	802	O
2	32470486	803	804	O
patients	32470486	805	813	O
(	32470486	814	815	O
1	32470486	816	817	O
ineligible	32470486	818	828	O
,	32470486	829	830	O
1	32470486	831	832	O
consent	32470486	833	840	O
withdrawn	32470486	841	850	O
)	32470486	851	852	O
from	32470486	853	857	O
the	32470486	858	861	O
ruxolitinib	32470486	862	873	B-Intervention
group	32470486	874	879	O
,	32470486	880	881	O
20	32470486	882	884	O
patients	32470486	885	893	O
in	32470486	894	896	O
the	32470486	897	900	O
intervention	32470486	901	913	B-Intervention
group	32470486	914	919	O
and	32470486	920	923	O
21	32470486	924	926	O
patients	32470486	927	935	O
in	32470486	936	938	O
the	32470486	939	942	O
control	32470486	943	950	B-Intervention
group	32470486	951	956	O
were	32470486	957	961	O
included	32470486	962	970	O
in	32470486	971	973	O
the	32470486	974	977	O
study	32470486	978	983	O
.	32470486	984	985	O

Treatment	32470486	986	995	O
with	32470486	996	1000	O
ruxolitinib	32470486	1001	1012	B-Intervention
plus	32470486	1013	1017	I-Intervention
standard	32470486	1018	1026	I-Intervention
-	32470486	1027	1028	I-Intervention
of	32470486	1029	1031	I-Intervention
-	32470486	1032	1033	I-Intervention
care	32470486	1034	1038	I-Intervention
was	32470486	1039	1042	O
not	32470486	1043	1046	O
associated	32470486	1047	1057	O
with	32470486	1058	1062	O
significantly	32470486	1063	1076	B-Observation
accelerated	32470486	1077	1088	I-Observation
clinical	32470486	1089	1097	B-Outcome
improvement	32470486	1098	1109	I-Outcome
in	32470486	1110	1112	O
severe	32470486	1113	1119	B-Participant
patients	32470486	1120	1128	I-Participant
with	32470486	1129	1133	O
coronavirus	32470486	1134	1145	B-Participant
disease	32470486	1146	1153	I-Participant
2019	32470486	1154	1158	O
,	32470486	1159	1160	O
although	32470486	1161	1169	O
ruxolitinib	32470486	1170	1181	B-Intervention
recipients	32470486	1182	1192	O
had	32470486	1193	1196	O
a	32470486	1197	1198	O
numerically	32470486	1199	1210	B-Observation
faster	32470486	1211	1217	I-Observation
clinical	32470486	1218	1226	B-Outcome
improvement	32470486	1227	1238	I-Outcome
.	32470486	1239	1240	O

Eighteen	32470486	1241	1249	B-Count
(	32470486	1250	1251	I-Count
90	32470486	1252	1254	I-Count
%	32470486	1255	1256	I-Count
)	32470486	1257	1258	I-Count
patients	32470486	1259	1267	I-Count
from	32470486	1268	1272	O
the	32470486	1273	1276	O
ruxolitinib	32470486	1277	1288	B-Intervention
group	32470486	1289	1294	O
showed	32470486	1295	1301	O
computed	32470486	1302	1310	B-Outcome
tomography	32470486	1311	1321	I-Outcome
improvement	32470486	1322	1333	I-Outcome
at	32470486	1334	1336	O
day	32470486	1337	1340	O
14	32470486	1341	1343	O
compared	32470486	1344	1352	O
with	32470486	1353	1357	O
13	32470486	1358	1360	B-Count
(	32470486	1361	1362	I-Count
61.9	32470486	1363	1367	I-Count
%	32470486	1368	1369	I-Count
)	32470486	1370	1371	I-Count
patients	32470486	1372	1380	I-Count
from	32470486	1381	1385	O
the	32470486	1386	1389	O
control	32470486	1390	1397	B-Intervention
group	32470486	1398	1403	O
(	32470486	1404	1405	O
P	32470486	1406	1407	O
=	32470486	1410	1411	O
.0495	32470486	1414	1419	O
)	32470486	1420	1421	O
.	32470486	1422	1423	O

Three	32470486	1424	1429	B-Count
patients	32470486	1430	1438	I-Count
in	32470486	1439	1441	O
the	32470486	1442	1445	O
control	32470486	1446	1453	B-Intervention
group	32470486	1454	1459	O
died	32470486	1460	1464	B-Outcome
of	32470486	1465	1467	I-Outcome
respiratory	32470486	1468	1479	I-Outcome
failure	32470486	1480	1487	I-Outcome
,	32470486	1488	1489	O
with	32470486	1490	1494	O
14.3	32470486	1495	1499	B-Observation
%	32470486	1500	1501	I-Observation
overall	32470486	1502	1509	B-Outcome
mortality	32470486	1510	1519	I-Outcome
at	32470486	1520	1522	O
day	32470486	1523	1526	O
28	32470486	1527	1529	O
;	32470486	1530	1531	O
no	32470486	1532	1534	B-Count
patients	32470486	1535	1543	I-Count
died	32470486	1544	1548	B-Outcome
in	32470486	1549	1551	O
the	32470486	1552	1555	O
ruxolitinib	32470486	1556	1567	B-Intervention
group	32470486	1568	1573	O
.	32470486	1574	1575	O

Ruxolitinib	32470486	1576	1587	B-Intervention
was	32470486	1588	1591	O
well	32470486	1592	1596	B-Observation
tolerated	32470486	1597	1606	B-Outcome
with	32470486	1607	1611	O
low	32470486	1612	1615	B-Observation
toxicities	32470486	1616	1626	B-Outcome
and	32470486	1627	1630	O
no	32470486	1631	1633	O
new	32470486	1634	1637	B-Observation
safety	32470486	1638	1644	B-Outcome
signals	32470486	1645	1652	I-Outcome
.	32470486	1653	1654	O

Levels	32470486	1655	1661	B-Outcome
of	32470486	1662	1664	I-Outcome
7	32470486	1665	1666	I-Outcome
cytokines	32470486	1667	1676	I-Outcome
were	32470486	1677	1681	O
significantly	32470486	1682	1695	B-Observation
decreased	32470486	1696	1705	I-Observation
in	32470486	1706	1708	O
the	32470486	1709	1712	O
ruxolitinib	32470486	1713	1724	B-Intervention
group	32470486	1725	1730	O
in	32470486	1731	1733	O
comparison	32470486	1734	1744	O
to	32470486	1745	1747	O
the	32470486	1748	1751	O
control	32470486	1752	1759	B-Intervention
group	32470486	1760	1765	O
.	32470486	1766	1767	O

CONCLUSIONS	32470486	1768	1779	O
:	32470486	1780	1781	O
Although	32470486	1782	1790	O
no	32470486	1791	1793	O
statistical	32470486	1794	1805	B-Observation
difference	32470486	1806	1816	I-Observation
was	32470486	1817	1820	O
observed	32470486	1821	1829	O
,	32470486	1830	1831	O
ruxolitinib	32470486	1832	1843	B-Intervention
recipients	32470486	1844	1854	O
had	32470486	1855	1858	O
a	32470486	1859	1860	O
numerically	32470486	1861	1872	B-Observation
faster	32470486	1873	1879	I-Observation
clinical	32470486	1880	1888	B-Outcome
improvement	32470486	1889	1900	I-Outcome
.	32470486	1901	1902	O

Significant	32470486	1903	1914	O
chest	32470486	1915	1920	B-Outcome
computed	32470486	1921	1929	I-Outcome
tomography	32470486	1930	1940	I-Outcome
improvement	32470486	1941	1952	B-Observation
,	32470486	1953	1954	O
a	32470486	1955	1956	O
faster	32470486	1957	1963	B-Observation
recovery	32470486	1964	1972	B-Outcome
from	32470486	1973	1977	I-Outcome
lymphopenia	32470486	1978	1989	I-Outcome
,	32470486	1990	1991	O
and	32470486	1992	1995	O
favorable	32470486	1996	2005	B-Observation
side	32470486	2006	2010	B-Outcome
-	32470486	2011	2012	I-Outcome
effect	32470486	2013	2019	I-Outcome
profile	32470486	2020	2027	I-Outcome
in	32470486	2028	2030	O
the	32470486	2031	2034	O
ruxolitinib	32470486	2035	2046	B-Intervention
group	32470486	2047	2052	O
were	32470486	2053	2057	O
encouraging	32470486	2058	2069	O
and	32470486	2070	2073	O
informative	32470486	2074	2085	O
to	32470486	2086	2088	O
future	32470486	2089	2095	O
trials	32470486	2096	2102	O
to	32470486	2103	2105	O
test	32470486	2106	2110	O
efficacy	32470486	2111	2119	O
of	32470486	2120	2122	O
ruxolitinib	32470486	2123	2134	B-Intervention
in	32470486	2135	2137	O
a	32470486	2138	2139	O
larger	32470486	2140	2146	O
population	32470486	2147	2157	O
.	32470486	2158	2159	O


Effect	32492084	0	6	O
of	32492084	7	9	O
Convalescent	32492084	10	22	B-Intervention
Plasma	32492084	23	29	I-Intervention
Therapy	32492084	30	37	I-Intervention
on	32492084	38	40	O
Time	32492084	41	45	B-Outcome
to	32492084	46	48	I-Outcome
Clinical	32492084	49	57	I-Outcome
Improvement	32492084	58	69	I-Outcome
in	32492084	70	72	O
Patients	32492084	73	81	O
With	32492084	82	86	O
Severe	32492084	87	93	B-Participant
and	32492084	94	97	I-Participant
Life	32492084	98	102	I-Participant
-	32492084	103	104	I-Participant
threatening	32492084	105	116	I-Participant
COVID-19	32492084	117	125	I-Participant
:	32492084	126	127	O
A	32492084	128	129	O
Randomized	32492084	130	140	O
Clinical	32492084	141	149	O
Trial	32492084	150	155	O
.	32492084	156	157	O

Convalescent	32492084	158	170	O
plasma	32492084	171	177	O
is	32492084	178	180	O
a	32492084	181	182	O
potential	32492084	183	192	O
therapeutic	32492084	193	204	O
option	32492084	205	211	O
for	32492084	212	215	O
patients	32492084	216	224	O
with	32492084	225	229	O
coronavirus	32492084	230	241	O
disease	32492084	242	249	O
2019	32492084	250	254	O
(	32492084	255	256	O
COVID-19	32492084	257	265	O
)	32492084	266	267	O
,	32492084	268	269	O
but	32492084	270	273	O
further	32492084	274	281	O
data	32492084	282	286	O
from	32492084	287	291	O
randomized	32492084	292	302	O
clinical	32492084	303	311	O
trials	32492084	312	318	O
are	32492084	319	322	O
needed	32492084	323	329	O
.	32492084	330	331	O

To	32492084	332	334	O
evaluate	32492084	335	343	O
the	32492084	344	347	O
efficacy	32492084	348	356	B-Outcome
and	32492084	357	360	O
adverse	32492084	361	368	B-Outcome
effects	32492084	369	376	I-Outcome
of	32492084	377	379	O
convalescent	32492084	380	392	B-Intervention
plasma	32492084	393	399	I-Intervention
therapy	32492084	400	407	I-Intervention
for	32492084	408	411	O
patients	32492084	412	420	O
with	32492084	421	425	O
COVID-19	32492084	426	434	B-Participant
.	32492084	435	436	O

Open	32492084	437	441	O
-	32492084	442	443	O
label	32492084	444	449	O
,	32492084	450	451	O
multicenter	32492084	452	463	O
,	32492084	464	465	O
randomized	32492084	466	476	O
clinical	32492084	477	485	O
trial	32492084	486	491	O
performed	32492084	492	501	O
in	32492084	502	504	O
7	32492084	505	506	O
medical	32492084	507	514	O
centers	32492084	515	522	O
in	32492084	523	525	O
Wuhan	32492084	526	531	O
,	32492084	532	533	O
China	32492084	534	539	O
,	32492084	540	541	O
from	32492084	542	546	O
February	32492084	547	555	O
14	32492084	556	558	O
,	32492084	559	560	O
2020	32492084	561	565	O
,	32492084	566	567	O
to	32492084	568	570	O
April	32492084	571	576	O
1	32492084	577	578	O
,	32492084	579	580	O
2020	32492084	581	585	O
,	32492084	586	587	O
with	32492084	588	592	O
final	32492084	593	598	O
follow	32492084	599	605	O
-	32492084	606	607	O
up	32492084	608	610	O
April	32492084	611	616	O
28	32492084	617	619	O
,	32492084	620	621	O
2020	32492084	622	626	O
.	32492084	627	628	O

The	32492084	629	632	O
trial	32492084	633	638	O
included	32492084	639	647	O
103	32492084	648	651	O
participants	32492084	652	664	O
with	32492084	665	669	O
laboratory	32492084	670	680	O
-	32492084	681	682	O
confirmed	32492084	683	692	O
COVID-19	32492084	693	701	B-Participant
that	32492084	702	706	O
was	32492084	707	710	O
severe	32492084	711	717	B-Participant
(	32492084	718	719	O
respiratory	32492084	720	731	B-Participant
distress	32492084	732	740	I-Participant
and/or	32492084	741	747	O
hypoxemia	32492084	748	757	B-Participant
)	32492084	758	759	O
or	32492084	760	762	O
life	32492084	763	767	B-Participant
-	32492084	768	769	I-Participant
threatening	32492084	770	781	I-Participant
(	32492084	782	783	O
shock	32492084	784	789	B-Participant
,	32492084	790	791	O
organ	32492084	792	797	B-Participant
failure	32492084	798	805	I-Participant
,	32492084	806	807	O
or	32492084	808	810	O
requiring	32492084	811	820	O
mechanical	32492084	821	831	B-Participant
ventilation	32492084	832	843	I-Participant
)	32492084	844	845	O
.	32492084	846	847	O

The	32492084	848	851	O
trial	32492084	852	857	O
was	32492084	858	861	O
terminated	32492084	862	872	O
early	32492084	873	878	O
after	32492084	879	884	O
103	32492084	885	888	O
of	32492084	889	891	O
a	32492084	892	893	O
planned	32492084	894	901	O
200	32492084	902	905	O
patients	32492084	906	914	O
were	32492084	915	919	O
enrolled	32492084	920	928	O
.	32492084	929	930	O

Convalescent	32492084	931	943	B-Intervention
plasma	32492084	944	950	I-Intervention
in	32492084	951	953	I-Intervention
addition	32492084	954	962	I-Intervention
to	32492084	963	965	I-Intervention
standard	32492084	966	974	I-Intervention
treatment	32492084	975	984	I-Intervention
(	32492084	985	986	O
n	32492084	987	988	O
=	32492084	991	992	O
52	32492084	995	997	O
)	32492084	998	999	O
vs	32492084	1000	1002	O
standard	32492084	1003	1011	B-Intervention
treatment	32492084	1012	1021	I-Intervention
alone	32492084	1022	1027	I-Intervention
(	32492084	1028	1029	O
control	32492084	1030	1037	O
)	32492084	1038	1039	O
(	32492084	1040	1041	O
n	32492084	1042	1043	O
=	32492084	1046	1047	O
51	32492084	1050	1052	O
)	32492084	1053	1054	O
,	32492084	1055	1056	O
stratified	32492084	1057	1067	O
by	32492084	1068	1070	O
disease	32492084	1071	1078	O
severity	32492084	1079	1087	O
.	32492084	1088	1089	O

Primary	32492084	1090	1097	O
outcome	32492084	1098	1105	O
was	32492084	1106	1109	O
time	32492084	1110	1114	B-Outcome
to	32492084	1115	1117	I-Outcome
clinical	32492084	1118	1126	I-Outcome
improvement	32492084	1127	1138	I-Outcome
within	32492084	1139	1145	I-Outcome
28	32492084	1146	1148	I-Outcome
days	32492084	1149	1153	I-Outcome
,	32492084	1154	1155	O
defined	32492084	1156	1163	O
as	32492084	1164	1166	O
patient	32492084	1167	1174	O
discharged	32492084	1175	1185	O
alive	32492084	1186	1191	O
or	32492084	1192	1194	O
reduction	32492084	1195	1204	O
of	32492084	1205	1207	O
2	32492084	1208	1209	O
points	32492084	1210	1216	O
on	32492084	1217	1219	O
a	32492084	1220	1221	O
6-point	32492084	1222	1229	O
disease	32492084	1230	1237	O
severity	32492084	1238	1246	O
scale	32492084	1247	1252	O
(	32492084	1253	1254	O
ranging	32492084	1255	1262	O
from	32492084	1263	1267	O
1	32492084	1268	1269	O
[	32492084	1270	1271	O
discharge	32492084	1272	1281	O
]	32492084	1282	1283	O
to	32492084	1284	1286	O
6	32492084	1287	1288	O
[	32492084	1289	1290	O
death	32492084	1291	1296	O
]	32492084	1297	1298	O
)	32492084	1299	1300	O
.	32492084	1301	1302	O

Secondary	32492084	1303	1312	O
outcomes	32492084	1313	1321	O
included	32492084	1322	1330	O
28-day	32492084	1331	1337	B-Outcome
mortality	32492084	1338	1347	I-Outcome
,	32492084	1348	1349	O
time	32492084	1350	1354	B-Outcome
to	32492084	1355	1357	I-Outcome
discharge	32492084	1358	1367	I-Outcome
,	32492084	1368	1369	O
and	32492084	1370	1373	O
the	32492084	1374	1377	O
rate	32492084	1378	1382	B-Outcome
of	32492084	1383	1385	I-Outcome
viral	32492084	1386	1391	I-Outcome
polymerase	32492084	1392	1402	I-Outcome
chain	32492084	1403	1408	I-Outcome
reaction	32492084	1409	1417	I-Outcome
(	32492084	1418	1419	I-Outcome
PCR	32492084	1420	1423	I-Outcome
)	32492084	1424	1425	I-Outcome
results	32492084	1426	1433	I-Outcome
turned	32492084	1434	1440	I-Outcome
from	32492084	1441	1445	I-Outcome
positive	32492084	1446	1454	I-Outcome
at	32492084	1455	1457	I-Outcome
baseline	32492084	1458	1466	I-Outcome
to	32492084	1467	1469	I-Outcome
negative	32492084	1470	1478	I-Outcome
at	32492084	1479	1481	I-Outcome
up	32492084	1482	1484	I-Outcome
to	32492084	1485	1487	I-Outcome
72	32492084	1488	1490	I-Outcome
hours	32492084	1491	1496	I-Outcome
.	32492084	1497	1498	O

Of	32492084	1499	1501	O
103	32492084	1502	1505	O
patients	32492084	1506	1514	O
who	32492084	1515	1518	O
were	32492084	1519	1523	O
randomized	32492084	1524	1534	O
(	32492084	1535	1536	O
median	32492084	1537	1543	O
age	32492084	1544	1547	O
,	32492084	1548	1549	O
70	32492084	1550	1552	O
years	32492084	1553	1558	O
;	32492084	1559	1560	O
60	32492084	1561	1563	O
[	32492084	1564	1565	O
58.3	32492084	1566	1570	O
%	32492084	1571	1572	O
]	32492084	1573	1574	O
male	32492084	1575	1579	O
)	32492084	1580	1581	O
,	32492084	1582	1583	O
101	32492084	1584	1587	O
(	32492084	1588	1589	O
98.1	32492084	1590	1594	O
%	32492084	1595	1596	O
)	32492084	1597	1598	O
completed	32492084	1599	1608	O
the	32492084	1609	1612	O
trial	32492084	1613	1618	O
.	32492084	1619	1620	O

Clinical	32492084	1621	1629	B-Outcome
improvement	32492084	1630	1641	I-Outcome
occurred	32492084	1642	1650	I-Outcome
within	32492084	1651	1657	I-Outcome
28	32492084	1658	1660	I-Outcome
days	32492084	1661	1665	I-Outcome
in	32492084	1666	1668	O
51.9	32492084	1669	1673	B-Count
%	32492084	1674	1675	I-Count
(	32492084	1676	1677	I-Count
27/52	32492084	1678	1683	I-Count
)	32492084	1684	1685	I-Count
of	32492084	1686	1688	O
the	32492084	1689	1692	O
convalescent	32492084	1693	1705	B-Intervention
plasma	32492084	1706	1712	I-Intervention
group	32492084	1713	1718	O
vs	32492084	1719	1721	O
43.1	32492084	1722	1726	B-Count
%	32492084	1727	1728	I-Count
(	32492084	1729	1730	I-Count
22/51	32492084	1731	1736	I-Count
)	32492084	1737	1738	I-Count
in	32492084	1739	1741	O
the	32492084	1742	1745	O
control	32492084	1746	1753	B-Intervention
group	32492084	1754	1759	O
(	32492084	1760	1761	O
difference	32492084	1762	1772	O
,	32492084	1773	1774	O
8.8	32492084	1775	1778	O
%	32492084	1779	1780	O
[	32492084	1781	1782	O
95	32492084	1783	1785	O
%	32492084	1786	1787	O
CI	32492084	1788	1790	O
,	32492084	1791	1792	O
-10.4	32492084	1793	1798	O
%	32492084	1799	1800	O
to	32492084	1801	1803	O
28.0	32492084	1804	1808	O
%	32492084	1809	1810	O
]	32492084	1811	1812	O
;	32492084	1813	1814	O
hazard	32492084	1815	1821	O
ratio	32492084	1822	1827	O
[	32492084	1828	1829	O
HR	32492084	1830	1832	O
]	32492084	1833	1834	O
,	32492084	1835	1836	O
1.40	32492084	1837	1841	O
[	32492084	1842	1843	O
95	32492084	1844	1846	O
%	32492084	1847	1848	O
CI	32492084	1849	1851	O
,	32492084	1852	1853	O
0.79	32492084	1854	1858	O
-	32492084	1859	1860	O
2.49	32492084	1861	1865	O
]	32492084	1866	1867	O
;	32492084	1868	1869	O
P	32492084	1870	1871	O
=	32492084	1874	1875	O
.26	32492084	1878	1881	O
)	32492084	1882	1883	O
.	32492084	1884	1885	O

Among	32492084	1886	1891	O
those	32492084	1892	1897	O
with	32492084	1898	1902	O
severe	32492084	1903	1909	B-Participant
disease	32492084	1910	1917	I-Participant
,	32492084	1918	1919	O
the	32492084	1920	1923	O
primary	32492084	1924	1931	B-Outcome
outcome	32492084	1932	1939	I-Outcome
occurred	32492084	1940	1948	O
in	32492084	1949	1951	O
91.3	32492084	1952	1956	B-Count
%	32492084	1957	1958	I-Count
(	32492084	1959	1960	I-Count
21/23	32492084	1961	1966	I-Count
)	32492084	1967	1968	I-Count
of	32492084	1969	1971	O
the	32492084	1972	1975	O
convalescent	32492084	1976	1988	B-Intervention
plasma	32492084	1989	1995	I-Intervention
group	32492084	1996	2001	O
vs	32492084	2002	2004	O
68.2	32492084	2005	2009	B-Count
%	32492084	2010	2011	I-Count
(	32492084	2012	2013	I-Count
15/22	32492084	2014	2019	I-Count
)	32492084	2020	2021	I-Count
of	32492084	2022	2024	O
the	32492084	2025	2028	O
control	32492084	2029	2036	B-Intervention
group	32492084	2037	2042	O
(	32492084	2043	2044	O
HR	32492084	2045	2047	O
,	32492084	2048	2049	O
2.15	32492084	2050	2054	O
[	32492084	2055	2056	O
95	32492084	2057	2059	O
%	32492084	2060	2061	O
CI	32492084	2062	2064	O
,	32492084	2065	2066	O
1.07	32492084	2067	2071	O
-	32492084	2072	2073	O
4.32	32492084	2074	2078	O
]	32492084	2079	2080	O
;	32492084	2081	2082	O
P	32492084	2083	2084	O
=	32492084	2087	2088	O
.03	32492084	2091	2094	O
)	32492084	2095	2096	O
;	32492084	2097	2098	O
among	32492084	2099	2104	O
those	32492084	2105	2110	O
with	32492084	2111	2115	O
life	32492084	2116	2120	B-Participant
-	32492084	2121	2122	I-Participant
threatening	32492084	2123	2134	I-Participant
disease	32492084	2135	2142	I-Participant
the	32492084	2143	2146	O
primary	32492084	2147	2154	B-Outcome
outcome	32492084	2155	2162	I-Outcome
occurred	32492084	2163	2171	O
in	32492084	2172	2174	O
20.7	32492084	2175	2179	B-Count
%	32492084	2180	2181	I-Count
(	32492084	2182	2183	I-Count
6/29	32492084	2184	2188	I-Count
)	32492084	2189	2190	I-Count
of	32492084	2191	2193	O
the	32492084	2194	2197	O
convalescent	32492084	2198	2210	B-Intervention
plasma	32492084	2211	2217	I-Intervention
group	32492084	2218	2223	O
vs	32492084	2224	2226	O
24.1	32492084	2227	2231	B-Count
%	32492084	2232	2233	I-Count
(	32492084	2234	2235	I-Count
7/29	32492084	2236	2240	I-Count
)	32492084	2241	2242	I-Count
of	32492084	2243	2245	O
the	32492084	2246	2249	O
control	32492084	2250	2257	B-Intervention
group	32492084	2258	2263	O
(	32492084	2264	2265	O
HR	32492084	2266	2268	O
,	32492084	2269	2270	O
0.88	32492084	2271	2275	O
[	32492084	2276	2277	O
95	32492084	2278	2280	O
%	32492084	2281	2282	O
CI	32492084	2283	2285	O
,	32492084	2286	2287	O
0.30	32492084	2288	2292	O
-	32492084	2293	2294	O
2.63	32492084	2295	2299	O
]	32492084	2300	2301	O
;	32492084	2302	2303	O
P	32492084	2304	2305	O
=	32492084	2308	2309	O
.83	32492084	2312	2315	O
)	32492084	2316	2317	O
(	32492084	2318	2319	O
P	32492084	2320	2321	O
for	32492084	2322	2325	O
interaction	32492084	2326	2337	O
=	32492084	2340	2341	O
.17	32492084	2344	2347	O
)	32492084	2348	2349	O
.	32492084	2350	2351	O

There	32492084	2352	2357	O
was	32492084	2358	2361	O
no	32492084	2362	2364	O
significant	32492084	2365	2376	B-Observation
difference	32492084	2377	2387	I-Observation
in	32492084	2388	2390	O
28-day	32492084	2391	2397	B-Outcome
mortality	32492084	2398	2407	I-Outcome
(	32492084	2408	2409	O
15.7	32492084	2410	2414	B-Observation
%	32492084	2415	2416	I-Observation
vs	32492084	2417	2419	O
24.0	32492084	2420	2424	B-Observation
%	32492084	2425	2426	I-Observation
;	32492084	2427	2428	O
OR	32492084	2429	2431	O
,	32492084	2432	2433	O
0.59	32492084	2434	2438	O
[	32492084	2439	2440	O
95	32492084	2441	2443	O
%	32492084	2444	2445	O
CI	32492084	2446	2448	O
,	32492084	2449	2450	O
0.22	32492084	2451	2455	O
-	32492084	2456	2457	O
1.59	32492084	2458	2462	O
]	32492084	2463	2464	O
;	32492084	2465	2466	O
P	32492084	2467	2468	O
=	32492084	2471	2472	O
.30	32492084	2475	2478	O
)	32492084	2479	2480	O
or	32492084	2481	2483	O
time	32492084	2484	2488	B-Outcome
from	32492084	2489	2493	I-Outcome
randomization	32492084	2494	2507	I-Outcome
to	32492084	2508	2510	I-Outcome
discharge	32492084	2511	2520	I-Outcome
(	32492084	2521	2522	O
51.0	32492084	2523	2527	B-Observation
%	32492084	2528	2529	I-Observation
vs	32492084	2530	2532	O
36.0	32492084	2533	2537	B-Observation
%	32492084	2538	2539	I-Observation
discharged	32492084	2540	2550	O
by	32492084	2551	2553	O
day	32492084	2554	2557	O
28	32492084	2558	2560	O
;	32492084	2561	2562	O
HR	32492084	2563	2565	O
,	32492084	2566	2567	O
1.61	32492084	2568	2572	O
[	32492084	2573	2574	O
95	32492084	2575	2577	O
%	32492084	2578	2579	O
CI	32492084	2580	2582	O
,	32492084	2583	2584	O
0.88	32492084	2585	2589	O
-	32492084	2590	2591	O
2.95	32492084	2592	2596	O
]	32492084	2597	2598	O
;	32492084	2599	2600	O
P	32492084	2601	2602	O
=	32492084	2605	2606	O
.12	32492084	2609	2612	O
)	32492084	2613	2614	O
.	32492084	2615	2616	O

Convalescent	32492084	2617	2629	B-Intervention
plasma	32492084	2630	2636	I-Intervention
treatment	32492084	2637	2646	I-Intervention
was	32492084	2647	2650	O
associated	32492084	2651	2661	O
with	32492084	2662	2666	O
a	32492084	2667	2668	O
negative	32492084	2669	2677	B-Outcome
conversion	32492084	2678	2688	I-Outcome
rate	32492084	2689	2693	I-Outcome
of	32492084	2694	2696	I-Outcome
viral	32492084	2697	2702	I-Outcome
PCR	32492084	2703	2706	I-Outcome
at	32492084	2707	2709	I-Outcome
72	32492084	2710	2712	I-Outcome
hours	32492084	2713	2718	I-Outcome
in	32492084	2719	2721	O
87.2	32492084	2722	2726	B-Observation
%	32492084	2727	2728	I-Observation
of	32492084	2729	2731	O
the	32492084	2732	2735	O
convalescent	32492084	2736	2748	B-Intervention
plasma	32492084	2749	2755	I-Intervention
group	32492084	2756	2761	O
vs	32492084	2762	2764	O
37.5	32492084	2765	2769	B-Observation
%	32492084	2770	2771	I-Observation
of	32492084	2772	2774	O
the	32492084	2775	2778	O
control	32492084	2779	2786	B-Intervention
group	32492084	2787	2792	O
(	32492084	2793	2794	O
OR	32492084	2795	2797	O
,	32492084	2798	2799	O
11.39	32492084	2800	2805	O
[	32492084	2806	2807	O
95	32492084	2808	2810	O
%	32492084	2811	2812	O
CI	32492084	2813	2815	O
,	32492084	2816	2817	O
3.91	32492084	2818	2822	O
-	32492084	2823	2824	O
33.18	32492084	2825	2830	O
]	32492084	2831	2832	O
;	32492084	2833	2834	O
P	32492084	2835	2836	O
<	32492084	2839	2840	O
.001	32492084	2843	2847	O
)	32492084	2848	2849	O
.	32492084	2850	2851	O

Two	32492084	2852	2855	B-Count
patients	32492084	2856	2864	I-Count
in	32492084	2865	2867	O
the	32492084	2868	2871	O
convalescent	32492084	2872	2884	B-Intervention
plasma	32492084	2885	2891	I-Intervention
group	32492084	2892	2897	O
experienced	32492084	2898	2909	O
adverse	32492084	2910	2917	B-Outcome
events	32492084	2918	2924	I-Outcome
within	32492084	2925	2931	O
hours	32492084	2932	2937	O
after	32492084	2938	2943	O
transfusion	32492084	2944	2955	O
that	32492084	2956	2960	O
improved	32492084	2961	2969	O
with	32492084	2970	2974	O
supportive	32492084	2975	2985	O
care	32492084	2986	2990	O
.	32492084	2991	2992	O

Among	32492084	2993	2998	O
patients	32492084	2999	3007	O
with	32492084	3008	3012	O
severe	32492084	3013	3019	B-Participant
or	32492084	3020	3022	I-Participant
life	32492084	3023	3027	I-Participant
-	32492084	3028	3029	I-Participant
threatening	32492084	3030	3041	I-Participant
COVID-19	32492084	3042	3050	I-Participant
,	32492084	3051	3052	O
convalescent	32492084	3053	3065	B-Intervention
plasma	32492084	3066	3072	I-Intervention
therapy	32492084	3073	3080	I-Intervention
added	32492084	3081	3086	I-Intervention
to	32492084	3087	3089	I-Intervention
standard	32492084	3090	3098	I-Intervention
treatment	32492084	3099	3108	I-Intervention
,	32492084	3109	3110	O
compared	32492084	3111	3119	O
with	32492084	3120	3124	O
standard	32492084	3125	3133	B-Intervention
treatment	32492084	3134	3143	I-Intervention
alone	32492084	3144	3149	O
,	32492084	3150	3151	O
did	32492084	3152	3155	O
not	32492084	3156	3159	O
result	32492084	3160	3166	O
in	32492084	3167	3169	O
a	32492084	3170	3171	O
statistically	32492084	3172	3185	B-Observation
significant	32492084	3186	3197	I-Observation
improvement	32492084	3198	3209	I-Observation
in	32492084	3210	3212	O
time	32492084	3213	3217	B-Outcome
to	32492084	3218	3220	I-Outcome
clinical	32492084	3221	3229	I-Outcome
improvement	32492084	3230	3241	I-Outcome
within	32492084	3242	3248	I-Outcome
28	32492084	3249	3251	I-Outcome
days	32492084	3252	3256	I-Outcome
.	32492084	3257	3258	O

Interpretation	32492084	3259	3273	O
is	32492084	3274	3276	O
limited	32492084	3277	3284	O
by	32492084	3285	3287	O
early	32492084	3288	3293	O
termination	32492084	3294	3305	O
of	32492084	3306	3308	O
the	32492084	3309	3312	O
trial	32492084	3313	3318	O
,	32492084	3319	3320	O
which	32492084	3321	3326	O
may	32492084	3327	3330	O
have	32492084	3331	3335	O
been	32492084	3336	3340	O
underpowered	32492084	3341	3353	O
to	32492084	3354	3356	O
detect	32492084	3357	3363	O
a	32492084	3364	3365	O
clinically	32492084	3366	3376	O
important	32492084	3377	3386	O
difference	32492084	3387	3397	O
.	32492084	3398	3399	O

Chinese	32492084	3400	3407	O
Clinical	32492084	3408	3416	O
Trial	32492084	3417	3422	O
Registry	32492084	3423	3431	O
:	32492084	3432	3433	O
ChiCTR2000029757	32492084	3434	3450	O
.	32492084	3451	3452	O


A	32492293	0	1	O
Randomized	32492293	2	12	O
Trial	32492293	13	18	O
of	32492293	19	21	O
Hydroxychloroquine	32492293	22	40	B-Intervention
as	32492293	41	43	O
Postexposure	32492293	44	56	B-Outcome
Prophylaxis	32492293	57	68	I-Outcome
for	32492293	69	72	O
Covid-19	32492293	73	81	B-Participant
.	32492293	82	83	O

Coronavirus	32492293	84	95	O
disease	32492293	96	103	O
2019	32492293	104	108	O
(	32492293	109	110	O
Covid-19	32492293	111	119	O
)	32492293	120	121	O
occurs	32492293	122	128	O
after	32492293	129	134	O
exposure	32492293	135	143	O
to	32492293	144	146	O
severe	32492293	147	153	O
acute	32492293	154	159	O
respiratory	32492293	160	171	O
syndrome	32492293	172	180	O
coronavirus	32492293	181	192	O
2	32492293	193	194	O
(	32492293	195	196	O
SARS	32492293	197	201	O
-	32492293	202	203	O
CoV-2	32492293	204	209	O
)	32492293	210	211	O
.	32492293	212	213	O

For	32492293	214	217	O
persons	32492293	218	225	O
who	32492293	226	229	O
are	32492293	230	233	O
exposed	32492293	234	241	O
,	32492293	242	243	O
the	32492293	244	247	O
standard	32492293	248	256	O
of	32492293	257	259	O
care	32492293	260	264	O
is	32492293	265	267	O
observation	32492293	268	279	O
and	32492293	280	283	O
quarantine	32492293	284	294	O
.	32492293	295	296	O

Whether	32492293	297	304	O
hydroxychloroquine	32492293	305	323	O
can	32492293	324	327	O
prevent	32492293	328	335	O
symptomatic	32492293	336	347	O
infection	32492293	348	357	O
after	32492293	358	363	O
SARS	32492293	364	368	O
-	32492293	369	370	O
CoV-2	32492293	371	376	O
exposure	32492293	377	385	O
is	32492293	386	388	O
unknown	32492293	389	396	O
.	32492293	397	398	O

We	32492293	399	401	O
conducted	32492293	402	411	O
a	32492293	412	413	O
randomized	32492293	414	424	O
,	32492293	425	426	O
double	32492293	427	433	O
-	32492293	434	435	O
blind	32492293	436	441	O
,	32492293	442	443	O
placebo	32492293	444	451	O
-	32492293	452	453	O
controlled	32492293	454	464	O
trial	32492293	465	470	O
across	32492293	471	477	O
the	32492293	478	481	O
United	32492293	482	488	O
States	32492293	489	495	O
and	32492293	496	499	O
parts	32492293	500	505	O
of	32492293	506	508	O
Canada	32492293	509	515	O
testing	32492293	516	523	O
hydroxychloroquine	32492293	524	542	B-Intervention
as	32492293	543	545	O
postexposure	32492293	546	558	B-Outcome
prophylaxis	32492293	559	570	I-Outcome
.	32492293	571	572	O

We	32492293	573	575	O
enrolled	32492293	576	584	O
adults	32492293	585	591	O
who	32492293	592	595	O
had	32492293	596	599	O
household	32492293	600	609	O
or	32492293	610	612	O
occupational	32492293	613	625	O
exposure	32492293	626	634	O
to	32492293	635	637	O
someone	32492293	638	645	O
with	32492293	646	650	O
confirmed	32492293	651	660	O
Covid-19	32492293	661	669	O
at	32492293	670	672	O
a	32492293	673	674	O
distance	32492293	675	683	O
of	32492293	684	686	O
less	32492293	687	691	O
than	32492293	692	696	O
6	32492293	697	698	O
ft	32492293	699	701	O
for	32492293	702	705	O
more	32492293	706	710	O
than	32492293	711	715	O
10	32492293	716	718	O
minutes	32492293	719	726	O
while	32492293	727	732	O
wearing	32492293	733	740	O
neither	32492293	741	748	O
a	32492293	749	750	O
face	32492293	751	755	O
mask	32492293	756	760	O
nor	32492293	761	764	O
an	32492293	765	767	O
eye	32492293	768	771	O
shield	32492293	772	778	O
(	32492293	779	780	O
high	32492293	781	785	B-Participant
-	32492293	786	787	I-Participant
risk	32492293	788	792	I-Participant
exposure	32492293	793	801	I-Participant
)	32492293	802	803	O
or	32492293	804	806	O
while	32492293	807	812	O
wearing	32492293	813	820	O
a	32492293	821	822	O
face	32492293	823	827	O
mask	32492293	828	832	O
but	32492293	833	836	O
no	32492293	837	839	O
eye	32492293	840	843	O
shield	32492293	844	850	O
(	32492293	851	852	O
moderate	32492293	853	861	B-Participant
-	32492293	862	863	I-Participant
risk	32492293	864	868	I-Participant
exposure	32492293	869	877	I-Participant
)	32492293	878	879	O
.	32492293	880	881	O

Within	32492293	882	888	O
4	32492293	889	890	O
days	32492293	891	895	O
after	32492293	896	901	O
exposure	32492293	902	910	O
,	32492293	911	912	O
we	32492293	913	915	O
randomly	32492293	916	924	O
assigned	32492293	925	933	O
participants	32492293	934	946	O
to	32492293	947	949	O
receive	32492293	950	957	O
either	32492293	958	964	O
placebo	32492293	965	972	B-Intervention
or	32492293	973	975	O
hydroxychloroquine	32492293	976	994	B-Intervention
(	32492293	995	996	O
800	32492293	997	1000	O
mg	32492293	1001	1003	O
once	32492293	1004	1008	O
,	32492293	1009	1010	O
followed	32492293	1011	1019	O
by	32492293	1020	1022	O
600	32492293	1023	1026	O
mg	32492293	1027	1029	O
in	32492293	1030	1032	O
6	32492293	1033	1034	O
to	32492293	1035	1037	O
8	32492293	1038	1039	O
hours	32492293	1040	1045	O
,	32492293	1046	1047	O
then	32492293	1048	1052	O
600	32492293	1053	1056	O
mg	32492293	1057	1059	O
daily	32492293	1060	1065	O
for	32492293	1066	1069	O
4	32492293	1070	1071	O
additional	32492293	1072	1082	O
days	32492293	1083	1087	O
)	32492293	1088	1089	O
.	32492293	1090	1091	O

The	32492293	1092	1095	O
primary	32492293	1096	1103	O
outcome	32492293	1104	1111	O
was	32492293	1112	1115	O
the	32492293	1116	1119	O
incidence	32492293	1120	1129	B-Outcome
of	32492293	1130	1132	I-Outcome
either	32492293	1133	1139	I-Outcome
laboratory	32492293	1140	1150	I-Outcome
-	32492293	1151	1152	I-Outcome
confirmed	32492293	1153	1162	I-Outcome
Covid-19	32492293	1163	1171	I-Outcome
or	32492293	1172	1174	O
illness	32492293	1175	1182	B-Outcome
compatible	32492293	1183	1193	I-Outcome
with	32492293	1194	1198	I-Outcome
Covid-19	32492293	1199	1207	I-Outcome
within	32492293	1208	1214	O
14	32492293	1215	1217	O
days	32492293	1218	1222	O
.	32492293	1223	1224	O

We	32492293	1225	1227	O
enrolled	32492293	1228	1236	O
821	32492293	1237	1240	O
asymptomatic	32492293	1241	1253	B-Participant
participants	32492293	1254	1266	O
.	32492293	1267	1268	O

Overall	32492293	1269	1276	O
,	32492293	1277	1278	O
87.6	32492293	1279	1283	O
%	32492293	1284	1285	O
of	32492293	1286	1288	O
the	32492293	1289	1292	O
participants	32492293	1293	1305	O
(	32492293	1306	1307	O
719	32492293	1308	1311	O
of	32492293	1312	1314	O
821	32492293	1315	1318	O
)	32492293	1319	1320	O
reported	32492293	1321	1329	O
a	32492293	1330	1331	O
high	32492293	1332	1336	B-Participant
-	32492293	1337	1338	I-Participant
risk	32492293	1339	1343	I-Participant
exposure	32492293	1344	1352	I-Participant
to	32492293	1353	1355	I-Participant
a	32492293	1356	1357	I-Participant
confirmed	32492293	1358	1367	I-Participant
Covid-19	32492293	1368	1376	I-Participant
contact	32492293	1377	1384	I-Participant
.	32492293	1385	1386	O

The	32492293	1387	1390	O
incidence	32492293	1391	1400	B-Outcome
of	32492293	1401	1403	I-Outcome
new	32492293	1404	1407	I-Outcome
illness	32492293	1408	1415	I-Outcome
compatible	32492293	1416	1426	I-Outcome
with	32492293	1427	1431	I-Outcome
Covid-19	32492293	1432	1440	I-Outcome
did	32492293	1441	1444	O
not	32492293	1445	1448	O
differ	32492293	1449	1455	B-Observation
significantly	32492293	1456	1469	I-Observation
between	32492293	1470	1477	O
participants	32492293	1478	1490	O
receiving	32492293	1491	1500	O
hydroxychloroquine	32492293	1501	1519	B-Intervention
(	32492293	1520	1521	O
49	32492293	1522	1524	B-Count
of	32492293	1525	1527	I-Count
414	32492293	1528	1531	I-Count
[	32492293	1532	1533	I-Count
11.8	32492293	1534	1538	I-Count
%	32492293	1539	1540	I-Count
]	32492293	1541	1542	I-Count
)	32492293	1543	1544	O
and	32492293	1545	1548	O
those	32492293	1549	1554	O
receiving	32492293	1555	1564	O
placebo	32492293	1565	1572	B-Intervention
(	32492293	1573	1574	O
58	32492293	1575	1577	B-Count
of	32492293	1578	1580	I-Count
407	32492293	1581	1584	I-Count
[	32492293	1585	1586	I-Count
14.3	32492293	1587	1591	I-Count
%	32492293	1592	1593	I-Count
]	32492293	1594	1595	I-Count
)	32492293	1596	1597	O
;	32492293	1598	1599	O
the	32492293	1600	1603	O
absolute	32492293	1604	1612	B-Outcome
difference	32492293	1613	1623	I-Outcome
was	32492293	1624	1627	O
-2.4	32492293	1628	1632	B-Observation
percentage	32492293	1633	1643	I-Observation
points	32492293	1644	1650	I-Observation
(	32492293	1651	1652	O
95	32492293	1653	1655	O
%	32492293	1656	1657	O
confidence	32492293	1658	1668	O
interval	32492293	1669	1677	O
,	32492293	1678	1679	O
-7.0	32492293	1680	1684	O
to	32492293	1685	1687	O
2.2	32492293	1688	1691	O
;	32492293	1692	1693	O
P	32492293	1694	1695	O
=	32492293	1698	1699	O
0.35	32492293	1702	1706	O
)	32492293	1707	1708	O
.	32492293	1709	1710	O

Side	32492293	1711	1715	B-Outcome
effects	32492293	1716	1723	I-Outcome
were	32492293	1724	1728	O
more	32492293	1729	1733	B-Observation
common	32492293	1734	1740	I-Observation
with	32492293	1741	1745	O
hydroxychloroquine	32492293	1746	1764	B-Intervention
than	32492293	1765	1769	O
with	32492293	1770	1774	O
placebo	32492293	1775	1782	B-Intervention
(	32492293	1783	1784	O
40.1	32492293	1785	1789	B-Observation
%	32492293	1790	1791	I-Observation
vs.	32492293	1792	1795	O
16.8	32492293	1796	1800	B-Observation
%	32492293	1801	1802	I-Observation
)	32492293	1803	1804	O
,	32492293	1805	1806	O
but	32492293	1807	1810	O
no	32492293	1811	1813	B-Count
serious	32492293	1814	1821	B-Outcome
adverse	32492293	1822	1829	I-Outcome
reactions	32492293	1830	1839	I-Outcome
were	32492293	1840	1844	O
reported	32492293	1845	1853	O
.	32492293	1854	1855	O

After	32492293	1856	1861	O
high	32492293	1862	1866	B-Participant
-	32492293	1867	1868	I-Participant
risk	32492293	1869	1873	I-Participant
or	32492293	1874	1876	I-Participant
moderate	32492293	1877	1885	I-Participant
-	32492293	1886	1887	I-Participant
risk	32492293	1888	1892	I-Participant
exposure	32492293	1893	1901	I-Participant
to	32492293	1902	1904	I-Participant
Covid-19	32492293	1905	1913	I-Participant
,	32492293	1914	1915	O
hydroxychloroquine	32492293	1916	1934	B-Intervention
did	32492293	1935	1938	O
not	32492293	1939	1942	O
prevent	32492293	1943	1950	B-Observation
illness	32492293	1951	1958	B-Outcome
compatible	32492293	1959	1969	I-Outcome
with	32492293	1970	1974	I-Outcome
Covid-19	32492293	1975	1983	I-Outcome
or	32492293	1984	1986	O
confirmed	32492293	1987	1996	B-Outcome
infection	32492293	1997	2006	I-Outcome
when	32492293	2007	2011	O
used	32492293	2012	2016	O
as	32492293	2017	2019	O
postexposure	32492293	2020	2032	O
prophylaxis	32492293	2033	2044	O
within	32492293	2045	2051	O
4	32492293	2052	2053	O
days	32492293	2054	2058	O
after	32492293	2059	2064	O
exposure	32492293	2065	2073	O
.	32492293	2074	2075	O

(	32492293	2076	2077	O
Funded	32492293	2078	2084	O
by	32492293	2085	2087	O
David	32492293	2088	2093	O
Baszucki	32492293	2094	2102	O
and	32492293	2103	2106	O
Jan	32492293	2107	2110	O
Ellison	32492293	2111	2118	O
Baszucki	32492293	2119	2127	O
and	32492293	2128	2131	O
others	32492293	2132	2138	O
;	32492293	2139	2140	O
ClinicalTrials.gov	32492293	2141	2159	O
number	32492293	2160	2166	O
,	32492293	2167	2168	O
NCT04308668	32492293	2169	2180	O
.	32492293	2181	2182	O
)	32492293	2183	2184	O
.	32492293	2185	2186	O


Rationale	32492354	0	9	O
and	32492354	10	13	O
Design	32492354	14	20	O
of	32492354	21	23	O
ORCHID	32492354	24	30	O
:	32492354	31	32	O
A	32492354	33	34	O
Randomized	32492354	35	45	O
Placebo	32492354	46	53	B-Intervention
-	32492354	54	55	O
controlled	32492354	56	66	O
Clinical	32492354	67	75	O
Trial	32492354	76	81	O
of	32492354	82	84	O
Hydroxychloroquine	32492354	85	103	B-Intervention
for	32492354	104	107	O
Adults	32492354	108	114	B-Participant
Hospitalized	32492354	115	127	B-Participant
with	32492354	128	132	O
COVID-19	32492354	133	141	B-Participant
.	32492354	142	143	O

[	32527346	0	1	O
Effect	32527346	2	8	O
of	32527346	9	11	O
Xuebijing	32527346	12	21	B-Intervention
injection	32527346	22	31	I-Intervention
on	32527346	32	34	O
inflammatory	32527346	35	47	B-Outcome
markers	32527346	48	55	I-Outcome
and	32527346	56	59	O
disease	32527346	60	67	B-Outcome
outcome	32527346	68	75	I-Outcome
of	32527346	76	78	O
coronavirus	32527346	79	90	B-Participant
disease	32527346	91	98	I-Participant
2019	32527346	99	103	I-Participant
]	32527346	104	105	O
.	32527346	106	107	O

OBJECTIVE	32527346	108	117	O
:	32527346	118	119	O
To	32527346	120	122	O
observe	32527346	123	130	O
the	32527346	131	134	O
influence	32527346	135	144	O
of	32527346	145	147	O
Xuebijing	32527346	148	157	B-Intervention
injection	32527346	158	167	I-Intervention
on	32527346	168	170	O
the	32527346	171	174	O
inflammatory	32527346	175	187	B-Outcome
markers	32527346	188	195	I-Outcome
and	32527346	196	199	O
prognosis	32527346	200	209	B-Outcome
of	32527346	210	212	O
coronavirus	32527346	213	224	B-Participant
disease	32527346	225	232	I-Participant
2019	32527346	233	237	I-Participant
(	32527346	238	239	I-Participant
COVID-19	32527346	240	248	I-Participant
)	32527346	249	250	I-Participant
patients	32527346	251	259	O
.	32527346	260	261	O

METHODS	32527346	262	269	O
:	32527346	270	271	O
Sixty	32527346	272	277	O
severe	32527346	278	284	B-Participant
COVID-19	32527346	285	293	I-Participant
patients	32527346	294	302	O
admitted	32527346	303	311	O
to	32527346	312	314	O
Changsha	32527346	315	323	O
Public	32527346	324	330	O
Health	32527346	331	337	O
Treatment	32527346	338	347	O
Center	32527346	348	354	O
(	32527346	355	356	O
North	32527346	357	362	O
Hospital	32527346	363	371	O
of	32527346	372	374	O
the	32527346	375	378	O
First	32527346	379	384	O
Hospital	32527346	385	393	O
of	32527346	394	396	O
Changsha	32527346	397	405	O
City	32527346	406	410	O
)	32527346	411	412	O
from	32527346	413	417	O
January	32527346	418	425	O
to	32527346	426	428	O
March	32527346	429	434	O
in	32527346	435	437	O
2020	32527346	438	442	O
were	32527346	443	447	O
randomly	32527346	448	456	O
divided	32527346	457	464	O
into	32527346	465	469	O
routine	32527346	470	477	O
treatment	32527346	478	487	O
group	32527346	488	493	O
,	32527346	494	495	O
Xuebijing	32527346	496	505	O
50	32527346	506	508	O
mL	32527346	509	511	O
group	32527346	512	517	O
and	32527346	518	521	O
Xuebijing	32527346	522	531	O
100	32527346	532	535	O
mL	32527346	536	538	O
group	32527346	539	544	O
,	32527346	545	546	O
with	32527346	547	551	O
20	32527346	552	554	O
cases	32527346	555	560	O
in	32527346	561	563	O
each	32527346	564	568	O
group	32527346	569	574	O
.	32527346	575	576	O

The	32527346	577	580	O
routine	32527346	581	588	O
treatment	32527346	589	598	O
group	32527346	599	604	O
was	32527346	605	608	O
treated	32527346	609	616	O
according	32527346	617	626	O
to	32527346	627	629	O
the	32527346	630	633	O
National	32527346	634	642	O
Health	32527346	643	649	O
Commission	32527346	650	660	O
's	32527346	661	663	O
guide	32527346	664	669	O
for	32527346	670	673	O
COVID-19	32527346	674	682	O
.	32527346	683	684	O

On	32527346	685	687	O
the	32527346	688	691	O
basis	32527346	692	697	O
of	32527346	698	700	O
conventional	32527346	701	713	B-Intervention
treatment	32527346	714	723	I-Intervention
,	32527346	724	725	O
Xuebijing	32527346	726	735	B-Intervention
injection	32527346	736	745	I-Intervention
was	32527346	746	749	O
injected	32527346	750	758	O
by	32527346	759	761	O
50	32527346	762	764	O
mL	32527346	765	767	O
twice	32527346	768	773	O
a	32527346	774	775	O
day	32527346	776	779	O
for	32527346	780	783	O
7	32527346	784	785	O
days	32527346	786	790	O
in	32527346	791	793	O
Xuebijing	32527346	794	803	B-Intervention
50	32527346	804	806	I-Intervention
mL	32527346	807	809	I-Intervention
group	32527346	810	815	O
,	32527346	816	817	O
while	32527346	818	823	O
by	32527346	824	826	O
100	32527346	827	830	O
mL	32527346	831	833	O
twice	32527346	834	839	O
a	32527346	840	841	O
day	32527346	842	845	O
for	32527346	846	849	O
7	32527346	850	851	O
days	32527346	852	856	O
in	32527346	857	859	O
Xuebijing	32527346	860	869	B-Intervention
100	32527346	870	873	I-Intervention
mL	32527346	874	876	I-Intervention
group	32527346	877	882	O
.	32527346	883	884	O

The	32527346	885	888	O
blood	32527346	889	894	B-Outcome
routine	32527346	895	902	I-Outcome
test	32527346	903	907	I-Outcome
,	32527346	908	909	O
C	32527346	910	911	B-Outcome
-	32527346	912	913	I-Outcome
reactive	32527346	914	922	I-Outcome
protein	32527346	923	930	I-Outcome
(	32527346	931	932	I-Outcome
CRP	32527346	933	936	I-Outcome
)	32527346	937	938	I-Outcome
,	32527346	939	940	O
erythrocyte	32527346	941	952	B-Outcome
sedimentation	32527346	953	966	I-Outcome
rate	32527346	967	971	I-Outcome
(	32527346	972	973	I-Outcome
ESR	32527346	974	977	I-Outcome
)	32527346	978	979	I-Outcome
,	32527346	980	981	O
acute	32527346	982	987	B-Outcome
physiology	32527346	988	998	I-Outcome
and	32527346	999	1002	I-Outcome
chronic	32527346	1003	1010	I-Outcome
health	32527346	1011	1017	I-Outcome
evaluation	32527346	1018	1028	I-Outcome
II	32527346	1029	1031	I-Outcome
(	32527346	1032	1033	I-Outcome
APACHE	32527346	1034	1040	I-Outcome
II	32527346	1041	1043	I-Outcome
)	32527346	1044	1045	I-Outcome
score	32527346	1046	1051	I-Outcome
,	32527346	1052	1053	O
2019	32527346	1054	1058	B-Outcome
novel	32527346	1059	1064	I-Outcome
coronavirus	32527346	1065	1076	I-Outcome
(	32527346	1077	1078	I-Outcome
2019-nCoV	32527346	1079	1088	I-Outcome
)	32527346	1089	1090	I-Outcome
nucleic	32527346	1091	1098	I-Outcome
acid	32527346	1099	1103	I-Outcome
test	32527346	1104	1108	I-Outcome
and	32527346	1109	1112	O
disease	32527346	1113	1120	B-Outcome
classification	32527346	1121	1135	I-Outcome
of	32527346	1136	1138	O
three	32527346	1139	1144	O
groups	32527346	1145	1151	O
before	32527346	1152	1158	O
and	32527346	1159	1162	O
8	32527346	1163	1164	O
days	32527346	1165	1169	O
after	32527346	1170	1175	O
treatment	32527346	1176	1185	O
were	32527346	1186	1190	O
observed	32527346	1191	1199	O
.	32527346	1200	1201	O

RESULTS	32527346	1202	1209	O
:	32527346	1210	1211	O
(	32527346	1212	1213	O
1	32527346	1214	1215	O
)	32527346	1216	1217	O
After	32527346	1218	1223	O
treatment	32527346	1224	1233	O
,	32527346	1234	1235	O
the	32527346	1236	1239	O
white	32527346	1240	1245	B-Outcome
blood	32527346	1246	1251	I-Outcome
cell	32527346	1252	1256	I-Outcome
count	32527346	1257	1262	I-Outcome
(	32527346	1263	1264	I-Outcome
WBC	32527346	1265	1268	I-Outcome
)	32527346	1269	1270	I-Outcome
and	32527346	1271	1274	O
lymphocyte	32527346	1275	1285	B-Outcome
count	32527346	1286	1291	I-Outcome
(	32527346	1292	1293	I-Outcome
LYM	32527346	1294	1297	I-Outcome
)	32527346	1298	1299	I-Outcome
of	32527346	1300	1302	O
three	32527346	1303	1308	B-Intervention
groups	32527346	1309	1315	I-Intervention
increased	32527346	1316	1325	B-Observation
,	32527346	1326	1327	O
meanwhile	32527346	1328	1337	O
CRP	32527346	1338	1341	B-Outcome
and	32527346	1342	1345	O
ESR	32527346	1346	1349	B-Outcome
decreased	32527346	1350	1359	B-Observation
.	32527346	1360	1361	O

Compared	32527346	1362	1370	O
with	32527346	1371	1375	O
routine	32527346	1376	1383	B-Intervention
treatment	32527346	1384	1393	I-Intervention
group	32527346	1394	1399	O
,	32527346	1400	1401	O
the	32527346	1402	1405	O
WBC	32527346	1406	1409	B-Outcome
count	32527346	1410	1415	I-Outcome
of	32527346	1416	1418	O
Xuebijing	32527346	1419	1428	B-Intervention
100	32527346	1429	1432	I-Intervention
mL	32527346	1433	1435	I-Intervention
group	32527346	1436	1441	O
after	32527346	1442	1447	O
treatment	32527346	1448	1457	O
significantly	32527346	1458	1471	B-Observation
increased	32527346	1472	1481	I-Observation
(	32527346	1482	1483	O
109	32527346	1484	1488	O
/	32527346	1489	1490	O
L	32527346	1491	1492	O
:	32527346	1493	1494	O
7.120.55	32527346	1495	1504	B-Observation
vs.	32527346	1505	1508	O
5.670.51	32527346	1509	1518	B-Observation
,	32527346	1519	1520	O
P	32527346	1521	1522	O
<	32527346	1523	1524	O
0.05	32527346	1525	1529	O
)	32527346	1530	1531	O
,	32527346	1532	1533	O
and	32527346	1534	1537	O
the	32527346	1538	1541	O
levels	32527346	1542	1548	B-Outcome
of	32527346	1549	1551	I-Outcome
CRP	32527346	1552	1555	I-Outcome
and	32527346	1556	1559	O
ESR	32527346	1560	1563	B-Outcome
in	32527346	1564	1566	O
Xuebijing	32527346	1567	1576	B-Intervention
50	32527346	1577	1579	I-Intervention
mL	32527346	1580	1582	I-Intervention
and	32527346	1583	1586	O
100	32527346	1587	1590	B-Intervention
mL	32527346	1591	1593	I-Intervention
groups	32527346	1594	1600	O
significantly	32527346	1601	1614	B-Observation
decreased	32527346	1615	1624	I-Observation
[	32527346	1625	1626	O
CRP	32527346	1627	1630	B-Outcome
(	32527346	1631	1632	O
mg	32527346	1633	1635	O
/	32527346	1636	1637	O
L	32527346	1638	1639	O
)	32527346	1640	1641	O
:	32527346	1642	1643	O
32.34.6	32527346	1644	1652	B-Observation
,	32527346	1653	1654	O
28.06.2	32527346	1655	1663	B-Observation
vs.	32527346	1664	1667	O
37.35.9	32527346	1668	1676	B-Observation
;	32527346	1677	1678	O
ESR	32527346	1679	1682	B-Outcome
(	32527346	1683	1684	O
mm/1	32527346	1685	1689	O
h	32527346	1690	1691	O
)	32527346	1692	1693	O
:	32527346	1694	1695	O
45.95.7	32527346	1696	1704	B-Observation
,	32527346	1705	1706	O
40.57.4	32527346	1707	1715	B-Observation
vs.	32527346	1716	1719	O
55.36.6	32527346	1720	1728	B-Observation
,	32527346	1729	1730	O
all	32527346	1731	1734	O
P	32527346	1735	1736	O
<	32527346	1737	1738	O
0.05	32527346	1739	1743	O
]	32527346	1744	1745	O
.	32527346	1746	1747	O

Compared	32527346	1748	1756	O
with	32527346	1757	1761	O
Xuebijing	32527346	1762	1771	B-Intervention
50	32527346	1772	1774	I-Intervention
mL	32527346	1775	1777	I-Intervention
group	32527346	1778	1783	O
,	32527346	1784	1785	O
the	32527346	1786	1789	O
increase	32527346	1790	1798	B-Observation
of	32527346	1799	1801	O
WBC	32527346	1802	1805	B-Outcome
,	32527346	1806	1807	O
and	32527346	1808	1811	O
the	32527346	1812	1815	O
decrease	32527346	1816	1824	B-Observation
of	32527346	1825	1827	O
CRP	32527346	1828	1831	B-Outcome
and	32527346	1832	1835	O
ESR	32527346	1836	1839	B-Outcome
were	32527346	1840	1844	O
more	32527346	1845	1849	B-Observation
significant	32527346	1850	1861	I-Observation
in	32527346	1862	1864	O
Xuebijing	32527346	1865	1874	B-Intervention
100	32527346	1875	1878	I-Intervention
mL	32527346	1879	1881	I-Intervention
group	32527346	1882	1887	O
[	32527346	1888	1889	O
WBC	32527346	1890	1893	B-Outcome
(	32527346	1894	1895	O
109	32527346	1896	1900	O
/	32527346	1901	1902	O
L	32527346	1903	1904	O
)	32527346	1905	1906	O
:	32527346	1907	1908	O
7.120.55	32527346	1909	1918	B-Observation
vs.	32527346	1919	1922	O
5.820.49	32527346	1923	1932	B-Observation
,	32527346	1933	1934	O
CRP	32527346	1935	1938	B-Outcome
(	32527346	1939	1940	O
mg	32527346	1941	1943	O
/	32527346	1944	1945	O
L	32527346	1946	1947	O
)	32527346	1948	1949	O
:	32527346	1950	1951	O
28.06.2	32527346	1952	1960	B-Observation
vs.	32527346	1961	1964	O
32.34.6	32527346	1965	1973	B-Observation
,	32527346	1974	1975	O
ESR	32527346	1976	1979	B-Outcome
(	32527346	1980	1981	O
mm/1	32527346	1982	1986	O
h	32527346	1987	1988	O
)	32527346	1989	1990	O
:	32527346	1991	1992	O
40.57.4	32527346	1993	2001	B-Observation
vs.	32527346	2002	2005	O
45.95.7	32527346	2006	2014	B-Observation
,	32527346	2015	2016	O
all	32527346	2017	2020	O
P	32527346	2021	2022	O
<	32527346	2023	2024	O
0.05	32527346	2025	2029	O
]	32527346	2030	2031	O
.	32527346	2032	2033	O

(	32527346	2034	2035	O
2	32527346	2036	2037	O
)	32527346	2038	2039	O
After	32527346	2040	2045	O
treatment	32527346	2046	2055	O
,	32527346	2056	2057	O
the	32527346	2058	2061	O
APACHE	32527346	2062	2068	B-Outcome
II	32527346	2069	2071	I-Outcome
score	32527346	2072	2077	I-Outcome
of	32527346	2078	2080	O
three	32527346	2081	2086	B-Intervention
groups	32527346	2087	2093	I-Intervention
decreased	32527346	2094	2103	B-Observation
.	32527346	2104	2105	O

In	32527346	2106	2108	O
Xuebijing	32527346	2109	2118	B-Intervention
100	32527346	2119	2122	I-Intervention
mL	32527346	2123	2125	I-Intervention
group	32527346	2126	2131	O
,	32527346	2132	2133	O
the	32527346	2134	2137	O
APACHE	32527346	2138	2144	B-Outcome
II	32527346	2145	2147	I-Outcome
score	32527346	2148	2153	I-Outcome
after	32527346	2154	2159	O
treatment	32527346	2160	2169	O
was	32527346	2170	2173	O
significantly	32527346	2174	2187	B-Observation
lower	32527346	2188	2193	I-Observation
than	32527346	2194	2198	O
those	32527346	2199	2204	O
in	32527346	2205	2207	O
routine	32527346	2208	2215	B-Intervention
treatment	32527346	2216	2225	I-Intervention
and	32527346	2226	2229	O
Xuebijing	32527346	2230	2239	B-Intervention
50	32527346	2240	2242	I-Intervention
mL	32527346	2243	2245	I-Intervention
groups	32527346	2246	2252	O
(	32527346	2253	2254	O
12.31.5	32527346	2255	2263	B-Observation
vs.	32527346	2264	2267	O
16.51.6	32527346	2268	2276	B-Observation
,	32527346	2277	2278	O
15.91.4	32527346	2279	2287	B-Observation
,	32527346	2288	2289	O
both	32527346	2290	2294	O
P	32527346	2295	2296	O
<	32527346	2297	2298	O
0.05	32527346	2299	2303	O
)	32527346	2304	2305	O
.	32527346	2306	2307	O

After	32527346	2308	2313	O
treatment	32527346	2314	2323	O
,	32527346	2324	2325	O
the	32527346	2326	2329	O
2019-nCoV	32527346	2330	2339	B-Outcome
nucleic	32527346	2340	2347	I-Outcome
acid	32527346	2348	2352	I-Outcome
test	32527346	2353	2357	I-Outcome
in	32527346	2358	2360	O
three	32527346	2361	2366	B-Intervention
groups	32527346	2367	2373	I-Intervention
partly	32527346	2374	2380	O
turned	32527346	2381	2387	O
negative	32527346	2388	2396	B-Observation
,	32527346	2397	2398	O
with	32527346	2399	2403	O
9	32527346	2404	2405	B-Count
cases	32527346	2406	2411	I-Count
in	32527346	2412	2414	O
routine	32527346	2415	2422	B-Intervention
treatment	32527346	2423	2432	I-Intervention
group	32527346	2433	2438	O
,	32527346	2439	2440	O
8	32527346	2441	2442	B-Count
cases	32527346	2443	2448	I-Count
in	32527346	2449	2451	O
Xuebijing	32527346	2452	2461	B-Intervention
50	32527346	2462	2464	I-Intervention
mL	32527346	2465	2467	I-Intervention
group	32527346	2468	2473	O
and	32527346	2474	2477	O
9	32527346	2478	2479	B-Count
cases	32527346	2480	2485	I-Count
in	32527346	2486	2488	O
Xuebijing	32527346	2489	2498	B-Intervention
100	32527346	2499	2502	I-Intervention
mL	32527346	2503	2505	I-Intervention
group	32527346	2506	2511	O
,	32527346	2512	2513	O
without	32527346	2514	2521	O
significant	32527346	2522	2533	O
difference	32527346	2534	2544	O
(	32527346	2545	2546	O
P	32527346	2547	2548	O
>	32527346	2549	2550	O
0.05	32527346	2551	2555	O
)	32527346	2556	2557	O
.	32527346	2558	2559	O

The	32527346	2560	2563	O
conditions	32527346	2564	2574	B-Outcome
of	32527346	2575	2577	I-Outcome
patients	32527346	2578	2586	I-Outcome
in	32527346	2587	2589	O
the	32527346	2590	2593	O
three	32527346	2594	2599	B-Intervention
groups	32527346	2600	2606	I-Intervention
were	32527346	2607	2611	O
improved	32527346	2612	2620	B-Observation
after	32527346	2621	2626	O
treatment	32527346	2627	2636	O
,	32527346	2637	2638	O
among	32527346	2639	2644	O
them	32527346	2645	2649	O
,	32527346	2650	2651	O
8	32527346	2652	2653	B-Count
cases	32527346	2654	2659	I-Count
in	32527346	2660	2662	O
the	32527346	2663	2666	O
routine	32527346	2667	2674	B-Intervention
treatment	32527346	2675	2684	I-Intervention
group	32527346	2685	2690	O
were	32527346	2691	2695	O
transformed	32527346	2696	2707	O
into	32527346	2708	2712	O
common	32527346	2713	2719	B-Outcome
type	32527346	2720	2724	I-Outcome
,	32527346	2725	2726	O
1	32527346	2727	2728	B-Count
case	32527346	2729	2733	I-Count
into	32527346	2734	2738	O
critical	32527346	2739	2747	B-Outcome
type	32527346	2748	2752	I-Outcome
;	32527346	2753	2754	O
9	32527346	2755	2756	B-Count
cases	32527346	2757	2762	I-Count
and	32527346	2763	2766	O
12	32527346	2767	2769	B-Count
cases	32527346	2770	2775	I-Count
of	32527346	2776	2778	O
Xuebijing	32527346	2779	2788	B-Intervention
50	32527346	2789	2791	I-Intervention
mL	32527346	2792	2794	I-Intervention
group	32527346	2795	2800	O
and	32527346	2801	2804	O
100	32527346	2805	2808	B-Intervention
mL	32527346	2809	2811	I-Intervention
group	32527346	2812	2817	I-Intervention
were	32527346	2818	2822	O
transformed	32527346	2823	2834	O
into	32527346	2835	2839	O
common	32527346	2840	2846	B-Outcome
type	32527346	2847	2851	I-Outcome
respectively	32527346	2852	2864	O
.	32527346	2865	2866	O

Xuebijing	32527346	2867	2876	B-Outcome
100	32527346	2877	2880	I-Outcome
mL	32527346	2881	2883	I-Outcome
group	32527346	2884	2889	O
was	32527346	2890	2893	O
improved	32527346	2894	2902	B-Observation
more	32527346	2903	2907	I-Observation
obviously	32527346	2908	2917	I-Observation
than	32527346	2918	2922	O
Xuebijing	32527346	2923	2932	B-Intervention
50	32527346	2933	2935	I-Intervention
mL	32527346	2936	2938	I-Intervention
group	32527346	2939	2944	O
and	32527346	2945	2948	O
routine	32527346	2949	2956	B-Intervention
treatment	32527346	2957	2966	I-Intervention
group	32527346	2967	2972	O
(	32527346	2973	2974	O
both	32527346	2975	2979	O
P	32527346	2980	2981	O
<	32527346	2982	2983	O
0.05	32527346	2984	2988	O
)	32527346	2989	2990	O
.	32527346	2991	2992	O

CONCLUSIONS	32527346	2993	3004	O
:	32527346	3005	3006	O
The	32527346	3007	3010	O
Xuebijing	32527346	3011	3020	B-Intervention
injection	32527346	3021	3030	I-Intervention
can	32527346	3031	3034	O
effectively	32527346	3035	3046	B-Observation
improve	32527346	3047	3054	I-Observation
the	32527346	3055	3058	O
inflammatory	32527346	3059	3071	B-Outcome
markers	32527346	3072	3079	I-Outcome
and	32527346	3080	3083	O
prognosis	32527346	3084	3093	B-Outcome
of	32527346	3094	3096	O
severe	32527346	3097	3103	B-Participant
COVID-19	32527346	3104	3112	I-Participant
patients	32527346	3113	3121	I-Participant
.	32527346	3122	3123	O


Tolerability	32563787	0	12	B-Outcome
and	32563787	13	16	O
effectiveness	32563787	17	30	B-Outcome
of	32563787	31	33	O
povidone	32563787	34	42	B-Intervention
-	32563787	43	44	I-Intervention
iodine	32563787	45	51	I-Intervention
or	32563787	52	54	O
mupirocin	32563787	55	64	B-Intervention
versus	32563787	65	71	O
saline	32563787	72	78	B-Intervention
sinus	32563787	79	84	I-Intervention
irrigations	32563787	85	96	I-Intervention
for	32563787	97	100	O
chronic	32563787	101	108	B-Participant
rhinosinusitis	32563787	109	123	I-Participant
.	32563787	124	125	O

OBJECTIVE	32563787	126	135	O
:	32563787	136	137	O
The	32563787	138	141	O
role	32563787	142	146	O
of	32563787	147	149	O
topical	32563787	150	157	O
anti	32563787	158	162	O
-	32563787	163	164	O
infectives	32563787	165	175	O
in	32563787	176	178	O
acute	32563787	179	184	O
exacerbations	32563787	185	198	O
of	32563787	199	201	O
chronic	32563787	202	209	O
rhinosinusitis	32563787	210	224	O
is	32563787	225	227	O
controversial	32563787	228	241	O
.	32563787	242	243	O

Povidone	32563787	244	252	O
-	32563787	253	254	O
iodine	32563787	255	261	O
is	32563787	262	264	O
an	32563787	265	267	O
anti	32563787	268	272	O
-	32563787	273	274	O
bacterial	32563787	275	284	O
and	32563787	285	288	O
anti	32563787	289	293	O
-	32563787	294	295	O
viral	32563787	296	301	O
that	32563787	302	306	O
is	32563787	307	309	O
affordable	32563787	310	320	O
and	32563787	321	324	O
available	32563787	325	334	O
over	32563787	335	339	O
-	32563787	340	341	O
the	32563787	342	345	O
-	32563787	346	347	O
counter	32563787	348	355	O
and	32563787	356	359	O
may	32563787	360	363	O
demonstrate	32563787	364	375	O
advantages	32563787	376	386	O
over	32563787	387	391	O
mupirocin	32563787	392	401	O
as	32563787	402	404	O
a	32563787	405	406	O
sinus	32563787	407	412	O
irrigation	32563787	413	423	O
therapy	32563787	424	431	O
.	32563787	432	433	O

The	32563787	434	437	O
objective	32563787	438	447	O
was	32563787	448	451	O
to	32563787	452	454	O
compare	32563787	455	462	O
povidone	32563787	463	471	B-Intervention
-	32563787	472	473	I-Intervention
iodine	32563787	474	480	I-Intervention
or	32563787	481	483	O
mupirocin	32563787	484	493	B-Intervention
versus	32563787	494	500	O
saline	32563787	501	507	B-Intervention
sinus	32563787	508	513	I-Intervention
irrigations	32563787	514	525	I-Intervention
for	32563787	526	529	O
sinusitis	32563787	530	539	B-Intervention
exacerbations	32563787	540	553	I-Intervention
in	32563787	554	556	O
post	32563787	557	561	B-Participant
-	32563787	562	563	I-Participant
surgery	32563787	564	571	I-Participant
subjects	32563787	572	580	O
as	32563787	581	583	O
well	32563787	584	588	O
as	32563787	589	591	O
to	32563787	592	594	O
assess	32563787	595	601	O
tolerability	32563787	602	614	B-Participant
of	32563787	615	617	O
povidone	32563787	618	626	B-Intervention
-	32563787	627	628	I-Intervention
iodine	32563787	629	635	I-Intervention
sinus	32563787	636	641	I-Intervention
irrigations	32563787	642	653	I-Intervention
.	32563787	654	655	O

METHODS	32563787	656	663	O
:	32563787	664	665	O
This	32563787	666	670	O
was	32563787	671	674	O
a	32563787	675	676	O
prospective	32563787	677	688	O
single	32563787	689	695	O
-	32563787	696	697	O
blinded	32563787	698	705	O
(	32563787	706	707	O
clinician	32563787	708	717	O
only	32563787	718	722	O
)	32563787	723	724	O
randomized	32563787	725	735	O
controlled	32563787	736	746	O
trial	32563787	747	752	O
.	32563787	753	754	O

Subjects	32563787	755	763	O
were	32563787	764	768	O
post	32563787	769	773	B-Participant
-	32563787	774	775	I-Participant
surgery	32563787	776	783	I-Participant
with	32563787	784	788	O
acute	32563787	789	794	B-Participant
exacerbations	32563787	795	808	I-Participant
of	32563787	809	811	I-Participant
chronic	32563787	812	819	I-Participant
rhinosinusitis	32563787	820	834	I-Participant
and	32563787	835	838	O
gram	32563787	839	843	B-Participant
-	32563787	844	845	I-Participant
positive	32563787	846	854	I-Participant
bacteria	32563787	855	863	I-Participant
on	32563787	864	866	I-Participant
culture	32563787	867	874	I-Participant
.	32563787	875	876	O

They	32563787	877	881	O
received	32563787	882	890	O
povidone	32563787	891	899	B-Intervention
-	32563787	900	901	I-Intervention
iodine	32563787	902	908	I-Intervention
,	32563787	909	910	O
mupirocin	32563787	911	920	B-Intervention
,	32563787	921	922	O
or	32563787	923	925	O
saline	32563787	926	932	B-Intervention
sinus	32563787	933	938	I-Intervention
irrigations	32563787	939	950	I-Intervention
,	32563787	951	952	O
twice	32563787	953	958	O
daily	32563787	959	964	O
for	32563787	965	968	O
30	32563787	969	971	O
days	32563787	974	978	O
.	32563787	979	980	O

Outcomes	32563787	981	989	O
were	32563787	990	994	O
post	32563787	995	999	B-Outcome
-	32563787	1000	1001	I-Outcome
treatment	32563787	1002	1011	I-Outcome
culture	32563787	1012	1019	I-Outcome
negativity	32563787	1020	1030	I-Outcome
(	32563787	1031	1032	O
primary	32563787	1033	1040	O
)	32563787	1041	1042	O
and	32563787	1043	1046	O
Sinonasal	32563787	1047	1056	B-Outcome
Outcome	32563787	1057	1064	I-Outcome
Test-20	32563787	1065	1072	I-Outcome
and	32563787	1073	1076	O
Lund	32563787	1077	1081	B-Outcome
-	32563787	1082	1083	I-Outcome
Kennedy	32563787	1084	1091	I-Outcome
endoscopic	32563787	1092	1102	I-Outcome
score	32563787	1103	1108	I-Outcome
change	32563787	1109	1115	I-Outcome
(	32563787	1116	1117	O
secondary	32563787	1118	1127	O
)	32563787	1128	1129	O
.	32563787	1130	1131	O

RESULTS	32563787	1132	1139	O
:	32563787	1140	1141	O
Of	32563787	1142	1144	O
the	32563787	1145	1148	O
62	32563787	1149	1151	O
subjects	32563787	1152	1160	O
analyzed	32563787	1161	1169	O
,	32563787	1170	1171	O
post	32563787	1172	1176	B-Outcome
-	32563787	1177	1178	I-Outcome
treatment	32563787	1179	1188	I-Outcome
culture	32563787	1189	1196	I-Outcome
negativity	32563787	1197	1207	I-Outcome
rate	32563787	1208	1212	I-Outcome
was	32563787	1213	1216	O
higher	32563787	1217	1223	B-Observation
in	32563787	1224	1226	O
the	32563787	1227	1230	O
MUP	32563787	1231	1234	B-Intervention
(	32563787	1235	1236	O
14/20	32563787	1237	1242	B-Observation
,	32563787	1243	1244	I-Observation
70	32563787	1245	1247	I-Observation
%	32563787	1248	1249	I-Observation
)	32563787	1250	1251	O
group	32563787	1252	1257	O
compared	32563787	1258	1266	O
to	32563787	1267	1269	O
the	32563787	1270	1273	O
PI	32563787	1274	1276	B-Intervention
(	32563787	1277	1278	O
9/21	32563787	1279	1283	B-Observation
,	32563787	1284	1285	I-Observation
43	32563787	1286	1288	I-Observation
%	32563787	1289	1290	I-Observation
)	32563787	1291	1292	O
and	32563787	1293	1296	O
SAL	32563787	1297	1300	B-Intervention
(	32563787	1301	1302	O
9/19	32563787	1303	1307	B-Observation
,	32563787	1308	1309	I-Observation
47	32563787	1310	1312	I-Observation
%	32563787	1313	1314	I-Observation
)	32563787	1315	1316	O
groups	32563787	1317	1323	O
,	32563787	1324	1325	O
although	32563787	1326	1334	O
this	32563787	1335	1339	O
was	32563787	1340	1343	O
not	32563787	1344	1347	O
significant	32563787	1348	1359	O
(	32563787	1360	1361	O
p	32563787	1362	1363	O
=	32563787	1366	1367	O
0.29	32563787	1370	1374	O
)	32563787	1375	1376	O
.	32563787	1377	1378	O

Povidone	32563787	1379	1387	B-Intervention
-	32563787	1388	1389	I-Intervention
iodine	32563787	1390	1396	I-Intervention
sinus	32563787	1397	1402	I-Intervention
irrigations	32563787	1403	1414	I-Intervention
at	32563787	1415	1417	I-Intervention
the	32563787	1418	1421	I-Intervention
1	32563787	1422	1423	I-Intervention
%	32563787	1424	1425	I-Intervention
concentration	32563787	1426	1439	I-Intervention
were	32563787	1440	1444	O
very	32563787	1445	1449	B-Observation
well	32563787	1450	1454	I-Observation
-	32563787	1455	1456	O
tolerated	32563787	1457	1466	B-Outcome
,	32563787	1467	1468	O
similar	32563787	1469	1476	B-Observation
to	32563787	1477	1479	O
saline	32563787	1480	1486	B-Intervention
irrigations	32563787	1487	1498	I-Intervention
.	32563787	1499	1500	O

There	32563787	1501	1506	O
were	32563787	1507	1511	O
no	32563787	1512	1514	O
significant	32563787	1515	1526	B-Observation
differences	32563787	1527	1538	I-Observation
in	32563787	1539	1541	O
Sinonasal	32563787	1542	1551	B-Outcome
Outcome	32563787	1552	1559	I-Outcome
Test-20	32563787	1560	1567	I-Outcome
score	32563787	1568	1573	I-Outcome
(	32563787	1574	1575	O
povidone	32563787	1576	1584	B-Intervention
-	32563787	1585	1586	I-Intervention
iodine	32563787	1587	1593	I-Intervention
-0.3	32563787	1594	1598	B-Observation
[	32563787	1599	1600	I-Observation
-0.6	32563787	1601	1605	I-Observation
,	32563787	1606	1607	I-Observation
0.05	32563787	1608	1612	I-Observation
]	32563787	1613	1614	I-Observation
vs.	32563787	1615	1618	O
mupirocin	32563787	1619	1628	B-Intervention
-0.3	32563787	1629	1633	B-Observation
[	32563787	1634	1635	I-Observation
-0.7	32563787	1636	1640	I-Observation
,	32563787	1641	1642	I-Observation
0.05	32563787	1643	1647	I-Observation
]	32563787	1648	1649	I-Observation
vs.	32563787	1650	1653	O
saline	32563787	1654	1660	B-Intervention
-0.4	32563787	1661	1665	B-Observation
[	32563787	1666	1667	I-Observation
-0.8	32563787	1668	1672	I-Observation
,	32563787	1673	1674	I-Observation
0.05	32563787	1675	1679	I-Observation
]	32563787	1680	1681	I-Observation
;	32563787	1682	1683	O
p	32563787	1684	1685	O
=	32563787	1688	1689	O
0.86	32563787	1692	1696	O
)	32563787	1697	1698	O
or	32563787	1699	1701	O
Lund	32563787	1702	1706	B-Outcome
-	32563787	1707	1708	I-Outcome
Kennedy	32563787	1709	1716	I-Outcome
endoscopic	32563787	1717	1727	I-Outcome
score	32563787	1728	1733	I-Outcome
(	32563787	1734	1735	O
povidone	32563787	1736	1744	B-Intervention
-	32563787	1745	1746	I-Intervention
iodine	32563787	1747	1753	I-Intervention
-3.5	32563787	1754	1758	B-Observation
[	32563787	1759	1760	I-Observation
-7	32563787	1761	1763	I-Observation
,	32563787	1764	1765	I-Observation
-0.5	32563787	1766	1770	I-Observation
]	32563787	1771	1772	I-Observation
vs.	32563787	1773	1776	O
mupirocin	32563787	1777	1786	B-Intervention
-2	32563787	1787	1789	B-Observation
[	32563787	1790	1791	I-Observation
-4	32563787	1792	1794	I-Observation
,	32563787	1795	1796	I-Observation
2	32563787	1797	1798	I-Observation
]	32563787	1799	1800	I-Observation
vs.	32563787	1801	1804	O
saline	32563787	1805	1811	B-Intervention
-3	32563787	1812	1814	B-Observation
[	32563787	1815	1816	I-Observation
-5	32563787	1817	1819	I-Observation
,	32563787	1820	1821	I-Observation
0	32563787	1822	1823	I-Observation
]	32563787	1824	1825	I-Observation
;	32563787	1826	1827	O
p	32563787	1828	1829	O
=	32563787	1832	1833	O
0.45	32563787	1836	1840	O
)	32563787	1841	1842	O
change	32563787	1843	1849	O
.	32563787	1850	1851	O

No	32563787	1852	1854	B-Count
serious	32563787	1855	1862	B-Outcome
adverse	32563787	1863	1870	I-Outcome
effects	32563787	1871	1878	I-Outcome
were	32563787	1879	1883	O
reported	32563787	1884	1892	O
.	32563787	1893	1894	O

CONCLUSIONS	32563787	1895	1906	O
:	32563787	1907	1908	O
In	32563787	1909	1911	O
patients	32563787	1912	1920	O
who	32563787	1921	1924	O
have	32563787	1925	1929	O
had	32563787	1930	1933	O
prior	32563787	1934	1939	B-Participant
sinus	32563787	1940	1945	I-Participant
surgery	32563787	1946	1953	I-Participant
with	32563787	1954	1958	O
acute	32563787	1959	1964	B-Participant
exacerbations	32563787	1965	1978	I-Participant
of	32563787	1979	1981	I-Participant
CRS	32563787	1982	1985	I-Participant
and	32563787	1986	1989	O
gram	32563787	1990	1994	B-Participant
-	32563787	1995	1996	I-Participant
positive	32563787	1997	2005	I-Participant
bacteria	32563787	2006	2014	I-Participant
on	32563787	2015	2017	I-Participant
culture	32563787	2018	2025	I-Participant
,	32563787	2026	2027	O
mupirocin	32563787	2028	2037	B-Intervention
sinus	32563787	2038	2043	I-Intervention
irrigations	32563787	2044	2055	I-Intervention
achieved	32563787	2056	2064	O
a	32563787	2065	2066	O
better	32563787	2067	2073	B-Observation
post	32563787	2074	2078	B-Outcome
-	32563787	2079	2080	I-Outcome
treatment	32563787	2081	2090	I-Outcome
culture	32563787	2091	2098	I-Outcome
"	32563787	2099	2100	I-Outcome
control	32563787	2101	2108	I-Outcome
"	32563787	2109	2110	I-Outcome
rate	32563787	2111	2115	I-Outcome
compared	32563787	2116	2124	O
to	32563787	2125	2127	O
saline	32563787	2128	2134	B-Intervention
and	32563787	2135	2138	O
povidone	32563787	2139	2147	B-Intervention
-	32563787	2148	2149	I-Intervention
iodine	32563787	2150	2156	I-Intervention
.	32563787	2157	2158	O

In	32563787	2159	2161	O
addition	32563787	2162	2170	O
,	32563787	2171	2172	O
1	32563787	2173	2174	B-Intervention
%	32563787	2175	2176	I-Intervention
povidone	32563787	2177	2185	I-Intervention
-	32563787	2186	2187	I-Intervention
iodine	32563787	2188	2194	I-Intervention
solution	32563787	2195	2203	I-Intervention
was	32563787	2204	2207	O
well	32563787	2208	2212	B-Observation
-	32563787	2213	2214	O
tolerated	32563787	2215	2224	B-Outcome
as	32563787	2225	2227	O
a	32563787	2228	2229	O
sinus	32563787	2230	2235	B-Intervention
irrigation	32563787	2236	2246	I-Intervention
and	32563787	2247	2250	O
may	32563787	2251	2254	O
represent	32563787	2255	2264	O
a	32563787	2265	2266	O
feasible	32563787	2267	2275	O
method	32563787	2276	2282	O
for	32563787	2283	2286	O
temporarily	32563787	2287	2298	O
disinfecting	32563787	2299	2311	O
the	32563787	2312	2315	O
sinonasal	32563787	2316	2325	O
cavity	32563787	2326	2332	O
of	32563787	2333	2335	O
bacteria	32563787	2336	2344	O
and	32563787	2345	2348	O
viruses	32563787	2349	2356	O
such	32563787	2357	2361	O
as	32563787	2362	2364	O
COVID-19	32563787	2365	2373	O
.	32563787	2374	2375	O


Oseltamivir	32571773	0	11	B-Intervention
for	32571773	12	15	O
coronavirus	32571773	16	27	B-Participant
illness	32571773	28	35	I-Participant
:	32571773	36	37	O
post	32571773	38	42	O
-	32571773	43	44	O
hoc	32571773	45	48	O
exploratory	32571773	49	60	O
analysis	32571773	61	69	O
of	32571773	70	72	O
an	32571773	73	75	O
open	32571773	76	80	O
-	32571773	81	82	O
label	32571773	83	88	O
,	32571773	89	90	O
pragmatic	32571773	91	100	O
,	32571773	101	102	O
randomised	32571773	103	113	O
controlled	32571773	114	124	O
trial	32571773	125	130	O
in	32571773	131	133	O
European	32571773	134	142	O
primary	32571773	143	150	O
care	32571773	151	155	O
from	32571773	156	160	O
2016	32571773	161	165	O
to	32571773	166	168	O
2018	32571773	169	173	O
.	32571773	174	175	O

Patients	32571773	176	184	O
infected	32571773	185	193	O
with	32571773	194	198	O
the	32571773	199	202	O
novel	32571773	203	208	O
coronavirus	32571773	209	220	O
(	32571773	221	222	O
SARS	32571773	223	227	O
-	32571773	228	229	O
CoV-2	32571773	230	235	O
)	32571773	236	237	O
are	32571773	238	241	O
being	32571773	242	247	O
treated	32571773	248	255	O
empirically	32571773	256	267	O
with	32571773	268	272	O
oseltamivir	32571773	273	284	O
,	32571773	285	286	O
but	32571773	287	290	O
there	32571773	291	296	O
is	32571773	297	299	O
little	32571773	300	306	O
evidence	32571773	307	315	O
from	32571773	316	320	O
randomised	32571773	321	331	O
controlled	32571773	332	342	O
trials	32571773	343	349	O
to	32571773	350	352	O
support	32571773	353	360	O
the	32571773	361	364	O
treatment	32571773	365	374	O
of	32571773	375	377	O
coronavirus	32571773	378	389	O
infections	32571773	390	400	O
with	32571773	401	405	O
oseltamivir	32571773	406	417	O
.	32571773	418	419	O

To	32571773	420	422	O
determine	32571773	423	432	O
whether	32571773	433	440	O
adding	32571773	441	447	O
oseltamivir	32571773	448	459	O
to	32571773	460	462	O
usual	32571773	463	468	O
care	32571773	469	473	O
reduces	32571773	474	481	O
time	32571773	482	486	O
to	32571773	487	489	O
recovery	32571773	490	498	O
in	32571773	499	501	O
symptomatic	32571773	502	513	O
patients	32571773	514	522	O
who	32571773	523	526	O
have	32571773	527	531	O
tested	32571773	532	538	O
positive	32571773	539	547	O
for	32571773	548	551	O
coronavirus	32571773	552	563	O
(	32571773	564	565	O
not	32571773	566	569	O
including	32571773	570	579	O
SARS	32571773	580	584	O
-	32571773	585	586	O
CoV-2	32571773	587	592	O
)	32571773	593	594	O
.	32571773	595	596	O

Exploratory	32571773	597	608	O
analysis	32571773	609	617	O
of	32571773	618	620	O
data	32571773	621	625	O
from	32571773	626	630	O
an	32571773	631	633	O
open	32571773	634	638	O
-	32571773	639	640	O
label	32571773	641	646	O
,	32571773	647	648	O
pragmatic	32571773	649	658	O
,	32571773	659	660	O
randomised	32571773	661	671	O
controlled	32571773	672	682	O
trial	32571773	683	688	O
during	32571773	689	695	O
three	32571773	696	701	O
influenza	32571773	702	711	O
seasons	32571773	712	719	O
,	32571773	720	721	O
from	32571773	722	726	O
2016	32571773	727	731	O
to	32571773	732	734	O
2018	32571773	735	739	O
,	32571773	740	741	O
in	32571773	742	744	O
primary	32571773	745	752	O
care	32571773	753	757	O
research	32571773	758	766	O
networks	32571773	767	775	O
,	32571773	776	777	O
in	32571773	778	780	O
15	32571773	781	783	O
European	32571773	784	792	O
countries	32571773	793	802	O
.	32571773	803	804	O

Patients	32571773	805	813	O
aged	32571773	814	818	B-Participant
	32571773	821	822	I-Participant
1	32571773	823	824	I-Participant
year	32571773	825	829	I-Participant
presenting	32571773	830	840	O
to	32571773	841	843	O
primary	32571773	844	851	O
care	32571773	852	856	O
with	32571773	857	861	O
influenza	32571773	862	871	B-Participant
-	32571773	872	873	I-Participant
like	32571773	874	878	I-Participant
illness	32571773	879	886	I-Participant
(	32571773	887	888	I-Participant
ILI	32571773	889	892	I-Participant
)	32571773	893	894	I-Participant
,	32571773	895	896	O
and	32571773	897	900	O
who	32571773	901	904	O
tested	32571773	905	911	O
positive	32571773	912	920	B-Participant
for	32571773	921	924	I-Participant
coronavirus	32571773	925	936	I-Participant
(	32571773	937	938	O
not	32571773	939	942	O
including	32571773	943	952	O
SARS	32571773	953	957	O
-	32571773	958	959	O
CoV-2	32571773	960	965	O
)	32571773	966	967	O
,	32571773	968	969	O
were	32571773	970	974	O
randomised	32571773	975	985	O
to	32571773	986	988	O
usual	32571773	989	994	B-Intervention
care	32571773	995	999	I-Intervention
or	32571773	1000	1002	O
usual	32571773	1003	1008	B-Intervention
care	32571773	1009	1013	I-Intervention
plus	32571773	1014	1018	I-Intervention
oseltamivir	32571773	1019	1030	I-Intervention
.	32571773	1031	1032	O

The	32571773	1033	1036	O
primary	32571773	1037	1044	O
outcome	32571773	1045	1052	O
was	32571773	1053	1056	O
time	32571773	1057	1061	B-Outcome
to	32571773	1062	1064	I-Outcome
recovery	32571773	1065	1073	I-Outcome
defined	32571773	1074	1081	O
as	32571773	1082	1084	O
a	32571773	1085	1086	O
return	32571773	1087	1093	O
to	32571773	1094	1096	O
usual	32571773	1097	1102	O
activities	32571773	1103	1113	O
,	32571773	1114	1115	O
with	32571773	1116	1120	O
minor	32571773	1121	1126	O
or	32571773	1127	1129	O
absent	32571773	1130	1136	O
fever	32571773	1137	1142	O
,	32571773	1143	1144	O
headache	32571773	1145	1153	O
,	32571773	1154	1155	O
and	32571773	1156	1159	O
muscle	32571773	1160	1166	O
ache	32571773	1167	1171	O
.	32571773	1172	1173	O

Coronaviruses	32571773	1174	1187	B-Participant
(	32571773	1188	1189	I-Participant
CoV-229E	32571773	1190	1198	I-Participant
,	32571773	1199	1200	I-Participant
CoV	32571773	1201	1204	I-Participant
-	32571773	1205	1206	I-Participant
OC43	32571773	1207	1211	I-Participant
,	32571773	1212	1213	I-Participant
CoV	32571773	1214	1217	I-Participant
-	32571773	1218	1219	I-Participant
KU1	32571773	1220	1223	I-Participant
and	32571773	1224	1227	I-Participant
CoV	32571773	1228	1231	I-Participant
-	32571773	1232	1233	I-Participant
NL63	32571773	1234	1238	I-Participant
)	32571773	1239	1240	I-Participant
were	32571773	1241	1245	O
identified	32571773	1246	1256	O
in	32571773	1257	1259	O
308	32571773	1260	1263	O
(	32571773	1264	1265	O
9	32571773	1266	1267	O
%	32571773	1268	1269	O
)	32571773	1270	1271	O
out	32571773	1272	1275	O
of	32571773	1276	1278	O
3266	32571773	1279	1283	O
randomised	32571773	1284	1294	O
participants	32571773	1295	1307	O
in	32571773	1308	1310	O
the	32571773	1311	1314	O
trial	32571773	1315	1320	O
;	32571773	1321	1322	O
153	32571773	1323	1326	O
of	32571773	1327	1329	O
these	32571773	1330	1335	O
were	32571773	1336	1340	O
allocated	32571773	1341	1350	O
to	32571773	1351	1353	O
usual	32571773	1354	1359	B-Intervention
care	32571773	1360	1364	I-Intervention
and	32571773	1365	1368	O
155	32571773	1369	1372	O
to	32571773	1373	1375	O
usual	32571773	1376	1381	B-Intervention
care	32571773	1382	1386	I-Intervention
plus	32571773	1387	1391	I-Intervention
oseltamivir	32571773	1392	1403	I-Intervention
;	32571773	1404	1405	O
the	32571773	1406	1409	O
primary	32571773	1410	1417	B-Outcome
outcome	32571773	1418	1425	I-Outcome
was	32571773	1426	1429	O
ascertained	32571773	1430	1441	O
in	32571773	1442	1444	O
136	32571773	1445	1448	O
and	32571773	1449	1452	O
147	32571773	1453	1456	O
participants	32571773	1457	1469	O
,	32571773	1470	1471	O
respectively	32571773	1472	1484	O
.	32571773	1485	1486	O

The	32571773	1487	1490	O
median	32571773	1491	1497	B-Outcome
time	32571773	1498	1502	I-Outcome
to	32571773	1503	1505	I-Outcome
recovery	32571773	1506	1514	I-Outcome
was	32571773	1515	1518	O
shorter	32571773	1519	1526	B-Observation
in	32571773	1527	1529	O
patients	32571773	1530	1538	O
randomised	32571773	1539	1549	O
to	32571773	1550	1552	O
oseltamivir	32571773	1553	1564	B-Intervention
:	32571773	1565	1566	O
4	32571773	1567	1568	B-Observation
days	32571773	1569	1573	I-Observation
(	32571773	1574	1575	O
interquartile	32571773	1576	1589	O
range	32571773	1590	1595	O
[	32571773	1596	1597	O
IQR	32571773	1598	1601	O
]	32571773	1602	1603	O
3	32571773	1604	1605	O
-	32571773	1606	1607	O
6	32571773	1608	1609	O
)	32571773	1610	1611	O
versus	32571773	1612	1618	O
5	32571773	1619	1620	B-Observation
days	32571773	1621	1625	I-Observation
(	32571773	1626	1627	O
IQR	32571773	1628	1631	O
3	32571773	1632	1633	O
-	32571773	1634	1635	O
8	32571773	1636	1637	O
;	32571773	1638	1639	O
hazard	32571773	1640	1646	O
ratio	32571773	1647	1652	O
1.31	32571773	1653	1657	O
;	32571773	1658	1659	O
95	32571773	1660	1662	O
%	32571773	1663	1664	O
confidence	32571773	1665	1675	O
interval	32571773	1676	1684	O
=	32571773	1685	1686	O
1.03	32571773	1687	1691	O
to	32571773	1692	1694	O
1.66	32571773	1695	1699	O
;	32571773	1700	1701	O
P	32571773	1702	1703	O
=	32571773	1704	1705	O
0.026	32571773	1706	1711	O
)	32571773	1712	1713	O
.	32571773	1714	1715	O

Primary	32571773	1716	1723	B-Participant
care	32571773	1724	1728	I-Participant
patients	32571773	1729	1737	I-Participant
with	32571773	1738	1742	I-Participant
ILI	32571773	1743	1746	I-Participant
testing	32571773	1747	1754	I-Participant
positive	32571773	1755	1763	I-Participant
for	32571773	1764	1767	I-Participant
coronavirus	32571773	1768	1779	I-Participant
(	32571773	1780	1781	I-Participant
not	32571773	1782	1785	I-Participant
including	32571773	1786	1795	I-Participant
SARS	32571773	1796	1800	I-Participant
-	32571773	1801	1802	I-Participant
CoV-2	32571773	1803	1808	I-Participant
)	32571773	1809	1810	I-Participant
recovered	32571773	1811	1820	B-Outcome
sooner	32571773	1821	1827	B-Observation
when	32571773	1828	1832	O
oseltamivir	32571773	1833	1844	B-Intervention
was	32571773	1845	1848	I-Intervention
added	32571773	1849	1854	I-Intervention
to	32571773	1855	1857	I-Intervention
usual	32571773	1858	1863	I-Intervention
care	32571773	1864	1868	I-Intervention
compared	32571773	1869	1877	O
with	32571773	1878	1882	O
usual	32571773	1883	1888	B-Intervention
care	32571773	1889	1893	I-Intervention
alone	32571773	1894	1899	I-Intervention
.	32571773	1900	1901	O

This	32571773	1902	1906	O
may	32571773	1907	1910	O
be	32571773	1911	1913	O
of	32571773	1914	1916	O
relevance	32571773	1917	1926	O
to	32571773	1927	1929	O
the	32571773	1930	1933	O
primary	32571773	1934	1941	O
care	32571773	1942	1946	O
management	32571773	1947	1957	O
of	32571773	1958	1960	O
COVID-19	32571773	1961	1969	O
.	32571773	1970	1971	O


Effect	32579195	0	6	O
of	32579195	7	9	O
Colchicine	32579195	10	20	B-Intervention
vs	32579195	21	23	O
Standard	32579195	24	32	B-Intervention
Care	32579195	33	37	I-Intervention
on	32579195	38	40	O
Cardiac	32579195	41	48	B-Outcome
and	32579195	49	52	I-Outcome
Inflammatory	32579195	53	65	I-Outcome
Biomarkers	32579195	66	76	I-Outcome
and	32579195	77	80	O
Clinical	32579195	81	89	B-Outcome
Outcomes	32579195	90	98	I-Outcome
in	32579195	99	101	O
Patients	32579195	102	110	O
Hospitalized	32579195	111	123	B-Participant
With	32579195	124	128	O
Coronavirus	32579195	129	140	B-Participant
Disease	32579195	141	148	I-Participant
2019	32579195	149	153	I-Participant
:	32579195	154	155	O
The	32579195	156	159	O
GRECCO-19	32579195	160	169	O
Randomized	32579195	170	180	O
Clinical	32579195	181	189	O
Trial	32579195	190	195	O
.	32579195	196	197	O

Severe	32579195	198	204	O
acute	32579195	205	210	O
respiratory	32579195	211	222	O
syndrome	32579195	223	231	O
coronavirus	32579195	232	243	O
2	32579195	244	245	O
infection	32579195	246	255	O
has	32579195	256	259	O
evolved	32579195	260	267	O
into	32579195	268	272	O
a	32579195	273	274	O
global	32579195	275	281	O
pandemic	32579195	282	290	O
.	32579195	291	292	O

Low	32579195	293	296	O
-	32579195	297	298	O
dose	32579195	299	303	O
colchicine	32579195	304	314	O
combines	32579195	315	323	O
anti	32579195	324	328	O
-	32579195	329	330	O
inflammatory	32579195	331	343	O
action	32579195	344	350	O
with	32579195	351	355	O
a	32579195	356	357	O
favorable	32579195	358	367	O
safety	32579195	368	374	O
profile	32579195	375	382	O
.	32579195	383	384	O

To	32579195	385	387	O
evaluate	32579195	388	396	O
the	32579195	397	400	O
effect	32579195	401	407	O
of	32579195	408	410	O
treatment	32579195	411	420	O
with	32579195	421	425	O
colchicine	32579195	426	436	B-Intervention
on	32579195	437	439	O
cardiac	32579195	440	447	B-Outcome
and	32579195	448	451	I-Outcome
inflammatory	32579195	452	464	I-Outcome
biomarkers	32579195	465	475	I-Outcome
and	32579195	476	479	O
clinical	32579195	480	488	B-Outcome
outcomes	32579195	489	497	I-Outcome
in	32579195	498	500	O
patients	32579195	501	509	O
hospitalized	32579195	510	522	B-Participant
with	32579195	523	527	O
coronavirus	32579195	528	539	B-Participant
disease	32579195	540	547	I-Participant
2019	32579195	548	552	I-Participant
(	32579195	553	554	I-Participant
COVID-19	32579195	555	563	I-Participant
)	32579195	564	565	I-Participant
.	32579195	566	567	O

In	32579195	568	570	O
this	32579195	571	575	O
prospective	32579195	576	587	O
,	32579195	588	589	O
open	32579195	590	594	O
-	32579195	595	596	O
label	32579195	597	602	O
,	32579195	603	604	O
randomized	32579195	605	615	O
clinical	32579195	616	624	O
trial	32579195	625	630	O
(	32579195	631	632	O
the	32579195	633	636	O
Greek	32579195	637	642	O
Study	32579195	643	648	O
in	32579195	649	651	O
the	32579195	652	655	O
Effects	32579195	656	663	O
of	32579195	664	666	O
Colchicine	32579195	667	677	O
in	32579195	678	680	O
COVID-19	32579195	681	689	O
Complications	32579195	690	703	O
Prevention	32579195	704	714	O
)	32579195	715	716	O
,	32579195	717	718	O
105	32579195	719	722	O
patients	32579195	723	731	O
hospitalized	32579195	732	744	B-Participant
with	32579195	745	749	O
COVID-19	32579195	750	758	B-Participant
were	32579195	759	763	O
randomized	32579195	764	774	O
in	32579195	775	777	O
a	32579195	778	779	O
1:1	32579195	780	783	O
allocation	32579195	784	794	O
from	32579195	795	799	O
April	32579195	800	805	O
3	32579195	806	807	O
to	32579195	808	810	O
April	32579195	811	816	O
27	32579195	817	819	O
,	32579195	820	821	O
2020	32579195	822	826	O
,	32579195	827	828	O
to	32579195	829	831	O
either	32579195	832	838	O
standard	32579195	839	847	B-Intervention
medical	32579195	848	855	I-Intervention
treatment	32579195	856	865	I-Intervention
or	32579195	866	868	O
colchicine	32579195	869	879	B-Intervention
with	32579195	880	884	I-Intervention
standard	32579195	885	893	I-Intervention
medical	32579195	894	901	I-Intervention
treatment	32579195	902	911	I-Intervention
.	32579195	912	913	O

The	32579195	914	917	O
study	32579195	918	923	O
took	32579195	924	928	O
place	32579195	929	934	O
in	32579195	935	937	O
16	32579195	938	940	O
tertiary	32579195	941	949	O
hospitals	32579195	950	959	O
in	32579195	960	962	O
Greece	32579195	963	969	O
.	32579195	970	971	O

Colchicine	32579195	972	982	B-Intervention
administration	32579195	983	997	I-Intervention
(	32579195	998	999	O
1.5-mg	32579195	1000	1006	O
loading	32579195	1007	1014	O
dose	32579195	1015	1019	O
followed	32579195	1020	1028	O
by	32579195	1029	1031	O
0.5	32579195	1032	1035	O
mg	32579195	1036	1038	O
after	32579195	1039	1044	O
60	32579195	1045	1047	O
min	32579195	1048	1051	O
and	32579195	1052	1055	O
maintenance	32579195	1056	1067	O
doses	32579195	1068	1073	O
of	32579195	1074	1076	O
0.5	32579195	1077	1080	O
mg	32579195	1081	1083	O
twice	32579195	1084	1089	O
daily	32579195	1090	1095	O
)	32579195	1096	1097	O
with	32579195	1098	1102	O
standard	32579195	1103	1111	O
medical	32579195	1112	1119	O
treatment	32579195	1120	1129	O
for	32579195	1130	1133	O
as	32579195	1134	1136	O
long	32579195	1137	1141	O
as	32579195	1142	1144	O
3	32579195	1145	1146	O
weeks	32579195	1147	1152	O
.	32579195	1153	1154	O

Primary	32579195	1155	1162	O
end	32579195	1163	1166	O
points	32579195	1167	1173	O
were	32579195	1174	1178	O
(	32579195	1179	1180	O
1	32579195	1181	1182	O
)	32579195	1183	1184	O
maximum	32579195	1185	1192	B-Outcome
high	32579195	1193	1197	I-Outcome
-	32579195	1198	1199	I-Outcome
sensitivity	32579195	1200	1211	I-Outcome
cardiac	32579195	1212	1219	I-Outcome
troponin	32579195	1220	1228	I-Outcome
level	32579195	1229	1234	I-Outcome
;	32579195	1235	1236	O
(	32579195	1237	1238	O
2	32579195	1239	1240	O
)	32579195	1241	1242	O
time	32579195	1243	1247	B-Outcome
for	32579195	1248	1251	I-Outcome
C	32579195	1252	1253	I-Outcome
-	32579195	1254	1255	I-Outcome
reactive	32579195	1256	1264	I-Outcome
protein	32579195	1265	1272	I-Outcome
to	32579195	1273	1275	I-Outcome
reach	32579195	1276	1281	I-Outcome
more	32579195	1282	1286	I-Outcome
than	32579195	1287	1291	I-Outcome
3	32579195	1292	1293	I-Outcome
times	32579195	1294	1299	I-Outcome
the	32579195	1300	1303	I-Outcome
upper	32579195	1304	1309	I-Outcome
reference	32579195	1310	1319	I-Outcome
limit	32579195	1320	1325	I-Outcome
;	32579195	1326	1327	O
and	32579195	1328	1331	O
(	32579195	1332	1333	O
3	32579195	1334	1335	O
)	32579195	1336	1337	O
time	32579195	1338	1342	B-Outcome
to	32579195	1343	1345	I-Outcome
deterioration	32579195	1346	1359	I-Outcome
by	32579195	1360	1362	I-Outcome
2	32579195	1363	1364	I-Outcome
points	32579195	1365	1371	I-Outcome
on	32579195	1372	1374	I-Outcome
a	32579195	1375	1376	I-Outcome
7-grade	32579195	1377	1384	I-Outcome
clinical	32579195	1385	1393	I-Outcome
status	32579195	1394	1400	I-Outcome
scale	32579195	1401	1406	I-Outcome
,	32579195	1407	1408	O
ranging	32579195	1409	1416	O
from	32579195	1417	1421	O
able	32579195	1422	1426	O
to	32579195	1427	1429	O
resume	32579195	1430	1436	O
normal	32579195	1437	1443	O
activities	32579195	1444	1454	O
to	32579195	1455	1457	O
death	32579195	1458	1463	O
.	32579195	1464	1465	O

Secondary	32579195	1466	1475	O
end	32579195	1476	1479	O
points	32579195	1480	1486	O
were	32579195	1487	1491	O
(	32579195	1492	1493	O
1	32579195	1494	1495	O
)	32579195	1496	1497	O
the	32579195	1498	1501	O
percentage	32579195	1502	1512	B-Outcome
of	32579195	1513	1515	I-Outcome
participants	32579195	1516	1528	I-Outcome
requiring	32579195	1529	1538	I-Outcome
mechanical	32579195	1539	1549	I-Outcome
ventilation	32579195	1550	1561	I-Outcome
,	32579195	1562	1563	O
(	32579195	1564	1565	O
2	32579195	1566	1567	O
)	32579195	1568	1569	O
all	32579195	1570	1573	B-Outcome
-	32579195	1574	1575	I-Outcome
cause	32579195	1576	1581	I-Outcome
mortality	32579195	1582	1591	I-Outcome
,	32579195	1592	1593	O
and	32579195	1594	1597	O
(	32579195	1598	1599	O
3	32579195	1600	1601	O
)	32579195	1602	1603	O
number	32579195	1604	1610	B-Outcome
,	32579195	1611	1612	I-Outcome
type	32579195	1613	1617	I-Outcome
,	32579195	1618	1619	I-Outcome
severity	32579195	1620	1628	I-Outcome
,	32579195	1629	1630	I-Outcome
and	32579195	1631	1634	I-Outcome
seriousness	32579195	1635	1646	I-Outcome
of	32579195	1647	1649	I-Outcome
adverse	32579195	1650	1657	I-Outcome
events	32579195	1658	1664	I-Outcome
.	32579195	1665	1666	O

The	32579195	1667	1670	O
primary	32579195	1671	1678	O
efficacy	32579195	1679	1687	O
analysis	32579195	1688	1696	O
was	32579195	1697	1700	O
performed	32579195	1701	1710	O
on	32579195	1711	1713	O
an	32579195	1714	1716	O
intention	32579195	1717	1726	O
-	32579195	1727	1728	O
to	32579195	1729	1731	O
-	32579195	1732	1733	O
treat	32579195	1734	1739	O
basis	32579195	1740	1745	O
.	32579195	1746	1747	O

A	32579195	1748	1749	O
total	32579195	1750	1755	O
of	32579195	1756	1758	O
105	32579195	1759	1762	O
patients	32579195	1763	1771	O
were	32579195	1772	1776	O
evaluated	32579195	1777	1786	O
(	32579195	1787	1788	O
61	32579195	1789	1791	O
[	32579195	1792	1793	O
58.1	32579195	1794	1798	O
%	32579195	1799	1800	O
]	32579195	1801	1802	O
men	32579195	1803	1806	O
;	32579195	1807	1808	O
median	32579195	1809	1815	O
[	32579195	1816	1817	O
interquartile	32579195	1818	1831	O
range	32579195	1832	1837	O
]	32579195	1838	1839	O
age	32579195	1840	1843	O
,	32579195	1844	1845	O
64	32579195	1846	1848	O
[	32579195	1849	1850	O
54	32579195	1851	1853	O
-	32579195	1854	1855	O
76	32579195	1856	1858	O
]	32579195	1859	1860	O
years	32579195	1861	1866	O
)	32579195	1867	1868	O
with	32579195	1869	1873	O
50	32579195	1874	1876	O
(	32579195	1877	1878	O
47.6	32579195	1879	1883	O
%	32579195	1884	1885	O
)	32579195	1886	1887	O
randomized	32579195	1888	1898	O
to	32579195	1899	1901	O
the	32579195	1902	1905	O
control	32579195	1906	1913	B-Intervention
group	32579195	1914	1919	O
and	32579195	1920	1923	O
55	32579195	1924	1926	O
(	32579195	1927	1928	O
52.4	32579195	1929	1933	O
%	32579195	1934	1935	O
)	32579195	1936	1937	O
to	32579195	1938	1940	O
the	32579195	1941	1944	O
colchicine	32579195	1945	1955	B-Intervention
group	32579195	1956	1961	O
.	32579195	1962	1963	O

Median	32579195	1964	1970	B-Outcome
(	32579195	1971	1972	I-Outcome
interquartile	32579195	1973	1986	I-Outcome
range	32579195	1987	1992	I-Outcome
)	32579195	1993	1994	I-Outcome
peak	32579195	1995	1999	I-Outcome
high	32579195	2000	2004	I-Outcome
-	32579195	2005	2006	I-Outcome
sensitivity	32579195	2007	2018	I-Outcome
cardiac	32579195	2019	2026	I-Outcome
troponin	32579195	2027	2035	I-Outcome
values	32579195	2036	2042	I-Outcome
were	32579195	2043	2047	O
0.0112	32579195	2048	2054	B-Observation
(	32579195	2055	2056	I-Observation
0.0043	32579195	2057	2063	I-Observation
-	32579195	2064	2065	I-Observation
0.0093	32579195	2066	2072	I-Observation
)	32579195	2073	2074	I-Observation
ng	32579195	2075	2077	I-Observation
/	32579195	2078	2079	I-Observation
mL	32579195	2080	2082	I-Observation
in	32579195	2083	2085	O
the	32579195	2086	2089	O
control	32579195	2090	2097	B-Intervention
group	32579195	2098	2103	O
and	32579195	2104	2107	O
0.008	32579195	2108	2113	B-Observation
(	32579195	2114	2115	I-Observation
0.004	32579195	2116	2121	I-Observation
-	32579195	2122	2123	I-Observation
0.0135	32579195	2124	2130	I-Observation
)	32579195	2131	2132	I-Observation
ng	32579195	2133	2135	I-Observation
/	32579195	2136	2137	I-Observation
mL	32579195	2138	2140	I-Observation
in	32579195	2141	2143	O
the	32579195	2144	2147	O
colchicine	32579195	2148	2158	B-Intervention
group	32579195	2159	2164	O
(	32579195	2165	2166	O
P	32579195	2167	2168	O
=	32579195	2171	2172	O
.34	32579195	2175	2178	O
)	32579195	2179	2180	O
.	32579195	2181	2182	O

Median	32579195	2183	2189	B-Outcome
(	32579195	2190	2191	I-Outcome
interquartile	32579195	2192	2205	I-Outcome
range	32579195	2206	2211	I-Outcome
)	32579195	2212	2213	I-Outcome
maximum	32579195	2214	2221	I-Outcome
C	32579195	2222	2223	I-Outcome
-	32579195	2224	2225	I-Outcome
reactive	32579195	2226	2234	I-Outcome
protein	32579195	2235	2242	I-Outcome
levels	32579195	2243	2249	I-Outcome
were	32579195	2250	2254	O
4.5	32579195	2255	2258	B-Observation
(	32579195	2259	2260	I-Observation
1.4	32579195	2261	2264	I-Observation
-	32579195	2265	2266	I-Observation
8.9	32579195	2267	2270	I-Observation
)	32579195	2271	2272	I-Observation
mg	32579195	2273	2275	I-Observation
/	32579195	2276	2277	I-Observation
dL	32579195	2278	2280	I-Observation
vs	32579195	2281	2283	O
3.1	32579195	2284	2287	B-Observation
(	32579195	2288	2289	I-Observation
0.8	32579195	2290	2293	I-Observation
-	32579195	2294	2295	I-Observation
9.8	32579195	2296	2299	I-Observation
)	32579195	2300	2301	I-Observation
mg	32579195	2302	2304	I-Observation
/	32579195	2305	2306	I-Observation
dL	32579195	2307	2309	I-Observation
(	32579195	2310	2311	O
P	32579195	2312	2313	O
=	32579195	2316	2317	O
.73	32579195	2320	2323	O
)	32579195	2324	2325	O
,	32579195	2326	2327	O
respectively	32579195	2328	2340	O
.	32579195	2341	2342	O

The	32579195	2343	2346	O
clinical	32579195	2347	2355	B-Outcome
primary	32579195	2356	2363	I-Outcome
end	32579195	2364	2367	I-Outcome
point	32579195	2368	2373	I-Outcome
rate	32579195	2374	2378	I-Outcome
was	32579195	2379	2382	O
14.0	32579195	2383	2387	B-Observation
%	32579195	2388	2389	I-Observation
in	32579195	2390	2392	O
the	32579195	2393	2396	O
control	32579195	2397	2404	B-Intervention
group	32579195	2405	2410	O
(	32579195	2411	2412	O
7	32579195	2413	2414	B-Count
of	32579195	2415	2417	I-Count
50	32579195	2418	2420	I-Count
patients	32579195	2421	2429	I-Count
)	32579195	2430	2431	O
and	32579195	2432	2435	O
1.8	32579195	2436	2439	B-Observation
%	32579195	2440	2441	I-Observation
in	32579195	2442	2444	O
the	32579195	2445	2448	O
colchicine	32579195	2449	2459	B-Intervention
group	32579195	2460	2465	O
(	32579195	2466	2467	O
1	32579195	2468	2469	B-Count
of	32579195	2470	2472	I-Count
55	32579195	2473	2475	I-Count
patients	32579195	2476	2484	I-Count
)	32579195	2485	2486	O
(	32579195	2487	2488	O
odds	32579195	2489	2493	O
ratio	32579195	2494	2499	O
,	32579195	2500	2501	O
0.11	32579195	2502	2506	O
;	32579195	2507	2508	O
95	32579195	2509	2511	O
%	32579195	2512	2513	O
CI	32579195	2514	2516	O
,	32579195	2517	2518	O
0.01	32579195	2519	2523	O
-	32579195	2524	2525	O
0.96	32579195	2526	2530	O
;	32579195	2531	2532	O
P	32579195	2533	2534	O
=	32579195	2537	2538	O
.02	32579195	2541	2544	O
)	32579195	2545	2546	O
.	32579195	2547	2548	O

Mean	32579195	2549	2553	B-Outcome
(	32579195	2554	2555	I-Outcome
SD	32579195	2556	2558	I-Outcome
)	32579195	2559	2560	I-Outcome
event	32579195	2561	2566	I-Outcome
-	32579195	2567	2568	I-Outcome
free	32579195	2569	2573	I-Outcome
survival	32579195	2574	2582	I-Outcome
time	32579195	2583	2587	I-Outcome
was	32579195	2588	2591	O
18.6	32579195	2592	2596	B-Observation
(	32579195	2597	2598	I-Observation
0.83	32579195	2599	2603	I-Observation
)	32579195	2604	2605	I-Observation
days	32579195	2606	2610	I-Observation
the	32579195	2611	2614	O
in	32579195	2615	2617	O
the	32579195	2618	2621	O
control	32579195	2622	2629	B-Intervention
group	32579195	2630	2635	O
vs	32579195	2636	2638	O
20.7	32579195	2639	2643	B-Observation
(	32579195	2644	2645	I-Observation
0.31	32579195	2646	2650	I-Observation
)	32579195	2651	2652	I-Observation
in	32579195	2653	2655	O
the	32579195	2656	2659	O
colchicine	32579195	2660	2670	B-Intervention
group	32579195	2671	2676	O
(	32579195	2677	2678	O
log	32579195	2679	2682	O
rank	32579195	2683	2687	O
P	32579195	2688	2689	O
=	32579195	2692	2693	O
.03	32579195	2696	2699	O
)	32579195	2700	2701	O
.	32579195	2702	2703	O

Adverse	32579195	2704	2711	B-Outcome
events	32579195	2712	2718	I-Outcome
were	32579195	2719	2723	O
similar	32579195	2724	2731	B-Observation
in	32579195	2732	2734	O
the	32579195	2735	2738	O
2	32579195	2739	2740	B-Intervention
groups	32579195	2741	2747	I-Intervention
,	32579195	2748	2749	O
except	32579195	2750	2756	O
for	32579195	2757	2760	O
diarrhea	32579195	2761	2769	B-Outcome
,	32579195	2770	2771	O
which	32579195	2772	2777	O
was	32579195	2778	2781	O
more	32579195	2782	2786	B-Observation
frequent	32579195	2787	2795	I-Observation
with	32579195	2796	2800	O
colchicine	32579195	2801	2811	B-Intervention
group	32579195	2812	2817	O
than	32579195	2818	2822	O
the	32579195	2823	2826	O
control	32579195	2827	2834	B-Intervention
group	32579195	2835	2840	O
(	32579195	2841	2842	O
25	32579195	2843	2845	B-Count
patients	32579195	2846	2854	I-Count
[	32579195	2855	2856	I-Count
45.5	32579195	2857	2861	I-Count
%	32579195	2862	2863	I-Count
]	32579195	2864	2865	I-Count
vs	32579195	2866	2868	O
9	32579195	2869	2870	B-Count
patients	32579195	2871	2879	I-Count
[	32579195	2880	2881	I-Count
18.0	32579195	2882	2886	I-Count
%	32579195	2887	2888	I-Count
]	32579195	2889	2890	I-Count
;	32579195	2891	2892	O
P	32579195	2893	2894	O
=	32579195	2897	2898	O
.003	32579195	2901	2905	O
)	32579195	2906	2907	O
.	32579195	2908	2909	O

In	32579195	2910	2912	O
this	32579195	2913	2917	O
randomized	32579195	2918	2928	O
clinical	32579195	2929	2937	O
trial	32579195	2938	2943	O
,	32579195	2944	2945	O
participants	32579195	2946	2958	O
who	32579195	2959	2962	O
received	32579195	2963	2971	O
colchicine	32579195	2972	2982	B-Intervention
had	32579195	2983	2986	O
statistically	32579195	2987	3000	B-Observation
significantly	32579195	3001	3014	I-Observation
improved	32579195	3015	3023	I-Observation
time	32579195	3024	3028	B-Outcome
to	32579195	3029	3031	I-Outcome
clinical	32579195	3032	3040	I-Outcome
deterioration	32579195	3041	3054	I-Outcome
.	32579195	3055	3056	O

There	32579195	3057	3062	O
were	32579195	3063	3067	O
no	32579195	3068	3070	O
significant	32579195	3071	3082	B-Observation
differences	32579195	3083	3094	I-Observation
in	32579195	3095	3097	O
high	32579195	3098	3102	B-Outcome
-	32579195	3103	3104	I-Outcome
sensitivity	32579195	3105	3116	I-Outcome
cardiac	32579195	3117	3124	I-Outcome
troponin	32579195	3125	3133	I-Outcome
or	32579195	3134	3136	O
C	32579195	3137	3138	B-Outcome
-	32579195	3139	3140	I-Outcome
reactive	32579195	3141	3149	I-Outcome
protein	32579195	3150	3157	I-Outcome
levels	32579195	3158	3164	I-Outcome
.	32579195	3165	3166	O

These	32579195	3167	3172	O
findings	32579195	3173	3181	O
should	32579195	3182	3188	O
be	32579195	3189	3191	O
interpreted	32579195	3192	3203	O
with	32579195	3204	3208	O
caution	32579195	3209	3216	O
.	32579195	3217	3218	O

ClinicalTrials.gov	32579195	3219	3237	O
Identifier	32579195	3238	3248	O
:	32579195	3249	3250	O
NCT04326790	32579195	3251	3262	O
.	32579195	3263	3264	O


Febuxostat	32603531	0	10	B-Intervention
therapy	32603531	11	18	I-Intervention
in	32603531	19	21	O
outpatients	32603531	22	33	B-Participant
with	32603531	34	38	O
suspected	32603531	39	48	B-Participant
COVID-19	32603531	49	57	I-Participant
:	32603531	58	59	O
A	32603531	60	61	O
clinical	32603531	62	70	O
trial	32603531	71	76	O
.	32603531	77	78	O

BACKGROUND	32603531	79	89	O
:	32603531	90	91	O
The	32603531	92	95	O
aim	32603531	96	99	O
of	32603531	100	102	O
this	32603531	103	107	O
clinical	32603531	108	116	O
trial	32603531	117	122	O
was	32603531	123	126	O
to	32603531	127	129	O
evaluate	32603531	130	138	O
the	32603531	139	142	O
effects	32603531	143	150	O
of	32603531	151	153	O
febuxostat	32603531	154	164	O
(	32603531	165	166	O
FBX	32603531	167	170	O
)	32603531	171	172	O
in	32603531	173	175	O
comparison	32603531	176	186	O
with	32603531	187	191	O
hydroxychloroquine	32603531	192	210	O
(	32603531	211	212	O
HCQ	32603531	213	216	O
)	32603531	217	218	O
on	32603531	219	221	O
clinical	32603531	222	230	O
symptoms	32603531	231	239	O
,	32603531	240	241	O
laboratory	32603531	242	252	O
tests	32603531	253	258	O
and	32603531	259	262	O
chest	32603531	263	268	O
CT	32603531	269	271	O
findings	32603531	272	280	O
in	32603531	281	283	O
outpatients	32603531	284	295	O
with	32603531	296	300	O
moderate	32603531	301	309	O
symptoms	32603531	310	318	O
of	32603531	319	321	O
COVID-19	32603531	322	330	O
infection	32603531	331	340	O
.	32603531	341	342	O

METHODS	32603531	343	350	O
:	32603531	351	352	O
We	32603531	353	355	O
conducted	32603531	356	365	O
a	32603531	366	367	O
clinical	32603531	368	376	O
trial	32603531	377	382	O
involving	32603531	383	392	O
adult	32603531	393	398	B-Participant
outpatients	32603531	399	410	I-Participant
with	32603531	411	415	O
the	32603531	416	419	O
moderate	32603531	420	428	B-Participant
respiratory	32603531	429	440	I-Participant
illness	32603531	441	448	I-Participant
following	32603531	449	458	O
COVID-19	32603531	459	467	B-Participant
infection	32603531	468	477	I-Participant
.	32603531	478	479	O

Patients	32603531	480	488	O
were	32603531	489	493	O
randomly	32603531	494	502	O
assigned	32603531	503	511	O
to	32603531	512	514	O
receive	32603531	515	522	O
either	32603531	523	529	O
FBX	32603531	530	533	B-Intervention
or	32603531	534	536	O
HCQ	32603531	537	540	B-Intervention
for	32603531	541	544	O
5	32603531	545	546	O
days	32603531	547	551	O
.	32603531	552	553	O

The	32603531	554	557	O
measured	32603531	558	566	O
variables	32603531	567	576	O
were	32603531	577	581	O
needs	32603531	582	587	B-Outcome
to	32603531	588	590	I-Outcome
hospitalisation	32603531	591	606	I-Outcome
,	32603531	607	608	O
clinical	32603531	609	617	B-Outcome
and	32603531	618	621	I-Outcome
laboratory	32603531	622	632	I-Outcome
data	32603531	633	637	I-Outcome
including	32603531	638	647	O
fever	32603531	648	653	B-Outcome
,	32603531	654	655	O
cough	32603531	656	661	B-Outcome
,	32603531	662	663	O
breathing	32603531	664	673	B-Outcome
rate	32603531	674	678	I-Outcome
,	32603531	679	680	O
C	32603531	681	682	B-Outcome
-	32603531	683	684	I-Outcome
Reactive	32603531	685	693	I-Outcome
Protein	32603531	694	701	I-Outcome
level	32603531	702	707	I-Outcome
,	32603531	708	709	O
lymphocytes	32603531	710	721	B-Outcome
count	32603531	722	727	I-Outcome
at	32603531	728	730	O
onset	32603531	731	736	O
of	32603531	737	739	O
admission	32603531	740	749	O
and	32603531	750	753	O
was	32603531	754	757	O
well	32603531	758	762	O
as	32603531	763	765	O
at	32603531	766	768	O
5	32603531	769	770	O
days	32603531	771	775	O
of	32603531	776	778	O
treatments	32603531	779	789	O
.	32603531	790	791	O

In	32603531	792	794	O
addition	32603531	795	803	O
,	32603531	804	805	O
CT	32603531	806	808	B-Outcome
findings	32603531	809	817	I-Outcome
were	32603531	818	822	O
evaluated	32603531	823	832	O
on	32603531	833	835	O
admission	32603531	836	845	O
and	32603531	846	849	O
14	32603531	850	852	O
days	32603531	853	857	O
after	32603531	858	863	O
initiation	32603531	864	874	O
of	32603531	875	877	O
treatment	32603531	878	887	O
.	32603531	888	889	O

RESULTS	32603531	890	897	O
:	32603531	898	899	O
Sixty	32603531	900	905	O
subjects	32603531	906	914	O
were	32603531	915	919	O
enrolled	32603531	920	928	O
in	32603531	929	931	O
the	32603531	932	935	O
study	32603531	936	941	O
with	32603531	942	946	O
a	32603531	947	948	O
1	32603531	949	950	O
to	32603531	951	953	O
1	32603531	954	955	O
ratio	32603531	956	961	O
in	32603531	962	964	O
FBX	32603531	965	968	B-Intervention
and	32603531	969	972	O
HCQ	32603531	973	976	B-Intervention
groups	32603531	977	983	O
.	32603531	984	985	O

On	32603531	986	988	O
admission	32603531	989	998	O
,	32603531	999	1000	O
fever	32603531	1001	1006	B-Outcome
(	32603531	1007	1008	O
66.7	32603531	1009	1013	B-Observation
%	32603531	1014	1015	I-Observation
)	32603531	1016	1017	O
,	32603531	1018	1019	O
cough	32603531	1020	1025	B-Outcome
(	32603531	1026	1027	O
87	32603531	1028	1030	B-Observation
%	32603531	1031	1032	I-Observation
)	32603531	1033	1034	O
,	32603531	1035	1036	O
tachypnoea	32603531	1037	1047	B-Outcome
(	32603531	1048	1049	O
44.4	32603531	1050	1054	B-Observation
%	32603531	1055	1056	I-Observation
)	32603531	1057	1058	O
,	32603531	1059	1060	O
dyspnoea	32603531	1061	1069	B-Outcome
(	32603531	1070	1071	O
35	32603531	1072	1074	B-Observation
%	32603531	1075	1076	I-Observation
)	32603531	1077	1078	O
,	32603531	1079	1080	O
elevated	32603531	1081	1089	B-Outcome
CRP	32603531	1090	1093	I-Outcome
value	32603531	1094	1099	I-Outcome
(	32603531	1100	1101	O
94.4	32603531	1102	1106	B-Observation
%	32603531	1107	1108	I-Observation
)	32603531	1109	1110	O
and	32603531	1111	1114	O
lung	32603531	1115	1119	B-Outcome
involvement	32603531	1120	1131	I-Outcome
according	32603531	1132	1141	O
to	32603531	1142	1144	O
chest	32603531	1145	1150	O
CT	32603531	1151	1153	O
(	32603531	1154	1155	O
100	32603531	1156	1159	B-Observation
%	32603531	1160	1161	I-Observation
)	32603531	1162	1163	O
were	32603531	1164	1168	O
documented	32603531	1169	1179	O
in	32603531	1180	1182	O
enrolled	32603531	1183	1191	O
patients	32603531	1192	1200	O
with	32603531	1201	1205	O
insignificant	32603531	1206	1219	B-Observation
difference	32603531	1220	1230	I-Observation
between	32603531	1231	1238	O
FBX	32603531	1239	1242	B-Intervention
and	32603531	1243	1246	O
HCQ	32603531	1247	1250	B-Intervention
groups	32603531	1251	1257	O
.	32603531	1258	1259	O

Fever	32603531	1260	1265	B-Outcome
,	32603531	1266	1267	O
cough	32603531	1268	1273	B-Outcome
and	32603531	1274	1277	O
tachypnoea	32603531	1278	1288	B-Outcome
were	32603531	1289	1293	O
significantly	32603531	1294	1307	B-Observation
mitigated	32603531	1308	1317	I-Observation
in	32603531	1318	1320	O
both	32603531	1321	1325	B-Intervention
groups	32603531	1326	1332	I-Intervention
after	32603531	1333	1338	O
five	32603531	1339	1343	O
days	32603531	1344	1348	O
of	32603531	1349	1351	O
treatments	32603531	1352	1362	O
without	32603531	1363	1370	O
any	32603531	1371	1374	O
significant	32603531	1375	1386	B-Observation
differences	32603531	1387	1398	I-Observation
between	32603531	1399	1406	B-Intervention
groups	32603531	1407	1413	I-Intervention
.	32603531	1414	1415	O

The	32603531	1416	1419	O
mean	32603531	1420	1424	B-Outcome
percentages	32603531	1425	1436	I-Outcome
of	32603531	1437	1439	I-Outcome
lung	32603531	1440	1444	I-Outcome
involvement	32603531	1445	1456	I-Outcome
were	32603531	1457	1461	O
significantly	32603531	1462	1475	B-Observation
reduced	32603531	1476	1483	I-Observation
to	32603531	1484	1486	I-Observation
7.3	32603531	1487	1490	I-Observation
%	32603531	1491	1492	I-Observation
and	32603531	1493	1496	O
8	32603531	1497	1498	B-Observation
%	32603531	1499	1500	I-Observation
after	32603531	1501	1506	O
14	32603531	1507	1509	O
days	32603531	1510	1514	O
of	32603531	1515	1517	O
treatment	32603531	1518	1527	O
with	32603531	1528	1532	O
FBX	32603531	1533	1536	B-Intervention
and	32603531	1537	1540	O
HCQ	32603531	1541	1544	B-Intervention
,	32603531	1545	1546	O
respectively	32603531	1547	1559	O
.	32603531	1560	1561	O

In	32603531	1562	1564	O
adult	32603531	1565	1570	B-Participant
outpatients	32603531	1571	1582	I-Participant
with	32603531	1583	1587	O
moderate	32603531	1588	1596	B-Participant
COVID-19	32603531	1597	1605	I-Participant
infection	32603531	1606	1615	I-Participant
,	32603531	1616	1617	O
the	32603531	1618	1621	O
effectiveness	32603531	1622	1635	O
of	32603531	1636	1638	O
FBX	32603531	1639	1642	B-Intervention
and	32603531	1643	1646	O
HCQ	32603531	1647	1650	B-Intervention
was	32603531	1651	1654	O
not	32603531	1655	1658	O
different	32603531	1659	1668	B-Observation
in	32603531	1669	1671	O
terms	32603531	1672	1677	O
of	32603531	1678	1680	O
resolution	32603531	1681	1691	B-Outcome
of	32603531	1692	1694	I-Outcome
clinical	32603531	1695	1703	I-Outcome
manifestations	32603531	1704	1718	I-Outcome
,	32603531	1719	1720	O
laboratory	32603531	1721	1731	B-Outcome
tests	32603531	1732	1737	I-Outcome
and	32603531	1738	1741	O
lung	32603531	1742	1746	B-Outcome
CT	32603531	1747	1749	I-Outcome
findings	32603531	1750	1758	I-Outcome
.	32603531	1759	1760	O

CONCLUSIONS	32603531	1761	1772	O
:	32603531	1773	1774	O
This	32603531	1775	1779	O
trial	32603531	1780	1785	O
suggests	32603531	1786	1794	O
that	32603531	1795	1799	O
FBX	32603531	1800	1803	O
is	32603531	1804	1806	O
as	32603531	1807	1809	O
an	32603531	1810	1812	O
alternative	32603531	1813	1824	O
treatment	32603531	1825	1834	O
to	32603531	1835	1837	O
HCQ	32603531	1838	1841	O
for	32603531	1842	1845	O
COVID-19	32603531	1846	1854	O
infection	32603531	1855	1864	O
and	32603531	1865	1868	O
may	32603531	1869	1872	O
be	32603531	1873	1875	O
considered	32603531	1876	1886	O
in	32603531	1887	1889	O
patients	32603531	1890	1898	O
with	32603531	1899	1903	O
a	32603531	1904	1905	O
contraindication	32603531	1906	1922	O
or	32603531	1923	1925	O
precaution	32603531	1926	1936	O
to	32603531	1937	1939	O
HCQ	32603531	1940	1943	O
.	32603531	1944	1945	O


Efficacy	32641091	0	8	B-Outcome
of	32641091	9	11	O
chloroquine	32641091	12	23	B-Intervention
versus	32641091	24	30	O
lopinavir	32641091	31	40	B-Intervention
/	32641091	41	42	I-Intervention
ritonavir	32641091	43	52	I-Intervention
in	32641091	53	55	O
mild	32641091	56	60	B-Participant
/	32641091	61	62	I-Participant
general	32641091	63	70	I-Participant
COVID-19	32641091	71	79	I-Participant
infection	32641091	80	89	I-Participant
:	32641091	90	91	O
a	32641091	92	93	O
prospective	32641091	94	105	O
,	32641091	106	107	O
open	32641091	108	112	O
-	32641091	113	114	O
label	32641091	115	120	O
,	32641091	121	122	O
multicenter	32641091	123	134	O
,	32641091	135	136	O
randomized	32641091	137	147	O
controlled	32641091	148	158	O
clinical	32641091	159	167	O
study	32641091	168	173	O
.	32641091	174	175	O

BACKGROUND	32641091	176	186	O
:	32641091	187	188	O
The	32641091	189	192	O
outbreak	32641091	193	201	O
of	32641091	202	204	O
COVID-19	32641091	205	213	O
(	32641091	214	215	O
caused	32641091	216	222	O
by	32641091	223	225	O
SARS	32641091	226	230	O
-	32641091	231	232	O
Cov-2	32641091	233	238	O
)	32641091	239	240	O
is	32641091	241	243	O
very	32641091	244	248	O
serious	32641091	249	256	O
,	32641091	257	258	O
and	32641091	259	262	O
no	32641091	263	265	O
effective	32641091	266	275	O
antiviral	32641091	276	285	O
treatment	32641091	286	295	O
has	32641091	296	299	O
yet	32641091	300	303	O
been	32641091	304	308	O
confirmed	32641091	309	318	O
.	32641091	319	320	O

The	32641091	321	324	O
adage	32641091	325	330	O
"	32641091	331	332	O
old	32641091	333	336	O
drug	32641091	337	341	O
,	32641091	342	343	O
new	32641091	344	347	O
trick	32641091	348	353	O
"	32641091	354	355	O
in	32641091	356	358	O
this	32641091	359	363	O
context	32641091	364	371	O
may	32641091	372	375	O
suggest	32641091	376	383	O
the	32641091	384	387	O
important	32641091	388	397	O
therapeutic	32641091	398	409	O
potential	32641091	410	419	O
of	32641091	420	422	O
existing	32641091	423	431	O
drugs	32641091	432	437	O
.	32641091	438	439	O

We	32641091	440	442	O
found	32641091	443	448	O
that	32641091	449	453	O
the	32641091	454	457	O
lopinavir	32641091	458	467	O
/	32641091	468	469	O
ritonavir	32641091	470	479	O
treatment	32641091	480	489	O
recommended	32641091	490	501	O
in	32641091	502	504	O
the	32641091	505	508	O
fifth	32641091	509	514	O
edition	32641091	515	522	O
of	32641091	523	525	O
the	32641091	526	529	O
Treatment	32641091	530	539	O
Plan	32641091	540	544	O
of	32641091	545	547	O
China	32641091	548	553	O
can	32641091	554	557	O
only	32641091	558	562	O
help	32641091	563	567	O
to	32641091	568	570	O
improve	32641091	571	578	O
a	32641091	579	580	O
minority	32641091	581	589	O
of	32641091	590	592	O
throat	32641091	593	599	O
-	32641091	600	601	O
swab	32641091	602	606	O
nucleic	32641091	607	614	O
-	32641091	615	616	O
acid	32641091	617	621	O
results	32641091	622	629	O
(	32641091	630	631	O
3/15	32641091	632	636	O
)	32641091	637	638	O
in	32641091	639	641	O
hospitals	32641091	642	651	O
.	32641091	652	653	O

Our	32641091	654	657	O
previous	32641091	658	666	O
use	32641091	667	670	O
of	32641091	671	673	O
chloroquine	32641091	674	685	O
to	32641091	686	688	O
treat	32641091	689	694	O
patients	32641091	695	703	O
with	32641091	704	708	O
COVID-19	32641091	709	717	O
infection	32641091	718	727	O
showed	32641091	728	734	O
an	32641091	735	737	O
improvement	32641091	738	749	O
in	32641091	750	752	O
more	32641091	753	757	O
throat	32641091	758	764	O
-	32641091	765	766	O
swab	32641091	767	771	O
nucleic	32641091	772	779	O
-	32641091	780	781	O
acid	32641091	782	786	O
results	32641091	787	794	O
(	32641091	795	796	O
5/10	32641091	797	801	O
)	32641091	802	803	O
than	32641091	804	808	O
the	32641091	809	812	O
use	32641091	813	816	O
of	32641091	817	819	O
lopinavir	32641091	820	829	O
/	32641091	830	831	O
ritonavir	32641091	832	841	O
.	32641091	842	843	O

METHODS	32641091	844	851	O
:	32641091	852	853	O
This	32641091	854	858	O
is	32641091	859	861	O
a	32641091	862	863	O
prospective	32641091	864	875	O
,	32641091	876	877	O
open	32641091	878	882	O
-	32641091	883	884	O
label	32641091	885	890	O
,	32641091	891	892	O
randomized	32641091	893	903	O
controlled	32641091	904	914	O
,	32641091	915	916	O
multicenter	32641091	917	928	O
clinical	32641091	929	937	O
study	32641091	938	943	O
.	32641091	944	945	O

The	32641091	946	949	O
study	32641091	950	955	O
consists	32641091	956	964	O
of	32641091	965	967	O
three	32641091	968	973	O
phases	32641091	974	980	O
:	32641091	981	982	O
a	32641091	983	984	O
screening	32641091	985	994	O
period	32641091	995	1001	O
,	32641091	1002	1003	O
a	32641091	1004	1005	O
treatment	32641091	1006	1015	O
period	32641091	1016	1022	O
of	32641091	1023	1025	O
no	32641091	1026	1028	O
more	32641091	1029	1033	O
than	32641091	1034	1038	O
10	32641091	1039	1041	O
days	32641091	1044	1048	O
,	32641091	1049	1050	O
and	32641091	1051	1054	O
a	32641091	1055	1056	O
follow	32641091	1057	1063	O
-	32641091	1064	1065	O
up	32641091	1066	1068	O
period	32641091	1069	1075	O
for	32641091	1076	1079	O
each	32641091	1080	1084	O
participant	32641091	1085	1096	O
.	32641091	1097	1098	O

Participants	32641091	1099	1111	O
with	32641091	1112	1116	O
COVID-19	32641091	1117	1125	B-Participant
infection	32641091	1126	1135	I-Participant
who	32641091	1136	1139	O
are	32641091	1140	1143	O
eligible	32641091	1144	1152	O
for	32641091	1153	1156	O
selection	32641091	1157	1166	O
for	32641091	1167	1170	O
the	32641091	1171	1174	O
study	32641091	1175	1180	O
will	32641091	1181	1185	O
be	32641091	1186	1188	O
randomly	32641091	1189	1197	O
allocated	32641091	1198	1207	O
to	32641091	1208	1210	O
the	32641091	1211	1214	O
trial	32641091	1215	1220	B-Intervention
group	32641091	1221	1226	O
or	32641091	1227	1229	O
the	32641091	1230	1233	O
control	32641091	1234	1241	B-Intervention
group	32641091	1242	1247	O
.	32641091	1248	1249	O

The	32641091	1250	1253	O
control	32641091	1254	1261	B-Intervention
group	32641091	1262	1267	O
will	32641091	1268	1272	O
be	32641091	1273	1275	O
given	32641091	1276	1281	O
lopinavir	32641091	1282	1291	B-Intervention
/	32641091	1292	1293	I-Intervention
ritonavir	32641091	1294	1303	I-Intervention
treatment	32641091	1304	1313	O
for	32641091	1314	1317	O
no	32641091	1318	1320	O
more	32641091	1321	1325	O
than	32641091	1326	1330	O
10	32641091	1331	1333	O
days	32641091	1336	1340	O
.	32641091	1341	1342	O

The	32641091	1343	1346	O
trial	32641091	1347	1352	B-Intervention
group	32641091	1353	1358	O
will	32641091	1359	1363	O
be	32641091	1364	1366	O
given	32641091	1367	1372	O
chloroquine	32641091	1373	1384	B-Intervention
phosphate	32641091	1385	1394	I-Intervention
treatment	32641091	1395	1404	I-Intervention
for	32641091	1405	1408	O
no	32641091	1409	1411	O
more	32641091	1412	1416	O
than	32641091	1417	1421	O
10	32641091	1422	1424	O
days	32641091	1427	1431	O
.	32641091	1432	1433	O

The	32641091	1434	1437	O
primary	32641091	1438	1445	O
outcome	32641091	1446	1453	O
is	32641091	1454	1456	O
the	32641091	1457	1460	O
clinical	32641091	1461	1469	B-Outcome
recovery	32641091	1470	1478	I-Outcome
time	32641091	1479	1483	I-Outcome
at	32641091	1484	1486	I-Outcome
no	32641091	1487	1489	I-Outcome
more	32641091	1490	1494	I-Outcome
than	32641091	1495	1499	I-Outcome
28	32641091	1500	1502	I-Outcome
days	32641091	1505	1509	I-Outcome
after	32641091	1510	1515	O
the	32641091	1516	1519	O
completion	32641091	1520	1530	O
of	32641091	1531	1533	O
therapy	32641091	1534	1541	O
and	32641091	1542	1545	O
follow	32641091	1546	1552	O
-	32641091	1553	1554	O
up	32641091	1555	1557	O
.	32641091	1558	1559	O

The	32641091	1560	1563	O
secondary	32641091	1564	1573	O
outcomes	32641091	1574	1582	O
include	32641091	1583	1590	O
the	32641091	1591	1594	O
rate	32641091	1595	1599	B-Outcome
of	32641091	1600	1602	I-Outcome
treatment	32641091	1603	1612	I-Outcome
success	32641091	1613	1620	I-Outcome
after	32641091	1621	1626	O
the	32641091	1627	1630	O
completion	32641091	1631	1641	O
of	32641091	1642	1644	O
therapy	32641091	1645	1652	O
and	32641091	1653	1656	O
follow	32641091	1657	1663	O
-	32641091	1664	1665	O
up	32641091	1666	1668	O
,	32641091	1669	1670	O
the	32641091	1671	1674	O
time	32641091	1675	1679	B-Outcome
of	32641091	1680	1682	I-Outcome
treatment	32641091	1683	1692	I-Outcome
success	32641091	1693	1700	I-Outcome
after	32641091	1701	1706	I-Outcome
no	32641091	1707	1709	I-Outcome
more	32641091	1710	1714	I-Outcome
than	32641091	1715	1719	I-Outcome
28	32641091	1720	1722	I-Outcome
days	32641091	1725	1729	I-Outcome
,	32641091	1730	1731	O
the	32641091	1732	1735	O
rate	32641091	1736	1740	B-Outcome
of	32641091	1741	1743	I-Outcome
serious	32641091	1744	1751	I-Outcome
adverse	32641091	1752	1759	I-Outcome
events	32641091	1760	1766	I-Outcome
during	32641091	1767	1773	O
the	32641091	1774	1777	O
completion	32641091	1778	1788	O
of	32641091	1789	1791	O
therapy	32641091	1792	1799	O
and	32641091	1800	1803	O
follow	32641091	1804	1810	O
-	32641091	1811	1812	O
up	32641091	1813	1815	O
,	32641091	1816	1817	O
and	32641091	1818	1821	O
the	32641091	1822	1825	O
time	32641091	1826	1830	B-Outcome
to	32641091	1831	1833	I-Outcome
return	32641091	1834	1840	I-Outcome
to	32641091	1841	1843	I-Outcome
normal	32641091	1844	1850	I-Outcome
temperature	32641091	1851	1862	I-Outcome
(	32641091	1863	1864	O
calculated	32641091	1865	1875	O
from	32641091	1876	1880	O
the	32641091	1881	1884	O
onset	32641091	1885	1890	O
of	32641091	1891	1893	O
illness	32641091	1894	1901	O
)	32641091	1902	1903	O
during	32641091	1904	1910	O
the	32641091	1911	1914	O
completion	32641091	1915	1925	O
of	32641091	1926	1928	O
therapy	32641091	1929	1936	O
and	32641091	1937	1940	O
follow	32641091	1941	1947	O
-	32641091	1948	1949	O
up	32641091	1950	1952	O
.	32641091	1953	1954	O

Intravenous	32641343	0	11	B-Intervention
high	32641343	12	16	I-Intervention
-	32641343	17	18	I-Intervention
dose	32641343	19	23	I-Intervention
vitamin	32641343	24	31	I-Intervention
C	32641343	32	33	I-Intervention
for	32641343	34	37	O
the	32641343	38	41	O
treatment	32641343	42	51	O
of	32641343	52	54	O
severe	32641343	55	61	B-Participant
COVID-19	32641343	62	70	I-Participant
:	32641343	71	72	O
study	32641343	73	78	O
protocol	32641343	79	87	O
for	32641343	88	91	O
a	32641343	92	93	O
multicentre	32641343	94	105	O
randomised	32641343	106	116	O
controlled	32641343	117	127	O
trial	32641343	128	133	O
.	32641343	134	135	O

The	32641343	136	139	O
rapid	32641343	140	145	O
worldwide	32641343	146	155	O
spread	32641343	156	162	O
of	32641343	163	165	O
COVID-19	32641343	166	174	O
has	32641343	175	178	O
caused	32641343	179	185	O
a	32641343	186	187	O
global	32641343	188	194	O
health	32641343	195	201	O
crisis	32641343	202	208	O
.	32641343	209	210	O

To	32641343	211	213	O
date	32641343	214	218	O
,	32641343	219	220	O
symptomatic	32641343	221	232	O
supportive	32641343	233	243	O
care	32641343	244	248	O
has	32641343	249	252	O
been	32641343	253	257	O
the	32641343	258	261	O
most	32641343	262	266	O
common	32641343	267	273	O
treatment	32641343	274	283	O
.	32641343	284	285	O

It	32641343	286	288	O
has	32641343	289	292	O
been	32641343	293	297	O
reported	32641343	298	306	O
that	32641343	307	311	O
the	32641343	312	315	O
mechanism	32641343	316	325	O
of	32641343	326	328	O
COVID-19	32641343	329	337	O
is	32641343	338	340	O
related	32641343	341	348	O
to	32641343	349	351	O
cytokine	32641343	352	360	O
storms	32641343	361	367	O
and	32641343	368	371	O
subsequent	32641343	372	382	O
immunogenic	32641343	383	394	O
damage	32641343	395	401	O
,	32641343	402	403	O
especially	32641343	404	414	O
damage	32641343	415	421	O
to	32641343	422	424	O
the	32641343	425	428	O
endothelium	32641343	429	440	O
and	32641343	441	444	O
alveolar	32641343	445	453	O
membrane	32641343	454	462	O
.	32641343	463	464	O

Vitamin	32641343	465	472	O
C	32641343	473	474	O
(	32641343	475	476	O
VC	32641343	477	479	O
)	32641343	480	481	O
,	32641343	482	483	O
also	32641343	484	488	O
known	32641343	489	494	O
as	32641343	495	497	O
L	32641343	498	499	O
-	32641343	500	501	O
ascorbic	32641343	502	510	O
acid	32641343	511	515	O
,	32641343	516	517	O
has	32641343	518	521	O
been	32641343	522	526	O
shown	32641343	527	532	O
to	32641343	533	535	O
have	32641343	536	540	O
antimicrobial	32641343	541	554	O
and	32641343	555	558	O
immunomodulatory	32641343	559	575	O
properties	32641343	576	586	O
.	32641343	587	588	O

A	32641343	589	590	O
high	32641343	591	595	O
dose	32641343	596	600	O
of	32641343	601	603	O
intravenous	32641343	604	615	O
VC	32641343	616	618	O
(	32641343	619	620	O
HIVC	32641343	621	625	O
)	32641343	626	627	O
was	32641343	628	631	O
proven	32641343	632	638	O
to	32641343	639	641	O
block	32641343	642	647	O
several	32641343	648	655	O
key	32641343	656	659	O
components	32641343	660	670	O
of	32641343	671	673	O
cytokine	32641343	674	682	O
storms	32641343	683	689	O
,	32641343	690	691	O
and	32641343	692	695	O
HIVC	32641343	696	700	O
showed	32641343	701	707	O
safety	32641343	708	714	O
and	32641343	715	718	O
varying	32641343	719	726	O
degrees	32641343	727	734	O
of	32641343	735	737	O
efficacy	32641343	738	746	O
in	32641343	747	749	O
clinical	32641343	750	758	O
trials	32641343	759	765	O
conducted	32641343	766	775	O
on	32641343	776	778	O
patients	32641343	779	787	O
with	32641343	788	792	O
bacterial	32641343	793	802	O
-	32641343	803	804	O
induced	32641343	805	812	O
sepsis	32641343	813	819	O
and	32641343	820	823	O
acute	32641343	824	829	O
respiratory	32641343	830	841	O
distress	32641343	842	850	O
syndrome	32641343	851	859	O
(	32641343	860	861	O
ARDS	32641343	862	866	O
)	32641343	867	868	O
.	32641343	869	870	O

Therefore	32641343	871	880	O
,	32641343	881	882	O
we	32641343	883	885	O
hypothesise	32641343	886	897	O
that	32641343	898	902	O
HIVC	32641343	903	907	B-Intervention
could	32641343	908	913	O
be	32641343	914	916	O
added	32641343	917	922	O
to	32641343	923	925	O
the	32641343	926	929	O
treatment	32641343	930	939	O
of	32641343	940	942	O
ARDS	32641343	943	947	B-Participant
and	32641343	948	951	O
multiorgan	32641343	952	962	B-Participant
dysfunction	32641343	963	974	I-Participant
related	32641343	975	982	I-Participant
to	32641343	983	985	I-Participant
COVID-19	32641343	986	994	I-Participant
.	32641343	995	996	O

The	32641343	997	1000	O
investigators	32641343	1001	1014	O
designed	32641343	1015	1023	O
a	32641343	1024	1025	O
multicentre	32641343	1026	1037	O
prospective	32641343	1038	1049	O
randomised	32641343	1050	1060	O
placebo	32641343	1061	1068	O
-	32641343	1069	1070	O
controlled	32641343	1071	1081	O
trial	32641343	1082	1087	O
that	32641343	1088	1092	O
is	32641343	1093	1095	O
planned	32641343	1096	1103	O
to	32641343	1104	1106	O
recruit	32641343	1107	1114	O
308	32641343	1115	1118	O
adults	32641343	1119	1125	B-Participant
diagnosed	32641343	1126	1135	O
with	32641343	1136	1140	O
COVID-19	32641343	1141	1149	B-Participant
and	32641343	1150	1153	O
transferred	32641343	1154	1165	O
into	32641343	1166	1170	O
the	32641343	1171	1174	O
intensive	32641343	1175	1184	B-Participant
care	32641343	1185	1189	I-Participant
unit	32641343	1190	1194	I-Participant
.	32641343	1195	1196	O

Participants	32641343	1197	1209	O
will	32641343	1210	1214	O
randomly	32641343	1215	1223	O
receive	32641343	1224	1231	O
HIVC	32641343	1232	1236	B-Intervention
diluted	32641343	1237	1244	I-Intervention
in	32641343	1245	1247	I-Intervention
sterile	32641343	1248	1255	I-Intervention
water	32641343	1256	1261	I-Intervention
or	32641343	1262	1264	O
placebo	32641343	1265	1272	B-Intervention
for	32641343	1273	1276	O
7	32641343	1277	1278	O
days	32641343	1279	1283	O
once	32641343	1284	1288	O
enrolled	32641343	1289	1297	O
.	32641343	1298	1299	O

Patients	32641343	1300	1308	O
with	32641343	1309	1313	O
a	32641343	1314	1315	O
history	32641343	1316	1323	B-Participant
of	32641343	1324	1326	I-Participant
VC	32641343	1327	1329	I-Participant
allergy	32641343	1330	1337	I-Participant
,	32641343	1338	1339	O
end	32641343	1340	1343	B-Participant
-	32641343	1344	1345	I-Participant
stage	32641343	1346	1351	I-Participant
pulmonary	32641343	1352	1361	I-Participant
disease	32641343	1362	1369	I-Participant
,	32641343	1370	1371	O
advanced	32641343	1372	1380	B-Participant
malignancy	32641343	1381	1391	I-Participant
or	32641343	1392	1394	O
glucose-6-phosphate	32641343	1395	1414	B-Participant
dehydrogenase	32641343	1415	1428	I-Participant
deficiency	32641343	1429	1439	I-Participant
will	32641343	1440	1444	O
be	32641343	1445	1447	O
excluded	32641343	1448	1456	O
.	32641343	1457	1458	O

The	32641343	1459	1462	O
primary	32641343	1463	1470	O
outcome	32641343	1471	1478	O
is	32641343	1479	1481	O
ventilation	32641343	1482	1493	B-Outcome
-	32641343	1494	1495	I-Outcome
free	32641343	1496	1500	I-Outcome
days	32641343	1501	1505	I-Outcome
within	32641343	1506	1512	I-Outcome
28	32641343	1513	1515	I-Outcome
observational	32641343	1516	1529	I-Outcome
days	32641343	1530	1534	I-Outcome
.	32641343	1535	1536	O

This	32641343	1537	1541	O
is	32641343	1542	1544	O
one	32641343	1545	1548	O
of	32641343	1549	1551	O
the	32641343	1552	1555	O
first	32641343	1556	1561	O
clinical	32641343	1562	1570	O
trials	32641343	1571	1577	O
applying	32641343	1578	1586	O
HIVC	32641343	1587	1591	B-Intervention
to	32641343	1592	1594	O
treat	32641343	1595	1600	O
COVID-19	32641343	1601	1609	B-Participant
,	32641343	1610	1611	O
and	32641343	1612	1615	O
it	32641343	1616	1618	O
will	32641343	1619	1623	O
provide	32641343	1624	1631	O
credible	32641343	1632	1640	O
efficacy	32641343	1641	1649	B-Outcome
and	32641343	1650	1653	O
safety	32641343	1654	1660	B-Outcome
data	32641343	1661	1665	O
.	32641343	1666	1667	O

We	32641343	1668	1670	O
predict	32641343	1671	1678	O
that	32641343	1679	1683	O
HIVC	32641343	1684	1688	B-Intervention
could	32641343	1689	1694	O
suppress	32641343	1695	1703	B-Observation
cytokine	32641343	1704	1712	B-Outcome
storms	32641343	1713	1719	I-Outcome
caused	32641343	1720	1726	O
by	32641343	1727	1729	O
COVID-19	32641343	1730	1738	O
,	32641343	1739	1740	O
help	32641343	1741	1745	O
improve	32641343	1746	1753	B-Observation
pulmonary	32641343	1754	1763	B-Outcome
function	32641343	1764	1772	I-Outcome
and	32641343	1773	1776	O
reduce	32641343	1777	1783	B-Observation
the	32641343	1784	1787	O
risk	32641343	1788	1792	B-Outcome
of	32641343	1793	1795	I-Outcome
ARDS	32641343	1796	1800	I-Outcome
of	32641343	1801	1803	I-Outcome
COVID-19	32641343	1804	1812	I-Outcome
.	32641343	1813	1814	O

The	32641343	1815	1818	O
study	32641343	1819	1824	O
protocol	32641343	1825	1833	O
was	32641343	1834	1837	O
approved	32641343	1838	1846	O
by	32641343	1847	1849	O
the	32641343	1850	1853	O
Ethics	32641343	1854	1860	O
Committee	32641343	1861	1870	O
of	32641343	1871	1873	O
Zhongnan	32641343	1874	1882	O
Hospital	32641343	1883	1891	O
of	32641343	1892	1894	O
Wuhan	32641343	1895	1900	O
University	32641343	1901	1911	O
(	32641343	1912	1913	O
identifiers	32641343	1914	1925	O
:	32641343	1926	1927	O
Clinical	32641343	1928	1936	O
Ethical	32641343	1937	1944	O
Approval	32641343	1945	1953	O
No	32641343	1954	1956	O
.	32641343	1957	1958	O
2020001	32641343	1959	1966	O
)	32641343	1967	1968	O
.	32641343	1969	1970	O

Findings	32641343	1971	1979	O
of	32641343	1980	1982	O
the	32641343	1983	1986	O
trial	32641343	1987	1992	O
will	32641343	1993	1997	O
be	32641343	1998	2000	O
disseminated	32641343	2001	2013	O
through	32641343	2014	2021	O
peer	32641343	2022	2026	O
-	32641343	2027	2028	O
reviewed	32641343	2029	2037	O
journals	32641343	2038	2046	O
and	32641343	2047	2050	O
scientific	32641343	2051	2061	O
conferences	32641343	2062	2073	O
.	32641343	2074	2075	O

NCT04264533	32641343	2076	2087	O
.	32641343	2088	2089	O


A	32661006	0	1	O
Randomized	32661006	2	12	O
Clinical	32661006	13	21	O
Trial	32661006	22	27	O
of	32661006	28	30	O
the	32661006	31	34	O
Efficacy	32661006	35	43	B-Outcome
and	32661006	44	47	O
Safety	32661006	48	54	B-Outcome
of	32661006	55	57	O
Interferon	32661006	58	68	B-Intervention
-1a	32661006	69	73	I-Intervention
in	32661006	74	76	O
Treatment	32661006	77	86	O
of	32661006	87	89	O
Severe	32661006	90	96	B-Participant
COVID-19	32661006	97	105	I-Participant
.	32661006	106	107	O

To	32661006	108	110	O
the	32661006	111	114	O
best	32661006	115	119	O
of	32661006	120	122	O
our	32661006	123	126	O
knowledge	32661006	127	136	O
,	32661006	137	138	O
there	32661006	139	144	O
is	32661006	145	147	O
no	32661006	148	150	O
published	32661006	151	160	O
study	32661006	161	166	O
on	32661006	167	169	O
the	32661006	170	173	O
use	32661006	174	177	O
of	32661006	178	180	O
interferon	32661006	181	191	O
-1a	32661006	192	196	O
(	32661006	197	198	O
IFN	32661006	199	202	O
-1a	32661006	203	207	O
)	32661006	208	209	O
in	32661006	210	212	O
the	32661006	213	216	O
treatment	32661006	217	226	O
of	32661006	227	229	O
severe	32661006	230	236	O
COVID-19	32661006	237	245	O
.	32661006	246	247	O

In	32661006	248	250	O
this	32661006	251	255	O
randomized	32661006	256	266	O
clinical	32661006	267	275	O
trial	32661006	276	281	O
,	32661006	282	283	O
the	32661006	284	287	O
efficacy	32661006	288	296	B-Outcome
and	32661006	297	300	O
safety	32661006	301	307	B-Outcome
of	32661006	308	310	O
IFN	32661006	311	314	B-Intervention
-1a	32661006	315	319	I-Intervention
were	32661006	320	324	O
evaluated	32661006	325	334	O
in	32661006	335	337	O
patients	32661006	338	346	O
with	32661006	347	351	O
severe	32661006	352	358	B-Participant
COVID-19	32661006	359	367	I-Participant
.	32661006	368	369	O

Forty	32661006	370	375	O
-	32661006	376	377	O
two	32661006	378	381	O
patients	32661006	382	390	O
in	32661006	391	393	O
the	32661006	394	397	O
interferon	32661006	398	408	O
group	32661006	409	414	O
received	32661006	415	423	O
IFN	32661006	424	427	B-Intervention
-1a	32661006	428	432	I-Intervention
in	32661006	433	435	I-Intervention
addition	32661006	436	444	I-Intervention
to	32661006	445	447	I-Intervention
the	32661006	448	451	I-Intervention
national	32661006	452	460	I-Intervention
protocol	32661006	461	469	I-Intervention
medications	32661006	470	481	I-Intervention
(	32661006	482	483	O
hydroxychloroquine	32661006	484	502	O
plus	32661006	503	507	O
lopinavir	32661006	508	517	O
-	32661006	518	519	O
ritonavir	32661006	520	529	O
or	32661006	530	532	O
atazanavir	32661006	533	543	O
-	32661006	544	545	O
ritonavir	32661006	546	555	O
)	32661006	556	557	O
.	32661006	558	559	O

Each	32661006	560	564	O
44-g	32661006	565	570	O
/	32661006	571	572	O
ml	32661006	573	575	O
(	32661006	576	577	O
12	32661006	578	580	O
million	32661006	581	588	O
IU	32661006	589	591	O
/	32661006	592	593	O
ml	32661006	594	596	O
)	32661006	597	598	O
dose	32661006	599	603	O
of	32661006	604	606	O
interferon	32661006	607	617	O
-1a	32661006	618	622	O
was	32661006	623	626	O
subcutaneously	32661006	627	641	O
injected	32661006	642	650	O
three	32661006	651	656	O
times	32661006	657	662	O
weekly	32661006	663	669	O
for	32661006	670	673	O
two	32661006	674	677	O
consecutive	32661006	678	689	O
weeks	32661006	690	695	O
.	32661006	696	697	O

The	32661006	698	701	O
control	32661006	702	709	O
group	32661006	710	715	O
consisted	32661006	716	725	O
of	32661006	726	728	O
39	32661006	729	731	O
patients	32661006	732	740	O
who	32661006	741	744	O
received	32661006	745	753	O
only	32661006	754	758	O
the	32661006	759	762	O
national	32661006	763	771	B-Intervention
protocol	32661006	772	780	I-Intervention
medications	32661006	781	792	I-Intervention
.	32661006	793	794	O

The	32661006	795	798	O
primary	32661006	799	806	O
outcome	32661006	807	814	O
of	32661006	815	817	O
the	32661006	818	821	O
study	32661006	822	827	O
was	32661006	828	831	O
time	32661006	832	836	B-Outcome
to	32661006	837	839	I-Outcome
reach	32661006	840	845	I-Outcome
clinical	32661006	846	854	I-Outcome
response	32661006	855	863	I-Outcome
.	32661006	864	865	O

Secondary	32661006	866	875	O
outcomes	32661006	876	884	O
were	32661006	885	889	O
duration	32661006	890	898	B-Outcome
of	32661006	899	901	I-Outcome
hospital	32661006	902	910	I-Outcome
stay	32661006	911	915	I-Outcome
,	32661006	916	917	O
length	32661006	918	924	B-Outcome
of	32661006	925	927	I-Outcome
intensive	32661006	928	937	I-Outcome
care	32661006	938	942	I-Outcome
unit	32661006	943	947	I-Outcome
stay	32661006	948	952	I-Outcome
,	32661006	953	954	O
28-day	32661006	955	961	B-Outcome
mortality	32661006	962	971	I-Outcome
,	32661006	972	973	O
effect	32661006	974	980	B-Outcome
of	32661006	981	983	I-Outcome
early	32661006	984	989	I-Outcome
or	32661006	990	992	I-Outcome
late	32661006	993	997	I-Outcome
administration	32661006	998	1012	I-Outcome
of	32661006	1013	1015	I-Outcome
IFN	32661006	1016	1019	I-Outcome
on	32661006	1020	1022	I-Outcome
mortality	32661006	1023	1032	I-Outcome
,	32661006	1033	1034	O
adverse	32661006	1035	1042	B-Outcome
effects	32661006	1043	1050	I-Outcome
,	32661006	1051	1052	O
and	32661006	1053	1056	O
complications	32661006	1057	1070	B-Outcome
during	32661006	1071	1077	I-Outcome
the	32661006	1078	1081	I-Outcome
hospitalization	32661006	1082	1097	I-Outcome
.	32661006	1098	1099	O

Between	32661006	1100	1107	O
29	32661006	1108	1110	O
February	32661006	1111	1119	O
and	32661006	1120	1123	O
3	32661006	1124	1125	O
April	32661006	1126	1131	O
2020	32661006	1132	1136	O
,	32661006	1137	1138	O
92	32661006	1139	1141	O
patients	32661006	1142	1150	O
were	32661006	1151	1155	O
recruited	32661006	1156	1165	O
,	32661006	1166	1167	O
and	32661006	1168	1171	O
a	32661006	1172	1173	O
total	32661006	1174	1179	O
of	32661006	1180	1182	O
42	32661006	1183	1185	O
patients	32661006	1186	1194	O
in	32661006	1195	1197	O
the	32661006	1198	1201	O
IFN	32661006	1202	1205	O
group	32661006	1206	1211	O
and	32661006	1212	1215	O
39	32661006	1216	1218	O
patients	32661006	1219	1227	O
in	32661006	1228	1230	O
the	32661006	1231	1234	O
control	32661006	1235	1242	O
group	32661006	1243	1248	O
completed	32661006	1249	1258	O
the	32661006	1259	1262	O
study	32661006	1263	1268	O
.	32661006	1269	1270	O

As	32661006	1271	1273	O
the	32661006	1274	1277	O
primary	32661006	1278	1285	O
outcome	32661006	1286	1293	O
,	32661006	1294	1295	O
time	32661006	1296	1300	B-Outcome
to	32661006	1301	1303	I-Outcome
the	32661006	1304	1307	I-Outcome
clinical	32661006	1308	1316	I-Outcome
response	32661006	1317	1325	I-Outcome
was	32661006	1326	1329	O
not	32661006	1330	1333	O
significantly	32661006	1334	1347	B-Observation
different	32661006	1348	1357	I-Observation
between	32661006	1358	1365	O
the	32661006	1366	1369	O
IFN	32661006	1370	1373	B-Intervention
and	32661006	1374	1377	O
the	32661006	1378	1381	O
control	32661006	1382	1389	B-Intervention
groups	32661006	1390	1396	O
(	32661006	1397	1398	O
9.7	32661006	1399	1402	B-Observation
	32661006	1405	1406	I-Observation
5.8	32661006	1409	1412	I-Observation
versus	32661006	1413	1419	O
8.3	32661006	1420	1423	B-Observation
	32661006	1426	1427	I-Observation
4.9	32661006	1430	1433	I-Observation
days	32661006	1436	1440	I-Observation
,	32661006	1441	1442	O
respectively	32661006	1443	1455	O
,	32661006	1456	1457	O
P	32661006	1458	1459	O
=	32661006	1462	1463	O
0.95	32661006	1466	1470	O
)	32661006	1471	1472	O
.	32661006	1473	1474	O

On	32661006	1475	1477	O
day	32661006	1478	1481	O
14	32661006	1482	1484	O
,	32661006	1485	1486	O
66.7	32661006	1487	1491	B-Count
%	32661006	1492	1493	I-Count
versus	32661006	1494	1500	O
43.6	32661006	1501	1505	B-Count
%	32661006	1506	1507	I-Count
of	32661006	1508	1510	I-Count
patients	32661006	1511	1519	I-Count
in	32661006	1520	1522	O
the	32661006	1523	1526	O
IFN	32661006	1527	1530	B-Intervention
group	32661006	1531	1536	O
and	32661006	1537	1540	O
the	32661006	1541	1544	O
control	32661006	1545	1552	B-Intervention
group	32661006	1553	1558	O
,	32661006	1559	1560	O
respectively	32661006	1561	1573	O
,	32661006	1574	1575	O
were	32661006	1576	1580	O
discharged	32661006	1581	1591	B-Outcome
(	32661006	1592	1593	O
odds	32661006	1594	1598	O
ratio	32661006	1599	1604	O
[	32661006	1605	1606	O
OR	32661006	1607	1609	O
]	32661006	1610	1611	O
,	32661006	1612	1613	O
2.5	32661006	1614	1617	O
;	32661006	1618	1619	O
95	32661006	1620	1622	O
%	32661006	1623	1624	O
confidence	32661006	1625	1635	O
interval	32661006	1636	1644	O
[	32661006	1645	1646	O
CI	32661006	1647	1649	O
]	32661006	1650	1651	O
,	32661006	1652	1653	O
1.05	32661006	1654	1658	O
to	32661006	1659	1661	O
6.37	32661006	1662	1666	O
)	32661006	1667	1668	O
.	32661006	1669	1670	O

The	32661006	1671	1674	O
28-day	32661006	1675	1681	B-Outcome
overall	32661006	1682	1689	I-Outcome
mortality	32661006	1690	1699	I-Outcome
was	32661006	1700	1703	O
significantly	32661006	1704	1717	B-Observation
lower	32661006	1718	1723	I-Observation
in	32661006	1724	1726	O
the	32661006	1727	1730	O
IFN	32661006	1731	1734	B-Intervention
than	32661006	1735	1739	O
the	32661006	1740	1743	O
control	32661006	1744	1751	B-Intervention
group	32661006	1752	1757	O
(	32661006	1758	1759	O
19	32661006	1760	1762	B-Observation
%	32661006	1763	1764	I-Observation
versus	32661006	1765	1771	O
43.6	32661006	1772	1776	B-Observation
%	32661006	1777	1778	I-Observation
,	32661006	1779	1780	O
respectively	32661006	1781	1793	O
,	32661006	1794	1795	O
P	32661006	1796	1797	O
=	32661006	1798	1799	O
0.015	32661006	1800	1805	O
)	32661006	1806	1807	O
.	32661006	1808	1809	O

Early	32661006	1810	1815	B-Intervention
administration	32661006	1816	1830	I-Intervention
significantly	32661006	1831	1844	B-Observation
reduced	32661006	1845	1852	I-Observation
mortality	32661006	1853	1862	B-Outcome
(	32661006	1863	1864	O
OR	32661006	1865	1867	O
,	32661006	1868	1869	O
13.5	32661006	1872	1876	O
;	32661006	1877	1878	O
95	32661006	1879	1881	O
%	32661006	1882	1883	O
CI	32661006	1884	1886	O
,	32661006	1887	1888	O
1.5	32661006	1889	1892	O
to	32661006	1893	1895	O
118	32661006	1896	1899	O
)	32661006	1900	1901	O
.	32661006	1902	1903	O

Although	32661006	1904	1912	O
IFN	32661006	1913	1916	B-Intervention
did	32661006	1917	1920	O
not	32661006	1921	1924	O
change	32661006	1925	1931	B-Observation
the	32661006	1932	1935	O
time	32661006	1936	1940	B-Outcome
to	32661006	1941	1943	I-Outcome
reach	32661006	1944	1949	I-Outcome
the	32661006	1950	1953	I-Outcome
clinical	32661006	1954	1962	I-Outcome
response	32661006	1963	1971	I-Outcome
,	32661006	1972	1973	O
adding	32661006	1974	1980	B-Intervention
it	32661006	1981	1983	I-Intervention
to	32661006	1984	1986	I-Intervention
the	32661006	1987	1990	I-Intervention
national	32661006	1991	1999	I-Intervention
protocol	32661006	2000	2008	I-Intervention
significantly	32661006	2009	2022	B-Observation
increased	32661006	2023	2032	I-Observation
discharge	32661006	2033	2042	B-Outcome
rate	32661006	2043	2047	I-Outcome
on	32661006	2048	2050	I-Outcome
day	32661006	2051	2054	I-Outcome
14	32661006	2055	2057	I-Outcome
and	32661006	2058	2061	O
decreased	32661006	2062	2071	B-Observation
28-day	32661006	2072	2078	B-Outcome
mortality	32661006	2079	2088	I-Outcome
.	32661006	2089	2090	O

(	32661006	2091	2092	O
This	32661006	2093	2097	O
study	32661006	2098	2103	O
is	32661006	2104	2106	O
in	32661006	2107	2109	O
the	32661006	2110	2113	O
Iranian	32661006	2114	2121	O
Registry	32661006	2122	2130	O
of	32661006	2131	2133	O
Clinical	32661006	2134	2142	O
Trials	32661006	2143	2149	O
under	32661006	2150	2155	O
identifier	32661006	2156	2166	O
IRCT20100228003449N28	32661006	2167	2188	O
.	32661006	2189	2190	O
)	32661006	2191	2192	O
.	32661006	2193	2194	O


Hydroxychloroquine	32673060	0	18	B-Intervention
in	32673060	19	21	O
Nonhospitalized	32673060	22	37	B-Participant
Adults	32673060	38	44	B-Participant
With	32673060	45	49	O
Early	32673060	50	55	B-Participant
COVID-19	32673060	56	64	I-Participant
:	32673060	65	66	O
A	32673060	67	68	O
Randomized	32673060	69	79	O
Trial	32673060	80	85	O
.	32673060	86	87	O

No	32673060	88	90	O
effective	32673060	91	100	O
oral	32673060	101	105	O
therapy	32673060	106	113	O
exists	32673060	114	120	O
for	32673060	121	124	O
early	32673060	125	130	O
coronavirus	32673060	131	142	O
disease	32673060	143	150	O
2019	32673060	151	155	O
(	32673060	156	157	O
COVID-19	32673060	158	166	O
)	32673060	167	168	O
.	32673060	169	170	O

To	32673060	171	173	O
investigate	32673060	174	185	O
whether	32673060	186	193	O
hydroxychloroquine	32673060	194	212	B-Intervention
could	32673060	213	218	O
reduce	32673060	219	225	B-Observation
COVID-19	32673060	226	234	B-Outcome
severity	32673060	235	243	I-Outcome
in	32673060	244	246	O
adult	32673060	247	252	B-Participant
outpatients	32673060	253	264	B-Participant
.	32673060	265	266	O

Randomized	32673060	267	277	O
,	32673060	278	279	O
double	32673060	280	286	O
-	32673060	287	288	O
blind	32673060	289	294	O
,	32673060	295	296	O
placebo	32673060	297	304	O
-	32673060	305	306	O
controlled	32673060	307	317	O
trial	32673060	318	323	O
conducted	32673060	324	333	O
from	32673060	334	338	O
22	32673060	339	341	O
March	32673060	342	347	O
through	32673060	348	355	O
20	32673060	356	358	O
May	32673060	359	362	O
2020	32673060	363	367	O
.	32673060	368	369	O
(	32673060	370	371	O
ClinicalTrials.gov	32673060	372	390	O
:	32673060	391	392	O
NCT04308668	32673060	393	404	O
)	32673060	405	406	O
.	32673060	407	408	O

Internet	32673060	409	417	O
-	32673060	418	419	O
based	32673060	420	425	O
trial	32673060	426	431	O
across	32673060	432	438	O
the	32673060	439	442	O
United	32673060	443	449	O
States	32673060	450	456	O
and	32673060	457	460	O
Canada	32673060	461	467	O
(	32673060	468	469	O
40	32673060	470	472	O
states	32673060	473	479	O
and	32673060	480	483	O
3	32673060	484	485	O
provinces	32673060	486	495	O
)	32673060	496	497	O
.	32673060	498	499	O

Symptomatic	32673060	500	511	B-Participant
,	32673060	512	513	O
nonhospitalized	32673060	514	529	B-Participant
adults	32673060	530	536	B-Participant
with	32673060	537	541	O
laboratory	32673060	542	552	B-Participant
-	32673060	553	554	I-Participant
confirmed	32673060	555	564	I-Participant
COVID-19	32673060	565	573	I-Participant
or	32673060	574	576	O
probable	32673060	577	585	B-Participant
COVID-19	32673060	586	594	I-Participant
and	32673060	595	598	O
high	32673060	599	603	B-Participant
-	32673060	604	605	I-Participant
risk	32673060	606	610	I-Participant
exposure	32673060	611	619	I-Participant
within	32673060	620	626	I-Participant
4	32673060	627	628	I-Participant
days	32673060	629	633	I-Participant
of	32673060	634	636	I-Participant
symptom	32673060	637	644	I-Participant
onset	32673060	645	650	I-Participant
.	32673060	651	652	O

Oral	32673060	653	657	B-Intervention
hydroxychloroquine	32673060	658	676	I-Intervention
(	32673060	677	678	O
800	32673060	679	682	O
mg	32673060	683	685	O
once	32673060	686	690	O
,	32673060	691	692	O
followed	32673060	693	701	O
by	32673060	702	704	O
600	32673060	705	708	O
mg	32673060	709	711	O
in	32673060	712	714	O
6	32673060	715	716	O
to	32673060	717	719	O
8	32673060	720	721	O
hours	32673060	722	727	O
,	32673060	728	729	O
then	32673060	730	734	O
600	32673060	735	738	O
mg	32673060	739	741	O
daily	32673060	742	747	O
for	32673060	748	751	O
4	32673060	752	753	O
more	32673060	754	758	O
days	32673060	759	763	O
)	32673060	764	765	O
or	32673060	766	768	O
masked	32673060	769	775	B-Intervention
placebo	32673060	776	783	I-Intervention
.	32673060	784	785	O

Symptoms	32673060	786	794	B-Outcome
and	32673060	795	798	O
severity	32673060	799	807	B-Outcome
at	32673060	808	810	O
baseline	32673060	811	819	O
and	32673060	820	823	O
then	32673060	824	828	O
at	32673060	829	831	O
days	32673060	832	836	O
3	32673060	837	838	O
,	32673060	839	840	O
5	32673060	841	842	O
,	32673060	843	844	O
10	32673060	845	847	O
,	32673060	848	849	O
and	32673060	850	853	O
14	32673060	854	856	O
using	32673060	857	862	O
a	32673060	863	864	O
10-point	32673060	865	873	O
visual	32673060	874	880	O
analogue	32673060	881	889	O
scale	32673060	890	895	O
.	32673060	896	897	O

The	32673060	898	901	O
primary	32673060	902	909	O
end	32673060	910	913	O
point	32673060	914	919	O
was	32673060	920	923	O
change	32673060	924	930	B-Outcome
in	32673060	931	933	I-Outcome
overall	32673060	934	941	I-Outcome
symptom	32673060	942	949	I-Outcome
severity	32673060	950	958	I-Outcome
over	32673060	959	963	I-Outcome
14	32673060	964	966	I-Outcome
days	32673060	967	971	I-Outcome
.	32673060	972	973	O

Of	32673060	974	976	O
491	32673060	977	980	O
patients	32673060	981	989	O
randomly	32673060	990	998	O
assigned	32673060	999	1007	O
to	32673060	1008	1010	O
a	32673060	1011	1012	O
group	32673060	1013	1018	O
,	32673060	1019	1020	O
423	32673060	1021	1024	O
contributed	32673060	1025	1036	O
primary	32673060	1037	1044	O
end	32673060	1045	1048	O
point	32673060	1049	1054	O
data	32673060	1055	1059	O
.	32673060	1060	1061	O

Of	32673060	1062	1064	O
these	32673060	1065	1070	O
,	32673060	1071	1072	O
341	32673060	1073	1076	O
(	32673060	1077	1078	O
81	32673060	1079	1081	O
%	32673060	1082	1083	O
)	32673060	1084	1085	O
had	32673060	1086	1089	O
laboratory	32673060	1090	1100	O
-	32673060	1101	1102	O
confirmed	32673060	1103	1112	O
infection	32673060	1113	1122	O
with	32673060	1123	1127	O
severe	32673060	1128	1134	O
acute	32673060	1135	1140	O
respiratory	32673060	1141	1152	O
syndrome	32673060	1153	1161	O
coronavirus	32673060	1162	1173	O
2	32673060	1174	1175	O
(	32673060	1176	1177	O
SARS	32673060	1178	1182	O
-	32673060	1183	1184	O
CoV-2	32673060	1185	1190	O
)	32673060	1191	1192	O
or	32673060	1193	1195	O
epidemiologically	32673060	1196	1213	O
linked	32673060	1214	1220	O
exposure	32673060	1221	1229	O
to	32673060	1230	1232	O
a	32673060	1233	1234	O
person	32673060	1235	1241	O
with	32673060	1242	1246	O
laboratory	32673060	1247	1257	O
-	32673060	1258	1259	O
confirmed	32673060	1260	1269	O
infection	32673060	1270	1279	O
;	32673060	1280	1281	O
56	32673060	1282	1284	O
%	32673060	1285	1286	O
(	32673060	1287	1288	O
236	32673060	1289	1292	O
of	32673060	1293	1295	O
423	32673060	1296	1299	O
)	32673060	1300	1301	O
were	32673060	1302	1306	O
enrolled	32673060	1307	1315	O
within	32673060	1316	1322	O
1	32673060	1323	1324	O
day	32673060	1325	1328	O
of	32673060	1329	1331	O
symptoms	32673060	1332	1340	O
starting	32673060	1341	1349	O
.	32673060	1350	1351	O

Change	32673060	1352	1358	B-Outcome
in	32673060	1359	1361	I-Outcome
symptom	32673060	1362	1369	I-Outcome
severity	32673060	1370	1378	I-Outcome
over	32673060	1379	1383	I-Outcome
14	32673060	1384	1386	I-Outcome
days	32673060	1387	1391	I-Outcome
did	32673060	1392	1395	O
not	32673060	1396	1399	O
differ	32673060	1400	1406	B-Observation
between	32673060	1407	1414	O
the	32673060	1415	1418	O
hydroxychloroquine	32673060	1419	1437	B-Intervention
and	32673060	1438	1441	O
placebo	32673060	1442	1449	B-Intervention
groups	32673060	1450	1456	O
(	32673060	1457	1458	O
difference	32673060	1459	1469	B-Outcome
in	32673060	1470	1472	I-Outcome
symptom	32673060	1473	1480	I-Outcome
severity	32673060	1481	1489	I-Outcome
:	32673060	1490	1491	O
relative	32673060	1492	1500	B-Observation
,	32673060	1501	1502	I-Observation
12	32673060	1503	1505	I-Observation
%	32673060	1506	1507	I-Observation
;	32673060	1508	1509	O
absolute	32673060	1510	1518	B-Observation
,	32673060	1519	1520	I-Observation
-0.27	32673060	1521	1526	I-Observation
point	32673060	1527	1532	I-Observation
[	32673060	1533	1534	O
95	32673060	1535	1537	O
%	32673060	1538	1539	O
CI	32673060	1540	1542	O
,	32673060	1543	1544	O
-0.61	32673060	1545	1550	O
to	32673060	1551	1553	O
0.07	32673060	1554	1558	O
point	32673060	1559	1564	O
]	32673060	1565	1566	O
;	32673060	1567	1568	O
P	32673060	1569	1570	O
=	32673060	1573	1574	O
0.117	32673060	1575	1580	O
)	32673060	1581	1582	O
.	32673060	1583	1584	O

At	32673060	1585	1587	O
14	32673060	1588	1590	O
days	32673060	1591	1595	O
,	32673060	1596	1597	O
24	32673060	1598	1600	B-Count
%	32673060	1601	1602	I-Count
(	32673060	1603	1604	I-Count
49	32673060	1605	1607	I-Count
of	32673060	1608	1610	I-Count
201	32673060	1611	1614	I-Count
)	32673060	1615	1616	I-Count
of	32673060	1617	1619	I-Count
participants	32673060	1620	1632	I-Count
receiving	32673060	1633	1642	O
hydroxychloroquine	32673060	1643	1661	B-Intervention
had	32673060	1662	1665	O
ongoing	32673060	1666	1673	B-Outcome
symptoms	32673060	1674	1682	I-Outcome
compared	32673060	1683	1691	O
with	32673060	1692	1696	O
30	32673060	1697	1699	B-Count
%	32673060	1700	1701	I-Count
(	32673060	1702	1703	I-Count
59	32673060	1704	1706	I-Count
of	32673060	1707	1709	I-Count
194	32673060	1710	1713	I-Count
)	32673060	1714	1715	I-Count
receiving	32673060	1716	1725	O
placebo	32673060	1726	1733	B-Intervention
(	32673060	1734	1735	O
P	32673060	1736	1737	O
=	32673060	1740	1741	O
0.21	32673060	1742	1746	O
)	32673060	1747	1748	O
.	32673060	1749	1750	O

Medication	32673060	1751	1761	B-Outcome
adverse	32673060	1762	1769	I-Outcome
effects	32673060	1770	1777	I-Outcome
occurred	32673060	1778	1786	O
in	32673060	1787	1789	O
43	32673060	1790	1792	B-Count
%	32673060	1793	1794	I-Count
(	32673060	1795	1796	I-Count
92	32673060	1797	1799	I-Count
of	32673060	1800	1802	I-Count
212	32673060	1803	1806	I-Count
)	32673060	1807	1808	I-Count
of	32673060	1809	1811	I-Count
participants	32673060	1812	1824	I-Count
receiving	32673060	1825	1834	O
hydroxychloroquine	32673060	1835	1853	B-Intervention
versus	32673060	1854	1860	O
22	32673060	1861	1863	B-Count
%	32673060	1864	1865	I-Count
(	32673060	1866	1867	I-Count
46	32673060	1868	1870	I-Count
of	32673060	1871	1873	I-Count
211	32673060	1874	1877	I-Count
)	32673060	1878	1879	I-Count
receiving	32673060	1880	1889	O
placebo	32673060	1890	1897	B-Intervention
(	32673060	1898	1899	O
P	32673060	1900	1901	O
<	32673060	1904	1905	O
0.001	32673060	1906	1911	O
)	32673060	1912	1913	O
.	32673060	1914	1915	O

With	32673060	1916	1920	O
placebo	32673060	1921	1928	B-Intervention
,	32673060	1929	1930	O
10	32673060	1931	1933	B-Count
hospitalizations	32673060	1934	1950	B-Outcome
occurred	32673060	1951	1959	O
(	32673060	1960	1961	O
2	32673060	1962	1963	B-Count
non	32673060	1964	1967	B-Outcome
-	32673060	1968	1969	I-Outcome
COVID-19-related	32673060	1970	1986	I-Outcome
)	32673060	1987	1988	O
,	32673060	1989	1990	O
including	32673060	1991	2000	O
1	32673060	2001	2002	B-Count
hospitalized	32673060	2003	2015	B-Outcome
death	32673060	2016	2021	I-Outcome
.	32673060	2022	2023	O

With	32673060	2024	2028	O
hydroxychloroquine	32673060	2029	2047	B-Intervention
,	32673060	2048	2049	O
4	32673060	2050	2051	B-Count
hospitalizations	32673060	2052	2068	B-Outcome
occurred	32673060	2069	2077	O
plus	32673060	2078	2082	O
1	32673060	2083	2084	B-Count
nonhospitalized	32673060	2085	2100	B-Outcome
death	32673060	2101	2106	I-Outcome
(	32673060	2107	2108	O
P	32673060	2109	2110	O
=	32673060	2113	2114	O
0.29	32673060	2115	2119	O
)	32673060	2120	2121	O
.	32673060	2122	2123	O

Only	32673060	2124	2128	O
58	32673060	2129	2131	B-Count
%	32673060	2132	2133	I-Count
of	32673060	2134	2136	I-Count
participants	32673060	2137	2149	I-Count
received	32673060	2150	2158	O
SARS	32673060	2159	2163	B-Outcome
-	32673060	2164	2165	I-Outcome
CoV-2	32673060	2166	2171	I-Outcome
testing	32673060	2172	2179	I-Outcome
because	32673060	2180	2187	O
of	32673060	2188	2190	O
severe	32673060	2191	2197	O
U.S.	32673060	2198	2202	O
testing	32673060	2203	2210	O
shortages	32673060	2211	2220	O
.	32673060	2221	2222	O

Hydroxychloroquine	32673060	2223	2241	B-Intervention
did	32673060	2242	2245	O
not	32673060	2246	2249	O
substantially	32673060	2250	2263	B-Observation
reduce	32673060	2264	2270	I-Observation
symptom	32673060	2271	2278	B-Outcome
severity	32673060	2279	2287	I-Outcome
in	32673060	2288	2290	O
outpatients	32673060	2291	2302	B-Participant
with	32673060	2303	2307	O
early	32673060	2308	2313	B-Participant
,	32673060	2314	2315	I-Participant
mild	32673060	2316	2320	I-Participant
COVID-19	32673060	2321	2329	I-Participant
.	32673060	2330	2331	O

Private	32673060	2332	2339	O
donors	32673060	2340	2346	O
.	32673060	2347	2348	O


Exploring	32676976	0	9	O
an	32676976	10	12	O
Integrative	32676976	13	24	B-Intervention
Therapy	32676976	25	32	I-Intervention
for	32676976	33	36	O
Treating	32676976	37	45	O
COVID-19	32676976	46	54	B-Participant
:	32676976	55	56	O
A	32676976	57	58	O
Randomized	32676976	59	69	O
Controlled	32676976	70	80	O
Trial	32676976	81	86	O
.	32676976	87	88	O

OBJECTIVE	32676976	89	98	O
:	32676976	99	100	O
To	32676976	101	103	O
develop	32676976	104	111	O
a	32676976	112	113	O
new	32676976	114	117	O
Chinese	32676976	118	125	B-Intervention
medicine	32676976	126	134	I-Intervention
(	32676976	135	136	I-Intervention
CM)-based	32676976	137	146	I-Intervention
drug	32676976	147	151	I-Intervention
and	32676976	152	155	O
to	32676976	156	158	O
evaluate	32676976	159	167	O
its	32676976	168	171	O
safety	32676976	172	178	B-Outcome
and	32676976	179	182	O
effect	32676976	183	189	B-Outcome
for	32676976	190	193	O
suppressing	32676976	194	205	B-Observation
acute	32676976	206	211	B-Outcome
respiratory	32676976	212	223	I-Outcome
distress	32676976	224	232	I-Outcome
syndrome	32676976	233	241	I-Outcome
(	32676976	242	243	I-Outcome
ARDS	32676976	244	248	I-Outcome
)	32676976	249	250	I-Outcome
in	32676976	251	253	O
COVID-19	32676976	254	262	B-Participant
patients	32676976	263	271	O
.	32676976	272	273	O

METHODS	32676976	274	281	O
:	32676976	282	283	O
A	32676976	284	285	O
putative	32676976	286	294	O
ARDS	32676976	295	299	O
-	32676976	300	301	O
suppressing	32676976	302	313	O
drug	32676976	314	318	O
Keguan-1	32676976	319	327	B-Intervention
was	32676976	328	331	O
first	32676976	332	337	O
developed	32676976	338	347	O
and	32676976	348	351	O
then	32676976	352	356	O
evaluated	32676976	357	366	O
by	32676976	367	369	O
a	32676976	370	371	O
randomized	32676976	372	382	O
,	32676976	383	384	O
controlled	32676976	385	395	O
two	32676976	396	399	O
-	32676976	400	401	O
arm	32676976	402	405	O
trial	32676976	406	411	O
.	32676976	412	413	O

The	32676976	414	417	O
two	32676976	418	421	O
arms	32676976	422	426	O
of	32676976	427	429	O
the	32676976	430	433	O
trial	32676976	434	439	O
consist	32676976	440	447	O
of	32676976	448	450	O
a	32676976	451	452	O
control	32676976	453	460	B-Intervention
therapy	32676976	461	468	I-Intervention
(	32676976	469	470	O
alpha	32676976	471	476	B-Intervention
interferon	32676976	477	487	I-Intervention
inhalation	32676976	488	498	I-Intervention
,	32676976	499	500	O
50	32676976	501	503	O
g	32676976	504	506	O
twice	32676976	507	512	O
daily	32676976	513	518	O
;	32676976	519	520	O
and	32676976	521	524	O
lopinavir	32676976	525	534	O
/	32676976	535	536	O
ritonavir	32676976	537	546	O
,	32676976	547	548	O
400	32676976	549	552	O
and	32676976	553	556	O
100	32676976	557	560	O
mg	32676976	561	563	O
twice	32676976	564	569	O
daily	32676976	570	575	O
,	32676976	576	577	O
respectively	32676976	578	590	O
)	32676976	591	592	O
and	32676976	593	596	O
a	32676976	597	598	O
testing	32676976	599	606	B-Intervention
therapy	32676976	607	614	I-Intervention
(	32676976	615	616	O
control	32676976	617	624	B-Intervention
therapy	32676976	625	632	I-Intervention
plus	32676976	633	637	I-Intervention
Keguan-1	32676976	638	646	I-Intervention
19.4	32676976	647	651	O
g	32676976	652	653	O
twice	32676976	654	659	O
daily	32676976	660	665	O
)	32676976	666	667	O
by	32676976	668	670	O
random	32676976	671	677	O
number	32676976	678	684	O
table	32676976	685	690	O
at	32676976	691	693	O
1:1	32676976	694	697	O
ratio	32676976	698	703	O
with	32676976	704	708	O
24	32676976	709	711	O
cases	32676976	712	717	O
each	32676976	718	722	O
group	32676976	723	728	O
.	32676976	729	730	O

After	32676976	731	736	O
2-week	32676976	737	743	O
treatment	32676976	744	753	O
,	32676976	754	755	O
adverse	32676976	756	763	B-Outcome
events	32676976	764	770	I-Outcome
,	32676976	771	772	O
time	32676976	773	777	B-Outcome
to	32676976	778	780	I-Outcome
fever	32676976	781	786	I-Outcome
resolution	32676976	787	797	I-Outcome
,	32676976	798	799	O
ARDS	32676976	800	804	B-Outcome
development	32676976	805	816	I-Outcome
,	32676976	817	818	O
and	32676976	819	822	O
lung	32676976	823	827	B-Outcome
injury	32676976	828	834	I-Outcome
on	32676976	835	837	O
newly	32676976	838	843	B-Participant
diagnosed	32676976	844	853	I-Participant
COVID-19	32676976	854	862	I-Participant
patients	32676976	863	871	O
were	32676976	872	876	O
assessed	32676976	877	885	O
.	32676976	886	887	O

RESULTS	32676976	888	895	O
:	32676976	896	897	O
An	32676976	898	900	O
analysis	32676976	901	909	O
of	32676976	910	912	O
the	32676976	913	916	O
data	32676976	917	921	O
from	32676976	922	926	O
the	32676976	927	930	O
first	32676976	931	936	O
30	32676976	937	939	O
participants	32676976	940	952	O
showed	32676976	953	959	O
that	32676976	960	964	O
the	32676976	965	968	O
control	32676976	969	976	B-Intervention
arm	32676976	977	980	O
and	32676976	981	984	O
the	32676976	985	988	O
testing	32676976	989	996	B-Intervention
arm	32676976	997	1000	O
did	32676976	1001	1004	O
not	32676976	1005	1008	O
exhibit	32676976	1009	1016	O
any	32676976	1017	1020	O
significant	32676976	1021	1032	B-Observation
differences	32676976	1033	1044	I-Observation
in	32676976	1045	1047	O
terms	32676976	1048	1053	O
of	32676976	1054	1056	O
adverse	32676976	1057	1064	B-Outcome
events	32676976	1065	1071	I-Outcome
.	32676976	1072	1073	O

Based	32676976	1074	1079	O
on	32676976	1080	1082	O
this	32676976	1083	1087	O
result	32676976	1088	1094	O
,	32676976	1095	1096	O
the	32676976	1097	1100	O
study	32676976	1101	1106	O
was	32676976	1107	1110	O
expanded	32676976	1111	1119	O
to	32676976	1120	1122	O
include	32676976	1123	1130	O
a	32676976	1131	1132	O
total	32676976	1133	1138	O
of	32676976	1139	1141	O
48	32676976	1142	1144	O
participants	32676976	1145	1157	O
(	32676976	1158	1159	O
24	32676976	1160	1162	O
cases	32676976	1163	1168	O
each	32676976	1169	1173	O
arm	32676976	1174	1177	O
)	32676976	1178	1179	O
.	32676976	1180	1181	O

The	32676976	1182	1185	O
results	32676976	1186	1193	O
show	32676976	1194	1198	O
that	32676976	1199	1203	O
compared	32676976	1204	1212	O
with	32676976	1213	1217	O
the	32676976	1218	1221	O
control	32676976	1222	1229	B-Intervention
arm	32676976	1230	1233	O
,	32676976	1234	1235	O
the	32676976	1236	1239	O
testing	32676976	1240	1247	B-Intervention
arm	32676976	1248	1251	O
exhibited	32676976	1252	1261	O
a	32676976	1262	1263	O
significant	32676976	1264	1275	B-Observation
improvement	32676976	1276	1287	I-Observation
in	32676976	1288	1290	O
time	32676976	1291	1295	B-Outcome
to	32676976	1296	1298	I-Outcome
fever	32676976	1299	1304	I-Outcome
resolution	32676976	1305	1315	I-Outcome
(	32676976	1316	1317	O
P=0.035	32676976	1318	1325	O
)	32676976	1326	1327	O
,	32676976	1328	1329	O
and	32676976	1330	1333	O
a	32676976	1334	1335	O
significant	32676976	1336	1347	B-Observation
reduction	32676976	1348	1357	I-Observation
in	32676976	1358	1360	O
the	32676976	1361	1364	O
development	32676976	1365	1376	B-Outcome
of	32676976	1377	1379	I-Outcome
ARDS	32676976	1380	1384	I-Outcome
(	32676976	1385	1386	O
P=0.048	32676976	1387	1394	O
)	32676976	1395	1396	O
.	32676976	1397	1398	O

CONCLUSIONS	32676976	1399	1410	O
:	32676976	1411	1412	O
Keguan-1-based	32676976	1413	1427	B-Intervention
integrative	32676976	1428	1439	I-Intervention
therapy	32676976	1440	1447	I-Intervention
was	32676976	1448	1451	O
safe	32676976	1452	1456	B-Observation
and	32676976	1457	1460	O
superior	32676976	1461	1469	B-Observation
to	32676976	1470	1472	O
the	32676976	1473	1476	O
standard	32676976	1477	1485	B-Intervention
therapy	32676976	1486	1493	I-Intervention
in	32676976	1494	1496	O
suppressing	32676976	1497	1508	B-Observation
the	32676976	1509	1512	O
development	32676976	1513	1524	B-Outcome
of	32676976	1525	1527	I-Outcome
ARDS	32676976	1528	1532	I-Outcome
in	32676976	1533	1535	O
COVID-19	32676976	1536	1544	B-Participant
patients	32676976	1545	1553	O
.	32676976	1554	1555	O

(	32676976	1556	1557	O
Trial	32676976	1558	1563	O
registration	32676976	1564	1576	O
No	32676976	1577	1579	O
.	32676976	1580	1581	O

NCT04251871	32676976	1582	1593	O
at	32676976	1594	1596	O
www.clinicaltrials.gov	32676976	1597	1619	O
)	32676976	1620	1621	O
.	32676976	1622	1623	O


Safety	32702298	0	6	B-Outcome
and	32702298	7	10	O
immunogenicity	32702298	11	25	B-Outcome
of	32702298	26	28	O
the	32702298	29	32	O
ChAdOx1	32702298	33	40	B-Intervention
nCoV-19	32702298	41	48	I-Intervention
vaccine	32702298	49	56	I-Intervention
against	32702298	57	64	O
SARS	32702298	65	69	B-Participant
-	32702298	70	71	I-Participant
CoV-2	32702298	72	77	I-Participant
:	32702298	78	79	O
a	32702298	80	81	O
preliminary	32702298	82	93	O
report	32702298	94	100	O
of	32702298	101	103	O
a	32702298	104	105	O
phase	32702298	106	111	O
1/2	32702298	112	115	O
,	32702298	116	117	O
single	32702298	118	124	O
-	32702298	125	126	O
blind	32702298	127	132	O
,	32702298	133	134	O
randomised	32702298	135	145	O
controlled	32702298	146	156	O
trial	32702298	157	162	O
.	32702298	163	164	O

The	32702298	165	168	O
pandemic	32702298	169	177	O
of	32702298	178	180	O
severe	32702298	181	187	O
acute	32702298	188	193	O
respiratory	32702298	194	205	O
syndrome	32702298	206	214	O
coronavirus	32702298	215	226	O
2	32702298	227	228	O
(	32702298	229	230	O
SARS	32702298	231	235	O
-	32702298	236	237	O
CoV-2	32702298	238	243	O
)	32702298	244	245	O
might	32702298	246	251	O
be	32702298	252	254	O
curtailed	32702298	255	264	O
by	32702298	265	267	O
vaccination	32702298	268	279	O
.	32702298	280	281	O

We	32702298	282	284	O
assessed	32702298	285	293	O
the	32702298	294	297	O
safety	32702298	298	304	B-Outcome
,	32702298	305	306	O
reactogenicity	32702298	307	321	B-Outcome
,	32702298	322	323	O
and	32702298	324	327	O
immunogenicity	32702298	328	342	B-Outcome
of	32702298	343	345	O
a	32702298	346	347	O
viral	32702298	348	353	B-Intervention
vectored	32702298	354	362	I-Intervention
coronavirus	32702298	363	374	I-Intervention
vaccine	32702298	375	382	I-Intervention
that	32702298	383	387	O
expresses	32702298	388	397	O
the	32702298	398	401	O
spike	32702298	402	407	O
protein	32702298	408	415	O
of	32702298	416	418	O
SARS	32702298	419	423	B-Participant
-	32702298	424	425	I-Participant
CoV-2	32702298	426	431	I-Participant
.	32702298	432	433	O

We	32702298	434	436	O
did	32702298	437	440	O
a	32702298	441	442	O
phase	32702298	443	448	O
1/2	32702298	449	452	O
,	32702298	453	454	O
single	32702298	455	461	O
-	32702298	462	463	O
blind	32702298	464	469	O
,	32702298	470	471	O
randomised	32702298	472	482	O
controlled	32702298	483	493	O
trial	32702298	494	499	O
in	32702298	500	502	O
five	32702298	503	507	O
trial	32702298	508	513	O
sites	32702298	514	519	O
in	32702298	520	522	O
the	32702298	523	526	O
UK	32702298	527	529	O
of	32702298	530	532	O
a	32702298	533	534	O
chimpanzee	32702298	535	545	B-Intervention
adenovirus	32702298	546	556	I-Intervention
-	32702298	557	558	I-Intervention
vectored	32702298	559	567	I-Intervention
vaccine	32702298	568	575	I-Intervention
(	32702298	576	577	I-Intervention
ChAdOx1	32702298	578	585	I-Intervention
nCoV-19	32702298	586	593	I-Intervention
)	32702298	594	595	I-Intervention
expressing	32702298	596	606	O
the	32702298	607	610	O
SARS	32702298	611	615	O
-	32702298	616	617	O
CoV-2	32702298	618	623	O
spike	32702298	624	629	O
protein	32702298	630	637	O
compared	32702298	638	646	O
with	32702298	647	651	O
a	32702298	652	653	O
meningococcal	32702298	654	667	B-Intervention
conjugate	32702298	668	677	I-Intervention
vaccine	32702298	678	685	I-Intervention
(	32702298	686	687	I-Intervention
MenACWY	32702298	688	695	I-Intervention
)	32702298	696	697	I-Intervention
as	32702298	698	700	O
control	32702298	701	708	O
.	32702298	709	710	O

Healthy	32702298	711	718	B-Participant
adults	32702298	719	725	B-Participant
aged	32702298	726	730	B-Participant
18	32702298	731	733	I-Participant
-	32702298	734	735	I-Participant
55	32702298	736	738	I-Participant
years	32702298	739	744	I-Participant
with	32702298	745	749	O
no	32702298	750	752	O
history	32702298	753	760	B-Participant
of	32702298	761	763	I-Participant
laboratory	32702298	764	774	I-Participant
confirmed	32702298	775	784	I-Participant
SARS	32702298	785	789	I-Participant
-	32702298	790	791	I-Participant
CoV-2	32702298	792	797	I-Participant
infection	32702298	798	807	I-Participant
or	32702298	808	810	O
of	32702298	811	813	O
COVID-19-like	32702298	814	827	B-Participant
symptoms	32702298	828	836	I-Participant
were	32702298	837	841	O
randomly	32702298	842	850	O
assigned	32702298	851	859	O
(	32702298	860	861	O
1:1	32702298	862	865	O
)	32702298	866	867	O
to	32702298	868	870	O
receive	32702298	871	878	O
ChAdOx1	32702298	879	886	B-Intervention
nCoV-19	32702298	887	894	I-Intervention
at	32702298	895	897	O
a	32702298	898	899	O
dose	32702298	900	904	O
of	32702298	905	907	O
5	32702298	908	909	O
	32702298	912	913	O
1010	32702298	916	920	O
viral	32702298	921	926	O
particles	32702298	927	936	O
or	32702298	937	939	O
MenACWY	32702298	940	947	B-Intervention
as	32702298	948	950	O
a	32702298	951	952	O
single	32702298	953	959	O
intramuscular	32702298	960	973	O
injection	32702298	974	983	O
.	32702298	984	985	O

A	32702298	986	987	O
protocol	32702298	988	996	O
amendment	32702298	997	1006	O
in	32702298	1007	1009	O
two	32702298	1010	1013	O
of	32702298	1014	1016	O
the	32702298	1017	1020	O
five	32702298	1021	1025	O
sites	32702298	1026	1031	O
allowed	32702298	1032	1039	O
prophylactic	32702298	1040	1052	O
paracetamol	32702298	1053	1064	O
to	32702298	1065	1067	O
be	32702298	1068	1070	O
administered	32702298	1071	1083	O
before	32702298	1084	1090	O
vaccination	32702298	1091	1102	O
.	32702298	1103	1104	O

Ten	32702298	1105	1108	O
participants	32702298	1109	1121	O
assigned	32702298	1122	1130	O
to	32702298	1131	1133	O
a	32702298	1134	1135	O
non	32702298	1136	1139	O
-	32702298	1140	1141	O
randomised	32702298	1142	1152	O
,	32702298	1153	1154	O
unblinded	32702298	1155	1164	O
ChAdOx1	32702298	1165	1172	B-Intervention
nCoV-19	32702298	1173	1180	I-Intervention
prime	32702298	1181	1186	I-Intervention
-	32702298	1187	1188	I-Intervention
boost	32702298	1189	1194	I-Intervention
group	32702298	1195	1200	O
received	32702298	1201	1209	O
a	32702298	1210	1211	O
two	32702298	1212	1215	O
-	32702298	1216	1217	O
dose	32702298	1218	1222	O
schedule	32702298	1223	1231	O
,	32702298	1232	1233	O
with	32702298	1234	1238	O
the	32702298	1239	1242	O
booster	32702298	1243	1250	O
vaccine	32702298	1251	1258	O
administered	32702298	1259	1271	O
28	32702298	1272	1274	O
days	32702298	1275	1279	O
after	32702298	1280	1285	O
the	32702298	1286	1289	O
first	32702298	1290	1295	O
dose	32702298	1296	1300	O
.	32702298	1301	1302	O

Humoral	32702298	1303	1310	B-Outcome
responses	32702298	1311	1320	I-Outcome
at	32702298	1321	1323	O
baseline	32702298	1324	1332	O
and	32702298	1333	1336	O
following	32702298	1337	1346	O
vaccination	32702298	1347	1358	O
were	32702298	1359	1363	O
assessed	32702298	1364	1372	O
using	32702298	1373	1378	O
a	32702298	1379	1380	O
standardised	32702298	1381	1393	O
total	32702298	1394	1399	O
IgG	32702298	1400	1403	O
ELISA	32702298	1404	1409	O
against	32702298	1410	1417	O
trimeric	32702298	1418	1426	O
SARS	32702298	1427	1431	O
-	32702298	1432	1433	O
CoV-2	32702298	1434	1439	O
spike	32702298	1440	1445	O
protein	32702298	1446	1453	O
,	32702298	1454	1455	O
a	32702298	1456	1457	O
muliplexed	32702298	1458	1468	O
immunoassay	32702298	1469	1480	O
,	32702298	1481	1482	O
three	32702298	1483	1488	O
live	32702298	1489	1493	O
SARS	32702298	1494	1498	O
-	32702298	1499	1500	O
CoV-2	32702298	1501	1506	O
neutralisation	32702298	1507	1521	O
assays	32702298	1522	1528	O
(	32702298	1529	1530	O
a	32702298	1531	1532	O
50	32702298	1533	1535	O
%	32702298	1536	1537	O
plaque	32702298	1538	1544	O
reduction	32702298	1545	1554	O
neutralisation	32702298	1555	1569	O
assay	32702298	1570	1575	O
[	32702298	1576	1577	O
PRNT50	32702298	1578	1584	O
]	32702298	1585	1586	O
;	32702298	1587	1588	O
a	32702298	1589	1590	O
microneutralisation	32702298	1591	1610	O
assay	32702298	1611	1616	O
[	32702298	1617	1618	O
MNA50	32702298	1619	1624	O
,	32702298	1625	1626	O
MNA80	32702298	1627	1632	O
,	32702298	1633	1634	O
and	32702298	1635	1638	O
MNA90	32702298	1639	1644	O
]	32702298	1645	1646	O
;	32702298	1647	1648	O
and	32702298	1649	1652	O
Marburg	32702298	1653	1660	O
VN	32702298	1661	1663	O
)	32702298	1664	1665	O
,	32702298	1666	1667	O
and	32702298	1668	1671	O
a	32702298	1672	1673	O
pseudovirus	32702298	1674	1685	O
neutralisation	32702298	1686	1700	O
assay	32702298	1701	1706	O
.	32702298	1707	1708	O

Cellular	32702298	1709	1717	B-Outcome
responses	32702298	1718	1727	I-Outcome
were	32702298	1728	1732	O
assessed	32702298	1733	1741	O
using	32702298	1742	1747	O
an	32702298	1748	1750	O
ex	32702298	1751	1753	O
-	32702298	1754	1755	O
vivo	32702298	1756	1760	O
interferon	32702298	1761	1771	O
-	32702298	1772	1773	O
	32702298	1774	1775	O
enzyme	32702298	1776	1782	O
-	32702298	1783	1784	O
linked	32702298	1785	1791	O
immunospot	32702298	1792	1802	O
assay	32702298	1803	1808	O
.	32702298	1809	1810	O

The	32702298	1811	1814	O
co	32702298	1815	1817	O
-	32702298	1818	1819	O
primary	32702298	1820	1827	O
outcomes	32702298	1828	1836	O
are	32702298	1837	1840	O
to	32702298	1841	1843	O
assess	32702298	1844	1850	O
efficacy	32702298	1851	1859	B-Outcome
,	32702298	1860	1861	O
as	32702298	1862	1864	O
measured	32702298	1865	1873	O
by	32702298	1874	1876	O
cases	32702298	1877	1882	B-Outcome
of	32702298	1883	1885	I-Outcome
symptomatic	32702298	1886	1897	I-Outcome
virologically	32702298	1898	1911	I-Outcome
confirmed	32702298	1912	1921	I-Outcome
COVID-19	32702298	1922	1930	I-Outcome
,	32702298	1931	1932	O
and	32702298	1933	1936	O
safety	32702298	1937	1943	B-Outcome
,	32702298	1944	1945	O
as	32702298	1946	1948	O
measured	32702298	1949	1957	O
by	32702298	1958	1960	O
the	32702298	1961	1964	O
occurrence	32702298	1965	1975	B-Outcome
of	32702298	1976	1978	I-Outcome
serious	32702298	1979	1986	I-Outcome
adverse	32702298	1987	1994	I-Outcome
events	32702298	1995	2001	I-Outcome
.	32702298	2002	2003	O

Analyses	32702298	2004	2012	O
were	32702298	2013	2017	O
done	32702298	2018	2022	O
by	32702298	2023	2025	O
group	32702298	2026	2031	O
allocation	32702298	2032	2042	O
in	32702298	2043	2045	O
participants	32702298	2046	2058	O
who	32702298	2059	2062	O
received	32702298	2063	2071	O
the	32702298	2072	2075	O
vaccine	32702298	2076	2083	O
.	32702298	2084	2085	O

Safety	32702298	2086	2092	B-Outcome
was	32702298	2093	2096	O
assessed	32702298	2097	2105	O
over	32702298	2106	2110	O
28	32702298	2111	2113	O
days	32702298	2114	2118	O
after	32702298	2119	2124	O
vaccination	32702298	2125	2136	O
.	32702298	2137	2138	O

Here	32702298	2139	2143	O
,	32702298	2144	2145	O
we	32702298	2146	2148	O
report	32702298	2149	2155	O
the	32702298	2156	2159	O
preliminary	32702298	2160	2171	O
findings	32702298	2172	2180	O
on	32702298	2181	2183	O
safety	32702298	2184	2190	B-Outcome
,	32702298	2191	2192	O
reactogenicity	32702298	2193	2207	B-Outcome
,	32702298	2208	2209	O
and	32702298	2210	2213	O
cellular	32702298	2214	2222	B-Outcome
and	32702298	2223	2226	I-Outcome
humoral	32702298	2227	2234	I-Outcome
immune	32702298	2235	2241	I-Outcome
responses	32702298	2242	2251	I-Outcome
.	32702298	2252	2253	O

The	32702298	2254	2257	O
study	32702298	2258	2263	O
is	32702298	2264	2266	O
ongoing	32702298	2267	2274	O
,	32702298	2275	2276	O
and	32702298	2277	2280	O
was	32702298	2281	2284	O
registered	32702298	2285	2295	O
at	32702298	2296	2298	O
ISRCTN	32702298	2299	2305	O
,	32702298	2306	2307	O
15281137	32702298	2308	2316	O
,	32702298	2317	2318	O
and	32702298	2319	2322	O
ClinicalTrials.gov	32702298	2323	2341	O
,	32702298	2342	2343	O
NCT04324606	32702298	2344	2355	O
.	32702298	2356	2357	O

Between	32702298	2358	2365	O
April	32702298	2366	2371	O
23	32702298	2372	2374	O
and	32702298	2375	2378	O
May	32702298	2379	2382	O
21	32702298	2383	2385	O
,	32702298	2386	2387	O
2020	32702298	2388	2392	O
,	32702298	2393	2394	O
1077	32702298	2395	2399	O
participants	32702298	2400	2412	O
were	32702298	2413	2417	O
enrolled	32702298	2418	2426	O
and	32702298	2427	2430	O
assigned	32702298	2431	2439	O
to	32702298	2440	2442	O
receive	32702298	2443	2450	O
either	32702298	2451	2457	O
ChAdOx1	32702298	2458	2465	B-Intervention
nCoV-19	32702298	2466	2473	I-Intervention
(	32702298	2474	2475	O
n=543	32702298	2476	2481	O
)	32702298	2482	2483	O
or	32702298	2484	2486	O
MenACWY	32702298	2487	2494	B-Intervention
(	32702298	2495	2496	O
n=534	32702298	2497	2502	O
)	32702298	2503	2504	O
,	32702298	2505	2506	O
ten	32702298	2507	2510	O
of	32702298	2511	2513	O
whom	32702298	2514	2518	O
were	32702298	2519	2523	O
enrolled	32702298	2524	2532	O
in	32702298	2533	2535	O
the	32702298	2536	2539	O
non	32702298	2540	2543	O
-	32702298	2544	2545	O
randomised	32702298	2546	2556	O
ChAdOx1	32702298	2557	2564	B-Intervention
nCoV-19	32702298	2565	2572	I-Intervention
prime	32702298	2573	2578	I-Intervention
-	32702298	2579	2580	I-Intervention
boost	32702298	2581	2586	I-Intervention
group	32702298	2587	2592	O
.	32702298	2593	2594	O

Local	32702298	2595	2600	B-Outcome
and	32702298	2601	2604	I-Outcome
systemic	32702298	2605	2613	I-Outcome
reactions	32702298	2614	2623	I-Outcome
were	32702298	2624	2628	O
more	32702298	2629	2633	B-Observation
common	32702298	2634	2640	I-Observation
in	32702298	2641	2643	O
the	32702298	2644	2647	O
ChAdOx1	32702298	2648	2655	B-Intervention
nCoV-19	32702298	2656	2663	I-Intervention
group	32702298	2664	2669	O
and	32702298	2670	2673	O
many	32702298	2674	2678	O
were	32702298	2679	2683	O
reduced	32702298	2684	2691	O
by	32702298	2692	2694	O
use	32702298	2695	2698	O
of	32702298	2699	2701	O
prophylactic	32702298	2702	2714	O
paracetamol	32702298	2715	2726	O
,	32702298	2727	2728	O
including	32702298	2729	2738	O
pain	32702298	2739	2743	O
,	32702298	2744	2745	O
feeling	32702298	2746	2753	O
feverish	32702298	2754	2762	O
,	32702298	2763	2764	O
chills	32702298	2765	2771	O
,	32702298	2772	2773	O
muscle	32702298	2774	2780	O
ache	32702298	2781	2785	O
,	32702298	2786	2787	O
headache	32702298	2788	2796	O
,	32702298	2797	2798	O
and	32702298	2799	2802	O
malaise	32702298	2803	2810	O
(	32702298	2811	2812	O
all	32702298	2813	2816	O
p<005	32702298	2817	2823	O
)	32702298	2824	2825	O
.	32702298	2826	2827	O

There	32702298	2828	2833	O
were	32702298	2834	2838	O
no	32702298	2839	2841	B-Count
serious	32702298	2842	2849	B-Outcome
adverse	32702298	2850	2857	I-Outcome
events	32702298	2858	2864	I-Outcome
related	32702298	2865	2872	O
to	32702298	2873	2875	O
ChAdOx1	32702298	2876	2883	B-Intervention
nCoV-19	32702298	2884	2891	I-Intervention
.	32702298	2892	2893	O

In	32702298	2894	2896	O
the	32702298	2897	2900	O
ChAdOx1	32702298	2901	2908	B-Intervention
nCoV-19	32702298	2909	2916	I-Intervention
group	32702298	2917	2922	O
,	32702298	2923	2924	O
spike	32702298	2925	2930	B-Outcome
-	32702298	2931	2932	I-Outcome
specific	32702298	2933	2941	I-Outcome
T	32702298	2942	2943	I-Outcome
-	32702298	2944	2945	I-Outcome
cell	32702298	2946	2950	I-Outcome
responses	32702298	2951	2960	I-Outcome
peaked	32702298	2961	2967	B-Observation
on	32702298	2968	2970	O
day	32702298	2971	2974	O
14	32702298	2975	2977	O
(	32702298	2978	2979	O
median	32702298	2980	2986	B-Observation
856	32702298	2987	2990	I-Observation
spot	32702298	2991	2995	I-Observation
-	32702298	2996	2997	I-Observation
forming	32702298	2998	3005	I-Observation
cells	32702298	3006	3011	I-Observation
per	32702298	3012	3015	I-Observation
million	32702298	3016	3023	I-Observation
peripheral	32702298	3024	3034	I-Observation
blood	32702298	3035	3040	I-Observation
mononuclear	32702298	3041	3052	I-Observation
cells	32702298	3053	3058	I-Observation
,	32702298	3059	3060	O
IQR	32702298	3061	3064	O
493	32702298	3065	3068	O
-	32702298	3069	3070	O
1802	32702298	3071	3075	O
;	32702298	3076	3077	O
n=43	32702298	3078	3082	O
)	32702298	3083	3084	O
.	32702298	3085	3086	O

Anti	32702298	3087	3091	B-Outcome
-	32702298	3092	3093	I-Outcome
spike	32702298	3094	3099	I-Outcome
IgG	32702298	3100	3103	I-Outcome
responses	32702298	3104	3113	I-Outcome
rose	32702298	3114	3118	B-Observation
by	32702298	3119	3121	O
day	32702298	3122	3125	O
28	32702298	3126	3128	O
(	32702298	3129	3130	O
median	32702298	3131	3137	B-Observation
157	32702298	3138	3141	I-Observation
ELISA	32702298	3142	3147	I-Observation
units	32702298	3148	3153	I-Observation
[	32702298	3154	3155	O
EU	32702298	3156	3158	O
]	32702298	3159	3160	O
,	32702298	3161	3162	O
96	32702298	3163	3165	O
-	32702298	3166	3167	O
317	32702298	3168	3171	O
;	32702298	3172	3173	O
n=127	32702298	3174	3179	O
)	32702298	3180	3181	O
,	32702298	3182	3183	O
and	32702298	3184	3187	O
were	32702298	3188	3192	O
boosted	32702298	3193	3200	B-Observation
following	32702298	3201	3210	O
a	32702298	3211	3212	O
second	32702298	3213	3219	B-Intervention
dose	32702298	3220	3224	I-Intervention
(	32702298	3225	3226	O
639	32702298	3227	3230	B-Observation
EU	32702298	3231	3233	I-Observation
,	32702298	3234	3235	O
360	32702298	3236	3239	O
-	32702298	3240	3241	O
792	32702298	3242	3245	O
;	32702298	3246	3247	O
n=10	32702298	3248	3252	O
)	32702298	3253	3254	O
.	32702298	3255	3256	O

Neutralising	32702298	3257	3269	B-Outcome
antibody	32702298	3270	3278	I-Outcome
responses	32702298	3279	3288	I-Outcome
against	32702298	3289	3296	I-Outcome
SARS	32702298	3297	3301	I-Outcome
-	32702298	3302	3303	I-Outcome
CoV-2	32702298	3304	3309	I-Outcome
were	32702298	3310	3314	O
detected	32702298	3315	3323	O
in	32702298	3324	3326	O
32	32702298	3327	3329	B-Count
(	32702298	3330	3331	I-Count
91	32702298	3332	3334	I-Count
%	32702298	3335	3336	I-Count
)	32702298	3337	3338	I-Count
of	32702298	3339	3341	I-Count
35	32702298	3342	3344	I-Count
participants	32702298	3345	3357	I-Count
after	32702298	3358	3363	O
a	32702298	3364	3365	O
single	32702298	3366	3372	B-Intervention
dose	32702298	3373	3377	I-Intervention
when	32702298	3378	3382	O
measured	32702298	3383	3391	O
in	32702298	3392	3394	O
MNA80	32702298	3395	3400	O
and	32702298	3401	3404	O
in	32702298	3405	3407	O
35	32702298	3408	3410	B-Count
(	32702298	3411	3412	I-Count
100	32702298	3413	3416	I-Count
%	32702298	3417	3418	I-Count
)	32702298	3419	3420	I-Count
participants	32702298	3421	3433	I-Count
when	32702298	3434	3438	O
measured	32702298	3439	3447	O
in	32702298	3448	3450	O
PRNT50	32702298	3451	3457	O
.	32702298	3458	3459	O

After	32702298	3460	3465	O
a	32702298	3466	3467	O
booster	32702298	3468	3475	B-Intervention
dose	32702298	3476	3480	I-Intervention
,	32702298	3481	3482	O
all	32702298	3483	3486	B-Count
participants	32702298	3487	3499	I-Count
had	32702298	3500	3503	O
neutralising	32702298	3504	3516	B-Outcome
activity	32702298	3517	3525	I-Outcome
(	32702298	3526	3527	O
nine	32702298	3528	3532	O
of	32702298	3533	3535	O
nine	32702298	3536	3540	O
in	32702298	3541	3543	O
MNA80	32702298	3544	3549	O
at	32702298	3550	3552	O
day	32702298	3553	3556	O
42	32702298	3557	3559	O
and	32702298	3560	3563	O
ten	32702298	3564	3567	O
of	32702298	3568	3570	O
ten	32702298	3571	3574	O
in	32702298	3575	3577	O
Marburg	32702298	3578	3585	O
VN	32702298	3586	3588	O
on	32702298	3589	3591	O
day	32702298	3592	3595	O
56	32702298	3596	3598	O
)	32702298	3599	3600	O
.	32702298	3601	3602	O

Neutralising	32702298	3603	3615	B-Outcome
antibody	32702298	3616	3624	I-Outcome
responses	32702298	3625	3634	I-Outcome
correlated	32702298	3635	3645	O
strongly	32702298	3646	3654	O
with	32702298	3655	3659	O
antibody	32702298	3660	3668	B-Outcome
levels	32702298	3669	3675	I-Outcome
measured	32702298	3676	3684	O
by	32702298	3685	3687	O
ELISA	32702298	3688	3693	O
(	32702298	3694	3695	O
R2=067	32702298	3696	3703	O
by	32702298	3704	3706	O
Marburg	32702298	3707	3714	O
VN	32702298	3715	3717	O
;	32702298	3718	3719	O
p<0001	32702298	3720	3727	O
)	32702298	3728	3729	O
.	32702298	3730	3731	O

ChAdOx1	32702298	3732	3739	B-Intervention
nCoV-19	32702298	3740	3747	I-Intervention
showed	32702298	3748	3754	O
an	32702298	3755	3757	O
acceptable	32702298	3758	3768	B-Observation
safety	32702298	3769	3775	B-Outcome
profile	32702298	3776	3783	I-Outcome
,	32702298	3784	3785	O
and	32702298	3786	3789	O
homologous	32702298	3790	3800	B-Intervention
boosting	32702298	3801	3809	I-Intervention
increased	32702298	3810	3819	B-Observation
antibody	32702298	3820	3828	B-Outcome
responses	32702298	3829	3838	I-Outcome
.	32702298	3839	3840	O

These	32702298	3841	3846	O
results	32702298	3847	3854	O
,	32702298	3855	3856	O
together	32702298	3857	3865	O
with	32702298	3866	3870	O
the	32702298	3871	3874	O
induction	32702298	3875	3884	O
of	32702298	3885	3887	O
both	32702298	3888	3892	O
humoral	32702298	3893	3900	O
and	32702298	3901	3904	O
cellular	32702298	3905	3913	O
immune	32702298	3914	3920	O
responses	32702298	3921	3930	O
,	32702298	3931	3932	O
support	32702298	3933	3940	O
large	32702298	3941	3946	O
-	32702298	3947	3948	O
scale	32702298	3949	3954	O
evaluation	32702298	3955	3965	O
of	32702298	3966	3968	O
this	32702298	3969	3973	O
candidate	32702298	3974	3983	O
vaccine	32702298	3984	3991	O
in	32702298	3992	3994	O
an	32702298	3995	3997	O
ongoing	32702298	3998	4005	O
phase	32702298	4006	4011	O
3	32702298	4012	4013	O
programme	32702298	4014	4023	O
.	32702298	4024	4025	O

UK	32702298	4026	4028	O
Research	32702298	4029	4037	O
and	32702298	4038	4041	O
Innovation	32702298	4042	4052	O
,	32702298	4053	4054	O
Coalition	32702298	4055	4064	O
for	32702298	4065	4068	O
Epidemic	32702298	4069	4077	O
Preparedness	32702298	4078	4090	O
Innovations	32702298	4091	4102	O
,	32702298	4103	4104	O
National	32702298	4105	4113	O
Institute	32702298	4114	4123	O
for	32702298	4124	4127	O
Health	32702298	4128	4134	O
Research	32702298	4135	4143	O
(	32702298	4144	4145	O
NIHR	32702298	4146	4150	O
)	32702298	4151	4152	O
,	32702298	4153	4154	O
NIHR	32702298	4155	4159	O
Oxford	32702298	4160	4166	O
Biomedical	32702298	4167	4177	O
Research	32702298	4178	4186	O
Centre	32702298	4187	4193	O
,	32702298	4194	4195	O
Thames	32702298	4196	4202	O
Valley	32702298	4203	4209	O
and	32702298	4210	4213	O
South	32702298	4214	4219	O
Midland	32702298	4220	4227	O
's	32702298	4228	4230	O
NIHR	32702298	4231	4235	O
Clinical	32702298	4236	4244	O
Research	32702298	4245	4253	O
Network	32702298	4254	4261	O
,	32702298	4262	4263	O
and	32702298	4264	4267	O
the	32702298	4268	4271	O
German	32702298	4272	4278	O
Center	32702298	4279	4285	O
for	32702298	4286	4289	O
Infection	32702298	4290	4299	O
Research	32702298	4300	4308	O
(	32702298	4309	4310	O
DZIF	32702298	4311	4315	O
)	32702298	4316	4317	O
,	32702298	4318	4319	O
Partner	32702298	4320	4327	O
site	32702298	4328	4332	O
Gieen	32702298	4333	4339	O
-	32702298	4340	4341	O
Marburg	32702298	4342	4349	O
-	32702298	4350	4351	O
Langen	32702298	4352	4358	O
.	32702298	4359	4360	O

Immunogenicity	32702299	0	14	B-Outcome
and	32702299	15	18	O
safety	32702299	19	25	B-Outcome
of	32702299	26	28	O
a	32702299	29	30	O
recombinant	32702299	31	42	B-Intervention
adenovirus	32702299	43	53	I-Intervention
type-5-vectored	32702299	54	69	I-Intervention
COVID-19	32702299	70	78	I-Intervention
vaccine	32702299	79	86	I-Intervention
in	32702299	87	89	O
healthy	32702299	90	97	B-Participant
adults	32702299	98	104	B-Participant
aged	32702299	105	109	B-Participant
18	32702299	110	112	I-Participant
years	32702299	113	118	I-Participant
or	32702299	119	121	I-Participant
older	32702299	122	127	I-Participant
:	32702299	128	129	O
a	32702299	130	131	O
randomised	32702299	132	142	O
,	32702299	143	144	O
double	32702299	145	151	O
-	32702299	152	153	O
blind	32702299	154	159	O
,	32702299	160	161	O
placebo	32702299	162	169	O
-	32702299	170	171	O
controlled	32702299	172	182	O
,	32702299	183	184	O
phase	32702299	185	190	O
2	32702299	191	192	O
trial	32702299	193	198	O
.	32702299	199	200	O

This	32702299	201	205	O
is	32702299	206	208	O
the	32702299	209	212	O
first	32702299	213	218	O
randomised	32702299	219	229	O
controlled	32702299	230	240	O
trial	32702299	241	246	O
for	32702299	247	250	O
assessment	32702299	251	261	O
of	32702299	262	264	O
the	32702299	265	268	O
immunogenicity	32702299	269	283	B-Outcome
and	32702299	284	287	O
safety	32702299	288	294	B-Outcome
of	32702299	295	297	O
a	32702299	298	299	O
candidate	32702299	300	309	B-Intervention
non	32702299	310	313	I-Intervention
-	32702299	314	315	I-Intervention
replicating	32702299	316	327	I-Intervention
adenovirus	32702299	328	338	I-Intervention
type-5	32702299	339	345	I-Intervention
(	32702299	346	347	I-Intervention
Ad5)-vectored	32702299	348	361	I-Intervention
COVID-19	32702299	362	370	I-Intervention
vaccine	32702299	371	378	I-Intervention
,	32702299	379	380	O
aiming	32702299	381	387	O
to	32702299	388	390	O
determine	32702299	391	400	O
an	32702299	401	403	O
appropriate	32702299	404	415	B-Outcome
dose	32702299	416	420	I-Outcome
of	32702299	421	423	O
the	32702299	424	427	O
candidate	32702299	428	437	B-Intervention
vaccine	32702299	438	445	I-Intervention
for	32702299	446	449	O
an	32702299	450	452	O
efficacy	32702299	453	461	O
study	32702299	462	467	O
.	32702299	468	469	O

This	32702299	470	474	O
randomised	32702299	475	485	O
,	32702299	486	487	O
double	32702299	488	494	O
-	32702299	495	496	O
blind	32702299	497	502	O
,	32702299	503	504	O
placebo	32702299	505	512	O
-	32702299	513	514	O
controlled	32702299	515	525	O
,	32702299	526	527	O
phase	32702299	528	533	O
2	32702299	534	535	O
trial	32702299	536	541	O
of	32702299	542	544	O
the	32702299	545	548	O
Ad5-vectored	32702299	549	561	B-Intervention
COVID-19	32702299	562	570	I-Intervention
vaccine	32702299	571	578	I-Intervention
was	32702299	579	582	O
done	32702299	583	587	O
in	32702299	588	590	O
a	32702299	591	592	O
single	32702299	593	599	O
centre	32702299	600	606	O
in	32702299	607	609	O
Wuhan	32702299	610	615	O
,	32702299	616	617	O
China	32702299	618	623	O
.	32702299	624	625	O

Healthy	32702299	626	633	B-Participant
adults	32702299	634	640	B-Participant
aged	32702299	641	645	B-Participant
18	32702299	646	648	I-Participant
years	32702299	649	654	I-Participant
or	32702299	655	657	I-Participant
older	32702299	658	663	I-Participant
,	32702299	664	665	O
who	32702299	666	669	O
were	32702299	670	674	O
HIV	32702299	675	678	B-Participant
-	32702299	679	680	I-Participant
negative	32702299	681	689	I-Participant
and	32702299	690	693	O
previous	32702299	694	702	O
severe	32702299	703	709	B-Participant
acute	32702299	710	715	I-Participant
respiratory	32702299	716	727	I-Participant
syndrome	32702299	728	736	I-Participant
coronavirus	32702299	737	748	I-Participant
2	32702299	749	750	I-Participant
(	32702299	751	752	I-Participant
SARS	32702299	753	757	I-Participant
-	32702299	758	759	I-Participant
CoV-2	32702299	760	765	I-Participant
)	32702299	766	767	I-Participant
infection	32702299	768	777	I-Participant
-	32702299	778	779	I-Participant
free	32702299	780	784	I-Participant
,	32702299	785	786	O
were	32702299	787	791	O
eligible	32702299	792	800	O
to	32702299	801	803	O
participate	32702299	804	815	O
and	32702299	816	819	O
were	32702299	820	824	O
randomly	32702299	825	833	O
assigned	32702299	834	842	O
to	32702299	843	845	O
receive	32702299	846	853	O
the	32702299	854	857	O
vaccine	32702299	858	865	B-Intervention
at	32702299	866	868	O
a	32702299	869	870	O
dose	32702299	871	875	O
of	32702299	876	878	O
1	32702299	879	880	B-Intervention
	32702299	883	884	I-Intervention
1011	32702299	887	891	I-Intervention
viral	32702299	892	897	I-Intervention
particles	32702299	898	907	I-Intervention
per	32702299	908	911	I-Intervention
mL	32702299	912	914	I-Intervention
or	32702299	915	917	O
5	32702299	918	919	B-Intervention
	32702299	922	923	I-Intervention
1010	32702299	926	930	I-Intervention
viral	32702299	931	936	I-Intervention
particles	32702299	937	946	I-Intervention
per	32702299	947	950	I-Intervention
mL	32702299	951	953	I-Intervention
,	32702299	954	955	O
or	32702299	956	958	O
placebo	32702299	959	966	B-Intervention
.	32702299	967	968	O

Investigators	32702299	969	982	O
allocated	32702299	983	992	O
participants	32702299	993	1005	O
at	32702299	1006	1008	O
a	32702299	1009	1010	O
ratio	32702299	1011	1016	O
of	32702299	1017	1019	O
2:1:1	32702299	1020	1025	O
to	32702299	1026	1028	O
receive	32702299	1029	1036	O
a	32702299	1037	1038	O
single	32702299	1039	1045	O
injection	32702299	1046	1055	O
intramuscularly	32702299	1056	1071	O
in	32702299	1072	1074	O
the	32702299	1075	1078	O
arm	32702299	1079	1082	O
.	32702299	1083	1084	O

The	32702299	1085	1088	O
randomisation	32702299	1089	1102	O
list	32702299	1103	1107	O
(	32702299	1108	1109	O
block	32702299	1110	1115	O
size	32702299	1116	1120	O
4	32702299	1121	1122	O
)	32702299	1123	1124	O
was	32702299	1125	1128	O
generated	32702299	1129	1138	O
by	32702299	1139	1141	O
an	32702299	1142	1144	O
independent	32702299	1145	1156	O
statistician	32702299	1157	1169	O
.	32702299	1170	1171	O

Participants	32702299	1172	1184	O
,	32702299	1185	1186	O
investigators	32702299	1187	1200	O
,	32702299	1201	1202	O
and	32702299	1203	1206	O
staff	32702299	1207	1212	O
undertaking	32702299	1213	1224	O
laboratory	32702299	1225	1235	O
analyses	32702299	1236	1244	O
were	32702299	1245	1249	O
masked	32702299	1250	1256	O
to	32702299	1257	1259	O
group	32702299	1260	1265	O
allocation	32702299	1266	1276	O
.	32702299	1277	1278	O

The	32702299	1279	1282	O
primary	32702299	1283	1290	O
endpoints	32702299	1291	1300	O
for	32702299	1301	1304	O
immunogenicity	32702299	1305	1319	O
were	32702299	1320	1324	O
the	32702299	1325	1328	O
geometric	32702299	1329	1338	B-Outcome
mean	32702299	1339	1343	I-Outcome
titres	32702299	1344	1350	I-Outcome
(	32702299	1351	1352	I-Outcome
GMTs	32702299	1353	1357	I-Outcome
)	32702299	1358	1359	I-Outcome
of	32702299	1360	1362	I-Outcome
specific	32702299	1363	1371	I-Outcome
ELISA	32702299	1372	1377	I-Outcome
antibody	32702299	1378	1386	I-Outcome
responses	32702299	1387	1396	I-Outcome
to	32702299	1397	1399	I-Outcome
the	32702299	1400	1403	I-Outcome
receptor	32702299	1404	1412	I-Outcome
binding	32702299	1413	1420	I-Outcome
domain	32702299	1421	1427	I-Outcome
(	32702299	1428	1429	I-Outcome
RBD	32702299	1430	1433	I-Outcome
)	32702299	1434	1435	I-Outcome
and	32702299	1436	1439	O
neutralising	32702299	1440	1452	B-Outcome
antibody	32702299	1453	1461	I-Outcome
responses	32702299	1462	1471	I-Outcome
at	32702299	1472	1474	I-Outcome
day	32702299	1475	1478	I-Outcome
28	32702299	1479	1481	I-Outcome
.	32702299	1482	1483	O

The	32702299	1484	1487	O
primary	32702299	1488	1495	O
endpoint	32702299	1496	1504	O
for	32702299	1505	1508	O
safety	32702299	1509	1515	O
evaluation	32702299	1516	1526	O
was	32702299	1527	1530	O
the	32702299	1531	1534	O
incidence	32702299	1535	1544	B-Outcome
of	32702299	1545	1547	I-Outcome
adverse	32702299	1548	1555	I-Outcome
reactions	32702299	1556	1565	I-Outcome
within	32702299	1566	1572	I-Outcome
14	32702299	1573	1575	I-Outcome
days	32702299	1576	1580	I-Outcome
.	32702299	1581	1582	O

All	32702299	1583	1586	O
recruited	32702299	1587	1596	O
participants	32702299	1597	1609	O
who	32702299	1610	1613	O
received	32702299	1614	1622	O
at	32702299	1623	1625	O
least	32702299	1626	1631	O
one	32702299	1632	1635	O
dose	32702299	1636	1640	O
were	32702299	1641	1645	O
included	32702299	1646	1654	O
in	32702299	1655	1657	O
the	32702299	1658	1661	O
primary	32702299	1662	1669	O
and	32702299	1670	1673	O
safety	32702299	1674	1680	O
analyses	32702299	1681	1689	O
.	32702299	1690	1691	O

This	32702299	1692	1696	O
study	32702299	1697	1702	O
is	32702299	1703	1705	O
registered	32702299	1706	1716	O
with	32702299	1717	1721	O
ClinicalTrials.gov	32702299	1722	1740	O
,	32702299	1741	1742	O
NCT04341389	32702299	1743	1754	O
.	32702299	1755	1756	O

603	32702299	1757	1760	O
volunteers	32702299	1761	1771	O
were	32702299	1772	1776	O
recruited	32702299	1777	1786	O
and	32702299	1787	1790	O
screened	32702299	1791	1799	O
for	32702299	1800	1803	O
eligibility	32702299	1804	1815	O
between	32702299	1816	1823	O
April	32702299	1824	1829	O
11	32702299	1830	1832	O
and	32702299	1833	1836	O
16	32702299	1837	1839	O
,	32702299	1840	1841	O
2020	32702299	1842	1846	O
.	32702299	1847	1848	O

508	32702299	1849	1852	O
eligible	32702299	1853	1861	O
participants	32702299	1862	1874	O
(	32702299	1875	1876	O
50	32702299	1877	1879	O
%	32702299	1880	1881	O
male	32702299	1882	1886	O
;	32702299	1887	1888	O
mean	32702299	1889	1893	O
age	32702299	1894	1897	O
397	32702299	1898	1902	O
years	32702299	1903	1908	O
,	32702299	1909	1910	O
SD	32702299	1911	1913	O
125	32702299	1914	1918	O
)	32702299	1919	1920	O
consented	32702299	1921	1930	O
to	32702299	1931	1933	O
participate	32702299	1934	1945	O
in	32702299	1946	1948	O
the	32702299	1949	1952	O
trial	32702299	1953	1958	O
and	32702299	1959	1962	O
were	32702299	1963	1967	O
randomly	32702299	1968	1976	O
assigned	32702299	1977	1985	O
to	32702299	1986	1988	O
receive	32702299	1989	1996	O
the	32702299	1997	2000	O
vaccine	32702299	2001	2008	B-Intervention
(	32702299	2009	2010	O
1	32702299	2011	2012	O
	32702299	2015	2016	O
1011	32702299	2019	2023	O
viral	32702299	2024	2029	O
particles	32702299	2030	2039	O
n=253	32702299	2040	2045	O
;	32702299	2046	2047	O
5	32702299	2048	2049	O
	32702299	2052	2053	O
1010	32702299	2056	2060	O
viral	32702299	2061	2066	O
particles	32702299	2067	2076	O
n=129	32702299	2077	2082	O
)	32702299	2083	2084	O
or	32702299	2085	2087	O
placebo	32702299	2088	2095	B-Intervention
(	32702299	2096	2097	O
n=126	32702299	2098	2103	O
)	32702299	2104	2105	O
.	32702299	2106	2107	O

In	32702299	2108	2110	O
the	32702299	2111	2114	O
1	32702299	2115	2116	B-Intervention
	32702299	2119	2120	I-Intervention
1011	32702299	2123	2127	I-Intervention
and	32702299	2128	2131	O
5	32702299	2132	2133	B-Intervention
	32702299	2136	2137	I-Intervention
1010	32702299	2140	2144	I-Intervention
viral	32702299	2145	2150	I-Intervention
particles	32702299	2151	2160	I-Intervention
dose	32702299	2161	2165	O
groups	32702299	2166	2172	O
,	32702299	2173	2174	O
the	32702299	2175	2178	O
RBD	32702299	2179	2182	B-Outcome
-	32702299	2183	2184	I-Outcome
specific	32702299	2185	2193	I-Outcome
ELISA	32702299	2194	2199	I-Outcome
antibodies	32702299	2200	2210	I-Outcome
peaked	32702299	2211	2217	B-Observation
at	32702299	2218	2220	I-Observation
6565	32702299	2221	2226	I-Observation
(	32702299	2227	2228	O
95	32702299	2229	2231	O
%	32702299	2232	2233	O
CI	32702299	2234	2236	O
5752	32702299	2237	2242	O
-	32702299	2243	2244	O
7492	32702299	2245	2250	O
)	32702299	2251	2252	O
and	32702299	2253	2256	O
5710	32702299	2257	2262	B-Observation
(	32702299	2263	2264	O
4676	32702299	2265	2270	O
-	32702299	2271	2272	O
6973	32702299	2273	2278	O
)	32702299	2279	2280	O
,	32702299	2281	2282	O
with	32702299	2283	2287	O
seroconversion	32702299	2288	2302	B-Outcome
rates	32702299	2303	2308	I-Outcome
at	32702299	2309	2311	O
96	32702299	2312	2314	B-Observation
%	32702299	2315	2316	I-Observation
(	32702299	2317	2318	O
95	32702299	2319	2321	O
%	32702299	2322	2323	O
CI	32702299	2324	2326	O
93	32702299	2327	2329	O
-	32702299	2330	2331	O
98	32702299	2332	2334	O
)	32702299	2335	2336	O
and	32702299	2337	2340	O
97	32702299	2341	2343	B-Observation
%	32702299	2344	2345	I-Observation
(	32702299	2346	2347	O
92	32702299	2348	2350	O
-	32702299	2351	2352	O
99	32702299	2353	2355	O
)	32702299	2356	2357	O
,	32702299	2358	2359	O
respectively	32702299	2360	2372	O
,	32702299	2373	2374	O
at	32702299	2375	2377	O
day	32702299	2378	2381	O
28	32702299	2382	2384	O
.	32702299	2385	2386	O

Both	32702299	2387	2391	B-Intervention
doses	32702299	2392	2397	I-Intervention
of	32702299	2398	2400	I-Intervention
the	32702299	2401	2404	I-Intervention
vaccine	32702299	2405	2412	I-Intervention
induced	32702299	2413	2420	B-Observation
significant	32702299	2421	2432	I-Observation
neutralising	32702299	2433	2445	B-Outcome
antibody	32702299	2446	2454	I-Outcome
responses	32702299	2455	2464	I-Outcome
to	32702299	2465	2467	I-Outcome
live	32702299	2468	2472	I-Outcome
SARS	32702299	2473	2477	I-Outcome
-	32702299	2478	2479	I-Outcome
CoV-2	32702299	2480	2485	I-Outcome
,	32702299	2486	2487	O
with	32702299	2488	2492	O
GMTs	32702299	2493	2497	B-Outcome
of	32702299	2498	2500	O
195	32702299	2501	2505	B-Observation
(	32702299	2506	2507	O
95	32702299	2508	2510	O
%	32702299	2511	2512	O
CI	32702299	2513	2515	O
168	32702299	2516	2520	O
-	32702299	2521	2522	O
227	32702299	2523	2527	O
)	32702299	2528	2529	O
and	32702299	2530	2533	O
183	32702299	2534	2538	B-Observation
(	32702299	2539	2540	O
144	32702299	2541	2545	O
-	32702299	2546	2547	O
233	32702299	2548	2552	O
)	32702299	2553	2554	O
in	32702299	2555	2557	O
participants	32702299	2558	2570	O
receiving	32702299	2571	2580	O
1	32702299	2581	2582	B-Intervention
	32702299	2585	2586	I-Intervention
1011	32702299	2589	2593	I-Intervention
and	32702299	2594	2597	O
5	32702299	2598	2599	B-Intervention
	32702299	2602	2603	I-Intervention
1010	32702299	2606	2610	I-Intervention
viral	32702299	2611	2616	I-Intervention
particles	32702299	2617	2626	I-Intervention
,	32702299	2627	2628	O
respectively	32702299	2629	2641	O
.	32702299	2642	2643	O

Specific	32702299	2644	2652	B-Outcome
interferon	32702299	2653	2663	I-Outcome
	32702299	2664	2665	I-Outcome
enzyme	32702299	2666	2672	I-Outcome
-	32702299	2673	2674	I-Outcome
linked	32702299	2675	2681	I-Outcome
immunospot	32702299	2682	2692	I-Outcome
assay	32702299	2693	2698	I-Outcome
responses	32702299	2699	2708	I-Outcome
post	32702299	2709	2713	O
vaccination	32702299	2714	2725	O
were	32702299	2726	2730	O
observed	32702299	2731	2739	O
in	32702299	2740	2742	O
227	32702299	2743	2746	B-Count
(	32702299	2747	2748	I-Count
90	32702299	2749	2751	I-Count
%	32702299	2752	2753	I-Count
,	32702299	2754	2755	I-Count
95	32702299	2756	2758	I-Count
%	32702299	2759	2760	I-Count
CI	32702299	2761	2763	I-Count
85	32702299	2764	2766	I-Count
-	32702299	2767	2768	I-Count
93	32702299	2769	2771	I-Count
)	32702299	2772	2773	I-Count
of	32702299	2774	2776	I-Count
253	32702299	2777	2780	I-Count
and	32702299	2781	2784	O
113	32702299	2785	2788	B-Count
(	32702299	2789	2790	I-Count
88	32702299	2791	2793	I-Count
%	32702299	2794	2795	I-Count
,	32702299	2796	2797	I-Count
81	32702299	2798	2800	I-Count
-	32702299	2801	2802	I-Count
92	32702299	2803	2805	I-Count
)	32702299	2806	2807	I-Count
of	32702299	2808	2810	I-Count
129	32702299	2811	2814	I-Count
participants	32702299	2815	2827	I-Count
in	32702299	2828	2830	O
the	32702299	2831	2834	O
1	32702299	2835	2836	B-Intervention
	32702299	2839	2840	I-Intervention
1011	32702299	2843	2847	I-Intervention
and	32702299	2848	2851	O
5	32702299	2852	2853	B-Intervention
	32702299	2856	2857	I-Intervention
1010	32702299	2860	2864	I-Intervention
viral	32702299	2865	2870	I-Intervention
particles	32702299	2871	2880	I-Intervention
dose	32702299	2881	2885	I-Intervention
groups	32702299	2886	2892	O
,	32702299	2893	2894	O
respectively	32702299	2895	2907	O
.	32702299	2908	2909	O

Solicited	32702299	2910	2919	B-Outcome
adverse	32702299	2920	2927	I-Outcome
reactions	32702299	2928	2937	I-Outcome
were	32702299	2938	2942	O
reported	32702299	2943	2951	O
by	32702299	2952	2954	O
183	32702299	2955	2958	B-Count
(	32702299	2959	2960	I-Count
72	32702299	2961	2963	I-Count
%	32702299	2964	2965	I-Count
)	32702299	2966	2967	I-Count
of	32702299	2968	2970	I-Count
253	32702299	2971	2974	I-Count
and	32702299	2975	2978	O
96	32702299	2979	2981	B-Count
(	32702299	2982	2983	I-Count
74	32702299	2984	2986	I-Count
%	32702299	2987	2988	I-Count
)	32702299	2989	2990	I-Count
of	32702299	2991	2993	I-Count
129	32702299	2994	2997	I-Count
participants	32702299	2998	3010	I-Count
in	32702299	3011	3013	O
the	32702299	3014	3017	O
1	32702299	3018	3019	B-Intervention
	32702299	3022	3023	I-Intervention
1011	32702299	3026	3030	I-Intervention
and	32702299	3031	3034	O
5	32702299	3035	3036	B-Intervention
	32702299	3039	3040	I-Intervention
1010	32702299	3043	3047	I-Intervention
viral	32702299	3048	3053	I-Intervention
particles	32702299	3054	3063	I-Intervention
dose	32702299	3064	3068	I-Intervention
groups	32702299	3069	3075	O
,	32702299	3076	3077	O
respectively	32702299	3078	3090	O
.	32702299	3091	3092	O

Severe	32702299	3093	3099	B-Outcome
adverse	32702299	3100	3107	I-Outcome
reactions	32702299	3108	3117	I-Outcome
were	32702299	3118	3122	O
reported	32702299	3123	3131	O
by	32702299	3132	3134	O
24	32702299	3135	3137	B-Count
(	32702299	3138	3139	I-Count
9	32702299	3140	3141	I-Count
%	32702299	3142	3143	I-Count
)	32702299	3144	3145	I-Count
participants	32702299	3146	3158	I-Count
in	32702299	3159	3161	O
the	32702299	3162	3165	O
1	32702299	3166	3167	B-Intervention
	32702299	3170	3171	I-Intervention
1011	32702299	3174	3178	I-Intervention
viral	32702299	3179	3184	I-Intervention
particles	32702299	3185	3194	I-Intervention
dose	32702299	3195	3199	I-Intervention
group	32702299	3200	3205	O
and	32702299	3206	3209	O
one	32702299	3210	3213	B-Count
(	32702299	3214	3215	I-Count
1	32702299	3216	3217	I-Count
%	32702299	3218	3219	I-Count
)	32702299	3220	3221	I-Count
participant	32702299	3222	3233	I-Count
in	32702299	3234	3236	O
the	32702299	3237	3240	O
5	32702299	3241	3242	B-Intervention
	32702299	3245	3246	I-Intervention
1010	32702299	3249	3253	I-Intervention
viral	32702299	3254	3259	I-Intervention
particles	32702299	3260	3269	I-Intervention
dose	32702299	3270	3274	I-Intervention
group	32702299	3275	3280	O
.	32702299	3281	3282	O

No	32702299	3283	3285	B-Count
serious	32702299	3286	3293	B-Outcome
adverse	32702299	3294	3301	I-Outcome
reactions	32702299	3302	3311	I-Outcome
were	32702299	3312	3316	O
documented	32702299	3317	3327	O
.	32702299	3328	3329	O

The	32702299	3330	3333	O
Ad5-vectored	32702299	3334	3346	B-Intervention
COVID-19	32702299	3347	3355	I-Intervention
vaccine	32702299	3356	3363	I-Intervention
at	32702299	3364	3366	I-Intervention
5	32702299	3367	3368	I-Intervention
	32702299	3371	3372	I-Intervention
1010	32702299	3375	3379	I-Intervention
viral	32702299	3380	3385	I-Intervention
particles	32702299	3386	3395	I-Intervention
is	32702299	3396	3398	O
safe	32702299	3399	3403	B-Observation
,	32702299	3404	3405	O
and	32702299	3406	3409	O
induced	32702299	3410	3417	B-Observation
significant	32702299	3418	3429	I-Observation
immune	32702299	3430	3436	B-Outcome
responses	32702299	3437	3446	I-Outcome
in	32702299	3447	3449	O
the	32702299	3450	3453	O
majority	32702299	3454	3462	O
of	32702299	3463	3465	O
recipients	32702299	3466	3476	O
after	32702299	3477	3482	O
a	32702299	3483	3484	O
single	32702299	3485	3491	O
immunisation	32702299	3492	3504	O
.	32702299	3505	3506	O

National	32702299	3507	3515	O
Key	32702299	3516	3519	O
R&D	32702299	3520	3523	O
Programme	32702299	3524	3533	O
of	32702299	3534	3536	O
China	32702299	3537	3542	O
,	32702299	3543	3544	O
National	32702299	3545	3553	O
Science	32702299	3554	3561	O
and	32702299	3562	3565	O
Technology	32702299	3566	3576	O
Major	32702299	3577	3582	O
Project	32702299	3583	3590	O
,	32702299	3591	3592	O
and	32702299	3593	3596	O
CanSino	32702299	3597	3604	O
Biologics	32702299	3605	3614	O
.	32702299	3615	3616	O


Hydroxychloroquine	32706953	0	18	B-Intervention
with	32706953	19	23	I-Intervention
or	32706953	24	26	I-Intervention
without	32706953	27	34	I-Intervention
Azithromycin	32706953	35	47	I-Intervention
in	32706953	48	50	O
Mild	32706953	51	55	B-Participant
-	32706953	56	57	I-Participant
to	32706953	58	60	I-Participant
-	32706953	61	62	I-Participant
Moderate	32706953	63	71	I-Participant
Covid-19	32706953	72	80	I-Participant
.	32706953	81	82	O

Hydroxychloroquine	32706953	83	101	O
and	32706953	102	105	O
azithromycin	32706953	106	118	O
have	32706953	119	123	O
been	32706953	124	128	O
used	32706953	129	133	O
to	32706953	134	136	O
treat	32706953	137	142	O
patients	32706953	143	151	O
with	32706953	152	156	O
coronavirus	32706953	157	168	O
disease	32706953	169	176	O
2019	32706953	177	181	O
(	32706953	182	183	O
Covid-19	32706953	184	192	O
)	32706953	193	194	O
.	32706953	195	196	O

However	32706953	197	204	O
,	32706953	205	206	O
evidence	32706953	207	215	O
on	32706953	216	218	O
the	32706953	219	222	O
safety	32706953	223	229	O
and	32706953	230	233	O
efficacy	32706953	234	242	O
of	32706953	243	245	O
these	32706953	246	251	O
therapies	32706953	252	261	O
is	32706953	262	264	O
limited	32706953	265	272	O
.	32706953	273	274	O

We	32706953	275	277	O
conducted	32706953	278	287	O
a	32706953	288	289	O
multicenter	32706953	290	301	O
,	32706953	302	303	O
randomized	32706953	304	314	O
,	32706953	315	316	O
open	32706953	317	321	O
-	32706953	322	323	O
label	32706953	324	329	O
,	32706953	330	331	O
three	32706953	332	337	O
-	32706953	338	339	O
group	32706953	340	345	O
,	32706953	346	347	O
controlled	32706953	348	358	O
trial	32706953	359	364	O
involving	32706953	365	374	O
hospitalized	32706953	375	387	B-Participant
patients	32706953	388	396	O
with	32706953	397	401	O
suspected	32706953	402	411	B-Participant
or	32706953	412	414	I-Participant
confirmed	32706953	415	424	I-Participant
Covid-19	32706953	425	433	I-Participant
who	32706953	434	437	O
were	32706953	438	442	O
receiving	32706953	443	452	O
either	32706953	453	459	O
no	32706953	460	462	O
supplemental	32706953	463	475	O
oxygen	32706953	476	482	O
or	32706953	483	485	O
a	32706953	486	487	O
maximum	32706953	488	495	O
of	32706953	496	498	O
4	32706953	499	500	O
liters	32706953	501	507	O
per	32706953	508	511	O
minute	32706953	512	518	O
of	32706953	519	521	O
supplemental	32706953	522	534	O
oxygen	32706953	535	541	O
.	32706953	542	543	O

Patients	32706953	544	552	O
were	32706953	553	557	O
randomly	32706953	558	566	O
assigned	32706953	567	575	O
in	32706953	576	578	O
a	32706953	579	580	O
1:1:1	32706953	581	586	O
ratio	32706953	587	592	O
to	32706953	593	595	O
receive	32706953	596	603	O
standard	32706953	604	612	B-Intervention
care	32706953	613	617	I-Intervention
,	32706953	618	619	O
standard	32706953	620	628	B-Intervention
care	32706953	629	633	I-Intervention
plus	32706953	634	638	I-Intervention
hydroxychloroquine	32706953	639	657	I-Intervention
at	32706953	658	660	I-Intervention
a	32706953	661	662	I-Intervention
dose	32706953	663	667	I-Intervention
of	32706953	668	670	I-Intervention
400	32706953	671	674	I-Intervention
mg	32706953	675	677	I-Intervention
twice	32706953	678	683	I-Intervention
daily	32706953	684	689	I-Intervention
,	32706953	690	691	O
or	32706953	692	694	O
standard	32706953	695	703	B-Intervention
care	32706953	704	708	I-Intervention
plus	32706953	709	713	I-Intervention
hydroxychloroquine	32706953	714	732	I-Intervention
at	32706953	733	735	I-Intervention
a	32706953	736	737	I-Intervention
dose	32706953	738	742	I-Intervention
of	32706953	743	745	I-Intervention
400	32706953	746	749	I-Intervention
mg	32706953	750	752	I-Intervention
twice	32706953	753	758	I-Intervention
daily	32706953	759	764	I-Intervention
plus	32706953	765	769	I-Intervention
azithromycin	32706953	770	782	I-Intervention
at	32706953	783	785	I-Intervention
a	32706953	786	787	I-Intervention
dose	32706953	788	792	I-Intervention
of	32706953	793	795	I-Intervention
500	32706953	796	799	I-Intervention
mg	32706953	800	802	I-Intervention
once	32706953	803	807	I-Intervention
daily	32706953	808	813	I-Intervention
for	32706953	814	817	I-Intervention
7	32706953	818	819	I-Intervention
days	32706953	820	824	I-Intervention
.	32706953	825	826	O

The	32706953	827	830	O
primary	32706953	831	838	O
outcome	32706953	839	846	O
was	32706953	847	850	O
clinical	32706953	851	859	B-Outcome
status	32706953	860	866	I-Outcome
at	32706953	867	869	I-Outcome
15	32706953	870	872	I-Outcome
days	32706953	873	877	I-Outcome
as	32706953	878	880	O
assessed	32706953	881	889	O
with	32706953	890	894	O
the	32706953	895	898	O
use	32706953	899	902	O
of	32706953	903	905	O
a	32706953	906	907	O
seven	32706953	908	913	O
-	32706953	914	915	O
level	32706953	916	921	O
ordinal	32706953	922	929	O
scale	32706953	930	935	O
(	32706953	936	937	O
with	32706953	938	942	O
levels	32706953	943	949	O
ranging	32706953	950	957	O
from	32706953	958	962	O
one	32706953	963	966	O
to	32706953	967	969	O
seven	32706953	970	975	O
and	32706953	976	979	O
higher	32706953	980	986	O
scores	32706953	987	993	O
indicating	32706953	994	1004	O
a	32706953	1005	1006	O
worse	32706953	1007	1012	O
condition	32706953	1013	1022	O
)	32706953	1023	1024	O
in	32706953	1025	1027	O
the	32706953	1028	1031	O
modified	32706953	1032	1040	O
intention	32706953	1041	1050	O
-	32706953	1051	1052	O
to	32706953	1053	1055	O
-	32706953	1056	1057	O
treat	32706953	1058	1063	O
population	32706953	1064	1074	O
(	32706953	1075	1076	O
patients	32706953	1077	1085	O
with	32706953	1086	1090	O
a	32706953	1091	1092	O
confirmed	32706953	1093	1102	O
diagnosis	32706953	1103	1112	O
of	32706953	1113	1115	O
Covid-19	32706953	1116	1124	O
)	32706953	1125	1126	O
.	32706953	1127	1128	O

Safety	32706953	1129	1135	B-Outcome
was	32706953	1136	1139	O
also	32706953	1140	1144	O
assessed	32706953	1145	1153	O
.	32706953	1154	1155	O

A	32706953	1156	1157	O
total	32706953	1158	1163	O
of	32706953	1164	1166	O
667	32706953	1167	1170	O
patients	32706953	1171	1179	O
underwent	32706953	1180	1189	O
randomization	32706953	1190	1203	O
;	32706953	1204	1205	O
504	32706953	1206	1209	O
patients	32706953	1210	1218	O
had	32706953	1219	1222	O
confirmed	32706953	1223	1232	B-Participant
Covid-19	32706953	1233	1241	I-Participant
and	32706953	1242	1245	O
were	32706953	1246	1250	O
included	32706953	1251	1259	O
in	32706953	1260	1262	O
the	32706953	1263	1266	O
modified	32706953	1267	1275	O
intention	32706953	1276	1285	O
-	32706953	1286	1287	O
to	32706953	1288	1290	O
-	32706953	1291	1292	O
treat	32706953	1293	1298	O
analysis	32706953	1299	1307	O
.	32706953	1308	1309	O

As	32706953	1310	1312	O
compared	32706953	1313	1321	O
with	32706953	1322	1326	O
standard	32706953	1327	1335	B-Intervention
care	32706953	1336	1340	I-Intervention
,	32706953	1341	1342	O
the	32706953	1343	1346	O
proportional	32706953	1347	1359	B-Outcome
odds	32706953	1360	1364	I-Outcome
of	32706953	1365	1367	I-Outcome
having	32706953	1368	1374	I-Outcome
a	32706953	1375	1376	I-Outcome
higher	32706953	1377	1383	I-Outcome
score	32706953	1384	1389	I-Outcome
on	32706953	1390	1392	I-Outcome
the	32706953	1393	1396	I-Outcome
seven	32706953	1397	1402	I-Outcome
-	32706953	1403	1404	I-Outcome
point	32706953	1405	1410	I-Outcome
ordinal	32706953	1411	1418	I-Outcome
scale	32706953	1419	1424	I-Outcome
at	32706953	1425	1427	I-Outcome
15	32706953	1428	1430	I-Outcome
days	32706953	1431	1435	I-Outcome
was	32706953	1436	1439	O
not	32706953	1440	1443	O
affected	32706953	1444	1452	B-Observation
by	32706953	1453	1455	O
either	32706953	1456	1462	O
hydroxychloroquine	32706953	1463	1481	B-Intervention
alone	32706953	1482	1487	I-Intervention
(	32706953	1488	1489	O
odds	32706953	1490	1494	O
ratio	32706953	1495	1500	O
,	32706953	1501	1502	O
1.21	32706953	1503	1507	O
;	32706953	1508	1509	O
95	32706953	1510	1512	O
%	32706953	1513	1514	O
confidence	32706953	1515	1525	O
interval	32706953	1526	1534	O
[	32706953	1535	1536	O
CI	32706953	1537	1539	O
]	32706953	1540	1541	O
,	32706953	1542	1543	O
0.69	32706953	1544	1548	O
to	32706953	1549	1551	O
2.11	32706953	1552	1556	O
;	32706953	1557	1558	O
P	32706953	1559	1560	O
=	32706953	1563	1564	O
1.00	32706953	1567	1571	O
)	32706953	1572	1573	O
or	32706953	1574	1576	O
hydroxychloroquine	32706953	1577	1595	B-Intervention
plus	32706953	1596	1600	I-Intervention
azithromycin	32706953	1601	1613	I-Intervention
(	32706953	1614	1615	O
odds	32706953	1616	1620	O
ratio	32706953	1621	1626	O
,	32706953	1627	1628	O
0.99	32706953	1629	1633	O
;	32706953	1634	1635	O
95	32706953	1636	1638	O
%	32706953	1639	1640	O
CI	32706953	1641	1643	O
,	32706953	1644	1645	O
0.57	32706953	1646	1650	O
to	32706953	1651	1653	O
1.73	32706953	1654	1658	O
;	32706953	1659	1660	O
P	32706953	1661	1662	O
=	32706953	1665	1666	O
1.00	32706953	1669	1673	O
)	32706953	1674	1675	O
.	32706953	1676	1677	O

Prolongation	32706953	1678	1690	B-Outcome
of	32706953	1691	1693	I-Outcome
the	32706953	1694	1697	I-Outcome
corrected	32706953	1698	1707	I-Outcome
QT	32706953	1708	1710	I-Outcome
interval	32706953	1711	1719	I-Outcome
and	32706953	1720	1723	O
elevation	32706953	1724	1733	B-Outcome
of	32706953	1734	1736	I-Outcome
liver	32706953	1737	1742	I-Outcome
-	32706953	1743	1744	I-Outcome
enzyme	32706953	1745	1751	I-Outcome
levels	32706953	1752	1758	I-Outcome
were	32706953	1759	1763	O
more	32706953	1764	1768	B-Observation
frequent	32706953	1769	1777	I-Observation
in	32706953	1778	1780	O
patients	32706953	1781	1789	O
receiving	32706953	1790	1799	O
hydroxychloroquine	32706953	1800	1818	B-Intervention
,	32706953	1819	1820	O
alone	32706953	1821	1826	O
or	32706953	1827	1829	O
with	32706953	1830	1834	B-Intervention
azithromycin	32706953	1835	1847	I-Intervention
,	32706953	1848	1849	O
than	32706953	1850	1854	O
in	32706953	1855	1857	O
those	32706953	1858	1863	O
who	32706953	1864	1867	O
were	32706953	1868	1872	O
not	32706953	1873	1876	B-Intervention
receiving	32706953	1877	1886	I-Intervention
either	32706953	1887	1893	I-Intervention
agent	32706953	1894	1899	I-Intervention
.	32706953	1900	1901	O

Among	32706953	1902	1907	O
patients	32706953	1908	1916	O
hospitalized	32706953	1917	1929	B-Participant
with	32706953	1930	1934	O
mild	32706953	1935	1939	B-Participant
-	32706953	1940	1941	I-Participant
to	32706953	1942	1944	I-Participant
-	32706953	1945	1946	I-Participant
moderate	32706953	1947	1955	I-Participant
Covid-19	32706953	1956	1964	I-Participant
,	32706953	1965	1966	O
the	32706953	1967	1970	O
use	32706953	1971	1974	O
of	32706953	1975	1977	O
hydroxychloroquine	32706953	1978	1996	B-Intervention
,	32706953	1997	1998	O
alone	32706953	1999	2004	B-Intervention
or	32706953	2005	2007	O
with	32706953	2008	2012	B-Intervention
azithromycin	32706953	2013	2025	I-Intervention
,	32706953	2026	2027	O
did	32706953	2028	2031	O
not	32706953	2032	2035	O
improve	32706953	2036	2043	B-Observation
clinical	32706953	2044	2052	B-Outcome
status	32706953	2053	2059	I-Outcome
at	32706953	2060	2062	I-Outcome
15	32706953	2063	2065	I-Outcome
days	32706953	2066	2070	I-Outcome
as	32706953	2071	2073	O
compared	32706953	2074	2082	O
with	32706953	2083	2087	O
standard	32706953	2088	2096	B-Intervention
care	32706953	2097	2101	I-Intervention
.	32706953	2102	2103	O
(	32706953	2104	2105	O
Funded	32706953	2106	2112	O
by	32706953	2113	2115	O
the	32706953	2116	2119	O
Coalition	32706953	2120	2129	O
Covid-19	32706953	2130	2138	O
Brazil	32706953	2139	2145	O
and	32706953	2146	2149	O
EMS	32706953	2150	2153	O
Pharma	32706953	2154	2160	O
;	32706953	2161	2162	O
ClinicalTrials.gov	32706953	2163	2181	O
number	32706953	2182	2188	O
,	32706953	2189	2190	O
NCT04322123	32706953	2191	2202	O
.	32706953	2203	2204	O
)	32706953	2205	2206	O
.	32706953	2207	2208	O


Historically	32719045	0	12	O
controlled	32719045	13	23	O
comparison	32719045	24	34	O
of	32719045	35	37	O
glucocorticoids	32719045	38	53	B-Intervention
with	32719045	54	58	I-Intervention
or	32719045	59	61	I-Intervention
without	32719045	62	69	I-Intervention
tocilizumab	32719045	70	81	I-Intervention
versus	32719045	82	88	O
supportive	32719045	89	99	B-Intervention
care	32719045	100	104	I-Intervention
only	32719045	105	109	I-Intervention
in	32719045	110	112	O
patients	32719045	113	121	O
with	32719045	122	126	O
COVID-19-associated	32719045	127	146	B-Participant
cytokine	32719045	147	155	I-Participant
storm	32719045	156	161	I-Participant
syndrome	32719045	162	170	I-Participant
:	32719045	171	172	O
results	32719045	173	180	O
of	32719045	181	183	O
the	32719045	184	187	O
CHIC	32719045	188	192	O
study	32719045	193	198	O
.	32719045	199	200	O

To	32719045	201	203	O
prospectively	32719045	204	217	O
investigate	32719045	218	229	O
in	32719045	230	232	O
patients	32719045	233	241	O
with	32719045	242	246	O
severe	32719045	247	253	B-Participant
COVID-19-associated	32719045	254	273	I-Participant
cytokine	32719045	274	282	I-Participant
storm	32719045	283	288	I-Participant
syndrome	32719045	289	297	I-Participant
(	32719045	298	299	I-Participant
CSS	32719045	300	303	I-Participant
)	32719045	304	305	I-Participant
whether	32719045	306	313	O
an	32719045	314	316	O
intensive	32719045	317	326	B-Intervention
course	32719045	327	333	I-Intervention
of	32719045	334	336	I-Intervention
glucocorticoids	32719045	337	352	I-Intervention
with	32719045	353	357	I-Intervention
or	32719045	358	360	I-Intervention
without	32719045	361	368	I-Intervention
tocilizumab	32719045	369	380	I-Intervention
accelerates	32719045	381	392	B-Observation
clinical	32719045	393	401	B-Outcome
improvement	32719045	402	413	I-Outcome
,	32719045	414	415	O
reduces	32719045	416	423	B-Observation
mortality	32719045	424	433	B-Outcome
and	32719045	434	437	O
prevents	32719045	438	446	B-Observation
invasive	32719045	447	455	B-Outcome
mechanical	32719045	456	466	I-Outcome
ventilation	32719045	467	478	I-Outcome
,	32719045	479	480	O
in	32719045	481	483	O
comparison	32719045	484	494	O
with	32719045	495	499	O
a	32719045	500	501	O
historic	32719045	502	510	O
control	32719045	511	518	O
group	32719045	519	524	O
of	32719045	525	527	O
patients	32719045	528	536	O
who	32719045	537	540	O
received	32719045	541	549	O
supportive	32719045	550	560	B-Intervention
care	32719045	561	565	I-Intervention
only	32719045	566	570	I-Intervention
.	32719045	571	572	O

From	32719045	573	577	O
1	32719045	578	579	O
April	32719045	580	585	O
2020	32719045	586	590	O
,	32719045	591	592	O
patients	32719045	593	601	O
with	32719045	602	606	O
COVID-19-associated	32719045	607	626	B-Participant
CSS	32719045	627	630	I-Participant
,	32719045	631	632	O
defined	32719045	633	640	O
as	32719045	641	643	O
rapid	32719045	644	649	B-Participant
respiratory	32719045	650	661	I-Participant
deterioration	32719045	662	675	I-Participant
plus	32719045	676	680	O
at	32719045	681	683	B-Participant
least	32719045	684	689	I-Participant
two	32719045	690	693	I-Participant
out	32719045	694	697	I-Participant
of	32719045	698	700	I-Participant
three	32719045	701	706	I-Participant
biomarkers	32719045	707	717	I-Participant
with	32719045	718	722	I-Participant
important	32719045	723	732	I-Participant
elevations	32719045	733	743	I-Participant
(	32719045	744	745	O
C	32719045	746	747	B-Participant
-	32719045	748	749	I-Participant
reactive	32719045	750	758	I-Participant
protein	32719045	759	766	I-Participant
>	32719045	767	768	I-Participant
100	32719045	769	772	I-Participant
mg	32719045	775	777	I-Participant
/	32719045	778	779	I-Participant
L	32719045	780	781	I-Participant
;	32719045	782	783	O
ferritin	32719045	784	792	B-Participant
>	32719045	793	794	I-Participant
900	32719045	795	798	I-Participant
g	32719045	801	803	I-Participant
/	32719045	804	805	I-Participant
L	32719045	806	807	I-Participant
;	32719045	808	809	O
D	32719045	810	811	B-Participant
-	32719045	812	813	I-Participant
dimer	32719045	814	819	I-Participant
>	32719045	820	821	I-Participant
1500	32719045	822	826	I-Participant
g	32719045	829	831	I-Participant
/	32719045	832	833	I-Participant
L	32719045	834	835	I-Participant
)	32719045	836	837	O
,	32719045	838	839	O
received	32719045	840	848	O
high	32719045	849	853	B-Intervention
-	32719045	854	855	I-Intervention
dose	32719045	856	860	I-Intervention
intravenous	32719045	861	872	I-Intervention
methylprednisolone	32719045	873	891	I-Intervention
for	32719045	892	895	O
5	32719045	896	897	O
consecutive	32719045	898	909	O
days	32719045	910	914	O
(	32719045	915	916	O
250	32719045	917	920	O
mg	32719045	923	925	O
on	32719045	926	928	O
day	32719045	929	932	O
1	32719045	933	934	O
followed	32719045	935	943	O
by	32719045	944	946	O
80	32719045	947	949	O
mg	32719045	952	954	O
on	32719045	955	957	O
days	32719045	958	962	O
2	32719045	963	964	O
-	32719045	965	966	O
5	32719045	967	968	O
)	32719045	969	970	O
.	32719045	971	972	O

If	32719045	973	975	O
the	32719045	976	979	O
respiratory	32719045	980	991	B-Outcome
condition	32719045	992	1001	I-Outcome
had	32719045	1002	1005	O
not	32719045	1006	1009	O
improved	32719045	1010	1018	B-Observation
sufficiently	32719045	1019	1031	I-Observation
(	32719045	1032	1033	O
in	32719045	1034	1036	O
43	32719045	1037	1039	B-Count
%	32719045	1040	1041	I-Count
)	32719045	1042	1043	O
,	32719045	1044	1045	O
the	32719045	1046	1049	O
interleukin-6	32719045	1050	1063	B-Intervention
receptor	32719045	1064	1072	I-Intervention
blocker	32719045	1073	1080	I-Intervention
tocilizumab	32719045	1081	1092	I-Intervention
(	32719045	1093	1094	O
8	32719045	1095	1096	O
mg	32719045	1099	1101	O
/	32719045	1102	1103	O
kg	32719045	1104	1106	O
body	32719045	1107	1111	O
weight	32719045	1112	1118	O
,	32719045	1119	1120	O
single	32719045	1121	1127	O
infusion	32719045	1128	1136	O
)	32719045	1137	1138	O
was	32719045	1139	1142	O
added	32719045	1143	1148	O
on	32719045	1149	1151	O
or	32719045	1152	1154	O
after	32719045	1155	1160	O
day	32719045	1161	1164	O
2	32719045	1165	1166	O
.	32719045	1167	1168	O

Control	32719045	1169	1176	B-Intervention
patients	32719045	1177	1185	O
with	32719045	1186	1190	O
COVID-19-associated	32719045	1191	1210	B-Participant
CSS	32719045	1211	1214	I-Participant
(	32719045	1215	1216	O
same	32719045	1217	1221	O
definition	32719045	1222	1232	O
)	32719045	1233	1234	O
were	32719045	1235	1239	O
retrospectively	32719045	1240	1255	O
sampled	32719045	1256	1263	O
from	32719045	1264	1268	O
the	32719045	1269	1272	O
pool	32719045	1273	1277	O
of	32719045	1278	1280	O
patients	32719045	1281	1289	O
(	32719045	1290	1291	O
n=350	32719045	1292	1297	O
)	32719045	1298	1299	O
admitted	32719045	1300	1308	O
between	32719045	1309	1316	O
7	32719045	1317	1318	O
March	32719045	1319	1324	O
and	32719045	1325	1328	O
31	32719045	1329	1331	O
March	32719045	1332	1337	O
,	32719045	1338	1339	O
and	32719045	1340	1343	O
matched	32719045	1344	1351	O
one	32719045	1352	1355	O
to	32719045	1356	1358	O
one	32719045	1359	1362	O
to	32719045	1363	1365	O
treated	32719045	1366	1373	O
patients	32719045	1374	1382	O
on	32719045	1383	1385	O
sex	32719045	1386	1389	O
and	32719045	1390	1393	O
age	32719045	1394	1397	O
.	32719045	1398	1399	O

The	32719045	1400	1403	O
primary	32719045	1404	1411	O
outcome	32719045	1412	1419	O
was	32719045	1420	1423	O
	32719045	1426	1427	B-Outcome
2	32719045	1428	1429	I-Outcome
stages	32719045	1430	1436	I-Outcome
of	32719045	1437	1439	I-Outcome
improvement	32719045	1440	1451	I-Outcome
on	32719045	1452	1454	O
a	32719045	1455	1456	O
7-item	32719045	1457	1463	O
WHO	32719045	1464	1467	O
-	32719045	1468	1469	O
endorsed	32719045	1470	1478	O
scale	32719045	1479	1484	O
for	32719045	1485	1488	O
trials	32719045	1489	1495	O
in	32719045	1496	1498	O
patients	32719045	1499	1507	O
with	32719045	1508	1512	O
severe	32719045	1513	1519	B-Participant
influenza	32719045	1520	1529	I-Participant
pneumonia	32719045	1530	1539	I-Participant
,	32719045	1540	1541	O
or	32719045	1542	1544	O
discharge	32719045	1545	1554	B-Outcome
from	32719045	1555	1559	I-Outcome
the	32719045	1560	1563	I-Outcome
hospital	32719045	1564	1572	I-Outcome
.	32719045	1573	1574	O

Secondary	32719045	1575	1584	O
outcomes	32719045	1585	1593	O
were	32719045	1594	1598	O
hospital	32719045	1599	1607	B-Outcome
mortality	32719045	1608	1617	I-Outcome
and	32719045	1618	1621	O
mechanical	32719045	1622	1632	B-Outcome
ventilation	32719045	1633	1644	I-Outcome
.	32719045	1645	1646	O

At	32719045	1647	1649	O
baseline	32719045	1650	1658	O
all	32719045	1659	1662	O
patients	32719045	1663	1671	O
with	32719045	1672	1676	O
COVID-19	32719045	1677	1685	B-Participant
in	32719045	1686	1688	O
the	32719045	1689	1692	O
treatment	32719045	1693	1702	B-Intervention
group	32719045	1703	1708	O
(	32719045	1709	1710	O
n=86	32719045	1711	1715	O
)	32719045	1716	1717	O
and	32719045	1718	1721	O
control	32719045	1722	1729	B-Intervention
group	32719045	1730	1735	O
(	32719045	1736	1737	O
n=86	32719045	1738	1742	O
)	32719045	1743	1744	O
had	32719045	1745	1748	O
symptoms	32719045	1749	1757	B-Participant
of	32719045	1758	1760	I-Participant
CSS	32719045	1761	1764	I-Participant
and	32719045	1765	1768	O
faced	32719045	1769	1774	O
acute	32719045	1775	1780	B-Participant
respiratory	32719045	1781	1792	I-Participant
failure	32719045	1793	1800	I-Participant
.	32719045	1801	1802	O

Treated	32719045	1803	1810	B-Intervention
patients	32719045	1811	1819	O
had	32719045	1820	1823	O
79	32719045	1824	1826	B-Observation
%	32719045	1827	1828	I-Observation
higher	32719045	1829	1835	I-Observation
likelihood	32719045	1836	1846	I-Observation
on	32719045	1847	1849	O
reaching	32719045	1850	1858	B-Outcome
the	32719045	1859	1862	I-Outcome
primary	32719045	1863	1870	I-Outcome
outcome	32719045	1871	1878	I-Outcome
(	32719045	1879	1880	O
HR	32719045	1881	1883	O
:	32719045	1884	1885	O
1.8	32719045	1886	1889	O
;	32719045	1890	1891	O
95	32719045	1892	1894	O
%	32719045	1895	1896	O
CI	32719045	1899	1901	O
1.2	32719045	1902	1905	O
to	32719045	1906	1908	O
2.7	32719045	1909	1912	O
)	32719045	1913	1914	O
(	32719045	1915	1916	O
7	32719045	1917	1918	O
days	32719045	1919	1923	O
earlier	32719045	1924	1931	O
)	32719045	1932	1933	O
,	32719045	1934	1935	O
65	32719045	1936	1938	B-Observation
%	32719045	1939	1940	I-Observation
less	32719045	1941	1945	I-Observation
mortality	32719045	1946	1955	B-Outcome
(	32719045	1956	1957	O
HR	32719045	1958	1960	O
:	32719045	1961	1962	O
0.35	32719045	1963	1967	O
;	32719045	1968	1969	O
95	32719045	1970	1972	O
%	32719045	1973	1974	O
CI	32719045	1977	1979	O
0.19	32719045	1980	1984	O
to	32719045	1985	1987	O
0.65	32719045	1988	1992	O
)	32719045	1993	1994	O
and	32719045	1995	1998	O
71	32719045	1999	2001	B-Observation
%	32719045	2002	2003	I-Observation
less	32719045	2004	2008	I-Observation
invasive	32719045	2009	2017	B-Outcome
mechanical	32719045	2018	2028	I-Outcome
ventilation	32719045	2029	2040	I-Outcome
(	32719045	2041	2042	O
HR	32719045	2043	2045	O
:	32719045	2046	2047	O
0.29	32719045	2048	2052	O
;	32719045	2053	2054	O
95	32719045	2055	2057	O
%	32719045	2058	2059	O
CI	32719045	2062	2064	O
0.14	32719045	2065	2069	O
to	32719045	2070	2072	O
0.65	32719045	2073	2077	O
)	32719045	2078	2079	O
.	32719045	2080	2081	O

Treatment	32719045	2082	2091	O
effects	32719045	2092	2099	O
remained	32719045	2100	2108	O
constant	32719045	2109	2117	O
in	32719045	2118	2120	O
confounding	32719045	2121	2132	O
and	32719045	2133	2136	O
sensitivity	32719045	2137	2148	O
analyses	32719045	2149	2157	O
.	32719045	2158	2159	O

A	32719045	2160	2161	O
strategy	32719045	2162	2170	O
involving	32719045	2171	2180	O
a	32719045	2181	2182	O
course	32719045	2183	2189	O
of	32719045	2190	2192	O
high	32719045	2193	2197	O
-	32719045	2198	2199	O
dose	32719045	2200	2204	O
methylprednisolone	32719045	2205	2223	O
,	32719045	2224	2225	O
followed	32719045	2226	2234	O
by	32719045	2235	2237	O
tocilizumab	32719045	2238	2249	O
if	32719045	2250	2252	O
needed	32719045	2253	2259	O
,	32719045	2260	2261	O
may	32719045	2262	2265	O
accelerate	32719045	2266	2276	O
respiratory	32719045	2277	2288	O
recovery	32719045	2289	2297	O
,	32719045	2298	2299	O
lower	32719045	2300	2305	O
hospital	32719045	2306	2314	O
mortality	32719045	2315	2324	O
and	32719045	2325	2328	O
reduce	32719045	2329	2335	O
the	32719045	2336	2339	O
likelihood	32719045	2340	2350	O
of	32719045	2351	2353	O
invasive	32719045	2354	2362	O
mechanical	32719045	2363	2373	O
ventilation	32719045	2374	2385	O
in	32719045	2386	2388	O
COVID-19-associated	32719045	2389	2408	O
CSS	32719045	2409	2412	O
.	32719045	2413	2414	O


SARS	32758689	0	4	B-Outcome
-	32758689	5	6	I-Outcome
CoV-2	32758689	7	12	I-Outcome
clearance	32758689	13	22	I-Outcome
in	32758689	23	25	O
COVID-19	32758689	26	34	B-Participant
patients	32758689	35	43	O
with	32758689	44	48	O
Novaferon	32758689	49	58	B-Intervention
treatment	32758689	59	68	O
:	32758689	69	70	O
A	32758689	71	72	O
randomized	32758689	73	83	O
,	32758689	84	85	O
open	32758689	86	90	O
-	32758689	91	92	O
label	32758689	93	98	O
,	32758689	99	100	O
parallel	32758689	101	109	O
-	32758689	110	111	O
group	32758689	112	117	O
trial	32758689	118	123	O
.	32758689	124	125	O

BACKGROUND	32758689	126	136	O
:	32758689	137	138	O
The	32758689	139	142	O
antiviral	32758689	143	152	O
effects	32758689	153	160	O
of	32758689	161	163	O
Novaferon	32758689	164	173	O
,	32758689	174	175	O
a	32758689	176	177	O
potent	32758689	178	184	O
antiviral	32758689	185	194	O
protein	32758689	195	202	O
drug	32758689	203	207	O
,	32758689	208	209	O
on	32758689	210	212	O
COVID-19	32758689	213	221	O
was	32758689	222	225	O
evaluated	32758689	226	235	O
in	32758689	236	238	O
the	32758689	239	242	O
laboratory	32758689	243	253	O
,	32758689	254	255	O
and	32758689	256	259	O
in	32758689	260	262	O
a	32758689	263	264	O
randomized	32758689	265	275	O
,	32758689	276	277	O
open	32758689	278	282	O
-	32758689	283	284	O
label	32758689	285	290	O
,	32758689	291	292	O
parallel	32758689	293	301	O
-	32758689	302	303	O
group	32758689	304	309	O
trial	32758689	310	315	O
.	32758689	316	317	O

METHODS	32758689	318	325	O
:	32758689	326	327	O
In	32758689	328	330	O
the	32758689	331	334	O
laboratory	32758689	335	345	O
,	32758689	346	347	O
Novaferon	32758689	348	357	B-Intervention
's	32758689	358	360	O
inhibition	32758689	361	371	B-Observation
of	32758689	372	374	O
viral	32758689	375	380	B-Outcome
replication	32758689	381	392	I-Outcome
in	32758689	393	395	I-Outcome
cells	32758689	396	401	I-Outcome
infected	32758689	402	410	I-Outcome
with	32758689	411	415	I-Outcome
SARS	32758689	416	420	I-Outcome
-	32758689	421	422	I-Outcome
CoV-2	32758689	423	428	I-Outcome
,	32758689	429	430	O
and	32758689	431	434	O
prevention	32758689	435	445	B-Observation
of	32758689	446	448	O
SARS	32758689	449	453	B-Outcome
-	32758689	454	455	I-Outcome
CoV-2	32758689	456	461	I-Outcome
entry	32758689	462	467	I-Outcome
into	32758689	468	472	I-Outcome
healthy	32758689	473	480	I-Outcome
cells	32758689	481	486	I-Outcome
was	32758689	487	490	O
determined	32758689	491	501	O
.	32758689	502	503	O

Antiviral	32758689	504	513	B-Outcome
effects	32758689	514	521	I-Outcome
of	32758689	522	524	O
Novaferon	32758689	525	534	B-Intervention
in	32758689	535	537	O
COVID-19	32758689	538	546	B-Participant
patients	32758689	547	555	O
with	32758689	556	560	O
treatment	32758689	561	570	O
of	32758689	571	573	O
Novaferon	32758689	574	583	B-Intervention
,	32758689	584	585	O
Novaferon	32758689	586	595	B-Intervention
plus	32758689	596	600	I-Intervention
Lopinavir	32758689	601	610	I-Intervention
/	32758689	611	612	I-Intervention
Ritonavir	32758689	613	622	I-Intervention
,	32758689	623	624	O
or	32758689	625	627	O
Lopinavir	32758689	628	637	B-Intervention
/	32758689	638	639	I-Intervention
Ritonavir	32758689	640	649	I-Intervention
were	32758689	650	654	O
evaluated	32758689	655	664	O
.	32758689	665	666	O

The	32758689	667	670	O
primary	32758689	671	678	O
endpoint	32758689	679	687	O
was	32758689	688	691	O
the	32758689	692	695	O
SARS	32758689	696	700	B-Outcome
-	32758689	701	702	I-Outcome
CoV-2	32758689	703	708	I-Outcome
clearance	32758689	709	718	I-Outcome
rates	32758689	719	724	I-Outcome
on	32758689	725	727	I-Outcome
day	32758689	728	731	I-Outcome
six	32758689	732	735	I-Outcome
of	32758689	736	738	O
treatment	32758689	739	748	O
,	32758689	749	750	O
and	32758689	751	754	O
the	32758689	755	758	O
secondary	32758689	759	768	O
endpoint	32758689	769	777	O
was	32758689	778	781	O
the	32758689	782	785	O
time	32758689	786	790	B-Outcome
to	32758689	791	793	I-Outcome
SARS	32758689	794	798	I-Outcome
-	32758689	799	800	I-Outcome
CoV-2	32758689	801	806	I-Outcome
clearance	32758689	807	816	I-Outcome
.	32758689	817	818	O

RESULTS	32758689	819	826	O
:	32758689	827	828	O
Novaferon	32758689	829	838	B-Intervention
inhibited	32758689	839	848	B-Observation
viral	32758689	849	854	B-Outcome
replication	32758689	855	866	I-Outcome
(	32758689	867	868	O
EC50=1.02ng	32758689	869	880	O
/	32758689	881	882	O
ml	32758689	883	885	O
)	32758689	886	887	O
,	32758689	888	889	O
and	32758689	890	893	O
prevented	32758689	894	903	B-Observation
viral	32758689	904	909	B-Outcome
infection	32758689	910	919	I-Outcome
(	32758689	920	921	O
EC50=0.10ng	32758689	922	933	O
/	32758689	934	935	O
ml	32758689	936	938	O
)	32758689	939	940	O
.	32758689	941	942	O

Results	32758689	943	950	O
from	32758689	951	955	O
the	32758689	956	959	O
89	32758689	960	962	O
enrolled	32758689	963	971	O
COVID-19	32758689	972	980	B-Participant
patients	32758689	981	989	O
showed	32758689	990	996	O
that	32758689	997	1001	O
both	32758689	1002	1006	O
Novaferon	32758689	1007	1016	B-Intervention
and	32758689	1017	1020	O
Novaferon	32758689	1021	1030	B-Intervention
plus	32758689	1031	1035	I-Intervention
Lopinavir	32758689	1036	1045	I-Intervention
/	32758689	1046	1047	I-Intervention
Ritonavir	32758689	1048	1057	I-Intervention
groups	32758689	1058	1064	O
had	32758689	1065	1068	O
significantly	32758689	1069	1082	B-Observation
higher	32758689	1083	1089	I-Observation
viral	32758689	1090	1095	B-Outcome
clearance	32758689	1096	1105	I-Outcome
rates	32758689	1106	1111	I-Outcome
on	32758689	1112	1114	I-Outcome
day	32758689	1115	1118	I-Outcome
six	32758689	1119	1122	I-Outcome
than	32758689	1123	1127	O
Lopinavir	32758689	1128	1137	B-Intervention
/	32758689	1138	1139	I-Intervention
Ritonavir	32758689	1140	1149	I-Intervention
group	32758689	1150	1155	I-Intervention
(	32758689	1156	1157	O
50.0	32758689	1158	1162	B-Observation
%	32758689	1163	1164	I-Observation
vs.	32758689	1165	1168	O
24.1	32758689	1169	1173	B-Observation
%	32758689	1174	1175	I-Observation
,	32758689	1176	1177	O
p=0.0400	32758689	1178	1186	O
,	32758689	1187	1188	O
and	32758689	1189	1192	O
60.0	32758689	1193	1197	B-Observation
%	32758689	1198	1199	I-Observation
vs.	32758689	1200	1203	O
24.1	32758689	1204	1208	B-Observation
%	32758689	1209	1210	I-Observation
,	32758689	1211	1212	O
p=0.0053	32758689	1213	1221	O
)	32758689	1222	1223	O
.	32758689	1224	1225	O

The	32758689	1226	1229	O
median	32758689	1230	1236	B-Outcome
time	32758689	1237	1241	I-Outcome
to	32758689	1242	1244	I-Outcome
viral	32758689	1245	1250	I-Outcome
clearance	32758689	1251	1260	I-Outcome
was	32758689	1261	1264	O
six	32758689	1265	1268	B-Observation
days	32758689	1269	1273	I-Observation
,	32758689	1274	1275	O
six	32758689	1276	1279	B-Observation
days	32758689	1280	1284	I-Observation
,	32758689	1285	1286	O
and	32758689	1287	1290	O
nine	32758689	1291	1295	B-Observation
days	32758689	1296	1300	I-Observation
for	32758689	1301	1304	O
three	32758689	1305	1310	B-Intervention
groups	32758689	1311	1317	I-Intervention
,	32758689	1318	1319	O
respectively	32758689	1320	1332	O
,	32758689	1333	1334	O
a	32758689	1335	1336	O
3-day	32758689	1337	1342	B-Observation
reduction	32758689	1343	1352	I-Observation
in	32758689	1353	1355	O
both	32758689	1356	1360	O
the	32758689	1361	1364	O
Novaferon	32758689	1365	1374	B-Intervention
and	32758689	1375	1378	O
Novaferon	32758689	1379	1388	B-Intervention
plus	32758689	1389	1393	I-Intervention
Lopinavir	32758689	1394	1403	I-Intervention
/	32758689	1404	1405	I-Intervention
Ritonavir	32758689	1406	1415	I-Intervention
groups	32758689	1416	1422	O
compared	32758689	1423	1431	O
with	32758689	1432	1436	O
the	32758689	1437	1440	O
Lopinavir	32758689	1441	1450	B-Intervention
/	32758689	1451	1452	I-Intervention
Ritonavir	32758689	1453	1462	I-Intervention
group	32758689	1463	1468	I-Intervention
.	32758689	1469	1470	O

CONCLUSIONS	32758689	1471	1482	O
:	32758689	1483	1484	O
Novaferon	32758689	1485	1494	B-Intervention
exhibited	32758689	1495	1504	B-Observation
anti	32758689	1505	1509	B-Outcome
-	32758689	1510	1511	I-Outcome
SARS	32758689	1512	1516	I-Outcome
-	32758689	1517	1518	I-Outcome
CoV-2	32758689	1519	1524	I-Outcome
effects	32758689	1525	1532	I-Outcome
in	32758689	1533	1535	O
vitro	32758689	1536	1541	B-Participant
and	32758689	1542	1545	O
in	32758689	1546	1548	O
COVID-19	32758689	1549	1557	B-Participant
patients	32758689	1558	1566	O
.	32758689	1567	1568	O

These	32758689	1569	1574	O
data	32758689	1575	1579	O
justify	32758689	1580	1587	O
further	32758689	1588	1595	O
evaluation	32758689	1596	1606	O
of	32758689	1607	1609	O
Novaferon	32758689	1610	1619	O
.	32758689	1620	1621	O

BACKGROUND	32758689	1622	1632	O
:	32758689	1633	1634	O
Number	32758689	1635	1641	O
ChiCTR2000029496	32758689	1642	1658	O
at	32758689	1659	1661	O
the	32758689	1662	1665	O
Chinese	32758689	1666	1673	O
Clinical	32758689	1674	1682	O
Trial	32758689	1683	1688	O
Registry	32758689	1689	1697	O
(	32758689	1698	1699	O
http://www.chictr.org.cn/	32758689	1700	1725	O
)	32758689	1726	1727	O
.	32758689	1728	1729	O


Pakistan	32771032	0	8	O
Randomized	32771032	9	19	O
and	32771032	20	23	O
Observational	32771032	24	37	O
Trial	32771032	38	43	O
to	32771032	44	46	O
Evaluate	32771032	47	55	O
Coronavirus	32771032	56	67	O
Treatment	32771032	68	77	O
(	32771032	78	79	O
PROTECT	32771032	80	87	O
)	32771032	88	89	O
of	32771032	90	92	O
Hydroxychloroquine	32771032	93	111	B-Intervention
,	32771032	112	113	O
Oseltamivir	32771032	114	125	B-Intervention
and	32771032	126	129	O
Azithromycin	32771032	130	142	B-Intervention
to	32771032	143	145	O
treat	32771032	146	151	O
newly	32771032	152	157	O
diagnosed	32771032	158	167	O
patients	32771032	168	176	O
with	32771032	177	181	O
COVID-19	32771032	182	190	B-Participant
infection	32771032	191	200	I-Participant
who	32771032	201	204	O
have	32771032	205	209	O
no	32771032	210	212	O
comorbidities	32771032	213	226	B-Participant
like	32771032	227	231	O
diabetes	32771032	232	240	B-Participant
mellitus	32771032	241	249	I-Participant
:	32771032	250	251	O
A	32771032	252	253	O
structured	32771032	254	264	O
summary	32771032	265	272	O
of	32771032	273	275	O
a	32771032	276	277	O
study	32771032	278	283	O
protocol	32771032	284	292	O
for	32771032	293	296	O
a	32771032	297	298	O
randomized	32771032	299	309	O
controlled	32771032	310	320	O
trial	32771032	321	326	O
.	32771032	327	328	O

OBJECTIVE	32771032	329	338	O
:	32771032	339	340	O
To	32771032	341	343	O
evaluate	32771032	344	352	O
the	32771032	353	356	O
effectiveness	32771032	357	370	O
of	32771032	371	373	O
Hydroxychloroquine	32771032	374	392	B-Intervention
Phosphate	32771032	393	402	I-Intervention
/	32771032	403	404	I-Intervention
Sulfate	32771032	405	412	I-Intervention
(	32771032	413	414	O
200	32771032	415	418	O
mg	32771032	419	421	O
orally	32771032	422	428	O
8	32771032	429	430	O
hourly	32771032	431	437	O
thrice	32771032	438	444	O
a	32771032	445	446	O
day	32771032	447	450	O
for	32771032	451	454	O
5	32771032	455	456	O
days	32771032	457	461	O
)	32771032	462	463	O
,	32771032	464	465	O
versus	32771032	466	472	O
oseltamivir	32771032	473	484	B-Intervention
(	32771032	485	486	O
75	32771032	487	489	O
mg	32771032	490	492	O
orally	32771032	493	499	O
twice	32771032	500	505	O
a	32771032	506	507	O
day	32771032	508	511	O
for	32771032	512	515	O
5	32771032	516	517	O
days	32771032	518	522	O
)	32771032	523	524	O
,	32771032	525	526	O
and	32771032	527	530	O
versus	32771032	531	537	O
Azithromycin	32771032	538	550	B-Intervention
(	32771032	551	552	O
500	32771032	553	556	O
mg	32771032	557	559	O
orally	32771032	560	566	O
daily	32771032	567	572	O
on	32771032	573	575	O
day	32771032	576	579	O
1	32771032	580	581	O
,	32771032	582	583	O
followed	32771032	584	592	O
by	32771032	593	595	O
250	32771032	596	599	O
mg	32771032	600	602	O
orally	32771032	603	609	O
twice	32771032	610	615	O
a	32771032	616	617	O
day	32771032	618	621	O
on	32771032	622	624	O
days	32771032	625	629	O
2	32771032	630	631	O
-	32771032	632	633	O
5	32771032	634	635	O
)	32771032	636	637	O
alone	32771032	638	643	O
and	32771032	644	647	O
in	32771032	648	650	O
combination	32771032	651	662	B-Intervention
(	32771032	663	664	O
in	32771032	665	667	O
all	32771032	668	671	O
seven	32771032	672	677	O
groups	32771032	678	684	O
)	32771032	685	686	O
,	32771032	687	688	O
in	32771032	689	691	O
clearing	32771032	692	700	B-Observation
the	32771032	701	704	O
coronavirus	32771032	705	716	B-Outcome
(	32771032	717	718	I-Outcome
COVID-19	32771032	719	727	I-Outcome
)	32771032	728	729	I-Outcome
nucleic	32771032	730	737	I-Outcome
acid	32771032	738	742	I-Outcome
from	32771032	743	747	I-Outcome
throat	32771032	748	754	I-Outcome
and	32771032	755	758	I-Outcome
nasal	32771032	759	764	I-Outcome
swab	32771032	765	769	I-Outcome
and	32771032	770	773	O
in	32771032	774	776	O
bringing	32771032	777	785	B-Observation
about	32771032	786	791	O
clinical	32771032	792	800	B-Outcome
improvement	32771032	801	812	I-Outcome
on	32771032	813	815	I-Outcome
day	32771032	816	819	I-Outcome
7	32771032	820	821	I-Outcome
of	32771032	822	824	O
follow	32771032	825	831	O
-	32771032	832	833	O
up	32771032	834	836	O
(	32771032	837	838	O
primary	32771032	839	846	O
outcomes	32771032	847	855	O
)	32771032	856	857	O
.	32771032	858	859	O

METHODS	32771032	860	867	O
:	32771032	868	869	O
An	32771032	870	872	O
adaptive	32771032	873	881	O
design	32771032	882	888	O
,	32771032	889	890	O
set	32771032	891	894	O
within	32771032	895	901	O
a	32771032	902	903	O
comprehensive	32771032	904	917	O
cohort	32771032	918	924	O
study	32771032	925	930	O
,	32771032	931	932	O
to	32771032	933	935	O
permit	32771032	936	942	O
flexibility	32771032	943	954	O
in	32771032	955	957	O
this	32771032	958	962	O
fast	32771032	963	967	O
-	32771032	968	969	O
changing	32771032	970	978	O
clinical	32771032	979	987	O
and	32771032	988	991	O
public	32771032	992	998	O
health	32771032	999	1005	O
scenario	32771032	1006	1014	O
.	32771032	1015	1016	O

The	32771032	1017	1020	O
randomized	32771032	1021	1031	O
study	32771032	1032	1037	O
will	32771032	1038	1042	O
be	32771032	1043	1045	O
a	32771032	1046	1047	O
multicenter	32771032	1048	1059	O
,	32771032	1060	1061	O
multiarm	32771032	1062	1070	O
,	32771032	1071	1072	O
multistage	32771032	1073	1083	O
,	32771032	1084	1085	O
randomized	32771032	1086	1096	O
controlled	32771032	1097	1107	O
trial	32771032	1108	1113	O
with	32771032	1114	1118	O
a	32771032	1119	1120	O
parallel	32771032	1121	1129	O
design	32771032	1130	1136	O
.	32771032	1137	1138	O

An	32771032	1139	1141	O
observation	32771032	1142	1153	O
only	32771032	1154	1158	O
cohort	32771032	1159	1165	O
will	32771032	1166	1170	O
emerge	32771032	1171	1177	O
from	32771032	1178	1182	O
those	32771032	1183	1188	O
not	32771032	1189	1192	O
consenting	32771032	1193	1203	O
to	32771032	1204	1206	O
randomization	32771032	1207	1220	O
.	32771032	1221	1222	O

METHODS	32771032	1223	1230	O
:	32771032	1231	1232	O
Eligible	32771032	1233	1241	O
will	32771032	1242	1246	O
be	32771032	1247	1249	O
newly	32771032	1250	1255	B-Participant
diagnosed	32771032	1256	1265	I-Participant
patients	32771032	1266	1274	O
,	32771032	1275	1276	O
either	32771032	1277	1283	O
hospitalized	32771032	1284	1296	B-Participant
or	32771032	1297	1299	O
in	32771032	1300	1302	O
self	32771032	1303	1307	B-Participant
-	32771032	1308	1309	I-Participant
isolation	32771032	1310	1319	I-Participant
,	32771032	1320	1321	O
without	32771032	1322	1329	O
any	32771032	1330	1333	O
comorbidities	32771032	1334	1347	B-Participant
or	32771032	1348	1350	O
with	32771032	1351	1355	O
controlled	32771032	1356	1366	B-Participant
chronic	32771032	1367	1374	I-Participant
medical	32771032	1375	1382	I-Participant
conditions	32771032	1383	1393	I-Participant
like	32771032	1394	1398	O
diabetes	32771032	1399	1407	B-Participant
mellitus	32771032	1408	1416	I-Participant
and	32771032	1417	1420	O
hypertension	32771032	1421	1433	B-Participant
.	32771032	1434	1435	O

Participants	32771032	1436	1448	O
of	32771032	1449	1451	O
any	32771032	1452	1455	O
gender	32771032	1456	1462	O
or	32771032	1463	1465	O
age	32771032	1466	1469	O
group	32771032	1470	1475	O
having	32771032	1476	1482	O
tested	32771032	1483	1489	O
positive	32771032	1490	1498	O
for	32771032	1499	1502	O
COVID-19	32771032	1503	1511	B-Participant
on	32771032	1512	1514	O
Real	32771032	1515	1519	O
-	32771032	1520	1521	O
Time	32771032	1522	1526	O
qRT	32771032	1527	1530	O
-	32771032	1531	1532	O
PCR	32771032	1533	1536	O
(	32771032	1537	1538	O
Quantitative	32771032	1539	1551	O
Reverse	32771032	1552	1559	O
Transcription	32771032	1560	1573	O
PCR	32771032	1574	1577	O
)	32771032	1578	1579	O
will	32771032	1580	1584	O
be	32771032	1585	1587	O
invited	32771032	1588	1595	O
to	32771032	1596	1598	O
take	32771032	1599	1603	O
part	32771032	1604	1608	O
in	32771032	1609	1611	O
study	32771032	1612	1617	O
at	32771032	1618	1620	O
twelve	32771032	1621	1627	O
centers	32771032	1628	1635	O
across	32771032	1636	1642	O
eight	32771032	1643	1648	O
cities	32771032	1649	1655	O
in	32771032	1656	1658	O
Pakistan	32771032	1659	1667	O
.	32771032	1668	1669	O

Those	32771032	1670	1675	O
pregnant	32771032	1676	1684	B-Participant
or	32771032	1685	1687	O
lactating	32771032	1688	1697	B-Participant
,	32771032	1698	1699	O
severely	32771032	1700	1708	B-Participant
dyspneic	32771032	1709	1717	I-Participant
or	32771032	1718	1720	O
with	32771032	1721	1725	O
respiratory	32771032	1726	1737	B-Participant
distress	32771032	1738	1746	I-Participant
,	32771032	1747	1748	O
already	32771032	1749	1756	O
undergoing	32771032	1757	1767	B-Participant
treatment	32771032	1768	1777	I-Participant
,	32771032	1778	1779	O
and	32771032	1780	1783	O
with	32771032	1784	1788	O
serious	32771032	1789	1796	B-Participant
comorbidities	32771032	1797	1810	I-Participant
like	32771032	1811	1815	O
liver	32771032	1816	1821	B-Participant
or	32771032	1822	1824	I-Participant
kidney	32771032	1825	1831	I-Participant
failure	32771032	1832	1839	I-Participant
will	32771032	1840	1844	O
be	32771032	1845	1847	O
excluded	32771032	1848	1856	O
.	32771032	1857	1858	O

UNASSIGNED	32771032	1859	1869	O
:	32771032	1870	1871	O
There	32771032	1872	1877	O
will	32771032	1878	1882	O
be	32771032	1883	1885	O
a	32771032	1886	1887	O
total	32771032	1888	1893	O
of	32771032	1894	1896	O
seven	32771032	1897	1902	O
comparator	32771032	1903	1913	O
groups	32771032	1914	1920	O
:	32771032	1921	1922	O
Each	32771032	1923	1927	O
drug	32771032	1928	1932	O
(	32771032	1933	1934	O
Hydroxychloroquine	32771032	1935	1953	B-Intervention
Phosphate	32771032	1954	1963	I-Intervention
/	32771032	1964	1965	I-Intervention
Sulfate	32771032	1966	1973	I-Intervention
,	32771032	1974	1975	O
Oseltamivir	32771032	1976	1987	B-Intervention
and	32771032	1988	1991	O
Azithromycin	32771032	1992	2004	B-Intervention
)	32771032	2005	2006	O
given	32771032	2007	2012	O
as	32771032	2013	2015	O
monotherapy	32771032	2016	2027	O
(	32771032	2028	2029	O
three	32771032	2030	2035	O
groups	32771032	2036	2042	O
)	32771032	2043	2044	O
;	32771032	2045	2046	O
combinations	32771032	2047	2059	B-Intervention
of	32771032	2060	2062	I-Intervention
each	32771032	2063	2067	I-Intervention
of	32771032	2068	2070	I-Intervention
two	32771032	2071	2074	I-Intervention
drugs	32771032	2075	2080	I-Intervention
(	32771032	2081	2082	O
three	32771032	2083	2088	O
groups	32771032	2089	2095	O
)	32771032	2096	2097	O
;	32771032	2098	2099	O
and	32771032	2100	2103	O
a	32771032	2104	2105	O
final	32771032	2106	2111	O
group	32771032	2112	2117	O
on	32771032	2118	2120	O
triple	32771032	2121	2127	B-Intervention
drug	32771032	2128	2132	I-Intervention
regimen	32771032	2133	2140	I-Intervention
.	32771032	2141	2142	O

RESULTS	32771032	2143	2150	O
:	32771032	2151	2152	O
The	32771032	2153	2156	O
laboratory	32771032	2157	2167	O
-	32771032	2168	2169	O
based	32771032	2170	2175	O
primary	32771032	2176	2183	O
outcome	32771032	2184	2191	O
will	32771032	2192	2196	O
be	32771032	2197	2199	O
turning	32771032	2200	2207	O
the	32771032	2208	2211	O
test	32771032	2212	2216	O
negative	32771032	2217	2225	B-Outcome
for	32771032	2226	2229	I-Outcome
COVID-19	32771032	2230	2238	I-Outcome
on	32771032	2239	2241	I-Outcome
qRT	32771032	2242	2245	I-Outcome
-	32771032	2246	2247	I-Outcome
PCR	32771032	2248	2251	I-Outcome
on	32771032	2252	2254	I-Outcome
day	32771032	2255	2258	I-Outcome
7	32771032	2259	2260	I-Outcome
of	32771032	2261	2263	O
follow	32771032	2264	2270	O
-	32771032	2271	2272	O
up	32771032	2273	2275	O
.	32771032	2276	2277	O

The	32771032	2278	2281	O
clinical	32771032	2282	2290	O
primary	32771032	2291	2298	O
outcome	32771032	2299	2306	O
will	32771032	2307	2311	O
be	32771032	2312	2314	O
improvement	32771032	2315	2326	B-Outcome
from	32771032	2327	2331	I-Outcome
baseline	32771032	2332	2340	I-Outcome
of	32771032	2341	2343	I-Outcome
two	32771032	2344	2347	I-Outcome
points	32771032	2348	2354	I-Outcome
on	32771032	2355	2357	O
a	32771032	2358	2359	O
seven	32771032	2360	2365	O
-	32771032	2366	2367	O
category	32771032	2368	2376	O
ordinal	32771032	2377	2384	O
scale	32771032	2385	2390	O
of	32771032	2391	2393	O
clinical	32771032	2394	2402	O
status	32771032	2403	2409	O
on	32771032	2410	2412	O
day	32771032	2413	2416	O
7	32771032	2417	2418	O
of	32771032	2419	2421	O
follow	32771032	2422	2428	O
-	32771032	2429	2430	O
up	32771032	2431	2433	O
.	32771032	2434	2435	O

UNASSIGNED	32771032	2436	2446	O
:	32771032	2447	2448	O
Participants	32771032	2449	2461	O
will	32771032	2462	2466	O
be	32771032	2467	2469	O
randomized	32771032	2470	2480	O
,	32771032	2481	2482	O
maintaining	32771032	2483	2494	O
concealment	32771032	2495	2506	O
of	32771032	2507	2509	O
allocation	32771032	2510	2520	O
sequence	32771032	2521	2529	O
,	32771032	2530	2531	O
using	32771032	2532	2537	O
a	32771032	2538	2539	O
computer	32771032	2540	2548	O
-	32771032	2549	2550	O
generated	32771032	2551	2560	O
random	32771032	2561	2567	O
number	32771032	2568	2574	O
list	32771032	2575	2579	O
of	32771032	2580	2582	O
variable	32771032	2583	2591	O
block	32771032	2592	2597	O
size	32771032	2598	2602	O
into	32771032	2603	2607	O
multiple	32771032	2608	2616	O
intervention	32771032	2617	2629	O
groups	32771032	2630	2636	O
in	32771032	2637	2639	O
the	32771032	2640	2643	O
allocation	32771032	2644	2654	O
ratio	32771032	2655	2660	O
of	32771032	2661	2663	O
1:1	32771032	2664	2667	O
for	32771032	2668	2671	O
all	32771032	2672	2675	O
groups	32771032	2676	2682	O
.	32771032	2683	2684	O

Phase	32785213	0	5	O
I	32785213	8	9	O
/	32785213	10	11	O
II	32785213	12	14	O
study	32785213	15	20	O
of	32785213	21	23	O
COVID-19	32785213	24	32	B-Participant
RNA	32785213	33	36	B-Intervention
vaccine	32785213	37	44	I-Intervention
BNT162b1	32785213	45	53	I-Intervention
in	32785213	54	56	O
adults	32785213	57	63	B-Participant
.	32785213	64	65	O

In	32785213	66	68	O
March	32785213	69	74	O
2020	32785213	75	79	O
,	32785213	80	81	O
the	32785213	82	85	O
World	32785213	86	91	O
Health	32785213	92	98	O
Organization	32785213	99	111	O
(	32785213	112	113	O
WHO	32785213	114	117	O
)	32785213	118	119	O
declared	32785213	120	128	O
coronavirus	32785213	129	140	O
disease	32785213	141	148	O
2019	32785213	149	153	O
(	32785213	154	155	O
COVID-19	32785213	156	164	O
)	32785213	165	166	O
,	32785213	167	168	O
which	32785213	169	174	O
is	32785213	175	177	O
caused	32785213	178	184	O
by	32785213	185	187	O
severe	32785213	188	194	O
acute	32785213	195	200	O
respiratory	32785213	201	212	O
syndrome	32785213	213	221	O
coronavirus	32785213	222	233	O
2	32785213	234	235	O
(	32785213	236	237	O
SARS	32785213	238	242	O
-	32785213	243	244	O
CoV-2)1	32785213	245	252	O
,	32785213	253	254	O
a	32785213	255	256	O
pandemic	32785213	257	265	O
.	32785213	266	267	O

With	32785213	268	272	O
rapidly	32785213	273	280	O
accumulating	32785213	281	293	O
numbers	32785213	294	301	O
of	32785213	302	304	O
cases	32785213	305	310	O
and	32785213	311	314	O
deaths	32785213	315	321	O
reported	32785213	322	330	O
globally2	32785213	331	340	O
,	32785213	341	342	O
a	32785213	343	344	O
vaccine	32785213	345	352	O
is	32785213	353	355	O
urgently	32785213	356	364	O
needed	32785213	365	371	O
.	32785213	372	373	O

Here	32785213	374	378	O
we	32785213	379	381	O
report	32785213	382	388	O
the	32785213	389	392	O
available	32785213	393	402	O
safety	32785213	403	409	B-Outcome
,	32785213	410	411	O
tolerability	32785213	412	424	B-Outcome
and	32785213	425	428	O
immunogenicity	32785213	429	443	B-Outcome
data	32785213	444	448	O
from	32785213	449	453	O
an	32785213	454	456	O
ongoing	32785213	457	464	O
placebo	32785213	465	472	O
-	32785213	473	474	O
controlled	32785213	475	485	O
,	32785213	486	487	O
observer	32785213	488	496	O
-	32785213	497	498	O
blinded	32785213	499	506	O
dose	32785213	507	511	O
-	32785213	512	513	O
escalation	32785213	514	524	O
study	32785213	525	530	O
(	32785213	531	532	O
ClinicalTrials.gov	32785213	533	551	O
identifier	32785213	552	562	O
NCT04368728	32785213	563	574	O
)	32785213	575	576	O
among	32785213	577	582	O
45	32785213	583	585	O
healthy	32785213	588	595	B-Participant
adults	32785213	596	602	B-Participant
(	32785213	603	604	O
18	32785213	605	607	B-Participant
-	32785213	608	609	I-Participant
55	32785213	610	612	I-Participant
years	32785213	615	620	I-Participant
of	32785213	621	623	I-Participant
age	32785213	624	627	I-Participant
)	32785213	628	629	O
,	32785213	630	631	O
who	32785213	632	635	O
were	32785213	636	640	O
randomized	32785213	641	651	O
to	32785213	652	654	O
receive	32785213	655	662	O
2	32785213	663	664	O
doses	32785213	665	670	O
-	32785213	671	672	O
separated	32785213	673	682	O
by	32785213	683	685	O
21	32785213	686	688	O
days	32785213	689	693	O
-	32785213	694	695	O
of	32785213	696	698	O
10	32785213	699	701	O
g	32785213	704	706	O
,	32785213	707	708	O
30	32785213	709	711	O
g	32785213	714	716	O
or	32785213	717	719	O
100	32785213	720	723	O
g	32785213	726	728	O
of	32785213	729	731	O
BNT162b1	32785213	732	740	B-Intervention
.	32785213	741	742	O

Effect	32789505	0	6	O
of	32789505	7	9	O
an	32789505	10	12	O
Inactivated	32789505	13	24	B-Intervention
Vaccine	32789505	25	32	I-Intervention
Against	32789505	33	40	O
SARS	32789505	41	45	B-Participant
-	32789505	46	47	I-Participant
CoV-2	32789505	48	53	I-Participant
on	32789505	54	56	O
Safety	32789505	57	63	B-Outcome
and	32789505	64	67	O
Immunogenicity	32789505	68	82	B-Outcome
Outcomes	32789505	83	91	O
:	32789505	92	93	O
Interim	32789505	94	101	O
Analysis	32789505	102	110	O
of	32789505	111	113	O
2	32789505	114	115	O
Randomized	32789505	116	126	O
Clinical	32789505	127	135	O
Trials	32789505	136	142	O
.	32789505	143	144	O

A	32789505	145	146	O
vaccine	32789505	147	154	O
against	32789505	155	162	O
coronavirus	32789505	163	174	O
disease	32789505	175	182	O
2019	32789505	183	187	O
(	32789505	188	189	O
COVID-19	32789505	190	198	O
)	32789505	199	200	O
is	32789505	201	203	O
urgently	32789505	204	212	O
needed	32789505	213	219	O
.	32789505	220	221	O

To	32789505	222	224	O
evaluate	32789505	225	233	O
the	32789505	234	237	O
safety	32789505	238	244	B-Outcome
and	32789505	245	248	O
immunogenicity	32789505	249	263	B-Outcome
of	32789505	264	266	O
an	32789505	267	269	O
investigational	32789505	270	285	B-Intervention
inactivated	32789505	286	297	I-Intervention
whole	32789505	298	303	I-Intervention
-	32789505	304	305	I-Intervention
virus	32789505	306	311	I-Intervention
COVID-19	32789505	312	320	I-Intervention
vaccine	32789505	321	328	I-Intervention
in	32789505	329	331	O
China	32789505	332	337	O
.	32789505	338	339	O

In	32789505	340	342	O
the	32789505	343	346	O
phase	32789505	347	352	O
1	32789505	353	354	O
trial	32789505	355	360	O
,	32789505	361	362	O
96	32789505	363	365	O
participants	32789505	366	378	O
were	32789505	379	383	O
assigned	32789505	384	392	O
to	32789505	393	395	O
1	32789505	396	397	O
of	32789505	398	400	O
the	32789505	401	404	O
3	32789505	405	406	O
dose	32789505	407	411	O
groups	32789505	412	418	O
(	32789505	419	420	O
2.5	32789505	421	424	B-Intervention
,	32789505	425	426	O
5	32789505	427	428	B-Intervention
,	32789505	429	430	O
and	32789505	431	434	O
10	32789505	435	437	B-Intervention
g	32789505	438	440	I-Intervention
/	32789505	441	442	I-Intervention
dose	32789505	443	447	I-Intervention
)	32789505	448	449	O
and	32789505	450	453	O
an	32789505	454	456	O
aluminum	32789505	457	465	B-Intervention
hydroxide	32789505	466	475	I-Intervention
(	32789505	476	477	I-Intervention
alum	32789505	478	482	I-Intervention
)	32789505	483	484	I-Intervention
adjuvant	32789505	485	493	I-Intervention
-	32789505	494	495	I-Intervention
only	32789505	496	500	I-Intervention
group	32789505	501	506	I-Intervention
(	32789505	507	508	O
n	32789505	509	510	O
=	32789505	513	514	O
24	32789505	517	519	O
in	32789505	520	522	O
each	32789505	523	527	O
group	32789505	528	533	O
)	32789505	534	535	O
,	32789505	536	537	O
and	32789505	538	541	O
received	32789505	542	550	O
3	32789505	551	552	O
intramuscular	32789505	553	566	O
injections	32789505	567	577	O
at	32789505	578	580	O
days	32789505	581	585	O
0	32789505	586	587	O
,	32789505	588	589	O
28	32789505	590	592	O
,	32789505	593	594	O
and	32789505	595	598	O
56	32789505	599	601	O
.	32789505	602	603	O

In	32789505	604	606	O
the	32789505	607	610	O
phase	32789505	611	616	O
2	32789505	617	618	O
trial	32789505	619	624	O
,	32789505	625	626	O
224	32789505	627	630	O
adults	32789505	631	637	O
were	32789505	638	642	O
randomized	32789505	643	653	O
to	32789505	654	656	O
5	32789505	657	658	B-Intervention
g	32789505	659	661	I-Intervention
/	32789505	662	663	I-Intervention
dose	32789505	664	668	I-Intervention
in	32789505	669	671	O
2	32789505	672	673	O
schedule	32789505	674	682	O
groups	32789505	683	689	O
(	32789505	690	691	O
injections	32789505	692	702	O
on	32789505	703	705	O
days	32789505	706	710	O
0	32789505	711	712	O
and	32789505	713	716	O
14	32789505	717	719	O
[	32789505	720	721	O
n	32789505	722	723	O
=	32789505	726	727	O
84	32789505	730	732	O
]	32789505	733	734	O
vs	32789505	735	737	O
alum	32789505	738	742	O
only	32789505	743	747	O
[	32789505	748	749	O
n	32789505	750	751	O
=	32789505	754	755	O
28	32789505	758	760	O
]	32789505	761	762	O
,	32789505	763	764	O
and	32789505	765	768	O
days	32789505	769	773	O
0	32789505	774	775	O
and	32789505	776	779	O
21	32789505	780	782	O
[	32789505	783	784	O
n	32789505	785	786	O
=	32789505	789	790	O
84	32789505	793	795	O
]	32789505	796	797	O
vs	32789505	798	800	O
alum	32789505	801	805	O
only	32789505	806	810	O
[	32789505	811	812	O
n	32789505	813	814	O
=	32789505	817	818	O
28	32789505	821	823	O
]	32789505	824	825	O
)	32789505	826	827	O
.	32789505	828	829	O

Interim	32789505	830	837	O
analysis	32789505	838	846	O
of	32789505	847	849	O
ongoing	32789505	850	857	O
randomized	32789505	858	868	O
,	32789505	869	870	O
double	32789505	871	877	O
-	32789505	878	879	O
blind	32789505	880	885	O
,	32789505	886	887	O
placebo	32789505	888	895	O
-	32789505	896	897	O
controlled	32789505	898	908	O
,	32789505	909	910	O
phase	32789505	911	916	O
1	32789505	917	918	O
and	32789505	919	922	O
2	32789505	923	924	O
clinical	32789505	925	933	O
trials	32789505	934	940	O
to	32789505	941	943	O
assess	32789505	944	950	O
an	32789505	951	953	O
inactivated	32789505	954	965	B-Intervention
COVID-19	32789505	966	974	I-Intervention
vaccine	32789505	975	982	I-Intervention
.	32789505	983	984	O

The	32789505	985	988	O
trials	32789505	989	995	O
were	32789505	996	1000	O
conducted	32789505	1001	1010	O
in	32789505	1011	1013	O
Henan	32789505	1014	1019	O
Province	32789505	1020	1028	O
,	32789505	1029	1030	O
China	32789505	1031	1036	O
,	32789505	1037	1038	O
among	32789505	1039	1044	O
96	32789505	1045	1047	O
(	32789505	1048	1049	O
phase	32789505	1050	1055	O
1	32789505	1056	1057	O
)	32789505	1058	1059	O
and	32789505	1060	1063	O
224	32789505	1064	1067	O
(	32789505	1068	1069	O
phase	32789505	1070	1075	O
2	32789505	1076	1077	O
)	32789505	1078	1079	O
healthy	32789505	1080	1087	O
adults	32789505	1088	1094	O
aged	32789505	1095	1099	O
between	32789505	1100	1107	O
18	32789505	1108	1110	O
and	32789505	1111	1114	O
59	32789505	1115	1117	O
years	32789505	1118	1123	O
.	32789505	1124	1125	O

Study	32789505	1126	1131	O
enrollment	32789505	1132	1142	O
began	32789505	1143	1148	O
on	32789505	1149	1151	O
April	32789505	1152	1157	O
12	32789505	1158	1160	O
,	32789505	1161	1162	O
2020	32789505	1163	1167	O
.	32789505	1168	1169	O

The	32789505	1170	1173	O
interim	32789505	1174	1181	O
analysis	32789505	1182	1190	O
was	32789505	1191	1194	O
conducted	32789505	1195	1204	O
on	32789505	1205	1207	O
June	32789505	1208	1212	O
16	32789505	1213	1215	O
,	32789505	1216	1217	O
2020	32789505	1218	1222	O
,	32789505	1223	1224	O
and	32789505	1225	1228	O
updated	32789505	1229	1236	O
on	32789505	1237	1239	O
July	32789505	1240	1244	O
27	32789505	1245	1247	O
,	32789505	1248	1249	O
2020	32789505	1250	1254	O
.	32789505	1255	1256	O

The	32789505	1257	1260	O
primary	32789505	1261	1268	O
safety	32789505	1269	1275	O
outcome	32789505	1276	1283	O
was	32789505	1284	1287	O
the	32789505	1288	1291	O
combined	32789505	1292	1300	B-Outcome
adverse	32789505	1301	1308	I-Outcome
reactions	32789505	1309	1318	I-Outcome
7	32789505	1319	1320	I-Outcome
days	32789505	1321	1325	I-Outcome
after	32789505	1326	1331	I-Outcome
each	32789505	1332	1336	I-Outcome
injection	32789505	1337	1346	I-Outcome
,	32789505	1347	1348	O
and	32789505	1349	1352	O
the	32789505	1353	1356	O
primary	32789505	1357	1364	O
immunogenicity	32789505	1365	1379	O
outcome	32789505	1380	1387	O
was	32789505	1388	1391	O
neutralizing	32789505	1392	1404	B-Outcome
antibody	32789505	1405	1413	I-Outcome
response	32789505	1414	1422	I-Outcome
14	32789505	1423	1425	I-Outcome
days	32789505	1426	1430	I-Outcome
after	32789505	1431	1436	I-Outcome
the	32789505	1437	1440	I-Outcome
whole	32789505	1441	1446	I-Outcome
-	32789505	1447	1448	I-Outcome
course	32789505	1449	1455	I-Outcome
vaccination	32789505	1456	1467	I-Outcome
,	32789505	1468	1469	O
which	32789505	1470	1475	O
was	32789505	1476	1479	O
measured	32789505	1480	1488	O
by	32789505	1489	1491	O
a	32789505	1492	1493	O
50	32789505	1494	1496	O
%	32789505	1497	1498	O
plaque	32789505	1499	1505	O
reduction	32789505	1506	1515	O
neutralization	32789505	1516	1530	O
test	32789505	1531	1535	O
against	32789505	1536	1543	O
live	32789505	1544	1548	O
severe	32789505	1549	1555	O
acute	32789505	1556	1561	O
respiratory	32789505	1562	1573	O
syndrome	32789505	1574	1582	O
coronavirus	32789505	1583	1594	O
2	32789505	1595	1596	O
(	32789505	1597	1598	O
SARS	32789505	1599	1603	O
-	32789505	1604	1605	O
CoV-2	32789505	1606	1611	O
)	32789505	1612	1613	O
.	32789505	1614	1615	O

Among	32789505	1616	1621	O
320	32789505	1622	1625	O
patients	32789505	1626	1634	O
who	32789505	1635	1638	O
were	32789505	1639	1643	O
randomized	32789505	1644	1654	O
(	32789505	1655	1656	O
mean	32789505	1657	1661	O
age	32789505	1662	1665	O
,	32789505	1666	1667	O
42.8	32789505	1668	1672	O
years	32789505	1673	1678	O
;	32789505	1679	1680	O
200	32789505	1681	1684	O
women	32789505	1685	1690	O
[	32789505	1691	1692	O
62.5	32789505	1693	1697	O
%	32789505	1698	1699	O
]	32789505	1700	1701	O
)	32789505	1702	1703	O
,	32789505	1704	1705	O
all	32789505	1706	1709	O
completed	32789505	1710	1719	O
the	32789505	1720	1723	O
trial	32789505	1724	1729	O
up	32789505	1730	1732	O
to	32789505	1733	1735	O
28	32789505	1736	1738	O
days	32789505	1739	1743	O
after	32789505	1744	1749	O
the	32789505	1750	1753	O
whole	32789505	1754	1759	O
-	32789505	1760	1761	O
course	32789505	1762	1768	O
vaccination	32789505	1769	1780	O
.	32789505	1781	1782	O

The	32789505	1783	1786	O
7-day	32789505	1787	1792	B-Outcome
adverse	32789505	1793	1800	I-Outcome
reactions	32789505	1801	1810	I-Outcome
occurred	32789505	1811	1819	O
in	32789505	1820	1822	O
3	32789505	1823	1824	B-Count
(	32789505	1825	1826	I-Count
12.5	32789505	1827	1831	I-Count
%	32789505	1832	1833	I-Count
)	32789505	1834	1835	I-Count
,	32789505	1836	1837	O
5	32789505	1838	1839	B-Count
(	32789505	1840	1841	I-Count
20.8	32789505	1842	1846	I-Count
%	32789505	1847	1848	I-Count
)	32789505	1849	1850	I-Count
,	32789505	1851	1852	O
4	32789505	1853	1854	B-Count
(	32789505	1855	1856	I-Count
16.7	32789505	1857	1861	I-Count
%	32789505	1862	1863	I-Count
)	32789505	1864	1865	I-Count
,	32789505	1866	1867	O
and	32789505	1868	1871	O
6	32789505	1872	1873	B-Count
(	32789505	1874	1875	I-Count
25.0	32789505	1876	1880	I-Count
%	32789505	1881	1882	I-Count
)	32789505	1883	1884	I-Count
patients	32789505	1885	1893	I-Count
in	32789505	1894	1896	O
the	32789505	1897	1900	O
alum	32789505	1901	1905	B-Intervention
only	32789505	1906	1910	I-Intervention
,	32789505	1911	1912	O
low	32789505	1913	1916	B-Intervention
-	32789505	1917	1918	I-Intervention
dose	32789505	1919	1923	I-Intervention
,	32789505	1924	1925	O
medium	32789505	1926	1932	B-Intervention
-	32789505	1933	1934	I-Intervention
dose	32789505	1935	1939	I-Intervention
,	32789505	1940	1941	O
and	32789505	1942	1945	O
high	32789505	1946	1950	B-Intervention
-	32789505	1951	1952	I-Intervention
dose	32789505	1953	1957	I-Intervention
groups	32789505	1958	1964	O
,	32789505	1965	1966	O
respectively	32789505	1967	1979	O
,	32789505	1980	1981	O
in	32789505	1982	1984	O
the	32789505	1985	1988	O
phase	32789505	1989	1994	O
1	32789505	1995	1996	O
trial	32789505	1997	2002	O
;	32789505	2003	2004	O
and	32789505	2005	2008	O
in	32789505	2009	2011	O
5	32789505	2012	2013	B-Count
(	32789505	2014	2015	I-Count
6.0	32789505	2016	2019	I-Count
%	32789505	2020	2021	I-Count
)	32789505	2022	2023	I-Count
and	32789505	2024	2027	O
4	32789505	2028	2029	B-Count
(	32789505	2030	2031	I-Count
14.3	32789505	2032	2036	I-Count
%	32789505	2037	2038	I-Count
)	32789505	2039	2040	I-Count
patients	32789505	2041	2049	I-Count
who	32789505	2050	2053	O
received	32789505	2054	2062	O
injections	32789505	2063	2073	O
on	32789505	2074	2076	O
days	32789505	2077	2081	O
0	32789505	2082	2083	O
and	32789505	2084	2087	O
14	32789505	2088	2090	O
for	32789505	2091	2094	O
vaccine	32789505	2095	2102	B-Intervention
and	32789505	2103	2106	O
alum	32789505	2107	2111	B-Intervention
only	32789505	2112	2116	I-Intervention
,	32789505	2117	2118	O
and	32789505	2119	2122	O
16	32789505	2123	2125	B-Count
(	32789505	2126	2127	I-Count
19.0	32789505	2128	2132	I-Count
%	32789505	2133	2134	I-Count
)	32789505	2135	2136	I-Count
and	32789505	2137	2140	O
5	32789505	2141	2142	B-Count
(	32789505	2143	2144	I-Count
17.9	32789505	2145	2149	I-Count
%	32789505	2150	2151	I-Count
)	32789505	2152	2153	I-Count
patients	32789505	2154	2162	I-Count
who	32789505	2163	2166	O
received	32789505	2167	2175	O
injections	32789505	2176	2186	O
on	32789505	2187	2189	O
days	32789505	2190	2194	O
0	32789505	2195	2196	O
and	32789505	2197	2200	O
21	32789505	2201	2203	O
for	32789505	2204	2207	O
vaccine	32789505	2208	2215	B-Intervention
and	32789505	2216	2219	O
alum	32789505	2220	2224	B-Intervention
only	32789505	2225	2229	I-Intervention
,	32789505	2230	2231	O
respectively	32789505	2232	2244	O
,	32789505	2245	2246	O
in	32789505	2247	2249	O
the	32789505	2250	2253	O
phase	32789505	2254	2259	O
2	32789505	2260	2261	O
trial	32789505	2262	2267	O
.	32789505	2268	2269	O

The	32789505	2270	2273	O
most	32789505	2274	2278	B-Observation
common	32789505	2279	2285	I-Observation
adverse	32789505	2286	2293	B-Outcome
reaction	32789505	2294	2302	I-Outcome
was	32789505	2303	2306	O
injection	32789505	2307	2316	B-Outcome
site	32789505	2317	2321	I-Outcome
pain	32789505	2322	2326	I-Outcome
,	32789505	2327	2328	O
followed	32789505	2329	2337	O
by	32789505	2338	2340	O
fever	32789505	2341	2346	B-Outcome
,	32789505	2347	2348	O
which	32789505	2349	2354	O
were	32789505	2355	2359	O
mild	32789505	2360	2364	O
and	32789505	2365	2368	O
self	32789505	2369	2373	O
-	32789505	2374	2375	O
limiting	32789505	2376	2384	O
;	32789505	2385	2386	O
no	32789505	2387	2389	B-Count
serious	32789505	2390	2397	B-Outcome
adverse	32789505	2398	2405	I-Outcome
reactions	32789505	2406	2415	I-Outcome
were	32789505	2416	2420	O
noted	32789505	2421	2426	O
.	32789505	2427	2428	O

The	32789505	2429	2432	O
geometric	32789505	2433	2442	B-Outcome
mean	32789505	2443	2447	I-Outcome
titers	32789505	2448	2454	I-Outcome
of	32789505	2455	2457	I-Outcome
neutralizing	32789505	2458	2470	I-Outcome
antibodies	32789505	2471	2481	I-Outcome
in	32789505	2482	2484	O
the	32789505	2485	2488	O
low-	32789505	2489	2493	B-Intervention
,	32789505	2494	2495	O
medium-	32789505	2496	2503	B-Intervention
,	32789505	2504	2505	O
and	32789505	2506	2509	O
high	32789505	2510	2514	B-Intervention
-	32789505	2515	2516	I-Intervention
dose	32789505	2517	2521	I-Intervention
groups	32789505	2522	2528	O
at	32789505	2529	2531	O
day	32789505	2532	2535	O
14	32789505	2536	2538	O
after	32789505	2539	2544	O
3	32789505	2545	2546	O
injections	32789505	2547	2557	O
were	32789505	2558	2562	O
316	32789505	2563	2566	B-Observation
(	32789505	2567	2568	I-Observation
95	32789505	2569	2571	O
%	32789505	2572	2573	O
CI	32789505	2574	2576	O
,	32789505	2577	2578	O
218	32789505	2579	2582	O
-	32789505	2583	2584	O
457	32789505	2585	2588	O
)	32789505	2589	2590	O
,	32789505	2591	2592	O
206	32789505	2593	2596	B-Observation
(	32789505	2597	2598	O
95	32789505	2599	2601	O
%	32789505	2602	2603	O
CI	32789505	2604	2606	O
,	32789505	2607	2608	O
123	32789505	2609	2612	O
-	32789505	2613	2614	O
343	32789505	2615	2618	O
)	32789505	2619	2620	O
,	32789505	2621	2622	O
and	32789505	2623	2626	O
297	32789505	2627	2630	B-Observation
(	32789505	2631	2632	O
95	32789505	2633	2635	O
%	32789505	2636	2637	O
CI	32789505	2638	2640	O
,	32789505	2641	2642	O
208	32789505	2643	2646	O
-	32789505	2647	2648	O
424	32789505	2649	2652	O
)	32789505	2653	2654	O
,	32789505	2655	2656	O
respectively	32789505	2657	2669	O
,	32789505	2670	2671	O
in	32789505	2672	2674	O
the	32789505	2675	2678	O
phase	32789505	2679	2684	O
1	32789505	2685	2686	O
trial	32789505	2687	2692	O
,	32789505	2693	2694	O
and	32789505	2695	2698	O
were	32789505	2699	2703	O
121	32789505	2704	2707	B-Observation
(	32789505	2708	2709	O
95	32789505	2710	2712	O
%	32789505	2713	2714	O
CI	32789505	2715	2717	O
,	32789505	2718	2719	O
95	32789505	2720	2722	O
-	32789505	2723	2724	O
154	32789505	2725	2728	O
)	32789505	2729	2730	O
and	32789505	2731	2734	O
247	32789505	2735	2738	B-Observation
(	32789505	2739	2740	O
95	32789505	2741	2743	O
%	32789505	2744	2745	O
CI	32789505	2746	2748	O
,	32789505	2749	2750	O
176	32789505	2751	2754	O
-	32789505	2755	2756	O
345	32789505	2757	2760	O
)	32789505	2761	2762	O
at	32789505	2763	2765	O
day	32789505	2766	2769	O
14	32789505	2770	2772	O
after	32789505	2773	2778	O
2	32789505	2779	2780	O
injections	32789505	2781	2791	O
in	32789505	2792	2794	O
participants	32789505	2795	2807	O
receiving	32789505	2808	2817	O
vaccine	32789505	2818	2825	B-Intervention
on	32789505	2826	2828	O
days	32789505	2829	2833	O
0	32789505	2834	2835	O
and	32789505	2836	2839	O
14	32789505	2840	2842	O
and	32789505	2843	2846	O
on	32789505	2847	2849	O
days	32789505	2850	2854	O
0	32789505	2855	2856	O
and	32789505	2857	2860	O
21	32789505	2861	2863	O
,	32789505	2864	2865	O
respectively	32789505	2866	2878	O
,	32789505	2879	2880	O
in	32789505	2881	2883	O
the	32789505	2884	2887	O
phase	32789505	2888	2893	O
2	32789505	2894	2895	O
trial	32789505	2896	2901	O
.	32789505	2902	2903	O

There	32789505	2904	2909	O
were	32789505	2910	2914	O
no	32789505	2915	2917	O
detectable	32789505	2918	2928	B-Observation
antibody	32789505	2929	2937	B-Outcome
responses	32789505	2938	2947	I-Outcome
in	32789505	2948	2950	O
all	32789505	2951	2954	O
alum	32789505	2955	2959	B-Intervention
-	32789505	2960	2961	I-Intervention
only	32789505	2962	2966	I-Intervention
groups	32789505	2967	2973	O
.	32789505	2974	2975	O

In	32789505	2976	2978	O
this	32789505	2979	2983	O
interim	32789505	2984	2991	O
report	32789505	2992	2998	O
of	32789505	2999	3001	O
the	32789505	3002	3005	O
phase	32789505	3006	3011	O
1	32789505	3012	3013	O
and	32789505	3014	3017	O
phase	32789505	3018	3023	O
2	32789505	3024	3025	O
trials	32789505	3026	3032	O
of	32789505	3033	3035	O
an	32789505	3036	3038	O
inactivated	32789505	3039	3050	B-Intervention
COVID-19	32789505	3051	3059	I-Intervention
vaccine	32789505	3060	3067	I-Intervention
,	32789505	3068	3069	O
patients	32789505	3070	3078	O
had	32789505	3079	3082	O
a	32789505	3083	3084	O
low	32789505	3085	3088	B-Observation
rate	32789505	3089	3093	I-Observation
of	32789505	3094	3096	O
adverse	32789505	3097	3104	B-Outcome
reactions	32789505	3105	3114	I-Outcome
and	32789505	3115	3118	O
demonstrated	32789505	3119	3131	O
immunogenicity	32789505	3132	3146	B-Outcome
;	32789505	3147	3148	O
the	32789505	3149	3152	O
study	32789505	3153	3158	O
is	32789505	3159	3161	O
ongoing	32789505	3162	3169	O
.	32789505	3170	3171	O

Efficacy	32789505	3172	3180	O
and	32789505	3181	3184	O
longer	32789505	3185	3191	O
-	32789505	3192	3193	O
term	32789505	3194	3198	O
adverse	32789505	3199	3206	O
event	32789505	3207	3212	O
assessment	32789505	3213	3223	O
will	32789505	3224	3228	O
require	32789505	3229	3236	O
phase	32789505	3237	3242	O
3	32789505	3243	3244	O
trials	32789505	3245	3251	O
.	32789505	3252	3253	O

Chinese	32789505	3254	3261	O
Clinical	32789505	3262	3270	O
Trial	32789505	3271	3276	O
Registry	32789505	3277	3285	O
Identifier	32789505	3286	3296	O
:	32789505	3297	3298	O
ChiCTR2000031809	32789505	3299	3315	O
.	32789505	3316	3317	O


Auxora	32795330	0	6	B-Intervention
versus	32795330	7	13	O
standard	32795330	14	22	B-Intervention
of	32795330	23	25	I-Intervention
care	32795330	26	30	I-Intervention
for	32795330	31	34	O
the	32795330	35	38	O
treatment	32795330	39	48	O
of	32795330	49	51	O
severe	32795330	52	58	B-Participant
or	32795330	59	61	I-Participant
critical	32795330	62	70	I-Participant
COVID-19	32795330	71	79	I-Participant
pneumonia	32795330	80	89	I-Participant
:	32795330	90	91	O
results	32795330	92	99	O
from	32795330	100	104	O
a	32795330	105	106	O
randomized	32795330	107	117	O
controlled	32795330	118	128	O
trial	32795330	129	134	O
.	32795330	135	136	O

Calcium	32795330	137	144	O
release	32795330	145	152	O
-	32795330	153	154	O
activated	32795330	155	164	O
calcium	32795330	165	172	O
(	32795330	173	174	O
CRAC	32795330	175	179	O
)	32795330	180	181	O
channel	32795330	182	189	O
inhibitors	32795330	190	200	O
stabilize	32795330	201	210	O
the	32795330	211	214	O
pulmonary	32795330	215	224	O
endothelium	32795330	225	236	O
and	32795330	237	240	O
block	32795330	241	246	O
proinflammatory	32795330	247	262	O
cytokine	32795330	263	271	O
release	32795330	272	279	O
,	32795330	280	281	O
potentially	32795330	282	293	O
mitigating	32795330	294	304	O
respiratory	32795330	305	316	O
complications	32795330	317	330	O
observed	32795330	331	339	O
in	32795330	340	342	O
patients	32795330	343	351	O
with	32795330	352	356	O
COVID-19	32795330	357	365	O
.	32795330	366	367	O

This	32795330	368	372	O
study	32795330	373	378	O
aimed	32795330	379	384	O
to	32795330	385	387	O
investigate	32795330	388	399	O
the	32795330	400	403	O
safety	32795330	404	410	B-Outcome
and	32795330	411	414	O
efficacy	32795330	415	423	B-Outcome
of	32795330	424	426	O
Auxora	32795330	427	433	B-Intervention
,	32795330	434	435	O
a	32795330	436	437	O
novel	32795330	438	443	O
,	32795330	444	445	O
intravenously	32795330	446	459	O
administered	32795330	460	472	O
CRAC	32795330	473	477	O
channel	32795330	478	485	O
inhibitor	32795330	486	495	O
,	32795330	496	497	O
in	32795330	498	500	O
adults	32795330	501	507	B-Participant
with	32795330	508	512	O
severe	32795330	513	519	B-Participant
or	32795330	520	522	I-Participant
critical	32795330	523	531	I-Participant
COVID-19	32795330	532	540	I-Participant
pneumonia	32795330	541	550	I-Participant
.	32795330	551	552	O

A	32795330	553	554	O
randomized	32795330	555	565	O
,	32795330	566	567	O
controlled	32795330	568	578	O
,	32795330	579	580	O
open	32795330	581	585	O
-	32795330	586	587	O
label	32795330	588	593	O
study	32795330	594	599	O
of	32795330	600	602	O
Auxora	32795330	603	609	B-Intervention
was	32795330	610	613	O
conducted	32795330	614	623	O
in	32795330	624	626	O
adults	32795330	627	633	B-Participant
with	32795330	634	638	O
severe	32795330	639	645	B-Participant
or	32795330	646	648	I-Participant
critical	32795330	649	657	I-Participant
COVID-19	32795330	658	666	I-Participant
pneumonia	32795330	667	676	I-Participant
.	32795330	677	678	O

Patients	32795330	679	687	O
were	32795330	688	692	O
randomized	32795330	693	703	O
2:1	32795330	704	707	O
to	32795330	708	710	O
receive	32795330	711	718	O
three	32795330	719	724	O
doses	32795330	725	730	O
of	32795330	731	733	O
once	32795330	734	738	O
-	32795330	739	740	O
daily	32795330	741	746	O
Auxora	32795330	747	753	B-Intervention
versus	32795330	754	760	O
standard	32795330	761	769	B-Intervention
of	32795330	770	772	I-Intervention
care	32795330	773	777	I-Intervention
(	32795330	778	779	I-Intervention
SOC	32795330	780	783	I-Intervention
)	32795330	784	785	I-Intervention
alone	32795330	786	791	I-Intervention
.	32795330	792	793	O

The	32795330	794	797	O
primary	32795330	798	805	O
objective	32795330	806	815	O
was	32795330	816	819	O
to	32795330	820	822	O
assess	32795330	823	829	O
the	32795330	830	833	O
safety	32795330	834	840	B-Outcome
and	32795330	841	844	O
tolerability	32795330	845	857	B-Outcome
of	32795330	858	860	O
Auxora	32795330	861	867	B-Intervention
.	32795330	868	869	O

Following	32795330	870	879	O
FDA	32795330	880	883	O
guidance	32795330	884	892	O
,	32795330	893	894	O
study	32795330	895	900	O
enrollment	32795330	901	911	O
was	32795330	912	915	O
halted	32795330	916	922	O
early	32795330	923	928	O
to	32795330	929	931	O
allow	32795330	932	937	O
for	32795330	938	941	O
transition	32795330	942	952	O
to	32795330	953	955	O
a	32795330	956	957	O
randomized	32795330	958	968	O
,	32795330	969	970	O
blinded	32795330	971	978	O
,	32795330	979	980	O
placebo	32795330	981	988	O
-	32795330	989	990	O
controlled	32795330	991	1001	O
study	32795330	1002	1007	O
.	32795330	1008	1009	O

In	32795330	1010	1012	O
total	32795330	1013	1018	O
,	32795330	1019	1020	O
17	32795330	1021	1023	O
patients	32795330	1024	1032	O
with	32795330	1033	1037	O
severe	32795330	1038	1044	B-Participant
and	32795330	1045	1048	O
three	32795330	1049	1054	O
with	32795330	1055	1059	O
critical	32795330	1060	1068	B-Participant
COVID-19	32795330	1069	1077	I-Participant
pneumonia	32795330	1078	1087	I-Participant
were	32795330	1088	1092	O
randomized	32795330	1093	1103	O
to	32795330	1104	1106	O
Auxora	32795330	1107	1113	B-Intervention
and	32795330	1114	1117	O
nine	32795330	1118	1122	O
with	32795330	1123	1127	O
severe	32795330	1128	1134	B-Participant
and	32795330	1135	1138	O
one	32795330	1139	1142	O
with	32795330	1143	1147	O
critical	32795330	1148	1156	B-Intervention
COVID-19	32795330	1157	1165	I-Intervention
pneumonia	32795330	1166	1175	I-Intervention
to	32795330	1176	1178	O
SOC	32795330	1179	1182	B-Participant
.	32795330	1183	1184	O

Similar	32795330	1185	1192	B-Count
proportions	32795330	1193	1204	I-Count
of	32795330	1205	1207	I-Count
patients	32795330	1208	1216	I-Count
receiving	32795330	1217	1226	O
Auxora	32795330	1227	1233	B-Intervention
and	32795330	1234	1237	O
SOC	32795330	1238	1241	B-Intervention
experienced	32795330	1242	1253	O
	32795330	1256	1257	B-Outcome
1	32795330	1260	1261	I-Outcome
adverse	32795330	1262	1269	I-Outcome
event	32795330	1270	1275	I-Outcome
(	32795330	1276	1277	O
75	32795330	1278	1280	B-Count
%	32795330	1281	1282	I-Count
versus	32795330	1283	1289	O
80	32795330	1290	1292	B-Count
%	32795330	1293	1294	I-Count
,	32795330	1295	1296	O
respectively	32795330	1297	1309	O
)	32795330	1310	1311	O
.	32795330	1312	1313	O

Fewer	32795330	1314	1319	B-Count
patients	32795330	1320	1328	I-Count
receiving	32795330	1329	1338	O
Auxora	32795330	1339	1345	B-Intervention
experienced	32795330	1346	1357	O
serious	32795330	1358	1365	B-Outcome
adverse	32795330	1366	1373	I-Outcome
events	32795330	1374	1380	I-Outcome
versus	32795330	1381	1387	O
SOC	32795330	1388	1391	B-Intervention
(	32795330	1392	1393	O
30	32795330	1394	1396	B-Count
%	32795330	1397	1398	I-Count
versus	32795330	1399	1405	O
50	32795330	1406	1408	B-Count
%	32795330	1409	1410	I-Count
,	32795330	1411	1412	O
respectively	32795330	1413	1425	O
)	32795330	1426	1427	O
.	32795330	1428	1429	O

Two	32795330	1430	1433	B-Count
patients	32795330	1434	1442	I-Count
(	32795330	1443	1444	I-Count
10	32795330	1445	1447	I-Count
%	32795330	1448	1449	I-Count
)	32795330	1450	1451	I-Count
receiving	32795330	1452	1461	O
Auxora	32795330	1462	1468	B-Intervention
and	32795330	1469	1472	O
two	32795330	1473	1476	B-Count
(	32795330	1477	1478	I-Count
20	32795330	1479	1481	I-Count
%	32795330	1482	1483	I-Count
)	32795330	1484	1485	I-Count
receiving	32795330	1486	1495	O
SOC	32795330	1496	1499	B-Intervention
died	32795330	1500	1504	B-Outcome
during	32795330	1505	1511	I-Outcome
the	32795330	1512	1515	I-Outcome
30	32795330	1518	1520	I-Outcome
days	32795330	1523	1527	I-Outcome
after	32795330	1528	1533	O
randomization	32795330	1534	1547	O
.	32795330	1548	1549	O

Among	32795330	1550	1555	O
patients	32795330	1556	1564	O
with	32795330	1565	1569	O
severe	32795330	1570	1576	B-Participant
COVID-19	32795330	1577	1585	I-Participant
pneumonia	32795330	1586	1595	I-Participant
,	32795330	1596	1597	O
the	32795330	1598	1601	O
median	32795330	1602	1608	B-Outcome
time	32795330	1609	1613	I-Outcome
to	32795330	1614	1616	I-Outcome
recovery	32795330	1617	1625	I-Outcome
with	32795330	1626	1630	O
Auxora	32795330	1631	1637	B-Intervention
was	32795330	1638	1641	O
5	32795330	1642	1643	B-Observation
days	32795330	1646	1650	I-Observation
versus	32795330	1651	1657	O
12	32795330	1658	1660	B-Observation
days	32795330	1663	1667	I-Observation
with	32795330	1668	1672	O
SOC	32795330	1673	1676	B-Intervention
;	32795330	1677	1678	O
the	32795330	1679	1682	O
recovery	32795330	1683	1691	B-Outcome
rate	32795330	1692	1696	I-Outcome
ratio	32795330	1697	1702	I-Outcome
was	32795330	1703	1706	O
1.87	32795330	1707	1711	B-Observation
(	32795330	1712	1713	O
95	32795330	1714	1716	O
%	32795330	1717	1718	O
CI	32795330	1719	1721	O
,	32795330	1722	1723	O
0.72	32795330	1724	1728	O
,	32795330	1729	1730	O
4.89	32795330	1731	1735	O
)	32795330	1736	1737	O
.	32795330	1738	1739	O

Invasive	32795330	1740	1748	B-Outcome
mechanical	32795330	1749	1759	I-Outcome
ventilation	32795330	1760	1771	I-Outcome
was	32795330	1772	1775	O
needed	32795330	1776	1782	O
in	32795330	1783	1785	O
18	32795330	1786	1788	B-Count
%	32795330	1789	1790	I-Count
of	32795330	1791	1793	I-Count
patients	32795330	1794	1802	I-Count
with	32795330	1803	1807	O
severe	32795330	1808	1814	B-Participant
COVID-19	32795330	1815	1823	I-Participant
pneumonia	32795330	1824	1833	I-Participant
receiving	32795330	1834	1843	O
Auxora	32795330	1844	1850	B-Intervention
versus	32795330	1851	1857	O
50	32795330	1858	1860	B-Count
%	32795330	1861	1862	I-Count
receiving	32795330	1863	1872	O
SOC	32795330	1873	1876	B-Intervention
(	32795330	1877	1878	O
absolute	32795330	1879	1887	B-Outcome
risk	32795330	1888	1892	I-Outcome
reduction	32795330	1893	1902	I-Outcome
=	32795330	1905	1906	O
32	32795330	1909	1911	B-Observation
%	32795330	1912	1913	I-Observation
;	32795330	1914	1915	O
95	32795330	1916	1918	O
%	32795330	1919	1920	O
CI	32795330	1921	1923	O
,	32795330	1924	1925	O
-	32795330	1926	1927	O
0.07	32795330	1930	1934	O
,	32795330	1935	1936	O
0.71	32795330	1937	1941	O
)	32795330	1942	1943	O
.	32795330	1944	1945	O

Outcomes	32795330	1946	1954	B-Outcome
measured	32795330	1955	1963	I-Outcome
by	32795330	1964	1966	I-Outcome
an	32795330	1967	1969	I-Outcome
8-point	32795330	1970	1977	I-Outcome
ordinal	32795330	1978	1985	I-Outcome
scale	32795330	1986	1991	I-Outcome
were	32795330	1992	1996	O
significantly	32795330	1997	2010	B-Observation
improved	32795330	2011	2019	I-Observation
for	32795330	2020	2023	O
patients	32795330	2024	2032	O
receiving	32795330	2033	2042	O
Auxora	32795330	2043	2049	B-Intervention
,	32795330	2050	2051	O
especially	32795330	2052	2062	O
for	32795330	2063	2066	O
patients	32795330	2067	2075	O
with	32795330	2076	2080	O
a	32795330	2081	2082	O
baseline	32795330	2083	2091	O
PaO2	32795330	2092	2096	O
/	32795330	2097	2098	O
FiO2	32795330	2099	2103	O
=	32795330	2106	2107	O
101	32795330	2110	2113	O
-	32795330	2114	2115	O
200	32795330	2116	2119	O
.	32795330	2120	2121	O

Auxora	32795330	2122	2128	B-Intervention
demonstrated	32795330	2129	2141	O
a	32795330	2142	2143	O
favorable	32795330	2144	2153	B-Observation
safety	32795330	2154	2160	B-Outcome
profile	32795330	2161	2168	I-Outcome
in	32795330	2169	2171	O
patients	32795330	2172	2180	O
with	32795330	2181	2185	O
severe	32795330	2186	2192	B-Participant
or	32795330	2193	2195	I-Participant
critical	32795330	2196	2204	I-Participant
COVID-19	32795330	2205	2213	I-Participant
pneumonia	32795330	2214	2223	I-Participant
and	32795330	2224	2227	O
improved	32795330	2228	2236	B-Observation
outcomes	32795330	2237	2245	B-Outcome
in	32795330	2246	2248	O
patients	32795330	2249	2257	O
with	32795330	2258	2262	O
severe	32795330	2263	2269	B-Participant
COVID-19	32795330	2270	2278	I-Participant
pneumonia	32795330	2279	2288	I-Participant
.	32795330	2289	2290	O

These	32795330	2291	2296	O
results	32795330	2297	2304	O
,	32795330	2305	2306	O
however	32795330	2307	2314	O
,	32795330	2315	2316	O
are	32795330	2317	2320	O
limited	32795330	2321	2328	O
by	32795330	2329	2331	O
the	32795330	2332	2335	O
open	32795330	2336	2340	O
-	32795330	2341	2342	O
label	32795330	2343	2348	O
study	32795330	2349	2354	O
design	32795330	2355	2361	O
and	32795330	2362	2365	O
small	32795330	2366	2371	O
patient	32795330	2372	2379	O
population	32795330	2380	2390	O
resulting	32795330	2391	2400	O
from	32795330	2401	2405	O
the	32795330	2406	2409	O
early	32795330	2410	2415	O
cessation	32795330	2416	2425	O
of	32795330	2426	2428	O
enrollment	32795330	2429	2439	O
in	32795330	2440	2442	O
response	32795330	2443	2451	O
to	32795330	2452	2454	O
regulatory	32795330	2455	2465	O
guidance	32795330	2466	2474	O
.	32795330	2475	2476	O

The	32795330	2477	2480	O
impact	32795330	2481	2487	O
of	32795330	2488	2490	O
Auxora	32795330	2491	2497	O
on	32795330	2498	2500	O
respiratory	32795330	2501	2512	O
complications	32795330	2513	2526	O
in	32795330	2527	2529	O
patients	32795330	2530	2538	O
with	32795330	2539	2543	O
severe	32795330	2544	2550	O
COVID-19	32795330	2551	2559	O
pneumonia	32795330	2560	2569	O
will	32795330	2570	2574	O
be	32795330	2575	2577	O
further	32795330	2578	2585	O
assessed	32795330	2586	2594	O
in	32795330	2595	2597	O
a	32795330	2598	2599	O
planned	32795330	2600	2607	O
randomized	32795330	2608	2618	O
,	32795330	2619	2620	O
blinded	32795330	2621	2628	O
,	32795330	2629	2630	O
placebo	32795330	2631	2638	O
-	32795330	2639	2640	O
controlled	32795330	2641	2651	O
study	32795330	2652	2657	O
.	32795330	2658	2659	O

ClinicalTrials.gov	32795330	2660	2678	O
,	32795330	2679	2680	O
NCT04345614	32795330	2681	2692	O
.	32795330	2693	2694	O

Submitted	32795330	2695	2704	O
on	32795330	2705	2707	O
7	32795330	2708	2709	O
April	32795330	2710	2715	O
2020	32795330	2716	2720	O
.	32795330	2721	2722	O


Treatment	32811531	0	9	O
of	32811531	10	12	O
severe	32811531	13	19	B-Participant
COVID-19	32811531	20	28	I-Participant
with	32811531	29	33	O
human	32811531	34	39	B-Intervention
umbilical	32811531	40	49	I-Intervention
cord	32811531	50	54	I-Intervention
mesenchymal	32811531	55	66	I-Intervention
stem	32811531	67	71	I-Intervention
cells	32811531	72	77	I-Intervention
.	32811531	78	79	O

COVID-19	32811531	80	88	O
is	32811531	89	91	O
a	32811531	92	93	O
highly	32811531	94	100	O
infectious	32811531	101	111	O
respiratory	32811531	112	123	O
disease	32811531	124	131	O
.	32811531	132	133	O

No	32811531	134	136	O
therapeutics	32811531	137	149	O
have	32811531	150	154	O
yet	32811531	155	158	O
been	32811531	159	163	O
proven	32811531	164	170	O
effective	32811531	171	180	O
for	32811531	181	184	O
treating	32811531	185	193	O
severe	32811531	194	200	O
COVID-19	32811531	201	209	O
.	32811531	210	211	O

To	32811531	212	214	O
determine	32811531	215	224	O
whether	32811531	225	232	O
human	32811531	233	238	B-Intervention
umbilical	32811531	239	248	I-Intervention
cord	32811531	249	253	I-Intervention
mesenchymal	32811531	254	265	I-Intervention
stem	32811531	266	270	I-Intervention
cell	32811531	271	275	I-Intervention
infusion	32811531	276	284	I-Intervention
may	32811531	285	288	O
be	32811531	289	291	O
effective	32811531	292	301	B-Observation
and	32811531	302	305	O
safe	32811531	306	310	B-Observation
for	32811531	311	314	O
the	32811531	315	318	O
treatment	32811531	319	328	O
of	32811531	329	331	O
severe	32811531	332	338	B-Participant
COVID-19	32811531	339	347	I-Participant
.	32811531	348	349	O

Patients	32811531	350	358	O
with	32811531	359	363	O
severe	32811531	364	370	B-Participant
COVID-19	32811531	371	379	I-Participant
were	32811531	380	384	O
randomly	32811531	385	393	O
divided	32811531	394	401	O
into	32811531	402	406	O
2	32811531	407	408	O
groups	32811531	409	415	O
:	32811531	416	417	O
the	32811531	418	421	O
standard	32811531	422	430	B-Intervention
treatment	32811531	431	440	I-Intervention
group	32811531	441	446	O
and	32811531	447	450	O
the	32811531	451	454	O
standard	32811531	455	463	B-Intervention
treatment	32811531	464	473	I-Intervention
plus	32811531	474	478	I-Intervention
hUC	32811531	479	482	I-Intervention
-	32811531	483	484	I-Intervention
MSC	32811531	485	488	I-Intervention
infusion	32811531	489	497	I-Intervention
group	32811531	498	503	O
.	32811531	504	505	O

The	32811531	506	509	O
incidence	32811531	510	519	B-Outcome
of	32811531	520	522	I-Outcome
progression	32811531	523	534	I-Outcome
from	32811531	535	539	I-Outcome
severe	32811531	540	546	I-Outcome
to	32811531	547	549	I-Outcome
critical	32811531	550	558	I-Outcome
illness	32811531	559	566	I-Outcome
,	32811531	567	568	O
28-day	32811531	569	575	B-Outcome
mortality	32811531	576	585	I-Outcome
,	32811531	586	587	O
clinical	32811531	588	596	B-Outcome
symptom	32811531	597	604	I-Outcome
improvement	32811531	605	616	I-Outcome
,	32811531	617	618	O
time	32811531	619	623	B-Outcome
to	32811531	624	626	I-Outcome
clinical	32811531	627	635	I-Outcome
symptom	32811531	636	643	I-Outcome
improvement	32811531	644	655	I-Outcome
,	32811531	656	657	O
hematologic	32811531	658	669	B-Outcome
indicators	32811531	670	680	I-Outcome
including	32811531	681	690	I-Outcome
C	32811531	691	692	I-Outcome
-	32811531	693	694	I-Outcome
reactive	32811531	695	703	I-Outcome
protein	32811531	704	711	I-Outcome
,	32811531	712	713	O
lymphocyte	32811531	714	724	B-Outcome
number	32811531	725	731	I-Outcome
,	32811531	732	733	O
and	32811531	734	737	O
interleukin	32811531	738	749	B-Outcome
6	32811531	750	751	I-Outcome
,	32811531	752	753	O
and	32811531	754	757	O
imaging	32811531	758	765	B-Outcome
changes	32811531	766	773	I-Outcome
were	32811531	774	778	O
observed	32811531	779	787	O
and	32811531	788	791	O
compared	32811531	792	800	O
between	32811531	801	808	B-Intervention
the	32811531	809	812	I-Intervention
two	32811531	813	816	I-Intervention
groups	32811531	817	823	I-Intervention
.	32811531	824	825	O

The	32811531	826	829	O
incidence	32811531	830	839	B-Outcome
of	32811531	840	842	I-Outcome
progression	32811531	843	854	I-Outcome
from	32811531	855	859	I-Outcome
severe	32811531	860	866	I-Outcome
to	32811531	867	869	I-Outcome
critical	32811531	870	878	I-Outcome
illness	32811531	879	886	I-Outcome
and	32811531	887	890	O
the	32811531	891	894	O
28-day	32811531	895	901	B-Outcome
mortality	32811531	902	911	I-Outcome
rate	32811531	912	916	I-Outcome
were	32811531	917	921	O
0	32811531	922	923	B-Observation
in	32811531	924	926	O
the	32811531	927	930	O
hUC	32811531	931	934	B-Intervention
-	32811531	935	936	I-Intervention
MSC	32811531	937	940	I-Intervention
treatment	32811531	941	950	I-Intervention
group	32811531	951	956	O
,	32811531	957	958	O
while	32811531	959	964	O
4	32811531	965	966	B-Count
patients	32811531	967	975	I-Count
in	32811531	976	978	O
the	32811531	979	982	O
control	32811531	983	990	B-Intervention
group	32811531	991	996	O
deteriorated	32811531	997	1009	B-Outcome
to	32811531	1010	1012	I-Outcome
critical	32811531	1013	1021	I-Outcome
condition	32811531	1022	1031	I-Outcome
and	32811531	1032	1035	O
received	32811531	1036	1044	O
invasive	32811531	1045	1053	B-Outcome
ventilation	32811531	1054	1065	I-Outcome
;	32811531	1066	1067	O
3	32811531	1068	1069	B-Count
of	32811531	1070	1072	I-Count
them	32811531	1073	1077	I-Count
died	32811531	1078	1082	B-Outcome
,	32811531	1083	1084	O
and	32811531	1085	1088	O
the	32811531	1089	1092	O
28-day	32811531	1093	1099	B-Outcome
mortality	32811531	1100	1109	I-Outcome
rate	32811531	1110	1114	I-Outcome
was	32811531	1115	1118	O
10.34	32811531	1119	1124	B-Observation
%	32811531	1125	1126	I-Observation
.	32811531	1127	1128	O

In	32811531	1129	1131	O
the	32811531	1132	1135	O
hUC	32811531	1136	1139	B-Intervention
-	32811531	1140	1141	I-Intervention
MSC	32811531	1142	1145	I-Intervention
treatment	32811531	1146	1155	I-Intervention
group	32811531	1156	1161	O
,	32811531	1162	1163	O
the	32811531	1164	1167	O
time	32811531	1168	1172	B-Outcome
to	32811531	1173	1175	I-Outcome
clinical	32811531	1176	1184	I-Outcome
improvement	32811531	1185	1196	I-Outcome
was	32811531	1197	1200	O
shorter	32811531	1201	1208	B-Observation
than	32811531	1209	1213	O
that	32811531	1214	1218	O
in	32811531	1219	1221	O
the	32811531	1222	1225	O
control	32811531	1226	1233	B-Intervention
group	32811531	1234	1239	O
.	32811531	1240	1241	O

Clinical	32811531	1242	1250	O
symptoms	32811531	1251	1259	O
of	32811531	1260	1262	O
weakness	32811531	1263	1271	B-Outcome
and	32811531	1272	1275	O
fatigue	32811531	1276	1283	B-Outcome
,	32811531	1284	1285	O
shortness	32811531	1286	1295	B-Outcome
of	32811531	1296	1298	I-Outcome
breath	32811531	1299	1305	I-Outcome
,	32811531	1306	1307	O
and	32811531	1308	1311	O
low	32811531	1312	1315	B-Outcome
oxygen	32811531	1316	1322	I-Outcome
saturation	32811531	1323	1333	I-Outcome
obviously	32811531	1334	1343	O
improved	32811531	1344	1352	B-Observation
beginning	32811531	1353	1362	O
on	32811531	1363	1365	O
the	32811531	1366	1369	O
third	32811531	1370	1375	O
day	32811531	1376	1379	O
of	32811531	1380	1382	O
stem	32811531	1383	1387	B-Intervention
cell	32811531	1388	1392	I-Intervention
infusion	32811531	1393	1401	I-Intervention
and	32811531	1402	1405	O
reached	32811531	1406	1413	O
a	32811531	1414	1415	O
significant	32811531	1416	1427	B-Observation
difference	32811531	1428	1438	I-Observation
on	32811531	1439	1441	O
day	32811531	1442	1445	O
7	32811531	1446	1447	O
.	32811531	1448	1449	O

CRP	32811531	1450	1453	B-Outcome
and	32811531	1454	1457	I-Outcome
IL-6	32811531	1458	1462	I-Outcome
levels	32811531	1463	1469	I-Outcome
were	32811531	1470	1474	O
significantly	32811531	1475	1488	B-Observation
lower	32811531	1489	1494	I-Observation
from	32811531	1495	1499	O
day	32811531	1500	1503	O
3	32811531	1504	1505	O
of	32811531	1506	1508	O
infusion	32811531	1509	1517	B-Intervention
,	32811531	1518	1519	O
the	32811531	1520	1523	O
time	32811531	1524	1528	B-Outcome
for	32811531	1529	1532	I-Outcome
the	32811531	1533	1536	I-Outcome
lymphocyte	32811531	1537	1547	I-Outcome
count	32811531	1548	1553	I-Outcome
to	32811531	1554	1556	I-Outcome
return	32811531	1557	1563	I-Outcome
to	32811531	1564	1566	I-Outcome
the	32811531	1567	1570	I-Outcome
normal	32811531	1571	1577	I-Outcome
range	32811531	1578	1583	I-Outcome
was	32811531	1584	1587	O
significantly	32811531	1588	1601	B-Observation
faster	32811531	1602	1608	I-Observation
,	32811531	1609	1610	O
and	32811531	1611	1614	O
lung	32811531	1615	1619	B-Outcome
inflammation	32811531	1620	1632	I-Outcome
absorption	32811531	1633	1643	I-Outcome
was	32811531	1644	1647	O
significantly	32811531	1648	1661	B-Observation
shorter	32811531	1662	1669	I-Observation
on	32811531	1670	1672	O
CT	32811531	1673	1675	O
imaging	32811531	1676	1683	O
in	32811531	1684	1686	O
the	32811531	1687	1690	O
hUC	32811531	1691	1694	B-Intervention
-	32811531	1695	1696	I-Intervention
MSC	32811531	1697	1700	I-Intervention
group	32811531	1701	1706	O
than	32811531	1707	1711	O
in	32811531	1712	1714	O
the	32811531	1715	1718	O
control	32811531	1719	1726	B-Intervention
group	32811531	1727	1732	O
.	32811531	1733	1734	O

Intravenous	32811531	1735	1746	B-Intervention
transplantation	32811531	1747	1762	I-Intervention
of	32811531	1763	1765	I-Intervention
hUC	32811531	1766	1769	I-Intervention
-	32811531	1770	1771	I-Intervention
MSCs	32811531	1772	1776	I-Intervention
is	32811531	1777	1779	O
a	32811531	1780	1781	O
safe	32811531	1782	1786	B-Observation
and	32811531	1787	1790	O
effective	32811531	1791	1800	B-Observation
method	32811531	1801	1807	O
that	32811531	1808	1812	O
can	32811531	1813	1816	O
be	32811531	1817	1819	O
considered	32811531	1820	1830	O
a	32811531	1831	1832	O
salvage	32811531	1833	1840	O
and	32811531	1841	1844	O
priority	32811531	1845	1853	O
treatment	32811531	1854	1863	O
option	32811531	1864	1870	O
for	32811531	1871	1874	O
severe	32811531	1875	1881	B-Participant
COVID-19	32811531	1882	1890	I-Participant
.	32811531	1891	1892	O

Chinese	32811531	1893	1900	O
Clinical	32811531	1901	1909	O
Trial	32811531	1910	1915	O
Registration	32811531	1916	1928	O
;	32811531	1929	1930	O
ChiCTR2000031494	32811531	1931	1947	O
;	32811531	1948	1949	O
Registered	32811531	1950	1960	O
on	32811531	1961	1963	O
2	32811531	1964	1965	O
April	32811531	1966	1971	O
2020	32811531	1972	1976	O
;	32811531	1977	1978	O
http://	32811531	1979	1986	O
www.medresman.org	32811531	1987	2004	O
.	32811531	2005	2006	O


Evaluation	32812025	0	10	O
of	32812025	11	13	O
the	32812025	14	17	O
efficacy	32812025	18	26	O
of	32812025	27	29	O
sofosbuvir	32812025	30	40	B-Intervention
plus	32812025	41	45	I-Intervention
daclatasvir	32812025	46	57	I-Intervention
in	32812025	58	60	I-Intervention
combination	32812025	61	72	I-Intervention
with	32812025	73	77	I-Intervention
ribavirin	32812025	78	87	I-Intervention
for	32812025	88	91	O
hospitalized	32812025	92	104	B-Participant
COVID-19	32812025	105	113	B-Participant
patients	32812025	114	122	O
with	32812025	123	127	O
moderate	32812025	128	136	B-Participant
disease	32812025	137	144	I-Participant
compared	32812025	145	153	O
with	32812025	154	158	O
standard	32812025	159	167	B-Intervention
care	32812025	168	172	I-Intervention
:	32812025	173	174	O
a	32812025	175	176	O
single	32812025	177	183	O
-	32812025	184	185	O
centre	32812025	186	192	O
,	32812025	193	194	O
randomized	32812025	195	205	O
controlled	32812025	206	216	O
trial	32812025	217	222	O
.	32812025	223	224	O

New	32812025	225	228	O
therapeutic	32812025	229	240	O
options	32812025	241	248	O
are	32812025	249	252	O
urgently	32812025	253	261	O
needed	32812025	262	268	O
to	32812025	269	271	O
tackle	32812025	272	278	O
the	32812025	279	282	O
novel	32812025	283	288	O
coronavirus	32812025	289	300	O
disease	32812025	301	308	O
2019	32812025	309	313	O
(	32812025	314	315	O
COVID-19	32812025	316	324	O
)	32812025	325	326	O
.	32812025	327	328	O

Repurposing	32812025	329	340	O
existing	32812025	341	349	O
pharmaceuticals	32812025	350	365	O
provides	32812025	366	374	O
an	32812025	375	377	O
immediate	32812025	378	387	O
treatment	32812025	388	397	O
opportunity	32812025	398	409	O
.	32812025	410	411	O

We	32812025	412	414	O
assessed	32812025	415	423	O
the	32812025	424	427	O
efficacy	32812025	428	436	B-Outcome
of	32812025	437	439	O
sofosbuvir	32812025	440	450	B-Intervention
and	32812025	451	454	I-Intervention
daclatasvir	32812025	455	466	I-Intervention
with	32812025	467	471	I-Intervention
ribavirin	32812025	472	481	I-Intervention
for	32812025	482	485	O
treating	32812025	486	494	O
patients	32812025	495	503	O
with	32812025	504	508	O
COVID-19	32812025	509	517	B-Participant
.	32812025	518	519	O

This	32812025	520	524	O
was	32812025	525	528	O
a	32812025	529	530	O
single	32812025	531	537	O
-	32812025	538	539	O
centre	32812025	540	546	O
,	32812025	547	548	O
randomized	32812025	549	559	O
controlled	32812025	560	570	O
trial	32812025	571	576	O
in	32812025	577	579	O
adults	32812025	580	586	B-Participant
with	32812025	587	591	O
moderate	32812025	592	600	B-Participant
COVID-19	32812025	601	609	I-Participant
admitted	32812025	610	618	B-Participant
to	32812025	619	621	O
the	32812025	622	625	O
Ghaem	32812025	626	631	O
Shahr	32812025	632	637	O
Razi	32812025	638	642	O
Hospital	32812025	643	651	O
in	32812025	652	654	O
Mazandaran	32812025	655	665	O
Province	32812025	666	674	O
,	32812025	675	676	O
Iran	32812025	677	681	O
.	32812025	682	683	O

Patients	32812025	684	692	O
were	32812025	693	697	O
randomly	32812025	698	706	O
assigned	32812025	707	715	O
to	32812025	716	718	O
400	32812025	719	722	B-Intervention
mg	32812025	725	727	I-Intervention
sofosbuvir	32812025	728	738	I-Intervention
,	32812025	739	740	I-Intervention
60	32812025	741	743	I-Intervention
mg	32812025	746	748	I-Intervention
daclatasvir	32812025	749	760	I-Intervention
and	32812025	761	764	I-Intervention
1200	32812025	765	769	I-Intervention
mg	32812025	772	774	I-Intervention
ribavirin	32812025	775	784	I-Intervention
(	32812025	785	786	O
intervention	32812025	787	799	O
group	32812025	800	805	O
)	32812025	806	807	O
or	32812025	808	810	O
to	32812025	811	813	O
standard	32812025	814	822	B-Intervention
care	32812025	823	827	I-Intervention
(	32812025	828	829	O
control	32812025	830	837	O
group	32812025	838	843	O
)	32812025	844	845	O
.	32812025	846	847	O

The	32812025	848	851	O
primary	32812025	852	859	O
endpoint	32812025	860	868	O
of	32812025	869	871	O
this	32812025	872	876	O
study	32812025	877	882	O
was	32812025	883	886	O
length	32812025	887	893	B-Outcome
of	32812025	894	896	I-Outcome
hospital	32812025	897	905	I-Outcome
stay	32812025	906	910	I-Outcome
.	32812025	911	912	O

This	32812025	913	917	O
study	32812025	918	923	O
is	32812025	924	926	O
registered	32812025	927	937	O
by	32812025	938	940	O
IRCT.ir	32812025	941	948	O
under	32812025	949	954	O
the	32812025	955	958	O
ID	32812025	959	961	O
:	32812025	962	963	O
IRCT20200328046886N1	32812025	964	984	O
.	32812025	985	986	O

Between	32812025	987	994	O
20	32812025	995	997	O
March	32812025	998	1003	O
2020	32812025	1004	1008	O
and	32812025	1009	1012	O
8	32812025	1013	1014	O
April	32812025	1015	1020	O
2020	32812025	1021	1025	O
,	32812025	1026	1027	O
48	32812025	1028	1030	O
patients	32812025	1031	1039	O
were	32812025	1040	1044	O
recruited	32812025	1045	1054	O
;	32812025	1055	1056	O
24	32812025	1057	1059	O
patients	32812025	1060	1068	O
were	32812025	1069	1073	O
randomly	32812025	1074	1082	O
assigned	32812025	1083	1091	O
to	32812025	1092	1094	O
the	32812025	1095	1098	O
intervention	32812025	1099	1111	B-Intervention
group	32812025	1112	1117	O
and	32812025	1118	1121	O
24	32812025	1122	1124	O
to	32812025	1125	1127	O
the	32812025	1128	1131	O
control	32812025	1132	1139	B-Intervention
group	32812025	1140	1145	O
.	32812025	1146	1147	O

The	32812025	1148	1151	O
median	32812025	1152	1158	B-Outcome
duration	32812025	1159	1167	I-Outcome
of	32812025	1168	1170	I-Outcome
hospital	32812025	1171	1179	I-Outcome
stay	32812025	1180	1184	I-Outcome
was	32812025	1185	1188	O
6	32812025	1189	1190	B-Observation
days	32812025	1193	1197	I-Observation
in	32812025	1198	1200	O
both	32812025	1201	1205	B-Intervention
groups	32812025	1206	1212	I-Intervention
(	32812025	1213	1214	O
P	32812025	1215	1216	O
=	32812025	1219	1220	O
0.398	32812025	1223	1228	O
)	32812025	1229	1230	O
.	32812025	1231	1232	O

The	32812025	1233	1236	O
number	32812025	1237	1243	B-Outcome
of	32812025	1244	1246	I-Outcome
ICU	32812025	1247	1250	I-Outcome
admissions	32812025	1251	1261	I-Outcome
in	32812025	1262	1264	O
the	32812025	1265	1268	O
sofosbuvir	32812025	1269	1279	B-Intervention
/	32812025	1280	1281	I-Intervention
daclatasvir	32812025	1282	1293	I-Intervention
/	32812025	1294	1295	I-Intervention
ribavirin	32812025	1296	1305	I-Intervention
group	32812025	1306	1311	O
was	32812025	1312	1315	O
not	32812025	1316	1319	O
significantly	32812025	1320	1333	B-Observation
lower	32812025	1334	1339	I-Observation
than	32812025	1340	1344	O
the	32812025	1345	1348	O
control	32812025	1349	1356	B-Intervention
group	32812025	1357	1362	O
(	32812025	1363	1364	O
0	32812025	1365	1366	B-Count
versus	32812025	1367	1373	O
4	32812025	1374	1375	B-Count
,	32812025	1376	1377	O
P	32812025	1378	1379	O
=	32812025	1382	1383	O
0.109	32812025	1386	1391	O
)	32812025	1392	1393	O
.	32812025	1394	1395	O

There	32812025	1396	1401	O
was	32812025	1402	1405	O
no	32812025	1406	1408	O
difference	32812025	1409	1419	B-Observation
in	32812025	1420	1422	O
the	32812025	1423	1426	O
number	32812025	1427	1433	B-Outcome
of	32812025	1434	1436	I-Outcome
deaths	32812025	1437	1443	I-Outcome
between	32812025	1444	1451	B-Intervention
the	32812025	1452	1455	I-Intervention
groups	32812025	1456	1462	I-Intervention
(	32812025	1463	1464	O
0	32812025	1465	1466	B-Count
versus	32812025	1467	1473	O
3	32812025	1474	1475	B-Count
,	32812025	1476	1477	O
P	32812025	1478	1479	O
=	32812025	1482	1483	O
0.234	32812025	1486	1491	O
)	32812025	1492	1493	O
.	32812025	1494	1495	O

The	32812025	1496	1499	O
cumulative	32812025	1500	1510	B-Outcome
incidence	32812025	1511	1520	I-Outcome
of	32812025	1521	1523	I-Outcome
recovery	32812025	1524	1532	I-Outcome
was	32812025	1533	1536	O
higher	32812025	1537	1543	B-Observation
in	32812025	1544	1546	O
the	32812025	1547	1550	O
sofosbuvir	32812025	1551	1561	B-Intervention
/	32812025	1562	1563	I-Intervention
daclatasvir	32812025	1564	1575	I-Intervention
/	32812025	1576	1577	I-Intervention
ribavirin	32812025	1578	1587	I-Intervention
arm	32812025	1588	1591	O
(	32812025	1592	1593	O
Gray	32812025	1594	1598	O
's	32812025	1599	1601	O
P	32812025	1602	1603	O
=	32812025	1606	1607	O
0.033	32812025	1610	1615	O
)	32812025	1616	1617	O
.	32812025	1618	1619	O

This	32812025	1620	1624	O
randomized	32812025	1625	1635	O
trial	32812025	1636	1641	O
was	32812025	1642	1645	O
too	32812025	1646	1649	O
small	32812025	1650	1655	O
to	32812025	1656	1658	O
make	32812025	1659	1663	O
definitive	32812025	1664	1674	O
conclusions	32812025	1675	1686	O
.	32812025	1687	1688	O

There	32812025	1689	1694	O
were	32812025	1695	1699	O
trends	32812025	1700	1706	B-Observation
in	32812025	1707	1709	I-Observation
favour	32812025	1710	1716	I-Observation
of	32812025	1717	1719	O
the	32812025	1720	1723	O
sofosbuvir	32812025	1724	1734	B-Intervention
/	32812025	1735	1736	I-Intervention
daclatasvir	32812025	1737	1748	I-Intervention
/	32812025	1749	1750	I-Intervention
ribavirin	32812025	1751	1760	I-Intervention
arm	32812025	1761	1764	O
for	32812025	1765	1768	O
recovery	32812025	1769	1777	B-Outcome
and	32812025	1778	1781	O
lower	32812025	1782	1787	B-Observation
death	32812025	1788	1793	B-Outcome
rates	32812025	1794	1799	I-Outcome
.	32812025	1800	1801	O

However	32812025	1802	1809	O
,	32812025	1810	1811	O
there	32812025	1812	1817	O
was	32812025	1818	1821	O
an	32812025	1822	1824	O
imbalance	32812025	1825	1834	O
in	32812025	1835	1837	O
the	32812025	1838	1841	O
baseline	32812025	1842	1850	O
characteristics	32812025	1851	1866	O
between	32812025	1867	1874	O
the	32812025	1875	1878	O
arms	32812025	1879	1883	O
.	32812025	1884	1885	O

Larger	32812025	1886	1892	O
randomized	32812025	1893	1903	O
trials	32812025	1904	1910	O
should	32812025	1911	1917	O
be	32812025	1918	1920	O
conducted	32812025	1921	1930	O
to	32812025	1931	1933	O
investigate	32812025	1934	1945	O
this	32812025	1946	1950	O
treatment	32812025	1951	1960	O
further	32812025	1961	1968	O
.	32812025	1969	1970	O


Sofosbuvir	32812039	0	10	B-Intervention
and	32812039	11	14	I-Intervention
daclatasvir	32812039	15	26	I-Intervention
compared	32812039	27	35	O
with	32812039	36	40	O
standard	32812039	41	49	B-Intervention
of	32812039	50	52	I-Intervention
care	32812039	53	57	I-Intervention
in	32812039	58	60	O
the	32812039	61	64	O
treatment	32812039	65	74	O
of	32812039	75	77	O
patients	32812039	78	86	O
admitted	32812039	87	95	B-Participant
to	32812039	96	98	I-Participant
hospital	32812039	99	107	I-Participant
with	32812039	108	112	O
moderate	32812039	113	121	B-Participant
or	32812039	122	124	I-Participant
severe	32812039	125	131	I-Participant
coronavirus	32812039	132	143	I-Participant
infection	32812039	144	153	I-Participant
(	32812039	154	155	I-Participant
COVID-19	32812039	156	164	I-Participant
)	32812039	165	166	I-Participant
:	32812039	167	168	O
a	32812039	169	170	O
randomized	32812039	171	181	O
controlled	32812039	182	192	O
trial	32812039	193	198	O
.	32812039	199	200	O

Currently	32812039	201	210	O
no	32812039	211	213	O
effective	32812039	214	223	O
antiviral	32812039	224	233	O
therapy	32812039	234	241	O
has	32812039	242	245	O
been	32812039	246	250	O
found	32812039	251	256	O
to	32812039	257	259	O
treat	32812039	260	265	O
COVID-19	32812039	266	274	O
.	32812039	275	276	O

The	32812039	277	280	O
aim	32812039	281	284	O
of	32812039	285	287	O
this	32812039	288	292	O
trial	32812039	293	298	O
was	32812039	299	302	O
to	32812039	303	305	O
assess	32812039	306	312	O
if	32812039	313	315	O
the	32812039	316	319	O
addition	32812039	320	328	B-Intervention
of	32812039	329	331	I-Intervention
sofosbuvir	32812039	332	342	I-Intervention
and	32812039	343	346	I-Intervention
daclatasvir	32812039	347	358	I-Intervention
improved	32812039	359	367	B-Observation
clinical	32812039	368	376	B-Outcome
outcomes	32812039	377	385	I-Outcome
in	32812039	386	388	O
patients	32812039	389	397	O
with	32812039	398	402	O
moderate	32812039	403	411	B-Participant
or	32812039	412	414	I-Participant
severe	32812039	415	421	I-Participant
COVID-19	32812039	422	430	I-Participant
.	32812039	431	432	O

This	32812039	433	437	O
was	32812039	438	441	O
an	32812039	442	444	O
open	32812039	445	449	O
-	32812039	450	451	O
label	32812039	452	457	O
,	32812039	458	459	O
multicentre	32812039	460	471	O
,	32812039	472	473	O
randomized	32812039	474	484	O
controlled	32812039	485	495	O
clinical	32812039	496	504	O
trial	32812039	505	510	O
in	32812039	511	513	O
adults	32812039	514	520	B-Participant
with	32812039	521	525	O
moderate	32812039	526	534	B-Participant
or	32812039	535	537	I-Participant
severe	32812039	538	544	I-Participant
COVID-19	32812039	545	553	I-Participant
admitted	32812039	554	562	B-Participant
to	32812039	563	565	O
four	32812039	566	570	O
university	32812039	571	581	O
hospitals	32812039	582	591	O
in	32812039	592	594	O
Iran	32812039	595	599	O
.	32812039	600	601	O

Patients	32812039	602	610	O
were	32812039	611	615	O
randomized	32812039	616	626	O
into	32812039	627	631	O
a	32812039	632	633	O
treatment	32812039	634	643	O
arm	32812039	644	647	O
receiving	32812039	648	657	O
sofosbuvir	32812039	658	668	B-Intervention
and	32812039	669	672	I-Intervention
daclatasvir	32812039	673	684	I-Intervention
plus	32812039	685	689	I-Intervention
standard	32812039	690	698	I-Intervention
care	32812039	699	703	I-Intervention
,	32812039	704	705	O
or	32812039	706	708	O
a	32812039	709	710	O
control	32812039	711	718	O
arm	32812039	719	722	O
receiving	32812039	723	732	O
standard	32812039	733	741	B-Intervention
care	32812039	742	746	I-Intervention
alone	32812039	747	752	I-Intervention
.	32812039	753	754	O

The	32812039	755	758	O
primary	32812039	759	766	O
endpoint	32812039	767	775	O
was	32812039	776	779	O
clinical	32812039	780	788	B-Outcome
recovery	32812039	789	797	I-Outcome
within	32812039	798	804	I-Outcome
14	32812039	805	807	I-Outcome
days	32812039	810	814	I-Outcome
of	32812039	815	817	I-Outcome
treatment	32812039	818	827	I-Outcome
.	32812039	828	829	O

The	32812039	830	833	O
study	32812039	834	839	O
is	32812039	840	842	O
registered	32812039	843	853	O
with	32812039	854	858	O
IRCT.ir	32812039	859	866	O
under	32812039	867	872	O
registration	32812039	873	885	O
number	32812039	886	892	O
IRCT20200128046294N2	32812039	893	913	O
.	32812039	914	915	O

Between	32812039	916	923	O
26	32812039	924	926	O
March	32812039	927	932	O
and	32812039	933	936	O
26	32812039	937	939	O
April	32812039	940	945	O
2020	32812039	946	950	O
,	32812039	951	952	O
66	32812039	953	955	O
patients	32812039	956	964	O
were	32812039	965	969	O
recruited	32812039	970	979	O
and	32812039	980	983	O
allocated	32812039	984	993	O
to	32812039	994	996	O
either	32812039	997	1003	O
the	32812039	1004	1007	O
treatment	32812039	1008	1017	B-Intervention
arm	32812039	1018	1021	O
(	32812039	1022	1023	O
n	32812039	1024	1025	O
=	32812039	1028	1029	O
33	32812039	1032	1034	O
)	32812039	1035	1036	O
or	32812039	1037	1039	O
the	32812039	1040	1043	O
control	32812039	1044	1051	B-Intervention
arm	32812039	1052	1055	O
(	32812039	1056	1057	O
n	32812039	1058	1059	O
=	32812039	1062	1063	O
33	32812039	1066	1068	O
)	32812039	1069	1070	O
.	32812039	1071	1072	O

Clinical	32812039	1073	1081	B-Outcome
recovery	32812039	1082	1090	I-Outcome
within	32812039	1091	1097	I-Outcome
14	32812039	1098	1100	I-Outcome
days	32812039	1103	1107	I-Outcome
was	32812039	1108	1111	O
achieved	32812039	1112	1120	O
by	32812039	1121	1123	O
29/33	32812039	1124	1129	B-Count
(	32812039	1130	1131	I-Count
88	32812039	1132	1134	I-Count
%	32812039	1135	1136	I-Count
)	32812039	1137	1138	I-Count
in	32812039	1139	1141	O
the	32812039	1142	1145	O
treatment	32812039	1146	1155	B-Intervention
arm	32812039	1156	1159	O
and	32812039	1160	1163	O
22/33	32812039	1164	1169	B-Count
(	32812039	1170	1171	I-Count
67	32812039	1172	1174	I-Count
%	32812039	1175	1176	I-Count
)	32812039	1177	1178	I-Count
in	32812039	1179	1181	O
the	32812039	1182	1185	O
control	32812039	1186	1193	B-Intervention
arm	32812039	1194	1197	O
(	32812039	1198	1199	O
P	32812039	1200	1201	O
=	32812039	1204	1205	O
0.076	32812039	1208	1213	O
)	32812039	1214	1215	O
.	32812039	1216	1217	O

The	32812039	1218	1221	O
treatment	32812039	1222	1231	B-Intervention
arm	32812039	1232	1235	O
had	32812039	1236	1239	O
a	32812039	1240	1241	O
significantly	32812039	1242	1255	B-Observation
shorter	32812039	1256	1263	I-Observation
median	32812039	1264	1270	B-Outcome
duration	32812039	1271	1279	I-Outcome
of	32812039	1280	1282	I-Outcome
hospitalization	32812039	1283	1298	I-Outcome
[	32812039	1299	1300	O
6	32812039	1301	1302	B-Observation
days	32812039	1305	1309	I-Observation
(	32812039	1310	1311	I-Observation
IQR	32812039	1312	1315	I-Observation
4	32812039	1316	1317	I-Observation
-	32812039	1318	1319	I-Observation
8	32812039	1320	1321	I-Observation
)	32812039	1322	1323	I-Observation
]	32812039	1324	1325	O
than	32812039	1326	1330	O
the	32812039	1331	1334	O
control	32812039	1335	1342	B-Intervention
group	32812039	1343	1348	O
[	32812039	1349	1350	O
8	32812039	1351	1352	B-Observation
days	32812039	1355	1359	I-Observation
(	32812039	1360	1361	I-Observation
IQR	32812039	1362	1365	I-Observation
5	32812039	1366	1367	I-Observation
-	32812039	1368	1369	I-Observation
13	32812039	1370	1372	I-Observation
)	32812039	1373	1374	I-Observation
]	32812039	1375	1376	O
;	32812039	1377	1378	O
P	32812039	1379	1380	O
=	32812039	1383	1384	O
0.029	32812039	1387	1392	O
.	32812039	1393	1394	O

Cumulative	32812039	1395	1405	B-Outcome
incidence	32812039	1406	1415	I-Outcome
of	32812039	1416	1418	I-Outcome
hospital	32812039	1419	1427	I-Outcome
discharge	32812039	1428	1437	I-Outcome
was	32812039	1438	1441	O
significantly	32812039	1442	1455	B-Observation
higher	32812039	1456	1462	I-Observation
in	32812039	1463	1465	O
the	32812039	1466	1469	O
treatment	32812039	1470	1479	B-Intervention
arm	32812039	1480	1483	O
versus	32812039	1484	1490	O
the	32812039	1491	1494	O
control	32812039	1495	1502	B-Intervention
(	32812039	1503	1504	O
Gray	32812039	1505	1509	O
's	32812039	1510	1512	O
P	32812039	1513	1514	O
=	32812039	1517	1518	O
0.041	32812039	1521	1526	O
)	32812039	1527	1528	O
.	32812039	1529	1530	O

Three	32812039	1531	1536	B-Count
patients	32812039	1537	1545	I-Count
died	32812039	1546	1550	B-Outcome
in	32812039	1551	1553	O
the	32812039	1554	1557	O
treatment	32812039	1558	1567	B-Intervention
arm	32812039	1568	1571	O
and	32812039	1572	1575	O
five	32812039	1576	1580	B-Count
in	32812039	1581	1583	O
the	32812039	1584	1587	O
control	32812039	1588	1595	B-Intervention
arm	32812039	1596	1599	O
.	32812039	1600	1601	O

No	32812039	1602	1604	B-Count
serious	32812039	1605	1612	B-Outcome
adverse	32812039	1613	1620	I-Outcome
events	32812039	1621	1627	I-Outcome
were	32812039	1628	1632	O
reported	32812039	1633	1641	O
.	32812039	1642	1643	O

The	32812039	1644	1647	O
addition	32812039	1648	1656	B-Intervention
of	32812039	1657	1659	I-Intervention
sofosbuvir	32812039	1660	1670	I-Intervention
and	32812039	1671	1674	I-Intervention
daclatasvir	32812039	1675	1686	I-Intervention
to	32812039	1687	1689	I-Intervention
standard	32812039	1690	1698	I-Intervention
care	32812039	1699	1703	I-Intervention
significantly	32812039	1704	1717	B-Observation
reduced	32812039	1718	1725	I-Observation
the	32812039	1726	1729	O
duration	32812039	1730	1738	B-Outcome
of	32812039	1739	1741	I-Outcome
hospital	32812039	1742	1750	I-Outcome
stay	32812039	1751	1755	I-Outcome
compared	32812039	1756	1764	O
with	32812039	1765	1769	O
standard	32812039	1770	1778	B-Intervention
care	32812039	1779	1783	I-Intervention
alone	32812039	1784	1789	I-Intervention
.	32812039	1790	1791	O

Although	32812039	1792	1800	O
fewer	32812039	1801	1806	B-Count
deaths	32812039	1807	1813	B-Outcome
were	32812039	1814	1818	O
observed	32812039	1819	1827	O
in	32812039	1828	1830	O
the	32812039	1831	1834	O
treatment	32812039	1835	1844	B-Intervention
arm	32812039	1845	1848	O
,	32812039	1849	1850	O
this	32812039	1851	1855	O
was	32812039	1856	1859	O
not	32812039	1860	1863	O
statistically	32812039	1864	1877	B-Observation
significant	32812039	1878	1889	I-Observation
.	32812039	1890	1891	O

Conducting	32812039	1892	1902	O
larger	32812039	1903	1909	O
scale	32812039	1910	1915	O
trials	32812039	1916	1922	O
seems	32812039	1923	1928	O
prudent	32812039	1929	1936	O
.	32812039	1937	1938	O


The	32812051	0	3	O
impact	32812051	4	10	O
of	32812051	11	13	O
sofosbuvir	32812051	14	24	B-Intervention
/	32812051	25	26	I-Intervention
daclatasvir	32812051	27	38	I-Intervention
or	32812051	39	41	O
ribavirin	32812051	42	51	B-Intervention
in	32812051	52	54	O
patients	32812051	55	63	O
with	32812051	64	68	O
severe	32812051	69	75	B-Participant
COVID-19	32812051	76	84	I-Participant
.	32812051	85	86	O

Sofosbuvir	32812051	87	97	O
and	32812051	98	101	O
daclatasvir	32812051	102	113	O
are	32812051	114	117	O
direct	32812051	118	124	O
-	32812051	125	126	O
acting	32812051	127	133	O
antivirals	32812051	134	144	O
highly	32812051	145	151	O
effective	32812051	152	161	O
against	32812051	162	169	O
hepatitis	32812051	170	179	O
C	32812051	180	181	O
virus	32812051	182	187	O
.	32812051	188	189	O

There	32812051	190	195	O
is	32812051	196	198	O
some	32812051	199	203	O
in	32812051	204	206	O
silico	32812051	207	213	O
and	32812051	214	217	O
in	32812051	218	220	O
vitro	32812051	221	226	O
evidence	32812051	227	235	O
that	32812051	236	240	O
suggests	32812051	241	249	O
these	32812051	250	255	O
agents	32812051	256	262	O
may	32812051	263	266	O
also	32812051	267	271	O
be	32812051	272	274	O
effective	32812051	275	284	O
against	32812051	285	292	O
SARS	32812051	293	297	O
-	32812051	298	299	O
CoV-2	32812051	300	305	O
.	32812051	306	307	O

This	32812051	308	312	O
trial	32812051	313	318	O
evaluated	32812051	319	328	O
the	32812051	329	332	O
effectiveness	32812051	333	346	B-Outcome
of	32812051	347	349	O
sofosbuvir	32812051	350	360	B-Intervention
in	32812051	361	363	I-Intervention
combination	32812051	364	375	I-Intervention
with	32812051	376	380	I-Intervention
daclatasvir	32812051	381	392	I-Intervention
in	32812051	393	395	O
treating	32812051	396	404	O
patients	32812051	405	413	O
with	32812051	414	418	O
COVID-19	32812051	419	427	B-Participant
.	32812051	428	429	O

Patients	32812051	430	438	O
with	32812051	439	443	O
a	32812051	444	445	O
positive	32812051	446	454	B-Participant
nasopharyngeal	32812051	455	469	I-Participant
swab	32812051	470	474	I-Participant
for	32812051	475	478	I-Participant
SARS	32812051	479	483	I-Participant
-	32812051	484	485	I-Participant
CoV-2	32812051	486	491	I-Participant
on	32812051	492	494	I-Participant
RT	32812051	495	497	I-Participant
-	32812051	498	499	I-Participant
PCR	32812051	500	503	I-Participant
or	32812051	504	506	O
bilateral	32812051	507	516	B-Participant
multi	32812051	517	522	I-Participant
-	32812051	523	524	I-Participant
lobar	32812051	525	530	I-Participant
ground	32812051	531	537	I-Participant
-	32812051	538	539	I-Participant
glass	32812051	540	545	I-Participant
opacity	32812051	546	553	I-Participant
on	32812051	554	556	I-Participant
their	32812051	557	562	I-Participant
chest	32812051	563	568	I-Participant
CT	32812051	569	571	I-Participant
and	32812051	572	575	O
signs	32812051	576	581	B-Participant
of	32812051	582	584	I-Participant
severe	32812051	585	591	I-Participant
COVID-19	32812051	592	600	I-Participant
were	32812051	601	605	O
included	32812051	606	614	O
.	32812051	615	616	O

Subjects	32812051	617	625	O
were	32812051	626	630	O
divided	32812051	631	638	O
into	32812051	639	643	O
two	32812051	644	647	O
arms	32812051	648	652	O
with	32812051	653	657	O
one	32812051	658	661	O
arm	32812051	662	665	O
receiving	32812051	666	675	O
ribavirin	32812051	676	685	B-Intervention
and	32812051	686	689	O
the	32812051	690	693	O
other	32812051	694	699	O
receiving	32812051	700	709	O
sofosbuvir	32812051	710	720	B-Intervention
/	32812051	721	722	I-Intervention
daclatasvir	32812051	723	734	I-Intervention
.	32812051	735	736	O

All	32812051	737	740	O
participants	32812051	741	753	O
also	32812051	754	758	O
received	32812051	759	767	O
the	32812051	768	771	O
recommended	32812051	772	783	O
national	32812051	784	792	O
standard	32812051	793	801	O
treatment	32812051	802	811	O
which	32812051	812	817	O
,	32812051	818	819	O
at	32812051	820	822	O
that	32812051	823	827	O
time	32812051	828	832	O
,	32812051	833	834	O
was	32812051	835	838	O
lopinavir	32812051	839	848	O
/	32812051	849	850	O
ritonavir	32812051	851	860	O
and	32812051	861	864	O
single	32812051	865	871	O
-	32812051	872	873	O
dose	32812051	874	878	O
hydroxychloroquine	32812051	879	897	O
.	32812051	898	899	O

The	32812051	900	903	O
primary	32812051	904	911	O
endpoint	32812051	912	920	O
was	32812051	921	924	O
time	32812051	925	929	B-Outcome
from	32812051	930	934	I-Outcome
starting	32812051	935	943	I-Outcome
the	32812051	944	947	I-Outcome
medication	32812051	948	958	I-Outcome
until	32812051	959	964	I-Outcome
discharge	32812051	965	974	I-Outcome
from	32812051	975	979	I-Outcome
hospital	32812051	980	988	I-Outcome
with	32812051	989	993	O
secondary	32812051	994	1003	O
endpoints	32812051	1004	1013	O
of	32812051	1014	1016	O
duration	32812051	1017	1025	B-Outcome
of	32812051	1026	1028	I-Outcome
ICU	32812051	1029	1032	I-Outcome
stay	32812051	1033	1037	I-Outcome
and	32812051	1038	1041	O
mortality	32812051	1042	1051	B-Outcome
.	32812051	1052	1053	O

Sixty	32812051	1054	1059	O
-	32812051	1060	1061	O
two	32812051	1062	1065	O
subjects	32812051	1066	1074	O
met	32812051	1075	1078	O
the	32812051	1079	1082	O
inclusion	32812051	1083	1092	O
criteria	32812051	1093	1101	O
,	32812051	1102	1103	O
with	32812051	1104	1108	O
35	32812051	1109	1111	O
enrolled	32812051	1112	1120	O
in	32812051	1121	1123	O
the	32812051	1124	1127	O
sofosbuvir	32812051	1128	1138	B-Intervention
/	32812051	1139	1140	I-Intervention
daclatasvir	32812051	1141	1152	I-Intervention
arm	32812051	1153	1156	O
and	32812051	1157	1160	O
27	32812051	1161	1163	O
in	32812051	1164	1166	O
the	32812051	1167	1170	O
ribavirin	32812051	1171	1180	B-Intervention
arm	32812051	1181	1184	O
.	32812051	1185	1186	O

The	32812051	1187	1190	O
median	32812051	1191	1197	B-Outcome
duration	32812051	1198	1206	I-Outcome
of	32812051	1207	1209	I-Outcome
stay	32812051	1210	1214	I-Outcome
was	32812051	1215	1218	O
5	32812051	1219	1220	B-Observation
days	32812051	1223	1227	I-Observation
for	32812051	1228	1231	O
the	32812051	1232	1235	O
sofosbuvir	32812051	1236	1246	B-Intervention
/	32812051	1247	1248	I-Intervention
daclatasvir	32812051	1249	1260	I-Intervention
group	32812051	1261	1266	O
and	32812051	1267	1270	O
9	32812051	1271	1272	B-Observation
days	32812051	1275	1279	I-Observation
for	32812051	1280	1283	O
the	32812051	1284	1287	O
ribavirin	32812051	1288	1297	B-Intervention
group	32812051	1298	1303	O
.	32812051	1304	1305	O

The	32812051	1306	1309	O
mortality	32812051	1310	1319	B-Outcome
in	32812051	1320	1322	O
the	32812051	1323	1326	O
sofosbuvir	32812051	1327	1337	B-Intervention
/	32812051	1338	1339	I-Intervention
daclatasvir	32812051	1340	1351	I-Intervention
group	32812051	1352	1357	O
was	32812051	1358	1361	O
2/35	32812051	1362	1366	B-Count
(	32812051	1367	1368	I-Count
6	32812051	1369	1370	I-Count
%	32812051	1371	1372	I-Count
)	32812051	1373	1374	I-Count
and	32812051	1375	1378	O
9/27	32812051	1379	1383	B-Count
(	32812051	1384	1385	I-Count
33	32812051	1386	1388	I-Count
%	32812051	1389	1390	I-Count
)	32812051	1391	1392	I-Count
for	32812051	1393	1396	O
the	32812051	1397	1400	O
ribavirin	32812051	1401	1410	B-Intervention
group	32812051	1411	1416	O
.	32812051	1417	1418	O

The	32812051	1419	1422	O
relative	32812051	1423	1431	B-Outcome
risk	32812051	1432	1436	I-Outcome
of	32812051	1437	1439	I-Outcome
death	32812051	1440	1445	I-Outcome
for	32812051	1446	1449	O
patients	32812051	1450	1458	O
treated	32812051	1459	1466	O
with	32812051	1467	1471	O
sofosbuvir	32812051	1472	1482	B-Intervention
/	32812051	1483	1484	I-Intervention
daclatasvir	32812051	1485	1496	I-Intervention
was	32812051	1497	1500	O
0.17	32812051	1501	1505	B-Observation
(	32812051	1506	1507	O
95	32812051	1508	1510	O
%	32812051	1511	1512	O
CI	32812051	1513	1515	O
0.04	32812051	1516	1520	O
-	32812051	1521	1522	O
0.73	32812051	1523	1527	O
,	32812051	1528	1529	O
P	32812051	1530	1531	O
=	32812051	1534	1535	O
0.02	32812051	1538	1542	O
)	32812051	1543	1544	O
and	32812051	1545	1548	O
the	32812051	1549	1552	O
number	32812051	1553	1559	B-Outcome
needed	32812051	1560	1566	I-Outcome
to	32812051	1567	1569	I-Outcome
treat	32812051	1570	1575	I-Outcome
for	32812051	1576	1579	I-Outcome
benefit	32812051	1580	1587	I-Outcome
was	32812051	1588	1591	O
3.6	32812051	1592	1595	B-Observation
(	32812051	1596	1597	O
95	32812051	1598	1600	O
%	32812051	1601	1602	O
CI	32812051	1603	1605	O
2.1	32812051	1606	1609	O
-	32812051	1610	1611	O
12.1	32812051	1612	1616	O
,	32812051	1617	1618	O
P	32812051	1619	1620	O
<	32812051	1623	1624	O
0.01	32812051	1627	1631	O
)	32812051	1632	1633	O
.	32812051	1634	1635	O

Given	32812051	1636	1641	O
these	32812051	1642	1647	O
encouraging	32812051	1648	1659	O
initial	32812051	1660	1667	O
results	32812051	1668	1675	O
,	32812051	1676	1677	O
and	32812051	1678	1681	O
the	32812051	1682	1685	O
current	32812051	1686	1693	O
lack	32812051	1694	1698	O
of	32812051	1699	1701	O
treatments	32812051	1702	1712	O
proven	32812051	1713	1719	O
to	32812051	1720	1722	O
decrease	32812051	1723	1731	O
mortality	32812051	1732	1741	O
in	32812051	1742	1744	O
COVID-19	32812051	1745	1753	O
,	32812051	1754	1755	O
further	32812051	1756	1763	O
investigation	32812051	1764	1777	O
in	32812051	1778	1780	O
larger	32812051	1781	1787	O
-	32812051	1788	1789	O
scale	32812051	1790	1795	O
trials	32812051	1796	1802	O
seems	32812051	1803	1808	O
warranted	32812051	1809	1818	O
.	32812051	1819	1820	O


Anti	32815416	0	4	B-Intervention
-	32815416	5	6	I-Intervention
Thrombotic	32815416	7	17	I-Intervention
Therapy	32815416	18	25	I-Intervention
to	32815416	26	28	O
Ameliorate	32815416	29	39	B-Observation
Complications	32815416	40	53	B-Outcome
of	32815416	54	56	O
COVID-19	32815416	57	65	B-Participant
(	32815416	66	67	O
ATTACC	32815416	68	74	O
)	32815416	75	76	O
:	32815416	77	78	O
Study	32815416	79	84	O
design	32815416	85	91	O
and	32815416	92	95	O
methodology	32815416	96	107	O
for	32815416	108	111	O
an	32815416	112	114	O
international	32815416	115	128	O
,	32815416	129	130	O
adaptive	32815416	131	139	O
Bayesian	32815416	140	148	O
randomized	32815416	149	159	O
controlled	32815416	160	170	O
trial	32815416	171	176	O
.	32815416	177	178	O

Mortality	32815416	179	188	O
from	32815416	189	193	O
COVID-19	32815416	194	202	O
is	32815416	203	205	O
high	32815416	206	210	O
among	32815416	211	216	O
hospitalized	32815416	217	229	O
patients	32815416	230	238	O
and	32815416	239	242	O
effective	32815416	243	252	O
therapeutics	32815416	253	265	O
are	32815416	266	269	O
lacking	32815416	270	277	O
.	32815416	278	279	O

Hypercoagulability	32815416	280	298	O
,	32815416	299	300	O
thrombosis	32815416	301	311	O
and	32815416	312	315	O
hyperinflammation	32815416	316	333	O
occur	32815416	334	339	O
in	32815416	340	342	O
COVID-19	32815416	343	351	O
and	32815416	352	355	O
may	32815416	356	359	O
contribute	32815416	360	370	O
to	32815416	371	373	O
severe	32815416	374	380	O
complications	32815416	381	394	O
.	32815416	395	396	O

Therapeutic	32815416	397	408	O
anticoagulation	32815416	409	424	O
may	32815416	425	428	O
improve	32815416	429	436	O
clinical	32815416	437	445	O
outcomes	32815416	446	454	O
through	32815416	455	462	O
anti	32815416	463	467	O
-	32815416	468	469	O
thrombotic	32815416	470	480	O
,	32815416	481	482	O
anti	32815416	483	487	O
-	32815416	488	489	O
inflammatory	32815416	490	502	O
and	32815416	503	506	O
anti	32815416	507	511	O
-	32815416	512	513	O
viral	32815416	514	519	O
mechanisms	32815416	520	530	O
.	32815416	531	532	O

Our	32815416	533	536	O
primary	32815416	537	544	O
objective	32815416	545	554	O
is	32815416	555	557	O
to	32815416	558	560	O
evaluate	32815416	561	569	O
whether	32815416	570	577	O
therapeutic	32815416	578	589	B-Intervention
-	32815416	590	591	I-Intervention
dose	32815416	592	596	I-Intervention
anticoagulation	32815416	597	612	I-Intervention
with	32815416	613	617	I-Intervention
low	32815416	618	621	I-Intervention
-	32815416	622	623	I-Intervention
molecular	32815416	624	633	I-Intervention
-	32815416	634	635	I-Intervention
weight	32815416	636	642	I-Intervention
heparin	32815416	643	650	I-Intervention
or	32815416	651	653	O
unfractionated	32815416	654	668	B-Intervention
heparin	32815416	669	676	I-Intervention
prevents	32815416	677	685	B-Observation
mechanical	32815416	686	696	B-Outcome
ventilation	32815416	697	708	I-Outcome
and/or	32815416	709	715	O
death	32815416	716	721	B-Outcome
in	32815416	722	724	O
patients	32815416	725	733	O
hospitalized	32815416	734	746	B-Participant
with	32815416	747	751	O
COVID-19	32815416	752	760	B-Participant
compared	32815416	761	769	O
to	32815416	770	772	O
usual	32815416	773	778	B-Intervention
care	32815416	779	783	I-Intervention
.	32815416	784	785	O

An	32815416	786	788	O
international	32815416	789	802	O
,	32815416	803	804	O
open	32815416	805	809	O
-	32815416	810	811	O
label	32815416	812	817	O
,	32815416	818	819	O
adaptive	32815416	820	828	O
randomized	32815416	829	839	O
controlled	32815416	840	850	O
trial	32815416	851	856	O
.	32815416	857	858	O

Using	32815416	859	864	O
a	32815416	865	866	O
Bayesian	32815416	867	875	O
framework	32815416	876	885	O
,	32815416	886	887	O
the	32815416	888	891	O
trial	32815416	892	897	O
will	32815416	898	902	O
declare	32815416	903	910	O
results	32815416	911	918	O
as	32815416	919	921	O
soon	32815416	922	926	O
as	32815416	927	929	O
pre	32815416	930	933	O
-	32815416	934	935	O
specified	32815416	936	945	O
posterior	32815416	946	955	O
probabilities	32815416	956	969	O
for	32815416	970	973	O
superiority	32815416	974	985	O
,	32815416	986	987	O
futility	32815416	988	996	O
,	32815416	997	998	O
or	32815416	999	1001	O
harm	32815416	1002	1006	O
are	32815416	1007	1010	O
reached	32815416	1011	1018	O
.	32815416	1019	1020	O

The	32815416	1021	1024	O
trial	32815416	1025	1030	O
uses	32815416	1031	1035	O
response	32815416	1036	1044	O
-	32815416	1045	1046	O
adaptive	32815416	1047	1055	O
randomization	32815416	1056	1069	O
to	32815416	1070	1072	O
maximize	32815416	1073	1081	O
the	32815416	1082	1085	O
probability	32815416	1086	1097	O
that	32815416	1098	1102	O
patients	32815416	1103	1111	O
will	32815416	1112	1116	O
receive	32815416	1117	1124	O
the	32815416	1125	1128	O
more	32815416	1129	1133	O
beneficial	32815416	1134	1144	O
treatment	32815416	1145	1154	O
approach	32815416	1155	1163	O
,	32815416	1164	1165	O
as	32815416	1166	1168	O
treatment	32815416	1169	1178	O
effect	32815416	1179	1185	O
information	32815416	1186	1197	O
accumulates	32815416	1198	1209	O
within	32815416	1210	1216	O
the	32815416	1217	1220	O
trial	32815416	1221	1226	O
.	32815416	1227	1228	O

By	32815416	1229	1231	O
leveraging	32815416	1232	1242	O
a	32815416	1243	1244	O
common	32815416	1245	1251	O
data	32815416	1252	1256	O
safety	32815416	1257	1263	O
monitoring	32815416	1264	1274	O
board	32815416	1275	1280	O
and	32815416	1281	1284	O
pooling	32815416	1285	1292	O
data	32815416	1293	1297	O
with	32815416	1298	1302	O
a	32815416	1303	1304	O
second	32815416	1305	1311	O
similar	32815416	1312	1319	O
international	32815416	1320	1333	O
Bayesian	32815416	1334	1342	O
adaptive	32815416	1343	1351	O
trial	32815416	1352	1357	O
(	32815416	1358	1359	O
REMAP	32815416	1360	1365	O
-	32815416	1366	1367	O
COVID	32815416	1368	1373	O
anticoagulation	32815416	1374	1389	O
domain	32815416	1390	1396	O
)	32815416	1397	1398	O
,	32815416	1399	1400	O
treatment	32815416	1401	1410	O
efficacy	32815416	1411	1419	O
and	32815416	1420	1423	O
safety	32815416	1424	1430	O
will	32815416	1431	1435	O
be	32815416	1436	1438	O
evaluated	32815416	1439	1448	O
as	32815416	1449	1451	O
efficiently	32815416	1452	1463	O
as	32815416	1464	1466	O
possible	32815416	1467	1475	O
.	32815416	1476	1477	O

The	32815416	1478	1481	O
primary	32815416	1482	1489	O
outcome	32815416	1490	1497	O
is	32815416	1498	1500	O
an	32815416	1501	1503	O
ordinal	32815416	1504	1511	B-Outcome
endpoint	32815416	1512	1520	I-Outcome
with	32815416	1521	1525	I-Outcome
three	32815416	1526	1531	I-Outcome
possible	32815416	1532	1540	I-Outcome
outcomes	32815416	1541	1549	I-Outcome
based	32815416	1550	1555	I-Outcome
on	32815416	1556	1558	I-Outcome
the	32815416	1559	1562	I-Outcome
worst	32815416	1563	1568	I-Outcome
status	32815416	1569	1575	I-Outcome
of	32815416	1576	1578	I-Outcome
each	32815416	1579	1583	I-Outcome
patient	32815416	1584	1591	I-Outcome
through	32815416	1592	1599	I-Outcome
day	32815416	1600	1603	I-Outcome
30	32815416	1604	1606	I-Outcome
:	32815416	1607	1608	O
no	32815416	1609	1611	B-Outcome
requirement	32815416	1612	1623	I-Outcome
for	32815416	1624	1627	I-Outcome
invasive	32815416	1628	1636	I-Outcome
mechanical	32815416	1637	1647	I-Outcome
ventilation	32815416	1648	1659	I-Outcome
,	32815416	1660	1661	O
invasive	32815416	1662	1670	B-Outcome
mechanical	32815416	1671	1681	I-Outcome
ventilation	32815416	1682	1693	I-Outcome
or	32815416	1694	1696	O
death	32815416	1697	1702	B-Outcome
.	32815416	1703	1704	O

Using	32815416	1705	1710	O
an	32815416	1711	1713	O
adaptive	32815416	1714	1722	O
trial	32815416	1723	1728	O
design	32815416	1729	1735	O
,	32815416	1736	1737	O
the	32815416	1738	1741	O
Anti	32815416	1742	1746	O
-	32815416	1747	1748	O
Thrombotic	32815416	1749	1759	O
Therapy	32815416	1760	1767	O
To	32815416	1768	1770	O
Ameliorate	32815416	1771	1781	O
Complications	32815416	1782	1795	O
of	32815416	1796	1798	O
COVID-19	32815416	1799	1807	O
trial	32815416	1808	1813	O
will	32815416	1814	1818	O
establish	32815416	1819	1828	O
whether	32815416	1829	1836	O
therapeutic	32815416	1837	1848	O
anticoagulation	32815416	1849	1864	O
can	32815416	1865	1868	O
reduce	32815416	1869	1875	O
mortality	32815416	1876	1885	O
and/or	32815416	1886	1892	O
avoid	32815416	1893	1898	O
the	32815416	1899	1902	O
need	32815416	1903	1907	O
for	32815416	1908	1911	O
mechanical	32815416	1912	1922	O
ventilation	32815416	1923	1934	O
in	32815416	1935	1937	O
patients	32815416	1938	1946	O
hospitalized	32815416	1947	1959	O
with	32815416	1960	1964	O
COVID-19	32815416	1965	1973	O
.	32815416	1974	1975	O

Leveraging	32815416	1976	1986	O
existing	32815416	1987	1995	O
networks	32815416	1996	2004	O
to	32815416	2005	2007	O
recruit	32815416	2008	2015	O
sites	32815416	2016	2021	O
will	32815416	2022	2026	O
increase	32815416	2027	2035	O
enrollment	32815416	2036	2046	O
and	32815416	2047	2050	O
mitigate	32815416	2051	2059	O
enrollment	32815416	2060	2070	O
risk	32815416	2071	2075	O
in	32815416	2076	2078	O
sites	32815416	2079	2084	O
with	32815416	2085	2089	O
declining	32815416	2090	2099	O
COVID-19	32815416	2100	2108	O
cases	32815416	2109	2114	O
.	32815416	2115	2116	O


Effect	32821939	0	6	O
of	32821939	7	9	O
Remdesivir	32821939	10	20	B-Intervention
vs	32821939	21	23	O
Standard	32821939	24	32	B-Intervention
Care	32821939	33	37	I-Intervention
on	32821939	38	40	O
Clinical	32821939	41	49	B-Outcome
Status	32821939	50	56	I-Outcome
at	32821939	57	59	I-Outcome
11	32821939	60	62	I-Outcome
Days	32821939	63	67	I-Outcome
in	32821939	68	70	O
Patients	32821939	71	79	O
With	32821939	80	84	O
Moderate	32821939	85	93	B-Participant
COVID-19	32821939	94	102	I-Participant
:	32821939	103	104	O
A	32821939	105	106	O
Randomized	32821939	107	117	O
Clinical	32821939	118	126	O
Trial	32821939	127	132	O
.	32821939	133	134	O

Remdesivir	32821939	135	145	O
demonstrated	32821939	146	158	O
clinical	32821939	159	167	O
benefit	32821939	168	175	O
in	32821939	176	178	O
a	32821939	179	180	O
placebo	32821939	181	188	O
-	32821939	189	190	O
controlled	32821939	191	201	O
trial	32821939	202	207	O
in	32821939	208	210	O
patients	32821939	211	219	O
with	32821939	220	224	O
severe	32821939	225	231	O
coronavirus	32821939	232	243	O
disease	32821939	244	251	O
2019	32821939	252	256	O
(	32821939	257	258	O
COVID-19	32821939	259	267	O
)	32821939	268	269	O
,	32821939	270	271	O
but	32821939	272	275	O
its	32821939	276	279	O
effect	32821939	280	286	O
in	32821939	287	289	O
patients	32821939	290	298	O
with	32821939	299	303	O
moderate	32821939	304	312	O
disease	32821939	313	320	O
is	32821939	321	323	O
unknown	32821939	324	331	O
.	32821939	332	333	O

To	32821939	334	336	O
determine	32821939	337	346	O
the	32821939	347	350	O
efficacy	32821939	351	359	O
of	32821939	360	362	O
5	32821939	363	364	O
or	32821939	365	367	O
10	32821939	368	370	O
days	32821939	371	375	O
of	32821939	376	378	O
remdesivir	32821939	379	389	B-Intervention
treatment	32821939	390	399	O
compared	32821939	400	408	O
with	32821939	409	413	O
standard	32821939	414	422	B-Intervention
care	32821939	423	427	I-Intervention
on	32821939	428	430	O
clinical	32821939	431	439	B-Outcome
status	32821939	440	446	I-Outcome
on	32821939	447	449	I-Outcome
day	32821939	450	453	I-Outcome
11	32821939	454	456	I-Outcome
after	32821939	457	462	O
initiation	32821939	463	473	O
of	32821939	474	476	O
treatment	32821939	477	486	O
.	32821939	487	488	O

Randomized	32821939	489	499	O
,	32821939	500	501	O
open	32821939	502	506	O
-	32821939	507	508	O
label	32821939	509	514	O
trial	32821939	515	520	O
of	32821939	521	523	O
hospitalized	32821939	524	536	O
patients	32821939	537	545	O
with	32821939	546	550	O
confirmed	32821939	551	560	O
severe	32821939	561	567	B-Participant
acute	32821939	568	573	I-Participant
respiratory	32821939	574	585	I-Participant
syndrome	32821939	586	594	I-Participant
coronavirus	32821939	595	606	I-Participant
2	32821939	607	608	I-Participant
(	32821939	609	610	I-Participant
SARS	32821939	611	615	I-Participant
-	32821939	616	617	I-Participant
CoV-2	32821939	618	623	I-Participant
)	32821939	624	625	I-Participant
infection	32821939	626	635	I-Participant
and	32821939	636	639	O
moderate	32821939	640	648	B-Participant
COVID-19	32821939	649	657	I-Participant
pneumonia	32821939	658	667	I-Participant
(	32821939	668	669	O
pulmonary	32821939	670	679	B-Participant
infiltrates	32821939	680	691	I-Participant
and	32821939	692	695	I-Participant
room	32821939	696	700	I-Participant
-	32821939	701	702	I-Participant
air	32821939	703	706	I-Participant
oxygen	32821939	707	713	I-Participant
saturation	32821939	714	724	I-Participant
>	32821939	725	726	I-Participant
94	32821939	727	729	I-Participant
%	32821939	730	731	I-Participant
)	32821939	732	733	O
enrolled	32821939	734	742	O
from	32821939	743	747	O
March	32821939	748	753	O
15	32821939	754	756	O
through	32821939	757	764	O
April	32821939	765	770	O
18	32821939	771	773	O
,	32821939	774	775	O
2020	32821939	776	780	O
,	32821939	781	782	O
at	32821939	783	785	O
105	32821939	786	789	O
hospitals	32821939	790	799	O
in	32821939	800	802	O
the	32821939	803	806	O
United	32821939	807	813	O
States	32821939	814	820	O
,	32821939	821	822	O
Europe	32821939	823	829	O
,	32821939	830	831	O
and	32821939	832	835	O
Asia	32821939	836	840	O
.	32821939	841	842	O

The	32821939	843	846	O
date	32821939	847	851	O
of	32821939	852	854	O
final	32821939	855	860	O
follow	32821939	861	867	O
-	32821939	868	869	O
up	32821939	870	872	O
was	32821939	873	876	O
May	32821939	877	880	O
20	32821939	881	883	O
,	32821939	884	885	O
2020	32821939	886	890	O
.	32821939	891	892	O

Patients	32821939	893	901	O
were	32821939	902	906	O
randomized	32821939	907	917	O
in	32821939	918	920	O
a	32821939	921	922	O
1:1:1	32821939	923	928	O
ratio	32821939	929	934	O
to	32821939	935	937	O
receive	32821939	938	945	O
a	32821939	946	947	O
10-day	32821939	948	954	B-Intervention
course	32821939	955	961	I-Intervention
of	32821939	962	964	I-Intervention
remdesivir	32821939	965	975	I-Intervention
(	32821939	976	977	O
n	32821939	978	979	O
=	32821939	982	983	O
197	32821939	986	989	O
)	32821939	990	991	O
,	32821939	992	993	O
a	32821939	994	995	O
5-day	32821939	996	1001	B-Intervention
course	32821939	1002	1008	I-Intervention
of	32821939	1009	1011	I-Intervention
remdesivir	32821939	1012	1022	I-Intervention
(	32821939	1023	1024	O
n	32821939	1025	1026	O
=	32821939	1029	1030	O
199	32821939	1033	1036	O
)	32821939	1037	1038	O
,	32821939	1039	1040	O
or	32821939	1041	1043	O
standard	32821939	1044	1052	B-Intervention
care	32821939	1053	1057	I-Intervention
(	32821939	1058	1059	O
n	32821939	1060	1061	O
=	32821939	1064	1065	O
200	32821939	1068	1071	O
)	32821939	1072	1073	O
.	32821939	1074	1075	O

Remdesivir	32821939	1076	1086	B-Intervention
was	32821939	1087	1090	O
dosed	32821939	1091	1096	O
intravenously	32821939	1097	1110	O
at	32821939	1111	1113	O
200	32821939	1114	1117	O
mg	32821939	1118	1120	O
on	32821939	1121	1123	O
day	32821939	1124	1127	O
1	32821939	1128	1129	O
followed	32821939	1130	1138	O
by	32821939	1139	1141	O
100	32821939	1142	1145	O
mg	32821939	1146	1148	O
/	32821939	1149	1150	O
d	32821939	1151	1152	O
.	32821939	1153	1154	O

The	32821939	1155	1158	O
primary	32821939	1159	1166	O
end	32821939	1167	1170	O
point	32821939	1171	1176	O
was	32821939	1177	1180	O
clinical	32821939	1181	1189	B-Outcome
status	32821939	1190	1196	I-Outcome
on	32821939	1197	1199	I-Outcome
day	32821939	1200	1203	I-Outcome
11	32821939	1204	1206	I-Outcome
on	32821939	1207	1209	O
a	32821939	1210	1211	O
7-point	32821939	1212	1219	O
ordinal	32821939	1220	1227	O
scale	32821939	1228	1233	O
ranging	32821939	1234	1241	O
from	32821939	1242	1246	O
death	32821939	1247	1252	O
(	32821939	1253	1254	O
category	32821939	1255	1263	O
1	32821939	1264	1265	O
)	32821939	1266	1267	O
to	32821939	1268	1270	O
discharged	32821939	1271	1281	O
(	32821939	1282	1283	O
category	32821939	1284	1292	O
7	32821939	1293	1294	O
)	32821939	1295	1296	O
.	32821939	1297	1298	O

Differences	32821939	1299	1310	B-Observation
between	32821939	1311	1318	O
remdesivir	32821939	1319	1329	B-Intervention
treatment	32821939	1330	1339	O
groups	32821939	1340	1346	O
and	32821939	1347	1350	O
standard	32821939	1351	1359	B-Intervention
care	32821939	1360	1364	I-Intervention
were	32821939	1365	1369	O
calculated	32821939	1370	1380	O
using	32821939	1381	1386	O
proportional	32821939	1387	1399	O
odds	32821939	1400	1404	O
models	32821939	1405	1411	O
and	32821939	1412	1415	O
expressed	32821939	1416	1425	O
as	32821939	1426	1428	O
odds	32821939	1429	1433	O
ratios	32821939	1434	1440	O
.	32821939	1441	1442	O

An	32821939	1443	1445	O
odds	32821939	1446	1450	O
ratio	32821939	1451	1456	O
greater	32821939	1457	1464	O
than	32821939	1465	1469	O
1	32821939	1470	1471	O
indicates	32821939	1472	1481	O
difference	32821939	1482	1492	B-Observation
in	32821939	1493	1495	O
clinical	32821939	1496	1504	B-Outcome
status	32821939	1505	1511	I-Outcome
distribution	32821939	1512	1524	I-Outcome
toward	32821939	1525	1531	I-Outcome
category	32821939	1532	1540	I-Outcome
7	32821939	1541	1542	I-Outcome
for	32821939	1543	1546	O
the	32821939	1547	1550	O
remdesivir	32821939	1551	1561	B-Intervention
group	32821939	1562	1567	O
vs	32821939	1568	1570	O
the	32821939	1571	1574	O
standard	32821939	1575	1583	B-Intervention
care	32821939	1584	1588	I-Intervention
group	32821939	1589	1594	O
.	32821939	1595	1596	O

Among	32821939	1597	1602	O
596	32821939	1603	1606	O
patients	32821939	1607	1615	O
who	32821939	1616	1619	O
were	32821939	1620	1624	O
randomized	32821939	1625	1635	O
,	32821939	1636	1637	O
584	32821939	1638	1641	O
began	32821939	1642	1647	O
the	32821939	1648	1651	O
study	32821939	1652	1657	O
and	32821939	1658	1661	O
received	32821939	1662	1670	O
remdesivir	32821939	1671	1681	B-Intervention
or	32821939	1682	1684	O
continued	32821939	1685	1694	O
standard	32821939	1695	1703	B-Intervention
care	32821939	1704	1708	I-Intervention
(	32821939	1709	1710	O
median	32821939	1711	1717	O
age	32821939	1718	1721	O
,	32821939	1722	1723	O
57	32821939	1724	1726	O
[	32821939	1727	1728	O
interquartile	32821939	1729	1742	O
range	32821939	1743	1748	O
,	32821939	1749	1750	O
46	32821939	1751	1753	O
-	32821939	1754	1755	O
66	32821939	1756	1758	O
]	32821939	1759	1760	O
years	32821939	1761	1766	O
;	32821939	1767	1768	O
227	32821939	1769	1772	O
[	32821939	1773	1774	O
39	32821939	1775	1777	O
%	32821939	1778	1779	O
]	32821939	1780	1781	O
women	32821939	1782	1787	O
;	32821939	1788	1789	O
56	32821939	1790	1792	O
%	32821939	1793	1794	O
had	32821939	1795	1798	O
cardiovascular	32821939	1799	1813	O
disease	32821939	1814	1821	O
,	32821939	1822	1823	O
42	32821939	1824	1826	O
%	32821939	1827	1828	O
hypertension	32821939	1829	1841	O
,	32821939	1842	1843	O
and	32821939	1844	1847	O
40	32821939	1848	1850	O
%	32821939	1851	1852	O
diabetes	32821939	1853	1861	O
)	32821939	1862	1863	O
,	32821939	1864	1865	O
and	32821939	1866	1869	O
533	32821939	1870	1873	O
(	32821939	1874	1875	O
91	32821939	1876	1878	O
%	32821939	1879	1880	O
)	32821939	1881	1882	O
completed	32821939	1883	1892	O
the	32821939	1893	1896	O
trial	32821939	1897	1902	O
.	32821939	1903	1904	O

Median	32821939	1905	1911	B-Outcome
length	32821939	1912	1918	I-Outcome
of	32821939	1919	1921	I-Outcome
treatment	32821939	1922	1931	I-Outcome
was	32821939	1932	1935	O
5	32821939	1936	1937	B-Observation
days	32821939	1938	1942	I-Observation
for	32821939	1943	1946	O
patients	32821939	1947	1955	O
in	32821939	1956	1958	O
the	32821939	1959	1962	O
5-day	32821939	1963	1968	B-Intervention
remdesivir	32821939	1969	1979	I-Intervention
group	32821939	1980	1985	O
and	32821939	1986	1989	O
6	32821939	1990	1991	B-Observation
days	32821939	1992	1996	I-Observation
for	32821939	1997	2000	O
patients	32821939	2001	2009	O
in	32821939	2010	2012	O
the	32821939	2013	2016	O
10-day	32821939	2017	2023	B-Intervention
remdesivir	32821939	2024	2034	I-Intervention
group	32821939	2035	2040	O
.	32821939	2041	2042	O

On	32821939	2043	2045	O
day	32821939	2046	2049	O
11	32821939	2050	2052	O
,	32821939	2053	2054	O
patients	32821939	2055	2063	O
in	32821939	2064	2066	O
the	32821939	2067	2070	O
5-day	32821939	2071	2076	B-Intervention
remdesivir	32821939	2077	2087	I-Intervention
group	32821939	2088	2093	O
had	32821939	2094	2097	O
statistically	32821939	2098	2111	B-Observation
significantly	32821939	2112	2125	I-Observation
higher	32821939	2126	2132	I-Observation
odds	32821939	2133	2137	B-Outcome
of	32821939	2138	2140	I-Outcome
a	32821939	2141	2142	I-Outcome
better	32821939	2143	2149	I-Outcome
clinical	32821939	2150	2158	I-Outcome
status	32821939	2159	2165	I-Outcome
distribution	32821939	2166	2178	I-Outcome
than	32821939	2179	2183	O
those	32821939	2184	2189	O
receiving	32821939	2190	2199	O
standard	32821939	2200	2208	B-Intervention
care	32821939	2209	2213	I-Intervention
(	32821939	2214	2215	O
odds	32821939	2216	2220	O
ratio	32821939	2221	2226	O
,	32821939	2227	2228	O
1.65	32821939	2229	2233	O
;	32821939	2234	2235	O
95	32821939	2236	2238	O
%	32821939	2239	2240	O
CI	32821939	2241	2243	O
,	32821939	2244	2245	O
1.09	32821939	2246	2250	O
-	32821939	2251	2252	O
2.48	32821939	2253	2257	O
;	32821939	2258	2259	O
P	32821939	2260	2261	O
=	32821939	2264	2265	O
.02	32821939	2268	2271	O
)	32821939	2272	2273	O
.	32821939	2274	2275	O

The	32821939	2276	2279	O
clinical	32821939	2280	2288	B-Outcome
status	32821939	2289	2295	I-Outcome
distribution	32821939	2296	2308	I-Outcome
on	32821939	2309	2311	I-Outcome
day	32821939	2312	2315	I-Outcome
11	32821939	2316	2318	I-Outcome
between	32821939	2319	2326	O
the	32821939	2327	2330	O
10-day	32821939	2331	2337	B-Intervention
remdesivir	32821939	2338	2348	I-Intervention
and	32821939	2349	2352	O
standard	32821939	2353	2361	B-Intervention
care	32821939	2362	2366	I-Intervention
groups	32821939	2367	2373	O
was	32821939	2374	2377	O
not	32821939	2378	2381	O
significantly	32821939	2382	2395	B-Observation
different	32821939	2396	2405	I-Observation
(	32821939	2406	2407	O
P	32821939	2408	2409	O
=	32821939	2412	2413	O
.18	32821939	2416	2419	O
by	32821939	2420	2422	O
Wilcoxon	32821939	2423	2431	O
rank	32821939	2432	2436	O
sum	32821939	2437	2440	O
test	32821939	2441	2445	O
)	32821939	2446	2447	O
.	32821939	2448	2449	O

By	32821939	2450	2452	O
day	32821939	2453	2456	O
28	32821939	2457	2459	O
,	32821939	2460	2461	O
9	32821939	2462	2463	B-Count
patients	32821939	2464	2472	I-Count
had	32821939	2473	2476	O
died	32821939	2477	2481	B-Outcome
:	32821939	2482	2483	O
2	32821939	2484	2485	B-Count
(	32821939	2486	2487	I-Count
1	32821939	2488	2489	I-Count
%	32821939	2490	2491	I-Count
)	32821939	2492	2493	I-Count
in	32821939	2494	2496	O
the	32821939	2497	2500	O
5-day	32821939	2501	2506	B-Intervention
remdesivir	32821939	2507	2517	I-Intervention
group	32821939	2518	2523	O
,	32821939	2524	2525	O
3	32821939	2526	2527	B-Count
(	32821939	2528	2529	I-Count
2	32821939	2530	2531	I-Count
%	32821939	2532	2533	I-Count
)	32821939	2534	2535	I-Count
in	32821939	2536	2538	O
the	32821939	2539	2542	O
10-day	32821939	2543	2549	B-Intervention
remdesivir	32821939	2550	2560	I-Intervention
group	32821939	2561	2566	O
,	32821939	2567	2568	O
and	32821939	2569	2572	O
4	32821939	2573	2574	B-Count
(	32821939	2575	2576	I-Count
2	32821939	2577	2578	I-Count
%	32821939	2579	2580	I-Count
)	32821939	2581	2582	I-Count
in	32821939	2583	2585	O
the	32821939	2586	2589	O
standard	32821939	2590	2598	B-Intervention
care	32821939	2599	2603	I-Intervention
group	32821939	2604	2609	O
.	32821939	2610	2611	O

Nausea	32821939	2612	2618	B-Outcome
(	32821939	2619	2620	O
10	32821939	2621	2623	B-Count
%	32821939	2624	2625	I-Count
vs	32821939	2626	2628	O
3	32821939	2629	2630	B-Count
%	32821939	2631	2632	I-Count
)	32821939	2633	2634	O
,	32821939	2635	2636	O
hypokalemia	32821939	2637	2648	B-Outcome
(	32821939	2649	2650	O
6	32821939	2651	2652	B-Count
%	32821939	2653	2654	I-Count
vs	32821939	2655	2657	O
2	32821939	2658	2659	B-Count
%	32821939	2660	2661	I-Count
)	32821939	2662	2663	O
,	32821939	2664	2665	O
and	32821939	2666	2669	O
headache	32821939	2670	2678	B-Outcome
(	32821939	2679	2680	O
5	32821939	2681	2682	B-Count
%	32821939	2683	2684	I-Count
vs	32821939	2685	2687	O
3	32821939	2688	2689	B-Count
%	32821939	2690	2691	I-Count
)	32821939	2692	2693	O
were	32821939	2694	2698	O
more	32821939	2699	2703	B-Observation
frequent	32821939	2704	2712	I-Observation
among	32821939	2713	2718	O
remdesivir	32821939	2719	2729	B-Intervention
-	32821939	2730	2731	I-Intervention
treated	32821939	2732	2739	I-Intervention
patients	32821939	2740	2748	O
compared	32821939	2749	2757	O
with	32821939	2758	2762	O
standard	32821939	2763	2771	B-Intervention
care	32821939	2772	2776	I-Intervention
.	32821939	2777	2778	O

Among	32821939	2779	2784	O
patients	32821939	2785	2793	O
with	32821939	2794	2798	O
moderate	32821939	2799	2807	B-Participant
COVID-19	32821939	2808	2816	I-Participant
,	32821939	2817	2818	O
those	32821939	2819	2824	O
randomized	32821939	2825	2835	O
to	32821939	2836	2838	O
a	32821939	2839	2840	O
10-day	32821939	2841	2847	B-Intervention
course	32821939	2848	2854	I-Intervention
of	32821939	2855	2857	I-Intervention
remdesivir	32821939	2858	2868	I-Intervention
did	32821939	2869	2872	O
not	32821939	2873	2876	O
have	32821939	2877	2881	O
a	32821939	2882	2883	O
statistically	32821939	2884	2897	B-Observation
significant	32821939	2898	2909	I-Observation
difference	32821939	2910	2920	I-Observation
in	32821939	2921	2923	O
clinical	32821939	2924	2932	B-Outcome
status	32821939	2933	2939	I-Outcome
compared	32821939	2940	2948	O
with	32821939	2949	2953	O
standard	32821939	2954	2962	B-Intervention
care	32821939	2963	2967	I-Intervention
at	32821939	2968	2970	O
11	32821939	2971	2973	O
days	32821939	2974	2978	O
after	32821939	2979	2984	O
initiation	32821939	2985	2995	O
of	32821939	2996	2998	O
treatment	32821939	2999	3008	O
.	32821939	3009	3010	O

Patients	32821939	3011	3019	O
randomized	32821939	3020	3030	O
to	32821939	3031	3033	O
a	32821939	3034	3035	O
5-day	32821939	3036	3041	B-Intervention
course	32821939	3042	3048	I-Intervention
of	32821939	3049	3051	I-Intervention
remdesivir	32821939	3052	3062	I-Intervention
had	32821939	3063	3066	O
a	32821939	3067	3068	O
statistically	32821939	3069	3082	B-Observation
significant	32821939	3083	3094	I-Observation
difference	32821939	3095	3105	I-Observation
in	32821939	3106	3108	O
clinical	32821939	3109	3117	B-Outcome
status	32821939	3118	3124	I-Outcome
compared	32821939	3125	3133	O
with	32821939	3134	3138	O
standard	32821939	3139	3147	B-Intervention
care	32821939	3148	3152	I-Intervention
,	32821939	3153	3154	O
but	32821939	3155	3158	O
the	32821939	3159	3162	O
difference	32821939	3163	3173	B-Observation
was	32821939	3174	3177	O
of	32821939	3178	3180	O
uncertain	32821939	3181	3190	O
clinical	32821939	3191	3199	O
importance	32821939	3200	3210	O
.	32821939	3211	3212	O

ClinicalTrials.gov	32821939	3213	3231	O
Identifier	32821939	3232	3242	O
:	32821939	3243	3244	O
NCT04292730	32821939	3245	3256	O
.	32821939	3257	3258	O


Hydroxychloroquine	32828135	0	18	B-Intervention
in	32828135	19	21	O
the	32828135	22	25	O
Treatment	32828135	26	35	O
of	32828135	36	38	O
COVID-19	32828135	39	47	B-Participant
:	32828135	48	49	O
A	32828135	50	51	O
Multicenter	32828135	52	63	O
Randomized	32828135	64	74	O
Controlled	32828135	75	85	O
Study	32828135	86	91	O
.	32828135	92	93	O

The	32828135	94	97	O
COVID-19	32828135	98	106	O
pandemic	32828135	107	115	O
is	32828135	116	118	O
showing	32828135	119	126	O
an	32828135	127	129	O
exponential	32828135	130	141	O
growth	32828135	142	148	O
,	32828135	149	150	O
mandating	32828135	151	160	O
an	32828135	161	163	O
urgent	32828135	164	170	O
need	32828135	171	175	O
to	32828135	176	178	O
develop	32828135	179	186	O
an	32828135	187	189	O
effective	32828135	190	199	O
treatment	32828135	200	209	O
.	32828135	210	211	O

Indeed	32828135	212	218	O
,	32828135	219	220	O
to	32828135	221	223	O
date	32828135	224	228	O
,	32828135	229	230	O
a	32828135	231	232	O
well	32828135	233	237	O
-	32828135	238	239	O
established	32828135	240	251	O
therapy	32828135	252	259	O
is	32828135	260	262	O
still	32828135	263	268	O
lacking	32828135	269	276	O
.	32828135	277	278	O

We	32828135	279	281	O
aimed	32828135	282	287	O
to	32828135	288	290	O
evaluate	32828135	291	299	O
the	32828135	300	303	O
safety	32828135	304	310	B-Outcome
and	32828135	311	314	O
efficacy	32828135	315	323	B-Outcome
of	32828135	324	326	O
hydroxychloroquine	32828135	327	345	B-Intervention
(	32828135	346	347	I-Intervention
HCQ	32828135	348	351	I-Intervention
)	32828135	352	353	I-Intervention
added	32828135	354	359	O
to	32828135	360	362	O
standard	32828135	363	371	B-Intervention
care	32828135	372	376	I-Intervention
in	32828135	377	379	O
patients	32828135	380	388	O
with	32828135	389	393	O
COVID-19	32828135	394	402	B-Participant
.	32828135	403	404	O

This	32828135	405	409	O
was	32828135	410	413	O
a	32828135	414	415	O
multicenter	32828135	416	427	O
,	32828135	428	429	O
randomized	32828135	430	440	O
controlled	32828135	441	451	O
trial	32828135	452	457	O
conducted	32828135	458	467	O
at	32828135	468	470	O
three	32828135	471	476	O
major	32828135	477	482	O
university	32828135	483	493	O
hospitals	32828135	494	503	O
in	32828135	504	506	O
Egypt	32828135	507	512	O
.	32828135	513	514	O

One	32828135	515	518	O
hundred	32828135	519	526	O
ninety	32828135	527	533	O
-	32828135	534	535	O
four	32828135	536	540	O
patients	32828135	541	549	O
with	32828135	550	554	O
confirmed	32828135	555	564	O
diagnosis	32828135	565	574	O
of	32828135	575	577	O
COVID-19	32828135	578	586	B-Participant
were	32828135	587	591	O
included	32828135	592	600	O
in	32828135	601	603	O
the	32828135	604	607	O
study	32828135	608	613	O
after	32828135	614	619	O
signing	32828135	620	627	O
informed	32828135	628	636	O
consent	32828135	637	644	O
.	32828135	645	646	O

They	32828135	647	651	O
were	32828135	652	656	O
equally	32828135	657	664	O
randomized	32828135	665	675	O
into	32828135	676	680	O
two	32828135	681	684	O
arms	32828135	685	689	O
:	32828135	690	691	O
97	32828135	692	694	O
patients	32828135	695	703	O
administrated	32828135	704	717	O
HCQ	32828135	718	721	B-Intervention
plus	32828135	722	726	I-Intervention
standard	32828135	727	735	I-Intervention
care	32828135	736	740	I-Intervention
(	32828135	741	742	O
HCQ	32828135	743	746	O
group	32828135	747	752	O
)	32828135	753	754	O
and	32828135	755	758	O
97	32828135	759	761	O
patients	32828135	762	770	O
administered	32828135	771	783	O
only	32828135	784	788	O
standard	32828135	789	797	B-Intervention
care	32828135	798	802	I-Intervention
as	32828135	803	805	O
a	32828135	806	807	O
control	32828135	808	815	O
arm	32828135	816	819	O
(	32828135	820	821	O
control	32828135	822	829	O
group	32828135	830	835	O
)	32828135	836	837	O
.	32828135	838	839	O

The	32828135	840	843	O
primary	32828135	844	851	O
endpoints	32828135	852	861	O
were	32828135	862	866	O
recovery	32828135	867	875	B-Outcome
within	32828135	876	882	I-Outcome
28	32828135	883	885	I-Outcome
days	32828135	886	890	I-Outcome
,	32828135	891	892	O
need	32828135	893	897	B-Outcome
for	32828135	898	901	I-Outcome
mechanical	32828135	902	912	I-Outcome
ventilation	32828135	913	924	I-Outcome
,	32828135	925	926	O
or	32828135	927	929	O
death	32828135	930	935	B-Outcome
.	32828135	936	937	O

The	32828135	938	941	O
two	32828135	942	945	O
groups	32828135	946	952	O
were	32828135	953	957	O
matched	32828135	958	965	O
for	32828135	966	969	O
age	32828135	970	973	O
and	32828135	974	977	O
gender	32828135	978	984	O
.	32828135	985	986	O

There	32828135	987	992	O
was	32828135	993	996	O
no	32828135	997	999	O
significant	32828135	1000	1011	B-Observation
difference	32828135	1012	1022	I-Observation
between	32828135	1023	1030	B-Intervention
them	32828135	1031	1035	I-Intervention
regarding	32828135	1036	1045	O
any	32828135	1046	1049	O
of	32828135	1050	1052	O
the	32828135	1053	1056	O
baseline	32828135	1057	1065	B-Outcome
characteristics	32828135	1066	1081	I-Outcome
or	32828135	1082	1084	O
laboratory	32828135	1085	1095	B-Outcome
parameters	32828135	1096	1106	I-Outcome
.	32828135	1107	1108	O

Four	32828135	1109	1113	B-Count
patients	32828135	1114	1122	I-Count
(	32828135	1123	1124	I-Count
4.1	32828135	1125	1128	I-Count
%	32828135	1129	1130	I-Count
)	32828135	1131	1132	I-Count
in	32828135	1133	1135	O
the	32828135	1136	1139	O
HCQ	32828135	1140	1143	B-Intervention
group	32828135	1144	1149	O
and	32828135	1150	1153	O
5	32828135	1154	1155	B-Count
(	32828135	1156	1157	I-Count
5.2	32828135	1158	1161	I-Count
%	32828135	1162	1163	I-Count
)	32828135	1164	1165	I-Count
patients	32828135	1166	1174	I-Count
in	32828135	1175	1177	O
the	32828135	1178	1181	O
control	32828135	1182	1189	B-Intervention
group	32828135	1190	1195	O
needed	32828135	1196	1202	O
mechanical	32828135	1203	1213	B-Outcome
ventilation	32828135	1214	1225	I-Outcome
(	32828135	1226	1227	O
P	32828135	1228	1229	O
=	32828135	1230	1231	O
0.75	32828135	1232	1236	O
)	32828135	1237	1238	O
.	32828135	1239	1240	O

The	32828135	1241	1244	O
overall	32828135	1245	1252	B-Outcome
mortality	32828135	1253	1262	I-Outcome
did	32828135	1263	1266	O
not	32828135	1267	1270	O
differ	32828135	1271	1277	B-Observation
between	32828135	1278	1285	B-Intervention
the	32828135	1286	1289	I-Intervention
two	32828135	1290	1293	I-Intervention
groups	32828135	1294	1300	I-Intervention
,	32828135	1301	1302	O
as	32828135	1303	1305	O
six	32828135	1306	1309	B-Count
patients	32828135	1310	1318	I-Count
(	32828135	1319	1320	I-Count
6.2	32828135	1321	1324	I-Count
%	32828135	1325	1326	I-Count
)	32828135	1327	1328	I-Count
died	32828135	1329	1333	B-Outcome
in	32828135	1334	1336	O
the	32828135	1337	1340	O
HCQ	32828135	1341	1344	B-Intervention
group	32828135	1345	1350	O
and	32828135	1351	1354	O
5	32828135	1355	1356	B-Count
(	32828135	1357	1358	I-Count
5.2	32828135	1359	1362	I-Count
%	32828135	1363	1364	I-Count
)	32828135	1365	1366	I-Count
died	32828135	1367	1371	B-Outcome
in	32828135	1372	1374	O
the	32828135	1375	1378	O
control	32828135	1379	1386	B-Intervention
group	32828135	1387	1392	O
(	32828135	1393	1394	O
P	32828135	1395	1396	O
=	32828135	1397	1398	O
0.77	32828135	1399	1403	O
)	32828135	1404	1405	O
.	32828135	1406	1407	O

Univariate	32828135	1408	1418	O
logistic	32828135	1419	1427	O
regression	32828135	1428	1438	O
analysis	32828135	1439	1447	O
showed	32828135	1448	1454	O
that	32828135	1455	1459	O
HCQ	32828135	1460	1463	B-Intervention
treatment	32828135	1464	1473	O
was	32828135	1474	1477	O
not	32828135	1478	1481	O
significantly	32828135	1482	1495	O
associated	32828135	1496	1506	O
with	32828135	1507	1511	O
decreased	32828135	1512	1521	B-Observation
mortality	32828135	1522	1531	B-Outcome
in	32828135	1532	1534	O
COVID-19	32828135	1535	1543	B-Participant
patients	32828135	1544	1552	O
.	32828135	1553	1554	O

So	32828135	1555	1557	O
,	32828135	1558	1559	O
adding	32828135	1560	1566	B-Intervention
HCQ	32828135	1567	1570	I-Intervention
to	32828135	1571	1573	I-Intervention
standard	32828135	1574	1582	I-Intervention
care	32828135	1583	1587	I-Intervention
did	32828135	1588	1591	O
not	32828135	1592	1595	O
add	32828135	1596	1599	B-Observation
significant	32828135	1600	1611	B-Outcome
benefit	32828135	1612	1619	I-Outcome
,	32828135	1620	1621	O
did	32828135	1622	1625	O
not	32828135	1626	1629	O
decrease	32828135	1630	1638	B-Observation
the	32828135	1639	1642	O
need	32828135	1643	1647	B-Outcome
for	32828135	1648	1651	I-Outcome
ventilation	32828135	1652	1663	I-Outcome
,	32828135	1664	1665	O
and	32828135	1666	1669	O
did	32828135	1670	1673	O
not	32828135	1674	1677	O
reduce	32828135	1678	1684	B-Observation
mortality	32828135	1685	1694	B-Outcome
rates	32828135	1695	1700	I-Outcome
in	32828135	1701	1703	O
COVID-19	32828135	1704	1712	B-Participant
patients	32828135	1713	1721	O
.	32828135	1722	1723	O


Face	32829745	0	4	B-Intervention
masks	32829745	5	10	I-Intervention
for	32829745	11	14	O
the	32829745	15	18	O
prevention	32829745	19	29	O
of	32829745	30	32	O
COVID-19	32829745	33	41	B-Participant
-	32829745	42	43	O
Rationale	32829745	44	53	O
and	32829745	54	57	O
design	32829745	58	64	O
of	32829745	65	67	O
the	32829745	68	71	O
randomised	32829745	72	82	O
controlled	32829745	83	93	O
trial	32829745	94	99	O
DANMASK-19	32829745	100	110	O
.	32829745	111	112	O

BACKGROUND	32829745	113	123	O
:	32829745	124	125	O
The	32829745	126	129	O
coronavirus	32829745	130	141	O
disease	32829745	142	149	O
19	32829745	150	152	O
(	32829745	153	154	O
COVID-19	32829745	155	163	O
)	32829745	164	165	O
pandemic	32829745	166	174	O
,	32829745	175	176	O
caused	32829745	177	183	O
by	32829745	184	186	O
Severe	32829745	187	193	O
Acute	32829745	194	199	O
Respiratory	32829745	200	211	O
Syndrome	32829745	212	220	O
Coronavirus	32829745	221	232	O
2	32829745	233	234	O
(	32829745	235	236	O
SARS	32829745	237	241	O
-	32829745	242	243	O
CoV-2	32829745	244	249	O
)	32829745	250	251	O
,	32829745	252	253	O
progresses	32829745	254	264	O
globally	32829745	265	273	O
,	32829745	274	275	O
and	32829745	276	279	O
means	32829745	280	285	O
to	32829745	286	288	O
reduce	32829745	289	295	O
the	32829745	296	299	O
transmission	32829745	300	312	O
are	32829745	313	316	O
needed	32829745	317	323	O
.	32829745	324	325	O

In	32829745	326	328	O
the	32829745	329	332	O
community	32829745	333	342	O
,	32829745	343	344	O
the	32829745	345	348	O
use	32829745	349	352	O
of	32829745	353	355	O
face	32829745	356	360	O
masks	32829745	361	366	O
is	32829745	367	369	O
increasing	32829745	370	380	O
world	32829745	381	386	O
-	32829745	387	388	O
wide	32829745	389	393	O
,	32829745	394	395	O
but	32829745	396	399	O
documentation	32829745	400	413	O
for	32829745	414	417	O
the	32829745	418	421	O
efficacy	32829745	422	430	O
of	32829745	431	433	O
this	32829745	434	438	O
remedy	32829745	439	445	O
is	32829745	446	448	O
lacking	32829745	449	456	O
.	32829745	457	458	O

This	32829745	459	463	O
trial	32829745	464	469	O
investigates	32829745	470	482	O
whether	32829745	483	490	O
the	32829745	491	494	O
use	32829745	495	498	O
of	32829745	499	501	O
face	32829745	502	506	B-Intervention
masks	32829745	507	512	I-Intervention
in	32829745	513	515	O
the	32829745	516	519	O
community	32829745	520	529	O
will	32829745	530	534	O
reduce	32829745	535	541	B-Observation
wearers	32829745	542	549	O
'	32829745	550	551	O
risk	32829745	552	556	B-Outcome
of	32829745	557	559	I-Outcome
SARS	32829745	560	564	I-Outcome
-	32829745	565	566	I-Outcome
CoV-2	32829745	567	572	I-Outcome
infection	32829745	573	582	I-Outcome
.	32829745	583	584	O

METHODS	32829745	585	592	O
:	32829745	593	594	O
This	32829745	595	599	O
study	32829745	600	605	O
will	32829745	606	610	O
be	32829745	611	613	O
a	32829745	614	615	O
two	32829745	616	619	O
-	32829745	620	621	O
arm	32829745	622	625	O
,	32829745	626	627	O
unblinded	32829745	628	637	O
,	32829745	638	639	O
randomised	32829745	640	650	O
controlled	32829745	651	661	O
trial	32829745	662	667	O
.	32829745	668	669	O

We	32829745	670	672	O
will	32829745	673	677	O
include	32829745	678	685	O
adults	32829745	686	692	B-Participant
(	32829745	693	694	O
>	32829745	695	696	B-Participant
18	32829745	697	699	I-Participant
years	32829745	700	705	I-Participant
of	32829745	706	708	I-Participant
age	32829745	709	712	I-Participant
)	32829745	713	714	O
without	32829745	715	722	O
prior	32829745	723	728	B-Participant
confirmed	32829745	729	738	I-Participant
COVID-19	32829745	739	747	I-Participant
or	32829745	748	750	O
symptoms	32829745	751	759	B-Participant
suggestive	32829745	760	770	I-Participant
of	32829745	771	773	I-Participant
COVID-19	32829745	774	782	I-Participant
,	32829745	783	784	O
who	32829745	785	788	O
spend	32829745	789	794	O
more	32829745	795	799	B-Participant
than	32829745	800	804	I-Participant
three	32829745	805	810	I-Participant
hours	32829745	811	816	I-Participant
per	32829745	817	820	I-Participant
day	32829745	821	824	I-Participant
outside	32829745	825	832	I-Participant
the	32829745	833	836	I-Participant
home	32829745	837	841	I-Participant
with	32829745	842	846	I-Participant
exposure	32829745	847	855	I-Participant
to	32829745	856	858	I-Participant
other	32829745	859	864	I-Participant
people	32829745	865	871	I-Participant
.	32829745	872	873	O

A	32829745	874	875	O
total	32829745	876	881	O
of	32829745	882	884	O
6,000	32829745	885	890	O
participants	32829745	891	903	O
are	32829745	904	907	O
randomly	32829745	908	916	O
assigned	32829745	917	925	O
1:1	32829745	926	929	O
to	32829745	930	932	O
use	32829745	933	936	O
face	32829745	937	941	B-Intervention
masks	32829745	942	947	I-Intervention
or	32829745	948	950	O
not	32829745	951	954	B-Intervention
for	32829745	955	958	O
a	32829745	959	960	O
30-day	32829745	961	967	O
period	32829745	968	974	O
during	32829745	975	981	O
the	32829745	982	985	O
pandemic	32829745	986	994	O
.	32829745	995	996	O

Participants	32829745	997	1009	O
will	32829745	1010	1014	O
perform	32829745	1015	1022	O
self	32829745	1023	1027	O
-	32829745	1028	1029	O
testing	32829745	1030	1037	O
;	32829745	1038	1039	O
quick	32829745	1040	1045	O
test	32829745	1046	1050	O
for	32829745	1051	1054	O
SARS	32829745	1055	1059	O
-	32829745	1060	1061	O
CoV-2	32829745	1062	1067	O
antibodies	32829745	1068	1078	O
(	32829745	1079	1080	O
immunoglobulin	32829745	1081	1095	O
M	32829745	1096	1097	O
(	32829745	1098	1099	O
IgM	32829745	1100	1103	O
)	32829745	1104	1105	O
and	32829745	1106	1109	O
immunoglobulin	32829745	1110	1124	O
G	32829745	1125	1126	O
(	32829745	1127	1128	O
IgG	32829745	1129	1132	O
)	32829745	1133	1134	O
)	32829745	1135	1136	O
(	32829745	1137	1138	O
the	32829745	1139	1142	O
Livzon	32829745	1143	1149	O
lateral	32829745	1150	1157	O
flow	32829745	1158	1162	O
test	32829745	1163	1167	O
)	32829745	1168	1169	O
and	32829745	1170	1173	O
oropharyngeal	32829745	1174	1187	O
/	32829745	1188	1189	O
nasal	32829745	1190	1195	O
swabs	32829745	1196	1201	O
for	32829745	1202	1205	O
viral	32829745	1206	1211	O
detection	32829745	1212	1221	O
using	32829745	1222	1227	O
polymerase	32829745	1228	1238	O
chain	32829745	1239	1244	O
reaction	32829745	1245	1253	O
(	32829745	1254	1255	O
PCR	32829745	1256	1259	O
)	32829745	1260	1261	O
.	32829745	1262	1263	O

The	32829745	1264	1267	O
primary	32829745	1268	1275	O
endpoint	32829745	1276	1284	O
following	32829745	1285	1294	O
the	32829745	1295	1298	O
30-day	32829745	1299	1305	O
study	32829745	1306	1311	O
period	32829745	1312	1318	O
is	32829745	1319	1321	O
the	32829745	1322	1325	O
difference	32829745	1326	1336	B-Observation
in	32829745	1337	1339	O
the	32829745	1340	1343	O
number	32829745	1344	1350	B-Outcome
of	32829745	1351	1353	I-Outcome
SARS	32829745	1354	1358	I-Outcome
-	32829745	1359	1360	I-Outcome
CoV-2-infected	32829745	1361	1375	I-Outcome
individuals	32829745	1376	1387	I-Outcome
between	32829745	1388	1395	B-Intervention
the	32829745	1396	1399	I-Intervention
two	32829745	1400	1403	I-Intervention
study	32829745	1404	1409	I-Intervention
groups	32829745	1410	1416	I-Intervention
as	32829745	1417	1419	O
assessed	32829745	1420	1428	O
by	32829745	1429	1431	O
a	32829745	1432	1433	O
positive	32829745	1434	1442	O
nasopharyngeal	32829745	1443	1457	O
swap	32829745	1458	1462	O
,	32829745	1463	1464	O
a	32829745	1465	1466	O
positive	32829745	1467	1475	O
antibody	32829745	1476	1484	O
test	32829745	1485	1489	O
or	32829745	1490	1492	O
a	32829745	1493	1494	O
hospital	32829745	1495	1503	O
-	32829745	1504	1505	O
based	32829745	1506	1511	O
diagnosis	32829745	1512	1521	O
of	32829745	1522	1524	O
SARS	32829745	1525	1529	O
-	32829745	1530	1531	O
CoV-2	32829745	1532	1537	O
infection	32829745	1538	1547	O
.	32829745	1548	1549	O

CONCLUSIONS	32829745	1550	1561	O
:	32829745	1562	1563	O
We	32829745	1564	1566	O
will	32829745	1567	1571	O
study	32829745	1572	1577	O
whether	32829745	1578	1585	O
a	32829745	1586	1587	O
face	32829745	1588	1592	B-Intervention
mask	32829745	1593	1597	I-Intervention
protects	32829745	1598	1606	O
the	32829745	1607	1610	O
wearer	32829745	1611	1617	O
of	32829745	1618	1620	O
the	32829745	1621	1624	O
mask	32829745	1625	1629	O
against	32829745	1630	1637	B-Observation
SARS	32829745	1638	1642	B-Outcome
-	32829745	1643	1644	I-Outcome
CoV-2	32829745	1645	1650	I-Outcome
infection	32829745	1651	1660	I-Outcome
.	32829745	1661	1662	O

The	32829745	1663	1666	O
findings	32829745	1667	1675	O
are	32829745	1676	1679	O
expected	32829745	1680	1688	O
to	32829745	1689	1691	O
apply	32829745	1692	1697	O
to	32829745	1698	1700	O
the	32829745	1701	1704	O
present	32829745	1705	1712	O
pandemic	32829745	1713	1721	O
and	32829745	1722	1725	O
to	32829745	1726	1728	O
future	32829745	1729	1735	O
viral	32829745	1736	1741	O
outbreaks	32829745	1742	1751	O
and	32829745	1752	1755	O
to	32829745	1756	1758	O
provide	32829745	1759	1766	O
evidence	32829745	1767	1775	O
for	32829745	1776	1779	O
authority	32829745	1780	1789	O
recommendations	32829745	1790	1805	O
across	32829745	1806	1812	O
the	32829745	1813	1816	O
world	32829745	1817	1822	O
.	32829745	1823	1824	O

BACKGROUND	32829745	1825	1835	O
:	32829745	1836	1837	O
This	32829745	1838	1842	O
study	32829745	1843	1848	O
was	32829745	1849	1852	O
funded	32829745	1853	1859	O
by	32829745	1860	1862	O
Salling	32829745	1863	1870	O
Fondene	32829745	1871	1878	O
.	32829745	1879	1880	O

BACKGROUND	32829745	1881	1891	O
:	32829745	1892	1893	O
ClinicalTrials.gov	32829745	1894	1912	O
Identifier	32829745	1913	1923	O
:	32829745	1924	1925	O
NCT04337541	32829745	1926	1937	O
.	32829745	1938	1939	O

Articles	32829745	1940	1948	O
published	32829745	1949	1958	O
in	32829745	1959	1961	O
the	32829745	1962	1965	O
DMJ	32829745	1966	1969	O
are	32829745	1970	1973	O
	32829745	1974	1975	O
open	32829745	1976	1980	O
access	32829745	1981	1987	O
	32829745	1988	1989	O
.	32829745	1990	1991	O

This	32829745	1992	1996	O
means	32829745	1997	2002	O
that	32829745	2003	2007	O
the	32829745	2008	2011	O
articles	32829745	2012	2020	O
are	32829745	2021	2024	O
distributed	32829745	2025	2036	O
under	32829745	2037	2042	O
the	32829745	2043	2046	O
terms	32829745	2047	2052	O
of	32829745	2053	2055	O
the	32829745	2056	2059	O
Creative	32829745	2060	2068	O
Commons	32829745	2069	2076	O
Attribution	32829745	2077	2088	O
Non	32829745	2089	2092	O
-	32829745	2093	2094	O
commercial	32829745	2095	2105	O
License	32829745	2106	2113	O
,	32829745	2114	2115	O
which	32829745	2116	2121	O
permits	32829745	2122	2129	O
any	32829745	2130	2133	O
non	32829745	2134	2137	O
-	32829745	2138	2139	O
commercial	32829745	2140	2150	O
use	32829745	2151	2154	O
,	32829745	2155	2156	O
distribution	32829745	2157	2169	O
,	32829745	2170	2171	O
and	32829745	2172	2175	O
reproduction	32829745	2176	2188	O
in	32829745	2189	2191	O
any	32829745	2192	2195	O
medium	32829745	2196	2202	O
,	32829745	2203	2204	O
provided	32829745	2205	2213	O
the	32829745	2214	2217	O
original	32829745	2218	2226	O
author(s	32829745	2227	2235	O
)	32829745	2236	2237	O
and	32829745	2238	2241	O
source	32829745	2242	2248	O
are	32829745	2249	2252	O
credited	32829745	2253	2261	O
.	32829745	2262	2263	O


Impact	32831151	0	6	O
of	32831151	7	9	O
Shenfu	32831151	10	16	B-Intervention
injection	32831151	17	26	I-Intervention
on	32831151	27	29	O
a	32831151	30	31	O
composite	32831151	32	41	B-Outcome
of	32831151	42	44	I-Outcome
organ	32831151	45	50	I-Outcome
dysfunction	32831151	51	62	I-Outcome
development	32831151	63	74	I-Outcome
in	32831151	75	77	O
critically	32831151	78	88	B-Participant
ill	32831151	89	92	I-Participant
patients	32831151	93	101	O
with	32831151	102	106	O
coronavirus	32831151	107	118	B-Participant
disease	32831151	119	126	I-Participant
2019	32831151	127	131	I-Participant
(	32831151	132	133	I-Participant
COVID-19	32831151	134	142	I-Participant
)	32831151	143	144	I-Participant
:	32831151	145	146	O
A	32831151	147	148	O
structured	32831151	149	159	O
summary	32831151	160	167	O
of	32831151	168	170	O
a	32831151	171	172	O
study	32831151	173	178	O
protocol	32831151	179	187	O
for	32831151	188	191	O
a	32831151	192	193	O
randomized	32831151	194	204	O
controlled	32831151	205	215	O
trial	32831151	216	221	O
.	32831151	222	223	O

OBJECTIVE	32831151	224	233	O
:	32831151	234	235	O
This	32831151	236	240	O
study	32831151	241	246	O
aims	32831151	247	251	O
to	32831151	252	254	O
determine	32831151	255	264	O
the	32831151	265	268	O
protection	32831151	269	279	O
provided	32831151	280	288	O
by	32831151	289	291	O
Shenfu	32831151	292	298	B-Intervention
injection	32831151	299	308	I-Intervention
(	32831151	309	310	O
a	32831151	311	312	O
traditional	32831151	313	324	O
Chinese	32831151	325	332	O
medicine	32831151	333	341	O
)	32831151	342	343	O
against	32831151	344	351	O
development	32831151	352	363	B-Outcome
of	32831151	364	366	I-Outcome
organ	32831151	367	372	I-Outcome
dysfunction	32831151	373	384	I-Outcome
in	32831151	385	387	O
critically	32831151	388	398	B-Participant
ill	32831151	399	402	I-Participant
patients	32831151	403	411	O
with	32831151	412	416	O
coronavirus	32831151	417	428	B-Participant
disease	32831151	429	436	I-Participant
2019	32831151	437	441	I-Participant
(	32831151	442	443	I-Participant
COVID-19	32831151	444	452	I-Participant
)	32831151	453	454	I-Participant
.	32831151	455	456	O

METHODS	32831151	457	464	O
:	32831151	465	466	O
This	32831151	467	471	O
study	32831151	472	477	O
is	32831151	478	480	O
a	32831151	481	482	O
multicenter	32831151	483	494	O
,	32831151	495	496	O
randomized	32831151	497	507	O
,	32831151	508	509	O
controlled	32831151	510	520	O
,	32831151	521	522	O
open	32831151	523	527	O
-	32831151	528	529	O
label	32831151	530	535	O
,	32831151	536	537	O
two	32831151	538	541	O
-	32831151	542	543	O
arm	32831151	544	547	O
ratio	32831151	548	553	O
1:1	32831151	554	557	O
,	32831151	558	559	O
parallel	32831151	560	568	O
group	32831151	569	574	O
clinical	32831151	575	583	O
trial	32831151	584	589	O
.	32831151	590	591	O

METHODS	32831151	592	599	O
:	32831151	600	601	O
The	32831151	602	605	O
patients	32831151	606	614	O
,	32831151	615	616	O
who	32831151	617	620	O
are	32831151	621	624	O
aged	32831151	625	629	O
from	32831151	630	634	O
18	32831151	635	637	B-Participant
to	32831151	638	640	I-Participant
75	32831151	641	643	I-Participant
years	32831151	644	649	I-Participant
old	32831151	650	653	I-Participant
,	32831151	654	655	O
with	32831151	656	660	O
a	32831151	661	662	O
confirmed	32831151	663	672	B-Participant
or	32831151	673	675	I-Participant
suspected	32831151	676	685	I-Participant
diagnosis	32831151	686	695	I-Participant
of	32831151	696	698	I-Participant
severe	32831151	699	705	I-Participant
or	32831151	706	708	I-Participant
critical	32831151	709	717	I-Participant
COVID-19	32831151	718	726	I-Participant
,	32831151	727	728	O
will	32831151	729	733	O
be	32831151	734	736	O
consecutively	32831151	737	750	O
recruited	32831151	751	760	O
in	32831151	761	763	O
the	32831151	764	767	O
study	32831151	768	773	O
,	32831151	774	775	O
according	32831151	776	785	O
to	32831151	786	788	O
the	32831151	789	792	O
guideline	32831151	793	802	O
on	32831151	803	805	O
diagnosis	32831151	806	815	O
and	32831151	816	819	O
treatment	32831151	820	829	O
of	32831151	830	832	O
COVID-19	32831151	833	841	O
(	32831151	842	843	O
the	32831151	844	847	O
7th	32831151	848	851	O
version	32831151	852	859	O
)	32831151	860	861	O
issued	32831151	862	868	O
by	32831151	869	871	O
National	32831151	872	880	O
Health	32831151	881	887	O
Commission	32831151	888	898	O
of	32831151	899	901	O
the	32831151	902	905	O
People	32831151	906	912	O
's	32831151	913	915	O
Republic	32831151	916	924	O
of	32831151	925	927	O
China	32831151	928	933	O
.	32831151	934	935	O

Exclusion	32831151	936	945	O
criteria	32831151	946	954	O
include	32831151	955	962	O
pregnant	32831151	963	971	B-Participant
and	32831151	972	975	O
breastfeeding	32831151	976	989	B-Participant
women	32831151	990	995	I-Participant
,	32831151	996	997	O
atopy	32831151	998	1003	B-Participant
or	32831151	1004	1006	O
allergies	32831151	1007	1016	B-Participant
to	32831151	1017	1019	I-Participant
Shenfu	32831151	1020	1026	I-Participant
Injection	32831151	1027	1036	I-Participant
(	32831151	1037	1038	I-Participant
SFI	32831151	1039	1042	I-Participant
)	32831151	1043	1044	I-Participant
,	32831151	1045	1046	O
severe	32831151	1047	1053	B-Participant
underlying	32831151	1054	1064	I-Participant
disease	32831151	1065	1072	I-Participant
(	32831151	1073	1074	O
malignant	32831151	1075	1084	B-Participant
tumor	32831151	1085	1090	I-Participant
with	32831151	1091	1095	I-Participant
multiple	32831151	1096	1104	I-Participant
metastases	32831151	1105	1115	I-Participant
,	32831151	1116	1117	O
uncontrolled	32831151	1118	1130	B-Participant
hemopathy	32831151	1131	1140	I-Participant
,	32831151	1141	1142	O
cachexia	32831151	1143	1151	B-Participant
,	32831151	1152	1153	O
severe	32831151	1154	1160	B-Participant
malnutrition	32831151	1161	1173	I-Participant
,	32831151	1174	1175	O
HIV	32831151	1176	1179	B-Participant
)	32831151	1180	1181	O
,	32831151	1182	1183	O
active	32831151	1184	1190	B-Participant
bleeding	32831151	1191	1199	I-Participant
,	32831151	1200	1201	O
obstructive	32831151	1202	1213	B-Participant
pneumonia	32831151	1214	1223	I-Participant
caused	32831151	1224	1230	I-Participant
by	32831151	1231	1233	I-Participant
lung	32831151	1234	1238	I-Participant
tumor	32831151	1239	1244	I-Participant
,	32831151	1245	1246	O
severe	32831151	1247	1253	B-Participant
pulmonary	32831151	1254	1263	I-Participant
interstitial	32831151	1264	1276	I-Participant
fibrosis	32831151	1277	1285	I-Participant
,	32831151	1286	1287	O
alveolar	32831151	1288	1296	B-Participant
proteinosis	32831151	1297	1308	I-Participant
and	32831151	1309	1312	O
allergic	32831151	1313	1321	B-Participant
alveolitis	32831151	1322	1332	I-Participant
,	32831151	1333	1334	O
continuous	32831151	1335	1345	B-Participant
use	32831151	1346	1349	I-Participant
of	32831151	1350	1352	I-Participant
immunosuppressive	32831151	1353	1370	I-Participant
drugs	32831151	1371	1376	I-Participant
in	32831151	1377	1379	I-Participant
last	32831151	1380	1384	I-Participant
6	32831151	1385	1386	I-Participant
months	32831151	1387	1393	I-Participant
,	32831151	1394	1395	O
organ	32831151	1396	1401	B-Participant
transplantation	32831151	1402	1417	I-Participant
,	32831151	1418	1419	O
expected	32831151	1420	1428	B-Participant
death	32831151	1429	1434	I-Participant
within	32831151	1435	1441	I-Participant
48	32831151	1442	1444	I-Participant
hours	32831151	1445	1450	I-Participant
,	32831151	1451	1452	O
the	32831151	1453	1456	O
patients	32831151	1457	1465	O
considered	32831151	1466	1476	O
unsuitable	32831151	1477	1487	O
for	32831151	1488	1491	O
this	32831151	1492	1496	O
study	32831151	1497	1502	O
by	32831151	1503	1505	O
researchers	32831151	1506	1517	O
.	32831151	1518	1519	O

The	32831151	1520	1523	O
study	32831151	1524	1529	O
is	32831151	1530	1532	O
conducted	32831151	1533	1542	O
in	32831151	1543	1545	O
11	32831151	1546	1548	O
ICUs	32831151	1549	1553	O
of	32831151	1554	1556	O
designated	32831151	1557	1567	O
hospitals	32831151	1568	1577	O
for	32831151	1578	1581	O
COVID-19	32831151	1582	1590	O
,	32831151	1591	1592	O
located	32831151	1593	1600	O
in	32831151	1601	1603	O
5	32831151	1604	1605	O
cities	32831151	1606	1612	O
of	32831151	1613	1615	O
China	32831151	1616	1621	O
.	32831151	1622	1623	O

UNASSIGNED	32831151	1624	1634	O
:	32831151	1635	1636	O
The	32831151	1637	1640	O
enrolled	32831151	1641	1649	O
patients	32831151	1650	1658	O
will	32831151	1659	1663	O
randomly	32831151	1664	1672	O
receive	32831151	1673	1680	O
100	32831151	1681	1684	O
ml	32831151	1685	1687	O
SFI	32831151	1688	1691	B-Intervention
(	32831151	1692	1693	O
study	32831151	1694	1699	O
group	32831151	1700	1705	O
)	32831151	1706	1707	O
or	32831151	1708	1710	O
identical	32831151	1711	1720	O
volume	32831151	1721	1727	O
of	32831151	1728	1730	O
saline	32831151	1731	1737	B-Intervention
(	32831151	1738	1739	O
control	32831151	1740	1747	O
group	32831151	1748	1753	O
)	32831151	1754	1755	O
twice	32831151	1756	1761	O
a	32831151	1762	1763	O
day	32831151	1764	1767	O
for	32831151	1768	1771	O
seven	32831151	1772	1777	O
consecutive	32831151	1778	1789	O
days	32831151	1790	1794	O
.	32831151	1795	1796	O

Patients	32831151	1797	1805	O
in	32831151	1806	1808	O
the	32831151	1809	1812	O
both	32831151	1813	1817	O
groups	32831151	1818	1824	O
will	32831151	1825	1829	O
be	32831151	1830	1832	O
given	32831151	1833	1838	O
usual	32831151	1839	1844	O
care	32831151	1845	1849	O
and	32831151	1850	1853	O
the	32831151	1854	1857	O
necessary	32831151	1858	1867	O
supportive	32831151	1868	1878	O
therapies	32831151	1879	1888	O
as	32831151	1889	1891	O
recommended	32831151	1892	1903	O
by	32831151	1904	1906	O
the	32831151	1907	1910	O
latest	32831151	1911	1917	O
edition	32831151	1918	1925	O
of	32831151	1926	1928	O
the	32831151	1929	1932	O
management	32831151	1933	1943	O
guidelines	32831151	1944	1954	O
for	32831151	1955	1958	O
COVID-19	32831151	1959	1967	O
(	32831151	1968	1969	O
the	32831151	1970	1973	O
7th	32831151	1974	1977	O
version	32831151	1978	1985	O
so	32831151	1986	1988	O
far	32831151	1989	1992	O
)	32831151	1993	1994	O
.	32831151	1995	1996	O

RESULTS	32831151	1997	2004	O
:	32831151	2005	2006	O
The	32831151	2007	2010	O
primary	32831151	2011	2018	O
endpoint	32831151	2019	2027	O
is	32831151	2028	2030	O
a	32831151	2031	2032	O
composite	32831151	2033	2042	B-Outcome
of	32831151	2043	2045	I-Outcome
newly	32831151	2046	2051	I-Outcome
developed	32831151	2052	2061	I-Outcome
or	32831151	2062	2064	I-Outcome
exacerbated	32831151	2065	2076	I-Outcome
organ	32831151	2077	2082	I-Outcome
dysfunction	32831151	2083	2094	I-Outcome
.	32831151	2095	2096	O

This	32831151	2097	2101	O
is	32831151	2102	2104	O
defined	32831151	2105	2112	O
as	32831151	2113	2115	O
an	32831151	2116	2118	O
increase	32831151	2119	2127	B-Outcome
in	32831151	2128	2130	I-Outcome
the	32831151	2131	2134	I-Outcome
sequential	32831151	2135	2145	I-Outcome
organ	32831151	2146	2151	I-Outcome
failure	32831151	2152	2159	I-Outcome
assessment	32831151	2160	2170	I-Outcome
(	32831151	2171	2172	I-Outcome
SOFA	32831151	2173	2177	I-Outcome
)	32831151	2178	2179	I-Outcome
score	32831151	2180	2185	I-Outcome
of	32831151	2186	2188	I-Outcome
two	32831151	2189	2192	I-Outcome
or	32831151	2193	2195	I-Outcome
more	32831151	2196	2200	I-Outcome
,	32831151	2201	2202	O
indicating	32831151	2203	2213	O
sepsis	32831151	2214	2220	O
and	32831151	2221	2224	O
involvement	32831151	2225	2236	O
of	32831151	2237	2239	O
at	32831151	2240	2242	O
least	32831151	2243	2248	O
one	32831151	2249	2252	O
organ	32831151	2253	2258	O
.	32831151	2259	2260	O

The	32831151	2261	2264	O
SOFA	32831151	2265	2269	B-Outcome
score	32831151	2270	2275	I-Outcome
will	32831151	2276	2280	O
be	32831151	2281	2283	O
measured	32831151	2284	2292	O
for	32831151	2293	2296	O
the	32831151	2297	2300	O
14	32831151	2301	2303	O
days	32831151	2304	2308	O
after	32831151	2309	2314	O
enrolment	32831151	2315	2324	O
from	32831151	2325	2329	O
the	32831151	2330	2333	O
baseline	32831151	2334	2342	O
(	32831151	2343	2344	O
the	32831151	2345	2348	O
score	32831151	2349	2354	O
at	32831151	2355	2357	O
randomization	32831151	2358	2371	O
)	32831151	2372	2373	O
.	32831151	2374	2375	O

The	32831151	2376	2379	O
secondary	32831151	2380	2389	O
endpoints	32831151	2390	2399	O
are	32831151	2400	2403	O
shown	32831151	2404	2409	O
below	32831151	2410	2415	O
:	32831151	2416	2417	O
	32831151	2418	2419	O
SOFA	32831151	2420	2424	B-Outcome
score	32831151	2425	2430	I-Outcome
in	32831151	2431	2433	I-Outcome
total	32831151	2434	2439	I-Outcome
	32831151	2440	2441	O
Pneumonia	32831151	2442	2451	B-Outcome
severity	32831151	2452	2460	I-Outcome
index	32831151	2461	2466	I-Outcome
score	32831151	2467	2472	I-Outcome
	32831151	2473	2474	O
Dosage	32831151	2475	2481	B-Outcome
of	32831151	2482	2484	I-Outcome
vasoactive	32831151	2485	2495	I-Outcome
drugs	32831151	2496	2501	I-Outcome
	32831151	2502	2503	O
Ventilation	32831151	2504	2515	B-Outcome
free	32831151	2516	2520	I-Outcome
days	32831151	2521	2525	I-Outcome
within	32831151	2526	2532	I-Outcome
28	32831151	2533	2535	I-Outcome
days	32831151	2536	2540	I-Outcome
	32831151	2541	2542	O
Length	32831151	2543	2549	B-Outcome
of	32831151	2550	2552	I-Outcome
stay	32831151	2553	2557	I-Outcome
in	32831151	2558	2560	I-Outcome
intensive	32831151	2561	2570	I-Outcome
care	32831151	2571	2575	I-Outcome
unit	32831151	2576	2580	I-Outcome
	32831151	2581	2582	O
Total	32831151	2583	2588	B-Outcome
hospital	32831151	2589	2597	I-Outcome
costs	32831151	2598	2603	I-Outcome
to	32831151	2604	2606	I-Outcome
treat	32831151	2607	2612	I-Outcome
the	32831151	2613	2616	I-Outcome
patient	32831151	2617	2624	I-Outcome
	32831151	2625	2626	O
28-day	32831151	2627	2633	B-Outcome
mortality	32831151	2634	2643	I-Outcome
	32831151	2644	2645	O
The	32831151	2646	2649	O
incidence	32831151	2650	2659	B-Outcome
of	32831151	2660	2662	I-Outcome
adverse	32831151	2663	2670	I-Outcome
drug	32831151	2671	2675	I-Outcome
events	32831151	2676	2682	I-Outcome
related	32831151	2683	2690	I-Outcome
to	32831151	2691	2693	I-Outcome
SFI	32831151	2694	2697	I-Outcome
RANDOMISATION	32831151	2698	2711	O
:	32831151	2712	2713	O
The	32831151	2714	2717	O
block	32831151	2718	2723	O
randomization	32831151	2724	2737	O
codes	32831151	2738	2743	O
were	32831151	2744	2748	O
generated	32831151	2749	2758	O
by	32831151	2759	2761	O
SAS	32831151	2762	2765	O
V.9.1	32831151	2766	2771	O
for	32831151	2772	2775	O
allocation	32831151	2776	2786	O
of	32831151	2787	2789	O
participants	32831151	2790	2802	O
in	32831151	2803	2805	O
this	32831151	2806	2810	O
study	32831151	2811	2816	O
.	32831151	2817	2818	O

The	32831151	2819	2822	O
ratio	32831151	2823	2828	O
of	32831151	2829	2831	O
random	32831151	2832	2838	O
distribution	32831151	2839	2851	O
is	32831151	2852	2854	O
1:1	32831151	2855	2858	O
.	32831151	2859	2860	O

The	32831151	2861	2864	O
sealed	32831151	2865	2871	O
envelope	32831151	2872	2880	O
method	32831151	2881	2887	O
is	32831151	2888	2890	O
used	32831151	2891	2895	O
for	32831151	2896	2899	O
allocation	32831151	2900	2910	O
concealment	32831151	2911	2922	O
.	32831151	2923	2924	O

UNASSIGNED	32831151	2925	2935	O
:	32831151	2936	2937	O
The	32831151	2938	2941	O
patients	32831151	2942	2950	O
and	32831151	2951	2954	O
statistical	32831151	2955	2966	O
personnel	32831151	2967	2976	O
analyzing	32831151	2977	2986	O
study	32831151	2987	2992	O
data	32831151	2993	2997	O
are	32831151	2998	3001	O
both	32831151	3002	3006	O
blinded	32831151	3007	3014	O
.	32831151	3015	3016	O

The	32831151	3017	3020	O
blinding	32831151	3021	3029	O
of	32831151	3030	3032	O
group	32831151	3033	3038	O
assignment	32831151	3039	3049	O
is	32831151	3050	3052	O
not	32831151	3053	3056	O
adopted	32831151	3057	3064	O
for	32831151	3065	3068	O
the	32831151	3069	3072	O
medical	32831151	3073	3080	O
staff	32831151	3081	3086	O
.	32831151	3087	3088	O

UNASSIGNED	32831151	3089	3099	O
:	32831151	3100	3101	O
This	32831151	3102	3106	O
study	32831151	3107	3112	O
is	32831151	3113	3115	O
expected	32831151	3116	3124	O
to	32831151	3125	3127	O
recruit	32831151	3128	3135	O
300	32831151	3136	3139	O
patients	32831151	3140	3148	O
with	32831151	3149	3153	O
COVID-19	32831151	3154	3162	O
,	32831151	3163	3164	O
(	32831151	3165	3166	O
150	32831151	3167	3170	O
in	32831151	3171	3173	O
each	32831151	3174	3178	O
group	32831151	3179	3184	O
)	32831151	3185	3186	O
.	32831151	3187	3188	O

UNASSIGNED	32831151	3189	3199	O
:	32831151	3200	3201	O
Protocol	32831151	3202	3210	O
version	32831151	3211	3218	O
2.0	32831151	3219	3222	O
,	32831151	3223	3224	O
February	32831151	3225	3233	O
15	32831151	3234	3236	O
,	32831151	3237	3238	O
2020	32831151	3239	3243	O
.	32831151	3244	3245	O

Patient	32831151	3246	3253	O
recruitment	32831151	3254	3265	O
started	32831151	3266	3273	O
on	32831151	3274	3276	O
February	32831151	3277	3285	O
25	32831151	3286	3288	O
,	32831151	3289	3290	O
and	32831151	3291	3294	O
will	32831151	3295	3299	O
end	32831151	3300	3303	O
on	32831151	3304	3306	O
August	32831151	3307	3313	O
31	32831151	3314	3316	O
,	32831151	3317	3318	O
2020	32831151	3319	3323	O
.	32831151	3324	3325	O

BACKGROUND	32831151	3326	3336	O
:	32831151	3337	3338	O
Chinese	32831151	3339	3346	O
Clinical	32831151	3347	3355	O
Trial	32831151	3356	3361	O
Registry	32831151	3362	3370	O
:	32831151	3371	3372	O
ChiCTR2000030043	32831151	3373	3389	O
.	32831151	3390	3391	O

Registered	32831151	3392	3402	O
February	32831151	3403	3411	O
21	32831151	3412	3414	O
,	32831151	3415	3416	O
2020	32831151	3417	3421	O
,	32831151	3422	3423	O
http://www.chictr.org.cn/showprojen.aspx?proj=49866	32831151	3424	3475	O
FULL	32831151	3476	3480	O
PROTOCOL	32831151	3481	3489	O
:	32831151	3490	3491	O
The	32831151	3492	3495	O
full	32831151	3496	3500	O
protocol	32831151	3501	3509	O
is	32831151	3510	3512	O
attached	32831151	3513	3521	O
as	32831151	3522	3524	O
an	32831151	3525	3527	O
additional	32831151	3528	3538	O
file	32831151	3539	3543	O
,	32831151	3544	3545	O
accessible	32831151	3546	3556	O
from	32831151	3557	3561	O
the	32831151	3562	3565	O
Trials	32831151	3566	3572	O
website	32831151	3573	3580	O
(	32831151	3581	3582	O
Additional	32831151	3583	3593	O
file	32831151	3594	3598	O
1	32831151	3599	3600	O
)	32831151	3601	3602	O
.	32831151	3603	3604	O

In	32831151	3605	3607	O
the	32831151	3608	3611	O
interest	32831151	3612	3620	O
in	32831151	3621	3623	O
expediting	32831151	3624	3634	O
dissemination	32831151	3635	3648	O
of	32831151	3649	3651	O
this	32831151	3652	3656	O
material	32831151	3657	3665	O
,	32831151	3666	3667	O
the	32831151	3668	3671	O
familiar	32831151	3672	3680	O
formatting	32831151	3681	3691	O
has	32831151	3692	3695	O
been	32831151	3696	3700	O
eliminated	32831151	3701	3711	O
;	32831151	3712	3713	O
this	32831151	3714	3718	O
letter	32831151	3719	3725	O
serves	32831151	3726	3732	O
as	32831151	3733	3735	O
a	32831151	3736	3737	O
summary	32831151	3738	3745	O
of	32831151	3746	3748	O
the	32831151	3749	3752	O
key	32831151	3753	3756	O
elements	32831151	3757	3765	O
of	32831151	3766	3768	O
the	32831151	3769	3772	O
full	32831151	3773	3777	O
protocol	32831151	3778	3786	O
.	32831151	3787	3788	O


High	32843098	0	4	B-Intervention
dose	32843098	5	9	I-Intervention
dexamethasone	32843098	10	23	I-Intervention
treatment	32843098	24	33	O
for	32843098	34	37	O
Acute	32843098	38	43	B-Participant
Respiratory	32843098	44	55	I-Participant
Distress	32843098	56	64	I-Participant
Syndrome	32843098	65	73	I-Participant
secondary	32843098	74	83	I-Participant
to	32843098	84	86	I-Participant
COVID-19	32843098	87	95	I-Participant
:	32843098	96	97	O
a	32843098	98	99	O
structured	32843098	100	110	O
summary	32843098	111	118	O
of	32843098	119	121	O
a	32843098	122	123	O
study	32843098	124	129	O
protocol	32843098	130	138	O
for	32843098	139	142	O
a	32843098	143	144	O
randomised	32843098	145	155	O
controlled	32843098	156	166	O
trial	32843098	167	172	O
.	32843098	173	174	O

OBJECTIVE	32843098	175	184	O
:	32843098	185	186	O
The	32843098	187	190	O
aim	32843098	191	194	O
of	32843098	195	197	O
this	32843098	198	202	O
study	32843098	203	208	O
is	32843098	209	211	O
to	32843098	212	214	O
explore	32843098	215	222	O
the	32843098	223	226	O
effectiveness	32843098	227	240	B-Outcome
and	32843098	241	244	O
safety	32843098	245	251	B-Outcome
of	32843098	252	254	O
high	32843098	255	259	B-Intervention
dose	32843098	260	264	I-Intervention
dexamethasone	32843098	265	278	I-Intervention
treatment	32843098	279	288	O
for	32843098	289	292	O
Acute	32843098	293	298	B-Participant
Respiratory	32843098	299	310	I-Participant
Distress	32843098	311	319	I-Participant
Syndrome	32843098	320	328	I-Participant
secondary	32843098	329	338	I-Participant
to	32843098	339	341	I-Participant
SARS	32843098	342	346	I-Participant
-	32843098	347	348	I-Participant
Cov-2	32843098	349	354	I-Participant
pneumonia	32843098	355	364	I-Participant
.	32843098	365	366	O

METHODS	32843098	367	374	O
:	32843098	375	376	O
Multicentre	32843098	377	388	O
,	32843098	389	390	O
randomized	32843098	391	401	O
clinical	32843098	402	410	O
trial	32843098	411	416	O
,	32843098	417	418	O
controlled	32843098	419	429	O
,	32843098	430	431	O
open	32843098	432	436	O
label	32843098	437	442	O
,	32843098	443	444	O
parallel	32843098	445	453	O
group	32843098	454	459	O
,	32843098	460	461	O
to	32843098	462	464	O
evaluate	32843098	465	473	O
the	32843098	474	477	O
effectiveness	32843098	478	491	B-Outcome
and	32843098	492	495	O
safety	32843098	496	502	B-Outcome
of	32843098	503	505	O
high	32843098	506	510	B-Intervention
dose	32843098	511	515	I-Intervention
dexamethasone	32843098	516	529	I-Intervention
in	32843098	530	532	O
adult	32843098	533	538	B-Participant
patients	32843098	539	547	O
with	32843098	548	552	O
confirmed	32843098	553	562	B-Participant
COVID-19	32843098	563	571	I-Participant
,	32843098	572	573	I-Participant
with	32843098	574	578	I-Participant
Acute	32843098	579	584	I-Participant
Respiratory	32843098	585	596	I-Participant
Distress	32843098	597	605	I-Participant
Syndrome	32843098	606	614	I-Participant
.	32843098	615	616	O

METHODS	32843098	617	624	O
:	32843098	625	626	O
We	32843098	627	629	O
will	32843098	630	634	O
include	32843098	635	642	O
patients	32843098	643	651	O
with	32843098	652	656	O
SARS	32843098	657	661	B-Participant
-	32843098	662	663	I-Participant
Cov-2	32843098	664	669	I-Participant
pneumonia	32843098	670	679	I-Participant
who	32843098	680	683	O
develop	32843098	684	691	O
acute	32843098	692	697	B-Participant
respiratory	32843098	698	709	I-Participant
distress	32843098	710	718	I-Participant
syndrome	32843098	719	727	I-Participant
,	32843098	728	729	O
in	32843098	730	732	O
several	32843098	733	740	B-Participant
intensive	32843098	741	750	I-Participant
care	32843098	751	755	I-Participant
units	32843098	756	761	I-Participant
(	32843098	762	763	I-Participant
ICU	32843098	764	767	I-Participant
)	32843098	768	769	I-Participant
in	32843098	770	772	O
Buenos	32843098	773	779	O
Aires	32843098	780	785	O
,	32843098	786	787	O
Argentina	32843098	788	797	O
(	32843098	798	799	O
CEMIC	32843098	800	805	O
,	32843098	806	807	O
Clinica	32843098	808	815	O
Bazterrica	32843098	816	826	O
,	32843098	827	828	O
Sanatorio	32843098	829	838	O
Sagrado	32843098	839	846	O
Corazon	32843098	847	854	O
)	32843098	855	856	O
.	32843098	857	858	O

Inclusion	32843098	859	868	O
criteria	32843098	869	877	O
:	32843098	878	879	O
Men	32843098	880	883	B-Participant
and	32843098	884	887	I-Participant
women	32843098	888	893	I-Participant
,	32843098	894	895	O
age	32843098	896	899	B-Participant
	32843098	902	903	I-Participant
18	32843098	906	908	I-Participant
years	32843098	909	914	I-Participant
old	32843098	915	918	I-Participant
.	32843098	919	920	O

Confirmed	32843098	921	930	O
diagnosis	32843098	931	940	O
of	32843098	941	943	O
SARS	32843098	944	948	B-Participant
-	32843098	949	950	I-Participant
CoV-2	32843098	951	956	I-Participant
infection	32843098	957	966	I-Participant
,	32843098	967	968	O
by	32843098	969	971	O
RT	32843098	972	974	O
-	32843098	975	976	O
PCR	32843098	977	980	O
.	32843098	981	982	O

Diagnosis	32843098	983	992	O
of	32843098	993	995	O
Acute	32843098	996	1001	B-Participant
Respiratory	32843098	1002	1013	I-Participant
Distress	32843098	1014	1022	I-Participant
Syndrome	32843098	1023	1031	I-Participant
(	32843098	1032	1033	O
hypoxemic	32843098	1034	1043	B-Participant
respiratory	32843098	1044	1055	I-Participant
failure	32843098	1056	1063	I-Participant
not	32843098	1064	1067	I-Participant
explained	32843098	1068	1077	I-Participant
by	32843098	1078	1080	I-Participant
cardiac	32843098	1081	1088	I-Participant
disease	32843098	1089	1096	I-Participant
+	32843098	1097	1098	O
PaO2	32843098	1099	1103	B-Participant
/	32843098	1104	1105	I-Participant
FiO2	32843098	1106	1110	I-Participant
ratio	32843098	1111	1116	I-Participant
<	32843098	1117	1118	I-Participant
300	32843098	1119	1122	I-Participant
with	32843098	1123	1127	I-Participant
a	32843098	1128	1129	I-Participant
Positive	32843098	1130	1138	I-Participant
End	32843098	1139	1142	I-Participant
-	32843098	1143	1144	O
Expiratory	32843098	1145	1155	B-Participant
Pressure	32843098	1156	1164	I-Participant
	32843098	1167	1168	I-Participant
5	32843098	1171	1172	I-Participant
cm	32843098	1173	1175	I-Participant
H2O	32843098	1176	1179	I-Participant
+	32843098	1180	1181	O
bilateral	32843098	1182	1191	B-Participant
pulmonary	32843098	1192	1201	I-Participant
infiltrates	32843098	1202	1213	I-Participant
)	32843098	1214	1215	O
.	32843098	1216	1217	O

Length	32843098	1218	1224	B-Participant
of	32843098	1225	1227	I-Participant
mechanical	32843098	1228	1238	I-Participant
ventilation	32843098	1239	1250	I-Participant
of	32843098	1251	1253	I-Participant
at	32843098	1254	1256	I-Participant
least	32843098	1257	1262	I-Participant
72	32843098	1263	1265	I-Participant
hours	32843098	1266	1271	I-Participant
.	32843098	1272	1273	O

Informed	32843098	1274	1282	O
consent	32843098	1283	1290	O
(	32843098	1291	1292	O
next	32843098	1293	1297	O
of	32843098	1298	1300	O
kin	32843098	1301	1304	O
/	32843098	1305	1306	O
legal	32843098	1307	1312	O
guardian	32843098	1313	1321	O
)	32843098	1322	1323	O
.	32843098	1324	1325	O

Exclusion	32843098	1326	1335	O
criteria	32843098	1336	1344	O
:	32843098	1345	1346	O
Pregnant	32843098	1347	1355	B-Participant
or	32843098	1356	1358	O
breast	32843098	1359	1365	B-Participant
-	32843098	1366	1367	I-Participant
feeding	32843098	1368	1375	I-Participant
women	32843098	1376	1381	I-Participant
.	32843098	1382	1383	O

Terminal	32843098	1384	1392	B-Participant
disease	32843098	1393	1400	I-Participant
(	32843098	1401	1402	O
advanced	32843098	1403	1411	B-Participant
cancer	32843098	1412	1418	I-Participant
;	32843098	1419	1420	O
under	32843098	1421	1426	B-Participant
palliative	32843098	1427	1437	I-Participant
care	32843098	1438	1442	I-Participant
;	32843098	1443	1444	O
cardiovascular	32843098	1445	1459	B-Participant
,	32843098	1460	1461	I-Participant
respiratory	32843098	1462	1473	I-Participant
,	32843098	1474	1475	I-Participant
or	32843098	1476	1478	I-Participant
renal	32843098	1479	1484	I-Participant
disease	32843098	1485	1492	I-Participant
with	32843098	1493	1497	O
a	32843098	1498	1499	O
life	32843098	1500	1504	B-Participant
expectancy	32843098	1505	1515	I-Participant
less	32843098	1516	1520	I-Participant
	32843098	1523	1524	I-Participant
1	32843098	1527	1528	I-Participant
year	32843098	1529	1533	I-Participant
)	32843098	1534	1535	O
.	32843098	1536	1537	O

Therapeutic	32843098	1538	1549	B-Participant
limitation	32843098	1550	1560	I-Participant
(	32843098	1561	1562	O
advance	32843098	1563	1570	O
directives	32843098	1571	1581	O
or	32843098	1582	1584	O
do	32843098	1585	1587	O
not	32843098	1588	1591	O
resuscitate	32843098	1592	1603	O
order	32843098	1604	1609	O
)	32843098	1610	1611	O
Severe	32843098	1612	1618	B-Participant
immunosuppression	32843098	1619	1636	I-Participant
(	32843098	1637	1638	O
HIV	32843098	1639	1642	B-Participant
infection	32843098	1643	1652	I-Participant
,	32843098	1653	1654	O
long	32843098	1655	1659	B-Participant
-	32843098	1660	1661	I-Participant
term	32843098	1662	1666	I-Participant
use	32843098	1667	1670	I-Participant
of	32843098	1671	1673	I-Participant
immunosuppressive	32843098	1674	1691	I-Participant
agents	32843098	1692	1698	I-Participant
,	32843098	1699	1700	O
active	32843098	1701	1707	B-Participant
cancer	32843098	1708	1714	I-Participant
)	32843098	1715	1716	O
.	32843098	1717	1718	O

Patients	32843098	1719	1727	O
under	32843098	1728	1733	O
chronic	32843098	1734	1741	B-Participant
treatment	32843098	1742	1751	I-Participant
with	32843098	1752	1756	I-Participant
glucocorticoids	32843098	1757	1772	I-Participant
for	32843098	1773	1776	O
other	32843098	1777	1782	O
diseases	32843098	1783	1791	O
(	32843098	1792	1793	O
	32843098	1794	1795	O
8	32843098	1798	1799	O
mg	32843098	1800	1802	O
prednisone	32843098	1803	1813	O
,	32843098	1814	1815	O
or	32843098	1816	1818	O
equivalent	32843098	1819	1829	O
)	32843098	1830	1831	O
Participation	32843098	1832	1845	O
in	32843098	1846	1848	O
another	32843098	1849	1856	O
randomized	32843098	1857	1867	O
clinical	32843098	1868	1876	O
trial	32843098	1877	1882	O
.	32843098	1883	1884	O

UNASSIGNED	32843098	1885	1895	O
:	32843098	1896	1897	O
Eligible	32843098	1898	1906	O
patients	32843098	1907	1915	O
will	32843098	1916	1920	O
be	32843098	1921	1923	O
randomized	32843098	1924	1934	O
to	32843098	1935	1937	O
receive	32843098	1938	1945	O
standard	32843098	1946	1954	B-Intervention
ICU	32843098	1955	1958	I-Intervention
patient	32843098	1959	1966	I-Intervention
care	32843098	1967	1971	I-Intervention
(	32843098	1972	1973	O
group	32843098	1974	1979	O
1	32843098	1980	1981	O
)	32843098	1982	1983	O
or	32843098	1984	1986	O
standard	32843098	1987	1995	B-Intervention
ICU	32843098	1996	1999	I-Intervention
patient	32843098	2000	2007	I-Intervention
care	32843098	2008	2012	I-Intervention
plus	32843098	2013	2017	I-Intervention
high	32843098	2018	2022	I-Intervention
dose	32843098	2023	2027	I-Intervention
dexamethasone	32843098	2028	2041	I-Intervention
(	32843098	2042	2043	O
group	32843098	2044	2049	O
2	32843098	2050	2051	O
)	32843098	2052	2053	O
.	32843098	2054	2055	O

Group	32843098	2056	2061	O
1	32843098	2062	2063	O
:	32843098	2064	2065	O
dexamethasone	32843098	2066	2079	B-Intervention
up	32843098	2080	2082	O
to	32843098	2083	2085	O
6	32843098	2086	2087	O
mg/24	32843098	2088	2093	O
hours	32843098	2094	2099	O
for	32843098	2100	2103	O
up	32843098	2104	2106	O
to	32843098	2107	2109	O
10	32843098	2110	2112	O
days	32843098	2113	2117	O
+	32843098	2118	2119	O
ventilatory	32843098	2120	2131	O
,	32843098	2132	2133	O
hemodynamic	32843098	2134	2145	O
,	32843098	2146	2147	O
nutritional	32843098	2148	2159	O
,	32843098	2160	2161	O
and	32843098	2162	2165	O
antimicrobial	32843098	2166	2179	O
support	32843098	2180	2187	O
according	32843098	2188	2197	O
to	32843098	2198	2200	O
international	32843098	2201	2214	O
guidelines	32843098	2215	2225	O
.	32843098	2226	2227	O

Group	32843098	2228	2233	O
2	32843098	2234	2235	O
:	32843098	2236	2237	O
dexamethasone	32843098	2238	2251	B-Intervention
16	32843098	2252	2254	O
mg/24	32843098	2255	2260	O
hours	32843098	2261	2266	O
for	32843098	2267	2270	O
5	32843098	2271	2272	O
days	32843098	2273	2277	O
followed	32843098	2278	2286	O
by	32843098	2287	2289	O
dexamethasone	32843098	2290	2303	O
8	32843098	2304	2305	O
mg/24	32843098	2306	2311	O
hours	32843098	2312	2317	O
for	32843098	2318	2321	O
5	32843098	2322	2323	O
days	32843098	2324	2328	O
+	32843098	2329	2330	O
ventilatory	32843098	2331	2342	O
,	32843098	2343	2344	O
hemodynamic	32843098	2345	2356	O
,	32843098	2357	2358	O
nutritional	32843098	2359	2370	O
,	32843098	2371	2372	O
and	32843098	2373	2376	O
antimicrobial	32843098	2377	2390	O
support	32843098	2391	2398	O
according	32843098	2399	2408	O
to	32843098	2409	2411	O
international	32843098	2412	2425	O
guidelines	32843098	2426	2436	O
.	32843098	2437	2438	O

RESULTS	32843098	2439	2446	O
:	32843098	2447	2448	O
The	32843098	2449	2452	O
main	32843098	2453	2457	O
result	32843098	2458	2464	O
is	32843098	2465	2467	O
ventilator	32843098	2468	2478	B-Outcome
-	32843098	2479	2480	I-Outcome
free	32843098	2481	2485	I-Outcome
days	32843098	2486	2490	I-Outcome
at	32843098	2491	2493	I-Outcome
28	32843098	2494	2496	I-Outcome
days	32843098	2497	2501	I-Outcome
(	32843098	2502	2503	O
Days	32843098	2504	2508	B-Outcome
without	32843098	2509	2516	I-Outcome
ventilator	32843098	2517	2527	I-Outcome
support	32843098	2528	2535	I-Outcome
in	32843098	2536	2538	I-Outcome
the	32843098	2539	2542	I-Outcome
first	32843098	2543	2548	I-Outcome
28	32843098	2549	2551	I-Outcome
days	32843098	2552	2556	I-Outcome
following	32843098	2557	2566	O
randomization	32843098	2567	2580	O
)	32843098	2581	2582	O
.	32843098	2583	2584	O

Secondary	32843098	2585	2594	O
outcomes	32843098	2595	2603	O
are	32843098	2604	2607	O
28-days	32843098	2608	2615	B-Outcome
and	32843098	2616	2619	I-Outcome
90-days	32843098	2620	2627	I-Outcome
mortality	32843098	2628	2637	I-Outcome
,	32843098	2638	2639	O
frequency	32843098	2640	2649	B-Outcome
of	32843098	2650	2652	I-Outcome
nosocomial	32843098	2653	2663	I-Outcome
infections	32843098	2664	2674	I-Outcome
in	32843098	2675	2677	I-Outcome
the	32843098	2678	2681	I-Outcome
first	32843098	2682	2687	I-Outcome
28	32843098	2688	2690	I-Outcome
days	32843098	2691	2695	I-Outcome
after	32843098	2696	2701	O
randomization	32843098	2702	2715	O
,	32843098	2716	2717	O
Sequential	32843098	2718	2728	B-Outcome
Organ	32843098	2729	2734	I-Outcome
Failure	32843098	2735	2742	I-Outcome
Assessment	32843098	2743	2753	I-Outcome
(	32843098	2754	2755	I-Outcome
SOFA	32843098	2756	2760	I-Outcome
)	32843098	2761	2762	I-Outcome
score	32843098	2763	2768	I-Outcome
variation	32843098	2769	2778	I-Outcome
and	32843098	2779	2782	O
prone	32843098	2783	2788	B-Outcome
position	32843098	2789	2797	I-Outcome
in	32843098	2798	2800	I-Outcome
the	32843098	2801	2804	I-Outcome
first	32843098	2805	2810	I-Outcome
10-days	32843098	2811	2818	I-Outcome
,	32843098	2819	2820	O
viral	32843098	2821	2826	B-Outcome
shedding	32843098	2827	2835	I-Outcome
28-days	32843098	2836	2843	I-Outcome
after	32843098	2844	2849	O
randomization	32843098	2850	2863	O
,	32843098	2864	2865	O
and	32843098	2866	2869	O
delirium	32843098	2870	2878	B-Outcome
and	32843098	2879	2882	O
muscle	32843098	2883	2889	B-Outcome
weakness	32843098	2890	2898	I-Outcome
at	32843098	2899	2901	I-Outcome
ICU	32843098	2902	2905	I-Outcome
discharge	32843098	2906	2915	I-Outcome
.	32843098	2916	2917	O

UNASSIGNED	32843098	2918	2928	O
:	32843098	2929	2930	O
Treatment	32843098	2931	2940	O
will	32843098	2941	2945	O
be	32843098	2946	2948	O
assigned	32843098	2949	2957	O
according	32843098	2958	2967	O
to	32843098	2968	2970	O
site	32843098	2971	2975	O
stratified	32843098	2976	2986	O
randomization	32843098	2987	3000	O
by	32843098	3001	3003	O
permuted	32843098	3004	3012	O
random	32843098	3013	3019	O
blocks	32843098	3020	3026	O
sequence	32843098	3027	3035	O
1:1	32843098	3036	3039	O
generated	32843098	3040	3049	O
with	32843098	3050	3054	O
a	32843098	3055	3056	O
table	32843098	3057	3062	O
in	32843098	3063	3065	O
R	32843098	3066	3067	O
language	32843098	3068	3076	O
concealed	32843098	3077	3086	O
in	32843098	3087	3089	O
a	32843098	3090	3091	O
randomization	32843098	3092	3105	O
tool	32843098	3106	3110	O
in	32843098	3111	3113	O
REDCap	32843098	3114	3120	O
(	32843098	3121	3122	O
Research	32843098	3123	3131	O
Electronic	32843098	3132	3142	O
Data	32843098	3143	3147	O
CAPture	32843098	3148	3155	O
)	32843098	3156	3157	O
platform	32843098	3158	3166	O
.	32843098	3167	3168	O

UNASSIGNED	32843098	3169	3179	O
:	32843098	3180	3181	O
This	32843098	3182	3186	O
is	32843098	3187	3189	O
an	32843098	3190	3192	O
open	32843098	3193	3197	O
trial	32843098	3198	3203	O
,	32843098	3204	3205	O
so	32843098	3206	3208	O
no	32843098	3209	3211	O
masking	32843098	3212	3219	O
of	32843098	3220	3222	O
treatment	32843098	3223	3232	O
assignment	32843098	3233	3243	O
will	32843098	3244	3248	O
be	32843098	3249	3251	O
used	32843098	3252	3256	O
.	32843098	3257	3258	O

UNASSIGNED	32843098	3259	3269	O
:	32843098	3270	3271	O
Assuming	32843098	3272	3280	O
a	32843098	3281	3282	O
3	32843098	3283	3284	O
days	32843098	3285	3289	O
difference	32843098	3290	3300	O
in	32843098	3301	3303	O
ventilator	32843098	3304	3314	O
-	32843098	3315	3316	O
free	32843098	3317	3321	O
days	32843098	3322	3326	O
between	32843098	3327	3334	O
treatment	32843098	3335	3344	O
groups	32843098	3345	3351	O
,	32843098	3352	3353	O
with	32843098	3354	3358	O
a	32843098	3359	3360	O
mean	32843098	3361	3365	O
of	32843098	3366	3368	O
9	32843098	3369	3370	O
days	32843098	3371	3375	O
,	32843098	3376	3377	O
and	32843098	3378	3381	O
a	32843098	3382	3383	O
standard	32843098	3384	3392	O
deviation	32843098	3393	3402	O
of	32843098	3403	3405	O
9	32843098	3406	3407	O
days	32843098	3408	3412	O
;	32843098	3413	3414	O
the	32843098	3415	3418	O
necessary	32843098	3419	3428	O
sample	32843098	3429	3435	O
size	32843098	3436	3440	O
would	32843098	3441	3446	O
be	32843098	3447	3449	O
284	32843098	3450	3453	O
subjects	32843098	3454	3462	O
(	32843098	3463	3464	O
142	32843098	3465	3468	O
per	32843098	3469	3472	O
group	32843098	3473	3478	O
)	32843098	3479	3480	O
,	32843098	3481	3482	O
with	32843098	3483	3487	O
a	32843098	3488	3489	O
power	32843098	3490	3495	O
of	32843098	3496	3498	O
80	32843098	3499	3501	O
%	32843098	3502	3503	O
and	32843098	3504	3507	O
a	32843098	3508	3509	O
two	32843098	3510	3513	O
-	32843098	3514	3515	O
tailed	32843098	3516	3522	O
alpha	32843098	3523	3528	O
error	32843098	3529	3534	O
of	32843098	3535	3537	O
0.05	32843098	3538	3542	O
.	32843098	3543	3544	O

UNASSIGNED	32843098	3545	3555	O
:	32843098	3556	3557	O
The	32843098	3558	3561	O
protocol	32843098	3562	3570	O
with	32843098	3571	3575	O
code	32843098	3576	3580	O
1264	32843098	3581	3585	O
,	32843098	3586	3587	O
version	32843098	3588	3595	O
3.0	32843098	3596	3599	O
on	32843098	3600	3602	O
date	32843098	3603	3607	O
:	32843098	3608	3609	O
May	32843098	3610	3613	O
13	32843098	3614	3616	O
,	32843098	3617	3618	O
2020	32843098	3619	3623	O
is	32843098	3624	3626	O
approved	32843098	3627	3635	O
by	32843098	3636	3638	O
the	32843098	3639	3642	O
local	32843098	3643	3648	O
Ethics	32843098	3649	3655	O
Committee	32843098	3656	3665	O
.	32843098	3666	3667	O

The	32843098	3668	3671	O
trial	32843098	3672	3677	O
is	32843098	3678	3680	O
in	32843098	3681	3683	O
the	32843098	3684	3687	O
recruitment	32843098	3688	3699	O
phase	32843098	3700	3705	O
.	32843098	3706	3707	O

Recruitment	32843098	3708	3719	O
began	32843098	3720	3725	O
May	32843098	3726	3729	O
22	32843098	3730	3732	O
,	32843098	3733	3734	O
2020	32843098	3735	3739	O
and	32843098	3740	3743	O
is	32843098	3744	3746	O
anticipated	32843098	3747	3758	O
to	32843098	3759	3761	O
be	32843098	3762	3764	O
complete	32843098	3765	3773	O
by	32843098	3774	3776	O
the	32843098	3777	3780	O
end	32843098	3781	3784	O
of	32843098	3785	3787	O
December	32843098	3788	3796	O
2021	32843098	3797	3801	O
.	32843098	3802	3803	O

BACKGROUND	32843098	3804	3814	O
:	32843098	3815	3816	O
The	32843098	3817	3820	O
trial	32843098	3821	3826	O
was	32843098	3827	3830	O
registered	32843098	3831	3841	O
under	32843098	3842	3847	O
the	32843098	3848	3851	O
title	32843098	3852	3857	O
"	32843098	3858	3859	O
Dexamethasone	32843098	3860	3873	O
for	32843098	3874	3877	O
COVID-19	32843098	3878	3886	O
Related	32843098	3887	3894	O
ARDS	32843098	3895	3899	O
:	32843098	3900	3901	O
a	32843098	3902	3903	O
Multicenter	32843098	3904	3915	O
,	32843098	3916	3917	O
Randomized	32843098	3918	3928	O
Clinical	32843098	3929	3937	O
Trial	32843098	3938	3943	O
"	32843098	3944	3945	O
with	32843098	3946	3950	O
ClinicalTrials	32843098	3951	3965	O
number	32843098	3966	3972	O
NCT04395105	32843098	3973	3984	O
,	32843098	3985	3986	O
https://clinicaltrials.gov/ct2/show/NCT04395105	32843098	3987	4034	O
,	32843098	4035	4036	O
registered	32843098	4037	4047	O
on	32843098	4048	4050	O
20	32843098	4051	4053	O
May	32843098	4054	4057	O
2020	32843098	4058	4062	O
.	32843098	4063	4064	O

UNASSIGNED	32843098	4065	4075	O
:	32843098	4076	4077	O
The	32843098	4078	4081	O
full	32843098	4082	4086	O
protocol	32843098	4087	4095	O
is	32843098	4096	4098	O
attached	32843098	4099	4107	O
as	32843098	4108	4110	O
an	32843098	4111	4113	O
additional	32843098	4114	4124	O
file	32843098	4125	4129	O
,	32843098	4130	4131	O
accessible	32843098	4132	4142	O
from	32843098	4143	4147	O
the	32843098	4148	4151	O
Trials	32843098	4152	4158	O
website	32843098	4159	4166	O
(	32843098	4167	4168	O
Additional	32843098	4169	4179	O
file	32843098	4180	4184	O
1	32843098	4185	4186	O
)	32843098	4187	4188	O
.	32843098	4189	4190	O

In	32843098	4191	4193	O
the	32843098	4194	4197	O
interest	32843098	4198	4206	O
in	32843098	4207	4209	O
expediting	32843098	4210	4220	O
dissemination	32843098	4221	4234	O
of	32843098	4235	4237	O
this	32843098	4238	4242	O
material	32843098	4243	4251	O
,	32843098	4252	4253	O
the	32843098	4254	4257	O
familiar	32843098	4258	4266	O
formatting	32843098	4267	4277	O
has	32843098	4278	4281	O
been	32843098	4282	4286	O
eliminated	32843098	4287	4297	O
;	32843098	4298	4299	O
this	32843098	4300	4304	O
Letter	32843098	4305	4311	O
serves	32843098	4312	4318	O
as	32843098	4319	4321	O
a	32843098	4322	4323	O
summary	32843098	4324	4331	O
of	32843098	4332	4334	O
the	32843098	4335	4338	O
key	32843098	4339	4342	O
elements	32843098	4343	4351	O
of	32843098	4352	4354	O
the	32843098	4355	4358	O
full	32843098	4359	4363	O
protocol	32843098	4364	4372	O
.	32843098	4373	4374	O


Safety	32853672	0	6	B-Outcome
and	32853672	7	10	O
effectiveness	32853672	11	24	B-Outcome
of	32853672	25	27	O
azithromycin	32853672	28	40	B-Intervention
in	32853672	41	43	O
patients	32853672	44	52	O
with	32853672	53	57	O
COVID-19	32853672	58	66	B-Participant
:	32853672	67	68	O
An	32853672	69	71	O
open	32853672	72	76	O
-	32853672	77	78	O
label	32853672	79	84	O
randomised	32853672	85	95	O
trial	32853672	96	101	O
.	32853672	102	103	O

As	32853672	104	106	O
no	32853672	107	109	O
specific	32853672	110	118	O
pharmacological	32853672	119	134	O
treatment	32853672	135	144	O
has	32853672	145	148	O
been	32853672	149	153	O
validated	32853672	154	163	O
for	32853672	164	167	O
use	32853672	168	171	O
in	32853672	172	174	O
coronavirus	32853672	175	186	O
disease	32853672	187	194	O
2019	32853672	195	199	O
(	32853672	200	201	O
COVID-19	32853672	202	210	O
)	32853672	211	212	O
,	32853672	213	214	O
we	32853672	215	217	O
aimed	32853672	218	223	O
to	32853672	224	226	O
assess	32853672	227	233	O
the	32853672	234	237	O
effectiveness	32853672	238	251	O
of	32853672	252	254	O
azithromycin	32853672	255	267	O
(	32853672	268	269	O
AZM	32853672	270	273	O
)	32853672	274	275	O
in	32853672	276	278	O
these	32853672	279	284	O
patients	32853672	285	293	O
at	32853672	294	296	O
a	32853672	297	298	O
referral	32853672	299	307	O
centre	32853672	308	314	O
in	32853672	315	317	O
Iran	32853672	318	322	O
.	32853672	323	324	O

An	32853672	325	327	O
open	32853672	328	332	O
-	32853672	333	334	O
label	32853672	335	340	O
,	32853672	341	342	O
randomised	32853672	343	353	O
controlled	32853672	354	364	O
trial	32853672	365	370	O
was	32853672	371	374	O
conducted	32853672	375	384	O
on	32853672	385	387	O
patients	32853672	388	396	O
with	32853672	397	401	O
laboratory	32853672	402	412	O
-	32853672	413	414	O
confirmed	32853672	415	424	O
COVID-19	32853672	425	433	B-Participant
.	32853672	434	435	O

A	32853672	436	437	O
total	32853672	438	443	O
of	32853672	444	446	O
55	32853672	447	449	O
patients	32853672	450	458	O
in	32853672	459	461	O
the	32853672	462	465	O
control	32853672	466	473	B-Intervention
group	32853672	474	479	O
receiving	32853672	480	489	O
hydroxychloroquine	32853672	490	508	B-Intervention
(	32853672	509	510	I-Intervention
HCQ	32853672	511	514	I-Intervention
)	32853672	515	516	I-Intervention
and	32853672	517	520	I-Intervention
lopinavir	32853672	521	530	I-Intervention
/	32853672	531	532	I-Intervention
ritonavir	32853672	533	542	I-Intervention
(	32853672	543	544	I-Intervention
LPV	32853672	545	548	I-Intervention
/	32853672	549	550	I-Intervention
r	32853672	551	552	I-Intervention
)	32853672	553	554	I-Intervention
were	32853672	555	559	O
compared	32853672	560	568	O
with	32853672	569	573	O
56	32853672	574	576	O
patients	32853672	577	585	O
in	32853672	586	588	O
the	32853672	589	592	O
case	32853672	593	597	B-Intervention
group	32853672	598	603	O
who	32853672	604	607	O
in	32853672	608	610	O
addition	32853672	611	619	O
to	32853672	620	622	O
the	32853672	623	626	O
same	32853672	627	631	O
regimen	32853672	632	639	O
also	32853672	640	644	O
received	32853672	645	653	O
AZM	32853672	654	657	B-Intervention
.	32853672	658	659	O

Patients	32853672	660	668	O
with	32853672	669	673	O
prior	32853672	674	679	B-Participant
cardiac	32853672	680	687	I-Participant
disease	32853672	688	695	I-Participant
were	32853672	696	700	O
excluded	32853672	701	709	O
from	32853672	710	714	O
the	32853672	715	718	O
study	32853672	719	724	O
.	32853672	725	726	O

Furthermore	32853672	727	738	O
,	32853672	739	740	O
patients	32853672	741	749	O
from	32853672	750	754	O
the	32853672	755	758	O
case	32853672	759	763	B-Intervention
group	32853672	764	769	O
were	32853672	770	774	O
assessed	32853672	775	783	O
for	32853672	784	787	O
cardiac	32853672	788	795	B-Outcome
arrythmia	32853672	796	805	I-Outcome
risk	32853672	806	810	I-Outcome
based	32853672	811	816	O
on	32853672	817	819	O
the	32853672	820	823	O
American	32853672	824	832	O
College	32853672	833	840	O
of	32853672	841	843	O
Cardiology	32853672	844	854	O
(	32853672	855	856	O
ACC	32853672	857	860	O
)	32853672	861	862	O
risk	32853672	863	867	O
assessment	32853672	868	878	O
for	32853672	879	882	O
use	32853672	883	886	O
of	32853672	887	889	O
AZM	32853672	890	893	B-Intervention
and	32853672	894	897	O
HCQ	32853672	898	901	B-Intervention
.	32853672	902	903	O

The	32853672	904	907	O
main	32853672	908	912	O
outcome	32853672	913	920	O
measures	32853672	921	929	O
were	32853672	930	934	O
vital	32853672	935	940	B-Outcome
signs	32853672	941	946	I-Outcome
,	32853672	947	948	O
SpO2	32853672	949	953	B-Outcome
levels	32853672	954	960	I-Outcome
,	32853672	961	962	O
duration	32853672	963	971	B-Outcome
of	32853672	972	974	I-Outcome
hospitalisation	32853672	975	990	I-Outcome
,	32853672	991	992	O
need	32853672	993	997	B-Outcome
for	32853672	998	1001	I-Outcome
and	32853672	1002	1005	I-Outcome
length	32853672	1006	1012	I-Outcome
of	32853672	1013	1015	I-Outcome
intensive	32853672	1016	1025	I-Outcome
care	32853672	1026	1030	I-Outcome
unit	32853672	1031	1035	I-Outcome
admission	32853672	1036	1045	I-Outcome
,	32853672	1046	1047	O
mortality	32853672	1048	1057	B-Outcome
rate	32853672	1058	1062	I-Outcome
and	32853672	1063	1066	O
results	32853672	1067	1074	B-Outcome
of	32853672	1075	1077	I-Outcome
30-day	32853672	1078	1084	I-Outcome
follow	32853672	1085	1091	I-Outcome
-	32853672	1092	1093	I-Outcome
up	32853672	1094	1096	I-Outcome
after	32853672	1097	1102	I-Outcome
discharge	32853672	1103	1112	I-Outcome
.	32853672	1113	1114	O

Initially	32853672	1115	1124	O
,	32853672	1125	1126	O
there	32853672	1127	1132	O
was	32853672	1133	1136	O
no	32853672	1137	1139	O
significant	32853672	1140	1151	B-Observation
difference	32853672	1152	1162	I-Observation
between	32853672	1163	1170	O
the	32853672	1171	1174	O
general	32853672	1175	1182	B-Outcome
conditions	32853672	1183	1193	I-Outcome
and	32853672	1194	1197	O
vital	32853672	1198	1203	B-Outcome
signs	32853672	1204	1209	I-Outcome
of	32853672	1210	1212	O
the	32853672	1213	1216	O
two	32853672	1217	1220	B-Intervention
groups	32853672	1221	1227	I-Intervention
.	32853672	1228	1229	O

The	32853672	1230	1233	O
SpO2	32853672	1234	1238	B-Outcome
levels	32853672	1239	1245	I-Outcome
at	32853672	1246	1248	I-Outcome
discharge	32853672	1249	1258	I-Outcome
were	32853672	1259	1263	O
significantly	32853672	1264	1277	B-Observation
higher	32853672	1278	1284	I-Observation
,	32853672	1285	1286	O
the	32853672	1287	1290	O
respiratory	32853672	1291	1302	B-Outcome
rate	32853672	1303	1307	I-Outcome
was	32853672	1308	1311	O
lower	32853672	1312	1317	B-Observation
and	32853672	1318	1321	O
the	32853672	1322	1325	O
duration	32853672	1326	1334	B-Outcome
of	32853672	1335	1337	I-Outcome
admission	32853672	1338	1347	I-Outcome
was	32853672	1348	1351	O
shorter	32853672	1352	1359	B-Observation
in	32853672	1360	1362	O
the	32853672	1363	1366	O
case	32853672	1367	1371	B-Intervention
group	32853672	1372	1377	O
.	32853672	1378	1379	O

There	32853672	1380	1385	O
was	32853672	1386	1389	O
no	32853672	1390	1392	O
significant	32853672	1393	1404	B-Observation
difference	32853672	1405	1415	I-Observation
in	32853672	1416	1418	O
the	32853672	1419	1422	O
mortality	32853672	1423	1432	B-Outcome
rate	32853672	1433	1437	I-Outcome
between	32853672	1438	1445	B-Intervention
the	32853672	1446	1449	I-Intervention
two	32853672	1450	1453	I-Intervention
groups	32853672	1454	1460	I-Intervention
.	32853672	1461	1462	O

Patients	32853672	1463	1471	O
who	32853672	1472	1475	O
received	32853672	1476	1484	O
AZM	32853672	1485	1488	B-Intervention
in	32853672	1489	1491	I-Intervention
addition	32853672	1492	1500	I-Intervention
to	32853672	1501	1503	I-Intervention
HCQ	32853672	1504	1507	I-Intervention
and	32853672	1508	1511	I-Intervention
LPV	32853672	1512	1515	I-Intervention
/	32853672	1516	1517	I-Intervention
r	32853672	1518	1519	I-Intervention
had	32853672	1520	1523	O
a	32853672	1524	1525	O
better	32853672	1526	1532	B-Observation
general	32853672	1533	1540	B-Outcome
condition	32853672	1541	1550	I-Outcome
.	32853672	1551	1552	O

HCQ+AZM	32853672	1553	1560	B-Intervention
combination	32853672	1561	1572	I-Intervention
may	32853672	1573	1576	O
be	32853672	1577	1579	O
beneficial	32853672	1580	1590	B-Observation
for	32853672	1591	1594	O
individuals	32853672	1595	1606	O
who	32853672	1607	1610	O
are	32853672	1611	1614	O
known	32853672	1615	1620	O
to	32853672	1621	1623	O
have	32853672	1624	1628	O
a	32853672	1629	1630	O
very	32853672	1631	1635	O
low	32853672	1636	1639	B-Participant
underlying	32853672	1640	1650	I-Participant
risk	32853672	1651	1655	I-Participant
for	32853672	1656	1659	I-Participant
cardiac	32853672	1660	1667	I-Participant
arrhythmia	32853672	1668	1678	I-Participant
based	32853672	1679	1684	O
on	32853672	1685	1687	O
the	32853672	1688	1691	O
ACC	32853672	1692	1695	O
criteria	32853672	1696	1704	O
.	32853672	1705	1706	O


Hydroxychloroquine	32854751	0	18	B-Intervention
for	32854751	19	22	O
post	32854751	23	27	B-Outcome
-	32854751	28	29	I-Outcome
exposure	32854751	30	38	I-Outcome
prophylaxis	32854751	39	50	I-Outcome
of	32854751	51	53	O
COVID-19	32854751	54	62	B-Participant
among	32854751	63	68	O
naval	32854751	69	74	B-Participant
personnel	32854751	75	84	I-Participant
in	32854751	85	87	O
Sri	32854751	88	91	O
Lanka	32854751	92	97	O
:	32854751	98	99	O
study	32854751	100	105	O
protocol	32854751	106	114	O
for	32854751	115	118	O
a	32854751	119	120	O
randomized	32854751	121	131	O
,	32854751	132	133	O
controlled	32854751	134	144	O
trial	32854751	145	150	O
.	32854751	151	152	O

BACKGROUND	32854751	153	163	O
:	32854751	164	165	O
The	32854751	166	169	O
first	32854751	170	175	O
case	32854751	176	180	O
of	32854751	181	183	O
a	32854751	184	185	O
coronavirus	32854751	186	197	O
2019	32854751	198	202	O
(	32854751	203	204	O
COVID-19	32854751	205	213	O
)	32854751	214	215	O
infection	32854751	216	225	O
in	32854751	226	228	O
a	32854751	229	230	O
Sri	32854751	231	234	O
Lankan	32854751	235	241	O
was	32854751	242	245	O
reported	32854751	246	254	O
on	32854751	255	257	O
March	32854751	258	263	O
11	32854751	264	266	O
,	32854751	267	268	O
2020	32854751	269	273	O
.	32854751	274	275	O

The	32854751	276	279	O
situation	32854751	280	289	O
in	32854751	290	292	O
Sri	32854751	293	296	O
Lanka	32854751	297	302	O
changed	32854751	303	310	O
with	32854751	311	315	O
the	32854751	316	319	O
rapid	32854751	320	325	O
increase	32854751	326	334	O
of	32854751	335	337	O
personnel	32854751	338	347	O
contracting	32854751	348	359	O
COVID-19	32854751	360	368	O
in	32854751	369	371	O
a	32854751	372	373	O
naval	32854751	374	379	O
base	32854751	380	384	O
camp	32854751	385	389	O
that	32854751	390	394	O
housed	32854751	395	401	O
more	32854751	402	406	O
than	32854751	407	411	O
4000	32854751	412	416	O
people	32854751	417	423	O
.	32854751	424	425	O

This	32854751	426	430	O
provided	32854751	431	439	O
a	32854751	440	441	O
unique	32854751	442	448	O
opportunity	32854751	449	460	O
to	32854751	461	463	O
study	32854751	464	469	O
the	32854751	470	473	O
effectiveness	32854751	474	487	O
of	32854751	488	490	O
hydroxychloroquine	32854751	491	509	O
(	32854751	510	511	O
HCQ	32854751	512	515	O
)	32854751	516	517	O
for	32854751	518	521	O
post	32854751	522	526	O
-	32854751	527	528	O
exposure	32854751	529	537	O
prophylaxis	32854751	538	549	O
(	32854751	550	551	O
PEP	32854751	552	555	O
)	32854751	556	557	O
,	32854751	558	559	O
while	32854751	560	565	O
taking	32854751	566	572	O
stringent	32854751	573	582	O
,	32854751	583	584	O
non	32854751	585	588	O
-	32854751	589	590	O
pharmacologic	32854751	591	604	O
,	32854751	605	606	O
public	32854751	607	613	O
health	32854751	614	620	O
measures	32854751	621	629	O
to	32854751	630	632	O
prevent	32854751	633	640	O
spread	32854751	641	647	O
.	32854751	648	649	O

Our	32854751	650	653	O
aim	32854751	654	657	O
is	32854751	658	660	O
to	32854751	661	663	O
study	32854751	664	669	O
the	32854751	670	673	O
effectiveness	32854751	674	687	B-Outcome
and	32854751	688	691	O
safety	32854751	692	698	B-Outcome
of	32854751	699	701	O
HCQ	32854751	702	705	B-Intervention
for	32854751	706	709	O
PEP	32854751	710	713	B-Outcome
among	32854751	714	719	O
naval	32854751	720	725	B-Participant
personnel	32854751	726	735	I-Participant
with	32854751	736	740	O
exposure	32854751	741	749	B-Participant
to	32854751	750	752	I-Participant
COVID-19-positive	32854751	753	770	I-Participant
patients	32854751	771	779	I-Participant
.	32854751	780	781	O

METHODS	32854751	782	789	O
:	32854751	790	791	O
This	32854751	792	796	O
is	32854751	797	799	O
a	32854751	800	801	O
placebo	32854751	802	809	O
-	32854751	810	811	O
controlled	32854751	812	822	O
,	32854751	823	824	O
randomized	32854751	825	835	O
,	32854751	836	837	O
clinical	32854751	838	846	O
trial	32854751	847	852	O
carried	32854751	853	860	O
out	32854751	861	864	O
in	32854751	865	867	O
the	32854751	868	871	O
naval	32854751	872	877	O
base	32854751	878	882	O
camp	32854751	883	887	O
and	32854751	888	891	O
quarantine	32854751	892	902	O
centers	32854751	903	910	O
of	32854751	911	913	O
the	32854751	914	917	O
Sri	32854751	918	921	O
Lanka	32854751	922	927	O
Navy	32854751	928	932	O
,	32854751	933	934	O
Ministry	32854751	935	943	O
of	32854751	944	946	O
Defense	32854751	947	954	O
,	32854751	955	956	O
Sri	32854751	957	960	O
Lanka	32854751	961	966	O
.	32854751	967	968	O

Navy	32854751	969	973	B-Participant
personnel	32854751	974	983	I-Participant
who	32854751	984	987	O
are	32854751	988	991	O
exposed	32854751	992	999	B-Participant
to	32854751	1000	1002	I-Participant
a	32854751	1003	1004	I-Participant
patient	32854751	1005	1012	I-Participant
with	32854751	1013	1017	I-Participant
confirmed	32854751	1018	1027	I-Participant
COVID-19	32854751	1028	1036	I-Participant
infection	32854751	1037	1046	I-Participant
but	32854751	1047	1050	O
test	32854751	1051	1055	B-Participant
negative	32854751	1056	1064	I-Participant
for	32854751	1065	1068	I-Participant
the	32854751	1069	1072	I-Participant
virus	32854751	1073	1078	I-Participant
on	32854751	1079	1081	I-Participant
reverse	32854751	1082	1089	I-Participant
real	32854751	1090	1094	I-Participant
-	32854751	1095	1096	I-Participant
time	32854751	1097	1101	I-Participant
polymerase	32854751	1102	1112	I-Participant
chain	32854751	1113	1118	I-Participant
reaction	32854751	1119	1127	I-Participant
(	32854751	1128	1129	I-Participant
rRT	32854751	1130	1133	I-Participant
-	32854751	1134	1135	I-Participant
PCR	32854751	1136	1139	I-Participant
)	32854751	1140	1141	I-Participant
at	32854751	1142	1144	O
recruitment	32854751	1145	1156	O
will	32854751	1157	1161	O
be	32854751	1162	1164	O
randomized	32854751	1165	1175	O
,	32854751	1176	1177	O
200	32854751	1178	1181	O
to	32854751	1182	1184	O
each	32854751	1185	1189	O
arm	32854751	1190	1193	O
,	32854751	1194	1195	O
to	32854751	1196	1198	O
receive	32854751	1199	1206	O
HCQ	32854751	1207	1210	B-Intervention
or	32854751	1211	1213	O
placebo	32854751	1214	1221	B-Intervention
and	32854751	1222	1225	O
monitored	32854751	1226	1235	O
for	32854751	1236	1239	O
the	32854751	1240	1243	O
development	32854751	1244	1255	B-Outcome
of	32854751	1256	1258	I-Outcome
symptoms	32854751	1259	1267	I-Outcome
or	32854751	1268	1270	O
rRT	32854751	1271	1274	B-Outcome
-	32854751	1275	1276	I-Outcome
PCR	32854751	1277	1280	I-Outcome
positivity	32854751	1281	1291	I-Outcome
for	32854751	1292	1295	I-Outcome
severe	32854751	1296	1302	I-Outcome
acute	32854751	1303	1308	I-Outcome
respiratory	32854751	1309	1320	I-Outcome
syndrome	32854751	1321	1329	I-Outcome
coronavirus	32854751	1330	1341	I-Outcome
2	32854751	1342	1343	I-Outcome
(	32854751	1344	1345	I-Outcome
SARS	32854751	1346	1350	I-Outcome
-	32854751	1351	1352	I-Outcome
CoV-2	32854751	1353	1358	I-Outcome
)	32854751	1359	1360	I-Outcome
virus	32854751	1361	1366	I-Outcome
for	32854751	1367	1370	O
14	32854751	1371	1373	O
days	32854751	1376	1380	O
.	32854751	1381	1382	O

CONCLUSIONS	32854751	1383	1394	O
:	32854751	1395	1396	O
This	32854751	1397	1401	O
trial	32854751	1402	1407	O
will	32854751	1408	1412	O
provide	32854751	1413	1420	O
high	32854751	1421	1425	O
-	32854751	1426	1427	O
quality	32854751	1428	1435	O
evidence	32854751	1436	1444	O
of	32854751	1445	1447	O
the	32854751	1448	1451	O
effectiveness	32854751	1452	1465	B-Outcome
and	32854751	1466	1469	O
safety	32854751	1470	1476	B-Outcome
of	32854751	1477	1479	O
HCQ	32854751	1480	1483	B-Intervention
as	32854751	1484	1486	O
PEP	32854751	1487	1490	B-Outcome
for	32854751	1491	1494	O
COVID-19	32854751	1495	1503	B-Participant
.	32854751	1504	1505	O

The	32854751	1506	1509	O
study	32854751	1510	1515	O
design	32854751	1516	1522	O
is	32854751	1523	1525	O
unique	32854751	1526	1532	O
due	32854751	1533	1536	O
to	32854751	1537	1539	O
the	32854751	1540	1543	O
circumstances	32854751	1544	1557	O
of	32854751	1558	1560	O
the	32854751	1561	1564	O
outbreak	32854751	1565	1573	O
in	32854751	1574	1576	O
a	32854751	1577	1578	O
confined	32854751	1579	1587	O
area	32854751	1588	1592	O
among	32854751	1593	1598	O
otherwise	32854751	1599	1608	O
healthy	32854751	1609	1616	O
adults	32854751	1617	1623	O
,	32854751	1624	1625	O
at	32854751	1626	1628	O
a	32854751	1629	1630	O
relatively	32854751	1631	1641	O
early	32854751	1642	1647	O
stage	32854751	1648	1653	O
of	32854751	1654	1656	O
its	32854751	1657	1660	O
spread	32854751	1661	1667	O
.	32854751	1668	1669	O

BACKGROUND	32854751	1670	1680	O
:	32854751	1681	1682	O
Sri	32854751	1683	1686	O
Lanka	32854751	1687	1692	O
Clinical	32854751	1693	1701	O
Trials	32854751	1702	1708	O
Registry	32854751	1709	1717	O
(	32854751	1718	1719	O
SLCTR	32854751	1720	1725	O
)	32854751	1726	1727	O
SLCTR/2020/011	32854751	1728	1742	O
.	32854751	1743	1744	O

Registered	32854751	1745	1755	O
on	32854751	1756	1758	O
04	32854751	1759	1761	O
May	32854751	1762	1765	O
2020	32854751	1766	1770	O
.	32854751	1771	1772	O


Interferon	32862111	0	10	B-Intervention
-1b	32862111	11	15	I-Intervention
in	32862111	16	18	O
treatment	32862111	19	28	O
of	32862111	29	31	O
severe	32862111	32	38	B-Participant
COVID-19	32862111	39	47	I-Participant
:	32862111	48	49	O
A	32862111	50	51	O
randomized	32862111	52	62	O
clinical	32862111	63	71	O
trial	32862111	72	77	O
.	32862111	78	79	O

In	32862111	80	82	O
this	32862111	83	87	O
study	32862111	88	93	O
,	32862111	94	95	O
efficacy	32862111	96	104	B-Outcome
and	32862111	105	108	O
safety	32862111	109	115	B-Outcome
of	32862111	116	118	O
interferon	32862111	119	129	B-Intervention
(	32862111	130	131	I-Intervention
IFN	32862111	132	135	I-Intervention
)	32862111	136	137	I-Intervention
-1b	32862111	138	142	I-Intervention
in	32862111	143	145	O
the	32862111	146	149	O
treatment	32862111	150	159	O
of	32862111	160	162	O
patients	32862111	163	171	O
with	32862111	172	176	O
severe	32862111	177	183	B-Participant
COVID-19	32862111	184	192	I-Participant
were	32862111	193	197	O
evaluated	32862111	198	207	O
.	32862111	208	209	O

Among	32862111	210	215	O
an	32862111	216	218	O
open	32862111	219	223	O
-	32862111	224	225	O
label	32862111	226	231	O
,	32862111	232	233	O
randomized	32862111	234	244	O
clinical	32862111	245	253	O
trial	32862111	254	259	O
,	32862111	260	261	O
adult	32862111	262	267	B-Participant
patients	32862111	268	276	O
(	32862111	277	278	O
	32862111	279	280	B-Participant
18	32862111	281	283	I-Participant
years	32862111	286	291	I-Participant
old	32862111	292	295	I-Participant
)	32862111	296	297	O
with	32862111	298	302	O
severe	32862111	303	309	B-Participant
COVID-19	32862111	310	318	I-Participant
were	32862111	319	323	O
randomly	32862111	324	332	O
assigned	32862111	333	341	O
(	32862111	342	343	O
1:1	32862111	344	347	O
)	32862111	348	349	O
to	32862111	350	352	O
the	32862111	353	356	O
IFN	32862111	357	360	B-Intervention
group	32862111	361	366	O
or	32862111	367	369	O
the	32862111	370	373	O
control	32862111	374	381	B-Intervention
group	32862111	382	387	O
.	32862111	388	389	O

Patients	32862111	390	398	O
in	32862111	399	401	O
the	32862111	402	405	O
IFN	32862111	406	409	B-Intervention
group	32862111	410	415	O
received	32862111	416	424	O
IFN	32862111	425	428	B-Intervention
-1b	32862111	429	433	I-Intervention
(	32862111	434	435	O
250	32862111	436	439	O
mcg	32862111	440	443	O
subcutaneously	32862111	444	458	O
every	32862111	459	464	O
other	32862111	465	470	O
day	32862111	471	474	O
for	32862111	475	478	O
two	32862111	479	482	O
consecutive	32862111	483	494	O
weeks	32862111	495	500	O
)	32862111	501	502	O
along	32862111	503	508	O
with	32862111	509	513	O
the	32862111	514	517	O
national	32862111	518	526	O
protocol	32862111	527	535	O
medications	32862111	536	547	O
while	32862111	548	553	O
in	32862111	554	556	O
the	32862111	557	560	O
control	32862111	561	568	B-Intervention
group	32862111	569	574	O
,	32862111	575	576	O
patients	32862111	577	585	O
received	32862111	586	594	O
only	32862111	595	599	O
the	32862111	600	603	O
national	32862111	604	612	B-Intervention
protocol	32862111	613	621	I-Intervention
medications	32862111	622	633	I-Intervention
(	32862111	634	635	O
lopinavir	32862111	636	645	O
/	32862111	646	647	O
ritonavir	32862111	648	657	O
or	32862111	658	660	O
atazanavir	32862111	661	671	O
/	32862111	672	673	O
ritonavir	32862111	674	683	O
plus	32862111	684	688	O
hydroxychloroquine	32862111	689	707	O
for	32862111	708	711	O
7	32862111	712	713	O
-	32862111	714	715	O
10	32862111	716	718	O
days	32862111	721	725	O
)	32862111	726	727	O
.	32862111	728	729	O

The	32862111	730	733	O
primary	32862111	734	741	O
outcome	32862111	742	749	O
of	32862111	750	752	O
the	32862111	753	756	O
study	32862111	757	762	O
was	32862111	763	766	O
time	32862111	767	771	B-Outcome
to	32862111	772	774	I-Outcome
clinical	32862111	775	783	I-Outcome
improvement	32862111	784	795	I-Outcome
.	32862111	796	797	O

Secondary	32862111	798	807	O
outcomes	32862111	808	816	O
were	32862111	817	821	O
in	32862111	822	824	B-Outcome
-	32862111	825	826	I-Outcome
hospital	32862111	827	835	I-Outcome
complications	32862111	836	849	I-Outcome
and	32862111	850	853	O
28-daymortality	32862111	854	869	B-Outcome
.	32862111	870	871	O

Between	32862111	872	879	O
April	32862111	880	885	O
20	32862111	886	888	O
and	32862111	889	892	O
May	32862111	893	896	O
20	32862111	897	899	O
,	32862111	900	901	O
2020	32862111	902	906	O
,	32862111	907	908	O
80	32862111	909	911	O
patients	32862111	912	920	O
were	32862111	921	925	O
enrolled	32862111	926	934	O
and	32862111	935	938	O
finally	32862111	939	946	O
33	32862111	947	949	O
patients	32862111	950	958	O
in	32862111	959	961	O
each	32862111	962	966	O
group	32862111	967	972	O
completed	32862111	973	982	O
the	32862111	983	986	O
study	32862111	987	992	O
.	32862111	993	994	O

Time	32862111	995	999	B-Outcome
to	32862111	1000	1002	I-Outcome
clinical	32862111	1003	1011	I-Outcome
improvment	32862111	1012	1022	I-Outcome
in	32862111	1023	1025	O
the	32862111	1026	1029	O
IFN	32862111	1030	1033	B-Intervention
group	32862111	1034	1039	O
was	32862111	1040	1043	O
significantly	32862111	1044	1057	B-Observation
shorter	32862111	1058	1065	I-Observation
than	32862111	1066	1070	O
the	32862111	1071	1074	O
control	32862111	1075	1082	B-Intervention
group	32862111	1083	1088	O
(	32862111	1089	1090	O
[	32862111	1091	1092	O
9(6	32862111	1093	1096	B-Observation
-	32862111	1097	1098	I-Observation
10	32862111	1099	1101	I-Observation
)	32862111	1102	1103	I-Observation
vs.	32862111	1104	1107	O
11(9	32862111	1108	1112	B-Observation
-	32862111	1113	1114	I-Observation
15	32862111	1115	1117	I-Observation
)	32862111	1118	1119	I-Observation
days	32862111	1120	1124	I-Observation
respectively	32862111	1125	1137	O
,	32862111	1138	1139	O
p	32862111	1140	1141	O
=	32862111	1144	1145	O
0.002	32862111	1148	1153	O
,	32862111	1154	1155	O
HR	32862111	1156	1158	O
=	32862111	1161	1162	O
2.30	32862111	1165	1169	O
;	32862111	1170	1171	O
95	32862111	1172	1174	O
%	32862111	1175	1176	O
CI	32862111	1177	1179	O
:	32862111	1180	1181	O
1.33	32862111	1182	1186	O
-	32862111	1187	1188	O
3.39	32862111	1189	1193	O
]	32862111	1194	1195	O
)	32862111	1196	1197	O
.	32862111	1198	1199	O

At	32862111	1200	1202	O
day	32862111	1203	1206	O
14	32862111	1207	1209	O
,	32862111	1210	1211	O
the	32862111	1212	1215	O
percentage	32862111	1216	1226	B-Outcome
of	32862111	1227	1229	I-Outcome
discharged	32862111	1230	1240	I-Outcome
patients	32862111	1241	1249	I-Outcome
was	32862111	1250	1253	O
78.79	32862111	1254	1259	B-Observation
%	32862111	1260	1261	I-Observation
and	32862111	1262	1265	O
54.55	32862111	1266	1271	B-Observation
%	32862111	1272	1273	I-Observation
in	32862111	1274	1276	O
the	32862111	1277	1280	O
IFN	32862111	1281	1284	B-Intervention
and	32862111	1285	1288	O
control	32862111	1289	1296	B-Intervention
groups	32862111	1297	1303	O
respectively	32862111	1304	1316	O
(	32862111	1317	1318	O
OR	32862111	1319	1321	O
=	32862111	1324	1325	O
3.09	32862111	1328	1332	O
;	32862111	1333	1334	O
95	32862111	1335	1337	O
%	32862111	1338	1339	O
CI	32862111	1340	1342	O
:	32862111	1343	1344	O
1.05	32862111	1345	1349	O
-	32862111	1350	1351	O
9.11	32862111	1352	1356	O
,	32862111	1357	1358	O
p	32862111	1359	1360	O
=	32862111	1363	1364	O
0.03	32862111	1367	1371	O
)	32862111	1372	1373	O
.	32862111	1374	1375	O

ICU	32862111	1376	1379	B-Outcome
admission	32862111	1380	1389	I-Outcome
rate	32862111	1390	1394	I-Outcome
in	32862111	1395	1397	O
the	32862111	1398	1401	O
control	32862111	1402	1409	B-Intervention
group	32862111	1410	1415	O
was	32862111	1416	1419	O
significantly	32862111	1420	1433	B-Observation
higher	32862111	1434	1440	I-Observation
than	32862111	1441	1445	O
the	32862111	1446	1449	O
IFN	32862111	1450	1453	B-Intervention
group	32862111	1454	1459	O
(	32862111	1460	1461	O
66.66	32862111	1462	1467	B-Observation
%	32862111	1468	1469	I-Observation
vs.	32862111	1470	1473	O
42.42	32862111	1474	1479	B-Observation
%	32862111	1480	1481	I-Observation
,	32862111	1482	1483	O
p	32862111	1484	1485	O
=	32862111	1488	1489	O
0.04	32862111	1492	1496	O
)	32862111	1497	1498	O
.	32862111	1499	1500	O

The	32862111	1501	1504	O
duration	32862111	1505	1513	B-Outcome
of	32862111	1514	1516	I-Outcome
hospitalization	32862111	1517	1532	I-Outcome
and	32862111	1533	1536	O
ICU	32862111	1537	1540	B-Outcome
stay	32862111	1541	1545	I-Outcome
were	32862111	1546	1550	O
not	32862111	1551	1554	O
significantly	32862111	1555	1568	B-Observation
different	32862111	1569	1578	I-Observation
between	32862111	1579	1586	B-Intervention
the	32862111	1587	1590	I-Intervention
groups	32862111	1591	1597	I-Intervention
.	32862111	1598	1599	O

All	32862111	1600	1603	B-Outcome
-	32862111	1604	1605	I-Outcome
cause	32862111	1606	1611	I-Outcome
28-day	32862111	1612	1618	I-Outcome
mortality	32862111	1619	1628	I-Outcome
was	32862111	1629	1632	O
6.06	32862111	1633	1637	B-Observation
%	32862111	1638	1639	I-Observation
and	32862111	1640	1643	O
18.18	32862111	1644	1649	B-Observation
%	32862111	1650	1651	I-Observation
in	32862111	1652	1654	O
the	32862111	1655	1658	O
IFN	32862111	1659	1662	B-Intervention
and	32862111	1663	1666	O
control	32862111	1667	1674	B-Intervention
groups	32862111	1675	1681	O
respectively	32862111	1682	1694	O
(	32862111	1695	1696	O
p	32862111	1697	1698	O
=	32862111	1701	1702	O
0.12	32862111	1705	1709	O
)	32862111	1710	1711	O
.	32862111	1712	1713	O

IFN	32862111	1714	1717	B-Intervention
-1b	32862111	1718	1722	I-Intervention
was	32862111	1723	1726	O
effective	32862111	1727	1736	O
in	32862111	1737	1739	O
shortening	32862111	1740	1750	B-Observation
the	32862111	1751	1754	O
time	32862111	1755	1759	B-Outcome
to	32862111	1760	1762	I-Outcome
clinical	32862111	1763	1771	I-Outcome
improvement	32862111	1772	1783	I-Outcome
without	32862111	1784	1791	O
serious	32862111	1792	1799	B-Outcome
adverse	32862111	1800	1807	I-Outcome
events	32862111	1808	1814	I-Outcome
in	32862111	1815	1817	O
patients	32862111	1818	1826	O
with	32862111	1827	1831	O
severe	32862111	1832	1838	B-Participant
COVID-19	32862111	1839	1847	I-Participant
.	32862111	1848	1849	O

Furthermore	32862111	1850	1861	O
,	32862111	1862	1863	O
admission	32862111	1864	1873	B-Outcome
in	32862111	1874	1876	I-Outcome
ICU	32862111	1877	1880	I-Outcome
and	32862111	1881	1884	O
need	32862111	1885	1889	B-Outcome
for	32862111	1890	1893	I-Outcome
invasive	32862111	1894	1902	I-Outcome
mechanical	32862111	1903	1913	I-Outcome
ventilation	32862111	1914	1925	I-Outcome
decreased	32862111	1926	1935	B-Observation
following	32862111	1936	1945	O
administration	32862111	1946	1960	O
of	32862111	1961	1963	O
IFN	32862111	1964	1967	B-Intervention
-1b	32862111	1968	1972	I-Intervention
.	32862111	1973	1974	O

Although	32862111	1975	1983	O
28-day	32862111	1984	1990	B-Outcome
mortality	32862111	1991	2000	I-Outcome
was	32862111	2001	2004	O
lower	32862111	2005	2010	B-Observation
in	32862111	2011	2013	O
the	32862111	2014	2017	O
IFN	32862111	2018	2021	B-Intervention
group	32862111	2022	2027	O
,	32862111	2028	2029	O
further	32862111	2030	2037	O
randomized	32862111	2038	2048	O
clinical	32862111	2049	2057	O
trials	32862111	2058	2064	O
with	32862111	2065	2069	O
large	32862111	2070	2075	O
sample	32862111	2076	2082	O
size	32862111	2083	2087	O
are	32862111	2088	2091	O
needed	32862111	2092	2098	O
for	32862111	2099	2102	O
exact	32862111	2103	2108	O
estimation	32862111	2109	2119	O
of	32862111	2120	2122	O
survival	32862111	2123	2131	O
benefit	32862111	2132	2139	O
of	32862111	2140	2142	O
IFN	32862111	2143	2146	B-Intervention
-1b	32862111	2147	2151	I-Intervention
.	32862111	2152	2153	O


Effect	32876689	0	6	O
of	32876689	7	9	O
Hydrocortisone	32876689	10	24	B-Intervention
on	32876689	25	27	O
21-Day	32876689	28	34	B-Outcome
Mortality	32876689	35	44	I-Outcome
or	32876689	45	47	O
Respiratory	32876689	48	59	B-Outcome
Support	32876689	60	67	I-Outcome
Among	32876689	68	73	O
Critically	32876689	74	84	B-Participant
Ill	32876689	85	88	I-Participant
Patients	32876689	89	97	O
With	32876689	98	102	O
COVID-19	32876689	103	111	B-Participant
:	32876689	112	113	O
A	32876689	114	115	O
Randomized	32876689	116	126	O
Clinical	32876689	127	135	O
Trial	32876689	136	141	O
.	32876689	142	143	O

Coronavirus	32876689	144	155	O
disease	32876689	156	163	O
2019	32876689	164	168	O
(	32876689	169	170	O
COVID-19	32876689	171	179	O
)	32876689	180	181	O
is	32876689	182	184	O
associated	32876689	185	195	O
with	32876689	196	200	O
severe	32876689	201	207	O
lung	32876689	208	212	O
damage	32876689	213	219	O
.	32876689	220	221	O

Corticosteroids	32876689	222	237	O
are	32876689	238	241	O
a	32876689	242	243	O
possible	32876689	244	252	O
therapeutic	32876689	253	264	O
option	32876689	265	271	O
.	32876689	272	273	O

To	32876689	274	276	O
determine	32876689	277	286	O
the	32876689	287	290	O
effect	32876689	291	297	O
of	32876689	298	300	O
hydrocortisone	32876689	301	315	B-Intervention
on	32876689	316	318	O
treatment	32876689	319	328	B-Outcome
failure	32876689	329	336	I-Outcome
on	32876689	337	339	I-Outcome
day	32876689	340	343	I-Outcome
21	32876689	344	346	I-Outcome
in	32876689	347	349	O
critically	32876689	350	360	B-Participant
ill	32876689	361	364	I-Participant
patients	32876689	365	373	O
with	32876689	374	378	O
severe	32876689	379	385	B-Participant
acute	32876689	386	391	I-Participant
respiratory	32876689	392	403	I-Participant
syndrome	32876689	404	412	I-Participant
coronavirus	32876689	413	424	I-Participant
2	32876689	425	426	I-Participant
(	32876689	427	428	I-Participant
SARS	32876689	429	433	I-Participant
-	32876689	434	435	I-Participant
CoV-2	32876689	436	441	I-Participant
)	32876689	442	443	I-Participant
infection	32876689	444	453	I-Participant
and	32876689	454	457	O
acute	32876689	458	463	B-Participant
respiratory	32876689	464	475	I-Participant
failure	32876689	476	483	I-Participant
.	32876689	484	485	O

Multicenter	32876689	486	497	O
randomized	32876689	498	508	O
double	32876689	509	515	O
-	32876689	516	517	O
blind	32876689	518	523	O
sequential	32876689	524	534	O
trial	32876689	535	540	O
conducted	32876689	541	550	O
in	32876689	551	553	O
France	32876689	554	560	O
,	32876689	561	562	O
with	32876689	563	567	O
interim	32876689	568	575	O
analyses	32876689	576	584	O
planned	32876689	585	592	O
every	32876689	593	598	O
50	32876689	599	601	O
patients	32876689	602	610	O
.	32876689	611	612	O

Patients	32876689	613	621	O
admitted	32876689	622	630	B-Participant
to	32876689	631	633	I-Participant
the	32876689	634	637	I-Participant
intensive	32876689	638	647	I-Participant
care	32876689	648	652	I-Participant
unit	32876689	653	657	I-Participant
(	32876689	658	659	I-Participant
ICU	32876689	660	663	I-Participant
)	32876689	664	665	I-Participant
for	32876689	666	669	O
COVID-19-related	32876689	670	686	B-Participant
acute	32876689	687	692	I-Participant
respiratory	32876689	693	704	I-Participant
failure	32876689	705	712	I-Participant
were	32876689	713	717	O
enrolled	32876689	718	726	O
from	32876689	727	731	O
March	32876689	732	737	O
7	32876689	738	739	O
to	32876689	740	742	O
June	32876689	743	747	O
1	32876689	748	749	O
,	32876689	750	751	O
2020	32876689	752	756	O
,	32876689	757	758	O
with	32876689	759	763	O
last	32876689	764	768	O
follow	32876689	769	775	O
-	32876689	776	777	O
up	32876689	778	780	O
on	32876689	781	783	O
June	32876689	784	788	O
29	32876689	789	791	O
,	32876689	792	793	O
2020	32876689	794	798	O
.	32876689	799	800	O

The	32876689	801	804	O
study	32876689	805	810	O
intended	32876689	811	819	O
to	32876689	820	822	O
enroll	32876689	823	829	O
290	32876689	830	833	O
patients	32876689	834	842	O
but	32876689	843	846	O
was	32876689	847	850	O
stopped	32876689	851	858	O
early	32876689	859	864	O
following	32876689	865	874	O
the	32876689	875	878	O
recommendation	32876689	879	893	O
of	32876689	894	896	O
the	32876689	897	900	O
data	32876689	901	905	O
and	32876689	906	909	O
safety	32876689	910	916	O
monitoring	32876689	917	927	O
board	32876689	928	933	O
.	32876689	934	935	O

Patients	32876689	936	944	O
were	32876689	945	949	O
randomized	32876689	950	960	O
to	32876689	961	963	O
receive	32876689	964	971	O
low	32876689	972	975	B-Intervention
-	32876689	976	977	I-Intervention
dose	32876689	978	982	I-Intervention
hydrocortisone	32876689	983	997	I-Intervention
(	32876689	998	999	O
n	32876689	1000	1001	O
=	32876689	1004	1005	O
76	32876689	1008	1010	O
)	32876689	1011	1012	O
or	32876689	1013	1015	O
placebo	32876689	1016	1023	B-Intervention
(	32876689	1024	1025	O
n	32876689	1026	1027	O
=	32876689	1030	1031	O
73	32876689	1034	1036	O
)	32876689	1037	1038	O
.	32876689	1039	1040	O

The	32876689	1041	1044	O
primary	32876689	1045	1052	O
outcome	32876689	1053	1060	O
,	32876689	1061	1062	O
treatment	32876689	1063	1072	B-Outcome
failure	32876689	1073	1080	I-Outcome
on	32876689	1081	1083	I-Outcome
day	32876689	1084	1087	I-Outcome
21	32876689	1088	1090	I-Outcome
,	32876689	1091	1092	O
was	32876689	1093	1096	O
defined	32876689	1097	1104	O
as	32876689	1105	1107	O
death	32876689	1108	1113	O
or	32876689	1114	1116	O
persistent	32876689	1117	1127	O
dependency	32876689	1128	1138	O
on	32876689	1139	1141	O
mechanical	32876689	1142	1152	O
ventilation	32876689	1153	1164	O
or	32876689	1165	1167	O
high	32876689	1168	1172	O
-	32876689	1173	1174	O
flow	32876689	1175	1179	O
oxygen	32876689	1180	1186	O
therapy	32876689	1187	1194	O
.	32876689	1195	1196	O

Prespecified	32876689	1197	1209	O
secondary	32876689	1210	1219	O
outcomes	32876689	1220	1228	O
included	32876689	1229	1237	O
the	32876689	1238	1241	O
need	32876689	1242	1246	B-Outcome
for	32876689	1247	1250	I-Outcome
tracheal	32876689	1251	1259	I-Outcome
intubation	32876689	1260	1270	I-Outcome
(	32876689	1271	1272	O
among	32876689	1273	1278	O
patients	32876689	1279	1287	O
not	32876689	1288	1291	O
intubated	32876689	1292	1301	O
at	32876689	1302	1304	O
baseline	32876689	1305	1313	O
)	32876689	1314	1315	O
;	32876689	1316	1317	O
cumulative	32876689	1318	1328	B-Outcome
incidences	32876689	1329	1339	I-Outcome
(	32876689	1340	1341	O
until	32876689	1342	1347	O
day	32876689	1348	1351	O
21	32876689	1352	1354	O
)	32876689	1355	1356	O
of	32876689	1357	1359	O
prone	32876689	1360	1365	O
position	32876689	1366	1374	O
sessions	32876689	1375	1383	O
,	32876689	1384	1385	O
extracorporeal	32876689	1386	1400	B-Outcome
membrane	32876689	1401	1409	I-Outcome
oxygenation	32876689	1410	1421	I-Outcome
,	32876689	1422	1423	O
and	32876689	1424	1427	O
inhaled	32876689	1428	1435	B-Outcome
nitric	32876689	1436	1442	I-Outcome
oxide	32876689	1443	1448	I-Outcome
;	32876689	1449	1450	O
Pao2	32876689	1451	1455	B-Outcome
:	32876689	1456	1457	I-Outcome
Fio2	32876689	1458	1462	I-Outcome
ratio	32876689	1463	1468	O
measured	32876689	1469	1477	O
daily	32876689	1478	1483	O
from	32876689	1484	1488	O
day	32876689	1489	1492	O
1	32876689	1493	1494	O
to	32876689	1495	1497	O
day	32876689	1498	1501	O
7	32876689	1502	1503	O
,	32876689	1504	1505	O
then	32876689	1506	1510	O
on	32876689	1511	1513	O
days	32876689	1514	1518	O
14	32876689	1519	1521	O
and	32876689	1522	1525	O
21	32876689	1526	1528	O
;	32876689	1529	1530	O
and	32876689	1531	1534	O
the	32876689	1535	1538	O
proportion	32876689	1539	1549	B-Outcome
of	32876689	1550	1552	I-Outcome
patients	32876689	1553	1561	I-Outcome
with	32876689	1562	1566	I-Outcome
secondary	32876689	1567	1576	I-Outcome
infections	32876689	1577	1587	I-Outcome
during	32876689	1588	1594	I-Outcome
their	32876689	1595	1600	I-Outcome
ICU	32876689	1601	1604	I-Outcome
stay	32876689	1605	1609	I-Outcome
.	32876689	1610	1611	O

The	32876689	1612	1615	O
study	32876689	1616	1621	O
was	32876689	1622	1625	O
stopped	32876689	1626	1633	O
after	32876689	1634	1639	O
149	32876689	1640	1643	O
patients	32876689	1644	1652	O
(	32876689	1653	1654	O
mean	32876689	1655	1659	O
age	32876689	1660	1663	O
,	32876689	1664	1665	O
62.2	32876689	1666	1670	O
years	32876689	1671	1676	O
;	32876689	1677	1678	O
30.2	32876689	1679	1683	O
%	32876689	1684	1685	O
women	32876689	1686	1691	O
;	32876689	1692	1693	O
81.2	32876689	1694	1698	O
%	32876689	1699	1700	O
mechanically	32876689	1701	1713	O
ventilated	32876689	1714	1724	O
)	32876689	1725	1726	O
were	32876689	1727	1731	O
enrolled	32876689	1732	1740	O
.	32876689	1741	1742	O

One	32876689	1743	1746	O
hundred	32876689	1747	1754	O
forty	32876689	1755	1760	O
-	32876689	1761	1762	O
eight	32876689	1763	1768	O
patients	32876689	1769	1777	O
(	32876689	1778	1779	O
99.3	32876689	1780	1784	O
%	32876689	1785	1786	O
)	32876689	1787	1788	O
completed	32876689	1789	1798	O
the	32876689	1799	1802	O
study	32876689	1803	1808	O
,	32876689	1809	1810	O
and	32876689	1811	1814	O
there	32876689	1815	1820	O
were	32876689	1821	1825	O
69	32876689	1826	1828	B-Count
treatment	32876689	1829	1838	B-Outcome
failure	32876689	1839	1846	I-Outcome
events	32876689	1847	1853	I-Outcome
,	32876689	1854	1855	O
including	32876689	1856	1865	O
11	32876689	1866	1868	B-Count
deaths	32876689	1869	1875	B-Outcome
in	32876689	1876	1878	O
the	32876689	1879	1882	O
hydrocortisone	32876689	1883	1897	B-Intervention
group	32876689	1898	1903	O
and	32876689	1904	1907	O
20	32876689	1908	1910	B-Count
deaths	32876689	1911	1917	B-Outcome
in	32876689	1918	1920	O
the	32876689	1921	1924	O
placebo	32876689	1925	1932	B-Intervention
group	32876689	1933	1938	O
.	32876689	1939	1940	O

The	32876689	1941	1944	O
primary	32876689	1945	1952	O
outcome	32876689	1953	1960	O
,	32876689	1961	1962	O
treatment	32876689	1963	1972	B-Outcome
failure	32876689	1973	1980	I-Outcome
on	32876689	1981	1983	I-Outcome
day	32876689	1984	1987	I-Outcome
21	32876689	1988	1990	I-Outcome
,	32876689	1991	1992	O
occurred	32876689	1993	2001	O
in	32876689	2002	2004	O
32	32876689	2005	2007	B-Count
of	32876689	2008	2010	I-Count
76	32876689	2011	2013	I-Count
patients	32876689	2014	2022	I-Count
(	32876689	2023	2024	I-Count
42.1	32876689	2025	2029	I-Count
%	32876689	2030	2031	I-Count
)	32876689	2032	2033	I-Count
in	32876689	2034	2036	O
the	32876689	2037	2040	O
hydrocortisone	32876689	2041	2055	B-Intervention
group	32876689	2056	2061	O
compared	32876689	2062	2070	O
with	32876689	2071	2075	O
37	32876689	2076	2078	B-Count
of	32876689	2079	2081	I-Count
73	32876689	2082	2084	I-Count
(	32876689	2085	2086	I-Count
50.7	32876689	2087	2091	I-Count
%	32876689	2092	2093	I-Count
)	32876689	2094	2095	I-Count
in	32876689	2096	2098	O
the	32876689	2099	2102	O
placebo	32876689	2103	2110	B-Intervention
group	32876689	2111	2116	O
(	32876689	2117	2118	O
difference	32876689	2119	2129	O
of	32876689	2130	2132	O
proportions	32876689	2133	2144	O
,	32876689	2145	2146	O
-8.6	32876689	2147	2151	O
%	32876689	2152	2153	O
[	32876689	2154	2155	O
95.48	32876689	2156	2161	O
%	32876689	2162	2163	O
CI	32876689	2164	2166	O
,	32876689	2167	2168	O
-24.9	32876689	2169	2174	O
%	32876689	2175	2176	O
to	32876689	2177	2179	O
7.7	32876689	2180	2183	O
%	32876689	2184	2185	O
]	32876689	2186	2187	O
;	32876689	2188	2189	O
P	32876689	2190	2191	O
=	32876689	2194	2195	O
.29	32876689	2198	2201	O
)	32876689	2202	2203	O
.	32876689	2204	2205	O

Of	32876689	2206	2208	O
the	32876689	2209	2212	O
4	32876689	2213	2214	B-Outcome
prespecified	32876689	2215	2227	I-Outcome
secondary	32876689	2228	2237	I-Outcome
outcomes	32876689	2238	2246	I-Outcome
,	32876689	2247	2248	O
none	32876689	2249	2253	O
showed	32876689	2254	2260	O
a	32876689	2261	2262	O
significant	32876689	2263	2274	B-Observation
difference	32876689	2275	2285	I-Observation
.	32876689	2286	2287	O

No	32876689	2288	2290	B-Count
serious	32876689	2291	2298	B-Outcome
adverse	32876689	2299	2306	I-Outcome
events	32876689	2307	2313	I-Outcome
were	32876689	2314	2318	O
related	32876689	2319	2326	O
to	32876689	2327	2329	O
the	32876689	2330	2333	O
study	32876689	2334	2339	O
treatment	32876689	2340	2349	O
.	32876689	2350	2351	O

In	32876689	2352	2354	O
this	32876689	2355	2359	O
study	32876689	2360	2365	O
of	32876689	2366	2368	O
critically	32876689	2369	2379	B-Participant
ill	32876689	2380	2383	I-Participant
patients	32876689	2384	2392	O
with	32876689	2393	2397	O
COVID-19	32876689	2398	2406	B-Participant
and	32876689	2407	2410	O
acute	32876689	2411	2416	B-Participant
respiratory	32876689	2417	2428	I-Participant
failure	32876689	2429	2436	I-Participant
,	32876689	2437	2438	O
low	32876689	2439	2442	B-Participant
-	32876689	2443	2444	I-Participant
dose	32876689	2445	2449	I-Participant
hydrocortisone	32876689	2450	2464	I-Participant
,	32876689	2465	2466	O
compared	32876689	2467	2475	O
with	32876689	2476	2480	O
placebo	32876689	2481	2488	B-Intervention
,	32876689	2489	2490	O
did	32876689	2491	2494	O
not	32876689	2495	2498	O
significantly	32876689	2499	2512	B-Observation
reduce	32876689	2513	2519	I-Observation
treatment	32876689	2520	2529	B-Outcome
failure	32876689	2530	2537	I-Outcome
(	32876689	2538	2539	I-Outcome
defined	32876689	2540	2547	I-Outcome
as	32876689	2548	2550	I-Outcome
death	32876689	2551	2556	I-Outcome
or	32876689	2557	2559	I-Outcome
persistent	32876689	2560	2570	I-Outcome
respiratory	32876689	2571	2582	I-Outcome
support	32876689	2583	2590	I-Outcome
)	32876689	2591	2592	I-Outcome
at	32876689	2593	2595	I-Outcome
day	32876689	2596	2599	I-Outcome
21	32876689	2600	2602	I-Outcome
.	32876689	2603	2604	O

However	32876689	2605	2612	O
,	32876689	2613	2614	O
the	32876689	2615	2618	O
study	32876689	2619	2624	O
was	32876689	2625	2628	O
stopped	32876689	2629	2636	O
early	32876689	2637	2642	O
and	32876689	2643	2646	O
likely	32876689	2647	2653	O
was	32876689	2654	2657	O
underpowered	32876689	2658	2670	O
to	32876689	2671	2673	O
find	32876689	2674	2678	O
a	32876689	2679	2680	O
statistically	32876689	2681	2694	O
and	32876689	2695	2698	O
clinically	32876689	2699	2709	O
important	32876689	2710	2719	O
difference	32876689	2720	2730	O
in	32876689	2731	2733	O
the	32876689	2734	2737	O
primary	32876689	2738	2745	O
outcome	32876689	2746	2753	O
.	32876689	2754	2755	O

ClinicalTrials.gov	32876689	2756	2774	O
Identifier	32876689	2775	2785	O
:	32876689	2786	2787	O
NCT02517489	32876689	2788	2799	O
.	32876689	2800	2801	O


Effect	32876695	0	6	O
of	32876695	7	9	O
Dexamethasone	32876695	10	23	B-Intervention
on	32876695	24	26	O
Days	32876695	27	31	B-Outcome
Alive	32876695	32	37	I-Outcome
and	32876695	38	41	O
Ventilator	32876695	42	52	B-Outcome
-	32876695	53	54	I-Outcome
Free	32876695	55	59	I-Outcome
in	32876695	60	62	O
Patients	32876695	63	71	O
With	32876695	72	76	O
Moderate	32876695	77	85	B-Participant
or	32876695	86	88	I-Participant
Severe	32876695	89	95	I-Participant
Acute	32876695	96	101	I-Participant
Respiratory	32876695	102	113	I-Participant
Distress	32876695	114	122	I-Participant
Syndrome	32876695	123	131	I-Participant
and	32876695	132	135	O
COVID-19	32876695	136	144	B-Participant
:	32876695	145	146	O
The	32876695	147	150	O
CoDEX	32876695	151	156	O
Randomized	32876695	157	167	O
Clinical	32876695	168	176	O
Trial	32876695	177	182	O
.	32876695	183	184	O

Acute	32876695	185	190	O
respiratory	32876695	191	202	O
distress	32876695	203	211	O
syndrome	32876695	212	220	O
(	32876695	221	222	O
ARDS	32876695	223	227	O
)	32876695	228	229	O
due	32876695	230	233	O
to	32876695	234	236	O
coronavirus	32876695	237	248	O
disease	32876695	249	256	O
2019	32876695	257	261	O
(	32876695	262	263	O
COVID-19	32876695	264	272	O
)	32876695	273	274	O
is	32876695	275	277	O
associated	32876695	278	288	O
with	32876695	289	293	O
substantial	32876695	294	305	O
mortality	32876695	306	315	O
and	32876695	316	319	O
use	32876695	320	323	O
of	32876695	324	326	O
health	32876695	327	333	O
care	32876695	334	338	O
resources	32876695	339	348	O
.	32876695	349	350	O

Dexamethasone	32876695	351	364	O
use	32876695	365	368	O
might	32876695	369	374	O
attenuate	32876695	375	384	O
lung	32876695	385	389	O
injury	32876695	390	396	O
in	32876695	397	399	O
these	32876695	400	405	O
patients	32876695	406	414	O
.	32876695	415	416	O

To	32876695	417	419	O
determine	32876695	420	429	O
whether	32876695	430	437	O
intravenous	32876695	438	449	B-Intervention
dexamethasone	32876695	450	463	I-Intervention
increases	32876695	464	473	B-Observation
the	32876695	474	477	O
number	32876695	478	484	B-Outcome
of	32876695	485	487	I-Outcome
ventilator	32876695	488	498	I-Outcome
-	32876695	499	500	I-Outcome
free	32876695	501	505	I-Outcome
days	32876695	506	510	I-Outcome
among	32876695	511	516	O
patients	32876695	517	525	O
with	32876695	526	530	O
COVID-19-associated	32876695	531	550	B-Participant
ARDS	32876695	551	555	I-Participant
.	32876695	556	557	O

Multicenter	32876695	558	569	O
,	32876695	570	571	O
randomized	32876695	572	582	O
,	32876695	583	584	O
open	32876695	585	589	O
-	32876695	590	591	O
label	32876695	592	597	O
,	32876695	598	599	O
clinical	32876695	600	608	O
trial	32876695	609	614	O
conducted	32876695	615	624	O
in	32876695	625	627	O
41	32876695	628	630	O
intensive	32876695	631	640	O
care	32876695	641	645	O
units	32876695	646	651	O
(	32876695	652	653	O
ICUs	32876695	654	658	O
)	32876695	659	660	O
in	32876695	661	663	O
Brazil	32876695	664	670	O
.	32876695	671	672	O

Patients	32876695	673	681	O
with	32876695	682	686	O
COVID-19	32876695	687	695	B-Participant
and	32876695	696	699	O
moderate	32876695	700	708	B-Participant
to	32876695	709	711	I-Participant
severe	32876695	712	718	I-Participant
ARDS	32876695	719	723	I-Participant
,	32876695	724	725	O
according	32876695	726	735	O
to	32876695	736	738	O
the	32876695	739	742	O
Berlin	32876695	743	749	O
definition	32876695	750	760	O
,	32876695	761	762	O
were	32876695	763	767	O
enrolled	32876695	768	776	O
from	32876695	777	781	O
April	32876695	782	787	O
17	32876695	788	790	O
to	32876695	791	793	O
June	32876695	794	798	O
23	32876695	799	801	O
,	32876695	802	803	O
2020	32876695	804	808	O
.	32876695	809	810	O

Final	32876695	811	816	O
follow	32876695	817	823	O
-	32876695	824	825	O
up	32876695	826	828	O
was	32876695	829	832	O
completed	32876695	833	842	O
on	32876695	843	845	O
July	32876695	846	850	O
21	32876695	851	853	O
,	32876695	854	855	O
2020	32876695	856	860	O
.	32876695	861	862	O

The	32876695	863	866	O
trial	32876695	867	872	O
was	32876695	873	876	O
stopped	32876695	877	884	O
early	32876695	885	890	O
following	32876695	891	900	O
publication	32876695	901	912	O
of	32876695	913	915	O
a	32876695	916	917	O
related	32876695	918	925	O
study	32876695	926	931	O
before	32876695	932	938	O
reaching	32876695	939	947	O
the	32876695	948	951	O
planned	32876695	952	959	O
sample	32876695	960	966	O
size	32876695	967	971	O
of	32876695	972	974	O
350	32876695	975	978	O
patients	32876695	979	987	O
.	32876695	988	989	O

Twenty	32876695	990	996	O
mg	32876695	997	999	O
of	32876695	1000	1002	O
dexamethasone	32876695	1003	1016	B-Intervention
intravenously	32876695	1017	1030	O
daily	32876695	1031	1036	O
for	32876695	1037	1040	O
5	32876695	1041	1042	O
days	32876695	1043	1047	O
,	32876695	1048	1049	O
10	32876695	1050	1052	O
mg	32876695	1053	1055	O
of	32876695	1056	1058	O
dexamethasone	32876695	1059	1072	B-Intervention
daily	32876695	1073	1078	O
for	32876695	1079	1082	O
5	32876695	1083	1084	O
days	32876695	1085	1089	O
or	32876695	1090	1092	O
until	32876695	1093	1098	O
ICU	32876695	1099	1102	O
discharge	32876695	1103	1112	O
,	32876695	1113	1114	O
plus	32876695	1115	1119	O
standard	32876695	1120	1128	O
care	32876695	1129	1133	O
(	32876695	1134	1135	O
n	32876695	1136	1137	O
=	32876695	1140	1141	O
151	32876695	1142	1145	O
)	32876695	1146	1147	O
or	32876695	1148	1150	O
standard	32876695	1151	1159	B-Intervention
care	32876695	1160	1164	I-Intervention
alone	32876695	1165	1170	I-Intervention
(	32876695	1171	1172	O
n	32876695	1173	1174	O
=	32876695	1177	1178	O
148	32876695	1181	1184	O
)	32876695	1185	1186	O
.	32876695	1187	1188	O

The	32876695	1189	1192	O
primary	32876695	1193	1200	O
outcome	32876695	1201	1208	O
was	32876695	1209	1212	O
ventilator	32876695	1213	1223	B-Outcome
-	32876695	1224	1225	I-Outcome
free	32876695	1226	1230	I-Outcome
days	32876695	1231	1235	I-Outcome
during	32876695	1236	1242	I-Outcome
the	32876695	1243	1246	I-Outcome
first	32876695	1247	1252	I-Outcome
28	32876695	1253	1255	I-Outcome
days	32876695	1256	1260	I-Outcome
,	32876695	1261	1262	O
defined	32876695	1263	1270	O
as	32876695	1271	1273	O
being	32876695	1274	1279	O
alive	32876695	1280	1285	O
and	32876695	1286	1289	O
free	32876695	1290	1294	O
from	32876695	1295	1299	O
mechanical	32876695	1300	1310	O
ventilation	32876695	1311	1322	O
.	32876695	1323	1324	O

Secondary	32876695	1325	1334	O
outcomes	32876695	1335	1343	O
were	32876695	1344	1348	O
all	32876695	1349	1352	B-Outcome
-	32876695	1353	1354	I-Outcome
cause	32876695	1355	1360	I-Outcome
mortality	32876695	1361	1370	I-Outcome
at	32876695	1371	1373	I-Outcome
28	32876695	1374	1376	I-Outcome
days	32876695	1377	1381	I-Outcome
,	32876695	1382	1383	O
clinical	32876695	1384	1392	B-Outcome
status	32876695	1393	1399	I-Outcome
of	32876695	1400	1402	I-Outcome
patients	32876695	1403	1411	I-Outcome
at	32876695	1412	1414	I-Outcome
day	32876695	1415	1418	I-Outcome
15	32876695	1419	1421	I-Outcome
using	32876695	1422	1427	O
a	32876695	1428	1429	O
6-point	32876695	1430	1437	O
ordinal	32876695	1438	1445	O
scale	32876695	1446	1451	O
(	32876695	1452	1453	O
ranging	32876695	1454	1461	O
from	32876695	1462	1466	O
1	32876695	1467	1468	O
,	32876695	1469	1470	O
not	32876695	1471	1474	O
hospitalized	32876695	1475	1487	O
to	32876695	1488	1490	O
6	32876695	1491	1492	O
,	32876695	1493	1494	O
death	32876695	1495	1500	O
)	32876695	1501	1502	O
,	32876695	1503	1504	O
ICU	32876695	1505	1508	B-Outcome
-	32876695	1509	1510	I-Outcome
free	32876695	1511	1515	I-Outcome
days	32876695	1516	1520	I-Outcome
during	32876695	1521	1527	I-Outcome
the	32876695	1528	1531	I-Outcome
first	32876695	1532	1537	I-Outcome
28	32876695	1538	1540	I-Outcome
days	32876695	1541	1545	I-Outcome
,	32876695	1546	1547	O
mechanical	32876695	1548	1558	B-Outcome
ventilation	32876695	1559	1570	I-Outcome
duration	32876695	1571	1579	I-Outcome
at	32876695	1580	1582	I-Outcome
28	32876695	1583	1585	I-Outcome
days	32876695	1586	1590	I-Outcome
,	32876695	1591	1592	O
and	32876695	1593	1596	O
Sequential	32876695	1597	1607	B-Outcome
Organ	32876695	1608	1613	I-Outcome
Failure	32876695	1614	1621	I-Outcome
Assessment	32876695	1622	1632	I-Outcome
(	32876695	1633	1634	I-Outcome
SOFA	32876695	1635	1639	I-Outcome
)	32876695	1640	1641	I-Outcome
scores	32876695	1642	1648	I-Outcome
(	32876695	1649	1650	O
range	32876695	1651	1656	O
,	32876695	1657	1658	O
0	32876695	1659	1660	O
-	32876695	1661	1662	O
24	32876695	1663	1665	O
,	32876695	1666	1667	O
with	32876695	1668	1672	O
higher	32876695	1673	1679	O
scores	32876695	1680	1686	O
indicating	32876695	1687	1697	O
greater	32876695	1698	1705	O
organ	32876695	1706	1711	O
dysfunction	32876695	1712	1723	O
)	32876695	1724	1725	O
at	32876695	1726	1728	O
48	32876695	1729	1731	O
hours	32876695	1732	1737	O
,	32876695	1738	1739	O
72	32876695	1740	1742	O
hours	32876695	1743	1748	O
,	32876695	1749	1750	O
and	32876695	1751	1754	O
7	32876695	1755	1756	O
days	32876695	1757	1761	O
.	32876695	1762	1763	O

A	32876695	1764	1765	O
total	32876695	1766	1771	O
of	32876695	1772	1774	O
299	32876695	1775	1778	O
patients	32876695	1779	1787	O
(	32876695	1788	1789	O
mean	32876695	1790	1794	O
[	32876695	1795	1796	O
SD	32876695	1797	1799	O
]	32876695	1800	1801	O
age	32876695	1802	1805	O
,	32876695	1806	1807	O
61	32876695	1808	1810	O
[	32876695	1811	1812	O
14	32876695	1813	1815	O
]	32876695	1816	1817	O
years	32876695	1818	1823	O
;	32876695	1824	1825	O
37	32876695	1826	1828	O
%	32876695	1829	1830	O
women	32876695	1831	1836	O
)	32876695	1837	1838	O
were	32876695	1839	1843	O
enrolled	32876695	1844	1852	O
and	32876695	1853	1856	O
all	32876695	1857	1860	O
completed	32876695	1861	1870	O
follow	32876695	1871	1877	O
-	32876695	1878	1879	O
up	32876695	1880	1882	O
.	32876695	1883	1884	O

Patients	32876695	1885	1893	O
randomized	32876695	1894	1904	O
to	32876695	1905	1907	O
the	32876695	1908	1911	O
dexamethasone	32876695	1912	1925	B-Intervention
group	32876695	1926	1931	O
had	32876695	1932	1935	O
a	32876695	1936	1937	O
mean	32876695	1938	1942	B-Observation
6.6	32876695	1943	1946	I-Observation
ventilator	32876695	1947	1957	B-Outcome
-	32876695	1958	1959	I-Outcome
free	32876695	1960	1964	I-Outcome
days	32876695	1965	1969	I-Outcome
(	32876695	1970	1971	O
95	32876695	1972	1974	O
%	32876695	1975	1976	O
CI	32876695	1977	1979	O
,	32876695	1980	1981	O
5.0	32876695	1982	1985	O
-	32876695	1986	1987	O
8.2	32876695	1988	1991	O
)	32876695	1992	1993	O
during	32876695	1994	2000	O
the	32876695	2001	2004	O
first	32876695	2005	2010	O
28	32876695	2011	2013	O
days	32876695	2014	2018	O
vs	32876695	2019	2021	O
4.0	32876695	2022	2025	B-Observation
ventilator	32876695	2026	2036	B-Outcome
-	32876695	2037	2038	I-Outcome
free	32876695	2039	2043	I-Outcome
days	32876695	2044	2048	I-Outcome
(	32876695	2049	2050	O
95	32876695	2051	2053	O
%	32876695	2054	2055	O
CI	32876695	2056	2058	O
,	32876695	2059	2060	O
2.9	32876695	2061	2064	O
-	32876695	2065	2066	O
5.4	32876695	2067	2070	O
)	32876695	2071	2072	O
in	32876695	2073	2075	O
the	32876695	2076	2079	O
standard	32876695	2080	2088	B-Intervention
care	32876695	2089	2093	I-Intervention
group	32876695	2094	2099	O
(	32876695	2100	2101	O
difference	32876695	2102	2112	O
,	32876695	2113	2114	O
2.26	32876695	2115	2119	O
;	32876695	2120	2121	O
95	32876695	2122	2124	O
%	32876695	2125	2126	O
CI	32876695	2127	2129	O
,	32876695	2130	2131	O
0.2	32876695	2132	2135	O
-	32876695	2136	2137	O
4.38	32876695	2138	2142	O
;	32876695	2143	2144	O
P	32876695	2145	2146	O
=	32876695	2149	2150	O
.04	32876695	2153	2156	O
)	32876695	2157	2158	O
.	32876695	2159	2160	O

At	32876695	2161	2163	O
7	32876695	2164	2165	O
days	32876695	2166	2170	O
,	32876695	2171	2172	O
patients	32876695	2173	2181	O
in	32876695	2182	2184	O
the	32876695	2185	2188	O
dexamethasone	32876695	2189	2202	B-Intervention
group	32876695	2203	2208	O
had	32876695	2209	2212	O
a	32876695	2213	2214	O
mean	32876695	2215	2219	B-Outcome
SOFA	32876695	2220	2224	I-Outcome
score	32876695	2225	2230	I-Outcome
of	32876695	2231	2233	O
6.1	32876695	2234	2237	B-Observation
(	32876695	2238	2239	O
95	32876695	2240	2242	O
%	32876695	2243	2244	O
CI	32876695	2245	2247	O
,	32876695	2248	2249	O
5.5	32876695	2250	2253	O
-	32876695	2254	2255	O
6.7	32876695	2256	2259	O
)	32876695	2260	2261	O
vs	32876695	2262	2264	O
7.5	32876695	2265	2268	B-Observation
(	32876695	2269	2270	O
95	32876695	2271	2273	O
%	32876695	2274	2275	O
CI	32876695	2276	2278	O
,	32876695	2279	2280	O
6.9	32876695	2281	2284	O
-	32876695	2285	2286	O
8.1	32876695	2287	2290	O
)	32876695	2291	2292	O
in	32876695	2293	2295	O
the	32876695	2296	2299	O
standard	32876695	2300	2308	B-Intervention
care	32876695	2309	2313	I-Intervention
group	32876695	2314	2319	O
(	32876695	2320	2321	O
difference	32876695	2322	2332	O
,	32876695	2333	2334	O
-1.16	32876695	2335	2340	O
;	32876695	2341	2342	O
95	32876695	2343	2345	O
%	32876695	2346	2347	O
CI	32876695	2348	2350	O
,	32876695	2351	2352	O
-1.94	32876695	2353	2358	O
to	32876695	2359	2361	O
-0.38	32876695	2362	2367	O
;	32876695	2368	2369	O
P	32876695	2370	2371	O
=	32876695	2372	2373	O
.004	32876695	2374	2378	O
)	32876695	2379	2380	O
.	32876695	2381	2382	O

There	32876695	2383	2388	O
was	32876695	2389	2392	O
no	32876695	2393	2395	O
significant	32876695	2396	2407	B-Observation
difference	32876695	2408	2418	I-Observation
in	32876695	2419	2421	O
the	32876695	2422	2425	O
prespecified	32876695	2426	2438	O
secondary	32876695	2439	2448	O
outcomes	32876695	2449	2457	O
of	32876695	2458	2460	O
all	32876695	2461	2464	B-Outcome
-	32876695	2465	2466	I-Outcome
cause	32876695	2467	2472	I-Outcome
mortality	32876695	2473	2482	I-Outcome
at	32876695	2483	2485	I-Outcome
28	32876695	2486	2488	I-Outcome
days	32876695	2489	2493	I-Outcome
,	32876695	2494	2495	O
ICU	32876695	2496	2499	B-Outcome
-	32876695	2500	2501	I-Outcome
free	32876695	2502	2506	I-Outcome
days	32876695	2507	2511	I-Outcome
during	32876695	2512	2518	I-Outcome
the	32876695	2519	2522	I-Outcome
first	32876695	2523	2528	I-Outcome
28	32876695	2529	2531	I-Outcome
days	32876695	2532	2536	I-Outcome
,	32876695	2537	2538	O
mechanical	32876695	2539	2549	B-Outcome
ventilation	32876695	2550	2561	I-Outcome
duration	32876695	2562	2570	I-Outcome
at	32876695	2571	2573	I-Outcome
28	32876695	2574	2576	I-Outcome
days	32876695	2577	2581	I-Outcome
,	32876695	2582	2583	O
or	32876695	2584	2586	O
the	32876695	2587	2590	O
6-point	32876695	2591	2598	B-Outcome
ordinal	32876695	2599	2606	I-Outcome
scale	32876695	2607	2612	I-Outcome
at	32876695	2613	2615	I-Outcome
15	32876695	2616	2618	I-Outcome
days	32876695	2619	2623	I-Outcome
.	32876695	2624	2625	O

Thirty	32876695	2626	2632	B-Count
-	32876695	2633	2634	I-Count
three	32876695	2635	2640	I-Count
patients	32876695	2641	2649	I-Count
(	32876695	2650	2651	I-Count
21.9	32876695	2652	2656	I-Count
%	32876695	2657	2658	I-Count
)	32876695	2659	2660	I-Count
in	32876695	2661	2663	O
the	32876695	2664	2667	O
dexamethasone	32876695	2668	2681	B-Intervention
group	32876695	2682	2687	O
vs	32876695	2688	2690	O
43	32876695	2691	2693	B-Count
(	32876695	2694	2695	I-Count
29.1	32876695	2696	2700	I-Count
%	32876695	2701	2702	I-Count
)	32876695	2703	2704	I-Count
in	32876695	2705	2707	O
the	32876695	2708	2711	O
standard	32876695	2712	2720	B-Intervention
care	32876695	2721	2725	I-Intervention
group	32876695	2726	2731	O
experienced	32876695	2732	2743	O
secondary	32876695	2744	2753	B-Outcome
infections	32876695	2754	2764	I-Outcome
,	32876695	2765	2766	O
47	32876695	2767	2769	B-Count
(	32876695	2770	2771	I-Count
31.1	32876695	2772	2776	I-Count
%	32876695	2777	2778	I-Count
)	32876695	2779	2780	I-Count
vs	32876695	2781	2783	O
42	32876695	2784	2786	B-Count
(	32876695	2787	2788	I-Count
28.3	32876695	2789	2793	I-Count
%	32876695	2794	2795	I-Count
)	32876695	2796	2797	I-Count
needed	32876695	2798	2804	O
insulin	32876695	2805	2812	B-Outcome
for	32876695	2813	2816	I-Outcome
glucose	32876695	2817	2824	I-Outcome
control	32876695	2825	2832	I-Outcome
,	32876695	2833	2834	O
and	32876695	2835	2838	O
5	32876695	2839	2840	B-Count
(	32876695	2841	2842	I-Count
3.3	32876695	2843	2846	I-Count
%	32876695	2847	2848	I-Count
)	32876695	2849	2850	I-Count
vs	32876695	2851	2853	O
9	32876695	2854	2855	B-Count
(	32876695	2856	2857	I-Count
6.1	32876695	2858	2861	I-Count
%	32876695	2862	2863	I-Count
)	32876695	2864	2865	I-Count
experienced	32876695	2866	2877	O
other	32876695	2878	2883	B-Outcome
serious	32876695	2884	2891	I-Outcome
adverse	32876695	2892	2899	I-Outcome
events	32876695	2900	2906	I-Outcome
.	32876695	2907	2908	O

Among	32876695	2909	2914	O
patients	32876695	2915	2923	O
with	32876695	2924	2928	O
COVID-19	32876695	2929	2937	B-Participant
and	32876695	2938	2941	O
moderate	32876695	2942	2950	B-Participant
or	32876695	2951	2953	I-Participant
severe	32876695	2954	2960	I-Participant
ARDS	32876695	2961	2965	I-Participant
,	32876695	2966	2967	O
use	32876695	2968	2971	O
of	32876695	2972	2974	O
intravenous	32876695	2975	2986	B-Intervention
dexamethasone	32876695	2987	3000	I-Intervention
plus	32876695	3001	3005	I-Intervention
standard	32876695	3006	3014	I-Intervention
care	32876695	3015	3019	I-Intervention
compared	32876695	3020	3028	O
with	32876695	3029	3033	O
standard	32876695	3034	3042	B-Intervention
care	32876695	3043	3047	I-Intervention
alone	32876695	3048	3053	I-Intervention
resulted	32876695	3054	3062	O
in	32876695	3063	3065	O
a	32876695	3066	3067	O
statistically	32876695	3068	3081	B-Observation
significant	32876695	3082	3093	I-Observation
increase	32876695	3094	3102	I-Observation
in	32876695	3103	3105	O
the	32876695	3106	3109	O
number	32876695	3110	3116	B-Outcome
of	32876695	3117	3119	I-Outcome
ventilator	32876695	3120	3130	I-Outcome
-	32876695	3131	3132	I-Outcome
free	32876695	3133	3137	I-Outcome
days	32876695	3138	3142	I-Outcome
(	32876695	3143	3144	I-Outcome
days	32876695	3145	3149	I-Outcome
alive	32876695	3150	3155	I-Outcome
and	32876695	3156	3159	I-Outcome
free	32876695	3160	3164	I-Outcome
of	32876695	3165	3167	I-Outcome
mechanical	32876695	3168	3178	I-Outcome
ventilation	32876695	3179	3190	I-Outcome
)	32876695	3191	3192	I-Outcome
over	32876695	3193	3197	I-Outcome
28	32876695	3198	3200	I-Outcome
days	32876695	3201	3205	I-Outcome
.	32876695	3206	3207	O

ClinicalTrials.gov	32876695	3208	3226	O
Identifier	32876695	3227	3237	O
:	32876695	3238	3239	O
NCT04327401	32876695	3240	3251	O
.	32876695	3252	3253	O


Effect	32876697	0	6	O
of	32876697	7	9	O
Hydrocortisone	32876697	10	24	O
on	32876697	25	27	O
Mortality	32876697	28	37	O
and	32876697	38	41	O
Organ	32876697	42	47	O
Support	32876697	48	55	O
in	32876697	56	58	O
Patients	32876697	59	67	O
With	32876697	68	72	O
Severe	32876697	73	79	O
COVID-19	32876697	80	88	O
:	32876697	89	90	O
The	32876697	91	94	O
REMAP	32876697	95	100	O
-	32876697	101	102	O
CAP	32876697	103	106	O
COVID-19	32876697	107	115	O
Corticosteroid	32876697	116	130	O
Domain	32876697	131	137	O
Randomized	32876697	138	148	O
Clinical	32876697	149	157	O
Trial	32876697	158	163	O
.	32876697	164	165	O

Evidence	32876697	166	174	O
regarding	32876697	175	184	O
corticosteroid	32876697	185	199	O
use	32876697	200	203	O
for	32876697	204	207	O
severe	32876697	208	214	O
coronavirus	32876697	215	226	O
disease	32876697	227	234	O
2019	32876697	235	239	O
(	32876697	240	241	O
COVID-19	32876697	242	250	O
)	32876697	251	252	O
is	32876697	253	255	O
limited	32876697	256	263	O
.	32876697	264	265	O

To	32876697	266	268	O
determine	32876697	269	278	O
whether	32876697	279	286	O
hydrocortisone	32876697	287	301	O
improves	32876697	302	310	O
outcome	32876697	311	318	O
for	32876697	319	322	O
patients	32876697	323	331	O
with	32876697	332	336	O
severe	32876697	337	343	O
COVID-19	32876697	344	352	O
.	32876697	353	354	O

An	32876697	355	357	O
ongoing	32876697	358	365	O
adaptive	32876697	366	374	O
platform	32876697	375	383	O
trial	32876697	384	389	O
testing	32876697	390	397	O
multiple	32876697	398	406	O
interventions	32876697	407	420	O
within	32876697	421	427	O
multiple	32876697	428	436	O
therapeutic	32876697	437	448	O
domains	32876697	449	456	O
,	32876697	457	458	O
for	32876697	459	462	O
example	32876697	463	470	O
,	32876697	471	472	O
antiviral	32876697	473	482	O
agents	32876697	483	489	O
,	32876697	490	491	O
corticosteroids	32876697	492	507	O
,	32876697	508	509	O
or	32876697	510	512	O
immunoglobulin	32876697	513	527	O
.	32876697	528	529	O

Between	32876697	530	537	O
March	32876697	538	543	O
9	32876697	544	545	O
and	32876697	546	549	O
June	32876697	550	554	O
17	32876697	555	557	O
,	32876697	558	559	O
2020	32876697	560	564	O
,	32876697	565	566	O
614	32876697	567	570	O
adult	32876697	571	576	O
patients	32876697	577	585	O
with	32876697	586	590	O
suspected	32876697	591	600	O
or	32876697	601	603	O
confirmed	32876697	604	613	O
COVID-19	32876697	614	622	O
were	32876697	623	627	O
enrolled	32876697	628	636	O
and	32876697	637	640	O
randomized	32876697	641	651	O
within	32876697	652	658	O
at	32876697	659	661	O
least	32876697	662	667	O
1	32876697	668	669	O
domain	32876697	670	676	O
following	32876697	677	686	O
admission	32876697	687	696	O
to	32876697	697	699	O
an	32876697	700	702	O
intensive	32876697	703	712	O
care	32876697	713	717	O
unit	32876697	718	722	O
(	32876697	723	724	O
ICU	32876697	725	728	O
)	32876697	729	730	O
for	32876697	731	734	O
respiratory	32876697	735	746	O
or	32876697	747	749	O
cardiovascular	32876697	750	764	O
organ	32876697	765	770	O
support	32876697	771	778	O
at	32876697	779	781	O
121	32876697	782	785	O
sites	32876697	786	791	O
in	32876697	792	794	O
8	32876697	795	796	O
countries	32876697	797	806	O
.	32876697	807	808	O

Of	32876697	809	811	O
these	32876697	812	817	O
,	32876697	818	819	O
403	32876697	820	823	O
were	32876697	824	828	O
randomized	32876697	829	839	O
to	32876697	840	842	O
open	32876697	843	847	O
-	32876697	848	849	O
label	32876697	850	855	O
interventions	32876697	856	869	O
within	32876697	870	876	O
the	32876697	877	880	O
corticosteroid	32876697	881	895	O
domain	32876697	896	902	O
.	32876697	903	904	O

The	32876697	905	908	O
domain	32876697	909	915	O
was	32876697	916	919	O
halted	32876697	920	926	O
after	32876697	927	932	O
results	32876697	933	940	O
from	32876697	941	945	O
another	32876697	946	953	O
trial	32876697	954	959	O
were	32876697	960	964	O
released	32876697	965	973	O
.	32876697	974	975	O

Follow	32876697	976	982	O
-	32876697	983	984	O
up	32876697	985	987	O
ended	32876697	988	993	O
August	32876697	994	1000	O
12	32876697	1001	1003	O
,	32876697	1004	1005	O
2020	32876697	1006	1010	O
.	32876697	1011	1012	O

The	32876697	1013	1016	O
corticosteroid	32876697	1017	1031	O
domain	32876697	1032	1038	O
randomized	32876697	1039	1049	O
participants	32876697	1050	1062	O
to	32876697	1063	1065	O
a	32876697	1066	1067	O
fixed	32876697	1068	1073	O
7-day	32876697	1074	1079	O
course	32876697	1080	1086	O
of	32876697	1087	1089	O
intravenous	32876697	1090	1101	O
hydrocortisone	32876697	1102	1116	O
(	32876697	1117	1118	O
50	32876697	1119	1121	O
mg	32876697	1122	1124	O
or	32876697	1125	1127	O
100	32876697	1128	1131	O
mg	32876697	1132	1134	O
every	32876697	1135	1140	O
6	32876697	1141	1142	O
hours	32876697	1143	1148	O
)	32876697	1149	1150	O
(	32876697	1151	1152	O
n	32876697	1153	1154	O
=	32876697	1157	1158	O
143	32876697	1161	1164	O
)	32876697	1165	1166	O
,	32876697	1167	1168	O
a	32876697	1169	1170	O
shock	32876697	1171	1176	O
-	32876697	1177	1178	O
dependent	32876697	1179	1188	O
course	32876697	1189	1195	O
(	32876697	1196	1197	O
50	32876697	1198	1200	O
mg	32876697	1201	1203	O
every	32876697	1204	1209	O
6	32876697	1210	1211	O
hours	32876697	1212	1217	O
when	32876697	1218	1222	O
shock	32876697	1223	1228	O
was	32876697	1229	1232	O
clinically	32876697	1233	1243	O
evident	32876697	1244	1251	O
)	32876697	1252	1253	O
(	32876697	1254	1255	O
n	32876697	1256	1257	O
=	32876697	1260	1261	O
152	32876697	1264	1267	O
)	32876697	1268	1269	O
,	32876697	1270	1271	O
or	32876697	1272	1274	O
no	32876697	1275	1277	O
hydrocortisone	32876697	1278	1292	O
(	32876697	1293	1294	O
n	32876697	1295	1296	O
=	32876697	1299	1300	O
108	32876697	1303	1306	O
)	32876697	1307	1308	O
.	32876697	1309	1310	O

The	32876697	1311	1314	O
primary	32876697	1315	1322	O
end	32876697	1323	1326	O
point	32876697	1327	1332	O
was	32876697	1333	1336	O
organ	32876697	1337	1342	O
support	32876697	1343	1350	O
-	32876697	1351	1352	O
free	32876697	1353	1357	O
days	32876697	1358	1362	O
(	32876697	1363	1364	O
days	32876697	1365	1369	O
alive	32876697	1370	1375	O
and	32876697	1376	1379	O
free	32876697	1380	1384	O
of	32876697	1385	1387	O
ICU	32876697	1388	1391	O
-	32876697	1392	1393	O
based	32876697	1394	1399	O
respiratory	32876697	1400	1411	O
or	32876697	1412	1414	O
cardiovascular	32876697	1415	1429	O
support	32876697	1430	1437	O
)	32876697	1438	1439	O
within	32876697	1440	1446	O
21	32876697	1447	1449	O
days	32876697	1450	1454	O
,	32876697	1455	1456	O
where	32876697	1457	1462	O
patients	32876697	1463	1471	O
who	32876697	1472	1475	O
died	32876697	1476	1480	O
were	32876697	1481	1485	O
assigned	32876697	1486	1494	O
-1	32876697	1495	1497	O
day	32876697	1498	1501	O
.	32876697	1502	1503	O

The	32876697	1504	1507	O
primary	32876697	1508	1515	O
analysis	32876697	1516	1524	O
was	32876697	1525	1528	O
a	32876697	1529	1530	O
bayesian	32876697	1531	1539	O
cumulative	32876697	1540	1550	O
logistic	32876697	1551	1559	O
model	32876697	1560	1565	O
that	32876697	1566	1570	O
included	32876697	1571	1579	O
all	32876697	1580	1583	O
patients	32876697	1584	1592	O
enrolled	32876697	1593	1601	O
with	32876697	1602	1606	O
severe	32876697	1607	1613	O
COVID-19	32876697	1614	1622	O
,	32876697	1623	1624	O
adjusting	32876697	1625	1634	O
for	32876697	1635	1638	O
age	32876697	1639	1642	O
,	32876697	1643	1644	O
sex	32876697	1645	1648	O
,	32876697	1649	1650	O
site	32876697	1651	1655	O
,	32876697	1656	1657	O
region	32876697	1658	1664	O
,	32876697	1665	1666	O
time	32876697	1667	1671	O
,	32876697	1672	1673	O
assignment	32876697	1674	1684	O
to	32876697	1685	1687	O
interventions	32876697	1688	1701	O
within	32876697	1702	1708	O
other	32876697	1709	1714	O
domains	32876697	1715	1722	O
,	32876697	1723	1724	O
and	32876697	1725	1728	O
domain	32876697	1729	1735	O
and	32876697	1736	1739	O
intervention	32876697	1740	1752	O
eligibility	32876697	1753	1764	O
.	32876697	1765	1766	O

Superiority	32876697	1767	1778	O
was	32876697	1779	1782	O
defined	32876697	1783	1790	O
as	32876697	1791	1793	O
the	32876697	1794	1797	O
posterior	32876697	1798	1807	O
probability	32876697	1808	1819	O
of	32876697	1820	1822	O
an	32876697	1823	1825	O
odds	32876697	1826	1830	O
ratio	32876697	1831	1836	O
greater	32876697	1837	1844	O
than	32876697	1845	1849	O
1	32876697	1850	1851	O
(	32876697	1852	1853	O
threshold	32876697	1854	1863	O
for	32876697	1864	1867	O
trial	32876697	1868	1873	O
conclusion	32876697	1874	1884	O
of	32876697	1885	1887	O
superiority	32876697	1888	1899	O
>	32876697	1900	1901	O
99	32876697	1902	1904	O
%	32876697	1905	1906	O
)	32876697	1907	1908	O
.	32876697	1909	1910	O

After	32876697	1911	1916	O
excluding	32876697	1917	1926	O
19	32876697	1927	1929	O
participants	32876697	1930	1942	O
who	32876697	1943	1946	O
withdrew	32876697	1947	1955	O
consent	32876697	1956	1963	O
,	32876697	1964	1965	O
there	32876697	1966	1971	O
were	32876697	1972	1976	O
384	32876697	1977	1980	O
patients	32876697	1981	1989	O
(	32876697	1990	1991	O
mean	32876697	1992	1996	O
age	32876697	1997	2000	O
,	32876697	2001	2002	O
60	32876697	2003	2005	O
years	32876697	2006	2011	O
;	32876697	2012	2013	O
29	32876697	2014	2016	O
%	32876697	2017	2018	O
female	32876697	2019	2025	O
)	32876697	2026	2027	O
randomized	32876697	2028	2038	O
to	32876697	2039	2041	O
the	32876697	2042	2045	O
fixed	32876697	2046	2051	O
-	32876697	2052	2053	O
dose	32876697	2054	2058	O
(	32876697	2059	2060	O
n	32876697	2061	2062	O
=	32876697	2065	2066	O
137	32876697	2069	2072	O
)	32876697	2073	2074	O
,	32876697	2075	2076	O
shock	32876697	2077	2082	O
-	32876697	2083	2084	O
dependent	32876697	2085	2094	O
(	32876697	2095	2096	O
n	32876697	2097	2098	O
=	32876697	2101	2102	O
146	32876697	2105	2108	O
)	32876697	2109	2110	O
,	32876697	2111	2112	O
and	32876697	2113	2116	O
no	32876697	2117	2119	O
(	32876697	2120	2121	O
n	32876697	2122	2123	O
=	32876697	2126	2127	O
101	32876697	2130	2133	O
)	32876697	2134	2135	O
hydrocortisone	32876697	2136	2150	O
groups	32876697	2151	2157	O
;	32876697	2158	2159	O
379	32876697	2160	2163	O
(	32876697	2164	2165	O
99	32876697	2166	2168	O
%	32876697	2169	2170	O
)	32876697	2171	2172	O
completed	32876697	2173	2182	O
the	32876697	2183	2186	O
study	32876697	2187	2192	O
and	32876697	2193	2196	O
were	32876697	2197	2201	O
included	32876697	2202	2210	O
in	32876697	2211	2213	O
the	32876697	2214	2217	O
analysis	32876697	2218	2226	O
.	32876697	2227	2228	O

The	32876697	2229	2232	O
mean	32876697	2233	2237	O
age	32876697	2238	2241	O
for	32876697	2242	2245	O
the	32876697	2246	2249	O
3	32876697	2250	2251	O
groups	32876697	2252	2258	O
ranged	32876697	2259	2265	O
between	32876697	2266	2273	O
59.5	32876697	2274	2278	O
and	32876697	2279	2282	O
60.4	32876697	2283	2287	O
years	32876697	2288	2293	O
;	32876697	2294	2295	O
most	32876697	2296	2300	O
patients	32876697	2301	2309	O
were	32876697	2310	2314	O
male	32876697	2315	2319	O
(	32876697	2320	2321	O
range	32876697	2322	2327	O
,	32876697	2328	2329	O
70.6%-71.5	32876697	2330	2340	O
%	32876697	2341	2342	O
)	32876697	2343	2344	O
;	32876697	2345	2346	O
mean	32876697	2347	2351	O
body	32876697	2352	2356	O
mass	32876697	2357	2361	O
index	32876697	2362	2367	O
ranged	32876697	2368	2374	O
between	32876697	2375	2382	O
29.7	32876697	2383	2387	O
and	32876697	2388	2391	O
30.9	32876697	2392	2396	O
;	32876697	2397	2398	O
and	32876697	2399	2402	O
patients	32876697	2403	2411	O
receiving	32876697	2412	2421	O
mechanical	32876697	2422	2432	O
ventilation	32876697	2433	2444	O
ranged	32876697	2445	2451	O
between	32876697	2452	2459	O
50.0	32876697	2460	2464	O
%	32876697	2465	2466	O
and	32876697	2467	2470	O
63.5	32876697	2471	2475	O
%	32876697	2476	2477	O
.	32876697	2478	2479	O

For	32876697	2480	2483	O
the	32876697	2484	2487	O
fixed	32876697	2488	2493	O
-	32876697	2494	2495	O
dose	32876697	2496	2500	O
,	32876697	2501	2502	O
shock	32876697	2503	2508	O
-	32876697	2509	2510	O
dependent	32876697	2511	2520	O
,	32876697	2521	2522	O
and	32876697	2523	2526	O
no	32876697	2527	2529	O
hydrocortisone	32876697	2530	2544	O
groups	32876697	2545	2551	O
,	32876697	2552	2553	O
respectively	32876697	2554	2566	O
,	32876697	2567	2568	O
the	32876697	2569	2572	O
median	32876697	2573	2579	O
organ	32876697	2580	2585	O
support	32876697	2586	2593	O
-	32876697	2594	2595	O
free	32876697	2596	2600	O
days	32876697	2601	2605	O
were	32876697	2606	2610	O
0	32876697	2611	2612	O
(	32876697	2613	2614	O
IQR	32876697	2615	2618	O
,	32876697	2619	2620	O
-1	32876697	2621	2623	O
to	32876697	2624	2626	O
15	32876697	2627	2629	O
)	32876697	2630	2631	O
,	32876697	2632	2633	O
0	32876697	2634	2635	O
(	32876697	2636	2637	O
IQR	32876697	2638	2641	O
,	32876697	2642	2643	O
-1	32876697	2644	2646	O
to	32876697	2647	2649	O
13	32876697	2650	2652	O
)	32876697	2653	2654	O
,	32876697	2655	2656	O
and	32876697	2657	2660	O
0	32876697	2661	2662	O
(	32876697	2663	2664	O
-1	32876697	2665	2667	O
to	32876697	2668	2670	O
11	32876697	2671	2673	O
)	32876697	2674	2675	O
days	32876697	2676	2680	O
(	32876697	2681	2682	O
composed	32876697	2683	2691	O
of	32876697	2692	2694	O
30	32876697	2695	2697	O
%	32876697	2698	2699	O
,	32876697	2700	2701	O
26	32876697	2702	2704	O
%	32876697	2705	2706	O
,	32876697	2707	2708	O
and	32876697	2709	2712	O
33	32876697	2713	2715	O
%	32876697	2716	2717	O
mortality	32876697	2718	2727	O
rates	32876697	2728	2733	O
and	32876697	2734	2737	O
11.5	32876697	2738	2742	O
,	32876697	2743	2744	O
9.5	32876697	2745	2748	O
,	32876697	2749	2750	O
and	32876697	2751	2754	O
6	32876697	2755	2756	O
median	32876697	2757	2763	O
organ	32876697	2764	2769	O
support	32876697	2770	2777	O
-	32876697	2778	2779	O
free	32876697	2780	2784	O
days	32876697	2785	2789	O
among	32876697	2790	2795	O
survivors	32876697	2796	2805	O
)	32876697	2806	2807	O
.	32876697	2808	2809	O

The	32876697	2810	2813	O
median	32876697	2814	2820	O
adjusted	32876697	2821	2829	O
odds	32876697	2830	2834	O
ratio	32876697	2835	2840	O
and	32876697	2841	2844	O
bayesian	32876697	2845	2853	O
probability	32876697	2854	2865	O
of	32876697	2866	2868	O
superiority	32876697	2869	2880	O
were	32876697	2881	2885	O
1.43	32876697	2886	2890	O
(	32876697	2891	2892	O
95	32876697	2893	2895	O
%	32876697	2896	2897	O
credible	32876697	2898	2906	O
interval	32876697	2907	2915	O
,	32876697	2916	2917	O
0.91	32876697	2918	2922	O
-	32876697	2923	2924	O
2.27	32876697	2925	2929	O
)	32876697	2930	2931	O
and	32876697	2932	2935	O
93	32876697	2936	2938	O
%	32876697	2939	2940	O
for	32876697	2941	2944	O
fixed	32876697	2945	2950	O
-	32876697	2951	2952	O
dose	32876697	2953	2957	O
hydrocortisone	32876697	2958	2972	O
,	32876697	2973	2974	O
respectively	32876697	2975	2987	O
,	32876697	2988	2989	O
and	32876697	2990	2993	O
were	32876697	2994	2998	O
1.22	32876697	2999	3003	O
(	32876697	3004	3005	O
95	32876697	3006	3008	O
%	32876697	3009	3010	O
credible	32876697	3011	3019	O
interval	32876697	3020	3028	O
,	32876697	3029	3030	O
0.76	32876697	3031	3035	O
-	32876697	3036	3037	O
1.94	32876697	3038	3042	O
)	32876697	3043	3044	O
and	32876697	3045	3048	O
80	32876697	3049	3051	O
%	32876697	3052	3053	O
for	32876697	3054	3057	O
shock	32876697	3058	3063	O
-	32876697	3064	3065	O
dependent	32876697	3066	3075	O
hydrocortisone	32876697	3076	3090	O
compared	32876697	3091	3099	O
with	32876697	3100	3104	O
no	32876697	3105	3107	O
hydrocortisone	32876697	3108	3122	O
.	32876697	3123	3124	O

Serious	32876697	3125	3132	O
adverse	32876697	3133	3140	O
events	32876697	3141	3147	O
were	32876697	3148	3152	O
reported	32876697	3153	3161	O
in	32876697	3162	3164	O
4	32876697	3165	3166	O
(	32876697	3167	3168	O
3	32876697	3169	3170	O
%	32876697	3171	3172	O
)	32876697	3173	3174	O
,	32876697	3175	3176	O
5	32876697	3177	3178	O
(	32876697	3179	3180	O
3	32876697	3181	3182	O
%	32876697	3183	3184	O
)	32876697	3185	3186	O
,	32876697	3187	3188	O
and	32876697	3189	3192	O
1	32876697	3193	3194	O
(	32876697	3195	3196	O
1	32876697	3197	3198	O
%	32876697	3199	3200	O
)	32876697	3201	3202	O
patients	32876697	3203	3211	O
in	32876697	3212	3214	O
the	32876697	3215	3218	O
fixed	32876697	3219	3224	O
-	32876697	3225	3226	O
dose	32876697	3227	3231	O
,	32876697	3232	3233	O
shock	32876697	3234	3239	O
-	32876697	3240	3241	O
dependent	32876697	3242	3251	O
,	32876697	3252	3253	O
and	32876697	3254	3257	O
no	32876697	3258	3260	O
hydrocortisone	32876697	3261	3275	O
groups	32876697	3276	3282	O
,	32876697	3283	3284	O
respectively	32876697	3285	3297	O
.	32876697	3298	3299	O

Among	32876697	3300	3305	O
patients	32876697	3306	3314	O
with	32876697	3315	3319	O
severe	32876697	3320	3326	O
COVID-19	32876697	3327	3335	O
,	32876697	3336	3337	O
treatment	32876697	3338	3347	O
with	32876697	3348	3352	O
a	32876697	3353	3354	O
7-day	32876697	3355	3360	O
fixed	32876697	3361	3366	O
-	32876697	3367	3368	O
dose	32876697	3369	3373	O
course	32876697	3374	3380	O
of	32876697	3381	3383	O
hydrocortisone	32876697	3384	3398	O
or	32876697	3399	3401	O
shock	32876697	3402	3407	O
-	32876697	3408	3409	O
dependent	32876697	3410	3419	O
dosing	32876697	3420	3426	O
of	32876697	3427	3429	O
hydrocortisone	32876697	3430	3444	O
,	32876697	3445	3446	O
compared	32876697	3447	3455	O
with	32876697	3456	3460	O
no	32876697	3461	3463	O
hydrocortisone	32876697	3464	3478	O
,	32876697	3479	3480	O
resulted	32876697	3481	3489	O
in	32876697	3490	3492	O
93	32876697	3493	3495	O
%	32876697	3496	3497	O
and	32876697	3498	3501	O
80	32876697	3502	3504	O
%	32876697	3505	3506	O
probabilities	32876697	3507	3520	O
of	32876697	3521	3523	O
superiority	32876697	3524	3535	O
with	32876697	3536	3540	O
regard	32876697	3541	3547	O
to	32876697	3548	3550	O
the	32876697	3551	3554	O
odds	32876697	3555	3559	O
of	32876697	3560	3562	O
improvement	32876697	3563	3574	O
in	32876697	3575	3577	O
organ	32876697	3578	3583	O
support	32876697	3584	3591	O
-	32876697	3592	3593	O
free	32876697	3594	3598	O
days	32876697	3599	3603	O
within	32876697	3604	3610	O
21	32876697	3611	3613	O
days	32876697	3614	3618	O
.	32876697	3619	3620	O

However	32876697	3621	3628	O
,	32876697	3629	3630	O
the	32876697	3631	3634	O
trial	32876697	3635	3640	O
was	32876697	3641	3644	O
stopped	32876697	3645	3652	O
early	32876697	3653	3658	O
and	32876697	3659	3662	O
no	32876697	3663	3665	O
treatment	32876697	3666	3675	O
strategy	32876697	3676	3684	O
met	32876697	3685	3688	O
prespecified	32876697	3689	3701	O
criteria	32876697	3702	3710	O
for	32876697	3711	3714	O
statistical	32876697	3715	3726	O
superiority	32876697	3727	3738	O
,	32876697	3739	3740	O
precluding	32876697	3741	3751	O
definitive	32876697	3752	3762	O
conclusions	32876697	3763	3774	O
.	32876697	3775	3776	O

ClinicalTrials.gov	32876697	3777	3795	O
Identifier	32876697	3796	3806	O
:	32876697	3807	3808	O
NCT02735707	32876697	3809	3820	O
.	32876697	3821	3822	O


Feasibility	32894251	0	11	O
,	32894251	12	13	O
Reliability	32894251	14	25	O
,	32894251	26	27	O
and	32894251	28	31	O
Value	32894251	32	37	O
of	32894251	38	40	O
Remote	32894251	41	47	O
Video	32894251	48	53	O
-	32894251	54	55	O
Based	32894251	56	61	O
Trial	32894251	62	67	O
Visits	32894251	68	74	O
in	32894251	75	77	O
Parkinson	32894251	78	87	O
's	32894251	88	90	O
Disease	32894251	91	98	O
.	32894251	99	100	O

There	32894251	101	106	O
is	32894251	107	109	O
rising	32894251	110	116	O
interest	32894251	117	125	O
in	32894251	126	128	O
remote	32894251	129	135	O
clinical	32894251	136	144	O
trial	32894251	145	150	O
assessments	32894251	151	162	O
,	32894251	163	164	O
particularly	32894251	165	177	O
in	32894251	178	180	O
the	32894251	181	184	O
setting	32894251	185	192	O
of	32894251	193	195	O
the	32894251	196	199	O
COVID-19	32894251	200	208	O
pandemic	32894251	209	217	O
.	32894251	218	219	O

To	32894251	220	222	O
demonstrate	32894251	223	234	O
the	32894251	235	238	O
feasibility	32894251	239	250	O
,	32894251	251	252	O
reliability	32894251	253	264	O
,	32894251	265	266	O
and	32894251	267	270	O
value	32894251	271	276	O
of	32894251	277	279	O
remote	32894251	280	286	O
visits	32894251	287	293	O
in	32894251	294	296	O
a	32894251	297	298	O
phase	32894251	299	304	O
III	32894251	305	308	O
clinical	32894251	309	317	O
trial	32894251	318	323	O
of	32894251	324	326	O
individuals	32894251	327	338	O
with	32894251	339	343	O
Parkinson	32894251	344	353	O
's	32894251	354	356	O
disease	32894251	357	364	O
.	32894251	365	366	O

We	32894251	367	369	O
invited	32894251	370	377	O
individuals	32894251	378	389	O
with	32894251	390	394	O
Parkinson	32894251	395	404	O
's	32894251	405	407	O
disease	32894251	408	415	O
enrolled	32894251	416	424	O
in	32894251	425	427	O
a	32894251	428	429	O
phase	32894251	430	435	O
III	32894251	436	439	O
clinical	32894251	440	448	O
trial	32894251	449	454	O
(	32894251	455	456	O
STEADY	32894251	457	463	O
-	32894251	464	465	O
PD	32894251	466	468	O
III	32894251	469	472	O
)	32894251	473	474	O
to	32894251	475	477	O
enroll	32894251	478	484	O
in	32894251	485	487	O
a	32894251	488	489	O
sub	32894251	490	493	O
-	32894251	494	495	O
study	32894251	496	501	O
of	32894251	502	504	O
remote	32894251	505	511	O
video	32894251	512	517	O
-	32894251	518	519	O
based	32894251	520	525	O
visits	32894251	526	532	O
.	32894251	533	534	O

Participants	32894251	535	547	O
completed	32894251	548	557	O
three	32894251	558	563	O
remote	32894251	564	570	O
visits	32894251	571	577	O
over	32894251	578	582	O
one	32894251	583	586	O
year	32894251	587	591	O
within	32894251	592	598	O
four	32894251	599	603	O
weeks	32894251	604	609	O
of	32894251	610	612	O
an	32894251	613	615	O
in	32894251	616	618	O
-	32894251	619	620	O
person	32894251	621	627	O
visit	32894251	628	633	O
and	32894251	634	637	O
completed	32894251	638	647	O
assessments	32894251	648	659	O
performed	32894251	660	669	O
during	32894251	670	676	O
the	32894251	677	680	O
remote	32894251	681	687	O
visit	32894251	688	693	O
.	32894251	694	695	O

We	32894251	696	698	O
evaluated	32894251	699	708	O
the	32894251	709	712	O
ability	32894251	713	720	O
to	32894251	721	723	O
complete	32894251	724	732	O
scheduled	32894251	733	742	O
assessments	32894251	743	754	O
remotely	32894251	755	763	O
;	32894251	764	765	O
agreement	32894251	766	775	O
between	32894251	776	783	O
remote	32894251	784	790	O
and	32894251	791	794	O
in	32894251	795	797	O
-	32894251	798	799	O
person	32894251	800	806	O
outcome	32894251	807	814	O
measures	32894251	815	823	O
;	32894251	824	825	O
and	32894251	826	829	O
opinions	32894251	830	838	O
of	32894251	839	841	O
remote	32894251	842	848	O
visits	32894251	849	855	O
.	32894251	856	857	O

We	32894251	858	860	O
enrolled	32894251	861	869	O
40	32894251	870	872	O
participants	32894251	873	885	O
(	32894251	886	887	O
mean	32894251	888	892	O
(	32894251	893	894	O
SD	32894251	895	897	O
)	32894251	898	899	O
age	32894251	900	903	O
64.3	32894251	904	908	O
(	32894251	909	910	O
10.4	32894251	911	915	O
)	32894251	916	917	O
,	32894251	918	919	O
29	32894251	920	922	O
%	32894251	923	924	O
women	32894251	925	930	O
)	32894251	931	932	O
,	32894251	933	934	O
and	32894251	935	938	O
38	32894251	939	941	O
(	32894251	942	943	O
95	32894251	944	946	O
%	32894251	947	948	O
)	32894251	949	950	O
completed	32894251	951	960	O
all	32894251	961	964	O
remote	32894251	965	971	O
visits	32894251	972	978	O
.	32894251	979	980	O

There	32894251	981	986	O
was	32894251	987	990	O
excellent	32894251	991	1000	O
correlation	32894251	1001	1012	O
(	32894251	1013	1014	O
ICC	32894251	1015	1018	O
0.81	32894251	1019	1023	O
-	32894251	1024	1025	O
0.87	32894251	1026	1030	O
)	32894251	1031	1032	O
between	32894251	1033	1040	O
remote	32894251	1041	1047	O
and	32894251	1048	1051	O
in	32894251	1052	1054	O
-	32894251	1055	1056	O
person	32894251	1057	1063	O
patient	32894251	1064	1071	O
-	32894251	1072	1073	O
reported	32894251	1074	1082	O
outcomes	32894251	1083	1091	O
,	32894251	1092	1093	O
and	32894251	1094	1097	O
moderate	32894251	1098	1106	O
correlation	32894251	1107	1118	O
(	32894251	1119	1120	O
ICC	32894251	1121	1124	O
0.43	32894251	1125	1129	O
-	32894251	1130	1131	O
0.51	32894251	1132	1136	O
)	32894251	1137	1138	O
between	32894251	1139	1146	O
remote	32894251	1147	1153	O
and	32894251	1154	1157	O
in	32894251	1158	1160	O
-	32894251	1161	1162	O
person	32894251	1163	1169	O
motor	32894251	1170	1175	O
assessments	32894251	1176	1187	O
.	32894251	1188	1189	O

On	32894251	1190	1192	O
average	32894251	1193	1200	O
,	32894251	1201	1202	O
remote	32894251	1203	1209	O
visits	32894251	1210	1216	O
took	32894251	1217	1221	O
around	32894251	1222	1228	O
one	32894251	1229	1232	O
quarter	32894251	1233	1240	O
of	32894251	1241	1243	O
the	32894251	1244	1247	O
time	32894251	1248	1252	O
of	32894251	1253	1255	O
in	32894251	1256	1258	O
-	32894251	1259	1260	O
person	32894251	1261	1267	O
visits	32894251	1268	1274	O
(	32894251	1275	1276	O
54	32894251	1277	1279	O
vs	32894251	1280	1282	O
190	32894251	1283	1286	O
minutes	32894251	1287	1294	O
)	32894251	1295	1296	O
.	32894251	1297	1298	O

Nearly	32894251	1299	1305	O
all	32894251	1306	1309	O
participants	32894251	1310	1322	O
liked	32894251	1323	1328	O
remote	32894251	1329	1335	O
visits	32894251	1336	1342	O
,	32894251	1343	1344	O
and	32894251	1345	1348	O
three	32894251	1349	1354	O
-	32894251	1355	1356	O
quarters	32894251	1357	1365	O
said	32894251	1366	1370	O
they	32894251	1371	1375	O
would	32894251	1376	1381	O
be	32894251	1382	1384	O
more	32894251	1385	1389	O
likely	32894251	1390	1396	O
to	32894251	1397	1399	O
participate	32894251	1400	1411	O
in	32894251	1412	1414	O
future	32894251	1415	1421	O
trials	32894251	1422	1428	O
if	32894251	1429	1431	O
some	32894251	1432	1436	O
visits	32894251	1437	1443	O
could	32894251	1444	1449	O
be	32894251	1450	1452	O
conducted	32894251	1453	1462	O
remotely	32894251	1463	1471	O
.	32894251	1472	1473	O

Remote	32894251	1474	1480	O
visits	32894251	1481	1487	O
are	32894251	1488	1491	O
feasible	32894251	1492	1500	O
and	32894251	1501	1504	O
reliable	32894251	1505	1513	O
in	32894251	1514	1516	O
a	32894251	1517	1518	O
phase	32894251	1519	1524	O
III	32894251	1525	1528	O
clinical	32894251	1529	1537	O
trial	32894251	1538	1543	O
of	32894251	1544	1546	O
individuals	32894251	1547	1558	O
with	32894251	1559	1563	O
early	32894251	1564	1569	O
,	32894251	1570	1571	O
untreated	32894251	1572	1581	O
Parkinson	32894251	1582	1591	O
's	32894251	1592	1594	O
disease	32894251	1595	1602	O
.	32894251	1603	1604	O

These	32894251	1605	1610	O
visits	32894251	1611	1617	O
are	32894251	1618	1621	O
shorter	32894251	1622	1629	O
,	32894251	1630	1631	O
reduce	32894251	1632	1638	O
participant	32894251	1639	1650	O
burden	32894251	1651	1657	O
,	32894251	1658	1659	O
and	32894251	1660	1663	O
enable	32894251	1664	1670	O
safe	32894251	1671	1675	O
conduct	32894251	1676	1683	O
of	32894251	1684	1686	O
research	32894251	1687	1695	O
visits	32894251	1696	1702	O
,	32894251	1703	1704	O
which	32894251	1705	1710	O
is	32894251	1711	1713	O
especially	32894251	1714	1724	O
important	32894251	1725	1734	O
in	32894251	1735	1737	O
the	32894251	1738	1741	O
COVID-19	32894251	1742	1750	O
pandemic	32894251	1751	1759	O
.	32894251	1760	1761	O


Anticoagulation	32895056	0	15	O
in	32895056	16	18	O
critically	32895056	19	29	O
ill	32895056	30	33	O
patients	32895056	34	42	O
on	32895056	43	45	O
mechanical	32895056	46	56	O
ventilation	32895056	57	68	O
suffering	32895056	69	78	O
from	32895056	79	83	O
COVID-19	32895056	84	92	O
disease	32895056	93	100	O
,	32895056	101	102	O
The	32895056	103	106	O
ANTI	32895056	107	111	O
-	32895056	112	113	O
CO	32895056	114	116	O
trial	32895056	117	122	O
:	32895056	123	124	O
A	32895056	125	126	O
structured	32895056	127	137	O
summary	32895056	138	145	O
of	32895056	146	148	O
a	32895056	149	150	O
study	32895056	151	156	O
protocol	32895056	157	165	O
for	32895056	166	169	O
a	32895056	170	171	O
randomised	32895056	172	182	O
controlled	32895056	183	193	O
trial	32895056	194	199	O
.	32895056	200	201	O

OBJECTIVE	32895056	202	211	O
:	32895056	212	213	O
To	32895056	214	216	O
assess	32895056	217	223	O
the	32895056	224	227	O
effect	32895056	228	234	O
of	32895056	235	237	O
anticoagulation	32895056	238	253	O
with	32895056	254	258	O
bivalirudin	32895056	259	270	O
administered	32895056	271	283	O
intravenously	32895056	284	297	O
on	32895056	298	300	O
gas	32895056	301	304	O
-	32895056	305	306	O
exchange	32895056	307	315	O
in	32895056	316	318	O
patients	32895056	319	327	O
with	32895056	328	332	O
COVID-19	32895056	333	341	O
and	32895056	342	345	O
respiratory	32895056	346	357	O
failure	32895056	358	365	O
using	32895056	366	371	O
invasive	32895056	372	380	O
mechanical	32895056	381	391	O
ventilation	32895056	392	403	O
.	32895056	404	405	O

METHODS	32895056	406	413	O
:	32895056	414	415	O
This	32895056	416	420	O
is	32895056	421	423	O
a	32895056	424	425	O
single	32895056	426	432	O
centre	32895056	433	439	O
parallel	32895056	440	448	O
group	32895056	449	454	O
,	32895056	455	456	O
superiority	32895056	457	468	O
,	32895056	469	470	O
randomized	32895056	471	481	O
(	32895056	482	483	O
1:1	32895056	484	487	O
allocation	32895056	488	498	O
ratio	32895056	499	504	O
)	32895056	505	506	O
controlled	32895056	507	517	O
trial	32895056	518	523	O
.	32895056	524	525	O

METHODS	32895056	526	533	O
:	32895056	534	535	O
All	32895056	536	539	O
patients	32895056	540	548	O
admitted	32895056	549	557	O
to	32895056	558	560	O
the	32895056	561	564	O
Hamad	32895056	565	570	O
Medical	32895056	571	578	O
Corporation	32895056	579	590	O
-ICU	32895056	591	595	O
in	32895056	596	598	O
Qatar	32895056	599	604	O
for	32895056	605	608	O
COVID-19	32895056	609	617	O
associated	32895056	618	628	O
respiratory	32895056	629	640	O
distress	32895056	641	649	O
and	32895056	650	653	O
in	32895056	654	656	O
need	32895056	657	661	O
of	32895056	662	664	O
mechanical	32895056	665	675	O
ventilation	32895056	676	687	O
are	32895056	688	691	O
screened	32895056	692	700	O
for	32895056	701	704	O
eligibility	32895056	705	716	O
.	32895056	717	718	O

METHODS	32895056	719	726	O
:	32895056	727	728	O
all	32895056	729	732	O
adult	32895056	733	738	O
patients	32895056	739	747	O
admitted	32895056	748	756	O
to	32895056	757	759	O
the	32895056	760	763	O
ICU	32895056	764	767	O
who	32895056	768	771	O
test	32895056	772	776	O
positive	32895056	777	785	O
for	32895056	786	789	O
COVID-19	32895056	790	798	O
by	32895056	799	801	O
PCR	32895056	802	805	O
-	32895056	806	807	O
test	32895056	808	812	O
and	32895056	813	816	O
in	32895056	817	819	O
need	32895056	820	824	O
for	32895056	825	828	O
mechanical	32895056	829	839	O
ventilation	32895056	840	851	O
are	32895056	852	855	O
eligible	32895056	856	864	O
for	32895056	865	868	O
inclusion	32895056	869	878	O
.	32895056	879	880	O

Upon	32895056	881	885	O
crossing	32895056	886	894	O
the	32895056	895	898	O
limit	32895056	899	904	O
of	32895056	905	907	O
D	32895056	908	909	O
-	32895056	910	911	O
dimers	32895056	912	918	O
(	32895056	919	920	O
1.2	32895056	921	924	O
mg	32895056	925	927	O
/	32895056	928	929	O
L	32895056	930	931	O
)	32895056	932	933	O
these	32895056	934	939	O
patients	32895056	940	948	O
are	32895056	949	952	O
routinely	32895056	953	962	O
treated	32895056	963	970	O
with	32895056	971	975	O
an	32895056	976	978	O
increased	32895056	979	988	O
dose	32895056	989	993	O
of	32895056	994	996	O
anticoagulant	32895056	997	1010	O
according	32895056	1011	1020	O
to	32895056	1021	1023	O
our	32895056	1024	1027	O
local	32895056	1028	1033	O
protocol	32895056	1034	1042	O
.	32895056	1043	1044	O

This	32895056	1045	1049	O
will	32895056	1050	1054	O
be	32895056	1055	1057	O
the	32895056	1058	1061	O
start	32895056	1062	1067	O
of	32895056	1068	1070	O
randomization	32895056	1071	1084	O
.	32895056	1085	1086	O

METHODS	32895056	1087	1094	O
:	32895056	1095	1096	O
pregnancy	32895056	1097	1106	O
,	32895056	1107	1108	O
allergic	32895056	1109	1117	O
to	32895056	1118	1120	O
the	32895056	1121	1124	O
drug	32895056	1125	1129	O
,	32895056	1130	1131	O
inherited	32895056	1132	1141	O
coagulation	32895056	1142	1153	O
abnormalities	32895056	1154	1167	O
,	32895056	1168	1169	O
no	32895056	1170	1172	O
informed	32895056	1173	1181	O
consent	32895056	1182	1189	O
.	32895056	1190	1191	O

UNASSIGNED	32895056	1192	1202	O
:	32895056	1203	1204	O
The	32895056	1205	1208	O
intervention	32895056	1209	1221	O
group	32895056	1222	1227	O
will	32895056	1228	1232	O
receive	32895056	1233	1240	O
the	32895056	1241	1244	O
anticoagulant	32895056	1245	1258	O
bivalirudin	32895056	1259	1270	O
intravenously	32895056	1271	1284	O
with	32895056	1285	1289	O
a	32895056	1290	1291	O
target	32895056	1292	1298	O
aPTT	32895056	1299	1303	O
of	32895056	1304	1306	O
45	32895056	1307	1309	O
-	32895056	1310	1311	O
70	32895056	1312	1314	O
sec	32895056	1315	1318	O
for	32895056	1319	1322	O
three	32895056	1323	1328	O
days	32895056	1329	1333	O
while	32895056	1334	1339	O
the	32895056	1340	1343	O
control	32895056	1344	1351	O
group	32895056	1352	1357	O
will	32895056	1358	1362	O
stay	32895056	1363	1367	O
on	32895056	1368	1370	O
the	32895056	1371	1374	O
standard	32895056	1375	1383	O
treatment	32895056	1384	1393	O
with	32895056	1394	1398	O
low	32895056	1399	1402	O
-	32895056	1403	1404	O
molecular	32895056	1405	1414	O
-	32895056	1415	1416	O
weight	32895056	1417	1423	O
heparins	32895056	1424	1432	O
/unfractionated	32895056	1433	1448	O
heparin	32895056	1449	1456	O
subcutaneously	32895056	1457	1471	O
(	32895056	1472	1473	O
see	32895056	1474	1477	O
scheme	32895056	1478	1484	O
in	32895056	1485	1487	O
Additional	32895056	1488	1498	O
file	32895056	1499	1503	O
1	32895056	1504	1505	O
)	32895056	1506	1507	O
.	32895056	1508	1509	O

All	32895056	1510	1513	O
other	32895056	1514	1519	O
treatment	32895056	1520	1529	O
will	32895056	1530	1534	O
be	32895056	1535	1537	O
unchanged	32895056	1538	1547	O
and	32895056	1548	1551	O
left	32895056	1552	1556	O
to	32895056	1557	1559	O
the	32895056	1560	1563	O
attending	32895056	1564	1573	O
physicians	32895056	1574	1584	O
.	32895056	1585	1586	O

RESULTS	32895056	1587	1594	O
:	32895056	1595	1596	O
As	32895056	1597	1599	O
a	32895056	1600	1601	O
surrogate	32895056	1602	1611	O
parameter	32895056	1612	1621	O
for	32895056	1622	1625	O
clinical	32895056	1626	1634	O
improvement	32895056	1635	1646	O
and	32895056	1647	1650	O
primary	32895056	1651	1658	O
outcome	32895056	1659	1666	O
we	32895056	1667	1669	O
will	32895056	1670	1674	O
use	32895056	1675	1678	O
the	32895056	1679	1682	O
PaO2	32895056	1683	1687	O
/	32895056	1688	1689	O
FiO2	32895056	1690	1694	O
(	32895056	1695	1696	O
P	32895056	1697	1698	O
/	32895056	1699	1700	O
F	32895056	1701	1702	O
)	32895056	1703	1704	O
ratio	32895056	1705	1710	O
.	32895056	1711	1712	O

UNASSIGNED	32895056	1713	1723	O
:	32895056	1724	1725	O
After	32895056	1726	1731	O
inclusion	32895056	1732	1741	O
,	32895056	1742	1743	O
the	32895056	1744	1747	O
patients	32895056	1748	1756	O
will	32895056	1757	1761	O
be	32895056	1762	1764	O
randomized	32895056	1765	1775	O
using	32895056	1776	1781	O
a	32895056	1782	1783	O
closed	32895056	1784	1790	O
envelope	32895056	1791	1799	O
method	32895056	1800	1806	O
into	32895056	1807	1811	O
the	32895056	1812	1815	O
conventional	32895056	1816	1828	O
treatment	32895056	1829	1838	O
group	32895056	1839	1844	O
,	32895056	1845	1846	O
which	32895056	1847	1852	O
uses	32895056	1853	1857	O
the	32895056	1858	1861	O
standard	32895056	1862	1870	O
strategy	32895056	1871	1879	O
and	32895056	1880	1883	O
the	32895056	1884	1887	O
experimental	32895056	1888	1900	O
group	32895056	1901	1906	O
which	32895056	1907	1912	O
receives	32895056	1913	1921	O
anticoagulation	32895056	1922	1937	O
treatment	32895056	1938	1947	O
with	32895056	1948	1952	O
bivalirudin	32895056	1953	1964	O
using	32895056	1965	1970	O
an	32895056	1971	1973	O
allocation	32895056	1974	1984	O
ratio	32895056	1985	1990	O
of	32895056	1991	1993	O
1:1	32895056	1994	1997	O
.	32895056	1998	1999	O

UNASSIGNED	32895056	2000	2010	O
:	32895056	2011	2012	O
Due	32895056	2013	2016	O
to	32895056	2017	2019	O
logistical	32895056	2020	2030	O
and	32895056	2031	2034	O
safety	32895056	2035	2041	O
reasons	32895056	2042	2049	O
(	32895056	2050	2051	O
assessment	32895056	2052	2062	O
of	32895056	2063	2065	O
aPTT	32895056	2066	2070	O
to	32895056	2071	2073	O
titrate	32895056	2074	2081	O
the	32895056	2082	2085	O
study	32895056	2086	2091	O
drug	32895056	2092	2096	O
)	32895056	2097	2098	O
only	32895056	2099	2103	O
the	32895056	2104	2107	O
data	32895056	2108	2112	O
-	32895056	2113	2114	O
analyst	32895056	2115	2122	O
will	32895056	2123	2127	O
be	32895056	2128	2130	O
blinded	32895056	2131	2138	O
to	32895056	2139	2141	O
the	32895056	2142	2145	O
groups	32895056	2146	2152	O
.	32895056	2153	2154	O

UNASSIGNED	32895056	2155	2165	O
:	32895056	2166	2167	O
We	32895056	2168	2170	O
performed	32895056	2171	2180	O
a	32895056	2181	2182	O
sample	32895056	2183	2189	O
size	32895056	2190	2194	O
calculation	32895056	2195	2206	O
and	32895056	2207	2210	O
assumed	32895056	2211	2218	O
the	32895056	2219	2222	O
data	32895056	2223	2227	O
for	32895056	2228	2231	O
P	32895056	2232	2233	O
/	32895056	2234	2235	O
F	32895056	2236	2237	O
ratio	32895056	2238	2243	O
(	32895056	2244	2245	O
according	32895056	2246	2255	O
to	32895056	2256	2258	O
literature	32895056	2259	2269	O
)	32895056	2270	2271	O
is	32895056	2272	2274	O
normally	32895056	2275	2283	O
distributed	32895056	2284	2295	O
and	32895056	2296	2299	O
used	32895056	2300	2304	O
the	32895056	2305	2308	O
mean	32895056	2309	2313	O
which	32895056	2314	2319	O
would	32895056	2320	2325	O
be	32895056	2326	2328	O
:	32895056	2329	2330	O
160	32895056	2331	2334	O
and	32895056	2335	2338	O
SD	32895056	2339	2341	O
is	32895056	2342	2344	O
80	32895056	2345	2347	O
.	32895056	2348	2349	O

We	32895056	2350	2352	O
expect	32895056	2353	2359	O
the	32895056	2360	2363	O
treatment	32895056	2364	2373	O
will	32895056	2374	2378	O
improve	32895056	2379	2386	O
this	32895056	2387	2391	O
by	32895056	2392	2394	O
30	32895056	2395	2397	O
%	32895056	2398	2399	O
.	32895056	2400	2401	O

In	32895056	2402	2404	O
order	32895056	2405	2410	O
to	32895056	2411	2413	O
reach	32895056	2414	2419	O
a	32895056	2420	2421	O
power	32895056	2422	2427	O
of	32895056	2428	2430	O
80	32895056	2431	2433	O
%	32895056	2434	2435	O
we	32895056	2436	2438	O
would	32895056	2439	2444	O
need	32895056	2445	2449	O
44	32895056	2450	2452	O
patients	32895056	2453	2461	O
per	32895056	2462	2465	O
group	32895056	2466	2471	O
(	32895056	2472	2473	O
in	32895056	2474	2476	O
total	32895056	2477	2482	O
88	32895056	2483	2485	O
patients	32895056	2486	2494	O
)	32895056	2495	2496	O
.	32895056	2497	2498	O

Taking	32895056	2499	2505	O
approximately	32895056	2506	2519	O
10	32895056	2520	2522	O
%	32895056	2523	2524	O
of	32895056	2525	2527	O
dropout	32895056	2528	2535	O
into	32895056	2536	2540	O
account	32895056	2541	2548	O
we	32895056	2549	2551	O
will	32895056	2552	2556	O
include	32895056	2557	2564	O
100	32895056	2565	2568	O
patients	32895056	2569	2577	O
(	32895056	2578	2579	O
50	32895056	2580	2582	O
in	32895056	2583	2585	O
each	32895056	2586	2590	O
group	32895056	2591	2596	O
)	32895056	2597	2598	O
.	32895056	2599	2600	O

UNASSIGNED	32895056	2601	2611	O
:	32895056	2612	2613	O
The	32895056	2614	2617	O
local	32895056	2618	2623	O
registration	32895056	2624	2636	O
number	32895056	2637	2643	O
is	32895056	2644	2646	O
MRC-05	32895056	2647	2653	O
-	32895056	2654	2655	O
082	32895056	2656	2659	O
with	32895056	2660	2664	O
the	32895056	2665	2668	O
protocol	32895056	2669	2677	O
version	32895056	2678	2685	O
number	32895056	2686	2692	O
2	32895056	2693	2694	O
.	32895056	2695	2696	O

The	32895056	2697	2700	O
date	32895056	2701	2705	O
of	32895056	2706	2708	O
approval	32895056	2709	2717	O
is	32895056	2718	2720	O
18th	32895056	2721	2725	O
June	32895056	2726	2730	O
2020	32895056	2731	2735	O
.	32895056	2736	2737	O

Recruitment	32895056	2738	2749	O
started	32895056	2750	2757	O
on	32895056	2758	2760	O
28th	32895056	2761	2765	O
June	32895056	2766	2770	O
and	32895056	2771	2774	O
is	32895056	2775	2777	O
expected	32895056	2778	2786	O
to	32895056	2787	2789	O
end	32895056	2790	2793	O
in	32895056	2794	2796	O
November	32895056	2797	2805	O
2020	32895056	2806	2810	O
.	32895056	2811	2812	O

BACKGROUND	32895056	2813	2823	O
:	32895056	2824	2825	O
The	32895056	2826	2829	O
protocol	32895056	2830	2838	O
is	32895056	2839	2841	O
registered	32895056	2842	2852	O
before	32895056	2853	2859	O
starting	32895056	2860	2868	O
subject	32895056	2869	2876	O
recruitment	32895056	2877	2888	O
under	32895056	2889	2894	O
the	32895056	2895	2898	O
title	32895056	2899	2904	O
:	32895056	2905	2906	O
"	32895056	2907	2908	O
Anticoagulation	32895056	2909	2924	O
in	32895056	2925	2927	O
patients	32895056	2928	2936	O
suffering	32895056	2937	2946	O
from	32895056	2947	2951	O
COVID-19	32895056	2952	2960	O
disease	32895056	2961	2968	O
.	32895056	2969	2970	O

The	32895056	2971	2974	O
ANTI	32895056	2975	2979	O
-	32895056	2980	2981	O
CO	32895056	2982	2984	O
Trial	32895056	2985	2990	O
"	32895056	2991	2992	O
in	32895056	2993	2995	O
ClinicalTrials.org	32895056	2996	3014	O
with	32895056	3015	3019	O
the	32895056	3020	3023	O
registration	32895056	3024	3036	O
number	32895056	3037	3043	O
:	32895056	3044	3045	O
NCT04445935	32895056	3046	3057	O
.	32895056	3058	3059	O

Registered	32895056	3060	3070	O
on	32895056	3071	3073	O
24	32895056	3074	3076	O
June	32895056	3077	3081	O
2020	32895056	3082	3086	O
.	32895056	3087	3088	O

UNASSIGNED	32895056	3089	3099	O
:	32895056	3100	3101	O
The	32895056	3102	3105	O
full	32895056	3106	3110	O
protocol	32895056	3111	3119	O
is	32895056	3120	3122	O
attached	32895056	3123	3131	O
as	32895056	3132	3134	O
an	32895056	3135	3137	O
additional	32895056	3138	3148	O
file	32895056	3149	3153	O
,	32895056	3154	3155	O
accessible	32895056	3156	3166	O
from	32895056	3167	3171	O
the	32895056	3172	3175	O
Trials	32895056	3176	3182	O
website	32895056	3183	3190	O
(	32895056	3191	3192	O
Additional	32895056	3193	3203	O
file	32895056	3204	3208	O
2	32895056	3209	3210	O
)	32895056	3211	3212	O
.	32895056	3213	3214	O

In	32895056	3215	3217	O
the	32895056	3218	3221	O
interest	32895056	3222	3230	O
in	32895056	3231	3233	O
expediting	32895056	3234	3244	O
dissemination	32895056	3245	3258	O
of	32895056	3259	3261	O
this	32895056	3262	3266	O
material	32895056	3267	3275	O
,	32895056	3276	3277	O
the	32895056	3278	3281	O
familiar	32895056	3282	3290	O
formatting	32895056	3291	3301	O
has	32895056	3302	3305	O
been	32895056	3306	3310	O
eliminated	32895056	3311	3321	O
;	32895056	3322	3323	O
this	32895056	3324	3328	O
Letter	32895056	3329	3335	O
serves	32895056	3336	3342	O
as	32895056	3343	3345	O
a	32895056	3346	3347	O
summary	32895056	3348	3355	O
of	32895056	3356	3358	O
the	32895056	3359	3362	O
key	32895056	3363	3366	O
elements	32895056	3367	3375	O
of	32895056	3376	3378	O
the	32895056	3379	3382	O
full	32895056	3383	3387	O
protocol	32895056	3388	3396	O
.	32895056	3397	3398	O


Azithromycin	32896292	0	12	O
in	32896292	13	15	O
addition	32896292	16	24	O
to	32896292	25	27	O
standard	32896292	28	36	O
of	32896292	37	39	O
care	32896292	40	44	O
versus	32896292	45	51	O
standard	32896292	52	60	O
of	32896292	61	63	O
care	32896292	64	68	O
alone	32896292	69	74	O
in	32896292	75	77	O
the	32896292	78	81	O
treatment	32896292	82	91	O
of	32896292	92	94	O
patients	32896292	95	103	O
admitted	32896292	104	112	O
to	32896292	113	115	O
the	32896292	116	119	O
hospital	32896292	120	128	O
with	32896292	129	133	O
severe	32896292	134	140	O
COVID-19	32896292	141	149	O
in	32896292	150	152	O
Brazil	32896292	153	159	O
(	32896292	160	161	O
COALITION	32896292	162	171	O
II	32896292	172	174	O
)	32896292	175	176	O
:	32896292	177	178	O
a	32896292	179	180	O
randomised	32896292	181	191	O
clinical	32896292	192	200	O
trial	32896292	201	206	O
.	32896292	207	208	O

The	32896292	209	212	O
efficacy	32896292	213	221	O
and	32896292	222	225	O
safety	32896292	226	232	O
of	32896292	233	235	O
azithromycin	32896292	236	248	O
in	32896292	249	251	O
the	32896292	252	255	O
treatment	32896292	256	265	O
of	32896292	266	268	O
COVID-19	32896292	269	277	O
remain	32896292	278	284	O
uncertain	32896292	285	294	O
.	32896292	295	296	O

We	32896292	297	299	O
assessed	32896292	300	308	O
whether	32896292	309	316	O
adding	32896292	317	323	O
azithromycin	32896292	324	336	O
to	32896292	337	339	O
standard	32896292	340	348	O
of	32896292	349	351	O
care	32896292	352	356	O
,	32896292	357	358	O
which	32896292	359	364	O
included	32896292	365	373	O
hydroxychloroquine	32896292	374	392	O
,	32896292	393	394	O
would	32896292	395	400	O
improve	32896292	401	408	O
clinical	32896292	409	417	O
outcomes	32896292	418	426	O
of	32896292	427	429	O
patients	32896292	430	438	O
admitted	32896292	439	447	O
to	32896292	448	450	O
the	32896292	451	454	O
hospital	32896292	455	463	O
with	32896292	464	468	O
severe	32896292	469	475	O
COVID-19	32896292	476	484	O
.	32896292	485	486	O

We	32896292	487	489	O
did	32896292	490	493	O
an	32896292	494	496	O
open	32896292	497	501	O
-	32896292	502	503	O
label	32896292	504	509	O
,	32896292	510	511	O
randomised	32896292	512	522	O
clinical	32896292	523	531	O
trial	32896292	532	537	O
at	32896292	538	540	O
57	32896292	541	543	O
centres	32896292	544	551	O
in	32896292	552	554	O
Brazil	32896292	555	561	O
.	32896292	562	563	O

We	32896292	564	566	O
enrolled	32896292	567	575	O
patients	32896292	576	584	O
admitted	32896292	585	593	O
to	32896292	594	596	O
hospital	32896292	597	605	O
with	32896292	606	610	O
suspected	32896292	611	620	O
or	32896292	621	623	O
confirmed	32896292	624	633	O
COVID-19	32896292	634	642	O
and	32896292	643	646	O
at	32896292	647	649	O
least	32896292	650	655	O
one	32896292	656	659	O
additional	32896292	660	670	O
severity	32896292	671	679	O
criteria	32896292	680	688	O
as	32896292	689	691	O
follows	32896292	692	699	O
:	32896292	700	701	O
use	32896292	702	705	O
of	32896292	706	708	O
oxygen	32896292	709	715	O
supplementation	32896292	716	731	O
of	32896292	732	734	O
more	32896292	735	739	O
than	32896292	740	744	O
4	32896292	745	746	O
L	32896292	747	748	O
/	32896292	749	750	O
min	32896292	751	754	O
flow	32896292	755	759	O
;	32896292	760	761	O
use	32896292	762	765	O
of	32896292	766	768	O
high	32896292	769	773	O
-	32896292	774	775	O
flow	32896292	776	780	O
nasal	32896292	781	786	O
cannula	32896292	787	794	O
;	32896292	795	796	O
use	32896292	797	800	O
of	32896292	801	803	O
non	32896292	804	807	O
-	32896292	808	809	O
invasive	32896292	810	818	O
mechanical	32896292	819	829	O
ventilation	32896292	830	841	O
;	32896292	842	843	O
or	32896292	844	846	O
use	32896292	847	850	O
of	32896292	851	853	O
invasive	32896292	854	862	O
mechanical	32896292	863	873	O
ventilation	32896292	874	885	O
.	32896292	886	887	O

Patients	32896292	888	896	O
were	32896292	897	901	O
randomly	32896292	902	910	O
assigned	32896292	911	919	O
(	32896292	920	921	O
1:1	32896292	922	925	O
)	32896292	926	927	O
to	32896292	928	930	O
azithromycin	32896292	931	943	O
(	32896292	944	945	O
500	32896292	946	949	O
mg	32896292	950	952	O
via	32896292	953	956	O
oral	32896292	957	961	O
,	32896292	962	963	O
nasogastric	32896292	964	975	O
,	32896292	976	977	O
or	32896292	978	980	O
intravenous	32896292	981	992	O
administration	32896292	993	1007	O
once	32896292	1008	1012	O
daily	32896292	1013	1018	O
for	32896292	1019	1022	O
10	32896292	1023	1025	O
days	32896292	1026	1030	O
)	32896292	1031	1032	O
plus	32896292	1033	1037	O
standard	32896292	1038	1046	O
of	32896292	1047	1049	O
care	32896292	1050	1054	O
or	32896292	1055	1057	O
to	32896292	1058	1060	O
standard	32896292	1061	1069	O
of	32896292	1070	1072	O
care	32896292	1073	1077	O
without	32896292	1078	1085	O
macrolides	32896292	1086	1096	O
.	32896292	1097	1098	O

All	32896292	1099	1102	O
patients	32896292	1103	1111	O
received	32896292	1112	1120	O
hydroxychloroquine	32896292	1121	1139	O
(	32896292	1140	1141	O
400	32896292	1142	1145	O
mg	32896292	1146	1148	O
twice	32896292	1149	1154	O
daily	32896292	1155	1160	O
for	32896292	1161	1164	O
10	32896292	1165	1167	O
days	32896292	1168	1172	O
)	32896292	1173	1174	O
because	32896292	1175	1182	O
that	32896292	1183	1187	O
was	32896292	1188	1191	O
part	32896292	1192	1196	O
of	32896292	1197	1199	O
standard	32896292	1200	1208	O
of	32896292	1209	1211	O
care	32896292	1212	1216	O
treatment	32896292	1217	1226	O
in	32896292	1227	1229	O
Brazil	32896292	1230	1236	O
for	32896292	1237	1240	O
patients	32896292	1241	1249	O
with	32896292	1250	1254	O
severe	32896292	1255	1261	O
COVID-19	32896292	1262	1270	O
.	32896292	1271	1272	O

The	32896292	1273	1276	O
primary	32896292	1277	1284	O
outcome	32896292	1285	1292	O
,	32896292	1293	1294	O
assessed	32896292	1295	1303	O
by	32896292	1304	1306	O
an	32896292	1307	1309	O
independent	32896292	1310	1321	O
adjudication	32896292	1322	1334	O
committee	32896292	1335	1344	O
masked	32896292	1345	1351	O
to	32896292	1352	1354	O
treatment	32896292	1355	1364	O
allocation	32896292	1365	1375	O
,	32896292	1376	1377	O
was	32896292	1378	1381	O
clinical	32896292	1382	1390	O
status	32896292	1391	1397	O
at	32896292	1398	1400	O
day	32896292	1401	1404	O
15	32896292	1405	1407	O
after	32896292	1408	1413	O
randomisation	32896292	1414	1427	O
,	32896292	1428	1429	O
assessed	32896292	1430	1438	O
by	32896292	1439	1441	O
a	32896292	1442	1443	O
six	32896292	1444	1447	O
-	32896292	1448	1449	O
point	32896292	1450	1455	O
ordinal	32896292	1456	1463	O
scale	32896292	1464	1469	O
,	32896292	1470	1471	O
with	32896292	1472	1476	O
levels	32896292	1477	1483	O
ranging	32896292	1484	1491	O
from	32896292	1492	1496	O
1	32896292	1497	1498	O
to	32896292	1499	1501	O
6	32896292	1502	1503	O
and	32896292	1504	1507	O
higher	32896292	1508	1514	O
scores	32896292	1515	1521	O
indicating	32896292	1522	1532	O
a	32896292	1533	1534	O
worse	32896292	1535	1540	O
condition	32896292	1541	1550	O
(	32896292	1551	1552	O
with	32896292	1553	1557	O
odds	32896292	1558	1562	O
ratio	32896292	1563	1568	O
[	32896292	1569	1570	O
OR	32896292	1571	1573	O
]	32896292	1574	1575	O
greater	32896292	1576	1583	O
than	32896292	1584	1588	O
100	32896292	1589	1593	O
favouring	32896292	1594	1603	O
the	32896292	1604	1607	O
control	32896292	1608	1615	O
group	32896292	1616	1621	O
)	32896292	1622	1623	O
.	32896292	1624	1625	O

The	32896292	1626	1629	O
primary	32896292	1630	1637	O
outcome	32896292	1638	1645	O
was	32896292	1646	1649	O
assessed	32896292	1650	1658	O
in	32896292	1659	1661	O
all	32896292	1662	1665	O
patients	32896292	1666	1674	O
in	32896292	1675	1677	O
the	32896292	1678	1681	O
intention	32896292	1682	1691	O
-	32896292	1692	1693	O
to	32896292	1694	1696	O
-	32896292	1697	1698	O
treat	32896292	1699	1704	O
(	32896292	1705	1706	O
ITT	32896292	1707	1710	O
)	32896292	1711	1712	O
population	32896292	1713	1723	O
who	32896292	1724	1727	O
had	32896292	1728	1731	O
severe	32896292	1732	1738	O
acute	32896292	1739	1744	O
respiratory	32896292	1745	1756	O
syndrome	32896292	1757	1765	O
coronavirus	32896292	1766	1777	O
2	32896292	1778	1779	O
infection	32896292	1780	1789	O
confirmed	32896292	1790	1799	O
by	32896292	1800	1802	O
molecular	32896292	1803	1812	O
or	32896292	1813	1815	O
serological	32896292	1816	1827	O
testing	32896292	1828	1835	O
before	32896292	1836	1842	O
randomisation	32896292	1843	1856	O
(	32896292	1857	1858	O
ie	32896292	1859	1861	O
,	32896292	1862	1863	O
modified	32896292	1864	1872	O
ITT	32896292	1873	1876	O
[	32896292	1877	1878	O
mITT	32896292	1879	1883	O
]	32896292	1884	1885	O
population	32896292	1886	1896	O
)	32896292	1897	1898	O
.	32896292	1899	1900	O

Safety	32896292	1901	1907	O
was	32896292	1908	1911	O
assessed	32896292	1912	1920	O
in	32896292	1921	1923	O
all	32896292	1924	1927	O
patients	32896292	1928	1936	O
according	32896292	1937	1946	O
to	32896292	1947	1949	O
which	32896292	1950	1955	O
treatment	32896292	1956	1965	O
they	32896292	1966	1970	O
received	32896292	1971	1979	O
,	32896292	1980	1981	O
regardless	32896292	1982	1992	O
of	32896292	1993	1995	O
original	32896292	1996	2004	O
group	32896292	2005	2010	O
assignment	32896292	2011	2021	O
.	32896292	2022	2023	O

This	32896292	2024	2028	O
trial	32896292	2029	2034	O
was	32896292	2035	2038	O
registered	32896292	2039	2049	O
at	32896292	2050	2052	O
ClinicalTrials.gov	32896292	2053	2071	O
,	32896292	2072	2073	O
NCT04321278	32896292	2074	2085	O
.	32896292	2086	2087	O

447	32896292	2088	2091	O
patients	32896292	2092	2100	O
were	32896292	2101	2105	O
enrolled	32896292	2106	2114	O
from	32896292	2115	2119	O
March	32896292	2120	2125	O
28	32896292	2126	2128	O
to	32896292	2129	2131	O
May	32896292	2132	2135	O
19	32896292	2136	2138	O
,	32896292	2139	2140	O
2020	32896292	2141	2145	O
.	32896292	2146	2147	O

COVID-19	32896292	2148	2156	O
was	32896292	2157	2160	O
confirmed	32896292	2161	2170	O
in	32896292	2171	2173	O
397	32896292	2174	2177	O
patients	32896292	2178	2186	O
who	32896292	2187	2190	O
constituted	32896292	2191	2202	O
the	32896292	2203	2206	O
mITT	32896292	2207	2211	O
population	32896292	2212	2222	O
,	32896292	2223	2224	O
of	32896292	2225	2227	O
whom	32896292	2228	2232	O
214	32896292	2233	2236	O
were	32896292	2237	2241	O
assigned	32896292	2242	2250	O
to	32896292	2251	2253	O
the	32896292	2254	2257	O
azithromycin	32896292	2258	2270	O
group	32896292	2271	2276	O
and	32896292	2277	2280	O
183	32896292	2281	2284	O
to	32896292	2285	2287	O
the	32896292	2288	2291	O
control	32896292	2292	2299	O
group	32896292	2300	2305	O
.	32896292	2306	2307	O

In	32896292	2308	2310	O
the	32896292	2311	2314	O
mITT	32896292	2315	2319	O
population	32896292	2320	2330	O
,	32896292	2331	2332	O
the	32896292	2333	2336	O
primary	32896292	2337	2344	O
endpoint	32896292	2345	2353	O
was	32896292	2354	2357	O
not	32896292	2358	2361	O
significantly	32896292	2362	2375	O
different	32896292	2376	2385	O
between	32896292	2386	2393	O
the	32896292	2394	2397	O
azithromycin	32896292	2398	2410	O
and	32896292	2411	2414	O
control	32896292	2415	2422	O
groups	32896292	2423	2429	O
(	32896292	2430	2431	O
OR	32896292	2432	2434	O
136	32896292	2435	2439	O
[	32896292	2440	2441	O
95	32896292	2442	2444	O
%	32896292	2445	2446	O
CI	32896292	2447	2449	O
094	32896292	2450	2454	O
-	32896292	2455	2456	O
197	32896292	2457	2461	O
]	32896292	2462	2463	O
,	32896292	2464	2465	O
p=011	32896292	2466	2472	O
)	32896292	2473	2474	O
.	32896292	2475	2476	O

Rates	32896292	2477	2482	O
of	32896292	2483	2485	O
adverse	32896292	2486	2493	O
events	32896292	2494	2500	O
,	32896292	2501	2502	O
including	32896292	2503	2512	O
clinically	32896292	2513	2523	O
relevant	32896292	2524	2532	O
ventricular	32896292	2533	2544	O
arrhythmias	32896292	2545	2556	O
,	32896292	2557	2558	O
resuscitated	32896292	2559	2571	O
cardiac	32896292	2572	2579	O
arrest	32896292	2580	2586	O
,	32896292	2587	2588	O
acute	32896292	2589	2594	O
kidney	32896292	2595	2601	O
failure	32896292	2602	2609	O
,	32896292	2610	2611	O
and	32896292	2612	2615	O
corrected	32896292	2616	2625	O
QT	32896292	2626	2628	O
interval	32896292	2629	2637	O
prolongation	32896292	2638	2650	O
,	32896292	2651	2652	O
were	32896292	2653	2657	O
not	32896292	2658	2661	O
significantly	32896292	2662	2675	O
different	32896292	2676	2685	O
between	32896292	2686	2693	O
groups	32896292	2694	2700	O
.	32896292	2701	2702	O

In	32896292	2703	2705	O
patients	32896292	2706	2714	O
with	32896292	2715	2719	O
severe	32896292	2720	2726	O
COVID-19	32896292	2727	2735	O
,	32896292	2736	2737	O
adding	32896292	2738	2744	O
azithromycin	32896292	2745	2757	O
to	32896292	2758	2760	O
standard	32896292	2761	2769	O
of	32896292	2770	2772	O
care	32896292	2773	2777	O
treatment	32896292	2778	2787	O
(	32896292	2788	2789	O
which	32896292	2790	2795	O
included	32896292	2796	2804	O
hydroxychloroquine	32896292	2805	2823	O
)	32896292	2824	2825	O
did	32896292	2826	2829	O
not	32896292	2830	2833	O
improve	32896292	2834	2841	O
clinical	32896292	2842	2850	O
outcomes	32896292	2851	2859	O
.	32896292	2860	2861	O

Our	32896292	2862	2865	O
findings	32896292	2866	2874	O
do	32896292	2875	2877	O
not	32896292	2878	2881	O
support	32896292	2882	2889	O
the	32896292	2890	2893	O
routine	32896292	2894	2901	O
use	32896292	2902	2905	O
of	32896292	2906	2908	O
azithromycin	32896292	2909	2921	O
in	32896292	2922	2924	O
combination	32896292	2925	2936	O
with	32896292	2937	2941	O
hydroxychloroquine	32896292	2942	2960	O
in	32896292	2961	2963	O
patients	32896292	2964	2972	O
with	32896292	2973	2977	O
severe	32896292	2978	2984	O
COVID-19	32896292	2985	2993	O
.	32896292	2994	2995	O

COALITION	32896292	2996	3005	O
COVID-19	32896292	3006	3014	O
Brazil	32896292	3015	3021	O
and	32896292	3022	3025	O
EMS	32896292	3026	3029	O
.	32896292	3030	3031	O


Validation	32910735	0	10	O
of	32910735	11	13	O
a	32910735	14	15	O
Novel	32910735	16	21	O
Wearable	32910735	22	30	O
Electromyography	32910735	31	47	O
Patch	32910735	48	53	O
for	32910735	54	57	O
Monitoring	32910735	58	68	O
Submental	32910735	69	78	O
Muscle	32910735	79	85	O
Activity	32910735	86	94	O
During	32910735	95	101	O
Swallowing	32910735	102	112	O
:	32910735	113	114	O
A	32910735	115	116	O
Randomized	32910735	117	127	O
Crossover	32910735	128	137	O
Trial	32910735	138	143	O
.	32910735	144	145	O

Purpose	32910735	146	153	O
Surface	32910735	154	161	O
electromyography	32910735	162	178	O
(	32910735	179	180	O
sEMG	32910735	181	185	O
)	32910735	186	187	O
is	32910735	188	190	O
often	32910735	191	196	O
used	32910735	197	201	O
for	32910735	202	205	O
biofeedback	32910735	206	217	O
during	32910735	218	224	O
swallowing	32910735	225	235	O
rehabilitation	32910735	236	250	O
.	32910735	251	252	O

However	32910735	253	260	O
,	32910735	261	262	O
commercially	32910735	263	275	O
available	32910735	276	285	O
sEMG	32910735	286	290	O
electrodes	32910735	291	301	O
are	32910735	302	305	O
not	32910735	306	309	O
optimized	32910735	310	319	O
for	32910735	320	323	O
the	32910735	324	327	O
head	32910735	328	332	O
and	32910735	333	336	O
neck	32910735	337	341	O
area	32910735	342	346	O
,	32910735	347	348	O
have	32910735	349	353	O
rigid	32910735	354	359	O
form	32910735	360	364	O
,	32910735	365	366	O
and	32910735	367	370	O
are	32910735	371	374	O
mostly	32910735	375	381	O
available	32910735	382	391	O
in	32910735	392	394	O
large	32910735	395	400	O
medical	32910735	401	408	O
centers	32910735	409	416	O
.	32910735	417	418	O

We	32910735	419	421	O
developed	32910735	422	431	O
an	32910735	432	434	O
ultrathin	32910735	435	444	O
,	32910735	445	446	O
soft	32910735	447	451	O
,	32910735	452	453	O
and	32910735	454	457	O
flexible	32910735	458	466	O
sEMG	32910735	467	471	O
patch	32910735	472	477	O
,	32910735	478	479	O
specifically	32910735	480	492	O
designed	32910735	493	501	O
to	32910735	502	504	O
conform	32910735	505	512	O
to	32910735	513	515	O
the	32910735	516	519	O
submental	32910735	520	529	O
anatomy	32910735	530	537	O
and	32910735	538	541	O
which	32910735	542	547	O
will	32910735	548	552	O
be	32910735	553	555	O
ultimately	32910735	556	566	O
incorporated	32910735	567	579	O
into	32910735	580	584	O
a	32910735	585	586	O
telehealth	32910735	587	597	O
system	32910735	598	604	O
.	32910735	605	606	O

To	32910735	607	609	O
validate	32910735	610	618	O
this	32910735	619	623	O
first	32910735	624	629	O
-	32910735	630	631	O
generation	32910735	632	642	O
sEMG	32910735	643	647	O
patch	32910735	648	653	O
,	32910735	654	655	O
we	32910735	656	658	O
compared	32910735	659	667	O
its	32910735	668	671	O
safety	32910735	672	678	O
,	32910735	679	680	O
efficiency	32910735	681	691	O
,	32910735	692	693	O
and	32910735	694	697	O
signal	32910735	698	704	O
quality	32910735	705	712	O
in	32910735	713	715	O
monitoring	32910735	716	726	O
submental	32910735	727	736	O
muscle	32910735	737	743	O
activity	32910735	744	752	O
with	32910735	753	757	O
that	32910735	758	762	O
of	32910735	763	765	O
widely	32910735	766	772	O
used	32910735	773	777	O
conventional	32910735	778	790	O
sEMG	32910735	791	795	O
electrodes	32910735	796	806	O
.	32910735	807	808	O

Method	32910735	809	815	O
A	32910735	816	817	O
randomized	32910735	818	828	O
crossover	32910735	829	838	O
design	32910735	839	845	O
was	32910735	846	849	O
used	32910735	850	854	O
to	32910735	855	857	O
compare	32910735	858	865	O
the	32910735	866	869	O
experimental	32910735	870	882	O
sEMG	32910735	883	887	O
patch	32910735	888	893	O
with	32910735	894	898	O
conventional	32910735	899	911	O
(	32910735	912	913	O
snap	32910735	914	918	O
-	32910735	919	920	O
on	32910735	921	923	O
)	32910735	924	925	O
sEMG	32910735	926	930	O
electrodes	32910735	931	941	O
.	32910735	942	943	O

Participants	32910735	944	956	O
completed	32910735	957	966	O
the	32910735	967	970	O
same	32910735	971	975	O
experimental	32910735	976	988	O
protocol	32910735	989	997	O
with	32910735	998	1002	O
both	32910735	1003	1007	O
electrodes	32910735	1008	1018	O
in	32910735	1019	1021	O
counterbalanced	32910735	1022	1037	O
order	32910735	1038	1043	O
.	32910735	1044	1045	O

Swallow	32910735	1046	1053	O
trials	32910735	1054	1060	O
included	32910735	1061	1069	O
five	32910735	1070	1074	O
trials	32910735	1075	1081	O
of	32910735	1082	1084	O
5-	32910735	1085	1087	O
and	32910735	1088	1091	O
10-ml	32910735	1092	1097	O
water	32910735	1098	1103	O
.	32910735	1104	1105	O

Comparisons	32910735	1106	1117	O
were	32910735	1118	1122	O
made	32910735	1123	1127	O
on	32910735	1128	1130	O
(	32910735	1131	1132	O
a	32910735	1133	1134	O
)	32910735	1135	1136	O
signal	32910735	1137	1143	O
-	32910735	1144	1145	O
related	32910735	1146	1153	O
factors	32910735	1154	1161	O
:	32910735	1162	1163	O
signal	32910735	1164	1170	O
-	32910735	1171	1172	O
to	32910735	1173	1175	O
-	32910735	1176	1177	O
noise	32910735	1178	1183	O
ratio	32910735	1184	1189	O
(	32910735	1190	1191	O
SNR	32910735	1192	1195	O
)	32910735	1196	1197	O
,	32910735	1198	1199	O
baseline	32910735	1200	1208	O
amplitude	32910735	1209	1218	O
,	32910735	1219	1220	O
normalized	32910735	1221	1231	O
mean	32910735	1232	1236	O
amplitude	32910735	1237	1246	O
,	32910735	1247	1248	O
and	32910735	1249	1252	O
sEMG	32910735	1253	1257	O
burst	32910735	1258	1263	O
duration	32910735	1264	1272	O
and	32910735	1273	1276	O
(	32910735	1277	1278	O
b	32910735	1279	1280	O
)	32910735	1281	1282	O
safety	32910735	1283	1289	O
/	32910735	1290	1291	O
preclinical	32910735	1292	1303	O
factors	32910735	1304	1311	O
:	32910735	1312	1313	O
safety	32910735	1314	1320	O
/	32910735	1321	1322	O
adverse	32910735	1323	1330	O
effects	32910735	1331	1338	O
,	32910735	1339	1340	O
efficiency	32910735	1341	1351	O
of	32910735	1352	1354	O
electrode	32910735	1355	1364	O
placement	32910735	1365	1374	O
,	32910735	1375	1376	O
and	32910735	1377	1380	O
satisfaction	32910735	1381	1393	O
/	32910735	1394	1395	O
comfort	32910735	1396	1403	O
.	32910735	1404	1405	O

Noninferiority	32910735	1406	1420	O
and	32910735	1421	1424	O
equivalence	32910735	1425	1436	O
tests	32910735	1437	1442	O
were	32910735	1443	1447	O
used	32910735	1448	1452	O
to	32910735	1453	1455	O
examine	32910735	1456	1463	O
signal	32910735	1464	1470	O
-	32910735	1471	1472	O
related	32910735	1473	1480	O
factors	32910735	1481	1488	O
.	32910735	1489	1490	O

Paired	32910735	1491	1497	O
t	32910735	1498	1499	O
tests	32910735	1500	1505	O
and	32910735	1506	1509	O
descriptive	32910735	1510	1521	O
statistics	32910735	1522	1532	O
were	32910735	1533	1537	O
used	32910735	1538	1542	O
to	32910735	1543	1545	O
examine	32910735	1546	1553	O
safety	32910735	1554	1560	O
/	32910735	1561	1562	O
preclinical	32910735	1563	1574	O
factors	32910735	1575	1582	O
.	32910735	1583	1584	O

Results	32910735	1585	1592	O
Forty	32910735	1593	1598	O
healthy	32910735	1599	1606	O
adults	32910735	1607	1613	O
participated	32910735	1614	1626	O
(	32910735	1627	1628	O
24	32910735	1629	1631	O
women	32910735	1632	1637	O
,	32910735	1638	1639	O
Mage	32910735	1640	1644	O
=	32910735	1645	1646	O
67.5	32910735	1647	1651	O
years	32910735	1652	1657	O
)	32910735	1658	1659	O
.	32910735	1660	1661	O

Signal	32910735	1662	1668	O
-	32910735	1669	1670	O
related	32910735	1671	1678	O
factors	32910735	1679	1686	O
:	32910735	1687	1688	O
SNR	32910735	1689	1692	O
of	32910735	1693	1695	O
the	32910735	1696	1699	O
experimental	32910735	1700	1712	O
patch	32910735	1713	1718	O
was	32910735	1719	1722	O
not	32910735	1723	1726	O
inferior	32910735	1727	1735	O
to	32910735	1736	1738	O
the	32910735	1739	1742	O
SNR	32910735	1743	1746	O
of	32910735	1747	1749	O
the	32910735	1750	1753	O
conventional	32910735	1754	1766	O
electrodes	32910735	1767	1777	O
(	32910735	1778	1779	O
p	32910735	1780	1781	O
<	32910735	1782	1783	O
.0056	32910735	1784	1789	O
)	32910735	1790	1791	O
.	32910735	1792	1793	O

Similarly	32910735	1794	1803	O
,	32910735	1804	1805	O
baseline	32910735	1806	1814	O
amplitude	32910735	1815	1824	O
obtained	32910735	1825	1833	O
with	32910735	1834	1838	O
the	32910735	1839	1842	O
experimental	32910735	1843	1855	O
patch	32910735	1856	1861	O
was	32910735	1862	1865	O
not	32910735	1866	1869	O
inferior	32910735	1870	1878	O
to	32910735	1879	1881	O
that	32910735	1882	1886	O
obtained	32910735	1887	1895	O
with	32910735	1896	1900	O
conventional	32910735	1901	1913	O
electrodes	32910735	1914	1924	O
(	32910735	1925	1926	O
p	32910735	1927	1928	O
<	32910735	1929	1930	O
.0001	32910735	1931	1936	O
)	32910735	1937	1938	O
.	32910735	1939	1940	O

Finally	32910735	1941	1948	O
,	32910735	1949	1950	O
normalized	32910735	1951	1961	O
amplitude	32910735	1962	1971	O
values	32910735	1972	1978	O
were	32910735	1979	1983	O
equivalent	32910735	1984	1994	O
across	32910735	1995	2001	O
swallows	32910735	2002	2010	O
(	32910735	2011	2012	O
5	32910735	2013	2014	O
ml	32910735	2015	2017	O
:	32910735	2018	2019	O
p	32910735	2020	2021	O
<	32910735	2022	2023	O
.025	32910735	2024	2028	O
;	32910735	2029	2030	O
10	32910735	2031	2033	O
ml	32910735	2034	2036	O
:	32910735	2037	2038	O
p	32910735	2039	2040	O
<	32910735	2041	2042	O
.0012	32910735	2043	2048	O
)	32910735	2049	2050	O
,	32910735	2051	2052	O
and	32910735	2053	2056	O
sEMG	32910735	2057	2061	O
burst	32910735	2062	2067	O
duration	32910735	2068	2076	O
was	32910735	2077	2080	O
also	32910735	2081	2085	O
equivalent	32910735	2086	2096	O
(	32910735	2097	2098	O
5	32910735	2099	2100	O
ml	32910735	2101	2103	O
:	32910735	2104	2105	O
p	32910735	2106	2107	O
<	32910735	2108	2109	O
.0001	32910735	2110	2115	O
;	32910735	2116	2117	O
10	32910735	2118	2120	O
ml	32910735	2121	2123	O
:	32910735	2124	2125	O
p	32910735	2126	2127	O
<	32910735	2128	2129	O
.0001	32910735	2130	2135	O
)	32910735	2136	2137	O
.	32910735	2138	2139	O

Safety	32910735	2140	2146	O
/	32910735	2147	2148	O
preclinical	32910735	2149	2160	O
factors	32910735	2161	2168	O
:	32910735	2169	2170	O
The	32910735	2171	2174	O
experimental	32910735	2175	2187	O
patch	32910735	2188	2193	O
resulted	32910735	2194	2202	O
in	32910735	2203	2205	O
fewer	32910735	2206	2211	O
mild	32910735	2212	2216	O
adverse	32910735	2217	2224	O
effects	32910735	2225	2232	O
.	32910735	2233	2234	O

Participant	32910735	2235	2246	O
satisfaction	32910735	2247	2259	O
was	32910735	2260	2263	O
higher	32910735	2264	2270	O
with	32910735	2271	2275	O
the	32910735	2276	2279	O
experimental	32910735	2280	2292	O
patch	32910735	2293	2298	O
(	32910735	2299	2300	O
p	32910735	2301	2302	O
=	32910735	2303	2304	O
.0476	32910735	2305	2310	O
,	32910735	2311	2312	O
d	32910735	2313	2314	O
=	32910735	2315	2316	O
0.226	32910735	2317	2322	O
)	32910735	2323	2324	O
.	32910735	2325	2326	O

Conclusions	32910735	2327	2338	O
Our	32910735	2339	2342	O
new	32910735	2343	2346	O
wearable	32910735	2347	2355	O
sEMG	32910735	2356	2360	O
patch	32910735	2361	2366	O
is	32910735	2367	2369	O
equivalent	32910735	2370	2380	O
with	32910735	2381	2385	O
widely	32910735	2386	2392	O
used	32910735	2393	2397	O
conventional	32910735	2398	2410	O
sEMG	32910735	2411	2415	O
electrodes	32910735	2416	2426	O
in	32910735	2427	2429	O
terms	32910735	2430	2435	O
of	32910735	2436	2438	O
technical	32910735	2439	2448	O
performance	32910735	2449	2460	O
.	32910735	2461	2462	O

In	32910735	2463	2465	O
addition	32910735	2466	2474	O
,	32910735	2475	2476	O
our	32910735	2477	2480	O
patch	32910735	2481	2486	O
is	32910735	2487	2489	O
safe	32910735	2490	2494	O
,	32910735	2495	2496	O
and	32910735	2497	2500	O
healthy	32910735	2501	2508	O
older	32910735	2509	2514	O
adults	32910735	2515	2521	O
are	32910735	2522	2525	O
satisfied	32910735	2526	2535	O
with	32910735	2536	2540	O
it	32910735	2541	2543	O
.	32910735	2544	2545	O

With	32910735	2546	2550	O
lessons	32910735	2551	2558	O
learned	32910735	2559	2566	O
from	32910735	2567	2571	O
the	32910735	2572	2575	O
current	32910735	2576	2583	O
COVID-19	32910735	2584	2592	O
pandemic	32910735	2593	2601	O
,	32910735	2602	2603	O
efforts	32910735	2604	2611	O
to	32910735	2612	2614	O
develop	32910735	2615	2622	O
optimal	32910735	2623	2630	O
swallowing	32910735	2631	2641	O
telerehabilitation	32910735	2642	2660	O
devices	32910735	2661	2668	O
are	32910735	2669	2672	O
more	32910735	2673	2677	O
urgent	32910735	2678	2684	O
than	32910735	2685	2689	O
ever	32910735	2690	2694	O
.	32910735	2695	2696	O

Upon	32910735	2697	2701	O
further	32910735	2702	2709	O
validation	32910735	2710	2720	O
,	32910735	2721	2722	O
this	32910735	2723	2727	O
new	32910735	2728	2731	O
technology	32910735	2732	2742	O
has	32910735	2743	2746	O
the	32910735	2747	2750	O
potential	32910735	2751	2760	O
to	32910735	2761	2763	O
improve	32910735	2764	2771	O
rehabilitation	32910735	2772	2786	O
and	32910735	2787	2790	O
telerehabilitation	32910735	2791	2809	O
efforts	32910735	2810	2817	O
for	32910735	2818	2821	O
patients	32910735	2822	2830	O
with	32910735	2831	2835	O
dysphagia	32910735	2836	2845	O
.	32910735	2846	2847	O

Supplemental	32910735	2848	2860	O
Material	32910735	2861	2869	O
https://doi.org/10.23641/asha.12915509	32910735	2870	2908	O
.	32910735	2909	2910	O


Time	32928122	0	4	O
to	32928122	5	7	O
adapt	32928122	8	13	O
in	32928122	14	16	O
the	32928122	17	20	O
pandemic	32928122	21	29	O
era	32928122	30	33	O
:	32928122	34	35	O
a	32928122	36	37	O
prospective	32928122	38	49	O
randomized	32928122	50	60	O
non	32928122	61	64	O
-inferiority	32928122	65	77	O
study	32928122	78	83	O
comparing	32928122	84	93	O
time	32928122	94	98	O
to	32928122	99	101	O
intubate	32928122	102	110	O
with	32928122	111	115	O
and	32928122	116	119	O
without	32928122	120	127	O
the	32928122	128	131	O
barrier	32928122	132	139	O
box	32928122	140	143	O
.	32928122	144	145	O

The	32928122	146	149	O
challenges	32928122	150	160	O
posed	32928122	161	166	O
by	32928122	167	169	O
the	32928122	170	173	O
spread	32928122	174	180	O
of	32928122	181	183	O
COVID-19	32928122	184	192	O
disease	32928122	193	200	O
through	32928122	201	208	O
aerosols	32928122	209	217	O
have	32928122	218	222	O
compelled	32928122	223	232	O
anesthesiologists	32928122	233	250	O
to	32928122	251	253	O
modify	32928122	254	260	O
their	32928122	261	266	O
airway	32928122	267	273	O
management	32928122	274	284	O
practices	32928122	285	294	O
.	32928122	295	296	O

Devices	32928122	297	304	O
such	32928122	305	309	O
as	32928122	310	312	O
barrier	32928122	313	320	O
boxes	32928122	321	326	O
are	32928122	327	330	O
being	32928122	331	336	O
considered	32928122	337	347	O
as	32928122	348	350	O
potential	32928122	351	360	O
adjuncts	32928122	361	369	O
to	32928122	370	372	O
full	32928122	373	377	O
PPE	32928122	378	381	O
's	32928122	382	384	O
to	32928122	385	387	O
limit	32928122	388	393	O
the	32928122	394	397	O
aerosol	32928122	398	405	O
spread	32928122	406	412	O
.	32928122	413	414	O

Usage	32928122	415	420	O
of	32928122	421	423	O
the	32928122	424	427	O
barrier	32928122	428	435	O
box	32928122	436	439	O
raises	32928122	440	446	O
concerns	32928122	447	455	O
of	32928122	456	458	O
delay	32928122	459	464	O
in	32928122	465	467	O
time	32928122	468	472	O
to	32928122	473	475	O
intubate	32928122	476	484	O
(	32928122	485	486	O
TTI	32928122	487	490	O
)	32928122	491	492	O
.	32928122	493	494	O

We	32928122	495	497	O
designed	32928122	498	506	O
our	32928122	507	510	O
study	32928122	511	516	O
to	32928122	517	519	O
determine	32928122	520	529	O
if	32928122	530	532	O
using	32928122	533	538	O
a	32928122	539	540	O
barrier	32928122	541	548	O
box	32928122	549	552	O
with	32928122	553	557	O
glidescope	32928122	558	568	O
delays	32928122	569	575	O
TTI	32928122	576	579	O
within	32928122	580	586	O
acceptable	32928122	587	597	O
parameters	32928122	598	608	O
to	32928122	609	611	O
make	32928122	612	616	O
relevant	32928122	617	625	O
clinical	32928122	626	634	O
conclusions	32928122	635	646	O
.	32928122	647	648	O

Seventy	32928122	649	656	O
-	32928122	657	658	O
eight	32928122	659	664	O
patients	32928122	665	673	O
were	32928122	674	678	O
enrolled	32928122	679	687	O
in	32928122	688	690	O
this	32928122	691	695	O
prospective	32928122	696	707	O
non	32928122	708	711	O
-	32928122	712	713	O
inferiority	32928122	714	725	O
controlled	32928122	726	736	O
trial	32928122	737	742	O
and	32928122	743	746	O
were	32928122	747	751	O
randomly	32928122	752	760	O
allocated	32928122	761	770	O
to	32928122	771	773	O
either	32928122	774	780	O
group	32928122	781	786	O
C	32928122	787	788	O
(	32928122	789	790	O
without	32928122	791	798	O
the	32928122	799	802	O
barrier	32928122	803	810	O
box	32928122	811	814	O
)	32928122	815	816	O
or	32928122	817	819	O
the	32928122	820	823	O
study	32928122	824	829	O
group	32928122	830	835	O
BB	32928122	836	838	O
(	32928122	839	840	O
using	32928122	841	846	O
barrier	32928122	847	854	O
box	32928122	855	858	O
)	32928122	859	860	O
.	32928122	861	862	O

The	32928122	863	866	O
primary	32928122	867	874	O
measured	32928122	875	883	O
endpoint	32928122	884	892	O
is	32928122	893	895	O
time	32928122	896	900	O
to	32928122	901	903	O
intubate	32928122	904	912	O
(	32928122	913	914	O
TTI	32928122	915	918	O
)	32928122	919	920	O
,	32928122	921	922	O
which	32928122	923	928	O
is	32928122	929	931	O
defined	32928122	932	939	O
as	32928122	940	942	O
time	32928122	943	947	O
taken	32928122	948	953	O
from	32928122	954	958	O
loss	32928122	959	963	O
of	32928122	964	966	O
twitches	32928122	967	975	O
confirmed	32928122	976	985	O
with	32928122	986	990	O
a	32928122	991	992	O
peripheral	32928122	993	1003	O
nerve	32928122	1004	1009	O
stimulator	32928122	1010	1020	O
to	32928122	1021	1023	O
confirmation	32928122	1024	1036	O
of	32928122	1037	1039	O
end	32928122	1040	1043	O
-	32928122	1044	1045	O
tidal	32928122	1046	1051	O
CO	32928122	1052	1054	O
2	32928122	1055	1056	O
.	32928122	1057	1058	O

15	32928122	1059	1061	O
s	32928122	1064	1065	O
was	32928122	1066	1069	O
used	32928122	1070	1074	O
as	32928122	1075	1077	O
non	32928122	1078	1081	O
-	32928122	1082	1083	O
inferiority	32928122	1084	1095	O
margin	32928122	1096	1102	O
for	32928122	1103	1106	O
the	32928122	1107	1110	O
purpose	32928122	1111	1118	O
of	32928122	1119	1121	O
the	32928122	1122	1125	O
study	32928122	1126	1131	O
.	32928122	1132	1133	O

We	32928122	1134	1136	O
used	32928122	1137	1141	O
an	32928122	1142	1144	O
unpaired	32928122	1145	1153	O
two	32928122	1154	1157	O
-	32928122	1158	1159	O
sample	32928122	1160	1166	O
single	32928122	1167	1173	O
-	32928122	1174	1175	O
sided	32928122	1176	1181	O
t	32928122	1182	1183	O
-	32928122	1184	1185	O
test	32928122	1186	1190	O
to	32928122	1191	1193	O
test	32928122	1194	1198	O
our	32928122	1199	1202	O
non-	32928122	1203	1207	O
inferiority	32928122	1208	1219	O
hypothesis	32928122	1220	1230	O
(	32928122	1231	1232	O
H	32928122	1233	1234	O
0	32928122	1235	1236	O
:	32928122	1237	1238	O
Mean	32928122	1239	1243	O
TTI	32928122	1244	1247	O
diff	32928122	1248	1252	O
	32928122	1255	1256	O
15	32928122	1257	1259	O
s	32928122	1262	1263	O
,	32928122	1264	1265	O
H	32928122	1266	1267	O
A	32928122	1268	1269	O
:	32928122	1270	1271	O
Mean	32928122	1272	1276	O
TTI	32928122	1277	1280	O
diff	32928122	1281	1285	O
<	32928122	1286	1287	O
15	32928122	1290	1292	O
s	32928122	1295	1296	O
)	32928122	1297	1298	O
.	32928122	1299	1300	O

Secondary	32928122	1301	1310	O
endpoints	32928122	1311	1320	O
include	32928122	1321	1328	O
the	32928122	1329	1332	O
number	32928122	1333	1339	O
of	32928122	1340	1342	O
attempts	32928122	1343	1351	O
at	32928122	1352	1354	O
intubation	32928122	1355	1365	O
,	32928122	1366	1367	O
lowest	32928122	1368	1374	O
oxygen	32928122	1375	1381	O
saturation	32928122	1382	1392	O
during	32928122	1393	1399	O
induction	32928122	1400	1409	O
,	32928122	1410	1411	O
and	32928122	1412	1415	O
the	32928122	1416	1419	O
need	32928122	1420	1424	O
for	32928122	1425	1428	O
bag	32928122	1429	1432	O
-	32928122	1433	1434	O
mask	32928122	1435	1439	O
ventilation	32928122	1440	1451	O
.	32928122	1452	1453	O

Mean	32928122	1454	1458	O
TTI	32928122	1459	1462	O
in	32928122	1463	1465	O
group	32928122	1466	1471	O
C	32928122	1472	1473	O
was	32928122	1474	1477	O
42	32928122	1478	1480	O
s	32928122	1483	1484	O
(	32928122	1485	1486	O
CI	32928122	1487	1489	O
19.2	32928122	1490	1494	O
to	32928122	1495	1497	O
64.8	32928122	1498	1502	O
)	32928122	1503	1504	O
vs.	32928122	1505	1508	O
52.1	32928122	1509	1513	O
s	32928122	1516	1517	O
(	32928122	1518	1519	O
CI	32928122	1520	1522	O
26.1	32928122	1523	1527	O
to	32928122	1528	1530	O
78	32928122	1531	1533	O
)	32928122	1534	1535	O
in	32928122	1536	1538	O
group	32928122	1539	1544	O
BB	32928122	1545	1547	O
.	32928122	1548	1549	O

The	32928122	1550	1553	O
difference	32928122	1554	1564	O
in	32928122	1565	1567	O
mean	32928122	1568	1572	O
TTI	32928122	1573	1576	O
was	32928122	1577	1580	O
10.1	32928122	1581	1585	O
s	32928122	1588	1589	O
(	32928122	1590	1591	O
CI	32928122	1592	1594	O
-	32928122	1595	1597	O
to	32928122	1598	1600	O
14.9	32928122	1601	1605	O
)	32928122	1606	1607	O
.	32928122	1608	1609	O

We	32928122	1610	1612	O
rejected	32928122	1613	1621	O
the	32928122	1622	1625	O
null	32928122	1626	1630	O
hypothesis	32928122	1631	1641	O
and	32928122	1642	1645	O
concluded	32928122	1646	1655	O
with	32928122	1656	1660	O
95	32928122	1661	1663	O
%	32928122	1664	1665	O
confidence	32928122	1666	1676	O
that	32928122	1677	1681	O
the	32928122	1682	1685	O
difference	32928122	1686	1696	O
of	32928122	1697	1699	O
the	32928122	1700	1703	O
mean	32928122	1704	1708	O
TTI	32928122	1709	1712	O
between	32928122	1713	1720	O
the	32928122	1721	1724	O
groups	32928122	1725	1731	O
is	32928122	1732	1734	O
less	32928122	1735	1739	O
than	32928122	1740	1744	O
<	32928122	1745	1746	O
15	32928122	1749	1751	O
s	32928122	1754	1755	O
(	32928122	1756	1757	O
95	32928122	1758	1760	O
%	32928122	1761	1762	O
CI	32928122	1763	1765	O
-	32928122	1766	1768	O
to	32928122	1769	1771	O
14.9,p	32928122	1772	1778	O
=	32928122	1781	1782	O
0.0461	32928122	1785	1791	O
)	32928122	1792	1793	O
.	32928122	1794	1795	O

Our	32928122	1796	1799	O
induction	32928122	1800	1809	O
times	32928122	1810	1815	O
were	32928122	1816	1820	O
comparable	32928122	1821	1831	O
(	32928122	1832	1833	O
67.7	32928122	1834	1838	O
vs.	32928122	1839	1842	O
65.9	32928122	1843	1847	O
s).100	32928122	1850	1856	O
%	32928122	1857	1858	O
of	32928122	1859	1861	O
our	32928122	1862	1865	O
patients	32928122	1866	1874	O
were	32928122	1875	1879	O
intubated	32928122	1880	1889	O
on	32928122	1890	1892	O
the	32928122	1893	1896	O
first	32928122	1897	1902	O
attempt	32928122	1903	1910	O
in	32928122	1911	1913	O
both	32928122	1914	1918	O
groups	32928122	1919	1925	O
.	32928122	1926	1927	O

None	32928122	1928	1932	O
of	32928122	1933	1935	O
our	32928122	1936	1939	O
patients	32928122	1940	1948	O
needed	32928122	1949	1955	O
rescue	32928122	1956	1962	O
breaths	32928122	1963	1970	O
.	32928122	1971	1972	O

We	32928122	1973	1975	O
conclude	32928122	1976	1984	O
that	32928122	1985	1989	O
in	32928122	1990	1992	O
patients	32928122	1993	2001	O
with	32928122	2002	2006	O
normal	32928122	2007	2013	O
airway	32928122	2014	2020	O
exam	32928122	2021	2025	O
,	32928122	2026	2027	O
scheduled	32928122	2028	2037	O
for	32928122	2038	2041	O
elective	32928122	2042	2050	O
surgeries	32928122	2051	2060	O
,	32928122	2061	2062	O
our	32928122	2063	2066	O
barrier	32928122	2067	2074	O
box	32928122	2075	2078	O
did	32928122	2079	2082	O
not	32928122	2083	2086	O
cause	32928122	2087	2092	O
any	32928122	2093	2096	O
clinically	32928122	2097	2107	O
significant	32928122	2108	2119	O
delay	32928122	2120	2125	O
in	32928122	2126	2128	O
TTI	32928122	2129	2132	O
when	32928122	2133	2137	O
airway	32928122	2138	2144	O
manipulation	32928122	2145	2157	O
is	32928122	2158	2160	O
performed	32928122	2161	2170	O
by	32928122	2171	2173	O
well	32928122	2174	2178	O
-	32928122	2179	2180	O
trained	32928122	2181	2188	O
providers	32928122	2189	2198	O
.	32928122	2199	2200	O

The	32928122	2201	2204	O
study	32928122	2205	2210	O
was	32928122	2211	2214	O
retrospectively	32928122	2215	2230	O
registered	32928122	2231	2241	O
at	32928122	2242	2244	O
clinicaltrials.gov	32928122	2245	2263	O
(	32928122	2264	2265	O
NCT04411056	32928122	2266	2277	O
)	32928122	2278	2279	O
on	32928122	2280	2282	O
May	32928122	2283	2286	O
27	32928122	2287	2289	O
,	32928122	2290	2291	O
2020	32928122	2292	2296	O
.	32928122	2297	2298	O


Activate	32941801	0	8	O
:	32941801	9	10	O
Randomized	32941801	11	21	O
Clinical	32941801	22	30	O
Trial	32941801	31	36	O
of	32941801	37	39	O
BCG	32941801	40	43	O
Vaccination	32941801	44	55	O
against	32941801	56	63	O
Infection	32941801	64	73	O
in	32941801	74	76	O
the	32941801	77	80	O
Elderly	32941801	81	88	O
.	32941801	89	90	O

BCG	32941801	91	94	O
vaccination	32941801	95	106	O
in	32941801	107	109	O
children	32941801	110	118	O
protects	32941801	119	127	O
against	32941801	128	135	O
heterologous	32941801	136	148	O
infections	32941801	149	159	O
and	32941801	160	163	O
improves	32941801	164	172	O
survival	32941801	173	181	O
independently	32941801	182	195	O
of	32941801	196	198	O
tuberculosis	32941801	199	211	O
prevention	32941801	212	222	O
.	32941801	223	224	O

The	32941801	225	228	O
phase	32941801	229	234	O
III	32941801	235	238	O
ACTIVATE	32941801	239	247	O
trial	32941801	248	253	O
assessed	32941801	254	262	O
whether	32941801	263	270	O
BCG	32941801	271	274	O
has	32941801	275	278	O
similar	32941801	279	286	O
effects	32941801	287	294	O
in	32941801	295	297	O
the	32941801	298	301	O
elderly	32941801	302	309	O
.	32941801	310	311	O

In	32941801	312	314	O
this	32941801	315	319	O
double	32941801	320	326	O
-	32941801	327	328	O
blind	32941801	329	334	O
,	32941801	335	336	O
randomized	32941801	337	347	O
trial	32941801	348	353	O
,	32941801	354	355	O
elderly	32941801	356	363	O
patients	32941801	364	372	O
(	32941801	373	374	O
n	32941801	375	376	O
=	32941801	379	380	O
198	32941801	381	384	O
)	32941801	385	386	O
received	32941801	387	395	O
BCG	32941801	396	399	O
or	32941801	400	402	O
placebo	32941801	403	410	O
vaccine	32941801	411	418	O
at	32941801	419	421	O
hospital	32941801	422	430	O
discharge	32941801	431	440	O
and	32941801	441	444	O
were	32941801	445	449	O
followed	32941801	450	458	O
for	32941801	459	462	O
12	32941801	463	465	O
months	32941801	468	474	O
for	32941801	475	478	O
new	32941801	479	482	O
infections	32941801	483	493	O
.	32941801	494	495	O

At	32941801	496	498	O
interim	32941801	499	506	O
analysis	32941801	507	515	O
,	32941801	516	517	O
BCG	32941801	518	521	O
vaccination	32941801	522	533	O
significantly	32941801	534	547	O
increased	32941801	548	557	O
the	32941801	558	561	O
time	32941801	562	566	O
to	32941801	567	569	O
first	32941801	570	575	O
infection	32941801	576	585	O
(	32941801	586	587	O
median	32941801	588	594	O
16	32941801	595	597	O
weeks	32941801	600	605	O
compared	32941801	606	614	O
to	32941801	615	617	O
11	32941801	618	620	O
weeks	32941801	623	628	O
after	32941801	629	634	O
placebo	32941801	635	642	O
)	32941801	643	644	O
.	32941801	645	646	O

The	32941801	647	650	O
incidence	32941801	651	660	O
of	32941801	661	663	O
new	32941801	664	667	O
infections	32941801	668	678	O
was	32941801	679	682	O
42.3	32941801	683	687	O
%	32941801	688	689	O
(	32941801	690	691	O
95	32941801	692	694	O
%	32941801	695	696	O
CIs	32941801	697	700	O
31.9%-53.4	32941801	701	711	O
%	32941801	712	713	O
)	32941801	714	715	O
after	32941801	716	721	O
placebo	32941801	722	729	O
vaccination	32941801	730	741	O
and	32941801	742	745	O
25.0	32941801	746	750	O
%	32941801	751	752	O
(	32941801	753	754	O
95	32941801	755	757	O
%	32941801	758	759	O
CIs	32941801	760	763	O
16.4%-36.1	32941801	764	774	O
%	32941801	775	776	O
)	32941801	777	778	O
after	32941801	779	784	O
BCG	32941801	785	788	O
vaccination	32941801	789	800	O
;	32941801	801	802	O
most	32941801	803	807	O
of	32941801	808	810	O
the	32941801	811	814	O
protection	32941801	815	825	O
was	32941801	826	829	O
against	32941801	830	837	O
respiratory	32941801	838	849	O
tract	32941801	850	855	O
infections	32941801	856	866	O
of	32941801	867	869	O
probable	32941801	870	878	O
viral	32941801	879	884	O
origin	32941801	885	891	O
(	32941801	892	893	O
hazard	32941801	894	900	O
ratio	32941801	901	906	O
0.21	32941801	907	911	O
,	32941801	912	913	O
p	32941801	914	915	O
=	32941801	918	919	O
0.013	32941801	920	925	O
)	32941801	926	927	O
.	32941801	928	929	O

No	32941801	930	932	O
difference	32941801	933	943	O
in	32941801	944	946	O
the	32941801	947	950	O
frequency	32941801	951	960	O
of	32941801	961	963	O
adverse	32941801	964	971	O
effects	32941801	972	979	O
was	32941801	980	983	O
found	32941801	984	989	O
.	32941801	990	991	O

Data	32941801	992	996	O
show	32941801	997	1001	O
that	32941801	1002	1006	O
BCG	32941801	1007	1010	O
vaccination	32941801	1011	1022	O
is	32941801	1023	1025	O
safe	32941801	1026	1030	O
and	32941801	1031	1034	O
can	32941801	1035	1038	O
protect	32941801	1039	1046	O
the	32941801	1047	1050	O
elderly	32941801	1051	1058	O
against	32941801	1059	1066	O
infections	32941801	1067	1077	O
.	32941801	1078	1079	O

Larger	32941801	1080	1086	O
studies	32941801	1087	1094	O
are	32941801	1095	1098	O
needed	32941801	1099	1105	O
to	32941801	1106	1108	O
assess	32941801	1109	1115	O
protection	32941801	1116	1126	O
against	32941801	1127	1134	O
respiratory	32941801	1135	1146	O
infections	32941801	1147	1157	O
,	32941801	1158	1159	O
including	32941801	1160	1169	O
COVID-19	32941801	1170	1178	O
(	32941801	1179	1180	O
ClinicalTrials.gov	32941801	1181	1199	O
NCT03296423	32941801	1200	1211	O
)	32941801	1212	1213	O
.	32941801	1214	1215	O


Protocol	32958495	0	8	O
for	32958495	9	12	O
the	32958495	13	16	O
DisCoVeRy	32958495	17	26	O
trial	32958495	27	32	O
:	32958495	33	34	O
multicentre	32958495	35	46	O
,	32958495	47	48	O
adaptive	32958495	49	57	O
,	32958495	58	59	O
randomised	32958495	60	70	O
trial	32958495	71	76	O
of	32958495	77	79	O
the	32958495	80	83	O
safety	32958495	84	90	O
and	32958495	91	94	O
efficacy	32958495	95	103	O
of	32958495	104	106	O
treatments	32958495	107	117	O
for	32958495	118	121	O
COVID-19	32958495	122	130	O
in	32958495	131	133	O
hospitalised	32958495	134	146	O
adults	32958495	147	153	O
.	32958495	154	155	O

To	32958495	156	158	O
find	32958495	159	163	O
effective	32958495	164	173	O
and	32958495	174	177	O
safe	32958495	178	182	O
treatments	32958495	183	193	O
for	32958495	194	197	O
COVID-19	32958495	198	206	O
,	32958495	207	208	O
the	32958495	209	212	O
WHO	32958495	213	216	O
recommended	32958495	217	228	O
to	32958495	229	231	O
systemically	32958495	232	244	O
evaluate	32958495	245	253	O
experimental	32958495	254	266	O
therapeutics	32958495	267	279	O
in	32958495	280	282	O
collaborative	32958495	283	296	O
randomised	32958495	297	307	O
clinical	32958495	308	316	O
trials	32958495	317	323	O
.	32958495	324	325	O

As	32958495	326	328	O
COVID-19	32958495	329	337	O
was	32958495	338	341	O
spreading	32958495	342	351	O
in	32958495	352	354	O
Europe	32958495	355	361	O
,	32958495	362	363	O
the	32958495	364	367	O
French	32958495	368	374	O
national	32958495	375	383	O
institute	32958495	384	393	O
for	32958495	394	397	O
Health	32958495	398	404	O
and	32958495	405	408	O
Medical	32958495	409	416	O
Research	32958495	417	425	O
(	32958495	426	427	O
Inserm	32958495	428	434	O
)	32958495	435	436	O
established	32958495	437	448	O
a	32958495	449	450	O
transdisciplinary	32958495	451	468	O
team	32958495	469	473	O
to	32958495	474	476	O
develop	32958495	477	484	O
a	32958495	485	486	O
multi	32958495	487	492	O
-	32958495	493	494	O
arm	32958495	495	498	O
randomised	32958495	499	509	O
controlled	32958495	510	520	O
trial	32958495	521	526	O
named	32958495	527	532	O
DisCoVeRy	32958495	533	542	O
.	32958495	543	544	O

The	32958495	545	548	O
objective	32958495	549	558	O
of	32958495	559	561	O
the	32958495	562	565	O
trial	32958495	566	571	O
is	32958495	572	574	O
to	32958495	575	577	O
evaluate	32958495	578	586	O
the	32958495	587	590	O
clinical	32958495	591	599	O
efficacy	32958495	600	608	O
and	32958495	609	612	O
safety	32958495	613	619	O
of	32958495	620	622	O
different	32958495	623	632	O
investigational	32958495	633	648	O
re	32958495	649	651	O
-	32958495	652	653	O
purposed	32958495	654	662	O
therapeutics	32958495	663	675	O
relative	32958495	676	684	O
to	32958495	685	687	O
Standard	32958495	688	696	O
of	32958495	697	699	O
Care	32958495	700	704	O
(	32958495	705	706	O
SoC	32958495	707	710	O
)	32958495	711	712	O
in	32958495	713	715	O
patients	32958495	716	724	O
hospitalised	32958495	725	737	O
with	32958495	738	742	O
COVID-19	32958495	743	751	O
.	32958495	752	753	O

DisCoVeRy	32958495	754	763	O
is	32958495	764	766	O
a	32958495	767	768	O
phase	32958495	769	774	O
III	32958495	775	778	O
,	32958495	779	780	O
open	32958495	781	785	O
-	32958495	786	787	O
label	32958495	788	793	O
,	32958495	794	795	O
adaptive	32958495	796	804	O
,	32958495	805	806	O
controlled	32958495	807	817	O
,	32958495	818	819	O
multicentre	32958495	820	831	O
clinical	32958495	832	840	O
trial	32958495	841	846	O
in	32958495	847	849	O
which	32958495	850	855	O
hospitalised	32958495	856	868	O
patients	32958495	869	877	O
with	32958495	878	882	O
COVID-19	32958495	883	891	O
in	32958495	892	894	O
need	32958495	895	899	O
of	32958495	900	902	O
oxygen	32958495	903	909	O
therapy	32958495	910	917	O
are	32958495	918	921	O
randomised	32958495	922	932	O
between	32958495	933	940	O
five	32958495	941	945	O
arms	32958495	946	950	O
:	32958495	951	952	O
(	32958495	953	954	O
1	32958495	955	956	O
)	32958495	957	958	O
a	32958495	959	960	O
control	32958495	961	968	O
group	32958495	969	974	O
managed	32958495	975	982	O
with	32958495	983	987	O
SoC	32958495	988	991	O
and	32958495	992	995	O
four	32958495	996	1000	O
therapeutic	32958495	1001	1012	O
arms	32958495	1013	1017	O
with	32958495	1018	1022	O
re	32958495	1023	1025	O
-	32958495	1026	1027	O
purposed	32958495	1028	1036	O
antiviral	32958495	1037	1046	O
agents	32958495	1047	1053	O
:	32958495	1054	1055	O
(	32958495	1056	1057	O
2	32958495	1058	1059	O
)	32958495	1060	1061	O
remdesivir	32958495	1062	1072	O
+	32958495	1073	1074	O
SoC	32958495	1075	1078	O
,	32958495	1079	1080	O
(	32958495	1081	1082	O
3	32958495	1083	1084	O
)	32958495	1085	1086	O
lopinavir	32958495	1087	1096	O
/	32958495	1097	1098	O
ritonavir	32958495	1099	1108	O
+	32958495	1109	1110	O
SoC	32958495	1111	1114	O
,	32958495	1115	1116	O
(	32958495	1117	1118	O
4	32958495	1119	1120	O
)	32958495	1121	1122	O
lopinavir	32958495	1123	1132	O
/	32958495	1133	1134	O
ritonavir	32958495	1135	1144	O
associated	32958495	1145	1155	O
with	32958495	1156	1160	O
interferon	32958495	1161	1171	O
(	32958495	1172	1173	O
IFN)--1a	32958495	1174	1183	O
+	32958495	1184	1185	O
SoC	32958495	1186	1189	O
and	32958495	1190	1193	O
(	32958495	1194	1195	O
5	32958495	1196	1197	O
)	32958495	1198	1199	O
hydroxychloroquine	32958495	1200	1218	O
+	32958495	1219	1220	O
SoC.	32958495	1221	1225	O
The	32958495	1226	1229	O
primary	32958495	1230	1237	O
endpoint	32958495	1238	1246	O
is	32958495	1247	1249	O
the	32958495	1250	1253	O
clinical	32958495	1254	1262	O
status	32958495	1263	1269	O
at	32958495	1270	1272	O
Day	32958495	1273	1276	O
15	32958495	1277	1279	O
on	32958495	1280	1282	O
the	32958495	1283	1286	O
7-point	32958495	1287	1294	O
ordinal	32958495	1295	1302	O
scale	32958495	1303	1308	O
of	32958495	1309	1311	O
the	32958495	1312	1315	O
WHO	32958495	1316	1319	O
Master	32958495	1320	1326	O
Protocol	32958495	1327	1335	O
(	32958495	1336	1337	O
V.3.0	32958495	1338	1343	O
,	32958495	1344	1345	O
3	32958495	1346	1347	O
March	32958495	1348	1353	O
2020	32958495	1354	1358	O
)	32958495	1359	1360	O
.	32958495	1361	1362	O

This	32958495	1363	1367	O
trial	32958495	1368	1373	O
involves	32958495	1374	1382	O
patients	32958495	1383	1391	O
hospitalised	32958495	1392	1404	O
in	32958495	1405	1407	O
conventional	32958495	1408	1420	O
departments	32958495	1421	1432	O
or	32958495	1433	1435	O
intensive	32958495	1436	1445	O
care	32958495	1446	1450	O
units	32958495	1451	1456	O
both	32958495	1457	1461	O
from	32958495	1462	1466	O
academic	32958495	1467	1475	O
or	32958495	1476	1478	O
non	32958495	1479	1482	O
-	32958495	1483	1484	O
academic	32958495	1485	1493	O
hospitals	32958495	1494	1503	O
throughout	32958495	1504	1514	O
Europe	32958495	1515	1521	O
.	32958495	1522	1523	O

A	32958495	1524	1525	O
sample	32958495	1526	1532	O
size	32958495	1533	1537	O
of	32958495	1538	1540	O
3100	32958495	1541	1545	O
patients	32958495	1546	1554	O
(	32958495	1555	1556	O
620	32958495	1557	1560	O
patients	32958495	1561	1569	O
per	32958495	1570	1573	O
arm	32958495	1574	1577	O
)	32958495	1578	1579	O
is	32958495	1580	1582	O
targeted	32958495	1583	1591	O
.	32958495	1592	1593	O

This	32958495	1594	1598	O
trial	32958495	1599	1604	O
has	32958495	1605	1608	O
begun	32958495	1609	1614	O
on	32958495	1615	1617	O
22	32958495	1618	1620	O
March	32958495	1621	1626	O
2020	32958495	1627	1631	O
.	32958495	1632	1633	O

Since	32958495	1634	1639	O
5	32958495	1640	1641	O
April	32958495	1642	1647	O
2020	32958495	1648	1652	O
,	32958495	1653	1654	O
DisCoVeRy	32958495	1655	1664	O
has	32958495	1665	1668	O
been	32958495	1669	1673	O
an	32958495	1674	1676	O
add	32958495	1677	1680	O
-	32958495	1681	1682	O
on	32958495	1683	1685	O
trial	32958495	1686	1691	O
of	32958495	1692	1694	O
the	32958495	1695	1698	O
Solidarity	32958495	1699	1709	O
consortium	32958495	1710	1720	O
of	32958495	1721	1723	O
trials	32958495	1724	1730	O
conducted	32958495	1731	1740	O
by	32958495	1741	1743	O
the	32958495	1744	1747	O
WHO	32958495	1748	1751	O
in	32958495	1752	1754	O
Europe	32958495	1755	1761	O
and	32958495	1762	1765	O
worldwide	32958495	1766	1775	O
.	32958495	1776	1777	O

On	32958495	1778	1780	O
8	32958495	1781	1782	O
June	32958495	1783	1787	O
2020	32958495	1788	1792	O
,	32958495	1793	1794	O
754	32958495	1795	1798	O
patients	32958495	1799	1807	O
have	32958495	1808	1812	O
been	32958495	1813	1817	O
included	32958495	1818	1826	O
.	32958495	1827	1828	O

Inserm	32958495	1829	1835	O
is	32958495	1836	1838	O
the	32958495	1839	1842	O
sponsor	32958495	1843	1850	O
of	32958495	1851	1853	O
DisCoVeRy	32958495	1854	1863	O
.	32958495	1864	1865	O

Ethical	32958495	1866	1873	O
approval	32958495	1874	1882	O
has	32958495	1883	1886	O
been	32958495	1887	1891	O
obtained	32958495	1892	1900	O
from	32958495	1901	1905	O
the	32958495	1906	1909	O
institutional	32958495	1910	1923	O
review	32958495	1924	1930	O
board	32958495	1931	1936	O
on	32958495	1937	1939	O
13	32958495	1940	1942	O
March	32958495	1943	1948	O
2020	32958495	1949	1953	O
(	32958495	1954	1955	O
20.03.06.51744	32958495	1956	1970	O
)	32958495	1971	1972	O
and	32958495	1973	1976	O
from	32958495	1977	1981	O
the	32958495	1982	1985	O
French	32958495	1986	1992	O
National	32958495	1993	2001	O
Agency	32958495	2002	2008	O
for	32958495	2009	2012	O
Medicines	32958495	2013	2022	O
and	32958495	2023	2026	O
Health	32958495	2027	2033	O
Products	32958495	2034	2042	O
(	32958495	2043	2044	O
ANSM	32958495	2045	2049	O
)	32958495	2050	2051	O
on	32958495	2052	2054	O
9	32958495	2055	2056	O
March	32958495	2057	2062	O
2020	32958495	2063	2067	O
.	32958495	2068	2069	O

Results	32958495	2070	2077	O
will	32958495	2078	2082	O
be	32958495	2083	2085	O
submitted	32958495	2086	2095	O
for	32958495	2096	2099	O
publication	32958495	2100	2111	O
in	32958495	2112	2114	O
peer	32958495	2115	2119	O
-	32958495	2120	2121	O
reviewed	32958495	2122	2130	O
journals	32958495	2131	2139	O
.	32958495	2140	2141	O

NCT04315948	32958495	2142	2153	O
Eudra	32958495	2154	2159	O
-	32958495	2160	2161	O
CT	32958495	2162	2164	O
2020	32958495	2165	2169	O
-	32958495	2170	2171	O
000936	32958495	2172	2178	O
-	32958495	2179	2180	O
23	32958495	2181	2183	O
.	32958495	2184	2185	O


Rationale	32965395	0	9	O
and	32965395	10	13	O
design	32965395	14	20	O
of	32965395	21	23	O
the	32965395	24	27	O
"	32965395	28	29	O
Tocilizumab	32965395	30	41	O
in	32965395	42	44	O
patients	32965395	45	53	O
with	32965395	54	58	O
moderate	32965395	59	67	O
to	32965395	68	70	O
severe	32965395	71	77	O
COVID-19	32965395	78	86	O
:	32965395	87	88	O
an	32965395	89	91	O
open	32965395	92	96	O
-	32965395	97	98	O
label	32965395	99	104	O
multicentre	32965395	105	116	O
randomized	32965395	117	127	O
controlled	32965395	128	138	O
"	32965395	139	140	O
trial	32965395	141	146	O
(	32965395	147	148	O
TOCIBRAS	32965395	149	157	O
)	32965395	158	159	O
.	32965395	160	161	O

BACKGROUND	32965395	162	172	O
:	32965395	173	174	O
Pro	32965395	175	178	O
-	32965395	179	180	O
inflammatory	32965395	181	193	O
markers	32965395	194	201	O
play	32965395	202	206	O
a	32965395	207	208	O
significant	32965395	209	220	O
role	32965395	221	225	O
in	32965395	226	228	O
the	32965395	229	232	O
disease	32965395	233	240	O
severity	32965395	241	249	O
of	32965395	250	252	O
patients	32965395	253	261	O
with	32965395	262	266	O
COVID-19	32965395	267	275	O
.	32965395	276	277	O

Thus	32965395	278	282	O
,	32965395	283	284	O
anti	32965395	285	289	O
-	32965395	290	291	O
inflammatory	32965395	292	304	O
therapies	32965395	305	314	O
are	32965395	315	318	O
attractive	32965395	319	329	O
agents	32965395	330	336	O
for	32965395	337	340	O
potentially	32965395	341	352	O
combating	32965395	353	362	O
the	32965395	363	366	O
uncontrolled	32965395	367	379	O
inflammatory	32965395	380	392	O
cascade	32965395	393	400	O
in	32965395	401	403	O
these	32965395	404	409	O
patients	32965395	410	418	O
.	32965395	419	420	O

We	32965395	421	423	O
designed	32965395	424	432	O
a	32965395	433	434	O
trial	32965395	435	440	O
testing	32965395	441	448	O
tocilizumab	32965395	449	460	O
versus	32965395	461	467	O
standard	32965395	468	476	O
of	32965395	477	479	O
care	32965395	480	484	O
intending	32965395	485	494	O
to	32965395	495	497	O
improve	32965395	498	505	O
the	32965395	506	509	O
outcomes	32965395	510	518	O
by	32965395	519	521	O
inhibiting	32965395	522	532	O
interleukin-6	32965395	533	546	O
,	32965395	547	548	O
an	32965395	549	551	O
important	32965395	552	561	O
inflammatory	32965395	562	574	O
mediator	32965395	575	583	O
in	32965395	584	586	O
COVID-19	32965395	587	595	O
.	32965395	596	597	O

UNASSIGNED	32965395	598	608	O
:	32965395	609	610	O
This	32965395	611	615	O
open	32965395	616	620	O
-	32965395	621	622	O
label	32965395	623	628	O
multicentre	32965395	629	640	O
randomized	32965395	641	651	O
controlled	32965395	652	662	O
trial	32965395	663	668	O
will	32965395	669	673	O
compare	32965395	674	681	O
clinical	32965395	682	690	O
outcomes	32965395	691	699	O
of	32965395	700	702	O
tocilizumab	32965395	703	714	O
plus	32965395	715	719	O
standard	32965395	720	728	O
of	32965395	729	731	O
care	32965395	732	736	O
versus	32965395	737	743	O
standard	32965395	744	752	O
of	32965395	753	755	O
care	32965395	756	760	O
alone	32965395	761	766	O
in	32965395	767	769	O
patients	32965395	770	778	O
with	32965395	779	783	O
moderate	32965395	784	792	O
to	32965395	793	795	O
severe	32965395	796	802	O
COVID-19	32965395	803	811	O
.	32965395	812	813	O

Two	32965395	814	817	O
of	32965395	818	820	O
the	32965395	821	824	O
following	32965395	825	834	O
four	32965395	835	839	O
criteria	32965395	840	848	O
are	32965395	849	852	O
required	32965395	853	861	O
for	32965395	862	865	O
protocol	32965395	866	874	O
enrolment	32965395	875	884	O
:	32965395	885	886	O
D	32965395	887	888	O
-	32965395	889	890	O
dimer	32965395	891	896	O
>	32965395	897	898	O
1,000ng	32965395	899	906	O
/	32965395	907	908	O
mL	32965395	909	911	O
;	32965395	912	913	O
C	32965395	914	915	O
reactive	32965395	916	924	O
protein	32965395	925	932	O
>	32965395	933	934	O
5	32965395	935	936	O
mg	32965395	936	938	O
/	32965395	939	940	O
dL	32965395	941	943	O
,	32965395	944	945	O
ferritin	32965395	946	954	O
>	32965395	955	956	O
300	32965395	957	960	O
mg	32965395	960	962	O
/	32965395	963	964	O
dL	32965395	965	967	O
,	32965395	968	969	O
and	32965395	970	973	O
lactate	32965395	974	981	O
dehydrogenase	32965395	982	995	O
>	32965395	996	997	O
upper	32965395	998	1003	O
limit	32965395	1004	1009	O
of	32965395	1010	1012	O
normal	32965395	1013	1019	O
.	32965395	1020	1021	O

The	32965395	1022	1025	O
primary	32965395	1026	1033	O
objective	32965395	1034	1043	O
will	32965395	1044	1048	O
be	32965395	1049	1051	O
to	32965395	1052	1054	O
compare	32965395	1055	1062	O
the	32965395	1063	1066	O
clinical	32965395	1067	1075	O
status	32965395	1076	1082	O
on	32965395	1083	1085	O
day	32965395	1086	1089	O
15	32965395	1090	1092	O
,	32965395	1093	1094	O
as	32965395	1095	1097	O
measured	32965395	1098	1106	O
by	32965395	1107	1109	O
a	32965395	1110	1111	O
7-point	32965395	1112	1119	O
ordinal	32965395	1120	1127	O
scale	32965395	1128	1133	O
applied	32965395	1134	1141	O
in	32965395	1142	1144	O
COVID-19	32965395	1145	1153	O
trials	32965395	1154	1160	O
worldwide	32965395	1161	1170	O
.	32965395	1171	1172	O

The	32965395	1173	1176	O
primary	32965395	1177	1184	O
endpoint	32965395	1185	1193	O
will	32965395	1194	1198	O
be	32965395	1199	1201	O
assessed	32965395	1202	1210	O
by	32965395	1211	1213	O
an	32965395	1214	1216	O
ordinal	32965395	1217	1224	O
logistic	32965395	1225	1233	O
regression	32965395	1234	1244	O
assuming	32965395	1245	1253	O
proportional	32965395	1254	1266	O
odds	32965395	1267	1271	O
ratios	32965395	1272	1278	O
adjusted	32965395	1279	1287	O
for	32965395	1288	1291	O
stratification	32965395	1292	1306	O
variables	32965395	1307	1316	O
(	32965395	1317	1318	O
age	32965395	1319	1322	O
and	32965395	1323	1326	O
sex	32965395	1327	1330	O
)	32965395	1331	1332	O
.	32965395	1333	1334	O

UNASSIGNED	32965395	1335	1345	O
:	32965395	1346	1347	O
The	32965395	1348	1351	O
TOCIBRAS	32965395	1352	1360	O
protocol	32965395	1361	1369	O
was	32965395	1370	1373	O
approved	32965395	1374	1382	O
by	32965395	1383	1385	O
local	32965395	1386	1391	O
and	32965395	1392	1395	O
central	32965395	1396	1403	O
(	32965395	1404	1405	O
national	32965395	1406	1414	O
)	32965395	1415	1416	O
ethical	32965395	1417	1424	O
committees	32965395	1425	1435	O
in	32965395	1436	1438	O
Brazil	32965395	1439	1445	O
following	32965395	1446	1455	O
current	32965395	1456	1463	O
national	32965395	1464	1472	O
and	32965395	1473	1476	O
international	32965395	1477	1490	O
guidelines	32965395	1491	1501	O
/	32965395	1502	1503	O
directives	32965395	1504	1514	O
.	32965395	1515	1516	O

Each	32965395	1517	1521	O
participating	32965395	1522	1535	O
center	32965395	1536	1542	O
had	32965395	1543	1546	O
the	32965395	1547	1550	O
study	32965395	1551	1556	O
protocol	32965395	1557	1565	O
approved	32965395	1566	1574	O
by	32965395	1575	1577	O
their	32965395	1578	1583	O
institutional	32965395	1584	1597	O
review	32965395	1598	1604	O
boards	32965395	1605	1611	O
before	32965395	1612	1618	O
initiating	32965395	1619	1629	O
protocol	32965395	1630	1638	O
enrolment	32965395	1639	1648	O
.	32965395	1649	1650	O

The	32965395	1651	1654	O
data	32965395	1655	1659	O
derived	32965395	1660	1667	O
from	32965395	1668	1672	O
this	32965395	1673	1677	O
trial	32965395	1678	1683	O
will	32965395	1684	1688	O
be	32965395	1689	1691	O
published	32965395	1692	1701	O
regardless	32965395	1702	1712	O
of	32965395	1713	1715	O
the	32965395	1716	1719	O
results	32965395	1720	1727	O
.	32965395	1728	1729	O

If	32965395	1730	1732	O
proven	32965395	1733	1739	O
active	32965395	1740	1746	O
,	32965395	1747	1748	O
this	32965395	1749	1753	O
strategy	32965395	1754	1762	O
could	32965395	1763	1768	O
alleviate	32965395	1769	1778	O
the	32965395	1779	1782	O
consequences	32965395	1783	1795	O
of	32965395	1796	1798	O
the	32965395	1799	1802	O
inflammatory	32965395	1803	1815	O
response	32965395	1816	1824	O
in	32965395	1825	1827	O
COVID-19	32965395	1828	1836	O
patients	32965395	1837	1845	O
and	32965395	1846	1849	O
improve	32965395	1850	1857	O
their	32965395	1858	1863	O
clinical	32965395	1864	1872	O
outcomes	32965395	1873	1881	O
.	32965395	1882	1883	O


Development	32970554	0	11	O
and	32970554	12	15	O
Usability	32970554	16	25	O
Testing	32970554	26	33	O
of	32970554	34	36	O
a	32970554	37	38	O
Web	32970554	39	42	O
-	32970554	43	44	O
based	32970554	45	50	O
COVID-19	32970554	51	59	O
Self	32970554	60	64	O
-	32970554	65	66	O
triage	32970554	67	73	O
Platform	32970554	74	82	O
.	32970554	83	84	O

BACKGROUND	32970554	85	95	O
:	32970554	96	97	O
The	32970554	98	101	O
development	32970554	102	113	O
and	32970554	114	117	O
deployment	32970554	118	128	O
of	32970554	129	131	O
a	32970554	132	133	O
web	32970554	134	137	O
-	32970554	138	139	O
based	32970554	140	145	O
,	32970554	146	147	O
self	32970554	148	152	O
-	32970554	153	154	O
triage	32970554	155	161	O
tool	32970554	162	166	O
for	32970554	167	170	O
severe	32970554	171	177	O
respiratory	32970554	178	189	O
syndrome	32970554	190	198	O
coronavirus	32970554	199	210	O
2	32970554	211	212	O
(	32970554	213	214	O
COVID-19	32970554	215	223	O
disease	32970554	224	231	O
)	32970554	232	233	O
aimed	32970554	234	239	O
at	32970554	240	242	O
preventing	32970554	243	253	O
surges	32970554	254	260	O
in	32970554	261	263	O
healthcare	32970554	264	274	O
utilization	32970554	275	286	O
could	32970554	287	292	O
provide	32970554	293	300	O
easily	32970554	301	307	O
understandable	32970554	308	322	O
health	32970554	323	329	O
guidance	32970554	330	338	O
with	32970554	339	343	O
the	32970554	344	347	O
goal	32970554	348	352	O
of	32970554	353	355	O
mitigating	32970554	356	366	O
unnecessary	32970554	367	378	O
emergency	32970554	379	388	O
department	32970554	389	399	O
(	32970554	400	401	O
ED	32970554	402	404	O
)	32970554	405	406	O
and	32970554	407	410	O
healthcare	32970554	411	421	O
visits	32970554	422	428	O
.	32970554	429	430	O

We	32970554	431	433	O
describe	32970554	434	442	O
the	32970554	443	446	O
iterative	32970554	447	456	O
development	32970554	457	468	O
and	32970554	469	472	O
usability	32970554	473	482	O
testing	32970554	483	490	O
of	32970554	491	493	O
such	32970554	494	498	O
a	32970554	499	500	O
tool	32970554	501	505	O
.	32970554	506	507	O

We	32970554	508	510	O
hypothesized	32970554	511	523	O
that	32970554	524	528	O
adult	32970554	529	534	O
users	32970554	535	540	O
could	32970554	541	546	O
understand	32970554	547	557	O
and	32970554	558	561	O
recall	32970554	562	568	O
the	32970554	569	572	O
recommendations	32970554	573	588	O
provided	32970554	589	597	O
by	32970554	598	600	O
a	32970554	601	602	O
COVID-19	32970554	603	611	O
web	32970554	612	615	O
-	32970554	616	617	O
based	32970554	618	623	O
,	32970554	624	625	O
self	32970554	626	630	O
-	32970554	631	632	O
triage	32970554	633	639	O
tool	32970554	640	644	O
.	32970554	645	646	O

METHODS	32970554	647	654	O
:	32970554	655	656	O
We	32970554	657	659	O
convened	32970554	660	668	O
a	32970554	669	670	O
multidisciplinary	32970554	671	688	O
panel	32970554	689	694	O
of	32970554	695	697	O
medical	32970554	698	705	O
experts	32970554	706	713	O
at	32970554	714	716	O
two	32970554	717	720	O
academic	32970554	721	729	O
medical	32970554	730	737	O
schools	32970554	738	745	O
in	32970554	746	748	O
an	32970554	749	751	O
iterative	32970554	752	761	O
redesign	32970554	762	770	O
process	32970554	771	778	O
of	32970554	779	781	O
a	32970554	782	783	O
previously	32970554	784	794	O
validated	32970554	795	804	O
web	32970554	805	808	O
-	32970554	809	810	O
based	32970554	811	816	O
,	32970554	817	818	O
epidemic	32970554	819	827	O
screening	32970554	828	837	O
tool	32970554	838	842	O
for	32970554	843	846	O
the	32970554	847	850	O
current	32970554	851	858	O
COVID-19	32970554	859	867	O
pandemic	32970554	868	876	O
.	32970554	877	878	O

We	32970554	879	881	O
then	32970554	882	886	O
conducted	32970554	887	896	O
a	32970554	897	898	O
cross	32970554	899	904	O
-	32970554	905	906	O
sectional	32970554	907	916	O
usability	32970554	917	926	O
study	32970554	927	932	O
over	32970554	933	937	O
a	32970554	938	939	O
24-hour	32970554	940	947	O
period	32970554	948	954	O
among	32970554	955	960	O
faculty	32970554	961	968	O
,	32970554	969	970	O
staff	32970554	971	976	O
,	32970554	977	978	O
and	32970554	979	982	O
students	32970554	983	991	O
at	32970554	992	994	O
the	32970554	995	998	O
two	32970554	999	1002	O
participating	32970554	1003	1016	O
universities	32970554	1017	1029	O
.	32970554	1030	1031	O

Participants	32970554	1032	1044	O
were	32970554	1045	1049	O
randomly	32970554	1050	1058	O
assigned	32970554	1059	1067	O
a	32970554	1068	1069	O
pre	32970554	1070	1073	O
-	32970554	1074	1075	O
written	32970554	1076	1083	O
health	32970554	1084	1090	O
script	32970554	1091	1097	O
to	32970554	1098	1100	O
enter	32970554	1101	1106	O
into	32970554	1107	1111	O
the	32970554	1112	1115	O
self	32970554	1116	1120	O
-	32970554	1121	1122	O
triage	32970554	1123	1129	O
website	32970554	1130	1137	O
for	32970554	1138	1141	O
testing	32970554	1142	1149	O
.	32970554	1150	1151	O

The	32970554	1152	1155	O
primary	32970554	1156	1163	O
outcome	32970554	1164	1171	O
was	32970554	1172	1175	O
immediate	32970554	1176	1185	O
recall	32970554	1186	1192	O
of	32970554	1193	1195	O
website	32970554	1196	1203	O
recommendations	32970554	1204	1219	O
.	32970554	1220	1221	O

Secondary	32970554	1222	1231	O
outcomes	32970554	1232	1240	O
included	32970554	1241	1249	O
usability	32970554	1250	1259	O
measures	32970554	1260	1268	O
.	32970554	1269	1270	O

We	32970554	1271	1273	O
stratified	32970554	1274	1284	O
outcomes	32970554	1285	1293	O
by	32970554	1294	1296	O
demographic	32970554	1297	1308	O
characteristics	32970554	1309	1324	O
.	32970554	1325	1326	O

RESULTS	32970554	1327	1334	O
:	32970554	1335	1336	O
A	32970554	1337	1338	O
final	32970554	1339	1344	O
sample	32970554	1345	1351	O
of	32970554	1352	1354	O
877	32970554	1355	1358	O
participants	32970554	1359	1371	O
(	32970554	1372	1373	O
mean	32970554	1374	1378	O
age	32970554	1379	1382	O
,	32970554	1383	1384	O
32	32970554	1385	1387	O
years	32970554	1388	1393	O
[	32970554	1394	1395	O
range	32970554	1396	1401	O
,	32970554	1402	1403	O
19	32970554	1404	1406	O
-	32970554	1407	1408	O
84	32970554	1409	1411	O
years	32970554	1412	1417	O
]	32970554	1418	1419	O
;	32970554	1420	1421	O
65.3	32970554	1422	1426	O
%	32970554	1427	1428	O
female	32970554	1429	1435	O
)	32970554	1436	1437	O
was	32970554	1438	1441	O
used	32970554	1442	1446	O
in	32970554	1447	1449	O
the	32970554	1450	1453	O
analysis	32970554	1454	1462	O
.	32970554	1463	1464	O

We	32970554	1465	1467	O
found	32970554	1468	1473	O
that	32970554	1474	1478	O
79.4	32970554	1479	1483	O
%	32970554	1484	1485	O
of	32970554	1486	1488	O
the	32970554	1489	1492	O
participants	32970554	1493	1505	O
accurately	32970554	1506	1516	O
recalled	32970554	1517	1525	O
the	32970554	1526	1529	O
recommendations	32970554	1530	1545	O
provided	32970554	1546	1554	O
by	32970554	1555	1557	O
the	32970554	1558	1561	O
website	32970554	1562	1569	O
.	32970554	1570	1571	O

Almost	32970554	1572	1578	O
all	32970554	1579	1582	O
participants	32970554	1583	1595	O
(	32970554	1596	1597	O
96.9	32970554	1598	1602	O
%	32970554	1603	1604	O
)	32970554	1605	1606	O
found	32970554	1607	1612	O
the	32970554	1613	1616	O
website	32970554	1617	1624	O
easy	32970554	1625	1629	O
to	32970554	1630	1632	O
use	32970554	1633	1636	O
and	32970554	1637	1640	O
navigate	32970554	1641	1649	O
.	32970554	1650	1651	O

CONCLUSIONS	32970554	1652	1663	O
:	32970554	1664	1665	O
Adult	32970554	1666	1671	O
users	32970554	1672	1677	O
of	32970554	1678	1680	O
a	32970554	1681	1682	O
COVID-19	32970554	1683	1691	O
self	32970554	1692	1696	O
-	32970554	1697	1698	O
triage	32970554	1699	1705	O
website	32970554	1706	1713	O
,	32970554	1714	1715	O
recruited	32970554	1716	1725	O
from	32970554	1726	1730	O
an	32970554	1731	1733	O
academic	32970554	1734	1742	O
setting	32970554	1743	1750	O
,	32970554	1751	1752	O
were	32970554	1753	1757	O
able	32970554	1758	1762	O
to	32970554	1763	1765	O
successfully	32970554	1766	1778	O
recall	32970554	1779	1785	O
self	32970554	1786	1790	O
-	32970554	1791	1792	O
care	32970554	1793	1797	O
instructions	32970554	1798	1810	O
from	32970554	1811	1815	O
the	32970554	1816	1819	O
website	32970554	1820	1827	O
and	32970554	1828	1831	O
found	32970554	1832	1837	O
it	32970554	1838	1840	O
user	32970554	1841	1845	O
-	32970554	1846	1847	O
friendly	32970554	1848	1856	O
.	32970554	1857	1858	O

This	32970554	1859	1863	O
website	32970554	1864	1871	O
appears	32970554	1872	1879	O
to	32970554	1880	1882	O
be	32970554	1883	1885	O
a	32970554	1886	1887	O
feasible	32970554	1888	1896	O
way	32970554	1897	1900	O
to	32970554	1901	1903	O
provide	32970554	1904	1911	O
evidence	32970554	1912	1920	O
-	32970554	1921	1922	O
based	32970554	1923	1928	O
health	32970554	1929	1935	O
guidance	32970554	1936	1944	O
to	32970554	1945	1947	O
adult	32970554	1948	1953	O
patients	32970554	1954	1962	O
during	32970554	1963	1969	O
a	32970554	1970	1971	O
pandemic	32970554	1972	1980	O
.	32970554	1981	1982	O

Website	32970554	1983	1990	O
guidance	32970554	1991	1999	O
could	32970554	2000	2005	O
be	32970554	2006	2008	O
used	32970554	2009	2013	O
to	32970554	2014	2016	O
reduce	32970554	2017	2023	O
unnecessary	32970554	2024	2035	O
ED	32970554	2036	2038	O
and	32970554	2039	2042	O
healthcare	32970554	2043	2053	O
visits	32970554	2054	2060	O
.	32970554	2061	2062	O


Barrier	32970558	0	7	O
Enclosure	32970558	8	17	O
for	32970558	18	21	O
Endotracheal	32970558	22	34	O
Intubation	32970558	35	45	O
in	32970558	46	48	O
a	32970558	49	50	O
Simulated	32970558	51	60	O
COVID-19	32970558	61	69	O
Scenario	32970558	70	78	O
:	32970558	79	80	O
A	32970558	81	82	O
Crossover	32970558	83	92	O
Study	32970558	93	98	O
.	32970558	99	100	O

BACKGROUND	32970558	101	111	O
:	32970558	112	113	O
Barrier	32970558	114	121	O
enclosures	32970558	122	132	O
have	32970558	133	137	O
been	32970558	138	142	O
developed	32970558	143	152	O
to	32970558	153	155	O
reduce	32970558	156	162	O
the	32970558	163	166	O
risk	32970558	167	171	O
of	32970558	172	174	O
COVID-19	32970558	175	183	O
transmission	32970558	184	196	O
to	32970558	197	199	O
healthcare	32970558	200	210	O
providers	32970558	211	220	O
during	32970558	221	227	O
intubation	32970558	228	238	O
,	32970558	239	240	O
but	32970558	241	244	O
little	32970558	245	251	O
is	32970558	252	254	O
known	32970558	255	260	O
about	32970558	261	266	O
their	32970558	267	272	O
impact	32970558	273	279	O
on	32970558	280	282	O
procedure	32970558	283	292	O
performance	32970558	293	304	O
.	32970558	305	306	O

We	32970558	307	309	O
sought	32970558	310	316	O
to	32970558	317	319	O
determine	32970558	320	329	O
whether	32970558	330	337	O
a	32970558	338	339	O
barrier	32970558	340	347	O
enclosure	32970558	348	357	O
delays	32970558	358	364	O
time	32970558	365	369	O
to	32970558	370	372	O
successful	32970558	373	383	O
intubation	32970558	384	394	O
by	32970558	395	397	O
experienced	32970558	398	409	O
airway	32970558	410	416	O
operators	32970558	417	426	O
.	32970558	427	428	O

METHODS	32970558	429	436	O
:	32970558	437	438	O
We	32970558	439	441	O
conducted	32970558	442	451	O
a	32970558	452	453	O
crossover	32970558	454	463	O
simulation	32970558	464	474	O
study	32970558	475	480	O
at	32970558	481	483	O
a	32970558	484	485	O
tertiary	32970558	486	494	O
academic	32970558	495	503	O
hospital	32970558	504	512	O
.	32970558	513	514	O

Participants	32970558	515	527	O
watched	32970558	528	535	O
a	32970558	536	537	O
four	32970558	538	542	O
-	32970558	543	544	O
minute	32970558	545	551	O
video	32970558	552	557	O
,	32970558	558	559	O
practiced	32970558	560	569	O
one	32970558	570	573	O
simulated	32970558	574	583	O
intubation	32970558	584	594	O
with	32970558	595	599	O
a	32970558	600	601	O
barrier	32970558	602	609	O
enclosure	32970558	610	619	O
,	32970558	620	621	O
and	32970558	622	625	O
then	32970558	626	630	O
completed	32970558	631	640	O
one	32970558	641	644	O
intubation	32970558	645	655	O
with	32970558	656	660	O
and	32970558	661	664	O
one	32970558	665	668	O
without	32970558	669	676	O
the	32970558	677	680	O
barrier	32970558	681	688	O
enclosure	32970558	689	698	O
(	32970558	699	700	O
randomized	32970558	701	711	O
to	32970558	712	714	O
determine	32970558	715	724	O
order	32970558	725	730	O
)	32970558	731	732	O
.	32970558	733	734	O

The	32970558	735	738	O
primary	32970558	739	746	O
outcome	32970558	747	754	O
measure	32970558	755	762	O
was	32970558	763	766	O
time	32970558	767	771	O
from	32970558	772	776	O
placement	32970558	777	786	O
of	32970558	787	789	O
the	32970558	790	793	O
video	32970558	794	799	O
laryngoscope	32970558	800	812	O
at	32970558	813	815	O
the	32970558	816	819	O
lips	32970558	820	824	O
to	32970558	825	827	O
first	32970558	828	833	O
delivered	32970558	834	843	O
ventilation	32970558	844	855	O
.	32970558	856	857	O

Secondary	32970558	858	867	O
outcomes	32970558	868	876	O
were	32970558	877	881	O
periprocedural	32970558	882	896	O
complications	32970558	897	910	O
and	32970558	911	914	O
participant	32970558	915	926	O
responses	32970558	927	936	O
to	32970558	937	939	O
a	32970558	940	941	O
post	32970558	942	946	O
-	32970558	947	948	O
study	32970558	949	954	O
survey	32970558	955	961	O
.	32970558	962	963	O

RESULTS	32970558	964	971	O
:	32970558	972	973	O
Proceduralists	32970558	974	988	O
(	32970558	989	990	O
n	32970558	991	992	O
=	32970558	993	994	O
50	32970558	995	997	O
)	32970558	998	999	O
from	32970558	1000	1004	O
emergency	32970558	1005	1014	O
medicine	32970558	1015	1023	O
and	32970558	1024	1027	O
anesthesiology	32970558	1028	1042	O
had	32970558	1043	1046	O
median	32970558	1047	1053	O
intubation	32970558	1054	1064	O
times	32970558	1065	1070	O
of	32970558	1071	1073	O
23.6	32970558	1074	1078	O
seconds	32970558	1079	1086	O
with	32970558	1087	1091	O
practice	32970558	1092	1100	O
barrier	32970558	1101	1108	O
enclosure	32970558	1109	1118	O
,	32970558	1119	1120	O
20.5	32970558	1121	1125	O
seconds	32970558	1126	1133	O
with	32970558	1134	1138	O
barrier	32970558	1139	1146	O
enclosure	32970558	1147	1156	O
,	32970558	1157	1158	O
and	32970558	1159	1162	O
16.7	32970558	1163	1167	O
seconds	32970558	1168	1175	O
with	32970558	1176	1180	O
no	32970558	1181	1183	O
barrier	32970558	1184	1191	O
.	32970558	1192	1193	O

Intubation	32970558	1194	1204	O
with	32970558	1205	1209	O
barrier	32970558	1210	1217	O
enclosure	32970558	1218	1227	O
averaged	32970558	1228	1236	O
4.5	32970558	1237	1240	O
seconds	32970558	1241	1248	O
longer	32970558	1249	1255	O
(	32970558	1256	1257	O
95	32970558	1258	1260	O
%	32970558	1261	1262	O
confidence	32970558	1263	1273	O
interval	32970558	1274	1282	O
,	32970558	1283	1284	O
2.7	32970558	1285	1288	O
-	32970558	1289	1290	O
6.4	32970558	1291	1294	O
,	32970558	1295	1296	O
p	32970558	1297	1298	O
<	32970558	1299	1300	O
.001	32970558	1301	1305	O
)	32970558	1306	1307	O
than	32970558	1308	1312	O
without	32970558	1313	1320	O
,	32970558	1321	1322	O
but	32970558	1323	1326	O
was	32970558	1327	1330	O
less	32970558	1331	1335	O
than	32970558	1336	1340	O
the	32970558	1341	1344	O
predetermined	32970558	1345	1358	O
clinical	32970558	1359	1367	O
significance	32970558	1368	1380	O
threshold	32970558	1381	1390	O
of	32970558	1391	1393	O
10	32970558	1394	1396	O
seconds	32970558	1397	1404	O
.	32970558	1405	1406	O

Three	32970558	1407	1412	O
complications	32970558	1413	1426	O
occurred	32970558	1427	1435	O
,	32970558	1436	1437	O
all	32970558	1438	1441	O
during	32970558	1442	1448	O
the	32970558	1449	1452	O
practice	32970558	1453	1461	O
intubation	32970558	1462	1472	O
.	32970558	1473	1474	O

Barrier	32970558	1475	1482	O
enclosure	32970558	1483	1492	O
made	32970558	1493	1497	O
intubation	32970558	1498	1508	O
more	32970558	1509	1513	O
challenging	32970558	1514	1525	O
according	32970558	1526	1535	O
to	32970558	1536	1538	O
48	32970558	1539	1541	O
%	32970558	1542	1543	O
,	32970558	1544	1545	O
but	32970558	1546	1549	O
90	32970558	1550	1552	O
%	32970558	1553	1554	O
indicated	32970558	1555	1564	O
they	32970558	1565	1569	O
would	32970558	1570	1575	O
consider	32970558	1576	1584	O
using	32970558	1585	1590	O
it	32970558	1591	1593	O
in	32970558	1594	1596	O
clinical	32970558	1597	1605	O
practice	32970558	1606	1614	O
.	32970558	1615	1616	O

CONCLUSIONS	32970558	1617	1628	O
:	32970558	1629	1630	O
Experienced	32970558	1631	1642	O
airway	32970558	1643	1649	O
operators	32970558	1650	1659	O
performed	32970558	1660	1669	O
intubation	32970558	1670	1680	O
using	32970558	1681	1686	O
a	32970558	1687	1688	O
barrier	32970558	1689	1696	O
enclosure	32970558	1697	1706	O
with	32970558	1707	1711	O
minimal	32970558	1712	1719	O
increased	32970558	1720	1729	O
time	32970558	1730	1734	O
to	32970558	1735	1737	O
procedure	32970558	1738	1747	O
completion	32970558	1748	1758	O
in	32970558	1759	1761	O
this	32970558	1762	1766	O
uncomplicated	32970558	1767	1780	O
airway	32970558	1781	1787	O
model	32970558	1788	1793	O
.	32970558	1794	1795	O

Given	32970558	1796	1801	O
potential	32970558	1802	1811	O
to	32970558	1812	1814	O
reduce	32970558	1815	1821	O
droplet	32970558	1822	1829	O
spread	32970558	1830	1836	O
,	32970558	1837	1838	O
use	32970558	1839	1842	O
of	32970558	1843	1845	O
a	32970558	1846	1847	O
barrier	32970558	1848	1855	O
enclosure	32970558	1856	1865	O
may	32970558	1866	1869	O
be	32970558	1870	1872	O
an	32970558	1873	1875	O
acceptable	32970558	1876	1886	O
adjunct	32970558	1887	1894	O
to	32970558	1895	1897	O
endotracheal	32970558	1898	1910	O
intubation	32970558	1911	1921	O
for	32970558	1922	1925	O
those	32970558	1926	1931	O
familiar	32970558	1932	1940	O
with	32970558	1941	1945	O
its	32970558	1946	1949	O
use	32970558	1950	1953	O
.	32970558	1954	1955	O


Angiotensin	32984892	0	11	O
-	32984892	12	13	O
converting	32984892	14	24	O
enzyme	32984892	25	31	O
2	32984892	32	33	O
(	32984892	34	35	O
ACE2	32984892	36	40	O
)	32984892	41	42	O
levels	32984892	43	49	O
in	32984892	50	52	O
relation	32984892	53	61	O
to	32984892	62	64	O
risk	32984892	65	69	O
factors	32984892	70	77	O
for	32984892	78	81	O
COVID-19	32984892	82	90	O
in	32984892	91	93	O
two	32984892	94	97	O
large	32984892	98	103	O
cohorts	32984892	104	111	O
of	32984892	112	114	O
patients	32984892	115	123	O
with	32984892	124	128	O
atrial	32984892	129	135	O
fibrillation	32984892	136	148	O
.	32984892	149	150	O

The	32984892	151	154	O
global	32984892	155	161	O
COVID-19	32984892	162	170	O
pandemic	32984892	171	179	O
is	32984892	180	182	O
caused	32984892	183	189	O
by	32984892	190	192	O
the	32984892	193	196	O
SARS	32984892	197	201	O
-	32984892	202	203	O
CoV-2	32984892	204	209	O
virus	32984892	210	215	O
entering	32984892	216	224	O
human	32984892	225	230	O
cells	32984892	231	236	O
using	32984892	237	242	O
angiotensin	32984892	243	254	O
-	32984892	255	256	O
converting	32984892	257	267	O
enzyme	32984892	268	274	O
2	32984892	275	276	O
(	32984892	277	278	O
ACE2	32984892	279	283	O
)	32984892	284	285	O
as	32984892	286	288	O
a	32984892	289	290	O
cell	32984892	291	295	O
surface	32984892	296	303	O
receptor	32984892	304	312	O
.	32984892	313	314	O

ACE2	32984892	315	319	O
is	32984892	320	322	O
shed	32984892	323	327	O
to	32984892	328	330	O
the	32984892	331	334	O
circulation	32984892	335	346	O
,	32984892	347	348	O
and	32984892	349	352	O
a	32984892	353	354	O
higher	32984892	355	361	O
plasma	32984892	362	368	O
level	32984892	369	374	O
of	32984892	375	377	O
soluble	32984892	378	385	O
ACE2	32984892	386	390	O
(	32984892	391	392	O
sACE2	32984892	393	398	O
)	32984892	399	400	O
might	32984892	401	406	O
reflect	32984892	407	414	O
a	32984892	415	416	O
higher	32984892	417	423	O
cellular	32984892	424	432	O
expression	32984892	433	443	O
of	32984892	444	446	O
ACE2	32984892	447	451	O
.	32984892	452	453	O

The	32984892	454	457	O
present	32984892	458	465	O
study	32984892	466	471	O
explored	32984892	472	480	O
the	32984892	481	484	O
associations	32984892	485	497	O
between	32984892	498	505	O
sACE2	32984892	506	511	O
and	32984892	512	515	O
clinical	32984892	516	524	O
factors	32984892	525	532	O
,	32984892	533	534	O
cardiovascular	32984892	535	549	O
biomarkers	32984892	550	560	O
,	32984892	561	562	O
and	32984892	563	566	O
genetic	32984892	567	574	O
variability	32984892	575	586	O
.	32984892	587	588	O

Plasma	32984892	589	595	O
and	32984892	596	599	O
DNA	32984892	600	603	O
samples	32984892	604	611	O
were	32984892	612	616	O
obtained	32984892	617	625	O
from	32984892	626	630	O
two	32984892	631	634	O
international	32984892	635	648	O
cohorts	32984892	649	656	O
of	32984892	657	659	O
elderly	32984892	660	667	O
patients	32984892	668	676	O
with	32984892	677	681	O
atrial	32984892	682	688	O
fibrillation	32984892	689	701	O
(	32984892	702	703	O
n	32984892	704	705	O
=	32984892	706	707	O
3999	32984892	708	712	O
and	32984892	713	716	O
n	32984892	717	718	O
=	32984892	719	720	O
1088	32984892	721	725	O
)	32984892	726	727	O
.	32984892	728	729	O

The	32984892	730	733	O
sACE2	32984892	734	739	O
protein	32984892	740	747	O
level	32984892	748	753	O
was	32984892	754	757	O
measured	32984892	758	766	O
by	32984892	767	769	O
the	32984892	770	773	O
Olink	32984892	774	779	O
Proteomics	32984892	780	790	O
	32984892	791	792	O
Multiplex	32984892	793	802	O
CVD	32984892	803	806	O
II96	32984892	807	811	O
	32984892	814	815	O
96	32984892	818	820	O
panel	32984892	821	826	O
.	32984892	827	828	O

Levels	32984892	829	835	O
of	32984892	836	838	O
the	32984892	839	842	O
biomarkers	32984892	843	853	O
high	32984892	854	858	O
-	32984892	859	860	O
sensitive	32984892	861	870	O
cardiac	32984892	871	878	O
troponin	32984892	879	887	O
T	32984892	888	889	O
(	32984892	890	891	O
hs	32984892	892	894	O
-	32984892	895	896	O
cTnT	32984892	897	901	O
)	32984892	902	903	O
,	32984892	904	905	O
N	32984892	906	907	O
-	32984892	908	909	O
terminal	32984892	910	918	O
probrain	32984892	919	927	O
natriuretic	32984892	928	939	O
peptide	32984892	940	947	O
(	32984892	948	949	O
NT	32984892	950	952	O
-	32984892	953	954	O
proBNP	32984892	955	961	O
)	32984892	962	963	O
,	32984892	964	965	O
growth	32984892	966	972	O
differentiation	32984892	973	988	O
factor	32984892	989	995	O
15	32984892	996	998	O
(	32984892	999	1000	O
GDF-15	32984892	1001	1007	O
)	32984892	1008	1009	O
,	32984892	1010	1011	O
C	32984892	1012	1013	O
-	32984892	1014	1015	O
reactive	32984892	1016	1024	O
protein	32984892	1025	1032	O
,	32984892	1033	1034	O
interleukin-6	32984892	1035	1048	O
,	32984892	1049	1050	O
D	32984892	1051	1052	O
-	32984892	1053	1054	O
dimer	32984892	1055	1060	O
,	32984892	1061	1062	O
and	32984892	1063	1066	O
cystatin	32984892	1067	1075	O
-	32984892	1076	1077	O
C	32984892	1078	1079	O
were	32984892	1080	1084	O
determined	32984892	1085	1095	O
by	32984892	1096	1098	O
immunoassays	32984892	1099	1111	O
.	32984892	1112	1113	O

Genome	32984892	1114	1120	O
-	32984892	1121	1122	O
wide	32984892	1123	1127	O
association	32984892	1128	1139	O
studies	32984892	1140	1147	O
were	32984892	1148	1152	O
performed	32984892	1153	1162	O
by	32984892	1163	1165	O
Illumina	32984892	1166	1174	O
chips	32984892	1175	1180	O
.	32984892	1181	1182	O

Higher	32984892	1183	1189	O
levels	32984892	1190	1196	O
of	32984892	1197	1199	O
sACE2	32984892	1200	1205	O
were	32984892	1206	1210	O
statistically	32984892	1211	1224	O
significantly	32984892	1225	1238	O
associated	32984892	1239	1249	O
with	32984892	1250	1254	O
male	32984892	1255	1259	O
sex	32984892	1260	1263	O
,	32984892	1264	1265	O
cardiovascular	32984892	1266	1280	O
disease	32984892	1281	1288	O
,	32984892	1289	1290	O
diabetes	32984892	1291	1299	O
,	32984892	1300	1301	O
and	32984892	1302	1305	O
older	32984892	1306	1311	O
age	32984892	1312	1315	O
.	32984892	1316	1317	O

The	32984892	1318	1321	O
sACE2	32984892	1322	1327	O
level	32984892	1328	1333	O
was	32984892	1334	1337	O
most	32984892	1338	1342	O
strongly	32984892	1343	1351	O
associated	32984892	1352	1362	O
with	32984892	1363	1367	O
the	32984892	1368	1371	O
levels	32984892	1372	1378	O
of	32984892	1379	1381	O
GDF-15	32984892	1382	1388	O
,	32984892	1389	1390	O
NT	32984892	1391	1393	O
-	32984892	1394	1395	O
proBNP	32984892	1396	1402	O
,	32984892	1403	1404	O
and	32984892	1405	1408	O
hs	32984892	1409	1411	O
-	32984892	1412	1413	O
cTnT.	32984892	1414	1419	O
When	32984892	1420	1424	O
adjusting	32984892	1425	1434	O
for	32984892	1435	1438	O
these	32984892	1439	1444	O
biomarkers	32984892	1445	1455	O
,	32984892	1456	1457	O
only	32984892	1458	1462	O
male	32984892	1463	1467	O
sex	32984892	1468	1471	O
remained	32984892	1472	1480	O
associated	32984892	1481	1491	O
with	32984892	1492	1496	O
sACE2	32984892	1497	1502	O
.	32984892	1503	1504	O

We	32984892	1505	1507	O
found	32984892	1508	1513	O
no	32984892	1514	1516	O
statistically	32984892	1517	1530	O
significant	32984892	1531	1542	O
genetic	32984892	1543	1550	O
regulation	32984892	1551	1561	O
of	32984892	1562	1564	O
the	32984892	1565	1568	O
sACE2	32984892	1569	1574	O
level	32984892	1575	1580	O
.	32984892	1581	1582	O

Male	32984892	1583	1587	O
sex	32984892	1588	1591	O
and	32984892	1592	1595	O
clinical	32984892	1596	1604	O
or	32984892	1605	1607	O
biomarker	32984892	1608	1617	O
indicators	32984892	1618	1628	O
of	32984892	1629	1631	O
biological	32984892	1632	1642	O
ageing	32984892	1643	1649	O
,	32984892	1650	1651	O
cardiovascular	32984892	1652	1666	O
disease	32984892	1667	1674	O
,	32984892	1675	1676	O
and	32984892	1677	1680	O
diabetes	32984892	1681	1689	O
are	32984892	1690	1693	O
associated	32984892	1694	1704	O
with	32984892	1705	1709	O
higher	32984892	1710	1716	O
sACE2	32984892	1717	1722	O
levels	32984892	1723	1729	O
.	32984892	1730	1731	O

The	32984892	1732	1735	O
levels	32984892	1736	1742	O
of	32984892	1743	1745	O
GDF-15	32984892	1746	1752	O
and	32984892	1753	1756	O
NT	32984892	1757	1759	O
-	32984892	1760	1761	O
proBNP	32984892	1762	1768	O
,	32984892	1769	1770	O
which	32984892	1771	1776	O
are	32984892	1777	1780	O
associated	32984892	1781	1791	O
both	32984892	1792	1796	O
with	32984892	1797	1801	O
the	32984892	1802	1805	O
sACE2	32984892	1806	1811	O
level	32984892	1812	1817	O
and	32984892	1818	1821	O
a	32984892	1822	1823	O
higher	32984892	1824	1830	O
risk	32984892	1831	1835	O
for	32984892	1836	1839	O
mortality	32984892	1840	1849	O
and	32984892	1850	1853	O
cardiovascular	32984892	1854	1868	O
disease	32984892	1869	1876	O
,	32984892	1877	1878	O
might	32984892	1879	1884	O
contribute	32984892	1885	1895	O
to	32984892	1896	1898	O
better	32984892	1899	1905	O
identification	32984892	1906	1920	O
of	32984892	1921	1923	O
risk	32984892	1924	1928	O
for	32984892	1929	1932	O
severe	32984892	1933	1939	O
COVID-19	32984892	1940	1948	O
infection	32984892	1949	1958	O
.	32984892	1959	1960	O


Contamination	32988954	0	13	O
and	32988954	14	17	O
washing	32988954	18	25	O
of	32988954	26	28	O
cloth	32988954	29	34	O
masks	32988954	35	40	O
and	32988954	41	44	O
risk	32988954	45	49	O
of	32988954	50	52	O
infection	32988954	53	62	O
among	32988954	63	68	O
hospital	32988954	69	77	O
health	32988954	78	84	O
workers	32988954	85	92	O
in	32988954	93	95	O
Vietnam	32988954	96	103	O
:	32988954	104	105	O
a	32988954	106	107	O
post	32988954	108	112	O
hoc	32988954	113	116	O
analysis	32988954	117	125	O
of	32988954	126	128	O
a	32988954	129	130	O
randomised	32988954	131	141	O
controlled	32988954	142	152	O
trial	32988954	153	158	O
.	32988954	159	160	O

In	32988954	161	163	O
a	32988954	164	165	O
previous	32988954	166	174	O
randomised	32988954	175	185	O
controlled	32988954	186	196	O
trial	32988954	197	202	O
(	32988954	203	204	O
RCT	32988954	205	208	O
)	32988954	209	210	O
in	32988954	211	213	O
hospital	32988954	214	222	O
healthcare	32988954	223	233	O
workers	32988954	234	241	O
(	32988954	242	243	O
HCWs	32988954	244	248	O
)	32988954	249	250	O
,	32988954	251	252	O
cloth	32988954	253	258	O
masks	32988954	259	264	O
resulted	32988954	265	273	O
in	32988954	274	276	O
a	32988954	277	278	O
higher	32988954	279	285	O
risk	32988954	286	290	O
of	32988954	291	293	O
respiratory	32988954	294	305	O
infections	32988954	306	316	O
compared	32988954	317	325	O
with	32988954	326	330	O
medical	32988954	331	338	O
masks	32988954	339	344	O
.	32988954	345	346	O

This	32988954	347	351	O
was	32988954	352	355	O
the	32988954	356	359	O
only	32988954	360	364	O
published	32988954	365	374	O
RCT	32988954	375	378	O
of	32988954	379	381	O
cloth	32988954	382	387	O
masks	32988954	388	393	O
at	32988954	394	396	O
the	32988954	397	400	O
time	32988954	401	405	O
of	32988954	406	408	O
the	32988954	409	412	O
COVID-19	32988954	413	421	O
pandemic	32988954	422	430	O
.	32988954	431	432	O

To	32988954	433	435	O
do	32988954	436	438	O
a	32988954	439	440	O
post	32988954	441	445	O
hoc	32988954	446	449	O
analysis	32988954	450	458	O
of	32988954	459	461	O
unpublished	32988954	462	473	O
data	32988954	474	478	O
on	32988954	479	481	O
mask	32988954	482	486	O
washing	32988954	487	494	O
and	32988954	495	498	O
mask	32988954	499	503	O
contamination	32988954	504	517	O
from	32988954	518	522	O
the	32988954	523	526	O
original	32988954	527	535	O
RCT	32988954	536	539	O
to	32988954	540	542	O
further	32988954	543	550	O
understand	32988954	551	561	O
poor	32988954	562	566	O
performance	32988954	567	578	O
of	32988954	579	581	O
the	32988954	582	585	O
two	32988954	586	589	O
-	32988954	590	591	O
layered	32988954	592	599	O
cotton	32988954	600	606	O
cloth	32988954	607	612	O
mask	32988954	613	617	O
used	32988954	618	622	O
by	32988954	623	625	O
HCWs	32988954	626	630	O
in	32988954	631	633	O
that	32988954	634	638	O
RCT	32988954	639	642	O
.	32988954	643	644	O

14	32988954	645	647	O
secondary	32988954	648	657	O
-	32988954	658	659	O
level	32988954	660	665	O
/	32988954	666	667	O
tertiary	32988954	668	676	O
-	32988954	677	678	O
level	32988954	679	684	O
hospitals	32988954	685	694	O
in	32988954	695	697	O
Hanoi	32988954	698	703	O
,	32988954	704	705	O
Vietnam	32988954	706	713	O
.	32988954	714	715	O

A	32988954	716	717	O
subgroup	32988954	718	726	O
of	32988954	727	729	O
607	32988954	730	733	O
HCWs	32988954	734	738	O
aged	32988954	739	743	O
	32988954	746	747	O
18	32988954	748	750	O
years	32988954	753	758	O
working	32988954	759	766	O
full	32988954	767	771	O
time	32988954	772	776	O
in	32988954	777	779	O
selected	32988954	780	788	O
high	32988954	789	793	O
-	32988954	794	795	O
risk	32988954	796	800	O
wards	32988954	801	806	O
,	32988954	807	808	O
who	32988954	809	812	O
used	32988954	813	817	O
a	32988954	818	819	O
two	32988954	820	823	O
-	32988954	824	825	O
layered	32988954	826	833	O
cloth	32988954	834	839	O
mask	32988954	840	844	O
and	32988954	845	848	O
were	32988954	849	853	O
part	32988954	854	858	O
of	32988954	859	861	O
a	32988954	862	863	O
randomised	32988954	864	874	O
controlled	32988954	875	885	O
clinical	32988954	886	894	O
trial	32988954	895	900	O
comparing	32988954	901	910	O
medical	32988954	911	918	O
masks	32988954	919	924	O
and	32988954	925	928	O
cloth	32988954	929	934	O
masks	32988954	935	940	O
.	32988954	941	942	O

Washing	32988954	943	950	O
method	32988954	951	957	O
for	32988954	958	961	O
cloth	32988954	962	967	O
masks	32988954	968	973	O
(	32988954	974	975	O
self	32988954	976	980	O
-	32988954	981	982	O
washing	32988954	983	990	O
or	32988954	991	993	O
hospital	32988954	994	1002	O
laundry	32988954	1003	1010	O
)	32988954	1011	1012	O
.	32988954	1013	1014	O

A	32988954	1015	1016	O
substudy	32988954	1017	1025	O
of	32988954	1026	1028	O
contamination	32988954	1029	1042	O
of	32988954	1043	1045	O
a	32988954	1046	1047	O
sample	32988954	1048	1054	O
of	32988954	1055	1057	O
15	32988954	1058	1060	O
cloth	32988954	1061	1066	O
and	32988954	1067	1070	O
medical	32988954	1071	1078	O
masks	32988954	1079	1084	O
was	32988954	1085	1088	O
also	32988954	1089	1093	O
conducted	32988954	1094	1103	O
.	32988954	1104	1105	O

Infection	32988954	1106	1115	O
rate	32988954	1116	1120	O
over	32988954	1121	1125	O
4	32988954	1126	1127	O
weeks	32988954	1128	1133	O
of	32988954	1134	1136	O
follow	32988954	1137	1143	O
up	32988954	1144	1146	O
and	32988954	1147	1150	O
viral	32988954	1151	1156	O
contamination	32988954	1157	1170	O
of	32988954	1171	1173	O
masks	32988954	1174	1179	O
tested	32988954	1180	1186	O
by	32988954	1187	1189	O
multiplex	32988954	1190	1199	O
PCR	32988954	1200	1203	O
.	32988954	1204	1205	O

Viral	32988954	1206	1211	O
contamination	32988954	1212	1225	O
with	32988954	1226	1230	O
rhinovirus	32988954	1231	1241	O
was	32988954	1242	1245	O
identified	32988954	1246	1256	O
on	32988954	1257	1259	O
both	32988954	1260	1264	O
used	32988954	1265	1269	O
medical	32988954	1270	1277	O
and	32988954	1278	1281	O
cloth	32988954	1282	1287	O
masks	32988954	1288	1293	O
.	32988954	1294	1295	O

Most	32988954	1296	1300	O
HCW	32988954	1301	1304	O
(	32988954	1305	1306	O
77	32988954	1307	1309	O
%	32988954	1310	1311	O
of	32988954	1312	1314	O
daily	32988954	1315	1320	O
washing	32988954	1321	1328	O
)	32988954	1329	1330	O
self	32988954	1331	1335	O
-	32988954	1336	1337	O
washed	32988954	1338	1344	O
their	32988954	1345	1350	O
masks	32988954	1351	1356	O
by	32988954	1357	1359	O
hand	32988954	1360	1364	O
.	32988954	1365	1366	O

The	32988954	1367	1370	O
risk	32988954	1371	1375	O
of	32988954	1376	1378	O
infection	32988954	1379	1388	O
was	32988954	1389	1392	O
more	32988954	1393	1397	O
than	32988954	1398	1402	O
double	32988954	1403	1409	O
among	32988954	1410	1415	O
HCW	32988954	1416	1419	O
self	32988954	1420	1424	O
-	32988954	1425	1426	O
washing	32988954	1427	1434	O
their	32988954	1435	1440	O
masks	32988954	1441	1446	O
compared	32988954	1447	1455	O
with	32988954	1456	1460	O
the	32988954	1461	1464	O
hospital	32988954	1465	1473	O
laundry	32988954	1474	1481	O
(	32988954	1482	1483	O
HR	32988954	1484	1486	O
2.04	32988954	1487	1491	O
(	32988954	1492	1493	O
95	32988954	1494	1496	O
%	32988954	1497	1498	O
CI	32988954	1499	1501	O
1.03	32988954	1502	1506	O
to	32988954	1507	1509	O
4.00	32988954	1510	1514	O
)	32988954	1515	1516	O
;	32988954	1517	1518	O
p=0.04	32988954	1519	1525	O
)	32988954	1526	1527	O
.	32988954	1528	1529	O

There	32988954	1530	1535	O
was	32988954	1536	1539	O
no	32988954	1540	1542	O
significant	32988954	1543	1554	O
difference	32988954	1555	1565	O
in	32988954	1566	1568	O
infection	32988954	1569	1578	O
between	32988954	1579	1586	O
HCW	32988954	1587	1590	O
who	32988954	1591	1594	O
wore	32988954	1595	1599	O
cloth	32988954	1600	1605	O
masks	32988954	1606	1611	O
washed	32988954	1612	1618	O
in	32988954	1619	1621	O
the	32988954	1622	1625	O
hospital	32988954	1626	1634	O
laundry	32988954	1635	1642	O
compared	32988954	1643	1651	O
with	32988954	1652	1656	O
medical	32988954	1657	1664	O
masks	32988954	1665	1670	O
(	32988954	1671	1672	O
p=0.5	32988954	1673	1678	O
)	32988954	1679	1680	O
.	32988954	1681	1682	O

Using	32988954	1683	1688	O
self	32988954	1689	1693	O
-	32988954	1694	1695	O
reported	32988954	1696	1704	O
method	32988954	1705	1711	O
of	32988954	1712	1714	O
washing	32988954	1715	1722	O
,	32988954	1723	1724	O
we	32988954	1725	1727	O
showed	32988954	1728	1734	O
double	32988954	1735	1741	O
the	32988954	1742	1745	O
risk	32988954	1746	1750	O
of	32988954	1751	1753	O
infection	32988954	1754	1763	O
with	32988954	1764	1768	O
seasonal	32988954	1769	1777	O
respiratory	32988954	1778	1789	O
viruses	32988954	1790	1797	O
if	32988954	1798	1800	O
masks	32988954	1801	1806	O
were	32988954	1807	1811	O
self	32988954	1812	1816	O
-	32988954	1817	1818	O
washed	32988954	1819	1825	O
by	32988954	1826	1828	O
hand	32988954	1829	1833	O
by	32988954	1834	1836	O
HCWs	32988954	1837	1841	O
.	32988954	1842	1843	O

The	32988954	1844	1847	O
majority	32988954	1848	1856	O
of	32988954	1857	1859	O
HCWs	32988954	1860	1864	O
in	32988954	1865	1867	O
the	32988954	1868	1871	O
study	32988954	1872	1877	O
reported	32988954	1878	1886	O
hand	32988954	1887	1891	O
-	32988954	1892	1893	O
washing	32988954	1894	1901	O
their	32988954	1902	1907	O
mask	32988954	1908	1912	O
themselves	32988954	1913	1923	O
.	32988954	1924	1925	O

This	32988954	1926	1930	O
could	32988954	1931	1936	O
explain	32988954	1937	1944	O
the	32988954	1945	1948	O
poor	32988954	1949	1953	O
performance	32988954	1954	1965	O
of	32988954	1966	1968	O
two	32988954	1969	1972	O
layered	32988954	1973	1980	O
cloth	32988954	1981	1986	O
masks	32988954	1987	1992	O
,	32988954	1993	1994	O
if	32988954	1995	1997	O
the	32988954	1998	2001	O
self	32988954	2002	2006	O
-	32988954	2007	2008	O
washing	32988954	2009	2016	O
was	32988954	2017	2020	O
inadequate	32988954	2021	2031	O
.	32988954	2032	2033	O

Cloth	32988954	2034	2039	O
masks	32988954	2040	2045	O
washed	32988954	2046	2052	O
in	32988954	2053	2055	O
the	32988954	2056	2059	O
hospital	32988954	2060	2068	O
laundry	32988954	2069	2076	O
were	32988954	2077	2081	O
as	32988954	2082	2084	O
protective	32988954	2085	2095	O
as	32988954	2096	2098	O
medical	32988954	2099	2106	O
masks	32988954	2107	2112	O
.	32988954	2113	2114	O

Both	32988954	2115	2119	O
cloth	32988954	2120	2125	O
and	32988954	2126	2129	O
medical	32988954	2130	2137	O
masks	32988954	2138	2143	O
were	32988954	2144	2148	O
contaminated	32988954	2149	2161	O
,	32988954	2162	2163	O
but	32988954	2164	2167	O
only	32988954	2168	2172	O
cloth	32988954	2173	2178	O
masks	32988954	2179	2184	O
were	32988954	2185	2189	O
reused	32988954	2190	2196	O
in	32988954	2197	2199	O
the	32988954	2200	2203	O
study	32988954	2204	2209	O
,	32988954	2210	2211	O
reiterating	32988954	2212	2223	O
the	32988954	2224	2227	O
importance	32988954	2228	2238	O
of	32988954	2239	2241	O
daily	32988954	2242	2247	O
washing	32988954	2248	2255	O
of	32988954	2256	2258	O
reusable	32988954	2259	2267	O
cloth	32988954	2268	2273	O
masks	32988954	2274	2279	O
using	32988954	2280	2285	O
proper	32988954	2286	2292	O
method	32988954	2293	2299	O
.	32988954	2300	2301	O

A	32988954	2302	2303	O
well	32988954	2304	2308	O
-	32988954	2309	2310	O
washed	32988954	2311	2317	O
cloth	32988954	2318	2323	O
mask	32988954	2324	2328	O
can	32988954	2329	2332	O
be	32988954	2333	2335	O
as	32988954	2336	2338	O
protective	32988954	2339	2349	O
as	32988954	2350	2352	O
a	32988954	2353	2354	O
medical	32988954	2355	2362	O
mask	32988954	2363	2367	O
.	32988954	2368	2369	O

ACTRN12610000887077	32988954	2370	2389	O
.	32988954	2390	2391	O


Effect	33031652	0	6	O
of	33031652	7	9	O
Hydroxychloroquine	33031652	10	28	B-Intervention
in	33031652	29	31	O
Hospitalized	33031652	32	44	B-Participant
Patients	33031652	45	53	O
with	33031652	54	58	O
Covid-19	33031652	59	67	B-Participant
.	33031652	68	69	O

BACKGROUND	33031652	70	80	O
:	33031652	81	82	O
Hydroxychloroquine	33031652	83	101	O
and	33031652	102	105	O
chloroquine	33031652	106	117	O
have	33031652	118	122	O
been	33031652	123	127	O
proposed	33031652	128	136	O
as	33031652	137	139	O
treatments	33031652	140	150	O
for	33031652	151	154	O
coronavirus	33031652	155	166	O
disease	33031652	167	174	O
2019	33031652	175	179	O
(	33031652	180	181	O
Covid-19	33031652	182	190	O
)	33031652	191	192	O
on	33031652	193	195	O
the	33031652	196	199	O
basis	33031652	200	205	O
of	33031652	206	208	O
in	33031652	209	211	O
vitro	33031652	212	217	O
activity	33031652	218	226	O
and	33031652	227	230	O
data	33031652	231	235	O
from	33031652	236	240	O
uncontrolled	33031652	241	253	O
studies	33031652	254	261	O
and	33031652	262	265	O
small	33031652	266	271	O
,	33031652	272	273	O
randomized	33031652	274	284	O
trials	33031652	285	291	O
.	33031652	292	293	O

METHODS	33031652	294	301	O
:	33031652	302	303	O
In	33031652	304	306	O
this	33031652	307	311	O
randomized	33031652	312	322	O
,	33031652	323	324	O
controlled	33031652	325	335	O
,	33031652	336	337	O
open	33031652	338	342	O
-	33031652	343	344	O
label	33031652	345	350	O
platform	33031652	351	359	O
trial	33031652	360	365	O
comparing	33031652	366	375	O
a	33031652	376	377	O
range	33031652	378	383	O
of	33031652	384	386	O
possible	33031652	387	395	O
treatments	33031652	396	406	O
with	33031652	407	411	O
usual	33031652	412	417	O
care	33031652	418	422	O
in	33031652	423	425	O
patients	33031652	426	434	O
hospitalized	33031652	435	447	B-Participant
with	33031652	448	452	O
Covid-19	33031652	453	461	B-Participant
,	33031652	462	463	O
we	33031652	464	466	O
randomly	33031652	467	475	O
assigned	33031652	476	484	O
1561	33031652	485	489	O
patients	33031652	490	498	O
to	33031652	499	501	O
receive	33031652	502	509	O
hydroxychloroquine	33031652	510	528	B-Intervention
and	33031652	529	532	O
3155	33031652	533	537	O
to	33031652	538	540	O
receive	33031652	541	548	O
usual	33031652	549	554	B-Intervention
care	33031652	555	559	I-Intervention
.	33031652	560	561	O

The	33031652	562	565	O
primary	33031652	566	573	O
outcome	33031652	574	581	O
was	33031652	582	585	O
28-day	33031652	586	592	B-Outcome
mortality	33031652	593	602	I-Outcome
.	33031652	603	604	O

RESULTS	33031652	605	612	O
:	33031652	613	614	O
The	33031652	615	618	O
enrollment	33031652	619	629	O
of	33031652	630	632	O
patients	33031652	633	641	O
in	33031652	642	644	O
the	33031652	645	648	O
hydroxychloroquine	33031652	649	667	B-Intervention
group	33031652	668	673	O
was	33031652	674	677	O
closed	33031652	678	684	O
on	33031652	685	687	O
June	33031652	688	692	O
5	33031652	693	694	O
,	33031652	695	696	O
2020	33031652	697	701	O
,	33031652	702	703	O
after	33031652	704	709	O
an	33031652	710	712	O
interim	33031652	713	720	O
analysis	33031652	721	729	O
determined	33031652	730	740	O
that	33031652	741	745	O
there	33031652	746	751	O
was	33031652	752	755	O
a	33031652	756	757	O
lack	33031652	758	762	O
of	33031652	763	765	O
efficacy	33031652	766	774	O
.	33031652	775	776	O

Death	33031652	777	782	B-Outcome
within	33031652	783	789	I-Outcome
28	33031652	790	792	I-Outcome
days	33031652	793	797	I-Outcome
occurred	33031652	798	806	O
in	33031652	807	809	O
421	33031652	810	813	B-Count
patients	33031652	814	822	I-Count
(	33031652	823	824	I-Count
27.0	33031652	825	829	I-Count
%	33031652	830	831	I-Count
)	33031652	832	833	I-Count
in	33031652	834	836	O
the	33031652	837	840	O
hydroxychloroquine	33031652	841	859	B-Intervention
group	33031652	860	865	O
and	33031652	866	869	O
in	33031652	870	872	O
790	33031652	873	876	B-Count
(	33031652	877	878	I-Count
25.0	33031652	879	883	I-Count
%	33031652	884	885	I-Count
)	33031652	886	887	I-Count
in	33031652	888	890	O
the	33031652	891	894	O
usual	33031652	895	900	B-Intervention
-	33031652	901	902	I-Intervention
care	33031652	903	907	I-Intervention
group	33031652	908	913	O
(	33031652	914	915	O
rate	33031652	916	920	O
ratio	33031652	921	926	O
,	33031652	927	928	O
1.09	33031652	929	933	O
;	33031652	934	935	O
95	33031652	936	938	O
%	33031652	939	940	O
confidence	33031652	941	951	O
interval	33031652	952	960	O
[	33031652	961	962	O
CI	33031652	963	965	O
]	33031652	966	967	O
,	33031652	968	969	O
0.97	33031652	970	974	O
to	33031652	975	977	O
1.23	33031652	978	982	O
;	33031652	983	984	O
P	33031652	985	986	O
=	33031652	989	990	O
0.15	33031652	993	997	O
)	33031652	998	999	O
.	33031652	1000	1001	O

Consistent	33031652	1002	1012	O
results	33031652	1013	1020	O
were	33031652	1021	1025	O
seen	33031652	1026	1030	O
in	33031652	1031	1033	O
all	33031652	1034	1037	O
prespecified	33031652	1038	1050	O
subgroups	33031652	1051	1060	O
of	33031652	1061	1063	O
patients	33031652	1064	1072	O
.	33031652	1073	1074	O

The	33031652	1075	1078	O
results	33031652	1079	1086	O
suggest	33031652	1087	1094	O
that	33031652	1095	1099	O
patients	33031652	1100	1108	O
in	33031652	1109	1111	O
the	33031652	1112	1115	O
hydroxychloroquine	33031652	1116	1134	B-Intervention
group	33031652	1135	1140	O
were	33031652	1141	1145	O
less	33031652	1146	1150	B-Observation
likely	33031652	1151	1157	I-Observation
to	33031652	1158	1160	O
be	33031652	1161	1163	O
discharged	33031652	1164	1174	B-Outcome
from	33031652	1175	1179	I-Outcome
the	33031652	1180	1183	I-Outcome
hospital	33031652	1184	1192	I-Outcome
alive	33031652	1193	1198	I-Outcome
within	33031652	1199	1205	I-Outcome
28	33031652	1206	1208	I-Outcome
days	33031652	1209	1213	I-Outcome
than	33031652	1214	1218	O
those	33031652	1219	1224	O
in	33031652	1225	1227	O
the	33031652	1228	1231	O
usual	33031652	1232	1237	B-Intervention
-	33031652	1238	1239	I-Intervention
care	33031652	1240	1244	I-Intervention
group	33031652	1245	1250	O
(	33031652	1251	1252	O
59.6	33031652	1253	1257	B-Observation
%	33031652	1258	1259	I-Observation
vs.	33031652	1260	1263	O
62.9	33031652	1264	1268	B-Observation
%	33031652	1269	1270	I-Observation
;	33031652	1271	1272	O
rate	33031652	1273	1277	O
ratio	33031652	1278	1283	O
,	33031652	1284	1285	O
0.90	33031652	1286	1290	O
;	33031652	1291	1292	O
95	33031652	1293	1295	O
%	33031652	1296	1297	O
CI	33031652	1298	1300	O
,	33031652	1301	1302	O
0.83	33031652	1303	1307	O
to	33031652	1308	1310	O
0.98	33031652	1311	1315	O
)	33031652	1316	1317	O
.	33031652	1318	1319	O

Among	33031652	1320	1325	O
the	33031652	1326	1329	O
patients	33031652	1330	1338	O
who	33031652	1339	1342	O
were	33031652	1343	1347	O
not	33031652	1348	1351	O
undergoing	33031652	1352	1362	O
mechanical	33031652	1363	1373	B-Participant
ventilation	33031652	1374	1385	I-Participant
at	33031652	1386	1388	O
baseline	33031652	1389	1397	O
,	33031652	1398	1399	O
those	33031652	1400	1405	O
in	33031652	1406	1408	O
the	33031652	1409	1412	O
hydroxychloroquine	33031652	1413	1431	B-Intervention
group	33031652	1432	1437	O
had	33031652	1438	1441	O
a	33031652	1442	1443	O
higher	33031652	1444	1450	B-Observation
frequency	33031652	1451	1460	I-Observation
of	33031652	1461	1463	O
invasive	33031652	1464	1472	B-Outcome
mechanical	33031652	1473	1483	I-Outcome
ventilation	33031652	1484	1495	I-Outcome
or	33031652	1496	1498	I-Outcome
death	33031652	1499	1504	I-Outcome
(	33031652	1505	1506	O
30.7	33031652	1507	1511	B-Observation
%	33031652	1512	1513	I-Observation
vs.	33031652	1514	1517	O
26.9	33031652	1518	1522	B-Observation
%	33031652	1523	1524	I-Observation
;	33031652	1525	1526	O
risk	33031652	1527	1531	O
ratio	33031652	1532	1537	O
,	33031652	1538	1539	O
1.14	33031652	1540	1544	O
;	33031652	1545	1546	O
95	33031652	1547	1549	O
%	33031652	1550	1551	O
CI	33031652	1552	1554	O
,	33031652	1555	1556	O
1.03	33031652	1557	1561	O
to	33031652	1562	1564	O
1.27	33031652	1565	1569	O
)	33031652	1570	1571	O
.	33031652	1572	1573	O

There	33031652	1574	1579	O
was	33031652	1580	1583	O
a	33031652	1584	1585	O
small	33031652	1586	1591	O
numerical	33031652	1592	1601	O
excess	33031652	1602	1608	O
of	33031652	1609	1611	O
cardiac	33031652	1612	1619	B-Outcome
deaths	33031652	1620	1626	I-Outcome
(	33031652	1627	1628	O
0.4	33031652	1629	1632	B-Observation
percentage	33031652	1633	1643	I-Observation
points	33031652	1644	1650	I-Observation
)	33031652	1651	1652	O
but	33031652	1653	1656	O
no	33031652	1657	1659	O
difference	33031652	1660	1670	B-Observation
in	33031652	1671	1673	O
the	33031652	1674	1677	O
incidence	33031652	1678	1687	B-Outcome
of	33031652	1688	1690	I-Outcome
new	33031652	1691	1694	I-Outcome
major	33031652	1695	1700	I-Outcome
cardiac	33031652	1701	1708	I-Outcome
arrhythmia	33031652	1709	1719	I-Outcome
among	33031652	1720	1725	O
the	33031652	1726	1729	O
patients	33031652	1730	1738	O
who	33031652	1739	1742	O
received	33031652	1743	1751	O
hydroxychloroquine	33031652	1752	1770	B-Intervention
.	33031652	1771	1772	O

CONCLUSIONS	33031652	1773	1784	O
:	33031652	1785	1786	O
Among	33031652	1787	1792	O
patients	33031652	1793	1801	O
hospitalized	33031652	1802	1814	B-Participant
with	33031652	1815	1819	O
Covid-19	33031652	1820	1828	B-Participant
,	33031652	1829	1830	O
those	33031652	1831	1836	O
who	33031652	1837	1840	O
received	33031652	1841	1849	O
hydroxychloroquine	33031652	1850	1868	B-Intervention
did	33031652	1869	1872	O
not	33031652	1873	1876	O
have	33031652	1877	1881	O
a	33031652	1882	1883	O
lower	33031652	1884	1889	B-Observation
incidence	33031652	1890	1899	B-Outcome
of	33031652	1900	1902	I-Outcome
death	33031652	1903	1908	I-Outcome
at	33031652	1909	1911	I-Outcome
28	33031652	1912	1914	I-Outcome
days	33031652	1915	1919	I-Outcome
than	33031652	1920	1924	O
those	33031652	1925	1930	O
who	33031652	1931	1934	O
received	33031652	1935	1943	O
usual	33031652	1944	1949	B-Intervention
care	33031652	1950	1954	I-Intervention
.	33031652	1955	1956	O
(	33031652	1957	1958	O
Funded	33031652	1959	1965	O
by	33031652	1966	1968	O
UK	33031652	1969	1971	O
Research	33031652	1972	1980	O
and	33031652	1981	1984	O
Innovation	33031652	1985	1995	O
and	33031652	1996	1999	O
National	33031652	2000	2008	O
Institute	33031652	2009	2018	O
for	33031652	2019	2022	O
Health	33031652	2023	2029	O
Research	33031652	2030	2038	O
and	33031652	2039	2042	O
others	33031652	2043	2049	O
;	33031652	2050	2051	O
RECOVERY	33031652	2052	2060	O
ISRCTN	33031652	2061	2067	O
number	33031652	2068	2074	O
,	33031652	2075	2076	O
ISRCTN50189673	33031652	2077	2091	O
;	33031652	2092	2093	O
ClinicalTrials.gov	33031652	2094	2112	O
number	33031652	2113	2119	O
,	33031652	2120	2121	O
NCT04381936	33031652	2122	2133	O
.	33031652	2134	2135	O
)	33031652	2136	2137	O
.	33031652	2138	2139	O


Home	33050924	0	4	O
Treatment	33050924	5	14	O
of	33050924	15	17	O
Older	33050924	18	23	O
People	33050924	24	30	O
with	33050924	31	35	O
Symptomatic	33050924	36	47	O
SARS	33050924	48	52	O
-	33050924	53	54	O
CoV-2	33050924	55	60	O
Infection	33050924	61	70	O
(	33050924	71	72	O
COVID-19	33050924	73	81	O
)	33050924	82	83	O
:	33050924	84	85	O
A	33050924	86	87	O
structured	33050924	88	98	O
Summary	33050924	99	106	O
of	33050924	107	109	O
a	33050924	110	111	O
Study	33050924	112	117	O
Protocol	33050924	118	126	O
for	33050924	127	130	O
a	33050924	131	132	O
Multi	33050924	133	138	O
-	33050924	139	140	O
Arm	33050924	141	144	O
Multi	33050924	145	150	O
-	33050924	151	152	O
Stage	33050924	153	158	O
(	33050924	159	160	O
MAMS	33050924	161	165	O
)	33050924	166	167	O
Randomized	33050924	168	178	O
Trial	33050924	179	184	O
to	33050924	185	187	O
Evaluate	33050924	188	196	O
the	33050924	197	200	O
Efficacy	33050924	201	209	O
and	33050924	210	213	O
Tolerability	33050924	214	226	O
of	33050924	227	229	O
Several	33050924	230	237	O
Experimental	33050924	238	250	O
Treatments	33050924	251	261	O
to	33050924	262	264	O
Reduce	33050924	265	271	O
the	33050924	272	275	O
Risk	33050924	276	280	O
of	33050924	281	283	O
Hospitalisation	33050924	284	299	O
or	33050924	300	302	O
Death	33050924	303	308	O
in	33050924	309	311	O
outpatients	33050924	312	323	O
aged	33050924	324	328	O
65	33050924	329	331	O
years	33050924	332	337	O
or	33050924	338	340	O
older	33050924	341	346	O
(	33050924	347	348	O
COVERAGE	33050924	349	357	O
trial	33050924	358	363	O
)	33050924	364	365	O
.	33050924	366	367	O

OBJECTIVE	33050924	368	377	O
:	33050924	378	379	O
To	33050924	380	382	O
assess	33050924	383	389	O
the	33050924	390	393	O
efficacy	33050924	394	402	O
of	33050924	403	405	O
several	33050924	406	413	O
repurposed	33050924	414	424	O
drugs	33050924	425	430	O
to	33050924	431	433	O
prevent	33050924	434	441	O
hospitalisation	33050924	442	457	O
or	33050924	458	460	O
death	33050924	461	466	O
in	33050924	467	469	O
patients	33050924	470	478	O
aged	33050924	479	483	O
65	33050924	484	486	O
or	33050924	487	489	O
more	33050924	490	494	O
with	33050924	495	499	O
recent	33050924	500	506	O
symptomatic	33050924	507	518	O
SARS	33050924	519	523	O
-	33050924	524	525	O
CoV-2	33050924	526	531	O
infection	33050924	532	541	O
(	33050924	542	543	O
COVID-19	33050924	544	552	O
)	33050924	553	554	O
and	33050924	555	558	O
no	33050924	559	561	O
criteria	33050924	562	570	O
for	33050924	571	574	O
hospitalisation	33050924	575	590	O
.	33050924	591	592	O

METHODS	33050924	593	600	O
:	33050924	601	602	O
Phase	33050924	603	608	O
III	33050924	609	612	O
,	33050924	613	614	O
multi	33050924	615	620	O
-	33050924	621	622	O
arm	33050924	623	626	O
(	33050924	627	628	O
5	33050924	629	630	O
)	33050924	631	632	O
and	33050924	633	636	O
multi	33050924	637	642	O
-	33050924	643	644	O
stage	33050924	645	650	O
(	33050924	651	652	O
MAMS	33050924	653	657	O
)	33050924	658	659	O
,	33050924	660	661	O
randomized	33050924	662	672	O
,	33050924	673	674	O
open	33050924	675	679	O
-	33050924	680	681	O
label	33050924	682	687	O
controlled	33050924	688	698	O
superiority	33050924	699	710	O
trial	33050924	711	716	O
.	33050924	717	718	O

Participants	33050924	719	731	O
will	33050924	732	736	O
be	33050924	737	739	O
randomly	33050924	740	748	O
allocated	33050924	749	758	O
1:1:1:1:1	33050924	759	768	O
to	33050924	769	771	O
the	33050924	772	775	O
following	33050924	776	785	O
strategies	33050924	786	796	O
:	33050924	797	798	O
Arm	33050924	799	802	O
1	33050924	803	804	O
:	33050924	805	806	O
Control	33050924	807	814	O
arm	33050924	815	818	O
Arms	33050924	819	823	O
2	33050924	824	825	O
to	33050924	826	828	O
5	33050924	829	830	O
:	33050924	831	832	O
Experimental	33050924	833	845	O
treatment	33050924	846	855	O
arms	33050924	856	860	O
Planned	33050924	861	868	O
interim	33050924	869	876	O
analyses	33050924	877	885	O
will	33050924	886	890	O
be	33050924	891	893	O
conducted	33050924	894	903	O
at	33050924	904	906	O
regular	33050924	907	914	O
intervals	33050924	915	924	O
.	33050924	925	926	O

Their	33050924	927	932	O
results	33050924	933	940	O
will	33050924	941	945	O
be	33050924	946	948	O
reviewed	33050924	949	957	O
by	33050924	958	960	O
an	33050924	961	963	O
Independent	33050924	964	975	O
Data	33050924	976	980	O
and	33050924	981	984	O
Safety	33050924	985	991	O
Monitoring	33050924	992	1002	O
Board	33050924	1003	1008	O
.	33050924	1009	1010	O

Experimental	33050924	1011	1023	O
arms	33050924	1024	1028	O
may	33050924	1029	1032	O
be	33050924	1033	1035	O
terminated	33050924	1036	1046	O
for	33050924	1047	1050	O
futility	33050924	1051	1059	O
,	33050924	1060	1061	O
efficacy	33050924	1062	1070	O
or	33050924	1071	1073	O
toxicity	33050924	1074	1082	O
before	33050924	1083	1089	O
the	33050924	1090	1093	O
end	33050924	1094	1097	O
of	33050924	1098	1100	O
the	33050924	1101	1104	O
trial	33050924	1105	1110	O
.	33050924	1111	1112	O

New	33050924	1113	1116	O
experimental	33050924	1117	1129	O
arms	33050924	1130	1134	O
may	33050924	1135	1138	O
be	33050924	1139	1141	O
added	33050924	1142	1147	O
if	33050924	1148	1150	O
new	33050924	1151	1154	O
evidence	33050924	1155	1163	O
suggests	33050924	1164	1172	O
that	33050924	1173	1177	O
other	33050924	1178	1183	O
treatments	33050924	1184	1194	O
should	33050924	1195	1201	O
be	33050924	1202	1204	O
tested	33050924	1205	1211	O
.	33050924	1212	1213	O

A	33050924	1214	1215	O
feasibility	33050924	1216	1227	O
and	33050924	1228	1231	O
acceptability	33050924	1232	1245	O
substudy	33050924	1246	1254	O
as	33050924	1255	1257	O
well	33050924	1258	1262	O
as	33050924	1263	1265	O
an	33050924	1266	1268	O
immunological	33050924	1269	1282	O
substudy	33050924	1283	1291	O
will	33050924	1292	1296	O
be	33050924	1297	1299	O
conducted	33050924	1300	1309	O
alongside	33050924	1310	1319	O
the	33050924	1320	1323	O
trial	33050924	1324	1329	O
.	33050924	1330	1331	O

METHODS	33050924	1332	1339	O
:	33050924	1340	1341	O
Inclusion	33050924	1342	1351	O
criteria	33050924	1352	1360	O
are	33050924	1361	1364	O
:	33050924	1365	1366	O
65-year	33050924	1367	1374	O
-	33050924	1375	1376	O
old	33050924	1377	1380	O
or	33050924	1381	1383	O
more	33050924	1384	1388	O
;	33050924	1389	1390	O
Positive	33050924	1391	1399	O
test	33050924	1400	1404	O
for	33050924	1405	1408	O
SARS	33050924	1409	1413	O
-	33050924	1414	1415	O
CoV-2	33050924	1416	1421	O
on	33050924	1422	1424	O
a	33050924	1425	1426	O
nasopharyngeal	33050924	1427	1441	O
swab	33050924	1442	1446	O
;	33050924	1447	1448	O
Symptoms	33050924	1449	1457	O
onset	33050924	1458	1463	O
within	33050924	1464	1470	O
3	33050924	1471	1472	O
days	33050924	1473	1477	O
before	33050924	1478	1484	O
diagnosis	33050924	1485	1494	O
;	33050924	1495	1496	O
No	33050924	1497	1499	O
hospitalisation	33050924	1500	1515	O
criteria	33050924	1516	1524	O
;	33050924	1525	1526	O
Signed	33050924	1527	1533	O
informed	33050924	1534	1542	O
consent	33050924	1543	1550	O
;	33050924	1551	1552	O
Health	33050924	1553	1559	O
insurance	33050924	1560	1569	O
.	33050924	1570	1571	O

Exclusion	33050924	1572	1581	O
criteria	33050924	1582	1590	O
are	33050924	1591	1594	O
:	33050924	1595	1596	O
Inability	33050924	1597	1606	O
to	33050924	1607	1609	O
make	33050924	1610	1614	O
an	33050924	1615	1617	O
informed	33050924	1618	1626	O
decision	33050924	1627	1635	O
to	33050924	1636	1638	O
participate	33050924	1639	1650	O
(	33050924	1651	1652	O
e.g.	33050924	1653	1657	O
:	33050924	1658	1659	O
dementia	33050924	1660	1668	O
,	33050924	1669	1670	O
guardianship	33050924	1671	1683	O
)	33050924	1684	1685	O
;	33050924	1686	1687	O
Rockwood	33050924	1688	1696	O
Clinical	33050924	1697	1705	O
Frailty	33050924	1706	1713	O
Scale	33050924	1714	1719	O
	33050924	1722	1723	O
7	33050924	1724	1725	O
;	33050924	1726	1727	O
Long	33050924	1728	1732	O
QT	33050924	1733	1735	O
syndrome	33050924	1736	1744	O
;	33050924	1745	1746	O
QTc	33050924	1747	1750	O
interval	33050924	1751	1759	O
>	33050924	1760	1761	O
500	33050924	1762	1765	O
ms	33050924	1766	1768	O
;	33050924	1769	1770	O
Heart	33050924	1771	1776	O
rate	33050924	1777	1781	O
<	33050924	1782	1783	O
50	33050924	1784	1786	O
/	33050924	1787	1788	O
min	33050924	1789	1792	O
;	33050924	1793	1794	O
Kalaemia	33050924	1795	1803	O
>	33050924	1804	1805	O
5.5	33050924	1806	1809	O
mmol	33050924	1810	1814	O
/	33050924	1815	1816	O
L	33050924	1817	1818	O
or	33050924	1819	1821	O
<	33050924	1822	1823	O
3.5	33050924	1824	1827	O
mmol	33050924	1828	1832	O
/	33050924	1833	1834	O
L	33050924	1835	1836	O
;	33050924	1837	1838	O
Ongoing	33050924	1839	1846	O
treatment	33050924	1847	1856	O
with	33050924	1857	1861	O
piperaquine	33050924	1862	1873	O
,	33050924	1874	1875	O
halofantrine	33050924	1876	1888	O
,	33050924	1889	1890	O
dasatinib	33050924	1891	1900	O
,	33050924	1901	1902	O
nilotinib	33050924	1903	1912	O
,	33050924	1913	1914	O
hydroxyzine	33050924	1915	1926	O
,	33050924	1927	1928	O
domperidone	33050924	1929	1940	O
,	33050924	1941	1942	O
citalopram	33050924	1943	1953	O
,	33050924	1954	1955	O
escitalopram	33050924	1956	1968	O
,	33050924	1969	1970	O
potent	33050924	1971	1977	O
inhibitors	33050924	1978	1988	O
or	33050924	1989	1991	O
inducers	33050924	1992	2000	O
of	33050924	2001	2003	O
cytochrome	33050924	2004	2014	O
P450	33050924	2015	2019	O
CYP3A4	33050924	2020	2026	O
isoenzyme	33050924	2027	2036	O
,	33050924	2037	2038	O
repaglinide	33050924	2039	2050	O
,	33050924	2051	2052	O
azathioprine	33050924	2053	2065	O
,	33050924	2066	2067	O
6-mercaptopurine	33050924	2068	2084	O
,	33050924	2085	2086	O
theophylline	33050924	2087	2099	O
,	33050924	2100	2101	O
pyrazinamide	33050924	2102	2114	O
,	33050924	2115	2116	O
warfarin	33050924	2117	2125	O
;	33050924	2126	2127	O
Known	33050924	2128	2133	O
hypersensitivity	33050924	2134	2150	O
to	33050924	2151	2153	O
any	33050924	2154	2157	O
of	33050924	2158	2160	O
the	33050924	2161	2164	O
trial	33050924	2165	2170	O
drugs	33050924	2171	2176	O
or	33050924	2177	2179	O
to	33050924	2180	2182	O
chloroquine	33050924	2183	2194	O
and	33050924	2195	2198	O
other	33050924	2199	2204	O
4-aminoquinolines	33050924	2205	2222	O
,	33050924	2223	2224	O
amodiaquine	33050924	2225	2236	O
,	33050924	2237	2238	O
mefloquine	33050924	2239	2249	O
,	33050924	2250	2251	O
glafenine	33050924	2252	2261	O
,	33050924	2262	2263	O
floctafenine	33050924	2264	2276	O
,	33050924	2277	2278	O
antrafenine	33050924	2279	2290	O
,	33050924	2291	2292	O
ARB	33050924	2293	2296	O
;	33050924	2297	2298	O
Hepatic	33050924	2299	2306	O
porphyria	33050924	2307	2316	O
;	33050924	2317	2318	O
Liver	33050924	2319	2324	O
failure	33050924	2325	2332	O
(	33050924	2333	2334	O
Child	33050924	2335	2340	O
-	33050924	2341	2342	O
Pugh	33050924	2343	2347	O
stage	33050924	2348	2353	O
	33050924	2356	2357	O
B	33050924	2358	2359	O
)	33050924	2360	2361	O
;	33050924	2362	2363	O
Stage	33050924	2364	2369	O
4	33050924	2370	2371	O
or	33050924	2372	2374	O
5	33050924	2375	2376	O
chronic	33050924	2377	2384	O
kidney	33050924	2385	2391	O
disease	33050924	2392	2399	O
(	33050924	2400	2401	O
GFR	33050924	2402	2405	O
<	33050924	2406	2407	O
30	33050924	2408	2410	O
mL	33050924	2411	2413	O
/	33050924	2414	2415	O
min/1.73	33050924	2416	2424	O
m	33050924	2425	2427	O
)	33050924	2428	2429	O
;	33050924	2430	2431	O
Dialysis	33050924	2432	2440	O
;	33050924	2441	2442	O
Hypersentivity	33050924	2443	2457	O
to	33050924	2458	2460	O
lactose	33050924	2461	2468	O
;	33050924	2469	2470	O
Lactase	33050924	2471	2478	O
deficiency	33050924	2479	2489	O
;	33050924	2490	2491	O
Abnormalities	33050924	2492	2505	O
in	33050924	2506	2508	O
galactose	33050924	2509	2518	O
metabolism	33050924	2519	2529	O
;	33050924	2530	2531	O
Malabsorption	33050924	2532	2545	O
syndrome	33050924	2546	2554	O
;	33050924	2555	2556	O
Glucose-6-phosphate	33050924	2557	2576	O
dehydrogenase	33050924	2577	2590	O
deficiency	33050924	2591	2601	O
;	33050924	2602	2603	O
Symptomatic	33050924	2604	2615	O
hyperuricemia	33050924	2616	2629	O
;	33050924	2630	2631	O
Ileus	33050924	2632	2637	O
;	33050924	2638	2639	O
Colitis	33050924	2640	2647	O
;	33050924	2648	2649	O
Enterocolitis	33050924	2650	2663	O
;	33050924	2664	2665	O
Chronic	33050924	2666	2673	O
hepatitis	33050924	2674	2683	O
B	33050924	2684	2685	O
virus	33050924	2686	2691	O
disease	33050924	2692	2699	O
.	33050924	2700	2701	O

The	33050924	2702	2705	O
trial	33050924	2706	2711	O
is	33050924	2712	2714	O
being	33050924	2715	2720	O
conducted	33050924	2721	2730	O
in	33050924	2731	2733	O
France	33050924	2734	2740	O
in	33050924	2741	2743	O
the	33050924	2744	2747	O
Bordeaux	33050924	2748	2756	O
,	33050924	2757	2758	O
Corse	33050924	2759	2764	O
,	33050924	2765	2766	O
Dijon	33050924	2767	2772	O
,	33050924	2773	2774	O
Nancy	33050924	2775	2780	O
,	33050924	2781	2782	O
Paris	33050924	2783	2788	O
and	33050924	2789	2792	O
Toulouse	33050924	2793	2801	O
areas	33050924	2802	2807	O
as	33050924	2808	2810	O
well	33050924	2811	2815	O
as	33050924	2816	2818	O
in	33050924	2819	2821	O
the	33050924	2822	2825	O
Grand	33050924	2826	2831	O
Duchy	33050924	2832	2837	O
of	33050924	2838	2840	O
Luxembourg	33050924	2841	2851	O
.	33050924	2852	2853	O

Participants	33050924	2854	2866	O
are	33050924	2867	2870	O
recruited	33050924	2871	2880	O
either	33050924	2881	2887	O
at	33050924	2888	2890	O
home	33050924	2891	2895	O
,	33050924	2896	2897	O
nursing	33050924	2898	2905	O
homes	33050924	2906	2911	O
,	33050924	2912	2913	O
general	33050924	2914	2921	O
practices	33050924	2922	2931	O
,	33050924	2932	2933	O
primary	33050924	2934	2941	O
care	33050924	2942	2946	O
centres	33050924	2947	2954	O
or	33050924	2955	2957	O
hospital	33050924	2958	2966	O
outpatient	33050924	2967	2977	O
consultations	33050924	2978	2991	O
.	33050924	2992	2993	O

UNASSIGNED	33050924	2994	3004	O
:	33050924	3005	3006	O
The	33050924	3007	3010	O
four	33050924	3011	3015	O
experimental	33050924	3016	3028	O
treatments	33050924	3029	3039	O
planned	33050924	3040	3047	O
in	33050924	3048	3050	O
protocol	33050924	3051	3059	O
version	33050924	3060	3067	O
1.2	33050924	3068	3071	O
(	33050924	3072	3073	O
April	33050924	3074	3079	O
8th	33050924	3080	3083	O
,	33050924	3084	3085	O
2020	33050924	3086	3090	O
)	33050924	3091	3092	O
are	33050924	3093	3096	O
:	33050924	3097	3098	O
(	33050924	3099	3100	O
1	33050924	3101	3102	O
)	33050924	3103	3104	O
Hydroxychloroquine	33050924	3105	3123	O
200	33050924	3124	3127	O
mg	33050924	3128	3130	O
,	33050924	3131	3132	O
2	33050924	3133	3134	O
tablets	33050924	3135	3142	O
BID	33050924	3143	3146	O
on	33050924	3147	3149	O
day	33050924	3150	3153	O
0	33050924	3154	3155	O
,	33050924	3156	3157	O
2	33050924	3158	3159	O
tablets	33050924	3160	3167	O
QD	33050924	3168	3170	O
from	33050924	3171	3175	O
day	33050924	3176	3179	O
1	33050924	3180	3181	O
to	33050924	3182	3184	O
9	33050924	3185	3186	O
;	33050924	3187	3188	O
(	33050924	3189	3190	O
2	33050924	3191	3192	O
)	33050924	3193	3194	O
Imatinib	33050924	3195	3203	O
400	33050924	3204	3207	O
mg	33050924	3208	3210	O
,	33050924	3211	3212	O
1	33050924	3213	3214	O
tablet	33050924	3215	3221	O
QD	33050924	3222	3224	O
from	33050924	3225	3229	O
day	33050924	3230	3233	O
0	33050924	3234	3235	O
to	33050924	3236	3238	O
9	33050924	3239	3240	O
;	33050924	3241	3242	O
(	33050924	3243	3244	O
3	33050924	3245	3246	O
)	33050924	3247	3248	O
Favipiravir	33050924	3249	3260	O
200	33050924	3261	3264	O
mg	33050924	3265	3267	O
,	33050924	3268	3269	O
12	33050924	3270	3272	O
tablets	33050924	3273	3280	O
BID	33050924	3281	3284	O
on	33050924	3285	3287	O
day	33050924	3288	3291	O
0	33050924	3292	3293	O
,	33050924	3294	3295	O
6	33050924	3296	3297	O
tablets	33050924	3298	3305	O
BID	33050924	3306	3309	O
from	33050924	3310	3314	O
day	33050924	3315	3318	O
1	33050924	3319	3320	O
to	33050924	3321	3323	O
9	33050924	3324	3325	O
;	33050924	3326	3327	O
(	33050924	3328	3329	O
4	33050924	3330	3331	O
)	33050924	3332	3333	O
Telmisartan	33050924	3334	3345	O
20	33050924	3346	3348	O
mg	33050924	3349	3351	O
,	33050924	3352	3353	O
1	33050924	3354	3355	O
tablet	33050924	3356	3362	O
QD	33050924	3363	3365	O
from	33050924	3366	3370	O
day	33050924	3371	3374	O
0	33050924	3375	3376	O
to	33050924	3377	3379	O
9	33050924	3380	3381	O
.	33050924	3382	3383	O

The	33050924	3384	3387	O
comparator	33050924	3388	3398	O
is	33050924	3399	3401	O
a	33050924	3402	3403	O
complex	33050924	3404	3411	O
of	33050924	3412	3414	O
vitamins	33050924	3415	3423	O
and	33050924	3424	3427	O
trace	33050924	3428	3433	O
elements	33050924	3434	3442	O
(	33050924	3443	3444	O
AZINC	33050924	3445	3450	O
Forme	33050924	3451	3456	O
et	33050924	3457	3459	O
Vitalit	33050924	3460	3468	O
	33050924	3469	3470	O
)	33050924	3471	3472	O
,	33050924	3473	3474	O
1	33050924	3475	3476	O
capsule	33050924	3477	3484	O
BID	33050924	3485	3488	O
for	33050924	3489	3492	O
10	33050924	3493	3495	O
days	33050924	3496	3500	O
,	33050924	3501	3502	O
for	33050924	3503	3506	O
which	33050924	3507	3512	O
there	33050924	3513	3518	O
is	33050924	3519	3521	O
no	33050924	3522	3524	O
reason	33050924	3525	3531	O
to	33050924	3532	3534	O
believe	33050924	3535	3542	O
that	33050924	3543	3547	O
they	33050924	3548	3552	O
are	33050924	3553	3556	O
active	33050924	3557	3563	O
on	33050924	3564	3566	O
the	33050924	3567	3570	O
virus	33050924	3571	3576	O
.	33050924	3577	3578	O

In	33050924	3579	3581	O
protocol	33050924	3582	3590	O
version	33050924	3591	3598	O
1.2	33050924	3599	3602	O
(	33050924	3603	3604	O
April	33050924	3605	3610	O
8th	33050924	3611	3614	O
,	33050924	3615	3616	O
2020	33050924	3617	3621	O
)	33050924	3622	3623	O
:	33050924	3624	3625	O
People	33050924	3626	3632	O
in	33050924	3633	3635	O
the	33050924	3636	3639	O
control	33050924	3640	3647	O
arm	33050924	3648	3651	O
will	33050924	3652	3656	O
receive	33050924	3657	3664	O
a	33050924	3665	3666	O
combination	33050924	3667	3678	O
of	33050924	3679	3681	O
vitamins	33050924	3682	3690	O
and	33050924	3691	3694	O
trace	33050924	3695	3700	O
elements	33050924	3701	3709	O
;	33050924	3710	3711	O
people	33050924	3712	3718	O
in	33050924	3719	3721	O
the	33050924	3722	3725	O
experimental	33050924	3726	3738	O
arms	33050924	3739	3743	O
will	33050924	3744	3748	O
receive	33050924	3749	3756	O
hydroxychloroquine	33050924	3757	3775	O
,	33050924	3776	3777	O
or	33050924	3778	3780	O
favipiravir	33050924	3781	3792	O
,	33050924	3793	3794	O
or	33050924	3795	3797	O
imatinib	33050924	3798	3806	O
,	33050924	3807	3808	O
or	33050924	3809	3811	O
telmisartan	33050924	3812	3823	O
.	33050924	3824	3825	O

RESULTS	33050924	3826	3833	O
:	33050924	3834	3835	O
The	33050924	3836	3839	O
primary	33050924	3840	3847	O
outcome	33050924	3848	3855	O
is	33050924	3856	3858	O
the	33050924	3859	3862	O
proportion	33050924	3863	3873	O
of	33050924	3874	3876	O
participants	33050924	3877	3889	O
with	33050924	3890	3894	O
an	33050924	3895	3897	O
incidence	33050924	3898	3907	O
of	33050924	3908	3910	O
hospitalisation	33050924	3911	3926	O
and/or	33050924	3927	3933	O
death	33050924	3934	3939	O
between	33050924	3940	3947	O
inclusion	33050924	3948	3957	O
and	33050924	3958	3961	O
day	33050924	3962	3965	O
14	33050924	3966	3968	O
in	33050924	3969	3971	O
each	33050924	3972	3976	O
arm	33050924	3977	3980	O
.	33050924	3981	3982	O

UNASSIGNED	33050924	3983	3993	O
:	33050924	3994	3995	O
Participants	33050924	3996	4008	O
are	33050924	4009	4012	O
randomized	33050924	4013	4023	O
in	33050924	4024	4026	O
a	33050924	4027	4028	O
1:1:1:1:1	33050924	4029	4038	O
ratio	33050924	4039	4044	O
to	33050924	4045	4047	O
each	33050924	4048	4052	O
arm	33050924	4053	4056	O
using	33050924	4057	4062	O
a	33050924	4063	4064	O
web	33050924	4065	4068	O
-	33050924	4069	4070	O
based	33050924	4071	4076	O
randomisation	33050924	4077	4090	O
tool	33050924	4091	4095	O
.	33050924	4096	4097	O

Participants	33050924	4098	4110	O
not	33050924	4111	4114	O
treated	33050924	4115	4122	O
with	33050924	4123	4127	O
an	33050924	4128	4130	O
ARB	33050924	4131	4134	O
or	33050924	4135	4137	O
ACEI	33050924	4138	4142	O
prior	33050924	4143	4148	O
to	33050924	4149	4151	O
enrolment	33050924	4152	4161	O
are	33050924	4162	4165	O
randomized	33050924	4166	4176	O
to	33050924	4177	4179	O
receive	33050924	4180	4187	O
the	33050924	4188	4191	O
comparator	33050924	4192	4202	O
or	33050924	4203	4205	O
one	33050924	4206	4209	O
of	33050924	4210	4212	O
the	33050924	4213	4216	O
four	33050924	4217	4221	O
experimental	33050924	4222	4234	O
drugs	33050924	4235	4240	O
.	33050924	4241	4242	O

Participants	33050924	4243	4255	O
already	33050924	4256	4263	O
treated	33050924	4264	4271	O
with	33050924	4272	4276	O
an	33050924	4277	4279	O
ARB	33050924	4280	4283	O
or	33050924	4284	4286	O
ACEI	33050924	4287	4291	O
are	33050924	4292	4295	O
randomized	33050924	4296	4306	O
to	33050924	4307	4309	O
receive	33050924	4310	4317	O
the	33050924	4318	4321	O
comparator	33050924	4322	4332	O
or	33050924	4333	4335	O
one	33050924	4336	4339	O
of	33050924	4340	4342	O
the	33050924	4343	4346	O
experimental	33050924	4347	4359	O
drugs	33050924	4360	4365	O
except	33050924	4366	4372	O
telmisartan	33050924	4373	4384	O
(	33050924	4385	4386	O
i.e.	33050924	4387	4391	O
:	33050924	4392	4393	O
hydroxychloroquine	33050924	4394	4412	O
,	33050924	4413	4414	O
imatinib	33050924	4415	4423	O
,	33050924	4424	4425	O
or	33050924	4426	4428	O
favipiravir	33050924	4429	4440	O
)	33050924	4441	4442	O
.	33050924	4443	4444	O

Randomisation	33050924	4445	4458	O
is	33050924	4459	4461	O
stratified	33050924	4462	4472	O
on	33050924	4473	4475	O
ACEI	33050924	4476	4480	O
or	33050924	4481	4483	O
ARBs	33050924	4484	4488	O
treatment	33050924	4489	4498	O
at	33050924	4499	4501	O
inclusion	33050924	4502	4511	O
and	33050924	4512	4515	O
on	33050924	4516	4518	O
the	33050924	4519	4522	O
type	33050924	4523	4527	O
of	33050924	4528	4530	O
residence	33050924	4531	4540	O
(	33050924	4541	4542	O
personal	33050924	4543	4551	O
home	33050924	4552	4556	O
vs.	33050924	4557	4560	O
nursing	33050924	4561	4568	O
home	33050924	4569	4573	O
)	33050924	4574	4575	O
.	33050924	4576	4577	O

UNASSIGNED	33050924	4578	4588	O
:	33050924	4589	4590	O
This	33050924	4591	4595	O
is	33050924	4596	4598	O
an	33050924	4599	4601	O
open	33050924	4602	4606	O
-	33050924	4607	4608	O
label	33050924	4609	4614	O
trial	33050924	4615	4620	O
.	33050924	4621	4622	O

Participants	33050924	4623	4635	O
,	33050924	4636	4637	O
caregivers	33050924	4638	4648	O
,	33050924	4649	4650	O
investigators	33050924	4651	4664	O
and	33050924	4665	4668	O
statisticians	33050924	4669	4682	O
are	33050924	4683	4686	O
not	33050924	4687	4690	O
blinded	33050924	4691	4698	O
to	33050924	4699	4701	O
group	33050924	4702	4707	O
assignment	33050924	4708	4718	O
.	33050924	4719	4720	O

UNASSIGNED	33050924	4721	4731	O
:	33050924	4732	4733	O
A	33050924	4734	4735	O
total	33050924	4736	4741	O
of	33050924	4742	4744	O
1057	33050924	4745	4749	O
participants	33050924	4750	4762	O
will	33050924	4763	4767	O
be	33050924	4768	4770	O
enrolled	33050924	4771	4779	O
if	33050924	4780	4782	O
all	33050924	4783	4786	O
arms	33050924	4787	4791	O
are	33050924	4792	4795	O
maintained	33050924	4796	4806	O
until	33050924	4807	4812	O
the	33050924	4813	4816	O
final	33050924	4817	4822	O
analysis	33050924	4823	4831	O
and	33050924	4832	4835	O
no	33050924	4836	4838	O
additional	33050924	4839	4849	O
arm	33050924	4850	4853	O
is	33050924	4854	4856	O
added	33050924	4857	4862	O
.	33050924	4863	4864	O

Three	33050924	4865	4870	O
successive	33050924	4871	4881	O
futility	33050924	4882	4890	O
interim	33050924	4891	4898	O
analyses	33050924	4899	4907	O
are	33050924	4908	4911	O
planned	33050924	4912	4919	O
,	33050924	4920	4921	O
when	33050924	4922	4926	O
the	33050924	4927	4930	O
number	33050924	4931	4937	O
of	33050924	4938	4940	O
participants	33050924	4941	4953	O
reaches	33050924	4954	4961	O
30	33050924	4962	4964	O
,	33050924	4965	4966	O
60	33050924	4967	4969	O
and	33050924	4970	4973	O
102	33050924	4974	4977	O
in	33050924	4978	4980	O
the	33050924	4981	4984	O
control	33050924	4985	4992	O
arm	33050924	4993	4996	O
.	33050924	4997	4998	O

Two	33050924	4999	5002	O
efficacy	33050924	5003	5011	O
analyses	33050924	5012	5020	O
(	33050924	5021	5022	O
interim	33050924	5023	5030	O
n	33050924	5031	5032	O
	33050924	5033	5034	O
3	33050924	5035	5036	O
and	33050924	5037	5040	O
final	33050924	5041	5046	O
)	33050924	5047	5048	O
will	33050924	5049	5053	O
be	33050924	5054	5056	O
performed	33050924	5057	5066	O
successively	33050924	5067	5079	O
.	33050924	5080	5081	O

UNASSIGNED	33050924	5082	5092	O
:	33050924	5093	5094	O
This	33050924	5095	5099	O
describes	33050924	5100	5109	O
the	33050924	5110	5113	O
Version	33050924	5114	5121	O
1.2	33050924	5122	5125	O
(	33050924	5126	5127	O
April	33050924	5128	5133	O
8th	33050924	5134	5137	O
,	33050924	5138	5139	O
2020	33050924	5140	5144	O
)	33050924	5145	5146	O
of	33050924	5147	5149	O
the	33050924	5150	5153	O
COVERAGE	33050924	5154	5162	O
protocol	33050924	5163	5171	O
that	33050924	5172	5176	O
was	33050924	5177	5180	O
approved	33050924	5181	5189	O
by	33050924	5190	5192	O
the	33050924	5193	5196	O
French	33050924	5197	5203	O
regulatory	33050924	5204	5214	O
authority	33050924	5215	5224	O
and	33050924	5225	5228	O
ethics	33050924	5229	5235	O
committee	33050924	5236	5245	O
.	33050924	5246	5247	O

The	33050924	5248	5251	O
trial	33050924	5252	5257	O
was	33050924	5258	5261	O
opened	33050924	5262	5268	O
for	33050924	5269	5272	O
enrolment	33050924	5273	5282	O
on	33050924	5283	5285	O
April	33050924	5286	5291	O
15th	33050924	5292	5296	O
,	33050924	5297	5298	O
2020	33050924	5299	5303	O
in	33050924	5304	5306	O
the	33050924	5307	5310	O
Nouvelle	33050924	5311	5319	O
Aquitaine	33050924	5320	5329	O
region	33050924	5330	5336	O
(	33050924	5337	5338	O
South	33050924	5339	5344	O
-	33050924	5345	5346	O
West	33050924	5347	5351	O
France	33050924	5352	5358	O
)	33050924	5359	5360	O
.	33050924	5361	5362	O

Given	33050924	5363	5368	O
the	33050924	5369	5372	O
current	33050924	5373	5380	O
decline	33050924	5381	5388	O
of	33050924	5389	5391	O
the	33050924	5392	5395	O
COVID-19	33050924	5396	5404	O
pandemic	33050924	5405	5413	O
in	33050924	5414	5416	O
France	33050924	5417	5423	O
and	33050924	5424	5427	O
its	33050924	5428	5431	O
unforeseeable	33050924	5432	5445	O
dynamic	33050924	5446	5453	O
in	33050924	5454	5456	O
the	33050924	5457	5460	O
coming	33050924	5461	5467	O
months	33050924	5468	5474	O
,	33050924	5475	5476	O
new	33050924	5477	5480	O
trial	33050924	5481	5486	O
sites	33050924	5487	5492	O
in	33050924	5493	5495	O
5	33050924	5496	5497	O
other	33050924	5498	5503	O
French	33050924	5504	5510	O
regions	33050924	5511	5518	O
and	33050924	5519	5522	O
in	33050924	5523	5525	O
Luxembourg	33050924	5526	5536	O
are	33050924	5537	5540	O
currently	33050924	5541	5550	O
being	33050924	5551	5556	O
opened	33050924	5557	5563	O
.	33050924	5564	5565	O

A	33050924	5566	5567	O
revised	33050924	5568	5575	O
version	33050924	5576	5583	O
of	33050924	5584	5586	O
the	33050924	5587	5590	O
protocol	33050924	5591	5599	O
was	33050924	5600	5603	O
submitted	33050924	5604	5613	O
to	33050924	5614	5616	O
the	33050924	5617	5620	O
regulatory	33050924	5621	5631	O
authority	33050924	5632	5641	O
and	33050924	5642	5645	O
ethics	33050924	5646	5652	O
committee	33050924	5653	5662	O
on	33050924	5663	5665	O
June	33050924	5666	5670	O
15th	33050924	5671	5675	O
,	33050924	5676	5677	O
2020	33050924	5678	5682	O
.	33050924	5683	5684	O

It	33050924	5685	5687	O
contains	33050924	5688	5696	O
the	33050924	5697	5700	O
following	33050924	5701	5710	O
amendments	33050924	5711	5721	O
:	33050924	5722	5723	O
(	33050924	5724	5725	O
i	33050924	5726	5727	O
)	33050924	5728	5729	O
Inclusion	33050924	5730	5739	O
criteria	33050924	5740	5748	O
:	33050924	5749	5750	O
age	33050924	5751	5754	O
	33050924	5757	5758	O
65	33050924	5759	5761	O
replaced	33050924	5762	5770	O
by	33050924	5771	5773	O
age	33050924	5774	5777	O
	33050924	5780	5781	O
60	33050924	5782	5784	O
;	33050924	5785	5786	O
time	33050924	5787	5791	O
since	33050924	5792	5797	O
first	33050924	5798	5803	O
symptoms	33050924	5804	5812	O
<3	33050924	5813	5815	O
days	33050924	5816	5820	O
replaced	33050924	5821	5829	O
by	33050924	5830	5832	O
time	33050924	5833	5837	O
since	33050924	5838	5843	O
first	33050924	5844	5849	O
symptoms	33050924	5850	5858	O
<	33050924	5859	5860	O
5	33050924	5861	5862	O
days	33050924	5863	5867	O
;	33050924	5868	5869	O
(	33050924	5870	5871	O
ii	33050924	5872	5874	O
)	33050924	5875	5876	O
Withdrawal	33050924	5877	5887	O
of	33050924	5888	5890	O
the	33050924	5891	5894	O
hydroxychloroquine	33050924	5895	5913	O
arm	33050924	5914	5917	O
(	33050924	5918	5919	O
due	33050924	5920	5923	O
to	33050924	5924	5926	O
external	33050924	5927	5935	O
data	33050924	5936	5940	O
)	33050924	5941	5942	O
;	33050924	5943	5944	O
(	33050924	5945	5946	O
iii	33050924	5947	5950	O
)	33050924	5951	5952	O
increase	33050924	5953	5961	O
in	33050924	5962	5964	O
the	33050924	5965	5968	O
number	33050924	5969	5975	O
of	33050924	5976	5978	O
trial	33050924	5979	5984	O
sites	33050924	5985	5990	O
.	33050924	5991	5992	O

BACKGROUND	33050924	5993	6003	O
:	33050924	6004	6005	O
The	33050924	6006	6009	O
trial	33050924	6010	6015	O
was	33050924	6016	6019	O
registered	33050924	6020	6030	O
on	33050924	6031	6033	O
Clinical	33050924	6034	6042	O
Trials.gov	33050924	6043	6053	O
on	33050924	6054	6056	O
April	33050924	6057	6062	O
22nd	33050924	6063	6067	O
,	33050924	6068	6069	O
2020	33050924	6070	6074	O
(	33050924	6075	6076	O
Identifier	33050924	6077	6087	O
:	33050924	6088	6089	O
NCT04356495	33050924	6090	6101	O
)	33050924	6102	6103	O
:	33050924	6104	6105	O
and	33050924	6106	6109	O
on	33050924	6110	6112	O
EudraCT	33050924	6113	6120	O
on	33050924	6121	6123	O
April	33050924	6124	6129	O
10th	33050924	6130	6134	O
,	33050924	6135	6136	O
2020	33050924	6137	6141	O
(	33050924	6142	6143	O
Identifier	33050924	6144	6154	O
:	33050924	6155	6156	O
2020	33050924	6157	6161	O
-	33050924	6162	6163	O
001435	33050924	6164	6170	O
-	33050924	6171	6172	O
27	33050924	6173	6175	O
)	33050924	6176	6177	O
.	33050924	6178	6179	O

UNASSIGNED	33050924	6180	6190	O
:	33050924	6191	6192	O
The	33050924	6193	6196	O
full	33050924	6197	6201	O
protocol	33050924	6202	6210	O
is	33050924	6211	6213	O
attached	33050924	6214	6222	O
as	33050924	6223	6225	O
an	33050924	6226	6228	O
additional	33050924	6229	6239	O
file	33050924	6240	6244	O
,	33050924	6245	6246	O
accessible	33050924	6247	6257	O
from	33050924	6258	6262	O
the	33050924	6263	6266	O
Trials	33050924	6267	6273	O
website	33050924	6274	6281	O
(	33050924	6284	6285	O
Additional	33050924	6286	6296	O
file	33050924	6297	6301	O
1	33050924	6302	6303	O
)	33050924	6304	6305	O
.	33050924	6306	6307	O

In	33050924	6308	6310	O
the	33050924	6311	6314	O
interest	33050924	6315	6323	O
of	33050924	6324	6326	O
expediting	33050924	6327	6337	O
dissemination	33050924	6338	6351	O
of	33050924	6352	6354	O
this	33050924	6355	6359	O
material	33050924	6360	6368	O
,	33050924	6369	6370	O
the	33050924	6371	6374	O
familiar	33050924	6375	6383	O
formatting	33050924	6384	6394	O
has	33050924	6395	6398	O
been	33050924	6399	6403	O
eliminated	33050924	6404	6414	O
;	33050924	6415	6416	O
this	33050924	6417	6421	O
Letter	33050924	6422	6428	O
serves	33050924	6429	6435	O
as	33050924	6436	6438	O
a	33050924	6439	6440	O
summary	33050924	6441	6448	O
of	33050924	6449	6451	O
the	33050924	6452	6455	O
key	33050924	6456	6459	O
elements	33050924	6460	6468	O
of	33050924	6469	6471	O
the	33050924	6472	6475	O
full	33050924	6476	6480	O
protocol	33050924	6481	6489	O
.	33050924	6490	6491	O

The	33050924	6492	6495	O
study	33050924	6496	6501	O
protocol	33050924	6502	6510	O
has	33050924	6511	6514	O
been	33050924	6515	6519	O
reported	33050924	6520	6528	O
in	33050924	6529	6531	O
accordance	33050924	6532	6542	O
with	33050924	6543	6547	O
the	33050924	6548	6551	O
Standard	33050924	6552	6560	O
Protocol	33050924	6561	6569	O
Items	33050924	6570	6575	O
:	33050924	6576	6577	O
Recommendations	33050924	6578	6593	O
for	33050924	6594	6597	O
Clinical	33050924	6598	6606	O
Interventional	33050924	6607	6621	O
Trials	33050924	6622	6628	O
(	33050924	6629	6630	O
SPIRIT	33050924	6631	6637	O
)	33050924	6638	6639	O
guidelines	33050924	6640	6650	O
(	33050924	6651	6652	O
Additional	33050924	6653	6663	O
file	33050924	6664	6668	O
2	33050924	6669	6670	O
)	33050924	6671	6672	O
.	33050924	6673	6674	O


The	33050945	0	3	O
Efficacy	33050945	4	12	O
of	33050945	13	15	O
Famotidine	33050945	16	26	O
in	33050945	27	29	O
improvement	33050945	30	41	O
of	33050945	42	44	O
outcomes	33050945	45	53	O
in	33050945	54	56	O
Hospitalized	33050945	57	69	O
COVID-19	33050945	70	78	O
Patients	33050945	79	87	O
:	33050945	88	89	O
A	33050945	90	91	O
structured	33050945	92	102	O
summary	33050945	103	110	O
of	33050945	111	113	O
a	33050945	114	115	O
study	33050945	116	121	O
protocol	33050945	122	130	O
for	33050945	131	134	O
a	33050945	135	136	O
randomised	33050945	137	147	O
controlled	33050945	148	158	O
trial	33050945	159	164	O
.	33050945	165	166	O

OBJECTIVE	33050945	167	176	O
:	33050945	177	178	O
This	33050945	179	183	O
study	33050945	184	189	O
aims	33050945	190	194	O
to	33050945	195	197	O
investigate	33050945	198	209	O
the	33050945	210	213	O
effect	33050945	214	220	O
of	33050945	221	223	O
Famotidine	33050945	224	234	O
on	33050945	235	237	O
the	33050945	238	241	O
recovery	33050945	242	250	O
process	33050945	251	258	O
of	33050945	259	261	O
COVID-19	33050945	262	270	O
patients	33050945	271	279	O
.	33050945	280	281	O

METHODS	33050945	282	289	O
:	33050945	290	291	O
This	33050945	292	296	O
phase	33050945	297	302	O
III	33050945	303	306	O
randomized	33050945	307	317	O
clinical	33050945	318	326	O
trial	33050945	327	332	O
was	33050945	333	336	O
designed	33050945	337	345	O
with	33050945	346	350	O
two	33050945	351	354	O
parallel	33050945	355	363	O
arms	33050945	364	368	O
,	33050945	369	370	O
placebo	33050945	371	378	O
-	33050945	379	380	O
controlled	33050945	381	391	O
,	33050945	392	393	O
single	33050945	394	400	O
-	33050945	401	402	O
blind	33050945	403	408	O
,	33050945	409	410	O
and	33050945	411	414	O
concealed	33050945	415	424	O
allocation	33050945	425	435	O
.	33050945	436	437	O

METHODS	33050945	438	445	O
:	33050945	446	447	O
All	33050945	448	451	O
COVID-19	33050945	452	460	O
patients	33050945	461	469	O
admitted	33050945	470	478	O
to	33050945	479	481	O
Shahid	33050945	482	488	O
Mohammadi	33050945	489	498	O
Hospital	33050945	499	507	O
in	33050945	508	510	O
Bandar	33050945	511	517	O
Abbas	33050945	518	523	O
whose	33050945	524	529	O
PCR	33050945	530	533	O
test	33050945	534	538	O
results	33050945	539	546	O
are	33050945	547	550	O
positive	33050945	551	559	O
for	33050945	560	563	O
SARS	33050945	564	568	O
-	33050945	569	570	O
Cov-2	33050945	571	576	O
and	33050945	577	580	O
sign	33050945	581	585	O
the	33050945	586	589	O
written	33050945	590	597	O
consent	33050945	598	605	O
of	33050945	606	608	O
the	33050945	609	612	O
study	33050945	613	618	O
are	33050945	619	622	O
included	33050945	623	631	O
in	33050945	632	634	O
the	33050945	635	638	O
study	33050945	639	644	O
and	33050945	645	648	O
immunocompromised	33050945	649	666	O
patients	33050945	667	675	O
,	33050945	676	677	O
end	33050945	678	681	O
-	33050945	682	683	O
stage	33050945	684	689	O
renal	33050945	690	695	O
disease	33050945	696	703	O
,	33050945	704	705	O
moderate	33050945	706	714	O
renal	33050945	715	720	O
failure	33050945	721	728	O
(	33050945	729	730	O
clearance	33050945	731	740	O
Creatinine	33050945	741	751	O
30	33050945	752	754	O
to	33050945	755	757	O
50	33050945	758	760	O
ml	33050945	761	763	O
/	33050945	764	765	O
min	33050945	766	769	O
)	33050945	770	771	O
or	33050945	772	774	O
stage	33050945	775	780	O
4	33050945	781	782	O
severe	33050945	783	789	O
chronic	33050945	790	797	O
kidney	33050945	798	804	O
disease	33050945	805	812	O
or	33050945	813	815	O
need	33050945	816	820	O
for	33050945	821	824	O
dialysis	33050945	825	833	O
(	33050945	834	835	O
creatinine	33050945	836	846	O
clearance	33050945	847	856	O
lesser	33050945	857	863	O
than	33050945	864	868	O
30	33050945	869	871	O
ml	33050945	872	874	O
/	33050945	875	876	O
min	33050945	877	880	O
)	33050945	881	882	O
,	33050945	883	884	O
history	33050945	885	892	O
of	33050945	893	895	O
liver	33050945	896	901	O
disease	33050945	902	909	O
,	33050945	910	911	O
hepatitis	33050945	912	921	O
C	33050945	922	923	O
infection	33050945	924	933	O
or	33050945	934	936	O
alcoholism	33050945	937	947	O
,	33050945	948	949	O
Glucose	33050945	950	957	O
6	33050945	958	959	O
phosphate	33050945	960	969	O
dehydrogenase	33050945	970	983	O
deficiency(G6PD	33050945	984	999	O
)	33050945	1000	1001	O
,	33050945	1002	1003	O
the	33050945	1004	1007	O
ratio	33050945	1008	1013	O
of	33050945	1014	1016	O
Alanine	33050945	1017	1024	O
transaminase	33050945	1025	1037	O
to	33050945	1038	1040	O
Aspartate	33050945	1041	1050	O
transaminase	33050945	1051	1063	O
5	33050945	1064	1065	O
times	33050945	1066	1071	O
above	33050945	1072	1077	O
the	33050945	1078	1081	O
normal	33050945	1082	1088	O
limit	33050945	1089	1094	O
,	33050945	1095	1096	O
history	33050945	1097	1104	O
or	33050945	1105	1107	O
evidence	33050945	1108	1116	O
of	33050945	1117	1119	O
long	33050945	1120	1124	O
QT	33050945	1125	1127	O
segment	33050945	1128	1135	O
on	33050945	1136	1138	O
Electrocardiogram	33050945	1139	1156	O
,	33050945	1157	1158	O
psoriasis	33050945	1159	1168	O
or	33050945	1169	1171	O
porphyria	33050945	1172	1181	O
,	33050945	1182	1183	O
pregnancy	33050945	1184	1193	O
,	33050945	1194	1195	O
use	33050945	1196	1199	O
of	33050945	1200	1202	O
oral	33050945	1203	1207	O
contraceptives	33050945	1208	1222	O
,	33050945	1223	1224	O
Dasatinib	33050945	1225	1234	O
,	33050945	1235	1236	O
Neratinib	33050945	1237	1246	O
,	33050945	1247	1248	O
Ozanimod	33050945	1249	1257	O
,	33050945	1258	1259	O
Pazopanib	33050945	1260	1269	O
,	33050945	1270	1271	O
Rilpivirine	33050945	1272	1283	O
,	33050945	1284	1285	O
Siponimod	33050945	1286	1295	O
and/or	33050945	1296	1302	O
Tizanidine	33050945	1303	1313	O
and	33050945	1314	1317	O
allergies	33050945	1318	1327	O
to	33050945	1328	1330	O
any	33050945	1331	1334	O
study	33050945	1335	1340	O
drug	33050945	1341	1345	O
are	33050945	1346	1349	O
excluded	33050945	1350	1358	O
.	33050945	1359	1360	O

UNASSIGNED	33050945	1361	1371	O
:	33050945	1372	1373	O
Intervention	33050945	1374	1386	O
group	33050945	1387	1392	O
receives	33050945	1393	1401	O
standard	33050945	1402	1410	O
pharmacotherapy	33050945	1411	1426	O
according	33050945	1427	1436	O
to	33050945	1437	1439	O
the	33050945	1440	1443	O
treatment	33050945	1444	1453	O
protocols	33050945	1454	1463	O
of	33050945	1464	1466	O
the	33050945	1467	1470	O
National	33050945	1471	1479	O
Committee	33050945	1480	1489	O
of	33050945	1490	1492	O
COVID-19	33050945	1493	1501	O
and	33050945	1502	1505	O
oral	33050945	1506	1510	O
famotidine	33050945	1511	1521	O
160	33050945	1522	1525	O
mg	33050945	1526	1528	O
(	33050945	1529	1530	O
Manufactured	33050945	1531	1543	O
by	33050945	1544	1546	O
Chemidarou	33050945	1547	1557	O
Pharmaceutical	33050945	1558	1572	O
Company	33050945	1573	1580	O
)	33050945	1581	1582	O
four	33050945	1583	1587	O
times	33050945	1588	1593	O
a	33050945	1594	1595	O
day	33050945	1596	1599	O
until	33050945	1600	1605	O
the	33050945	1606	1609	O
day	33050945	1610	1613	O
of	33050945	1614	1616	O
discharge	33050945	1617	1626	O
,	33050945	1627	1628	O
for	33050945	1629	1632	O
a	33050945	1633	1634	O
maximum	33050945	1635	1642	O
of	33050945	1643	1645	O
fourteen	33050945	1646	1654	O
days	33050945	1655	1659	O
.	33050945	1660	1661	O

Comparator	33050945	1662	1672	O
group	33050945	1673	1678	O
receives	33050945	1679	1687	O
standard	33050945	1688	1696	O
drug	33050945	1697	1701	O
therapy	33050945	1702	1709	O
according	33050945	1710	1719	O
to	33050945	1720	1722	O
the	33050945	1723	1726	O
treatment	33050945	1727	1736	O
protocols	33050945	1737	1746	O
of	33050945	1747	1749	O
the	33050945	1750	1753	O
National	33050945	1754	1762	O
Committee	33050945	1763	1772	O
of	33050945	1773	1775	O
COVID-19	33050945	1776	1784	O
and	33050945	1785	1788	O
placebo	33050945	1789	1796	O
in	33050945	1797	1799	O
the	33050945	1800	1803	O
same	33050945	1804	1808	O
dosage	33050945	1809	1815	O
.	33050945	1816	1817	O

RESULTS	33050945	1818	1825	O
:	33050945	1826	1827	O
Patients	33050945	1828	1836	O
'	33050945	1837	1838	O
temperature	33050945	1839	1850	O
,	33050945	1851	1852	O
respiration	33050945	1853	1864	O
rate	33050945	1865	1869	O
,	33050945	1870	1871	O
oxygen	33050945	1872	1878	O
saturation	33050945	1879	1889	O
,	33050945	1890	1891	O
lung	33050945	1892	1896	O
infiltration	33050945	1897	1909	O
,	33050945	1910	1911	O
lactate	33050945	1912	1919	O
dehydrogenase	33050945	1920	1933	O
and	33050945	1934	1937	O
complete	33050945	1938	1946	O
blood	33050945	1947	1952	O
count	33050945	1953	1958	O
were	33050945	1959	1963	O
measured	33050945	1964	1972	O
at	33050945	1973	1975	O
the	33050945	1976	1979	O
baseline	33050945	1980	1988	O
(	33050945	1989	1990	O
before	33050945	1991	1997	O
the	33050945	1998	2001	O
intervention	33050945	2002	2014	O
)	33050945	2015	2016	O
and	33050945	2017	2020	O
on	33050945	2021	2023	O
day	33050945	2024	2027	O
14	33050945	2028	2030	O
after	33050945	2031	2036	O
the	33050945	2037	2040	O
intervention	33050945	2041	2053	O
or	33050945	2054	2056	O
on	33050945	2057	2059	O
the	33050945	2060	2063	O
discharge	33050945	2064	2073	O
day	33050945	2074	2077	O
.	33050945	2078	2079	O

UNASSIGNED	33050945	2080	2090	O
:	33050945	2091	2092	O
The	33050945	2093	2096	O
person	33050945	2097	2103	O
who	33050945	2104	2107	O
has	33050945	2108	2111	O
no	33050945	2112	2114	O
role	33050945	2115	2119	O
in	33050945	2120	2122	O
admitting	33050945	2123	2132	O
patients	33050945	2133	2141	O
and	33050945	2142	2145	O
assigning	33050945	2146	2155	O
patients	33050945	2156	2164	O
to	33050945	2165	2167	O
random	33050945	2168	2174	O
codes	33050945	2175	2180	O
preparing	33050945	2181	2190	O
random	33050945	2191	2197	O
sequences	33050945	2198	2207	O
using	33050945	2208	2213	O
online	33050945	2214	2220	O
tools	33050945	2221	2226	O
and	33050945	2227	2230	O
by	33050945	2231	2233	O
permuted	33050945	2234	2242	O
block	33050945	2243	2248	O
randomization	33050945	2249	2262	O
method	33050945	2263	2269	O
.	33050945	2270	2271	O

Eligibility	33050945	2272	2283	O
criteria	33050945	2284	2292	O
are	33050945	2293	2296	O
monitored	33050945	2297	2306	O
by	33050945	2307	2309	O
the	33050945	2310	2313	O
person	33050945	2314	2320	O
responsible	33050945	2321	2332	O
for	33050945	2333	2336	O
admitting	33050945	2337	2346	O
patients	33050945	2347	2355	O
.	33050945	2356	2357	O

Codes	33050945	2358	2363	O
in	33050945	2364	2366	O
a	33050945	2367	2368	O
random	33050945	2369	2375	O
sequence	33050945	2376	2384	O
are	33050945	2385	2388	O
assigned	33050945	2389	2397	O
to	33050945	2398	2400	O
patients	33050945	2401	2409	O
by	33050945	2410	2412	O
the	33050945	2413	2416	O
treatment	33050945	2417	2426	O
team	33050945	2427	2431	O
without	33050945	2432	2439	O
knowing	33050945	2440	2447	O
that	33050945	2448	2452	O
each	33050945	2453	2457	O
code	33050945	2458	2462	O
is	33050945	2463	2465	O
in	33050945	2466	2468	O
the	33050945	2469	2472	O
intervention	33050945	2473	2485	O
or	33050945	2486	2488	O
comparator	33050945	2489	2499	O
group	33050945	2500	2505	O
.	33050945	2506	2507	O

Patient	33050945	2508	2515	O
codes	33050945	2516	2521	O
are	33050945	2522	2525	O
then	33050945	2526	2530	O
matched	33050945	2531	2538	O
to	33050945	2539	2541	O
randomly	33050945	2542	2550	O
generated	33050945	2551	2560	O
sequence	33050945	2561	2569	O
information	33050945	2570	2581	O
for	33050945	2582	2585	O
interventions	33050945	2586	2599	O
.	33050945	2600	2601	O

UNASSIGNED	33050945	2602	2612	O
:	33050945	2613	2614	O
All	33050945	2615	2618	O
participants	33050945	2619	2631	O
are	33050945	2632	2635	O
unaware	33050945	2636	2643	O
of	33050945	2644	2646	O
which	33050945	2647	2652	O
group	33050945	2653	2658	O
of	33050945	2659	2661	O
this	33050945	2662	2666	O
study	33050945	2667	2672	O
they	33050945	2673	2677	O
are	33050945	2678	2681	O
in	33050945	2682	2684	O
and	33050945	2685	2688	O
after	33050945	2689	2694	O
grouping	33050945	2695	2703	O
patients	33050945	2704	2712	O
in	33050945	2713	2715	O
the	33050945	2716	2719	O
groups	33050945	2720	2726	O
,	33050945	2727	2728	O
Patients	33050945	2729	2737	O
receive	33050945	2738	2745	O
Famotidine	33050945	2746	2756	O
in	33050945	2757	2759	O
the	33050945	2760	2763	O
treatment	33050945	2764	2773	O
group	33050945	2774	2779	O
and	33050945	2780	2783	O
receive	33050945	2784	2791	O
a	33050945	2792	2793	O
placebo	33050945	2794	2801	O
in	33050945	2802	2804	O
the	33050945	2805	2808	O
control	33050945	2809	2816	O
group	33050945	2817	2822	O
.	33050945	2823	2824	O

The	33050945	2825	2828	O
lead	33050945	2829	2833	O
researcher	33050945	2834	2844	O
,	33050945	2845	2846	O
care	33050945	2847	2851	O
givers	33050945	2852	2858	O
,	33050945	2859	2860	O
data	33050945	2861	2865	O
collectors	33050945	2866	2876	O
,	33050945	2877	2878	O
and	33050945	2879	2882	O
outcome	33050945	2883	2890	O
assessors	33050945	2891	2900	O
are	33050945	2901	2904	O
aware	33050945	2905	2910	O
of	33050945	2911	2913	O
the	33050945	2914	2917	O
grouping	33050945	2918	2926	O
of	33050945	2927	2929	O
patients	33050945	2930	2938	O
.	33050945	2939	2940	O

UNASSIGNED	33050945	2941	2951	O
:	33050945	2952	2953	O
As	33050945	2954	2956	O
there	33050945	2957	2962	O
is	33050945	2963	2965	O
no	33050945	2966	2968	O
prior	33050945	2969	2974	O
work	33050945	2975	2979	O
on	33050945	2980	2982	O
this	33050945	2983	2987	O
research	33050945	2988	2996	O
question	33050945	2997	3005	O
,	33050945	3006	3007	O
so	33050945	3008	3010	O
no	33050945	3011	3013	O
assumptions	33050945	3014	3025	O
for	33050945	3026	3029	O
the	33050945	3030	3033	O
sample	33050945	3034	3040	O
size	33050945	3041	3045	O
calculation	33050945	3046	3057	O
could	33050945	3058	3063	O
be	33050945	3064	3066	O
made	33050945	3067	3071	O
.	33050945	3072	3073	O

A	33050945	3074	3075	O
total	33050945	3076	3081	O
of	33050945	3082	3084	O
20	33050945	3085	3087	O
patients	33050945	3088	3096	O
participate	33050945	3097	3108	O
in	33050945	3109	3111	O
this	33050945	3112	3116	O
study	33050945	3117	3122	O
,	33050945	3123	3124	O
which	33050945	3125	3130	O
are	33050945	3131	3134	O
randomly	33050945	3135	3143	O
divided	33050945	3144	3151	O
into	33050945	3152	3156	O
two	33050945	3157	3160	O
groups	33050945	3161	3167	O
of	33050945	3168	3170	O
10	33050945	3171	3173	O
as	33050945	3174	3176	O
intervention	33050945	3177	3189	O
or	33050945	3190	3192	O
control	33050945	3193	3200	O
groups	33050945	3201	3207	O
.	33050945	3208	3209	O

UNASSIGNED	33050945	3210	3220	O
:	33050945	3221	3222	O
Version	33050945	3223	3230	O
3	33050945	3231	3232	O
of	33050945	3233	3235	O
the	33050945	3236	3239	O
protocol	33050945	3240	3248	O
was	33050945	3249	3252	O
approved	33050945	3253	3261	O
by	33050945	3262	3264	O
the	33050945	3265	3268	O
Deputy	33050945	3269	3275	O
of	33050945	3276	3278	O
Research	33050945	3279	3287	O
and	33050945	3288	3291	O
Technology	33050945	3292	3302	O
and	33050945	3303	3306	O
the	33050945	3307	3310	O
ethics	33050945	3311	3317	O
committee	33050945	3318	3327	O
of	33050945	3328	3330	O
Hormozgan	33050945	3331	3340	O
University	33050945	3341	3351	O
of	33050945	3352	3354	O
Medical	33050945	3355	3362	O
Sciences	33050945	3363	3371	O
on	33050945	3372	3374	O
August	33050945	3375	3381	O
2	33050945	3382	3383	O
,	33050945	3384	3385	O
2020	33050945	3386	3390	O
,	33050945	3391	3392	O
with	33050945	3393	3397	O
the	33050945	3398	3401	O
local	33050945	3402	3407	O
code	33050945	3408	3412	O
990245	33050945	3413	3419	O
,	33050945	3420	3421	O
and	33050945	3422	3425	O
the	33050945	3426	3429	O
recruitment	33050945	3430	3441	O
started	33050945	3442	3449	O
on	33050945	3450	3452	O
August	33050945	3453	3459	O
17	33050945	3460	3462	O
,	33050945	3463	3464	O
2020	33050945	3465	3469	O
.	33050945	3470	3471	O

recruitment	33050945	3472	3483	O
ended	33050945	3484	3489	O
on	33050945	3490	3492	O
August	33050945	3493	3499	O
31	33050945	3500	3502	O
,	33050945	3503	3504	O
2020	33050945	3505	3509	O
.	33050945	3510	3511	O

Since	33050945	3512	3517	O
the	33050945	3518	3521	O
recruitment	33050945	3522	3533	O
ended	33050945	3534	3539	O
earlier	33050945	3540	3547	O
than	33050945	3548	3552	O
expected	33050945	3553	3561	O
(	33050945	3562	3563	O
the	33050945	3564	3567	O
expected	33050945	3568	3576	O
recruitment	33050945	3577	3588	O
end	33050945	3589	3592	O
date	33050945	3593	3597	O
was	33050945	3598	3601	O
21/12/2020	33050945	3602	3612	O
)	33050945	3613	3614	O
,	33050945	3615	3616	O
we	33050945	3617	3619	O
submitted	33050945	3620	3629	O
post	33050945	3630	3634	O
recruitment	33050945	3635	3646	O
but	33050945	3647	3650	O
prior	33050945	3651	3656	O
to	33050945	3657	3659	O
publication	33050945	3660	3671	O
of	33050945	3672	3674	O
the	33050945	3675	3678	O
results	33050945	3679	3686	O
.	33050945	3687	3688	O

BACKGROUND	33050945	3689	3699	O
:	33050945	3700	3701	O
The	33050945	3702	3705	O
protocol	33050945	3706	3714	O
was	33050945	3715	3718	O
registered	33050945	3719	3729	O
before	33050945	3730	3736	O
starting	33050945	3737	3745	O
subject	33050945	3746	3753	O
recruitment	33050945	3754	3765	O
under	33050945	3766	3771	O
the	33050945	3772	3775	O
title	33050945	3776	3781	O
:	33050945	3782	3783	O
The	33050945	3784	3787	O
effect	33050945	3788	3794	O
of	33050945	3795	3797	O
Famotidine	33050945	3798	3808	O
on	33050945	3809	3811	O
the	33050945	3812	3815	O
improvement	33050945	3816	3827	O
of	33050945	3828	3830	O
patients	33050945	3831	3839	O
with	33050945	3840	3844	O
COVID-19	33050945	3845	3853	O
,	33050945	3854	3855	O
IRCT20200509047364N2	33050945	3856	3876	O
,	33050945	3877	3878	O
at	33050945	3879	3881	O
Iranian	33050945	3882	3889	O
Registry	33050945	3890	3898	O
of	33050945	3899	3901	O
clinical	33050945	3902	3910	O
trials	33050945	3911	3917	O
(	33050945	3918	3919	O
https://www.irct.ir/trial/49657	33050945	3920	3951	O
)	33050945	3952	3953	O
on	33050945	3954	3956	O
17	33050945	3957	3959	O
August	33050945	3960	3966	O
2020	33050945	3967	3971	O
.	33050945	3972	3973	O

UNASSIGNED	33050945	3974	3984	O
:	33050945	3985	3986	O
The	33050945	3987	3990	O
full	33050945	3991	3995	O
protocol	33050945	3996	4004	O
is	33050945	4005	4007	O
attached	33050945	4008	4016	O
as	33050945	4017	4019	O
an	33050945	4020	4022	O
additional	33050945	4023	4033	O
file	33050945	4034	4038	O
,	33050945	4039	4040	O
accessible	33050945	4041	4051	O
from	33050945	4052	4056	O
the	33050945	4057	4060	O
Trials	33050945	4061	4067	O
website	33050945	4068	4075	O
(	33050945	4076	4077	O
Additional	33050945	4078	4088	O
file	33050945	4089	4093	O
1	33050945	4094	4095	O
)	33050945	4096	4097	O
.	33050945	4098	4099	O

In	33050945	4100	4102	O
the	33050945	4103	4106	O
interest	33050945	4107	4115	O
in	33050945	4116	4118	O
expediting	33050945	4119	4129	O
dissemination	33050945	4130	4143	O
of	33050945	4144	4146	O
this	33050945	4147	4151	O
material	33050945	4152	4160	O
,	33050945	4161	4162	O
the	33050945	4163	4166	O
familiar	33050945	4167	4175	O
formatting	33050945	4176	4186	O
has	33050945	4187	4190	O
been	33050945	4191	4195	O
eliminated	33050945	4196	4206	O
;	33050945	4207	4208	O
this	33050945	4209	4213	O
Letter	33050945	4214	4220	O
serves	33050945	4221	4227	O
as	33050945	4228	4230	O
a	33050945	4231	4232	O
summary	33050945	4233	4240	O
of	33050945	4241	4243	O
the	33050945	4244	4247	O
key	33050945	4248	4251	O
elements	33050945	4252	4260	O
of	33050945	4261	4263	O
the	33050945	4264	4267	O
full	33050945	4268	4272	O
protocol	33050945	4273	4281	O
.	33050945	4282	4283	O

The	33050945	4284	4287	O
study	33050945	4288	4293	O
protocol	33050945	4294	4302	O
has	33050945	4303	4306	O
been	33050945	4307	4311	O
reported	33050945	4312	4320	O
in	33050945	4321	4323	O
accordance	33050945	4324	4334	O
with	33050945	4335	4339	O
the	33050945	4340	4343	O
Standard	33050945	4344	4352	O
Protocol	33050945	4353	4361	O
Items	33050945	4362	4367	O
:	33050945	4368	4369	O
Recommendations	33050945	4370	4385	O
for	33050945	4386	4389	O
Clinical	33050945	4390	4398	O
Interventional	33050945	4399	4413	O
Trials	33050945	4414	4420	O
(	33050945	4421	4422	O
SPIRIT	33050945	4423	4429	O
)	33050945	4430	4431	O
guidelines	33050945	4432	4442	O
(	33050945	4443	4444	O
Additional	33050945	4445	4455	O
file	33050945	4456	4460	O
2	33050945	4461	4462	O
)	33050945	4463	4464	O
.	33050945	4465	4466	O


An	33050947	0	2	O
adaptive	33050947	3	11	O
randomised	33050947	12	22	O
placebo	33050947	23	30	O
controlled	33050947	31	41	O
phase	33050947	42	47	O
II	33050947	48	50	O
trial	33050947	51	56	O
of	33050947	57	59	O
antivirals	33050947	60	70	O
for	33050947	71	74	O
COVID-19	33050947	75	83	O
infection	33050947	84	93	O
(	33050947	94	95	O
VIRCO	33050947	96	101	O
)	33050947	102	103	O
:	33050947	104	105	O
A	33050947	106	107	O
structured	33050947	108	118	O
summary	33050947	119	126	O
of	33050947	127	129	O
a	33050947	130	131	O
study	33050947	132	137	O
protocol	33050947	138	146	O
for	33050947	147	150	O
a	33050947	151	152	O
randomised	33050947	153	163	O
controlled	33050947	164	174	O
trial	33050947	175	180	O
.	33050947	181	182	O

OBJECTIVE	33050947	183	192	O
:	33050947	193	194	O
Primary	33050947	195	202	O
objective	33050947	203	212	O
:	33050947	213	214	O
To	33050947	215	217	O
determine	33050947	218	227	O
the	33050947	228	231	O
efficacy	33050947	232	240	O
of	33050947	241	243	O
a	33050947	244	245	O
candidate	33050947	246	255	O
antiviral	33050947	256	265	O
on	33050947	266	268	O
time	33050947	269	273	O
to	33050947	274	276	O
virological	33050947	277	288	O
cure	33050947	289	293	O
compared	33050947	294	302	O
to	33050947	303	305	O
standard	33050947	306	314	O
of	33050947	315	317	O
care	33050947	318	322	O
within	33050947	323	329	O
14	33050947	330	332	O
days	33050947	333	337	O
of	33050947	338	340	O
randomisation	33050947	341	354	O
Secondary	33050947	355	364	O
objectives	33050947	365	375	O
:	33050947	376	377	O
	33050947	378	379	O
To	33050947	380	382	O
determine	33050947	383	392	O
the	33050947	393	396	O
safety	33050947	397	403	O
of	33050947	404	406	O
the	33050947	407	410	O
antiviral	33050947	411	420	O
	33050947	421	422	O
To	33050947	423	425	O
determine	33050947	426	435	O
the	33050947	436	439	O
clinical	33050947	440	448	O
benefit	33050947	449	456	O
of	33050947	457	459	O
the	33050947	460	463	O
antiviral	33050947	464	473	O
over	33050947	474	478	O
placebo	33050947	479	486	O
according	33050947	487	496	O
to	33050947	497	499	O
the	33050947	500	503	O
WHO	33050947	504	507	O
7-point	33050947	508	515	O
ordinal	33050947	516	523	O
scale	33050947	524	529	O
	33050947	530	531	O
To	33050947	532	534	O
determine	33050947	535	544	O
the	33050947	545	548	O
clinical	33050947	549	557	O
benefit	33050947	558	565	O
of	33050947	566	568	O
the	33050947	569	572	O
antiviral	33050947	573	582	O
over	33050947	583	587	O
placebo	33050947	588	595	O
on	33050947	596	598	O
time	33050947	599	603	O
to	33050947	604	606	O
resolution	33050947	607	617	O
of	33050947	618	620	O
clinical	33050947	621	629	O
symptoms	33050947	630	638	O
	33050947	639	640	O
To	33050947	641	643	O
determine	33050947	644	653	O
the	33050947	654	657	O
effect	33050947	658	664	O
of	33050947	665	667	O
the	33050947	668	671	O
antiviral	33050947	672	681	O
over	33050947	682	686	O
placebo	33050947	687	694	O
on	33050947	695	697	O
biomarkers	33050947	698	708	O
of	33050947	709	711	O
inflammation	33050947	712	724	O
and	33050947	725	728	O
immune	33050947	729	735	O
activation	33050947	736	746	O
TRIAL	33050947	747	752	O
DESIGN	33050947	753	759	O
:	33050947	760	761	O
This	33050947	762	766	O
is	33050947	767	769	O
a	33050947	770	771	O
multi	33050947	772	777	O
-	33050947	778	779	O
centre	33050947	780	786	O
,	33050947	787	788	O
triple	33050947	789	795	O
-	33050947	796	797	O
blind	33050947	798	803	O
,	33050947	804	805	O
randomised	33050947	806	816	O
placebo	33050947	817	824	O
controlled	33050947	825	835	O
phase	33050947	836	841	O
II	33050947	842	844	O
,	33050947	845	846	O
2-arm	33050947	847	852	O
trial	33050947	853	858	O
with	33050947	859	863	O
parallel	33050947	864	872	O
-	33050947	873	874	O
group	33050947	875	880	O
design	33050947	881	887	O
with	33050947	888	892	O
allocation	33050947	893	903	O
ratio	33050947	904	909	O
1:1	33050947	910	913	O
.	33050947	914	915	O

METHODS	33050947	916	923	O
:	33050947	924	925	O
Inclusion	33050947	926	935	O
Criteria	33050947	936	944	O
:	33050947	945	946	O
	33050947	947	948	O
Provision	33050947	949	958	O
of	33050947	959	961	O
informed	33050947	962	970	O
consent	33050947	971	978	O
by	33050947	979	981	O
the	33050947	982	985	O
participant	33050947	986	997	O
	33050947	998	999	O
Age	33050947	1000	1003	O
	33050947	1006	1007	O
18	33050947	1008	1010	O
years	33050947	1011	1016	O
	33050947	1017	1018	O
Confirmed	33050947	1019	1028	O
SARS	33050947	1029	1033	O
-	33050947	1034	1035	O
CoV-2	33050947	1036	1041	O
by	33050947	1042	1044	O
nucleic	33050947	1045	1052	O
acid	33050947	1053	1057	O
testing	33050947	1058	1065	O
in	33050947	1066	1068	O
the	33050947	1069	1072	O
past	33050947	1073	1077	O
5	33050947	1078	1079	O
days	33050947	1080	1084	O
	33050947	1085	1086	O
COVID-19	33050947	1087	1095	O
related	33050947	1096	1103	O
symptom	33050947	1104	1111	O
initiation	33050947	1112	1122	O
within	33050947	1123	1129	O
5	33050947	1130	1131	O
days	33050947	1132	1136	O
	33050947	1137	1138	O
Female	33050947	1139	1145	O
patients	33050947	1146	1154	O
of	33050947	1155	1157	O
childbearing	33050947	1158	1170	O
potential	33050947	1171	1180	O
must	33050947	1181	1185	O
have	33050947	1186	1190	O
a	33050947	1191	1192	O
negative	33050947	1193	1201	O
pregnancy	33050947	1202	1211	O
test	33050947	1212	1216	O
at	33050947	1217	1219	O
Screening	33050947	1220	1229	O
.	33050947	1230	1231	O

Female	33050947	1232	1238	O
patients	33050947	1239	1247	O
of	33050947	1248	1250	O
childbearing	33050947	1251	1263	O
potential	33050947	1264	1273	O
and	33050947	1274	1277	O
fertile	33050947	1278	1285	O
male	33050947	1286	1290	O
patients	33050947	1291	1299	O
who	33050947	1300	1303	O
are	33050947	1304	1307	O
sexually	33050947	1308	1316	O
active	33050947	1317	1323	O
with	33050947	1324	1328	O
a	33050947	1329	1330	O
female	33050947	1331	1337	O
of	33050947	1338	1340	O
childbearing	33050947	1341	1353	O
potential	33050947	1354	1363	O
must	33050947	1364	1368	O
use	33050947	1369	1372	O
highly	33050947	1373	1379	O
effective	33050947	1380	1389	O
methods	33050947	1390	1397	O
of	33050947	1398	1400	O
contraception	33050947	1401	1414	O
throughout	33050947	1415	1425	O
the	33050947	1426	1429	O
study	33050947	1430	1435	O
and	33050947	1436	1439	O
for	33050947	1440	1443	O
1	33050947	1444	1445	O
week	33050947	1446	1450	O
following	33050947	1451	1460	O
the	33050947	1461	1464	O
last	33050947	1465	1469	O
dose	33050947	1470	1474	O
of	33050947	1475	1477	O
study	33050947	1478	1483	O
treatment	33050947	1484	1493	O
.	33050947	1494	1495	O

METHODS	33050947	1496	1503	O
:	33050947	1504	1505	O
	33050947	1506	1507	O
Known	33050947	1508	1513	O
allergy	33050947	1514	1521	O
to	33050947	1522	1524	O
the	33050947	1525	1528	O
study	33050947	1529	1534	O
medication	33050947	1535	1545	O
	33050947	1546	1547	O
Is	33050947	1548	1550	O
on	33050947	1551	1553	O
another	33050947	1554	1561	O
clinical	33050947	1562	1570	O
trial	33050947	1571	1576	O
investigating	33050947	1577	1590	O
an	33050947	1591	1593	O
antiviral	33050947	1594	1603	O
treatment	33050947	1604	1613	O
for	33050947	1614	1617	O
COVID-19	33050947	1618	1626	O
	33050947	1627	1628	O
Pregnancy	33050947	1629	1638	O
	33050947	1639	1640	O
Patients	33050947	1641	1649	O
with	33050947	1650	1654	O
severe	33050947	1655	1661	O
hepatic	33050947	1662	1669	O
dysfunction	33050947	1670	1681	O
equivalent	33050947	1682	1692	O
to	33050947	1693	1695	O
Grade	33050947	1696	1701	O
C	33050947	1702	1703	O
in	33050947	1704	1706	O
the	33050947	1707	1710	O
Child	33050947	1711	1716	O
-	33050947	1717	1718	O
Pugh	33050947	1719	1723	O
classification	33050947	1724	1738	O
	33050947	1739	1740	O
Patients	33050947	1741	1749	O
with	33050947	1750	1754	O
renal	33050947	1755	1760	O
impairment	33050947	1761	1771	O
requiring	33050947	1772	1781	O
dialysis	33050947	1782	1790	O
	33050947	1791	1792	O
Is	33050947	1793	1795	O
deemed	33050947	1796	1802	O
by	33050947	1803	1805	O
the	33050947	1806	1809	O
Investigator	33050947	1810	1822	O
to	33050947	1823	1825	O
be	33050947	1826	1828	O
ineligible	33050947	1829	1839	O
for	33050947	1840	1843	O
any	33050947	1844	1847	O
reason	33050947	1848	1854	O
Participants	33050947	1855	1867	O
will	33050947	1868	1872	O
be	33050947	1873	1875	O
recruited	33050947	1876	1885	O
from	33050947	1886	1890	O
,	33050947	1891	1892	O
and	33050947	1893	1896	O
the	33050947	1897	1900	O
study	33050947	1901	1906	O
visits	33050947	1907	1913	O
will	33050947	1914	1918	O
take	33050947	1919	1923	O
place	33050947	1924	1929	O
at	33050947	1930	1932	O
Alfred	33050947	1933	1939	O
Hospital	33050947	1940	1948	O
,	33050947	1949	1950	O
Monash	33050947	1951	1957	O
Health	33050947	1958	1964	O
,	33050947	1965	1966	O
Austin	33050947	1967	1973	O
Health	33050947	1974	1980	O
in	33050947	1981	1983	O
Victoria	33050947	1984	1992	O
,	33050947	1993	1994	O
Australia	33050947	1995	2004	O
for	33050947	2005	2008	O
hospitalised	33050947	2009	2021	O
participants	33050947	2022	2034	O
as	33050947	2035	2037	O
well	33050947	2038	2042	O
as	33050947	2043	2045	O
recruitment	33050947	2046	2057	O
in	33050947	2058	2060	O
the	33050947	2061	2064	O
community	33050947	2065	2074	O
in	33050947	2075	2077	O
participants	33050947	2078	2090	O
homes	33050947	2091	2096	O
for	33050947	2097	2100	O
eligible	33050947	2101	2109	O
people	33050947	2110	2116	O
not	33050947	2117	2120	O
requiring	33050947	2121	2130	O
hospitalisation	33050947	2131	2146	O
.	33050947	2147	2148	O

UNASSIGNED	33050947	2149	2159	O
:	33050947	2160	2161	O
The	33050947	2162	2165	O
first	33050947	2166	2171	O
candidate	33050947	2172	2181	O
antiviral	33050947	2182	2191	O
is	33050947	2192	2194	O
favipiravir	33050947	2195	2206	O
Arm	33050947	2207	2210	O
1	33050947	2211	2212	O
:	33050947	2213	2214	O
Favipiravir	33050947	2215	2226	O
1800	33050947	2227	2231	O
mg	33050947	2232	2234	O
favipiravir	33050947	2235	2246	O
BD	33050947	2247	2249	O
on	33050947	2250	2252	O
Day	33050947	2253	2256	O
1	33050947	2257	2258	O
followed	33050947	2259	2267	O
by	33050947	2268	2270	O
800	33050947	2271	2274	O
mg	33050947	2275	2277	O
BD	33050947	2278	2280	O
favipiravir	33050947	2281	2292	O
for	33050947	2293	2296	O
the	33050947	2297	2300	O
next	33050947	2301	2305	O
13	33050947	2306	2308	O
days	33050947	2309	2313	O
.	33050947	2314	2315	O

Arm	33050947	2316	2319	O
2	33050947	2320	2321	O
:	33050947	2322	2323	O
Placebo	33050947	2324	2331	O
MAIN	33050947	2332	2336	O
OUTCOMES	33050947	2337	2345	O
:	33050947	2346	2347	O
Primary	33050947	2348	2355	O
outcome	33050947	2356	2363	O
:	33050947	2364	2365	O
Time	33050947	2366	2370	O
to	33050947	2371	2373	O
virological	33050947	2374	2385	O
cure	33050947	2386	2390	O
as	33050947	2391	2393	O
defined	33050947	2394	2401	O
by	33050947	2402	2404	O
2	33050947	2405	2406	O
successive	33050947	2407	2417	O
throat	33050947	2418	2424	O
(	33050947	2425	2426	O
or	33050947	2427	2429	O
combined	33050947	2430	2438	O
nose	33050947	2439	2443	O
/	33050947	2444	2445	O
throat	33050947	2446	2452	O
)	33050947	2453	2454	O
swabs	33050947	2455	2460	O
negative	33050947	2461	2469	O
for	33050947	2470	2473	O
SARS	33050947	2474	2478	O
-	33050947	2479	2480	O
CoV-2	33050947	2481	2486	O
by	33050947	2487	2489	O
nucleic	33050947	2490	2497	O
acid	33050947	2498	2502	O
testing	33050947	2503	2510	O
during	33050947	2511	2517	O
the	33050947	2518	2521	O
14	33050947	2522	2524	O
days	33050947	2525	2529	O
after	33050947	2530	2535	O
enrolment	33050947	2536	2545	O
.	33050947	2546	2547	O

UNASSIGNED	33050947	2548	2558	O
:	33050947	2559	2560	O
Randomisation	33050947	2561	2574	O
performed	33050947	2575	2584	O
at	33050947	2585	2587	O
the	33050947	2588	2591	O
Alfred	33050947	2592	2598	O
Hospital	33050947	2599	2607	O
Clinical	33050947	2608	2616	O
Trials	33050947	2617	2623	O
Pharmacy	33050947	2624	2632	O
using	33050947	2633	2638	O
computer	33050947	2639	2647	O
generated	33050947	2648	2657	O
block	33050947	2658	2663	O
-	33050947	2664	2665	O
randomisation	33050947	2666	2679	O
lists	33050947	2680	2685	O
with	33050947	2686	2690	O
6	33050947	2691	2692	O
participants	33050947	2693	2705	O
per	33050947	2706	2709	O
block	33050947	2710	2715	O
.	33050947	2716	2717	O

Within	33050947	2718	2724	O
each	33050947	2725	2729	O
block	33050947	2730	2735	O
half	33050947	2736	2740	O
of	33050947	2741	2743	O
the	33050947	2744	2747	O
participants	33050947	2748	2760	O
will	33050947	2761	2765	O
be	33050947	2766	2768	O
randomised	33050947	2769	2779	O
to	33050947	2780	2782	O
the	33050947	2783	2786	O
candidate	33050947	2787	2796	O
antiviral	33050947	2797	2806	O
and	33050947	2807	2810	O
the	33050947	2811	2814	O
other	33050947	2815	2820	O
half	33050947	2821	2825	O
to	33050947	2826	2828	O
placebo	33050947	2829	2836	O
.	33050947	2837	2838	O

Randomisation	33050947	2839	2852	O
is	33050947	2853	2855	O
stratified	33050947	2856	2866	O
by	33050947	2867	2869	O
study	33050947	2870	2875	O
site	33050947	2876	2880	O
,	33050947	2881	2882	O
with	33050947	2883	2887	O
participants	33050947	2888	2900	O
enrolled	33050947	2901	2909	O
in	33050947	2910	2912	O
the	33050947	2913	2916	O
community	33050947	2917	2926	O
considered	33050947	2927	2937	O
as	33050947	2938	2940	O
a	33050947	2941	2942	O
study	33050947	2943	2948	O
site	33050947	2949	2953	O
.	33050947	2954	2955	O

UNASSIGNED	33050947	2956	2966	O
:	33050947	2967	2968	O
Study	33050947	2969	2974	O
participants	33050947	2975	2987	O
,	33050947	2988	2989	O
study	33050947	2990	2995	O
investigators	33050947	2996	3009	O
and	33050947	3010	3013	O
the	33050947	3014	3017	O
study	33050947	3018	3023	O
statistician	33050947	3024	3036	O
will	33050947	3037	3041	O
be	33050947	3042	3044	O
blinded	33050947	3045	3052	O
to	33050947	3053	3055	O
treatment	33050947	3056	3065	O
allocation	33050947	3066	3076	O
.	33050947	3077	3078	O

UNASSIGNED	33050947	3079	3089	O
:	33050947	3090	3091	O
The	33050947	3092	3095	O
study	33050947	3096	3101	O
aims	33050947	3102	3106	O
to	33050947	3107	3109	O
recruit	33050947	3110	3117	O
190	33050947	3118	3121	O
people	33050947	3122	3128	O
(	33050947	3129	3130	O
95	33050947	3131	3133	O
/	33050947	3134	3135	O
arm	33050947	3136	3139	O
)	33050947	3140	3141	O
with	33050947	3142	3146	O
the	33050947	3147	3150	O
first	33050947	3151	3156	O
candidate	33050947	3157	3166	O
antiviral	33050947	3167	3176	O
favipiravir	33050947	3177	3188	O
TRIAL	33050947	3189	3194	O
STATUS	33050947	3195	3201	O
:	33050947	3202	3203	O
Protocol	33050947	3204	3212	O
version	33050947	3213	3220	O
2.0	33050947	3221	3224	O
Dated	33050947	3225	3230	O
31-Jul-2020	33050947	3231	3242	O
.	33050947	3243	3244	O

Recruitment	33050947	3245	3256	O
will	33050947	3257	3261	O
take	33050947	3262	3266	O
place	33050947	3267	3272	O
between	33050947	3273	3280	O
July	33050947	3281	3285	O
2020	33050947	3286	3290	O
and	33050947	3291	3294	O
December	33050947	3295	3303	O
2020	33050947	3304	3308	O
.	33050947	3309	3310	O

BACKGROUND	33050947	3311	3321	O
:	33050947	3322	3323	O
clinicaltrials.gov	33050947	3324	3342	O
NCT04445467	33050947	3343	3354	O
First	33050947	3355	3360	O
posted	33050947	3361	3367	O
24-Jun-2020	33050947	3368	3379	O
FULL	33050947	3380	3384	O
PROTOCOL	33050947	3385	3393	O
:	33050947	3394	3395	O
The	33050947	3396	3399	O
full	33050947	3400	3404	O
protocol	33050947	3405	3413	O
is	33050947	3414	3416	O
attached	33050947	3417	3425	O
as	33050947	3426	3428	O
an	33050947	3429	3431	O
additional	33050947	3432	3442	O
file	33050947	3443	3447	O
,	33050947	3448	3449	O
accessible	33050947	3450	3460	O
from	33050947	3461	3465	O
the	33050947	3466	3469	O
Trials	33050947	3470	3476	O
website	33050947	3477	3484	O
(	33050947	3485	3486	O
Additional	33050947	3487	3497	O
file	33050947	3498	3502	O
1	33050947	3503	3504	O
)	33050947	3505	3506	O
.	33050947	3507	3508	O

In	33050947	3509	3511	O
the	33050947	3512	3515	O
interest	33050947	3516	3524	O
in	33050947	3525	3527	O
expediting	33050947	3528	3538	O
dissemination	33050947	3539	3552	O
of	33050947	3553	3555	O
this	33050947	3556	3560	O
material	33050947	3561	3569	O
,	33050947	3570	3571	O
the	33050947	3572	3575	O
familiar	33050947	3576	3584	O
formatting	33050947	3585	3595	O
has	33050947	3596	3599	O
been	33050947	3600	3604	O
eliminated	33050947	3605	3615	O
;	33050947	3616	3617	O
this	33050947	3618	3622	O
Letter	33050947	3623	3629	O
serves	33050947	3630	3636	O
as	33050947	3637	3639	O
a	33050947	3640	3641	O
summary	33050947	3642	3649	O
of	33050947	3650	3652	O
the	33050947	3653	3656	O
key	33050947	3657	3660	O
elements	33050947	3661	3669	O
of	33050947	3670	3672	O
the	33050947	3673	3676	O
full	33050947	3677	3681	O
protocol	33050947	3682	3690	O
.	33050947	3691	3692	O


COVID-19-associated	33053024	0	19	O
ARDS	33053024	20	24	O
treated	33053024	25	32	O
with	33053024	33	37	O
DEXamethasone	33053024	38	51	O
(	33053024	52	53	O
CoDEX	33053024	54	59	O
)	33053024	60	61	O
:	33053024	62	63	O
study	33053024	64	69	O
design	33053024	70	76	O
and	33053024	77	80	O
rationale	33053024	81	90	O
for	33053024	91	94	O
a	33053024	95	96	O
randomized	33053024	97	107	O
trial	33053024	108	113	O
.	33053024	114	115	O

OBJECTIVE	33053024	116	125	O
:	33053024	126	127	O
The	33053024	128	131	O
infection	33053024	132	141	O
caused	33053024	142	148	O
by	33053024	149	151	O
the	33053024	152	155	O
severe	33053024	156	162	O
acute	33053024	163	168	O
respiratory	33053024	169	180	O
syndrome	33053024	181	189	O
coronavirus	33053024	190	201	O
2	33053024	202	203	O
(	33053024	204	205	O
SARS	33053024	206	210	O
-	33053024	211	212	O
CoV-2	33053024	213	218	O
)	33053024	219	220	O
spreads	33053024	221	228	O
worldwide	33053024	229	238	O
and	33053024	239	242	O
is	33053024	243	245	O
considered	33053024	246	256	O
a	33053024	257	258	O
pandemic	33053024	259	267	O
.	33053024	268	269	O

The	33053024	270	273	O
most	33053024	274	278	O
common	33053024	279	285	O
manifestation	33053024	286	299	O
of	33053024	300	302	O
SARS	33053024	303	307	O
-	33053024	308	309	O
CoV-2	33053024	310	315	O
infection	33053024	316	325	O
(	33053024	326	327	O
coronavirus	33053024	328	339	O
disease	33053024	340	347	O
2019	33053024	348	352	O
-	33053024	353	354	O
COVID-19	33053024	355	363	O
)	33053024	364	365	O
is	33053024	366	368	O
viral	33053024	369	374	O
pneumonia	33053024	375	384	O
with	33053024	385	389	O
varying	33053024	390	397	O
degrees	33053024	398	405	O
of	33053024	406	408	O
respiratory	33053024	409	420	O
compromise	33053024	421	431	O
and	33053024	432	435	O
up	33053024	436	438	O
to	33053024	439	441	O
40	33053024	442	444	O
%	33053024	445	446	O
of	33053024	447	449	O
hospitalized	33053024	450	462	O
patients	33053024	463	471	O
might	33053024	472	477	O
develop	33053024	478	485	O
acute	33053024	486	491	O
respiratory	33053024	492	503	O
distress	33053024	504	512	O
syndrome	33053024	513	521	O
.	33053024	522	523	O

Several	33053024	524	531	O
clinical	33053024	532	540	O
trials	33053024	541	547	O
evaluated	33053024	548	557	O
the	33053024	558	561	O
role	33053024	562	566	O
of	33053024	567	569	O
corticosteroids	33053024	570	585	O
in	33053024	586	588	O
non	33053024	589	592	O
-	33053024	593	594	O
COVID-19	33053024	595	603	O
acute	33053024	604	609	O
respiratory	33053024	610	621	O
distress	33053024	622	630	O
syndrome	33053024	631	639	O
with	33053024	640	644	O
conflicting	33053024	645	656	O
results	33053024	657	664	O
.	33053024	665	666	O

We	33053024	667	669	O
designed	33053024	670	678	O
a	33053024	679	680	O
trial	33053024	681	686	O
to	33053024	687	689	O
evaluate	33053024	690	698	O
the	33053024	699	702	O
effectiveness	33053024	703	716	O
of	33053024	717	719	O
early	33053024	720	725	O
intravenous	33053024	726	737	O
dexamethasone	33053024	738	751	O
administration	33053024	752	766	O
on	33053024	767	769	O
the	33053024	770	773	O
number	33053024	774	780	O
of	33053024	781	783	O
days	33053024	784	788	O
alive	33053024	789	794	O
and	33053024	795	798	O
free	33053024	799	803	O
of	33053024	804	806	O
mechanical	33053024	807	817	O
ventilation	33053024	818	829	O
within	33053024	830	836	O
28	33053024	837	839	O
days	33053024	840	844	O
after	33053024	845	850	O
randomization	33053024	851	864	O
in	33053024	865	867	O
adult	33053024	868	873	O
patients	33053024	874	882	O
with	33053024	883	887	O
moderate	33053024	888	896	O
or	33053024	897	899	O
severe	33053024	900	906	O
acute	33053024	907	912	O
respiratory	33053024	913	924	O
distress	33053024	925	933	O
syndrome	33053024	934	942	O
due	33053024	943	946	O
to	33053024	947	949	O
confirmed	33053024	950	959	O
or	33053024	960	962	O
probable	33053024	963	971	O
COVID-19	33053024	972	980	O
.	33053024	981	982	O

METHODS	33053024	983	990	O
:	33053024	991	992	O
This	33053024	993	997	O
is	33053024	998	1000	O
a	33053024	1001	1002	O
pragmatic	33053024	1003	1012	O
,	33053024	1013	1014	O
prospective	33053024	1015	1026	O
,	33053024	1027	1028	O
randomized	33053024	1029	1039	O
,	33053024	1040	1041	O
stratified	33053024	1042	1052	O
,	33053024	1053	1054	O
multicenter	33053024	1055	1066	O
,	33053024	1067	1068	O
open	33053024	1069	1073	O
-	33053024	1074	1075	O
label	33053024	1076	1081	O
,	33053024	1082	1083	O
controlled	33053024	1084	1094	O
trial	33053024	1095	1100	O
including	33053024	1101	1110	O
350	33053024	1111	1114	O
patients	33053024	1115	1123	O
with	33053024	1124	1128	O
early	33053024	1129	1134	O
-	33053024	1135	1136	O
onset	33053024	1137	1142	O
(	33053024	1143	1144	O
less	33053024	1145	1149	O
than	33053024	1150	1154	O
48	33053024	1155	1157	O
hours	33053024	1158	1163	O
before	33053024	1164	1170	O
randomization	33053024	1171	1184	O
)	33053024	1185	1186	O
moderate	33053024	1187	1195	O
or	33053024	1196	1198	O
severe	33053024	1199	1205	O
acute	33053024	1206	1211	O
respiratory	33053024	1212	1223	O
distress	33053024	1224	1232	O
syndrome	33053024	1233	1241	O
,	33053024	1242	1243	O
defined	33053024	1244	1251	O
by	33053024	1252	1254	O
the	33053024	1255	1258	O
Berlin	33053024	1259	1265	O
criteria	33053024	1266	1274	O
,	33053024	1275	1276	O
due	33053024	1277	1280	O
to	33053024	1281	1283	O
COVID-19	33053024	1284	1292	O
.	33053024	1293	1294	O

Eligible	33053024	1295	1303	O
patients	33053024	1304	1312	O
will	33053024	1313	1317	O
be	33053024	1318	1320	O
randomly	33053024	1321	1329	O
allocated	33053024	1330	1339	O
to	33053024	1340	1342	O
either	33053024	1343	1349	O
standard	33053024	1350	1358	O
treatment	33053024	1359	1368	O
plus	33053024	1369	1373	O
dexamethasone	33053024	1374	1387	O
(	33053024	1388	1389	O
Intervention	33053024	1390	1402	O
Group	33053024	1403	1408	O
)	33053024	1409	1410	O
or	33053024	1411	1413	O
standard	33053024	1414	1422	O
treatment	33053024	1423	1432	O
without	33053024	1433	1440	O
dexamethasone	33053024	1441	1454	O
(	33053024	1455	1456	O
Control	33053024	1457	1464	O
Group	33053024	1465	1470	O
)	33053024	1471	1472	O
.	33053024	1473	1474	O

Patients	33053024	1475	1483	O
in	33053024	1484	1486	O
the	33053024	1487	1490	O
intervention	33053024	1491	1503	O
group	33053024	1504	1509	O
will	33053024	1510	1514	O
receive	33053024	1515	1522	O
dexamethasone	33053024	1523	1536	O
20	33053024	1537	1539	O
mg	33053024	1540	1542	O
intravenous	33053024	1543	1554	O
once	33053024	1555	1559	O
daily	33053024	1560	1565	O
for	33053024	1566	1569	O
5	33053024	1570	1571	O
days	33053024	1572	1576	O
,	33053024	1577	1578	O
followed	33053024	1579	1587	O
by	33053024	1588	1590	O
dexamethasone	33053024	1591	1604	O
10	33053024	1605	1607	O
mg	33053024	1608	1610	O
IV	33053024	1611	1613	O
once	33053024	1614	1618	O
daily	33053024	1619	1624	O
for	33053024	1625	1628	O
additional	33053024	1629	1639	O
5	33053024	1640	1641	O
days	33053024	1642	1646	O
or	33053024	1647	1649	O
until	33053024	1650	1655	O
intensive	33053024	1656	1665	O
care	33053024	1666	1670	O
unit	33053024	1671	1675	O
discharge	33053024	1676	1685	O
,	33053024	1686	1687	O
whichever	33053024	1688	1697	O
occurs	33053024	1698	1704	O
first	33053024	1705	1710	O
.	33053024	1711	1712	O

The	33053024	1713	1716	O
primary	33053024	1717	1724	O
outcome	33053024	1725	1732	O
is	33053024	1733	1735	O
ventilator	33053024	1736	1746	O
-	33053024	1747	1748	O
free	33053024	1749	1753	O
days	33053024	1754	1758	O
within	33053024	1759	1765	O
28	33053024	1766	1768	O
days	33053024	1769	1773	O
after	33053024	1774	1779	O
randomization	33053024	1780	1793	O
,	33053024	1794	1795	O
defined	33053024	1796	1803	O
as	33053024	1804	1806	O
days	33053024	1807	1811	O
alive	33053024	1812	1817	O
and	33053024	1818	1821	O
free	33053024	1822	1826	O
from	33053024	1827	1831	O
invasive	33053024	1832	1840	O
mechanical	33053024	1841	1851	O
ventilation	33053024	1852	1863	O
.	33053024	1864	1865	O

Secondary	33053024	1866	1875	O
outcomes	33053024	1876	1884	O
are	33053024	1885	1888	O
all	33053024	1889	1892	O
-	33053024	1893	1894	O
cause	33053024	1895	1900	O
mortality	33053024	1901	1910	O
rates	33053024	1911	1916	O
at	33053024	1917	1919	O
day	33053024	1920	1923	O
28	33053024	1924	1926	O
,	33053024	1927	1928	O
evaluation	33053024	1929	1939	O
of	33053024	1940	1942	O
the	33053024	1943	1946	O
clinical	33053024	1947	1955	O
status	33053024	1956	1962	O
at	33053024	1963	1965	O
day	33053024	1966	1969	O
15	33053024	1970	1972	O
assessed	33053024	1973	1981	O
with	33053024	1982	1986	O
a	33053024	1987	1988	O
6-level	33053024	1989	1996	O
ordinal	33053024	1997	2004	O
scale	33053024	2005	2010	O
,	33053024	2011	2012	O
mechanical	33053024	2013	2023	O
ventilation	33053024	2024	2035	O
duration	33053024	2036	2044	O
from	33053024	2045	2049	O
randomization	33053024	2050	2063	O
to	33053024	2064	2066	O
day	33053024	2067	2070	O
28	33053024	2071	2073	O
,	33053024	2074	2075	O
Sequential	33053024	2076	2086	O
Organ	33053024	2087	2092	O
Failure	33053024	2093	2100	O
Assessment	33053024	2101	2111	O
Score	33053024	2112	2117	O
evaluation	33053024	2118	2128	O
at	33053024	2129	2131	O
48	33053024	2132	2134	O
hours	33053024	2135	2140	O
,	33053024	2141	2142	O
72	33053024	2143	2145	O
hours	33053024	2146	2151	O
and	33053024	2152	2155	O
7	33053024	2156	2157	O
days	33053024	2158	2162	O
and	33053024	2163	2166	O
intensive	33053024	2167	2176	O
care	33053024	2177	2181	O
unit	33053024	2182	2186	O
-free	33053024	2187	2192	O
days	33053024	2193	2197	O
within	33053024	2198	2204	O
28	33053024	2205	2207	O
.	33053024	2208	2209	O


Double	33059771	0	6	O
-	33059771	7	8	O
Blind	33059771	9	14	O
,	33059771	15	16	O
Randomized	33059771	17	27	O
,	33059771	28	29	O
Placebo	33059771	30	37	O
-	33059771	38	39	O
Controlled	33059771	40	50	O
Phase	33059771	51	56	O
III	33059771	57	60	O
Clinical	33059771	61	69	O
Trial	33059771	70	75	O
to	33059771	76	78	O
Evaluate	33059771	79	87	O
the	33059771	88	91	O
Efficacy	33059771	92	100	O
and	33059771	101	104	O
Safety	33059771	105	111	O
of	33059771	112	114	O
treating	33059771	115	123	O
Healthcare	33059771	124	134	O
Professionals	33059771	135	148	O
with	33059771	149	153	O
the	33059771	154	157	O
Adsorbed	33059771	158	166	O
COVID-19	33059771	167	175	O
(	33059771	176	177	O
Inactivated	33059771	178	189	O
)	33059771	190	191	O
Vaccine	33059771	192	199	O
Manufactured	33059771	200	212	O
by	33059771	213	215	O
Sinovac	33059771	216	223	O
-	33059771	224	225	O
PROFISCOV	33059771	226	235	O
:	33059771	236	237	O
A	33059771	238	239	O
structured	33059771	240	250	O
summary	33059771	251	258	O
of	33059771	259	261	O
a	33059771	262	263	O
study	33059771	264	269	O
protocol	33059771	270	278	O
for	33059771	279	282	O
a	33059771	283	284	O
randomised	33059771	285	295	O
controlled	33059771	296	306	O
trial	33059771	307	312	O
.	33059771	313	314	O

OBJECTIVE	33059771	315	324	O
:	33059771	325	326	O
To	33059771	327	329	O
evaluate	33059771	330	338	O
the	33059771	339	342	O
efficacy	33059771	343	351	O
of	33059771	352	354	O
two	33059771	355	358	O
doses	33059771	359	364	O
of	33059771	365	367	O
the	33059771	368	371	O
adsorbed	33059771	372	380	O
vaccine	33059771	381	388	O
COVID-19	33059771	389	397	O
(	33059771	398	399	O
inactivated	33059771	400	411	O
)	33059771	412	413	O
produced	33059771	414	422	O
by	33059771	423	425	O
Sinovac	33059771	426	433	O
in	33059771	434	436	O
symptomatic	33059771	437	448	O
individuals	33059771	449	460	O
,	33059771	461	462	O
with	33059771	463	467	O
virological	33059771	468	479	O
confirmation	33059771	480	492	O
of	33059771	493	495	O
COVID-19	33059771	496	504	O
,	33059771	505	506	O
two	33059771	507	510	O
weeks	33059771	511	516	O
after	33059771	517	522	O
the	33059771	523	526	O
completion	33059771	527	537	O
of	33059771	538	540	O
the	33059771	541	544	O
two	33059771	545	548	O
-	33059771	549	550	O
dose	33059771	551	555	O
vaccination	33059771	556	567	O
regimen	33059771	568	575	O
,	33059771	576	577	O
aged	33059771	578	582	O
18	33059771	583	585	O
years	33059771	586	591	O
or	33059771	592	594	O
older	33059771	595	600	O
who	33059771	601	604	O
work	33059771	605	609	O
as	33059771	610	612	O
health	33059771	613	619	O
professionals	33059771	620	633	O
providing	33059771	634	643	O
care	33059771	644	648	O
to	33059771	649	651	O
patients	33059771	652	660	O
with	33059771	661	665	O
possible	33059771	666	674	O
or	33059771	675	677	O
confirmed	33059771	678	687	O
COVID-19	33059771	688	696	O
.	33059771	697	698	O

To	33059771	699	701	O
describe	33059771	702	710	O
the	33059771	711	714	O
occurrence	33059771	715	725	O
of	33059771	726	728	O
adverse	33059771	729	736	O
reactions	33059771	737	746	O
associated	33059771	747	757	O
with	33059771	758	762	O
the	33059771	763	766	O
administration	33059771	767	781	O
of	33059771	782	784	O
each	33059771	785	789	O
of	33059771	790	792	O
two	33059771	793	796	O
doses	33059771	797	802	O
of	33059771	803	805	O
the	33059771	806	809	O
adsorbed	33059771	810	818	O
vaccine	33059771	819	826	O
COVID-19	33059771	827	835	O
(	33059771	836	837	O
inactivated	33059771	838	849	O
)	33059771	850	851	O
produced	33059771	852	860	O
by	33059771	861	863	O
Sinovac	33059771	864	871	O
up	33059771	872	874	O
to	33059771	875	877	O
one	33059771	878	881	O
week	33059771	882	886	O
after	33059771	887	892	O
vaccination	33059771	893	904	O
in	33059771	905	907	O
Adults	33059771	908	914	O
(	33059771	915	916	O
18	33059771	917	919	O
-	33059771	920	921	O
59	33059771	922	924	O
years	33059771	925	930	O
of	33059771	931	933	O
age	33059771	934	937	O
)	33059771	938	939	O
and	33059771	940	943	O
Elderly	33059771	944	951	O
(	33059771	952	953	O
60	33059771	954	956	O
years	33059771	957	962	O
of	33059771	963	965	O
age	33059771	966	969	O
or	33059771	970	972	O
more	33059771	973	977	O
)	33059771	978	979	O
.	33059771	980	981	O

METHODS	33059771	982	989	O
:	33059771	990	991	O
This	33059771	992	996	O
is	33059771	997	999	O
a	33059771	1000	1001	O
Phase	33059771	1002	1007	O
III	33059771	1008	1011	O
,	33059771	1012	1013	O
randomized	33059771	1014	1024	O
,	33059771	1025	1026	O
multicenter	33059771	1027	1038	O
,	33059771	1039	1040	O
endpoint	33059771	1041	1049	O
driven	33059771	1050	1056	O
,	33059771	1057	1058	O
double	33059771	1059	1065	O
-	33059771	1066	1067	O
blind	33059771	1068	1073	O
,	33059771	1074	1075	O
placebo	33059771	1076	1083	O
-	33059771	1084	1085	O
controlled	33059771	1086	1096	O
clinical	33059771	1097	1105	O
trial	33059771	1106	1111	O
to	33059771	1112	1114	O
assess	33059771	1115	1121	O
the	33059771	1122	1125	O
efficacy	33059771	1126	1134	O
and	33059771	1135	1138	O
safety	33059771	1139	1145	O
of	33059771	1146	1148	O
the	33059771	1149	1152	O
adsorbed	33059771	1153	1161	O
vaccine	33059771	1162	1169	O
COVID-19	33059771	1170	1178	O
(	33059771	1179	1180	O
inactivated	33059771	1181	1192	O
)	33059771	1193	1194	O
produced	33059771	1195	1203	O
by	33059771	1204	1206	O
Sinovac	33059771	1207	1214	O
.	33059771	1215	1216	O

The	33059771	1217	1220	O
adsorbed	33059771	1221	1229	O
vaccine	33059771	1230	1237	O
COVID-19	33059771	1238	1246	O
(	33059771	1247	1248	O
inactivated	33059771	1249	1260	O
)	33059771	1261	1262	O
produced	33059771	1263	1271	O
by	33059771	1272	1274	O
Sinovac	33059771	1275	1282	O
(	33059771	1283	1284	O
product	33059771	1285	1292	O
under	33059771	1293	1298	O
investigation	33059771	1299	1312	O
)	33059771	1313	1314	O
will	33059771	1315	1319	O
be	33059771	1320	1322	O
compared	33059771	1323	1331	O
to	33059771	1332	1334	O
placebo	33059771	1335	1342	O
.	33059771	1343	1344	O

Voluntary	33059771	1345	1354	O
participants	33059771	1355	1367	O
will	33059771	1368	1372	O
be	33059771	1373	1375	O
randomized	33059771	1376	1386	O
to	33059771	1387	1389	O
receive	33059771	1390	1397	O
two	33059771	1398	1401	O
intramuscular	33059771	1402	1415	O
doses	33059771	1416	1421	O
of	33059771	1422	1424	O
the	33059771	1425	1428	O
investigational	33059771	1429	1444	O
product	33059771	1445	1452	O
or	33059771	1453	1455	O
the	33059771	1456	1459	O
placebo	33059771	1460	1467	O
,	33059771	1468	1469	O
in	33059771	1470	1472	O
a	33059771	1473	1474	O
1	33059771	1475	1476	O
:	33059771	1477	1478	O
1	33059771	1479	1480	O
ratio	33059771	1481	1486	O
,	33059771	1487	1488	O
stratified	33059771	1489	1499	O
by	33059771	1500	1502	O
age	33059771	1503	1506	O
group	33059771	1507	1512	O
(	33059771	1513	1514	O
18	33059771	1515	1517	O
to	33059771	1518	1520	O
59	33059771	1521	1523	O
years	33059771	1524	1529	O
and	33059771	1530	1533	O
60	33059771	1534	1536	O
years	33059771	1537	1542	O
or	33059771	1543	1545	O
more	33059771	1546	1550	O
)	33059771	1551	1552	O
and	33059771	1553	1556	O
will	33059771	1557	1561	O
be	33059771	1562	1564	O
monitored	33059771	1565	1574	O
for	33059771	1575	1578	O
one	33059771	1579	1582	O
year	33059771	1583	1587	O
by	33059771	1588	1590	O
active	33059771	1591	1597	O
surveillance	33059771	1598	1610	O
of	33059771	1611	1613	O
COVID-19	33059771	1614	1622	O
.	33059771	1623	1624	O

Two	33059771	1625	1628	O
databases	33059771	1629	1638	O
will	33059771	1639	1643	O
be	33059771	1644	1646	O
established	33059771	1647	1658	O
according	33059771	1659	1668	O
to	33059771	1669	1671	O
the	33059771	1672	1675	O
age	33059771	1676	1679	O
groups	33059771	1680	1686	O
:	33059771	1687	1688	O
one	33059771	1689	1692	O
for	33059771	1693	1696	O
adults	33059771	1697	1703	O
(	33059771	1704	1705	O
18	33059771	1706	1708	O
-	33059771	1709	1710	O
59	33059771	1711	1713	O
years	33059771	1714	1719	O
)	33059771	1720	1721	O
and	33059771	1722	1725	O
one	33059771	1726	1729	O
for	33059771	1730	1733	O
the	33059771	1734	1737	O
elderly	33059771	1738	1745	O
(	33059771	1746	1747	O
60	33059771	1748	1750	O
years	33059771	1751	1756	O
of	33059771	1757	1759	O
age	33059771	1760	1763	O
or	33059771	1764	1766	O
older	33059771	1767	1772	O
)	33059771	1773	1774	O
.	33059771	1775	1776	O

The	33059771	1777	1780	O
threshold	33059771	1781	1790	O
to	33059771	1791	1793	O
consider	33059771	1794	1802	O
the	33059771	1803	1806	O
vaccine	33059771	1807	1814	O
efficacious	33059771	1815	1826	O
will	33059771	1827	1831	O
be	33059771	1832	1834	O
to	33059771	1835	1837	O
reach	33059771	1838	1843	O
a	33059771	1844	1845	O
protection	33059771	1846	1856	O
level	33059771	1857	1862	O
of	33059771	1863	1865	O
at	33059771	1866	1868	O
least	33059771	1869	1874	O
50	33059771	1875	1877	O
%	33059771	1878	1879	O
,	33059771	1880	1881	O
as	33059771	1882	1884	O
proposed	33059771	1885	1893	O
by	33059771	1894	1896	O
the	33059771	1897	1900	O
World	33059771	1901	1906	O
Health	33059771	1907	1913	O
Organization	33059771	1914	1926	O
and	33059771	1927	1930	O
the	33059771	1931	1934	O
FDA	33059771	1935	1938	O
.	33059771	1939	1940	O

Success	33059771	1941	1948	O
in	33059771	1949	1951	O
this	33059771	1952	1956	O
criterion	33059771	1957	1966	O
will	33059771	1967	1971	O
be	33059771	1972	1974	O
defined	33059771	1975	1982	O
by	33059771	1983	1985	O
sequential	33059771	1986	1996	O
monitoring	33059771	1997	2007	O
with	33059771	2008	2012	O
adjustment	33059771	2013	2023	O
of	33059771	2024	2026	O
the	33059771	2027	2030	O
lower	33059771	2031	2036	O
limit	33059771	2037	2042	O
of	33059771	2043	2045	O
the	33059771	2046	2049	O
95	33059771	2050	2052	O
%	33059771	2053	2054	O
confidence	33059771	2055	2065	O
interval	33059771	2066	2074	O
above	33059771	2075	2080	O
30	33059771	2081	2083	O
%	33059771	2084	2085	O
for	33059771	2086	2089	O
the	33059771	2090	2093	O
primary	33059771	2094	2101	O
efficacy	33059771	2102	2110	O
endpoint	33059771	2111	2119	O
.	33059771	2120	2121	O

METHODS	33059771	2122	2129	O
:	33059771	2130	2131	O
Healthy	33059771	2132	2139	O
participants	33059771	2140	2152	O
and	33059771	2153	2156	O
/	33059771	2157	2158	O
or	33059771	2159	2161	O
participants	33059771	2162	2174	O
with	33059771	2175	2179	O
clinically	33059771	2180	2190	O
controlled	33059771	2191	2201	O
disease	33059771	2202	2209	O
,	33059771	2210	2211	O
of	33059771	2212	2214	O
both	33059771	2215	2219	O
genders	33059771	2220	2227	O
,	33059771	2228	2229	O
18	33059771	2230	2232	O
years	33059771	2233	2238	O
of	33059771	2239	2241	O
age	33059771	2242	2245	O
or	33059771	2246	2248	O
older	33059771	2249	2254	O
,	33059771	2255	2256	O
working	33059771	2257	2264	O
as	33059771	2265	2267	O
health	33059771	2268	2274	O
professionals	33059771	2275	2288	O
performing	33059771	2289	2299	O
care	33059771	2300	2304	O
in	33059771	2305	2307	O
units	33059771	2308	2313	O
specialized	33059771	2314	2325	O
in	33059771	2326	2328	O
direct	33059771	2329	2335	O
contact	33059771	2336	2343	O
with	33059771	2344	2348	O
people	33059771	2349	2355	O
with	33059771	2356	2360	O
possible	33059771	2361	2369	O
or	33059771	2370	2372	O
confirmed	33059771	2373	2382	O
cases	33059771	2383	2388	O
of	33059771	2389	2391	O
COVID-19	33059771	2392	2400	O
.	33059771	2401	2402	O

Participation	33059771	2403	2416	O
of	33059771	2417	2419	O
pregnant	33059771	2420	2428	O
women	33059771	2429	2434	O
and	33059771	2435	2438	O
those	33059771	2439	2444	O
who	33059771	2445	2448	O
are	33059771	2449	2452	O
breastfeeding	33059771	2453	2466	O
,	33059771	2467	2468	O
as	33059771	2469	2471	O
well	33059771	2472	2476	O
as	33059771	2477	2479	O
those	33059771	2480	2485	O
intending	33059771	2486	2495	O
to	33059771	2496	2498	O
become	33059771	2499	2505	O
pregnant	33059771	2506	2514	O
within	33059771	2515	2521	O
three	33059771	2522	2527	O
months	33059771	2528	2534	O
after	33059771	2535	2540	O
vaccination	33059771	2541	2552	O
will	33059771	2553	2557	O
not	33059771	2558	2561	O
be	33059771	2562	2564	O
allowed	33059771	2565	2572	O
.	33059771	2573	2574	O

Participants	33059771	2575	2587	O
will	33059771	2588	2592	O
only	33059771	2593	2597	O
be	33059771	2598	2600	O
included	33059771	2601	2609	O
after	33059771	2610	2615	O
signing	33059771	2616	2623	O
the	33059771	2624	2627	O
voluntary	33059771	2628	2637	O
Informed	33059771	2638	2646	O
Consent	33059771	2647	2654	O
Form	33059771	2655	2659	O
and	33059771	2660	2663	O
ensuring	33059771	2664	2672	O
they	33059771	2673	2677	O
undergo	33059771	2678	2685	O
screening	33059771	2686	2695	O
evaluation	33059771	2696	2706	O
and	33059771	2707	2710	O
conform	33059771	2711	2718	O
to	33059771	2719	2721	O
all	33059771	2722	2725	O
the	33059771	2726	2729	O
inclusion	33059771	2730	2739	O
and	33059771	2740	2743	O
exclusion	33059771	2744	2753	O
criteria	33059771	2754	2762	O
.	33059771	2763	2764	O

All	33059771	2765	2768	O
the	33059771	2769	2772	O
clinical	33059771	2773	2781	O
sites	33059771	2782	2787	O
are	33059771	2788	2791	O
located	33059771	2792	2799	O
in	33059771	2800	2802	O
Brazil	33059771	2803	2809	O
.	33059771	2810	2811	O

UNASSIGNED	33059771	2812	2822	O
:	33059771	2823	2824	O
Experimental	33059771	2825	2837	O
intervention	33059771	2838	2850	O
:	33059771	2851	2852	O
The	33059771	2853	2856	O
vaccine	33059771	2857	2864	O
was	33059771	2865	2868	O
manufactured	33059771	2869	2881	O
by	33059771	2882	2884	O
Sinovac	33059771	2885	2892	O
Life	33059771	2893	2897	O
Sciences	33059771	2898	2906	O
(	33059771	2907	2908	O
Beijing	33059771	2909	2916	O
,	33059771	2917	2918	O
China	33059771	2919	2924	O
)	33059771	2925	2926	O
and	33059771	2927	2930	O
contains	33059771	2931	2939	O
3	33059771	2940	2941	O
g/0.5	33059771	2942	2948	O
mL	33059771	2949	2951	O
(	33059771	2952	2953	O
equivalent	33059771	2954	2964	O
to	33059771	2965	2967	O
600	33059771	2968	2971	O
SU	33059771	2972	2974	O
per	33059771	2975	2978	O
dose	33059771	2979	2983	O
)	33059771	2984	2985	O
of	33059771	2986	2988	O
inactivated	33059771	2989	3000	O
SARS	33059771	3001	3005	O
-	33059771	3006	3007	O
CoV-2	33059771	3008	3013	O
virus	33059771	3014	3019	O
,	33059771	3020	3021	O
and	33059771	3022	3025	O
aluminium	33059771	3026	3035	O
hydroxide	33059771	3036	3045	O
as	33059771	3046	3048	O
adjuvant	33059771	3049	3057	O
.	33059771	3058	3059	O

Control	33059771	3060	3067	O
comparator	33059771	3068	3078	O
:	33059771	3079	3080	O
The	33059771	3081	3084	O
placebo	33059771	3085	3092	O
contains	33059771	3093	3101	O
aluminium	33059771	3102	3111	O
hydroxide	33059771	3112	3121	O
in	33059771	3122	3124	O
a	33059771	3125	3126	O
0.5	33059771	3127	3130	O
mL	33059771	3131	3133	O
solution	33059771	3134	3142	O
The	33059771	3143	3146	O
schedule	33059771	3147	3155	O
of	33059771	3156	3158	O
both	33059771	3159	3163	O
,	33059771	3164	3165	O
experimental	33059771	3166	3178	O
intervention	33059771	3179	3191	O
and	33059771	3192	3195	O
placebo	33059771	3196	3203	O
is	33059771	3204	3206	O
two	33059771	3207	3210	O
0.5	33059771	3211	3214	O
mL	33059771	3215	3217	O
doses	33059771	3218	3223	O
IM	33059771	3224	3226	O
(	33059771	3227	3228	O
deltoid	33059771	3229	3236	O
)	33059771	3237	3238	O
with	33059771	3239	3243	O
a	33059771	3244	3245	O
two	33059771	3246	3249	O
week	33059771	3250	3254	O
interval	33059771	3255	3263	O
.	33059771	3264	3265	O

RESULTS	33059771	3266	3273	O
:	33059771	3274	3275	O
The	33059771	3276	3279	O
primary	33059771	3280	3287	O
efficacy	33059771	3288	3296	O
endpoint	33059771	3297	3305	O
is	33059771	3306	3308	O
the	33059771	3309	3312	O
incidence	33059771	3313	3322	O
of	33059771	3323	3325	O
symptomatic	33059771	3326	3337	O
cases	33059771	3338	3343	O
of	33059771	3344	3346	O
virologically	33059771	3347	3360	O
confirmed	33059771	3361	3370	O
COVID-19	33059771	3371	3379	O
two	33059771	3380	3383	O
weeks	33059771	3384	3389	O
after	33059771	3390	3395	O
the	33059771	3396	3399	O
second	33059771	3400	3406	O
vaccination	33059771	3407	3418	O
.	33059771	3419	3420	O

The	33059771	3421	3424	O
virological	33059771	3425	3436	O
diagnosis	33059771	3437	3446	O
will	33059771	3447	3451	O
be	33059771	3452	3454	O
confirmed	33059771	3455	3464	O
by	33059771	3465	3467	O
detection	33059771	3468	3477	O
of	33059771	3478	3480	O
SARS	33059771	3481	3485	O
-	33059771	3486	3487	O
CoV-2	33059771	3488	3493	O
nucleic	33059771	3494	3501	O
acid	33059771	3502	3506	O
in	33059771	3507	3509	O
a	33059771	3510	3511	O
clinical	33059771	3512	3520	O
sample	33059771	3521	3527	O
.	33059771	3528	3529	O

The	33059771	3530	3533	O
primary	33059771	3534	3541	O
safety	33059771	3542	3548	O
endpoint	33059771	3549	3557	O
is	33059771	3558	3560	O
the	33059771	3561	3564	O
frequency	33059771	3565	3574	O
of	33059771	3575	3577	O
solicited	33059771	3578	3587	O
and	33059771	3588	3591	O
unsolicited	33059771	3592	3603	O
local	33059771	3604	3609	O
and	33059771	3610	3613	O
systemic	33059771	3614	3622	O
adverse	33059771	3623	3630	O
reactions	33059771	3631	3640	O
during	33059771	3641	3647	O
the	33059771	3648	3651	O
period	33059771	3652	3658	O
of	33059771	3659	3661	O
one	33059771	3662	3665	O
week	33059771	3666	3670	O
after	33059771	3671	3676	O
vaccination	33059771	3677	3688	O
according	33059771	3689	3698	O
to	33059771	3699	3701	O
age	33059771	3702	3705	O
group	33059771	3706	3711	O
in	33059771	3712	3714	O
adult	33059771	3715	3720	O
(	33059771	3721	3722	O
18	33059771	3723	3725	O
-	33059771	3726	3727	O
59	33059771	3728	3730	O
years	33059771	3731	3736	O
old	33059771	3737	3740	O
)	33059771	3741	3742	O
and	33059771	3743	3746	O
elder	33059771	3747	3752	O
(	33059771	3753	3754	O
60	33059771	3755	3757	O
years	33059771	3758	3763	O
of	33059771	3764	3766	O
age	33059771	3767	3770	O
or	33059771	3771	3773	O
older	33059771	3774	3779	O
)	33059771	3780	3781	O
subjects	33059771	3782	3790	O
.	33059771	3791	3792	O

Adverse	33059771	3793	3800	O
reactions	33059771	3801	3810	O
are	33059771	3811	3814	O
defined	33059771	3815	3822	O
as	33059771	3823	3825	O
adverse	33059771	3826	3833	O
events	33059771	3834	3840	O
that	33059771	3841	3845	O
have	33059771	3846	3850	O
a	33059771	3851	3852	O
reasonable	33059771	3853	3863	O
causal	33059771	3864	3870	O
relationship	33059771	3871	3883	O
to	33059771	3884	3886	O
vaccination	33059771	3887	3898	O
.	33059771	3899	3900	O

UNASSIGNED	33059771	3901	3911	O
:	33059771	3912	3913	O
There	33059771	3914	3919	O
will	33059771	3920	3924	O
be	33059771	3925	3927	O
two	33059771	3928	3931	O
randomization	33059771	3932	3945	O
lists	33059771	3946	3951	O
,	33059771	3952	3953	O
one	33059771	3954	3957	O
for	33059771	3958	3961	O
each	33059771	3962	3966	O
age	33059771	3967	3970	O
group	33059771	3971	3976	O
,	33059771	3977	3978	O
based	33059771	3979	3984	O
on	33059771	3985	3987	O
the	33059771	3988	3991	O
investigational	33059771	3992	4007	O
products	33059771	4008	4016	O
to	33059771	4017	4019	O
be	33059771	4020	4022	O
administered	33059771	4023	4035	O
,	33059771	4036	4037	O
i.e.	33059771	4038	4042	O
,	33059771	4043	4044	O
vaccine	33059771	4045	4052	O
or	33059771	4053	4055	O
placebo	33059771	4056	4063	O
at	33059771	4064	4066	O
a	33059771	4067	4068	O
1	33059771	4069	4070	O
:	33059771	4071	4072	O
1	33059771	4073	4074	O
ratio	33059771	4075	4080	O
.	33059771	4081	4082	O

Each	33059771	4083	4087	O
randomization	33059771	4088	4101	O
list	33059771	4102	4106	O
will	33059771	4107	4111	O
be	33059771	4112	4114	O
made	33059771	4115	4119	O
to	33059771	4120	4122	O
include	33059771	4123	4130	O
up	33059771	4131	4133	O
to	33059771	4134	4136	O
11,800	33059771	4137	4143	O
(	33059771	4144	4145	O
18	33059771	4146	4148	O
-	33059771	4149	4150	O
59	33059771	4151	4153	O
year	33059771	4154	4158	O
-	33059771	4159	4160	O
old	33059771	4161	4164	O
)	33059771	4165	4166	O
adults	33059771	4167	4173	O
,	33059771	4174	4175	O
and	33059771	4176	4179	O
1,260	33059771	4180	4185	O
elderly	33059771	4186	4193	O
(	33059771	4194	4195	O
60	33059771	4196	4198	O
y	33059771	4199	4200	O
-	33059771	4201	4202	O
o	33059771	4203	4204	O
and	33059771	4205	4208	O
older	33059771	4209	4214	O
)	33059771	4215	4216	O
participants	33059771	4217	4229	O
,	33059771	4230	4231	O
the	33059771	4232	4235	O
maximum	33059771	4236	4243	O
number	33059771	4244	4250	O
of	33059771	4251	4253	O
participants	33059771	4254	4266	O
needed	33059771	4267	4273	O
per	33059771	4274	4277	O
age	33059771	4278	4281	O
group	33059771	4282	4287	O
.	33059771	4288	4289	O

An	33059771	4290	4292	O
electronic	33059771	4293	4303	O
central	33059771	4304	4311	O
randomization	33059771	4312	4325	O
system	33059771	4326	4332	O
will	33059771	4333	4337	O
be	33059771	4338	4340	O
used	33059771	4341	4345	O
to	33059771	4346	4348	O
designate	33059771	4349	4358	O
the	33059771	4359	4362	O
investigational	33059771	4363	4378	O
product	33059771	4379	4386	O
that	33059771	4387	4391	O
each	33059771	4392	4396	O
participant	33059771	4397	4408	O
must	33059771	4409	4413	O
receive	33059771	4414	4421	O
.	33059771	4422	4423	O

UNASSIGNED	33059771	4424	4434	O
:	33059771	4435	4436	O
This	33059771	4437	4441	O
trial	33059771	4442	4447	O
is	33059771	4448	4450	O
designed	33059771	4451	4459	O
as	33059771	4460	4462	O
a	33059771	4463	4464	O
double	33059771	4465	4471	O
-	33059771	4472	4473	O
blind	33059771	4474	4479	O
study	33059771	4480	4485	O
to	33059771	4486	4488	O
avoid	33059771	4489	4494	O
introducing	33059771	4495	4506	O
bias	33059771	4507	4511	O
in	33059771	4512	4514	O
the	33059771	4515	4518	O
evaluation	33059771	4519	4529	O
of	33059771	4530	4532	O
efficacy	33059771	4533	4541	O
,	33059771	4542	4543	O
safety	33059771	4544	4550	O
and	33059771	4551	4554	O
immunogenicity	33059771	4555	4569	O
.	33059771	4570	4571	O

The	33059771	4572	4575	O
clinical	33059771	4576	4584	O
care	33059771	4585	4589	O
team	33059771	4590	4594	O
,	33059771	4595	4596	O
the	33059771	4597	4600	O
professionals	33059771	4601	4614	O
responsible	33059771	4615	4626	O
for	33059771	4627	4630	O
the	33059771	4631	4634	O
vaccination	33059771	4635	4646	O
and	33059771	4647	4650	O
the	33059771	4651	4654	O
participants	33059771	4655	4667	O
will	33059771	4668	4672	O
not	33059771	4673	4676	O
know	33059771	4677	4681	O
which	33059771	4682	4687	O
investigational	33059771	4688	4703	O
product	33059771	4704	4711	O
will	33059771	4712	4716	O
be	33059771	4717	4719	O
administered	33059771	4720	4732	O
.	33059771	4733	4734	O

Only	33059771	4735	4739	O
pharmacists	33059771	4740	4751	O
or	33059771	4752	4754	O
nurses	33059771	4755	4761	O
in	33059771	4762	4764	O
the	33059771	4765	4768	O
study	33059771	4769	4774	O
who	33059771	4775	4778	O
are	33059771	4779	4782	O
responsible	33059771	4783	4794	O
for	33059771	4795	4798	O
the	33059771	4799	4802	O
randomization	33059771	4803	4816	O
,	33059771	4817	4818	O
separation	33059771	4819	4829	O
and	33059771	4830	4833	O
blinding	33059771	4834	4842	O
of	33059771	4843	4845	O
the	33059771	4846	4849	O
investigational	33059771	4850	4865	O
product	33059771	4866	4873	O
will	33059771	4874	4878	O
have	33059771	4879	4883	O
access	33059771	4884	4890	O
to	33059771	4891	4893	O
unblinded	33059771	4894	4903	O
information	33059771	4904	4915	O
.	33059771	4916	4917	O

The	33059771	4918	4921	O
sponsor	33059771	4922	4929	O
's	33059771	4930	4932	O
operational	33059771	4933	4944	O
team	33059771	4945	4949	O
will	33059771	4950	4954	O
also	33059771	4955	4959	O
remain	33059771	4960	4966	O
blind	33059771	4967	4972	O
.	33059771	4973	4974	O

UNASSIGNED	33059771	4975	4985	O
:	33059771	4986	4987	O
The	33059771	4988	4991	O
total	33059771	4992	4997	O
number	33059771	4998	5004	O
of	33059771	5005	5007	O
participants	33059771	5008	5020	O
needed	33059771	5021	5027	O
to	33059771	5028	5030	O
evaluate	33059771	5031	5039	O
efficacy	33059771	5040	5048	O
,	33059771	5049	5050	O
13,060	33059771	5051	5057	O
participants	33059771	5058	5070	O
,	33059771	5071	5072	O
satisfies	33059771	5073	5082	O
the	33059771	5083	5086	O
needed	33059771	5087	5093	O
sample	33059771	5094	5100	O
size	33059771	5101	5105	O
calculated	33059771	5106	5116	O
to	33059771	5117	5119	O
evaluate	33059771	5120	5128	O
safety	33059771	5129	5135	O
.	33059771	5136	5137	O

Therefore	33059771	5138	5147	O
,	33059771	5148	5149	O
the	33059771	5150	5153	O
total	33059771	5154	5159	O
number	33059771	5160	5166	O
obtained	33059771	5167	5175	O
for	33059771	5176	5179	O
efficacy	33059771	5180	5188	O
will	33059771	5189	5193	O
be	33059771	5194	5196	O
the	33059771	5197	5200	O
number	33059771	5201	5207	O
retained	33059771	5208	5216	O
for	33059771	5217	5220	O
the	33059771	5221	5224	O
study	33059771	5225	5230	O
.	33059771	5231	5232	O

Up	33059771	5233	5235	O
to	33059771	5236	5238	O
13,060	33059771	5239	5245	O
participants	33059771	5246	5258	O
are	33059771	5259	5262	O
expected	33059771	5263	5271	O
to	33059771	5272	5274	O
enter	33059771	5275	5280	O
the	33059771	5281	5284	O
study	33059771	5285	5290	O
,	33059771	5291	5292	O
with	33059771	5293	5297	O
up	33059771	5298	5300	O
to	33059771	5301	5303	O
11,800	33059771	5304	5310	O
participants	33059771	5311	5323	O
aged	33059771	5324	5328	O
18	33059771	5329	5331	O
to	33059771	5332	5334	O
59	33059771	5335	5337	O
years	33059771	5338	5343	O
and	33059771	5344	5347	O
1,260	33059771	5348	5353	O
elderly	33059771	5354	5361	O
participants	33059771	5362	5374	O
aged	33059771	5375	5379	O
60	33059771	5380	5382	O
and	33059771	5383	5386	O
over	33059771	5387	5391	O
.	33059771	5392	5393	O

Half	33059771	5394	5398	O
of	33059771	5399	5401	O
the	33059771	5402	5405	O
participants	33059771	5406	5418	O
of	33059771	5419	5421	O
each	33059771	5422	5426	O
group	33059771	5427	5432	O
will	33059771	5433	5437	O
receive	33059771	5438	5445	O
the	33059771	5446	5449	O
experimental	33059771	5450	5462	O
vaccine	33059771	5463	5470	O
and	33059771	5471	5474	O
half	33059771	5475	5479	O
of	33059771	5480	5482	O
them	33059771	5483	5487	O
will	33059771	5488	5492	O
receive	33059771	5493	5500	O
the	33059771	5501	5504	O
placebo	33059771	5505	5512	O
.	33059771	5513	5514	O

The	33059771	5515	5518	O
recruitment	33059771	5519	5530	O
of	33059771	5531	5533	O
participants	33059771	5534	5546	O
may	33059771	5547	5550	O
be	33059771	5551	5553	O
modified	33059771	5554	5562	O
as	33059771	5563	5565	O
recommended	33059771	5566	5577	O
by	33059771	5578	5580	O
the	33059771	5581	5584	O
Data	33059771	5585	5589	O
Safety	33059771	5590	5596	O
Monitoring	33059771	5597	5607	O
Committee	33059771	5608	5617	O
at	33059771	5618	5620	O
time	33059771	5621	5625	O
of	33059771	5626	5628	O
the	33059771	5629	5632	O
interim	33059771	5633	5640	O
unblinded	33059771	5641	5650	O
analysis	33059771	5651	5659	O
or	33059771	5660	5662	O
blind	33059771	5663	5668	O
assessment	33059771	5669	5679	O
of	33059771	5680	5682	O
the	33059771	5683	5686	O
COVID-19	33059771	5687	5695	O
attack	33059771	5696	5702	O
rate	33059771	5703	5707	O
during	33059771	5708	5714	O
the	33059771	5715	5718	O
study	33059771	5719	5724	O
.	33059771	5725	5726	O

UNASSIGNED	33059771	5727	5737	O
:	33059771	5738	5739	O
Protocol	33059771	5740	5748	O
version	33059771	5749	5756	O
2.0	33059771	5757	5760	O
-	33059771	5761	5762	O
24-Aug-2020	33059771	5763	5774	O
.	33059771	5775	5776	O

Recruitment	33059771	5777	5788	O
started	33059771	5789	5796	O
on	33059771	5797	5799	O
July	33059771	5800	5804	O
21st	33059771	5805	5809	O
,	33059771	5810	5811	O
2020	33059771	5812	5816	O
.	33059771	5817	5818	O

The	33059771	5819	5822	O
recruitment	33059771	5823	5834	O
is	33059771	5835	5837	O
expected	33059771	5838	5846	O
to	33059771	5847	5849	O
conclude	33059771	5850	5858	O
in	33059771	5859	5861	O
October	33059771	5862	5869	O
2020	33059771	5870	5874	O
.	33059771	5875	5876	O

BACKGROUND	33059771	5877	5887	O
:	33059771	5888	5889	O
ClinicalTrials.gov	33059771	5890	5908	O
Identifier	33059771	5909	5919	O
:	33059771	5920	5921	O
NCT0445659	33059771	5922	5932	O
.	33059771	5933	5934	O

Registry	33059771	5935	5943	O
on	33059771	5944	5946	O
2	33059771	5947	5948	O
July	33059771	5949	5953	O
2020	33059771	5954	5958	O
FULL	33059771	5959	5963	O
PROTOCOL	33059771	5964	5972	O
:	33059771	5973	5974	O
The	33059771	5975	5978	O
full	33059771	5979	5983	O
protocol	33059771	5984	5992	O
is	33059771	5993	5995	O
attached	33059771	5996	6004	O
as	33059771	6005	6007	O
an	33059771	6008	6010	O
additional	33059771	6011	6021	O
file	33059771	6022	6026	O
,	33059771	6027	6028	O
accessible	33059771	6029	6039	O
from	33059771	6040	6044	O
the	33059771	6045	6048	O
Trials	33059771	6049	6055	O
website	33059771	6056	6063	O
(	33059771	6064	6065	O
Additional	33059771	6066	6076	O
file	33059771	6077	6081	O
1	33059771	6082	6083	O
)	33059771	6084	6085	O
.	33059771	6086	6087	O

In	33059771	6088	6090	O
the	33059771	6091	6094	O
interest	33059771	6095	6103	O
in	33059771	6104	6106	O
expediting	33059771	6107	6117	O
dissemination	33059771	6118	6131	O
of	33059771	6132	6134	O
this	33059771	6135	6139	O
material	33059771	6140	6148	O
,	33059771	6149	6150	O
the	33059771	6151	6154	O
familiar	33059771	6155	6163	O
formatting	33059771	6164	6174	O
has	33059771	6175	6178	O
been	33059771	6179	6183	O
eliminated	33059771	6184	6194	O
;	33059771	6195	6196	O
this	33059771	6197	6201	O
Letter	33059771	6202	6208	O
serves	33059771	6209	6215	O
as	33059771	6216	6218	O
a	33059771	6219	6220	O
summary	33059771	6221	6228	O
of	33059771	6229	6231	O
the	33059771	6232	6235	O
key	33059771	6236	6239	O
elements	33059771	6240	6248	O
of	33059771	6249	6251	O
the	33059771	6252	6255	O
full	33059771	6256	6260	O
protocol	33059771	6261	6269	O
.	33059771	6270	6271	O


Proactive	33081817	0	9	O
prophylaxis	33081817	10	21	O
with	33081817	22	26	O
azithromycin	33081817	27	39	O
and	33081817	40	43	O
hydroxychloroquine	33081817	44	62	O
in	33081817	63	65	O
hospitalized	33081817	66	78	O
patients	33081817	79	87	O
with	33081817	88	92	O
COVID-19	33081817	93	101	O
(	33081817	102	103	O
ProPAC	33081817	104	110	O
-	33081817	111	112	O
COVID	33081817	113	118	O
)	33081817	119	120	O
:	33081817	121	122	O
a	33081817	123	124	O
statistical	33081817	125	136	O
analysis	33081817	137	145	O
plan	33081817	146	150	O
.	33081817	151	152	O

BACKGROUND	33081817	153	163	O
:	33081817	164	165	O
There	33081817	166	171	O
is	33081817	172	174	O
an	33081817	175	177	O
urgent	33081817	178	184	O
need	33081817	185	189	O
for	33081817	190	193	O
treatments	33081817	194	204	O
that	33081817	205	209	O
can	33081817	210	213	O
shorten	33081817	214	221	O
hospitalization	33081817	222	237	O
and	33081817	238	241	O
lower	33081817	242	247	O
the	33081817	248	251	O
risk	33081817	252	256	O
of	33081817	257	259	O
secondary	33081817	260	269	O
infection	33081817	270	279	O
and	33081817	280	283	O
death	33081817	284	289	O
in	33081817	290	292	O
patients	33081817	293	301	O
with	33081817	302	306	O
corona	33081817	307	313	O
disease	33081817	314	321	O
.	33081817	322	323	O

The	33081817	324	327	O
ProPac	33081817	328	334	O
-	33081817	335	336	O
COVID	33081817	337	342	O
trial	33081817	343	348	O
evaluates	33081817	349	358	O
whether	33081817	359	366	O
combination	33081817	367	378	O
therapy	33081817	379	386	O
with	33081817	387	391	O
macrolide	33081817	392	401	O
azithromycin	33081817	402	414	O
and	33081817	415	418	O
hydroxychloroquine	33081817	419	437	O
via	33081817	438	441	O
anti	33081817	442	446	O
-	33081817	447	448	O
inflammation	33081817	449	461	O
/	33081817	462	463	O
immune	33081817	464	470	O
modulation	33081817	471	481	O
,	33081817	482	483	O
antiviral	33081817	484	493	O
efficacy	33081817	494	502	O
,	33081817	503	504	O
and	33081817	505	508	O
pre	33081817	509	512	O
-	33081817	513	514	O
emptive	33081817	515	522	O
treatment	33081817	523	532	O
of	33081817	533	535	O
supra	33081817	536	541	O
-	33081817	542	543	O
infections	33081817	544	554	O
can	33081817	555	558	O
shorten	33081817	559	566	O
hospitalization	33081817	567	582	O
duration	33081817	583	591	O
and	33081817	592	595	O
reduce	33081817	596	602	O
the	33081817	603	606	O
risk	33081817	607	611	O
of	33081817	612	614	O
non	33081817	615	618	O
-	33081817	619	620	O
invasive	33081817	621	629	O
ventilation	33081817	630	641	O
,	33081817	642	643	O
treatment	33081817	644	653	O
in	33081817	654	656	O
the	33081817	657	660	O
intensive	33081817	661	670	O
care	33081817	671	675	O
unit	33081817	676	680	O
,	33081817	681	682	O
and	33081817	683	686	O
death	33081817	687	692	O
in	33081817	693	695	O
patients	33081817	696	704	O
with	33081817	705	709	O
acute	33081817	710	715	O
hospital	33081817	716	724	O
admission	33081817	725	734	O
and	33081817	735	738	O
a	33081817	739	740	O
positive	33081817	741	749	O
test	33081817	750	754	O
for	33081817	755	758	O
2019-nCoV	33081817	759	768	O
and	33081817	769	772	O
symptoms	33081817	773	781	O
of	33081817	782	784	O
COVID-19	33081817	785	793	O
disease	33081817	794	801	O
.	33081817	802	803	O

METHODS	33081817	804	811	O
:	33081817	812	813	O
The	33081817	814	817	O
ProPAC	33081817	818	824	O
-	33081817	825	826	O
COVID	33081817	827	832	O
is	33081817	833	835	O
a	33081817	836	837	O
multi	33081817	838	843	O
-	33081817	844	845	O
center	33081817	846	852	O
,	33081817	853	854	O
randomized	33081817	855	865	O
,	33081817	866	867	O
placebo	33081817	868	875	O
-	33081817	876	877	O
controlled	33081817	878	888	O
,	33081817	889	890	O
double	33081817	891	897	O
-	33081817	898	899	O
blinded	33081817	900	907	O
clinical	33081817	908	916	O
trial	33081817	917	922	O
.	33081817	923	924	O

The	33081817	925	928	O
primary	33081817	929	936	O
outcome	33081817	937	944	O
is	33081817	945	947	O
number	33081817	948	954	O
of	33081817	955	957	O
days	33081817	958	962	O
spent	33081817	963	968	O
alive	33081817	969	974	O
and	33081817	975	978	O
out	33081817	979	982	O
of	33081817	983	985	O
hospital	33081817	986	994	O
within	33081817	995	1001	O
14	33081817	1002	1004	O
days	33081817	1007	1011	O
from	33081817	1012	1016	O
randomization	33081817	1017	1030	O
.	33081817	1031	1032	O

Randomization	33081817	1033	1046	O
will	33081817	1047	1051	O
be	33081817	1052	1054	O
in	33081817	1055	1057	O
blocks	33081817	1058	1064	O
of	33081817	1065	1067	O
unknown	33081817	1068	1075	O
size	33081817	1076	1080	O
,	33081817	1081	1082	O
and	33081817	1083	1086	O
the	33081817	1087	1090	O
final	33081817	1091	1096	O
allocation	33081817	1097	1107	O
will	33081817	1108	1112	O
be	33081817	1113	1115	O
stratified	33081817	1116	1126	O
for	33081817	1127	1130	O
age	33081817	1131	1134	O
,	33081817	1135	1136	O
site	33081817	1137	1141	O
of	33081817	1142	1144	O
recruitment	33081817	1145	1156	O
,	33081817	1157	1158	O
and	33081817	1159	1162	O
whether	33081817	1163	1170	O
the	33081817	1171	1174	O
patient	33081817	1175	1182	O
has	33081817	1183	1186	O
any	33081817	1187	1190	O
chronic	33081817	1191	1198	O
lung	33081817	1199	1203	O
diseases	33081817	1204	1212	O
.	33081817	1213	1214	O

Data	33081817	1215	1219	O
is	33081817	1220	1222	O
analyzed	33081817	1223	1231	O
using	33081817	1232	1237	O
intention	33081817	1238	1247	O
-	33081817	1248	1249	O
to	33081817	1250	1252	O
-	33081817	1253	1254	O
treat	33081817	1255	1260	O
(	33081817	1261	1262	O
ITT	33081817	1263	1266	O
)	33081817	1267	1268	O
principles	33081817	1269	1279	O
,	33081817	1280	1281	O
and	33081817	1282	1285	O
main	33081817	1286	1290	O
analyses	33081817	1291	1299	O
will	33081817	1300	1304	O
also	33081817	1305	1309	O
be	33081817	1310	1312	O
subject	33081817	1313	1320	O
to	33081817	1321	1323	O
modified	33081817	1324	1332	O
ITT	33081817	1333	1336	O
analysis	33081817	1337	1345	O
and	33081817	1346	1349	O
per	33081817	1350	1353	O
protocol	33081817	1354	1362	O
analysis	33081817	1363	1371	O
.	33081817	1372	1373	O

CONCLUSIONS	33081817	1374	1385	O
:	33081817	1386	1387	O
This	33081817	1388	1392	O
paper	33081817	1393	1398	O
describes	33081817	1399	1408	O
the	33081817	1409	1412	O
detailed	33081817	1413	1421	O
statistical	33081817	1422	1433	O
analysis	33081817	1434	1442	O
plan	33081817	1443	1447	O
for	33081817	1448	1451	O
the	33081817	1452	1455	O
evaluation	33081817	1456	1466	O
of	33081817	1467	1469	O
primary	33081817	1470	1477	O
and	33081817	1478	1481	O
secondary	33081817	1482	1491	O
endpoints	33081817	1492	1501	O
of	33081817	1502	1504	O
the	33081817	1505	1508	O
ProPAC	33081817	1509	1515	O
-	33081817	1516	1517	O
COVID	33081817	1518	1523	O
study	33081817	1524	1529	O
.	33081817	1530	1531	O

Enrolment	33081817	1532	1541	O
of	33081817	1542	1544	O
patients	33081817	1545	1553	O
to	33081817	1554	1556	O
the	33081817	1557	1560	O
ProPAC	33081817	1561	1567	O
-	33081817	1568	1569	O
COVID	33081817	1570	1575	O
study	33081817	1576	1581	O
is	33081817	1582	1584	O
still	33081817	1585	1590	O
ongoing	33081817	1591	1598	O
.	33081817	1599	1600	O

The	33081817	1601	1604	O
purpose	33081817	1605	1612	O
of	33081817	1613	1615	O
this	33081817	1616	1620	O
paper	33081817	1621	1626	O
is	33081817	1627	1629	O
to	33081817	1630	1632	O
provide	33081817	1633	1640	O
primary	33081817	1641	1648	O
publication	33081817	1649	1660	O
of	33081817	1661	1663	O
study	33081817	1664	1669	O
results	33081817	1670	1677	O
to	33081817	1678	1680	O
prevent	33081817	1681	1688	O
selective	33081817	1689	1698	O
reporting	33081817	1699	1708	O
of	33081817	1709	1711	O
outcomes	33081817	1712	1720	O
,	33081817	1721	1722	O
data	33081817	1723	1727	O
-	33081817	1728	1729	O
driven	33081817	1730	1736	O
analysis	33081817	1737	1745	O
,	33081817	1746	1747	O
and	33081817	1748	1751	O
to	33081817	1752	1754	O
increase	33081817	1755	1763	O
transparency	33081817	1764	1776	O
.	33081817	1777	1778	O

BACKGROUND	33081817	1779	1789	O
:	33081817	1790	1791	O
ClinicalTrials.gov	33081817	1792	1810	O
NCT04322396	33081817	1811	1822	O
.	33081817	1823	1824	O

Registered	33081817	1825	1835	O
on	33081817	1836	1838	O
26	33081817	1839	1841	O
March	33081817	1842	1847	O
2020	33081817	1848	1852	O
.	33081817	1853	1854	O


Safety	33081849	0	6	O
and	33081849	7	10	O
efficacy	33081849	11	19	O
of	33081849	20	22	O
antiviral	33081849	23	32	O
combination	33081849	33	44	O
therapy	33081849	45	52	O
in	33081849	53	55	O
symptomatic	33081849	56	67	O
patients	33081849	68	76	O
of	33081849	77	79	O
Covid-19	33081849	80	88	O
infection	33081849	89	98	O
-	33081849	99	100	O
a	33081849	101	102	O
randomised	33081849	103	113	O
controlled	33081849	114	124	O
trial	33081849	125	130	O
(	33081849	131	132	O
SEV	33081849	133	136	O
-	33081849	137	138	O
COVID	33081849	139	144	O
Trial	33081849	145	150	O
)	33081849	151	152	O
:	33081849	153	154	O
A	33081849	155	156	O
structured	33081849	157	167	O
summary	33081849	168	175	O
of	33081849	176	178	O
a	33081849	179	180	O
study	33081849	181	186	O
protocol	33081849	187	195	O
for	33081849	196	199	O
a	33081849	200	201	O
randomized	33081849	202	212	O
controlled	33081849	213	223	O
trial	33081849	224	229	O
.	33081849	230	231	O

OBJECTIVE	33081849	232	241	O
:	33081849	242	243	O
1	33081849	244	245	O
.	33081849	246	247	O

To	33081849	248	250	O
compare	33081849	251	258	O
the	33081849	259	262	O
safety	33081849	263	269	O
and	33081849	270	273	O
efficacy	33081849	274	282	O
of	33081849	283	285	O
Hydroxychloroquine	33081849	286	304	O
with	33081849	305	309	O
Ribavirin	33081849	310	319	O
and	33081849	320	323	O
standard	33081849	324	332	O
treatment	33081849	333	342	O
in	33081849	343	345	O
patients	33081849	346	354	O
with	33081849	355	359	O
non	33081849	360	363	O
-	33081849	364	365	O
severe	33081849	366	372	O
COVID-19	33081849	373	381	O
infection	33081849	382	391	O
2	33081849	392	393	O
.	33081849	394	395	O

To	33081849	396	398	O
compare	33081849	399	406	O
the	33081849	407	410	O
safety	33081849	411	417	O
and	33081849	418	421	O
efficacy	33081849	422	430	O
of	33081849	431	433	O
standard	33081849	434	442	O
treatment	33081849	443	452	O
,	33081849	453	454	O
Lopinavir	33081849	455	464	O
-	33081849	465	466	O
ritonavir	33081849	467	476	O
with	33081849	477	481	O
Ribavarin	33081849	482	491	O
,	33081849	492	493	O
and	33081849	494	497	O
Hydroxychloroquine	33081849	498	516	O
with	33081849	517	521	O
Ribavirin	33081849	522	531	O
in	33081849	532	534	O
patients	33081849	535	543	O
with	33081849	544	548	O
severe	33081849	549	555	O
COVID-19	33081849	556	564	O
infection	33081849	565	574	O
TRIAL	33081849	575	580	O
DESIGN	33081849	581	587	O
:	33081849	588	589	O
The	33081849	590	593	O
study	33081849	594	599	O
is	33081849	600	602	O
an	33081849	603	605	O
Open	33081849	606	610	O
label	33081849	611	616	O
,	33081849	617	618	O
Parallel	33081849	619	627	O
arm	33081849	628	631	O
design	33081849	632	638	O
,	33081849	639	640	O
stratified	33081849	641	651	O
randomised	33081849	652	662	O
controlled	33081849	663	673	O
trial	33081849	674	679	O
.	33081849	680	681	O

Patients	33081849	682	690	O
will	33081849	691	695	O
be	33081849	696	698	O
categorised	33081849	699	710	O
as	33081849	711	713	O
non	33081849	714	717	O
-	33081849	718	719	O
severe	33081849	720	726	O
or	33081849	727	729	O
severe	33081849	730	736	O
based	33081849	737	742	O
on	33081849	743	745	O
predefined	33081849	746	756	O
criteria	33081849	757	765	O
.	33081849	766	767	O

Those	33081849	768	773	O
who	33081849	774	777	O
satisfy	33081849	778	785	O
all	33081849	786	789	O
inclusion	33081849	790	799	O
criteria	33081849	800	808	O
and	33081849	809	812	O
no	33081849	813	815	O
exclusion	33081849	816	825	O
criteria	33081849	826	834	O
in	33081849	835	837	O
the	33081849	838	841	O
respective	33081849	842	852	O
categories	33081849	853	863	O
,	33081849	864	865	O
will	33081849	866	870	O
be	33081849	871	873	O
randomly	33081849	874	882	O
assigned	33081849	883	891	O
to	33081849	892	894	O
one	33081849	895	898	O
of	33081849	899	901	O
the	33081849	902	905	O
three	33081849	906	911	O
treatment	33081849	912	921	O
groups	33081849	922	928	O
in	33081849	929	931	O
a	33081849	932	933	O
ratio	33081849	934	939	O
of	33081849	940	942	O
1:1	33081849	943	946	O
in	33081849	947	949	O
the	33081849	950	953	O
non	33081849	954	957	O
-	33081849	958	959	O
severe	33081849	960	966	O
category	33081849	967	975	O
and	33081849	976	979	O
1:1:1	33081849	980	985	O
in	33081849	986	988	O
the	33081849	989	992	O
severe	33081849	993	999	O
category	33081849	1000	1008	O
.	33081849	1009	1010	O

METHODS	33081849	1011	1018	O
:	33081849	1019	1020	O
The	33081849	1021	1024	O
trial	33081849	1025	1030	O
will	33081849	1031	1035	O
be	33081849	1036	1038	O
undertaken	33081849	1039	1049	O
in	33081849	1050	1052	O
a	33081849	1053	1054	O
tertiary	33081849	1055	1063	O
care	33081849	1064	1068	O
center	33081849	1069	1075	O
of	33081849	1076	1078	O
the	33081849	1079	1082	O
country	33081849	1083	1090	O
where	33081849	1091	1096	O
both	33081849	1097	1101	O
Covid	33081849	1102	1107	O
and	33081849	1108	1111	O
non	33081849	1112	1115	O
-	33081849	1116	1117	O
Covid	33081849	1118	1123	O
patients	33081849	1124	1132	O
are	33081849	1133	1136	O
getting	33081849	1137	1144	O
treated	33081849	1145	1152	O
.	33081849	1153	1154	O

All	33081849	1155	1158	O
patients	33081849	1159	1167	O
who	33081849	1168	1171	O
are	33081849	1172	1175	O
confirmed	33081849	1176	1185	O
positive	33081849	1186	1194	O
and	33081849	1195	1198	O
admitted	33081849	1199	1207	O
will	33081849	1208	1212	O
be	33081849	1213	1215	O
screened	33081849	1216	1224	O
for	33081849	1225	1228	O
the	33081849	1229	1232	O
eligibility	33081849	1233	1244	O
criteria	33081849	1245	1253	O
and	33081849	1254	1257	O
will	33081849	1258	1262	O
be	33081849	1263	1265	O
enrolled	33081849	1266	1274	O
in	33081849	1275	1277	O
the	33081849	1278	1281	O
study	33081849	1282	1287	O
after	33081849	1288	1293	O
a	33081849	1294	1295	O
written	33081849	1296	1303	O
informed	33081849	1304	1312	O
consent	33081849	1313	1320	O
.	33081849	1321	1322	O

Patients	33081849	1323	1331	O
will	33081849	1332	1336	O
be	33081849	1337	1339	O
categorised	33081849	1340	1351	O
as	33081849	1352	1354	O
non	33081849	1355	1358	O
-	33081849	1359	1360	O
severe	33081849	1361	1367	O
or	33081849	1368	1370	O
severe	33081849	1371	1377	O
based	33081849	1378	1383	O
on	33081849	1384	1386	O
predefined	33081849	1387	1397	O
criteria	33081849	1398	1406	O
.	33081849	1407	1408	O

UNASSIGNED	33081849	1409	1419	O
:	33081849	1420	1421	O
1	33081849	1422	1423	O
.	33081849	1424	1425	O
Age	33081849	1426	1429	O
	33081849	1432	1433	O
18	33081849	1434	1436	O
years	33081849	1437	1442	O
at	33081849	1443	1445	O
time	33081849	1446	1450	O
of	33081849	1451	1453	O
participation	33081849	1454	1467	O
in	33081849	1468	1470	O
the	33081849	1471	1474	O
study	33081849	1475	1480	O
2	33081849	1481	1482	O
.	33081849	1483	1484	O

Laboratory	33081849	1485	1495	O
(	33081849	1496	1497	O
RT	33081849	1498	1500	O
-	33081849	1501	1502	O
PCR	33081849	1503	1506	O
)	33081849	1507	1508	O
confirmed	33081849	1509	1518	O
infection	33081849	1519	1528	O
with	33081849	1529	1533	O
SARS	33081849	1534	1538	O
-	33081849	1539	1540	O
CoV-2	33081849	1541	1546	O
3	33081849	1547	1548	O
.	33081849	1549	1550	O

Symptomatic	33081849	1551	1562	O
(	33081849	1563	1564	O
severe	33081849	1565	1571	O
or	33081849	1572	1574	O
non	33081849	1575	1578	O
-	33081849	1579	1580	O
severe	33081849	1581	1587	O
)	33081849	1588	1589	O
Covid-19	33081849	1590	1598	O
disease	33081849	1599	1606	O
4	33081849	1607	1608	O
.	33081849	1609	1610	O

Willingness	33081849	1611	1622	O
of	33081849	1623	1625	O
study	33081849	1626	1631	O
participant	33081849	1632	1643	O
to	33081849	1644	1646	O
accept	33081849	1647	1653	O
randomization	33081849	1654	1667	O
to	33081849	1668	1670	O
any	33081849	1671	1674	O
assigned	33081849	1675	1683	O
treatment	33081849	1684	1693	O
arm	33081849	1694	1697	O
EXCLUSION	33081849	1698	1707	O
CRITERIA	33081849	1708	1716	O
:	33081849	1717	1718	O
1	33081849	1719	1720	O
.	33081849	1721	1722	O

Use	33081849	1723	1726	O
of	33081849	1727	1729	O
medications	33081849	1730	1741	O
that	33081849	1742	1746	O
are	33081849	1747	1750	O
contraindicated	33081849	1751	1766	O
with	33081849	1767	1771	O
Lopinavir	33081849	1772	1781	O
/	33081849	1782	1783	O
Ritonavir	33081849	1784	1793	O
,	33081849	1794	1795	O
Hydroxychloroquine	33081849	1796	1814	O
/	33081849	1815	1816	O
Chloroquine	33081849	1817	1828	O
,	33081849	1829	1830	O
or	33081849	1831	1833	O
Ribavirin	33081849	1834	1843	O
and	33081849	1844	1847	O
that	33081849	1848	1852	O
can	33081849	1853	1856	O
not	33081849	1857	1860	O
be	33081849	1861	1863	O
replaced	33081849	1864	1872	O
or	33081849	1873	1875	O
stopped	33081849	1876	1883	O
2	33081849	1884	1885	O
.	33081849	1886	1887	O

Patient	33081849	1888	1895	O
already	33081849	1896	1903	O
on	33081849	1904	1906	O
antiretroviral	33081849	1907	1921	O
therapy	33081849	1922	1929	O
with	33081849	1930	1934	O
Lopinavir	33081849	1935	1944	O
-	33081849	1945	1946	O
Ritonavir	33081849	1947	1956	O
based	33081849	1957	1962	O
regimen	33081849	1963	1970	O
or	33081849	1971	1973	O
on	33081849	1974	1976	O
Hydroxychloroquine	33081849	1977	1995	O
/	33081849	1996	1997	O
Chloroquine	33081849	1998	2009	O
or	33081849	2010	2012	O
on	33081849	2013	2015	O
Ribavirin	33081849	2016	2025	O
3	33081849	2026	2027	O
.	33081849	2028	2029	O

Any	33081849	2030	2033	O
known	33081849	2034	2039	O
contraindication	33081849	2040	2056	O
to	33081849	2057	2059	O
test	33081849	2060	2064	O
drugs	33081849	2065	2070	O
such	33081849	2071	2075	O
as	33081849	2076	2078	O
retinopathy	33081849	2079	2090	O
and	33081849	2091	2094	O
QT	33081849	2095	2097	O
prolongation	33081849	2098	2110	O
4	33081849	2111	2112	O
.	33081849	2113	2114	O

Known	33081849	2115	2120	O
allergic	33081849	2121	2129	O
reaction	33081849	2130	2138	O
or	33081849	2139	2141	O
inability	33081849	2142	2151	O
to	33081849	2152	2154	O
take	33081849	2155	2159	O
orally	33081849	2160	2166	O
of	33081849	2167	2169	O
Lopinavir	33081849	2170	2179	O
-	33081849	2180	2181	O
ritonavir	33081849	2182	2191	O
,	33081849	2192	2193	O
Hydroxychloroquine/	33081849	2194	2213	O
Chloroquine	33081849	2214	2225	O
,	33081849	2226	2227	O
Ribavarin	33081849	2228	2237	O
5	33081849	2238	2239	O
.	33081849	2240	2241	O

Pregnant	33081849	2242	2250	O
or	33081849	2251	2253	O
breastfeeding	33081849	2254	2267	O
females	33081849	2268	2275	O
6	33081849	2276	2277	O
.	33081849	2278	2279	O

Receipt	33081849	2280	2287	O
of	33081849	2288	2290	O
any	33081849	2291	2294	O
experimental	33081849	2295	2307	O
treatment	33081849	2308	2317	O
for	33081849	2318	2321	O
2019-nCoV	33081849	2322	2331	O
(	33081849	2332	2333	O
off	33081849	2334	2337	O
-	33081849	2338	2339	O
label	33081849	2340	2345	O
,	33081849	2346	2347	O
compassionate	33081849	2348	2361	O
use	33081849	2362	2365	O
,	33081849	2366	2367	O
or	33081849	2368	2370	O
trial	33081849	2371	2376	O
related	33081849	2377	2384	O
)	33081849	2385	2386	O
within	33081849	2387	2393	O
30	33081849	2394	2396	O
days	33081849	2397	2401	O
prior	33081849	2402	2407	O
to	33081849	2408	2410	O
participation	33081849	2411	2424	O
in	33081849	2425	2427	O
the	33081849	2428	2431	O
present	33081849	2432	2439	O
study	33081849	2440	2445	O
or	33081849	2446	2448	O
want	33081849	2449	2453	O
to	33081849	2454	2456	O
participate	33081849	2457	2468	O
after	33081849	2469	2474	O
enrolment	33081849	2475	2484	O
INTERVENTION	33081849	2485	2497	O
AND	33081849	2498	2501	O
COMPARATOR	33081849	2502	2512	O
:	33081849	2513	2514	O
Two	33081849	2515	2518	O
therapeutic	33081849	2519	2530	O
interventions	33081849	2531	2544	O
for	33081849	2545	2548	O
non	33081849	2549	2552	O
-	33081849	2553	2554	O
severe	33081849	2555	2561	O
category	33081849	2562	2570	O
and	33081849	2571	2574	O
three	33081849	2575	2580	O
for	33081849	2581	2584	O
severe	33081849	2585	2591	O
category	33081849	2592	2600	O
as	33081849	2601	2603	O
described	33081849	2604	2613	O
below	33081849	2614	2619	O
NON	33081849	2620	2623	O
-	33081849	2624	2625	O
SEVERE	33081849	2626	2632	O
TREATMENT	33081849	2633	2642	O
ARMS	33081849	2643	2647	O
(	33081849	2648	2649	O
NS	33081849	2650	2652	O
-	33081849	2653	2654	O
GROUP	33081849	2655	2660	O
)	33081849	2661	2662	O
:	33081849	2663	2664	O
Treatment	33081849	2665	2674	O
Arm	33081849	2675	2678	O
Drug	33081849	2679	2683	O
A	33081849	2684	2685	O
Standard	33081849	2686	2694	O
Treatment	33081849	2695	2704	O
(	33081849	2705	2706	O
STNS	33081849	2707	2711	O
)	33081849	2712	2713	O
B	33081849	2714	2715	O
Hydroxychloroquine	33081849	2716	2734	O
400	33081849	2735	2738	O
mg	33081849	2739	2741	O
twice	33081849	2742	2747	O
on	33081849	2748	2750	O
first	33081849	2751	2756	O
day	33081849	2757	2760	O
followed	33081849	2761	2769	O
by	33081849	2770	2772	O
400	33081849	2773	2776	O
mg	33081849	2777	2779	O
per	33081849	2780	2783	O
oral	33081849	2784	2788	O
daily	33081849	2789	2794	O
for	33081849	2795	2798	O
10	33081849	2799	2801	O
days	33081849	2802	2806	O
+	33081849	2807	2808	O
Ribavirin	33081849	2809	2818	O
(	33081849	2819	2820	O
1.2	33081849	2821	2824	O
g	33081849	2825	2826	O
orally	33081849	2827	2833	O
as	33081849	2834	2836	O
a	33081849	2837	2838	O
loading	33081849	2839	2846	O
dose	33081849	2847	2851	O
followed	33081849	2852	2860	O
by	33081849	2861	2863	O
600	33081849	2864	2867	O
mg	33081849	2868	2870	O
orally	33081849	2871	2877	O
every	33081849	2878	2883	O
12	33081849	2884	2886	O
hours	33081849	2887	2892	O
)	33081849	2893	2894	O
for	33081849	2895	2898	O
10	33081849	2899	2901	O
days	33081849	2902	2906	O
+	33081849	2907	2908	O
Standard	33081849	2909	2917	O
Treatment	33081849	2918	2927	O
(	33081849	2928	2929	O
STNS	33081849	2930	2934	O
)	33081849	2935	2936	O
Standard	33081849	2937	2945	O
Treatment	33081849	2946	2955	O
for	33081849	2956	2959	O
non	33081849	2960	2963	O
-	33081849	2964	2965	O
severe	33081849	2966	2972	O
cases	33081849	2973	2978	O
(	33081849	2979	2980	O
STNS	33081849	2981	2985	O
)	33081849	2986	2987	O
:	33081849	2988	2989	O
Strict	33081849	2990	2996	O
Isolation	33081849	2997	3006	O
,	33081849	3007	3008	O
Standard	33081849	3009	3017	O
Precautions	33081849	3018	3029	O
(	33081849	3030	3031	O
Hand	33081849	3032	3036	O
hygiene	33081849	3037	3044	O
,	33081849	3045	3046	O
Cough	33081849	3047	3052	O
Etiquette	33081849	3053	3062	O
,	33081849	3063	3064	O
Wear	33081849	3065	3069	O
surgical	33081849	3070	3078	O
mask	33081849	3079	3083	O
)	33081849	3084	3085	O
,	33081849	3086	3087	O
Hydration	33081849	3088	3097	O
,	33081849	3098	3099	O
Proper	33081849	3100	3106	O
Nutrition	33081849	3107	3116	O
,	33081849	3117	3118	O
Supportive	33081849	3119	3129	O
Pharmacotherapy	33081849	3130	3145	O
(	33081849	3146	3147	O
Antipyretic	33081849	3148	3159	O
,	33081849	3160	3161	O
Antiallergic	33081849	3162	3174	O
,	33081849	3175	3176	O
Cough	33081849	3177	3182	O
Suppressant	33081849	3183	3194	O
)	33081849	3195	3196	O
,	33081849	3197	3198	O
Treatment	33081849	3199	3208	O
of	33081849	3209	3211	O
Comorbid	33081849	3212	3220	O
Diseases	33081849	3221	3229	O
,	33081849	3230	3231	O
Oseltamivir	33081849	3232	3243	O
(	33081849	3244	3245	O
75	33081849	3246	3248	O
mg	33081849	3249	3251	O
BD	33081849	3252	3254	O
)	33081849	3255	3256	O
for	33081849	3257	3260	O
patients	33081849	3261	3269	O
who	33081849	3270	3273	O
are	33081849	3274	3277	O
tested	33081849	3278	3284	O
positive	33081849	3285	3293	O
for	33081849	3294	3297	O
H1N1	33081849	3298	3302	O
.	33081849	3303	3304	O

UNASSIGNED	33081849	3305	3315	O
:	33081849	3316	3317	O
Treatment	33081849	3318	3327	O
Arm	33081849	3328	3331	O
Drug	33081849	3332	3336	O
A	33081849	3337	3338	O
Standard	33081849	3339	3347	O
Treatment	33081849	3348	3357	O
(	33081849	3358	3359	O
STs	33081849	3360	3363	O
)	33081849	3364	3365	O
B	33081849	3366	3367	O
Hydroxychloroquine	33081849	3368	3386	O
400	33081849	3387	3390	O
mg	33081849	3391	3393	O
BD	33081849	3394	3396	O
on	33081849	3397	3399	O
day1	33081849	3400	3404	O
followed	33081849	3405	3413	O
by	33081849	3414	3416	O
400	33081849	3417	3420	O
mg	33081849	3421	3423	O
once	33081849	3424	3428	O
daily	33081849	3429	3434	O
+	33081849	3435	3436	O
Ribavirin	33081849	3437	3446	O
(	33081849	3447	3448	O
1.2	33081849	3449	3452	O
g	33081849	3453	3454	O
orally	33081849	3455	3461	O
as	33081849	3462	3464	O
a	33081849	3465	3466	O
loading	33081849	3467	3474	O
dose	33081849	3475	3479	O
followed	33081849	3480	3488	O
by	33081849	3489	3491	O
600	33081849	3492	3495	O
mg	33081849	3496	3498	O
orally	33081849	3499	3505	O
every	33081849	3506	3511	O
12	33081849	3512	3514	O
hours	33081849	3515	3520	O
)	33081849	3521	3522	O
for	33081849	3523	3526	O
10	33081849	3527	3529	O
days	33081849	3530	3534	O
+	33081849	3535	3536	O
Standard	33081849	3537	3545	O
Treatment	33081849	3546	3555	O
(	33081849	3556	3557	O
STs	33081849	3558	3561	O
)	33081849	3562	3563	O
C	33081849	3564	3565	O
Lopinavir(200	33081849	3566	3579	O
mg	33081849	3580	3582	O
)	33081849	3583	3584	O
+	33081849	3585	3586	O
Ritonavir	33081849	3587	3596	O
(	33081849	3597	3598	O
50	33081849	3599	3601	O
mg	33081849	3602	3604	O
)	33081849	3605	3606	O
two	33081849	3607	3610	O
tablets	33081849	3611	3618	O
twice	33081849	3619	3624	O
daily+	33081849	3625	3631	O
Ribavirin	33081849	3632	3641	O
(	33081849	3642	3643	O
1.2	33081849	3644	3647	O
g	33081849	3648	3649	O
orally	33081849	3650	3656	O
as	33081849	3657	3659	O
a	33081849	3660	3661	O
loading	33081849	3662	3669	O
dose	33081849	3670	3674	O
followed	33081849	3675	3683	O
by	33081849	3684	3686	O
600	33081849	3687	3690	O
mg	33081849	3691	3693	O
orally	33081849	3694	3700	O
every	33081849	3701	3706	O
12	33081849	3707	3709	O
hours	33081849	3710	3715	O
)	33081849	3716	3717	O
for	33081849	3718	3721	O
10	33081849	3722	3724	O
days	33081849	3725	3729	O
+	33081849	3730	3731	O
Standard	33081849	3732	3740	O
Treatment	33081849	3741	3750	O
(	33081849	3751	3752	O
STs)6	33081849	3753	3758	O
Standard	33081849	3759	3767	O
Treatment	33081849	3768	3777	O
for	33081849	3778	3781	O
severe	33081849	3782	3788	O
patients	33081849	3789	3797	O
(	33081849	3798	3799	O
STs	33081849	3800	3803	O
)	33081849	3804	3805	O
:	33081849	3806	3807	O
Strict	33081849	3808	3814	O
Isolation	33081849	3815	3824	O
,	33081849	3825	3826	O
Standard	33081849	3827	3835	O
Precautions	33081849	3836	3847	O
(	33081849	3848	3849	O
Hand	33081849	3850	3854	O
hygiene	33081849	3855	3862	O
,	33081849	3863	3864	O
Cough	33081849	3865	3870	O
Etiquette	33081849	3871	3880	O
,	33081849	3881	3882	O
Wear	33081849	3883	3887	O
surgical	33081849	3888	3896	O
mask	33081849	3897	3901	O
)	33081849	3902	3903	O
,	33081849	3904	3905	O
Fluid	33081849	3906	3911	O
Therapy	33081849	3912	3919	O
,	33081849	3920	3921	O
Supportive	33081849	3922	3932	O
Pharmacotherapy	33081849	3933	3948	O
(	33081849	3949	3950	O
Antipyretic	33081849	3951	3962	O
,	33081849	3963	3964	O
Antiallergic	33081849	3965	3977	O
,	33081849	3978	3979	O
Cough	33081849	3980	3985	O
Suppressant	33081849	3986	3997	O
)	33081849	3998	3999	O
,	33081849	4000	4001	O
Oxygen	33081849	4002	4008	O
supplementation	33081849	4009	4024	O
(	33081849	4025	4026	O
As	33081849	4027	4029	O
required	33081849	4030	4038	O
)	33081849	4039	4040	O
,	33081849	4041	4042	O
Invasive	33081849	4043	4051	O
ventilation	33081849	4052	4063	O
(	33081849	4064	4065	O
As	33081849	4066	4068	O
required	33081849	4069	4077	O
)	33081849	4078	4079	O
,	33081849	4080	4081	O
Antibiotic	33081849	4082	4092	O
agents	33081849	4093	4099	O
for	33081849	4100	4103	O
other	33081849	4104	4109	O
associated	33081849	4110	4120	O
infections	33081849	4121	4131	O
(	33081849	4132	4133	O
according	33081849	4134	4143	O
to	33081849	4144	4146	O
2019	33081849	4147	4151	O
ATS	33081849	4152	4155	O
/	33081849	4156	4157	O
IDSA	33081849	4158	4162	O
guidelines	33081849	4163	4173	O
for	33081849	4174	4177	O
non	33081849	4178	4181	O
-	33081849	4182	4183	O
ICU	33081849	4184	4187	O
and	33081849	4188	4191	O
ICU	33081849	4192	4195	O
patients	33081849	4196	4204	O
)	33081849	4205	4206	O
,	33081849	4207	4208	O
Vasopressor	33081849	4209	4220	O
support	33081849	4221	4228	O
,	33081849	4229	4230	O
Renal	33081849	4231	4236	O
-	33081849	4237	4238	O
replacement	33081849	4239	4250	O
therapy	33081849	4251	4258	O
,	33081849	4259	4260	O
Treatment	33081849	4261	4270	O
of	33081849	4271	4273	O
Comorbid	33081849	4274	4282	O
Diseases	33081849	4283	4291	O
,	33081849	4292	4293	O
Oseltamivir	33081849	4294	4305	O
(	33081849	4306	4307	O
75	33081849	4308	4310	O
mg	33081849	4311	4313	O
BD	33081849	4314	4316	O
)	33081849	4317	4318	O
for	33081849	4319	4322	O
patients	33081849	4323	4331	O
who	33081849	4332	4335	O
are	33081849	4336	4339	O
tested	33081849	4340	4346	O
positive	33081849	4347	4355	O
for	33081849	4356	4359	O
H1N1	33081849	4360	4364	O
.	33081849	4365	4366	O

RESULTS	33081849	4367	4374	O
:	33081849	4375	4376	O
Primary	33081849	4377	4384	O
endpoints	33081849	4385	4394	O
:	33081849	4395	4396	O
(	33081849	4397	4398	O
1	33081849	4399	4400	O
)	33081849	4401	4402	O
Time	33081849	4403	4407	O
to	33081849	4408	4410	O
Clinical	33081849	4411	4419	O
recovery	33081849	4420	4428	O
(	33081849	4429	4430	O
TTCR	33081849	4431	4435	O
)	33081849	4436	4437	O
defined	33081849	4438	4445	O
as	33081849	4446	4448	O
the	33081849	4449	4452	O
time	33081849	4453	4457	O
(	33081849	4458	4459	O
in	33081849	4460	4462	O
hours	33081849	4463	4468	O
)	33081849	4469	4470	O
from	33081849	4471	4475	O
initiation	33081849	4476	4486	O
of	33081849	4487	4489	O
study	33081849	4490	4495	O
treatment	33081849	4496	4505	O
(	33081849	4506	4507	O
active	33081849	4508	4514	O
or	33081849	4515	4517	O
placebo	33081849	4518	4525	O
)	33081849	4526	4527	O
until	33081849	4528	4533	O
normalisation	33081849	4534	4547	O
of	33081849	4548	4550	O
fever	33081849	4551	4556	O
,	33081849	4557	4558	O
respiratory	33081849	4559	4570	O
rate	33081849	4571	4575	O
,	33081849	4576	4577	O
oxygen	33081849	4578	4584	O
saturation	33081849	4585	4595	O
,	33081849	4596	4597	O
and	33081849	4598	4601	O
alleviation	33081849	4602	4613	O
of	33081849	4614	4616	O
cough	33081849	4617	4622	O
,	33081849	4623	4624	O
sustained	33081849	4625	4634	O
for	33081849	4635	4638	O
at	33081849	4639	4641	O
least	33081849	4642	4647	O
72	33081849	4648	4650	O
hours	33081849	4651	4656	O
.	33081849	4657	4658	O

(	33081849	4659	4660	O
2	33081849	4661	4662	O
)	33081849	4663	4664	O
Time	33081849	4665	4669	O
to	33081849	4670	4672	O
SARS	33081849	4673	4677	O
-	33081849	4678	4679	O
CoV-2	33081849	4680	4685	O
RT	33081849	4686	4688	O
-	33081849	4689	4690	O
PCR	33081849	4691	4694	O
negative	33081849	4695	4703	O
in	33081849	4704	4706	O
upper	33081849	4707	4712	O
respiratory	33081849	4713	4724	O
tract	33081849	4725	4730	O
specimen	33081849	4731	4739	O
,	33081849	4740	4741	O
time	33081849	4742	4746	O
to	33081849	4747	4749	O
laboratory	33081849	4750	4760	O
recovery	33081849	4761	4769	O
of	33081849	4770	4772	O
each	33081849	4773	4777	O
organ	33081849	4778	4783	O
involvement	33081849	4784	4795	O
.	33081849	4796	4797	O

Secondary	33081849	4798	4807	O
Endpoints	33081849	4808	4817	O
:	33081849	4818	4819	O
All	33081849	4820	4823	O
causes	33081849	4824	4830	O
mortality	33081849	4831	4840	O
,	33081849	4841	4842	O
Frequency	33081849	4843	4852	O
of	33081849	4853	4855	O
respiratory	33081849	4856	4867	O
progression	33081849	4868	4879	O
(	33081849	4880	4881	O
defined	33081849	4882	4889	O
as	33081849	4890	4892	O
SPO2	33081849	4893	4897	O
	33081849	4898	4899	O
94	33081849	4902	4904	O
%	33081849	4905	4906	O
on	33081849	4907	4909	O
room	33081849	4910	4914	O
air	33081849	4915	4918	O
or	33081849	4919	4921	O
PaO2	33081849	4922	4926	O
/	33081849	4927	4928	O
FiO2	33081849	4929	4933	O
<	33081849	4934	4935	O
300mmHg	33081849	4936	4943	O
and	33081849	4944	4947	O
requirement	33081849	4948	4959	O
for	33081849	4960	4963	O
supplemental	33081849	4964	4976	O
oxygen	33081849	4977	4983	O
or	33081849	4984	4986	O
more	33081849	4987	4991	O
advanced	33081849	4992	5000	O
ventilator	33081849	5001	5011	O
support	33081849	5012	5019	O
)	33081849	5020	5021	O
,	33081849	5022	5023	O
time	33081849	5024	5028	O
to	33081849	5029	5031	O
defervescence	33081849	5032	5045	O
(	33081849	5046	5047	O
in	33081849	5048	5050	O
those	33081849	5051	5056	O
with	33081849	5057	5061	O
fever	33081849	5062	5067	O
at	33081849	5068	5070	O
enrolment	33081849	5071	5080	O
)	33081849	5081	5082	O
,	33081849	5083	5084	O
frequency	33081849	5085	5094	O
of	33081849	5095	5097	O
requirement	33081849	5098	5109	O
for	33081849	5110	5113	O
supplemental	33081849	5114	5126	O
oxygen	33081849	5127	5133	O
or	33081849	5134	5136	O
non	33081849	5137	5140	O
-	33081849	5141	5142	O
invasive	33081849	5143	5151	O
ventilation	33081849	5152	5163	O
,	33081849	5164	5165	O
frequency	33081849	5166	5175	O
of	33081849	5176	5178	O
requirement	33081849	5179	5190	O
for	33081849	5191	5194	O
mechanical	33081849	5195	5205	O
ventilation	33081849	5206	5217	O
,	33081849	5218	5219	O
frequency	33081849	5220	5229	O
of	33081849	5230	5232	O
serious	33081849	5233	5240	O
adverse	33081849	5241	5248	O
events	33081849	5249	5255	O
as	33081849	5256	5258	O
per	33081849	5259	5262	O
DAIDS	33081849	5263	5268	O
table	33081849	5269	5274	O
grade	33081849	5275	5280	O
of	33081849	5281	5283	O
severity	33081849	5284	5292	O
.	33081849	5293	5294	O

Outcomes	33081849	5295	5303	O
are	33081849	5304	5307	O
monitored	33081849	5308	5317	O
for	33081849	5318	5321	O
28	33081849	5322	5324	O
days	33081849	5325	5329	O
from	33081849	5330	5334	O
the	33081849	5335	5338	O
time	33081849	5339	5343	O
of	33081849	5344	5346	O
enrolment	33081849	5347	5356	O
into	33081849	5357	5361	O
the	33081849	5362	5365	O
study	33081849	5366	5371	O
OR	33081849	5372	5374	O
until	33081849	5375	5380	O
the	33081849	5381	5384	O
patient	33081849	5385	5392	O
is	33081849	5393	5395	O
discharged	33081849	5396	5406	O
or	33081849	5407	5409	O
death	33081849	5410	5415	O
whichever	33081849	5416	5425	O
is	33081849	5426	5428	O
longer	33081849	5429	5435	O
.	33081849	5436	5437	O

UNASSIGNED	33081849	5438	5448	O
:	33081849	5449	5450	O
The	33081849	5451	5454	O
randomization	33081849	5455	5468	O
will	33081849	5469	5473	O
be	33081849	5474	5476	O
done	33081849	5477	5481	O
using	33081849	5482	5487	O
a	33081849	5488	5489	O
secured	33081849	5490	5497	O
central	33081849	5498	5505	O
computer	33081849	5506	5514	O
-	33081849	5515	5516	O
based	33081849	5517	5522	O
randomization	33081849	5523	5536	O
using	33081849	5537	5542	O
a	33081849	5543	5544	O
secure	33081849	5545	5551	O
website	33081849	5552	5559	O
using	33081849	5560	5565	O
a	33081849	5566	5567	O
central	33081849	5568	5575	O
,	33081849	5576	5577	O
computer	33081849	5578	5586	O
-	33081849	5587	5588	O
based	33081849	5589	5594	O
randomisation	33081849	5595	5608	O
program	33081849	5609	5616	O
in	33081849	5617	5619	O
a	33081849	5620	5621	O
ratio	33081849	5622	5627	O
of	33081849	5628	5630	O
1:1	33081849	5631	5634	O
in	33081849	5635	5637	O
the	33081849	5638	5641	O
non	33081849	5642	5645	O
-	33081849	5646	5647	O
severe	33081849	5648	5654	O
category	33081849	5655	5663	O
and	33081849	5664	5667	O
1:1:1	33081849	5668	5673	O
in	33081849	5674	5676	O
the	33081849	5677	5680	O
severe	33081849	5681	5687	O
category	33081849	5688	5696	O
.	33081849	5697	5698	O

UNASSIGNED	33081849	5699	5709	O
:	33081849	5710	5711	O
This	33081849	5712	5716	O
is	33081849	5717	5719	O
an	33081849	5720	5722	O
open	33081849	5723	5727	O
labelled	33081849	5728	5736	O
study	33081849	5737	5742	O
i.e.	33081849	5743	5747	O
Study	33081849	5748	5753	O
assigned	33081849	5754	5762	O
treatment	33081849	5763	5772	O
will	33081849	5773	5777	O
be	33081849	5778	5780	O
known	33081849	5781	5786	O
to	33081849	5787	5789	O
the	33081849	5790	5793	O
research	33081849	5794	5802	O
team	33081849	5803	5807	O
,	33081849	5808	5809	O
the	33081849	5810	5813	O
investigators	33081849	5814	5827	O
and	33081849	5828	5831	O
participants	33081849	5832	5844	O
.	33081849	5845	5846	O

UNASSIGNED	33081849	5847	5857	O
:	33081849	5858	5859	O
Since	33081849	5860	5865	O
it	33081849	5866	5868	O
is	33081849	5869	5871	O
an	33081849	5872	5874	O
exploratory	33081849	5875	5886	O
trial	33081849	5887	5892	O
as	33081849	5893	5895	O
COVID-19	33081849	5896	5904	O
being	33081849	5905	5910	O
a	33081849	5911	5912	O
new	33081849	5913	5916	O
disease	33081849	5917	5924	O
,	33081849	5925	5926	O
all	33081849	5927	5930	O
patients	33081849	5931	5939	O
who	33081849	5940	5943	O
came	33081849	5944	5948	O
under	33081849	5949	5954	O
the	33081849	5955	5958	O
purview	33081849	5959	5966	O
of	33081849	5967	5969	O
the	33081849	5970	5973	O
inclusion	33081849	5974	5983	O
criteria	33081849	5984	5992	O
within	33081849	5993	5999	O
the	33081849	6000	6003	O
study	33081849	6004	6009	O
period	33081849	6010	6016	O
(	33081849	6017	6018	O
5	33081849	6019	6020	O
months	33081849	6021	6027	O
duration	33081849	6028	6036	O
of	33081849	6037	6039	O
the	33081849	6040	6043	O
recruitment	33081849	6044	6055	O
period	33081849	6056	6062	O
of	33081849	6063	6065	O
the	33081849	6066	6069	O
total	33081849	6070	6075	O
6	33081849	6076	6077	O
months	33081849	6078	6084	O
duration	33081849	6085	6093	O
of	33081849	6094	6096	O
the	33081849	6097	6100	O
study	33081849	6101	6106	O
i.e.	33081849	6107	6111	O
from	33081849	6112	6116	O
the	33081849	6117	6120	O
month	33081849	6121	6126	O
of	33081849	6127	6129	O
June	33081849	6130	6134	O
,	33081849	6135	6136	O
2020	33081849	6137	6141	O
to	33081849	6142	6144	O
October	33081849	6145	6152	O
2020	33081849	6153	6157	O
)	33081849	6158	6159	O
and	33081849	6160	6163	O
who	33081849	6164	6167	O
have	33081849	6168	6172	O
consented	33081849	6173	6182	O
for	33081849	6183	6186	O
the	33081849	6187	6190	O
study	33081849	6191	6196	O
will	33081849	6197	6201	O
be	33081849	6202	6204	O
included	33081849	6205	6213	O
.	33081849	6214	6215	O

UNASSIGNED	33081849	6216	6226	O
:	33081849	6227	6228	O
Protocol	33081849	6229	6237	O
version:1.0	33081849	6238	6249	O
Recruitment	33081849	6250	6261	O
start	33081849	6262	6267	O
:	33081849	6268	6269	O
June	33081849	6270	6274	O
3rd	33081849	6275	6278	O
,	33081849	6279	6280	O
2020	33081849	6281	6285	O
(	33081849	6286	6287	O
Ongoing	33081849	6288	6295	O
)	33081849	6296	6297	O
Recruitment	33081849	6298	6309	O
finish	33081849	6310	6316	O
(	33081849	6317	6318	O
expected	33081849	6319	6327	O
)	33081849	6328	6329	O
:	33081849	6330	6331	O
October	33081849	6332	6339	O
31st	33081849	6340	6344	O
,	33081849	6345	6346	O
2020	33081849	6347	6351	O
TRIAL	33081849	6352	6357	O
REGISTRATION	33081849	6358	6370	O
:	33081849	6371	6372	O
Clinical	33081849	6373	6381	O
Trial	33081849	6382	6387	O
Registry	33081849	6388	6396	O
of	33081849	6397	6399	O
India	33081849	6400	6405	O
(	33081849	6406	6407	O
CTRI	33081849	6408	6412	O
)	33081849	6413	6414	O
:	33081849	6415	6416	O
CTRI/2020/06/025575	33081849	6417	6436	O
.	33081849	6437	6438	O

Registration	33081849	6439	6451	O
on	33081849	6452	6454	O
03	33081849	6455	6457	O
June	33081849	6458	6462	O
2020	33081849	6463	6467	O
FULL	33081849	6468	6472	O
PROTOCOL	33081849	6473	6481	O
:	33081849	6482	6483	O
The	33081849	6484	6487	O
full	33081849	6488	6492	O
protocol	33081849	6493	6501	O
is	33081849	6502	6504	O
attached	33081849	6505	6513	O
as	33081849	6514	6516	O
an	33081849	6517	6519	O
additional	33081849	6520	6530	O
file	33081849	6531	6535	O
,	33081849	6536	6537	O
accessible	33081849	6538	6548	O
from	33081849	6549	6553	O
the	33081849	6554	6557	O
Trials	33081849	6558	6564	O
website	33081849	6565	6572	O
(	33081849	6573	6574	O
Additional	33081849	6575	6585	O
file	33081849	6586	6590	O
1	33081849	6591	6592	O
)	33081849	6593	6594	O
.	33081849	6595	6596	O

In	33081849	6597	6599	O
the	33081849	6600	6603	O
interest	33081849	6604	6612	O
in	33081849	6613	6615	O
expediting	33081849	6616	6626	O
dissemination	33081849	6627	6640	O
of	33081849	6641	6643	O
this	33081849	6644	6648	O
material	33081849	6649	6657	O
,	33081849	6658	6659	O
the	33081849	6660	6663	O
familiar	33081849	6664	6672	O
formatting	33081849	6673	6683	O
has	33081849	6684	6687	O
been	33081849	6688	6692	O
eliminated	33081849	6693	6703	O
;	33081849	6704	6705	O
this	33081849	6706	6710	O
letter	33081849	6711	6717	O
serves	33081849	6718	6724	O
as	33081849	6725	6727	O
a	33081849	6728	6729	O
summary	33081849	6730	6737	O
of	33081849	6738	6740	O
the	33081849	6741	6744	O
key	33081849	6745	6748	O
elements	33081849	6749	6757	O
of	33081849	6758	6760	O
the	33081849	6761	6764	O
full	33081849	6765	6769	O
protocol	33081849	6770	6778	O
.	33081849	6779	6780	O


A	33082342	0	1	O
pragmatic	33082342	2	11	O
randomized	33082342	12	22	O
controlled	33082342	23	33	O
trial	33082342	34	39	O
reports	33082342	40	47	O
lack	33082342	48	52	O
of	33082342	53	55	O
efficacy	33082342	56	64	O
of	33082342	65	67	O
hydroxychloroquine	33082342	68	86	O
on	33082342	87	89	O
coronavirus	33082342	90	101	O
disease	33082342	102	109	O
2019	33082342	110	114	O
viral	33082342	115	120	O
kinetics	33082342	121	129	O
.	33082342	130	131	O

Here	33082342	132	136	O
,	33082342	137	138	O
we	33082342	139	141	O
randomized	33082342	142	152	O
53	33082342	153	155	O
patients	33082342	156	164	O
hospitalized	33082342	165	177	O
with	33082342	178	182	O
coronavirus	33082342	183	194	O
disease	33082342	195	202	O
2019	33082342	203	207	O
(	33082342	208	209	O
COVID-19	33082342	210	218	O
)	33082342	219	220	O
to	33082342	221	223	O
hydroxychloroquine	33082342	224	242	O
therapy	33082342	243	250	O
(	33082342	251	252	O
at	33082342	253	255	O
a	33082342	256	257	O
dose	33082342	258	262	O
of	33082342	263	265	O
400	33082342	266	269	O
mg	33082342	272	274	O
twice	33082342	275	280	O
daily	33082342	281	286	O
for	33082342	287	290	O
seven	33082342	291	296	O
days	33082342	297	301	O
)	33082342	302	303	O
in	33082342	304	306	O
addition	33082342	307	315	O
to	33082342	316	318	O
standard	33082342	319	327	O
care	33082342	328	332	O
or	33082342	333	335	O
standard	33082342	336	344	O
care	33082342	345	349	O
alone	33082342	350	355	O
(	33082342	356	357	O
ClinicalTrials.gov	33082342	358	376	O
Identifier	33082342	377	387	O
,	33082342	388	389	O
NCT04316377	33082342	390	401	O
)	33082342	402	403	O
.	33082342	404	405	O

All	33082342	406	409	O
severe	33082342	410	416	O
acute	33082342	417	422	O
respiratory	33082342	423	434	O
syndrome	33082342	435	443	O
coronavirus	33082342	444	455	O
2	33082342	456	457	O
(	33082342	458	459	O
SARS	33082342	460	464	O
-	33082342	465	466	O
CoV-2	33082342	467	472	O
)	33082342	473	474	O
positive	33082342	475	483	O
patients	33082342	484	492	O
18	33082342	493	495	O
years	33082342	496	501	O
of	33082342	502	504	O
age	33082342	505	508	O
or	33082342	509	511	O
older	33082342	512	517	O
were	33082342	518	522	O
eligible	33082342	523	531	O
for	33082342	532	535	O
study	33082342	536	541	O
inclusion	33082342	542	551	O
if	33082342	552	554	O
they	33082342	555	559	O
had	33082342	560	563	O
moderately	33082342	564	574	O
severe	33082342	575	581	O
COVID-19	33082342	582	590	O
at	33082342	591	593	O
admission	33082342	594	603	O
.	33082342	604	605	O

Treatment	33082342	606	615	O
with	33082342	616	620	O
hydroxychloroquine	33082342	621	639	O
did	33082342	640	643	O
not	33082342	644	647	O
result	33082342	648	654	O
in	33082342	655	657	O
a	33082342	658	659	O
significantly	33082342	660	673	O
greater	33082342	674	681	O
rate	33082342	682	686	O
of	33082342	687	689	O
decline	33082342	690	697	O
in	33082342	698	700	O
SARS	33082342	701	705	O
-	33082342	706	707	O
CoV-2	33082342	708	713	O
oropharyngeal	33082342	714	727	O
viral	33082342	728	733	O
load	33082342	734	738	O
compared	33082342	739	747	O
to	33082342	748	750	O
standard	33082342	751	759	O
care	33082342	760	764	O
alone	33082342	765	770	O
during	33082342	771	777	O
the	33082342	778	781	O
first	33082342	782	787	O
five	33082342	788	792	O
days	33082342	793	797	O
.	33082342	798	799	O

Our	33082342	800	803	O
results	33082342	804	811	O
suggest	33082342	812	819	O
no	33082342	820	822	O
important	33082342	823	832	O
antiviral	33082342	833	842	O
effect	33082342	843	849	O
of	33082342	850	852	O
hydroxychloroquine	33082342	853	871	O
in	33082342	872	874	O
humans	33082342	875	881	O
infected	33082342	882	890	O
with	33082342	891	895	O
SARS	33082342	896	900	O
-	33082342	901	902	O
CoV-2	33082342	903	908	O
.	33082342	909	910	O


The	33087047	0	3	O
use	33087047	4	7	O
of	33087047	8	10	O
intravenous	33087047	11	22	O
immunoglobulin	33087047	23	37	O
gamma	33087047	38	43	O
for	33087047	44	47	O
the	33087047	48	51	O
treatment	33087047	52	61	O
of	33087047	62	64	O
severe	33087047	65	71	O
coronavirus	33087047	72	83	O
disease	33087047	84	91	O
2019	33087047	92	96	O
:	33087047	97	98	O
a	33087047	99	100	O
randomized	33087047	101	111	O
placebo	33087047	112	119	O
-	33087047	120	121	O
controlled	33087047	122	132	O
double	33087047	133	139	O
-	33087047	140	141	O
blind	33087047	142	147	O
clinical	33087047	148	156	O
trial	33087047	157	162	O
.	33087047	163	164	O

BACKGROUND	33087047	165	175	O
:	33087047	176	177	O
Coronavirus	33087047	178	189	O
disease	33087047	190	197	O
2019	33087047	198	202	O
(	33087047	203	204	O
COVID-19	33087047	205	213	O
)	33087047	214	215	O
has	33087047	216	219	O
infected	33087047	220	228	O
people	33087047	229	235	O
in	33087047	236	238	O
many	33087047	239	243	O
countries	33087047	244	253	O
worldwide	33087047	254	263	O
.	33087047	264	265	O

Discovering	33087047	266	277	O
an	33087047	278	280	O
effective	33087047	281	290	O
treatment	33087047	291	300	O
for	33087047	301	304	O
this	33087047	305	309	O
disease	33087047	310	317	O
,	33087047	318	319	O
particularly	33087047	320	332	O
in	33087047	333	335	O
severe	33087047	336	342	O
cases	33087047	343	348	O
,	33087047	349	350	O
has	33087047	351	354	O
become	33087047	355	361	O
the	33087047	362	365	O
subject	33087047	366	373	O
of	33087047	374	376	O
intense	33087047	377	384	O
scientific	33087047	385	395	O
investigation	33087047	396	409	O
.	33087047	410	411	O

Therefore	33087047	412	421	O
,	33087047	422	423	O
the	33087047	424	427	O
objective	33087047	428	437	O
of	33087047	438	440	O
this	33087047	441	445	O
study	33087047	446	451	O
was	33087047	452	455	O
to	33087047	456	458	O
evaluate	33087047	459	467	O
the	33087047	468	471	O
efficacy	33087047	472	480	O
of	33087047	481	483	O
intravenous	33087047	484	495	O
immunoglobulin	33087047	496	510	O
(	33087047	511	512	O
IVIg	33087047	513	517	O
)	33087047	518	519	O
in	33087047	520	522	O
patients	33087047	523	531	O
with	33087047	532	536	O
severe	33087047	537	543	O
COVID-19	33087047	544	552	O
infection	33087047	553	562	O
.	33087047	563	564	O

METHODS	33087047	565	572	O
:	33087047	573	574	O
This	33087047	575	579	O
study	33087047	580	585	O
was	33087047	586	589	O
conducted	33087047	590	599	O
as	33087047	600	602	O
a	33087047	603	604	O
randomized	33087047	605	615	O
placebo	33087047	616	623	O
-	33087047	624	625	O
controlled	33087047	626	636	O
double	33087047	637	643	O
-	33087047	644	645	O
blind	33087047	646	651	O
clinical	33087047	652	660	O
trial	33087047	661	666	O
.	33087047	667	668	O

Fifty	33087047	669	674	O
-	33087047	675	676	O
nine	33087047	677	681	O
patients	33087047	682	690	O
with	33087047	691	695	O
severe	33087047	696	702	O
COVID-19	33087047	703	711	O
infection	33087047	712	721	O
who	33087047	722	725	O
did	33087047	726	729	O
not	33087047	730	733	O
respond	33087047	734	741	O
to	33087047	742	744	O
initial	33087047	745	752	O
treatments	33087047	753	763	O
were	33087047	764	768	O
randomly	33087047	769	777	O
assigned	33087047	778	786	O
into	33087047	787	791	O
two	33087047	792	795	O
groups	33087047	796	802	O
.	33087047	803	804	O

One	33087047	805	808	O
group	33087047	809	814	O
received	33087047	815	823	O
IVIg	33087047	824	828	O
(	33087047	829	830	O
human)-four	33087047	831	842	O
vials	33087047	843	848	O
daily	33087047	849	854	O
for	33087047	855	858	O
3	33087047	859	860	O
days	33087047	861	865	O
(	33087047	866	867	O
in	33087047	868	870	O
addition	33087047	871	879	O
to	33087047	880	882	O
initial	33087047	883	890	O
treatment	33087047	891	900	O
)	33087047	901	902	O
,	33087047	903	904	O
while	33087047	905	910	O
the	33087047	911	914	O
other	33087047	915	920	O
group	33087047	921	926	O
received	33087047	927	935	O
a	33087047	936	937	O
placebo	33087047	938	945	O
.	33087047	946	947	O

Patients	33087047	948	956	O
'	33087047	957	958	O
demographic	33087047	959	970	O
,	33087047	971	972	O
clinical	33087047	973	981	O
,	33087047	982	983	O
and	33087047	984	987	O
select	33087047	988	994	O
laboratory	33087047	995	1005	O
test	33087047	1006	1010	O
results	33087047	1011	1018	O
,	33087047	1019	1020	O
as	33087047	1021	1023	O
well	33087047	1024	1028	O
as	33087047	1029	1031	O
the	33087047	1032	1035	O
occurrence	33087047	1036	1046	O
of	33087047	1047	1049	O
in	33087047	1050	1052	O
-	33087047	1053	1054	O
hospital	33087047	1055	1063	O
mortality	33087047	1064	1073	O
,	33087047	1074	1075	O
were	33087047	1076	1080	O
recorded	33087047	1081	1089	O
.	33087047	1090	1091	O

RESULTS	33087047	1092	1099	O
:	33087047	1100	1101	O
Among	33087047	1102	1107	O
total	33087047	1108	1113	O
study	33087047	1114	1119	O
subjects	33087047	1120	1128	O
,	33087047	1129	1130	O
30	33087047	1131	1133	O
patients	33087047	1134	1142	O
received	33087047	1143	1151	O
IVIg	33087047	1152	1156	O
and	33087047	1157	1160	O
29	33087047	1161	1163	O
patients	33087047	1164	1172	O
received	33087047	1173	1181	O
a	33087047	1182	1183	O
placebo	33087047	1184	1191	O
.	33087047	1192	1193	O

Demographics	33087047	1194	1206	O
,	33087047	1207	1208	O
clinical	33087047	1209	1217	O
characteristics	33087047	1218	1233	O
,	33087047	1234	1235	O
and	33087047	1236	1239	O
laboratory	33087047	1240	1250	O
tests	33087047	1251	1256	O
were	33087047	1257	1261	O
not	33087047	1262	1265	O
statistically	33087047	1266	1279	O
different	33087047	1280	1289	O
(	33087047	1290	1291	O
P	33087047	1292	1293	O
>	33087047	1296	1297	O
0.05	33087047	1300	1304	O
)	33087047	1305	1306	O
between	33087047	1307	1314	O
the	33087047	1315	1318	O
two	33087047	1319	1322	O
groups	33087047	1323	1329	O
.	33087047	1330	1331	O

The	33087047	1332	1335	O
in	33087047	1336	1338	O
-	33087047	1339	1340	O
hospital	33087047	1341	1349	O
mortality	33087047	1350	1359	O
rate	33087047	1360	1364	O
was	33087047	1365	1368	O
significantly	33087047	1369	1382	O
lower	33087047	1383	1388	O
in	33087047	1389	1391	O
the	33087047	1392	1395	O
IVIg	33087047	1396	1400	O
group	33087047	1401	1406	O
compared	33087047	1407	1415	O
to	33087047	1416	1418	O
the	33087047	1419	1422	O
control	33087047	1423	1430	O
group	33087047	1431	1436	O
(	33087047	1437	1438	O
6	33087047	1439	1440	O
[	33087047	1441	1442	O
20.0	33087047	1443	1447	O
%	33087047	1448	1449	O
]	33087047	1450	1451	O
vs.	33087047	1452	1455	O
14	33087047	1456	1458	O
[	33087047	1459	1460	O
48.3	33087047	1461	1465	O
%	33087047	1466	1467	O
]	33087047	1468	1469	O
,	33087047	1470	1471	O
respectively	33087047	1472	1484	O
;	33087047	1485	1486	O
P	33087047	1487	1488	O
=	33087047	1491	1492	O
0.022	33087047	1495	1500	O
)	33087047	1501	1502	O
.	33087047	1503	1504	O

Multivariate	33087047	1505	1517	O
regression	33087047	1518	1528	O
analysis	33087047	1529	1537	O
demonstrated	33087047	1538	1550	O
that	33087047	1551	1555	O
administration	33087047	1556	1570	O
of	33087047	1571	1573	O
IVIg	33087047	1574	1578	O
did	33087047	1579	1582	O
indeed	33087047	1583	1589	O
have	33087047	1590	1594	O
a	33087047	1595	1596	O
significant	33087047	1597	1608	O
impact	33087047	1609	1615	O
on	33087047	1616	1618	O
mortality	33087047	1619	1628	O
rate	33087047	1629	1633	O
(	33087047	1634	1635	O
aOR	33087047	1636	1639	O
=	33087047	1642	1643	O
0.003	33087047	1646	1651	O
[	33087047	1652	1653	O
95	33087047	1654	1656	O
%	33087047	1657	1658	O
CI	33087047	1659	1661	O
:	33087047	1662	1663	O
0.001	33087047	1664	1669	O
-	33087047	1670	1671	O
0.815	33087047	1672	1677	O
]	33087047	1678	1679	O
;	33087047	1680	1681	O
P	33087047	1682	1683	O
=	33087047	1686	1687	O
0.042	33087047	1690	1695	O
)	33087047	1696	1697	O
.	33087047	1698	1699	O

CONCLUSIONS	33087047	1700	1711	O
:	33087047	1712	1713	O
Our	33087047	1714	1717	O
study	33087047	1718	1723	O
demonstrated	33087047	1724	1736	O
that	33087047	1737	1741	O
the	33087047	1742	1745	O
administration	33087047	1746	1760	O
of	33087047	1761	1763	O
IVIg	33087047	1764	1768	O
in	33087047	1769	1771	O
patients	33087047	1772	1780	O
with	33087047	1781	1785	O
severe	33087047	1786	1792	O
COVID-19	33087047	1793	1801	O
infection	33087047	1802	1811	O
who	33087047	1812	1815	O
did	33087047	1816	1819	O
not	33087047	1820	1823	O
respond	33087047	1824	1831	O
to	33087047	1832	1834	O
initial	33087047	1835	1842	O
treatment	33087047	1843	1852	O
could	33087047	1853	1858	O
improve	33087047	1859	1866	O
their	33087047	1867	1872	O
clinical	33087047	1873	1881	O
outcome	33087047	1882	1889	O
and	33087047	1890	1893	O
significantly	33087047	1894	1907	O
reduce	33087047	1908	1914	O
mortality	33087047	1915	1924	O
rate	33087047	1925	1929	O
.	33087047	1930	1931	O

Further	33087047	1932	1939	O
multicenter	33087047	1940	1951	O
studies	33087047	1952	1959	O
with	33087047	1960	1964	O
larger	33087047	1965	1971	O
sample	33087047	1972	1978	O
sizes	33087047	1979	1984	O
are	33087047	1985	1988	O
nonetheless	33087047	1989	2000	O
required	33087047	2001	2009	O
to	33087047	2010	2012	O
confirm	33087047	2013	2020	O
the	33087047	2021	2024	O
appropriateness	33087047	2025	2040	O
of	33087047	2041	2043	O
this	33087047	2044	2048	O
medication	33087047	2049	2059	O
as	33087047	2060	2062	O
a	33087047	2063	2064	O
standard	33087047	2065	2073	O
treatment	33087047	2074	2083	O
.	33087047	2084	2085	O

BACKGROUND	33087047	2086	2096	O
:	33087047	2097	2098	O
A	33087047	2099	2100	O
study	33087047	2101	2106	O
protocol	33087047	2107	2115	O
was	33087047	2116	2119	O
registered	33087047	2120	2130	O
at	33087047	2131	2133	O
the	33087047	2134	2137	O
Iranian	33087047	2138	2145	O
Registry	33087047	2146	2154	O
of	33087047	2155	2157	O
Clinical	33087047	2158	2166	O
Trials	33087047	2167	2173	O
(	33087047	2174	2175	O
www	33087047	2176	2179	O
.	33087047	2179	2180	O
IRCT.ir	33087047	2180	2187	O
)	33087047	2188	2189	O
,	33087047	2190	2191	O
number	33087047	2192	2198	O
IRCT20200501047259N1	33087047	2199	2219	O
.	33087047	2220	2221	O

It	33087047	2222	2224	O
was	33087047	2225	2228	O
registered	33087047	2229	2239	O
retrospectively	33087047	2240	2255	O
on	33087047	2256	2258	O
May	33087047	2259	2262	O
17th	33087047	2263	2267	O
,	33087047	2268	2269	O
2020	33087047	2270	2274	O
.	33087047	2275	2276	O


Efficacy	33087178	0	8	O
of	33087178	9	11	O
an	33087178	12	14	O
online	33087178	15	21	O
cognitive	33087178	22	31	O
behavioral	33087178	32	42	O
therapy	33087178	43	50	O
program	33087178	51	58	O
developed	33087178	59	68	O
for	33087178	69	72	O
healthcare	33087178	73	83	O
workers	33087178	84	91	O
during	33087178	92	98	O
the	33087178	99	102	O
COVID-19	33087178	103	111	O
pandemic	33087178	112	120	O
:	33087178	121	122	O
the	33087178	123	126	O
REduction	33087178	127	136	O
of	33087178	137	139	O
STress	33087178	140	146	O
(	33087178	147	148	O
REST	33087178	149	153	O
)	33087178	154	155	O
study	33087178	156	161	O
protocol	33087178	162	170	O
for	33087178	171	174	O
a	33087178	175	176	O
randomized	33087178	177	187	O
controlled	33087178	188	198	O
trial	33087178	199	204	O
.	33087178	205	206	O

BACKGROUND	33087178	207	217	O
:	33087178	218	219	O
The	33087178	220	223	O
acknowledgment	33087178	224	238	O
of	33087178	239	241	O
the	33087178	242	245	O
mental	33087178	246	252	O
health	33087178	253	259	O
toll	33087178	260	264	O
of	33087178	265	267	O
the	33087178	268	271	O
COVID-19	33087178	272	280	O
epidemic	33087178	281	289	O
in	33087178	290	292	O
healthcare	33087178	293	303	O
workers	33087178	304	311	O
has	33087178	312	315	O
increased	33087178	316	325	O
considerably	33087178	326	338	O
as	33087178	339	341	O
the	33087178	342	345	O
disease	33087178	346	353	O
evolved	33087178	354	361	O
into	33087178	362	366	O
a	33087178	367	368	O
pandemic	33087178	369	377	O
status	33087178	378	384	O
.	33087178	385	386	O

Indeed	33087178	387	393	O
,	33087178	394	395	O
high	33087178	396	400	O
prevalence	33087178	401	411	O
rates	33087178	412	417	O
of	33087178	418	420	O
depression	33087178	421	431	O
,	33087178	432	433	O
sleep	33087178	434	439	O
disorders	33087178	440	449	O
,	33087178	450	451	O
and	33087178	452	455	O
post	33087178	456	460	O
-	33087178	461	462	O
traumatic	33087178	463	472	O
stress	33087178	473	479	O
disorder	33087178	480	488	O
(	33087178	489	490	O
PTSD	33087178	491	495	O
)	33087178	496	497	O
have	33087178	498	502	O
been	33087178	503	507	O
reported	33087178	508	516	O
in	33087178	517	519	O
Chinese	33087178	520	527	O
healthcare	33087178	528	538	O
workers	33087178	539	546	O
during	33087178	547	553	O
the	33087178	554	557	O
epidemic	33087178	558	566	O
peak	33087178	567	571	O
.	33087178	572	573	O

Symptoms	33087178	574	582	O
of	33087178	583	585	O
psychological	33087178	586	599	O
distress	33087178	600	608	O
are	33087178	609	612	O
expected	33087178	613	621	O
to	33087178	622	624	O
be	33087178	625	627	O
long	33087178	628	632	O
-	33087178	633	634	O
lasting	33087178	635	642	O
and	33087178	643	646	O
have	33087178	647	651	O
a	33087178	652	653	O
systemic	33087178	654	662	O
impact	33087178	663	669	O
on	33087178	670	672	O
healthcare	33087178	673	683	O
systems	33087178	684	691	O
,	33087178	692	693	O
warranting	33087178	694	704	O
the	33087178	705	708	O
need	33087178	709	713	O
for	33087178	714	717	O
evidence	33087178	718	726	O
-	33087178	727	728	O
based	33087178	729	734	O
psychological	33087178	735	748	O
treatments	33087178	749	759	O
aiming	33087178	760	766	O
at	33087178	767	769	O
relieving	33087178	770	779	O
immediate	33087178	780	789	O
stress	33087178	790	796	O
and	33087178	797	800	O
preventing	33087178	801	811	O
the	33087178	812	815	O
onset	33087178	816	821	O
of	33087178	822	824	O
psychological	33087178	825	838	O
disorders	33087178	839	848	O
in	33087178	849	851	O
this	33087178	852	856	O
population	33087178	857	867	O
.	33087178	868	869	O

In	33087178	870	872	O
the	33087178	873	876	O
current	33087178	877	884	O
COVID-19	33087178	885	893	O
context	33087178	894	901	O
,	33087178	902	903	O
internet	33087178	904	912	O
-	33087178	913	914	O
based	33087178	915	920	O
interventions	33087178	921	934	O
have	33087178	935	939	O
the	33087178	940	943	O
potential	33087178	944	953	O
to	33087178	954	956	O
circumvent	33087178	957	967	O
the	33087178	968	971	O
pitfalls	33087178	972	980	O
of	33087178	981	983	O
face	33087178	984	988	O
-	33087178	989	990	O
to	33087178	991	993	O
-	33087178	994	995	O
face	33087178	996	1000	O
formats	33087178	1001	1008	O
and	33087178	1009	1012	O
provide	33087178	1013	1020	O
the	33087178	1021	1024	O
flexibility	33087178	1025	1036	O
required	33087178	1037	1045	O
to	33087178	1046	1048	O
facilitate	33087178	1049	1059	O
accessibility	33087178	1060	1073	O
to	33087178	1074	1076	O
healthcare	33087178	1077	1087	O
workers	33087178	1088	1095	O
.	33087178	1096	1097	O

Online	33087178	1098	1104	O
cognitive	33087178	1105	1114	O
behavioral	33087178	1115	1125	O
therapy	33087178	1126	1133	O
(	33087178	1134	1135	O
CBT	33087178	1136	1139	O
)	33087178	1140	1141	O
in	33087178	1142	1144	O
particular	33087178	1145	1155	O
has	33087178	1156	1159	O
proved	33087178	1160	1166	O
to	33087178	1167	1169	O
be	33087178	1170	1172	O
effective	33087178	1173	1182	O
in	33087178	1183	1185	O
treating	33087178	1186	1194	O
and	33087178	1195	1198	O
preventing	33087178	1199	1209	O
a	33087178	1210	1211	O
number	33087178	1212	1218	O
of	33087178	1219	1221	O
stress	33087178	1222	1228	O
-	33087178	1229	1230	O
related	33087178	1231	1238	O
disorders	33087178	1239	1248	O
in	33087178	1249	1251	O
populations	33087178	1252	1263	O
other	33087178	1264	1269	O
than	33087178	1270	1274	O
healthcare	33087178	1275	1285	O
workers	33087178	1286	1293	O
.	33087178	1294	1295	O

The	33087178	1296	1299	O
aim	33087178	1300	1303	O
of	33087178	1304	1306	O
our	33087178	1307	1310	O
randomized	33087178	1311	1321	O
controlled	33087178	1322	1332	O
trial	33087178	1333	1338	O
study	33087178	1339	1344	O
protocol	33087178	1345	1353	O
is	33087178	1354	1356	O
to	33087178	1357	1359	O
evaluate	33087178	1360	1368	O
the	33087178	1369	1372	O
efficacy	33087178	1373	1381	O
of	33087178	1382	1384	O
the	33087178	1385	1388	O
'	33087178	1389	1390	O
My	33087178	1391	1393	O
Health	33087178	1394	1400	O
too	33087178	1401	1404	O
'	33087178	1405	1406	O
CBT	33087178	1407	1410	O
program	33087178	1411	1418	O
-	33087178	1419	1420	O
a	33087178	1421	1422	O
program	33087178	1423	1430	O
we	33087178	1431	1433	O
have	33087178	1434	1438	O
developed	33087178	1439	1448	O
for	33087178	1449	1452	O
healthcare	33087178	1453	1463	O
workers	33087178	1464	1471	O
facing	33087178	1472	1478	O
the	33087178	1479	1482	O
pandemic	33087178	1483	1491	O
-	33087178	1492	1493	O
on	33087178	1494	1496	O
immediate	33087178	1497	1506	O
perceived	33087178	1507	1516	O
stress	33087178	1517	1523	O
and	33087178	1524	1527	O
on	33087178	1528	1530	O
the	33087178	1531	1534	O
emergence	33087178	1535	1544	O
of	33087178	1545	1547	O
psychiatric	33087178	1548	1559	O
disorders	33087178	1560	1569	O
at	33087178	1570	1572	O
3-	33087178	1573	1575	O
and	33087178	1576	1579	O
6-month	33087178	1580	1587	O
follow	33087178	1588	1594	O
-	33087178	1595	1596	O
up	33087178	1597	1599	O
compared	33087178	1600	1608	O
to	33087178	1609	1611	O
an	33087178	1612	1614	O
active	33087178	1615	1621	O
control	33087178	1622	1629	O
group	33087178	1630	1635	O
(	33087178	1636	1637	O
i.e.	33087178	1638	1642	O
,	33087178	1643	1644	O
bibliotherapy	33087178	1645	1658	O
)	33087178	1659	1660	O
.	33087178	1661	1662	O

METHODS	33087178	1663	1670	O
:	33087178	1671	1672	O
Powered	33087178	1673	1680	O
for	33087178	1681	1684	O
superiority	33087178	1685	1696	O
testing	33087178	1697	1704	O
,	33087178	1705	1706	O
this	33087178	1707	1711	O
six	33087178	1712	1715	O
-	33087178	1716	1717	O
site	33087178	1718	1722	O
open	33087178	1723	1727	O
trial	33087178	1728	1733	O
involves	33087178	1734	1742	O
the	33087178	1743	1746	O
random	33087178	1747	1753	O
assignment	33087178	1754	1764	O
of	33087178	1765	1767	O
120	33087178	1768	1771	O
healthcare	33087178	1772	1782	O
workers	33087178	1783	1790	O
with	33087178	1791	1795	O
stress	33087178	1796	1802	O
levels	33087178	1803	1809	O
>	33087178	1810	1811	O
16	33087178	1814	1816	O
on	33087178	1817	1819	O
the	33087178	1820	1823	O
Perceived	33087178	1824	1833	O
Stress	33087178	1834	1840	O
Scale	33087178	1841	1846	O
(	33087178	1847	1848	O
PSS-10	33087178	1849	1855	O
)	33087178	1856	1857	O
to	33087178	1858	1860	O
either	33087178	1861	1867	O
the	33087178	1868	1871	O
7-session	33087178	1872	1881	O
online	33087178	1882	1888	O
CBT	33087178	1889	1892	O
program	33087178	1893	1900	O
or	33087178	1901	1903	O
bibliotherapy	33087178	1904	1917	O
.	33087178	1918	1919	O

The	33087178	1920	1923	O
primary	33087178	1924	1931	O
outcome	33087178	1932	1939	O
is	33087178	1940	1942	O
the	33087178	1943	1946	O
decrease	33087178	1947	1955	O
of	33087178	1956	1958	O
PSS-10	33087178	1959	1965	O
scores	33087178	1966	1972	O
at	33087178	1973	1975	O
8	33087178	1976	1977	O
weeks	33087178	1980	1985	O
.	33087178	1986	1987	O

Secondary	33087178	1988	1997	O
outcomes	33087178	1998	2006	O
include	33087178	2007	2014	O
depression	33087178	2015	2025	O
,	33087178	2026	2027	O
insomnia	33087178	2028	2036	O
,	33087178	2037	2038	O
and	33087178	2039	2042	O
PTSD	33087178	2043	2047	O
symptoms	33087178	2048	2056	O
;	33087178	2057	2058	O
self	33087178	2059	2063	O
-	33087178	2064	2065	O
reported	33087178	2066	2074	O
resilience	33087178	2075	2085	O
and	33087178	2086	2089	O
rumination	33087178	2090	2100	O
;	33087178	2101	2102	O
and	33087178	2103	2106	O
credibility	33087178	2107	2118	O
and	33087178	2119	2122	O
satisfaction	33087178	2123	2135	O
.	33087178	2136	2137	O

Assessments	33087178	2138	2149	O
are	33087178	2150	2153	O
scheduled	33087178	2154	2163	O
at	33087178	2164	2166	O
pretreatment	33087178	2167	2179	O
,	33087178	2180	2181	O
mid	33087178	2182	2185	O
-	33087178	2186	2187	O
treatment	33087178	2188	2197	O
(	33087178	2198	2199	O
at	33087178	2200	2202	O
4	33087178	2203	2204	O
weeks	33087178	2207	2212	O
)	33087178	2213	2214	O
,	33087178	2215	2216	O
end	33087178	2217	2220	O
of	33087178	2221	2223	O
active	33087178	2224	2230	O
treatment	33087178	2231	2240	O
(	33087178	2241	2242	O
at	33087178	2243	2245	O
8	33087178	2246	2247	O
weeks	33087178	2250	2255	O
)	33087178	2256	2257	O
,	33087178	2258	2259	O
and	33087178	2260	2263	O
at	33087178	2264	2266	O
3-month	33087178	2267	2274	O
and	33087178	2275	2278	O
6-month	33087178	2279	2286	O
follow	33087178	2287	2293	O
-	33087178	2294	2295	O
up	33087178	2296	2298	O
.	33087178	2299	2300	O

CONCLUSIONS	33087178	2301	2312	O
:	33087178	2313	2314	O
This	33087178	2315	2319	O
is	33087178	2320	2322	O
the	33087178	2323	2326	O
first	33087178	2327	2332	O
study	33087178	2333	2338	O
assessing	33087178	2339	2348	O
the	33087178	2349	2352	O
efficacy	33087178	2353	2361	O
and	33087178	2362	2365	O
the	33087178	2366	2369	O
acceptability	33087178	2370	2383	O
of	33087178	2384	2386	O
a	33087178	2387	2388	O
brief	33087178	2389	2394	O
online	33087178	2395	2401	O
CBT	33087178	2402	2405	O
program	33087178	2406	2413	O
specifically	33087178	2414	2426	O
developed	33087178	2427	2436	O
for	33087178	2437	2440	O
healthcare	33087178	2441	2451	O
workers	33087178	2452	2459	O
.	33087178	2460	2461	O

Given	33087178	2462	2467	O
the	33087178	2468	2471	O
potential	33087178	2472	2481	O
short-	33087178	2482	2488	O
and	33087178	2489	2492	O
long	33087178	2493	2497	O
-	33087178	2498	2499	O
term	33087178	2500	2504	O
consequences	33087178	2505	2517	O
of	33087178	2518	2520	O
the	33087178	2521	2524	O
COVID-19	33087178	2525	2533	O
pandemic	33087178	2534	2542	O
on	33087178	2543	2545	O
healthcare	33087178	2546	2556	O
workers	33087178	2557	2564	O
'	33087178	2565	2566	O
mental	33087178	2567	2573	O
health	33087178	2574	2580	O
,	33087178	2581	2582	O
but	33087178	2583	2586	O
also	33087178	2587	2591	O
on	33087178	2592	2594	O
healthcare	33087178	2595	2605	O
systems	33087178	2606	2613	O
,	33087178	2614	2615	O
our	33087178	2616	2619	O
findings	33087178	2620	2628	O
can	33087178	2629	2632	O
significantly	33087178	2633	2646	O
impact	33087178	2647	2653	O
clinical	33087178	2654	2662	O
practice	33087178	2663	2671	O
and	33087178	2672	2675	O
management	33087178	2676	2686	O
of	33087178	2687	2689	O
the	33087178	2690	2693	O
ongoing	33087178	2694	2701	O
,	33087178	2702	2703	O
and	33087178	2704	2707	O
probably	33087178	2708	2716	O
long	33087178	2717	2721	O
-	33087178	2722	2723	O
lasting	33087178	2724	2731	O
,	33087178	2732	2733	O
health	33087178	2734	2740	O
crisis	33087178	2741	2747	O
.	33087178	2748	2749	O

BACKGROUND	33087178	2750	2760	O
:	33087178	2761	2762	O
ClinicalTrials.gov	33087178	2763	2781	O
NCT04362358	33087178	2782	2793	O
,	33087178	2794	2795	O
registered	33087178	2796	2806	O
on	33087178	2807	2809	O
April	33087178	2810	2815	O
24	33087178	2816	2818	O
,	33087178	2819	2820	O
2020	33087178	2821	2825	O
.	33087178	2826	2827	O


"	33092632	0	1	O
Early	33092632	2	7	O
transfusion	33092632	8	19	O
of	33092632	20	22	O
convalescent	33092632	23	35	O
plasma	33092632	36	42	O
in	33092632	43	45	O
older	33092632	46	51	O
patients	33092632	52	60	O
with	33092632	61	65	O
COVID-19	33092632	66	74	O
to	33092632	75	77	O
prevent	33092632	78	85	O
disease	33092632	86	93	O
progression	33092632	94	105	O
:	33092632	106	107	O
A	33092632	108	109	O
structured	33092632	110	120	O
summary	33092632	121	128	O
of	33092632	129	131	O
a	33092632	132	133	O
study	33092632	134	139	O
protocol	33092632	140	148	O
for	33092632	149	152	O
a	33092632	153	154	O
randomised	33092632	155	165	O
controlled	33092632	166	176	O
trial	33092632	177	182	O
"	33092632	183	184	O
.	33092632	185	186	O

OBJECTIVE	33092632	187	196	O
:	33092632	197	198	O
The	33092632	199	202	O
primary	33092632	203	210	O
objective	33092632	211	220	O
is	33092632	221	223	O
to	33092632	224	226	O
demonstrate	33092632	227	238	O
that	33092632	239	243	O
COVID-19	33092632	244	252	O
convalescent	33092632	253	265	O
plasma	33092632	266	272	O
(	33092632	273	274	O
CCP	33092632	275	278	O
)	33092632	279	280	O
prevents	33092632	281	289	O
progression	33092632	290	301	O
to	33092632	302	304	O
severe	33092632	305	311	O
pneumonia	33092632	312	321	O
in	33092632	322	324	O
elderly	33092632	325	332	O
COVID-19	33092632	333	341	O
pneumonia	33092632	342	351	O
patients	33092632	352	360	O
with	33092632	361	365	O
chronic	33092632	366	373	O
comorbidities	33092632	374	387	O
.	33092632	388	389	O

Secondary	33092632	390	399	O
objectives	33092632	400	410	O
are	33092632	411	414	O
to	33092632	415	417	O
demonstrate	33092632	418	429	O
that	33092632	430	434	O
CCP	33092632	435	438	O
decreases	33092632	439	448	O
the	33092632	449	452	O
viral	33092632	453	458	O
load	33092632	459	463	O
in	33092632	464	466	O
nasopharyngeal	33092632	467	481	O
swabs	33092632	482	487	O
and	33092632	488	491	O
increases	33092632	492	501	O
the	33092632	502	505	O
anti	33092632	506	510	O
-	33092632	511	512	O
SARS	33092632	513	517	O
-	33092632	518	519	O
CoV-2	33092632	520	525	O
antibody	33092632	526	534	O
titre	33092632	535	540	O
in	33092632	541	543	O
recipients	33092632	544	554	O
.	33092632	555	556	O

METHODS	33092632	557	564	O
:	33092632	565	566	O
This	33092632	567	571	O
is	33092632	572	574	O
a	33092632	575	576	O
randomized	33092632	577	587	O
,	33092632	588	589	O
open	33092632	590	594	O
-	33092632	595	596	O
label	33092632	597	602	O
,	33092632	603	604	O
parallel	33092632	605	613	O
group	33092632	614	619	O
,	33092632	620	621	O
phase	33092632	622	627	O
II	33092632	628	630	O
/	33092632	631	632	O
III	33092632	633	636	O
study	33092632	637	642	O
with	33092632	643	647	O
a	33092632	648	649	O
superiority	33092632	650	661	O
framework	33092632	662	671	O
.	33092632	672	673	O

The	33092632	674	677	O
trial	33092632	678	683	O
starts	33092632	684	690	O
with	33092632	691	695	O
a	33092632	696	697	O
screening	33092632	698	707	O
phase	33092632	708	713	O
II	33092632	714	716	O
designed	33092632	717	725	O
with	33092632	726	730	O
two	33092632	731	734	O
-	33092632	735	736	O
tailed	33092632	737	743	O
alpha=0.2	33092632	744	753	O
.	33092632	754	755	O

In	33092632	756	758	O
case	33092632	759	763	O
of	33092632	764	766	O
positive	33092632	767	775	O
results	33092632	776	783	O
,	33092632	784	785	O
the	33092632	786	789	O
trial	33092632	790	795	O
will	33092632	796	800	O
proceed	33092632	801	808	O
in	33092632	809	811	O
a	33092632	812	813	O
formally	33092632	814	822	O
comparative	33092632	823	834	O
phase	33092632	835	840	O
III	33092632	841	844	O
(	33092632	845	846	O
alpha=0.05	33092632	847	857	O
)	33092632	858	859	O
.	33092632	860	861	O

METHODS	33092632	862	869	O
:	33092632	870	871	O
Adult	33092632	872	877	O
patients	33092632	878	886	O
with	33092632	887	891	O
confirmed	33092632	892	901	O
or	33092632	902	904	O
suspected	33092632	905	914	O
COVID-19	33092632	915	923	O
who	33092632	924	927	O
are	33092632	928	931	O
at	33092632	932	934	O
risk	33092632	935	939	O
according	33092632	940	949	O
to	33092632	950	952	O
CDC	33092632	953	956	O
definition	33092632	957	967	O
are	33092632	968	971	O
eligible	33092632	972	980	O
.	33092632	981	982	O

Inclusion	33092632	983	992	O
criteria	33092632	993	1001	O
are	33092632	1002	1005	O
all	33092632	1006	1009	O
the	33092632	1010	1013	O
following	33092632	1014	1023	O
:	33092632	1024	1025	O
age	33092632	1026	1029	O
	33092632	1032	1033	O
65	33092632	1036	1038	O
;	33092632	1039	1040	O
pneumonia	33092632	1041	1050	O
at	33092632	1051	1053	O
CT	33092632	1054	1056	O
scan	33092632	1057	1061	O
;	33092632	1062	1063	O
PaO2	33092632	1064	1068	O
/	33092632	1069	1070	O
FiO2	33092632	1071	1075	O
	33092632	1078	1079	O
300	33092632	1080	1083	O
mmHg	33092632	1084	1088	O
;	33092632	1089	1090	O
presence	33092632	1091	1099	O
of	33092632	1100	1102	O
one	33092632	1103	1106	O
or	33092632	1107	1109	O
more	33092632	1110	1114	O
comorbidities	33092632	1115	1128	O
;	33092632	1129	1130	O
signed	33092632	1131	1137	O
informed	33092632	1138	1146	O
consent	33092632	1147	1154	O
.	33092632	1155	1156	O

Exclusion	33092632	1157	1166	O
criteria	33092632	1167	1175	O
are	33092632	1176	1179	O
one	33092632	1180	1183	O
of	33092632	1184	1186	O
the	33092632	1187	1190	O
following	33092632	1191	1200	O
:	33092632	1201	1202	O
age	33092632	1203	1206	O
<	33092632	1207	1208	O
65	33092632	1209	1211	O
;	33092632	1212	1213	O
PaO2	33092632	1214	1218	O
/	33092632	1219	1220	O
FiO2	33092632	1221	1225	O
<	33092632	1226	1227	O
300	33092632	1228	1231	O
mmHg	33092632	1232	1236	O
;	33092632	1237	1238	O
pending	33092632	1239	1246	O
cardiopulmonary	33092632	1247	1262	O
arrest	33092632	1263	1269	O
;	33092632	1270	1271	O
refusal	33092632	1272	1279	O
to	33092632	1280	1282	O
blood	33092632	1283	1288	O
product	33092632	1289	1296	O
transfusions	33092632	1297	1309	O
;	33092632	1310	1311	O
severe	33092632	1312	1318	O
IgA	33092632	1319	1322	O
deficiency	33092632	1323	1333	O
;	33092632	1334	1335	O
any	33092632	1336	1339	O
life	33092632	1340	1344	O
-	33092632	1345	1346	O
threatening	33092632	1347	1358	O
comorbidity	33092632	1359	1370	O
or	33092632	1371	1373	O
any	33092632	1374	1377	O
other	33092632	1378	1383	O
medical	33092632	1384	1391	O
condition	33092632	1392	1401	O
which	33092632	1402	1407	O
,	33092632	1408	1409	O
in	33092632	1410	1412	O
the	33092632	1413	1416	O
opinion	33092632	1417	1424	O
of	33092632	1425	1427	O
the	33092632	1428	1431	O
investigator	33092632	1432	1444	O
,	33092632	1445	1446	O
makes	33092632	1447	1452	O
the	33092632	1453	1456	O
patient	33092632	1457	1464	O
unsuitable	33092632	1465	1475	O
for	33092632	1476	1479	O
inclusion	33092632	1480	1489	O
.	33092632	1490	1491	O

The	33092632	1492	1495	O
trial	33092632	1496	1501	O
is	33092632	1502	1504	O
being	33092632	1505	1510	O
conducted	33092632	1511	1520	O
at	33092632	1521	1523	O
three	33092632	1524	1529	O
reference	33092632	1530	1539	O
COVID-19	33092632	1540	1548	O
centres	33092632	1549	1556	O
in	33092632	1557	1559	O
the	33092632	1560	1563	O
middle	33092632	1564	1570	O
of	33092632	1571	1573	O
Italy	33092632	1574	1579	O
.	33092632	1580	1581	O

UNASSIGNED	33092632	1582	1592	O
:	33092632	1593	1594	O
Intervention	33092632	1595	1607	O
:	33092632	1608	1609	O
COVID-19	33092632	1610	1618	O
Convalescent	33092632	1619	1631	O
Plasma	33092632	1632	1638	O
(	33092632	1639	1640	O
CCP	33092632	1641	1644	O
)	33092632	1645	1646	O
in	33092632	1647	1649	O
addition	33092632	1650	1658	O
to	33092632	1659	1661	O
standard	33092632	1662	1670	O
therapy	33092632	1671	1678	O
.	33092632	1679	1680	O

Patients	33092632	1681	1689	O
receive	33092632	1690	1697	O
three	33092632	1698	1703	O
doses	33092632	1704	1709	O
(	33092632	1710	1711	O
200	33092632	1712	1715	O
ml	33092632	1716	1718	O
/	33092632	1719	1720	O
day	33092632	1721	1724	O
on	33092632	1725	1727	O
3	33092632	1728	1729	O
consecutive	33092632	1730	1741	O
days	33092632	1742	1746	O
)	33092632	1747	1748	O
of	33092632	1749	1751	O
ABO	33092632	1752	1755	O
matched	33092632	1756	1763	O
CCP	33092632	1764	1767	O
.	33092632	1768	1769	O

Comparator	33092632	1770	1780	O
:	33092632	1781	1782	O
Standard	33092632	1783	1791	O
therapy	33092632	1792	1799	O
MAIN	33092632	1800	1804	O
OUTCOMES	33092632	1805	1813	O
:	33092632	1814	1815	O
A.	33092632	1816	1818	O
Primary	33092632	1819	1826	O
outcome	33092632	1827	1834	O
for	33092632	1835	1838	O
Phase	33092632	1839	1844	O
II	33092632	1845	1847	O
:	33092632	1848	1849	O
Proportion	33092632	1850	1860	O
of	33092632	1861	1863	O
patients	33092632	1864	1872	O
without	33092632	1873	1880	O
progression	33092632	1881	1892	O
in	33092632	1893	1895	O
severity	33092632	1896	1904	O
of	33092632	1905	1907	O
pulmonary	33092632	1908	1917	O
disease	33092632	1918	1925	O
,	33092632	1926	1927	O
defined	33092632	1928	1935	O
as	33092632	1936	1938	O
worsening	33092632	1939	1948	O
of	33092632	1949	1951	O
2	33092632	1952	1953	O
points	33092632	1954	1960	O
in	33092632	1961	1963	O
the	33092632	1964	1967	O
ordinal	33092632	1968	1975	O
scale	33092632	1976	1981	O
of	33092632	1982	1984	O
WHO	33092632	1985	1988	O
by	33092632	1989	1991	O
day	33092632	1992	1995	O
14	33092632	1996	1998	O
.	33092632	1999	2000	O

B.	33092632	2001	2003	O
Primary	33092632	2004	2011	O
outcome	33092632	2012	2019	O
for	33092632	2020	2023	O
Phase	33092632	2024	2029	O
III	33092632	2030	2033	O
:	33092632	2034	2035	O
Proportion	33092632	2036	2046	O
of	33092632	2047	2049	O
patients	33092632	2050	2058	O
without	33092632	2059	2066	O
progression	33092632	2067	2078	O
in	33092632	2079	2081	O
severity	33092632	2082	2090	O
of	33092632	2091	2093	O
pulmonary	33092632	2094	2103	O
disease	33092632	2104	2111	O
,	33092632	2112	2113	O
defined	33092632	2114	2121	O
as	33092632	2122	2124	O
worsening	33092632	2125	2134	O
of	33092632	2135	2137	O
2	33092632	2138	2139	O
points	33092632	2140	2146	O
in	33092632	2147	2149	O
the	33092632	2150	2153	O
ordinal	33092632	2154	2161	O
scale	33092632	2162	2167	O
of	33092632	2168	2170	O
WHO	33092632	2171	2174	O
by	33092632	2175	2177	O
day	33092632	2178	2181	O
14	33092632	2182	2184	O
.	33092632	2185	2186	O

Secondary	33092632	2187	2196	O
outcomes	33092632	2197	2205	O
for	33092632	2206	2209	O
Phase	33092632	2210	2215	O
III	33092632	2216	2219	O
:	33092632	2220	2221	O
Decreased	33092632	2222	2231	O
viral	33092632	2232	2237	O
load	33092632	2238	2242	O
on	33092632	2243	2245	O
nasopharyngeal	33092632	2246	2260	O
swab	33092632	2261	2265	O
at	33092632	2266	2268	O
days	33092632	2269	2273	O
6	33092632	2274	2275	O
,	33092632	2276	2277	O
9	33092632	2278	2279	O
and	33092632	2280	2283	O
14	33092632	2284	2286	O
;	33092632	2287	2288	O
Decreased	33092632	2289	2298	O
viremia	33092632	2299	2306	O
at	33092632	2307	2309	O
days	33092632	2310	2314	O
6	33092632	2315	2316	O
and	33092632	2317	2320	O
9	33092632	2321	2322	O
;	33092632	2323	2324	O
Increased	33092632	2325	2334	O
antibody	33092632	2335	2343	O
titer	33092632	2344	2349	O
against	33092632	2350	2357	O
SARS	33092632	2358	2362	O
-	33092632	2363	2364	O
CoV2	33092632	2365	2369	O
at	33092632	2370	2372	O
days	33092632	2373	2377	O
30	33092632	2378	2380	O
and	33092632	2381	2384	O
60	33092632	2385	2387	O
;	33092632	2388	2389	O
Proportion	33092632	2390	2400	O
of	33092632	2401	2403	O
patients	33092632	2404	2412	O
with	33092632	2413	2417	O
negative	33092632	2418	2426	O
of	33092632	2427	2429	O
SARS	33092632	2430	2434	O
-	33092632	2435	2436	O
CoV2	33092632	2437	2441	O
nasopharyngeal	33092632	2442	2456	O
swab	33092632	2457	2461	O
at	33092632	2462	2464	O
day	33092632	2465	2468	O
30	33092632	2469	2471	O
;	33092632	2472	2473	O
Length	33092632	2474	2480	O
of	33092632	2481	2483	O
hospital	33092632	2484	2492	O
stay	33092632	2493	2497	O
;	33092632	2498	2499	O
Mortality	33092632	2500	2509	O
rate	33092632	2510	2514	O
at	33092632	2515	2517	O
day	33092632	2518	2521	O
28	33092632	2522	2524	O
;	33092632	2525	2526	O
Total	33092632	2527	2532	O
plasma	33092632	2533	2539	O
related	33092632	2540	2547	O
adverse	33092632	2548	2555	O
event	33092632	2556	2561	O
(	33092632	2562	2563	O
day	33092632	2564	2567	O
60	33092632	2568	2570	O
)	33092632	2571	2572	O
;	33092632	2573	2574	O
Total	33092632	2575	2580	O
non	33092632	2581	2584	O
-	33092632	2585	2586	O
plasma	33092632	2587	2593	O
related	33092632	2594	2601	O
adverse	33092632	2602	2609	O
events	33092632	2610	2616	O
(	33092632	2617	2618	O
day	33092632	2619	2622	O
60	33092632	2623	2625	O
)	33092632	2626	2627	O
;	33092632	2628	2629	O
Severe	33092632	2630	2636	O
adverse	33092632	2637	2644	O
events	33092632	2645	2651	O
(	33092632	2652	2653	O
SAE	33092632	2654	2657	O
)	33092632	2658	2659	O
(	33092632	2660	2661	O
day	33092632	2662	2665	O
60	33092632	2666	2668	O
)	33092632	2669	2670	O
.	33092632	2671	2672	O

UNASSIGNED	33092632	2673	2683	O
:	33092632	2684	2685	O
Treatment	33092632	2686	2695	O
allocation	33092632	2696	2706	O
is	33092632	2707	2709	O
randomized	33092632	2710	2720	O
with	33092632	2721	2725	O
a	33092632	2726	2727	O
ratio	33092632	2728	2733	O
1:1	33092632	2734	2737	O
in	33092632	2738	2740	O
both	33092632	2741	2745	O
phase	33092632	2746	2751	O
II	33092632	2752	2754	O
and	33092632	2755	2758	O
phase	33092632	2759	2764	O
III	33092632	2765	2768	O
.	33092632	2769	2770	O

Randomization	33092632	2771	2784	O
sequences	33092632	2785	2794	O
will	33092632	2795	2799	O
be	33092632	2800	2802	O
generated	33092632	2803	2812	O
at	33092632	2813	2815	O
Fondazione	33092632	2816	2826	O
Policlinico	33092632	2827	2838	O
Gemelli	33092632	2839	2846	O
IRCCS	33092632	2847	2852	O
through	33092632	2853	2860	O
the	33092632	2861	2864	O
RedCap	33092632	2865	2871	O
web	33092632	2872	2875	O
application	33092632	2876	2887	O
.	33092632	2888	2889	O

Randomized	33092632	2890	2900	O
stratification	33092632	2901	2915	O
is	33092632	2916	2918	O
performed	33092632	2919	2928	O
according	33092632	2929	2938	O
to	33092632	2939	2941	O
age	33092632	2942	2945	O
(	33092632	2946	2947	O
under	33092632	2948	2953	O
/	33092632	2954	2955	O
over	33092632	2956	2960	O
80	33092632	2961	2963	O
years	33092632	2964	2969	O
)	33092632	2970	2971	O
,	33092632	2972	2973	O
and	33092632	2974	2977	O
sex	33092632	2978	2981	O
.	33092632	2982	2983	O

UNASSIGNED	33092632	2984	2994	O
:	33092632	2995	2996	O
None	33092632	2997	3001	O
,	33092632	3002	3003	O
this	33092632	3004	3008	O
is	33092632	3009	3011	O
an	33092632	3012	3014	O
open	33092632	3015	3019	O
-	33092632	3020	3021	O
label	33092632	3022	3027	O
trial	33092632	3028	3033	O
.	33092632	3034	3035	O

UNASSIGNED	33092632	3036	3046	O
:	33092632	3047	3048	O
Phase	33092632	3049	3054	O
II	33092632	3055	3057	O
:	33092632	3058	3059	O
114	33092632	3060	3063	O
patients	33092632	3064	3072	O
(	33092632	3073	3074	O
57	33092632	3075	3077	O
per	33092632	3078	3081	O
arm	33092632	3082	3085	O
)	33092632	3086	3087	O
.	33092632	3088	3089	O

Phase	33092632	3090	3095	O
III	33092632	3096	3099	O
:	33092632	3100	3101	O
182	33092632	3102	3105	O
patients	33092632	3106	3114	O
(	33092632	3115	3116	O
91	33092632	3117	3119	O
per	33092632	3120	3123	O
arm	33092632	3124	3127	O
)	33092632	3128	3129	O
TRIAL	33092632	3130	3135	O
STATUS	33092632	3136	3142	O
:	33092632	3143	3144	O
The	33092632	3145	3148	O
trial	33092632	3149	3154	O
recruitment	33092632	3155	3166	O
started	33092632	3167	3174	O
on	33092632	3175	3177	O
May	33092632	3178	3181	O
27	33092632	3182	3184	O
,	33092632	3185	3186	O
2020	33092632	3187	3191	O
.	33092632	3192	3193	O

The	33092632	3194	3197	O
anticipated	33092632	3198	3209	O
date	33092632	3210	3214	O
of	33092632	3215	3217	O
recruitment	33092632	3218	3229	O
completion	33092632	3230	3240	O
is	33092632	3241	3243	O
April	33092632	3244	3249	O
30	33092632	3250	3252	O
,	33092632	3253	3254	O
2021	33092632	3255	3259	O
.	33092632	3260	3261	O

The	33092632	3262	3265	O
protocol	33092632	3266	3274	O
version	33092632	3275	3282	O
is	33092632	3283	3285	O
2	33092632	3286	3287	O
(	33092632	3288	3289	O
May	33092632	3290	3293	O
10	33092632	3294	3296	O
,	33092632	3297	3298	O
2020	33092632	3299	3303	O
)	33092632	3304	3305	O
.	33092632	3306	3307	O

BACKGROUND	33092632	3308	3318	O
:	33092632	3319	3320	O
The	33092632	3321	3324	O
trial	33092632	3325	3330	O
has	33092632	3331	3334	O
been	33092632	3335	3339	O
registered	33092632	3340	3350	O
on	33092632	3351	3353	O
ClinicalTrials.gov	33092632	3354	3372	O
(	33092632	3373	3374	O
May	33092632	3375	3378	O
5	33092632	3379	3380	O
,	33092632	3381	3382	O
2020	33092632	3383	3387	O
)	33092632	3388	3389	O
.	33092632	3390	3391	O

The	33092632	3392	3395	O
Identifier	33092632	3396	3406	O
number	33092632	3407	3413	O
is	33092632	3414	3416	O
NCT04374526	33092632	3417	3428	O
FULL	33092632	3429	3433	O
PROTOCOL	33092632	3434	3442	O
:	33092632	3443	3444	O
The	33092632	3445	3448	O
full	33092632	3449	3453	O
protocol	33092632	3454	3462	O
is	33092632	3463	3465	O
attached	33092632	3466	3474	O
as	33092632	3475	3477	O
an	33092632	3478	3480	O
additional	33092632	3481	3491	O
file	33092632	3492	3496	O
,	33092632	3497	3498	O
accessible	33092632	3499	3509	O
from	33092632	3510	3514	O
the	33092632	3515	3518	O
Trials	33092632	3519	3525	O
website	33092632	3526	3533	O
(	33092632	3534	3535	O
Additional	33092632	3536	3546	O
file	33092632	3547	3551	O
1	33092632	3552	3553	O
)	33092632	3554	3555	O
.	33092632	3556	3557	O

In	33092632	3558	3560	O
the	33092632	3561	3564	O
interest	33092632	3565	3573	O
in	33092632	3574	3576	O
expediting	33092632	3577	3587	O
dissemination	33092632	3588	3601	O
of	33092632	3602	3604	O
this	33092632	3605	3609	O
material	33092632	3610	3618	O
,	33092632	3619	3620	O
the	33092632	3621	3624	O
familiar	33092632	3625	3633	O
formatting	33092632	3634	3644	O
has	33092632	3645	3648	O
been	33092632	3649	3653	O
eliminated	33092632	3654	3664	O
;	33092632	3665	3666	O
this	33092632	3667	3671	O
Letter	33092632	3672	3678	O
serves	33092632	3679	3685	O
as	33092632	3686	3688	O
a	33092632	3689	3690	O
summary	33092632	3691	3698	O
of	33092632	3699	3701	O
the	33092632	3702	3705	O
key	33092632	3706	3709	O
elements	33092632	3710	3718	O
of	33092632	3719	3721	O
the	33092632	3722	3725	O
full	33092632	3726	3730	O
protocol	33092632	3731	3739	O
.	33092632	3740	3741	O


The	33092653	0	3	O
clinical	33092653	4	12	O
effect	33092653	13	19	O
of	33092653	20	22	O
Nano	33092653	23	27	O
micelles	33092653	28	36	O
containing	33092653	37	47	O
curcumin	33092653	48	56	O
as	33092653	57	59	O
a	33092653	60	61	O
therapeutic	33092653	62	73	O
supplement	33092653	74	84	O
in	33092653	85	87	O
patients	33092653	88	96	O
with	33092653	97	101	O
COVID-19	33092653	102	110	O
and	33092653	111	114	O
the	33092653	115	118	O
immune	33092653	119	125	O
responses	33092653	126	135	O
balance	33092653	136	143	O
changes	33092653	144	151	O
following	33092653	152	161	O
treatment	33092653	162	171	O
:	33092653	172	173	O
A	33092653	174	175	O
structured	33092653	176	186	O
summary	33092653	187	194	O
of	33092653	195	197	O
a	33092653	198	199	O
study	33092653	200	205	O
protocol	33092653	206	214	O
for	33092653	215	218	O
a	33092653	219	220	O
randomised	33092653	221	231	O
controlled	33092653	232	242	O
trial	33092653	243	248	O
.	33092653	249	250	O

OBJECTIVE	33092653	251	260	O
:	33092653	261	262	O
To	33092653	263	265	O
investigates	33092653	266	278	O
the	33092653	279	282	O
effectiveness	33092653	283	296	O
of	33092653	297	299	O
curcumin	33092653	300	308	O
-	33092653	309	310	O
containing	33092653	311	321	O
Nanomicelles	33092653	322	334	O
as	33092653	335	337	O
a	33092653	338	339	O
therapeutic	33092653	340	351	O
supplement	33092653	352	362	O
in	33092653	363	365	O
the	33092653	366	369	O
treatment	33092653	370	379	O
of	33092653	380	382	O
patients	33092653	383	391	O
with	33092653	392	396	O
COVID-19	33092653	397	405	O
and	33092653	406	409	O
its	33092653	410	413	O
effect	33092653	414	420	O
on	33092653	421	423	O
immune	33092653	424	430	O
responses	33092653	431	440	O
balance	33092653	441	448	O
changes	33092653	449	456	O
following	33092653	457	466	O
treatment	33092653	467	476	O
.	33092653	477	478	O

METHODS	33092653	479	486	O
:	33092653	487	488	O
This	33092653	489	493	O
study	33092653	494	499	O
is	33092653	500	502	O
conducted	33092653	503	512	O
as	33092653	513	515	O
a	33092653	516	517	O
prospective	33092653	518	529	O
,	33092653	530	531	O
placebo	33092653	532	539	O
-	33092653	540	541	O
controlled	33092653	542	552	O
with	33092653	553	557	O
parallel	33092653	558	566	O
group	33092653	567	572	O
,	33092653	573	574	O
single	33092653	575	581	O
-	33092653	582	583	O
center	33092653	584	590	O
randomized	33092653	591	601	O
clinical	33092653	602	610	O
trial	33092653	611	616	O
on	33092653	617	619	O
COVID-19	33092653	620	628	O
patients	33092653	629	637	O
.	33092653	638	639	O

METHODS	33092653	640	647	O
:	33092653	648	649	O
Patients	33092653	650	658	O
are	33092653	659	662	O
selected	33092653	663	671	O
from	33092653	672	676	O
the	33092653	677	680	O
COVID-19	33092653	681	689	O
ward	33092653	690	694	O
of	33092653	695	697	O
Shahid	33092653	698	704	O
Mohammadi	33092653	705	714	O
Hospital	33092653	715	723	O
in	33092653	724	726	O
Bandar	33092653	727	733	O
Abbas	33092653	734	739	O
,	33092653	740	741	O
Iran	33092653	742	746	O
.	33092653	747	748	O

METHODS	33092653	749	756	O
:	33092653	757	758	O
1	33092653	759	760	O
.	33092653	761	762	O

Real	33092653	763	767	O
time	33092653	768	772	O
PCR	33092653	773	776	O
-	33092653	777	778	O
approved	33092653	779	787	O
positive	33092653	788	796	O
COVID-19	33092653	797	805	O
test	33092653	806	810	O
.	33092653	811	812	O

2	33092653	813	814	O
.	33092653	815	816	O

Both	33092653	817	821	O
gender	33092653	822	828	O
3	33092653	829	830	O
.	33092653	831	832	O

Age	33092653	833	836	O
between	33092653	837	844	O
18	33092653	845	847	O
and	33092653	848	851	O
75	33092653	852	854	O
years	33092653	855	860	O
4	33092653	861	862	O
.	33092653	863	864	O

Signing	33092653	865	872	O
a	33092653	873	874	O
written	33092653	875	882	O
consent	33092653	883	890	O
5	33092653	891	892	O
.	33092653	893	894	O

Lack	33092653	895	899	O
of	33092653	900	902	O
participation	33092653	903	916	O
in	33092653	917	919	O
other	33092653	920	925	O
clinical	33092653	926	934	O
trials	33092653	935	941	O
Exclusion	33092653	942	951	O
criteria	33092653	952	960	O
:	33092653	961	962	O
1	33092653	963	964	O
.	33092653	965	966	O
Pregnancy	33092653	967	976	O
or	33092653	977	979	O
lactation	33092653	980	989	O
2	33092653	990	991	O
.	33092653	992	993	O

Allergy	33092653	994	1001	O
to	33092653	1002	1004	O
turmeric	33092653	1005	1013	O
or	33092653	1014	1016	O
curcumin	33092653	1017	1025	O
3	33092653	1026	1027	O
.	33092653	1028	1029	O

Smoking	33092653	1030	1037	O
4	33092653	1038	1039	O
.	33092653	1040	1041	O

Patient	33092653	1042	1049	O
connected	33092653	1050	1059	O
to	33092653	1060	1062	O
the	33092653	1063	1066	O
ventilator	33092653	1067	1077	O
5	33092653	1078	1079	O
.	33092653	1080	1081	O

SaO2	33092653	1082	1086	O
less	33092653	1087	1091	O
than	33092653	1092	1096	O
90	33092653	1097	1099	O
%	33092653	1100	1101	O
or	33092653	1102	1104	O
PaO2	33092653	1105	1109	O
less	33092653	1110	1114	O
than	33092653	1115	1119	O
8	33092653	1120	1121	O
kPa	33092653	1122	1125	O
6	33092653	1126	1127	O
.	33092653	1128	1129	O

Having	33092653	1130	1136	O
comorbidities	33092653	1137	1150	O
(	33092653	1151	1152	O
such	33092653	1153	1157	O
as	33092653	1158	1160	O
severe	33092653	1161	1167	O
renal	33092653	1168	1173	O
failure	33092653	1174	1181	O
,	33092653	1182	1183	O
Glomerular	33092653	1184	1194	O
filtration	33092653	1195	1205	O
rate	33092653	1206	1210	O
less	33092653	1211	1215	O
than	33092653	1216	1220	O
30	33092653	1221	1223	O
ml	33092653	1224	1226	O
/	33092653	1227	1228	O
min	33092653	1229	1232	O
,	33092653	1233	1234	O
liver	33092653	1235	1240	O
failure	33092653	1241	1248	O
,	33092653	1249	1250	O
Congestive	33092653	1251	1261	O
heart	33092653	1262	1267	O
failure	33092653	1268	1275	O
,	33092653	1276	1277	O
or	33092653	1278	1280	O
Chronic	33092653	1281	1288	O
obstructive	33092653	1289	1300	O
pulmonary	33092653	1301	1310	O
disease	33092653	1311	1318	O
)	33092653	1319	1320	O
7	33092653	1321	1322	O
.	33092653	1323	1324	O

History	33092653	1325	1332	O
of	33092653	1333	1335	O
gallstones	33092653	1336	1346	O
8	33092653	1347	1348	O
.	33092653	1349	1350	O

History	33092653	1351	1358	O
of	33092653	1359	1361	O
gastritis	33092653	1362	1371	O
or	33092653	1372	1374	O
active	33092653	1375	1381	O
gastrointestinal	33092653	1382	1398	O
ulcer	33092653	1399	1404	O
INTERVENTION	33092653	1405	1417	O
AND	33092653	1418	1421	O
COMPARATOR	33092653	1422	1432	O
:	33092653	1433	1434	O
In	33092653	1435	1437	O
addition	33092653	1438	1446	O
to	33092653	1447	1449	O
the	33092653	1450	1453	O
routine	33092653	1454	1461	O
standard	33092653	1462	1470	O
treatments	33092653	1471	1481	O
for	33092653	1482	1485	O
COVID-19	33092653	1486	1494	O
,	33092653	1495	1496	O
in	33092653	1497	1499	O
the	33092653	1500	1503	O
intervention	33092653	1504	1516	O
group	33092653	1517	1522	O
,	33092653	1523	1524	O
40	33092653	1525	1527	O
mg	33092653	1528	1530	O
nanomicelles	33092653	1531	1543	O
containing	33092653	1544	1554	O
curcumin	33092653	1555	1563	O
(	33092653	1564	1565	O
SinaCurcumin	33092653	1566	1578	O
Capsule	33092653	1579	1586	O
,	33092653	1587	1588	O
Exir	33092653	1589	1593	O
Nano	33092653	1594	1598	O
Sina	33092653	1599	1603	O
Company	33092653	1604	1611	O
,	33092653	1612	1613	O
Iran	33092653	1614	1618	O
)	33092653	1619	1620	O
,	33092653	1621	1622	O
four	33092653	1623	1627	O
times	33092653	1628	1633	O
per	33092653	1634	1637	O
day	33092653	1638	1641	O
(	33092653	1642	1643	O
after	33092653	1644	1649	O
breakfast	33092653	1650	1659	O
,	33092653	1660	1661	O
lunch	33092653	1662	1667	O
,	33092653	1668	1669	O
dinner	33092653	1670	1676	O
and	33092653	1677	1680	O
before	33092653	1681	1687	O
bedtime	33092653	1688	1695	O
)	33092653	1696	1697	O
and	33092653	1698	1701	O
in	33092653	1702	1704	O
the	33092653	1705	1708	O
placebo	33092653	1709	1716	O
group	33092653	1717	1722	O
as	33092653	1723	1725	O
the	33092653	1726	1729	O
control	33092653	1730	1737	O
group	33092653	1738	1743	O
,	33092653	1744	1745	O
capsules	33092653	1746	1754	O
with	33092653	1755	1759	O
the	33092653	1760	1763	O
same	33092653	1764	1768	O
appearance	33092653	1769	1779	O
and	33092653	1780	1783	O
characteristics	33092653	1784	1799	O
(	33092653	1800	1801	O
Placebo	33092653	1802	1809	O
capsules	33092653	1810	1818	O
,	33092653	1819	1820	O
Exir	33092653	1821	1825	O
Nano	33092653	1826	1830	O
Sina	33092653	1831	1835	O
Company	33092653	1836	1843	O
,	33092653	1844	1845	O
Iran	33092653	1846	1850	O
)	33092653	1851	1852	O
are	33092653	1853	1856	O
prescribed	33092653	1857	1867	O
for	33092653	1868	1871	O
two	33092653	1872	1875	O
weeks	33092653	1876	1881	O
.	33092653	1882	1883	O

RESULTS	33092653	1884	1891	O
:	33092653	1892	1893	O
The	33092653	1894	1897	O
effectiveness	33092653	1898	1911	O
of	33092653	1912	1914	O
Nano	33092653	1915	1919	O
micelles	33092653	1920	1928	O
containing	33092653	1929	1939	O
curcumin	33092653	1940	1948	O
treatment	33092653	1949	1958	O
will	33092653	1959	1963	O
be	33092653	1964	1966	O
evaluated	33092653	1967	1976	O
as	33092653	1977	1979	O
daily	33092653	1980	1985	O
clinical	33092653	1986	1994	O
examinations	33092653	1995	2007	O
of	33092653	2008	2010	O
patients	33092653	2011	2019	O
in	33092653	2020	2022	O
both	33092653	2023	2027	O
groups	33092653	2028	2034	O
and	33092653	2035	2038	O
,	33092653	2039	2040	O
on	33092653	2041	2043	O
days	33092653	2044	2048	O
0	33092653	2049	2050	O
,	33092653	2051	2052	O
7	33092653	2053	2054	O
and	33092653	2055	2058	O
14	33092653	2059	2061	O
,	33092653	2062	2063	O
complete	33092653	2064	2072	O
clinical	33092653	2073	2081	O
symptoms	33092653	2082	2090	O
and	33092653	2091	2094	O
laboratory	33092653	2095	2105	O
findings	33092653	2106	2114	O
including	33092653	2115	2124	O
peripheral	33092653	2125	2135	O
blood	33092653	2136	2141	O
and	33092653	2142	2145	O
serum	33092653	2146	2151	O
parameters	33092653	2152	2162	O
such	33092653	2163	2167	O
as	33092653	2168	2170	O
inflammatory	33092653	2171	2183	O
markers	33092653	2184	2191	O
will	33092653	2192	2196	O
be	33092653	2197	2199	O
measured	33092653	2200	2208	O
and	33092653	2209	2212	O
recorded	33092653	2213	2221	O
.	33092653	2222	2223	O

Moreover	33092653	2224	2232	O
,	33092653	2233	2234	O
in	33092653	2235	2237	O
order	33092653	2238	2243	O
to	33092653	2244	2246	O
evaluate	33092653	2247	2255	O
the	33092653	2256	2259	O
balance	33092653	2260	2267	O
of	33092653	2268	2270	O
immune	33092653	2271	2277	O
responses	33092653	2278	2287	O
changes	33092653	2288	2295	O
following	33092653	2296	2305	O
treatments	33092653	2306	2316	O
,	33092653	2317	2318	O
serum	33092653	2319	2324	O
level	33092653	2325	2330	O
of	33092653	2331	2333	O
IFN	33092653	2334	2337	O
-	33092653	2338	2339	O
	33092653	2340	2341	O
,	33092653	2342	2343	O
IL-17	33092653	2344	2349	O
,	33092653	2350	2351	O
Il-4	33092653	2352	2356	O
and	33092653	2357	2360	O
TGF	33092653	2361	2364	O
-	33092653	2365	2366	O
	33092653	2367	2368	O
serum	33092653	2369	2374	O
cytokines	33092653	2375	2384	O
will	33092653	2385	2389	O
be	33092653	2390	2392	O
measured	33092653	2393	2401	O
in	33092653	2402	2404	O
both	33092653	2405	2409	O
groups	33092653	2410	2416	O
at	33092653	2417	2419	O
time	33092653	2420	2424	O
points	33092653	2425	2431	O
of	33092653	2432	2434	O
0	33092653	2435	2436	O
,	33092653	2437	2438	O
7	33092653	2439	2440	O
and	33092653	2441	2444	O
14	33092653	2445	2447	O
days	33092653	2448	2452	O
post	33092653	2453	2457	O
treatment	33092653	2458	2467	O
.	33092653	2468	2469	O

Gene	33092653	2470	2474	O
expression	33092653	2475	2485	O
of	33092653	2486	2488	O
t	33092653	2489	2490	O
-	33092653	2491	2492	O
bet	33092653	2493	2496	O
,	33092653	2497	2498	O
GATA-3	33092653	2499	2505	O
,	33092653	2506	2507	O
FoxP3	33092653	2508	2513	O
and	33092653	2514	2517	O
ROR-	33092653	2518	2522	O
T	33092653	2523	2525	O
will	33092653	2526	2530	O
also	33092653	2531	2535	O
be	33092653	2536	2538	O
measured	33092653	2539	2547	O
at	33092653	2548	2550	O
mentioned	33092653	2551	2560	O
time	33092653	2561	2565	O
points	33092653	2566	2572	O
to	33092653	2573	2575	O
assess	33092653	2576	2582	O
the	33092653	2583	2586	O
shift	33092653	2587	2592	O
of	33092653	2593	2595	O
T	33092653	2596	2597	O
helper1	33092653	2598	2605	O
,	33092653	2606	2607	O
T	33092653	2608	2609	O
helper2	33092653	2610	2617	O
,	33092653	2618	2619	O
T	33092653	2620	2621	O
regulatory	33092653	2622	2632	O
and	33092653	2633	2636	O
T	33092653	2637	2638	O
helper	33092653	2639	2645	O
17	33092653	2646	2648	O
immune	33092653	2649	2655	O
responses	33092653	2656	2665	O
following	33092653	2666	2675	O
treatment	33092653	2676	2685	O
.	33092653	2686	2687	O

UNASSIGNED	33092653	2688	2698	O
:	33092653	2699	2700	O
Randomized	33092653	2701	2711	O
trials	33092653	2712	2718	O
will	33092653	2719	2723	O
be	33092653	2724	2726	O
performed	33092653	2727	2736	O
on	33092653	2737	2739	O
40	33092653	2740	2742	O
COVID-19	33092653	2743	2751	O
patients	33092653	2752	2760	O
which	33092653	2761	2766	O
will	33092653	2767	2771	O
be	33092653	2772	2774	O
randomized	33092653	2775	2785	O
using	33092653	2786	2791	O
encoded	33092653	2792	2799	O
sealed	33092653	2800	2806	O
boxes	33092653	2807	2812	O
with	33092653	2813	2817	O
computer	33092653	2818	2826	O
generated	33092653	2827	2836	O
random	33092653	2837	2843	O
digits	33092653	2844	2850	O
with	33092653	2851	2855	O
1:1	33092653	2856	2859	O
allocation	33092653	2860	2870	O
ratio	33092653	2871	2876	O
.	33092653	2877	2878	O

In	33092653	2879	2881	O
order	33092653	2882	2887	O
to	33092653	2888	2890	O
randomization	33092653	2891	2904	O
,	33092653	2905	2906	O
placebo	33092653	2907	2914	O
and	33092653	2915	2918	O
SinaCurcumin	33092653	2919	2931	O
Capsules	33092653	2932	2940	O
will	33092653	2941	2945	O
be	33092653	2946	2948	O
numbered	33092653	2949	2957	O
first	33092653	2958	2963	O
by	33092653	2964	2966	O
computer	33092653	2967	2975	O
generated	33092653	2976	2985	O
random	33092653	2986	2992	O
digits	33092653	2993	2999	O
.	33092653	3000	3001	O

SinaCurcumin	33092653	3002	3014	O
and	33092653	3015	3018	O
placebo	33092653	3019	3026	O
will	33092653	3027	3031	O
then	33092653	3032	3036	O
be	33092653	3037	3039	O
stored	33092653	3040	3046	O
and	33092653	3047	3050	O
numbered	33092653	3051	3059	O
in	33092653	3060	3062	O
sealed	33092653	3063	3069	O
packages	33092653	3070	3078	O
based	33092653	3079	3084	O
on	33092653	3085	3087	O
generated	33092653	3088	3097	O
random	33092653	3098	3104	O
numbers	33092653	3105	3112	O
.	33092653	3113	3114	O

Finally	33092653	3115	3122	O
,	33092653	3123	3124	O
according	33092653	3125	3134	O
to	33092653	3135	3137	O
the	33092653	3138	3141	O
order	33092653	3142	3147	O
in	33092653	3148	3150	O
which	33092653	3151	3156	O
patients	33092653	3157	3165	O
enter	33092653	3166	3171	O
the	33092653	3172	3175	O
study	33092653	3176	3181	O
,	33092653	3182	3183	O
packages	33092653	3184	3192	O
are	33092653	3193	3196	O
given	33092653	3197	3202	O
to	33092653	3203	3205	O
patients	33092653	3206	3214	O
based	33092653	3215	3220	O
on	33092653	3221	3223	O
their	33092653	3224	3229	O
number	33092653	3230	3236	O
.	33092653	3237	3238	O

UNASSIGNED	33092653	3239	3249	O
:	33092653	3250	3251	O
The	33092653	3252	3255	O
present	33092653	3256	3263	O
study	33092653	3264	3269	O
will	33092653	3270	3274	O
be	33092653	3275	3277	O
blind	33092653	3278	3283	O
for	33092653	3284	3287	O
all	33092653	3288	3291	O
patients	33092653	3292	3300	O
,	33092653	3301	3302	O
physicians	33092653	3303	3313	O
and	33092653	3314	3317	O
nurses	33092653	3318	3324	O
,	33092653	3325	3326	O
laboratory	33092653	3327	3337	O
technicians	33092653	3338	3349	O
and	33092653	3350	3353	O
statisticians	33092653	3354	3367	O
.	33092653	3368	3369	O

UNASSIGNED	33092653	3370	3380	O
:	33092653	3381	3382	O
A	33092653	3383	3384	O
total	33092653	3385	3390	O
of	33092653	3391	3393	O
40	33092653	3394	3396	O
patients	33092653	3397	3405	O
will	33092653	3406	3410	O
be	33092653	3411	3413	O
included	33092653	3414	3422	O
in	33092653	3423	3425	O
the	33092653	3426	3429	O
study	33092653	3430	3435	O
,	33092653	3436	3437	O
20	33092653	3438	3440	O
of	33092653	3441	3443	O
them	33092653	3444	3448	O
will	33092653	3449	3453	O
be	33092653	3454	3456	O
randomly	33092653	3457	3465	O
assigned	33092653	3466	3474	O
to	33092653	3475	3477	O
the	33092653	3478	3481	O
intervention	33092653	3482	3494	O
group	33092653	3495	3500	O
and	33092653	3501	3504	O
20	33092653	3505	3507	O
to	33092653	3508	3510	O
the	33092653	3511	3514	O
placebo	33092653	3515	3522	O
group	33092653	3523	3528	O
.	33092653	3529	3530	O

UNASSIGNED	33092653	3531	3541	O
:	33092653	3542	3543	O
This	33092653	3544	3548	O
is	33092653	3549	3551	O
Version	33092653	3552	3559	O
1.0	33092653	3560	3563	O
of	33092653	3564	3566	O
protocol	33092653	3567	3575	O
dated	33092653	3576	3581	O
21	33092653	3582	3584	O
May	33092653	3585	3588	O
2020	33092653	3589	3593	O
.	33092653	3594	3595	O

The	33092653	3596	3599	O
recruitment	33092653	3600	3611	O
was	33092653	3612	3615	O
started	33092653	3616	3623	O
June	33092653	3624	3628	O
24	33092653	3629	3631	O
,	33092653	3632	3633	O
2020	33092653	3634	3638	O
and	33092653	3639	3642	O
is	33092653	3643	3645	O
expected	33092653	3646	3654	O
to	33092653	3655	3657	O
be	33092653	3658	3660	O
completed	33092653	3661	3670	O
by	33092653	3671	3673	O
October	33092653	3674	3681	O
31	33092653	3682	3684	O
,	33092653	3685	3686	O
2020	33092653	3687	3691	O
.	33092653	3692	3693	O

BACKGROUND	33092653	3694	3704	O
:	33092653	3705	3706	O
This	33092653	3707	3711	O
present	33092653	3712	3719	O
clinical	33092653	3720	3728	O
trial	33092653	3729	3734	O
has	33092653	3735	3738	O
been	33092653	3739	3743	O
registered	33092653	3744	3754	O
in	33092653	3755	3757	O
the	33092653	3758	3761	O
Iranian	33092653	3762	3769	O
Registry	33092653	3770	3778	O
of	33092653	3779	3781	O
Clinical	33092653	3782	3790	O
Trials	33092653	3791	3797	O
(	33092653	3798	3799	O
IRCT	33092653	3800	3804	O
)	33092653	3805	3806	O
with	33092653	3807	3811	O
the	33092653	3812	3815	O
registration	33092653	3816	3828	O
code	33092653	3829	3833	O
of	33092653	3834	3836	O
"	33092653	3837	3838	O
IRCT20200611047735N1	33092653	3839	3859	O
"	33092653	3860	3861	O
,	33092653	3862	3863	O
https://www.irct.ir/trial/48843	33092653	3864	3895	O
.	33092653	3896	3897	O

Dated	33092653	3898	3903	O
:	33092653	3904	3905	O
19	33092653	3906	3908	O
June	33092653	3909	3913	O
2020	33092653	3914	3918	O
.	33092653	3919	3920	O

UNASSIGNED	33092653	3921	3931	O
:	33092653	3932	3933	O
The	33092653	3934	3937	O
full	33092653	3938	3942	O
protocol	33092653	3943	3951	O
is	33092653	3952	3954	O
attached	33092653	3955	3963	O
as	33092653	3964	3966	O
an	33092653	3967	3969	O
additional	33092653	3970	3980	O
file	33092653	3981	3985	O
,	33092653	3986	3987	O
accessible	33092653	3988	3998	O
from	33092653	3999	4003	O
the	33092653	4004	4007	O
Trials	33092653	4008	4014	O
website	33092653	4015	4022	O
(	33092653	4023	4024	O
Additional	33092653	4025	4035	O
file	33092653	4036	4040	O
1	33092653	4041	4042	O
)	33092653	4043	4044	O
.	33092653	4045	4046	O

In	33092653	4047	4049	O
the	33092653	4050	4053	O
interest	33092653	4054	4062	O
in	33092653	4063	4065	O
expediting	33092653	4066	4076	O
dissemination	33092653	4077	4090	O
of	33092653	4091	4093	O
this	33092653	4094	4098	O
material	33092653	4099	4107	O
,	33092653	4108	4109	O
the	33092653	4110	4113	O
familiar	33092653	4114	4122	O
formatting	33092653	4123	4133	O
has	33092653	4134	4137	O
been	33092653	4138	4142	O
eliminated	33092653	4143	4153	O
;	33092653	4154	4155	O
this	33092653	4156	4160	O
Letter	33092653	4161	4167	O
serves	33092653	4168	4174	O
as	33092653	4175	4177	O
a	33092653	4178	4179	O
summary	33092653	4180	4187	O
of	33092653	4188	4190	O
the	33092653	4191	4194	O
key	33092653	4195	4198	O
elements	33092653	4199	4207	O
of	33092653	4208	4210	O
the	33092653	4211	4214	O
full	33092653	4215	4219	O
protocol	33092653	4220	4228	O
.	33092653	4229	4230	O


Convalescent	33093056	0	12	O
plasma	33093056	13	19	O
in	33093056	20	22	O
the	33093056	23	26	O
management	33093056	27	37	O
of	33093056	38	40	O
moderate	33093056	41	49	O
covid-19	33093056	50	58	O
in	33093056	59	61	O
adults	33093056	62	68	O
in	33093056	69	71	O
India	33093056	72	77	O
:	33093056	78	79	O
open	33093056	80	84	O
label	33093056	85	90	O
phase	33093056	91	96	O
II	33093056	97	99	O
multicentre	33093056	100	111	O
randomised	33093056	112	122	O
controlled	33093056	123	133	O
trial	33093056	134	139	O
(	33093056	140	141	O
PLACID	33093056	142	148	O
Trial	33093056	149	154	O
)	33093056	155	156	O
.	33093056	157	158	O

To	33093056	159	161	O
investigate	33093056	162	173	O
the	33093056	174	177	O
effectiveness	33093056	178	191	O
of	33093056	192	194	O
using	33093056	195	200	O
convalescent	33093056	201	213	O
plasma	33093056	214	220	O
to	33093056	221	223	O
treat	33093056	224	229	O
moderate	33093056	230	238	O
coronavirus	33093056	239	250	O
disease	33093056	251	258	O
2019	33093056	259	263	O
(	33093056	264	265	O
covid-19	33093056	266	274	O
)	33093056	275	276	O
in	33093056	277	279	O
adults	33093056	280	286	O
in	33093056	287	289	O
India	33093056	290	295	O
.	33093056	296	297	O

Open	33093056	298	302	O
label	33093056	303	308	O
,	33093056	309	310	O
parallel	33093056	311	319	O
arm	33093056	320	323	O
,	33093056	324	325	O
phase	33093056	326	331	O
II	33093056	332	334	O
,	33093056	335	336	O
multicentre	33093056	337	348	O
,	33093056	349	350	O
randomised	33093056	351	361	O
controlled	33093056	362	372	O
trial	33093056	373	378	O
.	33093056	379	380	O

39	33093056	381	383	O
public	33093056	384	390	O
and	33093056	391	394	O
private	33093056	395	402	O
hospitals	33093056	403	412	O
across	33093056	413	419	O
India	33093056	420	425	O
.	33093056	426	427	O

464	33093056	428	431	O
adults	33093056	432	438	O
(	33093056	439	440	O
	33093056	441	442	O
18	33093056	443	445	O
years	33093056	446	451	O
)	33093056	452	453	O
admitted	33093056	454	462	O
to	33093056	463	465	O
hospital	33093056	466	474	O
(	33093056	475	476	O
screened	33093056	477	485	O
22	33093056	486	488	O
April	33093056	489	494	O
to	33093056	495	497	O
14	33093056	498	500	O
July	33093056	501	505	O
2020	33093056	506	510	O
)	33093056	511	512	O
with	33093056	513	517	O
confirmed	33093056	518	527	O
moderate	33093056	528	536	O
covid-19	33093056	537	545	O
(	33093056	546	547	O
partial	33093056	548	555	O
pressure	33093056	556	564	O
of	33093056	565	567	O
oxygen	33093056	568	574	O
in	33093056	575	577	O
arterial	33093056	578	586	O
blood	33093056	587	592	O
/	33093056	593	594	O
fraction	33093056	595	603	O
of	33093056	604	606	O
inspired	33093056	607	615	O
oxygen	33093056	616	622	O
(	33093056	623	624	O
PaO2	33093056	625	629	O
/	33093056	630	631	O
FiO2	33093056	632	636	O
)	33093056	637	638	O
ratio	33093056	639	644	O
between	33093056	645	652	O
200	33093056	653	656	O
mm	33093056	657	659	O
Hg	33093056	660	662	O
and	33093056	663	666	O
300	33093056	667	670	O
mm	33093056	671	673	O
Hg	33093056	674	676	O
or	33093056	677	679	O
a	33093056	680	681	O
respiratory	33093056	682	693	O
rate	33093056	694	698	O
of	33093056	699	701	O
more	33093056	702	706	O
than	33093056	707	711	O
24	33093056	712	714	O
/	33093056	715	716	O
min	33093056	717	720	O
with	33093056	721	725	O
oxygen	33093056	726	732	O
saturation	33093056	733	743	O
93	33093056	744	746	O
%	33093056	747	748	O
or	33093056	749	751	O
less	33093056	752	756	O
on	33093056	757	759	O
room	33093056	760	764	O
air	33093056	765	768	O
)	33093056	769	770	O
:	33093056	771	772	O
235	33093056	773	776	O
were	33093056	777	781	O
assigned	33093056	782	790	O
to	33093056	791	793	O
convalescent	33093056	794	806	O
plasma	33093056	807	813	O
with	33093056	814	818	O
best	33093056	819	823	O
standard	33093056	824	832	O
of	33093056	833	835	O
care	33093056	836	840	O
(	33093056	841	842	O
intervention	33093056	843	855	O
arm	33093056	856	859	O
)	33093056	860	861	O
and	33093056	862	865	O
229	33093056	866	869	O
to	33093056	870	872	O
best	33093056	873	877	O
standard	33093056	878	886	O
of	33093056	887	889	O
care	33093056	890	894	O
only	33093056	895	899	O
(	33093056	900	901	O
control	33093056	902	909	O
arm	33093056	910	913	O
)	33093056	914	915	O
.	33093056	916	917	O

Participants	33093056	918	930	O
in	33093056	931	933	O
the	33093056	934	937	O
intervention	33093056	938	950	O
arm	33093056	951	954	O
received	33093056	955	963	O
two	33093056	964	967	O
doses	33093056	968	973	O
of	33093056	974	976	O
200	33093056	977	980	O
mL	33093056	981	983	O
convalescent	33093056	984	996	O
plasma	33093056	997	1003	O
,	33093056	1004	1005	O
transfused	33093056	1006	1016	O
24	33093056	1017	1019	O
hours	33093056	1020	1025	O
apart	33093056	1026	1031	O
.	33093056	1032	1033	O

The	33093056	1034	1037	O
presence	33093056	1038	1046	O
and	33093056	1047	1050	O
levels	33093056	1051	1057	O
of	33093056	1058	1060	O
neutralising	33093056	1061	1073	O
antibodies	33093056	1074	1084	O
were	33093056	1085	1089	O
not	33093056	1090	1093	O
measured	33093056	1094	1102	O
a	33093056	1103	1104	O
priori	33093056	1105	1111	O
;	33093056	1112	1113	O
stored	33093056	1114	1120	O
samples	33093056	1121	1128	O
were	33093056	1129	1133	O
assayed	33093056	1134	1141	O
at	33093056	1142	1144	O
the	33093056	1145	1148	O
end	33093056	1149	1152	O
of	33093056	1153	1155	O
the	33093056	1156	1159	O
study	33093056	1160	1165	O
.	33093056	1166	1167	O

Composite	33093056	1168	1177	O
of	33093056	1178	1180	O
progression	33093056	1181	1192	O
to	33093056	1193	1195	O
severe	33093056	1196	1202	O
disease	33093056	1203	1210	O
(	33093056	1211	1212	O
PaO2	33093056	1213	1217	O
/	33093056	1218	1219	O
FiO2	33093056	1220	1224	O
<	33093056	1225	1226	O
100	33093056	1227	1230	O
mm	33093056	1231	1233	O
Hg	33093056	1234	1236	O
)	33093056	1237	1238	O
or	33093056	1239	1241	O
all	33093056	1242	1245	O
cause	33093056	1246	1251	O
mortality	33093056	1252	1261	O
at	33093056	1262	1264	O
28	33093056	1265	1267	O
days	33093056	1268	1272	O
post	33093056	1273	1277	O
-	33093056	1278	1279	O
enrolment	33093056	1280	1289	O
.	33093056	1290	1291	O

Progression	33093056	1292	1303	O
to	33093056	1304	1306	O
severe	33093056	1307	1313	O
disease	33093056	1314	1321	O
or	33093056	1322	1324	O
all	33093056	1325	1328	O
cause	33093056	1329	1334	O
mortality	33093056	1335	1344	O
at	33093056	1345	1347	O
28	33093056	1348	1350	O
days	33093056	1351	1355	O
after	33093056	1356	1361	O
enrolment	33093056	1362	1371	O
occurred	33093056	1372	1380	O
in	33093056	1381	1383	O
44	33093056	1384	1386	O
(	33093056	1387	1388	O
19	33093056	1389	1391	O
%	33093056	1392	1393	O
)	33093056	1394	1395	O
participants	33093056	1396	1408	O
in	33093056	1409	1411	O
the	33093056	1412	1415	O
intervention	33093056	1416	1428	O
arm	33093056	1429	1432	O
and	33093056	1433	1436	O
41	33093056	1437	1439	O
(	33093056	1440	1441	O
18	33093056	1442	1444	O
%	33093056	1445	1446	O
)	33093056	1447	1448	O
in	33093056	1449	1451	O
the	33093056	1452	1455	O
control	33093056	1456	1463	O
arm	33093056	1464	1467	O
(	33093056	1468	1469	O
risk	33093056	1470	1474	O
difference	33093056	1475	1485	O
0.008	33093056	1486	1491	O
(	33093056	1492	1493	O
95	33093056	1494	1496	O
%	33093056	1497	1498	O
confidence	33093056	1499	1509	O
interval	33093056	1510	1518	O
-0.062	33093056	1519	1525	O
to	33093056	1526	1528	O
0.078	33093056	1529	1534	O
)	33093056	1535	1536	O
;	33093056	1537	1538	O
risk	33093056	1539	1543	O
ratio	33093056	1544	1549	O
1.04	33093056	1550	1554	O
,	33093056	1555	1556	O
95	33093056	1557	1559	O
%	33093056	1560	1561	O
confidence	33093056	1562	1572	O
interval	33093056	1573	1581	O
0.71	33093056	1582	1586	O
to	33093056	1587	1589	O
1.54	33093056	1590	1594	O
)	33093056	1595	1596	O
.	33093056	1597	1598	O

Convalescent	33093056	1599	1611	O
plasma	33093056	1612	1618	O
was	33093056	1619	1622	O
not	33093056	1623	1626	O
associated	33093056	1627	1637	O
with	33093056	1638	1642	O
a	33093056	1643	1644	O
reduction	33093056	1645	1654	O
in	33093056	1655	1657	O
progression	33093056	1658	1669	O
to	33093056	1670	1672	O
severe	33093056	1673	1679	O
covid-19	33093056	1680	1688	O
or	33093056	1689	1691	O
all	33093056	1692	1695	O
cause	33093056	1696	1701	O
mortality	33093056	1702	1711	O
.	33093056	1712	1713	O

This	33093056	1714	1718	O
trial	33093056	1719	1724	O
has	33093056	1725	1728	O
high	33093056	1729	1733	O
generalisability	33093056	1734	1750	O
and	33093056	1751	1754	O
approximates	33093056	1755	1767	O
convalescent	33093056	1768	1780	O
plasma	33093056	1781	1787	O
use	33093056	1788	1791	O
in	33093056	1792	1794	O
real	33093056	1795	1799	O
life	33093056	1800	1804	O
settings	33093056	1805	1813	O
with	33093056	1814	1818	O
limited	33093056	1819	1826	O
laboratory	33093056	1827	1837	O
capacity	33093056	1838	1846	O
.	33093056	1847	1848	O

A	33093056	1849	1850	O
priori	33093056	1851	1857	O
measurement	33093056	1858	1869	O
of	33093056	1870	1872	O
neutralising	33093056	1873	1885	O
antibody	33093056	1886	1894	O
titres	33093056	1895	1901	O
in	33093056	1902	1904	O
donors	33093056	1905	1911	O
and	33093056	1912	1915	O
participants	33093056	1916	1928	O
might	33093056	1929	1934	O
further	33093056	1935	1942	O
clarify	33093056	1943	1950	O
the	33093056	1951	1954	O
role	33093056	1955	1959	O
of	33093056	1960	1962	O
convalescent	33093056	1963	1975	O
plasma	33093056	1976	1982	O
in	33093056	1983	1985	O
the	33093056	1986	1989	O
management	33093056	1990	2000	O
of	33093056	2001	2003	O
covid-19	33093056	2004	2012	O
.	33093056	2013	2014	O

Clinical	33093056	2015	2023	O
Trial	33093056	2024	2029	O
Registry	33093056	2030	2038	O
of	33093056	2039	2041	O
India	33093056	2042	2047	O
CTRI/2020/04/024775	33093056	2048	2067	O
.	33093056	2068	2069	O


Convalescent	33106167	0	12	O
plasma	33106167	13	19	O
transfusion	33106167	20	31	O
therapy	33106167	32	39	O
in	33106167	40	42	O
severe	33106167	43	49	O
COVID-19	33106167	50	58	O
patients-	33106167	59	68	O
a	33106167	69	70	O
safety	33106167	71	77	O
,	33106167	78	79	O
efficacy	33106167	80	88	O
and	33106167	89	92	O
dose	33106167	93	97	O
response	33106167	98	106	O
study	33106167	107	112	O
:	33106167	113	114	O
A	33106167	115	116	O
structured	33106167	117	127	O
summary	33106167	128	135	O
of	33106167	136	138	O
a	33106167	139	140	O
study	33106167	141	146	O
protocol	33106167	147	155	O
of	33106167	156	158	O
a	33106167	159	160	O
phase	33106167	161	166	O
II	33106167	167	169	O
randomized	33106167	170	180	O
controlled	33106167	181	191	O
trial	33106167	192	197	O
.	33106167	198	199	O

OBJECTIVE	33106167	200	209	O
:	33106167	210	211	O
General	33106167	212	219	O
:	33106167	220	221	O
To	33106167	222	224	O
assess	33106167	225	231	O
the	33106167	232	235	O
safety	33106167	236	242	O
,	33106167	243	244	O
efficacy	33106167	245	253	O
and	33106167	254	257	O
dose	33106167	258	262	O
response	33106167	263	271	O
of	33106167	272	274	O
convalescent	33106167	275	287	O
plasma	33106167	288	294	O
(	33106167	295	296	O
CP	33106167	297	299	O
)	33106167	300	301	O
transfusion	33106167	302	313	O
in	33106167	314	316	O
severe	33106167	317	323	O
COVID-19	33106167	324	332	O
patients	33106167	333	341	O
Specific	33106167	342	350	O
:	33106167	351	352	O
a.	33106167	353	355	O
To	33106167	356	358	O
identify	33106167	359	367	O
the	33106167	368	371	O
appropriate	33106167	372	383	O
effective	33106167	384	393	O
dose	33106167	394	398	O
of	33106167	399	401	O
CP	33106167	402	404	O
therapy	33106167	405	412	O
in	33106167	413	415	O
severe	33106167	416	422	O
patients	33106167	423	431	O
b.	33106167	432	434	O
To	33106167	435	437	O
identify	33106167	438	446	O
the	33106167	447	450	O
efficacy	33106167	451	459	O
of	33106167	460	462	O
the	33106167	463	466	O
therapy	33106167	467	474	O
with	33106167	475	479	O
their	33106167	480	485	O
end	33106167	486	489	O
point	33106167	490	495	O
based	33106167	496	501	O
on	33106167	502	504	O
clinical	33106167	505	513	O
improvement	33106167	514	525	O
within	33106167	526	532	O
seven	33106167	533	538	O
days	33106167	539	543	O
of	33106167	544	546	O
treatment	33106167	547	556	O
or	33106167	557	559	O
until	33106167	560	565	O
discharge	33106167	566	575	O
whichever	33106167	576	585	O
is	33106167	586	588	O
later	33106167	589	594	O
and	33106167	595	598	O
in	33106167	599	601	O
-	33106167	602	603	O
hospital	33106167	604	612	O
mortality	33106167	613	622	O
c.	33106167	623	625	O
To	33106167	626	628	O
assess	33106167	629	635	O
the	33106167	636	639	O
clinical	33106167	640	648	O
improvement	33106167	649	660	O
after	33106167	661	666	O
CP	33106167	667	669	O
transfusion	33106167	670	681	O
in	33106167	682	684	O
severe	33106167	685	691	O
COVID-19	33106167	692	700	O
patients	33106167	701	709	O
d.	33106167	710	712	O
To	33106167	713	715	O
assess	33106167	716	722	O
the	33106167	723	726	O
laboratory	33106167	727	737	O
improvement	33106167	738	749	O
after	33106167	750	755	O
CP	33106167	756	758	O
transfusion	33106167	759	770	O
in	33106167	771	773	O
severe	33106167	774	780	O
COVID-19	33106167	781	789	O
patients	33106167	790	798	O
TRIAL	33106167	799	804	O
DESIGN	33106167	805	811	O
:	33106167	812	813	O
This	33106167	814	818	O
is	33106167	819	821	O
a	33106167	822	823	O
multicentre	33106167	824	835	O
,	33106167	836	837	O
multi	33106167	838	843	O
-	33106167	844	845	O
arm	33106167	846	849	O
phase	33106167	850	855	O
II	33106167	856	858	O
Randomised	33106167	859	869	O
Controlled	33106167	870	880	O
Trial	33106167	881	886	O
.	33106167	887	888	O

METHODS	33106167	889	896	O
:	33106167	897	898	O
Age	33106167	899	902	O
and	33106167	903	906	O
sex	33106167	907	910	O
matched	33106167	911	918	O
COVID-19	33106167	919	927	O
positive	33106167	928	936	O
(	33106167	937	938	O
by	33106167	939	941	O
RT	33106167	942	944	O
-	33106167	945	946	O
PCR	33106167	947	950	O
)	33106167	951	952	O
severe	33106167	953	959	O
cases	33106167	960	965	O
will	33106167	966	970	O
be	33106167	971	973	O
enrolled	33106167	974	982	O
in	33106167	983	985	O
this	33106167	986	990	O
trial	33106167	991	996	O
.	33106167	997	998	O

Severe	33106167	999	1005	O
case	33106167	1006	1010	O
is	33106167	1011	1013	O
defined	33106167	1014	1021	O
by	33106167	1022	1024	O
the	33106167	1025	1028	O
World	33106167	1029	1034	O
Health	33106167	1035	1041	O
Organization	33106167	1042	1054	O
(	33106167	1055	1056	O
W.H.O	33106167	1057	1062	O
)	33106167	1063	1064	O
clinical	33106167	1065	1073	O
case	33106167	1074	1078	O
definition	33106167	1079	1089	O
.	33106167	1090	1091	O

The	33106167	1092	1095	O
inclusion	33106167	1096	1105	O
criteria	33106167	1106	1114	O
are	33106167	1115	1118	O
1	33106167	1119	1120	O
.	33106167	1121	1122	O

Respiratory	33106167	1123	1134	O
rate	33106167	1135	1139	O
>	33106167	1140	1141	O
30	33106167	1142	1144	O
breaths	33106167	1145	1152	O
/	33106167	1153	1154	O
min	33106167	1155	1158	O
;	33106167	1159	1160	O
PLUS	33106167	1161	1165	O
2	33106167	1166	1167	O
.	33106167	1168	1169	O

Severe	33106167	1170	1176	O
respiratory	33106167	1177	1188	O
distress	33106167	1189	1197	O
;	33106167	1198	1199	O
or	33106167	1200	1202	O
SpO2	33106167	1203	1207	O
	33106167	1210	1211	O
88	33106167	1214	1216	O
%	33106167	1217	1218	O
on	33106167	1219	1221	O
room	33106167	1222	1226	O
air	33106167	1227	1230	O
or	33106167	1231	1233	O
PaO2	33106167	1234	1238	O
/	33106167	1239	1240	O
FiO2	33106167	1241	1245	O
	33106167	1246	1247	O
300	33106167	1250	1253	O
mm	33106167	1254	1256	O
of	33106167	1257	1259	O
Hg	33106167	1260	1262	O
,	33106167	1263	1264	O
PLUS	33106167	1265	1269	O
3	33106167	1270	1271	O
.	33106167	1272	1273	O

Radiological	33106167	1274	1286	O
(	33106167	1287	1288	O
X	33106167	1289	1290	O
-	33106167	1291	1292	O
ray	33106167	1293	1296	O
or	33106167	1297	1299	O
CT	33106167	1300	1302	O
scan	33106167	1303	1307	O
)	33106167	1308	1309	O
evidence	33106167	1310	1318	O
of	33106167	1319	1321	O
bilateral	33106167	1322	1331	O
lung	33106167	1332	1336	O
infiltrate	33106167	1337	1347	O
,	33106167	1348	1349	O
AND	33106167	1350	1353	O
OR	33106167	1354	1356	O
4	33106167	1357	1358	O
.	33106167	1359	1360	O

Systolic	33106167	1361	1369	O
BP	33106167	1370	1372	O
<	33106167	1373	1374	O
90	33106167	1375	1377	O
mm	33106167	1378	1380	O
of	33106167	1381	1383	O
Hg	33106167	1384	1386	O
or	33106167	1387	1389	O
diastolic	33106167	1390	1399	O
BP	33106167	1400	1402	O
<	33106167	1403	1404	O
60	33106167	1405	1407	O
mm	33106167	1408	1410	O
of	33106167	1411	1413	O
Hg	33106167	1414	1416	O
.	33106167	1417	1418	O

AND	33106167	1419	1422	O
/	33106167	1423	1424	O
OR	33106167	1425	1427	O
5	33106167	1428	1429	O
.	33106167	1430	1431	O

Criteria	33106167	1432	1440	O
1	33106167	1441	1442	O
to	33106167	1443	1445	O
4	33106167	1446	1447	O
AND	33106167	1448	1451	O
or	33106167	1452	1454	O
patient	33106167	1455	1462	O
in	33106167	1463	1465	O
ventilator	33106167	1466	1476	O
support	33106167	1477	1484	O
Patients	33106167	1485	1493	O
'	33106167	1494	1495	O
below18	33106167	1496	1503	O
years	33106167	1504	1509	O
,	33106167	1510	1511	O
pregnant	33106167	1512	1520	O
and	33106167	1521	1524	O
lactating	33106167	1525	1534	O
women	33106167	1535	1540	O
,	33106167	1541	1542	O
previous	33106167	1543	1551	O
history	33106167	1552	1559	O
of	33106167	1560	1562	O
allergic	33106167	1563	1571	O
reaction	33106167	1572	1580	O
to	33106167	1581	1583	O
plasma	33106167	1584	1590	O
,	33106167	1591	1592	O
patients	33106167	1593	1601	O
who	33106167	1602	1605	O
have	33106167	1606	1610	O
already	33106167	1611	1618	O
received	33106167	1619	1627	O
plasma	33106167	1628	1634	O
from	33106167	1635	1639	O
a	33106167	1640	1641	O
different	33106167	1642	1651	O
source	33106167	1652	1658	O
will	33106167	1659	1663	O
be	33106167	1664	1666	O
excluded	33106167	1667	1675	O
.	33106167	1676	1677	O

Patients	33106167	1678	1686	O
will	33106167	1687	1691	O
be	33106167	1692	1694	O
enrolled	33106167	1695	1703	O
at	33106167	1704	1706	O
Bangabandhu	33106167	1707	1718	O
Sheikh	33106167	1719	1725	O
Mujib	33106167	1726	1731	O
Medical	33106167	1732	1739	O
University	33106167	1740	1750	O
(	33106167	1751	1752	O
BSMMU	33106167	1753	1758	O
)	33106167	1759	1760	O
hospital	33106167	1761	1769	O
,	33106167	1770	1771	O
Dhaka	33106167	1772	1777	O
medical	33106167	1778	1785	O
college	33106167	1786	1793	O
hospital	33106167	1794	1802	O
(	33106167	1803	1804	O
DMCH	33106167	1805	1809	O
)	33106167	1810	1811	O
and	33106167	1812	1815	O
Mugda	33106167	1816	1821	O
medical	33106167	1822	1829	O
college	33106167	1830	1837	O
hospital	33106167	1838	1846	O
(	33106167	1847	1848	O
MuMCH	33106167	1849	1854	O
)	33106167	1855	1856	O
.	33106167	1857	1858	O

Apheretic	33106167	1859	1868	O
plasma	33106167	1869	1875	O
will	33106167	1876	1880	O
be	33106167	1881	1883	O
collected	33106167	1884	1893	O
at	33106167	1894	1896	O
the	33106167	1897	1900	O
transfusion	33106167	1901	1912	O
medicine	33106167	1913	1921	O
department	33106167	1922	1932	O
of	33106167	1933	1935	O
SHNIBPS	33106167	1936	1943	O
hospital	33106167	1944	1952	O
,	33106167	1953	1954	O
ELISA	33106167	1955	1960	O
antibody	33106167	1961	1969	O
titre	33106167	1970	1975	O
will	33106167	1976	1980	O
be	33106167	1981	1983	O
done	33106167	1984	1988	O
at	33106167	1989	1991	O
BSMMU	33106167	1992	1997	O
and	33106167	1998	2001	O
CMBT	33106167	2004	2008	O
and	33106167	2009	2012	O
neutralizing	33106167	2013	2025	O
antibody	33106167	2026	2034	O
titre	33106167	2035	2040	O
will	33106167	2041	2045	O
be	33106167	2046	2048	O
checked	33106167	2049	2056	O
in	33106167	2057	2059	O
collaboration	33106167	2060	2073	O
with	33106167	2074	2078	O
the	33106167	2079	2082	O
University	33106167	2083	2093	O
of	33106167	2094	2096	O
Oxford	33106167	2097	2103	O
.	33106167	2104	2105	O

Patients	33106167	2106	2114	O
who	33106167	2115	2118	O
have	33106167	2119	2123	O
recovered	33106167	2124	2133	O
from	33106167	2134	2138	O
COVID-19	33106167	2139	2147	O
will	33106167	2148	2152	O
be	33106167	2153	2155	O
recruited	33106167	2156	2165	O
as	33106167	2166	2168	O
donors	33106167	2169	2175	O
of	33106167	2176	2178	O
CP	33106167	2179	2181	O
.	33106167	2182	2183	O

The	33106167	2184	2187	O
recovery	33106167	2188	2196	O
criteria	33106167	2197	2205	O
are	33106167	2206	2209	O
normality	33106167	2210	2219	O
of	33106167	2220	2222	O
body	33106167	2223	2227	O
temperature	33106167	2228	2239	O
for	33106167	2240	2243	O
more	33106167	2244	2248	O
than	33106167	2249	2253	O
3	33106167	2254	2255	O
days	33106167	2256	2260	O
,	33106167	2261	2262	O
resolution	33106167	2263	2273	O
of	33106167	2274	2276	O
respiratory	33106167	2277	2288	O
symptoms	33106167	2289	2297	O
,	33106167	2298	2299	O
two	33106167	2300	2303	O
consecutively	33106167	2304	2317	O
negative	33106167	2318	2326	O
results	33106167	2327	2334	O
of	33106167	2335	2337	O
sputum	33106167	2338	2344	O
SARS	33106167	2345	2349	O
-	33106167	2350	2351	O
CoV-2	33106167	2352	2357	O
by	33106167	2358	2360	O
RT	33106167	2361	2363	O
-	33106167	2364	2365	O
PCR	33106167	2366	2369	O
assay	33106167	2370	2375	O
(	33106167	2376	2377	O
at	33106167	2378	2380	O
least	33106167	2381	2386	O
24	33106167	2387	2389	O
hours	33106167	2390	2395	O
apart	33106167	2396	2401	O
)	33106167	2402	2403	O
22	33106167	2404	2406	O
to	33106167	2407	2409	O
35	33106167	2410	2412	O
days	33106167	2413	2417	O
of	33106167	2418	2420	O
post	33106167	2421	2425	O
onset	33106167	2426	2431	O
period	33106167	2432	2438	O
,	33106167	2439	2440	O
and	33106167	2441	2444	O
neutralizing	33106167	2445	2457	O
antibody	33106167	2460	2468	O
titre	33106167	2469	2474	O
	33106167	2477	2478	O
1:160	33106167	2481	2486	O
.	33106167	2487	2488	O

UNASSIGNED	33106167	2489	2499	O
:	33106167	2500	2501	O
This	33106167	2502	2506	O
RCT	33106167	2507	2510	O
consists	33106167	2511	2519	O
of	33106167	2520	2522	O
three	33106167	2523	2528	O
arms	33106167	2529	2533	O
,	33106167	2534	2535	O
a.	33106167	2536	2538	O
standard	33106167	2539	2547	O
care	33106167	2548	2552	O
,	33106167	2553	2554	O
b.	33106167	2555	2557	O
standard	33106167	2558	2566	O
care	33106167	2567	2571	O
and	33106167	2572	2575	O
200	33106167	2576	2579	O
ml	33106167	2580	2582	O
CP	33106167	2583	2585	O
and	33106167	2586	2589	O
c.	33106167	2590	2592	O
standard	33106167	2593	2601	O
care	33106167	2602	2606	O
and	33106167	2607	2610	O
400	33106167	2611	2614	O
ml	33106167	2615	2617	O
CP	33106167	2618	2620	O
.	33106167	2621	2622	O

Patients	33106167	2623	2631	O
will	33106167	2632	2636	O
receive	33106167	2637	2644	O
plasma	33106167	2645	2651	O
as	33106167	2652	2654	O
a	33106167	2655	2656	O
single	33106167	2657	2663	O
transfusion	33106167	2664	2675	O
.	33106167	2676	2677	O

Intervention	33106167	2678	2690	O
arms	33106167	2691	2695	O
will	33106167	2696	2700	O
be	33106167	2701	2703	O
compared	33106167	2704	2712	O
to	33106167	2713	2715	O
the	33106167	2716	2719	O
standard	33106167	2720	2728	O
care	33106167	2729	2733	O
arm	33106167	2734	2737	O
.	33106167	2738	2739	O

RESULTS	33106167	2740	2747	O
:	33106167	2748	2749	O
The	33106167	2750	2753	O
primary	33106167	2754	2761	O
outcome	33106167	2762	2769	O
will	33106167	2770	2774	O
be	33106167	2775	2777	O
time	33106167	2778	2782	O
to	33106167	2783	2785	O
clinical	33106167	2786	2794	O
improvement	33106167	2795	2806	O
within	33106167	2807	2813	O
seven	33106167	2814	2819	O
days	33106167	2820	2824	O
of	33106167	2825	2827	O
treatment	33106167	2828	2837	O
or	33106167	2838	2840	O
until	33106167	2841	2846	O
discharge	33106167	2847	2856	O
whichever	33106167	2857	2866	O
is	33106167	2867	2869	O
later	33106167	2870	2875	O
and	33106167	2876	2879	O
in	33106167	2880	2882	O
-	33106167	2883	2884	O
hospital	33106167	2885	2893	O
mortality	33106167	2894	2903	O
.	33106167	2904	2905	O

The	33106167	2906	2909	O
secondary	33106167	2910	2919	O
outcome	33106167	2920	2927	O
would	33106167	2928	2933	O
be	33106167	2934	2936	O
improvement	33106167	2937	2948	O
of	33106167	2949	2951	O
laboratory	33106167	2952	2962	O
parameters	33106167	2963	2973	O
after	33106167	2974	2979	O
therapy	33106167	2980	2987	O
(	33106167	2988	2989	O
neutrophil	33106167	2990	3000	O
,	33106167	3001	3002	O
lymphocyte	33106167	3003	3013	O
ratio	33106167	3014	3019	O
,	33106167	3020	3021	O
CRP	33106167	3022	3025	O
,	33106167	3026	3027	O
serum	33106167	3028	3033	O
ferritin	33106167	3034	3042	O
,	33106167	3043	3044	O
SGPT	33106167	3045	3049	O
,	33106167	3050	3051	O
SGOT	33106167	3052	3056	O
,	33106167	3057	3058	O
serum	33106167	3059	3064	O
creatinine	33106167	3065	3075	O
and	33106167	3076	3079	O
radiology	33106167	3080	3089	O
)	33106167	3090	3091	O
,	33106167	3092	3093	O
length	33106167	3094	3100	O
of	33106167	3101	3103	O
hospital	33106167	3104	3112	O
stay	33106167	3113	3117	O
,	33106167	3118	3119	O
length	33106167	3120	3126	O
of	33106167	3127	3129	O
ICU	33106167	3130	3133	O
stay	33106167	3134	3138	O
,	33106167	3139	3140	O
reduction	33106167	3141	3150	O
in	33106167	3151	3153	O
proportion	33106167	3154	3164	O
of	33106167	3165	3167	O
deaths	33106167	3168	3174	O
,	33106167	3175	3176	O
requirement	33106167	3177	3188	O
of	33106167	3189	3191	O
ventilator	33106167	3192	3202	O
and	33106167	3203	3206	O
duration	33106167	3207	3215	O
of	33106167	3216	3218	O
oxygen	33106167	3219	3225	O
and	33106167	3226	3229	O
ventilator	33106167	3230	3240	O
support	33106167	3241	3248	O
.	33106167	3249	3250	O

UNASSIGNED	33106167	3251	3261	O
:	33106167	3262	3263	O
Randomization	33106167	3264	3277	O
will	33106167	3278	3282	O
be	33106167	3283	3285	O
done	33106167	3286	3290	O
by	33106167	3291	3293	O
someone	33106167	3294	3301	O
not	33106167	3302	3305	O
associated	33106167	3306	3316	O
with	33106167	3317	3321	O
the	33106167	3322	3325	O
care	33106167	3326	3330	O
or	33106167	3331	3333	O
assessment	33106167	3334	3344	O
of	33106167	3345	3347	O
the	33106167	3348	3351	O
patients	33106167	3352	3360	O
by	33106167	3361	3363	O
means	33106167	3364	3369	O
of	33106167	3370	3372	O
a	33106167	3373	3374	O
computer	33106167	3375	3383	O
generated	33106167	3384	3393	O
random	33106167	3394	3400	O
number	33106167	3401	3407	O
table	33106167	3408	3413	O
using	33106167	3414	3419	O
an	33106167	3420	3422	O
allocation	33106167	3423	3433	O
ratio	33106167	3434	3439	O
of	33106167	3440	3442	O
1:1:1	33106167	3443	3448	O
.	33106167	3449	3450	O

UNASSIGNED	33106167	3451	3461	O
:	33106167	3462	3463	O
This	33106167	3464	3468	O
is	33106167	3469	3471	O
an	33106167	3472	3474	O
open	33106167	3475	3479	O
level	33106167	3480	3485	O
study	33106167	3486	3491	O
;	33106167	3492	3493	O
neither	33106167	3494	3501	O
the	33106167	3502	3505	O
physician	33106167	3506	3515	O
nor	33106167	3516	3519	O
the	33106167	3520	3523	O
patients	33106167	3524	3532	O
will	33106167	3533	3537	O
be	33106167	3538	3540	O
blinded	33106167	3541	3548	O
.	33106167	3549	3550	O

However	33106167	3551	3558	O
,	33106167	3559	3560	O
the	33106167	3561	3564	O
primary	33106167	3565	3572	O
and	33106167	3573	3576	O
secondary	33106167	3577	3586	O
outcome	33106167	3587	3594	O
(	33106167	3595	3596	O
oxygen	33106167	3597	3603	O
saturations	33106167	3604	3615	O
,	33106167	3616	3617	O
PaO2	33106167	3618	3622	O
/	33106167	3623	3624	O
FiO2	33106167	3625	3629	O
,	33106167	3630	3631	O
BP	33106167	3632	3634	O
,	33106167	3635	3636	O
day	33106167	3637	3640	O
specific	33106167	3641	3649	O
laboratory	33106167	3650	3660	O
tests	33106167	3661	3666	O
)	33106167	3667	3668	O
will	33106167	3669	3673	O
be	33106167	3674	3676	O
recorded	33106167	3677	3685	O
using	33106167	3686	3691	O
an	33106167	3692	3694	O
objective	33106167	3695	3704	O
automated	33106167	3705	3714	O
method	33106167	3715	3721	O
;	33106167	3722	3723	O
the	33106167	3724	3727	O
study	33106167	3728	3733	O
staff	33106167	3734	3739	O
will	33106167	3740	3744	O
not	33106167	3745	3748	O
be	33106167	3749	3751	O
able	33106167	3752	3756	O
to	33106167	3757	3759	O
influence	33106167	3760	3769	O
the	33106167	3770	3773	O
recording	33106167	3774	3783	O
of	33106167	3784	3786	O
these	33106167	3787	3792	O
data	33106167	3793	3797	O
.	33106167	3798	3799	O

UNASSIGNED	33106167	3800	3810	O
:	33106167	3811	3812	O
No	33106167	3813	3815	O
similar	33106167	3816	3823	O
study	33106167	3824	3829	O
has	33106167	3830	3833	O
been	33106167	3834	3838	O
performed	33106167	3839	3848	O
previously	33106167	3849	3859	O
.	33106167	3860	3861	O

Therefore	33106167	3862	3871	O
no	33106167	3872	3874	O
data	33106167	3875	3879	O
are	33106167	3880	3883	O
available	33106167	3884	3893	O
that	33106167	3894	3898	O
could	33106167	3899	3904	O
be	33106167	3905	3907	O
used	33106167	3908	3912	O
to	33106167	3913	3915	O
generate	33106167	3916	3924	O
a	33106167	3925	3926	O
sample	33106167	3927	3933	O
size	33106167	3934	3938	O
calculation	33106167	3939	3950	O
.	33106167	3951	3952	O

This	33106167	3953	3957	O
phase	33106167	3958	3963	O
II	33106167	3964	3966	O
study	33106167	3967	3972	O
is	33106167	3973	3975	O
required	33106167	3976	3984	O
to	33106167	3985	3987	O
provide	33106167	3988	3995	O
some	33106167	3996	4000	O
initial	33106167	4001	4008	O
data	33106167	4009	4013	O
on	33106167	4014	4016	O
efficacy	33106167	4017	4025	O
and	33106167	4026	4029	O
safety	33106167	4030	4036	O
that	33106167	4037	4041	O
will	33106167	4042	4046	O
allow	33106167	4047	4052	O
design	33106167	4053	4059	O
of	33106167	4060	4062	O
a	33106167	4063	4064	O
larger	33106167	4065	4071	O
study	33106167	4072	4077	O
.	33106167	4078	4079	O

The	33106167	4080	4083	O
trial	33106167	4084	4089	O
will	33106167	4090	4094	O
recruit	33106167	4095	4102	O
60	33106167	4103	4105	O
participants	33106167	4106	4118	O
(	33106167	4119	4120	O
20	33106167	4121	4123	O
in	33106167	4124	4126	O
each	33106167	4127	4131	O
arm	33106167	4132	4135	O
)	33106167	4136	4137	O
.	33106167	4138	4139	O

UNASSIGNED	33106167	4140	4150	O
:	33106167	4151	4152	O
Protocol	33106167	4153	4161	O
version	33106167	4162	4169	O
1.4	33106167	4170	4173	O
dated	33106167	4174	4179	O
May	33106167	4180	4183	O
5	33106167	4184	4185	O
,	33106167	4186	4187	O
2020	33106167	4188	4192	O
and	33106167	4193	4196	O
amended	33106167	4197	4204	O
version	33106167	4205	4212	O
1.5	33106167	4213	4216	O
,	33106167	4217	4218	O
dated	33106167	4219	4224	O
June	33106167	4225	4229	O
16	33106167	4230	4232	O
,	33106167	4233	4234	O
2020	33106167	4235	4239	O
.	33106167	4240	4241	O

First	33106167	4242	4247	O
case	33106167	4248	4252	O
was	33106167	4253	4256	O
recruited	33106167	4257	4266	O
on	33106167	4267	4269	O
May	33106167	4270	4273	O
27	33106167	4274	4276	O
,	33106167	4277	4278	O
2020	33106167	4279	4283	O
.	33106167	4284	4285	O

By	33106167	4286	4288	O
August	33106167	4289	4295	O
10	33106167	4296	4298	O
,	33106167	4299	4300	O
2020	33106167	4301	4305	O
,	33106167	4306	4307	O
the	33106167	4308	4311	O
trial	33106167	4312	4317	O
had	33106167	4318	4321	O
recruited	33106167	4322	4331	O
one	33106167	4332	4335	O
-	33106167	4336	4337	O
third	33106167	4338	4343	O
(	33106167	4344	4345	O
21	33106167	4346	4348	O
out	33106167	4349	4352	O
of	33106167	4353	4355	O
60	33106167	4356	4358	O
)	33106167	4359	4360	O
of	33106167	4361	4363	O
the	33106167	4364	4367	O
participants	33106167	4368	4380	O
.	33106167	4381	4382	O

The	33106167	4383	4386	O
recruitment	33106167	4387	4398	O
is	33106167	4399	4401	O
expected	33106167	4402	4410	O
to	33106167	4411	4413	O
finish	33106167	4414	4420	O
by	33106167	4421	4423	O
October	33106167	4424	4431	O
31	33106167	4432	4434	O
,	33106167	4435	4436	O
2020	33106167	4437	4441	O
.	33106167	4442	4443	O

BACKGROUND	33106167	4444	4454	O
:	33106167	4455	4456	O
Clinicaltrials.gov	33106167	4457	4475	O
ID	33106167	4476	4478	O
:	33106167	4479	4480	O
NCT04403477	33106167	4481	4492	O
.	33106167	4493	4494	O

Registered	33106167	4495	4505	O
26	33106167	4506	4508	O
May	33106167	4509	4512	O
,	33106167	4513	4514	O
2020	33106167	4515	4519	O
FULL	33106167	4520	4524	O
PROTOCOL	33106167	4525	4533	O
:	33106167	4534	4535	O
The	33106167	4536	4539	O
full	33106167	4540	4544	O
protocol	33106167	4545	4553	O
is	33106167	4554	4556	O
attached	33106167	4557	4565	O
as	33106167	4566	4568	O
an	33106167	4569	4571	O
additional	33106167	4572	4582	O
file	33106167	4583	4587	O
,	33106167	4588	4589	O
accessible	33106167	4590	4600	O
from	33106167	4601	4605	O
the	33106167	4606	4609	O
Trial	33106167	4610	4615	O
's	33106167	4616	4618	O
website	33106167	4619	4626	O
(	33106167	4627	4628	O
Additional	33106167	4629	4639	O
file	33106167	4640	4644	O
1	33106167	4645	4646	O
)	33106167	4647	4648	O
.	33106167	4649	4650	O

In	33106167	4651	4653	O
the	33106167	4654	4657	O
interest	33106167	4658	4666	O
in	33106167	4667	4669	O
expediting	33106167	4670	4680	O
dissemination	33106167	4681	4694	O
of	33106167	4695	4697	O
this	33106167	4698	4702	O
material	33106167	4703	4711	O
,	33106167	4712	4713	O
the	33106167	4714	4717	O
familiar	33106167	4718	4726	O
formatting	33106167	4727	4737	O
has	33106167	4738	4741	O
been	33106167	4742	4746	O
eliminated	33106167	4747	4757	O
;	33106167	4758	4759	O
this	33106167	4760	4764	O
letter	33106167	4765	4771	O
serves	33106167	4772	4778	O
as	33106167	4779	4781	O
a	33106167	4782	4783	O
summary	33106167	4784	4791	O
of	33106167	4792	4794	O
the	33106167	4795	4798	O
key	33106167	4799	4802	O
elements	33106167	4803	4811	O
of	33106167	4812	4814	O
the	33106167	4815	4818	O
full	33106167	4819	4823	O
protocol	33106167	4824	4832	O
.	33106167	4833	4834	O


BCG	33106170	0	3	O
revaccination	33106170	4	17	O
of	33106170	18	20	O
health	33106170	21	27	O
workers	33106170	28	35	O
in	33106170	36	38	O
Brazil	33106170	39	45	O
to	33106170	46	48	O
improve	33106170	49	56	O
innate	33106170	57	63	O
immune	33106170	64	70	O
responses	33106170	71	80	O
against	33106170	81	88	O
COVID-19	33106170	89	97	O
:	33106170	98	99	O
A	33106170	100	101	O
structured	33106170	102	112	O
summary	33106170	113	120	O
of	33106170	121	123	O
a	33106170	124	125	O
study	33106170	126	131	O
protocol	33106170	132	140	O
for	33106170	141	144	O
a	33106170	145	146	O
randomised	33106170	147	157	O
controlled	33106170	158	168	O
trial	33106170	169	174	O
.	33106170	175	176	O

OBJECTIVE	33106170	177	186	O
:	33106170	187	188	O
The	33106170	189	192	O
BCG	33106170	193	196	O
vaccine	33106170	197	204	O
,	33106170	205	206	O
widely	33106170	207	213	O
used	33106170	214	218	O
in	33106170	219	221	O
Brazil	33106170	222	228	O
in	33106170	229	231	O
new	33106170	232	235	O
-	33106170	236	237	O
borns	33106170	238	243	O
,	33106170	244	245	O
induces	33106170	246	253	O
adjuvant	33106170	254	262	O
protection	33106170	263	273	O
for	33106170	274	277	O
several	33106170	278	285	O
diseases	33106170	286	294	O
,	33106170	295	296	O
including	33106170	297	306	O
childhood	33106170	307	316	O
virus	33106170	317	322	O
infections	33106170	323	333	O
.	33106170	334	335	O

BCG	33106170	336	339	O
activates	33106170	340	349	O
monocytes	33106170	350	359	O
and	33106170	360	363	O
innate	33106170	364	370	O
memory	33106170	371	377	O
NK	33106170	378	380	O
cells	33106170	381	386	O
which	33106170	387	392	O
are	33106170	393	396	O
crucial	33106170	397	404	O
for	33106170	405	408	O
the	33106170	409	412	O
antiviral	33106170	413	422	O
immune	33106170	423	429	O
response	33106170	430	438	O
.	33106170	439	440	O

Therefore	33106170	441	450	O
,	33106170	451	452	O
strategies	33106170	453	463	O
to	33106170	464	466	O
prevent	33106170	467	474	O
COVID-19	33106170	475	483	O
in	33106170	484	486	O
health	33106170	487	493	O
workers	33106170	494	501	O
(	33106170	502	503	O
HW	33106170	504	506	O
)	33106170	507	508	O
should	33106170	509	515	O
be	33106170	516	518	O
carried	33106170	519	526	O
out	33106170	527	530	O
to	33106170	531	533	O
prevent	33106170	534	541	O
them	33106170	542	546	O
becoming	33106170	547	555	O
unwell	33106170	556	562	O
so	33106170	563	565	O
that	33106170	566	570	O
they	33106170	571	575	O
can	33106170	576	579	O
continue	33106170	580	588	O
to	33106170	589	591	O
work	33106170	592	596	O
during	33106170	597	603	O
the	33106170	604	607	O
pandemic	33106170	608	616	O
.	33106170	617	618	O

The	33106170	619	622	O
hypothesis	33106170	623	633	O
is	33106170	634	636	O
that	33106170	637	641	O
BCG	33106170	642	645	O
will	33106170	646	650	O
improve	33106170	651	658	O
the	33106170	659	662	O
innate	33106170	663	669	O
immune	33106170	670	676	O
response	33106170	677	685	O
and	33106170	686	689	O
prevent	33106170	690	697	O
symptomatic	33106170	698	709	O
infection	33106170	710	719	O
or	33106170	720	722	O
COVID-19	33106170	723	731	O
severity	33106170	732	740	O
.	33106170	741	742	O

The	33106170	743	746	O
primary	33106170	747	754	O
objective	33106170	755	764	O
is	33106170	765	767	O
to	33106170	768	770	O
verify	33106170	771	777	O
the	33106170	778	781	O
effectiveness	33106170	782	795	O
and	33106170	796	799	O
safety	33106170	800	806	O
of	33106170	807	809	O
the	33106170	810	813	O
BCG	33106170	814	817	O
vaccine	33106170	818	825	O
to	33106170	826	828	O
prevent	33106170	829	836	O
or	33106170	837	839	O
reduce	33106170	840	846	O
incidence	33106170	847	856	O
of	33106170	857	859	O
severe	33106170	860	866	O
acute	33106170	867	872	O
respiratory	33106170	873	884	O
syndrome	33106170	885	893	O
coronavirus-2	33106170	894	907	O
(	33106170	908	909	O
SARS	33106170	910	914	O
-	33106170	915	916	O
CoV-2	33106170	917	922	O
)	33106170	923	924	O
infection	33106170	925	934	O
in	33106170	935	937	O
the	33106170	938	941	O
city	33106170	942	946	O
of	33106170	947	949	O
Goinia	33106170	950	957	O
(	33106170	958	959	O
Brazil	33106170	960	966	O
)	33106170	967	968	O
among	33106170	969	974	O
HW	33106170	975	977	O
previously	33106170	978	988	O
vaccinated	33106170	989	999	O
with	33106170	1000	1004	O
BCG	33106170	1005	1008	O
and	33106170	1009	1012	O
also	33106170	1013	1017	O
its	33106170	1018	1021	O
severity	33106170	1022	1030	O
and	33106170	1031	1034	O
mortality	33106170	1035	1044	O
during	33106170	1045	1051	O
the	33106170	1052	1055	O
pandemic	33106170	1056	1064	O
of	33106170	1065	1067	O
the	33106170	1068	1071	O
disease	33106170	1072	1079	O
.	33106170	1080	1081	O

Secondary	33106170	1082	1091	O
objectives	33106170	1092	1102	O
are	33106170	1103	1106	O
to	33106170	1107	1109	O
estimate	33106170	1110	1118	O
the	33106170	1119	1122	O
incidence	33106170	1123	1132	O
of	33106170	1133	1135	O
COVID-19	33106170	1136	1144	O
among	33106170	1145	1150	O
these	33106170	1151	1156	O
professionals	33106170	1157	1170	O
and	33106170	1171	1174	O
the	33106170	1175	1178	O
innate	33106170	1179	1185	O
immune	33106170	1186	1192	O
response	33106170	1193	1201	O
elicited	33106170	1202	1210	O
to	33106170	1211	1213	O
BCG	33106170	1214	1217	O
.	33106170	1218	1219	O

METHODS	33106170	1220	1227	O
:	33106170	1228	1229	O
This	33106170	1230	1234	O
a	33106170	1235	1236	O
phase	33106170	1237	1242	O
II	33106170	1243	1245	O
trial	33106170	1246	1251	O
for	33106170	1252	1255	O
repositioning	33106170	1256	1269	O
BCG	33106170	1270	1273	O
as	33106170	1274	1276	O
a	33106170	1277	1278	O
preventive	33106170	1279	1289	O
strategy	33106170	1290	1298	O
against	33106170	1299	1306	O
COVID-19	33106170	1307	1315	O
.	33106170	1316	1317	O

The	33106170	1318	1321	O
trial	33106170	1322	1327	O
is	33106170	1328	1330	O
an	33106170	1331	1333	O
open	33106170	1334	1338	O
-	33106170	1339	1340	O
label	33106170	1341	1346	O
,	33106170	1347	1348	O
parallel	33106170	1349	1357	O
-	33106170	1358	1359	O
group	33106170	1360	1365	O
randomised	33106170	1366	1376	O
clinical	33106170	1377	1385	O
trial	33106170	1386	1391	O
,	33106170	1392	1393	O
comparing	33106170	1394	1403	O
HW	33106170	1404	1406	O
vaccinated	33106170	1407	1417	O
with	33106170	1418	1422	O
BCG	33106170	1423	1426	O
and	33106170	1427	1430	O
HW	33106170	1431	1433	O
not	33106170	1434	1437	O
vaccinated	33106170	1438	1448	O
.	33106170	1449	1450	O

METHODS	33106170	1451	1458	O
:	33106170	1459	1460	O
The	33106170	1461	1464	O
trial	33106170	1465	1470	O
will	33106170	1471	1475	O
recruit	33106170	1476	1483	O
800	33106170	1484	1487	O
HW	33106170	1488	1490	O
of	33106170	1491	1493	O
Goinia	33106170	1494	1501	O
-	33106170	1502	1503	O
Gois	33106170	1504	1509	O
,	33106170	1510	1511	O
Brazil	33106170	1512	1518	O
to	33106170	1519	1521	O
reach	33106170	1522	1527	O
a	33106170	1528	1529	O
total	33106170	1530	1535	O
of	33106170	1536	1538	O
400	33106170	1539	1542	O
HW	33106170	1543	1545	O
included	33106170	1546	1554	O
after	33106170	1555	1560	O
comorbidities	33106170	1561	1574	O
questioning	33106170	1575	1586	O
and	33106170	1587	1590	O
laboratorial	33106170	1591	1603	O
evaluation	33106170	1604	1614	O
.	33106170	1615	1616	O

Eligibility	33106170	1617	1628	O
criteria	33106170	1629	1637	O
:	33106170	1638	1639	O
Any	33106170	1640	1643	O
HW	33106170	1644	1646	O
presenting	33106170	1647	1657	O
BCG	33106170	1658	1661	O
vaccination	33106170	1662	1673	O
scar	33106170	1674	1678	O
with	33106170	1679	1683	O
direct	33106170	1684	1690	O
contact	33106170	1691	1698	O
with	33106170	1699	1703	O
suspected	33106170	1704	1713	O
COVID-19	33106170	1714	1722	O
patients	33106170	1723	1731	O
for	33106170	1732	1735	O
at	33106170	1736	1738	O
least	33106170	1739	1744	O
8	33106170	1745	1746	O
hours	33106170	1747	1752	O
per	33106170	1753	1756	O
week	33106170	1757	1761	O
,	33106170	1762	1763	O
whether	33106170	1764	1771	O
in	33106170	1772	1774	O
hospital	33106170	1775	1783	O
beds	33106170	1784	1788	O
,	33106170	1789	1790	O
ICU	33106170	1791	1794	O
,	33106170	1795	1796	O
or	33106170	1797	1799	O
in	33106170	1800	1802	O
transportation	33106170	1803	1817	O
or	33106170	1818	1820	O
admission	33106170	1821	1830	O
(	33106170	1831	1832	O
nurses	33106170	1833	1839	O
,	33106170	1840	1841	O
doctors	33106170	1842	1849	O
,	33106170	1850	1851	O
physiotherapists	33106170	1852	1868	O
,	33106170	1869	1870	O
nutritionists	33106170	1871	1884	O
,	33106170	1885	1886	O
receptionists	33106170	1887	1900	O
,	33106170	1901	1902	O
etc	33106170	1903	1906	O
.	33106170	1907	1908	O
)	33106170	1909	1910	O
who	33106170	1911	1914	O
have	33106170	1915	1919	O
negative	33106170	1920	1928	O
IgM	33106170	1929	1932	O
and	33106170	1933	1936	O
IgG	33106170	1937	1940	O
COVID-19	33106170	1941	1949	O
test	33106170	1950	1954	O
.	33106170	1955	1956	O

Participants	33106170	1957	1969	O
with	33106170	1970	1974	O
any	33106170	1975	1978	O
of	33106170	1979	1981	O
the	33106170	1982	1985	O
following	33106170	1986	1995	O
characteristics	33106170	1996	2011	O
will	33106170	2012	2016	O
be	33106170	2017	2019	O
excluded	33106170	2020	2028	O
:	33106170	2029	2030	O
-	33106170	2031	2032	O
Have	33106170	2033	2037	O
had	33106170	2038	2041	O
in	33106170	2042	2044	O
the	33106170	2045	2048	O
last	33106170	2049	2053	O
fifteen	33106170	2054	2061	O
days	33106170	2062	2066	O
any	33106170	2067	2070	O
signs	33106170	2071	2076	O
or	33106170	2077	2079	O
symptoms	33106170	2080	2088	O
of	33106170	2089	2091	O
virus	33106170	2092	2097	O
infection	33106170	2098	2107	O
,	33106170	2108	2109	O
including	33106170	2110	2119	O
COVID-19	33106170	2120	2128	O
;	33106170	2129	2130	O
-	33106170	2131	2132	O
Have	33106170	2133	2137	O
had	33106170	2138	2141	O
fever	33106170	2142	2147	O
in	33106170	2148	2150	O
the	33106170	2151	2154	O
last	33106170	2155	2159	O
fifteen	33106170	2160	2167	O
days	33106170	2168	2172	O
;	33106170	2173	2174	O
-	33106170	2175	2176	O
Have	33106170	2177	2181	O
been	33106170	2182	2186	O
vaccinated	33106170	2187	2197	O
fifteen	33106170	2198	2205	O
days	33106170	2206	2210	O
before	33106170	2211	2217	O
the	33106170	2218	2221	O
inclusion	33106170	2222	2231	O
;	33106170	2232	2233	O
-	33106170	2234	2235	O
Have	33106170	2236	2240	O
a	33106170	2241	2242	O
history	33106170	2243	2250	O
or	33106170	2251	2253	O
confirmation	33106170	2254	2266	O
of	33106170	2267	2269	O
any	33106170	2270	2273	O
immunosuppressive	33106170	2274	2291	O
disease	33106170	2292	2299	O
such	33106170	2300	2304	O
as	33106170	2305	2307	O
HIV	33106170	2308	2311	O
,	33106170	2312	2313	O
presented	33106170	2314	2323	O
solid	33106170	2324	2329	O
tumour	33106170	2330	2336	O
in	33106170	2337	2339	O
the	33106170	2340	2343	O
last	33106170	2344	2348	O
two	33106170	2349	2352	O
years	33106170	2353	2358	O
or	33106170	2359	2361	O
autoimmune	33106170	2362	2372	O
diseases	33106170	2373	2381	O
;	33106170	2382	2383	O
-	33106170	2384	2385	O
Are	33106170	2386	2389	O
under	33106170	2390	2395	O
preventive	33106170	2396	2406	O
medication	33106170	2407	2417	O
with	33106170	2418	2422	O
antibiotics	33106170	2423	2434	O
,	33106170	2435	2436	O
steroid	33106170	2437	2444	O
anti	33106170	2445	2449	O
-	33106170	2450	2451	O
inflammatories	33106170	2452	2466	O
,	33106170	2467	2468	O
or	33106170	2469	2471	O
chemotherapy	33106170	2472	2484	O
;	33106170	2485	2486	O
-	33106170	2487	2488	O
Have	33106170	2489	2493	O
less	33106170	2494	2498	O
than	33106170	2499	2503	O
500	33106170	2504	2507	O
neutrophils	33106170	2508	2519	O
per	33106170	2520	2523	O
mL	33106170	2524	2526	O
of	33106170	2527	2529	O
blood	33106170	2530	2535	O
;	33106170	2536	2537	O
-	33106170	2538	2539	O
Have	33106170	2540	2544	O
previously	33106170	2545	2555	O
been	33106170	2556	2560	O
diagnosed	33106170	2561	2570	O
with	33106170	2571	2575	O
tuberculosis	33106170	2576	2588	O
;	33106170	2589	2590	O
-	33106170	2591	2592	O
Are	33106170	2593	2596	O
breastfeeding	33106170	2597	2610	O
or	33106170	2611	2613	O
pregnant	33106170	2614	2622	O
;	33106170	2623	2624	O
-	33106170	2625	2626	O
Are	33106170	2627	2630	O
younger	33106170	2631	2638	O
than	33106170	2639	2643	O
18	33106170	2644	2646	O
years	33106170	2647	2652	O
old	33106170	2653	2656	O
;	33106170	2657	2658	O
-	33106170	2659	2660	O
Are	33106170	2661	2664	O
participating	33106170	2665	2678	O
as	33106170	2679	2681	O
an	33106170	2682	2684	O
investigator	33106170	2685	2697	O
in	33106170	2698	2700	O
this	33106170	2701	2705	O
clinical	33106170	2706	2714	O
trial	33106170	2715	2720	O
.	33106170	2721	2722	O

UNASSIGNED	33106170	2723	2733	O
:	33106170	2734	2735	O
HW	33106170	2736	2738	O
will	33106170	2739	2743	O
be	33106170	2744	2746	O
randomized	33106170	2747	2757	O
into	33106170	2758	2762	O
the	33106170	2763	2766	O
BCG	33106170	2767	2770	O
vaccinated	33106170	2771	2781	O
group	33106170	2782	2787	O
or	33106170	2788	2790	O
the	33106170	2791	2794	O
BCG	33106170	2795	2798	O
unvaccinated	33106170	2799	2811	O
control	33106170	2812	2819	O
group	33106170	2820	2825	O
.	33106170	2826	2827	O

The	33106170	2828	2831	O
BCG	33106170	2832	2835	O
vaccinated	33106170	2836	2846	O
group	33106170	2847	2852	O
will	33106170	2853	2857	O
receive	33106170	2858	2865	O
in	33106170	2866	2868	O
the	33106170	2869	2872	O
right	33106170	2873	2878	O
arm	33106170	2879	2882	O
,	33106170	2883	2884	O
intradermally	33106170	2885	2898	O
,	33106170	2899	2900	O
a	33106170	2901	2902	O
one	33106170	2903	2906	O
off	33106170	2907	2910	O
dose	33106170	2911	2915	O
of	33106170	2916	2918	O
0.1	33106170	2919	2922	O
mL	33106170	2923	2925	O
corresponding	33106170	2926	2939	O
to	33106170	2940	2942	O
approximately	33106170	2943	2956	O
2	33106170	2957	2958	O
x105	33106170	2959	2963	O
to	33106170	2964	2966	O
8	33106170	2967	2968	O
x105	33106170	2969	2973	O
CFU	33106170	2974	2977	O
of	33106170	2978	2980	O
live	33106170	2981	2985	O
,	33106170	2986	2987	O
freeze	33106170	2988	2994	O
-	33106170	2995	2996	O
dried	33106170	2997	3002	O
,	33106170	3003	3004	O
attenuated	33106170	3005	3015	O
BCG	33106170	3016	3019	O
Moscow	33106170	3020	3026	O
361-I	33106170	3027	3032	O
,	33106170	3033	3034	O
Bacillus	33106170	3035	3043	O
Calmette	33106170	3044	3052	O
Guerin	33106170	3053	3059	O
vaccine	33106170	3060	3067	O
(	33106170	3068	3069	O
Serum	33106170	3070	3075	O
Institute	33106170	3076	3085	O
of	33106170	3086	3088	O
India	33106170	3089	3094	O
PVT	33106170	3095	3098	O
.	33106170	3099	3100	O

LTD	33106170	3101	3104	O
.	33106170	3105	3106	O
)	33106170	3107	3108	O
.	33106170	3109	3110	O

The	33106170	3111	3114	O
unvaccinated	33106170	3115	3127	O
control	33106170	3128	3135	O
group	33106170	3136	3141	O
will	33106170	3142	3146	O
not	33106170	3147	3150	O
be	33106170	3151	3153	O
vaccinated	33106170	3154	3164	O
.	33106170	3165	3166	O

The	33106170	3167	3170	O
HW	33106170	3171	3173	O
allocated	33106170	3174	3183	O
in	33106170	3184	3186	O
both	33106170	3187	3191	O
groups	33106170	3192	3198	O
will	33106170	3199	3203	O
be	33106170	3204	3206	O
followed	33106170	3207	3215	O
up	33106170	3216	3218	O
at	33106170	3219	3221	O
specific	33106170	3222	3230	O
times	33106170	3231	3236	O
points	33106170	3237	3243	O
until	33106170	3244	3249	O
180	33106170	3250	3253	O
days	33106170	3254	3258	O
post	33106170	3259	3263	O
inclusion	33106170	3264	3273	O
.	33106170	3274	3275	O

The	33106170	3276	3279	O
vaccinated	33106170	3280	3290	O
and	33106170	3291	3294	O
control	33106170	3295	3302	O
groups	33106170	3303	3309	O
will	33106170	3310	3314	O
be	33106170	3315	3317	O
compared	33106170	3318	3326	O
according	33106170	3327	3336	O
to	33106170	3337	3339	O
COVID-19	33106170	3340	3348	O
related	33106170	3349	3356	O
outcomes	33106170	3357	3365	O
.	33106170	3366	3367	O

RESULTS	33106170	3368	3375	O
:	33106170	3376	3377	O
The	33106170	3378	3381	O
primary	33106170	3382	3389	O
outcomes	33106170	3390	3398	O
are	33106170	3399	3402	O
the	33106170	3403	3406	O
incidence	33106170	3407	3416	O
coefficient	33106170	3417	3428	O
of	33106170	3429	3431	O
infection	33106170	3432	3441	O
by	33106170	3442	3444	O
SARS	33106170	3445	3449	O
-	33106170	3450	3451	O
CoV-2	33106170	3452	3457	O
determined	33106170	3458	3468	O
by	33106170	3469	3471	O
RT	33106170	3472	3474	O
-	33106170	3475	3476	O
PCR	33106170	3477	3480	O
of	33106170	3481	3483	O
naso	33106170	3484	3488	O
-	33106170	3489	3490	O
oropharyngeal	33106170	3491	3504	O
swab	33106170	3505	3509	O
specimen	33106170	3510	3518	O
or	33106170	3519	3521	O
rapid	33106170	3522	3527	O
lateral	33106170	3528	3535	O
flow	33106170	3536	3540	O
IgG	33106170	3541	3544	O
and	33106170	3545	3548	O
IgM	33106170	3549	3552	O
test	33106170	3553	3557	O
,	33106170	3558	3559	O
and	33106170	3560	3563	O
presence	33106170	3564	3572	O
of	33106170	3573	3575	O
general	33106170	3576	3583	O
COVID-19	33106170	3584	3592	O
symptoms	33106170	3593	3601	O
,	33106170	3602	3603	O
disease	33106170	3604	3611	O
severity	33106170	3612	3620	O
and	33106170	3621	3624	O
admission	33106170	3625	3634	O
to	33106170	3635	3637	O
hospital	33106170	3638	3646	O
during	33106170	3647	3653	O
the	33106170	3654	3657	O
180	33106170	3658	3661	O
days	33106170	3662	3666	O
of	33106170	3667	3669	O
follow	33106170	3670	3676	O
up	33106170	3677	3679	O
.	33106170	3680	3681	O

The	33106170	3682	3685	O
secondary	33106170	3686	3695	O
outcome	33106170	3696	3703	O
is	33106170	3704	3706	O
the	33106170	3707	3710	O
innate	33106170	3711	3717	O
immune	33106170	3718	3724	O
response	33106170	3725	3733	O
elicited	33106170	3734	3742	O
15	33106170	3743	3745	O
-	33106170	3746	3747	O
20	33106170	3748	3750	O
days	33106170	3751	3755	O
after	33106170	3756	3761	O
vaccination	33106170	3762	3773	O
.	33106170	3774	3775	O

UNASSIGNED	33106170	3776	3786	O
:	33106170	3787	3788	O
The	33106170	3789	3792	O
vaccine	33106170	3793	3800	O
vial	33106170	3801	3805	O
contains	33106170	3806	3814	O
approximately	33106170	3815	3828	O
10	33106170	3829	3831	O
doses	33106170	3832	3837	O
.	33106170	3838	3839	O

In	33106170	3840	3842	O
order	33106170	3843	3848	O
to	33106170	3849	3851	O
optimize	33106170	3852	3860	O
the	33106170	3861	3864	O
vaccine	33106170	3865	3872	O
use	33106170	3873	3876	O
,	33106170	3877	3878	O
the	33106170	3879	3882	O
randomisation	33106170	3883	3896	O
was	33106170	3897	3900	O
performed	33106170	3901	3910	O
in	33106170	3911	3913	O
blocks	33106170	3914	3920	O
of	33106170	3921	3923	O
20	33106170	3924	3926	O
participants	33106170	3927	3939	O
using	33106170	3940	3945	O
the	33106170	3946	3949	O
platform	33106170	3950	3958	O
randomization.com	33106170	3959	3976	O
[	33106170	3977	3978	O
http://www.jerrydallal.com/random/permute.htm	33106170	3979	4024	O
]	33106170	4025	4026	O
.	33106170	4027	4028	O

The	33106170	4029	4032	O
randomization	33106170	4033	4046	O
was	33106170	4047	4050	O
prepared	33106170	4051	4059	O
before	33106170	4060	4066	O
any	33106170	4067	4070	O
HW	33106170	4071	4073	O
inclusion	33106170	4074	4083	O
.	33106170	4084	4085	O

The	33106170	4086	4089	O
results	33106170	4090	4097	O
were	33106170	4098	4102	O
printed	33106170	4103	4110	O
and	33106170	4111	4114	O
inserted	33106170	4115	4123	O
in	33106170	4124	4126	O
sealed	33106170	4127	4133	O
envelopes	33106170	4134	4143	O
that	33106170	4144	4148	O
were	33106170	4149	4153	O
numbered	33106170	4154	4162	O
with	33106170	4163	4167	O
BCG-001	33106170	4168	4175	O
to	33106170	4176	4178	O
BCG-400	33106170	4179	4186	O
.	33106170	4187	4188	O

The	33106170	4189	4192	O
printed	33106170	4193	4200	O
results	33106170	4201	4208	O
as	33106170	4209	4211	O
well	33106170	4212	4216	O
the	33106170	4217	4220	O
envelopes	33106170	4221	4230	O
had	33106170	4231	4234	O
the	33106170	4235	4238	O
same	33106170	4239	4243	O
numbers	33106170	4244	4251	O
.	33106170	4252	4253	O

At	33106170	4254	4256	O
the	33106170	4257	4260	O
time	33106170	4261	4265	O
of	33106170	4266	4268	O
the	33106170	4269	4272	O
randomisation	33106170	4273	4286	O
,	33106170	4287	4288	O
each	33106170	4289	4293	O
participant	33106170	4294	4305	O
that	33106170	4306	4310	O
meets	33106170	4311	4316	O
the	33106170	4317	4320	O
inclusion	33106170	4321	4330	O
criteria	33106170	4331	4339	O
will	33106170	4340	4344	O
receive	33106170	4345	4352	O
a	33106170	4353	4354	O
consecutive	33106170	4355	4366	O
participant	33106170	4367	4378	O
number	33106170	4379	4385	O
[	33106170	4386	4387	O
BCG-001-BCG-400	33106170	4388	4403	O
]	33106170	4404	4405	O
.	33106170	4406	4407	O

The	33106170	4408	4411	O
sealed	33106170	4412	4418	O
envelope	33106170	4419	4427	O
with	33106170	4428	4432	O
the	33106170	4433	4436	O
assigned	33106170	4437	4445	O
number	33106170	4446	4452	O
,	33106170	4453	4454	O
blinded	33106170	4455	4462	O
to	33106170	4463	4465	O
the	33106170	4466	4469	O
researchers	33106170	4470	4481	O
,	33106170	4482	4483	O
will	33106170	4484	4488	O
be	33106170	4489	4491	O
opened	33106170	4492	4498	O
in	33106170	4499	4501	O
front	33106170	4502	4507	O
of	33106170	4508	4510	O
the	33106170	4511	4514	O
participant	33106170	4515	4526	O
and	33106170	4527	4530	O
the	33106170	4531	4534	O
arm	33106170	4535	4538	O
allocation	33106170	4539	4549	O
will	33106170	4550	4554	O
be	33106170	4555	4557	O
known	33106170	4558	4563	O
.	33106170	4564	4565	O

UNASSIGNED	33106170	4566	4576	O
:	33106170	4577	4578	O
There	33106170	4579	4584	O
is	33106170	4585	4587	O
no	33106170	4588	4590	O
masking	33106170	4591	4598	O
for	33106170	4599	4602	O
the	33106170	4603	4606	O
participants	33106170	4607	4619	O
or	33106170	4620	4622	O
for	33106170	4623	4626	O
the	33106170	4627	4630	O
healthcare	33106170	4631	4641	O
providers	33106170	4642	4651	O
.	33106170	4652	4653	O

The	33106170	4654	4657	O
study	33106170	4658	4663	O
will	33106170	4664	4668	O
be	33106170	4669	4671	O
blinded	33106170	4672	4679	O
to	33106170	4680	4682	O
the	33106170	4683	4686	O
laboratory	33106170	4687	4697	O
researchers	33106170	4698	4709	O
and	33106170	4710	4713	O
to	33106170	4714	4716	O
those	33106170	4717	4722	O
who	33106170	4723	4726	O
will	33106170	4727	4731	O
be	33106170	4732	4734	O
evaluating	33106170	4735	4745	O
the	33106170	4746	4749	O
outcomes	33106170	4750	4758	O
and	33106170	4759	4762	O
performing	33106170	4763	4773	O
the	33106170	4774	4777	O
statistical	33106170	4778	4789	O
analyses	33106170	4790	4798	O
.	33106170	4799	4800	O

In	33106170	4801	4803	O
this	33106170	4804	4808	O
case	33106170	4809	4813	O
,	33106170	4814	4815	O
only	33106170	4816	4820	O
the	33106170	4821	4824	O
participant	33106170	4825	4836	O
identification	33106170	4837	4851	O
number	33106170	4852	4858	O
will	33106170	4859	4863	O
be	33106170	4864	4866	O
available	33106170	4867	4876	O
.	33106170	4877	4878	O

UNASSIGNED	33106170	4879	4889	O
:	33106170	4890	4891	O
Four	33106170	4892	4896	O
hundred	33106170	4897	4904	O
heath	33106170	4905	4910	O
workers	33106170	4911	4918	O
will	33106170	4919	4923	O
be	33106170	4924	4926	O
randomised	33106170	4927	4937	O
in	33106170	4938	4940	O
two	33106170	4941	4944	O
groups	33106170	4945	4951	O
.	33106170	4952	4953	O

Two	33106170	4954	4957	O
hundred	33106170	4958	4965	O
participants	33106170	4966	4978	O
will	33106170	4979	4983	O
be	33106170	4984	4986	O
vaccinated	33106170	4987	4997	O
,	33106170	4998	4999	O
and	33106170	5000	5003	O
200	33106170	5004	5007	O
participants	33106170	5008	5020	O
will	33106170	5021	5025	O
not	33106170	5026	5029	O
be	33106170	5030	5032	O
vaccinated	33106170	5033	5043	O
.	33106170	5044	5045	O

UNASSIGNED	33106170	5046	5056	O
:	33106170	5057	5058	O
The	33106170	5059	5062	O
protocol	33106170	5063	5071	O
approved	33106170	5072	5080	O
by	33106170	5081	5083	O
the	33106170	5084	5087	O
Brazilian	33106170	5088	5097	O
Ethical	33106170	5098	5105	O
Committee	33106170	5106	5115	O
is	33106170	5116	5118	O
the	33106170	5119	5122	O
seventh	33106170	5123	5130	O
version	33106170	5131	5138	O
,	33106170	5139	5140	O
number	33106170	5141	5147	O
CAAE	33106170	5148	5152	O
:	33106170	5153	5154	O
31783720.0.0000.5078	33106170	5155	5175	O
.	33106170	5176	5177	O

The	33106170	5178	5181	O
trial	33106170	5182	5187	O
has	33106170	5188	5191	O
been	33106170	5192	5196	O
recruiting	33106170	5197	5207	O
since	33106170	5208	5213	O
September	33106170	5214	5223	O
20th	33106170	5224	5228	O
,	33106170	5229	5230	O
2020	33106170	5231	5235	O
.	33106170	5236	5237	O

The	33106170	5238	5241	O
clinical	33106170	5242	5250	O
trial	33106170	5251	5256	O
protocol	33106170	5257	5265	O
was	33106170	5266	5269	O
registered	33106170	5270	5280	O
on	33106170	5281	5283	O
August	33106170	5284	5290	O
5th	33106170	5291	5294	O
,	33106170	5295	5296	O
2020	33106170	5297	5301	O
.	33106170	5302	5303	O

It	33106170	5304	5306	O
is	33106170	5307	5309	O
estimated	33106170	5310	5319	O
that	33106170	5320	5324	O
recruitment	33106170	5325	5336	O
will	33106170	5337	5341	O
finish	33106170	5342	5348	O
by	33106170	5349	5351	O
March	33106170	5352	5357	O
2021	33106170	5358	5362	O
.	33106170	5363	5364	O

BACKGROUND	33106170	5365	5375	O
:	33106170	5376	5377	O
The	33106170	5378	5381	O
protocol	33106170	5382	5390	O
number	33106170	5391	5397	O
was	33106170	5398	5401	O
registered	33106170	5402	5412	O
on	33106170	5413	5415	O
August	33106170	5416	5422	O
5th	33106170	5423	5426	O
,	33106170	5427	5428	O
2020	33106170	5429	5433	O
at	33106170	5434	5436	O
REBEC	33106170	5437	5442	O
(	33106170	5443	5444	O
Registro	33106170	5445	5453	O
Brasileiro	33106170	5454	5464	O
de	33106170	5465	5467	O
Ensaios	33106170	5468	5475	O
Clnicos	33106170	5476	5484	O
)	33106170	5485	5486	O
.	33106170	5487	5488	O

Register	33106170	5489	5497	O
number	33106170	5498	5504	O
:	33106170	5505	5506	O
RBR-4kjqtg	33106170	5507	5517	O
and	33106170	5518	5521	O
WHO	33106170	5522	5525	O
trial	33106170	5526	5531	O
registration	33106170	5532	5544	O
number	33106170	5545	5551	O
UTN	33106170	5552	5555	O
:	33106170	5556	5557	O
U1111	33106170	5558	5563	O
-	33106170	5564	5565	O
1256	33106170	5566	5570	O
-	33106170	5571	5572	O
3892	33106170	5573	5577	O
.	33106170	5578	5579	O

UNASSIGNED	33106170	5580	5590	O
:	33106170	5591	5592	O
The	33106170	5593	5596	O
full	33106170	5597	5601	O
protocol	33106170	5602	5610	O
is	33106170	5611	5613	O
attached	33106170	5614	5622	O
as	33106170	5623	5625	O
an	33106170	5626	5628	O
additional	33106170	5629	5639	O
file	33106170	5640	5644	O
,	33106170	5645	5646	O
accessible	33106170	5647	5657	O
from	33106170	5658	5662	O
the	33106170	5663	5666	O
Trials	33106170	5667	5673	O
website	33106170	5674	5681	O
(	33106170	5682	5683	O
Additional	33106170	5684	5694	O
file	33106170	5695	5699	O
1	33106170	5700	5701	O
)	33106170	5702	5703	O
.	33106170	5704	5705	O

In	33106170	5706	5708	O
the	33106170	5709	5712	O
interest	33106170	5713	5721	O
in	33106170	5722	5724	O
expediting	33106170	5725	5735	O
dissemination	33106170	5736	5749	O
of	33106170	5750	5752	O
this	33106170	5753	5757	O
material	33106170	5758	5766	O
,	33106170	5767	5768	O
the	33106170	5769	5772	O
familiar	33106170	5773	5781	O
formatting	33106170	5782	5792	O
has	33106170	5793	5796	O
been	33106170	5797	5801	O
eliminated	33106170	5802	5812	O
;	33106170	5813	5814	O
this	33106170	5815	5819	O
Letter	33106170	5820	5826	O
serves	33106170	5827	5833	O
as	33106170	5834	5836	O
a	33106170	5837	5838	O
summary	33106170	5839	5846	O
of	33106170	5847	5849	O
the	33106170	5850	5853	O
key	33106170	5854	5857	O
elements	33106170	5858	5866	O
of	33106170	5867	5869	O
the	33106170	5870	5873	O
full	33106170	5874	5878	O
protocol	33106170	5879	5887	O
.	33106170	5888	5889	O


Evaluation	33106171	0	10	O
of	33106171	11	13	O
the	33106171	14	17	O
efficacy	33106171	18	26	O
and	33106171	27	30	O
safety	33106171	31	37	O
of	33106171	38	40	O
Melatonin	33106171	41	50	O
in	33106171	51	53	O
moderately	33106171	54	64	O
ill	33106171	65	68	O
patients	33106171	69	77	O
with	33106171	78	82	O
COVID-19	33106171	83	91	O
:	33106171	92	93	O
A	33106171	94	95	O
structured	33106171	96	106	O
summary	33106171	107	114	O
of	33106171	115	117	O
a	33106171	118	119	O
study	33106171	120	125	O
protocol	33106171	126	134	O
for	33106171	135	138	O
a	33106171	139	140	O
randomized	33106171	141	151	O
controlled	33106171	152	162	O
trial	33106171	163	168	O
.	33106171	169	170	O

OBJECTIVE	33106171	171	180	O
:	33106171	181	182	O
We	33106171	183	185	O
will	33106171	186	190	O
evaluate	33106171	191	199	O
the	33106171	200	203	O
efficacy	33106171	204	212	O
and	33106171	213	216	O
safety	33106171	217	223	O
of	33106171	224	226	O
Melatonin	33106171	227	236	O
,	33106171	237	238	O
compared	33106171	239	247	O
to	33106171	248	250	O
the	33106171	251	254	O
standard	33106171	255	263	O
therapeutic	33106171	264	275	O
regimen	33106171	276	283	O
on	33106171	284	286	O
clinical	33106171	287	295	O
symptoms	33106171	296	304	O
and	33106171	305	308	O
serum	33106171	309	314	O
inflammatory	33106171	315	327	O
parameters	33106171	328	338	O
in	33106171	339	341	O
patients	33106171	342	350	O
with	33106171	351	355	O
confirmed	33106171	356	365	O
COVID-19	33106171	366	374	O
,	33106171	375	376	O
who	33106171	377	380	O
are	33106171	381	384	O
moderately	33106171	385	395	O
ill	33106171	396	399	O
.	33106171	400	401	O

METHODS	33106171	402	409	O
:	33106171	410	411	O
This	33106171	412	416	O
is	33106171	417	419	O
a	33106171	420	421	O
single	33106171	422	428	O
-	33106171	429	430	O
center	33106171	431	437	O
,	33106171	438	439	O
randomized	33106171	440	450	O
,	33106171	451	452	O
double	33106171	453	459	O
-	33106171	460	461	O
blind	33106171	462	467	O
,	33106171	468	469	O
placebo	33106171	470	477	O
-	33106171	478	479	O
controlled	33106171	480	490	O
clinical	33106171	491	499	O
trial	33106171	500	505	O
with	33106171	506	510	O
a	33106171	511	512	O
parallel	33106171	513	521	O
-	33106171	522	523	O
group	33106171	524	529	O
design	33106171	530	536	O
conducted	33106171	537	546	O
at	33106171	547	549	O
Shahid	33106171	550	556	O
Mohammadi	33106171	557	566	O
Hospital	33106171	567	575	O
,	33106171	576	577	O
Bandar	33106171	578	584	O
Abbas	33106171	585	590	O
,	33106171	591	592	O
Iran	33106171	593	597	O
.	33106171	598	599	O

METHODS	33106171	600	607	O
:	33106171	608	609	O
All	33106171	610	613	O
patients	33106171	614	622	O
admitted	33106171	623	631	O
to	33106171	632	634	O
Severe	33106171	635	641	O
Acute	33106171	642	647	O
Respiratory	33106171	648	659	O
Syndrome	33106171	660	668	O
Departments	33106171	669	680	O
of	33106171	681	683	O
Shahid	33106171	684	690	O
Mohammadi	33106171	691	700	O
Hospital	33106171	701	709	O
,	33106171	710	711	O
Bandar	33106171	712	718	O
Abbas	33106171	719	724	O
,	33106171	725	726	O
Iran	33106171	727	731	O
will	33106171	732	736	O
be	33106171	737	739	O
screened	33106171	740	748	O
for	33106171	749	752	O
the	33106171	753	756	O
following	33106171	757	766	O
criteria	33106171	767	775	O
.	33106171	776	777	O

METHODS	33106171	778	785	O
:	33106171	786	787	O
1	33106171	788	789	O
.	33106171	790	791	O
Age	33106171	792	795	O
	33106171	798	799	O
20	33106171	800	802	O
years	33106171	803	808	O
2	33106171	809	810	O
.	33106171	811	812	O

Confirmed	33106171	813	822	O
SARS	33106171	823	827	O
-	33106171	828	829	O
CoV-2	33106171	830	835	O
diagnosis	33106171	836	845	O
(	33106171	846	847	O
positive	33106171	848	856	O
polymerase	33106171	857	867	O
chain	33106171	868	873	O
reaction	33106171	874	882	O
)	33106171	883	884	O
.	33106171	885	886	O

3	33106171	887	888	O
.	33106171	889	890	O

Moderate	33106171	891	899	O
COVID-19	33106171	900	908	O
pneumonia	33106171	909	918	O
(	33106171	919	920	O
via	33106171	921	924	O
computed	33106171	925	933	O
tomography	33106171	934	944	O
and	33106171	945	948	O
or	33106171	949	951	O
X	33106171	952	953	O
-	33106171	954	955	O
ray	33106171	956	959	O
imaging	33106171	960	967	O
)	33106171	968	969	O
,	33106171	970	971	O
requiring	33106171	972	981	O
hospitalization	33106171	982	997	O
.	33106171	998	999	O

4	33106171	1000	1001	O
.	33106171	1002	1003	O
Hospitalized	33106171	1004	1016	O
	33106171	1019	1020	O
48	33106171	1021	1023	O
hours	33106171	1024	1029	O
.	33106171	1030	1031	O

5	33106171	1032	1033	O
.	33106171	1034	1035	O

Signing	33106171	1036	1043	O
informed	33106171	1044	1052	O
consent	33106171	1053	1060	O
and	33106171	1061	1064	O
willingness	33106171	1065	1076	O
of	33106171	1077	1079	O
the	33106171	1080	1083	O
participant	33106171	1084	1095	O
to	33106171	1096	1098	O
accept	33106171	1099	1105	O
randomization	33106171	1106	1119	O
to	33106171	1120	1122	O
any	33106171	1123	1126	O
assigned	33106171	1127	1135	O
treatment	33106171	1136	1145	O
arm	33106171	1146	1149	O
.	33106171	1150	1151	O

METHODS	33106171	1152	1159	O
:	33106171	1160	1161	O
1	33106171	1162	1163	O
.	33106171	1164	1165	O

Underlying	33106171	1166	1176	O
diseases	33106171	1177	1185	O
,	33106171	1186	1187	O
including	33106171	1188	1197	O
chronic	33106171	1198	1205	O
hypertension	33106171	1206	1218	O
,	33106171	1219	1220	O
diabetes	33106171	1221	1229	O
mellitus	33106171	1230	1238	O
,	33106171	1239	1240	O
seizure	33106171	1241	1248	O
,	33106171	1249	1250	O
depression	33106171	1251	1261	O
,	33106171	1262	1263	O
chronic	33106171	1264	1271	O
hepatitis	33106171	1272	1281	O
,	33106171	1282	1283	O
cirrhosis	33106171	1284	1293	O
,	33106171	1294	1295	O
and	33106171	1296	1299	O
cholestatic	33106171	1300	1311	O
liver	33106171	1312	1317	O
diseases	33106171	1318	1326	O
.	33106171	1327	1328	O

2	33106171	1329	1330	O
.	33106171	1331	1332	O
Severe	33106171	1333	1339	O
and	33106171	1340	1343	O
critical	33106171	1344	1352	O
COVID-19	33106171	1353	1361	O
pneumonia	33106171	1362	1371	O
.	33106171	1372	1373	O

3	33106171	1374	1375	O
.	33106171	1376	1377	O

Use	33106171	1378	1381	O
of	33106171	1382	1384	O
warfarin	33106171	1385	1393	O
,	33106171	1394	1395	O
corticosteroids	33106171	1396	1411	O
,	33106171	1412	1413	O
hormonal	33106171	1414	1422	O
drugs	33106171	1423	1428	O
,	33106171	1429	1430	O
alcohol	33106171	1431	1438	O
,	33106171	1439	1440	O
other	33106171	1441	1446	O
antiviral	33106171	1447	1456	O
and	33106171	1457	1460	O
investigational	33106171	1461	1476	O
medicines	33106171	1477	1486	O
,	33106171	1487	1488	O
and	33106171	1489	1492	O
illegal	33106171	1493	1500	O
drugs	33106171	1501	1506	O
(	33106171	1507	1508	O
during	33106171	1509	1515	O
the	33106171	1516	1519	O
last	33106171	1520	1524	O
30	33106171	1525	1527	O
days	33106171	1528	1532	O
)	33106171	1533	1534	O
.	33106171	1535	1536	O

4	33106171	1537	1538	O
.	33106171	1539	1540	O

History	33106171	1541	1548	O
of	33106171	1549	1551	O
known	33106171	1552	1557	O
allergy	33106171	1558	1565	O
to	33106171	1566	1568	O
Melatonin	33106171	1569	1578	O
.	33106171	1579	1580	O

5	33106171	1581	1582	O
.	33106171	1583	1584	O

Pregnancy	33106171	1585	1594	O
and	33106171	1595	1598	O
breastfeeding	33106171	1599	1612	O
.	33106171	1613	1614	O

UNASSIGNED	33106171	1615	1625	O
:	33106171	1626	1627	O
Intervention	33106171	1628	1640	O
group	33106171	1641	1646	O
:	33106171	1647	1648	O
The	33106171	1649	1652	O
standard	33106171	1653	1661	O
treatment	33106171	1662	1671	O
regimen	33106171	1672	1679	O
for	33106171	1680	1683	O
COVID-19	33106171	1684	1692	O
,	33106171	1693	1694	O
according	33106171	1695	1704	O
to	33106171	1705	1707	O
the	33106171	1708	1711	O
Iranian	33106171	1712	1719	O
Ministry	33106171	1720	1728	O
of	33106171	1729	1731	O
Health	33106171	1732	1738	O
and	33106171	1739	1742	O
Medical	33106171	1743	1750	O
Education	33106171	1751	1760	O
's	33106171	1761	1763	O
protocol	33106171	1764	1772	O
,	33106171	1773	1774	O
along	33106171	1775	1780	O
with	33106171	1781	1785	O
Melatonin	33106171	1786	1795	O
capsules	33106171	1796	1804	O
at	33106171	1805	1807	O
a	33106171	1808	1809	O
dose	33106171	1810	1814	O
of	33106171	1815	1817	O
50	33106171	1818	1820	O
mg	33106171	1821	1823	O
daily	33106171	1824	1829	O
for	33106171	1830	1833	O
a	33106171	1834	1835	O
period	33106171	1836	1842	O
of	33106171	1843	1845	O
seven	33106171	1846	1851	O
days	33106171	1852	1856	O
.	33106171	1857	1858	O

METHODS	33106171	1859	1866	O
:	33106171	1867	1868	O
The	33106171	1869	1872	O
standard	33106171	1873	1881	O
therapeutic	33106171	1882	1893	O
regimen	33106171	1894	1901	O
for	33106171	1902	1905	O
COVID-19	33106171	1906	1914	O
along	33106171	1915	1920	O
with	33106171	1921	1925	O
Melatonin	33106171	1926	1935	O
-	33106171	1936	1937	O
like	33106171	1938	1942	O
placebo	33106171	1943	1950	O
capsules	33106171	1951	1959	O
at	33106171	1960	1962	O
a	33106171	1963	1964	O
dose	33106171	1965	1969	O
of	33106171	1970	1972	O
one	33106171	1973	1976	O
capsule	33106171	1977	1984	O
daily	33106171	1985	1990	O
for	33106171	1991	1994	O
a	33106171	1995	1996	O
period	33106171	1997	2003	O
of	33106171	2004	2006	O
seven	33106171	2007	2012	O
days	33106171	2013	2017	O
.	33106171	2018	2019	O

Both	33106171	2020	2024	O
Melatonin	33106171	2025	2034	O
and	33106171	2035	2038	O
placebo	33106171	2039	2046	O
capsules	33106171	2047	2055	O
were	33106171	2056	2060	O
prepared	33106171	2061	2069	O
at	33106171	2070	2072	O
the	33106171	2073	2076	O
Faculty	33106171	2077	2084	O
of	33106171	2085	2087	O
Pharmacy	33106171	2088	2096	O
and	33106171	2097	2100	O
Pharmaceutical	33106171	2101	2115	O
Sciences	33106171	2116	2124	O
,	33106171	2125	2126	O
Hormozgan	33106171	2127	2136	O
University	33106171	2137	2147	O
of	33106171	2148	2150	O
Medical	33106171	2151	2158	O
Sciences	33106171	2159	2167	O
,	33106171	2168	2169	O
Bandar	33106171	2170	2176	O
Abbas	33106171	2177	2182	O
,	33106171	2183	2184	O
Iran	33106171	2185	2189	O
.	33106171	2190	2191	O

RESULTS	33106171	2192	2199	O
:	33106171	2200	2201	O
The	33106171	2202	2205	O
primary	33106171	2206	2213	O
outcomes	33106171	2214	2222	O
are	33106171	2223	2226	O
the	33106171	2227	2230	O
recovery	33106171	2231	2239	O
rate	33106171	2240	2244	O
of	33106171	2245	2247	O
clinical	33106171	2248	2256	O
symptoms	33106171	2257	2265	O
and	33106171	2266	2269	O
oxygen	33106171	2270	2276	O
saturation	33106171	2277	2287	O
as	33106171	2288	2290	O
well	33106171	2291	2295	O
as	33106171	2296	2298	O
improvement	33106171	2299	2310	O
of	33106171	2311	2313	O
serum	33106171	2314	2319	O
inflammatory	33106171	2320	2332	O
parameters	33106171	2333	2343	O
,	33106171	2344	2345	O
including	33106171	2346	2355	O
C	33106171	2356	2357	O
-	33106171	2358	2359	O
reactive	33106171	2360	2368	O
protein	33106171	2369	2376	O
,	33106171	2377	2378	O
tumor	33106171	2379	2384	O
necrosis	33106171	2385	2393	O
factor	33106171	2394	2400	O
-	33106171	2401	2402	O
alpha	33106171	2403	2408	O
(	33106171	2409	2410	O
TNF	33106171	2411	2414	O
-	33106171	2415	2416	O
	33106171	2417	2418	O
)	33106171	2419	2420	O
,	33106171	2421	2422	O
interleukin-1	33106171	2423	2437	O
(	33106171	2438	2439	O
IL-1	33106171	2440	2445	O
)	33106171	2446	2447	O
,	33106171	2448	2449	O
and	33106171	2450	2453	O
IL-6	33106171	2454	2458	O
within	33106171	2459	2465	O
seven	33106171	2466	2471	O
days	33106171	2472	2476	O
of	33106171	2477	2479	O
randomization	33106171	2480	2493	O
.	33106171	2494	2495	O

The	33106171	2496	2499	O
secondary	33106171	2500	2509	O
outcomes	33106171	2510	2518	O
are	33106171	2519	2522	O
the	33106171	2523	2526	O
time	33106171	2527	2531	O
to	33106171	2532	2534	O
improve	33106171	2535	2542	O
clinical	33106171	2543	2551	O
and	33106171	2552	2555	O
paraclinical	33106171	2556	2568	O
features	33106171	2569	2577	O
along	33106171	2578	2583	O
with	33106171	2584	2588	O
the	33106171	2589	2592	O
incidence	33106171	2593	2602	O
of	33106171	2603	2605	O
serious	33106171	2606	2613	O
adverse	33106171	2614	2621	O
drug	33106171	2622	2626	O
reactions	33106171	2627	2636	O
within	33106171	2637	2643	O
seven	33106171	2644	2649	O
days	33106171	2650	2654	O
of	33106171	2655	2657	O
randomization	33106171	2658	2671	O
.	33106171	2672	2673	O

UNASSIGNED	33106171	2674	2684	O
:	33106171	2685	2686	O
Included	33106171	2687	2695	O
patients	33106171	2696	2704	O
will	33106171	2705	2709	O
be	33106171	2710	2712	O
allocated	33106171	2713	2722	O
to	33106171	2723	2725	O
one	33106171	2726	2729	O
of	33106171	2730	2732	O
the	33106171	2733	2736	O
study	33106171	2737	2742	O
arms	33106171	2743	2747	O
using	33106171	2748	2753	O
block	33106171	2754	2759	O
randomization	33106171	2760	2773	O
in	33106171	2774	2776	O
a	33106171	2777	2778	O
1:1	33106171	2779	2782	O
ratio	33106171	2783	2788	O
(	33106171	2789	2790	O
each	33106171	2791	2795	O
block	33106171	2796	2801	O
consists	33106171	2802	2810	O
of	33106171	2811	2813	O
10	33106171	2814	2816	O
patients	33106171	2817	2825	O
)	33106171	2826	2827	O
.	33106171	2828	2829	O

This	33106171	2830	2834	O
randomization	33106171	2835	2848	O
method	33106171	2849	2855	O
ensures	33106171	2856	2863	O
a	33106171	2864	2865	O
balanced	33106171	2866	2874	O
allocation	33106171	2875	2885	O
between	33106171	2886	2893	O
the	33106171	2894	2897	O
arms	33106171	2898	2902	O
during	33106171	2903	2909	O
the	33106171	2910	2913	O
study	33106171	2914	2919	O
.	33106171	2920	2921	O

A	33106171	2922	2923	O
web	33106171	2924	2927	O
-	33106171	2928	2929	O
based	33106171	2930	2935	O
system	33106171	2936	2942	O
will	33106171	2943	2947	O
generate	33106171	2948	2956	O
random	33106171	2957	2963	O
numbers	33106171	2964	2971	O
for	33106171	2972	2975	O
the	33106171	2976	2979	O
allocation	33106171	2980	2990	O
sequence	33106171	2991	2999	O
and	33106171	3000	3003	O
concealment	33106171	3004	3015	O
of	33106171	3016	3018	O
participants	33106171	3019	3031	O
.	33106171	3032	3033	O

Each	33106171	3034	3038	O
number	33106171	3039	3045	O
relates	33106171	3046	3053	O
to	33106171	3054	3056	O
one	33106171	3057	3060	O
of	33106171	3061	3063	O
the	33106171	3064	3067	O
study	33106171	3068	3073	O
arms	33106171	3074	3078	O
.	33106171	3079	3080	O

UNASSIGNED	33106171	3081	3091	O
:	33106171	3092	3093	O
All	33106171	3094	3097	O
study	33106171	3098	3103	O
participants	33106171	3104	3116	O
,	33106171	3117	3118	O
clinicians	33106171	3119	3129	O
,	33106171	3130	3131	O
nurses	33106171	3132	3138	O
,	33106171	3139	3140	O
research	33106171	3141	3149	O
coordinators	33106171	3150	3162	O
,	33106171	3163	3164	O
and	33106171	3165	3168	O
those	33106171	3169	3174	O
analyzing	33106171	3175	3184	O
the	33106171	3185	3188	O
data	33106171	3189	3193	O
are	33106171	3194	3197	O
blinded	33106171	3198	3205	O
to	33106171	3206	3208	O
the	33106171	3209	3212	O
group	33106171	3213	3218	O
assignment	33106171	3219	3229	O
.	33106171	3230	3231	O

UNASSIGNED	33106171	3232	3242	O
:	33106171	3243	3244	O
A	33106171	3245	3246	O
total	33106171	3247	3252	O
of	33106171	3253	3255	O
60	33106171	3256	3258	O
patients	33106171	3259	3267	O
randomized	33106171	3268	3278	O
into	33106171	3279	3283	O
two	33106171	3284	3287	O
groups	33106171	3288	3294	O
(	33106171	3295	3296	O
30	33106171	3297	3299	O
in	33106171	3300	3302	O
each	33106171	3303	3307	O
group	33106171	3308	3313	O
)	33106171	3314	3315	O
.	33106171	3316	3317	O

UNASSIGNED	33106171	3318	3328	O
:	33106171	3329	3330	O
The	33106171	3331	3334	O
trial	33106171	3335	3340	O
protocol	33106171	3341	3349	O
is	33106171	3350	3352	O
Version	33106171	3353	3360	O
1.0	33106171	3361	3364	O
,	33106171	3365	3366	O
August	33106171	3367	3373	O
14	33106171	3374	3376	O
,	33106171	3377	3378	O
2020	33106171	3379	3383	O
.	33106171	3384	3385	O

Recruitment	33106171	3386	3397	O
began	33106171	3398	3403	O
August	33106171	3404	3410	O
22	33106171	3411	3413	O
,	33106171	3414	3415	O
2020	33106171	3416	3420	O
,	33106171	3421	3422	O
and	33106171	3423	3426	O
is	33106171	3427	3429	O
anticipated	33106171	3430	3441	O
to	33106171	3442	3444	O
be	33106171	3445	3447	O
completed	33106171	3448	3457	O
by	33106171	3458	3460	O
November	33106171	3461	3469	O
30	33106171	3470	3472	O
,	33106171	3473	3474	O
2020	33106171	3475	3479	O
.	33106171	3480	3481	O

BACKGROUND	33106171	3482	3492	O
:	33106171	3493	3494	O
The	33106171	3495	3498	O
trial	33106171	3499	3504	O
protocol	33106171	3505	3513	O
has	33106171	3514	3517	O
been	33106171	3518	3522	O
registered	33106171	3523	3533	O
in	33106171	3534	3536	O
the	33106171	3537	3540	O
Iranian	33106171	3541	3548	O
Registry	33106171	3549	3557	O
of	33106171	3558	3560	O
Clinical	33106171	3561	3569	O
Trials	33106171	3570	3576	O
(	33106171	3577	3578	O
IRCT	33106171	3579	3583	O
)	33106171	3584	3585	O
.	33106171	3586	3587	O

The	33106171	3588	3591	O
registration	33106171	3592	3604	O
number	33106171	3605	3611	O
is	33106171	3612	3614	O
"	33106171	3615	3616	O
IRCT20200506047323N5	33106171	3617	3637	O
"	33106171	3638	3639	O
.	33106171	3640	3641	O

The	33106171	3642	3645	O
registration	33106171	3646	3658	O
date	33106171	3659	3663	O
was	33106171	3664	3667	O
14	33106171	3668	3670	O
August	33106171	3671	3677	O
2020	33106171	3678	3682	O
.	33106171	3683	3684	O

UNASSIGNED	33106171	3685	3695	O
:	33106171	3696	3697	O
The	33106171	3698	3701	O
full	33106171	3702	3706	O
protocol	33106171	3707	3715	O
is	33106171	3716	3718	O
attached	33106171	3719	3727	O
as	33106171	3728	3730	O
an	33106171	3731	3733	O
additional	33106171	3734	3744	O
file	33106171	3745	3749	O
,	33106171	3750	3751	O
accessible	33106171	3752	3762	O
from	33106171	3763	3767	O
the	33106171	3768	3771	O
Trials	33106171	3772	3778	O
website	33106171	3779	3786	O
(	33106171	3787	3788	O
Additional	33106171	3789	3799	O
file	33106171	3800	3804	O
1	33106171	3805	3806	O
)	33106171	3807	3808	O
.	33106171	3809	3810	O

In	33106171	3811	3813	O
the	33106171	3814	3817	O
interest	33106171	3818	3826	O
in	33106171	3827	3829	O
expediting	33106171	3830	3840	O
the	33106171	3841	3844	O
dissemination	33106171	3845	3858	O
of	33106171	3859	3861	O
this	33106171	3862	3866	O
material	33106171	3867	3875	O
,	33106171	3876	3877	O
the	33106171	3878	3881	O
familiar	33106171	3882	3890	O
formatting	33106171	3891	3901	O
has	33106171	3902	3905	O
been	33106171	3906	3910	O
eliminated	33106171	3911	3921	O
;	33106171	3922	3923	O
this	33106171	3924	3928	O
Letter	33106171	3929	3935	O
serves	33106171	3936	3942	O
as	33106171	3943	3945	O
a	33106171	3946	3947	O
summary	33106171	3948	3955	O
of	33106171	3956	3958	O
the	33106171	3959	3962	O
key	33106171	3963	3966	O
elements	33106171	3967	3975	O
of	33106171	3976	3978	O
the	33106171	3979	3982	O
full	33106171	3983	3987	O
protocol	33106171	3988	3996	O
.	33106171	3997	3998	O


An	33106183	0	2	O
investigation	33106183	3	16	O
into	33106183	17	21	O
the	33106183	22	25	O
beneficial	33106183	26	36	O
effects	33106183	37	44	O
of	33106183	45	47	O
high	33106183	48	52	O
-	33106183	53	54	O
dose	33106183	55	59	O
interferon	33106183	60	70	O
beta	33106183	71	75	O
1-a	33106183	76	79	O
,	33106183	80	81	O
compared	33106183	82	90	O
to	33106183	91	93	O
low	33106183	94	97	O
-	33106183	98	99	O
dose	33106183	100	104	O
interferon	33106183	105	115	O
beta	33106183	116	120	O
1-a	33106183	121	124	O
(	33106183	125	126	O
the	33106183	127	130	O
base	33106183	131	135	O
therapeutic	33106183	136	147	O
regimen	33106183	148	155	O
)	33106183	156	157	O
in	33106183	158	160	O
moderate	33106183	161	169	O
to	33106183	170	172	O
severe	33106183	173	179	O
COVID-19	33106183	180	188	O
:	33106183	189	190	O
A	33106183	191	192	O
structured	33106183	193	203	O
summary	33106183	204	211	O
of	33106183	212	214	O
a	33106183	215	216	O
study	33106183	217	222	O
protocol	33106183	223	231	O
for	33106183	232	235	O
a	33106183	236	237	O
randomized	33106183	238	248	O
controlled	33106183	249	259	O
l	33106183	260	261	O
trial	33106183	262	267	O
.	33106183	268	269	O

OBJECTIVE	33106183	270	279	O
:	33106183	280	281	O
We	33106183	282	284	O
will	33106183	285	289	O
investigate	33106183	290	301	O
the	33106183	302	305	O
effectiveness	33106183	306	319	O
of	33106183	320	322	O
high	33106183	323	327	O
dose	33106183	328	332	O
Interferon	33106183	333	343	O
Beta	33106183	344	348	O
1a	33106183	349	351	O
,	33106183	352	353	O
compared	33106183	354	362	O
to	33106183	363	365	O
low	33106183	366	369	O
dose	33106183	370	374	O
Interferon	33106183	375	385	O
Beta	33106183	386	390	O
1a	33106183	391	393	O
(	33106183	394	395	O
the	33106183	396	399	O
base	33106183	400	404	O
therapeutic	33106183	405	416	O
regimen	33106183	417	424	O
)	33106183	425	426	O
in	33106183	427	429	O
COVID-19	33106183	430	438	O
Confirmed	33106183	439	448	O
Cases	33106183	449	454	O
(	33106183	455	456	O
Either	33106183	457	463	O
RT	33106183	464	466	O
-	33106183	467	468	O
PCR	33106183	469	472	O
or	33106183	473	475	O
CT	33106183	476	478	O
Scan	33106183	479	483	O
Confirmed	33106183	484	493	O
)	33106183	494	495	O
with	33106183	496	500	O
moderate	33106183	501	509	O
to	33106183	510	512	O
severe	33106183	513	519	O
disease	33106183	520	527	O
TRIAL	33106183	528	533	O
DESIGN	33106183	534	540	O
:	33106183	541	542	O
This	33106183	543	547	O
is	33106183	548	550	O
a	33106183	551	552	O
single	33106183	553	559	O
center	33106183	560	566	O
,	33106183	567	568	O
open	33106183	569	573	O
label	33106183	574	579	O
,	33106183	580	581	O
randomized	33106183	582	592	O
,	33106183	593	594	O
controlled	33106183	595	605	O
,	33106183	606	607	O
2-arm	33106183	608	613	O
parallel	33106183	614	622	O
group	33106183	623	628	O
(	33106183	629	630	O
1:1	33106183	631	634	O
ratio	33106183	635	640	O
)	33106183	641	642	O
,	33106183	643	644	O
clinical	33106183	645	653	O
trial	33106183	654	659	O
.	33106183	660	661	O

METHODS	33106183	662	669	O
:	33106183	670	671	O
The	33106183	672	675	O
eligibility	33106183	676	687	O
criteria	33106183	688	696	O
in	33106183	697	699	O
this	33106183	700	704	O
study	33106183	705	710	O
is	33106183	711	713	O
:	33106183	714	715	O
age	33106183	716	719	O
	33106183	722	723	O
18	33106183	726	728	O
years	33106183	729	734	O
,	33106183	735	736	O
oxygen	33106183	737	743	O
saturation	33106183	744	754	O
(	33106183	755	756	O
SPO2	33106183	757	761	O
)	33106183	762	763	O
	33106183	766	767	O
93	33106183	770	772	O
%	33106183	773	774	O
or	33106183	775	777	O
respiratory	33106183	778	789	O
rate	33106183	790	794	O
	33106183	797	798	O
24	33106183	801	803	O
,	33106183	804	805	O
at	33106183	806	808	O
least	33106183	809	814	O
one	33106183	815	818	O
of	33106183	819	821	O
the	33106183	822	825	O
following	33106183	826	835	O
manifestation	33106183	836	849	O
:	33106183	850	851	O
radiation	33106183	852	861	O
contactless	33106183	862	873	O
body	33106183	874	878	O
temperature	33106183	879	890	O
	33106183	893	894	O
37.8	33106183	895	899	O
,	33106183	900	901	O
Cough	33106183	902	907	O
,	33106183	908	909	O
shortness	33106183	910	919	O
of	33106183	920	922	O
breath	33106183	923	929	O
,	33106183	930	931	O
nasal	33106183	932	937	O
congestion/	33106183	938	949	O
discharge	33106183	950	959	O
,	33106183	960	961	O
myalgia	33106183	962	969	O
/	33106183	970	971	O
arthralgia	33106183	972	982	O
,	33106183	983	984	O
diarrhea	33106183	985	993	O
/	33106183	994	995	O
vomiting	33106183	996	1004	O
,	33106183	1005	1006	O
headache	33106183	1007	1015	O
or	33106183	1016	1018	O
fatigue	33106183	1019	1026	O
on	33106183	1027	1029	O
admission	33106183	1030	1039	O
.	33106183	1040	1041	O

The	33106183	1042	1045	O
onset	33106183	1046	1051	O
of	33106183	1052	1054	O
the	33106183	1055	1058	O
symptoms	33106183	1059	1067	O
should	33106183	1068	1074	O
be	33106183	1075	1077	O
acute	33106183	1078	1083	O
(	33106183	1084	1085	O
	33106183	1086	1087	O
14	33106183	1090	1092	O
days	33106183	1093	1097	O
)	33106183	1098	1099	O
.	33106183	1100	1101	O

The	33106183	1102	1105	O
exclusion	33106183	1106	1115	O
criteria	33106183	1116	1124	O
include	33106183	1125	1132	O
refusal	33106183	1133	1140	O
to	33106183	1141	1143	O
participate	33106183	1144	1155	O
,	33106183	1156	1157	O
using	33106183	1158	1163	O
drugs	33106183	1164	1169	O
with	33106183	1170	1174	O
potential	33106183	1175	1184	O
interaction	33106183	1185	1196	O
with	33106183	1197	1201	O
lopinavir	33106183	1202	1211	O
/	33106183	1212	1213	O
ritonavir	33106183	1214	1223	O
or	33106183	1224	1226	O
interferon	33106183	1227	1237	O
-	33106183	1238	1239	O
	33106183	1240	1241	O
1a	33106183	1242	1244	O
,	33106183	1245	1246	O
blood	33106183	1247	1252	O
ALT	33106183	1253	1256	O
/	33106183	1257	1258	O
AST	33106183	1259	1262	O
levels	33106183	1263	1269	O
>	33106183	1270	1271	O
5	33106183	1272	1273	O
times	33106183	1274	1279	O
the	33106183	1280	1283	O
upper	33106183	1284	1289	O
limit	33106183	1290	1295	O
of	33106183	1296	1298	O
normal	33106183	1299	1305	O
on	33106183	1306	1308	O
laboratory	33106183	1309	1319	O
results	33106183	1320	1327	O
,	33106183	1328	1329	O
pregnant	33106183	1330	1338	O
or	33106183	1339	1341	O
lactating	33106183	1342	1351	O
women	33106183	1352	1357	O
,	33106183	1358	1359	O
history	33106183	1360	1367	O
of	33106183	1368	1370	O
alcohol	33106183	1371	1378	O
or	33106183	1379	1381	O
drug	33106183	1382	1386	O
addiction	33106183	1387	1396	O
in	33106183	1397	1399	O
the	33106183	1400	1403	O
past	33106183	1404	1408	O
5	33106183	1409	1410	O
years	33106183	1411	1416	O
,	33106183	1417	1418	O
the	33106183	1419	1422	O
patients	33106183	1423	1431	O
who	33106183	1432	1435	O
be	33106183	1436	1438	O
intubated	33106183	1439	1448	O
less	33106183	1449	1453	O
than	33106183	1454	1458	O
one	33106183	1459	1462	O
hours	33106183	1463	1468	O
after	33106183	1469	1474	O
admission	33106183	1475	1484	O
to	33106183	1485	1487	O
hospital	33106183	1488	1496	O
.	33106183	1497	1498	O

This	33106183	1499	1503	O
study	33106183	1504	1509	O
will	33106183	1510	1514	O
be	33106183	1515	1517	O
undertaken	33106183	1518	1528	O
at	33106183	1529	1531	O
the	33106183	1532	1535	O
Loghman	33106183	1536	1543	O
Hakim	33106183	1544	1549	O
Hospital	33106183	1550	1558	O
,	33106183	1559	1560	O
Shahid	33106183	1561	1567	O
Beheshti	33106183	1568	1576	O
University	33106183	1577	1587	O
of	33106183	1588	1590	O
Medical	33106183	1591	1598	O
Sciences	33106183	1599	1607	O
.	33106183	1608	1609	O

UNASSIGNED	33106183	1610	1620	O
:	33106183	1621	1622	O
COVID-	33106183	1623	1629	O
19	33106183	1630	1632	O
confirmed	33106183	1633	1642	O
patients	33106183	1643	1651	O
(	33106183	1652	1653	O
using	33106183	1654	1659	O
the	33106183	1660	1663	O
RT	33106183	1664	1666	O
-	33106183	1667	1668	O
PCR	33106183	1669	1672	O
test	33106183	1673	1677	O
or	33106183	1678	1680	O
CT	33106183	1681	1683	O
scan	33106183	1684	1688	O
)	33106183	1689	1690	O
will	33106183	1691	1695	O
be	33106183	1696	1698	O
randomly	33106183	1699	1707	O
assigned	33106183	1708	1716	O
to	33106183	1717	1719	O
one	33106183	1720	1723	O
of	33106183	1724	1726	O
two	33106183	1727	1730	O
groups	33106183	1731	1737	O
.	33106183	1738	1739	O

The	33106183	1740	1743	O
intervention	33106183	1744	1756	O
group	33106183	1757	1762	O
(	33106183	1763	1764	O
Arms1	33106183	1765	1770	O
)	33106183	1771	1772	O
will	33106183	1773	1777	O
be	33106183	1778	1780	O
treated	33106183	1781	1788	O
with	33106183	1789	1793	O
lopinavir	33106183	1794	1803	O
/	33106183	1804	1805	O
ritonavir	33106183	1806	1815	O
(	33106183	1816	1817	O
Kaletra	33106183	1818	1825	O
)	33106183	1826	1827	O
+	33106183	1828	1829	O
high	33106183	1830	1834	O
dose	33106183	1835	1839	O
Interferon	33106183	1840	1850	O
-	33106183	1851	1852	O
	33106183	1853	1854	O
1a	33106183	1855	1857	O
(	33106183	1858	1859	O
Recigen	33106183	1860	1867	O
)	33106183	1868	1869	O
and	33106183	1870	1873	O
the	33106183	1874	1877	O
control	33106183	1878	1885	O
group	33106183	1886	1891	O
will	33106183	1892	1896	O
be	33106183	1897	1899	O
treated	33106183	1900	1907	O
with	33106183	1908	1912	O
lopinavir	33106183	1913	1922	O
/	33106183	1923	1924	O
ritonavir	33106183	1925	1934	O
(	33106183	1935	1936	O
Kaletra	33106183	1937	1944	O
)	33106183	1945	1946	O
+	33106183	1947	1948	O
low	33106183	1949	1952	O
dose	33106183	1953	1957	O
Interferon	33106183	1958	1968	O
-	33106183	1969	1970	O
	33106183	1971	1972	O
1a	33106183	1973	1975	O
(	33106183	1976	1977	O
Recigen	33106183	1978	1985	O
)	33106183	1986	1987	O
(	33106183	1988	1989	O
the	33106183	1990	1993	O
base	33106183	1994	1998	O
therapeutic	33106183	1999	2010	O
regimen	33106183	2011	2018	O
)	33106183	2019	2020	O
.	33106183	2021	2022	O

Both	33106183	2023	2027	O
groups	33106183	2028	2034	O
will	33106183	2035	2039	O
receive	33106183	2040	2047	O
standard	33106183	2048	2056	O
care	33106183	2057	2061	O
consisting	33106183	2062	2072	O
of	33106183	2073	2075	O
the	33106183	2076	2079	O
necessary	33106183	2080	2089	O
oxygen	33106183	2090	2096	O
support	33106183	2097	2104	O
,	33106183	2105	2106	O
non	33106183	2107	2110	O
-	33106183	2111	2112	O
invasive	33106183	2113	2121	O
,	33106183	2122	2123	O
or	33106183	2124	2126	O
invasive	33106183	2127	2135	O
mechanical	33106183	2136	2146	O
ventilation	33106183	2147	2158	O
.	33106183	2159	2160	O

RESULTS	33106183	2161	2168	O
:	33106183	2169	2170	O
Primary	33106183	2171	2178	O
outcome	33106183	2179	2186	O
:	33106183	2187	2188	O
Time	33106183	2189	2193	O
to	33106183	2194	2196	O
clinical	33106183	2197	2205	O
improvement	33106183	2206	2217	O
is	33106183	2218	2220	O
our	33106183	2221	2224	O
primary	33106183	2225	2232	O
outcome	33106183	2233	2240	O
measure	33106183	2241	2248	O
.	33106183	2249	2250	O

This	33106183	2251	2255	O
is	33106183	2256	2258	O
an	33106183	2259	2261	O
improvement	33106183	2262	2273	O
of	33106183	2274	2276	O
two	33106183	2277	2280	O
points	33106183	2281	2287	O
on	33106183	2288	2290	O
a	33106183	2291	2292	O
seven	33106183	2293	2298	O
-	33106183	2299	2300	O
category	33106183	2301	2309	O
ordinal	33106183	2310	2317	O
scale	33106183	2318	2323	O
(	33106183	2324	2325	O
recommended	33106183	2326	2337	O
by	33106183	2338	2340	O
the	33106183	2341	2344	O
World	33106183	2345	2350	O
Health	33106183	2351	2357	O
Organization	33106183	2358	2370	O
:	33106183	2371	2372	O
Coronavirus	33106183	2373	2384	O
disease	33106183	2385	2392	O
(	33106183	2393	2394	O
COVID-2019	33106183	2395	2405	O
)	33106183	2406	2407	O
R&D.	33106183	2408	2412	O
Geneva	33106183	2413	2419	O
:	33106183	2420	2421	O
World	33106183	2422	2427	O
Health	33106183	2428	2434	O
Organization	33106183	2435	2447	O
)	33106183	2448	2449	O
or	33106183	2450	2452	O
discharge	33106183	2453	2462	O
from	33106183	2463	2467	O
the	33106183	2468	2471	O
hospital	33106183	2472	2480	O
,	33106183	2481	2482	O
whichever	33106183	2483	2492	O
comes	33106183	2493	2498	O
first	33106183	2499	2504	O
.	33106183	2505	2506	O

RESULTS	33106183	2507	2514	O
:	33106183	2515	2516	O
mortality	33106183	2517	2526	O
from	33106183	2527	2531	O
the	33106183	2532	2535	O
date	33106183	2536	2540	O
of	33106183	2541	2543	O
randomization	33106183	2544	2557	O
until	33106183	2558	2563	O
the	33106183	2564	2567	O
last	33106183	2568	2572	O
day	33106183	2573	2576	O
of	33106183	2577	2579	O
the	33106183	2580	2583	O
study	33106183	2584	2589	O
which	33106183	2590	2595	O
will	33106183	2596	2600	O
be	33106183	2601	2603	O
the	33106183	2604	2607	O
day	33106183	2608	2611	O
all	33106183	2612	2615	O
of	33106183	2616	2618	O
the	33106183	2619	2622	O
patients	33106183	2623	2631	O
have	33106183	2632	2636	O
had	33106183	2637	2640	O
at	33106183	2641	2643	O
least	33106183	2644	2649	O
one	33106183	2650	2653	O
of	33106183	2654	2656	O
the	33106183	2657	2660	O
following	33106183	2661	2670	O
outcomes	33106183	2671	2679	O
:	33106183	2680	2681	O
1	33106183	2682	2683	O
)	33106183	2684	2685	O
Improvement	33106183	2686	2697	O
of	33106183	2698	2700	O
two	33106183	2701	2704	O
points	33106183	2705	2711	O
on	33106183	2712	2714	O
a	33106183	2715	2716	O
seven	33106183	2717	2722	O
-	33106183	2723	2724	O
category	33106183	2725	2733	O
ordinal	33106183	2734	2741	O
scale	33106183	2742	2747	O
.	33106183	2748	2749	O

2	33106183	2750	2751	O
)	33106183	2752	2753	O
Discharge	33106183	2754	2763	O
from	33106183	2764	2768	O
the	33106183	2769	2772	O
hospital	33106183	2773	2781	O
3	33106183	2782	2783	O
)	33106183	2784	2785	O
Death	33106183	2786	2791	O
.	33106183	2792	2793	O

Improvement	33106183	2794	2805	O
of	33106183	2806	2808	O
SPO2	33106183	2809	2813	O
during	33106183	2814	2820	O
the	33106183	2821	2824	O
hospitalization	33106183	2825	2840	O
,	33106183	2841	2842	O
duration	33106183	2843	2851	O
of	33106183	2852	2854	O
hospitalization	33106183	2855	2870	O
from	33106183	2871	2875	O
date	33106183	2876	2880	O
of	33106183	2881	2883	O
randomization	33106183	2884	2897	O
until	33106183	2898	2903	O
the	33106183	2904	2907	O
date	33106183	2908	2912	O
of	33106183	2913	2915	O
hospital	33106183	2916	2924	O
discharge	33106183	2925	2934	O
or	33106183	2935	2937	O
death	33106183	2938	2943	O
,	33106183	2944	2945	O
whichever	33106183	2946	2955	O
comes	33106183	2956	2961	O
first	33106183	2962	2967	O
.	33106183	2968	2969	O

The	33106183	2970	2973	O
incidence	33106183	2974	2983	O
of	33106183	2984	2986	O
new	33106183	2987	2990	O
mechanical	33106183	2991	3001	O
ventilation	33106183	3002	3013	O
uses	33106183	3014	3018	O
from	33106183	3019	3023	O
the	33106183	3024	3027	O
date	33106183	3028	3032	O
of	33106183	3033	3035	O
randomization	33106183	3036	3049	O
until	33106183	3050	3055	O
the	33106183	3056	3059	O
last	33106183	3060	3064	O
day	33106183	3065	3068	O
of	33106183	3069	3071	O
the	33106183	3072	3075	O
study	33106183	3076	3081	O
and	33106183	3082	3085	O
the	33106183	3086	3089	O
duration	33106183	3090	3098	O
of	33106183	3099	3101	O
it	33106183	3102	3104	O
will	33106183	3105	3109	O
be	33106183	3110	3112	O
extracted	33106183	3113	3122	O
.	33106183	3123	3124	O

Please	33106183	3125	3131	O
note	33106183	3132	3136	O
that	33106183	3137	3141	O
we	33106183	3142	3144	O
are	33106183	3145	3148	O
trying	33106183	3149	3155	O
to	33106183	3156	3158	O
add	33106183	3159	3162	O
further	33106183	3163	3170	O
secondary	33106183	3171	3180	O
outcomes	33106183	3181	3189	O
and	33106183	3190	3193	O
this	33106183	3194	3198	O
section	33106183	3199	3206	O
of	33106183	3207	3209	O
the	33106183	3210	3213	O
protocol	33106183	3214	3222	O
is	33106183	3223	3225	O
still	33106183	3226	3231	O
evolving	33106183	3232	3240	O
.	33106183	3241	3242	O

UNASSIGNED	33106183	3243	3253	O
:	33106183	3254	3255	O
Eligible	33106183	3256	3264	O
patients	33106183	3265	3273	O
with	33106183	3274	3278	O
confirmed	33106183	3279	3288	O
SARS	33106183	3289	3293	O
-	33106183	3294	3295	O
Cov-2	33106183	3296	3301	O
infections	33106183	3302	3312	O
will	33106183	3313	3317	O
be	33106183	3318	3320	O
randomly	33106183	3321	3329	O
assigned	33106183	3330	3338	O
in	33106183	3339	3341	O
a	33106183	3342	3343	O
1:1	33106183	3344	3347	O
ratio	33106183	3348	3353	O
to	33106183	3354	3356	O
two	33106183	3357	3360	O
therapeutic	33106183	3361	3372	O
arms	33106183	3373	3377	O
using	33106183	3378	3383	O
permuted	33106183	3384	3392	O
,	33106183	3393	3394	O
block	33106183	3395	3400	O
-	33106183	3401	3402	O
randomization	33106183	3403	3416	O
to	33106183	3417	3419	O
balance	33106183	3420	3427	O
the	33106183	3428	3431	O
number	33106183	3432	3438	O
of	33106183	3439	3441	O
patients	33106183	3442	3450	O
allocated	33106183	3451	3460	O
to	33106183	3461	3463	O
each	33106183	3464	3468	O
group	33106183	3469	3474	O
.	33106183	3475	3476	O

The	33106183	3477	3480	O
permuted	33106183	3481	3489	O
block	33106183	3490	3495	O
(	33106183	3496	3497	O
three	33106183	3498	3503	O
or	33106183	3504	3506	O
six	33106183	3507	3510	O
patients	33106183	3511	3519	O
per	33106183	3520	3523	O
block	33106183	3524	3529	O
)	33106183	3530	3531	O
randomization	33106183	3532	3545	O
sequence	33106183	3546	3554	O
will	33106183	3555	3559	O
be	33106183	3560	3562	O
generated	33106183	3563	3572	O
,	33106183	3573	3574	O
using	33106183	3575	3580	O
Package	33106183	3581	3588	O
'	33106183	3589	3590	O
randomizeR	33106183	3591	3601	O
'	33106183	3602	3603	O
in	33106183	3604	3606	O
R	33106183	3607	3608	O
software	33106183	3609	3617	O
version	33106183	3618	3625	O
3.6.1	33106183	3626	3631	O
.	33106183	3632	3633	O
and	33106183	3634	3637	O
placed	33106183	3638	3644	O
in	33106183	3645	3647	O
individual	33106183	3648	3658	O
sealed	33106183	3659	3665	O
and	33106183	3666	3669	O
opaque	33106183	3670	3676	O
envelopes	33106183	3677	3686	O
by	33106183	3687	3689	O
the	33106183	3690	3693	O
statistician	33106183	3694	3706	O
.	33106183	3707	3708	O

The	33106183	3709	3712	O
investigator	33106183	3713	3725	O
will	33106183	3726	3730	O
enroll	33106183	3731	3737	O
the	33106183	3738	3741	O
patients	33106183	3742	3750	O
and	33106183	3751	3754	O
only	33106183	3755	3759	O
then	33106183	3760	3764	O
open	33106183	3765	3769	O
envelopes	33106183	3770	3779	O
to	33106183	3780	3782	O
assign	33106183	3783	3789	O
patients	33106183	3790	3798	O
to	33106183	3799	3801	O
the	33106183	3802	3805	O
different	33106183	3806	3815	O
treatment	33106183	3816	3825	O
groups	33106183	3826	3832	O
.	33106183	3833	3834	O

This	33106183	3835	3839	O
method	33106183	3840	3846	O
of	33106183	3847	3849	O
allocation	33106183	3850	3860	O
concealment	33106183	3861	3872	O
will	33106183	3873	3877	O
result	33106183	3878	3884	O
in	33106183	3885	3887	O
minimum	33106183	3888	3895	O
selection	33106183	3896	3905	O
and	33106183	3906	3909	O
confounding	33106183	3910	3921	O
biases	33106183	3922	3928	O
.	33106183	3929	3930	O

UNASSIGNED	33106183	3931	3941	O
:	33106183	3942	3943	O
The	33106183	3944	3947	O
present	33106183	3948	3955	O
research	33106183	3956	3964	O
is	33106183	3965	3967	O
open	33106183	3968	3972	O
-	33106183	3973	3974	O
label	33106183	3975	3980	O
(	33106183	3981	3982	O
no	33106183	3983	3985	O
masking	33106183	3986	3993	O
)	33106183	3994	3995	O
of	33106183	3996	3998	O
patients	33106183	3999	4007	O
and	33106183	4008	4011	O
health	33106183	4012	4018	O
care	33106183	4019	4023	O
professionals	33106183	4024	4037	O
who	33106183	4038	4041	O
are	33106183	4042	4045	O
undertaking	33106183	4046	4057	O
outcome	33106183	4058	4065	O
assessment	33106183	4066	4076	O
of	33106183	4077	4079	O
the	33106183	4080	4083	O
primary	33106183	4084	4091	O
outcome	33106183	4092	4099	O
-	33106183	4100	4101	O
time	33106183	4102	4106	O
to	33106183	4107	4109	O
clinical	33106183	4110	4118	O
improvement	33106183	4119	4130	O
.	33106183	4131	4132	O

UNASSIGNED	33106183	4133	4143	O
:	33106183	4144	4145	O
Of	33106183	4146	4148	O
the	33106183	4149	4152	O
100	33106183	4153	4156	O
patients	33106183	4157	4165	O
randomised	33106183	4166	4176	O
,	33106183	4177	4178	O
50	33106183	4179	4181	O
patients	33106183	4182	4190	O
will	33106183	4191	4195	O
be	33106183	4196	4198	O
assigned	33106183	4199	4207	O
to	33106183	4208	4210	O
receive	33106183	4211	4218	O
high	33106183	4219	4223	O
dose	33106183	4224	4228	O
Interferon	33106183	4229	4239	O
beta-1a	33106183	4240	4247	O
plus	33106183	4248	4252	O
lopinavir	33106183	4253	4262	O
/	33106183	4263	4264	O
ritonavir	33106183	4265	4274	O
(	33106183	4275	4276	O
Kaletra	33106183	4277	4284	O
)	33106183	4285	4286	O
,	33106183	4287	4288	O
50	33106183	4289	4291	O
patients	33106183	4292	4300	O
will	33106183	4301	4305	O
be	33106183	4306	4308	O
assigned	33106183	4309	4317	O
to	33106183	4318	4320	O
receive	33106183	4321	4328	O
low	33106183	4329	4332	O
dose	33106183	4333	4337	O
Interferon	33106183	4338	4348	O
beta	33106183	4349	4353	O
1a	33106183	4354	4356	O
plus	33106183	4357	4361	O
lopinavir	33106183	4362	4371	O
/	33106183	4372	4373	O
ritonavir	33106183	4374	4383	O
(	33106183	4384	4385	O
Kaletra	33106183	4386	4393	O
)	33106183	4394	4395	O
.	33106183	4396	4397	O

UNASSIGNED	33106183	4398	4408	O
:	33106183	4409	4410	O
Protocol	33106183	4411	4419	O
version	33106183	4420	4427	O
1.2.1	33106183	4428	4433	O
.	33106183	4434	4435	O

Recruitment	33106183	4436	4447	O
is	33106183	4448	4450	O
finished	33106183	4451	4459	O
,	33106183	4460	4461	O
the	33106183	4462	4465	O
start	33106183	4466	4471	O
date	33106183	4472	4476	O
of	33106183	4477	4479	O
recruitment	33106183	4480	4491	O
was	33106183	4492	4495	O
on	33106183	4496	4498	O
August	33106183	4499	4505	O
20th	33106183	4506	4510	O
2020	33106183	4511	4515	O
,	33106183	4516	4517	O
and	33106183	4518	4521	O
the	33106183	4522	4525	O
end	33106183	4526	4529	O
date	33106183	4530	4534	O
was	33106183	4535	4538	O
on	33106183	4539	4541	O
September	33106183	4542	4551	O
4th	33106183	4552	4555	O
2020	33106183	4556	4560	O
.	33106183	4561	4562	O

Last	33106183	4563	4567	O
point	33106183	4568	4573	O
of	33106183	4574	4576	O
data	33106183	4577	4581	O
collection	33106183	4582	4592	O
will	33106183	4593	4597	O
be	33106183	4598	4600	O
the	33106183	4601	4604	O
last	33106183	4605	4609	O
day	33106183	4610	4613	O
on	33106183	4614	4616	O
which	33106183	4617	4622	O
all	33106183	4623	4626	O
of	33106183	4627	4629	O
the	33106183	4630	4633	O
100	33106183	4634	4637	O
participants	33106183	4638	4650	O
have	33106183	4651	4655	O
had	33106183	4656	4659	O
an	33106183	4660	4662	O
outcome	33106183	4663	4670	O
of	33106183	4671	4673	O
clinical	33106183	4674	4682	O
improvement	33106183	4683	4694	O
or	33106183	4695	4697	O
death	33106183	4698	4703	O
,	33106183	4704	4705	O
up	33106183	4706	4708	O
to	33106183	4709	4711	O
14th	33106183	4712	4716	O
days	33106183	4717	4721	O
after	33106183	4722	4727	O
hospitalization	33106183	4728	4743	O
.	33106183	4744	4745	O

BACKGROUND	33106183	4746	4756	O
:	33106183	4757	4758	O
This	33106183	4759	4763	O
study	33106183	4764	4769	O
was	33106183	4770	4773	O
registered	33106183	4774	4784	O
with	33106183	4785	4789	O
National	33106183	4790	4798	O
Institutes	33106183	4799	4809	O
of	33106183	4810	4812	O
Health	33106183	4813	4819	O
Clinical	33106183	4820	4828	O
trials	33106183	4829	4835	O
(	33106183	4836	4837	O
www.clinicaltrials.gov	33106183	4838	4860	O
;	33106183	4861	4862	O
identification	33106183	4863	4877	O
number	33106183	4878	4884	O
NCT04521400	33106183	4885	4896	O
,	33106183	4897	4898	O
https://clinicaltrials.gov/ct2/show/NCT04521400	33106183	4899	4946	O
,	33106183	4947	4948	O
registered	33106183	4949	4959	O
August	33106183	4960	4966	O
18	33106183	4967	4969	O
,	33106183	4970	4971	O
2020	33106183	4972	4976	O
and	33106183	4977	4980	O
first	33106183	4981	4986	O
available	33106183	4987	4996	O
online	33106183	4997	5003	O
August	33106183	5004	5010	O
20	33106183	5011	5013	O
,	33106183	5014	5015	O
2020	33106183	5016	5020	O
)	33106183	5021	5022	O
.	33106183	5023	5024	O

UNASSIGNED	33106183	5025	5035	O
:	33106183	5036	5037	O
The	33106183	5038	5041	O
full	33106183	5042	5046	O
protocol	33106183	5047	5055	O
is	33106183	5056	5058	O
attached	33106183	5059	5067	O
as	33106183	5068	5070	O
an	33106183	5071	5073	O
additional	33106183	5074	5084	O
file	33106183	5085	5089	O
,	33106183	5090	5091	O
accessible	33106183	5092	5102	O
from	33106183	5103	5107	O
the	33106183	5108	5111	O
Trials	33106183	5112	5118	O
website	33106183	5119	5126	O
(	33106183	5127	5128	O
Additional	33106183	5129	5139	O
file	33106183	5140	5144	O
1	33106183	5145	5146	O
)	33106183	5147	5148	O
.	33106183	5149	5150	O

In	33106183	5151	5153	O
the	33106183	5154	5157	O
interest	33106183	5158	5166	O
in	33106183	5167	5169	O
expediting	33106183	5170	5180	O
dissemination	33106183	5181	5194	O
of	33106183	5195	5197	O
this	33106183	5198	5202	O
material	33106183	5203	5211	O
,	33106183	5212	5213	O
the	33106183	5214	5217	O
familiar	33106183	5218	5226	O
formatting	33106183	5227	5237	O
has	33106183	5238	5241	O
been	33106183	5242	5246	O
eliminated	33106183	5247	5257	O
;	33106183	5258	5259	O
this	33106183	5260	5264	O
Letter	33106183	5265	5271	O
serves	33106183	5272	5278	O
as	33106183	5279	5281	O
a	33106183	5282	5283	O
summary	33106183	5284	5291	O
of	33106183	5292	5294	O
the	33106183	5295	5298	O
key	33106183	5299	5302	O
elements	33106183	5303	5311	O
of	33106183	5312	5314	O
the	33106183	5315	5318	O
full	33106183	5319	5323	O
protocol	33106183	5324	5332	O
.	33106183	5333	5334	O


Numbers	33115536	0	7	O
,	33115536	8	9	O
graphs	33115536	10	16	O
and	33115536	17	20	O
words	33115536	21	26	O
-	33115536	27	28	O
do	33115536	29	31	O
we	33115536	32	34	O
really	33115536	35	41	O
understand	33115536	42	52	O
the	33115536	53	56	O
lab	33115536	57	60	O
test	33115536	61	65	O
results	33115536	66	73	O
accessible	33115536	74	84	O
via	33115536	85	88	O
the	33115536	89	92	O
patient	33115536	93	100	O
portals	33115536	101	108	O
?	33115536	109	110	O

The	33115536	111	114	O
heavy	33115536	115	120	O
reliance	33115536	121	129	O
on	33115536	130	132	O
remote	33115536	133	139	O
patient	33115536	140	147	O
care	33115536	148	152	O
(	33115536	153	154	O
RPC	33115536	155	158	O
)	33115536	159	160	O
during	33115536	161	167	O
the	33115536	168	171	O
COVID-19	33115536	172	180	O
health	33115536	181	187	O
crisis	33115536	188	194	O
may	33115536	195	198	O
have	33115536	199	203	O
expedited	33115536	204	213	O
the	33115536	214	217	O
emergence	33115536	218	227	O
of	33115536	228	230	O
digital	33115536	231	238	O
health	33115536	239	245	O
tools	33115536	246	251	O
that	33115536	252	256	O
can	33115536	257	260	O
contribute	33115536	261	271	O
to	33115536	272	274	O
safely	33115536	275	281	O
and	33115536	282	285	O
effectively	33115536	286	297	O
moving	33115536	298	304	O
the	33115536	305	308	O
locus	33115536	309	314	O
of	33115536	315	317	O
care	33115536	318	322	O
from	33115536	323	327	O
the	33115536	328	331	O
hospital	33115536	332	340	O
to	33115536	341	343	O
the	33115536	344	347	O
community	33115536	348	357	O
.	33115536	358	359	O

Understanding	33115536	360	373	O
how	33115536	374	377	O
laypersons	33115536	378	388	O
interpret	33115536	389	398	O
the	33115536	399	402	O
personal	33115536	403	411	O
health	33115536	412	418	O
information	33115536	419	430	O
accessible	33115536	431	441	O
to	33115536	442	444	O
them	33115536	445	449	O
via	33115536	450	453	O
electronic	33115536	454	464	O
patient	33115536	465	472	O
records	33115536	473	480	O
(	33115536	481	482	O
EPRs	33115536	483	487	O
)	33115536	488	489	O
is	33115536	490	492	O
crucial	33115536	493	500	O
to	33115536	501	503	O
healthcare	33115536	504	514	O
planning	33115536	515	523	O
and	33115536	524	527	O
the	33115536	528	531	O
design	33115536	532	538	O
of	33115536	539	541	O
services	33115536	542	550	O
.	33115536	551	552	O

Yet	33115536	553	556	O
we	33115536	557	559	O
still	33115536	560	565	O
know	33115536	566	570	O
little	33115536	571	577	O
about	33115536	578	583	O
how	33115536	584	587	O
the	33115536	588	591	O
format	33115536	592	598	O
in	33115536	599	601	O
which	33115536	602	607	O
personal	33115536	608	616	O
medical	33115536	617	624	O
information	33115536	625	636	O
is	33115536	637	639	O
presented	33115536	640	649	O
in	33115536	650	652	O
the	33115536	653	656	O
EPR	33115536	657	660	O
(	33115536	661	662	O
numerically	33115536	663	674	O
,	33115536	675	676	O
verbally	33115536	677	685	O
,	33115536	686	687	O
or	33115536	688	690	O
graphically	33115536	691	702	O
)	33115536	703	704	O
affects	33115536	705	712	O
individuals	33115536	713	724	O
'	33115536	725	726	O
understanding	33115536	727	740	O
of	33115536	741	743	O
the	33115536	744	747	O
information	33115536	748	759	O
,	33115536	760	761	O
their	33115536	762	767	O
assessment	33115536	768	778	O
of	33115536	779	781	O
its	33115536	782	785	O
gravity	33115536	786	793	O
,	33115536	794	795	O
and	33115536	796	799	O
the	33115536	800	803	O
course	33115536	804	810	O
of	33115536	811	813	O
action	33115536	814	820	O
they	33115536	821	825	O
choose	33115536	826	832	O
in	33115536	833	835	O
response	33115536	836	844	O
.	33115536	845	846	O

We	33115536	847	849	O
employed	33115536	850	858	O
an	33115536	859	861	O
online	33115536	862	868	O
questionnaire	33115536	869	882	O
to	33115536	883	885	O
assess	33115536	886	892	O
respondents	33115536	893	904	O
'	33115536	905	906	O
reactions	33115536	907	916	O
to	33115536	917	919	O
10	33115536	920	922	O
medical	33115536	923	930	O
decision	33115536	931	939	O
-	33115536	940	941	O
making	33115536	942	948	O
scenarios	33115536	949	958	O
,	33115536	959	960	O
where	33115536	961	966	O
the	33115536	967	970	O
same	33115536	971	975	O
information	33115536	976	987	O
was	33115536	988	991	O
presented	33115536	992	1001	O
using	33115536	1002	1007	O
different	33115536	1008	1017	O
formats	33115536	1018	1025	O
.	33115536	1026	1027	O

In	33115536	1028	1030	O
each	33115536	1031	1035	O
scenario	33115536	1036	1044	O
,	33115536	1045	1046	O
respondents	33115536	1047	1058	O
were	33115536	1059	1063	O
presented	33115536	1064	1073	O
with	33115536	1074	1078	O
real	33115536	1079	1083	O
(	33115536	1084	1085	O
anonymized	33115536	1086	1096	O
)	33115536	1097	1098	O
patient	33115536	1099	1106	O
lab	33115536	1107	1110	O
results	33115536	1111	1118	O
using	33115536	1119	1124	O
either	33115536	1125	1131	O
numeric	33115536	1132	1139	O
expressions	33115536	1140	1151	O
,	33115536	1152	1153	O
graphs	33115536	1154	1160	O
,	33115536	1161	1162	O
or	33115536	1163	1165	O
verbal	33115536	1166	1172	O
expressions	33115536	1173	1184	O
.	33115536	1185	1186	O

Participants	33115536	1187	1199	O
were	33115536	1200	1204	O
asked	33115536	1205	1210	O
to	33115536	1211	1213	O
assess	33115536	1214	1220	O
the	33115536	1221	1224	O
gravity	33115536	1225	1232	O
of	33115536	1233	1235	O
the	33115536	1236	1239	O
hypothetical	33115536	1240	1252	O
patient	33115536	1253	1260	O
's	33115536	1261	1263	O
condition	33115536	1264	1273	O
and	33115536	1274	1277	O
the	33115536	1278	1281	O
course	33115536	1282	1288	O
of	33115536	1289	1291	O
action	33115536	1292	1298	O
they	33115536	1299	1303	O
would	33115536	1304	1309	O
follow	33115536	1310	1316	O
if	33115536	1317	1319	O
they	33115536	1320	1324	O
were	33115536	1325	1329	O
that	33115536	1330	1334	O
patient	33115536	1335	1342	O
.	33115536	1343	1344	O

The	33115536	1345	1348	O
questionnaire	33115536	1349	1362	O
was	33115536	1363	1366	O
distributed	33115536	1367	1378	O
to	33115536	1379	1381	O
more	33115536	1382	1386	O
than	33115536	1387	1391	O
300	33115536	1392	1395	O
participants	33115536	1396	1408	O
,	33115536	1409	1410	O
of	33115536	1411	1413	O
whom	33115536	1414	1418	O
225	33115536	1419	1422	O
submitted	33115536	1423	1432	O
usable	33115536	1433	1439	O
responses	33115536	1440	1449	O
.	33115536	1450	1451	O

Laypersons	33115536	1452	1462	O
were	33115536	1463	1467	O
more	33115536	1468	1472	O
likely	33115536	1473	1479	O
to	33115536	1480	1482	O
overestimate	33115536	1483	1495	O
the	33115536	1496	1499	O
gravity	33115536	1500	1507	O
of	33115536	1508	1510	O
the	33115536	1511	1514	O
information	33115536	1515	1526	O
when	33115536	1527	1531	O
it	33115536	1532	1534	O
was	33115536	1535	1538	O
presented	33115536	1539	1548	O
either	33115536	1549	1555	O
numerically	33115536	1556	1567	O
or	33115536	1568	1570	O
graphically	33115536	1571	1582	O
compared	33115536	1583	1591	O
to	33115536	1592	1594	O
the	33115536	1595	1598	O
narrative	33115536	1599	1608	O
format	33115536	1609	1615	O
.	33115536	1616	1617	O

High	33115536	1618	1622	O
perceived	33115536	1623	1632	O
gravity	33115536	1633	1640	O
was	33115536	1641	1644	O
most	33115536	1645	1649	O
likely	33115536	1650	1656	O
to	33115536	1657	1659	O
produce	33115536	1660	1667	O
an	33115536	1668	1670	O
inclination	33115536	1671	1682	O
to	33115536	1683	1685	O
actively	33115536	1686	1694	O
seek	33115536	1695	1699	O
medical	33115536	1700	1707	O
attention	33115536	1708	1717	O
,	33115536	1718	1719	O
even	33115536	1720	1724	O
when	33115536	1725	1729	O
unwarranted	33115536	1730	1741	O
.	33115536	1742	1743	O
"	33115536	1744	1745	O
Do	33115536	1746	1748	O
n't	33115536	1749	1752	O
know	33115536	1753	1757	O
"	33115536	1758	1759	O
responses	33115536	1760	1769	O
were	33115536	1770	1774	O
most	33115536	1775	1779	O
likely	33115536	1780	1786	O
to	33115536	1787	1789	O
produce	33115536	1790	1797	O
an	33115536	1798	1800	O
inclination	33115536	1801	1812	O
to	33115536	1813	1815	O
either	33115536	1816	1822	O
search	33115536	1823	1829	O
the	33115536	1830	1833	O
Internet	33115536	1834	1842	O
or	33115536	1843	1845	O
wait	33115536	1846	1850	O
for	33115536	1851	1854	O
the	33115536	1855	1858	O
doctor	33115536	1859	1865	O
to	33115536	1866	1868	O
call	33115536	1869	1873	O
.	33115536	1874	1875	O

We	33115536	1876	1878	O
discuss	33115536	1879	1886	O
the	33115536	1887	1890	O
study	33115536	1891	1896	O
's	33115536	1897	1899	O
implications	33115536	1900	1912	O
for	33115536	1913	1916	O
the	33115536	1917	1920	O
effective	33115536	1921	1930	O
design	33115536	1931	1937	O
of	33115536	1938	1940	O
lab	33115536	1941	1944	O
results	33115536	1945	1952	O
in	33115536	1953	1955	O
the	33115536	1956	1959	O
patient	33115536	1960	1967	O
portals	33115536	1968	1975	O
.	33115536	1976	1977	O

We	33115536	1978	1980	O
suggest	33115536	1981	1988	O
(	33115536	1989	1990	O
1	33115536	1991	1992	O
)	33115536	1993	1994	O
that	33115536	1995	1999	O
graphs	33115536	2000	2006	O
,	33115536	2007	2008	O
tables	33115536	2009	2015	O
,	33115536	2016	2017	O
and	33115536	2018	2021	O
charts	33115536	2022	2028	O
would	33115536	2029	2034	O
be	33115536	2035	2037	O
easier	33115536	2038	2044	O
to	33115536	2045	2047	O
interpret	33115536	2048	2057	O
if	33115536	2058	2060	O
coupled	33115536	2061	2068	O
with	33115536	2069	2073	O
a	33115536	2074	2075	O
brief	33115536	2076	2081	O
verbal	33115536	2082	2088	O
explanation	33115536	2089	2100	O
;	33115536	2101	2102	O
(	33115536	2103	2104	O
2	33115536	2105	2106	O
)	33115536	2107	2108	O
that	33115536	2109	2113	O
highlighting	33115536	2114	2126	O
an	33115536	2127	2129	O
overall	33115536	2130	2137	O
level	33115536	2138	2143	O
of	33115536	2144	2146	O
urgency	33115536	2147	2154	O
may	33115536	2155	2158	O
be	33115536	2159	2161	O
more	33115536	2162	2166	O
helpful	33115536	2167	2174	O
than	33115536	2175	2179	O
indicating	33115536	2180	2190	O
a	33115536	2191	2192	O
diversion	33115536	2193	2202	O
from	33115536	2203	2207	O
the	33115536	2208	2211	O
norm	33115536	2212	2216	O
;	33115536	2217	2218	O
and	33115536	2219	2222	O
(	33115536	2223	2224	O
3	33115536	2225	2226	O
)	33115536	2227	2228	O
that	33115536	2229	2233	O
statements	33115536	2234	2244	O
of	33115536	2245	2247	O
results	33115536	2248	2255	O
should	33115536	2256	2262	O
include	33115536	2263	2270	O
the	33115536	2271	2274	O
type	33115536	2275	2279	O
of	33115536	2280	2282	O
follow	33115536	2283	2289	O
-	33115536	2290	2291	O
up	33115536	2292	2294	O
required	33115536	2295	2303	O
.	33115536	2304	2305	O


Effect	33119613	0	6	O
of	33119613	7	9	O
disease	33119613	10	17	O
duration	33119613	18	26	O
in	33119613	27	29	O
a	33119613	30	31	O
randomized	33119613	32	42	O
Phase	33119613	43	48	O
III	33119613	49	52	O
trial	33119613	53	58	O
of	33119613	59	61	O
rintatolimod	33119613	62	74	O
,	33119613	75	76	O
an	33119613	77	79	O
immune	33119613	80	86	O
modulator	33119613	87	96	O
for	33119613	97	100	O
Myalgic	33119613	101	108	O
Encephalomyelitis	33119613	109	126	O
/	33119613	127	128	O
Chronic	33119613	129	136	O
Fatigue	33119613	137	144	O
Syndrome	33119613	145	153	O
.	33119613	154	155	O

Rintatolimod	33119613	156	168	O
is	33119613	169	171	O
a	33119613	172	173	O
selective	33119613	174	183	O
TLR3	33119613	184	188	O
agonist	33119613	189	196	O
,	33119613	197	198	O
which	33119613	199	204	O
has	33119613	205	208	O
demonstrated	33119613	209	221	O
clinical	33119613	222	230	O
activity	33119613	231	239	O
for	33119613	240	243	O
ME	33119613	244	246	O
/	33119613	247	248	O
CFS	33119613	249	252	O
in	33119613	253	255	O
Phase	33119613	256	261	O
II	33119613	262	264	O
and	33119613	265	268	O
Phase	33119613	269	274	O
III	33119613	275	278	O
double	33119613	279	285	O
-	33119613	286	287	O
blind	33119613	288	293	O
,	33119613	294	295	O
placebo	33119613	296	303	O
-	33119613	304	305	O
controlled	33119613	306	316	O
,	33119613	317	318	O
randomized	33119613	319	329	O
,	33119613	330	331	O
multi	33119613	332	337	O
-	33119613	338	339	O
site	33119613	340	344	O
clinical	33119613	345	353	O
trials	33119613	354	360	O
.	33119613	361	362	O

A	33119613	363	364	O
hypothesis	33119613	365	375	O
-	33119613	376	377	O
based	33119613	378	383	O
post	33119613	384	388	O
-	33119613	389	390	O
hoc	33119613	391	394	O
analysis	33119613	395	403	O
of	33119613	404	406	O
the	33119613	407	410	O
Intent	33119613	411	417	O
to	33119613	418	420	O
Treat	33119613	421	426	O
(	33119613	427	428	O
ITT	33119613	429	432	O
)	33119613	433	434	O
population	33119613	435	445	O
diagnosed	33119613	446	455	O
with	33119613	456	460	O
ME	33119613	461	463	O
/	33119613	464	465	O
CFS	33119613	466	469	O
from	33119613	470	474	O
12	33119613	475	477	O
independent	33119613	478	489	O
clinical	33119613	490	498	O
sites	33119613	499	504	O
of	33119613	505	507	O
a	33119613	508	509	O
Phase	33119613	510	515	O
III	33119613	516	519	O
trial	33119613	520	525	O
was	33119613	526	529	O
performed	33119613	530	539	O
to	33119613	540	542	O
evaluate	33119613	543	551	O
the	33119613	552	555	O
effect	33119613	556	562	O
of	33119613	563	565	O
rintatolimod	33119613	566	578	O
therapy	33119613	579	586	O
based	33119613	587	592	O
on	33119613	593	595	O
disease	33119613	596	603	O
duration	33119613	604	612	O
.	33119613	613	614	O

The	33119613	615	618	O
clinical	33119613	619	627	O
activity	33119613	628	636	O
of	33119613	637	639	O
rintatolimod	33119613	640	652	O
was	33119613	653	656	O
evaluated	33119613	657	666	O
by	33119613	667	669	O
exercise	33119613	670	678	O
treadmill	33119613	679	688	O
tolerance	33119613	689	698	O
(	33119613	699	700	O
ETT	33119613	701	704	O
)	33119613	705	706	O
using	33119613	707	712	O
a	33119613	713	714	O
modified	33119613	715	723	O
Bruce	33119613	724	729	O
protocol	33119613	730	738	O
.	33119613	739	740	O

The	33119613	741	744	O
ITT	33119613	745	748	O
population	33119613	749	759	O
(	33119613	760	761	O
n	33119613	762	763	O
=	33119613	764	765	O
208	33119613	766	769	O
)	33119613	770	771	O
was	33119613	772	775	O
divided	33119613	776	783	O
into	33119613	784	788	O
two	33119613	789	792	O
subsets	33119613	793	800	O
of	33119613	801	803	O
symptom	33119613	804	811	O
duration	33119613	812	820	O
.	33119613	821	822	O

Patients	33119613	823	831	O
with	33119613	832	836	O
symptom	33119613	837	844	O
duration	33119613	845	853	O
of	33119613	854	856	O
2	33119613	857	858	O
-	33119613	859	860	O
8	33119613	861	862	O
years	33119613	863	868	O
were	33119613	869	873	O
identified	33119613	874	884	O
as	33119613	885	887	O
the	33119613	888	891	O
Target	33119613	892	898	O
Subset	33119613	899	905	O
(	33119613	906	907	O
n	33119613	908	909	O
=	33119613	910	911	O
75	33119613	912	914	O
)	33119613	915	916	O
;	33119613	917	918	O
the	33119613	919	922	O
remainder	33119613	923	932	O
(	33119613	933	934	O
<	33119613	935	936	O
2	33119613	937	938	O
year	33119613	939	943	O
plus	33119613	944	948	O
>	33119613	949	950	O
8	33119613	951	952	O
year	33119613	953	957	O
)	33119613	958	959	O
were	33119613	960	964	O
identified	33119613	965	975	O
as	33119613	976	978	O
the	33119613	979	982	O
Non	33119613	983	986	O
-	33119613	987	988	O
Target	33119613	989	995	O
Subset	33119613	996	1002	O
(	33119613	1003	1004	O
n	33119613	1005	1006	O
=	33119613	1007	1008	O
133	33119613	1009	1012	O
)	33119613	1013	1014	O
.	33119613	1015	1016	O

Placebo	33119613	1017	1024	O
-	33119613	1025	1026	O
adjusted	33119613	1027	1035	O
percentage	33119613	1036	1046	O
improvements	33119613	1047	1059	O
in	33119613	1060	1062	O
exercise	33119613	1063	1071	O
duration	33119613	1072	1080	O
and	33119613	1081	1084	O
the	33119613	1085	1088	O
vertical	33119613	1089	1097	O
rise	33119613	1098	1102	O
for	33119613	1103	1106	O
the	33119613	1107	1110	O
Target	33119613	1111	1117	O
Subset	33119613	1118	1124	O
(	33119613	1125	1126	O
n	33119613	1127	1128	O
=	33119613	1129	1130	O
75	33119613	1131	1133	O
)	33119613	1134	1135	O
were	33119613	1136	1140	O
more	33119613	1141	1145	O
than	33119613	1146	1150	O
twice	33119613	1151	1156	O
that	33119613	1157	1161	O
of	33119613	1162	1164	O
the	33119613	1165	1168	O
ITT	33119613	1169	1172	O
population	33119613	1173	1183	O
.	33119613	1184	1185	O

The	33119613	1186	1189	O
Non	33119613	1190	1193	O
-	33119613	1194	1195	O
Target	33119613	1196	1202	O
Subset	33119613	1203	1209	O
(	33119613	1210	1211	O
n	33119613	1212	1213	O
=	33119613	1214	1215	O
133	33119613	1216	1219	O
)	33119613	1220	1221	O
failed	33119613	1222	1228	O
to	33119613	1229	1231	O
show	33119613	1232	1236	O
any	33119613	1237	1240	O
clinically	33119613	1241	1251	O
significant	33119613	1252	1263	O
ETT	33119613	1264	1267	O
response	33119613	1268	1276	O
to	33119613	1277	1279	O
rintatolimod	33119613	1280	1292	O
when	33119613	1293	1297	O
compared	33119613	1298	1306	O
to	33119613	1307	1309	O
placebo	33119613	1310	1317	O
.	33119613	1318	1319	O

Within	33119613	1320	1326	O
the	33119613	1327	1330	O
Target	33119613	1331	1337	O
Subset	33119613	1338	1344	O
,	33119613	1345	1346	O
51.2	33119613	1347	1351	O
%	33119613	1352	1353	O
of	33119613	1354	1356	O
rintatolimod	33119613	1357	1369	O
-	33119613	1370	1371	O
treated	33119613	1372	1379	O
patients	33119613	1380	1388	O
improved	33119613	1389	1397	O
their	33119613	1398	1403	O
exercise	33119613	1404	1412	O
duration	33119613	1413	1421	O
by	33119613	1422	1424	O
	33119613	1427	1428	O
25	33119613	1429	1431	O
%	33119613	1432	1433	O
(	33119613	1434	1435	O
p	33119613	1436	1437	O
=	33119613	1438	1439	O
0.003	33119613	1440	1445	O
)	33119613	1446	1447	O
despite	33119613	1448	1455	O
reduced	33119613	1456	1463	O
statistical	33119613	1464	1475	O
power	33119613	1476	1481	O
from	33119613	1482	1486	O
division	33119613	1487	1495	O
of	33119613	1496	1498	O
the	33119613	1499	1502	O
original	33119613	1503	1511	O
ITT	33119613	1512	1515	O
population	33119613	1516	1526	O
into	33119613	1527	1531	O
two	33119613	1532	1535	O
subsets	33119613	1536	1543	O
.	33119613	1544	1545	O

Analysis	33119613	1546	1554	O
of	33119613	1555	1557	O
ETT	33119613	1558	1561	O
from	33119613	1562	1566	O
a	33119613	1567	1568	O
Phase	33119613	1569	1574	O
III	33119613	1575	1578	O
trial	33119613	1579	1584	O
has	33119613	1585	1588	O
identified	33119613	1589	1599	O
within	33119613	1600	1606	O
the	33119613	1607	1610	O
ITT	33119613	1611	1614	O
population	33119613	1615	1625	O
,	33119613	1626	1627	O
a	33119613	1628	1629	O
subset	33119613	1630	1636	O
of	33119613	1637	1639	O
ME	33119613	1640	1642	O
/	33119613	1643	1644	O
CFS	33119613	1645	1648	O
patients	33119613	1649	1657	O
with	33119613	1658	1662	O
	33119613	1665	1666	O
2	33119613	1667	1668	O
fold	33119613	1669	1673	O
increased	33119613	1674	1683	O
exercise	33119613	1684	1692	O
response	33119613	1693	1701	O
to	33119613	1702	1704	O
rintatolimod	33119613	1705	1717	O
.	33119613	1718	1719	O

Substantial	33119613	1720	1731	O
improvement	33119613	1732	1743	O
in	33119613	1744	1746	O
physical	33119613	1747	1755	O
performance	33119613	1756	1767	O
was	33119613	1768	1771	O
seen	33119613	1772	1776	O
for	33119613	1777	1780	O
the	33119613	1781	1784	O
majority	33119613	1785	1793	O
(	33119613	1794	1795	O
51.2	33119613	1796	1800	O
%	33119613	1801	1802	O
)	33119613	1803	1804	O
of	33119613	1805	1807	O
these	33119613	1808	1813	O
severely	33119613	1814	1822	O
debilitated	33119613	1823	1834	O
patients	33119613	1835	1843	O
who	33119613	1844	1847	O
improved	33119613	1848	1856	O
exercise	33119613	1857	1865	O
duration	33119613	1866	1874	O
by	33119613	1875	1877	O
	33119613	1880	1881	O
25	33119613	1882	1884	O
%	33119613	1885	1886	O
.	33119613	1887	1888	O

This	33119613	1889	1893	O
magnitude	33119613	1894	1903	O
of	33119613	1904	1906	O
exercise	33119613	1907	1915	O
improvement	33119613	1916	1927	O
was	33119613	1928	1931	O
associated	33119613	1932	1942	O
with	33119613	1943	1947	O
clinically	33119613	1948	1958	O
significant	33119613	1959	1970	O
enhancements	33119613	1971	1983	O
in	33119613	1984	1986	O
quality	33119613	1987	1994	O
of	33119613	1995	1997	O
life	33119613	1998	2002	O
.	33119613	2003	2004	O

The	33119613	2005	2008	O
data	33119613	2009	2013	O
indicate	33119613	2014	2022	O
that	33119613	2023	2027	O
ME	33119613	2028	2030	O
/	33119613	2031	2032	O
CFS	33119613	2033	2036	O
patients	33119613	2037	2045	O
have	33119613	2046	2050	O
a	33119613	2051	2052	O
relatively	33119613	2053	2063	O
short	33119613	2064	2069	O
disease	33119613	2070	2077	O
duration	33119613	2078	2086	O
window	33119613	2087	2093	O
(	33119613	2094	2095	O
<	33119613	2096	2097	O
8	33119613	2098	2099	O
years	33119613	2100	2105	O
)	33119613	2106	2107	O
to	33119613	2108	2110	O
expect	33119613	2111	2117	O
a	33119613	2118	2119	O
significant	33119613	2120	2131	O
response	33119613	2132	2140	O
to	33119613	2141	2143	O
rintatolimod	33119613	2144	2156	O
under	33119613	2157	2162	O
the	33119613	2163	2166	O
dosing	33119613	2167	2173	O
conditions	33119613	2174	2184	O
utilized	33119613	2185	2193	O
in	33119613	2194	2196	O
this	33119613	2197	2201	O
Phase	33119613	2202	2207	O
III	33119613	2208	2211	O
clinical	33119613	2212	2220	O
trial	33119613	2221	2226	O
.	33119613	2227	2228	O

These	33119613	2229	2234	O
results	33119613	2235	2242	O
may	33119613	2243	2246	O
have	33119613	2247	2251	O
direct	33119613	2252	2258	O
relevance	33119613	2259	2268	O
to	33119613	2269	2271	O
the	33119613	2272	2275	O
cognitive	33119613	2276	2285	O
impairment	33119613	2286	2296	O
and	33119613	2297	2300	O
fatigue	33119613	2301	2308	O
being	33119613	2309	2314	O
experienced	33119613	2315	2326	O
by	33119613	2327	2329	O
patients	33119613	2330	2338	O
clinically	33119613	2339	2349	O
recovered	33119613	2350	2359	O
from	33119613	2360	2364	O
COVID-19	33119613	2365	2373	O
and	33119613	2374	2377	O
free	33119613	2378	2382	O
of	33119613	2383	2385	O
detectable	33119613	2386	2396	O
SARS	33119613	2397	2401	O
-	33119613	2402	2403	O
CoV-2	33119613	2404	2409	O
.	33119613	2410	2411	O

ClinicalTrials.gov	33119613	2412	2430	O
:	33119613	2431	2432	O
NCT00215800	33119613	2433	2444	O
.	33119613	2445	2446	O


Effects	33121028	0	7	O
of	33121028	8	10	O
S	33121028	11	12	O
-	33121028	13	14	O
PBL	33121028	15	18	O
in	33121028	19	21	O
Maternity	33121028	22	31	O
Nursing	33121028	32	39	O
Clinical	33121028	40	48	O
Practicum	33121028	49	58	O
on	33121028	59	61	O
Learning	33121028	62	70	O
Attitude	33121028	71	79	O
,	33121028	80	81	O
Metacognition	33121028	82	95	O
,	33121028	96	97	O
and	33121028	98	101	O
Critical	33121028	102	110	O
Thinking	33121028	111	119	O
in	33121028	120	122	O
Nursing	33121028	123	130	O
Students	33121028	131	139	O
:	33121028	140	141	O
A	33121028	142	143	O
Quasi	33121028	144	149	O
-	33121028	150	151	O
Experimental	33121028	152	164	O
Design	33121028	165	171	O
.	33121028	172	173	O

Due	33121028	174	177	O
to	33121028	178	180	O
the	33121028	181	184	O
coronavirus	33121028	185	196	O
disease	33121028	197	204	O
(	33121028	205	206	O
COVID-19	33121028	207	215	O
)	33121028	216	217	O
pandemic	33121028	218	226	O
,	33121028	227	228	O
there	33121028	229	234	O
are	33121028	235	238	O
many	33121028	239	243	O
restrictions	33121028	244	256	O
in	33121028	257	259	O
effect	33121028	260	266	O
in	33121028	267	269	O
clinical	33121028	270	278	O
nursing	33121028	279	286	O
practice	33121028	287	295	O
.	33121028	296	297	O

Since	33121028	298	303	O
effective	33121028	304	313	O
educational	33121028	314	325	O
strategies	33121028	326	336	O
are	33121028	337	340	O
required	33121028	341	349	O
to	33121028	350	352	O
enhance	33121028	353	360	O
nursing	33121028	361	368	O
students	33121028	369	377	O
'	33121028	378	379	O
competency	33121028	380	390	O
in	33121028	391	393	O
clinical	33121028	394	402	O
practice	33121028	403	411	O
,	33121028	412	413	O
this	33121028	414	418	O
study	33121028	419	424	O
sought	33121028	425	431	O
to	33121028	432	434	O
evaluate	33121028	435	443	O
the	33121028	444	447	O
effectiveness	33121028	448	461	O
of	33121028	462	464	O
simulation	33121028	465	475	O
problem	33121028	476	483	O
-	33121028	484	485	O
based	33121028	486	491	O
learning	33121028	492	500	O
(	33121028	501	502	O
S	33121028	503	504	O
-	33121028	505	506	O
PBL	33121028	507	510	O
)	33121028	511	512	O
.	33121028	513	514	O

A	33121028	515	516	O
quasi	33121028	517	522	O
-	33121028	523	524	O
experimental	33121028	525	537	O
control	33121028	538	545	O
group	33121028	546	551	O
pretest	33121028	552	559	O
-	33121028	560	561	O
post	33121028	562	566	O
-	33121028	567	568	O
test	33121028	569	573	O
design	33121028	574	580	O
was	33121028	581	584	O
used	33121028	585	589	O
.	33121028	590	591	O

Nursing	33121028	592	599	O
students	33121028	600	608	O
were	33121028	609	613	O
allocated	33121028	614	623	O
randomly	33121028	624	632	O
to	33121028	633	635	O
the	33121028	636	639	O
control	33121028	640	647	O
group	33121028	648	653	O
(	33121028	654	655	O
n	33121028	656	657	O
=	33121028	658	659	O
31	33121028	660	662	O
)	33121028	663	664	O
and	33121028	665	668	O
the	33121028	669	672	O
experimental	33121028	673	685	O
group	33121028	686	691	O
(	33121028	692	693	O
n	33121028	694	695	O
=	33121028	696	697	O
47	33121028	698	700	O
)	33121028	701	702	O
.	33121028	703	704	O

Students	33121028	705	713	O
in	33121028	714	716	O
the	33121028	717	720	O
control	33121028	721	728	O
group	33121028	729	734	O
participated	33121028	735	747	O
in	33121028	748	750	O
a	33121028	751	752	O
traditional	33121028	753	764	O
maternity	33121028	765	774	O
clinical	33121028	775	783	O
practicum	33121028	784	793	O
for	33121028	794	797	O
a	33121028	798	799	O
week	33121028	800	804	O
,	33121028	805	806	O
while	33121028	807	812	O
students	33121028	813	821	O
in	33121028	822	824	O
the	33121028	825	828	O
experimental	33121028	829	841	O
group	33121028	842	847	O
participated	33121028	848	860	O
S	33121028	861	862	O
-	33121028	863	864	O
PBL	33121028	865	868	O
for	33121028	869	872	O
a	33121028	873	874	O
week	33121028	875	879	O
.	33121028	880	881	O

The	33121028	882	885	O
students	33121028	886	894	O
in	33121028	895	897	O
the	33121028	898	901	O
experimental	33121028	902	914	O
group	33121028	915	920	O
were	33121028	921	925	O
trained	33121028	926	933	O
in	33121028	934	936	O
small	33121028	937	942	O
groups	33121028	943	949	O
using	33121028	950	955	O
a	33121028	956	957	O
childbirth	33121028	958	968	O
patient	33121028	969	976	O
simulator	33121028	977	986	O
(	33121028	987	988	O
Gaumard	33121028	989	996	O
	33121028	997	998	O
Noelle	33121028	999	1005	O
	33121028	1006	1007	O
S554.100	33121028	1008	1016	O
,	33121028	1017	1018	O
Miami	33121028	1019	1024	O
,	33121028	1025	1026	O
USA	33121028	1027	1030	O
)	33121028	1031	1032	O
based	33121028	1033	1038	O
on	33121028	1039	1041	O
a	33121028	1042	1043	O
standardized	33121028	1044	1056	O
scenario	33121028	1057	1065	O
related	33121028	1066	1073	O
to	33121028	1074	1076	O
obstetric	33121028	1077	1086	O
care	33121028	1087	1091	O
.	33121028	1092	1093	O

The	33121028	1094	1097	O
students	33121028	1098	1106	O
'	33121028	1107	1108	O
learning	33121028	1109	1117	O
attitude	33121028	1118	1126	O
,	33121028	1127	1128	O
metacognition	33121028	1129	1142	O
,	33121028	1143	1144	O
and	33121028	1145	1148	O
critical	33121028	1149	1157	O
thinking	33121028	1158	1166	O
were	33121028	1167	1171	O
then	33121028	1172	1176	O
measured	33121028	1177	1185	O
via	33121028	1186	1189	O
a	33121028	1190	1191	O
self	33121028	1192	1196	O
-	33121028	1197	1198	O
reported	33121028	1199	1207	O
questionnaire	33121028	1208	1221	O
.	33121028	1222	1223	O

Compared	33121028	1224	1232	O
with	33121028	1233	1237	O
the	33121028	1238	1241	O
control	33121028	1242	1249	O
group	33121028	1250	1255	O
,	33121028	1256	1257	O
the	33121028	1258	1261	O
pre	33121028	1262	1265	O
-	33121028	1266	1267	O
post	33121028	1268	1272	O
difference	33121028	1273	1283	O
in	33121028	1284	1286	O
learning	33121028	1287	1295	O
attitude	33121028	1296	1304	O
and	33121028	1305	1308	O
critical	33121028	1309	1317	O
thinking	33121028	1318	1326	O
increased	33121028	1327	1336	O
significantly	33121028	1337	1350	O
(	33121028	1351	1352	O
p	33121028	1353	1354	O
<	33121028	1355	1356	O
0.01	33121028	1357	1361	O
)	33121028	1362	1363	O
in	33121028	1364	1366	O
the	33121028	1367	1370	O
experimental	33121028	1371	1383	O
group	33121028	1384	1389	O
.	33121028	1390	1391	O

S	33121028	1392	1393	O
-	33121028	1394	1395	O
PBL	33121028	1396	1399	O
was	33121028	1400	1403	O
found	33121028	1404	1409	O
to	33121028	1410	1412	O
be	33121028	1413	1415	O
an	33121028	1416	1418	O
effective	33121028	1419	1428	O
strategy	33121028	1429	1437	O
for	33121028	1438	1441	O
improving	33121028	1442	1451	O
nursing	33121028	1452	1459	O
students	33121028	1460	1468	O
'	33121028	1469	1470	O
learning	33121028	1471	1479	O
transfer	33121028	1480	1488	O
.	33121028	1489	1490	O

Thus	33121028	1491	1495	O
,	33121028	1496	1497	O
S	33121028	1498	1499	O
-	33121028	1500	1501	O
PBL	33121028	1502	1505	O
that	33121028	1506	1510	O
reflects	33121028	1511	1519	O
various	33121028	1520	1527	O
clinical	33121028	1528	1536	O
situations	33121028	1537	1547	O
is	33121028	1548	1550	O
recommended	33121028	1551	1562	O
to	33121028	1563	1565	O
improve	33121028	1566	1573	O
the	33121028	1574	1577	O
training	33121028	1578	1586	O
in	33121028	1587	1589	O
maternal	33121028	1590	1598	O
health	33121028	1599	1605	O
nursing	33121028	1606	1613	O
.	33121028	1614	1615	O


[	33131470	0	1	O
Proactive	33131470	2	11	O
anti	33131470	12	16	O
-	33131470	17	18	O
inflammatory	33131470	19	31	O
and	33131470	32	35	O
anticoagulant	33131470	36	49	O
therapy	33131470	50	57	O
in	33131470	58	60	O
the	33131470	61	64	O
treatment	33131470	65	74	O
of	33131470	75	77	O
advanced	33131470	78	86	O
stages	33131470	87	93	O
of	33131470	94	96	O
novel	33131470	97	102	O
coronavirus	33131470	103	114	O
infection	33131470	115	124	O
(	33131470	125	126	O
COVID-19	33131470	127	135	O
)	33131470	136	137	O
.	33131470	138	139	O

Case	33131470	140	144	O
Series	33131470	145	151	O
and	33131470	152	155	O
Study	33131470	156	161	O
Design	33131470	162	168	O
:	33131470	169	170	O
COLchicine	33131470	171	181	O
versus	33131470	182	188	O
ruxolitinib	33131470	189	200	O
and	33131470	201	204	O
secukinumab	33131470	205	216	O
in	33131470	217	219	O
open	33131470	220	224	O
prospective	33131470	225	236	O
randomIzed	33131470	237	247	O
trial	33131470	248	253	O
(	33131470	254	255	O
COLORIT	33131470	256	263	O
)	33131470	264	265	O
]	33131470	266	267	O
.	33131470	268	269	O

The	33131470	270	273	O
article	33131470	274	281	O
is	33131470	282	284	O
devoted	33131470	285	292	O
to	33131470	293	295	O
the	33131470	296	299	O
treatment	33131470	300	309	O
of	33131470	310	312	O
the	33131470	313	316	O
new	33131470	317	320	O
coronavirus	33131470	321	332	O
infection	33131470	333	342	O
(	33131470	343	344	O
COVID-19	33131470	345	353	O
)	33131470	354	355	O
in	33131470	356	358	O
the	33131470	359	362	O
advanced	33131470	363	371	O
stages	33131470	372	378	O
of	33131470	379	381	O
the	33131470	382	385	O
disease	33131470	386	393	O
.	33131470	394	395	O

The	33131470	396	399	O
types	33131470	400	405	O
of	33131470	406	408	O
response	33131470	409	417	O
of	33131470	418	420	O
the	33131470	421	424	O
immune	33131470	425	431	O
system	33131470	432	438	O
to	33131470	439	441	O
the	33131470	442	445	O
viral	33131470	446	451	O
load	33131470	452	456	O
of	33131470	457	459	O
SARS	33131470	460	464	O
-	33131470	465	466	O
CoV-2	33131470	467	472	O
with	33131470	473	477	O
the	33131470	478	481	O
start	33131470	482	487	O
of	33131470	488	490	O
the	33131470	491	494	O
inflammation	33131470	495	507	O
process	33131470	508	515	O
are	33131470	516	519	O
considered	33131470	520	530	O
.	33131470	531	532	O

The	33131470	533	536	O
situation	33131470	537	546	O
is	33131470	547	549	O
analyzed	33131470	550	558	O
in	33131470	559	561	O
detail	33131470	562	568	O
in	33131470	569	571	O
which	33131470	572	577	O
the	33131470	578	581	O
growing	33131470	582	589	O
autoimmune	33131470	590	600	O
inflammation	33131470	601	613	O
(	33131470	614	615	O
up	33131470	616	618	O
to	33131470	619	621	O
the	33131470	622	625	O
development	33131470	626	637	O
of	33131470	638	640	O
a	33131470	641	642	O
"	33131470	643	644	O
cytokine	33131470	645	653	O
storm	33131470	654	659	O
"	33131470	660	661	O
)	33131470	662	663	O
affects	33131470	664	671	O
not	33131470	672	675	O
only	33131470	676	680	O
the	33131470	681	684	O
pulmonary	33131470	685	694	O
parenchyma	33131470	695	705	O
,	33131470	706	707	O
but	33131470	708	711	O
also	33131470	712	716	O
the	33131470	717	720	O
endothelium	33131470	721	732	O
of	33131470	733	735	O
the	33131470	736	739	O
small	33131470	740	745	O
vessels	33131470	746	753	O
of	33131470	754	756	O
the	33131470	757	760	O
lungs	33131470	761	766	O
.	33131470	767	768	O

Simultaneous	33131470	769	781	O
damage	33131470	782	788	O
to	33131470	789	791	O
the	33131470	792	795	O
alveoli	33131470	796	803	O
and	33131470	804	807	O
microthrombosis	33131470	808	823	O
of	33131470	824	826	O
the	33131470	827	830	O
pulmonary	33131470	831	840	O
vessels	33131470	841	848	O
are	33131470	849	852	O
accompanied	33131470	853	864	O
by	33131470	865	867	O
a	33131470	868	869	O
progressive	33131470	870	881	O
impairment	33131470	882	892	O
of	33131470	893	895	O
gas	33131470	896	899	O
exchange	33131470	900	908	O
,	33131470	909	910	O
the	33131470	911	914	O
development	33131470	915	926	O
of	33131470	927	929	O
acute	33131470	930	935	O
respiratory	33131470	936	947	O
distress	33131470	948	956	O
syndrome	33131470	957	965	O
,	33131470	966	967	O
the	33131470	968	971	O
treatment	33131470	972	981	O
of	33131470	982	984	O
which	33131470	985	990	O
,	33131470	991	992	O
even	33131470	993	997	O
with	33131470	998	1002	O
the	33131470	1003	1006	O
use	33131470	1007	1010	O
of	33131470	1011	1013	O
invasive	33131470	1014	1022	O
ventilation	33131470	1023	1034	O
,	33131470	1035	1036	O
is	33131470	1037	1039	O
ineffective	33131470	1040	1051	O
and	33131470	1052	1055	O
does	33131470	1056	1060	O
not	33131470	1061	1064	O
really	33131470	1065	1071	O
change	33131470	1072	1078	O
the	33131470	1079	1082	O
prognosis	33131470	1083	1092	O
of	33131470	1093	1095	O
patients	33131470	1096	1104	O
with	33131470	1105	1109	O
COVID-19	33131470	1110	1118	O
.	33131470	1119	1120	O

In	33131470	1121	1123	O
order	33131470	1124	1129	O
to	33131470	1130	1132	O
interrupt	33131470	1133	1142	O
the	33131470	1143	1146	O
pathological	33131470	1147	1159	O
process	33131470	1160	1167	O
at	33131470	1168	1170	O
the	33131470	1171	1174	O
earliest	33131470	1175	1183	O
stages	33131470	1184	1190	O
of	33131470	1191	1193	O
the	33131470	1194	1197	O
disease	33131470	1198	1205	O
,	33131470	1206	1207	O
the	33131470	1208	1211	O
necessity	33131470	1212	1221	O
of	33131470	1222	1224	O
proactive	33131470	1225	1234	O
anti	33131470	1235	1239	O
-	33131470	1240	1241	O
inflammatory	33131470	1242	1254	O
therapy	33131470	1255	1262	O
in	33131470	1263	1265	O
combination	33131470	1266	1277	O
with	33131470	1278	1282	O
active	33131470	1283	1289	O
anticoagulation	33131470	1290	1305	O
treatment	33131470	1306	1315	O
is	33131470	1316	1318	O
substantiated	33131470	1319	1332	O
.	33131470	1333	1334	O

The	33131470	1335	1338	O
results	33131470	1339	1346	O
of	33131470	1347	1349	O
the	33131470	1350	1353	O
first	33131470	1354	1359	O
randomized	33131470	1360	1370	O
studies	33131470	1371	1378	O
on	33131470	1379	1381	O
the	33131470	1382	1385	O
use	33131470	1386	1389	O
of	33131470	1390	1392	O
inhibitors	33131470	1393	1403	O
of	33131470	1404	1406	O
pro	33131470	1407	1410	O
-	33131470	1411	1412	O
inflammatory	33131470	1413	1425	O
cytokines	33131470	1426	1435	O
and	33131470	1436	1439	O
chemokines	33131470	1440	1450	O
(	33131470	1451	1452	O
interleukin-6	33131470	1453	1466	O
(	33131470	1467	1468	O
tocilizumab	33131470	1469	1480	O
)	33131470	1481	1482	O
,	33131470	1483	1484	O
interleukin-17	33131470	1485	1499	O
(	33131470	1500	1501	O
secukinumab	33131470	1502	1513	O
)	33131470	1514	1515	O
,	33131470	1516	1517	O
Janus	33131470	1518	1523	O
kinase	33131470	1524	1530	O
blockers	33131470	1531	1539	O
,	33131470	1540	1541	O
through	33131470	1542	1549	O
which	33131470	1550	1555	O
the	33131470	1556	1559	O
signal	33131470	1560	1566	O
is	33131470	1567	1569	O
transmitted	33131470	1570	1581	O
to	33131470	1582	1584	O
cells	33131470	1585	1590	O
(	33131470	1591	1592	O
ruxolitinib	33131470	1593	1604	O
)	33131470	1605	1606	O
)	33131470	1607	1608	O
,	33131470	1609	1610	O
which	33131470	1611	1616	O
have	33131470	1617	1621	O
potential	33131470	1622	1631	O
in	33131470	1632	1634	O
the	33131470	1635	1638	O
early	33131470	1639	1644	O
treatment	33131470	1645	1654	O
of	33131470	1655	1657	O
COVID-	33131470	1658	1664	O
19	33131470	1665	1667	O
.	33131470	1668	1669	O

The	33131470	1670	1673	O
use	33131470	1674	1677	O
of	33131470	1678	1680	O
a	33131470	1681	1682	O
well	33131470	1683	1687	O
-	33131470	1688	1689	O
known	33131470	1690	1695	O
anti	33131470	1696	1700	O
-	33131470	1701	1702	O
inflammatory	33131470	1703	1715	O
drug	33131470	1716	1720	O
colchicine	33131470	1721	1731	O
(	33131470	1732	1733	O
which	33131470	1734	1739	O
is	33131470	1740	1742	O
used	33131470	1743	1747	O
for	33131470	1748	1751	O
gout	33131470	1752	1756	O
treatment	33131470	1757	1766	O
)	33131470	1767	1768	O
in	33131470	1769	1771	O
patients	33131470	1772	1780	O
with	33131470	1781	1785	O
COVID-19	33131470	1786	1794	O
is	33131470	1795	1797	O
considered	33131470	1798	1808	O
.	33131470	1809	1810	O

The	33131470	1811	1814	O
design	33131470	1815	1821	O
of	33131470	1822	1824	O
the	33131470	1825	1828	O
original	33131470	1829	1837	O
COLORIT	33131470	1838	1845	O
comparative	33131470	1846	1857	O
study	33131470	1858	1863	O
on	33131470	1864	1866	O
the	33131470	1867	1870	O
use	33131470	1871	1874	O
of	33131470	1875	1877	O
colchicine	33131470	1878	1888	O
,	33131470	1889	1890	O
ruxolitinib	33131470	1891	1902	O
and	33131470	1903	1906	O
secukinumab	33131470	1907	1918	O
in	33131470	1919	1921	O
the	33131470	1922	1925	O
treatment	33131470	1926	1935	O
of	33131470	1936	1938	O
COVID-19	33131470	1939	1947	O
is	33131470	1948	1950	O
presented	33131470	1951	1960	O
.	33131470	1961	1962	O

Clinical	33131470	1963	1971	O
series	33131470	1972	1978	O
presented	33131470	1979	1988	O
,	33131470	1989	1990	O
illustrated	33131470	1991	2002	O
early	33131470	2003	2008	O
anti	33131470	2009	2013	O
-	33131470	2014	2015	O
inflammatory	33131470	2016	2028	O
therapy	33131470	2029	2036	O
together	33131470	2037	2045	O
with	33131470	2046	2050	O
anticoagulants	33131470	2051	2065	O
in	33131470	2066	2068	O
patients	33131470	2069	2077	O
with	33131470	2078	2082	O
COVID-19	33131470	2083	2091	O
and	33131470	2092	2095	O
the	33131470	2096	2099	O
dangers	33131470	2100	2107	O
associated	33131470	2108	2118	O
with	33131470	2119	2123	O
refusing	33131470	2124	2132	O
to	33131470	2133	2135	O
initiate	33131470	2136	2144	O
such	33131470	2145	2149	O
therapy	33131470	2150	2157	O
on	33131470	2158	2160	O
time	33131470	2161	2165	O
.	33131470	2166	2167	O


Comparative	33143327	0	11	O
Study	33143327	12	17	O
of	33143327	18	20	O
the	33143327	21	24	O
Restorative	33143327	25	36	O
Effects	33143327	37	44	O
of	33143327	45	47	O
Forest	33143327	48	54	O
and	33143327	55	58	O
Urban	33143327	59	64	O
Videos	33143327	65	71	O
during	33143327	72	78	O
COVID-19	33143327	79	87	O
Lockdown	33143327	88	96	O
:	33143327	97	98	O
Intrinsic	33143327	99	108	O
and	33143327	109	112	O
Benchmark	33143327	113	122	O
Values	33143327	123	129	O
.	33143327	130	131	O

The	33143327	132	135	O
prolonged	33143327	136	145	O
lockdown	33143327	146	154	O
imposed	33143327	155	162	O
to	33143327	163	165	O
contain	33143327	166	173	O
the	33143327	174	177	O
COrona	33143327	178	184	O
VIrus	33143327	185	190	O
Disease	33143327	191	198	O
19	33143327	199	201	O
COVID-19	33143327	202	210	O
pandemic	33143327	211	219	O
prevented	33143327	220	229	O
many	33143327	230	234	O
people	33143327	235	241	O
from	33143327	242	246	O
direct	33143327	247	253	O
contact	33143327	254	261	O
with	33143327	262	266	O
nature	33143327	267	273	O
and	33143327	274	277	O
greenspaces	33143327	278	289	O
,	33143327	290	291	O
raising	33143327	292	299	O
alarms	33143327	300	306	O
for	33143327	307	310	O
a	33143327	311	312	O
possible	33143327	313	321	O
worsening	33143327	322	331	O
of	33143327	332	334	O
mental	33143327	335	341	O
health	33143327	342	348	O
.	33143327	349	350	O

This	33143327	351	355	O
study	33143327	356	361	O
investigated	33143327	362	374	O
the	33143327	375	378	O
effectiveness	33143327	379	392	O
of	33143327	393	395	O
a	33143327	396	397	O
simple	33143327	398	404	O
and	33143327	405	408	O
affordable	33143327	409	419	O
remedy	33143327	420	426	O
for	33143327	427	430	O
improving	33143327	431	440	O
psychological	33143327	441	454	O
well	33143327	455	459	O
-	33143327	460	461	O
being	33143327	462	467	O
,	33143327	468	469	O
based	33143327	470	475	O
on	33143327	476	478	O
audio	33143327	479	484	O
-	33143327	485	486	O
visual	33143327	487	493	O
stimuli	33143327	494	501	O
brought	33143327	502	509	O
by	33143327	510	512	O
a	33143327	513	514	O
short	33143327	515	520	O
computer	33143327	521	529	O
video	33143327	530	535	O
showing	33143327	536	543	O
forest	33143327	544	550	O
environments	33143327	551	563	O
,	33143327	564	565	O
with	33143327	566	570	O
an	33143327	571	573	O
urban	33143327	574	579	O
video	33143327	580	585	O
as	33143327	586	588	O
a	33143327	589	590	O
control	33143327	591	598	O
.	33143327	599	600	O

Randomly	33143327	601	609	O
selected	33143327	610	618	O
participants	33143327	619	631	O
were	33143327	632	636	O
assigned	33143327	637	645	O
the	33143327	646	649	O
forest	33143327	650	656	O
or	33143327	657	659	O
urban	33143327	660	665	O
video	33143327	666	671	O
,	33143327	672	673	O
to	33143327	674	676	O
look	33143327	677	681	O
at	33143327	682	684	O
and	33143327	685	688	O
listen	33143327	689	695	O
to	33143327	696	698	O
early	33143327	699	704	O
in	33143327	705	707	O
the	33143327	708	711	O
morning	33143327	712	719	O
,	33143327	720	721	O
and	33143327	722	725	O
questionnaires	33143327	726	740	O
to	33143327	741	743	O
fill	33143327	744	748	O
out	33143327	749	752	O
.	33143327	753	754	O

In	33143327	755	757	O
particular	33143327	758	768	O
,	33143327	769	770	O
the	33143327	771	774	O
State	33143327	775	780	O
-	33143327	781	782	O
Trait	33143327	783	788	O
Anxiety	33143327	789	796	O
Inventory	33143327	797	806	O
(	33143327	807	808	O
STAI	33143327	809	813	O
)	33143327	814	815	O
Form	33143327	816	820	O
Y	33143327	821	822	O
collected	33143327	823	832	O
in	33143327	833	835	O
baseline	33143327	836	844	O
condition	33143327	845	854	O
and	33143327	855	858	O
at	33143327	859	861	O
the	33143327	862	865	O
end	33143327	866	869	O
of	33143327	870	872	O
the	33143327	873	876	O
study	33143327	877	882	O
and	33143327	883	886	O
the	33143327	887	890	O
Part	33143327	891	895	O
II	33143327	896	898	O
of	33143327	899	901	O
the	33143327	902	905	O
Sheehan	33143327	906	913	O
Patient	33143327	914	921	O
Rated	33143327	922	927	O
Anxiety	33143327	928	935	O
Scale	33143327	936	941	O
(	33143327	942	943	O
SPRAS	33143327	944	949	O
)	33143327	950	951	O
collected	33143327	952	961	O
every	33143327	962	967	O
day	33143327	968	971	O
immediately	33143327	972	983	O
before	33143327	984	990	O
and	33143327	991	994	O
after	33143327	995	1000	O
watching	33143327	1001	1009	O
the	33143327	1010	1013	O
video	33143327	1014	1019	O
.	33143327	1020	1021	O

The	33143327	1022	1025	O
virtual	33143327	1026	1033	O
exposure	33143327	1034	1042	O
to	33143327	1043	1045	O
forest	33143327	1046	1052	O
environments	33143327	1053	1065	O
showed	33143327	1066	1072	O
effective	33143327	1073	1082	O
to	33143327	1083	1085	O
reduce	33143327	1086	1092	O
perceived	33143327	1093	1102	O
anxiety	33143327	1103	1110	O
levels	33143327	1111	1117	O
in	33143327	1118	1120	O
people	33143327	1121	1127	O
forced	33143327	1128	1134	O
by	33143327	1135	1137	O
lockdown	33143327	1138	1146	O
in	33143327	1147	1149	O
limited	33143327	1150	1157	O
spaces	33143327	1158	1164	O
and	33143327	1165	1168	O
environmental	33143327	1169	1182	O
deprivation	33143327	1183	1194	O
.	33143327	1195	1196	O

Although	33143327	1197	1205	O
significant	33143327	1206	1217	O
,	33143327	1218	1219	O
the	33143327	1220	1223	O
effects	33143327	1224	1231	O
were	33143327	1232	1236	O
observed	33143327	1237	1245	O
only	33143327	1246	1250	O
in	33143327	1251	1253	O
the	33143327	1254	1257	O
short	33143327	1258	1263	O
term	33143327	1264	1268	O
,	33143327	1269	1270	O
highlighting	33143327	1271	1283	O
the	33143327	1284	1287	O
limitation	33143327	1288	1298	O
of	33143327	1299	1301	O
the	33143327	1302	1305	O
virtual	33143327	1306	1313	O
experiences	33143327	1314	1325	O
.	33143327	1326	1327	O

The	33143327	1328	1331	O
reported	33143327	1332	1340	O
effects	33143327	1341	1348	O
might	33143327	1349	1354	O
also	33143327	1355	1359	O
represent	33143327	1360	1369	O
a	33143327	1370	1371	O
benchmark	33143327	1372	1381	O
to	33143327	1382	1384	O
disentangle	33143327	1385	1396	O
the	33143327	1397	1400	O
determinants	33143327	1401	1413	O
of	33143327	1414	1416	O
health	33143327	1417	1423	O
effects	33143327	1424	1431	O
due	33143327	1432	1435	O
to	33143327	1436	1438	O
real	33143327	1439	1443	O
forest	33143327	1444	1450	O
experiences	33143327	1451	1462	O
,	33143327	1463	1464	O
for	33143327	1465	1468	O
example	33143327	1469	1476	O
,	33143327	1477	1478	O
the	33143327	1479	1482	O
inhalation	33143327	1483	1493	O
of	33143327	1494	1496	O
biogenic	33143327	1497	1505	O
volatile	33143327	1506	1514	O
organic	33143327	1515	1522	O
compounds	33143327	1523	1532	O
(	33143327	1533	1534	O
BVOC	33143327	1535	1539	O
)	33143327	1540	1541	O
.	33143327	1542	1543	O


Wearing	33153145	0	7	O
of	33153145	8	10	O
Cloth	33153145	11	16	O
or	33153145	17	19	O
Disposable	33153145	20	30	O
Surgical	33153145	31	39	O
Face	33153145	40	44	O
Masks	33153145	45	50	O
has	33153145	51	54	O
no	33153145	55	57	O
Effect	33153145	58	64	O
on	33153145	65	67	O
Vigorous	33153145	68	76	O
Exercise	33153145	77	85	O
Performance	33153145	86	97	O
in	33153145	98	100	O
Healthy	33153145	101	108	O
Individuals	33153145	109	120	O
.	33153145	121	122	O

Wearing	33153145	123	130	O
face	33153145	131	135	O
masks	33153145	136	141	O
is	33153145	142	144	O
recommended	33153145	145	156	O
for	33153145	157	160	O
the	33153145	161	164	O
prevention	33153145	165	175	O
of	33153145	176	178	O
contracting	33153145	179	190	O
or	33153145	191	193	O
exposing	33153145	194	202	O
others	33153145	203	209	O
to	33153145	210	212	O
cardiorespiratory	33153145	213	230	O
infections	33153145	231	241	O
,	33153145	242	243	O
such	33153145	244	248	O
as	33153145	249	251	O
COVID-19	33153145	252	260	O
.	33153145	261	262	O

Controversy	33153145	263	274	O
exists	33153145	275	281	O
on	33153145	282	284	O
whether	33153145	285	292	O
wearing	33153145	293	300	O
face	33153145	301	305	O
masks	33153145	306	311	O
during	33153145	312	318	O
vigorous	33153145	319	327	O
exercise	33153145	328	336	O
affects	33153145	337	344	O
performance	33153145	345	356	O
.	33153145	357	358	O

We	33153145	359	361	O
used	33153145	362	366	O
a	33153145	367	368	O
randomized	33153145	369	379	O
,	33153145	380	381	O
counterbalanced	33153145	382	397	O
cross	33153145	398	403	O
-	33153145	404	405	O
over	33153145	406	410	O
design	33153145	411	417	O
to	33153145	418	420	O
evaluate	33153145	421	429	O
the	33153145	430	433	O
effects	33153145	434	441	O
of	33153145	442	444	O
wearing	33153145	445	452	O
a	33153145	453	454	O
surgical	33153145	455	463	O
mask	33153145	464	468	O
,	33153145	469	470	O
a	33153145	471	472	O
cloth	33153145	473	478	O
mask	33153145	479	483	O
,	33153145	484	485	O
or	33153145	486	488	O
no	33153145	489	491	O
mask	33153145	492	496	O
in	33153145	497	499	O
14	33153145	500	502	O
participants	33153145	503	515	O
(	33153145	516	517	O
7	33153145	518	519	O
men	33153145	520	523	O
and	33153145	524	527	O
7	33153145	528	529	O
women	33153145	530	535	O
;	33153145	536	537	O
28.2	33153145	538	542	O
	33153145	543	544	O
8.7	33153145	545	548	O
y	33153145	549	550	O
)	33153145	551	552	O
during	33153145	553	559	O
a	33153145	560	561	O
cycle	33153145	562	567	O
ergometry	33153145	568	577	O
test	33153145	578	582	O
to	33153145	583	585	O
exhaustion	33153145	586	596	O
.	33153145	597	598	O

Arterial	33153145	599	607	O
oxygen	33153145	608	614	O
saturation	33153145	615	625	O
(	33153145	626	627	O
pulse	33153145	628	633	O
oximetry	33153145	634	642	O
)	33153145	643	644	O
and	33153145	645	648	O
tissue	33153145	649	655	O
oxygenation	33153145	656	667	O
index	33153145	668	673	O
(	33153145	674	675	O
indicator	33153145	676	685	O
of	33153145	686	688	O
hemoglobin	33153145	689	699	O
saturation	33153145	700	710	O
/	33153145	711	712	O
desaturation	33153145	713	725	O
)	33153145	726	727	O
at	33153145	728	730	O
vastus	33153145	731	737	O
lateralis	33153145	738	747	O
(	33153145	748	749	O
near	33153145	750	754	O
-	33153145	755	756	O
infrared	33153145	757	765	O
spectroscopy	33153145	766	778	O
)	33153145	779	780	O
were	33153145	781	785	O
assessed	33153145	786	794	O
throughout	33153145	795	805	O
the	33153145	806	809	O
exercise	33153145	810	818	O
tests	33153145	819	824	O
.	33153145	825	826	O

Wearing	33153145	827	834	O
face	33153145	835	839	O
masks	33153145	840	845	O
had	33153145	846	849	O
no	33153145	850	852	O
effect	33153145	853	859	O
on	33153145	860	862	O
performance	33153145	863	874	O
(	33153145	875	876	O
time	33153145	877	881	O
to	33153145	882	884	O
exhaustion	33153145	885	895	O
(	33153145	896	897	O
mean	33153145	898	902	O
	33153145	903	904	O
SD	33153145	905	907	O
)	33153145	908	909	O
:	33153145	910	911	O
no	33153145	912	914	O
mask	33153145	915	919	O
622	33153145	920	923	O
	33153145	924	925	O
141	33153145	926	929	O
s	33153145	930	931	O
,	33153145	932	933	O
surgical	33153145	934	942	O
mask	33153145	943	947	O
657	33153145	948	951	O
	33153145	952	953	O
158	33153145	954	957	O
s	33153145	958	959	O
,	33153145	960	961	O
cloth	33153145	962	967	O
mask	33153145	968	972	O
637	33153145	973	976	O
	33153145	977	978	O
153	33153145	979	982	O
s	33153145	983	984	O
(	33153145	985	986	O
p	33153145	987	988	O
=	33153145	989	990	O
0.20	33153145	991	995	O
)	33153145	996	997	O
;	33153145	998	999	O
peak	33153145	1000	1004	O
power	33153145	1005	1010	O
:	33153145	1011	1012	O
no	33153145	1013	1015	O
mask	33153145	1016	1020	O
234	33153145	1021	1024	O
	33153145	1025	1026	O
56	33153145	1027	1029	O
W	33153145	1030	1031	O
,	33153145	1032	1033	O
surgical	33153145	1034	1042	O
mask	33153145	1043	1047	O
241	33153145	1048	1051	O
	33153145	1052	1053	O
57	33153145	1054	1056	O
W	33153145	1057	1058	O
,	33153145	1059	1060	O
cloth	33153145	1061	1066	O
mask	33153145	1067	1071	O
241	33153145	1072	1075	O
	33153145	1076	1077	O
51	33153145	1078	1080	O
W	33153145	1081	1082	O
(	33153145	1083	1084	O
p	33153145	1085	1086	O
=	33153145	1087	1088	O
0.49	33153145	1089	1093	O
)	33153145	1094	1095	O
)	33153145	1096	1097	O
.	33153145	1098	1099	O

When	33153145	1100	1104	O
expressed	33153145	1105	1114	O
relative	33153145	1115	1123	O
to	33153145	1124	1126	O
peak	33153145	1127	1131	O
exercise	33153145	1132	1140	O
performance	33153145	1141	1152	O
,	33153145	1153	1154	O
no	33153145	1155	1157	O
differences	33153145	1158	1169	O
were	33153145	1170	1174	O
evident	33153145	1175	1182	O
between	33153145	1183	1190	O
wearing	33153145	1191	1198	O
or	33153145	1199	1201	O
not	33153145	1202	1205	O
wearing	33153145	1206	1213	O
a	33153145	1214	1215	O
mask	33153145	1216	1220	O
for	33153145	1221	1224	O
arterial	33153145	1225	1233	O
oxygen	33153145	1234	1240	O
saturation	33153145	1241	1251	O
,	33153145	1252	1253	O
tissue	33153145	1254	1260	O
oxygenation	33153145	1261	1272	O
index	33153145	1273	1278	O
,	33153145	1279	1280	O
rating	33153145	1281	1287	O
of	33153145	1288	1290	O
perceived	33153145	1291	1300	O
exertion	33153145	1301	1309	O
,	33153145	1310	1311	O
or	33153145	1312	1314	O
heart	33153145	1315	1320	O
rate	33153145	1321	1325	O
at	33153145	1326	1328	O
any	33153145	1329	1332	O
time	33153145	1333	1337	O
during	33153145	1338	1344	O
the	33153145	1345	1348	O
exercise	33153145	1349	1357	O
tests	33153145	1358	1363	O
.	33153145	1364	1365	O

Wearing	33153145	1366	1373	O
a	33153145	1374	1375	O
face	33153145	1376	1380	O
mask	33153145	1381	1385	O
during	33153145	1386	1392	O
vigorous	33153145	1393	1401	O
exercise	33153145	1402	1410	O
had	33153145	1411	1414	O
no	33153145	1415	1417	O
discernable	33153145	1418	1429	O
detrimental	33153145	1430	1441	O
effect	33153145	1442	1448	O
on	33153145	1449	1451	O
blood	33153145	1452	1457	O
or	33153145	1458	1460	O
muscle	33153145	1461	1467	O
oxygenation	33153145	1468	1479	O
,	33153145	1480	1481	O
and	33153145	1482	1485	O
exercise	33153145	1486	1494	O
performance	33153145	1495	1506	O
in	33153145	1507	1509	O
young	33153145	1510	1515	O
,	33153145	1516	1517	O
healthy	33153145	1518	1525	O
participants	33153145	1526	1538	O
(	33153145	1539	1540	O
ClinicalTrials.gov	33153145	1541	1559	O
,	33153145	1560	1561	O
NCT04557605	33153145	1562	1573	O
)	33153145	1574	1575	O
.	33153145	1576	1577	O


Efficacy	33167921	0	8	O
and	33167921	9	12	O
efficiency	33167921	13	23	O
of	33167921	24	26	O
a	33167921	27	28	O
new	33167921	29	32	O
therapeutic	33167921	33	44	O
approach	33167921	45	53	O
based	33167921	54	59	O
on	33167921	60	62	O
activity	33167921	63	71	O
-	33167921	72	73	O
oriented	33167921	74	82	O
proprioceptive	33167921	83	97	O
antiedema	33167921	98	107	O
therapy	33167921	108	115	O
(	33167921	116	117	O
TAPA	33167921	118	122	O
)	33167921	123	124	O
for	33167921	125	128	O
edema	33167921	129	134	O
reduction	33167921	135	144	O
and	33167921	145	148	O
improved	33167921	149	157	O
occupational	33167921	158	170	O
performance	33167921	171	182	O
in	33167921	183	185	O
the	33167921	186	189	O
rehabilitation	33167921	190	204	O
of	33167921	205	207	O
breast	33167921	208	214	O
cancer	33167921	215	221	O
-	33167921	222	223	O
related	33167921	224	231	O
arm	33167921	232	235	O
lymphedema	33167921	236	246	O
in	33167921	247	249	O
women	33167921	250	255	O
:	33167921	256	257	O
a	33167921	258	259	O
controlled	33167921	260	270	O
,	33167921	271	272	O
randomized	33167921	273	283	O
clinical	33167921	284	292	O
trial	33167921	293	298	O
.	33167921	299	300	O

BACKGROUND	33167921	301	311	O
:	33167921	312	313	O
Breast	33167921	314	320	O
cancer	33167921	321	327	O
(	33167921	328	329	O
BC	33167921	330	332	O
)	33167921	333	334	O
is	33167921	335	337	O
a	33167921	338	339	O
major	33167921	340	345	O
public	33167921	346	352	O
health	33167921	353	359	O
issue	33167921	360	365	O
.	33167921	366	367	O

More	33167921	368	372	O
than	33167921	373	377	O
one	33167921	378	381	O
out	33167921	382	385	O
of	33167921	386	388	O
five	33167921	389	393	O
women	33167921	394	399	O
treated	33167921	400	407	O
for	33167921	408	411	O
breast	33167921	412	418	O
cancer	33167921	419	425	O
will	33167921	426	430	O
develop	33167921	431	438	O
lymphedema	33167921	439	449	O
in	33167921	450	452	O
an	33167921	453	455	O
upper	33167921	456	461	O
extremity	33167921	462	471	O
.	33167921	472	473	O

Current	33167921	474	481	O
evidence	33167921	482	490	O
advocates	33167921	491	500	O
transdisciplinary	33167921	501	518	O
oncological	33167921	519	530	O
rehabilitation	33167921	531	545	O
.	33167921	546	547	O

Therefore	33167921	548	557	O
,	33167921	558	559	O
research	33167921	560	568	O
in	33167921	569	571	O
this	33167921	572	576	O
area	33167921	577	581	O
is	33167921	582	584	O
necessary	33167921	585	594	O
since	33167921	595	600	O
limited	33167921	601	608	O
consensus	33167921	609	618	O
having	33167921	619	625	O
been	33167921	626	630	O
reached	33167921	631	638	O
with	33167921	639	643	O
regard	33167921	644	650	O
to	33167921	651	653	O
the	33167921	654	657	O
basic	33167921	658	663	O
essential	33167921	664	673	O
components	33167921	674	684	O
of	33167921	685	687	O
this	33167921	688	692	O
rehabilitation	33167921	693	707	O
.	33167921	708	709	O

Consensus	33167921	710	719	O
has	33167921	720	723	O
,	33167921	724	725	O
however	33167921	726	733	O
,	33167921	734	735	O
been	33167921	736	740	O
reached	33167921	741	748	O
on	33167921	749	751	O
the	33167921	752	755	O
use	33167921	756	759	O
of	33167921	760	762	O
decongestive	33167921	763	775	O
lymphedema	33167921	776	786	O
therapy	33167921	787	794	O
(	33167921	795	796	O
DLT	33167921	797	800	O
)	33167921	801	802	O
,	33167921	803	804	O
but	33167921	805	808	O
due	33167921	809	812	O
to	33167921	813	815	O
a	33167921	816	817	O
lack	33167921	818	822	O
of	33167921	823	825	O
tests	33167921	826	831	O
,	33167921	832	833	O
the	33167921	834	837	O
necessary	33167921	838	847	O
dosages	33167921	848	855	O
are	33167921	856	859	O
unknown	33167921	860	867	O
and	33167921	868	871	O
its	33167921	872	875	O
level	33167921	876	881	O
is	33167921	882	884	O
moderately	33167921	885	895	O
strong	33167921	896	902	O
.	33167921	903	904	O

This	33167921	905	909	O
study	33167921	910	915	O
attempts	33167921	916	924	O
to	33167921	925	927	O
verify	33167921	928	934	O
both	33167921	935	939	O
the	33167921	940	943	O
efficacy	33167921	944	952	O
of	33167921	953	955	O
activity	33167921	956	964	O
-	33167921	965	966	O
oriented	33167921	967	975	O
proprioceptive	33167921	976	990	O
antiedema	33167921	991	1000	O
therapy	33167921	1001	1008	O
(	33167921	1009	1010	O
TAPA	33167921	1011	1015	O
)	33167921	1016	1017	O
,	33167921	1018	1019	O
as	33167921	1020	1022	O
compared	33167921	1023	1031	O
to	33167921	1032	1034	O
conventional	33167921	1035	1047	O
treatments	33167921	1048	1058	O
such	33167921	1059	1063	O
as	33167921	1064	1066	O
DLT	33167921	1067	1070	O
or	33167921	1071	1073	O
Complex	33167921	1074	1081	O
Physical	33167921	1082	1090	O
Therapy	33167921	1091	1098	O
(	33167921	1099	1100	O
CPT	33167921	1101	1104	O
)	33167921	1105	1106	O
,	33167921	1107	1108	O
as	33167921	1109	1111	O
well	33167921	1112	1116	O
as	33167921	1117	1119	O
its	33167921	1120	1123	O
efficiency	33167921	1124	1134	O
in	33167921	1135	1137	O
terms	33167921	1138	1143	O
of	33167921	1144	1146	O
cost	33167921	1147	1151	O
-	33167921	1152	1153	O
effectiveness	33167921	1154	1167	O
,	33167921	1168	1169	O
for	33167921	1170	1173	O
patients	33167921	1174	1182	O
affected	33167921	1183	1191	O
by	33167921	1192	1194	O
breast	33167921	1195	1201	O
cancer	33167921	1202	1208	O
-	33167921	1209	1210	O
related	33167921	1211	1218	O
arm	33167921	1219	1222	O
lymphedema	33167921	1223	1233	O
.	33167921	1234	1235	O

METHODS	33167921	1236	1243	O
:	33167921	1244	1245	O
Controlled	33167921	1246	1256	O
,	33167921	1257	1258	O
randomized	33167921	1259	1269	O
clinical	33167921	1270	1278	O
trial	33167921	1279	1284	O
with	33167921	1285	1289	O
dual	33167921	1290	1294	O
stratification	33167921	1295	1309	O
,	33167921	1310	1311	O
two	33167921	1312	1315	O
parallel	33167921	1316	1324	O
arms	33167921	1325	1329	O
,	33167921	1330	1331	O
longitudinal	33167921	1332	1344	O
and	33167921	1345	1348	O
single	33167921	1349	1355	O
blind	33167921	1356	1361	O
.	33167921	1362	1363	O

64	33167921	1364	1366	O
women	33167921	1367	1372	O
with	33167921	1373	1377	O
breast	33167921	1378	1384	O
cancer	33167921	1385	1391	O
-	33167921	1392	1393	O
related	33167921	1394	1401	O
arm	33167921	1402	1405	O
lymphedema	33167921	1406	1416	O
will	33167921	1417	1421	O
take	33167921	1422	1426	O
part	33167921	1427	1431	O
in	33167921	1432	1434	O
the	33167921	1435	1438	O
study	33167921	1439	1444	O
.	33167921	1445	1446	O

The	33167921	1447	1450	O
experimental	33167921	1451	1463	O
group	33167921	1464	1469	O
intervention	33167921	1470	1482	O
will	33167921	1483	1487	O
be	33167921	1488	1490	O
the	33167921	1491	1494	O
same	33167921	1495	1499	O
for	33167921	1500	1503	O
stage	33167921	1504	1509	O
I	33167921	1510	1511	O
and	33167921	1512	1515	O
II	33167921	1516	1518	O
,	33167921	1519	1520	O
and	33167921	1521	1524	O
will	33167921	1525	1529	O
consist	33167921	1530	1537	O
of	33167921	1538	1540	O
neuro	33167921	1541	1546	O
-	33167921	1547	1548	O
dynamic	33167921	1549	1556	O
exercises	33167921	1557	1566	O
oriented	33167921	1567	1575	O
to	33167921	1576	1578	O
the	33167921	1579	1582	O
activity	33167921	1583	1591	O
,	33167921	1592	1593	O
proprioceptive	33167921	1594	1608	O
neuromuscular	33167921	1609	1622	O
facilitation	33167921	1623	1635	O
activities	33167921	1636	1646	O
and	33167921	1647	1650	O
proprioceptive	33167921	1651	1665	O
anti	33167921	1666	1670	O
-	33167921	1671	1672	O
edema	33167921	1673	1678	O
bandaging	33167921	1679	1688	O
.	33167921	1689	1690	O

The	33167921	1691	1694	O
control	33167921	1695	1702	O
group	33167921	1703	1708	O
intervention	33167921	1709	1721	O
,	33167921	1722	1723	O
depending	33167921	1724	1733	O
on	33167921	1734	1736	O
the	33167921	1737	1740	O
stage	33167921	1741	1746	O
,	33167921	1747	1748	O
will	33167921	1749	1753	O
consist	33167921	1754	1761	O
of	33167921	1762	1764	O
preventive	33167921	1765	1775	O
measures	33167921	1776	1784	O
,	33167921	1785	1786	O
skin	33167921	1787	1791	O
care	33167921	1792	1796	O
and	33167921	1797	1800	O
exercise	33167921	1801	1809	O
-	33167921	1810	1811	O
prescribed	33167921	1812	1822	O
training	33167921	1823	1831	O
in	33167921	1832	1834	O
the	33167921	1835	1838	O
lymphedema	33167921	1839	1849	O
workshop	33167921	1850	1858	O
as	33167921	1859	1861	O
well	33167921	1862	1866	O
as	33167921	1867	1869	O
compression	33167921	1870	1881	O
garments	33167921	1882	1890	O
(	33167921	1891	1892	O
Stage	33167921	1893	1898	O
I	33167921	1899	1900	O
)	33167921	1901	1902	O
or	33167921	1903	1905	O
conservative	33167921	1906	1918	O
Complex	33167921	1919	1926	O
Decongestive	33167921	1927	1939	O
Therapy	33167921	1940	1947	O
treatment	33167921	1948	1957	O
(	33167921	1958	1959	O
skin	33167921	1960	1964	O
care	33167921	1965	1969	O
,	33167921	1970	1971	O
multi	33167921	1972	1977	O
-	33167921	1978	1979	O
layer	33167921	1980	1985	O
bandaging	33167921	1986	1995	O
,	33167921	1996	1997	O
manual	33167921	1998	2004	O
lymphatic	33167921	2005	2014	O
drainage	33167921	2015	2023	O
and	33167921	2024	2027	O
massage	33167921	2028	2035	O
therapy	33167921	2036	2043	O
)	33167921	2044	2045	O
(	33167921	2046	2047	O
Stage	33167921	2048	2053	O
II	33167921	2054	2056	O
)	33167921	2057	2058	O
.	33167921	2059	2060	O

RESULTS	33167921	2061	2068	O
:	33167921	2069	2070	O
Sociodemographic	33167921	2071	2087	O
and	33167921	2088	2091	O
clinical	33167921	2092	2100	O
variables	33167921	2101	2110	O
will	33167921	2111	2115	O
be	33167921	2116	2118	O
collected	33167921	2119	2128	O
for	33167921	2129	2132	O
the	33167921	2133	2136	O
measurement	33167921	2137	2148	O
of	33167921	2149	2151	O
edema	33167921	2152	2157	O
volume	33167921	2158	2164	O
and	33167921	2165	2168	O
ADL	33167921	2169	2172	O
performance	33167921	2173	2184	O
.	33167921	2185	2186	O

Statistical	33167921	2187	2198	O
analysis	33167921	2199	2207	O
will	33167921	2208	2212	O
be	33167921	2213	2215	O
performed	33167921	2216	2225	O
on	33167921	2226	2228	O
intent	33167921	2229	2235	O
to	33167921	2236	2238	O
treat	33167921	2239	2244	O
.	33167921	2245	2246	O

CONCLUSIONS	33167921	2247	2258	O
:	33167921	2259	2260	O
It	33167921	2261	2263	O
has	33167921	2264	2267	O
been	33167921	2268	2272	O
recommended	33167921	2273	2284	O
that	33167921	2285	2289	O
patient	33167921	2290	2297	O
training	33167921	2298	2306	O
be	33167921	2307	2309	O
added	33167921	2310	2315	O
to	33167921	2316	2318	O
DLT	33167921	2319	2322	O
,	33167921	2323	2324	O
as	33167921	2325	2327	O
well	33167921	2328	2332	O
as	33167921	2333	2335	O
a	33167921	2336	2337	O
re	33167921	2338	2340	O
-	33167921	2341	2342	O
designing	33167921	2343	2352	O
of	33167921	2353	2355	O
patient	33167921	2356	2363	O
lifestyles	33167921	2364	2374	O
and	33167921	2375	2378	O
the	33167921	2379	2382	O
promotion	33167921	2383	2392	O
of	33167921	2393	2395	O
health	33167921	2396	2402	O
-	33167921	2403	2404	O
related	33167921	2405	2412	O
aspects	33167921	2413	2420	O
.	33167921	2421	2422	O

In	33167921	2423	2425	O
addition	33167921	2426	2434	O
,	33167921	2435	2436	O
clinical	33167921	2437	2445	O
trials	33167921	2446	2452	O
should	33167921	2453	2459	O
be	33167921	2460	2462	O
undertaken	33167921	2463	2473	O
to	33167921	2474	2476	O
assess	33167921	2477	2483	O
neural	33167921	2484	2490	O
mobilization	33167921	2491	2503	O
techniques	33167921	2504	2514	O
and	33167921	2515	2518	O
proprioceptive	33167921	2519	2533	O
neuromuscular	33167921	2534	2547	O
facilitation	33167921	2548	2560	O
should	33167921	2561	2567	O
be	33167921	2568	2570	O
included	33167921	2571	2579	O
in	33167921	2580	2582	O
the	33167921	2583	2586	O
therapy	33167921	2587	2594	O
.	33167921	2595	2596	O

Cohesive	33167921	2597	2605	O
bandaging	33167921	2606	2615	O
will	33167921	2616	2620	O
also	33167921	2621	2625	O
be	33167921	2626	2628	O
performed	33167921	2629	2638	O
as	33167921	2639	2641	O
an	33167921	2642	2644	O
early	33167921	2645	2650	O
form	33167921	2651	2655	O
of	33167921	2656	2658	O
pressotherapy	33167921	2659	2672	O
.	33167921	2673	2674	O

The	33167921	2675	2678	O
proposed	33167921	2679	2687	O
study	33167921	2688	2693	O
combines	33167921	2694	2702	O
all	33167921	2703	2706	O
of	33167921	2707	2709	O
these	33167921	2710	2715	O
aspects	33167921	2716	2723	O
in	33167921	2724	2726	O
order	33167921	2727	2732	O
to	33167921	2733	2735	O
increased	33167921	2736	2745	O
comfort	33167921	2746	2753	O
and	33167921	2754	2757	O
promote	33167921	2758	2765	O
the	33167921	2766	2769	O
participation	33167921	2770	2783	O
of	33167921	2784	2786	O
individuals	33167921	2787	2798	O
with	33167921	2799	2803	O
lymphedema	33167921	2804	2814	O
in	33167921	2815	2817	O
everyday	33167921	2818	2826	O
situations	33167921	2827	2837	O
.	33167921	2838	2839	O

CONCLUSIONS	33167921	2840	2851	O
:	33167921	2852	2853	O
The	33167921	2854	2857	O
authors	33167921	2858	2865	O
have	33167921	2866	2870	O
proposed	33167921	2871	2879	O
the	33167921	2880	2883	O
assessment	33167921	2884	2894	O
of	33167921	2895	2897	O
the	33167921	2898	2901	O
experimental	33167921	2902	2914	O
treatment	33167921	2915	2924	O
for	33167921	2925	2928	O
stages	33167921	2929	2935	O
I	33167921	2936	2937	O
and	33167921	2938	2941	O
II	33167921	2942	2944	O
.	33167921	2945	2946	O

One	33167921	2947	2950	O
possible	33167921	2951	2959	O
limitation	33167921	2960	2970	O
is	33167921	2971	2973	O
the	33167921	2974	2977	O
lack	33167921	2978	2982	O
of	33167921	2983	2985	O
awareness	33167921	2986	2995	O
of	33167921	2996	2998	O
whether	33167921	2999	3006	O
or	33167921	3007	3009	O
not	33167921	3010	3013	O
this	33167921	3014	3018	O
treatment	33167921	3019	3028	O
would	33167921	3029	3034	O
be	33167921	3035	3037	O
effective	33167921	3038	3047	O
for	33167921	3048	3051	O
other	33167921	3052	3057	O
stages	33167921	3058	3064	O
as	33167921	3065	3067	O
well	33167921	3068	3072	O
as	33167921	3073	3075	O
the	33167921	3076	3079	O
concern	33167921	3080	3087	O
for	33167921	3088	3091	O
proper	33167921	3092	3098	O
hand	33167921	3099	3103	O
cleansing	33167921	3104	3113	O
during	33167921	3114	3120	O
use	33167921	3121	3124	O
of	33167921	3125	3127	O
bandages	33167921	3128	3136	O
,	33167921	3137	3138	O
given	33167921	3139	3144	O
the	33167921	3145	3148	O
current	33167921	3149	3156	O
COVID-19	33167921	3157	3165	O
pandemic	33167921	3166	3174	O
situation	33167921	3175	3184	O
.	33167921	3185	3186	O

BACKGROUND	33167921	3187	3197	O
:	33167921	3198	3199	O
This	33167921	3200	3204	O
trial	33167921	3205	3210	O
was	33167921	3211	3214	O
registered	33167921	3215	3225	O
in	33167921	3226	3228	O
ClinicalTrials.gov	33167921	3229	3247	O
(	33167921	3248	3249	O
NCT03762044	33167921	3250	3261	O
)	33167921	3262	3263	O
.	33167921	3264	3265	O

Date	33167921	3266	3270	O
of	33167921	3271	3273	O
registration	33167921	3274	3286	O
:	33167921	3287	3288	O
23	33167921	3289	3291	O
November	33167921	3292	3300	O
2018	33167921	3301	3305	O
.	33167921	3306	3307	O

Prospectively	33167921	3308	3321	O
Registered	33167921	3322	3332	O
.	33167921	3333	3334	O


Impact	33168097	0	6	O
of	33168097	7	9	O
an	33168097	10	12	O
e	33168097	13	14	O
-	33168097	15	16	O
learning	33168097	17	25	O
module	33168097	26	32	O
on	33168097	33	35	O
personal	33168097	36	44	O
protective	33168097	45	55	O
equipment	33168097	56	65	O
knowledge	33168097	66	75	O
in	33168097	76	78	O
student	33168097	79	86	O
paramedics	33168097	87	97	O
:	33168097	98	99	O
a	33168097	100	101	O
randomized	33168097	102	112	O
controlled	33168097	113	123	O
trial	33168097	124	129	O
.	33168097	130	131	O

Prehospital	33168097	132	143	O
professionals	33168097	144	157	O
such	33168097	158	162	O
as	33168097	163	165	O
emergency	33168097	166	175	O
physicians	33168097	176	186	O
or	33168097	187	189	O
paramedics	33168097	190	200	O
must	33168097	201	205	O
be	33168097	206	208	O
able	33168097	209	213	O
to	33168097	214	216	O
choose	33168097	217	223	O
and	33168097	224	227	O
adequately	33168097	228	238	O
don	33168097	239	242	O
and	33168097	243	246	O
doff	33168097	247	251	O
personal	33168097	252	260	O
protective	33168097	261	271	O
equipment	33168097	272	281	O
(	33168097	282	283	O
PPE	33168097	284	287	O
)	33168097	288	289	O
in	33168097	290	292	O
order	33168097	293	298	O
to	33168097	299	301	O
avoid	33168097	302	307	O
COVID-19	33168097	308	316	O
infection	33168097	317	326	O
.	33168097	327	328	O

Our	33168097	329	332	O
aim	33168097	333	336	O
was	33168097	337	340	O
to	33168097	341	343	O
evaluate	33168097	344	352	O
the	33168097	353	356	O
impact	33168097	357	363	O
of	33168097	364	366	O
a	33168097	367	368	O
gamified	33168097	369	377	O
e	33168097	378	379	O
-	33168097	380	381	O
learning	33168097	382	390	O
module	33168097	391	397	O
on	33168097	398	400	O
adequacy	33168097	401	409	O
of	33168097	410	412	O
PPE	33168097	413	416	O
in	33168097	417	419	O
student	33168097	420	427	O
paramedics	33168097	428	438	O
.	33168097	439	440	O

This	33168097	441	445	O
was	33168097	446	449	O
a	33168097	450	451	O
web	33168097	452	455	O
-	33168097	456	457	O
based	33168097	458	463	O
,	33168097	464	465	O
randomized	33168097	466	476	O
1:1	33168097	477	480	O
,	33168097	481	482	O
parallel	33168097	483	491	O
-	33168097	492	493	O
group	33168097	494	499	O
,	33168097	500	501	O
triple	33168097	502	508	O
-	33168097	509	510	O
blind	33168097	511	516	O
controlled	33168097	517	527	O
trial	33168097	528	533	O
.	33168097	534	535	O

Student	33168097	536	543	O
paramedics	33168097	544	554	O
from	33168097	555	559	O
three	33168097	560	565	O
Swiss	33168097	566	571	O
schools	33168097	572	579	O
were	33168097	580	584	O
invited	33168097	585	592	O
to	33168097	593	595	O
participate	33168097	596	607	O
.	33168097	608	609	O

They	33168097	610	614	O
were	33168097	615	619	O
informed	33168097	620	628	O
they	33168097	629	633	O
would	33168097	634	639	O
be	33168097	640	642	O
presented	33168097	643	652	O
with	33168097	653	657	O
both	33168097	658	662	O
an	33168097	663	665	O
e	33168097	666	667	O
-	33168097	668	669	O
learning	33168097	670	678	O
module	33168097	679	685	O
and	33168097	686	689	O
an	33168097	690	692	O
abridged	33168097	693	701	O
version	33168097	702	709	O
of	33168097	710	712	O
the	33168097	713	716	O
current	33168097	717	724	O
regional	33168097	725	733	O
prehospital	33168097	734	745	O
COVID-19	33168097	746	754	O
guidelines	33168097	755	765	O
,	33168097	766	767	O
albeit	33168097	768	774	O
not	33168097	775	778	O
in	33168097	779	781	O
which	33168097	782	787	O
order	33168097	788	793	O
.	33168097	794	795	O

After	33168097	796	801	O
a	33168097	802	803	O
set	33168097	804	807	O
of	33168097	808	810	O
22	33168097	811	813	O
questions	33168097	814	823	O
designed	33168097	824	832	O
to	33168097	833	835	O
assess	33168097	836	842	O
baseline	33168097	843	851	O
knowledge	33168097	852	861	O
,	33168097	862	863	O
the	33168097	864	867	O
control	33168097	868	875	O
group	33168097	876	881	O
was	33168097	882	885	O
shown	33168097	886	891	O
the	33168097	892	895	O
guidelines	33168097	896	906	O
before	33168097	907	913	O
answering	33168097	914	923	O
a	33168097	924	925	O
set	33168097	926	929	O
of	33168097	930	932	O
14	33168097	933	935	O
post	33168097	936	940	O
-	33168097	941	942	O
intervention	33168097	943	955	O
questions	33168097	956	965	O
.	33168097	966	967	O

The	33168097	968	971	O
e	33168097	972	973	O
-	33168097	974	975	O
learning	33168097	976	984	O
group	33168097	985	990	O
was	33168097	991	994	O
shown	33168097	995	1000	O
the	33168097	1001	1004	O
gamified	33168097	1005	1013	O
e	33168097	1014	1015	O
-	33168097	1016	1017	O
learning	33168097	1018	1026	O
module	33168097	1027	1033	O
right	33168097	1034	1039	O
after	33168097	1040	1045	O
the	33168097	1046	1049	O
guidelines	33168097	1050	1060	O
,	33168097	1061	1062	O
and	33168097	1063	1066	O
before	33168097	1067	1073	O
answering	33168097	1074	1083	O
post	33168097	1084	1088	O
-	33168097	1089	1090	O
intervention	33168097	1091	1103	O
questions	33168097	1104	1113	O
.	33168097	1114	1115	O

The	33168097	1116	1119	O
primary	33168097	1120	1127	O
outcome	33168097	1128	1135	O
was	33168097	1136	1139	O
the	33168097	1140	1143	O
difference	33168097	1144	1154	O
in	33168097	1155	1157	O
the	33168097	1158	1161	O
percentage	33168097	1162	1172	O
of	33168097	1173	1175	O
adequate	33168097	1176	1184	O
choices	33168097	1185	1192	O
of	33168097	1193	1195	O
PPE	33168097	1196	1199	O
before	33168097	1200	1206	O
and	33168097	1207	1210	O
after	33168097	1211	1216	O
the	33168097	1217	1220	O
intervention	33168097	1221	1233	O
.	33168097	1234	1235	O

The	33168097	1236	1239	O
participation	33168097	1240	1253	O
rate	33168097	1254	1258	O
was	33168097	1259	1262	O
of	33168097	1263	1265	O
71	33168097	1266	1268	O
%	33168097	1269	1270	O
(	33168097	1271	1272	O
98/138	33168097	1273	1279	O
)	33168097	1280	1281	O
.	33168097	1282	1283	O

A	33168097	1284	1285	O
total	33168097	1286	1291	O
of	33168097	1292	1294	O
90	33168097	1295	1297	O
answer	33168097	1298	1304	O
sets	33168097	1305	1309	O
was	33168097	1310	1313	O
analyzed	33168097	1314	1322	O
.	33168097	1323	1324	O

Adequate	33168097	1325	1333	O
choice	33168097	1334	1340	O
of	33168097	1341	1343	O
PPE	33168097	1344	1347	O
increased	33168097	1348	1357	O
significantly	33168097	1358	1371	O
both	33168097	1372	1376	O
in	33168097	1377	1379	O
the	33168097	1380	1383	O
control	33168097	1384	1391	O
(	33168097	1392	1393	O
50	33168097	1394	1396	O
%	33168097	1397	1398	O
[	33168097	1399	1400	O
33;83	33168097	1401	1406	O
]	33168097	1407	1408	O
vs	33168097	1409	1411	O
25	33168097	1412	1414	O
%	33168097	1415	1416	O
[	33168097	1417	1418	O
25;50	33168097	1419	1424	O
]	33168097	1425	1426	O
,	33168097	1427	1428	O
P	33168097	1429	1430	O
=	33168097	1433	1434	O
.013	33168097	1437	1441	O
)	33168097	1442	1443	O
and	33168097	1444	1447	O
in	33168097	1448	1450	O
the	33168097	1451	1454	O
e	33168097	1455	1456	O
-	33168097	1457	1458	O
learning	33168097	1459	1467	O
group	33168097	1468	1473	O
(	33168097	1474	1475	O
67	33168097	1476	1478	O
%	33168097	1479	1480	O
[	33168097	1481	1482	O
50;83	33168097	1483	1488	O
]	33168097	1489	1490	O
vs	33168097	1491	1493	O
25	33168097	1494	1496	O
%	33168097	1497	1498	O
[	33168097	1499	1500	O
25;50	33168097	1501	1506	O
]	33168097	1507	1508	O
,	33168097	1509	1510	O
P	33168097	1511	1512	O
=	33168097	1515	1516	O
.001	33168097	1519	1523	O
)	33168097	1524	1525	O
following	33168097	1526	1535	O
the	33168097	1536	1539	O
intervention	33168097	1540	1552	O
.	33168097	1553	1554	O

Though	33168097	1555	1561	O
the	33168097	1562	1565	O
median	33168097	1566	1572	O
of	33168097	1573	1575	O
the	33168097	1576	1579	O
difference	33168097	1580	1590	O
was	33168097	1591	1594	O
higher	33168097	1595	1601	O
in	33168097	1602	1604	O
the	33168097	1605	1608	O
e	33168097	1609	1610	O
-	33168097	1611	1612	O
learning	33168097	1613	1621	O
group	33168097	1622	1627	O
,	33168097	1628	1629	O
there	33168097	1630	1635	O
was	33168097	1636	1639	O
no	33168097	1640	1642	O
statistically	33168097	1643	1656	O
significant	33168097	1657	1668	O
superiority	33168097	1669	1680	O
over	33168097	1681	1685	O
the	33168097	1686	1689	O
control	33168097	1690	1697	O
(	33168097	1698	1699	O
33	33168097	1700	1702	O
%	33168097	1703	1704	O
[	33168097	1705	1706	O
0;58	33168097	1707	1711	O
]	33168097	1712	1713	O
vs	33168097	1714	1716	O
17	33168097	1717	1719	O
%	33168097	1720	1721	O
[	33168097	1722	1723	O
-	33168097	1724	1725	O
17;42	33168097	1728	1733	O
]	33168097	1734	1735	O
,	33168097	1736	1737	O
P	33168097	1738	1739	O
=	33168097	1742	1743	O
.087	33168097	1746	1750	O
)	33168097	1751	1752	O
.	33168097	1753	1754	O

The	33168097	1755	1758	O
e	33168097	1759	1760	O
-	33168097	1761	1762	O
learning	33168097	1763	1771	O
module	33168097	1772	1778	O
was	33168097	1779	1782	O
of	33168097	1783	1785	O
greatest	33168097	1786	1794	O
benefit	33168097	1795	1802	O
in	33168097	1803	1805	O
the	33168097	1806	1809	O
subgroup	33168097	1810	1818	O
of	33168097	1819	1821	O
student	33168097	1822	1829	O
paramedics	33168097	1830	1840	O
who	33168097	1841	1844	O
were	33168097	1845	1849	O
actively	33168097	1850	1858	O
working	33168097	1859	1866	O
in	33168097	1867	1869	O
an	33168097	1870	1872	O
ambulance	33168097	1873	1882	O
company	33168097	1883	1890	O
(	33168097	1891	1892	O
42	33168097	1893	1895	O
%	33168097	1896	1897	O
[	33168097	1898	1899	O
8;58	33168097	1900	1904	O
]	33168097	1905	1906	O
vs	33168097	1907	1909	O
25	33168097	1910	1912	O
%	33168097	1913	1914	O
[	33168097	1915	1916	O
-	33168097	1917	1918	O
17;42	33168097	1921	1926	O
]	33168097	1927	1928	O
,	33168097	1929	1930	O
P	33168097	1931	1932	O
=	33168097	1935	1936	O
0.021	33168097	1939	1944	O
)	33168097	1945	1946	O
.	33168097	1947	1948	O

There	33168097	1949	1954	O
was	33168097	1955	1958	O
no	33168097	1959	1961	O
significant	33168097	1962	1973	O
effect	33168097	1974	1980	O
in	33168097	1981	1983	O
student	33168097	1984	1991	O
paramedics	33168097	1992	2002	O
who	33168097	2003	2006	O
were	33168097	2007	2011	O
not	33168097	2012	2015	O
actively	33168097	2016	2024	O
working	33168097	2025	2032	O
in	33168097	2033	2035	O
an	33168097	2036	2038	O
ambulance	33168097	2039	2048	O
service	33168097	2049	2056	O
(	33168097	2057	2058	O
0	33168097	2059	2060	O
%	33168097	2061	2062	O
[	33168097	2063	2064	O
-	33168097	2065	2066	O
25;33	33168097	2069	2074	O
]	33168097	2075	2076	O
vs	33168097	2077	2079	O
17	33168097	2080	2082	O
%	33168097	2083	2084	O
[	33168097	2085	2086	O
-	33168097	2087	2088	O
8;50	33168097	2091	2095	O
]	33168097	2096	2097	O
,	33168097	2098	2099	O
P	33168097	2100	2101	O
=	33168097	2104	2105	O
.584	33168097	2108	2112	O
)	33168097	2113	2114	O
.	33168097	2115	2116	O

The	33168097	2117	2120	O
use	33168097	2121	2124	O
of	33168097	2125	2127	O
a	33168097	2128	2129	O
gamified	33168097	2130	2138	O
e	33168097	2139	2140	O
-	33168097	2141	2142	O
learning	33168097	2143	2151	O
module	33168097	2152	2158	O
increases	33168097	2159	2168	O
the	33168097	2169	2172	O
rate	33168097	2173	2177	O
of	33168097	2178	2180	O
adequate	33168097	2181	2189	O
choice	33168097	2190	2196	O
of	33168097	2197	2199	O
PPE	33168097	2200	2203	O
only	33168097	2204	2208	O
among	33168097	2209	2214	O
student	33168097	2215	2222	O
paramedics	33168097	2223	2233	O
actively	33168097	2234	2242	O
working	33168097	2243	2250	O
in	33168097	2251	2253	O
an	33168097	2254	2256	O
ambulance	33168097	2257	2266	O
service	33168097	2267	2274	O
.	33168097	2275	2276	O

In	33168097	2277	2279	O
this	33168097	2280	2284	O
subgroup	33168097	2285	2293	O
,	33168097	2294	2295	O
combining	33168097	2296	2305	O
this	33168097	2306	2310	O
teaching	33168097	2311	2319	O
modality	33168097	2320	2328	O
with	33168097	2329	2333	O
other	33168097	2334	2339	O
interventions	33168097	2340	2353	O
might	33168097	2354	2359	O
help	33168097	2360	2364	O
spare	33168097	2365	2370	O
PPE	33168097	2371	2374	O
and	33168097	2375	2378	O
efficiently	33168097	2379	2390	O
protect	33168097	2391	2398	O
against	33168097	2399	2406	O
COVID-19	33168097	2407	2415	O
infection	33168097	2416	2425	O
.	33168097	2426	2427	O


Zilucoplan	33213529	0	10	O
in	33213529	11	13	O
patients	33213529	14	22	O
with	33213529	23	27	O
acute	33213529	28	33	O
hypoxic	33213529	34	41	O
respiratory	33213529	42	53	O
failure	33213529	54	61	O
due	33213529	62	65	O
to	33213529	66	68	O
COVID-19	33213529	69	77	O
(	33213529	78	79	O
ZILU	33213529	80	84	O
-	33213529	85	86	O
COV	33213529	87	90	O
)	33213529	91	92	O
:	33213529	93	94	O
A	33213529	95	96	O
structured	33213529	97	107	O
summary	33213529	108	115	O
of	33213529	116	118	O
a	33213529	119	120	O
study	33213529	121	126	O
protocol	33213529	127	135	O
for	33213529	136	139	O
a	33213529	140	141	O
randomised	33213529	142	152	O
controlled	33213529	153	163	O
trial	33213529	164	169	O
.	33213529	170	171	O

OBJECTIVE	33213529	172	181	O
:	33213529	182	183	O
Zilucoplan	33213529	184	194	O
(	33213529	195	196	O
complement	33213529	197	207	O
C5	33213529	208	210	O
inhibitor	33213529	211	220	O
)	33213529	221	222	O
has	33213529	223	226	O
profound	33213529	227	235	O
effects	33213529	236	243	O
on	33213529	244	246	O
inhibiting	33213529	247	257	O
acute	33213529	258	263	O
lung	33213529	264	268	O
injury	33213529	269	275	O
post	33213529	276	280	O
COVID-19	33213529	281	289	O
,	33213529	290	291	O
and	33213529	292	295	O
can	33213529	296	299	O
promote	33213529	300	307	O
lung	33213529	308	312	O
repair	33213529	313	319	O
mechanisms	33213529	320	330	O
that	33213529	331	335	O
lead	33213529	336	340	O
to	33213529	341	343	O
improvement	33213529	344	355	O
in	33213529	356	358	O
lung	33213529	359	363	O
oxygenation	33213529	364	375	O
parameters	33213529	376	386	O
.	33213529	387	388	O

The	33213529	389	392	O
purpose	33213529	393	400	O
of	33213529	401	403	O
this	33213529	404	408	O
study	33213529	409	414	O
is	33213529	415	417	O
to	33213529	418	420	O
investigate	33213529	421	432	O
the	33213529	433	436	O
efficacy	33213529	437	445	O
and	33213529	446	449	O
safety	33213529	450	456	O
of	33213529	457	459	O
Zilucoplan	33213529	460	470	O
in	33213529	471	473	O
improving	33213529	474	483	O
oxygenation	33213529	484	495	O
and	33213529	496	499	O
short-	33213529	500	506	O
and	33213529	507	510	O
long	33213529	511	515	O
-	33213529	516	517	O
term	33213529	518	522	O
outcome	33213529	523	530	O
of	33213529	531	533	O
COVID-19	33213529	534	542	O
patients	33213529	543	551	O
with	33213529	552	556	O
acute	33213529	557	562	O
hypoxic	33213529	563	570	O
respiratory	33213529	571	582	O
failure	33213529	583	590	O
.	33213529	591	592	O

METHODS	33213529	593	600	O
:	33213529	601	602	O
This	33213529	603	607	O
is	33213529	608	610	O
a	33213529	611	612	O
phase	33213529	613	618	O
2	33213529	619	620	O
academic	33213529	621	629	O
,	33213529	630	631	O
prospective	33213529	632	643	O
,	33213529	644	645	O
2:1	33213529	646	649	O
randomized	33213529	650	660	O
,	33213529	661	662	O
open	33213529	663	667	O
-	33213529	668	669	O
label	33213529	670	675	O
,	33213529	676	677	O
multi	33213529	678	683	O
-	33213529	684	685	O
center	33213529	686	692	O
interventional	33213529	693	707	O
study	33213529	708	713	O
.	33213529	714	715	O

METHODS	33213529	716	723	O
:	33213529	724	725	O
Adult	33213529	726	731	O
patients	33213529	732	740	O
(	33213529	741	742	O
	33213529	743	744	O
18y	33213529	745	748	O
old	33213529	749	752	O
)	33213529	753	754	O
will	33213529	755	759	O
be	33213529	760	762	O
recruited	33213529	763	772	O
at	33213529	773	775	O
specialized	33213529	776	787	O
COVID-19	33213529	788	796	O
units	33213529	797	802	O
and	33213529	803	806	O
ICUs	33213529	807	811	O
at	33213529	812	814	O
9	33213529	815	816	O
Belgian	33213529	817	824	O
hospitals	33213529	825	834	O
.	33213529	835	836	O

The	33213529	837	840	O
main	33213529	841	845	O
eligibility	33213529	846	857	O
criteria	33213529	858	866	O
are	33213529	867	870	O
as	33213529	871	873	O
follows	33213529	874	881	O
:	33213529	882	883	O
1	33213529	884	885	O
)	33213529	886	887	O
Inclusion	33213529	888	897	O
criteria	33213529	898	906	O
:	33213529	907	908	O
a.	33213529	909	911	O
Recent	33213529	912	918	O
(	33213529	919	920	O
	33213529	921	922	O
6	33213529	923	924	O
days	33213529	925	929	O
and	33213529	930	933	O
	33213529	936	937	O
16	33213529	938	940	O
days	33213529	941	945	O
)	33213529	946	947	O
SARS	33213529	948	952	O
-	33213529	953	954	O
CoV-2	33213529	955	960	O
infection	33213529	961	970	O
.	33213529	971	972	O

b.	33213529	973	975	O
Chest	33213529	976	981	O
CT	33213529	982	984	O
scan	33213529	985	989	O
showing	33213529	990	997	O
bilateral	33213529	998	1007	O
infiltrates	33213529	1008	1019	O
within	33213529	1020	1026	O
the	33213529	1027	1030	O
last	33213529	1031	1035	O
2	33213529	1036	1037	O
days	33213529	1038	1042	O
prior	33213529	1043	1048	O
to	33213529	1049	1051	O
randomisation	33213529	1052	1065	O
.	33213529	1066	1067	O

c.	33213529	1068	1070	O
Acute	33213529	1071	1076	O
hypoxia	33213529	1077	1084	O
(	33213529	1085	1086	O
defined	33213529	1087	1094	O
as	33213529	1095	1097	O
PaO2	33213529	1098	1102	O
/	33213529	1103	1104	O
FiO2	33213529	1105	1109	O
below	33213529	1110	1115	O
350	33213529	1116	1119	O
mmHg	33213529	1120	1124	O
or	33213529	1125	1127	O
SpO2	33213529	1128	1132	O
below	33213529	1133	1138	O
93	33213529	1139	1141	O
%	33213529	1142	1143	O
on	33213529	1144	1146	O
minimal	33213529	1147	1154	O
2	33213529	1155	1156	O
L	33213529	1157	1158	O
/	33213529	1159	1160	O
min	33213529	1161	1164	O
supplemental	33213529	1165	1177	O
oxygen	33213529	1178	1184	O
)	33213529	1185	1186	O
.	33213529	1187	1188	O

d.	33213529	1189	1191	O
Signs	33213529	1192	1197	O
of	33213529	1198	1200	O
cytokine	33213529	1201	1209	O
release	33213529	1210	1217	O
syndrome	33213529	1218	1226	O
characterized	33213529	1227	1240	O
by	33213529	1241	1243	O
either	33213529	1244	1250	O
high	33213529	1251	1255	O
serum	33213529	1256	1261	O
ferritin	33213529	1262	1270	O
,	33213529	1271	1272	O
or	33213529	1273	1275	O
high	33213529	1276	1280	O
D	33213529	1281	1282	O
-	33213529	1283	1284	O
dimers	33213529	1285	1291	O
,	33213529	1292	1293	O
or	33213529	1294	1296	O
high	33213529	1297	1301	O
LDH	33213529	1302	1305	O
or	33213529	1306	1308	O
deep	33213529	1309	1313	O
lymphopenia	33213529	1314	1325	O
or	33213529	1326	1328	O
a	33213529	1329	1330	O
combination	33213529	1331	1342	O
of	33213529	1343	1345	O
those	33213529	1346	1351	O
.	33213529	1352	1353	O

2	33213529	1354	1355	O
)	33213529	1356	1357	O
Exclusion	33213529	1358	1367	O
criteria	33213529	1368	1376	O
:	33213529	1377	1378	O
e.	33213529	1379	1381	O
Mechanical	33213529	1382	1392	O
ventilation	33213529	1393	1404	O
for	33213529	1405	1408	O
more	33213529	1409	1413	O
than	33213529	1414	1418	O
24	33213529	1419	1421	O
hours	33213529	1422	1427	O
prior	33213529	1428	1433	O
to	33213529	1434	1436	O
randomisation	33213529	1437	1450	O
.	33213529	1451	1452	O

f.	33213529	1453	1455	O
Active	33213529	1456	1462	O
bacterial	33213529	1463	1472	O
or	33213529	1473	1475	O
fungal	33213529	1476	1482	O
infection	33213529	1483	1492	O
.	33213529	1493	1494	O

g.	33213529	1495	1497	O
History	33213529	1498	1505	O
of	33213529	1506	1508	O
meningococcal	33213529	1509	1522	O
disease	33213529	1523	1530	O
(	33213529	1531	1532	O
due	33213529	1533	1536	O
to	33213529	1537	1539	O
the	33213529	1540	1543	O
known	33213529	1544	1549	O
high	33213529	1550	1554	O
predisposition	33213529	1555	1569	O
to	33213529	1570	1572	O
invasive	33213529	1573	1581	O
,	33213529	1582	1583	O
often	33213529	1584	1589	O
recurrent	33213529	1590	1599	O
meningococcal	33213529	1600	1613	O
infections	33213529	1614	1624	O
of	33213529	1625	1627	O
individuals	33213529	1628	1639	O
deficient	33213529	1640	1649	O
in	33213529	1650	1652	O
components	33213529	1653	1663	O
of	33213529	1664	1666	O
the	33213529	1667	1670	O
alternative	33213529	1671	1682	O
and	33213529	1683	1686	O
terminal	33213529	1687	1695	O
complement	33213529	1696	1706	O
pathways	33213529	1707	1715	O
)	33213529	1716	1717	O
.	33213529	1718	1719	O

UNASSIGNED	33213529	1720	1730	O
:	33213529	1731	1732	O
Patients	33213529	1733	1741	O
in	33213529	1742	1744	O
the	33213529	1745	1748	O
experimental	33213529	1749	1761	O
arm	33213529	1762	1765	O
will	33213529	1766	1770	O
receive	33213529	1771	1778	O
daily	33213529	1779	1784	O
32,4	33213529	1785	1789	O
mg	33213529	1790	1792	O
Zilucoplan	33213529	1793	1803	O
subcutaneously	33213529	1804	1818	O
and	33213529	1819	1822	O
a	33213529	1823	1824	O
daily	33213529	1825	1830	O
IV	33213529	1831	1833	O
infusion	33213529	1834	1842	O
of	33213529	1843	1845	O
2	33213529	1846	1847	O
g	33213529	1848	1849	O
of	33213529	1850	1852	O
the	33213529	1853	1856	O
antibiotic	33213529	1857	1867	O
ceftriaxone	33213529	1868	1879	O
for	33213529	1880	1883	O
14	33213529	1884	1886	O
days	33213529	1887	1891	O
(	33213529	1892	1893	O
or	33213529	1894	1896	O
until	33213529	1897	1902	O
hospital	33213529	1903	1911	O
discharge	33213529	1912	1921	O
,	33213529	1922	1923	O
whichever	33213529	1924	1933	O
comes	33213529	1934	1939	O
first	33213529	1940	1945	O
)	33213529	1946	1947	O
in	33213529	1948	1950	O
addition	33213529	1951	1959	O
to	33213529	1960	1962	O
standard	33213529	1963	1971	O
of	33213529	1972	1974	O
care	33213529	1975	1979	O
.	33213529	1980	1981	O

These	33213529	1982	1987	O
patients	33213529	1988	1996	O
will	33213529	1997	2001	O
receive	33213529	2002	2009	O
additional	33213529	2010	2020	O
prophylactic	33213529	2021	2033	O
antibiotics	33213529	2034	2045	O
until	33213529	2046	2051	O
14	33213529	2052	2054	O
days	33213529	2055	2059	O
after	33213529	2060	2065	O
the	33213529	2066	2069	O
last	33213529	2070	2074	O
Zilucoplan	33213529	2075	2085	O
dose	33213529	2086	2090	O
:	33213529	2091	2092	O
hospitalized	33213529	2093	2105	O
patients	33213529	2106	2114	O
will	33213529	2115	2119	O
receive	33213529	2120	2127	O
a	33213529	2128	2129	O
daily	33213529	2130	2135	O
IV	33213529	2136	2138	O
infusion	33213529	2139	2147	O
of	33213529	2148	2150	O
2	33213529	2151	2152	O
g	33213529	2153	2154	O
of	33213529	2155	2157	O
ceftriaxone	33213529	2158	2169	O
,	33213529	2170	2171	O
discharged	33213529	2172	2182	O
patients	33213529	2183	2191	O
will	33213529	2192	2196	O
switch	33213529	2197	2203	O
to	33213529	2204	2206	O
daily	33213529	2207	2212	O
500	33213529	2213	2216	O
mg	33213529	2217	2219	O
of	33213529	2220	2222	O
oral	33213529	2223	2227	O
ciprofloxacin	33213529	2228	2241	O
.	33213529	2242	2243	O

The	33213529	2244	2247	O
control	33213529	2248	2255	O
group	33213529	2256	2261	O
will	33213529	2262	2266	O
receive	33213529	2267	2274	O
standard	33213529	2275	2283	O
of	33213529	2284	2286	O
care	33213529	2287	2291	O
and	33213529	2292	2295	O
a	33213529	2296	2297	O
daily	33213529	2298	2303	O
IV	33213529	2304	2306	O
infusion	33213529	2307	2315	O
of	33213529	2316	2318	O
2	33213529	2319	2320	O
g	33213529	2321	2322	O
of	33213529	2323	2325	O
ceftriaxone	33213529	2326	2337	O
for	33213529	2338	2341	O
1	33213529	2342	2343	O
week	33213529	2344	2348	O
(	33213529	2349	2350	O
or	33213529	2351	2353	O
until	33213529	2354	2359	O
hospital	33213529	2360	2368	O
discharge	33213529	2369	2378	O
,	33213529	2379	2380	O
whichever	33213529	2381	2390	O
comes	33213529	2391	2396	O
first	33213529	2397	2402	O
)	33213529	2403	2404	O
,	33213529	2405	2406	O
to	33213529	2407	2409	O
control	33213529	2410	2417	O
for	33213529	2418	2421	O
the	33213529	2422	2425	O
effects	33213529	2426	2433	O
of	33213529	2434	2436	O
antibiotics	33213529	2437	2448	O
on	33213529	2449	2451	O
the	33213529	2452	2455	O
clinical	33213529	2456	2464	O
course	33213529	2465	2471	O
of	33213529	2472	2474	O
COVID-19	33213529	2475	2483	O
.	33213529	2484	2485	O

RESULTS	33213529	2486	2493	O
:	33213529	2494	2495	O
The	33213529	2496	2499	O
primary	33213529	2500	2507	O
endpoint	33213529	2508	2516	O
is	33213529	2517	2519	O
the	33213529	2520	2523	O
improvement	33213529	2524	2535	O
of	33213529	2536	2538	O
oxygenation	33213529	2539	2550	O
as	33213529	2551	2553	O
measured	33213529	2554	2562	O
by	33213529	2563	2565	O
mean	33213529	2566	2570	O
and/or	33213529	2571	2577	O
median	33213529	2578	2584	O
change	33213529	2585	2591	O
from	33213529	2592	2596	O
pre	33213529	2597	2600	O
-	33213529	2601	2602	O
treatment	33213529	2603	2612	O
(	33213529	2613	2614	O
day	33213529	2615	2618	O
1	33213529	2619	2620	O
)	33213529	2621	2622	O
to	33213529	2623	2625	O
post	33213529	2626	2630	O
-	33213529	2631	2632	O
treatment	33213529	2633	2642	O
(	33213529	2643	2644	O
day	33213529	2645	2648	O
6	33213529	2649	2650	O
and	33213529	2651	2654	O
15	33213529	2655	2657	O
or	33213529	2658	2660	O
at	33213529	2661	2663	O
discharge	33213529	2664	2673	O
,	33213529	2674	2675	O
whichever	33213529	2676	2685	O
comes	33213529	2686	2691	O
first	33213529	2692	2697	O
)	33213529	2698	2699	O
in	33213529	2700	2702	O
PaO2	33213529	2703	2707	O
/	33213529	2708	2709	O
FiO2	33213529	2710	2714	O
ratio	33213529	2715	2720	O
,	33213529	2721	2722	O
P(A	33213529	2723	2726	O
-	33213529	2727	2728	O
a)O2	33213529	2729	2733	O
gradient	33213529	2734	2742	O
and	33213529	2743	2746	O
a	33213529	2747	2748	O
/	33213529	2749	2750	O
A	33213529	2751	2752	O
PO2	33213529	2753	2756	O
ratio	33213529	2757	2762	O
.	33213529	2763	2764	O

(	33213529	2765	2766	O
PAO2=	33213529	2767	2772	O
Partial	33213529	2773	2780	O
alveolar	33213529	2781	2789	O
pressure	33213529	2790	2798	O
of	33213529	2799	2801	O
oxygen	33213529	2802	2808	O
,	33213529	2809	2810	O
PaO2	33213529	2811	2815	O
=	33213529	2816	2817	O
partial	33213529	2818	2825	O
arterial	33213529	2826	2834	O
pressure	33213529	2835	2843	O
of	33213529	2844	2846	O
oxygen	33213529	2847	2853	O
,	33213529	2854	2855	O
FiO2	33213529	2856	2860	O
=	33213529	2861	2862	O
Fraction	33213529	2863	2871	O
of	33213529	2872	2874	O
inspired	33213529	2875	2883	O
oxygen	33213529	2884	2890	O
)	33213529	2891	2892	O
.	33213529	2893	2894	O

UNASSIGNED	33213529	2895	2905	O
:	33213529	2906	2907	O
Patients	33213529	2908	2916	O
will	33213529	2917	2921	O
be	33213529	2922	2924	O
randomized	33213529	2925	2935	O
in	33213529	2936	2938	O
a	33213529	2939	2940	O
2:1	33213529	2941	2944	O
ratio	33213529	2945	2950	O
(	33213529	2951	2952	O
Zilucoplan	33213529	2953	2963	O
:	33213529	2964	2965	O
control	33213529	2966	2973	O
)	33213529	2974	2975	O
.	33213529	2976	2977	O

Randomization	33213529	2978	2991	O
will	33213529	2992	2996	O
be	33213529	2997	2999	O
done	33213529	3000	3004	O
using	33213529	3005	3010	O
an	33213529	3011	3013	O
Interactive	33213529	3014	3025	O
Web	33213529	3026	3029	O
Response	33213529	3030	3038	O
System	33213529	3039	3045	O
(	33213529	3046	3047	O
REDCap	33213529	3048	3054	O
)	33213529	3055	3056	O
.	33213529	3057	3058	O

UNASSIGNED	33213529	3059	3069	O
:	33213529	3070	3071	O
In	33213529	3072	3074	O
this	33213529	3075	3079	O
open	33213529	3080	3084	O
-	33213529	3085	3086	O
label	33213529	3087	3092	O
trial	33213529	3093	3098	O
neither	33213529	3099	3106	O
participants	33213529	3107	3119	O
,	33213529	3120	3121	O
caregivers	33213529	3122	3132	O
,	33213529	3133	3134	O
nor	33213529	3135	3138	O
those	33213529	3139	3144	O
assessing	33213529	3145	3154	O
the	33213529	3155	3158	O
outcomes	33213529	3159	3167	O
will	33213529	3168	3172	O
be	33213529	3173	3175	O
blinded	33213529	3176	3183	O
to	33213529	3184	3186	O
group	33213529	3187	3192	O
assignment	33213529	3193	3203	O
.	33213529	3204	3205	O

UNASSIGNED	33213529	3206	3216	O
:	33213529	3217	3218	O
A	33213529	3219	3220	O
total	33213529	3221	3226	O
of	33213529	3227	3229	O
81	33213529	3230	3232	O
patients	33213529	3233	3241	O
will	33213529	3242	3246	O
be	33213529	3247	3249	O
enrolled	33213529	3250	3258	O
:	33213529	3259	3260	O
54	33213529	3261	3263	O
patients	33213529	3264	3272	O
will	33213529	3273	3277	O
be	33213529	3278	3280	O
randomized	33213529	3281	3291	O
to	33213529	3292	3294	O
the	33213529	3295	3298	O
experimental	33213529	3299	3311	O
arm	33213529	3312	3315	O
and	33213529	3316	3319	O
27	33213529	3320	3322	O
patients	33213529	3323	3331	O
to	33213529	3332	3334	O
the	33213529	3335	3338	O
control	33213529	3339	3346	O
arm	33213529	3347	3350	O
.	33213529	3351	3352	O

UNASSIGNED	33213529	3353	3363	O
:	33213529	3364	3365	O
ZILU	33213529	3366	3370	O
-	33213529	3371	3372	O
COV	33213529	3373	3376	O
protocol	33213529	3377	3385	O
Version	33213529	3386	3393	O
4.0	33213529	3394	3397	O
(	33213529	3398	3399	O
June	33213529	3400	3404	O
10	33213529	3405	3407	O
2020	33213529	3408	3412	O
)	33213529	3413	3414	O
.	33213529	3415	3416	O

Participant	33213529	3417	3428	O
recruitment	33213529	3429	3440	O
started	33213529	3441	3448	O
on	33213529	3449	3451	O
June	33213529	3452	3456	O
23	33213529	3457	3459	O
2020	33213529	3460	3464	O
and	33213529	3465	3468	O
is	33213529	3469	3471	O
ongoing	33213529	3472	3479	O
.	33213529	3480	3481	O

Given	33213529	3482	3487	O
the	33213529	3488	3491	O
uncertainty	33213529	3492	3503	O
of	33213529	3504	3506	O
the	33213529	3507	3510	O
pandemic	33213529	3511	3519	O
,	33213529	3520	3521	O
it	33213529	3522	3524	O
is	33213529	3525	3527	O
difficult	33213529	3528	3537	O
to	33213529	3538	3540	O
predict	33213529	3541	3548	O
the	33213529	3549	3552	O
anticipated	33213529	3553	3564	O
end	33213529	3565	3568	O
date	33213529	3569	3573	O
.	33213529	3574	3575	O

BACKGROUND	33213529	3576	3586	O
:	33213529	3587	3588	O
The	33213529	3589	3592	O
trial	33213529	3593	3598	O
was	33213529	3599	3602	O
registered	33213529	3603	3613	O
on	33213529	3614	3616	O
Clinical	33213529	3617	3625	O
Trials.gov	33213529	3626	3636	O
on	33213529	3637	3639	O
May	33213529	3640	3643	O
11th	33213529	3644	3648	O
,	33213529	3649	3650	O
2020	33213529	3651	3655	O
(	33213529	3656	3657	O
ClinicalTrials.gov	33213529	3658	3676	O
Identifier	33213529	3677	3687	O
:	33213529	3688	3689	O
NCT04382755	33213529	3690	3701	O
)	33213529	3702	3703	O
and	33213529	3704	3707	O
on	33213529	3708	3710	O
EudraCT	33213529	3711	3718	O
(	33213529	3719	3720	O
Identifier	33213529	3721	3731	O
:	33213529	3732	3733	O
2020	33213529	3734	3738	O
-	33213529	3739	3740	O
002130	33213529	3741	3747	O
-	33213529	3748	3749	O
33	33213529	3750	3752	O
)	33213529	3753	3754	O
.	33213529	3755	3756	O

UNASSIGNED	33213529	3757	3767	O
:	33213529	3768	3769	O
The	33213529	3770	3773	O
full	33213529	3774	3778	O
protocol	33213529	3779	3787	O
is	33213529	3788	3790	O
attached	33213529	3791	3799	O
as	33213529	3800	3802	O
an	33213529	3803	3805	O
additional	33213529	3806	3816	O
file	33213529	3817	3821	O
,	33213529	3822	3823	O
accessible	33213529	3824	3834	O
from	33213529	3835	3839	O
the	33213529	3840	3843	O
Trials	33213529	3844	3850	O
website	33213529	3851	3858	O
(	33213529	3859	3860	O
Additional	33213529	3861	3871	O
file	33213529	3872	3876	O
1	33213529	3877	3878	O
)	33213529	3879	3880	O
.	33213529	3881	3882	O

In	33213529	3883	3885	O
the	33213529	3886	3889	O
interest	33213529	3890	3898	O
in	33213529	3899	3901	O
expediting	33213529	3902	3912	O
dissemination	33213529	3913	3926	O
of	33213529	3927	3929	O
this	33213529	3930	3934	O
material	33213529	3935	3943	O
,	33213529	3944	3945	O
the	33213529	3946	3949	O
familiar	33213529	3950	3958	O
formatting	33213529	3959	3969	O
has	33213529	3970	3973	O
been	33213529	3974	3978	O
eliminated	33213529	3979	3989	O
;	33213529	3990	3991	O
this	33213529	3992	3996	O
Letter	33213529	3997	4003	O
serves	33213529	4004	4010	O
as	33213529	4011	4013	O
a	33213529	4014	4015	O
summary	33213529	4016	4023	O
of	33213529	4024	4026	O
the	33213529	4027	4030	O
key	33213529	4031	4034	O
elements	33213529	4035	4043	O
of	33213529	4044	4046	O
the	33213529	4047	4050	O
full	33213529	4051	4055	O
protocol	33213529	4056	4064	O
.	33213529	4065	4066	O


Glasgow	33213530	0	7	O
Early	33213530	8	13	O
Treatment	33213530	14	23	O
Arm	33213530	24	27	O
Favirpiravir	33213530	28	40	O
(	33213530	41	42	O
GETAFIX	33213530	43	50	O
)	33213530	51	52	O
for	33213530	53	56	O
adults	33213530	57	63	O
with	33213530	64	68	O
early	33213530	69	74	O
stage	33213530	75	80	O
COVID-19	33213530	81	89	O
:	33213530	90	91	O
A	33213530	92	93	O
structured	33213530	94	104	O
summary	33213530	105	112	O
of	33213530	113	115	O
a	33213530	116	117	O
study	33213530	118	123	O
protocol	33213530	124	132	O
for	33213530	133	136	O
a	33213530	137	138	O
randomised	33213530	139	149	O
controlled	33213530	150	160	O
trial	33213530	161	166	O
.	33213530	167	168	O

OBJECTIVE	33213530	169	178	O
:	33213530	179	180	O
The	33213530	181	184	O
GETAFIX	33213530	185	192	O
trial	33213530	193	198	O
will	33213530	199	203	O
test	33213530	204	208	O
the	33213530	209	212	O
hypothesis	33213530	213	223	O
that	33213530	224	228	O
favipiravir	33213530	229	240	O
is	33213530	241	243	O
a	33213530	244	245	O
more	33213530	246	250	O
effective	33213530	251	260	O
treatment	33213530	261	270	O
for	33213530	271	274	O
COVID-19	33213530	275	283	O
infection	33213530	284	293	O
in	33213530	294	296	O
patients	33213530	297	305	O
who	33213530	306	309	O
have	33213530	310	314	O
early	33213530	315	320	O
stage	33213530	321	326	O
disease	33213530	327	334	O
,	33213530	335	336	O
compared	33213530	337	345	O
to	33213530	346	348	O
current	33213530	349	356	O
standard	33213530	357	365	O
of	33213530	366	368	O
care	33213530	369	373	O
.	33213530	374	375	O

This	33213530	376	380	O
study	33213530	381	386	O
will	33213530	387	391	O
also	33213530	392	396	O
provide	33213530	397	404	O
an	33213530	405	407	O
important	33213530	408	417	O
opportunity	33213530	418	429	O
to	33213530	430	432	O
investigate	33213530	433	444	O
the	33213530	445	448	O
safety	33213530	449	455	O
and	33213530	456	459	O
tolerability	33213530	460	472	O
of	33213530	473	475	O
favipiravir	33213530	476	487	O
,	33213530	488	489	O
the	33213530	490	493	O
pharmacokinetic	33213530	494	509	O
and	33213530	510	513	O
pharmacodynamic	33213530	514	529	O
profile	33213530	530	537	O
of	33213530	538	540	O
this	33213530	541	545	O
drug	33213530	546	550	O
and	33213530	551	554	O
mechanisms	33213530	555	565	O
of	33213530	566	568	O
resistance	33213530	569	579	O
in	33213530	580	582	O
the	33213530	583	586	O
context	33213530	587	594	O
of	33213530	595	597	O
COVID-19	33213530	598	606	O
infection	33213530	607	616	O
,	33213530	617	618	O
as	33213530	619	621	O
well	33213530	622	626	O
as	33213530	627	629	O
the	33213530	630	633	O
effect	33213530	634	640	O
of	33213530	641	643	O
favipiravir	33213530	644	655	O
on	33213530	656	658	O
hospitalisation	33213530	659	674	O
duration	33213530	675	683	O
and	33213530	684	687	O
the	33213530	688	691	O
post	33213530	692	696	O
COVID-19	33213530	697	705	O
health	33213530	706	712	O
and	33213530	713	716	O
psycho	33213530	717	723	O
-	33213530	724	725	O
social	33213530	726	732	O
wellbeing	33213530	733	742	O
of	33213530	743	745	O
patients	33213530	746	754	O
recruited	33213530	755	764	O
to	33213530	765	767	O
the	33213530	768	771	O
study	33213530	772	777	O
.	33213530	778	779	O

METHODS	33213530	780	787	O
:	33213530	788	789	O
GETAFIX	33213530	790	797	O
is	33213530	798	800	O
an	33213530	801	803	O
open	33213530	804	808	O
label	33213530	809	814	O
,	33213530	815	816	O
parallel	33213530	817	825	O
group	33213530	826	831	O
,	33213530	832	833	O
two	33213530	834	837	O
arm	33213530	838	841	O
phase	33213530	842	847	O
II	33213530	848	850	O
/	33213530	851	852	O
III	33213530	853	856	O
randomised	33213530	857	867	O
trial	33213530	868	873	O
with	33213530	874	878	O
1:1	33213530	879	882	O
treatment	33213530	883	892	O
allocation	33213530	893	903	O
ratio	33213530	904	909	O
.	33213530	910	911	O

Patients	33213530	912	920	O
will	33213530	921	925	O
be	33213530	926	928	O
randomised	33213530	929	939	O
to	33213530	940	942	O
one	33213530	943	946	O
of	33213530	947	949	O
two	33213530	950	953	O
arms	33213530	954	958	O
and	33213530	959	962	O
the	33213530	963	966	O
primary	33213530	967	974	O
endpoint	33213530	975	983	O
will	33213530	984	988	O
assess	33213530	989	995	O
the	33213530	996	999	O
superiority	33213530	1000	1011	O
of	33213530	1012	1014	O
favipiravir	33213530	1015	1026	O
plus	33213530	1027	1031	O
standard	33213530	1032	1040	O
treatment	33213530	1041	1050	O
compared	33213530	1051	1059	O
to	33213530	1060	1062	O
standard	33213530	1063	1071	O
treatment	33213530	1072	1081	O
alone	33213530	1082	1087	O
.	33213530	1088	1089	O

METHODS	33213530	1090	1097	O
:	33213530	1098	1099	O
This	33213530	1100	1104	O
trial	33213530	1105	1110	O
will	33213530	1111	1115	O
recruit	33213530	1116	1123	O
adult	33213530	1124	1129	O
patients	33213530	1130	1138	O
with	33213530	1139	1143	O
confirmed	33213530	1144	1153	O
positive	33213530	1154	1162	O
valid	33213530	1163	1168	O
COVID-19	33213530	1169	1177	O
test	33213530	1178	1182	O
,	33213530	1183	1184	O
who	33213530	1185	1188	O
are	33213530	1189	1192	O
not	33213530	1193	1196	O
pregnant	33213530	1197	1205	O
or	33213530	1206	1208	O
breastfeeding	33213530	1209	1222	O
and	33213530	1223	1226	O
have	33213530	1227	1231	O
no	33213530	1232	1234	O
prior	33213530	1235	1240	O
major	33213530	1241	1246	O
co	33213530	1247	1249	O
-	33213530	1250	1251	O
morbidities	33213530	1252	1263	O
.	33213530	1264	1265	O

This	33213530	1266	1270	O
is	33213530	1271	1273	O
a	33213530	1274	1275	O
multi	33213530	1276	1281	O
-	33213530	1282	1283	O
centre	33213530	1284	1290	O
trial	33213530	1291	1296	O
,	33213530	1297	1298	O
patients	33213530	1299	1307	O
will	33213530	1308	1312	O
be	33213530	1313	1315	O
recruited	33213530	1316	1325	O
from	33213530	1326	1330	O
in	33213530	1331	1333	O
-	33213530	1334	1335	O
patients	33213530	1336	1344	O
and	33213530	1345	1348	O
outpatients	33213530	1349	1360	O
from	33213530	1361	1365	O
three	33213530	1366	1371	O
Glasgow	33213530	1372	1379	O
hospitals	33213530	1380	1389	O
:	33213530	1390	1391	O
Royal	33213530	1392	1397	O
Alexandra	33213530	1398	1407	O
Hospital	33213530	1408	1416	O
;	33213530	1417	1418	O
Queen	33213530	1419	1424	O
Elizabeth	33213530	1425	1434	O
University	33213530	1435	1445	O
Hospital	33213530	1446	1454	O
;	33213530	1455	1456	O
and	33213530	1457	1460	O
the	33213530	1461	1464	O
Glasgow	33213530	1465	1472	O
Royal	33213530	1473	1478	O
Infirmary	33213530	1479	1488	O
.	33213530	1489	1490	O

Patients	33213530	1491	1499	O
must	33213530	1500	1504	O
meet	33213530	1505	1509	O
all	33213530	1510	1513	O
of	33213530	1514	1516	O
the	33213530	1517	1520	O
following	33213530	1521	1530	O
criteria	33213530	1531	1539	O
:	33213530	1540	1541	O
1	33213530	1542	1543	O
.	33213530	1544	1545	O
Age	33213530	1546	1549	O
16	33213530	1550	1552	O
or	33213530	1553	1555	O
over	33213530	1556	1560	O
at	33213530	1561	1563	O
time	33213530	1564	1568	O
of	33213530	1569	1571	O
consent	33213530	1572	1579	O
2	33213530	1580	1581	O
.	33213530	1582	1583	O

Exhibiting	33213530	1584	1594	O
symptoms	33213530	1595	1603	O
associated	33213530	1604	1614	O
with	33213530	1615	1619	O
COVID-19	33213530	1620	1628	O
3	33213530	1629	1630	O
.	33213530	1631	1632	O

Positive	33213530	1633	1641	O
for	33213530	1642	1645	O
SARS	33213530	1646	1650	O
-	33213530	1651	1652	O
CoV-2	33213530	1653	1658	O
on	33213530	1659	1661	O
valid	33213530	1662	1667	O
COVID-19	33213530	1668	1676	O
test	33213530	1677	1681	O
4	33213530	1682	1683	O
.	33213530	1684	1685	O

Point	33213530	1686	1691	O
1	33213530	1692	1693	O
,	33213530	1694	1695	O
2	33213530	1696	1697	O
,	33213530	1698	1699	O
3	33213530	1700	1701	O
,	33213530	1702	1703	O
or	33213530	1704	1706	O
4	33213530	1707	1708	O
on	33213530	1709	1711	O
the	33213530	1712	1715	O
WHO	33213530	1716	1719	O
COVID-19	33213530	1720	1728	O
ordinal	33213530	1729	1736	O
severity	33213530	1737	1745	O
scale	33213530	1746	1751	O
at	33213530	1752	1754	O
time	33213530	1755	1759	O
of	33213530	1760	1762	O
randomisation	33213530	1763	1776	O
.	33213530	1777	1778	O
(	33213530	1779	1780	O
Asymptomatic	33213530	1781	1793	O
with	33213530	1794	1798	O
positive	33213530	1799	1807	O
valid	33213530	1808	1813	O
COVID-19	33213530	1814	1822	O
test	33213530	1823	1827	O
,	33213530	1828	1829	O
Symptomatic	33213530	1830	1841	O
Independent	33213530	1842	1853	O
,	33213530	1854	1855	O
Symptomatic	33213530	1856	1867	O
assistance	33213530	1868	1878	O
needed	33213530	1879	1885	O
,	33213530	1886	1887	O
Hospitalized	33213530	1888	1900	O
,	33213530	1901	1902	O
with	33213530	1903	1907	O
no	33213530	1908	1910	O
oxygen	33213530	1911	1917	O
therapy	33213530	1918	1925	O
)	33213530	1926	1927	O
5	33213530	1928	1929	O
.	33213530	1930	1931	O

Have	33213530	1932	1936	O
>	33213530	1937	1938	O
=	33213530	1939	1940	O
10	33213530	1941	1943	O
%	33213530	1944	1945	O
risk	33213530	1946	1950	O
of	33213530	1951	1953	O
death	33213530	1954	1959	O
should	33213530	1960	1966	O
they	33213530	1967	1971	O
be	33213530	1972	1974	O
admitted	33213530	1975	1983	O
to	33213530	1984	1986	O
hospital	33213530	1987	1995	O
as	33213530	1996	1998	O
defined	33213530	1999	2006	O
by	33213530	2007	2009	O
the	33213530	2010	2013	O
ISARIC4C	33213530	2014	2022	O
risk	33213530	2023	2027	O
index	33213530	2028	2033	O
:	33213530	2034	2035	O
https://isaric4c.net/risk	33213530	2036	2061	O
6	33213530	2062	2063	O
.	33213530	2064	2065	O

Able	33213530	2066	2070	O
to	33213530	2071	2073	O
provide	33213530	2074	2081	O
written	33213530	2082	2089	O
informed	33213530	2090	2098	O
consent	33213530	2099	2106	O
7	33213530	2107	2108	O
.	33213530	2109	2110	O

Negative	33213530	2111	2119	O
pregnancy	33213530	2120	2129	O
test	33213530	2130	2134	O
(	33213530	2135	2136	O
women	33213530	2137	2142	O
of	33213530	2143	2145	O
childbearing	33213530	2146	2158	O
potential	33213530	2159	2168	O
*	33213530	2169	2170	O
)	33213530	2171	2172	O
8	33213530	2173	2174	O
.	33213530	2175	2176	O

Able	33213530	2177	2181	O
to	33213530	2182	2184	O
swallow	33213530	2185	2192	O
oral	33213530	2193	2197	O
medication	33213530	2198	2208	O
Patients	33213530	2209	2217	O
will	33213530	2218	2222	O
be	33213530	2223	2225	O
excluded	33213530	2226	2234	O
from	33213530	2235	2239	O
the	33213530	2240	2243	O
trial	33213530	2244	2249	O
if	33213530	2250	2252	O
they	33213530	2253	2257	O
meet	33213530	2258	2262	O
any	33213530	2263	2266	O
of	33213530	2267	2269	O
the	33213530	2270	2273	O
following	33213530	2274	2283	O
criteria	33213530	2284	2292	O
:	33213530	2293	2294	O
1	33213530	2295	2296	O
.	33213530	2297	2298	O

Renal	33213530	2299	2304	O
impairment	33213530	2305	2315	O
requiring	33213530	2316	2325	O
,	33213530	2326	2327	O
or	33213530	2328	2330	O
likely	33213530	2331	2337	O
to	33213530	2338	2340	O
require	33213530	2341	2348	O
,	33213530	2349	2350	O
dialysis	33213530	2351	2359	O
or	33213530	2360	2362	O
haemofiltration	33213530	2363	2378	O
2	33213530	2379	2380	O
.	33213530	2381	2382	O

Pregnant	33213530	2383	2391	O
or	33213530	2392	2394	O
breastfeeding	33213530	2395	2408	O
3	33213530	2409	2410	O
.	33213530	2411	2412	O

Of	33213530	2413	2415	O
child	33213530	2416	2421	O
bearing	33213530	2422	2429	O
potential	33213530	2430	2439	O
(	33213530	2440	2441	O
women	33213530	2442	2447	O
)	33213530	2448	2449	O
,	33213530	2450	2451	O
or	33213530	2452	2454	O
with	33213530	2455	2459	O
female	33213530	2460	2466	O
partners	33213530	2467	2475	O
of	33213530	2476	2478	O
child	33213530	2479	2484	O
bearing	33213530	2485	2492	O
potential	33213530	2493	2502	O
(	33213530	2503	2504	O
men	33213530	2505	2508	O
)	33213530	2509	2510	O
who	33213530	2511	2514	O
do	33213530	2515	2517	O
not	33213530	2518	2521	O
agree	33213530	2522	2527	O
to	33213530	2528	2530	O
use	33213530	2531	2534	O
adequate	33213530	2535	2543	O
contraceptive	33213530	2544	2557	O
measures	33213530	2558	2566	O
for	33213530	2567	2570	O
the	33213530	2571	2574	O
duration	33213530	2575	2583	O
of	33213530	2584	2586	O
the	33213530	2587	2590	O
study	33213530	2591	2596	O
and	33213530	2597	2600	O
for	33213530	2601	2604	O
3	33213530	2605	2606	O
months	33213530	2607	2613	O
after	33213530	2614	2619	O
the	33213530	2620	2623	O
completion	33213530	2624	2634	O
of	33213530	2635	2637	O
study	33213530	2638	2643	O
treatment	33213530	2644	2653	O
4	33213530	2654	2655	O
.	33213530	2656	2657	O

History	33213530	2658	2665	O
of	33213530	2666	2668	O
hereditary	33213530	2669	2679	O
xanthinuria	33213530	2680	2691	O
5	33213530	2692	2693	O
.	33213530	2694	2695	O

Other	33213530	2696	2701	O
patients	33213530	2702	2710	O
judged	33213530	2711	2717	O
unsuitable	33213530	2718	2728	O
by	33213530	2729	2731	O
the	33213530	2732	2735	O
Principal	33213530	2736	2745	O
Investigator	33213530	2746	2758	O
or	33213530	2759	2761	O
sub	33213530	2762	2765	O
-	33213530	2766	2767	O
Investigator	33213530	2768	2780	O
6	33213530	2781	2782	O
.	33213530	2783	2784	O

Known	33213530	2785	2790	O
hypersensitivity	33213530	2791	2807	O
to	33213530	2808	2810	O
favipiravir	33213530	2811	2822	O
,	33213530	2823	2824	O
its	33213530	2825	2828	O
metabolites	33213530	2829	2840	O
or	33213530	2841	2843	O
any	33213530	2844	2847	O
excipients	33213530	2848	2858	O
7	33213530	2859	2860	O
.	33213530	2861	2862	O

Severe	33213530	2863	2869	O
co	33213530	2870	2872	O
-	33213530	2873	2874	O
morbidities	33213530	2875	2886	O
including	33213530	2887	2896	O
:	33213530	2897	2898	O
patients	33213530	2899	2907	O
with	33213530	2908	2912	O
severe	33213530	2913	2919	O
hepatic	33213530	2920	2927	O
impairment	33213530	2928	2938	O
,	33213530	2939	2940	O
defined	33213530	2941	2948	O
as	33213530	2949	2951	O
:	33213530	2952	2953	O
	33213530	2956	2957	O
greater	33213530	2958	2965	O
than	33213530	2966	2970	O
Child	33213530	2971	2976	O
-	33213530	2977	2978	O
Pugh	33213530	2979	2983	O
grade	33213530	2984	2989	O
A	33213530	2990	2991	O
	33213530	2994	2995	O
AST	33213530	2996	2999	O
or	33213530	3000	3002	O
ALT	33213530	3003	3006	O
>	33213530	3007	3008	O
5	33213530	3009	3010	O
x	33213530	3011	3012	O
ULN	33213530	3013	3016	O
	33213530	3019	3020	O
AST	33213530	3021	3024	O
or	33213530	3025	3027	O
ALT	33213530	3028	3031	O
>	33213530	3032	3033	O
3	33213530	3034	3035	O
x	33213530	3036	3037	O
ULN	33213530	3038	3041	O
and	33213530	3042	3045	O
Total	33213530	3046	3051	O
Bilirubin	33213530	3052	3061	O
>	33213530	3062	3063	O
2xULN	33213530	3064	3069	O
8	33213530	3070	3071	O
.	33213530	3072	3073	O

More	33213530	3074	3078	O
than	33213530	3079	3083	O
96	33213530	3084	3086	O
hours	33213530	3087	3092	O
since	33213530	3093	3098	O
first	33213530	3099	3104	O
positive	33213530	3105	3113	O
COVID-19	33213530	3114	3122	O
test	33213530	3123	3127	O
sample	33213530	3128	3134	O
was	33213530	3135	3138	O
taken	33213530	3139	3144	O
9	33213530	3145	3146	O
.	33213530	3147	3148	O

Unable	33213530	3149	3155	O
to	33213530	3156	3158	O
discontinue	33213530	3159	3170	O
contra	33213530	3171	3177	O
-	33213530	3178	3179	O
indicated	33213530	3180	3189	O
concomitant	33213530	3190	3201	O
medications	33213530	3202	3213	O
This	33213530	3214	3218	O
is	33213530	3219	3221	O
a	33213530	3222	3223	O
multi	33213530	3224	3229	O
-	33213530	3230	3231	O
centre	33213530	3232	3238	O
trial	33213530	3239	3244	O
,	33213530	3245	3246	O
patients	33213530	3247	3255	O
will	33213530	3256	3260	O
be	33213530	3261	3263	O
recruited	33213530	3264	3273	O
from	33213530	3274	3278	O
in	33213530	3279	3281	O
-	33213530	3282	3283	O
patients	33213530	3284	3292	O
and	33213530	3293	3296	O
outpatients	33213530	3297	3308	O
from	33213530	3309	3313	O
three	33213530	3314	3319	O
Glasgow	33213530	3320	3327	O
hospitals	33213530	3328	3337	O
:	33213530	3338	3339	O
Royal	33213530	3340	3345	O
Alexandra	33213530	3346	3355	O
Hospital	33213530	3356	3364	O
;	33213530	3365	3366	O
Queen	33213530	3367	3372	O
Elizabeth	33213530	3373	3382	O
University	33213530	3383	3393	O
Hospital	33213530	3394	3402	O
;	33213530	3403	3404	O
and	33213530	3405	3408	O
the	33213530	3409	3412	O
Glasgow	33213530	3413	3420	O
Royal	33213530	3421	3426	O
Infirmary	33213530	3427	3436	O
.	33213530	3437	3438	O

UNASSIGNED	33213530	3439	3449	O
:	33213530	3450	3451	O
Patients	33213530	3452	3460	O
randomised	33213530	3461	3471	O
to	33213530	3472	3474	O
the	33213530	3475	3478	O
experimental	33213530	3479	3491	O
arm	33213530	3492	3495	O
of	33213530	3496	3498	O
GETAFIX	33213530	3499	3506	O
will	33213530	3507	3511	O
receive	33213530	3512	3519	O
standard	33213530	3520	3528	O
treatment	33213530	3529	3538	O
for	33213530	3539	3542	O
COVID-19	33213530	3543	3551	O
at	33213530	3552	3554	O
the	33213530	3555	3558	O
discretion	33213530	3559	3569	O
of	33213530	3570	3572	O
the	33213530	3573	3576	O
treating	33213530	3577	3585	O
clinician	33213530	3586	3595	O
plus	33213530	3596	3600	O
favipiravir	33213530	3601	3612	O
.	33213530	3613	3614	O

These	33213530	3615	3620	O
patients	33213530	3621	3629	O
will	33213530	3630	3634	O
receive	33213530	3635	3642	O
a	33213530	3643	3644	O
loading	33213530	3645	3652	O
dose	33213530	3653	3657	O
of	33213530	3658	3660	O
favipiravir	33213530	3661	3672	O
on	33213530	3673	3675	O
day	33213530	3676	3679	O
1	33213530	3680	3681	O
of	33213530	3682	3684	O
3600	33213530	3685	3689	O
mg	33213530	3690	3692	O
(	33213530	3693	3694	O
1800	33213530	3695	3699	O
mg	33213530	3700	3702	O
12	33213530	3703	3705	O
hours	33213530	3706	3711	O
apart	33213530	3712	3717	O
)	33213530	3718	3719	O
.	33213530	3720	3721	O

On	33213530	3722	3724	O
days	33213530	3725	3729	O
2	33213530	3730	3731	O
-	33213530	3732	3733	O
10	33213530	3734	3736	O
,	33213530	3737	3738	O
patients	33213530	3739	3747	O
in	33213530	3748	3750	O
the	33213530	3751	3754	O
experimental	33213530	3755	3767	O
arm	33213530	3768	3771	O
will	33213530	3772	3776	O
receive	33213530	3777	3784	O
a	33213530	3785	3786	O
maintenance	33213530	3787	3798	O
dose	33213530	3799	3803	O
of	33213530	3804	3806	O
favipiravir	33213530	3807	3818	O
of	33213530	3819	3821	O
800	33213530	3822	3825	O
mg	33213530	3826	3828	O
12	33213530	3829	3831	O
hours	33213530	3832	3837	O
apart	33213530	3838	3843	O
(	33213530	3844	3845	O
total	33213530	3846	3851	O
of	33213530	3852	3854	O
18	33213530	3855	3857	O
doses	33213530	3858	3863	O
)	33213530	3864	3865	O
.	33213530	3866	3867	O

Patients	33213530	3868	3876	O
randomised	33213530	3877	3887	O
to	33213530	3888	3890	O
the	33213530	3891	3894	O
control	33213530	3895	3902	O
arm	33213530	3903	3906	O
of	33213530	3907	3909	O
the	33213530	3910	3913	O
GETAFIX	33213530	3914	3921	O
trial	33213530	3922	3927	O
will	33213530	3928	3932	O
receive	33213530	3933	3940	O
standard	33213530	3941	3949	O
treatment	33213530	3950	3959	O
for	33213530	3960	3963	O
COVID-19	33213530	3964	3972	O
at	33213530	3973	3975	O
the	33213530	3976	3979	O
discretion	33213530	3980	3990	O
of	33213530	3991	3993	O
the	33213530	3994	3997	O
treating	33213530	3998	4006	O
clinician	33213530	4007	4016	O
.	33213530	4017	4018	O

RESULTS	33213530	4019	4026	O
:	33213530	4027	4028	O
The	33213530	4029	4032	O
primary	33213530	4033	4040	O
outcome	33213530	4041	4048	O
being	33213530	4049	4054	O
assessed	33213530	4055	4063	O
in	33213530	4064	4066	O
the	33213530	4067	4070	O
GETAFIX	33213530	4071	4078	O
trial	33213530	4079	4084	O
is	33213530	4085	4087	O
the	33213530	4088	4091	O
efficacy	33213530	4092	4100	O
of	33213530	4101	4103	O
favipiravir	33213530	4104	4115	O
in	33213530	4116	4118	O
addition	33213530	4119	4127	O
to	33213530	4128	4130	O
standard	33213530	4131	4139	O
treatment	33213530	4140	4149	O
in	33213530	4150	4152	O
patients	33213530	4153	4161	O
with	33213530	4162	4166	O
COVID-19	33213530	4167	4175	O
in	33213530	4176	4178	O
reducing	33213530	4179	4187	O
the	33213530	4188	4191	O
severity	33213530	4192	4200	O
of	33213530	4201	4203	O
disease	33213530	4204	4211	O
compared	33213530	4212	4220	O
to	33213530	4221	4223	O
standard	33213530	4224	4232	O
treatment	33213530	4233	4242	O
alone	33213530	4243	4248	O
.	33213530	4249	4250	O

Disease	33213530	4251	4258	O
severity	33213530	4259	4267	O
will	33213530	4268	4272	O
be	33213530	4273	4275	O
assessed	33213530	4276	4284	O
using	33213530	4285	4290	O
WHO	33213530	4291	4294	O
COVID	33213530	4295	4300	O
10	33213530	4301	4303	O
point	33213530	4304	4309	O
ordinal	33213530	4310	4317	O
severity	33213530	4318	4326	O
scale	33213530	4327	4332	O
at	33213530	4333	4335	O
day	33213530	4336	4339	O
15	33213530	4340	4342	O
+	33213530	4343	4344	O
/-	33213530	4345	4347	O
48	33213530	4348	4350	O
hours	33213530	4351	4356	O
.	33213530	4357	4358	O

All	33213530	4359	4362	O
randomised	33213530	4363	4373	O
participants	33213530	4374	4386	O
will	33213530	4387	4391	O
be	33213530	4392	4394	O
followed	33213530	4395	4403	O
up	33213530	4404	4406	O
until	33213530	4407	4412	O
death	33213530	4413	4418	O
or	33213530	4419	4421	O
60	33213530	4422	4424	O
days	33213530	4425	4429	O
post	33213530	4430	4434	O
-	33213530	4435	4436	O
randomisation	33213530	4437	4450	O
(	33213530	4451	4452	O
whichever	33213530	4453	4462	O
is	33213530	4463	4465	O
sooner	33213530	4466	4472	O
)	33213530	4473	4474	O
.	33213530	4475	4476	O

UNASSIGNED	33213530	4477	4487	O
:	33213530	4488	4489	O
Patients	33213530	4490	4498	O
will	33213530	4499	4503	O
be	33213530	4504	4506	O
randomised	33213530	4507	4517	O
1:1	33213530	4518	4521	O
to	33213530	4522	4524	O
the	33213530	4525	4528	O
experimental	33213530	4529	4541	O
versus	33213530	4542	4548	O
control	33213530	4549	4556	O
arm	33213530	4557	4560	O
using	33213530	4561	4566	O
computer	33213530	4567	4575	O
generated	33213530	4576	4585	O
random	33213530	4586	4592	O
sequence	33213530	4593	4601	O
allocation	33213530	4602	4612	O
.	33213530	4613	4614	O

A	33213530	4615	4616	O
minimisation	33213530	4617	4629	O
algorithm	33213530	4630	4639	O
incorporating	33213530	4640	4653	O
a	33213530	4654	4655	O
random	33213530	4656	4662	O
component	33213530	4663	4672	O
will	33213530	4673	4677	O
be	33213530	4678	4680	O
used	33213530	4681	4685	O
to	33213530	4686	4688	O
allocate	33213530	4689	4697	O
patients	33213530	4698	4706	O
.	33213530	4707	4708	O

The	33213530	4709	4712	O
factors	33213530	4713	4720	O
used	33213530	4721	4725	O
in	33213530	4726	4728	O
the	33213530	4729	4732	O
minimisation	33213530	4733	4745	O
will	33213530	4746	4750	O
be	33213530	4751	4753	O
:	33213530	4754	4755	O
site	33213530	4756	4760	O
,	33213530	4761	4762	O
age	33213530	4763	4766	O
(	33213530	4767	4768	O
16	33213530	4769	4771	O
-	33213530	4772	4773	O
50/51	33213530	4774	4779	O
-	33213530	4780	4781	O
70/71	33213530	4782	4787	O
+	33213530	4788	4789	O
)	33213530	4790	4791	O
,	33213530	4792	4793	O
history	33213530	4794	4801	O
of	33213530	4802	4804	O
hypertension	33213530	4805	4817	O
or	33213530	4818	4820	O
currently	33213530	4821	4830	O
obsess	33213530	4831	4837	O
(	33213530	4838	4839	O
BMI>30	33213530	4840	4846	O
or	33213530	4847	4849	O
obesity	33213530	4850	4857	O
clinically	33213530	4858	4868	O
evident	33213530	4869	4876	O
;	33213530	4877	4878	O
yes	33213530	4879	4882	O
/	33213530	4883	4884	O
no	33213530	4885	4887	O
)	33213530	4888	4889	O
,	33213530	4890	4891	O
7	33213530	4892	4893	O
days	33213530	4894	4898	O
duration	33213530	4899	4907	O
of	33213530	4908	4910	O
symptoms	33213530	4911	4919	O
(	33213530	4920	4921	O
yes	33213530	4922	4925	O
/	33213530	4926	4927	O
no	33213530	4928	4930	O
/	33213530	4931	4932	O
unknown	33213530	4933	4940	O
)	33213530	4941	4942	O
,	33213530	4943	4944	O
sex	33213530	4945	4948	O
(	33213530	4949	4950	O
male	33213530	4951	4955	O
/	33213530	4956	4957	O
female	33213530	4958	4964	O
)	33213530	4965	4966	O
,	33213530	4967	4968	O
WHO	33213530	4969	4972	O
COVID-19	33213530	4973	4981	O
ordinal	33213530	4982	4989	O
severity	33213530	4990	4998	O
score	33213530	4999	5004	O
at	33213530	5005	5007	O
baseline	33213530	5008	5016	O
(	33213530	5017	5018	O
1/2or	33213530	5019	5024	O
3/4	33213530	5025	5028	O
)	33213530	5029	5030	O
.	33213530	5031	5032	O

UNASSIGNED	33213530	5033	5043	O
:	33213530	5044	5045	O
No	33213530	5046	5048	O
blinding	33213530	5049	5057	O
will	33213530	5058	5062	O
be	33213530	5063	5065	O
used	33213530	5066	5070	O
in	33213530	5071	5073	O
the	33213530	5074	5077	O
GETAFIX	33213530	5078	5085	O
trial	33213530	5086	5091	O
.	33213530	5092	5093	O

Both	33213530	5094	5098	O
participants	33213530	5099	5111	O
and	33213530	5112	5115	O
those	33213530	5116	5121	O
assessing	33213530	5122	5131	O
outcomes	33213530	5132	5140	O
will	33213530	5141	5145	O
be	33213530	5146	5148	O
aware	33213530	5149	5154	O
of	33213530	5155	5157	O
treatment	33213530	5158	5167	O
allocation	33213530	5168	5178	O
.	33213530	5179	5180	O

UNASSIGNED	33213530	5181	5191	O
:	33213530	5192	5193	O
In	33213530	5194	5196	O
total	33213530	5197	5202	O
,	33213530	5203	5204	O
302	33213530	5205	5208	O
patients	33213530	5209	5217	O
will	33213530	5218	5222	O
be	33213530	5223	5225	O
randomised	33213530	5226	5236	O
to	33213530	5237	5239	O
the	33213530	5240	5243	O
GETAFIX	33213530	5244	5251	O
trial	33213530	5252	5257	O
:	33213530	5258	5259	O
151	33213530	5260	5263	O
to	33213530	5264	5266	O
the	33213530	5267	5270	O
control	33213530	5271	5278	O
arm	33213530	5279	5282	O
and	33213530	5283	5286	O
151	33213530	5287	5290	O
to	33213530	5291	5293	O
the	33213530	5294	5297	O
experimental	33213530	5298	5310	O
arm	33213530	5311	5314	O
.	33213530	5315	5316	O

There	33213530	5317	5322	O
will	33213530	5323	5327	O
be	33213530	5328	5330	O
an	33213530	5331	5333	O
optional	33213530	5334	5342	O
consent	33213530	5343	5350	O
form	33213530	5351	5355	O
for	33213530	5356	5359	O
patients	33213530	5360	5368	O
who	33213530	5369	5372	O
may	33213530	5373	5376	O
want	33213530	5377	5381	O
to	33213530	5382	5384	O
contribute	33213530	5385	5395	O
to	33213530	5396	5398	O
more	33213530	5399	5403	O
frequent	33213530	5404	5412	O
PK	33213530	5413	5415	O
and	33213530	5416	5419	O
PD	33213530	5420	5422	O
sampling	33213530	5423	5431	O
.	33213530	5432	5433	O

The	33213530	5434	5437	O
maximum	33213530	5438	5445	O
number	33213530	5446	5452	O
of	33213530	5453	5455	O
patients	33213530	5456	5464	O
who	33213530	5465	5468	O
will	33213530	5469	5473	O
undergo	33213530	5474	5481	O
this	33213530	5482	5486	O
testing	33213530	5487	5494	O
will	33213530	5495	5499	O
be	33213530	5500	5502	O
sixteen	33213530	5503	5510	O
,	33213530	5511	5512	O
eight	33213530	5513	5518	O
males	33213530	5519	5524	O
and	33213530	5525	5528	O
eight	33213530	5529	5534	O
females	33213530	5535	5542	O
.	33213530	5543	5544	O

This	33213530	5545	5549	O
option	33213530	5550	5556	O
will	33213530	5557	5561	O
be	33213530	5562	5564	O
offered	33213530	5565	5572	O
to	33213530	5573	5575	O
all	33213530	5576	5579	O
patients	33213530	5580	5588	O
who	33213530	5589	5592	O
are	33213530	5593	5596	O
being	33213530	5597	5602	O
treated	33213530	5603	5610	O
in	33213530	5611	5613	O
hospital	33213530	5614	5622	O
at	33213530	5623	5625	O
the	33213530	5626	5629	O
time	33213530	5630	5634	O
of	33213530	5635	5637	O
taking	33213530	5638	5644	O
informed	33213530	5645	5653	O
consent	33213530	5654	5661	O
,	33213530	5662	5663	O
however	33213530	5664	5671	O
only	33213530	5672	5676	O
patients	33213530	5677	5685	O
in	33213530	5686	5688	O
the	33213530	5689	5692	O
experimental	33213530	5693	5705	O
arm	33213530	5706	5709	O
of	33213530	5710	5712	O
the	33213530	5713	5716	O
trial	33213530	5717	5722	O
will	33213530	5723	5727	O
be	33213530	5728	5730	O
able	33213530	5731	5735	O
to	33213530	5736	5738	O
undergo	33213530	5739	5746	O
this	33213530	5747	5751	O
testing	33213530	5752	5759	O
.	33213530	5760	5761	O

UNASSIGNED	33213530	5762	5772	O
:	33213530	5773	5774	O
The	33213530	5775	5778	O
current	33213530	5779	5786	O
GETAFIX	33213530	5787	5794	O
protocol	33213530	5795	5803	O
is	33213530	5804	5806	O
version	33213530	5807	5814	O
4.0	33213530	5815	5818	O
12th	33213530	5819	5823	O
September	33213530	5824	5833	O
2020	33213530	5834	5838	O
.	33213530	5839	5840	O

GETAFIX	33213530	5841	5848	O
opened	33213530	5849	5855	O
to	33213530	5856	5858	O
recruitment	33213530	5859	5870	O
on	33213530	5871	5873	O
26th	33213530	5874	5878	O
October	33213530	5879	5886	O
2020	33213530	5887	5891	O
and	33213530	5892	5895	O
will	33213530	5896	5900	O
recruit	33213530	5901	5908	O
patients	33213530	5909	5917	O
over	33213530	5918	5922	O
a	33213530	5923	5924	O
period	33213530	5925	5931	O
of	33213530	5932	5934	O
approximately	33213530	5935	5948	O
six	33213530	5949	5952	O
months	33213530	5953	5959	O
.	33213530	5960	5961	O

BACKGROUND	33213530	5962	5972	O
:	33213530	5973	5974	O
GETAFIX	33213530	5975	5982	O
was	33213530	5983	5986	O
registered	33213530	5987	5997	O
on	33213530	5998	6000	O
the	33213530	6001	6004	O
European	33213530	6005	6013	O
Union	33213530	6014	6019	O
Drug	33213530	6020	6024	O
Regulating	33213530	6025	6035	O
Authorities	33213530	6036	6047	O
Clinical	33213530	6048	6056	O
Trials	33213530	6057	6063	O
(	33213530	6064	6065	O
EudraCT	33213530	6066	6073	O
)	33213530	6074	6075	O
Database	33213530	6076	6084	O
on	33213530	6085	6087	O
15th	33213530	6088	6092	O
April	33213530	6093	6098	O
2020	33213530	6099	6103	O
;	33213530	6104	6105	O
Reference	33213530	6106	6115	O
number	33213530	6116	6122	O
2020	33213530	6123	6127	O
-	33213530	6128	6129	O
001904	33213530	6130	6136	O
-	33213530	6137	6138	O
41	33213530	6139	6141	O
(	33213530	6142	6143	O
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020	33213530	6144	6203	O
-	33213530	6203	6204	O
001904	33213530	6204	6210	O
-	33213530	6210	6211	O
41/GB	33213530	6211	6216	O
)	33213530	6217	6218	O
.	33213530	6219	6220	O

GETAFIX	33213530	6221	6228	O
was	33213530	6229	6232	O
registered	33213530	6233	6243	O
on	33213530	6244	6246	O
ISRCTN	33213530	6247	6253	O
on	33213530	6254	6256	O
7th	33213530	6257	6260	O
September	33213530	6261	6270	O
2020	33213530	6271	6275	O
;	33213530	6276	6277	O
Reference	33213530	6278	6287	O
number	33213530	6288	6294	O
ISRCTN31062548	33213530	6295	6309	O
(	33213530	6310	6311	O
https://www.isrctn.com/ISRCTN31062548	33213530	6312	6349	O
)	33213530	6350	6351	O
.	33213530	6352	6353	O

UNASSIGNED	33213530	6354	6364	O
:	33213530	6365	6366	O
The	33213530	6367	6370	O
full	33213530	6371	6375	O
protocol	33213530	6376	6384	O
is	33213530	6385	6387	O
attached	33213530	6388	6396	O
as	33213530	6397	6399	O
an	33213530	6400	6402	O
additional	33213530	6403	6413	O
file	33213530	6414	6418	O
,	33213530	6419	6420	O
accessible	33213530	6421	6431	O
from	33213530	6432	6436	O
the	33213530	6437	6440	O
Trials	33213530	6441	6447	O
website	33213530	6448	6455	O
(	33213530	6456	6457	O
Additional	33213530	6458	6468	O
file	33213530	6469	6473	O
1	33213530	6474	6475	O
)	33213530	6476	6477	O
.	33213530	6478	6479	O

In	33213530	6480	6482	O
the	33213530	6483	6486	O
interest	33213530	6487	6495	O
in	33213530	6496	6498	O
expediting	33213530	6499	6509	O
dissemination	33213530	6510	6523	O
of	33213530	6524	6526	O
this	33213530	6527	6531	O
material	33213530	6532	6540	O
,	33213530	6541	6542	O
the	33213530	6543	6546	O
familiar	33213530	6547	6555	O
formatting	33213530	6556	6566	O
has	33213530	6567	6570	O
been	33213530	6571	6575	O
eliminated	33213530	6576	6586	O
;	33213530	6587	6588	O
this	33213530	6589	6593	O
Letter	33213530	6594	6600	O
serves	33213530	6601	6607	O
as	33213530	6608	6610	O
a	33213530	6611	6612	O
summary	33213530	6613	6620	O
of	33213530	6621	6623	O
the	33213530	6624	6627	O
key	33213530	6628	6631	O
elements	33213530	6632	6640	O
of	33213530	6641	6643	O
the	33213530	6644	6647	O
full	33213530	6648	6652	O
protocol	33213530	6653	6661	O
.	33213530	6662	6663	O

The	33213530	6664	6667	O
study	33213530	6668	6673	O
protocol	33213530	6674	6682	O
has	33213530	6683	6686	O
been	33213530	6687	6691	O
reported	33213530	6692	6700	O
in	33213530	6701	6703	O
accordance	33213530	6704	6714	O
with	33213530	6715	6719	O
the	33213530	6720	6723	O
Standard	33213530	6724	6732	O
Protocol	33213530	6733	6741	O
Items	33213530	6742	6747	O
:	33213530	6748	6749	O
Recommendations	33213530	6750	6765	O
for	33213530	6766	6769	O
Clinical	33213530	6770	6778	O
Interventional	33213530	6779	6793	O
Trials	33213530	6794	6800	O
(	33213530	6801	6802	O
SPIRIT	33213530	6803	6809	O
)	33213530	6810	6811	O
guidelines	33213530	6812	6822	O
(	33213530	6823	6824	O
see	33213530	6825	6828	O
Additional	33213530	6829	6839	O
file	33213530	6840	6844	O
2	33213530	6845	6846	O
)	33213530	6847	6848	O
.	33213530	6849	6850	O


Interferon	33225960	0	10	O
-1a	33225960	11	15	O
(	33225960	16	17	O
IFN-1a	33225960	18	25	O
)	33225960	26	27	O
in	33225960	28	30	O
COVID-19	33225960	31	39	O
patients	33225960	40	48	O
(	33225960	49	50	O
INTERCOP	33225960	51	59	O
)	33225960	60	61	O
:	33225960	62	63	O
study	33225960	64	69	O
protocol	33225960	70	78	O
for	33225960	79	82	O
a	33225960	83	84	O
randomized	33225960	85	95	O
controlled	33225960	96	106	O
trial	33225960	107	112	O
.	33225960	113	114	O

BACKGROUND	33225960	115	125	O
:	33225960	126	127	O
Pharmacological	33225960	128	143	O
therapies	33225960	144	153	O
of	33225960	154	156	O
proven	33225960	157	163	O
efficacy	33225960	164	172	O
in	33225960	173	175	O
coronavirus	33225960	176	187	O
disease	33225960	188	195	O
2019	33225960	196	200	O
(	33225960	201	202	O
COVID-19	33225960	203	211	O
)	33225960	212	213	O
are	33225960	214	217	O
still	33225960	218	223	O
lacking	33225960	224	231	O
.	33225960	232	233	O

We	33225960	234	236	O
have	33225960	237	241	O
identified	33225960	242	252	O
IFN-1a	33225960	253	260	O
as	33225960	261	263	O
the	33225960	264	267	O
most	33225960	268	272	O
promising	33225960	273	282	O
drug	33225960	283	287	O
to	33225960	288	290	O
be	33225960	291	293	O
repurposed	33225960	294	304	O
for	33225960	305	308	O
COVID-19	33225960	309	317	O
.	33225960	318	319	O

The	33225960	320	323	O
rationale	33225960	324	333	O
relies	33225960	334	340	O
on	33225960	341	343	O
the	33225960	344	347	O
evidence	33225960	348	356	O
of	33225960	357	359	O
IFN	33225960	360	364	O
anti	33225960	365	369	O
-	33225960	370	371	O
viral	33225960	372	377	O
activity	33225960	378	386	O
in	33225960	387	389	O
vitro	33225960	390	395	O
against	33225960	396	403	O
SARS	33225960	404	408	O
-	33225960	409	410	O
CoV-2	33225960	411	416	O
and	33225960	417	420	O
animal	33225960	421	427	O
models	33225960	428	434	O
resembling	33225960	435	445	O
SARS	33225960	446	450	O
-	33225960	451	452	O
CoV-2	33225960	453	458	O
infection	33225960	459	468	O
and	33225960	469	472	O
on	33225960	473	475	O
a	33225960	476	477	O
recent	33225960	478	484	O
clinical	33225960	485	493	O
trial	33225960	494	499	O
where	33225960	500	505	O
IFN	33225960	506	510	O
was	33225960	511	514	O
indicated	33225960	515	524	O
as	33225960	525	527	O
the	33225960	528	531	O
key	33225960	532	535	O
component	33225960	536	545	O
of	33225960	546	548	O
a	33225960	549	550	O
successful	33225960	551	561	O
therapeutic	33225960	562	573	O
combination	33225960	574	585	O
.	33225960	586	587	O

METHODS	33225960	588	595	O
:	33225960	596	597	O
This	33225960	598	602	O
is	33225960	603	605	O
a	33225960	606	607	O
randomized	33225960	608	618	O
,	33225960	619	620	O
controlled	33225960	621	631	O
,	33225960	632	633	O
open	33225960	634	638	O
-	33225960	639	640	O
label	33225960	641	646	O
,	33225960	647	648	O
monocentric	33225960	649	660	O
,	33225960	661	662	O
phase	33225960	663	668	O
II	33225960	669	671	O
trial	33225960	672	677	O
(	33225960	678	679	O
INTERCOP	33225960	680	688	O
trial	33225960	689	694	O
)	33225960	695	696	O
.	33225960	697	698	O

One	33225960	699	702	O
hundred	33225960	703	710	O
twenty	33225960	711	717	O
-	33225960	718	719	O
six	33225960	720	723	O
patients	33225960	724	732	O
with	33225960	733	737	O
positive	33225960	738	746	O
swab	33225960	747	751	O
detection	33225960	752	761	O
of	33225960	762	764	O
SARS	33225960	765	769	O
-	33225960	770	771	O
CoV-2	33225960	772	777	O
,	33225960	778	779	O
radiological	33225960	780	792	O
signs	33225960	793	798	O
of	33225960	799	801	O
pneumonia	33225960	802	811	O
,	33225960	812	813	O
and	33225960	814	817	O
mild	33225960	818	822	O
-	33225960	823	824	O
to	33225960	825	827	O
-	33225960	828	829	O
moderate	33225960	830	838	O
disease	33225960	839	846	O
will	33225960	847	851	O
be	33225960	852	854	O
randomized	33225960	855	865	O
2:1	33225960	866	869	O
to	33225960	870	872	O
IFN-1a	33225960	873	880	O
in	33225960	881	883	O
addition	33225960	884	892	O
to	33225960	893	895	O
standard	33225960	896	904	O
of	33225960	905	907	O
care	33225960	908	912	O
vs	33225960	913	915	O
standard	33225960	916	924	O
of	33225960	925	927	O
care	33225960	928	932	O
alone	33225960	933	938	O
.	33225960	939	940	O

No	33225960	941	943	O
other	33225960	944	949	O
anti	33225960	950	954	O
-	33225960	955	956	O
viral	33225960	957	962	O
drugs	33225960	963	968	O
will	33225960	969	973	O
be	33225960	974	976	O
used	33225960	977	981	O
as	33225960	982	984	O
part	33225960	985	989	O
of	33225960	990	992	O
the	33225960	993	996	O
regimens	33225960	997	1005	O
,	33225960	1006	1007	O
both	33225960	1008	1012	O
in	33225960	1013	1015	O
the	33225960	1016	1019	O
control	33225960	1020	1027	O
and	33225960	1028	1031	O
the	33225960	1032	1035	O
intervention	33225960	1036	1048	O
arms	33225960	1049	1053	O
.	33225960	1054	1055	O

IFN-1a	33225960	1056	1063	O
will	33225960	1064	1068	O
be	33225960	1069	1071	O
administered	33225960	1072	1084	O
subcutaneously	33225960	1085	1099	O
at	33225960	1100	1102	O
the	33225960	1103	1106	O
dose	33225960	1107	1111	O
of	33225960	1112	1114	O
44	33225960	1115	1117	O
mcg	33225960	1118	1121	O
(	33225960	1122	1123	O
equivalent	33225960	1124	1134	O
to	33225960	1135	1137	O
12	33225960	1138	1140	O
million	33225960	1141	1148	O
international	33225960	1149	1162	O
units	33225960	1163	1168	O
)	33225960	1169	1170	O
three	33225960	1171	1176	O
times	33225960	1177	1182	O
per	33225960	1183	1186	O
week	33225960	1187	1191	O
,	33225960	1192	1193	O
at	33225960	1194	1196	O
least	33225960	1197	1202	O
48	33225960	1203	1205	O
h	33225960	1208	1209	O
apart	33225960	1210	1215	O
,	33225960	1216	1217	O
for	33225960	1218	1221	O
a	33225960	1222	1223	O
total	33225960	1224	1229	O
of	33225960	1230	1232	O
2	33225960	1233	1234	O
weeks	33225960	1237	1242	O
.	33225960	1243	1244	O

The	33225960	1245	1248	O
primary	33225960	1249	1256	O
outcome	33225960	1257	1264	O
is	33225960	1265	1267	O
the	33225960	1268	1271	O
time	33225960	1272	1276	O
to	33225960	1277	1279	O
negative	33225960	1280	1288	O
conversion	33225960	1289	1299	O
of	33225960	1300	1302	O
SARS	33225960	1303	1307	O
-	33225960	1308	1309	O
CoV-2	33225960	1310	1315	O
nasopharyngeal	33225960	1316	1330	O
swabs	33225960	1331	1336	O
.	33225960	1337	1338	O

Secondary	33225960	1339	1348	O
outcomes	33225960	1349	1357	O
include	33225960	1358	1365	O
improvement	33225960	1366	1377	O
or	33225960	1378	1380	O
worsening	33225960	1381	1390	O
in	33225960	1391	1393	O
a	33225960	1394	1395	O
clinical	33225960	1396	1404	O
severity	33225960	1405	1413	O
score	33225960	1414	1419	O
measured	33225960	1420	1428	O
on	33225960	1429	1431	O
a	33225960	1432	1433	O
7-point	33225960	1434	1441	O
ordinal	33225960	1442	1449	O
scale	33225960	1450	1455	O
(	33225960	1456	1457	O
including	33225960	1458	1467	O
transfer	33225960	1468	1476	O
to	33225960	1477	1479	O
intensive	33225960	1480	1489	O
care	33225960	1490	1494	O
unit	33225960	1495	1499	O
and	33225960	1500	1503	O
death	33225960	1504	1509	O
)	33225960	1510	1511	O
,	33225960	1512	1513	O
oxygen-	33225960	1514	1521	O
and	33225960	1522	1525	O
ventilator	33225960	1526	1536	O
-	33225960	1537	1538	O
free	33225960	1539	1543	O
days	33225960	1544	1548	O
,	33225960	1549	1550	O
mortality	33225960	1551	1560	O
,	33225960	1561	1562	O
changes	33225960	1563	1570	O
in	33225960	1571	1573	O
pulmonary	33225960	1574	1583	O
computed	33225960	1584	1592	O
tomography	33225960	1593	1603	O
severity	33225960	1604	1612	O
score	33225960	1613	1618	O
,	33225960	1619	1620	O
hospital	33225960	1621	1629	O
stay	33225960	1630	1634	O
duration	33225960	1635	1643	O
,	33225960	1644	1645	O
reduction	33225960	1646	1655	O
of	33225960	1656	1658	O
viral	33225960	1659	1664	O
load	33225960	1665	1669	O
measured	33225960	1670	1678	O
on	33225960	1679	1681	O
nasopharyngeal	33225960	1682	1696	O
swabs	33225960	1697	1702	O
,	33225960	1703	1704	O
number	33225960	1705	1711	O
of	33225960	1712	1714	O
serious	33225960	1715	1722	O
adverse	33225960	1723	1730	O
events	33225960	1731	1737	O
,	33225960	1738	1739	O
and	33225960	1740	1743	O
changes	33225960	1744	1751	O
in	33225960	1752	1754	O
biochemical	33225960	1755	1766	O
markers	33225960	1767	1774	O
of	33225960	1775	1777	O
organ	33225960	1778	1783	O
dysfunction	33225960	1784	1795	O
.	33225960	1796	1797	O

Exploratory	33225960	1798	1809	O
outcomes	33225960	1810	1818	O
include	33225960	1819	1826	O
blood	33225960	1827	1832	O
cell	33225960	1833	1837	O
counts	33225960	1838	1844	O
,	33225960	1845	1846	O
cytokine	33225960	1847	1855	O
and	33225960	1856	1859	O
inflammatory	33225960	1860	1872	O
profile	33225960	1873	1880	O
,	33225960	1881	1882	O
peripheral	33225960	1883	1893	O
mRNA	33225960	1894	1898	O
expression	33225960	1899	1909	O
profiles	33225960	1910	1918	O
of	33225960	1919	1921	O
interferon	33225960	1922	1932	O
-	33225960	1933	1934	O
stimulated	33225960	1935	1945	O
genes	33225960	1946	1951	O
,	33225960	1952	1953	O
and	33225960	1954	1957	O
antibodies	33225960	1958	1968	O
to	33225960	1969	1971	O
SARS	33225960	1972	1976	O
-	33225960	1977	1978	O
CoV-2	33225960	1979	1984	O
and	33225960	1985	1988	O
to	33225960	1989	1991	O
IFN-1a	33225960	1992	1999	O
.	33225960	2000	2001	O

INTERCOP	33225960	2002	2010	O
is	33225960	2011	2013	O
the	33225960	2014	2017	O
first	33225960	2018	2023	O
study	33225960	2024	2029	O
to	33225960	2030	2032	O
specifically	33225960	2033	2045	O
investigate	33225960	2046	2057	O
the	33225960	2058	2061	O
clinical	33225960	2062	2070	O
benefits	33225960	2071	2079	O
of	33225960	2080	2082	O
IFN-1a	33225960	2083	2090	O
in	33225960	2091	2093	O
COVID-19	33225960	2094	2102	O
patients	33225960	2103	2111	O
.	33225960	2112	2113	O

CONCLUSIONS	33225960	2114	2125	O
:	33225960	2126	2127	O
Potential	33225960	2128	2137	O
implications	33225960	2138	2150	O
of	33225960	2151	2153	O
this	33225960	2154	2158	O
trial	33225960	2159	2164	O
are	33225960	2165	2168	O
multifaceted	33225960	2169	2181	O
:	33225960	2182	2183	O
should	33225960	2184	2190	O
the	33225960	2191	2194	O
primary	33225960	2195	2202	O
outcome	33225960	2203	2210	O
be	33225960	2211	2213	O
fulfilled	33225960	2214	2223	O
and	33225960	2224	2227	O
the	33225960	2228	2231	O
treatment	33225960	2232	2241	O
be	33225960	2242	2244	O
safe	33225960	2245	2249	O
,	33225960	2250	2251	O
one	33225960	2252	2255	O
may	33225960	2256	2259	O
envisage	33225960	2260	2268	O
that	33225960	2269	2273	O
IFN-1a	33225960	2274	2281	O
be	33225960	2282	2284	O
used	33225960	2285	2289	O
to	33225960	2290	2292	O
reduce	33225960	2293	2299	O
the	33225960	2300	2303	O
infectivity	33225960	2304	2315	O
of	33225960	2316	2318	O
patients	33225960	2319	2327	O
with	33225960	2328	2332	O
mild	33225960	2333	2337	O
-	33225960	2338	2339	O
to	33225960	2340	2342	O
moderate	33225960	2343	2351	O
disease	33225960	2352	2359	O
.	33225960	2360	2361	O

In	33225960	2362	2364	O
case	33225960	2365	2369	O
IFN-1a	33225960	2370	2377	O
reduced	33225960	2378	2385	O
the	33225960	2386	2389	O
duration	33225960	2390	2398	O
of	33225960	2399	2401	O
hospital	33225960	2402	2410	O
stay	33225960	2411	2415	O
and/or	33225960	2416	2422	O
ameliorated	33225960	2423	2434	O
the	33225960	2435	2438	O
clinical	33225960	2439	2447	O
status	33225960	2448	2454	O
,	33225960	2455	2456	O
it	33225960	2457	2459	O
may	33225960	2460	2463	O
become	33225960	2464	2470	O
a	33225960	2471	2472	O
cornerstone	33225960	2473	2484	O
of	33225960	2485	2487	O
COVID-19	33225960	2488	2496	O
treatment	33225960	2497	2506	O
.	33225960	2507	2508	O

BACKGROUND	33225960	2509	2519	O
:	33225960	2520	2521	O
EudraCT	33225960	2522	2529	O
2020	33225960	2530	2534	O
-	33225960	2535	2536	O
002458	33225960	2537	2543	O
-	33225960	2544	2545	O
25	33225960	2546	2548	O
.	33225960	2549	2550	O

Registered	33225960	2551	2561	O
on	33225960	2562	2564	O
May	33225960	2565	2568	O
11	33225960	2569	2571	O
,	33225960	2572	2573	O
2020	33225960	2574	2578	O
ClinicalTrials.gov	33225960	2579	2597	O
Identifier	33225960	2598	2608	O
:	33225960	2609	2610	O
NCT04449380	33225960	2611	2622	O
.	33225960	2623	2624	O


Safety	33225970	0	6	O
and	33225970	7	10	O
efficacy	33225970	11	19	O
of	33225970	20	22	O
herbal	33225970	23	29	O
extracts	33225970	30	38	O
to	33225970	39	41	O
restore	33225970	42	49	O
respiratory	33225970	50	61	O
health	33225970	62	68	O
and	33225970	69	72	O
improve	33225970	73	80	O
innate	33225970	81	87	O
immunity	33225970	88	96	O
in	33225970	97	99	O
COVID-19	33225970	100	108	O
positive	33225970	109	117	O
patients	33225970	118	126	O
with	33225970	127	131	O
mild	33225970	132	136	O
to	33225970	137	139	O
moderate	33225970	140	148	O
severity	33225970	149	157	O
:	33225970	158	159	O
A	33225970	160	161	O
structured	33225970	162	172	O
summary	33225970	173	180	O
of	33225970	181	183	O
a	33225970	184	185	O
study	33225970	186	191	O
protocol	33225970	192	200	O
for	33225970	201	204	O
a	33225970	205	206	O
randomised	33225970	207	217	O
controlled	33225970	218	228	O
trial	33225970	229	234	O
.	33225970	235	236	O

OBJECTIVE	33225970	237	246	O
:	33225970	247	248	O
Primary	33225970	249	256	O
Objective	33225970	257	266	O
	33225970	267	268	O
To	33225970	269	271	O
assess	33225970	272	278	O
the	33225970	279	282	O
efficacy	33225970	283	291	O
of	33225970	292	294	O
herbal	33225970	295	301	O
extracts	33225970	302	310	O
in	33225970	311	313	O
boosting	33225970	314	322	O
innate	33225970	323	329	O
immunity	33225970	330	338	O
of	33225970	339	341	O
patients	33225970	342	350	O
with	33225970	351	355	O
COVID-19	33225970	356	364	O
infection	33225970	365	374	O
.	33225970	375	376	O

Secondary	33225970	377	386	O
Objectives	33225970	387	397	O
	33225970	398	399	O
To	33225970	400	402	O
assess	33225970	403	409	O
the	33225970	410	413	O
efficacy	33225970	414	422	O
of	33225970	423	425	O
herbal	33225970	426	432	O
extracts	33225970	433	441	O
in	33225970	442	444	O
restoring	33225970	445	454	O
respiratory	33225970	455	466	O
health	33225970	467	473	O
	33225970	474	475	O
To	33225970	476	478	O
assess	33225970	479	485	O
the	33225970	486	489	O
efficacy	33225970	490	498	O
of	33225970	499	501	O
Cap	33225970	502	505	O
.	33225970	506	507	O

IP	33225970	508	510	O
in	33225970	511	513	O
early	33225970	514	519	O
recovery	33225970	520	528	O
of	33225970	529	531	O
patients	33225970	532	540	O
and	33225970	541	544	O
decline	33225970	545	552	O
in	33225970	553	555	O
viral	33225970	556	561	O
load	33225970	562	566	O
	33225970	567	568	O
To	33225970	569	571	O
assess	33225970	572	578	O
the	33225970	579	582	O
safety	33225970	583	589	O
of	33225970	590	592	O
herbal	33225970	593	599	O
extracts	33225970	600	608	O
TRIAL	33225970	609	614	O
DESIGN	33225970	615	621	O
:	33225970	622	623	O
This	33225970	624	628	O
is	33225970	629	631	O
a	33225970	632	633	O
single	33225970	634	640	O
centre	33225970	641	647	O
,	33225970	648	649	O
randomized	33225970	650	660	O
,	33225970	661	662	O
2-arm	33225970	663	668	O
,	33225970	669	670	O
parallel	33225970	671	679	O
group	33225970	680	685	O
,	33225970	686	687	O
double	33225970	688	694	O
blind	33225970	695	700	O
,	33225970	701	702	O
1:1	33225970	703	706	O
ratio	33225970	707	712	O
,	33225970	713	714	O
controlled	33225970	715	725	O
,	33225970	726	727	O
exploratory	33225970	728	739	O
trial	33225970	740	745	O
with	33225970	746	750	O
a	33225970	751	752	O
study	33225970	753	758	O
period	33225970	759	765	O
of	33225970	766	768	O
30	33225970	769	771	O
days	33225970	772	776	O
from	33225970	777	781	O
the	33225970	782	785	O
day	33225970	786	789	O
of	33225970	790	792	O
enrolment	33225970	793	802	O
.	33225970	803	804	O

METHODS	33225970	805	812	O
:	33225970	813	814	O
Patients	33225970	815	823	O
attending	33225970	824	833	O
the	33225970	834	837	O
COVID	33225970	838	843	O
treatment	33225970	844	853	O
centre	33225970	854	860	O
at	33225970	861	863	O
Yashwantrao	33225970	864	875	O
Chavan	33225970	876	882	O
Memorial	33225970	883	891	O
Hospital	33225970	892	900	O
,	33225970	901	902	O
Nehrunagar	33225970	903	913	O
,	33225970	914	915	O
Pimpri	33225970	916	922	O
,	33225970	923	924	O
Pune	33225970	925	929	O
,	33225970	930	931	O
India	33225970	932	937	O
were	33225970	938	942	O
screened	33225970	943	951	O
for	33225970	952	955	O
their	33225970	956	961	O
participation	33225970	962	975	O
in	33225970	976	978	O
the	33225970	979	982	O
study	33225970	983	988	O
.	33225970	989	990	O

Patients	33225970	991	999	O
who	33225970	1000	1003	O
were	33225970	1004	1008	O
known	33225970	1009	1014	O
COVID-19	33225970	1015	1023	O
positive	33225970	1024	1032	O
(	33225970	1033	1034	O
with	33225970	1035	1039	O
positive	33225970	1040	1048	O
RT	33225970	1049	1051	O
-	33225970	1052	1053	O
PCR	33225970	1054	1057	O
)	33225970	1058	1059	O
,	33225970	1060	1061	O
eligible	33225970	1062	1070	O
and	33225970	1071	1074	O
willing	33225970	1075	1082	O
were	33225970	1083	1087	O
enrolled	33225970	1088	1096	O
in	33225970	1097	1099	O
the	33225970	1100	1103	O
study	33225970	1104	1109	O
.	33225970	1110	1111	O

UNASSIGNED	33225970	1112	1122	O
:	33225970	1123	1124	O
The	33225970	1125	1128	O
intervention	33225970	1129	1141	O
in	33225970	1142	1144	O
the	33225970	1145	1148	O
trial	33225970	1149	1154	O
has	33225970	1155	1158	O
a	33225970	1159	1160	O
background	33225970	1161	1171	O
in	33225970	1172	1174	O
'	33225970	1175	1176	O
Ayurved	33225970	1177	1184	O
'	33225970	1185	1186	O
.	33225970	1187	1188	O

Intervention	33225970	1189	1201	O
Arm	33225970	1202	1205	O
:	33225970	1206	1207	O
Two	33225970	1208	1211	O
capsules	33225970	1212	1220	O
,	33225970	1221	1222	O
Investigational	33225970	1223	1238	O
Product	33225970	1239	1246	O
(	33225970	1247	1248	O
IP	33225970	1249	1251	O
)	33225970	1252	1253	O
-	33225970	1254	1255	O
1	33225970	1256	1257	O
-	33225970	1258	1259	O
400	33225970	1260	1263	O
mg	33225970	1264	1266	O
and	33225970	1267	1270	O
Investigational	33225970	1271	1286	O
Product	33225970	1287	1294	O
-	33225970	1295	1296	O
2	33225970	1297	1298	O
-	33225970	1299	1300	O
450	33225970	1301	1304	O
mg	33225970	1305	1307	O
,	33225970	1308	1309	O
containing	33225970	1310	1320	O
herbal	33225970	1321	1327	O
extracts	33225970	1328	1336	O
(	33225970	1337	1338	O
a	33225970	1339	1340	O
blend	33225970	1341	1346	O
of	33225970	1347	1349	O
water	33225970	1350	1355	O
and	33225970	1356	1359	O
CO2	33225970	1360	1363	O
extracts	33225970	1364	1372	O
)	33225970	1373	1374	O
of	33225970	1375	1377	O
Shunthi	33225970	1378	1385	O
(	33225970	1386	1387	O
Zingiber	33225970	1388	1396	O
officinale	33225970	1397	1407	O
(	33225970	1408	1409	O
Ginger	33225970	1410	1416	O
)	33225970	1417	1418	O
,	33225970	1419	1420	O
Vidanga	33225970	1421	1428	O
(	33225970	1429	1430	O
Embelia	33225970	1431	1438	O
ribes	33225970	1439	1444	O
)	33225970	1445	1446	O
,	33225970	1447	1448	O
Yashtimadhu	33225970	1449	1460	O
(	33225970	1461	1462	O
Glycyrrhiza	33225970	1463	1474	O
glabra	33225970	1475	1481	O
)	33225970	1482	1483	O
,	33225970	1484	1485	O
Haritaki	33225970	1486	1494	O
(	33225970	1495	1496	O
Terminalia	33225970	1497	1507	O
chebula	33225970	1508	1515	O
)	33225970	1516	1517	O
,	33225970	1518	1519	O
Guduchi	33225970	1520	1527	O
(	33225970	1528	1529	O
Tinospora	33225970	1530	1539	O
cordifolia	33225970	1540	1550	O
)	33225970	1551	1552	O
,	33225970	1553	1554	O
Shatavari	33225970	1555	1564	O
(	33225970	1565	1566	O
Asparagus	33225970	1567	1576	O
racemosus	33225970	1577	1586	O
)	33225970	1587	1588	O
,	33225970	1589	1590	O
Aamalaki	33225970	1591	1599	O
(	33225970	1600	1601	O
Emblica	33225970	1602	1609	O
officinalis	33225970	1610	1621	O
)	33225970	1622	1623	O
,	33225970	1624	1625	O
Pippali	33225970	1626	1633	O
(	33225970	1634	1635	O
Piper	33225970	1636	1641	O
longum	33225970	1642	1648	O
)	33225970	1649	1650	O
and	33225970	1651	1654	O
calcined	33225970	1655	1663	O
Zinc	33225970	1664	1668	O
,	33225970	1669	1670	O
Shankha	33225970	1671	1678	O
bhasma	33225970	1679	1685	O
.	33225970	1686	1687	O

Placebo	33225970	1688	1695	O
Arm	33225970	1696	1699	O
:	33225970	1700	1701	O
Edible	33225970	1702	1708	O
starch	33225970	1709	1715	O
~	33225970	1716	1717	O
450	33225970	1718	1721	O
mg	33225970	1722	1724	O
.	33225970	1725	1726	O

The	33225970	1727	1730	O
look	33225970	1731	1735	O
and	33225970	1736	1739	O
feel	33225970	1740	1744	O
of	33225970	1745	1747	O
IP	33225970	1748	1750	O
and	33225970	1751	1754	O
of	33225970	1755	1757	O
Placebo	33225970	1758	1765	O
boxes	33225970	1766	1771	O
were	33225970	1772	1776	O
very	33225970	1777	1781	O
similar	33225970	1782	1789	O
.	33225970	1790	1791	O

Patients	33225970	1792	1800	O
are	33225970	1801	1804	O
to	33225970	1805	1807	O
take	33225970	1808	1812	O
two	33225970	1813	1816	O
capsules	33225970	1817	1825	O
(	33225970	1826	1827	O
one	33225970	1828	1831	O
each	33225970	1832	1836	O
of	33225970	1837	1839	O
IP-1	33225970	1840	1844	O
and	33225970	1845	1848	O
IP-2	33225970	1849	1853	O
)	33225970	1854	1855	O
twice	33225970	1856	1861	O
a	33225970	1862	1863	O
day	33225970	1864	1867	O
for	33225970	1868	1871	O
15	33225970	1872	1874	O
days	33225970	1875	1879	O
,	33225970	1880	1881	O
and	33225970	1882	1885	O
from	33225970	1886	1890	O
the	33225970	1891	1894	O
16th	33225970	1895	1899	O
day	33225970	1900	1903	O
,	33225970	1904	1905	O
one	33225970	1906	1909	O
capsule	33225970	1910	1917	O
of	33225970	1918	1920	O
IP-2	33225970	1921	1925	O
twice	33225970	1926	1931	O
a	33225970	1932	1933	O
day	33225970	1934	1937	O
up	33225970	1938	1940	O
-	33225970	1941	1942	O
to	33225970	1943	1945	O
day	33225970	1946	1949	O
30	33225970	1950	1952	O
.	33225970	1953	1954	O
Capsules	33225970	1955	1963	O
are	33225970	1964	1967	O
to	33225970	1968	1970	O
be	33225970	1971	1973	O
administered	33225970	1974	1986	O
orally	33225970	1987	1993	O
with	33225970	1994	1998	O
plain	33225970	1999	2004	O
water	33225970	2005	2010	O
.	33225970	2011	2012	O

The	33225970	2013	2016	O
IP	33225970	2017	2019	O
is	33225970	2020	2022	O
to	33225970	2023	2025	O
be	33225970	2026	2028	O
taken	33225970	2029	2034	O
with	33225970	2035	2039	O
all	33225970	2040	2043	O
other	33225970	2044	2049	O
concomitant	33225970	2050	2061	O
medicines	33225970	2062	2071	O
prescribed	33225970	2072	2082	O
by	33225970	2083	2085	O
the	33225970	2086	2089	O
treating	33225970	2090	2098	O
physician	33225970	2099	2108	O
/	33225970	2109	2110	O
doctor	33225970	2111	2117	O
.	33225970	2118	2119	O

The	33225970	2120	2123	O
dose	33225970	2124	2128	O
of	33225970	2129	2131	O
each	33225970	2132	2136	O
component	33225970	2137	2146	O
in	33225970	2147	2149	O
the	33225970	2150	2153	O
IP	33225970	2154	2156	O
is	33225970	2157	2159	O
very	33225970	2160	2164	O
safe	33225970	2165	2169	O
to	33225970	2170	2172	O
administer	33225970	2173	2183	O
.	33225970	2184	2185	O

The	33225970	2186	2189	O
investigational	33225970	2190	2205	O
products	33225970	2206	2214	O
are	33225970	2215	2218	O
registered	33225970	2219	2229	O
products	33225970	2230	2238	O
with	33225970	2239	2243	O
the	33225970	2244	2247	O
Indian	33225970	2248	2254	O
Government	33225970	2255	2265	O
and	33225970	2266	2269	O
have	33225970	2270	2274	O
been	33225970	2275	2279	O
used	33225970	2280	2284	O
for	33225970	2285	2288	O
more	33225970	2289	2293	O
than	33225970	2294	2298	O
6	33225970	2299	2300	O
months	33225970	2301	2307	O
in	33225970	2308	2310	O
various	33225970	2311	2318	O
health	33225970	2319	2325	O
conditions	33225970	2326	2336	O
but	33225970	2337	2340	O
not	33225970	2341	2344	O
for	33225970	2345	2348	O
COVID-19	33225970	2349	2357	O
.	33225970	2358	2359	O

RESULTS	33225970	2360	2367	O
:	33225970	2368	2369	O
Primary	33225970	2370	2377	O
Outcome	33225970	2378	2385	O
:	33225970	2386	2387	O
Efficacy	33225970	2388	2396	O
of	33225970	2397	2399	O
the	33225970	2400	2403	O
herbal	33225970	2404	2410	O
extracts	33225970	2411	2419	O
in	33225970	2420	2422	O
COVID	33225970	2423	2428	O
19	33225970	2429	2431	O
positive	33225970	2432	2440	O
patients	33225970	2441	2449	O
(	33225970	2450	2451	O
in	33225970	2452	2454	O
declining	33225970	2455	2464	O
viral	33225970	2465	2470	O
load	33225970	2471	2475	O
:	33225970	2476	2477	O
time	33225970	2478	2482	O
-	33225970	2483	2484	O
point	33225970	2485	2490	O
:	33225970	2491	2492	O
4	33225970	2493	2494	O
days	33225970	2495	2499	O
and	33225970	2500	2503	O
early	33225970	2504	2509	O
recovery	33225970	2510	2518	O
)	33225970	2519	2520	O
Secondary	33225970	2521	2530	O
Outcomes	33225970	2531	2539	O
:	33225970	2540	2541	O
Efficacy	33225970	2542	2550	O
of	33225970	2551	2553	O
the	33225970	2554	2557	O
herbal	33225970	2558	2564	O
extracts	33225970	2565	2573	O
as	33225970	2574	2576	O
an	33225970	2577	2579	O
immune	33225970	2580	2586	O
-	33225970	2587	2588	O
modulator	33225970	2589	2598	O
-	33225970	2599	2600	O
TH1	33225970	2601	2604	O
,	33225970	2605	2606	O
TH2	33225970	2607	2610	O
,	33225970	2611	2612	O
Th17	33225970	2613	2617	O
,	33225970	2618	2619	O
IL6	33225970	2620	2623	O
,	33225970	2624	2625	O
NK	33225970	2626	2628	O
Cells	33225970	2629	2634	O
and	33225970	2635	2638	O
CD	33225970	2639	2641	O
markers	33225970	2642	2649	O
;	33225970	2650	2651	O
Immunoglobulin	33225970	2652	2666	O
IGG	33225970	2667	2670	O
(	33225970	2671	2672	O
Serum	33225970	2673	2678	O
)	33225970	2679	2680	O
;	33225970	2681	2682	O
Immunoglobulin	33225970	2683	2697	O
IGM	33225970	2698	2701	O
(	33225970	2702	2703	O
Serum	33225970	2704	2709	O
)	33225970	2710	2711	O
-	33225970	2712	2713	O
at	33225970	2714	2716	O
30	33225970	2717	2719	O
days	33225970	2720	2724	O
.	33225970	2725	2726	O

Efficacy	33225970	2727	2735	O
of	33225970	2736	2738	O
the	33225970	2739	2742	O
investigational	33225970	2743	2758	O
product	33225970	2759	2766	O
in	33225970	2767	2769	O
reducing	33225970	2770	2778	O
sequela	33225970	2779	2786	O
of	33225970	2787	2789	O
the	33225970	2790	2793	O
disease	33225970	2794	2801	O
Safety	33225970	2802	2808	O
analysis	33225970	2809	2817	O
(	33225970	2818	2819	O
Liver	33225970	2820	2825	O
Function	33225970	2826	2834	O
Test	33225970	2835	2839	O
and	33225970	2840	2843	O
Kidney	33225970	2844	2850	O
Function	33225970	2851	2859	O
Test	33225970	2860	2864	O
)	33225970	2865	2866	O
including	33225970	2867	2876	O
serious	33225970	2877	2884	O
allergic	33225970	2885	2893	O
reaction	33225970	2894	2902	O
of	33225970	2903	2905	O
:	33225970	2906	2907	O
rash	33225970	2908	2912	O
,	33225970	2913	2914	O
itching	33225970	2915	2922	O
/	33225970	2923	2924	O
swelling	33225970	2925	2933	O
,	33225970	2934	2935	O
severe	33225970	2936	2942	O
dizziness	33225970	2943	2952	O
,	33225970	2953	2954	O
trouble	33225970	2955	2962	O
breathing	33225970	2963	2972	O
.	33225970	2973	2974	O

UNASSIGNED	33225970	2975	2985	O
:	33225970	2986	2987	O
An	33225970	2988	2990	O
alphanumeric	33225970	2991	3003	O
coded	33225970	3004	3009	O
set	33225970	3010	3013	O
of	33225970	3014	3016	O
IP	33225970	3017	3019	O
/	33225970	3020	3021	O
Placebo	33225970	3022	3029	O
containers	33225970	3030	3040	O
will	33225970	3041	3045	O
be	33225970	3046	3048	O
used	33225970	3049	3053	O
.	33225970	3054	3055	O

Participants	33225970	3056	3068	O
will	33225970	3069	3073	O
be	33225970	3074	3076	O
automatically	33225970	3077	3090	O
randomized	33225970	3091	3101	O
to	33225970	3102	3104	O
two	33225970	3105	3108	O
groups	33225970	3109	3115	O
in	33225970	3116	3118	O
the	33225970	3119	3122	O
ratio	33225970	3123	3128	O
1:1	33225970	3129	3132	O
.	33225970	3133	3134	O

UNASSIGNED	33225970	3135	3145	O
:	33225970	3146	3147	O
Participants	33225970	3148	3160	O
,	33225970	3161	3162	O
caregivers	33225970	3163	3173	O
and	33225970	3174	3177	O
investigators	33225970	3178	3191	O
were	33225970	3192	3196	O
blinded	33225970	3197	3204	O
.	33225970	3205	3206	O

UNASSIGNED	33225970	3207	3217	O
:	33225970	3218	3219	O
A	33225970	3220	3221	O
total	33225970	3222	3227	O
of	33225970	3228	3230	O
more	33225970	3231	3235	O
than	33225970	3236	3240	O
60	33225970	3241	3243	O
and	33225970	3244	3247	O
up	33225970	3248	3250	O
to	33225970	3251	3253	O
75	33225970	3254	3256	O
patients	33225970	3257	3265	O
were	33225970	3266	3270	O
to	33225970	3271	3273	O
be	33225970	3274	3276	O
enrolled	33225970	3277	3285	O
in	33225970	3286	3288	O
the	33225970	3289	3292	O
study	33225970	3293	3298	O
into	33225970	3299	3303	O
the	33225970	3304	3307	O
two	33225970	3308	3311	O
groups	33225970	3312	3318	O
,	33225970	3319	3320	O
considering	33225970	3321	3332	O
drop	33225970	3333	3337	O
-	33225970	3338	3339	O
outs	33225970	3340	3344	O
.	33225970	3345	3346	O

72	33225970	3347	3349	O
were	33225970	3350	3354	O
enrolled	33225970	3355	3363	O
with	33225970	3364	3368	O
37	33225970	3369	3371	O
into	33225970	3372	3376	O
the	33225970	3377	3380	O
intervention	33225970	3381	3393	O
group	33225970	3394	3399	O
and	33225970	3400	3403	O
35	33225970	3404	3406	O
into	33225970	3407	3411	O
the	33225970	3412	3415	O
placebo	33225970	3416	3423	O
group	33225970	3424	3429	O
.	33225970	3430	3431	O

UNASSIGNED	33225970	3432	3442	O
:	33225970	3443	3444	O
Protocol	33225970	3445	3453	O
number	33225970	3454	3460	O
:	33225970	3461	3462	O
CoviQuest-01	33225970	3463	3475	O
Protocol	33225970	3476	3484	O
version	33225970	3485	3492	O
number	33225970	3493	3499	O
:	33225970	3500	3501	O
1.2	33225970	3502	3505	O
Protocol	33225970	3506	3514	O
Date	33225970	3515	3519	O
:	33225970	3520	3521	O
1st	33225970	3522	3525	O
July	33225970	3526	3530	O
2020	33225970	3531	3535	O
The	33225970	3536	3539	O
recruitment	33225970	3540	3551	O
period	33225970	3552	3558	O
is	33225970	3559	3561	O
completed	33225970	3562	3571	O
for	33225970	3572	3575	O
the	33225970	3576	3579	O
trial	33225970	3580	3585	O
.	33225970	3586	3587	O

Date	33225970	3588	3592	O
of	33225970	3593	3595	O
1st	33225970	3596	3599	O
patient	33225970	3600	3607	O
enrolment	33225970	3608	3617	O
was	33225970	3618	3621	O
11th	33225970	3622	3626	O
Aug	33225970	3627	3630	O
2020	33225970	3631	3635	O
and	33225970	3636	3639	O
the	33225970	3640	3643	O
last	33225970	3644	3648	O
patient	33225970	3649	3656	O
was	33225970	3657	3660	O
enrolled	33225970	3661	3669	O
on	33225970	3670	3672	O
3rd	33225970	3673	3676	O
of	33225970	3677	3679	O
September	33225970	3680	3689	O
2020	33225970	3690	3694	O
.	33225970	3695	3696	O

This	33225970	3697	3701	O
is	33225970	3702	3704	O
to	33225970	3705	3707	O
state	33225970	3708	3713	O
that	33225970	3714	3718	O
it	33225970	3719	3721	O
was	33225970	3722	3725	O
a	33225970	3726	3727	O
late	33225970	3728	3732	O
submission	33225970	3733	3743	O
from	33225970	3744	3748	O
authors	33225970	3749	3756	O
for	33225970	3757	3760	O
publication	33225970	3761	3772	O
of	33225970	3773	3775	O
the	33225970	3776	3779	O
protocol	33225970	3780	3788	O
to	33225970	3789	3791	O
the	33225970	3792	3795	O
BMC	33225970	3796	3799	O
,	33225970	3800	3801	O
after	33225970	3802	3807	O
enrolment	33225970	3808	3817	O
in	33225970	3818	3820	O
the	33225970	3821	3824	O
study	33225970	3825	3830	O
was	33225970	3831	3834	O
over	33225970	3835	3839	O
.	33225970	3840	3841	O

Last	33225970	3842	3846	O
Participant	33225970	3847	3858	O
's	33225970	3859	3861	O
last	33225970	3862	3866	O
follow	33225970	3867	3873	O
-	33225970	3874	3875	O
up	33225970	3876	3878	O
is	33225970	3879	3881	O
scheduled	33225970	3882	3891	O
on	33225970	3892	3894	O
5th	33225970	3895	3898	O
October	33225970	3899	3906	O
2020	33225970	3907	3911	O
TRIAL	33225970	3912	3917	O
REGISTRATION	33225970	3918	3930	O
:	33225970	3931	3932	O
The	33225970	3933	3936	O
trial	33225970	3937	3942	O
was	33225970	3943	3946	O
prospectively	33225970	3947	3960	O
registered	33225970	3961	3971	O
with	33225970	3972	3976	O
the	33225970	3977	3980	O
CTRI	33225970	3981	3985	O
(	33225970	3986	3987	O
Clinical	33225970	3988	3996	O
Trial	33225970	3997	4002	O
Registry	33225970	4003	4011	O
of	33225970	4012	4014	O
India	33225970	4015	4020	O
)	33225970	4021	4022	O
.	33225970	4023	4024	O

Registration	33225970	4025	4037	O
number	33225970	4038	4044	O
is	33225970	4045	4047	O
CTRI/2020/07/026570	33225970	4048	4067	O
.	33225970	4068	4069	O

Registered	33225970	4070	4080	O
on	33225970	4081	4083	O
14	33225970	4084	4086	O
July	33225970	4087	4091	O
2020	33225970	4092	4096	O
FULL	33225970	4097	4101	O
PROTOCOL	33225970	4102	4110	O
:	33225970	4111	4112	O
The	33225970	4113	4116	O
full	33225970	4117	4121	O
protocol	33225970	4122	4130	O
is	33225970	4131	4133	O
attached	33225970	4134	4142	O
as	33225970	4143	4145	O
an	33225970	4146	4148	O
additional	33225970	4149	4159	O
file	33225970	4160	4164	O
,	33225970	4165	4166	O
accessible	33225970	4167	4177	O
from	33225970	4178	4182	O
the	33225970	4183	4186	O
Trials	33225970	4187	4193	O
website	33225970	4194	4201	O
(	33225970	4202	4203	O
Additional	33225970	4204	4214	O
file	33225970	4215	4219	O
1	33225970	4220	4221	O
)	33225970	4222	4223	O
.	33225970	4224	4225	O

In	33225970	4226	4228	O
the	33225970	4229	4232	O
interest	33225970	4233	4241	O
in	33225970	4242	4244	O
expediting	33225970	4245	4255	O
dissemination	33225970	4256	4269	O
of	33225970	4270	4272	O
this	33225970	4273	4277	O
material	33225970	4278	4286	O
,	33225970	4287	4288	O
the	33225970	4289	4292	O
familiar	33225970	4293	4301	O
formatting	33225970	4302	4312	O
has	33225970	4313	4316	O
been	33225970	4317	4321	O
eliminated	33225970	4322	4332	O
;	33225970	4333	4334	O
this	33225970	4335	4339	O
Letter	33225970	4340	4346	O
serves	33225970	4347	4353	O
as	33225970	4354	4356	O
a	33225970	4357	4358	O
summary	33225970	4359	4366	O
of	33225970	4367	4369	O
the	33225970	4370	4373	O
key	33225970	4374	4377	O
elements	33225970	4378	4386	O
of	33225970	4387	4389	O
the	33225970	4390	4393	O
full	33225970	4394	4398	O
protocol	33225970	4399	4407	O
.	33225970	4408	4409	O


Letter	33225989	0	6	O
to	33225989	7	9	O
the	33225989	10	13	O
editor	33225989	14	20	O
:	33225989	21	22	O
Study	33225989	23	28	O
Summary	33225989	29	36	O
-	33225989	37	38	O
Randomized	33225989	39	49	O
Control	33225989	50	57	O
Trial	33225989	58	63	O
of	33225989	64	66	O
Omega-3	33225989	67	74	O
Fatty	33225989	75	80	O
Acid	33225989	81	85	O
Supplementation	33225989	86	101	O
for	33225989	102	105	O
the	33225989	106	109	O
Treatment	33225989	110	119	O
of	33225989	120	122	O
COVID-19	33225989	123	131	O
Related	33225989	132	139	O
Olfactory	33225989	140	149	O
Dysfunction	33225989	150	161	O
.	33225989	162	163	O

OBJECTIVE	33225989	164	173	O
:	33225989	174	175	O
To	33225989	176	178	O
evaluate	33225989	179	187	O
a	33225989	188	189	O
therapeutic	33225989	190	201	O
role	33225989	202	206	O
for	33225989	207	210	O
omega-3	33225989	211	218	O
fatty	33225989	219	224	O
acid	33225989	225	229	O
supplementation	33225989	230	245	O
in	33225989	246	248	O
the	33225989	249	252	O
treatment	33225989	253	262	O
of	33225989	263	265	O
olfactory	33225989	266	275	O
dysfunction	33225989	276	287	O
associated	33225989	288	298	O
with	33225989	299	303	O
COVID-19	33225989	304	312	O
infection	33225989	313	322	O
TRIAL	33225989	323	328	O
DESIGN	33225989	329	335	O
:	33225989	336	337	O
Randomized	33225989	338	348	O
,	33225989	349	350	O
double	33225989	351	357	O
-	33225989	358	359	O
blinded	33225989	360	367	O
,	33225989	368	369	O
placebo	33225989	370	377	O
-	33225989	378	379	O
controlled	33225989	380	390	O
trial	33225989	391	396	O
PARTICIPANTS	33225989	397	409	O
:	33225989	410	411	O
Eligible	33225989	412	420	O
patients	33225989	421	429	O
are	33225989	430	433	O
adults	33225989	434	440	O
with	33225989	441	445	O
self	33225989	446	450	O
-	33225989	451	452	O
reported	33225989	453	461	O
new	33225989	462	465	O
-	33225989	466	467	O
onset	33225989	468	473	O
olfactory	33225989	474	483	O
dysfunction	33225989	484	495	O
of	33225989	496	498	O
any	33225989	499	502	O
duration	33225989	503	511	O
associated	33225989	512	522	O
with	33225989	523	527	O
laboratory	33225989	528	538	O
-	33225989	539	540	O
confirmed	33225989	541	550	O
or	33225989	551	553	O
clinically	33225989	554	564	O
suspected	33225989	565	574	O
COVID-19	33225989	575	583	O
patients	33225989	584	592	O
.	33225989	593	594	O

Exclusion	33225989	595	604	O
criteria	33225989	605	613	O
include	33225989	614	621	O
patients	33225989	622	630	O
with	33225989	631	635	O
pre	33225989	636	639	O
-	33225989	640	641	O
existing	33225989	642	650	O
olfactory	33225989	651	660	O
dysfunction	33225989	661	672	O
,	33225989	673	674	O
history	33225989	675	682	O
of	33225989	683	685	O
chronic	33225989	686	693	O
rhinosinusitis	33225989	694	708	O
or	33225989	709	711	O
history	33225989	712	719	O
of	33225989	720	722	O
sinus	33225989	723	728	O
surgery	33225989	729	736	O
,	33225989	737	738	O
current	33225989	739	746	O
use	33225989	747	750	O
of	33225989	751	753	O
nasal	33225989	754	759	O
steroid	33225989	760	767	O
sprays	33225989	768	774	O
or	33225989	775	777	O
omega-3	33225989	778	785	O
supplementation	33225989	786	801	O
,	33225989	802	803	O
fish	33225989	804	808	O
allergy	33225989	809	816	O
,	33225989	817	818	O
or	33225989	819	821	O
inability	33225989	822	831	O
to	33225989	832	834	O
provide	33225989	835	842	O
informed	33225989	843	851	O
consent	33225989	852	859	O
for	33225989	860	863	O
any	33225989	864	867	O
reason	33225989	868	874	O
.	33225989	875	876	O

The	33225989	877	880	O
trial	33225989	881	886	O
is	33225989	887	889	O
conducted	33225989	890	899	O
at	33225989	900	902	O
Mount	33225989	903	908	O
Sinai	33225989	909	914	O
Hospital	33225989	915	923	O
INTERVENTION	33225989	924	936	O
AND	33225989	937	940	O
COMPARATOR	33225989	941	951	O
:	33225989	952	953	O
The	33225989	954	957	O
intervention	33225989	958	970	O
group	33225989	971	976	O
will	33225989	977	981	O
receive	33225989	982	989	O
2000	33225989	990	994	O
mg	33225989	995	997	O
daily	33225989	998	1003	O
of	33225989	1004	1006	O
omega-3	33225989	1007	1014	O
supplementation	33225989	1015	1030	O
in	33225989	1031	1033	O
the	33225989	1034	1037	O
form	33225989	1038	1042	O
of	33225989	1043	1045	O
two	33225989	1046	1049	O
"	33225989	1050	1051	O
Fish	33225989	1052	1056	O
Oil	33225989	1057	1060	O
,	33225989	1061	1062	O
Ultra	33225989	1063	1068	O
Omega-3	33225989	1069	1076	O
"	33225989	1077	1078	O
capsules	33225989	1079	1087	O
(	33225989	1088	1089	O
product	33225989	1090	1097	O
of	33225989	1098	1100	O
Pharmavite	33225989	1101	1111	O
	33225989	1112	1113	O
)	33225989	1114	1115	O
daily	33225989	1116	1121	O
.	33225989	1122	1123	O

The	33225989	1124	1127	O
comparator	33225989	1128	1138	O
group	33225989	1139	1144	O
will	33225989	1145	1149	O
take	33225989	1150	1154	O
2	33225989	1155	1156	O
placebo	33225989	1157	1164	O
capsules	33225989	1165	1173	O
of	33225989	1174	1176	O
identical	33225989	1177	1186	O
size	33225989	1187	1191	O
,	33225989	1192	1193	O
shape	33225989	1194	1199	O
,	33225989	1200	1201	O
and	33225989	1202	1205	O
odor	33225989	1206	1210	O
daily	33225989	1211	1216	O
for	33225989	1217	1220	O
6	33225989	1221	1222	O
weeks	33225989	1223	1228	O
.	33225989	1229	1230	O

RESULTS	33225989	1231	1238	O
:	33225989	1239	1240	O
Each	33225989	1241	1245	O
subject	33225989	1246	1253	O
will	33225989	1254	1258	O
take	33225989	1259	1263	O
a	33225989	1264	1265	O
Brief	33225989	1266	1271	O
Smell	33225989	1272	1277	O
Identification	33225989	1278	1292	O
Test	33225989	1293	1297	O
at	33225989	1298	1300	O
study	33225989	1301	1306	O
enrolment	33225989	1307	1316	O
and	33225989	1317	1320	O
completion	33225989	1321	1331	O
after	33225989	1332	1337	O
6	33225989	1338	1339	O
weeks	33225989	1340	1345	O
.	33225989	1346	1347	O

The	33225989	1348	1351	O
primary	33225989	1352	1359	O
outcome	33225989	1360	1367	O
will	33225989	1368	1372	O
be	33225989	1373	1375	O
change	33225989	1376	1382	O
in	33225989	1383	1385	O
Brief	33225989	1386	1391	O
Smell	33225989	1392	1397	O
Identification	33225989	1398	1412	O
Test	33225989	1413	1417	O
over	33225989	1418	1422	O
the	33225989	1423	1426	O
6-week	33225989	1427	1433	O
period	33225989	1434	1440	O
.	33225989	1441	1442	O

UNASSIGNED	33225989	1443	1453	O
:	33225989	1454	1455	O
Patients	33225989	1456	1464	O
will	33225989	1465	1469	O
be	33225989	1470	1472	O
randomized	33225989	1473	1483	O
by	33225989	1484	1486	O
the	33225989	1487	1490	O
Investigational	33225989	1491	1506	O
Drug	33225989	1507	1511	O
Pharmacy	33225989	1512	1520	O
at	33225989	1521	1523	O
the	33225989	1524	1527	O
Icahn	33225989	1528	1533	O
School	33225989	1534	1540	O
of	33225989	1541	1543	O
Medicine	33225989	1544	1552	O
at	33225989	1553	1555	O
Sinai	33225989	1556	1561	O
via	33225989	1562	1565	O
a	33225989	1566	1567	O
computer	33225989	1568	1576	O
-	33225989	1577	1578	O
generated	33225989	1579	1588	O
sequence	33225989	1589	1597	O
in	33225989	1598	1600	O
a	33225989	1601	1602	O
1:1	33225989	1603	1606	O
allocation	33225989	1607	1617	O
to	33225989	1618	1620	O
treatment	33225989	1621	1630	O
or	33225989	1631	1633	O
control	33225989	1634	1641	O
arms	33225989	1642	1646	O
.	33225989	1647	1648	O

UNASSIGNED	33225989	1649	1659	O
:	33225989	1660	1661	O
Both	33225989	1662	1666	O
participants	33225989	1667	1679	O
and	33225989	1680	1683	O
researchers	33225989	1684	1695	O
will	33225989	1696	1700	O
be	33225989	1701	1703	O
blinded	33225989	1704	1711	O
.	33225989	1712	1713	O

UNASSIGNED	33225989	1714	1724	O
:	33225989	1725	1726	O
There	33225989	1727	1732	O
will	33225989	1733	1737	O
be	33225989	1738	1740	O
88	33225989	1741	1743	O
participants	33225989	1744	1756	O
randomized	33225989	1757	1767	O
to	33225989	1768	1770	O
each	33225989	1771	1775	O
group	33225989	1776	1781	O
.	33225989	1782	1783	O

A	33225989	1784	1785	O
total	33225989	1786	1791	O
of	33225989	1792	1794	O
176	33225989	1795	1798	O
participants	33225989	1799	1811	O
will	33225989	1812	1816	O
be	33225989	1817	1819	O
randomized	33225989	1820	1830	O
.	33225989	1831	1832	O

UNASSIGNED	33225989	1833	1843	O
:	33225989	1844	1845	O
Protocol	33225989	1846	1854	O
Version	33225989	1855	1862	O
1	33225989	1863	1864	O
,	33225989	1865	1866	O
8/3/2020	33225989	1867	1875	O
Recruitment	33225989	1876	1887	O
is	33225989	1888	1890	O
ongoing	33225989	1891	1898	O
,	33225989	1899	1900	O
started	33225989	1901	1908	O
8/5/2020	33225989	1909	1917	O
with	33225989	1918	1922	O
estimated	33225989	1923	1932	O
completion	33225989	1933	1943	O
11/30/2020	33225989	1944	1954	O
.	33225989	1955	1956	O

BACKGROUND	33225989	1957	1967	O
:	33225989	1968	1969	O
The	33225989	1970	1973	O
trial	33225989	1974	1979	O
is	33225989	1980	1982	O
registered	33225989	1983	1993	O
on	33225989	1994	1996	O
ClinicalTrials.gov	33225989	1997	2015	O
with	33225989	2016	2020	O
Protocol	33225989	2021	2029	O
Identifier	33225989	2030	2040	O
:	33225989	2041	2042	O
NCT04495816	33225989	2043	2054	O
.	33225989	2055	2056	O

BACKGROUND	33225989	2057	2067	O
:	33225989	2068	2069	O
ClinicalTrials.gov	33225989	2070	2088	O
,	33225989	2089	2090	O
NCT04495816	33225989	2091	2102	O
.	33225989	2103	2104	O

Registered	33225989	2105	2115	O
3	33225989	2116	2117	O
August	33225989	2118	2124	O
2020	33225989	2125	2129	O
FULL	33225989	2130	2134	O
PROTOCOL	33225989	2135	2143	O
:	33225989	2144	2145	O
The	33225989	2146	2149	O
full	33225989	2150	2154	O
protocol	33225989	2155	2163	O
is	33225989	2164	2166	O
attached	33225989	2167	2175	O
as	33225989	2176	2178	O
an	33225989	2179	2181	O
additional	33225989	2182	2192	O
file	33225989	2193	2197	O
,	33225989	2198	2199	O
accessible	33225989	2200	2210	O
from	33225989	2211	2215	O
the	33225989	2216	2219	O
Trials	33225989	2220	2226	O
website	33225989	2227	2234	O
(	33225989	2235	2236	O
Additional	33225989	2237	2247	O
file	33225989	2248	2252	O
1	33225989	2253	2254	O
)	33225989	2255	2256	O
.	33225989	2257	2258	O


Prone	33225990	0	5	O
positioning	33225990	6	17	O
in	33225990	18	20	O
non	33225990	21	24	O
-	33225990	25	26	O
intubated	33225990	27	36	O
patients	33225990	37	45	O
with	33225990	46	50	O
COVID-19	33225990	51	59	O
associated	33225990	60	70	O
acute	33225990	71	76	O
respiratory	33225990	77	88	O
failure	33225990	89	96	O
,	33225990	97	98	O
the	33225990	99	102	O
PRO	33225990	103	106	O
-	33225990	107	108	O
CARF	33225990	109	113	O
trial	33225990	114	119	O
:	33225990	120	121	O
A	33225990	122	123	O
structured	33225990	124	134	O
summary	33225990	135	142	O
of	33225990	143	145	O
a	33225990	146	147	O
study	33225990	148	153	O
protocol	33225990	154	162	O
for	33225990	163	166	O
a	33225990	167	168	O
randomised	33225990	169	179	O
controlled	33225990	180	190	O
trial	33225990	191	196	O
.	33225990	197	198	O

OBJECTIVE	33225990	199	208	O
:	33225990	209	210	O
To	33225990	211	213	O
assess	33225990	214	220	O
the	33225990	221	224	O
effect	33225990	225	231	O
of	33225990	232	234	O
prone	33225990	235	240	O
positioning	33225990	241	252	O
therapy	33225990	253	260	O
on	33225990	261	263	O
intubation	33225990	264	274	O
rate	33225990	275	279	O
in	33225990	280	282	O
awake	33225990	283	288	O
patients	33225990	289	297	O
with	33225990	298	302	O
COVID-19	33225990	303	311	O
and	33225990	312	315	O
acute	33225990	316	321	O
respiratory	33225990	322	333	O
failure	33225990	334	341	O
.	33225990	342	343	O

METHODS	33225990	344	351	O
:	33225990	352	353	O
This	33225990	354	358	O
is	33225990	359	361	O
a	33225990	362	363	O
two	33225990	364	367	O
-	33225990	368	369	O
center	33225990	370	376	O
parallel	33225990	377	385	O
group	33225990	386	391	O
,	33225990	392	393	O
superiority	33225990	394	405	O
,	33225990	406	407	O
randomized	33225990	408	418	O
(	33225990	419	420	O
1:1	33225990	421	424	O
allocation	33225990	425	435	O
ratio	33225990	436	441	O
)	33225990	442	443	O
controlled	33225990	444	454	O
trial	33225990	455	460	O
.	33225990	461	462	O

METHODS	33225990	463	470	O
:	33225990	471	472	O
All	33225990	473	476	O
patients	33225990	477	485	O
admitted	33225990	486	494	O
to	33225990	495	497	O
the	33225990	498	501	O
Hospital	33225990	502	510	O
Civil	33225990	511	516	O
de	33225990	517	519	O
Guadalajara	33225990	520	531	O
and	33225990	532	535	O
Hospital	33225990	536	544	O
General	33225990	545	552	O
de	33225990	553	555	O
Occidente	33225990	556	565	O
in	33225990	566	568	O
Mexico	33225990	569	575	O
for	33225990	576	579	O
COVID-19	33225990	580	588	O
associated	33225990	589	599	O
acute	33225990	600	605	O
respiratory	33225990	606	617	O
failure	33225990	618	625	O
and	33225990	626	629	O
in	33225990	630	632	O
need	33225990	633	637	O
of	33225990	638	640	O
supplementary	33225990	641	654	O
oxygen	33225990	655	661	O
through	33225990	662	669	O
high	33225990	670	674	O
-	33225990	675	676	O
flow	33225990	677	681	O
nasal	33225990	682	687	O
cannula	33225990	688	695	O
are	33225990	696	699	O
screened	33225990	700	708	O
for	33225990	709	712	O
eligibility	33225990	713	724	O
.	33225990	725	726	O

METHODS	33225990	727	734	O
:	33225990	735	736	O
all	33225990	737	740	O
adult	33225990	741	746	O
patients	33225990	747	755	O
admitted	33225990	756	764	O
to	33225990	765	767	O
the	33225990	768	771	O
COVID-19	33225990	772	780	O
unit	33225990	781	785	O
who	33225990	786	789	O
test	33225990	790	794	O
positive	33225990	795	803	O
for	33225990	804	807	O
COVID-19	33225990	808	816	O
by	33225990	817	819	O
PCR	33225990	820	823	O
-	33225990	824	825	O
test	33225990	826	830	O
and	33225990	831	834	O
in	33225990	835	837	O
need	33225990	838	842	O
for	33225990	843	846	O
oxygen	33225990	847	853	O
are	33225990	854	857	O
eligible	33225990	858	866	O
for	33225990	867	870	O
inclusion	33225990	871	880	O
.	33225990	881	882	O

Randomization	33225990	883	896	O
starts	33225990	897	903	O
upon	33225990	904	908	O
identification	33225990	909	923	O
of	33225990	924	926	O
requirement	33225990	927	938	O
of	33225990	939	941	O
a	33225990	942	943	O
fraction	33225990	944	952	O
of	33225990	953	955	O
inspired	33225990	956	964	O
oxygen	33225990	965	971	O
	33225990	974	975	O
30	33225990	976	978	O
%	33225990	979	980	O
for	33225990	981	984	O
an	33225990	985	987	O
oxygen	33225990	988	994	O
capillary	33225990	995	1004	O
saturation	33225990	1005	1015	O
of	33225990	1016	1018	O
	33225990	1021	1022	O
90	33225990	1023	1025	O
%	33225990	1026	1027	O
Exclusion	33225990	1028	1037	O
criteria	33225990	1038	1046	O
:	33225990	1047	1048	O
less	33225990	1049	1053	O
than	33225990	1054	1058	O
18	33225990	1059	1061	O
years	33225990	1062	1067	O
-	33225990	1068	1069	O
old	33225990	1070	1073	O
,	33225990	1074	1075	O
pregnancy	33225990	1076	1085	O
,	33225990	1086	1087	O
patients	33225990	1088	1096	O
with	33225990	1097	1101	O
immediate	33225990	1102	1111	O
need	33225990	1112	1116	O
of	33225990	1117	1119	O
invasive	33225990	1120	1128	O
mechanical	33225990	1129	1139	O
ventilation	33225990	1140	1151	O
(	33225990	1152	1153	O
altered	33225990	1154	1161	O
mental	33225990	1162	1168	O
status	33225990	1169	1175	O
,	33225990	1176	1177	O
fatigue	33225990	1178	1185	O
)	33225990	1186	1187	O
,	33225990	1188	1189	O
vasopressor	33225990	1190	1201	O
requirement	33225990	1202	1213	O
to	33225990	1214	1216	O
maintain	33225990	1217	1225	O
median	33225990	1226	1232	O
arterial	33225990	1233	1241	O
pressure	33225990	1242	1250	O
>	33225990	1251	1252	O
65	33225990	1253	1255	O
mmHg	33225990	1256	1260	O
,	33225990	1261	1262	O
contraindications	33225990	1263	1280	O
for	33225990	1281	1284	O
prone	33225990	1285	1290	O
positioning	33225990	1291	1302	O
therapy	33225990	1303	1310	O
(	33225990	1311	1312	O
recent	33225990	1313	1319	O
abdominal	33225990	1320	1329	O
or	33225990	1330	1332	O
thoracic	33225990	1333	1341	O
surgery	33225990	1342	1349	O
or	33225990	1350	1352	O
trauma	33225990	1353	1359	O
,	33225990	1360	1361	O
facial	33225990	1362	1368	O
,	33225990	1369	1370	O
pelvic	33225990	1371	1377	O
or	33225990	1378	1380	O
spine	33225990	1381	1386	O
fracture	33225990	1387	1395	O
,	33225990	1396	1397	O
untreated	33225990	1398	1407	O
pneumothorax	33225990	1408	1420	O
,	33225990	1421	1422	O
do	33225990	1423	1425	O
-	33225990	1426	1427	O
not	33225990	1428	1431	O
-	33225990	1432	1433	O
resuscitate	33225990	1434	1445	O
or	33225990	1446	1448	O
do	33225990	1449	1451	O
-	33225990	1452	1453	O
not	33225990	1454	1457	O
-	33225990	1458	1459	O
intubate	33225990	1460	1468	O
order	33225990	1469	1474	O
,	33225990	1475	1476	O
refusal	33225990	1477	1484	O
or	33225990	1485	1487	O
inability	33225990	1488	1497	O
of	33225990	1498	1500	O
the	33225990	1501	1504	O
patient	33225990	1505	1512	O
to	33225990	1513	1515	O
enroll	33225990	1516	1522	O
in	33225990	1523	1525	O
the	33225990	1526	1529	O
study	33225990	1530	1535	O
.	33225990	1536	1537	O

UNASSIGNED	33225990	1538	1548	O
:	33225990	1549	1550	O
Patients	33225990	1551	1559	O
of	33225990	1560	1562	O
the	33225990	1563	1566	O
intervention	33225990	1567	1579	O
group	33225990	1580	1585	O
will	33225990	1586	1590	O
be	33225990	1591	1593	O
asked	33225990	1594	1599	O
to	33225990	1600	1602	O
remain	33225990	1603	1609	O
in	33225990	1610	1612	O
a	33225990	1613	1614	O
prone	33225990	1615	1620	O
position	33225990	1621	1629	O
throughout	33225990	1630	1640	O
the	33225990	1641	1644	O
day	33225990	1645	1648	O
as	33225990	1649	1651	O
long	33225990	1652	1656	O
as	33225990	1657	1659	O
possible	33225990	1660	1668	O
,	33225990	1669	1670	O
with	33225990	1671	1675	O
breaks	33225990	1676	1682	O
according	33225990	1683	1692	O
to	33225990	1693	1695	O
tolerance	33225990	1696	1705	O
.	33225990	1706	1707	O

Pillows	33225990	1708	1715	O
will	33225990	1716	1720	O
be	33225990	1721	1723	O
offered	33225990	1724	1731	O
for	33225990	1732	1735	O
maximizing	33225990	1736	1746	O
comfort	33225990	1747	1754	O
at	33225990	1755	1757	O
chest	33225990	1758	1763	O
,	33225990	1764	1765	O
pelvis	33225990	1766	1772	O
and	33225990	1773	1776	O
knees	33225990	1777	1782	O
.	33225990	1783	1784	O

Monitoring	33225990	1785	1795	O
of	33225990	1796	1798	O
vital	33225990	1799	1804	O
signs	33225990	1805	1810	O
will	33225990	1811	1815	O
not	33225990	1816	1819	O
be	33225990	1820	1822	O
suspended	33225990	1823	1832	O
.	33225990	1833	1834	O

Inspired	33225990	1835	1843	O
fraction	33225990	1844	1852	O
of	33225990	1853	1855	O
oxygen	33225990	1856	1862	O
will	33225990	1863	1867	O
be	33225990	1868	1870	O
titrated	33225990	1871	1879	O
to	33225990	1880	1882	O
maintain	33225990	1883	1891	O
a	33225990	1892	1893	O
capillary	33225990	1894	1903	O
saturation	33225990	1904	1914	O
of	33225990	1915	1917	O
92%-95	33225990	1918	1924	O
%	33225990	1925	1926	O
.	33225990	1927	1928	O

For	33225990	1929	1932	O
patients	33225990	1933	1941	O
in	33225990	1942	1944	O
the	33225990	1945	1948	O
control	33225990	1949	1956	O
group	33225990	1957	1962	O
,	33225990	1963	1964	O
prone	33225990	1965	1970	O
positioning	33225990	1971	1982	O
will	33225990	1983	1987	O
be	33225990	1988	1990	O
allowed	33225990	1991	1998	O
as	33225990	1999	2001	O
a	33225990	2002	2003	O
rescue	33225990	2004	2010	O
therapy	33225990	2011	2018	O
.	33225990	2019	2020	O

Staff	33225990	2021	2026	O
intensivists	33225990	2027	2039	O
will	33225990	2040	2044	O
monitor	33225990	2045	2052	O
the	33225990	2053	2056	O
patient	33225990	2057	2064	O
's	33225990	2065	2067	O
status	33225990	2068	2074	O
in	33225990	2075	2077	O
both	33225990	2078	2082	O
groups	33225990	2083	2089	O
on	33225990	2090	2092	O
a	33225990	2093	2094	O
24/7	33225990	2095	2099	O
basis	33225990	2100	2105	O
.	33225990	2106	2107	O

All	33225990	2108	2111	O
other	33225990	2112	2117	O
treatment	33225990	2118	2127	O
will	33225990	2128	2132	O
be	33225990	2133	2135	O
unchanged	33225990	2136	2145	O
and	33225990	2146	2149	O
left	33225990	2150	2154	O
to	33225990	2155	2157	O
the	33225990	2158	2161	O
attending	33225990	2162	2171	O
physicians	33225990	2172	2182	O
.	33225990	2183	2184	O

RESULTS	33225990	2185	2192	O
:	33225990	2193	2194	O
Endotracheal	33225990	2195	2207	O
intubation	33225990	2208	2218	O
rate	33225990	2219	2223	O
for	33225990	2224	2227	O
mechanical	33225990	2228	2238	O
ventilation	33225990	2239	2250	O
at	33225990	2251	2253	O
28	33225990	2254	2256	O
days	33225990	2257	2261	O
.	33225990	2262	2263	O

UNASSIGNED	33225990	2264	2274	O
:	33225990	2275	2276	O
Patients	33225990	2277	2285	O
will	33225990	2286	2290	O
be	33225990	2291	2293	O
randomly	33225990	2294	2302	O
allocated	33225990	2303	2312	O
to	33225990	2313	2315	O
either	33225990	2316	2322	O
prone	33225990	2323	2328	O
positioning	33225990	2329	2340	O
or	33225990	2341	2343	O
control	33225990	2344	2351	O
group	33225990	2352	2357	O
at	33225990	2358	2360	O
1:1	33225990	2361	2364	O
ratio	33225990	2365	2370	O
.	33225990	2371	2372	O

Such	33225990	2373	2377	O
randomization	33225990	2378	2391	O
will	33225990	2392	2396	O
be	33225990	2397	2399	O
computer	33225990	2400	2408	O
generated	33225990	2409	2418	O
and	33225990	2419	2422	O
stratified	33225990	2423	2433	O
by	33225990	2434	2436	O
center	33225990	2437	2443	O
with	33225990	2444	2448	O
permuted	33225990	2449	2457	O
blocks	33225990	2458	2464	O
and	33225990	2465	2468	O
length	33225990	2469	2475	O
of	33225990	2476	2478	O
4	33225990	2479	2480	O
.	33225990	2481	2482	O

UNASSIGNED	33225990	2483	2493	O
:	33225990	2494	2495	O
Due	33225990	2496	2499	O
to	33225990	2500	2502	O
logistical	33225990	2503	2513	O
reasons	33225990	2514	2521	O
,	33225990	2522	2523	O
only	33225990	2524	2528	O
principal	33225990	2529	2538	O
investigators	33225990	2539	2552	O
and	33225990	2553	2556	O
the	33225990	2557	2560	O
data	33225990	2561	2565	O
analyst	33225990	2566	2573	O
will	33225990	2574	2578	O
be	33225990	2579	2581	O
blinded	33225990	2582	2589	O
to	33225990	2590	2592	O
group	33225990	2593	2598	O
assignment	33225990	2599	2609	O
.	33225990	2610	2611	O

UNASSIGNED	33225990	2612	2622	O
:	33225990	2623	2624	O
With	33225990	2625	2629	O
an	33225990	2630	2632	O
intubation	33225990	2633	2643	O
rate	33225990	2644	2648	O
of	33225990	2649	2651	O
60	33225990	2652	2654	O
%	33225990	2655	2656	O
according	33225990	2657	2666	O
to	33225990	2667	2669	O
recent	33225990	2670	2676	O
reports	33225990	2677	2684	O
from	33225990	2685	2689	O
some	33225990	2690	2694	O
American	33225990	2695	2703	O
centers	33225990	2704	2711	O
,	33225990	2712	2713	O
and	33225990	2714	2717	O
assuming	33225990	2718	2726	O
a	33225990	2727	2728	O
decrease	33225990	2729	2737	O
to	33225990	2738	2740	O
40	33225990	2741	2743	O
%	33225990	2744	2745	O
to	33225990	2746	2748	O
be	33225990	2749	2751	O
clinically	33225990	2752	2762	O
relevant	33225990	2763	2771	O
,	33225990	2772	2773	O
we	33225990	2774	2776	O
calculated	33225990	2777	2787	O
a	33225990	2788	2789	O
total	33225990	2790	2795	O
of	33225990	2796	2798	O
96	33225990	2799	2801	O
patients	33225990	2802	2810	O
per	33225990	2811	2814	O
group	33225990	2815	2820	O
,	33225990	2821	2822	O
for	33225990	2823	2826	O
a	33225990	2827	2828	O
beta	33225990	2829	2833	O
error	33225990	2834	2839	O
of	33225990	2840	2842	O
0.2	33225990	2843	2846	O
,	33225990	2847	2848	O
and	33225990	2849	2852	O
alpha	33225990	2853	2858	O
of	33225990	2859	2861	O
0.5	33225990	2862	2865	O
.	33225990	2866	2867	O

Therefore	33225990	2868	2877	O
,	33225990	2878	2879	O
we	33225990	2880	2882	O
plan	33225990	2883	2887	O
to	33225990	2888	2890	O
recruit	33225990	2891	2898	O
200	33225990	2899	2902	O
patients	33225990	2903	2911	O
,	33225990	2912	2913	O
accounting	33225990	2914	2924	O
for	33225990	2925	2928	O
minimal	33225990	2929	2936	O
losses	33225990	2937	2943	O
to	33225990	2944	2946	O
follow	33225990	2947	2953	O
up	33225990	2954	2956	O
,	33225990	2957	2958	O
with	33225990	2959	2963	O
100	33225990	2964	2967	O
non	33225990	2968	2971	O
-	33225990	2972	2973	O
intubated	33225990	2974	2983	O
patients	33225990	2984	2992	O
in	33225990	2993	2995	O
the	33225990	2996	2999	O
prone	33225990	3000	3005	O
position	33225990	3006	3014	O
group	33225990	3015	3020	O
and	33225990	3021	3024	O
a	33225990	3025	3026	O
100	33225990	3027	3030	O
in	33225990	3031	3033	O
the	33225990	3034	3037	O
control	33225990	3038	3045	O
group	33225990	3046	3051	O
.	33225990	3052	3053	O

UNASSIGNED	33225990	3054	3064	O
:	33225990	3065	3066	O
The	33225990	3067	3070	O
local	33225990	3071	3076	O
registration	33225990	3077	3089	O
number	33225990	3090	3096	O
is	33225990	3097	3099	O
048	33225990	3100	3103	O
-	33225990	3104	3105	O
20	33225990	3106	3108	O
,	33225990	3109	3110	O
with	33225990	3111	3115	O
the	33225990	3116	3119	O
protocol	33225990	3120	3128	O
version	33225990	3129	3136	O
number	33225990	3137	3143	O
2.0	33225990	3144	3147	O
.	33225990	3148	3149	O

The	33225990	3150	3153	O
date	33225990	3154	3158	O
of	33225990	3159	3161	O
approval	33225990	3162	3170	O
is	33225990	3171	3173	O
3rd	33225990	3174	3177	O
May	33225990	3178	3181	O
2020	33225990	3182	3186	O
.	33225990	3187	3188	O

Recruitment	33225990	3189	3200	O
started	33225990	3201	3208	O
on	33225990	3209	3211	O
3rd	33225990	3212	3215	O
May	33225990	3216	3219	O
and	33225990	3220	3223	O
is	33225990	3224	3226	O
expected	33225990	3227	3235	O
to	33225990	3236	3238	O
end	33225990	3239	3242	O
in	33225990	3243	3245	O
December	33225990	3246	3254	O
2020	33225990	3255	3259	O
.	33225990	3260	3261	O

BACKGROUND	33225990	3262	3272	O
:	33225990	3273	3274	O
The	33225990	3275	3278	O
protocol	33225990	3279	3287	O
was	33225990	3288	3291	O
retrospectively	33225990	3292	3307	O
registered	33225990	3308	3318	O
under	33225990	3319	3324	O
the	33225990	3325	3328	O
title	33225990	3329	3334	O
:	33225990	3335	3336	O
"	33225990	3337	3338	O
Prone	33225990	3339	3344	O
Positioning	33225990	3345	3356	O
in	33225990	3357	3359	O
Non	33225990	3360	3363	O
-	33225990	3364	3365	O
intubated	33225990	3366	3375	O
Patients	33225990	3376	3384	O
With	33225990	3385	3389	O
COVID-19	33225990	3390	3398	O
Associated	33225990	3399	3409	O
Acute	33225990	3410	3415	O
Respiratory	33225990	3416	3427	O
Failure	33225990	3428	3435	O
.	33225990	3436	3437	O

The	33225990	3438	3441	O
PRO	33225990	3442	3445	O
-	33225990	3446	3447	O
CARF	33225990	3448	3452	O
trial	33225990	3453	3458	O
"	33225990	3459	3460	O
in	33225990	3461	3463	O
ClinicalTrials.gov	33225990	3464	3482	O
with	33225990	3483	3487	O
the	33225990	3488	3491	O
registration	33225990	3492	3504	O
number	33225990	3505	3511	O
:	33225990	3512	3513	O
NCT04477655	33225990	3514	3525	O
.	33225990	3526	3527	O

Registered	33225990	3528	3538	O
on	33225990	3539	3541	O
20	33225990	3542	3544	O
July	33225990	3545	3549	O
2020	33225990	3550	3554	O
.	33225990	3555	3556	O

UNASSIGNED	33225990	3557	3567	O
:	33225990	3568	3569	O
The	33225990	3570	3573	O
full	33225990	3574	3578	O
protocol	33225990	3579	3587	O
is	33225990	3588	3590	O
attached	33225990	3591	3599	O
as	33225990	3600	3602	O
an	33225990	3603	3605	O
additional	33225990	3606	3616	O
file	33225990	3617	3621	O
,	33225990	3622	3623	O
accessible	33225990	3624	3634	O
from	33225990	3635	3639	O
the	33225990	3640	3643	O
Trials	33225990	3644	3650	O
website	33225990	3651	3658	O
(	33225990	3659	3660	O
Additional	33225990	3661	3671	O
file	33225990	3672	3676	O
1	33225990	3677	3678	O
)	33225990	3679	3680	O
.	33225990	3681	3682	O

In	33225990	3683	3685	O
the	33225990	3686	3689	O
interest	33225990	3690	3698	O
in	33225990	3699	3701	O
expediting	33225990	3702	3712	O
dissemination	33225990	3713	3726	O
of	33225990	3727	3729	O
this	33225990	3730	3734	O
material	33225990	3735	3743	O
,	33225990	3744	3745	O
the	33225990	3746	3749	O
familiar	33225990	3750	3758	O
formatting	33225990	3759	3769	O
has	33225990	3770	3773	O
been	33225990	3774	3778	O
eliminated	33225990	3779	3789	O
;	33225990	3790	3791	O
this	33225990	3792	3796	O
Letter	33225990	3797	3803	O
serves	33225990	3804	3810	O
as	33225990	3811	3813	O
a	33225990	3814	3815	O
summary	33225990	3816	3823	O
of	33225990	3824	3826	O
the	33225990	3827	3830	O
key	33225990	3831	3834	O
elements	33225990	3835	3843	O
of	33225990	3844	3846	O
the	33225990	3847	3850	O
full	33225990	3851	3855	O
protocol	33225990	3856	3864	O
.	33225990	3865	3866	O

The	33225990	3867	3870	O
study	33225990	3871	3876	O
protocol	33225990	3877	3885	O
has	33225990	3886	3889	O
been	33225990	3890	3894	O
reported	33225990	3895	3903	O
in	33225990	3904	3906	O
accordance	33225990	3907	3917	O
with	33225990	3918	3922	O
the	33225990	3923	3926	O
Standard	33225990	3927	3935	O
Protocol	33225990	3936	3944	O
Items	33225990	3945	3950	O
:	33225990	3951	3952	O
Recommendations	33225990	3953	3968	O
for	33225990	3969	3972	O
Clinical	33225990	3973	3981	O
Interventional	33225990	3982	3996	O
Trials	33225990	3997	4003	O
(	33225990	4004	4005	O
SPIRIT	33225990	4006	4012	O
)	33225990	4013	4014	O
guidelines	33225990	4015	4025	O
(	33225990	4026	4027	O
Additional	33225990	4028	4038	O
file	33225990	4039	4043	O
2	33225990	4044	4045	O
)	33225990	4046	4047	O
.	33225990	4048	4049	O


Comparison	33225995	0	10	O
of	33225995	11	13	O
four	33225995	14	18	O
COVID-19	33225995	19	27	O
screening	33225995	28	37	O
strategies	33225995	38	48	O
to	33225995	49	51	O
facilitate	33225995	52	62	O
early	33225995	63	68	O
case	33225995	69	73	O
identification	33225995	74	88	O
within	33225995	89	95	O
the	33225995	96	99	O
homeless	33225995	100	108	O
shelter	33225995	109	116	O
population	33225995	117	127	O
:	33225995	128	129	O
A	33225995	130	131	O
structured	33225995	132	142	O
summary	33225995	143	150	O
of	33225995	151	153	O
a	33225995	154	155	O
study	33225995	156	161	O
protocol	33225995	162	170	O
for	33225995	171	174	O
a	33225995	175	176	O
randomised	33225995	177	187	O
controlled	33225995	188	198	O
trial	33225995	199	204	O
.	33225995	205	206	O

OBJECTIVE	33225995	207	216	O
:	33225995	217	218	O
1	33225995	219	220	O
.	33225995	221	222	O

To	33225995	223	225	O
compare	33225995	226	233	O
the	33225995	234	237	O
effectiveness	33225995	238	251	O
of	33225995	252	254	O
four	33225995	255	259	O
different	33225995	260	269	O
surveillance	33225995	270	282	O
strategies	33225995	283	293	O
in	33225995	294	296	O
detecting	33225995	297	306	O
COVID-19	33225995	307	315	O
within	33225995	316	322	O
the	33225995	323	326	O
homeless	33225995	327	335	O
shelter	33225995	336	343	O
population	33225995	344	354	O
.	33225995	355	356	O

2	33225995	357	358	O
.	33225995	359	360	O

To	33225995	361	363	O
assess	33225995	364	370	O
the	33225995	371	374	O
participant	33225995	375	386	O
adherence	33225995	387	396	O
over	33225995	397	401	O
time	33225995	402	406	O
for	33225995	407	410	O
each	33225995	411	415	O
surveillance	33225995	416	428	O
method	33225995	429	435	O
.	33225995	436	437	O

METHODS	33225995	438	445	O
:	33225995	446	447	O
This	33225995	448	452	O
is	33225995	453	455	O
a	33225995	456	457	O
prospective	33225995	458	469	O
cluster	33225995	470	477	O
-	33225995	478	479	O
randomized	33225995	480	490	O
study	33225995	491	496	O
to	33225995	497	499	O
compare	33225995	500	507	O
the	33225995	508	511	O
effectiveness	33225995	512	525	O
of	33225995	526	528	O
four	33225995	529	533	O
different	33225995	534	543	O
surveillance	33225995	544	556	O
regimens	33225995	557	565	O
across	33225995	566	572	O
eight	33225995	573	578	O
homeless	33225995	579	587	O
shelters	33225995	588	596	O
in	33225995	597	599	O
the	33225995	600	603	O
city	33225995	604	608	O
of	33225995	609	611	O
Hamilton	33225995	612	620	O
.	33225995	621	622	O

METHODS	33225995	623	630	O
:	33225995	631	632	O
Participants	33225995	633	645	O
will	33225995	646	650	O
include	33225995	651	658	O
both	33225995	659	663	O
residents	33225995	664	673	O
of	33225995	674	676	O
,	33225995	677	678	O
and	33225995	679	682	O
the	33225995	683	686	O
staff	33225995	687	692	O
working	33225995	693	700	O
within	33225995	701	707	O
,	33225995	708	709	O
the	33225995	710	713	O
homeless	33225995	714	722	O
shelters	33225995	723	731	O
.	33225995	732	733	O

All	33225995	734	737	O
participants	33225995	738	750	O
aged	33225995	751	755	O
18	33225995	756	758	O
or	33225995	759	761	O
older	33225995	762	767	O
who	33225995	768	771	O
consent	33225995	772	779	O
to	33225995	780	782	O
the	33225995	783	786	O
study	33225995	787	792	O
and	33225995	793	796	O
are	33225995	797	800	O
able	33225995	801	805	O
to	33225995	806	808	O
collect	33225995	809	816	O
a	33225995	817	818	O
swab	33225995	819	823	O
sample	33225995	824	830	O
(	33225995	831	832	O
where	33225995	833	838	O
relevant	33225995	839	847	O
)	33225995	848	849	O
are	33225995	850	853	O
eligible	33225995	854	862	O
for	33225995	863	866	O
the	33225995	867	870	O
study	33225995	871	876	O
.	33225995	877	878	O

The	33225995	879	882	O
study	33225995	883	888	O
will	33225995	889	893	O
take	33225995	894	898	O
place	33225995	899	904	O
across	33225995	905	911	O
eight	33225995	912	917	O
homeless	33225995	918	926	O
shelters	33225995	927	935	O
(	33225995	936	937	O
four	33225995	938	942	O
men	33225995	943	946	O
-	33225995	947	948	O
only	33225995	949	953	O
and	33225995	954	957	O
four	33225995	958	962	O
women	33225995	963	968	O
-	33225995	969	970	O
only	33225995	971	975	O
)	33225995	976	977	O
in	33225995	978	980	O
the	33225995	981	984	O
City	33225995	985	989	O
of	33225995	990	992	O
Hamilton	33225995	993	1001	O
in	33225995	1002	1004	O
Ontario	33225995	1005	1012	O
,	33225995	1013	1014	O
Canada	33225995	1015	1021	O
.	33225995	1022	1023	O
UNASSIGNED	33225995	1024	1034	O
:	33225995	1035	1036	O
The	33225995	1037	1040	O
comparator	33225995	1041	1051	O
group	33225995	1052	1057	O
will	33225995	1058	1062	O
receive	33225995	1063	1070	O
active	33225995	1071	1077	O
daily	33225995	1078	1083	O
surveillance	33225995	1084	1096	O
of	33225995	1097	1099	O
symptoms	33225995	1100	1108	O
and	33225995	1109	1112	O
testing	33225995	1113	1120	O
will	33225995	1121	1125	O
only	33225995	1126	1130	O
be	33225995	1131	1133	O
completed	33225995	1134	1143	O
in	33225995	1144	1146	O
symptomatic	33225995	1147	1158	O
participants	33225995	1159	1171	O
(	33225995	1172	1173	O
i.e.	33225995	1174	1178	O
those	33225995	1179	1184	O
who	33225995	1185	1188	O
fail	33225995	1189	1193	O
screening	33225995	1194	1203	O
or	33225995	1204	1206	O
who	33225995	1207	1210	O
seek	33225995	1211	1215	O
care	33225995	1216	1220	O
for	33225995	1221	1224	O
potential	33225995	1225	1234	O
COVID-19	33225995	1235	1243	O
related	33225995	1244	1251	O
symptoms	33225995	1252	1260	O
)	33225995	1261	1262	O
.	33225995	1263	1264	O

The	33225995	1265	1268	O
three	33225995	1269	1274	O
intervention	33225995	1275	1287	O
arms	33225995	1288	1292	O
will	33225995	1293	1297	O
all	33225995	1298	1301	O
receive	33225995	1302	1309	O
active	33225995	1310	1316	O
daily	33225995	1317	1322	O
surveillance	33225995	1323	1335	O
of	33225995	1336	1338	O
symptoms	33225995	1339	1347	O
and	33225995	1348	1351	O
testing	33225995	1352	1359	O
of	33225995	1360	1362	O
symptomatic	33225995	1363	1374	O
participants	33225995	1375	1387	O
(	33225995	1388	1389	O
as	33225995	1390	1392	O
in	33225995	1393	1395	O
the	33225995	1396	1399	O
comparator	33225995	1400	1410	O
group	33225995	1411	1416	O
)	33225995	1417	1418	O
in	33225995	1419	1421	O
addition	33225995	1422	1430	O
to	33225995	1431	1433	O
one	33225995	1434	1437	O
of	33225995	1438	1440	O
the	33225995	1441	1444	O
following	33225995	1445	1454	O
:	33225995	1455	1456	O
1	33225995	1457	1458	O
.	33225995	1459	1460	O

Once	33225995	1461	1465	O
weekly	33225995	1466	1472	O
self	33225995	1473	1477	O
-	33225995	1478	1479	O
collected	33225995	1480	1489	O
oral	33225995	1490	1494	O
swabs	33225995	1495	1500	O
(	33225995	1501	1502	O
OS	33225995	1503	1505	O
)	33225995	1506	1507	O
regardless	33225995	1508	1518	O
of	33225995	1519	1521	O
symptoms	33225995	1522	1530	O
using	33225995	1531	1536	O
written	33225995	1537	1544	O
and	33225995	1545	1548	O
visual	33225995	1549	1555	O
instructions	33225995	1556	1568	O
.	33225995	1569	1570	O

2	33225995	1571	1572	O
.	33225995	1573	1574	O

Once	33225995	1575	1579	O
weekly	33225995	1580	1586	O
self	33225995	1587	1591	O
-	33225995	1592	1593	O
collected	33225995	1594	1603	O
oral	33225995	1604	1608	O
-	33225995	1609	1610	O
nares	33225995	1611	1616	O
swab	33225995	1617	1621	O
(	33225995	1622	1623	O
O	33225995	1624	1625	O
-	33225995	1626	1627	O
NS	33225995	1628	1630	O
)	33225995	1631	1632	O
regardless	33225995	1633	1643	O
of	33225995	1644	1646	O
symptoms	33225995	1647	1655	O
using	33225995	1656	1661	O
written	33225995	1662	1669	O
and	33225995	1670	1673	O
visual	33225995	1674	1680	O
instructions	33225995	1681	1693	O
.	33225995	1694	1695	O

3	33225995	1696	1697	O
.	33225995	1698	1699	O

Once	33225995	1700	1704	O
weekly	33225995	1705	1711	O
nurse	33225995	1712	1717	O
collected	33225995	1718	1727	O
nasopharyngeal	33225995	1728	1742	O
swab	33225995	1743	1747	O
(	33225995	1748	1749	O
NPS	33225995	1750	1753	O
)	33225995	1754	1755	O
regardless	33225995	1756	1766	O
of	33225995	1767	1769	O
symptoms	33225995	1770	1778	O
.	33225995	1779	1780	O

Participants	33225995	1781	1793	O
will	33225995	1794	1798	O
follow	33225995	1799	1805	O
verbal	33225995	1806	1812	O
and	33225995	1813	1816	O
written	33225995	1817	1824	O
instructions	33225995	1825	1837	O
for	33225995	1838	1841	O
the	33225995	1842	1845	O
collection	33225995	1846	1856	O
of	33225995	1857	1859	O
OS	33225995	1860	1862	O
and	33225995	1863	1866	O
O	33225995	1867	1868	O
-	33225995	1869	1870	O
NS	33225995	1871	1873	O
specimens	33225995	1874	1883	O
.	33225995	1884	1885	O

For	33225995	1886	1889	O
OS	33225995	1890	1892	O
collection	33225995	1893	1903	O
,	33225995	1904	1905	O
participants	33225995	1906	1918	O
are	33225995	1919	1922	O
instructed	33225995	1923	1933	O
to	33225995	1934	1936	O
first	33225995	1937	1942	O
moisten	33225995	1943	1950	O
the	33225995	1951	1954	O
swab	33225995	1955	1959	O
on	33225995	1960	1962	O
their	33225995	1963	1968	O
tongue	33225995	1969	1975	O
,	33225995	1976	1977	O
insert	33225995	1978	1984	O
the	33225995	1985	1988	O
swab	33225995	1989	1993	O
between	33225995	1994	2001	O
the	33225995	2002	2005	O
cheek	33225995	2006	2011	O
and	33225995	2012	2015	O
the	33225995	2016	2019	O
lower	33225995	2020	2025	O
gums	33225995	2026	2030	O
and	33225995	2031	2034	O
rotate	33225995	2035	2041	O
the	33225995	2042	2045	O
swab	33225995	2046	2050	O
three	33225995	2051	2056	O
times	33225995	2057	2062	O
.	33225995	2063	2064	O

This	33225995	2065	2069	O
is	33225995	2070	2072	O
repeated	33225995	2073	2081	O
on	33225995	2082	2084	O
the	33225995	2085	2088	O
other	33225995	2089	2094	O
side	33225995	2095	2099	O
.	33225995	2100	2101	O

For	33225995	2102	2105	O
O	33225995	2106	2107	O
-	33225995	2108	2109	O
NS	33225995	2110	2112	O
collection	33225995	2113	2123	O
,	33225995	2124	2125	O
after	33225995	2126	2131	O
oral	33225995	2132	2136	O
collection	33225995	2137	2147	O
,	33225995	2148	2149	O
the	33225995	2150	2153	O
swab	33225995	2154	2158	O
is	33225995	2159	2161	O
inserted	33225995	2162	2170	O
comfortably	33225995	2171	2182	O
(	33225995	2183	2184	O
about	33225995	2185	2190	O
2	33225995	2191	2192	O
-	33225995	2193	2194	O
3	33225995	2195	2196	O
cm	33225995	2197	2199	O
)	33225995	2200	2201	O
into	33225995	2202	2206	O
one	33225995	2207	2210	O
nostril	33225995	2211	2218	O
,	33225995	2219	2220	O
parallel	33225995	2221	2229	O
to	33225995	2230	2232	O
the	33225995	2233	2236	O
floor	33225995	2237	2242	O
and	33225995	2243	2246	O
turned	33225995	2247	2253	O
three	33225995	2254	2259	O
times	33225995	2260	2265	O
,	33225995	2266	2267	O
then	33225995	2268	2272	O
repeated	33225995	2273	2281	O
in	33225995	2282	2284	O
the	33225995	2285	2288	O
other	33225995	2289	2294	O
nostril	33225995	2295	2302	O
.	33225995	2303	2304	O

NPS	33225995	2305	2308	O
specimens	33225995	2309	2318	O
were	33225995	2319	2323	O
collected	33225995	2324	2333	O
by	33225995	2334	2336	O
the	33225995	2337	2340	O
nurse	33225995	2341	2346	O
following	33225995	2347	2356	O
standard	33225995	2357	2365	O
of	33225995	2366	2368	O
care	33225995	2369	2373	O
procedure	33225995	2374	2383	O
.	33225995	2384	2385	O

All	33225995	2386	2389	O
swabs	33225995	2390	2395	O
were	33225995	2396	2400	O
placed	33225995	2401	2407	O
into	33225995	2408	2412	O
a	33225995	2413	2414	O
viral	33225995	2415	2420	O
inactivation	33225995	2421	2433	O
medium	33225995	2434	2440	O
and	33225995	2441	2444	O
transported	33225995	2445	2456	O
to	33225995	2457	2459	O
the	33225995	2460	2463	O
laboratory	33225995	2464	2474	O
for	33225995	2475	2478	O
COVID-19	33225995	2479	2487	O
testing	33225995	2488	2495	O
.	33225995	2496	2497	O

Briefly	33225995	2498	2505	O
,	33225995	2506	2507	O
total	33225995	2508	2513	O
nucleic	33225995	2514	2521	O
acid	33225995	2522	2526	O
was	33225995	2527	2530	O
extracted	33225995	2531	2540	O
from	33225995	2541	2545	O
specimens	33225995	2546	2555	O
and	33225995	2556	2559	O
then	33225995	2560	2564	O
amplified	33225995	2565	2574	O
by	33225995	2575	2577	O
RT	33225995	2578	2580	O
-	33225995	2581	2582	O
PCR	33225995	2583	2586	O
for	33225995	2587	2590	O
the	33225995	2591	2594	O
UTR	33225995	2595	2598	O
and	33225995	2599	2602	O
Envelope	33225995	2603	2611	O
genes	33225995	2612	2617	O
of	33225995	2618	2620	O
SARS	33225995	2621	2625	O
-	33225995	2626	2627	O
CoV-2	33225995	2628	2633	O
and	33225995	2634	2637	O
the	33225995	2638	2641	O
human	33225995	2642	2647	O
RNase	33225995	2648	2653	O
P	33225995	2654	2655	O
gene	33225995	2656	2660	O
,	33225995	2661	2662	O
which	33225995	2663	2668	O
is	33225995	2669	2671	O
used	33225995	2672	2676	O
as	33225995	2677	2679	O
a	33225995	2680	2681	O
sample	33225995	2682	2688	O
adequacy	33225995	2689	2697	O
marker	33225995	2698	2704	O
.	33225995	2705	2706	O

RESULTS	33225995	2707	2714	O
:	33225995	2715	2716	O
1	33225995	2717	2718	O
.	33225995	2719	2720	O

METHODS	33225995	2721	2728	O
:	33225995	2729	2730	O
COVID-19	33225995	2731	2739	O
detection	33225995	2740	2749	O
rate	33225995	2750	2754	O
,	33225995	2755	2756	O
i.e.	33225995	2757	2761	O
the	33225995	2762	2765	O
number	33225995	2766	2772	O
of	33225995	2773	2775	O
new	33225995	2776	2779	O
positive	33225995	2780	2788	O
cases	33225995	2789	2794	O
over	33225995	2795	2799	O
the	33225995	2800	2803	O
study	33225995	2804	2809	O
period	33225995	2810	2816	O
of	33225995	2817	2819	O
8	33225995	2820	2821	O
weeks	33225995	2822	2827	O
in	33225995	2828	2830	O
each	33225995	2831	2835	O
arm	33225995	2836	2839	O
of	33225995	2840	2842	O
the	33225995	2843	2846	O
study	33225995	2847	2852	O
.	33225995	2853	2854	O

2	33225995	2855	2856	O
.	33225995	2857	2858	O
RESULTS	33225995	2859	2866	O
:	33225995	2867	2868	O
Qualitative	33225995	2869	2880	O
assessment	33225995	2881	2891	O
of	33225995	2892	2894	O
study	33225995	2895	2900	O
enrollment	33225995	2901	2911	O
over	33225995	2912	2916	O
8	33225995	2917	2918	O
weeks	33225995	2919	2924	O
.	33225995	2925	2926	O

Percentage	33225995	2927	2937	O
of	33225995	2938	2940	O
participants	33225995	2941	2953	O
who	33225995	2954	2957	O
performed	33225995	2958	2967	O
50	33225995	2968	2970	O
%	33225995	2971	2972	O
or	33225995	2973	2975	O
more	33225995	2976	2980	O
of	33225995	2981	2983	O
the	33225995	2984	2987	O
weekly	33225995	2988	2994	O
swabs	33225995	2995	3000	O
in	33225995	3001	3003	O
the	33225995	3004	3007	O
intervention	33225995	3008	3020	O
arms	33225995	3021	3025	O
in	33225995	3026	3028	O
the	33225995	3029	3032	O
8	33225995	3033	3034	O
week	33225995	3035	3039	O
study	33225995	3040	3045	O
period	33225995	3046	3052	O
.	33225995	3053	3054	O

UNASSIGNED	33225995	3055	3065	O
:	33225995	3066	3067	O
We	33225995	3068	3070	O
will	33225995	3071	3075	O
use	33225995	3076	3079	O
a	33225995	3080	3081	O
computer	33225995	3082	3090	O
-	33225995	3091	3092	O
generated	33225995	3093	3102	O
random	33225995	3103	3109	O
assignment	33225995	3110	3120	O
list	33225995	3121	3125	O
to	33225995	3126	3128	O
randomize	33225995	3129	3138	O
the	33225995	3139	3142	O
shelters	33225995	3143	3151	O
to	33225995	3152	3154	O
one	33225995	3155	3158	O
of	33225995	3159	3161	O
four	33225995	3162	3166	O
interventions	33225995	3167	3180	O
.	33225995	3181	3182	O

Shelters	33225995	3183	3191	O
were	33225995	3192	3196	O
stratified	33225995	3197	3207	O
by	33225995	3208	3210	O
gender	33225995	3211	3217	O
,	33225995	3218	3219	O
and	33225995	3220	3223	O
the	33225995	3224	3227	O
simple	33225995	3228	3234	O
randomization	33225995	3235	3248	O
scheme	33225995	3249	3255	O
was	33225995	3256	3259	O
applied	33225995	3260	3267	O
within	33225995	3268	3274	O
each	33225995	3275	3279	O
stratum	33225995	3280	3287	O
.	33225995	3288	3289	O

The	33225995	3290	3293	O
randomization	33225995	3294	3307	O
scheme	33225995	3308	3314	O
was	33225995	3315	3318	O
created	33225995	3319	3326	O
using	33225995	3327	3332	O
WinPEPI	33225995	3333	3340	O
.	33225995	3341	3342	O

UNASSIGNED	33225995	3343	3353	O
:	33225995	3354	3355	O
This	33225995	3356	3360	O
is	33225995	3361	3363	O
an	33225995	3364	3366	O
open	33225995	3367	3371	O
-	33225995	3372	3373	O
label	33225995	3374	3379	O
study	33225995	3380	3385	O
in	33225995	3386	3388	O
which	33225995	3389	3394	O
neither	33225995	3395	3402	O
participants	33225995	3403	3415	O
nor	33225995	3416	3419	O
assessors	33225995	3420	3429	O
are	33225995	3430	3433	O
blinded	33225995	3434	3441	O
.	33225995	3442	3443	O

UNASSIGNED	33225995	3444	3454	O
:	33225995	3455	3456	O
Since	33225995	3457	3462	O
we	33225995	3463	3465	O
are	33225995	3466	3469	O
including	33225995	3470	3479	O
our	33225995	3480	3483	O
total	33225995	3484	3489	O
sample	33225995	3490	3496	O
frame	33225995	3497	3502	O
,	33225995	3503	3504	O
a	33225995	3505	3506	O
sample	33225995	3507	3513	O
size	33225995	3514	3518	O
estimation	33225995	3519	3529	O
at	33225995	3530	3532	O
the	33225995	3533	3536	O
cluster	33225995	3537	3544	O
level	33225995	3545	3550	O
is	33225995	3551	3553	O
not	33225995	3554	3557	O
required	33225995	3558	3566	O
.	33225995	3567	3568	O

However	33225995	3569	3576	O
,	33225995	3577	3578	O
if	33225995	3579	3581	O
we	33225995	3582	3584	O
succeed	33225995	3585	3592	O
to	33225995	3593	3595	O
enroll	33225995	3596	3602	O
50	33225995	3603	3605	O
participants	33225995	3606	3618	O
per	33225995	3619	3622	O
shelter	33225995	3623	3630	O
from	33225995	3631	3635	O
8	33225995	3636	3637	O
shelters	33225995	3638	3646	O
(	33225995	3647	3648	O
n=400	33225995	3649	3654	O
)	33225995	3655	3656	O
,	33225995	3657	3658	O
and	33225995	3659	3662	O
the	33225995	3663	3666	O
detection	33225995	3667	3676	O
rate	33225995	3677	3681	O
is	33225995	3682	3684	O
3	33225995	3685	3686	O
times	33225995	3687	3692	O
higher	33225995	3693	3699	O
in	33225995	3700	3702	O
the	33225995	3703	3706	O
intervention	33225995	3707	3719	O
groups	33225995	3720	3726	O
(	33225995	3727	3728	O
0.15	33225995	3729	3733	O
)	33225995	3734	3735	O
than	33225995	3736	3740	O
in	33225995	3741	3743	O
the	33225995	3744	3747	O
comparator	33225995	3748	3758	O
groups	33225995	3759	3765	O
(	33225995	3766	3767	O
0.05	33225995	3768	3772	O
)	33225995	3773	3774	O
,	33225995	3775	3776	O
we	33225995	3777	3779	O
will	33225995	3780	3784	O
have	33225995	3785	3789	O
90	33225995	3790	3792	O
%	33225995	3793	3794	O
power	33225995	3795	3800	O
to	33225995	3801	3803	O
detect	33225995	3804	3810	O
a	33225995	3811	3812	O
statistically	33225995	3813	3826	O
significant	33225995	3827	3838	O
and	33225995	3839	3842	O
clinically	33225995	3843	3853	O
important	33225995	3854	3863	O
difference	33225995	3864	3874	O
at	33225995	3875	3877	O
a	33225995	3878	3879	O
type	33225995	3880	3884	O
I	33225995	3885	3886	O
error	33225995	3887	3892	O
rate	33225995	3893	3897	O
of	33225995	3898	3900	O
alpha=0.05	33225995	3901	3911	O
(	33225995	3912	3913	O
one	33225995	3914	3917	O
tailed	33225995	3918	3924	O
)	33225995	3925	3926	O
,	33225995	3927	3928	O
assuming	33225995	3929	3937	O
an	33225995	3938	3940	O
intraclass	33225995	3941	3951	O
correlation	33225995	3952	3963	O
of	33225995	3964	3966	O
~0.008	33225995	3967	3973	O
.	33225995	3974	3975	O

These	33225995	3976	3981	O
computations	33225995	3982	3994	O
were	33225995	3995	3999	O
done	33225995	4000	4004	O
using	33225995	4005	4010	O
WinPEPI	33225995	4011	4018	O
,	33225995	4019	4020	O
and	33225995	4021	4024	O
informed	33225995	4025	4033	O
by	33225995	4034	4036	O
conservative	33225995	4037	4049	O
estimates	33225995	4050	4059	O
from	33225995	4060	4064	O
other	33225995	4065	4070	O
studies	33225995	4071	4078	O
on	33225995	4079	4081	O
respiratory	33225995	4082	4093	O
illness	33225995	4094	4101	O
in	33225995	4102	4104	O
the	33225995	4105	4108	O
homeless	33225995	4109	4117	O
(	33225995	4118	4119	O
see	33225995	4120	4123	O
Full	33225995	4124	4128	O
protocol	33225995	4129	4137	O
)	33225995	4138	4139	O
.	33225995	4140	4141	O

UNASSIGNED	33225995	4142	4152	O
:	33225995	4153	4154	O
The	33225995	4155	4158	O
protocol	33225995	4159	4167	O
version	33225995	4168	4175	O
number	33225995	4176	4182	O
is	33225995	4183	4185	O
3.0	33225995	4186	4189	O
.	33225995	4190	4191	O

Recruitment	33225995	4192	4203	O
began	33225995	4204	4209	O
on	33225995	4210	4212	O
April	33225995	4213	4218	O
17	33225995	4219	4221	O
,	33225995	4222	4223	O
2020	33225995	4224	4228	O
and	33225995	4229	4232	O
is	33225995	4233	4235	O
ongoing	33225995	4236	4243	O
.	33225995	4244	4245	O

Due	33225995	4246	4249	O
to	33225995	4250	4252	O
low	33225995	4253	4256	O
numbers	33225995	4257	4264	O
of	33225995	4265	4267	O
COVID	33225995	4268	4273	O
cases	33225995	4274	4279	O
in	33225995	4280	4282	O
the	33225995	4283	4286	O
community	33225995	4287	4296	O
and	33225995	4297	4300	O
shelter	33225995	4301	4308	O
system	33225995	4309	4315	O
during	33225995	4316	4322	O
the	33225995	4323	4326	O
initial	33225995	4327	4334	O
study	33225995	4335	4340	O
period	33225995	4341	4347	O
,	33225995	4348	4349	O
the	33225995	4350	4353	O
trial	33225995	4354	4359	O
was	33225995	4360	4363	O
extended	33225995	4364	4372	O
.	33225995	4373	4374	O

The	33225995	4375	4378	O
estimated	33225995	4379	4388	O
date	33225995	4389	4393	O
for	33225995	4394	4397	O
the	33225995	4398	4401	O
end	33225995	4402	4405	O
of	33225995	4406	4408	O
the	33225995	4409	4412	O
extended	33225995	4413	4421	O
recruitment	33225995	4422	4433	O
period	33225995	4434	4440	O
is	33225995	4441	4443	O
Feb	33225995	4444	4447	O
1	33225995	4448	4449	O
,	33225995	4450	4451	O
2021	33225995	4452	4456	O
.	33225995	4457	4458	O

BACKGROUND	33225995	4459	4469	O
:	33225995	4470	4471	O
The	33225995	4472	4475	O
trial	33225995	4476	4481	O
was	33225995	4482	4485	O
registered	33225995	4486	4496	O
with	33225995	4497	4501	O
ClinicalTrials.gov	33225995	4502	4520	O
on	33225995	4521	4523	O
June	33225995	4524	4528	O
18	33225995	4529	4531	O
,	33225995	4532	4533	O
2020	33225995	4534	4538	O
with	33225995	4539	4543	O
the	33225995	4544	4547	O
identifier	33225995	4548	4558	O
NCT04438070	33225995	4559	4570	O
.	33225995	4571	4572	O

UNASSIGNED	33225995	4573	4583	O
:	33225995	4584	4585	O
The	33225995	4586	4589	O
full	33225995	4590	4594	O
protocol	33225995	4595	4603	O
is	33225995	4604	4606	O
attached	33225995	4607	4615	O
as	33225995	4616	4618	O
an	33225995	4619	4621	O
additional	33225995	4622	4632	O
file	33225995	4633	4637	O
,	33225995	4638	4639	O
accessible	33225995	4640	4650	O
from	33225995	4651	4655	O
the	33225995	4656	4659	O
Trials	33225995	4660	4666	O
website	33225995	4667	4674	O
(	33225995	4675	4676	O
Additional	33225995	4677	4687	O
file	33225995	4688	4692	O
1	33225995	4693	4694	O
)	33225995	4695	4696	O
.	33225995	4697	4698	O

In	33225995	4699	4701	O
the	33225995	4702	4705	O
interest	33225995	4706	4714	O
in	33225995	4715	4717	O
expediting	33225995	4718	4728	O
dissemination	33225995	4729	4742	O
of	33225995	4743	4745	O
this	33225995	4746	4750	O
material	33225995	4751	4759	O
,	33225995	4760	4761	O
the	33225995	4762	4765	O
familiar	33225995	4766	4774	O
formatting	33225995	4775	4785	O
has	33225995	4786	4789	O
been	33225995	4790	4794	O
eliminated	33225995	4795	4805	O
;	33225995	4806	4807	O
this	33225995	4808	4812	O
Letter	33225995	4813	4819	O
serves	33225995	4820	4826	O
as	33225995	4827	4829	O
a	33225995	4830	4831	O
summary	33225995	4832	4839	O
of	33225995	4840	4842	O
the	33225995	4843	4846	O
key	33225995	4847	4850	O
elements	33225995	4851	4859	O
of	33225995	4860	4862	O
the	33225995	4863	4866	O
full	33225995	4867	4871	O
protocol	33225995	4872	4880	O
.	33225995	4881	4882	O


The	8840371	0	3	O
comparative	8840371	4	15	B-Outcome
safety	8840371	16	22	I-Outcome
and	8840371	23	26	O
diagnostic	8840371	27	37	B-Outcome
accuracy	8840371	38	46	I-Outcome
of	8840371	47	49	O
adenosine	8840371	50	59	B-Participant
myocardial	8840371	60	70	I-Participant
perfusion	8840371	71	80	I-Participant
imaging	8840371	81	88	I-Participant
in	8840371	89	91	O
women	8840371	92	97	B-Intervention
versus	8840371	98	104	O
men	8840371	105	108	B-Intervention
.	8840371	109	110	O

STUDY	8840371	111	116	O
OBJECTIVE	8840371	117	126	O
To	8840371	127	129	O
determine	8840371	130	139	O
if	8840371	140	142	O
the	8840371	143	146	O
diagnostic	8840371	147	157	B-Outcome
accuracy	8840371	158	166	I-Outcome
and	8840371	167	170	O
safety	8840371	171	177	B-Outcome
of	8840371	178	180	O
intravenous	8840371	181	192	B-Participant
adenosine	8840371	193	202	I-Participant
myocardial	8840371	203	213	I-Participant
perfusion	8840371	214	223	I-Participant
imaging	8840371	224	231	I-Participant
is	8840371	232	234	O
significantly	8840371	235	248	B-Observation
different	8840371	249	258	I-Observation
in	8840371	259	261	O
men	8840371	262	265	B-Intervention
compared	8840371	266	274	O
with	8840371	275	279	O
women	8840371	280	285	B-Intervention
.	8840371	286	287	O

DESIGN	8840371	288	294	O
Prospective	8840371	295	306	O
,	8840371	307	308	O
comparative	8840371	309	320	O
,	8840371	321	322	O
open-label	8840371	323	333	O
clinical	8840371	334	342	O
trial	8840371	343	348	O
.	8840371	349	350	O

SETTING	8840371	351	358	O
Nuclear	8840371	359	366	O
medicine	8840371	367	375	O
laboratory	8840371	376	386	O
in	8840371	387	389	O
a	8840371	390	391	O
university-affiliated	8840371	392	413	O
hospital	8840371	414	422	O
.	8840371	423	424	O

PATIENTS	8840371	425	433	O
Consecutive	8840371	434	445	O
patients	8840371	446	454	O
who	8840371	455	458	O
were	8840371	459	463	O
referred	8840371	464	472	O
for	8840371	473	476	O
evaluation	8840371	477	487	O
of	8840371	488	490	O
known	8840371	491	496	O
or	8840371	497	499	O
suspected	8840371	500	509	O
coronary	8840371	510	518	O
artery	8840371	519	525	O
disease	8840371	526	533	O
.	8840371	534	535	O

Patients	8840371	536	544	O
were	8840371	545	549	O
judged	8840371	550	556	O
not	8840371	557	560	O
to	8840371	561	563	O
be	8840371	564	566	O
able	8840371	567	571	B-Participant
to	8840371	572	574	I-Participant
exercise	8840371	575	583	I-Participant
adequately	8840371	584	594	I-Participant
.	8840371	595	596	O

INTERVENTIONS	8840371	597	610	O
Coronary	8840371	611	619	O
angiography	8840371	620	631	O
was	8840371	632	635	O
conducted	8840371	636	645	O
within	8840371	646	652	O
6	8840371	653	654	O
weeks	8840371	655	660	O
of	8840371	661	663	O
an	8840371	664	666	O
adenosine	8840371	667	676	B-Participant
thallium-201	8840371	677	689	I-Participant
myocardial	8840371	690	700	I-Participant
perfusion	8840371	701	710	I-Participant
imaging	8840371	711	718	I-Participant
study	8840371	719	724	O
.	8840371	725	726	O

MEASUREMENTS	8840371	727	739	O
AND	8840371	740	743	O
MAIN	8840371	744	748	O
RESULTS	8840371	749	756	O
Diagnostic	8840371	757	767	B-Outcome
accuracy	8840371	768	776	I-Outcome
is	8840371	777	779	O
shown	8840371	780	785	O
in	8840371	786	788	O
the	8840371	789	792	O
table	8840371	793	798	O
.	8840371	799	800	O

[	8840371	801	802	O
table	8840371	803	808	O
:	8840371	809	810	O
see	8840371	811	814	O
text	8840371	815	819	O
]	8840371	820	821	O
Overall	8840371	822	829	O
,	8840371	830	831	O
side	8840371	832	836	B-Outcome
effects	8840371	837	844	I-Outcome
from	8840371	845	849	O
adenosine	8840371	850	859	O
were	8840371	860	864	O
not	8840371	865	868	O
different	8840371	869	878	B-Observation
between	8840371	879	886	O
men	8840371	887	890	B-Intervention
and	8840371	891	894	O
women	8840371	895	900	B-Intervention
.	8840371	901	902	O

The	8840371	903	906	O
frequencies	8840371	907	918	B-Outcome
of	8840371	919	921	I-Outcome
ST	8840371	922	924	I-Outcome
depression	8840371	925	935	I-Outcome
and	8840371	936	939	I-Outcome
chest	8840371	940	945	I-Outcome
pain	8840371	946	950	I-Outcome
were	8840371	951	955	O
significantly	8840371	956	969	B-Observation
greater	8840371	970	977	I-Observation
in	8840371	978	980	O
women	8840371	981	986	B-Intervention
than	8840371	987	991	O
men	8840371	992	995	B-Intervention
,	8840371	996	997	O
although	8840371	998	1006	O
their	8840371	1007	1012	O
etiologies	8840371	1013	1023	O
are	8840371	1024	1027	O
unknown	8840371	1028	1035	O
.	8840371	1036	1037	O

The	8840371	1038	1041	O
frequency	8840371	1042	1051	B-Outcome
of	8840371	1052	1054	I-Outcome
severe	8840371	1055	1061	I-Outcome
side	8840371	1062	1066	I-Outcome
effects	8840371	1067	1074	I-Outcome
such	8840371	1075	1079	O
as	8840371	1080	1082	O
heart	8840371	1083	1088	B-Outcome
block	8840371	1089	1094	I-Outcome
and	8840371	1095	1098	O
hypotension	8840371	1099	1110	B-Outcome
was	8840371	1111	1114	O
not	8840371	1115	1118	O
different	8840371	1119	1128	B-Observation
between	8840371	1129	1136	O
men	8840371	1137	1140	B-Intervention
and	8840371	1141	1144	O
women	8840371	1145	1150	B-Intervention
.	8840371	1151	1152	O

CONCLUSIONS	8840371	1153	1164	O
The	8840371	1165	1168	O
diagnostic	8840371	1169	1179	B-Outcome
accuracy	8840371	1180	1188	I-Outcome
and	8840371	1189	1192	O
safety	8840371	1193	1199	B-Outcome
of	8840371	1200	1202	O
adenosine	8840371	1203	1212	B-Participant
thallium-201	8840371	1213	1225	I-Participant
myocardial	8840371	1226	1236	I-Participant
perfusion	8840371	1237	1246	I-Participant
imaging	8840371	1247	1254	I-Participant
are	8840371	1255	1258	O
generally	8840371	1259	1268	B-Observation
similar	8840371	1269	1276	I-Observation
in	8840371	1277	1279	O
women	8840371	1280	1285	B-Intervention
and	8840371	1286	1289	O
men	8840371	1290	1293	B-Intervention
.	8840371	1294	1295	O

Cost-effectiveness	8841156	0	18	B-Outcome
analysis	8841156	19	27	O
of	8841156	28	30	O
serum	8841156	31	36	B-Intervention
vancomycin	8841156	37	47	I-Intervention
concentration	8841156	48	61	I-Intervention
monitoring	8841156	62	72	I-Intervention
in	8841156	73	75	O
patients	8841156	76	84	O
with	8841156	85	89	O
hematologic	8841156	90	101	B-Participant
malignancies	8841156	102	114	I-Participant
.	8841156	115	116	O

OBJECTIVE	8841156	117	126	O
This	8841156	127	131	O
study	8841156	132	137	O
evaluates	8841156	138	147	O
the	8841156	148	151	O
cost-effectiveness	8841156	152	170	B-Outcome
of	8841156	171	173	O
vancomycin	8841156	174	184	B-Intervention
serum	8841156	185	190	I-Intervention
concentration	8841156	191	204	I-Intervention
monitoring	8841156	205	215	I-Intervention
in	8841156	216	218	O
patients	8841156	219	227	O
with	8841156	228	232	O
hematologic	8841156	233	244	B-Participant
malignancies	8841156	245	257	I-Participant
.	8841156	258	259	O

METHODS	8841156	260	267	O
The	8841156	268	271	O
study	8841156	272	277	O
was	8841156	278	281	O
designed	8841156	282	290	O
as	8841156	291	293	O
a	8841156	294	295	O
prospective	8841156	296	307	O
randomized	8841156	308	318	O
study	8841156	319	324	O
.	8841156	325	326	O

Seventy	8841156	327	334	O
immunocompromised	8841156	335	352	B-Participant
febrile	8841156	353	360	B-Participant
patients	8841156	361	369	O
with	8841156	370	374	O
hematologic	8841156	375	386	B-Participant
malignancies	8841156	387	399	I-Participant
were	8841156	400	404	O
randomly	8841156	405	413	O
assigned	8841156	414	422	O
to	8841156	423	425	O
either	8841156	426	432	O
a	8841156	433	434	O
vancomycin	8841156	435	445	B-Intervention
therapeutic	8841156	446	457	I-Intervention
drug	8841156	458	462	I-Intervention
monitoring	8841156	463	473	I-Intervention
group	8841156	474	479	O
(	8841156	480	481	O
TDM	8841156	482	485	B-Intervention
group	8841156	486	491	O
;	8841156	492	493	O
n	8841156	494	495	O
=	8841156	496	497	O
37	8841156	498	500	O
)	8841156	501	502	O
or	8841156	503	505	O
to	8841156	506	508	O
a	8841156	509	510	O
control	8841156	511	518	B-Intervention
group	8841156	519	524	O
(	8841156	525	526	O
n	8841156	527	528	O
=	8841156	529	530	O
33	8841156	531	533	O
)	8841156	534	535	O
.	8841156	536	537	O

Intervention	8841156	538	550	O
in	8841156	551	553	O
the	8841156	554	557	O
TDM	8841156	558	561	B-Intervention
group	8841156	562	567	O
involved	8841156	568	576	O
patient	8841156	577	584	O
follow-up	8841156	585	594	O
by	8841156	595	597	O
a	8841156	598	599	O
clinical	8841156	600	608	O
pharmacist	8841156	609	619	O
to	8841156	620	622	O
obtain	8841156	623	629	O
and	8841156	630	633	O
pharmacokinetically	8841156	634	653	O
interpret	8841156	654	663	O
serum	8841156	664	669	O
vancomycin	8841156	670	680	O
concentrations	8841156	681	695	O
for	8841156	696	699	O
dosage	8841156	700	706	O
individualization	8841156	707	724	O
.	8841156	725	726	O

RESULTS	8841156	727	734	O
Evaluation	8841156	735	745	O
of	8841156	746	748	O
all	8841156	749	752	O
patients	8841156	753	761	O
included	8841156	762	770	O
global	8841156	771	777	B-Outcome
clinical	8841156	778	786	I-Outcome
response	8841156	787	795	I-Outcome
and	8841156	796	799	O
nephrotoxicity	8841156	800	814	B-Outcome
,	8841156	815	816	O
as	8841156	817	819	O
well	8841156	820	824	O
as	8841156	825	827	O
the	8841156	828	831	O
economic	8841156	832	840	B-Outcome
costs	8841156	841	846	I-Outcome
and	8841156	847	850	O
effectiveness	8841156	851	864	B-Outcome
derived	8841156	865	872	O
from	8841156	873	877	O
the	8841156	878	881	O
vancomycin	8841156	882	892	B-Intervention
monitoring	8841156	893	903	I-Intervention
program	8841156	904	911	I-Intervention
.	8841156	912	913	O

There	8841156	914	919	O
were	8841156	920	924	O
no	8841156	925	927	O
significant	8841156	928	939	B-Observation
differences	8841156	940	951	I-Observation
between	8841156	952	959	O
the	8841156	960	963	O
TDM	8841156	964	967	B-Intervention
and	8841156	968	971	O
control	8841156	972	979	B-Intervention
groups	8841156	980	986	O
in	8841156	987	989	O
the	8841156	990	993	O
outcome	8841156	994	1001	B-Outcome
measures	8841156	1002	1010	I-Outcome
,	8841156	1011	1012	O
except	8841156	1013	1019	O
for	8841156	1020	1023	O
the	8841156	1024	1027	O
incidence	8841156	1028	1037	B-Outcome
of	8841156	1038	1040	I-Outcome
nephrotoxicity	8841156	1041	1055	I-Outcome
:	8841156	1056	1057	O
the	8841156	1058	1061	O
rates	8841156	1062	1067	B-Outcome
of	8841156	1068	1070	I-Outcome
minor	8841156	1071	1076	I-Outcome
nephrotoxicity	8841156	1077	1091	I-Outcome
were	8841156	1092	1096	O
33.3	8841156	1097	1101	B-Observation
%	8841156	1102	1103	I-Observation
and	8841156	1104	1107	O
13.5	8841156	1108	1112	B-Observation
%	8841156	1113	1114	I-Observation
in	8841156	1115	1117	O
the	8841156	1118	1121	O
control	8841156	1122	1129	B-Intervention
and	8841156	1130	1133	O
TDM	8841156	1134	1137	B-Intervention
groups	8841156	1138	1144	O
,	8841156	1145	1146	O
respectively	8841156	1147	1159	O
.	8841156	1160	1161	O

The	8841156	1162	1165	O
corresponding	8841156	1166	1179	B-Outcome
figures	8841156	1180	1187	I-Outcome
for	8841156	1188	1191	I-Outcome
moderate	8841156	1192	1200	I-Outcome
nephrotoxicity	8841156	1201	1215	I-Outcome
were	8841156	1216	1220	O
9.1	8841156	1221	1224	B-Observation
%	8841156	1225	1226	I-Observation
and	8841156	1227	1230	O
0	8841156	1231	1232	B-Observation
%	8841156	1233	1234	I-Observation
.	8841156	1235	1236	O

Logistic	8841156	1237	1245	O
regression	8841156	1246	1256	O
analysis	8841156	1257	1265	O
confirmed	8841156	1266	1275	O
that	8841156	1276	1280	O
TDM	8841156	1281	1284	B-Intervention
independently	8841156	1285	1298	B-Observation
reduced	8841156	1299	1306	I-Observation
the	8841156	1307	1310	O
incidence	8841156	1311	1320	B-Outcome
of	8841156	1321	1323	I-Outcome
nephrotoxicity	8841156	1324	1338	I-Outcome
in	8841156	1339	1341	O
this	8841156	1342	1346	O
patient	8841156	1347	1354	O
population	8841156	1355	1365	O
.	8841156	1366	1367	O

On	8841156	1368	1370	O
the	8841156	1371	1374	O
basis	8841156	1375	1380	O
of	8841156	1381	1383	O
this	8841156	1384	1388	O
reduced	8841156	1389	1396	B-Observation
nephrotoxicity	8841156	1397	1411	B-Outcome
,	8841156	1412	1413	O
a	8841156	1414	1415	O
incremental	8841156	1416	1427	B-Outcome
cost	8841156	1428	1432	I-Outcome
of	8841156	1433	1435	I-Outcome
$	8841156	1436	1437	I-Outcome
435	8841156	1438	1441	I-Outcome
per	8841156	1442	1445	I-Outcome
case	8841156	1446	1450	I-Outcome
of	8841156	1451	1453	I-Outcome
nephrotoxicity	8841156	1454	1468	I-Outcome
prevented	8841156	1469	1478	B-Observation
was	8841156	1479	1482	O
found	8841156	1483	1488	O
for	8841156	1489	1492	O
vancomycin	8841156	1493	1503	B-Intervention
serum	8841156	1504	1509	I-Intervention
concentration	8841156	1510	1523	I-Intervention
monitoring	8841156	1524	1534	I-Intervention
.	8841156	1535	1536	O

CONCLUSIONS	8841156	1537	1548	O
A	8841156	1549	1550	O
decreased	8841156	1551	1560	B-Observation
incidence	8841156	1561	1570	B-Outcome
of	8841156	1571	1573	I-Outcome
nephrotoxicity	8841156	1574	1588	I-Outcome
provides	8841156	1589	1597	O
evidence	8841156	1598	1606	O
of	8841156	1607	1609	O
a	8841156	1610	1611	O
real	8841156	1612	1616	B-Observation
clinical	8841156	1617	1625	I-Observation
benefit	8841156	1626	1633	I-Observation
to	8841156	1634	1636	O
patient	8841156	1637	1644	B-Outcome
management	8841156	1645	1655	I-Outcome
in	8841156	1656	1658	O
patients	8841156	1659	1667	O
with	8841156	1668	1672	O
hematologic	8841156	1673	1684	B-Participant
malignancies	8841156	1685	1697	I-Participant
.	8841156	1698	1699	O

The	8841156	1700	1703	O
TDM	8841156	1704	1707	B-Intervention
for	8841156	1708	1711	O
vancomycin	8841156	1712	1722	B-Participant
therapy	8841156	1723	1730	I-Participant
in	8841156	1731	1733	O
this	8841156	1734	1738	O
high-risk	8841156	1739	1748	B-Participant
population	8841156	1749	1759	I-Participant
has	8841156	1760	1763	O
been	8841156	1764	1768	O
shown	8841156	1769	1774	O
to	8841156	1775	1777	O
be	8841156	1778	1780	O
a	8841156	1781	1782	O
cost-effective	8841156	1783	1797	B-Observation
procedure	8841156	1798	1807	O
.	8841156	1808	1809	O

An	8852235	0	2	O
occupation	8852235	3	13	B-Intervention
based	8852235	14	19	I-Intervention
physical	8852235	20	28	I-Intervention
activity	8852235	29	37	I-Intervention
intervention	8852235	38	50	I-Intervention
program	8852235	51	58	I-Intervention
:	8852235	59	60	O
improving	8852235	61	70	B-Observation
fitness	8852235	71	78	B-Outcome
and	8852235	79	82	O
decreasing	8852235	83	93	B-Observation
obesity	8852235	94	101	B-Outcome
.	8852235	102	103	O

The	8852235	104	107	O
purpose	8852235	108	115	O
of	8852235	116	118	O
this	8852235	119	123	O
quasi-experimental	8852235	124	142	O
study	8852235	143	148	O
was	8852235	149	152	O
to	8852235	153	155	O
determine	8852235	156	165	O
the	8852235	166	169	O
effectiveness	8852235	170	183	B-Outcome
of	8852235	184	186	O
an	8852235	187	189	O
occupation	8852235	190	200	B-Intervention
based	8852235	201	206	I-Intervention
health	8852235	207	213	I-Intervention
and	8852235	214	217	I-Intervention
fitness	8852235	218	225	I-Intervention
program	8852235	226	233	I-Intervention
.	8852235	234	235	O

Subjects	8852235	236	244	O
were	8852235	245	249	O
1,504	8852235	250	255	O
police	8852235	256	262	O
trainees	8852235	263	271	O
(	8852235	272	273	O
85	8852235	274	276	O
%	8852235	277	278	O
male	8852235	279	283	O
,	8852235	284	285	O
15	8852235	286	288	O
%	8852235	289	290	O
female	8852235	291	297	O
)	8852235	298	299	O
with	8852235	300	304	O
an	8852235	305	307	O
ethnic	8852235	308	314	O
distribution	8852235	315	327	O
of	8852235	328	330	O
82	8852235	331	333	O
%	8852235	334	335	O
white	8852235	336	341	O
,	8852235	342	343	O
16	8852235	344	346	O
%	8852235	347	348	O
African	8852235	349	356	O
American	8852235	357	365	O
,	8852235	366	367	O
and	8852235	368	371	O
2	8852235	372	373	O
%	8852235	374	375	O
other	8852235	376	381	O
.	8852235	382	383	O

Data	8852235	384	388	O
were	8852235	389	393	O
collected	8852235	394	403	O
at	8852235	404	406	O
25	8852235	407	409	O
sites	8852235	410	415	O
across	8852235	416	422	O
the	8852235	423	426	O
state	8852235	427	432	O
of	8852235	433	435	O
North	8852235	436	441	O
Carolina	8852235	442	450	O
.	8852235	451	452	O

The	8852235	453	456	O
sites	8852235	457	462	O
were	8852235	463	467	O
randomly	8852235	468	476	O
assigned	8852235	477	485	O
to	8852235	486	488	O
either	8852235	489	495	O
the	8852235	496	499	O
experimental	8852235	500	512	B-Intervention
group	8852235	513	518	O
(	8852235	519	520	O
implemented	8852235	521	532	O
the	8852235	533	536	O
intervention	8852235	537	549	B-Intervention
)	8852235	550	551	O
or	8852235	552	554	O
the	8852235	555	558	O
control	8852235	559	566	B-Intervention
group	8852235	567	572	O
(	8852235	573	574	O
continued	8852235	575	584	B-Intervention
usual	8852235	585	590	I-Intervention
training	8852235	591	599	I-Intervention
)	8852235	600	601	O
.	8852235	602	603	O

As	8852235	604	606	O
compared	8852235	607	615	O
with	8852235	616	620	O
controls	8852235	621	629	B-Intervention
,	8852235	630	631	O
subjects	8852235	632	640	O
at	8852235	641	643	O
the	8852235	644	647	O
experimental	8852235	648	660	B-Intervention
sites	8852235	661	666	O
improved	8852235	667	675	B-Observation
significantly	8852235	676	689	I-Observation
in	8852235	690	692	O
cardiovascular	8852235	693	707	B-Outcome
fitness	8852235	708	715	I-Outcome
(	8852235	716	717	O
aerobic	8852235	718	725	B-Outcome
power	8852235	726	731	I-Outcome
)	8852235	732	733	O
,	8852235	734	735	O
general	8852235	736	743	B-Outcome
muscular	8852235	744	752	I-Outcome
strength	8852235	753	761	I-Outcome
(	8852235	762	763	O
number	8852235	764	770	B-Outcome
of	8852235	771	773	I-Outcome
sit	8852235	774	777	I-Outcome
ups	8852235	778	781	I-Outcome
per	8852235	782	785	I-Outcome
minute	8852235	786	792	I-Outcome
)	8852235	793	794	O
,	8852235	795	796	O
and	8852235	797	800	O
flexibility	8852235	801	812	B-Outcome
,	8852235	813	814	O
and	8852235	815	818	O
lowered	8852235	819	826	B-Observation
their	8852235	827	832	O
body	8852235	833	837	B-Outcome
fat	8852235	838	841	I-Outcome
.	8852235	842	843	O

The	8852235	844	847	O
intervention	8852235	848	860	O
required	8852235	861	869	O
minimal	8852235	870	877	O
equipment	8852235	878	887	O
and	8852235	888	891	O
was	8852235	892	895	O
taught	8852235	896	902	O
primarily	8852235	903	912	O
by	8852235	913	915	O
peers	8852235	916	921	O
who	8852235	922	925	O
received	8852235	926	934	O
a	8852235	935	936	O
1	8852235	937	938	O
week	8852235	939	943	O
training	8852235	944	952	O
program	8852235	953	960	O
.	8852235	961	962	O

This	8852235	963	967	O
occupational	8852235	968	980	O
approach	8852235	981	989	O
to	8852235	990	992	O
improving	8852235	993	1002	O
health	8852235	1003	1009	O
could	8852235	1010	1015	O
be	8852235	1016	1018	O
particularly	8852235	1019	1031	O
useful	8852235	1032	1038	O
in	8852235	1039	1041	O
occupations	8852235	1042	1053	O
with	8852235	1054	1058	O
many	8852235	1059	1063	O
workers	8852235	1064	1071	O
who	8852235	1072	1075	O
seldom	8852235	1076	1082	O
engage	8852235	1083	1089	O
in	8852235	1090	1092	O
leisure	8852235	1093	1100	O
time	8852235	1101	1105	O
physical	8852235	1106	1114	O
activity	8852235	1115	1123	O
.	8852235	1124	1125	O

Counselling	8856425	0	11	B-Intervention
of	8856425	12	14	O
postnatal	8856425	15	24	B-Participant
depression	8856425	25	35	I-Participant
:	8856425	36	37	O
a	8856425	38	39	O
controlled	8856425	40	50	O
study	8856425	51	56	O
on	8856425	57	59	O
a	8856425	60	61	O
population	8856425	62	72	O
based	8856425	73	78	O
Swedish	8856425	79	86	O
sample	8856425	87	93	O
.	8856425	94	95	O

In	8856425	96	98	O
a	8856425	99	100	O
two-stage	8856425	101	110	O
screening	8856425	111	120	O
procedure	8856425	121	130	O
using	8856425	131	136	O
the	8856425	137	140	O
Edinburgh	8856425	141	150	O
Postnatal	8856425	151	160	O
Depression	8856425	161	171	O
Scale	8856425	172	177	O
(	8856425	178	179	O
EPDS	8856425	180	184	O
)	8856425	185	186	O
at	8856425	187	189	O
8	8856425	190	191	O
and	8856425	192	195	O
12	8856425	196	198	O
weeks	8856425	199	204	O
postpartum	8856425	205	215	B-Participant
and	8856425	216	219	O
the	8856425	220	223	O
Montgomery-Asberg	8856425	224	241	O
Depression	8856425	242	252	O
Rating	8856425	253	259	O
Scale	8856425	260	265	O
(	8856425	266	267	O
MADRS	8856425	268	273	O
)	8856425	274	275	O
and	8856425	276	279	O
DSM-III-R	8856425	280	289	O
at	8856425	290	292	O
about	8856425	293	298	O
13	8856425	299	301	O
weeks	8856425	302	307	O
postpartum	8856425	308	318	B-Participant
,	8856425	319	320	O
41	8856425	321	323	O
women	8856425	324	329	B-Participant
identified	8856425	330	340	O
as	8856425	341	343	O
depressed	8856425	344	353	B-Participant
were	8856425	354	358	O
randomly	8856425	359	367	O
allocated	8856425	368	377	O
to	8856425	378	380	O
a	8856425	381	382	O
study	8856425	383	388	B-Intervention
and	8856425	389	392	O
a	8856425	393	394	O
control	8856425	395	402	B-Intervention
group	8856425	403	408	O
.	8856425	409	410	O

The	8856425	411	414	O
women	8856425	415	420	B-Participant
in	8856425	421	423	O
the	8856425	424	427	O
study	8856425	428	433	O
group	8856425	434	439	O
received	8856425	440	448	O
6	8856425	449	450	O
weekly	8856425	451	457	O
,	8856425	458	459	O
counselling	8856425	460	471	B-Intervention
visits	8856425	472	478	I-Intervention
by	8856425	479	481	O
the	8856425	482	485	O
Child	8856425	486	491	O
Health	8856425	492	498	O
Clinic	8856425	499	505	O
nurse	8856425	506	511	O
and	8856425	512	515	O
the	8856425	516	519	O
control	8856425	520	527	O
group	8856425	528	533	O
received	8856425	534	542	O
routine	8856425	543	550	B-Intervention
primary	8856425	551	558	I-Intervention
care	8856425	559	563	I-Intervention
.	8856425	564	565	O

Twelve	8856425	566	572	B-Count
(	8856425	573	574	I-Count
80	8856425	575	577	I-Count
%	8856425	578	579	I-Count
)	8856425	580	581	I-Count
of	8856425	582	584	I-Count
15	8856425	585	587	I-Count
women	8856425	588	593	I-Count
with	8856425	594	598	O
major	8856425	599	604	B-Participant
depression	8856425	605	615	I-Participant
in	8856425	616	618	O
the	8856425	619	622	O
study	8856425	623	628	B-Intervention
group	8856425	629	634	O
were	8856425	635	639	O
fully	8856425	640	645	B-Outcome
recovered	8856425	646	655	I-Outcome
after	8856425	656	661	O
the	8856425	662	665	O
intervention	8856425	666	678	O
compared	8856425	679	687	O
to	8856425	688	690	O
4	8856425	691	692	B-Count
(	8856425	693	694	I-Count
25	8856425	695	697	I-Count
%	8856425	698	699	I-Count
)	8856425	700	701	I-Count
of	8856425	702	704	I-Count
16	8856425	705	707	I-Count
in	8856425	708	710	O
the	8856425	711	714	O
control	8856425	715	722	B-Intervention
group	8856425	723	728	O
.	8856425	729	730	O

Counselling	8856425	731	742	B-Intervention
by	8856425	743	745	I-Intervention
health	8856425	746	752	I-Intervention
nurses	8856425	753	759	I-Intervention
is	8856425	760	762	O
helpful	8856425	763	770	B-Observation
in	8856425	771	773	O
managing	8856425	774	782	B-Outcome
postnatal	8856425	783	792	B-Participant
depression	8856425	793	803	I-Participant
and	8856425	804	807	O
seems	8856425	808	813	O
to	8856425	814	816	O
work	8856425	817	821	O
well	8856425	822	826	O
within	8856425	827	833	O
the	8856425	834	837	O
Swedish	8856425	838	845	O
Primary	8856425	846	853	O
Health	8856425	854	860	O
Care	8856425	861	865	O
system	8856425	866	872	O
.	8856425	873	874	O

The	8873520	0	3	O
tension-free	8873520	4	16	B-Intervention
hernioplasty	8873520	17	29	I-Intervention
in	8873520	30	32	O
a	8873520	33	34	O
randomized	8873520	35	45	O
trial	8873520	46	51	O
.	8873520	52	53	O

BACKGROUND	8873520	54	64	O
The	8873520	65	68	O
tension-free	8873520	69	81	O
hernioplasty	8873520	82	94	O
as	8873520	95	97	O
introduced	8873520	98	108	O
by	8873520	109	111	O
Lichtenstein	8873520	112	124	O
has	8873520	125	128	O
gained	8873520	129	135	O
increasing	8873520	136	146	O
acceptance	8873520	147	157	O
during	8873520	158	164	O
the	8873520	165	168	O
last	8873520	169	173	O
decade	8873520	174	180	O
although	8873520	181	189	O
the	8873520	190	193	O
technique	8873520	194	203	O
has	8873520	204	207	O
not	8873520	208	211	O
been	8873520	212	216	O
evaluated	8873520	217	226	O
in	8873520	227	229	O
a	8873520	230	231	O
randomized	8873520	232	242	O
trial	8873520	243	248	O
.	8873520	249	250	O

METHODS	8873520	251	258	O
This	8873520	259	263	O
randomized	8873520	264	274	O
study	8873520	275	280	O
compares	8873520	281	289	O
the	8873520	290	293	O
2-year	8873520	294	300	B-Outcome
follow-up	8873520	301	310	I-Outcome
results	8873520	311	318	I-Outcome
after	8873520	319	324	O
102	8873520	325	328	O
tension-free	8873520	329	341	B-Intervention
hernioplasties	8873520	342	356	I-Intervention
with	8873520	357	361	I-Intervention
implantation	8873520	362	374	I-Intervention
of	8873520	375	377	I-Intervention
a	8873520	378	379	I-Intervention
prolene	8873520	380	387	I-Intervention
mesh	8873520	388	392	I-Intervention
in	8873520	393	395	O
all	8873520	396	399	O
groin	8873520	400	405	B-Participant
hernias	8873520	406	413	I-Participant
to	8873520	414	416	O
53	8873520	417	419	O
Cooper	8873520	420	426	B-Intervention
ligament	8873520	427	435	I-Intervention
repairs	8873520	436	443	I-Intervention
in	8873520	444	446	O
direct	8873520	447	453	B-Participant
hernias	8873520	454	461	I-Participant
and	8873520	462	465	O
53	8873520	466	468	O
abdominal	8873520	469	478	B-Intervention
ring	8873520	479	483	I-Intervention
repairs	8873520	484	491	I-Intervention
in	8873520	492	494	O
indirect	8873520	495	503	B-Participant
hernias	8873520	504	511	I-Participant
.	8873520	512	513	O

RESULTS	8873520	514	521	O
After	8873520	522	527	O
tension-free	8873520	528	540	B-Intervention
repairs	8873520	541	548	I-Intervention
five	8873520	549	553	B-Count
hernias	8873520	554	561	B-Outcome
recurred	8873520	562	570	I-Outcome
(	8873520	571	572	O
5	8873520	573	574	B-Count
%	8873520	575	576	I-Count
)	8873520	577	578	O
,	8873520	579	580	O
and	8873520	581	584	O
after	8873520	585	590	O
either	8873520	591	597	O
Cooper	8873520	598	604	B-Intervention
ligament	8873520	605	613	I-Intervention
or	8873520	614	616	I-Intervention
abdominal	8873520	617	626	I-Intervention
ring	8873520	627	631	I-Intervention
repair	8873520	632	638	I-Intervention
,	8873520	639	640	O
16	8873520	641	643	B-Count
recurrences	8873520	644	655	B-Outcome
were	8873520	656	660	O
found	8873520	661	666	O
(	8873520	667	668	O
15	8873520	669	671	B-Count
%	8873520	672	673	I-Count
)	8873520	674	675	O
(	8873520	676	677	O
P	8873520	678	679	O
=	8873520	680	681	O
0.025	8873520	682	687	O
)	8873520	688	689	O
.	8873520	690	691	O

No	8873520	692	694	O
indirect	8873520	695	703	B-Outcome
hernias	8873520	704	711	I-Outcome
recurred	8873520	712	720	B-Observation
after	8873520	721	726	O
a	8873520	727	728	O
tension-free	8873520	729	741	B-Intervention
repair	8873520	742	748	I-Intervention
;	8873520	749	750	O
2	8873520	751	752	B-Count
recurred	8873520	753	761	B-Outcome
after	8873520	762	767	O
abdominal	8873520	768	777	B-Intervention
ring	8873520	778	782	I-Intervention
repair	8873520	783	789	I-Intervention
(	8873520	790	791	O
4	8873520	792	793	B-Count
%	8873520	794	795	I-Count
;	8873520	796	797	O
NS	8873520	798	800	O
)	8873520	801	802	O
.	8873520	803	804	O

The	8873520	805	808	O
recurrence	8873520	809	819	B-Outcome
rate	8873520	820	824	I-Outcome
after	8873520	825	830	O
tension-free	8873520	831	843	B-Intervention
repairs	8873520	844	851	I-Intervention
for	8873520	852	855	O
primary	8873520	856	863	B-Participant
direct	8873520	864	870	I-Participant
inguinal	8873520	871	879	I-Participant
hernias	8873520	880	887	I-Participant
was	8873520	888	891	O
7	8873520	892	893	B-Observation
%	8873520	894	895	I-Observation
as	8873520	896	898	O
compared	8873520	899	907	O
with	8873520	908	912	O
30	8873520	913	915	B-Observation
%	8873520	916	917	I-Observation
after	8873520	918	923	O
Cooper	8873520	924	930	B-Intervention
ligament	8873520	931	939	I-Intervention
repair	8873520	940	946	I-Intervention
(	8873520	947	948	O
P	8873520	949	950	O
=	8873520	951	952	O
0.0081	8873520	953	959	O
)	8873520	960	961	O
.	8873520	962	963	O

No	8873520	964	966	O
difference	8873520	967	977	B-Observation
in	8873520	978	980	O
complication	8873520	981	993	B-Outcome
rate	8873520	994	998	I-Outcome
between	8873520	999	1006	O
the	8873520	1007	1010	O
tested	8873520	1011	1017	B-Intervention
methods	8873520	1018	1025	I-Intervention
was	8873520	1026	1029	O
found	8873520	1030	1035	O
.	8873520	1036	1037	O

CONCLUSION	8873520	1038	1048	O
Recurrence	8873520	1049	1059	B-Outcome
rate	8873520	1060	1064	I-Outcome
is	8873520	1065	1067	O
reduced	8873520	1068	1075	B-Observation
to	8873520	1076	1078	I-Observation
one-third	8873520	1079	1088	I-Observation
after	8873520	1089	1094	O
tension-free	8873520	1095	1107	B-Intervention
herniotomies	8873520	1108	1120	I-Intervention
as	8873520	1121	1123	O
compared	8873520	1124	1132	O
with	8873520	1133	1137	O
the	8873520	1138	1141	O
conventionel	8873520	1142	1154	B-Intervention
herniotomies	8873520	1155	1167	I-Intervention
without	8873520	1168	1175	O
increase	8873520	1176	1184	B-Observation
in	8873520	1185	1187	O
complication	8873520	1188	1200	B-Outcome
rate	8873520	1201	1205	I-Outcome
.	8873520	1206	1207	O

Adjvant	88754	0	7	B-Intervention
treatment	88754	8	17	I-Intervention
of	88754	18	20	O
tongue	88754	21	27	O
and	88754	28	31	O
floor	88754	32	37	O
of	88754	38	40	O
the	88754	41	44	O
mouth	88754	45	50	B-Participant
cancers	88754	51	58	I-Participant
.	88754	59	60	O

Since	88754	61	66	O
January	88754	67	74	O
1974	88754	75	79	O
,	88754	80	81	O
95	88754	82	84	O
patients	88754	85	93	O
with	88754	94	98	O
anterior	88754	99	107	O
tongue	88754	108	114	O
and	88754	115	118	O
floor	88754	119	124	O
of	88754	125	127	O
the	88754	128	131	O
mouth	88754	132	137	B-Participant
cancers	88754	138	145	I-Participant
were	88754	146	150	O
included	88754	151	159	O
in	88754	160	162	O
a	88754	163	164	O
randomized	88754	165	175	O
trial	88754	176	181	O
.	88754	182	183	O

After	88754	184	189	O
stratification	88754	190	204	O
according	88754	205	214	O
to	88754	215	217	O
staging	88754	218	225	O
and	88754	226	229	O
initial	88754	230	237	O
treatment	88754	238	247	O
,	88754	248	249	O
one-third	88754	250	259	O
of	88754	260	262	O
the	88754	263	266	O
patients	88754	267	275	O
received	88754	276	284	O
chemotherapy	88754	285	297	B-Intervention
for	88754	298	301	O
2	88754	302	303	O
years	88754	304	309	O
(	88754	310	311	O
methotrexate	88754	312	324	B-Intervention
400	88754	325	328	I-Intervention
mg	88754	329	331	I-Intervention
followed	88754	332	340	I-Intervention
by	88754	341	343	I-Intervention
citrovorum	88754	344	354	I-Intervention
factor	88754	355	361	I-Intervention
100	88754	362	365	I-Intervention
mg	88754	366	368	I-Intervention
+	88754	369	370	I-Intervention
bleomycin	88754	371	380	I-Intervention
60	88754	381	383	I-Intervention
mg/week	88754	384	391	I-Intervention
,	88754	392	393	O
during	88754	394	400	O
the	88754	401	404	O
first	88754	405	410	O
15	88754	411	413	O
weeks	88754	414	419	O
)	88754	420	421	O
,	88754	422	423	O
one-third	88754	424	433	O
of	88754	434	436	O
the	88754	437	440	O
patients	88754	441	449	O
received	88754	450	458	O
immunotherapy	88754	459	472	B-Intervention
with	88754	473	477	I-Intervention
weekly	88754	478	484	I-Intervention
C.	88754	485	487	I-Intervention
parvum	88754	488	494	I-Intervention
injections	88754	495	505	I-Intervention
during	88754	506	512	O
2	88754	513	514	O
years	88754	515	520	O
,	88754	521	522	O
while	88754	523	528	O
the	88754	529	532	O
remaining	88754	533	542	O
third	88754	543	548	O
did	88754	549	552	O
not	88754	553	556	O
receive	88754	557	564	O
any	88754	565	568	B-Intervention
treatment	88754	569	578	I-Intervention
.	88754	579	580	O

If	88754	581	583	O
adjuvant	88754	584	592	B-Intervention
treatment	88754	593	602	I-Intervention
seems	88754	603	608	O
to	88754	609	611	O
delay	88754	612	617	B-Observation
recurrence	88754	618	628	B-Outcome
it	88754	629	631	O
did	88754	632	635	O
not	88754	636	639	O
significantly	88754	640	653	B-Observation
decrease	88754	654	662	I-Observation
the	88754	663	666	O
recurrence	88754	667	677	B-Outcome
rate	88754	678	682	I-Outcome
.	88754	683	684	O

Survival	88754	685	693	B-Outcome
is	88754	694	696	O
also	88754	697	701	O
not	88754	702	705	O
signigicantly	88754	706	719	B-Observation
modified	88754	720	728	I-Observation
by	88754	729	731	O
adjuvant	88754	732	740	B-Intervention
treatment	88754	741	750	I-Intervention
and	88754	751	754	O
was	88754	755	758	O
better	88754	759	765	B-Observation
for	88754	766	769	O
patients	88754	770	778	O
with	88754	779	783	O
small	88754	784	789	B-Participant
tumors	88754	790	796	I-Participant
.	88754	797	798	O

Patients	88754	799	807	O
who	88754	808	811	O
previously	88754	812	822	O
received	88754	823	831	O
radiotherapy	88754	832	844	B-Participant
did	88754	845	848	O
not	88754	849	852	O
benefit	88754	853	860	B-Observation
from	88754	861	865	O
adjuvant	88754	866	874	B-Intervention
therapy	88754	875	882	I-Intervention
.	88754	883	884	O

Injection	8882257	0	9	B-Outcome
pain	8882257	10	14	I-Outcome
with	8882257	15	19	O
propofol	8882257	20	28	B-Participant
.	8882257	29	30	O

Reduction	8882257	31	40	B-Observation
with	8882257	41	45	O
aspiration	8882257	46	56	B-Intervention
of	8882257	57	59	I-Intervention
blood	8882257	60	65	I-Intervention
.	8882257	66	67	O

A	8882257	68	69	O
randomised	8882257	70	80	O
,	8882257	81	82	O
controlled	8882257	83	93	O
,	8882257	94	95	O
single-blind	8882257	96	108	O
study	8882257	109	114	O
was	8882257	115	118	O
performed	8882257	119	128	O
on	8882257	129	131	O
100	8882257	132	135	O
patients	8882257	136	144	O
to	8882257	145	147	O
investigate	8882257	148	159	O
a	8882257	160	161	O
new	8882257	162	165	O
method	8882257	166	172	O
of	8882257	173	175	O
reducing	8882257	176	184	B-Observation
pain	8882257	185	189	B-Outcome
on	8882257	190	192	O
propofol	8882257	193	201	B-Participant
injection	8882257	202	211	I-Participant
.	8882257	212	213	O

Aspiration	8882257	214	224	B-Intervention
of	8882257	225	227	I-Intervention
2	8882257	228	229	I-Intervention
ml	8882257	230	232	I-Intervention
of	8882257	233	235	I-Intervention
the	8882257	236	239	I-Intervention
patient	8882257	240	247	I-Intervention
's	8882257	248	250	I-Intervention
blood	8882257	251	256	I-Intervention
into	8882257	257	261	I-Intervention
a	8882257	262	263	I-Intervention
syringe	8882257	264	271	I-Intervention
of	8882257	272	274	I-Intervention
propofol	8882257	275	283	I-Intervention
immediately	8882257	284	295	I-Intervention
before	8882257	296	302	I-Intervention
injection	8882257	303	312	I-Intervention
was	8882257	313	316	O
compared	8882257	317	325	O
with	8882257	326	330	O
the	8882257	331	334	O
addition	8882257	335	343	B-Intervention
of	8882257	344	346	I-Intervention
lignocaine	8882257	347	357	I-Intervention
20	8882257	358	360	I-Intervention
mg	8882257	361	363	I-Intervention
or	8882257	364	366	I-Intervention
normal	8882257	367	373	I-Intervention
saline	8882257	374	380	I-Intervention
2	8882257	381	382	I-Intervention
ml	8882257	383	385	I-Intervention
to	8882257	386	388	I-Intervention
the	8882257	389	392	I-Intervention
propofol	8882257	393	401	I-Intervention
before	8882257	402	408	I-Intervention
injection	8882257	409	418	I-Intervention
.	8882257	419	420	O

The	8882257	421	424	O
addition	8882257	425	433	B-Intervention
of	8882257	434	436	I-Intervention
blood	8882257	437	442	I-Intervention
was	8882257	443	446	O
significantly	8882257	447	460	B-Observation
more	8882257	461	465	I-Observation
effective	8882257	466	475	I-Observation
in	8882257	476	478	O
reducing	8882257	479	487	B-Outcome
pain	8882257	488	492	I-Outcome
on	8882257	493	495	I-Outcome
injection	8882257	496	505	I-Outcome
than	8882257	506	510	O
the	8882257	511	514	O
addition	8882257	515	523	B-Intervention
of	8882257	524	526	I-Intervention
saline	8882257	527	533	I-Intervention
(	8882257	534	535	O
p	8882257	536	537	O
<	8882257	538	539	O
0.001	8882257	540	545	O
)	8882257	546	547	O
,	8882257	548	549	O
but	8882257	550	553	O
was	8882257	554	557	O
not	8882257	558	561	O
significantly	8882257	562	575	B-Observation
more	8882257	576	580	I-Observation
effective	8882257	581	590	I-Observation
than	8882257	591	595	O
the	8882257	596	599	O
addition	8882257	600	608	B-Intervention
of	8882257	609	611	I-Intervention
lignocaine	8882257	612	622	I-Intervention
.	8882257	623	624	O

Effects	8884623	0	7	O
of	8884623	8	10	O
perioperative	8884623	11	24	B-Intervention
indomethacin	8884623	25	37	I-Intervention
on	8884623	38	40	O
intracranial	8884623	41	53	B-Outcome
pressure	8884623	54	62	I-Outcome
,	8884623	63	64	O
cerebral	8884623	65	73	B-Outcome
blood	8884623	74	79	I-Outcome
flow	8884623	80	84	I-Outcome
,	8884623	85	86	O
and	8884623	87	90	O
cerebral	8884623	91	99	B-Outcome
metabolism	8884623	100	110	I-Outcome
in	8884623	111	113	O
patients	8884623	114	122	O
subjected	8884623	123	132	O
to	8884623	133	135	O
craniotomy	8884623	136	146	B-Participant
for	8884623	147	150	O
cerebral	8884623	151	159	B-Participant
tumors	8884623	160	166	I-Participant
.	8884623	167	168	O

This	8884623	169	173	O
study	8884623	174	179	O
was	8884623	180	183	O
carried	8884623	184	191	O
out	8884623	192	195	O
to	8884623	196	198	O
evaluate	8884623	199	207	O
the	8884623	208	211	O
effects	8884623	212	219	O
of	8884623	220	222	O
perioperative	8884623	223	236	B-Intervention
indomethacin	8884623	237	249	I-Intervention
on	8884623	250	252	O
intracranial	8884623	253	265	B-Outcome
pressure	8884623	266	274	I-Outcome
(	8884623	275	276	I-Outcome
ICP	8884623	277	280	I-Outcome
)	8884623	281	282	I-Outcome
,	8884623	283	284	O
cerebral	8884623	285	293	B-Outcome
blood	8884623	294	299	I-Outcome
flow	8884623	300	304	I-Outcome
(	8884623	305	306	I-Outcome
CBF	8884623	307	310	I-Outcome
)	8884623	311	312	I-Outcome
,	8884623	313	314	O
and	8884623	315	318	O
cerebral	8884623	319	327	B-Outcome
metabolism	8884623	328	338	I-Outcome
.	8884623	339	340	O

Twenty	8884623	341	347	O
patients	8884623	348	356	O
subjected	8884623	357	366	O
to	8884623	367	369	O
craniotomy	8884623	370	380	B-Participant
for	8884623	381	384	O
supratentorial	8884623	385	399	B-Participant
cerebral	8884623	400	408	I-Participant
tumors	8884623	409	415	I-Participant
were	8884623	416	420	O
anesthetized	8884623	421	433	O
with	8884623	434	438	O
thiopental	8884623	439	449	O
,	8884623	450	451	O
fentanyl	8884623	452	460	O
,	8884623	461	462	O
nitrous	8884623	463	470	O
oxide	8884623	471	476	O
,	8884623	477	478	O
and	8884623	479	482	O
isoflurane	8884623	483	493	O
.	8884623	494	495	O

A	8884623	496	497	O
PaCO2	8884623	498	503	O
level	8884623	504	509	O
averaging	8884623	510	519	O
4.8	8884623	520	523	O
kPa	8884623	524	527	O
(	8884623	528	529	O
median	8884623	530	536	O
)	8884623	537	538	O
was	8884623	539	542	O
achieved	8884623	543	551	O
.	8884623	552	553	O

The	8884623	554	557	O
patients	8884623	558	566	O
were	8884623	567	571	O
randomized	8884623	572	582	O
to	8884623	583	585	O
intravenous	8884623	586	597	B-Intervention
indomethacin	8884623	598	610	I-Intervention
50	8884623	611	613	O
mg	8884623	614	616	O
or	8884623	617	619	O
placebo	8884623	620	627	B-Intervention
administrated	8884623	628	641	O
after	8884623	642	647	O
exposure	8884623	648	656	O
of	8884623	657	659	O
the	8884623	660	663	O
dura	8884623	664	668	O
.	8884623	669	670	O

ICP	8884623	671	674	B-Outcome
was	8884623	675	678	O
measured	8884623	679	687	O
continuously	8884623	688	700	O
subdurally	8884623	701	711	O
with	8884623	712	716	O
a	8884623	717	718	O
22-gauge	8884623	719	727	O
canula	8884623	728	734	O
connected	8884623	735	744	O
to	8884623	745	747	O
a	8884623	748	749	O
transducer	8884623	750	760	O
.	8884623	761	762	O

CBF	8884623	763	766	B-Outcome
and	8884623	767	770	O
the	8884623	771	774	O
arteriovenous	8884623	775	788	B-Outcome
difference	8884623	789	799	I-Outcome
of	8884623	800	802	I-Outcome
oxygen	8884623	803	809	I-Outcome
(	8884623	810	811	I-Outcome
AVDO2	8884623	812	817	I-Outcome
)	8884623	818	819	I-Outcome
were	8884623	820	824	O
measured	8884623	825	833	O
twice	8884623	834	839	O
,	8884623	840	841	O
before	8884623	842	848	O
and	8884623	849	852	O
after	8884623	853	858	O
indomethacin/placebo	8884623	859	879	B-Intervention
administration	8884623	880	894	O
.	8884623	895	896	O

A	8884623	897	898	O
significant	8884623	899	910	B-Observation
decrease	8884623	911	919	I-Observation
in	8884623	920	922	O
ICP	8884623	923	926	B-Outcome
from	8884623	927	931	B-Observation
6.5	8884623	932	935	I-Observation
to	8884623	936	938	I-Observation
1.5	8884623	939	942	I-Observation
mm	8884623	943	945	I-Observation
Hg	8884623	946	948	I-Observation
(	8884623	949	950	O
median	8884623	951	957	O
)	8884623	958	959	O
was	8884623	960	963	O
found	8884623	964	969	O
after	8884623	970	975	O
indomethacin	8884623	976	988	B-Intervention
administration	8884623	989	1003	O
.	8884623	1004	1005	O

This	8884623	1006	1010	O
decrease	8884623	1011	1019	O
was	8884623	1020	1023	O
caused	8884623	1024	1030	O
by	8884623	1031	1033	O
a	8884623	1034	1035	O
significant	8884623	1036	1047	B-Observation
decrease	8884623	1048	1056	I-Observation
in	8884623	1057	1059	O
CBF	8884623	1060	1063	B-Outcome
associated	8884623	1064	1074	O
with	8884623	1075	1079	O
a	8884623	1080	1081	O
significant	8884623	1082	1093	B-Observation
increase	8884623	1094	1102	I-Observation
in	8884623	1103	1105	O
AVDO2	8884623	1106	1111	B-Outcome
.	8884623	1112	1113	O

Indomethacin	8884623	1114	1126	B-Intervention
did	8884623	1127	1130	O
not	8884623	1131	1134	O
affect	8884623	1135	1141	B-Observation
the	8884623	1142	1145	O
cerebral	8884623	1146	1154	B-Outcome
metabolic	8884623	1155	1164	I-Outcome
rate	8884623	1165	1169	I-Outcome
of	8884623	1170	1172	I-Outcome
oxygen	8884623	1173	1179	I-Outcome
,	8884623	1180	1181	O
the	8884623	1182	1185	O
arteriovenous	8884623	1186	1199	B-Outcome
difference	8884623	1200	1210	I-Outcome
of	8884623	1211	1213	I-Outcome
lactate	8884623	1214	1221	I-Outcome
,	8884623	1222	1223	O
or	8884623	1224	1226	O
the	8884623	1227	1230	O
lactate/oxygen	8884623	1231	1245	B-Outcome
index	8884623	1246	1251	I-Outcome
,	8884623	1252	1253	O
suggesting	8884623	1254	1264	O
that	8884623	1265	1269	O
indomethacin	8884623	1270	1282	B-Intervention
did	8884623	1283	1286	O
not	8884623	1287	1290	O
provoke	8884623	1291	1298	B-Observation
global	8884623	1299	1305	B-Outcome
cerebral	8884623	1306	1314	I-Outcome
ischemia	8884623	1315	1323	I-Outcome
.	8884623	1324	1325	O

In	8884623	1326	1328	O
the	8884623	1329	1332	O
indomethacin	8884623	1333	1345	B-Intervention
group	8884623	1346	1351	O
,	8884623	1352	1353	O
dura	8884623	1354	1358	B-Outcome
was	8884623	1359	1362	O
sufficiently	8884623	1363	1375	B-Observation
relaxed	8884623	1376	1383	I-Observation
in	8884623	1384	1386	O
eight	8884623	1387	1392	B-Count
of	8884623	1393	1395	I-Count
nine	8884623	1396	1400	I-Count
patients	8884623	1401	1409	O
and	8884623	1410	1413	O
dura	8884623	1414	1418	O
was	8884623	1419	1422	O
opened	8884623	1423	1429	O
without	8884623	1430	1437	O
the	8884623	1438	1441	O
occurrence	8884623	1442	1452	O
of	8884623	1453	1455	O
cerebral	8884623	1456	1464	B-Outcome
swelling	8884623	1465	1473	I-Outcome
.	8884623	1474	1475	O

In	8884623	1476	1478	O
one	8884623	1479	1482	B-Count
patient	8884623	1483	1490	I-Count
,	8884623	1491	1492	O
mannitol	8884623	1493	1501	B-Outcome
treatment	8884623	1502	1511	I-Outcome
was	8884623	1512	1515	O
necessary	8884623	1516	1525	B-Observation
to	8884623	1526	1528	O
prevent	8884623	1529	1536	O
dural	8884623	1537	1542	O
tightness	8884623	1543	1552	O
.	8884623	1553	1554	O

In	8884623	1555	1557	O
the	8884623	1558	1561	O
placebo	8884623	1562	1569	B-Intervention
group	8884623	1570	1575	O
,	8884623	1576	1577	O
mannitol	8884623	1578	1586	B-Outcome
supplemented	8884623	1587	1599	I-Outcome
with	8884623	1600	1604	I-Outcome
hypocapnia	8884623	1605	1615	I-Outcome
was	8884623	1616	1619	O
applied	8884623	1620	1627	O
in	8884623	1628	1630	O
five	8884623	1631	1635	B-Count
patients	8884623	1636	1644	I-Count
.	8884623	1645	1646	O

These	8884623	1647	1652	O
findings	8884623	1653	1661	O
suggest	8884623	1662	1669	O
that	8884623	1670	1674	O
perioperative	8884623	1675	1688	B-Intervention
treatment	8884623	1689	1698	I-Intervention
with	8884623	1699	1703	I-Intervention
indomethacin	8884623	1704	1716	I-Intervention
is	8884623	1717	1719	O
an	8884623	1720	1722	O
excellent	8884623	1723	1732	B-Observation
treatment	8884623	1733	1742	I-Observation
of	8884623	1743	1745	O
intracranial	8884623	1746	1758	B-Participant
hypertension	8884623	1759	1771	I-Participant
during	8884623	1772	1778	O
normocapnic	8884623	1779	1790	B-Participant
isoflurane	8884623	1791	1801	I-Participant
anesthesia	8884623	1802	1812	I-Participant
for	8884623	1813	1816	O
craniotomy	8884623	1817	1827	B-Participant
.	8884623	1828	1829	O

Efficacy	8885803	0	8	B-Outcome
and	8885803	9	12	O
safety	8885803	13	19	B-Outcome
of	8885803	20	22	O
triamcinolone	8885803	23	36	B-Intervention
acetonide	8885803	37	46	I-Intervention
aqueous	8885803	47	54	I-Intervention
nasal	8885803	55	60	I-Intervention
spray	8885803	61	66	I-Intervention
in	8885803	67	69	O
patients	8885803	70	78	O
with	8885803	79	83	O
seasonal	8885803	84	92	B-Participant
allergic	8885803	93	101	I-Participant
rhinitis	8885803	102	110	I-Participant
.	8885803	111	112	O

BACKGROUND	8885803	113	123	O
In	8885803	124	126	O
order	8885803	127	132	O
to	8885803	133	135	O
accommodate	8885803	136	147	O
increasing	8885803	148	158	O
patient	8885803	159	166	O
preferences	8885803	167	178	O
a	8885803	179	180	O
new	8885803	181	184	O
aqueous	8885803	185	192	O
formulation	8885803	193	204	O
of	8885803	205	207	O
triamcinolone	8885803	208	221	O
acetonide	8885803	222	231	O
nasal	8885803	232	237	O
spray	8885803	238	243	O
was	8885803	244	247	O
developed	8885803	248	257	O
for	8885803	258	261	O
the	8885803	262	265	O
relief	8885803	266	272	O
of	8885803	273	275	O
symptoms	8885803	276	284	O
associated	8885803	285	295	O
with	8885803	296	300	O
seasonal	8885803	301	309	O
and	8885803	310	313	O
perennial	8885803	314	323	O
allergic	8885803	324	332	O
rhinitis	8885803	333	341	O
.	8885803	342	343	O

OBJECTIVE	8885803	344	353	O
This	8885803	354	358	O
multicenter	8885803	359	370	O
,	8885803	371	372	O
randomized	8885803	373	383	O
,	8885803	384	385	O
double-blind	8885803	386	398	O
study	8885803	399	404	O
was	8885803	405	408	O
designed	8885803	409	417	O
to	8885803	418	420	O
compare	8885803	421	428	O
the	8885803	429	432	O
efficacy	8885803	433	441	B-Outcome
and	8885803	442	445	O
safety	8885803	446	452	B-Outcome
of	8885803	453	455	O
once-daily	8885803	456	466	O
triamcinolone	8885803	467	480	B-Intervention
acetonide	8885803	481	490	I-Intervention
aqueous	8885803	491	498	I-Intervention
nasal	8885803	499	504	I-Intervention
spray	8885803	505	510	I-Intervention
(	8885803	511	512	O
220	8885803	513	516	O
micrograms/day	8885803	517	531	O
)	8885803	532	533	O
with	8885803	534	538	O
placebo	8885803	539	546	B-Intervention
in	8885803	547	549	O
relieving	8885803	550	559	B-Observation
the	8885803	560	563	O
symptoms	8885803	564	572	B-Outcome
of	8885803	573	575	O
seasonal	8885803	576	584	B-Participant
allergic	8885803	585	593	I-Participant
rhinitis	8885803	594	602	I-Participant
due	8885803	603	606	I-Participant
to	8885803	607	609	I-Participant
ragweed	8885803	610	617	I-Participant
.	8885803	618	619	O

METHODS	8885803	620	627	O
One	8885803	628	631	O
hundred	8885803	632	639	O
forty	8885803	640	645	O
patients	8885803	646	654	O
received	8885803	655	663	O
either	8885803	664	670	O
a	8885803	671	672	O
once	8885803	673	677	O
daily	8885803	678	683	O
220-microgram	8885803	684	697	O
dose	8885803	698	702	O
of	8885803	703	705	O
triamcinolone	8885803	706	719	B-Intervention
acetonide	8885803	720	729	I-Intervention
aqueous	8885803	730	737	I-Intervention
nasal	8885803	738	743	I-Intervention
spray	8885803	744	749	I-Intervention
or	8885803	750	752	O
placebo	8885803	753	760	B-Intervention
for	8885803	761	764	O
2	8885803	765	766	O
weeks	8885803	767	772	O
.	8885803	773	774	O

Patients	8885803	775	783	O
evaluated	8885803	784	793	O
the	8885803	794	797	O
severity	8885803	798	806	B-Outcome
of	8885803	807	809	I-Outcome
seasonal	8885803	810	818	I-Outcome
allergic	8885803	819	827	I-Outcome
rhinitis	8885803	828	836	I-Outcome
symptoms	8885803	837	845	I-Outcome
daily	8885803	846	851	O
for	8885803	852	855	O
2	8885803	856	857	O
weeks	8885803	858	863	O
according	8885803	864	873	O
to	8885803	874	876	O
a	8885803	877	878	O
4-point	8885803	879	886	O
scale	8885803	887	892	O
(	8885803	893	894	O
0	8885803	895	896	O
=	8885803	897	898	O
absent	8885803	899	905	O
,	8885803	906	907	O
1	8885803	908	909	O
=	8885803	910	911	O
mild	8885803	912	916	O
,	8885803	917	918	O
2	8885803	919	920	O
=	8885803	921	922	O
moderate	8885803	923	931	O
,	8885803	932	933	O
3	8885803	934	935	O
=	8885803	936	937	O
severe	8885803	938	944	O
)	8885803	945	946	O
.	8885803	947	948	O

Physician	8885803	949	958	O
and	8885803	959	962	O
patient	8885803	963	970	O
global	8885803	971	977	O
evaluations	8885803	978	989	O
of	8885803	990	992	O
overall	8885803	993	1000	B-Outcome
treatment	8885803	1001	1010	I-Outcome
effectiveness	8885803	1011	1024	I-Outcome
were	8885803	1025	1029	O
assessed	8885803	1030	1038	O
at	8885803	1039	1041	O
the	8885803	1042	1045	O
end	8885803	1046	1049	O
of	8885803	1050	1052	O
the	8885803	1053	1056	O
treatment	8885803	1057	1066	O
period	8885803	1067	1073	O
.	8885803	1074	1075	O

RESULTS	8885803	1076	1083	O
Patients	8885803	1084	1092	O
receiving	8885803	1093	1102	O
triamcinolone	8885803	1103	1116	B-Intervention
acetonide	8885803	1117	1126	I-Intervention
aqueous	8885803	1127	1134	I-Intervention
nasal	8885803	1135	1140	I-Intervention
spray	8885803	1141	1146	I-Intervention
,	8885803	1147	1148	O
220	8885803	1149	1152	O
micrograms/day	8885803	1153	1167	O
,	8885803	1168	1169	O
had	8885803	1170	1173	O
significantly	8885803	1174	1187	B-Observation
(	8885803	1188	1189	I-Observation
P	8885803	1190	1191	I-Observation
<	8885803	1192	1193	I-Observation
.05	8885803	1194	1197	I-Observation
)	8885803	1198	1199	I-Observation
greater	8885803	1200	1207	I-Observation
improvements	8885803	1208	1220	I-Observation
in	8885803	1221	1223	O
all	8885803	1224	1227	O
rhinitis	8885803	1228	1236	B-Outcome
symptoms	8885803	1237	1245	I-Outcome
at	8885803	1246	1248	O
weeks	8885803	1249	1254	O
1	8885803	1255	1256	O
and	8885803	1257	1260	O
2	8885803	1261	1262	O
and	8885803	1263	1266	O
overall	8885803	1267	1274	O
for	8885803	1275	1278	O
the	8885803	1279	1282	O
2-week	8885803	1283	1289	O
treatment	8885803	1290	1299	O
period	8885803	1300	1306	O
compared	8885803	1307	1315	O
with	8885803	1316	1320	O
the	8885803	1321	1324	O
placebo	8885803	1325	1332	B-Intervention
group	8885803	1333	1338	O
.	8885803	1339	1340	O

A	8885803	1341	1342	O
significant	8885803	1343	1354	B-Observation
(	8885803	1355	1356	I-Observation
P	8885803	1357	1358	I-Observation
=	8885803	1359	1360	I-Observation
.006	8885803	1361	1365	I-Observation
)	8885803	1366	1367	I-Observation
improvement	8885803	1368	1379	I-Observation
in	8885803	1380	1382	O
the	8885803	1383	1386	O
nasal	8885803	1387	1392	B-Outcome
index	8885803	1393	1398	I-Outcome
occurred	8885803	1399	1407	O
as	8885803	1408	1410	O
early	8885803	1411	1416	O
as	8885803	1417	1419	O
12	8885803	1420	1422	O
hours	8885803	1423	1428	O
after	8885803	1429	1434	O
the	8885803	1435	1438	O
first	8885803	1439	1444	O
dose	8885803	1445	1449	O
of	8885803	1450	1452	O
triamcinolone	8885803	1453	1466	B-Intervention
acetonide	8885803	1467	1476	I-Intervention
aqueous	8885803	1477	1484	I-Intervention
nasal	8885803	1485	1490	I-Intervention
spray	8885803	1491	1496	I-Intervention
.	8885803	1497	1498	O

Both	8885803	1499	1503	O
patients	8885803	1504	1512	B-Participant
and	8885803	1513	1516	O
physicians	8885803	1517	1527	B-Participant
reported	8885803	1528	1536	O
a	8885803	1537	1538	O
greater	8885803	1539	1546	B-Observation
overall	8885803	1547	1554	I-Observation
improvement	8885803	1555	1566	I-Observation
in	8885803	1567	1569	O
symptoms	8885803	1570	1578	B-Outcome
for	8885803	1579	1582	O
the	8885803	1583	1586	O
triamcinolone	8885803	1587	1600	B-Intervention
acetonide	8885803	1601	1610	I-Intervention
aqueous	8885803	1611	1618	I-Intervention
nasal	8885803	1619	1624	I-Intervention
spray	8885803	1625	1630	I-Intervention
group	8885803	1631	1636	O
.	8885803	1637	1638	O

There	8885803	1639	1644	O
were	8885803	1645	1649	O
no	8885803	1650	1652	O
differences	8885803	1653	1664	B-Observation
between	8885803	1665	1672	O
the	8885803	1673	1676	O
two	8885803	1677	1680	B-Intervention
treatment	8885803	1681	1690	I-Intervention
groups	8885803	1691	1697	I-Intervention
in	8885803	1698	1700	O
the	8885803	1701	1704	O
incidence	8885803	1705	1714	B-Outcome
of	8885803	1715	1717	I-Outcome
adverse	8885803	1718	1725	I-Outcome
events	8885803	1726	1732	I-Outcome
.	8885803	1733	1734	O

CONCLUSIONS	8885803	1735	1746	O
This	8885803	1747	1751	O
study	8885803	1752	1757	O
confirmed	8885803	1758	1767	O
that	8885803	1768	1772	O
a	8885803	1773	1774	O
220-microgram	8885803	1775	1788	O
dose	8885803	1789	1793	O
of	8885803	1794	1796	O
triamcinolone	8885803	1797	1810	B-Intervention
acetonide	8885803	1811	1820	I-Intervention
aqueous	8885803	1821	1828	I-Intervention
nasal	8885803	1829	1834	I-Intervention
spray	8885803	1835	1840	I-Intervention
,	8885803	1841	1842	O
administered	8885803	1843	1855	O
once	8885803	1856	1860	O
daily	8885803	1861	1866	O
for	8885803	1867	1870	O
2	8885803	1871	1872	O
weeks	8885803	1873	1878	O
,	8885803	1879	1880	O
is	8885803	1881	1883	O
well	8885803	1884	1888	B-Observation
tolerated	8885803	1889	1898	I-Observation
and	8885803	1899	1902	O
reduces	8885803	1903	1910	B-Observation
effectively	8885803	1911	1922	I-Observation
the	8885803	1923	1926	O
severity	8885803	1927	1935	B-Outcome
of	8885803	1936	1938	I-Outcome
symptoms	8885803	1939	1947	I-Outcome
of	8885803	1948	1950	O
seasonal	8885803	1951	1959	B-Participant
allergic	8885803	1960	1968	I-Participant
rhinitis	8885803	1969	1977	I-Participant
due	8885803	1978	1981	I-Participant
to	8885803	1982	1984	I-Participant
ragweed	8885803	1985	1992	I-Participant
.	8885803	1993	1994	O

Levosulpiride	8891846	0	13	B-Intervention
in	8891846	14	16	O
functional	8891846	17	27	B-Participant
dyspepsia	8891846	28	37	I-Participant
:	8891846	38	39	O
a	8891846	40	41	O
multicentric	8891846	42	54	O
,	8891846	55	56	O
double-blind	8891846	57	69	O
,	8891846	70	71	O
controlled	8891846	72	82	O
trial	8891846	83	88	O
.	8891846	89	90	O

Abnormalities	8891846	91	104	O
in	8891846	105	107	O
gastrointestinal	8891846	108	124	O
motility	8891846	125	133	O
have	8891846	134	138	O
been	8891846	139	143	O
reported	8891846	144	152	O
in	8891846	153	155	O
a	8891846	156	157	O
substantial	8891846	158	169	O
proportion	8891846	170	180	O
of	8891846	181	183	O
patients	8891846	184	192	O
with	8891846	193	197	O
functional	8891846	198	208	O
dyspepsia	8891846	209	218	O
,	8891846	219	220	O
supporting	8891846	221	231	O
the	8891846	232	235	O
use	8891846	236	239	O
of	8891846	240	242	O
prokinetic	8891846	243	253	O
drugs	8891846	254	259	O
for	8891846	260	263	O
treatment	8891846	264	273	O
of	8891846	274	276	O
dyspeptic	8891846	277	286	O
symptoms	8891846	287	295	O
.	8891846	296	297	O

To	8891846	298	300	O
evaluate	8891846	301	309	O
efficacy	8891846	310	318	B-Outcome
and	8891846	319	322	O
safety	8891846	323	329	B-Outcome
of	8891846	330	332	O
levosulpiride	8891846	333	346	B-Intervention
in	8891846	347	349	O
short-term	8891846	350	360	O
treatment	8891846	361	370	O
,	8891846	371	372	O
1298	8891846	373	377	O
patients	8891846	378	386	O
were	8891846	387	391	O
enrolled	8891846	392	400	O
in	8891846	401	403	O
a	8891846	404	405	O
double-blind	8891846	406	418	O
multicentric	8891846	419	431	O
study	8891846	432	437	O
carried	8891846	438	445	O
out	8891846	446	449	O
in	8891846	450	452	O
45	8891846	453	455	O
Italian	8891846	456	463	O
Gastroenterology	8891846	464	480	O
Departments	8891846	481	492	O
.	8891846	493	494	O

Patients	8891846	495	503	O
were	8891846	504	508	O
randomly	8891846	509	517	O
assigned	8891846	518	526	O
to	8891846	527	529	O
either	8891846	530	536	O
levosulpiride	8891846	537	550	B-Intervention
(	8891846	551	552	O
25	8891846	553	555	O
mg	8891846	556	558	O
tid	8891846	559	562	O
)	8891846	563	564	O
,	8891846	565	566	O
domperidone	8891846	567	578	B-Intervention
(	8891846	579	580	O
10	8891846	581	583	O
mg	8891846	584	586	O
tid	8891846	587	590	O
)	8891846	591	592	O
,	8891846	593	594	O
metoclopramide	8891846	595	609	B-Intervention
(	8891846	610	611	O
10	8891846	612	614	O
mg	8891846	615	617	O
tid	8891846	618	621	O
)	8891846	622	623	O
or	8891846	624	626	O
placebo	8891846	627	634	B-Intervention
(	8891846	635	636	O
1	8891846	637	638	O
tablet	8891846	639	645	O
tid	8891846	646	649	O
)	8891846	650	651	O
for	8891846	652	655	O
4	8891846	656	657	O
weeks	8891846	658	663	O
.	8891846	664	665	O

Patients	8891846	666	674	O
were	8891846	675	679	O
selected	8891846	680	688	O
on	8891846	689	691	O
the	8891846	692	695	O
basis	8891846	696	701	O
of	8891846	702	704	O
:	8891846	705	706	O
a	8891846	707	708	O
)	8891846	709	710	O
occurrence	8891846	711	721	O
in	8891846	722	724	O
the	8891846	725	728	O
last	8891846	729	733	O
4	8891846	734	735	O
weeks	8891846	736	741	O
of	8891846	742	744	O
at	8891846	745	747	O
least	8891846	748	753	O
5/10	8891846	754	758	O
selected	8891846	759	767	B-Participant
symptoms	8891846	768	776	I-Participant
(	8891846	777	778	O
anorexia	8891846	779	787	B-Participant
,	8891846	788	789	O
nausea	8891846	790	796	B-Participant
,	8891846	797	798	O
vomiting	8891846	799	807	B-Participant
,	8891846	808	809	O
upper	8891846	810	815	B-Participant
abdominal	8891846	816	825	I-Participant
pain	8891846	826	830	I-Participant
,	8891846	831	832	O
postprandial	8891846	833	845	B-Participant
bloating	8891846	846	854	I-Participant
,	8891846	855	856	O
abdominal	8891846	857	866	B-Participant
fullness	8891846	867	875	I-Participant
,	8891846	876	877	O
early	8891846	878	883	B-Participant
satiety	8891846	884	891	I-Participant
,	8891846	892	893	O
belching	8891846	894	902	B-Participant
,	8891846	903	904	O
heartburn	8891846	905	914	B-Participant
,	8891846	915	916	O
regurgitation	8891846	917	930	B-Participant
)	8891846	931	932	O
,	8891846	933	934	O
severity	8891846	935	943	B-Participant
of	8891846	944	946	O
which	8891846	947	952	O
should	8891846	953	959	O
reach/exceed	8891846	960	972	O
a	8891846	973	974	O
total	8891846	975	980	O
score	8891846	981	986	O
of	8891846	987	989	O
8	8891846	990	991	O
,	8891846	992	993	O
as	8891846	994	996	O
assessed	8891846	997	1005	O
by	8891846	1006	1008	O
a	8891846	1009	1010	O
specific	8891846	1011	1019	O
scale	8891846	1020	1025	O
ranging	8891846	1026	1033	O
from	8891846	1034	1038	O
0	8891846	1039	1040	O
(	8891846	1041	1042	O
absent	8891846	1043	1049	O
)	8891846	1050	1051	O
to	8891846	1052	1054	O
3	8891846	1055	1056	O
(	8891846	1057	1058	O
severe	8891846	1059	1065	O
)	8891846	1066	1067	O
;	8891846	1068	1069	O
b	8891846	1070	1071	O
)	8891846	1072	1073	O
normal	8891846	1074	1080	O
results	8891846	1081	1088	O
of	8891846	1089	1091	O
routine	8891846	1092	1099	B-Participant
biochemical	8891846	1100	1111	I-Participant
,	8891846	1112	1113	O
ultrasound	8891846	1114	1124	B-Participant
and	8891846	1125	1128	O
endoscopic	8891846	1129	1139	B-Participant
examinations	8891846	1140	1152	I-Participant
.	8891846	1153	1154	O

In	8891846	1155	1157	O
addition	8891846	1158	1166	O
,	8891846	1167	1168	O
each	8891846	1169	1173	O
patient	8891846	1174	1181	O
subjectively	8891846	1182	1194	O
evaluated	8891846	1195	1204	O
efficacy	8891846	1205	1213	B-Outcome
of	8891846	1214	1216	O
treatment	8891846	1217	1226	O
by	8891846	1227	1229	O
a	8891846	1230	1231	O
visual	8891846	1232	1238	B-Outcome
analogue	8891846	1239	1247	I-Outcome
scale	8891846	1248	1253	I-Outcome
.	8891846	1254	1255	O

Significant	8891846	1256	1267	B-Observation
improvement	8891846	1268	1279	I-Observation
was	8891846	1280	1283	O
recorded	8891846	1284	1292	O
for	8891846	1293	1296	O
all	8891846	1297	1300	B-Outcome
symptoms	8891846	1301	1309	I-Outcome
at	8891846	1310	1312	O
days	8891846	1313	1317	O
10	8891846	1318	1320	O
and	8891846	1321	1324	O
28	8891846	1325	1327	O
in	8891846	1328	1330	O
all	8891846	1331	1334	B-Intervention
groups	8891846	1335	1341	I-Intervention
(	8891846	1342	1343	O
p	8891846	1344	1345	O
<	8891846	1346	1347	O
0.001	8891846	1348	1353	O
)	8891846	1354	1355	O
,	8891846	1356	1357	O
but	8891846	1358	1361	O
levosulpiride	8891846	1362	1375	B-Intervention
was	8891846	1376	1379	O
significantly	8891846	1380	1393	B-Observation
(	8891846	1394	1395	I-Observation
p	8891846	1396	1397	I-Observation
<	8891846	1398	1399	I-Observation
0.01	8891846	1400	1404	I-Observation
)	8891846	1405	1406	I-Observation
superior	8891846	1407	1415	I-Observation
to	8891846	1416	1418	O
domperidone	8891846	1419	1430	B-Intervention
,	8891846	1431	1432	O
metoclopramide	8891846	1433	1447	B-Intervention
and	8891846	1448	1451	O
placebo	8891846	1452	1459	B-Intervention
both	8891846	1460	1464	O
in	8891846	1465	1467	O
the	8891846	1468	1471	O
overall	8891846	1472	1479	B-Outcome
clinical	8891846	1480	1488	I-Outcome
improvement	8891846	1489	1500	I-Outcome
scale	8891846	1501	1506	I-Outcome
as	8891846	1507	1509	O
well	8891846	1510	1514	O
as	8891846	1515	1517	O
in	8891846	1518	1520	O
a	8891846	1521	1522	O
subgroup	8891846	1523	1531	B-Outcome
of	8891846	1532	1534	I-Outcome
symptoms	8891846	1535	1543	I-Outcome
(	8891846	1544	1545	O
postprandial	8891846	1546	1558	B-Outcome
bloating	8891846	1559	1567	I-Outcome
,	8891846	1568	1569	O
epigastric	8891846	1570	1580	B-Outcome
pain	8891846	1581	1585	I-Outcome
,	8891846	1586	1587	O
heartburn	8891846	1588	1597	B-Outcome
)	8891846	1598	1599	O
.	8891846	1600	1601	O

Active	8891846	1602	1608	B-Intervention
treatments	8891846	1609	1619	I-Intervention
and	8891846	1620	1623	O
placebo	8891846	1624	1631	B-Intervention
were	8891846	1632	1636	O
comparable	8891846	1637	1647	B-Observation
as	8891846	1648	1650	O
far	8891846	1651	1654	O
as	8891846	1655	1657	O
concerns	8891846	1658	1666	O
occurrence	8891846	1667	1677	B-Outcome
of	8891846	1678	1680	I-Outcome
side-effects	8891846	1681	1693	I-Outcome
(	8891846	1694	1695	O
12	8891846	1696	1698	B-Observation
-	8891846	1698	1699	I-Observation
20	8891846	1699	1701	I-Observation
%	8891846	1702	1703	I-Observation
)	8891846	1704	1705	O
including	8891846	1706	1715	O
galactorrhoea	8891846	1716	1729	B-Outcome
,	8891846	1730	1731	O
breast	8891846	1732	1738	B-Outcome
tenderness	8891846	1739	1749	I-Outcome
and	8891846	1750	1753	O
menstrual	8891846	1754	1763	B-Outcome
changes	8891846	1764	1771	I-Outcome
.	8891846	1772	1773	O

Intrathecal	8893393	0	11	B-Outcome
immunoactivation	8893393	12	28	I-Outcome
in	8893393	29	31	O
patients	8893393	32	40	O
with	8893393	41	45	O
HIV-1	8893393	46	51	B-Participant
infection	8893393	52	61	I-Participant
is	8893393	62	64	O
reduced	8893393	65	72	B-Observation
by	8893393	73	75	O
zidovudine	8893393	76	86	B-Intervention
but	8893393	87	90	O
not	8893393	91	94	O
by	8893393	95	97	O
didanosine	8893393	98	108	B-Intervention
.	8893393	109	110	O

The	8893393	111	114	O
effect	8893393	115	121	O
of	8893393	122	124	O
zidovudine	8893393	125	135	B-Intervention
and	8893393	136	139	O
didanosine	8893393	140	150	B-Intervention
on	8893393	151	153	O
the	8893393	154	157	O
cerebrospinal	8893393	158	171	B-Outcome
fluid	8893393	172	177	I-Outcome
(	8893393	178	179	I-Outcome
CSF	8893393	180	183	I-Outcome
)	8893393	184	185	I-Outcome
concentrations	8893393	186	200	I-Outcome
of	8893393	201	203	I-Outcome
neopterin	8893393	204	213	I-Outcome
was	8893393	214	217	O
studied	8893393	218	225	O
in	8893393	226	228	O
12	8893393	229	231	O
patients	8893393	232	240	O
with	8893393	241	245	O
human	8893393	246	251	B-Participant
immunodeficiency	8893393	252	268	I-Participant
virus	8893393	269	274	I-Participant
type-1	8893393	275	281	I-Participant
(	8893393	282	283	I-Participant
HIV-1	8893393	284	289	I-Participant
)	8893393	290	291	I-Participant
infection	8893393	292	301	I-Participant
3	8893393	302	303	O
-	8893393	303	304	O
12	8893393	304	306	O
months	8893393	307	313	O
after	8893393	314	319	O
initiation	8893393	320	330	O
of	8893393	331	333	O
antiretroviral	8893393	334	348	O
therapy	8893393	349	356	O
.	8893393	357	358	O

Ten	8893393	359	362	O
treatment	8893393	363	372	O
periods	8893393	373	380	O
on	8893393	381	383	O
zidovudine	8893393	384	394	B-Intervention
and	8893393	395	398	O
7	8893393	399	400	O
on	8893393	401	403	O
didanosine	8893393	404	414	B-Intervention
were	8893393	415	419	O
analysed	8893393	420	428	O
.	8893393	429	430	O

The	8893393	431	434	O
CSF	8893393	435	438	B-Outcome
concentrations	8893393	439	453	I-Outcome
of	8893393	454	456	I-Outcome
neopterin	8893393	457	466	I-Outcome
decreased	8893393	467	476	B-Observation
by	8893393	477	479	I-Observation
63	8893393	480	482	I-Observation
%	8893393	483	484	I-Observation
(	8893393	485	486	O
from	8893393	487	491	B-Observation
29.6	8893393	492	496	I-Observation
to	8893393	497	499	I-Observation
12.9	8893393	500	504	I-Observation
nmol/l	8893393	505	511	I-Observation
,	8893393	512	513	O
p	8893393	514	515	O
<	8893393	516	517	O
0.01	8893393	518	522	O
)	8893393	523	524	O
during	8893393	525	531	O
zidovudine	8893393	532	542	B-Intervention
but	8893393	543	546	O
increased	8893393	547	556	B-Observation
by	8893393	557	559	I-Observation
15	8893393	560	562	I-Observation
%	8893393	563	564	I-Observation
(	8893393	565	566	O
from	8893393	567	571	B-Observation
22.6	8893393	572	576	I-Observation
to	8893393	577	579	I-Observation
25.9	8893393	580	584	I-Observation
nmol/l	8893393	585	591	I-Observation
,	8893393	592	593	O
not	8893393	594	597	O
significant	8893393	598	609	O
during	8893393	610	616	O
didanosine	8893393	617	627	B-Intervention
treatment	8893393	628	637	O
.	8893393	638	639	O

The	8893393	640	643	O
CSF	8893393	644	647	B-Outcome
monocytic	8893393	648	657	I-Outcome
cell	8893393	658	662	I-Outcome
count	8893393	663	668	I-Outcome
decreased	8893393	669	678	B-Observation
during	8893393	679	685	O
zidovudine	8893393	686	696	B-Intervention
but	8893393	697	700	O
increased	8893393	701	710	B-Observation
during	8893393	711	717	O
didanosine	8893393	718	728	B-Intervention
treatment	8893393	729	738	O
.	8893393	739	740	O

The	8893393	741	744	O
results	8893393	745	752	O
suggest	8893393	753	760	O
that	8893393	761	765	O
zidovudine	8893393	766	776	B-Intervention
but	8893393	777	780	O
not	8893393	781	784	O
didanosine	8893393	785	795	B-Intervention
reduces	8893393	796	803	B-Observation
intrathecal	8893393	804	815	B-Outcome
immunoactivation	8893393	816	832	I-Outcome
during	8893393	833	839	O
HIV-1	8893393	840	845	B-Participant
infection	8893393	846	855	I-Participant
.	8893393	856	857	O

Final	8908288	0	5	O
report	8908288	6	12	O
of	8908288	13	15	O
a	8908288	16	17	O
randomized	8908288	18	28	O
controlled	8908288	29	39	O
study	8908288	40	45	O
with	8908288	46	50	O
streptococcal	8908288	51	64	B-Intervention
preparation	8908288	65	76	I-Intervention
OK-432	8908288	77	83	I-Intervention
as	8908288	84	86	O
a	8908288	87	88	O
supplementary	8908288	89	102	B-Outcome
immunopotentiator	8908288	103	120	I-Outcome
for	8908288	121	124	O
laryngeal	8908288	125	134	B-Participant
cancer	8908288	135	141	I-Participant
.	8908288	142	143	O

We	8908288	144	146	O
conducted	8908288	147	156	O
a	8908288	157	158	O
randomized	8908288	159	169	O
controlled	8908288	170	180	O
study	8908288	181	186	O
of	8908288	187	189	O
streptococcal	8908288	190	203	B-Intervention
preparation	8908288	204	215	I-Intervention
OK-432	8908288	216	222	I-Intervention
on	8908288	223	225	O
120	8908288	226	229	O
newly	8908288	230	235	O
identified	8908288	236	246	O
cases	8908288	247	252	O
of	8908288	253	255	O
laryngeal	8908288	256	265	B-Participant
squamous	8908288	266	274	I-Participant
cell	8908288	275	279	I-Participant
carcinoma	8908288	280	289	I-Participant
who	8908288	290	293	O
were	8908288	294	298	O
registered	8908288	299	309	O
at	8908288	310	312	O
10	8908288	313	315	O
participating	8908288	316	329	O
institutions	8908288	330	342	O
between	8908288	343	350	O
November	8908288	351	359	O
1984	8908288	360	364	O
and	8908288	365	368	O
October	8908288	369	376	O
1989	8908288	377	381	O
.	8908288	382	383	O

The	8908288	384	387	O
patients	8908288	388	396	O
were	8908288	397	401	O
divided	8908288	402	409	O
into	8908288	410	414	O
two	8908288	415	418	O
groups	8908288	419	425	O
:	8908288	426	427	O
those	8908288	428	433	O
in	8908288	434	436	O
early	8908288	437	442	B-Participant
stages	8908288	443	449	I-Participant
(	8908288	450	451	I-Participant
stage	8908288	452	457	I-Participant
I	8908288	458	459	I-Participant
or	8908288	460	462	I-Participant
II	8908288	463	465	I-Participant
)	8908288	466	467	I-Participant
and	8908288	468	471	O
those	8908288	472	477	O
in	8908288	478	480	O
advanced	8908288	481	489	B-Participant
stages	8908288	490	496	I-Participant
(	8908288	497	498	I-Participant
stage	8908288	499	504	I-Participant
III	8908288	505	508	I-Participant
or	8908288	509	511	I-Participant
IV	8908288	512	514	I-Participant
)	8908288	515	516	I-Participant
;	8908288	517	518	O
these	8908288	519	524	O
groups	8908288	525	531	O
were	8908288	532	536	O
further	8908288	537	544	O
subdivided	8908288	545	555	O
into	8908288	556	560	O
an	8908288	561	563	O
immunotherapy	8908288	564	577	B-Intervention
group	8908288	578	583	O
(	8908288	584	585	O
receiving	8908288	586	595	O
OK-432	8908288	596	602	B-Intervention
)	8908288	603	604	O
and	8908288	605	608	O
a	8908288	609	610	O
control	8908288	611	618	B-Intervention
group	8908288	619	624	O
(	8908288	625	626	O
who	8908288	627	630	O
did	8908288	631	634	O
not	8908288	635	638	O
receive	8908288	639	646	O
OK-432	8908288	647	653	B-Intervention
)	8908288	654	655	O
.	8908288	656	657	O

The	8908288	658	661	O
usefulness	8908288	662	672	B-Outcome
of	8908288	673	675	O
OK-432	8908288	676	682	B-Intervention
was	8908288	683	686	O
studied	8908288	687	694	O
using	8908288	695	700	O
the	8908288	701	704	O
sealed	8908288	705	711	O
envelope	8908288	712	720	O
method	8908288	721	727	O
.	8908288	728	729	O

The	8908288	730	733	O
basic	8908288	734	739	O
therapy	8908288	740	747	O
for	8908288	748	751	O
all	8908288	752	755	O
cases	8908288	756	761	O
was	8908288	762	765	O
radiotherapy	8908288	766	778	O
and	8908288	779	782	O
,	8908288	783	784	O
when	8908288	785	789	O
required	8908288	790	798	O
,	8908288	799	800	O
surgery	8908288	801	808	O
.	8908288	809	810	O

As	8908288	811	813	O
adjuvant	8908288	814	822	O
therapy	8908288	823	830	O
,	8908288	831	832	O
5Fu	8908288	833	836	O
or	8908288	837	839	O
derivatives	8908288	840	851	O
were	8908288	852	856	O
administered	8908288	857	869	O
to	8908288	870	872	O
all	8908288	873	876	O
cases	8908288	877	882	O
from	8908288	883	887	O
the	8908288	888	891	O
beginning	8908288	892	901	O
of	8908288	902	904	O
the	8908288	905	908	O
treatment	8908288	909	918	O
period	8908288	919	925	O
to	8908288	926	928	O
one	8908288	929	932	O
year	8908288	933	937	O
after	8908288	938	943	O
the	8908288	944	947	O
basic	8908288	948	953	O
therapy	8908288	954	961	O
,	8908288	962	963	O
with	8908288	964	968	O
the	8908288	969	972	O
exception	8908288	973	982	O
of	8908288	983	985	O
cases	8908288	986	991	O
in	8908288	992	994	O
whom	8908288	995	999	O
side	8908288	1000	1004	O
effects	8908288	1005	1012	O
were	8908288	1013	1017	O
serious	8908288	1018	1025	O
enough	8908288	1026	1032	O
to	8908288	1033	1035	O
contraindicate	8908288	1036	1050	O
use	8908288	1051	1054	O
of	8908288	1055	1057	O
the	8908288	1058	1061	O
drug	8908288	1062	1066	O
.	8908288	1067	1068	O

The	8908288	1069	1072	O
target	8908288	1073	1079	O
administration	8908288	1080	1094	O
period	8908288	1095	1101	O
was	8908288	1102	1105	O
5	8908288	1106	1107	O
years	8908288	1108	1113	O
.	8908288	1114	1115	O

Of	8908288	1116	1118	O
the	8908288	1119	1122	O
initial	8908288	1123	1130	O
120	8908288	1131	1134	O
cases	8908288	1135	1140	O
,	8908288	1141	1142	O
11	8908288	1143	1145	O
cases	8908288	1146	1151	O
were	8908288	1152	1156	O
disqualified	8908288	1157	1169	O
(	8908288	1170	1171	O
3	8908288	1172	1173	O
cases	8908288	1174	1179	O
of	8908288	1180	1182	O
double	8908288	1183	1189	O
cancer	8908288	1190	1196	O
and	8908288	1197	1200	O
8	8908288	1201	1202	O
of	8908288	1203	1205	O
incomplete	8908288	1206	1216	O
primary	8908288	1217	1224	O
therapy	8908288	1225	1232	O
)	8908288	1233	1234	O
and	8908288	1235	1238	O
the	8908288	1239	1242	O
remaining	8908288	1243	1252	O
109	8908288	1253	1256	O
were	8908288	1257	1261	O
used	8908288	1262	1266	O
for	8908288	1267	1270	O
evaluation	8908288	1271	1281	O
.	8908288	1282	1283	O

The	8908288	1284	1287	O
5-year	8908288	1288	1294	B-Outcome
survival	8908288	1295	1303	I-Outcome
rate	8908288	1304	1308	I-Outcome
and	8908288	1309	1312	O
the	8908288	1313	1316	O
5-year	8908288	1317	1323	B-Outcome
recurrence-free	8908288	1324	1339	I-Outcome
rate	8908288	1340	1344	I-Outcome
were	8908288	1345	1349	O
76	8908288	1350	1352	B-Observation
%	8908288	1353	1354	I-Observation
and	8908288	1355	1358	O
84	8908288	1359	1361	B-Observation
%	8908288	1362	1363	I-Observation
,	8908288	1364	1365	O
respectively	8908288	1366	1378	O
,	8908288	1379	1380	O
in	8908288	1381	1383	O
the	8908288	1384	1387	O
immunized	8908288	1388	1397	B-Intervention
groups	8908288	1398	1404	O
(	8908288	1405	1406	O
both	8908288	1407	1411	O
the	8908288	1412	1415	O
early	8908288	1416	1421	O
and	8908288	1422	1425	O
advanced	8908288	1426	1434	O
groups	8908288	1435	1441	O
)	8908288	1442	1443	O
,	8908288	1444	1445	O
whereas	8908288	1446	1453	O
the	8908288	1454	1457	O
same	8908288	1458	1462	O
rates	8908288	1463	1468	O
for	8908288	1469	1472	O
the	8908288	1473	1476	O
control	8908288	1477	1484	B-Intervention
groups	8908288	1485	1491	O
were	8908288	1492	1496	O
78	8908288	1497	1499	B-Observation
%	8908288	1500	1501	I-Observation
and	8908288	1502	1505	O
75	8908288	1506	1508	B-Observation
%	8908288	1509	1510	I-Observation
.	8908288	1511	1512	O

There	8908288	1513	1518	O
was	8908288	1519	1522	O
a	8908288	1523	1524	O
tendency	8908288	1525	1533	O
for	8908288	1534	1537	O
the	8908288	1538	1541	O
immunized	8908288	1542	1551	B-Intervention
groups	8908288	1552	1558	O
to	8908288	1559	1561	O
enjoy	8908288	1562	1567	O
a	8908288	1568	1569	O
slightly	8908288	1570	1578	B-Observation
longer	8908288	1579	1585	I-Observation
recurrence-free	8908288	1586	1601	B-Outcome
period	8908288	1602	1608	I-Outcome
.	8908288	1609	1610	O

Over	8908288	1611	1615	O
a	8908288	1616	1617	O
24-month	8908288	1618	1626	O
observation	8908288	1627	1638	O
period	8908288	1639	1645	O
the	8908288	1646	1649	O
immunized	8908288	1650	1659	B-Intervention
group	8908288	1660	1665	O
always	8908288	1666	1672	O
had	8908288	1673	1676	O
higher	8908288	1677	1683	B-Observation
levels	8908288	1684	1690	B-Outcome
of	8908288	1691	1693	I-Outcome
peripheral	8908288	1694	1704	I-Outcome
leukocytes	8908288	1705	1715	I-Outcome
and	8908288	1716	1719	I-Outcome
peripheral	8908288	1720	1730	I-Outcome
lymphocytes	8908288	1731	1742	I-Outcome
;	8908288	1743	1744	O
this	8908288	1745	1749	O
difference	8908288	1750	1760	B-Observation
was	8908288	1761	1764	I-Observation
significant	8908288	1765	1776	I-Observation
for	8908288	1777	1780	O
the	8908288	1781	1784	O
first	8908288	1785	1790	O
21	8908288	1791	1793	O
months	8908288	1794	1800	O
.	8908288	1801	1802	O

Inhibition	8908288	1803	1813	B-Observation
of	8908288	1814	1816	O
bone	8908288	1817	1821	B-Outcome
marrow	8908288	1822	1828	I-Outcome
function	8908288	1829	1837	I-Outcome
is	8908288	1838	1840	O
sometimes	8908288	1841	1850	O
observed	8908288	1851	1859	O
with	8908288	1860	1864	O
radiotherapy	8908288	1865	1877	B-Intervention
.	8908288	1878	1879	O

It	8908288	1880	1882	O
is	8908288	1883	1885	O
hoped	8908288	1886	1891	O
that	8908288	1892	1896	O
,	8908288	1897	1898	O
if	8908288	1899	1901	O
this	8908288	1902	1906	O
inhibition	8908288	1907	1917	O
can	8908288	1918	1921	O
be	8908288	1922	1924	O
mitigated	8908288	1925	1934	O
,	8908288	1935	1936	O
it	8908288	1937	1939	O
will	8908288	1940	1944	O
be	8908288	1945	1947	O
possible	8908288	1948	1956	O
to	8908288	1957	1959	O
assist	8908288	1960	1966	O
the	8908288	1967	1970	O
compromised	8908288	1971	1982	O
immune	8908288	1983	1989	O
system	8908288	1990	1996	O
and	8908288	1997	2000	O
maintain	8908288	2001	2009	O
a	8908288	2010	2011	O
certain	8908288	2012	2019	O
level	8908288	2020	2025	O
of	8908288	2026	2028	O
immune	8908288	2029	2035	O
performance	8908288	2036	2047	O
which	8908288	2048	2053	O
will	8908288	2054	2058	O
prevent	8908288	2059	2066	O
recurrence	8908288	2067	2077	O
and	8908288	2078	2081	O
improve	8908288	2082	2089	O
survival	8908288	2090	2098	O
rate	8908288	2099	2103	O
.	8908288	2104	2105	O

In	8908288	2106	2108	O
the	8908288	2109	2112	O
present	8908288	2113	2120	O
study	8908288	2121	2126	O
we	8908288	2127	2129	O
observed	8908288	2130	2138	O
a	8908288	2139	2140	O
tendency	8908288	2141	2149	B-Observation
of	8908288	2150	2152	I-Observation
the	8908288	2153	2156	I-Observation
lower	8908288	2157	2162	I-Observation
recurrence	8908288	2163	2173	B-Outcome
rate	8908288	2174	2178	I-Outcome
in	8908288	2179	2181	O
the	8908288	2182	2185	O
immunized	8908288	2186	2195	B-Intervention
group	8908288	2196	2201	O
,	8908288	2202	2203	O
and	8908288	2204	2207	O
we	8908288	2208	2210	O
hypothesize	8908288	2211	2222	O
that	8908288	2223	2227	O
OK-432	8908288	2228	2234	B-Intervention
is	8908288	2235	2237	O
effective	8908288	2238	2247	B-Observation
in	8908288	2248	2250	I-Observation
extending	8908288	2251	2260	I-Observation
the	8908288	2261	2264	O
recurrence-free	8908288	2265	2280	B-Outcome
period	8908288	2281	2287	I-Outcome
.	8908288	2288	2289	O

The	8911127	0	3	O
impact	8911127	4	10	O
of	8911127	11	13	O
a	8911127	14	15	O
psychological	8911127	16	29	B-Intervention
intervention	8911127	30	42	I-Intervention
on	8911127	43	45	O
quality	8911127	46	53	B-Outcome
of	8911127	54	56	I-Outcome
life	8911127	57	61	I-Outcome
in	8911127	62	64	O
non-metastatic	8911127	65	79	B-Participant
breast	8911127	80	86	I-Participant
cancer	8911127	87	93	I-Participant
.	8911127	94	95	O

The	8911127	96	99	O
aim	8911127	100	103	O
of	8911127	104	106	O
this	8911127	107	111	O
study	8911127	112	117	O
was	8911127	118	121	O
to	8911127	122	124	O
determine	8911127	125	134	O
whether	8911127	135	142	O
psychological	8911127	143	156	B-Intervention
intervention	8911127	157	169	I-Intervention
had	8911127	170	173	O
a	8911127	174	175	O
beneficial	8911127	176	186	B-Observation
effect	8911127	187	193	I-Observation
on	8911127	194	196	O
the	8911127	197	200	O
quality	8911127	201	208	B-Outcome
of	8911127	209	211	I-Outcome
life	8911127	212	216	I-Outcome
and	8911127	217	220	O
behaviour	8911127	221	230	B-Outcome
of	8911127	231	233	O
women	8911127	234	239	B-Participant
diagnosed	8911127	240	249	O
with	8911127	250	254	O
breast	8911127	255	261	B-Participant
cancer	8911127	262	268	I-Participant
.	8911127	269	270	O

36	8911127	271	273	O
consecutive	8911127	274	285	O
patients	8911127	286	294	O
with	8911127	295	299	O
non-metastatic	8911127	300	314	B-Participant
breast	8911127	315	321	I-Participant
cancer	8911127	322	328	I-Participant
assigned	8911127	329	337	O
to	8911127	338	340	O
surgery	8911127	341	348	B-Participant
and	8911127	349	352	O
systemic	8911127	353	361	B-Participant
chemotherapy	8911127	362	374	I-Participant
were	8911127	375	379	O
randomised	8911127	380	390	O
to	8911127	391	393	O
receive	8911127	394	401	O
either	8911127	402	408	O
psychological	8911127	409	422	B-Intervention
intervention	8911127	423	435	I-Intervention
(	8911127	436	437	O
weekly	8911127	438	444	B-Intervention
cognitive	8911127	445	454	I-Intervention
individual	8911127	455	465	I-Intervention
psychotherapy	8911127	466	479	I-Intervention
and	8911127	480	483	O
bimonthly	8911127	484	493	B-Intervention
family	8911127	494	500	I-Intervention
counselling	8911127	501	512	I-Intervention
)	8911127	513	514	O
or	8911127	515	517	O
standard	8911127	518	526	B-Intervention
follow-up	8911127	527	536	I-Intervention
.	8911127	537	538	O

Personality	8911127	539	550	B-Outcome
(	8911127	551	552	I-Outcome
16-PF	8911127	553	558	I-Outcome
and	8911127	559	562	I-Outcome
IIQ	8911127	563	566	I-Outcome
)	8911127	567	568	I-Outcome
,	8911127	569	570	O
quality	8911127	571	578	B-Outcome
of	8911127	579	581	I-Outcome
life	8911127	582	586	I-Outcome
(	8911127	587	588	I-Outcome
FLIC	8911127	589	593	I-Outcome
)	8911127	594	595	I-Outcome
,	8911127	596	597	O
and	8911127	598	601	O
depression	8911127	602	612	B-Outcome
(	8911127	613	614	I-Outcome
BDI	8911127	615	618	I-Outcome
)	8911127	619	620	I-Outcome
scores	8911127	621	627	I-Outcome
were	8911127	628	632	O
the	8911127	633	636	O
endpoints	8911127	637	646	O
for	8911127	647	650	O
this	8911127	651	655	O
study	8911127	656	661	O
,	8911127	662	663	O
and	8911127	664	667	O
the	8911127	668	671	O
questionnaires	8911127	672	686	B-Outcome
were	8911127	687	691	O
completed	8911127	692	701	O
by	8911127	702	704	O
the	8911127	705	708	O
patients	8911127	709	717	O
at	8911127	718	720	O
diagnosis	8911127	721	730	O
,	8911127	731	732	O
and	8911127	733	736	O
up	8911127	737	739	O
to	8911127	740	742	O
9	8911127	743	744	O
months	8911127	745	751	O
after	8911127	752	757	O
diagnosis	8911127	758	767	O
.	8911127	768	769	O

Cognitive	8911127	770	779	B-Intervention
psychotherapy	8911127	780	793	I-Intervention
and	8911127	794	797	O
family	8911127	798	804	B-Intervention
counselling	8911127	805	816	I-Intervention
improved	8911127	817	825	B-Observation
both	8911127	826	830	O
depression	8911127	831	841	B-Outcome
and	8911127	842	845	O
quality	8911127	846	853	B-Outcome
of	8911127	854	856	I-Outcome
life	8911127	857	861	I-Outcome
indexes	8911127	862	869	I-Outcome
compared	8911127	870	878	O
with	8911127	879	883	O
the	8911127	884	887	O
control	8911127	888	895	B-Intervention
group	8911127	896	901	O
.	8911127	902	903	O

Better	8911127	904	910	B-Observation
emotional	8911127	911	920	B-Outcome
coping	8911127	921	927	I-Outcome
behaviours	8911127	928	938	I-Outcome
were	8911127	939	943	O
also	8911127	944	948	O
revealed	8911127	949	957	O
by	8911127	958	960	O
some	8911127	961	965	B-Observation
changes	8911127	966	973	I-Observation
in	8911127	974	976	O
personality	8911127	977	988	B-Outcome
traits	8911127	989	995	I-Outcome
in	8911127	996	998	O
the	8911127	999	1002	O
intervention	8911127	1003	1015	B-Intervention
group	8911127	1016	1021	O
.	8911127	1022	1023	O

Improved	8918486	0	8	B-Observation
local	8918486	9	14	B-Outcome
control	8918486	15	22	I-Outcome
of	8918486	23	25	O
invasive	8918486	26	34	B-Participant
bladder	8918486	35	42	I-Participant
cancer	8918486	43	49	I-Participant
by	8918486	50	52	O
concurrent	8918486	53	63	B-Intervention
cisplatin	8918486	64	73	I-Intervention
and	8918486	74	77	I-Intervention
preoperative	8918486	78	90	I-Intervention
or	8918486	91	93	I-Intervention
definitive	8918486	94	104	I-Intervention
radiation	8918486	105	114	I-Intervention
.	8918486	115	116	O

The	8918486	117	120	O
National	8918486	121	129	O
Cancer	8918486	130	136	O
Institute	8918486	137	146	O
of	8918486	147	149	O
Canada	8918486	150	156	O
Clinical	8918486	157	165	O
Trials	8918486	166	172	O
Group	8918486	173	178	O
.	8918486	179	180	O

PURPOSE	8918486	181	188	O
A	8918486	189	190	O
prospective	8918486	191	202	O
randomized	8918486	203	213	O
trial	8918486	214	219	O
was	8918486	220	223	O
conducted	8918486	224	233	O
to	8918486	234	236	O
determine	8918486	237	246	O
whether	8918486	247	254	O
the	8918486	255	258	O
addition	8918486	259	267	B-Intervention
of	8918486	268	270	I-Intervention
concurrent	8918486	271	281	I-Intervention
cisplatin	8918486	282	291	I-Intervention
to	8918486	292	294	I-Intervention
preoperative	8918486	295	307	I-Intervention
or	8918486	308	310	I-Intervention
definitive	8918486	311	321	I-Intervention
radiation	8918486	322	331	I-Intervention
therapy	8918486	332	339	I-Intervention
in	8918486	340	342	O
patients	8918486	343	351	O
with	8918486	352	356	O
muscle-invasive	8918486	357	372	B-Participant
bladder	8918486	373	380	I-Participant
cancer	8918486	381	387	I-Participant
improved	8918486	388	396	B-Observation
local	8918486	397	402	B-Outcome
control	8918486	403	410	I-Outcome
or	8918486	411	413	O
survival	8918486	414	422	B-Outcome
.	8918486	423	424	O

PATIENTS	8918486	425	433	O
AND	8918486	434	437	O
METHODS	8918486	438	445	O
Ninety-nine	8918486	446	457	O
eligible	8918486	458	466	O
patients	8918486	467	475	O
with	8918486	476	480	O
T2	8918486	481	483	B-Participant
to	8918486	484	486	I-Participant
T4b	8918486	487	490	I-Participant
transitional	8918486	491	503	I-Participant
cell	8918486	504	508	I-Participant
bladder	8918486	509	516	I-Participant
cancer	8918486	517	523	I-Participant
participated	8918486	524	536	O
,	8918486	537	538	O
64	8918486	539	541	O
%	8918486	542	543	O
with	8918486	544	548	O
cT3b	8918486	549	553	B-Participant
or	8918486	554	556	O
cT4	8918486	557	560	B-Participant
.	8918486	561	562	O

Patients	8918486	563	571	O
and	8918486	572	575	O
their	8918486	576	581	O
physicians	8918486	582	592	O
selected	8918486	593	601	O
either	8918486	602	608	O
definitive	8918486	609	619	B-Participant
radiotherapy	8918486	620	632	I-Participant
or	8918486	633	635	O
precystectomy	8918486	636	649	B-Participant
radiotherapy	8918486	650	662	I-Participant
;	8918486	663	664	O
patients	8918486	665	673	O
were	8918486	674	678	O
then	8918486	679	683	O
randomly	8918486	684	692	O
allocated	8918486	693	702	O
to	8918486	703	705	O
receive	8918486	706	713	O
intravenous	8918486	714	725	B-Intervention
cisplatin	8918486	726	735	I-Intervention
100	8918486	736	739	O
mg/m2	8918486	740	745	O
at	8918486	746	748	O
2-week	8918486	749	755	O
intervals	8918486	756	765	O
for	8918486	766	769	O
three	8918486	770	775	O
cycles	8918486	776	782	O
concurrent	8918486	783	793	B-Intervention
with	8918486	794	798	I-Intervention
pelvic	8918486	799	805	I-Intervention
radiation	8918486	806	815	I-Intervention
,	8918486	816	817	O
or	8918486	818	820	O
to	8918486	821	823	O
receive	8918486	824	831	O
radiation	8918486	832	841	B-Intervention
without	8918486	842	849	I-Intervention
chemotherapy	8918486	850	862	I-Intervention
.	8918486	863	864	O

Patients	8918486	865	873	O
were	8918486	874	878	O
stratified	8918486	879	889	O
by	8918486	890	892	O
clinical	8918486	893	901	O
tumor	8918486	902	907	O
stage	8918486	908	913	O
and	8918486	914	917	O
by	8918486	918	920	O
radiation	8918486	921	930	O
plan	8918486	931	935	O
.	8918486	936	937	O

The	8918486	938	941	O
median	8918486	942	948	O
follow-up	8918486	949	958	O
duration	8918486	959	967	O
is	8918486	968	970	O
6.5	8918486	971	974	O
years	8918486	975	980	O
.	8918486	981	982	O

RESULTS	8918486	983	990	O
The	8918486	991	994	O
occurrence	8918486	995	1005	B-Outcome
of	8918486	1006	1008	I-Outcome
distant	8918486	1009	1016	I-Outcome
metastases	8918486	1017	1027	I-Outcome
was	8918486	1028	1031	O
the	8918486	1032	1035	O
same	8918486	1036	1040	B-Count
in	8918486	1041	1043	O
both	8918486	1044	1048	B-Intervention
study	8918486	1049	1054	I-Intervention
arms	8918486	1055	1059	I-Intervention
.	8918486	1060	1061	O

However	8918486	1062	1069	O
,	8918486	1070	1071	O
25	8918486	1072	1074	B-Count
of	8918486	1075	1077	I-Count
48	8918486	1078	1080	I-Count
control	8918486	1081	1088	B-Intervention
patients	8918486	1089	1097	O
have	8918486	1098	1102	O
had	8918486	1103	1106	O
a	8918486	1107	1108	O
first	8918486	1109	1114	B-Outcome
recurrence	8918486	1115	1125	I-Outcome
in	8918486	1126	1128	I-Outcome
the	8918486	1129	1132	I-Outcome
pelvis	8918486	1133	1139	I-Outcome
,	8918486	1140	1141	O
compared	8918486	1142	1150	O
with	8918486	1151	1155	O
15	8918486	1156	1158	B-Count
of	8918486	1159	1161	I-Count
51	8918486	1162	1164	I-Count
cisplatin-treated	8918486	1165	1182	B-Intervention
patients	8918486	1183	1191	O
(	8918486	1192	1193	O
P	8918486	1194	1195	O
=	8918486	1196	1197	O
.036	8918486	1198	1202	O
)	8918486	1203	1204	O
.	8918486	1205	1206	O

The	8918486	1207	1210	O
pelvic	8918486	1211	1217	B-Outcome
relapse	8918486	1218	1225	I-Outcome
rate	8918486	1226	1230	I-Outcome
in	8918486	1231	1233	O
the	8918486	1234	1237	O
two	8918486	1238	1241	O
groups	8918486	1242	1248	O
was	8918486	1249	1252	O
significantly	8918486	1253	1266	B-Observation
reduced	8918486	1267	1274	I-Observation
by	8918486	1275	1277	O
concurrent	8918486	1278	1288	B-Intervention
cisplatin	8918486	1289	1298	I-Intervention
(	8918486	1299	1300	O
P	8918486	1301	1302	O
=	8918486	1303	1304	O
.038	8918486	1305	1309	O
,	8918486	1310	1311	O
log-rank	8918486	1312	1320	O
test	8918486	1321	1325	O
)	8918486	1326	1327	O
and	8918486	1328	1331	O
this	8918486	1332	1336	O
effect	8918486	1337	1343	O
was	8918486	1344	1347	O
preserved	8918486	1348	1357	B-Observation
in	8918486	1358	1360	O
a	8918486	1361	1362	O
stepwise	8918486	1363	1371	B-Outcome
Cox	8918486	1372	1375	I-Outcome
regression	8918486	1376	1386	I-Outcome
model	8918486	1387	1392	I-Outcome
of	8918486	1393	1395	I-Outcome
prognostic	8918486	1396	1406	I-Outcome
factors	8918486	1407	1414	I-Outcome
(	8918486	1415	1416	O
hazards	8918486	1417	1424	O
ratio	8918486	1425	1430	O
,	8918486	1431	1432	O
0.50	8918486	1433	1437	O
;	8918486	1438	1439	O
90	8918486	1440	1442	O
%	8918486	1443	1444	O
confidence	8918486	1445	1455	O
interval	8918486	1456	1464	O
[	8918486	1465	1466	O
CI	8918486	1467	1469	O
]	8918486	1470	1471	O
,	8918486	1472	1473	O
0.29	8918486	1474	1478	O
to	8918486	1479	1481	O
0.86	8918486	1482	1486	O
;	8918486	1487	1488	O
P	8918486	1489	1490	O
=	8918486	1491	1492	O
.036	8918486	1493	1497	O
)	8918486	1498	1499	O
.	8918486	1500	1501	O

The	8918486	1502	1505	O
hazard	8918486	1506	1512	B-Outcome
reduction	8918486	1513	1522	I-Outcome
was	8918486	1523	1526	O
similar	8918486	1527	1534	B-Observation
for	8918486	1535	1538	O
both	8918486	1539	1543	B-Intervention
radiation	8918486	1544	1553	I-Intervention
plans	8918486	1554	1559	I-Intervention
.	8918486	1560	1561	O

Pretreatment	8918486	1562	1574	O
leukocytosis	8918486	1575	1587	O
and	8918486	1588	1591	O
high	8918486	1592	1596	O
clinical	8918486	1597	1605	O
stage	8918486	1606	1611	O
were	8918486	1612	1616	O
independent	8918486	1617	1628	B-Observation
adverse	8918486	1629	1636	I-Observation
factors	8918486	1637	1644	I-Observation
in	8918486	1645	1647	O
a	8918486	1648	1649	O
Cox	8918486	1650	1653	O
model	8918486	1654	1659	O
of	8918486	1660	1662	O
overall	8918486	1663	1670	B-Outcome
survival	8918486	1671	1679	I-Outcome
,	8918486	1680	1681	O
but	8918486	1682	1685	O
the	8918486	1686	1689	O
effect	8918486	1690	1696	O
of	8918486	1697	1699	O
cisplatin	8918486	1700	1709	B-Intervention
was	8918486	1710	1713	O
not	8918486	1714	1717	O
significant	8918486	1718	1729	B-Observation
.	8918486	1730	1731	O

CONCLUSION	8918486	1732	1742	O
Concurrent	8918486	1743	1753	B-Intervention
cisplatin	8918486	1754	1763	I-Intervention
may	8918486	1764	1767	O
improve	8918486	1768	1775	B-Observation
pelvic	8918486	1776	1782	B-Outcome
control	8918486	1783	1790	I-Outcome
of	8918486	1791	1793	O
locally	8918486	1794	1801	B-Participant
advanced	8918486	1802	1810	I-Participant
bladder	8918486	1811	1818	I-Participant
cancer	8918486	1819	1825	I-Participant
with	8918486	1826	1830	O
preoperative	8918486	1831	1843	B-Participant
or	8918486	1844	1846	I-Participant
definitive	8918486	1847	1857	I-Participant
radiation	8918486	1858	1867	I-Participant
,	8918486	1868	1869	O
but	8918486	1870	1873	O
has	8918486	1874	1877	O
not	8918486	1878	1881	O
been	8918486	1882	1886	O
shown	8918486	1887	1892	O
to	8918486	1893	1895	O
improve	8918486	1896	1903	B-Observation
overall	8918486	1904	1911	B-Outcome
survival	8918486	1912	1920	I-Outcome
.	8918486	1921	1922	O

The	8918486	1923	1926	O
use	8918486	1927	1930	O
of	8918486	1931	1933	O
concurrent	8918486	1934	1944	B-Intervention
cisplatin	8918486	1945	1954	I-Intervention
had	8918486	1955	1958	O
no	8918486	1959	1961	O
detectable	8918486	1962	1972	B-Observation
effect	8918486	1973	1979	I-Observation
on	8918486	1980	1982	O
distant	8918486	1983	1990	B-Outcome
metastases	8918486	1991	2001	I-Outcome
.	8918486	2002	2003	O

Effect	8921775	0	6	O
of	8921775	7	9	O
supplementary	8921775	10	23	B-Intervention
antioxidant	8921775	24	35	I-Intervention
vitamin	8921775	36	43	I-Intervention
intake	8921775	44	50	I-Intervention
on	8921775	51	53	O
carotid	8921775	54	61	B-Outcome
arterial	8921775	62	70	I-Outcome
wall	8921775	71	75	I-Outcome
intima-media	8921775	76	88	I-Outcome
thickness	8921775	89	98	I-Outcome
in	8921775	99	101	O
a	8921775	102	103	O
controlled	8921775	104	114	O
clinical	8921775	115	123	O
trial	8921775	124	129	O
of	8921775	130	132	O
cholesterol	8921775	133	144	B-Outcome
lowering	8921775	145	153	I-Outcome
.	8921775	154	155	O

BACKGROUND	8921775	156	166	O
There	8921775	167	172	O
is	8921775	173	175	O
accumulating	8921775	176	188	O
experimental	8921775	189	201	O
,	8921775	202	203	O
epidemiological	8921775	204	219	O
,	8921775	220	221	O
and	8921775	222	225	O
clinical	8921775	226	234	O
evidence	8921775	235	243	O
of	8921775	244	246	O
an	8921775	247	249	O
association	8921775	250	261	O
between	8921775	262	269	O
anti-oxidant	8921775	270	282	O
vitamin	8921775	283	290	O
intake	8921775	291	297	O
and	8921775	298	301	O
reduced	8921775	302	309	O
risk	8921775	310	314	O
of	8921775	315	317	O
coronary	8921775	318	326	O
heart	8921775	327	332	O
disease	8921775	333	340	O
.	8921775	341	342	O

Using	8921775	343	348	O
data	8921775	349	353	O
from	8921775	354	358	O
the	8921775	359	362	O
Cholesterol	8921775	363	374	O
Lowering	8921775	375	383	O
Atherosclerosis	8921775	384	399	O
Study	8921775	400	405	O
(	8921775	406	407	O
CLAS	8921775	408	412	O
)	8921775	413	414	O
,	8921775	415	416	O
we	8921775	417	419	O
explored	8921775	420	428	O
the	8921775	429	432	O
association	8921775	433	444	B-Observation
of	8921775	445	447	O
self-selected	8921775	448	461	B-Intervention
supplementary	8921775	462	475	I-Intervention
antioxidant	8921775	476	487	I-Intervention
vitamin	8921775	488	495	I-Intervention
intake	8921775	496	502	I-Intervention
on	8921775	503	505	O
the	8921775	506	509	O
rate	8921775	510	514	B-Outcome
of	8921775	515	517	I-Outcome
progression	8921775	518	529	I-Outcome
of	8921775	530	532	O
early	8921775	533	538	B-Participant
preintrusive	8921775	539	551	I-Participant
atherosclerosis	8921775	552	567	I-Participant
.	8921775	568	569	O

METHODS	8921775	570	577	O
AND	8921775	578	581	O
RESULTS	8921775	582	589	O
CLAS	8921775	590	594	O
was	8921775	595	598	O
an	8921775	599	601	O
arterial	8921775	602	610	O
imaging	8921775	611	618	O
trial	8921775	619	624	O
in	8921775	625	627	O
which	8921775	628	633	O
nonsmoking	8921775	634	644	O
40-	8921775	645	648	O
to	8921775	649	651	O
59-year-old	8921775	652	663	O
men	8921775	664	667	O
with	8921775	668	672	O
previous	8921775	673	681	B-Participant
coronary	8921775	682	690	I-Participant
artery	8921775	691	697	I-Participant
bypass	8921775	698	704	I-Participant
graft	8921775	705	710	I-Participant
surgery	8921775	711	718	I-Participant
were	8921775	719	723	O
randomized	8921775	724	734	O
to	8921775	735	737	O
colestipol/niacin	8921775	738	755	B-Participant
plus	8921775	756	760	I-Participant
diet	8921775	761	765	I-Participant
or	8921775	766	768	O
placebo	8921775	769	776	B-Participant
plus	8921775	777	781	I-Participant
diet	8921775	782	786	I-Participant
.	8921775	787	788	O

The	8921775	789	792	O
rate	8921775	793	797	B-Outcome
of	8921775	798	800	I-Outcome
progression	8921775	801	812	I-Outcome
of	8921775	813	815	O
early	8921775	816	821	B-Participant
preintrusive	8921775	822	834	I-Participant
atherosclerosis	8921775	835	850	I-Participant
was	8921775	851	854	O
determined	8921775	855	865	O
in	8921775	866	868	O
146	8921775	869	872	O
subjects	8921775	873	881	O
using	8921775	882	887	O
high-resolution	8921775	888	903	O
B-mode	8921775	904	910	O
ultrasound	8921775	911	921	O
quantification	8921775	922	936	O
of	8921775	937	939	O
the	8921775	940	943	O
distal	8921775	944	950	B-Outcome
common	8921775	951	957	I-Outcome
carotid	8921775	958	965	I-Outcome
artery	8921775	966	972	I-Outcome
far	8921775	973	976	I-Outcome
wall	8921775	977	981	I-Outcome
intima-media	8921775	982	994	I-Outcome
thickness	8921775	995	1004	I-Outcome
(	8921775	1005	1006	I-Outcome
IMT	8921775	1007	1010	I-Outcome
)	8921775	1011	1012	I-Outcome
.	8921775	1013	1014	O

From	8921775	1015	1019	O
the	8921775	1020	1023	O
nutritional	8921775	1024	1035	O
supplement	8921775	1036	1046	O
database	8921775	1047	1055	O
,	8921775	1056	1057	O
22	8921775	1058	1060	O
subjects	8921775	1061	1069	O
had	8921775	1070	1073	O
an	8921775	1074	1076	O
on-trial	8921775	1077	1085	B-Intervention
average	8921775	1086	1093	I-Intervention
supplementary	8921775	1094	1107	I-Intervention
vitamin	8921775	1108	1115	I-Intervention
E	8921775	1116	1117	I-Intervention
intake	8921775	1118	1124	I-Intervention
of	8921775	1125	1127	I-Intervention
>	8921775	1128	1129	I-Intervention
or	8921775	1130	1132	I-Intervention
=	8921775	1133	1134	I-Intervention
100	8921775	1135	1138	I-Intervention
IU	8921775	1139	1141	I-Intervention
per	8921775	1142	1145	I-Intervention
day	8921775	1146	1149	I-Intervention
(	8921775	1150	1151	O
high	8921775	1152	1156	B-Intervention
users	8921775	1157	1162	I-Intervention
)	8921775	1163	1164	O
and	8921775	1165	1168	O
29	8921775	1169	1171	O
subjects	8921775	1172	1180	O
had	8921775	1181	1184	O
an	8921775	1185	1187	O
average	8921775	1188	1195	B-Intervention
on-trial	8921775	1196	1204	I-Intervention
supplementary	8921775	1205	1218	I-Intervention
vitamin	8921775	1219	1226	I-Intervention
C	8921775	1227	1228	I-Intervention
intake	8921775	1229	1235	I-Intervention
of	8921775	1236	1238	I-Intervention
>	8921775	1239	1240	I-Intervention
or	8921775	1241	1243	I-Intervention
=	8921775	1244	1245	I-Intervention
250	8921775	1246	1249	I-Intervention
mg	8921775	1250	1252	I-Intervention
per	8921775	1253	1256	I-Intervention
day	8921775	1257	1260	I-Intervention
(	8921775	1261	1262	O
high	8921775	1263	1267	B-Intervention
users	8921775	1268	1273	I-Intervention
)	8921775	1274	1275	O
.	8921775	1276	1277	O

Within	8921775	1278	1284	O
the	8921775	1285	1288	O
placebo	8921775	1289	1296	B-Participant
group	8921775	1297	1302	O
,	8921775	1303	1304	O
less	8921775	1305	1309	B-Observation
carotid	8921775	1310	1317	B-Outcome
IMT	8921775	1318	1321	I-Outcome
progression	8921775	1322	1333	I-Outcome
was	8921775	1334	1337	O
found	8921775	1338	1343	O
for	8921775	1344	1347	O
high	8921775	1348	1352	B-Intervention
supplementary	8921775	1353	1366	I-Intervention
vitamin	8921775	1367	1374	I-Intervention
E	8921775	1375	1376	I-Intervention
users	8921775	1377	1382	I-Intervention
when	8921775	1383	1387	O
compared	8921775	1388	1396	O
with	8921775	1397	1401	O
low	8921775	1402	1405	B-Intervention
vitamin	8921775	1406	1413	I-Intervention
E	8921775	1414	1415	I-Intervention
users	8921775	1416	1421	I-Intervention
(	8921775	1422	1423	O
0.008	8921775	1424	1429	B-Observation
versus	8921775	1430	1436	O
0.023	8921775	1437	1442	B-Observation
mm/y	8921775	1443	1447	I-Observation
,	8921775	1448	1449	O
P	8921775	1450	1451	O
=	8921775	1452	1453	O
.03	8921775	1454	1457	O
)	8921775	1458	1459	O
.	8921775	1460	1461	O

No	8921775	1462	1464	O
effect	8921775	1465	1471	B-Observation
of	8921775	1472	1474	O
vitamin	8921775	1475	1482	B-Intervention
E	8921775	1483	1484	I-Intervention
within	8921775	1485	1491	O
the	8921775	1492	1495	O
drug	8921775	1496	1500	O
group	8921775	1501	1506	O
was	8921775	1507	1510	O
found	8921775	1511	1516	O
.	8921775	1517	1518	O

No	8921775	1519	1521	O
effect	8921775	1522	1528	B-Observation
of	8921775	1529	1531	O
vitamin	8921775	1532	1539	B-Intervention
C	8921775	1540	1541	I-Intervention
within	8921775	1542	1548	O
the	8921775	1549	1552	O
drug	8921775	1553	1557	O
or	8921775	1558	1560	O
placebo	8921775	1561	1568	O
group	8921775	1569	1574	O
was	8921775	1575	1578	O
found	8921775	1579	1584	O
.	8921775	1585	1586	O

CONCLUSIONS	8921775	1587	1598	O
Supplementary	8921775	1599	1612	B-Intervention
vitamin	8921775	1613	1620	I-Intervention
E	8921775	1621	1622	I-Intervention
intake	8921775	1623	1629	I-Intervention
appears	8921775	1630	1637	O
to	8921775	1638	1640	O
be	8921775	1641	1643	O
effective	8921775	1644	1653	O
in	8921775	1654	1656	O
reducing	8921775	1657	1665	B-Observation
the	8921775	1666	1669	O
progression	8921775	1670	1681	B-Outcome
of	8921775	1682	1684	I-Outcome
atherosclerosis	8921775	1685	1700	I-Outcome
in	8921775	1701	1703	O
subjects	8921775	1704	1712	O
not	8921775	1713	1716	O
treated	8921775	1717	1724	O
with	8921775	1725	1729	O
lipid-lowering	8921775	1730	1744	B-Participant
drugs	8921775	1745	1750	I-Participant
while	8921775	1751	1756	O
the	8921775	1757	1760	O
process	8921775	1761	1768	O
is	8921775	1769	1771	O
still	8921775	1772	1777	O
confined	8921775	1778	1786	O
to	8921775	1787	1789	O
the	8921775	1790	1793	O
arterial	8921775	1794	1802	O
wall	8921775	1803	1807	O
(	8921775	1808	1809	O
early	8921775	1810	1815	B-Participant
preintrusive	8921775	1816	1828	I-Participant
atherosclerosis	8921775	1829	1844	I-Participant
)	8921775	1845	1846	O
.	8921775	1847	1848	O

Durability	8936541	0	10	B-Outcome
of	8936541	11	13	O
central	8936541	14	21	B-Intervention
venous	8936541	22	28	I-Intervention
catheters	8936541	29	38	I-Intervention
.	8936541	39	40	O

A	8936541	41	42	O
randomized	8936541	43	53	O
trial	8936541	54	59	O
in	8936541	60	62	O
children	8936541	63	71	B-Participant
with	8936541	72	76	O
malignant	8936541	77	86	B-Participant
diseases	8936541	87	95	I-Participant
.	8936541	96	97	O

In	8936541	98	100	O
a	8936541	101	102	O
prospective	8936541	103	114	O
randomized	8936541	115	125	O
study	8936541	126	131	O
the	8936541	132	135	O
durability	8936541	136	146	B-Outcome
of	8936541	147	149	O
tunnelled	8936541	150	159	B-Intervention
and	8936541	160	163	I-Intervention
non-tunnelled	8936541	164	177	I-Intervention
central	8936541	178	185	I-Intervention
venous	8936541	186	192	I-Intervention
catheters	8936541	193	202	I-Intervention
was	8936541	203	206	O
investigated	8936541	207	219	O
in	8936541	220	222	O
children	8936541	223	231	B-Participant
with	8936541	232	236	O
malignant	8936541	237	246	B-Participant
diseases	8936541	247	255	I-Participant
.	8936541	256	257	O

Twenty	8936541	258	264	O
children	8936541	265	273	B-Participant
were	8936541	274	278	O
included	8936541	279	287	O
in	8936541	288	290	O
the	8936541	291	294	O
study	8936541	295	300	O
but	8936541	301	304	O
four	8936541	305	309	O
(	8936541	310	311	O
two	8936541	312	315	O
in	8936541	316	318	O
each	8936541	319	323	O
group	8936541	324	329	O
)	8936541	330	331	O
had	8936541	332	335	O
to	8936541	336	338	O
be	8936541	339	341	O
excluded	8936541	342	350	O
;	8936541	351	352	O
three	8936541	353	358	O
because	8936541	359	366	O
the	8936541	367	370	O
entry	8936541	371	376	O
criteria	8936541	377	385	O
turned	8936541	386	392	O
out	8936541	393	396	O
not	8936541	397	400	O
to	8936541	401	403	O
be	8936541	404	406	O
fulfilled	8936541	407	416	O
and	8936541	417	420	O
one	8936541	421	424	O
because	8936541	425	432	O
of	8936541	433	435	O
lack	8936541	436	440	O
of	8936541	441	443	O
data	8936541	444	448	O
.	8936541	449	450	O

The	8936541	451	454	O
median	8936541	455	461	B-Outcome
duration	8936541	462	470	I-Outcome
of	8936541	471	473	O
the	8936541	474	477	O
tunnelled	8936541	478	487	B-Intervention
catheters	8936541	488	497	I-Intervention
was	8936541	498	501	O
224	8936541	502	505	B-Observation
days	8936541	506	510	I-Observation
with	8936541	511	515	O
a	8936541	516	517	O
range	8936541	518	523	O
of	8936541	524	526	O
25	8936541	527	529	O
-	8936541	529	530	O
846	8936541	530	533	O
days	8936541	534	538	O
which	8936541	539	544	O
was	8936541	545	548	O
significantly	8936541	549	562	B-Observation
longer	8936541	563	569	I-Observation
than	8936541	570	574	O
that	8936541	575	579	O
of	8936541	580	582	O
conventional	8936541	583	595	B-Intervention
catheters	8936541	596	605	I-Intervention
(	8936541	606	607	O
39.5	8936541	608	612	B-Observation
days	8936541	613	617	I-Observation
,	8936541	618	619	O
range	8936541	620	625	O
9	8936541	626	627	O
-	8936541	627	628	O
228	8936541	628	631	O
days	8936541	632	636	O
)	8936541	637	638	O
.	8936541	639	640	O

In	8936541	641	643	O
addition	8936541	644	652	O
six	8936541	653	656	B-Count
of	8936541	657	659	I-Count
eight	8936541	660	665	I-Count
conventional	8936541	666	678	B-Intervention
catheters	8936541	679	688	I-Intervention
were	8936541	689	693	O
accidentally	8936541	694	706	B-Outcome
removed	8936541	707	714	I-Outcome
whereas	8936541	715	722	O
all	8936541	723	726	B-Count
catheters	8936541	727	736	B-Intervention
in	8936541	737	739	I-Intervention
the	8936541	740	743	I-Intervention
tunnelled	8936541	744	753	I-Intervention
group	8936541	754	759	O
had	8936541	760	763	O
to	8936541	764	766	O
be	8936541	767	769	O
removed	8936541	770	777	B-Outcome
via	8936541	778	781	I-Outcome
a	8936541	782	783	I-Outcome
small	8936541	784	789	I-Outcome
incision	8936541	790	798	I-Outcome
.	8936541	799	800	O

Three	8936541	801	806	B-Count
cases	8936541	807	812	I-Count
of	8936541	813	815	O
catheter	8936541	816	824	B-Outcome
related	8936541	825	832	I-Outcome
sepsis	8936541	833	839	I-Outcome
,	8936541	840	841	O
two	8936541	842	845	B-Count
in	8936541	846	848	O
the	8936541	849	852	O
tunnelled	8936541	853	862	B-Intervention
group	8936541	863	868	O
and	8936541	869	872	O
one	8936541	873	876	B-Count
in	8936541	877	879	O
the	8936541	880	883	O
conventional	8936541	884	896	B-Intervention
group	8936541	897	902	O
,	8936541	903	904	O
were	8936541	905	909	O
registered	8936541	910	920	O
.	8936541	921	922	O

The	8936541	923	926	O
corresponding	8936541	927	940	B-Outcome
number	8936541	941	947	I-Outcome
of	8936541	948	950	I-Outcome
infections	8936541	951	961	I-Outcome
per	8936541	962	965	I-Outcome
catheter	8936541	966	974	I-Outcome
days	8936541	975	979	I-Outcome
were	8936541	980	984	O
1	8936541	985	986	B-Observation
in	8936541	987	989	I-Observation
1189	8936541	990	994	I-Observation
days	8936541	995	999	I-Observation
and	8936541	1000	1003	O
1	8936541	1004	1005	B-Observation
in	8936541	1006	1008	I-Observation
522	8936541	1009	1012	I-Observation
days	8936541	1013	1017	I-Observation
,	8936541	1018	1019	O
respectively	8936541	1020	1032	O
.	8936541	1033	1034	O

In	8936541	1035	1037	O
conclusion	8936541	1038	1048	O
cuffed	8936541	1049	1055	B-Intervention
,	8936541	1056	1057	I-Intervention
tunnelled	8936541	1058	1067	I-Intervention
central	8936541	1068	1075	I-Intervention
venous	8936541	1076	1082	I-Intervention
catheters	8936541	1083	1092	I-Intervention
are	8936541	1093	1096	O
less	8936541	1097	1101	B-Observation
prone	8936541	1102	1107	I-Observation
to	8936541	1108	1110	O
displacement	8936541	1111	1123	B-Outcome
than	8936541	1124	1128	O
traditional	8936541	1129	1140	B-Intervention
percutaneous	8936541	1141	1153	I-Intervention
central	8936541	1154	1161	I-Intervention
venous	8936541	1162	1168	I-Intervention
catheters	8936541	1169	1178	I-Intervention
when	8936541	1179	1183	O
used	8936541	1184	1188	O
in	8936541	1189	1191	O
children	8936541	1192	1200	B-Participant
with	8936541	1201	1205	O
malignant	8936541	1206	1215	B-Participant
diseases	8936541	1216	1224	I-Participant
.	8936541	1225	1226	O

The	8940983	0	3	O
immunogenicity	8940983	4	18	B-Outcome
of	8940983	19	21	O
three	8940983	22	27	O
Haemophilus	8940983	28	39	B-Intervention
influenzae	8940983	40	50	I-Intervention
type	8940983	51	55	I-Intervention
B	8940983	56	57	I-Intervention
conjugate	8940983	58	67	I-Intervention
vaccines	8940983	68	76	I-Intervention
after	8940983	77	82	O
a	8940983	83	84	O
primary	8940983	85	92	B-Participant
vaccination	8940983	93	104	I-Participant
series	8940983	105	111	I-Participant
in	8940983	112	114	O
Philippine	8940983	115	125	O
infants	8940983	126	133	B-Participant
.	8940983	134	135	O

Serum	8940983	136	141	B-Outcome
antibody	8940983	142	150	I-Outcome
responses	8940983	151	160	I-Outcome
to	8940983	161	163	O
three	8940983	164	169	O
Haemophilus	8940983	170	181	B-Intervention
influenzae	8940983	182	192	I-Intervention
type	8940983	193	197	I-Intervention
b	8940983	198	199	I-Intervention
(	8940983	200	201	I-Intervention
Hib	8940983	202	205	I-Intervention
)	8940983	206	207	I-Intervention
capsular	8940983	208	216	I-Intervention
polysaccharide-protein	8940983	217	239	I-Intervention
conjugate	8940983	240	249	I-Intervention
vaccine	8940983	250	257	I-Intervention
(	8940983	258	259	O
PRP-OMP	8940983	260	267	B-Intervention
,	8940983	268	269	O
PRP-T	8940983	270	275	B-Intervention
,	8940983	276	277	O
and	8940983	278	281	O
HbOC	8940983	282	286	B-Intervention
)	8940983	287	288	O
were	8940983	289	293	O
evaluated	8940983	294	303	O
in	8940983	304	306	O
174	8940983	307	310	O
Philippine	8940983	311	321	O
infants	8940983	322	329	B-Participant
after	8940983	330	335	O
a	8940983	336	337	O
primary	8940983	338	345	B-Participant
vaccination	8940983	346	357	I-Participant
series	8940983	358	364	I-Participant
.	8940983	365	366	O

Children	8940983	367	375	B-Participant
were	8940983	376	380	O
randomized	8940983	381	391	O
to	8940983	392	394	O
receive	8940983	395	402	O
one	8940983	403	406	O
of	8940983	407	409	O
the	8940983	410	413	O
Hib	8940983	414	417	B-Intervention
vaccines	8940983	418	426	I-Intervention
(	8940983	427	428	O
Hib	8940983	429	432	O
groups	8940983	433	439	O
)	8940983	440	441	O
or	8940983	442	444	O
into	8940983	445	449	O
a	8940983	450	451	O
control	8940983	452	459	B-Intervention
group	8940983	460	465	O
.	8940983	466	467	O

Vaccination	8940983	468	479	O
was	8940983	480	483	O
carried	8940983	484	491	O
out	8940983	492	495	O
at	8940983	496	498	O
six	8940983	499	502	O
,	8940983	503	504	O
10	8940983	505	507	O
and	8940983	508	511	O
14	8940983	512	514	O
weeks	8940983	515	520	O
of	8940983	521	523	O
age	8940983	524	527	O
based	8940983	528	533	O
on	8940983	534	536	O
the	8940983	537	540	O
local	8940983	541	546	O
Expanded	8940983	547	555	O
Program	8940983	556	563	O
of	8940983	564	566	O
Immunization	8940983	567	579	O
schedule	8940983	580	588	O
.	8940983	589	590	O

Sera	8940983	591	595	O
were	8940983	596	600	O
collected	8940983	601	610	O
at	8940983	611	613	O
six	8940983	614	617	O
weeks	8940983	618	623	O
of	8940983	624	626	O
age	8940983	627	630	O
for	8940983	631	634	O
the	8940983	635	638	O
Hib	8940983	639	642	O
groups	8940983	643	649	O
and	8940983	650	653	O
one	8940983	654	657	O
month	8940983	658	663	O
after	8940983	664	669	O
the	8940983	670	673	O
third	8940983	674	679	O
dose	8940983	680	684	O
for	8940983	685	688	O
all	8940983	689	692	O
subjects	8940983	693	701	O
.	8940983	702	703	O

Anti-Hib	8940983	704	712	B-Outcome
concentrations	8940983	713	727	I-Outcome
were	8940983	728	732	O
determined	8940983	733	743	O
by	8940983	744	746	O
the	8940983	747	750	O
Farr-type	8940983	751	760	O
radioimmunoassay	8940983	761	777	O
.	8940983	778	779	O

There	8940983	780	785	O
were	8940983	786	790	O
no	8940983	791	793	O
significant	8940983	794	805	B-Observation
differences	8940983	806	817	I-Observation
(	8940983	818	819	O
P	8940983	820	821	O
=	8940983	822	823	O
0.3626	8940983	824	830	O
)	8940983	831	832	O
in	8940983	833	835	O
the	8940983	836	839	O
prevaccination	8940983	840	854	B-Outcome
anti-Hib	8940983	855	863	I-Outcome
geometric	8940983	864	873	I-Outcome
mean	8940983	874	878	I-Outcome
concentration	8940983	879	892	I-Outcome
(	8940983	893	894	I-Outcome
GMC	8940983	895	898	I-Outcome
)	8940983	899	900	I-Outcome
among	8940983	901	906	O
the	8940983	907	910	O
three	8940983	911	916	B-Intervention
Hib	8940983	917	920	I-Intervention
groups	8940983	921	927	O
.	8940983	928	929	O

Differences	8940983	930	941	B-Outcome
in	8940983	942	944	I-Outcome
the	8940983	945	948	I-Outcome
GMC	8940983	949	952	I-Outcome
after	8940983	953	958	O
the	8940983	959	962	O
primary	8940983	963	970	B-Intervention
series	8940983	971	977	I-Intervention
of	8940983	978	980	I-Intervention
three	8940983	981	986	I-Intervention
doses	8940983	987	992	I-Intervention
were	8940983	993	997	O
significant	8940983	998	1009	B-Observation
(	8940983	1010	1011	O
P	8940983	1012	1013	O
<	8940983	1014	1015	O
0.0001	8940983	1016	1022	O
)	8940983	1023	1024	O
;	8940983	1025	1026	O
GMC	8940983	1027	1030	B-Outcome
was	8940983	1031	1034	O
highest	8940983	1035	1042	B-Observation
for	8940983	1043	1046	O
PRP-T	8940983	1047	1052	B-Intervention
(	8940983	1053	1054	O
6.62	8940983	1055	1059	B-Observation
micrograms/ml	8940983	1060	1073	I-Observation
)	8940983	1074	1075	O
,	8940983	1076	1077	O
followed	8940983	1078	1086	O
by	8940983	1087	1089	O
HbOC	8940983	1090	1094	B-Intervention
(	8940983	1095	1096	O
1.9	8940983	1097	1100	B-Observation
micrograms/ml	8940983	1101	1114	I-Observation
)	8940983	1115	1116	O
,	8940983	1117	1118	O
then	8940983	1119	1123	O
PRP-OMP	8940983	1124	1131	B-Intervention
(	8940983	1132	1133	O
1.06	8940983	1134	1138	B-Observation
micrograms/ml	8940983	1139	1152	I-Observation
)	8940983	1153	1154	O
,	8940983	1155	1156	O
and	8940983	1157	1160	O
lowest	8940983	1161	1167	B-Observation
for	8940983	1168	1171	O
the	8940983	1172	1175	O
control	8940983	1176	1183	B-Intervention
group	8940983	1184	1189	O
(	8940983	1190	1191	O
0.11	8940983	1192	1196	B-Observation
microgram/ml	8940983	1197	1209	I-Observation
)	8940983	1210	1211	O
.	8940983	1212	1213	O

We	8940983	1214	1216	O
conclude	8940983	1217	1225	O
that	8940983	1226	1230	O
all	8940983	1231	1234	B-Intervention
three	8940983	1235	1240	I-Intervention
Hib	8940983	1241	1244	I-Intervention
conjugate	8940983	1245	1254	I-Intervention
vaccines	8940983	1255	1263	I-Intervention
(	8940983	1264	1265	I-Intervention
PRP-T	8940983	1266	1271	I-Intervention
,	8940983	1272	1273	I-Intervention
HbOC	8940983	1274	1278	I-Intervention
,	8940983	1279	1280	I-Intervention
and	8940983	1281	1284	I-Intervention
PRP-OMP	8940983	1285	1292	I-Intervention
)	8940983	1293	1294	I-Intervention
were	8940983	1295	1299	O
immunogenic	8940983	1300	1311	B-Outcome
after	8940983	1312	1317	O
three	8940983	1318	1323	O
primary	8940983	1324	1331	O
doses	8940983	1332	1337	O
among	8940983	1338	1343	O
Philippine	8940983	1344	1354	O
infants	8940983	1355	1362	B-Participant
.	8940983	1363	1364	O

Thoracoscopic	8957368	0	13	B-Intervention
talc	8957368	14	18	I-Intervention
insufflation	8957368	19	31	I-Intervention
versus	8957368	32	38	O
talc	8957368	39	43	B-Intervention
slurry	8957368	44	50	I-Intervention
for	8957368	51	54	O
symptomatic	8957368	55	66	B-Participant
malignant	8957368	67	76	I-Participant
pleural	8957368	77	84	I-Participant
effusion	8957368	85	93	I-Participant
.	8957368	94	95	O

BACKGROUND	8957368	96	106	O
Talc	8957368	107	111	O
has	8957368	112	115	O
been	8957368	116	120	O
generally	8957368	121	130	O
accepted	8957368	131	139	O
to	8957368	140	142	O
be	8957368	143	145	O
the	8957368	146	149	O
most	8957368	150	154	O
effective	8957368	155	164	O
sclerosant	8957368	165	175	O
for	8957368	176	179	O
chemical	8957368	180	188	O
pleurodesis	8957368	189	200	O
,	8957368	201	202	O
although	8957368	203	211	O
the	8957368	212	215	O
optimal	8957368	216	223	O
route	8957368	224	229	O
of	8957368	230	232	O
administration	8957368	233	247	O
remains	8957368	248	255	O
unclear	8957368	256	263	O
.	8957368	264	265	O

METHODS	8957368	266	273	O
We	8957368	274	276	O
designed	8957368	277	285	O
a	8957368	286	287	O
prospective	8957368	288	299	O
,	8957368	300	301	O
randomized	8957368	302	312	O
study	8957368	313	318	O
to	8957368	319	321	O
compare	8957368	322	329	O
video-assisted	8957368	330	344	B-Intervention
thoracoscopic	8957368	345	358	I-Intervention
talc	8957368	359	363	I-Intervention
insufflation	8957368	364	376	I-Intervention
with	8957368	377	381	O
bedside	8957368	382	389	B-Intervention
talc	8957368	390	394	I-Intervention
slurry	8957368	395	401	I-Intervention
in	8957368	402	404	O
the	8957368	405	408	O
treatment	8957368	409	418	O
of	8957368	419	421	O
malignant	8957368	422	431	B-Participant
pleural	8957368	432	439	I-Participant
effusion	8957368	440	448	I-Participant
.	8957368	449	450	O

From	8957368	451	455	O
September	8957368	456	465	O
1993	8957368	466	470	O
to	8957368	471	473	O
November	8957368	474	482	O
1995	8957368	483	487	O
,	8957368	488	489	O
57	8957368	490	492	O
patients	8957368	493	501	O
were	8957368	502	506	O
recruited	8957368	507	516	O
and	8957368	517	520	O
randomized	8957368	521	531	O
to	8957368	532	534	O
either	8957368	535	541	O
video-assisted	8957368	542	556	B-Intervention
thoracoscopic	8957368	557	570	I-Intervention
talc	8957368	571	575	I-Intervention
insufflation	8957368	576	588	I-Intervention
under	8957368	589	594	I-Intervention
general	8957368	595	602	I-Intervention
anesthesia	8957368	603	613	I-Intervention
(	8957368	614	615	O
n	8957368	616	617	O
=	8957368	618	619	O
28	8957368	620	622	O
)	8957368	623	624	O
or	8957368	625	627	O
talc	8957368	628	632	B-Intervention
slurry	8957368	633	639	I-Intervention
by	8957368	640	642	I-Intervention
the	8957368	643	646	I-Intervention
bedside	8957368	647	654	I-Intervention
(	8957368	655	656	O
n	8957368	657	658	O
=	8957368	659	660	O
29	8957368	661	663	O
)	8957368	664	665	O
.	8957368	666	667	O

Patients	8957368	668	676	O
with	8957368	677	681	O
poor	8957368	682	686	B-Participant
general	8957368	687	694	I-Participant
condition	8957368	695	704	I-Participant
(	8957368	705	706	O
Karnofsky	8957368	707	716	B-Participant
score	8957368	717	722	I-Participant
less	8957368	723	727	I-Participant
than	8957368	728	732	I-Participant
30	8957368	733	735	I-Participant
%	8957368	736	737	I-Participant
)	8957368	738	739	O
,	8957368	740	741	O
poor	8957368	742	746	B-Participant
pulmonary	8957368	747	756	I-Participant
function	8957368	757	765	I-Participant
(	8957368	766	767	O
forced	8957368	768	774	B-Participant
expiratory	8957368	775	785	I-Participant
volume	8957368	786	792	I-Participant
in	8957368	793	795	I-Participant
1	8957368	796	797	I-Participant
second	8957368	798	804	I-Participant
less	8957368	805	809	I-Participant
than	8957368	810	814	I-Participant
0.5	8957368	815	818	I-Participant
L	8957368	819	820	I-Participant
)	8957368	821	822	O
,	8957368	823	824	O
or	8957368	825	827	O
trapped	8957368	828	835	B-Participant
lungs	8957368	836	841	I-Participant
were	8957368	842	846	O
excluded	8957368	847	855	O
from	8957368	856	860	O
this	8957368	861	865	O
study	8957368	866	871	O
.	8957368	872	873	O

Five	8957368	874	878	O
grams	8957368	879	884	O
of	8957368	885	887	O
purified	8957368	888	896	O
talc	8957368	897	901	O
was	8957368	902	905	O
used	8957368	906	910	O
for	8957368	911	914	O
either	8957368	915	921	O
video-assisted	8957368	922	936	B-Intervention
thoracoscopic	8957368	937	950	I-Intervention
talc	8957368	951	955	I-Intervention
insufflation	8957368	956	968	I-Intervention
or	8957368	969	971	O
talc	8957368	972	976	B-Intervention
slurry	8957368	977	983	I-Intervention
.	8957368	984	985	O

RESULTS	8957368	986	993	O
There	8957368	994	999	O
was	8957368	1000	1003	O
no	8957368	1004	1006	O
statistically	8957368	1007	1020	B-Observation
significant	8957368	1021	1032	I-Observation
difference	8957368	1033	1043	I-Observation
between	8957368	1044	1051	O
the	8957368	1052	1055	O
two	8957368	1056	1059	B-Intervention
groups	8957368	1060	1066	I-Intervention
of	8957368	1067	1069	O
patients	8957368	1070	1078	O
with	8957368	1079	1083	O
respect	8957368	1084	1091	O
to	8957368	1092	1094	O
age	8957368	1095	1098	O
,	8957368	1099	1100	O
sex	8957368	1101	1104	O
ratio	8957368	1105	1110	O
,	8957368	1111	1112	O
chest	8957368	1113	1118	B-Outcome
drainage	8957368	1119	1127	I-Outcome
duration	8957368	1128	1136	I-Outcome
,	8957368	1137	1138	O
postprocedural	8957368	1139	1153	B-Outcome
hospital	8957368	1154	1162	I-Outcome
stay	8957368	1163	1167	I-Outcome
,	8957368	1168	1169	O
parenteral	8957368	1170	1180	B-Outcome
narcotics	8957368	1181	1190	I-Outcome
requirement	8957368	1191	1202	I-Outcome
,	8957368	1203	1204	O
complications	8957368	1205	1218	B-Outcome
,	8957368	1219	1220	O
or	8957368	1221	1223	O
procedure	8957368	1224	1233	B-Outcome
failure	8957368	1234	1241	I-Outcome
(	8957368	1242	1243	O
ie	8957368	1244	1246	O
,	8957368	1247	1248	O
recurrence	8957368	1249	1259	B-Outcome
)	8957368	1260	1261	O
.	8957368	1262	1263	O

CONCLUSIONS	8957368	1264	1275	O
Video-assisted	8957368	1276	1290	B-Intervention
thoracoscopic	8957368	1291	1304	I-Intervention
talc	8957368	1305	1309	I-Intervention
insufflation	8957368	1310	1322	I-Intervention
has	8957368	1323	1326	O
not	8957368	1327	1330	O
been	8957368	1331	1335	O
shown	8957368	1336	1341	O
to	8957368	1342	1344	O
be	8957368	1345	1347	O
a	8957368	1348	1349	O
superior	8957368	1350	1358	B-Observation
approach	8957368	1359	1367	O
compared	8957368	1368	1376	O
with	8957368	1377	1381	O
talc	8957368	1382	1386	B-Intervention
slurry	8957368	1387	1393	I-Intervention
in	8957368	1394	1396	O
our	8957368	1397	1400	O
study	8957368	1401	1406	O
.	8957368	1407	1408	O

Because	8957368	1409	1416	O
the	8957368	1417	1420	O
former	8957368	1421	1427	O
demands	8957368	1428	1435	O
more	8957368	1436	1440	O
resources	8957368	1441	1450	O
,	8957368	1451	1452	O
we	8957368	1453	1455	O
advocate	8957368	1456	1464	O
that	8957368	1465	1469	O
talc	8957368	1470	1474	O
slurry	8957368	1475	1481	O
should	8957368	1482	1488	O
be	8957368	1489	1491	O
considered	8957368	1492	1502	O
as	8957368	1503	1505	O
the	8957368	1506	1509	O
procedure	8957368	1510	1519	O
of	8957368	1520	1522	O
choice	8957368	1523	1529	O
in	8957368	1530	1532	O
the	8957368	1533	1536	O
treatment	8957368	1537	1546	O
of	8957368	1547	1549	O
symptomatic	8957368	1550	1561	O
malignant	8957368	1562	1571	O
pleural	8957368	1572	1579	O
effusion	8957368	1580	1588	O
in	8957368	1589	1591	O
patients	8957368	1592	1600	O
who	8957368	1601	1604	O
do	8957368	1605	1607	O
not	8957368	1608	1611	O
have	8957368	1612	1616	O
trapped	8957368	1617	1624	O
lungs	8957368	1625	1630	O
.	8957368	1631	1632	O

Dental	8960488	0	6	B-Outcome
bacteremia	8960488	7	17	I-Outcome
in	8960488	18	20	O
children	8960488	21	29	B-Participant
.	8960488	30	31	O

Bacteremia	8960488	32	42	O
resulting	8960488	43	52	O
from	8960488	53	57	O
dental	8960488	58	64	O
extraction	8960488	65	75	O
is	8960488	76	78	O
regarded	8960488	79	87	O
as	8960488	88	90	O
an	8960488	91	93	O
important	8960488	94	103	O
cause	8960488	104	109	O
of	8960488	110	112	O
bacterial	8960488	113	122	O
endocarditis	8960488	123	135	O
,	8960488	136	137	O
and	8960488	138	141	O
it	8960488	142	144	O
is	8960488	145	147	O
therefore	8960488	148	157	O
recommended	8960488	158	169	O
that	8960488	170	174	O
patients	8960488	175	183	O
undergoing	8960488	184	194	O
tooth	8960488	195	200	O
extraction	8960488	201	211	O
be	8960488	212	214	O
given	8960488	215	220	O
prophylactic	8960488	221	233	O
antibiotics	8960488	234	245	O
.	8960488	246	247	O

As	8960488	248	250	O
dental	8960488	251	257	O
procedures	8960488	258	268	O
other	8960488	269	274	O
than	8960488	275	279	O
extractions	8960488	280	291	O
may	8960488	292	295	O
also	8960488	296	300	O
cause	8960488	301	306	O
bacteremias	8960488	307	318	O
,	8960488	319	320	O
we	8960488	321	323	O
studied	8960488	324	331	O
a	8960488	332	333	O
variety	8960488	334	341	O
of	8960488	342	344	O
dental	8960488	345	351	B-Intervention
procedures	8960488	352	362	I-Intervention
routinely	8960488	363	372	O
used	8960488	373	377	O
in	8960488	378	380	O
pediatric	8960488	381	390	B-Participant
dentistry	8960488	391	400	I-Participant
.	8960488	401	402	O

Blood	8960488	403	408	B-Outcome
samples	8960488	409	416	I-Outcome
for	8960488	417	420	O
cultures	8960488	421	429	O
were	8960488	430	434	O
obtained	8960488	435	443	O
30	8960488	444	446	O
s	8960488	447	448	O
after	8960488	449	454	O
each	8960488	455	459	O
of	8960488	460	462	O
13	8960488	463	465	O
dental	8960488	466	472	O
operative	8960488	473	482	O
procedures	8960488	483	493	O
in	8960488	494	496	O
735	8960488	497	500	O
anesthetized	8960488	501	513	B-Participant
children	8960488	514	522	I-Participant
aged	8960488	523	527	O
2	8960488	528	529	O
-	8960488	529	530	O
16	8960488	530	532	O
years	8960488	533	538	O
.	8960488	539	540	O

Four	8960488	541	545	B-Intervention
procedures	8960488	546	556	I-Intervention
used	8960488	557	561	I-Intervention
for	8960488	562	565	I-Intervention
conservative	8960488	566	578	I-Intervention
dentistry	8960488	579	588	I-Intervention
caused	8960488	589	595	O
bacteremias	8960488	596	607	B-Outcome
significantly	8960488	608	621	B-Observation
more	8960488	622	626	I-Observation
often	8960488	627	632	I-Observation
than	8960488	633	637	O
the	8960488	638	641	O
baseline	8960488	642	650	B-Intervention
value	8960488	651	656	I-Intervention
of	8960488	657	659	O
9.4	8960488	660	663	B-Count
%	8960488	664	665	I-Count
:	8960488	666	667	O
polishing	8960488	668	677	B-Intervention
teeth	8960488	678	683	I-Intervention
24.5	8960488	684	688	B-Count
%	8960488	689	690	I-Count
,	8960488	691	692	O
intraligamental	8960488	693	708	B-Intervention
injection	8960488	709	718	I-Intervention
96.6	8960488	719	723	B-Count
%	8960488	724	725	I-Count
,	8960488	726	727	O
rubber	8960488	728	734	B-Intervention
dam	8960488	735	738	I-Intervention
placement	8960488	739	748	I-Intervention
29.4	8960488	749	753	B-Count
%	8960488	754	755	I-Count
,	8960488	756	757	O
and	8960488	758	761	O
matrix	8960488	762	768	B-Intervention
band	8960488	769	773	I-Intervention
with	8960488	774	778	I-Intervention
wedge	8960488	779	784	I-Intervention
placement	8960488	785	794	I-Intervention
32.1	8960488	795	799	B-Count
%	8960488	800	801	I-Count
.	8960488	802	803	O

In	8960488	804	806	O
comparison	8960488	807	817	O
,	8960488	818	819	O
toothbrushing	8960488	820	833	B-Intervention
alone	8960488	834	839	I-Intervention
caused	8960488	840	846	O
a	8960488	847	848	O
bacteremia	8960488	849	859	B-Outcome
on	8960488	860	862	O
38.5	8960488	863	867	B-Count
%	8960488	868	869	I-Count
of	8960488	870	872	I-Count
occasions	8960488	873	882	I-Count
.	8960488	883	884	O

The	8960488	885	888	O
organisms	8960488	889	898	B-Outcome
isolated	8960488	899	907	I-Outcome
were	8960488	908	912	O
typical	8960488	913	920	O
of	8960488	921	923	O
odontogenic	8960488	924	935	O
bacteremias	8960488	936	947	O
in	8960488	948	950	O
that	8960488	951	955	O
50	8960488	956	958	B-Count
%	8960488	959	960	I-Count
of	8960488	961	963	I-Count
the	8960488	964	967	I-Count
isolates	8960488	968	976	I-Count
were	8960488	977	981	O
identified	8960488	982	992	O
as	8960488	993	995	O
varieties	8960488	996	1005	B-Outcome
of	8960488	1006	1008	I-Outcome
viridans	8960488	1009	1017	I-Outcome
streptococci	8960488	1018	1030	I-Outcome
.	8960488	1031	1032	O

These	8960488	1033	1038	O
data	8960488	1039	1043	O
show	8960488	1044	1048	O
that	8960488	1049	1053	O
a	8960488	1054	1055	B-Observation
wider	8960488	1056	1061	I-Observation
variety	8960488	1062	1069	I-Observation
of	8960488	1070	1072	O
dental	8960488	1073	1079	B-Intervention
procedures	8960488	1080	1090	I-Intervention
than	8960488	1091	1095	O
was	8960488	1096	1099	O
previously	8960488	1100	1110	O
documented	8960488	1111	1121	O
cause	8960488	1122	1127	O
bacteremia	8960488	1128	1138	B-Outcome
.	8960488	1139	1140	O

Modulation	8964113	0	10	B-Outcome
of	8964113	11	13	I-Outcome
oxidant	8964113	14	21	I-Outcome
stress	8964113	22	28	I-Outcome
in	8964113	29	31	I-Outcome
vivo	8964113	32	36	I-Outcome
in	8964113	37	39	O
chronic	8964113	40	47	B-Participant
cigarette	8964113	48	57	I-Participant
smokers	8964113	58	65	I-Participant
.	8964113	66	67	O

BACKGROUND	8964113	68	78	O
Free	8964113	79	83	O
radical-induced	8964113	84	99	O
oxidative	8964113	100	109	O
damage	8964113	110	116	O
is	8964113	117	119	O
thought	8964113	120	127	O
to	8964113	128	130	O
be	8964113	131	133	O
involved	8964113	134	142	O
in	8964113	143	145	O
the	8964113	146	149	O
pathogenesis	8964113	150	162	O
of	8964113	163	165	O
diseases	8964113	166	174	O
associated	8964113	175	185	O
with	8964113	186	190	O
cigarette	8964113	191	200	O
smoking	8964113	201	208	O
.	8964113	209	210	O

We	8964113	211	213	O
examined	8964113	214	222	O
the	8964113	223	226	O
production	8964113	227	237	B-Outcome
of	8964113	238	240	I-Outcome
8-epi-prostaglandin	8964113	241	260	I-Outcome
(	8964113	261	262	I-Outcome
PG	8964113	263	265	I-Outcome
)	8964113	266	267	I-Outcome
F2	8964113	268	270	I-Outcome
alpha	8964113	271	276	I-Outcome
,	8964113	277	278	O
a	8964113	279	280	O
stable	8964113	281	287	O
product	8964113	288	295	O
of	8964113	296	298	O
lipid	8964113	299	304	O
peroxidation	8964113	305	317	O
in	8964113	318	320	O
vivo	8964113	321	325	O
,	8964113	326	327	O
and	8964113	328	331	O
its	8964113	332	335	O
modulation	8964113	336	346	B-Outcome
by	8964113	347	349	O
aspirin	8964113	350	357	B-Intervention
and	8964113	358	361	O
antioxidant	8964113	362	373	B-Intervention
vitamins	8964113	374	382	I-Intervention
in	8964113	383	385	O
chronic	8964113	386	393	B-Participant
cigarette	8964113	394	403	I-Participant
smokers	8964113	404	411	I-Participant
.	8964113	412	413	O

METHODS	8964113	414	421	O
AND	8964113	422	425	O
RESULTS	8964113	426	433	O
We	8964113	434	436	O
performed	8964113	437	446	O
the	8964113	447	450	O
following	8964113	451	460	O
studies	8964113	461	468	O
:	8964113	469	470	O
(	8964113	471	472	O
1	8964113	473	474	O
)	8964113	475	476	O
a	8964113	477	478	O
cross-sectional	8964113	479	494	O
comparison	8964113	495	505	O
of	8964113	506	508	O
smokers	8964113	509	516	B-Intervention
and	8964113	517	520	O
control	8964113	521	528	B-Intervention
subjects	8964113	529	537	O
,	8964113	538	539	O
(	8964113	540	541	O
2	8964113	542	543	O
)	8964113	544	545	O
an	8964113	546	548	O
examination	8964113	549	560	O
of	8964113	561	563	O
the	8964113	564	567	O
dose-response	8964113	568	581	B-Outcome
relationship	8964113	582	594	I-Outcome
,	8964113	595	596	O
(	8964113	597	598	O
3	8964113	599	600	O
)	8964113	601	602	O
an	8964113	603	605	O
exploration	8964113	606	617	O
of	8964113	618	620	O
the	8964113	621	624	O
effect	8964113	625	631	O
of	8964113	632	634	O
smoking	8964113	635	642	B-Intervention
cessation	8964113	643	652	I-Intervention
(	8964113	653	654	O
3	8964113	655	656	O
weeks	8964113	657	662	O
)	8964113	663	664	O
and	8964113	665	668	O
nicotine	8964113	669	677	B-Intervention
patch	8964113	678	683	I-Intervention
supplementation	8964113	684	699	I-Intervention
,	8964113	700	701	O
(	8964113	702	703	O
4	8964113	704	705	O
)	8964113	706	707	O
the	8964113	708	711	O
effect	8964113	712	718	O
of	8964113	719	721	O
aspirin	8964113	722	729	B-Intervention
consumption	8964113	730	741	I-Intervention
,	8964113	742	743	O
and	8964113	744	747	O
(	8964113	748	749	O
5	8964113	750	751	O
)	8964113	752	753	O
the	8964113	754	757	O
effects	8964113	758	765	O
of	8964113	766	768	O
5	8964113	769	770	O
days	8964113	771	775	O
'	8964113	776	777	O
dosing	8964113	778	784	O
with	8964113	785	789	O
vitamin	8964113	790	797	B-Intervention
E	8964113	798	799	I-Intervention
(	8964113	800	801	O
100	8964113	802	805	O
and	8964113	806	809	O
800	8964113	810	813	O
U	8964113	814	815	O
)	8964113	816	817	O
,	8964113	818	819	O
vitamin	8964113	820	827	B-Intervention
C	8964113	828	829	I-Intervention
(	8964113	830	831	O
2	8964113	832	833	O
g	8964113	834	835	O
)	8964113	836	837	O
,	8964113	838	839	O
and	8964113	840	843	O
their	8964113	844	849	O
combination	8964113	850	861	B-Intervention
.	8964113	862	863	O

8-epi-PGF2	8964113	864	874	B-Outcome
alpha	8964113	875	880	I-Outcome
excretion	8964113	881	890	I-Outcome
(	8964113	891	892	O
in	8964113	893	895	O
pmol/mmol	8964113	896	905	O
,	8964113	906	907	O
mean	8964113	908	912	O
+	8964113	913	914	O
/-	8964113	914	916	O
SEM	8964113	917	920	O
)	8964113	921	922	O
was	8964113	923	926	O
176.5+/-30.6	8964113	927	939	B-Observation
in	8964113	940	942	O
heavy	8964113	943	948	B-Intervention
smokers	8964113	949	956	I-Intervention
,	8964113	957	958	O
92.7+/-4.8	8964113	959	969	B-Observation
(	8964113	970	971	O
P	8964113	972	973	O
<	8964113	974	975	O
.05	8964113	976	979	O
)	8964113	980	981	O
in	8964113	982	984	O
moderate	8964113	985	993	B-Intervention
smokers	8964113	994	1001	I-Intervention
,	8964113	1002	1003	O
and	8964113	1004	1007	O
54.1+/-2.7	8964113	1008	1018	B-Observation
(	8964113	1019	1020	O
P	8964113	1021	1022	O
<	8964113	1023	1024	O
.005	8964113	1025	1029	O
)	8964113	1030	1031	O
in	8964113	1032	1034	O
nonsmokers	8964113	1035	1045	B-Intervention
.	8964113	1046	1047	O

Urinary	8964113	1048	1055	B-Outcome
levels	8964113	1056	1062	I-Outcome
fell	8964113	1063	1067	B-Observation
from	8964113	1068	1072	I-Observation
145.5+/-24.9	8964113	1073	1085	I-Observation
to	8964113	1086	1088	I-Observation
114.6+/-27.1	8964113	1089	1101	I-Observation
(	8964113	1102	1103	O
week	8964113	1104	1108	O
2	8964113	1109	1110	O
,	8964113	1111	1112	O
P	8964113	1113	1114	O
<	8964113	1115	1116	O
.05	8964113	1117	1120	O
)	8964113	1121	1122	O
and	8964113	1123	1126	O
112.6+/-24.9	8964113	1127	1139	B-Observation
(	8964113	1140	1141	O
week	8964113	1142	1146	O
3	8964113	1147	1148	O
,	8964113	1149	1150	O
P	8964113	1151	1152	O
<	8964113	1153	1154	O
.05	8964113	1155	1158	O
)	8964113	1159	1160	O
on	8964113	1161	1163	O
cessation	8964113	1164	1173	B-Intervention
of	8964113	1174	1176	I-Intervention
smoking	8964113	1177	1184	I-Intervention
.	8964113	1185	1186	O

Aspirin	8964113	1187	1194	B-Intervention
treatment	8964113	1195	1204	O
failed	8964113	1205	1211	O
to	8964113	1212	1214	O
suppress	8964113	1215	1223	B-Observation
urinary	8964113	1224	1231	B-Outcome
levels	8964113	1232	1238	I-Outcome
of	8964113	1239	1241	I-Outcome
8-epi-PGF2	8964113	1242	1252	I-Outcome
alpha	8964113	1253	1258	I-Outcome
despite	8964113	1259	1266	O
a	8964113	1267	1268	O
significant	8964113	1269	1280	B-Observation
reduction	8964113	1281	1290	I-Observation
in	8964113	1291	1293	O
urinary	8964113	1294	1301	B-Outcome
11-dehydro-TxB2	8964113	1302	1317	I-Outcome
production	8964113	1318	1328	I-Outcome
and	8964113	1329	1332	O
suppression	8964113	1333	1344	B-Observation
of	8964113	1345	1347	O
8-epi-PGF2	8964113	1348	1358	B-Outcome
alpha	8964113	1359	1364	I-Outcome
and	8964113	1365	1368	O
TxB2	8964113	1369	1373	B-Outcome
in	8964113	1374	1376	O
serum	8964113	1377	1382	O
.	8964113	1383	1384	O

Vitamin	8964113	1385	1392	B-Intervention
C	8964113	1393	1394	I-Intervention
(	8964113	1395	1396	O
pre	8964113	1397	1400	B-Observation
,	8964113	1401	1402	I-Observation
194.6+/-40.9	8964113	1403	1415	I-Observation
;	8964113	1416	1417	I-Observation
post	8964113	1418	1422	I-Observation
,	8964113	1423	1424	I-Observation
137.2+/-34.1	8964113	1425	1437	I-Observation
;	8964113	1438	1439	O
P	8964113	1440	1441	O
<	8964113	1442	1443	O
.05	8964113	1444	1447	O
)	8964113	1448	1449	O
and	8964113	1450	1453	O
a	8964113	1454	1455	O
combination	8964113	1456	1467	B-Intervention
of	8964113	1468	1470	I-Intervention
vitamin	8964113	1471	1478	I-Intervention
C	8964113	1479	1480	I-Intervention
and	8964113	1481	1484	I-Intervention
E	8964113	1485	1486	I-Intervention
(	8964113	1487	1488	O
pre	8964113	1489	1492	B-Observation
,	8964113	1493	1494	I-Observation
171.0+/-39.8	8964113	1495	1507	I-Observation
;	8964113	1508	1509	I-Observation
post	8964113	1510	1514	I-Observation
,	8964113	1515	1516	I-Observation
133.5+/-29.6	8964113	1517	1529	I-Observation
P	8964113	1530	1531	O
<	8964113	1532	1533	O
.05	8964113	1534	1537	O
)	8964113	1538	1539	O
suppressed	8964113	1540	1550	B-Observation
urinary	8964113	1551	1558	B-Outcome
8-epi-PGF2	8964113	1559	1569	I-Outcome
alpha	8964113	1570	1575	I-Outcome
,	8964113	1576	1577	O
whereas	8964113	1578	1585	O
vitamin	8964113	1586	1593	B-Intervention
E	8964113	1594	1595	I-Intervention
alone	8964113	1596	1601	I-Intervention
had	8964113	1602	1605	O
no	8964113	1606	1608	O
effect	8964113	1609	1615	B-Outcome
.	8964113	1616	1617	O

CONCLUSIONS	8964113	1618	1629	O
Urinary	8964113	1630	1637	B-Outcome
8-epi-PGF2	8964113	1638	1648	I-Outcome
alpha	8964113	1649	1654	I-Outcome
may	8964113	1655	1658	O
represent	8964113	1659	1668	O
a	8964113	1669	1670	O
noninvasive	8964113	1671	1682	O
,	8964113	1683	1684	O
quantitative	8964113	1685	1697	O
index	8964113	1698	1703	O
of	8964113	1704	1706	O
oxidant	8964113	1707	1714	O
stress	8964113	1715	1721	O
in	8964113	1722	1724	O
vivo	8964113	1725	1729	O
.	8964113	1730	1731	O

Elevated	8964113	1732	1740	B-Outcome
levels	8964113	1741	1747	I-Outcome
of	8964113	1748	1750	I-Outcome
8-epi-PGF2	8964113	1751	1761	I-Outcome
alpha	8964113	1762	1767	I-Outcome
in	8964113	1768	1770	O
smokers	8964113	1771	1778	B-Participant
may	8964113	1779	1782	O
be	8964113	1783	1785	O
modulated	8964113	1786	1795	B-Observation
by	8964113	1796	1798	O
quitting	8964113	1799	1807	B-Intervention
cigarettes	8964113	1808	1818	I-Intervention
and	8964113	1819	1822	O
switching	8964113	1823	1832	B-Intervention
to	8964113	1833	1835	I-Intervention
nicotine	8964113	1836	1844	I-Intervention
patches	8964113	1845	1852	I-Intervention
or	8964113	1853	1855	O
by	8964113	1856	1858	O
antioxidant	8964113	1859	1870	B-Intervention
vitamin	8964113	1871	1878	I-Intervention
therapy	8964113	1879	1886	I-Intervention
.	8964113	1887	1888	O

A	8964276	0	1	O
randomised	8964276	2	12	O
open	8964276	13	17	O
multicentre	8964276	18	29	O
comparative	8964276	30	41	O
trial	8964276	42	47	O
of	8964276	48	50	O
lamotrigine	8964276	51	62	B-Intervention
and	8964276	63	66	O
carbamazepine	8964276	67	80	B-Intervention
as	8964276	81	83	O
monotherapy	8964276	84	95	O
in	8964276	96	98	O
patients	8964276	99	107	O
with	8964276	108	112	O
newly	8964276	113	118	B-Participant
diagnosed	8964276	119	128	I-Participant
or	8964276	129	131	I-Participant
recurrent	8964276	132	141	I-Participant
epilepsy	8964276	142	150	I-Participant
.	8964276	151	152	O

The	8964276	153	156	O
efficacy	8964276	157	165	B-Outcome
and	8964276	166	169	O
safety	8964276	170	176	B-Outcome
of	8964276	177	179	O
lamotrigine	8964276	180	191	B-Intervention
and	8964276	192	195	O
carbamazepine	8964276	196	209	B-Intervention
as	8964276	210	212	O
monotherapy	8964276	213	224	O
in	8964276	225	227	O
patients	8964276	228	236	O
with	8964276	237	241	O
untreated	8964276	242	251	B-Participant
,	8964276	252	253	I-Participant
newly	8964276	254	259	I-Participant
diagnosed	8964276	260	269	I-Participant
or	8964276	270	272	I-Participant
recurrent	8964276	273	282	I-Participant
partial	8964276	283	290	I-Participant
and/or	8964276	291	297	I-Participant
generalised	8964276	298	309	I-Participant
tonic-clonic	8964276	310	322	I-Participant
seizures	8964276	323	331	I-Participant
,	8964276	332	333	O
were	8964276	334	338	O
compared	8964276	339	347	O
in	8964276	348	350	O
a	8964276	351	352	O
randomised	8964276	353	363	O
,	8964276	364	365	O
open	8964276	366	370	O
,	8964276	371	372	O
multicentre	8964276	373	384	O
study	8964276	385	390	O
.	8964276	391	392	O

Patients	8964276	393	401	O
received	8964276	402	410	O
24	8964276	411	413	O
weeks	8964276	414	419	O
'	8964276	420	421	O
treatment	8964276	422	431	O
with	8964276	432	436	O
oral	8964276	437	441	O
lamotrigine	8964276	442	453	B-Intervention
100	8964276	454	457	I-Intervention
mg	8964276	458	460	I-Intervention
(	8964276	461	462	O
LTG	8964276	463	466	B-Intervention
100	8964276	467	470	I-Intervention
,	8964276	471	472	O
n	8964276	473	474	O
=	8964276	475	476	O
115	8964276	477	480	O
)	8964276	481	482	O
or	8964276	483	485	O
200	8964276	486	489	B-Intervention
mg	8964276	490	492	I-Intervention
(	8964276	493	494	O
LTG	8964276	495	498	B-Intervention
200	8964276	499	502	I-Intervention
,	8964276	503	504	O
n	8964276	505	506	O
=	8964276	507	508	O
111	8964276	509	512	O
)	8964276	513	514	O
or	8964276	515	517	O
carbamazepine	8964276	518	531	B-Intervention
600	8964276	532	535	I-Intervention
mg	8964276	536	538	I-Intervention
(	8964276	539	540	O
CBZ	8964276	541	544	B-Intervention
600	8964276	545	548	I-Intervention
,	8964276	549	550	O
n	8964276	551	552	O
=	8964276	553	554	O
117	8964276	555	558	O
)	8964276	559	560	O
.	8964276	561	562	O

Efficacy	8964276	563	571	B-Outcome
measurements	8964276	572	584	I-Outcome
were	8964276	585	589	O
comparable	8964276	590	600	B-Observation
between	8964276	601	608	O
the	8964276	609	612	O
three	8964276	613	618	B-Intervention
treatment	8964276	619	628	I-Intervention
groups	8964276	629	635	I-Intervention
,	8964276	636	637	O
although	8964276	638	646	O
the	8964276	647	650	O
higher	8964276	651	657	B-Intervention
lamotrigine	8964276	658	669	I-Intervention
dose	8964276	670	674	I-Intervention
was	8964276	675	678	O
possibly	8964276	679	687	O
most	8964276	688	692	B-Observation
effective	8964276	693	702	I-Observation
,	8964276	703	704	O
with	8964276	705	709	O
60.4	8964276	710	714	B-Count
%	8964276	715	716	I-Count
completing	8964276	717	727	O
seizure	8964276	728	735	B-Outcome
free	8964276	736	740	I-Outcome
compared	8964276	741	749	O
with	8964276	750	754	O
51.3	8964276	755	759	B-Count
%	8964276	760	761	I-Count
(	8964276	762	763	O
LTG	8964276	764	767	B-Intervention
100	8964276	768	771	I-Intervention
)	8964276	772	773	O
and	8964276	774	777	O
54.7	8964276	778	782	B-Count
%	8964276	783	784	I-Count
(	8964276	785	786	O
CBZ	8964276	787	790	B-Intervention
600	8964276	791	794	I-Intervention
)	8964276	795	796	O
.	8964276	797	798	O

Both	8964276	799	803	B-Intervention
dosage	8964276	804	810	I-Intervention
regimens	8964276	811	819	I-Intervention
of	8964276	820	822	I-Intervention
lamotrigine	8964276	823	834	I-Intervention
were	8964276	835	839	O
well	8964276	840	844	B-Observation
tolerated	8964276	845	854	I-Observation
.	8964276	855	856	O

More	8964276	857	861	B-Count
patients	8964276	862	870	I-Count
on	8964276	871	873	O
CBZ	8964276	874	877	B-Intervention
600	8964276	878	881	I-Intervention
reported	8964276	882	890	O
adverse	8964276	891	898	B-Outcome
experiences	8964276	899	910	I-Outcome
,	8964276	911	912	O
66	8964276	913	915	B-Count
%	8964276	916	917	I-Count
versus	8964276	918	924	O
53	8964276	925	927	B-Count
%	8964276	928	929	I-Count
(	8964276	930	931	O
LTG	8964276	932	935	B-Intervention
100	8964276	936	939	I-Intervention
)	8964276	940	941	O
and	8964276	942	945	O
58	8964276	946	948	B-Count
%	8964276	949	950	I-Count
(	8964276	951	952	O
LTG	8964276	953	956	B-Intervention
200	8964276	957	960	I-Intervention
)	8964276	961	962	O
,	8964276	963	964	O
and	8964276	965	968	O
of	8964276	969	971	O
these	8964276	972	977	O
a	8964276	978	979	B-Count
greater	8964276	980	987	I-Count
proportion	8964276	988	998	I-Count
were	8964276	999	1003	O
attributed	8964276	1004	1014	O
to	8964276	1015	1017	O
CBZ	8964276	1018	1021	B-Intervention
600	8964276	1022	1025	I-Intervention
treatment	8964276	1026	1035	O
,	8964276	1036	1037	O
53	8964276	1038	1040	B-Count
%	8964276	1041	1042	I-Count
versus	8964276	1043	1049	O
23	8964276	1050	1052	B-Count
%	8964276	1053	1054	I-Count
(	8964276	1055	1056	O
LTG	8964276	1057	1060	B-Intervention
100	8964276	1061	1064	I-Intervention
)	8964276	1065	1066	O
and	8964276	1067	1070	O
28	8964276	1071	1073	B-Count
%	8964276	1074	1075	I-Count
(	8964276	1076	1077	O
LTG	8964276	1078	1081	B-Intervention
200	8964276	1082	1085	I-Intervention
)	8964276	1086	1087	O
.	8964276	1088	1089	O

Similarly	8964276	1090	1099	O
,	8964276	1100	1101	O
a	8964276	1102	1103	B-Count
greater	8964276	1104	1111	I-Count
proportion	8964276	1112	1122	I-Count
of	8964276	1123	1125	O
the	8964276	1126	1129	O
CBZ	8964276	1130	1133	B-Intervention
600	8964276	1134	1137	I-Intervention
group	8964276	1138	1143	O
required	8964276	1144	1152	O
a	8964276	1153	1154	O
change	8964276	1155	1161	B-Outcome
in	8964276	1162	1164	I-Outcome
dose	8964276	1165	1169	I-Outcome
,	8964276	1170	1171	O
47	8964276	1172	1174	B-Count
%	8964276	1175	1176	I-Count
versus	8964276	1177	1183	O
20	8964276	1184	1186	B-Count
%	8964276	1187	1188	I-Count
(	8964276	1189	1190	O
LTG	8964276	1191	1194	B-Intervention
100	8964276	1195	1198	I-Intervention
)	8964276	1199	1200	O
and	8964276	1201	1204	O
17	8964276	1205	1207	B-Count
%	8964276	1208	1209	I-Count
(	8964276	1210	1211	O
LTG	8964276	1212	1215	B-Intervention
200	8964276	1216	1219	I-Intervention
)	8964276	1220	1221	O
or	8964276	1222	1224	O
withdrew	8964276	1225	1233	B-Outcome
completely	8964276	1234	1244	I-Outcome
due	8964276	1245	1248	I-Outcome
to	8964276	1249	1251	I-Outcome
adverse	8964276	1252	1259	I-Outcome
experiences	8964276	1260	1271	I-Outcome
,	8964276	1272	1273	O
10.3	8964276	1274	1278	B-Count
%	8964276	1279	1280	I-Count
versus	8964276	1281	1287	O
4.3	8964276	1288	1291	B-Count
%	8964276	1292	1293	I-Count
(	8964276	1294	1295	O
LTG	8964276	1296	1299	B-Intervention
100	8964276	1300	1303	I-Intervention
)	8964276	1304	1305	O
and	8964276	1306	1309	O
4.5	8964276	1310	1313	B-Count
%	8964276	1314	1315	I-Count
(	8964276	1316	1317	O
LTG	8964276	1318	1321	B-Intervention
200	8964276	1322	1325	I-Intervention
)	8964276	1326	1327	O
.	8964276	1328	1329	O

The	8964276	1330	1333	O
most	8964276	1334	1338	B-Observation
common	8964276	1339	1345	I-Observation
adverse	8964276	1346	1353	O
experience	8964276	1354	1364	O
leading	8964276	1365	1372	O
to	8964276	1373	1375	O
withdrawal	8964276	1376	1386	O
was	8964276	1387	1390	O
rash	8964276	1391	1395	B-Outcome
,	8964276	1396	1397	O
with	8964276	1398	1402	O
approximately	8964276	1403	1416	O
double	8964276	1417	1423	B-Count
the	8964276	1424	1427	I-Count
proportion	8964276	1428	1438	I-Count
of	8964276	1439	1441	I-Count
reports	8964276	1442	1449	I-Count
occurring	8964276	1450	1459	O
in	8964276	1460	1462	O
patients	8964276	1463	1471	O
on	8964276	1472	1474	O
CBZ	8964276	1475	1478	B-Intervention
600	8964276	1479	1482	I-Intervention
(	8964276	1483	1484	O
5.1	8964276	1485	1488	B-Count
%	8964276	1489	1490	I-Count
)	8964276	1491	1492	O
compared	8964276	1493	1501	O
with	8964276	1502	1506	O
lamotrigine	8964276	1507	1518	B-Intervention
(	8964276	1519	1520	O
1.7	8964276	1521	1524	B-Count
%	8964276	1525	1526	I-Count
on	8964276	1527	1529	O
LTG	8964276	1530	1533	B-Intervention
100	8964276	1534	1537	I-Intervention
and	8964276	1538	1541	O
2.7	8964276	1542	1545	B-Count
%	8964276	1546	1547	I-Count
on	8964276	1548	1550	O
LTG	8964276	1551	1554	B-Intervention
200	8964276	1555	1558	I-Intervention
)	8964276	1559	1560	O
.	8964276	1561	1562	O

Overall	8964276	1563	1570	O
lamotrigine	8964276	1571	1582	B-Intervention
appeared	8964276	1583	1591	O
equally	8964276	1592	1599	B-Observation
effective	8964276	1600	1609	I-Observation
but	8964276	1610	1613	O
better	8964276	1614	1620	B-Observation
tolerated	8964276	1621	1630	I-Observation
compared	8964276	1631	1639	O
with	8964276	1640	1644	O
carbamazepine	8964276	1645	1658	B-Intervention
.	8964276	1659	1660	O

Effects	8964729	0	7	O
of	8964729	8	10	O
fenoterol	8964729	11	20	B-Intervention
on	8964729	21	23	O
inspiratory	8964729	24	35	B-Outcome
effort	8964729	36	42	I-Outcome
sensation	8964729	43	52	I-Outcome
and	8964729	53	56	O
fatigue	8964729	57	64	B-Outcome
during	8964729	65	71	O
inspiratory	8964729	72	83	B-Participant
threshold	8964729	84	93	I-Participant
loading	8964729	94	101	I-Participant
.	8964729	102	103	O

We	8964729	104	106	O
studied	8964729	107	114	O
the	8964729	115	118	O
effects	8964729	119	126	O
of	8964729	127	129	O
a	8964729	130	131	O
single	8964729	132	138	B-Intervention
dose	8964729	139	143	I-Intervention
of	8964729	144	146	I-Intervention
fenoterol	8964729	147	156	I-Intervention
on	8964729	157	159	O
the	8964729	160	163	O
relationship	8964729	164	176	B-Observation
between	8964729	177	184	B-Outcome
inspiratory	8964729	185	196	I-Outcome
effort	8964729	197	203	I-Outcome
sensation	8964729	204	213	I-Outcome
(	8964729	214	215	I-Outcome
IES	8964729	216	219	I-Outcome
)	8964729	220	221	I-Outcome
and	8964729	222	225	I-Outcome
inspiratory	8964729	226	237	I-Outcome
muscle	8964729	238	244	I-Outcome
fatigue	8964729	245	252	I-Outcome
induced	8964729	253	260	O
by	8964729	261	263	O
inspiratory	8964729	264	275	B-Participant
threshold	8964729	276	285	I-Participant
loading	8964729	286	293	I-Participant
in	8964729	294	296	O
healthy	8964729	297	304	B-Participant
subjects	8964729	305	313	O
.	8964729	314	315	O

The	8964729	316	319	O
magnitude	8964729	320	329	O
of	8964729	330	332	O
the	8964729	333	336	O
threshold	8964729	337	346	O
was	8964729	347	350	O
60	8964729	351	353	O
%	8964729	354	355	O
of	8964729	356	358	O
maximal	8964729	359	366	B-Outcome
static	8964729	367	373	I-Outcome
inspiratory	8964729	374	385	I-Outcome
mouth	8964729	386	391	I-Outcome
pressure	8964729	392	400	I-Outcome
(	8964729	401	402	O
PI	8964729	403	405	O
,	8964729	406	407	O
mmax	8964729	408	412	O
)	8964729	413	414	O
at	8964729	415	417	O
functional	8964729	418	428	O
residual	8964729	429	437	O
capacity	8964729	438	446	O
,	8964729	447	448	O
and	8964729	449	452	O
the	8964729	453	456	O
duty	8964729	457	461	O
cycle	8964729	462	467	O
was	8964729	468	471	O
0.5	8964729	472	475	O
.	8964729	476	477	O

Subjects	8964729	478	486	O
continued	8964729	487	496	O
the	8964729	497	500	O
threshold	8964729	501	510	O
loaded	8964729	511	517	O
breathing	8964729	518	527	O
until	8964729	528	533	O
the	8964729	534	537	O
target	8964729	538	544	O
mouth	8964729	545	550	O
pressure	8964729	551	559	O
could	8964729	560	565	O
no	8964729	566	568	O
longer	8964729	569	575	O
be	8964729	576	578	O
maintained	8964729	579	589	O
(	8964729	590	591	O
endurance	8964729	592	601	B-Outcome
time	8964729	602	606	I-Outcome
)	8964729	607	608	O
.	8964729	609	610	O

The	8964729	611	614	O
intensity	8964729	615	624	B-Outcome
of	8964729	625	627	I-Outcome
the	8964729	628	631	I-Outcome
IES	8964729	632	635	I-Outcome
was	8964729	636	639	O
scored	8964729	640	646	O
with	8964729	647	651	O
a	8964729	652	653	O
modified	8964729	654	662	O
Borg	8964729	663	667	O
scale	8964729	668	673	O
.	8964729	674	675	O

Either	8964729	676	682	O
fenoterol	8964729	683	692	B-Intervention
(	8964729	693	694	O
5	8964729	695	696	O
mg	8964729	697	699	O
)	8964729	700	701	O
or	8964729	702	704	O
a	8964729	705	706	O
placebo	8964729	707	714	B-Intervention
was	8964729	715	718	O
given	8964729	719	724	O
orally	8964729	725	731	O
2	8964729	732	733	O
h	8964729	734	735	O
before	8964729	736	742	O
loading	8964729	743	750	B-Participant
in	8964729	751	753	O
a	8964729	754	755	O
randomized	8964729	756	766	O
double-blind	8964729	767	779	O
crossover	8964729	780	789	O
protocol	8964729	790	798	O
.	8964729	799	800	O

The	8964729	801	804	O
endurance	8964729	805	814	B-Outcome
time	8964729	815	819	I-Outcome
with	8964729	820	824	O
fenoterol	8964729	825	834	B-Intervention
(	8964729	835	836	O
34.4	8964729	837	841	B-Observation
+	8964729	842	843	I-Observation
/-	8964729	843	845	I-Observation
8.6	8964729	846	849	I-Observation
min	8964729	850	853	I-Observation
)	8964729	854	855	O
was	8964729	856	859	O
longer	8964729	860	866	B-Observation
than	8964729	867	871	O
that	8964729	872	876	O
with	8964729	877	881	O
the	8964729	882	885	O
placebo	8964729	886	893	B-Intervention
(	8964729	894	895	O
22.2	8964729	896	900	B-Observation
+	8964729	901	902	I-Observation
/-	8964729	902	904	I-Observation
7.1	8964729	905	908	I-Observation
min	8964729	909	912	I-Observation
;	8964729	913	914	O
P	8964729	915	916	O
<	8964729	917	918	O
0.05	8964729	919	923	O
)	8964729	924	925	O
.	8964729	926	927	O

The	8964729	928	931	O
ratio	8964729	932	937	B-Outcome
of	8964729	938	940	I-Outcome
high-	8964729	941	946	I-Outcome
to	8964729	947	949	I-Outcome
low-frequency	8964729	950	963	I-Outcome
power	8964729	964	969	I-Outcome
of	8964729	970	972	I-Outcome
the	8964729	973	976	I-Outcome
diaphragmatic	8964729	977	990	I-Outcome
electromyogram	8964729	991	1005	I-Outcome
(	8964729	1006	1007	I-Outcome
EMGdi	8964729	1008	1013	I-Outcome
)	8964729	1014	1015	I-Outcome
decreased	8964729	1016	1025	B-Observation
during	8964729	1026	1032	O
loading	8964729	1033	1040	B-Participant
;	8964729	1041	1042	O
the	8964729	1043	1046	O
decrease	8964729	1047	1055	B-Observation
was	8964729	1056	1059	I-Observation
less	8964729	1060	1064	I-Observation
with	8964729	1065	1069	O
fenoterol	8964729	1070	1079	B-Intervention
(	8964729	1080	1081	O
P	8964729	1082	1083	O
<	8964729	1084	1085	O
0.05	8964729	1086	1090	O
)	8964729	1091	1092	O
.	8964729	1093	1094	O

The	8964729	1095	1098	O
EMGdi	8964729	1099	1104	B-Outcome
also	8964729	1105	1109	O
decreased	8964729	1110	1119	B-Observation
with	8964729	1120	1124	O
loading	8964729	1125	1132	B-Participant
;	8964729	1133	1134	O
the	8964729	1135	1138	O
decrease	8964729	1139	1147	B-Observation
was	8964729	1148	1151	I-Observation
greater	8964729	1152	1159	I-Observation
on	8964729	1160	1162	O
fenoterol	8964729	1163	1172	B-Intervention
treatment	8964729	1173	1182	O
(	8964729	1183	1184	O
P	8964729	1185	1186	O
<	8964729	1187	1188	O
0.01	8964729	1189	1193	O
)	8964729	1194	1195	O
.	8964729	1196	1197	O

The	8964729	1198	1201	O
PI	8964729	1202	1204	B-Outcome
,	8964729	1205	1206	I-Outcome
mmax	8964729	1207	1211	I-Outcome
and	8964729	1212	1215	O
maximal	8964729	1216	1223	B-Outcome
transdiaphragmatic	8964729	1224	1242	I-Outcome
pressure	8964729	1243	1251	I-Outcome
(	8964729	1252	1253	I-Outcome
Pdi	8964729	1254	1257	I-Outcome
)	8964729	1258	1259	I-Outcome
were	8964729	1260	1264	O
similarly	8964729	1265	1274	B-Observation
decreased	8964729	1275	1284	I-Observation
after	8964729	1285	1290	O
loading	8964729	1291	1298	B-Participant
on	8964729	1299	1301	O
either	8964729	1302	1308	B-Intervention
treatment	8964729	1309	1318	I-Intervention
.	8964729	1319	1320	O

The	8964729	1321	1324	O
intensity	8964729	1325	1334	B-Outcome
of	8964729	1335	1337	I-Outcome
the	8964729	1338	1341	I-Outcome
IES	8964729	1342	1345	I-Outcome
rose	8964729	1346	1350	B-Observation
with	8964729	1351	1355	O
time	8964729	1356	1360	O
during	8964729	1361	1367	O
loading	8964729	1368	1375	B-Participant
in	8964729	1376	1378	O
both	8964729	1379	1383	B-Intervention
groups	8964729	1384	1390	I-Intervention
but	8964729	1391	1394	O
was	8964729	1395	1398	O
lower	8964729	1399	1404	B-Observation
with	8964729	1405	1409	O
fenoterol	8964729	1410	1419	B-Intervention
than	8964729	1420	1424	O
with	8964729	1425	1429	O
the	8964729	1430	1433	O
placebo	8964729	1434	1441	B-Intervention
(	8964729	1442	1443	O
P	8964729	1444	1445	O
<	8964729	1446	1447	O
0.05	8964729	1448	1452	O
)	8964729	1453	1454	O
.	8964729	1455	1456	O

The	8964729	1457	1460	O
ratio	8964729	1461	1466	B-Outcome
of	8964729	1467	1469	I-Outcome
Pdi	8964729	1470	1473	I-Outcome
to	8964729	1474	1476	I-Outcome
integrated	8964729	1477	1487	I-Outcome
activity	8964729	1488	1496	I-Outcome
of	8964729	1497	1499	I-Outcome
the	8964729	1500	1503	I-Outcome
EMGdi	8964729	1504	1509	I-Outcome
increased	8964729	1510	1519	B-Observation
with	8964729	1520	1524	O
fenoterol	8964729	1525	1534	B-Intervention
(	8964729	1535	1536	O
P	8964729	1537	1538	O
<	8964729	1539	1540	O
0.05	8964729	1541	1545	O
)	8964729	1546	1547	O
.	8964729	1548	1549	O

Fenoterol	8964729	1550	1559	B-Intervention
treatment	8964729	1560	1569	O
increased	8964729	1570	1579	B-Observation
both	8964729	1580	1584	O
superimposed	8964729	1585	1597	B-Outcome
Pdi	8964729	1598	1601	I-Outcome
twitch	8964729	1602	1608	I-Outcome
and	8964729	1609	1612	O
Pdi	8964729	1613	1616	B-Outcome
twitch	8964729	1617	1623	I-Outcome
of	8964729	1624	1626	I-Outcome
relaxed	8964729	1627	1634	I-Outcome
diaphragm	8964729	1635	1644	I-Outcome
and	8964729	1645	1648	O
decreased	8964729	1649	1658	B-Observation
the	8964729	1659	1662	O
value	8964729	1663	1668	B-Outcome
of	8964729	1669	1671	I-Outcome
(	8964729	1672	1673	I-Outcome
1-superimposed	8964729	1674	1688	I-Outcome
Pdi	8964729	1689	1692	I-Outcome
twitch/Pdi	8964729	1693	1703	I-Outcome
twitch	8964729	1704	1710	I-Outcome
of	8964729	1711	1713	I-Outcome
relaxed	8964729	1714	1721	I-Outcome
diaphragm	8964729	1722	1731	I-Outcome
)	8964729	1732	1733	I-Outcome
.	8964729	1734	1735	O

Thus	8964729	1736	1740	O
we	8964729	1741	1743	O
conclude	8964729	1744	1752	O
that	8964729	1753	1757	O
in	8964729	1758	1760	O
normal	8964729	1761	1767	B-Participant
subjects	8964729	1768	1776	O
fenoterol	8964729	1777	1786	B-Intervention
reduces	8964729	1787	1794	B-Observation
diaphragmatic	8964729	1795	1808	B-Outcome
fatigue	8964729	1809	1816	I-Outcome
and	8964729	1817	1820	O
decreases	8964729	1821	1830	B-Observation
the	8964729	1831	1834	O
motor	8964729	1835	1840	B-Outcome
command	8964729	1841	1848	I-Outcome
to	8964729	1849	1851	I-Outcome
the	8964729	1852	1855	I-Outcome
diaphragm	8964729	1856	1865	I-Outcome
,	8964729	1866	1867	O
resulting	8964729	1868	1877	O
in	8964729	1878	1880	O
a	8964729	1881	1882	O
decrease	8964729	1883	1891	B-Observation
in	8964729	1892	1894	O
IES	8964729	1895	1898	B-Outcome
during	8964729	1899	1905	O
inspiratory	8964729	1906	1917	B-Participant
threshold	8964729	1918	1927	I-Participant
loading	8964729	1928	1935	I-Participant
and	8964729	1936	1939	O
a	8964729	1940	1941	O
prolongation	8964729	1942	1954	B-Observation
of	8964729	1955	1957	O
endurance	8964729	1958	1967	B-Outcome
.	8964729	1968	1969	O

[	8966003	0	1	O
Drug	8966003	2	6	B-Intervention
therapy	8966003	7	14	I-Intervention
of	8966003	15	17	O
condylomata	8966003	18	29	B-Participant
acuminata	8966003	30	39	I-Participant
]	8966003	40	41	O
.	8966003	42	43	O

This	8966003	44	48	O
study	8966003	49	54	O
seeks	8966003	55	60	O
to	8966003	61	63	O
evaluate	8966003	64	72	O
two	8966003	73	76	O
candidate	8966003	77	86	O
regimens	8966003	87	95	O
(	8966003	96	97	O
5-fluorouracil	8966003	98	112	B-Intervention
and	8966003	113	116	O
interferon	8966003	117	127	B-Intervention
)	8966003	128	129	O
as	8966003	130	132	O
adjuvants	8966003	133	142	O
to	8966003	143	145	O
optimally	8966003	146	155	O
performed	8966003	156	165	O
laser	8966003	166	171	B-Participant
surgery	8966003	172	179	I-Participant
in	8966003	180	182	O
the	8966003	183	186	O
treatment	8966003	187	196	O
of	8966003	197	199	O
condylomata	8966003	200	211	B-Participant
acuminata	8966003	212	221	I-Participant
.	8966003	222	223	O

Skillful	8966003	224	232	O
laser	8966003	233	238	O
ablation	8966003	239	247	O
can	8966003	248	251	O
remove	8966003	252	258	O
any	8966003	259	262	O
volume	8966003	263	269	O
of	8966003	270	272	O
human	8966003	273	278	O
papillomavirus-associated	8966003	279	304	O
vulvar	8966003	305	311	O
disease	8966003	312	319	O
but	8966003	320	323	O
can	8966003	324	327	O
not	8966003	328	331	O
prevent	8966003	332	339	O
reactivation	8966003	340	352	O
of	8966003	353	355	O
the	8966003	356	359	O
surrounding	8966003	360	371	O
latent	8966003	372	378	O
viral	8966003	379	384	O
reservoir	8966003	385	394	O
during	8966003	395	401	O
postoperative	8966003	402	415	O
healing	8966003	416	423	O
.	8966003	424	425	O

Conversely	8966003	426	436	O
,	8966003	437	438	O
interferon	8966003	439	449	O
and	8966003	450	453	O
5-fluorouracil	8966003	454	468	O
are	8966003	469	472	O
relatively	8966003	473	483	O
ineffective	8966003	484	495	O
as	8966003	496	498	O
primary	8966003	499	506	O
therapies	8966003	507	516	O
.	8966003	517	518	O

This	8966003	519	523	O
study	8966003	524	529	O
involves	8966003	530	538	O
118	8966003	539	542	O
evaluable	8966003	543	552	O
patients	8966003	553	561	O
:	8966003	562	563	O
32	8966003	564	566	O
in	8966003	567	569	O
the	8966003	570	573	O
laser-CO2	8966003	574	583	B-Intervention
group	8966003	584	589	O
,	8966003	590	591	O
34	8966003	592	594	O
in	8966003	595	597	O
the	8966003	598	601	O
5-fluorouracil	8966003	602	616	B-Intervention
group	8966003	617	622	O
and	8966003	623	626	O
52	8966003	627	629	O
in	8966003	630	632	O
the	8966003	633	636	O
interferon	8966003	637	647	B-Intervention
group	8966003	648	653	O
.	8966003	654	655	O

At	8966003	656	658	O
assessment	8966003	659	669	O
of	8966003	670	672	O
final	8966003	673	678	O
outcome	8966003	679	686	O
,	8966003	687	688	O
it	8966003	689	691	O
was	8966003	692	695	O
found	8966003	696	701	O
that	8966003	702	706	O
43	8966003	707	709	B-Count
of	8966003	710	712	I-Count
52	8966003	713	715	I-Count
(	8966003	716	717	I-Count
82	8966003	718	720	I-Count
%	8966003	721	722	I-Count
)	8966003	723	724	I-Count
assessable	8966003	725	735	I-Count
patients	8966003	736	744	I-Count
in	8966003	745	747	O
the	8966003	748	751	O
adjuvant	8966003	752	760	O
interferon	8966003	761	771	B-Intervention
arm	8966003	772	775	O
were	8966003	776	780	O
controlled	8966003	781	791	B-Outcome
by	8966003	792	794	I-Outcome
a	8966003	795	796	I-Outcome
single	8966003	797	803	I-Outcome
laser	8966003	804	809	I-Outcome
ablation	8966003	810	818	I-Outcome
as	8966003	819	821	O
compared	8966003	822	830	O
with	8966003	831	835	O
only	8966003	836	840	O
17	8966003	841	843	B-Count
of	8966003	844	846	I-Count
34	8966003	847	849	I-Count
(	8966003	850	851	I-Count
50	8966003	852	854	I-Count
%	8966003	855	856	I-Count
)	8966003	857	858	I-Count
in	8966003	859	861	O
the	8966003	862	865	O
5-fluorouracil	8966003	866	880	B-Intervention
group	8966003	881	886	O
and	8966003	887	890	O
13	8966003	891	893	B-Count
of	8966003	894	896	I-Count
32	8966003	897	899	I-Count
(	8966003	900	901	I-Count
40	8966003	902	904	I-Count
%	8966003	905	906	I-Count
)	8966003	907	908	I-Count
in	8966003	909	911	O
the	8966003	912	915	O
laser	8966003	916	921	B-Intervention
alone	8966003	922	927	I-Intervention
group	8966003	928	933	O
.	8966003	934	935	O

There	8966003	936	941	O
was	8966003	942	945	O
no	8966003	946	948	O
statistical	8966003	949	960	B-Observation
difference	8966003	961	971	I-Observation
in	8966003	972	974	O
outcome	8966003	975	982	B-Outcome
within	8966003	983	989	O
the	8966003	990	993	O
5-fluorouracil	8966003	994	1008	B-Intervention
and	8966003	1009	1012	O
laser	8966003	1013	1018	B-Intervention
only	8966003	1019	1023	I-Intervention
arms	8966003	1024	1028	O
.	8966003	1029	1030	O

Conversely	8966003	1031	1041	O
,	8966003	1042	1043	O
a	8966003	1044	1045	O
relatively	8966003	1046	1056	B-Intervention
low	8966003	1057	1060	I-Intervention
dose	8966003	1061	1065	I-Intervention
of	8966003	1066	1068	I-Intervention
recombinant	8966003	1069	1080	I-Intervention
interferon	8966003	1081	1091	I-Intervention
,	8966003	1092	1093	O
used	8966003	1094	1098	O
in	8966003	1099	1101	O
combination	8966003	1102	1113	O
with	8966003	1114	1118	O
effective	8966003	1119	1128	O
surgical	8966003	1129	1137	O
deleulking	8966003	1138	1148	O
,	8966003	1149	1150	O
can	8966003	1151	1154	O
markedly	8966003	1155	1163	O
reduce	8966003	1164	1170	B-Observation
the	8966003	1171	1174	O
risk	8966003	1175	1179	B-Outcome
of	8966003	1180	1182	I-Outcome
postoperative	8966003	1183	1196	I-Outcome
recurrence	8966003	1197	1207	I-Outcome
.	8966003	1208	1209	O

Trunk	8976475	0	5	B-Intervention
exercise	8976475	6	14	I-Intervention
combined	8976475	15	23	I-Intervention
with	8976475	24	28	I-Intervention
spinal	8976475	29	35	I-Intervention
manipulative	8976475	36	48	I-Intervention
or	8976475	49	51	I-Intervention
NSAID	8976475	52	57	I-Intervention
therapy	8976475	58	65	I-Intervention
for	8976475	66	69	O
chronic	8976475	70	77	B-Participant
low	8976475	78	81	I-Participant
back	8976475	82	86	I-Participant
pain	8976475	87	91	I-Participant
:	8976475	92	93	O
a	8976475	94	95	O
randomized	8976475	96	106	O
,	8976475	107	108	O
observer-blinded	8976475	109	125	O
clinical	8976475	126	134	O
trial	8976475	135	140	O
.	8976475	141	142	O

OBJECTIVES	8976475	143	153	O
To	8976475	154	156	O
study	8976475	157	162	O
the	8976475	163	166	O
relative	8976475	167	175	B-Outcome
efficacy	8976475	176	184	I-Outcome
of	8976475	185	187	O
three	8976475	188	193	O
different	8976475	194	203	O
treatment	8976475	204	213	B-Intervention
for	8976475	214	217	O
chronic	8976475	218	225	B-Participant
low	8976475	226	229	I-Participant
back	8976475	230	234	I-Participant
pain	8976475	235	239	I-Participant
(	8976475	240	241	I-Participant
CLBP	8976475	242	246	I-Participant
)	8976475	247	248	I-Participant
.	8976475	249	250	O

Two	8976475	251	254	O
preplanned	8976475	255	265	O
comparisons	8976475	266	277	O
were	8976475	278	282	O
made	8976475	283	287	O
:	8976475	288	289	O
(	8976475	290	291	O
a	8976475	292	293	O
)	8976475	294	295	O
Spinal	8976475	296	302	B-Intervention
manipulative	8976475	303	315	I-Intervention
therapy	8976475	316	323	I-Intervention
(	8976475	324	325	I-Intervention
SMT	8976475	326	329	I-Intervention
)	8976475	330	331	I-Intervention
combined	8976475	332	340	I-Intervention
with	8976475	341	345	I-Intervention
trunk	8976475	346	351	I-Intervention
strengthening	8976475	352	365	I-Intervention
exercises	8976475	366	375	I-Intervention
(	8976475	376	377	I-Intervention
TSE	8976475	378	381	I-Intervention
)	8976475	382	383	I-Intervention
vs.	8976475	384	387	O
SMT	8976475	388	391	B-Intervention
combined	8976475	392	400	I-Intervention
with	8976475	401	405	I-Intervention
trunk	8976475	406	411	I-Intervention
stretching	8976475	412	422	I-Intervention
exercises	8976475	423	432	I-Intervention
,	8976475	433	434	O
and	8976475	435	438	O
(	8976475	439	440	O
b	8976475	441	442	O
)	8976475	443	444	O
SMT	8976475	445	448	B-Intervention
combined	8976475	449	457	I-Intervention
with	8976475	458	462	I-Intervention
TSE	8976475	463	466	I-Intervention
vs.	8976475	467	470	O
nonsteroidal	8976475	471	483	B-Intervention
anti-inflammatory	8976475	484	501	I-Intervention
drug	8976475	502	506	I-Intervention
(	8976475	507	508	I-Intervention
NSAID	8976475	509	514	I-Intervention
)	8976475	515	516	I-Intervention
therapy	8976475	517	524	I-Intervention
combined	8976475	525	533	I-Intervention
with	8976475	534	538	I-Intervention
TSE	8976475	539	542	I-Intervention
.	8976475	543	544	O

STUDY	8976475	545	550	O
DESIGN	8976475	551	557	O
Interdisciplinary	8976475	558	575	O
,	8976475	576	577	O
prospective	8976475	578	589	O
,	8976475	590	591	O
observer-blinded	8976475	592	608	O
,	8976475	609	610	O
randomized	8976475	611	621	O
clinical	8976475	622	630	O
trial	8976475	631	636	O
with	8976475	637	641	O
a	8976475	642	643	O
1-yr	8976475	644	648	O
follow-up	8976475	649	658	O
period	8976475	659	665	O
.	8976475	666	667	O

The	8976475	668	671	O
trial	8976475	672	677	O
evaluated	8976475	678	687	O
therapies	8976475	688	697	O
in	8976475	698	700	O
combination	8976475	701	712	O
only	8976475	713	717	O
and	8976475	718	721	O
was	8976475	722	725	O
not	8976475	726	729	O
designed	8976475	730	738	O
to	8976475	739	741	O
test	8976475	742	746	O
the	8976475	747	750	O
individual	8976475	751	761	O
treatment	8976475	762	771	O
components	8976475	772	782	O
.	8976475	783	784	O

SETTING	8976475	785	792	O
Primary	8976475	793	800	O
contact	8976475	801	808	O
,	8976475	809	810	O
college	8976475	811	818	O
out-patient	8976475	819	830	O
clinic	8976475	831	837	O
.	8976475	838	839	O

PATIENTS	8976475	840	848	O
In	8976475	849	851	O
total	8976475	852	857	O
,	8976475	858	859	O
174	8976475	860	863	O
patients	8976475	864	872	O
aged	8976475	873	877	O
20	8976475	878	880	O
-	8976475	880	881	O
60	8976475	881	883	O
yr	8976475	884	886	O
were	8976475	887	891	O
admitted	8976475	892	900	O
to	8976475	901	903	O
the	8976475	904	907	O
study	8976475	908	913	O
.	8976475	914	915	O

MAIN	8976475	916	920	O
OUTCOME	8976475	921	928	O
MEASURES	8976475	929	937	O
Patient-rated	8976475	938	951	B-Outcome
low	8976475	952	955	I-Outcome
back	8976475	956	960	I-Outcome
pain	8976475	961	965	I-Outcome
,	8976475	966	967	O
disability	8976475	968	978	B-Outcome
,	8976475	979	980	O
and	8976475	981	984	O
functional	8976475	985	995	B-Outcome
health	8976475	996	1002	I-Outcome
status	8976475	1003	1009	I-Outcome
at	8976475	1010	1012	O
5	8976475	1013	1014	O
and	8976475	1015	1018	O
11	8976475	1019	1021	O
wk	8976475	1022	1024	O
.	8976475	1025	1026	O

INTERVENTIONS	8976475	1027	1040	O
Five	8976475	1041	1045	O
weeks	8976475	1046	1051	O
of	8976475	1052	1054	O
SMT	8976475	1055	1058	B-Intervention
or	8976475	1059	1061	I-Intervention
NSAID	8976475	1062	1067	I-Intervention
therapy	8976475	1068	1075	I-Intervention
in	8976475	1076	1078	I-Intervention
combination	8976475	1079	1090	I-Intervention
with	8976475	1091	1095	I-Intervention
supervised	8976475	1096	1106	I-Intervention
trunk	8976475	1107	1112	I-Intervention
exercise	8976475	1113	1121	I-Intervention
,	8976475	1122	1123	O
followed	8976475	1124	1132	O
by	8976475	1133	1135	O
and	8976475	1136	1139	O
additional	8976475	1140	1150	O
6	8976475	1151	1152	O
wk	8976475	1153	1155	O
of	8976475	1156	1158	O
supervised	8976475	1159	1169	O
exercise	8976475	1170	1178	O
alone	8976475	1179	1184	O
.	8976475	1185	1186	O

RESULTS	8976475	1187	1194	O
Individual	8976475	1195	1205	O
group	8976475	1206	1211	O
comparisons	8976475	1212	1223	O
after	8976475	1224	1229	O
5	8976475	1230	1231	O
and	8976475	1232	1235	O
11	8976475	1236	1238	O
wk	8976475	1239	1241	O
of	8976475	1242	1244	O
intervention	8976475	1245	1257	B-Intervention
on	8976475	1258	1260	O
all	8976475	1261	1264	O
three	8976475	1265	1270	O
main	8976475	1271	1275	B-Outcome
outcome	8976475	1276	1283	I-Outcome
measures	8976475	1284	1292	I-Outcome
did	8976475	1293	1296	O
not	8976475	1297	1300	O
reveal	8976475	1301	1307	O
any	8976475	1308	1311	O
clear	8976475	1312	1317	B-Observation
clinically	8976475	1318	1328	I-Observation
important	8976475	1329	1338	I-Observation
or	8976475	1339	1341	I-Observation
statistically	8976475	1342	1355	I-Observation
significant	8976475	1356	1367	I-Observation
differences	8976475	1368	1379	I-Observation
.	8976475	1380	1381	O

There	8976475	1382	1387	O
seemed	8976475	1388	1394	O
to	8976475	1395	1397	O
be	8976475	1398	1400	O
a	8976475	1401	1402	O
sustained	8976475	1403	1412	B-Observation
reduction	8976475	1413	1422	I-Observation
in	8976475	1423	1425	O
medication	8976475	1426	1436	B-Outcome
use	8976475	1437	1440	I-Outcome
at	8976475	1441	1443	O
the	8976475	1444	1447	O
1-yr	8976475	1448	1452	O
follow-up	8976475	1453	1462	O
.	8976475	1463	1464	O

in	8976475	1465	1467	O
the	8976475	1468	1471	O
SMT/TSE	8976475	1472	1479	B-Intervention
group	8976475	1480	1485	O
.	8976475	1486	1487	O

Continuance	8976475	1488	1499	B-Intervention
of	8976475	1500	1502	I-Intervention
exercise	8976475	1503	1511	I-Intervention
during	8976475	1512	1518	I-Intervention
the	8976475	1519	1522	I-Intervention
follow-up	8976475	1523	1532	I-Intervention
year	8976475	1533	1537	I-Intervention
,	8976475	1538	1539	I-Intervention
regardless	8976475	1540	1550	I-Intervention
of	8976475	1551	1553	I-Intervention
type	8976475	1554	1558	I-Intervention
,	8976475	1559	1560	O
was	8976475	1561	1564	O
associated	8976475	1565	1575	O
with	8976475	1576	1580	O
a	8976475	1581	1582	O
better	8976475	1583	1589	B-Observation
outcome	8976475	1590	1597	B-Outcome
.	8976475	1598	1599	O

CONCLUSION	8976475	1600	1610	O
Each	8976475	1611	1615	O
of	8976475	1616	1618	O
the	8976475	1619	1622	O
three	8976475	1623	1628	B-Intervention
therapeutic	8976475	1629	1640	I-Intervention
regimens	8976475	1641	1649	I-Intervention
was	8976475	1650	1653	O
associated	8976475	1654	1664	O
with	8976475	1665	1669	O
similar	8976475	1670	1677	B-Observation
and	8976475	1678	1681	I-Observation
clinically	8976475	1682	1692	I-Observation
important	8976475	1693	1702	I-Observation
improvement	8976475	1703	1714	I-Observation
over	8976475	1715	1719	O
time	8976475	1720	1724	O
that	8976475	1725	1729	O
was	8976475	1730	1733	O
considered	8976475	1734	1744	O
superior	8976475	1745	1753	B-Observation
to	8976475	1754	1756	O
the	8976475	1757	1760	O
expected	8976475	1761	1769	O
natural	8976475	1770	1777	O
history	8976475	1778	1785	O
of	8976475	1786	1788	O
long-standing	8976475	1789	1802	B-Participant
CLBP	8976475	1803	1807	I-Participant
.	8976475	1808	1809	O

For	8976475	1810	1813	O
the	8976475	1814	1817	O
management	8976475	1818	1828	O
of	8976475	1829	1831	O
CLBP	8976475	1832	1836	B-Participant
,	8976475	1837	1838	O
trunk	8976475	1839	1844	B-Intervention
exercise	8976475	1845	1853	I-Intervention
in	8976475	1854	1856	I-Intervention
combination	8976475	1857	1868	I-Intervention
with	8976475	1869	1873	I-Intervention
SMT	8976475	1874	1877	I-Intervention
or	8976475	1878	1880	I-Intervention
NSAID	8976475	1881	1886	I-Intervention
therapy	8976475	1887	1894	I-Intervention
seemed	8976475	1895	1901	O
to	8976475	1902	1904	O
be	8976475	1905	1907	O
beneficial	8976475	1908	1918	B-Observation
and	8976475	1919	1922	O
worthwhile	8976475	1923	1933	B-Observation
.	8976475	1934	1935	O

The	8976475	1936	1939	O
magnitude	8976475	1940	1949	O
of	8976475	1950	1952	O
nonspecific	8976475	1953	1964	O
therapeutic	8976475	1965	1976	O
(	8976475	1977	1978	O
placebo	8976475	1979	1986	O
)	8976475	1987	1988	O
effects	8976475	1989	1996	O
,	8976475	1997	1998	O
cost-effectiveness	8976475	1999	2017	O
and	8976475	2018	2021	O
relative	8976475	2022	2030	O
risks	8976475	2031	2036	O
of	8976475	2037	2039	O
side	8976475	2040	2044	O
effects	8976475	2045	2052	O
associated	8976475	2053	2063	O
with	8976475	2064	2068	O
these	8976475	2069	2074	O
types	8976475	2075	2080	O
of	8976475	2081	2083	O
therapy	8976475	2084	2091	O
need	8976475	2092	2096	O
to	8976475	2097	2099	O
be	8976475	2100	2102	O
addressed	8976475	2103	2112	O
in	8976475	2113	2115	O
future	8976475	2116	2122	O
studies	8976475	2123	2130	O
.	8976475	2131	2132	O

Single-dose	8980774	0	11	B-Outcome
pharmacokinetics	8980774	12	28	I-Outcome
of	8980774	29	31	O
delavirdine	8980774	32	43	B-Intervention
mesylate	8980774	44	52	I-Intervention
and	8980774	53	56	O
didanosine	8980774	57	67	B-Intervention
in	8980774	68	70	O
patients	8980774	71	79	O
with	8980774	80	84	O
human	8980774	85	90	B-Participant
immunodeficiency	8980774	91	107	I-Participant
virus	8980774	108	113	I-Participant
infection	8980774	114	123	I-Participant
.	8980774	124	125	O

Delavirdine	8980774	126	137	O
is	8980774	138	140	O
a	8980774	141	142	O
nonnucleoside	8980774	143	156	O
reverse	8980774	157	164	O
transcriptase	8980774	165	178	O
inhibitor	8980774	179	188	O
with	8980774	189	193	O
in	8980774	194	196	O
vitro	8980774	197	202	O
activity	8980774	203	211	O
against	8980774	212	219	O
human	8980774	220	225	O
immunodeficiency	8980774	226	242	O
virus	8980774	243	248	O
type	8980774	249	253	O
1	8980774	254	255	O
(	8980774	256	257	O
HIV-1	8980774	258	263	O
)	8980774	264	265	O
that	8980774	266	270	O
is	8980774	271	273	O
currently	8980774	274	283	O
being	8980774	284	289	O
evaluated	8980774	290	299	O
in	8980774	300	302	O
combination	8980774	303	314	O
regimens	8980774	315	323	O
with	8980774	324	328	O
various	8980774	329	336	O
nucleoside	8980774	337	347	O
analogs	8980774	348	355	O
,	8980774	356	357	O
including	8980774	358	367	O
didanosine	8980774	368	378	O
.	8980774	379	380	O

Due	8980774	381	384	O
to	8980774	385	387	O
the	8980774	388	391	O
pH-dependent	8980774	392	404	O
solubility	8980774	405	415	O
of	8980774	416	418	O
delavirdine	8980774	419	430	O
,	8980774	431	432	O
the	8980774	433	436	O
buffering	8980774	437	446	O
agents	8980774	447	453	O
in	8980774	454	456	O
didanosine	8980774	457	467	O
formulations	8980774	468	480	O
may	8980774	481	484	O
reduce	8980774	485	491	O
delavirdine	8980774	492	503	O
absorption	8980774	504	514	O
.	8980774	515	516	O

To	8980774	517	519	O
evaluate	8980774	520	528	O
the	8980774	529	532	O
potential	8980774	533	542	B-Outcome
interaction	8980774	543	554	I-Outcome
between	8980774	555	562	O
these	8980774	563	568	O
agents	8980774	569	575	O
,	8980774	576	577	O
12	8980774	578	580	O
HIV-infected	8980774	581	593	B-Participant
patients	8980774	594	602	O
(	8980774	603	604	O
mean	8980774	605	609	O
[	8980774	610	611	O
+	8980774	612	613	O
/-	8980774	613	615	O
standard	8980774	616	624	O
deviation	8980774	625	634	O
]	8980774	635	636	O
CD4	8980774	637	640	O
+	8980774	640	641	O
cell	8980774	642	646	O
count	8980774	647	652	O
,	8980774	653	654	O
304	8980774	655	658	O
+	8980774	659	660	O
/-	8980774	660	662	O
213/mm3	8980774	663	670	O
)	8980774	671	672	O
were	8980774	673	677	O
enrolled	8980774	678	686	O
in	8980774	687	689	O
a	8980774	690	691	O
three-way	8980774	692	701	O
crossover	8980774	702	711	O
single-dose	8980774	712	723	O
study	8980774	724	729	O
.	8980774	730	731	O

Didanosine	8980774	732	742	B-Intervention
(	8980774	743	744	O
125	8980774	745	748	O
to	8980774	749	751	O
200	8980774	752	755	O
mg	8980774	756	758	O
given	8980774	759	764	O
as	8980774	765	767	O
buffered	8980774	768	776	O
tablets	8980774	777	784	O
)	8980774	785	786	O
and	8980774	787	790	O
delavirdine	8980774	791	802	B-Intervention
mesylate	8980774	803	811	I-Intervention
(	8980774	812	813	O
400	8980774	814	817	O
mg	8980774	818	820	O
)	8980774	821	822	O
pharmacokinetics	8980774	823	839	B-Outcome
were	8980774	840	844	O
evaluated	8980774	845	854	O
when	8980774	855	859	O
each	8980774	860	864	O
drug	8980774	865	869	O
was	8980774	870	873	O
given	8980774	874	879	O
alone	8980774	880	885	B-Intervention
(	8980774	886	887	O
treatments	8980774	888	898	O
A	8980774	899	900	O
and	8980774	901	904	O
B	8980774	905	906	O
,	8980774	907	908	O
respectively	8980774	909	921	O
)	8980774	922	923	O
,	8980774	924	925	O
when	8980774	926	930	O
the	8980774	931	934	O
two	8980774	935	938	B-Intervention
drugs	8980774	939	944	I-Intervention
were	8980774	945	949	I-Intervention
given	8980774	950	955	I-Intervention
concurrently	8980774	956	968	I-Intervention
(	8980774	969	970	O
treatment	8980774	971	980	O
C	8980774	981	982	O
)	8980774	983	984	O
,	8980774	985	986	O
and	8980774	987	990	O
when	8980774	991	995	O
didanosine	8980774	996	1006	B-Intervention
was	8980774	1007	1010	I-Intervention
given	8980774	1011	1016	I-Intervention
1	8980774	1017	1018	I-Intervention
h	8980774	1019	1020	I-Intervention
after	8980774	1021	1026	I-Intervention
delavirdine	8980774	1027	1038	I-Intervention
(	8980774	1039	1040	O
treatment	8980774	1041	1050	O
D	8980774	1051	1052	O
)	8980774	1053	1054	O
.	8980774	1055	1056	O

Delavirdine	8980774	1057	1068	B-Outcome
exposure	8980774	1069	1077	I-Outcome
was	8980774	1078	1081	O
reduced	8980774	1082	1089	B-Observation
by	8980774	1090	1092	O
concurrent	8980774	1093	1103	B-Intervention
administration	8980774	1104	1118	I-Intervention
of	8980774	1119	1121	I-Intervention
didanosine	8980774	1122	1132	I-Intervention
.	8980774	1133	1134	O

The	8980774	1135	1138	O
maximum	8980774	1139	1146	B-Outcome
drug	8980774	1147	1151	I-Outcome
concentration	8980774	1152	1165	I-Outcome
in	8980774	1166	1168	I-Outcome
serum	8980774	1169	1174	I-Outcome
(	8980774	1175	1176	I-Outcome
Cmax	8980774	1177	1181	I-Outcome
)	8980774	1182	1183	I-Outcome
was	8980774	1184	1187	O
reduced	8980774	1188	1195	B-Observation
from	8980774	1196	1200	I-Observation
7.22	8980774	1201	1205	I-Observation
+	8980774	1206	1207	I-Observation
/-	8980774	1207	1209	I-Observation
4.0	8980774	1210	1213	I-Observation
to	8980774	1214	1216	I-Observation
3.51	8980774	1217	1221	I-Observation
+	8980774	1222	1223	I-Observation
/-	8980774	1223	1225	I-Observation
1.9	8980774	1226	1229	I-Observation
microM	8980774	1230	1236	I-Observation
,	8980774	1237	1238	O
and	8980774	1239	1242	O
the	8980774	1243	1246	O
area	8980774	1247	1251	B-Outcome
under	8980774	1252	1257	I-Outcome
the	8980774	1258	1261	I-Outcome
concentration-time	8980774	1262	1280	I-Outcome
curve	8980774	1281	1286	I-Outcome
from	8980774	1287	1291	I-Outcome
0	8980774	1292	1293	I-Outcome
h	8980774	1294	1295	I-Outcome
to	8980774	1296	1298	I-Outcome
infinity	8980774	1299	1307	I-Outcome
(	8980774	1308	1309	I-Outcome
AUC0	8980774	1310	1314	I-Outcome
--	8980774	1315	1317	I-Outcome
>	8980774	1318	1319	I-Outcome
infinity	8980774	1320	1328	I-Outcome
)	8980774	1329	1330	I-Outcome
was	8980774	1331	1334	O
reduced	8980774	1335	1342	B-Observation
from	8980774	1343	1347	I-Observation
22.5	8980774	1348	1352	I-Observation
+	8980774	1353	1354	I-Observation
/-	8980774	1354	1356	I-Observation
14	8980774	1357	1359	I-Observation
to	8980774	1360	1362	I-Observation
14	8980774	1363	1365	I-Observation
+	8980774	1366	1367	I-Observation
/-	8980774	1367	1369	I-Observation
5.7	8980774	1370	1373	I-Observation
microM.h	8980774	1374	1382	I-Observation
.	8980774	1383	1384	O

The	8980774	1385	1388	O
extent	8980774	1389	1395	B-Outcome
of	8980774	1396	1398	I-Outcome
N-dealkylation	8980774	1399	1413	I-Outcome
,	8980774	1414	1415	O
as	8980774	1416	1418	O
indicated	8980774	1419	1428	O
by	8980774	1429	1431	O
the	8980774	1432	1435	O
ratio	8980774	1436	1441	O
of	8980774	1442	1444	O
the	8980774	1445	1448	O
N-dealkylated	8980774	1449	1462	O
delavirdine	8980774	1463	1474	O
AUC0	8980774	1475	1479	O
--	8980774	1480	1482	O
>	8980774	1483	1484	O
infinity	8980774	1485	1493	O
to	8980774	1494	1496	O
the	8980774	1497	1500	O
delavirdine	8980774	1501	1512	O
AUC0	8980774	1513	1517	O
--	8980774	1518	1520	O
>	8980774	1521	1522	O
infinity	8980774	1523	1531	O
,	8980774	1532	1533	O
was	8980774	1534	1537	O
unchanged	8980774	1538	1547	B-Observation
across	8980774	1548	1554	B-Intervention
study	8980774	1555	1560	I-Intervention
treatments	8980774	1561	1571	I-Intervention
(	8980774	1572	1573	O
P	8980774	1574	1575	O
=	8980774	1576	1577	O
0.708	8980774	1578	1583	O
)	8980774	1584	1585	O
.	8980774	1586	1587	O

Reductions	8980774	1588	1598	B-Observation
in	8980774	1599	1601	O
didanosine	8980774	1602	1612	B-Outcome
exposure	8980774	1613	1621	I-Outcome
were	8980774	1622	1626	O
observed	8980774	1627	1635	O
during	8980774	1636	1642	O
concurrent	8980774	1643	1653	B-Intervention
administration	8980774	1654	1668	I-Intervention
with	8980774	1669	1673	I-Intervention
delavirdine	8980774	1674	1685	I-Intervention
with	8980774	1686	1690	O
a	8980774	1691	1692	O
Cmax	8980774	1693	1697	B-Outcome
reduction	8980774	1698	1707	B-Observation
from	8980774	1708	1712	I-Observation
4.65	8980774	1713	1717	I-Observation
+	8980774	1718	1719	I-Observation
/-	8980774	1719	1721	I-Observation
2.0	8980774	1722	1725	I-Observation
to	8980774	1726	1728	I-Observation
3.22	8980774	1729	1733	I-Observation
+	8980774	1734	1735	I-Observation
/-	8980774	1735	1737	I-Observation
0.59	8980774	1738	1742	I-Observation
microM	8980774	1743	1749	I-Observation
and	8980774	1750	1753	O
an	8980774	1754	1756	O
AUC0	8980774	1757	1761	B-Outcome
--	8980774	1762	1764	I-Outcome
>	8980774	1765	1766	I-Outcome
infinity	8980774	1767	1775	I-Outcome
reduction	8980774	1776	1785	B-Observation
from	8980774	1786	1790	I-Observation
7.93	8980774	1791	1795	I-Observation
+	8980774	1796	1797	I-Observation
/-	8980774	1797	1799	I-Observation
3.9	8980774	1800	1803	I-Observation
to	8980774	1804	1806	I-Observation
6.54	8980774	1807	1811	I-Observation
+	8980774	1812	1813	I-Observation
/-	8980774	1813	1815	I-Observation
2.3	8980774	1816	1819	I-Observation
microM.h	8980774	1820	1828	I-Observation
.	8980774	1829	1830	O

Thus	8980774	1831	1835	O
,	8980774	1836	1837	O
concurrent	8980774	1838	1848	B-Intervention
administration	8980774	1849	1863	I-Intervention
of	8980774	1864	1866	I-Intervention
delavirdine	8980774	1867	1878	I-Intervention
and	8980774	1879	1882	I-Intervention
didanosine	8980774	1883	1893	I-Intervention
may	8980774	1894	1897	O
reduce	8980774	1898	1904	B-Observation
the	8980774	1905	1908	O
AUC0	8980774	1909	1913	B-Outcome
--	8980774	1914	1916	I-Outcome
>	8980774	1917	1918	I-Outcome
infinity	8980774	1919	1927	I-Outcome
of	8980774	1928	1930	I-Outcome
both	8980774	1931	1935	I-Outcome
drugs	8980774	1936	1941	I-Outcome
,	8980774	1942	1943	O
although	8980774	1944	1952	O
the	8980774	1953	1956	O
clinical	8980774	1957	1965	B-Outcome
significance	8980774	1966	1978	I-Outcome
of	8980774	1979	1981	I-Outcome
this	8980774	1982	1986	I-Outcome
reduction	8980774	1987	1996	I-Outcome
is	8980774	1997	1999	O
unknown	8980774	2000	2007	B-Observation
.	8980774	2008	2009	O

Administration	8980774	2010	2024	O
of	8980774	2025	2027	O
delavirdine	8980774	2028	2039	B-Intervention
1	8980774	2040	2041	I-Intervention
h	8980774	2042	2043	I-Intervention
before	8980774	2044	2050	I-Intervention
didanosine	8980774	2051	2061	I-Intervention
avoided	8980774	2062	2069	B-Observation
the	8980774	2070	2073	O
interaction	8980774	2074	2085	B-Outcome
.	8980774	2086	2087	O

Due	8980774	2088	2091	O
to	8980774	2092	2094	O
the	8980774	2095	2098	O
single-dose	8980774	2099	2110	O
nature	8980774	2111	2117	O
of	8980774	2118	2120	O
this	8980774	2121	2125	O
study	8980774	2126	2131	O
,	8980774	2132	2133	O
these	8980774	2134	2139	O
findings	8980774	2140	2148	O
require	8980774	2149	2156	O
further	8980774	2157	2164	O
evaluation	8980774	2165	2175	O
at	8980774	2176	2178	O
steady	8980774	2179	2185	O
state	8980774	2186	2191	O
.	8980774	2192	2193	O

Comparison	9001833	0	10	O
of	9001833	11	13	O
electromotive	9001833	14	27	O
drug	9001833	28	32	O
administration	9001833	33	47	O
with	9001833	48	52	O
ketorolac	9001833	53	62	B-Intervention
or	9001833	63	65	O
with	9001833	66	70	O
placebo	9001833	71	78	B-Intervention
in	9001833	79	81	O
patients	9001833	82	90	O
with	9001833	91	95	O
pain	9001833	96	100	B-Participant
from	9001833	101	105	I-Participant
rheumatic	9001833	106	115	I-Participant
disease	9001833	116	123	I-Participant
:	9001833	124	125	O
a	9001833	126	127	O
double-masked	9001833	128	141	O
study	9001833	142	147	O
.	9001833	148	149	O

This	9001833	150	154	O
study	9001833	155	160	O
was	9001833	161	164	O
undertaken	9001833	165	175	O
to	9001833	176	178	O
assess	9001833	179	185	O
the	9001833	186	189	O
efficacy	9001833	190	198	O
of	9001833	199	201	O
ketorolac	9001833	202	211	B-Intervention
compared	9001833	212	220	O
with	9001833	221	225	O
placebo	9001833	226	233	B-Intervention
when	9001833	234	238	O
delivered	9001833	239	248	O
by	9001833	249	251	O
electromotive	9001833	252	265	O
drug	9001833	266	270	O
administration	9001833	271	285	O
(	9001833	286	287	O
EMDA	9001833	288	292	O
)	9001833	293	294	O
in	9001833	295	297	O
patients	9001833	298	306	O
with	9001833	307	311	O
pain	9001833	312	316	B-Participant
from	9001833	317	321	I-Participant
rheumatic	9001833	322	331	I-Participant
disease	9001833	332	339	I-Participant
.	9001833	340	341	O

In	9001833	342	344	O
EMDA	9001833	345	349	O
,	9001833	350	351	O
or	9001833	352	354	O
iontophoresis	9001833	355	368	O
,	9001833	369	370	O
a	9001833	371	372	O
low-intensity	9001833	373	386	O
electric	9001833	387	395	O
current	9001833	396	403	O
is	9001833	404	406	O
applied	9001833	407	414	O
over	9001833	415	419	O
the	9001833	420	423	O
skin	9001833	424	428	O
to	9001833	429	431	O
deliver	9001833	432	439	O
medication	9001833	440	450	O
into	9001833	451	455	O
body	9001833	456	460	O
tissues	9001833	461	468	O
.	9001833	469	470	O

Although	9001833	471	479	O
EMDA	9001833	480	484	O
has	9001833	485	488	O
been	9001833	489	493	O
used	9001833	494	498	O
to	9001833	499	501	O
treat	9001833	502	507	O
patients	9001833	508	516	O
with	9001833	517	521	O
various	9001833	522	529	O
diseases	9001833	530	538	O
,	9001833	539	540	O
controlled	9001833	541	551	O
studies	9001833	552	559	O
are	9001833	560	563	O
lacking	9001833	564	571	O
in	9001833	572	574	O
patients	9001833	575	583	O
with	9001833	584	588	O
rheumatic	9001833	589	598	O
disease	9001833	599	606	O
.	9001833	607	608	O

This	9001833	609	613	O
double-masked	9001833	614	627	O
study	9001833	628	633	O
included	9001833	634	642	O
60	9001833	643	645	O
patients	9001833	646	654	O
(	9001833	655	656	O
43	9001833	657	659	O
women	9001833	660	665	O
and	9001833	666	669	O
17	9001833	670	672	O
men	9001833	673	676	O
)	9001833	677	678	O
aged	9001833	679	683	O
31	9001833	684	686	O
to	9001833	687	689	O
80	9001833	690	692	O
years	9001833	693	698	O
with	9001833	699	703	O
the	9001833	704	707	O
following	9001833	708	717	O
conditions	9001833	718	728	O
:	9001833	729	730	O
12	9001833	731	733	O
,	9001833	734	735	O
epicondylitis	9001833	736	749	B-Participant
;	9001833	750	751	O
30	9001833	752	754	O
,	9001833	755	756	O
scapulohumeral	9001833	757	771	B-Participant
periarthritis	9001833	772	785	I-Participant
;	9001833	786	787	O
10	9001833	788	790	O
,	9001833	791	792	O
gonalgia	9001833	793	801	B-Participant
;	9001833	802	803	O
and	9001833	804	807	O
8	9001833	808	809	O
,	9001833	810	811	O
metatarsalgia	9001833	812	825	B-Participant
.	9001833	826	827	O

They	9001833	828	832	O
were	9001833	833	837	O
divided	9001833	838	845	O
randomly	9001833	846	854	O
by	9001833	855	857	O
a	9001833	858	859	O
physician	9001833	860	869	O
into	9001833	870	874	O
2	9001833	875	876	O
groups	9001833	877	883	O
of	9001833	884	886	O
30	9001833	887	889	O
patients	9001833	890	898	O
each	9001833	899	903	O
for	9001833	904	907	O
5	9001833	908	909	O
sessions	9001833	910	918	O
of	9001833	919	921	O
active	9001833	922	928	B-Intervention
treatment	9001833	929	938	I-Intervention
(	9001833	939	940	O
30	9001833	941	943	O
mg	9001833	944	946	O
of	9001833	947	949	O
ketorolac	9001833	950	959	B-Intervention
)	9001833	960	961	O
or	9001833	962	964	O
placebo	9001833	965	972	B-Intervention
(	9001833	973	974	O
5	9001833	975	976	O
mL	9001833	977	979	O
of	9001833	980	982	O
normal	9001833	983	989	B-Intervention
saline	9001833	990	996	I-Intervention
)	9001833	997	998	O
.	9001833	999	1000	O

Treatment	9001833	1001	1010	O
took	9001833	1011	1015	O
place	9001833	1016	1021	O
every	9001833	1022	1027	O
other	9001833	1028	1033	O
day	9001833	1034	1037	O
for	9001833	1038	1041	O
20	9001833	1042	1044	O
minutes	9001833	1045	1052	O
.	9001833	1053	1054	O

Immediately	9001833	1055	1066	O
before	9001833	1067	1073	O
and	9001833	1074	1077	O
after	9001833	1078	1083	O
the	9001833	1084	1087	O
five	9001833	1088	1092	O
treatment	9001833	1093	1102	O
sessions	9001833	1103	1111	O
and	9001833	1112	1115	O
7	9001833	1116	1117	O
days	9001833	1118	1122	O
after	9001833	1123	1128	O
treatment	9001833	1129	1138	O
ended	9001833	1139	1144	O
,	9001833	1145	1146	O
both	9001833	1147	1151	O
patient	9001833	1152	1159	O
and	9001833	1160	1163	O
physician	9001833	1164	1173	O
measured	9001833	1174	1182	O
the	9001833	1183	1186	O
degree	9001833	1187	1193	B-Outcome
of	9001833	1194	1196	I-Outcome
pain	9001833	1197	1201	I-Outcome
using	9001833	1202	1207	O
a	9001833	1208	1209	O
categoric	9001833	1210	1219	B-Outcome
scale	9001833	1220	1225	I-Outcome
(	9001833	1226	1227	O
no	9001833	1228	1230	O
pain	9001833	1231	1235	O
,	9001833	1236	1237	O
slight	9001833	1238	1244	O
pain	9001833	1245	1249	O
,	9001833	1250	1251	O
intermediate	9001833	1252	1264	O
pain	9001833	1265	1269	O
,	9001833	1270	1271	O
strong	9001833	1272	1278	O
pain	9001833	1279	1283	O
,	9001833	1284	1285	O
and	9001833	1286	1289	O
very	9001833	1290	1294	O
strong	9001833	1295	1301	O
pain	9001833	1302	1306	O
)	9001833	1307	1308	O
and	9001833	1309	1312	O
evaluated	9001833	1313	1322	O
pain	9001833	1323	1327	B-Outcome
intensity	9001833	1328	1337	I-Outcome
using	9001833	1338	1343	O
the	9001833	1344	1347	O
Scott	9001833	1348	1353	B-Outcome
and	9001833	1354	1357	I-Outcome
Huskisson	9001833	1358	1367	I-Outcome
Visual	9001833	1368	1374	I-Outcome
Analogue	9001833	1375	1383	I-Outcome
Scale	9001833	1384	1389	I-Outcome
(	9001833	1390	1391	I-Outcome
VAS	9001833	1392	1395	I-Outcome
)	9001833	1396	1397	I-Outcome
.	9001833	1398	1399	O

Seven	9001833	1400	1405	O
days	9001833	1406	1410	O
after	9001833	1411	1416	O
treatment	9001833	1417	1426	O
ended	9001833	1427	1432	O
,	9001833	1433	1434	O
both	9001833	1435	1439	O
physician	9001833	1440	1449	O
and	9001833	1450	1453	O
patient	9001833	1454	1461	O
judged	9001833	1462	1468	O
the	9001833	1469	1472	O
result	9001833	1473	1479	O
of	9001833	1480	1482	O
treatment	9001833	1483	1492	O
using	9001833	1493	1498	O
a	9001833	1499	1500	O
second	9001833	1501	1507	B-Outcome
categoric	9001833	1508	1517	I-Outcome
scale	9001833	1518	1523	I-Outcome
(	9001833	1524	1525	O
no	9001833	1526	1528	O
improvement	9001833	1529	1540	O
or	9001833	1541	1543	O
intermediate	9001833	1544	1556	O
,	9001833	1557	1558	O
good	9001833	1559	1563	O
,	9001833	1564	1565	O
or	9001833	1566	1568	O
very	9001833	1569	1573	O
good	9001833	1574	1578	O
result	9001833	1579	1585	O
)	9001833	1586	1587	O
.	9001833	1588	1589	O

Both	9001833	1590	1594	O
ketorolac	9001833	1595	1604	B-Intervention
and	9001833	1605	1608	O
placebo	9001833	1609	1616	B-Intervention
provided	9001833	1617	1625	O
immediate	9001833	1626	1635	B-Observation
,	9001833	1636	1637	I-Observation
significant	9001833	1638	1649	I-Observation
pain	9001833	1650	1654	B-Outcome
relief	9001833	1655	1661	I-Outcome
when	9001833	1662	1666	O
delivered	9001833	1667	1676	O
by	9001833	1677	1679	O
EMDA	9001833	1680	1684	O
,	9001833	1685	1686	O
but	9001833	1687	1690	O
only	9001833	1691	1695	O
those	9001833	1696	1701	O
patients	9001833	1702	1710	O
receiving	9001833	1711	1720	O
ketorolac	9001833	1721	1730	B-Intervention
experienced	9001833	1731	1742	O
a	9001833	1743	1744	O
further	9001833	1745	1752	B-Observation
reduction	9001833	1753	1762	I-Observation
in	9001833	1763	1765	O
pain	9001833	1766	1770	B-Outcome
7	9001833	1771	1772	O
days	9001833	1773	1777	O
after	9001833	1778	1783	O
treatment	9001833	1784	1793	O
;	9001833	1794	1795	O
those	9001833	1796	1801	O
receiving	9001833	1802	1811	O
placebo	9001833	1812	1819	B-Intervention
experienced	9001833	1820	1831	O
a	9001833	1832	1833	O
slight	9001833	1834	1840	B-Observation
increase	9001833	1841	1849	I-Observation
in	9001833	1850	1852	O
pain	9001833	1853	1857	B-Outcome
.	9001833	1858	1859	O

VAS	9001833	1860	1863	B-Outcome
values	9001833	1864	1870	I-Outcome
differed	9001833	1871	1879	B-Observation
significantly	9001833	1880	1893	I-Observation
between	9001833	1894	1901	B-Intervention
the	9001833	1902	1905	I-Intervention
two	9001833	1906	1909	I-Intervention
groups	9001833	1910	1916	I-Intervention
.	9001833	1917	1918	O

Poor	9001833	1919	1923	B-Outcome
results	9001833	1924	1931	I-Outcome
(	9001833	1932	1933	I-Outcome
no	9001833	1934	1936	I-Outcome
improvement	9001833	1937	1948	I-Outcome
)	9001833	1949	1950	I-Outcome
were	9001833	1951	1955	O
significantly	9001833	1956	1969	B-Observation
higher	9001833	1970	1976	I-Observation
in	9001833	1977	1979	O
the	9001833	1980	1983	O
placebo-treated	9001833	1984	1999	B-Intervention
group	9001833	2000	2005	O
,	9001833	2006	2007	O
while	9001833	2008	2013	O
good	9001833	2014	2018	B-Outcome
results	9001833	2019	2026	I-Outcome
were	9001833	2027	2031	O
significantly	9001833	2032	2045	B-Observation
higher	9001833	2046	2052	I-Observation
in	9001833	2053	2055	O
the	9001833	2056	2059	O
ketorolac-treated	9001833	2060	2077	B-Intervention
group	9001833	2078	2083	O
.	9001833	2084	2085	O

No	9001833	2086	2088	B-Count
patient	9001833	2089	2096	I-Count
reported	9001833	2097	2105	O
any	9001833	2106	2109	O
adverse	9001833	2110	2117	B-Outcome
effects	9001833	2118	2125	I-Outcome
during	9001833	2126	2132	O
treatment	9001833	2133	2142	O
.	9001833	2143	2144	O

This	9001833	2145	2149	O
study	9001833	2150	2155	O
demonstrates	9001833	2156	2168	O
that	9001833	2169	2173	O
ketorolac	9001833	2174	2183	B-Intervention
relieves	9001833	2184	2192	B-Observation
pain	9001833	2193	2197	B-Outcome
when	9001833	2198	2202	O
delivered	9001833	2203	2212	O
by	9001833	2213	2215	O
EMDA	9001833	2216	2220	O
and	9001833	2221	2224	O
offers	9001833	2225	2231	O
longer-lasting	9001833	2232	2246	B-Observation
pain	9001833	2247	2251	B-Outcome
relief	9001833	2252	2258	I-Outcome
than	9001833	2259	2263	O
does	9001833	2264	2268	O
placebo	9001833	2269	2276	B-Intervention
.	9001833	2277	2278	O

Topical	9003876	0	7	B-Intervention
beta-blockade	9003876	8	21	I-Intervention
with	9003876	22	26	I-Intervention
intrinsic	9003876	27	36	I-Intervention
sympathomimetic	9003876	37	52	I-Intervention
activity	9003876	53	61	I-Intervention
offers	9003876	62	68	O
no	9003876	69	71	O
advantage	9003876	72	81	B-Observation
for	9003876	82	85	O
the	9003876	86	89	O
respiratory	9003876	90	101	B-Outcome
and	9003876	102	105	I-Outcome
cardiovascular	9003876	106	120	I-Outcome
function	9003876	121	129	I-Outcome
of	9003876	130	132	O
elderly	9003876	133	140	B-Participant
people	9003876	141	147	I-Participant
.	9003876	148	149	O

Topical	9003876	150	157	O
therapy	9003876	158	165	O
with	9003876	166	170	O
beta-antagonists	9003876	171	187	O
,	9003876	188	189	O
such	9003876	190	194	O
as	9003876	195	197	O
timolol	9003876	198	205	O
,	9003876	206	207	O
may	9003876	208	211	O
cause	9003876	212	217	O
unrecognized	9003876	218	230	O
impairment	9003876	231	241	O
of	9003876	242	244	O
respiratory	9003876	245	256	O
and	9003876	257	260	O
cardiovascular	9003876	261	275	O
function	9003876	276	284	O
in	9003876	285	287	O
elderly	9003876	288	295	O
people	9003876	296	302	O
.	9003876	303	304	O

Beta-antagonists	9003876	305	321	O
with	9003876	322	326	O
intrinsic	9003876	327	336	O
sympathomimetic	9003876	337	352	O
or	9003876	353	355	O
cardioselective	9003876	356	371	O
properties	9003876	372	382	O
,	9003876	383	384	O
such	9003876	385	389	O
as	9003876	390	392	O
carteolol	9003876	393	402	O
or	9003876	403	405	O
betaxolol	9003876	406	415	O
,	9003876	416	417	O
may	9003876	418	421	O
cause	9003876	422	427	O
less	9003876	428	432	O
impairment	9003876	433	443	O
.	9003876	444	445	O

In	9003876	446	448	O
a	9003876	449	450	O
randomized	9003876	451	461	O
,	9003876	462	463	O
double-masked	9003876	464	477	O
study	9003876	478	483	O
of	9003876	484	486	O
glaucoma	9003876	487	495	B-Participant
patients	9003876	496	504	O
,	9003876	505	506	O
over	9003876	507	511	O
60	9003876	512	514	O
years	9003876	515	520	O
of	9003876	521	523	O
age	9003876	524	527	O
,	9003876	528	529	O
without	9003876	530	537	O
history	9003876	538	545	O
of	9003876	546	548	O
bronchospasm	9003876	549	561	B-Participant
and	9003876	562	565	O
who	9003876	566	569	O
were	9003876	570	574	O
using	9003876	575	580	O
timolol	9003876	581	588	B-Participant
(	9003876	589	590	O
0.5	9003876	591	594	O
%	9003876	595	596	O
)	9003876	597	598	O
,	9003876	599	600	O
60	9003876	601	603	O
patients	9003876	604	612	O
were	9003876	613	617	O
allocated	9003876	618	627	O
to	9003876	628	630	O
betaxolol	9003876	631	640	B-Intervention
(	9003876	641	642	O
0.5	9003876	643	646	O
%	9003876	647	648	O
)	9003876	649	650	O
or	9003876	651	653	O
carteolol	9003876	654	663	B-Intervention
(	9003876	664	665	O
2	9003876	666	667	O
%	9003876	668	669	O
)	9003876	670	671	O
or	9003876	672	674	O
continued	9003876	675	684	B-Intervention
timolol	9003876	685	692	I-Intervention
(	9003876	693	694	O
0.5	9003876	695	698	O
%	9003876	699	700	O
)	9003876	701	702	O
treatment	9003876	703	712	O
.	9003876	713	714	O

Spirometry	9003876	715	725	B-Outcome
,	9003876	726	727	O
pulse	9003876	728	733	B-Outcome
and	9003876	734	737	O
blood	9003876	738	743	B-Outcome
pressure	9003876	744	752	I-Outcome
were	9003876	753	757	O
measured	9003876	758	766	O
on	9003876	767	769	O
enrollment	9003876	770	780	O
and	9003876	781	784	O
after	9003876	785	790	O
4	9003876	791	792	O
weeks	9003876	793	798	O
.	9003876	799	800	O

In	9003876	801	803	O
the	9003876	804	807	O
timolol	9003876	808	815	B-Intervention
and	9003876	816	819	O
carteolol	9003876	820	829	B-Intervention
groups	9003876	830	836	O
there	9003876	837	842	O
were	9003876	843	847	O
no	9003876	848	850	O
significant	9003876	851	862	B-Observation
changes	9003876	863	870	I-Observation
in	9003876	871	873	O
mean	9003876	874	878	B-Outcome
spirometric	9003876	879	890	I-Outcome
values	9003876	891	897	I-Outcome
.	9003876	898	899	O

Changing	9003876	900	908	B-Intervention
to	9003876	909	911	I-Intervention
betaxolol	9003876	912	921	I-Intervention
improved	9003876	922	930	B-Observation
mean	9003876	931	935	B-Outcome
peak	9003876	936	940	I-Outcome
flow	9003876	941	945	I-Outcome
(	9003876	946	947	I-Outcome
PF	9003876	948	950	I-Outcome
)	9003876	951	952	I-Outcome
by	9003876	953	955	O
9.1	9003876	956	959	B-Observation
%	9003876	960	961	I-Observation
,	9003876	962	963	O
from	9003876	964	968	B-Observation
310	9003876	969	972	I-Observation
to	9003876	973	975	I-Observation
3411/min	9003876	976	984	I-Observation
(	9003876	985	986	O
p	9003876	987	988	O
<	9003876	989	990	O
0.05	9003876	991	995	O
)	9003876	996	997	O
and	9003876	998	1001	O
forced	9003876	1002	1008	B-Outcome
expiratory	9003876	1009	1019	I-Outcome
volume	9003876	1020	1026	I-Outcome
in	9003876	1027	1029	I-Outcome
1	9003876	1030	1031	I-Outcome
second	9003876	1032	1038	I-Outcome
(	9003876	1039	1040	I-Outcome
FEV1	9003876	1041	1045	I-Outcome
)	9003876	1046	1047	I-Outcome
by	9003876	1048	1050	O
9.4	9003876	1051	1054	B-Observation
%	9003876	1055	1056	I-Observation
,	9003876	1057	1058	O
from	9003876	1059	1063	B-Observation
1.74	9003876	1064	1068	I-Observation
to	9003876	1069	1071	I-Observation
1.861	9003876	1072	1077	I-Observation
(	9003876	1078	1079	O
p	9003876	1080	1081	O
<	9003876	1082	1083	O
0.05	9003876	1084	1088	O
)	9003876	1089	1090	O
.	9003876	1091	1092	O

Differences	9003876	1093	1104	B-Observation
in	9003876	1105	1107	O
the	9003876	1108	1111	O
changes	9003876	1112	1119	B-Outcome
in	9003876	1120	1122	I-Outcome
PF	9003876	1123	1125	I-Outcome
and	9003876	1126	1129	I-Outcome
FEV1	9003876	1130	1134	I-Outcome
between	9003876	1135	1142	O
betaxolol	9003876	1143	1152	B-Intervention
and	9003876	1153	1156	O
timolol	9003876	1157	1164	B-Intervention
as	9003876	1165	1167	O
well	9003876	1168	1172	O
as	9003876	1173	1175	O
betaxolol	9003876	1176	1185	B-Intervention
and	9003876	1186	1189	O
carteolol	9003876	1190	1199	B-Intervention
groups	9003876	1200	1206	O
were	9003876	1207	1211	O
statistically	9003876	1212	1225	B-Observation
significant	9003876	1226	1237	I-Observation
(	9003876	1238	1239	O
p	9003876	1240	1241	O
<	9003876	1242	1243	O
0.05	9003876	1244	1248	O
)	9003876	1249	1250	O
.	9003876	1251	1252	O

Twenty-one	9003876	1253	1263	B-Count
per	9003876	1264	1267	I-Count
cent	9003876	1268	1272	I-Count
of	9003876	1273	1275	O
those	9003876	1276	1281	O
allocated	9003876	1282	1291	O
to	9003876	1292	1294	O
betaxolol	9003876	1295	1304	B-Intervention
showed	9003876	1305	1311	O
clinically	9003876	1312	1322	B-Observation
significant	9003876	1323	1334	I-Observation
improvement	9003876	1335	1346	I-Observation
in	9003876	1347	1349	O
FEV1	9003876	1350	1354	B-Outcome
.	9003876	1355	1356	O

There	9003876	1357	1362	O
was	9003876	1363	1366	O
no	9003876	1367	1369	O
change	9003876	1370	1376	B-Observation
in	9003876	1377	1379	O
pulse	9003876	1380	1385	B-Outcome
or	9003876	1386	1388	O
blood	9003876	1389	1394	B-Outcome
pressure	9003876	1395	1403	I-Outcome
when	9003876	1404	1408	O
carteolol	9003876	1409	1418	B-Intervention
was	9003876	1419	1422	I-Intervention
substituted	9003876	1423	1434	I-Intervention
for	9003876	1435	1438	I-Intervention
timolol	9003876	1439	1446	I-Intervention
but	9003876	1447	1450	O
an	9003876	1451	1453	O
increase	9003876	1454	1462	B-Observation
of	9003876	1463	1465	I-Observation
10	9003876	1466	1468	I-Observation
beats	9003876	1469	1474	I-Observation
per	9003876	1475	1478	I-Observation
minute	9003876	1479	1485	I-Observation
(	9003876	1486	1487	O
p	9003876	1488	1489	O
<	9003876	1490	1491	O
0.05	9003876	1492	1496	O
)	9003876	1497	1498	O
in	9003876	1499	1501	O
mean	9003876	1502	1506	B-Outcome
resting	9003876	1507	1514	I-Outcome
pulse	9003876	1515	1520	I-Outcome
in	9003876	1521	1523	O
the	9003876	1524	1527	O
betaxolol	9003876	1528	1537	B-Intervention
group	9003876	1538	1543	O
.	9003876	1544	1545	O

Therapy	9003876	1546	1553	O
with	9003876	1554	1558	O
cardioselective	9003876	1559	1574	B-Intervention
beta-blockade	9003876	1575	1588	I-Intervention
may	9003876	1589	1592	O
offer	9003876	1593	1598	O
significant	9003876	1599	1610	B-Observation
advantages	9003876	1611	1621	I-Observation
in	9003876	1622	1624	O
respiratory	9003876	1625	1636	B-Outcome
function	9003876	1637	1645	I-Outcome
for	9003876	1646	1649	O
elderly	9003876	1650	1657	B-Participant
people	9003876	1658	1664	I-Participant
with	9003876	1665	1669	O
glaucoma	9003876	1670	1678	B-Participant
over	9003876	1679	1683	O
non-selective	9003876	1684	1697	B-Intervention
drugs	9003876	1698	1703	I-Intervention
,	9003876	1704	1705	O
even	9003876	1706	1710	O
if	9003876	1711	1713	O
they	9003876	1714	1718	O
have	9003876	1719	1723	O
sympathomimetic	9003876	1724	1739	O
activity	9003876	1740	1748	O
.	9003876	1749	1750	O

Maximal	937075	0	7	B-Outcome
bioavailability	937075	8	23	I-Outcome
of	937075	24	26	O
digoxin	937075	27	34	B-Intervention
from	937075	35	39	I-Intervention
tablets	937075	40	47	I-Intervention
and	937075	48	51	I-Intervention
oral	937075	52	56	I-Intervention
solution	937075	57	65	I-Intervention
in	937075	66	68	O
steady	937075	69	75	O
state	937075	76	81	O
.	937075	82	83	O

Comparison	937075	84	94	O
has	937075	95	98	O
been	937075	99	103	O
made	937075	104	108	O
between	937075	109	116	O
the	937075	117	120	O
absorption	937075	121	131	B-Outcome
of	937075	132	134	O
digoxin	937075	135	142	B-Intervention
from	937075	143	147	I-Intervention
Lanoxin	937075	148	155	I-Intervention
tablets	937075	156	163	I-Intervention
and	937075	164	167	O
the	937075	168	171	O
absorption	937075	172	182	B-Outcome
of	937075	183	185	O
international	937075	186	199	B-Intervention
chemical	937075	200	208	I-Intervention
reference	937075	209	218	I-Intervention
substance	937075	219	228	I-Intervention
digoxin	937075	229	236	I-Intervention
from	937075	237	241	I-Intervention
an	937075	242	244	I-Intervention
oral	937075	245	249	I-Intervention
solution	937075	250	258	I-Intervention
.	937075	259	260	O

Plasma	937075	261	267	B-Outcome
levels	937075	268	274	I-Outcome
,	937075	275	276	O
areas	937075	277	282	B-Outcome
under	937075	283	288	I-Outcome
24-hour	937075	289	296	I-Outcome
plasma	937075	297	303	I-Outcome
concentration	937075	304	317	I-Outcome
curves	937075	318	324	I-Outcome
and	937075	325	328	O
urinary	937075	329	336	B-Outcome
excretion	937075	337	346	I-Outcome
were	937075	347	351	O
similar	937075	352	359	B-Observation
by	937075	360	362	O
both	937075	363	367	B-Intervention
formulations	937075	368	380	I-Intervention
in	937075	381	383	O
steady	937075	384	390	O
state	937075	391	396	O
.	937075	397	398	O

78	937075	399	401	B-Count
%	937075	402	403	I-Count
of	937075	404	406	I-Count
the	937075	407	410	I-Count
digoxin	937075	411	418	I-Count
administered	937075	419	431	O
was	937075	432	435	O
absorbed	937075	436	444	B-Outcome
from	937075	445	449	O
the	937075	450	453	O
tablets	937075	454	461	B-Intervention
and	937075	462	465	O
76	937075	466	468	B-Count
%	937075	469	470	I-Count
from	937075	471	475	O
the	937075	476	479	O
solution	937075	480	488	B-Intervention
.	937075	489	490	O

Rapid	937075	491	496	B-Observation
dissolution	937075	497	508	B-Outcome
in	937075	509	511	I-Outcome
the	937075	512	515	I-Outcome
intestinal	937075	516	526	I-Outcome
fluids	937075	527	533	I-Outcome
accounts	937075	534	542	O
for	937075	543	546	O
the	937075	547	550	O
high	937075	551	555	B-Observation
digoxin	937075	556	563	B-Outcome
bioavailability	937075	564	579	I-Outcome
of	937075	580	582	O
the	937075	583	586	O
tablets	937075	587	594	B-Intervention
.	937075	595	596	O

Radiotherapy	939970	0	12	B-Intervention
and	939970	13	16	O
CCNU	939970	17	21	B-Intervention
in	939970	22	24	O
the	939970	25	28	O
treatment	939970	29	38	O
of	939970	39	41	O
high-grade	939970	42	52	B-Participant
supratentorial	939970	53	67	I-Participant
astrocytomas	939970	68	80	I-Participant
.	939970	81	82	O

Forty-one	939970	83	92	O
consecutive	939970	93	104	O
patients	939970	105	113	O
with	939970	114	118	O
supratentorial	939970	119	133	B-Participant
primary	939970	134	141	I-Participant
brain	939970	142	147	I-Participant
tumors	939970	148	154	I-Participant
(	939970	155	156	O
38	939970	157	159	O
Grade	939970	160	165	B-Participant
III	939970	166	169	I-Participant
and	939970	170	173	I-Participant
IV	939970	174	176	I-Participant
astrocytomas	939970	177	189	I-Participant
,	939970	190	191	O
one	939970	192	195	O
giant-cell	939970	196	206	B-Participant
astrocytoma	939970	207	218	I-Participant
,	939970	219	220	O
and	939970	221	224	O
two	939970	225	228	O
cases	939970	229	234	O
with	939970	235	239	O
insufficient	939970	240	252	B-Participant
tissue	939970	253	259	I-Participant
for	939970	260	263	I-Participant
diagnosis	939970	264	273	I-Participant
)	939970	274	275	O
were	939970	276	280	O
randomly	939970	281	289	O
allocated	939970	290	299	O
within	939970	300	306	O
2	939970	307	308	O
weeks	939970	309	314	O
of	939970	315	317	O
surgery	939970	318	325	O
to	939970	326	328	O
one	939970	329	332	O
of	939970	333	335	O
three	939970	336	341	O
therapeutic	939970	342	353	O
groups	939970	354	360	O
.	939970	361	362	O

Group	939970	363	368	O
1	939970	369	370	O
(	939970	371	372	O
15	939970	373	375	O
patients	939970	376	384	O
)	939970	385	386	O
received	939970	387	395	O
radiation	939970	396	405	B-Intervention
therapy	939970	406	413	I-Intervention
totaling	939970	414	422	O
4000	939970	423	427	O
to	939970	428	430	O
4500	939970	431	435	O
rads	939970	436	440	O
in	939970	441	443	O
4	939970	444	445	O
to	939970	446	448	O
5	939970	449	450	O
weeks	939970	451	456	O
.	939970	457	458	O

Group	939970	459	464	O
2	939970	465	466	O
(	939970	467	468	O
13	939970	469	471	O
patients	939970	472	480	O
)	939970	481	482	O
received	939970	483	491	O
1-	939970	492	494	B-Intervention
(	939970	495	496	I-Intervention
2-chloroethyl	939970	497	510	I-Intervention
)	939970	511	512	I-Intervention
-3-cyclohexyl-1-nitrosourea	939970	513	540	I-Intervention
CCNU	939970	541	545	I-Intervention
)	939970	546	547	I-Intervention
130	939970	548	551	O
mg/sq	939970	552	557	O
m	939970	558	559	O
orally	939970	560	566	O
every	939970	567	572	O
6	939970	573	574	O
weeks	939970	575	580	O
.	939970	581	582	O

Group	939970	583	588	O
3	939970	589	590	O
(	939970	591	592	O
13	939970	593	595	O
patients	939970	596	604	O
)	939970	605	606	O
received	939970	607	615	O
radiation	939970	616	625	B-Intervention
therapy	939970	626	633	I-Intervention
plus	939970	634	638	I-Intervention
CCNU	939970	639	643	I-Intervention
as	939970	644	646	O
for	939970	647	650	O
Groups	939970	651	657	O
1	939970	658	659	O
and	939970	660	663	O
2	939970	664	665	O
.	939970	666	667	O

When	939970	668	672	O
the	939970	673	676	O
disease	939970	677	684	B-Outcome
progressed	939970	685	695	I-Outcome
,	939970	696	697	O
patients	939970	698	706	O
in	939970	707	709	O
Groups	939970	710	716	B-Intervention
1	939970	717	718	I-Intervention
and	939970	719	722	O
2	939970	723	724	B-Intervention
were	939970	725	729	O
crossed	939970	730	737	O
over	939970	738	742	O
to	939970	743	745	O
receive	939970	746	753	O
CCNU	939970	754	758	B-Intervention
and	939970	759	762	O
irradiation	939970	763	774	B-Intervention
respectively	939970	775	787	O
.	939970	788	789	O

The	939970	790	793	O
median	939970	794	800	B-Outcome
survival	939970	801	809	I-Outcome
time	939970	810	814	I-Outcome
in	939970	815	817	O
these	939970	818	823	B-Intervention
groups	939970	824	830	I-Intervention
was	939970	831	834	O
188	939970	835	838	B-Observation
,	939970	839	840	O
259	939970	841	844	B-Observation
,	939970	845	846	O
and	939970	847	850	O
252	939970	851	854	B-Observation
days	939970	855	859	I-Observation
,	939970	860	861	O
and	939970	862	865	O
the	939970	866	869	O
mean	939970	870	874	B-Outcome
survival	939970	875	883	I-Outcome
263	939970	884	887	B-Observation
,	939970	888	889	O
262	939970	890	893	B-Observation
,	939970	894	895	O
and	939970	896	899	O
329	939970	900	903	B-Observation
days	939970	904	908	I-Observation
.	939970	909	910	O

The	939970	911	914	O
median	939970	915	921	B-Outcome
time	939970	922	926	I-Outcome
from	939970	927	931	I-Outcome
diagnosis	939970	932	941	I-Outcome
to	939970	942	944	I-Outcome
crossover	939970	945	954	I-Outcome
(	939970	955	956	O
Groups	939970	957	963	B-Intervention
1	939970	964	965	I-Intervention
and	939970	966	969	O
2	939970	970	971	B-Intervention
)	939970	972	973	O
or	939970	974	976	O
to	939970	977	979	B-Outcome
progression	939970	980	991	I-Outcome
(	939970	992	993	O
Group	939970	994	999	B-Intervention
3	939970	1000	1001	I-Intervention
)	939970	1002	1003	O
was	939970	1004	1007	O
163	939970	1008	1011	B-Observation
,	939970	1012	1013	O
99	939970	1014	1016	B-Observation
,	939970	1017	1018	O
and	939970	1019	1022	O
220	939970	1023	1026	B-Observation
days	939970	1027	1031	I-Observation
,	939970	1032	1033	O
and	939970	1034	1037	O
the	939970	1038	1041	O
mean	939970	1042	1046	B-Outcome
time	939970	1047	1051	I-Outcome
was	939970	1052	1055	O
172	939970	1056	1059	B-Observation
,	939970	1060	1061	O
108	939970	1062	1065	B-Observation
,	939970	1066	1067	O
and	939970	1068	1071	O
231	939970	1072	1075	B-Observation
days	939970	1076	1080	I-Observation
.	939970	1081	1082	O

There	939970	1083	1088	O
was	939970	1089	1092	O
no	939970	1093	1095	O
statistically	939970	1096	1109	B-Observation
significant	939970	1110	1121	I-Observation
difference	939970	1122	1132	I-Observation
between	939970	1133	1140	O
the	939970	1141	1144	O
means	939970	1145	1150	B-Outcome
or	939970	1151	1153	I-Outcome
medians	939970	1154	1161	I-Outcome
in	939970	1162	1164	I-Outcome
any	939970	1165	1168	I-Outcome
of	939970	1169	1171	I-Outcome
these	939970	1172	1177	I-Outcome
situations	939970	1178	1188	I-Outcome
.	939970	1189	1190	O

Erythropoiesis	9933852	0	14	B-Outcome
after	9933852	15	20	O
therapy	9933852	21	28	O
with	9933852	29	33	O
recombinant	9933852	34	45	B-Intervention
human	9933852	46	51	I-Intervention
erythropoietin	9933852	52	66	I-Intervention
:	9933852	67	68	O
a	9933852	69	70	O
dose-response	9933852	71	84	O
study	9933852	85	90	O
in	9933852	91	93	O
anemic	9933852	94	100	B-Participant
cancer	9933852	101	107	I-Participant
surgery	9933852	108	115	I-Participant
patients	9933852	116	124	O
.	9933852	125	126	O

BACKGROUND	9933852	127	137	O
AND	9933852	138	141	O
OBJECTIVES	9933852	142	152	O
Preoperative	9933852	153	165	O
treatment	9933852	166	175	O
with	9933852	176	180	O
600	9933852	181	184	O
U/kg	9933852	185	189	O
of	9933852	190	192	O
recombinant	9933852	193	204	O
human	9933852	205	210	O
erythropoietin	9933852	211	225	O
(	9933852	226	227	O
r-HuEPO	9933852	228	235	O
)	9933852	236	237	O
effectively	9933852	238	249	O
increases	9933852	250	259	O
erythropoiesis	9933852	260	274	O
in	9933852	275	277	O
cancer	9933852	278	284	O
patients	9933852	285	293	O
.	9933852	294	295	O

The	9933852	296	299	O
aim	9933852	300	303	O
of	9933852	304	306	O
this	9933852	307	311	O
study	9933852	312	317	O
was	9933852	318	321	O
to	9933852	322	324	O
evaluate	9933852	325	333	O
the	9933852	334	337	O
erythropoietic	9933852	338	352	B-Outcome
response	9933852	353	361	I-Outcome
after	9933852	362	367	O
different	9933852	368	377	B-Intervention
doses	9933852	378	383	I-Intervention
of	9933852	384	386	I-Intervention
r-HuEPO	9933852	387	394	I-Intervention
in	9933852	395	397	O
order	9933852	398	403	O
to	9933852	404	406	O
find	9933852	407	411	O
the	9933852	412	415	O
minimum	9933852	416	423	B-Outcome
effective	9933852	424	433	I-Outcome
dose	9933852	434	438	I-Outcome
.	9933852	439	440	O

MATERIALS	9933852	441	450	O
AND	9933852	451	454	O
METHODS	9933852	455	462	O
Twenty	9933852	463	469	O
anemic	9933852	470	476	B-Participant
sideropenic	9933852	477	488	I-Participant
patients	9933852	489	497	O
(	9933852	498	499	O
hemoglobin	9933852	500	510	O
<	9933852	511	512	O
/=110	9933852	513	518	O
g/l	9933852	519	522	O
;	9933852	523	524	O
serum	9933852	525	530	O
iron	9933852	531	535	O
<	9933852	536	537	O
600	9933852	538	541	O
microg/l	9933852	542	550	O
)	9933852	551	552	O
with	9933852	553	557	O
cancer	9933852	558	564	B-Participant
of	9933852	565	567	I-Participant
the	9933852	568	571	I-Participant
gastrointestinal	9933852	572	588	I-Participant
tract	9933852	589	594	I-Participant
were	9933852	595	599	O
randomly	9933852	600	608	O
allocated	9933852	609	618	O
to	9933852	619	621	O
two	9933852	622	625	O
groups	9933852	626	632	O
:	9933852	633	634	O
the	9933852	635	638	O
first	9933852	639	644	O
(	9933852	645	646	O
n	9933852	647	648	O
=	9933852	649	650	O
10	9933852	651	653	O
)	9933852	654	655	O
received	9933852	656	664	O
400	9933852	665	668	B-Intervention
U/kg	9933852	669	673	I-Intervention
of	9933852	674	676	I-Intervention
r-Hu	9933852	677	681	I-Intervention
EPO	9933852	682	685	I-Intervention
divided	9933852	686	693	I-Intervention
in	9933852	694	696	I-Intervention
4	9933852	697	698	I-Intervention
doses	9933852	699	704	I-Intervention
(	9933852	705	706	O
100	9933852	707	710	O
U/kg	9933852	711	715	O
each	9933852	716	720	O
,	9933852	721	722	O
every	9933852	723	728	O
4	9933852	729	730	O
days	9933852	731	735	O
)	9933852	736	737	O
;	9933852	738	739	O
the	9933852	740	743	O
second	9933852	744	750	O
(	9933852	751	752	O
n	9933852	753	754	O
=	9933852	755	756	O
10	9933852	757	759	O
)	9933852	760	761	O
received	9933852	762	770	O
200	9933852	771	774	B-Intervention
U/kg	9933852	775	779	I-Intervention
of	9933852	780	782	I-Intervention
r-HuEPO	9933852	783	790	I-Intervention
(	9933852	791	792	O
50	9933852	793	795	O
U/kg	9933852	796	800	O
each	9933852	801	805	O
,	9933852	806	807	O
every	9933852	808	813	O
4	9933852	814	815	O
days	9933852	816	820	O
)	9933852	821	822	O
.	9933852	823	824	O

Both	9933852	825	829	O
groups	9933852	830	836	O
were	9933852	837	841	O
given	9933852	842	847	O
intravenous	9933852	848	859	B-Intervention
iron	9933852	860	864	I-Intervention
gluconate	9933852	865	874	I-Intervention
(	9933852	875	876	O
125	9933852	877	880	O
mg	9933852	881	883	O
)	9933852	884	885	O
every	9933852	886	891	O
day	9933852	892	895	O
for	9933852	896	899	O
15	9933852	900	902	O
days	9933852	903	907	O
.	9933852	908	909	O

RESULTS	9933852	910	917	O
After	9933852	918	923	O
treatment	9933852	924	933	O
,	9933852	934	935	O
the	9933852	936	939	O
serum	9933852	940	945	B-Outcome
iron	9933852	946	950	I-Outcome
level	9933852	951	956	I-Outcome
significantly	9933852	957	970	B-Observation
rose	9933852	971	975	I-Observation
in	9933852	976	978	O
both	9933852	979	983	B-Intervention
groups	9933852	984	990	I-Intervention
.	9933852	991	992	O

The	9933852	993	996	O
production	9933852	997	1007	B-Outcome
of	9933852	1008	1010	I-Outcome
new	9933852	1011	1014	I-Outcome
red	9933852	1015	1018	I-Outcome
blood	9933852	1019	1024	I-Outcome
cells	9933852	1025	1030	I-Outcome
was	9933852	1031	1034	O
176.3+/-90.8	9933852	1035	1047	B-Observation
ml	9933852	1048	1050	I-Observation
in	9933852	1051	1053	O
the	9933852	1054	1057	O
200	9933852	1058	1061	B-Intervention
U/kg	9933852	1062	1066	I-Intervention
group	9933852	1067	1072	I-Intervention
and	9933852	1073	1076	O
268.4+/-79.4	9933852	1077	1089	B-Observation
ml	9933852	1090	1092	I-Observation
in	9933852	1093	1095	O
the	9933852	1096	1099	O
400	9933852	1100	1103	B-Intervention
U/kg	9933852	1104	1108	I-Intervention
group	9933852	1109	1114	I-Intervention
(	9933852	1115	1116	O
p	9933852	1117	1118	O
=	9933852	1119	1120	O
0.036	9933852	1121	1126	O
)	9933852	1127	1128	O
.	9933852	1129	1130	O

The	9933852	1131	1134	O
increase	9933852	1135	1143	B-Outcome
of	9933852	1144	1146	I-Outcome
hemoglobin	9933852	1147	1157	I-Outcome
was	9933852	1158	1161	O
significantly	9933852	1162	1175	B-Observation
higher	9933852	1176	1182	I-Observation
in	9933852	1183	1185	O
the	9933852	1186	1189	O
400	9933852	1190	1193	B-Intervention
U/kg	9933852	1194	1198	I-Intervention
group	9933852	1199	1204	I-Intervention
(	9933852	1205	1206	O
22.3+/-2.0	9933852	1207	1217	B-Observation
g/l	9933852	1218	1221	I-Observation
)	9933852	1222	1223	O
than	9933852	1224	1228	O
in	9933852	1229	1231	O
the	9933852	1232	1235	O
200	9933852	1236	1239	B-Intervention
U/kg	9933852	1240	1244	I-Intervention
group	9933852	1245	1250	I-Intervention
(	9933852	1251	1252	O
14.1+/-2.7	9933852	1253	1263	B-Observation
g/l	9933852	1264	1267	I-Observation
)	9933852	1268	1269	O
(	9933852	1270	1271	O
p	9933852	1272	1273	O
=	9933852	1274	1275	O
0.017	9933852	1276	1281	O
)	9933852	1282	1283	O
.	9933852	1284	1285	O

CONCLUSION	9933852	1286	1296	O
The	9933852	1297	1300	O
r-HuEPO	9933852	1301	1308	B-Intervention
dose	9933852	1309	1313	I-Intervention
of	9933852	1314	1316	I-Intervention
400	9933852	1317	1320	I-Intervention
U/kg	9933852	1321	1325	I-Intervention
appears	9933852	1326	1333	O
significantly	9933852	1334	1347	B-Observation
more	9933852	1348	1352	I-Observation
effective	9933852	1353	1362	I-Observation
than	9933852	1363	1367	O
the	9933852	1368	1371	O
200	9933852	1372	1375	B-Intervention
U/kg	9933852	1376	1380	I-Intervention
to	9933852	1381	1383	O
stimulate	9933852	1384	1393	O
erythropoiesis	9933852	1394	1408	B-Outcome
in	9933852	1409	1411	O
anemic	9933852	1412	1418	B-Participant
sideropenic	9933852	1419	1430	I-Participant
cancer	9933852	1431	1437	I-Participant
patients	9933852	1438	1446	O
.	9933852	1447	1448	O

The	9935005	0	3	O
influence	9935005	4	13	O
of	9935005	14	16	O
ventricular	9935005	17	28	B-Intervention
fibrillation	9935005	29	41	I-Intervention
duration	9935005	42	50	I-Intervention
on	9935005	51	53	O
defibrillation	9935005	54	68	B-Outcome
efficacy	9935005	69	77	I-Outcome
using	9935005	78	83	O
biphasic	9935005	84	92	O
waveforms	9935005	93	102	O
in	9935005	103	105	O
humans	9935005	106	112	O
.	9935005	113	114	O

OBJECTIVES	9935005	115	125	O
The	9935005	126	129	O
purpose	9935005	130	137	O
of	9935005	138	140	O
this	9935005	141	145	O
study	9935005	146	151	O
was	9935005	152	155	O
to	9935005	156	158	O
prospectively	9935005	159	172	O
investigate	9935005	173	184	O
the	9935005	185	188	O
influence	9935005	189	198	O
of	9935005	199	201	O
ventricular	9935005	202	213	B-Intervention
fibrillation	9935005	214	226	I-Intervention
(	9935005	227	228	I-Intervention
VF	9935005	229	231	I-Intervention
)	9935005	232	233	I-Intervention
durations	9935005	234	243	I-Intervention
of	9935005	244	246	I-Intervention
5	9935005	247	248	I-Intervention
,	9935005	249	250	I-Intervention
10	9935005	251	253	I-Intervention
and	9935005	254	257	I-Intervention
20	9935005	258	260	I-Intervention
s	9935005	261	262	I-Intervention
on	9935005	263	265	O
the	9935005	266	269	O
defibrillation	9935005	270	284	B-Outcome
threshold	9935005	285	294	I-Outcome
(	9935005	295	296	I-Outcome
DFT	9935005	297	300	I-Outcome
)	9935005	301	302	I-Outcome
during	9935005	303	309	O
implantable	9935005	310	321	B-Participant
cardioverter-defibrillator	9935005	322	348	I-Participant
(	9935005	349	350	I-Participant
ICD	9935005	351	354	I-Participant
)	9935005	355	356	I-Participant
implantation	9935005	357	369	I-Participant
.	9935005	370	371	O

BACKGROUND	9935005	372	382	O
Although	9935005	383	391	O
the	9935005	392	395	O
DFT	9935005	396	399	O
using	9935005	400	405	O
monophasic	9935005	406	416	O
waveforms	9935005	417	426	O
has	9935005	427	430	O
been	9935005	431	435	O
shown	9935005	436	441	O
to	9935005	442	444	O
increase	9935005	445	453	O
with	9935005	454	458	O
VF	9935005	459	461	O
duration	9935005	462	470	O
in	9935005	471	473	O
humans	9935005	474	480	O
,	9935005	481	482	O
the	9935005	483	486	O
effect	9935005	487	493	O
of	9935005	494	496	O
VF	9935005	497	499	O
duration	9935005	500	508	O
on	9935005	509	511	O
defibrillation	9935005	512	526	O
efficacy	9935005	527	535	O
using	9935005	536	541	O
biphasic	9935005	542	550	O
waveforms	9935005	551	560	O
in	9935005	561	563	O
humans	9935005	564	570	O
is	9935005	571	573	O
not	9935005	574	577	O
known	9935005	578	583	O
.	9935005	584	585	O

METHODS	9935005	586	593	O
Thirty	9935005	594	600	O
patients	9935005	601	609	O
undergoing	9935005	610	620	O
primary	9935005	621	628	B-Participant
ICD	9935005	629	632	I-Participant
implantation	9935005	633	645	I-Participant
or	9935005	646	648	O
pulse	9935005	649	654	B-Participant
generator	9935005	655	664	I-Participant
replacement	9935005	665	676	I-Participant
were	9935005	677	681	O
randomly	9935005	682	690	O
assigned	9935005	691	699	O
to	9935005	700	702	O
have	9935005	703	707	O
the	9935005	708	711	O
DFT	9935005	712	715	B-Outcome
determined	9935005	716	726	O
using	9935005	727	732	O
biphasic	9935005	733	741	O
shocks	9935005	742	748	O
at	9935005	749	751	O
two	9935005	752	755	B-Intervention
durations	9935005	756	765	I-Intervention
of	9935005	766	768	I-Intervention
VF	9935005	769	771	I-Intervention
each	9935005	772	776	O
(	9935005	777	778	O
5	9935005	779	780	B-Intervention
and	9935005	781	784	I-Intervention
10	9935005	785	787	I-Intervention
s	9935005	788	789	I-Intervention
,	9935005	790	791	O
10	9935005	792	794	B-Intervention
and	9935005	795	798	I-Intervention
20	9935005	799	801	I-Intervention
s	9935005	802	803	I-Intervention
or	9935005	804	806	O
5	9935005	807	808	B-Intervention
and	9935005	809	812	I-Intervention
20	9935005	813	815	I-Intervention
s	9935005	816	817	I-Intervention
)	9935005	818	819	O
.	9935005	820	821	O

RESULTS	9935005	822	829	O
There	9935005	830	835	O
was	9935005	836	839	O
no	9935005	840	842	O
statistically	9935005	843	856	B-Observation
significant	9935005	857	868	I-Observation
difference	9935005	869	879	I-Observation
in	9935005	880	882	O
the	9935005	883	886	O
mean	9935005	887	891	B-Outcome
DFT	9935005	892	895	I-Outcome
comparing	9935005	896	905	O
VF	9935005	906	908	B-Intervention
durations	9935005	909	918	I-Intervention
of	9935005	919	921	I-Intervention
5	9935005	922	923	I-Intervention
s	9935005	924	925	I-Intervention
(	9935005	926	927	O
9.5+/-6.0	9935005	928	937	B-Observation
J	9935005	938	939	I-Observation
)	9935005	940	941	O
and	9935005	942	945	O
10	9935005	946	948	B-Intervention
s	9935005	949	950	I-Intervention
(	9935005	951	952	O
10.8+/-7.0	9935005	953	963	B-Observation
J	9935005	964	965	I-Observation
)	9935005	966	967	O
(	9935005	968	969	O
p=0.4	9935005	970	975	O
)	9935005	976	977	O
.	9935005	978	979	O

The	9935005	980	983	O
mean	9935005	984	988	B-Outcome
DFT	9935005	989	992	I-Outcome
significantly	9935005	993	1006	B-Observation
increased	9935005	1007	1016	I-Observation
from	9935005	1017	1021	O
10.9+/-6.1	9935005	1022	1032	B-Observation
J	9935005	1033	1034	I-Observation
at	9935005	1035	1037	O
10	9935005	1038	1040	B-Intervention
s	9935005	1041	1042	I-Intervention
of	9935005	1043	1045	I-Intervention
VF	9935005	1046	1048	I-Intervention
to	9935005	1049	1051	O
12.6+/-5.6	9935005	1052	1062	B-Observation
J	9935005	1063	1064	I-Observation
(	9935005	1065	1066	O
p=0.03	9935005	1067	1073	O
)	9935005	1074	1075	O
at	9935005	1076	1078	O
20	9935005	1079	1081	B-Intervention
s	9935005	1082	1083	I-Intervention
of	9935005	1084	1086	I-Intervention
VF	9935005	1087	1089	I-Intervention
,	9935005	1090	1091	O
and	9935005	1092	1095	O
from	9935005	1096	1100	O
7.0+/-3.5	9935005	1101	1110	B-Observation
J	9935005	1111	1112	I-Observation
at	9935005	1113	1115	O
5	9935005	1116	1117	B-Intervention
s	9935005	1118	1119	I-Intervention
of	9935005	1120	1122	I-Intervention
VF	9935005	1123	1125	I-Intervention
to	9935005	1126	1128	O
10.5+/-6.3	9935005	1129	1139	B-Observation
J	9935005	1140	1141	I-Observation
(	9935005	1142	1143	O
p=0.04	9935005	1144	1150	O
)	9935005	1151	1152	O
at	9935005	1153	1155	O
20	9935005	1156	1158	B-Intervention
s	9935005	1159	1160	I-Intervention
of	9935005	1161	1163	I-Intervention
VF	9935005	1164	1166	I-Intervention
.	9935005	1167	1168	O

An	9935005	1169	1171	O
increase	9935005	1172	1180	B-Observation
in	9935005	1181	1183	O
the	9935005	1184	1187	O
DFT	9935005	1188	1191	B-Outcome
was	9935005	1192	1195	O
observed	9935005	1196	1204	O
in	9935005	1205	1207	O
14	9935005	1208	1210	B-Count
patients	9935005	1211	1219	I-Count
as	9935005	1220	1222	O
VF	9935005	1223	1225	B-Intervention
duration	9935005	1226	1234	I-Intervention
increased	9935005	1235	1244	I-Intervention
.	9935005	1245	1246	O

There	9935005	1247	1252	O
were	9935005	1253	1257	O
no	9935005	1258	1260	O
clinical	9935005	1261	1269	B-Outcome
characteristics	9935005	1270	1285	I-Outcome
that	9935005	1286	1290	O
differentiated	9935005	1291	1305	B-Observation
patients	9935005	1306	1314	O
with	9935005	1315	1319	B-Intervention
and	9935005	1320	1323	I-Intervention
without	9935005	1324	1331	I-Intervention
an	9935005	1332	1334	I-Intervention
increase	9935005	1335	1343	I-Intervention
in	9935005	1344	1346	I-Intervention
the	9935005	1347	1350	I-Intervention
DFT	9935005	1351	1354	I-Intervention
.	9935005	1355	1356	O

CONCLUSIONS	9935005	1357	1368	O
Defibrillation	9935005	1369	1383	B-Outcome
efficacy	9935005	1384	1392	I-Outcome
decreases	9935005	1393	1402	B-Observation
with	9935005	1403	1407	O
increasing	9935005	1408	1418	B-Intervention
VF	9935005	1419	1421	I-Intervention
duration	9935005	1422	1430	I-Intervention
using	9935005	1431	1436	O
biphasic	9935005	1437	1445	O
waveforms	9935005	1446	1455	O
in	9935005	1456	1458	O
humans	9935005	1459	1465	B-Participant
.	9935005	1466	1467	O

Ventricular	9935005	1468	1479	B-Intervention
fibrillation	9935005	1480	1492	I-Intervention
durations	9935005	1493	1502	I-Intervention
greater	9935005	1503	1510	I-Intervention
than	9935005	1511	1515	I-Intervention
10	9935005	1516	1518	I-Intervention
s	9935005	1519	1520	I-Intervention
may	9935005	1521	1524	O
negatively	9935005	1525	1535	B-Observation
affect	9935005	1536	1542	I-Observation
the	9935005	1543	1546	O
effectiveness	9935005	1547	1560	B-Outcome
of	9935005	1561	1563	I-Outcome
ICD	9935005	1564	1567	I-Outcome
therapy	9935005	1568	1575	I-Outcome
.	9935005	1576	1577	O

Active	9950438	0	6	B-Intervention
specific	9950438	7	15	I-Intervention
immunotherapy	9950438	16	29	I-Intervention
for	9950438	30	33	O
stage	9950438	34	39	B-Participant
II	9950438	40	42	I-Participant
and	9950438	43	46	I-Participant
stage	9950438	47	52	I-Participant
III	9950438	53	56	I-Participant
human	9950438	57	62	I-Participant
colon	9950438	63	68	I-Participant
cancer	9950438	69	75	I-Participant
:	9950438	76	77	O
a	9950438	78	79	O
randomised	9950438	80	90	O
trial	9950438	91	96	O
.	9950438	97	98	O

BACKGROUND	9950438	99	109	O
Colon	9950438	110	115	O
cancer	9950438	116	122	O
is	9950438	123	125	O
curable	9950438	126	133	O
by	9950438	134	136	O
surgery	9950438	137	144	O
,	9950438	145	146	O
but	9950438	147	150	O
cure	9950438	151	155	O
rate	9950438	156	160	O
depends	9950438	161	168	O
on	9950438	169	171	O
the	9950438	172	175	O
extent	9950438	176	182	O
of	9950438	183	185	O
disease	9950438	186	193	O
.	9950438	194	195	O

We	9950438	196	198	O
investigated	9950438	199	211	O
whether	9950438	212	219	O
adjuvant	9950438	220	228	B-Intervention
active	9950438	229	235	I-Intervention
specific	9950438	236	244	I-Intervention
immunotherapy	9950438	245	258	I-Intervention
(	9950438	259	260	I-Intervention
ASI	9950438	261	264	I-Intervention
)	9950438	265	266	I-Intervention
with	9950438	267	271	I-Intervention
an	9950438	272	274	I-Intervention
autologous	9950438	275	285	I-Intervention
tumour	9950438	286	292	I-Intervention
cell-BCG	9950438	293	301	I-Intervention
vaccine	9950438	302	309	I-Intervention
with	9950438	310	314	I-Intervention
surgical	9950438	315	323	I-Intervention
resection	9950438	324	333	I-Intervention
was	9950438	334	337	O
more	9950438	338	342	B-Observation
beneficial	9950438	343	353	I-Observation
than	9950438	354	358	O
resection	9950438	359	368	B-Intervention
alone	9950438	369	374	I-Intervention
in	9950438	375	377	O
stage	9950438	378	383	B-Participant
II	9950438	384	386	I-Participant
and	9950438	387	390	I-Participant
III	9950438	391	394	I-Participant
colon	9950438	395	400	I-Participant
cancer	9950438	401	407	I-Participant
.	9950438	408	409	O

METHODS	9950438	410	417	O
In	9950438	418	420	O
a	9950438	421	422	O
prospective	9950438	423	434	O
randomised	9950438	435	445	O
trial	9950438	446	451	O
,	9950438	452	453	O
254	9950438	454	457	O
patients	9950438	458	466	O
with	9950438	467	471	O
colon	9950438	472	477	B-Participant
cancer	9950438	478	484	I-Participant
were	9950438	485	489	O
randomly	9950438	490	498	O
assigned	9950438	499	507	O
postoperative	9950438	508	521	B-Intervention
ASI	9950438	522	525	I-Intervention
or	9950438	526	528	O
no	9950438	529	531	B-Intervention
adjuvant	9950438	532	540	I-Intervention
treatment	9950438	541	550	I-Intervention
.	9950438	551	552	O

ASI	9950438	553	556	B-Intervention
was	9950438	557	560	O
three	9950438	561	566	O
weekly	9950438	567	573	O
vaccinations	9950438	574	586	O
starting	9950438	587	595	O
4	9950438	596	597	O
weeks	9950438	598	603	O
after	9950438	604	609	O
surgery	9950438	610	617	O
,	9950438	618	619	O
with	9950438	620	624	O
a	9950438	625	626	O
booster	9950438	627	634	O
vaccination	9950438	635	646	O
at	9950438	647	649	O
6	9950438	650	651	O
months	9950438	652	658	O
with	9950438	659	663	O
10	9950438	664	666	O
(	9950438	667	668	O
7	9950438	669	670	O
)	9950438	671	672	O
irradiated	9950438	673	683	O
autologous	9950438	684	694	O
tumour	9950438	695	701	O
cells	9950438	702	707	O
.	9950438	708	709	O

The	9950438	710	713	O
first	9950438	714	719	O
vaccinations	9950438	720	732	O
contained	9950438	733	742	O
10	9950438	743	745	O
(	9950438	746	747	O
7	9950438	748	749	O
)	9950438	750	751	O
BCG	9950438	752	755	O
organisms	9950438	756	765	O
.	9950438	766	767	O

We	9950438	768	770	O
followed	9950438	771	779	O
up	9950438	780	782	O
patients	9950438	783	791	O
for	9950438	792	795	O
time	9950438	796	800	B-Outcome
to	9950438	801	803	I-Outcome
recurrence	9950438	804	814	I-Outcome
,	9950438	815	816	O
and	9950438	817	820	O
recurrence-free	9950438	821	836	B-Outcome
and	9950438	837	840	O
overall	9950438	841	848	B-Outcome
survival	9950438	849	857	I-Outcome
.	9950438	858	859	O

Analysis	9950438	860	868	O
was	9950438	869	872	O
by	9950438	873	875	O
intention	9950438	876	885	O
to	9950438	886	888	O
treat	9950438	889	894	O
.	9950438	895	896	O

FINDINGS	9950438	897	905	O
The	9950438	906	909	O
5.3	9950438	910	913	O
year	9950438	914	918	O
median	9950438	919	925	O
follow-up	9950438	926	935	O
(	9950438	936	937	O
range	9950438	938	943	O
8	9950438	944	945	O
months	9950438	946	952	O
to	9950438	953	955	O
8	9950438	956	957	O
years	9950438	958	963	O
11	9950438	964	966	O
months	9950438	967	973	O
)	9950438	974	975	O
showed	9950438	976	982	O
44	9950438	983	985	B-Observation
%	9950438	986	987	I-Observation
(	9950438	988	989	O
95	9950438	990	992	O
%	9950438	993	994	O
CI	9950438	995	997	O
7	9950438	998	999	O
-	9950438	999	1000	O
66	9950438	1000	1002	O
)	9950438	1003	1004	O
risk	9950438	1005	1009	B-Outcome
reduction	9950438	1010	1019	I-Outcome
for	9950438	1020	1023	I-Outcome
recurrence	9950438	1024	1034	I-Outcome
in	9950438	1035	1037	O
the	9950438	1038	1041	O
recurrence-free	9950438	1042	1057	O
period	9950438	1058	1064	O
in	9950438	1065	1067	O
all	9950438	1068	1071	O
patients	9950438	1072	1080	O
receiving	9950438	1081	1090	O
ASI	9950438	1091	1094	B-Intervention
(	9950438	1095	1096	O
p=0.023	9950438	1097	1104	O
)	9950438	1105	1106	O
.	9950438	1107	1108	O

Overall	9950438	1109	1116	O
,	9950438	1117	1118	O
there	9950438	1119	1124	O
were	9950438	1125	1129	O
40	9950438	1130	1132	B-Count
recurrences	9950438	1133	1144	B-Outcome
in	9950438	1145	1147	O
the	9950438	1148	1151	O
control	9950438	1152	1159	B-Intervention
group	9950438	1160	1165	O
and	9950438	1166	1169	O
25	9950438	1170	1172	B-Count
in	9950438	1173	1175	O
the	9950438	1176	1179	O
ASI	9950438	1180	1183	B-Intervention
group	9950438	1184	1189	O
.	9950438	1190	1191	O

Analysis	9950438	1192	1200	O
by	9950438	1201	1203	O
stage	9950438	1204	1209	O
showed	9950438	1210	1216	O
no	9950438	1217	1219	O
significant	9950438	1220	1231	B-Observation
benefit	9950438	1232	1239	I-Observation
of	9950438	1240	1242	O
ASI	9950438	1243	1246	B-Intervention
in	9950438	1247	1249	O
stage	9950438	1250	1255	B-Participant
III	9950438	1256	1259	I-Participant
disease	9950438	1260	1267	I-Participant
.	9950438	1268	1269	O

The	9950438	1270	1273	O
major	9950438	1274	1279	O
impact	9950438	1280	1286	O
of	9950438	1287	1289	O
ASI	9950438	1290	1293	B-Intervention
was	9950438	1294	1297	O
seen	9950438	1298	1302	O
in	9950438	1303	1305	O
patients	9950438	1306	1314	O
with	9950438	1315	1319	O
stage	9950438	1320	1325	B-Participant
II	9950438	1326	1328	I-Participant
disease	9950438	1329	1336	I-Participant
,	9950438	1337	1338	O
with	9950438	1339	1343	O
a	9950438	1344	1345	O
significantly	9950438	1346	1359	B-Observation
longer	9950438	1360	1366	I-Observation
recurrence-free	9950438	1367	1382	B-Outcome
period	9950438	1383	1389	I-Outcome
(	9950438	1390	1391	O
p=0.011	9950438	1392	1399	O
)	9950438	1400	1401	O
and	9950438	1402	1405	O
61	9950438	1406	1408	B-Observation
%	9950438	1409	1410	I-Observation
(	9950438	1411	1412	O
18	9950438	1413	1415	O
-	9950438	1415	1416	O
81	9950438	1416	1418	O
)	9950438	1419	1420	O
risk	9950438	1421	1425	B-Outcome
reduction	9950438	1426	1435	I-Outcome
for	9950438	1436	1439	I-Outcome
recurrences	9950438	1440	1451	I-Outcome
.	9950438	1452	1453	O

Recurrence-free	9950438	1454	1469	B-Outcome
survival	9950438	1470	1478	I-Outcome
was	9950438	1479	1482	O
significantly	9950438	1483	1496	B-Observation
longer	9950438	1497	1503	I-Observation
with	9950438	1504	1508	O
ASI	9950438	1509	1512	B-Intervention
(	9950438	1513	1514	O
42	9950438	1515	1517	B-Observation
%	9950438	1518	1519	I-Observation
risk	9950438	1520	1524	B-Outcome
reduction	9950438	1525	1534	I-Outcome
for	9950438	1535	1538	I-Outcome
recurrence	9950438	1539	1549	I-Outcome
or	9950438	1550	1552	I-Outcome
death	9950438	1553	1558	I-Outcome
[	9950438	1559	1560	O
0	9950438	1561	1562	O
-	9950438	1562	1563	O
68	9950438	1563	1565	O
]	9950438	1566	1567	O
,	9950438	1568	1569	O
p=0.032	9950438	1570	1577	O
)	9950438	1578	1579	O
and	9950438	1580	1583	O
there	9950438	1584	1589	O
was	9950438	1590	1593	O
a	9950438	1594	1595	O
trend	9950438	1596	1601	B-Observation
towards	9950438	1602	1609	I-Observation
improved	9950438	1610	1618	I-Observation
overall	9950438	1619	1626	B-Outcome
survival	9950438	1627	1635	I-Outcome
.	9950438	1636	1637	O

INTERPRETATION	9950438	1638	1652	O
ASI	9950438	1653	1656	B-Intervention
gave	9950438	1657	1661	O
significant	9950438	1662	1673	B-Observation
clinical	9950438	1674	1682	I-Observation
benefit	9950438	1683	1690	I-Observation
in	9950438	1691	1693	O
surgically	9950438	1694	1704	B-Participant
resected	9950438	1705	1713	I-Participant
patients	9950438	1714	1722	O
with	9950438	1723	1727	O
stage	9950438	1728	1733	B-Participant
II	9950438	1734	1736	I-Participant
colon	9950438	1737	1742	I-Participant
cancer	9950438	1743	1749	I-Participant
.	9950438	1750	1751	O

ASI	9950438	1752	1755	B-Intervention
has	9950438	1756	1759	O
minimal	9950438	1760	1767	B-Observation
adverse	9950438	1768	1775	B-Outcome
reactions	9950438	1776	1785	I-Outcome
and	9950438	1786	1789	O
should	9950438	1790	1796	O
be	9950438	1797	1799	O
considered	9950438	1800	1810	O
in	9950438	1811	1813	O
the	9950438	1814	1817	O
management	9950438	1818	1828	O
of	9950438	1829	1831	O
stage	9950438	1832	1837	B-Participant
II	9950438	1838	1840	I-Participant
colon	9950438	1841	1846	I-Participant
cancer	9950438	1847	1853	I-Participant
.	9950438	1854	1855	O

A	9951491	0	1	O
randomized	9951491	2	12	O
,	9951491	13	14	O
double-masked	9951491	15	28	O
,	9951491	29	30	O
placebo-controlled	9951491	31	49	O
parallel	9951491	50	58	O
study	9951491	59	64	O
of	9951491	65	67	O
loteprednol	9951491	68	79	B-Intervention
etabonate	9951491	80	89	I-Intervention
0.2	9951491	90	93	I-Intervention
%	9951491	94	95	I-Intervention
in	9951491	96	98	O
patients	9951491	99	107	O
with	9951491	108	112	O
seasonal	9951491	113	121	B-Participant
allergic	9951491	122	130	I-Participant
conjunctivitis	9951491	131	145	I-Participant
.	9951491	146	147	O

OBJECTIVE	9951491	148	157	O
To	9951491	158	160	O
evaluate	9951491	161	169	O
the	9951491	170	173	O
effects	9951491	174	181	O
of	9951491	182	184	O
loteprednol	9951491	185	196	B-Intervention
etabonate	9951491	197	206	I-Intervention
(	9951491	207	208	I-Intervention
LE	9951491	209	211	I-Intervention
)	9951491	212	213	I-Intervention
0.2	9951491	214	217	I-Intervention
%	9951491	218	219	I-Intervention
in	9951491	220	222	O
reducing	9951491	223	231	B-Observation
the	9951491	232	235	O
signs	9951491	236	241	B-Outcome
and	9951491	242	245	O
symptoms	9951491	246	254	B-Outcome
of	9951491	255	257	O
seasonal	9951491	258	266	B-Participant
allergic	9951491	267	275	I-Participant
conjunctivitis	9951491	276	290	I-Participant
.	9951491	291	292	O

DESIGN	9951491	293	299	O
Randomized	9951491	300	310	O
,	9951491	311	312	O
double-masked	9951491	313	326	O
,	9951491	327	328	O
placebo-controlled	9951491	329	347	O
,	9951491	348	349	O
parallel	9951491	350	358	O
group	9951491	359	364	O
multicenter	9951491	365	376	O
study	9951491	377	382	O
of	9951491	383	385	O
6	9951491	386	387	O
weeks	9951491	388	393	O
duration	9951491	394	402	O
.	9951491	403	404	O

PARTICIPANTS	9951491	405	417	O
A	9951491	418	419	O
total	9951491	420	425	O
of	9951491	426	428	O
135	9951491	429	432	O
patients	9951491	433	441	O
with	9951491	442	446	O
signs	9951491	447	452	O
and	9951491	453	456	O
symptoms	9951491	457	465	O
of	9951491	466	468	O
seasonal	9951491	469	477	B-Participant
allergic	9951491	478	486	I-Participant
conjunctivitis	9951491	487	501	I-Participant
participated	9951491	502	514	O
.	9951491	515	516	O

INTERVENTION	9951491	517	529	O
All	9951491	530	533	O
patients	9951491	534	542	O
received	9951491	543	551	O
either	9951491	552	558	O
LE	9951491	559	561	B-Intervention
0.2	9951491	562	565	I-Intervention
%	9951491	566	567	I-Intervention
or	9951491	568	570	O
placebo	9951491	571	578	B-Intervention
(	9951491	579	580	I-Intervention
vehicle	9951491	581	588	I-Intervention
)	9951491	589	590	I-Intervention
four	9951491	591	595	O
times	9951491	596	601	O
a	9951491	602	603	O
day	9951491	604	607	O
in	9951491	608	610	O
both	9951491	611	615	O
eyes	9951491	616	620	O
for	9951491	621	624	O
42	9951491	625	627	O
days	9951491	628	632	O
.	9951491	633	634	O

MAIN	9951491	635	639	O
OUTCOME	9951491	640	647	O
MEASURES	9951491	648	656	O
Bulbar	9951491	657	663	B-Outcome
conjunctival	9951491	664	676	I-Outcome
injection	9951491	677	686	I-Outcome
(	9951491	687	688	O
primary	9951491	689	696	O
sign	9951491	697	701	O
)	9951491	702	703	O
and	9951491	704	707	O
itching	9951491	708	715	B-Outcome
(	9951491	716	717	O
primary	9951491	718	725	O
symptom	9951491	726	733	O
)	9951491	734	735	O
over	9951491	736	740	O
the	9951491	741	744	O
first	9951491	745	750	O
2	9951491	751	752	O
weeks	9951491	753	758	O
of	9951491	759	761	O
treatment	9951491	762	771	B-Intervention
was	9951491	772	775	O
measured	9951491	776	784	O
.	9951491	785	786	O

RESULTS	9951491	787	794	O
A	9951491	795	796	O
reduction	9951491	797	806	B-Observation
in	9951491	807	809	O
severity	9951491	810	818	B-Outcome
was	9951491	819	822	O
seen	9951491	823	827	O
in	9951491	828	830	O
both	9951491	831	835	O
LE	9951491	836	838	B-Intervention
and	9951491	839	842	O
placebo	9951491	843	850	B-Intervention
groups	9951491	851	857	O
for	9951491	858	861	O
bulbar	9951491	862	868	B-Outcome
conjunctival	9951491	869	881	I-Outcome
injection	9951491	882	891	I-Outcome
(	9951491	892	893	O
1.5	9951491	894	897	B-Observation
vs.	9951491	898	901	O
1.0	9951491	902	905	B-Observation
units	9951491	906	911	I-Observation
on	9951491	912	914	O
a	9951491	915	916	O
0	9951491	917	918	O
-	9951491	918	919	O
3	9951491	919	920	O
scale	9951491	921	926	O
)	9951491	927	928	O
and	9951491	929	932	O
itching	9951491	933	940	B-Outcome
(	9951491	941	942	O
3.4	9951491	943	946	B-Observation
vs.	9951491	947	950	O
3.0	9951491	951	954	B-Observation
units	9951491	955	960	I-Observation
on	9951491	961	963	O
a	9951491	964	965	O
0	9951491	966	967	O
-	9951491	967	968	O
4	9951491	968	969	O
scale	9951491	970	975	O
)	9951491	976	977	O
over	9951491	978	982	O
the	9951491	983	986	O
first	9951491	987	992	O
2	9951491	993	994	O
weeks	9951491	995	1000	O
.	9951491	1001	1002	O

The	9951491	1003	1006	O
treatment	9951491	1007	1016	B-Outcome
effect	9951491	1017	1023	I-Outcome
by	9951491	1024	1026	O
these	9951491	1027	1032	O
measures	9951491	1033	1041	O
was	9951491	1042	1045	O
-0.5	9951491	1046	1050	B-Observation
and	9951491	1051	1054	O
-0.4	9951491	1055	1059	B-Observation
units	9951491	1060	1065	I-Observation
in	9951491	1066	1068	O
favor	9951491	1069	1074	O
of	9951491	1075	1077	O
LE	9951491	1078	1080	B-Intervention
(	9951491	1081	1082	O
P	9951491	1083	1084	O
<	9951491	1085	1086	O
or	9951491	1087	1089	O
=	9951491	1090	1091	O
0.008	9951491	1092	1097	O
)	9951491	1098	1099	O
.	9951491	1100	1101	O

Resolution	9951491	1102	1112	B-Outcome
(	9951491	1113	1114	O
i.e.	9951491	1115	1119	O
,	9951491	1120	1121	O
the	9951491	1122	1125	O
proportion	9951491	1126	1136	O
of	9951491	1137	1139	O
patients	9951491	1140	1148	O
with	9951491	1149	1153	O
signs	9951491	1154	1159	O
or	9951491	1160	1162	O
symptoms	9951491	1163	1171	O
no	9951491	1172	1174	O
longer	9951491	1175	1181	O
present	9951491	1182	1189	O
)	9951491	1190	1191	O
at	9951491	1192	1194	O
day	9951491	1195	1198	O
14	9951491	1199	1201	O
strongly	9951491	1202	1210	B-Observation
favored	9951491	1211	1218	I-Observation
LE-treated	9951491	1219	1229	B-Intervention
patients	9951491	1230	1238	O
(	9951491	1239	1240	O
36	9951491	1241	1243	B-Count
%	9951491	1244	1245	I-Count
and	9951491	1246	1249	O
15	9951491	1250	1252	B-Count
%	9951491	1253	1254	I-Count
;	9951491	1255	1256	O
58	9951491	1257	1259	B-Count
%	9951491	1260	1261	I-Count
and	9951491	1262	1265	O
38	9951491	1266	1268	B-Count
%	9951491	1269	1270	I-Count
,	9951491	1271	1272	O
for	9951491	1273	1276	O
injection	9951491	1277	1286	B-Outcome
and	9951491	1287	1290	O
itching	9951491	1291	1298	B-Outcome
,	9951491	1299	1300	O
respectively	9951491	1301	1313	O
)	9951491	1314	1315	O
.	9951491	1316	1317	O

Both	9951491	1318	1322	O
treatments	9951491	1323	1333	O
were	9951491	1334	1338	O
well	9951491	1339	1343	O
tolerated	9951491	1344	1353	O
.	9951491	1354	1355	O

One	9951491	1356	1359	B-Count
patient	9951491	1360	1367	I-Count
in	9951491	1368	1370	O
each	9951491	1371	1375	B-Intervention
treatment	9951491	1376	1385	I-Intervention
group	9951491	1386	1391	I-Intervention
(	9951491	1392	1393	O
1	9951491	1394	1395	B-Count
of	9951491	1396	1398	I-Count
67	9951491	1399	1401	I-Count
and	9951491	1402	1405	O
1	9951491	1406	1407	B-Count
of	9951491	1408	1410	I-Count
68	9951491	1411	1413	I-Count
,	9951491	1414	1415	O
respectively	9951491	1416	1428	O
)	9951491	1429	1430	O
had	9951491	1431	1434	O
an	9951491	1435	1437	O
elevation	9951491	1438	1447	B-Observation
of	9951491	1448	1450	O
intraocular	9951491	1451	1462	B-Outcome
pressure	9951491	1463	1471	I-Outcome
of	9951491	1472	1474	O
10	9951491	1475	1477	O
mmHg	9951491	1478	1482	O
or	9951491	1483	1485	O
greater	9951491	1486	1493	O
during	9951491	1494	1500	O
the	9951491	1501	1504	O
6	9951491	1505	1506	O
weeks	9951491	1507	1512	O
of	9951491	1513	1515	O
treatment	9951491	1516	1525	O
.	9951491	1526	1527	O

CONCLUSIONS	9951491	1528	1539	O
Loteprednol	9951491	1540	1551	B-Intervention
etabonate	9951491	1552	1561	I-Intervention
0.2	9951491	1562	1565	I-Intervention
%	9951491	1566	1567	I-Intervention
was	9951491	1568	1571	O
more	9951491	1572	1576	B-Observation
effective	9951491	1577	1586	I-Observation
than	9951491	1587	1591	O
placebo	9951491	1592	1599	B-Intervention
in	9951491	1600	1602	O
the	9951491	1603	1606	O
treatment	9951491	1607	1616	O
of	9951491	1617	1619	O
seasonal	9951491	1620	1628	B-Participant
allergic	9951491	1629	1637	I-Participant
conjunctivitis	9951491	1638	1652	I-Participant
.	9951491	1653	1654	O

Loteprednol	9951491	1655	1666	B-Intervention
etabonate	9951491	1667	1676	I-Intervention
0.2	9951491	1677	1680	I-Intervention
%	9951491	1681	1682	I-Intervention
had	9951491	1683	1686	O
a	9951491	1687	1688	O
safety	9951491	1689	1695	B-Outcome
profile	9951491	1696	1703	I-Outcome
comparable	9951491	1704	1714	B-Observation
to	9951491	1715	1717	O
placebo	9951491	1718	1725	B-Intervention
.	9951491	1726	1727	O

[	9987969	0	1	O
The	9987969	2	5	O
efficacy	9987969	6	14	B-Outcome
of	9987969	15	17	O
psychotherapy	9987969	18	31	B-Intervention
with	9987969	32	36	I-Intervention
biofeedback	9987969	37	48	I-Intervention
in	9987969	49	51	O
the	9987969	52	55	O
rehabilitation	9987969	56	70	B-Participant
of	9987969	71	73	O
hypertension	9987969	74	86	B-Participant
patients	9987969	87	95	O
]	9987969	96	97	O
.	9987969	98	99	O

85	9987969	100	102	O
females	9987969	103	110	B-Participant
with	9987969	111	115	O
borderline	9987969	116	126	B-Participant
mental	9987969	127	133	I-Participant
disorders	9987969	134	143	I-Participant
in	9987969	144	146	O
essential	9987969	147	156	B-Participant
hypertension	9987969	157	169	I-Participant
were	9987969	170	174	O
followed	9987969	175	183	O
up	9987969	184	186	O
for	9987969	187	190	O
a	9987969	191	192	O
month	9987969	193	198	O
and	9987969	199	202	O
6	9987969	203	204	O
months	9987969	205	211	O
after	9987969	212	217	O
the	9987969	218	221	O
treatment	9987969	222	231	B-Intervention
(	9987969	232	233	O
hypotensive	9987969	234	245	B-Intervention
drugs	9987969	246	251	I-Intervention
+	9987969	252	253	I-Intervention
psychotherapy	9987969	254	267	I-Intervention
with	9987969	268	272	I-Intervention
biofeedback	9987969	273	284	I-Intervention
or	9987969	285	287	O
hypotensive	9987969	288	299	B-Intervention
drugs	9987969	300	305	I-Intervention
only	9987969	306	310	I-Intervention
--	9987969	311	313	O
45	9987969	314	316	O
patients	9987969	317	325	O
and	9987969	326	329	O
40	9987969	330	332	O
controls	9987969	333	341	O
,	9987969	342	343	O
respectively	9987969	344	356	O
)	9987969	357	358	O
.	9987969	359	360	O

The	9987969	361	364	O
addition	9987969	365	373	B-Intervention
of	9987969	374	376	I-Intervention
psychotherapy	9987969	377	390	I-Intervention
to	9987969	391	393	I-Intervention
hypotensive	9987969	394	405	I-Intervention
drugs	9987969	406	411	I-Intervention
contributed	9987969	412	423	O
to	9987969	424	426	O
a	9987969	427	428	O
higher	9987969	429	435	B-Observation
hypotensive	9987969	436	447	B-Outcome
effect	9987969	448	454	I-Outcome
,	9987969	455	456	O
long-term	9987969	457	466	B-Observation
improvement	9987969	467	478	I-Observation
of	9987969	479	481	O
psychic	9987969	482	489	B-Outcome
condition	9987969	490	499	I-Outcome
,	9987969	500	501	O
more	9987969	502	506	B-Observation
active	9987969	507	513	I-Observation
attitude	9987969	514	522	B-Outcome
to	9987969	523	525	I-Outcome
the	9987969	526	529	I-Outcome
treatment	9987969	530	539	I-Outcome
process	9987969	540	547	I-Outcome
and	9987969	548	551	I-Outcome
psychic	9987969	552	559	I-Outcome
adaptation	9987969	560	570	I-Outcome
.	9987969	571	572	O

Better	9987969	573	579	B-Observation
quality	9987969	580	587	B-Outcome
of	9987969	588	590	I-Outcome
life	9987969	591	595	I-Outcome
was	9987969	596	599	O
achieved	9987969	600	608	O
.	9987969	609	610	O

Effectiveness	9989713	0	13	B-Outcome
of	9989713	14	16	O
active	9989713	17	23	B-Intervention
physical	9989713	24	32	I-Intervention
training	9989713	33	41	I-Intervention
as	9989713	42	44	O
treatment	9989713	45	54	O
for	9989713	55	58	O
long-standing	9989713	59	72	B-Participant
adductor-related	9989713	73	89	I-Participant
groin	9989713	90	95	I-Participant
pain	9989713	96	100	I-Participant
in	9989713	101	103	O
athletes	9989713	104	112	B-Participant
:	9989713	113	114	O
randomised	9989713	115	125	O
trial	9989713	126	131	O
.	9989713	132	133	O

BACKGROUND	9989713	134	144	O
Groin	9989713	145	150	O
pain	9989713	151	155	O
is	9989713	156	158	O
common	9989713	159	165	O
among	9989713	166	171	O
athletes	9989713	172	180	O
.	9989713	181	182	O

A	9989713	183	184	O
major	9989713	185	190	O
cause	9989713	191	196	O
of	9989713	197	199	O
long-standing	9989713	200	213	O
problems	9989713	214	222	O
is	9989713	223	225	O
adductor-related	9989713	226	242	O
groin	9989713	243	248	O
pain	9989713	249	253	O
.	9989713	254	255	O

The	9989713	256	259	O
purpose	9989713	260	267	O
of	9989713	268	270	O
this	9989713	271	275	O
randomised	9989713	276	286	O
clinical	9989713	287	295	O
trial	9989713	296	301	O
was	9989713	302	305	O
to	9989713	306	308	O
compare	9989713	309	316	O
an	9989713	317	319	O
active	9989713	320	326	B-Intervention
training	9989713	327	335	I-Intervention
programme	9989713	336	345	I-Intervention
(	9989713	346	347	I-Intervention
AT	9989713	348	350	I-Intervention
)	9989713	351	352	I-Intervention
with	9989713	353	357	O
a	9989713	358	359	O
physiotherapy	9989713	360	373	B-Intervention
treatment	9989713	374	383	I-Intervention
without	9989713	384	391	I-Intervention
active	9989713	392	398	I-Intervention
training	9989713	399	407	I-Intervention
(	9989713	408	409	I-Intervention
PT	9989713	410	412	I-Intervention
)	9989713	413	414	I-Intervention
in	9989713	415	417	O
the	9989713	418	421	O
treatment	9989713	422	431	O
of	9989713	432	434	O
adductor-related	9989713	435	451	B-Participant
groin	9989713	452	457	I-Participant
pain	9989713	458	462	I-Participant
in	9989713	463	465	O
athletes	9989713	466	474	B-Participant
.	9989713	475	476	O

METHODS	9989713	477	484	O
68	9989713	485	487	O
athletes	9989713	488	496	B-Participant
with	9989713	497	501	O
long-standing	9989713	502	515	B-Participant
(	9989713	516	517	I-Participant
median	9989713	518	524	I-Participant
40	9989713	525	527	I-Participant
weeks	9989713	528	533	I-Participant
)	9989713	534	535	I-Participant
adductor-related	9989713	536	552	I-Participant
groin	9989713	553	558	I-Participant
pain	9989713	559	563	I-Participant
--	9989713	564	566	O
after	9989713	567	572	O
examination	9989713	573	584	O
according	9989713	585	594	O
to	9989713	595	597	O
a	9989713	598	599	O
standardised	9989713	600	612	O
protocol	9989713	613	621	O
--	9989713	622	624	O
were	9989713	625	629	O
randomly	9989713	630	638	O
assigned	9989713	639	647	O
to	9989713	648	650	O
AT	9989713	651	653	B-Intervention
or	9989713	654	656	O
PT	9989713	657	659	B-Intervention
.	9989713	660	661	O

The	9989713	662	665	O
treatment	9989713	666	675	O
period	9989713	676	682	O
was	9989713	683	686	O
8	9989713	687	688	O
-	9989713	688	689	O
12	9989713	689	691	O
weeks	9989713	692	697	O
.	9989713	698	699	O

4	9989713	700	701	O
months	9989713	702	708	O
after	9989713	709	714	O
the	9989713	715	718	O
end	9989713	719	722	O
of	9989713	723	725	O
treatment	9989713	726	735	O
a	9989713	736	737	O
standardised	9989713	738	750	O
examination	9989713	751	762	O
was	9989713	763	766	O
done	9989713	767	771	O
.	9989713	772	773	O

The	9989713	774	777	O
examining	9989713	778	787	O
physician	9989713	788	797	O
was	9989713	798	801	O
unaware	9989713	802	809	O
of	9989713	810	812	O
the	9989713	813	816	O
treatment	9989713	817	826	O
allocation	9989713	827	837	O
.	9989713	838	839	O

The	9989713	840	843	O
ultimate	9989713	844	852	O
outcome	9989713	853	860	O
measure	9989713	861	868	O
was	9989713	869	872	O
full	9989713	873	877	B-Outcome
return	9989713	878	884	I-Outcome
to	9989713	885	887	I-Outcome
sports	9989713	888	894	I-Outcome
at	9989713	895	897	I-Outcome
the	9989713	898	901	I-Outcome
same	9989713	902	906	I-Outcome
level	9989713	907	912	I-Outcome
without	9989713	913	920	I-Outcome
groin	9989713	921	926	I-Outcome
pain	9989713	927	931	I-Outcome
.	9989713	932	933	O

Analyses	9989713	934	942	O
were	9989713	943	947	O
by	9989713	948	950	O
intention	9989713	951	960	O
to	9989713	961	963	O
treat	9989713	964	969	O
.	9989713	970	971	O

FINDINGS	9989713	972	980	O
23	9989713	981	983	B-Count
patients	9989713	984	992	I-Count
in	9989713	993	995	O
the	9989713	996	999	O
AT	9989713	1000	1002	B-Intervention
group	9989713	1003	1008	O
and	9989713	1009	1012	O
four	9989713	1013	1017	B-Count
in	9989713	1018	1020	O
the	9989713	1021	1024	O
PT	9989713	1025	1027	B-Intervention
group	9989713	1028	1033	O
returned	9989713	1034	1042	B-Outcome
to	9989713	1043	1045	I-Outcome
sports	9989713	1046	1052	I-Outcome
without	9989713	1053	1060	I-Outcome
groin	9989713	1061	1066	I-Outcome
pain	9989713	1067	1071	I-Outcome
(	9989713	1072	1073	O
odds	9989713	1074	1078	O
ratio	9989713	1079	1084	O
,	9989713	1085	1086	O
multiple-logistic-regression	9989713	1087	1115	O
analysis	9989713	1116	1124	O
,	9989713	1125	1126	O
12.7	9989713	1127	1131	O
[	9989713	1132	1133	O
95	9989713	1134	1136	O
%	9989713	1137	1138	O
CI	9989713	1139	1141	O
3.4	9989713	1142	1145	O
-	9989713	1145	1146	O
47.2	9989713	1146	1150	O
]	9989713	1151	1152	O
)	9989713	1153	1154	O
.	9989713	1155	1156	O

The	9989713	1157	1160	O
subjective	9989713	1161	1171	B-Outcome
global	9989713	1172	1178	I-Outcome
assessments	9989713	1179	1190	I-Outcome
of	9989713	1191	1193	I-Outcome
the	9989713	1194	1197	I-Outcome
effect	9989713	1198	1204	I-Outcome
of	9989713	1205	1207	I-Outcome
the	9989713	1208	1211	I-Outcome
treatments	9989713	1212	1222	I-Outcome
showed	9989713	1223	1229	O
a	9989713	1230	1231	O
significant	9989713	1232	1243	B-Observation
(	9989713	1244	1245	I-Observation
p=0.006	9989713	1246	1253	I-Observation
)	9989713	1254	1255	I-Observation
linear	9989713	1256	1262	I-Observation
trend	9989713	1263	1268	I-Observation
towards	9989713	1269	1276	I-Observation
a	9989713	1277	1278	I-Observation
better	9989713	1279	1285	I-Observation
effect	9989713	1286	1292	I-Observation
in	9989713	1293	1295	O
the	9989713	1296	1299	O
AT	9989713	1300	1302	B-Intervention
group	9989713	1303	1308	O
.	9989713	1309	1310	O

A	9989713	1311	1312	O
per-protocol	9989713	1313	1325	O
analysis	9989713	1326	1334	O
did	9989713	1335	1338	O
not	9989713	1339	1342	O
show	9989713	1343	1347	O
appreciably	9989713	1348	1359	O
different	9989713	1360	1369	O
results	9989713	1370	1377	O
.	9989713	1378	1379	O

INTERPRETATION	9989713	1380	1394	O
AT	9989713	1395	1397	B-Intervention
with	9989713	1398	1402	I-Intervention
a	9989713	1403	1404	I-Intervention
programme	9989713	1405	1414	I-Intervention
aimed	9989713	1415	1420	O
at	9989713	1421	1423	O
improving	9989713	1424	1433	B-Observation
strength	9989713	1434	1442	B-Outcome
and	9989713	1443	1446	I-Outcome
coordination	9989713	1447	1459	I-Outcome
of	9989713	1460	1462	I-Outcome
the	9989713	1463	1466	I-Outcome
muscles	9989713	1467	1474	I-Outcome
acting	9989713	1475	1481	I-Outcome
on	9989713	1482	1484	I-Outcome
the	9989713	1485	1488	I-Outcome
pelvis	9989713	1489	1495	I-Outcome
,	9989713	1496	1497	O
in	9989713	1498	1500	O
particular	9989713	1501	1511	O
the	9989713	1512	1515	O
adductor	9989713	1516	1524	O
muscles	9989713	1525	1532	O
,	9989713	1533	1534	O
is	9989713	1535	1537	O
very	9989713	1538	1542	O
effective	9989713	1543	1552	B-Observation
in	9989713	1553	1555	O
the	9989713	1556	1559	O
treatment	9989713	1560	1569	O
of	9989713	1570	1572	O
athletes	9989713	1573	1581	B-Participant
with	9989713	1582	1586	O
long-standing	9989713	1587	1600	B-Participant
adductor-related	9989713	1601	1617	I-Participant
groin	9989713	1618	1623	I-Participant
pain	9989713	1624	1628	I-Participant
.	9989713	1629	1630	O

The	9989713	1631	1634	O
potential	9989713	1635	1644	O
preventive	9989713	1645	1655	O
value	9989713	1656	1661	O
of	9989713	1662	1664	O
a	9989713	1665	1666	O
short	9989713	1667	1672	O
programme	9989713	1673	1682	O
based	9989713	1683	1688	O
upon	9989713	1689	1693	O
the	9989713	1694	1697	O
principles	9989713	1698	1708	O
of	9989713	1709	1711	O
AT	9989713	1712	1714	O
should	9989713	1715	1721	O
be	9989713	1722	1724	O
assessed	9989713	1725	1733	O
in	9989713	1734	1736	O
future	9989713	1737	1743	O
,	9989713	1744	1745	O
randomised	9989713	1746	1756	O
,	9989713	1757	1758	O
clinical	9989713	1759	1767	O
trials	9989713	1768	1774	O
.	9989713	1775	1776	O

